28482688|t|Subjective Cognitive Decline in Preclinical Alzheimer's Disease
28482688|a|Older adults with subjective cognitive decline (SCD) in the absence of objective neuropsychological dysfunction are increasingly viewed as at risk for non-normative cognitive decline and eventual progression to Alzheimer's disease (AD) dementia. The past decade has witnessed tremendous growth in research on SCD, which may reflect the recognition of SCD as the earliest symptomatic manifestation of AD. Yet methodological challenges associated with establishing common assessment and classification procedures hamper the construct. This article reviews essential features of SCD associated with preclinical AD and current measurement approaches, highlighting challenges in harmonizing study findings across settings. We consider the relation of SCD to important variables and outcomes (e.g., AD biomarkers, clinical progression). We also examine the role of self- and informant - reports in SCD and various psychological, medical, and demographic factors that influence the self-report of cognition. We conclude with a discussion of intervention strategies for SCD, ethical considerations, and future research priorities.
28482688	0	28	Subjective Cognitive Decline	T046	C0234985
28482688	32	43	Preclinical	T080	C1709630
28482688	44	63	Alzheimer's Disease	T047	C0002395
28482688	64	76	Older adults	T098	C0001792
28482688	82	110	subjective cognitive decline	T046	C0234985
28482688	112	115	SCD	T046	C0234985
28482688	145	175	neuropsychological dysfunction	T048	C0004936
28482688	215	246	non-normative cognitive decline	T046	C0234985
28482688	260	271	progression	T169	C0449258
28482688	275	294	Alzheimer's disease	T047	C0002395
28482688	296	298	AD	T047	C0002395
28482688	300	308	dementia	T048	C0497327
28482688	361	369	research	T062	C0035168
28482688	373	376	SCD	T046	C0234985
28482688	400	411	recognition	T080	C0205396
28482688	415	418	SCD	T046	C0234985
28482688	435	446	symptomatic	T184	C1457887
28482688	447	460	manifestation	T169	C0205319
28482688	464	466	AD	T047	C0002395
28482688	472	486	methodological	T169	C2700391
28482688	487	497	challenges	T058	C0805586
28482688	534	544	assessment	T058	C0220825
28482688	549	563	classification	T185	C0008902
28482688	564	574	procedures	T169	C2700391
28482688	602	609	article	T170	C1706852
28482688	610	617	reviews	T080	C1704362
28482688	640	643	SCD	T046	C0234985
28482688	660	671	preclinical	T080	C1709630
28482688	672	674	AD	T047	C0002395
28482688	687	698	measurement	T169	C0242485
28482688	699	709	approaches	T169	C1292724
28482688	724	734	challenges	T058	C0805586
28482688	738	755	harmonizing study	T062	C2603343
28482688	756	764	findings	T033	C0243095
28482688	798	806	relation	T080	C0439849
28482688	810	813	SCD	T046	C0234985
28482688	827	836	variables	T080	C0439828
28482688	841	849	outcomes	T169	C1274040
28482688	857	859	AD	T047	C0002395
28482688	860	870	biomarkers	T201	C0005516
28482688	872	880	clinical	T080	C0205210
28482688	881	892	progression	T169	C0449258
28482688	923	928	self-	T062	C2700446
28482688	933	942	informant	T169	C1550484
28482688	945	952	reports	T170	C0684224
28482688	956	959	SCD	T046	C0234985
28482688	972	985	psychological	T041	C0033898
28482688	987	994	medical	T169	C0205476
28482688	1000	1019	demographic factors	T078	C0011292
28482688	1039	1050	self-report	T062	C2700446
28482688	1054	1063	cognition	T041	C0009240
28482688	1098	1121	intervention strategies	T061	C0454040
28482688	1126	1129	SCD	T046	C0234985
28482688	1131	1138	ethical	T078	C0086264
28482688	1139	1153	considerations	T033	C0518609
28482688	1166	1185	research priorities	T062	C0376368

28348878|t|A phylogenomic framework for assessing the global emergence and evolution of clonal complex 398 methicillin-resistant Staphylococcus aureus
28348878|a|Distinct clones of methicillin-resistant Staphylococcus aureus (MRSA) have emerged as important causes of infection in individuals who have exposure to livestock (livestock -associated MRSA; LA-MRSA). Clonal complex 398 (CC398) is the most prevalent LA-MRSA clone, and has been reported from several geographical settings, including Europe, the Americas and Asia. To understand the factors contributing to the global dissemination of this clone, we analysed CC398 MRSA isolates from New Zealand (NZ), a geographically isolated country with an economy strongly dependent on livestock farming. We supplemented the NZ CC398 MRSA collection with global datasets of CC398 MRSA and CC398 methicillin-susceptible S. aureus. Here, we demonstrate multiple sporadic incursions of CC398 MRSA into NZ, as well as recent importation and spread of a swine -associated clade related to the European LA-MRSA lineage. Within a larger global phylogenomic framework, Bayesian modelling suggested that this NZ clade emerged in the late 2000s, with a probable origin in swine from Western Europe. Elucidating the factors responsible for the incursion and spread of LA-MRSA in geographically distant regions, such as NZ, provides important insights into global pathways of S. aureus transmission, and will inform strategies to control importation and spread.
28348878	43	49	global	T080	C2348867
28348878	50	59	emergence	T079	C0439659
28348878	64	73	evolution	T045	C3825184
28348878	77	95	clonal complex 398	T024	C1522642
28348878	96	139	methicillin-resistant Staphylococcus aureus	T007	C1265292
28348878	149	155	clones	T024	C1522642
28348878	159	202	methicillin-resistant Staphylococcus aureus	T007	C1265292
28348878	204	208	MRSA	T007	C1265292
28348878	246	255	infection	T046	C3714514
28348878	259	270	individuals	T098	C0027361
28348878	280	291	exposure to	T080	C0332157
28348878	292	301	livestock	T008	C2936506
28348878	303	312	livestock	T008	C2936506
28348878	325	329	MRSA	T007	C1265292
28348878	331	338	LA-MRSA	T007	C1265292
28348878	341	359	Clonal complex 398	T024	C1522642
28348878	361	366	CC398	T024	C1522642
28348878	390	397	LA-MRSA	T007	C1265292
28348878	398	403	clone	T024	C1522642
28348878	473	479	Europe	T083	C0015176
28348878	485	493	Americas	T083	C0002454
28348878	498	503	Asia.	T083	C0003980
28348878	522	529	factors	T169	C1521761
28348878	550	556	global	T080	C2348867
28348878	557	570	dissemination	T082	C0205221
28348878	579	584	clone	T024	C1522642
28348878	598	603	CC398	T024	C1522642
28348878	604	608	MRSA	T007	C1265292
28348878	609	617	isolates	T123	C1764827
28348878	623	634	New Zealand	T083	C0027978
28348878	636	638	NZ	T083	C0027978
28348878	643	674	geographically isolated country	T083	C0454664
28348878	683	690	economy	T081	C0870462
28348878	713	722	livestock	T008	C2936506
28348878	723	730	farming	T090	C0001829
28348878	752	754	NZ	T083	C0027978
28348878	755	760	CC398	T024	C1522642
28348878	761	765	MRSA	T007	C1265292
28348878	766	776	collection	T062	C0010995
28348878	782	797	global datasets	T170	C0150098
28348878	801	806	CC398	T024	C1522642
28348878	807	811	MRSA	T007	C1265292
28348878	816	821	CC398	T024	C1522642
28348878	822	855	methicillin-susceptible S. aureus	T007	C1635274
28348878	887	895	sporadic	T079	C0205422
28348878	896	906	incursions	T033	C1304680
28348878	910	915	CC398	T024	C1522642
28348878	916	920	MRSA	T007	C1265292
28348878	926	928	NZ	T083	C0027978
28348878	964	970	spread	T080	C0332261
28348878	976	981	swine	T015	C0039005
28348878	994	999	clade	T007	C1003859
28348878	1024	1031	LA-MRSA	T007	C1265292
28348878	1032	1039	lineage	T077	C1881379
28348878	1057	1063	global	T080	C2348867
28348878	1088	1106	Bayesian modelling	T081	C0242196
28348878	1127	1129	NZ	T083	C0027978
28348878	1130	1135	clade	T007	C1003859
28348878	1179	1185	origin	T079	C0439659
28348878	1189	1194	swine	T015	C0039005
28348878	1200	1214	Western Europe	T083	C0043129
28348878	1232	1239	factors	T169	C1521761
28348878	1260	1269	incursion	T033	C1304680
28348878	1274	1280	spread	T080	C0332261
28348878	1284	1291	LA-MRSA	T007	C1265292
28348878	1295	1325	geographically distant regions	T083	C0017446
28348878	1335	1337	NZ	T083	C0027978
28348878	1372	1378	global	T080	C2348867
28348878	1391	1400	S. aureus	T007	C0038172
28348878	1401	1413	transmission	T070	C1521797
28348878	1431	1441	strategies	T170	C0679716
28348878	1469	1475	spread	T080	C0332261

27778115|t|Influence of dentin thickness on intrapulpal temperature under simulated pulpal pressure during Nd:YAG laser irradiation
27778115|a|The aim of this study was to evaluate the effects of dentin thickness and pulpal pressure simulation (PPS) on the variation of intrapulpal temperature (∆T) when submitted to an adhesive technique using laser irradiation. Sixty sound human molars were sectioned and randomly divided into two groups (n = 30): group 1-1 mm of dentin thickness; group 2-2 mm of dentin thickness. Each group was divided into two subgroups (n = 15): subgroup A - absence of PPS; subgroup P - presence of PPS (15 cm H2O), sequentially treated with the following: 37 % phosphoric acid, adhesive system (Adper Single Bond), irradiation with Nd:YAG laser (1064 nm, 10 Hz, 60 s) using 60, 80, and 100 mJ/ pulse energy parameters and light-curing (10 s). The ∆T was evaluated during the laser irradiation with a digital thermometer. Data were analyzed by three-way ANOVA and Tukey tests (p < 0.05). Three-way ANOVA revealed no significant differences for dentin thickness (p = 0.6512) on ∆T. PPS significantly reduced ∆T (p = 0.0001). The laser energy parameters (p = 0.0027) indicated that 100 mJ presented with significantly greater ∆T when compared to the groups irradiated with 80 and 60 mJ. Dentin thickness did not affect ∆T. The presence of PPS reduced the mean temperature values. The Nd:YAG laser energy parameters had a negative influence on the variation of temperature in the absence of PPS. In the presence of PPS, there was no risk to the pulp, since this study obtained temperature increases below 5.5 °C for all energy parameters, showing the technical viability for in vivo conditions.
27778115	0	9	Influence	T077	C4054723
27778115	13	19	dentin	T031	C0011429
27778115	20	29	thickness	T080	C1280412
27778115	33	44	intrapulpal	T023	C0011399
27778115	45	56	temperature	T081	C0039476
27778115	63	88	simulated pulpal pressure	T081	C4284008
27778115	96	108	Nd:YAG laser	T074	C0392277
27778115	109	120	irradiation	T070	C1282930
27778115	137	142	study	T062	C2603343
27778115	150	158	evaluate	T058	C0220825
27778115	163	170	effects	T080	C1280500
27778115	174	180	dentin	T031	C0011429
27778115	181	190	thickness	T080	C1280412
27778115	195	221	pulpal pressure simulation	T081	C4284008
27778115	223	226	PPS	T081	C4284008
27778115	248	271	intrapulpal temperature	T081	C0039476
27778115	273	275	∆T	T081	C0039476
27778115	298	306	adhesive	T073	C0001516
27778115	307	316	technique	T169	C0449851
27778115	323	340	laser irradiation	T061	C0871799
27778115	354	359	human	T016	C0086418
27778115	360	366	molars	T023	C0026367
27778115	412	418	groups	T078	C0441833
27778115	429	434	group	T078	C0441833
27778115	445	451	dentin	T031	C0011429
27778115	452	461	thickness	T080	C1280412
27778115	463	468	group	T078	C0441833
27778115	479	485	dentin	T031	C0011429
27778115	486	495	thickness	T080	C1280412
27778115	502	507	group	T078	C0441833
27778115	529	538	subgroups	T185	C1515021
27778115	549	559	subgroup A	T185	C1515021
27778115	562	569	absence	T169	C0332197
27778115	573	576	PPS	T081	C4284008
27778115	578	588	subgroup P	T185	C1515021
27778115	591	599	presence	T033	C0150312
27778115	603	606	PPS	T081	C4284008
27778115	614	617	H2O	T121,T197	C0043047
27778115	620	640	sequentially treated	T169	C1522326
27778115	666	681	phosphoric acid	T121,T197	C0031700
27778115	683	698	adhesive system	T073	C0001516
27778115	700	717	Adper Single Bond	T122	C2975225
27778115	720	731	irradiation	T070	C1282930
27778115	737	749	Nd:YAG laser	T074	C0392277
27778115	799	822	pulse energy parameters	T077	C0549193
27778115	827	839	light-curing	T061	C2350282
27778115	852	854	∆T	T081	C0039476
27778115	859	868	evaluated	T058	C0220825
27778115	880	897	laser irradiation	T061	C0871799
27778115	905	924	digital thermometer	T074	C0728376
27778115	926	930	Data	T078	C1511726
27778115	948	963	three-way ANOVA	T081	C0002780
27778115	968	979	Tukey tests	T170	C0282574
27778115	992	1007	Three-way ANOVA	T081	C0002780
27778115	1020	1043	significant differences	T081	C1705241
27778115	1048	1054	dentin	T031	C0011429
27778115	1055	1064	thickness	T080	C1280412
27778115	1081	1083	∆T	T081	C0039476
27778115	1085	1088	PPS	T062	C0679083
27778115	1085	1088	PPS	T081	C4284008
27778115	1089	1110	significantly reduced	T080	C0392756
27778115	1111	1113	∆T	T081	C0039476
27778115	1132	1155	laser energy parameters	T077	C0549193
27778115	1206	1227	significantly greater	T081	C1704243
27778115	1228	1230	∆T	T081	C0039476
27778115	1252	1258	groups	T078	C0441833
27778115	1259	1269	irradiated	T070	C1282930
27778115	1289	1295	Dentin	T031	C0011429
27778115	1296	1305	thickness	T080	C1280412
27778115	1321	1323	∆T	T081	C0039476
27778115	1329	1337	presence	T033	C0150312
27778115	1341	1344	PPS	T081	C4284008
27778115	1345	1352	reduced	T080	C0392756
27778115	1357	1380	mean temperature values	T080	C0042295
27778115	1386	1398	Nd:YAG laser	T074	C0392276
27778115	1399	1416	energy parameters	T077	C0549193
27778115	1423	1441	negative influence	T077	C4054723
27778115	1449	1458	variation	T080	C0205419
27778115	1462	1473	temperature	T081	C0039476
27778115	1481	1488	absence	T169	C0332197
27778115	1492	1495	PPS	T081	C4284008
27778115	1504	1512	presence	T033	C0150312
27778115	1516	1519	PPS	T081	C4284008
27778115	1534	1538	risk	T078	C0035647
27778115	1546	1550	pulp	T023	C0011399
27778115	1563	1568	study	T062	C2603343
27778115	1578	1589	temperature	T081	C0039476
27778115	1590	1599	increases	T169	C0442805
27778115	1621	1638	energy parameters	T077	C0549193
27778115	1652	1671	technical viability	T080	C0443348
27778115	1676	1683	in vivo	T082	C1515655

27358636|t|Diagnostic value of diffusion weighted MRI and ADC in differential diagnosis of cavernous hemangioma of the liver
27358636|a|To investigate the use of diffusion weighted magnetic resonance imaging (DWI) and the apparent diffusion coefficient (ADC) values in the diagnosis of hemangioma. The study population consisted of 72 patients with liver masses larger than 1 cm (72 focal lesions). DWI examination with a b value of 600 s/mm2 was carried out for all patients. After DWI examination, an ADC map was created and ADC values were measured for 72 liver masses and normal liver tissue (control group). The average ADC values of normal liver tissue and focal liver lesions, the " cut-off " ADC values, and the diagnostic sensitivity and specificity of the ADC map in diagnosing hemangioma, benign and malignant lesions were researched. Of the 72 liver masses, 51 were benign and 21 were malignant. Benign lesions comprised 38 hemangiomas and 13 simple cysts. Malignant lesions comprised 9 hepatocellular carcinomas, and 12 metastases. The highest ADC values were measured for cysts (3.782±0.53×10(-3) mm(2)/s) and hemangiomas (2.705±0.63×10(-3) mm(2)/s). The average ADC value of hemangiomas was significantly higher than malignant lesions and the normal control group (p<0.001). The average ADC value of cysts were significantly higher when compared to hemangiomas and normal control group (p<0.001). To distinguish hemangiomas from malignant liver lesions, the " cut-off " ADC value of 1.800×10(-3) mm(2)/s had a sensitivity of 97.4% and a specificity of 90.9%. To distinguish hemangioma from normal liver parenchyma the " cut-off" value of 1.858×10(-3) mm(2)/s had a sensitivity of 97.4% and a specificity of 95.7%. To distinguish benign liver lesions from malignant liver lesions the " cut-off" value of 1.800×10(-3) mm(2)/s had a sensitivity of 96.1% and a specificity of 90.0%. DWI and quantitative measurement of ADC values can be used in differential diagnosis of benign and malignant liver lesions and also in the diagnosis and differentiation of hemangiomas. When dynamic examination cannot distinguish cases with vascular metastasis and lesions from hemangioma, DWI and ADC values can be useful in the primary diagnosis and differential diagnosis. The technique does not require contrast material, so it can safely be used in patients with renal failure.
27358636	0	16	Diagnostic value	T169	C0348026
27358636	20	42	diffusion weighted MRI	T060	C0598801
27358636	47	50	ADC	T077	C3890194
27358636	54	76	differential diagnosis	T060	C0011906
27358636	80	100	cavernous hemangioma	T191	C0018920
27358636	108	113	liver	T023	C0023884
27358636	117	128	investigate	T169	C1292732
27358636	133	139	use of	T169	C1524063
27358636	140	185	diffusion weighted magnetic resonance imaging	T060	C0598801
27358636	187	190	DWI	T060	C0598801
27358636	200	230	apparent diffusion coefficient	T077	C3890194
27358636	232	235	ADC	T077	C3890194
27358636	237	243	values	T081	C1522609
27358636	251	260	diagnosis	T062	C1704656
27358636	264	274	hemangioma	T191	C0018916
27358636	280	296	study population	T098	C2348561
27358636	313	321	patients	T101	C0030705
27358636	327	339	liver masses	T047	C0240225
27358636	361	374	focal lesions	T033	C0221198
27358636	377	380	DWI	T060	C0598801
27358636	381	392	examination	T058	C0582103
27358636	445	453	patients	T101	C0030705
27358636	461	464	DWI	T060	C0598801
27358636	465	476	examination	T058	C0582103
27358636	481	484	ADC	T077	C3890194
27358636	505	508	ADC	T077	C3890194
27358636	509	515	values	T081	C1522609
27358636	537	549	liver masses	T047	C0240225
27358636	554	560	normal	T080	C0205307
27358636	561	573	liver tissue	T023	C0736268
27358636	575	588	control group	T096	C0009932
27358636	595	602	average	T081	C1510992
27358636	603	606	ADC	T077	C3890194
27358636	607	613	values	T081	C1522609
27358636	617	623	normal	T080	C0205307
27358636	624	636	liver tissue	T023	C0736268
27358636	641	660	focal liver lesions	T033	C0577053
27358636	668	675	cut-off	T081	C1522609
27358636	678	681	ADC	T077	C3890194
27358636	682	688	values	T081	C1522609
27358636	698	720	diagnostic sensitivity	T081	C1511883
27358636	725	736	specificity	T081	C1511884
27358636	744	747	ADC	T077	C3890194
27358636	755	765	diagnosing	T062	C1704656
27358636	766	776	hemangioma	T191	C0018916
27358636	778	784	benign	T080	C0205183
27358636	789	798	malignant	T080	C0205282
27358636	799	806	lesions	T033	C0221198
27358636	834	846	liver masses	T047	C0240225
27358636	856	862	benign	T080	C0205183
27358636	875	884	malignant	T080	C0205282
27358636	886	892	Benign	T080	C0205183
27358636	893	900	lesions	T033	C0221198
27358636	914	925	hemangiomas	T191	C0018916
27358636	933	945	simple cysts	T190	C0037157
27358636	947	956	Malignant	T080	C0205282
27358636	957	964	lesions	T033	C0221198
27358636	977	1002	hepatocellular carcinomas	T191	C2239176
27358636	1011	1021	metastases	T191	C0027627
27358636	1035	1038	ADC	T077	C3890194
27358636	1039	1045	values	T081	C1522609
27358636	1064	1069	cysts	T047	C0010709
27358636	1102	1113	hemangiomas	T191	C0018916
27358636	1147	1154	average	T081	C1510992
27358636	1155	1158	ADC	T077	C3890194
27358636	1159	1164	value	T081	C1522609
27358636	1168	1179	hemangiomas	T191	C0018916
27358636	1184	1204	significantly higher	T081	C4055637
27358636	1210	1219	malignant	T080	C0205282
27358636	1220	1227	lesions	T033	C0221198
27358636	1236	1256	normal control group	T096	C0009932
27358636	1272	1279	average	T081	C1510992
27358636	1280	1283	ADC	T077	C3890194
27358636	1284	1289	value	T081	C1522609
27358636	1293	1298	cysts	T047	C0010709
27358636	1304	1324	significantly higher	T081	C4055637
27358636	1342	1353	hemangiomas	T191	C0018916
27358636	1358	1378	normal control group	T096	C0009932
27358636	1405	1416	hemangiomas	T191	C0018916
27358636	1422	1431	malignant	T080	C0205282
27358636	1432	1445	liver lesions	T033	C0577053
27358636	1453	1460	cut-off	T081	C1522609
27358636	1463	1466	ADC	T077	C3890194
27358636	1467	1472	value	T081	C1522609
27358636	1503	1514	sensitivity	T081	C1511883
27358636	1530	1541	specificity	T081	C1511884
27358636	1567	1577	hemangioma	T191	C0018916
27358636	1583	1589	normal	T080	C0205307
27358636	1590	1606	liver parenchyma	T023	C0736268
27358636	1613	1627	cut-off" value	T081	C1522609
27358636	1658	1669	sensitivity	T081	C1511883
27358636	1685	1696	specificity	T081	C1511884
27358636	1722	1728	benign	T080	C0205183
27358636	1729	1742	liver lesions	T033	C0577053
27358636	1748	1757	malignant	T080	C0205282
27358636	1758	1771	liver lesions	T033	C0577053
27358636	1778	1792	cut-off" value	T081	C1522609
27358636	1823	1834	sensitivity	T081	C1511883
27358636	1850	1861	specificity	T081	C1511884
27358636	1872	1875	DWI	T060	C0598801
27358636	1880	1904	quantitative measurement	T081	C0034384
27358636	1908	1911	ADC	T077	C3890194
27358636	1912	1918	values	T081	C1522609
27358636	1934	1956	differential diagnosis	T060	C0011906
27358636	1960	1966	benign	T080	C0205183
27358636	1971	1980	malignant	T080	C0205282
27358636	1981	1994	liver lesions	T033	C0577053
27358636	2011	2020	diagnosis	T062	C1704656
27358636	2025	2040	differentiation	T169	C2945687
27358636	2044	2055	hemangiomas	T191	C0018916
27358636	2062	2081	dynamic examination	T058	C0582103
27358636	2101	2106	cases	T077	C1706256
27358636	2112	2131	vascular metastasis	T191	C0027627
27358636	2136	2143	lesions	T033	C0221198
27358636	2149	2159	hemangioma	T191	C0018916
27358636	2161	2164	DWI	T060	C0598801
27358636	2169	2172	ADC	T077	C3890194
27358636	2173	2179	values	T081	C1522609
27358636	2201	2218	primary diagnosis	T080	C0332137
27358636	2223	2245	differential diagnosis	T060	C0011906
27358636	2251	2260	technique	T169	C0449851
27358636	2278	2295	contrast material	T130	C0009924
27358636	2325	2333	patients	T101	C0030705
27358636	2339	2352	renal failure	T047	C0035078

28412023|t|Precise prediction of activators for the human constitutive androstane receptor using structure -based three-dimensional quantitative structure-activity relationship methods
28412023|a|The constitutive androstane receptor (CAR, NR1I3) regulates the expression of numerous drug-metabolizing enzymes and transporters. The upregulation of various enzymes, including CYP2B6, by CAR activators is a critical problem leading to clinically severe drug-drug interactions (DDIs). To date, however, few effective computational approaches for identifying CAR activators exist. In this study, we aimed to develop three-dimensional quantitative structure-activity relationship (3D-QSAR) models to predict the CAR activating potency of compounds emerging in the drug-discovery process. Models were constructed using comparative molecular field analysis (CoMFA) based on the molecular alignments of ligands binding to CAR, which were obtained from ensemble ligand-docking using 28 compounds as a training set. The CoMFA model, modified by adding a lipophilic parameter with calculated logD7.4 (S+logD7.4), demonstrated statistically good predictive ability (r(2) = 0.99, q(2) = 0.74). We also confirmed the excellent predictability of the 3D-QSAR model for CAR activation (r(2)pred = 0.71) using seven compounds as a test set for external validation. Collectively, our results indicate that the 3D-QSAR model developed in this study provides precise prediction of CAR activating potency and, thus, should be useful for selecting drug candidates with minimized DDI risk related to enzyme-induction in the early drug-discovery stage.
28412023	8	18	prediction	T078	C0681842
28412023	22	32	activators	T121,T123	C0751968
28412023	41	46	human	T016	C0086418
28412023	47	79	constitutive androstane receptor	T116,T192	C0914906
28412023	86	95	structure	T085	C0026383
28412023	103	165	three-dimensional quantitative structure-activity relationship	T081	C0887820
28412023	166	173	methods	T170	C0025663
28412023	178	210	constitutive androstane receptor	T116,T192	C0914906
28412023	212	215	CAR	T116,T192	C0914906
28412023	217	223	NR1I3)	T116,T192	C0663285
28412023	224	248	regulates the expression	T045	C2755857
28412023	252	260	numerous	T081	C0439064
28412023	261	278	drug-metabolizing	T044	C0683140
28412023	279	286	enzymes	T116,T126	C0014442
28412023	291	303	transporters	T116,T123	C0007292
28412023	309	321	upregulation	T044	C0041904
28412023	333	340	enzymes	T116,T126	C0014442
28412023	352	358	CYP2B6	T116,T126	C0534137
28412023	363	366	CAR	T116,T192	C0914906
28412023	367	377	activators	T121,T123	C0751968
28412023	422	428	severe	T080	C0205082
28412023	429	451	drug-drug interactions	T044	C0687133
28412023	453	457	DDIs	T044	C0687133
28412023	482	491	effective	T080	C1704419
28412023	492	516	computational approaches	T062	C1516769
28412023	533	536	CAR	T116,T192	C0914906
28412023	590	652	three-dimensional quantitative structure-activity relationship	T081	C0887820
28412023	654	661	3D-QSAR	T081	C0887820
28412023	663	669	models	T170	C3161035
28412023	685	688	CAR	T116,T192	C0914906
28412023	689	699	activating	T043	C1514758
28412023	700	707	potency	T080	C3245505
28412023	711	720	compounds	T121	C1254351
28412023	737	751	drug-discovery	T062	C0920472
28412023	752	759	process	T067	C1522240
28412023	761	767	Models	T170	C3161035
28412023	791	827	comparative molecular field analysis	T063	C1513380
28412023	829	834	CoMFA	T063	C1513380
28412023	849	858	molecular	T167	C0567416
28412023	859	869	alignments	T081	C1706765
28412023	873	888	ligands binding	T044	C1517880
28412023	892	895	CAR	T116,T192	C0914906
28412023	931	945	ligand-docking	T044	C1522290
28412023	952	964	28 compounds	T121	C1254351
28412023	988	993	CoMFA	T063	C1513380
28412023	994	999	model	T170	C3161035
28412023	1001	1012	modified by	T080	C0205349
28412023	1022	1032	lipophilic	T081	C0598631
28412023	1033	1042	parameter	T081	C0598631
28412023	1112	1130	predictive ability	T080	C1514307
28412023	1191	1205	predictability	T081	C0237793
28412023	1213	1220	3D-QSAR	T081	C0887820
28412023	1221	1226	model	T170	C3161035
28412023	1231	1234	CAR	T116,T192	C0914906
28412023	1235	1245	activation	T043	C1514758
28412023	1276	1285	compounds	T121	C1254351
28412023	1304	1323	external validation	T062	C1519941
28412023	1343	1350	results	T169	C1274040
28412023	1369	1376	3D-QSAR	T081	C0887820
28412023	1377	1382	model	T170	C3161035
28412023	1416	1423	precise	T080	C2828393
28412023	1424	1434	prediction	T078	C0681842
28412023	1438	1441	CAR	T116,T192	C0914906
28412023	1442	1452	activating	T043	C1514758
28412023	1453	1460	potency	T080	C3245505
28412023	1503	1518	drug candidates	T121	C1254351
28412023	1524	1533	minimized	T080	C1524031
28412023	1534	1537	DDI	T044	C0687133
28412023	1538	1542	risk	T078	C0035647
28412023	1554	1570	enzyme-induction	T045	C0014431
28412023	1578	1583	early	T079	C1279919
28412023	1584	1598	drug-discovery	T062	C0920472
28412023	1599	1604	stage	T079	C1306673

28026207|t|Impact sports and bone fractures among adolescents
28026207|a|The objective of the present study was to investigate the effects of different sports on stress fractures among adolescents during a 9- month follow-up period. The sample was composed of 184 adolescents divided into three groups (impact sports [n = 102]; swimming [n = 35]; non-sports [n = 47]). The occurrence of stress fracture was reported by participants and coaches. As potential confounders we considered age, sex, resistance training, body composition variables and age at peak of height velocity. There were 13 adolescents who reported fractures during the 9- month period. Bone mineral density values were higher in adolescents engaged in impact sports (P-value = 0.002). Independently of confounders, the risk of stress fracture was lower in adolescents engaged in impact sports than in non-active adolescents (hazard ratio [HR] = 0.23 [95% confidence interval (CI) = 0.05 to 0.98]), while swimming practice was not associated to lower risk of fracture (HR = 0.49 [95% CI = 0.09 to 2.55]). In conclusion, the findings from this study indicate the importance of sports participation among adolescents in the reduction of stress fracture risk, especially with impact sports. More importantly, these results could be relevant for recognising adolescents in danger of not reaching their potential for peak bone mass and later an increased risk of fractures.
28026207	0	13	Impact sports	T056	C0038039
28026207	18	32	bone fractures	T037	C0016658
28026207	39	50	adolescents	T100	C0205653
28026207	80	85	study	T062	C2603343
28026207	93	104	investigate	T169	C1292732
28026207	109	119	effects of	T080	C1704420
28026207	120	129	different	T080	C1705242
28026207	130	136	sports	T056	C0038039
28026207	140	156	stress fractures	T037	C0016664
28026207	163	174	adolescents	T100	C0205653
28026207	187	192	month	T079	C0439231
28026207	193	202	follow-up	T058	C1522577
28026207	203	209	period	T079	C1948053
28026207	215	221	sample	T098	C1257890
28026207	242	253	adolescents	T100	C0205653
28026207	273	279	groups	T098	C1257890
28026207	281	294	impact sports	T056	C0038039
28026207	306	314	swimming	T056	C0039003
28026207	325	335	non-sports	T056	C0038039
28026207	351	361	occurrence	T079	C2745955
28026207	365	380	stress fracture	T037	C0016664
28026207	397	409	participants	T098	C0679646
28026207	414	421	coaches	T097	C0876909
28026207	436	447	confounders	T169	C0009673
28026207	462	465	age	T032	C0001779
28026207	467	470	sex	T032	C1522384
28026207	472	491	resistance training	T061	C0872279
28026207	493	509	body composition	T032	C0005885
28026207	510	519	variables	T080	C0439828
28026207	524	527	age	T032	C0001779
28026207	531	535	peak	T080	C0444505
28026207	539	554	height velocity	T081	C0439830
28026207	570	581	adolescents	T100	C0205653
28026207	595	604	fractures	T037	C0016658
28026207	619	624	month	T079	C0439231
28026207	625	631	period	T079	C1948053
28026207	633	653	Bone mineral density	T201	C0005938
28026207	654	660	values	T080	C0042295
28026207	676	687	adolescents	T100	C0205653
28026207	699	712	impact sports	T056	C0038039
28026207	714	721	P-value	T081	C1709380
28026207	749	760	confounders	T169	C0009673
28026207	766	770	risk	T078	C0035647
28026207	774	789	stress fracture	T037	C0016664
28026207	803	814	adolescents	T100	C0205653
28026207	826	839	impact sports	T056	C0038039
28026207	848	870	non-active adolescents	T100	C0205653
28026207	872	884	hazard ratio	T081	C2985465
28026207	886	888	HR	T081	C2985465
28026207	902	921	confidence interval	T081	C0009667
28026207	923	925	CI	T081	C0009667
28026207	951	959	swimming	T056	C0039003
28026207	960	968	practice	T041	C0032893
28026207	997	1001	risk	T078	C0035647
28026207	1005	1013	fracture	T037	C0016658
28026207	1015	1017	HR	T081	C2985465
28026207	1030	1032	CI	T081	C0009667
28026207	1070	1078	findings	T033	C0243095
28026207	1089	1094	study	T062	C2603343
28026207	1122	1128	sports	T056	C0038039
28026207	1129	1142	participation	T169	C0679823
28026207	1149	1160	adolescents	T100	C0205653
28026207	1168	1177	reduction	T080	C0392756
28026207	1181	1196	stress fracture	T037	C0016664
28026207	1197	1201	risk	T078	C0035647
28026207	1219	1232	impact sports	T056	C0038039
28026207	1258	1265	results	T169	C1274040
28026207	1275	1283	relevant	T080	C2347946
28026207	1300	1311	adolescents	T100	C0205653
28026207	1358	1362	peak	T080	C0444505
28026207	1363	1372	bone mass	T201	C0005938
28026207	1386	1395	increased	T081	C0205217
28026207	1396	1400	risk	T078	C0035647
28026207	1404	1413	fractures	T037	C0016658

28411263|t|Use of Platelet Function Testing Before Pipeline Embolization Device Placement: A Multicenter Cohort Study
28411263|a|Thromboembolic complications constitute a significant source of morbidity after neurointerventional procedures. Flow diversion using the pipeline embolization device for the treatment of intracranial aneurysms necessitates the use of dual antiplatelet therapy to reduce this risk. The use of platelet function testing before pipeline embolization device placement remains controversial. A retrospective review of prospectively maintained databases at 3 academic institutions was performed from the years 2009 to 2016 to identify patients with intracranial aneurysms treated with pipeline embolization device placement. Clinical and radiographic data were analyzed with emphasis on thromboembolic complications and clopidogrel responsiveness. A total of 402 patients underwent 414 pipeline embolization device procedures for the treatment of 465 intracranial aneurysms. Thromboembolic complications were encountered in 9.2% of procedures and were symptomatic in 5.6%. Clopidogrel nonresponders experienced a significantly higher rate of thromboembolic complications compared with clopidogrel responders (17.4% versus 5.6%). This risk was significantly lower in nonresponders who were switched to ticagrelor when compared with patients who remained on clopidogrel (2.7% versus 24.4%). In patients who remained on clopidogrel, the rate of thromboembolic complications was significantly lower in those who received a clopidogrel boost within 24 hours pre-procedure when compared with those who did not (9.8% versus 51.9%). There was no significant difference in the rate of hemorrhagic complications between groups. Clopidogrel nonresponders experienced a significantly higher rate of thromboembolic complications when compared with clopidogrel responders. However, this risk seems to be mitigated in nonresponders who were switched to ticagrelor or received a clopidogrel boost within 24 hours pre-procedure.
28411263	7	32	Platelet Function Testing	T059	C0032184
28411263	40	68	Pipeline Embolization Device	T074	C0491616
28411263	69	78	Placement	T058	C1533810
28411263	82	93	Multicenter	T062	C1096776
28411263	94	106	Cohort Study	T081	C0009247
28411263	107	121	Thromboembolic	T169	C0333214
28411263	122	135	complications	T046	C0009566
28411263	149	160	significant	T078	C0750502
28411263	161	167	source	T033	C0449416
28411263	171	180	morbidity	T081	C0026538
28411263	187	217	neurointerventional procedures	T061	C0184661
28411263	219	233	Flow diversion	T061	C4049519
28411263	244	272	pipeline embolization device	T074	C0491616
28411263	281	290	treatment	T061	C0087111
28411263	294	316	intracranial aneurysms	T047	C0007766
28411263	341	366	dual antiplatelet therapy	T061	C1096021
28411263	382	386	risk	T078	C0035647
28411263	399	424	platelet function testing	T059	C0032184
28411263	432	460	pipeline embolization device	T074	C0491616
28411263	461	470	placement	T058	C1533810
28411263	496	516	retrospective review	T062	C0035363
28411263	520	533	prospectively	T080	C0205556
28411263	534	544	maintained	T169	C1314677
28411263	545	554	databases	T170	C0242356
28411263	560	581	academic institutions	UnknownType	C0681331
28411263	586	595	performed	T169	C0884358
28411263	636	644	patients	T101	C0030705
28411263	650	672	intracranial aneurysms	T047	C0007766
28411263	673	685	treated with	T061	C0332293
28411263	686	714	pipeline embolization device	T074	C0491616
28411263	715	724	placement	T058	C1533810
28411263	726	734	Clinical	T170	C1516606
28411263	739	751	radiographic	T070	C0444708
28411263	752	756	data	T078	C1511726
28411263	762	770	analyzed	T062	C0936012
28411263	788	802	thromboembolic	T169	C0333214
28411263	803	816	complications	T046	C0009566
28411263	821	847	clopidogrel responsiveness	T043	C3894555
28411263	864	872	patients	T101	C0030705
28411263	887	915	pipeline embolization device	T074	C0491616
28411263	916	926	procedures	T169	C2700391
28411263	935	944	treatment	T061	C0087111
28411263	952	974	intracranial aneurysms	T047	C0007766
28411263	976	990	Thromboembolic	T169	C0333214
28411263	991	1004	complications	T046	C0009566
28411263	1010	1021	encountered	T058	C0422301
28411263	1033	1043	procedures	T169	C2700391
28411263	1053	1064	symptomatic	T169	C0231220
28411263	1074	1085	Clopidogrel	T109,T121	C0070166
28411263	1086	1099	nonresponders	T033	C0243095
28411263	1100	1111	experienced	T041	C0237607
28411263	1114	1134	significantly higher	T081	C4055637
28411263	1135	1139	rate	T081	C1521828
28411263	1143	1157	thromboembolic	T169	C0333214
28411263	1158	1171	complications	T046	C0009566
28411263	1172	1180	compared	T052	C1707455
28411263	1186	1197	clopidogrel	T109,T121	C0070166
28411263	1198	1208	responders	T033	C0919876
28411263	1235	1239	risk	T078	C0035647
28411263	1244	1263	significantly lower	T081	C4055638
28411263	1267	1280	nonresponders	T033	C0243095
28411263	1302	1312	ticagrelor	T114,T121	C1999375
28411263	1318	1326	compared	T052	C1707455
28411263	1332	1340	patients	T101	C0030705
28411263	1357	1368	clopidogrel	T109,T121	C0070166
28411263	1393	1401	patients	T101	C0030705
28411263	1418	1429	clopidogrel	T109,T121	C0070166
28411263	1435	1439	rate	T081	C1521828
28411263	1443	1457	thromboembolic	T169	C0333214
28411263	1458	1471	complications	T046	C0009566
28411263	1476	1495	significantly lower	T081	C4055638
28411263	1509	1517	received	T080	C1514756
28411263	1520	1531	clopidogrel	T109,T121	C0070166
28411263	1532	1537	boost	T169	C1511253
28411263	1554	1567	pre-procedure	T079	C3272300
28411263	1573	1581	compared	T052	C1707455
28411263	1639	1650	significant	T078	C0750502
28411263	1651	1661	difference	T033	C3842396
28411263	1669	1673	rate	T081	C1521828
28411263	1677	1688	hemorrhagic	T080	C0333275
28411263	1689	1702	complications	T046	C0009566
28411263	1711	1717	groups	T078	C0441833
28411263	1719	1730	Clopidogrel	T109,T121	C0070166
28411263	1731	1744	nonresponders	T033	C0243095
28411263	1759	1779	significantly higher	T081	C4055637
28411263	1780	1784	rate	T081	C1521828
28411263	1788	1802	thromboembolic	T169	C0333214
28411263	1803	1816	complications	T046	C0009566
28411263	1822	1830	compared	T052	C1707455
28411263	1836	1847	clopidogrel	T109,T121	C0070166
28411263	1848	1858	responders	T033	C0919876
28411263	1874	1878	risk	T078	C0035647
28411263	1891	1900	mitigated	T067	C1553901
28411263	1904	1917	nonresponders	T033	C0243095
28411263	1939	1949	ticagrelor	T114,T121	C1999375
28411263	1953	1961	received	T080	C1514756
28411263	1964	1975	clopidogrel	T109,T121	C0070166
28411263	1976	1981	boost	T169	C1511253
28411263	1998	2011	pre-procedure	T079	C3272300

27505653|t|Pupil dynamics with periodic flashes: effect of age on mesopic adaptation
27505653|a|The purpose of this study is to determine the pupillary dynamics with periodical flashes from a peripheral glare source, in similar conditions to night driving, while focusing on dependence with age. We measured two groups of people: youth and adults. Maximum pupil size decreases due to periodic flashes. Latency does not present significant differences. The reduction of pupil size is greater for older adults. The presence of a peripheral and periodic glare source modifies the pupil size. This leads to a reduction of retinal illuminance, which is greater for older adults.
27505653	0	5	Pupil	T023	C0034121
27505653	6	14	dynamics	T070	C3826426
27505653	20	28	periodic	T079	C0332182
27505653	29	36	flashes	T033	C0549326
27505653	38	44	effect	T080	C1280500
27505653	48	51	age	T032	C0001779
27505653	55	62	mesopic	T042	C2350310
27505653	63	73	adaptation	T038	C0392673
27505653	106	115	determine	T080	C0521095
27505653	120	129	pupillary	T023	C0034121
27505653	130	138	dynamics	T070	C3826426
27505653	144	154	periodical	T079	C0332182
27505653	155	162	flashes	T033	C0549326
27505653	170	180	peripheral	T041	C0234628
27505653	181	186	glare	T070	C0278215
27505653	187	193	source	T033	C0449416
27505653	198	205	similar	T080	C2348205
27505653	206	216	conditions	T080	C0348080
27505653	220	225	night	T079	C0240526
27505653	226	233	driving	T056	C0004379
27505653	253	263	dependence	T080	C1701901
27505653	269	272	age	T032	C0001779
27505653	277	285	measured	T080	C0444706
27505653	290	306	groups of people	T098	C1257890
27505653	308	313	youth	T100	C0087178
27505653	318	324	adults	T100	C0001675
27505653	326	333	Maximum	T081	C0806909
27505653	334	344	pupil size	T201	C0517965
27505653	345	354	decreases	T081	C0547047
27505653	362	370	periodic	T079	C0332182
27505653	371	378	flashes	T033	C0549326
27505653	380	387	Latency	T079	C0242465
27505653	388	428	does not present significant differences	T033	C3842396
27505653	434	443	reduction	T080	C0392756
27505653	447	457	pupil size	T201	C0517965
27505653	461	468	greater	T081	C1704243
27505653	473	485	older adults	T098	C0001792
27505653	491	499	presence	T033	C0150312
27505653	505	515	peripheral	T041	C0234628
27505653	520	528	periodic	T079	C0332182
27505653	529	534	glare	T070	C0278215
27505653	535	541	source	T033	C0449416
27505653	542	550	modifies	T169	C0392747
27505653	555	565	pupil size	T201	C0517965
27505653	583	592	reduction	T080	C0392756
27505653	596	603	retinal	T023	C0035298
27505653	604	615	illuminance	T081	C2349048
27505653	626	633	greater	T081	C1704243
27505653	638	650	older adults	T098	C0001792

27412526|t|Variability in conditioned pain modulation predicts response to NSAID treatment in patients with knee osteoarthritis
27412526|a|Patients with painful knee osteoarthritis (OA) demonstrate hyperalgesia and altered pain-modulatory responses. While some prior work has demonstrated cross-sectional associations between laboratory and clinical pain measures, it is unknown whether individual variability in quantitative sensory testing (QST) responses at baseline can prospectively predict analgesic treatment responses. Patients with knee OA (n = 35) were compared on QST responses to a demographically -matched pain-free control group (n = 39), after which patients completed a month-long treatment study of diclofenac sodium topical gel (1 %), applied up to 4 times daily. OA patients demonstrated reduced pain thresholds at multiple anatomic sites, as well as reduced conditioned pain modulation (CPM) and enhanced temporal summation of pain. The most pain-sensitive patients tended to report the most intense and neuropathic OA pain. Following diclofenac treatment, the knee OA cohort showed a roughly 30 % improvement in pain, regardless of the presence or absence of neuropathic symptoms. Baseline CPM scores, an index of endogenous pain-inhibitory capacity, were prospectively associated with treatment -related changes in clinical pain. Specifically, participants with higher CPM at baseline (i.e., better functioning endogenous pain - inhibitory systems) showed more reduction in pain at the end of treatment (p < .05). These results support prior findings of amplified pain sensitivity and reduced pain-inhibition in OA patients. Moreover, the moderate to strong associations between laboratory-based measures of pain sensitivity and indices of clinical pain highlight the clinical relevance of QST in this sample. Finally, the prospective association between CPM and diclofenac response suggests that QST-based phenotyping may have utility in explaining inter-patient variability in long-term analgesic treatment outcomes. ClinicalTrials .Gov Identifier: NCT01383954. Registered June 22, 2011.
27412526	0	11	Variability	T077	C2827666
27412526	15	42	conditioned pain modulation	T061	C0002766
27412526	52	60	response	T032	C0871261
27412526	64	69	NSAID	T121	C3536840
27412526	70	79	treatment	T061	C0087111
27412526	83	91	patients	T101	C0030705
27412526	97	116	knee osteoarthritis	T047	C0409959
27412526	117	125	Patients	T101	C0030705
27412526	131	138	painful	T184	C0030193
27412526	139	158	knee osteoarthritis	T047	C0409959
27412526	160	162	OA	T047	C0409959
27412526	176	188	hyperalgesia	T184	C0020429
27412526	193	200	altered	T169	C0392747
27412526	201	216	pain-modulatory	T061	C0002766
27412526	217	226	responses	T032	C0871261
27412526	267	295	cross-sectional associations	T062	C0010362
27412526	304	314	laboratory	T073,T093	C0022877
27412526	319	327	clinical	T080	C0205210
27412526	333	341	measures	T169	C1879489
27412526	376	387	variability	T077	C2827666
27412526	391	419	quantitative sensory testing	T060	C0430838
27412526	421	424	QST	T060	C0430838
27412526	426	435	responses	T032	C0871261
27412526	439	447	baseline	T081	C1442488
27412526	474	483	analgesic	T109,T121,T131	C0002771
27412526	484	503	treatment responses	T201	C0521982
27412526	505	513	Patients	T101	C0030705
27412526	519	526	knee OA	T047	C0409959
27412526	553	556	QST	T060	C0430838
27412526	557	566	responses	T032	C0871261
27412526	572	587	demographically	T090	C0011298
27412526	597	606	pain-free	T169	C0234226
27412526	607	620	control group	T096	C0009932
27412526	643	651	patients	T101	C0030705
27412526	675	690	treatment study	T062	C3161471
27412526	694	723	diclofenac sodium topical gel	T200	C0357603
27412526	731	738	applied	T169	C4048755
27412526	760	762	OA	T047	C0409959
27412526	763	771	patients	T101	C0030705
27412526	785	792	reduced	T080	C0392756
27412526	793	808	pain thresholds	T033	C0162703
27412526	821	835	anatomic sites	T029	C1515974
27412526	848	855	reduced	T080	C0392756
27412526	856	883	conditioned pain modulation	T061	C0002766
27412526	885	888	CPM	T061	C0002766
27412526	894	902	enhanced	T052	C2349975
27412526	903	921	temporal summation	T042	C0234110
27412526	925	929	pain	T184	C0030193
27412526	940	954	pain-sensitive	T033	C0162703
27412526	955	963	patients	T101	C0030705
27412526	990	997	intense	T080	C0522510
27412526	1002	1013	neuropathic	T033	C3714625
27412526	1014	1016	OA	T047	C0409959
27412526	1017	1021	pain	T184	C0030193
27412526	1033	1043	diclofenac	T109,T121	C0012091
27412526	1044	1053	treatment	T061	C0087111
27412526	1059	1066	knee OA	T047	C0409959
27412526	1067	1073	cohort	T098	C0599755
27412526	1111	1115	pain	T184	C0030193
27412526	1117	1127	regardless	T080	C3641650
27412526	1158	1178	neuropathic symptoms	T033	C3714625
27412526	1180	1188	Baseline	T081	C1442488
27412526	1189	1192	CPM	T061	C0002766
27412526	1213	1223	endogenous	T169	C0205227
27412526	1224	1248	pain-inhibitory capacity	T040	C3895972
27412526	1269	1284	associated with	T080	C0332281
27412526	1285	1294	treatment	T061	C0087111
27412526	1315	1323	clinical	T080	C0205210
27412526	1324	1328	pain	T184	C0030193
27412526	1344	1356	participants	T098	C0679646
27412526	1369	1372	CPM	T061	C0002766
27412526	1376	1384	baseline	T081	C1442488
27412526	1411	1421	endogenous	T169	C0205227
27412526	1422	1426	pain	T184	C0030193
27412526	1429	1447	inhibitory systems	T123	C0574031
27412526	1461	1470	reduction	T061	C0441610
27412526	1474	1478	pain	T184	C0030193
27412526	1493	1502	treatment	T061	C0087111
27412526	1520	1527	results	T034	C0456984
27412526	1542	1550	findings	T033	C0243095
27412526	1554	1580	amplified pain sensitivity	T033	C0162703
27412526	1585	1592	reduced	T080	C0392756
27412526	1593	1608	pain-inhibition	T040	C3895972
27412526	1612	1614	OA	T047	C0409959
27412526	1615	1623	patients	T101	C0030705
27412526	1679	1695	laboratory-based	T073,T093	C0022877
27412526	1696	1704	measures	T169	C1879489
27412526	1708	1724	pain sensitivity	T033	C0162703
27412526	1729	1736	indices	T169	C0205263
27412526	1740	1748	clinical	T080	C0205210
27412526	1749	1753	pain	T184	C0030193
27412526	1768	1776	clinical	T080	C0205210
27412526	1777	1786	relevance	T080	C2347946
27412526	1790	1793	QST	T060	C0430838
27412526	1855	1858	CPM	T061	C0002766
27412526	1863	1873	diclofenac	T109,T121	C0012091
27412526	1874	1882	response	T032	C0871261
27412526	1883	1891	suggests	T078	C1705535
27412526	1897	1906	QST-based	T060	C0430838
27412526	1907	1918	phenotyping	T169	C1314763
27412526	1950	1963	inter-patient	T101	C0030705
27412526	1964	1975	variability	T077	C2827666
27412526	1979	1988	long-term	T079	C0443252
27412526	1989	1998	analgesic	T109,T121,T131	C0002771
27412526	1999	2017	treatment outcomes	T080	C0085415
27412526	2019	2033	ClinicalTrials	T062	C0008976

27546724|t|The relationship between social functioning and subjective memory complaints in older persons: a population -based longitudinal cohort study
27546724|a|Poor social functioning is associated with cognitive decline in older adults. It is unclear whether social functioning is also associated with subjective memory complaints (SMC). We investigated the association between social functioning and incident SMC and SMC recovery. A population -based sample of 8762 older adults (aged ≥65 years) with good objective cognitive functioning at baseline (MMSE ≥26) from the LifeLines Cohort Study were followed for 1.5 years. Self-reported SMC were measured at baseline and after 1.5 years follow-up. Aspects of social functioning included marital status, household composition, social network size, social activity, quality of social relationships, social support, affection, behavioral confirmation, and status. Thirteen percent (513/3963) developed SMC during follow-up (incident SMC). Multivariate logistic regression analyses (adjusted for age, gender, education level, physical activity, alcohol use, smoking status, depression, arrhythmia, myocardial infarction, heart failure, stroke) showed that participants with better feelings of affection, behavioral confirmation and stable good social support had a lower risk of incident SMC. Thirty-four percent (1632/4799) reported recovery. Participants with good social functioning at baseline on all determinants reported more SMC recovery. People who remained stable in a relationship, stable in good quality of social relationships or increased in quality of social relationships more often report SMC recovery. Good social functioning is associated with less incident SMC and more SMC recovery over a follow-up period of 1.5 years. Albeit future confirmative studies are needed, we argue for targeting also social functioning when designing multidomain interventions to prevent or slow down cognitive decline. Copyright © 2016 John Wiley & Sons, Ltd.
27546724	4	16	relationship	T080	C0439849
27546724	25	43	social functioning	T054	C0037395
27546724	48	76	subjective memory complaints	T048	C0233794
27546724	80	93	older persons	T098	C3826770
27546724	97	107	population	T098	C1257890
27546724	115	127	longitudinal	T062	C0023981
27546724	128	140	cohort study	T081	C0009247
27546724	141	145	Poor	T080	C0542537
27546724	146	164	social functioning	T054	C0037395
27546724	168	183	associated with	T080	C0332281
27546724	184	201	cognitive decline	T048	C0338656
27546724	205	210	older	T098	C3826770
27546724	211	217	adults	T100	C0001675
27546724	225	232	unclear	T033	C3845108
27546724	241	259	social functioning	T054	C0037395
27546724	268	283	associated with	T080	C0332281
27546724	284	312	subjective memory complaints	T048	C0233794
27546724	314	317	SMC	T048	C0233794
27546724	323	335	investigated	T169	C1292732
27546724	340	351	association	T080	C0439849
27546724	360	378	social functioning	T054	C0037395
27546724	383	391	incident	T067	C1551358
27546724	392	395	SMC	T048	C0233794
27546724	400	403	SMC	T048	C0233794
27546724	404	412	recovery	T040	C2004454
27546724	416	426	population	T098	C1257890
27546724	434	440	sample	T167	C0370003
27546724	449	454	older	T098	C3826770
27546724	455	461	adults	T100	C0001675
27546724	472	477	years	T079	C0439234
27546724	484	488	good	T080	C0205170
27546724	499	520	cognitive functioning	T041	C0392335
27546724	524	532	baseline	T081	C1442488
27546724	534	538	MMSE	T060	C0451306
27546724	553	575	LifeLines Cohort Study	T081	C0009247
27546724	598	603	years	T079	C0439234
27546724	605	618	Self-reported	T062	C0681906
27546724	619	622	SMC	T048	C0233794
27546724	640	648	baseline	T081	C1442488
27546724	663	668	years	T079	C0439234
27546724	669	678	follow-up	T058	C1522577
27546724	691	709	social functioning	T054	C0037395
27546724	719	733	marital status	T102	C0024819
27546724	735	756	household composition	T033	C0595998
27546724	758	772	social network	T098	C0150775
27546724	773	777	size	T082	C0456389
27546724	779	794	social activity	T054	C2371613
27546724	796	803	quality	T080	C0332306
27546724	807	827	social relationships	T033	C1821395
27546724	829	843	social support	T054	C0037438
27546724	845	854	affection	T041	C0871641
27546724	856	866	behavioral	T053	C0004927
27546724	867	879	confirmation	T033	C0750484
27546724	885	891	status	T080	C0699806
27546724	931	934	SMC	T048	C0233794
27546724	942	951	follow-up	T058	C1522577
27546724	962	965	SMC	T048	C0233794
27546724	968	1009	Multivariate logistic regression analyses	T081	C0026777
27546724	1024	1027	age	T032	C0001779
27546724	1029	1035	gender	T032	C0079399
27546724	1037	1052	education level	T033	C1553770
27546724	1054	1071	physical activity	T056	C0026606
27546724	1073	1084	alcohol use	T055	C0001948
27546724	1086	1100	smoking status	T201	C1519386
27546724	1102	1112	depression	T048	C0011570
27546724	1114	1124	arrhythmia	T033	C0003811
27546724	1126	1147	myocardial infarction	T047	C0027051
27546724	1149	1162	heart failure	T047	C0018801
27546724	1164	1170	stroke	T047	C0038454
27546724	1184	1196	participants	T098	C0679646
27546724	1202	1208	better	T080	C0332272
27546724	1209	1217	feelings	T041	C1527305
27546724	1221	1230	affection	T041	C0871641
27546724	1232	1242	behavioral	T053	C0004927
27546724	1243	1255	confirmation	T033	C0750484
27546724	1260	1266	stable	T080	C0205360
27546724	1267	1271	good	T080	C0205170
27546724	1272	1286	social support	T054	C0037438
27546724	1293	1298	lower	T052	C2003888
27546724	1299	1303	risk	T078	C0035647
27546724	1307	1315	incident	T067	C1551358
27546724	1316	1319	SMC	T048	C0233794
27546724	1362	1370	recovery	T040	C2004454
27546724	1372	1384	Participants	T098	C0679646
27546724	1390	1394	good	T080	C0205170
27546724	1395	1413	social functioning	T054	C0037395
27546724	1417	1425	baseline	T081	C1442488
27546724	1460	1463	SMC	T048	C0233794
27546724	1464	1472	recovery	T040	C2004454
27546724	1474	1480	People	T098	C0027361
27546724	1494	1500	stable	T080	C0205360
27546724	1506	1518	relationship	T080	C0439849
27546724	1520	1526	stable	T080	C0205360
27546724	1530	1534	good	T080	C0205170
27546724	1535	1542	quality	T080	C0332306
27546724	1546	1566	social relationships	T033	C1821395
27546724	1570	1579	increased	T081	C0205217
27546724	1583	1590	quality	T080	C0332306
27546724	1594	1614	social relationships	T033	C1821395
27546724	1633	1636	SMC	T048	C0233794
27546724	1637	1645	recovery	T040	C2004454
27546724	1647	1651	Good	T080	C0205170
27546724	1652	1670	social functioning	T054	C0037395
27546724	1674	1689	associated with	T080	C0332281
27546724	1690	1694	less	T081	C0439092
27546724	1695	1703	incident	T067	C1551358
27546724	1704	1707	SMC	T048	C0233794
27546724	1712	1716	more	T081	C0205172
27546724	1717	1720	SMC	T048	C0233794
27546724	1721	1729	recovery	T040	C2004454
27546724	1737	1746	follow-up	T058	C1522577
27546724	1747	1753	period	T079	C1948053
27546724	1761	1766	years	T079	C0439234
27546724	1775	1781	future	T079	C0016884
27546724	1782	1794	confirmative	T033	C0750484
27546724	1795	1802	studies	T062	C0008972
27546724	1828	1837	targeting	T169	C1521840
27546724	1843	1861	social functioning	T054	C0037395
27546724	1867	1876	designing	T052	C1707689
27546724	1877	1902	multidomain interventions	T058	C1273869
27546724	1906	1913	prevent	T080	C2700409
27546724	1927	1944	cognitive decline	T048	C0338656

27378028|t|Demonstration and validation of a new pressure -based MRI -safe pain tolerance device
27378028|a|One of the barriers to studying the behavioral and emotional effects of pain using functional Magnetic Resonance Imaging (fMRI) is the absence of a commercially available, MRI - compatible, pressure -based algometer to elicit pain. The present study sought to address this barrier through creation and validation of a novel MRI -safe apparatus capable of delivering incremental, measurable amounts of pressure inside a scanning bore. We introduced an MR-safe device used to administer pressure -based pain. To test against a commercially available, MRI - incompatible algometer (AlgoMed), 199 participants reported their pain tolerance for both devices. A second experiment tested the validity of pressure -based pain in an MRI environment by comparing brain activation with established neural networks for pain. 10 participants performed an identical procedure to test for pain tolerance while being scanned in a 7T MRI scanner. Results support the validity and reliability of our novel device. In Study 1, pain tolerance with this device was strongly correlated with pain tolerance as measured by a commercially available algometer (r=0.78). In Study 2, this device yielded BOLD activation within the insula (BA 13) and anterior cingulate gyrus (BA 24); as pressure increased, activation in these areas parametrically increased. These findings correspond to other studies using thermal, electrical, or mechanical pain applications. Behavioral and functional data demonstrate that this new device is a valid method of administering pressure -related pain in MRI environments. Our novel MRI -safe device is a valid instrument to measure and administer pressure -based pain.
27378028	18	28	validation	T062	C1519941
27378028	38	46	pressure	T067	C0033095
27378028	54	57	MRI	T074	C0336660
27378028	64	78	pain tolerance	T033	C0162703
27378028	79	85	device	T074	C0025080
27378028	122	132	behavioral	T053	C0004927
27378028	137	146	emotional	T041	C0013987
27378028	147	154	effects	T080	C1280500
27378028	158	162	pain	T184	C0030193
27378028	169	206	functional Magnetic Resonance Imaging	T060	C0376335
27378028	208	212	fMRI	T060	C0376335
27378028	258	261	MRI	T074	C0336660
27378028	264	274	compatible	T080	C1524057
27378028	276	284	pressure	T067	C0033095
27378028	292	301	algometer	T074	C0025080
27378028	305	311	elicit	T080	C0449265
27378028	312	316	pain	T184	C0030193
27378028	410	413	MRI	T074	C0336660
27378028	420	429	apparatus	T074	C0025080
27378028	452	463	incremental	T081	C1705117
27378028	465	475	measurable	T169	C1513040
27378028	487	495	pressure	T067	C0033095
27378028	505	518	scanning bore	T074	C0183115
27378028	545	551	device	T074	C0025080
27378028	571	579	pressure	T067	C0033095
27378028	587	591	pain	T184	C0030193
27378028	596	600	test	T059	C0022885
27378028	635	638	MRI	T074	C0336660
27378028	641	653	incompatible	T080	C1524057
27378028	654	663	algometer	T074	C0025080
27378028	665	672	AlgoMed	T074	C0025080
27378028	707	721	pain tolerance	T033	C0162703
27378028	760	766	tested	T059	C0022885
27378028	783	791	pressure	T067	C0033095
27378028	799	803	pain	T184	C0030193
27378028	810	813	MRI	T074	C0336660
27378028	814	825	environment	T082	C0014406
27378028	839	844	brain	T023	C0006104
27378028	845	855	activation	T052	C1879547
27378028	873	888	neural networks	T023	C0242406
27378028	893	897	pain	T184	C0030193
27378028	951	955	test	T059	C0022885
27378028	960	964	pain	T184	C0030193
27378028	987	994	scanned	T060	C0441633
27378028	1003	1014	MRI scanner	T074	C0336660
27378028	1036	1060	validity and reliability	T080	C0035036
27378028	1074	1080	device	T074	C0025080
27378028	1094	1108	pain tolerance	T033	C0162703
27378028	1119	1125	device	T074	C0025080
27378028	1155	1169	pain tolerance	T033	C0162703
27378028	1210	1219	algometer	T074	C0025080
27378028	1247	1253	device	T074	C0025080
27378028	1262	1266	BOLD	T042	C1655730
27378028	1289	1295	insula	T023	C0021640
27378028	1297	1302	BA 13	T023	C2326439
27378028	1308	1332	anterior cingulate gyrus	T023	C0175190
27378028	1334	1339	BA 24	T029	C2334367
27378028	1345	1353	pressure	T067	C0033095
27378028	1354	1363	increased	T081	C0205217
27378028	1391	1405	parametrically	UnknownType	C0681933
27378028	1406	1415	increased	T081	C0205217
27378028	1466	1473	thermal	T061	C2032530
27378028	1475	1485	electrical	T061	C2032523
27378028	1490	1500	mechanical	T061	C0699886
27378028	1501	1518	pain applications	T184	C0521491
27378028	1520	1530	Behavioral	T053	C0004927
27378028	1535	1545	functional	T169	C0205245
27378028	1546	1550	data	T078	C1511726
27378028	1577	1583	device	T074	C0025080
27378028	1605	1618	administering	T061	C1533734
27378028	1619	1627	pressure	T067	C0033095
27378028	1637	1641	pain	T184	C0030193
27378028	1645	1648	MRI	T074	C0336660
27378028	1649	1661	environments	T082	C0014406
27378028	1673	1676	MRI	T074	C0336660
27378028	1683	1689	device	T074	C0025080
27378028	1701	1711	instrument	T074	C0348000
27378028	1715	1722	measure	T169	C0242485
27378028	1727	1737	administer	T169	C1621583
27378028	1738	1746	pressure	T067	C0033095
27378028	1754	1758	pain	T184	C0030193

27939879|t|Trends in Adolescent Overweight Perception and Its Association With Psychosomatic Health 2002-2014: Evidence From 33 Countries
27939879|a|Perceiving oneself as overweight is common and strongly associated with adolescents' subjective well-being. The prevalence of overweight perceptions and their impact on well-being may have increased over the past decade due to an increase in the salience of weight-related issues. This study examines trends (2002-2014) in the prevalence of adolescent overweight perceptions and their association with psychosomatic complaints. Data from 15-year-old adolescents were obtained between 2002 and 2014 in four rounds of the Health Behaviour in School-aged Children study in 33 countries in Europe and North America (N = 187,511). Design-adjusted logistic regressions were used to quantify changes in overweight perceptions over time. Linear modeling was used to assess change in the association between perceived overweight and self-reported psychosomatic complaint burden, adjusting for overweight status. Among boys, 10 of 33 countries saw an increase in overweight perceptions between 2002 and 2014, with Russia, Estonia, and Latvia showing the most pronounced year-on-year increases. Only England, France, Germany, and Norway saw an increase in the positive association between overweight perceptions and psychosomatic complaints among boys. Among girls, most countries (28/33) saw no change in the prevalence of overweight perceptions, with the prevalence over 40% in most nations. However, in 12 countries, the association between overweight perceptions and psychosomatic complaints increased among girls, with particularly strong changes seen in Scotland and Norway. Evidence is presented which suggests that for adolescent girls in 12 Northern and Western European countries and for boys in four perceiving oneself as overweight may be increasingly deleterious for psychosomatic health.
27939879	0	6	Trends	T079	C0040833
27939879	10	20	Adolescent	T100	C0205653
27939879	21	31	Overweight	T184	C0497406
27939879	32	42	Perception	T041	C0030971
27939879	51	62	Association	T080	C0332281
27939879	68	81	Psychosomatic	T078	C0243157
27939879	82	88	Health	T078	C0018684
27939879	100	108	Evidence	T078	C3887511
27939879	117	126	Countries	T083	C0454664
27939879	127	137	Perceiving	T041	C0030971
27939879	149	159	overweight	T184	C0497406
27939879	183	193	associated	T080	C0332281
27939879	199	211	adolescents'	T100	C0205653
27939879	212	233	subjective well-being	UnknownType	C0814111
27939879	239	249	prevalence	T081	C0220900
27939879	253	263	overweight	T184	C0497406
27939879	264	275	perceptions	T041	C0030971
27939879	286	292	impact	T080	C4049986
27939879	296	306	well-being	T078	C0018684
27939879	316	325	increased	T081	C0205217
27939879	357	365	increase	T169	C0442805
27939879	385	406	weight-related issues	T184	C0848241
27939879	428	434	trends	T079	C0040833
27939879	454	464	prevalence	T081	C0220900
27939879	468	478	adolescent	T100	C0205653
27939879	479	489	overweight	T184	C0497406
27939879	490	501	perceptions	T041	C0030971
27939879	512	523	association	T080	C0332281
27939879	529	542	psychosomatic	T078	C0243157
27939879	543	553	complaints	T184	C0871764
27939879	577	588	adolescents	T100	C0205653
27939879	647	663	Health Behaviour	T055	C0237121
27939879	667	687	School-aged Children	T100	C0008059
27939879	688	693	study	T062	C2603343
27939879	700	709	countries	T083	C0454664
27939879	713	719	Europe	T083	C0015176
27939879	724	737	North America	T083	C0028405
27939879	753	789	Design-adjusted logistic regressions	T062	C0206031
27939879	803	811	quantify	T081	C1709793
27939879	823	833	overweight	T184	C0497406
27939879	834	845	perceptions	T041	C0030971
27939879	857	872	Linear modeling	T081	C0023732
27939879	906	917	association	T080	C0332281
27939879	926	935	perceived	T041	C0030971
27939879	936	946	overweight	T184	C0497406
27939879	965	978	psychosomatic	T078	C0243157
27939879	979	995	complaint burden	T078	C2828008
27939879	1011	1021	overweight	T184	C0497406
27939879	1036	1040	boys	T100	C0870221
27939879	1051	1060	countries	T083	C0454664
27939879	1068	1076	increase	T169	C0442805
27939879	1080	1090	overweight	T184	C0497406
27939879	1091	1102	perceptions	T041	C0030971
27939879	1131	1137	Russia	T083	C0035970
27939879	1139	1146	Estonia	T083	C0014908
27939879	1152	1158	Latvia	T083	C0023128
27939879	1216	1223	England	T083	C0014282
27939879	1225	1231	France	T083	C0016674
27939879	1233	1240	Germany	T083	C0017480
27939879	1246	1252	Norway	T083	C0028423
27939879	1260	1268	increase	T169	C0442805
27939879	1276	1284	positive	T033	C1446409
27939879	1285	1296	association	T080	C0332281
27939879	1305	1315	overweight	T184	C0497406
27939879	1316	1327	perceptions	T041	C0030971
27939879	1332	1345	psychosomatic	T078	C0243157
27939879	1346	1356	complaints	T184	C0871764
27939879	1363	1367	boys	T100	C0870221
27939879	1375	1380	girls	T100	C0001588
27939879	1387	1396	countries	T083	C0454664
27939879	1409	1418	no change	T033	C0442739
27939879	1426	1436	prevalence	T081	C0220900
27939879	1440	1450	overweight	T184	C0497406
27939879	1451	1462	perceptions	T041	C0030971
27939879	1473	1483	prevalence	T081	C0220900
27939879	1501	1508	nations	T092	C1555720
27939879	1525	1534	countries	T083	C0454664
27939879	1540	1551	association	T080	C0332281
27939879	1560	1570	overweight	T184	C0497406
27939879	1571	1582	perceptions	T041	C0030971
27939879	1587	1600	psychosomatic	T078	C0243157
27939879	1601	1611	complaints	T184	C0871764
27939879	1612	1621	increased	T081	C0205217
27939879	1628	1633	girls	T098	C0043210
27939879	1653	1667	strong changes	T081	C0443172
27939879	1676	1684	Scotland	T083	C0036453
27939879	1689	1695	Norway	T083	C0028423
27939879	1743	1759	adolescent girls	T100	C0001588
27939879	1766	1774	Northern	T083	C0028413
27939879	1779	1786	Western	T083	C0043129
27939879	1787	1805	European countries	T083	C0454713
27939879	1814	1818	boys	T100	C0870221
27939879	1827	1837	perceiving	T041	C0030971
27939879	1849	1859	overweight	T184	C0497406
27939879	1896	1909	psychosomatic	T078	C0243157

27659602|t|The Aortic Root: Natural History After Root-Sparing Ascending Replacement in Nonsyndromic Aneurysmal Patients
27659602|a|Leaving native aortic tissue in situ in root-sparing ascending aortic replacement raises concern regarding potential later need for root reoperation or for the potential occurrence of localized dissections or rupture in the residual root. The purpose of this study was to evaluate the natural growth of the aortic root after root-sparing aortic replacement. In all, 102 consecutive patients (mean age 61.8 ± 12.5 years; 60% male) who had undergone root-sparing aortic replacement had sufficient retrievable information regarding their aortic root diameter at postoperative baseline and follow-up imaging by computed tomography or echocardiography. The annual growth rate was evaluated and also compared according to the influence of valve morphology and concomitant aortic valve replacement. Furthermore, the years of natural history that would require for root enlargement to meet a 50 mm threshold of the root diameter were calculated. The estimated growth rate of the aortic root after root-sparing aortic replacement is between 0.27 and 0.51 mm per year (mean 0.41 mm, varying according to the underlying diameter) and therefore fivefold less than other aortic regions. Accordingly, a root aneurysm indicating reoperation would not be expected for 29.1 years on average. Only patients with a diameter of 45 mm or more are at risk for reoperation, and not until at least after 10.4 years have passed. Neither the valve morphology (p = 0.62) nor concomitant aortic valve replacement (p = 0.86) influenced rate of root dilation. In nonsyndromic patients, the aortic root is the slowest growing portion of the thoracic aorta. Leaving the native root, as in root-sparing ascending aortic replacement, is a safe approach regarding secondary root intervention for aortic root diameters of 45 mm or less.
27659602	4	15	Aortic Root	T029	C0549113
27659602	17	32	Natural History	T090	C0175860
27659602	39	73	Root-Sparing Ascending Replacement	T061	C0729662
27659602	77	89	Nonsyndromic	T033	C2677304
27659602	90	109	Aneurysmal Patients	T101	C0030705
27659602	118	124	native	T169	C0302891
27659602	125	138	aortic tissue	T024	C0040300
27659602	139	146	in situ	T082	C0444498
27659602	150	191	root-sparing ascending aortic replacement	T061	C0729662
27659602	199	206	concern	T078	C2699424
27659602	217	226	potential	T080	C3245505
27659602	227	232	later	T079	C0205087
27659602	233	237	need	T080	C0027552
27659602	242	246	root	T029	C0549113
27659602	247	258	reoperation	T061	C0035110
27659602	270	279	potential	T080	C3245505
27659602	280	290	occurrence	T079	C2745955
27659602	294	303	localized	T082	C0392752
27659602	304	315	dissections	T047	C0340643
27659602	319	326	rupture	T037	C3203359
27659602	334	342	residual	T080	C1609982
27659602	343	347	root	T029	C0549113
27659602	353	374	purpose of this study	UnknownType	C0681832
27659602	382	390	evaluate	T058	C0184514
27659602	395	409	natural growth	T040	C0018270
27659602	417	428	aortic root	T029	C0549113
27659602	435	466	root-sparing aortic replacement	T061	C0729662
27659602	480	491	consecutive	T080	C1707491
27659602	492	500	patients	T101	C0030705
27659602	502	506	mean	T081	C0444504
27659602	507	510	age	T032	C0001779
27659602	523	528	years	T079	C0439234
27659602	534	538	male	T098	C0025266
27659602	558	589	root-sparing aortic replacement	T061	C0729662
27659602	594	604	sufficient	T080	C0205410
27659602	605	628	retrievable information	T078	C1533716
27659602	645	656	aortic root	T029	C0549113
27659602	657	665	diameter	T081	C1301886
27659602	669	682	postoperative	T079	C0032790
27659602	683	691	baseline	T081	C1442488
27659602	696	705	follow-up	T058	C1522577
27659602	706	713	imaging	T060	C0079595
27659602	717	736	computed tomography	T060	C0040405
27659602	740	756	echocardiography	T060	C0013516
27659602	762	768	annual	T079	C0332181
27659602	769	780	growth rate	T079	C0449249
27659602	785	794	evaluated	T052	C1516048
27659602	804	812	compared	T052	C1707455
27659602	830	839	influence	T077	C4054723
27659602	843	859	valve morphology	T080	C0332437
27659602	864	875	concomitant	T079	C0521115
27659602	876	900	aortic valve replacement	T061	C0003506
27659602	919	924	years	T079	C0439234
27659602	928	943	natural history	T090	C0175860
27659602	955	962	require	T169	C1514873
27659602	967	971	root	T029	C0549113
27659602	972	983	enlargement	T190	C2711450
27659602	997	999	mm	T081	C0439200
27659602	1000	1009	threshold	T080	C0449864
27659602	1017	1021	root	T029	C0549113
27659602	1022	1030	diameter	T081	C1301886
27659602	1036	1046	calculated	T052	C1441506
27659602	1052	1061	estimated	T081	C0750572
27659602	1062	1073	growth rate	T079	C0449249
27659602	1081	1092	aortic root	T029	C0549113
27659602	1099	1130	root-sparing aortic replacement	T061	C0729662
27659602	1156	1158	mm	T081	C0439200
27659602	1159	1167	per year	T079	C0439508
27659602	1169	1173	mean	T081	C0444504
27659602	1179	1181	mm	T081	C0439200
27659602	1208	1227	underlying diameter	T081	C1301886
27659602	1252	1261	less than	T081	C0439092
27659602	1268	1282	aortic regions	T029	C0225914
27659602	1299	1312	root aneurysm	T047	C1298820
27659602	1324	1335	reoperation	T061	C0035110
27659602	1349	1357	expected	T170	C1517001
27659602	1367	1372	years	T079	C0439234
27659602	1376	1383	average	T081	C1510992
27659602	1390	1398	patients	T101	C0030705
27659602	1406	1414	diameter	T081	C1301886
27659602	1421	1423	mm	T081	C0439200
27659602	1436	1443	at risk	T080	C1444641
27659602	1448	1459	reoperation	T061	C0035110
27659602	1469	1474	until	T170	C1720302
27659602	1484	1489	after	T079	C0687676
27659602	1495	1500	years	T079	C0439234
27659602	1501	1512	have passed	T033	C2828386
27659602	1514	1521	Neither	T080	C4284892
27659602	1526	1542	valve morphology	T080	C0332437
27659602	1558	1569	concomitant	T079	C0521115
27659602	1570	1594	aortic valve replacement	T061	C0003506
27659602	1606	1616	influenced	T077	C4054723
27659602	1617	1621	rate	T081	C1521828
27659602	1625	1638	root dilation	T047	C1866956
27659602	1643	1655	nonsyndromic	T033	C2677304
27659602	1656	1664	patients	T101	C0030705
27659602	1670	1681	aortic root	T029	C0549113
27659602	1689	1696	slowest	T080	C0439834
27659602	1697	1704	growing	T040	C0018270
27659602	1705	1712	portion	T082	C0449719
27659602	1720	1734	thoracic aorta	T023	C1522460
27659602	1748	1754	native	T169	C0302891
27659602	1755	1759	root	T029	C0549113
27659602	1767	1808	root-sparing ascending aortic replacement	T061	C0729662
27659602	1815	1828	safe approach	T082	C0449445
27659602	1839	1853	secondary root	T029	C0549113
27659602	1854	1866	intervention	T061	C0184661
27659602	1871	1882	aortic root	T029	C0549113
27659602	1883	1892	diameters	T081	C1301886
27659602	1899	1901	mm	T081	C0439200

27580908|t|Assessing the learning potential of an interactive digital game versus an interactive-style didactic lecture: the continued importance of didactic teaching in medical student education
27580908|a|Games with educational intent offer a possible advantage of being more interactive and increasing learner satisfaction. We conducted a two-armed experiment to evaluate student satisfaction and content mastery for an introductory pediatric radiology topic, taught by either an interactive digital game or with a traditional didactic lecture. Medical students participating in a fourth-year radiology elective were invited to participate. Student cohorts were alternatively given a faculty - supervised 1h session playing a simple interactive digital Tic-tac-toe quiz module on pediatric gastrointestinal radiology or a 1h didactic introductory lecture on the same topic. Survey questions assessed the learners' perceived ability to recall the material as well as their satisfaction with the educational experience. Results of an end-of-rotation exam were reviewed to evaluate a quantitative measure of learning between groups. Survey responses were analyzed with a chi-squared test. Exam results for both groups were analyzed with a paired Student's t-test. Students in the lecture group had higher test scores compared to students in the game group (4.0/5 versus 3.6/5, P = 0.045). Students in the lecture group reported greater understanding and recall of the material than students in the game group (P < 0.001 and P = 0.004, respectively). Students in the lecture group perceived the lecture to be more enjoyable and a better use of their time compared to those in the game group (P = 0.04 and P < 0.001, respectively). There was no statistically significant difference between the lecture and game group in ability to maintain interest (P = 0.187). In comparison to pre-survey results, there was a statistically significant decrease in interest for further digital interactive materials reported by students in the game group (P = 0.146). Our experience supported the use of a traditional lecture over a digital game module. While these results might be affected by the specific lecture and digital content in any given comparison, a digital module is not always the superior option.
27580908	0	9	Assessing	T058	C0184514
27580908	14	22	learning	T041	C0023185
27580908	23	32	potential	T080	C3245505
27580908	39	50	interactive	T065	C0815244
27580908	51	63	digital game	T073	C0870328
27580908	74	91	interactive-style	T065	C0815244
27580908	92	100	didactic	T080	C0205556
27580908	101	108	lecture	T170	C0376683
27580908	138	146	didactic	T080	C0205556
27580908	147	155	teaching	T065	C0039401
27580908	159	174	medical student	T097	C0038495
27580908	175	184	education	T065	C0013621
27580908	185	190	Games	T056	C0150593
27580908	196	207	educational	T065	C0013621
27580908	223	231	possible	T033	C0332149
27580908	256	267	interactive	T065	C0815244
27580908	272	282	increasing	T081	C0205217
27580908	283	290	learner	T098	C1257890
27580908	291	303	satisfaction	T041	C0242428
27580908	320	340	two-armed experiment	T062	C0681814
27580908	344	352	evaluate	T058	C0220825
27580908	353	360	student	T098	C0038492
27580908	361	373	satisfaction	T041	C0242428
27580908	378	385	content	T077	C0456205
27580908	386	393	mastery	T041	C0870851
27580908	414	433	pediatric radiology	T091	C1518934
27580908	434	439	topic	T170	C1555712
27580908	441	447	taught	T080	C0348054
27580908	461	472	interactive	T065	C0815244
27580908	473	485	digital game	T073	C0870328
27580908	496	507	traditional	T169	C0443324
27580908	508	516	didactic	T080	C0205556
27580908	517	524	lecture	T170	C0376683
27580908	526	542	Medical students	T097	C0038495
27580908	543	556	participating	T169	C0679823
27580908	574	583	radiology	T091	C0034599
27580908	584	592	elective	T079	C0439608
27580908	609	620	participate	T169	C0679823
27580908	622	629	Student	T098	C0038492
27580908	630	637	cohorts	T098	C0599755
27580908	643	656	alternatively	T077	C1523987
27580908	665	672	faculty	T097	C0015535
27580908	675	685	supervised	T065	C0039401
27580908	689	696	session	T077	C1883017
27580908	697	704	playing	T056	C0032214
27580908	714	725	interactive	T065	C0815244
27580908	726	733	digital	T080	C1883674
27580908	734	745	Tic-tac-toe	T056	C0150593
27580908	746	757	quiz module	T077	C1709061
27580908	761	797	pediatric gastrointestinal radiology	T060	C0203054
27580908	806	814	didactic	T080	C0205556
27580908	828	835	lecture	T170	C0376683
27580908	848	853	topic	T170	C1555712
27580908	855	861	Survey	T170	C0038951
27580908	862	871	questions	T170	C1522634
27580908	872	880	assessed	T052	C1516048
27580908	885	894	learners'	T098	C1257890
27580908	895	904	perceived	T041	C0030971
27580908	905	922	ability to recall	T201	C1718058
27580908	927	935	material	T167	C0520510
27580908	953	965	satisfaction	T041	C0242428
27580908	975	986	educational	T065	C0013621
27580908	987	997	experience	T041	C0596545
27580908	1013	1028	end-of-rotation	T079	C1254367
27580908	1029	1033	exam	T169	C4284036
27580908	1039	1047	reviewed	T080	C1709940
27580908	1051	1059	evaluate	T058	C0220825
27580908	1062	1082	quantitative measure	T081	C0034384
27580908	1086	1094	learning	T041	C0023185
27580908	1103	1109	groups	T078	C0441833
27580908	1111	1117	Survey	T170	C0038951
27580908	1118	1127	responses	T041	C2911692
27580908	1133	1141	analyzed	T062	C0936012
27580908	1149	1165	chi-squared test	T170	C0008041
27580908	1167	1171	Exam	T169	C4284036
27580908	1189	1195	groups	T078	C0441833
27580908	1201	1209	analyzed	T062	C0936012
27580908	1224	1240	Student's t-test	T081,T170	C0871453
27580908	1242	1250	Students	T098	C0038492
27580908	1258	1265	lecture	T170	C0376683
27580908	1266	1271	group	T078	C0441833
27580908	1276	1282	higher	T080	C0205250
27580908	1283	1294	test scores	T080	C0237855
27580908	1295	1303	compared	T052	C1707455
27580908	1307	1315	students	T098	C0038492
27580908	1323	1327	game	T056	C0150593
27580908	1328	1333	group	T078	C0441833
27580908	1367	1375	Students	T098	C0038492
27580908	1383	1390	lecture	T170	C0376683
27580908	1391	1396	group	T078	C0441833
27580908	1397	1405	reported	T058	C0700287
27580908	1406	1413	greater	T081	C1704243
27580908	1414	1427	understanding	T041	C0162340
27580908	1432	1438	recall	T041	C0034770
27580908	1446	1454	material	T167	C0520510
27580908	1460	1468	students	T098	C0038492
27580908	1476	1480	game	T056	C0150593
27580908	1481	1486	group	T078	C0441833
27580908	1528	1536	Students	T098	C0038492
27580908	1544	1551	lecture	T170	C0376683
27580908	1552	1557	group	T078	C0441833
27580908	1558	1567	perceived	T041	C0030971
27580908	1572	1579	lecture	T170	C0376683
27580908	1591	1600	enjoyable	T033	C3843343
27580908	1627	1631	time	T079	C0040223
27580908	1632	1640	compared	T052	C1707455
27580908	1657	1661	game	T056	C0150593
27580908	1662	1667	group	T078	C0441833
27580908	1721	1746	statistically significant	T081	C0237881
27580908	1747	1757	difference	T033	C3842396
27580908	1770	1777	lecture	T170	C0376683
27580908	1782	1786	game	T056	C0150593
27580908	1787	1792	group	T078	C0441833
27580908	1796	1803	ability	T032	C0085732
27580908	1816	1824	interest	T054	C0162400
27580908	1855	1865	pre-survey	T079	C1254367
27580908	1887	1912	statistically significant	T081	C0237881
27580908	1913	1921	decrease	T081	C0547047
27580908	1925	1933	interest	T054	C0162400
27580908	1946	1953	digital	T080	C1883674
27580908	1954	1965	interactive	T065	C0815244
27580908	1966	1975	materials	T167	C0520510
27580908	1976	1984	reported	T058	C0700287
27580908	1988	1996	students	T098	C0038492
27580908	2004	2008	game	T056	C0150593
27580908	2009	2014	group	T078	C0441833
27580908	2032	2042	experience	T041	C0596545
27580908	2066	2077	traditional	T169	C0443324
27580908	2078	2085	lecture	T170	C0376683
27580908	2093	2105	digital game	T073	C0870328
27580908	2143	2151	affected	T169	C0392760
27580908	2159	2167	specific	T080	C0205369
27580908	2168	2175	lecture	T170	C0376683
27580908	2180	2187	digital	T080	C1883674
27580908	2188	2195	content	T077	C0456205
27580908	2209	2219	comparison	T052	C1707455
27580908	2223	2230	digital	T080	C1883674
27580908	2231	2237	module	T077	C1709061

27484604|t|Evaluation of Spontaneous Bone Regeneration after Enucleation of Large Cysts of the Jaws using Radiographic Computed Software
27484604|a|Spontaneous regeneration of bone is commonly seen in the small surgical defects caused by enucleation of cysts. However, in case of large surgical defects caused by the enucleation, spontaneous regeneration of bone is a rare phenomenon and it depends on factors, such as age of the patient, intact periosteum, and proper stabilization. The study included 16 patients, who reported to the department of oral and maxillofacial surgery with the complaint of pain and swelling in the jaws diagnosed as cyst. The sample included equal numbers of male and female subjects aged between 15 and 40 years. Panoramic radiographs were taken pre- and postoperatively on day 2 of the enucleation. The dimensions of the cyst were evaluated on the radiograph according to the proforma. Subsequent radiographs were taken at regular intervals of 1.5, 3, and 6 months using standard parameters and were analyzed using MCID™ analysis software of imaging research. Mean reduction was seen in up to 39 and 60% in the cystic cavity size and increase in the mean density up to 59 and 90.2% at 3 and 6 months intervals respectively. Spontaneous bone regeneration was seen even after primary closure of the large cystic defect without the need for placement of foreign substances or grafts and it also eliminated the complications resulting from placement of foreign substance. Further studies are required in a larger sample with longer follow-up durations to confirm the outcome of the present work for the benefit of patients. The present study depicted that spontaneous bone regeneration can occur with accepted results after simple enucleation of jaw cyst without the aid of any graft material. Hence, simple enucleation may be considered as a first line of treatment modality for cystic lesion of the jaws. This simplifies the surgical procedure, decreases the economic and biologic costs, and reduces the risk of postoperative complications. Follow-up is necessary along with patient's compliance for the success of treatment.
27484604	0	10	Evaluation	T058	C0220825
27484604	14	25	Spontaneous	T169	C0205359
27484604	26	43	Bone Regeneration	T042	C0005972
27484604	50	61	Enucleation	T061	C0014392
27484604	65	70	Large	T081	C0549177
27484604	71	76	Cysts	T047	C0010709
27484604	84	88	Jaws	T023	C0022359
27484604	95	107	Radiographic	T070	C0444708
27484604	108	116	Computed	T059	C1441526
27484604	117	125	Software	T073,T170	C0037585
27484604	126	137	Spontaneous	T169	C0205359
27484604	138	158	regeneration of bone	T042	C0005972
27484604	162	170	commonly	T081	C0205214
27484604	183	188	small	T081	C0700321
27484604	189	197	surgical	T061	C0543467
27484604	198	205	defects	T169	C1457869
27484604	216	227	enucleation	T061	C0014392
27484604	231	236	cysts	T047	C0010709
27484604	258	263	large	T081	C0549177
27484604	264	272	surgical	T061	C0543467
27484604	273	280	defects	T169	C1457869
27484604	295	306	enucleation	T061	C0014392
27484604	308	319	spontaneous	T169	C0205359
27484604	320	340	regeneration of bone	T042	C0005972
27484604	346	350	rare	T080	C0522498
27484604	351	361	phenomenon	T067	C1882365
27484604	369	376	depends	T080	C1701901
27484604	380	387	factors	T169	C1521761
27484604	397	400	age	T032	C0001779
27484604	408	415	patient	T101	C0030705
27484604	417	423	intact	T080	C0205266
27484604	424	434	periosteum	T024	C0031110
27484604	447	460	stabilization	T061	C1293130
27484604	466	471	study	T062	C2603343
27484604	472	480	included	T169	C0332257
27484604	484	492	patients	T101	C0030705
27484604	498	506	reported	T058	C0700287
27484604	514	558	department of oral and maxillofacial surgery	T073,T093	C0019961
27484604	568	577	complaint	T047	C0012634
27484604	581	585	pain	T184	C0030193
27484604	590	598	swelling	T033	C0038999
27484604	606	610	jaws	T023	C0022359
27484604	611	620	diagnosed	T033	C0011900
27484604	624	628	cyst	T047	C0010709
27484604	634	640	sample	T077	C2347026
27484604	641	649	included	T169	C0332257
27484604	656	663	numbers	T081	C0237753
27484604	667	671	male	T032	C0086582
27484604	676	682	female	T032	C0086287
27484604	683	691	subjects	T096	C0681850
27484604	692	696	aged	T032	C0001779
27484604	722	743	Panoramic radiographs	T060	C0034579
27484604	755	759	pre-	T079	C0445204
27484604	764	779	postoperatively	T079	C0032790
27484604	796	807	enucleation	T061	C0014392
27484604	813	823	dimensions	T081	C0439534
27484604	831	835	cyst	T047	C0010709
27484604	841	850	evaluated	T058	C0220825
27484604	858	868	radiograph	T060	C1306645
27484604	886	894	proforma	T169	C0205245
27484604	896	906	Subsequent	T079	C0332282
27484604	907	918	radiographs	T060	C1306645
27484604	933	940	regular	T080	C0205272
27484604	941	950	intervals	T079	C1272706
27484604	981	989	standard	T081	C0034925
27484604	990	1000	parameters	T077	C0549193
27484604	1010	1018	analyzed	T062	C0936012
27484604	1025	1039	MCID™ analysis	T170	C3203917
27484604	1040	1048	software	T073,T170	C0037585
27484604	1052	1068	imaging research	T060	C1881134
27484604	1070	1074	Mean	T081	C0444504
27484604	1075	1084	reduction	T061	C0441610
27484604	1121	1127	cystic	T080	C0205207
27484604	1128	1134	cavity	T190	C1510420
27484604	1135	1139	size	T082	C0456389
27484604	1144	1152	increase	T169	C0442805
27484604	1160	1164	mean	T081	C0444504
27484604	1165	1172	density	T081	C0178587
27484604	1210	1219	intervals	T079	C1272706
27484604	1234	1245	Spontaneous	T169	C0205359
27484604	1246	1263	bone regeneration	T042	C0005972
27484604	1284	1291	primary	T080	C0205225
27484604	1292	1299	closure	T061	C0185003
27484604	1307	1312	large	T081	C0549177
27484604	1313	1319	cystic	T080	C0205207
27484604	1320	1326	defect	T169	C1457869
27484604	1339	1343	need	T080	C0027552
27484604	1348	1357	placement	T058	C0441587
27484604	1361	1379	foreign substances	T167	C0729652
27484604	1383	1389	grafts	T122	C0181074
27484604	1402	1412	eliminated	T080	C0849355
27484604	1417	1430	complications	T046	C0009566
27484604	1431	1445	resulting from	T169	C0678226
27484604	1446	1455	placement	T058	C0441587
27484604	1459	1476	foreign substance	T167	C0729652
27484604	1486	1493	studies	T062	C2603343
27484604	1498	1506	required	T169	C1514873
27484604	1512	1518	larger	T081	C0549177
27484604	1519	1525	sample	T077	C2347026
27484604	1531	1537	longer	T080	C0205166
27484604	1538	1547	follow-up	T058	C1522577
27484604	1548	1557	durations	T079	C0449238
27484604	1561	1568	confirm	T080	C1456348
27484604	1573	1600	outcome of the present work	T080	C0085415
27484604	1609	1616	benefit	T081	C0814225
27484604	1620	1628	patients	T101	C0030705
27484604	1634	1641	present	T079	C0521116
27484604	1642	1647	study	T062	C2603343
27484604	1662	1673	spontaneous	T169	C0205359
27484604	1674	1691	bone regeneration	T042	C0005972
27484604	1707	1715	accepted	T080	C1272684
27484604	1716	1723	results	T033	C0808233
27484604	1730	1736	simple	T080	C0205352
27484604	1737	1748	enucleation	T061	C0014392
27484604	1752	1755	jaw	T023	C0022359
27484604	1756	1760	cyst	T047	C0010709
27484604	1773	1776	aid	T080	C1269765
27484604	1784	1798	graft material	T122	C0181074
27484604	1807	1813	simple	T080	C0205352
27484604	1814	1825	enucleation	T061	C0014392
27484604	1833	1843	considered	T078	C0750591
27484604	1849	1872	first line of treatment	T061	C1708063
27484604	1873	1881	modality	T078	C0695347
27484604	1886	1892	cystic	T080	C0205207
27484604	1893	1899	lesion	T033	C0221198
27484604	1907	1911	jaws	T023	C0022359
27484604	1933	1951	surgical procedure	T061	C0543467
27484604	1953	1962	decreases	T081	C0547047
27484604	1967	1975	economic	T169	C0013557
27484604	1980	1988	biologic	T080	C0205460
27484604	1989	1994	costs	T081	C0010186
27484604	2000	2007	reduces	T061	C0441610
27484604	2012	2016	risk	T078	C0035647
27484604	2020	2047	postoperative complications	T046	C0032787
27484604	2049	2058	Follow-up	T058	C1522577
27484604	2083	2092	patient's	T101	C0030705
27484604	2093	2103	compliance	T055	C1321605
27484604	2112	2132	success of treatment	T080	C0679864

27997759|t|Down-regulation of cladofulvin biosynthesis is required for biotrophic growth of Cladosporium fulvum on tomato
27997759|a|Fungal biotrophy is associated with a reduced capacity to produce potentially toxic secondary metabolites (SMs). Yet, the genome of the biotrophic plant pathogen Cladosporium fulvum contains many SM biosynthetic gene clusters, with several related to toxin production. These gene clusters are, however, poorly expressed during the colonization of tomato. The sole detectable SM produced by C. fulvum during in vitro growth is the anthraquinone cladofulvin. Although this pigment is not detected in infected leaves, cladofulvin biosynthetic genes are expressed throughout the pre-penetration phase and during conidiation at the end of the infection cycle, but are repressed during the biotrophic phase of tomato colonization. It has been suggested that the tight regulation of SM gene clusters is required for C. fulvum to behave as a biotrophic pathogen, whilst retaining potential fitness determinants for growth and survival outside its host. To address this hypothesis, we analysed the disease symptoms caused by mutant C. fulvum strains that do not produce or over-produce cladofulvin during the biotrophic growth phase. Non-producers infected tomato in a similar manner to the wild-type, suggesting that cladofulvin is not a virulence factor. In contrast, the cladofulvin over-producers caused strong necrosis and desiccation of tomato leaves, which, in turn, arrested conidiation. Consistent with the role of pigments in survival against abiotic stresses, cladofulvin protects conidia against UV light and low-temperature stress. Overall, this study demonstrates that the repression of cladofulvin production is required for C. fulvum to sustain its biotrophic lifestyle in tomato, whereas its production is important for survival outside its host.
27997759	0	15	Down-regulation	T044	C0013081
27997759	19	30	cladofulvin	T123	C0574031
27997759	31	43	biosynthesis	T038	C0220781
27997759	60	77	biotrophic growth	T040	C0018270
27997759	81	100	Cladosporium fulvum	T004	C0997666
27997759	104	110	tomato	T002	C1140676
27997759	111	127	Fungal biotrophy	T004	C3826297
27997759	131	146	associated with	T080	C0332281
27997759	149	156	reduced	T080	C0392756
27997759	177	188	potentially	T080	C3245505
27997759	189	194	toxic	T080	C1407029
27997759	195	216	secondary metabolites	T123	C0870883
27997759	218	221	SMs	T123	C0870883
27997759	233	239	genome	T028	C0017428
27997759	247	263	biotrophic plant	T002	C0032098
27997759	264	272	pathogen	T001	C0450254
27997759	273	292	Cladosporium fulvum	T004	C0997666
27997759	307	309	SM	T123	C0870883
27997759	310	322	biosynthetic	T038	C0220781
27997759	323	336	gene clusters	T028	C0017258
27997759	362	378	toxin production	T131	C0444622
27997759	386	399	gene clusters	T028	C0017258
27997759	414	420	poorly	T080	C0542537
27997759	421	430	expressed	T045	C0017262
27997759	442	454	colonization	T033	C4289767
27997759	458	464	tomato	T002	C1140676
27997759	486	488	SM	T123	C0870883
27997759	501	510	C. fulvum	T004	C0997666
27997759	518	526	in vitro	T080	C1533691
27997759	527	533	growth	T040	C0018270
27997759	541	566	anthraquinone cladofulvin	T123	C0574031
27997759	582	589	pigment	T120	C0031916
27997759	593	605	not detected	T033	C0442737
27997759	609	617	infected	T033	C0439663
27997759	618	624	leaves	T002	C0242724
27997759	626	637	cladofulvin	T123	C0574031
27997759	638	650	biosynthetic	T038	C0220781
27997759	651	656	genes	T028	C0017337
27997759	661	670	expressed	T045	C0017262
27997759	686	707	pre-penetration phase	T079	C0205390
27997759	719	730	conidiation	T043	C2613267
27997759	749	764	infection cycle	T046	C3714514
27997759	774	783	repressed	T169	C1260953
27997759	795	811	biotrophic phase	T079	C0205390
27997759	815	821	tomato	T002	C1140676
27997759	822	834	colonization	T033	C4289767
27997759	867	883	tight regulation	T038	C1327622
27997759	887	889	SM	T123	C0870883
27997759	890	903	gene clusters	T028	C0017258
27997759	920	929	C. fulvum	T004	C0997666
27997759	945	964	biotrophic pathogen	T001	C0450254
27997759	983	992	potential	T080	C3245505
27997759	993	1013	fitness determinants	T169	C1521761
27997759	1018	1024	growth	T040	C0018270
27997759	1029	1037	survival	T052	C0038952
27997759	1050	1054	host	T001	C1167395
27997759	1100	1107	disease	T047	C0012634
27997759	1108	1116	symptoms	T184	C1457887
27997759	1127	1133	mutant	T049	C0596988
27997759	1134	1143	C. fulvum	T004	C0997666
27997759	1144	1151	strains	T001	C1518614
27997759	1188	1199	cladofulvin	T123	C0574031
27997759	1211	1228	biotrophic growth	T040	C0018270
27997759	1229	1234	phase	T079	C0205390
27997759	1236	1249	Non-producers	T033	C0243095
27997759	1259	1265	tomato	T002	C1140676
27997759	1293	1302	wild-type	T028	C1883559
27997759	1320	1331	cladofulvin	T123	C0574031
27997759	1341	1357	virulence factor	T109,T123,T131	C1136170
27997759	1376	1387	cladofulvin	T123	C0574031
27997759	1388	1402	over-producers	T033	C0243095
27997759	1417	1425	necrosis	T042	C0027540
27997759	1430	1441	desiccation	T070	C0011682
27997759	1445	1451	tomato	T002	C1140676
27997759	1452	1458	leaves	T002	C0242724
27997759	1485	1496	conidiation	T043	C2613267
27997759	1526	1534	pigments	T120	C0031916
27997759	1538	1546	survival	T052	C0038952
27997759	1555	1571	abiotic stresses	T046	C0449430
27997759	1573	1584	cladofulvin	T123	C0574031
27997759	1585	1593	protects	T033	C1545588
27997759	1594	1601	conidia	T004	C0521049
27997759	1610	1618	UV light	T070	C0041625
27997759	1623	1645	low-temperature stress	T046	C0449430
27997759	1689	1699	repression	T169	C1260953
27997759	1703	1714	cladofulvin	T123	C0574031
27997759	1715	1725	production	T057	C0033268
27997759	1742	1751	C. fulvum	T004	C0997666
27997759	1767	1787	biotrophic lifestyle	T038	C3714634
27997759	1791	1797	tomato	T002	C1140676
27997759	1811	1821	production	T057	C0033268
27997759	1839	1847	survival	T052	C0038952
27997759	1860	1864	host	T001	C1167395

28179308|t|Renieramycin M Attenuates Cancer Stem Cell -like Phenotypes in H460 Lung Cancer Cells
28179308|a|Cancer stem cells (CSCs) are a subpopulation of cancer cells that possess self-renewal and differentiation capacities. CSCs contribute to drug-resistance, cancer recurrence and metastasis, thus development of CSC -targeted therapeutic strategies has recently received significant attention in cancer research. In this study, the potential efficacy of renieramycin M (RM) isolated from the sponge Xestospongia species, was examined against lung CSCs. Colony and spheroid formation assays, as well as western blotting analysis of lung CSC protein markers were employed to determine the CSC -like phenotypes of H460 lung cancer cells after treatment with RM at non-toxic concentrations. RM treatment reduced significantly colony and spheroid formation of H460 cells. Moreover, the CSC markers CD133, CD44 and ALDH1A1 of CSC -enriched H460 cells were reduced significantly following RM treatment. RM could be a potent anti-metastatic agent by suppressing lung CSC -like phenotypes in H460 cells.
28179308	0	14	Renieramycin M	T109	C1435644
28179308	26	42	Cancer Stem Cell	T025	C1956422
28179308	49	59	Phenotypes	T032	C0031437
28179308	63	67	H460	T025	C0597032
28179308	68	72	Lung	T023	C0024109
28179308	73	85	Cancer Cells	T025	C0597032
28179308	86	103	Cancer stem cells	T025	C1956422
28179308	105	109	CSCs	T025	C1956422
28179308	134	146	cancer cells	T025	C0597032
28179308	160	172	self-renewal	T043	C1155711
28179308	177	192	differentiation	T043	C0007589
28179308	205	209	CSCs	T025	C1956422
28179308	224	239	drug-resistance	T038	C0013203
28179308	241	258	cancer recurrence	T191	C0920420
28179308	263	273	metastasis	T046	C4255448
28179308	280	291	development	T169	C1527148
28179308	295	298	CSC	T025	C1956422
28179308	309	331	therapeutic strategies	T061	C0087111
28179308	379	394	cancer research	T062	C1516225
28179308	404	409	study	T062	C2603343
28179308	425	433	efficacy	T080	C1280519
28179308	437	451	renieramycin M	T109	C1435644
28179308	453	455	RM	T109	C1435644
28179308	475	481	sponge	T204	C0032699
28179308	482	502	Xestospongia species	T204	C1204055
28179308	508	516	examined	T033	C0332128
28179308	525	529	lung	T023	C0024109
28179308	530	534	CSCs	T025	C1956422
28179308	536	572	Colony and spheroid formation assays	T059	C0005507
28179308	585	610	western blotting analysis	T059,T063	C0005863
28179308	614	618	lung	T023	C0024109
28179308	619	622	CSC	T025	C1956422
28179308	623	630	protein	T116,T123	C0033684
28179308	631	638	markers	T123	C0041365
28179308	670	673	CSC	T025	C1956422
28179308	680	690	phenotypes	T032	C0031437
28179308	694	698	H460	T025	C0597032
28179308	699	703	lung	T023	C0024109
28179308	704	716	cancer cells	T025	C0597032
28179308	723	732	treatment	T061	C0087111
28179308	738	740	RM	T109	C1435644
28179308	744	768	non-toxic concentrations	UnknownType	C0678563
28179308	770	772	RM	T109	C1435644
28179308	773	782	treatment	T061	C0087111
28179308	805	834	colony and spheroid formation	T059	C0005507
28179308	838	848	H460 cells	T025	C0597032
28179308	864	867	CSC	T025	C1956422
28179308	868	875	markers	T123	C0041365
28179308	876	881	CD133	T116,T123	C0673026
28179308	883	887	CD44	T116,T129	C1097299
28179308	892	899	ALDH1A1	T116,T126	C1721673
28179308	903	906	CSC	T025	C1956422
28179308	917	927	H460 cells	T025	C0597032
28179308	965	967	RM	T109	C1435644
28179308	968	977	treatment	T061	C0087111
28179308	979	981	RM	T109	C1435644
28179308	1000	1021	anti-metastatic agent	T121	C1516021
28179308	1037	1041	lung	T023	C0024109
28179308	1042	1045	CSC	T025	C1956422
28179308	1052	1062	phenotypes	T032	C0031437
28179308	1066	1076	H460 cells	T025	C0597032

28521617|t|Fingerprint -based background checks for personal care workers: Stakeholder views of policy criteria
28521617|a|Decision makers face difficult choices when tasked with identifying and implementing appropriate mechanisms for protecting the elderly and other vulnerable adults from abuse. A pilot project involving fingerprint -based criminal history background checks for personal care workers in Michigan has supplied an opportunity to examine one such mechanism. In conjunction with the pilot project, we have conducted a stakeholder analysis with the aim of informing decision makers about stakeholder perceptions of standard policy criteria like effectiveness, efficiency, and equity. We employed focus groups and a web-based survey to collect data from stakeholders. While stakeholders generally see fingerprint -based background checks for personal care workers as potentially effective and as a net benefit, they also point to a variety of contingencies. They also recognize difficulties and constraints for government involvement. This preliminary analysis provides solid foundational information for decision makers and for more extensive benefit-cost analysis.
28521617	0	11	Fingerprint	T073	C0016126
28521617	19	36	background checks	T033	C0243095
28521617	41	62	personal care workers	T097	C1522486
28521617	64	75	Stakeholder	T098	C0027361
28521617	76	81	views	T078	C1254370
28521617	85	91	policy	T170	C0242456
28521617	92	100	criteria	T078	C0243161
28521617	101	116	Decision makers	T098	C1257890
28521617	173	185	implementing	T052	C1708476
28521617	198	208	mechanisms	T169	C0441712
28521617	213	223	protecting	T033	C0516529
28521617	228	235	elderly	T098	C0001792
28521617	246	263	vulnerable adults	T033	C1562367
28521617	269	274	abuse	T051	C1546935
28521617	278	291	pilot project	T062	C0031928
28521617	302	313	fingerprint	T073	C0016126
28521617	321	329	criminal	T098	C2607966
28521617	338	355	background checks	T033	C0243095
28521617	360	381	personal care workers	T097	C1522486
28521617	385	393	Michigan	T083	C1548669
28521617	410	421	opportunity	T062	C0683937
28521617	442	451	mechanism	T169	C0441712
28521617	456	467	conjunction	T078	C2699427
28521617	477	490	pilot project	T062	C0031928
28521617	512	523	stakeholder	T097	C1522486
28521617	524	532	analysis	T062	C0936012
28521617	559	574	decision makers	T098	C1257890
28521617	581	592	stakeholder	T098	C0027361
28521617	593	604	perceptions	T041	C0030971
28521617	608	616	standard	T170	C3244099
28521617	617	623	policy	T170	C0242456
28521617	624	632	criteria	T078	C0243161
28521617	638	651	effectiveness	T080	C1280519
28521617	653	663	efficiency	T081	C0013682
28521617	669	675	equity	T080	C0237597
28521617	689	701	focus groups	UnknownType	C0681860
28521617	708	724	web-based survey	T170	C0038951
28521617	728	735	collect	T062	C0010995
28521617	736	740	data	T078	C1511726
28521617	746	758	stakeholders	T098	C0027361
28521617	766	778	stakeholders	T098	C0027361
28521617	793	804	fingerprint	T073	C0016126
28521617	812	829	background checks	T033	C0243095
28521617	834	855	personal care workers	T097	C1522486
28521617	871	880	effective	T080	C1704419
28521617	890	901	net benefit	T081	C0814225
28521617	935	948	contingencies	T051	C0441471
28521617	970	982	difficulties	T033	C0425101
28521617	987	998	constraints	T169	C0443288
28521617	1003	1013	government	T092	C0018104
28521617	1014	1025	involvement	T169	C1314939
28521617	1032	1052	preliminary analysis	T062	C0936012
28521617	1068	1092	foundational information	T078	C1533716
28521617	1097	1112	decision makers	T098	C1257890
28521617	1136	1157	benefit-cost analysis	T057	C0010174

28113347|t|NEMo: An Evolutionary Model With Modularity for PPI Networks
28113347|a|Modeling the evolution of biological networks is a major challenge. Biological networks are usually represented as graphs; evolutionary events not only include addition and removal of vertices and edges but also duplication of vertices and their associated edges. Since duplication is viewed as a primary driver of genomic evolution, recent work has focused on duplication -based models. Missing from these models is any embodiment of modularity, a widely accepted attribute of biological networks. Some models spontaneously generate modular structures, but none is known to maintain and evolve them. We describe network evolution with modularity (NEMo), a new model that embodies modularity. NEMo allows modules to appear and disappear and to fission and to merge, all driven by the underlying edge-level events using a duplication -based process. We also introduce measures to compare biological networks in terms of their modular structure; we present comparisons between NEMo and existing duplication -based models and run our measuring tools on both generated and published networks.
28113347	0	4	NEMo	T170	C0282574
28113347	9	43	Evolutionary Model With Modularity	T170	C0282574
28113347	48	60	PPI Networks	T169	C3178902
28113347	61	69	Modeling	T062	C0870071
28113347	74	83	evolution	T045	C0015219
28113347	87	97	biological	T080	C0205460
28113347	98	106	networks	T169	C1882071
28113347	129	139	Biological	T080	C0205460
28113347	140	148	networks	T169	C1882071
28113347	176	182	graphs	T170	C0681493
28113347	184	203	evolutionary events	T051	C0441471
28113347	221	229	addition	T169	C1883712
28113347	234	241	removal	T052	C1883720
28113347	245	253	vertices	T077	C2697524
28113347	258	263	edges	T082	C0205154
28113347	273	284	duplication	T169	C0332597
28113347	288	296	vertices	T077	C2697524
28113347	307	317	associated	T080	C0332281
28113347	318	323	edges	T082	C0205154
28113347	331	342	duplication	T045	C0017261
28113347	376	393	genomic evolution	T045	C0015219
28113347	422	433	duplication	T045	C0017261
28113347	441	447	models	T170	C3161035
28113347	468	474	models	T170	C3161035
28113347	496	506	modularity	T169	C0205245
28113347	539	549	biological	T080	C0205460
28113347	550	558	networks	T169	C1882071
28113347	565	571	models	T170	C3161035
28113347	572	585	spontaneously	T169	C0205359
28113347	595	613	modular structures	T082	C0678594
28113347	636	644	maintain	T052	C0024501
28113347	649	655	evolve	T052	C0441655
28113347	674	707	network evolution with modularity	T170	C0282574
28113347	709	713	NEMo	T170	C0282574
28113347	722	727	model	T170	C3161035
28113347	742	752	modularity	T169	C0205245
28113347	754	758	NEMo	T170	C0282574
28113347	766	773	modules	T077	C1709061
28113347	777	783	appear	T078	C1254370
28113347	788	797	disappear	T078	C1254370
28113347	805	812	fission	T052	C0441655
28113347	820	825	merge	T052	C1881786
28113347	856	873	edge-level events	T051	C0441471
28113347	882	893	duplication	T045	C0017261
28113347	901	908	process	T067	C1522240
28113347	928	936	measures	T081	C0079809
28113347	948	958	biological	T080	C0205460
28113347	959	967	networks	T169	C1882071
28113347	986	1003	modular structure	T082	C0678594
28113347	1016	1027	comparisons	T052	C1707455
28113347	1036	1040	NEMo	T170	C0282574
28113347	1054	1065	duplication	T045	C0017261
28113347	1073	1079	models	T170	C3161035
28113347	1092	1101	measuring	T080	C0444706
28113347	1102	1107	tools	T073	C0336791
28113347	1116	1125	generated	T169	C0205245
28113347	1130	1139	published	T169	C0205245
28113347	1140	1148	networks	T169	C1882071

27405997|t|Vestibular ablation and a semicircular canal prosthesis affect postural stability during head turns
27405997|a|In our study, we examined postural stability during head turns for two rhesus monkeys: one animal study contrasted normal and mild bilateral vestibular ablation and a second animal study contrasted severe bilateral vestibular ablation with and without prosthetic stimulation. The monkeys freely stood, unrestrained on a balance platform and made voluntary head turns between visual targets. To quantify each animals ' posture, motions of the head and trunk, as well as torque about the body's center of mass, were measured. In the mildly ablated animal, we observed less foretrunk sway in comparison with the normal state. When the canal prosthesis provided electric stimulation to the severely ablated animal, it showed a decrease in trunk sway during head turns. Because the rhesus monkey with severe bilateral vestibular loss exhibited a decrease in trunk sway when receiving vestibular prosthetic stimulation, we propose that the prosthetic electrical stimulation partially restored head velocity information. Our results provide an indication that a semicircular canal prosthesis may be an effective way to improve postural stability in patients with severe peripheral vestibular dysfunction.
27405997	0	10	Vestibular	T030	C0042606
27405997	11	19	ablation	T061	C0547070
27405997	26	44	semicircular canal	T023	C0036622
27405997	45	55	prosthesis	T074	C0175649
27405997	56	62	affect	T169	C0392760
27405997	63	81	postural stability	T201	C3166208
27405997	82	88	during	T079	C0347984
27405997	89	99	head turns	T040	C0376591
27405997	126	144	postural stability	T201	C3166208
27405997	145	151	during	T079	C0347984
27405997	152	162	head turns	T040	C0376591
27405997	167	170	two	T081	C0205448
27405997	171	185	rhesus monkeys	T015	C0024400
27405997	187	190	one	T081	C0205447
27405997	191	203	animal study	T008	C0683949
27405997	215	221	normal	T080	C0205307
27405997	226	230	mild	T080	C2945599
27405997	231	240	bilateral	T082	C0238767
27405997	241	251	vestibular	T030	C0042606
27405997	252	260	ablation	T061	C0547070
27405997	267	273	second	T081	C0205436
27405997	274	286	animal study	T008	C0683949
27405997	298	304	severe	T080	C0205082
27405997	305	314	bilateral	T082	C0238767
27405997	315	325	vestibular	T030	C0042606
27405997	326	334	ablation	T061	C0547070
27405997	352	362	prosthetic	T074	C0175649
27405997	363	374	stimulation	T061	C1292856
27405997	380	387	monkeys	T015	C0026447
27405997	388	394	freely	T169	C0332296
27405997	395	400	stood	T082	C0231472
27405997	402	414	unrestrained	T078	C0016694
27405997	420	427	balance	T074	C0179199
27405997	446	455	voluntary	T055	C0439656
27405997	456	466	head turns	T040	C0376591
27405997	475	481	visual	T169	C0234621
27405997	482	489	targets	T169	C1521840
27405997	494	502	quantify	T081	C1709793
27405997	508	515	animals	T008	C0003062
27405997	518	525	posture	T032	C1262869
27405997	527	534	motions	T070	C0026597
27405997	542	546	head	T029	C0018670
27405997	551	556	trunk	T029	C0460005
27405997	569	575	torque	T067	C0376590
27405997	586	607	body's center of mass	T032	C0005910
27405997	614	622	measured	T080	C0444706
27405997	631	637	mildly	T080	C2945599
27405997	638	645	ablated	T061	C0547070
27405997	646	652	animal	T008	C0003062
27405997	657	665	observed	T169	C1441672
27405997	666	670	less	T080	C0547044
27405997	671	680	foretrunk	T029	C0460005
27405997	681	685	sway	T184	C0857226
27405997	689	699	comparison	T052	C1707455
27405997	709	715	normal	T080	C0205307
27405997	716	721	state	T169	C1442792
27405997	732	748	canal prosthesis	T074	C0175649
27405997	758	778	electric stimulation	T061	C0013786
27405997	786	794	severely	T080	C0205082
27405997	795	809	ablated animal	T008	C0003062
27405997	823	831	decrease	T081	C0547047
27405997	835	840	trunk	T029	C0460005
27405997	841	845	sway	T184	C0857226
27405997	846	852	during	T079	C0347984
27405997	853	863	head turns	T040	C0376591
27405997	877	890	rhesus monkey	T015	C0024400
27405997	896	902	severe	T080	C0205082
27405997	903	928	bilateral vestibular loss	T047	C4255193
27405997	941	949	decrease	T081	C0547047
27405997	953	958	trunk	T029	C0460005
27405997	959	963	sway	T184	C0857226
27405997	969	978	receiving	T080	C1514756
27405997	979	989	vestibular	T030	C0042606
27405997	990	1000	prosthetic	T074	C0175649
27405997	1001	1012	stimulation	T061	C1292856
27405997	1034	1044	prosthetic	T074	C0175649
27405997	1045	1067	electrical stimulation	T061	C0013786
27405997	1068	1077	partially	T081	C0728938
27405997	1078	1086	restored	T061	C1283255
27405997	1087	1100	head velocity	T040	C0376591
27405997	1101	1112	information	T078	C1533716
27405997	1118	1125	results	T169	C1274040
27405997	1137	1147	indication	T033	C1444656
27405997	1155	1173	semicircular canal	T023	C0036622
27405997	1174	1184	prosthesis	T074	C0175649
27405997	1195	1204	effective	T080	C1704419
27405997	1205	1208	way	T169	C1522326
27405997	1212	1219	improve	T080	C1272745
27405997	1220	1238	postural stability	T201	C3166208
27405997	1242	1250	patients	T101	C0030705
27405997	1256	1262	severe	T080	C0205082
27405997	1263	1296	peripheral vestibular dysfunction	T047	C2919598

27871298|t|Socioeconomic variation in incidence of primary and secondary major cardiovascular disease events: an Australian population-based prospective cohort study
27871298|a|Cardiovascular disease (CVD) disproportionately affects disadvantaged people, but reliable quantitative evidence on socioeconomic variation in CVD incidence in Australia is lacking. This study aimed to quantify socioeconomic variation in rates of primary and secondary CVD events in mid- age and older Australians. Baseline data (2006-2009) from the 45 and Up Study, an Australian cohort involving 267,153 men and women aged ≥ 45, were linked to hospital and death data (to December 2013). Outcomes comprised first event - death or hospital admission - for major CVD combined, as well as myocardial infarction and stroke, in those with and without prior CVD (secondary and primary events, respectively). Cox regression estimated hazard ratios (HRs) for each outcome in relation to education (and income and area-level disadvantage), separately by age group (45-64, 65-79, and ≥ 80 years), adjusting for age and sex, and additional sociodemographic factors. There were 18,207 primary major CVD events over 1,144,845 years of follow-up (15.9/1000 person-years), and 20,048 secondary events over 260,357 years (77.0/1000 person-years). For both primary and secondary events, incidence increased with decreasing education, with the absolute difference between education groups largest for secondary events. Age - sex adjusted hazard ratios were highest in the 45-64 years group: for major CVD s, HR (no qualifications vs university degree) = 1.62 (95% CI: 1.49-1.77) for primary events, and HR = 1.49 (1.34-1.65) for secondary events; myocardial infarction HR = 2.31 (1.87-2.85) and HR = 2.57 (1.90-3.47) respectively; stroke HR = 1.48 (1.16-1.87) and HR = 1.97 (1.42-2.74) respectively. Similar but attenuated results were seen in older age groups, and with income. For area-level disadvantage, CVD gradients were weak and non-significant in older people (> 64 years). Individual-level data are important for quantifying socioeconomic variation in CVD incidence, which is shown to be substantial among both those with and without prior CVD. Findings reinforce the opportunity for, and importance of, primary and secondary prevention and treatment in reducing socioeconomic variation in CVD and consequently the overall burden of CVD morbidity and mortality in Australia.
27871298	0	23	Socioeconomic variation	T033	C0682194
27871298	27	36	incidence	T081	C0021149
27871298	40	47	primary	T047	C0033141
27871298	52	61	secondary	T047	C0036529
27871298	62	67	major	T080	C0205164
27871298	68	90	cardiovascular disease	T047	C0007222
27871298	91	97	events	T051	C0441471
27871298	102	112	Australian	T098	C0238711
27871298	113	129	population-based	T062	C1709599
27871298	130	154	prospective cohort study	T062	C1709709
27871298	155	177	Cardiovascular disease	T047	C0007222
27871298	179	182	CVD	T047	C0007222
27871298	184	202	disproportionately	T080	C0205350
27871298	211	224	disadvantaged	T098	C0012613
27871298	225	231	people	T098	C0027361
27871298	237	245	reliable	T170	C3858758
27871298	246	258	quantitative	T081	C0392762
27871298	259	267	evidence	T078	C3887511
27871298	271	294	socioeconomic variation	T033	C0682194
27871298	298	301	CVD	T047	C0007222
27871298	302	311	incidence	T081	C0021149
27871298	315	324	Australia	T083	C0004340
27871298	342	347	study	T062	C2603343
27871298	357	365	quantify	T081	C1709793
27871298	366	389	socioeconomic variation	T033	C0682194
27871298	393	398	rates	T081	C1521828
27871298	402	409	primary	T047	C0033141
27871298	414	427	secondary CVD	T047	C0036529
27871298	428	434	events	T051	C0441471
27871298	443	446	age	T032	C0001779
27871298	451	456	older	T098	C0001792
27871298	457	468	Australians	T098	C0238711
27871298	470	478	Baseline	T081	C1442488
27871298	479	483	data	T078	C1511726
27871298	515	520	Study	T062	C2603343
27871298	525	535	Australian	T098	C0238711
27871298	536	542	cohort	T098	C0599755
27871298	561	564	men	T098	C0025266
27871298	569	574	women	T098	C0043210
27871298	575	579	aged	T032	C0001779
27871298	601	609	hospital	T073,T093	C0019994
27871298	614	619	death	T040	C0011065
27871298	620	624	data	T078	C1511726
27871298	645	653	Outcomes	T057	C0085565
27871298	670	675	event	T051	C0441471
27871298	678	683	death	T040	C0011065
27871298	687	705	hospital admission	T058	C0184666
27871298	712	717	major	T080	C0205164
27871298	718	721	CVD	T047	C0007222
27871298	722	730	combined	T080	C0205195
27871298	743	764	myocardial infarction	T047	C0027051
27871298	769	775	stroke	T047	C0038454
27871298	803	808	prior	T079	C0332152
27871298	809	812	CVD	T047	C0007222
27871298	814	823	secondary	T047	C0036529
27871298	828	835	primary	T047	C0033141
27871298	836	842	events	T051	C0441471
27871298	859	873	Cox regression	T062	C0242481
27871298	884	897	hazard ratios	T081	C2985465
27871298	899	902	HRs	T081	C2985465
27871298	913	920	outcome	T057	C0085565
27871298	936	945	education	T065	C0013621
27871298	951	957	income	T081	C0021162
27871298	962	972	area-level	T081	C1708236
27871298	973	985	disadvantage	T185	C2985113
27871298	988	998	separately	T080	C0443299
27871298	1002	1011	age group	T100	C0027362
27871298	1058	1061	age	T032	C0001779
27871298	1066	1069	sex	T032	C0079399
27871298	1086	1102	sociodemographic	T078	C0011292
27871298	1103	1110	factors	T169	C1521761
27871298	1130	1137	primary	T047	C0033141
27871298	1138	1143	major	T080	C0205164
27871298	1144	1147	CVD	T047	C0007222
27871298	1148	1154	events	T051	C0441471
27871298	1179	1188	follow-up	T058	C1522577
27871298	1226	1235	secondary	T047	C0036529
27871298	1236	1242	events	T051	C0441471
27871298	1297	1304	primary	T047	C0033141
27871298	1309	1318	secondary	T047	C0036529
27871298	1319	1325	events	T051	C0441471
27871298	1327	1336	incidence	T081	C0021149
27871298	1337	1346	increased	T081	C0205217
27871298	1352	1362	decreasing	T081	C0205216
27871298	1363	1372	education	T065	C0013621
27871298	1383	1391	absolute	T080	C0205344
27871298	1392	1402	difference	T081	C1705241
27871298	1411	1420	education	T065	C0013621
27871298	1421	1427	groups	T078	C0441833
27871298	1440	1449	secondary	T047	C0036529
27871298	1450	1456	events	T051	C0441471
27871298	1458	1461	Age	T032	C0001779
27871298	1464	1467	sex	T032	C0079399
27871298	1477	1490	hazard ratios	T081	C2985465
27871298	1523	1528	group	T078	C0441833
27871298	1534	1539	major	T080	C0205164
27871298	1540	1543	CVD	T047	C0007222
27871298	1547	1549	HR	T081	C2985465
27871298	1551	1568	no qualifications	UnknownType	C0524325
27871298	1572	1589	university degree	T170	C0542560
27871298	1603	1605	CI	T081	C0009667
27871298	1622	1629	primary	T047	C0033141
27871298	1630	1636	events	T051	C0441471
27871298	1642	1644	HR	T081	C2985465
27871298	1668	1677	secondary	T047	C0036529
27871298	1678	1684	events	T051	C0441471
27871298	1686	1707	myocardial infarction	T047	C0027051
27871298	1708	1710	HR	T081	C2985465
27871298	1734	1736	HR	T081	C2985465
27871298	1770	1776	stroke	T047	C0038454
27871298	1777	1779	HR	T081	C2985465
27871298	1803	1805	HR	T081	C2985465
27871298	1839	1846	Similar	T080	C2348205
27871298	1851	1861	attenuated	T080	C0332161
27871298	1862	1869	results	T034	C0456984
27871298	1883	1888	older	T098	C0001792
27871298	1889	1899	age groups	T100	C0027362
27871298	1910	1916	income	T081	C0021162
27871298	1922	1932	area-level	T081	C1708236
27871298	1933	1945	disadvantage	T185	C2985113
27871298	1947	1950	CVD	T047	C0007222
27871298	1951	1960	gradients	T081	C0812409
27871298	1966	1970	weak	T080	C1762617
27871298	1975	1990	non-significant	T080	C0205556
27871298	1994	1999	older	T098	C0001792
27871298	2000	2006	people	T098	C0027361
27871298	2021	2042	Individual-level data	UnknownType	C0814855
27871298	2047	2056	important	T080	C3898777
27871298	2061	2072	quantifying	T081	C1709793
27871298	2073	2096	socioeconomic variation	T033	C0682194
27871298	2100	2103	CVD	T047	C0007222
27871298	2104	2113	incidence	T081	C0021149
27871298	2182	2187	prior	T079	C0332152
27871298	2188	2191	CVD	T047	C0007222
27871298	2193	2201	Findings	T033	C0243095
27871298	2216	2227	opportunity	T062	C0683937
27871298	2237	2247	importance	T080	C0205556
27871298	2252	2259	primary	T061	C0033144
27871298	2264	2284	secondary prevention	T061	C0679699
27871298	2289	2298	treatment	T061	C0087111
27871298	2302	2310	reducing	T080	C0392756
27871298	2311	2334	socioeconomic variation	T033	C0682194
27871298	2338	2341	CVD	T047	C0007222
27871298	2346	2358	consequently	T033	C3845876
27871298	2363	2370	overall	T080	C1561607
27871298	2371	2377	burden	T078	C2828008
27871298	2381	2384	CVD	T047	C0007222
27871298	2385	2394	morbidity	T081	C0026538
27871298	2399	2408	mortality	T081	C0178686
27871298	2412	2421	Australia	T083	C0004340

27748824|t|Cardiovascular diseases related to ionizing radiation: The risk of low - dose exposure (Review)
27748824|a|Traditionally, non-cancer diseases are not considered as health risks following exposure to low doses of ionizing radiation. Indeed, non-cancer diseases are classified as deterministic tissue reactions, which are characterized by a threshold dose. It is judged that below an absorbed dose of 100 mGy, no clinically relevant tissue damage occurs, forming the basis for the current radiation protection system concerning non-cancer effects. Recent epidemiological findings point, however, to an excess risk of non-cancer diseases following exposure to lower doses of ionizing radiation than was previously thought. The evidence is the most sound for cardiovascular disease (CVD) and cataract. Due to limited statistical power, the dose - risk relationship is undetermined below 0.5 Gy; however, if this relationship proves to be without a threshold, it may have considerable impact on current low ‑ dose health risk estimates. In this review, we describe the CVD risk related to low doses of ionizing radiation, the clinical manifestation and the pathology of radiation-induced CVD, as well as the importance of the endothelium models in CVD research as a way forward to complement the epidemiological data with the underlying biological and molecular mechanisms.
27748824	0	23	Cardiovascular diseases	T047	C0007222
27748824	35	53	ionizing radiation	T070	C0034538
27748824	59	63	risk	T078	C0035647
27748824	67	70	low	T080	C0205251
27748824	73	77	dose	T081	C0034524
27748824	78	86	exposure	T080	C0332157
27748824	88	94	Review	T170	C0282443
27748824	111	121	non-cancer	T033	C3898132
27748824	122	130	diseases	T047	C0012634
27748824	153	159	health	T078	C0018684
27748824	160	165	risks	T078	C0035647
27748824	176	187	exposure to	T080	C0332157
27748824	188	191	low	T080	C0205251
27748824	192	197	doses	T081	C0034524
27748824	201	219	ionizing radiation	T070	C0034538
27748824	229	239	non-cancer	T033	C3898132
27748824	240	248	diseases	T047	C0012634
27748824	267	297	deterministic tissue reactions	T033	C1708386
27748824	328	337	threshold	T080	C0449864
27748824	338	342	dose	T081	C0034524
27748824	371	384	absorbed dose	T081	C0556643
27748824	400	410	clinically	T080	C0205210
27748824	411	419	relevant	T080	C2347946
27748824	420	433	tissue damage	T037	C0010957
27748824	434	440	occurs	T052	C1709305
27748824	468	475	current	T079	C0521116
27748824	476	503	radiation protection system	T061	C0034533
27748824	515	533	non-cancer effects	T080	C1280500
27748824	542	557	epidemiological	T169	C1516907
27748824	589	595	excess	T080	C1979886
27748824	596	600	risk	T078	C0035647
27748824	604	614	non-cancer	T033	C3898132
27748824	615	623	diseases	T047	C0012634
27748824	634	645	exposure to	T080	C0332157
27748824	646	651	lower	T080	C0205251
27748824	652	657	doses	T081	C0034524
27748824	661	679	ionizing radiation	T070	C0034538
27748824	713	721	evidence	T078	C3887511
27748824	744	766	cardiovascular disease	T047	C0007222
27748824	768	771	CVD	T047	C0007222
27748824	777	785	cataract	T020	C0086543
27748824	794	801	limited	T169	C0439801
27748824	802	819	statistical power	T062	C0814897
27748824	825	829	dose	T081	C0034524
27748824	832	836	risk	T078	C0035647
27748824	837	849	relationship	T080	C0439849
27748824	853	865	undetermined	T080	C3536725
27748824	897	909	relationship	T080	C0439849
27748824	923	930	without	T080	C0332288
27748824	933	942	threshold	T080	C0449864
27748824	969	975	impact	T080	C4049986
27748824	979	986	current	T079	C0521116
27748824	987	990	low	T080	C0205251
27748824	993	997	dose	T081	C0034524
27748824	998	1004	health	T078	C0018684
27748824	1005	1009	risk	T078	C0035647
27748824	1010	1019	estimates	T081	C0750572
27748824	1029	1035	review	T170	C0282443
27748824	1053	1056	CVD	T047	C0007222
27748824	1057	1061	risk	T078	C0035647
27748824	1073	1076	low	T080	C0205251
27748824	1077	1082	doses	T081	C0034524
27748824	1086	1104	ionizing radiation	T070	C0034538
27748824	1110	1118	clinical	T080	C0205210
27748824	1119	1132	manifestation	T169	C0205319
27748824	1141	1150	pathology	T046	C0677042
27748824	1154	1175	radiation-induced CVD	T047	C1527225
27748824	1210	1221	endothelium	T024	C0014257
27748824	1222	1228	models	T050	C1519523
27748824	1232	1235	CVD	T047	C0007222
27748824	1236	1244	research	T062	C0035168
27748824	1280	1295	epidemiological	T169	C0014508
27748824	1296	1300	data	T078	C1511726
27748824	1321	1331	biological	T080	C0205460
27748824	1336	1345	molecular	T080	C1521991
27748824	1346	1356	mechanisms	T169	C0441712

27806383|t|Transplacental Passage of Acetaminophen in Term Pregnancy
27806383|a|Objective The objective of this study was to determine the maternal and fetal pharmacokinetic (PK) profiles of acetaminophen after administration of a therapeutic oral dose. Study Design After obtaining Institutional Review Board approval and their written informed consent, pregnant women were given a single oral dose (1,000 mg) of acetaminophen upon admission for scheduled cesarean delivery. Maternal venous blood and fetal cord blood were obtained at the time of delivery and acetaminophen levels were measured using gas chromatography-mass spectroscopy. PK parameters were calculated by noncompartmental analysis. Nonparametric correlation of maternal / fetal acetaminophen levels and PK curves were calculated. Results In this study, 34 subjects were enrolled (median, 32 years; range, 25-39 years). The median maternal weight was 82 kg (range, 62-100 kg). All but two subjects were delivered beyond 39 weeks' gestation. The median newborn birth weight was 3,590 g (interquartile range, 3,403-3,848 g). Noncompartmental analysis described similar PK parameters in the maternal (T1/2, 84 minutes; apparent clearance [Cl/F], 28.8 L/h; apparent volume of distribution [Vd/F], 57.5 L) and fetal compartments (T1/2, 82 minutes; Cl/F, 31.2 L/h; Vd/F, 61.2 L). Paired maternal / fetal acetaminophen levels were highly correlated (p < 0.0001). Conclusion Fetal acetaminophen PKs in the fetus parallels that in the mother suggesting that placental transfer is flow limited. Maternal acetaminophen levels can be used as a surrogate for fetal exposure.
27806383	0	14	Transplacental	T082	C0442375
27806383	15	22	Passage	T067	C1254366
27806383	26	39	Acetaminophen	T109,T121	C0000970
27806383	43	57	Term Pregnancy	T040	C0232991
27806383	58	67	Objective	T170	C0018017
27806383	72	81	objective	T170	C0018017
27806383	117	125	maternal	T099	C0026591
27806383	130	135	fetal	T018	C0015965
27806383	136	151	pharmacokinetic	T039	C0031327
27806383	153	155	PK	T039	C0031327
27806383	153	155	PK	T039	C0031327
27806383	157	165	profiles	T059	C1979963
27806383	169	182	acetaminophen	T109,T121	C0000970
27806383	189	203	administration	T061	C0001563
27806383	209	220	therapeutic	T169	C0302350
27806383	221	230	oral dose	T122	C1272919
27806383	232	244	Study Design	T062	C0035171
27806383	261	296	Institutional Review Board approval	T170	C2346499
27806383	307	331	written informed consent	T058	C0811741
27806383	333	347	pregnant women	T098	C0033011
27806383	368	377	oral dose	T122	C1272919
27806383	392	405	acetaminophen	T109,T121	C0000970
27806383	411	420	admission	T058	C0184666
27806383	435	452	cesarean delivery	T061	C0869915
27806383	454	462	Maternal	T099	C0026591
27806383	463	475	venous blood	T031	C0229667
27806383	480	485	fetal	T018	C0015965
27806383	486	496	cord blood	T031	C0162371
27806383	502	510	obtained	T033	C1277697
27806383	518	534	time of delivery	T201	C1301668
27806383	539	559	acetaminophen levels	T059	C0373527
27806383	565	573	measured	T080	C0444706
27806383	580	616	gas chromatography-mass spectroscopy	T059	C0024868
27806383	618	620	PK	T039	C0031327
27806383	621	631	parameters	T033	C0449381
27806383	637	647	calculated	T169	C0444686
27806383	651	667	noncompartmental	T082	C1254362
27806383	668	676	analysis	T062	C0936012
27806383	678	703	Nonparametric correlation	T080	C1707520
27806383	707	715	maternal	T099	C0026591
27806383	718	723	fetal	T018	C0015965
27806383	724	744	acetaminophen levels	T059	C0373527
27806383	749	751	PK	T039	C0031327
27806383	764	774	calculated	T169	C0444686
27806383	776	783	Results	T169	C1274040
27806383	792	797	study	T062	C2603343
27806383	802	810	subjects	T098	C2349001
27806383	826	832	median	T081	C0876920
27806383	869	875	median	T081	C0876920
27806383	876	884	maternal	T099	C0026591
27806383	885	891	weight	T032	C0005910
27806383	934	942	subjects	T098	C2349001
27806383	948	957	delivered	T061	C0011209
27806383	965	984	39 weeks' gestation	T079	C0233046
27806383	990	996	median	T081	C0876920
27806383	997	1017	newborn birth weight	T033	C0243095
27806383	1011	1017	weight	T032	C0005910
27806383	1031	1050	interquartile range	T081	C1711350
27806383	1068	1084	Noncompartmental	T082	C1254362
27806383	1085	1093	analysis	T062	C0936012
27806383	1094	1103	described	T078	C1552738
27806383	1112	1114	PK	T039	C0031327
27806383	1115	1125	parameters	T033	C0449381
27806383	1133	1141	maternal	T099	C0026591
27806383	1161	1179	apparent clearance	UnknownType	C0678760
27806383	1181	1185	Cl/F	UnknownType	C0678760
27806383	1198	1229	apparent volume of distribution	T081	C0683148
27806383	1231	1235	Vd/F	T081	C0683148
27806383	1250	1255	fetal	T018	C0015965
27806383	1256	1268	compartments	T030	C0005888
27806383	1288	1292	Cl/F	UnknownType	C0678760
27806383	1304	1308	Vd/F	T081	C0683148
27806383	1326	1334	maternal	T099	C0026591
27806383	1337	1342	fetal	T018	C0015965
27806383	1343	1363	acetaminophen levels	T059	C0373527
27806383	1401	1411	Conclusion	T078	C1707478
27806383	1412	1417	Fetal	T018	C0015965
27806383	1418	1431	acetaminophen	T109,T121	C0000970
27806383	1432	1435	PKs	T039	C0031327
27806383	1443	1448	fetus	T018	C0015965
27806383	1471	1477	mother	T099	C0026591
27806383	1494	1512	placental transfer	T042	C0597250
27806383	1530	1538	Maternal	T099	C0026591
27806383	1539	1559	acetaminophen levels	T059	C0373527
27806383	1591	1596	fetal	T018	C0015965
27806383	1597	1605	exposure	T080	C0332157

28213871|t|Thieno[2,3-b]pyridine derivatives: a new class of antiviral drugs against Mayaro virus
28213871|a|Mayaro virus (MAYV) is an arthropod-borne virus and a member of the family Togaviridae, genus Alphavirus. Its infection leads to an acute illness accompanied by long-lasting arthralgia. To date, there are no antiviral drugs or vaccines against infection with MAYV and resources for the prevention or treatment of other alphaviruses are very limited. MAYV has served as a model to study the antiviral potential of several substances on alphavirus replication. In this work we evaluated the antiviral effect of seven new derivatives of thieno[2,3-b]pyridine against MAYV replication in a mammalian cell line. All derivatives were able to reduce viral production effectively at concentrations that were non-toxic for Vero cells. Molecular modeling assays predicted low toxicity risk and good oral bioavailability of the substances in humans. One of the molecules, selected for further study, demonstrated a strong anti-MAYV effect at early stages of replication, as it protected pre-treated cells and also during the late stages, affecting virus morphogenesis. This study is the first to demonstrate the antiviral effect of thienopyridine derivatives on MAYV replication in vitro, suggesting the potential application of these substances as antiviral molecules against alphaviruses. Additional in vivo research will be needed to expand the putative therapeutic applications.
28213871	0	21	Thieno[2,3-b]pyridine	T109,T121	C1120149
28213871	22	33	derivatives	T104	C0243072
28213871	50	65	antiviral drugs	T121	C0003451
28213871	74	86	Mayaro virus	T005	C0318738
28213871	87	99	Mayaro virus	T005	C0318738
28213871	101	105	MAYV	T005	C0318738
28213871	113	134	arthropod-borne virus	T005	C0003725
28213871	155	161	family	T185	C2700055
28213871	162	173	Togaviridae	T005	C0040360
28213871	175	180	genus	T185	C1708235
28213871	181	191	Alphavirus	T005	C0002331
28213871	197	206	infection	T046	C3714514
28213871	219	232	acute illness	T046	C4061114
28213871	261	271	arthralgia	T184	C0003862
28213871	295	310	antiviral drugs	T121	C0003451
28213871	314	322	vaccines	T121,T129	C0042210
28213871	331	340	infection	T046	C3714514
28213871	346	350	MAYV	T005	C0318738
28213871	355	364	resources	T078	C0035201
28213871	373	383	prevention	T080	C2700409
28213871	387	396	treatment	T169	C0039798
28213871	406	418	alphaviruses	T005	C0002331
28213871	437	441	MAYV	T005	C0318738
28213871	458	463	model	T075	C0026339
28213871	467	472	study	T062	C2603343
28213871	477	496	antiviral potential	T080	C3245505
28213871	508	518	substances	T121	C1254351
28213871	522	532	alphavirus	T005	C0002331
28213871	533	544	replication	T043	C0042774
28213871	576	592	antiviral effect	T080	C1280500
28213871	606	617	derivatives	T104	C0243072
28213871	621	642	thieno[2,3-b]pyridine	T109,T121	C1120149
28213871	651	655	MAYV	T005	C0318738
28213871	656	667	replication	T043	C0042774
28213871	673	682	mammalian	T015	C0024660
28213871	683	692	cell line	T025	C0007634
28213871	698	709	derivatives	T104	C0243072
28213871	723	729	reduce	T081	C0547047
28213871	730	746	viral production	T043	C0042774
28213871	762	776	concentrations	T081	C0678756
28213871	801	811	Vero cells	T025	C0042542
28213871	813	838	Molecular modeling assays	T059	C0005507
28213871	853	861	toxicity	T037	C0600688
28213871	862	866	risk	T078	C0035647
28213871	876	880	oral	T082	C0442027
28213871	881	896	bioavailability	T081	C0005508
28213871	904	914	substances	T121	C1254351
28213871	918	924	humans	T016	C0086418
28213871	937	946	molecules	T121	C1254351
28213871	969	974	study	T062	C2603343
28213871	998	1014	anti-MAYV effect	T080	C1280500
28213871	1018	1030	early stages	T079	C2363430
28213871	1034	1045	replication	T043	C0042774
28213871	1063	1080	pre-treated cells	T025	C0007634
28213871	1101	1112	late stages	T079	C1279941
28213871	1124	1129	virus	T005	C0042776
28213871	1130	1143	morphogenesis	T040	C0026559
28213871	1150	1155	study	T062	C2603343
28213871	1188	1204	antiviral effect	T080	C1280500
28213871	1208	1222	thienopyridine	T109,T121	C1120149
28213871	1223	1234	derivatives	T104	C0243072
28213871	1238	1242	MAYV	T005	C0318738
28213871	1243	1254	replication	T043	C0042774
28213871	1255	1263	in vitro	T080	C1533691
28213871	1311	1321	substances	T121	C1254351
28213871	1325	1344	antiviral molecules	T121	C0003451
28213871	1353	1365	alphaviruses	T005	C0002331
28213871	1378	1385	in vivo	T082	C1515655
28213871	1386	1394	research	T062	C0035168
28213871	1433	1444	therapeutic	T169	C0302350
28213871	1445	1457	applications	T052	C1708476

27798219|t|Impact of antibiotic de-escalation on clinical outcomes in community-acquired pneumococcal pneumonia
27798219|a|Although antibiotic de-escalation is regarded as a measure that reduces selection pressure, adverse drug effects and costs, evidence supporting this practice in community-acquired pneumococcal pneumonia (CAPP) is lacking. We carried out a retrospective analysis of prospectively collected data of a cohort of hospitalized adults with CAPP. Pneumococcal aetiology was established in patients with one or more positive cultures for Streptococcus pneumoniae obtained from blood, sterile fluids or sputum, and/or a positive urinary antigen test. De-escalation therapy was considered when the initial antibiotic therapy was narrowed to penicillin, amoxicillin or amoxicillin/clavulanate within the first 72 h after admission. The primary outcomes were 30 day mortality and length of hospital stay (LOS). Adjustment for confounders was performed with multivariate and propensity score analyses. Of 1410 episodes of CAPP, antibiotic de-escalation within the first 72 h after admission was performed in 166 cases. After adjustment, antibiotic de-escalation was not associated with a higher risk of mortality (OR = 0.83, 95% CI = 0.24-2.81), but it was found to be a protective factor for prolonged LOS (above the median) (OR = 0.46, 95% CI = 0.30-0.70). Similar results were found in patients classified into high-risk pneumonia severity index classes (IV-V), those with clinical instability and those with bacteraemia. No significant differences were documented in adverse drug reactions or readmission (<30 days). Antibiotic de-escalation seems to be safe and effective in reducing the duration of LOS, and did not adversely affect outcomes of patients with CAPP, even those with bacteraemia and severe disease, and those who were clinically unstable.
27798219	0	6	Impact	T080	C4049986
27798219	10	20	antibiotic	T195	C0003232
27798219	21	34	de-escalation	T061	C3651014
27798219	38	55	clinical outcomes	T169	C1274040
27798219	59	77	community-acquired	T080	C0456394
27798219	78	100	pneumococcal pneumonia	T047	C0032300
27798219	110	120	antibiotic	T195	C0003232
27798219	121	134	de-escalation	T061	C3651014
27798219	165	172	reduces	T080	C0392756
27798219	193	213	adverse drug effects	T046	C0041755
27798219	218	223	costs	T081	C0085123
27798219	225	233	evidence	T078	C3887511
27798219	262	303	community-acquired pneumococcal pneumonia	T047	C0032300
27798219	305	309	CAPP	T047	C0032300
27798219	314	321	lacking	T080	C0332268
27798219	340	353	retrospective	T080	C1514923
27798219	354	362	analysis	T062	C0936012
27798219	390	394	data	T078	C1511726
27798219	400	406	cohort	T098	C0599755
27798219	410	429	hospitalized adults	T101	C0001585
27798219	435	439	CAPP	T047	C0032300
27798219	441	453	Pneumococcal	T047	C0032300
27798219	454	463	aetiology	T169	C1314792
27798219	468	479	established	T080	C0443211
27798219	483	491	patients	T101	C0030705
27798219	509	526	positive cultures	T033	C0159125
27798219	531	555	Streptococcus pneumoniae	T007	C0038410
27798219	570	575	blood	T031	C0005767
27798219	577	591	sterile fluids	T031	C0005889
27798219	595	601	sputum	T031	C0038056
27798219	612	620	positive	T033	C1446409
27798219	621	641	urinary antigen test	T059	C1319561
27798219	643	664	De-escalation therapy	T061	C3651014
27798219	697	715	antibiotic therapy	T061	C0338237
27798219	732	742	penicillin	T109,T195	C0220892
27798219	744	755	amoxicillin	T109,T195	C0002645
27798219	759	782	amoxicillin/clavulanate	T121	C0054066
27798219	811	820	admission	T058	C0184666
27798219	834	842	outcomes	T169	C1274040
27798219	851	854	day	T079	C0439228
27798219	855	864	mortality	T081	C0205848
27798219	869	892	length of hospital stay	T079	C3826195
27798219	894	897	LOS	T079	C3826195
27798219	900	910	Adjustment	T169	C0456081
27798219	931	940	performed	T169	C0884358
27798219	946	958	multivariate	T081	C0026777
27798219	963	979	propensity score	T081	C2718044
27798219	980	988	analyses	T062	C0936012
27798219	1010	1014	CAPP	T047	C0032300
27798219	1016	1026	antibiotic	T195	C0003232
27798219	1027	1040	de-escalation	T061	C3651014
27798219	1069	1078	admission	T058	C0184666
27798219	1083	1092	performed	T169	C0884358
27798219	1100	1105	cases	T169	C0868928
27798219	1113	1123	adjustment	T169	C0456081
27798219	1125	1135	antibiotic	T195	C0003232
27798219	1136	1149	de-escalation	T061	C3651014
27798219	1158	1173	associated with	T080	C0332281
27798219	1183	1187	risk	T078	C0035647
27798219	1191	1200	mortality	T081	C0205848
27798219	1202	1204	OR	T081	C0028873
27798219	1217	1219	CI	T081	C0009667
27798219	1259	1276	protective factor	T055	C0679688
27798219	1281	1290	prolonged	T079	C0439590
27798219	1291	1294	LOS	T079	C3826195
27798219	1306	1312	median	T081	C0876920
27798219	1315	1317	OR	T081	C0028873
27798219	1330	1332	CI	T081	C0009667
27798219	1355	1362	results	T169	C1274040
27798219	1377	1385	patients	T101	C0030705
27798219	1402	1411	high-risk	T033	C0332167
27798219	1412	1421	pneumonia	T047	C0032285
27798219	1464	1484	clinical instability	T033	C1444783
27798219	1500	1511	bacteraemia	T047	C0004610
27798219	1513	1539	No significant differences	T033	C3842396
27798219	1545	1555	documented	T058	C1301725
27798219	1559	1581	adverse drug reactions	T046	C0041755
27798219	1585	1596	readmission	T058	C0184666
27798219	1602	1606	days	T079	C0439228
27798219	1609	1619	Antibiotic	T195	C0003232
27798219	1620	1633	de-escalation	T061	C3651014
27798219	1655	1664	effective	T080	C1704419
27798219	1668	1676	reducing	T080	C0392756
27798219	1681	1689	duration	T079	C0449238
27798219	1693	1696	LOS	T079	C3826195
27798219	1710	1726	adversely affect	T046	C0879626
27798219	1727	1735	outcomes	T169	C1274040
27798219	1739	1747	patients	T101	C0030705
27798219	1753	1757	CAPP	T047	C0032300
27798219	1775	1786	bacteraemia	T047	C0004610
27798219	1791	1805	severe disease	T047	C0012634
27798219	1826	1845	clinically unstable	T033	C0443343

28545358|t|Molecular Imaging of Tumor Angiogenesis and Therapeutic Effects with Dual Bioluminescence
28545358|a|Angiogenesis is critical for the growth of tumor by supplying nutrients and oxygen that exacerbates the metastasis and progression of cancer. Noninvasive imaging of angiogenesis during the tumor therapeutic processes may provide novel opportunities for image-guided tumor management. Here, we want to develop a mouse animal model for assessing cancer progression and angiogenesis in the same individuals by molecular imaging. Breast cancer model was developed with mouse breast cancer cell line 4T1 carrying a reporter system encoding a triple fusion (TF) reporter gene consisting of renilla luciferase (Rluc), red fluorescent protein (RFP) and herpes simplex virus truncated thymidine kinase (HSV-ttk) in transgenic mice, which expressed firefly luciferase (Fluc) under the promoter of vascular endothelial growth factor receptor 2 (Vegfr2-luc). The mice were subsequently treated with ganciclovir (GCV) and the tumor angiogenesis was tracked by Fluc imaging and the growth status of tumor was monitored by imaging of Rluc simultaneously. Overall, this traceable breast cancer model can simultaneously image the tumor growth and angiogenesis in single individual, which may facilitate a better understanding the mechanisms of angiogenesis in the progression and regression of tumor.
28545358	0	17	Molecular Imaging	T060	C1537028
28545358	21	39	Tumor Angiogenesis	T191	C1519670
28545358	44	63	Therapeutic Effects	T201	C1527144
28545358	69	89	Dual Bioluminescence	T038	C0162404
28545358	90	102	Angiogenesis	T042	C0302600
28545358	106	114	critical	T080	C1511545
28545358	123	129	growth	T040	C0018270
28545358	133	138	tumor	T191	C0027651
28545358	142	151	supplying	T169	C1561604
28545358	152	161	nutrients	T168	C0678695
28545358	166	172	oxygen	T121,T123,T196	C0030054
28545358	178	189	exacerbates	T033	C0436331
28545358	194	204	metastasis	T046	C4255448
28545358	209	220	progression	T169	C0449258
28545358	224	230	cancer	T191	C0006826
28545358	232	243	Noninvasive	T185	C2986496
28545358	244	251	imaging	T060	C0011923
28545358	255	267	angiogenesis	T042	C0302600
28545358	279	284	tumor	T191	C0027651
28545358	285	306	therapeutic processes	T061	C0935606
28545358	319	324	novel	T080	C0205314
28545358	325	338	opportunities	T062	C0683937
28545358	343	355	image-guided	T061	C1171347
28545358	356	361	tumor	T191	C0027651
28545358	362	372	management	T058	C0376636
28545358	401	419	mouse animal model	T050	C2986594
28545358	424	433	assessing	T058	C0184514
28545358	434	440	cancer	T191	C0006826
28545358	441	452	progression	T046	C0242656
28545358	457	469	angiogenesis	T042	C0302600
28545358	482	493	individuals	T098	C0237401
28545358	497	514	molecular imaging	T060	C1537028
28545358	516	535	Breast cancer model	T050	C1511291
28545358	555	560	mouse	T015	C0025929
28545358	561	574	breast cancer	T191	C0678222
28545358	575	584	cell line	T025	C0085983
28545358	585	588	4T1	T025	C0007634
28545358	600	615	reporter system	T077	C1705915
28545358	616	624	encoding	T052	C2700640
28545358	627	659	triple fusion (TF) reporter gene	T028	C1533585
28545358	674	692	renilla luciferase	T116,T126,T130	C1450145
28545358	694	698	Rluc	T116,T126,T130	C1450145
28545358	701	724	red fluorescent protein	T116	C0960938
28545358	726	729	RFP	T116	C0960938
28545358	735	755	herpes simplex virus	T005	C0319232
28545358	756	782	truncated thymidine kinase	T116,T126	C0040078
28545358	784	791	HSV-ttk	T116,T126	C0040078
28545358	796	811	transgenic mice	T015	C0025936
28545358	829	847	firefly luciferase	T116,T126	C0311727
28545358	849	853	Fluc	T116,T126	C0311727
28545358	865	873	promoter	T114,T123	C0086860
28545358	877	922	vascular endothelial growth factor receptor 2	T116,T192	C0378796
28545358	924	934	Vegfr2-luc	T116,T192	C0378796
28545358	941	945	mice	T015	C0025929
28545358	964	971	treated	T169	C1522326
28545358	977	988	ganciclovir	T114,T121	C0017066
28545358	990	993	GCV	T114,T121	C0017066
28545358	1003	1021	tumor angiogenesis	T191	C1519670
28545358	1037	1041	Fluc	T116,T126	C0311727
28545358	1042	1049	imaging	T060	C0011923
28545358	1058	1064	growth	T040	C0018270
28545358	1065	1071	status	T080	C0449438
28545358	1075	1080	tumor	T191	C0027651
28545358	1098	1105	imaging	T060	C0011923
28545358	1109	1113	Rluc	T116,T126,T130	C1450145
28545358	1154	1173	breast cancer model	T050	C1511291
28545358	1193	1198	image	T170	C1704922
28545358	1203	1215	tumor growth	T191	C0598934
28545358	1220	1232	angiogenesis	T042	C0302600
28545358	1243	1253	individual	T098	C0237401
28545358	1285	1298	understanding	T041	C0162340
28545358	1303	1313	mechanisms	T169	C0441712
28545358	1317	1329	angiogenesis	T042	C0302600
28545358	1337	1348	progression	T046	C0242656
28545358	1353	1363	regression	T046	C0684320
28545358	1367	1372	tumor	T191	C0027651

27306647|t|Delayed progression of rabies transmitted by a vampire bat
27306647|a|Here, we compared the growth kinetics, cell-to-cell spread, and virus internalization kinetics in N2a cells of RABV variants isolated from vampire bats (V-3), domestic dogs (V-2) and marmosets (V-M) as well as the clinical symptoms and mortality caused by these variants. The replication rate of V-3 was significantly higher than those of V-2 and V-M. However, the uptake and spread of these RABV variants into N2a cells were inversely proportional. Nevertheless, V-3 had longer incubation and evolution periods. Our results provide evidence that the clinical manifestations of infection with bat RABV variant occur at a later time when compared to what was observed with canine and marmoset rabies virus variants.
27306647	0	7	Delayed	T079	C0205421
27306647	8	19	progression	T046	C0242656
27306647	23	29	rabies	T047	C0034494
27306647	30	41	transmitted	T046	C0242781
27306647	47	58	vampire bat	T015	C0324765
27306647	68	76	compared	T052	C1707455
27306647	81	87	growth	T040	C0018270
27306647	88	96	kinetics	T070	C0022702
27306647	98	117	cell-to-cell spread	T040	C1160712
27306647	123	144	virus internalization	T038	C1537068
27306647	145	153	kinetics	T070	C0022702
27306647	157	166	N2a cells	T025	C0007634
27306647	170	174	RABV	T005	C0034497
27306647	175	183	variants	T033	C4284334
27306647	184	192	isolated	T169	C0205409
27306647	198	210	vampire bats	T015	C0324765
27306647	212	215	V-3	T033	C4284334
27306647	218	231	domestic dogs	T015	C0012984
27306647	233	236	V-2	T033	C4284334
27306647	242	251	marmosets	T015	C0006764
27306647	253	256	V-M	T033	C4284334
27306647	273	281	clinical	T080	C0205210
27306647	282	290	symptoms	T184	C1457887
27306647	295	304	mortality	T081	C0205848
27306647	321	329	variants	T033	C4284334
27306647	335	346	replication	T043	C0042774
27306647	347	351	rate	T081	C1521828
27306647	355	358	V-3	T033	C4284334
27306647	363	383	significantly higher	T081	C4055637
27306647	398	401	V-2	T033	C4284334
27306647	406	409	V-M	T033	C4284334
27306647	424	430	uptake	T043	C3888108
27306647	435	441	spread	T040	C1160712
27306647	451	455	RABV	T005	C0034497
27306647	456	464	variants	T033	C4284334
27306647	470	479	N2a cells	T025	C0007634
27306647	485	494	inversely	T080	C0439850
27306647	495	507	proportional	T080	C0205351
27306647	523	526	V-3	T033	C4284334
27306647	531	537	longer	T080	C0205166
27306647	538	548	incubation	T033	C1320226
27306647	553	562	evolution	T045	C0015219
27306647	563	570	periods	T079	C1948053
27306647	576	583	results	T169	C1274040
27306647	592	600	evidence	T078	C3887511
27306647	610	618	clinical	T080	C0205210
27306647	619	636	manifestations of	T080	C1280464
27306647	637	646	infection	T046	C3714514
27306647	652	655	bat	T015	C0324765
27306647	656	660	RABV	T005	C0034497
27306647	661	668	variant	T033	C4284334
27306647	669	674	occur	T052	C1709305
27306647	680	690	later time	T079	C1548197
27306647	696	704	compared	T052	C1707455
27306647	717	725	observed	T169	C1441672
27306647	731	737	canine	T015	C0012984
27306647	742	750	marmoset	T015	C0006764
27306647	751	763	rabies virus	T005	C0034497
27306647	764	772	variants	T033	C4284334

27872234|t|Downregulation of Endothelial Transient Receptor Potential Vanilloid Type 4 Channel and Small-Conductance of Ca2+-Activated K+ Channels Underpins Impaired Endothelium-Dependent Hyperpolarization in Hypertension
27872234|a|Endothelium-dependent hyperpolarization (EDH)-mediated responses are impaired in hypertension, but the underlying mechanisms have not yet been determined. The activation of small- and intermediate-conductance of Ca(2+)-activated K(+) channels (SKCa and IKCa) underpins EDH -mediated responses. It was recently reported that Ca(2+) influx through endothelial transient receptor potential vanilloid type 4 channel (TRPV4) is a prerequisite for the activation of SKCa / IKCa in endothelial cells in specific beds. Here, we attempted to determine whether the impairment of EDH in hypertension is attributable to the dysfunction of TRPV4 and S / IKCa, using isolated superior mesenteric arteries of 20-week-old stroke-prone spontaneously hypertensive rats (SHRSP) and age-matched Wistar-Kyoto (WKY) rats. In the WKY arteries, EDH -mediated responses were reduced by a combination of SKCa / IKCa blockers (apamin plus TRAM-34; 1-[(2-chlorophenyl)diphenylmethl]-1H-pyrazole) and by the blockade of TRPV4 with the selective antagonist RN-1734 or HC-067047. In the SHRSP arteries, EDH-mediated hyperpolarization and relaxation were significantly impaired when compared with WKY. GSK1016790A, a selective TRPV4 activator, evoked robust hyperpolarization and relaxation in WKY arteries. In contrast, in SHRSP arteries, the GSK1016790A -evoked hyperpolarization was small and relaxation was absent. Hyperpolarization and relaxation to cyclohexyl-[2-(3,5-dimethyl-pyrazol-1-yl)-6-methyl-pyrimidin-4-yl]-amine, a selective SKCa activator, were marginally decreased in SHRSP arteries compared with WKY arteries. The expression of endothelial TRPV4 and SKCa protein was significantly decreased in the SHRSP mesenteric arteries compared with those of WKY, whereas function and expression of IKCa were preserved in SHRSP arteries. These findings suggest that EDH -mediated responses are impaired in superior mesenteric arteries of SHRSP because of a reduction in both TRPV4 and SKCa input to EDH.
27872234	0	14	Downregulation	T044	C0013081
27872234	18	83	Endothelial Transient Receptor Potential Vanilloid Type 4 Channel	T116,T123	C1563722
27872234	88	135	Small-Conductance of Ca2+-Activated K+ Channels	T116,T123	C1571638
27872234	146	154	Impaired	T169	C0221099
27872234	155	194	Endothelium-Dependent Hyperpolarization	T123	C0082428
27872234	198	210	Hypertension	T047	C0020538
27872234	211	250	Endothelium-dependent hyperpolarization	T123	C0082428
27872234	252	255	EDH	T123	C0082428
27872234	266	275	responses	T033	C1704632
27872234	280	288	impaired	T169	C0221099
27872234	292	304	hypertension	T047	C0020538
27872234	325	335	mechanisms	T169	C0441712
27872234	370	380	activation	T052	C1879547
27872234	384	390	small-	T116,T123	C1571638
27872234	395	453	intermediate-conductance of Ca(2+)-activated K(+) channels	T116,T123	C1571649
27872234	455	459	SKCa	T116,T123	C1571638
27872234	464	468	IKCa	T116,T123	C1571649
27872234	480	483	EDH	T123	C0082428
27872234	494	503	responses	T033	C1704632
27872234	521	529	reported	T170	C0684224
27872234	535	548	Ca(2+) influx	T043	C3158761
27872234	557	622	endothelial transient receptor potential vanilloid type 4 channel	T116,T123	C1563722
27872234	624	629	TRPV4	T116,T123	C1563722
27872234	636	648	prerequisite	T078	C0679209
27872234	657	667	activation	T052	C1879547
27872234	671	675	SKCa	T116,T123	C1571638
27872234	678	682	IKCa	T116,T123	C1571649
27872234	686	703	endothelial cells	T025	C0225336
27872234	731	740	attempted	T051	C1516084
27872234	766	776	impairment	T169	C0221099
27872234	780	783	EDH	T123	C0082428
27872234	787	799	hypertension	T047	C0020538
27872234	823	834	dysfunction	T077	C3887504
27872234	838	843	TRPV4	T116,T123	C1563722
27872234	848	849	S	T116,T123	C1571638
27872234	852	856	IKCa	T116,T123	C1571649
27872234	873	901	superior mesenteric arteries	T023	C0162861
27872234	917	961	stroke-prone spontaneously hypertensive rats	T015	C0034705
27872234	963	968	SHRSP	T015	C0034705
27872234	986	1009	Wistar-Kyoto (WKY) rats	T015	C0034709
27872234	1018	1021	WKY	T015	C0034709
27872234	1022	1030	arteries	T023	C0003842
27872234	1032	1035	EDH	T123	C0082428
27872234	1046	1055	responses	T033	C1704632
27872234	1061	1068	reduced	T080	C0392756
27872234	1074	1085	combination	T080	C0205195
27872234	1089	1093	SKCa	T116,T123	C1571638
27872234	1096	1100	IKCa	T116,T123	C1571649
27872234	1101	1109	blockers	T121	C0870261
27872234	1111	1117	apamin	T116,T123,T131	C0003521
27872234	1123	1130	TRAM-34	T109,T121	C0916207
27872234	1132	1177	1-[(2-chlorophenyl)diphenylmethl]-1H-pyrazole	T109,T121	C0916207
27872234	1190	1198	blockade	T169	C0332206
27872234	1202	1207	TRPV4	T116,T123	C1563722
27872234	1227	1237	antagonist	T120	C0243076
27872234	1238	1245	RN-1734	T109	C2744078
27872234	1249	1258	HC-067047	T109,T121	C3493142
27872234	1267	1272	SHRSP	T015	C0034705
27872234	1273	1281	arteries	T023	C0003842
27872234	1283	1313	EDH-mediated hyperpolarization	T123	C0082428
27872234	1318	1328	relaxation	T052	C0035028
27872234	1334	1347	significantly	T078	C0750502
27872234	1348	1356	impaired	T169	C0221099
27872234	1376	1379	WKY	T015	C0034709
27872234	1381	1392	GSK1016790A	T109	C2604031
27872234	1406	1411	TRPV4	T116,T123	C1563722
27872234	1412	1421	activator	T121	C0243192
27872234	1437	1454	hyperpolarization	T043	C2262820
27872234	1459	1469	relaxation	T052	C0035028
27872234	1473	1476	WKY	T015	C0034709
27872234	1477	1485	arteries	T023	C0003842
27872234	1503	1508	SHRSP	T015	C0034705
27872234	1509	1517	arteries	T023	C0003842
27872234	1523	1534	GSK1016790A	T109	C2604031
27872234	1543	1560	hyperpolarization	T043	C2262820
27872234	1575	1585	relaxation	T052	C0035028
27872234	1590	1596	absent	T169	C0332197
27872234	1598	1615	Hyperpolarization	T043	C2262820
27872234	1620	1630	relaxation	T052	C0035028
27872234	1634	1706	cyclohexyl-[2-(3,5-dimethyl-pyrazol-1-yl)-6-methyl-pyrimidin-4-yl]-amine	T109,T121	C2976731
27872234	1720	1724	SKCa	T116,T123	C1571638
27872234	1725	1734	activator	T121	C0243192
27872234	1741	1751	marginally	T080	C1947914
27872234	1752	1761	decreased	T081	C0205216
27872234	1765	1770	SHRSP	T015	C0034705
27872234	1771	1779	arteries	T023	C0003842
27872234	1794	1797	WKY	T015	C0034709
27872234	1798	1806	arteries	T023	C0003842
27872234	1812	1822	expression	T045	C1171362
27872234	1826	1843	endothelial TRPV4	T116,T123	C1563722
27872234	1848	1852	SKCa	T116,T123	C1571638
27872234	1865	1888	significantly decreased	T081	C4055638
27872234	1896	1901	SHRSP	T015	C0034705
27872234	1902	1921	mesenteric arteries	T023	C0162861
27872234	1945	1948	WKY	T015	C0034709
27872234	1958	1966	function	T169	C0542341
27872234	1971	1981	expression	T045	C1171362
27872234	1985	1989	IKCa	T116,T123	C1571649
27872234	2008	2013	SHRSP	T015	C0034705
27872234	2014	2022	arteries	T023	C0003842
27872234	2030	2038	findings	T033	C0243095
27872234	2052	2055	EDH	T123	C0082428
27872234	2066	2075	responses	T033	C1704632
27872234	2080	2088	impaired	T169	C0221099
27872234	2092	2120	superior mesenteric arteries	T023	C0162861
27872234	2124	2129	SHRSP	T015	C0034705
27872234	2143	2152	reduction	T061	C0441610
27872234	2161	2166	TRPV4	T116,T123	C1563722
27872234	2171	2175	SKCa	T116,T123	C1571638
27872234	2176	2181	input	T077	C1708517
27872234	2185	2188	EDH	T123	C0082428

27565266|t|Considering Cost-Effectiveness in Cardiology Clinical Guidelines: Progress and Prospects
27565266|a|Since the 1980s, when the American College of Cardiology (ACC) and the American Heart Association (AHA) established a joint task force to examine the use of cardiovascular procedures and therapies, cardiologists have been leaders in the development of clinical practice guidelines. The ACC/AHA guidelines development process has evolved considerably over the last 30 or more years. Guidelines now focus on clinical conditions, such as angina, instead of procedures, such as bypass surgery. There is a formal organizational structure, with dedicated staff, a standing committee on practice guidelines, and specific panels of volunteer experts on each topic. This process tightly manages conflicts of interest and strives for evidence-based, as opposed to opinion-based, guidelines, with a clear citation of the supporting evidence. Traditional clinical guidelines consider only what is best for the individual patient, and have explicitly not considered the cost to society. Nevertheless, in many guidelines development meetings, high cost was implicitly considered: if a procedure was extremely costly, the evidence needed to be very strong. The Guidelines Committee recognized that cost considerations ought to be made more transparent, and that the evidence on economic value should be explicitly cited when available. These considerations were formalized by a recent white paper on incorporating economic considerations into ACC/AHA guidelines. In considering value, it is necessary to assess the quality of the evidence as well as to define levels of value. The next ACC/AHA guideline will incorporate value as a part of its recommendations. This will be an evidence-based process in which published economic assessments relating to key questions will be reviewed.
27565266	0	11	Considering	T078	C0750591
27565266	12	30	Cost-Effectiveness	T081	C0010181
27565266	34	44	Cardiology	T091	C0007189
27565266	45	64	Clinical Guidelines	T170	C0282451
27565266	115	151	American College of Cardiology (ACC)	T093	C0920545
27565266	160	186	American Heart Association	T093	C0002458
27565266	188	191	AHA	T093	C0002458
27565266	246	271	cardiovascular procedures	T061	C0189573
27565266	276	285	therapies	T061	C0087111
27565266	287	300	cardiologists	T097	C0175906
27565266	326	337	development	T169	C1527148
27565266	341	369	clinical practice guidelines	T170	C0282451
27565266	375	382	ACC/AHA	T170	C4072694
27565266	383	393	guidelines	T170	C0282451
27565266	394	405	development	T169	C1527148
27565266	471	481	Guidelines	T170	C0282451
27565266	495	514	clinical conditions	T091	C0030667
27565266	524	530	angina	T184	C0002962
27565266	543	553	procedures	T061	C0184661
27565266	563	577	bypass surgery	T061	C1536078
27565266	597	621	organizational structure	T170	C0687114
27565266	638	643	staff	T097	C0851286
27565266	656	665	committee	T096	C2699414
27565266	669	688	practice guidelines	T170	C0282451
27565266	713	730	volunteer experts	T097	C0019989
27565266	813	827	evidence-based	T169	C1510541
27565266	858	868	guidelines	T170	C0282451
27565266	910	918	evidence	T078	C3887511
27565266	932	951	clinical guidelines	T170	C0282451
27565266	987	997	individual	T098	C0237401
27565266	998	1005	patient	T101	C0030705
27565266	1046	1061	cost to society	T081	C0683770
27565266	1085	1095	guidelines	T170	C0282451
27565266	1096	1107	development	T169	C1527148
27565266	1108	1116	meetings	T052	C0556656
27565266	1118	1127	high cost	T090	C0039425
27565266	1143	1153	considered	T078	C0750591
27565266	1160	1169	procedure	T061	C0184661
27565266	1174	1190	extremely costly	T033	C0243095
27565266	1196	1204	evidence	T078	C3887511
27565266	1235	1245	Guidelines	T170	C0282451
27565266	1246	1255	Committee	T096	C2699414
27565266	1272	1276	cost	T081	C0010186
27565266	1277	1291	considerations	T033	C0518609
27565266	1314	1325	transparent	T080	C0522503
27565266	1340	1348	evidence	T078	C3887511
27565266	1352	1360	economic	T169	C0013557
27565266	1416	1430	considerations	T033	C0518609
27565266	1488	1496	economic	T169	C0013557
27565266	1497	1511	considerations	T033	C0518609
27565266	1517	1524	ACC/AHA	T170	C4072694
27565266	1525	1535	guidelines	T170	C0282451
27565266	1589	1596	quality	T080	C0332306
27565266	1604	1612	evidence	T078	C3887511
27565266	1634	1649	levels of value	T080	C0441889
27565266	1660	1667	ACC/AHA	T170	C4072694
27565266	1668	1677	guideline	T170	C0282451
27565266	1751	1773	evidence-based process	T169	C1510541
27565266	1783	1792	published	T057	C0034037
27565266	1793	1801	economic	T169	C0013557
27565266	1802	1813	assessments	T058	C0220825

27507702|t|Transcriptome sequencing and de novo characterization of Korean endemic land snail, Koreanohadra kurodana for functional transcripts and SSR markers
27507702|a|The Korean endemic land snail Koreanohadra kurodana (Gastropoda: Bradybaenidae) found in humid areas of broadleaf forests and shrubs have been considered vulnerable as the number of individuals are declining in recent years. The species is poorly characterized at the genomic level that limits the understanding of functions at the molecular and genetics level. In the present study, we performed de novo transcriptome sequencing to produce a comprehensive transcript dataset of visceral mass tissue of K. kurodana by the Illumina paired-end sequencing technology. Over 234 million quality reads were assembled to a total of 315,924 contigs and 191,071 unigenes, with an average and N50 length of 585.6 and 715 bp and 678 and 927 bp, respectively. Overall, 36.32 % of the unigenes found matches to known protein / nucleotide sequences in the public databases. The direction of the unigenes to functional categories was determined using COG, GO, KEGG, and InterProScan protein domain search. The GO analysis search resulted in 22,967 unigenes (12.02 %) being categorized into 40 functional groups. The KEGG annotation revealed that metabolism pathway genes were enriched. The most prominent protein motifs include the zinc finger, ribonuclease H, reverse transcriptase, and ankyrin repeat domains. The simple sequence repeats (SSRs) identified from >1 kb length of unigenes show a dominancy of dinucleotide repeat motifs followed with tri- and tetranucleotide motifs. A number of unigenes were putatively assessed to belong to adaptation and defense mechanisms including heat shock proteins 70, Toll-like receptor 4, AMP-activated protein kinase, aquaporin-2, etc. Our data provide a rich source for the identification and functional characterization of new genes and candidate polymorphic SSR markers in K. kurodana. The availability of transcriptome information (http://bioinfo.sch.ac.kr/submission/) would promote the utilization of the resources for phylogenetics study and genetic diversity assessment.
27507702	0	24	Transcriptome sequencing	T059	C4086963
27507702	29	36	de novo	T078	C1515568
27507702	37	53	characterization	T052	C1880022
27507702	57	63	Korean	T083	C0022771
27507702	72	82	land snail	T204	C0037378
27507702	84	105	Koreanohadra kurodana	T204	C0037378
27507702	121	132	transcripts	T114	C1519595
27507702	137	140	SSR	T114,T123	C1519302
27507702	141	148	markers	T045	C0017393
27507702	153	159	Korean	T083	C0022771
27507702	168	178	land snail	T204	C0037378
27507702	179	200	Koreanohadra kurodana	T204	C0037378
27507702	202	212	Gastropoda	T204	C0324023
27507702	214	227	Bradybaenidae	T204	C1040093
27507702	238	249	humid areas	T067	C0563027
27507702	253	270	broadleaf forests	T070	C0086312
27507702	275	281	shrubs	T002	C0446286
27507702	331	342	individuals	T098	C0237401
27507702	367	372	years	T079	C0439234
27507702	378	385	species	T204	C0684063
27507702	417	430	genomic level	T028	C0017428
27507702	464	473	functions	T169	C0542341
27507702	481	490	molecular	T080	C1521991
27507702	495	509	genetics level	T169	C0314603
27507702	526	531	study	T062	C2603343
27507702	546	553	de novo	T078	C1515568
27507702	554	578	transcriptome sequencing	T059	C4086963
27507702	606	616	transcript	T114	C1519595
27507702	617	624	dataset	T170	C0150098
27507702	628	648	visceral mass tissue	T024	C0040300
27507702	652	663	K. kurodana	T204	C0037378
27507702	671	712	Illumina paired-end sequencing technology	T063	C1513384
27507702	782	789	contigs	T082	C1511491
27507702	802	810	unigenes	T170	C1710539
27507702	832	835	N50	T114	C0028630
27507702	836	842	length	T081	C1444754
27507702	921	929	unigenes	T170	C1710539
27507702	953	960	protein	T087	C0002518
27507702	963	983	nucleotide sequences	T086	C0004793
27507702	991	1007	public databases	T170	C0242356
27507702	1013	1022	direction	T082	C0449738
27507702	1030	1038	unigenes	T170	C1710539
27507702	1085	1088	COG	T170	C0242356
27507702	1090	1092	GO	T170	C1138831
27507702	1094	1098	KEGG	T170	C0242356
27507702	1104	1116	InterProScan	T170	C2826595
27507702	1117	1131	protein domain	T087	C1514562
27507702	1132	1138	search	T052	C1706202
27507702	1144	1146	GO	T170	C1138831
27507702	1147	1155	analysis	T062	C0936012
27507702	1182	1190	unigenes	T170	C1710539
27507702	1227	1244	functional groups	T120	C0598132
27507702	1250	1265	KEGG annotation	T170	C0242356
27507702	1280	1298	metabolism pathway	T169	C1291081
27507702	1299	1304	genes	T028	C0017337
27507702	1339	1353	protein motifs	T087	C1514562
27507702	1366	1377	zinc finger	T087	C0080347
27507702	1379	1393	ribonuclease H	T116,T126	C0085431
27507702	1395	1416	reverse transcriptase	T116,T126	C0035379
27507702	1422	1444	ankyrin repeat domains	T044	C1956127
27507702	1450	1473	simple sequence repeats	T114,T123	C1519302
27507702	1475	1479	SSRs	T114,T123	C1519302
27507702	1503	1509	length	T081	C1444754
27507702	1513	1521	unigenes	T170	C1710539
27507702	1542	1568	dinucleotide repeat motifs	T114,T123	C0282524
27507702	1583	1587	tri-	T114,T123	C0282537
27507702	1592	1614	tetranucleotide motifs	T114,T123	C0282521
27507702	1628	1636	unigenes	T170	C1710539
27507702	1675	1685	adaptation	T038	C0392673
27507702	1690	1708	defense mechanisms	T041	C0011142
27507702	1719	1741	heat shock proteins 70	T116,T123	C0243043
27507702	1743	1763	Toll-like receptor 4	T116,T192	C1411976
27507702	1765	1793	AMP-activated protein kinase	T116,T126	C2350345
27507702	1795	1806	aquaporin-2	T116,T123	C0213238
27507702	1852	1866	identification	T080	C0205396
27507702	1882	1898	characterization	T052	C1880022
27507702	1906	1911	genes	T028	C0017337
27507702	1926	1937	polymorphic	T080	C1882417
27507702	1938	1941	SSR	T114,T123	C1519302
27507702	1942	1949	markers	T045	C0017393
27507702	1953	1964	K. kurodana	T204	C0037378
27507702	1986	1999	transcriptome	T086	C3178810
27507702	2013	2049	http://bioinfo.sch.ac.kr/submission/	T170	C0872179
27507702	2102	2121	phylogenetics study	T062	C1519068
27507702	2126	2143	genetic diversity	T070	C0042333
27507702	2144	2154	assessment	T052	C1516048

28127757|t|Donor bone marrow cells are essential for iNKT cell -mediated Foxp3 + Treg cell expansion in a murine model of transplantation tolerance
28127757|a|Mixed chimerism induction is the most reliable method for establishing transplantation tolerance. We previously described a novel treatment using a suboptimal dose of anti-CD40 ligand (anti-CD40L) and liposomal formulation of a ligand for invariant natural killer T cells administered to sub-lethally irradiated recipient mice after donor bone marrow cell (BMC) transfer. Recipient mice treated with this regimen showed expansion of a Foxp3 -positive regulatory T(Treg) cell phenotype, and formation of mixed chimera. However, the mechanism of expansion and bioactivity of Treg cells remains unclear. Here, we examine the role of donor BMCs in the expansion of bioactive Treg cells. The mouse model was transplanted with a heart allograft the day after treatment. The results showed that transfer of spleen cells in place of BMCs failed to deplete host interferon (IFN)-γ -producing CD8(+) T cells, expand host Ki67(+) CD4(+) CD25(+) Foxp3(+) Treg cells, and prolong graft survival. Severe combined immunodeficiency mice who received Treg cells obtained from BMC-recipients accepted skin grafts in an allo-specific manner. Myeloid-derived suppressor cells, which were a copious cell subset in BMCs, enhanced the Ki67 expression of Treg cells. This suggests that donor BMCs are indispensable for the expansion of host bioactive Treg cells in our novel treatment for transplant tolerance induction.
28127757	0	5	Donor	T098	C0013018
28127757	6	23	bone marrow cells	T025	C0005955
28127757	42	51	iNKT cell	T025	C2350467
28127757	62	67	Foxp3	T116,T123	C1505260
28127757	70	79	Treg cell	T025	C0039198
28127757	80	89	expansion	T043	C0007595
28127757	95	101	murine	T015	C0026809
28127757	102	107	model	T008	C0599779
28127757	111	136	transplantation tolerance	T040	C0887936
28127757	137	152	Mixed chimerism	T032	C0333678
28127757	153	162	induction	T045	C0017391
28127757	184	190	method	T170	C0025663
28127757	208	233	transplantation tolerance	T040	C0887936
28127757	267	276	treatment	T061	C0087111
28127757	285	300	suboptimal dose	T081	C0178602
28127757	304	320	anti-CD40 ligand	T121	C1254351
28127757	322	332	anti-CD40L	T121	C1254351
28127757	338	347	liposomal	T109	C0023828
28127757	348	359	formulation	T122	C0013058
28127757	376	408	invariant natural killer T cells	T025	C2350467
28127757	409	421	administered	T169	C1521801
28127757	425	437	sub-lethally	T033	C0243095
28127757	449	463	recipient mice	T015	C0025929
28127757	470	475	donor	T098	C0013018
28127757	476	492	bone marrow cell	T025	C0005955
28127757	494	497	BMC	T025	C0005955
28127757	499	507	transfer	T061	C0040732
28127757	509	523	Recipient mice	T015	C0025929
28127757	524	536	treated with	T061	C0332293
28127757	542	549	regimen	T061	C0040808
28127757	557	566	expansion	T043	C0007595
28127757	572	577	Foxp3	T116,T123	C1505260
28127757	588	611	regulatory T(Treg) cell	T025	C0039198
28127757	612	621	phenotype	T032	C0031437
28127757	640	653	mixed chimera	T001	C0206612
28127757	668	677	mechanism	T043	C0007613
28127757	681	690	expansion	T043	C0007595
28127757	695	706	bioactivity	T052	C0441655
28127757	710	720	Treg cells	T025	C0039198
28127757	747	754	examine	T033	C0332128
28127757	767	772	donor	T098	C0013018
28127757	773	777	BMCs	T025	C0005955
28127757	785	794	expansion	T043	C0007595
28127757	808	818	Treg cells	T025	C0039198
28127757	824	835	mouse model	T050	C2986594
28127757	840	852	transplanted	T061	C0040732
28127757	860	875	heart allograft	T023	C0564471
28127757	880	883	day	T079	C0439228
28127757	890	899	treatment	T061	C0087111
28127757	925	933	transfer	T061	C0040732
28127757	937	943	spleen	T023	C0037993
28127757	944	949	cells	T025	C0007634
28127757	962	966	BMCs	T025	C0005955
28127757	985	989	host	T026	C1819995
28127757	990	1008	interferon (IFN)-γ	T116,T121,T129	C3539881
28127757	1020	1034	CD8(+) T cells	T025	C0242629
28127757	1043	1047	host	T026	C1819995
28127757	1048	1090	Ki67(+) CD4(+) CD25(+) Foxp3(+) Treg cells	T025	C0039198
28127757	1104	1118	graft survival	T042	C0018131
28127757	1136	1152	immunodeficiency	T047	C0021051
28127757	1153	1157	mice	T015	C0025929
28127757	1171	1181	Treg cells	T025	C0039198
28127757	1196	1210	BMC-recipients	T101	C0376387
28127757	1220	1231	skin grafts	T122	C0181078
28127757	1260	1292	Myeloid-derived suppressor cells	T025	C4277543
28127757	1307	1326	copious cell subset	T025	C0007634
28127757	1330	1334	BMCs	T025	C0005955
28127757	1349	1353	Ki67	T116,T129,T130	C0208804
28127757	1354	1364	expression	T045	C1171362
28127757	1368	1378	Treg cells	T025	C0039198
28127757	1399	1404	donor	T098	C0013018
28127757	1405	1409	BMCs	T025	C0005955
28127757	1436	1445	expansion	T043	C0007595
28127757	1449	1453	host	T026	C1819995
28127757	1464	1474	Treg cells	T025	C0039198
28127757	1488	1497	treatment	T061	C0087111
28127757	1502	1532	transplant tolerance induction	T038	C1817969

28466270|t|Synaptic NMDA Receptor Activation Induces Ubiquitination and Degradation of STEP61
28466270|a|NMDA receptor signaling is critical for the development of synaptic plasticity, learning, and memory, and dysregulation of NMDAR signaling is implicated in a number of neurological disorders including schizophrenia (SZ). Previous work has demonstrated that the STriatal-Enriched protein tyrosine Phosphatase 61 kDa (STEP61) is elevated in human SZ postmortem cortical samples and after administration of psychotomimetics to cultures or mice. Here, we report that activation of synaptic NMDAR by bicuculline or D-serine results in the ubiquitination and proteasomal degradation of STEP61, and increased surface localization of GluN1 / GluN2B receptors. Moreover, bicuculline or D-serine treatments rescue the motor and cognitive deficits in MK-801 -treated mice and reduce STEP61 in mouse frontal cortex. These results suggest that STEP61 may contribute to the therapeutic effects of D-serine.
28466270	0	8	Synaptic	T030	C0039062
28466270	9	22	NMDA Receptor	T116,T192	C0080093
28466270	23	33	Activation	T043	C1514758
28466270	42	56	Ubiquitination	T044	C1519751
28466270	61	72	Degradation	T044	C0597297
28466270	76	82	STEP61	T116,T126	C1453844
28466270	83	96	NMDA receptor	T116,T192	C0080093
28466270	97	106	signaling	T043	C0037083
28466270	142	161	synaptic plasticity	T042	C0027880
28466270	163	171	learning	T041	C0023185
28466270	177	183	memory	T041	C0025260
28466270	189	202	dysregulation	T169	C0221099
28466270	206	211	NMDAR	T116,T192	C0080093
28466270	212	221	signaling	T043	C0037083
28466270	251	273	neurological disorders	T047	C0027765
28466270	284	297	schizophrenia	T048	C0036341
28466270	299	301	SZ	T048	C0036341
28466270	344	397	STriatal-Enriched protein tyrosine Phosphatase 61 kDa	T116,T126	C1453844
28466270	399	405	STEP61	T116,T126	C1453844
28466270	422	427	human	T016	C0086418
28466270	428	430	SZ	T048	C0036341
28466270	431	441	postmortem	T060	C0004398
28466270	442	450	cortical	T023	C0007776
28466270	451	458	samples	T077	C2347026
28466270	469	483	administration	T061	C1533734
28466270	487	503	psychotomimetics	UnknownType	C0684170
28466270	507	515	cultures	T059	C0040284
28466270	519	523	mice	T015	C0025929
28466270	546	556	activation	T043	C1514758
28466270	560	568	synaptic	T030	C0039062
28466270	569	574	NMDAR	T116,T192	C0080093
28466270	578	589	bicuculline	T109,T121	C0005372
28466270	593	601	D-serine	T116	C1880218
28466270	617	631	ubiquitination	T044	C1519751
28466270	636	659	proteasomal degradation	T044	C0597297
28466270	663	669	STEP61	T116,T126	C1447230
28466270	709	714	GluN1	T116,T192	C0061465
28466270	717	733	GluN2B receptors	T192	C1099474
28466270	745	756	bicuculline	T109,T121	C0005372
28466270	760	768	D-serine	T116	C1880218
28466270	769	779	treatments	T061	C0087111
28466270	791	796	motor	T033	C0521654
28466270	801	819	cognitive deficits	T048	C0009241
28466270	823	829	MK-801	T109,T121	C0813872
28466270	839	843	mice	T015	C0025929
28466270	855	861	STEP61	T116,T126	C1447230
28466270	865	870	mouse	T015	C0025929
28466270	871	885	frontal cortex	T023	C0016733
28466270	893	900	results	T169	C1274040
28466270	914	920	STEP61	T116,T126	C1447230
28466270	943	962	therapeutic effects	T201	C1527144
28466270	966	974	D-serine	T116	C1880218

27441638|t|Potentiation of LPS - Induced Apoptotic Cell Death in Human Hepatoma HepG2 Cells by Aspirin via ROS and Mitochondrial Dysfunction: Protection by N-Acetyl Cysteine
27441638|a|Cytotoxicity and inflammation - associated toxic responses have been observed to be induced by bacterial lipopolysaccharides (LPS) in vitro and in vivo respectively. Use of nonsteroidal anti-inflammatory drugs (NSAIDs), such as aspirin, has been reported to be beneficial in inflammation - associated diseases like cancer, diabetes and cardiovascular disorders. Their precise molecular mechanisms, however, are not clearly understood. Our previous studies on aspirin treated HepG2 cells strongly suggest cell cycle arrest and induction of apoptosis associated with mitochondrial dysfunction. In the present study, we have further demonstrated that HepG2 cells treated with LPS alone or in combination with aspirin induces subcellular toxic responses which are accompanied by increase in reactive oxygen species (ROS) production, oxidative stress, mitochondrial respiratory dysfunction and apoptosis. The LPS / Aspirin induced toxicity was attenuated by pre-treatment of cells with N-acetyl cysteine (NAC). Alterations in oxidative stress and glutathione - dependent redox-homeostasis were more pronounced in mitochondria compared to extra - mitochondrial cellular compartments. Pre-treatment of HepG2 cells with NAC exhibited a selective protection in redox homeostasis and mitochondrial dysfunction. Our results suggest that the altered redox metabolism, oxidative stress and mitochondrial function in HepG2 cells play a critical role in LPS / aspirin - induced cytotoxicity. These results may help in better understanding the pharmacological, toxicological and therapeutic properties of NSAIDs in cancer cells exposed to bacterial endotoxins.
27441638	0	12	Potentiation	T061	C0279023
27441638	16	19	LPS	T109	C0023810
27441638	22	29	Induced	T046	C0007994
27441638	30	50	Apoptotic Cell Death	T043	C0162638
27441638	54	80	Human Hepatoma HepG2 Cells	T025	C2717940
27441638	84	91	Aspirin	T109,T121	C0004057
27441638	96	99	ROS	T123,T196	C0162772
27441638	104	129	Mitochondrial Dysfunction	T033	C4021734
27441638	131	141	Protection	T033	C1545588
27441638	145	162	N-Acetyl Cysteine	T116,T121	C0001047
27441638	163	175	Cytotoxicity	T049	C0596402
27441638	180	192	inflammation	T046	C0021368
27441638	195	205	associated	T046	C0243082
27441638	206	211	toxic	T080	C1407029
27441638	212	221	responses	T032	C0871261
27441638	232	240	observed	T169	C1441672
27441638	247	254	induced	T169	C0205263
27441638	258	267	bacterial	T080	C0521009
27441638	268	287	lipopolysaccharides	T109	C0023810
27441638	289	292	LPS	T109	C0023810
27441638	294	302	in vitro	T080	C1533691
27441638	307	314	in vivo	T082	C1515655
27441638	336	372	nonsteroidal anti-inflammatory drugs	T121	C0003211
27441638	374	380	NSAIDs	T121	C0003211
27441638	391	398	aspirin	T109,T121	C0004057
27441638	409	417	reported	T058	C0700287
27441638	438	450	inflammation	T046	C0021368
27441638	453	472	associated diseases	T046	C0243083
27441638	478	484	cancer	T191	C0006826
27441638	486	494	diabetes	T047	C0011847
27441638	499	523	cardiovascular disorders	T047	C0007222
27441638	539	548	molecular	T080	C1521991
27441638	549	559	mechanisms	T169	C0441712
27441638	611	618	studies	T062	C0008972
27441638	622	629	aspirin	T109,T121	C0004057
27441638	630	637	treated	T061	C0332293
27441638	638	649	HepG2 cells	T025	C2717940
27441638	667	684	cell cycle arrest	T043	C1155873
27441638	689	698	induction	T169	C0205263
27441638	702	711	apoptosis	T043	C0162638
27441638	712	727	associated with	T080	C0332281
27441638	728	753	mitochondrial dysfunction	T033	C4021734
27441638	770	775	study	T062	C0008972
27441638	811	822	HepG2 cells	T025	C2717940
27441638	823	835	treated with	T061	C0332293
27441638	836	839	LPS	T109	C0023810
27441638	852	863	combination	T080	C0205195
27441638	869	876	aspirin	T109,T121	C0004057
27441638	877	884	induces	T169	C0205263
27441638	885	896	subcellular	T026	C0729605
27441638	897	912	toxic responses	T043	C3549372
27441638	938	946	increase	T169	C0442805
27441638	950	973	reactive oxygen species	T123,T196	C0162772
27441638	975	978	ROS	T123,T196	C0162772
27441638	992	1008	oxidative stress	T049	C0242606
27441638	1010	1047	mitochondrial respiratory dysfunction	T033	C4021734
27441638	1052	1061	apoptosis	T043	C0162638
27441638	1067	1070	LPS	T109	C0023810
27441638	1073	1080	Aspirin	T109,T121	C0004057
27441638	1081	1088	induced	T169	C0205263
27441638	1089	1097	toxicity	T037	C0600688
27441638	1102	1112	attenuated	T052	C0599946
27441638	1116	1129	pre-treatment	T079	C2709094
27441638	1133	1138	cells	T025	C0007634
27441638	1144	1161	N-acetyl cysteine	T116,T121	C0001047
27441638	1163	1166	NAC	T116,T121	C0001047
27441638	1184	1200	oxidative stress	T049	C0242606
27441638	1205	1216	glutathione	T116,T123	C0017817
27441638	1219	1228	dependent	T080	C0851827
27441638	1229	1246	redox-homeostasis	T043	C1156287
27441638	1271	1283	mitochondria	T026	C0026237
27441638	1284	1292	compared	T052	C1707455
27441638	1296	1301	extra	T082	C1254362
27441638	1304	1317	mitochondrial	T026	C0026237
27441638	1318	1339	cellular compartments	T026	C1166607
27441638	1341	1354	Pre-treatment	T079	C2709094
27441638	1358	1369	HepG2 cells	T025	C2717940
27441638	1375	1378	NAC	T116,T121	C0001047
27441638	1401	1411	protection	T033	C1545588
27441638	1415	1432	redox homeostasis	T043	C1156287
27441638	1437	1462	mitochondrial dysfunction	T033	C4021734
27441638	1468	1475	results	T033	C0683954
27441638	1493	1500	altered	T169	C0392747
27441638	1501	1517	redox metabolism	T043	C1156287
27441638	1519	1535	oxidative stress	T049	C0242606
27441638	1540	1553	mitochondrial	T026	C0026237
27441638	1554	1562	function	T169	C0542341
27441638	1566	1577	HepG2 cells	T025	C2717940
27441638	1602	1605	LPS	T109	C0023810
27441638	1608	1615	aspirin	T109,T121	C0004057
27441638	1618	1625	induced	T169	C0205263
27441638	1626	1638	cytotoxicity	T049	C0596402
27441638	1646	1653	results	T033	C0683954
27441638	1691	1706	pharmacological	T169	C0205464
27441638	1708	1721	toxicological	T169	C0205472
27441638	1726	1748	therapeutic properties	T169	C0039798
27441638	1752	1758	NSAIDs	T121	C0003211
27441638	1762	1774	cancer cells	T025	C0334227
27441638	1775	1782	exposed	T080	C0332157
27441638	1786	1806	bacterial endotoxins	T109,T131	C0014264

27370179|t|A case based reflection on communicating end of life information in non-English speaking patients
27370179|a|Mr X was a 56 year old Chinese man (non-English speaking), who presented to the emergency department with a range of non-specific symptoms. On full workup, he was diagnosed with an advanced cancer of the pancreas. It was an aggressive, highly treatment resistant cancer, with an alarmingly poor prognosis. Before the diagnosis had been made, the family had informed our team that we were not to discuss medical issues with Mr X directly, and that upon arriving on a diagnosis we were to come to them first and they would subsequently inform him. They reported that Mr X was in support of this arrangement. Eventually we told the family about Mr X's diagnosis, and they asserted their collective will to keep this information from him, reaffirming that all medical discussion go through them. However, the doctor in charge explained the diagnosis to Mr X using an interpreter while his family were away from his bed. In this discussion, I consider this case from the perspective of respecting patients' and families' preferences around medical treatment and care.
27370179	2	6	case	T169	C0868928
27370179	13	23	reflection	T033	C0243095
27370179	27	44	communicating end	T169	C0205196
27370179	48	52	life	T078	C0376558
27370179	53	64	information	T078	C1533716
27370179	68	88	non-English speaking	T033	C1546417
27370179	89	97	patients	T101	C0030705
27370179	112	120	year old	T079	C1510829
27370179	121	128	Chinese	T098	C0152035
27370179	129	132	man	T098	C0025266
27370179	134	154	non-English speaking	T033	C1546417
27370179	178	198	emergency department	T073,T093	C0562508
27370179	215	227	non-specific	T080	C0205370
27370179	228	236	symptoms	T184	C1457887
27370179	261	270	diagnosed	T033	C0011900
27370179	279	310	advanced cancer of the pancreas	T191	C0235974
27370179	322	332	aggressive	T191	C2945759
27370179	341	367	treatment resistant cancer	T047	C0871547
27370179	388	402	poor prognosis	T033	C0278252
27370179	415	424	diagnosis	T033	C0011900
27370179	444	450	family	T099	C0015576
27370179	468	472	team	T058	C0086390
27370179	501	508	medical	T169	C0205476
27370179	509	515	issues	T033	C0033213
27370179	564	573	diagnosis	T033	C0011900
27370179	675	682	support	T077	C1521721
27370179	727	733	family	T099	C0015576
27370179	747	756	diagnosis	T033	C0011900
27370179	782	797	collective will	UnknownType	C0680341
27370179	811	822	information	T078	C1533716
27370179	854	861	medical	T169	C0205476
27370179	862	872	discussion	T061	C0557061
27370179	903	919	doctor in charge	T097	C0031831
27370179	934	943	diagnosis	T033	C0011900
27370179	961	972	interpreter	T097	C0150646
27370179	983	989	family	T099	C0015576
27370179	1009	1012	bed	T073	C0004916
27370179	1050	1054	case	T169	C0868928
27370179	1079	1125	respecting patients' and families' preferences	T061	C1279750
27370179	1133	1159	medical treatment and care	T058	C0237726

28316382|t|Effect of Punica granatum fruit peel on glucose-6-phosphate dehydrogenase and malate dehydrogenase in amphistome Gastrothylax indicus
28316382|a|Increasing anthelmintic resistance and the impact of conventional anthelmintics on the environment, it is important to look for alternative strategies against helminth parasite in sheep. Important lipogenic enzymes like glucose-6-phosphate dehydrogenase (G-6-PDH) and malate dehydrogenase (MDH) show subcellular distribution pattern. Activity of G-6-PDH was largely restricted to cytosolic fraction while MDH was found in both cytosolic and mitochondrial fraction in Gastrothylax indicus. Following in vitro treatment with ethanolic and aqueous extracts of Punica granatum fruit peel and commercial anthelmintic, albendazole G-6-PDH activity was decreased by 19-32 %, whereas MDH was suppressed by 24-41 %, compared to the respective control. Albendazole was quite effective when compared with negative control and both the extracts. The results indicate that phytochemicals of plant may act as potential vermifuge or vermicide.
28316382	0	6	Effect	T080	C1280500
28316382	10	25	Punica granatum	T002	C1001173
28316382	26	36	fruit peel	T168	C0016767
28316382	40	73	glucose-6-phosphate dehydrogenase	T116,T126	C0017757
28316382	78	98	malate dehydrogenase	T116,T126	C0024544
28316382	102	112	amphistome	T204	C0684063
28316382	113	133	Gastrothylax indicus	T204	C3006520
28316382	134	144	Increasing	T169	C0442808
28316382	145	157	anthelmintic	T121	C0003158
28316382	158	168	resistance	T038	C0013203
28316382	177	183	impact	T080	C4049986
28316382	200	213	anthelmintics	T121	C0003158
28316382	221	232	environment	T082	C0014406
28316382	293	310	helminth parasite	T204	C0018893
28316382	314	319	sheep	T015	C0036945
28316382	331	348	lipogenic enzymes	T116,T126	C0014442
28316382	354	387	glucose-6-phosphate dehydrogenase	T116,T126	C0017757
28316382	389	396	G-6-PDH	T116,T126	C0017757
28316382	402	422	malate dehydrogenase	T116,T126	C0024544
28316382	424	427	MDH	T116,T126	C0024544
28316382	434	445	subcellular	T026	C3893246
28316382	446	466	distribution pattern	T082	C0449775
28316382	468	476	Activity	T044	C0243102
28316382	480	487	G-6-PDH	T116,T126	C0017757
28316382	514	532	cytosolic fraction	T026	C1511625
28316382	539	542	MDH	T116,T126	C0024544
28316382	561	570	cytosolic	T026	C1511625
28316382	575	597	mitochondrial fraction	T026	C0026237
28316382	601	621	Gastrothylax indicus	T204	C3006520
28316382	633	641	in vitro	T080	C1533691
28316382	642	651	treatment	T169	C1522326
28316382	657	666	ethanolic	T109,T121	C0001962
28316382	671	687	aqueous extracts	T167	C2828366
28316382	691	706	Punica granatum	T002	C1001173
28316382	707	717	fruit peel	T168	C0016767
28316382	733	745	anthelmintic	T121	C0003158
28316382	747	758	albendazole	T109,T121	C0001911
28316382	759	766	G-6-PDH	T116,T126	C0017757
28316382	767	775	activity	T044	C0243102
28316382	780	789	decreased	T080	C0392756
28316382	810	813	MDH	T116,T126	C0024544
28316382	818	828	suppressed	T169	C1260953
28316382	868	875	control	T167	C1550141
28316382	877	888	Albendazole	T109,T121	C0001911
28316382	899	908	effective	T080	C1704419
28316382	928	944	negative control	T077	C1947986
28316382	958	966	extracts	T167	C2828366
28316382	972	979	results	T169	C1274040
28316382	994	1008	phytochemicals	T109,T123	C0577749
28316382	1012	1017	plant	T002	C0032098
28316382	1029	1038	potential	T080	C3245505
28316382	1039	1048	vermifuge	T121	C0003158
28316382	1052	1061	vermicide	T131	C1254354

27613509|t|Improved individualized prediction of schizophrenia in subjects at familial high risk, based on neuroanatomical data, schizotypal and neurocognitive features
27613509|a|To date, there are no reliable markers for predicting onset of schizophrenia in individuals at high risk (HR). Substantial promise is, however, shown by a variety of pattern classification approaches to neuroimaging data. Here, we examined the predictive accuracy of support vector machine (SVM) in later diagnosing schizophrenia, at a single-subject level, using a cohort of HR individuals drawn from multiply affected families and a combination of neuroanatomical, schizotypal and neurocognitive variables. Baseline structural magnetic resonance imaging (MRI), schizotypal and neurocognitive data from 17 HR subjects, who subsequently developed schizophrenia and a matched group of 17 HR subjects who did not make the transition, yet had psychotic symptoms, were included in the analysis. We employed recursive feature elimination (RFE), in a nested cross-validation scheme to identify the most significant predictors of disease transition and enhance diagnostic performance. Classification accuracy was 94% when a self-completed measure of schizotypy, a declarative memory test and structural MRI data were combined into a single learning algorithm; higher than when either quantitative measure was used alone. The discriminative neuroanatomical pattern involved gray matter volume differences in frontal, orbito-frontal and occipital lobe regions bilaterally as well as parts of the superior, medial temporal lobe and cerebellar regions. Our findings suggest that an early SVM -based prediction of schizophrenia is possible and can be improved by combining schizotypal and neurocognitive features with neuroanatomical variables. However, our predictive model needs to be tested by classifying a new, independent HR cohort in order to estimate its validity.
27613509	9	23	individualized	T080	C1881197
27613509	24	34	prediction	T078	C0681842
27613509	38	51	schizophrenia	T048	C0036341
27613509	55	63	subjects	T098	C2349001
27613509	67	75	familial	T169	C0241888
27613509	76	85	high risk	T033	C0332167
27613509	96	116	neuroanatomical data	T078	C1511726
27613509	118	129	schizotypal	T048	C1443045
27613509	134	157	neurocognitive features	T048	C4041080
27613509	189	196	markers	T201	C0005516
27613509	201	211	predicting	T078	C0681842
27613509	212	220	onset of	T080	C0332162
27613509	221	234	schizophrenia	T048	C0036341
27613509	238	249	individuals	T098	C0237401
27613509	253	262	high risk	T033	C0332167
27613509	264	266	HR	T033	C0332167
27613509	324	331	pattern	T082	C0449774
27613509	332	346	classification	T185	C0008902
27613509	361	378	neuroimaging data	T060	C0679575
27613509	402	412	predictive	T080	C0681890
27613509	413	421	accuracy	T080	C4035952
27613509	425	447	support vector machine	T081	C2699740
27613509	449	452	SVM	T081	C2699740
27613509	463	473	diagnosing	T033	C0011900
27613509	474	487	schizophrenia	T048	C0036341
27613509	494	508	single-subject	T098	C2349001
27613509	524	530	cohort	T098	C0599755
27613509	534	536	HR	T033	C0332167
27613509	537	548	individuals	T098	C0237401
27613509	569	577	affected	T169	C0392760
27613509	578	586	families	T099	C0015576
27613509	608	623	neuroanatomical	T091	C0027816
27613509	625	636	schizotypal	T048	C1443045
27613509	641	665	neurocognitive variables	T170	C0518895
27613509	667	675	Baseline	T081	C1442488
27613509	687	713	magnetic resonance imaging	T060	C0024485
27613509	715	718	MRI	T060	C0024485
27613509	721	732	schizotypal	T048	C1443045
27613509	737	751	neurocognitive	T170	C0518895
27613509	752	756	data	T078	C1511726
27613509	765	767	HR	T033	C0332167
27613509	768	776	subjects	T098	C2349001
27613509	805	818	schizophrenia	T048	C0036341
27613509	825	838	matched group	T096	C0024908
27613509	845	847	HR	T033	C0332167
27613509	848	856	subjects	T098	C2349001
27613509	878	888	transition	T068	C0376627
27613509	894	916	had psychotic symptoms	T033	C0459435
27613509	939	947	analysis	T062	C0936012
27613509	961	990	recursive feature elimination	T170	C0002045
27613509	992	995	RFE	T170	C0002045
27613509	1010	1026	cross-validation	T062	C0681935
27613509	1067	1077	predictors	T078	C2698872
27613509	1081	1088	disease	T047	C0012634
27613509	1089	1099	transition	T052	C2700061
27613509	1112	1122	diagnostic	T169	C0348026
27613509	1136	1150	Classification	T185	C0008902
27613509	1151	1159	accuracy	T080	C0443131
27613509	1215	1238	declarative memory test	T041	C1285656
27613509	1254	1257	MRI	T060	C0024485
27613509	1258	1262	data	T078	C1511726
27613509	1300	1309	algorithm	T170	C0002045
27613509	1335	1355	quantitative measure	T081	C0392762
27613509	1391	1414	neuroanatomical pattern	T082	C0449774
27613509	1424	1435	gray matter	T024	C0018220
27613509	1436	1442	volume	T081	C0449468
27613509	1443	1454	differences	T081	C1705241
27613509	1458	1465	frontal	T029	C0549224
27613509	1467	1481	orbito-frontal	T029	C0549224
27613509	1486	1508	occipital lobe regions	T023	C0028785
27613509	1509	1520	bilaterally	T082	C0238767
27613509	1545	1553	superior	T023	C0039485
27613509	1555	1575	medial temporal lobe	T023	C0039485
27613509	1580	1598	cerebellar regions	T023	C0007765
27613509	1635	1638	SVM	T081	C2699740
27613509	1646	1656	prediction	T078	C0681842
27613509	1660	1673	schizophrenia	T048	C0036341
27613509	1719	1730	schizotypal	T048	C1443045
27613509	1735	1758	neurocognitive features	T048	C4041080
27613509	1764	1789	neuroanatomical variables	T080	C0439828
27613509	1804	1814	predictive	T080	C0681890
27613509	1874	1876	HR	T033	C0332167
27613509	1877	1883	cohort	T098	C0599755

27738460|t|Thrombosis of the Saphenous Vein Stump after Varicose Vein Surgery
27738460|a|We evaluated thrombus extension in the proximal stump of the saphenous vein at 6 days, 4 weeks, and 16 weeks after saphenous vein surgery performed between July 2013 and March 2014 (18 patients, 29 limbs, and 31 stumps) using duplex ultrasonography. All thrombotic events were classified as endovenous heat-induced thrombosis (EHIT). Thrombus was observed in 27 stumps (87.1%), with only four (12.9%) stumps remaining without thrombus on postoperative day 6. Thrombus as EHIT class 2 was observed in one stump and as EHIT class 3 in another; in the remaining 25 stumps, it was observed as EHIT class 1 postoperatively. No further extension of thrombus was found at 4 and 16 weeks after surgery. The rate of thrombus formation in the proximal stump of the saphenous vein after conventional surgery is comparatively higher than that after thermoablation techniques. Further studies are required to determine adequate evaluation methods and appropriate therapies for stump thrombosis after varicose vein surgery. (This article is a translation of J Jpn Coll Angiol 2015; 55: 105-110).
27738460	0	10	Thrombosis	T046	C0040053
27738460	18	32	Saphenous Vein	T023	C0036186
27738460	33	38	Stump	T020	C0002690
27738460	45	66	Varicose Vein Surgery	T061	C0521235
27738460	70	79	evaluated	T058	C0220825
27738460	80	88	thrombus	T046	C0087086
27738460	89	98	extension	T169	C0231448
27738460	106	114	proximal	T082	C0205107
27738460	115	120	stump	T020	C0002690
27738460	128	142	saphenous vein	T023	C0036186
27738460	148	152	days	T079	C0439228
27738460	156	161	weeks	T079	C0439230
27738460	170	175	weeks	T079	C0439230
27738460	182	196	saphenous vein	T023	C0036186
27738460	197	204	surgery	T061	C0543467
27738460	223	227	July	T080	C3829447
27738460	237	242	March	T079	C3829202
27738460	252	260	patients	T101	C0030705
27738460	265	270	limbs	T023	C0015385
27738460	279	285	stumps	T020	C0002690
27738460	293	315	duplex ultrasonography	T060	C3825392
27738460	321	338	thrombotic events	T051	C0441471
27738460	344	354	classified	T185	C0008902
27738460	358	368	endovenous	T030	C0524444
27738460	369	392	heat-induced thrombosis	T046	C0040053
27738460	394	398	EHIT	T046	C0040053
27738460	401	409	Thrombus	T046	C0087086
27738460	429	435	stumps	T020	C0002690
27738460	468	474	stumps	T020	C0002690
27738460	475	484	remaining	T080	C1527428
27738460	493	501	thrombus	T046	C0087086
27738460	505	518	postoperative	T079	C0032790
27738460	519	522	day	T079	C0439228
27738460	526	534	Thrombus	T046	C0087086
27738460	538	542	EHIT	T046	C0040053
27738460	543	550	class 2	T170	C0441886
27738460	571	576	stump	T020	C0002690
27738460	584	588	EHIT	T046	C0040053
27738460	589	596	class 3	T170	C0441887
27738460	616	625	remaining	T080	C1527428
27738460	629	635	stumps	T020	C0002690
27738460	656	660	EHIT	T046	C0040053
27738460	661	668	class 1	T185	C0441885
27738460	669	684	postoperatively	T033	C0241311
27738460	686	688	No	T033	C1513916
27738460	697	706	extension	T169	C0231448
27738460	710	718	thrombus	T046	C0087086
27738460	741	746	weeks	T079	C0439230
27738460	753	760	surgery	T061	C0543467
27738460	766	770	rate	T081	C1521828
27738460	774	782	thrombus	T046	C0087086
27738460	783	792	formation	T169	C1522492
27738460	800	808	proximal	T082	C0205107
27738460	809	814	stump	T020	C0002690
27738460	822	836	saphenous vein	T023	C0036186
27738460	843	863	conventional surgery	T061	C1521745
27738460	881	887	higher	T080	C0205250
27738460	904	929	thermoablation techniques	T061	C0441476
27738460	973	981	adequate	T080	C0205411
27738460	982	1000	evaluation methods	T062	C2911685
27738460	1005	1016	appropriate	T080	C1548787
27738460	1017	1026	therapies	T061	C0087111
27738460	1031	1036	stump	T020	C0002690
27738460	1037	1047	thrombosis	T046	C0040053
27738460	1054	1075	varicose vein surgery	T061	C0521235

28433910|t|Succinic acid production by immobilized cultures using spent sulphite liquor as fermentation medium
28433910|a|Spent sulphite liquor (SSL) was used as carbon source for the production of succinic acid using immobilized cultures of Actinobacillus succinogenes and Basfia succiniciproducens on two different supports, delignified cellulosic material (DCM) and alginate beads. Fed-batch immobilized cultures with A. succinogenes in alginates resulted in higher sugar to succinic acid conversion yield (0.81g/g) than the respective yield achieved (0.65g/g) when DCM immobilized cultures were used. The final succinic acid concentration and yield achieved in fed-batch with immobilized cultures of B. succiniciproducens in alginates (45g/L and 0.66g/g) were higher than A. succinogenes immobilized cultures (35.4g/L and 0.61g/g) using nano - filtrated SSL as fermentation medium. Immobilized cultures of B. succiniciproducens in alginate beads were reused in four sequential fed-batch fermentations of nano - filtrated SSL leading to the production of 64.7g of succinic acid with a yield range of 0.42-0.67g/g and productivity range of 0.29-0.65g/L/h. The immobilized cultures improved the efficiency of succinic acid production as compared to free cell cultures.
28433910	0	13	Succinic acid	T109,T121	C0075429
28433910	14	24	production	T052	C1883254
28433910	28	39	immobilized	T025	C0282542
28433910	40	48	cultures	T059	C0007585
28433910	55	76	spent sulphite liquor	T167	C0302908
28433910	80	92	fermentation	T044	C0015852
28433910	93	99	medium	T167	C1705217
28433910	100	121	Spent sulphite liquor	T130	C0010454
28433910	123	126	SSL	T130	C0010454
28433910	140	146	carbon	T196	C0007009
28433910	147	153	source	T033	C0449416
28433910	162	172	production	T052	C1883254
28433910	176	189	succinic acid	T109,T121	C0075429
28433910	196	207	immobilized	T025	C0282542
28433910	208	216	cultures	T059	C0007585
28433910	220	247	Actinobacillus succinogenes	T007	C1026661
28433910	252	277	Basfia succiniciproducens	T007	C3716734
28433910	295	303	supports	T167	C0439861
28433910	305	336	delignified cellulosic material	T121	C3256315
28433910	338	341	DCM	T121	C3256315
28433910	347	355	alginate	T109,T122	C0102137
28433910	356	361	beads	T167	C0439861
28433910	363	393	Fed-batch immobilized cultures	T059	C3179109
28433910	399	414	A. succinogenes	T007	C1026661
28433910	418	427	alginates	T109,T122	C0102137
28433910	440	446	higher	T080	C0205250
28433910	447	452	sugar	T109,T121	C0242209
28433910	456	469	succinic acid	T109,T121	C0075429
28433910	470	486	conversion yield	T081	C0392762
28433910	517	522	yield	T081	C0392762
28433910	547	550	DCM	T121	C3256315
28433910	551	562	immobilized	T025	C0282542
28433910	563	571	cultures	T059	C0007585
28433910	593	606	succinic acid	T109,T121	C0075429
28433910	607	620	concentration	T081	C1446561
28433910	625	630	yield	T081	C0392762
28433910	643	652	fed-batch	T059	C3179109
28433910	658	669	immobilized	T025	C0282542
28433910	670	678	cultures	T059	C0007585
28433910	682	703	B. succiniciproducens	T007	C3716734
28433910	707	716	alginates	T109,T122	C0102137
28433910	742	748	higher	T080	C0205250
28433910	754	769	A. succinogenes	T007	C1026661
28433910	770	781	immobilized	T025	C0282542
28433910	782	790	cultures	T059	C0007585
28433910	819	823	nano	T081	C1553036
28433910	826	839	filtrated SSL	T167	C0302908
28433910	843	855	fermentation	T044	C0015852
28433910	856	862	medium	T167	C1705217
28433910	864	875	Immobilized	T025	C0282542
28433910	876	884	cultures	T059	C0007585
28433910	888	909	B. succiniciproducens	T007	C3716734
28433910	913	921	alginate	T109,T122	C0102137
28433910	922	927	beads	T167	C0439861
28433910	948	968	sequential fed-batch	T059	C3179109
28433910	969	982	fermentations	T044	C0015852
28433910	986	990	nano	T081	C1553036
28433910	993	1006	filtrated SSL	T130	C0010454
28433910	1022	1032	production	T052	C1883254
28433910	1045	1058	succinic acid	T109,T121	C0075429
28433910	1066	1071	yield	T081	C0392762
28433910	1098	1110	productivity	T081	C0033269
28433910	1140	1151	immobilized	T025	C0282542
28433910	1152	1160	cultures	T059	C0007585
28433910	1174	1184	efficiency	T081	C0013682
28433910	1188	1201	succinic acid	T109,T121	C0075429
28433910	1202	1212	production	T052	C1883254
28433910	1216	1224	compared	T052	C1707455
28433910	1228	1246	free cell cultures	T059	C0007585

28468745|t|Erosion of Digital Professionalism During Medical Students' Core Clinical Clerkships
28468745|a|The increased use of social media, cloud computing, and mobile devices has led to the emergence of guidelines and novel teaching efforts to guide students toward the appropriate use of technology. Despite this, violations of professional conduct are common. We sought to explore professional behaviors specific to appropriate use of technology by looking at changes in third-year medical students' attitudes and behaviors at the beginning and conclusion of their clinical clerkships. After formal teaching about digital professionalism, we administered a survey to medical students that described 35 technology - related behaviors and queried students about professionalism of the behavior (on a 5-point Likert scale), observation of others engaging in the behavior (yes or no), as well as personal participation in the behavior (yes or no). Students were resurveyed at the end of the academic year. Over the year, perceptions of what is considered acceptable behavior regarding privacy, data security, communications, and social media boundaries changed, despite formal teaching sessions to reinforce professional behavior. Furthermore, medical students who observed unprofessional behaviors were more likely to participate in such behaviors. Although technology is a useful tool to enhance teaching and learning, our results reflect an erosion of professionalism related to information security that occurred despite medical school and hospital -based teaching sessions to promote digital professionalism. True alteration of trainee behavior will require a cultural shift that includes continual education, better role models, and frequent reminders for faculty, house staff, students, and staff.
28468745	0	7	Erosion	T067	C1254366
28468745	11	18	Digital	T080	C1883674
28468745	19	34	Professionalism	T080	C0815219
28468745	42	59	Medical Students'	T097	C0038495
28468745	60	84	Core Clinical Clerkships	T065	C0008955
28468745	89	98	increased	T081	C0205217
28468745	99	105	use of	T169	C1524063
28468745	106	118	social media	T170	C3179065
28468745	120	135	cloud computing	T066	C4042841
28468745	141	155	mobile devices	T073	C1136359
28468745	184	194	guidelines	T170	C0162791
28468745	199	204	novel	T080	C0205314
28468745	205	221	teaching efforts	T065	C0039401
28468745	231	239	students	T097	C0038495
28468745	251	262	appropriate	T080	C1548787
28468745	263	269	use of	T169	C1524063
28468745	270	280	technology	T090	C0039421
28468745	296	306	violations	T053	C0004927
28468745	310	330	professional conduct	T053	C0004927
28468745	364	386	professional behaviors	T053	C0004927
28468745	399	410	appropriate	T080	C1548787
28468745	411	417	use of	T169	C1524063
28468745	418	428	technology	T090	C0039421
28468745	443	450	changes	T169	C0392747
28468745	454	464	third-year	T079	C1254367
28468745	465	482	medical students'	T097	C0038495
28468745	483	492	attitudes	T041	C0004271
28468745	497	506	behaviors	T053	C0004927
28468745	514	523	beginning	T079	C0439659
28468745	528	538	conclusion	T078	C1707478
28468745	548	567	clinical clerkships	T065	C0008955
28468745	575	590	formal teaching	T065	C0039401
28468745	597	604	digital	T080	C1883674
28468745	605	620	professionalism	T080	C0815219
28468745	625	637	administered	T169	C1521801
28468745	640	646	survey	T170	C0038951
28468745	650	666	medical students	T097	C0038495
28468745	685	695	technology	T090	C0039421
28468745	698	705	related	T169	C1552599
28468745	706	715	behaviors	T053	C0004927
28468745	728	736	students	T098	C0038492
28468745	743	758	professionalism	T080	C0815219
28468745	766	774	behavior	T053	C0004927
28468745	781	801	5-point Likert scale	T170	C0451267
28468745	804	815	observation	T078	C1554188
28468745	826	834	engaging	T169	C0205245
28468745	842	850	behavior	T053	C0004927
28468745	852	861	yes or no	T185	C1512698
28468745	875	897	personal participation	T169	C0679823
28468745	905	913	behavior	T053	C0004927
28468745	915	924	yes or no	T185	C1512698
28468745	927	935	Students	T097	C0038495
28468745	941	951	resurveyed	T169	C0205245
28468745	959	962	end	T079	C2746065
28468745	970	983	academic year	T079	C3258203
28468745	994	998	year	T079	C0439234
28468745	1000	1011	perceptions	T041	C0030971
28468745	1034	1044	acceptable	T080	C1879533
28468745	1045	1053	behavior	T053	C0004927
28468745	1064	1071	privacy	T078	C0080048
28468745	1073	1086	data security	T080	C0086100
28468745	1088	1102	communications	T054	C0009452
28468745	1108	1120	social media	T170	C3179065
28468745	1121	1131	boundaries	T082	C1254362
28468745	1132	1139	changed	T169	C0392747
28468745	1149	1164	formal teaching	T065	C0039401
28468745	1165	1173	sessions	T051	C1883016
28468745	1177	1186	reinforce	T169	C0205245
28468745	1187	1208	professional behavior	T053	C0004927
28468745	1223	1239	medical students	T097	C0038495
28468745	1253	1277	unprofessional behaviors	T053	C0004927
28468745	1318	1327	behaviors	T053	C0004927
28468745	1338	1348	technology	T090	C0039421
28468745	1361	1365	tool	T073	C0336791
28468745	1377	1385	teaching	T065	C0039401
28468745	1390	1398	learning	T041	C0023185
28468745	1423	1430	erosion	T067	C1254366
28468745	1434	1449	professionalism	T080	C0815219
28468745	1461	1472	information	T078	C1533716
28468745	1473	1481	security	T080	C0086100
28468745	1487	1495	occurred	T052	C1709305
28468745	1504	1518	medical school	T073,T093	C0036378
28468745	1523	1531	hospital	T073,T093	C0019994
28468745	1539	1547	teaching	T065	C0039401
28468745	1548	1556	sessions	T051	C1883016
28468745	1568	1575	digital	T080	C1883674
28468745	1576	1591	professionalism	T080	C0815219
28468745	1598	1608	alteration	T078	C1515926
28468745	1612	1619	trainee	T097	C1522486
28468745	1620	1628	behavior	T053	C0004927
28468745	1673	1682	continual	T079	C0439598
28468745	1683	1692	education	T065	C0039401
28468745	1701	1712	role models	T098	C0178835
28468745	1718	1726	frequent	T079	C0332183
28468745	1727	1736	reminders	T077	C1709896
28468745	1741	1748	faculty	T097	C0015537
28468745	1750	1761	house staff	T097	C0020044
28468745	1763	1771	students	T097	C0038495
28468745	1777	1782	staff	T097	C0851286

27849546|t|Physical Stimulation -Based Osteogenesis: Effect of Secretion In Vitro on Fluid Dynamic Shear Stress of Human Alveolar Bone -Derived Mesenchymal Stem Cells
27849546|a|Human alveolar bone -derived mesenchymal stem cells (hABMSCs) are promising candidates for bone therapies, which have the capacity to differentiate into osteoblasts. Recently, secretion of inducible cytokines and growth factors from mesenchymal stem cells (MSCs) has been discovered, and we also have reported the osteogenic effects of cell physical stimulation. In this study, we investigated the effects of hABMSCs - conditioned secretion media (B-CSM) on osteogenic differentiation of hABMSCs in vitro. Furthermore, we analyzed the B-CSM by proteomics array to identify inducible factors which facilitate osteogenic differentiation. To determine optimal concentration, B-CSM was firstly added at varying amounts (5, 10, 20, 40, and 60%) relative to culture medium. The viability and proliferation of hABMSCs were higher after treating with 5-20% B-CSM to the cells, compared to 40-60%. In addition, the expression of stem cells markers CD146 and STRO-1 was increased in the cells treated with 5-20% B-CSM, but decreased with 40-60%. We also found that B-CSM promoted osteogenic differentiation of hABMSCs such as mineralized nodules were strongly generated by 5-20%. B-CSM was most effective in increasing the expression of Vinculin and osteocalcin (OCN) in osteogenic differentiation of hABMSCs. Taken together, the results of our study ultimately indicate that B-CSM from hABMSCs induced by physical stimulation induce the proliferation and osteogenic differentiation of hABMSCs.
27849546	0	20	Physical Stimulation	T068	C0031817
27849546	28	40	Osteogenesis	T042	C0029433
27849546	42	48	Effect	T080	C1280500
27849546	52	61	Secretion	T038	C0036536
27849546	62	70	In Vitro	T080	C1533691
27849546	74	100	Fluid Dynamic Shear Stress	T070	C1171318
27849546	104	109	Human	T016	C0086418
27849546	110	123	Alveolar Bone	T023	C1440080
27849546	133	155	Mesenchymal Stem Cells	T025	C1257975
27849546	156	161	Human	T016	C0086418
27849546	162	175	alveolar bone	T023	C1440080
27849546	185	207	mesenchymal stem cells	T025	C1257975
27849546	209	216	hABMSCs	T025	C1257975
27849546	247	261	bone therapies	T061	C0947815
27849546	278	286	capacity	T081	C1516240
27849546	290	303	differentiate	T043	C1159974
27849546	309	320	osteoblasts	T025	C0029418
27849546	332	341	secretion	T038	C0036536
27849546	345	354	inducible	T169	C0205263
27849546	355	364	cytokines	T116,T129	C0079189
27849546	369	383	growth factors	T116,T123	C0018284
27849546	389	411	mesenchymal stem cells	T025	C1257975
27849546	413	417	MSCs	T025	C1257975
27849546	470	480	osteogenic	T025	C0222677
27849546	481	491	effects of	T080	C1704420
27849546	492	496	cell	T025	C0007634
27849546	497	517	physical stimulation	T068	C0031817
27849546	537	549	investigated	T169	C1292732
27849546	554	564	effects of	T080	C1704420
27849546	565	572	hABMSCs	T025	C1257975
27849546	575	602	conditioned secretion media	T130	C0162518
27849546	604	609	B-CSM	T130	C0162518
27849546	614	640	osteogenic differentiation	T043	C1159974
27849546	644	651	hABMSCs	T025	C1257975
27849546	652	660	in vitro	T080	C1533691
27849546	678	686	analyzed	T062	C0936012
27849546	691	696	B-CSM	T130	C0162518
27849546	700	716	proteomics array	T063	C1138433
27849546	729	738	inducible	T169	C0205263
27849546	739	746	factors	T169	C1521761
27849546	764	790	osteogenic differentiation	T043	C1159974
27849546	805	812	optimal	T080	C2698651
27849546	813	826	concentration	T081	C1446561
27849546	828	833	B-CSM	T130	C0162518
27849546	846	851	added	T169	C1524062
27849546	863	870	amounts	T081	C1265611
27849546	908	922	culture medium	T130	C0010454
27849546	928	937	viability	T043	C0007620
27849546	942	955	proliferation	T043	C0596290
27849546	959	966	hABMSCs	T025	C1257975
27849546	985	993	treating	T169	C1522326
27849546	1005	1010	B-CSM	T130	C0162518
27849546	1018	1023	cells	T025	C1257975
27849546	1025	1033	compared	T052	C1707455
27849546	1062	1072	expression	T045	C1171362
27849546	1076	1086	stem cells	T025	C1257975
27849546	1087	1094	markers	T201	C0005516
27849546	1095	1100	CD146	T116,T129	C1457876
27849546	1105	1111	STRO-1	T129	C2003357
27849546	1116	1125	increased	T081	C0205217
27849546	1133	1138	cells	T025	C1257975
27849546	1139	1151	treated with	T169	C1522326
27849546	1158	1163	B-CSM	T130	C0162518
27849546	1169	1178	decreased	T081	C0205216
27849546	1211	1216	B-CSM	T130	C0162518
27849546	1226	1252	osteogenic differentiation	T043	C1159974
27849546	1256	1263	hABMSCs	T025	C1257975
27849546	1272	1291	mineralized nodules	T033	C0243095
27849546	1306	1315	generated	T052	C3146294
27849546	1326	1331	B-CSM	T130	C0162518
27849546	1341	1350	effective	T080	C1704419
27849546	1354	1364	increasing	T169	C0442808
27849546	1369	1379	expression	T045	C1171362
27849546	1383	1391	Vinculin	T116,T123	C0085175
27849546	1396	1407	osteocalcin	T116,T123	C0029419
27849546	1409	1412	OCN	T116,T123	C0029419
27849546	1417	1443	osteogenic differentiation	T043	C1159974
27849546	1447	1454	hABMSCs	T025	C1257975
27849546	1476	1483	results	T169	C1274040
27849546	1522	1527	B-CSM	T130	C0162518
27849546	1533	1540	hABMSCs	T025	C1257975
27849546	1552	1572	physical stimulation	T068	C0031817
27849546	1584	1597	proliferation	T043	C0596290
27849546	1602	1628	osteogenic differentiation	T043	C1159974
27849546	1632	1639	hABMSCs	T025	C1257975

27326914|t|Prevalence of Coronary Artery to Pulmonary Artery Collaterals in Patients with Chronic Thromboembolic Pulmonary Hypertension: Retrospective Analysis from a Single Center
27326914|a|Background Our aim was to determine the prevalence of coronary artery - pulmonary artery collaterals in patients with chronic thromboembolic pulmonary hypertension (CTEPH) by retrospectively evaluating coronary angiograms of eligible consecutive patients who had undergone pulmonary endarterectomy (PEA). We also aimed to evaluate predictors and potential clinical associates of these collaterals. Methods Coronary angiograms of 83 consecutive CTEPH patients who had undergone coronary angiography before PEA operation between January 1, 2012 and June 1, 2015 were retrospectively evaluated for presence of coronary artery - pulmonary artery collaterals. Medical records of all patients were also retrospectively reviewed for demographic information, cardiovascular risk factors, preoperative right heart catheterization reports, operation reports, and follow-up data. Data of CTEPH patients with coronary artery - pulmonary artery collaterals were compared with data of CTEPH patients without such collaterals. Results There were 15 patients (18.1%) with definite and 4 patients (4.8%) with probable coronary artery - pulmonary artery collaterals among the study population. CTEPH patients with collaterals had higher preoperative pulmonary artery pressures, higher pulmonary vascular resistance (PVR) and lower cardiac index values compared with CTEPH patients without collaterals. However, CTEPH patients with collaterals displayed higher amount of reduction in PVR after PEA compared with patients without collaterals. There were no significant differences between groups regarding incidence of reperfusion injury or mortality. Conclusion Prevalence of coronary artery - pulmonary artery collaterals seems to be increased in our CTEPH patients compared with the general population. The presence of coronary artery - pulmonary artery collaterals is often combined with proximal disease with the possibility of increased reduction of PVR after PEA operation.
27326914	0	10	Prevalence	T081	C0033106
27326914	14	29	Coronary Artery	T033	C0428837
27326914	33	61	Pulmonary Artery Collaterals	T019	C0345095
27326914	65	73	Patients	T101	C0030705
27326914	79	124	Chronic Thromboembolic Pulmonary Hypertension	T047	C2363973
27326914	126	148	Retrospective Analysis	T062	C0035363
27326914	210	220	prevalence	T081	C0033106
27326914	224	239	coronary artery	T033	C0428837
27326914	242	270	pulmonary artery collaterals	T019	C0345095
27326914	274	282	patients	T101	C0030705
27326914	288	333	chronic thromboembolic pulmonary hypertension	T047	C2363973
27326914	335	340	CTEPH	T047	C2363973
27326914	345	360	retrospectively	T062	C0035363
27326914	372	391	coronary angiograms	T060	C0085532
27326914	404	415	consecutive	T080	C1707491
27326914	416	424	patients	T101	C0030705
27326914	443	467	pulmonary endarterectomy	T061	C2066034
27326914	469	472	PEA	T061	C2066034
27326914	492	500	evaluate	T058	C0220825
27326914	501	511	predictors	T170	C0683956
27326914	526	534	clinical	T080	C0205210
27326914	535	545	associates	T078	C0750490
27326914	555	566	collaterals	T023	C1185727
27326914	576	595	Coronary angiograms	T060	C0085532
27326914	602	613	consecutive	T080	C1707491
27326914	614	619	CTEPH	T047	C2363973
27326914	620	628	patients	T101	C0030705
27326914	647	667	coronary angiography	T060	C0085532
27326914	675	678	PEA	T061	C2066034
27326914	679	688	operation	T061	C0543467
27326914	697	704	January	T080	C3829466
27326914	717	721	June	T079	C3829443
27326914	735	750	retrospectively	T062	C0035363
27326914	751	760	evaluated	T058	C0220825
27326914	777	792	coronary artery	T033	C0428837
27326914	795	823	pulmonary artery collaterals	T019	C0345095
27326914	825	840	Medical records	T170	C0025102
27326914	848	856	patients	T101	C0030705
27326914	867	882	retrospectively	T062	C0035363
27326914	896	919	demographic information	T033	C0578829
27326914	921	948	cardiovascular risk factors	T047	C0850624
27326914	950	962	preoperative	T079	C0445204
27326914	963	998	right heart catheterization reports	T170	C4303224
27326914	1000	1017	operation reports	T170	C1269801
27326914	1023	1037	follow-up data	T170	C1704685
27326914	1039	1043	Data	T078	C1511726
27326914	1047	1052	CTEPH	T047	C2363973
27326914	1053	1061	patients	T101	C0030705
27326914	1067	1082	coronary artery	T033	C0428837
27326914	1085	1113	pulmonary artery collaterals	T019	C0345095
27326914	1141	1146	CTEPH	T047	C2363973
27326914	1147	1155	patients	T101	C0030705
27326914	1169	1180	collaterals	T023	C1185727
27326914	1204	1212	patients	T101	C0030705
27326914	1226	1234	definite	T080	C0439544
27326914	1241	1249	patients	T101	C0030705
27326914	1262	1270	probable	T081	C0033204
27326914	1271	1286	coronary artery	T033	C0428837
27326914	1289	1317	pulmonary artery collaterals	T019	C0345095
27326914	1328	1344	study population	T098	C2348561
27326914	1346	1351	CTEPH	T047	C2363973
27326914	1352	1360	patients	T101	C0030705
27326914	1366	1377	collaterals	T023	C1185727
27326914	1389	1401	preoperative	T079	C0445204
27326914	1402	1428	pulmonary artery pressures	T034	C0428642
27326914	1430	1436	higher	T080	C0205250
27326914	1437	1466	pulmonary vascular resistance	T033	C0456261
27326914	1468	1471	PVR	T033	C0456261
27326914	1477	1482	lower	T080	C0205251
27326914	1483	1503	cardiac index values	T033	C0428776
27326914	1518	1523	CTEPH	T047	C2363973
27326914	1524	1532	patients	T101	C0030705
27326914	1541	1552	collaterals	T023	C1185727
27326914	1563	1568	CTEPH	T047	C2363973
27326914	1569	1577	patients	T101	C0030705
27326914	1583	1594	collaterals	T023	C1185727
27326914	1622	1638	reduction in PVR	T033	C0855340
27326914	1645	1648	PEA	T061	C2066034
27326914	1663	1671	patients	T101	C0030705
27326914	1680	1691	collaterals	T023	C1185727
27326914	1704	1730	no significant differences	T033	C3842396
27326914	1739	1745	groups	T078	C0441833
27326914	1756	1765	incidence	T081	C0021149
27326914	1769	1787	reperfusion injury	T037	C0035126
27326914	1791	1800	mortality	T081	C0205848
27326914	1813	1823	Prevalence	T081	C0033106
27326914	1827	1842	coronary artery	T033	C0428837
27326914	1845	1873	pulmonary artery collaterals	T019	C0345095
27326914	1903	1908	CTEPH	T047	C2363973
27326914	1909	1917	patients	T101	C0030705
27326914	1936	1954	general population	T098	C0683971
27326914	1972	1987	coronary artery	T033	C0428837
27326914	1990	2018	pulmonary artery collaterals	T019	C0345095
27326914	2042	2050	proximal	T082	C0205107
27326914	2051	2058	disease	T047	C0012634
27326914	2093	2109	reduction of PVR	T033	C0855340
27326914	2116	2119	PEA	T061	C2066034

27765873|t|Active packaging of chicken meats with modified atmosphere including oxygen scavengers
27765873|a|The effects of modified atmosphere packaging (MAP -70% CO2 /30% N2) and iron -based oxygen scavengers (OS) with various absorption capacities (Ageless(®) ss100, ss300, and ss500) as an active packaging system on microbiological and oxidative changes in chicken thigh meats were evaluated during refrigerated storage (4°C) for 19 d at 3- day intervals. Total aerobic mesophilic bacteria counts exceeded the acceptability limit at d 7 in the control group without MAP (AIR), and at d 19 in MAP and OS containing samples. OS utilization resulted in around 1.5 and 1.0 log unit reductions in Pseudomonas spp. counts at d 7 and d 10 of storage, respectively, as compared with AIR and MAP groups (P < 0.05). MAP and OS groups had fewer (P < 0.05) coliform counts than did the AIR group, with an approximately 1.0 log reduction observed at d 10. Although in some cases OS utilization resulted in lower TBARS values and carbonyl and sulphydryl contents, particularly during later stages of refrigerated storage as compared to AIR and MAP groups, in general, these effects were not always apparent. The results of this study suggested that MAP suppressed microbiological growth and retarded lipid and protein oxidation in chicken thigh meats, with a 9- day shelf-life extention with insignificant effects of OS.
27765873	0	6	Active	T169	C0205177
27765873	7	16	packaging	T068	C0030176
27765873	20	33	chicken meats	T168	C0677521
27765873	39	47	modified	T169	C0392747
27765873	48	58	atmosphere	T070	C0935443
27765873	69	75	oxygen	T121,T123,T196	C0030054
27765873	76	86	scavengers	T120	C1254355
27765873	91	101	effects of	T080	C1704420
27765873	102	110	modified	T169	C0392747
27765873	111	121	atmosphere	T070	C0935443
27765873	122	131	packaging	T068	C0030176
27765873	133	136	MAP	T070	C0935443
27765873	142	145	CO2	T123,T197	C0007012
27765873	151	153	N2	T123,T196	C0028158
27765873	159	163	iron	T121,T123,T196	C0302583
27765873	171	177	oxygen	T121,T123,T196	C0030054
27765873	178	188	scavengers	T120	C1254355
27765873	190	192	OS	T120	C1254355
27765873	279	295	packaging system	T073	C0178791
27765873	299	314	microbiological	T170	C0025953
27765873	319	328	oxidative	T169	C0311404
27765873	329	336	changes	T169	C0392747
27765873	340	359	chicken thigh meats	T168	C0677521
27765873	382	402	refrigerated storage	T169	C1698986
27765873	424	427	day	T079	C0439228
27765873	428	437	intervals	T079	C1272706
27765873	439	479	Total aerobic mesophilic bacteria counts	T081	C0392762
27765873	493	512	acceptability limit	T081	C0392762
27765873	527	540	control group	T096	C0009932
27765873	549	552	MAP	T070	C0935443
27765873	554	557	AIR	T167	C0001861
27765873	575	578	MAP	T070	C0935443
27765873	583	585	OS	T120	C1254355
27765873	597	604	samples	T167	C0370003
27765873	606	608	OS	T120	C1254355
27765873	609	620	utilization	T169	C0042153
27765873	661	671	reductions	T080	C0392756
27765873	675	691	Pseudomonas spp.	T007	C0033808
27765873	692	698	counts	T081	C0439157
27765873	718	725	storage	T169	C1698986
27765873	758	761	AIR	T167	C0001861
27765873	766	769	MAP	T070	C0935443
27765873	770	776	groups	T078	C0441833
27765873	789	792	MAP	T070	C0935443
27765873	797	799	OS	T120	C1254355
27765873	800	806	groups	T078	C0441833
27765873	828	843	coliform counts	T081	C0805715
27765873	857	860	AIR	T167	C0001861
27765873	861	866	group	T078	C0441833
27765873	898	907	reduction	T080	C0392756
27765873	943	948	cases	T169	C0868928
27765873	949	951	OS	T120	C1254355
27765873	952	963	utilization	T169	C0042153
27765873	982	987	TBARS	T109,T130	C0162781
27765873	988	994	values	T081	C1522609
27765873	999	1007	carbonyl	T077	C0456205
27765873	1012	1031	sulphydryl contents	T077	C0456205
27765873	1059	1065	stages	T079	C1306673
27765873	1069	1089	refrigerated storage	T169	C1698986
27765873	1105	1108	AIR	T167	C0001861
27765873	1113	1116	MAP	T070	C0935443
27765873	1117	1123	groups	T078	C0441833
27765873	1143	1150	effects	T080	C1280500
27765873	1218	1221	MAP	T070	C0935443
27765873	1222	1232	suppressed	T169	C1260953
27765873	1233	1255	microbiological growth	T067	C2911660
27765873	1269	1274	lipid	T044	C2612546
27765873	1279	1296	protein oxidation	T044	C1159301
27765873	1300	1319	chicken thigh meats	T168	C0677521
27765873	1331	1334	day	T079	C0439228
27765873	1335	1345	shelf-life	T070	C4279909
27765873	1375	1385	effects of	T080	C1704420
27765873	1386	1388	OS	T120	C1254355

28550521|t|Assessment of periodontal bone level revisited: a controlled study on the diagnostic accuracy of clinical evaluation methods and intra-oral radiography
28550521|a|The accuracy of analogue and especially digital intra-oral radiography in assessing interdental bone level needs further documentation. The aim of this study was to compare clinical and radiographic bone level assessment to intra-surgical bone level registration (1) and to identify the clinical variables rendering interdental bone level assessment inaccurate (2). The study sample included 49 interdental sites in 17 periodontitis patients. Evaluation methods included vertical relative probing attachment level (RAL-V), analogue and digital intra-oral radiography and bone sounding without and with flap elevation. The latter was considered the true bone level. Five examiners evaluated all radiographs. Significant underestimation of the true bone level was observed for all evaluation methods pointing to 2.7 mm on average for analogue radiography, 2.5 mm for digital radiography, 1.8 mm for RAL-V and 0.6 mm for bone sounding without flap elevation (p < 0.001). Radiographic underestimation of the true bone level was higher in the (pre)molar region (p ≤ 0.047) and increased with defect depth (p < 0.001). Variation between clinicians was huge (range analogue radiography 2.2-3.2 mm; range digital radiography 2.1-3.0 mm). All evaluation methods significantly underestimated the true bone level. Bone sounding was most accurate, whereas intra-oral radiographs were least accurate. Deep periodontal defects in the (pre)molar region were most underrated by intra-oral radiography. Bone sounding had the highest accuracy in assessing interdental bone level.
28550521	0	10	Assessment	T052	C1516048
28550521	14	25	periodontal	T080	C0332275
28550521	26	36	bone level	T201	C1317144
28550521	50	66	controlled study	T062	C0681867
28550521	74	93	diagnostic accuracy	T080	C0598285
28550521	97	116	clinical evaluation	T058	C4084924
28550521	117	124	methods	T170	C0025663
28550521	129	151	intra-oral radiography	T060	C0430022
28550521	156	164	accuracy	T080	C0443131
28550521	168	176	analogue	T060	C0034575
28550521	192	222	digital intra-oral radiography	T060	C0430022
28550521	226	235	assessing	T058	C0184514
28550521	236	247	interdental	T082	C0442104
28550521	248	258	bone level	T201	C1317144
28550521	273	286	documentation	T170	C0920316
28550521	325	333	clinical	T080	C0205210
28550521	338	350	radiographic	T060	C0043299
28550521	351	361	bone level	T201	C1317144
28550521	362	372	assessment	T058	C0220825
28550521	376	390	intra-surgical	T079	C0456904
28550521	391	401	bone level	T201	C1317144
28550521	402	414	registration	T058	C1514821
28550521	439	447	clinical	T080	C0205210
28550521	448	457	variables	T080	C0439828
28550521	468	479	interdental	T082	C0442104
28550521	480	490	bone level	T201	C1317144
28550521	491	501	assessment	T058	C0220825
28550521	502	512	inaccurate	T080	C0443236
28550521	547	558	interdental	T082	C0442104
28550521	559	564	sites	T082	C0205145
28550521	571	584	periodontitis	T047	C0031099
28550521	585	593	patients	T101	C0030705
28550521	595	613	Evaluation methods	T062	C2911685
28550521	623	665	vertical relative probing attachment level	T201	C1317110
28550521	666	672	(RAL-V	T201	C1317110
28550521	675	683	analogue	T060	C0034575
28550521	688	718	digital intra-oral radiography	T060	C0202592
28550521	723	736	bone sounding	T060	C0430022
28550521	737	744	without	T080	C0332288
28550521	754	758	flap	T024	C1266913
28550521	759	768	elevation	T061	C0439775
28550521	800	804	true	T080	C0205238
28550521	805	815	bone level	T201	C1317144
28550521	822	831	examiners	T097	C0025082
28550521	832	841	evaluated	T058	C0220825
28550521	846	857	radiographs	T060	C0034575
28550521	859	870	Significant	T078	C0750502
28550521	871	886	underestimation	T033	C0243095
28550521	894	898	true	T080	C0205238
28550521	899	909	bone level	T201	C1317144
28550521	914	922	observed	T169	C1441672
28550521	931	949	evaluation methods	T062	C2911685
28550521	984	1004	analogue radiography	T060	C0034575
28550521	1017	1036	digital radiography	T060	C0012249
28550521	1049	1054	RAL-V	T201	C1317110
28550521	1070	1083	bone sounding	T060	C0430022
28550521	1092	1096	flap	T024	C1266913
28550521	1097	1106	elevation	T061	C0439775
28550521	1120	1132	Radiographic	T060	C0043299
28550521	1133	1148	underestimation	T033	C0243095
28550521	1156	1160	true	T080	C0205238
28550521	1161	1171	bone level	T201	C1317144
28550521	1176	1182	higher	T080	C0205250
28550521	1191	1207	pre)molar region	T029	C0927672
28550521	1224	1233	increased	T081	C0205217
28550521	1239	1245	defect	T169	C1457869
28550521	1246	1251	depth	T082	C0205125
28550521	1265	1274	Variation	T080	C0205419
28550521	1283	1293	clinicians	T097	C0871685
28550521	1298	1302	huge	T033	C0450093
28550521	1304	1309	range	T081	C1514721
28550521	1310	1330	analogue radiography	T060	C0034575
28550521	1343	1348	range	T081	C1514721
28550521	1349	1368	digital radiography	T060	C0012249
28550521	1386	1404	evaluation methods	T062	C2911685
28550521	1405	1418	significantly	T078	C0750502
28550521	1438	1442	true	T080	C0205238
28550521	1443	1453	bone level	T201	C1317144
28550521	1455	1468	Bone sounding	T060	C0430022
28550521	1473	1477	most	T081	C0205393
28550521	1478	1486	accurate	T080	C0443131
28550521	1496	1518	intra-oral radiographs	T060	C0202592
28550521	1524	1529	least	T080	C0205251
28550521	1530	1538	accurate	T080	C0443131
28550521	1540	1544	Deep	T082	C0205125
28550521	1545	1556	periodontal	T080	C0332275
28550521	1557	1564	defects	T169	C0243067
28550521	1572	1589	(pre)molar region	T029	C0927672
28550521	1614	1636	intra-oral radiography	T060	C0202592
28550521	1638	1651	Bone sounding	T060	C0430022
28550521	1660	1667	highest	T080	C1522410
28550521	1668	1676	accuracy	T080	C0443131
28550521	1690	1701	interdental	T082	C0442104
28550521	1702	1712	bone level	T201	C1317144

27466053|t|Visual Analytics for Pattern Discovery in Home Care. Clinical Relevance for Quality Improvement
27466053|a|Visualization can reduce the cognitive load of information, allowing users to easily interpret and assess large amounts of data. The purpose of our study was to examine home health data using visual analysis techniques to discover clinically salient associations between patient characteristics with problem-oriented health outcomes of older adult home health patients during the home health service period. Knowledge, Behavior and Status ratings at discharge as well as change from admission to discharge that was coded using the Omaha System was collected from a dataset on 988 de-identified patient data from 15 home health agencies. SPSS Visualization Designer v1.0 was used to visually analyze patterns between independent and outcome variables using heat maps and histograms. Visualizations suggesting clinical salience were tested for significance using correlation analysis. The mean age of the patients was 80 years, with the majority female (66%). Of the 150 visualizations, 69 potentially meaningful patterns were statistically evaluated through bivariate associations, revealing 21 significant associations. Further, 14 associations between episode length and Charlson co-morbidity index mainly with urinary related diagnoses and problems remained significant after adjustment analyses. Through visual analysis, the adverse association of the longer home health episode length and higher Charlson co-morbidity index with behavior or status outcomes for patients with impaired urinary function was revealed. We have demonstrated the use of visual analysis to discover novel patterns that described high-needs subgroups among the older home health patient population. The effective presentation of these data patterns can allow clinicians to identify areas of patient improvement, and time periods that are most effective for implementing home health interventions to improve patient outcomes.
27466053	0	16	Visual Analytics	T060	C0042825
27466053	21	38	Pattern Discovery	T041	C1518918
27466053	42	51	Home Care	T058	C0994454
27466053	53	71	Clinical Relevance	T080	C2347946
27466053	76	95	Quality Improvement	T057	C2936612
27466053	96	109	Visualization	T041	C0175631
27466053	125	154	cognitive load of information	T081	C0870301
27466053	181	190	interpret	T169	C1285553
27466053	195	223	assess large amounts of data	T058	C0184514
27466053	265	281	home health data	T170	C3878819
27466053	288	314	visual analysis techniques	T060	C3536884
27466053	327	345	clinically salient	T080	C0449440
27466053	346	358	associations	T078	C0750490
27466053	367	390	patient characteristics	T201	C0815172
27466053	396	428	problem-oriented health outcomes	T170	C1550208
27466053	432	464	older adult home health patients	T058	C1443513
27466053	476	495	home health service	T058	C0184605
27466053	504	513	Knowledge	T170	C0376554
27466053	515	523	Behavior	T053	C0004927
27466053	528	542	Status ratings	T081,T170	C0681889
27466053	546	555	discharge	T058	C0030685
27466053	579	588	admission	T058	C0030673
27466053	592	601	discharge	T058	C0030685
27466053	627	639	Omaha System	T170	C1140113
27466053	661	668	dataset	T170	C0150098
27466053	690	702	patient data	T170	C2707520
27466053	711	731	home health agencies	T093	C0019859
27466053	733	765	SPSS Visualization Designer v1.0	T170	C0037589
27466053	778	803	visually analyze patterns	T060	C0042825
27466053	852	861	heat maps	T078	C1609081
27466053	866	876	histograms	T073	C2348974
27466053	878	892	Visualizations	T041	C0175631
27466053	904	921	clinical salience	T033	C2826293
27466053	927	933	tested	T169	C0039593
27466053	957	977	correlation analysis	T062,T170	C0010101
27466053	999	1007	patients	T101	C0030705
27466053	1040	1046	female	T032	C0086287
27466053	1065	1079	visualizations	T041	C0175631
27466053	1096	1115	meaningful patterns	T078	C1609081
27466053	1153	1175	bivariate associations	UnknownType	C0681927
27466053	1202	1214	associations	T078	C0750490
27466053	1228	1240	associations	T078	C0750490
27466053	1268	1295	Charlson co-morbidity index	T170	C3714916
27466053	1308	1315	urinary	T080	C1524119
27466053	1324	1346	diagnoses and problems	T047	C0338067
27466053	1403	1418	visual analysis	T060	C0042825
27466053	1432	1443	association	T078	C0750490
27466053	1458	1477	home health episode	T058	C0085554
27466053	1496	1523	Charlson co-morbidity index	T170	C3714916
27466053	1529	1556	behavior or status outcomes	T033	C0243095
27466053	1561	1569	patients	T101	C0030705
27466053	1575	1600	impaired urinary function	T047	C0871563
27466053	1647	1662	visual analysis	T060	C0042825
27466053	1716	1725	subgroups	T185	C1515021
27466053	1736	1772	older home health patient population	T081	C2361270
27466053	1810	1823	data patterns	T078	C1609081
27466053	1834	1844	clinicians	T097	C0871685
27466053	1866	1885	patient improvement	T057	C3858649
27466053	1945	1970	home health interventions	T058	C1553498
27466053	1982	1998	patient outcomes	T058	C0030698

28036301|t|ITPR3 gene haplotype is associated with cervical squamous cell carcinoma risk in Taiwanese women
28036301|a|Host immunogenetic background plays an important role in human papillomavirus (HPV) infection and cervical cancer development. Inositol 1,4,5-triphosphate receptor type 3 (ITPR3) is essential for both immune activation and cancer pathogenesis. We aim to investigate if ITPR3 genetic polymorphisms are associated with the risk of cervical cancer in Taiwanese women. ITPR3 rs3748079 A/G and rs2229634 C/T polymorphisms were genotyped in a hospital-based study of 462 women with cervical squamous cell carcinoma (CSCC) and 921 age-matched healthy control women. The presence and genotypes of HPV in CSCC was determined. No significant association of individual ITPR3 variants were found among controls, CSCC, and HPV-16 positive CSCC. However, we found a significant association of haplotype AT between CSCC and controls (OR = 2.28, 95% CI 1.31-3.97, P = 2.83 × 10-3) and the OR increased further in CSCC patients infected with HPV-16 (OR = 2.89, 95% CI 1.55-5.37, P = 4.54 × 10-4). The linkage disequilibrium analysis demonstrated that ITPR3 association with CSCC was independent of HLA-DRB1 alleles. In conclusion, these findings suggest that AT haplotype in the ITPR3 gene may serve as a potential marker for genetic susceptibility to CSCC.
28036301	0	10	ITPR3 gene	T028	C1416519
28036301	11	20	haplotype	T032	C0018591
28036301	40	72	cervical squamous cell carcinoma	T191	C0279671
28036301	73	77	risk	T078	C0035647
28036301	81	90	Taiwanese	T098	C1556096
28036301	91	96	women	T098	C0043210
28036301	97	115	Host immunogenetic	T091	C0021005
28036301	154	190	human papillomavirus (HPV) infection	T047	C0343641
28036301	195	222	cervical cancer development	T191	C1516170
28036301	224	267	Inositol 1,4,5-triphosphate receptor type 3	T028	C1416519
28036301	269	274	ITPR3	T028	C1416519
28036301	298	315	immune activation	T043	C1155000
28036301	320	326	cancer	T191	C0006826
28036301	327	339	pathogenesis	T046	C0699748
28036301	366	371	ITPR3	T028	C1416519
28036301	372	393	genetic polymorphisms	T045	C0032529
28036301	418	441	risk of cervical cancer	T081	C0596244
28036301	445	454	Taiwanese	T098	C1556096
28036301	455	460	women	T098	C0043210
28036301	462	467	ITPR3	T028	C1416519
28036301	468	481	rs3748079 A/G	T086	C0752046
28036301	486	513	rs2229634 C/T polymorphisms	T086	C0752046
28036301	519	528	genotyped	T032	C0017431
28036301	534	554	hospital-based study	T062	C2603343
28036301	562	567	women	T098	C0043210
28036301	573	605	cervical squamous cell carcinoma	T191	C0279671
28036301	607	611	CSCC	T191	C0279671
28036301	633	648	healthy control	T080	C2986479
28036301	649	654	women	T098	C0043210
28036301	673	682	genotypes	T032	C0017431
28036301	686	689	HPV	T005	C0021344
28036301	693	697	CSCC	T191	C0279671
28036301	755	760	ITPR3	T028	C1416519
28036301	761	769	variants	T028	C0678941
28036301	797	801	CSCC	T191	C0279671
28036301	807	822	HPV-16 positive	T034	C4288937
28036301	823	827	CSCC	T191	C0279671
28036301	876	888	haplotype AT	T032	C0018591
28036301	897	901	CSCC	T191	C0279671
28036301	916	918	OR	T081	C0028873
28036301	931	933	CI	T081	C0009667
28036301	970	972	OR	T081	C0028873
28036301	994	998	CSCC	T191	C0279671
28036301	999	1016	patients infected	T101	C0030705
28036301	1022	1028	HPV-16	T005	C0999806
28036301	1030	1032	OR	T081	C0028873
28036301	1045	1047	CI	T081	C0009667
28036301	1081	1112	linkage disequilibrium analysis	T063	C1517888
28036301	1131	1136	ITPR3	T028	C1416519
28036301	1137	1148	association	T063	C2717881
28036301	1154	1158	CSCC	T191	C0279671
28036301	1178	1186	HLA-DRB1	T028	C1415576
28036301	1187	1194	alleles	T028	C0002085
28036301	1239	1251	AT haplotype	T032	C0018591
28036301	1259	1269	ITPR3 gene	T028	C1416519
28036301	1285	1301	potential marker	T045	C0017393
28036301	1306	1328	genetic susceptibility	T032	C0314657
28036301	1332	1336	CSCC	T191	C0279671

28269453|t|Endurance based personalized fitness planner
28269453|a|Endurance is an important factor of cardiovascular fitness indicating the capacity of an individual to perform exercise for a longer duration with increased intensity. Various subject specific and exercise related parameters affect endurance of an individual. In this work, we propose a statistical technique to model endurance as a function of these factors incorporating the serial dependence of observations generated by individuals over time. The proposed model provides a device to predict future endurance of a test subject following particular exercise regime. This facilitates a test user with a fitness planner with the provision to fix exercise regimes to reach a set fitness goal.
28269453	0	9	Endurance	T033	C0518031
28269453	16	44	personalized fitness planner	T170	C0282574
28269453	45	54	Endurance	T033	C0518031
28269453	61	70	important	T080	C3898777
28269453	71	77	factor	T169	C1521761
28269453	81	103	cardiovascular fitness	T040	C2981722
28269453	119	127	capacity	T081	C1516240
28269453	134	144	individual	T098	C0237401
28269453	148	155	perform	T169	C0884358
28269453	156	164	exercise	T056	C0015259
28269453	171	186	longer duration	T079	C0449238
28269453	192	201	increased	T081	C0205217
28269453	202	211	intensity	T080	C0522510
28269453	221	237	subject specific	T080	C0205369
28269453	242	250	exercise	T056	C0015259
28269453	259	269	parameters	T077	C0549193
28269453	277	286	endurance	T033	C0518031
28269453	293	303	individual	T098	C0237401
28269453	332	353	statistical technique	T062	C1710191
28269453	357	362	model	T170	C3161035
28269453	363	372	endurance	T033	C0518031
28269453	396	403	factors	T169	C1521761
28269453	443	455	observations	T062	C0302523
28269453	469	480	individuals	T098	C0237401
28269453	481	490	over time	T079	C0040223
28269453	496	504	proposed	T080	C1553874
28269453	505	510	model	T170	C3161035
28269453	522	528	device	T074	C0025080
28269453	547	556	endurance	T033	C0518031
28269453	567	574	subject	T096	C0681850
28269453	596	611	exercise regime	T061	C0454291
28269453	632	641	test user	T078	C1548600
28269453	649	664	fitness planner	T170	C0282574
28269453	691	707	exercise regimes	T061	C0454291
28269453	723	730	fitness	T056	C1456706
28269453	731	735	goal	T170	C0018017

28010143|t|Chikungunya Virus Infection Manifesting as Intermediate Uveitis
28010143|a|To describe a case of intermediate uveitis caused by chikungunya virus infection in the Western Hemisphere. Case report of a patient diagnosed with chikungunya infection presenting with blurry vision and floaters. Exam revealed a unilateral intermediate uveitis, with an extensive work-up positive for chikungunya virus immunoglobulin M and G titers. The patient responded to oral corticosteroids with signs and symptoms resolving over the course of 3 months ' treatment. While anterior uveitis and retinitis are the most common ocular manifestations of chikungunya infection, we report here a case of chikungunya infection presenting as an intermediate uveitis, responding well to oral corticosteroids. This case demonstrates the varied presentation of chikungunya -related uveitis and highlights its consideration in the differential diagnoses of those who have had preceding systemic viral symptoms and uveitis.
28010143	0	17	Chikungunya Virus	T005	C0008056
28010143	18	27	Infection	T046	C3714514
28010143	28	39	Manifesting	T169	C0205319
28010143	43	63	Intermediate Uveitis	T047	C0042166
28010143	78	82	case	T077	C1706256
28010143	86	106	intermediate uveitis	T047	C0042166
28010143	117	134	chikungunya virus	T005	C0008056
28010143	135	144	infection	T046	C3714514
28010143	152	170	Western Hemisphere	UnknownType	C0681784
28010143	172	183	Case report	T170	C0085973
28010143	189	196	patient	T101	C0030705
28010143	197	206	diagnosed	T033	C0011900
28010143	212	223	chikungunya	T005	C0008056
28010143	224	233	infection	T046	C3714514
28010143	250	263	blurry vision	T184	C0344232
28010143	268	276	floaters	T184	C0497199
28010143	294	304	unilateral	T082	C0205092
28010143	305	325	intermediate uveitis	T047	C0042166
28010143	335	344	extensive	T080	C0205231
28010143	345	352	work-up	T060	C0750430
28010143	353	361	positive	T033	C1446409
28010143	366	383	chikungunya virus	T005	C0008056
28010143	384	400	immunoglobulin M	T116,T129	C0020861
28010143	405	406	G	T116,T121,T129	C0020852
28010143	407	413	titers	T081	C0475208
28010143	419	426	patient	T101	C0030705
28010143	427	436	responded	T033	C1704632
28010143	440	444	oral	T082	C0442027
28010143	445	460	corticosteroids	T109,T121,T125	C0001617
28010143	466	484	signs and symptoms	T184	C0037088
28010143	485	494	resolving	T077	C1709864
28010143	504	510	course	T079	C0750729
28010143	516	522	months	T079	C0439231
28010143	525	534	treatment	T061	C0087111
28010143	542	558	anterior uveitis	T047	C0042165
28010143	563	572	retinitis	T047	C0035333
28010143	593	614	ocular manifestations	T184	C0015411
28010143	618	629	chikungunya	T005	C0008056
28010143	630	639	infection	T046	C3714514
28010143	658	662	case	T077	C1706256
28010143	666	677	chikungunya	T005	C0008056
28010143	678	687	infection	T046	C3714514
28010143	705	725	intermediate uveitis	T047	C0042166
28010143	727	737	responding	T033	C1704632
28010143	746	750	oral	T082	C0442027
28010143	751	766	corticosteroids	T109,T121,T125	C0001617
28010143	773	777	case	T077	C1706256
28010143	778	790	demonstrates	T052	C3687625
28010143	802	814	presentation	T078	C0449450
28010143	818	829	chikungunya	T005	C0008056
28010143	839	846	uveitis	T047	C0042164
28010143	866	879	consideration	T033	C0518609
28010143	887	909	differential diagnoses	T060	C0011906
28010143	942	950	systemic	T169	C0205373
28010143	951	965	viral symptoms	T184	C1457887
28010143	970	977	uveitis	T047	C0042164

27704589|t|Identifying research priorities with nurses at a tertiary children's hospital in the United Kingdom
27704589|a|The objective of this study was to undertake a research priority setting exercise with the aim of maximizing efficiency and impact in research activity undertaken by nurses at one children's tertiary healthcare institution by ensuring the clinical staff directly shaped a coherent, transparent and consensus driven nurse-led research agenda. In Round 1, the research topics of 147 nurses were elicited using a modified nominal group technique as the consensus method. The number of participants in the 24 separate discussions ranged from 3 to 21, generating lists of between 6 and 23 topics. In Round 2, nurses from the clinical areas ranked topics of importance resulting in a set of four to five priorities. In Round 3, the divisional heads of nursing consulted with staff in all of their clinical areas to each finalize their five divisional priorities. The Nursing Research Working Group discussed and refined the divisions' priorities and voted on the final list to agree the top five research priorities for the organization. A total of 269 research topics were initially generated. Following three rounds of ranking and prioritizing, five priorities were agreed at Divisional level, and from these, the five top organizational priorities were selected. These were (i) understanding and improving all aspects of the patient journey through the hospital system; (ii) play; (iii) staff wellbeing, patient care and productivity; (iv) team work - linking to a more efficient service; and (v) supporting parents / parent pathway. Divisional priorities have been disseminated widely to clinical teams to inform a patient-specific nurse-led research agenda. Organizational priorities agreed upon have been disseminated through management structures and processes to ensure engagement at all levels. A subgroup of the Nursing Research Working Group has been delegated to take this work forward so that the agreed priorities continue to contribute towards shaping nurse-led research activity, thereby going some way to inform and embed an evidence-based culture of inquiry.
27704589	12	31	research priorities	T062	C0376368
27704589	37	43	nurses	T097	C0028661
27704589	58	68	children's	T100	C0008059
27704589	69	77	hospital	T073,T093	C0019994
27704589	85	99	United Kingdom	T083	C0041700
27704589	122	127	study	T062	C2603343
27704589	147	164	research priority	T062	C0376368
27704589	209	219	efficiency	T081	C0013682
27704589	224	230	impact	T080	C4049986
27704589	234	251	research activity	T062	C0079816
27704589	266	272	nurses	T097	C0028661
27704589	280	290	children's	T100	C0008059
27704589	300	322	healthcare institution	T093	C1274109
27704589	339	353	clinical staff	T097	C0025106
27704589	372	380	coherent	T033	C4068804
27704589	382	393	transparent	T080	C0205556
27704589	398	407	consensus	T054	C0376298
27704589	415	440	nurse-led research agenda	T062	C0681798
27704589	458	473	research topics	UnknownType	C0681795
27704589	481	487	nurses	T097	C0028661
27704589	510	542	modified nominal group technique	T062	C0035177
27704589	550	566	consensus method	T170	C0025663
27704589	582	594	participants	T098	C0679646
27704589	704	710	nurses	T097	C0028661
27704589	720	734	clinical areas	T078	C1547541
27704589	735	741	ranked	T170	C0699794
27704589	798	808	priorities	T062	C0376368
27704589	826	842	divisional heads	T097	C0018676
27704589	846	853	nursing	T091	C0028677
27704589	869	874	staff	T097	C0025106
27704589	891	905	clinical areas	T078	C1547541
27704589	934	955	divisional priorities	T062	C0376368
27704589	961	991	Nursing Research Working Group	T097	C0027363
27704589	1018	1039	divisions' priorities	T062	C0376368
27704589	1044	1049	voted	T055	C0042978
27704589	1090	1109	research priorities	T062	C0376368
27704589	1118	1130	organization	T093	C1274109
27704589	1147	1162	research topics	UnknownType	C0681795
27704589	1215	1222	ranking	T170	C0699794
27704589	1246	1256	priorities	T062	C0376368
27704589	1272	1288	Divisional level	T092	C2919030
27704589	1319	1344	organizational priorities	T062	C0376368
27704589	1422	1429	patient	T101	C0030705
27704589	1450	1465	hospital system	T073,T093	C0019994
27704589	1472	1476	play	T056	C0032214
27704589	1484	1499	staff wellbeing	T078	C0018684
27704589	1501	1513	patient care	T058	C0017313
27704589	1518	1530	productivity	T081	C0033269
27704589	1537	1546	team work	T057	C0043227
27704589	1577	1584	service	T057	C0557854
27704589	1594	1612	supporting parents	T099	C0030551
27704589	1615	1621	parent	T099	C0030551
27704589	1642	1652	priorities	T062	C0376368
27704589	1686	1700	clinical teams	T058	C0086390
27704589	1713	1755	patient-specific nurse-led research agenda	T062	C0681798
27704589	1757	1782	Organizational priorities	T062	C0376368
27704589	1826	1847	management structures	T090	C3273539
27704589	1900	1908	subgroup	T097	C0027363
27704589	1916	1946	Nursing Research Working Group	T097	C0027363
27704589	2011	2021	priorities	T062	C0376368
27704589	2061	2088	nurse-led research activity	T062	C0079816
27704589	2162	2169	inquiry	T052	C2987583

28225881|t|Zinc and metalloproteinases 2 and 9: What is their relation with breast cancer?
28225881|a|Zinc is the catalytic component of proteins that regulate responses to DNA damage, intracellular signaling enzymes, and matrix metalloproteinases, which are important proteins in carcinogenesis. The objective of this review is to bring current information on the participation of zinc and matrix metalloproteinases types 2 and 9 in mechanisms involved in the pathogenesis of breast cancer. We conducted a literature review, in consultation with the PubMed, Lilacs, and Scielo databases. The zinc and cysteine residues are structural elements shared by all members of the family of matrix metalloproteinases, and these proteins appear to be involved in the propagation of various types of neoplasms, including breast cancer. Moreover, transported zinc is likely to be used for the metalation of the catalytic domain of the newly synthesized metalloproteinases before the latter are secreted. Accordingly, increase in zinc concentrations in cellular compartments and the reduction of this trace element in the blood of patients with breast cancer appear to alter the activity of metalloproteinases 2 and 9, contributing to the occurrence of malignancy. Thus, it is necessary to carry out further studies with a view to clarify the role of zinc and metalloproteinases 2 and 9 in the pathogenesis of breast cancer.
28225881	0	4	Zinc	T121,T123,T196	C0043481
28225881	9	29	metalloproteinases 2	T116,T126	C0172537
28225881	34	35	9	T116,T126	C0165519
28225881	51	59	relation	T080	C0439849
28225881	65	78	breast cancer	T191	C0006142
28225881	80	84	Zinc	T121,T123,T196	C0043481
28225881	92	111	catalytic component	T077	C1705248
28225881	115	123	proteins	T116,T123	C0033684
28225881	129	137	regulate	T038	C1327622
28225881	151	161	DNA damage	T049	C0012860
28225881	163	194	intracellular signaling enzymes	T116,T126	C0014442
28225881	200	225	matrix metalloproteinases	T116,T126	C0623362
28225881	247	255	proteins	T116,T123	C0033684
28225881	259	273	carcinogenesis	T191	C0596263
28225881	297	303	review	T170	C0282443
28225881	316	335	current information	T170	C2598106
28225881	343	356	participation	T169	C0679823
28225881	360	364	zinc	T121,T123,T196	C0043481
28225881	369	402	matrix metalloproteinases types 2	T116,T126	C0172537
28225881	407	408	9	T116,T126	C0165519
28225881	412	422	mechanisms	T169	C0441712
28225881	439	451	pathogenesis	T046	C0699748
28225881	455	468	breast cancer	T191	C0006142
28225881	485	502	literature review	T170	C0282441
28225881	529	535	PubMed	T170	C1138432
28225881	537	543	Lilacs	T170	C0242356
28225881	549	565	Scielo databases	T170	C0242356
28225881	571	575	zinc	T121,T123,T196	C0043481
28225881	580	588	cysteine	T116,T123	C0010654
28225881	589	597	residues	T077	C1709915
28225881	602	621	structural elements	T082	C4277569
28225881	661	686	matrix metalloproteinases	T116,T126	C0623362
28225881	698	706	proteins	T116,T123	C0033684
28225881	736	747	propagation	T033	C1334939
28225881	768	777	neoplasms	T191	C0027651
28225881	789	802	breast cancer	T191	C0006142
28225881	826	830	zinc	T121,T123,T196	C0043481
28225881	860	870	metalation	T070	C1254365
28225881	878	894	catalytic domain	T087	C0600499
28225881	908	919	synthesized	T052	C1883254
28225881	920	938	metalloproteinases	T116,T126	C0623362
28225881	984	992	increase	T169	C0442805
28225881	996	1000	zinc	T121,T123,T196	C0043481
28225881	1001	1015	concentrations	T081	C1446561
28225881	1019	1040	cellular compartments	T017	C2349967
28225881	1049	1058	reduction	T080	C0392756
28225881	1067	1080	trace element	T123,T196	C0040577
28225881	1088	1093	blood	T031	C0005767
28225881	1097	1105	patients	T101	C0030705
28225881	1111	1124	breast cancer	T191	C0006142
28225881	1135	1140	alter	T169	C0392747
28225881	1145	1153	activity	T052	C0441655
28225881	1157	1177	metalloproteinases 2	T116,T126	C0172537
28225881	1182	1183	9	T116,T126	C0165519
28225881	1205	1215	occurrence	T079	C2745955
28225881	1219	1229	malignancy	T191	C4282132
28225881	1317	1321	zinc	T121,T123,T196	C0043481
28225881	1326	1346	metalloproteinases 2	T116,T126	C0172537
28225881	1351	1352	9	T116,T126	C0165519
28225881	1360	1372	pathogenesis	T046	C0699748
28225881	1376	1389	breast cancer	T191	C0006142

28209454|t|Treatment of Carcinoma In Situ of the Glans Penis With Topical Imiquimod Followed by Carbon Dioxide Laser Excision
28209454|a|Different approaches have been described in published studies for carcinoma in situ (CIS) of the glans penis (erythroplasia of Queyrat), including topical chemotherapy or immunotherapy and laser or surgical excision. We evaluated the efficacy of topical imiquimod (IQ) followed by carbon dioxide laser ablation of the lesion. From 2010 to 2015, 10 patients affected by CIS of the glans were treated by IQ, followed by carbon dioxide laser ablation. For every patient, we performed histologic examination before and after IQ. Local toxicity and adverse effects were recorded. After treatment, histologic examination showed no residual tumor in 6 patients (complete response [CR]), stable disease in 2 patients, and progressive disease in 2 patients. Those with a CR had human papillomavirus - related lesions, and they had no experienced relapses after a mean follow-up of 26 months. The 2 patients with progressive disease underwent total penectomy. All patients were alive at the last follow-up examination. All patients experienced a mild local toxicity (burning erythema) but no major adverse effects. Local treatment with IQ for glans CIS is effective mainly for human papillomavirus - related lesions. The present study is the first to record the histologic examination findings before and after IQ treatment. The small number of patients, owing to the rarity of this disease, was the main limitation of the present study. IQ must be used carefully, and a close follow-up protocol is mandatory because of the lack of long-term efficacy data.
28209454	0	9	Treatment	T169	C0039798
28209454	13	49	Carcinoma In Situ of the Glans Penis	T191	C0686217
28209454	55	72	Topical Imiquimod	T200	C3215046
28209454	85	105	Carbon Dioxide Laser	T074	C0392251
28209454	106	114	Excision	T061	C0728940
28209454	115	124	Different	T080	C1705242
28209454	125	135	approaches	T169	C1292724
28209454	146	155	described	T078	C1552738
28209454	181	223	carcinoma in situ (CIS) of the glans penis	T191	C0686217
28209454	225	249	erythroplasia of Queyrat	T191	C0154089
28209454	252	261	including	T169	C0332257
28209454	262	282	topical chemotherapy	T061	C1519552
28209454	286	299	immunotherapy	T061	C0021083
28209454	304	309	laser	UnknownType	C0441543
28209454	313	330	surgical excision	T061	C0728940
28209454	335	344	evaluated	T061	C0728940
28209454	349	357	efficacy	T080	C1280519
28209454	361	378	topical imiquimod	T200	C3215046
28209454	380	382	IQ	T200	C3215046
28209454	396	416	carbon dioxide laser	T074	C0392251
28209454	417	425	ablation	T061	C0348007
28209454	433	439	lesion	T033	C0221198
28209454	463	480	patients affected	T080	C0522476
28209454	484	487	CIS	T191	C0686217
28209454	495	500	glans	T023	C1550261
28209454	506	513	treated	T061	C0332293
28209454	517	519	IQ	T200	C3215046
28209454	533	553	carbon dioxide laser	T074	C0392251
28209454	554	562	ablation	T061	C0348007
28209454	574	581	patient	T101	C0030705
28209454	586	595	performed	T169	C0884358
28209454	596	618	histologic examination	T059	C0019637
28209454	619	625	before	T079	C0332152
28209454	630	635	after	T079	C0687676
28209454	636	638	IQ	T200	C3215046
28209454	646	654	toxicity	T037	C0013221
28209454	659	674	adverse effects	T046	C0879626
28209454	690	705	After treatment	T079	C2709088
28209454	707	729	histologic examination	T059	C0019637
28209454	737	754	no residual tumor	T034	C0332652
28209454	760	768	patients	T101	C0030705
28209454	770	787	complete response	T033	C4050307
28209454	789	791	CR	T033	C4050307
28209454	795	809	stable disease	T033	C0677946
28209454	815	823	patients	T101	C0030705
28209454	829	848	progressive disease	T047	C1335499
28209454	854	862	patients	T101	C0030705
28209454	877	879	CR	T033	C4050307
28209454	884	904	human papillomavirus	T005	C0021344
28209454	907	914	related	T080	C0439849
28209454	915	922	lesions	T033	C0221198
28209454	937	939	no	T033	C1513916
28209454	952	960	relapses	T067	C0035020
28209454	961	966	after	T079	C0687676
28209454	974	983	follow-up	T058	C1522577
28209454	990	996	months	T079	C0439231
28209454	1004	1012	patients	T101	C0030705
28209454	1018	1037	progressive disease	T047	C1335499
28209454	1054	1063	penectomy	T061	C0194708
28209454	1069	1077	patients	T101	C0030705
28209454	1083	1088	alive	T033	C2584946
28209454	1101	1122	follow-up examination	T033	C0260832
28209454	1128	1136	patients	T101	C0030705
28209454	1151	1155	mild	T080	C2945599
28209454	1162	1170	toxicity	T037	C0013221
28209454	1172	1188	burning erythema	T184	C0085624
28209454	1194	1196	no	T033	C1513916
28209454	1197	1202	major	T080	C0205164
28209454	1203	1218	adverse effects	T046	C0879626
28209454	1226	1235	treatment	T169	C0039798
28209454	1241	1243	IQ	T200	C3215046
28209454	1248	1253	glans	T023	C1550261
28209454	1254	1257	CIS	T191	C0686217
28209454	1261	1270	effective	T080	C1704419
28209454	1282	1302	human papillomavirus	T005	C0021344
28209454	1305	1312	related	T080	C0439849
28209454	1313	1320	lesions	T033	C0221198
28209454	1367	1389	histologic examination	T059	C0019637
28209454	1399	1405	before	T079	C0332152
28209454	1410	1415	after	T079	C0687676
28209454	1416	1418	IQ	T200	C3215046
28209454	1419	1428	treatment	T169	C0039798
28209454	1450	1458	patients	T101	C0030705
28209454	1473	1479	rarity	T080	C0522498
28209454	1488	1495	disease	T047	C0012634
28209454	1510	1520	limitation	T169	C0449295
28209454	1543	1545	IQ	T200	C3215046
28209454	1582	1591	follow-up	T058	C1522577
28209454	1592	1600	protocol	T170	C0442711
28209454	1604	1613	mandatory	T061	C0683517
28209454	1629	1633	lack	T080	C0332268
28209454	1637	1646	long-term	T079	C0443252
28209454	1647	1655	efficacy	T080	C1280519

28273482|t|Orai1 -Mediated Antimicrobial Secretion from Pancreatic Acini Shapes the Gut Microbiome and Regulates Gut Innate Immunity
28273482|a|The gut microbiome participates in numerous physiologic functions and communicates intimately with the host immune system. Antimicrobial peptides are critica l components of intestinal innate immunity. We report a prominent role for antimicrobials secreted by pancreatic acini in shaping the gut microbiome that is essential for intestinal innate immunity, barrier function, and survival. Deletion of the Ca(2+) channel Orai1 in pancreatic acini of adult mice resulted in 60%-70% mortality within 3 weeks. Despite robust activation of the intestinal innate immune response, mice lacking acinar Orai1 exhibited intestinal bacterial outgrowth and dysbiosis, ultimately causing systemic translocation, inflammation, and death. While digestive enzyme supplementation was ineffective, treatments constraining bacterial outgrowth (purified liquid diet, broad-spectrum antibiotics) rescued survival, feeding, and weight gain. Pancreatic levels of cathelicidin -related antimicrobial peptide (CRAMP) were reduced, and supplement of synthetic CRAMP prevented intestinal disease. These findings reveal a critical role for antimicrobial pancreatic secretion in gut innate immunity.
28273482	0	5	Orai1	T116,T123	C4255013
28273482	16	29	Antimicrobial	T121	C1136254
28273482	30	39	Secretion	T031	C0036537
28273482	45	61	Pancreatic Acini	T023	C0227578
28273482	73	87	Gut Microbiome	T001	C4018878
28273482	92	101	Regulates	T040	C1155268
28273482	102	105	Gut	T023	C0699819
28273482	106	121	Innate Immunity	T032	C0020969
28273482	126	140	gut microbiome	T001	C4018878
28273482	166	187	physiologic functions	T039	C1254359
28273482	192	204	communicates	T033	C0566001
28273482	225	229	host	T001	C1167395
28273482	230	243	immune system	T022	C0020962
28273482	245	267	Antimicrobial peptides	T116,T121	C4084937
28273482	272	279	critica	T080	C1511545
28273482	282	292	components	T116,T123	C1179435
28273482	296	306	intestinal	T023	C0021853
28273482	307	322	innate immunity	T032	C0020969
28273482	336	345	prominent	T080	C0205402
28273482	355	378	antimicrobials secreted	T043	C1819788
28273482	382	398	pancreatic acini	T023	C0227578
28273482	414	428	gut microbiome	T001	C4018878
28273482	451	461	intestinal	T023	C0021853
28273482	462	477	innate immunity	T032	C0020969
28273482	479	495	barrier function	T042	C1254358
28273482	501	509	survival	T169	C0220921
28273482	511	519	Deletion	T052	C1880274
28273482	527	547	Ca(2+) channel Orai1	T028	C1823405
28273482	551	567	pancreatic acini	T023	C0227578
28273482	577	581	mice	T015	C0026809
28273482	602	611	mortality	T081	C0026565
28273482	643	694	activation of the intestinal innate immune response	T040	C1817386
28273482	696	700	mice	T015	C0026809
28273482	709	715	acinar	T082	C0332207
28273482	716	721	Orai1	T028	C1823405
28273482	732	742	intestinal	T023	C0021853
28273482	743	752	bacterial	T080	C0521009
28273482	753	762	outgrowth	T043	C0007613
28273482	767	776	dysbiosis	T184	C4287543
28273482	797	805	systemic	T169	C0205373
28273482	806	819	translocation	T043	C0599718
28273482	821	833	inflammation	T046	C0021368
28273482	839	844	death	T040	C0011065
28273482	852	868	digestive enzyme	T116,T121,T126	C0544420
28273482	869	884	supplementation	T061	C0948571
28273482	889	900	ineffective	T078	C3242229
28273482	902	912	treatments	T061	C0087111
28273482	926	935	bacterial	T080	C0521009
28273482	936	945	outgrowth	T043	C0007613
28273482	947	955	purified	T169	C1998793
28273482	956	967	liquid diet	T061	C0301571
28273482	969	995	broad-spectrum antibiotics	T195	C0003232
28273482	1005	1013	survival	T169	C0220921
28273482	1015	1022	feeding	T052	C2987508
28273482	1028	1039	weight gain	T033	C0043094
28273482	1041	1058	Pancreatic levels	T034	C1306845
28273482	1062	1074	cathelicidin	T116,T123	C0671062
28273482	1084	1105	antimicrobial peptide	T116,T121	C4084937
28273482	1107	1112	CRAMP	T116,T121	C4084937
28273482	1119	1126	reduced	T080	C0392756
28273482	1132	1142	supplement	T169	C2348609
28273482	1156	1161	CRAMP	T116,T121	C4084937
28273482	1172	1190	intestinal disease	T047	C0021831
28273482	1198	1206	findings	T033	C0243095
28273482	1216	1224	critical	T080	C1511545
28273482	1234	1247	antimicrobial	T121	C1136254
28273482	1248	1268	pancreatic secretion	T042	C0232787
28273482	1272	1275	gut	T023	C0699819
28273482	1276	1291	innate immunity	T032	C0020969

28443672|t|Heightened HIV antibody responses in postpartum women as exemplified by recent infection assays: implications for incidence estimates
28443672|a|Laboratory assays that identify recent HIV infections are important for assessing impacts of interventions aimed at reducing HIV incidence. Kinetics of HIV humoral responses can vary with inherent assay properties, and between HIV subtypes, populations and physiological states. They are important in determining mean duration of recent infection (MDRI) for antibody-based assays for detecting recent HIV infections. We determined MDRIs for BED-CEIA, LAg and BRAI assays for 101 seroconverting postpartum women, recruited in Harare in 1997- 2000 during the Zimbabwe Vitamin A for Mothers and Babies (ZVITAMBO) Trial, comparing them against published MDRIs estimated from seroconverting cases in the general population. We also compared MDRIs for women who seroconverted either during the first nine months, or at later stages, postpartum. At cut-offs (C) of 0.8 for BED, 1.5 for LAg and 40% for BRAI, estimated MDRIs for postpartum mothers, were 192, 104 and 144 days, 33%, 32-41% and 52% lower than published estimates of 287, 152-177 and 298 days, respectively, for clade C samples from general populations. Point estimates of MDRI values were 7 - 19% shorter for women who seroconverted in the first 9- months postpartum, compared with those seroconverting later. MDRI values for three HIV incidence biomarkers are longer in the general population than among postpartum women, particularly those who recently gave birth, consistent with heightened immunologic activation soon after birth. Our results provide a caution that MDRI may vary significantly between subjects in different physiological states.
28443672	0	10	Heightened	T080	C0442803
28443672	11	23	HIV antibody	T116,T129	C0019683
28443672	24	33	responses	T038	C0003261
28443672	37	53	postpartum women	T101	C0032804
28443672	79	95	infection assays	T059	C0005507
28443672	97	109	implications	T078	C1705535
28443672	114	123	incidence	T081	C0021149
28443672	124	133	estimates	T081	C0750572
28443672	134	151	Laboratory assays	T059	C0005507
28443672	157	165	identify	T080	C0205396
28443672	166	187	recent HIV infections	T047	C0019693
28443672	206	215	assessing	T058	C0184514
28443672	216	223	impacts	T080	C4049986
28443672	227	240	interventions	T058	C1273869
28443672	250	258	reducing	T080	C0392756
28443672	259	262	HIV	T047	C0019693
28443672	263	272	incidence	T081	C0021149
28443672	274	282	Kinetics	T070	C0022702
28443672	286	289	HIV	T047	C0019693
28443672	290	307	humoral responses	T043	C1155229
28443672	322	347	inherent assay properties	T080	C0871161
28443672	361	364	HIV	T005	C0019682
28443672	365	373	subtypes	T185	C0449560
28443672	375	386	populations	T098	C1257890
28443672	391	411	physiological states	T039	C0031843
28443672	452	460	duration	T079	C0449238
28443672	464	480	recent infection	T033	C2169571
28443672	482	486	MDRI	T033	C2169571
28443672	492	513	antibody-based assays	T059	C0005507
28443672	518	527	detecting	T061	C1511790
28443672	528	549	recent HIV infections	T047	C0019693
28443672	565	570	MDRIs	T033	C2169571
28443672	575	583	BED-CEIA	T059	C0086231
28443672	585	588	LAg	T059	C0086231
28443672	593	604	BRAI assays	T059	C0086231
28443672	613	627	seroconverting	T070	C4042908
28443672	628	644	postpartum women	T101	C0032804
28443672	659	665	Harare	UnknownType	C0681784
28443672	691	749	Zimbabwe Vitamin A for Mothers and Babies (ZVITAMBO) Trial	T062	C0008976
28443672	751	760	comparing	T052	C1707455
28443672	774	783	published	T170	C0993637
28443672	784	789	MDRIs	T033	C2169571
28443672	790	799	estimated	T081	C0750572
28443672	805	819	seroconverting	T070	C4042908
28443672	820	825	cases	T077	C1706256
28443672	833	851	general population	T098	C0683971
28443672	861	869	compared	T052	C1707455
28443672	870	875	MDRIs	T033	C2169571
28443672	880	885	women	T098	C0043210
28443672	890	903	seroconverted	T070	C4042908
28443672	933	939	months	T079	C0439231
28443672	953	959	stages	T079	C0205390
28443672	961	971	postpartum	T079	C0086839
28443672	1000	1003	BED	T059	C0086231
28443672	1013	1016	LAg	T059	C0086231
28443672	1029	1033	BRAI	T059	C0086231
28443672	1035	1044	estimated	T081	C0750572
28443672	1045	1050	MDRIs	T033	C2169571
28443672	1055	1073	postpartum mothers	T101	C0032804
28443672	1097	1101	days	T079	C0439228
28443672	1123	1128	lower	T080	C0205251
28443672	1134	1153	published estimates	T170	C0993637
28443672	1178	1182	days	T079	C0439228
28443672	1202	1209	clade C	T185	C0449560
28443672	1210	1217	samples	T077	C2347026
28443672	1223	1242	general populations	T098	C0683971
28443672	1244	1259	Point estimates	T062	C1709586
28443672	1263	1267	MDRI	T033	C2169571
28443672	1268	1274	values	T170	C1285164
28443672	1288	1295	shorter	T080	C0205251
28443672	1300	1305	women	T098	C0043210
28443672	1310	1323	seroconverted	T070	C4042908
28443672	1340	1346	months	T079	C0439231
28443672	1347	1357	postpartum	T079	C0086839
28443672	1379	1393	seroconverting	T070	C4042908
28443672	1401	1405	MDRI	T033	C2169571
28443672	1406	1412	values	T170	C1285164
28443672	1423	1426	HIV	T047	C0019693
28443672	1427	1436	incidence	T081	C0021149
28443672	1437	1447	biomarkers	T201	C0005516
28443672	1452	1458	longer	T080	C0205250
28443672	1466	1484	general population	T098	C0683971
28443672	1496	1512	postpartum women	T101	C0032804
28443672	1551	1556	birth	T040	C0005615
28443672	1558	1573	consistent with	T078	C0332290
28443672	1574	1584	heightened	T080	C0442803
28443672	1585	1607	immunologic activation	T039	C1512670
28443672	1619	1624	birth	T040	C0005615
28443672	1630	1637	results	T169	C1274040
28443672	1661	1665	MDRI	T033	C2169571
28443672	1675	1688	significantly	T078	C0750502
28443672	1697	1705	subjects	T098	C2349001
28443672	1719	1739	physiological states	T039	C0031843

28320554|t|Pregnancy and Kidney Outcomes in Patients With IgA Nephropathy: A Cohort Study
28320554|a|The outcomes of pregnancy in immunoglobulin A nephropathy (IgAN) are controversial. This cohort study assessed the effects of pregnancy on kidney disease progression and risk factors for adverse pregnancy outcomes in patients with IgAN. A cohort study. Women of child-bearing age with IgAN and minimum follow-up of 1 year after biopsy from December 2003 to September 2014. Pregnancy, treated as a time-dependent variable; baseline (at time of biopsy) estimated glomerular filtration rate (eGFR), proteinuria, blood pressure, and kidney pathology (Oxford MEST classification). Kidney disease progression event, defined as 30% decline in eGFR or end-stage kidney disease; rate of eGFR decline; and adverse pregnancy outcomes, including severe preeclampsia and fetal loss. Of 413 patients enrolled, 266 (64.4%), 101 (24.5%), 40 (9.6%), and 6 (1.5%) had chronic kidney disease (CKD) stages 1, 2, 3, and 4, respectively. During follow-up, 104 had 116 pregnancies, of which 110 continued beyond week 20; 309 patients did not become pregnant. After adjustment for age, eGFR, mean arterial pressure, proteinuria, and pathology class at the time of biopsy, subsequent pregnancy among patients with CKD stages 3 to 4, but not CKD stages 1 to 2, was associated with faster eGFR decline (-7.44 vs -3.90mL/min/1.73m(2) per year; P=0.007) and increased incidence of kidney progression events (HR, 5.14; 95% CI, 1.16-22.74) compared with patients who did not become pregnant. Relatively small sample size and single-center experience. Pregnancy accelerated kidney disease progression in women with IgAN and CKD stage 3, but not in those at stage 1 or 2.
28320554	0	9	Pregnancy	T033	C0032972
28320554	14	20	Kidney	T023	C0022646
28320554	21	29	Outcomes	T169	C1274040
28320554	33	41	Patients	T101	C0030705
28320554	47	62	IgA Nephropathy	T047	C0017661
28320554	66	78	Cohort Study	T081	C0009247
28320554	83	104	outcomes of pregnancy	T033	C0032972
28320554	108	136	immunoglobulin A nephropathy	T047	C0017661
28320554	138	142	IgAN	T047	C0017661
28320554	168	180	cohort study	T081	C0009247
28320554	205	214	pregnancy	T040	C0032961
28320554	218	224	kidney	T023	C0022646
28320554	225	244	disease progression	T046	C0242656
28320554	249	261	risk factors	T033	C0035648
28320554	266	273	adverse	T033	C1705586
28320554	274	292	pregnancy outcomes	T033	C0032972
28320554	296	304	patients	T101	C0030705
28320554	310	314	IgAN	T047	C0017661
28320554	318	330	cohort study	T081	C0009247
28320554	332	337	Women	T098	C0043210
28320554	341	358	child-bearing age	T033	C1960468
28320554	364	368	IgAN	T047	C0017661
28320554	381	390	follow-up	T058	C1522577
28320554	407	413	biopsy	T060	C0005558
28320554	452	461	Pregnancy	T040	C0032961
28320554	463	470	treated	T169	C1522326
28320554	501	509	baseline	T081	C1442488
28320554	522	528	biopsy	T060	C0005558
28320554	540	566	glomerular filtration rate	T060	C0017654
28320554	568	572	eGFR	T060	C0017654
28320554	575	586	proteinuria	T033	C0033687
28320554	588	602	blood pressure	T040	C0005823
28320554	608	614	kidney	T023	C0022646
28320554	615	624	pathology	T046	C0677042
28320554	626	652	Oxford MEST classification	T185	C0008902
28320554	655	661	Kidney	T023	C0022646
28320554	662	681	disease progression	T046	C0242656
28320554	682	687	event	T051	C0441471
28320554	704	711	decline	T080	C0392756
28320554	715	719	eGFR	T060	C0017654
28320554	723	747	end-stage kidney disease	T047	C0022661
28320554	757	761	eGFR	T060	C0017654
28320554	762	769	decline	T080	C0392756
28320554	775	782	adverse	T033	C1705586
28320554	783	801	pregnancy outcomes	T033	C0032972
28320554	820	832	preeclampsia	T046	C0032914
28320554	837	847	fetal loss	T046	C0687675
28320554	856	864	patients	T101	C0030705
28320554	929	966	chronic kidney disease (CKD) stages 1	T047	C2316401
28320554	968	969	2	T047	C2316786
28320554	971	972	3	T047	C2316787
28320554	978	979	4	T047	C2317473
28320554	1002	1011	follow-up	T058	C1522577
28320554	1025	1036	pregnancies	T040	C0032961
28320554	1081	1089	patients	T101	C0030705
28320554	1094	1113	not become pregnant	T033	C0232973
28320554	1136	1139	age	T032	C0001779
28320554	1141	1145	eGFR	T060	C0017654
28320554	1147	1169	mean arterial pressure	T033	C0428886
28320554	1171	1182	proteinuria	T033	C0033687
28320554	1188	1197	pathology	T091	C0030664
28320554	1219	1225	biopsy	T060	C0005558
28320554	1238	1247	pregnancy	T040	C0032961
28320554	1254	1262	patients	T101	C0030705
28320554	1268	1280	CKD stages 3	T047	C2316787
28320554	1284	1285	4	T047	C2317473
28320554	1295	1307	CKD stages 1	T047	C2316401
28320554	1311	1312	2	T047	C2316786
28320554	1318	1333	associated with	T080	C0332281
28320554	1341	1345	eGFR	T060	C0017654
28320554	1346	1353	decline	T080	C0392756
28320554	1408	1417	increased	T081	C0205217
28320554	1418	1427	incidence	T081	C0021149
28320554	1431	1437	kidney	T023	C0022646
28320554	1438	1449	progression	T169	C0449258
28320554	1450	1456	events	T051	C0441471
28320554	1502	1510	patients	T101	C0030705
28320554	1519	1538	not become pregnant	T033	C0232973
28320554	1551	1556	small	T081	C0700321
28320554	1557	1568	sample size	T081	C0242618
28320554	1599	1608	Pregnancy	T040	C0032961
28320554	1609	1620	accelerated	T169	C0521110
28320554	1621	1627	kidney	T023	C0022646
28320554	1628	1647	disease progression	T046	C0242656
28320554	1651	1656	women	T098	C0043210
28320554	1662	1666	IgAN	T047	C0017661
28320554	1671	1682	CKD stage 3	T047	C2316787
28320554	1704	1711	stage 1	T047	C2316401
28320554	1715	1716	2	T047	C2316786

28509526|t|Paraoxonases and psoriasis: negative imbalance of anti--oxidant endogenous mechanisms
28509526|a|Numerous reports have shown that psoriasis patients are more exposed to lipoprotein peroxidation and to a decrease in the activity of paraoxonase (PON)1, an anti-oxidant and anti-inflammatory enzyme. Thus, it has been suggested that malfunction of the anti-oxidant system and an increased production of reactive oxygen species drive immune inflammatory events, that result in progressive skin cell damage in patients with psoriasis. The PON protein family, including PON1, PON2 and PON3, is one of the most important endogenous defense mechanisms against oxidative stress. In the present study, we investigated PON gene expression in psoriasis and in cutaneous oxidative stress. The study population included 10 patients affected by moderate -to- severe plaque psoriasis and 15 healthy donors who have undergone to plastic surgery, were used as control. Skin punch biopsies of lesional and non lesional psoriatic skin were performed for analysis of PON2 and PON3 gene expression. In addition, oxidation assays in ex vivo full-thickness healthy skin organ cultures were performed. No significant differences were observed between PON2 and PON3 gene expression in psoriatic lesional and non lesional skin compared with healthy controls. H2O2 treatment induced a significant decrease of PON2 and PON3 expression in ex vivo full-thickness healthy skin organ cultures; conversely the pre-treatment of samples with the anti-oxidant reagent N-acetyl-L-cysteine (NAC) induced a significant increase. Interestingly, no significant alterations were reported for PON2 and PON3 expression in ex vivo full-thickness healthy skin organ cultures stimulated with IL-17. Taken together our findings have revealed that a strong pro-oxidative activity is not effectively countered by anti-oxidant endogenous mechanisms both in psoriatic skin and in ex vivo experimental model.
28509526	0	12	Paraoxonases	T116,T126	C0052451
28509526	17	26	psoriasis	T047	C0033860
28509526	28	36	negative	T033	C0205160
28509526	37	46	imbalance	T184	C1397014
28509526	50	63	anti--oxidant	T121	C0003402
28509526	64	74	endogenous	T169	C0205227
28509526	75	85	mechanisms	T044	C0678659
28509526	119	128	psoriasis	T047	C0033860
28509526	129	137	patients	T101	C0030705
28509526	147	157	exposed to	T080	C0332157
28509526	158	182	lipoprotein peroxidation	T044	C0023775
28509526	192	200	decrease	T081	C0547047
28509526	208	216	activity	T044	C2257843
28509526	220	238	paraoxonase (PON)1	T116,T126	C1121571
28509526	243	255	anti-oxidant	T121	C0003402
28509526	260	277	anti-inflammatory	T121	C0003209
28509526	278	284	enzyme	T116,T126	C0014442
28509526	319	330	malfunction	T169	C0231174
28509526	338	357	anti-oxidant system	T121	C0003402
28509526	365	374	increased	T081	C0205217
28509526	375	385	production	T038	C3714634
28509526	389	412	reactive oxygen species	T123,T196	C0162772
28509526	419	425	immune	T169	C0439662
28509526	426	438	inflammatory	T169	C0333348
28509526	439	445	events	T051	C0441471
28509526	452	458	result	T169	C1274040
28509526	462	473	progressive	T169	C0205329
28509526	474	483	skin cell	T025	C0814995
28509526	484	490	damage	T049	C0599732
28509526	494	502	patients	T101	C0030705
28509526	508	517	psoriasis	T047	C0033860
28509526	523	526	PON	T116,T126	C0052451
28509526	527	541	protein family	T116,T123	C1335532
28509526	553	557	PON1	T116,T126	C1257646
28509526	559	563	PON2	T116,T126	C0755726
28509526	568	572	PON3	T116,T126	C1447656
28509526	603	613	endogenous	T169	C0205227
28509526	614	632	defense mechanisms	T041	C0011142
28509526	641	657	oxidative stress	T049	C0242606
28509526	674	679	study	T062	C2603343
28509526	684	696	investigated	T169	C1292732
28509526	697	705	PON gene	T028	C0017337
28509526	706	716	expression	T045	C0017262
28509526	720	729	psoriasis	T047	C0033860
28509526	737	746	cutaneous	T082	C0221912
28509526	747	763	oxidative stress	T049	C0242606
28509526	769	774	study	T062	C2603343
28509526	775	785	population	T098	C1257890
28509526	798	806	patients	T101	C0030705
28509526	807	815	affected	T169	C0392760
28509526	819	827	moderate	T080	C0205081
28509526	833	839	severe	T080	C0205082
28509526	840	856	plaque psoriasis	T047	C0033860
28509526	864	871	healthy	T080	C3898900
28509526	872	878	donors	T098	C0013018
28509526	901	916	plastic surgery	T061	C0677616
28509526	931	938	control	T096	C0009932
28509526	940	959	Skin punch biopsies	T060	C0191321
28509526	963	971	lesional	T022	C1123023
28509526	976	1003	non lesional psoriatic skin	T022	C1123023
28509526	1023	1031	analysis	T062	C0936012
28509526	1035	1039	PON2	T028	C1418755
28509526	1044	1048	PON3	T028	C1418756
28509526	1049	1064	gene expression	T045	C0017262
28509526	1079	1088	oxidation	T044	C0030011
28509526	1089	1095	assays	T059	C0005507
28509526	1099	1106	ex vivo	T169	C2348480
28509526	1107	1121	full-thickness	T081	C0439809
28509526	1122	1129	healthy	T080	C3898900
28509526	1130	1134	skin	T022	C1123023
28509526	1135	1149	organ cultures	T059	C0029205
28509526	1155	1164	performed	T169	C0884358
28509526	1166	1192	No significant differences	T033	C3842396
28509526	1215	1219	PON2	T028	C1418755
28509526	1224	1228	PON3	T028	C1418756
28509526	1229	1244	gene expression	T045	C0017262
28509526	1248	1266	psoriatic lesional	T022	C1123023
28509526	1271	1288	non lesional skin	T022	C1123023
28509526	1289	1297	compared	T052	C1707455
28509526	1303	1319	healthy controls	T080	C2986479
28509526	1321	1325	H2O2	T121,T130,T197	C0020281
28509526	1326	1335	treatment	T169	C1522326
28509526	1336	1343	induced	T169	C0205263
28509526	1358	1366	decrease	T081	C0547047
28509526	1370	1374	PON2	T028	C1418755
28509526	1379	1383	PON3	T028	C1418756
28509526	1384	1394	expression	T045	C0017262
28509526	1398	1405	ex vivo	T169	C2348480
28509526	1406	1420	full-thickness	T081	C0439809
28509526	1421	1428	healthy	T080	C3898900
28509526	1429	1433	skin	T022	C1123023
28509526	1434	1448	organ cultures	T059	C0029205
28509526	1465	1478	pre-treatment	T079	C2709094
28509526	1482	1489	samples	T167	C0370003
28509526	1499	1519	anti-oxidant reagent	T121	C0003402
28509526	1520	1539	N-acetyl-L-cysteine	T116,T121	C0001047
28509526	1541	1544	NAC	T116,T121	C0001047
28509526	1546	1553	induced	T169	C0205263
28509526	1568	1576	increase	T169	C0442805
28509526	1593	1607	no significant	T033	C3694175
28509526	1608	1619	alterations	T169	C0392747
28509526	1638	1642	PON2	T028	C1418755
28509526	1647	1651	PON3	T028	C1418756
28509526	1652	1662	expression	T045	C0017262
28509526	1666	1673	ex vivo	T169	C2348480
28509526	1674	1688	full-thickness	T081	C0439809
28509526	1689	1696	healthy	T080	C3898900
28509526	1697	1701	skin	T022	C1123023
28509526	1702	1716	organ cultures	T059	C0029205
28509526	1717	1727	stimulated	T042	C1254358
28509526	1733	1738	IL-17	T116,T129	C0384648
28509526	1759	1767	findings	T033	C0243095
28509526	1789	1795	strong	T080	C0442821
28509526	1796	1818	pro-oxidative activity	T044	C2266999
28509526	1851	1863	anti-oxidant	T121	C0003402
28509526	1864	1874	endogenous	T169	C0205227
28509526	1875	1885	mechanisms	T044	C0678659
28509526	1894	1903	psoriatic	T047	C0033860
28509526	1904	1908	skin	T022	C1123023
28509526	1916	1923	ex vivo	T169	C2348480
28509526	1924	1942	experimental model	T170	C0086272

27820857|t|Identification of In-Chain-Functionalized Compounds and Methyl-Branched Alkanes in Cuticular Waxes of Triticum aestivum cv. Bethlehem
27820857|a|In this work, cuticular waxes from flag leaf blades and peduncles of Triticum aestivum cv. Bethlehem were investigated in search for novel wax compounds. Seven wax compound classes were detected that had previously not been reported, and their structures were elucidated using gas chromatography-mass spectrometry of various derivatives. Six of the classes were identified as series of homologs differing by two methylene units, while the seventh was a homologous series with homologs with single methylene unit differences. In the waxes of flag leaf blades, secondary alcohols (predominantly C27 and C33), primary / secondary diols (predominantly C28) and esters of primary / secondary diols (predominantly C50, combining C28 diol with C22 acid) were found, all sharing similar secondary hydroxyl group positions at and around C-12 or ω-12. 7- and 8-hydroxy-2-alkanol esters (predominantly C35), 7- and 8-oxo-2-alkanol esters (predominantly C35), and 4-alkylbutan-4-olides (predominantly C28) were found both in flag leaf and peduncle wax mixtures. Finally, a series of even - and odd-numbered alkane homologs was identified in both leaf and peduncle waxes, with an internal methyl branch preferentially on C-11 and C-13 of homologs with even total carbon number and on C-12 of odd-numbered homologs. Biosynthetic pathways are suggested for all compounds, based on common structural features and matching chain length profiles with other wheat wax compound classes.
27820857	0	14	Identification	T080	C0205396
27820857	18	51	In-Chain-Functionalized Compounds	T103	C1706082
27820857	56	79	Methyl-Branched Alkanes	T109	C0002065
27820857	83	92	Cuticular	T002	C2699479
27820857	93	98	Waxes	T122	C0043076
27820857	102	133	Triticum aestivum cv. Bethlehem	T002	C1123020
27820857	148	157	cuticular	T002	C2699479
27820857	158	163	waxes	T122	C0043076
27820857	169	178	flag leaf	T002	C0242724
27820857	179	185	blades	T002	C2700402
27820857	190	199	peduncles	T002	C2698753
27820857	203	234	Triticum aestivum cv. Bethlehem	T002	C1123020
27820857	240	252	investigated	T169	C1292732
27820857	267	272	novel	T080	C0205314
27820857	273	286	wax compounds	T122	C0043076
27820857	294	306	wax compound	T122	C0043076
27820857	307	314	classes	T185	C1705943
27820857	320	328	detected	T033	C0442726
27820857	378	388	structures	T170	C0220807
27820857	411	447	gas chromatography-mass spectrometry	T059	C0024868
27820857	459	470	derivatives	T104	C0243072
27820857	510	528	series of homologs	T081	C0205549
27820857	529	538	differing	T080	C1705242
27820857	542	561	two methylene units	T104	C1254350
27820857	587	604	homologous series	T081	C0205549
27820857	610	645	homologs with single methylene unit	T104	C1254350
27820857	666	671	waxes	T122	C0043076
27820857	675	684	flag leaf	T002	C0242724
27820857	685	691	blades	T002	C2700402
27820857	693	711	secondary alcohols	UnknownType	C0682927
27820857	713	726	predominantly	T080	C1542147
27820857	727	730	C27	UnknownType	C0682927
27820857	735	738	C33	UnknownType	C0682927
27820857	741	748	primary	T109	C0017951
27820857	751	766	secondary diols	T109	C0017951
27820857	768	781	predominantly	T080	C1542147
27820857	782	785	C28	T109	C0017951
27820857	791	808	esters of primary	T109	C0014898
27820857	811	826	secondary diols	T109	C0014898
27820857	828	841	predominantly	T080	C1542147
27820857	842	845	C50	T109	C0014898
27820857	857	865	C28 diol	T109	C0017945
27820857	871	879	C22 acid	T109	C0369760
27820857	913	947	secondary hydroxyl group positions	T104	C1254350
27820857	976	978	7-	T109	C0014898
27820857	983	1009	8-hydroxy-2-alkanol esters	T109	C0014898
27820857	1011	1024	predominantly	T080	C1542147
27820857	1025	1028	C35	T109	C0014898
27820857	1031	1033	7-	T109	C0014898
27820857	1038	1060	8-oxo-2-alkanol esters	T109	C0014898
27820857	1062	1075	predominantly	T080	C1542147
27820857	1076	1079	C35	T109	C0014898
27820857	1086	1107	4-alkylbutan-4-olides	T109	C0022947
27820857	1109	1122	predominantly	T080	C1542147
27820857	1123	1126	C28	T109	C0022947
27820857	1147	1156	flag leaf	T002	C0242724
27820857	1161	1169	peduncle	T002	C2698753
27820857	1170	1173	wax	T122	C0043076
27820857	1195	1201	series	T081	C0205549
27820857	1205	1209	even	T104	C1254350
27820857	1216	1244	odd-numbered alkane homologs	T104	C1254350
27820857	1268	1272	leaf	T002	C0242724
27820857	1277	1285	peduncle	T002	C2698753
27820857	1286	1291	waxes	T122	C0043076
27820857	1301	1323	internal methyl branch	T104	C1254350
27820857	1342	1346	C-11	T109	C0029224
27820857	1351	1397	C-13 of homologs with even total carbon number	T109	C0029224
27820857	1405	1434	C-12 of odd-numbered homologs	T109	C0029224
27820857	1436	1457	Biosynthetic pathways	T044	C1721101
27820857	1480	1489	compounds	T080	C0205198
27820857	1507	1517	structural	T170	C0220807
27820857	1518	1526	features	T080	C2348519
27820857	1540	1552	chain length	T081	C0596310
27820857	1553	1561	profiles	T169	C2003903
27820857	1573	1578	wheat	T002	C1510495
27820857	1579	1591	wax compound	T122	C0043076

27781034|t|Generalized Epilepsy and Myoclonic Seizures in 22q11.2 Deletion Syndrome
27781034|a|Prompted by the observations of juvenile myoclonic epilepsy (JME) in 22q11.2 deletion syndrome (22q11DS) and recurrent copy number variants in genetic generalized epilepsy (GGE), we searched for further evidence supporting a possible correlation of 22q11DS with GGE and with myoclonic seizures. Through routine diagnostics, we identified 3 novel individuals with the seemingly uncommon combination of 22q11DS and JME. We subsequently screened the literature for reports focussing on the epilepsy phenotype in 22q11DS. We additionally screened a database of 173 22q11DS patients and identified a fourth individual with JME as well as 2 additional cases with GGE. We describe 6 novel and 22 published cases with co-occurrence of 22q11DS and GGE. In many patients, GGE was associated with myoclonic seizures allowing for a diagnosis of JME in at least 6 individuals. Seventeen of the 173 22q11DS cases (10%) had a diagnosis of either focal or generalized epilepsy. In these cases, focal epilepsy could often be attributed to syndrome-associated hypocalcaemia, cerebral bleeds, or structural brain anomalies. However, the cause of GGE remained unclear. In this study, we describe and review 28 individuals with 22q11DS and GGE (especially JME), showing that both disorders frequently co-occur. Compared to the reported prevalence of 15-21%, in our case series only 10% of 22q11DS individuals were found to have epilepsy, often GGE. Since 22q11.2 does not contain convincing GGE candidate genes, we discuss the possibility of an aetiological correlation through a possibly disturbed interaction with the GABAB receptor.
27781034	0	20	Generalized Epilepsy	T047	C0014548
27781034	25	43	Myoclonic Seizures	T047	C0014550
27781034	47	72	22q11.2 Deletion Syndrome	T047	C0012236
27781034	105	132	juvenile myoclonic epilepsy	T047	C0270853
27781034	134	137	JME	T047	C0270853
27781034	142	167	22q11.2 deletion syndrome	T047	C0012236
27781034	169	176	22q11DS	T047	C0012236
27781034	182	212	recurrent copy number variants	T086	C1511518
27781034	216	223	genetic	T169	C0017399
27781034	224	244	generalized epilepsy	T047	C0014548
27781034	246	249	GGE	T047	C0014548
27781034	307	318	correlation	T080	C1707520
27781034	322	329	22q11DS	T047	C0012236
27781034	335	338	GGE	T047	C0014548
27781034	348	366	myoclonic seizures	T047	C0014550
27781034	376	395	routine diagnostics	T060	C0086143
27781034	419	430	individuals	T098	C0027361
27781034	450	458	uncommon	T080	C0522498
27781034	459	470	combination	T080	C0205195
27781034	474	481	22q11DS	T047	C0012236
27781034	486	489	JME	T047	C0270853
27781034	507	515	screened	T058	C0220908
27781034	520	530	literature	T170	C0023866
27781034	535	542	reports	T170	C0684224
27781034	560	578	epilepsy phenotype	T032	C0031437
27781034	582	589	22q11DS	T047	C0012236
27781034	607	615	screened	T058	C0220908
27781034	618	626	database	T170	C0242356
27781034	634	641	22q11DS	T047	C0012236
27781034	642	650	patients	T101	C0030705
27781034	675	685	individual	T098	C0027361
27781034	691	694	JME	T047	C0270853
27781034	719	724	cases	T169	C0868928
27781034	730	733	GGE	T047	C0014548
27781034	749	754	novel	T080	C0205314
27781034	762	771	published	T057	C0034037
27781034	772	777	cases	T169	C0868928
27781034	783	796	co-occurrence	T033	C0243095
27781034	800	807	22q11DS	T047	C0012236
27781034	812	815	GGE	T047	C0014548
27781034	825	833	patients	T101	C0030705
27781034	835	838	GGE	T047	C0014548
27781034	843	858	associated with	T080	C0332281
27781034	859	877	myoclonic seizures	T047	C0014550
27781034	893	902	diagnosis	T033	C0011900
27781034	906	909	JME	T047	C0270853
27781034	924	935	individuals	T098	C0027361
27781034	958	965	22q11DS	T047	C0012236
27781034	966	971	cases	T169	C0868928
27781034	984	993	diagnosis	T033	C0011900
27781034	1004	1009	focal	T047	C0014547
27781034	1013	1033	generalized epilepsy	T047	C0014548
27781034	1044	1049	cases	T169	C0868928
27781034	1051	1065	focal epilepsy	T047	C0014547
27781034	1095	1128	syndrome-associated hypocalcaemia	T047	C0020598
27781034	1130	1145	cerebral bleeds	T033	C2937358
27781034	1150	1176	structural brain anomalies	T033	C3280971
27781034	1200	1203	GGE	T047	C0014548
27781034	1230	1235	study	T062	C2603343
27781034	1263	1274	individuals	T098	C0027361
27781034	1280	1287	22q11DS	T047	C0012236
27781034	1292	1295	GGE	T047	C0014548
27781034	1308	1311	JME	T047	C0270853
27781034	1332	1341	disorders	T047	C0012634
27781034	1342	1361	frequently co-occur	T033	C0243095
27781034	1379	1398	reported prevalence	T081	C0220900
27781034	1417	1428	case series	T062	C0150093
27781034	1441	1448	22q11DS	T047	C0012236
27781034	1449	1460	individuals	T098	C0027361
27781034	1480	1488	epilepsy	T047	C0014544
27781034	1496	1499	GGE	T047	C0014548
27781034	1507	1514	22q11.2	T026	C1521104
27781034	1543	1546	GGE	T047	C0014548
27781034	1547	1562	candidate genes	T028	C1332838
27781034	1597	1609	aetiological	T169	C0015127
27781034	1610	1621	correlation	T080	C1707520
27781034	1672	1686	GABAB receptor	T116,T192	C0052887

28471941|t|Basic science and pathogenesis of ageing with HIV: potential mechanisms and biomarkers
28471941|a|: The increased prevalence of age -related comorbidities and mortality is worrisome in ageing HIV-infected patients. Here, we aim to analyse the different ageing mechanisms with regard to HIV infection. Ageing results from the time - dependent accumulation of random cellular damage. Epigenetic modifications and mitochondrial DNA haplogroups modulate ageing. In antiretroviral treatment -controlled patients, epigenetic clock appears to be advanced, and some haplogroups are associated with HIV infection severity. Telomere shortening is enhanced in HIV-infected patients because of HIV and some nucleoside analogue reverse transcriptase inhibitors. Mitochondria -related oxidative stress and mitochondrial DNA mutations are increased during ageing and also by some nucleoside analogue reverse transcriptase inhibitors. Overall, increased inflammation or ' inflammageing ' is a major driver of ageing and could result from cell senescence with secreted proinflammatory mediators, altered gut microbiota, and coinfections. In HIV-infected patients, the level of inflammation and innate immunity activation is enhanced and related to most comorbidities and to mortality. This status could result, in addition to age, from the virus itself or viral protein released from reservoirs, from HIV -enhanced gut permeability and dysbiosis, from antiretroviral treatment, from frequent cytomegalovirus and hepatitis C virus coinfections, and also from personal and environmental factors, as central fat accumulation or smoking. Adaptive immune activation and immunosenescence are associated with comorbidities and mortality in the general population but are less predictive in HIV-infected patients. Biomarkers to evaluate ageing in HIV-infected patients are required. Numerous systemic or cellular inflammatory, immune activation, oxidative stress, or senescence markers can be tested in serum or peripheral blood mononuclear cells. The novel European Study to Establish Biomarkers of Human Ageing MARK-AGE algorithm, evaluating the biological age, is currently assessed in HIV-infected patients and reveals an advanced biological age. Some enhanced inflammatory or innate immune activation markers are interesting but still not validated for the patient's follow-up. To be able to assess patients ' biological age is an important objective to improve their healthspan.
28471941	0	13	Basic science	T062	C0681833
28471941	18	30	pathogenesis	T046	C0699748
28471941	34	40	ageing	T040	C0001811
28471941	46	49	HIV	T047	C0019693
28471941	61	71	mechanisms	T169	C0441712
28471941	76	86	biomarkers	T201	C0005516
28471941	103	113	prevalence	T081	C0220900
28471941	117	120	age	T032	C0001779
28471941	130	143	comorbidities	T078	C0009488
28471941	148	157	mortality	T081	C0178686
28471941	161	170	worrisome	T033	C0233481
28471941	174	180	ageing	T040	C0001811
28471941	181	193	HIV-infected	T047	C0019693
28471941	194	202	patients	T101	C0030705
28471941	213	216	aim	T078	C1947946
28471941	220	227	analyse	T062	C0936012
28471941	242	248	ageing	T040	C0001811
28471941	249	259	mechanisms	T169	C0441712
28471941	275	288	HIV infection	T047	C0019693
28471941	290	296	Ageing	T040	C0001811
28471941	314	318	time	T079	C0040223
28471941	321	330	dependent	T169	C3244310
28471941	331	343	accumulation	T033	C4055506
28471941	354	369	cellular damage	T049	C0599732
28471941	371	395	Epigenetic modifications	T045	C1516924
28471941	400	417	mitochondrial DNA	T114,T123	C0012929
28471941	418	429	haplogroups	T032	C0018591
28471941	430	438	modulate	T082	C0443264
28471941	439	445	ageing	T040	C0001811
28471941	450	474	antiretroviral treatment	T061	C1963724
28471941	487	495	patients	T101	C0030705
28471941	497	513	epigenetic clock	T040	C0085759
28471941	547	558	haplogroups	T032	C0018591
28471941	579	592	HIV infection	T047	C0019693
28471941	593	601	severity	T080	C0439793
28471941	603	622	Telomere shortening	T049	C1515263
28471941	638	650	HIV-infected	T047	C0019693
28471941	651	659	patients	T101	C0030705
28471941	671	674	HIV	T005	C0019682
28471941	684	703	nucleoside analogue	T114,T121	C1579410
28471941	704	736	reverse transcriptase inhibitors	T121	C0282519
28471941	738	750	Mitochondria	T026	C0026237
28471941	760	776	oxidative stress	T049	C0242606
28471941	781	798	mitochondrial DNA	T114,T123	C0012929
28471941	799	808	mutations	T045	C0026882
28471941	830	836	ageing	T040	C0001811
28471941	854	873	nucleoside analogue	T114,T121	C1579410
28471941	874	906	reverse transcriptase inhibitors	T121	C0282519
28471941	927	939	inflammation	T046	C0021368
28471941	945	958	inflammageing	T046	C0021368
28471941	982	988	ageing	T040	C0001811
28471941	1011	1026	cell senescence	T043	C0007581
28471941	1041	1066	proinflammatory mediators	T121	C0243042
28471941	1076	1090	gut microbiota	T001	C2985398
28471941	1096	1108	coinfections	T047	C0275524
28471941	1113	1125	HIV-infected	T047	C0019693
28471941	1126	1134	patients	T101	C0030705
28471941	1140	1145	level	T080	C0441889
28471941	1149	1161	inflammation	T046	C0021368
28471941	1166	1181	innate immunity	T032	C0020969
28471941	1182	1192	activation	T052	C1879547
28471941	1225	1238	comorbidities	T078	C0009488
28471941	1246	1255	mortality	T081	C0178686
28471941	1298	1301	age	T032	C0001779
28471941	1312	1317	virus	T005	C0042776
28471941	1328	1341	viral protein	T116,T123	C0042736
28471941	1356	1366	reservoirs	T078	C0012653
28471941	1373	1376	HIV	T005	C0019682
28471941	1387	1390	gut	T023	C0699819
28471941	1391	1403	permeability	T070	C0031164
28471941	1408	1417	dysbiosis	T046	C3658208
28471941	1424	1448	antiretroviral treatment	T061	C1963724
28471941	1464	1479	cytomegalovirus	T005	C0010825
28471941	1484	1501	hepatitis C virus	T005	C0220847
28471941	1502	1514	coinfections	T047	C0275524
28471941	1543	1564	environmental factors	T169	C1516998
28471941	1577	1593	fat accumulation	T033	C0333574
28471941	1597	1604	smoking	T055	C0037369
28471941	1606	1621	Adaptive immune	T039	C0678209
28471941	1622	1632	activation	T052	C1879547
28471941	1637	1653	immunosenescence	T039	C0596761
28471941	1674	1687	comorbidities	T078	C0009488
28471941	1692	1701	mortality	T081	C0178686
28471941	1709	1727	general population	T098	C0683971
28471941	1741	1751	predictive	T080	C0681890
28471941	1755	1767	HIV-infected	T047	C0019693
28471941	1768	1776	patients	T101	C0030705
28471941	1778	1788	Biomarkers	T201	C0005516
28471941	1792	1800	evaluate	T058	C0220825
28471941	1801	1807	ageing	T040	C0001811
28471941	1811	1823	HIV-infected	T047	C0019693
28471941	1824	1832	patients	T101	C0030705
28471941	1856	1864	systemic	T169	C0205373
28471941	1868	1889	cellular inflammatory	T025	C0440752
28471941	1891	1897	immune	T169	C0439662
28471941	1898	1908	activation	T052	C1879547
28471941	1910	1926	oxidative stress	T049	C0242606
28471941	1942	1949	markers	T201	C0005516
28471941	1957	1963	tested	T169	C0039593
28471941	1967	1972	serum	T031	C0229671
28471941	1976	2010	peripheral blood mononuclear cells	T025	C1321301
28471941	2022	2030	European	T083	C0015176
28471941	2031	2036	Study	T062	C2603343
28471941	2050	2060	Biomarkers	T201	C0005516
28471941	2064	2095	Human Ageing MARK-AGE algorithm	T170	C0002045
28471941	2097	2107	evaluating	T058	C0220825
28471941	2112	2122	biological	T080	C0205460
28471941	2123	2126	age	T032	C0001779
28471941	2153	2165	HIV-infected	T047	C0019693
28471941	2166	2174	patients	T101	C0030705
28471941	2199	2209	biological	T080	C0205460
28471941	2210	2213	age	T032	C0001779
28471941	2229	2241	inflammatory	T169	C0333348
28471941	2245	2258	innate immune	T032	C0020969
28471941	2259	2269	activation	T052	C1879547
28471941	2270	2277	markers	T201	C0005516
28471941	2326	2335	patient's	T101	C0030705
28471941	2336	2345	follow-up	T058	C1522577
28471941	2368	2376	patients	T101	C0030705
28471941	2379	2389	biological	T080	C0205460
28471941	2390	2393	age	T032	C0001779
28471941	2437	2447	healthspan	T078	C0018684

27729641|t|Intracellular localization of Saffold virus Leader (L) protein differs in Vero and HEp-2 cells
27729641|a|The Saffold virus (SAFV) genome is translated as a single long polyprotein precursor and co-translationally cleaved to yield 12 separate viral proteins. Little is known about the activities of SAFV proteins although their homologs in other picornaviruses have already been described. To further support research on functions and activities of respective viral proteins, we investigated the spatio-temporal distribution of SAFV proteins in Vero and HEp-2 cells that had been either transfected with plasmids that express individual viral proteins or infected with live SAFV. Our results revealed that, with the exception of the Leader (L) protein, all viral proteins were localized in the cytoplasm at all the time points assayed. The L protein was found in the cytoplasm at an early time point but was subsequently translocated to the nucleus of HEp-2, but not Vero, cells. This was observed in both transfected and infected cells. Further mutational analysis of L protein revealed that Threonine 58 of the Ser / Thr -rich domain of L protein is crucial for protein trafficking between the cytoplasm and nucleus in HEp-2 cells. These findings contribute to a deeper understanding and stimulate investigation of the differetial cellular responses of HEp-2 cells in comparison to other mammalian cell lines during SAFV infection.
27729641	0	13	Intracellular	T082	C0178719
27729641	14	26	localization	T169	C0475264
27729641	30	43	Saffold virus	T005	C0031886
27729641	44	62	Leader (L) protein	T116,T123	C0042736
27729641	74	78	Vero	T025	C0042542
27729641	83	94	HEp-2 cells	T025	C0018873
27729641	99	112	Saffold virus	T005	C0031886
27729641	114	118	SAFV	T005	C0031886
27729641	120	126	genome	T028	C0042720
27729641	130	140	translated	T045	C1519614
27729641	146	152	single	T081	C0205171
27729641	153	157	long	T080	C0205166
27729641	158	179	polyprotein precursor	T116,T123	C0033665
27729641	184	202	co-translationally	T045	C1519614
27729641	203	210	cleaved	T082	C0205242
27729641	223	231	separate	T080	C0443299
27729641	232	246	viral proteins	T116,T123	C0042736
27729641	274	284	activities	T052	C0441655
27729641	288	292	SAFV	T005	C0031886
27729641	293	301	proteins	T116,T123	C0042736
27729641	317	325	homologs	T085	C0162774
27729641	335	349	picornaviruses	T005	C1265371
27729641	368	377	described	T078	C1552738
27729641	390	397	support	T077	C1521721
27729641	398	406	research	T062	C0035168
27729641	410	419	functions	T169	C0542341
27729641	424	434	activities	T052	C0441655
27729641	449	463	viral proteins	T116,T123	C0042736
27729641	468	480	investigated	T169	C1292732
27729641	485	513	spatio-temporal distribution	T062	C3494293
27729641	517	521	SAFV	T005	C0031886
27729641	522	530	proteins	T116,T123	C0042736
27729641	534	538	Vero	T025	C0042542
27729641	543	554	HEp-2 cells	T025	C0018873
27729641	576	587	transfected	T063	C0040669
27729641	593	601	plasmids	T114,T123	C0032136
27729641	607	614	express	T045	C1171362
27729641	626	640	viral proteins	T116,T123	C0042736
27729641	644	652	infected	T046	C3714514
27729641	658	662	live	T080	C1548795
27729641	663	667	SAFV	T005	C0031886
27729641	673	680	results	T033	C0683954
27729641	681	689	revealed	T080	C0443289
27729641	705	714	exception	T077	C1705847
27729641	722	740	Leader (L) protein	T116,T123	C0042736
27729641	746	760	viral proteins	T116,T123	C0042736
27729641	766	775	localized	T082	C0392752
27729641	783	792	cytoplasm	T026	C0010834
27729641	804	815	time points	T079	C0439547
27729641	816	823	assayed	T059	C1510438
27729641	829	838	L protein	T116,T123	C0042736
27729641	856	865	cytoplasm	T026	C0010834
27729641	872	877	early	T079	C1279919
27729641	878	888	time point	T079	C2348792
27729641	897	909	subsequently	T079	C0332282
27729641	910	922	translocated	T043	C0599893
27729641	930	937	nucleus	T026	C0007610
27729641	941	946	HEp-2	T025	C0018873
27729641	956	960	Vero	T025	C0042542
27729641	962	967	cells	T025	C0007634
27729641	978	986	observed	T169	C1441672
27729641	995	1006	transfected	T063	C0040669
27729641	1011	1019	infected	T046	C3714514
27729641	1020	1025	cells	T025	C0007634
27729641	1035	1054	mutational analysis	T059	C0796357
27729641	1058	1067	L protein	T116,T123	C0042736
27729641	1068	1076	revealed	T080	C0443289
27729641	1082	1094	Threonine 58	T116,T121,T123	C0040005
27729641	1102	1105	Ser	T116,T121,T123	C0036720
27729641	1108	1111	Thr	T116,T121,T123	C0040005
27729641	1118	1124	domain	T087	C1514562
27729641	1128	1137	L protein	T116,T123	C0042736
27729641	1153	1160	protein	T116,T123	C0042736
27729641	1161	1172	trafficking	T043	C0599896
27729641	1185	1194	cytoplasm	T026	C0010834
27729641	1199	1206	nucleus	T026	C0007610
27729641	1210	1221	HEp-2 cells	T025	C0018873
27729641	1229	1237	findings	T033	C0243095
27729641	1289	1302	investigation	T169	C1292732
27729641	1310	1321	differetial	T080	C0443199
27729641	1322	1330	cellular	T025	C0007634
27729641	1331	1340	responses	T032	C0871261
27729641	1344	1355	HEp-2 cells	T025	C0018873
27729641	1359	1369	comparison	T052	C1707455
27729641	1379	1388	mammalian	T015	C0024660
27729641	1389	1399	cell lines	T025	C0007600
27729641	1407	1411	SAFV	T005	C0031886
27729641	1412	1421	infection	T046	C3714514

28259683|t|Inhibition of Sebum Production with the Acetyl Coenzyme A Carboxylase Inhibitor Olumacostat Glasaretil
28259683|a|Olumacostat glasaretil (OG) is a small molecule inhibitor of acetyl coenzyme A (CoA) carboxylase (ACC), the enzyme that controls the first rate-limiting step in fatty acid biosynthesis. Inhibition of ACC activity in the sebaceous glands is designed to substantially affect sebum production, because over 80% of human sebum components contain fatty acids. OG inhibits de novo lipid synthesis in primary and transformed human sebocytes. TrueMass Sebum Panel analyses showed a reduction in saturated and monounsaturated fatty acyl chains across lipid species, including di- and triacylglycerols, phospholipids, cholesteryl esters, and wax esters in OG - treated sebocytes. There was no shift to shorter acyl chain lengths observed, suggesting that the fatty acid chain elongation process was not affected. OG is a pro-drug of the ACC inhibitor 5-(tetradecyloxy)-2-furoic acid and was designed to enhance delivery in vivo. Topical application of OG but not 5-(tetradecyloxy)-2-furoic acid significantly reduced hamster ear sebaceous gland size, indicating that this pro-drug approach was critical to obtain the desired activity in vivo. High-performance liquid chromatography analyses of hamster ear extracts showed that OG treatment increased ACC levels and the ratio of acetyl-CoA to free CoA in these animals, indicating increased fatty acid oxidation. These changes are consistent with ACC inhibition. Matrix-assisted laser desorption/ionization imaging showed that OG applied onto Yorkshire pig ears accumulated in sebaceous glands relative to the surrounding dermis. Sebaceous gland ACC represents an attractive therapeutic target given its central role in formation of sebum, a key factor in acne pathogenesis.
28259683	0	10	Inhibition	T052	C3463820
28259683	14	19	Sebum	T031	C0036511
28259683	20	30	Production	T169	C0005572
28259683	40	69	Acetyl Coenzyme A Carboxylase	T116,T126	C0001022
28259683	70	79	Inhibitor	T080	C1999216
28259683	80	102	Olumacostat Glasaretil	T121	C1254351
28259683	103	125	Olumacostat glasaretil	T121	C1254351
28259683	127	129	OG	T121	C1254351
28259683	151	160	inhibitor	T080	C1999216
28259683	164	199	acetyl coenzyme A (CoA) carboxylase	T116,T126	C0001022
28259683	201	204	ACC	T116,T126	C0001022
28259683	211	217	enzyme	T116,T126	C0014442
28259683	223	231	controls	T169	C2587213
28259683	264	287	fatty acid biosynthesis	T044	C0596562
28259683	289	299	Inhibition	T052	C3463820
28259683	303	315	ACC activity	T044	C1150657
28259683	323	339	sebaceous glands	T023	C0036505
28259683	343	351	designed	T052	C1707689
28259683	369	375	affect	T169	C0392760
28259683	376	381	sebum	T031	C0036511
28259683	382	392	production	T169	C0005572
28259683	414	419	human	T016	C0086418
28259683	420	436	sebum components	T031	C0036511
28259683	445	456	fatty acids	T109	C0015684
28259683	458	460	OG	T121	C1254351
28259683	461	469	inhibits	T080	C0311403
28259683	470	477	de novo	T078	C1515568
28259683	478	493	lipid synthesis	T040	C1563744
28259683	497	504	primary	T080	C0205225
28259683	509	520	transformed	T081	C0443172
28259683	521	526	human	T016	C0086418
28259683	527	536	sebocytes	T025	C1710037
28259683	538	567	TrueMass Sebum Panel analyses	T062	C0936012
28259683	577	586	reduction	T070	C0301630
28259683	590	599	saturated	T109,T123	C0443609
28259683	604	637	monounsaturated fatty acyl chains	T109,T123	C0015687
28259683	645	658	lipid species	T109	C0023779
28259683	670	673	di-	T109,T121	C0012262
28259683	678	694	triacylglycerols	T109,T123	C0041004
28259683	696	709	phospholipids	T109,T123	C0031676
28259683	711	729	cholesteryl esters	T109,T123	C0008387
28259683	735	745	wax esters	T109	C0014898
28259683	749	751	OG	T121	C1254351
28259683	754	761	treated	T169	C1522326
28259683	762	771	sebocytes	T025	C1710037
28259683	795	802	shorter	T081	C1806781
28259683	803	813	acyl chain	T104	C1254350
28259683	814	821	lengths	T081	C1444754
28259683	822	830	observed	T169	C1441672
28259683	852	862	fatty acid	T109	C0015684
28259683	863	887	chain elongation process	T067	C1522240
28259683	892	895	not	T033	C1513916
28259683	896	904	affected	T169	C0392760
28259683	906	908	OG	T121	C1254351
28259683	914	922	pro-drug	T120	C0033262
28259683	930	933	ACC	T116,T126	C0001022
28259683	934	943	inhibitor	T080	C1999216
28259683	944	975	5-(tetradecyloxy)-2-furoic acid	T109,T121	C0146177
28259683	984	992	designed	T052	C1707689
28259683	996	1003	enhance	T052	C2349975
28259683	1013	1020	in vivo	T082	C1515655
28259683	1022	1041	Topical application	T061	C0683174
28259683	1045	1047	OG	T121	C1254351
28259683	1056	1087	5-(tetradecyloxy)-2-furoic acid	T109,T121	C0146177
28259683	1102	1109	reduced	T080	C0392756
28259683	1110	1117	hamster	T015	C0018557
28259683	1118	1121	ear	T023	C0013443
28259683	1122	1137	sebaceous gland	T023	C0036505
28259683	1138	1142	size	T082	C0456389
28259683	1165	1173	pro-drug	T120	C0033262
28259683	1174	1182	approach	T082	C0449445
28259683	1199	1205	obtain	T169	C1301820
28259683	1218	1226	activity	T052	C0441655
28259683	1227	1234	in vivo	T082	C1515655
28259683	1236	1283	High-performance liquid chromatography analyses	T059	C1579831
28259683	1287	1294	hamster	T015	C0018557
28259683	1295	1298	ear	T023	C0013443
28259683	1299	1307	extracts	T167	C2828366
28259683	1320	1322	OG	T121	C1254351
28259683	1323	1332	treatment	T061	C0087111
28259683	1333	1342	increased	T081	C0205217
28259683	1343	1346	ACC	T116,T126	C0001022
28259683	1347	1353	levels	T080	C0441889
28259683	1362	1367	ratio	T081	C0456603
28259683	1371	1381	acetyl-CoA	T114,T123	C0001026
28259683	1385	1393	free CoA	T114,T123	C0009226
28259683	1403	1410	animals	T008	C0003062
28259683	1423	1432	increased	T081	C0205217
28259683	1433	1443	fatty acid	T109	C0015684
28259683	1444	1453	oxidation	T044	C0030011
28259683	1461	1468	changes	T169	C0392747
28259683	1473	1488	consistent with	T078	C0332290
28259683	1489	1492	ACC	T116,T126	C0001022
28259683	1493	1503	inhibition	T052	C3463820
28259683	1505	1548	Matrix-assisted laser desorption/ionization	T059	C0282597
28259683	1549	1556	imaging	T060	C0079595
28259683	1569	1571	OG	T121	C1254351
28259683	1572	1579	applied	T169	C4048755
28259683	1585	1598	Yorkshire pig	T015	C0324292
28259683	1599	1603	ears	T023	C0013443
28259683	1619	1635	sebaceous glands	T023	C0036505
28259683	1636	1644	relative	T080	C0205345
28259683	1664	1670	dermis	T024	C0011646
28259683	1672	1687	Sebaceous gland	T023	C0036505
28259683	1688	1691	ACC	T116,T126	C0001022
28259683	1706	1716	attractive	T080	C2346874
28259683	1717	1728	therapeutic	T169	C0302350
28259683	1729	1735	target	T169	C1521840
28259683	1775	1780	sebum	T031	C0036511
28259683	1798	1802	acne	T047	C0702166
28259683	1803	1815	pathogenesis	T046	C0699748

28254372|t|Tumor accumulation of liposomal doxorubicin in three murine models: Optimizing delivery efficiency
28254372|a|Systemic drug delivery to a solid tumor involves a sequence of steps that determine efficacy and survival. Extravasation from circulation at the tumor site is a critical step in this sequence since it regulates how much of the drug accumulates in the tumor. Despite its importance in determining outcomes, extravasation from circulation remains a "black box." The objective of this study is to develop predictive tools for optimization of drug delivery systems. By comparing pharmacokinetics of liposomal doxorubicin in tumor -free and tumor bearing mice we quantitatively assess the rate constants for distribution, elimination, and tumor accumulation. We then relate these rate constants to the tumor -type and drug delivery system. We compare tumor accumulation in three tumor types and show a 10-fold difference between a colorectal adenocarcinoma and a pancreatic adenocarcinoma. Finally, we show how quantitative predictions of changes in tumor accumulation can be used to optimize drug delivery system s.
28254372	0	5	Tumor	T191	C0027651
28254372	6	18	accumulation	T033	C4055506
28254372	22	43	liposomal doxorubicin	T109,T195	C0717726
28254372	53	59	murine	T015	C0026809
28254372	60	66	models	T008	C0599779
28254372	79	87	delivery	T074	C0085104
28254372	88	98	efficiency	T081	C0013682
28254372	108	121	drug delivery	T074	C0085104
28254372	127	138	solid tumor	T191	C0280100
28254372	183	191	efficacy	T080	C1280519
28254372	196	204	survival	T169	C0220921
28254372	206	219	Extravasation	T046	C0015376
28254372	225	236	circulation	T040	C1516559
28254372	244	249	tumor	T191	C0027651
28254372	326	342	drug accumulates	UnknownType	C0678759
28254372	350	355	tumor	T191	C0027651
28254372	405	418	extravasation	T046	C0015376
28254372	424	435	circulation	T040	C1516559
28254372	481	486	study	T062	C0008972
28254372	522	534	optimization	T052	C2698650
28254372	538	559	drug delivery systems	T074	C0085104
28254372	574	590	pharmacokinetics	T039	C0031327
28254372	594	615	liposomal doxorubicin	T109,T195	C0717726
28254372	619	624	tumor	T191	C0027651
28254372	635	640	tumor	T191	C0027651
28254372	649	653	mice	T015	C0026809
28254372	657	678	quantitatively assess	T081	C0034384
28254372	683	697	rate constants	T081	C2986811
28254372	702	714	distribution	UnknownType	C0699903
28254372	716	727	elimination	T040	C0683141
28254372	733	738	tumor	T191	C0027651
28254372	739	751	accumulation	T033	C4055506
28254372	774	788	rate constants	T081	C2986811
28254372	796	801	tumor	T191	C0027651
28254372	812	832	drug delivery system	T074	C0085104
28254372	845	850	tumor	T191	C0027651
28254372	851	863	accumulation	T033	C4055506
28254372	873	878	tumor	T191	C0027651
28254372	925	950	colorectal adenocarcinoma	T191	C1319315
28254372	957	982	pancreatic adenocarcinoma	T191	C0281361
28254372	1005	1029	quantitative predictions	T081	C0034384
28254372	1044	1049	tumor	T191	C0027651
28254372	1050	1062	accumulation	T033	C4055506
28254372	1078	1086	optimize	T052	C2698650
28254372	1087	1107	drug delivery system	T074	C0085104

27086366|t|The Role of TRAF4 and B3GAT1 Gene Expression in the Food Hypersensitivity and Insect Venom Allergy in Mastocytosis
27086366|a|Mastocytosis is an uncommon disease classified as a myeloproliferative neoplasm, however, its symptoms are broad and place patients at crossroads between dermatology, hematology and allergology. Patients with mastocytosis often suffer from symptoms resulting from the activation and release of mediators from the mast cells, such as generalized itching, redness, headache, abdominal cramps, diarrhea, bone pain or arthritis, hypotension and shock. The possible severe, fatal or near fatal reactions caused by food hypersensitivity are reasons for the research focused on marker identification. The aim of the study was to analyse the gene expression differences in mastocytosis patients with and without food and drug hypersensitivity and insect venom allergy (IVA). A total of 57 Caucasian patients with mastocytosis were studied [median age 41.8; range 18-77 years; 15 (26.3 %) males and 42 (73.7 %) females]. Quantitative RT-PCRs of 11 genes plus ribosomal 18S RNA were run. Symptoms of food hypersensitivity were found in 12 patients (21 %), including 3 patients (13 %) with cutaneous mastocytosis (CM), and 9 (28 %) with indolent systemic mastocytosis (ISM). IVA was confirmed in 13 patients (22.8 %) including 6 patients (10.5 %) with CM, and 7 patients (12.3 %) with ISM. Drug hypersensitivity was diagnosed in 10 patients (17.5 %). Significant differences in the gene expression were found for TRAF4 (p = 0.008) in the comparison of the mastocytosis patients with and without concomitant food hypersensitivity. Furthermore significant differences were found in gene expression for B3GAT1 (p = 0.003) in patients with IVA compared to patients without insect sting anaphylaxis in the medical history. The expression of studied genes did not differ according to the presence of drug hypersensitivity. The TRAF4 expression was higher in mastocytosis patients with food hypersensitivity in their medical history, the B3GAT1 expression was lower in mastocytosis patients with IVA in history.
27086366	12	17	TRAF4	T028	C1336665
27086366	22	28	B3GAT1	T028	C1412716
27086366	29	44	Gene Expression	T045	C0017262
27086366	52	73	Food Hypersensitivity	T046	C0016470
27086366	78	98	Insect Venom Allergy	T046	C0020517
27086366	102	114	Mastocytosis	T047	C0024899
27086366	115	127	Mastocytosis	T047	C0024899
27086366	143	150	disease	T047	C0012634
27086366	167	194	myeloproliferative neoplasm	T191	C0027022
27086366	209	217	symptoms	T184	C1457887
27086366	238	246	patients	T101	C0030705
27086366	269	280	dermatology	T091	C0011627
27086366	282	292	hematology	T091	C0018943
27086366	310	318	Patients	T101	C0030705
27086366	324	336	mastocytosis	T047	C0024899
27086366	355	363	symptoms	T184	C1457887
27086366	383	393	activation	T052	C1879547
27086366	428	438	mast cells	T025	C0024880
27086366	460	467	itching	T184	C0033774
27086366	469	476	redness	T047	C0041834
27086366	478	486	headache	T184	C0018681
27086366	488	504	abdominal cramps	T184	C0000729
27086366	506	514	diarrhea	T184	C0011991
27086366	516	525	bone pain	T184	C0151825
27086366	529	538	arthritis	T047	C0003864
27086366	540	551	hypotension	T033	C0020649
27086366	556	561	shock	T046	C0036974
27086366	584	589	fatal	T080	C1302234
27086366	598	603	fatal	T080	C1302234
27086366	624	645	food hypersensitivity	T046	C0016470
27086366	686	692	marker	T201	C0005516
27086366	724	729	study	T062	C2603343
27086366	749	764	gene expression	T045	C0017262
27086366	780	792	mastocytosis	T047	C0024899
27086366	793	801	patients	T101	C0030705
27086366	819	823	food	T046	C0016470
27086366	828	849	drug hypersensitivity	T046	C0013182
27086366	854	874	insect venom allergy	T046	C0020517
27086366	876	879	IVA	T046	C0020517
27086366	896	905	Caucasian	T098	C0043157
27086366	906	914	patients	T101	C0030705
27086366	920	932	mastocytosis	T047	C0024899
27086366	954	957	age	T032	C0001779
27086366	976	981	years	T079	C0439234
27086366	995	1000	males	T032	C0086582
27086366	1017	1024	females	T032	C0086287
27086366	1027	1047	Quantitative RT-PCRs	T063	C3179034
27086366	1054	1059	genes	T028	C0017337
27086366	1065	1082	ribosomal 18S RNA	T114,T123	C0035703
27086366	1093	1101	Symptoms	T184	C1457887
27086366	1105	1126	food hypersensitivity	T046	C0016470
27086366	1144	1152	patients	T101	C0030705
27086366	1173	1181	patients	T101	C0030705
27086366	1194	1216	cutaneous mastocytosis	T191	C1136033
27086366	1218	1220	CM	T191	C1136033
27086366	1241	1271	indolent systemic mastocytosis	T047	C0272203
27086366	1273	1276	ISM	T047	C0272203
27086366	1279	1282	IVA	T046	C0020517
27086366	1303	1311	patients	T101	C0030705
27086366	1333	1341	patients	T101	C0030705
27086366	1356	1358	CM	T191	C1136033
27086366	1366	1374	patients	T101	C0030705
27086366	1389	1392	ISM	T047	C0272203
27086366	1394	1415	Drug hypersensitivity	T046	C0013182
27086366	1420	1429	diagnosed	T033	C0011900
27086366	1436	1444	patients	T101	C0030705
27086366	1486	1501	gene expression	T045	C0017262
27086366	1517	1522	TRAF4	T028	C1336665
27086366	1560	1572	mastocytosis	T047	C0024899
27086366	1573	1581	patients	T101	C0030705
27086366	1611	1632	food hypersensitivity	T046	C0016470
27086366	1684	1699	gene expression	T045	C0017262
27086366	1704	1710	B3GAT1	T028	C1412716
27086366	1726	1734	patients	T101	C0030705
27086366	1740	1743	IVA	T046	C0020517
27086366	1756	1764	patients	T101	C0030705
27086366	1773	1785	insect sting	T037	C0079626
27086366	1786	1797	anaphylaxis	T046	C0002792
27086366	1826	1836	expression	T045	C0017262
27086366	1848	1853	genes	T028	C0017337
27086366	1898	1919	drug hypersensitivity	T046	C0013182
27086366	1925	1930	TRAF4	T028	C1336665
27086366	1931	1941	expression	T045	C0017262
27086366	1956	1968	mastocytosis	T047	C0024899
27086366	1969	1977	patients	T101	C0030705
27086366	1983	2004	food hypersensitivity	T046	C0016470
27086366	2014	2029	medical history	T033	C0262926
27086366	2035	2041	B3GAT1	T028	C1412716
27086366	2042	2052	expression	T045	C0017262
27086366	2066	2078	mastocytosis	T047	C0024899
27086366	2079	2087	patients	T101	C0030705
27086366	2093	2096	IVA	T046	C0020517

28446912|t|Temporal and Spatial Variability of Fungal Structures and Host Responses in an Incompatible Rust-Wheat Interaction
28446912|a|Information about temporal and spatial variability of fungal structures and host responses is scarce in comparison to the vast amount of genetic, biochemical, and physiological studies of host-pathogen interactions. In this study, we used avirulent wild type and virulent mutant isolates of Puccinia striiformis to characterize the interactions in wheat carrying yellow rust Yr2 resistance. Both conventional and advanced microscopic techniques were used for a detailed study of morphology and growth of fungal colonies and associated host cell responses. The growth of the wild type isolates was highly restricted due to hypersensitive response (HR, plant cell death) indicated by autofluorescence and change in the shape of the affected plant cells. The host response appeared post - haustorial, but large variation in the time and stage of arrest was observed for individual fungal colonies, probably due to a delay between detection and response. Some colonies were stopped right after the formation of the primary infection hyphae whereas others formed highly branched mycelia. HR was first observed in host cells in direct contact with fungal structures, after which the defense responses spread to adjacent host cells, and eventually led to encasement of the fungal colony. Several cells with HR contained haustoria, which were small and underdeveloped, but some cells contained normal sized haustoria without signs of hypersensitivity. The growth of the virulent mutants in the resistant plants was similar to the growth in plants without Yr2 resistance, which is a strong indication that the incompatible phenotype was associated with Yr2. The interaction between P. striiformis and wheat with Yr2 resistance was highly variable in time and space, which demonstrate that histological studies are important for a deeper understanding of host-pathogen interactions and plant defense mechanisms in general.
28446912	0	8	Temporal	T079	C2362314
28446912	13	20	Spatial	T082	C1254362
28446912	21	32	Variability	T077	C2827666
28446912	36	53	Fungal Structures	T017	C2717804
28446912	58	72	Host Responses	T042	C0301872
28446912	79	114	Incompatible Rust-Wheat Interaction	T040	C1155325
28446912	115	126	Information	T078	C1533716
28446912	133	141	temporal	T079	C2362314
28446912	146	153	spatial	T082	C1254362
28446912	154	165	variability	T077	C2827666
28446912	169	186	fungal structures	T017	C2717804
28446912	191	205	host responses	T042	C0301872
28446912	209	215	scarce	T080	C0231180
28446912	219	229	comparison	T052	C1707455
28446912	242	248	amount	T081	C1265611
28446912	252	259	genetic	T169	C0314603
28446912	261	272	biochemical	T169	C0205474
28446912	278	291	physiological	T169	C0205463
28446912	292	299	studies	T062	C2603343
28446912	303	329	host-pathogen interactions	T040	C1752856
28446912	339	344	study	T062	C2603343
28446912	349	353	used	T169	C0457083
28446912	354	363	avirulent	T080	C0205556
28446912	364	373	wild type	T028	C1883559
28446912	378	386	virulent	T080	C1520022
28446912	387	393	mutant	T028	C0678941
28446912	394	402	isolates	T123	C1764827
28446912	406	426	Puccinia striiformis	T004	C1001443
28446912	430	442	characterize	T052	C1880022
28446912	447	459	interactions	T169	C1704675
28446912	463	468	wheat	T168	C0043137
28446912	469	477	carrying	T052	C0206243
28446912	478	489	yellow rust	T004	C1001443
28446912	490	493	Yr2	T004	C1001443
28446912	494	504	resistance	T046	C4087433
28446912	511	523	conventional	T080	C1442989
28446912	528	536	advanced	T080	C0205179
28446912	537	548	microscopic	T080	C0205288
28446912	549	559	techniques	T169	C0449851
28446912	565	569	used	T169	C0457083
28446912	576	584	detailed	T080	C1522508
28446912	585	590	study	T062	C2603343
28446912	594	604	morphology	T080	C0332437
28446912	609	615	growth	T040	C0018270
28446912	619	625	fungal	T169	C0521033
28446912	626	634	colonies	T025	C1947989
28446912	639	649	associated	T080	C0332281
28446912	650	669	host cell responses	T042	C0301872
28446912	675	681	growth	T040	C0018270
28446912	689	698	wild type	T028	C1883559
28446912	699	707	isolates	T123	C1764827
28446912	712	718	highly	T080	C0205250
28446912	719	729	restricted	T169	C0443288
28446912	737	760	hypersensitive response	T046	C0020517
28446912	762	764	HR	T046	C0020517
28446912	766	771	plant	T002	C0032098
28446912	772	782	cell death	T043	C0007587
28446912	784	793	indicated	T033	C1444656
28446912	797	813	autofluorescence	T059	C0544711
28446912	818	824	change	T169	C0392747
28446912	832	837	shape	T082	C0332479
28446912	845	853	affected	T169	C0392760
28446912	854	865	plant cells	T025	C3178867
28446912	871	884	host response	T042	C0301872
28446912	885	893	appeared	T080	C0700364
28446912	894	898	post	T079	C0687676
28446912	901	911	haustorial	T017	C2717804
28446912	917	922	large	T081	C0549177
28446912	923	932	variation	T080	C0205419
28446912	940	944	time	T079	C0040223
28446912	949	954	stage	T079	C0205390
28446912	958	964	arrest	T046	C0333951
28446912	969	977	observed	T169	C1441672
28446912	982	992	individual	T098	C0237401
28446912	993	999	fungal	T169	C0521033
28446912	1000	1008	colonies	T025	C1947989
28446912	1010	1018	probably	T078	C0750492
28446912	1028	1033	delay	T079	C0205421
28446912	1034	1041	between	T082	C0205103
28446912	1042	1051	detection	T061	C1511790
28446912	1056	1064	response	T032	C0871261
28446912	1071	1079	colonies	T025	C1947989
28446912	1085	1092	stopped	T079	C2746065
28446912	1093	1104	right after	T079	C0205253
28446912	1109	1118	formation	T169	C1522492
28446912	1126	1143	primary infection	T047	C0948192
28446912	1144	1150	hyphae	T004	C0521057
28446912	1166	1172	formed	T169	C0205431
28446912	1173	1179	highly	T080	C0205250
28446912	1180	1188	branched	T082	C2700384
28446912	1189	1196	mycelia	T004	C0949695
28446912	1198	1200	HR	T046	C0020517
28446912	1211	1219	observed	T169	C1441672
28446912	1223	1233	host cells	T026	C1819995
28446912	1237	1243	direct	T080	C1947931
28446912	1244	1251	contact	T067	C0392367
28446912	1257	1274	fungal structures	T017	C2717804
28446912	1292	1309	defense responses	T040	C1154988
28446912	1310	1316	spread	T080	C0332261
28446912	1320	1328	adjacent	T082	C0205117
28446912	1329	1339	host cells	T026	C1819995
28446912	1363	1373	encasement	T082	C1254362
28446912	1381	1387	fungal	T169	C0521033
28446912	1388	1394	colony	T025	C1947989
28446912	1396	1403	Several	T081	C0443302
28446912	1404	1409	cells	T025	C0007634
28446912	1415	1417	HR	T046	C0020517
28446912	1418	1427	contained	T052	C2700400
28446912	1428	1437	haustoria	T017	C2717804
28446912	1450	1455	small	T081	C0700321
28446912	1460	1474	underdeveloped	T080	C0205252
28446912	1480	1484	some	T081	C0205392
28446912	1485	1490	cells	T025	C0007634
28446912	1491	1500	contained	T052	C2700400
28446912	1501	1507	normal	T080	C0205307
28446912	1508	1513	sized	T082	C0456389
28446912	1514	1523	haustoria	T017	C2717804
28446912	1532	1537	signs	T184	C0037088
28446912	1541	1557	hypersensitivity	T046	C0020517
28446912	1563	1569	growth	T040	C0018270
28446912	1577	1585	virulent	T080	C1520022
28446912	1586	1593	mutants	T028	C0678941
28446912	1601	1610	resistant	T169	C0332325
28446912	1611	1617	plants	T002	C0032098
28446912	1622	1629	similar	T080	C2348205
28446912	1637	1643	growth	T040	C0018270
28446912	1647	1653	plants	T002	C0032098
28446912	1662	1665	Yr2	T004	C1001443
28446912	1666	1676	resistance	T046	C4087433
28446912	1689	1695	strong	T080	C0442821
28446912	1696	1706	indication	T078	C3146298
28446912	1716	1728	incompatible	T080	C1881865
28446912	1729	1738	phenotype	T032	C0031437
28446912	1743	1753	associated	T080	C0332281
28446912	1759	1762	Yr2	T004	C1001443
28446912	1768	1779	interaction	T169	C1704675
28446912	1780	1787	between	T082	C0205103
28446912	1788	1802	P. striiformis	T004	C1001443
28446912	1807	1812	wheat	T168	C0043137
28446912	1818	1821	Yr2	T004	C1001443
28446912	1822	1832	resistance	T046	C4087433
28446912	1837	1843	highly	T080	C0205250
28446912	1844	1852	variable	T080	C0439828
28446912	1856	1860	time	T079	C0040223
28446912	1865	1870	space	T082	C1254362
28446912	1878	1889	demonstrate	T080	C0443289
28446912	1895	1907	histological	T091	C0019638
28446912	1908	1915	studies	T062	C2603343
28446912	1920	1929	important	T080	C3898777
28446912	1936	1956	deeper understanding	T041	C0162340
28446912	1960	1986	host-pathogen interactions	T040	C1752856
28446912	1991	1996	plant	T002	C0032098
28446912	1997	2004	defense	T042	C0520990
28446912	2005	2015	mechanisms	T169	C0441712
28446912	2019	2026	general	T082	C0205246

28293289|t|Novel Acinetobacter parvus HANDI 309 microbial biomass for the production of N-acetyl-β-d-glucosamine (GlcNAc) using swollen chitin substrate in submerged fermentation
28293289|a|N-acetyl-β-d-glucosamine (GlcNAc)6 is extensively used as an important bio-agent and a functional food additive. The traditional chemical process for GlcNAc production has some problems such as high production cost, low yield, and acidic pollution .Therefore, to discover a novel chitinase that is suitable for bioconversion of chitin to GlcNAc would be of great value. Here, we describe the complete isolation and functional characterization of a novel exo-chitinase from Acinetobacter parvus HANDI 309 for the conversion of chitin. The identified exo-chitinase mainly produced N-acetyl-d-glucosamine, using chitin as a substrate by submerged fermentation. The A. parvus HANDI 309 biofuels producing exo-chitinase were characterized by TLC, and was further validated and quantified by HPLC. Furthermore, the optimal temperature and pH for the exo-chitinase activity was obtained in the culture conditions of 30 °C and 7.0, respectively. The maximum growth of the stationary phase was reached in 24 h after incubation. These results suggest that A. parvus HANDI 309 biofuels producing exo-chitinases may have great potential in chitin to N-acetyl-d-glucosamine conversion. The excellent thermostability and hydrolytic properties may give the exo-chitinase great potential in chitin to GlcNAc conversion in industry. This is the first report that A. parvus HANDI 309 is a novel bacterial strain that has the ability to produce an enormous amount of exo-chitinase - producing bio-agents in a short time on an industrial scale without any pretreatment, as well as being potentially valuable in the food and pharmaceutical industries.
28293289	0	5	Novel	T080	C0205314
28293289	6	36	Acinetobacter parvus HANDI 309	T007	C1064930
28293289	37	46	microbial	T001	C0599840
28293289	47	54	biomass	T081	C0005535
28293289	63	73	production	T057	C0033268
28293289	77	101	N-acetyl-β-d-glucosamine	T109,T121	C0001056
28293289	103	109	GlcNAc	T109,T121	C0001056
28293289	125	131	chitin	T109,T123	C0008141
28293289	132	141	substrate	T167	C3891814
28293289	145	167	submerged fermentation	T044	C0015852
28293289	168	192	N-acetyl-β-d-glucosamine	T109,T121	C0001056
28293289	193	202	(GlcNAc)6	T109,T121	C0001056
28293289	229	238	important	T080	C3898777
28293289	239	248	bio-agent	T123	C0005515
28293289	255	265	functional	T169	C0205245
28293289	266	279	food additive	T168	C0016453
28293289	297	313	chemical process	T070	C2350458
28293289	318	324	GlcNAc	T109,T121	C0001056
28293289	325	335	production	T057	C0033268
28293289	345	353	problems	T033	C0033213
28293289	362	366	high	T080	C0205250
28293289	367	377	production	T057	C0033268
28293289	378	382	cost	T081	C0010186
28293289	384	387	low	T080	C0205251
28293289	388	393	yield	T081	C1265611
28293289	399	405	acidic	T103	C0001128
28293289	406	415	pollution	T069	C0392355
28293289	442	447	novel	T080	C0205314
28293289	448	457	chitinase	T116,T126	C0008145
28293289	479	492	bioconversion	T169	C0439836
28293289	496	502	chitin	T109,T123	C0008141
28293289	506	512	GlcNAc	T109,T121	C0001056
28293289	560	568	complete	T080	C0205197
28293289	569	578	isolation	T169	C0205409
28293289	583	593	functional	T169	C0205245
28293289	594	610	characterization	T052	C1880022
28293289	616	621	novel	T080	C0205314
28293289	622	635	exo-chitinase	T116,T126	C0213288
28293289	641	671	Acinetobacter parvus HANDI 309	T007	C1064930
28293289	680	690	conversion	T169	C0439836
28293289	694	700	chitin	T109,T123	C0008141
28293289	706	716	identified	T080	C0205396
28293289	717	730	exo-chitinase	T116,T126	C0213288
28293289	747	769	N-acetyl-d-glucosamine	T109,T121	C0001056
28293289	777	783	chitin	T109,T123	C0008141
28293289	789	798	substrate	T167	C3891814
28293289	802	824	submerged fermentation	T044	C0015852
28293289	830	849	A. parvus HANDI 309	T007	C1064930
28293289	850	858	biofuels	T109	C2717891
28293289	859	868	producing	T169	C0205245
28293289	869	882	exo-chitinase	T116,T126	C0213288
28293289	888	901	characterized	T052	C1880022
28293289	905	908	TLC	T059	C0008569
28293289	926	935	validated	T062	C1519941
28293289	940	950	quantified	T081	C1709793
28293289	954	958	HPLC	T059	C0008562
28293289	977	984	optimal	T080	C2698651
28293289	985	996	temperature	T081	C0039476
28293289	1001	1003	pH	T081	C0020283
28293289	1012	1034	exo-chitinase activity	T044	C3271333
28293289	1039	1047	obtained	T169	C1301820
28293289	1055	1073	culture conditions	T080	C0348080
28293289	1110	1117	maximum	T081	C0806909
28293289	1118	1124	growth	T040	C0018270
28293289	1132	1142	stationary	T080	C0439835
28293289	1143	1148	phase	T079	C0205390
28293289	1175	1185	incubation	T033	C1320226
28293289	1193	1200	results	T033	C2825142
28293289	1214	1233	A. parvus HANDI 309	T007	C1064930
28293289	1234	1242	biofuels	T109	C2717891
28293289	1243	1252	producing	T169	C0205245
28293289	1253	1267	exo-chitinases	T116,T126	C0213288
28293289	1283	1292	potential	T080	C3245505
28293289	1296	1302	chitin	T109,T123	C0008141
28293289	1306	1328	N-acetyl-d-glucosamine	T109,T121	C0001056
28293289	1329	1339	conversion	T169	C0439836
28293289	1345	1354	excellent	T080	C1961136
28293289	1355	1370	thermostability	T070	C0597571
28293289	1375	1385	hydrolytic	T070	C0020291
28293289	1386	1396	properties	T080	C0871161
28293289	1410	1423	exo-chitinase	T116,T126	C0213288
28293289	1430	1439	potential	T080	C3245505
28293289	1443	1449	chitin	T109,T123	C0008141
28293289	1453	1459	GlcNAc	T109,T121	C0001056
28293289	1460	1470	conversion	T169	C0439836
28293289	1474	1482	industry	T057	C0021267
28293289	1514	1533	A. parvus HANDI 309	T007	C1064930
28293289	1539	1544	novel	T080	C0205314
28293289	1545	1554	bacterial	T007	C0004611
28293289	1555	1561	strain	T001	C1518614
28293289	1575	1582	ability	T032	C0085732
28293289	1606	1612	amount	T081	C1265611
28293289	1616	1629	exo-chitinase	T116,T126	C0213288
28293289	1632	1641	producing	T169	C0205245
28293289	1642	1652	bio-agents	T123	C0005515
28293289	1658	1663	short	T081	C1806781
28293289	1664	1668	time	T079	C0040223
28293289	1675	1685	industrial	T057	C0021267
28293289	1704	1716	pretreatment	T052	C3539076
28293289	1735	1746	potentially	T080	C3245505
28293289	1763	1767	food	T057	C0524863
28293289	1772	1797	pharmaceutical industries	T093	C0013185

27822189|t|Flexible Coordination of Stationary and Mobile Conversations with Gaze: Resource Allocation among Multiple Joint Activities
27822189|a|Gaze is instrumental in coordinating face-to-face social interactions. But little is known about gaze use when social interactions co-occur with other joint activities. We investigated the case of walking while talking. We assessed how gaze gets allocated among various targets in mobile conversations, whether allocation of gaze to other targets affects conversational coordination, and whether reduced availability of gaze for conversational coordination affects conversational performance and content. In an experimental study, pairs were videotaped in four conditions of mobility (standing still, talking while walking along a straight-line itinerary, talking while walking along a complex itinerary, or walking along a complex itinerary with no conversational task). Gaze to partners was substantially reduced in mobile conversations, but gaze was still used to coordinate conversation via displays of mutual orientation, and conversational performance and content was not different between stationary and mobile conditions. Results expand the phenomena of multitasking to joint activities.
27822189	0	8	Flexible	T080	C0443220
27822189	9	21	Coordination	T169	C0700114
27822189	25	35	Stationary	T080	C0439835
27822189	40	46	Mobile	T169	C0231435
27822189	47	60	Conversations	T054	C0871703
27822189	66	70	Gaze	T033	C0553544
27822189	72	91	Resource Allocation	T081	C0086914
27822189	98	123	Multiple Joint Activities	T056	C0026606
27822189	124	128	Gaze	T033	C0553544
27822189	148	160	coordinating	T169	C0700114
27822189	161	173	face-to-face	T169	C1553514
27822189	174	193	social interactions	T033	C0037420
27822189	221	225	gaze	T033	C0553544
27822189	235	254	social interactions	T033	C0037420
27822189	255	263	co-occur	T052	C1709305
27822189	275	291	joint activities	T056	C0026606
27822189	296	308	investigated	T169	C1292732
27822189	321	328	walking	T056	C0080331
27822189	335	342	talking	T056	C0234856
27822189	347	355	assessed	T052	C1516048
27822189	360	364	gaze	T033	C0553544
27822189	370	379	allocated	T052	C1706778
27822189	394	401	targets	T098	C0039309
27822189	405	411	mobile	T169	C0231435
27822189	412	425	conversations	T054	C0871703
27822189	435	445	allocation	T052	C1706778
27822189	449	453	gaze	T033	C0553544
27822189	463	470	targets	T098	C0039309
27822189	471	478	affects	T041	C0001721
27822189	479	493	conversational	T054	C0871703
27822189	494	506	coordination	T169	C0700114
27822189	520	527	reduced	T080	C0392756
27822189	528	543	availability of	T169	C0470187
27822189	544	548	gaze	T033	C0553544
27822189	553	567	conversational	T054	C0871703
27822189	568	580	coordination	T169	C0700114
27822189	581	588	affects	T041	C0001721
27822189	589	603	conversational	T054	C0871703
27822189	604	615	performance	T055	C0597198
27822189	620	627	content	T077	C0456205
27822189	635	653	experimental study	T062	C0681814
27822189	666	676	videotaped	T073	C0042654
27822189	685	695	conditions	T080	C0449910
27822189	699	707	mobility	T033	C0425245
27822189	709	723	standing still	T082	C0231472
27822189	725	732	talking	T056	C0234856
27822189	739	778	walking along a straight-line itinerary	T060	C0522230
27822189	780	787	talking	T056	C0234856
27822189	794	801	walking	T056	C0080331
27822189	810	827	complex itinerary	T080	C0439855
27822189	832	839	walking	T056	C0080331
27822189	848	865	complex itinerary	T080	C0439855
27822189	871	888	no conversational	T033	C0243095
27822189	889	893	task	T057	C3540678
27822189	896	900	Gaze	T033	C0553544
27822189	904	912	partners	T098	C0026767
27822189	917	938	substantially reduced	T080	C0392756
27822189	942	948	mobile	T169	C0231435
27822189	949	962	conversations	T054	C0871703
27822189	968	972	gaze	T033	C0553544
27822189	991	1001	coordinate	T169	C0700114
27822189	1002	1014	conversation	T054	C0871703
27822189	1019	1027	displays	T169	C0870432
27822189	1031	1037	mutual	T080	C1709100
27822189	1038	1049	orientation	T082	C1704322
27822189	1055	1069	conversational	T054	C0871703
27822189	1070	1081	performance	T055	C0597198
27822189	1086	1093	content	T077	C0456205
27822189	1102	1111	different	T080	C1705242
27822189	1120	1130	stationary	T080	C0439835
27822189	1135	1141	mobile	T169	C0231435
27822189	1142	1152	conditions	T080	C0449910
27822189	1154	1161	Results	T034	C0456984
27822189	1173	1182	phenomena	T067	C1882365
27822189	1202	1218	joint activities	T056	C0026606

28505472|t|Improvement of older - person - specific QOL after hearing aid fitting and its relation to social interaction
28505472|a|This study aimed to investigate whether hearing aids use is associated with improvement of older - person - specific QOL and whether social interactions modify the association. The WHOQOL-OLD questionnaire was answered by 105 older adults aged 60 to 90 years who were newly fitted hearing aids on the day of fitting and at 2 - 6 months afterward. The associations between the daily hours of hearing aid usage and social relations with changes in the WHOQOL-OLD total score after hearing aids fitting were estimated adjusting for possible confounders. Older persons with hearing loss experienced significant increases in WHOQOL-OLD total score after hearing aid fitting. Regular use of hearing aid was associated with a greater increase in the total score. The combined categorical variable of social relations and hearing aid usage revealed no separate effects of these two variables, but a combined effect; only those with frequent social interactions who used their hearing aid regularly had a significantly greater increase in WHOQOL-OLD total score. This study's findings indicate that hearing aid fitting may be associated with a subsequent improvement in older - person - specific QOL by improvements in hearing due to the hearing aid, and possibly enhanced communication opportunities.
28505472	0	11	Improvement	T077	C2986411
28505472	15	20	older	T098	C0001792
28505472	23	29	person	T098	C0027361
28505472	32	40	specific	T080	C0205369
28505472	41	44	QOL	T078	C0034380
28505472	51	62	hearing aid	T074	C0018768
28505472	63	70	fitting	T061	C0185023
28505472	79	87	relation	T080	C0439849
28505472	91	109	social interaction	T033	C0037420
28505472	115	120	study	T062	C2603343
28505472	121	126	aimed	T078	C1947946
28505472	130	141	investigate	T169	C1292732
28505472	150	162	hearing aids	T074	C0018768
28505472	170	185	associated with	T080	C0332281
28505472	186	197	improvement	T077	C2986411
28505472	201	206	older	T098	C0001792
28505472	209	215	person	T098	C0027361
28505472	218	226	specific	T080	C0205369
28505472	227	230	QOL	T078	C0034380
28505472	243	262	social interactions	T033	C0037420
28505472	263	269	modify	T169	C0392747
28505472	274	285	association	T080	C0439849
28505472	291	315	WHOQOL-OLD questionnaire	T170	C0034394
28505472	320	328	answered	T170	C1706817
28505472	336	348	older adults	T098	C0001792
28505472	349	353	aged	T032	C0001779
28505472	378	383	newly	T078	C0750546
28505472	384	390	fitted	T061	C0185023
28505472	391	403	hearing aids	T074	C0018768
28505472	418	425	fitting	T061	C0185023
28505472	446	455	afterward	T079	C0205087
28505472	461	473	associations	T080	C0439849
28505472	501	512	hearing aid	T074	C0018768
28505472	513	518	usage	T169	C0457083
28505472	523	539	social relations	UnknownType	C0683633
28505472	545	552	changes	T169	C0392747
28505472	560	570	WHOQOL-OLD	T170	C0034394
28505472	571	582	total score	T081	C2964552
28505472	589	601	hearing aids	T074	C0018768
28505472	602	609	fitting	T061	C0185023
28505472	615	624	estimated	T081	C0750572
28505472	625	634	adjusting	T061	C0849719
28505472	639	647	possible	T033	C0332149
28505472	648	659	confounders	T169	C0009673
28505472	661	666	Older	T098	C0001792
28505472	667	674	persons	T098	C0027361
28505472	680	692	hearing loss	T033	C3887873
28505472	693	704	experienced	T052	C1709305
28505472	705	716	significant	T078	C0750502
28505472	717	726	increases	T169	C0442805
28505472	730	740	WHOQOL-OLD	T170	C0034394
28505472	741	752	total score	T081	C2964552
28505472	759	770	hearing aid	T074	C0018768
28505472	771	778	fitting	T061	C0185023
28505472	780	787	Regular	T080	C0205272
28505472	788	794	use of	T169	C1524063
28505472	795	806	hearing aid	T074	C0018768
28505472	811	826	associated with	T080	C0332281
28505472	829	836	greater	T081	C1704243
28505472	837	845	increase	T169	C0442805
28505472	853	864	total score	T081	C2964552
28505472	870	878	combined	T080	C0205195
28505472	879	890	categorical	T170	C0683312
28505472	891	899	variable	T080	C0439828
28505472	903	919	social relations	UnknownType	C0683633
28505472	924	935	hearing aid	T074	C0018768
28505472	936	941	usage	T169	C0457083
28505472	942	950	revealed	T080	C0443289
28505472	954	962	separate	T080	C0443299
28505472	963	970	effects	T080	C1280500
28505472	984	993	variables	T080	C0439828
28505472	1001	1009	combined	T080	C0205195
28505472	1010	1016	effect	T080	C1280500
28505472	1034	1042	frequent	T079	C0332183
28505472	1043	1062	social interactions	T033	C0037420
28505472	1078	1089	hearing aid	T074	C0018768
28505472	1090	1099	regularly	T080	C0205272
28505472	1106	1119	significantly	T078	C0750502
28505472	1120	1127	greater	T081	C1704243
28505472	1128	1136	increase	T169	C0442805
28505472	1140	1150	WHOQOL-OLD	T170	C0034394
28505472	1151	1162	total score	T081	C2964552
28505472	1169	1176	study's	T062	C2603343
28505472	1177	1185	findings	T169	C2607943
28505472	1186	1194	indicate	T080	C1521902
28505472	1200	1211	hearing aid	T074	C0018768
28505472	1212	1219	fitting	T061	C0185023
28505472	1227	1242	associated with	T080	C0332281
28505472	1245	1255	subsequent	T079	C0332282
28505472	1256	1267	improvement	T077	C2986411
28505472	1271	1276	older	T098	C0001792
28505472	1279	1285	person	T098	C0027361
28505472	1288	1296	specific	T080	C0205369
28505472	1297	1300	QOL	T078	C0034380
28505472	1304	1316	improvements	T077	C2986411
28505472	1320	1327	hearing	T039	C0018767
28505472	1339	1350	hearing aid	T074	C0018768
28505472	1356	1364	possibly	T033	C0332149
28505472	1365	1373	enhanced	T052	C2349975
28505472	1374	1387	communication	T054	C0009452
28505472	1388	1401	opportunities	T080	C0237506

28269352|t|Fall risk factors analysis based on sample entropy of plantar kinematic signal during stance phase
28269352|a|Falls are a multi-causal phenomenon with a complex interaction. The aim of our research is to study the effect of multiple variables for potential risk of falls and construct an elderly fall risk assessment model based on demographics data and gait characteristics. A total of 101 subjects, whom belong to Malianwa Street, aged above 50 years old and participated in questionnaire survey. Participants were classified into three groups (high, medium and low risk group) according to the score of elderly fall risk assessment scale. In addition, the data of ground reaction force (GRF) and ground reaction moment (GRM) was record when they performed walking at comfortable state. The demographic variables, sample entropy of GRF and GRM, and impulse difference of bilateral foot were considered as potential explanatory variables of risk assessment model. Firstly, we investigated whether different groups could present difference in every variable. Statistical differences were found for the following variables: age (p=2.28e-05); impulse difference (p=0.02036); sample entropy of GRF in vertical direction (p=0.0144); sample entropy of GRM in anterior-posterior direction (p=0.0387). Finally, the multiple regression analysis results indicated that age, impulse difference and sample entropy of resultant GRM could identify individuals who had different levels of fall risk. Therefore, those results could potentially be useful in the fall risk assessment and monitor the state of physical function in elderly population.
28269352	0	4	Fall	T033	C0085639
28269352	5	17	risk factors	T033	C0035648
28269352	18	26	analysis	T062	C0936012
28269352	36	50	sample entropy	T067	C0376522
28269352	54	61	plantar	T029	C0230463
28269352	62	71	kinematic	T070	C1254365
28269352	72	78	signal	T067	C1710082
28269352	86	98	stance phase	T033	C2019827
28269352	99	104	Falls	T033	C0085639
28269352	111	134	multi-causal phenomenon	T067	C1882365
28269352	142	149	complex	T080	C0439855
28269352	150	161	interaction	T169	C1704675
28269352	178	186	research	T062	C0035168
28269352	193	198	study	T062	C2603343
28269352	203	209	effect	T080	C1280500
28269352	213	221	multiple	T081	C0439064
28269352	222	231	variables	T080	C0439828
28269352	236	245	potential	T080	C3245505
28269352	246	259	risk of falls	T033	C1268740
28269352	264	273	construct	T185	C2827421
28269352	277	311	elderly fall risk assessment model	T170	C3161035
28269352	321	333	demographics	T090	C0011298
28269352	334	338	data	T078	C1511726
28269352	343	363	gait characteristics	T033	C2045693
28269352	380	388	subjects	T098	C2349001
28269352	405	420	Malianwa Street	T073	C0442658
28269352	422	426	aged	T032	C0001779
28269352	436	445	years old	T079	C1510829
28269352	450	462	participated	T169	C0679823
28269352	466	479	questionnaire	T170	C0034394
28269352	480	486	survey	T170	C0038951
28269352	488	500	Participants	T098	C0679646
28269352	528	534	groups	T078	C0441833
28269352	536	540	high	T098	C0684030
28269352	542	548	medium	T098	C2348561
28269352	553	561	low risk	T081	C3538919
28269352	562	567	group	T078	C0441833
28269352	586	591	score	T081	C0449820
28269352	595	629	elderly fall risk assessment scale	T170	C0349674
28269352	648	652	data	T078	C1511726
28269352	656	677	ground reaction force	T070	C0336996
28269352	679	682	GRF	T070	C0336996
28269352	688	710	ground reaction moment	T070	C1254365
28269352	712	715	GRM	T070	C1254365
28269352	721	727	record	T080	C2355580
28269352	738	747	performed	T169	C0884358
28269352	748	755	walking	T056	C0080331
28269352	759	776	comfortable state	T033	C1822395
28269352	782	793	demographic	T102	C0683970
28269352	794	803	variables	T080	C0439828
28269352	805	819	sample entropy	T067	C0376522
28269352	823	826	GRF	T070	C0336996
28269352	831	834	GRM	T070	C1254365
28269352	840	858	impulse difference	T081	C1705241
28269352	862	876	bilateral foot	T023	C4299794
28269352	896	905	potential	T080	C3245505
28269352	906	917	explanatory	T170	C0681841
28269352	918	927	variables	T080	C0439828
28269352	931	946	risk assessment	T058	C0086930
28269352	947	952	model	T170	C3161035
28269352	966	978	investigated	T169	C1292732
28269352	997	1003	groups	T078	C0441833
28269352	1018	1028	difference	T081	C1705241
28269352	1038	1046	variable	T080	C0439828
28269352	1048	1071	Statistical differences	T081	C1705241
28269352	1077	1082	found	T033	C0150312
28269352	1101	1110	variables	T080	C0439828
28269352	1112	1115	age	T032	C0001779
28269352	1130	1148	impulse difference	T081	C1705241
28269352	1162	1176	sample entropy	T067	C0376522
28269352	1180	1183	GRF	T070	C0336996
28269352	1187	1195	vertical	T082	C0205128
28269352	1196	1205	direction	T082	C0449738
28269352	1218	1232	sample entropy	T067	C0376522
28269352	1236	1239	GRM	T070	C1254365
28269352	1243	1261	anterior-posterior	T082	C1999039
28269352	1262	1271	direction	T082	C0449738
28269352	1297	1305	multiple	T081	C0439064
28269352	1306	1325	regression analysis	T170	C0034980
28269352	1326	1333	results	T169	C1274040
28269352	1334	1343	indicated	T033	C1444656
28269352	1349	1352	age	T032	C0001779
28269352	1354	1372	impulse difference	T081	C1705241
28269352	1377	1391	sample entropy	T067	C0376522
28269352	1405	1408	GRM	T070	C1254365
28269352	1424	1435	individuals	T098	C0237401
28269352	1454	1473	levels of fall risk	T058	C1532976
28269352	1492	1499	results	T169	C1274040
28269352	1506	1517	potentially	T080	C3245505
28269352	1521	1527	useful	T080	C3827682
28269352	1535	1555	fall risk assessment	T058	C1532976
28269352	1560	1567	monitor	T058	C0150369
28269352	1572	1577	state	T169	C1442792
28269352	1581	1598	physical function	T033	C0516981
28269352	1602	1620	elderly population	T098	C0001792

27667643|t|' Yarn with me': applying clinical yarning to improve clinician - patient communication in Aboriginal health care
27667643|a|Although successful communication is at the heart of the clinical consultation, communication between Aboriginal patients and practitioners such as doctors, nurses and allied health professionals, continues to be problematic and is arguably the biggest barrier to the delivery of successful health care to Aboriginal people. This paper presents an overarching framework for practitioners to help them reorientate their communication with Aboriginal patients using ' clinical yarning '. Clinical yarning is a patient -centred approach that marries Aboriginal cultural communication preferences with biomedical understandings of health and disease. Clinical yarning consists of three interrelated areas: the social yarn, in which the practitioner aims to find common ground and develop the interpersonal relationship; the diagnostic yarn, in which the practitioner facilitates the patient's health story while interpreting it through a biomedical or scientific lens; and the management yarn, that employs stories and metaphors as tools for patients to help them understand a health issue so a collaborative management approach can be adopted. There is cultural and research evidence that supports this approach. Clinical yarning has the potential to improve outcomes for patients and practitioners.
27667643	2	6	Yarn	T058	C1512347
27667643	26	42	clinical yarning	T058	C1512347
27667643	54	63	clinician	T097	C0871685
27667643	66	73	patient	T101	C0030705
27667643	74	87	communication	T054	C0009452
27667643	91	101	Aboriginal	T098	C0935542
27667643	102	113	health care	T058	C0086388
27667643	134	147	communication	T054	C0009452
27667643	171	192	clinical consultation	T058	C0009818
27667643	194	207	communication	T054	C0009452
27667643	216	226	Aboriginal	T098	C0935542
27667643	227	235	patients	T101	C0030705
27667643	240	253	practitioners	T097	C0017319
27667643	262	269	doctors	T097	C0031831
27667643	271	277	nurses	T097	C0028661
27667643	282	309	allied health professionals	T097	C0002122
27667643	327	338	problematic	T033	C0033213
27667643	405	416	health care	T058	C0086388
27667643	420	437	Aboriginal people	T098	C0935542
27667643	462	483	overarching framework	T170	C0282574
27667643	488	501	practitioners	T097	C0017319
27667643	533	546	communication	T054	C0009452
27667643	552	562	Aboriginal	T098	C0935542
27667643	563	571	patients	T101	C0030705
27667643	580	596	clinical yarning	T058	C1512347
27667643	600	616	Clinical yarning	T058	C1512347
27667643	622	629	patient	T101	C0030705
27667643	661	671	Aboriginal	T098	C0935542
27667643	672	694	cultural communication	T054	C0009452
27667643	712	722	biomedical	T091	C1879848
27667643	741	759	health and disease	T070	C0679215
27667643	761	777	Clinical yarning	T058	C1512347
27667643	820	826	social	T169	C0728831
27667643	827	831	yarn	T058	C1512347
27667643	846	858	practitioner	T097	C0017319
27667643	902	928	interpersonal relationship	T054	C0021797
27667643	934	944	diagnostic	T169	C0348026
27667643	945	949	yarn	T058	C1512347
27667643	964	976	practitioner	T097	C0017319
27667643	993	1002	patient's	T101	C0030705
27667643	1003	1015	health story	T078	C1254370
27667643	1048	1058	biomedical	T091	C1879848
27667643	1062	1077	scientific lens	T059	C0947630
27667643	1098	1102	yarn	T058	C1512347
27667643	1109	1124	employs stories	T078	C1254370
27667643	1129	1138	metaphors	T078	C0302829
27667643	1152	1160	patients	T101	C0030705
27667643	1187	1199	health issue	T033	C0243095
27667643	1205	1238	collaborative management approach	T062	C0681804
27667643	1264	1272	cultural	T169	C0220814
27667643	1277	1285	research	T062	C0242481
27667643	1286	1294	evidence	T078	C3887511
27667643	1324	1340	Clinical yarning	T058	C1512347
27667643	1370	1378	outcomes	T169	C1274040
27667643	1383	1391	patients	T101	C0030705
27667643	1396	1409	practitioners	T097	C0017319

28397533|t|Socioeconomic Predictors of Adherence Behavior Among HIV-Positive Patients Receiving Antiretroviral Therapy in Selangor, Malaysia
28397533|a|Medication adherence remains a critical link between the prescribed ART regimen and treatment outcome. Several factors may influence adherence behavior. This cross-sectional study aimed to highlight socioeconomic predictors of adherence behavior among a cohort of 242 adult Malaysian patients receiving antiretroviral therapy in Hospital Sungai Buloh, Malaysia, where they were enrolled in a parent study (single-blinded randomized controlled trial) between January and December 2014. Statistical analysis of secondary data on adherence behavior and sociodemographic characteristics of the patients revealed mean age of 33.4 years and ranged from 18 to 64 years; 88.8% were males. A total of 224 (93%) patients who completed 6 months' adherence assessment were included in the model. Of these, 135 (60.3%) achieved optimal adherence. Multivariate binary logistic regression analysis revealed that patient's income and ethnicity were significant predictors of adherence behavior. This may be valuable for targeted programmatic interventions to further enhance successful treatment outcomes among the target population.
28397533	0	13	Socioeconomic	T077	C0748878
28397533	14	24	Predictors	T078	C2698872
28397533	28	46	Adherence Behavior	T033	C0516638
28397533	53	65	HIV-Positive	T034	C0019699
28397533	66	74	Patients	T101	C0030705
28397533	75	84	Receiving	T080	C1514756
28397533	85	107	Antiretroviral Therapy	T061	C1963724
28397533	111	119	Selangor	T083	C0017446
28397533	121	129	Malaysia	T083	C0024552
28397533	130	150	Medication adherence	T033	C2364172
28397533	161	169	critical	T080	C1511545
28397533	187	197	prescribed	T058	C0278329
28397533	198	201	ART	T061	C1963724
28397533	202	209	regimen	T061	C0040808
28397533	214	231	treatment outcome	T080	C0085415
28397533	233	240	Several	T081	C0443302
28397533	241	248	factors	T169	C1521761
28397533	253	262	influence	T077	C4054723
28397533	263	281	adherence behavior	T033	C0516638
28397533	288	309	cross-sectional study	T062	C0010362
28397533	310	315	aimed	T078	C1947946
28397533	329	342	socioeconomic	T077	C0748878
28397533	343	353	predictors	T078	C2698872
28397533	357	375	adherence behavior	T033	C0516638
28397533	384	390	cohort	T098	C0599755
28397533	398	403	adult	T100	C0001675
28397533	404	413	Malaysian	T098	C0240293
28397533	414	422	patients	T101	C0030705
28397533	423	432	receiving	T080	C1514756
28397533	433	455	antiretroviral therapy	T061	C1963724
28397533	459	480	Hospital Sungai Buloh	T073,T093	C0019994
28397533	482	490	Malaysia	T083	C0024552
28397533	536	550	single-blinded	T062	C0242570
28397533	551	578	randomized controlled trial	T062	C0206035
28397533	588	595	January	T080	C3829466
28397533	600	608	December	T080	C3830550
28397533	615	635	Statistical analysis	T062	C0871424
28397533	639	653	secondary data	UnknownType	C0683944
28397533	657	675	adherence behavior	T033	C0516638
28397533	680	712	sociodemographic characteristics	T102	C0683970
28397533	720	728	patients	T101	C0030705
28397533	729	737	revealed	T080	C0443289
28397533	738	746	mean age	T033	C0243095
28397533	755	760	years	T079	C0439234
28397533	765	771	ranged	T081	C1514721
28397533	786	791	years	T079	C0439234
28397533	804	809	males	T032	C0086582
28397533	832	840	patients	T101	C0030705
28397533	865	885	adherence assessment	T058	C1254363
28397533	891	899	included	T169	C0332257
28397533	936	944	achieved	T033	C0432600
28397533	945	952	optimal	T080	C2698651
28397533	953	962	adherence	T169	C1510802
28397533	964	1012	Multivariate binary logistic regression analysis	T170	C0034980
28397533	1013	1021	revealed	T080	C0443289
28397533	1027	1036	patient's	T101	C0030705
28397533	1037	1043	income	T081	C0021162
28397533	1048	1057	ethnicity	T080	C0243103
28397533	1063	1074	significant	T078	C0750502
28397533	1075	1085	predictors	T078	C2698872
28397533	1089	1107	adherence behavior	T033	C0516638
28397533	1134	1142	targeted	T169	C1521840
28397533	1143	1169	programmatic interventions	T061	C0184661
28397533	1181	1188	enhance	T052	C2349975
28397533	1189	1209	successful treatment	T201	C0521982
28397533	1210	1218	outcomes	T169	C1274040
28397533	1229	1246	target population	T098	C0039309

27392220|t|Eliminating Cancer Stem Cells in CML with Combination Transcriptional Therapy
27392220|a|Leukemia stem cells (LSCs) are resistant to current therapies used to treat chronic myeloid leukemia (CML). Abraham et al. (2016) have identified a molecular network critical for CML LSC survival and propose that simultaneously targeting two of their major transcriptional regulators, p53 and c-Myc, may facilitate their eradication.
27392220	12	29	Cancer Stem Cells	T025	C1956422
27392220	33	36	CML	T191	C0023473
27392220	54	69	Transcriptional	T045	C0040649
27392220	70	77	Therapy	T061	C0087111
27392220	78	86	Leukemia	T191	C0023418
27392220	87	97	stem cells	T025	C1956422
27392220	99	103	LSCs	T025	C1956422
27392220	130	139	therapies	T061	C0087111
27392220	154	178	chronic myeloid leukemia	T191	C0023473
27392220	180	183	CML	T191	C0023473
27392220	226	243	molecular network	T044	C1148560
27392220	244	252	critical	T169	C0231242
27392220	257	260	CML	T191	C0023473
27392220	261	264	LSC	T025	C1956422
27392220	265	273	survival	T043	C0007620
27392220	335	361	transcriptional regulators	T116,T123	C0040648
27392220	363	366	p53	T028	C0079419
27392220	371	376	c-Myc	T116,T123	C0314684
27392220	399	410	eradication	T045	C2248542

27271969|t|Spatio-Temporal Distribution of Bark and Ambrosia Beetles in a Brazilian Tropical Dry Forest
27271969|a|Bark and the ambrosia beetles dig into host plants and live most of their lives in concealed tunnels. We assessed beetle community dynamics in tropical dry forest sites in early, intermediate, and late successional stages, evaluating the influence of resource availability and seasonal variations in guild structure. We collected a total of 763 beetles from 23 species, including 14 bark beetle species, and 9 ambrosia beetle species. Local richness of bark and ambrosia beetles was estimated at 31 species. Bark and ambrosia composition was similar over the successional stages gradient, and beta diversity among sites was primarily determined by species turnover, mainly in the bark beetle community. Bark beetle richness and abundance were higher at intermediate stages; availability of wood was the main spatial mechanism. Climate factors were effectively non-seasonal. Ambrosia beetles were not influenced by successional stages, however the increase in wood resulted in increased abundance. We found higher richness at the end of the dry and wet seasons, and abundance increased with air moisture and decreased with higher temperatures and greater rainfall. In summary, bark beetle species accumulation was higher at sites with better wood production, while the needs of fungi (host and air moisture), resulted in a favorable conditions for species accumulation of ambrosia. The overall biological pattern among guilds differed from tropical rain forests, showing patterns similar to dry forest areas.
27271969	0	28	Spatio-Temporal Distribution	T169	C1704711
27271969	32	36	Bark	T002	C0949119
27271969	41	49	Ambrosia	T002	C0331432
27271969	50	57	Beetles	T204	C0009276
27271969	63	72	Brazilian	T083	C0006137
27271969	73	92	Tropical Dry Forest	T070	C0086312
27271969	93	97	Bark	T002	C0949119
27271969	106	114	ambrosia	T002	C0331432
27271969	115	122	beetles	T204	C0009276
27271969	132	143	host plants	UnknownType	C0868970
27271969	186	193	tunnels	T082	C1116506
27271969	198	206	assessed	T052	C1516048
27271969	207	213	beetle	T204	C0009276
27271969	214	223	community	T096	C0009462
27271969	224	232	dynamics	T102	C0237587
27271969	236	255	tropical dry forest	T070	C0086312
27271969	256	261	sites	T082	C0205145
27271969	265	270	early	T079	C1279919
27271969	272	284	intermediate	T079	C1254367
27271969	290	294	late	T079	C0205087
27271969	295	314	successional stages	T079	C1306673
27271969	344	352	resource	T078	C0035201
27271969	353	365	availability	T169	C0470187
27271969	370	389	seasonal variations	T079	C0036496
27271969	393	408	guild structure	T080	C0205556
27271969	413	422	collected	T078	C1516695
27271969	438	445	beetles	T204	C0009276
27271969	454	461	species	T185	C1705920
27271969	476	480	bark	T002	C0949119
27271969	481	487	beetle	T204	C0009276
27271969	488	495	species	T185	C1705920
27271969	503	511	ambrosia	T002	C0331432
27271969	512	518	beetle	T204	C0009276
27271969	519	526	species	T185	C1705920
27271969	528	533	Local	T082	C0205276
27271969	534	542	richness	T080	C0205556
27271969	546	550	bark	T002	C0949119
27271969	555	563	ambrosia	T002	C0331432
27271969	564	571	beetles	T204	C0009276
27271969	592	599	species	T185	C1705920
27271969	601	605	Bark	T002	C0949119
27271969	610	618	ambrosia	T002	C0331432
27271969	619	630	composition	T078	C1254370
27271969	652	671	successional stages	T079	C1306673
27271969	672	680	gradient	T081	C0812409
27271969	686	700	beta diversity	T080	C1880371
27271969	707	712	sites	T082	C0205145
27271969	741	748	species	T185	C1705920
27271969	773	777	bark	T002	C0949119
27271969	778	784	beetle	T204	C0009276
27271969	785	794	community	T096	C0009462
27271969	796	800	Bark	T002	C0949119
27271969	801	807	beetle	T204	C0009276
27271969	808	816	richness	T080	C0205556
27271969	821	830	abundance	T080	C2346714
27271969	846	865	intermediate stages	T079	C1306673
27271969	867	882	availability of	T169	C0470187
27271969	883	887	wood	T167	C0043217
27271969	901	918	spatial mechanism	T169	C0441712
27271969	920	927	Climate	T070	C0008946
27271969	928	935	factors	T169	C1521761
27271969	953	965	non-seasonal	T080	C0205556
27271969	967	975	Ambrosia	T002	C0331432
27271969	976	983	beetles	T204	C0009276
27271969	1007	1026	successional stages	T079	C1306673
27271969	1040	1048	increase	T169	C0442805
27271969	1052	1056	wood	T167	C0043217
27271969	1069	1078	increased	T081	C0205217
27271969	1079	1088	abundance	T080	C2346714
27271969	1106	1114	richness	T080	C0205556
27271969	1133	1136	dry	T079	C0036497
27271969	1141	1152	wet seasons	T079	C0036497
27271969	1158	1167	abundance	T080	C2346714
27271969	1168	1177	increased	T081	C0205217
27271969	1183	1186	air	T167	C0001861
27271969	1187	1195	moisture	T167	C0868994
27271969	1222	1234	temperatures	T081	C0039476
27271969	1247	1255	rainfall	T070	C0034640
27271969	1269	1273	bark	T002	C0949119
27271969	1274	1280	beetle	T204	C0009276
27271969	1281	1288	species	T185	C1705920
27271969	1289	1301	accumulation	T169	C0205245
27271969	1316	1321	sites	T082	C0205145
27271969	1334	1338	wood	T167	C0043217
27271969	1339	1349	production	T052	C0441655
27271969	1370	1375	fungi	T004	C0016832
27271969	1377	1381	host	UnknownType	C0868970
27271969	1386	1389	air	T167	C0001861
27271969	1390	1398	moisture	T167	C0868994
27271969	1425	1435	conditions	T080	C0348080
27271969	1440	1447	species	T185	C1705920
27271969	1448	1460	accumulation	T169	C0205245
27271969	1464	1472	ambrosia	T002	C0331432
27271969	1486	1496	biological	T080	C0205460
27271969	1497	1504	pattern	T080	C0205556
27271969	1532	1553	tropical rain forests	T070	C0086312
27271969	1583	1599	dry forest areas	T070	C0086312

28112421|t|Re-emerging of rabies in Shaanxi Province, China, 2009 to 2015
28112421|a|To explore the epidemiological, phylogeographic and migration characteristics of human rabies in Shaanxi Province, China from 2009 to 2015. The collected data were described and the sequenced glycoprotein (G) and nucleoprotein (N) genes were implemented to estimate the evolutionary rates and phylogeographic patterns using BEAST v.1.8.2. 269 rabies cases were reported and 70.26% of the cases were male and 61.71% were between the ages of 19 to 59. The majority of the cases were farmers (83.27%). The estimated evolutionary rate of the N genes was 2.4 × 10(-4) substitutions/site/year and the G genes was 3.4 × 10(-4). The time of the most recent common ancestor(TMRCA) was estimated around 1990. We detected viral migration paths from Sichuan, Guizhou and Hunan to Hanzhong prefecture of Shaanxi and then spreaded to Xi'an and other prefectures. The main population affected by rabies virus was male adult farmers. The evolution rate of rabies viruses in Shaanxi was similar with the prior results reported by others and the ancestor virus should be circulating in neighboring province Sichuan around 1990 and then transmitted to Shaanxi. Promptly standard wound treatment and timely post-exposure prophylaxis should be compulsory for the dog-bitten victims. This article is protected by copyright. All rights reserved.
28112421	0	11	Re-emerging	T046	C2825055
28112421	15	21	rabies	T047	C0034494
28112421	25	48	Shaanxi Province, China	T083	C0008115
28112421	78	93	epidemiological	T091	C0014507
28112421	95	110	phylogeographic	T090	C2936603
28112421	115	124	migration	T046	C0242781
28112421	144	156	human rabies	T047	C1321098
28112421	160	183	Shaanxi Province, China	T083	C0008115
28112421	207	221	collected data	T033	C4019276
28112421	245	267	sequenced glycoprotein	T028	C0017337
28112421	269	270	G	T028	C0017337
28112421	276	289	nucleoprotein	T028	C0017337
28112421	290	299	(N) genes	T028	C0017337
28112421	333	351	evolutionary rates	T081	C1521828
28112421	356	371	phylogeographic	T090	C2936603
28112421	372	380	patterns	T082	C0449774
28112421	387	405	BEAST v.1.8.2. 269	T081	C0242196
28112421	406	418	rabies cases	T077	C1706256
28112421	451	456	cases	T077	C1706256
28112421	462	466	male	T032	C0086582
28112421	544	551	farmers	T097	C0221460
28112421	576	593	evolutionary rate	T081	C1521828
28112421	601	608	N genes	T028	C0017337
28112421	658	665	G genes	T028	C0017337
28112421	765	773	detected	T033	C0442726
28112421	774	779	viral	T169	C0521026
28112421	780	795	migration paths	T082	C0449444
28112421	801	808	Sichuan	T083	C0017446
28112421	810	817	Guizhou	T083	C0017446
28112421	822	827	Hunan	T083	C0017446
28112421	831	850	Hanzhong prefecture	T083	C1709636
28112421	854	861	Shaanxi	T083	C0017446
28112421	883	888	Xi'an	T083	C1709636
28112421	893	910	other prefectures	T083	C1709636
28112421	944	956	rabies virus	T005	C0034497
28112421	961	971	male adult	T100	C0001675
28112421	972	979	farmers	T097	C0221460
28112421	1003	1017	rabies viruses	T005	C0034497
28112421	1021	1028	Shaanxi	T083	C0017446
28112421	1091	1105	ancestor virus	T005	C0042776
28112421	1131	1159	neighboring province Sichuan	T083	C0017446
28112421	1181	1192	transmitted	T046	C0242781
28112421	1196	1203	Shaanxi	T083	C0017446
28112421	1223	1238	wound treatment	T061	C1272654
28112421	1250	1275	post-exposure prophylaxis	T061	C1443861
28112421	1286	1296	compulsory	T061	C0683517
28112421	1305	1315	dog-bitten	T037	C0479207
28112421	1316	1323	victims	T098	C0680681

27257613|t|Data set of interactomes and metabolic pathways of proteins differentially expressed in brains with Alzheimer׳s disease
27257613|a|Alzheimer׳s disease is one of the main causes of dementia in the elderly and its frequency is on the rise worldwide. It is considered the result of complex interactions between genetic and environmental factors, being many of them unknown. Therefore, there is a dire necessity for the identification of novel molecular players for the understanding of this disease. In this data article we determined the protein expression profiles of whole protein extracts from cortex regions of brains from patients with Alzheimer׳s disease in comparison to a normal brain. We identified 721 iTRAQ-labeled polypeptides with more than 95% in confidence. We analyzed all proteins that changed in their expression level and located them in the KEGG metabolic pathways, as well as in the mitochondrial complexes of the electron transport chain and ATP synthase. In addition, we analyzed the over- and sub-expressed polypeptides through IPA software, specifically Core I and Biomarkers I modules. Data in this article is related to the research article "Identification of proteins that are differentially expressed in brains with Alzheimer's disease using iTRAQ labeling and tandem mass spectrometry " (Minjarez et al., 2016) [1].
27257613	0	8	Data set	T170	C0150098
27257613	12	24	interactomes	T044	C0872079
27257613	29	47	metabolic pathways	T169	C1291081
27257613	51	59	proteins	T116,T123	C0033684
27257613	75	84	expressed	T045	C1171362
27257613	88	94	brains	T023	C0006104
27257613	100	119	Alzheimer׳s disease	T047	C0002395
27257613	120	139	Alzheimer׳s disease	T047	C0002395
27257613	169	177	dementia	T048	C0497327
27257613	185	192	elderly	T098	C0001792
27257613	201	210	frequency	T079	C0439603
27257613	226	235	worldwide	T098	C2700280
27257613	268	275	complex	T080	C0439855
27257613	276	288	interactions	T169	C1704675
27257613	297	304	genetic	T080	C0814299
27257613	309	330	environmental factors	T080	C0686732
27257613	429	446	molecular players	T116,T123	C0033684
27257613	477	484	disease	T047	C0002395
27257613	494	498	data	T078	C1511726
27257613	499	506	article	T170	C1706852
27257613	525	543	protein expression	T045	C1171362
27257613	562	569	protein	T116,T123	C0033684
27257613	570	578	extracts	T167	C2828366
27257613	584	608	cortex regions of brains	T029	C0458324
27257613	614	622	patients	T101	C0030705
27257613	628	647	Alzheimer׳s disease	T047	C0002395
27257613	667	679	normal brain	T023	C0006104
27257613	684	694	identified	T080	C0205396
27257613	699	712	iTRAQ-labeled	T130	C2986808
27257613	713	725	polypeptides	T116	C1305923
27257613	763	771	analyzed	T062	C0936012
27257613	776	784	proteins	T116,T123	C0033684
27257613	807	823	expression level	T081	C3244092
27257613	848	871	KEGG metabolic pathways	T170	C3826812
27257613	891	946	mitochondrial complexes of the electron transport chain	T026	C1325653
27257613	951	963	ATP synthase	T116,T126	C0949692
27257613	981	989	analyzed	T062	C0936012
27257613	994	1030	over- and sub-expressed polypeptides	T116	C1305923
27257613	1039	1051	IPA software	T073,T170	C0037585
27257613	1066	1097	Core I and Biomarkers I modules	T170	C0037589
27257613	1099	1103	Data	T078	C1511726
27257613	1112	1119	article	T170	C1706852
27257613	1138	1146	research	T062	C0035168
27257613	1147	1154	article	T170	C1706852
27257613	1174	1182	proteins	T116,T123	C0033684
27257613	1207	1216	expressed	T045	C1171362
27257613	1220	1226	brains	T023	C0006104
27257613	1232	1251	Alzheimer's disease	T047	C0002395
27257613	1258	1272	iTRAQ labeling	T059	C0022885
27257613	1277	1301	tandem mass spectrometry	T063	C0599748

27280034|t|Changes in risk factors for young male suicide in Newcastle upon Tyne, 1961-2009
27280034|a|Aims and method To ascertain differences in patterns of suicide in young men over three decades (1960s, 1990s and 2000s) and discuss implications for suicide prevention. Data on suicides and open verdicts in men aged 15-34 were obtained from coroner's records in Newcastle upon Tyne and analysed using SPSS software. Results An increase in suicide rates from the first to the second decade was followed by a fall in the third decade. This was associated with an increasing proportion of single men, those living alone, unemployment, consumption of alcohol, use of hanging, previous suicide attempt and history of treatment for mental illness. Clinical implications This study highlights the need for more interventions and focus to be given to young males in the suicide prevention area and is of high importance in the field of public health. Areas that could be tackled include reducing access to means of suicide, reducing alcohol use, support for relationship difficulties, engagement with mental health services and management of chronic illness.
27280034	0	7	Changes	T169	C0392747
27280034	11	23	risk factors	T033	C0035648
27280034	28	33	young	T079	C0332239
27280034	34	38	male	T032	C0086582
27280034	39	46	suicide	T033	C0038661
27280034	50	69	Newcastle upon Tyne	T083	C0017446
27280034	81	85	Aims	T078	C1947946
27280034	90	96	method	T170	C0025663
27280034	110	121	differences	T080	C1705242
27280034	125	144	patterns of suicide	T033	C0038661
27280034	148	153	young	T079	C0332239
27280034	154	157	men	T098	C0025266
27280034	169	176	decades	T081	C2981279
27280034	214	226	implications	T080	C0205556
27280034	231	238	suicide	T033	C0038661
27280034	239	249	prevention	T080	C2700409
27280034	251	255	Data	T078	C1511726
27280034	259	267	suicides	T033	C0038661
27280034	272	285	open verdicts	T064	C0680738
27280034	289	292	men	T098	C0025266
27280034	323	340	coroner's records	T170	C0282574
27280034	344	363	Newcastle upon Tyne	T083	C0017446
27280034	368	376	analysed	T062	C0936012
27280034	383	396	SPSS software	T073,T170	C0037585
27280034	398	405	Results	T169	C1274040
27280034	409	417	increase	T169	C0442805
27280034	421	434	suicide rates	T033	C1822575
27280034	464	470	decade	T081	C2981279
27280034	507	513	decade	T081	C2981279
27280034	524	539	associated with	T080	C0332281
27280034	543	553	increasing	T169	C0442808
27280034	554	564	proportion	T081	C1709707
27280034	568	574	single	T081	C0205171
27280034	575	578	men	T098	C0025266
27280034	586	598	living alone	T033	C0260794
27280034	600	612	unemployment	T033	C0041674
27280034	614	636	consumption of alcohol	T055	C0001948
27280034	645	652	hanging	T037	C0544691
27280034	654	662	previous	T079	C0205156
27280034	663	678	suicide attempt	T033	C0038663
27280034	683	703	history of treatment	UnknownType	C0814462
27280034	708	722	mental illness	T048	C0004936
27280034	724	732	Clinical	T080	C0205210
27280034	733	745	implications	T080	C0205556
27280034	751	756	study	T062	C2603343
27280034	786	799	interventions	T061	C0184661
27280034	804	809	focus	T041	C0589098
27280034	825	830	young	T079	C0332239
27280034	831	836	males	T032	C0086582
27280034	844	851	suicide	T033	C0038661
27280034	852	867	prevention area	T080	C2700409
27280034	901	923	field of public health	T170	C3244304
27280034	961	969	reducing	T080	C0392756
27280034	970	976	access	T082	C0444454
27280034	980	985	means	T077	C1704970
27280034	989	996	suicide	T033	C0038661
27280034	998	1006	reducing	T080	C0392756
27280034	1007	1018	alcohol use	T055	C0001948
27280034	1020	1027	support	T077	C1521721
27280034	1032	1044	relationship	T080	C0439849
27280034	1045	1057	difficulties	T080	C0332218
27280034	1059	1069	engagement	T058	C3508152
27280034	1075	1097	mental health services	T058	C0025355
27280034	1102	1112	management	T058	C0376636
27280034	1116	1131	chronic illness	T047	C0008679

27998307|t|Neuro-Behcet disease presenting as a solitary cerebellar hemorrhagic lesion: a case report and review of the literature
27998307|a|Behcet's disease is a heterogeneous, multisystem, inflammatory disorder of unknown etiology. The classic triad of oral and genital ulcerations in conjunction with uveitis was originally described by the Turkish dermatologist Hulusi Behcet in 1937, but associated symptoms of the cardiovascular, central nervous, pulmonary, and gastrointestinal systems were later identified. In fact, Behcet's disease with neurological involvement (neuro-Behcet's disease) is not uncommon. Patients with neuro-Behcet's disease typically exhibit a diverse array of symptoms, most commonly in the brainstem and diencephalic regions. Herein, we report an unusual case of neuro-Behcet's disease in a patient who presented with a solitary cerebellar hemorrhage. A 39-year-old Asian woman was admitted to our hospital with complaints of a sudden speech difficulty that had manifested the same morning, and dizziness and mild vomiting experienced over the previous 3 days. Magnetic resonance images revealed target-like hemorrhagic lesions in the right hemisphere of the cerebellum. Risk factors that may result in cerebellar hemorrhage, such as high blood pressure or bleeding diathesis, were ruled out, and subsequent brain angiograms were normal. These findings suggest that the patient's cerebellar hemorrhage could have been due to intracranial vasculitis in a rare, if not unique, complication of neuro-Behcet's disease.
27998307	0	20	Neuro-Behcet disease	T047	C0858762
27998307	21	31	presenting	T078	C0449450
27998307	46	68	cerebellar hemorrhagic	T046	C0149854
27998307	69	75	lesion	T033	C0221198
27998307	79	90	case report	T170	C0085973
27998307	95	119	review of the literature	T170	C0282441
27998307	120	136	Behcet's disease	T047	C0004943
27998307	142	155	heterogeneous	T033	C1858576
27998307	157	168	multisystem	T047	C0559758
27998307	170	191	inflammatory disorder	T047	C1290884
27998307	195	211	unknown etiology	T033	C0743626
27998307	234	238	oral	T047	C0149745
27998307	243	262	genital ulcerations	T047	C0151281
27998307	266	277	conjunction	T078	C2699427
27998307	283	290	uveitis	T047	C0042164
27998307	306	315	described	T078	C1552738
27998307	323	330	Turkish	T098	C0549217
27998307	331	344	dermatologist	T097	C0259831
27998307	372	391	associated symptoms	T184	C0521989
27998307	399	413	cardiovascular	T022	C0007226
27998307	415	430	central nervous	T022	C3714787
27998307	432	441	pulmonary	T022	C0884309
27998307	447	471	gastrointestinal systems	T022	C0012240
27998307	483	493	identified	T080	C0205396
27998307	504	520	Behcet's disease	T047	C0004943
27998307	526	550	neurological involvement	T047	C0027765
27998307	552	574	neuro-Behcet's disease	T047	C0858762
27998307	593	601	Patients	T101	C0030705
27998307	607	629	neuro-Behcet's disease	T047	C0858762
27998307	667	675	symptoms	T184	C1457887
27998307	677	681	most	T081	C0205393
27998307	682	690	commonly	T081	C0205214
27998307	698	707	brainstem	T023	C0006121
27998307	712	724	diencephalic	T023	C0012144
27998307	725	732	regions	T082	C0205147
27998307	745	751	report	T170	C0684224
27998307	755	762	unusual	T080	C2700116
27998307	763	767	case	T169	C0868928
27998307	771	793	neuro-Behcet's disease	T047	C0858762
27998307	799	806	patient	T101	C0030705
27998307	811	820	presented	T078	C0449450
27998307	837	858	cerebellar hemorrhage	T046	C0149854
27998307	862	873	39-year-old	T100	C0001675
27998307	874	879	Asian	T098	C0078988
27998307	880	885	woman	T098	C0043210
27998307	890	898	admitted	T058	C0809949
27998307	906	914	hospital	T073,T093	C0019994
27998307	920	930	complaints	T033	C0277786
27998307	936	942	sudden	T080	C1276802
27998307	943	960	speech difficulty	T033	C0233715
27998307	970	980	manifested	T169	C0205319
27998307	985	989	same	T080	C0445247
27998307	990	997	morning	T079	C0332170
27998307	1003	1012	dizziness	T184	C0012833
27998307	1017	1021	mild	T080	C2945599
27998307	1022	1030	vomiting	T184	C0042963
27998307	1043	1047	over	T079	C0347984
27998307	1052	1060	previous	T079	C0205156
27998307	1063	1067	days	T079	C0439228
27998307	1069	1094	Magnetic resonance images	T170	C3890166
27998307	1095	1103	revealed	T080	C0443289
27998307	1116	1127	hemorrhagic	T046	C0149854
27998307	1128	1135	lesions	T033	C0221198
27998307	1143	1177	right hemisphere of the cerebellum	T023	C2335345
27998307	1179	1191	Risk factors	T033	C0035648
27998307	1201	1207	result	T169	C1274040
27998307	1211	1232	cerebellar hemorrhage	T046	C0149854
27998307	1242	1261	high blood pressure	T047	C0020538
27998307	1265	1283	bleeding diathesis	T046	C1458140
27998307	1290	1299	ruled out	T033	C1410834
27998307	1305	1315	subsequent	T079	C0332282
27998307	1316	1321	brain	T023	C0006104
27998307	1322	1332	angiograms	T060	C0002978
27998307	1338	1344	normal	T080	C0205307
27998307	1352	1360	findings	T033	C0243095
27998307	1361	1368	suggest	T078	C1705535
27998307	1378	1387	patient's	T101	C0030705
27998307	1388	1409	cerebellar hemorrhage	T046	C0149854
27998307	1426	1432	due to	T169	C0678226
27998307	1433	1445	intracranial	T029	C0524466
27998307	1446	1456	vasculitis	T047	C0042384
27998307	1462	1466	rare	T080	C0522498
27998307	1483	1495	complication	T046	C0009566
27998307	1499	1521	neuro-Behcet's disease	T047	C0858762

27576608|t|Ocular toxicity of AUY922 in pigmented and albino rats
27576608|a|AUY922, a heat shock protein 90 inhibitor is associated with ocular adverse events (AEs). To provide a better understanding of ocular AEs in patients, 4 investigative studies were performed in a step-wise approach to assess retinal structure and function in pigmented (Brown Norway) and albino (Wistar) rats. In rats administered 30mg/kg of AUY922, the AUC 0-24 h and Cmax are comparable to that in patients at 70mg/m(2). AUY922 at ≥30mg/kg was poorly tolerated by rats with morbidity or mortality generally after the third weekly treatment. Electroretinography (ERG) changes were observed at doses ≥30mg/kg. The ERG changes were dose dependent, consistent with an effect on the photoreceptors, and fully reversible. The ERG effects could not be minimized by decreasing the Cmax while maintaining AUC. Histopathological changes were seen mainly when rats were administered AUY922 at 100mg/kg. The 2- hour infusion of AUY922 at 100mg/kg caused disorganization of the outer segment photoreceptor morphology in male Brown Norway rats; the severity of the disorganization increased with the number of administrations, but was reversible during a 4- week posttreatment period. There was no major difference in ocular response between Brown Norway and Wistar rats. No changes in serum iron levels, and no changes in rhodopsin, PDE6α, β-transducin concentrations, or retinal pigment epithelium-specific protein RPE65 expression were observed after single and multiple infusions of AUY922 at 100mg/kg compared to vehicle-treated controls. AUY922 retinal toxicity in rats recapitulates and further characterizes that reported in patients and is shown to be reversible, while a precise molecular mechanism for the effect was not determined.
27576608	0	15	Ocular toxicity	T037	C1262036
27576608	19	25	AUY922	T109,T121	C2348996
27576608	29	38	pigmented	T015	C0034700
27576608	43	54	albino rats	T015	C0684072
27576608	55	61	AUY922	T109,T121	C2348996
27576608	65	86	heat shock protein 90	T116,T123	C0243044
27576608	87	96	inhibitor	T080	C1999216
27576608	116	122	ocular	T023	C0015392
27576608	123	137	adverse events	T046	C0877248
27576608	139	142	AEs	T046	C0877248
27576608	182	188	ocular	T023	C0015392
27576608	189	192	AEs	T046	C0877248
27576608	196	204	patients	T101	C0030705
27576608	208	229	investigative studies	T062	C2603343
27576608	250	268	step-wise approach	T082	C0449445
27576608	279	296	retinal structure	T023	C0035298
27576608	313	322	pigmented	T015	C0034700
27576608	324	336	Brown Norway	T015	C0034700
27576608	342	362	albino (Wistar) rats	T015	C0684072
27576608	350	356	Wistar	T015	C0034716
27576608	367	371	rats	T015	C0034721
27576608	372	384	administered	T169	C1521801
27576608	396	402	AUY922	T109,T121	C2348996
27576608	408	411	AUC	T081	C0376690
27576608	417	418	h	T079	C0439227
27576608	423	427	Cmax	T081	C2347813
27576608	454	462	patients	T101	C0030705
27576608	477	483	AUY922	T109,T121	C2348996
27576608	520	524	rats	T015	C0034721
27576608	530	539	morbidity	T081	C0026538
27576608	543	552	mortality	T081	C0596099
27576608	579	585	weekly	T079	C0332174
27576608	586	595	treatment	T061	C0087111
27576608	597	616	Electroretinography	T060	C0013867
27576608	618	621	ERG	T060	C0013867
27576608	623	630	changes	T169	C0392747
27576608	648	653	doses	T081	C0178602
27576608	668	671	ERG	T060	C0013867
27576608	672	679	changes	T169	C0392747
27576608	685	699	dose dependent	T081	C1512045
27576608	701	711	consistent	T078	C0332290
27576608	734	748	photoreceptors	T025	C0031760
27576608	760	770	reversible	T169	C0205343
27576608	776	779	ERG	T060	C0013867
27576608	829	833	Cmax	T081	C2347813
27576608	852	855	AUC	T081	C0376690
27576608	857	874	Histopathological	T169	C0243140
27576608	875	882	changes	T169	C0392747
27576608	905	909	rats	T015	C0034721
27576608	915	927	administered	T169	C1521801
27576608	928	934	AUY922	T109,T121	C2348996
27576608	955	959	hour	T079	C0439227
27576608	960	968	infusion	T061	C0574032
27576608	972	978	AUY922	T109,T121	C2348996
27576608	998	1013	disorganization	T033	C4061689
27576608	1021	1048	outer segment photoreceptor	T026	C1325525
27576608	1049	1059	morphology	T080	C0332437
27576608	1063	1067	male	T032	C0086582
27576608	1068	1085	Brown Norway rats	T015	C0034700
27576608	1107	1122	disorganization	T033	C4061689
27576608	1152	1167	administrations	T061	C1533734
27576608	1177	1187	reversible	T169	C0205343
27576608	1200	1204	week	T079	C0439230
27576608	1205	1225	posttreatment period	T079	C2709088
27576608	1260	1266	ocular	T023	C0015392
27576608	1267	1275	response	T032	C0871261
27576608	1284	1296	Brown Norway	T015	C0034700
27576608	1301	1312	Wistar rats	T015	C0034716
27576608	1328	1345	serum iron levels	T034	C0036810
27576608	1365	1374	rhodopsin	T116,T123	C0035499
27576608	1376	1381	PDE6α	T116,T126	C1567350
27576608	1383	1395	β-transducin	T116,T123	C0040665
27576608	1396	1410	concentrations	T081	C0392762
27576608	1415	1464	retinal pigment epithelium-specific protein RPE65	T116,T123	C1571376
27576608	1465	1475	expression	T045	C0017262
27576608	1516	1525	infusions	T061	C0574032
27576608	1529	1535	AUY922	T109,T121	C2348996
27576608	1560	1584	vehicle-treated controls	T096	C0009932
27576608	1586	1592	AUY922	T109,T121	C2348996
27576608	1593	1609	retinal toxicity	T190	C0877104
27576608	1613	1617	rats	T015	C0034721
27576608	1675	1683	patients	T101	C0030705
27576608	1703	1713	reversible	T169	C0205343
27576608	1731	1750	molecular mechanism	T044	C1258062

27239953|t|Body mass index and suicide methods
27239953|a|Overweight and obesity is associated with lower rates of suicide. However, little is known about the association with different suicide methods. We studied the association between groups of body mass index and suicide methods. We identified all medicolegal autopsy cases with a cause of death due to external causes in Sweden during 1999-2013 (N = 39,368) and included 11,715 suicides and 13,316 accidents or homicides as controls. We applied multinomial regression models adjusted for age, sex, year and season of death. Obesity was associated with suicidal intoxication, OR 1.15 [95% confidence interval (CI) 1.02, 1.30] and negatively associated with all other suicide methods studied. Underweight showed a negative association with suicidal drowning and there was an indication towards a negative association with hanging in men OR 0.81 (95% CI 0.65, 1.01). We conclude that body mass index (BMI) is associated with the choice of suicide method. This may be of importance in a public health perspective, e.g. potential for prevention of intoxications. In the practice of forensic medicine, the physician's level of suspicion may rise if the apparent suicidal method is less common for the individual characteristics of the deceased, such as BMI.
27239953	0	15	Body mass index	T201	C1305855
27239953	20	27	suicide	T033	C0038661
27239953	28	35	methods	T169	C0449851
27239953	36	46	Overweight	T184	C0497406
27239953	51	58	obesity	T047	C0028754
27239953	62	77	associated with	T080	C0332281
27239953	78	89	lower rates	T081	C1521828
27239953	93	100	suicide	T033	C0038661
27239953	137	148	association	T080	C0439849
27239953	164	171	suicide	T033	C0038661
27239953	172	179	methods	T169	C0449851
27239953	196	207	association	T080	C0439849
27239953	226	241	body mass index	T201	C1305855
27239953	246	253	suicide	T033	C0038661
27239953	254	261	methods	T169	C0449851
27239953	281	292	medicolegal	T089	C0243119
27239953	293	300	autopsy	T060	C0004398
27239953	301	306	cases	T169	C0868928
27239953	314	328	cause of death	T033	C0007465
27239953	336	351	external causes	T033	C1407879
27239953	355	361	Sweden	T083	C0038995
27239953	396	404	included	T169	C0332257
27239953	412	420	suicides	T033	C0038661
27239953	432	441	accidents	T067	C0000924
27239953	445	454	homicides	T055	C0019872
27239953	458	466	controls	T096	C0009932
27239953	479	490	multinomial	T081	C1709090
27239953	491	508	regression models	T170	C0034980
27239953	522	525	age	T032	C0001779
27239953	527	530	sex	T032	C0079399
27239953	532	536	year	T079	C0439234
27239953	541	547	season	T079	C0036497
27239953	551	556	death	T033	C1306577
27239953	558	565	Obesity	T047	C0028754
27239953	570	585	associated with	T080	C0332281
27239953	586	594	suicidal	T033	C0438696
27239953	595	607	intoxication	T033	C0728899
27239953	609	611	OR	T081	C0028873
27239953	622	641	confidence interval	T081	C0009667
27239953	643	645	CI	T081	C0009667
27239953	663	673	negatively	T033	C0205160
27239953	674	689	associated with	T080	C0332281
27239953	700	707	suicide	T033	C0038661
27239953	708	715	methods	T169	C0449851
27239953	725	736	Underweight	T033	C0041667
27239953	746	754	negative	T033	C0205160
27239953	755	766	association	T080	C0439849
27239953	772	780	suicidal	T033	C0438696
27239953	781	789	drowning	T037	C0013142
27239953	807	817	indication	T078	C3146298
27239953	828	836	negative	T033	C0205160
27239953	837	848	association	T080	C0439849
27239953	854	861	hanging	T037	C0544691
27239953	865	868	men	T098	C0025266
27239953	869	871	OR	T081	C0028873
27239953	882	884	CI	T081	C0009667
27239953	901	909	conclude	T078	C1707478
27239953	915	930	body mass index	T201	C1305855
27239953	932	935	BMI	T201	C1305855
27239953	940	955	associated with	T080	C0332281
27239953	970	977	suicide	T033	C0038661
27239953	978	984	method	T169	C0449851
27239953	1017	1042	public health perspective	T058	C0699943
27239953	1049	1058	potential	T080	C3245505
27239953	1063	1073	prevention	T061	C0204732
27239953	1077	1090	intoxications	T033	C0728899
27239953	1111	1128	forensic medicine	T091	C0016557
27239953	1134	1145	physician's	T097	C0031831
27239953	1155	1164	suspicion	T041	C0242114
27239953	1181	1189	apparent	T078	C0750489
27239953	1190	1198	suicidal	T033	C0438696
27239953	1209	1220	less common	T081	C0205214
27239953	1229	1255	individual characteristics	T080	C1521970
27239953	1263	1271	deceased	T040	C0011065
27239953	1281	1284	BMI	T201	C1305855

27500005|t|Operative surgical nuances of modified extradural temporopolar approach with mini-peeling of dura propria based on cadaveric anatomical study of lateral cavernous structures
27500005|a|Extradural temporopolar approach (ETA) has been modified as less invasive manner and named as trans-superior orbital fissure (SOF) approach with mini-peeling technique. The present study discusses the operative nuances of this modified technique on the basis of cadaveric study of lateral cavernous structures. In five consecutive cadaveric specimens, we performed an extradural anterior clinoidectomy with mini-peeling of the dura propria to expose the anterior clinoid process entirely. We also investigated the histological characteristics of the lateral cavernous sinus (CS) between the dura propria and periosteal dura at the SOF, foramen rotundum (FR), and foramen ovale (FO) levels, and of each trigeminal nerve division. Coronal histological examination of the lateral wall of the CS showed invagination of the dura propria and periosteal dura into the SOF. In contrast, no such invagination was observed at the levels of the FR and FO. This finding supports the technical rationale of the only skeletonization of the SOF for peeling of the dura propria but not FR. In addition, our modified ETA method needs only minimal dural incision between the SOF and FR where no cranial nerves are present. Our technical modification of ETA may be recommended for surgical treatment of paraclinoid lesions to reduce the risk of intraoperative neurovascular injury.
27500005	0	26	Operative surgical nuances	T033	C0243095
27500005	30	38	modified	T169	C0392747
27500005	39	71	extradural temporopolar approach	T061	C0543467
27500005	77	89	mini-peeling	T169	C0441602
27500005	93	105	dura propria	T023	C0013313
27500005	115	141	cadaveric anatomical study	T062	C0242481
27500005	145	152	lateral	T082	C0205093
27500005	153	173	cavernous structures	T030	C0007473
27500005	174	206	Extradural temporopolar approach	T061	C0543467
27500005	208	211	ETA	T061	C0543467
27500005	222	230	modified	T169	C0392747
27500005	268	282	trans-superior	T082	C1282910
27500005	283	298	orbital fissure	T030	C0459562
27500005	300	303	SOF	T030	C0459562
27500005	305	313	approach	T061	C0543467
27500005	319	331	mini-peeling	T169	C0441602
27500005	332	341	technique	T169	C0449851
27500005	375	392	operative nuances	T033	C0243095
27500005	401	409	modified	T169	C0392747
27500005	410	419	technique	T169	C0449851
27500005	436	451	cadaveric study	T062	C0242481
27500005	455	462	lateral	T082	C0205093
27500005	463	483	cavernous structures	T030	C0007473
27500005	493	504	consecutive	T080	C1707491
27500005	505	524	cadaveric specimens	T167	C0370003
27500005	542	552	extradural	T030	C0014537
27500005	553	561	anterior	T082	C0205094
27500005	562	575	clinoidectomy	T061	C0087111
27500005	581	593	mini-peeling	T169	C0441602
27500005	601	613	dura propria	T023	C0013313
27500005	628	652	anterior clinoid process	T029	C0230053
27500005	688	700	histological	T169	C0205462
27500005	701	716	characteristics	T080	C1521970
27500005	724	731	lateral	T082	C0205093
27500005	732	747	cavernous sinus	T030	C0007473
27500005	749	751	CS	T030	C0007473
27500005	765	777	dura propria	T023	C0013313
27500005	782	797	periosteal dura	T023	C1518991
27500005	805	808	SOF	T030	C0459562
27500005	810	826	foramen rotundum	T030	C0222687
27500005	828	830	FR	T030	C0222687
27500005	856	862	levels	T080	C0441889
27500005	876	901	trigeminal nerve division	T023	C0024695
27500005	903	935	Coronal histological examination	T060	C0430022
27500005	943	955	lateral wall	T082	C0205093
27500005	963	965	CS	T030	C0007473
27500005	973	985	invagination	T190	C0221224
27500005	993	1005	dura propria	T023	C0013313
27500005	1010	1025	periosteal dura	T023	C1518991
27500005	1035	1038	SOF	T030	C0459562
27500005	1053	1055	no	T033	C1513916
27500005	1061	1073	invagination	T190	C0221224
27500005	1094	1100	levels	T080	C0441889
27500005	1108	1110	FR	T030	C0222687
27500005	1124	1131	finding	T169	C2607943
27500005	1177	1192	skeletonization	T033	C0277760
27500005	1200	1203	SOF	T030	C0459562
27500005	1208	1215	peeling	T169	C0441602
27500005	1223	1235	dura propria	T023	C0013313
27500005	1244	1246	FR	T030	C0222687
27500005	1265	1273	modified	T169	C0392747
27500005	1274	1277	ETA	T061	C0543467
27500005	1278	1284	method	T169	C0449851
27500005	1296	1303	minimal	T080	C1524031
27500005	1304	1318	dural incision	T061	C0184898
27500005	1331	1334	SOF	T030	C0459562
27500005	1339	1341	FR	T030	C0222687
27500005	1351	1365	cranial nerves	T023	C0010268
27500005	1383	1405	technical modification	T061	C1299575
27500005	1409	1412	ETA	T061	C0543467
27500005	1436	1454	surgical treatment	T061	C0543467
27500005	1458	1477	paraclinoid lesions	T033	C0221198
27500005	1481	1487	reduce	T081	C0547047
27500005	1492	1496	risk	T078	C0035647
27500005	1500	1514	intraoperative	T079	C0456904
27500005	1515	1535	neurovascular injury	T037	C1997626

27273307|t|Pathophysiology, treatment and prevention of ovarian hyperstimulation syndrome
27273307|a|Severe ovarian hyperstimulation syndrome (OHSS) is an iatrogenic condition that affects 1% of women that undergo treatment with assisted reproductive technology. The review aims to summarize recent evidence on pathophysiology, treatment, and prevention of OHSS. The pathophysiology is still not completely understood; however, vascular endothelial growth factor is likely to be an important mediator. Human chorionic gonadotropin was previously thought to be necessary for OHSS to occur; however, recent case reports have proven otherwise. The contribution of an attenuated anti-Mullerian hormone signalling pathway and CD11c + HLA-DR + dendritic cells and associated interleukins has been explored recently as contributors to pathogenesis. Treatment is largely supportive and is based mainly on consensus statements rather than evidence. Therefore, it is important to prevent this condition by identifying women at risk, allowing the clinician to implement preventive strategies, including the use of GnRH antagonist cycles with agonist triggers. More research is required to elucidate the pathophysiology behind the condition. Clinicians should employ strategies to prevent OHSS.
27273307	0	15	Pathophysiology	T169	C0031847
27273307	17	26	treatment	T061	C0087111
27273307	31	41	prevention	T061	C0199176
27273307	45	78	ovarian hyperstimulation syndrome	T047	C0085083
27273307	79	85	Severe	T080	C0205082
27273307	86	119	ovarian hyperstimulation syndrome	T047	C0085083
27273307	121	125	OHSS	T047	C0085083
27273307	133	143	iatrogenic	T080	C0439669
27273307	144	153	condition	T080	C0348080
27273307	159	166	affects	T077	C4054723
27273307	173	178	women	T098	C0043210
27273307	192	201	treatment	T061	C0087111
27273307	207	239	assisted reproductive technology	T061	C0872104
27273307	245	251	review	T170	C0282443
27273307	252	256	aims	T078	C1947946
27273307	260	269	summarize	T170	C1706244
27273307	270	276	recent	T079	C0332185
27273307	277	285	evidence	T078	C3887511
27273307	289	304	pathophysiology	T169	C0031847
27273307	306	315	treatment	T061	C0087111
27273307	321	331	prevention	T061	C0199176
27273307	335	339	OHSS	T047	C0085083
27273307	345	360	pathophysiology	T169	C0031847
27273307	374	384	completely	T080	C0205197
27273307	385	395	understood	T041	C0162340
27273307	406	440	vascular endothelial growth factor	T116,T123	C0078058
27273307	460	469	important	T080	C3898777
27273307	480	508	Human chorionic gonadotropin	T116,T121,T125	C1141639
27273307	524	531	thought	T041	C0039869
27273307	552	556	OHSS	T047	C0085083
27273307	560	565	occur	T052	C1709305
27273307	576	595	recent case reports	T170	C0007320
27273307	601	607	proven	T080	C0456369
27273307	623	635	contribution	T052	C1880177
27273307	642	652	attenuated	T052	C0599946
27273307	653	675	anti-Mullerian hormone	T116,T121,T125	C0066928
27273307	676	694	signalling pathway	T043	C0037083
27273307	699	704	CD11c	T116,T129,T192	C0023395
27273307	707	713	HLA-DR	T116,T129	C0019764
27273307	716	731	dendritic cells	T025	C0011306
27273307	736	746	associated	T080	C0332281
27273307	747	759	interleukins	T116,T129	C0021764
27273307	778	786	recently	T079	C0332185
27273307	790	802	contributors	T052	C1880177
27273307	806	818	pathogenesis	T046	C0699748
27273307	820	829	Treatment	T061	C0087111
27273307	841	851	supportive	T061	C0344211
27273307	859	864	based	T078	C1705938
27273307	875	884	consensus	T054	C0376298
27273307	885	895	statements	T078	C1710187
27273307	908	916	evidence	T078	C3887511
27273307	935	944	important	T080	C3898777
27273307	948	955	prevent	T169	C1292733
27273307	961	970	condition	T080	C0348080
27273307	974	985	identifying	T058	C1269815
27273307	986	991	women	T098	C0043210
27273307	992	999	at risk	T080	C1444641
27273307	1001	1009	allowing	T054	C0683607
27273307	1014	1023	clinician	T097	C0871685
27273307	1027	1036	implement	T052	C1708476
27273307	1037	1058	preventive strategies	T170	C0679716
27273307	1060	1069	including	T169	C0332257
27273307	1081	1096	GnRH antagonist	T121,T125	C1268855
27273307	1097	1103	cycles	T079	C0001289
27273307	1109	1116	agonist	T121	C2987634
27273307	1132	1140	research	T062	C0035168
27273307	1144	1152	required	T169	C1514873
27273307	1170	1185	pathophysiology	T169	C0031847
27273307	1197	1206	condition	T080	C0348080
27273307	1208	1218	Clinicians	T097	C0871685
27273307	1226	1232	employ	T169	C0457083
27273307	1233	1243	strategies	T041	C0679199
27273307	1247	1254	prevent	T061	C0679698
27273307	1255	1259	OHSS	T047	C0085083

28533317|t|Cardiovascular Toxicity of Illicit Anabolic-Androgenic Steroid Use
28533317|a|Millions of individuals have used illicit anabolic-androgenic steroids (AAS), but the long-term cardiovascular associations of these drugs remain incompletely understood. Using a cross-sectional cohort design, we recruited 140 experienced male weightlifters 34 to 54 years of age, comprising 86 men reporting ≥2 years of cumulative lifetime AAS use and 54 nonusing men. Using transthoracic echocardiography and coronary computed tomography angiography, we assessed 3 primary outcome measures: left ventricular (LV) systolic function (left ventricular ejection fraction), LV diastolic function (early relaxation velocity), and coronary atherosclerosis (coronary artery plaque volume). Compared with nonusers, AAS users demonstrated relatively reduced LV systolic function (mean ± SD left ventricular ejection fraction = 52±11% versus 63±8%; P<0.001) and diastolic function (early relaxation velocity = 9.3±2.4 cm/second versus 11.1±2.0 cm/second; P<0.001). Users currently taking AAS at the time of evaluation (N=58) showed significantly reduced LV systolic (left ventricular ejection fraction = 49±10% versus 58±10%; P<0.001) and diastolic function (early relaxation velocity = 8.9±2.4 cm/second versus 10.1±2.4 cm/second; P=0.035) compared with users currently off - drug (N=28). In addition, AAS users demonstrated higher coronary artery plaque volume than nonusers (median [interquartile range] 3 [0, 174] mL(3) versus 0 [0, 69] mL(3); P=0.012). Lifetime AAS dose was strongly associated with coronary atherosclerotic burden (increase [95% confidence interval] in rank of plaque volume for each 10- year increase in cumulative duration of AAS use: 0.60 SD units [0.16-1.03 SD units]; P=0.008). Long-term AAS use appears to be associated with myocardial dysfunction and accelerated coronary atherosclerosis. These forms of AAS - associated adverse cardiovascular phenotypes may represent a previously underrecognized public-health problem.
28533317	0	14	Cardiovascular	T029	C3887460
28533317	15	23	Toxicity	T037	C0600688
28533317	27	34	Illicit	T169	C0332266
28533317	35	62	Anabolic-Androgenic Steroid	T109	C0038317
28533317	63	66	Use	T169	C0457083
28533317	67	75	Millions	T081	C1881839
28533317	79	90	individuals	T098	C0237401
28533317	101	108	illicit	T169	C0332266
28533317	109	137	anabolic-androgenic steroids	T109	C0038317
28533317	139	142	AAS	T109	C0038317
28533317	153	162	long-term	T079	C0443252
28533317	163	177	cardiovascular	T029	C3887460
28533317	178	190	associations	T080	C0439849
28533317	200	205	drugs	T121	C1254351
28533317	213	225	incompletely	T080	C0205257
28533317	226	236	understood	T041	C0162340
28533317	246	275	cross-sectional cohort design	T062	C0035171
28533317	280	289	recruited	T052	C2949735
28533317	294	305	experienced	T041	C0596545
28533317	306	324	male weightlifters	T098	C0025266
28533317	334	346	years of age	T079	C1510829
28533317	348	358	comprising	T052	C2700400
28533317	362	365	men	T098	C0025266
28533317	366	375	reporting	T058	C0700287
28533317	376	384	≥2 years	T033	C3843647
28533317	388	398	cumulative	T080	C1511559
28533317	399	407	lifetime	T079	C4071830
28533317	408	411	AAS	T109	C0038317
28533317	412	415	use	T169	C0457083
28533317	423	431	nonusing	T169	C0205245
28533317	432	435	men	T098	C0025266
28533317	443	473	transthoracic echocardiography	T060	C0430462
28533317	478	518	coronary computed tomography angiography	T060	C1634617
28533317	523	531	assessed	T052	C1516048
28533317	534	558	primary outcome measures	T080	C3274433
28533317	560	599	left ventricular (LV) systolic function	T042	C0080310
28533317	601	635	left ventricular ejection fraction	T201	C0428772
28533317	638	659	LV diastolic function	T042	C0080310
28533317	661	666	early	T079	C1279919
28533317	667	677	relaxation	T052	C0035028
28533317	678	686	velocity	T081	C0439830
28533317	693	717	coronary atherosclerosis	T047	C0010054
28533317	719	734	coronary artery	T023	C0205042
28533317	735	741	plaque	T033	C0332461
28533317	742	748	volume	T081	C0449468
28533317	751	759	Compared	T052	C1707455
28533317	765	773	nonusers	T098	C1257890
28533317	775	778	AAS	T109	C0038317
28533317	779	784	users	T101	C0338666
28533317	798	808	relatively	T080	C0205345
28533317	809	816	reduced	T080	C0392756
28533317	817	837	LV systolic function	T042	C0080310
28533317	839	843	mean	T081	C0444504
28533317	846	848	SD	T081	C0871420
28533317	849	883	left ventricular ejection fraction	T201	C0428772
28533317	920	938	diastolic function	T042	C0080310
28533317	940	945	early	T079	C1279919
28533317	946	956	relaxation	T052	C0035028
28533317	957	965	velocity	T081	C0439830
28533317	976	985	cm/second	T081	C0439392
28533317	1002	1011	cm/second	T081	C0439392
28533317	1023	1028	Users	T101	C0338666
28533317	1029	1038	currently	T079	C0521116
28533317	1039	1045	taking	T058	C1515187
28533317	1046	1049	AAS	T109	C0038317
28533317	1065	1075	evaluation	T052	C1516048
28533317	1090	1111	significantly reduced	T081	C4055638
28533317	1112	1123	LV systolic	T042	C0080310
28533317	1125	1159	left ventricular ejection fraction	T201	C0428772
28533317	1197	1215	diastolic function	T042	C0080310
28533317	1217	1222	early	T079	C1279919
28533317	1223	1233	relaxation	T052	C0035028
28533317	1234	1242	velocity	T081	C0439830
28533317	1253	1262	cm/second	T081	C0439392
28533317	1279	1288	cm/second	T081	C0439392
28533317	1299	1307	compared	T052	C1707455
28533317	1313	1318	users	T101	C0338666
28533317	1319	1328	currently	T079	C0521116
28533317	1329	1332	off	T080	C1518543
28533317	1335	1339	drug	T121	C1254351
28533317	1348	1359	In addition	T169	C0332287
28533317	1361	1364	AAS	T109	C0038317
28533317	1365	1370	users	T101	C0338666
28533317	1384	1390	higher	T080	C0205250
28533317	1391	1406	coronary artery	T023	C0205042
28533317	1407	1413	plaque	T033	C0332461
28533317	1414	1420	volume	T081	C0449468
28533317	1426	1434	nonusers	T098	C1257890
28533317	1436	1442	median	T081	C0876920
28533317	1444	1463	interquartile range	T081	C1711350
28533317	1516	1524	Lifetime	T079	C4071830
28533317	1525	1528	AAS	T109	C0038317
28533317	1529	1533	dose	T081	C0178602
28533317	1538	1562	strongly associated with	T080	C0332281
28533317	1563	1587	coronary atherosclerotic	T047	C0010054
28533317	1588	1594	burden	T078	C2828008
28533317	1596	1604	increase	T169	C0442805
28533317	1610	1629	confidence interval	T081	C0009667
28533317	1642	1648	plaque	T033	C0332461
28533317	1649	1655	volume	T081	C0449468
28533317	1660	1664	each	T081	C1457900
28533317	1669	1673	year	T079	C0439234
28533317	1674	1682	increase	T169	C0442805
28533317	1686	1696	cumulative	T080	C1511559
28533317	1697	1705	duration	T079	C0449238
28533317	1709	1712	AAS	T109	C0038317
28533317	1713	1716	use	T169	C0457083
28533317	1723	1725	SD	T081	C0871420
28533317	1726	1731	units	T081	C1519795
28533317	1743	1745	SD	T081	C0871420
28533317	1746	1751	units	T081	C1519795
28533317	1764	1773	Long-term	T079	C0443252
28533317	1774	1777	AAS	T109	C0038317
28533317	1778	1781	use	T169	C0457083
28533317	1796	1811	associated with	T080	C0332281
28533317	1812	1834	myocardial dysfunction	T046	C0340515
28533317	1839	1850	accelerated	T169	C0521110
28533317	1851	1875	coronary atherosclerosis	T047	C0010054
28533317	1883	1888	forms	T080	C0348078
28533317	1892	1895	AAS	T109	C0038317
28533317	1898	1908	associated	T080	C0332281
28533317	1909	1916	adverse	T046	C0879626
28533317	1917	1931	cardiovascular	T029	C3887460
28533317	1932	1942	phenotypes	T032	C0031437
28533317	1947	1956	represent	T052	C1882932
28533317	1959	1969	previously	T079	C0205156
28533317	1986	2007	public-health problem	T033	C1398682

28373991|t|Semianalytical Solution for the Deformation of an Elastic Layer under an Axisymmetrically Distributed Power-Form Load: Application to Fluid-Jet-Induced Indentation of Biological Soft Tissues
28373991|a|Fluid-jet-based indentation is used as a noncontact excitation technique by systems measuring the mechanical properties of soft tissues. However, the application of these devices has been hindered by the lack of theoretical solutions. This study developed a mathematical model for testing the indentation induced by a fluid jet and determined a semianalytical solution. The soft tissue was modeled as an elastic layer bonded to a rigid base. The pressure of the fluid jet impinging on the soft tissue was assumed to have a power-form function. The semianalytical solution was verified in detail using finite-element modeling, with excellent agreement being achieved. The effects of several parameters on the solution behaviors are reported, and a method for applying the solution to determine the mechanical properties of soft tissues is suggested.
28373991	0	23	Semianalytical Solution	T033	C0243095
28373991	32	43	Deformation	T169	C0205245
28373991	50	63	Elastic Layer	T077	C1254372
28373991	73	89	Axisymmetrically	T082	C1254362
28373991	90	101	Distributed	T169	C1704711
28373991	102	117	Power-Form Load	T081	C0392762
28373991	119	130	Application	T169	C0205245
28373991	134	163	Fluid-Jet-Induced Indentation	T059	C0022885
28373991	167	177	Biological	T080	C0205460
28373991	178	190	Soft Tissues	T024	C0225317
28373991	191	218	Fluid-jet-based indentation	T059	C0022885
28373991	232	263	noncontact excitation technique	T169	C0449851
28373991	267	274	systems	T169	C0449913
28373991	275	284	measuring	T080	C0444706
28373991	289	310	mechanical properties	T080	C0871161
28373991	314	326	soft tissues	T024	C0225317
28373991	341	352	application	T169	C0205245
28373991	362	369	devices	T074	C0025080
28373991	395	399	lack	T080	C0332268
28373991	403	424	theoretical solutions	T170	C0282574
28373991	431	436	study	T062	C2603343
28373991	449	467	mathematical model	T170	C0876936
28373991	472	479	testing	T169	C0039593
28373991	484	495	indentation	T059	C0022885
28373991	496	503	induced	T169	C0205263
28373991	509	518	fluid jet	T167	C1704353
28373991	536	559	semianalytical solution	T033	C0243095
28373991	565	576	soft tissue	T024	C0225317
28373991	581	588	modeled	T062	C0870071
28373991	595	608	elastic layer	T077	C1254372
28373991	609	615	bonded	T169	C0205245
28373991	621	631	rigid base	T167	C3891814
28373991	637	645	pressure	T081	C4284008
28373991	653	662	fluid jet	T167	C1704353
28373991	663	672	impinging	T169	C0205245
28373991	680	691	soft tissue	T024	C0225317
28373991	714	733	power-form function	T169	C0542341
28373991	739	762	semianalytical solution	T033	C0243095
28373991	767	775	verified	T169	C1711411
28373991	792	815	finite-element modeling	T062	C0870071
28373991	862	872	effects of	T080	C1704420
28373991	873	880	several	T081	C0443302
28373991	881	891	parameters	T033	C0449381
28373991	899	917	solution behaviors	T033	C0243095
28373991	938	944	method	T169	C0449851
28373991	949	957	applying	T169	C1632850
28373991	962	970	solution	T033	C0243095
28373991	988	1009	mechanical properties	T080	C0871161
28373991	1013	1025	soft tissues	T024	C0225317

27875815|t|Wang's Forceps -Assisted Catheter Reposition and Fixation: An Easy and Reliable Rescue Method
27875815|a|Catheter migration and omental wrap are the most common causes of catheter malfunction, which usually result in catheter removal or replacement. The conventional open surgery for catheter reposition has many disadvantages. A new tunnel is needed throughout the procedure of catheter replacement causing more pain and frustration to the patients. Another drawback is that the incidence of catheter migration after conventional catheter reposition surgery is still as high as it was before the procedure. Wang's forceps, an instrument commonly used in our peritoneal dialysis center, is easy and effective in catheter insertion and fixation. Recently, we have successfully used the Wang's forceps to resolve the catheter displacement for 10 patients, including 1 patient who suffered from catheter tip migration 3 times and had undergone conventional catheter rescue by both open surgery and laparoscopy. This new technique was easy and reliable, and the original tunnel was maintained, which reduced pain and risk of infection in the patients. These advantages may grant the Wang's forceps technique favorable over the conventional surgical approach.
27875815	0	14	Wang's Forceps	T074	C0016533
27875815	25	44	Catheter Reposition	T061	C2053856
27875815	49	57	Fixation	T061	C1301628
27875815	80	93	Rescue Method	T061	C0842343
27875815	94	112	Catheter migration	T046	C0403577
27875815	117	129	omental wrap	T061	C0450185
27875815	160	180	catheter malfunction	T046	C1397894
27875815	206	222	catheter removal	T061	C0204835
27875815	226	237	replacement	T061	C2053855
27875815	243	255	conventional	T080	C0439858
27875815	256	268	open surgery	T061	C4283938
27875815	273	292	catheter reposition	T061	C2053856
27875815	323	329	tunnel	T074	C0025080
27875815	368	388	catheter replacement	T061	C0522774
27875815	402	406	pain	T184	C0030193
27875815	411	422	frustration	T041	C0016770
27875815	430	438	patients	T101	C0030705
27875815	469	478	incidence	T169	C0220856
27875815	482	500	catheter migration	T046	C0403577
27875815	507	519	conventional	T080	C0439858
27875815	520	547	catheter reposition surgery	T061	C2053856
27875815	597	611	Wang's forceps	T074	C0016533
27875815	616	626	instrument	T074	C0348000
27875815	648	658	peritoneal	T029	C0442034
27875815	659	674	dialysis center	T093	C1707735
27875815	688	697	effective	T080	C1704419
27875815	701	732	catheter insertion and fixation	T061	C0842343
27875815	774	788	Wang's forceps	T074	C0016533
27875815	804	825	catheter displacement	T046	C3649352
27875815	833	841	patients	T101	C0030705
27875815	855	862	patient	T101	C0030705
27875815	881	893	catheter tip	T074	C0444304
27875815	894	903	migration	T169	C0232902
27875815	930	942	conventional	T080	C0439858
27875815	943	958	catheter rescue	T061	C0842343
27875815	967	979	open surgery	T061	C4283938
27875815	984	995	laparoscopy	T061	C1883297
27875815	1006	1015	technique	T169	C0449851
27875815	1047	1055	original	T078	C0205313
27875815	1056	1062	tunnel	T074	C0025080
27875815	1085	1097	reduced pain	T033	C2712015
27875815	1102	1106	risk	T081	C3538919
27875815	1110	1119	infection	T046	C3714514
27875815	1127	1135	patients	T101	C0030705
27875815	1168	1182	Wang's forceps	T074	C0016533
27875815	1183	1192	technique	T169	C0449851
27875815	1193	1202	favorable	T080	C3640814
27875815	1212	1224	conventional	T080	C0439858
27875815	1225	1242	surgical approach	T169	C0449446

28183596|t|A numerical study on the application of the functionally graded materials in the stent design
28183596|a|Undesirable deformation of the stent can induce a significant amount of injure not only to the blood vessel but also to the plaque. The objective of this study was to reduce/minimize these undesirable deformations by the application of Functionally Graded Materials (FGM). To do this, Finite Element (FE) method was employed to simulate the expansion of a stent and the corresponding displacement of the stenosis plaque. Three hyperelastic plaque types as well as five elastoplastic stents were simulated. Dogboning, foreshortening, maximum stress in the plaque, and the pressure which is needed to fully expand the stent for different stent materials, were acquired. While all FGMs had lower dogboning in comparison to the stents made of the uniform materials, the stent with the lowest heterogeneous index displayed the lowest amount of dogboning. Steel stent showed the lowest foreshortening and fully expansion pressure but the difference was much lower than that the one for dogboning. Therefore, the FGM with the heterogeneous index of 0.5 is expected to exhibit the most suitable results. In addition, the results revealed that the material parameters has crucial effects on the deformation of the stent and, as a result, as a design point of view the FGM parameters can be tailored to achieve the goal of the biomechanical optimization.
28183596	2	11	numerical	T081	C0237753
28183596	12	17	study	T062	C2603343
28183596	44	73	functionally graded materials	T073	C3273359
28183596	81	86	stent	T074	C0038257
28183596	87	93	design	T052	C1707689
28183596	94	105	Undesirable	T080	C1883420
28183596	106	117	deformation	T080	C2919017
28183596	125	130	stent	T074	C0038257
28183596	144	155	significant	T037	C0178324
28183596	166	172	injure	T037	C3263723
28183596	189	201	blood vessel	T023	C0005847
28183596	218	224	plaque	T033	C0332461
28183596	261	276	reduce/minimize	T033	C0243095
28183596	283	294	undesirable	T080	C1883420
28183596	295	307	deformations	T080	C2919017
28183596	330	359	Functionally Graded Materials	T073	C3273359
28183596	361	364	FGM	T073	C3273359
28183596	379	405	Finite Element (FE) method	T170	C3826344
28183596	410	418	employed	T033	C0557351
28183596	422	430	simulate	T062	C0679083
28183596	435	444	expansion	T169	C0442805
28183596	450	455	stent	T074	C0038257
28183596	478	490	displacement	T067	C2347509
28183596	498	506	stenosis	T046	C1261287
28183596	507	513	plaque	T033	C0332461
28183596	521	533	hyperelastic	T073	C0450146
28183596	534	540	plaque	T033	C0332461
28183596	563	583	elastoplastic stents	T074	C0441289
28183596	600	609	Dogboning	T169	C0001688
28183596	611	625	foreshortening	T033	C0243095
28183596	627	634	maximum	T081	C0806909
28183596	635	641	stress	T033	C0038435
28183596	649	655	plaque	T033	C0332461
28183596	665	673	pressure	T067	C0033095
28183596	699	705	expand	T082	C0205229
28183596	710	715	stent	T074	C0038257
28183596	730	735	stent	T074	C0038257
28183596	736	745	materials	T167	C0520510
28183596	772	776	FGMs	T073	C3273359
28183596	781	786	lower	T080	C0547044
28183596	787	796	dogboning	T169	C0001688
28183596	818	824	stents	T074	C0038257
28183596	837	844	uniform	T080	C0205375
28183596	845	854	materials	T167	C0520510
28183596	860	865	stent	T074	C0038257
28183596	875	881	lowest	T080	C1708760
28183596	882	901	heterogeneous index	T170	C0918012
28183596	916	922	lowest	T080	C1708760
28183596	933	942	dogboning	T169	C0001688
28183596	944	949	Steel	T122,T197	C0038239
28183596	950	955	stent	T074	C0038257
28183596	967	973	lowest	T080	C1708760
28183596	974	988	foreshortening	T033	C0243095
28183596	999	1017	expansion pressure	T081	C4049814
28183596	1026	1036	difference	T081	C1705241
28183596	1046	1051	lower	T080	C0547044
28183596	1074	1083	dogboning	T169	C0001688
28183596	1100	1103	FGM	T073	C3273359
28183596	1113	1132	heterogeneous index	T170	C0918012
28183596	1172	1180	suitable	T080	C3900053
28183596	1181	1188	results	T169	C1274040
28183596	1207	1214	results	T169	C1274040
28183596	1233	1241	material	T167	C0520510
28183596	1242	1252	parameters	T077	C0549193
28183596	1257	1264	crucial	T080	C1511545
28183596	1265	1272	effects	T080	C1280500
28183596	1280	1291	deformation	T080	C2919017
28183596	1299	1304	stent	T074	C0038257
28183596	1315	1321	result	T169	C1274040
28183596	1328	1334	design	T052	C1707689
28183596	1353	1356	FGM	T073	C3273359
28183596	1357	1367	parameters	T077	C0549193
28183596	1411	1424	biomechanical	T081	C0009563
28183596	1425	1437	optimization	T052	C2698650

27585843|t|Radiation risk of breast screening in England with digital mammography
27585843|a|To estimate the risks and benefits of breast screening in terms of number of deaths due to radiation-induced cancers and the number of lives saved owing to modern screening in the National Health Service Breast Screening Programme (NHSBSP) in England. Radiation risk model, patient dose data and data from national screening statistics were used to estimate the number of deaths due to radiation-induced breast cancers in the NHSBSP in England. Dose and dose effectiveness factors (DDREFs) equal to one and two were assumed. The breast cancer mortality reduction in the invited population due to screening and the percentage of females diagnosed with symptomatic breast cancer, who die from breast cancer, were collated from the literature. The number of lives saved owing to screening was calculated. Assuming, a total of 1,770,436 females between the ages of 50-70 years were screened each year, and a breast cancer mortality reduction of 20% due to screening in the invited population, the number of screen-detected cancers were 14,872 annually, resulting in 1071 lives saved. Conversely, for the same mortality reduction, the number of radiation-induced cancer s was 36 and 18 for DDREFs of 1 and 2, respectively. This resulted in seven and three deaths due to radiation-induced cancers annually for DDREFs of 1 and 2, respectively. The ratios of lives saved owing to screening to radiation-induced cancers were 30: 1 and 60: 1 for DDREFs of 1 and 2. The ratios of lives saved owing to screening to deaths due to radiation-induced cancer s were 156: 1 and 312: 1 for DDREFs of 1 and 2. For the 1.8% of the screening population with very thick breasts, the latter ratios decrease to 94: 1 and 187: 1 for DDREFs of 1 and 2. The breast cancer mortality reduction due to screening greatly outweighs the risk of death due to radiation-induced cancer s. Advances in knowledge: Estimation of the radiation risk for modern breast screening in England using digital mammography.
27585843	0	9	Radiation	T037	C0015333
27585843	10	14	risk	T058	C0086930
27585843	18	34	breast screening	T061	C0281182
27585843	38	45	England	T083	C0014282
27585843	51	70	digital mammography	T060	C0860950
27585843	74	82	estimate	T081	C0750572
27585843	87	92	risks	T058	C0086930
27585843	97	105	benefits	T081	C0814225
27585843	109	125	breast screening	T061	C0281182
27585843	138	154	number of deaths	T033	C0243095
27585843	155	161	due to	T169	C0678226
27585843	162	187	radiation-induced cancers	T191	C0751366
27585843	196	211	number of lives	T033	C0243095
27585843	227	243	modern screening	T058	C1710032
27585843	251	301	National Health Service Breast Screening Programme	T058	C1254363
27585843	303	309	NHSBSP	T058	C1254363
27585843	314	321	England	T083	C0014282
27585843	323	332	Radiation	T037	C0015333
27585843	333	343	risk model	T170	C1511297
27585843	338	343	model	T170	C0282574
27585843	345	362	patient dose data	T170	C0282574
27585843	367	406	data from national screening statistics	T170	C0282574
27585843	420	428	estimate	T081	C0750572
27585843	433	449	number of deaths	T033	C0243095
27585843	450	456	due to	T169	C0678226
27585843	457	489	radiation-induced breast cancers	T191	C0751366
27585843	497	503	NHSBSP	T058	C1254363
27585843	507	514	England	T083	C0014282
27585843	516	551	Dose and dose effectiveness factors	T061	C2169146
27585843	553	559	DDREFs	T061	C2169146
27585843	561	566	equal	T080	C0205163
27585843	587	594	assumed	T170	C3242379
27585843	600	613	breast cancer	T191	C0006142
27585843	614	633	mortality reduction	T081	C0282251
27585843	641	659	invited population	T098	C1257890
27585843	660	666	due to	T169	C0678226
27585843	667	676	screening	T058	C1710032
27585843	685	695	percentage	T081	C0439165
27585843	699	706	females	T032	C0086287
27585843	707	716	diagnosed	T033	C0011900
27585843	722	733	symptomatic	T169	C0231220
27585843	734	747	breast cancer	T191	C0006142
27585843	762	775	breast cancer	T191	C0006142
27585843	800	810	literature	T170	C0023866
27585843	816	831	number of lives	T033	C0243095
27585843	847	856	screening	T058	C1710032
27585843	861	871	calculated	T052	C1441506
27585843	904	911	females	T032	C0086287
27585843	924	943	ages of 50-70 years	T033	C1860866
27585843	949	957	screened	T058	C1254363
27585843	975	988	breast cancer	T191	C0006142
27585843	989	1008	mortality reduction	T081	C0282251
27585843	1023	1032	screening	T058	C1710032
27585843	1040	1058	invited population	T098	C1257890
27585843	1064	1097	number of screen-detected cancers	T033	C0243095
27585843	1120	1132	resulting in	T169	C0332294
27585843	1138	1149	lives saved	T033	C0243095
27585843	1176	1195	mortality reduction	T081	C0282251
27585843	1201	1237	number of radiation-induced cancer s	T033	C0243095
27585843	1211	1235	radiation-induced cancer	T191	C0751366
27585843	1211	1237	radiation-induced cancer s	T191	C0751366
27585843	1256	1262	DDREFs	T061	C2169146
27585843	1306	1311	seven	T081	C0392762
27585843	1316	1328	three deaths	T081	C0392762
27585843	1336	1361	radiation-induced cancers	T191	C0751366
27585843	1362	1370	annually	T079	C0332181
27585843	1375	1381	DDREFs	T061	C2169146
27585843	1412	1418	ratios	T081	C0456603
27585843	1443	1452	screening	T058	C1710032
27585843	1456	1481	radiation-induced cancers	T191	C0751366
27585843	1507	1513	DDREFs	T061	C2169146
27585843	1588	1612	radiation-induced cancer	T191	C0751366
27585843	1642	1648	DDREFs	T061	C2169146
27585843	1681	1701	screening population	T033	C1822510
27585843	1712	1717	thick	T080	C1280412
27585843	1718	1725	breasts	T023	C0006141
27585843	1738	1744	ratios	T081	C0456603
27585843	1745	1753	decrease	T081	C0547047
27585843	1778	1784	DDREFs	T061	C2169146
27585843	1801	1814	breast cancer	T191	C0006142
27585843	1815	1834	mortality reduction	T081	C0282251
27585843	1835	1841	due to	T169	C0678226
27585843	1842	1851	screening	T058	C1710032
27585843	1852	1869	greatly outweighs	T033	C3840786
27585843	1874	1887	risk of death	T033	C0243095
27585843	1888	1894	due to	T169	C0678226
27585843	1895	1919	radiation-induced cancer	T191	C0751366
27585843	1946	1956	Estimation	T081	C0750572
27585843	1964	1973	radiation	T037	C0015333
27585843	1974	1978	risk	T058	C0086930
27585843	1983	2006	modern breast screening	T061	C0281182
27585843	2010	2017	England	T083	C0014282
27585843	2024	2043	digital mammography	T060	C0860950

27827387|t|DNA sequence diversity and the efficiency of natural selection in animal mitochondrial DNA
27827387|a|Selection is expected to be more efficient in species that are more diverse because both the efficiency of natural selection and DNA sequence diversity are expected to depend upon the effective population size. We explore this relationship across a data set of 751 mammal species for which we have mitochondrial polymorphism data. We introduce a method by which we can examine the relationship between our measure of the efficiency of natural selection, the nonsynonymous relative to the synonymous nucleotide site diversity (πN / πS), and synonymous nucleotide diversity (πS), avoiding the statistical non-independence between the two quantities. We show that these two variables are strongly negatively and linearly correlated on a log scale. The slope is such that as πS doubles, πN / πS is reduced by 34%. We show that the slope of this relationship differs between the two phylogenetic groups for which we have the most data, rodents and bats, and that it also differs between species with high and low body mass, and between those with high and low mass -specific metabolic rate.
27827387	0	12	DNA sequence	T086	C0162326
27827387	13	22	diversity	T080	C1880371
27827387	31	41	efficiency	T081	C0013682
27827387	45	62	natural selection	T070	C0086685
27827387	66	72	animal	T008	C0003062
27827387	73	90	mitochondrial DNA	T114,T123	C0012929
27827387	91	100	Selection	T070	C0086685
27827387	137	144	species	T185	C1705920
27827387	159	166	diverse	T080	C1880371
27827387	184	194	efficiency	T081	C0013682
27827387	198	215	natural selection	T070	C0086685
27827387	220	232	DNA sequence	T086	C0162326
27827387	233	242	diversity	T080	C1880371
27827387	285	300	population size	T081	C0032683
27827387	340	348	data set	T170	C0150098
27827387	356	362	mammal	T015	C0024660
27827387	363	370	species	T185	C1705920
27827387	389	402	mitochondrial	T026	C0026237
27827387	403	415	polymorphism	T045	C0032529
27827387	416	420	data	T078	C1511726
27827387	437	443	method	T170	C0025663
27827387	512	522	efficiency	T081	C0013682
27827387	526	543	natural selection	T070	C0086685
27827387	549	562	nonsynonymous	T086	C1709259
27827387	579	615	synonymous nucleotide site diversity	T086	C1710267
27827387	617	619	πN	T086	C1709259
27827387	622	624	πS	T086	C1710267
27827387	631	662	synonymous nucleotide diversity	T086	C1710267
27827387	664	666	πS	T086	C1710267
27827387	682	693	statistical	T081	C0237751
27827387	727	737	quantities	T081	C1265611
27827387	762	771	variables	T080	C0439828
27827387	825	834	log scale	T081	C2986775
27827387	840	845	slope	T081	C0807955
27827387	862	872	πS doubles	T086	C1710267
27827387	874	876	πN	T086	C1709259
27827387	879	881	πS	T086	C1710267
27827387	918	923	slope	T081	C0807955
27827387	969	981	phylogenetic	T080	C1519069
27827387	982	988	groups	T078	C0441833
27827387	1016	1020	data	T078	C1511726
27827387	1022	1029	rodents	T015	C0035804
27827387	1034	1038	bats	T015	C0008139
27827387	1073	1080	species	T185	C1705920
27827387	1086	1090	high	T080	C0205250
27827387	1095	1098	low	T080	C0205251
27827387	1099	1108	body mass	T033	C0518010
27827387	1133	1137	high	T080	C0205250
27827387	1142	1145	low	T080	C0205251
27827387	1146	1150	mass	T033	C0518010
27827387	1161	1175	metabolic rate	T039	C0870882

28525754|t|Regulated Intron Removal Integrates Motivational State and Experience
28525754|a|Myriad experiences produce transient memory, yet, contingent on the internal state of the organism and the saliency of the experience, only some memories persist over time. How experience and internal state influence the duration of memory at the molecular level remains unknown. A self-assembled aggregated state of Drosophila Orb2A protein is required specifically for long-lasting memory. We report that in the adult fly brain the mRNA encoding Orb2A protein exists in an unspliced non-protein-coding form. The convergence of experience and internal drive transiently increases the spliced protein-coding Orb2A mRNA. A screen identified pasilla, the fly ortholog of mammalian Nova-1 / 2, as a mediator of Orb2A mRNA processing. A single-nucleotide substitution in the intronic region that reduces Pasilla binding and intron removal selectively impairs long-term memory. We posit that pasilla -mediated processing of unspliced Orb2A mRNA integrates experience and internal state to control Orb2A protein abundance and long-term memory formation.
28525754	0	9	Regulated	T045	C0017263
28525754	10	16	Intron	T114,T123	C0021920
28525754	17	24	Removal	T052	C1883720
28525754	36	54	Motivational State	T041	C3825945
28525754	59	69	Experience	T041	C0596545
28525754	77	88	experiences	T041	C0596545
28525754	97	113	transient memory	T041	C0025265
28525754	138	152	internal state	T041	C0025361
28525754	160	168	organism	T001	C0029235
28525754	193	203	experience	T041	C0596545
28525754	215	223	memories	T041	C0025260
28525754	237	241	time	T079	C0040223
28525754	247	257	experience	T041	C0596545
28525754	262	276	internal state	T041	C0025361
28525754	277	286	influence	T077	C4054723
28525754	291	299	duration	T079	C0449238
28525754	303	309	memory	T041	C0025260
28525754	352	377	self-assembled aggregated	T080	C0205418
28525754	387	411	Drosophila Orb2A protein	T116,T123	C0949989
28525754	441	460	long-lasting memory	T041	C0423909
28525754	484	493	adult fly	T204	C1440070
28525754	494	499	brain	T023	C0006104
28525754	504	508	mRNA	T114,T123	C0035696
28525754	509	517	encoding	T052	C2700640
28525754	518	531	Orb2A protein	T116,T123	C0949989
28525754	545	578	unspliced non-protein-coding form	T114,T123	C0026661
28525754	584	595	convergence	T052	C2700387
28525754	599	609	experience	T041	C0596545
28525754	614	628	internal drive	T041	C0013126
28525754	641	650	increases	T169	C0442805
28525754	655	688	spliced protein-coding Orb2A mRNA	T114,T123	C0035696
28525754	710	717	pasilla	T116,T123	C1100909
28525754	723	726	fly	T204	C1440070
28525754	739	748	mammalian	T015	C0024660
28525754	749	755	Nova-1	T116,T123	C0033684
28525754	758	759	2	T116,T123	C0033684
28525754	766	774	mediator	T116,T123	C1363844
28525754	778	788	Orb2A mRNA	T114,T123	C0035696
28525754	789	799	processing	T045	C0314627
28525754	803	820	single-nucleotide	T114	C0028630
28525754	821	833	substitution	T044	C0596324
28525754	841	849	intronic	T114,T123	C0021920
28525754	862	869	reduces	T080	C0392756
28525754	870	877	Pasilla	T116,T123	C1100909
28525754	878	885	binding	T044	C0033618
28525754	890	896	intron	T114,T123	C0021920
28525754	897	904	removal	T052	C1883720
28525754	917	924	impairs	T169	C0221099
28525754	925	941	long-term memory	T041	C0423909
28525754	957	964	pasilla	T116,T123	C1100909
28525754	975	985	processing	T045	C0314627
28525754	989	1009	unspliced Orb2A mRNA	T114,T123	C0035696
28525754	1021	1031	experience	T041	C0596545
28525754	1036	1050	internal state	T041	C0025361
28525754	1062	1075	Orb2A protein	T116,T123	C0949989
28525754	1076	1085	abundance	T080	C2346714
28525754	1090	1106	long-term memory	T041	C0423909
28525754	1107	1116	formation	T169	C1522492

27430240|t|Adenosine and the adenosine A2A receptor agonist, CGS21680, upregulate CD39 and CD73 expression through E2F-1 and CREB in regulatory T cells isolated from septic mice
27430240|a|The number of regulatory T cells (Treg cells) and the expression of ectonucleoside triphosphate diphosphohydrolase 1 (ENTPD1; also known as CD39) and 5'-ectonucleotidase (NT5E; also known as CD73) on the Treg cell surface are increased during sepsis. In this study, to determine the factors leading to the high expression of CD39 and CD73, and the regulation of the CD39 / CD73 / adenosine pathway in Treg cells under septic conditions, we constructed a mouse model of sepsis and separated the Treg cells using a flow cytometer. The Treg cells isolated from the peritoneal lavage and splenocytes of the mice were treated with adenosine or the specific adenosine A2A receptor agonist, CGS21680, and were transfected with specific siRNA targeting E2F transcription factor 1 (E2F-1) or cyclic adenosine monophosphate (cAMP) response element-binding protein (CREB), which are predicted transcription regulatory factors of CD39 or CD73. The regulatory relationships among these factors were then determined by western blot analysis and dual-luciferase reporter assay. In addition, changes in adenosine metabolism were measured in the treated cells. The results revealed that adenosine and CGS21680 significantly upregulated CD39 and CD73 expression (P<0.01). E2F-1 and CREB induced CD39 and CD73 expression, and were upregulated by adenosine and CGS21680. Adenosine triphosphate (ATP) hydrolysis and adenosine generation were inhibited by the knockdown of E2F-1 or CREB, and were accelerated in the presence of CGS21680. Based on these results, it can be inferred that adenosine, the adenosine A2A receptor agonist, E2F-1 and CREB are the possible factors contributing to the high expression of CD39 and CD73 on the Treg cell surface during sepsis. Adenosine and its A2A receptor agonist served as the signal transducer factors of the CD39 / CD73 / adenosine pathway, accelerating adenosine generation. Our study may benefit further research on adenosine metabolism for the treatment of sepsis.
27430240	0	9	Adenosine	T114,T121,T123	C0001443
27430240	18	48	adenosine A2A receptor agonist	T121	C2936552
27430240	50	58	CGS21680	T109,T121	C0055233
27430240	60	70	upregulate	T044	C0949479
27430240	71	75	CD39	T129	C0108783
27430240	80	84	CD73	T116,T126,T129	C0000530
27430240	85	95	expression	T045	C0597360
27430240	104	109	E2F-1	T116,T123	C1384539
27430240	114	118	CREB	T116,T123	C0056695
27430240	122	140	regulatory T cells	T025	C0039198
27430240	141	149	isolated	T169	C0205409
27430240	155	161	septic	T169	C0333534
27430240	162	166	mice	T015	C0025929
27430240	181	199	regulatory T cells	T025	C0039198
27430240	201	211	Treg cells	T025	C0039198
27430240	221	231	expression	T045	C0597360
27430240	235	283	ectonucleoside triphosphate diphosphohydrolase 1	T129	C0108783
27430240	285	291	ENTPD1	T129	C0108783
27430240	307	311	CD39	T129	C0108783
27430240	317	336	5'-ectonucleotidase	T116,T126,T129	C0000530
27430240	338	342	NT5E	T116,T126,T129	C0000530
27430240	358	362	CD73	T116,T126,T129	C0000530
27430240	371	380	Treg cell	T025	C0039198
27430240	381	388	surface	T082	C0205148
27430240	393	402	increased	T081	C0205217
27430240	410	416	sepsis	T047	C0243026
27430240	450	457	factors	T123	C0005515
27430240	473	477	high	T080	C0205250
27430240	478	488	expression	T045	C0597360
27430240	492	496	CD39	T129	C0108783
27430240	501	505	CD73	T116,T126,T129	C0000530
27430240	515	528	regulation of	T038	C1327622
27430240	533	537	CD39	T129	C0108783
27430240	540	544	CD73	T116,T126,T129	C0000530
27430240	547	556	adenosine	T114,T121,T123	C0001443
27430240	557	564	pathway	T077	C1705987
27430240	568	578	Treg cells	T025	C0039198
27430240	585	591	septic	T169	C0333534
27430240	621	632	mouse model	T050	C2986594
27430240	636	642	sepsis	T047	C0243026
27430240	661	671	Treg cells	T025	C0039198
27430240	680	694	flow cytometer	T074	C0180279
27430240	700	710	Treg cells	T025	C0039198
27430240	711	719	isolated	T169	C0205409
27430240	729	746	peritoneal lavage	T058	C0031148
27430240	751	762	splenocytes	T025	C1519477
27430240	770	774	mice	T015	C0025929
27430240	780	792	treated with	T061	C0332293
27430240	793	802	adenosine	T114,T121,T123	C0001443
27430240	819	849	adenosine A2A receptor agonist	T121	C2936552
27430240	851	859	CGS21680	T109,T121	C0055233
27430240	870	881	transfected	T063	C0040669
27430240	896	901	siRNA	T114,T123	C1099354
27430240	902	911	targeting	T169	C1521840
27430240	912	938	E2F transcription factor 1	T116,T123	C1384539
27430240	940	945	E2F-1	T116,T123	C1384539
27430240	950	1020	cyclic adenosine monophosphate (cAMP) response element-binding protein	T116,T123	C0056695
27430240	1022	1026	CREB	T116,T123	C0056695
27430240	1049	1081	transcription regulatory factors	T116,T123	C0040648
27430240	1085	1089	CD39	T129	C0108783
27430240	1093	1097	CD73	T116,T126,T129	C0000530
27430240	1103	1113	regulatory	T038	C1327622
27430240	1140	1147	factors	T123	C0005515
27430240	1172	1193	western blot analysis	T059	C0949466
27430240	1198	1228	dual-luciferase reporter assay	T059	C0022885
27430240	1243	1250	changes	T169	C0392747
27430240	1254	1274	adenosine metabolism	T044	C1158592
27430240	1296	1303	treated	T169	C1522326
27430240	1304	1309	cells	T025	C0007634
27430240	1337	1346	adenosine	T114,T121,T123	C0001443
27430240	1351	1359	CGS21680	T109,T121	C0055233
27430240	1374	1385	upregulated	T044	C0949479
27430240	1386	1390	CD39	T129	C0108783
27430240	1395	1399	CD73	T116,T126,T129	C0000530
27430240	1400	1410	expression	T045	C0597360
27430240	1421	1426	E2F-1	T116,T123	C1384539
27430240	1431	1435	CREB	T116,T123	C0056695
27430240	1444	1448	CD39	T129	C0108783
27430240	1453	1457	CD73	T116,T126,T129	C0000530
27430240	1458	1468	expression	T045	C0597360
27430240	1479	1490	upregulated	T044	C0949479
27430240	1494	1503	adenosine	T114,T121,T123	C0001443
27430240	1508	1516	CGS21680	T109,T121	C0055233
27430240	1518	1557	Adenosine triphosphate (ATP) hydrolysis	T044	C1510699
27430240	1562	1571	adenosine	T114,T121,T123	C0001443
27430240	1572	1582	generation	T052	C3146294
27430240	1588	1597	inhibited	T052	C3463820
27430240	1605	1614	knockdown	T080	C0849355
27430240	1618	1623	E2F-1	T116,T123	C1384539
27430240	1627	1631	CREB	T116,T123	C0056695
27430240	1642	1653	accelerated	T169	C0521110
27430240	1673	1681	CGS21680	T109,T121	C0055233
27430240	1731	1740	adenosine	T114,T121,T123	C0001443
27430240	1746	1776	adenosine A2A receptor agonist	T121	C2936552
27430240	1778	1783	E2F-1	T116,T123	C1384539
27430240	1788	1792	CREB	T116,T123	C0056695
27430240	1810	1817	factors	T123	C0005515
27430240	1838	1842	high	T080	C0205250
27430240	1843	1853	expression	T045	C0597360
27430240	1857	1861	CD39	T129	C0108783
27430240	1866	1870	CD73	T116,T126,T129	C0000530
27430240	1878	1887	Treg cell	T025	C0039198
27430240	1888	1895	surface	T082	C0205148
27430240	1903	1909	sepsis	T047	C0243026
27430240	1911	1920	Adenosine	T114,T121,T123	C0001443
27430240	1929	1949	A2A receptor agonist	T121	C2936552
27430240	1964	1981	signal transducer	T044	C1152628
27430240	1982	1989	factors	T123	C0005515
27430240	1997	2001	CD39	T129	C0108783
27430240	2004	2008	CD73	T116,T126,T129	C0000530
27430240	2011	2020	adenosine	T114,T121,T123	C0001443
27430240	2021	2028	pathway	T077	C1705987
27430240	2030	2042	accelerating	T169	C0521110
27430240	2043	2052	adenosine	T114,T121,T123	C0001443
27430240	2053	2063	generation	T052	C3146294
27430240	2095	2103	research	T062	C0035168
27430240	2107	2127	adenosine metabolism	T044	C1158592
27430240	2136	2145	treatment	T061	C0087111
27430240	2149	2155	sepsis	T047	C0243026

28387851|t|Does Intrawound Vancomycin Application During Spine Surgery Create Vancomycin-Resistant Organism?
28387851|a|Surgical site infection (SSI) following spine surgery is a morbid and expensive complication. The use of intrawound vancomycin is emerging as a solution to reduce SSI. The development of vancomycin-resistant pathogens is an understandable concern. To determine the occurrence of vancomycin-resistant SSI in patients with and without use of intrawound vancomycin. Patients undergoing elective spine surgery were dichotomized based on whether intrawound vancomycin was applied. Outcome was occurrence of SSI requiring return to the operating room within postoperative 90 days. The intrawound culture and vancomycin minimal inhibitory concentrations (MIC) were reviewed. Analyses were conducted to compare the pathogen profile and MIC for vancomycin in patients who received vancomycin and those who did not. Of the total 2802 patients, 43% (n = 1215) had intrawound vancomycin application during the index surgery. The use of vancomycin was associated with significantly lower deep SSI rates (1.6% [n = 20] vs 2.5% [n = 40], P = .02). The occurrence of Staphylococcus aureus SSI was significantly lower in the patients who had application of intrawound vancomycin (32% vs 65%, P = .003). None of the patients who had application of intrawound vancomycin powder, and subsequently developed an S aureus SSI, demonstrated pathogens with resistance to vancomycin. All patients had MIC < 2 μg/mL, the vancomycin susceptibility threshold. The occurrence of gram-negative SSI (28% vs 7%) and culture negative fluid collection (16% vs 5%) was higher in the vancomycin cohort. The use of intrawound vancomycin during the index spine surgery was protective against SSI following spine surgery. The application of intrawound vancomycin during index surgery does not appear to create vancomycin-resistant organisms in the event of an SSI.
28387851	5	26	Intrawound Vancomycin	T116,T195	C0042313
28387851	27	38	Application	T169	C4048755
28387851	46	59	Spine Surgery	T061	C2608059
28387851	67	87	Vancomycin-Resistant	T032	C0752078
28387851	88	96	Organism	T001	C0029235
28387851	98	121	Surgical site infection	T046	C0038941
28387851	123	126	SSI	T046	C0038941
28387851	138	151	spine surgery	T061	C2608059
28387851	157	163	morbid	T080	C0205556
28387851	168	190	expensive complication	T169	C1171258
28387851	203	224	intrawound vancomycin	T116,T195	C0042313
28387851	261	264	SSI	T046	C0038941
28387851	285	305	vancomycin-resistant	T032	C0752078
28387851	306	315	pathogens	T001	C0450254
28387851	363	373	occurrence	T079	C2745955
28387851	377	397	vancomycin-resistant	T032	C0752078
28387851	398	401	SSI	T046	C0038941
28387851	405	413	patients	T101	C0030705
28387851	438	459	intrawound vancomycin	T116,T195	C0042313
28387851	461	469	Patients	T101	C0030705
28387851	461	469	Patients	T101	C0030705
28387851	490	503	spine surgery	T061	C2608059
28387851	509	521	dichotomized	T080	C0443299
28387851	539	560	intrawound vancomycin	T116,T195	C0042313
28387851	586	596	occurrence	T079	C2745955
28387851	600	603	SSI	T046	C0038941
28387851	628	642	operating room	T073,T093	C0029064
28387851	650	671	postoperative 90 days	T079	C0032790
28387851	677	695	intrawound culture	T059	C0596932
28387851	700	710	vancomycin	T116,T195	C0042313
28387851	711	744	minimal inhibitory concentrations	T059	C0427978
28387851	746	749	MIC	T059	C0427978
28387851	805	821	pathogen profile	T001	C0450254
28387851	826	829	MIC	T059	C0427978
28387851	834	844	vancomycin	T116,T195	C0042313
28387851	848	856	patients	T101	C0030705
28387851	870	880	vancomycin	T116,T195	C0042313
28387851	922	930	patients	T101	C0030705
28387851	951	972	intrawound vancomycin	T116,T195	C0042313
28387851	985	1009	during the index surgery	T079	C1254367
28387851	1022	1032	vancomycin	T116,T195	C0042313
28387851	1053	1072	significantly lower	T081	C4055638
28387851	1078	1081	SSI	T046	C0038941
28387851	1082	1087	rates	T023	C0037993
28387851	1135	1145	occurrence	T079	C2745955
28387851	1149	1170	Staphylococcus aureus	T007	C0038172
28387851	1171	1174	SSI	T046	C0038941
28387851	1179	1198	significantly lower	T081	C4055638
28387851	1206	1214	patients	T101	C0030705
28387851	1223	1234	application	T169	C4048755
28387851	1238	1259	intrawound vancomycin	T116,T195	C0042313
28387851	1296	1304	patients	T101	C0030705
28387851	1313	1324	application	T169	C4048755
28387851	1328	1356	intrawound vancomycin powder	T116,T195	C0042313
28387851	1388	1396	S aureus	T007	C0038172
28387851	1397	1400	SSI	T046	C0038941
28387851	1415	1424	pathogens	T001	C0450254
28387851	1430	1454	resistance to vancomycin	T033	C3265908
28387851	1460	1468	patients	T101	C0030705
28387851	1473	1476	MIC	T059	C0427978
28387851	1492	1502	vancomycin	T116,T195	C0042313
28387851	1533	1543	occurrence	T079	C2745955
28387851	1547	1560	gram-negative	T047	C0085423
28387851	1561	1564	SSI	T046	C0038941
28387851	1581	1614	culture negative fluid collection	T033	C0429652
28387851	1631	1637	higher	T080	C0205250
28387851	1645	1655	vancomycin	T116,T195	C0042313
28387851	1656	1662	cohort	T098	C0599755
28387851	1675	1696	intrawound vancomycin	T116,T195	C0042313
28387851	1714	1727	spine surgery	T061	C2608059
28387851	1751	1754	SSI	T046	C0038941
28387851	1765	1778	spine surgery	T061	C2608059
28387851	1784	1795	application	T169	C4048755
28387851	1799	1820	intrawound vancomycin	T116,T195	C0042313
28387851	1821	1841	during index surgery	T079	C1254367
28387851	1868	1888	vancomycin-resistant	T032	C0752078
28387851	1889	1898	organisms	T001	C0029235
28387851	1918	1921	SSI	T046	C0038941

28034357|t|Psychological Stress in Pathogenesis of Essential Hypertension
28034357|a|The article represents literature review and provides evidence for psychological stress to play essential role in the development of arterial hypertension. The pathogenesis of hypertension is complex with a significant diversity and variability of the mechanisms involved in individual patient. In this regard, the determination of specific pathogenic pathways underlying sustained blood pressure elevation in each patient would substantially individualize therapeutic approaches, and hence increase the effectiveness of treatment. Psychological stress is proposed as a significant factor contributing to the development of hypertension. Global urbanization, sedentary lifestyle, daily stress at workplace, lack of physical activity and social support lead to increased anxiety, uncertainty, and finally to chronic mental and emotional stress. This review provides information about alterations in neuroendocrine and immune systems as the main pathogenic pathways linking psychological stress and hypertension. Endothelial dysfunction is considered not only as a consequence but also a primary factor causing prohypertensive state. Moreover, physical inactivity is discussed as one of the plausible mechanisms playing a key role in the development of hypertension in modern lifestyle conditions. Particularly the loss of connection between psychosocial strain and physical activity may underlie the deleterious effect of stress on cardiovascular and metabolic health.
28034357	0	20	Psychological Stress	T048	C0038443
28034357	24	36	Pathogenesis	T046	C0699748
28034357	40	62	Essential Hypertension	T047	C0085580
28034357	86	103	literature review	T170	C0282441
28034357	117	125	evidence	T078	C3887511
28034357	130	150	psychological stress	T048	C0038443
28034357	181	192	development	T169	C1527148
28034357	196	217	arterial hypertension	T047	C0020538
28034357	223	235	pathogenesis	T046	C0699748
28034357	239	251	hypertension	T047	C0020538
28034357	255	262	complex	T080	C0439855
28034357	282	291	diversity	T080	C1880371
28034357	296	307	variability	T077	C2827666
28034357	315	325	mechanisms	T169	C0441712
28034357	338	348	individual	T098	C0237401
28034357	349	356	patient	T101	C0030705
28034357	378	391	determination	T059	C1148554
28034357	404	423	pathogenic pathways	T077	C1511986
28034357	435	444	sustained	T169	C0443318
28034357	445	469	blood pressure elevation	T033	C0497247
28034357	478	485	patient	T101	C0030705
28034357	520	542	therapeutic approaches	T061	C0087111
28034357	554	562	increase	T169	C0442805
28034357	567	593	effectiveness of treatment	T080	C0087113
28034357	595	615	Psychological stress	T048	C0038443
28034357	645	651	factor	T169	C1521761
28034357	672	683	development	T169	C1527148
28034357	687	699	hypertension	T047	C0020538
28034357	701	720	Global urbanization	T068	C0041938
28034357	722	741	sedentary lifestyle	T033	C1532253
28034357	743	748	daily	T079	C0332173
28034357	749	768	stress at workplace	T033	C0558919
28034357	770	795	lack of physical activity	T033	C0086439
28034357	800	814	social support	T054	C0037438
28034357	823	832	increased	T081	C0205217
28034357	833	840	anxiety	T033	C0003467
28034357	842	853	uncertainty	T033	C0087130
28034357	870	884	chronic mental	T048	C0038443
28034357	889	905	emotional stress	T048	C0086209
28034357	912	918	review	T170	C0282443
28034357	946	957	alterations	T078	C1515926
28034357	961	975	neuroendocrine	T022	C0027912
28034357	980	994	immune systems	T022	C0020962
28034357	1007	1026	pathogenic pathways	T077	C1511986
28034357	1035	1055	psychological stress	T048	C0038443
28034357	1060	1072	hypertension	T047	C0020538
28034357	1074	1097	Endothelial dysfunction	T047	C0856169
28034357	1126	1137	consequence	T169	C0686907
28034357	1149	1156	primary	T080	C0205225
28034357	1157	1163	factor	T169	C1521761
28034357	1172	1193	prohypertensive state	T033	C0857121
28034357	1205	1224	physical inactivity	T056	C3890554
28034357	1262	1272	mechanisms	T169	C0441712
28034357	1299	1310	development	T169	C1527148
28034357	1314	1326	hypertension	T047	C0020538
28034357	1330	1346	modern lifestyle	T054	C0023676
28034357	1347	1357	conditions	T080	C0348080
28034357	1403	1422	psychosocial strain	T184	C1510453
28034357	1427	1444	physical activity	T056	C0026606
28034357	1462	1480	deleterious effect	T080	C1280500
28034357	1484	1490	stress	T048	C0038443
28034357	1494	1508	cardiovascular	T029	C3887460
28034357	1513	1522	metabolic	T169	C0311400
28034357	1523	1529	health	T078	C0018684

27678020|t|Bending rules: the shape of the perceptual generalisation gradient is sensitive to inference rules
27678020|a|Generalising what is learned about one stimulus to other but perceptually related stimuli is a basic behavioural phenomenon. We evaluated whether a rule learning mechanism may serve to explain such generalisation. To this end, we assessed whether inference rules communicated through verbal instructions affect generalisation. Expectancy ratings, but not valence ratings, proved sensitive to this manipulation. In addition to revealing a role for inference rules in generalisation, our study has clinical implications as well. More specifically, we argue that targeting inference rules might prove to be an effective strategy to affect the excessive generalisation that is often observed in psychopathology.
27678020	0	13	Bending rules	T170	C0870077
27678020	19	24	shape	T082	C0332479
27678020	32	42	perceptual	T041	C0030971
27678020	43	57	generalisation	T041	C0017324
27678020	58	66	gradient	T081	C0812409
27678020	70	79	sensitive	T169	C0332324
27678020	83	98	inference rules	T170	C0870077
27678020	99	111	Generalising	T041	C0017326
27678020	120	127	learned	T041	C0023185
27678020	138	146	stimulus	T067	C0234402
27678020	160	172	perceptually	T041	C0030971
27678020	181	188	stimuli	T067	C0234402
27678020	200	211	behavioural	T053	C0004927
27678020	212	222	phenomenon	T067	C1882365
27678020	227	236	evaluated	T058	C0220825
27678020	247	251	rule	T170	C0870077
27678020	252	260	learning	T041	C0023185
27678020	261	270	mechanism	T169	C0441712
27678020	297	311	generalisation	T041	C0017324
27678020	329	337	assessed	T052	C1516048
27678020	346	361	inference rules	T170	C0870077
27678020	362	374	communicated	T033	C0566001
27678020	383	402	verbal instructions	T058	C1254363
27678020	410	424	generalisation	T041	C0017324
27678020	426	436	Expectancy	T078	C0679138
27678020	437	444	ratings	T052	C0871208
27678020	462	469	ratings	T052	C0871208
27678020	478	487	sensitive	T169	C0332324
27678020	496	508	manipulation	T053	C0018578
27678020	537	541	role	T170	C1704326
27678020	546	561	inference rules	T170	C0870077
27678020	565	579	generalisation	T041	C0017324
27678020	585	590	study	T062	C2603343
27678020	595	603	clinical	T080	C0205210
27678020	604	616	implications	T169	C0205245
27678020	659	668	targeting	T169	C1521840
27678020	669	684	inference rules	T170	C0870077
27678020	716	724	strategy	T041	C0679199
27678020	739	748	excessive	T080	C0442802
27678020	749	763	generalisation	T041	C0017324
27678020	790	805	psychopathology	T091	C0033927

27902690|t|Decoding the Interactions Regulating the Active State Mechanics of Eukaryotic Protein Kinases
27902690|a|Eukaryotic protein kinases regulate most cellular functions by phosphorylating targeted protein substrates through a highly conserved catalytic core. In the active state, the catalytic core oscillates between open, intermediate, and closed conformations. Currently, the intramolecular interactions that regulate the active state mechanics are not well understood. Here, using cAMP-dependent protein kinase as a representative model coupled with biochemical, biophysical, and computational techniques, we define a set of highly conserved electrostatic and hydrophobic interactions working harmoniously to regulate these mechanics. These include the previously identified salt bridge between a lysine from the β3-strand and a glutamate from the αC-helix as well as an electrostatic interaction between the phosphorylated activation loop and αC-helix and an ensemble of hydrophobic residues of the Regulatory spine and Shell. Moreover, for over three decades it was thought that the highly conserved β3 -lysine was essential for phosphoryl transfer, but our findings show that the β3 -lysine is not required for phosphoryl transfer but is essential for the active state mechanics.
27902690	0	8	Decoding	T041	C0870395
27902690	13	25	Interactions	T043	C1373094
27902690	26	36	Regulating	T080	C0243148
27902690	41	53	Active State	T033	C0679217
27902690	54	63	Mechanics	T070	C0376706
27902690	67	77	Eukaryotic	T204	C0684063
27902690	78	93	Protein Kinases	T116,T126	C0033640
27902690	94	104	Eukaryotic	T204	C0684063
27902690	105	120	protein kinases	T116,T126	C0033640
27902690	121	129	regulate	T080	C0243148
27902690	135	153	cellular functions	T043	C0007613
27902690	157	172	phosphorylating	T044	C1158886
27902690	173	181	targeted	T169	C1521840
27902690	182	189	protein	T116,T123	C0033684
27902690	190	200	substrates	T167	C3891814
27902690	201	208	through	T169	C0332273
27902690	211	217	highly	T080	C0205250
27902690	218	227	conserved	T169	C0443318
27902690	228	242	catalytic core	T026	C0243092
27902690	251	263	active state	T033	C0679217
27902690	269	283	catalytic core	T026	C0243092
27902690	284	294	oscillates	T061	C0695434
27902690	303	307	open	T082	C0175566
27902690	309	321	intermediate	T082	C0205103
27902690	327	333	closed	T082	C0677512
27902690	334	347	conformations	T082	C0033625
27902690	349	358	Currently	T079	C0521116
27902690	364	391	intramolecular interactions	T043	C1373094
27902690	397	405	regulate	T080	C0243148
27902690	410	422	active state	T033	C0679217
27902690	423	432	mechanics	T070	C0376706
27902690	437	456	not well understood	T080	C0205556
27902690	470	499	cAMP-dependent protein kinase	T116,T126	C0010531
27902690	505	519	representative	T052	C1882932
27902690	520	525	model	T075	C0026336
27902690	526	533	coupled	T169	C1948027
27902690	539	550	biochemical	T169	C0205474
27902690	552	563	biophysical	T038	C1511162
27902690	569	593	computational techniques	T062	C1516769
27902690	614	620	highly	T080	C0205250
27902690	621	630	conserved	T080	C2347858
27902690	631	644	electrostatic	UnknownType	C0683119
27902690	649	673	hydrophobic interactions	T044	C0678607
27902690	682	694	harmoniously	T054	C0699798
27902690	698	706	regulate	T080	C0243148
27902690	713	722	mechanics	T070	C0376706
27902690	730	737	include	T169	C0332257
27902690	742	752	previously	T079	C0205156
27902690	753	763	identified	T080	C0205396
27902690	764	775	salt bridge	T044	C0023745
27902690	786	792	lysine	T116,T121,T123	C0024337
27902690	802	811	β3-strand	T082	C0600383
27902690	818	827	glutamate	T116,T123	C0220839
27902690	837	845	αC-helix	T082	C0162805
27902690	860	885	electrostatic interaction	UnknownType	C0683119
27902690	898	912	phosphorylated	T044	C0031715
27902690	913	923	activation	T052	C1879547
27902690	924	928	loop	T082	C0445022
27902690	933	941	αC-helix	T082	C0162805
27902690	949	957	ensemble	T081	C0444667
27902690	961	972	hydrophobic	T080	C0598629
27902690	973	981	residues	T077	C1709915
27902690	1042	1049	decades	T081	C2981279
27902690	1074	1080	highly	T080	C0205250
27902690	1081	1090	conserved	T169	C0443318
27902690	1091	1093	β3	T082	C0600383
27902690	1091	1101	β3 -lysine	T116,T121,T123	C0024337
27902690	1106	1115	essential	T080	C0205224
27902690	1120	1139	phosphoryl transfer	T044	C1148560
27902690	1149	1157	findings	T169	C2607943
27902690	1172	1174	β3	T082	C0600383
27902690	1172	1182	β3 -lysine	T116,T121,T123	C0024337
27902690	1203	1222	phosphoryl transfer	T044	C1148560
27902690	1230	1239	essential	T080	C0205224
27902690	1248	1260	active state	T033	C0679217
27902690	1261	1270	mechanics	T070	C0376706

27837176|t|Chondrocyte proliferation, viability and differentiation is declined following administration of methylphenidate utilized for the treatment of attention-deficit/hyperactivity disorder
27837176|a|Methylphenidate (MPH) derivative drugs are used because of psychostimulants effects on attention-deficit hyperactivity disorder in children and adults. As far as we know, toxic or anti-proliferative effects of MPH against cartilage tissue were not studied in the literature. The present study was carried out to investigate the possible effects of MPH on the proliferation, viability and differentiation of primary human chondrocytes, in vitro. Monolayer primary chondrocyte cultures were prepared using osteochondral tissue obtained from patients who underwent a total knee prosthesis operation. Stock solution of MPH was prepared and aliquots having 1-1000 µM concentrations of the drug was composed. These solutions were applied to the wells containing cultured chondrocyte samples within the well plates. Control groups were composed of pure chondrocyte culture and no solution was added into them. All groups were evaluated at 24, 48 and 72 h in order to determine the possible negative effects of the drug on the chondrocytes. The data were evaluated by Tukey's honestly significantly different test following analysis of variance. In the group where MPH was applied, it was found that viability, proliferation and stage-specific embryonic antigen-1 protein expression were decreased in comparison to the control group. It was emphasized that clinicians should not disregard the fact that this drug might suppress chondrocyte cell proliferation and chondrogenic differentiation.
27837176	0	25	Chondrocyte proliferation	T043	C3271470
27837176	27	36	viability	T043	C0007620
27837176	41	56	differentiation	T043	C0007589
27837176	60	68	declined	T081	C0205216
27837176	79	93	administration	T061	C1533734
27837176	97	112	methylphenidate	T109,T121	C0025810
27837176	130	139	treatment	T061	C0087111
27837176	143	183	attention-deficit/hyperactivity disorder	T048	C1263846
27837176	184	216	Methylphenidate (MPH) derivative	T109	C1320172
27837176	217	222	drugs	T121	C1254351
27837176	243	259	psychostimulants	T121	C0304403
27837176	260	267	effects	T080	C1280500
27837176	271	311	attention-deficit hyperactivity disorder	T048	C1263846
27837176	315	323	children	T100	C0008059
27837176	328	334	adults	T100	C0001675
27837176	355	360	toxic	T080	C1407029
27837176	364	390	anti-proliferative effects	T033	C0243095
27837176	394	397	MPH	T109,T121	C0025810
27837176	406	422	cartilage tissue	T024	C0007301
27837176	447	457	literature	T170	C0023866
27837176	471	476	study	T062	C2603343
27837176	496	507	investigate	T169	C1292732
27837176	512	520	possible	T033	C0332149
27837176	521	528	effects	T080	C1280500
27837176	532	535	MPH	T109,T121	C0025810
27837176	543	556	proliferation	T043	C3271470
27837176	558	567	viability	T043	C0007620
27837176	572	587	differentiation	T043	C0007589
27837176	591	598	primary	T080	C0205225
27837176	599	604	human	T016	C0086418
27837176	605	617	chondrocytes	T025	C0225369
27837176	619	627	in vitro	T080	C1533691
27837176	639	646	primary	T080	C0205225
27837176	647	658	chondrocyte	T025	C0225369
27837176	659	667	cultures	T059	C1331092
27837176	673	681	prepared	T033	C4082130
27837176	688	701	osteochondral	T029	C2937247
27837176	702	708	tissue	T024	C0040300
27837176	709	717	obtained	T169	C1301820
27837176	723	731	patients	T101	C0030705
27837176	748	779	total knee prosthesis operation	T061	C0086511
27837176	781	795	Stock solution	T122	C0525069
27837176	799	802	MPH	T109,T121	C0025810
27837176	807	815	prepared	T033	C4082130
27837176	820	828	aliquots	T081	C1510844
27837176	846	872	concentrations of the drug	T081	C0678756
27837176	893	902	solutions	T122	C0525069
27837176	908	915	applied	T169	C4048755
27837176	923	928	wells	T082	C4283957
27837176	929	939	containing	T169	C0332256
27837176	940	960	cultured chondrocyte	T025	C0225369
27837176	961	968	samples	T077	C2347026
27837176	980	991	well plates	T074	C0180454
27837176	993	1007	Control groups	T096	C0009932
27837176	1030	1041	chondrocyte	T025	C0225369
27837176	1042	1049	culture	T059	C1331092
27837176	1054	1065	no solution	T033	C0243095
27837176	1070	1075	added	T169	C1524062
27837176	1091	1097	groups	T096	C0681850
27837176	1144	1153	determine	T080	C0521095
27837176	1158	1166	possible	T033	C0332149
27837176	1167	1175	negative	T033	C0205160
27837176	1176	1183	effects	T080	C1280500
27837176	1191	1195	drug	T121	C1254351
27837176	1203	1215	chondrocytes	T025	C0225369
27837176	1221	1225	data	T078	C1511726
27837176	1244	1289	Tukey's honestly significantly different test	T081	C0392762
27837176	1300	1320	analysis of variance	T081	C0002780
27837176	1329	1334	group	T096	C0681850
27837176	1341	1344	MPH	T109,T121	C0025810
27837176	1349	1356	applied	T169	C4048755
27837176	1376	1385	viability	T043	C0007620
27837176	1387	1400	proliferation	T043	C0596290
27837176	1405	1439	stage-specific embryonic antigen-1	T109,T129	C0080188
27837176	1440	1458	protein expression	T045	C1171362
27837176	1464	1473	decreased	T081	C0205216
27837176	1477	1487	comparison	T052	C1707455
27837176	1495	1508	control group	T096	C0009932
27837176	1533	1543	clinicians	T097	C0871685
27837176	1584	1588	drug	T121	C1254351
27837176	1595	1603	suppress	T169	C1260953
27837176	1604	1634	chondrocyte cell proliferation	T043	C3271470
27837176	1639	1667	chondrogenic differentiation	T043	C0007589

27259677|t|The "tight orbit": Incidence and management of the orbital compartment syndrome
27259677|a|The orbital compartment syndrome (OCS) constitutes a severe emergency, requiring immediate clinical diagnosis and surgical decompression. The key symptom is progressive visual impairment caused by an increase in intraorbital pressure, impairing the perfusion of relevant neurovascular and neurosensory structures. Intraorbital bleeding due to trauma and surgical intervention is known to be the main etiological factor. A retrospective analysis of all patients affected by an OCS between January 1, 2012, and May 31, 2015, was performed. Patients' records were reviewed with regard to etiology, initial ophthalmologic status, fracture pattern, concomitant medication, surgical management, and postoperative outcome. The incidence of OCS was calculated based on the total number of craniomaxillofacial (CMF) emergencies. Within 3.5 years, a total of 18,093 CMF emergencies were registered. In 16 patients, an OCS was documented, corresponding to an incidence of 0.088%. The mean patient age was 67.31 ± 23.86 years, ranging from 22 to 102 years. The etiology varied, but trauma with subsequent intraorbital bleeding was the main cause. The use of anticoagulative medication was documented in 50% of the cases. In 14 patients, immediate surgical orbital decompression was performed: in 10 patients, vision could be preserved; in three patients, blindness resulted; and one patient was lost to follow-up. Two patients were managed without surgery. With regard to the total number of CMF emergencies, OCS is a rare condition. Early clinical diagnosis and surgical decompression are required to prevent permanent vision impairment. Anticoagulative medication must be considered as a predisposing factor for an orbital compartment syndrome in patients affected by periorbital trauma.
27259677	19	28	Incidence	T081	C0021149
27259677	33	43	management	T058	C0376636
27259677	51	79	orbital compartment syndrome	T047	C0009492
27259677	84	112	orbital compartment syndrome	T047	C0009492
27259677	114	117	OCS	T047	C0009492
27259677	140	149	emergency	T067	C0013956
27259677	161	170	immediate	T079	C0205253
27259677	171	189	clinical diagnosis	T060	C0332140
27259677	194	216	surgical decompression	T061	C0376530
27259677	226	233	symptom	T184	C1457887
27259677	237	266	progressive visual impairment	T033	C1839364
27259677	280	288	increase	T169	C0442805
27259677	292	313	intraorbital pressure	T042	C0021888
27259677	315	324	impairing	T169	C0221099
27259677	329	338	perfusion	T061	C0031001
27259677	342	350	relevant	T080	C2347946
27259677	351	364	neurovascular	T023	C2338723
27259677	369	392	neurosensory structures	T023	C0446849
27259677	394	415	Intraorbital bleeding	T046	C0019080
27259677	423	429	trauma	T037	C3714660
27259677	434	455	surgical intervention	T033	C0549433
27259677	502	515	retrospective	T080	C1514923
27259677	516	524	analysis	T062	C0936012
27259677	532	540	patients	T101	C0030705
27259677	541	549	affected	T169	C0392760
27259677	556	559	OCS	T047	C0009492
27259677	607	616	performed	T169	C0884358
27259677	618	627	Patients'	T101	C0030705
27259677	628	635	records	T170	C0034869
27259677	641	649	reviewed	T080	C1709940
27259677	665	673	etiology	T169	C1314792
27259677	675	682	initial	T079	C0205265
27259677	683	697	ophthalmologic	T169	C0205481
27259677	698	704	status	T080	C0449438
27259677	706	722	fracture pattern	T033	C0243095
27259677	724	746	concomitant medication	T078	C2347852
27259677	748	767	surgical management	T058	C1515089
27259677	773	786	postoperative	T079	C0032790
27259677	787	794	outcome	T169	C1274040
27259677	800	809	incidence	T081	C0021149
27259677	813	816	OCS	T047	C0009492
27259677	821	831	calculated	T052	C1441506
27259677	845	857	total number	T081	C4288115
27259677	861	880	craniomaxillofacial	T029	C0005898
27259677	882	885	CMF	T029	C0005898
27259677	887	898	emergencies	T046	C2745965
27259677	911	916	years	T079	C0439234
27259677	936	939	CMF	T029	C0005898
27259677	940	951	emergencies	T046	C2745965
27259677	957	967	registered	T058	C1514821
27259677	975	983	patients	T101	C0030705
27259677	988	991	OCS	T047	C0009492
27259677	996	1006	documented	T058	C1301725
27259677	1028	1037	incidence	T081	C0021149
27259677	1053	1057	mean	T081	C0444504
27259677	1058	1065	patient	T101	C0030705
27259677	1066	1069	age	T032	C0001779
27259677	1088	1093	years	T079	C0439234
27259677	1095	1102	ranging	T081	C1514721
27259677	1118	1123	years	T079	C0439234
27259677	1129	1137	etiology	T169	C1314792
27259677	1150	1156	trauma	T037	C3714660
27259677	1173	1194	intraorbital bleeding	T046	C0019080
27259677	1208	1213	cause	T033	C0552510
27259677	1226	1252	anticoagulative medication	T061	C0003281
27259677	1257	1267	documented	T058	C1301725
27259677	1282	1287	cases	T169	C0868928
27259677	1295	1303	patients	T101	C0030705
27259677	1305	1314	immediate	T079	C0205253
27259677	1315	1345	surgical orbital decompression	T061	C3267044
27259677	1350	1359	performed	T169	C0884358
27259677	1367	1375	patients	T101	C0030705
27259677	1377	1383	vision	T040	C0042789
27259677	1393	1402	preserved	T059	C0033085
27259677	1413	1421	patients	T101	C0030705
27259677	1423	1432	blindness	T033	C0456909
27259677	1433	1441	resulted	T169	C1274040
27259677	1451	1458	patient	T101	C0030705
27259677	1463	1467	lost	T169	C0745777
27259677	1471	1480	follow-up	T058	C1522577
27259677	1486	1494	patients	T101	C0030705
27259677	1516	1523	surgery	T061	C0543467
27259677	1544	1556	total number	T081	C4288115
27259677	1560	1563	CMF	T029	C0005898
27259677	1564	1575	emergencies	T046	C2745965
27259677	1577	1580	OCS	T047	C0009492
27259677	1586	1590	rare	T080	C0522498
27259677	1591	1600	condition	T080	C0348080
27259677	1602	1607	Early	T079	C1279919
27259677	1608	1626	clinical diagnosis	T060	C0332140
27259677	1631	1653	surgical decompression	T061	C0376530
27259677	1658	1666	required	T169	C1514873
27259677	1670	1677	prevent	T080	C2700409
27259677	1678	1687	permanent	T079	C0205355
27259677	1688	1705	vision impairment	T033	C3665347
27259677	1707	1733	Anticoagulative medication	T061	C0003281
27259677	1758	1777	predisposing factor	T079	C0032946
27259677	1785	1813	orbital compartment syndrome	T047	C0009492
27259677	1817	1825	patients	T101	C0030705
27259677	1826	1834	affected	T169	C0392760
27259677	1838	1856	periorbital trauma	UnknownType	C0747513

27611967|t|Identification of Altered Metabolomic Profiles Following a Panchakarma -based Ayurvedic Intervention in Healthy Subjects: The Self-Directed Biological Transformation Initiative (SBTI)
27611967|a|The effects of integrative medicine practices such as meditation and Ayurveda on human physiology are not fully understood. The aim of this study was to identify altered metabolomic profiles following an Ayurveda -based intervention. In the experimental group, 65 healthy male and female subjects participated in a 6-day Panchakarma -based Ayurvedic intervention which included herbs, vegetarian diet, meditation, yoga, and massage. A set of 12 plasma phosphatidylcholines decreased (adjusted p < 0.01) post-intervention in the experimental (n = 65) compared to control group (n = 54) after Bonferroni correction for multiple testing; within these compounds, the phosphatidylcholine with the greatest decrease in abundance was PC ae C36:4 (delta = -0.34). Application of a 10% FDR revealed an additional 57 metabolites that were differentially abundant between groups. Pathway analysis suggests that the intervention results in changes in metabolites across many pathways such as phospholipid biosynthesis, choline metabolism, and lipoprotein metabolism. The observed plasma metabolomic alterations may reflect a Panchakarma - induced modulation of metabotypes. Panchakarma promoted statistically significant changes in plasma levels of phosphatidylcholines, sphingomyelins and others in just 6 days. Forthcoming studies that integrate metabolomics with genomic, microbiome and physiological parameters may facilitate a broader systems - level understanding and mechanistic insights into these integrative practices that are employed to promote health and well-being.
27611967	0	14	Identification	T033	C0243095
27611967	18	25	Altered	T078	C1515926
27611967	26	46	Metabolomic Profiles	T091	C1328813
27611967	59	70	Panchakarma	T061	C1883583
27611967	78	87	Ayurvedic	T091	C0025122
27611967	88	100	Intervention	T061	C0184661
27611967	104	120	Healthy Subjects	T098	C1708335
27611967	126	176	Self-Directed Biological Transformation Initiative	T093	C1708333
27611967	178	182	SBTI	T093	C1708333
27611967	188	198	effects of	T080	C1704420
27611967	211	229	medicine practices	T091	C3825997
27611967	238	248	meditation	T041	C0150277
27611967	253	261	Ayurveda	T091	C0025122
27611967	265	270	human	T016	C0086418
27611967	271	281	physiology	T039	C0031843
27611967	337	345	identify	T033	C0243095
27611967	346	353	altered	T078	C1515926
27611967	354	374	metabolomic profiles	T091	C1328813
27611967	388	396	Ayurveda	T091	C0025122
27611967	404	416	intervention	T061	C0184661
27611967	425	443	experimental group	T078	C0441833
27611967	448	455	healthy	T080	C3898900
27611967	456	460	male	T032	C0086582
27611967	465	471	female	T032	C0086287
27611967	472	480	subjects	T098	C0080105
27611967	505	516	Panchakarma	T061	C1883583
27611967	524	533	Ayurvedic	T091	C0025122
27611967	534	546	intervention	T061	C0184661
27611967	562	567	herbs	T002	C0025125
27611967	569	584	vegetarian diet	T033	C0311164
27611967	586	596	meditation	T041	C0150277
27611967	598	602	yoga	T056	C2979879
27611967	608	615	massage	T061	C0024875
27611967	629	635	plasma	T031	C0032105
27611967	636	656	phosphatidylcholines	T109,T121,T123	C1959616
27611967	657	666	decreased	T081	C0205216
27611967	687	704	post-intervention	T170	C2347647
27611967	712	724	experimental	T078	C0441833
27611967	746	759	control group	T096	C0009932
27611967	775	796	Bonferroni correction	T081	C2347434
27611967	801	817	multiple testing	T169	C0039593
27611967	832	841	compounds	T103	C1706082
27611967	847	866	phosphatidylcholine	T109,T121,T123	C1959616
27611967	897	906	abundance	T080	C2346714
27611967	911	916	PC ae	T109,T121,T123	C1959616
27611967	961	964	FDR	T081	C1880720
27611967	991	1002	metabolites	T123	C0870883
27611967	1028	1036	abundant	T080	C2346714
27611967	1045	1051	groups	T078	C0441833
27611967	1053	1069	Pathway analysis	T170	C0868995
27611967	1088	1100	intervention	T061	C0184661
27611967	1101	1108	results	T169	C1274040
27611967	1112	1119	changes	T169	C0392747
27611967	1123	1134	metabolites	T123	C0870883
27611967	1147	1155	pathways	T077	C1705987
27611967	1164	1189	phospholipid biosynthesis	T044	C1157377
27611967	1191	1209	choline metabolism	T044	C1156927
27611967	1215	1237	lipoprotein metabolism	T044	C1158917
27611967	1252	1258	plasma	T031	C0032105
27611967	1259	1270	metabolomic	T123	C0870883
27611967	1271	1282	alterations	T078	C1515926
27611967	1297	1308	Panchakarma	T061	C1883583
27611967	1311	1318	induced	T169	C0205263
27611967	1319	1329	modulation	T169	C0205245
27611967	1333	1344	metabotypes	T123	C0870883
27611967	1346	1357	Panchakarma	T061	C1883583
27611967	1393	1400	changes	T169	C0392747
27611967	1404	1410	plasma	T031	C0032105
27611967	1411	1417	levels	T080	C0441889
27611967	1421	1441	phosphatidylcholines	T109,T121,T123	C1959616
27611967	1443	1457	sphingomyelins	T109,T123	C0037906
27611967	1479	1483	days	T079	C0439228
27611967	1510	1519	integrate	T169	C0205245
27611967	1520	1532	metabolomics	T091	C1328813
27611967	1538	1545	genomic	T091	C0887950
27611967	1547	1557	microbiome	T001	C1956108
27611967	1562	1575	physiological	T169	C0205463
27611967	1576	1586	parameters	T033	C0449381
27611967	1612	1619	systems	T169	C0449913
27611967	1622	1627	level	T080	C0441889
27611967	1678	1689	integrative	T169	C0205245
27611967	1690	1699	practices	T169	C0205245
27611967	1729	1735	health	T078	C0018684
27611967	1740	1750	well-being	T078	C0018684

28394935|t|eNOS S-nitrosylates β-actin on Cys374 and regulates PKC-θ at the immune synapse by impairing actin binding to profilin-1
28394935|a|The actin cytoskeleton coordinates the organization of signaling microclusters at the immune synapse (IS); however, the mechanisms involved remain poorly understood. We show here that nitric oxide (NO) generated by endothelial nitric oxide synthase (eNOS) controls the coalescence of protein kinase C-θ (PKC-θ) at the central supramolecular activation cluster (c-SMAC) of the IS. eNOS translocated with the Golgi to the IS and partially colocalized with F-actin around the c-SMAC. This resulted in reduced actin polymerization and centripetal retrograde flow of β-actin and PKC-θ from the lamellipodium-like distal (d)-SMAC, promoting PKC-θ activation. Furthermore, eNOS -derived NO S-nitrosylated β-actin on Cys374 and impaired actin binding to profilin-1 (PFN1), as confirmed with the transnitrosylating agent S-nitroso-L-cysteine (Cys-NO). The importance of NO and the formation of PFN1-actin complexes on the regulation of PKC-θ was corroborated by overexpression of PFN1 - and actin-binding defective mutants of β-actin (C374S) and PFN1 (H119E), respectively, which reduced the coalescence of PKC-θ at the c-SMAC. These findings unveil a novel NO -dependent mechanism by which the actin cytoskeleton controls the organization and activation of signaling microclusters at the IS.
28394935	0	4	eNOS	T116,T126	C0132555
28394935	5	19	S-nitrosylates	T044	C1159123
28394935	20	27	β-actin	T116,T123	C0005186
28394935	31	37	Cys374	T116,T123	C0010654
28394935	42	51	regulates	T044	C1327623
28394935	52	57	PKC-θ	T116,T126	C0171420
28394935	65	79	immune synapse	T026	C1171348
28394935	83	92	impairing	T169	C0221099
28394935	93	106	actin binding	T044	C1149245
28394935	110	120	profilin-1	T116,T123	C0525216
28394935	125	172	actin cytoskeleton coordinates the organization	T043	C1155966
28394935	176	199	signaling microclusters	T129	C0021054
28394935	207	221	immune synapse	T026	C1171348
28394935	223	225	IS	T026	C1171348
28394935	241	251	mechanisms	T044	C3537153
28394935	305	317	nitric oxide	T121,T123,T197	C0028128
28394935	319	321	NO	T121,T123,T197	C0028128
28394935	336	369	endothelial nitric oxide synthase	T116,T126	C0132555
28394935	371	375	eNOS	T116,T126	C0132555
28394935	405	423	protein kinase C-θ	T116,T126	C0171420
28394935	425	430	PKC-θ	T116,T126	C0171420
28394935	439	480	central supramolecular activation cluster	T026	C1171348
28394935	482	488	c-SMAC	T026	C1171348
28394935	497	499	IS	T026	C1171348
28394935	501	505	eNOS	T116,T126	C0132555
28394935	506	518	translocated	T043	C0599893
28394935	528	533	Golgi	T026	C0018042
28394935	541	543	IS	T026	C1171348
28394935	558	569	colocalized	T082	C0392752
28394935	575	582	F-actin	T116,T123	C1180307
28394935	594	600	c-SMAC	T026	C1171348
28394935	627	647	actin polymerization	T043	C1155982
28394935	664	679	retrograde flow	T067	C1709934
28394935	683	690	β-actin	T116,T123	C0005186
28394935	695	700	PKC-θ	T116,T126	C0171420
28394935	710	728	lamellipodium-like	T026	C0230628
28394935	729	735	distal	T082	C0205108
28394935	736	744	(d)-SMAC	T026	C1171348
28394935	746	755	promoting	T052	C0033414
28394935	756	761	PKC-θ	T116,T126	C0171420
28394935	762	772	activation	T044	C0014429
28394935	787	791	eNOS	T116,T126	C0132555
28394935	801	803	NO	T121,T123,T197	C0028128
28394935	804	818	S-nitrosylated	T044	C1159123
28394935	819	826	β-actin	T116,T123	C0005186
28394935	830	836	Cys374	T116,T123	C0010654
28394935	841	849	impaired	T169	C0221099
28394935	850	863	actin binding	T044	C1149245
28394935	867	877	profilin-1	T116,T123	C0525216
28394935	879	883	PFN1	T116,T123	C0525216
28394935	908	926	transnitrosylating	T044	C3158785
28394935	933	953	S-nitroso-L-cysteine	T109,T121,T123	C0073896
28394935	955	961	Cys-NO	T109,T121,T123	C0073896
28394935	982	984	NO	T121,T123,T197	C0028128
28394935	1006	1026	PFN1-actin complexes	T116,T123	C1180347
28394935	1034	1044	regulation	T044	C1327623
28394935	1048	1053	PKC-θ	T116,T126	C0171420
28394935	1074	1088	overexpression	T045	C1514559
28394935	1092	1096	PFN1	T028	C1456390
28394935	1103	1116	actin-binding	T044	C1149245
28394935	1127	1134	mutants	T049	C0596988
28394935	1138	1153	β-actin (C374S)	T028	C1384510
28394935	1158	1170	PFN1 (H119E)	T028	C1456390
28394935	1219	1224	PKC-θ	T116,T126	C0171420
28394935	1232	1238	c-SMAC	T026	C1171348
28394935	1270	1272	NO	T121,T123,T197	C0028128
28394935	1284	1293	mechanism	T044	C3537153
28394935	1307	1351	actin cytoskeleton controls the organization	T043	C1155966
28394935	1356	1366	activation	T052	C1879547
28394935	1370	1393	signaling microclusters	T129	C0021054
28394935	1401	1403	IS	T026	C1171348

28135040|t|Lipid levels and risk of recurrent venous thrombosis: results from the MEGA follow-up study
28135040|a|Essentials The role of lipid levels in the risk of recurrent venous thrombosis is unclear. Lipids were assessed in patients with a first venous thrombosis (n = 2106) followed for 6.9 years. Lipids were not associated with recurrence, overall or in patients with unprovoked first events. Testing lipid levels is not useful to identify patients at an increased risk of recurrence. Background Knowledge of risk factors for recurrent venous thrombosis may guide decisions on duration of anticoagulation. The association between lipid levels and first venous thrombosis has been studied extensively. However, data on the role of lipids in the risk of recurrence are scarce. Objective To assess the association between lipid levels and recurrent venous thrombosis. Patients /Methods Patients with a first venous thrombosis from the MEGA study were included. Follow-up started at the date of end of anticoagulant treatment. Percentile categories of total / low-density lipoprotein / high-density lipoprotein cholesterol, triglycerides and apolipoproteins B and A1 were established (< 10th, 10th-25th, 25th-75th [reference], 75th-90th, > 90th percentile). Lipids were measured at least 3 months after discontinuing anticoagulation. Results Of 2106 patients followed for a median of 6.9 years, 326 developed recurrence (incidence rate, 2.7/100 patient - years; 95% confidence interval [CI], 2.5-3.1). With hazard ratios ranging from 0.88 (95% CI, 0.55-1.42) to 1.33 (95% CI, 0.86-2.04) in the highest percentile category vs. the reference, we found no association across percentile categories between recurrence and lipid levels in age- and sex -adjusted models, nor after further adjustments for body mass index, diabetes, estrogen and statin use, and duration of anticoagulation. Subgroup analyses stratified by unprovoked or provoked first events, location (deep vein thrombosis or pulmonary embolism) and sex also did not reveal an association with any of the lipid levels studied. Conclusions Testing lipid levels did not identify patients at an increased risk of recurrent venous thrombosis in this study, including those with unprovoked first events, and these should not influence decisions on duration of anticoagulation.
28135040	0	12	Lipid levels	T059	C0523744
28135040	17	21	risk	T078	C0035647
28135040	25	52	recurrent venous thrombosis	T046	C1735901
28135040	54	61	results	T169	C1274040
28135040	71	91	MEGA follow-up study	T062	C0016441
28135040	115	127	lipid levels	T059	C0523744
28135040	135	139	risk	T078	C0035647
28135040	143	170	recurrent venous thrombosis	T046	C1735901
28135040	174	181	unclear	T033	C3845108
28135040	183	189	Lipids	T109	C0023779
28135040	195	203	assessed	T052	C1516048
28135040	207	215	patients	T101	C0030705
28135040	229	246	venous thrombosis	T046	C0042487
28135040	258	266	followed	T079	C0332283
28135040	275	280	years	T079	C0439234
28135040	282	288	Lipids	T109	C0023779
28135040	298	313	associated with	T080	C0332281
28135040	314	324	recurrence	T067	C0034897
28135040	340	348	patients	T101	C0030705
28135040	371	377	events	T051	C0441471
28135040	379	399	Testing lipid levels	T059	C0523744
28135040	407	413	useful	T080	C3827682
28135040	417	425	identify	T080	C0205396
28135040	426	434	patients	T101	C0030705
28135040	441	450	increased	T081	C0205217
28135040	451	455	risk	T078	C0035647
28135040	459	469	recurrence	T067	C0034897
28135040	495	507	risk factors	T033	C0035648
28135040	512	539	recurrent venous thrombosis	T046	C1735901
28135040	563	571	duration	T079	C0449238
28135040	575	590	anticoagulation	T061	C0003281
28135040	596	607	association	T080	C0439849
28135040	616	628	lipid levels	T059	C0523744
28135040	639	656	venous thrombosis	T046	C0042487
28135040	696	700	data	T078	C1511726
28135040	716	722	lipids	T109	C0023779
28135040	730	734	risk	T078	C0035647
28135040	738	748	recurrence	T067	C0034897
28135040	774	780	assess	T052	C1516048
28135040	785	796	association	T080	C0439849
28135040	805	817	lipid levels	T059	C0523744
28135040	822	849	recurrent venous thrombosis	T046	C1735901
28135040	851	859	Patients	T101	C0030705
28135040	869	877	Patients	T101	C0030705
28135040	891	908	venous thrombosis	T046	C0042487
28135040	918	928	MEGA study	T062	C0016441
28135040	934	942	included	T169	C0332257
28135040	944	953	Follow-up	T058	C1522577
28135040	954	961	started	T080	C1272689
28135040	969	973	date	T079	C0011008
28135040	977	980	end	T082	C0444930
28135040	984	1007	anticoagulant treatment	T061	C0150457
28135040	1009	1019	Percentile	T081	C1264641
28135040	1020	1030	categories	T170	C0683312
28135040	1034	1039	total	T109	C0543421
28135040	1042	1065	low-density lipoprotein	T109,T123	C0023824
28135040	1068	1104	high-density lipoprotein cholesterol	T109,T123	C0023822
28135040	1106	1119	triglycerides	T109,T123	C0041004
28135040	1124	1141	apolipoproteins B	T116,T123	C0003593
28135040	1146	1148	A1	T116,T123	C0085201
28135040	1154	1165	established	T080	C0443211
28135040	1197	1206	reference	T081	C0034925
28135040	1227	1237	percentile	T081	C1264641
28135040	1240	1246	Lipids	T109	C0023779
28135040	1252	1260	measured	T080	C0444706
28135040	1272	1278	months	T079	C0439231
28135040	1285	1298	discontinuing	T033	C1444662
28135040	1299	1314	anticoagulation	T061	C0003281
28135040	1316	1323	Results	T169	C1274040
28135040	1332	1340	patients	T101	C0030705
28135040	1370	1375	years	T079	C0439234
28135040	1391	1401	recurrence	T067	C0034897
28135040	1403	1417	incidence rate	T081	C1708485
28135040	1427	1434	patient	T101	C0030705
28135040	1437	1442	years	T079	C0439234
28135040	1448	1467	confidence interval	T081	C0009667
28135040	1469	1471	CI	T081	C0009667
28135040	1489	1502	hazard ratios	T081	C2985465
28135040	1503	1510	ranging	T081	C1514721
28135040	1526	1528	CI	T081	C0009667
28135040	1554	1556	CI	T081	C0009667
28135040	1584	1594	percentile	T081	C1264641
28135040	1595	1603	category	T170	C0683312
28135040	1612	1621	reference	T081	C0034925
28135040	1635	1646	association	T080	C0439849
28135040	1654	1664	percentile	T081	C1264641
28135040	1665	1675	categories	T170	C0683312
28135040	1684	1694	recurrence	T067	C0034897
28135040	1699	1711	lipid levels	T059	C0523744
28135040	1715	1719	age-	T032	C0001779
28135040	1724	1727	sex	T032	C0079399
28135040	1738	1744	models	T075	C0026339
28135040	1756	1763	further	T082	C1517331
28135040	1764	1775	adjustments	T169	C0456081
28135040	1780	1795	body mass index	T201	C1305855
28135040	1797	1805	diabetes	T047	C0011847
28135040	1807	1815	estrogen	T109,T121,T125	C0014939
28135040	1820	1826	statin	T109,T121	C0360714
28135040	1827	1830	use	T169	C0457083
28135040	1836	1844	duration	T079	C0449238
28135040	1848	1863	anticoagulation	T061	C0003281
28135040	1865	1873	Subgroup	T185	C1515021
28135040	1874	1882	analyses	T062	C0936012
28135040	1883	1893	stratified	T080	C0205363
28135040	1911	1919	provoked	T080	C1444748
28135040	1926	1932	events	T051	C0441471
28135040	1934	1942	location	T082	C0450429
28135040	1944	1964	deep vein thrombosis	T047	C0149871
28135040	1968	1986	pulmonary embolism	T047	C0034065
28135040	1992	1995	sex	T032	C0079399
28135040	2009	2015	reveal	T080	C0443289
28135040	2019	2030	association	T080	C0439849
28135040	2047	2059	lipid levels	T059	C0523744
28135040	2081	2101	Testing lipid levels	T059	C0523744
28135040	2110	2118	identify	T080	C0205396
28135040	2119	2127	patients	T101	C0030705
28135040	2134	2143	increased	T081	C0205217
28135040	2144	2148	risk	T078	C0035647
28135040	2152	2179	recurrent venous thrombosis	T046	C1735901
28135040	2188	2193	study	T062	C2603343
28135040	2233	2239	events	T051	C0441471
28135040	2262	2271	influence	T077	C4054723
28135040	2285	2293	duration	T079	C0449238
28135040	2297	2312	anticoagulation	T061	C0003281

27644674|t|Breast Cancer Detection Rate, Incidence, Prevalence and Interval Cancer -related Mammography Screening Times among Thai Women
27644674|a|A recent guideline by the American Cancer Society recommended that mammography (MMG) should be done for women starting in their mid-40s. In Thailand, information on opportunistic mammography screening is limited and data on the total incidence of breast cancer are also lacking. The purpose of this study was to estimate the breast cancer detection, incident and prevalence rates among Thai women. We retrospectively reviewed the opportunistic mammography screening of normal women between 30 and 80 years who underwent the procedure between 2001 and 2010. All cases were followed until 2012. The detection rate was calculated for the whole period of observation using ' number of women with positive findings ' divided by ' total number of women screened '. The incidence rate was calculated only at the first MMG while the subsequence rate was calculated based on all new cases detected at each subsequent MMG. Among the 47,430 women, there were 152,091 MMGs or approximately 3.2 occasions per person (range, 1-10). The average duration of the interval between each subsequence visit was 1.8 years. Overall, breast cancer was detected in 543 women, with a detection rate of 10.3 per 1,000 persons. The prevalence rate of breast cancer at the first visit was 5.78 per 1,000 person s. The incidence or new cases detected at any follow-up visit was 10.4 per 1,000 person s. The overall interval cancer was 0.91 per 1,000 women, mainly detected before their second and third MMG, with a rate of 0.0.47 and 0.76 per 1,000 women. Opportunistic mammography screening in Thailand detected 10 cases of breast cancer from each 1,000 women. This paper indicated a high rate of cancer detection during a two year interval, hence, a screening mammogram should be performed more often.
27644674	0	13	Breast Cancer	T191	C0006142
27644674	14	28	Detection Rate	T081	C0392762
27644674	30	39	Incidence	T081	C0021149
27644674	41	51	Prevalence	T081	C0220900
27644674	56	64	Interval	T079	C1272706
27644674	65	71	Cancer	T191	C0006826
27644674	81	102	Mammography Screening	T061	C0203028
27644674	103	108	Times	T079	C0040223
27644674	115	119	Thai	T098	C0337910
27644674	120	125	Women	T098	C0043210
27644674	135	144	guideline	T170	C0162791
27644674	152	175	American Cancer Society	T094	C0002455
27644674	193	204	mammography	T060	C0024671
27644674	206	209	MMG	T060	C0024671
27644674	230	235	women	T098	C0043210
27644674	266	274	Thailand	T083	C0039725
27644674	291	326	opportunistic mammography screening	T058	C0422389
27644674	330	337	limited	T169	C0439801
27644674	342	346	data	T078	C1511726
27644674	360	369	incidence	T081	C0021149
27644674	373	386	breast cancer	T191	C0006142
27644674	425	430	study	T062	C0008972
27644674	438	446	estimate	T081	C0750572
27644674	451	464	breast cancer	T191	C0006142
27644674	465	474	detection	T058	C1516193
27644674	476	484	incident	T067	C1551358
27644674	489	505	prevalence rates	T081	C0220900
27644674	512	516	Thai	T098	C0337910
27644674	517	522	women	T098	C0043210
27644674	556	591	opportunistic mammography screening	T058	C0422389
27644674	602	607	women	T098	C0043210
27644674	626	631	years	T079	C0439234
27644674	650	659	procedure	T058	C0220908
27644674	723	737	detection rate	T081	C0392762
27644674	777	788	observation	T062	C0302523
27644674	797	803	number	T081	C0237753
27644674	807	812	women	T098	C0043210
27644674	818	835	positive findings	T033	C0586815
27644674	851	863	total number	T081	C4288115
27644674	867	872	women	T098	C0043210
27644674	873	881	screened	T060	C0199230
27644674	889	903	incidence rate	T081	C1708485
27644674	908	918	calculated	T169	C0444686
27644674	937	940	MMG	T060	C0024671
27644674	1006	1014	detected	T033	C0442726
27644674	1034	1037	MMG	T060	C0024671
27644674	1056	1061	women	T098	C0043210
27644674	1082	1086	MMGs	T060	C0024671
27644674	1122	1128	person	T098	C0027361
27644674	1156	1164	duration	T079	C0449238
27644674	1172	1180	interval	T079	C1272706
27644674	1220	1225	years	T079	C0439234
27644674	1236	1249	breast cancer	T191	C0006142
27644674	1254	1262	detected	T033	C0442726
27644674	1270	1275	women	T098	C0043210
27644674	1284	1298	detection rate	T081	C0392762
27644674	1317	1324	persons	T098	C0027361
27644674	1330	1345	prevalence rate	T081	C0220900
27644674	1349	1362	breast cancer	T191	C0006142
27644674	1401	1407	person	T098	C0027361
27644674	1415	1424	incidence	T081	C0021149
27644674	1438	1446	detected	T033	C0442726
27644674	1489	1495	person	T098	C0027361
27644674	1511	1519	interval	T079	C1272706
27644674	1546	1551	women	T098	C0043210
27644674	1560	1568	detected	T033	C0442726
27644674	1599	1602	MMG	T060	C0024671
27644674	1645	1650	women	T098	C0043210
27644674	1652	1687	Opportunistic mammography screening	T058	C0422389
27644674	1691	1699	Thailand	T083	C0039725
27644674	1700	1708	detected	T033	C0442726
27644674	1721	1734	breast cancer	T191	C0006142
27644674	1751	1756	women	T098	C0043210
27644674	1794	1810	cancer detection	T058	C1516193
27644674	1829	1837	interval	T079	C1272706
27644674	1848	1867	screening mammogram	T061	C0203028

28415499|t|Antibacterial effect of PEO coating with silver on AA7075
28415499|a|In this work, plasma electrolytic oxidation (PEO) coatings were produced on AA7075 using alkaline solution containing silicates compounds and silver micrometric particles in order to give to the coating an antimicrobial effect. In the optic of circular economy, silver chloride derived from the acid pre-treatment of electronic scraps was used as raw material and successively silver powders were synthesized from silver chloride solution using glucose syrup as reducing agent. The coatings were characterized by scanning electron microscope (SEM), X-ray diffraction analysis (XRD), X-ray photoelectron spectroscopy (XPS), potentiodynamic polarization test and antimicrobial tests. The results evidenced that the obtained coatings were homogenous and give to the samples higher corrosion resistance than untreated alloy. The silver particles, found both inside and outside of the pores that characterize the PEO layer, produced an efficacious antimicrobial effect both against E. coli and S. aureus.
28415499	0	20	Antibacterial effect	T043	C1516022
28415499	24	27	PEO	T067	C1254366
28415499	28	35	coating	T080	C1522408
28415499	41	47	silver	T196	C0037125
28415499	51	57	AA7075	T122,T197	C0002154
28415499	72	101	plasma electrolytic oxidation	T067	C1254366
28415499	103	106	PEO	T067	C1254366
28415499	108	116	coatings	T080	C1522408
28415499	134	140	AA7075	T122,T197	C0002154
28415499	147	155	alkaline	T080	C1979842
28415499	156	164	solution	T167	C0037633
28415499	176	195	silicates compounds	T197	C0086983
28415499	200	206	silver	T196	C0037125
28415499	207	228	micrometric particles	T104	C0597177
28415499	253	260	coating	T080	C1522408
28415499	264	284	antimicrobial effect	T043	C1516022
28415499	293	298	optic	T082	C0449911
28415499	302	318	circular economy	T081	C0870462
28415499	320	335	silver chloride	T197	C0074536
28415499	353	357	acid	T103	C0001128
28415499	358	371	pre-treatment	T079	C2709094
28415499	375	392	electronic scraps	T068	C2936634
28415499	405	408	raw	T080	C1709843
28415499	409	417	material	T167	C0520510
28415499	435	441	silver	T196	C0037125
28415499	442	449	powders	T167	C1382110
28415499	455	466	synthesized	T052	C1883254
28415499	472	487	silver chloride	T197	C0074536
28415499	488	496	solution	T167	C0037633
28415499	503	516	glucose syrup	T109,T121,T123	C0017725
28415499	520	534	reducing agent	T130	C0376446
28415499	540	548	coatings	T080	C1522408
28415499	571	599	scanning electron microscope	T074	C0262878
28415499	601	604	SEM	T074	C0262878
28415499	607	633	X-ray diffraction analysis	T059	C0599643
28415499	635	638	XRD	T059	C0599643
28415499	641	673	X-ray photoelectron spectroscopy	T059	C2700282
28415499	675	678	XPS	T059	C2700282
28415499	681	714	potentiodynamic polarization test	T059	C0022885
28415499	719	738	antimicrobial tests	T059	C0201179
28415499	780	788	coatings	T080	C1522408
28415499	794	804	homogenous	T082	C0439713
28415499	821	828	samples	T167	C0370003
28415499	829	835	higher	T080	C0205250
28415499	836	845	corrosion	T070	C0010106
28415499	846	856	resistance	T169	C4281815
28415499	862	871	untreated	T033	C0243095
28415499	872	877	alloy	T122,T197	C0002154
28415499	883	889	silver	T196	C0037125
28415499	890	899	particles	T104	C0597177
28415499	912	918	inside	T082	C0205102
28415499	923	930	outside	T082	C0205101
28415499	938	943	pores	T081	C3829176
28415499	966	969	PEO	T067	C1254366
28415499	970	975	layer	T080	C1522408
28415499	989	1000	efficacious	T080	C1704419
28415499	1001	1021	antimicrobial effect	T043	C1516022
28415499	1027	1034	against	T080	C0521124
28415499	1035	1042	E. coli	T007	C0014834
28415499	1047	1056	S. aureus	T007	C0038172

27598262|t|Macular Ganglion Cell - Inner Plexiform Layer Thickness Is Associated with Clinical Progression in Mild Cognitive Impairment and Alzheimers Disease
27598262|a|We investigated the association of the macular ganglion cell - inner plexiform layer (GCIPL) and peripapillary retinal nerve fiber layer (RNFL) thicknesses with disease progression in mild cognitive impairment (MCI) and Alzheimer's disease (AD). We recruited 42 patients with AD, 26 with MCI, and 66 normal elderly controls. The thicknesses of the RNFL and GCIPL were measured via spectral-domain optic coherent tomography in all participants at baseline. The patients with MCI or AD underwent clinical and neuropsychological tests at baseline and once every year thereafter for 2 years. The Clinical Dementia Rating scale-Sum of Boxes (CDR-SB) score exhibited significant negative relationships with the average GCIPL thickness (β = -0.15, p < 0.05) and the GCIPL thickness in the superotemporal, superonasal, and inferonasal sectors. The composite memory score exhibited significant positive associations with the average GCIPL thickness and the GCIPL thickness in the superotemporal, inferonasal, and inferotemporal sectors. The temporal RNFL thickness, the average and minimum GCIPL thicknesses, and the GCIPL thickness in the inferonasal, inferior, and inferotemporal sectors at baseline were significantly reduced in MCI patients who were converted to AD compared to stable MCI patients. The change of CDR-SB from baseline to 2 years exhibited significant negative associations with the average (β = -0.150, p = 0.006) and minimum GCIPL thicknesses as well as GCIPL thickness in the superotemporal, superior, superonasal, and inferonasal sectors at baseline. Our data suggest that macular GCIPL thickness represents a promising biomarker for monitoring the progression of MCI and AD.
27598262	0	7	Macular	T082	C0332574
27598262	8	21	Ganglion Cell	T025	C0228071
27598262	24	45	Inner Plexiform Layer	T023	C1512785
27598262	46	55	Thickness	T080	C1280412
27598262	59	74	Associated with	T080	C0332281
27598262	75	95	Clinical Progression	T046	C0242656
27598262	99	124	Mild Cognitive Impairment	T047	C1719378
27598262	129	147	Alzheimers Disease	T047	C0002395
27598262	187	194	macular	T082	C0332574
27598262	195	208	ganglion cell	T025	C0228071
27598262	211	232	inner plexiform layer	T023	C1512785
27598262	234	239	GCIPL	T023	C1512785
27598262	245	284	peripapillary retinal nerve fiber layer	T023	C1517753
27598262	286	290	RNFL	T023	C1517753
27598262	292	303	thicknesses	T080	C1280412
27598262	309	328	disease progression	T046	C0242656
27598262	332	357	mild cognitive impairment	T047	C1719378
27598262	359	362	MCI	T047	C1719378
27598262	368	387	Alzheimer's disease	T047	C0002395
27598262	389	391	AD	T047	C0002395
27598262	410	418	patients	T101	C0030705
27598262	424	426	AD	T047	C0002395
27598262	436	439	MCI	T047	C1719378
27598262	455	471	elderly controls	T096	C0009932
27598262	477	488	thicknesses	T080	C1280412
27598262	496	500	RNFL	T023	C1517753
27598262	505	510	GCIPL	T023	C1512785
27598262	529	570	spectral-domain optic coherent tomography	T074	C3876157
27598262	578	590	participants	T098	C0679646
27598262	594	602	baseline	T081	C1442488
27598262	608	616	patients	T101	C0030705
27598262	622	625	MCI	T047	C1719378
27598262	629	631	AD	T047	C0002395
27598262	642	650	clinical	T080	C0205210
27598262	655	679	neuropsychological tests	T060	C0027902
27598262	683	691	baseline	T081	C1442488
27598262	696	734	once every year thereafter for 2 years	T079	C1254367
27598262	740	783	Clinical Dementia Rating scale-Sum of Boxes	T170	C3827230
27598262	785	791	CDR-SB	T170	C3827230
27598262	793	798	score	T081	C0449820
27598262	821	829	negative	T033	C0205160
27598262	830	843	relationships	T080	C0439849
27598262	853	866	average GCIPL	T023	C1512785
27598262	867	876	thickness	T080	C1280412
27598262	907	912	GCIPL	T023	C1512785
27598262	913	922	thickness	T080	C1280412
27598262	930	944	superotemporal	T029	C1275875
27598262	946	957	superonasal	T029	C1275872
27598262	963	982	inferonasal sectors	T029	C1275873
27598262	988	1010	composite memory score	T081	C0449820
27598262	1033	1041	positive	T033	C1446409
27598262	1042	1054	associations	T080	C0439849
27598262	1064	1077	average GCIPL	T023	C1512785
27598262	1078	1087	thickness	T080	C1280412
27598262	1096	1101	GCIPL	T023	C1512785
27598262	1102	1111	thickness	T080	C1280412
27598262	1119	1133	superotemporal	T029	C1275875
27598262	1135	1146	inferonasal	T029	C1275873
27598262	1152	1174	inferotemporal sectors	T029	C1275868
27598262	1180	1193	temporal RNFL	T023	C1517753
27598262	1194	1203	thickness	T080	C1280412
27598262	1229	1234	GCIPL	T023	C1512785
27598262	1235	1246	thicknesses	T080	C1280412
27598262	1256	1261	GCIPL	T023	C1512785
27598262	1262	1271	thickness	T080	C1280412
27598262	1279	1290	inferonasal	T029	C1275873
27598262	1292	1300	inferior	T029	C0005898
27598262	1306	1328	inferotemporal sectors	T029	C1275868
27598262	1332	1340	baseline	T081	C1442488
27598262	1360	1367	reduced	T080	C0392756
27598262	1371	1374	MCI	T047	C1719378
27598262	1375	1383	patients	T101	C0030705
27598262	1406	1408	AD	T047	C0002395
27598262	1428	1431	MCI	T047	C1719378
27598262	1432	1440	patients	T101	C0030705
27598262	1456	1462	CDR-SB	T170	C3827230
27598262	1468	1476	baseline	T081	C1442488
27598262	1482	1487	years	T079	C0439234
27598262	1510	1518	negative	T033	C0205160
27598262	1519	1531	associations	T080	C0439849
27598262	1577	1590	minimum GCIPL	T023	C1512785
27598262	1591	1602	thicknesses	T080	C1280412
27598262	1614	1619	GCIPL	T023	C1512785
27598262	1620	1629	thickness	T080	C1280412
27598262	1637	1651	superotemporal	T029	C1275875
27598262	1653	1661	superior	T029	C0005898
27598262	1663	1674	superonasal	T029	C1275872
27598262	1680	1699	inferonasal sectors	T029	C1275873
27598262	1703	1711	baseline	T081	C1442488
27598262	1743	1748	GCIPL	T023	C1512785
27598262	1749	1758	thickness	T080	C1280412
27598262	1782	1791	biomarker	T201	C0005516
27598262	1811	1822	progression	T046	C0242656
27598262	1826	1829	MCI	T047	C1719378
27598262	1834	1836	AD	T047	C0002395

27282214|t|Individual differences in behavioral activation and cardiac vagal control influence affective startle modification
27282214|a|The startle response (SR) has a close relationship with stress responses. Startle modification (SRM) has been widely used to study stress disorders (e.g., posttraumatic stress disorder). The framework of the behavioral inhibition and activation systems (BIS / BAS) has been thought to correspond with withdrawal and approach motivational processes underlying affective SRM and can influence stress reactivity. Vagally-mediated cardiac activity as indexed by heart rate variability (HRV) has been associated with SRM and regulatory processes during stress. In the present study, the influence of individual differences in the BIS / BAS and resting HRV on affective SRM were examined. Eighty-six subjects viewed affective pictures while acoustic SR stimuli were delivered. Individual differences in motivation were measured by the BIS/BAS scales. The magnitude of SR was assessed as electromyographic activity of the SR eyeblink during pictures of different valences. Resting HRV was derived from electrocardiography. In contrast to previous studies, the present results showed that startle inhibition and potentiation were related to BAS and HRV, but not to BIS. There was also an interaction of BAS and HRV, indicating that the relationship between HRV and SRM strengthened as BAS scores decreased. The present findings suggest that BAS may relate to both withdrawal and approach, and trait stress reactivity is influence d by BAS and cardiac vagal activity. In addition, BAS moderates the relationship between cardiac vagal activity and SRM. These findings have both theoretical and practical implications for the study of SRM, stress disorders, and health.
27282214	0	22	Individual differences	T054	C0021228
27282214	26	47	behavioral activation	T040	C2253866
27282214	52	73	cardiac vagal control	T044	C1148560
27282214	74	83	influence	T077	C4054723
27282214	94	114	startle modification	T169	C0449851
27282214	119	135	startle response	T040	C0038186
27282214	137	139	SR	T040	C0038186
27282214	153	165	relationship	T080	C0439849
27282214	171	187	stress responses	T039	C0149784
27282214	189	209	Startle modification	T169	C0449851
27282214	211	214	SRM	T169	C0449851
27282214	246	262	stress disorders	T048	C0004936
27282214	270	299	posttraumatic stress disorder	T048	C0038436
27282214	323	344	behavioral inhibition	T041	C0039474
27282214	369	372	BIS	T041	C0039474
27282214	440	462	motivational processes	T041	C0026605
27282214	484	487	SRM	T169	C0449851
27282214	496	505	influence	T077	C4054723
27282214	506	523	stress reactivity	T039	C2350025
27282214	525	558	Vagally-mediated cardiac activity	T033	C0443168
27282214	562	569	indexed	T170	C0918012
27282214	573	595	heart rate variability	T033	C0243095
27282214	597	600	HRV	T033	C0243095
27282214	611	626	associated with	T080	C0332281
27282214	627	630	SRM	T169	C0449851
27282214	635	655	regulatory processes	T038	C1327622
27282214	663	669	stress	T033	C0038435
27282214	697	706	influence	T077	C4054723
27282214	710	732	individual differences	T054	C0021228
27282214	740	743	BIS	T041	C0039474
27282214	762	765	HRV	T033	C0243095
27282214	779	782	SRM	T169	C0449851
27282214	788	796	examined	T033	C0332128
27282214	798	817	Eighty-six subjects	T096	C0681850
27282214	835	843	pictures	T073	C0441469
27282214	850	869	acoustic SR stimuli	T070	C0683110
27282214	886	908	Individual differences	T054	C0021228
27282214	912	922	motivation	T041	C0026605
27282214	928	936	measured	T080	C0444706
27282214	944	958	BIS/BAS scales	T170	C0282574
27282214	964	973	magnitude	T081	C1704240
27282214	977	979	SR	T040	C0038186
27282214	984	992	assessed	T052	C1516048
27282214	996	1013	electromyographic	T060	C0013839
27282214	1014	1022	activity	T052	C0441655
27282214	1030	1032	SR	T040	C0038186
27282214	1033	1041	eyeblink	T042	C0005757
27282214	1049	1057	pictures	T073	C0441469
27282214	1071	1079	valences	T080	C0205556
27282214	1089	1092	HRV	T033	C0243095
27282214	1110	1129	electrocardiography	T060	C1623258
27282214	1176	1183	results	T169	C1274040
27282214	1196	1214	startle inhibition	T044	C1148560
27282214	1219	1231	potentiation	T044	C1148560
27282214	1256	1259	HRV	T033	C0243095
27282214	1272	1275	BIS	T041	C0039474
27282214	1295	1306	interaction	T169	C1704675
27282214	1318	1321	HRV	T033	C0243095
27282214	1343	1355	relationship	T080	C0439849
27282214	1364	1367	HRV	T033	C0243095
27282214	1372	1375	SRM	T169	C0449851
27282214	1396	1402	scores	T081	C0449820
27282214	1426	1434	findings	T033	C0243095
27282214	1500	1505	trait	T032	C0599883
27282214	1506	1523	stress reactivity	T039	C2350025
27282214	1527	1536	influence	T077	C4054723
27282214	1550	1572	cardiac vagal activity	T033	C0443168
27282214	1605	1617	relationship	T080	C0439849
27282214	1626	1648	cardiac vagal activity	T033	C0443168
27282214	1653	1656	SRM	T169	C0449851
27282214	1664	1672	findings	T033	C0243095
27282214	1683	1721	theoretical and practical implications	T169	C0205245
27282214	1739	1742	SRM	T169	C0449851
27282214	1744	1760	stress disorders	T048	C0004936
27282214	1766	1772	health	T078	C0018684

28299685|t|Fabrication of Lab-on-Paper Using Porous Au-Paper Electrode: Application to Tumor Marker Electrochemical Immunoassays
28299685|a|A simple, low-cost, and sensitive electrochemical lab-on-paper assay is developed based on a novel gold nanoparticle modified porous paper working electrode for use in point-of-care testing (POCT). Electrochemical methods are introduced for lab-on-paper based on screen-printed paper electrodes. To further improve specificity, performance, and sensitivity for point-of-care testing, a novel porous Au-paper working electrode (Au-PWE) is designed for lab-on-paper using growth of an interconnected Au nanoparticle (NP) layer on the surface of cellulose fibers in order to enhance the conductivity of the paper sample zone and immobilize the primary antibodies (Ab1). With a sandwich-type immunoassay format, Pd - Au bimetallic nanoparticles possessing peroxidase-like activity are used as a matrix to immobilize secondary antibodies (Ab2) for rapid detection of targets. This lab-on-paper based immunodevice is applied to the diagnosis of a cancer biomarker in clinical serum samples.
28299685	0	11	Fabrication	T058	C1254363
28299685	15	27	Lab-on-Paper	T074	C0025080
28299685	34	40	Porous	T082	C1254362
28299685	41	59	Au-Paper Electrode	T074	C0025080
28299685	61	72	Application	T169	C4048755
28299685	76	88	Tumor Marker	T123	C0041365
28299685	89	117	Electrochemical Immunoassays	T059	C2957197
28299685	120	126	simple	T080	C0205352
28299685	128	136	low-cost	T081	C0010186
28299685	142	151	sensitive	T169	C0332324
28299685	152	186	electrochemical lab-on-paper assay	T059	C2957197
28299685	217	221	gold	T121,T196	C0018026
28299685	222	234	nanoparticle	T073	C1721060
28299685	244	250	porous	T082	C1254362
28299685	251	256	paper	T073	C0030351
28299685	257	274	working electrode	T074	C0013812
28299685	286	307	point-of-care testing	T058	C1319069
28299685	309	313	POCT	T058	C1319069
28299685	316	339	Electrochemical methods	T059	C2350499
28299685	359	371	lab-on-paper	T074	C0025080
28299685	396	401	paper	T073	C0030351
28299685	402	412	electrodes	T074	C0013812
28299685	433	444	specificity	T081	C0037791
28299685	446	457	performance	T080	C0205556
28299685	463	474	sensitivity	T080	C0205556
28299685	479	500	point-of-care testing	T058	C1319069
28299685	510	516	porous	T082	C1254362
28299685	517	543	Au-paper working electrode	T074	C0013812
28299685	545	551	Au-PWE	T074	C0013812
28299685	569	581	lab-on-paper	T074	C0025080
28299685	588	594	growth	T067	C2911660
28299685	616	618	Au	T121,T196	C0018026
28299685	619	631	nanoparticle	T073	C1721060
28299685	633	635	NP	T073	C1721060
28299685	661	670	cellulose	T109,T123	C0007648
28299685	671	677	fibers	T109,T121	C0225326
28299685	702	714	conductivity	T080	C0205556
28299685	722	727	paper	T073	C0030351
28299685	744	754	immobilize	T052	C0441655
28299685	759	777	primary antibodies	T116,T129	C0003241
28299685	779	782	Ab1	T116,T129	C0003241
28299685	806	824	immunoassay format	T170	C1301627
28299685	826	828	Pd	T196	C0030230
28299685	831	833	Au	T121,T196	C0018026
28299685	834	858	bimetallic nanoparticles	T073	C1721060
28299685	870	894	peroxidase-like activity	T070	C1254365
28299685	909	915	matrix	T082	C1704640
28299685	919	929	immobilize	T052	C0441655
28299685	930	950	secondary antibodies	T116,T129	C0003241
28299685	952	955	Ab2	T116,T129	C0003241
28299685	994	1006	lab-on-paper	T074	C0025080
28299685	1013	1025	immunodevice	T074	C0025080
28299685	1044	1053	diagnosis	T033	C0011900
28299685	1059	1065	cancer	T191	C0006826
28299685	1066	1075	biomarker	T201	C0005516
28299685	1079	1087	clinical	T080	C0205210
28299685	1088	1101	serum samples	T031	C1550100

27553395|t|Nutrient intake of infants and toddlers in the United Arab Emirates: the Feeding Infants and Toddlers Study
27553395|a|This descriptive study evaluated the nutrient adequacy of the diet of infants (aged 6-11.9 months) and toddlers (aged 12-24 months) in the United Arab Emirates. A random sample of 1000 infants and toddlers was recruited from 2 cities (Al Ain and Dubai) from March 2011 to February 2012 and their usual nutrient intake was determined using 24-hour recall. In all, 54.2% of infants and 25.2% of toddlers were breastfeeding. Mean energy intake of infant girls in Al Ain and Dubai was 747 (SD 189) kcal and 773 (SD 215) kcal respectively and 810.5 (SD 232.2) kcal and 821.9 (SD 262) kcal for boys. In toddlers, mean energy intake for girls in Al Ain and Dubai was 1032.8 (SD 252) kcal and 1013 (SD 339.1) kcal respectively and 1057.2 (SD 201.8) kcal and 1030.3 (SD 341.7) kcal for boys. Iron intake was low in both groups. Mean body mass index and body weight and height were similar to World Health Organization figures but significant numbers of infants and toddlers of both sexes were over - or underweight. Although mean energy and macronutrient intakes were comparable to the RDA, significant numbers were over - or underfed.
27553395	0	15	Nutrient intake	T058	C0558027
27553395	19	26	infants	T100	C0021270
27553395	31	39	toddlers	T100	C0682053
27553395	47	67	United Arab Emirates	T083	C0041698
27553395	81	88	Infants	T100	C0021270
27553395	93	101	Toddlers	T100	C0682053
27553395	145	162	nutrient adequacy	T081	C0006777
27553395	170	174	diet	T168	C0012155
27553395	178	185	infants	T100	C0021270
27553395	211	219	toddlers	T100	C0682053
27553395	247	267	United Arab Emirates	T083	C0041698
27553395	293	300	infants	T100	C0021270
27553395	305	313	toddlers	T100	C0682053
27553395	343	349	Al Ain	T083	C0041698
27553395	354	359	Dubai	T083	C0041698
27553395	366	371	March	T079	C3829202
27553395	380	388	February	T080	C3830166
27553395	410	425	nutrient intake	T058	C0558027
27553395	480	487	infants	T100	C0021270
27553395	501	509	toddlers	T100	C0682053
27553395	515	528	breastfeeding	T040	C0006147
27553395	535	548	energy intake	T081	C0006777
27553395	552	564	infant girls	T100	C0870604
27553395	568	574	Al Ain	T083	C0041698
27553395	579	584	Dubai	T083	C0041698
27553395	602	606	kcal	T081	C0439259
27553395	624	628	kcal	T081	C0439259
27553395	663	667	kcal	T081	C0439259
27553395	687	691	kcal	T081	C0439259
27553395	696	700	boys	T100	C0870221
27553395	705	713	toddlers	T100	C0682053
27553395	720	733	energy intake	T081	C0006777
27553395	738	743	girls	T100	C0870604
27553395	784	788	kcal	T081	C0439259
27553395	809	813	kcal	T081	C0439259
27553395	849	853	kcal	T081	C0439259
27553395	876	880	kcal	T081	C0439259
27553395	885	889	boys	T100	C0870221
27553395	891	902	Iron intake	T033	C0518043
27553395	907	910	low	T080	C0205251
27553395	932	947	body mass index	T201	C1305855
27553395	952	963	body weight	T032	C0005910
27553395	968	974	height	T032	C0005890
27553395	991	1016	World Health Organization	T093	C0043237
27553395	1052	1059	infants	T100	C0021270
27553395	1064	1072	toddlers	T100	C0682053
27553395	1092	1096	over	T184	C0497406
27553395	1102	1113	underweight	T033	C0041667
27553395	1140	1153	macronutrient	T077	C2346926
27553395	1154	1161	intakes	T058	C0558027
27553395	1185	1188	RDA	T170	C0524787
27553395	1215	1219	over	T047	C1257763
27553395	1225	1233	underfed	T047	C0162429

28042952|t|Uncoupling protein 2 downregulation by hypoxia through repression of peroxisome proliferator-activated receptor γ promotes chemoresistance of non-small cell lung cancer
28042952|a|Hypoxic microenvironment is critically involved in the response of non-small cell lung cancer (NSCLC) to chemotherapy, the mechanisms of which remain largely unknown. Here, we found that NSCLC patients exhibited increased chemotherapeutic resistance when complicated by chronic obstructive pulmonary disease (COPD), a critical cause of chronic hypoxemia. The downregulation of uncoupling protein 2 (UCP2), which is attributed to hypoxia-inducible factor 1 (HIF-1)-mediated suppression of the transcriptional factor peroxisome proliferator-activated receptor γ (PPARγ), was involved in NSCLC chemoresistance, and predicted a poor survival rate of patients receiving routine chemotherapy. UCP2 suppression induced reactive oxygen species production and upregulation of the ABC transporter protein ABCG2, which leads to chemoresistance by promoting drug efflux. UCP2 downregulation also altered metabolic rates as shown by elevated glucose uptake and reduced oxygen consumption. These data suggest that UCP2 is a key mediator of hypoxia -triggered chemoresistance of NSCLCs, which can be potentially targeted in clinical treatment of chemo-refractory NSCLCs.
28042952	0	20	Uncoupling protein 2	T116,T121	C0536847
28042952	21	35	downregulation	T044	C0013081
28042952	39	46	hypoxia	T046	C0242184
28042952	55	65	repression	T045	C0920533
28042952	69	113	peroxisome proliferator-activated receptor γ	T116,T192	C0166417
28042952	123	138	chemoresistance	T039	C1514892
28042952	142	168	non-small cell lung cancer	T191	C0007131
28042952	169	176	Hypoxic	T046	C0242184
28042952	177	193	microenvironment	T082	C0014406
28042952	224	232	response	T032	C0871261
28042952	236	262	non-small cell lung cancer	T191	C0007131
28042952	264	269	NSCLC	T191	C0007131
28042952	274	286	chemotherapy	T061	C3665472
28042952	292	302	mechanisms	T169	C0441712
28042952	356	361	NSCLC	T191	C0007131
28042952	362	370	patients	T101	C0030705
28042952	381	390	increased	T081	C0205217
28042952	391	418	chemotherapeutic resistance	T039	C1514892
28042952	424	435	complicated	T169	C0231242
28042952	439	476	chronic obstructive pulmonary disease	T047	C0024117
28042952	478	482	COPD	T047	C0024117
28042952	487	495	critical	T080	C1511545
28042952	496	501	cause	T169	C0015127
28042952	505	522	chronic hypoxemia	T033	C0745188
28042952	528	542	downregulation	T044	C0013081
28042952	546	566	uncoupling protein 2	T116,T121	C0536847
28042952	568	572	UCP2	T116,T121	C0536847
28042952	598	624	hypoxia-inducible factor 1	T116,T123	C0215848
28042952	626	631	HIF-1	T116,T123	C0215848
28042952	642	653	suppression	T045	C0038855
28042952	661	683	transcriptional factor	T116,T123	C0040648
28042952	684	728	peroxisome proliferator-activated receptor γ	T116,T192	C0166417
28042952	730	735	PPARγ	T116,T192	C0166417
28042952	754	759	NSCLC	T191	C0007131
28042952	760	775	chemoresistance	T039	C1514892
28042952	793	797	poor	T080	C2700379
28042952	798	811	survival rate	T081	C0038954
28042952	815	823	patients	T101	C0030705
28042952	834	841	routine	T080	C0205547
28042952	842	854	chemotherapy	T061	C3665472
28042952	856	860	UCP2	T116,T121	C0536847
28042952	861	872	suppression	T039	C1514892
28042952	873	880	induced	T169	C0205263
28042952	881	904	reactive oxygen species	T123,T196	C0162772
28042952	920	932	upregulation	T044	C0041904
28042952	940	963	ABC transporter protein	T116,T123	C0242738
28042952	964	969	ABCG2	T116,T123	C0761993
28042952	986	1001	chemoresistance	T039	C1514892
28042952	1005	1014	promoting	T052	C0033414
28042952	1015	1026	drug efflux	T044	C1512072
28042952	1028	1032	UCP2	T116,T121	C0536847
28042952	1033	1047	downregulation	T044	C0013081
28042952	1053	1060	altered	T169	C0392747
28042952	1061	1076	metabolic rates	T039	C0870882
28042952	1089	1097	elevated	T080	C3163633
28042952	1098	1112	glucose uptake	T043	C1159527
28042952	1117	1124	reduced	T080	C0392756
28042952	1125	1143	oxygen consumption	T201	C0030055
28042952	1169	1173	UCP2	T116,T121	C0536847
28042952	1195	1202	hypoxia	T046	C0242184
28042952	1214	1229	chemoresistance	T039	C1514892
28042952	1233	1239	NSCLCs	T191	C0007131
28042952	1278	1296	clinical treatment	T061	C1516635
28042952	1300	1316	chemo-refractory	T169	C0205269
28042952	1317	1323	NSCLCs	T191	C0007131

28438506|t|Diacylglycerol Kinase ζ Limits Cytokine -dependent Expansion of CD8(+) T Cells with Broad Antitumor Capacity
28438506|a|Interleukin-2 and -15 drive expansion / differentiation of cytotoxic CD8(+) T cells that eliminate targets via antigen-independent killing. This property is clinically relevant for the improvement of T cell -based antitumor therapies. Diacylglycerol kinase α and ζ (DGKα / ζ) metabolize the diacylglycerol generated following antigen recognition by T lymphocytes. Enhanced expression of these two lipid kinases in tumor-infiltrating CD8(+) T cells promotes a hyporesponsive state that contributes to tumor immune escape. Inhibition of these two enzymes might thus be of interest for potentiating conventional antigen -directed tumor elimination. In this study, we sought to characterize the contribution of DGKα and ζ to antigen -independent cytotoxic functions of CD8(+) T cells. Analysis of DGKζ - deficient mice showed an increase in bystander memory -like CD8(+) T cell populations not observed in DGKα - deficient mice. We demonstrate that DGKζ limits cytokine responses in an antigen -independent manner. Cytokine -specific expansion of DGKζ - deficient CD8(+) T cells promoted enhanced differentiation of innate-like cytotoxic cells in vitro, and correlated with the more potent in vivo anti-tumor responses of DGKζ - deficient mice engrafted with the murine A20 lymphoma. Our studies reveal a isoform - specific function for DGKζ downstream of IL-2 / IL-15 -mediated expansion of innate-like cytotoxic T cells, Pharmacological manipulation of DGKζ activity is of therapeutic interest for cytokine -directed anti-tumor treatments.
28438506	0	23	Diacylglycerol Kinase ζ	T116,T123	C1743812
28438506	31	39	Cytokine	T116,T129	C0079189
28438506	51	60	Expansion	T043	C0007595
28438506	64	78	CD8(+) T Cells	T025	C0242629
28438506	90	108	Antitumor Capacity	T033	C0243095
28438506	109	122	Interleukin-2	T116,T129	C0021756
28438506	127	130	-15	T116,T129	C0254610
28438506	137	146	expansion	T043	C0007595
28438506	149	164	differentiation	T043	C0007589
28438506	168	192	cytotoxic CD8(+) T cells	T025	C0039195
28438506	220	247	antigen-independent killing	T043	C0599733
28438506	254	262	property	T080	C0871161
28438506	266	276	clinically	T080	C0205210
28438506	277	285	relevant	T080	C2347946
28438506	309	315	T cell	T025	C0242629
28438506	323	342	antitumor therapies	T061	C0087111
28438506	344	367	Diacylglycerol kinase α	T116,T126	C3815868
28438506	372	373	ζ	T116,T123	C1743812
28438506	375	379	DGKα	T116,T126	C3815868
28438506	382	383	ζ	T116,T123	C1743812
28438506	385	395	metabolize	T044	C1148560
28438506	400	414	diacylglycerol	T109,T121,T123	C0043791
28438506	435	454	antigen recognition	UnknownType	C0678894
28438506	458	471	T lymphocytes	T025	C0242629
28438506	482	492	expression	T045	C1171362
28438506	506	519	lipid kinases	T116,T126	C0113519
28438506	523	556	tumor-infiltrating CD8(+) T cells	T025	C0079722
28438506	568	588	hyporesponsive state	T169	C1442792
28438506	609	628	tumor immune escape	T046	C0282683
28438506	630	640	Inhibition	T039	C1524081
28438506	654	661	enzymes	T116,T126	C0014442
28438506	718	725	antigen	T129	C0003320
28438506	736	741	tumor	T191	C0027651
28438506	742	753	elimination	T058	C3178995
28438506	783	795	characterize	T052	C1880022
28438506	800	812	contribution	T052	C1880177
28438506	816	820	DGKα	T116,T126	C3815868
28438506	825	826	ζ	T116,T123	C1743812
28438506	830	837	antigen	T129	C0003320
28438506	851	860	cytotoxic	T169	C1511636
28438506	861	870	functions	T169	C0542341
28438506	874	888	CD8(+) T cells	T025	C0242629
28438506	890	898	Analysis	T062	C0936012
28438506	902	906	DGKζ	T116,T123	C1743812
28438506	909	918	deficient	T169	C0011155
28438506	919	923	mice	T015	C0025929
28438506	934	942	increase	T169	C0442805
28438506	946	962	bystander memory	T043	C0949629
28438506	969	994	CD8(+) T cell populations	T025	C0242629
28438506	1011	1015	DGKα	T116,T126	C3815868
28438506	1018	1027	deficient	T169	C0011155
28438506	1028	1032	mice	T015	C0025929
28438506	1054	1058	DGKζ	T116,T123	C1743812
28438506	1066	1084	cytokine responses	T043	C2247677
28438506	1091	1098	antigen	T129	C0003320
28438506	1112	1118	manner	T169	C0205245
28438506	1120	1128	Cytokine	T116,T129	C0079189
28438506	1139	1148	expansion	T043	C0007595
28438506	1152	1156	DGKζ	T116,T123	C1743812
28438506	1159	1168	deficient	T169	C0011155
28438506	1169	1183	CD8(+) T cells	T025	C0242629
28438506	1202	1217	differentiation	T043	C0007589
28438506	1221	1248	innate-like cytotoxic cells	T025	C0039195
28438506	1249	1257	in vitro	T080	C1533691
28438506	1295	1302	in vivo	T082	C1515655
28438506	1303	1323	anti-tumor responses	T033	C0243095
28438506	1327	1331	DGKζ	T116,T123	C1743812
28438506	1334	1343	deficient	T169	C0011155
28438506	1344	1348	mice	T015	C0025929
28438506	1368	1378	murine A20	T015	C0026809
28438506	1379	1387	lymphoma	T191	C0024299
28438506	1410	1417	isoform	T116	C0597298
28438506	1420	1428	specific	T080	C0205369
28438506	1429	1437	function	T169	C0542341
28438506	1442	1446	DGKζ	T116,T123	C1743812
28438506	1447	1457	downstream	T082	C0522506
28438506	1461	1465	IL-2	T116,T129	C0021756
28438506	1468	1473	IL-15	T116,T129	C0254610
28438506	1484	1493	expansion	T043	C0007595
28438506	1497	1526	innate-like cytotoxic T cells	T025	C0039195
28438506	1528	1543	Pharmacological	T169	C0205464
28438506	1544	1556	manipulation	T061	C0947647
28438506	1560	1564	DGKζ	T116,T123	C1743812
28438506	1565	1573	activity	T044	C0243102
28438506	1605	1613	cytokine	T116,T129	C0079189
28438506	1624	1645	anti-tumor treatments	T061	C0087111

27976741|t|Weighing Scale -Based Pulse Transit Time is a Superior Marker of Blood Pressure than Conventional Pulse Arrival Time
27976741|a|Pulse transit time (PTT) is being widely pursued for cuff-less blood pressure (BP) monitoring. Most efforts have employed the time delay between ECG and finger photoplethysmography (PPG) waveforms as a convenient surrogate of PTT. However, these conventional pulse arrival time (PAT) measurements include the pre-ejection period (PEP) and the time delay through small, muscular arteries and may thus be an unreliable marker of BP. We assessed a bathroom weighing scale-like system for convenient measurement of ballistocardiography and foot PPG waveforms - and thus PTT through larger, more elastic arteries - in terms of its ability to improve tracking of BP in individual subjects. We measured " scale PTT ", conventional PAT, and cuff BP in humans during interventions that increased BP but changed PEP and smooth muscle contraction differently. Scale PTT tracked the diastolic BP changes well, with correlation coefficient of -0.80 ± 0.02 (mean ± SE) and root-mean-squared-error of 7.6 ± 0.5 mmHg after a best-case calibration. Conventional PAT was significantly inferior in tracking these changes, with correlation coefficien t of -0.60 ± 0.04 and root-mean-squared-error of 14.6 ± 1.5 mmHg (p < 0.05). Scale PTT also tracked the systolic BP changes better than conventional PAT but not to an acceptable level. With further development, scale PTT may permit reliable, convenient measurement of BP.
27976741	0	14	Weighing Scale	T074	C0183106
27976741	22	40	Pulse Transit Time	T081	C3494432
27976741	55	61	Marker	T080	C0008963
27976741	65	79	Blood Pressure	T040	C0005823
27976741	98	116	Pulse Arrival Time	T081	C0392762
27976741	117	135	Pulse transit time	T081	C3494432
27976741	137	140	PTT	T081	C3494432
27976741	170	210	cuff-less blood pressure (BP) monitoring	T058	C0026426
27976741	243	253	time delay	T079	C0522486
27976741	262	265	ECG	T060	C1623258
27976741	270	276	finger	T023	C0016129
27976741	277	297	photoplethysmography	T060	C0162599
27976741	299	302	PPG	T060	C0162599
27976741	304	313	waveforms	T033	C0428727
27976741	343	346	PTT	T081	C3494432
27976741	376	394	pulse arrival time	T081	C0392762
27976741	396	399	PAT	T081	C0392762
27976741	401	413	measurements	T169	C0242485
27976741	426	445	pre-ejection period	T201	C0807477
27976741	447	450	PEP	T201	C0807477
27976741	460	470	time delay	T079	C0522486
27976741	486	503	muscular arteries	T023	C0226002
27976741	534	540	marker	T080	C0008963
27976741	544	546	BP	T040	C0005823
27976741	562	597	bathroom weighing scale-like system	T074	C0025080
27976741	613	624	measurement	T169	C0242485
27976741	628	648	ballistocardiography	T060	C0004700
27976741	658	661	PPG	T060	C0162599
27976741	662	671	waveforms	T033	C0428727
27976741	683	686	PTT	T081	C3494432
27976741	708	724	elastic arteries	T023	C0226008
27976741	762	770	tracking	T082	C0546881
27976741	774	776	BP	T040	C0005823
27976741	780	799	individual subjects	UnknownType	C0681857
27976741	815	820	scale	T074	C0025080
27976741	821	824	PTT	T081	C3494432
27976741	841	844	PAT	T081	C0392762
27976741	850	854	cuff	T023	C1550244
27976741	855	857	BP	T040	C0005823
27976741	861	867	humans	T016	C0086418
27976741	904	906	BP	T040	C0005823
27976741	919	922	PEP	T201	C0807477
27976741	927	952	smooth muscle contraction	T042	C1155937
27976741	966	971	Scale	T074	C0025080
27976741	972	975	PTT	T081	C3494432
27976741	976	983	tracked	T082	C0546881
27976741	988	1000	diastolic BP	T201	C0428883
27976741	1020	1043	correlation coefficient	T081	C1707429
27976741	1076	1099	root-mean-squared-error	T080	C0743559
27976741	1113	1117	mmHg	T081	C0439475
27976741	1162	1165	PAT	T081	C0392762
27976741	1196	1204	tracking	T082	C0546881
27976741	1225	1247	correlation coefficien	T081	C1707429
27976741	1270	1293	root-mean-squared-error	T080	C0743559
27976741	1308	1312	mmHg	T081	C0439475
27976741	1325	1330	Scale	T074	C0025080
27976741	1331	1334	PTT	T081	C3494432
27976741	1352	1363	systolic BP	T201	C0871470
27976741	1397	1400	PAT	T081	C0392762
27976741	1459	1464	scale	T074	C0025080
27976741	1465	1468	PTT	T081	C3494432
27976741	1501	1512	measurement	T169	C0242485
27976741	1516	1518	BP	T040	C0005823

28491259|t|The Antibacterial Effect of Additional Photodynamic Therapy in Failed Endodontically Treated Teeth: A Pilot Study
28491259|a|Introduction: Root canal therapy as a routine dental procedure has resulted in retention of millions of teeth that would otherwise be lost. Unfortunately, successful outcomes are not always achievable within initial endodontic treatments, and that necessitates further treatment. Nonsurgical retreatment is the first choice in most clinical situations. The aim of this clinical pilot study was to assess the effect of additional photodynamic therapy (PDT) on intraradicular bacterial load following retreatment of failed previously root treated teeth. Methods: Thirty single-rooted / canalled endodontically treated matured teeth (in 27 healthy patients) accompanied by apical periodontitis (AP) were selected for this study. Standard protocol was followed for nonsurgical retreatment of each tooth. Microbiological samples were taken after establishment of apical patency, finished cleaning/shaping procedure, and PDT (665 nm, 1 W, 240 seconds). All samples were cultured for 72 hours and colony-forming unit (CFU) was counted. McNemar test was used for statistical analysis of the data. The level of significance was set at 0.001. Results: Routine cleaning and shaping resulted in twenty four negative (80%) out of 30 cultures. Four additional negative results were obtained after additional PDT (93.3%). The addition of PDT to routine procedures significantly enhanced the number of bacteria -free samples (P < 0.001). Conclusion: Regarding elimination of intraradicular microbiota, additional PDT may increase the effectiveness of conventional chemomechanical preparation in previously root filled teeth accompanied by AP. Well controlled randomized clinical trials should be planned for future.
28491259	4	24	Antibacterial Effect	T043	C1516022
28491259	28	38	Additional	T169	C1524062
28491259	39	59	Photodynamic Therapy	T061	C0031740
28491259	63	69	Failed	T169	C0231175
28491259	70	98	Endodontically Treated Teeth	T047	C0376699
28491259	102	113	Pilot Study	T062	C0031928
28491259	128	146	Root canal therapy	T061	C0035849
28491259	152	159	routine	T080	C0205547
28491259	160	176	dental procedure	T061	C0011331
28491259	181	189	resulted	T169	C1274040
28491259	193	202	retention	T169	C0333117
28491259	206	214	millions	T081	C1881839
28491259	218	223	teeth	T023	C0040426
28491259	248	252	lost	T169	C0745777
28491259	269	279	successful	T080	C1272703
28491259	280	288	outcomes	T169	C1274040
28491259	330	351	endodontic treatments	T061	C0700632
28491259	362	374	necessitates	T080	C0205556
28491259	383	392	treatment	T169	C1522326
28491259	394	417	Nonsurgical retreatment	T061	C0376495
28491259	446	454	clinical	T080	C0205210
28491259	455	465	situations	T080	C0205556
28491259	483	491	clinical	T080	C0205210
28491259	492	503	pilot study	T062	C0031928
28491259	511	517	assess	T052	C1516048
28491259	522	528	effect	T080	C1280500
28491259	532	542	additional	T169	C1524062
28491259	543	563	photodynamic therapy	T061	C0031740
28491259	565	568	PDT	T061	C0031740
28491259	573	587	intraradicular	T082	C1254362
28491259	588	602	bacterial load	T081	C2936404
28491259	613	624	retreatment	T061	C0376495
28491259	628	634	failed	T169	C0231175
28491259	635	645	previously	T079	C0205156
28491259	646	650	root	T023	C0040452
28491259	651	658	treated	T169	C1522326
28491259	659	664	teeth	T023	C0040426
28491259	675	681	Thirty	T081	C3816446
28491259	682	695	single-rooted	T023	C0040452
28491259	698	706	canalled	T030	C0086881
28491259	707	743	endodontically treated matured teeth	T047	C0376699
28491259	751	758	healthy	T080	C3898900
28491259	759	767	patients	T101	C0030705
28491259	784	804	apical periodontitis	T047	C0031030
28491259	806	808	AP	T047	C0031030
28491259	815	823	selected	T052	C1707391
28491259	833	838	study	T062	C2603343
28491259	840	857	Standard protocol	T170	C2348563
28491259	875	898	nonsurgical retreatment	T061	C0376495
28491259	907	912	tooth	T023	C0040426
28491259	914	937	Microbiological samples	T059	C0430351
28491259	955	968	establishment	T080	C0443211
28491259	972	978	apical	T082	C0205111
28491259	979	986	patency	T082	C0175566
28491259	997	1023	cleaning/shaping procedure	T061	C0087111
28491259	1029	1032	PDT	T061	C0031740
28491259	1065	1072	samples	T077	C2347026
28491259	1078	1086	cultured	T059	C0430400
28491259	1094	1099	hours	T079	C0439227
28491259	1104	1123	colony-forming unit	T081	C0553561
28491259	1125	1128	CFU	T081	C0553561
28491259	1134	1141	counted	T081	C0750480
28491259	1143	1155	McNemar test	T170	C0237913
28491259	1169	1201	statistical analysis of the data	T081	C0010998
28491259	1207	1228	level of significance	T062	C0814896
28491259	1256	1263	Routine	T080	C0205547
28491259	1264	1272	cleaning	T052	C1947930
28491259	1277	1284	shaping	T061	C0087111
28491259	1297	1308	twenty four	T081	C3715070
28491259	1309	1317	negative	T033	C0205160
28491259	1334	1342	cultures	T059	C0430400
28491259	1349	1359	additional	T169	C1524062
28491259	1360	1368	negative	T033	C0205160
28491259	1369	1376	results	T169	C1274040
28491259	1382	1390	obtained	T169	C1301820
28491259	1397	1407	additional	T169	C1524062
28491259	1408	1411	PDT	T061	C0031740
28491259	1425	1433	addition	T169	C1524062
28491259	1437	1440	PDT	T061	C0031740
28491259	1444	1451	routine	T080	C0205547
28491259	1452	1462	procedures	T169	C0025664
28491259	1463	1476	significantly	T078	C0750502
28491259	1477	1485	enhanced	T052	C2349975
28491259	1490	1496	number	T081	C0237753
28491259	1500	1508	bacteria	T007	C0004611
28491259	1515	1522	samples	T077	C2347026
28491259	1558	1569	elimination	T169	C0542341
28491259	1573	1587	intraradicular	T082	C1254362
28491259	1588	1598	microbiota	T001	C0445623
28491259	1600	1610	additional	T169	C1524062
28491259	1611	1614	PDT	T061	C0031740
28491259	1619	1627	increase	T169	C0442805
28491259	1632	1645	effectiveness	T080	C1280519
28491259	1662	1689	chemomechanical preparation	T061	C0087111
28491259	1704	1715	root filled	T061	C0035848
28491259	1716	1721	teeth	T023	C0040426
28491259	1737	1739	AP	T047	C0031030
28491259	1741	1756	Well controlled	T169	C3853142
28491259	1757	1783	randomized clinical trials	T062,T170	C0206034
28491259	1794	1801	planned	T169	C1301732
28491259	1806	1812	future	T079	C0016884

28286333|t|Early non-persistence with dabigatran and rivaroxaban in patients with atrial fibrillation
28286333|a|Dabigatran and rivaroxaban are novel oral anticoagulants (NOACs) approved for stroke prevention in atrial fibrillation (AF). Although NOACs are more convenient than warfarin, their lack of monitoring may predispose patients to non-persistence. Limited information is available on NOAC non-persistence rates and related clinical outcomes in clinical practice. We conducted a retrospective cohort study using administrative data from Ontario, Canada, from January 1998 to March 2014 of patients with AF who were dispensed dabigatran or rivaroxaban. Non-persistence was defined as a gap in dabigatran or rivaroxaban prescriptions ≥14 days. A multivariable Cox proportional hazards model was used to estimate the primary composite outcome of stroke, transient ischaemic attack (TIA) and mortality associated with non-persistence. The cohort consisted of 15 857 dabigatran (age 80.7±6.7 year) and 10 119 rivaroxaban users (age 77.0±7.1 year) with women comprising 52% of each medication group. At 6 months, 36.4% of patients were non-persistent to dabigatran, while 31.9% of patients were non-persistent to rivaroxaban. Stroke / TIA / death was significantly higher for those non-persistent to dabigatran (HR 1.76 (95% CI 1.60 to 1.94); p<0.0001) or rivaroxaban (HR 1.89 (95% CI 1.64 to 2.19); p<0.0001) compared with those who were persistent. Risk of stroke / TIA was markedly higher in non-persistent patients to dabigatran (HR 3.75 (95% CI 2.59 to 5.43); p<0.0001) and rivaroxaban (HR 6.25 (95% CI 3.37 to 11.58); p<0.0001) than those persistent. NOAC non-persistence rates are high in clinical practice, with approximately one in three patients becoming non-persistent to dabigatran or rivaroxaban within 6 months after drug initiation. Non-persistence with either dabigatran or rivaroxaban is significantly associated with worse clinical outcomes of stroke / TIA / death.
28286333	0	5	Early	T079	C1279919
28286333	6	21	non-persistence	T033	C0243095
28286333	27	37	dabigatran	T109,T121	C2348066
28286333	42	53	rivaroxaban	T109,T121	C1739768
28286333	57	65	patients	T101	C0030705
28286333	71	90	atrial fibrillation	T047	C0004238
28286333	91	101	Dabigatran	T109,T121	C2348066
28286333	106	117	rivaroxaban	T109,T121	C1739768
28286333	122	147	novel oral anticoagulants	T109,T121	C0354604
28286333	149	154	NOACs	T109,T121	C0354604
28286333	169	186	stroke prevention	T061	C1277289
28286333	190	209	atrial fibrillation	T047	C0004238
28286333	211	213	AF	T047	C0004238
28286333	225	230	NOACs	T109,T121	C0354604
28286333	256	264	warfarin	T109,T121,T131	C0043031
28286333	280	290	monitoring	T058	C1283169
28286333	306	314	patients	T101	C0030705
28286333	318	333	non-persistence	T033	C0243095
28286333	371	375	NOAC	T109,T121	C0354604
28286333	376	391	non-persistence	T033	C0243095
28286333	410	418	clinical	T080	C0205210
28286333	419	427	outcomes	T169	C1274040
28286333	431	448	clinical practice	T170	C0282574
28286333	465	491	retrospective cohort study	T062	C2985505
28286333	498	517	administrative data	T170	C0282574
28286333	523	530	Ontario	T083	C0029040
28286333	532	538	Canada	T083	C0006823
28286333	575	583	patients	T101	C0030705
28286333	589	591	AF	T047	C0004238
28286333	601	610	dispensed	T058	C1880359
28286333	611	621	dabigatran	T109,T121	C2348066
28286333	625	636	rivaroxaban	T109,T121	C1739768
28286333	638	653	Non-persistence	T033	C0243095
28286333	678	688	dabigatran	T109,T121	C2348066
28286333	692	703	rivaroxaban	T109,T121	C1739768
28286333	704	717	prescriptions	T170	C0033081
28286333	730	774	multivariable Cox proportional hazards model	T170	C3161035
28286333	787	795	estimate	T081	C0750572
28286333	808	817	composite	T080	C0205199
28286333	818	825	outcome	T169	C1274040
28286333	829	835	stroke	T047	C0038454
28286333	837	863	transient ischaemic attack	T047	C0007787
28286333	865	868	TIA	T047	C0007787
28286333	884	899	associated with	T080	C0332281
28286333	900	915	non-persistence	T033	C0243095
28286333	921	927	cohort	T098	C0599755
28286333	948	958	dabigatran	T109,T121	C2348066
28286333	990	1001	rivaroxaban	T109,T121	C1739768
28286333	1033	1038	women	T098	C0043210
28286333	1062	1078	medication group	T098	C1257890
28286333	1102	1110	patients	T101	C0030705
28286333	1116	1130	non-persistent	T033	C0243095
28286333	1134	1144	dabigatran	T109,T121	C2348066
28286333	1161	1169	patients	T101	C0030705
28286333	1175	1189	non-persistent	T033	C0243095
28286333	1193	1204	rivaroxaban	T109,T121	C1739768
28286333	1206	1212	Stroke	T047	C0038454
28286333	1215	1218	TIA	T047	C0007787
28286333	1221	1226	death	T040	C0011065
28286333	1262	1276	non-persistent	T033	C0243095
28286333	1280	1290	dabigatran	T109,T121	C2348066
28286333	1336	1347	rivaroxaban	T109,T121	C1739768
28286333	1419	1429	persistent	T079	C0205322
28286333	1431	1435	Risk	T078	C0035647
28286333	1439	1445	stroke	T047	C0038454
28286333	1448	1451	TIA	T047	C0007787
28286333	1475	1489	non-persistent	T033	C0243095
28286333	1490	1498	patients	T101	C0030705
28286333	1502	1512	dabigatran	T109,T121	C2348066
28286333	1559	1570	rivaroxaban	T109,T121	C1739768
28286333	1625	1635	persistent	T079	C0205322
28286333	1637	1641	NOAC	T109,T121	C0354604
28286333	1642	1657	non-persistence	T033	C0243095
28286333	1676	1693	clinical practice	T170	C0282574
28286333	1727	1735	patients	T101	C0030705
28286333	1745	1759	non-persistent	T033	C0243095
28286333	1763	1773	dabigatran	T109,T121	C2348066
28286333	1777	1788	rivaroxaban	T109,T121	C1739768
28286333	1811	1815	drug	T121	C0013227
28286333	1816	1826	initiation	T169	C1704686
28286333	1828	1843	Non-persistence	T033	C0243095
28286333	1856	1866	dabigatran	T109,T121	C2348066
28286333	1870	1881	rivaroxaban	T109,T121	C1739768
28286333	1899	1914	associated with	T080	C0332281
28286333	1921	1929	clinical	T080	C0205210
28286333	1930	1938	outcomes	T169	C1274040
28286333	1942	1948	stroke	T047	C0038454
28286333	1951	1954	TIA	T047	C0007787
28286333	1957	1962	death	T040	C0011065

27271775|t|Effect of target animacy on hand preference in Sichuan snub-nosed monkeys (Rhinopithecus roxellana)
27271775|a|Twenty-eight captive Sichuan snub-nosed monkeys (Rhinopithecus roxellana) were involved in the current study. Many individuals showed handedness, with a modest tendency toward left-hand use especially for animate targets, although no group-level handedness was found. There was no significant gender difference in the direction and strength of hand preference for both targets. Females showed a significantly higher overall rate of actions toward animate targets than inanimate targets for both hands, whereas males displayed almost the reversed pattern. There were no significant interactions between lateral hand use and target animacy for either males or females. Most individuals showed rightward or leftward laterality shift trends between inanimate and animate targets. These findings to some extent support the existence of a potential trend concerning a categorical neural distinction between targets demanding functional manipulation (inanimate objects) and those demanding social manipulation (animate objects), even though specialized hand preference based on target animacy has not been fully established in this arboreal Old World monkey species.
27271775	0	6	Effect	T080	C1280500
27271775	10	16	target	T169	C1521840
27271775	28	43	hand preference	T033	C0422881
27271775	47	73	Sichuan snub-nosed monkeys	T015	C1022940
27271775	75	98	Rhinopithecus roxellana	T015	C1022940
27271775	100	112	Twenty-eight	T081	C4283787
27271775	121	147	Sichuan snub-nosed monkeys	T015	C1022940
27271775	149	172	Rhinopithecus roxellana	T015	C1022940
27271775	179	187	involved	T169	C1314939
27271775	203	208	study	T062	C2603343
27271775	234	244	handedness	T032	C0023114
27271775	276	289	left-hand use	T033	C0234418
27271775	305	320	animate targets	T169	C1521840
27271775	346	356	handedness	T032	C0023114
27271775	361	366	found	T033	C0150312
27271775	378	392	no significant	T033	C1273937
27271775	393	410	gender difference	T032	C0036866
27271775	418	427	direction	T082	C0449738
27271775	432	440	strength	T081	C0237897
27271775	444	459	hand preference	T033	C0422881
27271775	464	468	both	T080	C1706086
27271775	469	476	targets	T169	C1521840
27271775	478	485	Females	T032	C0086287
27271775	495	508	significantly	T078	C0750502
27271775	509	515	higher	T080	C0205250
27271775	516	523	overall	T080	C1561607
27271775	524	528	rate	T081	C1521828
27271775	532	539	actions	T052	C3266814
27271775	540	546	toward	T169	C1280477
27271775	547	562	animate targets	T169	C1521840
27271775	568	585	inanimate targets	T169	C1521840
27271775	590	594	both	T080	C1706086
27271775	595	600	hands	T023	C0018563
27271775	610	615	males	T032	C0086582
27271775	616	625	displayed	T169	C0870432
27271775	626	632	almost	T080	C3828842
27271775	637	645	reversed	T169	C1555029
27271775	666	680	no significant	T033	C1273937
27271775	681	693	interactions	T169	C1704675
27271775	702	709	lateral	T082	C0205093
27271775	710	718	hand use	T040	C0562230
27271775	723	729	target	T169	C1521840
27271775	742	748	either	T033	C3844638
27271775	749	754	males	T032	C0086582
27271775	758	765	females	T032	C0086287
27271775	824	829	shift	T169	C0333051
27271775	830	836	trends	T079	C1521798
27271775	859	874	animate targets	T169	C1521840
27271775	882	890	findings	T033	C0243095
27271775	891	905	to some extent	T080	C1555600
27271775	906	913	support	T077	C1521721
27271775	918	927	existence	T077	C2987476
27271775	933	942	potential	T080	C3245505
27271775	943	948	trend	T079	C1521798
27271775	974	980	neural	T169	C3714606
27271775	981	992	distinction	T080	C1705242
27271775	1001	1008	targets	T169	C1521840
27271775	1019	1029	functional	T169	C0205245
27271775	1030	1042	manipulation	T033	C1832073
27271775	1044	1061	inanimate objects	T072	C0347997
27271775	1083	1089	social	T169	C0728831
27271775	1090	1102	manipulation	T033	C1832073
27271775	1104	1119	animate objects	T072	C0347997
27271775	1134	1145	specialized	T077	C1704211
27271775	1146	1161	hand preference	T033	C0422881
27271775	1171	1185	target animacy	T169	C1521840
27271775	1205	1216	established	T080	C0443211
27271775	1225	1258	arboreal Old World monkey species	T015	C1022940

28003476|t|Efficient DNA binding of NF-κB requires the chaperone -like function of NPM1
28003476|a|NPM1/nucleophosmin is frequently overexpressed in various tumors, although the oncogenic role of NPM1 remains unclear. Here we revealed the link between NPM1 and nuclear factor-κB (NF-κB), a master regulator of inflammation. We found that NPM1 knockdown decreased NF-κB -mediated transcription of selected target genes by decreasing the recruitment of NF-κB p65 to the gene promoters. NPM1 is directly associated with the DNA binding domain of p65 to enhance its DNA binding activity without being a part of the DNA - NF-κB complex. This result suggests that NF-κB requires the chaperone -like function of NPM1 for DNA binding. Furthermore, we demonstrated that NPM1 was required for efficient inflammatory gene expression induced by tumor necrosis factor alpha (TNF-α) and lipopolysaccharide in fibroblasts and macrophages. The NF-κB - mediated invasion of breast cancer cells was significantly decreased by NPM1 knockdown. Our study suggests a novel mechanistic insight into the NF-κB -mediated transcription and an oncogenic role of NPM1 in both tumor cells and the tumor micro-environment through the regulation of NF-κB.
28003476	0	9	Efficient	T080	C0442799
28003476	10	21	DNA binding	T045	C1148673
28003476	25	30	NF-κB	T116,T129	C0079904
28003476	44	53	chaperone	T116,T123	C0243041
28003476	72	76	NPM1	T028	C1334894
28003476	77	95	NPM1/nucleophosmin	T028	C1334894
28003476	110	123	overexpressed	T045	C0017262
28003476	135	141	tumors	T191	C0027651
28003476	156	165	oncogenic	T028	C0029016
28003476	174	178	NPM1	T028	C1334894
28003476	230	234	NPM1	T028	C1334894
28003476	239	256	nuclear factor-κB	T116,T129	C0079904
28003476	258	263	NF-κB	T116,T129	C0079904
28003476	275	284	regulator	T077	C1704735
28003476	288	300	inflammation	T046	C0021368
28003476	316	320	NPM1	T028	C1334894
28003476	321	330	knockdown	T063	C2350567
28003476	331	340	decreased	T081	C0205216
28003476	341	346	NF-κB	T116,T129	C0079904
28003476	357	370	transcription	T045	C0040649
28003476	383	395	target genes	T028	C0017337
28003476	399	409	decreasing	T033	C0442797
28003476	414	425	recruitment	T052	C2949735
28003476	429	438	NF-κB p65	T116,T123	C0214222
28003476	446	460	gene promoters	T028	C0314621
28003476	462	466	NPM1	T028	C1334894
28003476	479	494	associated with	T080	C0332281
28003476	499	517	DNA binding domain	T087	C1511662
28003476	521	524	p65	T116,T123	C0214222
28003476	528	535	enhance	T052	C2349975
28003476	540	551	DNA binding	T045	C1148673
28003476	589	592	DNA	T114,T123	C0012854
28003476	595	600	NF-κB	T116,T129	C0079904
28003476	601	608	complex	T026	C2246376
28003476	636	641	NF-κB	T116,T129	C0079904
28003476	655	664	chaperone	T116,T123	C0243041
28003476	683	687	NPM1	T028	C1334894
28003476	692	703	DNA binding	T045	C1148673
28003476	739	743	NPM1	T028	C1334894
28003476	761	770	efficient	T080	C0442799
28003476	771	783	inflammatory	T046	C0021368
28003476	784	799	gene expression	T045	C0017262
28003476	800	807	induced	T169	C0205263
28003476	811	838	tumor necrosis factor alpha	T116,T129	C1456820
28003476	840	845	TNF-α	T116,T129	C1456820
28003476	851	869	lipopolysaccharide	T109	C0023810
28003476	873	884	fibroblasts	T025	C0016030
28003476	889	900	macrophages	T025	C0024432
28003476	906	911	NF-κB	T116,T129	C0079904
28003476	914	931	mediated invasion	T046	C2699153
28003476	935	954	breast cancer cells	T025	C1512505
28003476	973	982	decreased	T081	C0205216
28003476	986	990	NPM1	T028	C1334894
28003476	991	1000	knockdown	T063	C2350567
28003476	1023	1028	novel	T080	C0205314
28003476	1029	1048	mechanistic insight	T041	C0233820
28003476	1058	1063	NF-κB	T116,T129	C0079904
28003476	1074	1087	transcription	T045	C0040649
28003476	1095	1104	oncogenic	T028	C0029016
28003476	1113	1117	NPM1	T028	C1334894
28003476	1126	1137	tumor cells	T025	C0597032
28003476	1146	1169	tumor micro-environment	T070	C2936626
28003476	1182	1192	regulation	T043	C1157519
28003476	1196	1201	NF-κB	T116,T129	C0079904

28463704|t|Recovery of orthographic processing after stroke: A longitudinal fMRI study
28463704|a|An intact orthographic processing system is critical for normal reading and spelling. Here we investigate the neural changes associated with impairment and subsequent recovery of the orthographic lexical processing system in an individual with an ischemic left posterior cerebral artery (PCA) stroke. This work describes a longitudinal case study of a patient, whose initials are MMY, with impairments in orthographic lexical processing for reading and spelling at stroke onset, and who recovered these skills within 1 year post stroke. We tested the hypothesis that this acute impairment to reading and spelling would be associated with a selective loss of neural activation in the left fusiform gyrus (FG), and that subsequent recovery would be associated with a gain of neural activation in this region. MMY's case provided a unique opportunity to assess the selectivity of neural changes because she demonstrated a behavioral recovery of naming as well; i.e., if there is neural recovery for reading and spelling, but not naming, then these neural changes are selective to the recovery of orthographic processing. To test our hypothesis, we examined longitudinal behavioral and functional magnetic resonance imaging (fMRI) data of reading, spelling, and visual object naming acquired acutely, 3 weeks, 5 months, and one year post stroke. In confirmation of our hypothesis, the loss and subsequent gain of orthographic lexical processing was associated with up-regulation of neural activation in areas previously associated with orthographic lexical processing: i.e., the left mid-FG and inferior frontal junction (IFJ). Furthermore, these neural changes were found to be selective to orthographic processing, as they were observed for reading and spelling, but not for visual object naming within the left mid-FG. This work shows that left PCA stroke can temporarily and selectively disrupt the orthographic lexical processing system, not only in the posterior region adjacent to the stroke, but also in relatively distant frontal orthographic processing regions.
28463704	0	11	Recovery of	T052	C0237820
28463704	12	24	orthographic	T090	C0871846
28463704	25	35	processing	T041	C0025361
28463704	42	48	stroke	T047	C0038454
28463704	52	64	longitudinal	T062	C0023981
28463704	65	69	fMRI	T060	C0376335
28463704	86	98	orthographic	T090	C0871846
28463704	99	109	processing	T041	C0025361
28463704	133	160	normal reading and spelling	T048	C1404290
28463704	186	200	neural changes	T169	C3714606
28463704	217	227	impairment	T169	C0221099
28463704	243	251	recovery	T052	C0237820
28463704	259	271	orthographic	T090	C0871846
28463704	272	290	lexical processing	T041	C0871801
28463704	323	331	ischemic	T046	C0022116
28463704	332	375	left posterior cerebral artery (PCA) stroke	T047	C2062605
28463704	399	422	longitudinal case study	T062	C0023981
28463704	456	459	MMY	T016	C0086418
28463704	466	477	impairments	T169	C0221099
28463704	481	493	orthographic	T090	C0871846
28463704	494	512	lexical processing	T041	C0871801
28463704	517	537	reading and spelling	T048	C1404290
28463704	541	547	stroke	T047	C0038454
28463704	548	553	onset	T079	C0277793
28463704	605	611	stroke	T047	C0038454
28463704	627	637	hypothesis	T078	C1512571
28463704	648	653	acute	T079	C0205178
28463704	654	664	impairment	T169	C0221099
28463704	668	688	reading and spelling	T048	C1404290
28463704	726	733	loss of	T081	C1517945
28463704	734	751	neural activation	T169	C3714606
28463704	759	778	left fusiform gyrus	T023	C2337131
28463704	780	782	FG	T023	C2337131
28463704	841	848	gain of	T081	C1517378
28463704	849	866	neural activation	T169	C3714606
28463704	883	888	MMY's	T016	C0086418
28463704	953	967	neural changes	T169	C3714606
28463704	995	1005	behavioral	T053	C0004927
28463704	1006	1032	recovery of naming as well	T040	C2004454
28463704	1052	1067	neural recovery	T169	C3714606
28463704	1072	1092	reading and spelling	T048	C1404290
28463704	1121	1135	neural changes	T169	C3714606
28463704	1169	1181	orthographic	T090	C0871846
28463704	1182	1192	processing	T041	C0025361
28463704	1230	1253	longitudinal behavioral	T062	C0004939
28463704	1258	1295	functional magnetic resonance imaging	T060	C0376335
28463704	1297	1301	fMRI	T060	C0376335
28463704	1311	1318	reading	T041	C0586739
28463704	1320	1328	spelling	UnknownType	C0869025
28463704	1334	1354	visual object naming	T170	C0451342
28463704	1410	1416	stroke	T047	C0038454
28463704	1441	1451	hypothesis	T078	C1512571
28463704	1485	1497	orthographic	T090	C0871846
28463704	1498	1516	lexical processing	T041	C0871801
28463704	1537	1550	up-regulation	T044	C0041904
28463704	1554	1571	neural activation	T169	C3714606
28463704	1608	1620	orthographic	T090	C0871846
28463704	1621	1639	lexical processing	T041	C0871801
28463704	1651	1662	left mid-FG	T029	C2953769
28463704	1667	1692	inferior frontal junction	T023	C0152298
28463704	1694	1697	IFJ	T023	C0152298
28463704	1719	1733	neural changes	T169	C3714606
28463704	1764	1776	orthographic	T090	C0871846
28463704	1777	1787	processing	T041	C0025361
28463704	1815	1822	reading	T041	C0586739
28463704	1827	1835	spelling	UnknownType	C0869025
28463704	1849	1869	visual object naming	T170	C0451342
28463704	1881	1892	left mid-FG	T029	C2953769
28463704	1915	1930	left PCA stroke	T047	C2062605
28463704	1975	1987	orthographic	T090	C0871846
28463704	1988	2006	lexical processing	T041	C0871801
28463704	2031	2047	posterior region	T082	C1254362
28463704	2048	2056	adjacent	T082	C0205117
28463704	2064	2070	stroke	T047	C0038454
28463704	2095	2110	distant frontal	T082	C1254362
28463704	2111	2123	orthographic	T090	C0871846
28463704	2124	2134	processing	T041	C0025361

28075453|t|miR-375 inhibits cancer stem cell phenotype and tamoxifen resistance by degrading HOXB3 in human ER-positive breast cancer
28075453|a|Cancer stem cell (CSC) formation and epithelial-mesenchymal transition (EMT) are pivotal events in tumor cell invasion and metastasis. They have been shown to occur in resistance to tamoxifen. Moreover, microRNAs (miRNAs) have been associated with CSCs, EMT as well as tamoxifen resistance. Studying molecular mechanism of CSCs, EMT as well as tamoxifen resistance will help us to further understand the pathogenesis and progression of the disease and offer new targets for effective therapies. In the present study, we showed that miR-375 inhibits CSC traits in breast cancer MCF-7 cells. Bioinformatics analysis and experimental validation identified HOXB3 as a direct target of miR-375. Overexpressing miR-375 degraded HOXB3 mRNA in MCF-7 cells. Moreover, overexpression of HOXB3 induced formation of CSC phenotypes, EMT and tamoxifen - resistance as well as enhanced ability of migration and invasion in MCF-7 cells. Most ER-positive breast cancer -related deaths occur, because of resistance to standard therapies and metastasis, restoring miR-375 or targeting HOXB3 might serve as potential therapeutic approaches for the treatment of tamoxifen-resistant breast cancer.
28075453	0	7	miR-375	T028	C1537896
28075453	8	16	inhibits	T052	C3463820
28075453	17	33	cancer stem cell	T025	C1956422
28075453	34	43	phenotype	T032	C0031437
28075453	48	57	tamoxifen	T109,T121	C0039286
28075453	58	68	resistance	T038	C0013203
28075453	82	87	HOXB3	T028	C1415666
28075453	91	96	human	T016	C0086418
28075453	97	108	ER-positive	T034	C3640067
28075453	109	122	breast cancer	T191	C0678222
28075453	123	139	Cancer stem cell	T025	C1956422
28075453	141	144	CSC	T025	C1956422
28075453	146	155	formation	T169	C1522492
28075453	160	193	epithelial-mesenchymal transition	T043	C1523298
28075453	195	198	EMT	T043	C1523298
28075453	222	241	tumor cell invasion	T033	C1269955
28075453	246	256	metastasis	T046	C4255448
28075453	291	301	resistance	T038	C0013203
28075453	305	314	tamoxifen	T109,T121	C0039286
28075453	326	335	microRNAs	T114,T123	C1101610
28075453	337	343	miRNAs	T114,T123	C1101610
28075453	355	370	associated with	T080	C0332281
28075453	371	375	CSCs	T025	C1956422
28075453	377	380	EMT	T043	C1523298
28075453	392	401	tamoxifen	T109,T121	C0039286
28075453	402	412	resistance	T038	C0013203
28075453	414	422	Studying	T062	C2603343
28075453	423	442	molecular mechanism	T044	C3537153
28075453	446	450	CSCs	T025	C1956422
28075453	452	455	EMT	T043	C1523298
28075453	467	476	tamoxifen	T109,T121	C0039286
28075453	477	487	resistance	T038	C0013203
28075453	527	539	pathogenesis	T046	C0699748
28075453	544	570	progression of the disease	T046	C0242656
28075453	607	616	therapies	T061	C0087111
28075453	633	638	study	T062	C2603343
28075453	655	662	miR-375	T028	C1537896
28075453	663	671	inhibits	T052	C3463820
28075453	672	682	CSC traits	T025	C1956422
28075453	686	699	breast cancer	T191	C0678222
28075453	700	711	MCF-7 cells	T025	C0596890
28075453	713	727	Bioinformatics	T091	C1140694
28075453	728	736	analysis	T062	C0936012
28075453	741	764	experimental validation	T062	C1519941
28075453	776	781	HOXB3	T028	C1415666
28075453	804	811	miR-375	T028	C1537896
28075453	813	827	Overexpressing	T045	C0017262
28075453	828	835	miR-375	T028	C1537896
28075453	845	850	HOXB3	T028	C1415666
28075453	851	855	mRNA	T114,T123	C0035696
28075453	859	870	MCF-7 cells	T025	C0596890
28075453	882	896	overexpression	T045	C0017262
28075453	900	905	HOXB3	T028	C1415666
28075453	927	941	CSC phenotypes	T025	C1956422
28075453	943	946	EMT	T043	C1523298
28075453	951	960	tamoxifen	T109,T121	C0039286
28075453	963	973	resistance	T038	C0013203
28075453	1005	1014	migration	T039	C1533574
28075453	1019	1027	invasion	T046	C2699153
28075453	1031	1042	MCF-7 cells	T025	C0596890
28075453	1049	1060	ER-positive	T034	C3640067
28075453	1061	1074	breast cancer	T191	C0678222
28075453	1084	1090	deaths	T040	C0011065
28075453	1109	1119	resistance	T169	C4281815
28075453	1132	1141	therapies	T061	C0087111
28075453	1146	1156	metastasis	T046	C4255448
28075453	1168	1175	miR-375	T028	C1537896
28075453	1189	1194	HOXB3	T028	C1415666
28075453	1220	1242	therapeutic approaches	T169	C0039798
28075453	1251	1260	treatment	T061	C0087111
28075453	1264	1297	tamoxifen-resistant breast cancer	T191	C0678222

27393252|t|Parkinson subtype -specific Granger-causal coupling and coherence frequency in the subthalamic area
27393252|a|Previous work on Parkinson's disease (PD) has indicated a predominantly afferent coupling between affected arm muscle activity and electrophysiological activity within the subthalamic nucleus (STN). So far, no information is available indicating which frequency components drive the afferent information flow in PD patients. Non-directional coupling e.g. by measuring coherence is primarily established in the beta band as well as at tremor frequency. Based on previous evidence it is likely that different subtypes of the disease are associated with different connectivity patterns. Therefore, we determined coherence and causality between local field potentials (LFPs) in the STN and surface electromyograms (EMGs) from the contralateral arm in 18 akinetic-rigid (AR) PD patients and 8 tremor-dominant (TD) PD patients. During the intraoperative recording, patients were asked to lift their forearm contralateral to the recording side. Significantly more afferent connections were detected for the TD patients for tremor -periods and non- tremor -periods combined as well as for only tremor periods. Within the STN 74% and 63% of the afferent connections are associated with coherence from 4-8Hz and 8-12Hz, respectively. However, when considering only tremor -periods significantly more afferent than efferent connections were associated with coherence from 12 to 20Hz across all recording heights. No difference between efferent and afferent connections is seen in the frequency range from 4 to 12Hz for all recording heights. For the AR patients, no significant difference in afferent and efferent connections within the STN was found for the different frequency bands. Still, for the AR patients dorsal of the STN significantly more afferent than efferent connections were associated with coherence in the frequency range from 12 to 16Hz. These results provide further evidence for the differential pathological oscillations and pathways present in AR and TD Parkinson patients.
27393252	0	9	Parkinson	T047	C0030567
27393252	10	17	subtype	T185	C0872379
27393252	28	51	Granger-causal coupling	T062	C0242481
27393252	56	65	coherence	T041	C3178983
27393252	83	94	subthalamic	T023	C1281060
27393252	117	136	Parkinson's disease	T047	C0030567
27393252	138	140	PD	T047	C0030567
27393252	172	180	afferent	T082	C0205115
27393252	181	189	coupling	T169	C1948027
27393252	207	210	arm	T023	C1269078
27393252	211	226	muscle activity	T040	C2265874
27393252	231	260	electrophysiological activity	T040	C2350528
27393252	272	291	subthalamic nucleus	T023	C1281060
27393252	293	296	STN	T023	C1281060
27393252	383	391	afferent	T082	C0205115
27393252	392	408	information flow	T052	C0021418
27393252	412	414	PD	T047	C0030567
27393252	415	423	patients	T101	C0030705
27393252	468	477	coherence	T041	C3178983
27393252	510	519	beta band	T026	C0230715
27393252	534	540	tremor	T184	C0040822
27393252	541	550	frequency	T079	C0439603
27393252	607	615	subtypes	T185	C0872379
27393252	623	630	disease	T047	C0012634
27393252	635	650	associated with	T080	C0332281
27393252	661	673	connectivity	T169	C1707489
27393252	674	682	patterns	T082	C0449774
27393252	709	718	coherence	T041	C3178983
27393252	741	763	local field potentials	T040	C2350528
27393252	765	769	LFPs	T040	C2350528
27393252	778	781	STN	T023	C1281060
27393252	794	809	electromyograms	T033	C4085371
27393252	811	815	EMGs	T033	C4085371
27393252	826	843	contralateral arm	T082	C0442306
27393252	850	864	akinetic-rigid	T047	C1446219
27393252	866	868	AR	T047	C1446219
27393252	870	872	PD	T047	C0030567
27393252	873	881	patients	T101	C0030705
27393252	888	903	tremor-dominant	T047	C0856077
27393252	905	907	TD	T047	C0856077
27393252	909	911	PD	T047	C0030567
27393252	912	920	patients	T101	C0030705
27393252	933	947	intraoperative	T079	C0456904
27393252	959	967	patients	T101	C0030705
27393252	993	1000	forearm	T023	C0016536
27393252	1001	1014	contralateral	T082	C0442306
27393252	1057	1065	afferent	T082	C0205115
27393252	1066	1077	connections	T082	C0449379
27393252	1100	1102	TD	T047	C0856077
27393252	1103	1111	patients	T101	C0030705
27393252	1116	1122	tremor	T184	C0040822
27393252	1141	1147	tremor	T184	C0040822
27393252	1186	1192	tremor	T184	C0040822
27393252	1213	1216	STN	T023	C1281060
27393252	1236	1244	afferent	T082	C0205115
27393252	1245	1256	connections	T082	C0449379
27393252	1261	1276	associated with	T080	C0332281
27393252	1277	1286	coherence	T041	C3178983
27393252	1355	1361	tremor	T184	C0040822
27393252	1390	1398	afferent	T082	C0205115
27393252	1404	1412	efferent	T082	C0205116
27393252	1413	1424	connections	T082	C0449379
27393252	1430	1445	associated with	T080	C0332281
27393252	1446	1455	coherence	T041	C3178983
27393252	1524	1532	efferent	T082	C0205116
27393252	1537	1545	afferent	T082	C0205115
27393252	1546	1557	connections	T082	C0449379
27393252	1573	1582	frequency	T080	C1561548
27393252	1583	1588	range	T081	C1514721
27393252	1639	1641	AR	T047	C1446219
27393252	1642	1650	patients	T101	C0030705
27393252	1681	1689	afferent	T082	C0205115
27393252	1694	1702	efferent	T082	C0205116
27393252	1703	1714	connections	T082	C0449379
27393252	1726	1729	STN	T023	C1281060
27393252	1758	1773	frequency bands	T082	C0439645
27393252	1790	1792	AR	T047	C1446219
27393252	1793	1801	patients	T101	C0030705
27393252	1802	1808	dorsal	T082	C0205095
27393252	1816	1819	STN	T023	C1281060
27393252	1839	1847	afferent	T082	C0205115
27393252	1853	1861	efferent	T082	C0205116
27393252	1862	1873	connections	T082	C0449379
27393252	1879	1894	associated with	T080	C0332281
27393252	1895	1904	coherence	T041	C3178983
27393252	2005	2030	pathological oscillations	T169	C1521733
27393252	2035	2043	pathways	T169	C1521733
27393252	2055	2057	AR	T047	C1446219
27393252	2062	2064	TD	T047	C0856077
27393252	2065	2074	Parkinson	T047	C0030567
27393252	2075	2083	patients	T101	C0030705

27474557|t|Xylan-based temperature / pH sensitive hydrogels for drug controlled release
27474557|a|Xylan-based temperature / pH sensitive hydrogels were prepared by the crosslinking copolymerization of xylan with N-isopropylacrylamide (NIPAm) and acrylic acid (AA) using N,Ń-methylenebis-acrylamide (MBA) as a cross-linker and 2,2-dimethoxy-2-phenylacetophenone as a photoinitiator via ultraviolet irradiation. The influence of the NIPAm, AA and MBA amount on properties of xylan-based hydrogels was discussed. The morphology and interactions of hydrogels were characterized by SEM and FTIR. The lower critical solution temperature (LCST) of hydrogels was investigated by DSC. The results indicated that the LCST of hydrogels emerged at around 34°C and increased with increasing the AA content. The drug encapsulation efficiency of as-prepared hydrogels reached to 97.60% and the cumulative release rate of acetylsalicylic acid was 90.12% and 26.35% in the intestinal and gastric fluid, respectively. Xylan-based hydrogels were proved to be biocompatible with NIH3T3 cell by MTT assay and showed the promising application as drug carriers for the intestinal - targeted oral drug delivery.
27474557	0	11	Xylan-based	T109	C0062221
27474557	12	23	temperature	T081	C0039476
27474557	26	28	pH	T081	C0020283
27474557	29	38	sensitive	T169	C0332324
27474557	39	48	hydrogels	T122	C0600484
27474557	53	76	drug controlled release	T122	C1707506
27474557	77	88	Xylan-based	T109	C0062221
27474557	89	100	temperature	T081	C0039476
27474557	103	105	pH	T081	C0020283
27474557	106	115	sensitive	T169	C0332324
27474557	116	125	hydrogels	T122	C0600484
27474557	147	176	crosslinking copolymerization	T044	C1880180
27474557	180	185	xylan	T109	C0062221
27474557	191	212	N-isopropylacrylamide	T109	C0083668
27474557	214	219	NIPAm	T109	C0083668
27474557	225	237	acrylic acid	T109,T122	C1321887
27474557	239	241	AA	T109,T122	C1321887
27474557	249	277	N,Ń-methylenebis-acrylamide	T109,T130	C0067314
27474557	279	282	MBA	T109,T130	C0067314
27474557	289	301	cross-linker	T130	C0034760
27474557	306	340	2,2-dimethoxy-2-phenylacetophenone	T109	C1121773
27474557	346	360	photoinitiator	T109	C0029224
27474557	365	388	ultraviolet irradiation	T070	C0041625
27474557	394	403	influence	T077	C4054723
27474557	411	416	NIPAm	T109	C0083668
27474557	418	420	AA	T109,T122	C1321887
27474557	425	428	MBA	T109,T130	C0067314
27474557	453	464	xylan-based	T109	C0062221
27474557	465	474	hydrogels	T122	C0600484
27474557	494	504	morphology	T080	C0332437
27474557	509	521	interactions	T169	C1704675
27474557	525	534	hydrogels	T122	C0600484
27474557	540	553	characterized	T052	C1880022
27474557	557	560	SEM	T059	C0026020
27474557	565	569	FTIR	T062	C0206055
27474557	575	610	lower critical solution temperature	T081	C0039476
27474557	612	616	LCST	T081	C0039476
27474557	621	630	hydrogels	T122	C0600484
27474557	635	647	investigated	T169	C1292732
27474557	651	654	DSC	T059	C0006780
27474557	660	667	results	T033	C0683954
27474557	687	691	LCST	T081	C0039476
27474557	695	704	hydrogels	T122	C0600484
27474557	762	764	AA	T109,T122	C1321887
27474557	778	782	drug	T121	C0013227
27474557	783	796	encapsulation	T067	C2348438
27474557	797	807	efficiency	T081	C0013682
27474557	823	832	hydrogels	T122	C0600484
27474557	859	869	cumulative	T080	C1511559
27474557	870	877	release	T070	C3850077
27474557	878	882	rate	T081	C1521828
27474557	886	906	acetylsalicylic acid	T109,T121	C0004057
27474557	936	946	intestinal	T023	C0021853
27474557	951	964	gastric fluid	T031	C2828094
27474557	980	991	Xylan-based	T109	C0062221
27474557	992	1001	hydrogels	T122	C0600484
27474557	1020	1033	biocompatible	T080	C1524057
27474557	1039	1050	NIH3T3 cell	T025	C0007600
27474557	1054	1063	MTT assay	T062	C2986858
27474557	1104	1117	drug carriers	T122	C0013161
27474557	1126	1136	intestinal	T023	C0021853
27474557	1139	1147	targeted	T169	C1521840
27474557	1148	1166	oral drug delivery	T061	C0001563

28146639|t|Fifty Years of Research in ARDS. Setting Positive End-expiratory Pressure in the Acute Respiratory Distress Syndrome
28146639|a|Positive end-expiratory pressure (PEEP) has been utilized during mechanical ventilation since the first description of the acute respiratory distress syndrome (ARDS). In the subsequent decades, many different strategies for optimally titrating PEEP have been proposed. Higher PEEP can improve arterial oxygenation, reduce tidal lung stress and strain, and promote more homogenous ventilation by preventing alveolar collapse at end expiration. However, PEEP may also cause circulatory depression and contribute to ventilator-induced lung injury through alveolar overdistention. The overall effect of PEEP is primarily related to the balance between the number of alveoli that are recruited to participate in ventilation and the amount of lung that is overdistended when PEEP is applied. Techniques to assess lung recruitment from PEEP may help to direct safer and more effective PEEP titration. Some PEEP titration strategies attempt to weigh beneficial effects on arterial oxygenation and on prevention of cyclic alveolar collapse with the harmful potential of overdistention. One method for PEEP titration is a PEEP / FiO2 table, which prioritizes support for arterial oxygenation. Other methods set PEEP based on mechanical parameters such as the plateau pressure, respiratory system compliance, or transpulmonary pressure. No single method of PEEP titration has been shown to improve clinical outcomes compared to other approaches of setting PEEP. Future trials should focus on identifying patients who respond to higher PEEP with recruitment and on clinically important outcomes such as mortality.
28146639	6	11	Years	T079	C0439234
28146639	15	23	Research	T062	C0035168
28146639	27	31	ARDS	T047	C0035222
28146639	33	73	Setting Positive End-expiratory Pressure	T033	C0807495
28146639	81	116	Acute Respiratory Distress Syndrome	T047	C0035222
28146639	117	149	Positive end-expiratory pressure	T061	C0032740
28146639	151	155	PEEP	T061	C0032740
28146639	182	204	mechanical ventilation	T061	C0199470
28146639	221	232	description	T170	C0678257
28146639	240	275	acute respiratory distress syndrome	T047	C0035222
28146639	277	281	ARDS	T047	C0035222
28146639	302	309	decades	T081	C2981279
28146639	316	325	different	T080	C1705242
28146639	341	365	optimally titrating PEEP	T061	C0032740
28146639	393	397	PEEP	T061	C0032740
28146639	402	409	improve	T033	C0184511
28146639	410	418	arterial	T023	C0003842
28146639	419	430	oxygenation	T042	C0231940
28146639	445	449	lung	T023	C0024109
28146639	450	456	stress	T033	C0038435
28146639	461	467	strain	T033	C0243095
28146639	486	496	homogenous	T082	C0439713
28146639	497	508	ventilation	T039	C2945579
28146639	523	531	alveolar	T023	C1440080
28146639	532	540	collapse	T033	C0344329
28146639	544	558	end expiration	T039	C0442700
28146639	569	573	PEEP	T061	C0032740
28146639	589	611	circulatory depression	T047	C1610069
28146639	630	660	ventilator-induced lung injury	T037	C2350350
28146639	669	677	alveolar	T023	C1440080
28146639	678	692	overdistention	T046	C0012359
28146639	706	712	effect	T080	C1280500
28146639	716	720	PEEP	T061	C0032740
28146639	749	756	balance	T169	C0205415
28146639	769	775	number	T081	C0237753
28146639	779	786	alveoli	T023	C1515933
28146639	809	820	participate	T169	C0679823
28146639	824	835	ventilation	T039	C2945579
28146639	854	858	lung	T023	C0024109
28146639	867	880	overdistended	T046	C0012359
28146639	886	890	PEEP	T061	C0032740
28146639	903	913	Techniques	T169	C0449851
28146639	924	928	lung	T023	C0024109
28146639	946	950	PEEP	T061	C0032740
28146639	985	994	effective	T080	C1704419
28146639	995	1009	PEEP titration	T061	C0032740
28146639	1016	1030	PEEP titration	T061	C0032740
28146639	1081	1089	arterial	T023	C0003842
28146639	1090	1101	oxygenation	T042	C0231940
28146639	1130	1138	alveolar	T023	C1440080
28146639	1139	1147	collapse	T033	C0344329
28146639	1178	1192	overdistention	T046	C0012359
28146639	1209	1223	PEEP titration	T061	C0032740
28146639	1229	1233	PEEP	T061	C0032740
28146639	1236	1240	FiO2	T033	C0428167
28146639	1241	1246	table	T170	C1706074
28146639	1278	1286	arterial	T023	C0003842
28146639	1287	1298	oxygenation	T042	C0231940
28146639	1318	1322	PEEP	T061	C0032740
28146639	1343	1353	parameters	T077	C0549193
28146639	1366	1382	plateau pressure	T081	C0445176
28146639	1384	1413	respiratory system compliance	T033	C4054143
28146639	1418	1441	transpulmonary pressure	T034	C0428642
28146639	1463	1477	PEEP titration	T061	C0032740
28146639	1504	1512	clinical	T080	C0205210
28146639	1513	1521	outcomes	T169	C1274040
28146639	1522	1530	compared	T052	C1707455
28146639	1540	1550	approaches	T169	C1292724
28146639	1562	1566	PEEP	T061	C0032740
28146639	1568	1574	Future	T079	C0016884
28146639	1575	1581	trials	T062	C0008976
28146639	1598	1618	identifying patients	T058	C1269815
28146639	1641	1645	PEEP	T061	C0032740
28146639	1670	1680	clinically	T080	C0205210
28146639	1681	1690	important	T080	C3898777
28146639	1691	1699	outcomes	T169	C1274040
28146639	1708	1717	mortality	T081	C0205848

27876369|t|Multi-component model of intramural hematoma
27876369|a|A novel multi-component model is introduced for studying interaction between blood flow and deforming aortic wall with intramural hematoma (IMH). The aortic wall is simulated by a composite structure submodel representing material properties of the three main wall layers. The IMH is described by a poroelasticity submodel which takes into account both the pressure inside hematoma and its deformation. The submodel of the hematoma is fully coupled with the aortic submodel as well as with the submodel of the pulsatile blood flow. Model simulations are used to investigate the relation between the peak wall stress, hematoma thickness and permeability in patients of different age. The results indicate that an increase in hematoma thickness leads to larger wall stress, which is in agreement with clinical data. Further simulations demonstrate that a hematoma with smaller permeability results in larger wall stress, suggesting that blood coagulation in hematoma might increase its mechanical stability. This is in agreement with previous experimental observations of coagulation having a beneficial effect on the condition of a patient with the IMH.
27876369	0	21	Multi-component model	T075	C0026339
27876369	25	44	intramural hematoma	T046	C0333200
27876369	53	74	multi-component model	T075	C0026339
27876369	93	101	studying	T062	C2603343
27876369	102	113	interaction	T169	C1704675
27876369	122	132	blood flow	T039	C0232338
27876369	137	146	deforming	T033	C1562006
27876369	147	158	aortic wall	T023	C0507851
27876369	164	183	intramural hematoma	T046	C0333200
27876369	185	188	IMH	T046	C0333200
27876369	195	206	aortic wall	T023	C0507851
27876369	210	219	simulated	T062	C0679083
27876369	225	253	composite structure submodel	T075	C0026339
27876369	267	286	material properties	T080	C0205556
27876369	305	316	wall layers	T023	C0934502
27876369	322	325	IMH	T046	C0333200
27876369	344	367	poroelasticity submodel	T075	C0026339
27876369	402	410	pressure	T070	C0001876
27876369	418	426	hematoma	T046	C0018944
27876369	435	446	deformation	T033	C1562006
27876369	452	460	submodel	T075	C0026339
27876369	468	476	hematoma	T046	C0018944
27876369	503	518	aortic submodel	T075	C0026339
27876369	539	547	submodel	T075	C0026339
27876369	555	575	pulsatile blood flow	T067	C0034106
27876369	577	594	Model simulations	T062	C0679083
27876369	607	618	investigate	T169	C1292732
27876369	662	670	hematoma	T046	C0018944
27876369	685	697	permeability	T070	C0031164
27876369	701	709	patients	T101	C0030705
27876369	723	726	age	T032	C0001779
27876369	769	777	hematoma	T046	C0018944
27876369	804	815	wall stress	T033	C0038435
27876369	844	857	clinical data	T170	C1516606
27876369	867	878	simulations	T062	C0679083
27876369	898	906	hematoma	T046	C0018944
27876369	920	932	permeability	T070	C0031164
27876369	951	962	wall stress	T033	C0038435
27876369	980	997	blood coagulation	T042	C0005778
27876369	1001	1009	hematoma	T046	C0018944
27876369	1029	1049	mechanical stability	T033	C0243095
27876369	1086	1098	experimental	T080	C1517586
27876369	1099	1111	observations	T062	C0302523
27876369	1115	1126	coagulation	T042	C0005778
27876369	1136	1153	beneficial effect	T080	C1280500
27876369	1176	1183	patient	T101	C0030705
27876369	1193	1196	IMH	T046	C0333200

27411238|t|Medical Devices; Gastroenterology-Urology Devices; Classification of the Metallic Biliary Stent System for Benign Strictures. Final order
27411238|a|The Food and Drug Administration (FDA) is classifying the metallic biliary stent system for benign strictures into class II (special controls). The special controls that will apply to the device are identified in this order and will be part of the codified language for the metallic biliary stent system for benign strictures ' classification. The Agency is classifying the device into class II (special controls) in order to provide a reasonable assurance of safety and effectiveness of the device.
27411238	0	15	Medical Devices	T074	C0025080
27411238	17	49	Gastroenterology-Urology Devices	T074	C0025080
27411238	51	65	Classification	T185	C0008902
27411238	73	81	Metallic	T197	C0025552
27411238	82	95	Biliary Stent	T074	C0183512
27411238	96	102	System	T169	C0449913
27411238	107	124	Benign Strictures	T047	C0341130
27411238	142	170	Food and Drug Administration	T093	C0041714
27411238	172	175	FDA	T093	C0041714
27411238	180	191	classifying	T185	C0008902
27411238	196	204	metallic	T197	C0025552
27411238	205	218	biliary stent	T074	C0183512
27411238	219	225	system	T169	C0449913
27411238	230	247	benign strictures	T047	C0341130
27411238	253	261	class II	T170	C0441886
27411238	263	279	special controls	T170	C1553903
27411238	286	302	special controls	T170	C1553903
27411238	326	332	device	T074	C0025080
27411238	337	347	identified	T080	C0205396
27411238	386	403	codified language	UnknownType	C0868934
27411238	412	420	metallic	T197	C0025552
27411238	421	434	biliary stent	T074	C0183512
27411238	435	441	system	T169	C0449913
27411238	446	463	benign strictures	T047	C0341130
27411238	466	480	classification	T185	C0008902
27411238	486	492	Agency	T093	C0041714
27411238	496	507	classifying	T185	C0008902
27411238	512	518	device	T074	C0025080
27411238	524	532	class II	T170	C0441886
27411238	534	550	special controls	T170	C1553903
27411238	598	604	safety	T058	C0014680
27411238	609	622	effectiveness	T080	C1280519
27411238	630	636	device	T074	C0025080

27780748|t|Prophylactic Use of Oral Dexamethasone to Alleviate Fatigue During Regorafenib Treatment for Patients With Metastatic Colorectal Cancer
27780748|a|Fatigue is the most common toxicity of all grade toxicities with regorafenib, was the second most common toxicity in the CORRECT (regorafenib monotherapy for previously treated metastatic colorectal cancer) study, and is a major reason for early dose modification. The results from a recent randomized study suggested that dexamethasone (DEX) can improve cancer-related fatigue. We retrospectively analyzed the effect of prophylactic use of an oral DEX on fatigue during regorafenib treatment in patients with metastatic colorectal cancer (mCRC). A total of 105 patients who had received regorafenib at our institution from May 2013 to August 2014 were divided into 2 groups according to oral DEX use (2 mg/day; at the physician's discretion). Of the 105 patients, 31 received prophylactic DEX and 74 received regorafenib alone. The time to dose modification was significantly longer in the DEX group than in the no DEX group (15 days vs. 9 days; P = .009). The incidence of fatigue (grade ≥ 1) was significantly lower with DEX than without DEX (25.8% vs. 50.0%; P = .022). Fewer patients experienced a decreased appetite (grade ≥ 1; 3.2% vs. 35.1%; P < .001) and hand-foot skin reaction (HFSR; grade ≥ 3; 3.2% vs. 25.7%, P = .002) with DEX than without DEX. DEX was effective in reducing fatigue during regorafenib treatment, resulting in prolonging the time to dose modification for regorafenib. The decreased incidence of appetite loss and HFSR also suggest that concurrent DEX administration with regorafenib warrants further investigation.
27780748	0	12	Prophylactic	T169	C0445202
27780748	20	38	Oral Dexamethasone	T200	C0360528
27780748	42	51	Alleviate	T061	C1274136
27780748	52	59	Fatigue	T184	C0015672
27780748	60	66	During	T079	C0347984
27780748	67	78	Regorafenib	T109,T121	C2980094
27780748	79	88	Treatment	T169	C0039798
27780748	93	101	Patients	T101	C0030705
27780748	107	135	Metastatic Colorectal Cancer	T191	C0948380
27780748	136	143	Fatigue	T184	C0015672
27780748	156	162	common	T081	C0205214
27780748	163	171	toxicity	T037	C0600688
27780748	179	184	grade	T185	C0441800
27780748	185	195	toxicities	T037	C0600688
27780748	201	212	regorafenib	T109,T121	C2980094
27780748	234	240	common	T081	C0205214
27780748	241	249	toxicity	T037	C0600688
27780748	257	264	CORRECT	T170	C0282574
27780748	266	348	regorafenib monotherapy for previously treated metastatic colorectal cancer) study	T170	C0282574
27780748	359	364	major	T080	C0205164
27780748	365	371	reason	T078	C0392360
27780748	376	381	early	T079	C1279919
27780748	382	399	dose modification	T062	C1707811
27780748	427	443	randomized study	T062	C2986910
27780748	459	472	dexamethasone	T109,T121	C0011777
27780748	474	477	DEX	T109,T121	C0011777
27780748	483	490	improve	T033	C0184511
27780748	491	513	cancer-related fatigue	T033	C4274302
27780748	518	542	retrospectively analyzed	T062	C0035363
27780748	547	553	effect	T080	C1280500
27780748	557	569	prophylactic	T169	C0445202
27780748	580	588	oral DEX	T200	C0360528
27780748	592	599	fatigue	T184	C0015672
27780748	607	618	regorafenib	T109,T121	C2980094
27780748	619	628	treatment	T169	C0039798
27780748	632	640	patients	T101	C0030705
27780748	646	674	metastatic colorectal cancer	T191	C0948380
27780748	676	680	mCRC	T191	C0948380
27780748	698	706	patients	T101	C0030705
27780748	724	735	regorafenib	T109,T121	C2980094
27780748	743	754	institution	T093	C2607850
27780748	789	796	divided	T169	C0332849
27780748	804	810	groups	T078	C0441833
27780748	824	832	oral DEX	T200	C0360528
27780748	855	866	physician's	T097	C0031831
27780748	891	899	patients	T101	C0030705
27780748	904	912	received	T080	C1514756
27780748	913	925	prophylactic	T169	C0445202
27780748	926	929	DEX	T109,T121	C0011777
27780748	946	957	regorafenib	T109,T121	C2980094
27780748	958	963	alone	T081	C0205171
27780748	977	994	dose modification	T062	C1707811
27780748	1027	1030	DEX	T109,T121	C0011777
27780748	1031	1036	group	T078	C0441833
27780748	1052	1055	DEX	T109,T121	C0011777
27780748	1098	1107	incidence	T081	C0021149
27780748	1111	1118	fatigue	T184	C0015672
27780748	1160	1163	DEX	T109,T121	C0011777
27780748	1169	1176	without	T080	C0332288
27780748	1177	1180	DEX	T109,T121	C0011777
27780748	1216	1224	patients	T101	C0030705
27780748	1225	1236	experienced	T041	C0596545
27780748	1239	1257	decreased appetite	T033	C0232462
27780748	1259	1264	grade	T185	C0441800
27780748	1300	1323	hand-foot skin reaction	T046	C2721716
27780748	1325	1329	HFSR	T046	C2721716
27780748	1331	1336	grade	T185	C0441800
27780748	1373	1376	DEX	T109,T121	C0011777
27780748	1382	1389	without	T080	C0332288
27780748	1390	1393	DEX	T109,T121	C0011777
27780748	1395	1398	DEX	T109,T121	C0011777
27780748	1403	1412	effective	T080	C1704419
27780748	1416	1424	reducing	T080	C0392756
27780748	1425	1432	fatigue	T184	C0015672
27780748	1440	1451	regorafenib	T109,T121	C2980094
27780748	1452	1461	treatment	T169	C0039798
27780748	1476	1486	prolonging	T079	C0439590
27780748	1491	1495	time	T079	C0040223
27780748	1499	1516	dose modification	T062	C1707811
27780748	1521	1532	regorafenib	T109,T121	C2980094
27780748	1538	1547	decreased	T081	C0205216
27780748	1548	1557	incidence	T081	C0021149
27780748	1561	1574	appetite loss	T033	C1971624
27780748	1579	1583	HFSR	T046	C2721716
27780748	1589	1596	suggest	T078	C1705535
27780748	1602	1612	concurrent	T079	C0205420
27780748	1613	1616	DEX	T109,T121	C0011777
27780748	1617	1631	administration	T061	C1533734
27780748	1637	1648	regorafenib	T109,T121	C2980094
27780748	1666	1679	investigation	T058	C0220825

28249926|t|The A312 Allele (c.280A>T) Is Responsible for the Weak A Phenotype
28249926|a|The ABO*A312 allele was found in a 71- year-old Korean male with ABO discrepancy and in his two sons. Although the ABO*A312 allele (c.280A>T, I94F) in an AwB case was registered in GenBank, the impact of the I94F mutation of the ABO gene on the activity of A transferase has not been studied. Transient transfection experiments were performed in HeLa cells using A101, A102, and A312 alleles synthesized by site-directed mutagenesis, and the functional expression level of A antigen was assessed by flow cytometry. The results showed that the A102 and A312 alleles expressed A antigen levels that were 80.28% and 19.32%, respectively, of that of the A101 allele. Our study results demonstrate that the c.280A>T variant is responsible for the weakened expression of A antigen.
28249926	4	26	A312 Allele (c.280A>T)	T028	C0002085
28249926	30	41	Responsible	T033	C1273518
28249926	50	66	Weak A Phenotype	T129	C0021054
28249926	71	86	ABO*A312 allele	T028	C0002085
28249926	106	114	year-old	T079	C1510829
28249926	115	121	Korean	T098	C1556095
28249926	122	126	male	T098	C0025266
28249926	132	135	ABO	T028	C1412099
28249926	136	147	discrepancy	T033	C1290905
28249926	163	167	sons	T099	C0037683
28249926	182	214	ABO*A312 allele (c.280A>T, I94F)	T028	C0002085
28249926	221	229	AwB case	T077	C1706256
28249926	248	255	GenBank	T170	C0598211
28249926	275	288	I94F mutation	T045	C0026882
28249926	296	304	ABO gene	T028	C1412099
28249926	312	320	activity	T044	C0243102
28249926	324	337	A transferase	T116,T126	C0040676
28249926	360	394	Transient transfection experiments	T059	C0022885
28249926	413	423	HeLa cells	T025	C0018873
28249926	430	434	A101	T028	C0002085
28249926	436	440	A102	T028	C0002085
28249926	446	458	A312 alleles	T028	C0002085
28249926	474	499	site-directed mutagenesis	T045	C0079870
28249926	509	519	functional	T169	C0205245
28249926	520	536	expression level	T081	C3244092
28249926	540	549	A antigen	T129	C0348042
28249926	554	562	assessed	T052	C1516048
28249926	566	580	flow cytometry	T059	C0016263
28249926	610	614	A102	T028	C0002085
28249926	619	631	A312 alleles	T028	C0002085
28249926	632	641	expressed	T045	C0017262
28249926	642	651	A antigen	T129	C0348042
28249926	652	658	levels	T080	C0441889
28249926	717	728	A101 allele	T028	C0002085
28249926	769	785	c.280A>T variant	T028	C0678941
28249926	809	817	weakened	T080	C1762617
28249926	818	828	expression	T045	C0017262
28249926	832	841	A antigen	T129	C0348042

27508301|t|Incidence of Diabetes Mellitus and Obesity and the Overlap of Comorbidities in HIV+ Hispanics Initiating Antiretroviral Therapy
27508301|a|Cardiovascular disease (CVD) is a leading health threat for HIV+ patients on antiretroviral therapy (ART); cardiometabolic comorbidities are key predictors of risk. Data are limited on incidence of metabolic comorbidities in HIV+ individuals initiating ART in low and middle income countries (LMICs), particularly for Hispanics. We examined incidence of diabetes and obesity in a prospective cohort of those initiating ART in the Dominican Republic. Participants ≥18 years, initiating ART <90 days prior to study enrollment, were examined for incidence of impaired fasting glucose (IFG), diabetes mellitus (DM), overweight, and obesity. Fasting plasma glucose (FPG) 100-125mg/dl defined IFG; FPG ≥126 mg/dl, diagnosis per medical record, or use of hypoglycemic medication defined DM. Overweight and obesity were BMI 25-30 and ≥30kg/m2, respectively. Dyslipidemia was total cholesterol ≥240mg/dl or use of lipid-lowering medication. Framingham risk equation was used to determine ten-year CVD risk at the end of observation. Of 153 initiating ART, 8 (6%) had DM and 23 (16%) had IFG at baseline, 6 developed DM (28/1000 person - years follow up [PYFU]) and 46 developed IFG (329/1000 PYFU). At baseline, 24 (18%) were obese and 36 (27%) were overweight, 15 became obese (69/1000 PYFU) and 22 became overweight (163/1000 PYFU). Median observation periods for the diabetes and obesity analyses were 23.5 months and 24.3 months, respectively. Increased CVD risk (≥10% 10-year Framingham risk score) was present for 13% of the cohort; 79% of the cohort had ≥1 cardiometabolic comorbidity, 48% had ≥2, and 13% had all three. In this Hispanic cohort in an LMIC, incidences of IFG / DM and overweight / obesity were similar to or higher than that found in high income countries, and cardiometabolic disorders affected three-quarters of those initiating ART. Care models incorporating cardiovascular risk reduction into HIV treatment programs are needed to prevent CVD - associated mortality in this vulnerable population.
27508301	0	9	Incidence	T081	C0021149
27508301	13	30	Diabetes Mellitus	T047	C0011849
27508301	35	42	Obesity	T047	C0028754
27508301	51	58	Overlap	T079	C1948020
27508301	62	75	Comorbidities	T078	C0009488
27508301	79	83	HIV+	T034	C0019699
27508301	84	93	Hispanics	T098	C0086409
27508301	94	104	Initiating	T169	C1704686
27508301	105	127	Antiretroviral Therapy	T061	C1963724
27508301	128	150	Cardiovascular disease	T047	C0007222
27508301	152	155	CVD	T047	C0007222
27508301	170	176	health	T078	C0018684
27508301	177	183	threat	T078	C0749385
27508301	188	192	HIV+	T034	C0019699
27508301	193	201	patients	T101	C0030705
27508301	205	227	antiretroviral therapy	T061	C1963724
27508301	229	232	ART	T061	C1963724
27508301	235	250	cardiometabolic	T047	C0025517
27508301	251	264	comorbidities	T078	C0009488
27508301	273	291	predictors of risk	T033	C0035648
27508301	293	297	Data	T078	C1511726
27508301	313	322	incidence	T081	C0021149
27508301	326	335	metabolic	T169	C0311400
27508301	336	349	comorbidities	T078	C0009488
27508301	353	357	HIV+	T034	C0019699
27508301	358	369	individuals	T098	C0237401
27508301	370	380	initiating	T169	C1704686
27508301	381	384	ART	T061	C1963724
27508301	388	391	low	T080	C0870823
27508301	396	409	middle income	T080	C0870890
27508301	410	419	countries	T083	C0454664
27508301	421	426	LMICs	T083	C0454664
27508301	429	441	particularly	T080	C0205556
27508301	446	455	Hispanics	T098	C0086409
27508301	460	468	examined	T033	C0332128
27508301	469	478	incidence	T081	C0021149
27508301	482	490	diabetes	T047	C0011847
27508301	495	502	obesity	T047	C0028754
27508301	508	526	prospective cohort	T098	C0599755
27508301	536	546	initiating	T169	C1704686
27508301	547	550	ART	T061	C1963724
27508301	558	576	Dominican Republic	T083	C0013014
27508301	578	590	Participants	T098	C0679646
27508301	595	600	years	T079	C0439234
27508301	602	612	initiating	T169	C1704686
27508301	613	616	ART	T061	C1963724
27508301	621	625	days	T079	C0439228
27508301	635	640	study	T062	C2603343
27508301	641	651	enrollment	T058	C1516879
27508301	658	666	examined	T033	C0332128
27508301	671	680	incidence	T081	C0021149
27508301	684	708	impaired fasting glucose	T033	C1272092
27508301	710	713	IFG	T033	C1272092
27508301	716	733	diabetes mellitus	T047	C0011849
27508301	735	737	DM	T047	C0011849
27508301	740	763	overweight, and obesity	T047	C1561826
27508301	765	787	Fasting plasma glucose	T059	C0583513
27508301	789	792	FPG	T059	C0583513
27508301	815	818	IFG	T033	C1272092
27508301	820	823	FPG	T059	C0583513
27508301	836	845	diagnosis	T062	C1704656
27508301	850	864	medical record	T170	C0025102
27508301	876	899	hypoglycemic medication	T121	C0020616
27508301	908	910	DM	T047	C0011849
27508301	912	934	Overweight and obesity	T047	C1561826
27508301	940	943	BMI	T201	C1305855
27508301	978	990	Dyslipidemia	T047	C0242339
27508301	995	1012	total cholesterol	T109	C0543421
27508301	1026	1032	use of	T169	C1524063
27508301	1033	1058	lipid-lowering medication	T121	C0003367
27508301	1060	1084	Framingham risk equation	T170	C3176199
27508301	1089	1093	used	T033	C1273517
27508301	1097	1106	determine	T080	C0521095
27508301	1107	1115	ten-year	T079	C0439234
27508301	1116	1119	CVD	T047	C0007222
27508301	1120	1124	risk	T058	C0086930
27508301	1132	1150	end of observation	T062	C0302523
27508301	1159	1169	initiating	T169	C1704686
27508301	1170	1173	ART	T061	C1963724
27508301	1186	1188	DM	T047	C0011849
27508301	1206	1209	IFG	T033	C1272092
27508301	1213	1221	baseline	T081	C1442488
27508301	1235	1237	DM	T047	C0011849
27508301	1247	1253	person	T098	C0027361
27508301	1256	1261	years	T079	C0439234
27508301	1262	1271	follow up	T058	C1522577
27508301	1273	1277	PYFU	T058	C1522577
27508301	1297	1300	IFG	T033	C1272092
27508301	1311	1315	PYFU	T058	C1522577
27508301	1321	1329	baseline	T081	C1442488
27508301	1345	1350	obese	T047	C0028754
27508301	1369	1379	overweight	T184	C0497406
27508301	1391	1396	obese	T047	C0028754
27508301	1406	1410	PYFU	T058	C1522577
27508301	1426	1436	overweight	T184	C0497406
27508301	1447	1451	PYFU	T058	C1522577
27508301	1454	1460	Median	T082	C2939193
27508301	1461	1472	observation	T058	C0700325
27508301	1473	1480	periods	T079	C1948053
27508301	1489	1497	diabetes	T047	C0011847
27508301	1502	1509	obesity	T047	C0028754
27508301	1510	1518	analyses	T062	C0936012
27508301	1529	1535	months	T079	C0439231
27508301	1545	1551	months	T079	C0439231
27508301	1567	1576	Increased	T081	C0205217
27508301	1577	1580	CVD	T047	C0007222
27508301	1581	1585	risk	T058	C0086930
27508301	1592	1621	10-year Framingham risk score	T033	C4086295
27508301	1627	1634	present	T033	C0150312
27508301	1650	1656	cohort	T098	C0599755
27508301	1669	1675	cohort	T098	C0599755
27508301	1683	1710	cardiometabolic comorbidity	T078	C0009488
27508301	1755	1763	Hispanic	T098	C0086409
27508301	1764	1770	cohort	T098	C0599755
27508301	1777	1781	LMIC	T083	C0454664
27508301	1783	1793	incidences	T081	C0021149
27508301	1797	1800	IFG	T033	C1272092
27508301	1803	1805	DM	T047	C0011849
27508301	1810	1820	overweight	T184	C0497406
27508301	1823	1830	obesity	T047	C0028754
27508301	1836	1843	similar	T080	C2348205
27508301	1850	1861	higher than	T080	C0205250
27508301	1867	1872	found	T033	C0150312
27508301	1876	1887	high income	T033	C0948433
27508301	1888	1897	countries	T083	C0454664
27508301	1903	1928	cardiometabolic disorders	T047	C0025517
27508301	1929	1937	affected	T169	C0392760
27508301	1962	1972	initiating	T169	C1704686
27508301	1973	1976	ART	T061	C1963724
27508301	1978	1989	Care models	T170	C0596657
27508301	2004	2023	cardiovascular risk	T047	C0850624
27508301	2024	2033	reduction	T061	C0441610
27508301	2039	2042	HIV	T047	C0019693
27508301	2043	2061	treatment programs	T058	C0679841
27508301	2066	2072	needed	T080	C0027552
27508301	2076	2083	prevent	T169	C1292733
27508301	2084	2087	CVD	T047	C0007222
27508301	2090	2100	associated	T080	C0332281
27508301	2101	2110	mortality	T081	C0205848
27508301	2119	2140	vulnerable population	T098	C0949366

28181538|t|Epigenetic Editing of Ascl1 Gene in Neural Stem Cells by Optogenetics
28181538|a|Enzymes involved in epigenetic processes such as methyltransferases or demethylases are becoming highly utilized for their persistent DNA or histone modifying efficacy. Herein, we have developed an optogenetic toolbox fused to the catalytic domain (CD) of DNA-methyltransferase3A (DNMT3A - CD) or Ten-Eleven Dioxygenase-1 (TET1 - CD) for loci - specific alteration of the methylation state at the promoter of Ascl1 (Mash1), a candidate proneuron gene. Optogenetical protein pairs, CRY2 linked to DNMT3A - CD or TET1 - CD and CIB1 fused to a Transcription Activator-Like Element (TALE) locating an Ascl1 promoter region, were designed for site specific epigenetic editing. A differentially methylated region at the Ascl1 promoter, isolated from murine dorsal root ganglion (hypermethylated) and striated cells (hypomethylated), was targeted with these optogenetic-epigenetic constructs. Optimized blue-light illumination triggered the co-localization of TALE constructs with DNMT3A - CD or TET1 - CD fusion proteins at the targeted site of the Ascl1 promoter. We found that this spatiotemporal association of the fusion proteins selectively alters the methylation state and also regulates gene activity. This proof of concept developed herein holds immense promise for the ability to regulate gene activity via epigenetic modulation with spatiotemporal precision.
28181538	0	18	Epigenetic Editing	T063	C4277689
28181538	22	32	Ascl1 Gene	T028	C1332009
28181538	36	53	Neural Stem Cells	T025	C1113654
28181538	57	69	Optogenetics	T063	C3494301
28181538	70	77	Enzymes	T116,T126	C0014442
28181538	90	110	epigenetic processes	T045	C1516924
28181538	119	137	methyltransferases	T116,T126	C0025831
28181538	141	153	demethylases	T116,T126	C0014442
28181538	167	173	highly	T080	C0205250
28181538	174	182	utilized	T169	C0457083
28181538	193	207	persistent DNA	T114,T123	C0012854
28181538	211	228	histone modifying	T044	C1156199
28181538	229	237	efficacy	T080	C1280519
28181538	268	279	optogenetic	T063	C3494301
28181538	280	287	toolbox	T170	C0282574
28181538	301	317	catalytic domain	T087	C0600499
28181538	319	321	CD	T087	C0600499
28181538	326	349	DNA-methyltransferase3A	T116,T126	C2348048
28181538	351	357	DNMT3A	T116,T126	C2348048
28181538	360	362	CD	T087	C0600499
28181538	367	391	Ten-Eleven Dioxygenase-1	T116,T126	C2987138
28181538	393	397	TET1	T116,T126	C2987138
28181538	400	402	CD	T087	C0600499
28181538	408	412	loci	T082	C1708726
28181538	415	423	specific	T080	C0205369
28181538	424	434	alteration	T045	C0026882
28181538	442	453	methylation	T044	C0376452
28181538	454	459	state	T169	C1442792
28181538	467	475	promoter	T114,T123	C0086860
28181538	479	484	Ascl1	T028	C1332009
28181538	486	491	Mash1	T028	C1332009
28181538	496	520	candidate proneuron gene	T028	C0017337
28181538	522	549	Optogenetical protein pairs	T116,T123	C0033684
28181538	551	555	CRY2	T116	C3813555
28181538	566	572	DNMT3A	T116,T126	C2348048
28181538	575	577	CD	T087	C0600499
28181538	581	585	TET1	T116,T126	C2987138
28181538	588	590	CD	T087	C0600499
28181538	595	599	CIB1	T116,T123	C1447592
28181538	600	605	fused	T169	C0699952
28181538	611	647	Transcription Activator-Like Element	T116,T123	C0033684
28181538	649	653	TALE	T116,T123	C0033684
28181538	667	672	Ascl1	T028	C1332009
28181538	673	688	promoter region	T114,T123	C0033413
28181538	708	721	site specific	T082	C0449604
28181538	722	740	epigenetic editing	T063	C4277689
28181538	744	758	differentially	T080	C0443199
28181538	759	776	methylated region	T082	C1254362
28181538	784	789	Ascl1	T028	C1332009
28181538	790	798	promoter	T114,T123	C0086860
28181538	800	808	isolated	T169	C0205409
28181538	814	820	murine	T015	C0035804
28181538	821	841	dorsal root ganglion	T023	C0017070
28181538	843	858	hypermethylated	T044	C0376452
28181538	864	872	striated	T080	C0205364
28181538	873	878	cells	T025	C0007634
28181538	880	894	hypomethylated	T044	C0376452
28181538	901	909	targeted	T169	C1521840
28181538	921	954	optogenetic-epigenetic constructs	T116,T123	C0033684
28181538	966	976	blue-light	T070	C0303896
28181538	977	989	illumination	T059	C0684292
28181538	990	999	triggered	T080	C1444748
28181538	1004	1019	co-localization	T067	C1254366
28181538	1023	1038	TALE constructs	T116,T123	C0033684
28181538	1044	1050	DNMT3A	T116,T126	C2348048
28181538	1053	1055	CD	T087	C0600499
28181538	1059	1063	TET1	T116,T126	C2987138
28181538	1066	1068	CD	T087	C0600499
28181538	1069	1084	fusion proteins	T116,T123	C0162768
28181538	1092	1105	targeted site	T082	C1254362
28181538	1113	1118	Ascl1	T028	C1332009
28181538	1119	1127	promoter	T114,T123	C0086860
28181538	1148	1162	spatiotemporal	T080	C0205556
28181538	1182	1197	fusion proteins	T116,T123	C0162768
28181538	1210	1216	alters	T169	C0392747
28181538	1221	1232	methylation	T044	C0376452
28181538	1233	1238	state	T169	C1442792
28181538	1248	1257	regulates	T045	C0017263
28181538	1258	1271	gene activity	T045	C0017255
28181538	1287	1294	concept	T078	C0178566
28181538	1318	1325	immense	T081	C1704243
28181538	1326	1333	promise	T078	C1555307
28181538	1353	1361	regulate	T044	C1148560
28181538	1362	1375	gene activity	T045	C0017255
28181538	1380	1401	epigenetic modulation	T063	C4277689
28181538	1407	1421	spatiotemporal	T080	C0205556
28181538	1422	1431	precision	T080	C1706245

27669157|t|A Patient Registry to Improve Patient Safety: Recording General Neurosurgery Complications
27669157|a|To improve the transparency of the local health care system, treatment cost was recently referenced to disease related groups. Treatment quality must be legally documented in a patient registry, in particular for the highly specialized treatments provided by neurosurgery departments. In 2013 we have installed a patient registry focused on cranial neurosurgery. Surgeries are characterized by indication, treatment, location and other specific neurosurgical parameters. Preoperative state and postoperative outcome are recorded prospectively using neurological and sociological scales. Complications are graded by their severity in a therapy-oriented complication score system (Clavien-Dindo-Grading system, CDG). Results are presented at the monthly clinical staff meeting. Data acquisition compatible with the clinic workflow permitted to include all eligible patients into the registry. Until December 2015, we have registered 2880 patients that were treated in 3959 surgeries and 8528 consultations. Since the registry is fully operational (August 2014), we have registered 325 complications on 1341 patient discharge forms (24%). In 64% of these complications, no or only pharmacological treatment was required. At discharge, there was a clear correlation of the severity of the complication and the Karnofsky Performance Status (KPS, ρ = -0.3, slope -6 KPS percentage points per increment of CDG) and the length of stay (ρ = 0.4, slope 1.5 days per increment of CDG). While the therapy-oriented complication scores correlate reasonably well with outcome and length of stay, they do not account for new deficits that cannot be treated. Outcome grading and complication severity grading thus serve a complimentary purpose. Overall, the registry serves to streamline and to complete information flow in the clinic, to identify complication rates and trends early for the internal quality monitoring and communication with patients. Conversely, the registry influences clinical practice in that it demands rigorous documentation and standard operating procedures.
27669157	2	18	Patient Registry	T062	C0920631
27669157	30	44	Patient Safety	T058	C1113679
27669157	64	76	Neurosurgery	T061	C0524850
27669157	77	90	Complications	T046	C0009566
27669157	126	150	local health care system	T093	C0018696
27669157	152	166	treatment cost	T081	C0087112
27669157	194	201	disease	T047	C0012634
27669157	210	216	groups	T098	C1257890
27669157	218	227	Treatment	T061	C0087111
27669157	228	235	quality	T080	C0332306
27669157	244	262	legally documented	T170	C0681483
27669157	268	284	patient registry	T062	C0920631
27669157	327	337	treatments	T061	C0087111
27669157	350	374	neurosurgery departments	T093	C0587523
27669157	404	420	patient registry	T062	C0920631
27669157	432	452	cranial neurosurgery	T061	C0195775
27669157	454	463	Surgeries	T061	C0543467
27669157	485	495	indication	T078	C3146298
27669157	497	506	treatment	T061	C0087111
27669157	508	516	location	T082	C4041236
27669157	536	560	neurosurgical parameters	T169	C0038895
27669157	562	580	Preoperative state	T033	C0178808
27669157	585	606	postoperative outcome	T080	C0085415
27669157	640	652	neurological	T170	C0282574
27669157	657	676	sociological scales	T170	C0282574
27669157	678	691	Complications	T046	C0009566
27669157	712	720	severity	T080	C0439793
27669157	726	768	therapy-oriented complication score system	T170	C0282574
27669157	770	798	Clavien-Dindo-Grading system	T170	C0282574
27669157	800	803	CDG	T170	C0282574
27669157	835	842	monthly	T079	C0332177
27669157	843	857	clinical staff	T097	C0025106
27669157	858	865	meeting	T052	C0556656
27669157	867	871	Data	T078	C1511726
27669157	872	883	acquisition	T052	C1706701
27669157	904	910	clinic	T073,T093	C0442592
27669157	911	919	workflow	T077	C1710679
27669157	954	962	patients	T101	C0030705
27669157	972	980	registry	T062	C0920631
27669157	1027	1035	patients	T101	C0030705
27669157	1046	1053	treated	T169	C1522326
27669157	1062	1071	surgeries	T061	C0543467
27669157	1081	1094	consultations	T058	C0009818
27669157	1106	1114	registry	T062	C0920631
27669157	1174	1187	complications	T046	C0009566
27669157	1196	1213	patient discharge	T058	C0030685
27669157	1214	1219	forms	T170	C0282574
27669157	1243	1256	complications	T046	C0009566
27669157	1269	1294	pharmacological treatment	T061	C0013216
27669157	1312	1321	discharge	T058	C0030685
27669157	1360	1368	severity	T080	C0439793
27669157	1376	1388	complication	T046	C0009566
27669157	1397	1425	Karnofsky Performance Status	T060	C0206065
27669157	1427	1430	KPS	T060	C0206065
27669157	1451	1454	KPS	T060	C0206065
27669157	1477	1486	increment	T081	C1705117
27669157	1490	1493	CDG	T170	C0282574
27669157	1503	1517	length of stay	T079	C0023303
27669157	1538	1542	days	T079	C0439228
27669157	1547	1556	increment	T081	C1705117
27669157	1560	1563	CDG	T170	C0282574
27669157	1576	1612	therapy-oriented complication scores	T081	C0449820
27669157	1644	1651	outcome	T169	C1274040
27669157	1656	1670	length of stay	T079	C0023303
27669157	1724	1731	treated	T169	C1522326
27669157	1733	1740	Outcome	T169	C1274040
27669157	1741	1748	grading	T185	C0441800
27669157	1753	1765	complication	T046	C0009566
27669157	1766	1774	severity	T080	C0439793
27669157	1775	1782	grading	T185	C0441800
27669157	1832	1840	registry	T062	C0920631
27669157	1902	1908	clinic	T073,T093	C0442592
27669157	1922	1934	complication	T046	C0009566
27669157	1975	1982	quality	T080	C0332306
27669157	1983	1993	monitoring	T058	C1283169
27669157	1998	2011	communication	T054	C0009452
27669157	2017	2025	patients	T101	C0030705
27669157	2043	2051	registry	T062	C0920631
27669157	2063	2080	clinical practice	T058	C1254363
27669157	2109	2122	documentation	T170	C0920316
27669157	2127	2156	standard operating procedures	T170	C3889288

27427386|t|Biochemical evidence for a mitochondrial genetic modifier in the phenotypic manifestation of Leber's hereditary optic neuropathy -associated mitochondrial DNA mutation
27427386|a|Leber's hereditary optic neuropathy (LHON) is the most common mitochondrial disease. Mitochondrial modifiers are proposed to modify the phenotypic expression of primary LHON -associated mitochondrial DNA (mtDNA) mutations. In this study, we demonstrated that the LHON susceptibility allele (m.14502T > C, p. 58I > V) in the ND6 gene modulated the phenotypic expression of primary LHON -associated m.11778G > A mutation. Twenty-two Han Chinese pedigrees carrying m.14502T > C and m.11778G > A mutations exhibited significantly higher penetrance of optic neuropathy than those carrying only m.11778G > A mutation. We performed functional assays using the cybrid cell models, generated by fusing mtDNA-less ρ(o) cells with enucleated cells from LHON patients carrying both m.11778G > A and m.14502T > C mutations, only m.14502T > C or m.11778G > A mutation and a control belonging to the same mtDNA haplogroup. These cybrids cell lines bearing m.14502T > C mutation exhibited mild effects on mitochondrial functions compared with those carrying only m.11778G > A mutation. However, more severe mitochondrial dysfunctions were observed in cell lines bearing both m.14502T > C and m.11778G > A mutations than those carrying only m.11778G > A or m.14502T > C mutation. In particular, the m.14502T > C mutation altered assemble of complex I, thereby aggravating the respiratory phenotypes associated with m.11778G > A mutation, resulted in a more defective complex I. Furthermore, more reductions in the levels of mitochondrial ATP and increasing production of reactive oxygen species were also observed in mutant cells bearing both m.14502T > C and m.11778G > A mutation than those carrying only 11778G > A mutation. Our findings provided new insights into the pathophysiology of LHON that were manifested by interaction between primary and secondary mtDNA mutations.
27427386	0	11	Biochemical	T169	C0205474
27427386	27	40	mitochondrial	T026	C0026237
27427386	41	48	genetic	T169	C0314603
27427386	49	57	modifier	T028	C3178895
27427386	65	75	phenotypic	T032	C0031437
27427386	76	89	manifestation	T169	C0205319
27427386	93	128	Leber's hereditary optic neuropathy	T047	C0917796
27427386	141	167	mitochondrial DNA mutation	T019	C0948444
27427386	168	203	Leber's hereditary optic neuropathy	T047	C0917796
27427386	205	209	LHON	T047	C0917796
27427386	230	251	mitochondrial disease	T047	C0751651
27427386	253	266	Mitochondrial	T026	C0026237
27427386	267	276	modifiers	T028	C3178895
27427386	304	325	phenotypic expression	T032	C0031437
27427386	337	341	LHON	T047	C0917796
27427386	354	371	mitochondrial DNA	T114,T123	C0012929
27427386	373	378	mtDNA	T114,T123	C0012929
27427386	380	389	mutations	T019	C0948444
27427386	399	404	study	T062	C2603343
27427386	431	435	LHON	T047	C0917796
27427386	436	450	susceptibility	T201	C0012655
27427386	451	457	allele	T028	C0002085
27427386	459	471	m.14502T > C	T028	C0002085
27427386	473	483	p. 58I > V	T028	C0002085
27427386	492	500	ND6 gene	T028	C1537995
27427386	501	510	modulated	T082	C0443264
27427386	515	536	phenotypic expression	T032	C0031437
27427386	548	552	LHON	T047	C0917796
27427386	565	586	m.11778G > A mutation	T045	C0026882
27427386	599	610	Han Chinese	UnknownType	C0814942
27427386	611	620	pedigrees	T170	C0030761
27427386	630	642	m.14502T > C	T045	C0026882
27427386	647	669	m.11778G > A mutations	T045	C0026882
27427386	701	711	penetrance	T081	C0524899
27427386	715	731	optic neuropathy	T047	C3887709
27427386	757	778	m.11778G > A mutation	T045	C0026882
27427386	793	803	functional	T169	C0205245
27427386	804	810	assays	T059	C0005507
27427386	821	839	cybrid cell models	T025	C0007600
27427386	861	882	mtDNA-less ρ(o) cells	T025	C0007634
27427386	888	904	enucleated cells	T025	C0007634
27427386	910	914	LHON	T047	C0917796
27427386	915	923	patients	T101	C0030705
27427386	938	950	m.11778G > A	T045	C0026882
27427386	955	977	m.14502T > C mutations	T045	C0026882
27427386	984	996	m.14502T > C	T045	C0026882
27427386	1000	1021	m.11778G > A mutation	T045	C0026882
27427386	1058	1063	mtDNA	T114,T123	C0012929
27427386	1064	1074	haplogroup	T032	C0018591
27427386	1082	1100	cybrids cell lines	T025	C0007600
27427386	1109	1130	m.14502T > C mutation	T045	C0026882
27427386	1146	1153	effects	T080	C1280500
27427386	1157	1170	mitochondrial	T026	C0026237
27427386	1171	1180	functions	T169	C0542341
27427386	1215	1236	m.11778G > A mutation	T045	C0026882
27427386	1259	1272	mitochondrial	T026	C0026237
27427386	1273	1285	dysfunctions	T077	C3887504
27427386	1303	1313	cell lines	T025	C0007600
27427386	1327	1339	m.14502T > C	T045	C0026882
27427386	1344	1366	m.11778G > A mutations	T045	C0026882
27427386	1392	1404	m.11778G > A	T045	C0026882
27427386	1408	1429	m.14502T > C mutation	T045	C0026882
27427386	1450	1471	m.14502T > C mutation	T045	C0026882
27427386	1492	1501	complex I	T116,T126	C0171406
27427386	1527	1538	respiratory	T169	C0521346
27427386	1539	1549	phenotypes	T032	C0031437
27427386	1566	1587	m.11778G > A mutation	T045	C0026882
27427386	1608	1617	defective	T169	C0332452
27427386	1618	1627	complex I	T116,T126	C0171406
27427386	1675	1688	mitochondrial	T026	C0026237
27427386	1689	1692	ATP	T114,T121,T123	C0001480
27427386	1722	1745	reactive oxygen species	T123,T196	C0162772
27427386	1768	1774	mutant	T049	C0596988
27427386	1775	1780	cells	T025	C0007634
27427386	1794	1806	m.14502T > C	T045	C0026882
27427386	1811	1832	m.11778G > A mutation	T045	C0026882
27427386	1858	1877	11778G > A mutation	T045	C0026882
27427386	1923	1938	pathophysiology	T169	C0031847
27427386	1942	1946	LHON	T047	C0917796
27427386	1957	1970	manifested by	T080	C1280444
27427386	2013	2018	mtDNA	T114,T123	C0012929
27427386	2019	2028	mutations	T019	C0948444

27561345|t|Teriparatide: benefit and safety for bone disease in CKD patients undergoing hemodialysis
27561345|a|Teriparatide, 1-34 parathyroid hormone, is one of effective treatments for osteoporosis. Teriparatide shows an anabolic effect for bone formation, as a result, increases bone mineral density as well as prevention of fractures in the general population. On the other hand, there are a few report about the effect of teriparatide on increase of bone mineral density in maintenance hemodialysis patients. In addition to CKD-MBD, osteoporosis is also an important pathological change in ESRD patients, therefore its safety and efficacy should be discussed in more detail.
27561345	0	12	Teriparatide	T116,T121,T125	C0070093
27561345	14	21	benefit	T081	C0814225
27561345	26	32	safety	T080	C0205556
27561345	37	49	bone disease	T047	C0005940
27561345	53	56	CKD	T047	C1561643
27561345	57	65	patients	T101	C0030705
27561345	77	89	hemodialysis	T061	C0019004
27561345	90	102	Teriparatide	T116,T121,T125	C0070093
27561345	104	128	1-34 parathyroid hormone	T116,T123	C1956225
27561345	150	160	treatments	T061	C0087111
27561345	165	177	osteoporosis	T047	C0029456
27561345	179	191	Teriparatide	T116,T121,T125	C0070093
27561345	201	216	anabolic effect	T039	C3179309
27561345	221	235	bone formation	T042	C0029433
27561345	250	259	increases	T169	C0442805
27561345	260	280	bone mineral density	T201	C0005938
27561345	292	302	prevention	T080	C2700409
27561345	306	315	fractures	T037	C0016658
27561345	331	341	population	T098	C1257890
27561345	395	404	effect of	T080	C1704420
27561345	405	417	teriparatide	T116,T121,T125	C0070093
27561345	421	429	increase	T169	C0442805
27561345	433	453	bone mineral density	T201	C0005938
27561345	457	468	maintenance	T052	C0024501
27561345	469	481	hemodialysis	T061	C0019004
27561345	482	490	patients	T101	C0030705
27561345	507	514	CKD-MBD	T047	C4076240
27561345	516	528	osteoporosis	T047	C0029456
27561345	550	562	pathological	T091	C0030664
27561345	563	569	change	T169	C0392747
27561345	573	577	ESRD	T047	C0022661
27561345	578	586	patients	T101	C0030705
27561345	602	608	safety	T062	C1705187
27561345	613	621	efficacy	T062	C1707887

28338376|t|Pembrolizumab for the treatment of non-small cell lung cancer
28338376|a|In the last years, a spectacular development of immunotherapeutic agents aimed at the PD-1 / PD-L1 axis has taken place. This development of these checkpoint inhibitors has greatly influenced our approach to the treatment of lung cancer in first and second line. The limited toxicity profile and the ability to treat for prolonged periods, even in smokers, is a welcome expansion of the therapeutic arsenal of the oncologist. Areas covered: This review highlights the results of recent clinical trials on pembrolizumab for the treatment of non-small cell lung cancer. The authors discuss both first and second line treatment with pembrolizumab as monotherapy and in combination therapies. Additionally, implications of the PD-L1 immunohistochemistry assay with the 22C3 antibody and its use in clinical practice and trials is discussed. Expert commentary: A higher overall response, overall survival and a moderate toxicity profile is observed with the use of pembrolizumab, compared to chemotherapy, in both first and second line. These promising results have already translated into the registration of pembrolizumab in first and second line in patients with a high expression of PD-L1. However, as PD-L1 staining does not sufficiently discriminate responders from non-responders for all checkpoint inhibitors, there still is a need for a better predictive biomarker.
28338376	0	13	Pembrolizumab	T116,T121,T129	C3658706
28338376	22	31	treatment	T061	C0087111
28338376	35	61	non-small cell lung cancer	T191	C0007131
28338376	95	106	development	T169	C1527148
28338376	110	134	immunotherapeutic agents	T121,T129	C0876248
28338376	148	152	PD-1	T116,T129,T192	C2986635
28338376	155	160	PD-L1	T129	C4300350
28338376	188	199	development	T169	C1527148
28338376	209	230	checkpoint inhibitors	T120	C0243077
28338376	274	283	treatment	T061	C0087111
28338376	287	298	lung cancer	T191	C0242379
28338376	302	307	first	T061	C1708063
28338376	312	323	second line	T061	C1710038
28338376	329	336	limited	T169	C0439801
28338376	337	345	toxicity	T037	C0013221
28338376	373	378	treat	T061	C0087111
28338376	383	392	prolonged	T079	C0439590
28338376	393	400	periods	T079	C1948053
28338376	410	417	smokers	T033	C0337664
28338376	476	486	oncologist	T097	C0259990
28338376	508	514	review	T170	C0282443
28338376	530	537	results	T169	C1274040
28338376	548	563	clinical trials	T062	C0008976
28338376	567	580	pembrolizumab	T116,T121,T129	C3658706
28338376	589	598	treatment	T061	C0087111
28338376	602	628	non-small cell lung cancer	T191	C0007131
28338376	634	641	authors	T097	C3812881
28338376	655	660	first	T061	C1708063
28338376	665	686	second line treatment	T061	C1710038
28338376	692	705	pembrolizumab	T116,T121,T129	C3658706
28338376	709	720	monotherapy	T061	C0087111
28338376	728	749	combination therapies	T061	C0013218
28338376	785	790	PD-L1	T129	C4300350
28338376	791	817	immunohistochemistry assay	T059	C0020980
28338376	827	840	22C3 antibody	T116,T129	C0003241
28338376	849	852	use	T169	C0457083
28338376	856	873	clinical practice	T062	C0008967
28338376	878	884	trials	T062	C0008976
28338376	920	926	higher	T080	C0205250
28338376	927	943	overall response	T033	C3272903
28338376	945	961	overall survival	T081	C4086681
28338376	968	976	moderate	T080	C0205081
28338376	977	985	toxicity	T037	C0013221
28338376	1015	1018	use	T169	C0457083
28338376	1022	1035	pembrolizumab	T116,T121,T129	C3658706
28338376	1049	1061	chemotherapy	T061	C3665472
28338376	1071	1076	first	T061	C1708063
28338376	1081	1092	second line	T061	C1710038
28338376	1110	1117	results	T169	C1274040
28338376	1151	1163	registration	T058	C1514821
28338376	1167	1180	pembrolizumab	T116,T121,T129	C3658706
28338376	1184	1189	first	T061	C1708063
28338376	1194	1205	second line	T061	C1710038
28338376	1209	1217	patients	T101	C0030705
28338376	1225	1229	high	T080	C0205250
28338376	1230	1240	expression	T045	C1171362
28338376	1244	1249	PD-L1	T129	C4300350
28338376	1263	1268	PD-L1	T129	C4300350
28338376	1269	1277	staining	T059	C0487602
28338376	1313	1323	responders	T033	C0919876
28338376	1329	1343	non-responders	T033	C0919875
28338376	1352	1373	checkpoint inhibitors	T120	C0243077
28338376	1410	1420	predictive	T080	C0681890
28338376	1421	1430	biomarker	T201	C0005516

28341161|t|Predictive position computations mediated by parietal areas: TMS evidence
28341161|a|When objects move or the eyes move, the visual system can predict the consequence and generate a percept of the target at its new position. This predictive localization may depend on eye movement control in the frontal eye fields (FEF) and the intraparietal sulcus (IPS) and on motion analysis in the medial temporal area (MT). Across two experiments we examined whether repetitive transcranial magnetic stimulation (rTMS) over right FEF, right IPS, righ t MT, and a control site, peripheral V1 / V2, diminished participants ' perception of two cases of predictive position perception: trans-saccadic fusion, and the flash grab illusion, both presented in the contralateral visual field. In trans-saccadic fusion trials, participants saccade toward a stimulus that is replaced with another stimulus during the saccade. Frequently, predictive position mechanisms lead to a fused percept of pre - and post - saccade stimuli (Paeye et al., 2017). We found that rTMS to IPS significantly decreased the frequency of perceiving trans-saccadic fusion within the first 10min after stimulation. In the flash grab illusion, a target is flashed on a moving background leading to the percept that the target has shifted in the direction of the motion after the flash (Cavanagh and Anstis, 2013). In the first experiment, the reduction in the flash grab illusion after rTMS to IPS and FEF did not reach significance. In the second experiment, using a stronger version of the flash grab, the illusory shift did decrease significantly after rTMS to IPS although not after rTMS to FEF or to MT. These findings suggest that right IPS contributes to predictive position perception during saccades and motion processing in the contralateral visual field.
28341161	0	10	Predictive	T080	C0681890
28341161	11	19	position	T082	C0733755
28341161	20	32	computations	T052	C1880157
28341161	45	59	parietal areas	T023	C0030560
28341161	61	64	TMS	T061	C0436548
28341161	79	86	objects	T072	C0347997
28341161	87	91	move	T033	C0578671
28341161	99	108	eyes move	T039	C0015413
28341161	114	127	visual system	T022	C3536733
28341161	132	139	predict	T078	C0681842
28341161	144	155	consequence	T169	C0686907
28341161	171	178	percept	T041	C0030971
28341161	186	192	target	T169	C1521840
28341161	204	212	position	T082	C0733755
28341161	219	229	predictive	T080	C0681890
28341161	230	242	localization	T169	C0475264
28341161	257	269	eye movement	T039	C0015413
28341161	270	277	control	T169	C2587213
28341161	285	303	frontal eye fields	T023	C3498745
28341161	305	308	FEF	T023	C3498745
28341161	318	338	intraparietal sulcus	T030	C0228213
28341161	340	343	IPS	T030	C0228213
28341161	352	358	motion	T070	C0026597
28341161	359	367	analysis	T169	C1524024
28341161	375	395	medial temporal area	T023	C0039485
28341161	397	399	MT	T023	C0039485
28341161	413	424	experiments	T062	C0681815
28341161	445	489	repetitive transcranial magnetic stimulation	T061	C0872259
28341161	491	495	rTMS	T061	C0872259
28341161	502	507	right	T082	C0205090
28341161	508	511	FEF	T023	C3498745
28341161	513	522	right IPS	T030	C2950912
28341161	524	528	righ	T082	C0205090
28341161	531	533	MT	T023	C0039485
28341161	541	548	control	T169	C2587213
28341161	549	553	site	T029	C1515974
28341161	555	568	peripheral V1	T023	C0042817
28341161	571	573	V2	T023	C0042817
28341161	586	598	participants	T098	C0679646
28341161	601	611	perception	T041	C0042830
28341161	628	638	predictive	T080	C0681890
28341161	639	647	position	T082	C0733755
28341161	648	658	perception	T041	C0042830
28341161	660	674	trans-saccadic	T042	C0036019
28341161	675	681	fusion	T041	C0237661
28341161	691	710	flash grab illusion	T041	C0029139
28341161	748	760	visual field	T082	C0042826
28341161	765	779	trans-saccadic	T042	C0036019
28341161	780	786	fusion	T041	C0237661
28341161	787	793	trials	T062	C0681815
28341161	795	807	participants	T098	C0679646
28341161	808	815	saccade	T042	C0036019
28341161	825	833	stimulus	T067	C0234402
28341161	864	872	stimulus	T067	C0234402
28341161	884	891	saccade	T042	C0036019
28341161	905	915	predictive	T080	C0681890
28341161	916	924	position	T082	C0733755
28341161	946	959	fused percept	T041	C0042830
28341161	963	966	pre	T079	C0332152
28341161	973	977	post	T079	C0687676
28341161	980	987	saccade	T042	C0036019
28341161	988	995	stimuli	T067	C0234402
28341161	1032	1036	rTMS	T061	C0872259
28341161	1040	1043	IPS	T030	C0228213
28341161	1044	1057	significantly	T078	C0750502
28341161	1058	1067	decreased	T081	C0547047
28341161	1072	1081	frequency	T079	C0439603
28341161	1085	1095	perceiving	T041	C0030971
28341161	1096	1110	trans-saccadic	T042	C0036019
28341161	1111	1117	fusion	T041	C0237661
28341161	1147	1158	stimulation	T041	C0036602
28341161	1167	1186	flash grab illusion	T041	C0029139
28341161	1190	1196	target	T169	C1521840
28341161	1213	1219	moving	T033	C0578671
28341161	1220	1230	background	T077	C1706907
28341161	1246	1253	percept	T041	C0042830
28341161	1263	1269	target	T169	C1521840
28341161	1289	1298	direction	T082	C0449738
28341161	1306	1312	motion	T070	C0026597
28341161	1323	1328	flash	T067	C1764741
28341161	1371	1381	experiment	T062	C0681815
28341161	1404	1423	flash grab illusion	T041	C0029139
28341161	1430	1434	rTMS	T061	C0872259
28341161	1438	1441	IPS	T030	C0228213
28341161	1446	1449	FEF	T023	C3498745
28341161	1450	1476	did not reach significance	T033	C1273937
28341161	1492	1502	experiment	T062	C0681815
28341161	1536	1546	flash grab	T041	C0029139
28341161	1552	1566	illusory shift	T041	C0029139
28341161	1571	1579	decrease	T081	C0547047
28341161	1580	1593	significantly	T078	C0750502
28341161	1600	1604	rTMS	T061	C0872259
28341161	1608	1611	IPS	T030	C0228213
28341161	1631	1635	rTMS	T061	C0872259
28341161	1639	1642	FEF	T023	C3498745
28341161	1649	1651	MT	T023	C0039485
28341161	1687	1690	IPS	T030	C0228213
28341161	1706	1716	predictive	T080	C0681890
28341161	1717	1725	position	T082	C0733755
28341161	1726	1736	perception	T041	C0042830
28341161	1744	1752	saccades	T042	C0036019
28341161	1757	1763	motion	T070	C0026597
28341161	1782	1795	contralateral	T082	C0441988
28341161	1796	1808	visual field	T082	C0042826

27623532|t|Task-Oriented Training with Computer Games for People with Rheumatoid Arthritis or Hand Osteoarthritis: A Feasibility Randomized Controlled Trial
27623532|a|To examine the feasibility of a clinical trial on a novel, home-based task-oriented training with conventional hand exercises in people with rheumatoid arthritis or hand osteoarthritis. To explore the experiences of participants who completed their respective home exercise programmes. Thirty volunteer participants aged between 30 and 60 years and diagnosed with rheumatoid arthritis or hand osteoarthritis were proposed for a single-center, assessor-blinded, randomized controlled trial (ClinicalTrials.gov: NCT01635582). Participants received task-oriented training with interactive computer games and objects of daily life or finger mobility and strengthening exercises. Both programmes were home based and were done four sessions per week with 20 minutes each session for 6 weeks. Major feasibility outcomes were number of volunteers screened, randomized, and retained; completion of blinded assessments, exercise training, and home exercise sessions; equipment and data management; and clinical outcomes of hand function. Reaching the recruitment target in 18 months and achieving exercise compliance >80% were set as success criteria. Concurrent with the trial, focus group interviews explored experiences of those participants who completed their respective programmes. After trial initiation, revisions in inclusion criteria were required to promote recruitment. A total of 17 participants were randomized and 15 were retained. Completion of assessments, exercise training, and home exercise sessions; equipment and data collection and management demonstrated excellent feasibility. Both groups improved in hand function outcomes and exercise compliance was above 85%. Participants perceived both programmes as appropriate and acceptable. Participants who completed task-oriented training also agreed that playing different computer games was enjoyable, engaging, and motivating. Findings demonstrate initial evidence on recruitment, feasibility of trial procedures, and acceptability of task-oriented training in people with rheumatoid arthritis or hand osteoarthritis. Since the pilot trial was unsuccessful in participant recruitment, a large trial will not follow.
27623532	0	13	Task-Oriented	T033	C0243095
27623532	14	22	Training	T065	C0220931
27623532	28	42	Computer Games	T073	C0870328
27623532	47	53	People	T098	C0027361
27623532	59	79	Rheumatoid Arthritis	T047	C0003873
27623532	83	102	Hand Osteoarthritis	T047	C0263746
27623532	118	145	Randomized Controlled Trial	T062	C0206035
27623532	178	192	clinical trial	T062	C0008976
27623532	198	203	novel	T080	C0205314
27623532	216	229	task-oriented	T033	C0243095
27623532	230	238	training	T065	C0220931
27623532	244	271	conventional hand exercises	T061	C0454330
27623532	275	281	people	T098	C0027361
27623532	287	307	rheumatoid arthritis	T047	C0003873
27623532	311	330	hand osteoarthritis	T047	C0263746
27623532	362	374	participants	T098	C0679646
27623532	406	430	home exercise programmes	T061	C0475647
27623532	449	461	participants	T098	C0679646
27623532	495	504	diagnosed	T033	C0011900
27623532	510	530	rheumatoid arthritis	T047	C0003873
27623532	534	553	hand osteoarthritis	T047	C0263746
27623532	589	605	assessor-blinded	T062	C2347038
27623532	607	634	randomized controlled trial	T062	C0206035
27623532	670	682	Participants	T098	C0679646
27623532	692	705	task-oriented	T033	C0243095
27623532	706	714	training	T065	C0220931
27623532	720	731	interactive	T169	C1704675
27623532	732	746	computer games	T073	C0870328
27623532	776	782	finger	T023	C0016129
27623532	783	791	mobility	T033	C0425245
27623532	796	819	strengthening exercises	T061	C0452260
27623532	826	836	programmes	T169	C3484370
27623532	872	880	sessions	T051	C1883016
27623532	911	918	session	T051	C1883016
27623532	974	984	volunteers	T097	C0042960
27623532	995	1005	randomized	T033	C3815594
27623532	1011	1019	retained	T169	C0333118
27623532	1035	1042	blinded	T062	C0150108
27623532	1043	1054	assessments	T058	C0220825
27623532	1056	1064	exercise	T056	C0015259
27623532	1065	1073	training	T065	C0220931
27623532	1079	1101	home exercise sessions	T061	C0475647
27623532	1117	1132	data management	T062	C0596404
27623532	1138	1155	clinical outcomes	T033	C0243095
27623532	1159	1172	hand function	T040	C0562230
27623532	1187	1198	recruitment	T052	C2949735
27623532	1233	1241	exercise	T056	C0015259
27623532	1242	1252	compliance	T033	C3714738
27623532	1270	1277	success	T054	C0597535
27623532	1278	1286	criteria	T078	C0243161
27623532	1288	1298	Concurrent	T079	C0205420
27623532	1308	1313	trial	T062	C0008976
27623532	1315	1337	focus group interviews	T062	C0018260
27623532	1368	1380	participants	T098	C0679646
27623532	1412	1422	programmes	T169	C3484370
27623532	1430	1435	trial	T062	C0008976
27623532	1436	1446	initiation	T169	C1704686
27623532	1461	1470	inclusion	T080	C1512693
27623532	1471	1479	criteria	T078	C0243161
27623532	1505	1516	recruitment	T052	C2949735
27623532	1532	1544	participants	T098	C0679646
27623532	1550	1560	randomized	T033	C3815594
27623532	1573	1581	retained	T169	C0333118
27623532	1583	1593	Completion	T080	C1554962
27623532	1597	1608	assessments	T058	C1261322
27623532	1610	1618	exercise	T056	C0015259
27623532	1619	1627	training	T065	C0220931
27623532	1633	1655	home exercise sessions	T061	C0475647
27623532	1671	1686	data collection	T062	C0010995
27623532	1691	1701	management	T062	C0596404
27623532	1762	1775	hand function	T040	C0562230
27623532	1789	1797	exercise	T056	C0015259
27623532	1798	1808	compliance	T033	C3714738
27623532	1824	1836	Participants	T098	C0679646
27623532	1852	1862	programmes	T058	C0032678
27623532	1866	1877	appropriate	T080	C1548787
27623532	1882	1892	acceptable	T080	C1879533
27623532	1894	1906	Participants	T098	C0679646
27623532	1921	1934	task-oriented	T033	C0243095
27623532	1935	1943	training	T065	C0220931
27623532	1961	1968	playing	T056	C0032214
27623532	1979	1993	computer games	T073	C0870328
27623532	1998	2007	enjoyable	T033	C0243095
27623532	2009	2017	engaging	T033	C0243095
27623532	2023	2033	motivating	T033	C0243095
27623532	2035	2043	Findings	T033	C0243095
27623532	2076	2087	recruitment	T052	C2949735
27623532	2104	2109	trial	T062	C0008976
27623532	2110	2120	procedures	T169	C2700391
27623532	2126	2139	acceptability	T080	C0814633
27623532	2143	2156	task-oriented	T033	C0243095
27623532	2157	2165	training	T065	C0220931
27623532	2169	2175	people	T098	C0027361
27623532	2181	2201	rheumatoid arthritis	T047	C0003873
27623532	2205	2224	hand osteoarthritis	T047	C0263746
27623532	2242	2247	trial	T062	C0008976
27623532	2268	2279	participant	T098	C0679646
27623532	2280	2291	recruitment	T052	C2949735
27623532	2301	2306	trial	T062	C0008976

28341674|t|Interbacterial Adhesion Networks within Early Oral Biofilms of Single Human Hosts
28341674|a|Specific interbacterial adhesion, termed coaggregation, is well established for three early colonizers of the plaque biofilm: streptococci, actinomyces, and veillonellae. However, little is known about interactions of other early colonizers and about the extent of interactions within the bacterial community from a single host. To address these gaps, subject - specific culture collections from two individuals were established using an intraoral biofilm retrieval device. Molecular taxonomy (Human Oral Microbe Identification Microarray [HOMIM]) analysis of biofilm samples confirmed the integrity and completeness of the collections. HOMIM analysis verified the isolation of Streptococcus gordonii and S. anginosus from only one subject, as well as isolation of a previously uncultivated streptococcal phylotype from the other subject. Strains representative of clonal diversity within each collection were further characterized. Greater than 70% of these streptococcal strains from each subject coaggregated with at least one other coisolate. One-third of the strains carry a known coaggregation mediator: receptor polysaccharide (RPS). Almost all nonstreptococcal isolates coaggregated with other coisolates. Importantly, certain Rothia strains demonstrated more coaggregations with their coisolated bacteria than did any Streptococcus or Actinomyces strain, and certain Haemophilus isolates participated in twice as many. Confocal microscopy of undisturbed biofilms showed that Rothia and Haemophilus each occur in small multispecies microcolonies. However, in confluent high - biomass regions, Rothia occurred in islands whereas Haemophilus was distributed throughout. Together, the data demonstrate that coaggregation networks within an individual's oral microflora are extensive and that Rothia and Haemophilus can be important initiators of cell-cell interactions in the early biofilm .IMPORTANCE Extensive involvement of specific interbacterial adhesion in dental plaque biofilm formation has been postulated based on in vitro coaggregation between oral bacteria from culture collections that are not subject specific. In the present study, subject - specific culture collections were obtained from early plaque biofilm of two volunteers, and coaggregations within each culture collection were assayed. Coaggregations, several of which involved a coaggregation -mediating cell surface molecule known from well-studied streptococci, were widespread. Unexpectedly, the little-studied organisms Haemophilus and Rothia participated in the greatest numbers of interactions with community members; these two organisms showed different distributions within the undisturbed biofilm. The data show that coaggregation networks encompass most organisms within the biofilm community of each individual, and they indicate prominent participation of organisms such as Haemophilus and Rothia in early plaque biofilm formation.
28341674	0	14	Interbacterial	T080	C0521009
28341674	15	23	Adhesion	T040	C0004614
28341674	24	32	Networks	T169	C1882071
28341674	46	50	Oral	T082	C0442027
28341674	51	59	Biofilms	T007	C0081786
28341674	63	81	Single Human Hosts	T016	C0086418
28341674	91	105	interbacterial	T080	C0521009
28341674	106	114	adhesion	T040	C0004614
28341674	123	136	coaggregation	T169	C0332621
28341674	174	184	colonizers	T025	C1947989
28341674	192	198	plaque	T047	C0011389
28341674	199	206	biofilm	T007	C0081786
28341674	208	220	streptococci	T007	C0038402
28341674	222	233	actinomyces	T007	C0001250
28341674	239	251	veillonellae	T007	C0042446
28341674	284	296	interactions	T169	C1704675
28341674	312	322	colonizers	T025	C1947989
28341674	347	359	interactions	T169	C1704675
28341674	371	390	bacterial community	T007	C0004611
28341674	398	409	single host	T001	C1167395
28341674	434	441	subject	T098	C2349001
28341674	444	452	specific	T080	C0205369
28341674	453	472	culture collections	T060	C0204880
28341674	482	493	individuals	T098	C0027361
28341674	520	529	intraoral	T082	C0442027
28341674	530	537	biofilm	T007	C0081786
28341674	538	554	retrieval device	T074	C0025080
28341674	556	565	Molecular	T080	C1521991
28341674	566	574	taxonomy	T090	C0087066
28341674	575	638	(Human Oral Microbe Identification Microarray [HOMIM]) analysis	T059	C1449575
28341674	642	657	biofilm samples	T007	C0081786
28341674	672	681	integrity	T080	C1947912
28341674	686	698	completeness	T080	C0439812
28341674	706	717	collections	T060	C0204880
28341674	719	733	HOMIM analysis	T059	C1449575
28341674	747	756	isolation	T059	C0007616
28341674	760	782	Streptococcus gordonii	T007	C0348055
28341674	787	799	S. anginosus	T007	C0318147
28341674	814	821	subject	T098	C2349001
28341674	834	843	isolation	T169	C0205409
28341674	873	886	streptococcal	T007	C0038402
28341674	887	896	phylotype	T078	C0031797
28341674	912	919	subject	T098	C2349001
28341674	921	928	Strains	T001	C1518614
28341674	947	953	clonal	T024	C1522642
28341674	954	963	diversity	T080	C1880371
28341674	976	986	collection	T077	C2347026
28341674	1000	1013	characterized	T052	C1880022
28341674	1041	1062	streptococcal strains	T007	C0038402
28341674	1073	1080	subject	T098	C2349001
28341674	1081	1093	coaggregated	T169	C0332621
28341674	1118	1127	coisolate	T123	C1764827
28341674	1146	1153	strains	T001	C1518614
28341674	1168	1181	coaggregation	T169	C0332621
28341674	1192	1215	receptor polysaccharide	T116,T192	C0597357
28341674	1217	1220	RPS	T116,T192	C0597357
28341674	1251	1259	isolates	T123	C1764827
28341674	1260	1272	coaggregated	T169	C0332621
28341674	1284	1294	coisolates	T123	C1764827
28341674	1317	1331	Rothia strains	T007	C0318136
28341674	1350	1364	coaggregations	T169	C0332621
28341674	1376	1395	coisolated bacteria	T123	C1764827
28341674	1409	1422	Streptococcus	T007	C0038402
28341674	1426	1444	Actinomyces strain	T007	C0001250
28341674	1458	1478	Haemophilus isolates	T007	C0018479
28341674	1510	1529	Confocal microscopy	T059	C0242842
28341674	1545	1553	biofilms	T007	C0081786
28341674	1566	1572	Rothia	T007	C0318136
28341674	1577	1588	Haemophilus	T007	C0018479
28341674	1609	1635	multispecies microcolonies	T040	C1658609
28341674	1649	1658	confluent	T080	C0205200
28341674	1659	1663	high	T080	C0205250
28341674	1666	1673	biomass	T081	C0005535
28341674	1674	1681	regions	T082	C0205147
28341674	1683	1689	Rothia	T007	C0318136
28341674	1718	1729	Haemophilus	T007	C0018479
28341674	1772	1776	data	T078	C1511726
28341674	1794	1807	coaggregation	T169	C0332621
28341674	1808	1816	networks	T169	C1882071
28341674	1840	1855	oral microflora	T001	C4084880
28341674	1879	1885	Rothia	T007	C0318136
28341674	1890	1901	Haemophilus	T007	C0018479
28341674	1919	1929	initiators	T169	C0205263
28341674	1933	1955	cell-cell interactions	T043	C0007582
28341674	1969	1976	biofilm	T007	C0081786
28341674	1999	2010	involvement	T169	C1314939
28341674	2014	2022	specific	T080	C0205369
28341674	2023	2037	interbacterial	T080	C0521009
28341674	2038	2046	adhesion	T040	C0004614
28341674	2050	2063	dental plaque	T047	C0011389
28341674	2064	2081	biofilm formation	T043	C1325881
28341674	2111	2119	in vitro	T080	C1533691
28341674	2120	2133	coaggregation	T169	C0332621
28341674	2142	2155	oral bacteria	T007	C0597134
28341674	2161	2180	culture collections	T077	C2347026
28341674	2194	2201	subject	T098	C2349001
28341674	2202	2210	specific	T080	C0205369
28341674	2227	2232	study	T062	C0008972
28341674	2234	2241	subject	T098	C2349001
28341674	2244	2252	specific	T080	C0205369
28341674	2253	2272	culture collections	T077	C2347026
28341674	2305	2312	biofilm	T007	C0081786
28341674	2320	2330	volunteers	T101	C0237950
28341674	2336	2350	coaggregations	T169	C0332621
28341674	2396	2410	Coaggregations	T169	C0332621
28341674	2440	2453	coaggregation	T169	C0332621
28341674	2465	2477	cell surface	T026	C0699040
28341674	2478	2486	molecule	T167	C0567416
28341674	2511	2523	streptococci	T007	C0038402
28341674	2575	2584	organisms	T001	C0029235
28341674	2585	2596	Haemophilus	T007	C0018479
28341674	2601	2607	Rothia	T007	C0318136
28341674	2648	2660	interactions	T169	C1704675
28341674	2695	2704	organisms	T001	C0029235
28341674	2722	2735	distributions	T169	C1704711
28341674	2759	2766	biofilm	T007	C0081786
28341674	2772	2776	data	T078	C1511726
28341674	2787	2800	coaggregation	T169	C0332621
28341674	2801	2809	networks	T169	C1882071
28341674	2825	2834	organisms	T001	C0029235
28341674	2846	2863	biofilm community	T007	C0081786
28341674	2872	2882	individual	T098	C0027361
28341674	2902	2911	prominent	T080	C0205402
28341674	2929	2938	organisms	T001	C0029235
28341674	2947	2958	Haemophilus	T007	C0018479
28341674	2963	2969	Rothia	T007	C0318136
28341674	2979	2985	plaque	T047	C0011389
28341674	2986	3003	biofilm formation	T043	C1325881

27834716|t|Draft Genome Sequence of the Soil Isolate Lysinibacillus fusiformis M5, a Potential Hypoxanthine Producer
27834716|a|Lysinibacillus fusiformis strain M5 is a potential hypoxanthine producer that was isolated from clay soil. Here, we present the draft genome sequence that was annotated in order to facilitate future studies of L. fusiformis M5.
27834716	0	21	Draft Genome Sequence	T085	C2348746
27834716	29	33	Soil	T167	C0037592
27834716	34	41	Isolate	T123	C1764827
27834716	42	70	Lysinibacillus fusiformis M5	T007	C1095838
27834716	74	83	Potential	T080	C3245505
27834716	84	96	Hypoxanthine	T109,T123	C0020684
27834716	106	141	Lysinibacillus fusiformis strain M5	T007	C1095838
27834716	147	156	potential	T080	C3245505
27834716	157	169	hypoxanthine	T109,T123	C0020684
27834716	188	196	isolated	T123	C1764827
27834716	202	206	clay	T197	C0055863
27834716	207	211	soil	T167	C0037592
27834716	234	255	draft genome sequence	T085	C2348746
27834716	265	274	annotated	T063	C2936606
27834716	305	312	studies	T062	C2603343
27834716	316	333	L. fusiformis M5.	T007	C1095838

27702924|t|Effect of acute heat stress and slaughter processing on poultry meat quality and postmortem carbohydrate metabolism
27702924|a|This study investigated the effects of acute heat stress and slaughter processing on poultry meat quality and carbohydrate metabolism. Broilers (200) were randomly divided into 2 groups receiving heat stress (HS; 36°C for one h), compared to a non-stressed control (C). At slaughter, each group was further divided into 2 groups for slaughter processing (L = laboratory; F = commercial factory). L group breasts were removed immediately after bleeding without carcass scalding or defeathering, and stored at 4°C. F group broilers were scalded (60°C, 45 s) after bleeding and defeathering. Then the breasts were removed and cooled in ice water until the core temperature was ≤4°C. Rates of Pectoralis core temperature and pH decline were changed by slaughter processing, but only HS affected ultimate pH in group L. HS muscles had higher L * values (P < 0.05) than controls at 24 h postmortem. Laboratory processing " hot-deboning " increased drip loss, which resulted in a lower cooked loss (P < 0.05). Postmortem glycolysis was affected only by HS. The speed of lactic acid accumulation and glycogen degradation was faster in the HS group than controls at 5 min postmortem. During storage the glycolysis rates were not different (P > 0.05). Sarcoplasmic protein solubility was higher in F processed birds (P < 0.05). HS decreased the solubility of myofibrillar and total protein in the L - slaughtered birds. Thus, HS caused a higher frequency of accelerated muscle glycolysis than controls. Factory processing (chilling) could not completely eliminate the effects of accelerated glycolysis caused by pre- slaughter HS.
27702924	0	6	Effect	T080	C1280500
27702924	10	15	acute	T079	C0205178
27702924	16	20	heat	T070	C0018837
27702924	21	27	stress	T033	C0038435
27702924	32	41	slaughter	T033	C0424328
27702924	56	68	poultry meat	T168	C0452888
27702924	69	76	quality	T080	C0332306
27702924	81	91	postmortem	T079	C0580205
27702924	92	115	carbohydrate metabolism	T044	C0302820
27702924	121	126	study	T059	C0947630
27702924	127	139	investigated	T169	C1292732
27702924	144	151	effects	T080	C1280500
27702924	155	160	acute	T079	C0205178
27702924	161	165	heat	T070	C0018837
27702924	166	172	stress	T033	C0038435
27702924	177	197	slaughter processing	T052	C1709694
27702924	201	213	poultry meat	T168	C0452888
27702924	214	221	quality	T080	C0332306
27702924	226	249	carbohydrate metabolism	T044	C0302820
27702924	251	259	Broilers	T012	C2698565
27702924	271	279	randomly	T080	C0439605
27702924	280	287	divided	T169	C0332849
27702924	295	301	groups	T096	C1642385
27702924	312	316	heat	T070	C0018837
27702924	317	323	stress	T033	C0038435
27702924	325	327	HS	T033	C0038435
27702924	342	343	h	T079	C0439227
27702924	360	380	non-stressed control	T096	C0009932
27702924	382	383	C	T096	C0009932
27702924	389	398	slaughter	T033	C0424328
27702924	405	410	group	T096	C1642385
27702924	423	430	divided	T169	C0332849
27702924	438	444	groups	T096	C1642385
27702924	449	469	slaughter processing	T052	C1709694
27702924	471	472	L	T073,T093	C0022877
27702924	475	485	laboratory	T073,T093	C0022877
27702924	487	488	F	T073	C0442614
27702924	491	509	commercial factory	T073	C0442614
27702924	512	513	L	T073,T093	C0022877
27702924	514	519	group	T096	C1642385
27702924	520	527	breasts	T023	C0006141
27702924	533	540	removed	T080	C0849355
27702924	559	567	bleeding	T169	C0205245
27702924	576	583	carcass	T021	C0229961
27702924	584	592	scalding	T037	C0332691
27702924	596	608	defeathering	T033	C1319064
27702924	614	620	stored	T169	C1698986
27702924	629	630	F	T073	C0442614
27702924	631	636	group	T096	C1642385
27702924	637	645	broilers	T012	C2698565
27702924	651	658	scalded	T037	C0332691
27702924	678	686	bleeding	T169	C0205245
27702924	691	703	defeathering	T033	C1319064
27702924	714	721	breasts	T023	C0006141
27702924	727	734	removed	T080	C0849355
27702924	739	745	cooled	T070	C0678568
27702924	749	758	ice water	T121,T197	C0043047
27702924	769	785	core temperature	T081	C0039476
27702924	796	801	Rates	T081	C1521828
27702924	805	815	Pectoralis	T023	C0030747
27702924	816	832	core temperature	T081	C0039476
27702924	837	839	pH	T081	C0020283
27702924	840	847	decline	T081	C0547047
27702924	853	860	changed	T169	C0392747
27702924	864	884	slaughter processing	T052	C1709694
27702924	895	897	HS	T033	C0038435
27702924	898	906	affected	T169	C0392760
27702924	916	918	pH	T081	C0020283
27702924	922	927	group	T096	C1642385
27702924	928	929	L	T073,T093	C0022877
27702924	931	933	HS	T033	C0038435
27702924	934	941	muscles	T023	C0030747
27702924	946	952	higher	T080	C0205250
27702924	953	954	L	T073,T093	C0022877
27702924	980	988	controls	T096	C0009932
27702924	997	1007	postmortem	T079	C0580205
27702924	1009	1030	Laboratory processing	T057	C0016487
27702924	1033	1045	hot-deboning	T080	C0849355
27702924	1048	1057	increased	T081	C0205217
27702924	1058	1067	drip loss	T033	C1262477
27702924	1075	1083	resulted	T169	C1274040
27702924	1089	1094	lower	T080	C0205251
27702924	1095	1101	cooked	T168	C0453809
27702924	1102	1106	loss	T081	C1517945
27702924	1119	1129	Postmortem	T079	C0580205
27702924	1130	1140	glycolysis	T044	C0017952
27702924	1145	1153	affected	T169	C0392760
27702924	1162	1164	HS	T033	C0038435
27702924	1170	1175	speed	T081	C0678536
27702924	1179	1190	lactic acid	T109,T121,T123	C0064582
27702924	1191	1203	accumulation	T033	C4055506
27702924	1208	1228	glycogen degradation	T044	C0596624
27702924	1233	1239	faster	T080	C0456962
27702924	1247	1249	HS	T033	C0038435
27702924	1250	1255	group	T096	C1642385
27702924	1261	1269	controls	T096	C0009932
27702924	1275	1278	min	T079	C0439232
27702924	1279	1289	postmortem	T079	C0580205
27702924	1298	1305	storage	T169	C1698986
27702924	1310	1320	glycolysis	T044	C0017952
27702924	1321	1326	rates	T081	C1521828
27702924	1358	1370	Sarcoplasmic	T026	C0682566
27702924	1371	1378	protein	T116,T123	C0033684
27702924	1379	1389	solubility	T080	C0037628
27702924	1394	1400	higher	T080	C0205250
27702924	1404	1405	F	T073	C0442614
27702924	1416	1421	birds	T012	C0005595
27702924	1434	1436	HS	T033	C0038435
27702924	1437	1446	decreased	T080	C0392756
27702924	1451	1461	solubility	T080	C0037628
27702924	1465	1477	myofibrillar	T026	C0027075
27702924	1488	1495	protein	T116,T123	C0033684
27702924	1503	1504	L	T073,T093	C0022877
27702924	1507	1518	slaughtered	T033	C0424328
27702924	1519	1524	birds	T012	C0005595
27702924	1532	1534	HS	T033	C0038435
27702924	1535	1541	caused	T078	C0085978
27702924	1544	1560	higher frequency	T079	C0205212
27702924	1564	1575	accelerated	T169	C0521110
27702924	1576	1582	muscle	T023	C0030747
27702924	1583	1593	glycolysis	T044	C0017952
27702924	1599	1607	controls	T096	C0009932
27702924	1609	1627	Factory processing	T057	C0016487
27702924	1660	1669	eliminate	T080	C0849355
27702924	1674	1681	effects	T080	C1280500
27702924	1685	1696	accelerated	T169	C0521110
27702924	1697	1707	glycolysis	T044	C0017952
27702924	1708	1714	caused	T078	C0085978
27702924	1723	1732	slaughter	T033	C0424328
27702924	1733	1735	HS	T033	C0038435

28436493|t|An attenuated Mycobacterium tuberculosis clinical strain with a defect in ESX-1 secretion induces minimal host immune responses and pathology
28436493|a|Although Mycobacterium tuberculosis (M.tb) DK9897 is an attenuated strain, it was isolated from a patient with extrapulmonary tuberculosis and vaccination with a subunit vaccine (H56) induced poor protection against it. Both attenuation and lack of protection are because M.tb DK9897 cannot secrete the EsxA virulence factor nor induce a host response against it. Genome sequencing identified a frameshift mutation in the eccCa1 gene. Since the encoded EccCa1 protein provides energy for ESX-1 secretion, it suggested a defect in the ESX-1 type VII secretion system. Genetic complementation with a plasmid carrying the M.tb H37Rv sequence of eccCa1-eccCb1-pe35 re-established EsxA secretion, host specific EsxA T-cell responses, and increased strain virulence. The ESX-1 secretion defect prevents several virulence factors from being functional during infection and therefore attenuates M.tb. It precludes specific T-cell responses against strong antigens and we found very little in vivo cytokine production, gross pathology or granuloma formation in lungs from M.tb DK9897 infected animals. This coincides with M.tb DK9897 being unable to disrupt the phagosome membrane and make contact to the cytosol.
28436493	3	13	attenuated	T052	C0599946
28436493	14	40	Mycobacterium tuberculosis	T007	C0026926
28436493	41	49	clinical	T080	C0205210
28436493	50	56	strain	T001	C1518614
28436493	64	70	defect	T169	C1457869
28436493	74	79	ESX-1	T116,T129	C1744314
28436493	80	89	secretion	T038	C0036536
28436493	98	105	minimal	T080	C0547040
28436493	106	110	host	T001	C1167395
28436493	111	127	immune responses	T042	C0301872
28436493	132	141	pathology	T091	C0030664
28436493	151	191	Mycobacterium tuberculosis (M.tb) DK9897	T007	C0026926
28436493	198	208	attenuated	T052	C0599946
28436493	209	215	strain	T001	C1518614
28436493	224	232	isolated	T169	C0205409
28436493	240	247	patient	T101	C0030705
28436493	253	280	extrapulmonary tuberculosis	T047	C0679362
28436493	285	296	vaccination	T061	C0042196
28436493	304	319	subunit vaccine	T121,T129	C0887892
28436493	321	324	H56	T121,T129	C0887892
28436493	326	333	induced	T169	C0205263
28436493	334	338	poor	T080	C0542537
28436493	339	349	protection	T033	C1545588
28436493	367	378	attenuation	T052	C0599946
28436493	383	387	lack	T080	C0332268
28436493	391	401	protection	T033	C1545588
28436493	414	425	M.tb DK9897	T007	C0026926
28436493	433	440	secrete	T038	C0036536
28436493	445	449	EsxA	T116,T129	C1744314
28436493	450	466	virulence factor	T109,T123,T131	C1136170
28436493	480	493	host response	T042	C0301872
28436493	506	523	Genome sequencing	T063	C1328887
28436493	537	556	frameshift mutation	T049	C0079380
28436493	564	575	eccCa1 gene	T028	C0017337
28436493	587	594	encoded	T052	C2700640
28436493	595	609	EccCa1 protein	T116	C1254349
28436493	619	625	energy	T081	C1442080
28436493	630	635	ESX-1	T116,T129	C1744314
28436493	636	645	secretion	T038	C0036536
28436493	662	668	defect	T169	C1457869
28436493	676	681	ESX-1	T116,T129	C1744314
28436493	682	707	type VII secretion system	T043	C3159197
28436493	709	732	Genetic complementation	T045	C0178654
28436493	740	747	plasmid	T114,T123	C0032136
28436493	761	771	M.tb H37Rv	T007	C0026926
28436493	784	802	eccCa1-eccCb1-pe35	T114	C0012931
28436493	818	822	EsxA	T116,T129	C1744314
28436493	823	832	secretion	T038	C0036536
28436493	834	838	host	T001	C1167395
28436493	848	852	EsxA	T116,T129	C1744314
28436493	853	859	T-cell	T025	C0039194
28436493	860	869	responses	T042	C0301872
28436493	875	884	increased	T081	C0205217
28436493	885	891	strain	T001	C1518614
28436493	892	901	virulence	T038	C0042765
28436493	907	912	ESX-1	T116,T129	C1744314
28436493	913	922	secretion	T038	C0036536
28436493	923	929	defect	T169	C1457869
28436493	930	938	prevents	T169	C1292733
28436493	947	964	virulence factors	T109,T123,T131	C1136170
28436493	994	1003	infection	T046	C3714514
28436493	1018	1028	attenuates	T052	C0599946
28436493	1029	1033	M.tb	T007	C0026926
28436493	1057	1063	T-cell	T025	C0039194
28436493	1064	1073	responses	T042	C0301872
28436493	1089	1097	antigens	T129	C0003320
28436493	1123	1130	in vivo	T082	C1515655
28436493	1131	1150	cytokine production	T040	C1327413
28436493	1152	1167	gross pathology	T034	C0428094
28436493	1171	1190	granuloma formation	T038	C1817882
28436493	1194	1199	lungs	T023	C0024109
28436493	1205	1216	M.tb DK9897	T007	C0026926
28436493	1217	1233	infected animals	T033	C0237158
28436493	1255	1266	M.tb DK9897	T007	C0026926
28436493	1295	1313	phagosome membrane	T026	C1166752
28436493	1338	1345	cytosol	T026	C1383501

27771196|t|Fluid-Attenuated Inversion Recovery Hyperintensity Is Associated with Hemorrhagic Transformation following Reperfusion Therapy
27771196|a|It is still controversial whether early fluid-attenuated inversion recovery (FLAIR) hyperintensity within acute ischemic lesions carries the risk of hemorrhagic transformation (HT) after reperfusion therapy. Furthermore, the association between the location of FLAIR hyperintensity and HT has not been investigated. We retrospectively reviewed patients who underwent reperfusion therapy within 6 hours of stroke onset and magnetic resonance imaging including a FLAIR sequence before completing reperfusion therapy. FLAIR hyperintensity within the diffusion-weighted imaging (DWI) lesion was rated qualitatively, and HT was assessed on follow-up gradient echo imaging. The location of the FLAIR change and HT was classified as subcortical, cortical, or cortico-subcortical. Of 134 patients with acute ischemic stroke included in this study, early FLAIR changes within DWI lesions were identified in 56 (41.8%) patients, and HT was noted in 51 (38.1%) patients. FLAIR change was independently associated with HT (odds ratio: 4.37, 95% confidence interval: 1.72-11.12). Geographically, 48.2% of the patients with a FLAIR change developed a matched HT (restricted to the region with the FLAIR change), and the risk of HT was further increased in patients with a FLAIR change in the cortico-subcortical region (68.8%). In patients in the acute stage of stroke, an early FLAIR change is associated with the risk of HT following reperfusion therapy with a highly matched geographic relationship and common risk factors. Thus, identification of FLAIR change may be a useful surrogate marker to assess the likelihood of subsequent HT in patients treated with reperfusion therapy.
27771196	0	35	Fluid-Attenuated Inversion Recovery	T060	C2826145
27771196	36	50	Hyperintensity	T046	C2938912
27771196	54	69	Associated with	T080	C0332281
27771196	70	96	Hemorrhagic Transformation	T047	C1096400
27771196	107	126	Reperfusion Therapy	T061	C0035124
27771196	167	202	fluid-attenuated inversion recovery	T060	C2826145
27771196	204	209	FLAIR	T060	C2826145
27771196	211	225	hyperintensity	T046	C2938912
27771196	233	238	acute	T079	C0205178
27771196	239	247	ischemic	T046	C0022116
27771196	248	255	lesions	T033	C0221198
27771196	268	272	risk	T078	C0035647
27771196	276	302	hemorrhagic transformation	T047	C1096400
27771196	304	306	HT	T047	C1096400
27771196	314	333	reperfusion therapy	T061	C0035124
27771196	376	384	location	T029	C1515974
27771196	388	393	FLAIR	T060	C2826145
27771196	394	408	hyperintensity	T046	C2938912
27771196	413	415	HT	T047	C1096400
27771196	429	441	investigated	T169	C1292732
27771196	446	461	retrospectively	T080	C1514923
27771196	462	470	reviewed	T080	C1709940
27771196	471	479	patients	T101	C0030705
27771196	494	513	reperfusion therapy	T061	C0035124
27771196	532	538	stroke	T047	C1096400
27771196	539	544	onset	T080	C0332162
27771196	549	575	magnetic resonance imaging	T060	C0024485
27771196	588	593	FLAIR	T060	C2826145
27771196	594	602	sequence	T169	C1519249
27771196	621	640	reperfusion therapy	T061	C0035124
27771196	642	647	FLAIR	T060	C2826145
27771196	648	662	hyperintensity	T046	C2938912
27771196	674	700	diffusion-weighted imaging	T060	C0598801
27771196	702	705	DWI	T060	C0598801
27771196	707	713	lesion	T033	C0221198
27771196	718	723	rated	T052	C0871208
27771196	724	737	qualitatively	T080	C0205556
27771196	743	745	HT	T047	C1096400
27771196	750	758	assessed	T052	C1516048
27771196	762	771	follow-up	T079	C0332283
27771196	772	780	gradient	T081	C0812409
27771196	781	793	echo imaging	T060	C0162734
27771196	815	820	FLAIR	T060	C2826145
27771196	821	827	change	T169	C0392747
27771196	832	834	HT	T047	C1096400
27771196	853	864	subcortical	T029	C0815275
27771196	866	874	cortical	T023	C0007776
27771196	879	898	cortico-subcortical	T029	C1515974
27771196	907	915	patients	T101	C0030705
27771196	921	926	acute	T079	C0205178
27771196	927	942	ischemic stroke	T047	C0948008
27771196	973	978	FLAIR	T060	C2826145
27771196	979	986	changes	T169	C0392747
27771196	994	997	DWI	T060	C0598801
27771196	998	1005	lesions	T033	C0221198
27771196	1036	1044	patients	T101	C0030705
27771196	1050	1052	HT	T047	C1096400
27771196	1077	1085	patients	T101	C0030705
27771196	1087	1092	FLAIR	T060	C2826145
27771196	1093	1099	change	T169	C0392747
27771196	1104	1117	independently	T078	C0085862
27771196	1118	1133	associated with	T080	C0332281
27771196	1134	1136	HT	T047	C1096400
27771196	1194	1208	Geographically	UnknownType	C0681784
27771196	1223	1231	patients	T101	C0030705
27771196	1239	1244	FLAIR	T060	C2826145
27771196	1245	1251	change	T169	C0392747
27771196	1272	1274	HT	T047	C1096400
27771196	1310	1315	FLAIR	T060	C2826145
27771196	1316	1322	change	T169	C0392747
27771196	1333	1337	risk	T078	C0035647
27771196	1341	1343	HT	T047	C1096400
27771196	1356	1365	increased	T081	C0205217
27771196	1369	1377	patients	T101	C0030705
27771196	1385	1390	FLAIR	T060	C2826145
27771196	1391	1397	change	T169	C0392747
27771196	1405	1431	cortico-subcortical region	T029	C1515974
27771196	1444	1452	patients	T101	C0030705
27771196	1460	1465	acute	T079	C0205178
27771196	1466	1471	stage	T079	C1306673
27771196	1475	1481	stroke	T047	C1096400
27771196	1492	1497	FLAIR	T060	C2826145
27771196	1498	1504	change	T169	C0392747
27771196	1508	1523	associated with	T080	C0332281
27771196	1528	1532	risk	T078	C0035647
27771196	1536	1538	HT	T047	C1096400
27771196	1549	1568	reperfusion therapy	T061	C0035124
27771196	1626	1638	risk factors	T033	C0035648
27771196	1646	1660	identification	T080	C0205396
27771196	1664	1669	FLAIR	T060	C2826145
27771196	1670	1676	change	T169	C0392747
27771196	1693	1709	surrogate marker	T080	C0086589
27771196	1713	1719	assess	T058	C0184514
27771196	1724	1734	likelihood	T081	C0033204
27771196	1749	1751	HT	T047	C1096400
27771196	1755	1763	patients	T101	C0030705
27771196	1764	1776	treated with	T061	C0332293
27771196	1777	1796	reperfusion therapy	T061	C0035124

28385075|t|Propensity Score Matched Comparison of Partial to Whole Gland Cryotherapy for Intermediate-Risk Prostate Cancer: An analysis of the COLD registry data
28385075|a|To compare the oncological and functional outcomes of partial versus whole - gland cryotherapy for men with intermediate-risk prostate cancer. Men with intermediate-risk prostate cancer treated with primary prostate cryotherapy from 1993-2013 were selected from the Cryo On-Line Data Registry for a 1:1 matched comparison between those undergoing whole - gland and partial prostate cryotherapy (targeted-ablation, unilateral/bilateral nerve-sparing ablations). A propensity score was developed based on age, pre-biopsy serum PSA, biopsy Gleason score, clinical stage, prostate volume, neoadjuvant androgen deprivation status, year of surgery and pre-treatment potency. Outcomes were biochemical progression-free survival (BPFS) using ASTRO and Phoenix criteria, 12-month continence (strictly pad-free) and sexual function (potency sufficient for sexual intercourse). After propensity score - matching, BPFS was compared using Kaplan-Meier analysis and functional outcomes using chi-square tests. In all, 897 men were identified (731 whole - gland and 166 partial). Post-matching, 166 pairs of men were analysed (mean follow-up 31 months). The 2/5 year BPFS rate was 87.2%/76.4% for whole - gland vs. 80.7%/70.0% for partial ablation using Phoenix (p=0.26) and 72.3%/69.6% for whole gland vs. 82.1%/75.0% for partial ablation using ASTRO criteria (p=0.10). Of 164 pairs, the 12-month continence rate was similar 94.1% vs. 95.1% (p=0.803). Of 139 pairs, the 12-month rate of successful intercourse was 29.5% for whole - gland and 46.8% for partial ablation (OR 2.1, p=0.003). The incidence of post-treatment urinary retention was 6.0% and 6.6% (p=0.88) following whole - gland and partial ablation respectively and that of rectourethral fistula was 1.2% and 0% (p=0.50) Conclusion: Partial ablation results in better post-treatment sexual function compared to whole - gland ablation in men with intermediate-risk prostate cancer. We did not observe a difference in early BPFS between the two groups.
28385075	0	16	Propensity Score	T081	C2718044
28385075	25	35	Comparison	T052	C1707455
28385075	39	46	Partial	T081	C0728938
28385075	50	55	Whole	T081	C0444667
28385075	56	61	Gland	T023	C0033572
28385075	62	73	Cryotherapy	T061	C3544233
28385075	78	95	Intermediate-Risk	T033	C3640764
28385075	96	111	Prostate Cancer	T191	C0376358
28385075	116	124	analysis	T062	C0936012
28385075	132	150	COLD registry data	T170	C0282574
28385075	166	177	oncological	T191	C0027651
28385075	182	192	functional	T169	C0205245
28385075	193	201	outcomes	T080	C0085415
28385075	205	212	partial	T081	C0728938
28385075	220	225	whole	T081	C0444667
28385075	228	233	gland	T023	C0033572
28385075	234	245	cryotherapy	T061	C3544233
28385075	250	253	men	T098	C0025266
28385075	259	276	intermediate-risk	T033	C3640764
28385075	277	292	prostate cancer	T191	C0376358
28385075	294	297	Men	T098	C0025266
28385075	303	320	intermediate-risk	T033	C3640764
28385075	321	336	prostate cancer	T191	C0376358
28385075	337	349	treated with	T061	C0332293
28385075	350	357	primary	T080	C0205225
28385075	358	378	prostate cryotherapy	T061	C3544233
28385075	417	443	Cryo On-Line Data Registry	T170	C0282574
28385075	454	461	matched	T062	C0150103
28385075	462	472	comparison	T052	C1707455
28385075	498	503	whole	T081	C0444667
28385075	506	511	gland	T023	C0033572
28385075	516	523	partial	T081	C0728938
28385075	524	544	prostate cryotherapy	T061	C3544233
28385075	546	563	targeted-ablation	T061	C0547070
28385075	565	609	unilateral/bilateral nerve-sparing ablations	T061	C0547070
28385075	614	630	propensity score	T081	C2718044
28385075	654	657	age	T032	C0001779
28385075	659	675	pre-biopsy serum	T031	C0229671
28385075	676	679	PSA	T116,T126,T129	C0138741
28385075	681	701	biopsy Gleason score	T033	C2123503
28385075	703	717	clinical stage	T079	C0205563
28385075	719	734	prostate volume	T081	C1441416
28385075	736	768	neoadjuvant androgen deprivation	T061	C1515985
28385075	769	775	status	T080	C0449438
28385075	777	781	year	T079	C0439234
28385075	785	792	surgery	T061	C0543467
28385075	797	810	pre-treatment	T079	C2709094
28385075	820	828	Outcomes	T080	C0085415
28385075	834	845	biochemical	T170	C3897727
28385075	846	871	progression-free survival	T081	C0242792
28385075	873	877	BPFS	T081	C0242792
28385075	885	890	ASTRO	T170	C0935549
28385075	895	911	Phoenix criteria	T170	C0935549
28385075	922	932	continence	T040	C0542565
28385075	957	972	sexual function	T040	C0278092
28385075	982	992	sufficient	T080	C0205410
28385075	997	1015	sexual intercourse	T040	C0009253
28385075	1024	1040	propensity score	T081	C2718044
28385075	1043	1051	matching	T062	C0150103
28385075	1053	1057	BPFS	T081	C0242792
28385075	1062	1070	compared	T052	C1707455
28385075	1077	1098	Kaplan-Meier analysis	T081	C1720943
28385075	1103	1113	functional	T169	C0205245
28385075	1114	1122	outcomes	T080	C0085415
28385075	1129	1145	chi-square tests	T170	C0008041
28385075	1159	1162	men	T098	C0025266
28385075	1168	1178	identified	T080	C0205396
28385075	1184	1189	whole	T081	C0444667
28385075	1192	1197	gland	T023	C0033572
28385075	1206	1213	partial	T081	C0728938
28385075	1216	1229	Post-matching	T079	C1254367
28385075	1244	1247	men	T098	C0025266
28385075	1253	1261	analysed	T062	C0936012
28385075	1268	1277	follow-up	T058	C1522577
28385075	1303	1307	BPFS	T081	C0242792
28385075	1308	1312	rate	T081	C1521828
28385075	1333	1338	whole	T081	C0444667
28385075	1341	1346	gland	T023	C0033572
28385075	1367	1374	partial	T081	C0728938
28385075	1375	1383	ablation	T061	C0547070
28385075	1390	1397	Phoenix	T170	C0935549
28385075	1427	1432	whole	T081	C0444667
28385075	1433	1438	gland	T023	C0033572
28385075	1459	1466	partial	T081	C0728938
28385075	1467	1475	ablation	T061	C0547070
28385075	1482	1487	ASTRO	T170	C0935549
28385075	1534	1544	continence	T040	C0542565
28385075	1545	1549	rate	T081	C1521828
28385075	1554	1561	similar	T080	C2348205
28385075	1624	1634	successful	T080	C1272703
28385075	1635	1646	intercourse	T040	C0009253
28385075	1661	1666	whole	T081	C0444667
28385075	1669	1674	gland	T023	C0033572
28385075	1689	1696	partial	T081	C0728938
28385075	1697	1705	ablation	T061	C0547070
28385075	1729	1738	incidence	T081	C0021149
28385075	1742	1756	post-treatment	T079	C2709088
28385075	1757	1774	urinary retention	T033	C0080274
28385075	1812	1817	whole	T081	C0444667
28385075	1820	1825	gland	T023	C0033572
28385075	1830	1837	partial	T081	C0728938
28385075	1838	1846	ablation	T061	C0547070
28385075	1872	1893	rectourethral fistula	T047	C0268875
28385075	1931	1938	Partial	T081	C0728938
28385075	1939	1947	ablation	T061	C0547070
28385075	1948	1955	results	T033	C0808233
28385075	1959	1965	better	T080	C0332272
28385075	1966	1980	post-treatment	T079	C2709088
28385075	1981	1996	sexual function	T040	C0278092
28385075	1997	2005	compared	T052	C1707455
28385075	2009	2014	whole	T081	C0444667
28385075	2017	2022	gland	T023	C0033572
28385075	2023	2031	ablation	T061	C0547070
28385075	2035	2038	men	T098	C0025266
28385075	2044	2061	intermediate-risk	T033	C3640764
28385075	2062	2077	prostate cancer	T191	C0376358
28385075	2114	2119	early	T079	C1279919
28385075	2120	2124	BPFS	T081	C0242792
28385075	2141	2147	groups	T078	C0441833

28187742|t|Regulatory role of cytosolic phospholipase A2 alpha in the induction of CD40 in microglia
28187742|a|The aberrant expression of CD40, a co-stimulatory receptor found on the antigen-presenting cells, is involved in the pathogenesis of various degenerative diseases. Our previous study demonstrated that the reduction of cytosolic phospholipase A2 alpha (cPLA2α) protein overexpression and activation in the spinal cord of a mouse model of ALS, hmSOD1 G93A, inhibited CD40 upregulation in microglia. The present study was designed to determine whether cPLA2α has a direct, participatory role in the molecular events leading to CD40 induction. Cultures of primary mouse microglia or BV-2 microglia cell line exposed to lipopolysaccharide (LPS) or interferon gamma (IFNγ) for different periods of time, in order to study the role of cPLA2α in the events leading to CD40 protein induction. Addition of LPS or IFNγ caused a significant upregulation of cPLA2α and of CD40, while prevention of cPLA2α upregulation by a specific oligonucleotide antisense (AS) prevented the induction of CD40, suggesting a role of cPLA2α in the induction of CD40. Addition of LPS to microglia caused an immediate activation of cPLA2α detected by its phosphorylated form, while addition of IFNγ induced cPLA2α activation at a later time scale (4 h). The activation of cPLA2α is mediated by ERK activity. Suppression of cPLA2α activity inhibited superoxide production by NOX2-NADPH oxidase and activation of NF-κB detected by the phosphorylation of p65 on serine 536 at 15 min by LPS and at 4 h by IFNγ. Inhibition of NOX2 prevented NF-κB activation and CD40 induction but did not affect cPLA2α activation, suggesting cPLA2α is located upstream to NOX2 and NF-κB. The activation of cPLA2 by LPS was mediated by both adaptor proteins downstream to LPS receptor; TRIF and MyD88, while the activation of cPLA2α by IFNγ was mediated by the secreted TNF-α at 4 h. The early activation of STAT1α (detected by phospho-serine727 and phoshpo-tyrosine701) by IFNγ and the late activation of STAT1α by LPS were not affected in the presence of cPLA2α inhibitors, indicating that STAT1α is not under cPLA2α regulation. Our results show for the first time that cPLA2 upregulates CD40 protein expression induced by either LPS or IFNγ, and this regulatory effect is mediated via the activation of NOX2-NADPH oxidase and NF-κB. Cumulatively, our results indicate that cPLA2α may serve as a pivotal amplifier of the inflammatory response in the CNS.
28187742	0	15	Regulatory role	T038	C1327622
28187742	19	51	cytosolic phospholipase A2 alpha	T116,T126	C1744635
28187742	59	68	induction	T169	C0205263
28187742	72	76	CD40	T116,T129,T192	C0054959
28187742	80	89	microglia	T025	C0206116
28187742	94	102	aberrant	T080	C0443127
28187742	103	113	expression	T045	C0597360
28187742	117	121	CD40	T116,T129,T192	C0054959
28187742	140	148	receptor	T116,T192	C0597357
28187742	162	186	antigen-presenting cells	T025	C0003315
28187742	207	219	pathogenesis	T046	C0699748
28187742	231	252	degenerative diseases	T047	C1285162
28187742	295	304	reduction	T080	C0392756
28187742	308	340	cytosolic phospholipase A2 alpha	T116,T126	C1744635
28187742	342	348	cPLA2α	T116,T126	C1744635
28187742	350	372	protein overexpression	T045	C1514559
28187742	377	387	activation	T045	C0599177
28187742	395	406	spinal cord	T023	C0037925
28187742	412	423	mouse model	T050	C2986594
28187742	427	430	ALS	T047	C0002736
28187742	432	443	hmSOD1 G93A	T116,T126	C0668601
28187742	445	454	inhibited	T044	C0021469
28187742	455	459	CD40	T116,T129,T192	C0054959
28187742	460	472	upregulation	T044	C0949479
28187742	476	485	microglia	T025	C0206116
28187742	539	545	cPLA2α	T116,T126	C1744635
28187742	614	618	CD40	T116,T129,T192	C0054959
28187742	619	628	induction	T169	C0205263
28187742	630	638	Cultures	T059	C1449562
28187742	650	655	mouse	T015	C0026809
28187742	656	665	microglia	T025	C0206116
28187742	669	693	BV-2 microglia cell line	T025	C0007600
28187742	705	723	lipopolysaccharide	T109	C0023810
28187742	725	728	LPS	T109	C0023810
28187742	733	749	interferon gamma	T116,T121,T129	C3539881
28187742	751	755	IFNγ	T116,T121,T129	C3539881
28187742	818	824	cPLA2α	T116,T126	C1744635
28187742	850	854	CD40	T116,T129,T192	C0054959
28187742	855	862	protein	T116,T123	C0033684
28187742	863	872	induction	T169	C0205263
28187742	886	889	LPS	T109	C0023810
28187742	893	897	IFNγ	T116,T121,T129	C3539881
28187742	919	931	upregulation	T044	C0041904
28187742	935	941	cPLA2α	T116,T126	C1744635
28187742	949	953	CD40	T116,T129,T192	C0054959
28187742	975	981	cPLA2α	T116,T126	C1744635
28187742	982	994	upregulation	T044	C0041904
28187742	1009	1034	oligonucleotide antisense	T114,T123,T130	C0079925
28187742	1036	1038	AS	T114,T123,T130	C0079925
28187742	1040	1049	prevented	T080	C2700409
28187742	1054	1063	induction	T169	C0205263
28187742	1067	1071	CD40	T116,T129,T192	C0054959
28187742	1094	1100	cPLA2α	T116,T126	C1744635
28187742	1108	1117	induction	T169	C0205263
28187742	1121	1125	CD40	T116,T129,T192	C0054959
28187742	1139	1142	LPS	T109	C0023810
28187742	1146	1155	microglia	T025	C0206116
28187742	1176	1186	activation	T045	C0599177
28187742	1190	1196	cPLA2α	T116,T126	C1744635
28187742	1213	1227	phosphorylated	T044	C1158886
28187742	1252	1256	IFNγ	T116,T121,T129	C3539881
28187742	1257	1264	induced	T169	C0205263
28187742	1265	1271	cPLA2α	T116,T126	C1744635
28187742	1272	1282	activation	T045	C0599177
28187742	1316	1326	activation	T045	C0599177
28187742	1330	1336	cPLA2α	T116,T126	C1744635
28187742	1352	1364	ERK activity	T044	C2261601
28187742	1381	1387	cPLA2α	T116,T126	C1744635
28187742	1388	1396	activity	T044	C1537044
28187742	1397	1406	inhibited	T080	C0311403
28187742	1407	1450	superoxide production by NOX2-NADPH oxidase	T116,T126	C0897757
28187742	1455	1465	activation	T039	C1512670
28187742	1469	1474	NF-κB	T116,T129	C0079904
28187742	1491	1506	phosphorylation	T044	C0031715
28187742	1517	1527	serine 536	T116,T121,T123	C0036720
28187742	1541	1544	LPS	T109	C0023810
28187742	1559	1563	IFNγ	T116,T121,T129	C3539881
28187742	1565	1575	Inhibition	T039	C1524081
28187742	1579	1583	NOX2	T116,T126	C0068355
28187742	1594	1599	NF-κB	T116,T129	C0079904
28187742	1600	1610	activation	T039	C1512670
28187742	1615	1619	CD40	T116,T129,T192	C0054959
28187742	1620	1629	induction	T169	C0205263
28187742	1649	1655	cPLA2α	T116,T126	C1744635
28187742	1656	1666	activation	T045	C0599177
28187742	1679	1685	cPLA2α	T116,T126	C1744635
28187742	1697	1705	upstream	T082	C0522505
28187742	1709	1713	NOX2	T116,T126	C0068355
28187742	1718	1723	NF-κB	T116,T129	C0079904
28187742	1729	1739	activation	T045	C0599177
28187742	1743	1748	cPLA2	T116,T126	C1744635
28187742	1752	1755	LPS	T109	C0023810
28187742	1777	1793	adaptor proteins	T116,T123	C1449886
28187742	1794	1804	downstream	T082	C0522506
28187742	1808	1820	LPS receptor	T116,T129,T192	C0108768
28187742	1822	1826	TRIF	T044	C3158853
28187742	1831	1836	MyD88	T044	C1819764
28187742	1848	1858	activation	T045	C0599177
28187742	1862	1868	cPLA2α	T116,T126	C1744635
28187742	1872	1876	IFNγ	T116,T121,T129	C3539881
28187742	1897	1905	secreted	T038	C0036536
28187742	1906	1911	TNF-α	T116,T129	C1456820
28187742	1930	1940	activation	T045	C0599177
28187742	1944	1950	STAT1α	T116	C0379862
28187742	1964	1981	phospho-serine727	T116,T123	C0031721
28187742	1986	2005	phoshpo-tyrosine701	T116,T123	C0070948
28187742	2010	2014	IFNγ	T116,T121,T129	C3539881
28187742	2028	2038	activation	T045	C0599177
28187742	2042	2048	STAT1α	T116	C0379862
28187742	2052	2055	LPS	T109	C0023810
28187742	2065	2073	affected	T169	C0392760
28187742	2093	2099	cPLA2α	T116,T126	C1744635
28187742	2100	2110	inhibitors	T121	C0033671
28187742	2128	2134	STAT1α	T116	C0379862
28187742	2148	2154	cPLA2α	T116,T126	C1744635
28187742	2155	2165	regulation	T044	C1522756
28187742	2208	2213	cPLA2	T116,T126	C1744635
28187742	2214	2225	upregulates	T044	C0041904
28187742	2226	2230	CD40	T116,T129,T192	C0054959
28187742	2231	2249	protein expression	T045	C1171362
28187742	2250	2257	induced	T169	C0205263
28187742	2268	2271	LPS	T109	C0023810
28187742	2275	2279	IFNγ	T116,T121,T129	C3539881
28187742	2290	2300	regulatory	T038	C1327622
28187742	2301	2307	effect	T080	C1280500
28187742	2328	2338	activation	T044	C0014429
28187742	2342	2360	NOX2-NADPH oxidase	T116,T126	C0068355
28187742	2365	2370	NF-κB	T116,T129	C0079904
28187742	2412	2418	cPLA2α	T116,T126	C1744635
28187742	2459	2480	inflammatory response	T046	C1155266
28187742	2488	2491	CNS	T022	C3714787

27580729|t|Use of Six Sigma Methodology to Reduce Appointment Lead-Time in Obstetrics Outpatient Department
27580729|a|This paper focuses on the issue of longer appointment lead-time in the obstetrics outpatient department of a maternal-child hospital in Colombia. Because of extended appointment lead-time, women with high-risk pregnancy could develop severe complications in their health status and put their babies at risk. This problem was detected through a project selection process explained in this article and to solve it, Six Sigma methodology has been used. First, the process was defined through a SIPOC diagram to identify its input and output variables. Second, six sigma performance indicators were calculated to establish the process baseline. Then, a fishbone diagram was used to determine the possible causes of the problem. These causes were validated with the aid of correlation analysis and other statistical tools. Later, improvement strategies were designed to reduce appointment lead-time in this department. Project results evidenced that average appointment lead-time reduced from 6,89 days to 4,08 days and the deviation standard dropped from 1,57 days to 1,24 days. In this way, the hospital will serve pregnant women faster, which represents a risk reduction of perinatal and maternal mortality.
27580729	7	28	Six Sigma Methodology	T080	C4042770
27580729	32	38	Reduce	T080	C0392756
27580729	39	50	Appointment	T079	C0003629
27580729	51	60	Lead-Time	T079	C0040223
27580729	64	96	Obstetrics Outpatient Department	T093	C0028775
27580729	123	128	issue	T033	C0033213
27580729	139	150	appointment	T079	C0003629
27580729	151	160	lead-time	T079	C0040223
27580729	168	200	obstetrics outpatient department	T093	C0028775
27580729	206	229	maternal-child hospital	T093	C0024927
27580729	233	241	Colombia	T083	C3245499
27580729	254	262	extended	T169	C0231448
27580729	263	274	appointment	T079	C0003629
27580729	275	284	lead-time	T079	C0040223
27580729	286	291	women	T098	C0043210
27580729	297	316	high-risk pregnancy	T046	C0242786
27580729	338	351	complications	T046	C0009566
27580729	361	374	health status	T080	C0018759
27580729	389	395	babies	T100	C0021270
27580729	399	403	risk	T078	C0035647
27580729	410	417	problem	T033	C0033213
27580729	422	430	detected	T033	C0442726
27580729	441	448	project	T062	C0700032
27580729	449	458	selection	T052	C1707391
27580729	459	466	process	T067	C1522240
27580729	485	492	article	T170	C0282420
27580729	500	505	solve	T077	C2699488
27580729	510	531	Six Sigma methodology	T080	C4042770
27580729	541	545	used	T033	C1273517
27580729	558	565	process	T067	C1522240
27580729	588	601	SIPOC diagram	T170	C0681494
27580729	618	623	input	T077	C1708517
27580729	628	634	output	T077	C1709366
27580729	635	644	variables	T080	C0439828
27580729	654	663	six sigma	T080	C4042770
27580729	664	675	performance	T052	C1882330
27580729	676	686	indicators	T080	C0525060
27580729	692	702	calculated	T052	C1441506
27580729	706	715	establish	T080	C0443211
27580729	720	727	process	T067	C1522240
27580729	728	736	baseline	T081	C1442488
27580729	746	762	fishbone diagram	T170	C0681494
27580729	798	804	causes	T078	C0085978
27580729	812	819	problem	T033	C0033213
27580729	827	833	causes	T078	C0085978
27580729	839	848	validated	T062	C1519941
27580729	865	885	correlation analysis	T062,T170	C0010101
27580729	896	913	statistical tools	T062	C1710191
27580729	922	933	improvement	T077	C2986411
27580729	950	958	designed	T052	C1707689
27580729	962	968	reduce	T080	C0392756
27580729	969	980	appointment	T079	C0003629
27580729	981	990	lead-time	T079	C0040223
27580729	999	1009	department	T093	C0028775
27580729	1011	1018	Project	T062	C0700032
27580729	1019	1026	results	T169	C1274040
27580729	1027	1036	evidenced	T078	C3887511
27580729	1050	1061	appointment	T079	C0003629
27580729	1062	1071	lead-time	T079	C0040223
27580729	1072	1079	reduced	T080	C0392756
27580729	1090	1094	days	T079	C0439228
27580729	1103	1107	days	T079	C0439228
27580729	1116	1134	deviation standard	T081	C0871420
27580729	1135	1142	dropped	T052	C1705648
27580729	1153	1157	days	T079	C0439228
27580729	1166	1170	days	T079	C0439228
27580729	1189	1197	hospital	T073,T093	C0019994
27580729	1209	1223	pregnant women	T098	C0033011
27580729	1224	1230	faster	T080	C0456962
27580729	1238	1248	represents	T052	C1882932
27580729	1251	1265	risk reduction	T055	C1137094
27580729	1269	1278	perinatal	T033	C0701826
27580729	1283	1301	maternal mortality	T081	C0024923

28068871|t|Predilation technique with balloon angioplasty to facilitate percutaneous groin access of large size sheath through scar tissue
28068871|a|Purpose Percutaneous remote access for endovascular aortic repair is an advantageous alternative to open access. Previous surgery in the femoral region and the presence of synthetic vascular grafts in the femoral / iliac arteries represent major limitations to percutaneous remote access. The aim of this study was to evaluate an original technique used for enabling percutaneous remote access for thoracic or abdominal endovascular aortic repair in patients with scar tissue and/or a vascular graft in the groin. Methods Twenty-five consecutive patients with a thoracic (11/25; 44%) or an aortic aneurysm (14/25; 66%) and with a synthetic vascular graft in the groin (16/25; 64%) or a redo groin access (9/25; 36%) were managed through the percutaneous remote access. In all patients, a percutaneous transluminal angioplasty balloon was used to predilate the scar tissue and the femoral artery or the synthetic vascular graft after preclosing (ProGlide®; Abbott Vascular, Santa Clara, CA, USA). In 10 patients, requiring a 20 Fr sheath, a 6 mm percutaneous transluminal angioplasty balloon was used; and in the remaining 15, requiring a 24 Fr sheath, an 8 mm percutaneous transluminal angioplasty balloon. Preclosing was exclusively performed using ProGlide®. Mean follow-up was 15 months. Results In all cases, stent-graft deployment was successful. There was one surgical conversion (4%; 1/25) due to bleeding from a femoral anastomosis. Two cases required additional percutaneous maneuvers (postclosing with another system in one patient and endoluminal shielding with stent-graft in the other patient). No pseudoaneurysm or access complication occurred during the follow-up. Conclusions Percutaneous access in redo groins with scar tissue and/or synthetic vascular graft using ultrasound-guided punction, preclosing with ProGlide® system and predilation with percutaneous transluminal angioplasty balloon to introduce large size sheath as used for endovascular aortic repair showed to be feasible, safe and with few local complications.
28068871	0	21	Predilation technique	T061	C1322279
28068871	27	46	balloon angioplasty	T061	C0002996
28068871	61	79	percutaneous groin	T029	C0018246
28068871	80	86	access	T082	C0444454
28068871	90	100	large size	T033	C0332509
28068871	101	107	sheath	T074	C0025080
28068871	116	127	scar tissue	T033	C0241158
28068871	136	162	Percutaneous remote access	T082	C0522523
28068871	167	193	endovascular aortic repair	T061	C0003506
28068871	233	239	access	T082	C0444454
28068871	250	257	surgery	T061	C0543467
28068871	265	279	femoral region	T029	C0230417
28068871	300	325	synthetic vascular grafts	T074	C0500213
28068871	333	340	femoral	T023	C0015801
28068871	343	357	iliac arteries	T023	C0020887
28068871	389	415	percutaneous remote access	T082	C0522523
28068871	467	476	technique	T169	C0449851
28068871	495	521	percutaneous remote access	T082	C0522523
28068871	526	534	thoracic	T061	C0521233
28068871	538	574	abdominal endovascular aortic repair	T061	C0918249
28068871	578	586	patients	T101	C0030705
28068871	592	603	scar tissue	T033	C0241158
28068871	613	627	vascular graft	T074	C0500213
28068871	635	640	groin	T029	C0018246
28068871	650	661	Twenty-five	T081	C3715062
28068871	662	673	consecutive	T080	C1707491
28068871	674	682	patients	T101	C0030705
28068871	690	698	thoracic	T047	C0162872
28068871	718	733	aortic aneurysm	T047	C0003486
28068871	758	782	synthetic vascular graft	T074	C0500213
28068871	790	795	groin	T029	C0018246
28068871	814	824	redo groin	T029	C0018246
28068871	825	831	access	T082	C0444454
28068871	869	895	percutaneous remote access	T082	C0522523
28068871	904	912	patients	T101	C0030705
28068871	916	961	percutaneous transluminal angioplasty balloon	T061	C0411287
28068871	974	983	predilate	T061	C1322279
28068871	988	999	scar tissue	T033	C0241158
28068871	1008	1022	femoral artery	T023	C0015801
28068871	1030	1054	synthetic vascular graft	T074	C0500213
28068871	1061	1071	preclosing	T061	C0411299
28068871	1073	1082	ProGlide®	T074	C0025080
28068871	1084	1099	Abbott Vascular	T093	C0331761
28068871	1101	1116	Santa Clara, CA	T083	C3828240
28068871	1118	1121	USA	T083	C0041703
28068871	1130	1138	patients	T101	C0030705
28068871	1158	1164	sheath	T074	C0025080
28068871	1173	1218	percutaneous transluminal angioplasty balloon	T061	C0411287
28068871	1272	1278	sheath	T074	C0025080
28068871	1288	1333	percutaneous transluminal angioplasty balloon	T061	C0411287
28068871	1335	1345	Preclosing	T061	C0411299
28068871	1378	1387	ProGlide®	T074	C0025080
28068871	1411	1417	months	T079	C0439231
28068871	1441	1463	stent-graft deployment	T061	C0522776
28068871	1494	1513	surgical conversion	T061	C3494226
28068871	1532	1540	bleeding	T046	C0019080
28068871	1548	1567	femoral anastomosis	T061	C0843288
28068871	1573	1578	cases	T169	C0868928
28068871	1599	1621	percutaneous maneuvers	T082	C0522523
28068871	1623	1634	postclosing	T061	C0411299
28068871	1662	1669	patient	T101	C0030705
28068871	1674	1712	endoluminal shielding with stent-graft	T074	C1322796
28068871	1726	1733	patient	T101	C0030705
28068871	1739	1753	pseudoaneurysm	T046	C1510412
28068871	1757	1763	access	T082	C0444454
28068871	1764	1776	complication	T046	C0009566
28068871	1820	1839	Percutaneous access	T082	C0522523
28068871	1843	1854	redo groins	T029	C0018246
28068871	1860	1871	scar tissue	T033	C0241158
28068871	1879	1903	synthetic vascular graft	T074	C0500213
28068871	1910	1936	ultrasound-guided punction	T074	C1875843
28068871	1938	1948	preclosing	T061	C0411299
28068871	1954	1970	ProGlide® system	T074	C0025080
28068871	1975	1986	predilation	T061	C1322279
28068871	1992	2037	percutaneous transluminal angioplasty balloon	T061	C0411287
28068871	2051	2061	large size	T033	C0332509
28068871	2062	2068	sheath	T074	C0025080
28068871	2081	2107	endovascular aortic repair	T061	C0003506
28068871	2155	2168	complications	T046	C0009566

27599001|t|A Single Nanoprobe for Ratiometric Imaging and Biosensing of Hypochlorite and Glutathione in Live Cells Using Surface-Enhanced Raman Scattering
27599001|a|Hypochlorite (ClO(-)) and glutathione (GSH) have been reported to closely correlate with oxidative stress and related diseases; however, a clear mechanism is still unknown, mainly owing to a lack of accurate analytical methods for live cells. Herein we create a novel surface-enhanced Raman scattering (SERS) nanoprobe, 4-mercaptophenol (4-MP)-functionalized gold flowers (AuF / MP), for imaging and biosensing of ClO(-) and GSH in RAW 264.7 macrophage cells upon oxidative stress. The SERS spectra of AuF / MP change with the reaction between ClO(-) and 4-MP on AuFs within 1 min and then recover after reaction with GSH, resulting in the ratiometric detection of ClO(-) and GSH with high accuracy. The single SERS probe also shows high selectivity for ClO(-) and GSH detection against other reactive oxygen species and amino acids which may exist in biological systems, as well as remarkable sensitivity ascribed to a larger amount of hot spots on AuFs. The significant analytical performance of the developed nanoprobe, together with good biocompatibility and high cell-permeability, enables the present SERS probe imaging and real-time detection of ClO(-) and GSH in live cells upon oxidative stress.
27599001	9	18	Nanoprobe	T073	C1881978
27599001	23	42	Ratiometric Imaging	T060	C0079595
27599001	47	57	Biosensing	T059	C0005567
27599001	61	73	Hypochlorite	T196	C0122922
27599001	78	89	Glutathione	T116,T123	C0017817
27599001	93	103	Live Cells	T025	C0007634
27599001	110	143	Surface-Enhanced Raman Scattering	T059	C0037815
27599001	144	156	Hypochlorite	T196	C0122922
27599001	158	164	ClO(-)	T196	C0122922
27599001	170	181	glutathione	T116,T123	C0017817
27599001	183	186	GSH	T116,T123	C0017817
27599001	218	227	correlate	T080	C1707520
27599001	233	249	oxidative stress	T049	C0242606
27599001	262	270	diseases	T047	C0012634
27599001	289	298	mechanism	T169	C0441712
27599001	335	339	lack	T080	C0332268
27599001	343	351	accurate	T080	C0443131
27599001	352	370	analytical methods	T170	C0178476
27599001	375	385	live cells	T025	C0007634
27599001	406	411	novel	T080	C0205314
27599001	412	462	surface-enhanced Raman scattering (SERS) nanoprobe	T073	C1881978
27599001	464	480	4-mercaptophenol	T109	C1667730
27599001	482	486	4-MP	T109	C1667730
27599001	503	515	gold flowers	T121,T196	C0018026
27599001	517	520	AuF	T121,T196	C0018026
27599001	523	525	MP	T109	C1667730
27599001	532	539	imaging	T060	C0079595
27599001	544	554	biosensing	T059	C0005567
27599001	558	564	ClO(-)	T196	C0122922
27599001	569	572	GSH	T116,T123	C0017817
27599001	576	602	RAW 264.7 macrophage cells	T025	C4042840
27599001	608	624	oxidative stress	T049	C0242606
27599001	630	634	SERS	T059	C0037815
27599001	635	642	spectra	T077	C2827424
27599001	646	649	AuF	T121,T196	C0018026
27599001	652	654	MP	T109	C1667730
27599001	671	679	reaction	T169	C0443286
27599001	688	694	ClO(-)	T196	C0122922
27599001	699	703	4-MP	T109	C1667730
27599001	707	711	AuFs	T121,T196	C0018026
27599001	721	724	min	T079	C0439232
27599001	734	741	recover	T080	C0521108
27599001	748	756	reaction	T169	C0443286
27599001	762	765	GSH	T116,T123	C0017817
27599001	767	779	resulting in	T169	C0332294
27599001	784	805	ratiometric detection	T061	C1511790
27599001	809	815	ClO(-)	T196	C0122922
27599001	820	823	GSH	T116,T123	C0017817
27599001	829	833	high	T080	C0205250
27599001	834	842	accuracy	T080	C0443131
27599001	855	865	SERS probe	T073	C1881978
27599001	877	881	high	T080	C0205250
27599001	898	904	ClO(-)	T196	C0122922
27599001	909	912	GSH	T116,T123	C0017817
27599001	913	922	detection	T061	C1511790
27599001	937	960	reactive oxygen species	T123,T196	C0162772
27599001	965	976	amino acids	T116,T121,T123	C0002520
27599001	996	1014	biological systems	T001	C0029235
27599001	1038	1049	sensitivity	T081	C0036667
27599001	1081	1090	hot spots	T082	C1521990
27599001	1094	1098	AuFs	T121,T196	C0018026
27599001	1104	1115	significant	T078	C0750502
27599001	1127	1138	performance	T055	C0597198
27599001	1146	1155	developed	T169	C1527148
27599001	1156	1165	nanoprobe	T073	C1881978
27599001	1186	1202	biocompatibility	T044	C0596177
27599001	1207	1211	high	T080	C0205250
27599001	1212	1229	cell-permeability	T043	C0007605
27599001	1251	1269	SERS probe imaging	T060	C0079595
27599001	1274	1293	real-time detection	T061	C1511790
27599001	1297	1303	ClO(-)	T196	C0122922
27599001	1308	1311	GSH	T116,T123	C0017817
27599001	1315	1325	live cells	T025	C0007634
27599001	1331	1347	oxidative stress	T049	C0242606

28069611|t|Bioresorbable Vascular Scaffolds for the Treatment of Chronic Total Occlusions: An International Multicenter Registry
28069611|a|There are only limited studies reporting clinical outcomes after bioresorbable vascular scaffold (BVS; Absorb; Abbott Vascular, Santa Clara, CA) implantation for coronary chronic total occlusions (CTO). The aim of this study was to evaluate the real-world feasibility and safety of BVS implantation for the treatment of CTO. We retrospectively evaluated CTO cases treated with BVS from a multicenter registry. The primary end point was target lesion failure defined as a composite of cardiac death, target vessel myocardial infarction, and clinically driven target lesion revascularization. From September 2012 to November 2015, 65 patients with CTO were successfully treated with BVS. The mean age of patients was 60.8±11.0 years; 89.2% were male and 40.0% diabetic. The mean ejection fraction was 57.7±10.8%. The mean reference vessel diameter and CTO lesion length were 3.0±0.4 and 20.2±3.0 mm, respectively. The mean number of BVS deployed per patient was 1.8±0.7, of which mean diameter and total length were 3.0±0.4 and 47.6±19.9 mm, respectively. Postdilatation with noncompliant balloons (mean diameter 3.3±0.3 mm) was performed at high pressures (18.6±5.3 atm) in all cases. Intravascular ultrasound (n=34) or optical coherence tomography (n=31) was performed in all cases. During the follow-up period (median: 453 days, 25th and 75th percentiles: 230 and 703), there were no occurrences of target lesion failure or scaffold thrombosis. BVS implantation for the treatment of CTO seems feasible and safe. Appropriate lesion preparation, high-pressure postdilatation, and the use of intravascular imaging are recommended to obtain the best possible final result.
28069611	0	32	Bioresorbable Vascular Scaffolds	T074	C4264469
28069611	41	50	Treatment	T169	C0039798
28069611	54	78	Chronic Total Occlusions	T047	C3275069
28069611	83	117	International Multicenter Registry	T170	C0034975
28069611	159	167	clinical	T080	C0205210
28069611	168	176	outcomes	T080	C0085415
28069611	183	214	bioresorbable vascular scaffold	T074	C4264469
28069611	216	219	BVS	T074	C4264469
28069611	229	244	Abbott Vascular	T073,T092	C0683757
28069611	246	261	Santa Clara, CA	T083	C3828240
28069611	263	275	implantation	T061	C0021107
28069611	280	288	coronary	T023	C0018787
28069611	289	313	chronic total occlusions	T047	C3275069
28069611	315	318	CTO	T047	C3275069
28069611	350	358	evaluate	T058	C0220825
28069611	363	385	real-world feasibility	T062,T170	C0015730
28069611	390	396	safety	T058	C0014680
28069611	400	403	BVS	T074	C4264469
28069611	404	416	implantation	T061	C0021107
28069611	425	434	treatment	T169	C0039798
28069611	438	441	CTO	T047	C3275069
28069611	446	461	retrospectively	T062	C0035363
28069611	462	471	evaluated	T058	C0220825
28069611	472	475	CTO	T047	C3275069
28069611	482	494	treated with	T061	C0332293
28069611	495	498	BVS	T074	C4264469
28069611	506	526	multicenter registry	T170	C0034975
28069611	540	549	end point	T080	C2349179
28069611	554	560	target	T029	C0449618
28069611	561	567	lesion	T033	C3272304
28069611	568	575	failure	T169	C0231174
28069611	589	598	composite	T080	C0205199
28069611	602	615	cardiac death	T046	C0376297
28069611	617	630	target vessel	T029	C0449618
28069611	631	652	myocardial infarction	T047	C0027051
28069611	658	675	clinically driven	T080	C0205210
28069611	676	682	target	T029	C0449618
28069611	683	689	lesion	T033	C3272304
28069611	690	707	revascularization	T061	C0027056
28069611	750	758	patients	T101	C0030705
28069611	764	767	CTO	T047	C3275069
28069611	786	798	treated with	T061	C0332293
28069611	799	802	BVS	T074	C4264469
28069611	820	828	patients	T101	C0030705
28069611	861	865	male	T032	C0086582
28069611	876	884	diabetic	T201	C1315719
28069611	895	912	ejection fraction	T033	C2700378
28069611	933	963	mean reference vessel diameter	T082	C3898449
28069611	968	971	CTO	T047	C3275069
28069611	972	985	lesion length	T033	C1443266
28069611	1049	1052	BVS	T074	C4264469
28069611	1053	1061	deployed	T052	C3640039
28069611	1066	1073	patient	T101	C0030705
28069611	1172	1213	Postdilatation with noncompliant balloons	T061	C0002997
28069611	1245	1254	performed	T169	C0884358
28069611	1258	1272	high pressures	T067	C0563294
28069611	1302	1326	Intravascular ultrasound	T060	C1456025
28069611	1337	1365	optical coherence tomography	T060	C0920367
28069611	1377	1386	performed	T169	C0884358
28069611	1412	1421	follow-up	T058	C1522577
28069611	1422	1428	period	T079	C1948053
28069611	1500	1502	no	T169	C1518422
28069611	1503	1514	occurrences	T079	C2745955
28069611	1518	1524	target	T029	C0449618
28069611	1525	1531	lesion	T033	C3272304
28069611	1532	1539	failure	T169	C0231174
28069611	1543	1562	scaffold thrombosis	T046	C3897493
28069611	1564	1567	BVS	T074	C4264469
28069611	1568	1580	implantation	T061	C0021107
28069611	1589	1598	treatment	T169	C0039798
28069611	1602	1605	CTO	T047	C3275069
28069611	1643	1649	lesion	T033	C3272304
28069611	1663	1676	high-pressure	T067	C0563294
28069611	1677	1691	postdilatation	T061	C0004704
28069611	1708	1729	intravascular imaging	T060	C1456016
28069611	1780	1786	result	T169	C1274040

28162764|t|Gastrojejunostomy tube complications - A single center experience and systematic review
28162764|a|Gastrojejunostomy tubes (GJTs) enable enteral nutrition in infants / children with feeding intolerance. However, complications may be increased in small infants. We evaluated our single-institution GJT complication rate and systematically reviewed existing literature. With REB approval, a retrospective single-institution analysis of GJT placements between 2009 and 2015 was performed. For the systematic review, MOOSE guidelines were followed. At our institution, 48 children underwent 154/159 successful insertions primarily for gastroesophageal reflux (n=27; 55%) and aspiration (n=11; 23%). Median age at first GJT insertion was 2.2years (0.2-18). Thirty-five (73%) had an index insertion when ≤10kg. GJTs caused 2 perforations and 1 death. The systematic review assessed 48 articles representing 2726 procedures. Overall perforation rate was estimated as 2.1% (n=36 studies, 23/1092, 95% CI: 1.0-3.2). Perforation rates in children <10kg versus ≥10kg were estimated as 3.1%/ procedure (95% CI: 1.1%-5.0%) and 0.1%/ procedure (95% CI: 0%-0.3%), respectively. The relative risk of perforation was 9.4 (95% CI: 2.8-31.3). Overall mortality was estimated as 0.9%/ patient (n=39 studies; 95% CI: 0.2-1.6%). Most perforations (19/23; 83%) occurred ≤30days of attempted tube placement. Gastrojejunostomy tubes are associated with significant complications and frequently require revision/replacement. Insertion in patients <10kg is associated with increased perforation risk. Caution is warranted in this subgroup. Level II.
28162764	0	22	Gastrojejunostomy tube	T074	C3880870
28162764	23	36	complications	T169	C1171258
28162764	70	87	systematic review	T170	C1955832
28162764	88	111	Gastrojejunostomy tubes	T074	C3880870
28162764	113	117	GJTs	T074	C3880870
28162764	126	143	enteral nutrition	T061	C0014327
28162764	147	154	infants	T100	C0021270
28162764	157	165	children	T100	C0008059
28162764	171	190	feeding intolerance	T033	C1820738
28162764	201	214	complications	T169	C1171258
28162764	222	231	increased	T081	C0205217
28162764	235	240	small	T081	C0700321
28162764	241	248	infants	T100	C0021270
28162764	253	262	evaluated	T058	C0220825
28162764	286	289	GJT	T074	C3880870
28162764	290	307	complication rate	T081	C1521828
28162764	312	335	systematically reviewed	T170	C1955832
28162764	345	355	literature	T170	C0023866
28162764	362	365	REB	T170	C1552679
28162764	366	374	approval	T080	C0205540
28162764	378	391	retrospective	T080	C1514923
28162764	392	419	single-institution analysis	T062	C0936012
28162764	423	426	GJT	T074	C3880870
28162764	427	437	placements	T061	C0883304
28162764	464	473	performed	T169	C0884358
28162764	483	500	systematic review	T170	C1955832
28162764	502	518	MOOSE guidelines	T170	C0162791
28162764	524	532	followed	T079	C0332283
28162764	541	552	institution	T073,T093	C0018704
28162764	557	565	children	T100	C0008059
28162764	584	594	successful	T080	C1272703
28162764	595	605	insertions	T058	C0441587
28162764	620	643	gastroesophageal reflux	T047	C0017168
28162764	660	670	aspiration	T058	C0220787
28162764	684	690	Median	T081	C0876920
28162764	691	694	age	T032	C0001779
28162764	704	707	GJT	T074	C3880870
28162764	708	717	insertion	T058	C0441587
28162764	772	781	insertion	T058	C0441587
28162764	794	798	GJTs	T074	C3880870
28162764	808	820	perforations	T047	C0014860
28162764	827	832	death	T040	C0011065
28162764	838	855	systematic review	T170	C1955832
28162764	856	864	assessed	T052	C1516048
28162764	895	905	procedures	T169	C2700391
28162764	907	914	Overall	T080	C1561607
28162764	915	931	perforation rate	T081	C1521828
28162764	936	945	estimated	T081	C0750572
28162764	960	967	studies	T062	C0008972
28162764	996	1013	Perforation rates	T081	C1521828
28162764	1017	1025	children	T100	C0008059
28162764	1050	1059	estimated	T081	C0750572
28162764	1069	1078	procedure	T169	C2700391
28162764	1109	1118	procedure	T169	C2700391
28162764	1156	1169	relative risk	T081	C0242492
28162764	1173	1184	perforation	T047	C0014860
28162764	1213	1220	Overall	T080	C1561607
28162764	1221	1230	mortality	T081	C0178686
28162764	1235	1244	estimated	T081	C0750572
28162764	1254	1261	patient	T101	C0030705
28162764	1301	1313	perforations	T047	C0014860
28162764	1327	1335	occurred	T052	C1709305
28162764	1347	1356	attempted	T051	C1516084
28162764	1357	1371	tube placement	T061	C0883304
28162764	1373	1396	Gastrojejunostomy tubes	T074	C3880870
28162764	1401	1411	associated	T080	C0332281
28162764	1417	1428	significant	T078	C0750502
28162764	1429	1442	complications	T169	C1171258
28162764	1488	1497	Insertion	T058	C0441587
28162764	1501	1509	patients	T101	C0030705
28162764	1519	1534	associated with	T080	C0332281
28162764	1535	1544	increased	T081	C0205217
28162764	1545	1556	perforation	T047	C0014860
28162764	1557	1561	risk	T078	C0035647
28162764	1563	1570	Caution	T033	C4296874
28162764	1592	1600	subgroup	T185	C1515021

27313637|t|Steamed and Fermented Ethanolic Extract from Codonopsis lanceolata Attenuates Amyloid-β - Induced Memory Impairment in Mice
27313637|a|Codonopsis lanceolata (C. lanceolata) is a traditional medicinal plant used for the treatment of certain inflammatory diseases such as asthma, tonsillitis, and pharyngitis. We evaluated whether steamed and fermented C. lanceolata (SFC) extract improves amyloid-β - (Aβ-) induced learning and memory impairment in mice. The Morris water maze and passive avoidance tests were used to evaluate the effect of SFC extract. Moreover, we investigated acetylcholinesterase (AChE) activity and brain-derived neurotrophic factor (BDNF), cyclic AMP response element-binding protein (CREB), and extracellular signal-regulated kinase (ERK) signaling in the hippocampus of mice to determine a possible mechanism for the cognitive - enhancing effect. Saponin compounds in SFC were identified by Ultra Performance Liquid Chromatography-Quadrupole-Time-of-Flight Mass Spectrometry (UPLC-Q-TOF-MS). SFC extract ameliorated amyloid-β - induced memory impairment in the Morris water maze and passive avoidance tests. SFC extract inhibited AChE activity and also significantly increased the level of CREB phosphorylation, BDNF expression, and ERK activation in hippocampal tissue of amyloid-β - treated mice. Lancemasides A, B, C, D, E, and G and foetidissimoside A compounds present in SFC were determined by UPLC-Q-TOF-MS. These results indicate that SFC extract improves Aβ - induced memory deficits and that AChE inhibition and CREB / BDNF / ERK expression is important for the effect of the SFC extract. In addition, lancemaside A specifically may be responsible for efficacious effect of SFC.
27313637	0	21	Steamed and Fermented	T067	C1254366
27313637	22	39	Ethanolic Extract	T123	C0032081
27313637	45	66	Codonopsis lanceolata	T002	C1048063
27313637	67	77	Attenuates	T052	C0599946
27313637	78	87	Amyloid-β	T116	C3484390
27313637	90	97	Induced	T169	C0205263
27313637	98	115	Memory Impairment	T048	C0233794
27313637	119	123	Mice	T015	C0025929
27313637	124	145	Codonopsis lanceolata	T002	C1048063
27313637	147	160	C. lanceolata	T002	C1048063
27313637	179	194	medicinal plant	T002	C0032100
27313637	208	217	treatment	T169	C1522326
27313637	229	250	inflammatory diseases	T047	C1290884
27313637	259	265	asthma	T047	C0004096
27313637	267	278	tonsillitis	T047	C0040425
27313637	284	295	pharyngitis	T047	C0031350
27313637	318	339	steamed and fermented	T067	C1254366
27313637	340	353	C. lanceolata	T002	C1048063
27313637	355	358	SFC	T002	C1048063
27313637	360	367	extract	T123	C0032081
27313637	368	376	improves	T033	C0184511
27313637	377	386	amyloid-β	T116	C3484390
27313637	390	393	Aβ-	T116	C3484390
27313637	395	402	induced	T169	C0205263
27313637	403	411	learning	T041	C0023185
27313637	416	433	memory impairment	T048	C0233794
27313637	437	441	mice	T015	C0025929
27313637	447	464	Morris water maze	T059	C0022885
27313637	469	486	passive avoidance	T041	C0871047
27313637	487	492	tests	T059	C0022885
27313637	519	525	effect	T080	C1280500
27313637	529	540	SFC extract	T123	C0032081
27313637	555	567	investigated	T169	C1292732
27313637	568	604	acetylcholinesterase (AChE) activity	T044	C1149827
27313637	609	642	brain-derived neurotrophic factor	T116,T123	C0107103
27313637	644	648	BDNF	T116,T123	C0107103
27313637	651	694	cyclic AMP response element-binding protein	T116,T123	C0056695
27313637	696	700	CREB	T116,T123	C0056695
27313637	707	744	extracellular signal-regulated kinase	T116,T126	C0600388
27313637	746	749	ERK	T116,T126	C0600388
27313637	751	760	signaling	T044	C0037080
27313637	768	779	hippocampus	T023	C0019564
27313637	783	787	mice	T015	C0025929
27313637	812	821	mechanism	T169	C0441712
27313637	830	839	cognitive	T041	C0009240
27313637	842	851	enhancing	T052	C2349975
27313637	852	858	effect	T080	C1280500
27313637	860	867	Saponin	T109	C0520481
27313637	868	877	compounds	T103	C1706082
27313637	881	884	SFC	T002	C1048063
27313637	890	900	identified	T080	C0205396
27313637	904	987	Ultra Performance Liquid Chromatography-Quadrupole-Time-of-Flight Mass Spectrometry	T059	C0599827
27313637	989	1002	UPLC-Q-TOF-MS	T059	C0599827
27313637	1005	1016	SFC extract	T123	C0032081
27313637	1017	1028	ameliorated	T033	C0243095
27313637	1029	1038	amyloid-β	T116	C3484390
27313637	1041	1048	induced	T169	C0205263
27313637	1049	1066	memory impairment	T048	C0233794
27313637	1074	1091	Morris water maze	T059	C0022885
27313637	1096	1113	passive avoidance	T041	C0871047
27313637	1114	1119	tests	T059	C0022885
27313637	1121	1132	SFC extract	T123	C0032081
27313637	1133	1142	inhibited	T080	C0311403
27313637	1143	1156	AChE activity	T044	C1149827
27313637	1180	1189	increased	T081	C0205217
27313637	1194	1199	level	T080	C0441889
27313637	1203	1207	CREB	T116,T123	C0056695
27313637	1208	1223	phosphorylation	T044	C0031715
27313637	1225	1229	BDNF	T116,T123	C0107103
27313637	1230	1240	expression	T045	C1171362
27313637	1246	1249	ERK	T116,T126	C0600388
27313637	1250	1260	activation	T044	C0014429
27313637	1264	1282	hippocampal tissue	T023	C0459385
27313637	1286	1295	amyloid-β	T116	C3484390
27313637	1298	1305	treated	T169	C1522326
27313637	1306	1310	mice	T015	C0025929
27313637	1312	1326	Lancemasides A	T109	C2606537
27313637	1328	1329	B	T121	C1254351
27313637	1331	1332	C	T121	C1254351
27313637	1334	1335	D	T121	C1254351
27313637	1337	1338	E	T121	C1254351
27313637	1344	1345	G	T121	C1254351
27313637	1350	1368	foetidissimoside A	T121	C1254351
27313637	1369	1378	compounds	T103	C1706082
27313637	1390	1393	SFC	T002	C1048063
27313637	1413	1426	UPLC-Q-TOF-MS	T059	C0599827
27313637	1434	1441	results	T169	C1274040
27313637	1456	1467	SFC extract	T123	C0032081
27313637	1468	1476	improves	T033	C0184511
27313637	1477	1479	Aβ	T116	C3484390
27313637	1482	1489	induced	T169	C0205263
27313637	1490	1505	memory deficits	T048	C0233794
27313637	1515	1519	AChE	T116,T126	C0001044
27313637	1520	1530	inhibition	T052	C3463820
27313637	1535	1539	CREB	T116,T123	C0056695
27313637	1542	1546	BDNF	T116,T123	C0107103
27313637	1549	1552	ERK	T116,T126	C0600388
27313637	1553	1563	expression	T045	C1171362
27313637	1567	1576	important	T080	C3898777
27313637	1585	1591	effect	T080	C1280500
27313637	1599	1610	SFC extract	T123	C0032081
27313637	1625	1638	lancemaside A	T109	C2606537
27313637	1675	1686	efficacious	T080	C1704419
27313637	1687	1693	effect	T080	C1280500
27313637	1697	1700	SFC	T002	C1048063

27318951|t|Preventing Youth Internalizing Symptoms Through the Familias Unidas Intervention: Examining Variation in Response
27318951|a|Prevention programs that strengthen parenting and family functioning have been found to reduce poor behavioral outcomes in adolescents, including substance use, HIV risk, externalizing and internalizing problems. However, there is evidence that not all youth benefit similarly from these programs. Familias Unidas is a family-focused intervention designed to prevent substance use and sexual risk among Hispanic youth and has recently demonstrated unanticipated reductions in internalizing symptoms for some youth. This paper examines variation in intervention response for internalizing symptoms using individual-level data pooled across four distinct Familias Unidas trials: (1) 266 eighth grade students recruited from the general school population; (2) 160 ninth grade students from the general school population; (3) 213 adolescents with conduct, aggression, and/or attention problems; and (4) 242 adolescents with a delinquency history. Causal inference growth mixture modeling suggests a three- class model. The two largest classes represent youth with low (60 %) and medium (27 %) internalizing symptoms at baseline, and both intervention and control participants show reductions in internalizing symptoms. The third class (13 %) represents youth with high levels of baseline internalizing symptoms who remain at steady levels of internalizing symptoms when exposed to the intervention, but who experience an increase in symptoms under the control condition. Female gender, low baseline levels of parent - adolescent communication, and older age were associated with membership in the high-risk class. These synthesis analyses involving a large sample of youth with varying initial risk levels represent a further step toward strengthening our knowledge of preventive intervention response and improving preventive interventions.
27318951	11	16	Youth	T100	C0087178
27318951	17	39	Internalizing Symptoms	T048	C1398215
27318951	52	67	Familias Unidas	UnknownType	C0814781
27318951	68	80	Intervention	UnknownType	C0683495
27318951	92	101	Variation	T081	C1705241
27318951	105	113	Response	T201	C0521982
27318951	114	133	Prevention programs	T170	C0679717
27318951	150	159	parenting	T054	C0085092
27318951	164	182	family functioning	T054	C0680051
27318951	202	208	reduce	T061	C0441610
27318951	209	224	poor behavioral	T184	C1398200
27318951	237	248	adolescents	T100	C0205653
27318951	260	273	substance use	T048	C0237123
27318951	275	283	HIV risk	T033	C0744979
27318951	303	325	internalizing problems	T048	C1398215
27318951	367	372	youth	T100	C0087178
27318951	402	410	programs	T170	C0679717
27318951	412	427	Familias Unidas	UnknownType	C0814781
27318951	433	460	family-focused intervention	UnknownType	C0683495
27318951	481	494	substance use	T048	C0237123
27318951	499	510	sexual risk	T033	C1563228
27318951	517	525	Hispanic	T098	C0086409
27318951	526	531	youth	T100	C0087178
27318951	576	586	reductions	T061	C0441610
27318951	590	612	internalizing symptoms	T048	C1398215
27318951	622	627	youth	T100	C0087178
27318951	662	674	intervention	UnknownType	C0683495
27318951	688	710	internalizing symptoms	T048	C1398215
27318951	717	738	individual-level data	UnknownType	C0814855
27318951	767	782	Familias Unidas	UnknownType	C0814781
27318951	783	789	trials	T062	C1515364
27318951	799	811	eighth grade	T033	C2135624
27318951	812	820	students	T098	C0038492
27318951	848	865	school population	T098	C0242445
27318951	875	886	ninth grade	T033	C2135625
27318951	887	895	students	T098	C0038492
27318951	913	930	school population	T098	C0242445
27318951	940	951	adolescents	T100	C0205653
27318951	957	964	conduct	T048	C0149654
27318951	966	976	aggression	T055	C0001807
27318951	985	1003	attention problems	T033	C3843050
27318951	1017	1028	adolescents	T100	C0205653
27318951	1036	1047	delinquency	T048	C0522174
27318951	1057	1097	Causal inference growth mixture modeling	UnknownType	C0814921
27318951	1116	1121	class	T185	C0008902
27318951	1122	1127	model	T170	C3161035
27318951	1145	1152	classes	T185	C0008902
27318951	1163	1168	youth	T100	C0087178
27318951	1174	1177	low	T080	C0205251
27318951	1189	1195	medium	T081	C0439536
27318951	1203	1225	internalizing symptoms	T048	C1398215
27318951	1229	1237	baseline	T081	C1442488
27318951	1248	1260	intervention	UnknownType	C0683495
27318951	1265	1272	control	T096	C0009932
27318951	1273	1285	participants	T098	C0679646
27318951	1291	1301	reductions	T061	C0441610
27318951	1305	1327	internalizing symptoms	T048	C1398215
27318951	1339	1344	class	T185	C0008902
27318951	1363	1368	youth	T100	C0087178
27318951	1374	1378	high	T080	C0205250
27318951	1379	1385	levels	T080	C0441889
27318951	1389	1397	baseline	T081	C1442488
27318951	1398	1420	internalizing symptoms	T048	C1398215
27318951	1435	1441	steady	T080	C0205361
27318951	1442	1448	levels	T080	C0441889
27318951	1452	1474	internalizing symptoms	T048	C1398215
27318951	1480	1490	exposed to	T080	C0332157
27318951	1495	1507	intervention	UnknownType	C0683495
27318951	1543	1551	symptoms	T048	C1398215
27318951	1562	1579	control condition	T080	C0243148
27318951	1581	1594	Female gender	T032	C0086287
27318951	1596	1599	low	T080	C0205251
27318951	1600	1608	baseline	T081	C1442488
27318951	1609	1615	levels	T080	C0441889
27318951	1619	1625	parent	T099	C0030551
27318951	1628	1638	adolescent	T100	C0205653
27318951	1639	1652	communication	T054	C0009452
27318951	1658	1667	older age	T098	C1999167
27318951	1707	1716	high-risk	T033	C0332167
27318951	1717	1722	class	T185	C0008902
27318951	1777	1782	youth	T100	C0087178
27318951	1796	1815	initial risk levels	T080	C3166291
27318951	1879	1902	preventive intervention	UnknownType	C0683495
27318951	1903	1911	response	T201	C0521982
27318951	1926	1950	preventive interventions	UnknownType	C0683495

27378175|t|Optimizing Survival of Patients With Marginally Operable Stage IIIA Non-Small-Cell Lung Cancer Receiving Chemoradiotherapy With or Without Surgery
27378175|a|For marginally operable stage IIIA non-small-cell lung cancer (NSCLC), surgery might not be done as planned after neoadjuvant concurrent chemoradiotherapy (CCRT) for reasons (unresectable or medically inoperable conditions, or patient refusal). This study aims to investigate the outcomes of a phased CCRT protocol established to maximize the operability of marginally operable stage IIIA NSCLC and to care for reassessed inoperable patients, in comparison with continuous-course definitive CCRT. Forty-seven patients with marginally operable stage IIIA NSCLC receiving CCRT were included. Twenty-eight patients were treated with our phased CCRT protocol, including neoadjuvant CCRT followed by surgery (group A, n = 16) or, for reassessed inoperable patients, maintenance chemotherapy and split-course CCRT boost (group B, n = 12). The other 19 were treated with continuous-course definitive CCRT (group C). Overall survival (OS) and progression-free survival (PFS) were analyzed. Among all, median OS and PFS were 35.6 and 12.8 months, respectively (median follow-up, 22.3 months). The median OS of group A (not reached) was better than that of group B (34.4 months) and group C (15.2 months) (P = .009). On multivariate analysis, performance status 0 to 1 (hazard ratio [HR], 0.026; P < .001), adenocarcinoma (HR, 0.156; P = .003), and group A (HR, 0.199; P = .033) were independent prognostic factors. The OS of group B (HR, 0.450; 95% confidence interval, 0.118-1.717; P = .243) was not statistically different from that of group C. For marginally operable stage IIIA NSCLC, our phased CCRT strategy may optimize survival by maximizing operability and maintain an acceptable survival for reassessed inoperable patients by split-course CCRT boost following maintenance chemotherapy.
27378175	0	10	Optimizing	T052	C2698650
27378175	11	19	Survival	T169	C0220921
27378175	23	31	Patients	T101	C0030705
27378175	37	56	Marginally Operable	T080	C0205188
27378175	57	94	Stage IIIA Non-Small-Cell Lung Cancer	T191	C0278983
27378175	105	122	Chemoradiotherapy	T061	C0436307
27378175	123	127	With	T169	C0038895
27378175	131	138	Without	T080	C0332288
27378175	139	146	Surgery	T169	C0038895
27378175	151	170	marginally operable	T080	C0205188
27378175	171	208	stage IIIA non-small-cell lung cancer	T191	C0278983
27378175	210	215	NSCLC	T191	C0278983
27378175	218	225	surgery	T169	C0038895
27378175	261	272	neoadjuvant	T061	C0600558
27378175	273	301	concurrent chemoradiotherapy	T061	C3178775
27378175	303	307	CCRT	T061	C3178775
27378175	322	334	unresectable	T201	C1519810
27378175	338	358	medically inoperable	T080	C0205187
27378175	359	369	conditions	T080	C0348080
27378175	374	389	patient refusal	T055	C0040809
27378175	397	402	study	T062	C2603343
27378175	411	422	investigate	T169	C1292732
27378175	427	435	outcomes	T169	C1274040
27378175	441	461	phased CCRT protocol	T061	C0040808
27378175	490	501	operability	T169	C0205245
27378175	505	524	marginally operable	T080	C0205188
27378175	525	541	stage IIIA NSCLC	T191	C0278983
27378175	558	568	reassessed	T052	C1516048
27378175	569	588	inoperable patients	T101	C0030705
27378175	609	642	continuous-course definitive CCRT	T061	C3178775
27378175	656	664	patients	T101	C0030705
27378175	670	689	marginally operable	T080	C0205188
27378175	690	706	stage IIIA NSCLC	T191	C0278983
27378175	717	721	CCRT	T061	C3178775
27378175	750	758	patients	T101	C0030705
27378175	764	771	treated	T169	C1522326
27378175	781	801	phased CCRT protocol	T061	C0040808
27378175	813	824	neoadjuvant	T061	C0600558
27378175	825	829	CCRT	T061	C3178775
27378175	842	849	surgery	T169	C0038895
27378175	851	858	group A	T078	C0441833
27378175	876	886	reassessed	T052	C1516048
27378175	887	906	inoperable patients	T101	C0030705
27378175	898	906	patients	T101	C0030705
27378175	908	932	maintenance chemotherapy	T033	C0481504
27378175	937	954	split-course CCRT	T061	C3178775
27378175	955	960	boost	T169	C1511253
27378175	962	969	group B	T078	C0441833
27378175	998	1005	treated	T169	C1522326
27378175	1011	1044	continuous-course definitive CCRT	T061	C3178775
27378175	1046	1053	group C	T078	C0441833
27378175	1056	1072	Overall survival	T081	C4086681
27378175	1074	1076	OS	T081	C4086681
27378175	1082	1107	progression-free survival	T081	C0242792
27378175	1109	1112	PFS	T081	C0242792
27378175	1119	1127	analyzed	T062	C0936012
27378175	1140	1146	median	T081	C0876920
27378175	1147	1149	OS	T081	C4086681
27378175	1154	1157	PFS	T081	C0242792
27378175	1177	1183	months	T079	C0439231
27378175	1199	1205	median	T081	C0876920
27378175	1206	1215	follow-up	T058	C1522577
27378175	1222	1228	months	T079	C0439231
27378175	1235	1241	median	T081	C0876920
27378175	1242	1244	OS	T081	C4086681
27378175	1248	1255	group A	T078	C0441833
27378175	1294	1301	group B	T078	C0441833
27378175	1308	1314	months	T079	C0439231
27378175	1320	1327	group C	T078	C0441833
27378175	1334	1340	months	T079	C0439231
27378175	1357	1378	multivariate analysis	T081	C0026777
27378175	1380	1398	performance status	T201	C1518965
27378175	1407	1419	hazard ratio	T081	C2985465
27378175	1421	1423	HR	T081	C2985465
27378175	1444	1458	adenocarcinoma	T191	C0001418
27378175	1460	1462	HR	T081	C2985465
27378175	1486	1493	group A	T078	C0441833
27378175	1495	1497	HR	T081	C2985465
27378175	1521	1551	independent prognostic factors	T201	C1514474
27378175	1557	1559	OS	T081	C4086681
27378175	1563	1570	group B	T078	C0441833
27378175	1572	1574	HR	T081	C2985465
27378175	1587	1606	confidence interval	T081	C0009667
27378175	1639	1662	statistically different	T080	C1705242
27378175	1676	1683	group C	T078	C0441833
27378175	1689	1708	marginally operable	T080	C0205188
27378175	1709	1725	stage IIIA NSCLC	T191	C0278983
27378175	1731	1751	phased CCRT strategy	T061	C0040808
27378175	1756	1764	optimize	T052	C2698650
27378175	1765	1773	survival	T169	C0220921
27378175	1788	1799	operability	T169	C0205245
27378175	1827	1835	survival	T169	C0220921
27378175	1840	1850	reassessed	T052	C1516048
27378175	1851	1870	inoperable patients	T101	C0030705
27378175	1874	1891	split-course CCRT	T061	C3178775
27378175	1892	1897	boost	T169	C1511253
27378175	1908	1932	maintenance chemotherapy	T033	C0481504

27321892|t|Dual-color STED microscopy reveals a sandwich structure of Bassoon and Piccolo in active zones of adult and aged mice
27321892|a|Presynaptic active zones play a pivotal role as synaptic vesicle release sites for synaptic transmission, but the molecular architecture of active zones in mammalian neuromuscular junctions (NMJs) at sub-diffraction limited resolution remains unknown. Bassoon and Piccolo are active zone specific cytosolic proteins essential for active zone assembly in NMJs, ribbon synapses, and brain synapses. These proteins are thought to colocalize and share some functions at active zones. Here, we report an unexpected finding of non-overlapping localization of these two proteins in mouse NMJs revealed using dual-color stimulated emission depletion (STED) super resolution microscopy. Piccolo puncta sandwiched Bassoon puncta and aligned in a Piccolo - Bassoon - Piccolo structure in adult NMJs. P/Q-type voltage-gated calcium channel (VGCC) puncta colocalized with Bassoon puncta. The P/Q-type VGCC and Bassoon protein levels decreased significantly in NMJs from aged mouse. In contrast, the Piccolo levels in NMJs from aged mice were comparable to levels in adult mice. This study revealed the molecular architecture of active zones in mouse NMJs at sub-diffraction limited resolution, and described the selective degeneration mechanism of active zone proteins in NMJs from aged mice. Interestingly, the localization pattern of active zone proteins described herein is similar to active zone structures described using electron microscope tomography.
27321892	0	26	Dual-color STED microscopy	T059	C0026018
27321892	37	55	sandwich structure	T082	C0678594
27321892	59	66	Bassoon	T116,T123	C1454967
27321892	71	78	Piccolo	T116,T123	C1452991
27321892	82	94	active zones	T026	C3541837
27321892	98	103	adult	T100	C0001675
27321892	108	112	aged	T032	C0001779
27321892	113	117	mice	T015	C0025929
27321892	118	142	Presynaptic active zones	T026	C3541837
27321892	166	182	synaptic vesicle	T026	C0039065
27321892	183	196	release sites	T029	C0005898
27321892	201	222	synaptic transmission	T043	C0027793
27321892	232	254	molecular architecture	T082	C1254362
27321892	258	270	active zones	T026	C3541837
27321892	274	283	mammalian	T015	C0024660
27321892	284	307	neuromuscular junctions	T026	C0027869
27321892	309	313	NMJs	T026	C0027869
27321892	318	352	sub-diffraction limited resolution	T077	C2699488
27321892	370	377	Bassoon	T116,T123	C1454967
27321892	382	389	Piccolo	T116,T123	C1452991
27321892	394	405	active zone	T026	C3541837
27321892	415	424	cytosolic	T026	C1383501
27321892	425	433	proteins	T116,T123	C0033684
27321892	448	468	active zone assembly	T043	C3896009
27321892	472	476	NMJs	T026	C0027869
27321892	478	493	ribbon synapses	T030	C1179874
27321892	499	504	brain	T023	C0006104
27321892	505	513	synapses	T030	C0039062
27321892	521	529	proteins	T116,T123	C0033684
27321892	545	555	colocalize	T082	C0392752
27321892	584	596	active zones	T026	C3541837
27321892	639	667	non-overlapping localization	T043	C0597704
27321892	681	689	proteins	T116,T123	C0033684
27321892	693	698	mouse	T015	C0025929
27321892	699	703	NMJs	T026	C0027869
27321892	719	759	dual-color stimulated emission depletion	T070	C1254365
27321892	761	765	STED	T070	C1254365
27321892	767	794	super resolution microscopy	T059	C0026018
27321892	796	803	Piccolo	T116,T123	C1452991
27321892	804	810	puncta	T033	C0243095
27321892	822	829	Bassoon	T116,T123	C1454967
27321892	830	836	puncta	T033	C0243095
27321892	841	848	aligned	T081	C1706765
27321892	854	861	Piccolo	T116,T123	C1452991
27321892	864	871	Bassoon	T116,T123	C1454967
27321892	874	881	Piccolo	T116,T123	C1452991
27321892	882	891	structure	T082	C0678594
27321892	895	900	adult	T100	C0001675
27321892	901	905	NMJs	T026	C0027869
27321892	907	945	P/Q-type voltage-gated calcium channel	T116,T123	C0814022
27321892	947	951	VGCC	T116,T123	C0814022
27321892	953	959	puncta	T033	C0243095
27321892	960	971	colocalized	T082	C0392752
27321892	977	984	Bassoon	T116,T123	C1454967
27321892	985	991	puncta	T033	C0243095
27321892	997	1010	P/Q-type VGCC	T116,T123	C0814022
27321892	1015	1022	Bassoon	T116,T123	C1454967
27321892	1023	1037	protein levels	T034	C0428479
27321892	1038	1047	decreased	T081	C0205216
27321892	1065	1069	NMJs	T026	C0027869
27321892	1075	1079	aged	T032	C0001779
27321892	1080	1085	mouse	T015	C0025929
27321892	1104	1111	Piccolo	T116,T123	C1452991
27321892	1112	1118	levels	T034	C0428479
27321892	1122	1126	NMJs	T026	C0027869
27321892	1132	1136	aged	T032	C0001779
27321892	1137	1141	mice	T015	C0025929
27321892	1161	1167	levels	T034	C0428479
27321892	1171	1176	adult	T100	C0001675
27321892	1177	1181	mice	T015	C0025929
27321892	1207	1229	molecular architecture	T082	C1254362
27321892	1233	1245	active zones	T026	C3541837
27321892	1249	1254	mouse	T015	C0025929
27321892	1255	1259	NMJs	T026	C0027869
27321892	1263	1297	sub-diffraction limited resolution	T077	C2699488
27321892	1317	1349	selective degeneration mechanism	T043	C0007613
27321892	1353	1364	active zone	T026	C3541837
27321892	1365	1373	proteins	T116,T123	C0033684
27321892	1377	1381	NMJs	T026	C0027869
27321892	1387	1391	aged	T032	C0001779
27321892	1392	1396	mice	T015	C0025929
27321892	1417	1437	localization pattern	T043	C0597704
27321892	1441	1452	active zone	T026	C3541837
27321892	1453	1461	proteins	T116,T123	C0033684
27321892	1493	1504	active zone	T026	C3541837
27321892	1505	1515	structures	T082	C0678594
27321892	1532	1562	electron microscope tomography	T059	C2350255

28194562|t|The Iboga Alkaloids
28194562|a|Iboga alkaloids are a particular class of indolomonoterpenes most often characterized by an isoquinuclidine nucleus. Their first occurrence was detected in the roots of Tabernanthe iboga, a sacred plant to the people of Gabon, which made it cult object. Ibogaine is the main representative of this class of alkaloids and its psychoactive properties are well documented. It has been proposed as a drug cessation treatment and has a wide range of activities in targeting opioids, cocaine, and alcohol. The purpose of this chapter is to provide a background on this molecule and related compounds and to update knowledge on the most recent advances made. Difficulties linked to the status of ibogaine as a drug in several countries have hampered its development, but 18-methoxycoronaridine is currently under evaluation for the same purposes and for the treatment of leishmaniasis. The chapter is divided into six parts: an introduction aiming at defining what is called an iboga alkaloid, and this is followed by current knowledge on their biosynthesis, which unfortunately remains a " black box " as far as the key construction step is concerned. Many of these alkaloids are still being discovered and the third and fourth parts of the chapter discuss the analytical tools in use for this purpose and give lists of new monomeric and dimeric alkaloids belonging to this class. When necessary, the structures are discussed especially with regard to absolute configuration determinations, which remain a point of weakness in their assignments. Part V gives an account of progress made in the synthesis, partial and total, which the authors believe is key to providing solid solutions to the industrial development of the most promising molecules. The last part of the chapter is devoted to the biological properties of iboga alkaloids, with particular emphasis on ibogaine and 18-methoxycoronaridine.
28194562	4	19	Iboga Alkaloids	T109,T121	C0598647
28194562	20	35	Iboga alkaloids	T109,T121	C0598647
28194562	53	58	class	T170	C0456387
28194562	62	80	indolomonoterpenes	T109	C0682997
28194562	92	105	characterized	T052	C1880022
28194562	112	135	isoquinuclidine nucleus	T109	C0034439
28194562	149	159	occurrence	T079	C2745955
28194562	164	172	detected	T033	C0442726
28194562	180	185	roots	T002	C0242726
28194562	189	206	Tabernanthe iboga	T002	C0950092
28194562	210	216	sacred	T033	C0557075
28194562	217	222	plant	T002	C0032098
28194562	230	236	people	T098	C0027361
28194562	240	245	Gabon	T083	C0016910
28194562	261	265	cult	T098	C0337775
28194562	266	272	object	T072	C0347997
28194562	274	282	Ibogaine	T109,T121,T123	C0020737
28194562	295	309	representative	T052	C1882932
28194562	318	323	class	T170	C0456387
28194562	327	336	alkaloids	T109,T121	C0002062
28194562	345	357	psychoactive	T121,T131	C0682880
28194562	358	368	properties	T080	C0871161
28194562	378	388	documented	T058	C1301725
28194562	402	410	proposed	T080	C1553874
28194562	416	440	drug cessation treatment	T061	C3161924
28194562	451	455	wide	T082	C0332464
28194562	456	461	range	T081	C1514721
28194562	465	475	activities	T052	C0441655
28194562	479	488	targeting	T169	C1521840
28194562	489	496	opioids	T109,T121	C0029112
28194562	498	505	cocaine	T109,T131	C0009170
28194562	511	518	alcohol	T109,T121	C0001975
28194562	524	531	purpose	T169	C1285529
28194562	540	547	chapter	T078	C1552857
28194562	554	561	provide	T052	C1999230
28194562	564	574	background	T077	C1706907
28194562	583	591	molecule	T167	C0567416
28194562	596	603	related	T080	C0439849
28194562	604	613	compounds	T103	C1706082
28194562	621	627	update	T079	C1519814
28194562	628	637	knowledge	T170	C0376554
28194562	650	656	recent	T079	C0332185
28194562	657	665	advances	T078	C1519201
28194562	672	684	Difficulties	T033	C1299586
28194562	699	705	status	T080	C0332306
28194562	709	717	ibogaine	T109,T121,T123	C0020737
28194562	723	727	drug	T121	C1254351
28194562	739	748	countries	T083	C0454664
28194562	754	762	hampered	T052	C3463820
28194562	767	778	development	T169	C1527148
28194562	784	806	18-methoxycoronaridine	T109	C0533693
28194562	810	819	currently	T079	C0521116
28194562	826	836	evaluation	T058	C0220825
28194562	845	849	same	T080	C0445247
28194562	850	858	purposes	T169	C1285529
28194562	871	880	treatment	T061	C0087111
28194562	884	897	leishmaniasis	T047	C0023281
28194562	903	910	chapter	T078	C1552857
28194562	931	936	parts	T082	C0449719
28194562	941	953	introduction	T170	C4282183
28194562	954	960	aiming	T078	C1947946
28194562	991	1005	iboga alkaloid	T109,T121	C0598647
28194562	1031	1038	current	T079	C0521116
28194562	1039	1048	knowledge	T170	C0376554
28194562	1058	1070	biosynthesis	T169	C0005572
28194562	1104	1113	black box	T077	C1254372
28194562	1130	1133	key	T077	C1706198
28194562	1134	1146	construction	T052	C1883254
28194562	1147	1151	step	T077	C1261552
28194562	1155	1164	concerned	T078	C2699424
28194562	1180	1189	alkaloids	T109,T121	C0002062
28194562	1206	1216	discovered	T052	C1880355
28194562	1242	1247	parts	T082	C0449719
28194562	1255	1262	chapter	T078	C1552857
28194562	1275	1291	analytical tools	T170	C0178476
28194562	1308	1315	purpose	T169	C1285529
28194562	1338	1347	monomeric	T104	C0596973
28194562	1352	1359	dimeric	T104	C0596448
28194562	1360	1369	alkaloids	T109,T121	C0002062
28194562	1388	1393	class	T170	C0456387
28194562	1400	1409	necessary	T080	C3898777
28194562	1415	1425	structures	T170	C0220807
28194562	1440	1450	especially	T080	C0205555
28194562	1466	1474	absolute	T080	C0205344
28194562	1475	1488	configuration	T082	C0026377
28194562	1489	1503	determinations	T059	C1148554
28194562	1520	1525	point	T082	C3714763
28194562	1529	1537	weakness	T080	C1762617
28194562	1547	1558	assignments	T169	C1516050
28194562	1560	1564	Part	T082	C0449719
28194562	1576	1583	account	T170	C0684224
28194562	1587	1595	progress	T169	C1280477
28194562	1608	1617	synthesis	T052	C1883254
28194562	1619	1626	partial	T081	C0728938
28194562	1631	1636	total	T080	C0439810
28194562	1648	1655	authors	T097	C3812881
28194562	1667	1670	key	T077	C1706198
28194562	1674	1683	providing	T052	C1999230
28194562	1684	1689	solid	T080	C0442821
28194562	1690	1699	solutions	T077	C2699488
28194562	1707	1717	industrial	T092	C0007983
28194562	1718	1729	development	T169	C1527148
28194562	1742	1751	promising	T033	C3843166
28194562	1752	1761	molecules	T167	C0567416
28194562	1772	1776	part	T082	C0449719
28194562	1784	1791	chapter	T078	C1552857
28194562	1810	1820	biological	T080	C0205460
28194562	1821	1831	properties	T080	C0871161
28194562	1835	1850	iboga alkaloids	T109,T121	C0598647
28194562	1868	1876	emphasis	T079	C0549179
28194562	1880	1888	ibogaine	T109,T121,T123	C0020737
28194562	1893	1915	18-methoxycoronaridine	T109	C0533693

27441507|t|The Evidence Behind Integrating Palliative Care Into Oncology Practice
27441507|a|Palliative care services provided alongside traditional oncology care have been shown to be beneficial to patients and families. This article provides a brief history of palliative care, a pathway to implementing these services into currently established oncology programs, and a brief discussion of common barriers.
27441507	4	12	Evidence	T078	C3887511
27441507	20	31	Integrating	T052	C1881786
27441507	32	47	Palliative Care	T091	C0030231
27441507	53	61	Oncology	T191	C0027651
27441507	62	70	Practice	T057	C0033284
27441507	71	95	Palliative care services	T093	C0587605
27441507	96	104	provided	T052	C1999230
27441507	115	126	traditional	T169	C0443324
27441507	127	140	oncology care	T058	C3244201
27441507	163	173	beneficial	T080	C0205556
27441507	177	185	patients	T101	C0030705
27441507	190	198	families	T099	C0015576
27441507	205	212	article	T170	C1706852
27441507	224	229	brief	T079	C1879313
27441507	230	237	history	T090	C0019664
27441507	241	256	palliative care	T091	C0030231
27441507	271	283	implementing	T052	C1705848
27441507	290	298	services	T057	C0557854
27441507	304	313	currently	T079	C0521116
27441507	314	325	established	T080	C0443211
27441507	326	343	oncology programs	T058	C1516732
27441507	357	367	discussion	T054	C2584313
27441507	371	386	common barriers	T080	C4045969

28364409|t|Metabolomics analysis of anaphylactoid reaction reveals its mechanism in a rat model
28364409|a|Anaphylactoid reactions, accounting for more than 77% of all immune-mediated immediate hypersensitivity reactions, have become a serious threat to public health, but their effect mechanism is not clear and diagnostic tests are limited. Comprehensive metabolite analysis may reveal the anaphylactoid effect mechanism systematically and provide reference for future diagnostic purposes. Plasma from Brown Norway rats given intravenous injection of saline, compound 48/80 (2.5 mL/kg) or ovalbumin (20 mL/kg) in 20 s for the first time was used to study the effect mechanism of anaphylactoid reactions through metabolomics (UPLC-qTOF-MS/MS). Metabolomics integrated with proteomics data were used to analyze the anaphylactoid pathways by MetaboAnalyst followed by integrated pathway analysis. Thirty metabolites were identified through the METLIN database by MS/MS and 18 of them were confirmed by authentic standards. The results showed that adenosine, histamine, N-acetylhistamine, N(α)-γ-glutamylhistamine, malate and xanthine are important indices for anaphylactoid reactions. It could be concluded that the effect mechanism is mainly composed of histidine metabolism, arachidonic acid metabolism, energy metabolism, purine metabolism and other small molecules through 30 metabolites. Multiple linear regression analysis indicated that not only histamine but also N(α)-γ-glutamylhistamine and arachidonic acid could be used to evaluate anaphylactoid symptoms of animals. Furthermore, the citrate cycle, histidine metabolism and arachidonic acid metabolism could be the main pathways of anaphylactoid reactions as determined by MetaboAnalyst. The results may provide a reference to improve diagnostic accuracy and predict and monitor treatment efficacy in anaphylactoid reactions in the clinical setting.
28364409	0	12	Metabolomics	T123	C0870883
28364409	13	21	analysis	T062	C0936012
28364409	25	47	anaphylactoid reaction	T046	C0340865
28364409	48	55	reveals	T080	C0443289
28364409	60	69	mechanism	T169	C0441712
28364409	75	78	rat	T015	C0034721
28364409	79	84	model	T008	C0599779
28364409	85	108	Anaphylactoid reactions	T046	C0340865
28364409	146	198	immune-mediated immediate hypersensitivity reactions	T047	C0301918
28364409	214	221	serious	T080	C0205404
28364409	222	228	threat	T078	C0749385
28364409	232	245	public health	T058	C0699943
28364409	257	263	effect	T080	C1280500
28364409	264	273	mechanism	T169	C0441712
28364409	277	286	not clear	T033	C3845108
28364409	291	307	diagnostic tests	T060	C0086143
28364409	312	319	limited	T169	C0439801
28364409	321	334	Comprehensive	T080	C1880156
28364409	335	345	metabolite	T123	C0870883
28364409	346	354	analysis	T062	C0936012
28364409	359	365	reveal	T080	C0443289
28364409	370	383	anaphylactoid	T080	C1706805
28364409	384	390	effect	T080	C1280500
28364409	391	400	mechanism	T169	C0441712
28364409	401	415	systematically	T169	C0220922
28364409	420	427	provide	T052	C1999230
28364409	428	437	reference	T081	C0034925
28364409	442	448	future	T079	C0016884
28364409	449	459	diagnostic	T169	C0348026
28364409	460	468	purposes	T169	C1285529
28364409	470	476	Plasma	T031	C0032105
28364409	482	499	Brown Norway rats	T015	C0034700
28364409	506	527	intravenous injection	T169	C0021494
28364409	531	537	saline	T167	C0036082
28364409	539	553	compound 48/80	T109,T121	C0009574
28364409	569	578	ovalbumin	T116,T123	C0029923
28364409	621	625	used	T169	C1524063
28364409	629	634	study	T062	C2603343
28364409	639	645	effect	T080	C1280500
28364409	646	655	mechanism	T169	C0441712
28364409	659	682	anaphylactoid reactions	T046	C0340865
28364409	691	703	metabolomics	T123	C0870883
28364409	705	720	UPLC-qTOF-MS/MS	T063	C0599748
28364409	723	735	Metabolomics	T123	C0870883
28364409	752	767	proteomics data	T170	C0242356
28364409	773	777	used	T169	C1524063
28364409	781	788	analyze	T062	C0936012
28364409	793	806	anaphylactoid	T080	C1706805
28364409	807	815	pathways	T044	C1704259
28364409	819	832	MetaboAnalyst	T170	C0037589
28364409	833	844	followed by	T079	C0332283
28364409	856	872	pathway analysis	T170	C0868995
28364409	881	892	metabolites	T123	C0870883
28364409	898	908	identified	T080	C0205396
28364409	921	936	METLIN database	T170	C0242356
28364409	940	945	MS/MS	T063	C0599748
28364409	966	978	confirmed by	T080	C0521093
28364409	979	998	authentic standards	T081	C0034925
28364409	1004	1011	results	T169	C1274040
28364409	1024	1033	adenosine	T114,T121,T123	C0001443
28364409	1035	1044	histamine	T109,T123	C0019588
28364409	1046	1063	N-acetylhistamine	T109	C0067730
28364409	1065	1089	N(α)-γ-glutamylhistamine	T109	C0061063
28364409	1091	1097	malate	T109,T123,T130	C0220873
28364409	1102	1110	xanthine	T114,T123	C0043314
28364409	1115	1124	important	T080	C3898777
28364409	1137	1160	anaphylactoid reactions	T046	C0340865
28364409	1193	1199	effect	T080	C1280500
28364409	1200	1209	mechanism	T169	C0441712
28364409	1232	1252	histidine metabolism	T044	C1156823
28364409	1254	1281	arachidonic acid metabolism	T044	C1158360
28364409	1283	1300	energy metabolism	T039	C0014272
28364409	1302	1319	purine metabolism	T169	C0920640
28364409	1324	1329	other	T080	C0205394
28364409	1330	1335	small	T081	C0700321
28364409	1336	1345	molecules	T167	C0567416
28364409	1346	1353	through	T169	C0332273
28364409	1357	1368	metabolites	T123	C0870883
28364409	1370	1405	Multiple linear regression analysis	UnknownType	C0681925
28364409	1406	1415	indicated	T033	C1444656
28364409	1421	1424	not	T169	C1518422
28364409	1425	1429	only	T081	C0205171
28364409	1430	1439	histamine	T109,T123	C0019588
28364409	1449	1473	N(α)-γ-glutamylhistamine	T109	C0061063
28364409	1478	1494	arachidonic acid	T109	C0003695
28364409	1504	1508	used	T169	C1524063
28364409	1521	1534	anaphylactoid	T080	C1706805
28364409	1535	1543	symptoms	T184	C1457887
28364409	1547	1554	animals	T008	C0003062
28364409	1573	1586	citrate cycle	T044	C1516586
28364409	1588	1608	histidine metabolism	T044	C1156823
28364409	1613	1640	arachidonic acid metabolism	T044	C1158360
28364409	1654	1658	main	T080	C1542147
28364409	1659	1667	pathways	T044	C1704259
28364409	1671	1694	anaphylactoid reactions	T046	C0340865
28364409	1698	1711	determined by	T080	C0521095
28364409	1712	1725	MetaboAnalyst	T170	C0037589
28364409	1731	1738	results	T169	C1274040
28364409	1743	1750	provide	T052	C1999230
28364409	1753	1762	reference	T170	C1514811
28364409	1766	1773	improve	T033	C0184511
28364409	1774	1793	diagnostic accuracy	T080	C0598285
28364409	1798	1805	predict	T078	C0681842
28364409	1818	1836	treatment efficacy	T080	C0087113
28364409	1840	1863	anaphylactoid reactions	T046	C0340865
28364409	1871	1887	clinical setting	T082	C3176918

27859167|t|Variation in the age of first reproduction: different strategies or individual quality?
27859167|a|Although age at first reproduction is a key demographic parameter that is probably under high selective pressure, it is highly variable and the cause of this variability is not well understood. Two non-exclusive hypotheses may explain such variability. It could be the expression of different individual strategies, i.e., different allocation strategies in fitness components, or the consequences of individual difference in intrinsic quality, i.e., some individuals always doing better than others in all fitness components. We tested these hypotheses in the Wandering Albatross investigating relationships between the age at first reproduction and subsequent adult demographic traits. Using finite mixture capture recapture modeling, we demonstrate that the age at first reproduction is negatively related to both reproductive performances and adult survival, suggesting that individual quality was an important factor explaining variation in the age at first reproduction. Our results suggest that age at first breeding is a good predictor of quality in this long-lived seabird species.
27859167	0	20	Variation in the age	T100	C0699810
27859167	24	42	first reproduction	T040	C0035150
27859167	44	64	different strategies	T080	C0205556
27859167	68	86	individual quality	T080	C0332306
27859167	97	100	age	T032	C0001779
27859167	104	122	first reproduction	T040	C0035150
27859167	132	153	demographic parameter	T078	C0011292
27859167	177	200	high selective pressure	T033	C0460139
27859167	215	223	variable	T080	C0439828
27859167	246	257	variability	T077	C2827666
27859167	300	310	hypotheses	T078	C1512571
27859167	328	339	variability	T077	C2827666
27859167	357	367	expression	T055	C0565975
27859167	381	402	individual strategies	T080	C0205556
27859167	420	441	allocation strategies	T052	C1706778
27859167	445	463	fitness components	T078	C0031812
27859167	488	509	individual difference	T054	C0021228
27859167	513	530	intrinsic quality	T082	C0205102
27859167	543	554	individuals	T098	C0237401
27859167	594	612	fitness components	T078	C0031812
27859167	617	623	tested	T169	C0039593
27859167	630	640	hypotheses	T078	C1512571
27859167	648	667	Wandering Albatross	T012	C0325368
27859167	682	695	relationships	T080	C0439849
27859167	708	711	age	T032	C0001779
27859167	715	733	first reproduction	T040	C0035150
27859167	749	754	adult	T100	C0001675
27859167	755	766	demographic	T090	C0011298
27859167	767	773	traits	T032	C0599883
27859167	781	822	finite mixture capture recapture modeling	T062	C0870071
27859167	848	851	age	T032	C0001779
27859167	855	873	first reproduction	T040	C0035150
27859167	877	887	negatively	T033	C1513916
27859167	904	916	reproductive	T040	C0035150
27859167	917	929	performances	T055	C0597198
27859167	934	939	adult	T100	C0001675
27859167	940	948	survival	T052	C0038952
27859167	966	984	individual quality	T080	C0332306
27859167	1020	1029	variation	T077	C2827666
27859167	1037	1040	age	T032	C0001779
27859167	1044	1062	first reproduction	T040	C0035150
27859167	1089	1092	age	T032	C0001779
27859167	1096	1110	first breeding	T040	C0006159
27859167	1121	1130	predictor	T078	C2698872
27859167	1134	1141	quality	T080	C0332306
27859167	1161	1176	seabird species	T012	C0325368

28508943|t|Perceived ethnic discrimination in relation to smoking and alcohol consumption in ethnic minority groups in The Netherlands: the HELIUS study
28508943|a|We examined the associations of perceived ethnic discrimination (PED) with smoking and alcohol consumption in ethnic minority groups residing in a middle-sized European city. Data were derived from the HELIUS study in Amsterdam, The Netherlands. We included 23,126 participants aged 18-70 years of Dutch, South-Asian Surinamese, African Surinamese, Ghanaian, Turkish, and Moroccan origin. We collected self-reported data on PED, current smoking, heavy smoking, nicotine dependence, current drinking, excessive drinking, and alcohol dependence. Logistic regression was used. In general, we observed positive associations in participants of African Surinamese and Ghanaian origin, but no associations in those of South-Asian Surinamese, Turkish, or Moroccan origin. In African Surinamese, the associations were positive for current smoking, nicotine, and alcohol dependence (odds ratios of 1.16; 95% confidence interval: 1.06-1.27, 1.34; 1.15-1.57 and 1.40; 1.20-1.64, respectively). In Ghanaians, positive association was observed for current drinking (1.21; 1.08-1.36). The associations of PED with smoking and alcohol consumption considerably varied by ethnicity and outcome measure. This suggests that ethnic minority groups in Europe might use different behavioural strategies to cope with PED.
28508943	0	31	Perceived ethnic discrimination	T054	C0870511
28508943	47	54	smoking	T055	C0037369
28508943	59	78	alcohol consumption	T055	C0001948
28508943	82	104	ethnic minority groups	T098	C0026192
28508943	108	123	The Netherlands	T083	C0027778
28508943	129	141	HELIUS study	T062	C0681876
28508943	158	170	associations	T080	C0439849
28508943	174	205	perceived ethnic discrimination	T054	C0870511
28508943	207	210	PED	T054	C0870511
28508943	217	224	smoking	T055	C0037369
28508943	229	248	alcohol consumption	T055	C0001948
28508943	252	274	ethnic minority groups	T098	C0026192
28508943	302	315	European city	T083	C0015176
28508943	317	321	Data	T078	C1511726
28508943	344	356	HELIUS study	T062	C0681876
28508943	360	369	Amsterdam	T083	C0017446
28508943	371	386	The Netherlands	T083	C0027778
28508943	407	419	participants	T098	C0679646
28508943	440	445	Dutch	T098	C0013331
28508943	447	458	South-Asian	T083	C0003983
28508943	459	469	Surinamese	T098	C1257890
28508943	471	478	African	T083	C0001737
28508943	479	489	Surinamese	T098	C1257890
28508943	491	499	Ghanaian	T098	C0337834
28508943	501	508	Turkish	T098	C0549217
28508943	514	522	Moroccan	T098	C1257890
28508943	523	529	origin	T185	C0079946
28508943	558	562	data	T078	C1511726
28508943	566	569	PED	T054	C0870511
28508943	571	578	current	T079	C0521116
28508943	579	586	smoking	T055	C0037369
28508943	588	601	heavy smoking	T033	C3845546
28508943	603	622	nicotine dependence	T048	C0028043
28508943	624	631	current	T079	C0521116
28508943	632	640	drinking	T055	C0001948
28508943	642	651	excessive	T080	C0442802
28508943	652	660	drinking	T055	C0001948
28508943	666	684	alcohol dependence	T048	C0001973
28508943	686	705	Logistic regression	T062	C0206031
28508943	740	748	positive	T033	C1446409
28508943	749	761	associations	T080	C0439849
28508943	765	777	participants	T098	C0679646
28508943	789	799	Surinamese	T098	C1257890
28508943	804	812	Ghanaian	T098	C0337834
28508943	813	819	origin	T185	C0079946
28508943	828	840	associations	T080	C0439849
28508943	853	864	South-Asian	T083	C0003983
28508943	865	875	Surinamese	T098	C1257890
28508943	877	884	Turkish	T098	C0549217
28508943	889	897	Moroccan	T098	C1257890
28508943	898	904	origin	T185	C0079946
28508943	909	916	African	T083	C0001737
28508943	917	927	Surinamese	T098	C1257890
28508943	933	945	associations	T080	C0439849
28508943	951	959	positive	T033	C1446409
28508943	964	971	current	T079	C0521116
28508943	972	979	smoking	T055	C0037369
28508943	981	989	nicotine	T048	C0028043
28508943	995	1013	alcohol dependence	T048	C0001973
28508943	1015	1026	odds ratios	T081	C0028873
28508943	1040	1059	confidence interval	T081	C0009667
28508943	1127	1136	Ghanaians	T098	C0337834
28508943	1138	1146	positive	T033	C1446409
28508943	1147	1158	association	T080	C0439849
28508943	1176	1183	current	T079	C0521116
28508943	1184	1192	drinking	T055	C0001948
28508943	1216	1228	associations	T080	C0439849
28508943	1232	1235	PED	T054	C0870511
28508943	1241	1248	smoking	T055	C0037369
28508943	1253	1272	alcohol consumption	T055	C0001948
28508943	1296	1305	ethnicity	T080	C0243103
28508943	1310	1325	outcome measure	T081	C0086749
28508943	1346	1368	ethnic minority groups	T098	C0026192
28508943	1372	1378	Europe	T083	C0015176
28508943	1399	1421	behavioural strategies	T041	C0679199
28508943	1435	1438	PED	T054	C0870511

27383496|t|In vitro genotoxicity of pyridine in human lymphocytes
27383496|a|This work was carried out to study the genotoxicity of pyridine in vitro on human leucocyte culture. Cyclophosphamide, a well-known carcinogen was used as positive control. The four different concentrations of pyridine and cyclophosphamide showed breaks and pulverization of chromosomes in dose dependent manner. Higher number of pulverization was observed with higher concentration of pyridine (3.25μg/mL). Based on this data, our results confirm that both pyridine and its precursor showed genotoxicity against human lymphocytes.
27383496	0	8	In vitro	T080	C1533691
27383496	9	21	genotoxicity	T049	C0598309
27383496	25	33	pyridine	T109,T130	C0034251
27383496	37	42	human	T016	C0086418
27383496	43	54	lymphocytes	T025	C0024264
27383496	94	106	genotoxicity	T049	C0598309
27383496	110	118	pyridine	T109,T130	C0034251
27383496	119	127	in vitro	T080	C1533691
27383496	131	136	human	T016	C0086418
27383496	137	146	leucocyte	T025	C0023516
27383496	147	154	culture	UnknownType	C0681854
27383496	156	172	Cyclophosphamide	T109,T121	C0010583
27383496	187	197	carcinogen	T131	C0007090
27383496	210	226	positive control	T077	C1883676
27383496	247	261	concentrations	T081	C0457929
27383496	265	273	pyridine	T109,T130	C0034251
27383496	278	294	cyclophosphamide	T109,T121	C0010583
27383496	302	308	breaks	T049	C0333704
27383496	313	341	pulverization of chromosomes	T049	C0333708
27383496	345	359	dose dependent	T081	C1512045
27383496	368	381	Higher number	T081	C0205217
27383496	385	398	pulverization	T049	C0333708
27383496	417	423	higher	T080	C0205250
27383496	424	437	concentration	T081	C0457929
27383496	441	449	pyridine	T109,T130	C0034251
27383496	487	502	results confirm	T170	C3242807
27383496	513	521	pyridine	T109,T130	C0034251
27383496	530	539	precursor	T078	C1709634
27383496	547	559	genotoxicity	T049	C0598309
27383496	568	573	human	T016	C0086418
27383496	574	585	lymphocytes	T025	C0024264

28057994|t|A completely calcified prostate
28057994|a|Prostatic calcification and prostatic calculus formation is commonly seen in adult population with chronic prostatitis, however, gross prostatic calcification which involves more than 3 cm(2) of the gland is quite rare. We are presenting here one such case in which almost whole glandular prostate was converted into stone which is never reported so far.
28057994	2	12	completely	T080	C0205197
28057994	13	22	calcified	T080	C0175895
28057994	23	31	prostate	T023	C0033572
28057994	32	55	Prostatic calcification	T047	C1868729
28057994	60	78	prostatic calculus	T047	C0149525
28057994	79	88	formation	T169	C1522492
28057994	109	114	adult	T100	C0001675
28057994	115	125	population	T098	C1257890
28057994	131	150	chronic prostatitis	T047	C0085696
28057994	167	190	prostatic calcification	T047	C1868729
28057994	231	236	gland	T023	C0033572
28057994	246	250	rare	T080	C0522498
28057994	259	269	presenting	T078	C0449450
28057994	284	288	case	T169	C0868928
28057994	311	329	glandular prostate	T023	C0033572
28057994	334	343	converted	T169	C0392747
28057994	349	354	stone	T031	C0006736

27463423|t|Impaired autophagy in macrophages promotes inflammatory eye disease
27463423|a|Autophagy is critical for maintaining cellular homeostasis. Organs such as the eye and brain are immunologically privileged. Here, we demonstrate that autophagy is essential for maintaining ocular immune privilege. Deletion of multiple autophagy genes in macrophages leads to an inflammation-mediated eye disease called uveitis that can cause blindness. Loss of autophagy activates inflammasome -mediated IL1B secretion that increases disease severity. Inhibition of caspase activity by gene deletion or pharmacological means completely reverses the disease phenotype. Of interest, experimental uveitis was also increased in a model of Crohn disease, a systemic autoimmune disease in which patients often develop uveitis, offering a potential mechanistic link between macrophage autophagy and systemic disease. These findings directly implicate the homeostatic process of autophagy in blinding eye disease and identify novel pathways for therapeutic intervention in uveitis.
27463423	0	8	Impaired	T169	C0221099
27463423	9	18	autophagy	T043	C0004391
27463423	22	33	macrophages	T025	C0024432
27463423	43	67	inflammatory eye disease	T047	C0042164
27463423	68	77	Autophagy	T043	C0004391
27463423	106	126	cellular homeostasis	T043	C2244223
27463423	128	134	Organs	T023	C0178784
27463423	147	150	eye	T023	C0015392
27463423	155	160	brain	T023	C0006104
27463423	165	180	immunologically	T169	C0205470
27463423	219	228	autophagy	T043	C0004391
27463423	258	264	ocular	T023	C0015392
27463423	265	271	immune	T169	C0439662
27463423	283	291	Deletion	T045	C0017260
27463423	295	303	multiple	T081	C0439064
27463423	304	313	autophagy	T043	C0004391
27463423	314	319	genes	T028	C0017337
27463423	323	334	macrophages	T025	C0024432
27463423	347	380	inflammation-mediated eye disease	T047	C0042164
27463423	388	395	uveitis	T047	C0042164
27463423	411	420	blindness	T033	C0456909
27463423	422	426	Loss	T081	C1517945
27463423	430	439	autophagy	T043	C0004391
27463423	440	449	activates	T052	C1879547
27463423	450	462	inflammasome	T116,T123	C2936529
27463423	473	477	IL1B	T116,T123	C1702300
27463423	478	487	secretion	T043	C1327616
27463423	503	519	disease severity	T080	C0521117
27463423	521	531	Inhibition	T052	C3463820
27463423	535	551	caspase activity	T044	C1150130
27463423	555	568	gene deletion	T045	C0017260
27463423	572	587	pharmacological	T169	C0205464
27463423	605	635	reverses the disease phenotype	T033	C4086829
27463423	650	662	experimental	T080	C1517586
27463423	663	670	uveitis	T047	C0042164
27463423	695	700	model	T170	C3161035
27463423	704	717	Crohn disease	T047	C0010346
27463423	721	729	systemic	T047	C0442893
27463423	730	748	autoimmune disease	T047	C0004364
27463423	758	766	patients	T101	C0030705
27463423	781	788	uveitis	T047	C0042164
27463423	836	846	macrophage	T025	C0024432
27463423	847	856	autophagy	T043	C0004391
27463423	861	877	systemic disease	T047	C0442893
27463423	917	936	homeostatic process	T038	C0019868
27463423	940	949	autophagy	T043	C0004391
27463423	953	961	blinding	T062	C0150108
27463423	962	973	eye disease	T047	C0015397
27463423	987	992	novel	T080	C0205314
27463423	993	1001	pathways	T077	C1705987
27463423	1006	1030	therapeutic intervention	T061	C0808232
27463423	1034	1041	uveitis	T047	C0042164

27932645|t|Complete Genome Sequences of the Endophytic Streptomyces Strains EN16, EN23, and EN27, Isolated from Wheat Plants
27932645|a|The complete genome sequences of three endophytic Streptomyces species were compared. Strains EN16, EN23, and EN27 were isolated from surface- sterilized roots of wheat plants from South Australia. In field trials, these strains are effective in suppressing fungal root diseases of wheat when added as spore coatings to wheat seed.
27932645	9	25	Genome Sequences	T059	C3854164
27932645	33	43	Endophytic	T033	C3842357
27932645	44	69	Streptomyces Strains EN16	T007	C1226924
27932645	71	75	EN23	T007	C1226925
27932645	81	85	EN27	T007	C1226332
27932645	101	113	Wheat Plants	T002	C0087114
27932645	127	143	genome sequences	T059	C3854164
27932645	153	163	endophytic	T033	C3842357
27932645	164	184	Streptomyces species	T007	C1295886
27932645	200	212	Strains EN16	T007	C1226924
27932645	214	218	EN23	T007	C1226925
27932645	224	228	EN27	T007	C1226332
27932645	257	267	sterilized	T080	C0232920
27932645	268	273	roots	T002	C0242726
27932645	277	289	wheat plants	T002	C0087114
27932645	295	310	South Australia	T083	C0037715
27932645	335	342	strains	T007	C1295886
27932645	372	378	fungal	T169	C0521033
27932645	379	383	root	T002	C0242726
27932645	384	392	diseases	T047	C0012634
27932645	396	401	wheat	T002	C0087114
27932645	416	421	spore	T007	C0038028
27932645	422	430	coatings	T080	C1522408
27932645	434	444	wheat seed	T168	C0043137

27321745|t|Bisphenol-A removal by the halophyte Juncus acutus in a phytoremediation pilot: Characterization and potential role of the endophytic community
27321745|a|A phytoremediation pilot emulating a shallow aquifer planted with Juncus acutus showed to be effective for remediating Bisphenol-A (BPA) contaminated groundwater. Biostimulation with root exudates, low molecular weight organic acids, of J. acutus did not improve BPA - degradation rates. Furthermore, the endophytic bacterial community of J. acutus was isolated and characterized. Many strains were found to possess increased tolerance to metals such as Zn, Ni, Pb and Cd. Moreover, several endophytic bacterial strains tolerated and even used BPA and/or two antibiotics (ciprofloxacin and sulfamethoxazole) as a sole carbon source. Our results demonstrate that the cultivable bacterial endophytic community of J. acutus is able to use organic contaminants as carbon sources, tolerates metals and is equipped with plant-growth promoting traits. Therefore, J. acutus has potential to be exploited in constructed wetlands when co-contamination is one of the restricting factors.
27321745	0	11	Bisphenol-A	T109,T131	C0053800
27321745	12	19	removal	T061	C0185115
27321745	27	36	halophyte	T002	C2350261
27321745	37	50	Juncus acutus	T002	C1639894
27321745	56	72	phytoremediation	T069	C1720751
27321745	73	78	pilot	T062	C0031928
27321745	80	96	Characterization	T052	C1880022
27321745	101	110	potential	T080	C3245505
27321745	111	115	role	T077	C1705810
27321745	123	133	endophytic	T004	C1265415
27321745	134	143	community	T096	C0009462
27321745	146	162	phytoremediation	T069	C1720751
27321745	163	168	pilot	T062	C0031928
27321745	181	188	shallow	T082	C1254362
27321745	189	196	aquifer	T070	C3178977
27321745	210	223	Juncus acutus	T002	C1639894
27321745	237	246	effective	T080	C1704419
27321745	251	262	remediating	T069	C1720751
27321745	263	274	Bisphenol-A	T109,T131	C0053800
27321745	276	279	BPA	T109,T131	C0053800
27321745	281	293	contaminated	T169	C0205279
27321745	294	305	groundwater	T121,T197	C0043047
27321745	307	321	Biostimulation	T052	C0441655
27321745	327	331	root	T002	C0242726
27321745	332	340	exudates	T167	C0439861
27321745	342	345	low	T080	C0205251
27321745	346	362	molecular weight	T081	C0026385
27321745	363	376	organic acids	T109	C0369760
27321745	381	390	J. acutus	T002	C1639894
27321745	399	406	improve	T033	C0184511
27321745	407	410	BPA	T109,T131	C0053800
27321745	413	424	degradation	T169	C0243125
27321745	425	430	rates	T081	C1521828
27321745	449	459	endophytic	T004	C1265415
27321745	460	469	bacterial	T007	C0004611
27321745	470	479	community	T096	C0009462
27321745	483	492	J. acutus	T002	C1639894
27321745	497	505	isolated	T169	C0205409
27321745	510	523	characterized	T052	C1880022
27321745	530	537	strains	T001	C1518614
27321745	552	559	possess	T078	C3154893
27321745	560	579	increased tolerance	T033	C0151956
27321745	583	589	metals	T197	C0025552
27321745	598	600	Zn	T121,T123,T196	C0043481
27321745	602	604	Ni	T123,T196	C0028013
27321745	606	608	Pb	T131,T196	C0023175
27321745	613	615	Cd	T131,T196	C0006632
27321745	627	634	several	T081	C0443302
27321745	635	645	endophytic	T004	C1265415
27321745	646	655	bacterial	T007	C0004611
27321745	656	663	strains	T001	C1518614
27321745	688	691	BPA	T109,T131	C0053800
27321745	703	714	antibiotics	T195	C0003232
27321745	716	729	ciprofloxacin	T109,T121	C0008809
27321745	734	750	sulfamethoxazole	T109,T195	C0038689
27321745	762	768	carbon	T196	C0007009
27321745	769	775	source	T033	C0449416
27321745	781	788	results	T033	C0683954
27321745	821	830	bacterial	T007	C0004611
27321745	831	841	endophytic	T004	C1265415
27321745	842	851	community	T096	C0009462
27321745	855	864	J. acutus	T002	C1639894
27321745	880	887	organic	T109	C0029224
27321745	888	900	contaminants	T167	C2827365
27321745	904	910	carbon	T196	C0007009
27321745	911	918	sources	T033	C0449416
27321745	930	936	metals	T197	C0025552
27321745	958	970	plant-growth	T040	C0597252
27321745	971	980	promoting	T052	C0033414
27321745	981	987	traits	T032	C0599883
27321745	1000	1009	J. acutus	T002	C1639894
27321745	1014	1023	potential	T080	C3245505
27321745	1055	1063	wetlands	T070	C1721088
27321745	1069	1085	co-contamination	T078	C2349974
27321745	1100	1111	restricting	T169	C0443288
27321745	1112	1119	factors	T169	C1521761

27556586|t|Impact of LbSapSal Vaccine in Canine Immunological and Parasitological Features before and after Leishmania chagasi - Challenge
27556586|a|Dogs represent the most important domestic reservoir of L. chagasi (syn. L. infantum). A vaccine against canine visceral leishmaniasis (CVL) would be an important tool for decreasing the anxiety related to possible L. chagasi infection and for controlling human visceral leishmaniasis (VL). Because the sand fly salivary proteins are potent immunogens obligatorily co-deposited during transmission of Leishmania parasites, their inclusion in an anti-Leishmania vaccine has been investigated in past decades. We investigated the immunogenicity of the "LbSapSal" vaccine (L. braziliensis antigens, saponin as adjuvant, and Lutzomyia longipalpis salivary gland extract) in dogs at baseline (T0), during the post-vaccination protocol (T3rd) and after early (T90) and late (T885) times following L. chagasi - challenge. Our major data indicated that immunization with " LbSapSal " is able to induce biomarkers characterized by enhanced amounts of type I (tumor necrosis factor [TNF]-α, interleukin [IL]-12, interferon [IFN]-γ) cytokines and reduction in type II cytokines (IL-4 and TGF-β), even after experimental challenge. The establishment of a prominent pro-inflammatory immune response after " LbSapSal " immunization supported the increased levels of nitric oxide production, favoring a reduction in spleen parasitism (78.9%) and indicating long-lasting protection against L. chagasi infection. In conclusion, these results confirmed the hypothesis that the " LbSapSal " vaccination is a potential tool to control the Leishmania chagasi infection.
27556586	0	6	Impact	T080	C4049986
27556586	10	26	LbSapSal Vaccine	T121,T129	C0042210
27556586	30	36	Canine	T015	C1280551
27556586	37	50	Immunological	T169	C0205470
27556586	55	70	Parasitological	T080	C0205468
27556586	97	115	Leishmania chagasi	T204	C0446195
27556586	118	127	Challenge	T058	C0805586
27556586	128	132	Dogs	T015	C0012984
27556586	184	194	L. chagasi	T204	C0446195
27556586	201	212	L. infantum	T204	C0023272
27556586	217	224	vaccine	T121,T129	C0042210
27556586	233	239	canine	T015	C1280551
27556586	240	262	visceral leishmaniasis	T047	C0023290
27556586	264	267	CVL	T047	C0023290
27556586	315	322	anxiety	T033	C0003467
27556586	343	363	L. chagasi infection	T047	C1400587
27556586	384	389	human	T016	C0086418
27556586	390	412	visceral leishmaniasis	T047	C0023290
27556586	414	416	VL	T047	C0023290
27556586	431	439	sand fly	T204	C0036158
27556586	440	457	salivary proteins	T116,T123	C0036100
27556586	469	479	immunogens	T129	C0003320
27556586	513	525	transmission	T070	C1521797
27556586	529	549	Leishmania parasites	T204	C1095819
27556586	573	596	anti-Leishmania vaccine	T121,T129	C1548483
27556586	627	634	decades	T081	C2981279
27556586	656	670	immunogenicity	T038	C4277607
27556586	678	696	"LbSapSal" vaccine	T121,T129	C0042210
27556586	698	713	L. braziliensis	T204	C0023271
27556586	714	722	antigens	T129	C0003320
27556586	724	731	saponin	T109	C0520481
27556586	735	743	adjuvant	T121,T129	C0001551
27556586	749	770	Lutzomyia longipalpis	T204	C0322761
27556586	771	785	salivary gland	T023	C0036098
27556586	786	793	extract	T167	C2828366
27556586	798	802	dogs	T015	C0012984
27556586	832	848	post-vaccination	T079	C1254367
27556586	919	929	L. chagasi	T204	C0446195
27556586	932	941	challenge	T058	C0805586
27556586	973	985	immunization	T061	C0020971
27556586	993	1001	LbSapSal	T121,T129	C0042210
27556586	1022	1032	biomarkers	T201	C0005516
27556586	1070	1076	type I	T116,T129	C0041368
27556586	1078	1107	tumor necrosis factor [TNF]-α	T116,T129	C1456820
27556586	1109	1128	interleukin [IL]-12	T116,T121,T129	C0123759
27556586	1130	1148	interferon [IFN]-γ	T116,T121,T129	C0021745
27556586	1150	1159	cytokines	T116,T129	C0079189
27556586	1177	1194	type II cytokines	T116,T129	C0079189
27556586	1196	1200	IL-4	T116,T129	C0021758
27556586	1205	1210	TGF-β	T116,T123	C0040690
27556586	1237	1246	challenge	T058	C0805586
27556586	1281	1297	pro-inflammatory	T169	C0333348
27556586	1298	1313	immune response	T042	C0301872
27556586	1322	1330	LbSapSal	T121,T129	C0042210
27556586	1333	1345	immunization	T061	C0020971
27556586	1380	1392	nitric oxide	T121,T123,T197	C0028128
27556586	1393	1403	production	T052	C1883254
27556586	1429	1435	spleen	T023	C0037993
27556586	1436	1446	parasitism	T070	C0677482
27556586	1483	1493	protection	T033	C1545588
27556586	1502	1522	L. chagasi infection	T047	C1400587
27556586	1567	1577	hypothesis	T078	C1512571
27556586	1589	1597	LbSapSal	T121,T129	C0042210
27556586	1600	1611	vaccination	T061	C0042196
27556586	1627	1631	tool	T169	C0449851
27556586	1635	1642	control	T080	C0243148
27556586	1647	1675	Leishmania chagasi infection	T047	C1400587

27775720|t|A neuronal PI(3,4,5)P3 -dependent program of oligodendrocyte precursor recruitment and myelination
27775720|a|The molecular trigger of CNS myelination is unknown. By targeting Pten in cerebellar granule cells and activating the AKT1 - mTOR pathway, we increased the caliber of normally unmyelinated axons and the expression of numerous genes encoding regulatory proteins. This led to the expansion of genetically wild-type oligodendrocyte progenitor cells, oligodendrocyte differentiation and de novo myelination of parallel fibers. Thus, a neuronal program dependent on the phosphoinositide PI(3,4,5)P3 is sufficient to trigger all steps of myelination.
27775720	2	10	neuronal	T025	C0027882
27775720	11	22	PI(3,4,5)P3	T109	C0765553
27775720	34	41	program	T169	C3484370
27775720	45	60	oligodendrocyte	T025	C0028944
27775720	61	70	precursor	T078	C1709634
27775720	71	82	recruitment	T052	C2949735
27775720	87	98	myelination	T043	C0596991
27775720	103	120	molecular trigger	T044	C1148560
27775720	124	127	CNS	T022	C3714787
27775720	128	139	myelination	T043	C0596991
27775720	143	150	unknown	T080	C0439673
27775720	155	164	targeting	T169	C1521840
27775720	165	169	Pten	T116,T126	C1530899
27775720	173	197	cerebellar granule cells	T025	C0007634
27775720	202	212	activating	T052	C1879547
27775720	217	221	AKT1	T116,T126	C0285558
27775720	224	228	mTOR	T116,T123	C0293060
27775720	229	236	pathway	T044	C0086982
27775720	241	250	increased	T081	C0205217
27775720	266	274	normally	T080	C0205307
27775720	275	293	unmyelinated axons	T026	C1179986
27775720	302	312	expression	T045	C1171362
27775720	316	324	numerous	T081	C0439064
27775720	325	330	genes	T028	C0017337
27775720	331	339	encoding	T052	C2700640
27775720	340	359	regulatory proteins	T116,T123	C0815047
27775720	377	386	expansion	T043	C0007595
27775720	390	411	genetically wild-type	T028	C1883559
27775720	412	427	oligodendrocyte	T025	C0028944
27775720	428	444	progenitor cells	T025	C0038250
27775720	446	461	oligodendrocyte	T025	C0028944
27775720	462	477	differentiation	T043	C0007589
27775720	482	489	de novo	T078	C1515568
27775720	490	501	myelination	T043	C0596991
27775720	505	520	parallel fibers	T026	C3546707
27775720	530	538	neuronal	T025	C0027882
27775720	539	546	program	T169	C3484370
27775720	564	580	phosphoinositide	T109,T123	C0031621
27775720	581	592	PI(3,4,5)P3	T109	C0765553
27775720	610	617	trigger	T044	C1148560
27775720	622	627	steps	T077	C1261552
27775720	631	642	myelination	T043	C0596991

28118752|t|The impact of adjunctive guanfacine extended release on stimulant adherence in children / adolescents with attention-deficit / hyperactivity disorder
28118752|a|To assess stimulant adherence among children / adolescents with attention-deficit / hyperactivity disorder (ADHD) augmenting stimulants with guanfacine extended-release (GXR). Inclusion criteria: 6-17 years, ≥1 ADHD diagnosis, ≥1 long-acting and/or short-acting stimulant with GXR augmentation. Modified medication possession ratio (mMPR; days medication available / days in period, excluding medication holidays) was assessed; mMPR < 0.80 nonadherent. Regression models assessed change in mMPR adjusting for demographic and clinical characteristics. Among patients nonadherent to stimulants pre - augmentation (n = 165), unadjusted mean (SD) pre - and post - stimulant mMPRs were 0.68 (0.11) and 0.87 (0.16). Adjusted mean change in mMPR was 0.20 for long-acting versus 0.18 for short-acting stimulants (p = 0.34). Among patients nonadherent to stimulants, GXR augmentation was associated with increased stimulant adherence.
28118752	4	10	impact	T080	C4049986
28118752	14	24	adjunctive	T061	C0677850
28118752	25	35	guanfacine	T109,T121	C0079466
28118752	36	52	extended release	T122	C1707968
28118752	56	65	stimulant	T121	C0304402
28118752	66	75	adherence	T169	C1510802
28118752	79	87	children	T100	C0008059
28118752	90	101	adolescents	T100	C0205653
28118752	107	124	attention-deficit	T048	C0041671
28118752	127	149	hyperactivity disorder	T048	C1263846
28118752	160	169	stimulant	T121	C0304402
28118752	170	179	adherence	T169	C1510802
28118752	186	194	children	T100	C0008059
28118752	197	208	adolescents	T100	C0205653
28118752	214	231	attention-deficit	T048	C0041671
28118752	234	256	hyperactivity disorder	T048	C1263846
28118752	258	262	ADHD	T048	C1263846
28118752	264	285	augmenting stimulants	T120	C0449986
28118752	275	285	stimulants	T121	C0304402
28118752	291	318	guanfacine extended-release	T122	C1707968
28118752	320	323	GXR	T122	C1707968
28118752	326	344	Inclusion criteria	T078	C0243161
28118752	351	356	years	T079	C0439234
28118752	361	365	ADHD	T048	C1263846
28118752	366	375	diagnosis	T033	C0011900
28118752	380	391	long-acting	T121	C0304402
28118752	399	421	short-acting stimulant	T121	C0304402
28118752	427	430	GXR	T122	C1707968
28118752	431	443	augmentation	T061	C1293122
28118752	445	481	Modified medication possession ratio	T081	C0456603
28118752	483	487	mMPR	T081	C0456603
28118752	489	493	days	T079	C0439228
28118752	494	504	medication	T058	C2081612
28118752	505	514	available	T169	C0470187
28118752	517	521	days	T079	C0439228
28118752	525	531	period	T079	C1948053
28118752	533	542	excluding	T169	C0332196
28118752	543	553	medication	T058	C2081612
28118752	554	562	holidays	T052	C0019843
28118752	578	582	mMPR	T081	C0456603
28118752	590	601	nonadherent	T033	C3845923
28118752	603	613	Regression	T170	C0034980
28118752	614	620	models	T170	C3161035
28118752	621	629	assessed	T058	C0184514
28118752	630	636	change	T169	C0392747
28118752	640	644	mMPR	T081	C0456603
28118752	645	654	adjusting	T169	C0456081
28118752	659	670	demographic	T102	C0683970
28118752	675	699	clinical characteristics	T201	C0683325
28118752	707	715	patients	T101	C0030705
28118752	716	727	nonadherent	T033	C3845923
28118752	731	741	stimulants	T121	C0304402
28118752	742	745	pre	T079	C0332152
28118752	748	760	augmentation	T061	C1293122
28118752	772	782	unadjusted	T169	C1439367
28118752	789	791	SD	T081	C0871420
28118752	793	796	pre	T079	C0332152
28118752	803	807	post	T079	C0687676
28118752	810	819	stimulant	T121	C0304402
28118752	820	825	mMPRs	T081	C0456603
28118752	860	868	Adjusted	T169	C0456081
28118752	874	880	change	T169	C0392747
28118752	884	888	mMPR	T081	C0456603
28118752	902	913	long-acting	T121	C0304402
28118752	930	953	short-acting stimulants	T121	C0304402
28118752	972	980	patients	T101	C0030705
28118752	981	992	nonadherent	T033	C3845923
28118752	996	1006	stimulants	T121	C0304402
28118752	1008	1011	GXR	T122	C1707968
28118752	1012	1024	augmentation	T061	C1293122
28118752	1029	1044	associated with	T080	C0332281
28118752	1045	1054	increased	T081	C0205217
28118752	1055	1064	stimulant	T121	C0304402
28118752	1065	1074	adherence	T169	C1510802

28128333|t|ComB proteins expression levels determine Helicobacter pylori competence capacity
28128333|a|Helicobacter pylori chronically colonises half of the world's human population and is the main cause of ulcers and gastric cancers. Its prevalence and the increase in antibiotic resistance observed recently reflect the high genetic adaptability of this pathogen. Together with high mutation rates and an efficient DNA recombination system, horizontal gene transfer through natural competence makes of H. pylori one of the most genetically diverse bacteria. We show here that transformation capacity is enhanced in strains defective for recN, extending previous work with other homologous recombination genes. However, inactivation of either mutY or polA has no effect on DNA transformation, suggesting that natural competence can be boosted in H. pylori by the persistence of DNA breaks but not by enhanced mutagenesis. The transformation efficiency of the different DNA repair impaired strains correlates with the number of transforming DNA foci formed on the cell surface and with the expression of comB8 and comB10 competence genes. Overexpression of the comB6-B10 operon is sufficient to increase the transformation capacity of a wild type strain, indicating that the ComB complex, present in the bacterial wall and essential for DNA uptake, can be a limiting factor for transformation efficiency.
28128333	0	13	ComB proteins	T116,T123	C0033684
28128333	14	24	expression	T045	C1171362
28128333	25	31	levels	T080	C0441889
28128333	42	61	Helicobacter pylori	T007	C0079488
28128333	62	72	competence	T080	C3179113
28128333	73	81	capacity	T081	C1516240
28128333	82	101	Helicobacter pylori	T007	C0079488
28128333	102	113	chronically	T079	C0205191
28128333	114	123	colonises	T033	C2747813
28128333	136	143	world's	T098	C2700280
28128333	144	160	human population	T081	C0032665
28128333	177	182	cause	T078	C0085978
28128333	186	192	ulcers	T047	C0041582
28128333	197	212	gastric cancers	T191	C0024623
28128333	218	228	prevalence	T081	C0220900
28128333	237	245	increase	T169	C0442805
28128333	249	270	antibiotic resistance	T032	C0949669
28128333	306	326	genetic adaptability	T038	C0392673
28128333	335	343	pathogen	T001	C0450254
28128333	364	378	mutation rates	T080	C3178846
28128333	386	395	efficient	T080	C0442799
28128333	396	420	DNA recombination system	T045	C0034865
28128333	422	446	horizontal gene transfer	T045	C0887912
28128333	447	454	through	T169	C0332273
28128333	455	462	natural	T169	C0205296
28128333	463	473	competence	T080	C3179113
28128333	483	492	H. pylori	T007	C0079488
28128333	509	520	genetically	T169	C0017399
28128333	521	528	diverse	T080	C1880371
28128333	529	537	bacteria	T007	C0004611
28128333	557	571	transformation	T045	C0040684
28128333	572	580	capacity	T081	C1516240
28128333	584	592	enhanced	T052	C2349975
28128333	596	603	strains	T001	C1518614
28128333	604	613	defective	T169	C0332452
28128333	618	622	recN	T116,T126	C1437157
28128333	659	683	homologous recombination	T045	C0599773
28128333	684	689	genes	T028	C0017337
28128333	700	712	inactivation	T045	C0598496
28128333	723	727	mutY	T028	C1417505
28128333	731	735	polA	T028	C1826642
28128333	740	749	no effect	T080	C1301751
28128333	753	771	DNA transformation	T045	C0040684
28128333	789	796	natural	T169	C0205296
28128333	797	807	competence	T080	C3179113
28128333	826	835	H. pylori	T007	C0079488
28128333	858	868	DNA breaks	T044	C1721104
28128333	873	876	not	T169	C1518422
28128333	880	888	enhanced	T052	C2349975
28128333	889	900	mutagenesis	T044	C0079866
28128333	906	920	transformation	T045	C0040684
28128333	921	931	efficiency	T081	C0013682
28128333	949	959	DNA repair	T045	C0012899
28128333	960	968	impaired	T169	C0221099
28128333	969	976	strains	T001	C1518614
28128333	1007	1019	transforming	T045	C0040684
28128333	1020	1028	DNA foci	T026	C3159064
28128333	1043	1055	cell surface	T026	C0699040
28128333	1069	1079	expression	T045	C0017262
28128333	1083	1088	comB8	T028	C0017337
28128333	1093	1099	comB10	T028	C0017337
28128333	1100	1110	competence	T080	C3179113
28128333	1111	1116	genes	T028	C0017337
28128333	1118	1132	Overexpression	T045	C1514559
28128333	1140	1156	comB6-B10 operon	T028	C0029073
28128333	1160	1170	sufficient	T080	C0205410
28128333	1174	1182	increase	T169	C0442805
28128333	1187	1201	transformation	T045	C0040684
28128333	1202	1210	capacity	T081	C1516240
28128333	1216	1225	wild type	T028	C1883559
28128333	1226	1232	strain	T001	C1518614
28128333	1254	1266	ComB complex	T116,T123	C1180347
28128333	1283	1297	bacterial wall	T026	C0007623
28128333	1302	1311	essential	T080	C0205224
28128333	1316	1326	DNA uptake	T043	C1158477
28128333	1337	1345	limiting	T169	C0439801
28128333	1346	1352	factor	T169	C1521761
28128333	1357	1371	transformation	T045	C0040684
28128333	1372	1382	efficiency	T081	C0013682

27544871|t|The Effect of Image Review before Patient Discharge on Study Completeness and Sonographer Job Satisfaction in a Pediatric Echocardiographic Laboratory
27544871|a|Incomplete echocardiographic assessment accounts for approximately 10% of preventable diagnostic errors and may place children at risk for adverse outcomes or increased testing. The aim of this study was to determine if physician review of images improves study completeness. A prospective quality improvement (QI) study initiated physician review of first-time echocardiographic studies for completeness before patient discharge. Studies were incomplete if not all anatomic structures were diagnostically demonstrated. QI examinations were compared with controls obtained before study initiation. Demographic and clinical information and duration of scan were collected during the control and QI periods. An anonymous survey was administered to the sonographers to assess perceptions of the intervention. There were no differences between the QI (n = 63) and control (n = 63) groups in age, height, weight, and technical barriers. After study completion, 35% of control scans versus 5% of QI scans were incomplete (P < .001). In the QI group, the sonographer, physician, or both returned to scan in 12 (19%), nine (14%), and two (3%) studies, respectively. QI studies were longer than control studies (44 vs 36 min, P = .003) before review. Physician review added a median of 6 min (range, 1-28 min). The majority of sonographers believed that immediate review improved communication, and 50% believed that it improved their job satisfaction. Review of initial outpatient echocardiographic examinations before patient discharge significantly improves study completeness. Review adds a nominal amount of time to total study duration, improves sonographer - physician communication, and may prevent unnecessary testing, potentially reducing the cost of care.
27544871	14	19	Image	T170	C1704254
27544871	20	26	Review	T058	C0262501
27544871	34	51	Patient Discharge	T058	C0030685
27544871	55	60	Study	T062	C2603343
27544871	61	73	Completeness	T080	C0439812
27544871	78	89	Sonographer	T097	C1954848
27544871	90	106	Job Satisfaction	T041	C0022397
27544871	112	139	Pediatric Echocardiographic	T060	C2316452
27544871	140	150	Laboratory	T073,T093	C0022877
27544871	162	179	echocardiographic	T060	C0013516
27544871	180	190	assessment	T058	C0220825
27544871	237	254	diagnostic errors	T080	C0011922
27544871	269	277	children	T100	C0008059
27544871	281	285	risk	T078	C0035647
27544871	290	306	adverse outcomes	T033	C1705586
27544871	320	327	testing	T060	C0683443
27544871	345	350	study	T062	C2603343
27544871	371	380	physician	T097	C0031831
27544871	381	387	review	T058	C0262501
27544871	391	397	images	T170	C1704254
27544871	407	412	study	T062	C2603343
27544871	413	425	completeness	T080	C0439812
27544871	441	460	quality improvement	T057	C3858649
27544871	462	464	QI	T057	C3858649
27544871	466	471	study	T062	C2603343
27544871	466	471	study	T062	C2603343
27544871	482	491	physician	T097	C0031831
27544871	492	498	review	T058	C0262501
27544871	513	530	echocardiographic	T060	C0013516
27544871	531	538	studies	T062	C2603343
27544871	543	555	completeness	T080	C0439812
27544871	563	580	patient discharge	T058	C0030685
27544871	582	589	Studies	T062	C2603343
27544871	617	636	anatomic structures	T017	C0700276
27544871	642	656	diagnostically	T169	C0348026
27544871	671	673	QI	T057	C3858649
27544871	674	686	examinations	T058	C0582103
27544871	731	736	study	T062	C2603343
27544871	737	747	initiation	T169	C1704686
27544871	749	760	Demographic	T090	C0011298
27544871	765	785	clinical information	T170	C2708733
27544871	790	798	duration	T079	C0449238
27544871	802	806	scan	T060	C0441633
27544871	845	847	QI	T057	C3858649
27544871	848	855	periods	T079	C1948053
27544871	870	876	survey	T170	C0038951
27544871	901	913	sonographers	T097	C1954848
27544871	924	935	perceptions	T041	C0030971
27544871	943	955	intervention	T061	C0184661
27544871	995	997	QI	T057	C3858649
27544871	1011	1034	control (n = 63) groups	T096	C0009932
27544871	1038	1041	age	T032	C0001779
27544871	1043	1049	height	T032	C0489786
27544871	1051	1057	weight	T032	C0005910
27544871	1089	1094	study	T062	C2603343
27544871	1122	1127	scans	T060	C0441633
27544871	1141	1143	QI	T057	C3858649
27544871	1144	1149	scans	T060	C0441633
27544871	1185	1187	QI	T057	C3858649
27544871	1188	1193	group	T098	C1257890
27544871	1199	1210	sonographer	T097	C1954848
27544871	1212	1221	physician	T097	C0031831
27544871	1243	1247	scan	T060	C0441633
27544871	1286	1293	studies	T062	C2603343
27544871	1309	1311	QI	T057	C3858649
27544871	1312	1319	studies	T062	C2603343
27544871	1337	1352	control studies	T062	C0007328
27544871	1385	1391	review	T058	C0262501
27544871	1393	1402	Physician	T097	C0031831
27544871	1403	1409	review	T058	C0262501
27544871	1469	1481	sonographers	T097	C1954848
27544871	1506	1512	review	T058	C0262501
27544871	1522	1535	communication	T054	C0009452
27544871	1577	1593	job satisfaction	T041	C0022397
27544871	1595	1601	Review	T058	C0262501
27544871	1613	1623	outpatient	T101	C0029921
27544871	1624	1641	echocardiographic	T060	C0013516
27544871	1642	1654	examinations	T058	C0582103
27544871	1662	1679	patient discharge	T058	C0030685
27544871	1703	1708	study	T062	C2603343
27544871	1709	1721	completeness	T080	C0439812
27544871	1723	1729	Review	T058	C0262501
27544871	1769	1774	study	T062	C2603343
27544871	1775	1783	duration	T079	C0449238
27544871	1794	1805	sonographer	T097	C1954848
27544871	1808	1817	physician	T097	C0031831
27544871	1818	1831	communication	T054	C0009452
27544871	1861	1868	testing	T060	C0683443
27544871	1895	1907	cost of care	T081	C0086600

28353042|t|Beneficial Effects of Phyllanthus amarus Against High Fructose Diet Induced Insulin Resistance and Hepatic Oxidative Stress in Male Wistar Rats
28353042|a|Insulin resistance (IR) is a characteristic feature of obesity, type 2 diabetes mellitus, and cardiovascular diseases. Emerging evidence suggests that the high-fructose consumption is a potential and important factor responsible for the rising incidence of IR. The present study investigates the beneficial effects of aqueous extract of Phyllanthus amaru s (PAAE) on IR and oxidative stress in high-fructose (HF) fed male Wistar rats. HF diet (66% of fructose) and PAAE (200 mg/kg body weight/day) were given concurrently to the rats for a period of 60 days. Fructose-fed rats showed weight gain, hyperglycemia, hyperinsulinemia, impaired glucose tolerance, impaired insulin sensitivity, dyslipidemia, hyperleptinemia, and hypoadiponectinemia (P < 0.05) after 60 days. Co-administration of PAAE along with HF diet significantly ameliorated all these alterations. Regarding hepatic antioxidant status, higher lipid peroxidation and protein oxidation, lower reduced glutathione levels and lower activities of enzymatic antioxidants, and the histopathological changes like mild to severe distortion of the normal architecture as well as the prominence and widening of the liver sinusoids observed in the HF diet -fed rats were significantly prevented by PAAE treatment. These findings indicate that PAAE is beneficial in improving insulin sensitivity and attenuating metabolic syndrome and hepatic oxidative stress in fructose-fed rats.
28353042	0	18	Beneficial Effects	T080	C1280500
28353042	22	40	Phyllanthus amarus	T002	C0950041
28353042	49	67	High Fructose Diet	T168	C0012155
28353042	76	94	Insulin Resistance	T046	C0021655
28353042	99	123	Hepatic Oxidative Stress	T049	C0242606
28353042	127	131	Male	T032	C0086582
28353042	132	143	Wistar Rats	T015	C0034716
28353042	144	162	Insulin resistance	T046	C0021655
28353042	164	166	IR	T046	C0021655
28353042	199	206	obesity	T047	C0028754
28353042	208	232	type 2 diabetes mellitus	T047	C0011860
28353042	238	261	cardiovascular diseases	T047	C0007222
28353042	299	312	high-fructose	T109,T121	C0016745
28353042	313	324	consumption	T039	C1947907
28353042	330	339	potential	T080	C3245505
28353042	354	360	factor	T169	C1521761
28353042	381	397	rising incidence	T169	C0220888
28353042	401	403	IR	T046	C0021655
28353042	417	422	study	T062	C2603343
28353042	423	435	investigates	T169	C1292732
28353042	440	458	beneficial effects	T080	C1280500
28353042	462	477	aqueous extract	T167	C2828366
28353042	481	498	Phyllanthus amaru	T002	C0950041
28353042	502	506	PAAE	T167	C2828366
28353042	511	513	IR	T046	C0021655
28353042	518	534	oxidative stress	T049	C0242606
28353042	538	551	high-fructose	T109,T121	C0016745
28353042	553	555	HF	T109,T121	C0016745
28353042	561	565	male	T032	C0086582
28353042	566	577	Wistar rats	T015	C0034716
28353042	579	586	HF diet	T168	C0012155
28353042	609	613	PAAE	T167	C2828366
28353042	653	665	concurrently	T079	C0205420
28353042	673	677	rats	T015	C0034716
28353042	703	715	Fructose-fed	T080	C0205556
28353042	716	720	rats	T015	C0034716
28353042	728	739	weight gain	T033	C0043094
28353042	741	754	hyperglycemia	T047	C0020456
28353042	756	772	hyperinsulinemia	T047	C0020459
28353042	774	800	impaired glucose tolerance	T047	C0271650
28353042	802	830	impaired insulin sensitivity	T046	C0920563
28353042	832	844	dyslipidemia	T047	C0242339
28353042	846	861	hyperleptinemia	T047	C0012634
28353042	867	886	hypoadiponectinemia	T047	C2675519
28353042	913	930	Co-administration	T061	C1533734
28353042	934	938	PAAE	T167	C2828366
28353042	950	957	HF diet	T168	C0012155
28353042	994	1005	alterations	T078	C1515926
28353042	1017	1024	hepatic	T029	C0205054
28353042	1025	1043	antioxidant status	T044	C1148564
28353042	1052	1070	lipid peroxidation	T044	C0023775
28353042	1075	1092	protein oxidation	T044	C1159301
28353042	1100	1119	reduced glutathione	T034	C0034917
28353042	1131	1147	lower activities	T038	C3890174
28353042	1151	1173	enzymatic antioxidants	T121	C0003402
28353042	1183	1208	histopathological changes	T169	C0243140
28353042	1229	1239	distortion	T080	C2919017
28353042	1313	1328	liver sinusoids	T023	C0227523
28353042	1345	1352	HF diet	T168	C0012155
28353042	1358	1362	rats	T015	C0034716
28353042	1395	1399	PAAE	T167	C2828366
28353042	1400	1409	treatment	T061	C0087111
28353042	1440	1444	PAAE	T167	C2828366
28353042	1472	1491	insulin sensitivity	T046	C0920563
28353042	1508	1526	metabolic syndrome	T047	C0025517
28353042	1531	1555	hepatic oxidative stress	T049	C0242606
28353042	1559	1571	fructose-fed	T080	C0205556
28353042	1572	1576	rats	T015	C0034716

27676379|t|Postprandial anti-hyperglycemic activity of marine Streptomyces coelicoflavus SRBVIT13 mediated gold nanoparticles in streptozotocin induced diabetic male albino Wister rats
27676379|a|The present study focuses on the biosynthesis of gold nanoparticles (AuNPs) using Streptomyces coelicoflavus (S. coelicoflavus) SRBVIT13 isolated from marine salt pan soils collected from Ongole, Andhra Pradesh, India. The biosynthesised AuNPs are characterised by UV-visible spectroscopy, X-ray diffraction, Fourier transform infrared spectroscopy, high-resolution transmission electron microscopy and energy-dispersive X-ray analysis. Transmission electron microscopy study suggests that the biosynthesised AuNPs are spherical in shape within a size range of 12-20 nm (mean diameter as 14 nm). The anti-type II diabetes activity of AuNPs is carried out by testing it in vitro α-glucosidase and α-amylase enzyme inhibition activity and in vivo postprandial anti-hyperglycemic activity in sucrose and glucose -loaded streptozotocin induced diabetic albino Wister rats. AuNPs has shown a significant inhibitory activity of 84.70 and 87.82% with IC50 values of 67.65 and 65.59 μg/mL to α-glucosidase and α-amylase enzymes, while the diabetic rats have shown significant reduction in the post postprandial blood glucose level by 57.80 and 88.09%, respectively compared with control group after AuNPs treatment at the concentration of 300 and 600 mg/kg body weight. Hence, this biosynthesised AuNPs might be useful in combating type II diabetes mellitus for the betterment of human life.
27676379	0	12	Postprandial	T079	C0376674
27676379	13	40	anti-hyperglycemic activity	T033	C2825141
27676379	44	50	marine	T001	C0599383
27676379	51	86	Streptomyces coelicoflavus SRBVIT13	T007	C1656173
27676379	96	100	gold	T121,T196	C0018026
27676379	101	114	nanoparticles	T073	C1721060
27676379	118	132	streptozotocin	T109,T195	C0038432
27676379	133	140	induced	T169	C0205263
27676379	141	149	diabetic	T047	C0011847
27676379	150	154	male	T032	C0086582
27676379	155	173	albino Wister rats	T015	C0034716
27676379	207	219	biosynthesis	T169	C0005572
27676379	223	227	gold	T121,T196	C0018026
27676379	228	241	nanoparticles	T073	C1721060
27676379	243	248	AuNPs	T073	C1721060
27676379	256	310	Streptomyces coelicoflavus (S. coelicoflavus) SRBVIT13	T007	C1656173
27676379	311	319	isolated	T169	C0205409
27676379	325	346	marine salt pan soils	T167	C0037592
27676379	362	368	Ongole	UnknownType	C0681784
27676379	370	384	Andhra Pradesh	UnknownType	C0681784
27676379	386	391	India	T083	C0021201
27676379	397	411	biosynthesised	T169	C0005572
27676379	412	417	AuNPs	T073	C1721060
27676379	422	435	characterised	T062	C1881968
27676379	439	462	UV-visible spectroscopy	T059	C0037812
27676379	464	481	X-ray diffraction	T059	C0043301
27676379	483	522	Fourier transform infrared spectroscopy	T062	C0206055
27676379	524	572	high-resolution transmission electron microscopy	T059	C2697588
27676379	577	609	energy-dispersive X-ray analysis	T059	C0599643
27676379	611	643	Transmission electron microscopy	T059	C0678118
27676379	668	682	biosynthesised	T169	C0005572
27676379	683	688	AuNPs	T073	C1721060
27676379	693	711	spherical in shape	T082	C0332501
27676379	721	725	size	T082	C0456389
27676379	745	758	mean diameter	T081	C0552409
27676379	774	804	anti-type II diabetes activity	T033	C2825141
27676379	808	813	AuNPs	T073	C1721060
27676379	832	839	testing	T169	C0039593
27676379	843	851	in vitro	T080	C1533691
27676379	852	865	α-glucosidase	T116,T121,T126	C0002272
27676379	870	879	α-amylase	T116,T121,T126	C3853624
27676379	880	906	enzyme inhibition activity	T040	C2248397
27676379	911	918	in vivo	T082	C1515655
27676379	919	931	postprandial	T079	C0376674
27676379	932	959	anti-hyperglycemic activity	T033	C2825141
27676379	963	970	sucrose	T109,T121,T123	C0038636
27676379	975	982	glucose	T109,T121,T123	C0017725
27676379	991	1005	streptozotocin	T109,T195	C0038432
27676379	1006	1013	induced	T169	C0205263
27676379	1014	1022	diabetic	T047	C0011847
27676379	1023	1041	albino Wister rats	T015	C0034716
27676379	1043	1048	AuNPs	T073	C1721060
27676379	1073	1092	inhibitory activity	T040	C2248397
27676379	1118	1122	IC50	T081	C0600495
27676379	1158	1171	α-glucosidase	T116,T121,T126	C0002272
27676379	1176	1185	α-amylase	T116,T121,T126	C3853624
27676379	1186	1193	enzymes	T116,T126	C0014442
27676379	1205	1213	diabetic	T047	C0011847
27676379	1214	1218	rats	T015	C0034693
27676379	1242	1251	reduction	T080	C0392756
27676379	1264	1276	postprandial	T079	C0376674
27676379	1277	1296	blood glucose level	T034	C0428554
27676379	1345	1358	control group	T096	C0009932
27676379	1365	1370	AuNPs	T073	C1721060
27676379	1371	1380	treatment	T169	C1522326
27676379	1388	1401	concentration	T081	C0392762
27676379	1417	1434	mg/kg body weight	T081	C0560741
27676379	1448	1462	biosynthesised	T169	C0005572
27676379	1463	1468	AuNPs	T073	C1721060
27676379	1498	1523	type II diabetes mellitus	T047	C0011860
27676379	1546	1551	human	T016	C0086418
27676379	1552	1556	life	T078	C0376558

28085530|t|Invasive fungal infections in renal transplant patients: a single center study
28085530|a|Timely diagnosis of invasive fungal infections (IFI) in renal transplant (RT) patients on immunosuppression is often difficult, jeopardizing their life and graft. We reported IFI and their causative fungal agents in post- RT patients. This was a retrospective 6-year clinical study carried out from 2010 to 2015 on 1900 RT patients. Clinical data included patient - donor demographics, time to onset of infection, risk factors and graft function in terms of serum creatinine (SCr). To identify IFI, we examined bronchoalveolar lavage (BAL), blood, tissue, and wound swab samples by conventional mycological methods. IFI were diagnosed in 30 (1.56%) patients on triple immunosuppression, mainly males (n = 25) with mean age of 36.57 ± 11.9 years at 13.12 ± 18.35 months post- RT. Aspergillus species was identified in 11 BAL, one tissue, and one wound specimen each, 30.76% of these were fatal and 15.38% caused graft loss; Candida albicans was in nine BAL, four blood, two wound swab, and one tissue specimens, 25% of these were fatal and 25% had graft loss and one mucor in BAL which was fatal. Seven patients were diabetic, 10 had superadded cytomegalovirus infection, and 15 were anti-rejected. IFI are associated with increased morbidity and mortality in RT patients. Triple immunosuppression, broad spectrum antibiotics for ≥ two weeks, diabetes and superadded infection are added risks for these patients. Prevention, early diagnosis, and appropriate management are necessary to improve their prognosis.
28085530	0	26	Invasive fungal infections	T047	C1262313
28085530	30	46	renal transplant	T061	C0022671
28085530	47	55	patients	T101	C0030705
28085530	59	78	single center study	T062	C0242481
28085530	86	95	diagnosis	T033	C0011900
28085530	99	125	invasive fungal infections	T047	C1262313
28085530	127	130	IFI	T047	C1262313
28085530	135	151	renal transplant	T061	C0022671
28085530	153	155	RT	T061	C0022671
28085530	157	165	patients	T101	C0030705
28085530	169	186	immunosuppression	T061	C0021079
28085530	207	219	jeopardizing	T184	C2128832
28085530	226	230	life	T078	C0376558
28085530	235	240	graft	T024	C0332835
28085530	254	257	IFI	T047	C1262313
28085530	268	291	causative fungal agents	T033	C0449411
28085530	301	303	RT	T061	C0022671
28085530	304	312	patients	T101	C0030705
28085530	325	338	retrospective	T080	C1514923
28085530	346	360	clinical study	T062	C0008972
28085530	399	401	RT	T061	C0022671
28085530	402	410	patients	T101	C0030705
28085530	412	425	Clinical data	T170	C1516606
28085530	435	442	patient	T101	C0030705
28085530	445	450	donor	T098	C0040288
28085530	451	463	demographics	T090	C0011298
28085530	482	491	infection	T046	C3714514
28085530	493	505	risk factors	T033	C0035648
28085530	510	524	graft function	T046	C0877382
28085530	537	553	serum creatinine	T059	C0201976
28085530	555	558	SCr	T059	C0201976
28085530	573	576	IFI	T047	C1262313
28085530	590	612	bronchoalveolar lavage	T061	C1535502
28085530	614	617	BAL	T061	C1535502
28085530	620	625	blood	T031	C0005767
28085530	627	633	tissue	T024	C0040300
28085530	639	657	wound swab samples	T031	C0438733
28085530	674	693	mycological methods	T059	C0085127
28085530	695	698	IFI	T047	C1262313
28085530	704	713	diagnosed	T033	C0011900
28085530	728	736	patients	T101	C0030705
28085530	740	764	triple immunosuppression	T061	C0021079
28085530	773	778	males	T032	C0086582
28085530	793	801	mean age	T033	C1834001
28085530	854	856	RT	T061	C0022671
28085530	858	877	Aspergillus species	T004	C0004034
28085530	899	902	BAL	T061	C1535502
28085530	908	914	tissue	T024	C0040300
28085530	924	938	wound specimen	T031	C0438733
28085530	966	971	fatal	T080	C1302234
28085530	990	995	graft	T024	C0332835
28085530	1002	1018	Candida albicans	T004	C0006837
28085530	1031	1034	BAL	T061	C1535502
28085530	1041	1046	blood	T031	C0005767
28085530	1052	1062	wound swab	T031	C0438733
28085530	1072	1088	tissue specimens	T024	C1292533
28085530	1108	1113	fatal	T080	C1302234
28085530	1126	1131	graft	T024	C0332835
28085530	1145	1150	mucor	T004	C0026716
28085530	1154	1157	BAL	T061	C1535502
28085530	1168	1173	fatal	T080	C1302234
28085530	1181	1189	patients	T101	C0030705
28085530	1195	1203	diabetic	T033	C0241863
28085530	1223	1248	cytomegalovirus infection	T047	C0010823
28085530	1262	1275	anti-rejected	T061	C0021079
28085530	1277	1280	IFI	T047	C1262313
28085530	1311	1320	morbidity	T081	C0026538
28085530	1325	1334	mortality	T081	C0178686
28085530	1338	1340	RT	T061	C0022671
28085530	1341	1349	patients	T101	C0030705
28085530	1351	1375	Triple immunosuppression	T061	C0021079
28085530	1377	1403	broad spectrum antibiotics	T195	C0003232
28085530	1414	1419	weeks	T079	C0439230
28085530	1421	1429	diabetes	T047	C0011847
28085530	1434	1454	superadded infection	T047	C0038826
28085530	1465	1470	risks	T078	C0035647
28085530	1481	1489	patients	T101	C0030705
28085530	1509	1518	diagnosis	T033	C0011900
28085530	1578	1587	prognosis	T058	C0033325

28274609|t|Tongxinluo improves cognition by decreasing β-amyloid in spontaneous hypertensive rats
28274609|a|β-Amyloid (Aβ) accumulation in the brain is the major pathophysiology of Alzheimer disease (AD). Hypertension is a risk factor for AD by promoting Aβ deposition. Traditional Chinese medicinal compound tongxinluo (TXL) can improve blood circulation and endothelium -dependent vasodilation. This study investigates the effects of TXL on cognition and Aβ using spontaneously hypertensive rats (SHRs). TXL was intragastrically administered to SHRs at low-dose, mid- dose and high-dose for 15, 30 or 60 days. Cognition was evaluated with a Morris Water Maze (MWM). Aβ in the brain was detected by western blot, ELISA and Thioflavin-S staining. Western blot and RT-PCR were employed to exam the expression of receptor for advanced glycation end products (RAGE), low-density lipoprotein receptor-related protein-1 (LRP-1) and amyloid precursor protein (APP). After TXL treatment for 60 days, compared with the vehicle, the number of crossed platform and the time spent in the target quadrant increased in parallel with the increasing length of treatment in MWM. Moreover, the Aβ in the hippocampus significantly decreased compared to the vehicle group, both in western blot and ELISA. Additionally, TXL reduced RAGE expression in a dose - and time -depended manner, but LRP-1 expression had no difference between TXL groups and vehicle groups. Furthermore, the β-secretase expression was significantly decreased compared to the vehicle group, but APP expression had no difference. In conclusion, TXL improved cognition and decreased Aβ in SHRs in a dose - and time -dependent manner, the underlying mechanism may involved in inhibiting RAGE and β-secretase expression.
28274609	0	10	Tongxinluo	T123	C1742872
28274609	11	19	improves	T033	C0184511
28274609	20	29	cognition	T041	C0009240
28274609	33	43	decreasing	T033	C0442797
28274609	44	53	β-amyloid	T116	C3484390
28274609	57	86	spontaneous hypertensive rats	T015	C0034705
28274609	87	96	β-Amyloid	T116	C3484390
28274609	98	100	Aβ	T116	C3484390
28274609	102	114	accumulation	T033	C4055506
28274609	122	127	brain	T023	C0006104
28274609	141	156	pathophysiology	T169	C0031847
28274609	160	177	Alzheimer disease	T047	C0002395
28274609	179	181	AD	T047	C0002395
28274609	184	196	Hypertension	T047	C0020538
28274609	202	213	risk factor	T033	C0035648
28274609	218	220	AD	T047	C0002395
28274609	224	233	promoting	T052	C0033414
28274609	234	236	Aβ	T116	C3484390
28274609	237	247	deposition	T169	C0333562
28274609	249	278	Traditional Chinese medicinal	T091	C0025124
28274609	279	287	compound	T121	C0013229
28274609	288	298	tongxinluo	T123	C1742872
28274609	300	303	TXL	T123	C1742872
28274609	317	334	blood circulation	T039	C0005775
28274609	339	350	endothelium	T024	C0014257
28274609	362	374	vasodilation	T042	C0042401
28274609	381	386	study	T062	C2603343
28274609	387	399	investigates	T169	C1292732
28274609	404	414	effects of	T080	C1704420
28274609	415	418	TXL	T123	C1742872
28274609	422	431	cognition	T041	C0009240
28274609	436	438	Aβ	T116	C3484390
28274609	445	476	spontaneously hypertensive rats	T015	C0034705
28274609	478	482	SHRs	T015	C0034705
28274609	485	488	TXL	T123	C1742872
28274609	510	522	administered	T169	C1521801
28274609	526	530	SHRs	T015	C0034705
28274609	534	542	low-dose	T081	C0445550
28274609	549	553	dose	T081	C0178602
28274609	558	567	high-dose	T081	C0444956
28274609	585	589	days	T079	C0439228
28274609	591	600	Cognition	T041	C0009240
28274609	605	614	evaluated	T058	C0220825
28274609	622	639	Morris Water Maze	T059	C0022885
28274609	641	644	MWM	T059	C0022885
28274609	647	649	Aβ	T116	C3484390
28274609	657	662	brain	T023	C0006104
28274609	667	675	detected	T033	C0442726
28274609	679	691	western blot	T059	C0949466
28274609	693	698	ELISA	T059	C0014441
28274609	703	715	Thioflavin-S	T109,T130	C0952039
28274609	716	724	staining	T059	C0487602
28274609	726	738	Western blot	T059	C0949466
28274609	743	749	RT-PCR	T063	C0599161
28274609	776	786	expression	T045	C0597360
28274609	790	834	receptor for advanced glycation end products	T116,T192	C0101725
28274609	836	840	RAGE	T116,T192	C0101725
28274609	843	893	low-density lipoprotein receptor-related protein-1	T116,T192	C0051300
28274609	895	900	LRP-1	T116,T192	C0051300
28274609	906	931	amyloid precursor protein	T116	C0085151
28274609	933	936	APP	T116	C0085151
28274609	945	948	TXL	T123	C1742872
28274609	949	958	treatment	T169	C1522326
28274609	966	970	days	T079	C0439228
28274609	1103	1120	increasing length	T033	C0425939
28274609	1124	1133	treatment	T169	C1522326
28274609	1137	1140	MWM	T059	C0022885
28274609	1156	1158	Aβ	T116	C3484390
28274609	1166	1177	hippocampus	T023	C0019564
28274609	1192	1201	decreased	T081	C0205216
28274609	1241	1253	western blot	T059	C0949466
28274609	1258	1263	ELISA	T059	C0014441
28274609	1279	1282	TXL	T123	C1742872
28274609	1291	1295	RAGE	T116,T192	C0101725
28274609	1296	1306	expression	T045	C1171362
28274609	1312	1316	dose	T081	C0178602
28274609	1323	1327	time	T079	C0040223
28274609	1350	1355	LRP-1	T116,T192	C0051300
28274609	1356	1366	expression	T045	C1171362
28274609	1371	1384	no difference	T033	C3842396
28274609	1393	1396	TXL	T123	C1742872
28274609	1441	1452	β-secretase	T116,T126	C1454853
28274609	1453	1463	expression	T045	C1171362
28274609	1482	1491	decreased	T081	C0205216
28274609	1527	1530	APP	T116	C0085151
28274609	1531	1541	expression	T045	C1171362
28274609	1546	1559	no difference	T033	C3842396
28274609	1576	1579	TXL	T123	C1742872
28274609	1589	1598	cognition	T041	C0009240
28274609	1603	1612	decreased	T081	C0205216
28274609	1613	1615	Aβ	T116	C3484390
28274609	1619	1623	SHRs	T015	C0034705
28274609	1629	1633	dose	T081	C0178602
28274609	1640	1644	time	T079	C0040223
28274609	1679	1688	mechanism	T169	C0441712
28274609	1705	1715	inhibiting	T052	C3463820
28274609	1716	1720	RAGE	T116,T192	C0101725
28274609	1725	1736	β-secretase	T116,T126	C1454853
28274609	1737	1747	expression	T045	C1171362

28458643|t|Grammatical Language Impairment in Autism Spectrum Disorder: Exploring Language Phenotypes Beyond Standardized Testing
28458643|a|Linguistic and cognitive abilities manifest huge heterogeneity in children with autism spectrum disorder (ASD). Some children present with commensurate language and cognitive abilities, while others show more variable patterns of development. Using spontaneous language samples, we investigate the presence and extent of grammatical language impairment in a heterogeneous sample of children with ASD. Findings from our sample suggest that children with ASD can be categorized into three meaningful subgroups: those with normal language, those with marked difficulty in grammatical production but relatively intact vocabulary, and those with more globally low language abilities. These findings support the use of sensitive assessment measures to evaluate language in autism, as well as the utility of within- disorder comparisons, in order to comprehensively define the various cognitive and linguistic phenotypes in this heterogeneous disorder.
28458643	0	11	Grammatical	T090	C0870615
28458643	12	31	Language Impairment	T048	C0023015
28458643	35	59	Autism Spectrum Disorder	T048	C1510586
28458643	71	79	Language	T171	C0023008
28458643	80	90	Phenotypes	T078	C0441833
28458643	98	118	Standardized Testing	T170	C0237892
28458643	119	129	Linguistic	T090	C0023741
28458643	134	153	cognitive abilities	T041	C0392334
28458643	168	181	heterogeneity	T080	C0019409
28458643	185	193	children	T100	C0008059
28458643	199	223	autism spectrum disorder	T048	C1510586
28458643	225	228	ASD	T048	C1510586
28458643	236	244	children	T100	C0008059
28458643	271	279	language	T171	C0023008
28458643	284	303	cognitive abilities	T041	C0392334
28458643	349	360	development	T169	C1527148
28458643	380	388	language	T171	C0023008
28458643	440	451	grammatical	T090	C0870615
28458643	452	471	language impairment	T048	C0023015
28458643	501	509	children	T100	C0008059
28458643	515	518	ASD	T048	C1510586
28458643	520	528	Findings	T033	C0243095
28458643	558	566	children	T100	C0008059
28458643	572	575	ASD	T048	C1510586
28458643	617	626	subgroups	T185	C1515021
28458643	646	654	language	T171	C0023008
28458643	674	710	difficulty in grammatical production	T033	C0566045
28458643	726	732	intact	T080	C0205266
28458643	733	743	vocabulary	T170	C0042926
28458643	774	777	low	T080	C0205251
28458643	778	796	language abilities	T041	C1145677
28458643	804	812	findings	T033	C0243095
28458643	874	882	language	T171	C0023008
28458643	886	892	autism	T048	C0004352
28458643	928	936	disorder	T047	C0012634
28458643	997	1006	cognitive	T169	C1516691
28458643	1011	1021	linguistic	T090	C0023741
28458643	1022	1032	phenotypes	T078	C0441833
28458643	1041	1063	heterogeneous disorder	T033	C1858576

28322190|t|Activity patterns of serotonin neurons underlying cognitive flexibility
28322190|a|Serotonin is implicated in mood and affective disorders. However, growing evidence suggests that a core endogenous role is to promote flexible adaptation to changes in the causal structure of the environment, through behavioral inhibition and enhanced plasticity. We used long-term photometric recordings in mice to study a population of dorsal raphe serotonin neurons, whose activity we could link to normal reversal learning using pharmacogenetics. We found that these neurons are activated by both positive and negative prediction errors, and thus report signals similar to those proposed to promote learning in conditions of uncertainty. Furthermore, by comparing the cue responses of serotonin and dopamine neurons, we found differences in learning rates that could explain the importance of serotonin in inhibiting perseverative responding. Our findings show how the activity patterns of serotonin neurons support a role in cognitive flexibility, and suggest a revised model of dopamine - serotonin opponency with potential clinical implications.
28322190	0	17	Activity patterns	T043	C0007613
28322190	21	38	serotonin neurons	T025	C3178783
28322190	50	71	cognitive flexibility	T041	C2370892
28322190	72	81	Serotonin	T109,T123	C0036751
28322190	99	103	mood	T041	C0026516
28322190	108	127	affective disorders	T048	C0525045
28322190	146	154	evidence	T078	C3887511
28322190	155	163	suggests	T078	C1705535
28322190	171	175	core	T082	C0444669
28322190	176	186	endogenous	T169	C0205227
28322190	187	191	role	T077	C1705810
28322190	198	205	promote	T052	C0033414
28322190	206	214	flexible	T080	C0443220
28322190	215	225	adaptation	T038	C0392673
28322190	229	236	changes	T169	C0392747
28322190	251	260	structure	T082	C0678594
28322190	268	279	environment	T082	C0014406
28322190	289	299	behavioral	T053	C0004927
28322190	300	310	inhibition	T052	C3463820
28322190	315	323	enhanced	T052	C2349975
28322190	324	334	plasticity	T042	C0027880
28322190	339	343	used	T169	C1524063
28322190	344	353	long-term	T079	C0443252
28322190	354	376	photometric recordings	T060	C0430022
28322190	380	384	mice	T015	C0025929
28322190	388	393	study	T062	C2603343
28322190	396	406	population	T081	C0237753
28322190	410	422	dorsal raphe	T023	C0175392
28322190	423	440	serotonin neurons	T025	C3178783
28322190	448	456	activity	T043	C0007613
28322190	474	480	normal	T080	C0205307
28322190	481	498	reversal learning	T062	C0035375
28322190	499	504	using	T169	C1524063
28322190	505	521	pharmacogenetics	T091	C0031325
28322190	526	531	found	T033	C0150312
28322190	543	550	neurons	T025	C0027882
28322190	555	564	activated	T169	C1515877
28322190	573	581	positive	T033	C1446409
28322190	586	594	negative	T033	C0205160
28322190	595	605	prediction	T078	C0681842
28322190	606	612	errors	T080	C0743559
28322190	630	637	signals	T043	C0037083
28322190	638	645	similar	T080	C2348205
28322190	655	663	proposed	T078	C1705535
28322190	667	674	promote	T052	C0033414
28322190	675	683	learning	T041	C0023185
28322190	687	697	conditions	T080	C0348080
28322190	701	712	uncertainty	T033	C0087130
28322190	730	739	comparing	T052	C1707455
28322190	744	757	cue responses	UnknownType	C0814079
28322190	761	770	serotonin	T025	C3178783
28322190	775	791	dopamine neurons	T025	C1512035
28322190	796	801	found	T033	C0150312
28322190	802	813	differences	T080	C1705242
28322190	817	831	learning rates	T041	C0870792
28322190	855	865	importance	T080	C3898777
28322190	869	878	serotonin	T109,T123	C0036751
28322190	882	892	inhibiting	T052	C3463820
28322190	893	917	perseverative responding	UnknownType	C0679047
28322190	923	931	findings	T033	C0243095
28322190	945	962	activity patterns	T043	C0007613
28322190	966	983	serotonin neurons	T025	C3178783
28322190	994	998	role	T077	C1705810
28322190	1002	1023	cognitive flexibility	T041	C2370892
28322190	1029	1036	suggest	T078	C1705535
28322190	1039	1046	revised	T169	C1947976
28322190	1047	1052	model	T170	C3161035
28322190	1056	1064	dopamine	T109,T121,T123	C0013030
28322190	1067	1076	serotonin	T109,T123	C0036751
28322190	1092	1101	potential	T080	C3245505
28322190	1102	1110	clinical	T080	C0205210
28322190	1111	1123	implications	T078	C1705535

27617056|t|An improved high-quality draft genome sequence of Carnobacterium inhibens subsp. inhibens strain K1(T)
27617056|a|Despite their ubiquity and their involvement in food spoilage, the genus Carnobacterium remains rather sparsely characterized at the genome level. Carnobacterium inhibens K1(T) is a member of the Carnobacteriaceae family within the class Bacilli. This strain is a Gram-positive, rod-shaped bacterium isolated from the intestine of an Atlantic salmon. The present study determined the genome sequence and annotation of Carnobacterium inhibens K1(T). The genome comprised 2,748,608 bp with a G + C content of 34.85 %, which included 2621 protein-coding genes and 116 RNA genes. The strain contained five contigs corresponding to presumptive plasmids of sizes: 19,036; 24,250; 26,581; 65,272; and 65,904 bp.
27617056	31	37	genome	T028	C0017428
27617056	38	46	sequence	T086	C0004793
27617056	50	102	Carnobacterium inhibens subsp. inhibens strain K1(T)	T007	C1482078
27617056	136	147	involvement	T169	C1314939
27617056	151	164	food spoilage	T033	C0518423
27617056	170	175	genus	T185	C1708235
27617056	176	190	Carnobacterium	T007	C0996228
27617056	236	242	genome	T028	C0017428
27617056	250	279	Carnobacterium inhibens K1(T)	T007	C1482078
27617056	299	316	Carnobacteriaceae	T007	C1210583
27617056	317	323	family	T099	C0015576
27617056	335	348	class Bacilli	T007	C1040746
27617056	355	361	strain	T001	C1518614
27617056	355	361	strain	T001	C1518614
27617056	367	380	Gram-positive	T007	C0018154
27617056	382	402	rod-shaped bacterium	T007	C1563018
27617056	403	411	isolated	T169	C0205409
27617056	421	430	intestine	T023	C0021853
27617056	437	452	Atlantic salmon	T013	C0327949
27617056	458	471	present study	T062	C2603343
27617056	472	482	determined	T078	C0205258
27617056	487	493	genome	T028	C0017428
27617056	494	502	sequence	T086	C0004793
27617056	507	517	annotation	T063	C2936606
27617056	521	550	Carnobacterium inhibens K1(T)	T007	C1482078
27617056	556	562	genome	T028	C0017428
27617056	583	585	bp	T114	C0028630
27617056	593	606	G + C content	T081	C1135899
27617056	639	659	protein-coding genes	T028	C3839127
27617056	668	677	RNA genes	T028	C0035899
27617056	683	689	strain	T001	C1518614
27617056	705	712	contigs	T082	C1511491
27617056	730	741	presumptive	T080	C3640893
27617056	742	750	plasmids	T114,T123	C0032136
27617056	754	759	sizes	T082	C0456389
27617056	804	806	bp	T114	C0028630

27609916|t|Draft Genome Sequences of 15 Isolates of Listeria monocytogenes Serotype 1/2a, Subgroup ST204
27609916|a|Listeria monocytogenes sequence type 204 (ST204) strains have been isolated from a range of food, environmental, and clinical sources in Australia. This study describes the draft genome sequences of 15 isolates collected from meat and dairy associated sources.
27609916	0	22	Draft Genome Sequences	T085	C2348746
27609916	29	37	Isolates	T123	C3494793
27609916	41	77	Listeria monocytogenes Serotype 1/2a	T007	C3472320
27609916	79	87	Subgroup	T185	C1515021
27609916	88	93	ST204	T001	C1518614
27609916	94	116	Listeria monocytogenes	T007	C0023861
27609916	117	150	sequence type 204 (ST204) strains	T001	C1518614
27609916	161	169	isolated	T169	C0205409
27609916	177	190	range of food	T168	C0016452
27609916	192	205	environmental	T082	C0014406
27609916	211	219	clinical	T080	C0205210
27609916	220	227	sources	T033	C0449416
27609916	231	240	Australia	T083	C0004340
27609916	267	289	draft genome sequences	T085	C2348746
27609916	320	324	meat	T168	C0025017
27609916	329	353	dairy associated sources	T168	C0010947

28004744|t|Mitoxantrone and Analogues Bind and Stabilize i-Motif Forming DNA Sequences
28004744|a|There are hundreds of ligands which can interact with G-quadruplex DNA, yet very few which target i-motif. To appreciate an understanding between the dynamics between these structures and how they can be affected by intervention with small molecule ligands, more i-motif binding compounds are required. Herein we describe how the drug mitoxantrone can bind, induce folding of and stabilise i-motif forming DNA sequences, even at physiological pH. Additionally, mitoxantrone was found to bind i-motif forming sequences preferentially over double helical DNA. We also describe the stabilisation properties of analogues of mitoxantrone. This offers a new family of ligands with potential for use in experiments into the structure and function of i-motif forming DNA sequences.
28004744	0	12	Mitoxantrone	T109,T121	C0026259
28004744	17	26	Analogues	T104	C0002776
28004744	27	31	Bind	T039	C0678749
28004744	46	75	i-Motif Forming DNA Sequences	T086	C3178798
28004744	98	105	ligands	T103	C0023688
28004744	116	124	interact	T044	C0687133
28004744	130	146	G-quadruplex DNA	T086	C1956090
28004744	174	181	i-motif	T086	C3178798
28004744	226	234	dynamics	T070	C3826426
28004744	249	259	structures	T114	C1511699
28004744	310	332	small molecule ligands	T103	C0023688
28004744	339	354	i-motif binding	T045	C1148673
28004744	406	423	drug mitoxantrone	T109,T121	C0026259
28004744	428	432	bind	T039	C0678749
28004744	434	440	induce	T169	C0205263
28004744	441	448	folding	T044	C1511668
28004744	466	495	i-motif forming DNA sequences	T086	C0162326
28004744	505	521	physiological pH	T081	C0020283
28004744	537	549	mitoxantrone	T109,T121	C0026259
28004744	563	567	bind	T039	C0678749
28004744	568	593	i-motif forming sequences	T086	C3178798
28004744	614	632	double helical DNA	T114,T123	C0012854
28004744	683	692	analogues	T104	C0002776
28004744	696	708	mitoxantrone	T109,T121	C0026259
28004744	738	745	ligands	T103	C0023688
28004744	793	802	structure	T114	C1511699
28004744	807	815	function	T044	C1148560
28004744	819	848	i-motif forming DNA sequences	T086	C3178798

28479016|t|The impact of rate of weight loss on body composition and compensatory mechanisms during weight reduction: A randomized control trial
28479016|a|Rapid weight loss (WL) has been associated with a larger loss of fat free mass and a disproportional reduction in resting metabolic rate (RMR), but the evidence is inconclusive. We aimed to evaluate the impact of WL rate on body composition and compensatory mechanisms activated with WL (reduced RMR, increased exercise efficiency (ExEff) and appetite), both during negative and neutral energy balance (EB). Thirty-five participants with obesity were randomized to lose a similar weight rapidly (4 weeks) or gradually (8 weeks), and afterwards to maintain it (4 weeks). Body weight and composition, RMR, ExEff (10, 25 and 50 W), appetite feelings and appetite-regulating hormones (active ghrelin, cholecystokinin, total peptide YY (PYY), active glucagon-like peptide-1 and insulin), in fasting and every 30 min up to 2.5 h, were measured at baseline and after each phase. Changes in body weight (≈9%) and composition were similar in both groups. With WL, RMR decreased and ExEff at 10 W increased significantly in the rapid WL group only. However, fasting hunger increased significantly with gradual WL only, while fasting and postprandial prospective food consumption, and postprandial hunger decreased (and postprandial fullness increased) significantly with rapid WL only. Basal total PYY, and basal and postprandial insulin decreased significantly, and similarly in both groups. After weight stabilization and no ketosis no differences between groups were found. Despite differences while under negative EB, WL rate does not seem to have a significant impact on body composition or on compensatory mechanisms, once EB is reestablished. NCT01912742 (the study was registered in clinicaltrial.gov).
28479016	4	10	impact	T080	C4049986
28479016	14	18	rate	T081	C1521828
28479016	22	33	weight loss	T033	C1262477
28479016	37	53	body composition	T032	C0005885
28479016	58	70	compensatory	T169	C0231186
28479016	71	81	mechanisms	T169	C0441712
28479016	89	105	weight reduction	T033	C1262477
28479016	109	133	randomized control trial	T062	C0206035
28479016	134	139	Rapid	T080	C0456962
28479016	140	151	weight loss	T033	C1262477
28479016	153	155	WL	T033	C1262477
28479016	166	181	associated with	T080	C0332281
28479016	191	195	loss	T081	C1517945
28479016	199	212	fat free mass	T033	C0424679
28479016	219	244	disproportional reduction	T081	C0547047
28479016	248	270	resting metabolic rate	T040	C4082350
28479016	272	275	RMR	T040	C4082350
28479016	337	343	impact	T080	C4049986
28479016	347	349	WL	T033	C1262477
28479016	350	354	rate	T081	C1521828
28479016	358	374	body composition	T032	C0005885
28479016	379	391	compensatory	T169	C0231186
28479016	392	402	mechanisms	T169	C0441712
28479016	418	420	WL	T033	C1262477
28479016	422	429	reduced	T080	C0392756
28479016	430	433	RMR	T040	C4082350
28479016	435	444	increased	T081	C0205217
28479016	445	453	exercise	T056	C0015259
28479016	454	464	efficiency	T081	C0013682
28479016	466	471	ExEff	T081	C0013682
28479016	477	485	appetite	T040	C0003618
28479016	500	508	negative	T033	C0205160
28479016	513	520	neutral	T080	C0205556
28479016	521	535	energy balance	T040	C0597987
28479016	537	539	EB	T040	C0597987
28479016	554	566	participants	T098	C0679646
28479016	585	595	randomized	T062	C0034656
28479016	599	620	lose a similar weight	T033	C1262477
28479016	621	628	rapidly	T080	C0456962
28479016	632	637	weeks	T079	C0439230
28479016	642	651	gradually	T080	C0439833
28479016	655	660	weeks	T079	C0439230
28479016	696	701	weeks	T079	C0439230
28479016	704	715	Body weight	T032	C0005910
28479016	720	731	composition	T032	C0005885
28479016	733	736	RMR	T040	C4082350
28479016	738	743	ExEff	T081	C0013682
28479016	763	771	appetite	T040	C0003618
28479016	772	780	feelings	T041	C1527305
28479016	785	813	appetite-regulating hormones	T116,T125	C0916615
28479016	815	829	active ghrelin	T116,T125	C0911014
28479016	831	846	cholecystokinin	T116,T121,T125	C0008328
28479016	848	864	total peptide YY	T116,T125	C0070358
28479016	866	869	PYY	T116,T125	C0070358
28479016	872	902	active glucagon-like peptide-1	T116	C0061355
28479016	907	914	insulin	T116,T121,T125	C0021641
28479016	920	927	fasting	T033	C0015663
28479016	975	983	baseline	T081	C1442488
28479016	999	1004	phase	T079	C0205390
28479016	1006	1013	Changes	T169	C0392747
28479016	1017	1028	body weight	T032	C0005910
28479016	1039	1050	composition	T032	C0005885
28479016	1072	1078	groups	T078	C0441833
28479016	1085	1087	WL	T033	C1262477
28479016	1089	1092	RMR	T040	C4082350
28479016	1093	1102	decreased	T081	C0205216
28479016	1107	1112	ExEff	T081	C0013682
28479016	1121	1130	increased	T081	C0205217
28479016	1152	1157	rapid	T080	C0456962
28479016	1158	1160	WL	T033	C1262477
28479016	1161	1166	group	T078	C0441833
28479016	1182	1189	fasting	T033	C0015663
28479016	1190	1196	hunger	T184	C0020175
28479016	1197	1206	increased	T081	C0205217
28479016	1226	1233	gradual	T080	C0439833
28479016	1234	1236	WL	T033	C1262477
28479016	1249	1256	fasting	T033	C0015663
28479016	1261	1273	postprandial	T079	C0376674
28479016	1274	1302	prospective food consumption	T052	C2983605
28479016	1308	1320	postprandial	T079	C0376674
28479016	1321	1327	hunger	T184	C0020175
28479016	1328	1337	decreased	T081	C0205216
28479016	1343	1355	postprandial	T079	C0376674
28479016	1365	1374	increased	T081	C0205217
28479016	1395	1400	rapid	T080	C0456962
28479016	1401	1403	WL	T033	C1262477
28479016	1410	1415	Basal	T082	C0205112
28479016	1416	1425	total PYY	T116,T125	C0070358
28479016	1431	1436	basal	T082	C0205112
28479016	1441	1453	postprandial	T079	C0376674
28479016	1454	1461	insulin	T116,T121,T125	C0021641
28479016	1462	1471	decreased	T081	C0205216
28479016	1509	1515	groups	T078	C0441833
28479016	1523	1529	weight	T032	C0005910
28479016	1530	1543	stabilization	T052	C0441655
28479016	1548	1558	no ketosis	T033	C2749744
28479016	1559	1573	no differences	T033	C3842396
28479016	1582	1588	groups	T078	C0441833
28479016	1609	1620	differences	T080	C1705242
28479016	1633	1641	negative	T033	C0205160
28479016	1642	1644	EB	T040	C0597987
28479016	1646	1648	WL	T033	C1262477
28479016	1649	1653	rate	T081	C1521828
28479016	1690	1696	impact	T080	C4049986
28479016	1700	1716	body composition	T032	C0005885
28479016	1723	1735	compensatory	T169	C0231186
28479016	1736	1746	mechanisms	T169	C0441712
28479016	1753	1755	EB	T040	C0597987

28295125|t|Treatment of Locked Posterior Shoulder Dislocation With Bone Defect
28295125|a|Locked posterior shoulder dislocation is an uncommon condition and is associated with a reverse Hill-Sachs lesion in 50% of cases. The condition is likely to occur in cases of violent trauma, seizures, or electric shock. Unrecognized dislocation with humeral head fracture affects joint function and humeral head vascularity and may lead to chronic instability, osteonecrosis, and osteoarthritis. A group of 12 patients, including 10 men and 2 women, with neglected locked posterior shoulder dislocation with a reverse Hill-Sachs lesion were treated with the modified McLaughlin technique. The added bone graft from the iliac crest was impacted in the defect and fixed with screws. Mean follow-up was 30 months (range, 24-48 months). The range of forward flexion was 150˚ to 175˚ (average, 165˚), external rotation ranged from 60˚ to 80˚ (average, 75˚), internal rotation ranged from 40˚ to 60˚ (average, 50˚), and average abduction was 150˚ (range, 145˚-160˚). The modified University of California Los Angeles (UCLA) scoring system was used for postoperative clinical evaluation. Total UCLA scores immediately postoperatively ranged from 22 to 28 points (average, 26.5 points) and averaged 30 points (range, 28-33 points) at last follow-up. No recurrence of dislocation occurred during the follow-up period. Of the study patients, 10 returned to their previous job and 2 modified their manual work. The modified McLaughlin technique with added iliac crest bone graft to fill the defect and prevent humeral head deformity is a successful technique for the treatment of patients with chronic locked posterior shoulder dislocation. [Orthopedics. 201x; xx(x):xx-xx.].
28295125	0	9	Treatment	T061	C0087111
28295125	13	50	Locked Posterior Shoulder Dislocation	T037	C0347739
28295125	56	60	Bone	T023	C0262950
28295125	61	67	Defect	T169	C1457869
28295125	68	105	Locked posterior shoulder dislocation	T037	C0347739
28295125	121	130	condition	T080	C0348080
28295125	138	153	associated with	T080	C0332281
28295125	156	181	reverse Hill-Sachs lesion	T020	C0410329
28295125	192	197	cases	T077	C1706256
28295125	203	212	condition	T080	C0348080
28295125	235	240	cases	T077	C1706256
28295125	244	258	violent trauma	T037	C3714660
28295125	260	268	seizures	T184	C0036572
28295125	273	287	electric shock	T037	C0013781
28295125	289	313	Unrecognized dislocation	T037	C0012691
28295125	319	340	humeral head fracture	T037	C0281849
28295125	349	363	joint function	T042	C1535551
28295125	368	392	humeral head vascularity	T042	C1254358
28295125	430	443	osteonecrosis	T046	C0029445
28295125	449	463	osteoarthritis	T047	C0029408
28295125	467	472	group	T078	C0441833
28295125	479	487	patients	T101	C0030705
28295125	502	505	men	T098	C0025266
28295125	512	517	women	T098	C0043210
28295125	534	571	locked posterior shoulder dislocation	T037	C0347739
28295125	579	604	reverse Hill-Sachs lesion	T020	C0410329
28295125	610	617	treated	T169	C1522326
28295125	627	635	modified	T169	C0392747
28295125	636	656	McLaughlin technique	T061	C0087111
28295125	668	678	bone graft	T122	C0181075
28295125	688	699	iliac crest	T023	C0223651
28295125	720	726	defect	T169	C1457869
28295125	731	736	fixed	T067	C3714578
28295125	742	748	screws	T074	C0005975
28295125	750	764	Mean follow-up	T058	C1522577
28295125	772	778	months	T079	C0439231
28295125	793	799	months	T079	C0439231
28295125	815	822	forward	T082	C0439780
28295125	823	830	flexion	T042	C0231452
28295125	865	882	external rotation	T169	C0231462
28295125	922	939	internal rotation	T169	C0231459
28295125	983	1000	average abduction	T039	C0231456
28295125	1034	1042	modified	T169	C0392747
28295125	1043	1079	University of California Los Angeles	T092	C1561598
28295125	1081	1085	UCLA	T092	C1561598
28295125	1087	1101	scoring system	T170	C0451542
28295125	1115	1148	postoperative clinical evaluation	T058	C4084924
28295125	1150	1167	Total UCLA scores	T081	C0449820
28295125	1295	1299	last	T080	C1517741
28295125	1300	1309	follow-up	T058	C1522577
28295125	1311	1313	No	T033	C1513916
28295125	1314	1324	recurrence	T067	C0034897
28295125	1328	1339	dislocation	T037	C0012691
28295125	1360	1369	follow-up	T058	C1522577
28295125	1370	1376	period	T079	C1948053
28295125	1391	1399	patients	T101	C0030705
28295125	1431	1434	job	T090	C0028811
28295125	1441	1449	modified	T169	C0392747
28295125	1456	1462	manual	T169	C0175674
28295125	1463	1467	work	T057	C0043227
28295125	1473	1481	modified	T169	C0392747
28295125	1482	1502	McLaughlin technique	T061	C0087111
28295125	1514	1525	iliac crest	T023	C0223651
28295125	1526	1536	bone graft	T122	C0181075
28295125	1549	1555	defect	T169	C1457869
28295125	1560	1567	prevent	T080	C2700409
28295125	1568	1590	humeral head deformity	T037	C0281849
28295125	1607	1616	technique	T169	C0449851
28295125	1625	1634	treatment	T061	C0087111
28295125	1638	1646	patients	T101	C0030705
28295125	1652	1697	chronic locked posterior shoulder dislocation	T037	C0347739

27330995|t|A comparative analysis of lncRNAs in prostate cancer exosomes and their parental cell lines
27330995|a|Prostate cancer is the second leading cancer in men world - wide. Due to its heterogeneous nature, a considerable amount of research effort has been dedicated in identifying effective clinical biomarkers with a focus on proteins, messenger RNA and microRNAs [1]. However, there is limited data on the role and expression of long noncoding RNAs (lncRNAs) in prostate cancer exosomes [2]. This array dataset which is linked to our publication describes the profiling of human lncRNAs in prostate cancer and their exosomes from five different cell lines [3]. From this dataset, we identified a list of statistically significant prostate cancer lncRNAs which are differentially expressed in the exosomes compared to their parent cell lines. This dataset has been deposited into Gene Expression Omnibus (GSE81034).
27330995	2	22	comparative analysis	T062	C0683941
27330995	26	33	lncRNAs	T114	C2982391
27330995	37	52	prostate cancer	T191	C0600139
27330995	53	61	exosomes	T026	C2350332
27330995	72	80	parental	T080	C0205556
27330995	81	91	cell lines	T025	C0007600
27330995	92	107	Prostate cancer	T191	C0600139
27330995	115	121	second	T081	C0205436
27330995	122	129	leading	T169	C1522538
27330995	130	136	cancer	T191	C0007097
27330995	140	143	men	T098	C0025266
27330995	144	149	world	T098	C2700280
27330995	152	156	wide	T082	C0332464
27330995	158	164	Due to	T169	C0678226
27330995	169	182	heterogeneous	T080	C0019409
27330995	183	189	nature	T078	C0349590
27330995	206	212	amount	T081	C1265611
27330995	216	224	research	T062	C0035168
27330995	225	231	effort	T040	C0015264
27330995	254	265	identifying	T080	C0205396
27330995	266	275	effective	T080	C1704419
27330995	276	284	clinical	T080	C0205210
27330995	285	295	biomarkers	T201	C0005516
27330995	303	308	focus	T169	C1285542
27330995	312	320	proteins	T116,T123	C0033684
27330995	322	335	messenger RNA	T114,T123	C0035696
27330995	340	349	microRNAs	T114,T123	C1101610
27330995	373	380	limited	T169	C0439801
27330995	381	385	data	T078	C1511726
27330995	393	397	role	T077	C1705810
27330995	402	412	expression	T045	C0017262
27330995	416	435	long noncoding RNAs	T114	C2982391
27330995	437	444	lncRNAs	T114	C2982391
27330995	449	464	prostate cancer	T191	C0600139
27330995	465	473	exosomes	T026	C2350332
27330995	484	489	array	T082	C1510941
27330995	490	497	dataset	T170	C0150098
27330995	521	532	publication	T073,T170	C0034036
27330995	547	556	profiling	T169	C2003903
27330995	560	565	human	T016	C0086418
27330995	566	573	lncRNAs	T114	C2982391
27330995	577	592	prostate cancer	T191	C0600139
27330995	603	611	exosomes	T026	C2350332
27330995	622	631	different	T080	C1705242
27330995	632	642	cell lines	T025	C0007600
27330995	658	665	dataset	T170	C0150098
27330995	670	680	identified	T080	C0205396
27330995	691	716	statistically significant	T081	C0237881
27330995	717	732	prostate cancer	T191	C0600139
27330995	733	740	lncRNAs	T114	C2982391
27330995	751	765	differentially	T080	C0443199
27330995	766	775	expressed	T045	C0017262
27330995	783	791	exosomes	T026	C2350332
27330995	792	800	compared	T052	C1707455
27330995	817	827	cell lines	T025	C0007600
27330995	834	841	dataset	T170	C0150098
27330995	851	860	deposited	T169	C0333562
27330995	866	889	Gene Expression Omnibus	T170	C0150098

27718023|t|Expression of caspase 3 in ovarian follicle cells of the lizard Podarcis sicula
27718023|a|In this study, our aim was to determine whether caspase 3 plays a role, during previtellogenesis, in the ovarian follicular epithelium of the lizard Podarcis sicula. We investigated the presence and localization of proform and active caspase 3 by enzyme assay, Western blotting and immunocytochemistry. In parallel, a fragment of caspase 3 was cloned for the first time in this species, sequenced and used for in situ hybridization to localize messengers and analysed by a phylogenetic survey to shed light on its homology with reptilian caspases. Results demonstrated that: (1) the follicle cells expressed a caspase of the 3/7 group and the mRNA for caspase 3 was transcribed in the stem phase and was completely translated during cell differentiation; (2) the proform protein was stored during the differentiated (nurse) stage and activated at the end of previtellogenesis provoking the degeneration of cells; (3) the predicted protein sequence, although partial, had a strong similarity with the known reptilian caspases 3. The epithelial cells of the ovarian follicle, therefore, do not employ caspase 3 during the nurse stage but, instead, prepare for apoptosis long before the process actually begins. The relevance of this strategy is discussed.
27718023	0	10	Expression	T045	C1171362
27718023	14	23	caspase 3	T116,T126	C0291573
27718023	27	43	ovarian follicle	T023	C0018120
27718023	44	49	cells	T025	C0007634
27718023	57	63	lizard	T014	C0023916
27718023	64	79	Podarcis sicula	T014	C1025381
27718023	128	137	caspase 3	T116,T126	C0291573
27718023	159	176	previtellogenesis	T042	C0042895
27718023	185	192	ovarian	T023	C0205065
27718023	193	214	follicular epithelium	T024	C0040300
27718023	222	228	lizard	T014	C0023916
27718023	229	244	Podarcis sicula	T014	C1025381
27718023	279	291	localization	T169	C0475264
27718023	314	323	caspase 3	T116,T126	C0291573
27718023	327	339	enzyme assay	T059	C2717977
27718023	341	357	Western blotting	T059,T063	C0005863
27718023	362	381	immunocytochemistry	T059	C0242349
27718023	398	406	fragment	T080	C1708096
27718023	410	419	caspase 3	T028	C1413132
27718023	424	430	cloned	T059,T063	C0598888
27718023	458	465	species	T185	C1705920
27718023	467	476	sequenced	T169	C1561491
27718023	490	511	in situ hybridization	T063	C0162788
27718023	515	523	localize	T082	C0392752
27718023	524	534	messengers	UnknownType	C0815028
27718023	553	572	phylogenetic survey	T062	C1519068
27718023	594	602	homology	T080	C2697616
27718023	608	617	reptilian	T014	C0035161
27718023	618	626	caspases	T116,T126	C0010656
27718023	663	671	follicle	T023	C1571705
27718023	672	677	cells	T025	C0007634
27718023	678	687	expressed	T045	C1171362
27718023	690	697	caspase	T116,T126	C0010656
27718023	723	727	mRNA	T114,T123	C0035696
27718023	732	741	caspase 3	T116,T126	C0291573
27718023	746	757	transcribed	T045	C0040649
27718023	765	775	stem phase	T079	C0205390
27718023	795	805	translated	T044	C0597295
27718023	813	833	cell differentiation	T043	C0007589
27718023	843	858	proform protein	T116,T123	C0033684
27718023	881	909	differentiated (nurse) stage	T080	C0205615
27718023	914	923	activated	T045	C0599177
27718023	938	955	previtellogenesis	T042	C0042895
27718023	970	991	degeneration of cells	T046	C0333467
27718023	1011	1027	protein sequence	T087	C0002518
27718023	1086	1095	reptilian	T014	C0035161
27718023	1096	1106	caspases 3	T116,T126	C0291573
27718023	1112	1128	epithelial cells	T025	C0014597
27718023	1136	1152	ovarian follicle	T023	C0018120
27718023	1179	1188	caspase 3	T116,T126	C0291573
27718023	1200	1211	nurse stage	T080	C0205615
27718023	1238	1247	apoptosis	T043	C0162638

27246120|t|Assessment of laparoscopic stomach preserving surgery with sentinel basin dissection versus standard gastrectomy with lymphadenectomy in early gastric cancer -A multicenter randomized phase III clinical trial (SENORITA trial) protocol
27246120|a|Along with the marked increase in early gastric cancer (EGC) in the Eastern countries, there has been an effort to adopt the sentinel node concept in EGC to preserve gastric function and reduce the occurrence of postoperative complications. Based on promising results from a previous quality control study, this prospective multicenter randomized controlled phase III clinical trial aims to elucidate the oncologic safety of laparoscopic stomach-preserving surgery with sentinel basin dissection (SBD) compared to a standard laparoscopic gastrectomy. This trial is an investigator-initiated, open-label, multicenter randomized controlled phase III trial with a non-inferiority design. Patients diagnosed with a single lesion of clinical stage T1N0M0 gastric adenocarcinoma, with a diameter of 3 cm or less are eligible for the present study. A total of 580 patients (290 per group) will be randomized to either laparoscopic stomach-preserving surgery with SBD or standard surgery. The primary end-point is 3-year disease-free survival (DFS) and the secondary endpoints include postoperative morbidity and mortality, quality of life, 5-year DFS, and overall survival. Qualified investigators who completed the prior quality control study are exclusively allowed to participate in this phase III clinical trial. The proposed trial is expected to verify whether laparoscopic stomach-preserving surgery with SBD achieves similar oncologic outcomes and improved quality of life compared to a standard gastrectomy in EGC patients. This study was registered at the NIH ClinicalTrial.gov database (NCT01804998) on March 4th, 2013.
27246120	0	10	Assessment	T058	C0220825
27246120	14	53	laparoscopic stomach preserving surgery	T061	C0812574
27246120	59	84	sentinel basin dissection	T061	C0242382
27246120	101	112	gastrectomy	T061	C0017118
27246120	118	133	lymphadenectomy	T061	C0024203
27246120	137	157	early gastric cancer	T191	C0349530
27246120	161	234	multicenter randomized phase III clinical trial (SENORITA trial) protocol	T062	C0282461
27246120	269	289	early gastric cancer	T191	C0349530
27246120	291	294	EGC	T191	C0349530
27246120	303	320	Eastern countries	T083	C0017446
27246120	360	373	sentinel node	T023	C1522495
27246120	385	388	EGC	T191	C0349530
27246120	401	417	gastric function	T042	C0232538
27246120	447	474	postoperative complications	T046	C0032787
27246120	510	540	previous quality control study	T062	C3850080
27246120	547	617	prospective multicenter randomized controlled phase III clinical trial	T062	C0282461
27246120	640	649	oncologic	T091	C0205478
27246120	650	656	safety	T062	C1705187
27246120	660	699	laparoscopic stomach-preserving surgery	T061	C0812574
27246120	705	730	sentinel basin dissection	T061	C0242382
27246120	732	735	SBD	T061	C0242382
27246120	760	772	laparoscopic	T082	C0393360
27246120	773	784	gastrectomy	T061	C0017118
27246120	839	888	multicenter randomized controlled phase III trial	T062	C0282461
27246120	896	918	non-inferiority design	T062	C0015320
27246120	920	938	Patients diagnosed	UnknownType	C0679829
27246120	946	959	single lesion	T033	C0577304
27246120	963	984	clinical stage T1N0M0	T079	C0205563
27246120	985	1007	gastric adenocarcinoma	T191	C0278701
27246120	1092	1100	patients	T101	C0030705
27246120	1125	1135	randomized	T033	C3815594
27246120	1146	1185	laparoscopic stomach-preserving surgery	T061	C0812574
27246120	1191	1194	SBD	T061	C0242382
27246120	1198	1214	standard surgery	T061	C0017118
27246120	1248	1269	disease-free survival	T081	C0242793
27246120	1271	1274	DFS	T081	C0242793
27246120	1312	1335	postoperative morbidity	T033	C1822479
27246120	1340	1349	mortality	T081	C0205848
27246120	1351	1366	quality of life	T078	C0034380
27246120	1375	1378	DFS	T081	C0242793
27246120	1384	1400	overall survival	T081	C4086681
27246120	1402	1425	Qualified investigators	T097	C0008961
27246120	1450	1471	quality control study	T169	C0034378
27246120	1519	1543	phase III clinical trial	T062	C0282461
27246120	1594	1633	laparoscopic stomach-preserving surgery	T061	C0812574
27246120	1639	1642	SBD	T061	C0242382
27246120	1660	1678	oncologic outcomes	T033	C0679250
27246120	1692	1707	quality of life	T078	C0034380
27246120	1722	1742	standard gastrectomy	T061	C0017118
27246120	1746	1749	EGC	T191	C0349530
27246120	1750	1758	patients	T101	C0030705

27375774|t|Changes in parenting strategies after a young person's self-harm: a qualitative study
27375774|a|When faced with the discovery of their child's self-harm, mothers and fathers may re-evaluate their parenting strategies. This can include changes to the amount of support they provide their child and changes to the degree to which they control and monitor their child. We conducted an in-depth qualitative study with 37 parents of young people who had self-harmed in which we explored how and why their parenting changed after the discovery of self-harm. Early on, parents often found themselves "walking on eggshells" so as not to upset their child, but later they felt more able to take some control. Parents ' reactions to the self-harm often depended on how they conceptualised it: as part of adolescence, as a mental health issue or as " naughty behaviour ". Parenting of other children in the family could also be affected, with parents worrying about less of their time being available for siblings. Many parents developed specific strategies they felt helped them to be more effective parents, such as learning to avoid blaming themselves or their child for the self-harm and developing new ways to communicate with their child. Parents were generally eager to pass their knowledge on to other people in the same situation. Parents reported changes in their parenting behaviours after the discovery of a child 's self-harm. Professionals involved in the care of young people who self-harm might use this information in supporting and advising parents.
27375774	0	7	Changes	T169	C0392747
27375774	11	20	parenting	T054	C0085092
27375774	21	31	strategies	T041	C0679199
27375774	40	45	young	T079	C0332239
27375774	46	54	person's	T098	C0027361
27375774	55	64	self-harm	T037	C0424366
27375774	68	85	qualitative study	T062	C0949415
27375774	106	115	discovery	T052	C1880355
27375774	125	132	child's	T100	C0008059
27375774	133	142	self-harm	T037	C0424366
27375774	144	151	mothers	T099	C0026591
27375774	156	163	fathers	T099	C0015671
27375774	168	179	re-evaluate	T058	C0220825
27375774	186	195	parenting	T054	C0085092
27375774	196	206	strategies	T041	C0679199
27375774	225	232	changes	T169	C0392747
27375774	250	257	support	T054	C0037438
27375774	277	282	child	T100	C0008059
27375774	287	294	changes	T169	C0392747
27375774	302	308	degree	T081	C0449286
27375774	323	330	control	T080	C0243148
27375774	335	342	monitor	T052	C0441655
27375774	349	354	child	T100	C0008059
27375774	372	398	in-depth qualitative study	T062	C0949415
27375774	407	414	parents	T099	C0030551
27375774	418	423	young	T079	C0332239
27375774	424	430	people	T098	C0027361
27375774	439	450	self-harmed	T037	C0424366
27375774	490	499	parenting	T054	C0085092
27375774	500	507	changed	T169	C0392747
27375774	518	527	discovery	T052	C1880355
27375774	531	540	self-harm	T037	C0424366
27375774	542	547	Early	T079	C1279919
27375774	552	559	parents	T099	C0030551
27375774	619	624	upset	T041	C3887804
27375774	631	636	child	T100	C0008059
27375774	681	688	control	T080	C0243148
27375774	690	697	Parents	T099	C0030551
27375774	700	709	reactions	T169	C0443286
27375774	717	726	self-harm	T037	C0424366
27375774	784	795	adolescence	T079	C0001578
27375774	802	821	mental health issue	T048	C4061796
27375774	830	847	naughty behaviour	T053	C0004927
27375774	851	860	Parenting	T054	C0085092
27375774	870	878	children	T100	C0008059
27375774	886	892	family	T099	C0015576
27375774	922	929	parents	T099	C0030551
27375774	959	963	time	T079	C0040223
27375774	984	992	siblings	T099	C0037047
27375774	999	1006	parents	T099	C0030551
27375774	1026	1036	strategies	T041	C0679199
27375774	1080	1087	parents	T099	C0030551
27375774	1097	1105	learning	T041	C0023185
27375774	1115	1122	blaming	T041	C0870209
27375774	1143	1148	child	T100	C0008059
27375774	1157	1166	self-harm	T037	C0424366
27375774	1194	1205	communicate	T033	C0566001
27375774	1217	1222	child	T100	C0008059
27375774	1224	1231	Parents	T099	C0030551
27375774	1267	1276	knowledge	T170	C0376554
27375774	1289	1295	people	T098	C0027361
27375774	1308	1317	situation	T169	C0868928
27375774	1319	1326	Parents	T099	C0030551
27375774	1336	1343	changes	T169	C0392747
27375774	1353	1362	parenting	T054	C0085092
27375774	1363	1373	behaviours	T053	C0004927
27375774	1384	1393	discovery	T052	C1880355
27375774	1399	1404	child	T100	C0008059
27375774	1408	1417	self-harm	T037	C0424366
27375774	1419	1432	Professionals	T097	C0679924
27375774	1449	1453	care	T052	C1947933
27375774	1457	1462	young	T079	C0332239
27375774	1463	1469	people	T098	C0027361
27375774	1474	1483	self-harm	T037	C0424366
27375774	1499	1510	information	T078	C1533716
27375774	1514	1524	supporting	T077	C1521721
27375774	1529	1537	advising	T052	C1828381
27375774	1538	1545	parents	T099	C0030551

27929083|t|Applicability of drinking water treatment residue for lake restoration in relation to metal / metalloid risk assessment
27929083|a|Drinking water treatment residue (DWTR), a byproduct generated during potable water production, exhibits a high potential for recycling to control eutrophication. However, this beneficial recycling is hampered by unclear metal / metalloid pollution risks related to DWTR. In this study, the pollution risks of Al, As, Ba, Be, Cd, Co, Cr, Cu, Fe, Mn, Mo, Ni, Pb, and Zn due to DWTR application were first evaluated for lake water based on human health risk assessment models and comparison of regulatory standards. The risks of DWTR were also evaluated for sediments on the basis of toxicity characteristics leaching procedure and fractionation in relation to risk assessment code. Variations in the biological behaviors of metal / metalloid in sediments caused by DWTR were assessed using Chironomus plumosus larvae and Hydrilla verticillata. Kinetic luminescent bacteria test (using Aliivibrio fischeri) was conducted to analyze the possibility of acute and chronic detrimental effects of sediment with DWTR application. According to the obtained results, we identify a potential undesirable effect of DWTR related to Fe and Mn (typically under anaerobic conditions); roughly present a dosage threshold calculation model; and recommend a procedure for DWTR prescreening to ensure safe application. Overall, managed DWTR application is necessary for successful eutrophication control.
27929083	0	13	Applicability	T169	C4048755
27929083	17	31	drinking water	T167	C0599638
27929083	32	41	treatment	T169	C1522326
27929083	42	49	residue	T167	C0439861
27929083	54	58	lake	T083	C0337049
27929083	59	70	restoration	T069	C1720906
27929083	86	91	metal	T197	C0025552
27929083	94	103	metalloid	T196	C0439879
27929083	104	119	risk assessment	T058	C0086930
27929083	120	134	Drinking water	T167	C0599638
27929083	135	144	treatment	T169	C1522326
27929083	145	152	residue	T167	C0439861
27929083	154	158	DWTR	T167	C0439861
27929083	163	172	byproduct	T167	C0439861
27929083	190	203	potable water	T197	C3179004
27929083	204	214	production	T057	C0033268
27929083	232	241	potential	T080	C3245505
27929083	246	255	recycling	T068	C0282114
27929083	259	266	control	T080	C0243148
27929083	267	281	eutrophication	T067	C0015191
27929083	297	307	beneficial	T081	C0814225
27929083	308	317	recycling	T068	C0282114
27929083	341	346	metal	T197	C0025552
27929083	349	358	metalloid	T196	C0439879
27929083	359	368	pollution	T069	C0392355
27929083	369	374	risks	T078	C0035647
27929083	386	390	DWTR	T167	C0439861
27929083	400	405	study	T062	C2603343
27929083	411	420	pollution	T069	C0392355
27929083	421	426	risks	T078	C0035647
27929083	430	432	Al	T196	C0002367
27929083	434	436	As	T121,T131,T196	C0003818
27929083	438	440	Ba	T196	C0004749
27929083	442	444	Be	T131,T196	C0005139
27929083	446	448	Cd	T131,T196	C0006632
27929083	450	452	Co	T123,T196	C0009148
27929083	454	456	Cr	T131,T196	C0008574
27929083	458	460	Cu	T121,T123,T196	C0009968
27929083	462	464	Fe	T121,T123,T196	C0302583
27929083	466	468	Mn	T123,T196	C0024706
27929083	470	472	Mo	T123,T196	C0026402
27929083	474	476	Ni	T123,T196	C0028013
27929083	478	480	Pb	T131,T196	C0023175
27929083	486	488	Zn	T121,T123,T196	C0043481
27929083	496	500	DWTR	T167	C0439861
27929083	501	512	application	T169	C4048755
27929083	524	533	evaluated	T058	C0220825
27929083	538	548	lake water	T167	C1719772
27929083	558	563	human	T016	C0086418
27929083	564	570	health	T078	C0018684
27929083	571	586	risk assessment	T058	C0086930
27929083	587	593	models	T170	C3161035
27929083	598	608	comparison	T052	C1707455
27929083	612	622	regulatory	T089	C0220905
27929083	623	632	standards	T170	C0038137
27929083	638	643	risks	T078	C0035647
27929083	647	651	DWTR	T167	C0439861
27929083	662	671	evaluated	T058	C0220825
27929083	676	685	sediments	T167	C1550099
27929083	702	710	toxicity	T037	C0600688
27929083	711	726	characteristics	T080	C1521970
27929083	727	735	leaching	T067	C1522240
27929083	736	745	procedure	T169	C2700391
27929083	779	794	risk assessment	T058	C0086930
27929083	795	799	code	T170	C1548762
27929083	801	811	Variations	T080	C0205419
27929083	819	829	biological	T080	C0205460
27929083	843	848	metal	T197	C0025552
27929083	851	860	metalloid	T196	C0439879
27929083	864	873	sediments	T167	C1550099
27929083	884	888	DWTR	T167	C0439861
27929083	894	902	assessed	T052	C1516048
27929083	909	928	Chironomus plumosus	T204	C1004462
27929083	929	935	larvae	T204	C0023047
27929083	940	961	Hydrilla verticillata	T002	C1015712
27929083	963	996	Kinetic luminescent bacteria test	T059	C0022885
27929083	1004	1023	Aliivibrio fischeri	T007	C0318276
27929083	1069	1074	acute	T079	C0205178
27929083	1079	1086	chronic	T079	C0205191
27929083	1087	1106	detrimental effects	T169	C0001688
27929083	1110	1118	sediment	T167	C1550099
27929083	1124	1128	DWTR	T167	C0439861
27929083	1129	1140	application	T169	C4048755
27929083	1168	1175	results	T169	C1274040
27929083	1191	1200	potential	T080	C3245505
27929083	1201	1219	undesirable effect	T169	C0001688
27929083	1223	1227	DWTR	T167	C0439861
27929083	1239	1241	Fe	T121,T123,T196	C0302583
27929083	1246	1248	Mn	T123,T196	C0024706
27929083	1266	1275	anaerobic	T080	C3641081
27929083	1276	1286	conditions	T080	C0348080
27929083	1307	1313	dosage	T081	C0178602
27929083	1314	1323	threshold	T080	C0449864
27929083	1324	1341	calculation model	T170	C3161035
27929083	1359	1368	procedure	T169	C2700391
27929083	1373	1377	DWTR	T167	C0439861
27929083	1406	1417	application	T169	C4048755
27929083	1436	1440	DWTR	T167	C0439861
27929083	1441	1452	application	T169	C4048755
27929083	1481	1495	eutrophication	T067	C0015191
27929083	1496	1503	control	T080	C0243148

27320055|t|Methamphetamine, 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxypyrovalerone (MDPV) induce differential cytotoxic effects in bovine brain microvessel endothelial cells
27320055|a|Designer drugs such as synthetic psychostimulants are indicative of a worldwide problem of drug abuse and addiction. In addition to methamphetamine (METH), these drugs include 3,4-methylenedioxy-methamphetamine (MDMA) and commercial preparations of synthetic cathinones including 3,4-methylenedioxypyrovalerone (MDPV), typically referred to as " bath salts ." These psychostimulants exert neurotoxic effects by altering monoamine systems in the brain. Additionally, METH and MDMA adversely affect the integrity of the blood-brain barrier (BBB): there are no current reports on the effects of MDPV on the BBB. The aim of this study was to compare the effects of METH, MDMA and MDPV on bovine brain microvessel endothelial cells (bBMVECs), an accepted in vitro model of the BBB. Confluent bBMVEC monolayers were treated with METH, MDMA and MDPV (0.5mM-2.5mM) for 24h. METH and MDMA increased lactate dehydrogenase release only at the highest concentration (2.5mM), whereas MDPV induced cytotoxicity at all concentration s. MDMA and METH decreased cellular proliferation only at 2.5mM, with similar effects observed after MDPV exposures starting at 1mM. Only MDPV increased reactive oxygen species production at all concentrations tested whereas all 3 drugs increased nitric oxide production. Morphological analysis revealed different patterns of compound - induced cell damage. METH induced vacuole formatio n at 1mM and disruption of the monolayer at 2.5mM. MDMA induced disruption of the endothelial monolayer from 1mM without vacuolization. On the other hand, MDPV induced monolayer disruption at doses ≥0.5mM without vacuole formation; at 2.5mM, the few remaining cells lacked endothelial morphology. These data suggest that even though these synthetic psychostimulants alter monoaminergic systems, they each induce BBB toxicity by different mechanisms with MDPV being the most toxic.
27320055	0	15	Methamphetamine	T109,T131	C0025611
27320055	17	50	3,4-methylenedioxymethamphetamine	T109,T121,T131	C0115471
27320055	52	56	MDMA	T109,T121,T131	C0115471
27320055	62	92	3,4-methylenedioxypyrovalerone	T109	C2974592
27320055	94	98	MDPV	T109	C2974592
27320055	100	106	induce	T169	C0205263
27320055	107	119	differential	T080	C0443199
27320055	120	137	cytotoxic effects	T049	C0596402
27320055	141	147	bovine	T015	C0007452
27320055	148	153	brain	T023	C0006104
27320055	154	165	microvessel	T023	C2350570
27320055	166	183	endothelial cells	T025	C0225336
27320055	184	198	Designer drugs	T131	C0011684
27320055	207	233	synthetic psychostimulants	T121	C0304403
27320055	264	271	problem	T033	C0033213
27320055	275	285	drug abuse	T048	C0013146
27320055	290	299	addiction	T048	C1510472
27320055	316	331	methamphetamine	T109,T131	C0025611
27320055	333	337	METH	T109,T131	C0025611
27320055	346	351	drugs	T131	C0011684
27320055	360	394	3,4-methylenedioxy-methamphetamine	T109,T121,T131	C0115471
27320055	396	400	MDMA	T109,T121,T131	C0115471
27320055	406	416	commercial	T170	C0680536
27320055	417	429	preparations	T052	C1521827
27320055	433	453	synthetic cathinones	T109,T121	C0054876
27320055	464	494	3,4-methylenedioxypyrovalerone	T109	C2974592
27320055	496	500	MDPV	T109	C2974592
27320055	530	540	bath salts	T109,T121	C0771243
27320055	550	566	psychostimulants	T121	C0304403
27320055	573	591	neurotoxic effects	T037	C0235032
27320055	595	603	altering	T078	C1515926
27320055	604	621	monoamine systems	UnknownType	C0815020
27320055	629	634	brain	T023	C0006104
27320055	650	654	METH	T109,T131	C0025611
27320055	659	663	MDMA	T109,T121,T131	C0115471
27320055	664	680	adversely affect	T046	C0879626
27320055	685	694	integrity	T080	C1947912
27320055	702	721	blood-brain barrier	T023	C0005854
27320055	723	726	BBB	T023	C0005854
27320055	750	757	reports	T170	C0684224
27320055	765	775	effects of	T080	C1704420
27320055	776	780	MDPV	T109	C2974592
27320055	788	791	BBB	T023	C0005854
27320055	809	814	study	T062	C2603343
27320055	822	829	compare	T052	C1707455
27320055	834	844	effects of	T080	C1704420
27320055	845	849	METH	T109,T131	C0025611
27320055	851	855	MDMA	T109,T121,T131	C0115471
27320055	860	864	MDPV	T109	C2974592
27320055	868	874	bovine	T015	C0007452
27320055	875	880	brain	T023	C0006104
27320055	881	892	microvessel	T023	C2350570
27320055	893	910	endothelial cells	T025	C0225336
27320055	912	919	bBMVECs	T025	C0225336
27320055	934	948	in vitro model	T062	C1515654
27320055	956	959	BBB	T023	C0005854
27320055	961	970	Confluent	T080	C0205200
27320055	971	977	bBMVEC	T025	C0225336
27320055	978	988	monolayers	T023	C0934502
27320055	994	1001	treated	T169	C1522326
27320055	1007	1011	METH	T109,T131	C0025611
27320055	1013	1017	MDMA	T109,T121,T131	C0115471
27320055	1022	1026	MDPV	T109	C2974592
27320055	1050	1054	METH	T109,T131	C0025611
27320055	1059	1063	MDMA	T109,T121,T131	C0115471
27320055	1064	1073	increased	T081	C0205217
27320055	1074	1095	lactate dehydrogenase	T116,T126	C0022917
27320055	1096	1103	release	T169	C1283071
27320055	1116	1123	highest	T080	C1522410
27320055	1124	1137	concentration	T081	C1446561
27320055	1155	1159	MDPV	T109	C2974592
27320055	1160	1167	induced	T169	C0205263
27320055	1168	1180	cytotoxicity	T049	C0596402
27320055	1188	1201	concentration	T081	C1446561
27320055	1205	1209	MDMA	T109,T121,T131	C0115471
27320055	1214	1218	METH	T109,T131	C0025611
27320055	1219	1228	decreased	T081	C0205216
27320055	1229	1251	cellular proliferation	T043	C0596290
27320055	1280	1287	effects	T080	C1280500
27320055	1303	1307	MDPV	T109	C2974592
27320055	1308	1317	exposures	T080	C0332157
27320055	1340	1344	MDPV	T109	C2974592
27320055	1345	1354	increased	T081	C0205217
27320055	1355	1378	reactive oxygen species	T123,T196	C0162772
27320055	1379	1389	production	T052	C1883254
27320055	1397	1411	concentrations	T081	C1446561
27320055	1412	1418	tested	T169	C0039593
27320055	1433	1438	drugs	T131	C0011684
27320055	1439	1448	increased	T081	C0205217
27320055	1449	1461	nitric oxide	T121,T123,T197	C0028128
27320055	1462	1472	production	T052	C1883254
27320055	1474	1496	Morphological analysis	T062	C0936012
27320055	1506	1515	different	T080	C1705242
27320055	1528	1536	compound	T103	C1706082
27320055	1539	1546	induced	T169	C0205263
27320055	1547	1558	cell damage	T049	C0599732
27320055	1560	1564	METH	T109,T131	C0025611
27320055	1565	1572	induced	T169	C0205263
27320055	1573	1580	vacuole	T026	C0042219
27320055	1581	1589	formatio	T169	C1522492
27320055	1603	1613	disruption	T169	C0332453
27320055	1621	1630	monolayer	T023	C0934502
27320055	1641	1645	MDMA	T109,T121,T131	C0115471
27320055	1646	1653	induced	T169	C0205263
27320055	1654	1664	disruption	T169	C0332453
27320055	1672	1683	endothelial	T025	C0225336
27320055	1684	1693	monolayer	T023	C0934502
27320055	1711	1724	vacuolization	T033	C0010840
27320055	1745	1749	MDPV	T109	C2974592
27320055	1750	1757	induced	T169	C0205263
27320055	1758	1767	monolayer	T023	C0934502
27320055	1768	1778	disruption	T169	C0332453
27320055	1782	1787	doses	T081	C0178602
27320055	1803	1810	vacuole	T026	C0042219
27320055	1811	1820	formation	T169	C1522492
27320055	1850	1855	cells	T025	C0007634
27320055	1863	1885	endothelial morphology	T080	C0332437
27320055	1893	1897	data	T078	C1511726
27320055	1929	1955	synthetic psychostimulants	T121	C0304403
27320055	1962	1983	monoaminergic systems	UnknownType	C0815020
27320055	1995	2001	induce	T169	C0205263
27320055	2002	2005	BBB	T023	C0005854
27320055	2006	2014	toxicity	T037	C0013221
27320055	2018	2027	different	T080	C1705242
27320055	2028	2038	mechanisms	T169	C0441712
27320055	2044	2048	MDPV	T109	C2974592
27320055	2064	2069	toxic	T080	C1407029

27688460|t|Experience of Varied Presentation of Chronic Progressive Disseminated Histoplasmosis in Immunocompetent Patients: A Diagnostic Conundrum
27688460|a|We report two cases of chronic progressive disseminated histoplasmosis with unusual and rare clinical picture in a patient with no underlying risk factor. One 50-year-old male, presented with hoarseness of voice, chronic cough, with a history of nonresponding anti-tubercular therapy, revealed mucocutaneous lesions on examination. Fungating vocal cord lesions were visualized on bronchoscopy, raised suspicion of carcinoma. The second case, a 22-year- old female, referred to hospital with suspected vasculitis, with complaints of "off and on" fever with decreased oral intake, arthralgia, who later developed generalized nodular skin eruptions. On investigation, human immunodeficiency virus test was found to be negative in both the cases. Histopathological findings of skin biopsy, adrenal and bone marrow aspirates raised suspicion, whereas fungal cultures confirmed Histoplasma infection. Although diagnosis was delayed, but both of them were successfully treated with amphotericin B.
27688460	21	33	Presentation	T078	C0449450
27688460	37	44	Chronic	T079	C0205191
27688460	45	84	Progressive Disseminated Histoplasmosis	T047	C0343900
27688460	88	103	Immunocompetent	T201	C1512656
27688460	104	112	Patients	T101	C0030705
27688460	116	126	Diagnostic	T169	C0348026
27688460	193	207	histoplasmosis	T047	C0019655
27688460	213	220	unusual	T080	C2700116
27688460	225	229	rare	T080	C0522498
27688460	230	246	clinical picture	T201	C0683325
27688460	252	259	patient	T101	C0030705
27688460	279	290	risk factor	T033	C0850664
27688460	308	312	male	T032	C0086582
27688460	329	348	hoarseness of voice	T184	C0019825
27688460	350	363	chronic cough	T184	C0010201
27688460	383	396	nonresponding	UnknownType	C0184782
27688460	397	420	anti-tubercular therapy	T061	C0749724
27688460	431	444	mucocutaneous	T030	C0221941
27688460	445	452	lesions	T033	C0221198
27688460	469	478	Fungating	T047	C2609067
27688460	479	497	vocal cord lesions	T033	C0577903
27688460	517	529	bronchoscopy	T060	C0006290
27688460	538	547	suspicion	T041	C0242114
27688460	551	560	carcinoma	T191	C0007097
27688460	590	600	old female	T032	C0086287
27688460	614	622	hospital	T073,T093	C0019994
27688460	638	648	vasculitis	T047	C0042384
27688460	682	687	fever	T184	C0015967
27688460	693	714	decreased oral intake	T033	C1504561
27688460	716	726	arthralgia	T184	C0003862
27688460	748	759	generalized	T082	C0205246
27688460	760	782	nodular skin eruptions	T047	C0014743
27688460	787	800	investigation	T058	C0220825
27688460	802	835	human immunodeficiency virus test	T059	C1321876
27688460	852	860	negative	T033	C1513916
27688460	880	906	Histopathological findings	T034	C4086448
27688460	910	921	skin biopsy	T060	C0150866
27688460	923	930	adrenal	T024	C1515890
27688460	935	956	bone marrow aspirates	T031	C0857285
27688460	964	973	suspicion	T041	C0242114
27688460	983	998	fungal cultures	T059	C0200954
27688460	999	1008	confirmed	T033	C0750484
27688460	1009	1030	Histoplasma infection	T047	C0019655
27688460	1041	1050	diagnosis	T033	C0011900
27688460	1055	1062	delayed	T079	C0205421
27688460	1086	1098	successfully	T080	C1272703
27688460	1099	1111	treated with	T061	C0332293
27688460	1112	1126	amphotericin B	T109,T195	C0002679

27807521|t|Assessment of isokinetic muscle function in Korea male volleyball athletes
27807521|a|Volleyball players performed numerous repetitions of spike actions, which uses and requires strong and explosive force, and control of the muscles of the shoulder, lower back, and legs. Muscle imbalance is one of the main causes of sport injuries. The purpose of this study was to assess isokinetic muscle functions in male volleyball players. We thus aim to accurately evaluate their muscle functions, and identify the best training strategy to achieve optimal muscle strength balance in future training programs. The participants in this study consisted of 14 male volleyball players. Muscle strength was measured using the isokinetic dynamometer. Muscle strength was evaluated in terms of peak torque and average power, calculated from five repeated measurements at an angular speed of 60°/sec. Three players who were left attackers showed shoulder imbalance, four players showed trunk joint imbalance, nine players had knee joint of extension/flexion imbalance and four players showed left/right imbalance. The results showed that the number of volleyball players with differences between the strength of the bilateral knee muscles, and between the strength of the hamstrings and quadriceps muscles was higher than the number of players with differences between the strength of the shoulder internal and external rotation muscles, and higher than the number of players with differences between the strength of the lower back extension and flexion muscles.
27807521	0	10	Assessment	T058	C0220825
27807521	14	40	isokinetic muscle function	T033	C1562476
27807521	44	49	Korea	T083	C0022771
27807521	50	54	male	T032	C0086582
27807521	55	65	volleyball	T056	C1956059
27807521	66	74	athletes	T097	C0238703
27807521	75	85	Volleyball	T056	C1956059
27807521	86	93	players	T097	C0238703
27807521	104	112	numerous	T081	C0439064
27807521	113	124	repetitions	T169	C0205341
27807521	128	141	spike actions	T042	C0920875
27807521	167	173	strong	T080	C0442821
27807521	178	193	explosive force	T042	C0517349
27807521	199	206	control	T169	C2587213
27807521	214	221	muscles	T024	C0026845
27807521	229	237	shoulder	T029	C0037004
27807521	239	249	lower back	T029	C2939142
27807521	255	259	legs	T023	C1140621
27807521	261	277	Muscle imbalance	T033	C0262561
27807521	307	312	sport	T056	C0038039
27807521	313	321	injuries	T037	C0043251
27807521	343	348	study	T062	C2603343
27807521	363	390	isokinetic muscle functions	T033	C1562476
27807521	394	398	male	T032	C0086582
27807521	399	409	volleyball	T056	C1956059
27807521	410	417	players	T097	C0238703
27807521	445	453	evaluate	T169	C1292732
27807521	460	476	muscle functions	T042	C0231484
27807521	500	517	training strategy	T056	C0015259
27807521	529	552	optimal muscle strength	T042	C0517349
27807521	571	588	training programs	T065	C0040607
27807521	594	606	participants	T098	C0679646
27807521	615	620	study	T062	C2603343
27807521	637	641	male	T032	C0086582
27807521	642	652	volleyball	T056	C1956059
27807521	653	660	players	T097	C0238703
27807521	662	677	Muscle strength	T042	C0517349
27807521	682	690	measured	T080	C0444706
27807521	701	723	isokinetic dynamometer	T074	C0180572
27807521	725	740	Muscle strength	T042	C0517349
27807521	767	778	peak torque	T067	C0376590
27807521	791	796	power	T081	C3854080
27807521	828	840	measurements	T169	C0242485
27807521	847	860	angular speed	T081	C0678536
27807521	879	886	players	T097	C0238703
27807521	901	910	attackers	T097	C0238703
27807521	918	926	shoulder	T029	C0037004
27807521	927	936	imbalance	T033	C0262561
27807521	943	950	players	T097	C0238703
27807521	958	969	trunk joint	T030	C0224674
27807521	970	979	imbalance	T033	C0262561
27807521	986	993	players	T097	C0238703
27807521	998	1008	knee joint	T030	C0022745
27807521	1012	1029	extension/flexion	T082	C0444509
27807521	1030	1039	imbalance	T033	C0262561
27807521	1049	1056	players	T097	C0238703
27807521	1064	1074	left/right	T082	C0238767
27807521	1075	1084	imbalance	T033	C0262561
27807521	1090	1097	results	T169	C1274040
27807521	1114	1120	number	T081	C0237753
27807521	1124	1134	volleyball	T056	C1956059
27807521	1135	1142	players	T097	C0238703
27807521	1172	1180	strength	T042	C0517349
27807521	1188	1202	bilateral knee	T030	C0582801
27807521	1203	1210	muscles	T024	C0026845
27807521	1228	1236	strength	T042	C0517349
27807521	1244	1254	hamstrings	T023	C0584895
27807521	1259	1277	quadriceps muscles	T023	C0224440
27807521	1308	1315	players	T097	C0238703
27807521	1345	1353	strength	T042	C0517349
27807521	1361	1369	shoulder	T029	C0037004
27807521	1370	1400	internal and external rotation	T082	C0442222
27807521	1401	1408	muscles	T024	C0026845
27807521	1440	1447	players	T097	C0238703
27807521	1477	1485	strength	T042	C0517349
27807521	1493	1503	lower back	T029	C2939142
27807521	1504	1525	extension and flexion	T082	C0444509
27807521	1526	1533	muscles	T024	C0026845

27494906|t|Impact of AAC(6')-Ib-cr in combination with chromosomal -mediated mechanisms on clinical quinolone resistance in Escherichia coli
27494906|a|aac(6')-Ib-cr is the most prevalent plasmid -mediated fluoroquinolone (FQ) resistance mechanism in Enterobacteriaceae. We aimed to analyse the interplay between this plasmid -mediated gene and chromosomal -mediated quinolone resistance mechanisms on both FQ resistance and bacterial fitness in Escherichia coli. E. coli ATCC 25922 and derived isogenic strains carrying chromosomal -mediated quinolone resistance modifications (Ser83Leu-Asp87Asn in GyrA, Ser80Arg in ParC and/or a marR gene deletion) were electroporated with a pBK-CMV vector encoding AAC(6')-Ib-cr. The MICs of FQs were determined by microdilution and bactericidal activity was determined using time-kill curves. A peritoneal sepsis murine model was used to evaluate the in vivo impact. Bacterial fitness was analysed using growth curves and competition assays. The presence of the aac(6')-Ib-cr gene increased the MICs of ciprofloxacin and norfloxacin 4-8-fold for all E. coli genotypes, independently of the initial resistance level. Combination of the aac(6')-Ib-cr gene with three or four chromosomal mechanisms was necessary to reach MIC values above the susceptible category. Killing curve assays showed a clear selective advantage for survival in strains harbouring the aac(6')-Ib-cr gene (up to 7 log10 cfu/mL after 24 h). AAC(6')-Ib-cr significantly reduced the ciprofloxacin efficacy in vivo. In terms of bacterial fitness cost, maximal OD was significantly lower for all strains harbouring the aac(6')-Ib-cr gene, independently of chromosomal mutations associated. The aac(6')-Ib-cr gene, in spite of producing low-level resistance by itself, plays a relevant role in acquisition of a clinical level of ciprofloxacin and norfloxacin resistance, when combined with three or four chromosomal mutations, both in vitro and in vivo.
27494906	10	23	AAC(6')-Ib-cr	T116,T126	C0051639
27494906	44	55	chromosomal	T026	C0008633
27494906	66	76	mechanisms	T169	C0441712
27494906	80	88	clinical	T080	C0205210
27494906	89	98	quinolone	T109	C0034428
27494906	99	109	resistance	T038	C0013203
27494906	113	129	Escherichia coli	T007	C0014834
27494906	130	143	aac(6')-Ib-cr	T028	C0017337
27494906	166	173	plasmid	T114,T123	C0032136
27494906	184	199	fluoroquinolone	T109,T121	C0949665
27494906	201	203	FQ	T109,T121	C0949665
27494906	205	225	resistance mechanism	T039	C1514892
27494906	229	247	Enterobacteriaceae	T007	C0014346
27494906	296	303	plasmid	T114,T123	C0032136
27494906	314	318	gene	T028	C0017337
27494906	323	334	chromosomal	T026	C0008633
27494906	345	354	quinolone	T109	C0034428
27494906	355	376	resistance mechanisms	T039	C1514892
27494906	385	387	FQ	T109,T121	C0949665
27494906	388	398	resistance	T038	C0013203
27494906	403	412	bacterial	T007	C0004611
27494906	413	420	fitness	T045	C2717776
27494906	424	440	Escherichia coli	T007	C0014834
27494906	442	460	E. coli ATCC 25922	T007	C0014834
27494906	473	489	isogenic strains	T001	C1512692
27494906	499	510	chromosomal	T026	C0008633
27494906	521	530	quinolone	T109	C0034428
27494906	531	541	resistance	T038	C0013203
27494906	542	555	modifications	T063	C4277689
27494906	557	574	Ser83Leu-Asp87Asn	T045	C0026882
27494906	578	582	GyrA	T116,T126	C0949782
27494906	584	592	Ser80Arg	T045	C0026882
27494906	596	600	ParC	T116,T126	C0209525
27494906	610	628	marR gene deletion	T045	C0017260
27494906	635	649	electroporated	T059	C0206691
27494906	657	664	pBK-CMV	T114,T123	C0032136
27494906	665	671	vector	T114	C0017397
27494906	672	680	encoding	T052	C2700640
27494906	681	694	AAC(6')-Ib-cr	T116,T126	C0051639
27494906	700	704	MICs	T034	C1304747
27494906	708	711	FQs	T109,T121	C0949665
27494906	731	744	microdilution	T059	C0201207
27494906	749	770	bactericidal activity	T039	C0544570
27494906	792	808	time-kill curves	T081	C0683162
27494906	812	842	peritoneal sepsis murine model	T008	C0599779
27494906	868	875	in vivo	T082	C1515655
27494906	884	893	Bacterial	T007	C0004611
27494906	894	901	fitness	T045	C2717776
27494906	939	957	competition assays	T059	C0005507
27494906	979	997	aac(6')-Ib-cr gene	T028	C0017337
27494906	1012	1016	MICs	T034	C1304747
27494906	1020	1033	ciprofloxacin	T109,T121	C0008809
27494906	1038	1049	norfloxacin	T109,T195	C0028365
27494906	1067	1074	E. coli	T007	C0014834
27494906	1075	1084	genotypes	T032	C0017431
27494906	1115	1125	resistance	T038	C0013203
27494906	1152	1170	aac(6')-Ib-cr gene	T028	C0017337
27494906	1190	1201	chromosomal	T026	C0008633
27494906	1202	1212	mechanisms	T169	C0441712
27494906	1236	1246	MIC values	T034	C1304747
27494906	1279	1299	Killing curve assays	T081	C0683162
27494906	1339	1347	survival	T052	C0038952
27494906	1351	1358	strains	T080	C0456178
27494906	1374	1392	aac(6')-Ib-cr gene	T028	C0017337
27494906	1428	1441	AAC(6')-Ib-cr	T116,T126	C0051639
27494906	1468	1481	ciprofloxacin	T109,T121	C0008809
27494906	1491	1498	in vivo	T082	C1515655
27494906	1512	1521	bacterial	T007	C0004611
27494906	1522	1534	fitness cost	T045	C2717776
27494906	1579	1586	strains	T080	C0456178
27494906	1602	1620	aac(6')-Ib-cr gene	T028	C0017337
27494906	1639	1660	chromosomal mutations	T049	C0948447
27494906	1677	1695	aac(6')-Ib-cr gene	T028	C0017337
27494906	1729	1739	resistance	T038	C0013203
27494906	1793	1801	clinical	T080	C0205210
27494906	1802	1807	level	T080	C0441889
27494906	1811	1824	ciprofloxacin	T109,T121	C0008809
27494906	1829	1840	norfloxacin	T109,T195	C0028365
27494906	1841	1851	resistance	T038	C0013203
27494906	1886	1907	chromosomal mutations	T049	C0948447
27494906	1914	1922	in vitro	T080	C1533691
27494906	1927	1934	in vivo	T082	C1515655

28318886|t|Airway inflammation phenotype prediction in asthma patients using lung sound analysis with fractional exhaled nitric oxide
28318886|a|We previously reported the results of lung sound analysis in patients with bronchial asthma and demonstrated that the exhalation -to- inhalation sound pressure ratio in the low frequency range between 100 and 200 Hz (E/I LF) was correlated with the presence of airway inflammation and airway obstruction. We classified asthma patients by airway inflammation phenotype using the induced sputum eosinophil and neutrophil ratio and determined whether this phenotype could be predicted using E/I LF and fractional exhaled nitric oxide values. Steroid-naive bronchial asthma patients were classified into four phenotypes, including " Low inflammation " (35 patients), " Eosinophilic type " (58 patients), " Neutrophilic type " (15 patients), and " Mixed type " (15 patients) based on the results of induced sputum examinations. The E/I LF data and FeNO levels were then evaluated for the four phenotype groups; the prediction powers of these two indices were then analyzed for each phenotype. The median E/I LF value was highest in the " Mixed type " and lowest in the " Low inflammation " group. FeNO differentiated between the " Low inflammation " and " Eosinophilic type " groups, " Low inflammation " and " Neutrophilic type " groups, and " Neutrophilic type " and " Mixed type " (p < 0.0001, p = 0.007, and p = 0.04, respectively). E/I LF differentiated between the " Low inflammation " and " Eosinophilic type " groups (p = 0.006). E/I LF could distinguish the " Mixed type " group from the " Low inflammation " and " Eosinophilic type " groups (p = 0.002). A combination of the E/I LF value and FeNO may be useful for the classification of the airway inflammation phenotype in patients with bronchial asthma.
28318886	0	6	Airway	T023	C0458827
28318886	7	19	inflammation	T046	C0021368
28318886	20	29	phenotype	T032	C0031437
28318886	30	40	prediction	T078	C0681842
28318886	44	50	asthma	T047	C0004096
28318886	51	59	patients	T101	C0030705
28318886	66	70	lung	T023	C0024109
28318886	71	85	sound analysis	T059	C0022885
28318886	91	122	fractional exhaled nitric oxide	T121,T123,T197	C3700245
28318886	161	165	lung	T023	C0024109
28318886	166	180	sound analysis	T059	C0022885
28318886	184	192	patients	T101	C0030705
28318886	198	214	bronchial asthma	T047	C0004096
28318886	241	251	exhalation	T040	C0231800
28318886	257	267	inhalation	T040	C0004048
28318886	268	288	sound pressure ratio	T081	C1442095
28318886	296	309	low frequency	T079	C0205213
28318886	340	346	E/I LF	T081	C1442095
28318886	352	362	correlated	T080	C1707520
28318886	384	390	airway	T023	C0458827
28318886	391	403	inflammation	T046	C0021368
28318886	408	426	airway obstruction	T047	C0001883
28318886	442	448	asthma	T047	C0004096
28318886	449	457	patients	T101	C0030705
28318886	461	467	airway	T023	C0458827
28318886	468	480	inflammation	T046	C0021368
28318886	481	490	phenotype	T032	C0031437
28318886	501	515	induced sputum	T031	C3179346
28318886	516	526	eosinophil	T025	C0014467
28318886	531	541	neutrophil	T025	C0027950
28318886	542	547	ratio	T081	C0456603
28318886	576	585	phenotype	T032	C0031437
28318886	595	604	predicted	T078	C0681842
28318886	611	617	E/I LF	T081	C1442095
28318886	622	653	fractional exhaled nitric oxide	T121,T123,T197	C3700245
28318886	654	660	values	T080	C0042295
28318886	662	692	Steroid-naive bronchial asthma	T047	C0004096
28318886	693	701	patients	T101	C0030705
28318886	707	717	classified	T185	C0008902
28318886	728	738	phenotypes	T032	C0031437
28318886	752	755	Low	T080	C0205251
28318886	756	768	inflammation	T046	C0021368
28318886	775	783	patients	T101	C0030705
28318886	788	800	Eosinophilic	T033	C3687252
28318886	801	805	type	T080	C0332307
28318886	812	820	patients	T101	C0030705
28318886	825	837	Neutrophilic	T046	C0021368
28318886	838	842	type	T080	C0332307
28318886	849	857	patients	T101	C0030705
28318886	866	876	Mixed type	T080	C0332307
28318886	883	891	patients	T101	C0030705
28318886	917	931	induced sputum	T031	C3179346
28318886	932	944	examinations	T058	C0582103
28318886	950	956	E/I LF	T081	C1442095
28318886	957	961	data	T078	C1511726
28318886	966	970	FeNO	T121,T123,T197	C3700245
28318886	971	977	levels	T080	C0441889
28318886	1011	1020	phenotype	T032	C0031437
28318886	1021	1027	groups	T078	C0441833
28318886	1033	1043	prediction	T078	C0681842
28318886	1064	1071	indices	T170	C0918012
28318886	1082	1090	analyzed	T062	C0936012
28318886	1100	1109	phenotype	T032	C0031437
28318886	1115	1121	median	T081	C0876920
28318886	1122	1128	E/I LF	T081	C1442095
28318886	1129	1134	value	T080	C0042295
28318886	1156	1166	Mixed type	T080	C0332307
28318886	1189	1192	Low	T080	C0205251
28318886	1193	1205	inflammation	T046	C0021368
28318886	1208	1213	group	T078	C0441833
28318886	1215	1219	FeNO	T121,T123,T197	C3700245
28318886	1249	1252	Low	T080	C0205251
28318886	1253	1265	inflammation	T046	C0021368
28318886	1274	1286	Eosinophilic	T033	C3687252
28318886	1287	1291	type	T080	C0332307
28318886	1294	1300	groups	T078	C0441833
28318886	1304	1307	Low	T080	C0205251
28318886	1308	1320	inflammation	T046	C0021368
28318886	1329	1341	Neutrophilic	T046	C0021368
28318886	1342	1346	type	T080	C0332307
28318886	1349	1355	groups	T078	C0441833
28318886	1363	1375	Neutrophilic	T046	C0021368
28318886	1376	1380	type	T080	C0332307
28318886	1389	1399	Mixed type	T080	C0332307
28318886	1455	1461	E/I LF	T081	C1442095
28318886	1491	1494	Low	T080	C0205251
28318886	1495	1507	inflammation	T046	C0021368
28318886	1516	1528	Eosinophilic	T033	C3687252
28318886	1529	1533	type	T080	C0332307
28318886	1536	1542	groups	T078	C0441833
28318886	1556	1562	E/I LF	T081	C1442095
28318886	1587	1597	Mixed type	T080	C0332307
28318886	1600	1605	group	T078	C0441833
28318886	1617	1620	Low	T080	C0205251
28318886	1621	1633	inflammation	T046	C0021368
28318886	1642	1654	Eosinophilic	T033	C3687252
28318886	1655	1659	type	T080	C0332307
28318886	1662	1668	groups	T078	C0441833
28318886	1684	1695	combination	T080	C0205195
28318886	1703	1709	E/I LF	T081	C1442095
28318886	1710	1715	value	T080	C0042295
28318886	1720	1724	FeNO	T121,T123,T197	C3700245
28318886	1747	1761	classification	T185	C0008902
28318886	1769	1775	airway	T023	C0458827
28318886	1776	1788	inflammation	T046	C0021368
28318886	1789	1798	phenotype	T032	C0031437
28318886	1802	1810	patients	T101	C0030705
28318886	1816	1832	bronchial asthma	T047	C0004096

28478867|t|Targeting accuracy of single-isocenter intensity-modulated radiosurgery for multiple lesions
28478867|a|To investigate the targeting accuracy of intensity-modulated SRS (IMRS) plans designed to simultaneously treat multiple brain metastases with a single isocenter. A home-made acrylic phantom able to support a film (EBT3) in its coronal plane was used. The phantom was CT scanned and three coplanar small targets (a central and two peripheral) were outlined in the Eclipse system. Peripheral targets were 6 cm apart from the central one. A reference IMRS plan was designed to simultaneously treat the three targets, but only a single isocenter located at the center of the central target was used. After positioning the phantom on the linac using the room lasers, a CBCT scan was acquired and the reference plan were mapped on it, by placing the planned isocenter at the intersection of the landmarks used in the film showing the linac isocenter. The mapped plan was then recalculated and delivered. The film dose distribution was derived using a cloud computing application (www.radiochromic.com) that uses a triple-channel dosimetry algorithm. Comparison of dose distributions using the gamma index (5%/1 mm) were performed over a 5 × 5 cm(2) region centered over each target. 2D shifts required to get the best gamma passing rates on the peripheral target regions were compared with the reported ones for the central target. The experiment was repeated ten times in different sessions. Average 2D shifts required to achieve optimal gamma passing rates (99%, 97%, 99%) were 0.7 mm (SD: 0.3 mm), 0.8 mm (SD: 0.4 mm) and 0.8 mm (SD: 0.3 mm), for the central and the two peripheral targets, respectively. No statistical differences (p > 0.05) were found for targeting accuracy between the central and the two peripheral targets. The study revealed a targeting accuracy within 1 mm for off- isocenter targets within 6 cm of the linac isocenter, when a single-isocenter IMRS plan is designed.
28478867	0	9	Targeting	T169	C1521840
28478867	10	18	accuracy	T080	C0443131
28478867	22	38	single-isocenter	T082	C1881275
28478867	39	58	intensity-modulated	T061	C1512814
28478867	59	71	radiosurgery	T061	C0085203
28478867	85	92	lesions	T033	C0221198
28478867	96	107	investigate	T169	C1292732
28478867	112	121	targeting	T169	C1521840
28478867	122	130	accuracy	T080	C0443131
28478867	134	153	intensity-modulated	T061	C1512814
28478867	154	157	SRS	T061	C0085203
28478867	159	163	IMRS	T061	C0085203
28478867	165	170	plans	T170	C0599880
28478867	213	218	brain	T023	C0006104
28478867	219	229	metastases	T046	C4255448
28478867	237	253	single isocenter	T082	C1881275
28478867	257	274	home-made acrylic	T122	C0001222
28478867	275	282	phantom	T073	C0282611
28478867	301	305	film	T167	C1561572
28478867	307	311	EBT3	T167	C1561572
28478867	320	333	coronal plane	T082	C0205123
28478867	348	355	phantom	T073	C0282611
28478867	360	370	CT scanned	T060	C0040405
28478867	396	403	targets	T169	C1521840
28478867	407	414	central	T082	C0205099
28478867	423	433	peripheral	T082	C0205100
28478867	456	470	Eclipse system	T061	C2363849
28478867	472	482	Peripheral	T082	C0205100
28478867	483	490	targets	T169	C1521840
28478867	516	523	central	T082	C0205099
28478867	541	545	IMRS	T061	C0085203
28478867	546	550	plan	T170	C0599880
28478867	598	605	targets	T169	C1521840
28478867	618	634	single isocenter	T082	C1881275
28478867	664	671	central	T082	C0205099
28478867	672	678	target	T169	C1521840
28478867	695	706	positioning	T082	C1550045
28478867	711	718	phantom	T073	C0282611
28478867	726	731	linac	T074	C0023730
28478867	742	746	room	T082	C1547703
28478867	747	753	lasers	T073	C0023089
28478867	757	766	CBCT scan	T060	C0040405
28478867	798	802	plan	T170	C0599880
28478867	808	814	mapped	T052	C1283195
28478867	845	854	isocenter	T082	C1881275
28478867	862	874	intersection	T078	C1555443
28478867	904	908	film	T167	C1561572
28478867	921	926	linac	T074	C0023730
28478867	927	936	isocenter	T082	C1881275
28478867	942	948	mapped	T052	C1283195
28478867	949	953	plan	T170	C0599880
28478867	963	975	recalculated	T052	C1441506
28478867	980	989	delivered	T169	C1705822
28478867	995	999	film	T167	C1561572
28478867	1000	1017	dose distribution	T061	C0087111
28478867	1038	1065	cloud computing application	T170	C3873720
28478867	1067	1087	www.radiochromic.com	T170	C3873720
28478867	1116	1125	dosimetry	T059	C0016103
28478867	1126	1135	algorithm	T170	C0002045
28478867	1151	1169	dose distributions	T061	C0087111
28478867	1180	1191	gamma index	T081	C1708185
28478867	1262	1268	target	T169	C1521840
28478867	1270	1279	2D shifts	T169	C0333051
28478867	1305	1310	gamma	T070	C0017011
28478867	1332	1342	peripheral	T082	C0205100
28478867	1343	1349	target	T169	C1521840
28478867	1403	1410	central	T082	C0205099
28478867	1411	1417	target	T169	C1521840
28478867	1423	1433	experiment	T062	C0681814
28478867	1470	1478	sessions	T061	C0481503
28478867	1488	1497	2D shifts	T169	C0333051
28478867	1526	1531	gamma	T070	C0017011
28478867	1641	1648	central	T082	C0205099
28478867	1661	1671	peripheral	T082	C0205100
28478867	1672	1679	targets	T169	C1521840
28478867	1748	1757	targeting	T169	C1521840
28478867	1758	1766	accuracy	T080	C0443131
28478867	1779	1786	central	T082	C0205099
28478867	1799	1809	peripheral	T082	C0205100
28478867	1810	1817	targets	T169	C1521840
28478867	1823	1828	study	T062	C2603343
28478867	1840	1849	targeting	T169	C1521840
28478867	1850	1858	accuracy	T080	C0443131
28478867	1880	1889	isocenter	T082	C1881275
28478867	1890	1897	targets	T169	C1521840
28478867	1917	1922	linac	T074	C0023730
28478867	1923	1932	isocenter	T082	C1881275
28478867	1941	1957	single-isocenter	T082	C1881275
28478867	1958	1962	IMRS	T061	C0085203
28478867	1963	1967	plan	T170	C0599880

28442343|t|Pig has no uncoupling protein 1
28442343|a|Brown adipose tissue (BAT) is critical for mammal's survival in the cold environment. Uncoupling protein 1 (UCP1) is responsible for the non-shivering thermogenesis in the BAT. Pig is important economically as a meat -producing livestock. However, whether BAT or more precisely UCP1 protein exists in pig remains a controversy. The objective of this study was to ascertain whether pig has UCP1 protein. In this study, we used rapid amplification of cDNA ends (RACE) technique to obtain the UCP1 mRNA 3' end sequence, confirmed only exons 1 and 2 of the UCP1 gene are transcribed in the pig. Then we cloned the pig UCP1 gene exons 1 and 2, and expressed the UCP1 protein from the truncated pig gene using E. coli BL21. We used the expressed pig UCP1 protein as antigen for antibody production in a rabbit. We could not detect any UCP1 protein expression in different pig adipose tissues by the specific pig UCP1 antibody, while our antibody can detect the cloned pig UCP1 as well as the mice adipose UCP1 protein. This result shows although exons 1 and 2 of the pig UCP1 gene were transcribed but not translated in the pig adipose tissue. Furthermore, we detected no uncoupled respiration in the isolated pig adipocytes. Thus, these results unequivocally demonstrate that pig has no UCP1 protein. Our results have resolved the controversy of whether pigs have the brown adipose tissue.
28442343	0	3	Pig	T015	C0039005
28442343	8	10	no	T033	C1513916
28442343	11	31	uncoupling protein 1	T116,T123	C0107264
28442343	32	52	Brown adipose tissue	T024	C0006298
28442343	54	57	BAT	T024	C0006298
28442343	75	83	mammal's	T015	C0024660
28442343	84	92	survival	T052	C0038952
28442343	100	116	cold environment	T067	C0241842
28442343	118	138	Uncoupling protein 1	T116,T123	C0107264
28442343	140	144	UCP1	T116,T123	C0107264
28442343	169	196	non-shivering thermogenesis	T033	C0518713
28442343	204	207	BAT	T024	C0006298
28442343	209	212	Pig	T015	C0039005
28442343	244	248	meat	T168	C0025017
28442343	260	269	livestock	T008	C2936506
28442343	288	291	BAT	T024	C0006298
28442343	310	322	UCP1 protein	T116,T123	C0107264
28442343	333	336	pig	T015	C0039005
28442343	347	358	controversy	T054	C0680243
28442343	364	373	objective	T078	C2985627
28442343	382	387	study	T062	C2603343
28442343	413	416	pig	T015	C0039005
28442343	421	433	UCP1 protein	T116,T123	C0107264
28442343	443	448	study	T062	C2603343
28442343	458	507	rapid amplification of cDNA ends (RACE) technique	T063	C0887814
28442343	522	526	UCP1	T116,T123	C0107264
28442343	527	547	mRNA 3' end sequence	T045	C1623057
28442343	549	558	confirmed	T033	C0750484
28442343	564	577	exons 1 and 2	T114,T123	C0015295
28442343	585	594	UCP1 gene	T028	C1421313
28442343	599	610	transcribed	T045	C0040649
28442343	618	621	pig	T015	C0039005
28442343	631	637	cloned	T059,T063	C0598888
28442343	642	645	pig	T015	C0039005
28442343	646	655	UCP1 gene	T028	C1421313
28442343	656	669	exons 1 and 2	T114,T123	C0015295
28442343	675	684	expressed	T045	C1171362
28442343	689	701	UCP1 protein	T116,T123	C0107264
28442343	721	724	pig	T015	C0039005
28442343	725	729	gene	T028	C0017337
28442343	736	748	E. coli BL21	T007	C0014834
28442343	762	771	expressed	T045	C1171362
28442343	772	775	pig	T015	C0039005
28442343	776	788	UCP1 protein	T116,T123	C0107264
28442343	792	799	antigen	T129	C0003320
28442343	804	823	antibody production	T038	C0003261
28442343	829	835	rabbit	T015	C3887509
28442343	850	856	detect	T033	C0442726
28442343	861	873	UCP1 protein	T116,T123	C0107264
28442343	874	884	expression	T045	C1171362
28442343	898	901	pig	T015	C0039005
28442343	902	917	adipose tissues	T024	C0001527
28442343	934	937	pig	T015	C0039005
28442343	938	942	UCP1	T116,T123	C0107264
28442343	943	951	antibody	T116,T129	C0003241
28442343	963	971	antibody	T116,T129	C0003241
28442343	976	982	detect	T033	C0442726
28442343	987	993	cloned	T059,T063	C0598888
28442343	994	997	pig	T015	C0039005
28442343	998	1002	UCP1	T116,T123	C0107264
28442343	1018	1022	mice	T015	C0025929
28442343	1023	1043	adipose UCP1 protein	T116,T123	C0107264
28442343	1050	1056	result	T034	C0456984
28442343	1072	1085	exons 1 and 2	T114,T123	C0015295
28442343	1093	1096	pig	T015	C0039005
28442343	1097	1106	UCP1 gene	T028	C1421313
28442343	1112	1123	transcribed	T045	C0040649
28442343	1132	1142	translated	T045	C1519614
28442343	1150	1153	pig	T015	C0039005
28442343	1154	1168	adipose tissue	T024	C0001527
28442343	1186	1194	detected	T033	C0442726
28442343	1195	1197	no	T033	C1513916
28442343	1198	1219	uncoupled respiration	T039	C0035203
28442343	1227	1235	isolated	T169	C0205409
28442343	1236	1239	pig	T015	C0039005
28442343	1240	1250	adipocytes	T025	C0206131
28442343	1264	1271	results	T034	C0456984
28442343	1303	1306	pig	T015	C0039005
28442343	1311	1313	no	T033	C1513916
28442343	1314	1326	UCP1 protein	T116,T123	C0107264
28442343	1332	1339	results	T034	C0456984
28442343	1345	1353	resolved	T033	C3714811
28442343	1358	1369	controversy	T054	C0680243
28442343	1381	1385	pigs	T015	C0039005
28442343	1395	1415	brown adipose tissue	T024	C0006298

27641480|t|Mild encephalitis/encephalopathy with reversible splenial lesion (MERS) associated with Streptococcus pneumoniae Bacteraemia
27641480|a|Mild encephalopathy with a reversible splenial lesion (MERS) is a clinico-radiological syndrome that can be related to infectious and non-infectious conditions. Patients present with mild neurological symptoms, and magnetic resonance imaging typically demonstrate a reversible lesion with transiently reduced diffusion in the splenium of the corpus callosum. Here, we describe MERS in a 10-year-old boy who presented with fever and consciousness and who completely recovered within a few days. Streptococcus pneumoniae was the causative agent. Although viruses (especially influenza A and B) are the most common pathogen of MERS, for proper management, bacteria should be considered, as they may also lead to this condition.
27641480	0	64	Mild encephalitis/encephalopathy with reversible splenial lesion	T047	C0039082
27641480	66	70	MERS	T047	C0039082
27641480	88	112	Streptococcus pneumoniae	T007	C0038410
27641480	113	124	Bacteraemia	T047	C0152964
27641480	125	178	Mild encephalopathy with a reversible splenial lesion	T047	C0039082
27641480	180	184	MERS	T047	C0039082
27641480	191	220	clinico-radiological syndrome	T047	C0039082
27641480	233	240	related	T080	C0439849
27641480	244	254	infectious	T033	C1948090
27641480	259	284	non-infectious conditions	T169	C0521118
27641480	286	294	Patients	T101	C0030705
27641480	313	334	neurological symptoms	T184	C0235031
27641480	340	366	magnetic resonance imaging	T060	C0024485
27641480	451	482	splenium of the corpus callosum	T023	C0152319
27641480	502	506	MERS	T047	C0039082
27641480	524	527	boy	T100	C0870221
27641480	547	552	fever	T184	C0015967
27641480	557	570	consciousness	T033	C0517960
27641480	579	599	completely recovered	T033	C2826210
27641480	609	617	few days	T079	C1254367
27641480	619	643	Streptococcus pneumoniae	T007	C0038410
27641480	652	667	causative agent	T033	C0449411
27641480	678	685	viruses	T005	C0042776
27641480	698	709	influenza A	T005	C0029347
27641480	714	715	B	T005	C0029348
27641480	730	736	common	T081	C0205214
27641480	737	745	pathogen	T001	C0450254
27641480	749	753	MERS	T047	C0039082
27641480	778	786	bacteria	T007	C0004611
27641480	797	807	considered	T078	C0750591
27641480	826	830	lead	T169	C1522538
27641480	839	848	condition	T047	C0039082

27437203|t|Hypovitaminosis D and Associated Cardiometabolic Risk in Women with PCOS
27437203|a|Women with Polycystic Ovary Syndrome (PCOS) frequently suffer from metabolic disturbances like insulin resistance, hypertension and atherogenic dyslipidemia. Accumulating evidences suggest that Vitamin D deficiency is common in PCOS and may be associated with metabolic and endocrinal dysfunctions in PCOS. Thus women with PCOS may be at elevated risk of cardiovascular disease. Present study aims to evaluate Vitamin D status and to assess its association with metabolic and endocrinal dysregulations in women with PCOS, which might help in early identification and prevention of future symptomatic cardiac disease. A total of 44 women with PCOS, diagnosed by Rotterdam criteria and 45 healthy control without PCOS, were evaluated for Vitamin D and cardiometabolic risk factors, including fasting plasma glucose, insulin resistance, dyslipidemia, hs-CRP. That apart, several endocrinal parameters of hyperandrogenism were also examined. Several correlation studies were determined to establish the role of Vitamin D as a cardiometabolic risk factor in PCOS. Results were expressed as mean±SD and were statistically analysed using SPSS software version 16, unpaired student's t-test and Pearson's correlation coefficient. We found lower levels of Vitamin D, which was statistically significant as compared to healthy controls. Hyperinsulinemia, rise in insulin resistance and marked dyslipidemia was observed in the present study. Another relevant finding was significant correlation of Vitamin D with insulin and Homeostatic Model of Assessment- Insulin Resistance Index (HOMA-IR). Hypovitaminosis D was prevalent in PCOS. This was related to metabolic and hormonal disorders in PCOS. Possibly this combined with impaired fasting glucose, IR and dyslipidemia, could account for Cardio vascular risks in PCOS. Further prospective observational studies and randomized control trials are required to explore the above hypothesis.
27437203	0	17	Hypovitaminosis D	T047	C0042870
27437203	33	53	Cardiometabolic Risk	T078	C0035647
27437203	57	62	Women	T098	C0043210
27437203	68	72	PCOS	T047	C0032460
27437203	73	78	Women	T098	C0043210
27437203	84	109	Polycystic Ovary Syndrome	T047	C0032460
27437203	111	115	PCOS	T047	C0032460
27437203	140	162	metabolic disturbances	T047	C0746556
27437203	168	186	insulin resistance	T046	C0021655
27437203	188	200	hypertension	T047	C0020538
27437203	205	229	atherogenic dyslipidemia	T047	C0242339
27437203	231	243	Accumulating	T033	C4055506
27437203	267	287	Vitamin D deficiency	T047	C0042870
27437203	301	305	PCOS	T047	C0032460
27437203	317	332	associated with	T080	C0332281
27437203	333	342	metabolic	T047	C0025517
27437203	347	370	endocrinal dysfunctions	T047	C1397856
27437203	374	378	PCOS	T047	C0032460
27437203	385	390	women	T098	C0043210
27437203	396	400	PCOS	T047	C0032460
27437203	420	424	risk	T078	C0035647
27437203	428	450	cardiovascular disease	T047	C0007222
27437203	460	465	study	T062	C2603343
27437203	483	492	Vitamin D	T109,T121,T127	C0042866
27437203	535	544	metabolic	T047	C0025517
27437203	549	574	endocrinal dysregulations	T047	C1397856
27437203	578	583	women	T098	C0043210
27437203	589	593	PCOS	T047	C0032460
27437203	615	635	early identification	T061	C0814435
27437203	640	650	prevention	T061	C0679698
27437203	661	672	symptomatic	T169	C0231220
27437203	673	688	cardiac disease	T047	C0018799
27437203	704	709	women	T098	C0043210
27437203	715	719	PCOS	T047	C0032460
27437203	734	752	Rotterdam criteria	T170	C0679228
27437203	760	775	healthy control	T080	C2986479
27437203	784	788	PCOS	T047	C0032460
27437203	809	818	Vitamin D	T109,T121,T127	C0042866
27437203	823	851	cardiometabolic risk factors	T033	C0035648
27437203	863	885	fasting plasma glucose	T034	C1318375
27437203	887	905	insulin resistance	T046	C0021655
27437203	907	919	dyslipidemia	T047	C0242339
27437203	921	927	hs-CRP	T033	C0742906
27437203	949	959	endocrinal	T169	C0521425
27437203	960	970	parameters	T077	C0549193
27437203	974	990	hyperandrogenism	T047	C0206081
27437203	1019	1038	correlation studies	T062,T170	C0010101
27437203	1080	1089	Vitamin D	T109,T121,T127	C0042866
27437203	1095	1122	cardiometabolic risk factor	T033	C0035648
27437203	1126	1130	PCOS	T047	C0032460
27437203	1175	1197	statistically analysed	T062	C0871424
27437203	1204	1228	SPSS software version 16	T073,T170	C0037585
27437203	1230	1255	unpaired student's t-test	T170	C1710574
27437203	1260	1293	Pearson's correlation coefficient	T081	C0871052
27437203	1320	1329	Vitamin D	T109,T121,T127	C0042866
27437203	1382	1398	healthy controls	T080	C2986479
27437203	1400	1416	Hyperinsulinemia	T047	C0020459
27437203	1426	1444	insulin resistance	T046	C0021655
27437203	1456	1468	dyslipidemia	T047	C0242339
27437203	1497	1502	study	T062	C2603343
27437203	1560	1569	Vitamin D	T109,T121,T127	C0042866
27437203	1575	1582	insulin	T116,T121,T125	C0021641
27437203	1587	1644	Homeostatic Model of Assessment- Insulin Resistance Index	T059	C3639411
27437203	1646	1653	HOMA-IR	T059	C3639411
27437203	1656	1673	Hypovitaminosis D	T047	C0042870
27437203	1691	1695	PCOS	T047	C0032460
27437203	1717	1726	metabolic	T047	C0025517
27437203	1731	1749	hormonal disorders	T033	C3263685
27437203	1753	1757	PCOS	T047	C0032460
27437203	1787	1811	impaired fasting glucose	T033	C1272092
27437203	1813	1815	IR	T046	C0021655
27437203	1820	1832	dyslipidemia	T047	C0242339
27437203	1852	1873	Cardio vascular risks	T078	C0035647
27437203	1877	1881	PCOS	T047	C0032460
27437203	1903	1924	observational studies	T170	C3658316
27437203	1929	1954	randomized control trials	T062	C0206035
27437203	1989	1999	hypothesis	T078	C1512571

27768522|t|Masters Athletes: Exemplars of Successful Aging?
27768522|a|Global population aging has raised academic interest in successful aging to a public policy priority. Currently there is no consensus regarding the definition of successful aging. However, a synthesis of research shows successful aging can be defined as a late-life process of change characterized by high physical, psychological, cognitive, and social functioning. Masters athletes systematically train for, and compete in, organized forms of team and individual sport specifically designed for older adults. Masters athletes are often proposed as exemplars of successful aging. However, their aging status has never been examined using a comprehensive multidimensional successful aging definition. Here, we examine the successful aging literature, propose a successful aging definition based on this literature, present evidence which suggests masters athletes could be considered exemplars of successful aging according to the proposed definition, and list future experimental research directions.
27768522	0	16	Masters Athletes	T097	C0682271
27768522	31	47	Successful Aging	T040	C0001811
27768522	49	66	Global population	T098	C1257890
27768522	67	72	aging	T040	C0001811
27768522	77	101	raised academic interest	T033	C0243095
27768522	105	121	successful aging	T040	C0001811
27768522	127	140	public policy	T064	C0034033
27768522	173	182	consensus	T054	C0376298
27768522	211	227	successful aging	T040	C0001811
27768522	268	284	successful aging	T040	C0001811
27768522	305	332	late-life process of change	T048	C0233441
27768522	350	363	high physical	T033	C0516981
27768522	365	378	psychological	T041	C0233398
27768522	380	389	cognitive	T041	C0392335
27768522	395	413	social functioning	T054	C0037395
27768522	415	431	Masters athletes	T097	C0682271
27768522	432	452	systematically train	T080	C2673163
27768522	462	472	compete in	T054	C0679932
27768522	474	497	organized forms of team	T096	C0871489
27768522	502	518	individual sport	T056	C0681652
27768522	545	557	older adults	T098	C0001792
27768522	559	575	Masters athletes	T097	C0682271
27768522	611	627	successful aging	T040	C0001811
27768522	644	656	aging status	T033	C0518170
27768522	689	702	comprehensive	T080	C1880156
27768522	703	719	multidimensional	T082	C2347299
27768522	720	736	successful aging	T040	C0001811
27768522	770	797	successful aging literature	T170	C0023866
27768522	809	825	successful aging	T040	C0001811
27768522	851	861	literature	T170	C0023866
27768522	895	911	masters athletes	T097	C0682271
27768522	945	961	successful aging	T040	C0001811
27768522	1016	1037	experimental research	T062	C0681814

27772674|t|Geolocalization of Influenza Outbreak Within an Acute Care Population: A Layered-Surveillance Approach
27772674|a|We seek to use a novel layered-surveillance approach to localize influenza clusters within an acute care population. The first layer of this system is a syndromic surveillance screen to guide rapid polymerase chain reaction testing. The second layer is geolocalization and cluster analysis of these patients. We posit that any identified clusters could represent at-risk populations who could serve as high-yield targets for preventive medical interventions. This was a prospective observational surveillance study. Patients were screened with a previously derived clinical decision guideline that has a 90% sensitivity and 30% specificity for influenza. Patients received points for the following signs and symptoms within the past 7 days: cough (2 points), headache (1 point), subjective fever (1 point), and documented fever at triage (temperature >38°C [100.4°F]) (1 point). Patients scoring 3 points or higher were indicated for influenza testing. Patients were tested with Xpert Flu (Cepheid, Sunnyvale, CA), a rapid polymerase chain reaction test. Positive results were mapped with ArcGIS (ESRI, Redlands, CA) and analyzed with kernel density estimation to create heat maps. There were 1,360 patients tested with Xpert Flu with retrievable addresses within the greater Phoenix metro area. One hundred sixty-seven (12%) of them tested positive for influenza A and 23 (2%) tested positive for influenza B. The influenza A virus exhibited a clear cluster pattern within this patient population. The densest cluster was located in an approximately 1- square-mile region southeast of our hospital. Our layered-surveillance approach was effective in localizing a cluster of influenza A outbreak. This region may house a high-yield target population for public health intervention. Further collaborative efforts will be made between our hospital and the Maricopa County Department of Public Health to perform a series of community vaccination events before the next influenza season. We hope these efforts will ultimately serve to reduce the burden of this disease on our patient population, and that this system will serve as a framework for future investigations locating at-risk populations.
27772674	0	15	Geolocalization	T083	C0017446
27772674	19	28	Influenza	T047	C0021400
27772674	29	37	Outbreak	T067	C0012652
27772674	48	58	Acute Care	T058	C0679878
27772674	59	69	Population	T098	C1257890
27772674	73	93	Layered-Surveillance	T169	C0220920
27772674	94	102	Approach	T082	C0449445
27772674	126	146	layered-surveillance	T169	C0220920
27772674	147	155	approach	T082	C0449445
27772674	159	167	localize	T082	C0392752
27772674	168	177	influenza	T047	C0021400
27772674	178	186	clusters	T081	C0012641
27772674	197	207	acute care	T058	C0679878
27772674	208	218	population	T098	C1257890
27772674	244	250	system	T169	C0449913
27772674	256	265	syndromic	T047	C0039082
27772674	266	285	surveillance screen	T058	C1444548
27772674	295	334	rapid polymerase chain reaction testing	T059	C1658604
27772674	340	346	second	T081	C0205436
27772674	356	371	geolocalization	T083	C0017446
27772674	376	392	cluster analysis	T062	C0009085
27772674	402	410	patients	T101	C0030705
27772674	430	440	identified	T080	C0205396
27772674	441	449	clusters	T081	C0012641
27772674	466	485	at-risk populations	T098	C0242444
27772674	505	515	high-yield	T081	C0392762
27772674	516	523	targets	T169	C1521840
27772674	528	560	preventive medical interventions	T061	C3836383
27772674	573	617	prospective observational surveillance study	T062	C0033522
27772674	619	627	Patients	T101	C0030705
27772674	633	641	screened	T058	C0220908
27772674	668	695	clinical decision guideline	T170	C0282451
27772674	711	722	sensitivity	T081	C0036667
27772674	731	742	specificity	T081	C0037791
27772674	747	756	influenza	T047	C0021400
27772674	758	766	Patients	T101	C0030705
27772674	776	782	points	T081	C1552961
27772674	801	819	signs and symptoms	T184	C0037088
27772674	831	835	past	T079	C1444637
27772674	838	842	days	T079	C0439228
27772674	844	849	cough	T184	C0010200
27772674	862	870	headache	T184	C0018681
27772674	882	898	subjective fever	UnknownType	C0743979
27772674	914	930	documented fever	T184	C0015967
27772674	934	940	triage	T061	C0040861
27772674	942	953	temperature	T081	C0039476
27772674	982	990	Patients	T101	C0030705
27772674	991	998	scoring	T081	C0449820
27772674	1023	1032	indicated	T033	C1444656
27772674	1037	1046	influenza	T047	C0021400
27772674	1047	1054	testing	T169	C0039593
27772674	1056	1064	Patients	T101	C0030705
27772674	1070	1076	tested	T169	C0039593
27772674	1082	1091	Xpert Flu	T059	C1510438
27772674	1093	1100	Cepheid	T073,T092	C0683757
27772674	1102	1111	Sunnyvale	T083	C0017446
27772674	1113	1115	CA	T083	C0006754
27772674	1120	1156	rapid polymerase chain reaction test	T059	C1658604
27772674	1158	1166	Positive	T033	C1446409
27772674	1167	1174	results	T169	C1274040
27772674	1180	1186	mapped	T170	C3858752
27772674	1192	1198	ArcGIS	T170	C0815319
27772674	1200	1204	ESRI	T073,T092	C0683757
27772674	1206	1214	Redlands	T083	C0017446
27772674	1216	1218	CA	T083	C0006754
27772674	1224	1232	analyzed	T062	C0936012
27772674	1238	1263	kernel density estimation	T062	C4279908
27772674	1274	1283	heat maps	T073	C0024779
27772674	1302	1310	patients	T101	C0030705
27772674	1311	1317	tested	T169	C0039593
27772674	1323	1332	Xpert Flu	T059	C1510438
27772674	1338	1349	retrievable	T080	C0205556
27772674	1350	1359	addresses	T170	C1442065
27772674	1379	1397	Phoenix metro area	UnknownType	C0815251
27772674	1437	1443	tested	T169	C0039593
27772674	1444	1468	positive for influenza A	T034	C2748182
27772674	1481	1487	tested	T169	C0039593
27772674	1488	1512	positive for influenza B	T034	C2748175
27772674	1518	1535	influenza A virus	T005	C0029347
27772674	1548	1561	clear cluster	T081	C1704332
27772674	1562	1569	pattern	T082	C0449774
27772674	1582	1589	patient	T101	C0030705
27772674	1590	1600	population	T098	C1257890
27772674	1606	1621	densest cluster	T081	C1704332
27772674	1626	1633	located	T082	C0450429
27772674	1657	1668	square-mile	T081	C1552923
27772674	1669	1675	region	T083	C0017446
27772674	1676	1685	southeast	T082	C1711190
27772674	1693	1701	hospital	T073,T093	C0019994
27772674	1707	1727	layered-surveillance	T169	C0220920
27772674	1728	1736	approach	T082	C0449445
27772674	1741	1750	effective	T080	C1704419
27772674	1754	1764	localizing	T082	C0392752
27772674	1767	1774	cluster	T081	C1704332
27772674	1778	1789	influenza A	T047	C2062441
27772674	1790	1798	outbreak	T067	C0012652
27772674	1805	1811	region	T083	C0017446
27772674	1816	1821	house	T073	C2003847
27772674	1824	1834	high-yield	T081	C0392762
27772674	1835	1841	target	T169	C1521840
27772674	1842	1852	population	T098	C1257890
27772674	1857	1883	public health intervention	T058	C0699943
27772674	1893	1906	collaborative	T054	C0282116
27772674	1940	1948	hospital	T073,T093	C0019994
27772674	1957	1972	Maricopa County	T083	C3829199
27772674	1973	2000	Department of Public Health	T073,T093	C3897811
27772674	2004	2011	perform	T169	C0884358
27772674	2024	2033	community	T096	C0009462
27772674	2034	2045	vaccination	T061	C0042196
27772674	2046	2052	events	T051	C0441471
27772674	2069	2078	influenza	T047	C0021400
27772674	2079	2085	season	T079	C0036497
27772674	2134	2140	reduce	T080	C0392756
27772674	2145	2151	burden	T078	C2828008
27772674	2160	2167	disease	T047	C0012634
27772674	2175	2182	patient	T101	C0030705
27772674	2183	2193	population	T098	C1257890
27772674	2209	2215	system	T169	C0449913
27772674	2246	2252	future	T079	C0016884
27772674	2253	2267	investigations	T058	C0220825
27772674	2277	2296	at-risk populations	T098	C0242444

27851974|t|eFORGE: A Tool for Identifying Cell Type-Specific Signal in Epigenomic Data
27851974|a|Epigenome-wide association studies (EWAS) provide an alternative approach for studying human disease through consideration of non-genetic variants such as altered DNA methylation. To advance the complex interpretation of EWAS, we developed eFORGE (http://eforge.cs.ucl.ac.uk/), a new standalone and web-based tool for the analysis and interpretation of EWAS data. eFORGE determines the cell type - specific regulatory component of a set of EWAS -identified differentially methylated positions. This is achieved by detecting enrichment of overlap with DNase I hypersensitive sites across 454 samples (tissues, primary cell types, and cell lines) from the ENCODE, Roadmap Epigenomics, and BLUEPRINT projects. Application of eFORGE to 20 publicly available EWAS datasets identified disease - relevant cell types for several common diseases, a stem cell -like signature in cancer, and demonstrated the ability to detect cell - composition effects for EWAS performed on heterogeneous tissues. Our approach bridges the gap between large-scale epigenomics data and EWAS - derived target selection to yield insight into disease etiology.
27851974	0	6	eFORGE	T073,T170	C0037585
27851974	10	14	Tool	T073,T170	C0037585
27851974	31	56	Cell Type-Specific Signal	T043	C0037083
27851974	60	70	Epigenomic	T091	C2936263
27851974	71	75	Data	T078	C1511726
27851974	76	110	Epigenome-wide association studies	T063	C2350277
27851974	112	116	EWAS	T063	C2350277
27851974	154	162	studying	T062	C0008972
27851974	163	168	human	T016	C0086418
27851974	169	176	disease	T047	C0012634
27851974	202	222	non-genetic variants	T080	C0205419
27851974	239	254	DNA methylation	T044	C0376452
27851974	297	301	EWAS	T063	C2350277
27851974	316	322	eFORGE	T073,T170	C0037585
27851974	375	389	web-based tool	T073,T170	C0037585
27851974	398	406	analysis	T169	C1524024
27851974	429	433	EWAS	T063	C2350277
27851974	434	438	data	T078	C1511726
27851974	440	446	eFORGE	T073,T170	C0037585
27851974	462	471	cell type	T170	C0449475
27851974	474	482	specific	T080	C0205369
27851974	483	493	regulatory	T077	C1704735
27851974	494	503	component	T167	C0729650
27851974	516	520	EWAS	T063	C2350277
27851974	533	547	differentially	T080	C0443199
27851974	548	558	methylated	T044	C0376452
27851974	559	568	positions	T082	C0733755
27851974	590	599	detecting	T033	C0442726
27851974	614	621	overlap	T052	C2700387
27851974	627	634	DNase I	T116,T126	C0011519
27851974	635	655	hypersensitive sites	T086	C0004793
27851974	667	674	samples	T077	C2347026
27851974	676	683	tissues	T024	C0040300
27851974	685	692	primary	T080	C0205225
27851974	693	703	cell types	T170	C0449475
27851974	709	719	cell lines	T025	C0007600
27851974	730	736	ENCODE	T170	C0282574
27851974	738	757	Roadmap Epigenomics	T170	C0282574
27851974	763	781	BLUEPRINT projects	T170	C0282574
27851974	798	804	eFORGE	T073,T170	C0037585
27851974	830	834	EWAS	T063	C2350277
27851974	835	843	datasets	T170	C0150098
27851974	855	862	disease	T047	C0012634
27851974	865	873	relevant	T080	C2347946
27851974	874	884	cell types	T170	C0449475
27851974	897	903	common	T081	C0205214
27851974	904	912	diseases	T047	C0012634
27851974	916	925	stem cell	T025	C0038250
27851974	945	951	cancer	T191	C0006826
27851974	985	991	detect	T033	C0442726
27851974	992	996	cell	T025	C0007634
27851974	999	1010	composition	T201	C0486616
27851974	1011	1018	effects	T080	C1280500
27851974	1023	1027	EWAS	T063	C2350277
27851974	1041	1062	heterogeneous tissues	T024	C1179404
27851974	1113	1124	epigenomics	T091	C2936263
27851974	1125	1129	data	T078	C1511726
27851974	1134	1138	EWAS	T063	C2350277
27851974	1141	1148	derived	T080	C1441547
27851974	1149	1155	target	T169	C1521840
27851974	1156	1165	selection	T052	C1707391
27851974	1188	1204	disease etiology	T169	C1314792

27623725|t|Spectrum and prevalence of thyroid diseases seen at a tertiary health facility in Sagamu, South-West Nigeria
27623725|a|The prevalence of goitrous swelling has reduced in Nigeria since the introduction of salt iodisation programme. Thyroid disorders are the second most common endocrine disorder after diabetes mellitus worldwide. They present to general outpatient, medical and surgical clinics accompanied by great anxiety and poor health-related quality of life. The study aimed to determine and describe the spectrum of thyroid disorders seen at Olabisi Onabanjo University Teaching Hospital over a 10- year period. This was a retrospective analysis of records of patients who presented to the hospital with thyroid swellings over a 10- year period (June 2004 to June 2014). Clinicopathological and demographic data obtained from hospital records in 175 patients diagnosed by clinical examination, thyroid ultrasound, hormone profile and histological confirmation in cases that had surgery were analysed for this study. The records of 175 patients were obtained comprising 151 (86.3%) females and 24 (13.7%) males (female to male ratio of 6.3:1) with age range from 18 to 76 years and mean age of 42.3 years, standard deviation 13.5. With clinical diagnosis, distribution of thyroid diseases was simple goitre 103 (58.9%), toxic goitre 64 (36.6%), hypothyroidism 3 (1.7%), malignant goitre 4 (2.3%) and thyroiditis 1 (0.6%). The age group of 30-49 years had the highest prevalence of the thyroid diseases 100 (57.2%) while the extremes of age, below 20 and over 70 years had the least (5.1 and 2.9%, respectively). The prevalent form of thyroid diseases seen at Olabisi Onabanjo University Teaching Hospital was simple goitre and most common in females. Studies on autoimmunity and other goitrogens are required to further elucidate the cause of this high prevalence.
27623725	0	8	Spectrum	T077	C1254372
27623725	13	23	prevalence	T081	C0220900
27623725	27	43	thyroid diseases	T047	C0040128
27623725	54	78	tertiary health facility	T073,T093	C0018704
27623725	82	88	Sagamu	T083	C0017446
27623725	90	108	South-West Nigeria	T083	C0028075
27623725	113	123	prevalence	T081	C0220900
27623725	127	144	goitrous swelling	T046	C0018021
27623725	160	167	Nigeria	T083	C0028075
27623725	194	219	salt iodisation programme	T169	C3484370
27623725	221	238	Thyroid disorders	T047	C0040128
27623725	266	284	endocrine disorder	T047	C0014130
27623725	291	308	diabetes mellitus	T047	C0011849
27623725	344	354	outpatient	T073,T093	C0029916
27623725	356	363	medical	T073,T093	C0338037
27623725	368	384	surgical clinics	T093	C3825617
27623725	406	413	anxiety	T033	C0003467
27623725	418	422	poor	T080	C0542537
27623725	423	453	health-related quality of life	T078	C4279947
27623725	459	464	study	T062	C2603343
27623725	501	509	spectrum	T077	C1254372
27623725	513	530	thyroid disorders	T047	C0040128
27623725	539	584	Olabisi Onabanjo University Teaching Hospital	T073,T093	C0019994
27623725	596	600	year	T079	C0439234
27623725	620	633	retrospective	T080	C1514923
27623725	634	642	analysis	T062	C0936012
27623725	646	665	records of patients	T170	C0025102
27623725	687	695	hospital	T073,T093	C0019994
27623725	701	718	thyroid swellings	T046	C0018021
27623725	730	734	year	T079	C0439234
27623725	768	787	Clinicopathological	T078	C1511726
27623725	792	808	demographic data	T078	C1511726
27623725	823	839	hospital records	T073,T170	C0019980
27623725	847	855	patients	T101	C0030705
27623725	856	865	diagnosed	T033	C0011900
27623725	869	889	clinical examination	T033	C1456356
27623725	891	909	thyroid ultrasound	T060	C0877525
27623725	911	926	hormone profile	T059	C0022885
27623725	931	943	histological	T169	C0205462
27623725	944	956	confirmation	T033	C0750484
27623725	960	965	cases	T169	C0868928
27623725	975	982	surgery	T169	C0038895
27623725	988	996	analysed	T062	C0936012
27623725	1006	1011	study	T062	C2603343
27623725	1017	1024	records	T170	C0034869
27623725	1032	1040	patients	T101	C0030705
27623725	1078	1085	females	T032	C0086287
27623725	1101	1106	males	T032	C0086582
27623725	1108	1114	female	T032	C0086287
27623725	1118	1122	male	T032	C0086582
27623725	1123	1128	ratio	T081	C0456603
27623725	1144	1147	age	T032	C0001779
27623725	1168	1173	years	T079	C0439234
27623725	1183	1186	age	T032	C0001779
27623725	1195	1200	years	T079	C0439234
27623725	1202	1220	standard deviation	T081	C0871420
27623725	1232	1250	clinical diagnosis	T060	C0332140
27623725	1268	1284	thyroid diseases	T047	C0040128
27623725	1289	1302	simple goitre	T047	C0018022
27623725	1316	1328	toxic goitre	T047	C0600086
27623725	1341	1355	hypothyroidism	T047	C0020676
27623725	1366	1382	malignant goitre	T191	C0877414
27623725	1396	1407	thyroiditis	T047	C0040147
27623725	1422	1431	age group	T100	C0027362
27623725	1441	1446	years	T079	C0439234
27623725	1463	1473	prevalence	T081	C0220900
27623725	1481	1497	thyroid diseases	T047	C0040128
27623725	1532	1535	age	T032	C0001779
27623725	1558	1563	years	T079	C0439234
27623725	1630	1646	thyroid diseases	T047	C0040128
27623725	1655	1700	Olabisi Onabanjo University Teaching Hospital	T073,T093	C0019994
27623725	1705	1718	simple goitre	T047	C0018022
27623725	1738	1745	females	T032	C0086287
27623725	1747	1754	Studies	T062	C2603343
27623725	1758	1770	autoimmunity	T046	C0004368
27623725	1781	1791	goitrogens	T121	C0018025
27623725	1849	1859	prevalence	T081	C0220900

28430965|t|Nrf2 regulates the inflammatory response, including heme oxygenase-1 induction, by mycoplasma pneumoniae lipid-associated membrane proteins in THP-1 cells
28430965|a|A series of inflammatory responses caused by Mycoplasma pneumoniae largely depend on the lipid-associated membrane proteins (LAMPs). Nuclear factor E2-related factor 2 (Nrf2), a transcription factor, is considered to be a critical modulator of inflammatory responses and cellular redox homeostasis. Monocytes play an important role in the invasion and immunity to resist pathogens. Here, we investigated the role of Nrf2 in the anti-inflammatory response stimulated by LAMPs using the human monocyte cell line THP-1. LAMPs were shown to affect the localization of Nrf2, and the levels of reactive oxygen species and inflammatory reactants, including nitric oxide (NO), prostaglandin E2 (PGE2) and cytokines (IL-6, IL-8), were highly elevated in LAMP -stimulated Nrf2 -silenced THP-1 cells. Moreover, LAMPs induced the levels of mRNA and the expression of heme oxygenase-1 (HO-1). In summary, our results demonstrated that LAMPs cause nuclear translocation of Nrf2, which further suppresses the expression of inflammatory reactants in THP-1 cells.
28430965	0	4	Nrf2	T116,T123	C0289507
28430965	19	40	inflammatory response	T046	C1155266
28430965	52	68	heme oxygenase-1	T116,T126	C0538674
28430965	83	104	mycoplasma pneumoniae	T007	C0026941
28430965	105	139	lipid-associated membrane proteins	T116,T123	C2936482
28430965	143	154	THP-1 cells	T025	C0682523
28430965	167	189	inflammatory responses	T046	C1155266
28430965	200	221	Mycoplasma pneumoniae	T007	C0026941
28430965	244	278	lipid-associated membrane proteins	T116,T123	C2936482
28430965	280	285	LAMPs	T116,T123	C2936482
28430965	288	322	Nuclear factor E2-related factor 2	T116,T123	C0289507
28430965	324	328	Nrf2	T116,T123	C0289507
28430965	333	353	transcription factor	T116,T123	C0040648
28430965	399	421	inflammatory responses	T046	C1155266
28430965	426	452	cellular redox homeostasis	T043	C1156287
28430965	454	463	Monocytes	T025	C0026473
28430965	494	502	invasion	T046	C2699153
28430965	507	515	immunity	T039	C0020964
28430965	526	535	pathogens	T001	C0450254
28430965	571	575	Nrf2	T116,T123	C0289507
28430965	583	609	anti-inflammatory response	T040	C1327441
28430965	624	629	LAMPs	T116,T123	C2936482
28430965	640	670	human monocyte cell line THP-1	T025	C0682523
28430965	672	677	LAMPs	T116,T123	C2936482
28430965	703	715	localization	T169	C0475264
28430965	719	723	Nrf2	T116,T123	C0289507
28430965	743	766	reactive oxygen species	T123,T196	C0162772
28430965	771	793	inflammatory reactants	T123	C0574031
28430965	805	817	nitric oxide	T121,T123,T197	C0028128
28430965	819	821	NO	T121,T123,T197	C0028128
28430965	824	840	prostaglandin E2	T109	C3813211
28430965	842	846	PGE2	T109	C3813211
28430965	852	861	cytokines	T116,T129	C0079189
28430965	863	867	IL-6	T116,T129	C0021760
28430965	869	873	IL-8	T116,T129	C0079633
28430965	900	904	LAMP	T116,T123	C2936482
28430965	917	921	Nrf2	T116,T123	C0289507
28430965	932	943	THP-1 cells	T025	C0682523
28430965	955	960	LAMPs	T116,T123	C2936482
28430965	983	987	mRNA	T114,T123	C0035696
28430965	996	1006	expression	T045	C1171362
28430965	1010	1026	heme oxygenase-1	T116,T126	C0538674
28430965	1028	1032	HO-1	T116,T126	C0538674
28430965	1077	1082	LAMPs	T116,T123	C2936482
28430965	1089	1110	nuclear translocation	T044	C1518440
28430965	1114	1118	Nrf2	T116,T123	C0289507
28430965	1149	1159	expression	T045	C1171362
28430965	1163	1185	inflammatory reactants	T123	C0574031
28430965	1189	1200	THP-1 cells	T025	C0682523

27710899|t|Proliferation -enhancing effects of gastrodin on RSC96 Schwann cells by regulating ERK1 / 2 and PI3K signaling pathways
27710899|a|The proliferation and migration of Schwann cells (SCs) are essential in the process of peripheral nerve repair. A large amount of studies focused on the promotion of the growth of SCs for cell based therapy. Gastrodin (GAS), the main constituent of a Chinese traditional herbal medicine named Gastrodia elata Blume, has been reported to be associated with neuroprotective properties. Besides, GAS activated MAPK and PI3K signaling pathways which are often involved in growth of nerve cells were also reported. Based on the hypothesis that GAS may have an effect on SCs growth, we studied the effect of GAS on rat RSC96 Schwann cells (SCs) and further explored the underlying mechanism. Various concentration of GAS (0μM, 50μM, 100μM, and 200μM) was used for treatment of RSC96 SCs, with the cell proliferation and gene expression of several neurotrophic factors to be detected. Regulation of MAPK and PI3K signaling pathways were assayed by detecting phosphorylation of ERK1 / 2 and Akt. The results showed that GAS could effectively promote proliferation of RSC96 SCs in a dose - and time -dependent manner. The best performance was obtained at the concentration of 200μM. Exploration of the underlying mechanism showed that GAS probably affects SCs metabolism through inhibiting ERK1 / 2 phosphorylation and activating Akt phosphorylation in RSC96 SCs. This study may provide reference for its application in treatment of peripheral nerve injuries.
27710899	0	13	Proliferation	T043	C0596290
27710899	25	35	effects of	T080	C1704420
27710899	36	45	gastrodin	T109	C0061139
27710899	49	68	RSC96 Schwann cells	T025	C0036387
27710899	72	82	regulating	T038	C1327622
27710899	83	87	ERK1	T116,T126	C0082529
27710899	90	91	2	T116,T126	C0170168
27710899	96	100	PI3K	T116,T126	C0044602
27710899	101	119	signaling pathways	T044	C0037080
27710899	124	137	proliferation	T043	C0596290
27710899	142	151	migration	T043	C1622501
27710899	155	168	Schwann cells	T025	C0036387
27710899	170	173	SCs	T025	C0036387
27710899	196	203	process	T067	C1522240
27710899	207	230	peripheral nerve repair	T061	C0196777
27710899	273	282	promotion	T052	C0033414
27710899	290	296	growth	T043	C0007595
27710899	300	303	SCs	T025	C0036387
27710899	308	326	cell based therapy	T061	C3658313
27710899	328	337	Gastrodin	T109	C0061139
27710899	339	342	GAS	T109	C0061139
27710899	371	390	Chinese traditional	T091	C0025124
27710899	391	406	herbal medicine	T121	C2240391
27710899	413	434	Gastrodia elata Blume	T002	C1040858
27710899	445	453	reported	T058	C0700287
27710899	460	475	associated with	T080	C0332281
27710899	476	502	neuroprotective properties	T043	C0598958
27710899	513	516	GAS	T109	C0061139
27710899	517	526	activated	T052	C1879547
27710899	527	531	MAPK	T116,T126	C0752312
27710899	536	540	PI3K	T116,T126	C0044602
27710899	541	559	signaling pathways	T044	C0037080
27710899	588	594	growth	T043	C0007595
27710899	598	609	nerve cells	T025	C0027882
27710899	620	628	reported	T058	C0700287
27710899	643	653	hypothesis	T078	C1512571
27710899	659	662	GAS	T109	C0061139
27710899	685	688	SCs	T025	C0036387
27710899	689	695	growth	T043	C0007595
27710899	712	721	effect of	T080	C1704420
27710899	722	725	GAS	T109	C0061139
27710899	729	732	rat	T015	C0034693
27710899	733	752	RSC96 Schwann cells	T025	C0036387
27710899	754	757	SCs	T025	C0036387
27710899	795	804	mechanism	T169	C0441712
27710899	814	827	concentration	T081	C1446561
27710899	831	834	GAS	T109	C0061139
27710899	878	887	treatment	T061	C0087111
27710899	891	900	RSC96 SCs	T025	C0036387
27710899	911	929	cell proliferation	T043	C0596290
27710899	934	949	gene expression	T045	C0017262
27710899	961	981	neurotrophic factors	T116,T123	C0027754
27710899	998	1011	Regulation of	T038	C1327622
27710899	1012	1016	MAPK	T116,T126	C0752312
27710899	1021	1025	PI3K	T116,T126	C0044602
27710899	1026	1044	signaling pathways	T044	C0037080
27710899	1071	1086	phosphorylation	T044	C1158886
27710899	1090	1094	ERK1	T116,T126	C0082529
27710899	1097	1098	2	T116,T126	C0170168
27710899	1103	1106	Akt	T116,T126	C0164786
27710899	1132	1135	GAS	T109	C0061139
27710899	1154	1161	promote	T052	C0033414
27710899	1162	1175	proliferation	T043	C0596290
27710899	1179	1188	RSC96 SCs	T025	C0036387
27710899	1194	1198	dose	T081	C0178602
27710899	1205	1209	time	T079	C0040223
27710899	1270	1283	concentration	T081	C1446561
27710899	1294	1305	Exploration	T061	C1280903
27710899	1324	1333	mechanism	T169	C0441712
27710899	1346	1349	GAS	T109	C0061139
27710899	1367	1370	SCs	T025	C0036387
27710899	1371	1381	metabolism	T043	C1524026
27710899	1390	1400	inhibiting	T052	C3463820
27710899	1401	1405	ERK1	T116,T126	C0082529
27710899	1408	1409	2	T116,T126	C0170168
27710899	1410	1425	phosphorylation	T044	C1158886
27710899	1430	1440	activating	T052	C1879547
27710899	1441	1444	Akt	T116,T126	C0164786
27710899	1445	1460	phosphorylation	T044	C1158886
27710899	1464	1473	RSC96 SCs	T025	C0036387
27710899	1531	1540	treatment	T061	C0087111
27710899	1544	1569	peripheral nerve injuries	T037	C0262593

27499974|t|Short-term effects of a vibrotactile neck -based treatment device for positional obstructive sleep apnea: preliminary data on tolerability and efficacy
27499974|a|Positional supine obstructive sleep apnea syndrome (OSAS) characterizes a subgroup of patients suffering from OSAS. Several devices designed to limit supine position have been developed, but evidences of their efficacy and safety are lacking. It is unclear whether a neck-worn vibrating device could induce positional change in patients with positional OSAS. We evaluated the efficacy of a neck -worn device to induce supine avoidance positional feedback over a short-term trial in OSAS patients and its impact on sleep quality and polysomnographyc indexes. Twenty patients with positional apneas / hypopneas were prospectively studied. Baseline characteristics of daytime somnolence and risk of sleep apnea were screened and the efficacy of a 3-day trial of supine - avoidance therapy by vibrotactile neck worn device assessed by reporting the self-perceived change in quality of sleep and performing cardio-respiratory polysomnography. Comparison between baseline and treatment results was performed. The neck device produced a reduction in overall apnea-hypopnea index (AHI) (mean AHI pre =16.8/h and post =4.4/h, P<0.0001), oxygen desaturation (pre =13.7/h and post =3.8/h, P<0.0001) and Respiratory Disturbance Indexes (RDI) (20.0/h vs. 5.2/h; P<0.0001).The time spent in supine position decreased from 62.1% to 33.7% of the total (P<0.001). However, the impact on the perceived quality of sleep was unpredictable. The neck position therapy device is effective in restricting supine sleep, improving AHI and related polysomnographic indexes. However, at least in a short-term trial, it seems unable to improve the patient's sleep quality.
27499974	0	10	Short-term	T079	C0443303
27499974	11	18	effects	T033	C1518681
27499974	24	36	vibrotactile	T081	C0871577
27499974	37	41	neck	T029	C0027530
27499974	49	65	treatment device	T074	C0336568
27499974	70	104	positional obstructive sleep apnea	T047	C0520679
27499974	106	117	preliminary	T079	C0439611
27499974	118	122	data	T078	C1511726
27499974	126	138	tolerability	T062	C3274448
27499974	143	151	efficacy	T062	C1707887
27499974	152	169	Positional supine	T082	C0038846
27499974	170	202	obstructive sleep apnea syndrome	T047	C0520679
27499974	204	208	OSAS	T047	C0520679
27499974	226	234	subgroup	T185	C1515021
27499974	238	246	patients	T101	C0030705
27499974	247	256	suffering	T048	C0683278
27499974	262	266	OSAS	T047	C0520679
27499974	268	275	Several	T081	C0443302
27499974	276	283	devices	T074	C0336568
27499974	302	317	supine position	T082	C0038846
27499974	343	355	evidences of	T169	C0332120
27499974	362	370	efficacy	T080	C1280519
27499974	375	381	safety	T080	C0025079
27499974	386	393	lacking	T080	C0332268
27499974	401	408	unclear	T033	C3845108
27499974	419	428	neck-worn	T029	C0027530
27499974	429	445	vibrating device	T074	C0025080
27499974	459	476	positional change	T033	C0560786
27499974	480	488	patients	T101	C0030705
27499974	494	509	positional OSAS	T047	C0520679
27499974	514	523	evaluated	T058	C0220825
27499974	528	536	efficacy	T080	C1280519
27499974	542	546	neck	T029	C0027530
27499974	553	559	device	T074	C0025080
27499974	563	569	induce	T169	C0205263
27499974	570	576	supine	T082	C0038846
27499974	577	586	avoidance	T033	C0231426
27499974	587	597	positional	T082	C0038846
27499974	614	624	short-term	T079	C0443303
27499974	634	638	OSAS	T047	C0520679
27499974	639	647	patients	T101	C0030705
27499974	656	662	impact	T080	C4049986
27499974	666	671	sleep	T040	C0037313
27499974	672	679	quality	T080	C0332306
27499974	684	708	polysomnographyc indexes	T060	C0162701
27499974	717	725	patients	T101	C0030705
27499974	731	748	positional apneas	T047	C0520679
27499974	751	760	hypopneas	T047	C4285910
27499974	766	787	prospectively studied	T062	C0033522
27499974	789	797	Baseline	T081	C1442488
27499974	798	813	characteristics	T080	C1521970
27499974	817	835	daytime somnolence	T184	C2219848
27499974	840	844	risk	T033	C0035648
27499974	848	859	sleep apnea	T047	C0037315
27499974	865	873	screened	T060	C1710031
27499974	882	890	efficacy	T080	C1280519
27499974	911	917	supine	T082	C0038846
27499974	920	929	avoidance	T033	C0231426
27499974	930	937	therapy	T061	C0087111
27499974	941	953	vibrotactile	T081	C0871577
27499974	954	963	neck worn	T029	C0027530
27499974	964	970	device	T074	C0025080
27499974	1012	1018	change	T169	C0392747
27499974	1022	1038	quality of sleep	T033	C0424563
27499974	1054	1088	cardio-respiratory polysomnography	T060	C0162701
27499974	1090	1100	Comparison	T052	C1707455
27499974	1109	1117	baseline	T033	C0243095
27499974	1122	1139	treatment results	T033	C0243095
27499974	1144	1153	performed	T169	C0884358
27499974	1159	1163	neck	T029	C0027530
27499974	1164	1170	device	T074	C0025080
27499974	1182	1191	reduction	T080	C0392756
27499974	1195	1202	overall	T080	C1561607
27499974	1203	1223	apnea-hypopnea index	T170	C4083070
27499974	1225	1228	AHI	T170	C4083070
27499974	1236	1239	AHI	T170	C4083070
27499974	1240	1243	pre	T079	C0332152
27499974	1256	1260	post	T079	C0687676
27499974	1280	1299	oxygen desaturation	T033	C4061338
27499974	1301	1304	pre	T079	C0332152
27499974	1317	1321	post	T079	C0687676
27499974	1344	1375	Respiratory Disturbance Indexes	T033	C2111853
27499974	1377	1380	RDI	T033	C2111853
27499974	1429	1444	supine position	T082	C0038846
27499974	1445	1454	decreased	T081	C0205216
27499974	1512	1518	impact	T080	C4049986
27499974	1536	1552	quality of sleep	T033	C0424563
27499974	1557	1570	unpredictable	T033	C0243095
27499974	1576	1580	neck	T029	C0027530
27499974	1581	1589	position	T082	C0733755
27499974	1590	1604	therapy device	T074	C0336568
27499974	1608	1617	effective	T080	C1704419
27499974	1621	1632	restricting	T169	C0443288
27499974	1633	1639	supine	T082	C0038846
27499974	1640	1645	sleep	T040	C0037313
27499974	1647	1656	improving	T080	C1272745
27499974	1657	1660	AHI	T170	C4083070
27499974	1673	1697	polysomnographic indexes	T060	C0162701
27499974	1722	1732	short-term	T079	C0443303
27499974	1749	1755	unable	T033	C1299582
27499974	1759	1766	improve	T080	C1272745
27499974	1771	1780	patient's	T101	C0030705
27499974	1781	1786	sleep	T040	C0037313
27499974	1787	1794	quality	T080	C0332306

27993971|t|The CD9, CD81, and CD151 EC2 domains bind to the classical RGD-binding site of integrin αvβ3
27993971|a|Tetraspanins play important roles in normal (e.g., cell adhesion, motility, activation, and proliferation), and pathological conditions (e.g., metastasis and viral infection). Tetraspanins interact with integrins and regulate integrin functions, but the specifics of tetraspanin - integrin interaction are unclear. Using co-immunoprecipitation with integrins as a sole method to detect interaction between integrins and full-length tetraspanins, it has been proposed that the variable region (helices D and E) of the extracellular-2 (EC2) of tetraspanins laterally associate with non-ligand-binding site of integrins. We describe that, using adhesion assays, the EC2 domain of CD81, CD9, and CD151 bound to integrin αvβ3 and this binding was suppressed by cRGDfV, a specific inhibitor of αvβ3, and antibody 7E3 that is mapped to the ligand-binding site of β3. We also present evidence that the specificity loop of β3 directly bound to the EC2 domains. This suggests that the EC2 domains specifically binds to the classical ligand-binding site of αvβ3. αvβ3 was a more effective receptor for the EC2 domains than previously known tetraspanin receptors α3β1, α4β1, and α6β1. Docking simulation predicted that the helices A and B of CD81 EC2 binds to the RGD-binding site of αvβ3. Substituting Lys residues at position 116, 144/148 of CD81 EC2 in the predicted integrin - binding interface reduced the binding of CD81 EC2 to αvβ3, consistent with the docking model. These findings suggest that, in contrast to previous models, the ligand-binding site of integrin αvβ3, a new tetraspanin receptor, binds to the constant region (helices A and B) of the EC2 domain.
27993971	4	7	CD9	T116,T129	C1701084
27993971	9	13	CD81	T116,T129	C1452163
27993971	19	24	CD151	T116,T129	C0389372
27993971	25	36	EC2 domains	T082	C1517050
27993971	37	41	bind	T044	C1167622
27993971	59	75	RGD-binding site	UnknownType	C0684162
27993971	79	92	integrin αvβ3	T116,T192	C1138427
27993971	93	105	Tetraspanins	T116,T123	C3178812
27993971	121	126	roles	T077	C1705810
27993971	144	157	cell adhesion	T043	C0007577
27993971	159	167	motility	T040	C0007608
27993971	169	179	activation	T043	C1326120
27993971	185	198	proliferation	T043	C0596290
27993971	205	217	pathological	T169	C1521733
27993971	218	228	conditions	T080	C0348080
27993971	236	246	metastasis	T046	C4255448
27993971	251	266	viral infection	T047	C0042769
27993971	269	281	Tetraspanins	T116,T123	C3178812
27993971	282	290	interact	T043	C0007582
27993971	296	305	integrins	T116,T129,T192	C0021701
27993971	319	327	integrin	T116,T129,T192	C0021701
27993971	328	337	functions	T044	C1148560
27993971	360	371	tetraspanin	T116,T123	C3178812
27993971	374	382	integrin	T116,T129,T192	C0021701
27993971	383	394	interaction	T043	C0007582
27993971	399	406	unclear	T033	C3845108
27993971	414	436	co-immunoprecipitation	T059	C1449705
27993971	442	451	integrins	T116,T129,T192	C0021701
27993971	479	490	interaction	T043	C0007582
27993971	499	508	integrins	T116,T129,T192	C0021701
27993971	525	537	tetraspanins	T116,T123	C3178812
27993971	569	584	variable region	T082	C1254362
27993971	586	595	helices D	T082	C1254362
27993971	600	601	E	T082	C1254362
27993971	610	625	extracellular-2	T082	C1517050
27993971	627	630	EC2	T082	C1517050
27993971	635	647	tetraspanins	T116,T123	C3178812
27993971	658	672	associate with	T080	C0332281
27993971	673	696	non-ligand-binding site	T192	C0005456
27993971	700	709	integrins	T116,T129,T192	C0021701
27993971	735	743	adhesion	T043	C0007577
27993971	744	750	assays	T059	C0005507
27993971	756	766	EC2 domain	T082	C1517050
27993971	770	774	CD81	T116,T129	C1452163
27993971	776	779	CD9	T116,T129	C1701084
27993971	785	790	CD151	T116,T129	C0389372
27993971	800	813	integrin αvβ3	T116,T192	C1138427
27993971	823	830	binding	T044	C1167622
27993971	835	845	suppressed	T169	C1260953
27993971	849	855	cRGDfV	T116,T121	C0762960
27993971	868	877	inhibitor	T120	C0003139
27993971	881	885	αvβ3	T116,T192	C1138427
27993971	891	903	antibody 7E3	T116,T121,T129	C0288672
27993971	926	945	ligand-binding site	T087	C0682969
27993971	949	951	β3	T116,T123	C0245726
27993971	999	1003	loop	T082	C0445022
27993971	1007	1009	β3	T116,T123	C0245726
27993971	1019	1024	bound	T044	C1167622
27993971	1032	1043	EC2 domains	T082	C1517050
27993971	1050	1058	suggests	T078	C1705535
27993971	1068	1079	EC2 domains	T082	C1517050
27993971	1093	1098	binds	T044	C1167622
27993971	1116	1135	ligand-binding site	T087	C0682969
27993971	1139	1143	αvβ3	T116,T192	C1138427
27993971	1145	1149	αvβ3	T116,T192	C1138427
27993971	1161	1170	effective	T080	C1704419
27993971	1171	1179	receptor	T116,T192	C0597357
27993971	1188	1199	EC2 domains	T082	C1517050
27993971	1222	1233	tetraspanin	T116,T123	C3178812
27993971	1234	1243	receptors	T116,T192	C0597357
27993971	1244	1248	α3β1	T116,T192	C0246766
27993971	1250	1254	α4β1	T116,T192	C0209606
27993971	1260	1264	α6β1	T116,T192	C0246951
27993971	1266	1284	Docking simulation	T063	C3494273
27993971	1285	1294	predicted	T078	C0681842
27993971	1304	1313	helices A	T082	C1254362
27993971	1318	1319	B	T082	C1254362
27993971	1323	1327	CD81	T116,T129	C1452163
27993971	1328	1331	EC2	T082	C1517050
27993971	1332	1337	binds	T044	C1167622
27993971	1345	1361	RGD-binding site	UnknownType	C0684162
27993971	1365	1369	αvβ3	T116,T192	C1138427
27993971	1384	1396	Lys residues	T116,T121,T123	C0024337
27993971	1400	1408	position	T082	C0733755
27993971	1425	1429	CD81	T116,T129	C1452163
27993971	1430	1433	EC2	T082	C1517050
27993971	1441	1450	predicted	T078	C0681842
27993971	1451	1459	integrin	T116,T129,T192	C0021701
27993971	1462	1469	binding	T044	C1167622
27993971	1480	1487	reduced	T080	C0392756
27993971	1492	1499	binding	T044	C1167622
27993971	1503	1507	CD81	T116,T129	C1452163
27993971	1508	1511	EC2	T082	C1517050
27993971	1515	1519	αvβ3	T116,T192	C1138427
27993971	1521	1536	consistent with	T078	C0332290
27993971	1541	1554	docking model	T063	C3494273
27993971	1562	1570	findings	T033	C0243095
27993971	1571	1578	suggest	T078	C1705535
27993971	1585	1596	in contrast	T033	C3641828
27993971	1600	1608	previous	T079	C0205156
27993971	1609	1615	models	T170	C0026344
27993971	1621	1640	ligand-binding site	T087	C0682969
27993971	1644	1657	integrin αvβ3	T116,T192	C1138427
27993971	1665	1676	tetraspanin	T116,T123	C3178812
27993971	1677	1685	receptor	T116,T192	C0597357
27993971	1687	1692	binds	T044	C1167622
27993971	1700	1715	constant region	T082	C1254362
27993971	1717	1726	helices A	T082	C1254362
27993971	1731	1732	B	T082	C1254362
27993971	1741	1751	EC2 domain	T082	C1517050

28507142|t|Quantitative assessment of passive electrical properties of the cardiac T-tubular system by FRAP microscopy
28507142|a|Well-coordinated activation of all cardiomyocytes must occur on every heartbeat. At the cell level, a complex network of sarcolemmal invaginations, called the transverse-axial tubular system (TATS), propagates membrane potential changes to the cell core, ensuring synchronous and uniform excitation-contraction coupling. Although myocardial conduction of excitation has been widely described, the electrical properties of the TATS remain mostly unknown. Here, we exploit the formal analogy between diffusion and electrical conductivity to link the latter with the diffusional properties of TATS. Fluorescence recovery after photobleaching (FRAP) microscopy is used to probe the diffusion properties of TATS in isolated rat cardiomyocytes: A fluorescent dextran inside TATS lumen is photobleached, and signal recovery by diffusion of unbleached dextran from the extracellular space is monitored. We designed a mathematical model to correlate the time constant of fluorescence recovery with the apparent diffusion coefficient of the fluorescent molecules. Then, apparent diffusion is linked to electrical conductivity and used to evaluate the efficiency of the passive spread of membrane depolarization along TATS. The method is first validated in cells where most TATS elements are acutely detached by osmotic shock and then applied to probe TATS electrical conductivity in failing heart cells. We find that acute and pathological tubular remodeling significantly affect TATS electrical conductivity. This may explain the occurrence of defects in action potential propagation at the level of single T-tubules, recently observed in diseased cardiomyocytes.
28507142	0	12	Quantitative	T081	C0392762
28507142	13	23	assessment	T058	C0220825
28507142	27	34	passive	T080	C3686820
28507142	35	45	electrical	T169	C0442828
28507142	46	56	properties	T042	C0231493
28507142	64	88	cardiac T-tubular system	T022	C0018796
28507142	92	96	FRAP	T059	C1138405
28507142	97	107	microscopy	T059	C0026018
28507142	125	135	activation	T052	C1879547
28507142	143	157	cardiomyocytes	T025	C0225828
28507142	178	187	heartbeat	T042	C0425583
28507142	196	200	cell	T025	C0007634
28507142	210	217	complex	T080	C0439855
28507142	218	225	network	T169	C1882071
28507142	229	240	sarcolemmal	T026	C0036208
28507142	241	254	invaginations	T190	C0221224
28507142	267	298	transverse-axial tubular system	T026	C1179122
28507142	300	304	TATS	T026	C1179122
28507142	307	317	propagates	T043	C4236672
28507142	318	336	membrane potential	T043	C0025251
28507142	352	356	cell	T025	C0007634
28507142	357	361	core	T082	C0444669
28507142	372	383	synchronous	T079	C0439580
28507142	396	427	excitation-contraction coupling	T039	C2717948
28507142	438	448	myocardial	T024	C0027061
28507142	449	459	conduction	T042	C0232217
28507142	463	473	excitation	T052	C0549255
28507142	505	515	electrical	T169	C0442828
28507142	516	526	properties	T042	C0231493
28507142	534	538	TATS	T026	C1179122
28507142	590	597	analogy	T078	C0679213
28507142	606	615	diffusion	T070	C0012222
28507142	620	643	electrical conductivity	T081	C0013777
28507142	672	683	diffusional	T070	C0012222
28507142	684	694	properties	T042	C0231493
28507142	698	702	TATS	T026	C1179122
28507142	704	746	Fluorescence recovery after photobleaching	T059	C1138405
28507142	748	752	FRAP	T059	C1138405
28507142	754	764	microscopy	T059	C0026018
28507142	776	781	probe	T062	C0936012
28507142	786	795	diffusion	T070	C0012222
28507142	796	806	properties	T042	C0231493
28507142	810	814	TATS	T026	C1179122
28507142	818	826	isolated	T169	C0205409
28507142	827	830	rat	T015	C0034693
28507142	831	845	cardiomyocytes	T025	C0225828
28507142	849	868	fluorescent dextran	T130	C0021212
28507142	876	880	TATS	T026	C1179122
28507142	881	886	lumen	T030	C0524461
28507142	890	903	photobleached	T070	C1138417
28507142	909	915	signal	T067	C1710082
28507142	916	924	recovery	T052	C0237820
28507142	928	937	diffusion	T070	C0012222
28507142	952	959	dextran	T130	C0021212
28507142	969	988	extracellular space	T030	C0015352
28507142	992	1001	monitored	T058	C1283169
28507142	1017	1035	mathematical model	T170	C0876936
28507142	1070	1091	fluorescence recovery	T059	C1138405
28507142	1101	1131	apparent diffusion coefficient	T077	C3890194
28507142	1139	1160	fluorescent molecules	T130	C0016320
28507142	1168	1176	apparent	T078	C0750489
28507142	1177	1186	diffusion	T070	C0012222
28507142	1200	1223	electrical conductivity	T081	C0013777
28507142	1236	1244	evaluate	T058	C0220825
28507142	1249	1259	efficiency	T081	C0013682
28507142	1267	1274	passive	T080	C3686820
28507142	1285	1308	membrane depolarization	T043	C1816453
28507142	1315	1319	TATS	T026	C1179122
28507142	1354	1359	cells	T025	C0007634
28507142	1371	1375	TATS	T026	C1179122
28507142	1397	1405	detached	T169	C0687118
28507142	1409	1422	osmotic shock	T070	C0524680
28507142	1443	1448	probe	T120	C2347609
28507142	1449	1453	TATS	T026	C1179122
28507142	1454	1477	electrical conductivity	T081	C0013777
28507142	1489	1500	heart cells	T025	C0920751
28507142	1515	1520	acute	T079	C0205178
28507142	1525	1537	pathological	T046	C0030660
28507142	1538	1545	tubular	T026	C1179122
28507142	1546	1556	remodeling	T038	C1820201
28507142	1578	1582	TATS	T026	C1179122
28507142	1583	1606	electrical conductivity	T081	C0013777
28507142	1654	1682	action potential propagation	T043	C4236672
28507142	1699	1715	single T-tubules	T026	C1179122
28507142	1738	1746	diseased	T047	C0012634
28507142	1747	1761	cardiomyocytes	T025	C0225828

27964731|t|Use of single molecule sequencing for comparative genomics of an environmental and a clinical isolate of Clostridium difficile ribotype 078
27964731|a|How the pathogen Clostridium difficile might survive, evolve and be transferred between reservoirs within the natural environment is poorly understood. Some ribotypes are found both in clinical and environmental settings. Whether these strains are distinct from each another and evolve in the specific environments is not established. The possession of a highly mobile genome has contributed to the genetic diversity and ongoing evolution of C. difficile. Interpretations of genetic diversity have been limited by fragmented assemblies resulting from short-read length sequencing approaches and by a limited understanding of epigenetic regulation of diversity. To address this, single molecule real time (SMRT) sequencing was used in this study as it produces high quality genome sequences, with resolution of repeat regions (including those found in mobile elements) and can generate data to determine methylation modifications across the sequence (the methylome). Chromosomal rearrangements and ribosomal operon duplications were observed in both genomes. The rearrangements occurred at insertion sites within two mobile genetic elements (MGEs), Tn6164 and Tn6293, present only in the M120 and CD105HS27 genomes, respectively. The gene content of these two transposons differ considerably which could impact upon horizontal gene transfer; differences include CDSs encoding methylases and a conjugative prophage only in Tn6164. To investigate mechanisms which could affect MGE transfer, the methylome, restriction modification (RM) and the CRISPR/Cas systems were characterised for each strain. Notably, the environmental isolate, CD105HS27, does not share a consensus motif for (m4)C methylation, but has one additional spacer when compared to the clinical isolate M120. These findings show key differences between the two strains in terms of their genetic capacity for MGE transfer. The carriage of horizontally transferred genes appear to have genome wide effects based on two different methylation patterns. The CRISPR/Cas system appears active although perhaps slow to evolve. Data suggests that both mechanisms are functional and impact upon horizontal gene transfer and genome evolution within C. difficile.
27964731	0	6	Use of	T169	C1524063
27964731	7	33	single molecule sequencing	T063	C1328887
27964731	50	58	genomics	T091	C0887950
27964731	65	78	environmental	T082	C0014406
27964731	85	93	clinical	T080	C0205210
27964731	94	101	isolate	T123	C1764827
27964731	105	126	Clostridium difficile	T007	C0079134
27964731	127	139	ribotype 078	T034	C0887835
27964731	148	156	pathogen	T001	C0450254
27964731	157	178	Clostridium difficile	T007	C0079134
27964731	194	200	evolve	T169	C0332253
27964731	208	219	transferred	T169	C1705822
27964731	228	238	reservoirs	T083	C0442537
27964731	250	269	natural environment	T082	C0014406
27964731	273	279	poorly	T080	C0205169
27964731	297	306	ribotypes	T034	C0887835
27964731	325	333	clinical	T080	C0205210
27964731	338	351	environmental	T082	C0014406
27964731	376	383	strains	T001	C1518614
27964731	388	396	distinct	T080	C1705242
27964731	419	425	evolve	T169	C0332253
27964731	433	441	specific	T080	C0205369
27964731	442	454	environments	T082	C0014406
27964731	462	473	established	T080	C0443211
27964731	479	489	possession	T081	C0871103
27964731	502	515	mobile genome	T028	C0017428
27964731	520	531	contributed	T052	C1880177
27964731	539	556	genetic diversity	T070	C0042333
27964731	569	578	evolution	T045	C0015219
27964731	582	594	C. difficile	T007	C0079134
27964731	615	632	genetic diversity	T070	C0042333
27964731	643	650	limited	T169	C0439801
27964731	654	664	fragmented	T080	C1708096
27964731	665	675	assemblies	T044	C0872376
27964731	676	685	resulting	T169	C0678226
27964731	691	730	short-read length sequencing approaches	T063	C1328887
27964731	765	786	epigenetic regulation	T043	C1160454
27964731	790	799	diversity	T070	C0042333
27964731	818	861	single molecule real time (SMRT) sequencing	T063	C1328887
27964731	879	884	study	T062	C2603343
27964731	905	912	quality	T080	C0332306
27964731	913	929	genome sequences	T085	C2348746
27964731	936	946	resolution	T077	C2699488
27964731	957	964	regions	T082	C1254362
27964731	991	1006	mobile elements	T114,T123	C1257903
27964731	1016	1024	generate	T052	C3146294
27964731	1025	1029	data	T078	C1511726
27964731	1043	1054	methylation	T044	C0376452
27964731	1055	1068	modifications	T169	C0392747
27964731	1080	1088	sequence	T085	C2348746
27964731	1094	1103	methylome	T080	C3829112
27964731	1106	1132	Chromosomal rearrangements	T049	C1515001
27964731	1137	1166	ribosomal operon duplications	T045	C0017261
27964731	1172	1180	observed	T169	C1441672
27964731	1189	1196	genomes	T028	C0017428
27964731	1202	1216	rearrangements	T045	C0017287
27964731	1217	1225	occurred	T052	C1709305
27964731	1229	1244	insertion sites	T082	C0449682
27964731	1256	1279	mobile genetic elements	T114,T123	C1257903
27964731	1281	1285	MGEs	T114,T123	C1257903
27964731	1288	1294	Tn6164	T114	C0600205
27964731	1299	1305	Tn6293	T114	C0600205
27964731	1307	1314	present	T033	C0150312
27964731	1327	1331	M120	T028	C0017428
27964731	1336	1353	CD105HS27 genomes	T028	C0017428
27964731	1373	1385	gene content	T028	C0017337
27964731	1399	1410	transposons	T114	C0600205
27964731	1411	1417	differ	T080	C1705242
27964731	1443	1449	impact	T080	C4049986
27964731	1455	1479	horizontal gene transfer	T045	C0887912
27964731	1481	1492	differences	T081	C1705241
27964731	1501	1505	CDSs	T086	C0004793
27964731	1515	1525	methylases	T116,T126	C0025831
27964731	1532	1552	conjugative prophage	T005	C1136253
27964731	1561	1567	Tn6164	T114	C0600205
27964731	1572	1583	investigate	T169	C1292732
27964731	1584	1594	mechanisms	T169	C0441712
27964731	1614	1617	MGE	T114,T123	C1257903
27964731	1618	1626	transfer	T045	C0887912
27964731	1632	1641	methylome	T080	C3829112
27964731	1643	1667	restriction modification	T045	C2265065
27964731	1669	1671	RM	T045	C2265065
27964731	1681	1699	CRISPR/Cas systems	T044	C3658355
27964731	1705	1718	characterised	T052	C1880022
27964731	1728	1734	strain	T001	C1518614
27964731	1749	1762	environmental	T082	C0014406
27964731	1763	1770	isolate	T123	C1764827
27964731	1772	1781	CD105HS27	T028	C0017428
27964731	1820	1837	(m4)C methylation	T044	C0376452
27964731	1874	1882	compared	T052	C1707455
27964731	1890	1898	clinical	T080	C0205210
27964731	1899	1906	isolate	T123	C1764827
27964731	1907	1911	M120	T028	C0017428
27964731	1919	1927	findings	T033	C0243095
27964731	1937	1948	differences	T081	C1705241
27964731	1965	1972	strains	T001	C1518614
27964731	1991	1998	genetic	T169	C0314603
27964731	1999	2007	capacity	T081	C1516240
27964731	2012	2015	MGE	T114,T123	C1257903
27964731	2016	2024	transfer	T045	C0887912
27964731	2042	2072	horizontally transferred genes	T028	C0017337
27964731	2073	2079	appear	T080	C0700364
27964731	2088	2094	genome	T028	C0017428
27964731	2100	2107	effects	T080	C1280500
27964731	2121	2130	different	T080	C1705242
27964731	2131	2142	methylation	T044	C0376452
27964731	2143	2151	patterns	T082	C0449774
27964731	2157	2174	CRISPR/Cas system	T044	C3658355
27964731	2175	2182	appears	T080	C0700364
27964731	2183	2189	active	T169	C0205177
27964731	2215	2221	evolve	T169	C0332253
27964731	2223	2227	Data	T078	C1511726
27964731	2247	2257	mechanisms	T169	C0441712
27964731	2262	2272	functional	T169	C0205245
27964731	2277	2283	impact	T080	C4049986
27964731	2289	2313	horizontal gene transfer	T045	C0887912
27964731	2318	2324	genome	T028	C0017428
27964731	2325	2334	evolution	T169	C0332253
27964731	2342	2354	C. difficile	T007	C0079134

27689386|t|Copolymer Brush -Based Ultralow-Fouling Biorecognition Surface Platform for Food Safety
27689386|a|Functional polymer coatings that combine the ability to resist nonspecific fouling from complex media with high biorecognition element (BRE) immobilization capacity represent an emerging class of new functional materials for a number of bioanalytical and biosensor technologies for medical diagnostics, security, and food safety. Here, we report on a random copolymer brush surface - poly(CBMAA-ran-HPMAA) - providing high BRE immobilization capacity while simultaneously exhibiting ultralow-fouling behavior in complex food media. We demonstrate that both the functionalization and fouling resistance capabilities of such copolymer brushes can be tuned by changing the surface contents of the two monomer units: nonionic N-(2-hydroxypropyl) methacrylamide (HPMAA) and carboxy-functional zwitterionic carboxybetaine methacrylamide (CBMAA). It is demonstrated that the resistance to fouling decreases with the surface content of CBMAA; poly(CBMAA-ran-HPMAA) brushes with CBMAA molar content up to 15 mol % maintain excellent resistance to fouling from a variety of homogenized foods (hamburger, cucumber, milk, and lettuce) even after covalent attachment of BREs to carboxy groups of CBMAA. The poly(CBMAA 15 mol %-ran-HPMAA) brushes functionalized with antibodies are demonstrated to exhibit fouling resistance from food samples by up to 3 orders of magnitude better when compared with the widely used low-fouling carboxy-functional oligo(ethylene glycol) (OEG)-based alkanethiolate self-assembled monolayers (AT SAMs) and, furthermore, by up to 2 orders of magnitude better when compared with the most successful ultralow-fouling biorecognition coatings - poly(carboxybetaine acrylamide), poly(CBAA). When model SPR detections of food-borne bacterial pathogens in homogenized foods are used, it is also demonstrated that the antibody - functionalized poly(CBMAA 15 mol %-ran-HPMAA) brush exhibits superior biorecognition properties over the poly(CBAA).
27689386	0	15	Copolymer Brush	T104	C0596383
27689386	23	71	Ultralow-Fouling Biorecognition Surface Platform	T075	C1710360
27689386	76	87	Food Safety	T057	C1456535
27689386	88	98	Functional	T169	C0205245
27689386	99	106	polymer	T104,T122	C0032521
27689386	107	115	coatings	T080	C1522408
27689386	121	128	combine	T073	C0336789
27689386	151	162	nonspecific	T078	C0750540
27689386	163	170	fouling	T070	C3826310
27689386	176	189	complex media	T167	C0439861
27689386	195	199	high	T080	C0205250
27689386	200	222	biorecognition element	T122	C0005479
27689386	224	227	BRE	T122	C0005479
27689386	229	252	immobilization capacity	T081	C1516240
27689386	284	287	new	T080	C0205314
27689386	288	298	functional	T169	C0205245
27689386	299	308	materials	T167	C0520510
27689386	315	321	number	T081	C0237753
27689386	343	352	biosensor	T075	C0600364
27689386	353	365	technologies	T090	C0039421
27689386	370	389	medical diagnostics	T060	C0871813
27689386	391	399	security	T080	C3178753
27689386	405	416	food safety	T057	C1456535
27689386	439	461	random copolymer brush	T104	C0596383
27689386	462	469	surface	T082	C0205148
27689386	472	493	poly(CBMAA-ran-HPMAA)	T104	C0596383
27689386	506	510	high	T080	C0205250
27689386	511	514	BRE	T122	C0005479
27689386	515	538	immobilization capacity	T081	C1516240
27689386	545	559	simultaneously	T079	C0521115
27689386	571	587	ultralow-fouling	T070	C3826310
27689386	588	596	behavior	T053	C0004927
27689386	600	618	complex food media	T168	C0016452
27689386	649	666	functionalization	T169	C0205245
27689386	671	678	fouling	T070	C3826310
27689386	679	689	resistance	T169	C4281815
27689386	690	702	capabilities	T080	C2698977
27689386	711	728	copolymer brushes	T104	C0596383
27689386	745	753	changing	T169	C0392747
27689386	758	765	surface	T082	C0205148
27689386	766	774	contents	T077	C0456205
27689386	786	799	monomer units	T104	C0596973
27689386	801	844	nonionic N-(2-hydroxypropyl) methacrylamide	T109,T130	C0067475
27689386	846	851	HPMAA	T109,T130	C0067475
27689386	857	918	carboxy-functional zwitterionic carboxybetaine methacrylamide	T109	C0029224
27689386	920	925	CBMAA	T109	C0029224
27689386	956	966	resistance	T169	C4281815
27689386	970	977	fouling	T070	C3826310
27689386	978	987	decreases	T081	C0547047
27689386	997	1004	surface	T082	C0205148
27689386	1005	1012	content	T077	C0456205
27689386	1016	1021	CBMAA	T109	C0029224
27689386	1023	1052	poly(CBMAA-ran-HPMAA) brushes	T122	C0005479
27689386	1058	1063	CBMAA	T109	C0029224
27689386	1070	1077	content	T077	C0456205
27689386	1102	1111	excellent	T080	C1961136
27689386	1112	1122	resistance	T169	C4281815
27689386	1126	1133	fouling	T070	C3826310
27689386	1141	1148	variety	T077	C2346866
27689386	1152	1169	homogenized foods	T168	C0016452
27689386	1171	1180	hamburger	T168	C0452929
27689386	1182	1190	cucumber	T168	C0973457
27689386	1192	1196	milk	T168	C0349374
27689386	1202	1209	lettuce	T168	C0242765
27689386	1222	1230	covalent	T070	C0596391
27689386	1231	1241	attachment	T052	C1947904
27689386	1245	1249	BREs	T122	C0005479
27689386	1253	1267	carboxy groups	T109	C0029224
27689386	1271	1276	CBMAA	T109	C0029224
27689386	1282	1320	poly(CBMAA 15 mol %-ran-HPMAA) brushes	T122	C0005479
27689386	1321	1335	functionalized	T169	C0205245
27689386	1341	1351	antibodies	T116,T129	C0003241
27689386	1380	1387	fouling	T070	C3826310
27689386	1388	1398	resistance	T169	C4281815
27689386	1404	1416	food samples	T167	C0444315
27689386	1426	1447	3 orders of magnitude	T081	C1704240
27689386	1448	1454	better	T080	C0332272
27689386	1460	1468	compared	T052	C1707455
27689386	1490	1501	low-fouling	T070	C3826310
27689386	1502	1596	carboxy-functional oligo(ethylene glycol) (OEG)-based alkanethiolate self-assembled monolayers	T122	C0005479
27689386	1598	1605	AT SAMs	T122	C0005479
27689386	1634	1655	2 orders of magnitude	T081	C1704240
27689386	1656	1662	better	T080	C0332272
27689386	1668	1676	compared	T052	C1707455
27689386	1691	1701	successful	T080	C1272703
27689386	1702	1718	ultralow-fouling	T070	C3826310
27689386	1719	1742	biorecognition coatings	T122	C0005479
27689386	1745	1776	poly(carboxybetaine acrylamide)	T109	C2606199
27689386	1778	1788	poly(CBAA)	T109	C2606199
27689386	1795	1800	model	T075	C0026339
27689386	1801	1804	SPR	T063	C0597731
27689386	1805	1815	detections	T061	C1511790
27689386	1819	1849	food-borne bacterial pathogens	T001	C0450254
27689386	1853	1870	homogenized foods	T168	C0016452
27689386	1914	1922	antibody	T116,T129	C0003241
27689386	1925	1939	functionalized	T169	C0205245
27689386	1940	1976	poly(CBMAA 15 mol %-ran-HPMAA) brush	T122	C0005479
27689386	1986	1994	superior	T082	C1282910
27689386	1995	2020	biorecognition properties	T080	C0871161
27689386	2030	2040	poly(CBAA)	T109	C2606199

28468175|t|Wiedemann-Rautenstrauch Syndrome With Bilateral Tarsal Kink: Three Sutures for Correction
28468175|a|The authors describe a 5- month-old male infant with Wiedemann-Rautenstrauch syndrome, which is an extremely rare condition. He had tarsal kink in upper eyelids in both eyes. The authors treated bilateral tarsal kink with an everting suture via a transconjunctival approach under local anesthesia.
28468175	0	32	Wiedemann-Rautenstrauch Syndrome	T047	C0406586
28468175	38	47	Bilateral	T082	C0238767
28468175	48	59	Tarsal Kink	T019	C1303000
28468175	67	74	Sutures	T061	C0038968
28468175	79	89	Correction	T169	C1947976
28468175	116	125	month-old	T079	C0580836
28468175	126	130	male	T032	C0086582
28468175	131	137	infant	T100	C0021270
28468175	143	175	Wiedemann-Rautenstrauch syndrome	T047	C0406586
28468175	199	203	rare	T080	C0522498
28468175	204	213	condition	T047	C0012634
28468175	222	233	tarsal kink	T019	C1303000
28468175	237	250	upper eyelids	T023	C0585636
28468175	254	263	both eyes	T023	C0229118
28468175	277	284	treated	T169	C1522326
28468175	285	294	bilateral	T082	C0238767
28468175	295	306	tarsal kink	T019	C1303000
28468175	315	323	everting	T058	C0455231
28468175	324	330	suture	T061	C0038968
28468175	337	363	transconjunctival approach	T082	C0442347
28468175	370	386	local anesthesia	T061	C0002921

27485594|t|Systematic Quantification of GPCR / cAMP - Controlled Protein Kinase A Interactions
27485594|a|The diffusible second messenger cyclic AMP (cAMP) originates from multiple G protein-coupled receptor (GPCR) cascades activating the intracellular key effector protein kinase A (PKA). Spatially and temporally restricted cAMP - fluxes are directly sensed by macromolecular PKA complexes. The consequences are alterations of molecular interactions, which lead to activation of compartmentalized PKA phosphotransferase activities, regulating a vast array of cellular functions. To decode cell-type and cell-compartment specific PKA functions, the spatio-temporal dynamics of small molecule:protein interactions, protein:protein interactions (PPIs), cAMP - mobilization, and phosphotransferase activities need to be determined directly in the appropriate cellular context. A collection of cell-based reporters has been developed to either visualize or quantitatively measure kinase activities or PKA complex formation / dissociation. In this review, we list a collection of unimolecular and bimolecular PKA biosensors, followed by the specification of the modular design of a Renilla luciferase based protein-fragment complementation assay (PCA) platform for measuring PKA network interactions. We discuss the application spectrum of the PCA reporter to identify, quantify, and dissect dynamic and transient PKA complexes downstream of specific GPCR activities. We specify the implementation of a PCA PKA platform to systematically quantify the concurrent involvement of receptor - cAMP signaling, post-translational modifications, and kinase subunit mutations / perturbations in PKA activation. The systematic quantification of transient PKA network interactions will contribute to a better understanding how GPCR -recognized input signals are streamlined through the compartmentalized and cAMP - interacting PKA signalosome.
27485594	0	10	Systematic	T169	C0220922
27485594	11	25	Quantification	T081	C1709793
27485594	29	33	GPCR	T116,T192	C0682972
27485594	36	40	cAMP	T114,T121,T123	C0001455
27485594	43	53	Controlled	T169	C2587213
27485594	54	70	Protein Kinase A	T116,T126	C0033640
27485594	71	83	Interactions	T044	C1148560
27485594	88	98	diffusible	T082	C0205219
27485594	99	115	second messenger	T123	C1508748
27485594	116	126	cyclic AMP	T114,T121,T123	C0001455
27485594	128	132	cAMP	T114,T121,T123	C0001455
27485594	159	185	G protein-coupled receptor	T116,T192	C0682972
27485594	187	191	GPCR	T116,T192	C0682972
27485594	202	212	activating	T052	C1879547
27485594	217	230	intracellular	T082	C0178719
27485594	244	260	protein kinase A	T116,T126	C0033640
27485594	262	265	PKA	T116,T126	C0033640
27485594	268	277	Spatially	T082	C1254362
27485594	282	292	temporally	T079	C1254367
27485594	293	303	restricted	T169	C0443288
27485594	304	308	cAMP	T114,T121,T123	C0001455
27485594	311	317	fluxes	T070	C2348693
27485594	341	355	macromolecular	T104	C0178735
27485594	356	369	PKA complexes	T026	C3823671
27485594	375	387	consequences	T169	C0686907
27485594	392	403	alterations	T078	C1515926
27485594	407	429	molecular interactions	T044	C1148560
27485594	445	455	activation	T052	C1879547
27485594	477	510	PKA phosphotransferase activities	T044	C2261493
27485594	539	557	cellular functions	T043	C0007613
27485594	569	578	cell-type	T170	C0449475
27485594	583	599	cell-compartment	T017	C2349967
27485594	609	612	PKA	T116,T126	C0033640
27485594	628	652	spatio-temporal dynamics	T062	C3494293
27485594	656	691	small molecule:protein interactions	T044	C1148560
27485594	693	721	protein:protein interactions	T044	C0872079
27485594	723	727	PPIs	T044	C0872079
27485594	730	734	cAMP	T114,T121,T123	C0001455
27485594	737	749	mobilization	T044	C1148560
27485594	755	784	phosphotransferase activities	T044	C2261493
27485594	835	851	cellular context	T080	C0010820
27485594	855	865	collection	T169	C1516698
27485594	869	889	cell-based reporters	T130	C1522485
27485594	919	928	visualize	T169	C0234621
27485594	932	946	quantitatively	T081	C0392762
27485594	947	954	measure	T081	C0079809
27485594	955	972	kinase activities	T044	C2261493
27485594	976	987	PKA complex	T026	C3823671
27485594	988	997	formation	T044	C1148560
27485594	1000	1012	dissociation	T044	C1148560
27485594	1040	1050	collection	T169	C1516698
27485594	1054	1066	unimolecular	T080	C1521991
27485594	1071	1082	bimolecular	T080	C1521991
27485594	1083	1086	PKA	T116,T126	C0033640
27485594	1087	1097	biosensors	T075	C0600364
27485594	1136	1150	modular design	T052	C1707689
27485594	1156	1174	Renilla luciferase	T116,T126,T130	C1450145
27485594	1181	1219	protein-fragment complementation assay	T059	C0005507
27485594	1221	1224	PCA	T059	C0005507
27485594	1239	1248	measuring	T081	C0079809
27485594	1249	1252	PKA	T116,T126	C0033640
27485594	1249	1252	PKA	T116,T126	C0033640
27485594	1253	1273	network interactions	T044	C1148560
27485594	1302	1310	spectrum	T059	C0037812
27485594	1318	1321	PCA	T059	C0005507
27485594	1322	1330	reporter	T130	C1522485
27485594	1334	1342	identify	T033	C0243095
27485594	1344	1352	quantify	T081	C1709793
27485594	1358	1373	dissect dynamic	T169	C0729333
27485594	1378	1387	transient	T079	C0205374
27485594	1388	1391	PKA	T116,T126	C0033640
27485594	1388	1401	PKA complexes	T026	C3823671
27485594	1402	1412	downstream	T082	C0522506
27485594	1425	1429	GPCR	T116,T192	C0682972
27485594	1430	1440	activities	T052	C0441655
27485594	1457	1471	implementation	T052	C1708476
27485594	1477	1480	PCA	T059	C0005507
27485594	1481	1484	PKA	T116,T126	C0033640
27485594	1481	1484	PKA	T116,T126	C0033640
27485594	1497	1511	systematically	T169	C0220922
27485594	1512	1520	quantify	T081	C1709793
27485594	1525	1535	concurrent	T079	C0205420
27485594	1536	1547	involvement	T169	C1314939
27485594	1551	1559	receptor	T116,T192	C0597357
27485594	1562	1576	cAMP signaling	T044	C1155589
27485594	1578	1610	post-translational modifications	T044	C0033666
27485594	1616	1630	kinase subunit	T116,T126	C1956042
27485594	1631	1640	mutations	T045	C0026882
27485594	1643	1656	perturbations	T169	C0332453
27485594	1660	1674	PKA activation	T043	C1819041
27485594	1680	1690	systematic	T169	C0220922
27485594	1691	1705	quantification	T081	C1709793
27485594	1709	1718	transient	T079	C0205374
27485594	1719	1722	PKA	T116,T126	C0033640
27485594	1723	1730	network	T044	C1148560
27485594	1731	1743	interactions	T169	C1704675
27485594	1790	1794	GPCR	T116,T192	C0682972
27485594	1813	1820	signals	T038	C3537152
27485594	1871	1875	cAMP	T114,T121,T123	C0001455
27485594	1878	1889	interacting	T169	C1704675
27485594	1890	1893	PKA	T116,T126	C0033640
27485594	1894	1905	signalosome	T026	C1167160

27436524|t|Effects of complex life cycles on genetic diversity: cyclical parthenogenesis
27436524|a|Neutral patterns of population genetic diversity in species with complex life cycles are difficult to anticipate. Cyclical parthenogenesis (CP), in which organisms undergo several rounds of clonal reproduction followed by a sexual event, is one such life cycle. Many species, including crop pests (aphids), human parasites (trematodes) or models used in evolutionary science (Daphnia), are cyclical parthenogens. It is therefore crucial to understand the impact of such a life cycle on neutral genetic diversity. In this paper, we describe distributions of genetic diversity under conditions of CP with various clonal phase lengths. Using a Markov chain model of CP for a single locus and individual-based simulations for two loci, our analysis first demonstrates that strong departures from full sexuality are observed after only a few generations of clonality. The convergence towards predictions made under conditions of full clonality during the clonal phase depends on the balance between mutations and genetic drift. Second, the sexual event of CP usually resets the genetic diversity at a single locus towards predictions made under full sexuality. However, this single recombination event is insufficient to reshuffle gametic phases towards full-sexuality predictions. Finally, for similar levels of clonality, CP and acyclic partial clonality (wherein a fixed proportion of individuals are clonally produced within each generation) differentially affect the distribution of genetic diversity. Overall, this work provides solid predictions of neutral genetic diversity that may serve as a null model in detecting the action of common evolutionary or demographic processes in cyclical parthenogens (for example, selection or bottlenecks).
27436524	0	10	Effects of	T080	C1704420
27436524	11	18	complex	T080	C0439855
27436524	19	30	life cycles	T079	C0023675
27436524	34	51	genetic diversity	T070	C0042333
27436524	53	77	cyclical parthenogenesis	T040	C0030596
27436524	98	108	population	T098	C1257890
27436524	109	126	genetic diversity	T070	C0042333
27436524	130	137	species	T185	C1705920
27436524	143	150	complex	T080	C0439855
27436524	151	162	life cycles	T079	C0023675
27436524	180	190	anticipate	T078	C0681842
27436524	192	216	Cyclical parthenogenesis	T040	C0030596
27436524	218	220	CP	T040	C0030596
27436524	232	241	organisms	T001	C0029235
27436524	268	274	clonal	T024	C1522642
27436524	275	287	reproduction	T040	C0035150
27436524	302	314	sexual event	T053	C0036864
27436524	328	338	life cycle	T079	C0023675
27436524	345	352	species	T185	C1705920
27436524	364	368	crop	T002	C0242775
27436524	369	374	pests	T008	C0869004
27436524	376	382	aphids	T204	C0003562
27436524	385	400	human parasites	T204	C0585165
27436524	402	412	trematodes	T204	C3889286
27436524	417	423	models	T170	C3161035
27436524	432	452	evolutionary science	T091	C0017398
27436524	454	461	Daphnia	T204	C0010979
27436524	468	489	cyclical parthenogens	T001	C0029235
27436524	550	560	life cycle	T079	C0023675
27436524	572	589	genetic diversity	T070	C0042333
27436524	618	631	distributions	T169	C1704711
27436524	635	652	genetic diversity	T070	C0042333
27436524	659	669	conditions	T080	C0348080
27436524	673	675	CP	T040	C0030596
27436524	689	695	clonal	T024	C1522642
27436524	696	701	phase	T079	C0205390
27436524	702	709	lengths	T081	C1444754
27436524	719	737	Markov chain model	T081	C0024828
27436524	741	743	CP	T040	C0030596
27436524	750	756	single	T081	C0205171
27436524	757	762	locus	T082	C1708726
27436524	784	795	simulations	T062	C0679083
27436524	800	803	two	T081	C0205448
27436524	804	808	loci	T082	C1708726
27436524	854	864	departures	T052	C1706081
27436524	875	884	sexuality	T053	C0036915
27436524	915	926	generations	T079	C0079411
27436524	930	939	clonality	T080	C1704387
27436524	945	956	convergence	T052	C2700387
27436524	965	976	predictions	T078	C0681842
27436524	1007	1016	clonality	T080	C1704387
27436524	1028	1034	clonal	T024	C1522642
27436524	1035	1040	phase	T079	C0205390
27436524	1072	1081	mutations	T045	C0026882
27436524	1086	1099	genetic drift	T045	C0917892
27436524	1113	1125	sexual event	T053	C0036864
27436524	1129	1131	CP	T040	C0030596
27436524	1151	1168	genetic diversity	T070	C0042333
27436524	1174	1180	single	T081	C0205171
27436524	1181	1186	locus	T082	C1708726
27436524	1195	1206	predictions	T078	C0681842
27436524	1223	1232	sexuality	T053	C0036915
27436524	1255	1268	recombination	T045	C0034865
27436524	1304	1318	gametic phases	T043	C0007613
27436524	1327	1341	full-sexuality	T053	C0036915
27436524	1342	1353	predictions	T078	C0681842
27436524	1386	1395	clonality	T080	C1704387
27436524	1397	1399	CP	T040	C0030596
27436524	1412	1419	partial	T081	C0728938
27436524	1420	1429	clonality	T080	C1704387
27436524	1461	1472	individuals	T098	C0237401
27436524	1477	1485	clonally	T080	C1704387
27436524	1507	1517	generation	T079	C0079411
27436524	1545	1557	distribution	T169	C1704711
27436524	1561	1578	genetic diversity	T070	C0042333
27436524	1614	1625	predictions	T078	C0681842
27436524	1637	1654	genetic diversity	T070	C0042333
27436524	1675	1685	null model	T170	C3161035
27436524	1720	1732	evolutionary	T045	C0015219
27436524	1736	1747	demographic	T090	C0011298
27436524	1748	1757	processes	T067	C1522240
27436524	1761	1782	cyclical parthenogens	T001	C0029235

27266322|t|The biological effect of metal ions on the granulation of aerobic granular activated sludge
27266322|a|As a special biofilm structure, microbial attachment is believed to play an important role in the granulation of aerobic granular activated sludge (AGAS). This experiment was to investigate the biological effect of Ca(2+), Mg(2+), Cu(2+), Fe(2+), Zn(2+), and K(+) which are the most common ions present in biological wastewater treatment systems, on the microbial attachment of AGAS and flocculent activated sludge (FAS), from which AGAS is always derived, in order to provide a new strategy for the rapid cultivation and stability control of AGAS. The result showed that attachment biomass of AGAS was about 300% higher than that of FAS without the addition of metal ions. Different metal ions had different effects on the process of microbial attachment. FAS and AGAS reacted differently to the metal ions as well, and in fact, AGAS was more sensitive to the metal ions. Specifically, Ca(2+), Mg(2+), and K(+) could increase the microbial attachment ability of both AGAS and FAS under appropriate concentrations, Cu(2+), Fe(2+), and Zn(2+) were also beneficial to the microbial attachment of FAS at low concentrations, but Cu(2+), Fe(2+), and Zn(2+) greatly inhibited the attachment process of AGAS even at extremely low concentrations. In addition, the acylated homoserine lactone (AHL)-based quorum sensing system, the content of extracellular polymeric substances and the relative hydrophobicity of the sludges were greatly influenced by metal ions. As all these parameters had close relationships with the microbial attachment process, the microbial attachment may be affected by changes of these parameters.
27266322	4	14	biological	T080	C0205460
27266322	15	21	effect	T080	C1280500
27266322	25	30	metal	T197	C0025552
27266322	31	35	ions	T196	C0022023
27266322	43	54	granulation	T059	C4281706
27266322	58	65	aerobic	T080	C1510824
27266322	66	74	granular	T080	C0205248
27266322	75	84	activated	T052	C1879547
27266322	85	91	sludge	T069	C0282346
27266322	105	112	biofilm	T007	C0081786
27266322	124	133	microbial	T001	C0599840
27266322	134	144	attachment	T052	C1947904
27266322	190	201	granulation	T059	C4281706
27266322	213	221	granular	T080	C0205248
27266322	222	231	activated	T052	C1879547
27266322	232	238	sludge	T069	C0282346
27266322	240	244	AGAS	T069	C0282346
27266322	270	281	investigate	T169	C1292732
27266322	286	296	biological	T080	C0205460
27266322	297	303	effect	T080	C1280500
27266322	307	314	Ca(2+),	T121,T196	C0596235
27266322	315	321	Mg(2+)	T121,T196	C2346927
27266322	323	329	Cu(2+)	T121,T197	C1177210
27266322	331	337	Fe(2+)	T196	C2346592
27266322	339	345	Zn(2+)	T121,T196	C2346521
27266322	351	355	K(+)	T121,T196	C0597277
27266322	382	386	ions	T196	C0022023
27266322	398	408	biological	T080	C0205460
27266322	409	419	wastewater	T069	C3494254
27266322	420	429	treatment	T057	C0597684
27266322	446	455	microbial	T001	C0599840
27266322	456	466	attachment	T052	C1947904
27266322	470	474	AGAS	T069	C0282346
27266322	479	489	flocculent	T043	C0016243
27266322	490	499	activated	T052	C1879547
27266322	500	506	sludge	T069	C0282346
27266322	508	511	FAS	T069	C0282346
27266322	525	529	AGAS	T069	C0282346
27266322	592	597	rapid	T080	C0456962
27266322	598	609	cultivation	T169	C0220814
27266322	614	623	stability	T080	C0205360
27266322	624	631	control	T080	C0243148
27266322	635	639	AGAS	T069	C0282346
27266322	664	674	attachment	T052	C1947904
27266322	675	682	biomass	T081	C0005535
27266322	686	690	AGAS	T069	C0282346
27266322	726	729	FAS	T069	C0282346
27266322	754	759	metal	T197	C0025552
27266322	760	764	ions	T196	C0022023
27266322	776	781	metal	T197	C0025552
27266322	782	786	ions	T196	C0022023
27266322	801	808	effects	T080	C1280500
27266322	816	823	process	T067	C1522240
27266322	827	836	microbial	T001	C0599840
27266322	837	847	attachment	T052	C1947904
27266322	849	852	FAS	T069	C0282346
27266322	857	861	AGAS	T069	C0282346
27266322	889	894	metal	T197	C0025552
27266322	895	899	ions	T196	C0022023
27266322	922	926	AGAS	T069	C0282346
27266322	936	945	sensitive	T169	C0332324
27266322	953	958	metal	T197	C0025552
27266322	959	963	ions	T196	C0022023
27266322	979	985	Ca(2+)	T121,T196	C0596235
27266322	987	993	Mg(2+)	T121,T196	C2346927
27266322	999	1003	K(+)	T121,T196	C0597277
27266322	1023	1032	microbial	T001	C0599840
27266322	1033	1043	attachment	T052	C1947904
27266322	1060	1064	AGAS	T069	C0282346
27266322	1069	1072	FAS	T069	C0282346
27266322	1079	1090	appropriate	T080	C1548787
27266322	1091	1105	concentrations	T081	C1446561
27266322	1107	1113	Cu(2+)	T121,T197	C1177210
27266322	1115	1121	Fe(2+)	T196	C2346592
27266322	1127	1133	Zn(2+)	T121,T196	C2346521
27266322	1162	1171	microbial	T001	C0599840
27266322	1172	1182	attachment	T052	C1947904
27266322	1186	1189	FAS	T069	C0282346
27266322	1193	1196	low	T080	C0205251
27266322	1197	1211	concentrations	T081	C1446561
27266322	1217	1223	Cu(2+)	T121,T197	C1177210
27266322	1225	1231	Fe(2+)	T196	C2346592
27266322	1237	1243	Zn(2+)	T121,T196	C2346521
27266322	1266	1284	attachment process	T052	C1947904
27266322	1288	1292	AGAS	T069	C0282346
27266322	1301	1310	extremely	T080	C0205403
27266322	1311	1314	low	T080	C0205251
27266322	1315	1329	concentrations	T081	C1446561
27266322	1348	1375	acylated homoserine lactone	T109	C1313745
27266322	1377	1380	AHL	T109	C1313745
27266322	1388	1409	quorum sensing system	T043	C1154599
27266322	1426	1439	extracellular	T026	C0521119
27266322	1440	1460	polymeric substances	T104,T122	C0032521
27266322	1478	1492	hydrophobicity	T080	C0598629
27266322	1500	1507	sludges	T069	C0282346
27266322	1535	1540	metal	T197	C0025552
27266322	1541	1545	ions	T196	C0022023
27266322	1560	1570	parameters	T077	C0549193
27266322	1604	1613	microbial	T001	C0599840
27266322	1614	1632	attachment process	T052	C1947904
27266322	1638	1647	microbial	T001	C0599840
27266322	1648	1658	attachment	T052	C1947904
27266322	1678	1685	changes	T169	C0392747
27266322	1695	1705	parameters	T077	C0549193

27491687|t|Neonatal infections: Case definition and guidelines for data collection, analysis, and presentation of immunisation safety data
27491687|a|Maternal vaccination is an important area of research and requires appropriate and internationally comparable definitions and safety standards. The GAIA group, part of the Brighton Collaboration was created with the mandate of proposing standardised definitions applicable to maternal vaccine research. This study proposes international definitions for neonatal infections. The neonatal infections GAIA working group performed a literature review using Medline, EMBASE and the Cochrane collaboration and collected definitions in use in neonatal and public health networks. The common criteria derived from the extensive search formed the basis for a consensus process that resulted in three separate definitions for neonatal blood stream infections (BSI), meningitis and lower respiratory tract infections (LRTI). For each definition three levels of evidence are proposed to ensure the applicability of the definitions to different settings. Recommendations about data collection, analysis and presentation are presented and harmonized with the Brighton Collaboration and GAIA format and other existing international standards for study reporting.
27491687	0	19	Neonatal infections	T047	C0854706
27491687	21	36	Case definition	T170	C1704788
27491687	41	51	guidelines	T170	C0162791
27491687	56	71	data collection	T062	C0010995
27491687	73	81	analysis	T062	C0936012
27491687	87	99	presentation	T078	C0449450
27491687	103	115	immunisation	T061	C0020971
27491687	116	127	safety data	T078	C1511726
27491687	128	136	Maternal	T033	C1858460
27491687	137	148	vaccination	T061	C0042196
27491687	173	181	research	T062	C0035168
27491687	238	249	definitions	T170	C1704788
27491687	254	270	safety standards	T170	C2828392
27491687	276	286	GAIA group	T097	C1522486
27491687	300	322	Brighton Collaboration	T097	C1522486
27491687	378	389	definitions	T170	C1704788
27491687	404	412	maternal	T033	C1858460
27491687	413	420	vaccine	T121,T129	C0042210
27491687	421	429	research	T062	C0035168
27491687	436	441	study	T062	C2603343
27491687	465	476	definitions	T170	C1704788
27491687	481	500	neonatal infections	T047	C0854706
27491687	506	525	neonatal infections	T047	C0854706
27491687	526	530	GAIA	T097	C1522486
27491687	531	544	working group	T098	C1883562
27491687	557	567	literature	T170	C0023866
27491687	568	574	review	T169	C0565989
27491687	581	588	Medline	T170	C0025141
27491687	590	596	EMBASE	T170	C0242356
27491687	605	627	Cochrane collaboration	T169	C1882071
27491687	642	653	definitions	T170	C1704788
27491687	664	672	neonatal	T169	C1882071
27491687	677	699	public health networks	T169	C1882071
27491687	712	720	criteria	T078	C0243161
27491687	721	728	derived	T080	C1441547
27491687	778	795	consensus process	T054	C0376298
27491687	828	839	definitions	T170	C1704788
27491687	844	852	neonatal	T100	C0021289
27491687	853	876	blood stream infections	T046	C2316160
27491687	878	881	BSI	T046	C2316160
27491687	884	894	meningitis	T047	C0025289
27491687	899	933	lower respiratory tract infections	T047	C0149725
27491687	935	939	LRTI	T047	C0149725
27491687	951	961	definition	T170	C1704788
27491687	1035	1046	definitions	T170	C1704788
27491687	1092	1107	data collection	T062	C0010995
27491687	1109	1117	analysis	T062	C0936012
27491687	1122	1134	presentation	T078	C0449450
27491687	1153	1163	harmonized	T062	C0150103
27491687	1173	1195	Brighton Collaboration	T097	C1522486
27491687	1200	1204	GAIA	T097	C1522486
27491687	1205	1211	format	T170	C1301627
27491687	1231	1254	international standards	T170	C2828392
27491687	1259	1264	study	T062	C2603343
27491687	1265	1274	reporting	T062	C0011000

28077772|t|Phylogenomics provides new insight into evolutionary relationships and genealogical discordance in the reef-building coral genus Acropora
28077772|a|Understanding the genetic basis of reproductive isolation is a long-standing goal of speciation research. In recently diverged populations, genealogical discordance may reveal genes and genomic regions that contribute to the speciation process. Previous work has shown that conspecific colonies of Acropora that spawn in different seasons (spring and autumn) are associated with highly diverged lineages of the phylogenetic marker PaxC Here, we used 10 034 single-nucleotide polymorphisms to generate a genome -wide phylogeny and compared it with gene genealogies from the PaxC intron and the mtDNA Control Region in 20 species of Acropora, including three species with spring - and autumn - spawning cohorts. The PaxC phylogeny separated conspecific autumn and spring spawners into different genetic clusters in all three species; however, this pattern was not supported in two of the three species at the genome level, suggesting a selective connection between PaxC and reproductive timing in Acropora corals. This genome -wide phylogeny provides an improved foundation for resolving phylogenetic relationships in Acropora and, combined with PaxC, provides a fascinating platform for future research into regions of the genome that influence reproductive isolation and speciation in corals.
28077772	0	13	Phylogenomics	T091	C0887950
28077772	40	52	evolutionary	T045	C0015219
28077772	71	83	genealogical	T170	C0030761
28077772	84	95	discordance	T077	C3639994
28077772	103	122	reef-building coral	T070	C2936266
28077772	123	128	genus	T185	C1708235
28077772	129	137	Acropora	T204	C0997909
28077772	156	163	genetic	T169	C0314603
28077772	164	169	basis	T169	C1527178
28077772	173	195	reproductive isolation	T070	C3178896
28077772	215	219	goal	T170	C0018017
28077772	223	233	speciation	T070	C1563692
28077772	234	242	research	T062	C0035168
28077772	256	264	diverged	T033	C3840275
28077772	265	276	populations	T081	C0032659
28077772	278	290	genealogical	T170	C0030761
28077772	291	302	discordance	T077	C3639994
28077772	314	319	genes	T028	C0017337
28077772	324	339	genomic regions	T028	C0017428
28077772	363	381	speciation process	T070	C1563692
28077772	412	432	conspecific colonies	T025	C1947989
28077772	436	444	Acropora	T204	C0997909
28077772	450	455	spawn	T032	C2826216
28077772	469	476	seasons	T079	C0036497
28077772	478	484	spring	T079	C0241232
28077772	489	495	autumn	T079	C0238715
28077772	524	532	diverged	T033	C3840275
28077772	533	541	lineages	T077	C1881379
28077772	549	568	phylogenetic marker	T086	C0012872
28077772	569	573	PaxC	T086	C0012872
28077772	595	626	single-nucleotide polymorphisms	T086	C0752046
28077772	630	638	generate	T052	C3146294
28077772	641	647	genome	T028	C0017428
28077772	654	663	phylogeny	T078	C0031797
28077772	685	689	gene	T028	C0017337
28077772	690	701	genealogies	T170	C0017298
28077772	711	715	PaxC	T086	C0012872
28077772	716	722	intron	T114,T123	C0021920
28077772	731	751	mtDNA Control Region	T028	C1819716
28077772	758	765	species	T185	C1705920
28077772	769	777	Acropora	T204	C0997909
28077772	795	802	species	T185	C1705920
28077772	808	814	spring	T079	C0241232
28077772	821	827	autumn	T079	C0238715
28077772	830	838	spawning	T032	C2826216
28077772	839	846	cohorts	T098	C0599755
28077772	852	856	PaxC	T086	C0012872
28077772	857	866	phylogeny	T078	C0031797
28077772	867	876	separated	T080	C0443299
28077772	889	895	autumn	T079	C0238715
28077772	900	906	spring	T079	C0241232
28077772	907	915	spawners	T204	C0684063
28077772	931	947	genetic clusters	T028	C0017258
28077772	961	968	species	T185	C1705920
28077772	984	991	pattern	T082	C0449774
28077772	1030	1037	species	T185	C1705920
28077772	1045	1051	genome	T028	C0017428
28077772	1052	1057	level	T080	C0441889
28077772	1082	1092	connection	T082	C0449379
28077772	1101	1105	PaxC	T086	C0012872
28077772	1110	1122	reproductive	T040	C0035150
28077772	1123	1129	timing	T079	C0449243
28077772	1133	1141	Acropora	T204	C0997909
28077772	1142	1148	corals	T204	C0324034
28077772	1155	1161	genome	T028	C0017428
28077772	1168	1177	phylogeny	T078	C0031797
28077772	1214	1223	resolving	T033	C3714811
28077772	1224	1236	phylogenetic	UnknownType	C0683236
28077772	1254	1262	Acropora	T204	C0997909
28077772	1268	1276	combined	T080	C0205195
28077772	1282	1286	PaxC	T086	C0012872
28077772	1331	1339	research	T062	C0035168
28077772	1345	1366	regions of the genome	T028	C0017428
28077772	1372	1381	influence	T077	C4054723
28077772	1382	1404	reproductive isolation	T070	C3178896
28077772	1409	1419	speciation	T070	C1563692
28077772	1423	1429	corals	T204	C0324034

28092840|t|Suppressive effect of Spirulina fusiformis on diclofenac - induced hepato-renal injury and gastrointestinal ulcer in Wistar albino rats: A biochemical and histological approach
28092840|a|The non-steroidal anti-inflammatory drug (NSAID), diclofenac causes hepato-renal toxicity and gastric ulcer. The aim of this study was to investigate the protective effect of Spirulina fusiformis on Diclofenac - induced toxicity in Wistar albino rats. Rats were treated as follows: normal control (group I); diclofenac (50mg/kgb.w., i.p.) treated rats (group II); diclofenac - induced (50mg/kgb.w., i.p.) rats treated with Spirulina fusiformis (400mg/kgb.w., p.o.) (group III); diclofenac - induced (50mg/kgb.w., i.p.) rats treated with silymarin (25mg/kgb.w., p.o.) (group IV); Spirulina fusiformis (400mg/kgb.w., p.o.) alone treated rats (group V). Biochemical (liver and kidney functional markers) and antioxidant parameters (enzymic and non-enzymic antioxidants) were measured in the blood and tissue homogenates of the rats. Evaluation of intestinal ulcer score and assessment of liver and kidney histology were also done. Alterations in the levels of biochemical and antioxidant assays and histopathological changes in liver and kidney proved the toxic effect of diclofenac. The ulcer score was significantly increased in the diclofenac treated rats. Spirulina fusiformis showed to reduce such changes and was able to restore normal antioxidant status in the rats. Our study proves the hepato-renal and gastroprotective activity of Spirulina fusiformis in diclofenac - treated rats.
28092840	0	11	Suppressive	T169	C0205367
28092840	12	18	effect	T080	C1280500
28092840	22	42	Spirulina fusiformis	T109,T121	C0075026
28092840	46	56	diclofenac	T109,T121	C0012091
28092840	59	66	induced	T169	C0205263
28092840	67	79	hepato-renal	T023	C0545792
28092840	80	86	injury	T037	C3263722
28092840	91	113	gastrointestinal ulcer	T047	C0237938
28092840	117	135	Wistar albino rats	T015	C0034693
28092840	139	150	biochemical	T169	C0205474
28092840	155	176	histological approach	T059	C0019637
28092840	181	217	non-steroidal anti-inflammatory drug	T121	C0003211
28092840	219	224	NSAID	T121	C0003211
28092840	227	237	diclofenac	T109,T121	C0012091
28092840	245	257	hepato-renal	T023	C0545792
28092840	258	266	toxicity	T037	C0600688
28092840	271	284	gastric ulcer	T047	C0038358
28092840	302	307	study	T062	C2603343
28092840	315	326	investigate	T169	C1292732
28092840	331	348	protective effect	UnknownType	C0678771
28092840	352	372	Spirulina fusiformis	T109,T121	C0075026
28092840	376	386	Diclofenac	T109,T121	C0012091
28092840	389	396	induced	T169	C0205263
28092840	397	405	toxicity	T037	C0600688
28092840	409	427	Wistar albino rats	T015	C0034693
28092840	429	433	Rats	T015	C0034693
28092840	439	446	treated	T169	C1522326
28092840	459	473	normal control	T080	C2705716
28092840	475	480	group	T096	C0009932
28092840	485	495	diclofenac	T109,T121	C0012091
28092840	516	523	treated	T169	C1522326
28092840	524	528	rats	T015	C0034693
28092840	530	535	group	T078	C0441833
28092840	541	551	diclofenac	T109,T121	C0012091
28092840	554	561	induced	T169	C0205263
28092840	582	586	rats	T015	C0034693
28092840	587	594	treated	T169	C1522326
28092840	600	620	Spirulina fusiformis	T109,T121	C0075026
28092840	643	648	group	T078	C0441833
28092840	655	665	diclofenac	T109,T121	C0012091
28092840	668	675	induced	T169	C0205263
28092840	696	700	rats	T015	C0034693
28092840	701	708	treated	T169	C1522326
28092840	714	723	silymarin	T109,T121	C0037135
28092840	745	750	group	T078	C0441833
28092840	756	776	Spirulina fusiformis	T109,T121	C0075026
28092840	804	811	treated	T169	C1522326
28092840	812	816	rats	T015	C0034693
28092840	818	823	group	T078	C0441833
28092840	828	839	Biochemical	T169	C0205474
28092840	841	846	liver	T023	C0023884
28092840	851	857	kidney	T023	C0022646
28092840	858	868	functional	T169	C0205245
28092840	869	876	markers	T201	C0005516
28092840	882	893	antioxidant	T121	C0003402
28092840	894	904	parameters	T077	C0549193
28092840	906	913	enzymic	T116,T126	C0014442
28092840	918	942	non-enzymic antioxidants	T121	C0003402
28092840	949	957	measured	T080	C0444706
28092840	965	970	blood	T031	C0005767
28092840	975	981	tissue	T024	C0040300
28092840	982	993	homogenates	T072	C3829671
28092840	1001	1005	rats	T015	C0034693
28092840	1007	1017	Evaluation	T058	C0220825
28092840	1021	1037	intestinal ulcer	T047	C0237938
28092840	1038	1043	score	T081	C0449820
28092840	1048	1058	assessment	T052	C1516048
28092840	1062	1067	liver	T023	C0023884
28092840	1072	1078	kidney	T023	C0022646
28092840	1079	1088	histology	T091	C0019638
28092840	1105	1116	Alterations	T078	C1515926
28092840	1124	1130	levels	T080	C0441889
28092840	1134	1145	biochemical	T169	C0205474
28092840	1150	1161	antioxidant	T121	C0003402
28092840	1162	1168	assays	T059	C0005507
28092840	1173	1190	histopathological	T169	C0243140
28092840	1191	1198	changes	T169	C0392747
28092840	1202	1207	liver	T023	C0023884
28092840	1212	1218	kidney	T023	C0022646
28092840	1230	1242	toxic effect	T037	C0600688
28092840	1246	1256	diclofenac	T109,T121	C0012091
28092840	1262	1267	ulcer	T047	C0041582
28092840	1268	1273	score	T081	C0449820
28092840	1292	1301	increased	T081	C0205217
28092840	1309	1319	diclofenac	T109,T121	C0012091
28092840	1320	1327	treated	T169	C1522326
28092840	1328	1332	rats	T015	C0034693
28092840	1334	1354	Spirulina fusiformis	T109,T121	C0075026
28092840	1365	1371	reduce	T080	C0392756
28092840	1377	1384	changes	T169	C0392747
28092840	1416	1427	antioxidant	T121	C0003402
28092840	1428	1434	status	T080	C0449438
28092840	1442	1446	rats	T015	C0034693
28092840	1452	1457	study	T062	C2603343
28092840	1469	1481	hepato-renal	T023	C0545792
28092840	1515	1535	Spirulina fusiformis	T109,T121	C0075026
28092840	1539	1549	diclofenac	T109,T121	C0012091
28092840	1552	1559	treated	T169	C1522326
28092840	1560	1564	rats	T015	C0034693

27695327|t|Fabrication of gelatin methacrylate / nanohydroxyapatite microgel arrays for periodontal tissue regeneration
27695327|a|Periodontitis is a chronic infectious disease and is the major cause of tooth loss and other oral health issues around the world. Periodontal tissue regeneration has therefore always been the ultimate goal of dentists and researchers. Existing fabrication methods mainly focused on a top-down tissue engineering strategy in which several drawbacks remain, including low throughput and limited diffusion properties resulting from a large sample size. Gelatin methacrylate (GelMA) is a kind of photocrosslinkable and biocompatible hydrogel, with the capacities of enabling cell encapsulation and regeneration of functional tissues. Here, we developed a novel method to fabricate GelMA / nanohydroxylapatite (nHA) microgel arrays using a photocrosslinkable strategy. The viability, proliferation, and osteogenic differentiation and in vivo osteogenesis of human periodontal ligament stem cells (hPDLSCs) encapsulated in microgels were evaluated. The results suggested that such microgels provide great potential for periodontal tissue repair and regeneration. Microgel arrays were fabricated by blending different weight ratios of GelMA and nHA. hPDLSCs were encapsulated in GelMA / nHA microgels of various ratios for a systematic evaluation of cell viability, proliferation, and osteogenic differentiation. In vivo osteogenesis in nude mice was also studied. The GelMA / nHA microgels exhibited appropriate microarchitecture, mechanical strength, and surface roughness, thus enabling cell adhesion and proliferation. Additionally, the GelMA / nHA microgels (10%/2% w/v) enhanced the osteogenic differentiation of hPDLSCs by elevating the expression levels of osteogenic biomarker genes, such as ALP, BSP, OCN, and RUNX2. In vivo ectopic transplantation results showed that GelMA / nHA microgels (10%/2% w/v) increased mineralized tissue formation with abundant vascularization, compared with the 1%, 3%, and the pure GelMA group. The GelMA / nHA microgels (10%/2% w/v) facilitated hPDLSCs viability, proliferation, and osteogenic differentiation in vitro and further promoted new bone formation in vivo, suggesting that the GelMA / nHA microgels (10%/2% w/v) provide great potential for periodontal tissue regeneration.
27695327	0	11	Fabrication	T067	C1522240
27695327	15	35	gelatin methacrylate	T109	C0029224
27695327	38	56	nanohydroxyapatite	T197	C0020326
27695327	57	65	microgel	T122	C0017243
27695327	66	72	arrays	T082	C1510941
27695327	77	108	periodontal tissue regeneration	T061	C1448477
27695327	109	122	Periodontitis	T047	C0031099
27695327	128	154	chronic infectious disease	T047	C0151317
27695327	166	177	major cause	T033	C1333617
27695327	181	191	tooth loss	T020	C0080233
27695327	202	213	oral health	T058	C0029162
27695327	214	220	issues	T033	C0033213
27695327	232	237	world	T098	C2700280
27695327	239	270	Periodontal tissue regeneration	T061	C1448477
27695327	301	314	ultimate goal	T170	C0018017
27695327	318	326	dentists	T097	C0011441
27695327	331	342	researchers	T097	C0035173
27695327	353	364	fabrication	T067	C1522240
27695327	365	372	methods	T170	C0025663
27695327	380	387	focused	T169	C1285542
27695327	393	420	top-down tissue engineering	T061	C0596171
27695327	421	429	strategy	T041	C0679199
27695327	447	456	drawbacks	T080	C0205556
27695327	457	463	remain	T033	C0243095
27695327	475	489	low throughput	T080	C0205556
27695327	502	511	diffusion	T070	C0012222
27695327	512	522	properties	T080	C0871161
27695327	523	532	resulting	T169	C0332294
27695327	540	557	large sample size	T081	C0242618
27695327	559	579	Gelatin methacrylate	T109	C0029224
27695327	581	586	GelMA	T109	C0029224
27695327	601	619	photocrosslinkable	T070	C0178576
27695327	624	637	biocompatible	T122	C0005479
27695327	638	646	hydrogel	T109,T121	C0063083
27695327	657	667	capacities	T081	C1516240
27695327	671	679	enabling	T041	C1171285
27695327	680	698	cell encapsulation	T059	C3831155
27695327	703	737	regeneration of functional tissues	T042	C1623047
27695327	760	765	novel	T080	C0205314
27695327	766	772	method	T169	C0449851
27695327	776	785	fabricate	T067	C1522240
27695327	786	791	GelMA	T109	C0029224
27695327	794	813	nanohydroxylapatite	T197	C0020326
27695327	815	818	nHA	T197	C0020326
27695327	820	828	microgel	T122	C0017243
27695327	829	835	arrays	T082	C1510941
27695327	844	862	photocrosslinkable	T070	C0178576
27695327	863	871	strategy	T041	C0679199
27695327	877	886	viability	T043	C0007620
27695327	888	901	proliferation	T043	C0596290
27695327	907	933	osteogenic differentiation	T043	C1159974
27695327	938	945	in vivo	T082	C1515655
27695327	946	958	osteogenesis	T042	C0029433
27695327	962	967	human	T016	C0086418
27695327	968	988	periodontal ligament	T023	C0031093
27695327	989	999	stem cells	T025	C0038250
27695327	1001	1008	hPDLSCs	T025	C0038250
27695327	1010	1022	encapsulated	T080	C0205223
27695327	1026	1035	microgels	T122	C0017243
27695327	1041	1050	evaluated	T058	C0220825
27695327	1056	1063	results	T169	C1274040
27695327	1064	1073	suggested	T078	C1705535
27695327	1084	1093	microgels	T122	C0017243
27695327	1094	1101	provide	T052	C1999230
27695327	1108	1117	potential	T080	C3245505
27695327	1122	1164	periodontal tissue repair and regeneration	T061	C1448477
27695327	1166	1174	Microgel	T122	C0017243
27695327	1175	1181	arrays	T082	C1510941
27695327	1187	1197	fabricated	T067	C1522240
27695327	1201	1209	blending	T068	C0678946
27695327	1210	1219	different	T080	C1705242
27695327	1220	1233	weight ratios	T081	C2919747
27695327	1237	1242	GelMA	T109	C0029224
27695327	1247	1250	nHA	T197	C0020326
27695327	1252	1259	hPDLSCs	T025	C0038250
27695327	1265	1277	encapsulated	T080	C0205223
27695327	1281	1286	GelMA	T109	C0029224
27695327	1289	1292	nHA	T197	C0020326
27695327	1293	1302	microgels	T122	C0017243
27695327	1314	1320	ratios	T081	C0456603
27695327	1327	1337	systematic	T169	C0220922
27695327	1338	1348	evaluation	T058	C0220825
27695327	1352	1366	cell viability	T043	C0007620
27695327	1368	1381	proliferation	T043	C0596290
27695327	1387	1413	osteogenic differentiation	T043	C1159974
27695327	1415	1422	In vivo	T082	C1515655
27695327	1423	1435	osteogenesis	T042	C0029433
27695327	1439	1448	nude mice	T015	C0025932
27695327	1471	1476	GelMA	T109	C0029224
27695327	1479	1482	nHA	T197	C0020326
27695327	1483	1492	microgels	T122	C0017243
27695327	1503	1514	appropriate	T080	C1548787
27695327	1515	1532	microarchitecture	T080	C0205556
27695327	1534	1553	mechanical strength	T078	C0808080
27695327	1559	1566	surface	T082	C0205148
27695327	1567	1576	roughness	T080	C0205556
27695327	1592	1605	cell adhesion	T043	C0007577
27695327	1610	1623	proliferation	T043	C0596290
27695327	1643	1648	GelMA	T109	C0029224
27695327	1651	1654	nHA	T197	C0020326
27695327	1655	1664	microgels	T122	C0017243
27695327	1678	1686	enhanced	T052	C2349975
27695327	1691	1717	osteogenic differentiation	T043	C1159974
27695327	1721	1728	hPDLSCs	T025	C0038250
27695327	1732	1741	elevating	T080	C3163633
27695327	1746	1763	expression levels	T081	C3244092
27695327	1767	1787	osteogenic biomarker	T201	C0005516
27695327	1788	1793	genes	T028	C0017337
27695327	1803	1806	ALP	T028	C0017337
27695327	1808	1811	BSP	T028	C1415840
27695327	1813	1816	OCN	T028	C1412791
27695327	1822	1827	RUNX2	T028	C1419771
27695327	1829	1836	In vivo	T082	C1515655
27695327	1837	1844	ectopic	T082	C0574895
27695327	1845	1860	transplantation	T061	C0040732
27695327	1861	1868	results	T169	C1274040
27695327	1881	1886	GelMA	T109	C0029224
27695327	1889	1892	nHA	T197	C0020326
27695327	1893	1902	microgels	T122	C0017243
27695327	1916	1925	increased	T081	C0205217
27695327	1926	1944	mineralized tissue	T024	C0040300
27695327	1945	1954	formation	T169	C1522492
27695327	1960	1968	abundant	T080	C2346714
27695327	1969	1984	vascularization	T169	C0042382
27695327	1986	1994	compared	T052	C1707455
27695327	2025	2036	GelMA group	T109	C0029224
27695327	2042	2047	GelMA	T109	C0029224
27695327	2050	2053	nHA	T197	C0020326
27695327	2054	2063	microgels	T122	C0017243
27695327	2089	2096	hPDLSCs	T025	C0038250
27695327	2097	2106	viability	T043	C0007620
27695327	2108	2121	proliferation	T043	C0596290
27695327	2127	2153	osteogenic differentiation	T043	C1159974
27695327	2154	2162	in vitro	T080	C1533691
27695327	2167	2174	further	T082	C1517331
27695327	2175	2183	promoted	T052	C0033414
27695327	2184	2187	new	T080	C0205314
27695327	2188	2202	bone formation	T042	C0029433
27695327	2203	2210	in vivo	T082	C1515655
27695327	2232	2237	GelMA	T109	C0029224
27695327	2240	2243	nHA	T197	C0020326
27695327	2244	2253	microgels	T122	C0017243
27695327	2267	2274	provide	T052	C1999230
27695327	2281	2290	potential	T080	C3245505
27695327	2295	2326	periodontal tissue regeneration	T061	C1448477

27332210|t|Information Literacy in a Digital Era: Understanding the Impact of Mobile Information for Undergraduate Nursing Students
27332210|a|Recent entry -to- practice nursing informatics competencies for Registered Nurses in Canada mean nurse educators need educational strategies to promote student competency within the rapidly evolving informatics field. A collaborative research team from three Canadian nursing programs completed a mixed method survey to describe how nursing students used mobile nursing information support and the extent of this support for learning. The Mobile Information Support Evaluation Tool (MISET) assessed Usefulness / Helpfulness, Information Literacy Support, and Use of Evidence -Based Sources. The quantitative and qualitative data were analyzed to describe students' perspectives and the ways they used mobile resources in learning situations. Findings suggest nursing students mainly accessed mobile resources to support clinical learning, and specifically for task - oriented information such as drug medication or patient conditions/diagnoses. Researchers recommend a paradigm shift whereby educators emphasize information literacy in a way that supports evidence -based quality care.
27332210	0	20	Information Literacy	T041	C2936607
27332210	26	33	Digital	T080	C1883674
27332210	34	37	Era	T079	C1254367
27332210	39	52	Understanding	T041	C0162340
27332210	57	63	Impact	T080	C4049986
27332210	67	73	Mobile	T073	C1136360
27332210	74	85	Information	T078	C1533716
27332210	90	120	Undergraduate Nursing Students	T065	C0013638
27332210	121	127	Recent	T079	C0332185
27332210	128	133	entry	UnknownType	C0680254
27332210	139	147	practice	T041	C0237607
27332210	148	167	nursing informatics	T057	C1449810
27332210	168	180	competencies	T080	C0008956
27332210	185	202	Registered Nurses	T097	C0687673
27332210	206	212	Canada	T083	C0006823
27332210	213	217	mean	T081	C2347634
27332210	218	233	nurse educators	T097	C0015538
27332210	239	261	educational strategies	T065	C0516411
27332210	265	272	promote	T052	C0033414
27332210	273	280	student	T097	C0038496
27332210	281	291	competency	T080	C0086035
27332210	303	310	rapidly	T080	C0456962
27332210	311	319	evolving	T169	C0332253
27332210	320	337	informatics field	T090	C0599807
27332210	341	363	collaborative research	T062	C0681804
27332210	364	368	team	T096	C0871489
27332210	380	388	Canadian	T033	C0238884
27332210	389	405	nursing programs	T062	C0028686
27332210	406	415	completed	T080	C0205197
27332210	418	423	mixed	T169	C0205430
27332210	424	430	method	T170	C0025663
27332210	431	437	survey	T170	C0038951
27332210	454	470	nursing students	T097	C0038496
27332210	476	482	mobile	T073	C1136360
27332210	483	510	nursing information support	T170	C1518475
27332210	519	525	extent	T082	C0439792
27332210	534	541	support	T080	C1269765
27332210	546	554	learning	T041	C0023185
27332210	560	602	Mobile Information Support Evaluation Tool	T170	C0037589
27332210	603	610	(MISET)	T170	C0037589
27332210	611	619	assessed	T052	C1516048
27332210	620	630	Usefulness	T080	C3827682
27332210	633	644	Helpfulness	T080	C3898897
27332210	646	666	Information Literacy	T041	C2936607
27332210	667	674	Support	T080	C1269765
27332210	680	686	Use of	T169	C1524063
27332210	687	695	Evidence	T078	C3887511
27332210	703	710	Sources	T033	C0449416
27332210	716	728	quantitative	T081	C0392762
27332210	733	744	qualitative	T080	C0205556
27332210	745	749	data	T078	C1511726
27332210	755	763	analyzed	T062	C0936012
27332210	776	785	students'	T097	C0038496
27332210	786	798	perspectives	T078	C1254370
27332210	822	828	mobile	T073	C1136360
27332210	829	838	resources	T078	C0035201
27332210	842	850	learning	T041	C0023185
27332210	863	871	Findings	T033	C0243095
27332210	872	879	suggest	T078	C1705535
27332210	880	896	nursing students	T097	C0038496
27332210	904	912	accessed	T082	C0444454
27332210	913	919	mobile	T073	C1136360
27332210	920	929	resources	T078	C0035201
27332210	933	940	support	T080	C1269765
27332210	941	949	clinical	T080	C0205210
27332210	950	958	learning	T041	C0023185
27332210	964	976	specifically	T080	C0205369
27332210	981	985	task	T057	C3540678
27332210	988	996	oriented	T033	C3842076
27332210	997	1008	information	T078	C1533716
27332210	1017	1032	drug medication	T061	C2094270
27332210	1036	1064	patient conditions/diagnoses	UnknownType	C0679829
27332210	1066	1077	Researchers	T097	C0035173
27332210	1078	1087	recommend	T078	C0034866
27332210	1090	1104	paradigm shift	T062	C0681797
27332210	1113	1122	educators	T097	C0259853
27332210	1133	1153	information literacy	T041	C2936607
27332210	1168	1176	supports	T080	C1269765
27332210	1177	1185	evidence	T078	C3887511
27332210	1193	1205	quality care	T058	C0034379

27721673|t|Trauma-Informed Medical Care: Patient Response to a Primary Care Provider Communication Training
27721673|a|Trauma exposure predicts mental disorders and health outcomes; yet there is little training of primary care providers about trauma's effects, and how to better interact with trauma survivors. This study adapted a theory-based approach to working with trauma survivors, Risking Connection, into a 6-hour CME course, Trauma-Informed Medical Care (TI-Med), to evaluate its feasibility and preliminary efficacy. We randomized four primary care sites to training or wait-list conditions; PCPs at wait-list sites were trained after reassessment. Primary care providers (PCPs) were Family Medicine residents (n = 17; 2 sites) or community physicians (n = 13; 2 sites). Outcomes reported here comprised a survey of 400 actual patients seen by the PCPs in the study. Patients, mostly minority, completed surveys before or after their provider received training. Patients rated PCPs significantly higher after training on a scale encompassing partnership issues. Breakdowns showed lower partnership scores for those with trauma or posttraumatic stress symptoms. Future studies will need to include more specific trauma-related outcomes. Nevertheless, this training is a promising initial approach to teaching trauma-informed communication skills to PCPs.
27721673	0	28	Trauma-Informed Medical Care	T058	C0496674
27721673	30	37	Patient	T101	C0030705
27721673	38	46	Response	T032	C0871261
27721673	52	73	Primary Care Provider	T097	C2735026
27721673	74	96	Communication Training	T065	C0220931
27721673	97	103	Trauma	T037	C3714660
27721673	104	112	exposure	T080	C0332157
27721673	122	138	mental disorders	T048	C0004936
27721673	143	158	health outcomes	T170	C1550208
27721673	180	188	training	T065	C0220931
27721673	192	214	primary care providers	T097	C2735026
27721673	221	237	trauma's effects	T046	C1313864
27721673	257	265	interact	T033	C0037420
27721673	271	287	trauma survivors	T033	C0850430
27721673	294	299	study	T062	C2603343
27721673	310	331	theory-based approach	T078	C1254370
27721673	335	342	working	T057	C0043227
27721673	348	364	trauma survivors	T033	C0850430
27721673	366	384	Risking Connection	T170	C0282574
27721673	393	399	6-hour	T079	C1292428
27721673	400	410	CME course	T065	C0013632
27721673	412	440	Trauma-Informed Medical Care	T058	C0496674
27721673	442	448	TI-Med	T058	C0496674
27721673	467	478	feasibility	T062,T170	C0015730
27721673	495	503	efficacy	T080	C1280519
27721673	524	542	primary care sites	T093	C2711449
27721673	546	554	training	T065	C0220931
27721673	580	584	PCPs	T097	C2735026
27721673	623	635	reassessment	T058	C0220825
27721673	637	659	Primary care providers	T097	C2735026
27721673	661	665	PCPs	T097	C2735026
27721673	672	697	Family Medicine residents	UnknownType	C0259967
27721673	719	739	community physicians	T097	C0031831
27721673	759	767	Outcomes	T170	C1550208
27721673	794	800	survey	T062	C0376688
27721673	815	823	patients	T101	C0030705
27721673	836	840	PCPs	T097	C2735026
27721673	848	853	study	T062	C2603343
27721673	855	863	Patients	T101	C0030705
27721673	892	899	surveys	T062	C0376688
27721673	922	930	provider	T097	C2735026
27721673	940	948	training	T065	C0220931
27721673	950	958	Patients	T101	C0030705
27721673	965	969	PCPs	T097	C2735026
27721673	997	1005	training	T065	C0220931
27721673	1030	1048	partnership issues	T078	C1254370
27721673	1050	1060	Breakdowns	T033	C0557503
27721673	1074	1092	partnership scores	T033	C0243095
27721673	1108	1114	trauma	T037	C3714660
27721673	1118	1147	posttraumatic stress symptoms	T048	C0038436
27721673	1156	1163	studies	T062	C2603343
27721673	1199	1222	trauma-related outcomes	T169	C1274040
27721673	1243	1251	training	T065	C0220931
27721673	1287	1295	teaching	T065	C0039401
27721673	1296	1332	trauma-informed communication skills	T032	C0870313
27721673	1336	1340	PCPs	T097	C2735026

28132824|t|Physiological Properties and Behavioral Correlates of Hippocampal Granule Cells and Mossy Cells
28132824|a|The hippocampal dentate gyrus is often viewed as a segregator of upstream information. Physiological support for such function has been hampered by a lack of well-defined characteristics that can identify granule cells and mossy cells. We developed an electrophysiology -based classification of dentate granule cells and mossy cells in mice that we validated by optogenetic tagging of mossy cells. Granule cells exhibited sparse firing, had a single place field, and showed only modest changes when the mouse was tested in different mazes in the same room. In contrast, mossy cells were more active, had multiple place fields and showed stronger remapping of place fields under the same conditions. Although the granule cell - mossy cell synapse was strong and facilitating, mossy cells rarely "inherited" place fields from single granule cells. Our findings suggest that the granule cells and mossy cells could be modulated separately and their joint action may be critical for pattern separation.
28132824	0	13	Physiological	T169	C0205463
28132824	14	24	Properties	T080	C0871161
28132824	29	39	Behavioral	T053	C0004927
28132824	40	50	Correlates	T080	C1707520
28132824	54	65	Hippocampal	T023	C0019564
28132824	66	79	Granule Cells	T025	C0007634
28132824	84	95	Mossy Cells	T025	C0007634
28132824	100	111	hippocampal	T023	C0019564
28132824	112	125	dentate gyrus	T023	C0152314
28132824	147	157	segregator	T169	C0205245
28132824	161	181	upstream information	T042	C1254358
28132824	183	204	Physiological support	T039	C0031843
28132824	214	222	function	T169	C0542341
28132824	246	250	lack	T080	C0332268
28132824	254	266	well-defined	T080	C0442825
28132824	267	282	characteristics	T080	C1521970
28132824	301	314	granule cells	T025	C0007634
28132824	319	330	mossy cells	T025	C0007634
28132824	348	365	electrophysiology	UnknownType	C0678837
28132824	373	387	classification	T185	C0008902
28132824	391	398	dentate	T023	C0152314
28132824	399	412	granule cells	T025	C0007634
28132824	417	428	mossy cells	T025	C0007634
28132824	432	436	mice	T015	C0025929
28132824	458	477	optogenetic tagging	T063	C3494301
28132824	481	492	mossy cells	T025	C0007634
28132824	494	507	Granule cells	T025	C0007634
28132824	525	531	firing	T043	C0007613
28132824	539	545	single	T081	C0205171
28132824	546	557	place field	T082	C1254362
28132824	582	589	changes	T169	C0392747
28132824	599	604	mouse	T015	C0025929
28132824	609	615	tested	T169	C0039593
28132824	629	634	mazes	T073	C0870866
28132824	647	651	room	T082	C1547703
28132824	666	677	mossy cells	T025	C0007634
28132824	688	694	active	T169	C0205177
28132824	700	708	multiple	T081	C0439064
28132824	709	721	place fields	T082	C1254362
28132824	755	767	place fields	T082	C1254362
28132824	783	793	conditions	T080	C0348080
28132824	808	820	granule cell	T025	C0007634
28132824	823	833	mossy cell	T025	C0007634
28132824	834	841	synapse	T030	C0039062
28132824	871	882	mossy cells	T025	C0007634
28132824	902	914	place fields	T082	C1254362
28132824	920	926	single	T081	C0205171
28132824	927	940	granule cells	T025	C0007634
28132824	946	954	findings	T169	C2607943
28132824	972	985	granule cells	T025	C0007634
28132824	990	1001	mossy cells	T025	C0007634
28132824	1011	1020	modulated	T082	C0443264
28132824	1048	1054	action	T052	C3266814
28132824	1075	1093	pattern separation	T169	C0205245

27635073|t|Clinical Experience With the Subcutaneous Implantable Cardioverter-Defibrillator in Adults With Congenital Heart Disease
27635073|a|Sudden cardiac death is a major contributor to mortality for adults with congenital heart disease. The subcutaneous implantable cardioverter-defibrillator (ICD) has emerged as a novel tool for prevention of sudden cardiac death, but clinical performance data for adults with congenital heart disease are limited. A retrospective study involving 7 centers over a 5- year period beginning in 2011 was performed. Twenty-one patients (median 33.9 years) were identified. The most common diagnosis was single ventricle physiology (52%), 9 palliated by Fontan operation and 2 by aortopulmonary shunts: d-transposition of the great arteries after Mustard / Senning (n=2), tetralogy of Fallot (n=2), aortic valve disease (n=2), and other biventricular surgery (n=4). A prior cardiac device had been implanted in 7 (33%). The ICD indication was primary prevention in 67% and secondary in 33% patient s. The most common reason for subcutaneous ICD placement was limited transvenous access for ventricular lead placement (n=10) followed by intracardiac right-to-left shunt (n=5). Ventricular arrhythmia was induced in 17 (81%) and was converted with ≤80 Joules in all. There was one implant complication related to infection, not requiring device removal. Over a median follow-up of 14 months, 4 patients (21%) received inappropriate and 1 (5%) patient received appropriate shocks. There was one arrhythmic death related to asystole in a single ventricle patient. Subcutaneous ICD implantation is feasible for adults with congenital heart disease patients. Most candidates have single ventricle heart disease and limited transvenous options for ICD placement. Despite variable anatomy, this study demonstrates successful conversion of induced ventricular arrhythmia and reasonable rhythm discrimination during follow-up.
27635073	0	8	Clinical	T080	C0205210
27635073	9	19	Experience	T067	C0023672
27635073	29	80	Subcutaneous Implantable Cardioverter-Defibrillator	T074	C3694431
27635073	84	90	Adults	T100	C0001675
27635073	96	120	Congenital Heart Disease	T019	C0152021
27635073	121	141	Sudden cardiac death	T046	C0085298
27635073	168	177	mortality	T081	C0205848
27635073	182	188	adults	T100	C0001675
27635073	194	218	congenital heart disease	T019	C0152021
27635073	224	236	subcutaneous	T082	C0443315
27635073	237	275	implantable cardioverter-defibrillator	T074	C0162589
27635073	277	280	ICD	T074	C0162589
27635073	299	304	novel	T080	C0205314
27635073	305	309	tool	T073	C0336791
27635073	314	324	prevention	T080	C2700409
27635073	328	348	sudden cardiac death	T046	C0085298
27635073	354	374	clinical performance	T033	C3266594
27635073	375	379	data	T078	C1511726
27635073	384	390	adults	T100	C0001675
27635073	396	420	congenital heart disease	T019	C0152021
27635073	436	455	retrospective study	T062	C0035363
27635073	486	490	year	T079	C0439234
27635073	491	497	period	T079	C1948053
27635073	520	529	performed	T169	C0884358
27635073	542	550	patients	T101	C0030705
27635073	552	558	median	T081	C2347635
27635073	564	569	years	T079	C0439234
27635073	604	613	diagnosis	T033	C0011900
27635073	618	634	single ventricle	T019	C0152424
27635073	635	645	physiology	T039	C0031843
27635073	655	664	palliated	T061	C1274136
27635073	668	684	Fontan operation	T061	C0190010
27635073	694	715	aortopulmonary shunts	T061	C0397538
27635073	717	754	d-transposition of the great arteries	T019,T047	C1275836
27635073	761	768	Mustard	T061	C1306542
27635073	771	778	Senning	T061	C0339890
27635073	786	805	tetralogy of Fallot	T019	C0039685
27635073	813	833	aortic valve disease	T047	C1260873
27635073	851	864	biventricular	T082	C0699808
27635073	865	872	surgery	T061	C0543467
27635073	888	902	cardiac device	T074	C0018825
27635073	912	921	implanted	T061	C0948629
27635073	938	941	ICD	T074	C0162589
27635073	942	952	indication	T078	C3146298
27635073	957	975	primary prevention	T061	C0033144
27635073	987	996	secondary	T061	C0679699
27635073	1004	1013	patient s	T101	C0030705
27635073	1042	1054	subcutaneous	T082	C0443315
27635073	1055	1058	ICD	T074	C0162589
27635073	1059	1068	placement	T058	C0441587
27635073	1081	1099	transvenous access	T082	C0522521
27635073	1104	1120	ventricular lead	T074	C2825199
27635073	1121	1130	placement	T058	C0441587
27635073	1150	1182	intracardiac right-to-left shunt	T033	C0489644
27635073	1190	1212	Ventricular arrhythmia	T047	C0085612
27635073	1217	1224	induced	T169	C0205263
27635073	1264	1270	Joules	T081	C0439256
27635073	1293	1334	implant complication related to infection	T046	C0085073
27635073	1336	1339	not	T080	C0332288
27635073	1350	1364	device removal	T061	C0752250
27635073	1373	1379	median	T081	C2347635
27635073	1380	1389	follow-up	T058	C1522577
27635073	1396	1402	months	T079	C0439231
27635073	1406	1414	patients	T101	C0030705
27635073	1430	1443	inappropriate	T047	C0340944
27635073	1455	1462	patient	T101	C0030705
27635073	1472	1490	appropriate shocks	T046	C0036984
27635073	1506	1522	arrhythmic death	T033	C3844298
27635073	1534	1542	asystole	T047	C0018790
27635073	1548	1564	single ventricle	T019	C0152424
27635073	1565	1572	patient	T101	C0030705
27635073	1574	1586	Subcutaneous	T082	C0443315
27635073	1587	1590	ICD	T074	C0162589
27635073	1591	1603	implantation	T061	C0021107
27635073	1620	1626	adults	T100	C0001675
27635073	1632	1656	congenital heart disease	T019	C0152021
27635073	1657	1665	patients	T101	C0030705
27635073	1672	1682	candidates	T101	C0030705
27635073	1688	1704	single ventricle	T019	C0152424
27635073	1705	1718	heart disease	T047	C0018799
27635073	1731	1750	transvenous options	T082	C0522521
27635073	1755	1758	ICD	T074	C0162589
27635073	1759	1768	placement	T058	C0441587
27635073	1778	1786	variable	T080	C0439828
27635073	1787	1794	anatomy	T080	C1384516
27635073	1801	1806	study	T062	C2603343
27635073	1820	1830	successful	T080	C1272703
27635073	1831	1841	conversion	T169	C0439836
27635073	1845	1852	induced	T169	C0205263
27635073	1853	1875	ventricular arrhythmia	T047	C0085612
27635073	1880	1890	reasonable	T033	C0184784
27635073	1891	1897	rhythm	T042	C0232187
27635073	1898	1912	discrimination	T042	C0234412
27635073	1920	1929	follow-up	T058	C1522577

28240704|t|Calibration of Self-Report Measures of Physical Activity and Sedentary Behavior
28240704|a|Calibration equations offer potential to improve the accuracy and utility of self-report measures of physical activity (PA) and sedentary behavior (SB) by re-scaling potentially biased estimates. The present study evaluates calibration models designed to estimate PA and SB in a representative sample of adults from the Physical Activity Measurement Survey (PAMS). Participants in the PAMS project completed replicate single day trials that involved wearing a Sensewear armband (SWA) monitor for 24 hours followed by a telephone administered 24-hour physical activity recall (PAR). Comprehensive statistical model selection and validation procedures were used to develop and test separate calibration models designed to predict objectively - measured SB and moderate to vigorous PA (MVPA from self-reported PAR data. Equivalence testing was used to evaluate the equivalence of the model- predicted values with the objective measures in a separate holdout sample. The final prediction model for both SB and MVPA included reported time spent in SB and MVPA, as well as terms capturing sex, age, education, and BMI. Cross-validation analyses on an independent sample exhibited high correlations with observed SB (r = 0.72) and MVPA (r = 0.75). Equivalence testing demonstrated that the model- predicted values were statistically equivalent to the corresponding objective values for both SB and MVPA. The results demonstrate that simple regression models can be used to statistically adjust for over or underestimation in self-report measures among different segments of the population. The models produced group estimates from the PAR that were statistically equivalent to the observed time spent in SB and MVPA obtained from the objective SWA monitor; however additional work is needed to correct for estimates of individual behavior.
28240704	0	11	Calibration	T081	C0006751
28240704	15	26	Self-Report	T062	C2700446
28240704	27	35	Measures	T081	C0079809
28240704	39	56	Physical Activity	T056	C0026606
28240704	61	79	Sedentary Behavior	T033	C3824706
28240704	80	91	Calibration	T081	C0006751
28240704	92	101	equations	T077	C0552449
28240704	108	117	potential	T080	C3245505
28240704	121	128	improve	T080	C1272747
28240704	133	141	accuracy	T080	C4035952
28240704	157	168	self-report	T062	C2700446
28240704	169	177	measures	T081	C0079809
28240704	181	198	physical activity	T056	C0026606
28240704	200	202	PA	T056	C0026606
28240704	208	226	sedentary behavior	T033	C3824706
28240704	228	230	SB	T033	C3824706
28240704	235	245	re-scaling	T052	C1947916
28240704	246	257	potentially	T080	C3245505
28240704	265	274	estimates	T081	C0750572
28240704	304	315	calibration	T081	C0006751
28240704	316	322	models	T081,T170	C0026348
28240704	335	343	estimate	T081	C0750572
28240704	344	346	PA	T056	C0026606
28240704	351	353	SB	T033	C3824706
28240704	359	373	representative	T081	C1299385
28240704	384	390	adults	T100	C0001675
28240704	400	417	Physical Activity	T056	C0026606
28240704	418	436	Measurement Survey	T062	C0376688
28240704	438	442	PAMS	T062	C0376688
28240704	445	457	Participants	T098	C0679646
28240704	465	469	PAMS	T062	C0376688
28240704	509	515	trials	T062	C0681815
28240704	540	563	Sensewear armband (SWA)	T073	C1301852
28240704	564	571	monitor	T074	C0596972
28240704	576	584	24 hours	T079	C0439584
28240704	599	608	telephone	T062	C0021823
28240704	609	621	administered	T169	C1519231
28240704	630	654	physical activity recall	T058	C1254363
28240704	656	659	PAR	T058	C1254363
28240704	676	693	statistical model	T081,T170	C0026348
28240704	708	718	validation	T169	C2984648
28240704	719	729	procedures	T169	C2700391
28240704	769	780	calibration	T081	C0006751
28240704	781	787	models	T081,T170	C0026348
28240704	800	807	predict	UnknownType	C0681843
28240704	808	819	objectively	T062,T170	C0683957
28240704	822	830	measured	T081	C0079809
28240704	831	833	SB	T033	C3824706
28240704	838	861	moderate to vigorous PA	T056	C0026606
28240704	863	867	MVPA	T056	C0026606
28240704	873	886	self-reported	T062	C2700446
28240704	887	890	PAR	T058	C1254363
28240704	897	908	Equivalence	UnknownType	C0814870
28240704	942	953	equivalence	UnknownType	C0814870
28240704	968	977	predicted	UnknownType	C0681843
28240704	994	1003	objective	T062,T170	C0683957
28240704	1004	1012	measures	T081	C0079809
28240704	1079	1081	SB	T033	C3824706
28240704	1086	1090	MVPA	T056	C0026606
28240704	1123	1125	SB	T033	C3824706
28240704	1130	1134	MVPA	T056	C0026606
28240704	1163	1166	sex	T032	C1522384
28240704	1168	1171	age	T033	C3172266
28240704	1173	1182	education	T033	C0424927
28240704	1188	1191	BMI	T201	C1305855
28240704	1193	1209	Cross-validation	T062	C0681935
28240704	1210	1218	analyses	T081	C0002780
28240704	1286	1288	SB	T033	C3824706
28240704	1304	1308	MVPA	T056	C0026606
28240704	1321	1332	Equivalence	UnknownType	C0814870
28240704	1370	1379	predicted	UnknownType	C0681843
28240704	1392	1405	statistically	T081	C0237881
28240704	1438	1447	objective	T062,T170	C0683957
28240704	1464	1466	SB	T033	C3824706
28240704	1471	1475	MVPA	T056	C0026606
28240704	1513	1523	regression	T170	C0034980
28240704	1524	1530	models	T081,T170	C0026348
28240704	1546	1559	statistically	T081	C0237881
28240704	1598	1609	self-report	T062	C2700446
28240704	1610	1618	measures	T081	C0079809
28240704	1651	1661	population	T098	C1257890
28240704	1667	1673	models	T081,T170	C0026348
28240704	1689	1698	estimates	T081	C0750572
28240704	1708	1711	PAR	T058	C1254363
28240704	1722	1735	statistically	T081	C0237881
28240704	1777	1779	SB	T033	C3824706
28240704	1784	1788	MVPA	T056	C0026606
28240704	1817	1820	SWA	T073	C1301852
28240704	1821	1828	monitor	T074	C0596972
28240704	1879	1888	estimates	T081	C0750572
28240704	1892	1911	individual behavior	T055	C0946284

28404634|t|Mucosal IgM Antibody with d-Mannose Affinity in Fugu Takifugu rubripes Is Utilized by a Monogenean Parasite Heterobothrium okamotoi for Host Recognition
28404634|a|How parasites recognize their definitive hosts is a mystery; however, parasitism is reportedly initiated by recognition of certain molecules on host surfaces. Fish ectoparasites make initial contact with their hosts at body surfaces, such as skin and gills, which are covered with mucosa that are similar to those of mammalian guts. Fish are among the most primitive vertebrates with immune systems that are equivalent to those in mammals, and they produce and secrete IgM into mucus. In this study, we showed that the monogenean parasite Heterobothrium okamotoi utilizes IgM to recognize its host, fugu Takifugu rubripes Oncomiracidia are infective larvae of H. okamotoi that shed their cilia and metamorphose into juveniles when exposed to purified d-mannose - binding fractions from fugu mucus. Using liquid chromatography-tandem mass spectrometry analysis, proteins contained in the fraction were identified as d-mannose -specific IgM with two d-mannose -binding lectins. However, although deciliation was significantly induced by IgM and was inhibited by d-mannose or a specific Ab against fugu IgM, other lectins had no effect, and IgM without d-mannose affinity induced deciliation to a limited degree. Subsequent immunofluorescent staining experiments showed that fugu d-mannose -specific IgM binds ciliated epidermal cells of oncomiracidium. These observations suggest that deciliation is triggered by binding of fugu IgM to cell surface Ags via Ag binding sites. Moreover, concentrations of d-mannose - binding IgM in gill mucus were sufficient to induce deciliation in vitro, indicating that H. okamotoi parasites initially use host Abs to colonize host gills.
28404634	0	7	Mucosal	T024	C0026724
28404634	8	20	IgM Antibody	T116,T129	C1292066
28404634	26	35	d-Mannose	T109,T121	C0024742
28404634	36	44	Affinity	T070	C1510827
28404634	48	70	Fugu Takifugu rubripes	T013	C0949586
28404634	88	98	Monogenean	T204	C0322374
28404634	99	107	Parasite	T204	C0030498
28404634	108	131	Heterobothrium okamotoi	T204	C1499594
28404634	136	152	Host Recognition	T040	C1658611
28404634	157	166	parasites	T204	C0030498
28404634	167	176	recognize	T041	C0524637
28404634	183	193	definitive	T079	C0443196
28404634	194	199	hosts	T001	C1167395
28404634	223	233	parasitism	T070	C0677482
28404634	261	272	recognition	T041	C0524637
28404634	284	293	molecules	T167	C0567416
28404634	297	310	host surfaces	T026	C2752522
28404634	312	316	Fish	T013	C0016163
28404634	317	330	ectoparasites	T204	C0562634
28404634	336	351	initial contact	T033	C1320656
28404634	363	368	hosts	T001	C1167395
28404634	372	385	body surfaces	T032	C0489451
28404634	395	399	skin	T022	C1123023
28404634	404	409	gills	T023	C0017558
28404634	421	428	covered	T169	C0439844
28404634	434	440	mucosa	T024	C0026724
28404634	470	484	mammalian guts	T023	C0699819
28404634	486	490	Fish	T013	C0016163
28404634	510	531	primitive vertebrates	T010	C0042567
28404634	537	551	immune systems	T022	C0020962
28404634	584	591	mammals	T015	C0024660
28404634	614	621	secrete	T038	C0036536
28404634	622	625	IgM	T116,T129	C0020861
28404634	631	636	mucus	T031	C0026727
28404634	672	682	monogenean	T204	C0322374
28404634	683	691	parasite	T204	C0030498
28404634	692	715	Heterobothrium okamotoi	T204	C1499594
28404634	725	728	IgM	T116,T129	C0020861
28404634	732	741	recognize	UnknownType	C0678894
28404634	746	750	host	T001	C1167395
28404634	752	788	fugu Takifugu rubripes Oncomiracidia	T013	C0949586
28404634	793	809	infective larvae	T204	C0686891
28404634	813	824	H. okamotoi	T204	C1499594
28404634	841	846	cilia	T026	C0008778
28404634	851	863	metamorphose	T040	C0025558
28404634	869	878	juveniles	T100	C3146221
28404634	895	903	purified	T169	C1998793
28404634	904	913	d-mannose	T109,T121	C0024742
28404634	916	923	binding	T052	C1145667
28404634	924	933	fractions	T081	C1264633
28404634	939	943	fugu	T013	C0949586
28404634	939	943	fugu	T013	C0949586
28404634	944	949	mucus	T031	C0026727
28404634	957	1012	liquid chromatography-tandem mass spectrometry analysis	T059	C4049918
28404634	1014	1022	proteins	T116,T123	C0033684
28404634	1040	1048	fraction	T081	C1264633
28404634	1054	1064	identified	T080	C0205396
28404634	1068	1077	d-mannose	T109,T121	C0024742
28404634	1088	1091	IgM	T116,T129	C0020861
28404634	1101	1110	d-mannose	T109,T121	C0024742
28404634	1101	1119	d-mannose -binding	T052	C1145667
28404634	1120	1127	lectins	T116,T123	C0023206
28404634	1147	1158	deciliation	T039	C0031843
28404634	1177	1184	induced	T169	C0205263
28404634	1188	1191	IgM	T116,T129	C0020861
28404634	1200	1209	inhibited	T080	C0311403
28404634	1213	1222	d-mannose	T109,T121	C0024742
28404634	1237	1239	Ab	T116,T129	C0003241
28404634	1248	1252	fugu	T013	C0949586
28404634	1253	1256	IgM	T116,T129	C0020861
28404634	1264	1271	lectins	T116,T123	C0023206
28404634	1276	1285	no effect	T080	C1301751
28404634	1291	1294	IgM	T116,T129	C0020861
28404634	1303	1312	d-mannose	T109,T121	C0024742
28404634	1313	1321	affinity	T070	C1510827
28404634	1322	1329	induced	T169	C0205263
28404634	1330	1341	deciliation	T039	C0031843
28404634	1374	1412	immunofluorescent staining experiments	T059	C1318793
28404634	1425	1429	fugu	T013	C0949586
28404634	1430	1439	d-mannose	T109,T121	C0024742
28404634	1450	1453	IgM	T116,T129	C0020861
28404634	1454	1459	binds	T052	C1145667
28404634	1460	1484	ciliated epidermal cells	T025	C1179149
28404634	1488	1502	oncomiracidium	T013	C0949586
28404634	1510	1522	observations	T078	C1554188
28404634	1536	1547	deciliation	T039	C0031843
28404634	1551	1563	triggered by	T080	C1444748
28404634	1564	1571	binding	T052	C1145667
28404634	1575	1579	fugu	T013	C0949586
28404634	1580	1583	IgM	T116,T129	C0020861
28404634	1587	1603	cell surface Ags	T129	C0003339
28404634	1608	1624	Ag binding sites	T129	C0221114
28404634	1636	1650	concentrations	T081	C1446561
28404634	1654	1663	d-mannose	T109,T121	C0024742
28404634	1666	1673	binding	T052	C1145667
28404634	1674	1677	IgM	T116,T129	C0020861
28404634	1681	1691	gill mucus	T031	C0026727
28404634	1711	1717	induce	T169	C0205263
28404634	1718	1729	deciliation	T039	C0031843
28404634	1730	1738	in vitro	T080	C1533691
28404634	1740	1750	indicating	T078	C3146298
28404634	1756	1777	H. okamotoi parasites	T204	C1499594
28404634	1788	1791	use	T169	C0457083
28404634	1792	1796	host	T001	C1167395
28404634	1797	1800	Abs	T116,T129	C0003241
28404634	1804	1812	colonize	T033	C4289767
28404634	1813	1817	host	T001	C1167395
28404634	1818	1823	gills	T023	C0017558

27404405|t|A Retrospective Review of Forensic Odontology Reports Written by the Joint POW/MIA Accounting Command Central Identification Laboratory for Remains Identified from the Korean War
27404405|a|As of August 2014, the Joint POW/MIA Accounting Command has identified the remains of 1980 previously unknown U.S. service members; 280 were from the Korean War. To determine the accuracy and completeness of the available antemortem (AM) dental records, a review of the AM / postmortem (AM / PM) dental record comparisons from 233 Forensic Odontology Reports written in support of remains identified from the Korean War was performed. Seventy-two AM / PM comparisons resulted in exact dental chartings while 161 contained discrepancies which were explainable. Explainable discrepancies include undocumented treatment (103), incorrectly charted third molars as missing (82), differing opinions of specific molars present / missing (20), and erroneous treatment documentation and/or misidentification of teeth present / missing (22, other than molars). Reassessment has revealed varying levels of completeness for our available AM dental records, the need to thoroughly review our computerized comparisons, adjust our comparisons to include molar pattern variations / third molars, and updating our database comparison program.
27404405	2	15	Retrospective	T080	C1514923
27404405	16	22	Review	T170	C0282443
27404405	26	53	Forensic Odontology Reports	T170	C0684224
27404405	69	101	Joint POW/MIA Accounting Command	T092	C2936635
27404405	102	135	Central Identification Laboratory	T073,T093	C0022877
27404405	140	147	Remains	T023	C4280042
27404405	148	158	Identified	T080	C0205396
27404405	168	178	Korean War	T052	C1449776
27404405	202	234	Joint POW/MIA Accounting Command	T092	C2936635
27404405	239	249	identified	T080	C0205396
27404405	254	261	remains	T023	C4280042
27404405	289	293	U.S.	T083	C0041703
27404405	294	309	service members	T097	C0027363
27404405	329	339	Korean War	T052	C1449776
27404405	358	366	accuracy	T080	C0443131
27404405	371	383	completeness	T080	C0439812
27404405	401	411	antemortem	T079	C1254367
27404405	413	415	AM	T079	C1254367
27404405	417	431	dental records	T170	C0011412
27404405	435	441	review	T170	C0282443
27404405	449	451	AM	T079	C1254367
27404405	454	464	postmortem	T079	C0580205
27404405	466	468	AM	T079	C1254367
27404405	471	473	PM	T079	C0580205
27404405	475	488	dental record	T170	C0011412
27404405	489	500	comparisons	T052	C1707455
27404405	510	537	Forensic Odontology Reports	T170	C0684224
27404405	560	567	remains	T023	C4280042
27404405	568	578	identified	T080	C0205396
27404405	588	598	Korean War	T052	C1449776
27404405	626	628	AM	T079	C1254367
27404405	631	633	PM	T079	C0580205
27404405	634	645	comparisons	T052	C1707455
27404405	664	680	dental chartings	T170	C0011412
27404405	701	714	discrepancies	T033	C1290905
27404405	751	764	discrepancies	T033	C1290905
27404405	773	785	undocumented	T033	C0243095
27404405	786	795	treatment	T061	C0087111
27404405	815	822	charted	T170	C0011412
27404405	823	828	third	T081	C0205437
27404405	829	835	molars	T023	C0026367
27404405	839	846	missing	T080	C1705492
27404405	884	890	molars	T023	C0026367
27404405	891	898	present	T033	C0150312
27404405	901	908	missing	T080	C1705492
27404405	919	928	erroneous	T078	C1547323
27404405	929	938	treatment	T061	C0087111
27404405	939	952	documentation	T170	C0920316
27404405	960	977	misidentification	T033	C0243095
27404405	981	986	teeth	T023	C0040426
27404405	987	994	present	T033	C0150312
27404405	997	1004	missing	T080	C1705492
27404405	1021	1027	molars	T023	C0026367
27404405	1064	1070	levels	T080	C0441889
27404405	1074	1086	completeness	T080	C0439812
27404405	1105	1107	AM	T079	C1254367
27404405	1108	1122	dental records	T170	C0011412
27404405	1147	1153	review	T170	C0282443
27404405	1158	1182	computerized comparisons	T052	C1707455
27404405	1195	1206	comparisons	T052	C1707455
27404405	1218	1223	molar	T023	C0026367
27404405	1224	1231	pattern	T082	C0449774
27404405	1232	1242	variations	T080	C0205419
27404405	1245	1250	third	T081	C0205437
27404405	1251	1257	molars	T023	C0026367
27404405	1276	1284	database	T170	C0242356
27404405	1285	1295	comparison	T052	C1707455
27404405	1296	1303	program	T169	C3484370

28340580|t|Toll-like receptors genes polymorphisms and the occurrence of HCMV infection among pregnant women
28340580|a|Human cytomegalovirus (HCMV) is the most common cause of intrauterine infections worldwide. The toll-like receptors (TLRs) have been reported as important factors in immune response against HCMV. Particularly, TLR2, TLR4 and TLR9 have been shown to be involved in antiviral immunity. Evaluation of the role of single nucleotide polymorphisms (SNPs), located within TLR2, TLR4 and TLR9 genes, in the development of human cytomegalovirus (HCMV) infection in pregnant women and their fetuses and neonates, was performed. The study was performed for 131 pregnant women, including 66 patients infected with HCMV during pregnancy, and 65 age - matched control pregnant individuals. The patients were selected to the study, based on serological status of anti-HCMV IgG and IgM antibodies and on the presence of viral DNA in their body fluids. Genotypes in TLR2 2258 A > G, TLR4 896 G > A and 1196 C > T and TLR9 2848 G > A SNPs were determined by self-designed nested PCR - RFLP assays. Randomly selected PCR products, representative for distinct genotypes in TLR SNPs, were confirmed by sequencing. A relationship between the genotypes, alleles, haplotypes and multiple variants in the studied polymorphisms, and the occurrence of HCMV infection in pregnant women and their offsprings, was determined, using a logistic regression model. Genotypes in all the analyzed polymorphisms preserved the Hardy-Weinberg equilibrium in pregnant women, both infected and uninfected with HCMV (P > 0.050). G G homozygotic and G A heterozygotic status in TLR9 2848 G > A SNP decreased significantly the occurrence of HCMV infection (OR 0.44 95% CI 0.21-0.94 in the dominant model, P ≤ 0.050). The G allele in TLR9 SNP was significantly more frequent among the uninfected pregnant women than among the infected ones (χ(2) = 4.14, P ≤ 0.050). Considering other polymorphisms, similar frequencies of distinct genotypes, haplotypes and multiple-SNP variants were observed between the studied groups of patients. TLR9 2848 G > A SNP may be associated with HCMV infection in pregnant women.
28340580	0	19	Toll-like receptors	T116,T192	C0670896
28340580	20	39	genes polymorphisms	T045	C0678951
28340580	48	58	occurrence	T079	C2745955
28340580	62	76	HCMV infection	T047	C0010823
28340580	83	97	pregnant women	T098	C0033011
28340580	98	119	Human cytomegalovirus	T005	C3810552
28340580	121	125	HCMV	T005	C3810552
28340580	146	151	cause	T169	C0015127
28340580	155	178	intrauterine infections	T047	C1112157
28340580	194	213	toll-like receptors	T116,T192	C0670896
28340580	215	219	TLRs	T116,T192	C0670896
28340580	243	260	important factors	T169	C1521761
28340580	264	279	immune response	T042	C0301872
28340580	288	292	HCMV	T005	C3810552
28340580	308	312	TLR2	T028	C1336634
28340580	314	318	TLR4	T028	C1336636
28340580	323	327	TLR9	T028	C1423633
28340580	350	358	involved	T169	C1314939
28340580	362	380	antiviral immunity	T039	C0020964
28340580	382	392	Evaluation	T078	C1550157
28340580	408	439	single nucleotide polymorphisms	T086	C0752046
28340580	441	445	SNPs	T086	C0752046
28340580	448	462	located within	T082	C0332285
28340580	463	467	TLR2	T028	C1336634
28340580	469	473	TLR4	T028	C1336636
28340580	478	488	TLR9 genes	T028	C1423633
28340580	497	508	development	T169	C1527148
28340580	512	550	human cytomegalovirus (HCMV) infection	T047	C0010823
28340580	554	568	pregnant women	T098	C0033011
28340580	579	586	fetuses	T018	C0015965
28340580	591	599	neonates	T100	C0021289
28340580	605	614	performed	T169	C0884358
28340580	630	639	performed	T169	C0884358
28340580	648	662	pregnant women	T098	C0033011
28340580	677	685	patients	T101	C0030705
28340580	686	694	infected	T033	C0439663
28340580	700	704	HCMV	T005	C3810552
28340580	712	721	pregnancy	T040	C0032961
28340580	730	733	age	T032	C0001779
28340580	736	743	matched	T096	C0024908
28340580	744	751	control	T096	C0009932
28340580	752	772	pregnant individuals	T098	C0033011
28340580	778	786	patients	T101	C0030705
28340580	792	800	selected	T052	C1707391
28340580	824	842	serological status	T169	C0220911
28340580	846	859	anti-HCMV IgG	T116,T129	C0369080
28340580	864	878	IgM antibodies	T116,T129	C0369081
28340580	902	911	viral DNA	T114	C0012939
28340580	921	932	body fluids	T031	C0005889
28340580	934	943	Genotypes	T032	C0017431
28340580	947	951	TLR2	T028	C1336634
28340580	957	958	A	T114,T121,T123	C0001443
28340580	961	962	G	T114,T121	C0018330
28340580	964	968	TLR4	T028	C1336636
28340580	973	974	G	T114,T121	C0018330
28340580	977	978	A	T114,T121,T123	C0001443
28340580	988	989	C	T114	C0010715
28340580	992	993	T	T114,T123	C0040077
28340580	998	1002	TLR9	T028	C1423633
28340580	1008	1009	G	T114,T121	C0018330
28340580	1012	1013	A	T114,T121,T123	C0001443
28340580	1014	1018	SNPs	T086	C0752046
28340580	1038	1062	self-designed nested PCR	T063	C0242574
28340580	1065	1076	RFLP assays	T059	C0200930
28340580	1096	1099	PCR	T063	C0032520
28340580	1100	1108	products	T071	C1514468
28340580	1138	1147	genotypes	T032	C0017431
28340580	1155	1159	SNPs	T086	C0752046
28340580	1179	1189	sequencing	T059	C1294197
28340580	1193	1205	relationship	T080	C0439849
28340580	1218	1227	genotypes	T032	C0017431
28340580	1229	1236	alleles	T028	C0002085
28340580	1238	1248	haplotypes	T032	C0018591
28340580	1253	1270	multiple variants	T028	C0678941
28340580	1286	1299	polymorphisms	T045	C0678951
28340580	1309	1319	occurrence	T079	C2745955
28340580	1323	1337	HCMV infection	T047	C0010823
28340580	1341	1355	pregnant women	T098	C0033011
28340580	1366	1376	offsprings	T099	C0680063
28340580	1402	1427	logistic regression model	UnknownType	C0681925
28340580	1429	1438	Genotypes	T032	C0017431
28340580	1450	1472	analyzed polymorphisms	T045	C0032529
28340580	1487	1513	Hardy-Weinberg equilibrium	T077	C1881032
28340580	1517	1531	pregnant women	T098	C0033011
28340580	1538	1546	infected	T033	C0439663
28340580	1567	1571	HCMV	T005	C3810552
28340580	1585	1586	G	T114,T121	C0018330
28340580	1587	1588	G	T114,T121	C0018330
28340580	1589	1600	homozygotic	T032	C0019904
28340580	1605	1606	G	T114,T121	C0018330
28340580	1607	1608	A	T114,T121,T123	C0001443
28340580	1609	1622	heterozygotic	T032	C0019425
28340580	1633	1637	TLR9	T028	C1423633
28340580	1643	1644	G	T114,T121	C0018330
28340580	1647	1648	A	T114,T121,T123	C0001443
28340580	1649	1652	SNP	T086	C0752046
28340580	1653	1662	decreased	T081	C0205216
28340580	1681	1691	occurrence	T079	C2745955
28340580	1695	1709	HCMV infection	T047	C0010823
28340580	1711	1713	OR	T081	C0028873
28340580	1723	1725	CI	T081	C0009667
28340580	1743	1757	dominant model	T170	C0026343
28340580	1775	1776	G	T114,T121	C0018330
28340580	1777	1783	allele	T028	C0002085
28340580	1787	1791	TLR9	T028	C1423633
28340580	1792	1795	SNP	T086	C0752046
28340580	1819	1827	frequent	T079	C0332183
28340580	1849	1863	pregnant women	T098	C0033011
28340580	1879	1887	infected	T033	C0439663
28340580	1937	1950	polymorphisms	T045	C0678951
28340580	1960	1971	frequencies	T081	C0017270
28340580	1984	1993	genotypes	T032	C0017431
28340580	1995	2005	haplotypes	T032	C0018591
28340580	2010	2031	multiple-SNP variants	T028	C0678941
28340580	2058	2072	studied groups	UnknownType	C0681860
28340580	2076	2084	patients	T101	C0030705
28340580	2086	2090	TLR9	T028	C1423633
28340580	2096	2097	G	T114,T121	C0018330
28340580	2100	2101	A	T114,T121,T123	C0001443
28340580	2102	2105	SNP	T086	C0752046
28340580	2113	2128	associated with	T080	C0332281
28340580	2129	2143	HCMV infection	T047	C0010823
28340580	2147	2161	pregnant women	T098	C0033011

28238581|t|Correlation of Technetium-99m Macroaggregated Albumin and Yttrium-90 Glass Microsphere Biodistribution in Hepatocellular Carcinoma: A Retrospective Review of Pretreatment Single Photon Emission CT and Posttreatment Positron Emission Tomography/CT
28238581|a|To evaluate whether technetium-99 ((99m)Tc)-labeled macroaggregated albumin (MAA) can predict subsequent yttrium-90 ((90)Y) distribution and imaging response in patients with hepatocellular carcinoma (HCC). Retrospective review was performed of records of 83 patients with HCC who underwent (90)Y glass microsphere radioembolization with (99m)Tc-MAA single photon emission computed tomography (SPECT) and (90)Y positron emission tomography (PET)/CT between January 2013 and December 2014. Images were fused to segment the whole liver normal tissue (WLNT) and the largest tumors. Fused images were reviewed and analyzed for comparison of absorbed dose (AD) to tumors and WLNT as calculated from (99m)Tc-MAA SPECT and from (90)Y PET/CT, subjective imaging comparison of (99m)Tc-MAA SPECT and (90)Y PET for tumors and WLNT, and correlation of tumoral AD with response on follow-up CT. Final analysis included 73 and 63 patients for WLNT and tumor (99m)Tc-MAA / (90)Y correlation, respectively, and 62 patients for AD vs response. (99m)Tc-MAA / (90)Y limit of agreement for each reviewer was viewed as clinically acceptable only for WLNT (-15 to 15 Gy). AD interreviewer variability was clinically acceptable for WLNT but was too broad for tumor. Mean tumor AD for objective response (78%) was 313 Gy vs 234 Gy for nonresponders. No threshold was found between tumor AD and response (P > .1). Catheter mismatch between (99m)Tc-MAA and (90)Y had a direct impact on AD mismatch between the 2 image sets. (99m)Tc-MAA was found to be a poor surrogate to quantitatively predict subsequent (90)Y AD to hepatocellular tumors. (99m)Tc-MAA distribution correlated with (90)Y distribution in the normal hepatic parenchyma.
28238581	0	11	Correlation	T062,T170	C0010101
28238581	15	53	Technetium-99m Macroaggregated Albumin	T130,T196	C3838747
28238581	58	68	Yttrium-90	T130,T196	C0303596
28238581	69	86	Glass Microsphere	T074	C0026032
28238581	87	102	Biodistribution	T082	C1254362
28238581	106	130	Hepatocellular Carcinoma	T191	C2239176
28238581	134	154	Retrospective Review	T062	C0035363
28238581	158	196	Pretreatment Single Photon Emission CT	T060	C0032743
28238581	201	246	Posttreatment Positron Emission Tomography/CT	T060	C0032743
28238581	267	322	technetium-99 ((99m)Tc)-labeled macroaggregated albumin	T130,T196	C3838747
28238581	324	327	MAA	T130,T196	C3838747
28238581	352	362	yttrium-90	T130,T196	C0303596
28238581	364	369	(90)Y	T130,T196	C0303596
28238581	371	383	distribution	T169	C1704711
28238581	388	395	imaging	T060	C0011923
28238581	396	404	response	T032	C0871261
28238581	408	416	patients	T101	C0030705
28238581	422	446	hepatocellular carcinoma	T191	C2239176
28238581	448	451	HCC	T191	C2239176
28238581	454	474	Retrospective review	T062	C0035363
28238581	492	499	records	T073,T170	C0019980
28238581	506	514	patients	T101	C0030705
28238581	520	523	HCC	T191	C2239176
28238581	538	543	(90)Y	T130,T196	C0303596
28238581	544	561	glass microsphere	T074	C0026032
28238581	562	579	radioembolization	T061	C2985560
28238581	585	596	(99m)Tc-MAA	T130,T196	C3838747
28238581	597	639	single photon emission computed tomography	T060	C0040399
28238581	641	646	SPECT	T060	C0040399
28238581	652	657	(90)Y	T130,T196	C0303596
28238581	658	686	positron emission tomography	T060	C0032743
28238581	687	695	(PET)/CT	T060	C1699633
28238581	736	742	Images	T170	C1704254
28238581	748	753	fused	T169	C0699952
28238581	769	794	whole liver normal tissue	T023	C0736268
28238581	796	800	WLNT	T023	C0736268
28238581	818	824	tumors	T191	C0027651
28238581	826	831	Fused	T169	C0699952
28238581	832	838	images	T170	C1704254
28238581	844	852	reviewed	T080	C1709940
28238581	857	865	analyzed	T062	C0936012
28238581	870	880	comparison	T052	C1707455
28238581	884	897	absorbed dose	T081	C0454216
28238581	899	901	AD	T081	C0454216
28238581	906	912	tumors	T191	C0027651
28238581	917	921	WLNT	T023	C0736268
28238581	941	952	(99m)Tc-MAA	T130,T196	C3838747
28238581	953	958	SPECT	T060	C0040399
28238581	968	973	(90)Y	T130,T196	C0303596
28238581	974	980	PET/CT	T060	C1699633
28238581	993	1000	imaging	T060	C0011923
28238581	1001	1011	comparison	T052	C1707455
28238581	1015	1026	(99m)Tc-MAA	T130,T196	C3838747
28238581	1027	1032	SPECT	T060	C0040399
28238581	1037	1042	(90)Y	T130,T196	C0303596
28238581	1043	1046	PET	T060	C0032743
28238581	1051	1057	tumors	T191	C0027651
28238581	1062	1066	WLNT	T023	C0736268
28238581	1072	1083	correlation	T062,T170	C0010101
28238581	1087	1094	tumoral	T191	C0006826
28238581	1095	1097	AD	T081	C0454216
28238581	1103	1111	response	T032	C0871261
28238581	1115	1124	follow-up	T058	C1522577
28238581	1125	1127	CT	T060	C0040398
28238581	1129	1143	Final analysis	T170	C3899116
28238581	1163	1171	patients	T101	C0030705
28238581	1176	1180	WLNT	T023	C0736268
28238581	1185	1190	tumor	T191	C0027651
28238581	1191	1202	(99m)Tc-MAA	T130,T196	C3838747
28238581	1205	1210	(90)Y	T130,T196	C0303596
28238581	1211	1222	correlation	T062,T170	C0010101
28238581	1245	1253	patients	T101	C0030705
28238581	1258	1260	AD	T081	C0454216
28238581	1264	1272	response	T032	C0871261
28238581	1274	1285	(99m)Tc-MAA	T130,T196	C3838747
28238581	1288	1293	(90)Y	T130,T196	C0303596
28238581	1322	1330	reviewer	T098	C1882950
28238581	1345	1355	clinically	T080	C0205210
28238581	1356	1366	acceptable	T080	C1879533
28238581	1376	1380	WLNT	T023	C0736268
28238581	1397	1399	AD	T081	C0454216
28238581	1400	1413	interreviewer	T098	C1882950
28238581	1430	1440	clinically	T080	C0205210
28238581	1441	1451	acceptable	T080	C1879533
28238581	1456	1460	WLNT	T023	C0736268
28238581	1483	1488	tumor	T191	C0027651
28238581	1495	1500	tumor	T191	C0027651
28238581	1501	1503	AD	T081	C0454216
28238581	1518	1526	response	T032	C0871261
28238581	1558	1571	nonresponders	T098	C1257890
28238581	1604	1609	tumor	T191	C0027651
28238581	1610	1612	AD	T081	C0454216
28238581	1617	1625	response	T032	C0871261
28238581	1636	1644	Catheter	T074	C0085590
28238581	1645	1653	mismatch	T077	C1709041
28238581	1662	1673	(99m)Tc-MAA	T130,T196	C3838747
28238581	1678	1683	(90)Y	T130,T196	C0303596
28238581	1707	1709	AD	T081	C0454216
28238581	1710	1718	mismatch	T077	C1709041
28238581	1733	1738	image	T170	C1704254
28238581	1745	1756	(99m)Tc-MAA	T130,T196	C3838747
28238581	1793	1807	quantitatively	T081	C0392762
28238581	1827	1832	(90)Y	T130,T196	C0303596
28238581	1833	1835	AD	T081	C0454216
28238581	1839	1860	hepatocellular tumors	T191	C2239176
28238581	1862	1873	(99m)Tc-MAA	T130,T196	C3838747
28238581	1874	1886	distribution	T169	C1704711
28238581	1887	1897	correlated	T062,T170	C0010101
28238581	1903	1908	(90)Y	T130,T196	C0303596
28238581	1909	1921	distribution	T169	C1704711
28238581	1936	1954	hepatic parenchyma	T023	C0736268

27242761|t|Cobalamin Protection against Oxidative Stress in the Acidophilic Iron-oxidizing Bacterium Leptospirillum Group II CF-1
27242761|a|Members of the genus Leptospirillum are aerobic iron-oxidizing bacteria belonging to the phylum Nitrospira. They are important members of microbial communities that catalyze the biomining of sulfidic ores, thereby solubilizing metal ions. These microorganisms live under extremely acidic and metal -loaded environments and thus must tolerate high concentrations of reactive oxygen species (ROS). Cobalamin (vitamin B12) is a cobalt -containing tetrapyrrole cofactor involved in intramolecular rearrangement reactions and has recently been suggested to be an intracellular antioxidant. In this work, we investigated the effect of the exogenous addition of cobalamin on oxidative stress parameters in Leptospirillum group II strain CF-1. Our results revealed that the external supplementation of cobalamin reduces the levels of intracellular ROSs and the damage to biomolecules, and also stimulates the growth and survival of cells exposed to oxidative stress exerted by ferric ion, hydrogen peroxide, chromate and diamide. Furthermore, exposure of strain CF-1 to oxidative stress elicitors resulted in the transcriptional activation of the cbiA gene encoding CbiA of the cobalamin biosynthetic pathway. Altogether, these data suggest that cobalamin plays an important role in redox protection of Leptospirillum strain CF-1, supporting survival of this microorganism under extremely oxidative environmental conditions. Understanding the mechanisms underlying the protective effect of cobalamin against oxidative stress may help to develop strategies to make biomining processes more effective.
27242761	0	9	Cobalamin	T114,T127	C0086024
27242761	10	20	Protection	T033	C1545588
27242761	29	45	Oxidative Stress	T049	C0242606
27242761	53	64	Acidophilic	T169	C0333931
27242761	65	89	Iron-oxidizing Bacterium	T007	C0004611
27242761	90	118	Leptospirillum Group II CF-1	T007	C2758310
27242761	140	154	Leptospirillum	T007	C0995279
27242761	159	166	aerobic	T080	C1510824
27242761	167	190	iron-oxidizing bacteria	T007	C0004611
27242761	208	225	phylum Nitrospira	T007	C0995591
27242761	257	266	microbial	T001	C0599840
27242761	267	278	communities	T070	C1253910
27242761	284	292	catalyze	T070	C2350294
27242761	297	306	biomining	T057	C0026175
27242761	310	323	sulfidic ores	T104	C0567321
27242761	346	356	metal ions	T196	C0022023
27242761	364	378	microorganisms	T001	C0445623
27242761	411	416	metal	T197	C0025552
27242761	425	437	environments	T082	C0014406
27242761	466	480	concentrations	T081	C1446561
27242761	484	507	reactive oxygen species	T123,T196	C0162772
27242761	509	512	ROS	T123,T196	C0162772
27242761	515	524	Cobalamin	T114,T127	C0086024
27242761	526	537	vitamin B12	T109,T121,T127	C0042845
27242761	544	550	cobalt	T123,T196	C0009148
27242761	563	575	tetrapyrrole	T109,T123	C0076335
27242761	576	584	cofactor	T123	C0178555
27242761	597	635	intramolecular rearrangement reactions	T067	C0596965
27242761	677	690	intracellular	T082	C0178719
27242761	691	702	antioxidant	T121	C0003402
27242761	721	733	investigated	T169	C1292732
27242761	738	744	effect	T080	C1280500
27242761	752	761	exogenous	T169	C0205228
27242761	774	783	cobalamin	T114,T127	C0086024
27242761	787	803	oxidative stress	T049	C0242606
27242761	804	814	parameters	T077	C0549193
27242761	818	853	Leptospirillum group II strain CF-1	T007	C2758310
27242761	867	875	revealed	T080	C0443289
27242761	885	909	external supplementation	T168	C0681579
27242761	913	922	cobalamin	T114,T127	C0086024
27242761	945	958	intracellular	T082	C0178719
27242761	959	963	ROSs	T123,T196	C0162772
27242761	972	978	damage	T169	C1883709
27242761	982	994	biomolecules	T123	C0574031
27242761	1005	1015	stimulates	T070	C1948023
27242761	1020	1026	growth	T040	C0018270
27242761	1031	1048	survival of cells	T043	C0007620
27242761	1060	1076	oxidative stress	T049	C0242606
27242761	1088	1098	ferric ion	T196	C2346593
27242761	1100	1117	hydrogen peroxide	T121,T130,T197	C0020281
27242761	1119	1127	chromate	T197	C0008543
27242761	1132	1139	diamide	T109,T121,T130	C0011953
27242761	1166	1177	strain CF-1	T007	C0995279
27242761	1181	1197	oxidative stress	T049	C0242606
27242761	1224	1250	transcriptional activation	T045	C0162493
27242761	1258	1267	cbiA gene	T028	C0017337
27242761	1277	1281	CbiA	T116,T123	C0033684
27242761	1289	1298	cobalamin	T114,T127	C0086024
27242761	1299	1319	biosynthetic pathway	T044	C1721101
27242761	1339	1343	data	T078	C1511726
27242761	1357	1366	cobalamin	T114,T127	C0086024
27242761	1394	1399	redox	T044	C0030012
27242761	1400	1410	protection	T033	C1545588
27242761	1414	1440	Leptospirillum strain CF-1	T007	C0995279
27242761	1470	1483	microorganism	T001	C0445623
27242761	1500	1509	oxidative	T169	C0311404
27242761	1510	1534	environmental conditions	T080	C0348080
27242761	1554	1564	mechanisms	T169	C0441712
27242761	1580	1590	protective	T033	C1545588
27242761	1591	1597	effect	T080	C1280500
27242761	1601	1610	cobalamin	T114,T127	C0086024
27242761	1619	1635	oxidative stress	T049	C0242606
27242761	1675	1684	biomining	T057	C0026175
27242761	1685	1694	processes	T067	C1522240
27242761	1700	1709	effective	T080	C1704419

27503926|t|SIRT2 Deacetylates and Inhibits the Peroxidase Activity of Peroxiredoxin-1 to Sensitize Breast Cancer Cells to Oxidant Stress - Inducing Agents
27503926|a|SIRT2 is a protein deacetylase with tumor suppressor activity in breast and liver tumors where it is mutated; however, the critical substrates mediating its antitumor activity are not fully defined. Here we demonstrate that SIRT2 binds, deacetylates, and inhibits the peroxidase activity of the antioxidant protein peroxiredoxin (Prdx-1) in breast cancer cells. Ectopic overexpression of SIRT2, but not its catalytically dead mutant, increased intracellular levels of reactive oxygen species (ROS) induced by hydrogen peroxide, which led to increased levels of an overoxidized and multimeric form of Prdx-1 with activity as a molecular chaperone. Elevated levels of SIRT2 sensitized breast cancer cells to intracellular DNA damage and cell death induced by oxidative stress, as associated with increased levels of nuclear FOXO3A and the proapoptotic BIM protein. In addition, elevated levels of SIRT2 sensitized breast cancer cells to arsenic trioxide, an approved therapeutic agent, along with other intracellular ROS - inducing agents. Conversely, antisense RNA - mediated attenuation of SIRT2 reversed ROS - induced toxicity as demonstrated in a zebrafish embryo model system. Collectively, our findings suggest that the tumor suppressor activity of SIRT2 requires its ability to restrict the antioxidant activity of Prdx-1, thereby sensitizing breast cancer cells to ROS - induced DNA damage and cell cytotoxicity. Cancer Res; 76(18); 5467-78. ©2016 AACR.
27503926	0	5	SIRT2	T116,T126	C2720168
27503926	6	18	Deacetylates	T044	C2246982
27503926	23	55	Inhibits the Peroxidase Activity	T044	C3893923
27503926	59	74	Peroxiredoxin-1	T116,T126	C0672553
27503926	78	107	Sensitize Breast Cancer Cells	T025	C1512505
27503926	111	125	Oxidant Stress	T049	C0242606
27503926	128	136	Inducing	T169	C0205263
27503926	144	149	SIRT2	T116,T126	C2720168
27503926	155	174	protein deacetylase	T044	C2246982
27503926	180	205	tumor suppressor activity	T043	C1325410
27503926	209	215	breast	T191	C0006142
27503926	220	232	liver tumors	T191	C0345904
27503926	245	252	mutated	T049	C1705285
27503926	276	286	substrates	T167	C3891814
27503926	301	319	antitumor activity	T033	C0243095
27503926	368	373	SIRT2	T116,T126	C2720168
27503926	374	379	binds	T044	C1149286
27503926	381	393	deacetylates	T044	C1511737
27503926	399	431	inhibits the peroxidase activity	T044	C3893923
27503926	439	472	antioxidant protein peroxiredoxin	T116,T126	C0672553
27503926	474	480	Prdx-1	T116,T126	C0672553
27503926	485	504	breast cancer cells	T025	C1512505
27503926	506	513	Ectopic	T082	C0574895
27503926	514	528	overexpression	T045	C0017262
27503926	532	537	SIRT2	T116,T126	C2720168
27503926	551	576	catalytically dead mutant	T049	C0596988
27503926	578	587	increased	T081	C0205217
27503926	588	608	intracellular levels	T082	C0178719
27503926	612	635	reactive oxygen species	T123,T196	C0162772
27503926	637	640	ROS	T123,T196	C0162772
27503926	642	671	induced by hydrogen peroxide,	T121,T130,T197	C0020281
27503926	685	694	increased	T081	C0205217
27503926	695	701	levels	T080	C0441889
27503926	708	750	overoxidized and multimeric form of Prdx-1	T116,T126	C0672553
27503926	756	789	activity as a molecular chaperone	T116,T123	C0243041
27503926	791	799	Elevated	T080	C3163633
27503926	800	806	levels	T080	C0441889
27503926	810	815	SIRT2	T028	C1420071
27503926	816	846	sensitized breast cancer cells	T025	C1512505
27503926	850	874	intracellular DNA damage	T049	C0012860
27503926	879	917	cell death induced by oxidative stress	T043	C3894015
27503926	938	947	increased	T081	C0205217
27503926	948	954	levels	T080	C0441889
27503926	958	972	nuclear FOXO3A	T116,T123	C1333633
27503926	981	1005	proapoptotic BIM protein	T116,T123	C4282114
27503926	1020	1028	elevated	T080	C3163633
27503926	1029	1035	levels	T080	C0441889
27503926	1039	1044	SIRT2	T116,T126	C2720168
27503926	1045	1075	sensitized breast cancer cells	T025	C1512505
27503926	1079	1095	arsenic trioxide	T121,T131,T197	C0052416
27503926	1109	1126	therapeutic agent	T073	C0304231
27503926	1145	1162	intracellular ROS	T123,T196	C0162772
27503926	1165	1180	inducing agents	T121	C1254351
27503926	1194	1207	antisense RNA	T114,T123,T130	C0080124
27503926	1210	1230	mediated attenuation	T052	C0599946
27503926	1234	1239	SIRT2	T116,T126	C2720168
27503926	1240	1248	reversed	T169	C1555029
27503926	1249	1252	ROS	T123,T196	C0162772
27503926	1255	1271	induced toxicity	T037	C1516457
27503926	1293	1302	zebrafish	T013	C0043457
27503926	1303	1322	embryo model system	T018	C0013935
27503926	1368	1393	tumor suppressor activity	T043	C1325410
27503926	1397	1402	SIRT2	T116,T126	C2720168
27503926	1427	1435	restrict	T169	C0443288
27503926	1440	1460	antioxidant activity	T044	C1148564
27503926	1464	1470	Prdx-1	T116,T126	C0672553
27503926	1480	1511	sensitizing breast cancer cells	T025	C1512505
27503926	1515	1518	ROS	T123,T196	C0162772
27503926	1521	1539	induced DNA damage	T049	C0012860
27503926	1544	1561	cell cytotoxicity	T049	C0596402

27678317|t|Thyroid cancer burden in Central and South America
27678317|a|Incidence of thyroid cancer (TC) is rapidly increasing worldwide, but little is known about the TC burden in Central and South America (CSA). We describe the geographic patterns and trends of TC by sex in CSA. We obtained regional - and national-level incidence data from 48 population-based cancer registries in 13 countries and nationwide cancer deaths from the WHO mortality database for 18 countries. We estimated world population age-standardized incidence rates (ASRs) and age-standardized mortality rates (ASMRs) per 100,000 person - years. We calculated ASRs by histological subtype. We estimated the annual percentage change (EAPC) to describe time trends. Between CSA countries, TC incidence and mortality rates varied from 8-fold to 12-fold and from 2-fold to 5-fold, respectively. In 2003-2007, the highest TC ASRs in females and males were in Ecuador (16.0 and 3.5, respectively), Brazil (14.4 and 3.4), Costa Rica (12.6 and 2.1) and Colombia (10.7 and 2.5). The highest ASMRs were in Ecuador, Colombia, Mexico, Peru and Panama (0.68-0.91 in females and 0.41-0.48 in males). Papillary TC was the most commonly diagnosed histological subtype, following the same incidence pattern as overall TC. In Argentinean, Brazilian, Chilean and Costa Rican females TC incidence increased by 2.2-17.9% annually, and papillary TC increased by 9.1-15.0% annually, while mortality remained stable between 1997 and 2008. In males, trends in TC were stable. TC occurred more frequently in females than in males. The overall high incidence and low mortality of TC suggest identification of subclinical disease due to improved detection methods.
27678317	0	14	Thyroid cancer	T191	C0007115
27678317	15	21	burden	T081	C1516167
27678317	25	32	Central	T083	C0007674
27678317	37	50	South America	T083	C0037713
27678317	51	60	Incidence	T081	C0021149
27678317	64	78	thyroid cancer	T191	C0007115
27678317	80	82	TC	T191	C0007115
27678317	87	94	rapidly	T080	C0456962
27678317	95	105	increasing	T169	C0442808
27678317	106	115	worldwide	T078	C0043236
27678317	147	149	TC	T191	C0007115
27678317	150	156	burden	T081	C1516167
27678317	160	167	Central	T083	C0007674
27678317	172	185	South America	T083	C0037713
27678317	187	190	CSA	T083	C0002454
27678317	209	228	geographic patterns	T082	C0442527
27678317	233	239	trends	T079	C0040833
27678317	243	245	TC	T191	C0007115
27678317	249	252	sex	T032	C0079399
27678317	256	259	CSA	T083	C0002454
27678317	273	281	regional	UnknownType	C0683928
27678317	288	302	national-level	T082	C0681788
27678317	303	312	incidence	T081	C1708485
27678317	313	317	data	T078	C1511726
27678317	326	360	population-based cancer registries	T170	C1514227
27678317	367	376	countries	T083	C0454664
27678317	392	405	cancer deaths	T081	C1516192
27678317	415	418	WHO	T093	C0043237
27678317	419	428	mortality	T081	C0205848
27678317	429	437	database	T170	C0242356
27678317	445	454	countries	T083	C0454664
27678317	469	474	world	T098	C2700280
27678317	486	518	age-standardized incidence rates	T081	C1706747
27678317	520	524	ASRs	T081	C1706747
27678317	530	562	age-standardized mortality rates	T081	C1706748
27678317	564	569	ASMRs	T081	C1706748
27678317	583	589	person	T098	C0027361
27678317	592	597	years	T079	C0439234
27678317	613	617	ASRs	T081	C1706747
27678317	621	641	histological subtype	T201	C0449574
27678317	646	684	estimated the annual percentage change	T081	C0023732
27678317	686	690	EAPC	T081	C0023732
27678317	704	715	time trends	T079	C0040833
27678317	725	728	CSA	T083	C0002454
27678317	729	738	countries	T083	C0454664
27678317	740	742	TC	T191	C0007115
27678317	743	752	incidence	T081	C1708485
27678317	757	772	mortality rates	T081	C0205848
27678317	862	869	highest	T080	C1522410
27678317	870	872	TC	T191	C0007115
27678317	873	877	ASRs	T081	C1706747
27678317	881	888	females	T032	C0086287
27678317	893	898	males	T032	C0086582
27678317	907	914	Ecuador	T083	C0013593
27678317	945	951	Brazil	T083	C0006137
27678317	968	978	Costa Rica	T083	C0010182
27678317	998	1006	Colombia	T083	C3245499
27678317	1027	1034	highest	T080	C1522410
27678317	1035	1040	ASMRs	T081	C1706748
27678317	1049	1056	Ecuador	T083	C0013593
27678317	1058	1066	Colombia	T083	C3245499
27678317	1068	1074	Mexico	T083	C0025885
27678317	1076	1080	Peru	T083	C0031238
27678317	1085	1091	Panama	T083	C0030266
27678317	1106	1113	females	T032	C0086287
27678317	1131	1136	males	T032	C0086582
27678317	1139	1151	Papillary TC	T191	C0238463
27678317	1174	1183	diagnosed	T033	C0011900
27678317	1184	1204	histological subtype	T201	C0449574
27678317	1225	1242	incidence pattern	T081	C1708485
27678317	1254	1256	TC	T191	C0007115
27678317	1261	1272	Argentinean	T098	C0238689
27678317	1274	1283	Brazilian	T033	C0238815
27678317	1285	1292	Chilean	T098	C0239045
27678317	1297	1308	Costa Rican	T098	C0239127
27678317	1309	1316	females	T032	C0086287
27678317	1317	1319	TC	T191	C0007115
27678317	1320	1329	incidence	T081	C1708485
27678317	1330	1339	increased	T081	C0205217
27678317	1353	1361	annually	T079	C0332181
27678317	1367	1379	papillary TC	T191	C0238463
27678317	1380	1389	increased	T081	C0205217
27678317	1403	1411	annually	T079	C0332181
27678317	1419	1428	mortality	T081	C0205848
27678317	1438	1444	stable	T080	C0205360
27678317	1471	1476	males	T032	C0086582
27678317	1478	1484	trends	T079	C0040833
27678317	1488	1490	TC	T191	C0007115
27678317	1496	1502	stable	T080	C0205360
27678317	1504	1506	TC	T191	C0007115
27678317	1507	1515	occurred	T052	C1709305
27678317	1521	1531	frequently	T079	C0332183
27678317	1535	1542	females	T032	C0086287
27678317	1551	1556	males	T032	C0086582
27678317	1562	1569	overall	T080	C1561607
27678317	1570	1574	high	T080	C0205250
27678317	1575	1584	incidence	T081	C1708485
27678317	1589	1592	low	T080	C0205251
27678317	1593	1602	mortality	T081	C0205848
27678317	1606	1608	TC	T191	C0007115
27678317	1609	1616	suggest	T078	C1705535
27678317	1635	1654	subclinical disease	T047	C0277544
27678317	1662	1670	improved	T080	C0332272
27678317	1671	1688	detection methods	T170	C0449335

27708808|t|Managing perturbations during handover meetings: a joint activity framework
27708808|a|To document the prevalence of perturbations of handover meetings and understand how nurses manage temporal, physical and social meeting boundaries in response to perturbations. Handovers are joint activities performed collaboratively by participating nurses. Perturbations of handover are frequent and may potentially threaten continuity of care. We observed and videotaped handovers during five successive days in four nursing care units in two Swiss hospitals in 2009. Videorecordings were transcribed. All perturbations during the handovers were noted. We performed content analysis of the sources of perturbations from the notes and interactional micro-analyses of handover interactions based on video and transcripts. Nurses are the most frequent sources of perturbations during handovers. Perturbations are collaboratively managed. A tacit division of labour is enacted via multimodal communication strategies, whereby perturbations are dealt with using both linguistic and bodily signals.
27708808	9	22	perturbations	T169	C0332453
27708808	30	47	handover meetings	T058	C3494292
27708808	92	102	prevalence	T081	C0033106
27708808	106	119	perturbations	T169	C0332453
27708808	123	140	handover meetings	T058	C3494292
27708808	160	166	nurses	T097	C0028661
27708808	167	173	manage	T058	C0184516
27708808	174	182	temporal	T079	C2362314
27708808	184	192	physical	T169	C0205485
27708808	197	203	social	T169	C0728831
27708808	204	211	meeting	T052	C0556656
27708808	238	251	perturbations	T169	C0332453
27708808	253	262	Handovers	T058	C3494292
27708808	267	283	joint activities	T052	C0441655
27708808	294	309	collaboratively	T054	C0282116
27708808	313	326	participating	T169	C0679823
27708808	327	333	nurses	T097	C0028661
27708808	335	348	Perturbations	T169	C0332453
27708808	352	360	handover	T058	C3494292
27708808	365	373	frequent	T079	C0332183
27708808	382	393	potentially	T080	C3245505
27708808	394	402	threaten	T033	C2826244
27708808	403	421	continuity of care	T058	C0009853
27708808	426	434	observed	T169	C1441672
27708808	439	449	videotaped	T073	C0042654
27708808	450	459	handovers	T058	C3494292
27708808	472	482	successive	T080	C1707491
27708808	483	487	days	T079	C0439228
27708808	496	514	nursing care units	T073,T093	C0019988
27708808	522	527	Swiss	T083	C0039021
27708808	528	537	hospitals	T073,T093	C0019994
27708808	547	562	Videorecordings	T073	C0042654
27708808	568	579	transcribed	T170	C3273171
27708808	585	598	perturbations	T169	C0332453
27708808	610	619	handovers	T058	C3494292
27708808	635	644	performed	T169	C0884358
27708808	645	661	content analysis	T062	C0681915
27708808	669	676	sources	T033	C0449416
27708808	680	693	perturbations	T169	C0332453
27708808	713	741	interactional micro-analyses	T062	C0936012
27708808	745	766	handover interactions	T169	C1704675
27708808	776	781	video	T073	C0042650
27708808	786	797	transcripts	T170	C1301746
27708808	799	805	Nurses	T097	C0028661
27708808	819	827	frequent	T079	C0332183
27708808	828	835	sources	T033	C0449416
27708808	839	852	perturbations	T169	C0332453
27708808	860	869	handovers	T058	C3494292
27708808	871	884	Perturbations	T169	C0332453
27708808	889	904	collaboratively	T054	C0282116
27708808	905	912	managed	T058	C0184516
27708808	922	940	division of labour	T078	C0870436
27708808	967	980	communication	T054	C0009452
27708808	981	991	strategies	T041	C0679199
27708808	1001	1014	perturbations	T169	C0332453
27708808	1041	1051	linguistic	T090	C0023741
27708808	1056	1070	bodily signals	T052	C3266814

28245982|t|Comparative analysis of microRNA and mRNA expression profiles in cells and exosomes under toluene exposure
28245982|a|Recent studies have illustrated the growing importance of exosomes (small extracellular vesicles) and their constituent microRNA s (miRNAs) in the fields of toxicology and pathology. The mechanism of toxicity of toluene, a highly-prevalent and volatile organic compound, is largely unknown. To examine the role of miRNAs in toluene-induced toxicity, we investigated miRNAs and toluene-induced gene expression in HL-60 human promyelocytic leukemia cells and exosomes using microarrays. A total of 54 miRNAs were differentially expressed in HL-60 cell lines exposed to toluene and exosomes from the cells. Four out of the 54 miRNAs (hsa-miR-1290, hsa-miR-718, hsa-miR-3663-3p, and hsa-miR-320c) were subsequently validated by qRT-PCR. Integrated analysis of miRNA and mRNA expression profiles identified 8 miRNA - mRNA correlations. By performing Comparative Toxicogenomics Database analysis, we found that the eight putative target genes of the differentially expressed miRNAs under toluene exposure (EXOSC6, RHOH, GFER, HERC2, GOLGA4, SLC7A11, GCLM, and BACH1) are related to diverse disease categories such as nervous system disease, cancer, cardiovascular disease, and respiratory tract disease. In conclusion, our data demonstrated that miRNA - mRNA networks provide a better understanding of toxicological mechanism caused by environmental pollutants in vitro using HL-60 cells and exosomes.
28245982	0	20	Comparative analysis	T062	C0683941
28245982	24	32	microRNA	T028	C2825314
28245982	37	41	mRNA	T114,T123	C0035696
28245982	42	61	expression profiles	T081	C1956267
28245982	65	70	cells	T025	C0007634
28245982	75	83	exosomes	T026	C2350332
28245982	90	97	toluene	T109	C0040383
28245982	98	106	exposure	T080	C0332157
28245982	107	121	Recent studies	T062	C2603343
28245982	165	173	exosomes	T026	C2350332
28245982	175	203	small extracellular vesicles	T026	C3894683
28245982	215	226	constituent	T167	C0729650
28245982	227	235	microRNA	T114,T123	C1101610
28245982	239	245	miRNAs	T114,T123	C1101610
28245982	254	274	fields of toxicology	T091	C0040541
28245982	279	288	pathology	T091	C0030664
28245982	294	303	mechanism	T169	C0441712
28245982	307	326	toxicity of toluene	T037	C1516457
28245982	330	346	highly-prevalent	T081	C1512456
28245982	351	359	volatile	T080	C1963547
28245982	360	376	organic compound	T109	C0029224
28245982	421	427	miRNAs	T114,T123	C1101610
28245982	431	455	toluene-induced toxicity	T037	C1516457
28245982	460	472	investigated	T169	C1292732
28245982	473	479	miRNAs	T028	C2825314
28245982	484	499	toluene-induced	T046	C0007994
28245982	500	515	gene expression	T045	C0017262
28245982	519	524	HL-60	T025	C1512310
28245982	525	559	human promyelocytic leukemia cells	T025	C0282549
28245982	564	572	exosomes	T026	C2350332
28245982	579	590	microarrays	T075	C3853655
28245982	606	612	miRNAs	T028	C2825314
28245982	618	642	differentially expressed	T045	C0017262
28245982	646	662	HL-60 cell lines	T025	C0282549
28245982	674	681	toluene	T109	C0040383
28245982	686	694	exosomes	T026	C2350332
28245982	704	709	cells	T025	C0007634
28245982	730	736	miRNAs	T028	C2825314
28245982	738	750	hsa-miR-1290	T028	C2681774
28245982	752	763	hsa-miR-718	T028	C2829676
28245982	765	780	hsa-miR-3663-3p	T028	C3147923
28245982	786	798	hsa-miR-320c	T028	C2681673
28245982	818	827	validated	T062	C1519941
28245982	831	838	qRT-PCR	T063	C1514628
28245982	840	859	Integrated analysis	T062	C0936012
28245982	863	868	miRNA	T114,T123	C1101610
28245982	873	877	mRNA	T114,T123	C0035696
28245982	878	897	expression profiles	T081	C1956267
28245982	898	908	identified	T080	C0205396
28245982	911	916	miRNA	T114,T123	C1101610
28245982	919	923	mRNA	T114,T123	C0035696
28245982	924	936	correlations	T080	C1707520
28245982	952	987	Comparative Toxicogenomics Database	T170	C0242356
28245982	988	996	analysis	T062	C0936012
28245982	1022	1043	putative target genes	T028	C0017337
28245982	1051	1075	differentially expressed	T045	C0017262
28245982	1076	1082	miRNAs	T028	C2825314
28245982	1089	1096	toluene	T109	C0040383
28245982	1097	1105	exposure	T080	C0332157
28245982	1107	1113	EXOSC6	T028	C1425980
28245982	1115	1119	RHOH	T028	C1332112
28245982	1121	1125	GFER	T028	C1415043
28245982	1127	1132	HERC2	T028	C1415512
28245982	1134	1140	GOLGA4	T028	C1415176
28245982	1142	1149	SLC7A11	T028	C1420222
28245982	1151	1155	GCLM	T028	C1415098
28245982	1161	1166	BACH1	T028	C1412729
28245982	1183	1190	diverse	T080	C1880371
28245982	1191	1209	disease categories	T201	C3699655
28245982	1218	1240	nervous system disease	T047	C0027765
28245982	1242	1248	cancer	T191	C0006826
28245982	1250	1272	cardiovascular disease	T047	C0007222
28245982	1278	1303	respiratory tract disease	T047	C0035242
28245982	1324	1328	data	T078	C1511726
28245982	1347	1352	miRNA	T114,T123	C1101610
28245982	1355	1359	mRNA	T114,T123	C0035696
28245982	1360	1368	networks	T169	C1882071
28245982	1403	1426	toxicological mechanism	T038	C4042799
28245982	1437	1461	environmental pollutants	T131	C0014417
28245982	1462	1470	in vitro	T080	C1533691
28245982	1477	1488	HL-60 cells	T025	C0282549
28245982	1493	1501	exosomes	T026	C2350332

28282592|t|Development of an automaton model of rotational activity driving atrial fibrillation
28282592|a|Atrial fibrillation (AF) is difficult to treat effectively, owing to uncertainty in where to best ablate to eliminate arrhythmogenic substrate. A model providing insight into the electrical activation events would be useful to guide catheter ablation strategy. Method A two-dimensional, 576×576 node automaton was developed to simulate atrial electrical activity. The substrate field was altered by the presence of differing refractory period at varying locations. Fibrosis was added in the form of short, randomly positioned lines of conduction block. Larger areas of block were used to simulate ablation lesions. Anisotropy was imposed in a 2:1 ratio. A premature electrical impulse from one of four grid corners was utilized to initiate activation. Rotational activity was uninducible when refractory patch dimensions were less than 20×20mm. For larger refractory regions, a single premature stimulus was capable of inducing an average of 1.19±1.10 rotors, which often formed near the patch edges. A maximum of 5 rotors formed when refractory patch dimensions approached the size of the entire left atrial virtual field. Rotors formed along a refractory patch edge, after wavefront arrival was delayed at turning points or due to the presence of a fiber cluster of sufficient size. However, rotational activity could also occur around a large fiber cluster without the need of spatially variable refractoriness. When obstacles to conduction were lacking in size, nascent rotors drifted and either extinguished, or stabilized upon anchoring at a sufficiently large fiber cluster elsewhere in the field. Transient rotors terminated when traversing a region with differing refractory periods, if no obstacle to conduction was present to sufficiently delay wavefront arrival beyond the longest refractory period. Other rotors were annihilated when a nearby rotor with faster spin rate gradually interrupted the activation pathway. Elimination of anchors by removal, or by simulated ablation over a sufficient region, prevented rotor onset at a particular location where it would otherwise form. The presence of obstacles to conduction and spatial differences in refractory period are important parameters for initiating and maintaining rotational activity in this simulation of an atrial substrate.
28282592	0	11	Development	T039	C0243107
28282592	18	33	automaton model	T075	C0026336
28282592	37	56	rotational activity	T052	C0441655
28282592	65	84	atrial fibrillation	T047	C0004238
28282592	85	104	Atrial fibrillation	T047	C0004238
28282592	106	108	AF	T047	C0004238
28282592	126	131	treat	T061	C0087111
28282592	132	143	effectively	T080	C1704419
28282592	154	165	uncertainty	T033	C0087130
28282592	183	189	ablate	T061	C0162563
28282592	193	202	eliminate	T052	C0441655
28282592	203	217	arrhythmogenic	T046	C0085611
28282592	218	227	substrate	T167	C3891814
28282592	231	236	model	T075	C0026336
28282592	264	274	electrical	T169	C0442828
28282592	275	285	activation	T052	C1879547
28282592	286	292	events	T051	C0441471
28282592	318	344	catheter ablation strategy	T061	C0162559
28282592	355	370	two-dimensional	T082	C1705052
28282592	372	394	576×576 node automaton	T073	C0336537
28282592	412	420	simulate	T052	C0441655
28282592	421	427	atrial	T023	C0018792
28282592	421	447	atrial electrical activity	T042	C0596673
28282592	453	462	substrate	T167	C3891814
28282592	500	509	differing	T080	C1705242
28282592	510	527	refractory period	T043	C0678839
28282592	539	548	locations	T082	C0450429
28282592	550	558	Fibrosis	T046	C0016059
28282592	620	630	conduction	T042	C0232217
28282592	631	636	block	T047	C0018794
28282592	638	644	Larger	T081	C0549177
28282592	645	650	areas	T082	C0205146
28282592	654	659	block	T046	C0028778
28282592	673	681	simulate	T052	C0441655
28282592	682	698	ablation lesions	T033	C0221198
28282592	700	710	Anisotropy	T070	C0085406
28282592	732	737	ratio	T081	C0456603
28282592	741	750	premature	T079	C1254367
28282592	751	769	electrical impulse	T043	C1720744
28282592	816	824	initiate	T078	C1548602
28282592	825	835	activation	T052	C1879547
28282592	837	856	Rotational activity	T052	C0441655
28282592	878	905	refractory patch dimensions	T081	C0439534
28282592	934	940	larger	T081	C0549177
28282592	941	959	refractory regions	T082	C1254362
28282592	970	979	premature	T079	C1254367
28282592	980	988	stimulus	T067	C0234402
28282592	1004	1012	inducing	T169	C0205263
28282592	1016	1023	average	T081	C1510992
28282592	1037	1043	rotors	T074	C0025080
28282592	1073	1084	patch edges	T082	C1254362
28282592	1088	1095	maximum	T081	C0806909
28282592	1101	1107	rotors	T074	C0025080
28282592	1120	1147	refractory patch dimensions	T081	C0439534
28282592	1163	1167	size	T082	C0456389
28282592	1182	1193	left atrial	T023	C0225860
28282592	1194	1207	virtual field	T082	C1254362
28282592	1209	1215	Rotors	T074	C0025080
28282592	1231	1252	refractory patch edge	T082	C1254362
28282592	1260	1289	wavefront arrival was delayed	T033	C0243095
28282592	1336	1341	fiber	T024	C1304649
28282592	1342	1349	cluster	T081	C1704332
28282592	1364	1368	size	T082	C0456389
28282592	1379	1398	rotational activity	T052	C0441655
28282592	1425	1430	large	T081	C0549177
28282592	1431	1436	fiber	T024	C1304649
28282592	1437	1444	cluster	T081	C1704332
28282592	1465	1498	spatially variable refractoriness	T080	C0205556
28282592	1505	1514	obstacles	T080	C4045969
28282592	1518	1528	conduction	T042	C0232217
28282592	1534	1541	lacking	T080	C0332268
28282592	1545	1549	size	T082	C0456389
28282592	1551	1565	nascent rotors	T074	C0025080
28282592	1602	1612	stabilized	T033	C0184512
28282592	1618	1627	anchoring	T044	C1624581
28282592	1646	1651	large	T081	C0549177
28282592	1652	1657	fiber	T024	C1304649
28282592	1658	1665	cluster	T081	C1704332
28282592	1690	1699	Transient	T079	C0205374
28282592	1700	1706	rotors	T074	C0025080
28282592	1723	1733	traversing	T052	C0441655
28282592	1736	1742	region	T082	C0205147
28282592	1758	1776	refractory periods	T043	C0678839
28282592	1784	1792	obstacle	T080	C4045969
28282592	1796	1806	conduction	T042	C0232217
28282592	1835	1858	delay wavefront arrival	T033	C0243095
28282592	1870	1877	longest	T080	C1522425
28282592	1878	1895	refractory period	T043	C0678839
28282592	1903	1909	rotors	T074	C0025080
28282592	1941	1946	rotor	T074	C0025080
28282592	1959	1968	spin rate	T081	C0392762
28282592	1995	2013	activation pathway	T044	C1148560
28282592	2015	2026	Elimination	T052	C0441655
28282592	2030	2037	anchors	T061	C1293132
28282592	2041	2048	removal	T061	C0015252
28282592	2066	2074	ablation	T061	C0162563
28282592	2093	2099	region	T082	C0205147
28282592	2111	2116	rotor	T074	C0025080
28282592	2117	2122	onset	T080	C0332162
28282592	2139	2147	location	T029	C1515974
28282592	2195	2204	obstacles	T080	C4045969
28282592	2208	2218	conduction	T042	C0232217
28282592	2223	2242	spatial differences	T033	C0243095
28282592	2246	2263	refractory period	T043	C0678839
28282592	2278	2288	parameters	T078	C0237767
28282592	2308	2319	maintaining	T169	C1314677
28282592	2320	2339	rotational activity	T052	C0441655
28282592	2348	2358	simulation	T062	C0679083
28282592	2365	2371	atrial	T023	C0018792
28282592	2372	2381	substrate	T167	C3891814

27958356|t|On-Chip Optical Nonreciprocity Using an Active Microcavity
27958356|a|Optically nonreciprocal devices provide critical functionalities such as light isolation and circulation in integrated photonic circuits for optical communications and information processing, but have been difficult to achieve. By exploring gain-saturation nonlinearity, we demonstrate on-chip optical nonreciprocity with excellent isolation performance within telecommunication wavelengths using only one toroid microcavity. Compatible with current complementary metal-oxide-semiconductor process, our compact and simple scheme works for a very wide range of input power levels from ~10 microwatts down to ~10 nanowatts, and exhibits remarkable properties of one-way light transport with sufficiently low insertion loss. These superior features make our device become a promising critical building block indispensable for future integrated nanophotonic networks.
27958356	0	30	On-Chip Optical Nonreciprocity	T067	C1254366
27958356	40	58	Active Microcavity	T073	C0699733
27958356	59	90	Optically nonreciprocal devices	T073	C0699733
27958356	132	137	light	T070	C0023693
27958356	138	147	isolation	T169	C0205409
27958356	152	163	circulation	T033	C0237318
27958356	167	195	integrated photonic circuits	T073	C1708525
27958356	200	222	optical communications	T170	C0597132
27958356	227	249	information processing	T066	C0021420
27958356	265	274	difficult	T080	C0332218
27958356	278	285	achieve	T033	C0243095
27958356	300	328	gain-saturation nonlinearity	T067	C1254366
27958356	345	375	on-chip optical nonreciprocity	T067	C1254366
27958356	391	400	isolation	T169	C0205409
27958356	401	412	performance	T052	C1882330
27958356	420	437	telecommunication	T066	C0039449
27958356	438	449	wavelengths	T081	C0449819
27958356	465	483	toroid microcavity	T073	C3273359
27958356	509	556	complementary metal-oxide-semiconductor process	T067	C1254366
27958356	562	569	compact	T033	C1333134
27958356	574	587	simple scheme	T170	C1519193
27958356	588	593	works	T057	C0043227
27958356	619	637	input power levels	T081	C3854080
27958356	694	715	remarkable properties	T080	C0205556
27958356	719	742	one-way light transport	T067	C1254366
27958356	765	779	insertion loss	T081	C0392762
27958356	814	820	device	T073	C0699733
27958356	840	863	critical building block	T077	C1254372
27958356	864	877	indispensable	T080	C0205224
27958356	889	921	integrated nanophotonic networks	T169	C1882071

27834836|t|Proteomic Analysis of Tung Tree (Vernicia fordii) Oilseeds during the Developmental Stages
27834836|a|The tung tree (Vernicia fordii), a non-model woody plant belonging to the Euphorbiaceae family, is a promising economic plant due to the high content of a novel high-value oil in its seeds. Many metabolic pathways are active during seed development. Oil (triacylglycerols (TAGs)) accumulates in oil bodies distributed in the endosperm cells of tung tree seeds. The relationship between oil bodies and oil content during tung tree seed development was analyzed using ultrastructural observations, which confirmed that oil accumulation was correlated with the volumes and numbers of oil bodies in the endosperm cells during three different developmental stages. For a deeper understanding of seed development, we carried out proteomic analyses. At least 144 proteins were differentially expressed during three different developmental stages. A total of 76 proteins were successfully identified using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry / mass spectrometry (MALDI-TOF/MS / MS). These proteins were grouped into 11 classes according to their functions. The major groups of differentially expressed proteins were associated with energy metabolism (25%), fatty acid metabolism (15.79%) and defense (14.47%). These results strongly suggested that a very high percentage of gene expression in seed development is dedicated to the synthesis and accumulation of TAGs.
27834836	0	18	Proteomic Analysis	T059	C1327760
27834836	22	31	Tung Tree	T002	C0330604
27834836	33	48	Vernicia fordii	T002	C0330604
27834836	50	58	Oilseeds	T002	C0036563
27834836	70	90	Developmental Stages	T079	C0870411
27834836	95	104	tung tree	T002	C0330604
27834836	106	121	Vernicia fordii	T002	C0330604
27834836	136	147	woody plant	T002	C2699642
27834836	165	185	Euphorbiaceae family	T002	C0446243
27834836	202	210	economic	T169	C0013557
27834836	211	216	plant	T002	C0032098
27834836	228	232	high	T080	C0205250
27834836	233	240	content	T077	C0456205
27834836	246	251	novel	T080	C0205314
27834836	252	262	high-value	T080	C0205250
27834836	263	266	oil	T109,T123	C0032085
27834836	274	279	seeds	T002	C0036563
27834836	286	304	metabolic pathways	T169	C1291081
27834836	309	315	active	T169	C0205177
27834836	323	339	seed development	T039	C1522860
27834836	341	344	Oil	T109,T123	C0032085
27834836	346	362	triacylglycerols	T109,T123	C0041004
27834836	364	368	TAGs	T109,T123	C0041004
27834836	371	382	accumulates	T033	C4055506
27834836	386	396	oil bodies	T026	C1166870
27834836	397	408	distributed	T169	C1704711
27834836	416	425	endosperm	T002	C2717855
27834836	426	431	cells	T025	C0007634
27834836	435	444	tung tree	T002	C0330604
27834836	445	450	seeds	T002	C0036563
27834836	456	468	relationship	T080	C0439849
27834836	477	487	oil bodies	T026	C1166870
27834836	492	495	oil	T109,T123	C0032085
27834836	496	503	content	T077	C0456205
27834836	511	520	tung tree	T002	C0330604
27834836	521	537	seed development	T039	C1522860
27834836	542	550	analyzed	T062	C0936012
27834836	557	572	ultrastructural	T078	C0041623
27834836	573	585	observations	T169	C1441672
27834836	593	602	confirmed	T080	C0521093
27834836	608	611	oil	T109,T123	C0032085
27834836	612	624	accumulation	T033	C4055506
27834836	629	639	correlated	T080	C1707520
27834836	649	656	volumes	T081	C0449468
27834836	661	668	numbers	T081	C0237753
27834836	672	682	oil bodies	T026	C1166870
27834836	690	699	endosperm	T002	C2717855
27834836	700	705	cells	T025	C0007634
27834836	719	728	different	T080	C1705242
27834836	729	749	developmental stages	T079	C0870411
27834836	781	797	seed development	T039	C1522860
27834836	814	832	proteomic analyses	T059	C1327760
27834836	847	855	proteins	T116,T123	C0033684
27834836	861	885	differentially expressed	T045	C1171362
27834836	899	908	different	T080	C1705242
27834836	909	929	developmental stages	T079	C0870411
27834836	945	953	proteins	T116,T123	C0033684
27834836	972	982	identified	T080	C0205396
27834836	989	1065	matrix-assisted laser desorption/ionization time-of-flight mass spectrometry	T062	C1518101
27834836	1068	1085	mass spectrometry	T059	C0037813
27834836	1087	1099	MALDI-TOF/MS	T062	C1518101
27834836	1102	1104	MS	T059	C0037813
27834836	1113	1121	proteins	T116,T123	C0033684
27834836	1127	1134	grouped	T078	C0441833
27834836	1143	1150	classes	T170	C0456387
27834836	1170	1179	functions	T169	C0542341
27834836	1191	1197	groups	T078	C0441833
27834836	1201	1225	differentially expressed	T045	C1171362
27834836	1226	1234	proteins	T116,T123	C0033684
27834836	1240	1255	associated with	T080	C0332281
27834836	1256	1273	energy metabolism	T039	C0014272
27834836	1281	1302	fatty acid metabolism	T044	C0596563
27834836	1316	1323	defense	T077	C1880266
27834836	1340	1347	results	T169	C1274040
27834836	1357	1366	suggested	T078	C1705535
27834836	1379	1383	high	T080	C0205250
27834836	1384	1394	percentage	T081	C0439165
27834836	1398	1413	gene expression	T045	C0017262
27834836	1417	1433	seed development	T039	C1522860
27834836	1454	1463	synthesis	T052	C1883254
27834836	1468	1480	accumulation	T033	C4055506
27834836	1484	1488	TAGs	T109,T123	C0041004

27660548|t|Thymectomy for Myasthenia Gravis: A 10- year Review of Cases at the Hospital Universiti Sains Malaysia
27660548|a|A thymectomy is considered effective for patients with myasthenia gravis (MG). Although a few studies have described the role of a thymectomy in the treatment of MG in Asians countries, there are no published data on the application of this surgical approach for MG in Malaysia. We aimed to describe the clinical outcomes of MG patients who underwent a thymectomy and the factors affecting these outcomes. This was a retrospective study involving 16 patients with MG who underwent a thymectomy at the Hospital Universiti Sains Malaysia (HUSM) from January 2002 until December 2012, with a follow-up period ranging from 3-120 months. The study consisted of 16 patients aged 22-78 years, 10 of whom were males. The overall remission / improvement rate was 87.5%, and the rate of clinical outcomes classified as unchanged / worsened was 12.5%. Thymomamatous or non-thymomamatous MG, histology features, Osserman stage and the duration of follow-up were not significant prognostic factors. Post-operative mortality was 6.2% (1 of 16 patients died of septic shock). A thymectomy seems to be an effective treatment for MG, with low surgical morbidity. Patients with a lower Osserman stage and those with/without thymomas had favourable outcomes.
27660548	0	10	Thymectomy	T061	C0040071
27660548	15	32	Myasthenia Gravis	T047	C0026896
27660548	40	44	year	T079	C0439234
27660548	45	51	Review	T170	C0282443
27660548	55	60	Cases	T169	C0868928
27660548	68	102	Hospital Universiti Sains Malaysia	T093	C1708333
27660548	105	115	thymectomy	T061	C0040071
27660548	130	139	effective	T080	C1704419
27660548	144	152	patients	T101	C0030705
27660548	158	175	myasthenia gravis	T047	C0026896
27660548	177	179	MG	T047	C0026896
27660548	197	204	studies	T062	C2603343
27660548	234	244	thymectomy	T061	C0040071
27660548	252	261	treatment	T169	C0039798
27660548	265	267	MG	T047	C0026896
27660548	271	287	Asians countries	T083	C0454705
27660548	302	316	published data	T078	C1511726
27660548	324	335	application	T058	C0185125
27660548	344	361	surgical approach	T169	C0449446
27660548	366	368	MG	T047	C0026896
27660548	372	380	Malaysia	T083	C0024552
27660548	407	424	clinical outcomes	T033	C0243095
27660548	428	430	MG	T047	C0026896
27660548	431	439	patients	T101	C0030705
27660548	456	466	thymectomy	T061	C0040071
27660548	475	482	factors	T169	C1521761
27660548	483	492	affecting	T169	C0392760
27660548	499	507	outcomes	T169	C1274040
27660548	520	539	retrospective study	T062	C0035363
27660548	553	561	patients	T101	C0030705
27660548	567	569	MG	T047	C0026896
27660548	586	596	thymectomy	T061	C0040071
27660548	604	638	Hospital Universiti Sains Malaysia	T093	C1708333
27660548	640	644	HUSM	T093	C1708333
27660548	651	658	January	T080	C3829466
27660548	670	678	December	T080	C3830550
27660548	692	701	follow-up	T058	C1522577
27660548	702	708	period	T079	C1948053
27660548	728	734	months	T079	C0439231
27660548	740	745	study	T062	C2603343
27660548	762	770	patients	T101	C0030705
27660548	771	775	aged	T032	C0001779
27660548	782	787	years	T079	C0439234
27660548	805	810	males	T032	C0086582
27660548	816	833	overall remission	T033	C0544452
27660548	836	847	improvement	T077	C2986411
27660548	848	852	rate	T081	C1521828
27660548	872	876	rate	T081	C1521828
27660548	880	897	clinical outcomes	T033	C1333602
27660548	912	921	unchanged	T033	C0442739
27660548	924	932	worsened	T033	C1457868
27660548	944	957	Thymomamatous	T191	C0040100
27660548	961	981	non-thymomamatous MG	T047	C0026896
27660548	983	992	histology	T169	C4048239
27660548	993	1001	features	T080	C2348519
27660548	1003	1017	Osserman stage	T047	C0012634
27660548	1026	1034	duration	T079	C0449238
27660548	1038	1047	follow-up	T058	C1522577
27660548	1069	1087	prognostic factors	T201	C1514474
27660548	1089	1103	Post-operative	T079	C0032790
27660548	1104	1113	mortality	T033	C1408811
27660548	1132	1140	patients	T101	C0030705
27660548	1141	1145	died	T040	C0011065
27660548	1149	1161	septic shock	T046	C0036983
27660548	1166	1176	thymectomy	T061	C0040071
27660548	1192	1211	effective treatment	T169	C0039798
27660548	1216	1218	MG	T047	C0026896
27660548	1229	1237	surgical	T061	C0543467
27660548	1238	1247	morbidity	T081	C0026538
27660548	1249	1257	Patients	T101	C0030705
27660548	1271	1285	Osserman stage	T047	C0012634
27660548	1309	1317	thymomas	T191	C0040100
27660548	1322	1341	favourable outcomes	T169	C1274040

28528624|t|Root Cause Analysis of Adverse Events in an Outpatient Anticoagulation Management Consortium
28528624|a|A number of factors can lead to adverse events (AEs) in patients taking warfarin. Performing a root cause analysis (RCA) of serious AEs is one systematic way of determining the causes of these events. Multidisciplinary teams were formed at Michigan Anticoagulation Quality Improvement Initiative (MAQI(2)) sites with organized anticoagulation management services (AMS). Medical records from patients who suffered serious AEs (major bleed, embolic stroke, venous thromboembolism) were reviewed, and AMS staff were interviewed to determine the root cause using the "5 Whys" technique. More than 600 patients had an AE and underwent screening by trained RNs. Of these, 79 required full review by a multidisciplinary panel. All potential contributing factors (comorbidities, concurrent medications, current protocols) were assessed to determine the main factor that caused the AE. Full RCA was completed in 79 cases. The main contributing factor was identified in 69/79 (87%) cases. Most identified AEs, 55/69 (80%), were due to patient - specific factors such as comorbidities. Patient -to- provider and provider -to- provider communication accounted for 16/69 (23%) of events and was the second most common cause. Other causes included protocol non-adherence and technology / equipment issues. After each detailed review, the multidisciplinary panel recommended system changes that addressed the primary cause. The majority of severe AEs for patients taking warfarin were related to nonmodifiable patient -related issues. The remaining AEs were primarily due to patient -to- provider and provider -to- provider communication issues. Methods for improving communication need to be addressed, and methods for more effective patient education should be investigated.
28528624	0	19	Root Cause Analysis	T080	C3179036
28528624	23	37	Adverse Events	T046	C0877248
28528624	44	54	Outpatient	T101	C0029921
28528624	55	70	Anticoagulation	T033	C2919015
28528624	71	81	Management	T058	C0376636
28528624	82	92	Consortium	T097	C1513822
28528624	105	112	factors	T169	C1521761
28528624	125	139	adverse events	T046	C0877248
28528624	141	144	AEs	T046	C0877248
28528624	149	157	patients	T101	C0030705
28528624	165	173	warfarin	T109,T121,T131	C0043031
28528624	188	207	root cause analysis	T080	C3179036
28528624	209	212	RCA	T080	C3179036
28528624	225	228	AEs	T046	C0877248
28528624	236	250	systematic way	T169	C0220922
28528624	270	276	causes	T169	C0015127
28528624	286	292	events	T046	C0877248
28528624	294	317	Multidisciplinary teams	T096	C0871489
28528624	333	341	Michigan	T083	C0025939
28528624	420	455	anticoagulation management services	T092	C0282196
28528624	457	460	AMS	T092	C0282196
28528624	463	478	Medical records	T170	C0025102
28528624	484	492	patients	T101	C0030705
28528624	514	517	AEs	T046	C0877248
28528624	519	530	major bleed	T046	C3160769
28528624	532	546	embolic stroke	T047	C0262469
28528624	548	570	venous thromboembolism	T047	C1861172
28528624	577	585	reviewed	T080	C1709940
28528624	591	594	AMS	T092	C0282196
28528624	595	600	staff	T097	C0851286
28528624	606	617	interviewed	T052	C0021822
28528624	635	645	root cause	T169	C0015127
28528624	656	674	"5 Whys" technique	T170	C0282574
28528624	690	698	patients	T101	C0030705
28528624	706	708	AE	T046	C0877248
28528624	723	732	screening	T058	C0220908
28528624	744	747	RNs	T097	C1522486
28528624	776	782	review	T078	C1552617
28528624	788	811	multidisciplinary panel	T078	C0441833
28528624	840	847	factors	T169	C1521761
28528624	849	862	comorbidities	T078	C0009488
28528624	864	874	concurrent	T079	C0205420
28528624	875	886	medications	T058	C2081612
28528624	896	905	protocols	T170	C0442711
28528624	912	920	assessed	T052	C1516048
28528624	943	949	factor	T169	C1521761
28528624	966	968	AE	T046	C0877248
28528624	975	978	RCA	T080	C3179036
28528624	999	1004	cases	T077	C1706256
28528624	1028	1034	factor	T169	C1521761
28528624	1039	1049	identified	T080	C0205396
28528624	1065	1070	cases	T077	C1706256
28528624	1077	1087	identified	T080	C0205396
28528624	1088	1091	AEs	T046	C0877248
28528624	1118	1125	patient	T101	C0030705
28528624	1128	1136	specific	T080	C0205369
28528624	1137	1144	factors	T169	C1521761
28528624	1153	1166	comorbidities	T078	C0009488
28528624	1168	1175	Patient	T101	C0030705
28528624	1181	1189	provider	T097	C0018724
28528624	1194	1202	provider	T097	C0018724
28528624	1208	1216	provider	T097	C0018724
28528624	1217	1230	communication	T054	C0009452
28528624	1260	1266	events	T046	C0877248
28528624	1298	1303	cause	T169	C0015127
28528624	1311	1317	causes	T169	C0015127
28528624	1327	1335	protocol	T170	C0442711
28528624	1336	1349	non-adherence	T080	C0205556
28528624	1354	1364	technology	T058	C0752189
28528624	1367	1376	equipment	T073	C0014672
28528624	1377	1383	issues	T033	C0033213
28528624	1405	1411	review	T078	C1552617
28528624	1417	1440	multidisciplinary panel	T078	C0441833
28528624	1453	1459	system	T093	C0018696
28528624	1460	1467	changes	T169	C0392747
28528624	1487	1494	primary	T080	C0205225
28528624	1495	1500	cause	T169	C0015127
28528624	1518	1524	severe	T080	C0205082
28528624	1525	1528	AEs	T046	C0877248
28528624	1533	1541	patients	T101	C0030705
28528624	1549	1557	warfarin	T109,T121,T131	C0043031
28528624	1574	1587	nonmodifiable	T080	C0205556
28528624	1588	1595	patient	T101	C0030705
28528624	1605	1611	issues	T033	C0033213
28528624	1627	1630	AEs	T046	C0877248
28528624	1653	1660	patient	T101	C0030705
28528624	1666	1674	provider	T097	C0018724
28528624	1679	1687	provider	T097	C0018724
28528624	1693	1701	provider	T097	C0018724
28528624	1702	1715	communication	T054	C0009452
28528624	1716	1722	issues	T033	C0033213
28528624	1724	1731	Methods	T169	C0025664
28528624	1746	1759	communication	T054	C0009452
28528624	1786	1793	methods	T169	C0025664
28528624	1813	1830	patient education	T065	C0030688
28528624	1841	1853	investigated	T169	C1292732

27255214|t|Hierarchical Targeting Strategy for Enhanced Tumor Tissue Accumulation / Retention and Cellular Internalization
27255214|a|Targeted delivery of therapeutic agents is an important way to improve the therapeutic index and reduce side effects. To design nanoparticles for targeted delivery, both enhanced tumor tissue accumulation / retention and enhanced cellular internalization should be considered simultaneously. So far, there have been very few nanoparticles with immutable structures that can achieve this goal efficiently. Hierarchical targeting, a novel targeting strategy based on stimuli responsiveness, shows good potential to enhance both tumor tissue accumulation / retention and cellular internalization. Here, the recent design and development of hierarchical targeting nanoplatforms, based on changeable particle sizes, switchable surface charges and activatable surface ligands, will be introduced. In general, the targeting moieties in these nanoplatforms are not activated during blood circulation for efficient tumor tissue accumulation, but re-activated by certain internal or external stimuli in the tumor microenvironment for enhanced cellular internalization.
27255214	0	22	Hierarchical Targeting	T169	C1521840
27255214	23	31	Strategy	T062	C0035171
27255214	36	44	Enhanced	T169	C0442805
27255214	45	57	Tumor Tissue	T024	C0475358
27255214	58	70	Accumulation	UnknownType	C0678759
27255214	73	82	Retention	T039	C0814008
27255214	87	111	Cellular Internalization	T043	C0014139
27255214	112	120	Targeted	T169	C1521840
27255214	121	129	delivery	T067	C1254366
27255214	133	151	therapeutic agents	T121	C1611640
27255214	158	167	important	T080	C3898777
27255214	168	171	way	T067	C1522240
27255214	175	182	improve	T080	C1272747
27255214	187	204	therapeutic index	T081	C0678793
27255214	209	215	reduce	T080	C0392756
27255214	216	228	side effects	T046	C0041755
27255214	233	239	design	T052	C1707689
27255214	240	253	nanoparticles	T073	C1450054
27255214	258	266	targeted	T169	C1521840
27255214	267	275	delivery	T067	C1254366
27255214	282	290	enhanced	T169	C0442805
27255214	291	303	tumor tissue	T024	C0475358
27255214	304	316	accumulation	UnknownType	C0678759
27255214	319	328	retention	T039	C0814008
27255214	333	341	enhanced	T169	C0442805
27255214	342	366	cellular internalization	T043	C0014139
27255214	377	387	considered	T078	C0750591
27255214	388	402	simultaneously	T079	C0521115
27255214	437	450	nanoparticles	T073	C1450054
27255214	466	476	structures	T082	C0678594
27255214	499	503	goal	T078	C1947946
27255214	504	515	efficiently	T080	C0442799
27255214	517	539	Hierarchical targeting	T169	C1521840
27255214	543	548	novel	T080	C0205314
27255214	549	558	targeting	T169	C1521840
27255214	559	567	strategy	T062	C0035171
27255214	577	584	stimuli	T067	C0234402
27255214	585	599	responsiveness	T032	C0871261
27255214	612	621	potential	T080	C3245505
27255214	625	632	enhance	T169	C0442805
27255214	638	650	tumor tissue	T024	C0475358
27255214	651	663	accumulation	UnknownType	C0678759
27255214	666	675	retention	T039	C0814008
27255214	680	704	cellular internalization	T043	C0014139
27255214	723	729	design	T052	C1707689
27255214	734	745	development	T169	C1527148
27255214	749	771	hierarchical targeting	T169	C1521840
27255214	796	806	changeable	T169	C0392747
27255214	807	821	particle sizes	T081	C0030608
27255214	823	833	switchable	T169	C0205245
27255214	834	849	surface charges	T080	C0205556
27255214	854	865	activatable	T169	C0205245
27255214	866	873	surface	T082	C0205148
27255214	874	881	ligands	T103	C0023688
27255214	891	901	introduced	T169	C1292748
27255214	919	928	targeting	T169	C1521840
27255214	929	937	moieties	T077	C3641152
27255214	979	985	during	T079	C0347984
27255214	986	1003	blood circulation	T039	C0005775
27255214	1008	1017	efficient	T080	C0442799
27255214	1018	1030	tumor tissue	T024	C0475358
27255214	1031	1043	accumulation	UnknownType	C0678759
27255214	1049	1061	re-activated	T169	C0205245
27255214	1073	1081	internal	T082	C0205102
27255214	1085	1093	external	T082	C0205101
27255214	1094	1101	stimuli	T067	C0234402
27255214	1109	1131	tumor microenvironment	T070	C2936626
27255214	1136	1144	enhanced	T169	C0442805
27255214	1145	1169	cellular internalization	T043	C0014139

28276986|t|Platelet rich plasma versus steroid on lateral epicondylitis: meta-analysis of randomized clinical trials
28276986|a|Lateral epicondylitis (LE) is a common tendinopathy for which an effective treatment is still unknown. The purpose of this meta-analysis was to compare the effectiveness of platelet rich plasma (PRP) vs steroid in reducing pain and improving function of the elbow in the treatment of LE. A systematic search of the literature was conducted to identify related articles published from January 1980 to September 2016 in Pubmed, Embase, the Cochrane Library and SpringerLink. All studies that compared PRP with steroid administration on LE were included. Main outcomes were collected and analyzed by the Review Manager 5.1. Eight randomized controlled trials (RCTs) that involved 511 patients met the criteria. This meta-analysis showed that there was no significant difference in pain relief in the short-term (2 to 4 weeks: SMD = 1.02, P = .03; 6 to 8 weeks: SMD = .73, P = .24) and the intermediate-term (12 weeks: SMD = -0.28, P = .35). Steroid exhibited a better efficacy of function in the short-term (2 to 4 weeks: SMD = .61, P < .001; 6 to 8 weeks: SMD = .53, P < .001). However, PRP was superior to steroid for pain relief in the long-term (half year: SMD = -1.6, P < .001; one year: SMD = -1.45, P < .001), and also for function improving in the intermediate-term (12 weeks: SMD = -0.53, P < .001) and the long-term (half year: SMD = -0.56, P < .001; one year: SMD = -0.7, P < .001). No serious adverse effects of treatment were observed in the two groups. Treatment of patients with LE by steroid could slightly relieve pain and significantly improve function of elbow in the short-term (2 to 4 weeks, 6 to 8 weeks). PRP appears to be more effective in relieving pain and improving function in the intermediate-term (12 weeks) and long-term (half year and one year). Considering the long-term effectiveness of PRP, we recommend PRP as the preferred option for LE.
28276986	0	20	Platelet rich plasma	T031	C0370220
28276986	28	35	steroid	T109	C0038317
28276986	39	60	lateral epicondylitis	T047	C0039516
28276986	62	75	meta-analysis	T062	C0920317
28276986	79	105	randomized clinical trials	T062,T170	C0206034
28276986	106	127	Lateral epicondylitis	T047	C0039516
28276986	129	131	LE	T047	C0039516
28276986	145	157	tendinopathy	T047	C1568272
28276986	171	180	effective	T080	C1704419
28276986	181	190	treatment	T061	C0087111
28276986	200	207	unknown	T080	C0439673
28276986	229	242	meta-analysis	T062	C0920317
28276986	250	257	compare	T052	C1707455
28276986	262	275	effectiveness	T080	C1280519
28276986	279	299	platelet rich plasma	T031	C0370220
28276986	301	304	PRP	T031	C0370220
28276986	309	316	steroid	T109	C0038317
28276986	320	328	reducing	T080	C0392756
28276986	329	333	pain	T184	C0030193
28276986	338	347	improving	T080	C1272745
28276986	348	356	function	T169	C0542341
28276986	364	369	elbow	T029	C0013769
28276986	377	386	treatment	T061	C0087111
28276986	390	392	LE	T047	C0039516
28276986	396	406	systematic	T169	C0220922
28276986	407	413	search	T052	C1706202
28276986	421	431	literature	T170	C0023866
28276986	449	457	identify	T080	C0205396
28276986	466	474	articles	T170	C1706852
28276986	490	497	January	T080	C3829466
28276986	506	515	September	T079	C3828193
28276986	524	530	Pubmed	T170	C1138432
28276986	532	538	Embase	T170	C0282574
28276986	544	560	Cochrane Library	T170	C0282574
28276986	565	577	SpringerLink	T170	C0282574
28276986	583	590	studies	T062	C2603343
28276986	596	604	compared	T052	C1707455
28276986	605	608	PRP	T031	C0370220
28276986	614	621	steroid	T109	C0038317
28276986	622	636	administration	T081	C0001555
28276986	640	642	LE	T047	C0039516
28276986	648	656	included	T169	C0332257
28276986	663	671	outcomes	T169	C1274040
28276986	677	686	collected	T169	C1516698
28276986	691	699	analyzed	T062	C0936012
28276986	707	725	Review Manager 5.1	T073,T170	C0037585
28276986	733	761	randomized controlled trials	T062	C0206035
28276986	763	767	RCTs	T062	C0206035
28276986	774	782	involved	T169	C1314939
28276986	787	795	patients	T101	C0030705
28276986	796	799	met	T067	C1550543
28276986	804	812	criteria	T078	C0243161
28276986	819	832	meta-analysis	T062	C0920317
28276986	855	880	no significant difference	T033	C3842396
28276986	884	895	pain relief	T061	C0451615
28276986	903	913	short-term	T079	C0443303
28276986	922	927	weeks	T079	C0439230
28276986	929	932	SMD	T081	C0392762
28276986	957	962	weeks	T079	C0439230
28276986	964	967	SMD	T081	C0392762
28276986	992	1009	intermediate-term	T079	C1515273
28276986	1014	1019	weeks	T079	C0439230
28276986	1021	1024	SMD	T081	C0392762
28276986	1044	1051	Steroid	T109	C0038317
28276986	1071	1079	efficacy	T080	C1280519
28276986	1083	1091	function	T169	C0542341
28276986	1099	1109	short-term	T079	C0443303
28276986	1118	1123	weeks	T079	C0439230
28276986	1125	1128	SMD	T081	C0392762
28276986	1153	1158	weeks	T079	C0439230
28276986	1160	1163	SMD	T081	C0392762
28276986	1191	1194	PRP	T031	C0370220
28276986	1211	1218	steroid	T109	C0038317
28276986	1223	1234	pain relief	T061	C0451615
28276986	1242	1251	long-term	T079	C0443252
28276986	1258	1262	year	T079	C0439234
28276986	1264	1267	SMD	T081	C0392762
28276986	1286	1294	one year	T079	C4082117
28276986	1296	1299	SMD	T081	C0392762
28276986	1333	1341	function	T169	C0542341
28276986	1342	1351	improving	T080	C1272745
28276986	1359	1376	intermediate-term	T079	C1515273
28276986	1381	1386	weeks	T079	C0439230
28276986	1388	1391	SMD	T081	C0392762
28276986	1419	1428	long-term	T079	C0443252
28276986	1435	1439	year	T079	C0439234
28276986	1441	1444	SMD	T081	C0392762
28276986	1464	1472	one year	T079	C4082117
28276986	1474	1477	SMD	T081	C0392762
28276986	1500	1507	serious	T080	C0205404
28276986	1508	1523	adverse effects	T046	C0879626
28276986	1527	1536	treatment	T061	C0087111
28276986	1542	1550	observed	T169	C1441672
28276986	1562	1568	groups	T078	C0441833
28276986	1570	1579	Treatment	T061	C0087111
28276986	1583	1591	patients	T101	C0030705
28276986	1597	1599	LE	T047	C0039516
28276986	1603	1610	steroid	T109	C0038317
28276986	1626	1638	relieve pain	T061	C0451615
28276986	1657	1664	improve	T080	C1272745
28276986	1665	1673	function	T169	C0542341
28276986	1677	1682	elbow	T029	C0013769
28276986	1690	1700	short-term	T079	C0443303
28276986	1709	1714	weeks	T079	C0439230
28276986	1723	1728	weeks	T079	C0439230
28276986	1731	1734	PRP	T031	C0370220
28276986	1754	1763	effective	T080	C1704419
28276986	1767	1781	relieving pain	T061	C0451615
28276986	1786	1795	improving	T080	C1272745
28276986	1796	1804	function	T169	C0542341
28276986	1812	1829	intermediate-term	T079	C1515273
28276986	1834	1839	weeks	T079	C0439230
28276986	1845	1854	long-term	T079	C0443252
28276986	1861	1865	year	T079	C0439234
28276986	1870	1878	one year	T079	C4082117
28276986	1897	1906	long-term	T079	C0443252
28276986	1907	1920	effectiveness	T080	C1280519
28276986	1924	1927	PRP	T031	C0370220
28276986	1932	1941	recommend	T078	C0034866
28276986	1942	1945	PRP	T031	C0370220
28276986	1953	1962	preferred	T078	C0558295
28276986	1963	1969	option	T169	C1518601
28276986	1974	1976	LE	T047	C0039516

27270311|t|Direct contact with perivascular tumor cells enhances integrin αvβ3 signaling and migration of endothelial cells
27270311|a|The secretion of soluble pro-angiogenic factors by tumor cells and stromal cells in the perivascular niche promotes the aggressive angiogenesis that is typical of glioblastoma (GBM). Here, we show that angiogenesis also can be promoted by a direct interaction between brain tumor cells, including tumor cells with cancer stem -like properties (CSCs), and endothelial cells (ECs). As shown in vitro, this direct interaction is mediated by binding of integrin αvβ3 expressed on ECs to the RGD-peptide in L1CAM expressed on CSCs. It promotes both EC network formation and enhances directed migration toward basic fibroblast growth factor. Activation of αvβ3 and bone marrow tyrosine kinase on chromosome X (BMX) is required for migration stimulated by direct binding but not for migration stimulated by soluble factors. RGD-peptide treatment of mice with established intracerebral GBM xenografts significantly reduced the percentage of Sox2 -positive tumor cells and CSCs in close proximity to ECs, decreased integrin αvβ3 and BMX activation and p130CAS phosphorylation in the ECs, and reduced the vessel surface area. These results reveal a previously unrecognized aspect of the regulation of angiogenesis in GBM that can impact therapeutic anti-angiogenic targeting.
27270311	20	32	perivascular	T023	C0005847
27270311	33	44	tumor cells	T025	C0597032
27270311	54	67	integrin αvβ3	T116,T192	C1138427
27270311	68	77	signaling	T044	C1514762
27270311	82	91	migration	T043	C1622501
27270311	95	112	endothelial cells	T025	C0225336
27270311	117	126	secretion	T043	C1327616
27270311	138	160	pro-angiogenic factors	T123	C0002976
27270311	164	175	tumor cells	T025	C0597032
27270311	180	193	stromal cells	T025	C0162597
27270311	201	213	perivascular	T023	C0005847
27270311	233	256	aggressive angiogenesis	T191	C1519670
27270311	276	288	glioblastoma	T191	C0017636
27270311	290	293	GBM	T191	C0017636
27270311	315	327	angiogenesis	T191	C1519670
27270311	381	386	brain	T023	C0006104
27270311	387	398	tumor cells	T025	C0597032
27270311	410	421	tumor cells	T025	C0597032
27270311	427	438	cancer stem	T025	C1956422
27270311	457	461	CSCs	T025	C1956422
27270311	468	485	endothelial cells	T025	C0225336
27270311	487	490	ECs	T025	C0225336
27270311	502	510	in vitro	T080	C1533691
27270311	551	558	binding	T044	C0597358
27270311	562	575	integrin αvβ3	T116,T192	C1138427
27270311	576	585	expressed	T045	C0597360
27270311	589	592	ECs	T025	C0225336
27270311	600	611	RGD-peptide	T116,T123	C0052350
27270311	615	620	L1CAM	T116,T123	C0950625
27270311	621	630	expressed	T045	C1171362
27270311	634	638	CSCs	T025	C1956422
27270311	657	659	EC	T025	C0225336
27270311	660	677	network formation	T043	C0007613
27270311	700	709	migration	T043	C1622501
27270311	723	747	fibroblast growth factor	T116,T123	C0016026
27270311	749	759	Activation	T052	C1879547
27270311	763	767	αvβ3	T116,T192	C1138427
27270311	772	815	bone marrow tyrosine kinase on chromosome X	T116,T126	C1384557
27270311	817	820	BMX	T116,T126	C1453891
27270311	838	847	migration	T043	C1622501
27270311	869	876	binding	T044	C0597358
27270311	889	898	migration	T043	C1622501
27270311	930	941	RGD-peptide	T116,T123	C0052350
27270311	942	951	treatment	T169	C1522326
27270311	955	959	mice	T015	C0025929
27270311	977	990	intracerebral	T082	C0442111
27270311	991	994	GBM	T191	C0017636
27270311	995	1005	xenografts	T122	C0522537
27270311	1046	1050	Sox2	T116,T123	C0300483
27270311	1061	1072	tumor cells	T025	C0597032
27270311	1077	1081	CSCs	T025	C1956422
27270311	1104	1107	ECs	T025	C0225336
27270311	1119	1132	integrin αvβ3	T116,T192	C1138427
27270311	1137	1140	BMX	T116,T126	C1453891
27270311	1156	1163	p130CAS	T116,T123	C1451358
27270311	1164	1179	phosphorylation	T044	C1158886
27270311	1187	1190	ECs	T025	C0225336
27270311	1208	1214	vessel	T023	C0005847
27270311	1215	1227	surface area	T082	C0205146
27270311	1290	1300	regulation	T038	C1327622
27270311	1304	1316	angiogenesis	T191	C1519670
27270311	1320	1323	GBM	T191	C0017636
27270311	1340	1351	therapeutic	T169	C0302350
27270311	1352	1367	anti-angiogenic	T121,T123	C0596087

28515354|t|Clinical application and outcomes of sentinel node navigation surgery in patients with early gastric cancer
28515354|a|Sentinel node navigation surgery (SNNS) has been recognized as a minimally invasive tool for individualized lymphadenectomy in patients with early gastric cancer (EGC). The aim of this study was to compare clinicopathological factors, adverse events, and clinical outcomes between sentinel node mapping (SNM) and SN dissection (SND) groups and assess the clinical utility of SNNS in patients with EGC. The clinical data of 157 patients with EGC, diagnosed as clinical T1N0M0 with tumors ≤ 40 mm, undergoing SNNS between March 2004 and April 2016 were retrospectively reviewed. Twenty-seven patients were excluded from the analysis. In the remaining 130 patients, 59 and 71 patients underwent standard lymphadenectomy for SNM and SND, respectively. The sentinel node detection rate in the SNM and SND groups was 98.3% (58/59) and 100% (71/71), respectively. Two (3.5%), 15 (25.9%), and 41 (70.7%) patients having sentinel nodes underwent total gastrectomy, proximal gastrectomy (PG), and distal gastrectomy (DG), respectively, in the SNM group. One (1.4%), 5 (7.0%), 10 (14.1%), 39 (54.9%), and 16 (22.5%) patients underwent PG, DG, segmental gastrectomy, local resection, and endoscopic submucosal dissection, respectively, in the SND group. There was no significant difference in postoperative complications between the SNM and SND groups (P = 0.781). Survival did not differ between the both groups (P = 0.856). The present results suggest that personalized surgery with SND provides technical safety and curability related with a favorable survival outcome in patients with EGC.
28515354	0	8	Clinical	T080	C0205210
28515354	9	20	application	T169	C4048755
28515354	25	33	outcomes	T169	C1274040
28515354	37	69	sentinel node navigation surgery	T061	C0543467
28515354	73	81	patients	T101	C0030705
28515354	87	107	early gastric cancer	T191	C0349530
28515354	108	140	Sentinel node navigation surgery	T061	C0543467
28515354	142	146	SNNS	T061	C0543467
28515354	201	215	individualized	T080	C1709510
28515354	216	231	lymphadenectomy	T061	C0024203
28515354	235	243	patients	T101	C0030705
28515354	249	269	early gastric cancer	T191	C0349530
28515354	271	274	EGC	T191	C0349530
28515354	293	298	study	T062	C2603343
28515354	306	313	compare	T052	C1707455
28515354	314	333	clinicopathological	T169	C1521733
28515354	334	341	factors	T169	C1521761
28515354	343	357	adverse events	T046	C0877248
28515354	363	371	clinical	T080	C0205210
28515354	372	380	outcomes	T169	C1274040
28515354	389	410	sentinel node mapping	T060	C1519247
28515354	412	415	SNM	T060	C1519247
28515354	421	434	SN dissection	T061	C0242382
28515354	436	439	SND	T061	C0242382
28515354	441	447	groups	T078	C0441833
28515354	463	471	clinical	T080	C0205210
28515354	472	479	utility	T169	C0457083
28515354	483	487	SNNS	T061	C0543467
28515354	491	499	patients	T101	C0030705
28515354	505	508	EGC	T191	C0349530
28515354	514	527	clinical data	T170	C1516606
28515354	535	543	patients	T101	C0030705
28515354	549	552	EGC	T191	C0349530
28515354	554	563	diagnosed	T033	C0011900
28515354	567	575	clinical	T080	C0205210
28515354	576	594	T1N0M0 with tumors	T191	C0027651
28515354	615	619	SNNS	T061	C0543467
28515354	659	674	retrospectively	T080	C1514923
28515354	675	683	reviewed	T080	C1709940
28515354	698	706	patients	T101	C0030705
28515354	712	720	excluded	T052	C2828389
28515354	730	738	analysis	T062	C0936012
28515354	761	769	patients	T101	C0030705
28515354	781	789	patients	T101	C0030705
28515354	809	824	lymphadenectomy	T061	C0024203
28515354	829	832	SNM	T060	C1519247
28515354	837	840	SND	T061	C0242382
28515354	860	873	sentinel node	T023	C1522495
28515354	874	883	detection	T061	C1511790
28515354	884	888	rate	T081	C1521828
28515354	896	899	SNM	T060	C1519247
28515354	904	907	SND	T061	C0242382
28515354	908	914	groups	T078	C0441833
28515354	1004	1012	patients	T101	C0030705
28515354	1020	1034	sentinel nodes	T023	C1522495
28515354	1051	1062	gastrectomy	T061	C0017118
28515354	1064	1084	proximal gastrectomy	T061	C0399713
28515354	1086	1088	PG	T061	C0399713
28515354	1095	1113	distal gastrectomy	T061	C0192440
28515354	1115	1117	DG	T061	C0192440
28515354	1141	1144	SNM	T060	C1519247
28515354	1145	1150	group	T078	C0441833
28515354	1213	1221	patients	T101	C0030705
28515354	1232	1234	PG	T061	C0399713
28515354	1236	1238	DG	T061	C0192440
28515354	1240	1249	segmental	T082	C0205122
28515354	1250	1261	gastrectomy	T061	C0017118
28515354	1263	1278	local resection	T061	C0278259
28515354	1284	1316	endoscopic submucosal dissection	T061	C1700929
28515354	1339	1342	SND	T061	C0242382
28515354	1343	1348	group	T078	C0441833
28515354	1389	1416	postoperative complications	T046	C0032787
28515354	1429	1432	SNM	T060	C1519247
28515354	1437	1440	SND	T061	C0242382
28515354	1441	1447	groups	T078	C0441833
28515354	1461	1469	Survival	T081	C0038954
28515354	1502	1508	groups	T078	C0441833
28515354	1534	1541	results	T169	C1274040
28515354	1555	1567	personalized	T080	C1709510
28515354	1568	1575	surgery	T061	C0543467
28515354	1581	1584	SND	T061	C0242382
28515354	1594	1610	technical safety	T068	C0036043
28515354	1651	1659	survival	T052	C0038952
28515354	1660	1667	outcome	T169	C1274040
28515354	1671	1679	patients	T101	C0030705
28515354	1685	1688	EGC	T191	C0349530

27532819|t|Self-Cloning CRISPR CRISPR/Cas9 - gene editing has emerged as a revolutionary technology to easily modify specific genomic loci by designing complementary sgRNA sequences and introducing these into cells along with Cas9. Self-cloning CRISPR/Cas9 (scCRISPR) uses a self-cleaving palindromic sgRNA plasmid (sgPal) that recombines with short PCR - amplified site-specific sgRNA sequences within the target cell by homologous recombination to circumvent the process of sgRNA plasmid construction. Through this mechanism, scCRISPR enables gene editing within 2 hr once sgRNA oligos are available, with high efficiency equivalent to conventional sgRNA targeting: >90% gene knockout in both mouse and human embryonic stem cells and cancer cell lines. Furthermore, using PCR-based addition of short homology arms, we achieve efficient site-specific knock-in of transgenes such as GFP without traditional plasmid cloning or genome-integrated selection cassette (2% to 4% knock-in rate). The methods in this paper describe the most rapid and efficient means of CRISPR gene editing. © 2016 by John Wiley & Sons, Inc.
27532819|a|Journal Article 2016-08-18 00:00:00
27532819	20	31	CRISPR/Cas9	T044	C3658355
27532819	34	46	gene editing	T063	C4277689
27532819	64	88	revolutionary technology	T090	C0039421
27532819	99	105	modify	T169	C0392747
27532819	106	114	specific	T080	C0205369
27532819	115	127	genomic loci	T028	C0678933
27532819	131	140	designing	T052	C1707689
27532819	141	154	complementary	T114	C0056208
27532819	155	170	sgRNA sequences	T114,T123	C0082774
27532819	198	203	cells	T025	C0007634
27532819	215	219	Cas9	T028	C0017337
27532819	221	245	Self-cloning CRISPR/Cas9	T028	C3661477
27532819	247	255	scCRISPR	T028	C3661477
27532819	264	289	self-cleaving palindromic	T114,T123	C2350254
27532819	290	303	sgRNA plasmid	T114,T123	C0082774
27532819	305	310	sgPal	T114,T123	C0082774
27532819	317	327	recombines	T052	C0441655
27532819	339	342	PCR	T063	C0032520
27532819	345	354	amplified	T045	C0017256
27532819	355	384	site-specific sgRNA sequences	T086	C0314659
27532819	396	402	target	T169	C1521840
27532819	403	407	cell	T025	C0007634
27532819	411	435	homologous recombination	T045	C0599773
27532819	454	461	process	T067	C1522240
27532819	465	478	sgRNA plasmid	T114,T123	C0082774
27532819	479	491	construction	T169	C0205245
27532819	506	515	mechanism	T169	C0441712
27532819	517	525	scCRISPR	T028	C3661477
27532819	534	546	gene editing	T063	C4277689
27532819	534	546	gene editing	T063	C4277689
27532819	564	569	sgRNA	T114,T123	C0082774
27532819	570	576	oligos	T114	C0028953
27532819	581	590	available	T169	C0470187
27532819	597	612	high efficiency	T081	C0013682
27532819	613	623	equivalent	T080	C0205163
27532819	627	639	conventional	T080	C0439858
27532819	640	645	sgRNA	T114,T123	C0082774
27532819	646	655	targeting	T169	C1521840
27532819	662	666	gene	T028	C0017337
27532819	667	675	knockout	T050	C1522225
27532819	684	689	mouse	T025	C4042879
27532819	694	720	human embryonic stem cells	T025	C1171346
27532819	725	742	cancer cell lines	T025	C0085983
27532819	763	772	PCR-based	T063	C0032520
27532819	791	804	homology arms	T028	C1334043
27532819	817	826	efficient	T080	C0442799
27532819	827	849	site-specific knock-in	T062	C1517676
27532819	853	863	transgenes	T028	C0282641
27532819	872	875	GFP	T116,T130	C0120285
27532819	884	895	traditional	T169	C0443324
27532819	896	903	plasmid	T114,T123	C0032136
27532819	904	911	cloning	T059,T063	C0598888
27532819	915	951	genome-integrated selection cassette	T028	C0017337
27532819	962	970	knock-in	T062	C1517676
27532819	971	975	rate	T081	C1521828
27532819	982	989	methods	T170	C0025663
27532819	1022	1027	rapid	T080	C0456962
27532819	1032	1041	efficient	T080	C0442799
27532819	1042	1047	means	T077	C1704970
27532819	1051	1057	CRISPR	T114	C3658200
27532819	1058	1070	gene editing	T063	C4277689

28013256|t|From training to practice: the impact of ENGAGE, Ireland's national men's health training programme
28013256|a|Ireland's National Men's Health Policy recommended developing training programmes tailored to the needs of those working in health and allied health professionals and ENGAGE was developed to meet that recommendation. This study evaluated the impact of ENGAGE on frontline service providers' self-reported knowledge, skills, capacity and practice up to 5-months post training. Between 2012 and 2015, ENGAGE Trainers (n = 57) delivered 62 1-day training programmes to 810 participants. This study was conducted on a subset of those training days (n = 26) and participants. Quantitative methodologies were used to collect pre (n = 295), post (n = 295) and 5-month post (n = 128) training questionnaire data. Overall, participants were highly satisfied with the training immediately post training (8.60 ± 1.60 out of 10) and at 5-month follow up (8.06 ± 1.43 out of 10). Participants' self-reported level of knowledge, skill and capacity in identifying priorities, engaging men and influencing practice beyond their own organisation increased immediately following training (P < 0.001) and, with the exception of improving capacity to engage men and influencing practice beyond their organisation, these improvements were sustained at 5-month post training (P < 0.001). The vast majority of service providers (93.4%) reported that ENGAGE had impacted their work practice up to 5-month post training. The findings suggest that ENGAGE has succeeded in improving service providers' capacity to engage and work with men; improving gender competency in the delivery of health and health related services may increase the utilisation of such services by men and thereby improve health outcomes for men.
28013256	5	13	training	T065	C0220931
28013256	17	25	practice	T057	C0033284
28013256	31	37	impact	T080	C4049986
28013256	41	47	ENGAGE	T093	C1708333
28013256	49	58	Ireland's	T083	C0022067
28013256	59	99	national men's health training programme	T065	C0040607
28013256	100	109	Ireland's	T083	C0022067
28013256	110	138	National Men's Health Policy	T170	C0027458
28013256	139	150	recommended	T078	C0034866
28013256	162	181	training programmes	T065	C0040607
28013256	182	190	tailored	T058	C2986593
28013256	198	203	needs	T080	C0027552
28013256	213	220	working	T057	C0043227
28013256	224	230	health	T097	C1704312
28013256	235	262	allied health professionals	T097	C0002122
28013256	267	273	ENGAGE	T093	C1708333
28013256	301	315	recommendation	T078	C0034866
28013256	322	327	study	T062	C2603343
28013256	328	337	evaluated	T058	C0220825
28013256	342	348	impact	T080	C4049986
28013256	352	358	ENGAGE	T093	C1708333
28013256	362	390	frontline service providers'	T058	C0679886
28013256	391	414	self-reported knowledge	T033	C1948177
28013256	416	422	skills	T055	C0678856
28013256	424	432	capacity	T081	C1516240
28013256	437	445	practice	T057	C0033284
28013256	461	465	post	T079	C0687676
28013256	466	474	training	T065	C0220931
28013256	499	505	ENGAGE	T093	C1708333
28013256	506	514	Trainers	T073	C0453962
28013256	543	562	training programmes	T065	C0040607
28013256	570	582	participants	T098	C0679646
28013256	589	594	study	T062	C2603343
28013256	614	620	subset	T185	C1515021
28013256	630	638	training	T065	C0220931
28013256	657	669	participants	T098	C0679646
28013256	671	683	Quantitative	T081	C0392762
28013256	684	697	methodologies	T062	C0038949
28013256	734	738	post	T079	C0687676
28013256	761	765	post	T079	C0687676
28013256	776	784	training	T065	C0220931
28013256	785	798	questionnaire	T170	C0034394
28013256	805	812	Overall	T080	C1561607
28013256	814	826	participants	T098	C0679646
28013256	839	848	satisfied	T170	C4084799
28013256	858	866	training	T065	C0220931
28013256	867	878	immediately	T079	C0205253
28013256	879	883	post	T079	C0687676
28013256	884	892	training	T065	C0220931
28013256	932	941	follow up	T033	C0589120
28013256	967	980	Participants'	T098	C0679646
28013256	981	1013	self-reported level of knowledge	T033	C1948177
28013256	1015	1020	skill	T055	C0678856
28013256	1025	1033	capacity	T081	C1516240
28013256	1049	1059	priorities	T079	C0439607
28013256	1070	1073	men	T098	C0025266
28013256	1078	1089	influencing	T077	C4054723
28013256	1090	1098	practice	T057	C0033284
28013256	1116	1128	organisation	T057	C0029236
28013256	1129	1138	increased	T081	C0205217
28013256	1139	1150	immediately	T079	C0205253
28013256	1161	1169	training	T065	C0220931
28013256	1196	1205	exception	T077	C1705847
28013256	1209	1218	improving	T080	C1272745
28013256	1219	1227	capacity	T081	C1516240
28013256	1238	1241	men	T098	C0025266
28013256	1246	1257	influencing	T077	C4054723
28013256	1258	1266	practice	T057	C0033284
28013256	1280	1292	organisation	T057	C0029236
28013256	1300	1312	improvements	T057	C2936612
28013256	1318	1327	sustained	T169	C0443318
28013256	1339	1343	post	T079	C0687676
28013256	1344	1352	training	T065	C0220931
28013256	1375	1383	majority	T054	C0680220
28013256	1387	1404	service providers	T058	C0679886
28013256	1413	1421	reported	T058	C0700287
28013256	1427	1433	ENGAGE	T093	C1708333
28013256	1438	1446	impacted	T080	C4049986
28013256	1453	1457	work	T057	C0043227
28013256	1458	1466	practice	T057	C0033284
28013256	1481	1485	post	T079	C0687676
28013256	1486	1494	training	T065	C0220931
28013256	1500	1508	findings	T033	C0243095
28013256	1509	1516	suggest	T078	C1705535
28013256	1522	1528	ENGAGE	T093	C1708333
28013256	1533	1542	succeeded	T033	C0243095
28013256	1546	1555	improving	T080	C1272745
28013256	1556	1574	service providers'	T058	C0679886
28013256	1575	1583	capacity	T081	C1516240
28013256	1598	1602	work	T057	C0043227
28013256	1608	1611	men	T098	C0025266
28013256	1613	1622	improving	T080	C1272745
28013256	1623	1629	gender	T032	C0079399
28013256	1630	1640	competency	T080	C0086035
28013256	1660	1666	health	T078	C0018684
28013256	1671	1694	health related services	T058	C0018747
28013256	1699	1707	increase	T081	C0205217
28013256	1712	1723	utilisation	T058	C0042155
28013256	1732	1740	services	T058	C0018747
28013256	1744	1747	men	T098	C0025266
28013256	1760	1767	improve	T033	C0184511
28013256	1768	1783	health outcomes	T057	C0085565
28013256	1788	1791	men	T098	C0025266

27480504|t|Impact of systemic alitretinoin treatment on skin barrier gene and protein expression in patients with chronic hand eczema
27480504|a|Chronic hand eczema (CHE) is a common inflammatory skin disease that affects approximately 10% of the population. Systemic alitretinoin has been shown to be effective in patients with CHE who are refractory to topical corticosteroids. To analyse the impact of alitretinoin on the skin barrier genes and protein expression in the skin lesions of patients with CHE. Fifteen patients with CHE were treated with 30 mg daily of alitretinoin for up to 27 weeks. Disease severity was assessed using a clinical score. Skin biopsies from all the patients were evaluated before and after therapy for the expression of Ki-67, various skin barrier genes and thymic stromal lymphopoietin (TSLP) by real-time quantitative polymerase chain reaction and immunohistochemistry. After alitretinoin application, an improvement in the clinical severity of CHE was observed in the majority of patients. Analysis of skin biopsies before treatment showed a significant increase in Ki-67 - positive cells in the suprabasal layer and a dysregulated expression of various skin barrier genes, such as claudin 1, loricrin, filaggrin and cytokeratin 10, which were normalized after treatment. TSLP was significantly upregulated in patients with CHE and also normalized after alitretinoin treatment and negatively correlated with filaggrin. Our data indicate that the expression of barrier genes and proteins was normalized following treatment with alitretinoin in patients with CHE. The change in expression levels of these genes correlated with the clinical efficacy, suggesting that alitretinoin exhibits a disease - modifying activity. TSLP is upregulated in CHE and seems to counteract filaggrin expression in the skin.
27480504	0	6	Impact	T080	C4049986
27480504	10	18	systemic	T169	C0205373
27480504	19	31	alitretinoin	T109,T121,T127	C0281666
27480504	32	41	treatment	T061	C0087111
27480504	45	57	skin barrier	T042	C2246986
27480504	58	62	gene	T045	C0017262
27480504	67	85	protein expression	T045	C1171362
27480504	89	97	patients	T101	C0030705
27480504	103	122	chronic hand eczema	T047	C1276092
27480504	123	142	Chronic hand eczema	T047	C1276092
27480504	144	147	CHE	T047	C1276092
27480504	161	186	inflammatory skin disease	T047	C3875321
27480504	200	213	approximately	T080	C0332232
27480504	225	235	population	T098	C1257890
27480504	237	245	Systemic	T169	C0205373
27480504	246	258	alitretinoin	T109,T121,T127	C0281666
27480504	280	289	effective	T080	C1704419
27480504	293	301	patients	T101	C0030705
27480504	307	310	CHE	T047	C1276092
27480504	319	329	refractory	T169	C0205269
27480504	333	356	topical corticosteroids	T121	C0304604
27480504	373	379	impact	T080	C4049986
27480504	383	395	alitretinoin	T109,T121,T127	C0281666
27480504	403	415	skin barrier	T042	C2246986
27480504	416	421	genes	T028	C0017337
27480504	426	444	protein expression	T045	C1171362
27480504	452	464	skin lesions	T047	C0037284
27480504	468	476	patients	T101	C0030705
27480504	482	485	CHE	T047	C1276092
27480504	495	503	patients	T101	C0030705
27480504	509	512	CHE	T047	C1276092
27480504	518	530	treated with	T061	C0332293
27480504	537	542	daily	T079	C0332173
27480504	546	558	alitretinoin	T109,T121,T127	C0281666
27480504	572	577	weeks	T079	C0439230
27480504	579	595	Disease severity	T080	C0521117
27480504	600	608	assessed	T052	C1516048
27480504	617	625	clinical	T080	C0205210
27480504	626	631	score	T081	C0449820
27480504	633	646	Skin biopsies	T060	C0150866
27480504	660	668	patients	T101	C0030705
27480504	674	683	evaluated	T058	C0220825
27480504	684	690	before	T079	C0332152
27480504	695	700	after	T079	C0687676
27480504	701	708	therapy	T061	C0087111
27480504	717	727	expression	T045	C1171362
27480504	731	736	Ki-67	T116,T129,T130	C0208804
27480504	746	758	skin barrier	T042	C2246986
27480504	759	764	genes	T028	C0017337
27480504	769	797	thymic stromal lymphopoietin	T116,T129	C0762640
27480504	799	803	TSLP	T116,T129	C0762640
27480504	808	856	real-time quantitative polymerase chain reaction	T063	C3179034
27480504	861	881	immunohistochemistry	T060	C0021044
27480504	889	901	alitretinoin	T109,T121,T127	C0281666
27480504	918	929	improvement	T077	C2986411
27480504	937	945	clinical	T080	C0205210
27480504	946	954	severity	T080	C0439793
27480504	958	961	CHE	T047	C1276092
27480504	982	990	majority	T054	C0680220
27480504	994	1002	patients	T101	C0030705
27480504	1004	1012	Analysis	T062	C0936012
27480504	1016	1029	skin biopsies	T060	C0150866
27480504	1030	1036	before	T079	C0332152
27480504	1037	1046	treatment	T061	C0087111
27480504	1056	1067	significant	T078	C0750502
27480504	1068	1076	increase	T169	C0442805
27480504	1080	1085	Ki-67	T028	C1334508
27480504	1088	1096	positive	T033	C1514241
27480504	1097	1102	cells	T025	C0007634
27480504	1110	1126	suprabasal layer	T026	C0243092
27480504	1133	1156	dysregulated expression	T045	C0017263
27480504	1168	1180	skin barrier	T042	C2246986
27480504	1181	1186	genes	T028	C0017337
27480504	1196	1205	claudin 1	T028	C1413460
27480504	1207	1215	loricrin	T028	C1416897
27480504	1217	1226	filaggrin	T028	C1414633
27480504	1231	1245	cytokeratin 10	T028	C1416714
27480504	1258	1268	normalized	T062	C1882115
27480504	1275	1284	treatment	T061	C0087111
27480504	1286	1290	TSLP	T116,T129	C0762640
27480504	1309	1320	upregulated	T044	C0041904
27480504	1324	1332	patients	T101	C0030705
27480504	1338	1341	CHE	T047	C1276092
27480504	1351	1361	normalized	T062	C1882115
27480504	1368	1380	alitretinoin	T109,T121,T127	C0281666
27480504	1381	1390	treatment	T061	C0087111
27480504	1395	1405	negatively	T033	C1513916
27480504	1406	1416	correlated	T080	C1707520
27480504	1422	1431	filaggrin	T116,T123	C0117738
27480504	1482	1487	genes	T028	C0017337
27480504	1492	1500	proteins	T116,T123	C0033684
27480504	1505	1515	normalized	T062	C1882115
27480504	1526	1535	treatment	T061	C0087111
27480504	1541	1553	alitretinoin	T109,T121,T127	C0281666
27480504	1557	1565	patients	T101	C0030705
27480504	1571	1574	CHE	T047	C1276092
27480504	1580	1586	change	T169	C0392747
27480504	1590	1600	expression	T045	C0017262
27480504	1601	1607	levels	T080	C0441889
27480504	1617	1622	genes	T028	C0017337
27480504	1623	1633	correlated	T080	C1707520
27480504	1643	1660	clinical efficacy	T080	C3850123
27480504	1678	1690	alitretinoin	T109,T121,T127	C0281666
27480504	1702	1709	disease	T047	C0012634
27480504	1712	1721	modifying	T169	C0392747
27480504	1722	1730	activity	T052	C0441655
27480504	1732	1736	TSLP	T116,T129	C0762640
27480504	1740	1751	upregulated	T044	C0041904
27480504	1755	1758	CHE	T047	C1276092
27480504	1783	1792	filaggrin	T116,T123	C0117738
27480504	1793	1803	expression	T045	C1171362
27480504	1811	1815	skin	T022	C1123023

28327645|t|A Novel Point-of-Care Smartphone Based System for Monitoring the Cardiac and Respiratory Systems
28327645|a|Cardio-respiratory monitoring is one of the most demanding areas in the rapidly growing, mobile-device, based health care delivery. We developed a 12-lead smartphone -based electrocardiogram (ECG) acquisition and monitoring system (called " cvrPhone "), and an application to assess underlying ischemia, and estimate the respiration rate (RR) and tidal volume (TV) from analysis of electrocardiographic (ECG) signals only. During in-vivo swine studies (n = 6), 12-lead ECG signals were recorded at baseline and following coronary artery occlusion. Ischemic indices calculated from each lead showed statistically significant (p < 0.05) increase within 2 min of occlusion compared to baseline. Following myocardial infarction, spontaneous ventricular tachycardia episodes (n = 3) were preceded by significant (p < 0.05) increase of the ischemic index ~1-4 min prior to the onset of the tachy-arrhythmias. In order to assess the respiratory status during apnea, the mechanical ventilator was paused for up to 2 min during normal breathing. We observed that the RR and TV estimation algorithms detected apnea within 7.9 ± 1.1 sec and 5.5 ± 2.2 sec, respectively, while the estimated RR and TV values were 0 breaths/min and less than 100 ml, respectively. In conclusion, the cvrPhone can be used to detect myocardial ischemia and periods of respiratory apnea using a readily available mobile platform.
28327645	8	21	Point-of-Care	T078	C1547702
28327645	22	32	Smartphone	T073	C3204335
28327645	39	45	System	T169	C0449913
28327645	50	60	Monitoring	T061	C3544157
28327645	65	72	Cardiac	T022	C0007226
28327645	77	96	Respiratory Systems	T022	C0035237
28327645	97	126	Cardio-respiratory monitoring	T061	C3544157
28327645	186	199	mobile-device	T073	C1136360
28327645	207	227	health care delivery	T058	C0011211
28327645	252	262	smartphone	T073	C3204335
28327645	270	287	electrocardiogram	T033	C0013798
28327645	289	292	ECG	T033	C0013798
28327645	294	305	acquisition	T052	C1706701
28327645	310	327	monitoring system	T074	C1139730
28327645	338	346	cvrPhone	T074	C1139730
28327645	391	399	ischemia	T046	C0022116
28327645	418	434	respiration rate	T201	C0231832
28327645	436	438	RR	T201	C0231832
28327645	444	456	tidal volume	T034	C0040210
28327645	458	460	TV	T034	C0040210
28327645	467	475	analysis	T062	C0936012
28327645	479	513	electrocardiographic (ECG) signals	T033	C0428732
28327645	527	534	in-vivo	T082	C1515655
28327645	535	548	swine studies	T062	C2603343
28327645	566	577	ECG signals	T033	C0428732
28327645	595	603	baseline	T081	C1442488
28327645	618	643	coronary artery occlusion	T047	C0151814
28327645	645	661	Ischemic indices	T081	C0392762
28327645	732	740	increase	T169	C0442805
28327645	757	766	occlusion	T047	C0151814
28327645	779	787	baseline	T081	C1442488
28327645	799	820	myocardial infarction	T047	C0027051
28327645	822	833	spontaneous	T169	C0205359
28327645	834	866	ventricular tachycardia episodes	T034	C0344428
28327645	892	903	significant	T078	C0750502
28327645	931	945	ischemic index	T081	C0392762
28327645	968	976	onset of	T080	C0332162
28327645	981	998	tachy-arrhythmias	T033	C0080203
28327645	1023	1041	respiratory status	T033	C1998827
28327645	1049	1054	apnea	T046	C0003578
28327645	1060	1081	mechanical ventilator	T074	C0042497
28327645	1116	1132	normal breathing	T040	C0231795
28327645	1155	1157	RR	T201	C0231832
28327645	1162	1164	TV	T034	C0040210
28327645	1165	1175	estimation	T081	C0750572
28327645	1176	1186	algorithms	T170	C0002045
28327645	1196	1201	apnea	T046	C0003578
28327645	1266	1275	estimated	T081	C0750572
28327645	1276	1278	RR	T201	C0231832
28327645	1283	1285	TV	T034	C0040210
28327645	1300	1311	breaths/min	T081	C0439386
28327645	1351	1361	conclusion	T078	C1707478
28327645	1367	1375	cvrPhone	T074	C1139730
28327645	1398	1417	myocardial ischemia	T047	C0151744
28327645	1422	1429	periods	T079	C1948053
28327645	1433	1450	respiratory apnea	T046	C0003578
28327645	1477	1483	mobile	T073	C1136360

27450703|t|Peripheral interactions between cannabinoid and opioid receptor agonists in a model of inflammatory mechanical hyperalgesia
27450703|a|Activation of opioid and cannabinoid receptors expressed in nociceptors induces effective antihyperalgesia. In this study, we examined whether combinations of opioid and cannabinoid receptor agonists directed at the injured site would enhance therapeutic effectiveness. Behavioral pharmacology experiments were performed to compare the effects of DAMGO, a selective agonist for μ-opioid receptor (MOR), ACPA, a specific agonist for CB1, and combinations of DAMGO and ACPA in attenuating complete Freund's adjuvant (CFA)-induced mechanical hyperalgesia in the rat hindpaw. DAMGO (1μg-1mg) or ACPA (1μg-2mg) was administered into the inflamed paw when mechanical hyperalgesia was fully developed. When administered individually, DAMGO and ACPA dose -dependently reversed the mechanical hyperalgesia. DAMGO displayed a lower ED50 value (57.4±2.49μg) than ACPA (111.6±2.18μg), but ACPA produced longer lasting antihyperalgesic effects. Combinations of DAMGO and ACPA also dose -dependently attenuated mechanical hyperalgesia, but the antihyperalgesic effects were partial and transient even at high doses. Using isobolographic analysis, we determined that combined treatment with DAMGO and ACPA produced antagonistic effects with the observed ED50 of 128.4±2.28μg. Our findings showed that MOR and CB1 agonists directed at the inflamed site effectively attenuate mechanical hyperalgesia when administered individually, but exert opposing effects when administered together. The antagonistic interactions between the two classes of drugs at the inflamed site suggest distinct mechanisms unique to peripheral nociceptors or inflamed tissue, and therefore require further studies to investigate whether the therapeutic utility of the combined drug treatments in chronic pain conditions can be optimized.
27450703	0	10	Peripheral	T082	C0205100
27450703	11	23	interactions	T169	C1704675
27450703	32	43	cannabinoid	T116,T192	C0054594
27450703	48	63	opioid receptor	T116,T192	C0034801
27450703	64	72	agonists	T121	C0243192
27450703	78	83	model	T050	C0684309
27450703	87	99	inflammatory	T046	C0021368
27450703	100	123	mechanical hyperalgesia	T184	C2936719
27450703	124	134	Activation	T043	C1514758
27450703	138	144	opioid	T116,T192	C0034801
27450703	149	170	cannabinoid receptors	T116,T192	C0054594
27450703	171	180	expressed	T045	C0597360
27450703	184	195	nociceptors	T023	C0028246
27450703	214	230	antihyperalgesia	T033	C3540840
27450703	267	279	combinations	T080	C0205195
27450703	283	289	opioid	T116,T192	C0034801
27450703	294	314	cannabinoid receptor	T116,T192	C0054594
27450703	315	323	agonists	T121	C0243192
27450703	340	347	injured	T169	C0332664
27450703	348	352	site	T082	C0205145
27450703	367	378	therapeutic	T169	C0302350
27450703	379	392	effectiveness	T080	C1280519
27450703	394	417	Behavioral pharmacology	T091	C0872109
27450703	418	429	experiments	T062	C0681814
27450703	448	455	compare	T052	C1707455
27450703	460	470	effects of	T080	C1704420
27450703	471	476	DAMGO	T116,T121	C0525773
27450703	490	497	agonist	T121	C0243192
27450703	502	519	μ-opioid receptor	T116,T192	C0066908
27450703	521	524	MOR	T116,T192	C0066908
27450703	527	531	ACPA	T109	C0767831
27450703	544	551	agonist	T121	C0243192
27450703	556	559	CB1	T116,T192	C0378126
27450703	565	577	combinations	T080	C0205195
27450703	581	586	DAMGO	T116,T121	C0525773
27450703	591	595	ACPA	T109	C0767831
27450703	599	610	attenuating	T052	C0599946
27450703	611	637	complete Freund's adjuvant	T121,T129	C0016712
27450703	639	642	CFA	T121,T129	C0016712
27450703	652	675	mechanical hyperalgesia	T184	C2936719
27450703	683	686	rat	T015	C0034693
27450703	687	694	hindpaw	T029	C0230459
27450703	696	701	DAMGO	T116,T121	C0525773
27450703	715	719	ACPA	T109	C0767831
27450703	734	746	administered	T169	C1521801
27450703	756	764	inflamed	T046	C0021368
27450703	765	768	paw	T023	C0687080
27450703	774	797	mechanical hyperalgesia	T184	C2936719
27450703	824	836	administered	T169	C1521801
27450703	851	856	DAMGO	T116,T121	C0525773
27450703	861	865	ACPA	T109	C0767831
27450703	866	870	dose	T081	C0178602
27450703	897	920	mechanical hyperalgesia	T184	C2936719
27450703	922	927	DAMGO	T116,T121	C0525773
27450703	946	956	ED50 value	UnknownType	C0678794
27450703	976	980	ACPA	T109	C0767831
27450703	1001	1005	ACPA	T109	C0767831
27450703	1030	1054	antihyperalgesic effects	T033	C3540840
27450703	1056	1068	Combinations	T080	C0205195
27450703	1072	1077	DAMGO	T116,T121	C0525773
27450703	1082	1086	ACPA	T109	C0767831
27450703	1092	1096	dose	T081	C0178602
27450703	1110	1120	attenuated	T052	C0599946
27450703	1121	1144	mechanical hyperalgesia	T184	C2936719
27450703	1154	1178	antihyperalgesic effects	T033	C3540840
27450703	1184	1191	partial	T081	C0728938
27450703	1196	1205	transient	T079	C0205374
27450703	1214	1224	high doses	T081	C0444956
27450703	1232	1255	isobolographic analysis	T059	C0022885
27450703	1285	1294	treatment	T061	C0087111
27450703	1300	1305	DAMGO	T116,T121	C0525773
27450703	1310	1314	ACPA	T109	C0767831
27450703	1324	1344	antagonistic effects	UnknownType	C0683167
27450703	1363	1367	ED50	UnknownType	C0678794
27450703	1389	1397	findings	T169	C2607943
27450703	1410	1413	MOR	T116,T192	C0066908
27450703	1418	1421	CB1	T116,T192	C0378126
27450703	1422	1430	agonists	T121	C0243192
27450703	1447	1455	inflamed	T046	C0021368
27450703	1456	1460	site	T082	C0205145
27450703	1473	1482	attenuate	T052	C0599946
27450703	1483	1506	mechanical hyperalgesia	T184	C2936719
27450703	1512	1524	administered	T169	C1521801
27450703	1543	1548	exert	T040	C0015264
27450703	1571	1583	administered	T169	C1521801
27450703	1598	1623	antagonistic interactions	UnknownType	C0678797
27450703	1651	1656	drugs	T121	C0013227
27450703	1664	1672	inflamed	T046	C0021368
27450703	1673	1677	site	T082	C0205145
27450703	1706	1712	unique	T080	C1710548
27450703	1716	1726	peripheral	T082	C0205100
27450703	1727	1738	nociceptors	T023	C0028246
27450703	1742	1750	inflamed	T046	C0021368
27450703	1751	1757	tissue	T024	C0040300
27450703	1800	1811	investigate	T169	C1292732
27450703	1824	1835	therapeutic	T169	C0302350
27450703	1836	1843	utility	T169	C3669222
27450703	1851	1859	combined	T080	C0205195
27450703	1860	1875	drug treatments	T061	C0013216
27450703	1879	1891	chronic pain	T184	C0150055
27450703	1910	1919	optimized	T052	C2698650

27531288|t|Untoward events associated with aberrant fluid infusion during cataract surgery: Laboratory study with corroborative clinical observations
27531288|a|To determine the relationship between untoward events noted during phacoemulsification surgery associated with aberrant infusion misdirection and their causal relationship to current infusion sleeve design. The New York Eye & Ear Infirmary of Mt. Sinai, New York, New York, USA. Retrospective case reports and experimental study. Observations of live cataract surgery were documented with high-definition videography using 3 commercial phacoemulsification platforms. Laboratory studies using a Photron MC2 high-speed camera and the Kitaro cataract surgical system were used to simulate surgical maneuvers and assess flow patterns and visualize the dynamics of fluid movement in the anterior chamber. Color-flow Doppler ultrasound studies were used to demonstrate the effect of infusion fluid on the iris during surgery. Misdirected infusion and floppy-iris leaflets were determined to be secondary to a fulcrum effect at the corneal wound that constrained movement of the standard silicone sleeves. The phacoemulsification needles could therefore decenter independently of the infusion sleeve, attenuating infusion volume down 1 side of the sleeve and, as a result, obstructing fluid exiting the ipsilateral port. Untoward events associated with aberrant fluid infusion during phacoemulsification surgery were secondary to a fulcrum effect at the corneal wound. Complications included misdirected infusion that facilitated the transport of retained nuclear fragments to the vitreous, inconsistent lens followability during phacoemulsification, and exaggerated movements of the iris particularly consistent with intraoperative floppy-iris syndrome and pseudoexfoliation. None of the authors has a financial or proprietary interest in any material or method mentioned.
27531288	0	15	Untoward events	T051	C0441471
27531288	16	31	associated with	T080	C0332281
27531288	32	40	aberrant	T080	C0443127
27531288	41	46	fluid	T167	C1704353
27531288	47	55	infusion	T061	C0574032
27531288	63	79	cataract surgery	T061	C2939459
27531288	81	97	Laboratory study	T059	C0681827
27531288	103	138	corroborative clinical observations	T058	C3889687
27531288	156	168	relationship	T080	C0439849
27531288	177	192	untoward events	T051	C0441471
27531288	206	233	phacoemulsification surgery	T061	C0282545
27531288	234	249	associated with	T080	C0332281
27531288	250	258	aberrant	T080	C0443127
27531288	259	267	infusion	T061	C0574032
27531288	268	280	misdirection	T169	C0205245
27531288	298	310	relationship	T080	C0439849
27531288	322	330	infusion	T061	C0574032
27531288	331	337	sleeve	T074	C0183336
27531288	338	344	design	T052	C1707689
27531288	350	391	New York Eye & Ear Infirmary of Mt. Sinai	T073,T093	C0019994
27531288	393	401	New York	T083	C0027977
27531288	403	411	New York	T083	C0027977
27531288	413	416	USA	T083	C0041703
27531288	418	431	Retrospective	T080	C1514923
27531288	432	444	case reports	T170	C0007320
27531288	449	467	experimental study	T062	C0681814
27531288	469	481	Observations	T062	C0302523
27531288	485	489	live	T078	C1254370
27531288	490	506	cataract surgery	T061	C2939459
27531288	512	522	documented	T058	C1301725
27531288	528	555	high-definition videography	T170	C0282574
27531288	564	574	commercial	T170	C0680536
27531288	575	594	phacoemulsification	T061	C0282545
27531288	595	604	platforms	T075	C1710360
27531288	606	624	Laboratory studies	T059	C0681827
27531288	633	662	Photron MC2 high-speed camera	T074	C0179533
27531288	671	702	Kitaro cataract surgical system	T074	C0025080
27531288	716	724	simulate	T169	C0205245
27531288	725	743	surgical maneuvers	T060	C0430022
27531288	748	754	assess	T058	C0184514
27531288	755	768	flow patterns	T033	C0243095
27531288	773	782	visualize	T077	C1254372
27531288	787	813	dynamics of fluid movement	T070	C2936194
27531288	821	837	anterior chamber	T023	C0003151
27531288	839	876	Color-flow Doppler ultrasound studies	T060	C0162481
27531288	906	915	effect of	T080	C1704420
27531288	916	924	infusion	T061	C0574032
27531288	925	930	fluid	T167	C1704353
27531288	938	942	iris	T023	C0022077
27531288	950	957	surgery	T061	C2939459
27531288	959	970	Misdirected	T169	C0205245
27531288	971	979	infusion	T061	C0574032
27531288	984	1004	floppy-iris leaflets	T023	C0022077
27531288	1027	1039	secondary to	T080	C0175668
27531288	1042	1056	fulcrum effect	T080	C0205556
27531288	1064	1071	corneal	T023	C0010031
27531288	1072	1077	wound	T037	C0043250
27531288	1083	1094	constrained	T077	C1707494
27531288	1095	1103	movement	T169	C0205245
27531288	1111	1119	standard	T080	C1442989
27531288	1120	1136	silicone sleeves	T074	C0183336
27531288	1142	1161	phacoemulsification	T061	C0282545
27531288	1162	1169	needles	T074	C0027551
27531288	1216	1224	infusion	T061	C0574032
27531288	1225	1231	sleeve	T074	C0183336
27531288	1233	1244	attenuating	T052	C0599946
27531288	1245	1253	infusion	T061	C0574032
27531288	1254	1260	volume	T081	C0449468
27531288	1261	1265	down	T033	C0085639
27531288	1266	1272	1 side	T082	C1254362
27531288	1280	1286	sleeve	T074	C0183336
27531288	1305	1316	obstructing	T169	C0205245
27531288	1317	1322	fluid	T167	C1704353
27531288	1323	1330	exiting	T082	C0337094
27531288	1335	1346	ipsilateral	T082	C0441989
27531288	1347	1351	port	T074	C0725247
27531288	1353	1368	Untoward events	T051	C0441471
27531288	1369	1384	associated with	T080	C0332281
27531288	1385	1393	aberrant	T080	C0443127
27531288	1394	1399	fluid	T167	C1704353
27531288	1400	1408	infusion	T061	C0574032
27531288	1416	1443	phacoemulsification surgery	T061	C0282545
27531288	1449	1461	secondary to	T080	C0175668
27531288	1464	1478	fulcrum effect	T080	C0205556
27531288	1486	1493	corneal	T023	C0010031
27531288	1494	1499	wound	T037	C0043250
27531288	1501	1514	Complications	T046	C0009566
27531288	1524	1535	misdirected	T169	C0205245
27531288	1536	1544	infusion	T061	C0574032
27531288	1566	1575	transport	T052	C0206243
27531288	1579	1587	retained	T169	C0333118
27531288	1588	1605	nuclear fragments	T033	C2112806
27531288	1613	1621	vitreous	T033	C0423292
27531288	1623	1635	inconsistent	T080	C0442809
27531288	1636	1640	lens	T023	C0023317
27531288	1662	1681	phacoemulsification	T061	C0282545
27531288	1687	1698	exaggerated	T080	C0442801
27531288	1699	1708	movements	T169	C0205245
27531288	1716	1720	iris	T023	C0022077
27531288	1734	1749	consistent with	T078	C0332290
27531288	1750	1785	intraoperative floppy-iris syndrome	T047	C1688637
27531288	1790	1807	pseudoexfoliation	T046	C4022815
27531288	1821	1828	authors	T097	C3812881
27531288	1835	1868	financial or proprietary interest	T041	C0543488
27531288	1876	1884	material	T167	C0520510
27531288	1888	1894	method	T170	C0025663

27571215|t|Vasopressin regulates the growth of the biliary epithelium in polycystic liver disease
27571215|a|The neurohypophysial hormone arginine vasopressin (AVP) acts by three distinct receptor subtypes: V1a, V1b, and V2. In the liver, AVP is involved in ureogenesis, glycogenolysis, neoglucogenesis and regeneration. No data exist about the presence of AVP in the biliary epithelium. Cholangiocytes are the target cells in a number of animal models of cholestasis, including bile duct ligation (BDL), and in several human pathologies, such as polycystic liver disease characterized by the presence of cysts that bud from the biliary epithelium. In vivo, liver fragments from normal and BDL mice and rats as well as liver samples from normal and ADPKD patients were collected to evaluate: (i) intrahepatic bile duct mass by immunohistochemistry for cytokeratin-19; and (ii) expression of V1a, V1b and V2 by immunohistochemistry, immunofluorescence and real-time PCR. In vitro, small and large mouse cholangiocytes, H69 (non-malignant human cholangiocytes) and LCDE (human cholangiocytes from the cystic epithelium) were stimulated with vasopressin in the absence/ presence of AVP antagonists such as OPC-31260 and Tolvaptan, before assessing cellular growth by MTT assay and cAMP levels. Cholangiocytes express V2 receptor that was upregulated following BDL and in ADPKD liver samples. Administration of AVP increased proliferation and cAMP levels of small cholangiocytes and LCDE cells. We found no effect in the proliferation of large mouse cholangiocytes and H69 cells. Increases were blocked by preincubation with the AVP antagonists. These results showed that AVP and its receptors may be important in the modulation of the proliferation rate of the biliary epithelium.
27571215	0	11	Vasopressin	T116,T121,T125	C0042413
27571215	12	32	regulates the growth	T043	C0596286
27571215	40	58	biliary epithelium	T025	C3686472
27571215	62	86	polycystic liver disease	T019,T047	C0158683
27571215	91	115	neurohypophysial hormone	T116,T121,T125	C0032017
27571215	116	136	arginine vasopressin	T116,T121,T125	C0003779
27571215	138	141	AVP	T116,T121,T125	C0003779
27571215	166	174	receptor	T116,T192	C0597357
27571215	185	188	V1a	T116,T192	C0284725
27571215	190	193	V1b	T116,T192	C0284726
27571215	199	201	V2	T116,T192	C0162829
27571215	210	215	liver	T023	C0023884
27571215	217	220	AVP	T116,T121,T125	C0003779
27571215	224	232	involved	T169	C1314939
27571215	236	247	ureogenesis	T044	C0597619
27571215	249	263	glycogenolysis	T044	C0596624
27571215	265	280	neoglucogenesis	T044	C0598530
27571215	285	297	regeneration	T042	C0034963
27571215	323	331	presence	T033	C0150312
27571215	335	338	AVP	T116,T121,T125	C0003779
27571215	346	364	biliary epithelium	T025	C3686472
27571215	366	380	Cholangiocytes	T025	C3686472
27571215	389	401	target cells	T025	C0221284
27571215	417	430	animal models	T050	C0012644
27571215	434	445	cholestasis	T047	C0008370
27571215	457	466	bile duct	T023	C0005400
27571215	467	475	ligation	T061	C0023690
27571215	477	480	BDL	T061	C0023690
27571215	498	503	human	T016	C0086418
27571215	504	515	pathologies	T091	C0030664
27571215	525	549	polycystic liver disease	T019,T047	C0158683
27571215	550	563	characterized	T052	C1880022
27571215	571	579	presence	T033	C0150312
27571215	583	588	cysts	T047	C0010709
27571215	607	625	biliary epithelium	T025	C3686472
27571215	627	634	In vivo	T082	C1515655
27571215	636	641	liver	T023	C0023884
27571215	642	651	fragments	T031	C0486805
27571215	668	671	BDL	T061	C0023690
27571215	672	676	mice	T015	C0025929
27571215	681	685	rats	T015	C0034721
27571215	697	710	liver samples	T024	C0586689
27571215	727	732	ADPKD	T019,T047	C0085413
27571215	733	741	patients	T101	C0030705
27571215	774	786	intrahepatic	T082	C1512948
27571215	787	796	bile duct	T023	C0005400
27571215	797	801	mass	T033	C0577559
27571215	805	825	immunohistochemistry	T060	C0021044
27571215	830	844	cytokeratin-19	T116	C0010803
27571215	855	865	expression	T045	C0597360
27571215	869	872	V1a	T116,T192	C0284725
27571215	874	877	V1b	T116,T192	C0284726
27571215	882	884	V2	T116,T192	C0162829
27571215	888	908	immunohistochemistry	T060	C0021044
27571215	910	928	immunofluorescence	T059	C0079603
27571215	933	946	real-time PCR	T063	C1709846
27571215	948	956	In vitro	T080	C1533691
27571215	974	979	mouse	T015	C0025929
27571215	980	994	cholangiocytes	T025	C3686472
27571215	996	999	H69	T025	C0007634
27571215	1001	1014	non-malignant	T080	C1518371
27571215	1015	1020	human	T016	C0086418
27571215	1021	1035	cholangiocytes	T025	C3686472
27571215	1041	1045	LCDE	T025	C0007634
27571215	1047	1052	human	T016	C0086418
27571215	1053	1067	cholangiocytes	T025	C3686472
27571215	1077	1094	cystic epithelium	T190	C0259770
27571215	1101	1111	stimulated	T044	C0038337
27571215	1117	1128	vasopressin	T116,T121,T125	C0042413
27571215	1145	1153	presence	T033	C0150312
27571215	1157	1172	AVP antagonists	T116,T121,T125	C1719946
27571215	1181	1190	OPC-31260	T109,T121	C0171458
27571215	1195	1204	Tolvaptan	T109,T121	C1176308
27571215	1223	1238	cellular growth	T043	C0007595
27571215	1242	1251	MTT assay	T059	C0201596
27571215	1256	1260	cAMP	T114,T121,T123	C0001455
27571215	1269	1283	Cholangiocytes	T025	C3686472
27571215	1292	1303	V2 receptor	T116,T192	C0162829
27571215	1313	1324	upregulated	T044	C0041904
27571215	1335	1338	BDL	T061	C0023690
27571215	1346	1351	ADPKD	T019,T047	C0085413
27571215	1352	1365	liver samples	T024	C0586689
27571215	1367	1381	Administration	T061	C1533734
27571215	1385	1388	AVP	T116,T121,T125	C0003779
27571215	1389	1398	increased	T081	C0205217
27571215	1399	1412	proliferation	T043	C0596290
27571215	1417	1421	cAMP	T114,T121,T123	C0001455
27571215	1438	1452	cholangiocytes	T025	C3686472
27571215	1457	1467	LCDE cells	T025	C0007634
27571215	1478	1487	no effect	T080	C1301751
27571215	1495	1508	proliferation	T043	C0596290
27571215	1518	1523	mouse	T015	C0025929
27571215	1524	1538	cholangiocytes	T025	C3686472
27571215	1543	1552	H69 cells	T025	C0007634
27571215	1554	1563	Increases	T169	C0442805
27571215	1569	1576	blocked	T169	C0332206
27571215	1580	1593	preincubation	T059	C1441618
27571215	1603	1618	AVP antagonists	T116,T121,T125	C1719946
27571215	1626	1633	results	T169	C1274040
27571215	1646	1649	AVP	T116,T121,T125	C0003779
27571215	1658	1667	receptors	T116,T192	C0597357
27571215	1692	1702	modulation	UnknownType	C0544633
27571215	1710	1728	proliferation rate	T034	C0812425
27571215	1736	1754	biliary epithelium	T025	C3686472

28463933|t|Brief Potentially Ictal Rhythmic Discharges [B(I)RDs] in Noncritically Ill Adults
28463933|a|Brief potentially ictal rhythmic discharges (B(I)RDs) have been described in neonates and critically ill adults, and their association with seizures has been demonstrated. Their significance in noncritically ill adults remains unclear. We aimed to investigate their prevalence, electrographic characteristics, and clinical significance. We identified adult patients with B(I)RDs who received long-term EEG recordings either in the epilepsy monitoring unit or in the ambulatory setting. Patients with acute findings on imaging or status epilepticus were excluded. B(I)RDs were defined as very brief (<10 seconds) runs of focal or generalized sharply contoured rhythmic activity greater than 4 Hz, with or without evolution, that were not consistent with any known normal or benign pattern. The clinical history, EEG, and imaging results were retrieved. Each patient with B(I)RDs was matched by age and etiology to a control group with epileptiform discharges but without B(I)RDs in a 1:2 ratio. We identified B(I)RDs in 15 patients of 1,230 EEGs (1.2%). The pattern typically consisted of 0.5 to 4 second runs of sharply contoured alpha activity without evolution. All patients with B(I)RDs had epilepsy, and, when compared with controls with epilepsy but without BIRDs, were more likely to be medically refractory (10 of 15 [67%] vs. 5 of 30 [17%]; P < 0.01). All seizure onsets colocalized to the B(I)RDs, and most were morphologically similar. In noncritically ill patients, B(I)RDs are associated with refractory epilepsy and their location is correlated with the seizure onset area.
28463933	0	43	Brief Potentially Ictal Rhythmic Discharges	T033	C0243095
28463933	45	52	B(I)RDs	T033	C0243095
28463933	57	70	Noncritically	T080	C0205556
28463933	71	74	Ill	T184	C0221423
28463933	75	81	Adults	T100	C0001675
28463933	82	125	Brief potentially ictal rhythmic discharges	T033	C0243095
28463933	127	134	B(I)RDs	T033	C0243095
28463933	159	167	neonates	T100	C0021289
28463933	172	186	critically ill	T047	C0010340
28463933	187	193	adults	T100	C0001675
28463933	205	216	association	T080	C0439849
28463933	222	230	seizures	T184	C0036572
28463933	260	272	significance	T078	C0750502
28463933	276	289	noncritically	T080	C0205556
28463933	290	293	ill	T184	C0221423
28463933	294	300	adults	T100	C0001675
28463933	309	316	unclear	T033	C3845108
28463933	330	341	investigate	T169	C1292732
28463933	348	358	prevalence	T081	C0220900
28463933	360	390	electrographic characteristics	T080	C1521970
28463933	396	417	clinical significance	T033	C2826293
28463933	433	438	adult	T100	C0001675
28463933	439	447	patients	T101	C0030705
28463933	453	460	B(I)RDs	T033	C0243095
28463933	465	473	received	T080	C1514756
28463933	474	483	long-term	T079	C0443252
28463933	484	487	EEG	T060	C0013819
28463933	488	498	recordings	T170	C0025102
28463933	513	521	epilepsy	T047	C0014544
28463933	522	537	monitoring unit	T074	C0025080
28463933	568	576	Patients	T101	C0030705
28463933	582	596	acute findings	T184	C0037088
28463933	600	607	imaging	T060	C0011923
28463933	611	629	status epilepticus	T047	C0038220
28463933	645	652	B(I)RDs	T033	C0243095
28463933	674	679	brief	T079	C1879313
28463933	723	758	sharply contoured rhythmic activity	T033	C0243095
28463933	794	803	evolution	T169	C0205245
28463933	819	834	consistent with	T078	C0332290
28463933	845	851	normal	T080	C0205307
28463933	855	861	benign	T080	C0205183
28463933	862	869	pattern	T082	C0449774
28463933	875	891	clinical history	T169	C1285163
28463933	893	896	EEG	T060	C0013819
28463933	902	909	imaging	T060	C0011923
28463933	939	946	patient	T101	C0030705
28463933	952	959	B(I)RDs	T033	C0243095
28463933	964	971	matched	T080	C1708943
28463933	975	978	age	T032	C0001779
28463933	983	991	etiology	T169	C1314792
28463933	997	1010	control group	T096	C0009932
28463933	1016	1039	epileptiform discharges	T033	C0243095
28463933	1052	1059	B(I)RDs	T033	C0243095
28463933	1079	1089	identified	T080	C0205396
28463933	1090	1097	B(I)RDs	T033	C0243095
28463933	1104	1112	patients	T101	C0030705
28463933	1122	1126	EEGs	T060	C0013819
28463933	1139	1146	pattern	T082	C0449774
28463933	1194	1226	sharply contoured alpha activity	T033	C0243095
28463933	1235	1244	evolution	T169	C0205245
28463933	1250	1258	patients	T101	C0030705
28463933	1264	1271	B(I)RDs	T033	C0243095
28463933	1276	1284	epilepsy	T047	C0014544
28463933	1310	1318	controls	T096	C0009932
28463933	1324	1332	epilepsy	T047	C0014544
28463933	1345	1350	BIRDs	T033	C0243095
28463933	1375	1395	medically refractory	T169	C0205269
28463933	1446	1453	seizure	T184	C0036572
28463933	1454	1460	onsets	T079	C1299997
28463933	1480	1487	B(I)RDs	T033	C0243095
28463933	1503	1518	morphologically	T080	C0205556
28463933	1531	1544	noncritically	T080	C0205556
28463933	1545	1548	ill	T184	C0221423
28463933	1549	1557	patients	T101	C0030705
28463933	1559	1566	B(I)RDs	T033	C0243095
28463933	1571	1586	associated with	T080	C0332281
28463933	1587	1597	refractory	T169	C0205269
28463933	1598	1606	epilepsy	T047	C0014544
28463933	1617	1625	location	T082	C0450429
28463933	1649	1656	seizure	T184	C0036572
28463933	1657	1667	onset area	T033	C0243095

28288758|t|Epidemiological patterns of bovine besnoitiosis in an endemic beef cattle herd reared under extensive conditions
28288758|a|Bovine besnoitiosis is a parasitic disease caused by the protozoan Besnoitia besnoiti. Described many decades ago, recent epidemiological studies reveal its important spread within Europe in the last years. To date, many epidemiological aspects related to life cycle, routes of transmission, incidence rates and associated risk factors are lacking; hence, the establishment of appropriate disease control programmes poses an important challenge. Thus, the aim of the present study was to determine the epidemiological pattern of the disease in an endemic herd reared under extensive conditions (Spanish Pyrenees) by identifying main factors associated with infection and clinical disease dynamics. The study population consisted of 276 Brown Swiss and Pirenaica adult animals and 145 calves born and weaned at the farm during the study. Three sampling time frames were used: January 2010, September 2010 and February 2011, which allowed us to differentiate two periods designated as mountain and valley periods. The data related to animals (breed, sex and age) and herd management (animal grouping and time in housing) were recorded. The data collection methodology was mainly based on clinical examinations and defining the serological status against bovine besnoitiosis by the immunofluorescent antibody testing of blood samples. The total prevalence among adult animals was 38.34% (CI 95%: 34.53-42.07), with 18.54% of seropositive animals showing clinical signs. In regard to the cumulative incidence, 34.57% of new infections were detected during the mountain period, in contrast to the 24.59% observed in the valley period. The incidence density was 0.058 and 0.061 new infections per animal - month for the mountain and valley periods, respectively. According to the seroepidemiological study, the seroconversion probability of B. besnoiti infection was directly associated with the number of seropositive cows with whom an animal had been stabled as well as the housing period duration, supporting horizontal transmission by close contact as one of the most important methods of disease spread. In addition, the risk of developing the clinical course increased with age, and the presence of clinical signs was related to higher antibody responses. Among calves (from 3.1 to 7.1 months old) sampled once at weaning, the total seroprevalence was 15.17% (CI 95%: 9.36-21.04), and the chronic stage was observed in three animals, supporting the ability of B. besnoiti to infect and even cause disease in animals less than 6 months old. Finally, the risk of calf seroconversion was positively related to the serological status of the cows, suggesting postnatal transmission between dams and offspring by contact during the suckling period.
28288758	0	15	Epidemiological	T169	C0014508
28288758	16	24	patterns	T082	C0449774
28288758	28	34	bovine	T015	C0007452
28288758	35	47	besnoitiosis	T047	C0005146
28288758	54	61	endemic	T169	C0302891
28288758	62	73	beef cattle	T015	C0175923
28288758	74	78	herd	T054	C1690528
28288758	79	85	reared	T082	C3687023
28288758	113	119	Bovine	T015	C0007452
28288758	120	132	besnoitiosis	T047	C0005146
28288758	138	155	parasitic disease	T047	C0030499
28288758	170	179	protozoan	T204	C0033739
28288758	180	198	Besnoitia besnoiti	T204	C0320701
28288758	235	258	epidemiological studies	T062	C0002783
28288758	294	300	Europe	T083	C0015176
28288758	313	318	years	T079	C0439234
28288758	334	349	epidemiological	T169	C0014508
28288758	350	357	aspects	T080	C1879746
28288758	391	403	transmission	T046	C0242781
28288758	405	420	incidence rates	T081	C1708485
28288758	436	448	risk factors	T033	C0035648
28288758	453	460	lacking	T080	C0332268
28288758	490	517	appropriate disease control	T058	C0009449
28288758	518	528	programmes	T170	C0009457
28288758	588	593	study	T062	C2603343
28288758	615	630	epidemiological	T169	C0014508
28288758	631	638	pattern	T082	C0449774
28288758	646	653	disease	T047	C0012634
28288758	660	667	endemic	T169	C0302891
28288758	668	672	herd	T054	C1690528
28288758	673	679	reared	T082	C3687023
28288758	708	715	Spanish	T083	C0037747
28288758	716	724	Pyrenees	T083	C0442533
28288758	754	769	associated with	T080	C0332281
28288758	770	779	infection	T046	C3714514
28288758	784	800	clinical disease	T047	C0012634
28288758	801	809	dynamics	T070	C3826426
28288758	815	831	study population	T062	C0681876
28288758	849	860	Brown Swiss	T015	C0324052
28288758	865	874	Pirenaica	T015	C0007452
28288758	875	888	adult animals	T008	C0596888
28288758	897	903	calves	T015	C3668829
28288758	904	908	born	T040	C0005615
28288758	913	919	weaned	T033	C0420986
28288758	927	931	farm	T082	C0557759
28288758	943	948	study	T062	C2603343
28288758	956	964	sampling	T078	C0870078
28288758	965	976	time frames	T079	C0332168
28288758	1074	1081	periods	T079	C0010339
28288758	1096	1104	mountain	T083	C0442533
28288758	1109	1115	valley	T082	C0563004
28288758	1116	1123	periods	T079	C0010339
28288758	1129	1133	data	T078	C1511726
28288758	1145	1152	animals	T008	C0003062
28288758	1154	1159	breed	T185	C1704650
28288758	1161	1164	sex	T032	C0079399
28288758	1169	1172	age	T032	C0001779
28288758	1178	1182	herd	T054	C1690528
28288758	1183	1193	management	T057	C1273870
28288758	1195	1210	animal grouping	T096	C1642385
28288758	1215	1219	time	T079	C0040223
28288758	1223	1230	housing	T073	C0020057
28288758	1251	1266	data collection	T062	C0010995
28288758	1267	1278	methodology	T078	C3266812
28288758	1299	1320	clinical examinations	T033	C1456356
28288758	1338	1349	serological	T169	C0205473
28288758	1350	1356	status	T080	C0449438
28288758	1365	1371	bovine	T015	C0007452
28288758	1372	1384	besnoitiosis	T047	C0005146
28288758	1392	1426	immunofluorescent antibody testing	T059	C0016318
28288758	1430	1443	blood samples	T031	C0178913
28288758	1455	1465	prevalence	T081	C0033105
28288758	1472	1485	adult animals	T008	C0596888
28288758	1498	1500	CI	T081	C0009667
28288758	1535	1547	seropositive	T080	C0521143
28288758	1548	1555	animals	T008	C0003062
28288758	1597	1617	cumulative incidence	T081	C0021149
28288758	1629	1632	new	T080	C0205314
28288758	1633	1643	infections	T046	C3714514
28288758	1649	1657	detected	T033	C0442726
28288758	1669	1677	mountain	T083	C0442533
28288758	1678	1684	period	T079	C0010339
28288758	1728	1734	valley	T082	C0563004
28288758	1735	1741	period	T079	C0010339
28288758	1747	1764	incidence density	T081	C1708485
28288758	1785	1788	new	T080	C0205314
28288758	1789	1799	infections	T046	C3714514
28288758	1804	1810	animal	T008	C0003062
28288758	1813	1818	month	T079	C0439231
28288758	1827	1835	mountain	T083	C0442533
28288758	1840	1846	valley	T082	C0563004
28288758	1847	1854	periods	T079	C0010339
28288758	1887	1912	seroepidemiological study	T062	C0036744
28288758	1918	1932	seroconversion	T070	C4042908
28288758	1933	1944	probability	T081	C0033204
28288758	1948	1959	B. besnoiti	T204	C0320701
28288758	1960	1969	infection	T046	C3714514
28288758	1983	1998	associated with	T080	C0332281
28288758	2003	2009	number	T081	C0237753
28288758	2013	2025	seropositive	T080	C0521143
28288758	2026	2030	cows	T015	C0007452
28288758	2044	2050	animal	T008	C0003062
28288758	2083	2090	housing	T073	C0020057
28288758	2091	2097	period	T079	C0010339
28288758	2098	2106	duration	T079	C0449238
28288758	2119	2142	horizontal transmission	T046	C4288956
28288758	2200	2207	disease	T047	C0012634
28288758	2208	2214	spread	T080	C0332261
28288758	2233	2237	risk	T078	C0035647
28288758	2256	2271	clinical course	T079	C0449259
28288758	2272	2281	increased	T081	C0205217
28288758	2287	2290	age	T032	C0001779
28288758	2300	2308	presence	T033	C0150312
28288758	2312	2326	clinical signs	T033	C3540840
28288758	2342	2348	higher	T080	C0205250
28288758	2349	2367	antibody responses	T038	C0003261
28288758	2375	2381	calves	T015	C3668829
28288758	2399	2405	months	T079	C0439231
28288758	2406	2409	old	T079	C0580836
28288758	2427	2434	weaning	T033	C0043084
28288758	2446	2460	seroprevalence	T062	C0600367
28288758	2473	2475	CI	T081	C0009667
28288758	2502	2509	chronic	T079	C0205191
28288758	2510	2515	stage	T079	C1306673
28288758	2538	2545	animals	T008	C0003062
28288758	2573	2584	B. besnoiti	T204	C0320701
28288758	2588	2594	infect	T046	C3714514
28288758	2604	2609	cause	T169	C0015127
28288758	2610	2617	disease	T047	C0012634
28288758	2621	2628	animals	T008	C0003062
28288758	2641	2647	months	T079	C0439231
28288758	2648	2651	old	T079	C0580836
28288758	2666	2670	risk	T078	C0035647
28288758	2674	2678	calf	T015	C3668829
28288758	2679	2693	seroconversion	T070	C4042908
28288758	2724	2735	serological	T169	C0205473
28288758	2736	2742	status	T080	C0449438
28288758	2750	2754	cows	T015	C0007452
28288758	2767	2776	postnatal	T079	C0443281
28288758	2777	2789	transmission	T046	C0242781
28288758	2798	2802	dams	T015	C0007452
28288758	2807	2816	offspring	T015	C3668829
28288758	2839	2847	suckling	T015	C0003068
28288758	2848	2854	period	T079	C0010339

27514764|t|Renoprotective Effect of Plantago Major Against Nephrotoxicity and Oxidative Stress Induced by Cisplatin
27514764|a|The aim of this study was to investigate the possible renoprotective effect of Plantago major extract against cisplatin -induced nephrotoxicity in rats. Rats were divided into 6 groups. The first group was the control, group 2 was treated with cisplatin (7 mg/kg, single dose), and groups 3 to 6 received cisplatin with vitamin E (100 mg/kg) and Plantago major extract at doses of 300 mg/kg, 600 mg/kg, and 1200 mg/kg, for 20 days. On day12, serum concentration of urea, creatinine, and potassium significantly increased and sodium concentration significantly decreased in the cisplatin group compared with the control rats. However, serum creatinine, urea, and potassium concentrations were significantly lower in all of the Plantago major groups compared to the cisplatin group. Also, there was a significant elevation in serum sodium concentration in the Plantago major 600 mg/kg group compared to the cisplatin group on day12. Injection of cisplatin caused a significant elevation in malondialdehyde concentration but a significant decrease in catalase activity and total thiol content compared to the control group. Plantago major extract at 1200 mg/kg significantly improved malondialdehyde concentration and total thiol content compared to the cisplatin group. Catalase activity with Plantago major significantly increased at all doses compared to the cisplatin group. The current study suggests that Plantago major extract and vitamin E are able to improve kidney function as well as oxidative stress in cisplatin -induced renal toxicity in the rat.
27514764	0	21	Renoprotective Effect	T201	C1527144
27514764	25	39	Plantago Major	T109,T121	C3488573
27514764	48	62	Nephrotoxicity	T037	C0599918
27514764	67	83	Oxidative Stress	T049	C0242606
27514764	95	104	Cisplatin	T121,T197	C0008838
27514764	159	180	renoprotective effect	T201	C1527144
27514764	184	206	Plantago major extract	T109,T121	C3488573
27514764	215	224	cisplatin	T121,T197	C0008838
27514764	234	248	nephrotoxicity	T037	C0599918
27514764	252	256	rats	T015	C0034721
27514764	258	262	Rats	T015	C0034721
27514764	301	306	group	T078	C0441833
27514764	315	322	control	T096	C0009932
27514764	324	331	group 2	T078	C0441833
27514764	336	348	treated with	T061	C0332293
27514764	349	358	cisplatin	T121,T197	C0008838
27514764	369	375	single	T081	C0205171
27514764	376	380	dose	T081	C0870450
27514764	387	395	groups 3	T078	C0441833
27514764	401	409	received	T061	C0332293
27514764	410	419	cisplatin	T121,T197	C0008838
27514764	425	434	vitamin E	T109,T121,T127	C0042874
27514764	451	473	Plantago major extract	T109,T121	C3488573
27514764	477	482	doses	T081	C0870450
27514764	547	566	serum concentration	T081	C0683149
27514764	570	574	urea	T033	C0857448
27514764	576	586	creatinine	T033	C0700225
27514764	592	625	potassium significantly increased	T033	C0553704
27514764	630	674	sodium concentration significantly decreased	T033	C1559979
27514764	682	691	cisplatin	T121,T197	C0008838
27514764	692	697	group	T078	C0441833
27514764	716	723	control	T096	C0009932
27514764	724	728	rats	T015	C0034721
27514764	739	755	serum creatinine	T033	C0428282
27514764	757	761	urea	T033	C0236032
27514764	767	816	potassium concentrations were significantly lower	T033	C0595885
27514764	831	845	Plantago major	T109,T121	C3488573
27514764	846	852	groups	T078	C0441833
27514764	869	878	cisplatin	T121,T197	C0008838
27514764	879	884	group	T078	C0441833
27514764	916	955	elevation in serum sodium concentration	T033	C1559973
27514764	963	977	Plantago major	T109,T121	C3488573
27514764	988	993	group	T078	C0441833
27514764	1010	1019	cisplatin	T121,T197	C0008838
27514764	1020	1025	group	T078	C0441833
27514764	1036	1045	Injection	T061	C0021485
27514764	1049	1058	cisplatin	T121,T197	C0008838
27514764	1080	1089	elevation	T082	C0702240
27514764	1093	1122	malondialdehyde concentration	T059	C2322214
27514764	1141	1170	decrease in catalase activity	T033	C4022869
27514764	1175	1194	total thiol content	T059	C2367104
27514764	1211	1224	control group	T096	C0009932
27514764	1226	1248	Plantago major extract	T109,T121	C3488573
27514764	1277	1285	improved	T033	C0184511
27514764	1286	1315	malondialdehyde concentration	T059	C2322214
27514764	1320	1339	total thiol content	T059	C2367104
27514764	1356	1365	cisplatin	T121,T197	C0008838
27514764	1366	1371	group	T078	C0441833
27514764	1373	1390	Catalase activity	T044	C1151515
27514764	1396	1410	Plantago major	T109,T121	C3488573
27514764	1425	1434	increased	T081	C0205217
27514764	1442	1447	doses	T081	C0870450
27514764	1464	1473	cisplatin	T121,T197	C0008838
27514764	1474	1479	group	T078	C0441833
27514764	1513	1535	Plantago major extract	T109,T121	C3488573
27514764	1540	1549	vitamin E	T109,T121,T127	C0042874
27514764	1570	1585	kidney function	T042	C0232804
27514764	1597	1613	oxidative stress	T049	C0242606
27514764	1617	1626	cisplatin	T121,T197	C0008838
27514764	1636	1650	renal toxicity	T037	C0599918
27514764	1658	1661	rat	T015	C0034721

27888348|t|Pathogenesis of COPD and Asthma
27888348|a|Asthma and COPD remain two diseases of the respiratory tract with unmet medical needs. This review considers the current state of play with respect to what is known about the underlying pathogenesis of these two chronic inflammatory diseases of the lung. The review highlights why they are different conditions requiring different approaches to treatment and provides a backdrop for the subsequent chapters in this volume discussing recent advances in the pharmacology and treatment of asthma and COPD.
27888348	0	12	Pathogenesis	T046	C0699748
27888348	16	20	COPD	T047	C0024117
27888348	25	31	Asthma	T047	C0004096
27888348	32	38	Asthma	T047	C0004096
27888348	43	47	COPD	T047	C0024117
27888348	59	92	diseases of the respiratory tract	T047	C0035242
27888348	98	103	unmet	T052	C3274904
27888348	104	111	medical	T169	C0205476
27888348	112	117	needs	T080	C0027552
27888348	124	130	review	T170	C0282443
27888348	218	230	pathogenesis	T046	C0699748
27888348	244	273	chronic inflammatory diseases	T047	C1290886
27888348	281	285	lung	T023	C0024109
27888348	291	297	review	T170	C0282443
27888348	332	342	conditions	T080	C0348080
27888348	377	386	treatment	T061	C0087111
27888348	488	500	pharmacology	T091	C0031330
27888348	505	514	treatment	T061	C0087111
27888348	518	524	asthma	T047	C0004096
27888348	529	533	COPD	T047	C0024117

28383652|t|Th1 and Innate Lymphoid Cells accumulate in Primary Sclerosing Cholangitis - associated Inflammatory Bowel Disease
28383652|a|Primary sclerosing cholangitis (PSC) is an idiopathic chronic disorder of the hepatobiliary system associated with inflammatory bowel disease (IBD), mainly ulcerative colitis (UC). Colitis in patients with PSC and UC (PSC - UC) exhibits characteristic features and is linked to increased colon cancer risk. Genetic studies have identified immune - related susceptibility genes that only partially overlap with those involved in IBD. These observations suggest that PSC - UC may represent a distinct form of IBD. It remains to be elucidated whether different immune-mechanisms are involved in colitis in these patients. We aimed to evaluate systemic and intestinal T-cell and innate lymphoid cell (ILC) responses, previously associated to IBD, in patients with PSC - UC compared to patients with UC and healthy controls. Blood samples and colorectal biopsies were collected from patients with PSC - UC, patients with UC and healthy controls. T-cell and ILC phenotype was analysed by multicolour flow cytometry. Chemokine receptor (CCR) profiling of circulating T-cell s showed decreased CCR6-CXCR3+ Th1 cells in PSC - UC, but increased CCR6-CCR4+ Th2 cells only in UC, while increased CCR6+CCR4+ Th17 cells were found in both patient groups compared to healthy controls. Increased frequencies of IFN-γ secreting T-cells were found in the colon of patients with PSC - UC compared to UC. Interestingly, we observed accumulation of ILC in the colon in PSC - UC. Our study suggests that PSC - UC represent a different immunological disorder from UC, characterised by increased intestinal Th1 and ILC responses. These results provide further evidence that PSC - UC may represent a distinct form of IBD.
28383652	0	3	Th1	T025	C0242632
28383652	8	29	Innate Lymphoid Cells	T025	C0086574
28383652	30	40	accumulate	T169	C0205245
28383652	44	74	Primary Sclerosing Cholangitis	T047	C0566602
28383652	77	87	associated	T080	C0332281
28383652	88	114	Inflammatory Bowel Disease	T047	C0021390
28383652	115	145	Primary sclerosing cholangitis	T047	C0566602
28383652	147	150	PSC	T047	C0566602
28383652	158	185	idiopathic chronic disorder	T047	C0008679
28383652	193	213	hepatobiliary system	T022	C1711359
28383652	214	224	associated	T080	C0332281
28383652	230	256	inflammatory bowel disease	T047	C0021390
28383652	258	261	IBD	T047	C0021390
28383652	271	289	ulcerative colitis	T047	C0009324
28383652	291	293	UC	T047	C0009324
28383652	296	303	Colitis	T047	C0009324
28383652	307	315	patients	T101	C0030705
28383652	321	324	PSC	T047	C0566602
28383652	329	331	UC	T047	C0009324
28383652	333	336	PSC	T047	C0566602
28383652	339	341	UC	T047	C0009324
28383652	352	375	characteristic features	T080	C1521970
28383652	393	420	increased colon cancer risk	T033	C4295579
28383652	422	437	Genetic studies	T062	C2827447
28383652	443	453	identified	T080	C0205396
28383652	454	460	immune	T169	C0439662
28383652	463	470	related	T169	C1552599
28383652	471	485	susceptibility	T201	C0012655
28383652	486	491	genes	T028	C0017337
28383652	502	511	partially	T081	C0728938
28383652	512	519	overlap	T079	C1948020
28383652	543	546	IBD	T047	C0021390
28383652	554	566	observations	T058	C0700325
28383652	580	583	PSC	T047	C0566602
28383652	586	588	UC	T047	C0009324
28383652	622	625	IBD	T047	C0021390
28383652	663	672	different	T080	C1705242
28383652	673	690	immune-mechanisms	T033	C0243095
28383652	707	714	colitis	T047	C0009324
28383652	724	732	patients	T101	C0030705
28383652	746	754	evaluate	T058	C0220825
28383652	755	763	systemic	T169	C0205373
28383652	768	778	intestinal	T023	C0021853
28383652	779	785	T-cell	T025	C0039194
28383652	790	810	innate lymphoid cell	T025	C0086574
28383652	812	815	ILC	T025	C0086574
28383652	817	826	responses	T043	C0007613
28383652	839	849	associated	T080	C0332281
28383652	853	856	IBD	T047	C0021390
28383652	861	869	patients	T101	C0030705
28383652	875	878	PSC	T047	C0566602
28383652	881	883	UC	T047	C0009324
28383652	896	904	patients	T101	C0030705
28383652	910	912	UC	T047	C0009324
28383652	917	924	healthy	T080	C3898900
28383652	925	933	controls	T096	C0009932
28383652	935	948	Blood samples	T031	C0178913
28383652	953	963	colorectal	T082	C0555952
28383652	964	972	biopsies	T060	C0005558
28383652	978	987	collected	T078	C1516695
28383652	993	1001	patients	T101	C0030705
28383652	1007	1010	PSC	T047	C0566602
28383652	1013	1015	UC	T047	C0009324
28383652	1017	1025	patients	T101	C0030705
28383652	1031	1033	UC	T047	C0009324
28383652	1038	1045	healthy	T080	C3898900
28383652	1046	1054	controls	T096	C0009932
28383652	1056	1062	T-cell	T025	C0039194
28383652	1067	1070	ILC	T025	C0086574
28383652	1071	1080	phenotype	T032	C0031437
28383652	1085	1093	analysed	T062	C0936012
28383652	1097	1123	multicolour flow cytometry	T059	C0016263
28383652	1125	1143	Chemokine receptor	T116,T129,T192	C0524914
28383652	1145	1148	CCR	T116,T129,T192	C0524914
28383652	1150	1159	profiling	T059	C0444680
28383652	1163	1174	circulating	T169	C0175630
28383652	1175	1181	T-cell	T025	C0039194
28383652	1191	1200	decreased	T081	C0205216
28383652	1201	1222	CCR6-CXCR3+ Th1 cells	T025	C0242632
28383652	1226	1229	PSC	T047	C0566602
28383652	1232	1234	UC	T047	C0009324
28383652	1240	1249	increased	T081	C0205217
28383652	1250	1270	CCR6-CCR4+ Th2 cells	T025	C0242633
28383652	1279	1281	UC	T047	C0009324
28383652	1289	1298	increased	T081	C0205217
28383652	1299	1320	CCR6+CCR4+ Th17 cells	T025	C2936411
28383652	1340	1347	patient	T101	C0030705
28383652	1348	1354	groups	T078	C0441833
28383652	1367	1374	healthy	T080	C3898900
28383652	1375	1383	controls	T096	C0009932
28383652	1385	1394	Increased	T081	C0205217
28383652	1395	1406	frequencies	T079	C0439603
28383652	1410	1415	IFN-γ	T116,T121,T129	C0021745
28383652	1416	1425	secreting	T043	C1327616
28383652	1426	1433	T-cells	T025	C0039194
28383652	1452	1457	colon	T023	C0009368
28383652	1461	1469	patients	T101	C0030705
28383652	1475	1478	PSC	T047	C0566602
28383652	1481	1483	UC	T047	C0009324
28383652	1496	1498	UC	T047	C0009324
28383652	1527	1539	accumulation	T033	C4055506
28383652	1543	1546	ILC	T025	C0086574
28383652	1554	1559	colon	T023	C0009368
28383652	1563	1566	PSC	T047	C0566602
28383652	1569	1571	UC	T047	C0009324
28383652	1577	1582	study	T062	C2603343
28383652	1597	1600	PSC	T047	C0566602
28383652	1603	1605	UC	T047	C0009324
28383652	1618	1627	different	T080	C1705242
28383652	1628	1650	immunological disorder	T047	C0021053
28383652	1656	1658	UC	T047	C0009324
28383652	1677	1686	increased	T081	C0205217
28383652	1687	1697	intestinal	T023	C0021853
28383652	1698	1701	Th1	T025	C0242632
28383652	1706	1709	ILC	T025	C0086574
28383652	1710	1719	responses	T043	C0007613
28383652	1751	1759	evidence	T078	C3887511
28383652	1765	1768	PSC	T047	C0566602
28383652	1771	1773	UC	T047	C0009324
28383652	1807	1810	IBD	T047	C0021390

28477843|t|Development and validation of an easy-to-use risk assessment tool for cumulative low back loading: The Lifting Fatigue Failure Tool (LiFFT)
28477843|a|Recent evidence suggests that musculoskeletal disorders (MSDs) may be the result of a fatigue failure process in affected tissues. This paper describes a new low back exposure assessment tool (the Lifting Fatigue Failure Tool [LiFFT]), which estimates a " daily dose " of cumulative loading on the low back using fatigue failure principles. Only three variables are necessary to derive the cumulative load associated with a lifting task: the weight of the load, the maximum horizontal distance from the spine to the load, and the number of repetitions for tasks performed during the workday. The new tool was validated using two existing epidemiological databases: the Lumbar Motion Monitor (LMM) database, and a database from a U.S. automotive manufacturer. The LiFFT cumulative damage metric explained 92% of the deviance in low back disorders (LBDs) in the LMM database and 72-95% of the deviance in low back outcomes in the automotive database (depending on the outcome measure). Thus, LiFFT is practitioner friendly and its cumulative damage metric highly related to low back outcomes.
28477843	0	11	Development	T169	C1527148
28477843	16	26	validation	T062	C1519941
28477843	45	65	risk assessment tool	T058	C0086930
28477843	81	89	low back	T023	C0230102
28477843	90	97	loading	T032	C1318107
28477843	103	131	Lifting Fatigue Failure Tool	T122	C0005479
28477843	133	138	LiFFT	T122	C0005479
28477843	170	195	musculoskeletal disorders	T047	C0026857
28477843	197	201	MSDs	T047	C0026857
28477843	226	233	fatigue	T184	C0015672
28477843	234	249	failure process	T169	C0231174
28477843	253	261	affected	T169	C0392760
28477843	262	269	tissues	T024	C0040300
28477843	298	315	low back exposure	T032	C1318107
28477843	316	331	assessment tool	T122	C0005479
28477843	337	365	Lifting Fatigue Failure Tool	T122	C0005479
28477843	367	372	LiFFT	T122	C0005479
28477843	396	406	daily dose	T081	C2348070
28477843	412	422	cumulative	T080	C1511559
28477843	423	430	loading	T032	C1318107
28477843	438	446	low back	T023	C0230102
28477843	453	460	fatigue	T184	C0015672
28477843	461	468	failure	T169	C0231174
28477843	469	479	principles	T078	C0178566
28477843	492	501	variables	T080	C0439828
28477843	530	540	cumulative	T080	C1511559
28477843	541	545	load	T032	C1318107
28477843	546	561	associated with	T080	C0332281
28477843	564	571	lifting	T052	C0206244
28477843	572	576	task	T057	C3540678
28477843	582	600	weight of the load	T081	C0043100
28477843	614	633	horizontal distance	T081	C0012751
28477843	643	648	spine	T023	C0037949
28477843	649	660	to the load	T032	C1318107
28477843	680	691	repetitions	T169	C0205341
28477843	696	711	tasks performed	T061	C0039333
28477843	723	730	workday	T079	C0680192
28477843	736	744	new tool	T122	C0005479
28477843	749	758	validated	T062	C1519941
28477843	778	793	epidemiological	T169	C1516907
28477843	794	803	databases	T170	C0242356
28477843	809	822	Lumbar Motion	T033	C0575375
28477843	809	830	Lumbar Motion Monitor	T033	C0575375
28477843	832	835	LMM	T033	C0575375
28477843	837	845	database	T170	C0242356
28477843	853	861	database	T170	C0242356
28477843	869	872	U.S	T083	C0041703
28477843	874	897	automotive manufacturer	T090	C3641679
28477843	903	908	LiFFT	T122	C0005479
28477843	909	933	cumulative damage metric	T058	C0558029
28477843	967	985	low back disorders	T184	C0024031
28477843	987	991	LBDs	T184	C0024031
28477843	1000	1012	LMM database	UnknownType	C0677336
28477843	1043	1060	low back outcomes	T080	C0085415
28477843	1068	1087	automotive database	T073	C0589476
28477843	1106	1121	outcome measure	T081	C0086749
28477843	1130	1135	LiFFT	T122	C0005479
28477843	1139	1160	practitioner friendly	T080	C0205556
28477843	1169	1179	cumulative	T080	C1511559
28477843	1180	1193	damage metric	T058	C0558029
28477843	1212	1229	low back outcomes	T080	C0085415

27481342|t|Analgesic and anti-inflammatory actions on bradykinin route of a polysulfated fraction from alga Ulva lactuca
27481342|a|We investigated structural features of polysaccharides from Ulva lactuca and their effects on the classical models of nociception and inflammation. Crude extract was obtained by enzymatic digestion and isolated by ion exchange chromatography on DEAE-cellulose. The fraction with higher yield was used in the tests (SP-Ul). Swiss mice received SP-Ul (1, 3 or 9mg/kg; i.v.), 30min prior to injection of 0.8%- acetic acid or 1%- formalin or prior to a thermal stimulus. At same doses, SP-Ul was tested on Wistar rats on paw edema elicited by different irritants (carrageenan, dextran, bradykinin, histamine or serotonin). The results of infrared characterization indicated the presence of hydroxyl groups, sulfate, uronic acid and glycosidic linkages in all SP fractions spectrums. SP-Ul decreased significantly the antinociception in response to acetic acid or formalin (second phase), but not in the hot-plate test, suggesting that its analgesia occurs through a peripheral mechanism. SP-Ul did not reduce carrageenan - induced paw edema as supported by both histological and myeloperoxidase activity assessments. However, SP-Ul (1mg/kg; s.c.) reduced dextran -elicited edema, showing vascular anti-inflammatory effect, with bradykinin as major target because it did not reduce histamine - and serotonin - induced paw edemas. Therefore, SP-Ul acts on bradykinin pathway in its antinociceptive and anti-inflammatory responses.
27481342	0	9	Analgesic	T033	C0948482
27481342	14	39	anti-inflammatory actions	T080	C1515999
27481342	43	53	bradykinin	T116,T125	C0006100
27481342	65	86	polysulfated fraction	T109,T121	C2349012
27481342	92	96	alga	T204	C0002028
27481342	97	109	Ulva lactuca	T002	C1024150
27481342	113	125	investigated	T169	C1292732
27481342	126	136	structural	T082	C0678594
27481342	137	145	features	T080	C2348519
27481342	149	164	polysaccharides	T109,T121	C0032594
27481342	170	182	Ulva lactuca	T002	C1024150
27481342	208	224	classical models	T075	C0026339
27481342	228	239	nociception	T042	C0234194
27481342	244	256	inflammation	T046	C0021368
27481342	258	271	Crude extract	T167	C2828366
27481342	288	307	enzymatic digestion	T059	C0519157
27481342	312	320	isolated	T169	C0205409
27481342	324	351	ion exchange chromatography	T059	C0008564
27481342	355	369	DEAE-cellulose	T109,T122	C0011050
27481342	375	383	fraction	T121	C1254351
27481342	396	401	yield	T081	C0392762
27481342	418	423	tests	T059	C0022885
27481342	425	430	SP-Ul	T109,T121	C0032594
27481342	433	443	Swiss mice	T015	C0162416
27481342	453	458	SP-Ul	T109,T121	C0032594
27481342	498	507	injection	T169	C1828121
27481342	517	528	acetic acid	T109,T121,T130	C0000983
27481342	536	544	formalin	T109,T121,T131	C0949307
27481342	559	575	thermal stimulus	T038	C1621333
27481342	585	590	doses	T081	C0178602
27481342	592	597	SP-Ul	T109,T121	C0032594
27481342	602	608	tested	T169	C0039593
27481342	612	623	Wistar rats	T015	C0034716
27481342	627	630	paw	T023	C0687080
27481342	631	636	edema	T184	C0013604
27481342	659	668	irritants	T131	C0022108
27481342	670	681	carrageenan	T109,T121,T123	C0007289
27481342	683	690	dextran	T109,T121	C0086140
27481342	692	702	bradykinin	T116,T125	C0006100
27481342	704	713	histamine	T109,T123	C0019588
27481342	717	726	serotonin	T109,T123	C0036751
27481342	733	740	results	T033	C0683954
27481342	744	752	infrared	T080	C1532326
27481342	753	769	characterization	T052	C1880022
27481342	796	811	hydroxyl groups	T197	C0700307
27481342	813	820	sulfate	T197	C0038720
27481342	822	833	uronic acid	T109	C0042081
27481342	838	857	glycosidic linkages	T070	C0596391
27481342	865	877	SP fractions	T109,T121	C0032594
27481342	878	887	spectrums	T077	C2827424
27481342	889	894	SP-Ul	T109,T121	C0032594
27481342	895	904	decreased	T081	C0205216
27481342	905	918	significantly	T078	C0750502
27481342	923	938	antinociception	T042	C1254358
27481342	942	950	response	T032	C0871261
27481342	954	965	acetic acid	T109,T121,T130	C0000983
27481342	969	977	formalin	T109,T121,T131	C0949307
27481342	1009	1023	hot-plate test	T059	C0022885
27481342	1045	1054	analgesia	T061	C3202977
27481342	1055	1061	occurs	T052	C1709305
27481342	1072	1092	peripheral mechanism	T169	C0441712
27481342	1094	1099	SP-Ul	T109,T121	C0032594
27481342	1108	1114	reduce	T081	C0547047
27481342	1115	1126	carrageenan	T109,T121,T123	C0007289
27481342	1129	1136	induced	T169	C0205263
27481342	1137	1140	paw	T023	C0687080
27481342	1141	1146	edema	T184	C0013604
27481342	1168	1180	histological	T044	C1148560
27481342	1185	1209	myeloperoxidase activity	T044	C1151518
27481342	1210	1221	assessments	T058	C1261322
27481342	1232	1237	SP-Ul	T109,T121	C0032594
27481342	1253	1260	reduced	T080	C0392756
27481342	1261	1268	dextran	T109,T121	C0086140
27481342	1279	1284	edema	T184	C0013604
27481342	1294	1302	vascular	T023	C0005847
27481342	1303	1327	anti-inflammatory effect	T080	C1515999
27481342	1334	1344	bradykinin	T116,T125	C0006100
27481342	1354	1360	target	T169	C1521840
27481342	1380	1386	reduce	T081	C0547047
27481342	1387	1396	histamine	T109,T123	C0019588
27481342	1403	1412	serotonin	T109,T123	C0036751
27481342	1415	1422	induced	T169	C0205263
27481342	1423	1426	paw	T023	C0687080
27481342	1427	1433	edemas	T184	C0013604
27481342	1446	1451	SP-Ul	T109,T121	C0032594
27481342	1460	1470	bradykinin	T116,T125	C0006100
27481342	1471	1478	pathway	T044	C1704259
27481342	1486	1501	antinociceptive	T042	C1254358
27481342	1506	1533	anti-inflammatory responses	T080	C1515999

27817780|t|Identification of gene mutation and prenatal diagnosis in a family with X-linked ichthyosis
27817780|a|X-linked ichthyosis (XLI) is a metabolic disease with steroid sulfatase deficiency and often occurs at birth or shortly after birth. The encoding gene of steroid sulfatase, STS, is located on the short arm of the X chromosome, and STS deletion or mutation can lead to the development of this disease. This study collected the data on the clinical phenotype from a family, and the proband, a boy aged 11 years with full-term vaginal delivery, had dry and rough skin and black-brown scaly patches, mainly in the abdomen and extensor aspect of extremities. Peripheral blood samples were collected from each family member and DNA was extracted. Multiplex ligation-dependent probe amplification (MLPA) was used to measure the copy number of STS on the X chromosome. Whole-genome microarray was used to determine the size of the segment with microdeletion in the X chromosome. MLPA was then used for prenatal diagnosis for the mother of the proband. The results revealed that the proband and another two male patients had hemizygotes in STS deletion. Gene microarray identified a rare deletion with a size of 1.6 Mb at Xp22.31 (chrX: 6,516,735-8,131,442). Two female family members were found to be carriers. Prenatal diagnosis showed that the fetus carried by the proband's mother was a carrier of this microdeletion. This study showed STS gene deletion in this family of XLI, which causes the unique skin lesions of XLI. MLPA is a convenient and reliable technique for the molecular and prenatal diagnosis of XLI.
27817780	0	14	Identification	T080	C0205396
27817780	18	31	gene mutation	T045	C0596611
27817780	36	54	prenatal diagnosis	T060	C0033053
27817780	72	91	X-linked ichthyosis	T047	C0079588
27817780	92	111	X-linked ichthyosis	T047	C0079588
27817780	113	116	XLI	T047	C0079588
27817780	123	140	metabolic disease	T047	C0025517
27817780	146	163	steroid sulfatase	T116,T126	C0052456
27817780	164	174	deficiency	T169	C0011155
27817780	195	200	birth	T040	C0005615
27817780	212	223	after birth	T018	C0392917
27817780	229	237	encoding	T052	C2700640
27817780	238	242	gene	T028	C0017337
27817780	246	263	steroid sulfatase	T116,T126	C0052456
27817780	265	268	STS	T028	C1420490
27817780	273	280	located	T082	C0332285
27817780	288	317	short arm of the X chromosome	T086	C1520168
27817780	323	326	STS	T028	C1420490
27817780	327	335	deletion	T045	C0017260
27817780	339	347	mutation	T045	C0596611
27817780	364	375	development	T169	C1527148
27817780	384	391	disease	T047	C0012634
27817780	398	403	study	T062	C0008972
27817780	404	413	collected	T169	C1516698
27817780	418	422	data	T078	C1511726
27817780	430	438	clinical	T080	C0205210
27817780	439	448	phenotype	T032	C0031437
27817780	456	462	family	T099	C0015576
27817780	472	479	proband	T099	C1948021
27817780	483	486	boy	T100	C0870221
27817780	487	491	aged	T032	C0001779
27817780	495	500	years	T079	C1510829
27817780	506	532	full-term vaginal delivery	T033	C1384485
27817780	538	556	dry and rough skin	T033	C3277145
27817780	561	586	black-brown scaly patches	T033	C0243095
27817780	602	609	abdomen	T029	C0000726
27817780	614	622	extensor	T029	C1184148
27817780	633	644	extremities	T023	C0015385
27817780	646	656	Peripheral	T082	C0205100
27817780	657	670	blood samples	T031	C0178913
27817780	676	685	collected	T169	C1516698
27817780	696	709	family member	T099	C0086282
27817780	714	717	DNA	T114,T123	C0012854
27817780	733	781	Multiplex ligation-dependent probe amplification	T063	C3494189
27817780	783	787	MLPA	T063	C3494189
27817780	801	808	measure	T081	C0079809
27817780	813	824	copy number	T081	C1707513
27817780	828	831	STS	T028	C1420490
27817780	839	851	X chromosome	T026	C0043292
27817780	853	876	Whole-genome microarray	T059	C1449575
27817780	903	907	size	T082	C0456389
27817780	928	941	microdeletion	T034	C3532201
27817780	949	961	X chromosome	T026	C0043292
27817780	963	967	MLPA	T063	C3494189
27817780	986	1004	prenatal diagnosis	T060	C0033053
27817780	1013	1019	mother	T099	C0026591
27817780	1027	1034	proband	T099	C1948021
27817780	1040	1047	results	T033	C0683954
27817780	1066	1073	proband	T099	C1948021
27817780	1090	1094	male	T098	C0025266
27817780	1095	1103	patients	T101	C0030705
27817780	1108	1119	hemizygotes	T032	C0314649
27817780	1123	1126	STS	T028	C1420490
27817780	1127	1135	deletion	T045	C0017260
27817780	1137	1152	Gene microarray	T063	C1522053
27817780	1153	1163	identified	T080	C0205396
27817780	1171	1179	deletion	T045	C0017260
27817780	1187	1191	size	T082	C0456389
27817780	1205	1212	Xp22.31	T026	C1520175
27817780	1246	1252	female	T098	C0043210
27817780	1253	1267	family members	T099	C0086282
27817780	1285	1293	carriers	T033	C0560175
27817780	1295	1313	Prenatal diagnosis	T060	C0033053
27817780	1330	1335	fetus	T018	C0015965
27817780	1351	1360	proband's	T099	C1948021
27817780	1361	1367	mother	T099	C0026591
27817780	1374	1381	carrier	T033	C0560175
27817780	1390	1403	microdeletion	T047	C1954751
27817780	1410	1415	study	T062	C0008972
27817780	1423	1426	STS	T028	C1420490
27817780	1427	1440	gene deletion	T045	C0017260
27817780	1459	1462	XLI	T047	C0079588
27817780	1481	1487	unique	T080	C1710548
27817780	1488	1500	skin lesions	T047	C0037284
27817780	1504	1507	XLI	T047	C0079588
27817780	1509	1513	MLPA	T063	C3494189
27817780	1519	1529	convenient	T080	C3831015
27817780	1534	1542	reliable	T080	C0205556
27817780	1543	1552	technique	T063	C1513384
27817780	1561	1570	molecular	T080	C1521991
27817780	1575	1593	prenatal diagnosis	T060	C0033053
27817780	1597	1600	XLI	T047	C0079588

28115057|t|Optogenetic Demonstration of Functional Innervation of Mouse Colon by Neurons Derived From Transplanted Neural Cells
28115057|a|Cell therapy offers the potential to treat gastrointestinal motility disorders caused by diseased or absent enteric neurons. We examined whether neurons generated from transplanted enteric neural cells provide a functional innervation of bowel smooth muscle in mice. Enteric neural cells expressing the light-sensitive ion channel, channelrhodopsin, were isolated from the fetal or postnatal mouse bowel and transplanted into the distal colon of 3- to 4- week -old wild-type recipient mice. Intracellular electrophysiological recordings of responses to light stimulation of the transplanted cells were made from colonic smooth muscle cells in recipient mice. Electrical stimulation of endogenous enteric neurons was used as a control. The axons of graft -derived neurons formed a plexus in the circular muscle layer. Selective stimulation of graft -derived cells by light resulted in excitatory and inhibitory junction potentials, the electrical events underlying contraction and relaxation, respectively, in colonic muscle cells. Graft -derived excitatory and inhibitory motor neurons released the same neurotransmitters as endogenous motor neurons - acetylcholine and a combination of adenosine triphosphate and nitric oxide, respectively. Graft -derived neurons also included interneurons that provided synaptic inputs to motor neurons, but the pharmacologic properties of interneurons varied with the age of the donors from which enteric neural cells were obtained. Enteric neural cells transplanted into the bowel give rise to multiple functional types of neurons that integrate and provide a functional innervation of the smooth muscle of the bowel wall. Circuits composed of both motor neurons and interneurons were established, but the age at which cells are isolated influences the neurotransmitter phenotype of interneurons that are generated.
28115057	0	11	Optogenetic	T063	C3494301
28115057	12	25	Demonstration	T052	C0441655
28115057	29	39	Functional	T169	C0205245
28115057	40	51	Innervation	T042	C0021516
28115057	55	60	Mouse	T015	C0025929
28115057	61	66	Colon	T023	C0009368
28115057	70	77	Neurons	T025	C0027882
28115057	91	103	Transplanted	T169	C0700106
28115057	104	116	Neural Cells	T025	C0027882
28115057	117	129	Cell therapy	T061	C0302189
28115057	154	159	treat	T169	C1522326
28115057	160	195	gastrointestinal motility disorders	T047	C0854121
28115057	206	214	diseased	T025	C0027882
28115057	218	224	absent	T169	C0332197
28115057	225	232	enteric	T082	C1304890
28115057	233	240	neurons	T025	C0027882
28115057	262	269	neurons	T025	C0027882
28115057	285	297	transplanted	T169	C0700106
28115057	298	305	enteric	T082	C1304890
28115057	306	318	neural cells	T025	C0027882
28115057	329	339	functional	T169	C0205245
28115057	340	351	innervation	T042	C0021516
28115057	355	360	bowel	T023	C0021853
28115057	361	374	smooth muscle	T024	C1267092
28115057	378	382	mice	T015	C0025929
28115057	384	391	Enteric	T082	C1304890
28115057	392	404	neural cells	T025	C0027882
28115057	420	447	light-sensitive ion channel	T116,T123	C0022009
28115057	449	465	channelrhodopsin	T116,T123	C0033684
28115057	472	480	isolated	T169	C0205409
28115057	490	495	fetal	T169	C0521457
28115057	499	508	postnatal	T079	C0443281
28115057	509	514	mouse	T015	C0025929
28115057	515	520	bowel	T023	C0021853
28115057	525	537	transplanted	T169	C0700106
28115057	547	559	distal colon	T024	C1517729
28115057	572	576	week	T079	C0439230
28115057	582	591	wild-type	T028	C1883559
28115057	592	606	recipient mice	T015	C0025929
28115057	608	621	Intracellular	T082	C0178719
28115057	622	653	electrophysiological recordings	T059	C0022885
28115057	657	666	responses	T169	C0205245
28115057	670	687	light stimulation	UnknownType	C0240188
28115057	695	707	transplanted	T169	C0700106
28115057	708	713	cells	T025	C0027882
28115057	729	736	colonic	T023	C0009368
28115057	737	756	smooth muscle cells	T025	C1135918
28115057	760	774	recipient mice	T015	C0025929
28115057	776	798	Electrical stimulation	T067	C1254366
28115057	802	812	endogenous	T169	C0205227
28115057	813	820	enteric	T082	C1304890
28115057	821	828	neurons	T025	C0027882
28115057	843	850	control	T096	C0009932
28115057	856	861	axons	T026	C0004461
28115057	865	870	graft	T024	C0332835
28115057	880	887	neurons	T025	C0027882
28115057	897	903	plexus	T023	C1184808
28115057	911	932	circular muscle layer	T023	C0734812
28115057	934	955	Selective stimulation	T067	C1254366
28115057	959	964	graft	T024	C0332835
28115057	974	979	cells	T025	C0027882
28115057	983	988	light	T070	C0023693
28115057	1001	1011	excitatory	T042	C0234121
28115057	1016	1046	inhibitory junction potentials	T042	C0234122
28115057	1052	1062	electrical	T169	C0442828
28115057	1063	1069	events	T051	C0441471
28115057	1081	1092	contraction	T039	C0026820
28115057	1097	1107	relaxation	T042	C0026836
28115057	1126	1133	colonic	T023	C0009368
28115057	1134	1146	muscle cells	T025	C1135918
28115057	1148	1153	Graft	T024	C0332835
28115057	1163	1173	excitatory	T025	C0026609
28115057	1178	1202	inhibitory motor neurons	T025	C0026609
28115057	1221	1238	neurotransmitters	T123	C0027908
28115057	1242	1252	endogenous	T169	C0205227
28115057	1253	1266	motor neurons	T025	C0026609
28115057	1269	1282	acetylcholine	T109,T121,T123	C0001041
28115057	1304	1326	adenosine triphosphate	T114,T121,T123	C0001480
28115057	1331	1343	nitric oxide	T121,T123,T197	C0028128
28115057	1359	1364	Graft	T024	C0332835
28115057	1374	1381	neurons	T025	C0027882
28115057	1396	1408	interneurons	T025	C0021792
28115057	1448	1455	neurons	T025	C0027882
28115057	1465	1489	pharmacologic properties	T080	C0871161
28115057	1493	1505	interneurons	T025	C0021792
28115057	1522	1525	age	T032	C0001779
28115057	1533	1539	donors	T098	C0013018
28115057	1551	1558	enteric	T082	C1304890
28115057	1559	1571	neural cells	T025	C0027882
28115057	1587	1594	Enteric	T082	C1304890
28115057	1595	1607	neural cells	T025	C0027882
28115057	1608	1620	transplanted	T169	C0700106
28115057	1630	1635	bowel	T023	C0021853
28115057	1649	1657	multiple	T081	C0439064
28115057	1658	1668	functional	T169	C0205245
28115057	1669	1674	types	T080	C0332307
28115057	1678	1685	neurons	T025	C0027882
28115057	1715	1725	functional	T169	C0205245
28115057	1726	1737	innervation	T042	C0021516
28115057	1745	1758	smooth muscle	T024	C1267092
28115057	1766	1776	bowel wall	T023	C1283694
28115057	1778	1786	Circuits	UnknownType	C0814033
28115057	1804	1817	motor neurons	T025	C0026609
28115057	1822	1834	interneurons	T025	C0021792
28115057	1861	1864	age	T032	C0001779
28115057	1874	1879	cells	T025	C0027882
28115057	1908	1924	neurotransmitter	T123	C0027908
28115057	1925	1934	phenotype	T032	C0031437
28115057	1938	1950	interneurons	T025	C0021792

27352133|t|The phonetic landscape in infant consonant perception is an uneven terrain
27352133|a|Previous research revealing universal biases in infant vowel perception forms the basis of the Natural Referent Vowel (NRV) framework (Polka & Bohn, 2011). To explore the feasibility of extending this framework to consonant manner perception, we investigated perception of the stop vs. fricative consonant contrast /b/-/v/ to test the hypothesis that young infants will display a perceptual bias grounded in the acoustic - phonetic properties of these sounds. We examined perception of stop-initial /bas/ and fricative-initial /vas/ syllables in English - learning and French - learning 5- to 6-month-olds. The /b/ and /v/ sounds distinguish words in English and French but have different distributional patterns; in spoken English /b/ occurs more frequently than /v/ whereas in spoken French /v/ occurs more frequently than /b/. A perceptual bias favoring /b/ over /v/ emerged in two experiments. In Experiment 1, a directional asymmetry was observed in discrimination; infants noticed when /vas/ changed to /bas/ but not when /bas/ changed to /vas/. In Experiment 2, a robust listening preference favoring stop-initial /bas/ was evident in responses from the same infants. This is the first study to show a perceptual bias related to consonant manner and to directly measure a consonant perception bias within the same infants. These data encourage further efforts to extend the NRV principles to perception of consonant manner. These findings indicate that we need to reform our view of infant speech perception to accommodate the fact that both discrimination abilities and biases shape speech perception during infancy.
27352133	4	12	phonetic	T170	C0871073
27352133	26	32	infant	T100	C0021270
27352133	33	42	consonant	T170	C0871699
27352133	43	53	perception	T041	C0030971
27352133	60	74	uneven terrain	T083	C0017446
27352133	84	92	research	T062	C0035168
27352133	113	119	biases	T078	C0242568
27352133	123	129	infant	T100	C0021270
27352133	130	135	vowel	T170	C0871955
27352133	136	146	perception	T041	C0030971
27352133	170	208	Natural Referent Vowel (NRV) framework	T170	C0282574
27352133	246	257	feasibility	T062,T170	C0015730
27352133	276	285	framework	T170	C0282574
27352133	289	298	consonant	T170	C0871699
27352133	306	316	perception	T041	C0030971
27352133	334	344	perception	T041	C0030971
27352133	352	356	stop	T170	C0871699
27352133	361	380	fricative consonant	T170	C0871699
27352133	410	420	hypothesis	T078	C1512571
27352133	426	431	young	T079	C0332239
27352133	432	439	infants	T100	C0021270
27352133	455	465	perceptual	T041	C0030971
27352133	466	470	bias	T078	C0242568
27352133	487	495	acoustic	T070	C0001166
27352133	498	506	phonetic	T170	C0871073
27352133	527	533	sounds	T070	C0037709
27352133	547	557	perception	T041	C0030971
27352133	608	617	syllables	T170	C0871464
27352133	621	628	English	T171	C0376245
27352133	631	639	learning	T041	C0023185
27352133	644	650	French	T171	C0376246
27352133	653	661	learning	T041	C0023185
27352133	698	704	sounds	T070	C0037709
27352133	717	722	words	T171	C0237957
27352133	726	733	English	T171	C0376245
27352133	738	744	French	T171	C0376246
27352133	792	798	spoken	T056	C0234856
27352133	799	806	English	T171	C0376245
27352133	854	860	spoken	T056	C0234856
27352133	861	867	French	T171	C0376246
27352133	907	917	perceptual	T041	C0030971
27352133	918	922	bias	T078	C0242568
27352133	960	971	experiments	T062	C0681814
27352133	976	988	Experiment 1	T062	C0681814
27352133	992	1013	directional asymmetry	T082	C0332514
27352133	1030	1044	discrimination	T041	C0012632
27352133	1046	1053	infants	T100	C0021270
27352133	1130	1142	Experiment 2	T062	C0681814
27352133	1153	1162	listening	T041	C2584303
27352133	1217	1226	responses	T032	C0871261
27352133	1241	1248	infants	T100	C0021270
27352133	1268	1273	study	T062	C2603343
27352133	1284	1294	perceptual	T041	C0030971
27352133	1295	1299	bias	T078	C0242568
27352133	1311	1320	consonant	T170	C0871699
27352133	1354	1363	consonant	T170	C0871699
27352133	1364	1374	perception	T041	C0030971
27352133	1375	1379	bias	T078	C0242568
27352133	1396	1403	infants	T100	C0021270
27352133	1411	1415	data	T078	C1511726
27352133	1456	1459	NRV	T170	C0282574
27352133	1474	1484	perception	T041	C0030971
27352133	1488	1497	consonant	T170	C0871699
27352133	1565	1571	infant	T100	C0021270
27352133	1572	1578	speech	T040	C0037817
27352133	1579	1589	perception	T041	C0030971
27352133	1624	1638	discrimination	T041	C0012632
27352133	1653	1659	biases	T078	C0242568
27352133	1666	1672	speech	T040	C0037817
27352133	1673	1683	perception	T041	C0030971
27352133	1691	1698	infancy	T079	C0231330

27634004|t|Young Children See a Single Action and Infer a Social Norm
27634004|a|Human social life depends heavily on social norms that prescribe and proscribe specific actions. Typically, young children learn social norms from adult instruction. In the work reported here, we showed that this is not the whole story: Three- year-old children are promiscuous normativists. In other words, they spontaneously inferred the presence of social norms even when an adult had done nothing to indicate such a norm in either language or behavior. And children of this age even went so far as to enforce these self-inferred norms when third parties "broke" them. These results suggest that children do not just passively acquire social norms from adult behavior and instruction; rather, they have a natural and proactive tendency to go from "is" to "ought." That is, children go from observed actions to prescribed actions and do not perceive them simply as guidelines for their own behavior but rather as objective normative rules applying to everyone equally.
27634004	0	5	Young	T079	C0332239
27634004	6	14	Children	T100	C0008059
27634004	21	27	Single	T081	C0205171
27634004	28	34	Action	T052	C3266814
27634004	39	44	Infer	T041	C0679201
27634004	47	58	Social Norm	T078	C0237750
27634004	59	64	Human	T016	C0086418
27634004	65	76	social life	T054	C0815198
27634004	96	108	social norms	T078	C0237750
27634004	147	154	actions	T052	C3266814
27634004	167	172	young	T079	C0332239
27634004	173	181	children	T100	C0008059
27634004	188	200	social norms	T078	C0237750
27634004	206	211	adult	T100	C0001675
27634004	212	223	instruction	T170	C1442085
27634004	303	311	year-old	T079	C1510829
27634004	312	320	children	T100	C0008059
27634004	325	336	promiscuous	T054	C0562558
27634004	337	349	normativists	T098	C1257890
27634004	372	385	spontaneously	T169	C0205359
27634004	386	394	inferred	T041	C0679201
27634004	411	423	social norms	T078	C0237750
27634004	437	442	adult	T100	C0001675
27634004	479	483	norm	T078	C0237750
27634004	494	502	language	T171	C0023008
27634004	506	514	behavior	T053	C0004927
27634004	520	528	children	T100	C0008059
27634004	537	540	age	T032	C0001779
27634004	578	591	self-inferred	T041	C0679201
27634004	592	597	norms	T078	C0237750
27634004	658	666	children	T100	C0008059
27634004	679	688	passively	T080	C3686820
27634004	689	696	acquire	T052	C1706701
27634004	697	709	social norms	T078	C0237750
27634004	715	720	adult	T100	C0001675
27634004	721	729	behavior	T053	C0004927
27634004	734	745	instruction	T170	C1442085
27634004	767	774	natural	T053	C0004927
27634004	779	797	proactive tendency	T053	C0004927
27634004	835	843	children	T100	C0008059
27634004	852	860	observed	T169	C1441672
27634004	861	868	actions	T052	C3266814
27634004	872	882	prescribed	T169	C0205245
27634004	883	890	actions	T052	C3266814
27634004	926	936	guidelines	T170	C0162791
27634004	951	959	behavior	T053	C0004927
27634004	974	983	objective	T080	C1571702
27634004	984	999	normative rules	T170	C0870077

28338634|t|Construction of an Acetylcholinesterase Sensor Based on Synthesized Paramagnetic Nanoparticles, a Simple Tool for Neurotoxic Compounds Assay
28338634|a|Magnetic particles (MPs) have been widely used in biological applications in recent years as a carrier for various molecules. Their big advantage is in repeated use of immobilized molecules including enzymes. Acetylcholinesterase (AChE) is an enzyme playing crucial role in neurotransmission and the enzyme is targeted by various molecules like Alzheimer's drugs, pesticides and warfare agents. In this work, an electrochemical biosensor having AChE immobilized onto MPs and stabilized through glutaraldehyde (GA) molecule was proposed for assay of the neurotoxic compounds. The prepared nanoparticles were modified by pure AChE and they were used for the measurement anti-Alzheimer's drug galantamine and carbamate pesticide carbofuran with limit of detection 1.5 µM and 20 nM, respectively. All measurements were carried out using screen-printed sensor with carbon working, silver reference, and carbon auxiliary electrode. Standard Ellman's assay was used for validation measurement of both inhibitors. Part of this work was the elimination of reversible inhibitors represented by galantamine from the active site of AChE. For this purpose, we used a lower pH to get the original activity of AChE after inhibition by galantamine. We also observed decarbamylation of the AChE - carbofuran adduct. Influence of organic solvents to AChE as well as repeatability of measurement with MPs with AChE was also established.
28338634	19	39	Acetylcholinesterase	T116,T126	C0001044
28338634	40	46	Sensor	T075	C0600364
28338634	56	94	Synthesized Paramagnetic Nanoparticles	T130	C2713587
28338634	114	134	Neurotoxic Compounds	T131	C0260049
28338634	135	140	Assay	T059	C1510438
28338634	141	159	Magnetic particles	T130	C2713587
28338634	161	164	MPs	T130	C2713587
28338634	191	214	biological applications	T169	C0205245
28338634	256	265	molecules	T167	C0567416
28338634	309	320	immobilized	T067	C1254366
28338634	321	330	molecules	T167	C0567416
28338634	341	348	enzymes	T116,T126	C0014442
28338634	350	370	Acetylcholinesterase	T116,T126	C0001044
28338634	372	376	AChE	T116,T126	C0001044
28338634	384	390	enzyme	T116,T126	C0014442
28338634	415	432	neurotransmission	T043	C0027793
28338634	441	447	enzyme	T116,T126	C0014442
28338634	451	459	targeted	T169	C1521840
28338634	471	480	molecules	T167	C0567416
28338634	486	497	Alzheimer's	T047	C0002395
28338634	498	503	drugs	T121	C1254351
28338634	505	515	pesticides	T131	C0031253
28338634	520	534	warfare agents	T109,T131	C1113670
28338634	553	578	electrochemical biosensor	T075	C0600364
28338634	586	590	AChE	T116,T126	C0001044
28338634	591	602	immobilized	T116,T126,T130	C0014444
28338634	608	611	MPs	T130	C2713587
28338634	616	626	stabilized	T033	C0184512
28338634	635	663	glutaraldehyde (GA) molecule	T109,T122,T130	C0017814
28338634	681	686	assay	T059	C1510438
28338634	694	714	neurotoxic compounds	T131	C0260049
28338634	720	742	prepared nanoparticles	T073	C1450054
28338634	748	759	modified by	T080	C0205349
28338634	760	769	pure AChE	T116,T126	C0001044
28338634	797	808	measurement	T169	C0242485
28338634	809	825	anti-Alzheimer's	T033	C0243095
28338634	826	830	drug	T121	C1254351
28338634	831	842	galantamine	T109,T121	C0016967
28338634	847	866	carbamate pesticide	T109,T121,T131	C0360422
28338634	867	877	carbofuran	T109,T131	C0006995
28338634	883	888	limit	T078	C1549649
28338634	892	901	detection	T033	C0442726
28338634	938	950	measurements	T169	C0242485
28338634	974	995	screen-printed sensor	T075	C0600364
28338634	1001	1007	carbon	T196	C0007009
28338634	1008	1015	working	T074	C0013812
28338634	1017	1023	silver	T196	C0037125
28338634	1024	1033	reference	T074	C4067887
28338634	1039	1045	carbon	T196	C0007009
28338634	1046	1065	auxiliary electrode	T074	C0013812
28338634	1067	1090	Standard Ellman's assay	T059	C1510438
28338634	1104	1114	validation	T062	C1519941
28338634	1115	1126	measurement	T169	C0242485
28338634	1135	1145	inhibitors	T120	C0243077
28338634	1173	1184	elimination	T052	C1883720
28338634	1188	1198	reversible	T169	C0205343
28338634	1199	1209	inhibitors	T120	C0243077
28338634	1225	1236	galantamine	T109,T121	C0016967
28338634	1246	1257	active site	T169	C0205681
28338634	1261	1265	AChE	T116,T126	C0001044
28338634	1295	1300	lower	T052	C2003888
28338634	1301	1303	pH	T081	C0020283
28338634	1315	1323	original	T078	C0205313
28338634	1324	1332	activity	T052	C0441655
28338634	1336	1340	AChE	T116,T126	C0001044
28338634	1347	1357	inhibition	T052	C3463820
28338634	1361	1372	galantamine	T109,T121	C0016967
28338634	1382	1390	observed	T169	C1441672
28338634	1391	1406	decarbamylation	T067	C1254366
28338634	1414	1418	AChE	T116,T126	C0001044
28338634	1421	1431	carbofuran	T109,T131	C0006995
28338634	1432	1438	adduct	T104	C0596040
28338634	1453	1469	organic solvents	T109	C0360100
28338634	1473	1477	AChE	T116,T126	C0001044
28338634	1506	1517	measurement	T169	C0242485
28338634	1523	1526	MPs	T130	C2713587
28338634	1532	1536	AChE	T116,T126	C0001044

27563025|t|The construction of three-dimensional composite fibrous macrostructures with nanotextures for biomedical applications
27563025|a|The development of modern biomedical nanotechnology requires three-dimensional macrostructures with nanotextures to meet the requirements for practical applications in intricate biological systems. Additionally, the restoration and regeneration of some specific body tissues and organs rely on the function of conductive polymers, which can provide electrical cues for cells. In this study, we fabricated three-dimensional composite nanofibre macrostructures of polycaprolactone (PCL) with different concentrations of polyaniline (PANi) by employing an improved electrospinning technology with a specially designed collector. The 3D structures possessed cap-like macrostructures with centimetre-scale thickness and interconnected pore nanotextures with nanometre-scale nanofibres. To estimate the biocompatibility of the 3D PCL / PANi composite nanofibre macrostructures, mouse myoblasts (C2C12 cells) were cultured as model cells. The initial responses of C2C12 cells to the 3D PCL / PANi composite macrostructures were significantly superior to those to pure PCL, that is, the cells exhibited typical myoblast-like morphologies with obvious pseudopodia and the moderate incorporation (less than 2.0 wt%) of conductive PANi facilitated cell proliferation, which indicated that PANi has appreciable cell affinity. Moreover, the addition of conductive PANi to the 3D composite nanofibre macrostructures considerably enhanced myoblast differentiation and myotube maturation. These results suggest that electrospun 3D PCL / PANi composite nanofibre macrostructures would have promising applications in tissue engineering.
27563025	4	16	construction	T052	C1521827
27563025	20	37	three-dimensional	T082	C0450363
27563025	38	47	composite	T122	C0009570
27563025	48	55	fibrous	T080	C0439709
27563025	56	71	macrostructures	T082	C0678594
27563025	72	89	with nanotextures	T080	C0449582
27563025	94	104	biomedical	T091	C1879848
27563025	105	117	applications	T169	C4048755
27563025	144	154	biomedical	T091	C1879848
27563025	155	169	nanotechnology	T090	C0872323
27563025	179	196	three-dimensional	T082	C0450363
27563025	197	212	macrostructures	T082	C0678594
27563025	213	230	with nanotextures	T080	C0449582
27563025	270	282	applications	T169	C4048755
27563025	296	314	biological systems	T022	C0460002
27563025	334	345	restoration	UnknownType	C0678689
27563025	350	362	regeneration	T040	C0815081
27563025	380	392	body tissues	T024	C0040300
27563025	397	403	organs	T023	C0178784
27563025	428	447	conductive polymers	T104,T122	C0032521
27563025	467	477	electrical	T169	C0442828
27563025	478	482	cues	T078	C0010439
27563025	487	492	cells	T025	C0007634
27563025	523	540	three-dimensional	T082	C0450363
27563025	541	550	composite	T122	C0009570
27563025	551	560	nanofibre	T073	C1881960
27563025	561	576	macrostructures	T082	C0678594
27563025	580	596	polycaprolactone	T109	C0137734
27563025	598	601	PCL	T109	C0137734
27563025	618	632	concentrations	T081	C1446561
27563025	636	647	polyaniline	T109	C0962453
27563025	649	653	PANi	T109	C0962453
27563025	680	706	electrospinning technology	T169	C0449851
27563025	748	750	3D	T082	C0450363
27563025	751	761	structures	T082	C0678594
27563025	772	796	cap-like macrostructures	T082	C0678594
27563025	802	818	centimetre-scale	T081	C0475210
27563025	819	828	thickness	T080	C1280412
27563025	848	865	pore nanotextures	T080	C0449582
27563025	871	886	nanometre-scale	T081	C0439202
27563025	887	897	nanofibres	T073	C1881960
27563025	915	931	biocompatibility	T044	C0596177
27563025	939	941	3D	T082	C0450363
27563025	942	945	PCL	T109	C0137734
27563025	948	952	PANi	T109	C0962453
27563025	953	962	composite	T122	C0009570
27563025	963	972	nanofibre	T073	C1881960
27563025	973	988	macrostructures	T082	C0678594
27563025	990	995	mouse	T015	C0025929
27563025	996	1005	myoblasts	T025	C0596995
27563025	1007	1018	C2C12 cells	T025	C0596995
27563025	1037	1042	model	T050	C2986594
27563025	1043	1048	cells	T025	C0007634
27563025	1075	1086	C2C12 cells	T025	C0596995
27563025	1094	1096	3D	T082	C0450363
27563025	1097	1100	PCL	T109	C0137734
27563025	1103	1107	PANi	T109	C0962453
27563025	1108	1117	composite	T122	C0009570
27563025	1118	1133	macrostructures	T082	C0678594
27563025	1179	1182	PCL	T109	C0137734
27563025	1197	1202	cells	T025	C0007634
27563025	1221	1247	myoblast-like morphologies	T080	C0332437
27563025	1261	1272	pseudopodia	T026	C0033827
27563025	1338	1342	PANi	T109	C0962453
27563025	1355	1373	cell proliferation	T043	C0596290
27563025	1396	1400	PANi	T109	C0962453
27563025	1417	1430	cell affinity	T038	C3714634
27563025	1458	1468	conductive	T080	C0205556
27563025	1469	1473	PANi	T109	C0962453
27563025	1481	1483	3D	T082	C0450363
27563025	1484	1493	composite	T122	C0009570
27563025	1494	1503	nanofibre	T073	C1881960
27563025	1504	1519	macrostructures	T082	C0678594
27563025	1542	1566	myoblast differentiation	T043	C1159966
27563025	1571	1589	myotube maturation	T043	C2265916
27563025	1618	1629	electrospun	T080	C0205556
27563025	1630	1632	3D	T082	C0450363
27563025	1633	1636	PCL	T109	C0137734
27563025	1639	1643	PANi	T109	C0962453
27563025	1644	1653	composite	T122	C0009570
27563025	1654	1663	nanofibre	T073	C1881960
27563025	1664	1679	macrostructures	T082	C0678594
27563025	1664	1679	macrostructures	T082	C0678594
27563025	1701	1713	applications	T169	C4048755
27563025	1717	1735	tissue engineering	T061	C0596171

27931138|t|Medicinal plants and natural products in amelioration of arsenic toxicity: a short review
27931138|a|Chronic arsenic toxicity (arsenicosis) is considered a serious public health menace worldwide, as there is no specific, safe, and efficacious therapeutic management of arsenicosis. To collate the studies on medicinal plants and natural products with arsenic toxicity ameliorative effect, active pre-clinically and/or clinically. Literature survey was carried out by using Google, Scholar Google and Pub-Med. Only the scientific journal articles found on the internet for last two decades were considered. Minerals and semi-synthetic or synthetic analogs of natural products were excluded. Literature study revealed that 34 medicinal plants and 14 natural products exhibited significant protection from arsenic toxicity, mostly in preclinical trials and a few in clinical studies. This research could lead to development of a potentially useful agent in clinical management of arsenicosis in humans.
27931138	0	16	Medicinal plants	T002	C0032100
27931138	21	37	natural products	T123	C1566558
27931138	57	64	arsenic	T121,T131,T196	C0003818
27931138	65	73	toxicity	T037	C0600688
27931138	90	114	Chronic arsenic toxicity	T037	C0238007
27931138	116	127	arsenicosis	T037	C0238007
27931138	153	166	public health	T058	C0699943
27931138	220	231	efficacious	T080	C1704419
27931138	232	254	therapeutic management	T061	C1444271
27931138	258	269	arsenicosis	T037	C0238007
27931138	297	313	medicinal plants	T002	C0032100
27931138	318	334	natural products	T123	C1566558
27931138	340	347	arsenic	T121,T131,T196	C0003818
27931138	348	356	toxicity	T037	C0600688
27931138	407	417	clinically	T080	C0443178
27931138	419	436	Literature survey	T170	C0178732
27931138	462	468	Google	T170	C0282574
27931138	470	484	Scholar Google	T170	C0282574
27931138	489	496	Pub-Med	T170	C1138432
27931138	507	534	scientific journal articles	T170	C0282420
27931138	548	556	internet	T073	C0282111
27931138	595	603	Minerals	T197	C0026162
27931138	608	643	semi-synthetic or synthetic analogs	T104	C0243071
27931138	647	663	natural products	T123	C1566558
27931138	679	689	Literature	T170	C0023866
27931138	690	695	study	T062	C2603343
27931138	713	729	medicinal plants	T002	C0032100
27931138	737	753	natural products	T123	C1566558
27931138	776	786	protection	T033	C1545588
27931138	792	799	arsenic	T121,T131,T196	C0003818
27931138	800	808	toxicity	T037	C0600688
27931138	820	838	preclinical trials	T058	C1254363
27931138	852	868	clinical studies	T062	C0008972
27931138	875	883	research	T062	C0035168
27931138	898	909	development	T169	C1527148
27931138	943	962	clinical management	T058	C1516615
27931138	966	977	arsenicosis	T037	C0238007
27931138	981	987	humans	T016	C0086418

28539349|t|Sleep Loss Promotes Astrocytic Phagocytosis and Microglial Activation in Mouse Cerebral Cortex
28539349|a|We previously found that Mertk and its ligand Gas6, astrocytic genes involved in phagocytosis, are upregulated after acute sleep deprivation. These results suggested that astrocytes may engage in phagocytic activity during extended wake, but direct evidence was lacking. Studies in humans and rodents also found that sleep loss increases peripheral markers of inflammation, but whether these changes are associated with neuroinflammation and/or activation of microglia, the brain's resident innate immune cells, was unknown. Here we used serial block-face scanning electron microscopy to obtain 3D volume measurements of synapses and surrounding astrocytic processes in mouse frontal cortex after 6-8 h of sleep, spontaneous wake, or sleep deprivation (SD) and after chronic (∼5 d) sleep restriction (CSR). Astrocytic phagocytosis, mainly of presynaptic components of large synapses, increased after both acute and chronic sleep loss relative to sleep and wake. MERTK expression and lipid peroxidation in synaptoneurosomes also increased to a similar extent after short and long sleep loss, suggesting that astrocytic phagocytosis may represent the brain's response to the increase in synaptic activity associated with prolonged wake, clearing worn components of heavily used synapses. Using confocal microscopy, we then found that CSR but not SD mice show morphological signs of microglial activation and enhanced microglial phagocytosis of synaptic elements, without obvious signs of neuroinflammation in the CSF. Because low - level sustained microglia activation can lead to abnormal responses to a secondary insult, these results suggest that chronic sleep loss, through microglia priming, may predispose the brain to further damage .SIGNIFICANCE STATEMENT We find that astrocytic phagocytosis of synaptic elements, mostly of presynaptic origin and in large synapses, is upregulated already after a few hours of sleep deprivation and shows a further significant increase after prolonged and severe sleep loss, suggesting that it may promote the housekeeping of heavily used and strong synapses in response to the increased neuronal activity of extended wake. By contrast, chronic sleep restriction but not acute sleep loss activates microglia, promotes their phagocytic activity, and does so in the absence of overt signs of neuroinflammation, suggesting that like many other stressors, extended sleep disruption may lead to a state of sustained microglia activation, perhaps increasing the brain's susceptibility to other forms of damage.
28539349	0	10	Sleep Loss	T033	C0235161
28539349	11	19	Promotes	T052	C0033414
28539349	20	30	Astrocytic	T029	C0521395
28539349	31	43	Phagocytosis	T043	C0031308
28539349	48	69	Microglial Activation	T043	C1326169
28539349	73	94	Mouse Cerebral Cortex	T024	C1522579
28539349	120	125	Mertk	T116,T126,T192	C1259418
28539349	134	145	ligand Gas6	T116,T123	C1567829
28539349	147	157	astrocytic	T029	C0521395
28539349	158	163	genes	T028	C0017337
28539349	176	188	phagocytosis	T043	C0031308
28539349	194	205	upregulated	T044	C0041904
28539349	206	211	after	T079	C0687676
28539349	212	217	acute	T079	C0205178
28539349	218	235	sleep deprivation	T033	C0037316
28539349	266	276	astrocytes	T025	C0004112
28539349	291	310	phagocytic activity	T043	C0031308
28539349	311	317	during	T079	C0347984
28539349	318	326	extended	T082	C0231449
28539349	327	331	wake	T039	C0442696
28539349	337	343	direct	T080	C1947931
28539349	344	352	evidence	T078	C3887511
28539349	357	364	lacking	T080	C0332268
28539349	366	373	Studies	T062	C2603343
28539349	377	383	humans	T016	C0086418
28539349	388	395	rodents	T015	C0035804
28539349	401	406	found	T033	C0150312
28539349	412	422	sleep loss	T033	C0235161
28539349	423	432	increases	T169	C0442805
28539349	433	443	peripheral	T082	C0205100
28539349	444	451	markers	T201	C0005516
28539349	455	467	inflammation	T046	C0021368
28539349	487	494	changes	T169	C0392747
28539349	499	514	associated with	T080	C0332281
28539349	515	532	neuroinflammation	UnknownType	C0683396
28539349	540	550	activation	T043	C1326120
28539349	554	563	microglia	T025	C0206116
28539349	569	576	brain's	T023	C0006104
28539349	586	605	innate immune cells	T025	C0312740
28539349	611	618	unknown	T080	C0439673
28539349	628	632	used	T169	C1524063
28539349	633	679	serial block-face scanning electron microscopy	T059	C0026020
28539349	693	699	volume	T081	C0449468
28539349	700	712	measurements	T169	C0242485
28539349	716	724	synapses	T030	C0039062
28539349	729	740	surrounding	T082	C1282914
28539349	741	751	astrocytic	T029	C0521395
28539349	752	761	processes	T038	C3714634
28539349	765	770	mouse	T015	C0025929
28539349	771	785	frontal cortex	T023	C0016733
28539349	786	791	after	T079	C0687676
28539349	801	806	sleep	T040	C0037313
28539349	808	819	spontaneous	T169	C0205359
28539349	820	824	wake	T039	C0442696
28539349	829	846	sleep deprivation	T033	C0037316
28539349	848	850	SD	T033	C0037316
28539349	856	861	after	T079	C0687676
28539349	862	894	chronic (∼5 d) sleep restriction	T169	C0443288
28539349	896	899	CSR	T169	C0443288
28539349	902	912	Astrocytic	T029	C0521395
28539349	913	925	phagocytosis	T043	C0031308
28539349	937	977	presynaptic components of large synapses	T026	C1179895
28539349	979	988	increased	T081	C0205217
28539349	989	994	after	T079	C0687676
28539349	995	999	both	T080	C1706086
28539349	1000	1005	acute	T079	C0205178
28539349	1010	1017	chronic	T079	C0205191
28539349	1018	1028	sleep loss	T033	C0235161
28539349	1029	1037	relative	T080	C0205345
28539349	1041	1046	sleep	T040	C0037313
28539349	1051	1055	wake	T039	C0442696
28539349	1057	1062	MERTK	T116,T126,T192	C1259417
28539349	1063	1073	expression	T045	C1171362
28539349	1078	1096	lipid peroxidation	T044	C0023775
28539349	1100	1117	synaptoneurosomes	T026	C0039067
28539349	1123	1132	increased	T081	C0205217
28539349	1138	1145	similar	T080	C2348205
28539349	1146	1152	extent	T082	C0439792
28539349	1153	1158	after	T079	C0687676
28539349	1159	1164	short	T081	C1806781
28539349	1169	1173	long	T080	C0205166
28539349	1174	1184	sleep loss	T033	C0235161
28539349	1202	1212	astrocytic	T029	C0521395
28539349	1213	1225	phagocytosis	T043	C0031308
28539349	1230	1239	represent	T052	C1882932
28539349	1244	1251	brain's	T023	C0006104
28539349	1252	1260	response	T032	C0871261
28539349	1268	1276	increase	T169	C0442805
28539349	1280	1297	synaptic activity	T043	C0027793
28539349	1298	1313	associated with	T080	C0332281
28539349	1314	1323	prolonged	T079	C0439590
28539349	1324	1328	wake	T039	C0442696
28539349	1330	1338	clearing	T080	C2963144
28539349	1366	1370	used	T169	C1524063
28539349	1371	1379	synapses	T030	C0039062
28539349	1381	1386	Using	T169	C1524063
28539349	1387	1406	confocal microscopy	T059	C0242842
28539349	1416	1421	found	T033	C0150312
28539349	1427	1430	CSR	T169	C0443288
28539349	1435	1438	not	T169	C1518422
28539349	1439	1441	SD	T033	C0037316
28539349	1442	1446	mice	T015	C0025929
28539349	1452	1465	morphological	T082	C0543482
28539349	1466	1471	signs	T184	C0037088
28539349	1475	1496	microglial activation	T043	C1326169
28539349	1501	1509	enhanced	T052	C2349975
28539349	1510	1520	microglial	T029	C0521398
28539349	1521	1533	phagocytosis	T043	C0031308
28539349	1537	1554	synaptic elements	T026	C3893360
28539349	1556	1563	without	T080	C0332288
28539349	1572	1577	signs	T184	C0037088
28539349	1581	1598	neuroinflammation	UnknownType	C0683396
28539349	1606	1609	CSF	T031	C0007806
28539349	1619	1622	low	T080	C0205251
28539349	1625	1630	level	T080	C0441889
28539349	1631	1640	sustained	T169	C0443318
28539349	1641	1661	microglia activation	T043	C1326169
28539349	1674	1682	abnormal	T033	C0205161
28539349	1683	1692	responses	T032	C0871261
28539349	1698	1707	secondary	T080	C0175668
28539349	1708	1714	insult	T037	C0598698
28539349	1722	1729	results	T169	C1274040
28539349	1730	1737	suggest	T078	C1705535
28539349	1743	1750	chronic	T079	C0205191
28539349	1751	1761	sleep loss	T033	C0235161
28539349	1763	1770	through	T169	C0332273
28539349	1771	1780	microglia	T025	C0206116
28539349	1781	1788	priming	T043	C0007613
28539349	1809	1814	brain	T023	C0006104
28539349	1818	1825	further	T082	C1517331
28539349	1826	1832	damage	T169	C1883709
28539349	1860	1864	find	T033	C0243095
28539349	1870	1880	astrocytic	T029	C0521395
28539349	1881	1893	phagocytosis	T043	C0031308
28539349	1897	1914	synaptic elements	T026	C3893360
28539349	1926	1944	presynaptic origin	T026	C3893360
28539349	1952	1957	large	T081	C0549177
28539349	1958	1966	synapses	T030	C0039062
28539349	1971	1982	upregulated	T044	C0041904
28539349	1991	1996	after	T079	C0687676
28539349	1999	2002	few	T081	C0205388
28539349	2003	2008	hours	T079	C0439227
28539349	2012	2029	sleep deprivation	T033	C0037316
28539349	2042	2049	further	T082	C1517331
28539349	2050	2061	significant	T078	C0750502
28539349	2062	2070	increase	T169	C0442805
28539349	2071	2076	after	T079	C0687676
28539349	2077	2086	prolonged	T079	C0439590
28539349	2091	2097	severe	T080	C0205082
28539349	2098	2108	sleep loss	T033	C0235161
28539349	2133	2140	promote	T052	C0033414
28539349	2145	2157	housekeeping	T057	C0020053
28539349	2169	2173	used	T169	C1524063
28539349	2178	2184	strong	T080	C0442821
28539349	2185	2193	synapses	T030	C0039062
28539349	2197	2205	response	T032	C0871261
28539349	2213	2222	increased	T081	C0205217
28539349	2223	2231	neuronal	T025	C0027882
28539349	2232	2240	activity	T043	C0007613
28539349	2244	2252	extended	T082	C0231449
28539349	2253	2257	wake	T039	C0442696
28539349	2262	2270	contrast	T080	C1979874
28539349	2272	2297	chronic sleep restriction	T169	C0443288
28539349	2302	2305	not	T169	C1518422
28539349	2306	2311	acute	T079	C0205178
28539349	2312	2322	sleep loss	T033	C0235161
28539349	2323	2332	activates	T043	C1326120
28539349	2333	2342	microglia	T025	C0206116
28539349	2344	2352	promotes	T052	C0033414
28539349	2359	2378	phagocytic activity	T043	C0031308
28539349	2399	2406	absence	T169	C0332197
28539349	2416	2421	signs	T184	C0037088
28539349	2425	2442	neuroinflammation	UnknownType	C0683396
28539349	2470	2475	other	T080	C0205394
28539349	2476	2485	stressors	T078	C0597530
28539349	2487	2495	extended	T082	C0231449
28539349	2496	2512	sleep disruption	T033	C1821308
28539349	2527	2532	state	T169	C1442792
28539349	2536	2545	sustained	T169	C0443318
28539349	2546	2566	microglia activation	T043	C1326169
28539349	2576	2586	increasing	T169	C0442808
28539349	2591	2598	brain's	T023	C0006104
28539349	2599	2613	susceptibility	T169	C1264642
28539349	2617	2622	other	T080	C0205394
28539349	2623	2628	forms	T169	C1522492
28539349	2632	2638	damage	T169	C1883709

28284685|t|Identifying priorities to improve paediatric in-hospital antimicrobial use by cross-sectional evaluation of prevalence and appropriateness of prescription
28284685|a|Information about paediatric in-hospital antimicrobial usage and prescribing patterns to guide improvement strategies is scant. We aim to use an evaluation of the prevalence and appropriateness of antimicrobial prescription to identify antimicrobial stewardship priorities in children. A cross-sectional point study was performed on hospitalised paediatric patients in a Spanish tertiary hospital, assessing the prevalence of antimicrobial prescription (PAP) and appropriateness of antimicrobial prescription (AAP). AAP was defined as a correct indication plus an appropriate prescribing pattern (dose, spectrum and interval). Evaluation was performed using established antimicrobial guidelines. Other factors that may have a bearing on antimicrobial prescription were also analysed. A total of 171 patients were included. PAP was 49.7% (85/171) and AAP was 60.9% (91/161). The most common indications for antimicrobial use were antimicrobial prophylaxis (28.3%, 32/113) and pneumonia (8.2%, 8/113). Overall, 161 antimicrobials were prescribed (1.9 antimicrobials per patient): 55.3% (89/161) were empiric, 16.1% (26/161) were targeted and 28.6% (46/161) were prophylactic. Amoxicillin/clavulanate (8.2%, 14/171) and sulfamethoxazole/trimethoprim (8.2%, 14/171) were the most prescribed antimicrobials. The prescription of antifungals (11.7%, 20/171) and antivirals (1.8%, 3/171) was analysed. Major causes of inappropriate antibiotic use were prolonged prescriptions (21.7%, 35/161) and use of agents with an excessively broad coverage spectrum (21.1%, 34/161). PAP and AAP varied between wards and antimicrobials. Measurement of PAP and AAP offers valuable information for detecting priorities in hospital settings and monitoring antimicrobial usage prior to the development of antimicrobial stewardship programmes. In our setting, the main areas for improvement are duration of therapy and proper use of broad-spectrum antimicrobials.
28284685	12	22	priorities	T080	C0018736
28284685	34	44	paediatric	T100	C0008059
28284685	45	56	in-hospital	T073,T093	C0019994
28284685	57	70	antimicrobial	T121	C1136254
28284685	71	74	use	T169	C0457083
28284685	78	104	cross-sectional evaluation	T062	C0010362
28284685	108	118	prevalence	T081	C0033106
28284685	123	138	appropriateness	T080	C0814634
28284685	142	154	prescription	T058	C0033080
28284685	173	183	paediatric	T100	C0008059
28284685	184	195	in-hospital	T073,T093	C0019994
28284685	196	209	antimicrobial	T121	C1136254
28284685	210	215	usage	T169	C0457083
28284685	220	240	prescribing patterns	T057	C2713413
28284685	250	261	improvement	T077	C2986411
28284685	262	272	strategies	T041	C0679199
28284685	300	310	evaluation	T058	C0220825
28284685	318	328	prevalence	T081	C0033106
28284685	333	348	appropriateness	T080	C0814634
28284685	352	365	antimicrobial	T121	C1136254
28284685	366	378	prescription	T058	C0033080
28284685	391	404	antimicrobial	T121	C1136254
28284685	405	416	stewardship	T170	C1554086
28284685	417	427	priorities	T080	C0018736
28284685	431	439	children	T100	C0008059
28284685	443	470	cross-sectional point study	T062	C0010362
28284685	488	520	hospitalised paediatric patients	T101	C0870668
28284685	526	533	Spanish	T083	C0037747
28284685	534	551	tertiary hospital	T073,T093	C0019994
28284685	567	607	prevalence of antimicrobial prescription	T081	C0033106
28284685	609	612	PAP	T081	C0033106
28284685	618	663	appropriateness of antimicrobial prescription	T080	C0814634
28284685	665	668	AAP	T080	C0814634
28284685	671	674	AAP	T080	C0814634
28284685	700	710	indication	T078	C3146298
28284685	731	750	prescribing pattern	T057	C2713413
28284685	752	756	dose	T081	C0178602
28284685	758	766	spectrum	T077	C2827424
28284685	771	779	interval	T079	C1272706
28284685	782	792	Evaluation	T058	C0220825
28284685	825	838	antimicrobial	T121	C1136254
28284685	839	849	guidelines	T170	C0162791
28284685	892	905	antimicrobial	T121	C1136254
28284685	906	918	prescription	T058	C0033080
28284685	929	937	analysed	T062	C0936012
28284685	954	962	patients	T101	C0030705
28284685	978	981	PAP	T081	C0033106
28284685	1005	1008	AAP	T080	C0814634
28284685	1045	1056	indications	T078	C3146298
28284685	1061	1074	antimicrobial	T121	C1136254
28284685	1075	1078	use	T169	C0457083
28284685	1084	1097	antimicrobial	T121	C1136254
28284685	1098	1109	prophylaxis	T061	C3853787
28284685	1130	1139	pneumonia	T047	C0032285
28284685	1168	1182	antimicrobials	T121	C1136254
28284685	1188	1198	prescribed	T058	C0278329
28284685	1204	1218	antimicrobials	T121	C1136254
28284685	1223	1230	patient	T101	C0030705
28284685	1253	1260	empiric	T080	C1880496
28284685	1315	1327	prophylactic	T169	C0445202
28284685	1329	1352	Amoxicillin/clavulanate	T121	C0054066
28284685	1372	1401	sulfamethoxazole/trimethoprim	T121	C0041044
28284685	1442	1456	antimicrobials	T121	C1136254
28284685	1462	1474	prescription	T058	C0033080
28284685	1478	1489	antifungals	T121	C0003308
28284685	1510	1520	antivirals	T121	C0003451
28284685	1539	1547	analysed	T062	C0936012
28284685	1579	1589	antibiotic	T195	C0003232
28284685	1590	1593	use	T169	C0457083
28284685	1599	1608	prolonged	T079	C0439590
28284685	1609	1622	prescriptions	T058	C0033080
28284685	1643	1646	use	T169	C0457083
28284685	1650	1656	agents	T121	C1254351
28284685	1692	1700	spectrum	T077	C2827424
28284685	1718	1721	PAP	T081	C0033106
28284685	1726	1729	AAP	T080	C0814634
28284685	1745	1750	wards	T073,T093	C1305702
28284685	1755	1769	antimicrobials	T121	C1136254
28284685	1771	1782	Measurement	T169	C0242485
28284685	1786	1789	PAP	T081	C0033106
28284685	1794	1797	AAP	T080	C0814634
28284685	1840	1850	priorities	T080	C0018736
28284685	1854	1871	hospital settings	T073,T093	C0019994
28284685	1876	1886	monitoring	T058	C1283169
28284685	1887	1900	antimicrobial	T121	C1136254
28284685	1901	1906	usage	T169	C0457083
28284685	1920	1931	development	T169	C1527148
28284685	1935	1948	antimicrobial	T121	C1136254
28284685	1949	1960	stewardship	T170	C1554086
28284685	1961	1971	programmes	T169	C3484370
28284685	2008	2019	improvement	T077	C2986411
28284685	2024	2032	duration	T079	C0449238
28284685	2036	2043	therapy	T061	C0087111
28284685	2055	2058	use	T169	C0457083
28284685	2062	2091	broad-spectrum antimicrobials	T121	C1136254

28447828|t|Gender Differences in Depression in Representative National Samples: Meta-Analyses of Diagnoses and Symptoms
28447828|a|In 2 meta-analyses on gender differences in depression in nationally representative samples, we advance previous work by including studies of depression diagnoses and symptoms to (a) estimate the magnitude of the gender difference in depression across a wide array of nations and ages; (b) use a developmental perspective to elucidate patterns of gender differences across the life span; and (c) incorporate additional theory-driven moderators (e.g., gender equity). For major depression diagnoses and depression symptoms, respectively, we meta-analyzed data from 65 and 95 articles and their corresponding national data sets, representing data from 1,716,195 and 1,922,064 people in over 90 different nations. Overall, odds ratio (OR) = 1.95, 95% confidence interval (CI) [1.88, 2.03], and d = 0.27 [0.26, 0.29]. Age was the strongest predictor of effect size. The gender difference for diagnoses emerged earlier than previously thought, with OR = 2.37 at age 12. For both meta-analyses, the gender difference peaked in adolescence (OR = 3.02 for ages 13-15, and d = 0.47 for age 16) but then declined and remained stable in adulthood. Cross-national analyses indicated that larger gender differences were found in nations with greater gender equity, for major depression, but not depression symptoms. The gender difference in depression represents a health disparity, especially in adolescence, yet the magnitude of the difference indicates that depression in men should not be overlooked. (PsycINFO Database Record
28447828	0	18	Gender Differences	T032	C0036866
28447828	22	32	Depression	T048	C0011570
28447828	36	67	Representative National Samples	T167	C0370003
28447828	69	82	Meta-Analyses	T062	C0920317
28447828	86	95	Diagnoses	T033	C0011900
28447828	100	108	Symptoms	T184	C1457887
28447828	114	127	meta-analyses	T062	C0920317
28447828	131	149	gender differences	T032	C0036866
28447828	153	163	depression	T048	C0011570
28447828	167	200	nationally representative samples	T167	C0370003
28447828	205	212	advance	T079	C3854260
28447828	213	221	previous	T079	C0205156
28447828	222	226	work	T057	C0043227
28447828	230	239	including	T169	C0332257
28447828	240	247	studies	T062	C0681814
28447828	251	261	depression	T048	C0011570
28447828	262	271	diagnoses	T033	C0011900
28447828	276	284	symptoms	T184	C1457887
28447828	292	300	estimate	T081	C0750572
28447828	305	314	magnitude	T081	C1704240
28447828	322	339	gender difference	T032	C0036866
28447828	343	353	depression	T048	C0011570
28447828	363	373	wide array	T082	C1510941
28447828	377	384	nations	UnknownType	C0683734
28447828	389	393	ages	T032	C0001779
28447828	405	418	developmental	T080	C0458003
28447828	419	430	perspective	T041	C0030971
28447828	444	452	patterns	T082	C0449774
28447828	456	474	gender differences	T032	C0036866
28447828	486	495	life span	T102	C0870809
28447828	517	527	additional	T169	C1524062
28447828	528	541	theory-driven	T078	C0871935
28447828	542	552	moderators	T080	C0205556
28447828	560	566	gender	T032	C0079399
28447828	567	573	equity	T080	C0205556
28447828	586	596	depression	T048	C0011570
28447828	597	606	diagnoses	T033	C0011900
28447828	611	621	depression	T048	C0011570
28447828	622	630	symptoms	T184	C1457887
28447828	649	667	meta-analyzed data	T057	C0010992
28447828	683	691	articles	T170	C1706852
28447828	716	734	national data sets	T170	C0150098
28447828	749	753	data	T078	C1511726
28447828	783	789	people	T098	C0027361
28447828	801	810	different	T080	C1705242
28447828	811	818	nations	UnknownType	C0683734
28447828	820	827	Overall	T080	C1561607
28447828	829	839	odds ratio	T081	C0028873
28447828	841	843	OR	T081	C0028873
28447828	857	876	confidence interval	T081	C0009667
28447828	878	880	CI	T081	C0009667
28447828	923	926	Age	T032	C0001779
28447828	935	954	strongest predictor	T078	C2698872
28447828	958	969	effect size	T081	C0237589
28447828	975	992	gender difference	T032	C0036866
28447828	997	1006	diagnoses	T033	C0011900
28447828	1015	1022	earlier	T079	C1279919
28447828	1028	1038	previously	T079	C0205156
28447828	1053	1055	OR	T081	C0028873
28447828	1066	1069	age	T032	C0001779
28447828	1083	1096	meta-analyses	T062	C0920317
28447828	1102	1119	gender difference	T032	C0036866
28447828	1120	1126	peaked	T080	C0444505
28447828	1130	1141	adolescence	T079	C0001578
28447828	1143	1145	OR	T081	C0028873
28447828	1157	1161	ages	T032	C0001779
28447828	1186	1189	age	T032	C0001779
28447828	1225	1231	stable	T080	C0205360
28447828	1235	1244	adulthood	T079	C0700597
28447828	1246	1269	Cross-national analyses	T062	C0936012
28447828	1270	1279	indicated	T033	C1444656
28447828	1285	1291	larger	T081	C0549177
28447828	1292	1310	gender differences	T032	C0036866
28447828	1316	1321	found	T033	C0150312
28447828	1325	1332	nations	UnknownType	C0683734
28447828	1338	1345	greater	T081	C1704243
28447828	1346	1352	gender	T032	C0079399
28447828	1353	1359	equity	T080	C0205556
28447828	1365	1370	major	T080	C0205164
28447828	1371	1381	depression	T048	C0011570
28447828	1391	1401	depression	T048	C0011570
28447828	1402	1410	symptoms	T184	C1457887
28447828	1416	1433	gender difference	T032	C0036866
28447828	1437	1447	depression	T048	C0011570
28447828	1448	1458	represents	T052	C1882932
28447828	1461	1477	health disparity	T033	C1171307
28447828	1493	1504	adolescence	T079	C0001578
28447828	1514	1523	magnitude	T081	C1704240
28447828	1531	1541	difference	T080	C1705242
28447828	1557	1567	depression	T048	C0011570
28447828	1571	1574	men	T098	C0025266

28432098|t|Inhibitory effect of coumarin on syntrophic fatty acid oxidizing and methanogenic cultures and biogas reactor microbiomes
28432098|a|Coumarins are widely found in plants as natural constituents having antimicrobial activity. When considering plants rich in coumarins for biogas production, adverse effects on microorganisms driving the anaerobic digestion process are expected. Furthermore, coumarin derivatives like warfarin, which are used as anti-coagulating medicine, are found in wastewater affecting its treatment. Coumarin as the structure common to all coumarins inhibits the anaerobic digestion process. However, details of this inhibition are still elusive. Here, we studied the impact of coumarin on acetogenesis and methanogenesis. First, coumarin was applied at four concentrations between 0.25 and 1 g L(-1) to pure cultures of the methanogens Methanosarcina barkeri and Methanospirillum hungatei leading to up to 25% less methane production. Acetate production of syntrophic propionate and butyrate degrading cultures of Syntrophobacter fumaroxidans and Syntrophomonas wolfei were inhibited by 72% at a coumarin concentration of 1 g L(-1) Coumarin also inhibited acetogenesis and acetoclastic methanogenesis in a complex biogas reactor microbiome. When a coumarin-adapted microbiome was used, acetogenesis and methanogenesis were not inhibited. According to amplicon sequencing of bacterial 16S rRNA genes and mcrA genes, the microbial communities of both microbiomes were similar though Methanoculleus was more and Methanobacterium was less abundant in the coumarin-adapted than in the non-adapted microbiome. Our results suggest that well-dosed feeding with coumarin -rich feedstocks to full-scale biogas reactors keeping the coumarin concentrations below 0.5 g L(-1) will allow adaptation to coumarins by structural and functional community reorganization and coumarin degradation .IMPORTANCE Coumarins from natural and anthropogenic sources have an inhibitory impact on the anaerobic digestion process. Here, we studied in detail the adverse effects of the model compound coumarin on acetogenesis and methanogenesis, which are two important steps of the anaerobic digestion process. Coumarin concentrations lower than 0.5 g L(-1) had only a minor impact. Even though similar inhibitory effects can be assumed for coumarin derivatives, little effects on the anaerobic treatment of wastewater are expected where concentrations of coumarin derivatives are lower than 0.5 g L(-1) However, when full scale reactors are fed with coumarin -rich feedstocks, the biogas processes might be inhibited. Hence, these feedstocks should be utilized in a well- dosed manner or after adaptation of the microbial community.
28432098	0	10	Inhibitory	T044	C0021469
28432098	11	17	effect	T080	C1280500
28432098	21	29	coumarin	T109,T121	C0010206
28432098	33	54	syntrophic fatty acid	T109	C0015684
28432098	55	64	oxidizing	T044	C0030011
28432098	69	90	methanogenic cultures	T059	C2242979
28432098	95	101	biogas	T109	C2717893
28432098	102	109	reactor	T073	C3273359
28432098	110	121	microbiomes	T001	C1956108
28432098	122	131	Coumarins	T109,T121	C0010206
28432098	152	158	plants	T002	C0032098
28432098	162	169	natural	T169	C0205296
28432098	170	182	constituents	T167	C0729650
28432098	190	212	antimicrobial activity	T034	C1271650
28432098	231	237	plants	T002	C0032098
28432098	246	255	coumarins	T109,T121	C0010206
28432098	260	266	biogas	T109	C2717893
28432098	279	294	adverse effects	T046	C0879626
28432098	298	312	microorganisms	T001	C0445623
28432098	325	334	anaerobic	T080	C3641081
28432098	335	352	digestion process	T040	C0596937
28432098	380	400	coumarin derivatives	T109,T121	C0010206
28432098	406	414	warfarin	T109,T121,T131	C0043031
28432098	434	459	anti-coagulating medicine	T121	C0003280
28432098	474	484	wastewater	T069	C3494254
28432098	485	494	affecting	T169	C0392760
28432098	499	508	treatment	T169	C1522326
28432098	510	518	Coumarin	T109,T121	C0010206
28432098	550	559	coumarins	T109,T121	C0010206
28432098	560	568	inhibits	T044	C0021469
28432098	573	582	anaerobic	T080	C3641081
28432098	583	600	digestion process	T040	C0596937
28432098	627	637	inhibition	T044	C0021469
28432098	688	696	coumarin	T109,T121	C0010206
28432098	700	712	acetogenesis	T038	C0220781
28432098	717	731	methanogenesis	T044	C1157690
28432098	740	748	coumarin	T109,T121	C0010206
28432098	769	783	concentrations	T081	C1446561
28432098	819	827	cultures	T059	C3826495
28432098	835	846	methanogens	T194	C0524822
28432098	847	869	Methanosarcina barkeri	T194	C0085530
28432098	874	899	Methanospirillum hungatei	T194	C0995897
28432098	926	944	methane production	T040	C1855163
28432098	946	953	Acetate	T109,T121	C0000975
28432098	954	964	production	T038	C0220781
28432098	968	989	syntrophic propionate	T109	C0392214
28432098	994	1002	butyrate	T109	C0220802
28432098	1013	1021	cultures	T059	C3826495
28432098	1025	1053	Syntrophobacter fumaroxidans	T007	C1057281
28432098	1058	1079	Syntrophomonas wolfei	T007	C1080717
28432098	1085	1094	inhibited	T044	C0021469
28432098	1107	1115	coumarin	T109,T121	C0010206
28432098	1116	1129	concentration	T081	C1446561
28432098	1143	1151	Coumarin	T109,T121	C0010206
28432098	1157	1166	inhibited	T044	C0021469
28432098	1167	1179	acetogenesis	T038	C0220781
28432098	1184	1211	acetoclastic methanogenesis	T044	C1157690
28432098	1225	1231	biogas	T109	C2717893
28432098	1232	1239	reactor	T073	C3273359
28432098	1240	1250	microbiome	T001	C1956108
28432098	1259	1286	coumarin-adapted microbiome	T001	C1956108
28432098	1297	1309	acetogenesis	T038	C0220781
28432098	1314	1328	methanogenesis	T044	C1157690
28432098	1338	1347	inhibited	T044	C0021469
28432098	1362	1381	amplicon sequencing	T059	C1441475
28432098	1385	1394	bacterial	T080	C0521009
28432098	1395	1409	16S rRNA genes	T028	C0035899
28432098	1414	1424	mcrA genes	T028	C0017337
28432098	1430	1439	microbial	T001	C0599840
28432098	1440	1451	communities	T070	C1253910
28432098	1460	1471	microbiomes	T001	C1956108
28432098	1492	1506	Methanoculleus	T194	C1012319
28432098	1520	1536	Methanobacterium	T194	C0085523
28432098	1562	1578	coumarin-adapted	T001	C1956108
28432098	1591	1613	non-adapted microbiome	T001	C1956108
28432098	1664	1672	coumarin	T109,T121	C0010206
28432098	1679	1689	feedstocks	T167	C0439861
28432098	1704	1710	biogas	T109	C2717893
28432098	1711	1719	reactors	T073	C3273359
28432098	1732	1740	coumarin	T109,T121	C0010206
28432098	1741	1755	concentrations	T081	C1446561
28432098	1785	1795	adaptation	T038	C0392673
28432098	1799	1808	coumarins	T109,T121	C0010206
28432098	1812	1822	structural	T082	C0678594
28432098	1827	1837	functional	T169	C0205245
28432098	1838	1847	community	T070	C1253910
28432098	1867	1875	coumarin	T109,T121	C0010206
28432098	1876	1887	degradation	T169	C0243125
28432098	1900	1909	Coumarins	T109,T121	C0010206
28432098	1915	1922	natural	T169	C0205296
28432098	1927	1940	anthropogenic	T131	C0014417
28432098	1941	1948	sources	T033	C0449416
28432098	1957	1967	inhibitory	T044	C0021469
28432098	1982	1991	anaerobic	T080	C3641081
28432098	1992	2009	digestion process	T040	C0596937
28432098	2042	2057	adverse effects	T046	C0879626
28432098	2080	2088	coumarin	T109,T121	C0010206
28432098	2092	2104	acetogenesis	T038	C0220781
28432098	2109	2123	methanogenesis	T044	C1157690
28432098	2162	2171	anaerobic	T080	C3641081
28432098	2172	2189	digestion process	T040	C0596937
28432098	2191	2199	Coumarin	T109,T121	C0010206
28432098	2200	2214	concentrations	T081	C1446561
28432098	2283	2293	inhibitory	T044	C0021469
28432098	2294	2301	effects	T080	C1280500
28432098	2321	2341	coumarin derivatives	T109,T121	C0010206
28432098	2350	2357	effects	T080	C1280500
28432098	2365	2374	anaerobic	T080	C3641081
28432098	2375	2384	treatment	T169	C1522326
28432098	2388	2398	wastewater	T069	C3494254
28432098	2418	2432	concentrations	T081	C1446561
28432098	2436	2456	coumarin derivatives	T109,T121	C0010206
28432098	2509	2517	reactors	T073	C3273359
28432098	2531	2539	coumarin	T109,T121	C0010206
28432098	2546	2556	feedstocks	T167	C0439861
28432098	2562	2578	biogas processes	T067	C1522240
28432098	2588	2597	inhibited	T044	C0021469
28432098	2612	2622	feedstocks	T167	C0439861
28432098	2653	2658	dosed	T081	C0178602
28432098	2675	2685	adaptation	T038	C0392673
28432098	2693	2702	microbial	T001	C0599840
28432098	2703	2712	community	T070	C1253910

27409644|t|Pregnancy suppresses the daily rhythmicity of core body temperature and adipose metabolic gene expression in the mouse
27409644|a|Maternal adaptations in lipid metabolism are crucial for pregnancy success due to the role of white adipose tissue as an energy store and the dynamic nature of energy needs across gestation. Because lipid metabolism is regulated by the rhythmic expression of clock genes, it was hypothesised that maternal metabolic adaptations involve changes in both adipose clock gene expression and the rhythmic expression of downstream metabolic genes. Maternal core body temperature (Tc) was investigated as a possible mechanism driving pregnancy -induced changes in clock gene expression. Gonadal adipose tissue and plasma were collected from C57Bl/6J mice before and on days 6, 10, 14 and 18 of pregnancy (term = d19) at 4 hourly intervals across a 24-h period. Adipose expression of clock genes and downstream metabolic genes were determined by RT-qPCR and Tc was measured by intraperitoneal temperature loggers. Adipose clock gene expression showed robust rhythmicity throughout pregnancy, but absolute levels varied substantially across gestation. Rhythmic expression of the metabolic genes Lipe, Pnpla2 and Lpl was clearly evident before pregnancy; however, this rhythmicity was lost with the onset of pregnancy. Tc rhythm was significantly altered by pregnancy with a 65% decrease in amplitude by term and a 0.61°C decrease in mesor between days 6 and 18. These changes in Tc, however, did not appear to be linked to adipose clock gene expression across pregnancy. Overall, our data show marked adaptations in the adipose clock in pregnancy, with an apparent decoupling of adipose clock and lipolytic / lipogenic gene rhythms from early in gestation.
27409644	0	9	Pregnancy	T040	C0032961
27409644	10	20	suppresses	T169	C1260953
27409644	25	42	daily rhythmicity	T040	C0008810
27409644	46	67	core body temperature	T033	C0456240
27409644	72	79	adipose	T024	C0001527
27409644	80	105	metabolic gene expression	T045	C0017262
27409644	113	118	mouse	T015	C0026809
27409644	119	127	Maternal	T033	C1858460
27409644	128	139	adaptations	T070	C0001398
27409644	143	159	lipid metabolism	T044	C0598783
27409644	176	185	pregnancy	T040	C0032961
27409644	213	233	white adipose tissue	T024	C1704223
27409644	240	246	energy	T081	C1442080
27409644	279	285	energy	T081	C1442080
27409644	299	308	gestation	T040	C0032961
27409644	318	334	lipid metabolism	T044	C0598783
27409644	355	363	rhythmic	T039	C1523018
27409644	364	374	expression	T045	C0017262
27409644	378	389	clock genes	T028	C1413503
27409644	416	424	maternal	T033	C1858460
27409644	425	446	metabolic adaptations	T070	C0001398
27409644	471	478	adipose	T024	C0001527
27409644	479	484	clock	T028	C1413503
27409644	485	500	gene expression	T045	C0017262
27409644	509	517	rhythmic	T039	C1523018
27409644	518	528	expression	T045	C0017262
27409644	543	558	metabolic genes	T028	C0017337
27409644	560	568	Maternal	T033	C1858460
27409644	569	590	core body temperature	T033	C0456240
27409644	592	594	Tc	T033	C0456240
27409644	645	654	pregnancy	T040	C0032961
27409644	675	680	clock	T028	C1413503
27409644	681	696	gene expression	T045	C0017262
27409644	698	705	Gonadal	T023	C0018067
27409644	706	720	adipose tissue	T024	C0001527
27409644	725	731	plasma	T031	C0032105
27409644	752	765	C57Bl/6J mice	T015	C0025929
27409644	780	784	days	T079	C0439228
27409644	805	814	pregnancy	T040	C0032961
27409644	833	839	hourly	T079	C0558292
27409644	872	879	Adipose	T024	C0001527
27409644	880	890	expression	T045	C0017262
27409644	894	905	clock genes	T028	C1413503
27409644	921	936	metabolic genes	T028	C0017337
27409644	956	963	RT-qPCR	T063	C1709846
27409644	968	970	Tc	T033	C0456240
27409644	987	1002	intraperitoneal	T082	C0442120
27409644	1003	1014	temperature	T032	C0005903
27409644	1024	1031	Adipose	T024	C0001527
27409644	1032	1037	clock	T028	C1413503
27409644	1038	1053	gene expression	T045	C0017262
27409644	1068	1079	rhythmicity	T079	C0031084
27409644	1091	1100	pregnancy	T040	C0032961
27409644	1150	1159	gestation	T040	C0032961
27409644	1161	1169	Rhythmic	T039	C1523018
27409644	1170	1180	expression	T045	C0017262
27409644	1188	1203	metabolic genes	T028	C0017337
27409644	1204	1208	Lipe	T028	C1416868
27409644	1210	1216	Pnpla2	T028	C1538686
27409644	1221	1224	Lpl	T028	C1416902
27409644	1252	1261	pregnancy	T040	C0032961
27409644	1277	1288	rhythmicity	T079	C0031084
27409644	1316	1325	pregnancy	T040	C0032961
27409644	1327	1329	Tc	T033	C0456240
27409644	1330	1336	rhythm	T039	C1523018
27409644	1366	1375	pregnancy	T040	C0032961
27409644	1456	1460	days	T079	C0439228
27409644	1488	1490	Tc	T033	C0456240
27409644	1532	1539	adipose	T024	C0001527
27409644	1540	1545	clock	T028	C1413503
27409644	1546	1561	gene expression	T045	C0017262
27409644	1569	1578	pregnancy	T040	C0032961
27409644	1593	1597	data	T078	C1511726
27409644	1610	1621	adaptations	T070	C0001398
27409644	1629	1636	adipose	T024	C0001527
27409644	1637	1642	clock	T028	C1413503
27409644	1646	1655	pregnancy	T040	C0032961
27409644	1688	1695	adipose	T024	C0001527
27409644	1696	1701	clock	T028	C1413503
27409644	1706	1715	lipolytic	T028	C0017337
27409644	1718	1732	lipogenic gene	T028	C0017337
27409644	1733	1740	rhythms	T039	C1523018
27409644	1746	1751	early	T079	C1279919
27409644	1755	1764	gestation	T040	C0032961

28487818|t|Modeling adsorption of brominated, chlorinated and mixed bromo / chloro-dibenzo-p-dioxins on C60 fullerene using Nano-QSPR
28487818|a|Many technological implementations in the field of nanotechnology have involved carbon nanomaterials, including fullerenes such as the buckminsterfullerene, C60. The unprecedented properties of such organic nanomaterials (in particular their large surface area) gained extensive attention for their potential use as organic pollutant sorbents. Sorption interactions can be very hazardous and useful at the same time. This work investigates the influence of halogenation by bromine and/or chlorine in dibenzo-p-dioxins on their sorption ability on the C60 fullerene surface. Halogenated dibenzo-p-dioxins (PXDDs, where X = Br or Cl) are ever-present in the environment and accidently produced in many technological processes in only approximately known quantities. If all combinatorial Br and/or Cl dioxin substitution possibilities are present in the environment, the experimental characterization and investigation of sorbent effectiveness is more than difficult. In this work, we have developed a quantitative structure-property relationship (QSPR) model (R(2) = 0.998), predicting the adsorption energy [kcal/mol] for 1,701 PXDDs adsorbed on C60 (PXDD @ C60). Based on the QSPR model reported herein, we concluded that the lowest energy PXDD @ C60 complexes are those that the World Health Organization (WHO) considers to be less dangerous with respect to the aryl hydrocarbon receptor (AhR) toxicity mechanism. Therefore, the effectiveness of fullerenes as sorbent agents may be underestimated as sorption could be less effective for toxic congeners than previously believed.
28487818	0	8	Modeling	T062	C0870071
28487818	9	19	adsorption	T059	C0001674
28487818	23	33	brominated	T109	C1723493
28487818	35	46	chlorinated	T109,T131	C4277576
28487818	57	62	bromo	T109	C1723493
28487818	65	89	chloro-dibenzo-p-dioxins	T109,T131	C4277576
28487818	93	106	C60 fullerene	T109,T121	C0118354
28487818	113	122	Nano-QSPR	T081	C1564131
28487818	128	141	technological	UnknownType	C0681539
28487818	142	157	implementations	T052	C1708476
28487818	174	188	nanotechnology	T090	C0872323
28487818	203	209	carbon	T196	C0007009
28487818	210	223	nanomaterials	T073	C1450053
28487818	235	245	fullerenes	T104	C0302934
28487818	258	278	buckminsterfullerene	T109	C3665327
28487818	280	283	C60	T109	C3665327
28487818	303	313	properties	T080	C0871161
28487818	322	329	organic	T080	C0747055
28487818	330	343	nanomaterials	T073	C1450053
28487818	371	383	surface area	T082	C1254362
28487818	392	401	extensive	T080	C0205231
28487818	422	431	potential	T080	C3245505
28487818	439	446	organic	T080	C0747055
28487818	447	456	pollutant	T131	C0599786
28487818	457	465	sorbents	T073	C3273359
28487818	467	475	Sorption	T067	C1882365
28487818	476	488	interactions	T169	C1704675
28487818	501	510	hazardous	T080	C0337044
28487818	515	521	useful	T080	C3827682
28487818	550	562	investigates	T169	C1292732
28487818	567	576	influence	T077	C4054723
28487818	580	592	halogenation	T067	C0259913
28487818	596	603	bromine	T131,T196	C0006223
28487818	611	619	chlorine	T131,T196	C0008209
28487818	623	640	dibenzo-p-dioxins	T109	C1723493
28487818	650	666	sorption ability	T067	C1882365
28487818	674	687	C60 fullerene	T109,T121	C0118354
28487818	688	695	surface	T082	C0205148
28487818	697	708	Halogenated	T080	C0205556
28487818	709	726	dibenzo-p-dioxins	T109	C1723493
28487818	728	733	PXDDs	T109	C1723493
28487818	745	747	Br	T131,T196	C0006223
28487818	751	753	Cl	T131,T196	C0008209
28487818	779	790	environment	T082	C0014406
28487818	795	805	accidently	T033	C0243095
28487818	823	846	technological processes	UnknownType	C0681539
28487818	855	868	approximately	T080	C0332232
28487818	875	885	quantities	T081	C1265611
28487818	894	907	combinatorial	T080	C0205556
28487818	908	910	Br	T131,T196	C0006223
28487818	918	920	Cl	T131,T196	C0008209
28487818	921	927	dioxin	T109,T131	C0012503
28487818	928	940	substitution	T044	C0596324
28487818	959	966	present	T033	C0150312
28487818	974	985	environment	T082	C0014406
28487818	991	1003	experimental	T080	C1517586
28487818	1004	1020	characterization	T185	C0243175
28487818	1025	1038	investigation	T058	C0220825
28487818	1042	1049	sorbent	T073	C3273359
28487818	1050	1063	effectiveness	T080	C1280519
28487818	1077	1086	difficult	T080	C0332218
28487818	1122	1166	quantitative structure-property relationship	T081	C1564131
28487818	1168	1172	QSPR	T081	C1564131
28487818	1174	1179	model	T170	C3161035
28487818	1211	1221	adsorption	T059	C0001674
28487818	1222	1228	energy	T070	C0542479
28487818	1250	1255	PXDDs	T109	C1723493
28487818	1256	1264	adsorbed	T067	C1882365
28487818	1268	1271	C60	T109	C3665327
28487818	1273	1277	PXDD	T109	C1723493
28487818	1280	1283	C60	T109	C3665327
28487818	1299	1303	QSPR	T081	C1564131
28487818	1304	1309	model	T170	C3161035
28487818	1310	1318	reported	T170	C0684224
28487818	1349	1355	lowest	T080	C1708760
28487818	1356	1362	energy	T070	C0542479
28487818	1363	1367	PXDD	T109	C1723493
28487818	1370	1373	C60	T109	C3665327
28487818	1374	1383	complexes	T104	C1704241
28487818	1403	1428	World Health Organization	T093	C0043237
28487818	1430	1433	WHO	T093	C0043237
28487818	1435	1444	considers	T078	C0750591
28487818	1486	1511	aryl hydrocarbon receptor	T116,T192	C0052441
28487818	1513	1516	AhR	T116,T192	C0052441
28487818	1518	1526	toxicity	T080	C0040539
28487818	1527	1536	mechanism	T169	C0441712
28487818	1553	1566	effectiveness	T080	C1280519
28487818	1570	1580	fullerenes	T104	C0302934
28487818	1584	1591	sorbent	T073	C3273359
28487818	1592	1598	agents	T120	C0450442
28487818	1624	1632	sorption	T067	C1882365
28487818	1647	1656	effective	T080	C1704419
28487818	1661	1666	toxic	T080	C1407029
28487818	1667	1676	congeners	T104	C0678518

27916455|t|Phosphodiesterase 10A Inhibition Improves Cortico-Basal Ganglia Function in Huntington's Disease Models
27916455|a|Huntington's disease (HD) symptoms are driven to a large extent by dysfunction of the basal ganglia circuitry. HD patients exhibit reduced striatal phoshodiesterase 10 (PDE10) levels. Using HD mouse models that exhibit reduced PDE10, we demonstrate the benefit of pharmacologic PDE10 inhibition to acutely correct basal ganglia circuitry deficits. PDE10 inhibition restored corticostriatal input and boosted cortically driven indirect pathway activity. Cyclic nucleotide signaling is impaired in HD models, and PDE10 loss may represent a homeostatic adaptation to maintain signaling. Elevation of both cAMP and cGMP by PDE10 inhibition was required for rescue. Phosphoproteomic profiling of striatum in response to PDE10 inhibition highlighted plausible neural substrates responsible for the improvement. Early chronic PDE10 inhibition in Q175 mice showed improvements beyond those seen with acute administration after symptom onset, including partial reversal of striatal deregulated transcripts and the prevention of the emergence of HD neurophysiological deficits. VIDEO ABSTRACT.
27916455	0	21	Phosphodiesterase 10A	T116,T126	C1452465
27916455	22	32	Inhibition	T052	C3463820
27916455	42	63	Cortico-Basal Ganglia	T023	C0004781
27916455	64	72	Function	T039	C0031843
27916455	76	96	Huntington's Disease	T047	C0020179
27916455	97	103	Models	T050	C0012644
27916455	104	124	Huntington's disease	T047	C0020179
27916455	126	128	HD	T047	C0020179
27916455	130	138	symptoms	T184	C1457887
27916455	155	167	large extent	T080	C1555602
27916455	171	182	dysfunction	T077	C3887504
27916455	190	203	basal ganglia	T023	C0004781
27916455	204	213	circuitry	T023	C0599854
27916455	215	217	HD	T047	C0020179
27916455	218	226	patients	T101	C0030705
27916455	243	271	striatal phoshodiesterase 10	T116,T126	C1447737
27916455	273	278	PDE10	T116,T126	C1447737
27916455	294	296	HD	T047	C0020179
27916455	297	309	mouse models	T050	C2986594
27916455	331	336	PDE10	T116,T126	C1452465
27916455	357	364	benefit	T081	C0814225
27916455	368	381	pharmacologic	T169	C0205464
27916455	382	387	PDE10	T116,T126	C1452465
27916455	388	398	inhibition	T052	C3463820
27916455	418	431	basal ganglia	T023	C0004781
27916455	432	441	circuitry	T023	C0599854
27916455	442	450	deficits	T080	C2987487
27916455	452	457	PDE10	T116,T126	C1452465
27916455	458	468	inhibition	T052	C3463820
27916455	478	493	corticostriatal	T023	C0229962
27916455	494	499	input	T077	C1708517
27916455	530	538	indirect	T080	C0439852
27916455	539	546	pathway	T077	C1705987
27916455	547	555	activity	T052	C0441655
27916455	557	584	Cyclic nucleotide signaling	T044	C1155588
27916455	588	596	impaired	T169	C0221099
27916455	600	602	HD	T047	C0020179
27916455	603	609	models	T050	C0012644
27916455	615	620	PDE10	T116,T126	C1452465
27916455	642	653	homeostatic	T038	C0019868
27916455	654	664	adaptation	T038	C0392673
27916455	677	686	signaling	T038	C3537152
27916455	688	697	Elevation	T061	C0439775
27916455	706	710	cAMP	T114,T121,T123	C0001455
27916455	715	719	cGMP	T114,T123	C0018338
27916455	723	728	PDE10	T116,T126	C1452465
27916455	729	739	inhibition	T052	C3463820
27916455	765	791	Phosphoproteomic profiling	T059	C1327760
27916455	795	803	striatum	T023	C0229962
27916455	819	824	PDE10	T116,T126	C1452465
27916455	825	835	inhibition	T052	C3463820
27916455	858	864	neural	T169	C3714606
27916455	865	875	substrates	T167	C3891814
27916455	896	907	improvement	T077	C2986411
27916455	915	922	chronic	T079	C0205191
27916455	923	928	PDE10	T116,T126	C1452465
27916455	929	939	inhibition	T052	C3463820
27916455	943	952	Q175 mice	T050	C2986594
27916455	960	972	improvements	T077	C2986411
27916455	996	1001	acute	T079	C0205178
27916455	1002	1016	administration	T061	C1533734
27916455	1023	1030	symptom	T184	C1457887
27916455	1031	1036	onset	T080	C0332162
27916455	1048	1055	partial	T081	C0728938
27916455	1056	1064	reversal	T169	C0443290
27916455	1068	1076	striatal	T023	C0229962
27916455	1077	1088	deregulated	T052	C1880287
27916455	1089	1100	transcripts	T114	C1519595
27916455	1109	1119	prevention	T080	C2700409
27916455	1127	1136	emergence	T052	C1706079
27916455	1140	1142	HD	T047	C0020179
27916455	1143	1161	neurophysiological	T040	C1327471
27916455	1162	1170	deficits	T080	C2987487

27271951|t|Association of Autoimmune Encephalitis With Combined Immune Checkpoint Inhibitor Treatment for Metastatic Cancer
27271951|a|Paraneoplastic encephalitides usually precede a diagnosis of cancer and are often refractory to immunosuppressive therapy. Conversely, autoimmune encephalitides are reversible conditions that can occur in the presence or absence of cancer. To report the induction of autoimmune encephalitis in 2 patients after treatment of metastatic cancer with a combination of the immune checkpoint inhibitors nivolumab and ipilimumab. A retrospective case study was conducted of the clinical and management course of 2 patients with progressive, treatment - refractory metastatic cancer who were treated with a single dose each (concomitantly) of the immune checkpoint inhibitors nivolumab, 1 mg/kg, and ipilimumab, 3 mg/kg. Nivolumab and ipilimumab. The clinical response to immunosuppressive therapy in suspected autoimmune encephalitis in the setting of immune checkpoint inhibitor use. Autoantibody testing confirmed identification of anti-N-methyl-D-aspartate receptor antibodies in the cerebrospinal fluid of 1 patient. Withdrawal of immune checkpoint inhibitors and initiation of immunosuppressive therapy, consisting of intravenous methylprednisolone sodium succinate equivalent to 1000 mg of methylprednisolone for 5 days, 0.4 mg/kg/d of intravenous immunoglobulin for 5 days, and 2 doses of rituximab, 1000 mg, in 1 patient and oral prednisone, 60 mg/d, in the other patient, resulted in improved neurologic symptoms. Immune checkpoint inhibition may favor the development of immune responses against neuronal antigens, leading to autoimmune encephalitis. Early recognition and treatment of autoimmune encephalitis in patients receiving immune checkpoint blockade therapy will likely be essential for maximizing clinical recovery and minimizing the effect of drug-related toxic effects. The mechanisms by which immune checkpoint inhibition may contribute to autoimmune encephalitis require further study.
27271951	0	11	Association	T080	C0439849
27271951	15	38	Autoimmune Encephalitis	T047	C0393639
27271951	53	80	Immune Checkpoint Inhibitor	T121	C1254351
27271951	81	90	Treatment	T169	C0039798
27271951	95	112	Metastatic Cancer	T191	C0027627
27271951	113	142	Paraneoplastic encephalitides	T047	C0338430
27271951	161	180	diagnosis of cancer	T060	C0920688
27271951	195	205	refractory	T169	C0205269
27271951	209	234	immunosuppressive therapy	T061	C0021079
27271951	248	273	autoimmune encephalitides	T047	C0393639
27271951	278	288	reversible	T169	C0205343
27271951	289	299	conditions	T080	C0348080
27271951	309	314	occur	T052	C1709305
27271951	322	330	presence	T033	C0150312
27271951	334	341	absence	T169	C0332197
27271951	345	351	cancer	T191	C0006826
27271951	367	376	induction	T169	C0205263
27271951	380	403	autoimmune encephalitis	T047	C0393639
27271951	409	417	patients	T101	C0030705
27271951	424	433	treatment	T169	C0039798
27271951	437	454	metastatic cancer	T191	C0027627
27271951	462	473	combination	T080	C0205195
27271951	481	509	immune checkpoint inhibitors	T121	C1254351
27271951	510	519	nivolumab	T116,T121,T129	C3657270
27271951	524	534	ipilimumab	T116,T121,T129	C1367202
27271951	538	562	retrospective case study	T062	C0035363
27271951	584	607	clinical and management	T058	C1516615
27271951	608	614	course	T079	C0750729
27271951	620	628	patients	T101	C0030705
27271951	634	645	progressive	T169	C0205329
27271951	647	656	treatment	T169	C0039798
27271951	659	687	refractory metastatic cancer	T191	C0677936
27271951	697	709	treated with	T061	C0332293
27271951	712	723	single dose	T081	C0869039
27271951	730	743	concomitantly	T079	C0521115
27271951	752	780	immune checkpoint inhibitors	T121	C1254351
27271951	781	790	nivolumab	T116,T121,T129	C3657270
27271951	805	815	ipilimumab	T116,T121,T129	C1367202
27271951	826	835	Nivolumab	T116,T121,T129	C3657270
27271951	840	850	ipilimumab	T116,T121,T129	C1367202
27271951	856	873	clinical response	T033	C4055223
27271951	877	902	immunosuppressive therapy	T061	C0021079
27271951	906	915	suspected	T080	C0332147
27271951	916	939	autoimmune encephalitis	T047	C0393639
27271951	958	985	immune checkpoint inhibitor	T121	C1254351
27271951	991	1011	Autoantibody testing	T059	C1272321
27271951	1012	1021	confirmed	T033	C0750484
27271951	1022	1036	identification	T080	C0205396
27271951	1040	1085	anti-N-methyl-D-aspartate receptor antibodies	T116,T129	C3203613
27271951	1093	1112	cerebrospinal fluid	T031	C0007806
27271951	1118	1125	patient	T101	C0030705
27271951	1127	1137	Withdrawal	T052	C2349954
27271951	1141	1169	immune checkpoint inhibitors	T121	C1254351
27271951	1174	1184	initiation	T169	C1704686
27271951	1188	1213	immunosuppressive therapy	T061	C0021079
27271951	1229	1240	intravenous	T169	C0013153
27271951	1241	1320	methylprednisolone sodium succinate equivalent to 1000 mg of methylprednisolone	T200	C4083084
27271951	1327	1331	days	T079	C0439228
27271951	1348	1374	intravenous immunoglobulin	T116,T121,T129	C0085297
27271951	1381	1385	days	T079	C0439228
27271951	1393	1398	doses	T081	C0178602
27271951	1402	1411	rituximab	T116,T121,T129	C0393022
27271951	1427	1434	patient	T101	C0030705
27271951	1439	1454	oral prednisone	T200	C0305834
27271951	1478	1485	patient	T101	C0030705
27271951	1499	1507	improved	T033	C0184511
27271951	1508	1527	neurologic symptoms	T184	C0235031
27271951	1529	1557	Immune checkpoint inhibition	T040	C2255931
27271951	1572	1583	development	T169	C1527148
27271951	1587	1603	immune responses	T042	C0301872
27271951	1612	1629	neuronal antigens	T129	C0521390
27271951	1642	1665	autoimmune encephalitis	T047	C0393639
27271951	1667	1684	Early recognition	T061	C0814435
27271951	1689	1698	treatment	T169	C0039798
27271951	1702	1725	autoimmune encephalitis	T047	C0393639
27271951	1729	1737	patients	T101	C0030705
27271951	1748	1782	immune checkpoint blockade therapy	T061	C0021079
27271951	1798	1807	essential	T080	C0205224
27271951	1823	1831	clinical	T080	C0205210
27271951	1832	1840	recovery	T052	C0237820
27271951	1870	1896	drug-related toxic effects	T033	C1408407
27271951	1922	1950	immune checkpoint inhibition	T040	C2255931
27271951	1969	1992	autoimmune encephalitis	T047	C0393639

28423032|t|Complete study demonstrating the absence of rhabdovirus in a distinct Sf9 cell line
28423032|a|A putative novel rhabdovirus (SfRV) was previously identified in a Spodoptera frugiperda cell line (Sf9 cells [ATCC CRL-1711 lot 58078522]) by next generation sequencing and extensive bioinformatic analysis. We performed an extensive analysis of our Sf9 cell bank (ATCC CRL-1711 lot 5814 [Sf9L5814]) to determine whether this virus was already present in cells obtained from ATCC in 1987. Inverse PCR of DNA isolated from Sf9 L5814 cellular DNA revealed integration of SfRV sequences in the cellular genome. RT-PCR of total RNA showed a deletion of 320 nucleotides in the SfRV RNA that includes the transcriptional motifs for genes X and L. Concentrated cell culture supernatant was analyzed by sucrose density gradient centrifugation and revealed a single band at a density of 1.14 g/ml. This fraction was further analysed by electron microscopy and showed amorphous and particulate debris that did not resemble a rhabdovirus in morphology or size. SDS-PAGE analysis confirmed that the protein composition did not contain the typical five rhabdovirus structural proteins and LC-MS/MS analysis revealed primarily of exosomal marker proteins, the SfRV N protein, and truncated forms of SfRV N, P, and G proteins. The SfRV L gene fragment RNA sequence was recovered from the supernatant after ultracentrifugation of the 1.14 g/ml fraction treated with diethyl ether suggesting that the SfRV L gene fragment sequence is not associated with a diethyl ether resistant nucleocapsid. Interestingly, the 1.14 g/ml fraction was able to transfer baculovirus DNA into Sf9L5814 cells, consistent with the presence of functional exosomes. Our results demonstrate the absence of viral particles in ATCC CRL-1711 lot 5814 Sf9 cells in contrast to a previous study that suggested the presence of infectious rhabdoviral particles in Sf9 cells from a different lot. This study highlights how cell lines with different lineages may present different virosomes and therefore no general conclusions can be drawn across Sf9 cells from different laboratories.
28423032	0	8	Complete	T080	C0205197
28423032	9	14	study	T062	C2603343
28423032	33	40	absence	T169	C0332197
28423032	44	55	rhabdovirus	T005	C0035414
28423032	70	83	Sf9 cell line	T025	C0597447
28423032	101	112	rhabdovirus	T005	C0035414
28423032	114	118	SfRV	T005	C0035414
28423032	135	145	identified	T080	C0205396
28423032	151	182	Spodoptera frugiperda cell line	T025	C0599415
28423032	184	193	Sf9 cells	T025	C3494245
28423032	195	221	ATCC CRL-1711 lot 58078522	T025	C3494245
28423032	227	253	next generation sequencing	T063	C2936622
28423032	258	267	extensive	T080	C0205231
28423032	268	281	bioinformatic	T091	C1140694
28423032	282	290	analysis	T062	C0936012
28423032	308	317	extensive	T080	C0205231
28423032	318	326	analysis	T062	C0936012
28423032	334	337	Sf9	T025	C3494245
28423032	338	347	cell bank	T073,T170	C0920429
28423032	349	371	ATCC CRL-1711 lot 5814	T025	C3494245
28423032	373	381	Sf9L5814	T025	C3494245
28423032	410	415	virus	T005	C0042776
28423032	428	435	present	T033	C0150312
28423032	439	444	cells	T025	C0007634
28423032	445	453	obtained	T169	C1301820
28423032	459	463	ATCC	T092	C0598079
28423032	473	484	Inverse PCR	T059,T063	C0079639
28423032	488	491	DNA	T114,T123	C0012854
28423032	492	500	isolated	T169	C0205409
28423032	506	524	Sf9 L5814 cellular	T025	C3494245
28423032	525	528	DNA	T114,T123	C0012854
28423032	529	537	revealed	T080	C0443289
28423032	538	549	integration	T045	C1158478
28423032	553	557	SfRV	T005	C0035414
28423032	558	567	sequences	T086	C0162326
28423032	575	583	cellular	T025	C0007634
28423032	584	590	genome	T028	C0017428
28423032	592	598	RT-PCR	T063	C0599161
28423032	608	611	RNA	T114	C0035668
28423032	621	629	deletion	T045	C2753464
28423032	637	648	nucleotides	T114	C0028630
28423032	656	660	SfRV	T005	C0035414
28423032	661	664	RNA	T114	C0035668
28423032	683	698	transcriptional	T045	C0040649
28423032	699	705	motifs	T086	C3178796
28423032	710	723	genes X and L	T028	C0017337
28423032	738	750	cell culture	T059	C0007585
28423032	751	762	supernatant	T031	C1550101
28423032	779	818	sucrose density gradient centrifugation	T059	C0201799
28423032	823	831	revealed	T080	C0443289
28423032	878	886	fraction	T081	C1264633
28423032	911	930	electron microscopy	T059	C0026019
28423032	942	951	amorphous	T080	C1979848
28423032	956	967	particulate	T167	C0457784
28423032	968	974	debris	T167	C0440266
28423032	984	987	not	T169	C1518422
28423032	988	996	resemble	T080	C0205556
28423032	999	1010	rhabdovirus	T005	C0035414
28423032	1014	1024	morphology	T080	C0332437
28423032	1028	1032	size	T082	C0456389
28423032	1034	1051	SDS-PAGE analysis	T059,T062	C0600209
28423032	1071	1078	protein	T116,T123	C0033684
28423032	1079	1090	composition	T201	C0486616
28423032	1095	1098	not	T169	C1518422
28423032	1124	1135	rhabdovirus	T005	C0035414
28423032	1136	1155	structural proteins	T116,T123	C0582263
28423032	1160	1177	LC-MS/MS analysis	T059	C0872318
28423032	1178	1186	revealed	T080	C0443289
28423032	1187	1196	primarily	T080	C0205225
28423032	1200	1208	exosomal	T026	C2350332
28423032	1209	1224	marker proteins	T116,T123	C0033684
28423032	1230	1234	SfRV	T005	C0035414
28423032	1235	1244	N protein	T116,T123	C0524816
28423032	1250	1259	truncated	T044	C1514568
28423032	1269	1273	SfRV	T005	C0035414
28423032	1274	1275	N	T116,T123	C0524816
28423032	1277	1278	P	T116,T123	C0031689
28423032	1284	1294	G proteins	T116,T126	C0086376
28423032	1300	1304	SfRV	T005	C0035414
28423032	1305	1320	L gene fragment	T028	C0017337
28423032	1321	1333	RNA sequence	T086	C0162327
28423032	1338	1352	recovered from	T080	C0521108
28423032	1357	1368	supernatant	T031	C1550101
28423032	1375	1394	ultracentrifugation	T059	C0041609
28423032	1412	1420	fraction	T081	C1264633
28423032	1434	1447	diethyl ether	T109,T121	C0014994
28423032	1468	1472	SfRV	T005	C0035414
28423032	1473	1488	L gene fragment	T028	C0017337
28423032	1489	1497	sequence	T086	C0314659
28423032	1501	1504	not	T169	C1518422
28423032	1505	1520	associated with	T080	C0332281
28423032	1523	1536	diethyl ether	T109,T121	C0014994
28423032	1537	1546	resistant	T169	C0332325
28423032	1547	1559	nucleocapsid	T114,T116,T123	C0178774
28423032	1590	1598	fraction	T081	C1264633
28423032	1611	1619	transfer	T169	C1705822
28423032	1620	1631	baculovirus	T005	C0935640
28423032	1632	1635	DNA	T114,T123	C0012854
28423032	1641	1655	Sf9L5814 cells	T025	C3494245
28423032	1657	1672	consistent with	T080	C1524057
28423032	1677	1685	presence	T033	C0150312
28423032	1689	1699	functional	T169	C0205245
28423032	1700	1708	exosomes	T026	C2350332
28423032	1738	1745	absence	T169	C0332197
28423032	1749	1764	viral particles	T026	C0042760
28423032	1768	1790	ATCC CRL-1711 lot 5814	T025	C3494245
28423032	1791	1800	Sf9 cells	T025	C3494245
28423032	1804	1812	contrast	T080	C1979874
28423032	1827	1832	study	T062	C2603343
28423032	1864	1874	infectious	T080	C1550587
28423032	1875	1896	rhabdoviral particles	T026	C0042760
28423032	1900	1909	Sf9 cells	T025	C3494245
28423032	1917	1926	different	T080	C1705242
28423032	1927	1930	lot	T080	C1518000
28423032	1937	1942	study	T062	C2603343
28423032	1958	1968	cell lines	T025	C0007634
28423032	1974	1983	different	T080	C1705242
28423032	1984	1992	lineages	T077	C1881379
28423032	1997	2004	present	T033	C0150312
28423032	2005	2014	different	T080	C1705242
28423032	2015	2024	virosomes	T116,T121	C0887910
28423032	2050	2061	conclusions	T078	C1707478
28423032	2082	2091	Sf9 cells	T025	C3494245
28423032	2107	2119	laboratories	T073,T093	C0022877

27909143|t|Interobserver and Intraobserver Reliability of Clinical Assessments in Knee Osteoarthritis
27909143|a|Clinical examination of the knee is subject to measurement error. The aim of this analysis was to determine interobserver and intraobserver reliability of commonly used clinical tests in patients with knee osteoarthritis (OA). We studied subjects with symptomatic knee OA who were participants in an open-label clinical trial of intraarticular steroid therapy. Following standardization of the clinical test procedures, 2 clinicians assessed 25 subjects independently at the same visit, and the same clinician assessed 88 subjects over an interval period of 2-10 weeks; in both cases prior to the steroid intervention. Clinical examination included assessment of bony enlargement, crepitus, quadriceps wasting, knee effusion, joint-line and anserine tenderness, and knee range of movement (ROM). Intraclass correlation coefficients (ICC), estimated kappa (κ), weighted kappa (κω), and Bland-Altman plots were used to determine interobserver and intraobserver levels of agreement. Using Landis and Koch criteria, interobserver κ scores were moderate for patellofemoral joint (κ = 0.53) and anserine tenderness (κ = 0.48); good for bony enlargement (κ = 0.66), quadriceps wasting (κ = 0.78), crepitus (κ = 0.78), medial tibiofemoral joint tenderness (κ = 0.76), and effusion assessed by ballottement (κ = 0.73) and bulge sign (κω = 0.78); and excellent for lateral tibiofemoral joint tenderness (κ = 1.00), flexion (ICC = 0.97), and extension (ICC = 0.87) ROM. Intraobserver κ scores were moderate for lateral tibiofemoral joint tenderness (κ = 0.60); good for crepitus (κ = 0.78), effusion assessed by ballottement test (κ = 0.77), patellofemoral joint (κ = 0.66), medial tibiofemoral joint (κ = 0.64), and anserine tenderness (κ = 0.73); and excellent for effusion assessed by bulge sign (κω = 0.83), bony enlargement (κ = 0.98), quadriceps wasting (κ = 0.83), flexion (ICC = 0.99), and extension (ICC = 0.96) ROM. Among individuals with symptomatic knee OA, the reliability of clinical examination of the knee was at least good for the majority of clinical signs of knee OA.
27909143	0	13	Interobserver	T170	C0870736
27909143	18	31	Intraobserver	T096	C0870992
27909143	32	43	Reliability	T081	C2347947
27909143	47	67	Clinical Assessments	T033	C3845884
27909143	71	90	Knee Osteoarthritis	T047	C0409959
27909143	91	111	Clinical examination	T033	C1456356
27909143	119	123	knee	T023	C0022742
27909143	138	155	measurement error	T081	C0681899
27909143	199	212	interobserver	T170	C0870736
27909143	217	230	intraobserver	T096	C0870992
27909143	231	242	reliability	T081	C2347947
27909143	278	286	patients	T101	C0030705
27909143	292	311	knee osteoarthritis	T047	C0409959
27909143	313	315	OA	T047	C0409959
27909143	329	337	subjects	T096	C0681850
27909143	343	354	symptomatic	T169	C0231220
27909143	355	362	knee OA	T047	C0409959
27909143	372	384	participants	T098	C0679646
27909143	391	416	open-label clinical trial	T062	C1709323
27909143	420	450	intraarticular steroid therapy	T061	C0585373
27909143	462	477	standardization	T062	C0038136
27909143	485	509	clinical test procedures	T059	C0022885
27909143	513	523	clinicians	T097	C0871685
27909143	524	532	assessed	T058	C0220825
27909143	536	544	subjects	T096	C0681850
27909143	571	576	visit	T058	C1512346
27909143	591	600	clinician	T097	C0871685
27909143	601	609	assessed	T058	C0220825
27909143	613	621	subjects	T096	C0681850
27909143	630	645	interval period	T079	C1272706
27909143	688	695	steroid	T061	C0149783
27909143	696	708	intervention	T061	C0184661
27909143	710	730	Clinical examination	T033	C1456356
27909143	731	739	included	T169	C0332257
27909143	740	750	assessment	T058	C0220825
27909143	754	770	bony enlargement	UnknownType	C0221610
27909143	772	780	crepitus	T046	C0277964
27909143	782	800	quadriceps wasting	T033	C0555751
27909143	802	815	knee effusion	T033	C0343166
27909143	817	827	joint-line	T029	C0446569
27909143	832	840	anserine	T023	C0224834
27909143	841	851	tenderness	T184	C0240094
27909143	857	879	knee range of movement	T033	C0576094
27909143	881	884	ROM	T033	C0576094
27909143	887	922	Intraclass correlation coefficients	T081	C0392762
27909143	924	927	ICC	T081	C0392762
27909143	930	945	estimated kappa	T081	C0392762
27909143	947	948	κ	T081	C0392762
27909143	951	965	weighted kappa	T081	C0392762
27909143	967	969	κω	T081	C0392762
27909143	976	994	Bland-Altman plots	T081	C0392762
27909143	1018	1031	interobserver	T170	C0870736
27909143	1036	1049	intraobserver	T096	C0870992
27909143	1050	1056	levels	T080	C0441889
27909143	1060	1069	agreement	T054	C0680240
27909143	1077	1101	Landis and Koch criteria	T081	C0871425
27909143	1103	1125	interobserver κ scores	T080	C0237855
27909143	1131	1139	moderate	T080	C0205081
27909143	1144	1164	patellofemoral joint	T030	C0447801
27909143	1166	1167	κ	T081	C0392762
27909143	1180	1188	anserine	T023	C0224834
27909143	1189	1199	tenderness	T184	C0240094
27909143	1201	1202	κ	T081	C0392762
27909143	1212	1216	good	T080	C0205170
27909143	1221	1237	bony enlargement	UnknownType	C0221610
27909143	1239	1240	κ	T081	C0392762
27909143	1250	1268	quadriceps wasting	T033	C0555751
27909143	1270	1271	κ	T081	C0392762
27909143	1281	1289	crepitus	T046	C0277964
27909143	1291	1292	κ	T081	C0392762
27909143	1302	1308	medial	T082	C0205098
27909143	1309	1327	tibiofemoral joint	T030	C0447795
27909143	1328	1338	tenderness	T184	C0240094
27909143	1340	1341	κ	T081	C0392762
27909143	1355	1363	effusion	T033	C0343166
27909143	1376	1388	ballottement	T184	C0231756
27909143	1390	1391	κ	T081	C0392762
27909143	1404	1414	bulge sign	T060	C3696902
27909143	1416	1418	κω	T081	C0392762
27909143	1432	1441	excellent	T080	C1548784
27909143	1446	1453	lateral	T082	C0205093
27909143	1454	1472	tibiofemoral joint	T030	C0447795
27909143	1473	1483	tenderness	T184	C0240094
27909143	1485	1486	κ	T081	C0392762
27909143	1496	1503	flexion	T042	C0231452
27909143	1505	1508	ICC	T081	C0392762
27909143	1522	1531	extension	T169	C0231448
27909143	1533	1536	ICC	T081	C0392762
27909143	1545	1548	ROM	T033	C0576094
27909143	1550	1572	Intraobserver κ scores	T080	C0237855
27909143	1578	1586	moderate	T080	C0205081
27909143	1591	1598	lateral	T082	C0205093
27909143	1599	1617	tibiofemoral joint	T030	C0447795
27909143	1618	1628	tenderness	T184	C0234233
27909143	1630	1631	κ	T081	C0392762
27909143	1660	1661	κ	T081	C0392762
27909143	1671	1679	effusion	T033	C0343166
27909143	1692	1709	ballottement test	T184	C0231756
27909143	1711	1712	κ	T081	C0392762
27909143	1722	1742	patellofemoral joint	T030	C0447801
27909143	1744	1745	κ	T081	C0392762
27909143	1755	1761	medial	T082	C0205098
27909143	1762	1780	tibiofemoral joint	T030	C0447795
27909143	1782	1783	κ	T081	C0392762
27909143	1797	1805	anserine	T023	C0224834
27909143	1806	1816	tenderness	T184	C0234233
27909143	1818	1819	κ	T081	C0392762
27909143	1833	1842	excellent	T080	C1548784
27909143	1847	1855	effusion	T033	C0343166
27909143	1868	1878	bulge sign	T060	C3696902
27909143	1880	1882	κω	T081	C0392762
27909143	1892	1908	bony enlargement	UnknownType	C0221610
27909143	1910	1911	κ	T081	C0392762
27909143	1921	1939	quadriceps wasting	T033	C0555751
27909143	1941	1942	κ	T081	C0392762
27909143	1952	1959	flexion	T042	C0231452
27909143	1961	1964	ICC	T081	C0392762
27909143	1978	1987	extension	T169	C0231448
27909143	1989	1992	ICC	T081	C0392762
27909143	2001	2004	ROM	T033	C0576094
27909143	2012	2023	individuals	T098	C0237401
27909143	2029	2040	symptomatic	T169	C0231220
27909143	2041	2048	knee OA	T047	C0409959
27909143	2054	2065	reliability	T081	C2347947
27909143	2069	2089	clinical examination	T033	C1456356
27909143	2097	2101	knee	T023	C0022742
27909143	2140	2154	clinical signs	T033	C3540840
27909143	2158	2165	knee OA	T047	C0409959

28175980|t|Spine fracture prevalence in a nationally representative sample of US women and men aged ≥40 years: results from the National Health and Nutrition Examination Survey (NHANES) 2013-2014
28175980|a|Spine fracture prevalence is similar in men and women, increasing from <5 % in those <60 to 11 % in those 70-79 and 18 % in those ≥80 years. Prevalence was higher with age, lower bone mineral density (BMD), and in those meeting criteria for spine imaging. Most subjects with spine fractures were unaware of them. Spine fractures have substantial medical significance but are seldom recognized. This study collected contemporary nationally representative spine fracture prevalence data. Cross-sectional analysis of 3330 US adults aged ≥40 years participating in NHANES 2013-2014 with evaluable Vertebral Fracture Assessment (VFA). VFA was graded by semiquantitative measurement. BMD and an osteoporosis questionnaire were collected. Overall spine fracture prevalence was 5.4 % and similar in men and women. Prevalence increased with age from <5 % in those <60 to 11 % in those 70-79 and 18 % in those ≥80 years. Fractures were more common in non-Hispanic whites and in people with lower body mass index and BMD. Among subjects with spine fracture, 26 % met BMD criteria for osteoporosis. Prevalence was higher in subjects who met National Osteoporosis Foundation (NOF) criteria for spine imaging (14 vs 4.7 %, P < 0.001). Only 8 % of people with a spine fracture diagnosed by VFA had a self-reported fracture, and among those who self-reported a spine fracture, only 21 % were diagnosed with fracture by VFA. Spine fracture prevalence is similar in women and men and increases with age and lower BMD, although most subjects with spine fracture do not meet BMD criteria for osteoporosis. Since most (>90 %) individuals were unaware of their spine fractures, lateral spine imaging is needed to identify these women and men. Spine fracture prevalence was threefold higher in individuals meeting NOF criteria for spine imaging (∼1 in 7 undergoing VFA). Identifying spine fractures as part of comprehensive risk assessment may improve clinical decision making.
28175980	0	14	Spine fracture	T037	C0080179
28175980	15	25	prevalence	T081	C0033105
28175980	31	56	nationally representative	T082	C0681788
28175980	67	69	US	T083	C0041703
28175980	70	75	women	T098	C0043210
28175980	80	83	men	T098	C0025266
28175980	84	88	aged	T032	C0001779
28175980	117	165	National Health and Nutrition Examination Survey	T062	C0376344
28175980	167	173	NHANES	T062	C0376344
28175980	185	199	Spine fracture	T037	C0080179
28175980	200	210	prevalence	T081	C0033105
28175980	225	228	men	T098	C0025266
28175980	233	238	women	T098	C0043210
28175980	326	336	Prevalence	T081	C0033105
28175980	341	347	higher	T080	C0205250
28175980	353	356	age	T032	C0001779
28175980	353	356	age	T032	C0001779
28175980	358	363	lower	T080	C0205251
28175980	364	384	bone mineral density	T201	C0005938
28175980	386	389	BMD	T201	C0005938
28175980	413	421	criteria	T080	C0242801
28175980	426	439	spine imaging	T060	C1532547
28175980	446	454	subjects	T062	C0178693
28175980	460	475	spine fractures	T037	C0080179
28175980	481	488	unaware	T033	C0589402
28175980	498	513	Spine fractures	T037	C0080179
28175980	531	538	medical	T169	C0205476
28175980	560	566	seldom	T080	C0522498
28175980	613	638	nationally representative	T082	C0681788
28175980	639	653	spine fracture	T037	C0080179
28175980	654	664	prevalence	T081	C0033105
28175980	671	695	Cross-sectional analysis	T062	C0010362
28175980	704	706	US	T083	C0041703
28175980	707	713	adults	T100	C0001675
28175980	714	718	aged	T032	C0001779
28175980	746	752	NHANES	T062	C0376344
28175980	778	796	Vertebral Fracture	T037	C0080179
28175980	809	812	VFA	T060	C0185141
28175980	815	818	VFA	T060	C0185141
28175980	863	866	BMD	T201	C0005938
28175980	874	886	osteoporosis	T047	C0029456
28175980	887	900	questionnaire	T170	C0034394
28175980	925	939	spine fracture	T037	C0080179
28175980	940	950	prevalence	T081	C0033105
28175980	976	979	men	T098	C0025266
28175980	984	989	women	T098	C0043210
28175980	991	1001	Prevalence	T081	C0033105
28175980	1017	1020	age	T032	C0001779
28175980	1096	1105	Fractures	T037	C0016658
28175980	1126	1145	non-Hispanic whites	T098	C1257890
28175980	1165	1170	lower	T080	C0205251
28175980	1171	1186	body mass index	T201	C1305855
28175980	1191	1194	BMD	T201	C0005938
28175980	1202	1210	subjects	T062	C0178693
28175980	1216	1230	spine fracture	T037	C0080179
28175980	1241	1244	BMD	T201	C0005938
28175980	1245	1253	criteria	T080	C0242801
28175980	1258	1270	osteoporosis	T047	C0029456
28175980	1272	1282	Prevalence	T081	C0033105
28175980	1287	1293	higher	T080	C0205250
28175980	1297	1305	subjects	T062	C0178693
28175980	1314	1346	National Osteoporosis Foundation	UnknownType	C0679938
28175980	1348	1351	NOF	UnknownType	C0679938
28175980	1353	1361	criteria	T080	C0242801
28175980	1366	1379	spine imaging	T060	C1532547
28175980	1432	1446	spine fracture	T037	C0080179
28175980	1447	1456	diagnosed	T033	C0011900
28175980	1460	1463	VFA	T060	C0185141
28175980	1470	1483	self-reported	T062	C0681906
28175980	1484	1492	fracture	T037	C0016658
28175980	1514	1527	self-reported	T062	C0681906
28175980	1530	1544	spine fracture	T037	C0080179
28175980	1561	1570	diagnosed	T033	C0011900
28175980	1576	1584	fracture	T037	C0016658
28175980	1588	1591	VFA	T060	C0185141
28175980	1593	1607	Spine fracture	T037	C0080179
28175980	1608	1618	prevalence	T081	C0033105
28175980	1633	1638	women	T098	C0043210
28175980	1643	1646	men	T098	C0025266
28175980	1666	1669	age	T032	C0001779
28175980	1674	1679	lower	T080	C0205251
28175980	1680	1683	BMD	T201	C0005938
28175980	1699	1707	subjects	T062	C0178693
28175980	1713	1727	spine fracture	T037	C0080179
28175980	1740	1743	BMD	T201	C0005938
28175980	1757	1769	osteoporosis	T047	C0029456
28175980	1790	1801	individuals	T098	C0237401
28175980	1807	1814	unaware	T033	C0589402
28175980	1824	1839	spine fractures	T037	C0080179
28175980	1841	1848	lateral	T082	C0205093
28175980	1849	1862	spine imaging	T060	C1532547
28175980	1891	1896	women	T098	C0043210
28175980	1901	1904	men	T098	C0025266
28175980	1906	1920	Spine fracture	T037	C0080179
28175980	1921	1931	prevalence	T081	C0033105
28175980	1946	1952	higher	T080	C0205250
28175980	1956	1967	individuals	T098	C0237401
28175980	1976	1979	NOF	UnknownType	C0679938
28175980	1980	1988	criteria	T080	C0242801
28175980	1993	2006	spine imaging	T060	C1532547
28175980	2027	2030	VFA	T060	C0185141
28175980	2045	2060	spine fractures	T037	C0080179
28175980	2072	2085	comprehensive	T080	C1880156
28175980	2086	2101	risk assessment	T058	C0086930
28175980	2106	2113	improve	T033	C0184511
28175980	2114	2138	clinical decision making	T060	C4042877

27812586|t|Large-scale synthesis and structural analysis of a synthetic glycopeptide dendrimer as an anti-cancer vaccine candidate
27812586|a|Herein, we report a new process that enables the gram-scale production of a fully synthetic anti-cancer vaccine for human use. This therapeutic vaccine candidate, named MAG-Tn3, is a high-molecular-weight tetrameric glycopeptide encompassing carbohydrate tumor-associated Tn antigen clusters and peptidic CD4(+) T-cell epitopes. The synthetic process involves (i) the stepwise solid-phase assembly of protected amino acids, including the high value-added Tn building blocks with only 1.5 equivalents, (ii) a single isolated intermediate, and (iii) the simultaneous deprotection of 36 hindered protective groups. The resulting MAG-Tn3 was unambiguously characterized using a combination of techniques, including a structural analysis by nuclear magnetic resonance spectroscopy. The four peptidic chains are flexible in solution, with a more constrained but extended conformation at the Tn3 antigen motif. Finally, we demonstrate that, when injected into HLA-DR1 - expressing transgenic mice, this vaccine induces Tn-specific antibodies that mediate the killing of human Tn-positive tumor cells. These studies led to a clinical batch of the MAG-Tn3, currently investigated in breast cancer patients (phase I clinical trial). The current study demonstrates the feasibility of the multigram-scale synthesis of a highly pure complex glycopeptide, and it opens new avenues for the use of synthetic glycopeptides as drugs in humans.
27812586	0	11	Large-scale	T081	C0392762
27812586	12	21	synthesis	T052	C1883254
27812586	26	36	structural	T085	C0026383
27812586	37	45	analysis	T169	C1524024
27812586	51	60	synthetic	T052	C1883254
27812586	61	73	glycopeptide	T116	C0017953
27812586	74	83	dendrimer	T104,T122	C1563732
27812586	90	109	anti-cancer vaccine	T116,T121,T129	C0376659
27812586	140	143	new	T080	C0205314
27812586	144	151	process	T169	C1519894
27812586	169	179	gram-scale	T081	C0392762
27812586	180	190	production	T057	C0033268
27812586	202	211	synthetic	T052	C1883254
27812586	212	231	anti-cancer vaccine	T116,T121,T129	C0376659
27812586	236	241	human	T016	C0086418
27812586	252	271	therapeutic vaccine	T116,T121,T129	C0301521
27812586	289	296	MAG-Tn3	T121	C1254351
27812586	303	324	high-molecular-weight	T080	C1979900
27812586	325	348	tetrameric glycopeptide	T116	C0017953
27812586	362	402	carbohydrate tumor-associated Tn antigen	T109,T129	C0003341
27812586	403	411	clusters	T081	C1704332
27812586	416	424	peptidic	T116	C0030956
27812586	425	438	CD4(+) T-cell	T025	C0039215
27812586	439	447	epitopes	T129	C0003316
27812586	453	470	synthetic process	T052	C1883254
27812586	497	517	solid-phase assembly	T052	C0441655
27812586	521	530	protected	T080	C0205556
27812586	531	542	amino acids	T116,T121,T123	C0002520
27812586	575	577	Tn	T109,T129	C0076765
27812586	578	593	building blocks	T080	C0205556
27812586	635	643	isolated	T169	C0205409
27812586	644	656	intermediate	T167	C0439861
27812586	672	684	simultaneous	T079	C0521115
27812586	685	697	deprotection	T070	C2350458
27812586	713	730	protective groups	T120	C0597294
27812586	746	753	MAG-Tn3	T121	C1254351
27812586	772	785	characterized	T052	C1880022
27812586	794	805	combination	T080	C0205195
27812586	809	819	techniques	T169	C0449851
27812586	833	843	structural	T085	C0026383
27812586	844	852	analysis	T169	C1524024
27812586	856	895	nuclear magnetic resonance spectroscopy	T060	C0877853
27812586	906	914	peptidic	T116	C0030956
27812586	926	934	flexible	T080	C0443220
27812586	960	971	constrained	T077	C1707494
27812586	985	997	conformation	T082	C1518960
27812586	1005	1016	Tn3 antigen	T109,T129	C0076765
27812586	1073	1080	HLA-DR1	T129	C0019768
27812586	1083	1093	expressing	T045	C1171362
27812586	1094	1109	transgenic mice	T015	C0025936
27812586	1116	1123	vaccine	T116,T121,T129	C0376659
27812586	1124	1131	induces	T169	C0205263
27812586	1132	1154	Tn-specific antibodies	T116,T129	C0003241
27812586	1172	1179	killing	T043	C0599733
27812586	1183	1188	human	T016	C0086418
27812586	1189	1212	Tn-positive tumor cells	T025	C0431085
27812586	1259	1266	MAG-Tn3	T121	C1254351
27812586	1278	1290	investigated	T169	C1292732
27812586	1294	1307	breast cancer	T191	C0006142
27812586	1308	1316	patients	T101	C0030705
27812586	1318	1340	phase I clinical trial	T062	C0282459
27812586	1397	1412	multigram-scale	T081	C0392762
27812586	1413	1422	synthesis	T052	C1883254
27812586	1428	1434	highly	T080	C0205250
27812586	1435	1439	pure	T080	C0205556
27812586	1440	1447	complex	T104	C1704241
27812586	1448	1460	glycopeptide	T116	C0017953
27812586	1475	1478	new	T080	C0205314
27812586	1502	1511	synthetic	T052	C1883254
27812586	1512	1525	glycopeptides	T116	C0017953
27812586	1529	1534	drugs	T121	C0013227
27812586	1538	1544	humans	T016	C0086418

28323926|t|Psychological Distress Is More Prevalent in Fertile Age and Premenopausal Women with PCOS Symptoms -15-yr Follow-up
28323926|a|Polycystic ovary syndrome (PCOS) is associated with increased psychological distress; obesity and hyperandrogenism being suggested as key promoters. To investigate the prevalence of anxiety / depression and their coexistence in women with PCOS / PCOS symptoms at age s 31 and 46. The roles of obesity, hyperandrogenism and awareness of PCOS on psychological distress were also assessed. Population based follow-up. Northern Finland Birth Cohort 1966 with 15- year follow-up. At age 31 a questionnaire-based screening for oligoamenorrhea (OA) and hirsutism (H): 2188 asymptomatic (controls), 331 OA, 323 H, 125 OA + H (PCOS). 46 year old follow-up: 1576 controls, 239 OA, 231 H and 85 PCOS. Questionnaire-based screening for anxiety and depression symptoms (Hopkins Symptom Checklist-25) and previously diagnosed / treated depression at age 31 and 46. BMI, serum testosterone / free androgen index (FAI) and awareness of polycystic ovaries / PCOS on psychological distress were also assessed. Population-based prevalence of anxiety and/or depression in women with PCOS / PCOS symptoms at age s 31 and 46. Anxiety and/or depression symptoms, their coexistence and rate of depression were increased at age 31 and 46 in women with PCOS or isolated H compared with controls. High BMI or hyperandrogenism did not associate with increased anxiety or depression symptoms. The awareness of PCOS was associated with increased anxiety. Women with PCOS or isolated H present more often with anxiety and/or depression symptoms and their coexistence compared with controls. High BMI or hyperandrogenism did not provoke psychological distress in PCOS. The awareness of PCOS increased anxiety but did not associate with severe anxiety or depression.
28323926	0	22	Psychological Distress	T048	C0815107
28323926	44	51	Fertile	T040	C0015895
28323926	52	55	Age	T032	C0001779
28323926	60	73	Premenopausal	T039	C0206158
28323926	74	79	Women	T098	C0043210
28323926	85	89	PCOS	T047	C0032460
28323926	90	98	Symptoms	T184	C1457887
28323926	106	115	Follow-up	T058	C1522577
28323926	116	141	Polycystic ovary syndrome	T047	C0032460
28323926	143	147	PCOS	T047	C0032460
28323926	178	200	psychological distress	T048	C0815107
28323926	202	209	obesity	T047	C0028754
28323926	214	230	hyperandrogenism	T047	C0206081
28323926	254	263	promoters	T052	C0033414
28323926	268	279	investigate	T169	C1292732
28323926	284	294	prevalence	T081	C0683921
28323926	298	305	anxiety	T048	C0003469
28323926	308	318	depression	T048	C0011581
28323926	344	349	women	T098	C0043210
28323926	355	359	PCOS	T047	C0032460
28323926	362	366	PCOS	T047	C0032460
28323926	367	375	symptoms	T184	C1457887
28323926	379	382	age	T032	C0001779
28323926	409	416	obesity	T047	C0028754
28323926	418	434	hyperandrogenism	T047	C0206081
28323926	439	448	awareness	T041	C0004448
28323926	452	456	PCOS	T047	C0032460
28323926	460	482	psychological distress	T048	C0815107
28323926	493	501	assessed	T052	C1516048
28323926	503	529	Population based follow-up	T062	C1709599
28323926	531	547	Northern Finland	T083	C0016132
28323926	548	560	Birth Cohort	T081	C1706962
28323926	575	579	year	T079	C0439234
28323926	580	589	follow-up	T058	C1522577
28323926	594	597	age	T032	C0001779
28323926	603	632	questionnaire-based screening	T062	C1134635
28323926	637	652	oligoamenorrhea	T046	C0028949
28323926	654	656	OA	T046	C0028949
28323926	662	671	hirsutism	T047	C0271610
28323926	673	674	H	T047	C0271610
28323926	682	694	asymptomatic	T033	C0231221
28323926	696	704	controls	T096	C0009932
28323926	711	713	OA	T046	C0028949
28323926	719	720	H	T047	C0271610
28323926	726	728	OA	T046	C0028949
28323926	731	732	H	T047	C0271610
28323926	734	738	PCOS	T047	C0032460
28323926	744	748	year	T079	C0439234
28323926	753	762	follow-up	T058	C1522577
28323926	769	777	controls	T096	C0009932
28323926	783	785	OA	T046	C0028949
28323926	791	792	H	T047	C0271610
28323926	800	804	PCOS	T047	C0032460
28323926	806	835	Questionnaire-based screening	T062	C1134635
28323926	840	847	anxiety	T048	C0003469
28323926	852	871	depression symptoms	T184	C0086132
28323926	873	901	Hopkins Symptom Checklist-25	T170	C0451218
28323926	918	927	diagnosed	T033	C0011900
28323926	930	937	treated	T033	C0332154
28323926	938	948	depression	T048	C0011581
28323926	952	955	age	T032	C0001779
28323926	967	970	BMI	T201	C1305855
28323926	972	990	serum testosterone	T059	C4064092
28323926	993	1012	free androgen index	T059	C0428629
28323926	1014	1017	FAI	T059	C0428629
28323926	1023	1032	awareness	T041	C0004448
28323926	1036	1054	polycystic ovaries	T047	C0032460
28323926	1057	1061	PCOS	T047	C0032460
28323926	1065	1087	psychological distress	T048	C0815107
28323926	1098	1106	assessed	T052	C1516048
28323926	1108	1135	Population-based prevalence	T081	C1709597
28323926	1139	1146	anxiety	T048	C0003469
28323926	1154	1164	depression	T048	C0011581
28323926	1168	1173	women	T098	C0043210
28323926	1179	1183	PCOS	T047	C0032460
28323926	1186	1190	PCOS	T047	C0032460
28323926	1191	1199	symptoms	T184	C1457887
28323926	1203	1206	age	T032	C0001779
28323926	1220	1227	Anxiety	T048	C0003469
28323926	1235	1254	depression symptoms	T184	C0086132
28323926	1286	1296	depression	T048	C0011581
28323926	1315	1318	age	T032	C0001779
28323926	1332	1337	women	T098	C0043210
28323926	1343	1347	PCOS	T047	C0032460
28323926	1360	1361	H	T047	C0271610
28323926	1376	1384	controls	T096	C0009932
28323926	1391	1394	BMI	T201	C1305855
28323926	1398	1414	hyperandrogenism	T047	C0206081
28323926	1448	1455	anxiety	T048	C0003469
28323926	1459	1478	depression symptoms	T184	C0086132
28323926	1484	1493	awareness	T041	C0004448
28323926	1497	1501	PCOS	T047	C0032460
28323926	1532	1539	anxiety	T048	C0003469
28323926	1541	1546	Women	T098	C0043210
28323926	1552	1556	PCOS	T047	C0032460
28323926	1569	1570	H	T047	C0271610
28323926	1595	1602	anxiety	T048	C0003469
28323926	1610	1629	depression symptoms	T184	C0086132
28323926	1666	1674	controls	T096	C0009932
28323926	1681	1684	BMI	T201	C1305855
28323926	1688	1704	hyperandrogenism	T047	C0206081
28323926	1721	1743	psychological distress	T048	C0815107
28323926	1747	1751	PCOS	T047	C0032460
28323926	1757	1766	awareness	T041	C0004448
28323926	1770	1774	PCOS	T047	C0032460
28323926	1785	1792	anxiety	T048	C0003469
28323926	1827	1834	anxiety	T048	C0003469
28323926	1838	1848	depression	T048	C0011581

27572277|t|Gut microbiota after Roux-en-Y gastric bypass and sleeve gastrectomy in a diabetic rat model: Increased diversity and associations of discriminant genera with metabolic changes
27572277|a|Recent work with gut microbiota after bariatric surgery is limited, and the results have not been in agreement. Given the role of the gut microbiota in regulating host metabolism, we explored the effect of Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) on the modifications of gut microbiota with regard to the potential influence of food intake and/or weight loss and examined their links with host metabolism. Zucker diabetic fatty rats were divided into the following groups: RYGB; sham-operated with pair-fed as RYGB; sham-operated fed ad libitum; and SG. The metabolic effects and gut microbiota profile were analyzed 10 weeks postoperatively. Associations between discriminating genera and metabolic markers after RYGB were explored. The 2 procedures induced similar glucose improvement and increased flora diversity after 10 weeks compared with sham-operated groups. RYGB induced a marked higher relative abundance of Proteobacteria / Gammaproteobacteria and Betaproteobacteria and increased emergence of Fusobacteria and Clostridium, whereas SG resulted in more abundant Actinobacteria compared with other groups. Most of the 12 discriminant genera correlated with changes in metabolic phenotype, but only 28.6% of these correlations were independent of weight, and 4 discriminant genera still negatively correlated with serum insulin level independent of food intake and weight loss after RYGB. These data demonstrate that RYGB and SG surgery produced similar diversity but different microbiota compositions changes in Zucker diabetic fatty rats. These findings stimulate deeper explorations of functions of the discriminate microbiota and the mechanisms linking postsurgical modulation of gut microbiota and improvements in insulin resistance.
27572277	0	14	Gut microbiota	T001	C2985398
27572277	21	45	Roux-en-Y gastric bypass	T061	C0585179
27572277	50	68	sleeve gastrectomy	T061	C3160799
27572277	74	82	diabetic	T047	C0011847
27572277	83	86	rat	T015	C0034721
27572277	87	92	model	T050	C0012644
27572277	104	113	diversity	T080	C1880371
27572277	134	146	discriminant	T080	C0205235
27572277	147	153	genera	T185	C1708235
27572277	159	168	metabolic	T040	C0025519
27572277	169	176	changes	T169	C0392747
27572277	194	208	gut microbiota	T001	C2985398
27572277	215	232	bariatric surgery	T061	C1456587
27572277	311	325	gut microbiota	T001	C2985398
27572277	340	344	host	T001	C1167395
27572277	345	355	metabolism	T040	C0025519
27572277	383	407	Roux-en-Y gastric bypass	T061	C0585179
27572277	409	413	RYGB	T061	C0585179
27572277	419	437	sleeve gastrectomy	T061	C3160799
27572277	439	441	SG	T061	C3160799
27572277	467	481	gut microbiota	T001	C2985398
27572277	524	528	food	T168	C0016452
27572277	529	535	intake	T169	C1512806
27572277	543	549	weight	T032	C0005910
27572277	550	554	loss	T081	C1517945
27572277	550	554	loss	T081	C1517945
27572277	585	589	host	T001	C1167395
27572277	590	600	metabolism	T040	C0025519
27572277	609	617	diabetic	T047	C0011847
27572277	618	628	fatty rats	T015	C0034721
27572277	661	667	groups	T078	C0441833
27572277	669	673	RYGB	T061	C0585179
27572277	675	688	sham-operated	T061	C0032042
27572277	706	710	RYGB	T061	C0585179
27572277	712	725	sham-operated	T061	C0032042
27572277	746	748	SG	T061	C3160799
27572277	754	771	metabolic effects	T039	C2945675
27572277	776	790	gut microbiota	T001	C2985398
27572277	791	798	profile	T169	C2003903
27572277	804	812	analyzed	T062	C0936012
27572277	816	821	weeks	T079	C0439230
27572277	860	874	discriminating	T080	C0205235
27572277	875	881	genera	T185	C1708235
27572277	886	903	metabolic markers	T123	C1513159
27572277	910	914	RYGB	T061	C0585179
27572277	936	946	procedures	T061	C0087111
27572277	963	970	glucose	T109,T121,T123	C0017725
27572277	971	982	improvement	T077	C2986411
27572277	997	1002	flora	T001	C2985398
27572277	1003	1012	diversity	T080	C1880371
27572277	1022	1027	weeks	T079	C0439230
27572277	1028	1036	compared	T052	C1707455
27572277	1042	1055	sham-operated	T061	C0032042
27572277	1064	1068	RYGB	T061	C0585179
27572277	1115	1129	Proteobacteria	T007	C0751985
27572277	1132	1151	Gammaproteobacteria	T007	C0751988
27572277	1156	1174	Betaproteobacteria	T007	C0751987
27572277	1202	1214	Fusobacteria	T007	C1222477
27572277	1219	1230	Clostridium	T007	C0009054
27572277	1240	1242	SG	T061	C3160799
27572277	1269	1283	Actinobacteria	T007	C0600148
27572277	1284	1292	compared	T052	C1707455
27572277	1327	1339	discriminant	T080	C0205235
27572277	1340	1346	genera	T185	C1708235
27572277	1347	1357	correlated	T080	C1707520
27572277	1363	1370	changes	T169	C0392747
27572277	1374	1383	metabolic	T040	C0025519
27572277	1384	1393	phenotype	T032	C0031437
27572277	1419	1431	correlations	T080	C1707520
27572277	1452	1458	weight	T032	C0005910
27572277	1466	1478	discriminant	T080	C0205235
27572277	1479	1485	genera	T185	C1708235
27572277	1503	1513	correlated	T080	C1707520
27572277	1519	1538	serum insulin level	T034	C1261415
27572277	1554	1558	food	T168	C0016452
27572277	1559	1565	intake	T169	C1512806
27572277	1570	1576	weight	T032	C0005910
27572277	1577	1581	loss	T081	C1517945
27572277	1588	1592	RYGB	T061	C0585179
27572277	1600	1604	data	T078	C1511726
27572277	1622	1626	RYGB	T061	C0585179
27572277	1631	1633	SG	T061	C3160799
27572277	1634	1641	surgery	T169	C0038895
27572277	1659	1668	diversity	T080	C1880371
27572277	1683	1693	microbiota	T001	C2985398
27572277	1725	1733	diabetic	T047	C0011847
27572277	1734	1744	fatty rats	T015	C0034721
27572277	1794	1803	functions	T040	C0025519
27572277	1811	1823	discriminate	T080	C0205235
27572277	1824	1834	microbiota	T001	C2985398
27572277	1843	1853	mechanisms	T169	C0441712
27572277	1862	1874	postsurgical	T079	C1254367
27572277	1875	1885	modulation	T082	C0443264
27572277	1889	1903	gut microbiota	T001	C2985398
27572277	1908	1920	improvements	T077	C2986411
27572277	1924	1942	insulin resistance	T046	C0021655

28388318|t|Rotary and High - Pressure Nozzle Spray Plume Droplet Analysis For Aerially Applied Mosquito Adulticides: Laser Diffraction Characterization
28388318|a|The droplet spectrum of a mosquito adulticide spray plume determines its ability to drift through the target area, impinge on the mosquito, deliver a toxic dose, and the risk of environmental contamination. This paper provides data on droplet spectra produced from 6 nozzles in a high - pressure nozzle spray system and 5 rotary nozzle systems for common mosquito adulticides. Spray plume spectra were measured by laser diffraction. High - pressure nozzles were evaluated at pressure s ranging from 500 psi to 6,000 psi. Rotary nozzles were evaluated at rotational speeds ranging from 500 rpm to 24,000 rpm. Measurements were made at wind speeds of 129 km/h (80 mph) to 225 km/h (140 mph). Adulticides included were Fyfanon (®), Aqua-Reslin (®), Dibrom (®), Duet (®), Permanone (®), and the inert mineral oil, Orchex(®) 796. High- pressure nozzles produced spray plumes within the US Environmental Protection Agency (EPA) label requirements for all configurations tested except for one at a wind speed of 225 km/h, BETE(®) MW125. Air speed had no significant effect on the spray plume volume median diameter (Dv (0.5)) at the speeds tested with Fyfanon (®). The spray plume 90% drop volume diameter (Dv (0.9)) significantly decreased, 13% at the higher wind speed of 225 km/h. Drop size was inversely related to pressure. Dilution of the product formulations increased the Dv (0.5) of the spray plume but it did not exceed the label requirements. For the PJ15 nozzle, orientation of the nozzle into the wind of up to 135° showed a significant increase in Dv (0.5) at 500 psi, 750 psi, and 1,500 psi. The Dv (0.5) varied <5 μm over the 3 angles examined for any specific pressure. Rotary nozzles produced spray plumes within the EPA label requirements for all test configurations examined. Air speed had no significant effect on Dv (0.5) or Dv (0.9) of the plume at speeds tested with Fyfanon for the ASC A20 nozzle. The rotary AU5000 nozzle using Orchex 796 produced plumes of larger drops in all configurations than any of the rotary nozzles of similar configurations using active ingredient formulations and within EPA label requirements.
28388318	11	15	High	T080	C0205250
28388318	18	26	Pressure	T067	C0033095
28388318	27	33	Nozzle	T073	C1709278
28388318	34	45	Spray Plume	T082	C1254362
28388318	46	53	Droplet	T081	C4048603
28388318	54	62	Analysis	T062	C0936012
28388318	84	92	Mosquito	T204	C0026584
28388318	93	104	Adulticides	T131	C0021576
28388318	106	140	Laser Diffraction Characterization	T060	C0430022
28388318	145	152	droplet	T081	C4048603
28388318	153	161	spectrum	T077	C2827424
28388318	167	175	mosquito	T204	C0026584
28388318	176	186	adulticide	T131	C0021576
28388318	187	198	spray plume	T082	C1254362
28388318	243	254	target area	T082	C0205146
28388318	271	279	mosquito	T204	C0026584
28388318	291	296	toxic	T037	C0600688
28388318	297	301	dose	T081	C0178602
28388318	311	315	risk	T078	C0035647
28388318	319	346	environmental contamination	T069	C0014419
28388318	368	372	data	T078	C1511726
28388318	376	383	droplet	T081	C4048603
28388318	384	391	spectra	T077	C2827424
28388318	408	415	nozzles	T073	C1709278
28388318	421	425	high	T080	C0205250
28388318	428	436	pressure	T067	C0033095
28388318	437	456	nozzle spray system	T073	C1709278
28388318	463	484	rotary nozzle systems	T073	C1709278
28388318	496	504	mosquito	T204	C0026584
28388318	505	516	adulticides	T131	C0021576
28388318	518	529	Spray plume	T082	C1254362
28388318	530	537	spectra	T077	C2827424
28388318	555	572	laser diffraction	T060	C0430022
28388318	574	578	High	T080	C0205250
28388318	581	589	pressure	T067	C0033095
28388318	590	597	nozzles	T073	C1709278
28388318	616	624	pressure	T067	C0033095
28388318	662	676	Rotary nozzles	T073	C1709278
28388318	706	712	speeds	T081	C0678536
28388318	749	761	Measurements	T169	C0242485
28388318	775	779	wind	T070	C0043187
28388318	780	786	speeds	T081	C0678536
28388318	831	842	Adulticides	T131	C0021576
28388318	857	864	Fyfanon	T131	C1254354
28388318	870	881	Aqua-Reslin	T131	C1254354
28388318	887	893	Dibrom	T109,T131	C0729220
28388318	899	903	Duet	T131	C1254354
28388318	909	918	Permanone	T109,T121,T131	C1321593
28388318	932	949	inert mineral oil	T131	C1254354
28388318	951	964	Orchex(®) 796	T131	C1254354
28388318	972	980	pressure	T067	C0033095
28388318	981	988	nozzles	T073	C1709278
28388318	998	1010	spray plumes	T082	C1254362
28388318	1022	1056	US Environmental Protection Agency	T092	C0041712
28388318	1058	1061	EPA	T092	C0041712
28388318	1063	1068	label	T073	C0181496
28388318	1069	1081	requirements	T169	C1514873
28388318	1132	1136	wind	T070	C0043187
28388318	1137	1142	speed	T081	C0678536
28388318	1156	1169	BETE(®) MW125	T073	C3273359
28388318	1171	1174	Air	T167	C0001861
28388318	1175	1180	speed	T081	C0678536
28388318	1214	1225	spray plume	T082	C1254362
28388318	1226	1232	volume	T081	C0449468
28388318	1233	1248	median diameter	T081	C1301886
28388318	1250	1252	Dv	T081	C1301886
28388318	1267	1273	speeds	T081	C0678536
28388318	1286	1293	Fyfanon	T131	C1254354
28388318	1303	1314	spray plume	T082	C1254362
28388318	1319	1323	drop	T081	C4048603
28388318	1324	1330	volume	T081	C0449468
28388318	1331	1339	diameter	T081	C1301886
28388318	1341	1343	Dv	T081	C1301886
28388318	1394	1398	wind	T070	C0043187
28388318	1399	1404	speed	T081	C0678536
28388318	1418	1422	Drop	T081	C4048603
28388318	1418	1422	Drop	T081	C4048603
28388318	1423	1427	size	T082	C0456389
28388318	1453	1461	pressure	T067	C0033095
28388318	1463	1471	Dilution	T169	C1948037
28388318	1479	1486	product	T071	C1514468
28388318	1487	1499	formulations	T167	C0439962
28388318	1514	1516	Dv	T081	C1301886
28388318	1530	1541	spray plume	T082	C1254362
28388318	1568	1573	label	T073	C0181496
28388318	1574	1586	requirements	T169	C1514873
28388318	1596	1607	PJ15 nozzle	T073	C1709278
28388318	1609	1620	orientation	T082	C1704322
28388318	1628	1634	nozzle	T073	C1709278
28388318	1644	1648	wind	T070	C0043187
28388318	1696	1698	Dv	T081	C1301886
28388318	1745	1747	Dv	T081	C1301886
28388318	1811	1819	pressure	T067	C0033095
28388318	1821	1835	Rotary nozzles	T073	C1709278
28388318	1845	1857	spray plumes	T082	C1254362
28388318	1869	1872	EPA	T092	C0041712
28388318	1873	1878	label	T073	C0181496
28388318	1879	1891	requirements	T169	C1514873
28388318	1930	1933	Air	T167	C0001861
28388318	1934	1939	speed	T081	C0678536
28388318	1969	1971	Dv	T081	C1301886
28388318	1981	1983	Dv	T081	C1301886
28388318	1997	2002	plume	T082	C1254362
28388318	2006	2012	speeds	T081	C0678536
28388318	2025	2032	Fyfanon	T131	C1254354
28388318	2041	2055	ASC A20 nozzle	T073	C1709278
28388318	2061	2081	rotary AU5000 nozzle	T073	C1709278
28388318	2088	2098	Orchex 796	T131	C0021576
28388318	2108	2114	plumes	T082	C1254362
28388318	2125	2130	drops	T081	C4048603
28388318	2169	2183	rotary nozzles	T073	C1709278
28388318	2234	2246	formulations	T167	C0439962
28388318	2258	2261	EPA	T092	C0041712
28388318	2262	2267	label	T073	C0181496
28388318	2268	2280	requirements	T169	C1514873

27725796|t|Agency and Anxiety: Delusions of Control and Loss of Control in Schizophrenia and Agoraphobia
27725796|a|We review the distinction between sense of agency and sense of ownership, and then explore these concepts, and their reflective attributions, in schizophrenic symptoms and agoraphobia. We show how the underlying dynamics of these experiences are different across these disorders. We argue that these concepts are complex and cannot be reduced to neural mechanisms, but involve embodied and situated processes that include the physical and social environments. We conclude by arguing that the subjective and intersubjective dimensions of agency and ownership cannot be considered in isolation from one another, but instead form an interdependent pairing.
27725796	0	6	Agency	T033	C0516894
27725796	11	18	Anxiety	T033	C0003467
27725796	20	29	Delusions	T048	C0011253
27725796	64	77	Schizophrenia	T048	C0036341
27725796	82	93	Agoraphobia	T048	C0001818
27725796	128	143	sense of agency	T033	C0516894
27725796	148	166	sense of ownership	T033	C0516951
27725796	191	199	concepts	T078	C0178566
27725796	211	221	reflective	T041	C0558058
27725796	222	234	attributions	T041	C0596130
27725796	239	252	schizophrenic	T048	C0036341
27725796	253	261	symptoms	T184	C1457887
27725796	266	277	agoraphobia	T048	C0001818
27725796	306	314	dynamics	T070	C3826426
27725796	324	335	experiences	T041	C0596545
27725796	363	372	disorders	T047	C0012634
27725796	394	402	concepts	T078	C0178566
27725796	407	414	complex	T080	C0439855
27725796	429	436	reduced	T080	C0392756
27725796	440	446	neural	T169	C3714606
27725796	447	457	mechanisms	T070	C0376706
27725796	471	502	embodied and situated processes	T067	C1522240
27725796	520	528	physical	T082	C0557720
27725796	533	552	social environments	T078	C0037414
27725796	586	627	subjective and intersubjective dimensions	T081	C0439534
27725796	631	637	agency	T033	C0516894
27725796	642	651	ownership	T033	C0516951
27725796	676	685	isolation	T169	C0205409
27725796	724	738	interdependent	T169	C3244310
27725796	739	746	pairing	T080	C1709450

28186107|t|Blubber transcriptome response to acute stress axis activation involves transient changes in adipogenesis and lipolysis in a fasting -adapted marine mammal
28186107|a|Stress can compromise an animal's ability to conserve metabolic stores and participate in energy -demanding activities that are critical for fitness. Understanding how wild animals, especially those already experiencing physiological extremes (e.g. fasting), regulate stress responses is critical for evaluating the impacts of anthropogenic disturbance on physiology and fitness, key challenges for conservation. However, studies of stress in wildlife are often limited to baseline endocrine measurements and few have investigated stress effects in fasting -adapted species. We examined downstream molecular consequences of hypothalamic-pituitary-adrenal (HPA) axis activation by exogenous adrenocorticotropic hormone (ACTH) in blubber of northern elephant seals due to the ease of blubber sampling and its key role in metabolic regulation in marine mammals. We report the first phocid blubber transcriptome produced by RNAseq, containing over 140,000 annotated transcripts, including metabolic and adipocytokine genes of interest. The acute response of blubber to stress axis activation, measured 2 hours after ACTH administration, involved highly specific, transient (lasting <24 hours) induction of gene networks that promote lipolysis and adipogenesis in mammalian adipocytes. Differentially expressed genes included key adipogenesis factors which can be used as blubber -specific markers of acute stress in marine mammals of concern for which sampling of other tissues is not possible.
28186107	0	7	Blubber	T024	C0225324
28186107	8	21	transcriptome	T086	C3178810
28186107	34	62	acute stress axis activation	T044	C1148560
28186107	72	81	transient	T079	C0205374
28186107	82	89	changes	T169	C0392747
28186107	93	105	adipogenesis	T044	C0596843
28186107	110	119	lipolysis	T040	C0023796
28186107	125	132	fasting	T033	C0015663
28186107	142	155	marine mammal	T015	C0024660
28186107	156	162	Stress	T033	C0038435
28186107	181	189	animal's	T008	C0003062
28186107	190	197	ability	T032	C0085732
28186107	210	219	metabolic	T169	C0311400
28186107	220	226	stores	T169	C1698986
28186107	246	252	energy	T081	C1442080
28186107	264	274	activities	T052	C0441655
28186107	297	304	fitness	T056	C1456706
28186107	324	336	wild animals	T008	C0003070
28186107	376	398	physiological extremes	T033	C0243095
28186107	405	412	fasting	T033	C0015663
28186107	415	423	regulate	T038	C1327622
28186107	424	440	stress responses	T039	C0149784
28186107	472	479	impacts	T080	C4049986
28186107	512	522	physiology	T039	C0031843
28186107	527	534	fitness	T056	C1456706
28186107	555	567	conservation	T080	C2347858
28186107	589	595	stress	T033	C0038435
28186107	599	607	wildlife	T008	C0003070
28186107	629	660	baseline endocrine measurements	T059	C0022885
28186107	687	693	stress	T033	C0038435
28186107	694	701	effects	T080	C1280500
28186107	705	712	fasting	T033	C0015663
28186107	722	729	species	T185	C1705920
28186107	743	776	downstream molecular consequences	T059	C0022885
28186107	780	821	hypothalamic-pituitary-adrenal (HPA) axis	T022	C0597719
28186107	822	832	activation	T044	C1148560
28186107	836	845	exogenous	T169	C0205228
28186107	846	873	adrenocorticotropic hormone	T116,T121,T125	C0001655
28186107	875	879	ACTH	T116,T121,T125	C0001655
28186107	884	891	blubber	T024	C0225324
28186107	895	903	northern	T082	C1709269
28186107	904	918	elephant seals	T015	C1265526
28186107	938	945	blubber	T024	C0225324
28186107	946	954	sampling	T078	C0870078
28186107	967	971	role	T077	C1705810
28186107	975	995	metabolic regulation	T169	C0518894
28186107	999	1013	marine mammals	T015	C0024660
28186107	1035	1041	phocid	T015	C0325125
28186107	1042	1049	blubber	T024	C0225324
28186107	1050	1063	transcriptome	T086	C3178810
28186107	1076	1082	RNAseq	T059,T063	C0917793
28186107	1118	1129	transcripts	T114	C1519595
28186107	1141	1150	metabolic	T028	C0017337
28186107	1155	1174	adipocytokine genes	T028	C0017337
28186107	1192	1197	acute	T079	C0205178
28186107	1198	1206	response	T169	C0205245
28186107	1210	1217	blubber	T024	C0225324
28186107	1221	1243	stress axis activation	T044	C1148560
28186107	1268	1272	ACTH	T116,T121,T125	C0001655
28186107	1273	1287	administration	T061	C0199780
28186107	1305	1313	specific	T080	C0205369
28186107	1315	1324	transient	T079	C0205374
28186107	1345	1354	induction	T169	C0205263
28186107	1358	1371	gene networks	T044	C1720950
28186107	1385	1394	lipolysis	T040	C0023796
28186107	1399	1411	adipogenesis	T044	C0596843
28186107	1415	1424	mammalian	T015	C0024660
28186107	1425	1435	adipocytes	T025	C0206131
28186107	1452	1461	expressed	T045	C0017262
28186107	1462	1467	genes	T028	C0017337
28186107	1481	1493	adipogenesis	T044	C0596843
28186107	1494	1501	factors	T169	C1521761
28186107	1523	1530	blubber	T024	C0225324
28186107	1541	1548	markers	T201	C0005516
28186107	1552	1557	acute	T079	C0205178
28186107	1558	1564	stress	T033	C0038435
28186107	1568	1582	marine mammals	T015	C0024660
28186107	1604	1612	sampling	T078	C0870078
28186107	1622	1629	tissues	T024	C0040300

27301681|t|Sequence-specific DNA binding by long hairpin pyrrole-imidazole polyamides containing an 8-amino-3,6-dioxaoctanoic acid unit
27301681|a|With the aim of improving aqueous solubility, we designed and synthesized five N-methylpyrrole (Py)-N-methylimidazole (Im) polyamides capable of recognizing 9-bp sequences. Their DNA-binding affinities and sequence specificities were evaluated by SPR and Bind-n-Seq analyses. The design of polyamide 1 was based on a conventional model, with three consecutive Py or Im rings separated by a β-alanine to match the curvature and twist of long DNA helices. Polyamides 2 and 3 contained an 8-amino-3,6-dioxaoctanoic acid (AO) unit, which has previously only been used as a linker within linear Py-Im polyamides or between Py - Im hairpin motifs for tandem hairpin. It is demonstrated herein that AO also functions as a linker element that can extend to 2-bp in hairpin motifs. Notably, although the AO -containing unit can fail to bind the expected sequence, polyamide 4, which has two AO units facing each other in a hairpin form, successfully showed the expected motif and a KD value of 16nM was recorded. Polyamide 5, containing a β-alanine-β-alanine unit instead of the AO of polyamide 2, was synthesized for comparison. The aqueous solubilities and nuclear localization of three of the polyamides were also examined. The results suggest the possibility of applying the AO unit in the core of Py-Im polyamide compounds.
27301681	0	29	Sequence-specific DNA binding	T045	C1624609
27301681	33	45	long hairpin	T104	C1254350
27301681	46	74	pyrrole-imidazole polyamides	T109	C0029224
27301681	89	119	8-amino-3,6-dioxaoctanoic acid	T109	C0029224
27301681	151	169	aqueous solubility	T081	C0597682
27301681	174	182	designed	T052	C1707689
27301681	187	198	synthesized	T052	C1883254
27301681	204	258	N-methylpyrrole (Py)-N-methylimidazole (Im) polyamides	T109	C0029224
27301681	282	296	9-bp sequences	T086	C0004793
27301681	304	315	DNA-binding	T045	C1148673
27301681	316	326	affinities	T070	C1510827
27301681	331	339	sequence	T086	C0004793
27301681	340	353	specificities	T081	C0037791
27301681	372	375	SPR	T063	C0597731
27301681	380	399	Bind-n-Seq analyses	T062	C0936012
27301681	405	411	design	T052	C1707689
27301681	415	426	polyamide 1	T109	C0029224
27301681	455	460	model	T170	C3161035
27301681	485	487	Py	T109	C0383659
27301681	491	493	Im	T109	C0044472
27301681	515	524	β-alanine	T116,T121,T123	C0000392
27301681	552	557	twist	T082	C0231467
27301681	566	569	DNA	T114,T123	C0012854
27301681	570	577	helices	T082	C1254362
27301681	579	597	Polyamides 2 and 3	T109	C0029224
27301681	611	641	8-amino-3,6-dioxaoctanoic acid	T109	C0029224
27301681	643	645	AO	T109	C0029224
27301681	694	700	linker	T109	C0029224
27301681	715	731	Py-Im polyamides	T109	C0029224
27301681	743	745	Py	T109	C0383659
27301681	743	765	Py - Im hairpin motifs	T104	C1254350
27301681	748	750	Im	T109	C0044472
27301681	770	784	tandem hairpin	T104	C1254350
27301681	817	819	AO	T109	C0029224
27301681	840	854	linker element	T109	C0029224
27301681	874	878	2-bp	T086	C0004793
27301681	882	896	hairpin motifs	T104	C1254350
27301681	920	922	AO	T109	C0029224
27301681	944	948	fail	T169	C0231175
27301681	952	956	bind	T052	C1145667
27301681	970	978	sequence	T086	C0004793
27301681	980	991	polyamide 4	T109	C0029224
27301681	1007	1009	AO	T109	C0029224
27301681	1039	1051	hairpin form	T082	C1254362
27301681	1086	1091	motif	T082	C1254362
27301681	1098	1106	KD value	T081	C0392762
27301681	1129	1140	Polyamide 5	T109	C0029224
27301681	1155	1174	β-alanine-β-alanine	T116,T121,T123	C0000392
27301681	1195	1197	AO	T109	C0029224
27301681	1201	1212	polyamide 2	T109	C0029224
27301681	1218	1229	synthesized	T052	C1883254
27301681	1234	1244	comparison	T052	C1707455
27301681	1250	1270	aqueous solubilities	T081	C0597682
27301681	1275	1295	nuclear localization	T038	C1659087
27301681	1312	1322	polyamides	T109	C0029224
27301681	1347	1354	results	T169	C1274040
27301681	1395	1397	AO	T109	C0029224
27301681	1410	1414	core	T082	C0444669
27301681	1418	1443	Py-Im polyamide compounds	T109	C0029224

27461771|t|Chelation competition induced polymerization (CCIP): construction of integrated hollow polydopamine nanocontainers with tailorable functionalities
27461771|a|A novel ' chelation competition induced polymerization ' route was developed to construct hollow polydopamine nanocontainers with tailorable functionalities. The mechanism is systematically investigated and the nanocontainers constructed through this method show excellent chemo-thermo performance in vitro. This strategy is facile and is expected to be used for the construction of a series of hollow polymer nanostructures.
27461771	0	21	Chelation competition	T121,T130	C0007974
27461771	22	29	induced	T169	C0205263
27461771	30	44	polymerization	T067	C0314672
27461771	46	50	CCIP	T067	C0314672
27461771	53	65	construction	UnknownType	C0868944
27461771	80	99	hollow polydopamine	T109,T121	C3252413
27461771	100	114	nanocontainers	T073	C1881956
27461771	120	146	tailorable functionalities	T077	C1254372
27461771	157	178	chelation competition	T121,T130	C0007974
27461771	179	186	induced	T169	C0205263
27461771	187	201	polymerization	T067	C0314672
27461771	237	256	hollow polydopamine	T109,T121	C3252413
27461771	257	271	nanocontainers	T073	C1881956
27461771	277	303	tailorable functionalities	T077	C1254372
27461771	358	372	nanocontainers	T073	C1881956
27461771	373	384	constructed	UnknownType	C0868944
27461771	420	444	chemo-thermo performance	T033	C0243095
27461771	501	505	used	T033	C3258071
27461771	514	526	construction	UnknownType	C0868944
27461771	542	556	hollow polymer	T104,T122	C0032521
27461771	557	571	nanostructures	T073	C1450053

27555752|t|Modeling the hospital safety partnership preferences of patients and their families: a discrete choice conjoint experiment
27555752|a|Patients and their families play an important role in efforts to improve health service safety. The objective of this study is to understand the safety partnership preferences of patients and their families. We used a discrete choice conjoint experiment to model the safety partnership preferences of 1,084 patients or those such as parents acting on their behalf. Participants made choices between hypothetical safety partnerships composed by experimentally varying 15 four-level partnership design attributes. Participants preferred an approach to safety based on partnerships between patients and staff rather than a model delegating responsibility for safety to hospital staff. They valued the opportunity to participate in point of service safety partnerships, such as identity and medication double checks, that might afford an immediate risk reduction. Latent class analysis yielded two segments. Actively engaged participants (73.3%) comprised outpatients with higher education, who anticipated more benefits to safety partnerships, were more confident in their ability to contribute, and were more intent on participating. They were more likely to prefer a personal engagement strategy, valued scientific evidence, preferred a more active approach to safety education, and advocated disclosure of errors. The passively engaged segment (26.7%) anticipated fewer benefits, were less confident in their ability to contribute, and were less intent on participating. They were more likely to prefer an engagement strategy based on signage. They preferred that staff explain why they thought patients should help make care safer and decide whether errors were disclosed. Inpatients, those with immigrant backgrounds, and those with less education were more likely to be in this segment. Health services need to communicate information regarding risks, ask about partnership preferences, create opportunities respecting individual differences, and ensure a positive response when patients raise safety concerns.
27555752	0	8	Modeling	T062	C0870071
27555752	13	21	hospital	T073,T093	C0019994
27555752	22	28	safety	T068	C0036043
27555752	29	40	partnership	T058	C3826012
27555752	41	64	preferences of patients	T080	C0376409
27555752	75	83	families	T099	C0015576
27555752	87	95	discrete	T080	C0443299
27555752	96	102	choice	T055	C0008300
27555752	103	122	conjoint experiment	T062	C0681814
27555752	123	131	Patients	T101	C0030705
27555752	142	150	families	T099	C0015576
27555752	169	173	role	T077	C1705810
27555752	188	195	improve	T077	C2986411
27555752	196	210	health service	T058	C0018747
27555752	211	217	safety	T068	C0036043
27555752	223	232	objective	T170	C0018017
27555752	241	246	study	T062	C2603343
27555752	268	274	safety	T068	C0036043
27555752	275	286	partnership	T058	C3826012
27555752	287	310	preferences of patients	T080	C0376409
27555752	321	329	families	T099	C0015576
27555752	341	349	discrete	T080	C0443299
27555752	350	356	choice	T055	C0008300
27555752	357	376	conjoint experiment	T062	C0681814
27555752	390	396	safety	T068	C0036043
27555752	397	408	partnership	T058	C3826012
27555752	409	420	preferences	T080	C0376409
27555752	430	438	patients	T101	C0030705
27555752	456	463	parents	T099	C0030551
27555752	488	500	Participants	T098	C0679646
27555752	506	513	choices	T055	C0008300
27555752	535	541	safety	T068	C0036043
27555752	542	554	partnerships	T058	C3826012
27555752	604	615	partnership	T058	C3826012
27555752	616	622	design	T052	C1707689
27555752	623	633	attributes	T055	C0037401
27555752	635	647	Participants	T098	C0679646
27555752	648	657	preferred	T078	C0558295
27555752	661	669	approach	T082	C0449445
27555752	673	679	safety	T068	C0036043
27555752	689	701	partnerships	T058	C3826012
27555752	710	718	patients	T101	C0030705
27555752	723	728	staff	T097	C0025106
27555752	760	774	responsibility	T055	C0678341
27555752	779	785	safety	T068	C0036043
27555752	789	803	hospital staff	T097	C0025109
27555752	821	847	opportunity to participate	UnknownType	C0814559
27555752	868	874	safety	T068	C0036043
27555752	875	887	partnerships	T058	C3826012
27555752	910	934	medication double checks	T058	C1254363
27555752	957	966	immediate	T079	C0205253
27555752	967	981	risk reduction	T055	C1137094
27555752	996	1004	analysis	T062	C0936012
27555752	1027	1056	Actively engaged participants	T098	C0679646
27555752	1075	1086	outpatients	T101	C0029921
27555752	1092	1108	higher education	T065	C2584301
27555752	1114	1125	anticipated	T033	C3840775
27555752	1131	1139	benefits	T081	C0814225
27555752	1143	1149	safety	T068	C0036043
27555752	1150	1162	partnerships	T058	C3826012
27555752	1169	1183	more confident	T033	C3840600
27555752	1193	1200	ability	T032	C0085732
27555752	1204	1214	contribute	T052	C1880177
27555752	1230	1236	intent	T080	C1283828
27555752	1240	1253	participating	T169	C0679823
27555752	1280	1286	prefer	T080	C0376409
27555752	1298	1308	engagement	T058	C3508152
27555752	1309	1317	strategy	T041	C0679199
27555752	1326	1345	scientific evidence	T078	C3887511
27555752	1347	1356	preferred	T078	C0558295
27555752	1371	1379	approach	T082	C0449445
27555752	1383	1399	safety education	T065	C1272340
27555752	1415	1435	disclosure of errors	T080	C4046003
27555752	1475	1486	anticipated	T033	C3840775
27555752	1487	1492	fewer	T081	C0205388
27555752	1493	1501	benefits	T081	C0814225
27555752	1513	1522	confident	T055	C0558095
27555752	1532	1539	ability	T032	C0085732
27555752	1543	1553	contribute	T052	C1880177
27555752	1579	1592	participating	T169	C0679823
27555752	1629	1639	engagement	T058	C3508152
27555752	1640	1648	strategy	T041	C0679199
27555752	1658	1665	signage	T073	C4054026
27555752	1672	1681	preferred	T078	C0558295
27555752	1687	1692	staff	T097	C0025106
27555752	1718	1726	patients	T101	C0030705
27555752	1744	1748	care	T058	C0086388
27555752	1774	1780	errors	T080	C0376531
27555752	1797	1807	Inpatients	T101	C0021562
27555752	1820	1841	immigrant backgrounds	T033	C2242882
27555752	1858	1872	less education	T033	C0013658
27555752	1913	1928	Health services	T058	C0018747
27555752	1949	1960	information	T078	C1533716
27555752	1971	1976	risks	T078	C0035647
27555752	1988	1999	partnership	T058	C3826012
27555752	2000	2011	preferences	T080	C0376409
27555752	2020	2033	opportunities	UnknownType	C0814559
27555752	2045	2067	individual differences	T054	C0021228
27555752	2082	2099	positive response	T033	C1514241
27555752	2105	2113	patients	T101	C0030705
27555752	2120	2126	safety	T068	C0036043
27555752	2127	2135	concerns	T078	C2699424

27989819|t|Detachment of the fucoxanthin chlorophyll a/c binding protein (FCP) antenna is not involved in the acclimative regulation of photoprotection in the pennate diatom Phaeodactylum tricornutum
27989819|a|When grown under intermittent light (IL), the pennate diatom Phaeodactylum tricornutum forms 'super' non-photochemical fluorescence quenching (NPQ) in response to excess light. The current model of diatom NPQ mechanism involves two quenching sites, one of which detaches from photosystem II reaction centres (RCIIs) and aggregates into oligomeric complexes. Here we addressed how antenna reorganisation controls NPQ kinetics in P. tricornutum cells grown under continuous light (CL) and IL. Overall, IL acclimation induced: (i) reorganisation of chloroplasts, containing greater pigment pools without a strongly enhanced operation of the xanthophyll cycle, and (ii) ' super NPQ ' causing a remarkable reduction of the chlorophyll excited state lifetime at Fm '. Regardless of different levels of NPQ formed in both culture conditions, its dark recovery was rapid and similar fractions of their antenna uncoupled (~50%). Although antenna detachment relieved excitation pressure, it provided a minor protective contribution equivalent to NPQ ~1, while the largest NPQ was 4.4±0.2 (CL) and 13±0.8 (IL). The PSII cross-section decrease took place only at relatively low NPQ values, beyond which the cross-section remained constant whilst NPQ continued to rise. This finding suggests that the energy trapping efficiency of diatom antenna quenchers cannot over-compete that of RCIIs, similarly to what has been observed on higher plants. We conclude that such ' economic photoprotection ' operates to flexibly adjust the overall efficiency of diatom light harvesting.
27989819	0	10	Detachment	T067	C1254366
27989819	18	61	fucoxanthin chlorophyll a/c binding protein	T116,T123	C3179068
27989819	63	66	FCP	T116,T123	C3179068
27989819	68	75	antenna	T026	C1167304
27989819	99	110	acclimative	T040	C1154962
27989819	111	121	regulation	T038	C1327622
27989819	125	140	photoprotection	T040	C0597230
27989819	148	162	pennate diatom	T204	C0162769
27989819	163	188	Phaeodactylum tricornutum	T002	C0996301
27989819	206	224	intermittent light	T070	C0023693
27989819	226	228	IL	T070	C0023693
27989819	235	249	pennate diatom	T204	C0162769
27989819	250	275	Phaeodactylum tricornutum	T002	C0996301
27989819	282	330	'super' non-photochemical fluorescence quenching	T040	C1327582
27989819	332	335	NPQ	T040	C1327582
27989819	340	348	response	T032	C0871261
27989819	359	364	light	T070	C0023693
27989819	378	383	model	T170	C3161035
27989819	387	393	diatom	T204	C0162769
27989819	394	397	NPQ	T040	C1327582
27989819	398	407	mechanism	T169	C0441712
27989819	421	436	quenching sites	T026	C0243092
27989819	451	459	detaches	T169	C0687118
27989819	465	496	photosystem II reaction centres	T026	C1167312
27989819	498	503	RCIIs	T026	C1167312
27989819	509	519	aggregates	T169	C0332621
27989819	525	545	oligomeric complexes	T116,T123	C1180347
27989819	569	576	antenna	T026	C1167304
27989819	577	591	reorganisation	T078	C0680829
27989819	592	600	controls	T080	C0243148
27989819	601	604	NPQ	T040	C1327582
27989819	605	613	kinetics	T070	C0022702
27989819	617	631	P. tricornutum	T002	C0996301
27989819	632	637	cells	T025	C0007634
27989819	650	660	continuous	T078	C0549178
27989819	661	666	light	T070	C0023693
27989819	668	670	CL	T070	C0023693
27989819	676	678	IL	T070	C0023693
27989819	689	691	IL	T070	C0023693
27989819	692	703	acclimation	T040	C1154962
27989819	717	747	reorganisation of chloroplasts	T043	C1156112
27989819	768	781	pigment pools	T120	C0031916
27989819	827	844	xanthophyll cycle	T044	C1327206
27989819	857	866	super NPQ	T040	C1327582
27989819	890	899	reduction	T080	C0392756
27989819	907	918	chlorophyll	T109,T123	C0008260
27989819	919	941	excited state lifetime	T079	C1254367
27989819	945	947	Fm	T079	C1254367
27989819	975	981	levels	T080	C0441889
27989819	985	988	NPQ	T040	C1327582
27989819	1004	1011	culture	T059	C0007585
27989819	1012	1022	conditions	T080	C0348080
27989819	1028	1041	dark recovery	T080	C0205556
27989819	1064	1076	fractions of	T081	C1264633
27989819	1083	1090	antenna	T026	C1167304
27989819	1091	1100	uncoupled	T080	C0205556
27989819	1118	1125	antenna	T026	C1167304
27989819	1126	1136	detachment	T067	C1254366
27989819	1146	1156	excitation	T052	C0549255
27989819	1157	1165	pressure	T169	C1306345
27989819	1225	1228	NPQ	T040	C1327582
27989819	1251	1254	NPQ	T040	C1327582
27989819	1268	1270	CL	T070	C0023693
27989819	1284	1286	IL	T070	C0023693
27989819	1293	1297	PSII	T026	C0599132
27989819	1298	1311	cross-section	T169	C0205245
27989819	1355	1358	NPQ	T040	C1327582
27989819	1359	1365	values	T080	C0042295
27989819	1384	1397	cross-section	T169	C0205245
27989819	1423	1426	NPQ	T040	C1327582
27989819	1451	1458	finding	T033	C0243095
27989819	1507	1513	diatom	T204	C0162769
27989819	1514	1521	antenna	T026	C1167304
27989819	1522	1531	quenchers	T116,T123	C0033684
27989819	1560	1565	RCIIs	T026	C1167312
27989819	1613	1619	plants	T002	C0032098
27989819	1645	1669	economic photoprotection	T040	C0597230
27989819	1712	1722	efficiency	T081	C0013682
27989819	1726	1732	diatom	T204	C0162769
27989819	1733	1749	light harvesting	T044	C1623297

28070679|t|Diversity of Microbial Carbohydrate-Active enZYmes (CAZYmes) Associated with Freshwater and Soil Samples from Caatinga Biome
28070679|a|Semi-arid and arid areas occupy about 33% of terrestrial ecosystems. However, little information is available about microbial diversity in the semi-arid Caatinga, which represents a unique biome that extends to about 11% of the Brazilian territory and is home to extraordinary diversity and high endemism level of species. In this study, we characterized the diversity of microbial genes associated with biomass conversion (carbohydrate-active enzymes, or so-called CAZYmes) in soil and freshwater of the Caatinga. Our results showed distinct CAZYme profiles in the soil and freshwater samples. Glycoside hydrolases and glycosyltransferases were the most abundant CAZYme families, with glycoside hydrolases more dominant in soil (∼44%) and glycosyltransferases more abundant in freshwater (∼50%). The abundances of individual glycoside hydrolase, glycosyltransferase, and carbohydrate-binding module subfamilies varied widely between soil and water samples. A predominance of glycoside hydrolases was observed in soil, and a higher contribution of enzymes involved in carbohydrate biosynthesis was observed in freshwater. The main taxa associated with the CAZYme sequences were Planctomycetia (relative abundance in soil, 29%) and Alphaproteobacteria (relative abundance in freshwater, 27%). Approximately 5-7% of CAZYme sequences showed low similarity with sequences deposited in non-redundant databases, suggesting putative homologues. Our findings represent a first attempt to describe specific microbial CAZYme profiles for environmental samples. Characterizing these enzyme groups associated with the conversion of carbohydrates in nature will improve our understanding of the significant roles of enzymes in the carbon cycle. We identified a CAZYme signature that can be used to discriminate between soil and freshwater samples, and this signature may be related to the microbial species adapted to the habitat. The data show the potential ecological roles of the CAZYme repertoire and associated biotechnological applications.
28070679	0	9	Diversity	T080	C1880371
28070679	13	22	Microbial	T001	C0599840
28070679	23	50	Carbohydrate-Active enZYmes	T116,T126	C0014442
28070679	52	59	CAZYmes	T116,T126	C0014442
28070679	61	76	Associated with	T080	C0332281
28070679	77	87	Freshwater	T167	C0016710
28070679	92	104	Soil Samples	T167	C3687777
28070679	110	118	Caatinga	UnknownType	C0681784
28070679	119	124	Biome	T070	C3853023
28070679	125	134	Semi-arid	T082	C1254362
28070679	139	149	arid areas	T082	C1254362
28070679	170	192	terrestrial ecosystems	T070	C0162358
28070679	210	221	information	T078	C1533716
28070679	241	260	microbial diversity	T080	C1880371
28070679	268	286	semi-arid Caatinga	UnknownType	C0681784
28070679	307	313	unique	T080	C1710548
28070679	314	319	biome	T070	C3853023
28070679	325	332	extends	T082	C0439792
28070679	353	372	Brazilian territory	T083	C2983136
28070679	402	411	diversity	T080	C1880371
28070679	421	429	endemism	T082	C1254362
28070679	439	446	species	T185	C1705920
28070679	456	461	study	T062	C2603343
28070679	466	479	characterized	T052	C1880022
28070679	484	493	diversity	T080	C1880371
28070679	497	512	microbial genes	T028	C3658343
28070679	529	536	biomass	T081	C0005535
28070679	537	547	conversion	T169	C0439836
28070679	549	576	carbohydrate-active enzymes	T116,T126	C0014442
28070679	591	598	CAZYmes	T116,T126	C0014442
28070679	603	607	soil	T167	C0037592
28070679	612	622	freshwater	T167	C0016710
28070679	630	638	Caatinga	UnknownType	C0681784
28070679	644	651	results	T033	C0683954
28070679	668	674	CAZYme	T116,T126	C0014442
28070679	675	683	profiles	T081	C0392762
28070679	691	695	soil	T167	C3687777
28070679	700	718	freshwater samples	T167	C0016710
28070679	720	740	Glycoside hydrolases	T116,T121,T126	C0017976
28070679	745	765	glycosyltransferases	T116,T126	C0085249
28070679	780	788	abundant	T080	C2346714
28070679	789	795	CAZYme	T116,T126	C0014442
28070679	811	831	glycoside hydrolases	T116,T121,T126	C0017976
28070679	849	853	soil	T167	C0037592
28070679	865	885	glycosyltransferases	T116,T126	C0085249
28070679	891	899	abundant	T080	C2346714
28070679	903	913	freshwater	T167	C0016710
28070679	926	936	abundances	T080	C2346714
28070679	951	970	glycoside hydrolase	T116,T121,T126	C0017976
28070679	972	991	glycosyltransferase	T116,T126	C0085249
28070679	997	1017	carbohydrate-binding	T044	C1148582
28070679	1018	1024	module	T077	C1709061
28070679	1025	1036	subfamilies	T185	C1711207
28070679	1059	1063	soil	T167	C3687777
28070679	1068	1081	water samples	T167	C0016710
28070679	1101	1121	glycoside hydrolases	T116,T121,T126	C0017976
28070679	1138	1142	soil	T167	C0037592
28070679	1157	1169	contribution	T052	C1880177
28070679	1173	1180	enzymes	T116,T126	C0014442
28070679	1193	1218	carbohydrate biosynthesis	T044	C0596247
28070679	1235	1245	freshwater	T167	C0016710
28070679	1256	1260	taxa	T077	C1515221
28070679	1261	1276	associated with	T080	C0332281
28070679	1281	1297	CAZYme sequences	T087	C0002518
28070679	1303	1317	Planctomycetia	T007	C1222578
28070679	1328	1337	abundance	T080	C2346714
28070679	1341	1345	soil	T167	C0037592
28070679	1356	1375	Alphaproteobacteria	T007	C0751986
28070679	1386	1395	abundance	T080	C2346714
28070679	1399	1409	freshwater	T167	C0016710
28070679	1439	1455	CAZYme sequences	T087	C0002518
28070679	1463	1477	low similarity	T080	C2348205
28070679	1483	1492	sequences	T087	C0002518
28070679	1506	1519	non-redundant	T169	C1313915
28070679	1520	1529	databases	T170	C0242356
28070679	1542	1561	putative homologues	T085	C0162774
28070679	1567	1575	findings	T033	C0243095
28070679	1594	1601	attempt	T051	C1516084
28070679	1614	1622	specific	T080	C0205369
28070679	1623	1632	microbial	T001	C0599840
28070679	1633	1639	CAZYme	T116,T126	C0014442
28070679	1640	1648	profiles	T081	C0392762
28070679	1653	1666	environmental	T082	C0014406
28070679	1667	1674	samples	T167	C0370003
28070679	1697	1710	enzyme groups	T116,T126	C0014442
28070679	1711	1726	associated with	T080	C0332281
28070679	1731	1741	conversion	T169	C0439836
28070679	1745	1758	carbohydrates	T109	C0007004
28070679	1762	1768	nature	UnknownType	C0683930
28070679	1774	1781	improve	T033	C0184511
28070679	1786	1799	understanding	T041	C0162340
28070679	1819	1835	roles of enzymes	T116,T126	C0014442
28070679	1843	1855	carbon cycle	T070	C2936196
28070679	1860	1870	identified	T080	C0205396
28070679	1873	1879	CAZYme	T116,T126	C0014442
28070679	1910	1922	discriminate	T080	C0205235
28070679	1931	1935	soil	T167	C3687777
28070679	1940	1958	freshwater samples	T167	C0016710
28070679	2001	2010	microbial	T001	C0599840
28070679	2011	2018	species	T185	C1705920
28070679	2034	2041	habitat	T082	C0871648
28070679	2047	2051	data	T078	C1511726
28070679	2061	2070	potential	T080	C3245505
28070679	2071	2087	ecological roles	T080	C0205556
28070679	2095	2101	CAZYme	T116,T126	C0014442
28070679	2102	2112	repertoire	T080	C0205556
28070679	2128	2157	biotechnological applications	T169	C0457083

27742630|t|Predicting frequent hospital admission risk in Singapore: a retrospective cohort study to investigate the impact of comorbidities, acute illness burden and social determinants of health
27742630|a|To evaluate the impact of comorbidities, acute illness burden and social determinants of health on predicting the risk of frequent hospital admissions. Multivariable logistic regression was used to associate the predictive variables extracted from electronic health records and frequent hospital admission risk. The model's performance of our predictive model was evaluated using a 10-fold cross-validation. A single tertiary hospital in Singapore. All adult patients admitted to the hospital between 1 January 2013 and 31 May 2014 (n=25 244). Frequent hospital admissions, defined as 3 or more inpatient admissions within 12 months of discharge. Ar ea under the receiver operating characteristic curve (AUC) of the predictive model, and the sensitivity, specificity and positive predictive values for various cut-offs. 4322 patients (17.1%) met the primary outcome. 11 variables were observed as significant predictors and included in the final regression model. The strongest independent predictor was treatment with antidepressants in the past 1 year (adjusted OR 2.51, 95% CI 2.26 to 2.78). Other notable predictors include requiring dialysis and treatment with intravenous furosemide during the index admission. The predictive model achieved an AUC of 0.84 (95% CI 0.83 to 0.85) for predicting frequent hospital admission risk, with a sensitivity of 73.9% (95% CI 72.6% to 75.2%), specificity of 79.1% (78.5% to 79.6%) and positive predictive value of 42.2% (95% CI 41.1% to 43.3%) at the cut-off of 0.235. We have identified several predictors for assessing the risk of frequent hospital admissions that achieved high discriminative model performance. Further research is necessary using an external validation cohort.
27742630	0	10	Predicting	T078	C0681842
27742630	11	19	frequent	T079	C0332183
27742630	20	38	hospital admission	T058	C0184666
27742630	39	43	risk	T078	C0035647
27742630	47	56	Singapore	T083	C0037173
27742630	60	86	retrospective cohort study	T062	C2985505
27742630	106	112	impact	T080	C4049986
27742630	116	129	comorbidities	T078	C0009488
27742630	131	144	acute illness	T046	C4061114
27742630	137	151	illness burden	T081	C0162698
27742630	156	185	social determinants of health	T058	C3658315
27742630	202	208	impact	T080	C4049986
27742630	212	225	comorbidities	T078	C0009488
27742630	227	240	acute illness	T046	C4061114
27742630	233	247	illness burden	T081	C0162698
27742630	252	281	social determinants of health	T058	C3658315
27742630	285	295	predicting	T078	C0681842
27742630	300	304	risk	T078	C0035647
27742630	308	316	frequent	T079	C0332183
27742630	317	336	hospital admissions	T058	C0184666
27742630	338	371	Multivariable logistic regression	T062	C0206031
27742630	398	418	predictive variables	T170	C0683956
27742630	434	459	electronic health records	T170	C2362543
27742630	464	472	frequent	T079	C0332183
27742630	473	491	hospital admission	T058	C0184666
27742630	492	496	risk	T078	C0035647
27742630	502	509	model's	T170	C0086272
27742630	510	521	performance	T052	C1882330
27742630	529	545	predictive model	T170	C0086272
27742630	576	592	cross-validation	T062	C0681935
27742630	603	620	tertiary hospital	T073,T093	C0337954
27742630	624	633	Singapore	T083	C0037173
27742630	639	644	adult	T100	C0001675
27742630	645	653	patients	T101	C0030705
27742630	670	678	hospital	T073,T093	C0019994
27742630	730	738	Frequent	T079	C0332183
27742630	739	758	hospital admissions	T058	C0184666
27742630	781	801	inpatient admissions	T058	C0030673
27742630	822	831	discharge	T058	C0030685
27742630	836	888	ea under the receiver operating characteristic curve	T081	C0376690
27742630	890	893	AUC	T081	C0376690
27742630	902	918	predictive model	T170	C0086272
27742630	928	939	sensitivity	T081	C1511883
27742630	941	952	specificity	T081	C0037791
27742630	957	983	positive predictive values	T081	C1514243
27742630	1011	1019	patients	T101	C0030705
27742630	1036	1051	primary outcome	T080	C3274433
27742630	1056	1065	variables	T080	C0439828
27742630	1095	1105	predictors	T078	C2698872
27742630	1164	1175	independent	T169	C0870693
27742630	1176	1185	predictor	T078	C2698872
27742630	1190	1199	treatment	T061	C0087111
27742630	1205	1220	antidepressants	T121	C0003289
27742630	1250	1252	OR	T081	C0028873
27742630	1263	1265	CI	T081	C0009667
27742630	1295	1305	predictors	T078	C2698872
27742630	1324	1332	dialysis	T061	C0011946
27742630	1337	1346	treatment	T061	C0087111
27742630	1352	1363	intravenous	T082	C0348016
27742630	1364	1374	furosemide	T109,T121	C0016860
27742630	1407	1423	predictive model	T170	C0086272
27742630	1436	1439	AUC	T081	C0376690
27742630	1453	1455	CI	T081	C0009667
27742630	1474	1484	predicting	T078	C0681842
27742630	1485	1493	frequent	T079	C0332183
27742630	1494	1512	hospital admission	T058	C0184666
27742630	1513	1517	risk	T078	C0035647
27742630	1526	1537	sensitivity	T081	C1511883
27742630	1552	1554	CI	T081	C0009667
27742630	1572	1583	specificity	T081	C0037791
27742630	1614	1639	positive predictive value	T081	C1514243
27742630	1654	1656	CI	T081	C0009667
27742630	1725	1735	predictors	T078	C2698872
27742630	1740	1758	assessing the risk	T058	C0086930
27742630	1762	1770	frequent	T079	C0332183
27742630	1771	1790	hospital admissions	T058	C0184666
27742630	1825	1830	model	T170	C0086272
27742630	1831	1842	performance	T052	C1882330
27742630	1903	1909	cohort	T098	C0599755

28485268|t|Biochemical studies of amylase, lipase and protease in Callosobruchus maculatus (Coleoptera: Chrysomelidae) populations fed with Vigna unguiculata grain cultivated with diazotrophic bacteria strains
28485268|a|The objective of this study was to evaluate the enzymatic activity of homogenates of insects fed on grain of cowpea, Vigna unguiculata (L.), cultivars grown with different nitrogen sources. For the experiment we used aliquots of the homogenate of 100 unsexed adult insects, emerged from 10 g of grain obtained from four cowpea cultivars: ' BRS Acauã ', ' BRS Carijó ', ' BRS Pujante ', and ' BRS Tapaihum ' grown under different regimes of nitrogen sources: mineral fertilizer, inoculation with strains of diazotrophs (BR 3267, BR 3262, BR 3299; INPA 03-11B, 03-84 UFLA, as well as the control (with soil nitrogen). The parameters evaluated were enzymatic activities of insect protease, amylase and lipase and the starch content of the grains. There were differences in the enzymatic activity of amylase, lipase and protease of insect homogenate according to the food source. A lower activity of the enzyme amylase from C. maculatus homogenate was observed when insects were fed grain of the cultivar BRS Carijó. A lower activity of lipase enzyme from C. maculatus homogenate was observed when the insects fed on grain from the interaction of the cultivar Tapaihum inoculated with BR 3262 diazotrophs. The lowest proteolytic activity was observed in homogenate of insects fed on interaction of ' BRS Carijó ' inoculated with BR 3262 diazotroph s. Starch content correlated positively with the amylase activity of C. maculatus homogenate. The cultivar BRS Carijó had a different behavior from the other cultivars, according to the cluster analysis.
28485268	0	11	Biochemical	T169	C0205474
28485268	12	19	studies	T062	C2603343
28485268	23	30	amylase	T116,T121,T126	C0002712
28485268	32	38	lipase	T116,T121,T126	C0023764
28485268	43	51	protease	T116,T126	C0030940
28485268	55	79	Callosobruchus maculatus	T204	C1024702
28485268	81	91	Coleoptera	T204	C0009276
28485268	93	106	Chrysomelidae	T204	C1001499
28485268	108	119	populations	T098	C1257890
28485268	129	146	Vigna unguiculata	T002	C0996865
28485268	147	152	grain	T168	C0007757
28485268	153	163	cultivated	T062	C0242481
28485268	169	198	diazotrophic bacteria strains	T007	C0004611
28485268	221	226	study	T062	C2603343
28485268	247	265	enzymatic activity	T044	C0243102
28485268	269	280	homogenates	T072	C3829671
28485268	284	291	insects	T204	C0021585
28485268	299	304	grain	T168	C0007757
28485268	308	314	cowpea	T002	C0996865
28485268	316	338	Vigna unguiculata (L.)	T002	C0996865
28485268	340	349	cultivars	T002	C0032098
28485268	371	379	nitrogen	T123,T196	C0028158
28485268	432	442	homogenate	T072	C3829671
28485268	458	463	adult	T100	C0001675
28485268	464	471	insects	T204	C0021585
28485268	494	499	grain	T168	C0007757
28485268	519	525	cowpea	T002	C0996865
28485268	526	535	cultivars	T002	C0032098
28485268	539	548	BRS Acauã	T002	C0032098
28485268	554	564	BRS Carijó	T002	C0032098
28485268	570	581	BRS Pujante	T002	C0032098
28485268	591	603	BRS Tapaihum	T002	C0032098
28485268	639	647	nitrogen	T123,T196	C0028158
28485268	657	664	mineral	T197	C0026162
28485268	665	675	fertilizer	T073,T131	C0015919
28485268	677	688	inoculation	T059	C0022885
28485268	694	716	strains of diazotrophs	T007	C0004611
28485268	718	725	BR 3267	T007	C3917457
28485268	727	734	BR 3262	T007	C3917456
28485268	736	743	BR 3299	T007	C0004611
28485268	745	756	INPA 03-11B	T007	C0004611
28485268	758	768	03-84 UFLA	T007	C0004611
28485268	785	792	control	T096	C0009932
28485268	799	803	soil	T167	C0037592
28485268	804	812	nitrogen	T123,T196	C0028158
28485268	845	865	enzymatic activities	T044	C0243102
28485268	869	875	insect	T204	C0021585
28485268	876	884	protease	T116,T126	C0030940
28485268	886	893	amylase	T116,T121,T126	C0002712
28485268	898	904	lipase	T116,T121,T126	C0023764
28485268	913	919	starch	T109,T121,T123	C0038179
28485268	935	941	grains	T168	C0007757
28485268	973	991	enzymatic activity	T044	C0243102
28485268	995	1002	amylase	T116,T121,T126	C0002712
28485268	1004	1010	lipase	T116,T121,T126	C0023764
28485268	1015	1023	protease	T116,T126	C0030940
28485268	1027	1033	insect	T204	C0021585
28485268	1034	1044	homogenate	T072	C3829671
28485268	1062	1066	food	T168	C0016452
28485268	1083	1105	activity of the enzyme	T044	C0243102
28485268	1106	1113	amylase	T116,T121,T126	C0002712
28485268	1119	1131	C. maculatus	T204	C1024702
28485268	1132	1142	homogenate	T072	C3829671
28485268	1161	1168	insects	T204	C0021585
28485268	1178	1183	grain	T168	C0007757
28485268	1191	1210	cultivar BRS Carijó	T002	C0032098
28485268	1220	1245	activity of lipase enzyme	T044	C1149836
28485268	1251	1263	C. maculatus	T204	C1024702
28485268	1264	1274	homogenate	T072	C3829671
28485268	1297	1304	insects	T204	C0021585
28485268	1312	1317	grain	T168	C0007757
28485268	1346	1363	cultivar Tapaihum	T002	C0032098
28485268	1380	1399	BR 3262 diazotrophs	T007	C3917456
28485268	1412	1432	proteolytic activity	T044	C0597304
28485268	1449	1459	homogenate	T072	C3829671
28485268	1463	1470	insects	T204	C0021585
28485268	1495	1505	BRS Carijó	T002	C0032098
28485268	1524	1542	BR 3262 diazotroph	T007	C3917456
28485268	1546	1552	Starch	T109,T121,T123	C0038179
28485268	1592	1608	amylase activity	T044	C1150038
28485268	1612	1624	C. maculatus	T204	C1024702
28485268	1625	1635	homogenate	T072	C3829671
28485268	1641	1660	cultivar BRS Carijó	T002	C0032098
28485268	1701	1710	cultivars	T002	C0032098
28485268	1729	1745	cluster analysis	T062	C0009085

27492044|t|Dysplasia discrimination in intestinal - type neoplasia of the esophagus and colon via digital image analysis
27492044|a|Determining gastrointestinal tract dysplasia level is clinically important but can be difficult, and given this challenge, we investigated colonic and esophageal dysplastic progression using digital image analysis (IA). Whole slide images were obtained for colonic normal mucosa (NCM), hyperplastic polyps (HP), conventional tubular adenomas (TA), and adenomas with high-grade dysplasia (HGD), and esophageal intestinal metaplasia negative for dysplasia (IM), indefinite for dysplasia (IFD), low-grade dysplasia (LGD), and HGD. Characteristic nuclei were circumscribed, and parameters discriminating groups included nuclear circumference (μm), area (μm(2)), and 15 positive pixel count (PPC) algorithm IA measurements. In colon polyps and esophageal lesions, average nuclear area and circumference ranged 30-108.6 μm(2) and 27.5-48.9 μm, respectively. Differences for average nuclear area and circumference met statistical significance (p < 0.05) between diagnostic groups in the esophagus and colon, except for IM versus IFD nuclear area. Pixel intensity (brightness) separated lesions within both groups with statistical significance except for colonic TAs versus HPs and esophageal LGD versus IM. HGD nuclei in both groups demonstrated more pixel staining heterogeneity than other lesions. Hierarchical clustering and principal component analysis demonstrated that lesions with similar diagnoses tended to cluster together on a low- to high-grade spectrum. Our results confirm that quantitative IA is an effective adjunct reflecting dysplasia in colon polyps and Barrett esophagus lesions. Nuclear area, circumference, and PPC algorithm findings distinguished lesions in a statistically significant manner. This suggests utility for future studies on similar methods, which may provide an adjunctive ancillary technique for pathologists and enhance patient care.
27492044	0	9	Dysplasia	T046	C0334044
27492044	10	24	discrimination	T080	C0205235
27492044	28	38	intestinal	T023	C0021853
27492044	41	45	type	T080	C0332307
27492044	46	55	neoplasia	T191	C0027651
27492044	63	72	esophagus	T023	C0014876
27492044	77	82	colon	T023	C0009368
27492044	83	86	via	T078	C1550513
27492044	87	109	digital image analysis	T060	C2348290
27492044	122	144	gastrointestinal tract	T022	C0017189
27492044	145	154	dysplasia	T046	C0334044
27492044	155	160	level	T185	C0456079
27492044	196	206	difficult,	T080	C0332218
27492044	236	248	investigated	T169	C1292732
27492044	249	256	colonic	T023	C0009368
27492044	261	271	esophageal	T082	C1522619
27492044	272	282	dysplastic	T046	C0334044
27492044	283	294	progression	T169	C0449258
27492044	301	323	digital image analysis	T060	C2348290
27492044	325	327	IA	T060	C2348290
27492044	336	348	slide images	T170	C1704254
27492044	396	415	hyperplastic polyps	T191	C0333983
27492044	417	419	HP	T191	C0333983
27492044	435	451	tubular adenomas	T191	C0334292
27492044	453	455	TA	T191	C0334292
27492044	462	470	adenomas	T191	C0001430
27492044	476	496	high-grade dysplasia	T191	C1333450
27492044	498	501	HGD	T191	C1333450
27492044	508	540	esophageal intestinal metaplasia	T047	C2363785
27492044	541	549	negative	T033	C0205160
27492044	554	563	dysplasia	T046	C0334044
27492044	565	567	IM	T047	C2363785
27492044	570	594	indefinite for dysplasia	T033	C2987259
27492044	596	599	IFD	T033	C2987259
27492044	602	621	low-grade dysplasia	T047	C0586355
27492044	623	626	LGD	T047	C0586355
27492044	633	636	HGD	T191	C1333450
27492044	726	733	nuclear	T082	C0521447
27492044	734	747	circumference	T081	C0332520
27492044	754	758	area	T082	C0205146
27492044	775	814	positive pixel count (PPC) algorithm IA	T059	C0022885
27492044	815	827	measurements	T169	C0242485
27492044	832	844	colon polyps	T190	C0009376
27492044	849	859	esophageal	T082	C1522619
27492044	860	867	lesions	T033	C0221198
27492044	869	889	average nuclear area	T033	C0243095
27492044	894	907	circumference	T081	C0332520
27492044	908	914	ranged	T081	C1514721
27492044	978	998	average nuclear area	T033	C0243095
27492044	1003	1016	circumference	T081	C0332520
27492044	1021	1045	statistical significance	T081	C0237881
27492044	1065	1075	diagnostic	T169	C0348026
27492044	1076	1082	groups	T078	C0441833
27492044	1090	1099	esophagus	T023	C0014876
27492044	1104	1109	colon	T023	C0009368
27492044	1122	1124	IM	T047	C2363785
27492044	1132	1135	IFD	T033	C2987259
27492044	1150	1165	Pixel intensity	T080	C0205556
27492044	1167	1177	brightness	T080	C0205556
27492044	1189	1196	lesions	T033	C0221198
27492044	1221	1245	statistical significance	T081	C0237881
27492044	1257	1268	colonic TAs	T191	C1112503
27492044	1276	1279	HPs	T191	C0333983
27492044	1284	1298	esophageal LGD	T047	C0586355
27492044	1310	1313	HGD	T191	C1333450
27492044	1354	1359	pixel	T077	C1709558
27492044	1369	1382	heterogeneity	T080	C0019409
27492044	1394	1401	lesions	T033	C0221198
27492044	1403	1426	Hierarchical clustering	T062	C1881045
27492044	1431	1459	principal component analysis	T081	C0429865
27492044	1478	1485	lesions	T033	C0221198
27492044	1499	1508	diagnoses	T033	C0011900
27492044	1519	1526	cluster	T081	C1704332
27492044	1595	1610	quantitative IA	T059	C0200767
27492044	1617	1626	effective	T080	C1704419
27492044	1627	1634	adjunct	T169	C1719882
27492044	1646	1655	dysplasia	T046	C0334044
27492044	1659	1671	colon polyps	T190	C0009376
27492044	1676	1693	Barrett esophagus	T047	C0004763
27492044	1694	1701	lesions	T033	C0221198
27492044	1703	1715	Nuclear area	T033	C0243095
27492044	1717	1730	circumference	T081	C0332520
27492044	1736	1749	PPC algorithm	T170	C0002045
27492044	1773	1780	lesions	T033	C0221198
27492044	1786	1811	statistically significant	T081	C0237881
27492044	1902	1912	adjunctive	T169	C1719882
27492044	1913	1922	ancillary	T078	C1549485
27492044	1923	1932	technique	T169	C0449851
27492044	1937	1949	pathologists	T097	C0334866
27492044	1954	1961	enhance	T052	C2349975
27492044	1962	1974	patient care	T058	C0017313

27634338|t|Residual contamination and bioburden after reprocessing of single-use endoscopic ultrasound needles: An ex vivo study
27634338|a|Endoscopic ultrasound (EUS) aspiration needles are single-use devices. However, in many centers, because of cost - constraints, these devices are reused multiple times. We studied microbiological contamination and bioburden on reprocessed needles to evaluate whether these devices can be successfully sterilized. We studied 10 EUS needles each of 19 G, 22 G, and 25 G in size, and five 22-G ProCore needles. After initial use, each needle was reprocessed by a standardized protocol. We used standard microbiological cultures, as well as ATP bioluminescence technique to quantify bioburden as relative light units (RLU). We defined significant soil contamination by RLU values >200. We also used extractant fluid to disrupt cell membranes in an attempt to enhance ATP detection. We found culture positivity in 3/34 (8.8%), and detectable bioburden on the exposed surface of 33/35 (94.3%), and inside lumen of 29 (82.9%) reprocessed FNA needles. Significant bioburden was found in three (8.6%) and two (5.7%) needles on the surface and lumen, respectively. We found that use of extractant fluid enhanced detection of bioburden. Larger (19 G) needles had higher surface contamination (P = 0.016), but there was no relation of luminal contamination with needle diameter (P = 0.138). Sheath design and presence of side bevel did not influence extent of contamination. There was significant correlation between the surface and intraluminal bioburden (P < 0.001). There is significant bioburden in reprocessed EUS needles; standard microbiological cultures have low sensitivity for detection of needle contamination. We have provided objective evidence for the futility of reprocessing attempts, and practice of EUS needle reuse should be discontinued.
27634338	0	8	Residual	T080	C1609982
27634338	9	22	contamination	T051	C1881659
27634338	27	36	bioburden	T067	C1879778
27634338	43	55	reprocessing	T052	C1711371
27634338	59	69	single-use	T074	C1707708
27634338	70	99	endoscopic ultrasound needles	T074	C0490922
27634338	104	111	ex vivo	T169	C2348480
27634338	112	117	study	T062	C2603343
27634338	118	164	Endoscopic ultrasound (EUS) aspiration needles	T074	C0490922
27634338	169	187	single-use devices	T074	C1707708
27634338	206	213	centers	T073,T093	C1552416
27634338	226	230	cost	T081	C0010186
27634338	233	244	constraints	T169	C0443288
27634338	252	259	devices	T074	C0025080
27634338	264	270	reused	T169	C1709937
27634338	271	279	multiple	T081	C0439064
27634338	280	285	times	T079	C0040223
27634338	298	313	microbiological	T007	C0577610
27634338	314	327	contamination	T051	C1881659
27634338	332	341	bioburden	T067	C1879778
27634338	345	364	reprocessed needles	T074	C1262420
27634338	368	376	evaluate	T058	C0220825
27634338	391	398	devices	T074	C0025080
27634338	406	418	successfully	T080	C1272703
27634338	419	429	sterilized	T058	C1443991
27634338	445	456	EUS needles	T074	C0490922
27634338	489	493	size	T082	C0449965
27634338	509	524	ProCore needles	T074	C0181960
27634338	532	543	initial use	T169	C1705685
27634338	550	556	needle	T074	C0027551
27634338	561	572	reprocessed	T052	C1711371
27634338	578	590	standardized	T080	C1442989
27634338	591	599	protocol	T170	C0442711
27634338	609	617	standard	T080	C1442989
27634338	618	642	microbiological cultures	T059	C2242979
27634338	655	658	ATP	T114,T121,T123	C0001480
27634338	659	684	bioluminescence technique	T059	C3179184
27634338	688	696	quantify	T081	C1709793
27634338	697	706	bioburden	T067	C1879778
27634338	710	730	relative light units	T081	C1519795
27634338	732	735	RLU	T081	C1519795
27634338	749	760	significant	T078	C0750502
27634338	761	765	soil	T167	C0037592
27634338	766	779	contamination	T078	C2349974
27634338	783	786	RLU	T081	C1519795
27634338	813	829	extractant fluid	T167	C1704353
27634338	833	840	disrupt	T080	C0332454
27634338	841	855	cell membranes	T026	C0007603
27634338	862	869	attempt	T051	C1516084
27634338	873	880	enhance	T052	C2349975
27634338	881	884	ATP	T114,T121,T123	C0001480
27634338	885	894	detection	T033	C0442726
27634338	905	923	culture positivity	T033	C0159125
27634338	944	954	detectable	T201	C3830527
27634338	955	964	bioburden	T067	C1879778
27634338	972	979	exposed	T080	C0332157
27634338	980	987	surface	T082	C0205148
27634338	1010	1016	inside	T082	C0205102
27634338	1017	1022	lumen	T030	C0524461
27634338	1037	1048	reprocessed	T052	C1711371
27634338	1049	1060	FNA needles	T074	C0181959
27634338	1062	1073	Significant	T078	C0750502
27634338	1074	1083	bioburden	T067	C1879778
27634338	1125	1132	needles	T074	C0027551
27634338	1140	1147	surface	T082	C0205148
27634338	1152	1157	lumen	T030	C0524461
27634338	1194	1210	extractant fluid	T167	C1704353
27634338	1211	1219	enhanced	T052	C2349975
27634338	1220	1229	detection	T033	C0442726
27634338	1233	1242	bioburden	T067	C1879778
27634338	1244	1250	Larger	T081	C0549177
27634338	1258	1265	needles	T074	C0027551
27634338	1270	1276	higher	T080	C0205250
27634338	1277	1284	surface	T082	C0205148
27634338	1285	1298	contamination	T051	C1881659
27634338	1326	1337	no relation	T033	C0243095
27634338	1341	1348	luminal	T082	C0524462
27634338	1349	1362	contamination	T051	C1881659
27634338	1368	1374	needle	T074	C0027551
27634338	1375	1383	diameter	T081	C1301886
27634338	1397	1403	Sheath	T074	C0490966
27634338	1404	1410	design	T057	C0086137
27634338	1415	1423	presence	T033	C0150312
27634338	1427	1431	side	T082	C0441987
27634338	1432	1437	bevel	T074	C1720515
27634338	1438	1455	did not influence	T033	C0243095
27634338	1456	1462	extent	T082	C0439792
27634338	1466	1479	contamination	T051	C1881659
27634338	1491	1502	significant	T078	C0750502
27634338	1503	1514	correlation	T080	C1707520
27634338	1527	1534	surface	T082	C0205148
27634338	1539	1551	intraluminal	T082	C0442115
27634338	1552	1561	bioburden	T067	C1879778
27634338	1584	1595	significant	T078	C0750502
27634338	1596	1605	bioburden	T067	C1879778
27634338	1609	1620	reprocessed	T052	C1711371
27634338	1621	1632	EUS needles	T074	C0490922
27634338	1634	1642	standard	T080	C1442989
27634338	1643	1667	microbiological cultures	T059	C2242979
27634338	1673	1676	low	T080	C0205251
27634338	1677	1688	sensitivity	T059	C0455287
27634338	1693	1702	detection	T033	C0442726
27634338	1706	1726	needle contamination	T051	C1881659
27634338	1745	1754	objective	T080	C1571702
27634338	1755	1763	evidence	T078	C3887511
27634338	1772	1780	futility	T078	C0242652
27634338	1784	1796	reprocessing	T052	C1711371
27634338	1797	1805	attempts	T051	C1516084
27634338	1823	1833	EUS needle	T074	C0490922
27634338	1834	1839	reuse	T169	C1709937
27634338	1850	1862	discontinued	T033	C1444662

27994747|t|Discovery and Optimization of a Novel Triazole Series of GPR142 Agonists for the Treatment of Type 2 Diabetes
27994747|a|GPR142 has been identified as a potential glucose-stimulated insulin secretion (GSIS) target for the treatment of type 2 diabetes mellitus (T2DM). A class of triazole GPR142 agonists was discovered through a high throughput screen. The lead compound 4 suffered from poor metabolic stability and poor solubility. Lead optimization strategies to improve potency, efficacy, metabolic stability, and solubility are described. This optimization led to compound 20e, which showed significant reduction of glucose excursion in wild-type but not in GPR142 deficient mice in an oral glucose tolerance test (oGTT) study. These studies provide strong evidence that reduction of glucose excursion through treatment with 20e is GPR142 -mediated, and GPR142 agonists could be used as a potential treatment for type 2 diabetes.
27994747	0	9	Discovery	T052	C1880355
27994747	14	26	Optimization	T052	C2698650
27994747	32	37	Novel	T080	C0205314
27994747	38	53	Triazole Series	T109,T121	C1689939
27994747	57	63	GPR142	T116,T192	C1570380
27994747	64	72	Agonists	T121	C0243192
27994747	81	90	Treatment	T169	C1522326
27994747	94	109	Type 2 Diabetes	T047	C0011860
27994747	110	116	GPR142	T116,T192	C1570380
27994747	142	151	potential	T080	C3245505
27994747	152	188	glucose-stimulated insulin secretion	T043	C2245393
27994747	190	194	GSIS	T043	C2245393
27994747	196	202	target	T169	C1521840
27994747	211	220	treatment	T169	C1522326
27994747	224	248	type 2 diabetes mellitus	T047	C0011860
27994747	250	254	T2DM	T047	C0011860
27994747	259	276	class of triazole	T109,T121	C1689939
27994747	277	283	GPR142	T116,T192	C1570380
27994747	284	292	agonists	T121	C0243192
27994747	297	307	discovered	T052	C1880355
27994747	318	340	high throughput screen	T060	C0872187
27994747	346	361	lead compound 4	T121	C1254351
27994747	376	380	poor	T080	C0542537
27994747	381	390	metabolic	T169	C0311400
27994747	391	400	stability	T080	C0205360
27994747	405	409	poor	T080	C0542537
27994747	410	420	solubility	T080	C0037628
27994747	427	439	optimization	T052	C2698650
27994747	454	461	improve	T033	C0184511
27994747	462	469	potency	T080	C0205556
27994747	471	479	efficacy	T080	C1280519
27994747	481	490	metabolic	T169	C0311400
27994747	491	500	stability	T080	C0205360
27994747	506	516	solubility	T080	C0037628
27994747	537	549	optimization	T052	C2698650
27994747	557	569	compound 20e	T121	C1254351
27994747	596	605	reduction	T080	C0392756
27994747	609	626	glucose excursion	T034	C0428548
27994747	630	639	wild-type	T015	C1520150
27994747	651	657	GPR142	T116,T192	C1723023
27994747	658	667	deficient	T169	C0011155
27994747	668	672	mice	T015	C0025929
27994747	679	706	oral glucose tolerance test	T060	C0029161
27994747	708	712	oGTT	T060	C0029161
27994747	727	734	studies	T062	C2603343
27994747	764	773	reduction	T080	C0392756
27994747	777	794	glucose excursion	T034	C0428548
27994747	803	812	treatment	T169	C1522326
27994747	818	821	20e	T121	C1254351
27994747	825	831	GPR142	T116,T192	C1723023
27994747	847	853	GPR142	T116,T192	C1723023
27994747	854	862	agonists	T121	C0243192
27994747	882	891	potential	T080	C3245505
27994747	892	901	treatment	T169	C1522326
27994747	906	921	type 2 diabetes	T047	C0011860

27694728|t|Molecular diagnosis of infectious diseases in São Miguel Island (Azores, Portugal): A hospital -based descriptive study
27694728|a|We performed a descriptive analysis of molecular diagnosis of infectious agents in the São Miguel Island population, in order to address questions like what is the frequency of clinical requests, is it observable seasonality of pathogens, and what is the positive rate for the clinical diagnosis. This was a retrospective and descriptive study based on 878 individuals suspected of harboring infectious diseases during two consecutive years, 2012-2013. More than 25 different pathogens were investigated by polymerase chain reaction (PCR)-based methods. The individuals were stratified into gender, occupation, and age groups. The pathogen with more clinical requests was hepatitis C virus, investigated in 225 individuals (30.0%), followed by Leptospira spp ., in 187 (24.9%). Overall, data demonstrated a gender distribution bias, where 72.9% of cases were males. The age group of 25 to 44 years was the class with more clinical requests. Regarding occupation, a predominance of construction workers (12.0%) was observed, followed by retired workers (11.0%). Patient distribution per year showed a higher number of patients in the fall months. Diagnoses of leptospirosis and respiratory virus infections presented seasonality. The present study provides a valid contribution to the knowledge of the epidemiology of infectious diseases in the São Miguel Island (Azores, Portugal) population.
27694728	0	19	Molecular diagnosis	T059	C1513388
27694728	23	42	infectious diseases	T047	C0009450
27694728	46	63	São Miguel Island	T083	C0017446
27694728	65	71	Azores	T083	C0004511
27694728	73	81	Portugal	T083	C0032729
27694728	86	94	hospital	T073,T093	C0019994
27694728	102	119	descriptive study	T062	C2603343
27694728	135	155	descriptive analysis	T062	C0936012
27694728	159	178	molecular diagnosis	T059	C1513388
27694728	182	199	infectious agents	T001	C0314732
27694728	207	224	São Miguel Island	T083	C0017446
27694728	225	235	population	T081	C0032659
27694728	297	314	clinical requests	T078	C1548104
27694728	333	344	seasonality	T079	C0683922
27694728	348	357	pathogens	T001	C0450254
27694728	397	415	clinical diagnosis	T060	C0332140
27694728	428	441	retrospective	T080	C1514923
27694728	446	463	descriptive study	T062	C2603343
27694728	477	488	individuals	T098	C0237401
27694728	489	498	suspected	T047	C0277540
27694728	512	531	infectious diseases	T047	C0009450
27694728	555	560	years	T079	C0439234
27694728	596	605	pathogens	T001	C0450254
27694728	611	623	investigated	T169	C1292732
27694728	627	652	polymerase chain reaction	T063	C0032520
27694728	654	657	PCR	T063	C0032520
27694728	678	689	individuals	T098	C0237401
27694728	695	705	stratified	T080	C0205363
27694728	711	717	gender	T032	C0079399
27694728	719	729	occupation	T090	C0028811
27694728	735	745	age groups	T100	C0027362
27694728	751	759	pathogen	T001	C0450254
27694728	770	778	clinical	T080	C0205210
27694728	792	809	hepatitis C virus	T005	C0220847
27694728	811	823	investigated	T169	C1292732
27694728	831	842	individuals	T098	C0237401
27694728	864	878	Leptospira spp	T007	C1265223
27694728	907	911	data	T078	C1511726
27694728	927	933	gender	T032	C0079399
27694728	934	946	distribution	T169	C1704711
27694728	947	951	bias	T078	C0242568
27694728	979	984	males	T032	C0086582
27694728	990	999	age group	T100	C0027362
27694728	1012	1017	years	T079	C0439234
27694728	1042	1059	clinical requests	T078	C1548104
27694728	1071	1081	occupation	T090	C0028811
27694728	1085	1097	predominance	T033	C0243095
27694728	1101	1121	construction workers	T097	C0403066
27694728	1156	1171	retired workers	T097	C4076599
27694728	1181	1188	Patient	T101	C0030705
27694728	1189	1201	distribution	T169	C1704711
27694728	1206	1210	year	T079	C0439234
27694728	1237	1245	patients	T101	C0030705
27694728	1258	1264	months	T079	C0439231
27694728	1266	1275	Diagnoses	T033	C0011900
27694728	1279	1292	leptospirosis	T047	C0023364
27694728	1297	1325	respiratory virus infections	T047	C0035235
27694728	1336	1347	seasonality	T079	C0683922
27694728	1361	1366	study	T062	C2603343
27694728	1384	1396	contribution	T052	C1880177
27694728	1404	1413	knowledge	T170	C0376554
27694728	1421	1433	epidemiology	T091	C0014507
27694728	1437	1456	infectious diseases	T047	C0009450
27694728	1464	1481	São Miguel Island	T083	C0017446
27694728	1483	1489	Azores	T083	C0004511
27694728	1491	1499	Portugal	T083	C0032729
27694728	1501	1511	population	T081	C0032659

28237953|t|Evaluating the relative effectiveness of high-intensity and low-intensity models of behaviour change communication interventions for abortion care-seeking in Bihar and Jharkhand, India: a cross-sectional study
28237953|a|This study aimed to compare the effectiveness of a high-intensity model (HIM) and a low-intensity model (LIM) of behaviour change communication interventions in Bihar and Jharkhand states of India designed to improve women's knowledge and usage of safe abortion services, as well as the dose effect of intervention exposure. We conducted two cross-sectional household surveys among married women aged 15-49 years in intervention and comparison districts. Difference-in-difference models were used to assess the efficacy of the intervention, adjusting for sociodemographic characteristics. Although both intervention types improved abortion knowledge, the HIM intervention was more effective in improving comprehensive knowledge about abortion. In particular, there were improvements in knowledge on legality of abortion (AOR=2.2; 95% CI 1.6 to 2.9) and nearby sources of safe abortion care (AOR=1.7; 95% CI 1.2 to 1.3). Higher level of exposure to abortion-related messages was related to more accurate knowledge about abortion within both intervention groups. Evidence was mixed on changes in abortion care-seeking behaviour. More work is needed to ensure that women seek safe abortion services in lieu of informal services that may be more likely to lead to postabortion complications.
28237953	15	37	relative effectiveness	T081	C0035023
28237953	41	55	high-intensity	T185	C4081854
28237953	60	80	low-intensity models	T081	C0392762
28237953	84	100	behaviour change	T055	C0542299
28237953	101	128	communication interventions	T061	C1274143
28237953	133	141	abortion	T033	C0156543
28237953	142	154	care-seeking	T055	C0018695
28237953	158	163	Bihar	UnknownType	C0681784
28237953	168	177	Jharkhand	UnknownType	C0681784
28237953	179	184	India	T083	C0021201
28237953	188	209	cross-sectional study	T062	C0010362
28237953	242	255	effectiveness	T080	C1280519
28237953	261	281	high-intensity model	T185	C4081854
28237953	283	286	HIM	T185	C4081854
28237953	294	313	low-intensity model	T081	C0392762
28237953	315	318	LIM	T081	C0392762
28237953	323	339	behaviour change	T055	C0542299
28237953	340	367	communication interventions	T061	C1274143
28237953	371	376	Bihar	UnknownType	C0681784
28237953	381	390	Jharkhand	UnknownType	C0681784
28237953	401	406	India	T083	C0021201
28237953	427	434	women's	T098	C0043210
28237953	435	444	knowledge	T033	C1948177
28237953	458	471	safe abortion	T033	C0156543
28237953	497	508	dose effect	UnknownType	C0683160
28237953	512	524	intervention	T061	C0184661
28237953	552	585	cross-sectional household surveys	T062	C0010362
28237953	592	599	married	T033	C0555047
28237953	600	605	women	T098	C0043210
28237953	606	610	aged	T032	C0001779
28237953	626	638	intervention	T061	C0184661
28237953	654	663	districts	UnknownType	C0681784
28237953	665	696	Difference-in-difference models	T081	C0392762
28237953	721	729	efficacy	T080	C1280519
28237953	737	749	intervention	T061	C0184661
28237953	765	797	sociodemographic characteristics	T033	C0243095
28237953	813	825	intervention	T061	C0184661
28237953	841	849	abortion	T033	C0156543
28237953	850	859	knowledge	T170	C0376554
28237953	865	868	HIM	T185	C4081854
28237953	869	881	intervention	T061	C0184661
28237953	914	937	comprehensive knowledge	T170	C0376554
28237953	944	952	abortion	T033	C0156543
28237953	996	1005	knowledge	T170	C0376554
28237953	1009	1029	legality of abortion	T061	C0000812
28237953	1081	1099	safe abortion care	T058	C3697217
28237953	1213	1222	knowledge	T170	C0376554
28237953	1229	1237	abortion	T033	C0156543
28237953	1250	1262	intervention	T061	C0184661
28237953	1304	1312	abortion	T033	C0156543
28237953	1313	1325	care-seeking	T055	C0018695
28237953	1326	1335	behaviour	T053	C0004927
28237953	1372	1377	women	T098	C0043210
28237953	1383	1396	safe abortion	T033	C0156543
28237953	1470	1496	postabortion complications	T046	C0851640

27938482|t|Repetitive and Prolonged Omega-3 Fatty Acid Treatment After Traumatic Brain Injury Enhances Long-Term Tissue Restoration and Cognitive Recovery
27938482|a|Traumatic brain injury (TBI) is one of the most disabling clinical conditions that could lead to neurocognitive disorders in survivors. Our group and others previously reported that prophylactic enrichment of dietary omega-3 polyunsaturated fatty acids (n-3 PUFAs) markedly ameliorate cognitive deficits after TBI. However, it remains unclear whether a clinically relevant therapeutic regimen with n-3 PUFAs administered after TBI would still offer significant improvement of long-term cognitive recovery. In the present study, we employed the decline of spatial cognitive function as a main outcome after TBI to investigate the therapeutic efficacy of post - TBI n-3 PUFA treatment and the underlying mechanisms. Mice were subjected to sham operation or controlled cortical impact, followed by random assignment to receive the following four treatments: (1) vehicle control; (2) daily intraperitoneal injections of n-3 PUFAs for 2 weeks, beginning 2 h after TBI; (3) fish oil dietary supplementation throughout the study, beginning 1 day after TBI; or (4) combination of treatments (2) and (3). Spatial cognitive deficits and chronic brain tissue loss, as well as endogenous brain repair processes such as neurogenesis, angiogenesis, and oligodendrogenesis, were evaluated up to 35 days after TBI. The results revealed prominent spatial cognitive deficits and massive tissue loss caused by TBI. Among all mice receiving post-TBI n-3 PUFA treatments, the combined treatment of fish oil dietary supplement and n-3 PUFA injections demonstrated a reproducible beneficial effect in attenuating cognitive deficits although without reducing gross tissue loss. Mechanistically, the combined treatment promoted post-TBI restorative processes in the brain, including generation of immature neurons, microvessels, and oligodendrocytes, each of which was significantly correlated with the improved cognitive recovery. These results indicated that repetitive and prolonged n-3 PUFA treatments after TBI are capable of enhancing brain remodeling and could be developed as a potential therapy to treat TBI victims in the clinic.
27938482	0	10	Repetitive	T079	C2945760
27938482	15	24	Prolonged	T079	C0439590
27938482	25	43	Omega-3 Fatty Acid	T109,T121,T123	C0015689
27938482	44	53	Treatment	T061	C0087111
27938482	54	59	After	T079	C0687676
27938482	60	82	Traumatic Brain Injury	T037	C0876926
27938482	83	91	Enhances	T052	C2349975
27938482	92	101	Long-Term	T079	C0443252
27938482	102	108	Tissue	T024	C0040300
27938482	109	120	Restoration	T061	C0087111
27938482	125	143	Cognitive Recovery	T061	C0009244
27938482	144	166	Traumatic brain injury	T037	C0876926
27938482	168	171	TBI	T037	C0876926
27938482	192	221	disabling clinical conditions	T033	C4061999
27938482	233	237	lead	T169	C1522538
27938482	241	265	neurocognitive disorders	T048	C4041080
27938482	269	278	survivors	T101	C0206194
27938482	284	289	group	T098	C1705429
27938482	294	300	others	T098	C1257890
27938482	312	320	reported	T170	C0684224
27938482	326	349	prophylactic enrichment	T061	C0199176
27938482	353	360	dietary	T169	C2699635
27938482	361	396	omega-3 polyunsaturated fatty acids	T109,T121,T123	C0015689
27938482	398	407	n-3 PUFAs	T109,T121,T123	C0015689
27938482	418	428	ameliorate	T169	C0332303
27938482	429	447	cognitive deficits	T048	C0009241
27938482	448	453	after	T079	C0687676
27938482	454	457	TBI	T037	C0876926
27938482	479	486	unclear	T033	C3845108
27938482	497	507	clinically	T080	C0443178
27938482	508	516	relevant	T080	C2347946
27938482	517	536	therapeutic regimen	T061	C1276413
27938482	542	551	n-3 PUFAs	T109,T121,T123	C0015689
27938482	552	564	administered	T169	C1521801
27938482	565	570	after	T079	C0687676
27938482	571	574	TBI	T037	C0876926
27938482	605	616	improvement	T077	C2986411
27938482	620	629	long-term	T079	C0443252
27938482	630	648	cognitive recovery	T061	C0009244
27938482	665	670	study	T062	C2603343
27938482	688	695	decline	T080	C1511741
27938482	707	725	cognitive function	T048	C0009241
27938482	731	735	main	T080	C1542147
27938482	736	743	outcome	T169	C1274040
27938482	744	749	after	T079	C0687676
27938482	750	753	TBI	T037	C0876926
27938482	757	768	investigate	T169	C1292732
27938482	773	793	therapeutic efficacy	T080	C2348767
27938482	797	801	post	T079	C0687676
27938482	804	807	TBI	T037	C0876926
27938482	808	816	n-3 PUFA	T109,T121,T123	C0015689
27938482	817	826	treatment	T061	C0087111
27938482	846	856	mechanisms	T169	C0441712
27938482	858	862	Mice	T015	C0025929
27938482	881	895	sham operation	T061	C0141287
27938482	899	909	controlled	T169	C2587213
27938482	910	918	cortical	T023	C0007776
27938482	919	925	impact	T080	C4049986
27938482	939	956	random assignment	UnknownType	C0814868
27938482	960	967	receive	T080	C1514756
27938482	982	986	four	T081	C0205450
27938482	987	997	treatments	T061	C0087111
27938482	1003	1010	vehicle	T122	C0042444
27938482	1011	1018	control	T169	C2587213
27938482	1024	1029	daily	T079	C0332173
27938482	1030	1056	intraperitoneal injections	T061	C0021493
27938482	1060	1069	n-3 PUFAs	T109,T121,T123	C0015689
27938482	1076	1081	weeks	T079	C0439230
27938482	1083	1092	beginning	T079	C0439659
27938482	1095	1096	h	T079	C0439227
27938482	1097	1102	after	T079	C0687676
27938482	1103	1106	TBI	T037	C0876926
27938482	1112	1128	fish oil dietary	T168	C0556145
27938482	1129	1144	supplementation	T061	C0242297
27938482	1160	1165	study	T062	C2603343
27938482	1167	1176	beginning	T079	C0439659
27938482	1179	1182	day	T079	C0439228
27938482	1183	1188	after	T079	C0687676
27938482	1189	1192	TBI	T037	C0876926
27938482	1201	1212	combination	T080	C0205195
27938482	1216	1226	treatments	T061	C0087111
27938482	1271	1278	chronic	T079	C0205191
27938482	1279	1291	brain tissue	T023	C0459385
27938482	1292	1296	loss	T081	C1517945
27938482	1309	1319	endogenous	T169	C0205227
27938482	1320	1342	brain repair processes	T061	C0161849
27938482	1351	1363	neurogenesis	T040	C0814002
27938482	1365	1377	angiogenesis	T042	C0302600
27938482	1383	1401	oligodendrogenesis	T038	C3714634
27938482	1427	1431	days	T079	C0439228
27938482	1432	1437	after	T079	C0687676
27938482	1438	1441	TBI	T037	C0876926
27938482	1447	1454	results	T169	C1274040
27938482	1455	1463	revealed	T080	C0443289
27938482	1482	1500	cognitive deficits	T048	C0009241
27938482	1505	1512	massive	T080	C0522501
27938482	1513	1519	tissue	T023	C0459385
27938482	1520	1524	loss	T081	C1517945
27938482	1535	1538	TBI	T037	C0876926
27938482	1550	1554	mice	T015	C0025929
27938482	1555	1564	receiving	T080	C1514756
27938482	1565	1573	post-TBI	T037	C0876926
27938482	1574	1582	n-3 PUFA	T109,T121,T123	C0015689
27938482	1583	1593	treatments	T061	C0087111
27938482	1599	1607	combined	T080	C0205195
27938482	1608	1617	treatment	T061	C0087111
27938482	1621	1637	fish oil dietary	T168	C0556145
27938482	1638	1648	supplement	T168	C0242295
27938482	1653	1661	n-3 PUFA	T109,T121,T123	C0015689
27938482	1662	1672	injections	T122	C1272883
27938482	1673	1685	demonstrated	T052	C3687625
27938482	1688	1718	reproducible beneficial effect	UnknownType	C0683156
27938482	1734	1752	cognitive deficits	T048	C0009241
27938482	1770	1778	reducing	T080	C0392756
27938482	1779	1784	gross	T080	C0439806
27938482	1785	1791	tissue	T023	C0459385
27938482	1792	1796	loss	T081	C1517945
27938482	1828	1837	treatment	T061	C0087111
27938482	1838	1846	promoted	T052	C0033414
27938482	1847	1855	post-TBI	T037	C0876926
27938482	1856	1877	restorative processes	T061	C0541662
27938482	1885	1890	brain	T023	C0006104
27938482	1892	1901	including	T169	C0332257
27938482	1916	1932	immature neurons	T025	C0027882
27938482	1934	1946	microvessels	T023	C2350570
27938482	1952	1968	oligodendrocytes	T025	C0028944
27938482	2002	2012	correlated	T080	C1707520
27938482	2022	2030	improved	T033	C0184511
27938482	2031	2049	cognitive recovery	T169	C1274040
27938482	2057	2064	results	T169	C1274040
27938482	2065	2074	indicated	T033	C1444656
27938482	2080	2090	repetitive	T079	C2945760
27938482	2095	2104	prolonged	T079	C0439590
27938482	2105	2113	n-3 PUFA	T109,T121,T123	C0015689
27938482	2114	2124	treatments	T061	C0087111
27938482	2125	2130	after	T079	C0687676
27938482	2131	2134	TBI	T037	C0876926
27938482	2150	2159	enhancing	T052	C2349975
27938482	2160	2165	brain	T023	C0006104
27938482	2166	2176	remodeling	UnknownType	C0678692
27938482	2205	2214	potential	T080	C3245505
27938482	2215	2222	therapy	T061	C0087111
27938482	2232	2235	TBI	T037	C0876926
27938482	2236	2243	victims	T098	C0680681
27938482	2251	2257	clinic	T073,T093	C0442592

27940904|t|Predicting Zambian Grandmothers ' Sensitivity Toward Their Grandchildren
27940904|a|Whereas child care by grandmothers is widespread in the African cultural context, few studies have examined predictors of the quality of grandmaternal care in Africa. In the current study, we collected observational data to investigate predictors of the quality of grandmother - grandchild interactions in Zambia. Data were collected from 46 grandmothers and their 12 to 27- month -old infant grandchildren. The results revealed that grandmothers with fewer children and those who enjoyed the grandparenting tasks more were more sensitive in their interactions with their grandchildren. Unexpectedly, parenting beliefs favoring sensitive parenting predicted lower observed sensitivity in grandmothers. Further, grandmothers with a more individualistic cultural orientation were more intrusive toward their grandchildren. The results underscore the importance of time and emotional resources as predictors of sensitive parenting among grandmothers.
27940904	0	10	Predicting	T078	C0681842
27940904	11	18	Zambian	T098	C1257890
27940904	19	31	Grandmothers	T099	C0337474
27940904	34	45	Sensitivity	T041	C0312418
27940904	59	72	Grandchildren	T099	C0337548
27940904	81	91	child care	T054	C0008091
27940904	95	107	grandmothers	T099	C0337474
27940904	111	121	widespread	T082	C0205391
27940904	129	136	African	T098	C0027567
27940904	137	153	cultural context	T077	C0282495
27940904	159	166	studies	T062	C2603343
27940904	172	180	examined	T033	C0332128
27940904	181	191	predictors	T078	C2698872
27940904	199	206	quality	T080	C0332306
27940904	210	228	grandmaternal care	T052	C1947933
27940904	232	238	Africa	T083	C0001737
27940904	247	254	current	T079	C0521116
27940904	255	260	study	T062	C2603343
27940904	265	293	collected observational data	T033	C4019276
27940904	297	308	investigate	T169	C1292732
27940904	309	319	predictors	T078	C2698872
27940904	327	334	quality	T080	C0332306
27940904	338	349	grandmother	T099	C0337474
27940904	352	362	grandchild	T099	C0337548
27940904	363	375	interactions	T033	C0037420
27940904	379	385	Zambia	T083	C0043445
27940904	387	406	Data were collected	T033	C4019276
27940904	415	427	grandmothers	T099	C0337474
27940904	448	453	month	T079	C0439231
27940904	459	465	infant	T100	C0021270
27940904	466	479	grandchildren	T099	C0337548
27940904	485	492	results	T033	C0243095
27940904	493	501	revealed	T080	C0443289
27940904	507	519	grandmothers	T099	C0337474
27940904	525	530	fewer	T081	C0205388
27940904	531	539	children	T099	C0337548
27940904	554	561	enjoyed	T041	C0018592
27940904	566	580	grandparenting	T054	C0085092
27940904	581	586	tasks	T057	C3540678
27940904	597	611	more sensitive	T033	C0243095
27940904	621	633	interactions	T033	C0037420
27940904	645	658	grandchildren	T099	C0337548
27940904	674	683	parenting	T054	C0085092
27940904	684	691	beliefs	T078	C0004951
27940904	701	710	sensitive	T169	C0332324
27940904	711	720	parenting	T054	C0085092
27940904	721	730	predicted	T078	C0681842
27940904	731	736	lower	T052	C2003888
27940904	737	745	observed	T169	C1441672
27940904	746	757	sensitivity	T041	C0312418
27940904	761	773	grandmothers	T099	C0337474
27940904	784	796	grandmothers	T099	C0337474
27940904	809	845	individualistic cultural orientation	T169	C0220814
27940904	851	865	more intrusive	T033	C0243095
27940904	879	892	grandchildren	T099	C0337548
27940904	898	905	results	T033	C0243095
27940904	935	939	time	T079	C0040223
27940904	944	953	emotional	T033	C0849912
27940904	967	977	predictors	T078	C2698872
27940904	981	990	sensitive	T169	C0332324
27940904	991	1000	parenting	T054	C0085092
27940904	1007	1019	grandmothers	T099	C0337474

27322135|t|Structure of Carbon Nanotube Porins in Lipid Bilayers: An in Situ Small-Angle X-ray Scattering (SAXS) Study
27322135|a|Carbon nanotube porins (CNTPs), small segments of carbon nanotubes capable of forming defined pores in lipid membranes, are important future components for bionanoelectronic devices as they could provide a robust analog of biological membrane channels. In order to control the incorporation of these CNT channels into lipid bilayers, it is important to understand the structure of the CNTPs before and after insertion into the lipid bilayer as well as the impact of such insertion on the bilayer structure. Here we employed a noninvasive in situ probe, small-angle X-ray scattering, to study the integration of CNT porins into dioleoylphosphatidylcholine bilayers. Our results show that CNTPs in solution are stabilized by a monolayer of lipid molecules wrapped around their outer surface. We also demonstrate that insertion of CNTPs into the lipid bilayer results in decreased bilayer thickness with the magnitude of this effect increasing with the concentration of CNTPs.
27322135	0	9	Structure	T082	C0678594
27322135	13	28	Carbon Nanotube	T104	C1138408
27322135	29	35	Porins	T116,T129	C0071728
27322135	39	53	Lipid Bilayers	T026	C0023768
27322135	58	65	in Situ	T082	C0444498
27322135	66	94	Small-Angle X-ray Scattering	T059	C1537058
27322135	96	100	SAXS	T059	C1537058
27322135	102	107	Study	T062	C2603343
27322135	108	123	Carbon nanotube	T104	C1138408
27322135	124	130	porins	T116,T129	C0071728
27322135	132	138	CNTPs)	T116,T129	C0071728
27322135	158	174	carbon nanotubes	T104	C1138408
27322135	202	207	pores	T026	C0028587
27322135	211	226	lipid membranes	T026	C0023768
27322135	249	259	components	T073	C0449432
27322135	264	289	bionanoelectronic devices	T074	C0025080
27322135	314	320	robust	T080	C2986815
27322135	321	327	analog	T104	C0243071
27322135	331	350	biological membrane	T026	C0682529
27322135	351	359	channels	T116,T123	C0022009
27322135	373	380	control	T169	C2587213
27322135	385	398	incorporation	T169	C0243126
27322135	408	411	CNT	T104	C1138408
27322135	412	420	channels	T116,T123	C0022009
27322135	426	440	lipid bilayers	T026	C0023768
27322135	476	485	structure	T082	C0678594
27322135	493	498	CNTPs	T116,T129	C0071728
27322135	516	525	insertion	T169	C1883719
27322135	535	548	lipid bilayer	T026	C0023768
27322135	564	570	impact	T080	C4049986
27322135	579	588	insertion	T169	C1883719
27322135	596	603	bilayer	T026	C0023768
27322135	604	613	structure	T082	C0678594
27322135	634	645	noninvasive	T185	C2986496
27322135	646	653	in situ	T082	C0444498
27322135	654	659	probe	T074	C0182400
27322135	661	689	small-angle X-ray scattering	T059	C1537058
27322135	694	699	study	T062	C2603343
27322135	704	715	integration	T169	C0243126
27322135	719	722	CNT	T104	C1138408
27322135	723	729	porins	T116,T129	C0071728
27322135	735	771	dioleoylphosphatidylcholine bilayers	T109	C0058325
27322135	777	784	results	T033	C0683954
27322135	795	800	CNTPs	T116,T129	C0071728
27322135	804	812	solution	T167	C0037633
27322135	817	827	stabilized	T033	C0184512
27322135	833	842	monolayer	T026	C2612536
27322135	846	861	lipid molecules	T109,T123	C1180309
27322135	889	896	surface	T082	C0205148
27322135	923	932	insertion	T169	C1883719
27322135	936	941	CNTPs	T116,T129	C0071728
27322135	951	964	lipid bilayer	T026	C0023768
27322135	965	972	results	T169	C1274040
27322135	976	985	decreased	T081	C0205216
27322135	986	993	bilayer	T026	C0023768
27322135	994	1003	thickness	T080	C1280412
27322135	1013	1022	magnitude	T081	C1704240
27322135	1031	1037	effect	T080	C1280500
27322135	1038	1048	increasing	T169	C0442808
27322135	1058	1071	concentration	T081	C1446561
27322135	1075	1080	CNTPs	T116,T129	C0071728

27723907|t|Ultrasonography for acute appendicitis - the way it looks today
27723907|a|Despite sophisticated physical examination and laboratory support, diagnosis of acute appendicitis remained challenging in clinical practice with a negative appendectomy rate of 15 - 30 %. As a remarkable clue and as early as 1986, ultrasonography (US) has been proven a reliable diagnostic method that is also explicitly helpful in difficult cases with atypical presentation and enables to rule out many differential diagnoses .Recent publications emphasized the role of multidetector computed tomography (CT) resulting in a significant reduction of false negative findings at operation. Extensive as well as uncritical application of this method even in children inevitably causes substantial radiation exposure, a sequel to either pure ignorance or unqualified/ inadequate performance of US in this particular situation, which in turn can be considered sequel to either egocentric or economic preponderance .Recent data shed new light on the role of US (and CT) in acute appendicitis. Therefore, 1 generation after US with graded compression was etched in stone as the method of choice for diagnosing acute appendicitis (Puylaert), a visual arousal fostering its role and performance in clinical medicine appears justified.
27723907	0	15	Ultrasonography	T060	C0041618
27723907	20	38	acute appendicitis	T047	C0003615
27723907	86	106	physical examination	T058	C0031809
27723907	111	129	laboratory support	T059	C0022885
27723907	131	140	diagnosis	T033	C0011900
27723907	144	162	acute appendicitis	T047	C0003615
27723907	187	204	clinical practice	T057	C0205897
27723907	212	233	negative appendectomy	T061	C0003611
27723907	234	238	rate	T081	C1521828
27723907	296	311	ultrasonography	T060	C0041618
27723907	313	315	US	T060	C0041618
27723907	335	343	reliable	T170	C3858758
27723907	344	361	diagnostic method	T060	C0086143
27723907	418	426	atypical	T080	C0205182
27723907	427	439	presentation	T078	C0449450
27723907	455	463	rule out	T169	C0332196
27723907	469	491	differential diagnoses	T060	C0011906
27723907	500	512	publications	T073,T170	C0034036
27723907	536	569	multidetector computed tomography	T060	C3179130
27723907	571	573	CT	T060	C3179130
27723907	615	638	false negative findings	T034	C0205558
27723907	642	651	operation	T061	C0543467
27723907	653	662	Extensive	T080	C0205231
27723907	674	696	uncritical application	T061	C0441485
27723907	720	728	children	T100	C0008059
27723907	759	777	radiation exposure	T037	C0418228
27723907	829	839	inadequate	T080	C0205412
27723907	840	851	performance	T052	C1882330
27723907	855	857	US	T060	C0041618
27723907	937	947	egocentric	T033	C0564559
27723907	951	959	economic	T169	C0013557
27723907	960	973	preponderance	T081	C0220900
27723907	1017	1019	US	T060	C0041618
27723907	1025	1027	CT	T060	C3179130
27723907	1032	1050	acute appendicitis	T047	C0003615
27723907	1082	1108	US with graded compression	T060	C0041618
27723907	1157	1167	diagnosing	T033	C0011900
27723907	1168	1186	acute appendicitis	T047	C0003615
27723907	1201	1207	visual	T169	C0234621
27723907	1208	1215	arousal	T041	C0003808
27723907	1216	1225	fostering	T056	C0242298
27723907	1254	1271	clinical medicine	T091	C0008964

27979025|t|Atopy patch test in children with atopic dermatitis
27979025|a|Atopic dermatitis is frequently associated with food and/or aeroallergen allergy. To evaluate atopy patch tests (APTs) and skin prick tests (SPTs) in children with atopic dermatitis, using allergen extracts from locally lyophilized foods (cow's milk, egg white, egg yolk, wheat, soy, and shrimp), Dermatophagoides pteronyssinus, Dermatophagoides farinae, and American cockroach. This study was a prospective, self-controlled study in children with atopic dermatitis. APTs, SPTs, and oral food challenge tests were performed in the cases with written informed consent. Fifty-six children with atopic dermatitis were enrolled. According to the Severity Scoring of Atopic Dermatitis Index, moderate atopic dermatitis was the most common severity (49.1%) followed by mild (20%) and severe atopic dermatitis (13.2%). APT results were positive for food allergens in 49% of participants; SPT results were positive in 54.7%. The sensitivity, specificity, positive predictive value, and negative predictive value of APTs for foods were 40%, 90.2%, 65.2%, and 76.6%, respectively. For SPTs, those values were 40%, 93.9%, 75%, and 77.3%, respectively. APT results for D farinae, D pteronyssinus, and American cockroach were positive in 33.9%, 35.8%, and 21.8% of participants, respectively. SPT results for these allergens were positive in 28.3%, 24.5%, and 9.4% of participants, respectively. No serious complications occurred. APTs with locally prepared lyophilized allergen extracts were safe and had high specificity, median positive predictive value, and low sensitivity for evaluation of suspected food allergy in children with atopic dermatitis. clinicaltrials.gov Identifier: NCT01164293.
27979025	0	16	Atopy patch test	T060	C0030646
27979025	20	28	children	T100	C0008059
27979025	34	51	atopic dermatitis	T047	C0011615
27979025	52	69	Atopic dermatitis	T047	C0011615
27979025	73	83	frequently	T079	C0332183
27979025	84	99	associated with	T080	C0332281
27979025	100	104	food	T168	C0016452
27979025	100	104	food	T046	C0016470
27979025	112	124	aeroallergen	T129	C0001697
27979025	125	132	allergy	T046	C1527304
27979025	137	145	evaluate	T058	C0220825
27979025	146	163	atopy patch tests	T060	C0030646
27979025	165	169	APTs	T060	C0030646
27979025	175	191	skin prick tests	T060	C0430561
27979025	193	197	SPTs	T060	C0430561
27979025	202	210	children	T100	C0008059
27979025	216	233	atopic dermatitis	T047	C0011615
27979025	241	258	allergen extracts	T121,T130	C0440016
27979025	264	271	locally	T082	C1517927
27979025	272	283	lyophilized	T059	C0016698
27979025	284	289	foods	T168	C0016452
27979025	291	301	cow's milk	T168	C0349374
27979025	303	312	egg white	T168	C0013704
27979025	314	322	egg yolk	T168	C0013707
27979025	324	329	wheat	T168	C0043137
27979025	331	334	soy	T168	C0037733
27979025	340	346	shrimp	T168	C0457931
27979025	349	379	Dermatophagoides pteronyssinus	T204	C1122992
27979025	381	405	Dermatophagoides farinae	T204	C0323677
27979025	411	429	American cockroach	T204	C0242223
27979025	436	441	study	T062	C2603343
27979025	448	459	prospective	T062	C0033522
27979025	461	476	self-controlled	T033	C1287165
27979025	477	482	study	T062	C2603343
27979025	486	494	children	T100	C0008059
27979025	500	517	atopic dermatitis	T047	C0011615
27979025	519	523	APTs	T060	C0030646
27979025	525	529	SPTs	T060	C0430561
27979025	535	560	oral food challenge tests	T059	C1315011
27979025	566	575	performed	T169	C0884358
27979025	594	618	written informed consent	T058	C0811741
27979025	630	638	children	T100	C0008059
27979025	644	661	atopic dermatitis	T047	C0011615
27979025	694	710	Severity Scoring	T081	C0457451
27979025	714	731	Atopic Dermatitis	T047	C0011615
27979025	739	747	moderate	T080	C0205081
27979025	748	765	atopic dermatitis	T047	C0011615
27979025	779	785	common	T081	C0205214
27979025	786	794	severity	T080	C0439793
27979025	815	819	mild	T080	C2945599
27979025	830	836	severe	T080	C0205082
27979025	837	854	atopic dermatitis	T047	C0011615
27979025	864	867	APT	T060	C0030646
27979025	868	875	results	T169	C1274040
27979025	881	889	positive	T033	C1446409
27979025	894	908	food allergens	T129	C1320239
27979025	919	931	participants	T098	C0679646
27979025	933	936	SPT	T060	C0430561
27979025	937	944	results	T169	C1274040
27979025	950	958	positive	T033	C1446409
27979025	973	984	sensitivity	T081	C0036667
27979025	986	997	specificity	T081	C0037791
27979025	999	1024	positive predictive value	T081	C1514243
27979025	1030	1055	negative predictive value	T081	C1513918
27979025	1059	1063	APTs	T060	C0030646
27979025	1068	1073	foods	T168	C0016452
27979025	1127	1131	SPTs	T060	C0430561
27979025	1193	1196	APT	T060	C0030646
27979025	1197	1204	results	T169	C1274040
27979025	1209	1218	D farinae	T204	C0323677
27979025	1220	1235	D pteronyssinus	T204	C1122992
27979025	1241	1259	American cockroach	T204	C0242223
27979025	1265	1273	positive	T033	C1446409
27979025	1304	1316	participants	T098	C0679646
27979025	1332	1335	SPT	T060	C0430561
27979025	1336	1343	results	T169	C1274040
27979025	1354	1363	allergens	T129	C0002092
27979025	1369	1377	positive	T033	C1446409
27979025	1407	1419	participants	T098	C0679646
27979025	1446	1459	complications	T046	C0009566
27979025	1470	1474	APTs	T060	C0030646
27979025	1480	1487	locally	T082	C1517927
27979025	1497	1508	lyophilized	T059	C0016698
27979025	1509	1526	allergen extracts	T121,T130	C0440016
27979025	1545	1549	high	T080	C0205250
27979025	1550	1561	specificity	T081	C0037791
27979025	1563	1569	median	T081	C2348144
27979025	1570	1595	positive predictive value	T081	C1514243
27979025	1605	1616	sensitivity	T081	C0036667
27979025	1621	1631	evaluation	T058	C0220825
27979025	1645	1657	food allergy	T046	C0016470
27979025	1661	1669	children	T100	C0008059
27979025	1675	1692	atopic dermatitis	T047	C0011615
27979025	1694	1712	clinicaltrials.gov	T170	C4086204

27759877|t|Pharmacological Venous Thromboembolism Prophylaxis in Meningioma Patients: Should It Be Earlier Than Clinical Practice?
27759877|a|We read the report by Çeltikçi et al in the Turkish Neurosurgery with great interest. In this single-center retrospective study, they analysed 449 intracranial meningioma patients underwent open surgery. They stated that venous thromboembolism (VTE) had been seen in 21 (4.6%) of their patients. This is an important issue because VTE, including deep vein thrombosis (DVT) and pulmonary embolism (PE), is the most common overall complication in meningioma surgery and is fatal in up to one third of patients (2). We suppose that prophylaxis of VTE is most effective when mechanical and pharmacological prophylaxis are combined. We consider that there key some practical questions to be answered for a proper clinical extrapolation.
27759877	0	50	Pharmacological Venous Thromboembolism Prophylaxis	T061	C0199242
27759877	54	64	Meningioma	T191	C0025286
27759877	65	73	Patients	T101	C0030705
27759877	101	118	Clinical Practice	T061	C0695275
27759877	132	138	report	T170	C2936319
27759877	164	184	Turkish Neurosurgery	T073,T093	C1552762
27759877	228	247	retrospective study	T062	C0035363
27759877	267	290	intracranial meningioma	T191	C0349604
27759877	291	299	patients	T101	C0030705
27759877	310	322	open surgery	T061	C4283938
27759877	341	363	venous thromboembolism	T047	C1861172
27759877	365	368	VTE	T047	C1861172
27759877	406	414	patients	T101	C0030705
27759877	451	454	VTE	T047	C1861172
27759877	466	486	deep vein thrombosis	T047	C0149871
27759877	488	491	DVT	T047	C0149871
27759877	497	515	pulmonary embolism	T047	C0034065
27759877	517	519	PE	T047	C0034065
27759877	549	561	complication	T046	C0009566
27759877	565	583	meningioma surgery	T061	C1096493
27759877	619	627	patients	T101	C0030705
27759877	649	660	prophylaxis	T061	C0199176
27759877	664	667	VTE	T047	C1861172
27759877	706	733	pharmacological prophylaxis	T061	C0420172
27759877	828	850	clinical extrapolation	T169	C0205245

27665550|t|Unconventional Protein Secretion in Plants
27665550|a|Unconventional protein secretion (UPS) describes secretion pathways that bypass one or several of the canonical secretion pit-stops on the way to the plasma membrane, and/or involve the secretion of leaderless proteins. So far, alternatives to conventional secretion were primarily observed and studied in yeast and animal cells. The sessile lifestyle of plants brings with it unique restraints on how they adapt to adverse conditions and environmental challenges. Recently, attention towards unconventional secretion pathways in plant cells has substantially increased, with the large number of leaderless proteins identified through proteomic studies. While UPS pathways in plants are certainly not yet exhaustively researched, an emerging notion is that induction of UPS pathways is correlated with pathogenesis and stress responses. Given the multitude UPS events observed, comprehensively organizing the routes proteins take to the apoplast in defined UPS categories is challenging. With the establishment of a larger collection of studied plant proteins taking these UPS pathways, a clearer picture of endomembrane trafficking as a whole will emerge. There are several novel enabling technologies, such as vesicle proteomics and chemical genomics, with great potential for dissecting secretion pathways, providing information about the cargo that travels along them and the conditions that induce them.
27665550	0	14	Unconventional	T080	C2700116
27665550	15	32	Protein Secretion	T043	C1159339
27665550	36	42	Plants	T002	C0032098
27665550	43	57	Unconventional	T080	C2700116
27665550	58	75	protein secretion	T043	C1159339
27665550	77	80	UPS	T043	C1159339
27665550	82	91	describes	T078	C1552738
27665550	92	110	secretion pathways	T043	C1159342
27665550	130	137	several	T081	C0443302
27665550	145	154	canonical	T081	C0870245
27665550	155	164	secretion	T038	C0036536
27665550	193	208	plasma membrane	T026	C0007603
27665550	217	224	involve	T169	C1314939
27665550	229	238	secretion	T038	C0036536
27665550	253	261	proteins	T116,T123	C0033684
27665550	271	283	alternatives	T077	C1523987
27665550	287	299	conventional	T080	C3538928
27665550	300	309	secretion	T038	C0036536
27665550	315	324	primarily	T080	C0205225
27665550	325	333	observed	T169	C1441672
27665550	338	345	studied	T062	C0008972
27665550	349	354	yeast	T004	C0043393
27665550	359	371	animal cells	T025	C0007634
27665550	377	384	sessile	T080	C0205348
27665550	398	404	plants	T002	C0032098
27665550	420	426	unique	T080	C1710548
27665550	450	477	adapt to adverse conditions	T040	C0001400
27665550	482	506	environmental challenges	T082	C0557737
27665550	518	527	attention	T041	C0004268
27665550	536	550	unconventional	T080	C2700116
27665550	551	569	secretion pathways	T043	C1159342
27665550	573	584	plant cells	T025	C3178867
27665550	650	658	proteins	T116,T123	C0033684
27665550	659	669	identified	T080	C0205396
27665550	678	695	proteomic studies	T091	C0872252
27665550	703	706	UPS	T043	C1159339
27665550	707	715	pathways	T077	C1705987
27665550	719	725	plants	T002	C0032098
27665550	800	809	induction	T169	C0205263
27665550	813	816	UPS	T043	C1159339
27665550	817	825	pathways	T077	C1705987
27665550	829	839	correlated	T080	C1707520
27665550	845	857	pathogenesis	T046	C0699748
27665550	862	878	stress responses	T039	C2350025
27665550	900	903	UPS	T043	C1159339
27665550	921	936	comprehensively	T080	C1880156
27665550	937	947	organizing	T169	C1300196
27665550	959	967	proteins	T116,T123	C0033684
27665550	980	988	apoplast	T026	C1325756
27665550	1000	1003	UPS	T043	C1159339
27665550	1040	1053	establishment	T080	C0443211
27665550	1066	1076	collection	T169	C1516698
27665550	1088	1102	plant proteins	T116	C0032089
27665550	1116	1119	UPS	T043	C1159339
27665550	1120	1128	pathways	T077	C1705987
27665550	1151	1163	endomembrane	T026	C1167315
27665550	1164	1175	trafficking	T043	C0599896
27665550	1210	1217	several	T081	C0443302
27665550	1218	1223	novel	T080	C0205314
27665550	1224	1232	enabling	T041	C1171285
27665550	1233	1245	technologies	T090	C0039421
27665550	1255	1262	vesicle	T026	C1622418
27665550	1263	1273	proteomics	T091	C0872252
27665550	1278	1286	chemical	T103	C0220806
27665550	1287	1295	genomics	T091	C0887950
27665550	1308	1317	potential	T080	C3245505
27665550	1322	1332	dissecting	T169	C0205239
27665550	1333	1351	secretion pathways	T043	C1159342
27665550	1353	1362	providing	T052	C1999230
27665550	1363	1374	information	T078	C1533716
27665550	1439	1445	induce	T169	C0205263

27602898|t|Early goal-directed treatment versus standard care in management of early septic shock: Meta-analysis of randomized trials
27602898|a|Since the incorporation of the early hemodynamic resuscitation in septic shock according to the early goal-directed therapy (EGDT) protocol among the 6- hour resuscitation bundle of the Surviving Sepsis Campaign guidelines, a great debate has been raised about the issue. The present meta-analysis aims to determine whether the resuscitative phase really takes advantages by being performed with EGDT. A systematic review with meta-analysis of randomized controlled trials (RCTs) of EGDT versus usual care in patients with early septic shock was performed. Four high- quality RCTs have been included with 4,464 patients (1990 in EGDT and 2013 in usual care arm). ICU admission and cardiovascular support necessity increased in the EGDT group (OR = 2.00, 95% CI 1.55-2.57 and OR = 1.33, 95% CI 1.08-1.64, respectively). EGDT has no significant effect on mortality (90 days, 60 days, 28 days, and mortality by the time of hospital discharge). EGDT has no significant effect in reducing the length of hospital stay, the necessity of respiratory and renal function support, and the duration of respiratory and cardiocirculatory support. EGDT seems to increase the resource demand in terms of ICU admissions and cardiocirculatory support necessity without reducing mortality, renal and respiratory organ support necessity, respiratory and cardiocirculatory support duration, and length of hospital stay. Systematic review, level I.
27602898	0	29	Early goal-directed treatment	T061	C1271494
27602898	37	50	standard care	T061	C2936643
27602898	54	64	management	T058	C1254363
27602898	68	73	early	T079	C1279919
27602898	74	86	septic shock	T046	C0036983
27602898	88	101	Meta-analysis	T062	C0920317
27602898	105	122	randomized trials	T062,T170	C0206034
27602898	133	146	incorporation	T169	C0243126
27602898	154	159	early	T079	C1279919
27602898	160	171	hemodynamic	T042	C0019010
27602898	172	185	resuscitation	T061	C0035273
27602898	189	201	septic shock	T046	C0036983
27602898	219	246	early goal-directed therapy	T061	C1271494
27602898	248	252	EGDT	T061	C1271494
27602898	254	262	protocol	T061	C0040808
27602898	276	280	hour	T079	C0439227
27602898	281	294	resuscitation	T061	C0035273
27602898	309	345	Surviving Sepsis Campaign guidelines	T170	C0282574
27602898	407	420	meta-analysis	T062	C0920317
27602898	451	464	resuscitative	T061	C0035273
27602898	465	470	phase	T079	C0205390
27602898	519	523	EGDT	T061	C1271494
27602898	550	563	meta-analysis	T062	C0920317
27602898	567	595	randomized controlled trials	T062	C0206035
27602898	597	601	RCTs	T062	C0206035
27602898	606	610	EGDT	T061	C1271494
27602898	618	628	usual care	T061	C2936643
27602898	632	640	patients	T101	C0030705
27602898	646	651	early	T079	C1279919
27602898	652	664	septic shock	T046	C0036983
27602898	691	698	quality	T080	C0332306
27602898	699	703	RCTs	T062	C0206035
27602898	734	742	patients	T101	C0030705
27602898	752	756	EGDT	T061	C1271494
27602898	769	783	usual care arm	T061	C2936643
27602898	786	799	ICU admission	T058	C0583239
27602898	804	826	cardiovascular support	T058	C1254363
27602898	837	846	increased	T081	C0205217
27602898	854	858	EGDT	T061	C1271494
27602898	859	864	group	T078	C0441833
27602898	942	946	EGDT	T061	C1271494
27602898	951	972	no significant effect	T080	C1301751
27602898	976	985	mortality	T081	C0026565
27602898	990	994	days	T079	C0439228
27602898	999	1003	days	T079	C0439228
27602898	1008	1012	days	T079	C0439228
27602898	1018	1027	mortality	T081	C0026565
27602898	1035	1039	time	T079	C0040223
27602898	1043	1061	hospital discharge	T058	C0586003
27602898	1064	1068	EGDT	T061	C1271494
27602898	1073	1094	no significant effect	T080	C1301751
27602898	1098	1106	reducing	T080	C0392756
27602898	1111	1134	length of hospital stay	T079	C0023303
27602898	1140	1149	necessity	UnknownType	C0814498
27602898	1153	1164	respiratory	T058	C4035997
27602898	1169	1191	renal function support	T058	C1254363
27602898	1201	1209	duration	T079	C0449238
27602898	1213	1224	respiratory	T058	C4035997
27602898	1229	1254	cardiocirculatory support	T058	C1254363
27602898	1256	1260	EGDT	T061	C1271494
27602898	1270	1278	increase	T169	C0442805
27602898	1283	1291	resource	T078	C0035201
27602898	1292	1298	demand	T078	C0699784
27602898	1311	1325	ICU admissions	T058	C0583239
27602898	1330	1355	cardiocirculatory support	T058	C1254363
27602898	1374	1392	reducing mortality	T081	C0282251
27602898	1394	1399	renal	T023	C0022646
27602898	1404	1429	respiratory organ support	T058	C1254363
27602898	1441	1452	respiratory	T058	C4035997
27602898	1457	1482	cardiocirculatory support	T058	C1254363
27602898	1483	1491	duration	T079	C0449238
27602898	1497	1520	length of hospital stay	T079	C0023303

27623945|t|Hint1 suppresses migration and invasion of hepatocellular carcinoma cells in vitro by modulating girdin activity
27623945|a|Histidine triad nucleotide-binding protein 1 (Hint1) is a haploinsufficient tumor suppressor gene. Its role in cancer cell migration has not been previously speculated. In the current study, we examined the expression of Hint1 in metastatic and non-metastatic lymph nodes of hepatocellular carcinoma (HCC) patients and further elucidated the effect of Hint1 expression on girdin expression and phosphorylation of AKT and ERK1 / 2 and on the migration of HCC cells in vitro. Expression of Hint1 and girdin in primary HCC tissues and metastatic and non-metastatic lymph nodes was determined by RT-PCR assays. HepG2 cells were transfected with plasmid vectors overexpressing Hint1 or small interfering RNA (siRNA) targeting Hint1, girdin, Hint1 plus girdin, or the scrambled RNA. Migration and invasion of HCC cells were examined by wound and Transwell assays. Protein expression was detected by immunofluorescence and immunoblotting assays. RT-PCR assays revealed that the messenger RNA (mRNA) transcript levels of Hint1 were markedly lower than those of primary HCC tissues and non-metastatic lymph nodes (P < 0.01). By contrast, the mRNA transcript levels of girdin were significantly higher than non-metastatic lymph nodes (P < 0.05). Furthermore, siRNA knockdown of HINT1 resulted in a significant increase in the mRNA transcript levels of girdin in HepG2 cells (P < 0.05). Wound assays and Transwell assays showed that Hint1 knockdown by siRNA significantly enhanced the migration and invasion of HepG2 cells compared to HepG2 cells transfected with scrambled siRNA. Hint1 knockdown also led to significantly increased phosphorylation of girdin and AKT in HepG2 cells (P < 0.05), which, however, was effectively aborted by girdin knockdown by siRNA (P < 0.05). Hint1 is downregulated in metastatic lymph nodes and is implicated in migration and invasion of HCC cells in vitro by modulating girdin and AKT expression and phosphorylation. The Hint1 - girdin - AKT signaling axis should be further dissected for its role in HCC migration and invasion and may be therapeutically targeted to suppress tumor growth and metastasis.
27623945	0	5	Hint1	T028	C1415545
27623945	6	16	suppresses	T169	C1260953
27623945	17	26	migration	T191	C0027627
27623945	31	39	invasion	T046	C0027626
27623945	43	67	hepatocellular carcinoma	T191	C2239176
27623945	68	73	cells	T025	C0007634
27623945	74	82	in vitro	T080	C1533691
27623945	86	96	modulating	T082	C0443264
27623945	97	103	girdin	T116,T123	C1571428
27623945	104	112	activity	T169	C0205177
27623945	113	157	Histidine triad nucleotide-binding protein 1	T028	C1415545
27623945	159	164	Hint1	T028	C1415545
27623945	171	188	haploinsufficient	T049	C2936267
27623945	189	210	tumor suppressor gene	T028	C0079427
27623945	224	245	cancer cell migration	T191	C0027627
27623945	297	302	study	T062	C2603343
27623945	307	315	examined	T033	C0332128
27623945	320	330	expression	T045	C0017262
27623945	334	339	Hint1	T028	C1415545
27623945	343	353	metastatic	T191	C0027627
27623945	358	372	non-metastatic	T191	C1334991
27623945	373	384	lymph nodes	T023	C0024204
27623945	388	412	hepatocellular carcinoma	T191	C2239176
27623945	414	417	HCC	T191	C2239176
27623945	419	427	patients	T101	C0030705
27623945	465	470	Hint1	T028	C1415545
27623945	471	481	expression	T045	C0017262
27623945	485	491	girdin	T116,T123	C1571428
27623945	492	502	expression	T045	C1171362
27623945	507	522	phosphorylation	T044	C0031715
27623945	526	529	AKT	T116,T126	C0164786
27623945	534	538	ERK1	T116,T126	C4082284
27623945	541	542	2	T116,T126	C2713871
27623945	554	563	migration	T191	C0027627
27623945	567	570	HCC	T191	C2239176
27623945	571	576	cells	T025	C0007634
27623945	577	585	in vitro	T080	C1533691
27623945	587	597	Expression	T045	C0017262
27623945	601	606	Hint1	T028	C1415545
27623945	611	617	girdin	T028	C1428495
27623945	629	632	HCC	T191	C2239176
27623945	633	640	tissues	T024	C0040300
27623945	645	655	metastatic	T191	C0027627
27623945	660	674	non-metastatic	T191	C1334991
27623945	675	686	lymph nodes	T023	C0024204
27623945	705	718	RT-PCR assays	T059	C2732732
27623945	720	731	HepG2 cells	T025	C2717940
27623945	737	748	transfected	T063	C0040669
27623945	754	769	plasmid vectors	T114	C1514152
27623945	770	784	overexpressing	T045	C1514559
27623945	785	790	Hint1	T116,T123	C1505103
27623945	794	815	small interfering RNA	T114,T123	C1099354
27623945	817	822	siRNA	T114,T123	C1099354
27623945	824	833	targeting	T044	C1159372
27623945	834	839	Hint1	T116,T123	C1505103
27623945	841	847	girdin	T116,T123	C1571428
27623945	849	854	Hint1	T116,T123	C1505103
27623945	860	866	girdin	T116,T123	C1571428
27623945	885	888	RNA	T114	C0035668
27623945	890	899	Migration	T191	C0027627
27623945	904	912	invasion	T046	C0027626
27623945	916	919	HCC	T191	C2239176
27623945	920	925	cells	T025	C0007634
27623945	931	939	examined	T033	C0332128
27623945	943	969	wound and Transwell assays	T059	C1513300
27623945	971	989	Protein expression	T045	C1171362
27623945	1006	1024	immunofluorescence	T059	C0079603
27623945	1029	1050	immunoblotting assays	T059	C0020985
27623945	1052	1065	RT-PCR assays	T059	C2732732
27623945	1084	1097	messenger RNA	T114,T123	C0035696
27623945	1099	1103	mRNA	T114,T123	C0035696
27623945	1105	1115	transcript	T114	C1519595
27623945	1126	1131	Hint1	T028	C1415545
27623945	1174	1177	HCC	T191	C2239176
27623945	1178	1185	tissues	T024	C0040300
27623945	1190	1204	non-metastatic	T191	C1334991
27623945	1205	1216	lymph nodes	T023	C0024204
27623945	1246	1250	mRNA	T114,T123	C0035696
27623945	1251	1261	transcript	T114	C1519595
27623945	1272	1278	girdin	T116,T123	C1571428
27623945	1284	1304	significantly higher	T081	C4055637
27623945	1310	1324	non-metastatic	T191	C1334991
27623945	1325	1336	lymph nodes	T023	C0024204
27623945	1362	1367	siRNA	T114,T123	C1099354
27623945	1368	1377	knockdown	T063	C2350567
27623945	1381	1386	HINT1	T028	C1415545
27623945	1401	1412	significant	T078	C0750502
27623945	1429	1433	mRNA	T114,T123	C0035696
27623945	1434	1444	transcript	T114	C1519595
27623945	1455	1461	girdin	T116,T123	C1571428
27623945	1465	1476	HepG2 cells	T025	C2717940
27623945	1489	1522	Wound assays and Transwell assays	T059	C1513300
27623945	1535	1540	Hint1	T028	C1415545
27623945	1541	1550	knockdown	T063	C2350567
27623945	1554	1559	siRNA	T114,T123	C1099354
27623945	1560	1573	significantly	T078	C0750502
27623945	1574	1582	enhanced	T052	C2349975
27623945	1587	1596	migration	T191	C0027627
27623945	1601	1609	invasion	T046	C0027626
27623945	1613	1624	HepG2 cells	T025	C2717940
27623945	1637	1648	HepG2 cells	T025	C2717940
27623945	1649	1660	transfected	T063	C0040669
27623945	1676	1681	siRNA	T114,T123	C1099354
27623945	1683	1688	Hint1	T028	C1415545
27623945	1689	1698	knockdown	T063	C2350567
27623945	1711	1724	significantly	T078	C0750502
27623945	1735	1750	phosphorylation	T044	C0031715
27623945	1754	1760	girdin	T116,T123	C1571428
27623945	1765	1768	AKT	T116,T126	C0164786
27623945	1772	1783	HepG2 cells	T025	C2717940
27623945	1828	1835	aborted	T169	C1609614
27623945	1839	1845	girdin	T028	C1428495
27623945	1846	1855	knockdown	T063	C2350567
27623945	1859	1864	siRNA	T114,T123	C1099354
27623945	1877	1882	Hint1	T028	C1415545
27623945	1886	1899	downregulated	T044	C0013081
27623945	1903	1913	metastatic	T191	C0027627
27623945	1914	1925	lymph nodes	T023	C0024204
27623945	1947	1956	migration	T191	C0027627
27623945	1961	1969	invasion	T046	C0027626
27623945	1973	1976	HCC	T191	C2239176
27623945	1977	1982	cells	T025	C0007634
27623945	1983	1991	in vitro	T080	C1533691
27623945	1995	2005	modulating	T082	C0443264
27623945	2006	2012	girdin	T116,T123	C1571428
27623945	2017	2020	AKT	T116,T126	C0164786
27623945	2021	2031	expression	T045	C1171362
27623945	2036	2051	phosphorylation	T044	C0031715
27623945	2057	2062	Hint1	T116,T123	C1505103
27623945	2065	2071	girdin	T116,T123	C1571428
27623945	2074	2077	AKT	T116,T126	C0164786
27623945	2078	2087	signaling	T038	C3537152
27623945	2111	2120	dissected	T169	C0205239
27623945	2137	2140	HCC	T191	C2239176
27623945	2141	2150	migration	T191	C0027627
27623945	2155	2163	invasion	T046	C0027626
27623945	2175	2190	therapeutically	T061	C0087111
27623945	2203	2211	suppress	T169	C1260953
27623945	2212	2224	tumor growth	T191	C0598934
27623945	2229	2239	metastasis	T191	C0027627

28266699|t|Rapidly Progressive and Almost Lethal Pneumonia
28266699|a|We herein describe the case of a 65- year -old male patient who presented with Osler's triad, which is the combination of endocarditis, pneumonia, and meningitis. This report is even more unusual since the pathogen isolated was the invasive and virulent strain of Streptococcus pneumoniae serotype 3. The clinical entity described is also called Austrian syndrome. Even though rare in this antibiotic era, the syndrome remains one of high morbidity and mortality. This particular case is of paramount importance for the clinician reader. First, it documents the clinical features associated with invasive pneumococcal disease and the Austrian syndrome. Second, and equally important, it highlights why following the Surviving Sepsis Campaign guidelines saves lives. For this case, the following steps were taken: 1. As a surrogate for perfusion, early and aggressive fluid resuscitation therapy (guided by lactic acid levels) was instituted; 2. also early in the treatment, broad spectrum antibiotics were administered; 3. to guide antibiotic therapy, microbiological cultures were obtained. The patient subsequently improved and was transferred to the internal medicine ward to complete 4 weeks of antibiotic therapy.
28266699	8	19	Progressive	T169	C0205329
28266699	31	47	Lethal Pneumonia	T047	C0032285
28266699	71	75	case	T077	C1706256
28266699	85	89	year	T079	C1510829
28266699	95	99	male	T098	C0025266
28266699	100	107	patient	T101	C0030705
28266699	127	140	Osler's triad	UnknownType	C0747067
28266699	170	182	endocarditis	T047	C0014118
28266699	184	193	pneumonia	T047	C0032285
28266699	199	209	meningitis	T047	C0025289
28266699	254	262	pathogen	T001	C0450254
28266699	263	271	isolated	T169	C0205409
28266699	280	288	invasive	T080	C0205281
28266699	293	308	virulent strain	T001	C1518614
28266699	312	347	Streptococcus pneumoniae serotype 3	T007	C0522401
28266699	353	361	clinical	T080	C0205210
28266699	362	368	entity	T071	C1551338
28266699	394	411	Austrian syndrome	T047	C0039082
28266699	438	448	antibiotic	T195	C0003232
28266699	449	452	era	T079	C1254367
28266699	458	466	syndrome	T047	C0039082
28266699	487	496	morbidity	T081	C0026538
28266699	501	510	mortality	T081	C0205848
28266699	528	532	case	T077	C1706256
28266699	568	584	clinician reader	T097	C0871685
28266699	610	627	clinical features	T201	C0683325
28266699	628	643	associated with	T080	C0332281
28266699	644	673	invasive pneumococcal disease	T047	C1320214
28266699	682	699	Austrian syndrome	T047	C0039082
28266699	764	800	Surviving Sepsis Campaign guidelines	T170	C0162791
28266699	807	812	lives	T078	C0376558
28266699	823	827	case	T077	C1706256
28266699	843	859	steps were taken	T201	C3166374
28266699	869	878	surrogate	T099	C4053457
28266699	883	892	perfusion	T061	C0031001
28266699	894	899	early	T079	C1279919
28266699	904	914	aggressive	T079	C0580822
28266699	915	942	fluid resuscitation therapy	T061	C0150238
28266699	954	972	lactic acid levels	T059	C0202115
28266699	998	1003	early	T079	C1279919
28266699	1011	1020	treatment	T169	C0039798
28266699	1037	1048	antibiotics	T195	C0003232
28266699	1054	1066	administered	T169	C1521801
28266699	1080	1098	antibiotic therapy	T061	C0338237
28266699	1100	1124	microbiological cultures	T059	C0430402
28266699	1144	1151	patient	T101	C0030705
28266699	1182	1193	transferred	T058	C0030704
28266699	1201	1223	internal medicine ward	T073,T093	C1305702
28266699	1238	1243	weeks	T079	C0439230
28266699	1247	1265	antibiotic therapy	T061	C0338237

28220061|t|A Model of Induction of Cerebellar Long-Term Depression Including RKIP Inactivation of Raf and MEK
28220061|a|We report an updated stochastic model of cerebellar Long Term Depression (LTD) with improved realism. Firstly, we verify experimentally that dissociation of Raf kinase inhibitor protein (RKIP) from Mitogen-activated protein kinase kinase (MEK) is required for cerebellar LTD and add this interaction to an earlier published model, along with the known requirement of dissociation of RKIP from Raf kinase. We update Ca(2+) dynamics as a constant-rate influx, which captures experimental input profiles accurately. We improve α-amino-3-hydroxy-5-methyl-4 isoxazolepropionic acid (AMPA) receptor interactions by adding phosphorylation and dephosphorylation of AMPA receptors when bound to glutamate receptor interacting protein (GRIP). The updated model is tuned to reproduce experimental Ca(2+) peak vs. LTD amplitude curves at four different Ca(2+) pulse durations as closely as possible. We find that the updated model is generally more robust with these changes, yet we still observe some sensitivity of LTD induction to copy number of the key signaling molecule Protein kinase C (PKC). We predict natural variability in this number by stochastic diffusion may influence the probabilistic LTD response to Ca(2+) input in Purkinje cell spines and propose this as an extra source of stochasticity that may be important also in other signaling systems.
28220061	2	7	Model	T075	C0026336
28220061	11	20	Induction	T169	C0205263
28220061	24	34	Cerebellar	T023	C0007765
28220061	35	55	Long-Term Depression	T042	C2610415
28220061	56	65	Including	T169	C0332257
28220061	66	70	RKIP	T116,T123	C0300821
28220061	71	83	Inactivation	T169	C0544461
28220061	87	90	Raf	T116,T126	C1449849
28220061	95	98	MEK	T116,T126	C0169101
28220061	102	108	report	T170	C0684224
28220061	112	119	updated	T079	C1519814
28220061	120	136	stochastic model	T062	C0871922
28220061	140	150	cerebellar	T023	C0007765
28220061	151	171	Long Term Depression	T042	C2610415
28220061	173	176	LTD	T042	C2610415
28220061	183	191	improved	T033	C0184511
28220061	192	199	realism	T078	C0237815
28220061	220	234	experimentally	T080	C1517586
28220061	256	284	Raf kinase inhibitor protein	T116,T123	C0300821
28220061	286	290	RKIP	T116,T123	C0300821
28220061	297	336	Mitogen-activated protein kinase kinase	T116,T126	C0169101
28220061	338	341	MEK	T116,T126	C0169101
28220061	359	369	cerebellar	T023	C0007765
28220061	370	373	LTD	T042	C2610415
28220061	387	398	interaction	T169	C1704675
28220061	413	422	published	T057	C0034037
28220061	423	428	model	T075	C0026336
28220061	451	462	requirement	T169	C1514873
28220061	482	486	RKIP	T116,T123	C0300821
28220061	492	502	Raf kinase	T116,T126	C1449849
28220061	507	513	update	T079	C1519814
28220061	514	520	Ca(2+)	T121,T196	C0596235
28220061	521	529	dynamics	T062	C1514544
28220061	535	555	constant-rate influx	T081	C2986767
28220061	572	584	experimental	T080	C1517586
28220061	585	590	input	T077	C1708517
28220061	591	599	profiles	T081	C0237801
28220061	600	610	accurately	T080	C0443131
28220061	615	622	improve	T033	C0184511
28220061	623	675	α-amino-3-hydroxy-5-methyl-4 isoxazolepropionic acid	T109,T121,T130	C0051318
28220061	677	681	AMPA	T109,T121,T130	C0051318
28220061	683	691	receptor	T116,T192	C0597357
28220061	692	704	interactions	T169	C1704675
28220061	715	730	phosphorylation	T044	C0031715
28220061	735	752	dephosphorylation	T044	C1158884
28220061	756	760	AMPA	T109,T121,T130	C0051318
28220061	761	770	receptors	T116,T192	C0597357
28220061	776	781	bound	T044	C1167622
28220061	785	823	glutamate receptor interacting protein	T116,T123	C0033684
28220061	825	829	GRIP	T116,T123	C0033684
28220061	836	843	updated	T079	C1519814
28220061	844	849	model	T075	C0026336
28220061	872	884	experimental	T080	C1517586
28220061	885	891	Ca(2+)	T121,T196	C0596235
28220061	901	904	LTD	T042	C2610415
28220061	905	914	amplitude	T082	C2346753
28220061	930	939	different	T080	C1705242
28220061	940	946	Ca(2+)	T121,T196	C0596235
28220061	947	962	pulse durations	T079	C1254367
28220061	1004	1011	updated	T079	C1519814
28220061	1012	1017	model	T075	C0026336
28220061	1036	1042	robust	T080	C2986815
28220061	1054	1061	changes	T081	C0443172
28220061	1076	1083	observe	T169	C1441672
28220061	1089	1100	sensitivity	T081	C1511883
28220061	1104	1107	LTD	T042	C2610415
28220061	1108	1117	induction	T169	C0205263
28220061	1121	1132	copy number	T081	C1707513
28220061	1144	1162	signaling molecule	T123	C1519315
28220061	1163	1179	Protein kinase C	T116,T126	C1259877
28220061	1181	1184	PKC	T116,T126	C1259877
28220061	1190	1197	predict	T078	C0681842
28220061	1198	1205	natural	T169	C0205296
28220061	1206	1217	variability	T077	C2827666
28220061	1236	1246	stochastic	T081	C0038347
28220061	1247	1256	diffusion	T070	C0012222
28220061	1261	1270	influence	T077	C4054723
28220061	1275	1288	probabilistic	T080	C0205556
28220061	1289	1292	LTD	T042	C2610415
28220061	1293	1301	response	T032	C0871261
28220061	1305	1311	Ca(2+)	T121,T196	C0596235
28220061	1312	1317	input	T077	C1708517
28220061	1321	1334	Purkinje cell	T025	C0034143
28220061	1335	1341	spines	T082	C1254362
28220061	1346	1353	propose	T080	C1553874
28220061	1371	1377	source	T033	C0449416
28220061	1381	1394	stochasticity	T081	C0038347
28220061	1407	1416	important	T080	C3898777
28220061	1431	1448	signaling systems	T044	C1148560

28497407|t|Tobacco use is not associated with groin hernia repair, a population-based study
28497407|a|The pathogenesis of groin hernia is not fully understood and some suggested risk factors are debatable. This population-based study evaluates the association between groin hernia repair and tobacco use. An observational study based on register linkage between the Swedish Hernia Register and the Västerbotten Intervention Program (VIP). All primary groin hernia repairs performed from 2001 to 2013 in the county of Västerbotten, Sweden, were included. VIP provided data on the use of tobacco in 102,857 individuals. Neither smoking nor the use of snus, increased the risk for requiring a groin hernia repair. On the contrary, heavy smoking decreased the risk for men, HR 0.75 (95% CI 0.58-0.96), as did having a BMI over 30 kg/m(2) HR (men) 0.33 (95% CI 0.27-0.40). Tobacco use is not a risk factor for requiring a groin hernia repair, whereas having a low BMI significantly increases the risk.
28497407	0	7	Tobacco	T109,T131	C0040329
28497407	8	11	use	T169	C0457083
28497407	19	34	associated with	T080	C0332281
28497407	35	54	groin hernia repair	T061	C3514453
28497407	58	80	population-based study	T062	C1709599
28497407	85	97	pathogenesis	T046	C0699748
28497407	101	106	groin	T029	C0816951
28497407	107	113	hernia	T190	C0019270
28497407	157	169	risk factors	T033	C0035648
28497407	174	183	debatable	T201	C3830527
28497407	190	212	population-based study	T062	C1709599
28497407	213	222	evaluates	T058	C0220825
28497407	227	238	association	T080	C0439849
28497407	247	266	groin hernia repair	T061	C3514453
28497407	271	278	tobacco	T109,T131	C0040329
28497407	279	282	use	T169	C0457083
28497407	287	306	observational study	T062	C1518527
28497407	345	368	Swedish Hernia Register	T170	C0034975
28497407	377	410	Västerbotten Intervention Program	T058	C3863932
28497407	412	415	VIP	T058	C3863932
28497407	422	429	primary	T080	C0205225
28497407	430	450	groin hernia repairs	T061	C3514453
28497407	451	460	performed	T061	C0450010
28497407	486	508	county of Västerbotten	T083	C0454664
28497407	510	516	Sweden	T083	C0038995
28497407	533	536	VIP	T058	C3863932
28497407	546	550	data	T078	C1511726
28497407	558	564	use of	T169	C1524063
28497407	565	572	tobacco	T109,T131	C0040329
28497407	584	595	individuals	T098	C0237401
28497407	597	604	Neither	T080	C4284892
28497407	605	612	smoking	T055	C0453996
28497407	621	627	use of	T169	C1524063
28497407	628	632	snus	T131	C4288198
28497407	634	643	increased	T081	C0205217
28497407	648	652	risk	T078	C0035647
28497407	669	688	groin hernia repair	T061	C3514453
28497407	707	720	heavy smoking	T033	C3845546
28497407	721	730	decreased	T081	C0205216
28497407	735	739	risk	T078	C0035647
28497407	744	747	men	T098	C0025266
28497407	749	751	HR	T081	C2985465
28497407	762	764	CI	T081	C0009667
28497407	793	796	BMI	T201	C1305855
28497407	813	815	HR	T081	C2985465
28497407	817	820	men	T098	C0025266
28497407	832	834	CI	T081	C0009667
28497407	847	854	Tobacco	T109,T131	C0040329
28497407	855	858	use	T169	C0457083
28497407	868	879	risk factor	T033	C0035648
28497407	896	915	groin hernia repair	T061	C3514453
28497407	934	937	low	T080	C0205251
28497407	938	941	BMI	T201	C1305855
28497407	956	965	increases	T169	C0442805
28497407	970	974	risk	T078	C0035647

27401409|t|Development of a Novel Quantitative Structure-Activity Relationship Model to Accurately Predict Pulmonary Absorption and Replace Routine Use of the Isolated Perfused Respiring Rat Lung Model
27401409|a|We developed and tested a novel Quantitative Structure-Activity Relationship (QSAR) model to better understand the physicochemical drivers of pulmonary absorption, and to facilitate compound design through improved prediction of absorption. The model was tested using a large array of both existing and newly designed compounds. Pulmonary absorption data was generated using the isolated perfused respiring rat lung (IPRLu) model for 82 drug discovery compounds and 17 marketed drugs. This dataset was used to build a novel QSAR model based on calculated physicochemical properties. A further 9 compounds were used to test the model's predictive capability. The QSAR model performed well on the 9 compounds in the " Test set " with a predicted versus observed correlation of R(2) = 0.85, and >65% of compounds correctly categorised. Calculated descriptors associated with permeability and hydrophobicity positively correlated with pulmonary absorption, whereas those associated with charge, ionisation and size negatively correlated. The novel QSAR model described here can replace routine generation of IPRLu model data for ranking and classifying compounds prior to synthesis. It will also provide scientists working in the field of inhaled drug discovery with a deeper understanding of the physicochemical drivers of pulmonary absorption based on a relevant respiratory compound dataset.
27401409	23	67	Quantitative Structure-Activity Relationship	T081	C0887819
27401409	68	73	Model	T170	C3161035
27401409	96	116	Pulmonary Absorption	T042	C3852990
27401409	148	156	Isolated	T169	C0205409
27401409	157	165	Perfused	T169	C1549542
27401409	166	175	Respiring	T039	C0035203
27401409	176	184	Rat Lung	T023	C1882727
27401409	185	190	Model	T170	C3161035
27401409	223	267	Quantitative Structure-Activity Relationship	T081	C0887819
27401409	269	273	QSAR	T081	C0887819
27401409	275	280	model	T170	C3161035
27401409	306	321	physicochemical	T070	C2350461
27401409	333	353	pulmonary absorption	T042	C3852990
27401409	373	388	compound design	T090	C0013171
27401409	406	416	prediction	T078	C0681842
27401409	420	430	absorption	T067	C2347023
27401409	436	441	model	T170	C3161035
27401409	509	518	compounds	T121	C0013227
27401409	520	540	Pulmonary absorption	T042	C3852990
27401409	570	578	isolated	T169	C0205409
27401409	579	587	perfused	T169	C1549542
27401409	588	597	respiring	T039	C0035203
27401409	598	606	rat lung	T023	C1882727
27401409	608	613	IPRLu	T023	C1882727
27401409	615	620	model	T170	C3161035
27401409	628	642	drug discovery	T062	C0920472
27401409	643	652	compounds	T121	C0013227
27401409	660	674	marketed drugs	T121	C1254351
27401409	715	719	QSAR	T081	C0887819
27401409	720	725	model	T170	C3161035
27401409	746	772	physicochemical properties	T070	C2350461
27401409	786	795	compounds	T121	C0013227
27401409	818	825	model's	T170	C3161035
27401409	837	847	capability	T080	C2698977
27401409	853	857	QSAR	T081	C0887819
27401409	858	863	model	T170	C3161035
27401409	888	897	compounds	T121	C0013227
27401409	907	915	Test set	T170	C0150098
27401409	951	962	correlation	T081	C0010100
27401409	991	1000	compounds	T121	C0013227
27401409	1063	1075	permeability	T070	C0031164
27401409	1080	1094	hydrophobicity	T080	C0598629
27401409	1122	1142	pulmonary absorption	T042	C3852990
27401409	1174	1180	charge	T080	C0205556
27401409	1182	1192	ionisation	T067	C0596801
27401409	1197	1201	size	T082	C0456389
27401409	1235	1239	QSAR	T081	C0887819
27401409	1240	1245	model	T170	C3161035
27401409	1295	1300	IPRLu	T023	C1882727
27401409	1301	1306	model	T170	C3161035
27401409	1316	1323	ranking	T170	C0699794
27401409	1328	1339	classifying	T185	C0008902
27401409	1340	1349	compounds	T121	C0013227
27401409	1359	1368	synthesis	T052	C1883254
27401409	1426	1448	inhaled drug discovery	T062	C0920472
27401409	1484	1499	physicochemical	T070	C2350461
27401409	1511	1531	pulmonary absorption	T042	C3852990
27401409	1564	1572	compound	T121	C0013227
27401409	1573	1580	dataset	T170	C0150098

27928650|t|Cytoglobin: a potential marker for adipogenic differentiation in preadipocytes in vitro
27928650|a|Obesity, mainly characterized by the excess fat storage, is a global health problem resulting in serious morbidity and mortality. Identification of molecular mechanisms in adipogenic differentiation pathway might lead to development of new strategies for diagnosis, prevention and therapy of obesity and associated diseases. Discovery of new genes and proteins in the differentiation pathway could help to understand the key specific regulators of the adipogenesis. Cytoglobin (Cygb), identified as a new globin family member protein, is expressed in various tissues. Although its interaction with oxygen and nitric oxide indicates the potential role in antioxidant pathways, the exact role remains unclear. In the current study, expression level of Cygb was determined in proliferating and differentiating 3T3-F442A cells by gene expression and protein expression analysis. Results revealed that Cygb expression up-regulated in differentiated cells in parallel with adipogenic differentiation markers; PPARγ, CEBPα and FABP4 expressions. Besides, Cygb overexpression in preadipocytes contributed to the adipogenic differentiation as verified by detection of higher lipid droplets and increased PPARγ, CEBPα and FABP4 expressions with respect to control cells. These findings will shed light on the unknown roles of Cygb in adipogenesis and obesity.
27928650	0	10	Cytoglobin	T116	C1137148
27928650	24	30	marker	T201	C0005516
27928650	35	61	adipogenic differentiation	T043	C1159884
27928650	65	78	preadipocytes	T025	C0007634
27928650	79	87	in vitro	T080	C1533691
27928650	88	95	Obesity	T047	C0028754
27928650	125	131	excess	T080	C1979886
27928650	132	135	fat	T109,T121	C0015677
27928650	136	143	storage	T169	C1698986
27928650	150	171	global health problem	T078	C0021788
27928650	172	184	resulting in	T169	C0332294
27928650	193	202	morbidity	T081	C0026538
27928650	207	216	mortality	T081	C0205848
27928650	236	256	molecular mechanisms	T169	C0441712
27928650	260	294	adipogenic differentiation pathway	T043	C1516345
27928650	309	320	development	T169	C1527148
27928650	324	327	new	T080	C0205314
27928650	328	338	strategies	T041	C0679199
27928650	343	352	diagnosis	T033	C0011900
27928650	354	364	prevention	T080	C2700409
27928650	369	376	therapy	T169	C0039798
27928650	380	387	obesity	T047	C0028754
27928650	392	411	associated diseases	T047	C0012634
27928650	413	422	Discovery	T052	C1880355
27928650	430	435	genes	T028	C0017337
27928650	440	448	proteins	T116,T123	C0033684
27928650	456	479	differentiation pathway	T043	C1516345
27928650	522	532	regulators	T077	C1704735
27928650	540	552	adipogenesis	T044	C0596843
27928650	554	564	Cytoglobin	T116	C1137148
27928650	566	570	Cygb	T116	C1137148
27928650	593	599	globin	T116,T123	C0017645
27928650	614	621	protein	T116,T123	C0033684
27928650	626	635	expressed	T045	C1171362
27928650	647	654	tissues	T024	C0001527
27928650	669	680	interaction	T169	C1704675
27928650	686	692	oxygen	T121,T123,T196	C0030054
27928650	697	709	nitric oxide	T121,T123,T197	C0028128
27928650	724	738	potential role	T077	C1705810
27928650	742	762	antioxidant pathways	T044	C1704259
27928650	818	834	expression level	T081	C3244092
27928650	838	842	Cygb	T116	C1137148
27928650	861	874	proliferating	T169	C1514485
27928650	879	894	differentiating	T043	C0007589
27928650	895	910	3T3-F442A cells	T025	C0007634
27928650	914	929	gene expression	T045	C0017262
27928650	934	952	protein expression	T045	C1171362
27928650	953	961	analysis	T062	C0936012
27928650	985	989	Cygb	T116	C1137148
27928650	990	1000	expression	T045	C1171362
27928650	1017	1037	differentiated cells	T025	C0007634
27928650	1055	1081	adipogenic differentiation	T043	C1159884
27928650	1082	1089	markers	T201	C0005516
27928650	1091	1096	PPARγ	T116,T192	C0166417
27928650	1098	1103	CEBPα	T116,T123	C0033684
27928650	1108	1113	FABP4	T116,T123	C1312689
27928650	1114	1125	expressions	T045	C1171362
27928650	1136	1140	Cygb	T116	C1137148
27928650	1141	1155	overexpression	T045	C1514559
27928650	1159	1172	preadipocytes	T025	C0007634
27928650	1192	1218	adipogenic differentiation	T043	C1159884
27928650	1234	1243	detection	T061	C1511790
27928650	1254	1268	lipid droplets	T026	C0230704
27928650	1283	1288	PPARγ	T116,T192	C0166417
27928650	1290	1295	CEBPα	T116,T123	C0033684
27928650	1300	1305	FABP4	T116,T123	C1312689
27928650	1306	1317	expressions	T045	C1171362
27928650	1334	1347	control cells	T025	C0007634
27928650	1404	1408	Cygb	T116	C1137148
27928650	1412	1424	adipogenesis	T044	C0596843
27928650	1429	1436	obesity	T047	C0028754

27245524|t|Ehlers-Danlos syndrome
27245524|a|The Ehlers-Danlos syndromes (EDSs) were originally described by Ehlers in Denmark and Danlos in Paris in 1898 and 1908, respectively. They had both published individual case studies in which the common factor was laxity of ligaments leading to joint hypermobility and hyperextensibility of the skin. The choice of the name of this eponymous disease had been made by Dr Parkes Weber, an eminent London physician in the 1930s, who had a penchant for eponymous diseases, having had no less than seven attributed to himself, at least in part. Unfortunately, this was before the age of a computerised literature search, and Parkes Weber had inadvertently overlooked the very first description of EDS which had been made by Tchernabogov, a Russian dermatologist, whose description was published in 1891 and remains one of the best descriptions of EDS in the literature.
27245524	0	22	Ehlers-Danlos syndrome	T047	C0013720
27245524	27	50	Ehlers-Danlos syndromes	T047	C0013720
27245524	52	56	EDSs	T047	C0013720
27245524	74	83	described	T170	C0678257
27245524	87	93	Ehlers	T016	C0086418
27245524	97	104	Denmark	T083	C0011318
27245524	109	115	Danlos	T016	C0086418
27245524	119	124	Paris	T083	C0030561
27245524	171	180	published	T057	C0034037
27245524	192	204	case studies	T170	C0085973
27245524	236	255	laxity of ligaments	T046	C0158359
27245524	267	286	joint hypermobility	T184	C0086437
27245524	291	321	hyperextensibility of the skin	T033	C0241074
27245524	341	345	name	T170	C0027365
27245524	354	371	eponymous disease	T170	C0282574
27245524	389	404	Dr Parkes Weber	T016	C0086418
27245524	417	423	London	T083	C0023973
27245524	424	433	physician	T097	C0031831
27245524	458	466	penchant	T055	C3826173
27245524	471	489	eponymous diseases	T170	C0282574
27245524	606	629	computerised literature	T170	C0023866
27245524	630	636	search	T052	C1706202
27245524	642	654	Parkes Weber	T016	C0086418
27245524	699	710	description	T170	C0678257
27245524	714	717	EDS	T047	C0013720
27245524	741	753	Tchernabogov	T016	C0086418
27245524	757	764	Russian	T098	C0337816
27245524	765	778	dermatologist	T097	C0259831
27245524	786	797	description	T170	C0678257
27245524	802	811	published	T057	C0034037
27245524	848	860	descriptions	T170	C0678257
27245524	864	867	EDS	T047	C0013720
27245524	875	885	literature	T170	C0023866

27470706|t|Health-Related Quality of Life in Patients With α1 Antitrypsin Deficency: A Cross Sectional Study
27470706|a|Measures of health related quality of life (HRQoL) in patients with α1-antitrypsin deficiency (AATD) can help to determine the impact of the disease and provide an important insight into the intervention outcomes. There is few data regarding this issue in the literature. The aim of this study is to assess the relationship between HRQoL and gender, functional parameters and history of hospitalizations in patients with AATD. This is a cross-sectional study of 26 patients with severe AATD recruited in the pulmonology outpatient clinic at a tertiary care medical center. Social-demographic, clinical and functional parameters were recorded and HRQoL was assessed with the Portuguese version of the medical outcome study short form-36 (SF-36) self-administered questionnaire. Older patients, females and patients with at least one hospitalization in the previous year due to respiratory disease had statistical lower scores in some dimensions of the SF-36 questionnaire. Superior FEV1 and higher distance mark in the 6-min walking test distance influenced positively several dimensions of the questionnaire. Higher scores in the mMRC scale influenced negatively the HRQoL. These data suggests that older and female patients with AATD have worse HRQoL. Hospitalizations and functional markers of respiratory disease progression influenced negatively the HRQoL, suggesting that the SF-36 questionnaire could be useful as an outcome for AATD patients with lung involvement.
27470706	0	30	Health-Related Quality of Life	T078	C4279947
27470706	34	42	Patients	T101	C0030705
27470706	48	72	α1 Antitrypsin Deficency	T047	C0221757
27470706	76	97	Cross Sectional Study	T062	C0010362
27470706	110	140	health related quality of life	T078	C4279947
27470706	142	147	HRQoL	T078	C4279947
27470706	152	160	patients	T101	C0030705
27470706	166	191	α1-antitrypsin deficiency	T047	C0221757
27470706	193	197	AATD	T047	C0221757
27470706	225	231	impact	T080	C4049986
27470706	239	246	disease	T047	C0012634
27470706	289	301	intervention	T061	C0184661
27470706	302	310	outcomes	T080	C0085415
27470706	325	329	data	T078	C1511726
27470706	358	368	literature	T170	C0023866
27470706	386	391	study	T062	C0008972
27470706	398	404	assess	T052	C1516048
27470706	409	421	relationship	T080	C0439849
27470706	430	435	HRQoL	T078	C4279947
27470706	440	446	gender	T032	C0079399
27470706	448	458	functional	T169	C0205245
27470706	459	469	parameters	T033	C0449381
27470706	474	481	history	T033	C0262926
27470706	485	501	hospitalizations	T058	C0019993
27470706	505	513	patients	T101	C0030705
27470706	519	523	AATD	T047	C0221757
27470706	535	556	cross-sectional study	T062	C0010362
27470706	563	571	patients	T101	C0030705
27470706	577	583	severe	T080	C0205082
27470706	584	588	AATD	T047	C0221757
27470706	606	617	pulmonology	T091	C0034060
27470706	618	635	outpatient clinic	T073,T093	C0002424
27470706	641	669	tertiary care medical center	T073,T093	C0587437
27470706	671	689	Social-demographic	T080	C0205556
27470706	691	699	clinical	T080	C0205210
27470706	704	714	functional	T169	C0205245
27470706	715	725	parameters	T033	C0449381
27470706	744	749	HRQoL	T078	C4279947
27470706	754	762	assessed	T052	C1516048
27470706	772	782	Portuguese	T098	C0032730
27470706	783	790	version	T170	C0333052
27470706	798	819	medical outcome study	T062	C0543472
27470706	820	873	short form-36 (SF-36) self-administered questionnaire	T170	C1519136
27470706	875	880	Older	T098	C0001792
27470706	881	889	patients	T101	C0030705
27470706	891	898	females	T098	C0043210
27470706	903	911	patients	T101	C0030705
27470706	930	945	hospitalization	T058	C0019993
27470706	974	993	respiratory disease	T047	C0035204
27470706	1010	1015	lower	T052	C2003888
27470706	1016	1022	scores	T081	C0449820
27470706	1031	1041	dimensions	T081	C0439534
27470706	1049	1068	SF-36 questionnaire	T170	C1519136
27470706	1070	1078	Superior	T082	C1282910
27470706	1079	1083	FEV1	T033	C0429706
27470706	1088	1094	higher	T080	C0205250
27470706	1095	1103	distance	T081	C0012751
27470706	1104	1108	mark	T071	C1708936
27470706	1122	1143	walking test distance	T058	C3160837
27470706	1144	1154	influenced	T077	C4054723
27470706	1155	1165	positively	T033	C1446409
27470706	1174	1184	dimensions	T081	C0439534
27470706	1192	1205	questionnaire	T170	C0034394
27470706	1207	1213	Higher	T080	C0205250
27470706	1214	1220	scores	T081	C0449820
27470706	1228	1238	mMRC scale	T170	C3826977
27470706	1239	1249	influenced	T077	C4054723
27470706	1250	1260	negatively	T033	C0205160
27470706	1265	1270	HRQoL	T078	C4279947
27470706	1278	1282	data	T078	C1511726
27470706	1297	1302	older	T098	C0001792
27470706	1307	1313	female	T098	C0043210
27470706	1314	1322	patients	T101	C0030705
27470706	1328	1332	AATD	T047	C0221757
27470706	1338	1343	worse	T033	C1457868
27470706	1344	1349	HRQoL	T078	C4279947
27470706	1351	1367	Hospitalizations	T058	C0019993
27470706	1372	1382	functional	T169	C0205245
27470706	1394	1413	respiratory disease	T047	C0035204
27470706	1414	1425	progression	T046	C0242656
27470706	1426	1436	influenced	T077	C4054723
27470706	1437	1447	negatively	T033	C0205160
27470706	1452	1457	HRQoL	T078	C4279947
27470706	1479	1498	SF-36 questionnaire	T170	C1519136
27470706	1521	1528	outcome	T169	C1274040
27470706	1533	1537	AATD	T047	C0221757
27470706	1538	1546	patients	T101	C0030705
27470706	1552	1556	lung	T023	C0024109
27470706	1557	1568	involvement	T169	C1314939

27580517|t|Assessment of cerebral blood perfusion reserve with acetazolamide using 3D spiral ASL MRI: Preliminary experience in pediatric patients
27580517|a|To demonstrate the clinical feasibility of a new non-Cartesian cylindrically-distributed spiral 3D pseudo-continuous arterial spin labeling (pCASL) magnetic resonance imaging (MRI) pulse sequence in pediatric patients in quantifying cerebral blood flow (CBF) response to an acetazolamide (ACZ) vasodilator challenge. MRI exams were performed on two 3 Tesla Philips Ingenia systems using 32 channel head coil arrays. After local institutional review board approval, the 3D spiral-based pCASL technique was added to a standard brain MRI exam and evaluated in 13 pediatric patients (average age: 11.7±6.4years, range: 1.4-22.2years). All patients were administered ACZ for clinically indicated reasons. Quantitative whole-brain CBF measurements were computed pre - and post - ACZ to assess cerebrovascular reserve. 3D spiral pCASL data were successfully reconstructed in all 13 cases. In 11 patients, CBF increased 2.8% to 93.2% after administration of ACZ. In the two remaining patients, CBF decreased by 2.4 to 6.0% after ACZ. The group average change in CBF due to ACZ was approximately 25.0% and individual changes were statistically significant (p<0.01) in all patients using a paired t-test analysis. CBF perfusion data were diagnostically useful in supporting conventional MR angiography and clinical findings. 3D cylindrically-distributed spiral pCASL MRI provides a robust approach to assess cerebral blood flow and reserve in pediatric patients.
27580517	0	10	Assessment	T058	C0220825
27580517	14	22	cerebral	T023	C0006104
27580517	23	38	blood perfusion	T042	C0599705
27580517	52	65	acetazolamide	T109,T121	C0000981
27580517	72	89	3D spiral ASL MRI	T060	C3891302
27580517	117	126	pediatric	T080	C1521725
27580517	127	135	patients	T101	C0030705
27580517	155	175	clinical feasibility	T062,T170	C0015730
27580517	185	316	non-Cartesian cylindrically-distributed spiral 3D pseudo-continuous arterial spin labeling (pCASL) magnetic resonance imaging (MRI)	T060	C3891302
27580517	317	331	pulse sequence	T082	C3828438
27580517	335	344	pediatric	T080	C1521725
27580517	345	353	patients	T101	C0030705
27580517	357	368	quantifying	T081	C1709793
27580517	369	388	cerebral blood flow	T033	C0428714
27580517	390	393	CBF	T033	C0428714
27580517	410	441	acetazolamide (ACZ) vasodilator	T121	C0042402
27580517	453	462	MRI exams	T060	C0024485
27580517	485	550	3 Tesla Philips Ingenia systems using 32 channel head coil arrays	T073	C3273359
27580517	564	599	institutional review board approval	T170	C2346499
27580517	605	636	3D spiral-based pCASL technique	T060	C3891302
27580517	661	675	brain MRI exam	T060	C0412675
27580517	696	705	pediatric	T080	C1521725
27580517	706	714	patients	T101	C0030705
27580517	771	779	patients	T101	C0030705
27580517	785	797	administered	T058	C3469597
27580517	798	801	ACZ	T109,T121	C0000981
27580517	806	826	clinically indicated	T033	C2985739
27580517	849	877	whole-brain CBF measurements	T060	C0005776
27580517	892	895	pre	T079	C0332152
27580517	902	906	post	T079	C0687676
27580517	909	912	ACZ	T109,T121	C0000981
27580517	923	946	cerebrovascular reserve	T042	C0007818
27580517	948	963	3D spiral pCASL	T060	C3891302
27580517	964	968	data	T078	C1511726
27580517	1011	1016	cases	T062	C0150093
27580517	1024	1032	patients	T101	C0030705
27580517	1034	1037	CBF	T033	C0428714
27580517	1068	1085	administration of	T058	C3469597
27580517	1086	1089	ACZ	T109,T121	C0000981
27580517	1112	1120	patients	T101	C0030705
27580517	1122	1125	CBF	T033	C0428714
27580517	1157	1160	ACZ	T109,T121	C0000981
27580517	1190	1193	CBF	T033	C0428714
27580517	1201	1204	ACZ	T109,T121	C0000981
27580517	1257	1282	statistically significant	T081	C0237881
27580517	1299	1307	patients	T101	C0030705
27580517	1323	1338	t-test analysis	T170	C0871472
27580517	1340	1343	CBF	T033	C0428714
27580517	1344	1353	perfusion	T042	C0599705
27580517	1413	1427	MR angiography	T060	C1636167
27580517	1432	1449	clinical findings	T170	C0455712
27580517	1451	1496	3D cylindrically-distributed spiral pCASL MRI	T060	C3891302
27580517	1527	1533	assess	T058	C0184514
27580517	1534	1553	cerebral blood flow	T033	C0428714
27580517	1569	1578	pediatric	T080	C1521725
27580517	1579	1587	patients	T101	C0030705

28267199|t|Real-world impact of non-breast cancer-specific death on overall survival in resectable breast cancer
28267199|a|The real-world occurrence rate of non-breast cancer-specific death (non-BCSD) and its impact on patients with breast cancer are poorly recognized. Women with resectable breast cancer from 1990 to 2007 in the Surveillance, Epidemiology, and End Results database (n = 199,963) were analyzed. The outcome events of breast cancer were classified as breast cancer-specific death (BCSD), non-BCSD, or survival. Binary logistics was used to estimate the occurrence rates of non-BCSD and BCSD with different clinicopathological factors. The Gray method was used to measure the cumulative incidence of non-BCSD and BCSD. The ratio of non-BCSDs to all causes of death and stacked cumulative incidence function plots were used to present the impact of non-BCSD on overall survival (OS). Models of Cox proportional hazards regression and competing risk regression were compared to highlight the suitable model. There were 12,879 non-BCSDs (6.44%) and 28,784 BCSDs (14.39%). The oldest age group (>62 years), black race, and a single or divorced marital status were associated with more non-BCSDs. With adjustments for age, a hormone receptor-positive (HoR+) status was no longer related to increased non-BCSD s. In patients with grade 1, stage I disease and an HoR+ status as well as the oldest subgroup, a great dilution of non-BCSD on all causes of death could be observed, and this led to incorrect interpretations. The inaccuracy, caused by the commonly used Cox proportional hazards model, could be corrected by a competing risk model. OS was largely impaired by non-BCSD during early breast cancer. For some future clinical trial planning, especially for the oldest patients and those with HoR+ breast cancer, non-BCSD should be considered a competing risk event. Cancer 2017. © 2017 American Cancer Society.
28267199	0	17	Real-world impact	T080	C4049986
28267199	21	53	non-breast cancer-specific death	T033	C1408354
28267199	57	73	overall survival	T081	C4086681
28267199	77	87	resectable	T080	C1514888
28267199	88	101	breast cancer	T191	C0006142
28267199	117	132	occurrence rate	T081	C1521828
28267199	136	168	non-breast cancer-specific death	T033	C1408354
28267199	170	178	non-BCSD	T033	C1408354
28267199	188	194	impact	T080	C4049986
28267199	198	206	patients	T101	C0030705
28267199	212	225	breast cancer	T191	C0006142
28267199	249	254	Women	T098	C0043210
28267199	260	270	resectable	T080	C1514888
28267199	271	284	breast cancer	T191	C0006142
28267199	310	362	Surveillance, Epidemiology, and End Results database	T093	C0242638
28267199	382	390	analyzed	T062	C0936012
28267199	396	403	outcome	T169	C1274040
28267199	404	410	events	T051	C0441471
28267199	414	427	breast cancer	T191	C0006142
28267199	447	475	breast cancer-specific death	T081	C1516192
28267199	477	481	BCSD	T081	C1516192
28267199	484	492	non-BCSD	T033	C1408354
28267199	497	505	survival	T052	C0038952
28267199	507	523	Binary logistics	T062	C0206031
28267199	536	544	estimate	T081	C0750572
28267199	549	565	occurrence rates	T081	C1521828
28267199	569	577	non-BCSD	T033	C1408354
28267199	582	586	BCSD	T081	C1516192
28267199	602	629	clinicopathological factors	T169	C1521761
28267199	635	646	Gray method	T170	C0282574
28267199	659	666	measure	T081	C0079809
28267199	671	691	cumulative incidence	T081	C0021149
28267199	695	703	non-BCSD	T033	C1408354
28267199	708	712	BCSD	T081	C1516192
28267199	718	723	ratio	T081	C0456603
28267199	727	736	non-BCSDs	T033	C1408354
28267199	744	759	causes of death	T033	C0007465
28267199	764	771	stacked	T082	C3272897
28267199	772	792	cumulative incidence	T081	C0021149
28267199	793	807	function plots	T170	C0681493
28267199	833	839	impact	T080	C4049986
28267199	843	851	non-BCSD	T033	C1408354
28267199	855	871	overall survival	T081	C4086681
28267199	873	875	OS	T081	C4086681
28267199	878	923	Models of Cox proportional hazards regression	T081,T170	C0010235
28267199	928	953	competing risk regression	T170	C0034980
28267199	985	999	suitable model	T170	C3161035
28267199	1019	1028	non-BCSDs	T033	C1408354
28267199	1048	1053	BCSDs	T081	C1516192
28267199	1068	1084	oldest age group	T100	C0027362
28267199	1098	1108	black race	T098	C0005680
28267199	1116	1149	single or divorced marital status	T033	C4060922
28267199	1155	1170	associated with	T080	C0332281
28267199	1176	1185	non-BCSDs	T033	C1408354
28267199	1208	1211	age	T032	C0001779
28267199	1215	1254	hormone receptor-positive (HoR+) status	T191	C1562029
28267199	1280	1289	increased	T081	C0205217
28267199	1290	1298	non-BCSD	T033	C1408354
28267199	1305	1313	patients	T101	C0030705
28267199	1319	1343	grade 1, stage I disease	T047	C0012634
28267199	1351	1362	HoR+ status	T191	C1562029
28267199	1415	1423	non-BCSD	T033	C1408354
28267199	1431	1446	causes of death	T033	C0007465
28267199	1482	1507	incorrect interpretations	T033	C3845771
28267199	1513	1523	inaccuracy	T080	C0443236
28267199	1553	1583	Cox proportional hazards model	T081,T170	C0010235
28267199	1609	1629	competing risk model	T170	C0034980
28267199	1631	1633	OS	T081	C4086681
28267199	1646	1654	impaired	T169	C0221099
28267199	1658	1666	non-BCSD	T033	C1408354
28267199	1680	1693	breast cancer	T191	C0006142
28267199	1711	1725	clinical trial	T062	C0008976
28267199	1726	1734	planning	T058	C1254363
28267199	1755	1761	oldest	T100	C0001795
28267199	1762	1770	patients	T101	C0030705
28267199	1786	1790	HoR+	T191	C1562029
28267199	1791	1804	breast cancer	T191	C0006142
28267199	1806	1814	non-BCSD	T033	C1408354
28267199	1838	1858	competing risk event	UnknownType	C0814316
28267199	1880	1903	American Cancer Society	T094	C0002455

28018968|t|ATG16L1 governs placental infection risk and preterm birth in mice and women
28018968|a|The placenta is a barrier against maternal-fetal transmission of pathogens. Placental infections can cause several adverse pregnancy outcomes, including preterm birth (PTB). Yet, we have limited knowledge regarding the mechanisms the placenta uses to control infections. Here, we show that autophagy, a cellular recycling pathway important for host defense against pathogens, and the autophagy gene Atg16L1 play a key role in placental defense and are negatively associated with PTB in pregnant women. First, we demonstrate that placentas from women who delivered preterm exhibit reduced autophagy activity and are associated with higher infection indicators. Second, we identify the cellular location of the autophagy activity as being in syncytial trophoblasts. Third, we demonstrate that higher levels of autophagy and ATG16L1 in human trophoblasts were associated with increased resistance to infection. Accordingly, loss of autophagy or ATG16L1 impaired trophoblast antibacterial defenses. Fourth, we show that Atg16l1 - deficient mice gave birth prematurely upon an inflammatory stimulus and their placentas were significantly less able to withstand infection. Finally, global induction of autophagy in both mouse placentas and human trophoblasts increased infection resistance. Our study has significant implications for understanding the etiology of placental infections and prematurity and developing strategies to mitigate placental infection - induced PTB.
28018968	0	7	ATG16L1	T116,T123	C0033684
28018968	16	35	placental infection	T033	C0566701
28018968	36	40	risk	T201	C0012655
28018968	45	58	preterm birth	T033	C0151526
28018968	62	66	mice	T015	C0025929
28018968	71	76	women	T098	C0043210
28018968	81	89	placenta	T018	C0032043
28018968	111	138	maternal-fetal transmission	T046	C0282474
28018968	142	151	pathogens	T001	C0450254
28018968	153	173	Placental infections	T033	C0566701
28018968	192	199	adverse	T046	C0559546
28018968	200	218	pregnancy outcomes	T033	C0032972
28018968	230	243	preterm birth	T033	C0151526
28018968	245	248	PTB	T033	C0151526
28018968	264	271	limited	T169	C0439801
28018968	272	281	knowledge	T170	C0376554
28018968	296	306	mechanisms	T169	C0441712
28018968	311	319	placenta	T018	C0032043
28018968	328	335	control	T169	C2587213
28018968	336	346	infections	T047	C0009450
28018968	367	376	autophagy	T043	C0004391
28018968	380	406	cellular recycling pathway	T043	C0007613
28018968	421	433	host defense	T042	C0520990
28018968	442	451	pathogens	T001	C0450254
28018968	461	470	autophagy	T043	C0004391
28018968	471	475	gene	T028	C0017337
28018968	476	483	Atg16L1	T028	C1825502
28018968	503	512	placental	T018	C0032043
28018968	513	520	defense	T077	C1880266
28018968	529	539	negatively	T033	C1513916
28018968	540	555	associated with	T080	C0332281
28018968	556	559	PTB	T033	C0151526
28018968	563	577	pregnant women	T098	C0033011
28018968	606	615	placentas	T018	C0032043
28018968	621	626	women	T098	C0043210
28018968	631	648	delivered preterm	T033	C0151526
28018968	657	664	reduced	T080	C0392756
28018968	665	674	autophagy	T043	C0004391
28018968	675	683	activity	T052	C0441655
28018968	692	707	associated with	T080	C0332281
28018968	708	714	higher	T080	C0205250
28018968	715	724	infection	T047	C0009450
28018968	725	735	indicators	T169	C1522602
28018968	748	756	identify	T080	C0205396
28018968	761	769	cellular	T025	C0007634
28018968	770	778	location	T082	C0450429
28018968	786	795	autophagy	T043	C0004391
28018968	796	804	activity	T052	C0441655
28018968	817	839	syncytial trophoblasts	T018	C1135936
28018968	868	874	higher	T080	C0205250
28018968	885	894	autophagy	T043	C0004391
28018968	899	906	ATG16L1	T116,T123	C1870238
28018968	910	915	human	T016	C0086418
28018968	916	928	trophoblasts	T018	C0041178
28018968	934	949	associated with	T080	C0332281
28018968	950	959	increased	T081	C0205217
28018968	960	983	resistance to infection	T038	C0520988
28018968	998	1002	loss	T081	C1517945
28018968	1006	1015	autophagy	T043	C0004391
28018968	1019	1026	ATG16L1	T116,T123	C1870238
28018968	1027	1035	impaired	T169	C0221099
28018968	1036	1047	trophoblast	T018	C0041178
28018968	1048	1070	antibacterial defenses	T040	C1516002
28018968	1093	1100	Atg16l1	T028	C1825502
28018968	1103	1112	deficient	T169	C0011155
28018968	1113	1117	mice	T015	C0025929
28018968	1123	1140	birth prematurely	T033	C0151526
28018968	1149	1161	inflammatory	T169	C0333348
28018968	1162	1170	stimulus	T067	C0234402
28018968	1181	1190	placentas	T018	C0032043
28018968	1196	1214	significantly less	T081	C4055638
28018968	1233	1242	infection	T047	C0009450
28018968	1260	1269	induction	T169	C0205263
28018968	1273	1282	autophagy	T043	C0004391
28018968	1291	1296	mouse	T015	C0025929
28018968	1297	1306	placentas	T018	C0032043
28018968	1311	1316	human	T016	C0086418
28018968	1317	1329	trophoblasts	T018	C0041178
28018968	1330	1339	increased	T081	C0205217
28018968	1340	1360	infection resistance	T038	C0520988
28018968	1376	1387	significant	T078	C0750502
28018968	1423	1431	etiology	T169	C1314792
28018968	1435	1455	placental infections	T033	C0566701
28018968	1460	1471	prematurity	T047	C0021294
28018968	1501	1509	mitigate	T067	C1553901
28018968	1510	1529	placental infection	T033	C0566701
28018968	1532	1539	induced	T169	C0205263
28018968	1540	1543	PTB	T033	C0151526

27390504|t|Custom ocular prosthesis in rehabilitation of a child operated for retinoblastoma
27390504|a|A maxillofacial prosthodontist forms an important link in the interdisciplinary management of a patient with anopthalmosis. Prosthetic management of an anopthalmic defect aims to deliver a well-fitting ocular prosthesis that can mimic the original eye as closely as possible, and thus restoring the patient's self-confidence and thereby rehabilitating them in the society. The fabrication of a custom ocular prosthesis is a demanding art. This case report presents a simplified technique for the fabrication of a custom ocular prosthesis for a child who had lost his eye to enucleation following retinoblastoma. Early and effective rehabilitation of the defect goes a long way in restoring the self-image of a child in its early character building age.
27390504	7	24	ocular prosthesis	T074	C0015417
27390504	28	42	rehabilitation	T061	C0034991
27390504	48	53	child	T100	C0008059
27390504	67	81	retinoblastoma	T191	C0035335
27390504	84	112	maxillofacial prosthodontist	T061	C2193570
27390504	122	131	important	T080	C3898777
27390504	162	185	management of a patient	T058	C1610129
27390504	191	204	anopthalmosis	T019	C0003119
27390504	206	227	Prosthetic management	T061	C0087111
27390504	234	252	anopthalmic defect	T019	C0003119
27390504	284	301	ocular prosthesis	T074	C0015417
27390504	330	333	eye	T023	C0015392
27390504	381	390	patient's	T101	C0030705
27390504	391	406	self-confidence	T041	C0237529
27390504	419	433	rehabilitating	T169	C0034992
27390504	446	453	society	T092	C0037455
27390504	459	470	fabrication	T061	C0087111
27390504	483	500	ocular prosthesis	T074	C0015417
27390504	526	537	case report	T170	C0007320
27390504	560	569	technique	T169	C0449851
27390504	578	589	fabrication	T061	C0087111
27390504	602	619	ocular prosthesis	T074	C0015417
27390504	626	631	child	T100	C0008059
27390504	640	644	lost	T169	C0745777
27390504	649	652	eye	T023	C0015392
27390504	656	667	enucleation	T061	C0014392
27390504	678	692	retinoblastoma	T191	C0035335
27390504	714	728	rehabilitation	T061	C0034991
27390504	776	786	self-image	T058	C2712201
27390504	792	797	child	T100	C0008059

27774519|t|Radiotherapy: Changing the Game in Immunotherapy
27774519|a|Immune checkpoint inhibitors are effective in cancer treatment. A pre-existing immune response demonstrated by significant pretreatment tumor lymphocytic infiltration is a pre-requisite for response. Within such infiltrated tumors, referred as "hot", immune checkpoint inhibitors rescue anti-tumor T cells activity. In contrast, "cold" tumors lack lymphocytic infiltration and are refractory to immunotherapy. Preclinical data show that radiotherapy sensitizes refractory tumors to immune checkpoint inhibitors by recruiting anti-tumor T cells. Despite the growing number of clinical studies testing radiation's ability to enhance immunotherapy, clinical evidence that it converts cold tumors into responsive ones remains elusive. Here we review evidence that radiotherapy is not only an occasional enhancer of immunotherapy's effects but a "game changer", and propose a blueprint to test this.
27774519	0	12	Radiotherapy	T061	C1522449
27774519	35	48	Immunotherapy	T061	C0021083
27774519	49	55	Immune	T022	C0020962
27774519	56	77	checkpoint inhibitors	T121	C1254351
27774519	95	111	cancer treatment	T061	C0920425
27774519	128	143	immune response	T042	C0301872
27774519	172	184	pretreatment	T052	C3539076
27774519	185	215	tumor lymphocytic infiltration	T047	C1262091
27774519	239	247	response	T042	C0301872
27774519	261	279	infiltrated tumors	T191	C0677898
27774519	300	306	immune	T022	C0020962
27774519	307	328	checkpoint inhibitors	T121	C1254351
27774519	347	363	T cells activity	T044	C1152851
27774519	378	391	"cold" tumors	T191	C0027651
27774519	397	421	lymphocytic infiltration	T047	C1262091
27774519	444	457	immunotherapy	T061	C0021083
27774519	459	475	Preclinical data	T170	C1516606
27774519	486	498	radiotherapy	T061	C1522449
27774519	510	527	refractory tumors	T191	C1335729
27774519	531	537	immune	T022	C0020962
27774519	538	559	checkpoint inhibitors	T121	C1254351
27774519	574	584	anti-tumor	T109,T121	C0003392
27774519	585	592	T cells	T025	C0039194
27774519	624	640	clinical studies	T062	C0008972
27774519	649	660	radiation's	T070	C0851346
27774519	680	693	immunotherapy	T061	C0021083
27774519	695	712	clinical evidence	T078	C3887511
27774519	730	741	cold tumors	T191	C0027651
27774519	788	794	review	T080	C1704362
27774519	809	821	radiotherapy	T061	C1522449
27774519	860	875	immunotherapy's	T061	C0021083

27275025|t|Phytoplankton production and taxon - specific growth rates in the Costa Rica Dome
27275025|a|During summer 2010, we investigated phytoplankton production and growth rates at 19 stations in the eastern tropical Pacific, where winds and strong opposing currents generate the Costa Rica Dome (CRD), an open - ocean upwelling feature. Primary production ((14)C - incorporation) and group-specific growth and net growth rates (two-treatment seawater dilution method) were estimated from samples incubated in situ at eight depths. Our cruise coincided with a mild El Niño event, and only weak upwelling was observed in the CRD. Nevertheless, the highest phytoplankton abundances were found near the dome center. However, mixed-layer growth rates were lowest in the dome center (∼0.5-0.9 day(-1)), but higher on the edge of the dome (∼0.9-1.0 day(-1)) and in adjacent coastal waters (0.9-1.3 day(-1)). We found good agreement between independent methods to estimate growth rates. Mixed-layer growth rates of Prochlorococcus and Synechococcus were largely balanced by mortality, whereas eukaryotic phytoplankton showed positive net growth (∼0.5-0.6 day(-1)), that is, growth available to support larger (mesozooplankton) consumer biomass. These are the first group-specific phytoplankton rate estimates in this region, and they demonstrate that integrated primary production is high, exceeding 1 g C m(-2) day(-1) on average, even during a period of reduced upwelling.
27275025	0	13	Phytoplankton	T002	C0031865
27275025	14	24	production	T169	C1522492
27275025	29	34	taxon	T077	C1515221
27275025	37	45	specific	T080	C0205369
27275025	46	58	growth rates	T079	C0449249
27275025	66	81	Costa Rica Dome	T083	C0010182
27275025	89	95	summer	T079	C0241301
27275025	105	117	investigated	T169	C1292732
27275025	118	131	phytoplankton	T002	C0031865
27275025	132	142	production	T169	C1522492
27275025	147	159	growth rates	T079	C0449249
27275025	166	206	stations in the eastern tropical Pacific	UnknownType	C0681784
27275025	214	219	winds	T070	C0043187
27275025	224	230	strong	T080	C0442821
27275025	231	248	opposing currents	T070	C1254365
27275025	249	257	generate	T052	C3146294
27275025	262	277	Costa Rica Dome	T083	C0010182
27275025	279	282	CRD	T083	C0010182
27275025	288	292	open	T082	C0175566
27275025	295	300	ocean	T083	C0028814
27275025	301	318	upwelling feature	T070	C1254365
27275025	320	327	Primary	T080	C0205225
27275025	328	338	production	T169	C1522492
27275025	340	345	(14)C	T130,T196	C0302945
27275025	348	361	incorporation	T169	C0243126
27275025	367	381	group-specific	T078	C3858709
27275025	382	388	growth	T040	C0597252
27275025	393	409	net growth rates	T079	C0449249
27275025	411	424	two-treatment	T169	C1522326
27275025	425	433	seawater	T167	C0036499
27275025	434	449	dilution method	T059	C0079240
27275025	456	465	estimated	T081	C0750572
27275025	471	478	samples	T002	C0032098
27275025	479	488	incubated	T059	C1439852
27275025	489	496	in situ	T082	C0444498
27275025	506	512	depths	T082	C0205125
27275025	542	546	mild	T080	C2945599
27275025	547	554	El Niño	T070	C2936615
27275025	555	560	event	T051	C0441471
27275025	566	570	only	T081	C0205171
27275025	571	575	weak	T080	C1762617
27275025	576	585	upwelling	T070	C1254365
27275025	590	598	observed	T169	C1441672
27275025	606	609	CRD	T083	C0010182
27275025	629	636	highest	T080	C1522410
27275025	637	650	phytoplankton	T002	C0031865
27275025	651	661	abundances	T080	C2346714
27275025	682	686	dome	UnknownType	C0681784
27275025	687	693	center	T082	C0205099
27275025	704	715	mixed-layer	T082	C1883067
27275025	716	728	growth rates	T079	C0449249
27275025	734	740	lowest	T080	C1708760
27275025	748	752	dome	UnknownType	C0681784
27275025	753	759	center	T082	C0205099
27275025	784	790	higher	T080	C0205250
27275025	798	802	edge	T082	C1254362
27275025	810	814	dome	UnknownType	C0681784
27275025	841	849	adjacent	T082	C0205117
27275025	850	864	coastal waters	T083	C0442542
27275025	893	897	good	T080	C0205170
27275025	898	907	agreement	T080	C0332529
27275025	916	927	independent	T078	C0085862
27275025	928	947	methods to estimate	T081	C2825570
27275025	948	960	growth rates	T079	C0449249
27275025	962	973	Mixed-layer	T082	C1883067
27275025	974	986	growth rates	T079	C0449249
27275025	990	1005	Prochlorococcus	T007	C0995582
27275025	1010	1023	Synechococcus	T007	C0995533
27275025	1049	1058	mortality	T081	C0205848
27275025	1068	1092	eukaryotic phytoplankton	T002	C0031865
27275025	1100	1108	positive	T033	C1446409
27275025	1109	1119	net growth	T040	C0018270
27275025	1149	1155	growth	T040	C0597252
27275025	1156	1165	available	T169	C0470187
27275025	1177	1183	larger	T081	C0549177
27275025	1185	1200	mesozooplankton	T204	C0043530
27275025	1202	1210	consumer	T080	C0205556
27275025	1211	1218	biomass	T081	C0005535
27275025	1234	1239	first	T080	C1279901
27275025	1240	1254	group-specific	T078	C3858709
27275025	1255	1268	phytoplankton	T002	C0031865
27275025	1269	1273	rate	T081	C1521828
27275025	1274	1283	estimates	T081	C0750572
27275025	1292	1298	region	T083	C0017446
27275025	1337	1344	primary	T080	C0205225
27275025	1345	1355	production	T169	C1522492
27275025	1359	1363	high	T080	C0205250
27275025	1398	1405	average	T081	C1510992
27275025	1421	1427	period	T079	C1948053
27275025	1431	1438	reduced	T080	C0392756
27275025	1439	1448	upwelling	T070	C1254365

28456987|t|Next-Generation Sequencing Approaches to Define the Role of the Autophagy Lysosomal Pathway in Human Disease: The Example of LysoPlex
28456987|a|Next-Generation Sequencing (NGS) technologies have deeply changed the throughput of genetic testing allowing analyzing millions of DNA fragments in parallel. One key application is the understanding of genetically heterogeneous and complex diseases where 50-100 different genes may converge to control the same pathways. These disorders cannot be studied using traditional approaches, based on gene-by-gene Sanger sequencing. We have set up an NGS protocol based on a specific selection of DNA regions belonging to about 900 genes of the autophagy-lysosomal (ALP) pathway. We here specify all the technical steps and challenges of our protocol, named LysoPlex. This is based on the Haloplex technology and together with high-coverage sequencing empowers a high and uniform coverage of ALP genes. LysoPlex outplays other NGS applications in sensitivity and specificity, providing an accurate picture of all variations in ALP genes.
28456987	0	26	Next-Generation Sequencing	T063	C2936622
28456987	27	37	Approaches	T169	C1292724
28456987	52	56	Role	T077	C1705810
28456987	64	91	Autophagy Lysosomal Pathway	T043	C0007613
28456987	95	100	Human	T016	C0086418
28456987	101	108	Disease	T047	C0012634
28456987	114	121	Example	T077	C1707959
28456987	125	133	LysoPlex	T170	C0442711
28456987	134	179	Next-Generation Sequencing (NGS) technologies	T063	C2936622
28456987	204	214	throughput	T081	C2986816
28456987	218	233	genetic testing	T059	C0679560
28456987	265	278	DNA fragments	UnknownType	C0684192
28456987	282	290	parallel	T080	C0205556
28456987	300	311	application	T169	C0205245
28456987	336	347	genetically	T169	C0314603
28456987	348	361	heterogeneous	T033	C1858576
28456987	366	382	complex diseases	T047	C0012634
28456987	406	411	genes	T028	C0017337
28456987	428	435	control	T080	C0243148
28456987	445	453	pathways	T044	C1704259
28456987	461	470	disorders	T047	C0012634
28456987	495	506	traditional	T169	C0443324
28456987	507	517	approaches	T169	C1292724
28456987	528	558	gene-by-gene Sanger sequencing	T063	C1511897
28456987	578	581	NGS	T063	C2936622
28456987	582	590	protocol	T170	C0442711
28456987	611	620	selection	T052	C1707391
28456987	624	635	DNA regions	T114,T123	C0012854
28456987	659	664	genes	T028	C0017337
28456987	672	705	autophagy-lysosomal (ALP) pathway	T043	C0007613
28456987	731	746	technical steps	T077	C1261552
28456987	751	761	challenges	T058	C0805586
28456987	769	777	protocol	T170	C0442711
28456987	785	793	LysoPlex	T170	C0442711
28456987	854	878	high-coverage sequencing	UnknownType	C0687728
28456987	919	928	ALP genes	T028	C0017337
28456987	930	938	LysoPlex	T170	C0442711
28456987	954	957	NGS	T063	C2936622
28456987	958	970	applications	T169	C0205245
28456987	974	1001	sensitivity and specificity	T081	C0036668
28456987	1040	1050	variations	T070	C0042333
28456987	1054	1063	ALP genes	T028	C0017337

27965132|t|Low-Volume vs High-Volume Centers and Management of Fournier's Gangrene in Washington State
27965132|a|Fournier's gangrene (FG) is a life-threatening infection affecting the perineum and genitals. Complex patient management often necessitates transfer to tertiary centers. We aimed to characterize hospital transfer patterns and assess morbidity among patients with FG in Washington State. The Washington State Comprehensive Hospital Abstract Reporting System includes claims from all hospital discharges in Washington. We identified patients with FG between 2007 and 2013, based on diagnosis and treatment codes. Analyses were stratified by center volume (low-volume centers [LVCs] or high-volume centers [HVCs]), and transfer status. Variables of interest included number of debridements, septic shock, acute renal failure, acute respiratory failure, length of hospitalization, and death. We identified 165 FG patients. Only 1 HVC treated more than 2 FG patients per year. Overall mortality was 6.7%. Most patients (57%) were treated entirely at LVCs; 87% of patients treated at the HVC were transferred from an LVC. High-volume center -treated patients had similar baseline comorbidities (p = 0.77) and similar mortality (p = 0.87), despite higher rates of septic shock (p < 0.01) and respiratory failure (p = 0.01) compared with LVC patients. Among HVC - transferred patients, immediate compared with delayed transfer was associated with fewer debridements (p < 0.01), lower rates of septic shock (p = 0.05), and acute renal failure (p = 0.04). Patients treated at the HVC were more acutely ill, yet mortality was similar compared with patients treated solely at LVCs, suggesting a benefit to transfer of high acuity patients. Immediate vs delayed transfer may benefit FG health outcomes; however, this may also reflect greater disease acuity of patients with delayed transfer status.
27965132	0	10	Low-Volume	T073,T093	C3494217
27965132	14	33	High-Volume Centers	T073,T093	C3494218
27965132	38	71	Management of Fournier's Gangrene	T058	C0376636
27965132	52	71	Fournier's Gangrene	T047	C0238419
27965132	75	91	Washington State	T083	C0043038
27965132	92	111	Fournier's gangrene	T047	C0238419
27965132	113	115	FG	T047	C0238419
27965132	122	148	life-threatening infection	T033	C1859430
27965132	149	158	affecting	T169	C0392760
27965132	163	171	perineum	T029	C0031066
27965132	176	184	genitals	T023	C0017420
27965132	186	193	Complex	T080	C0439855
27965132	194	212	patient management	T058	C1610129
27965132	244	260	tertiary centers	T073,T093	C0587437
27965132	287	304	hospital transfer	T058	C2065834
27965132	305	313	patterns	T082	C0449774
27965132	325	334	morbidity	T081	C0026538
27965132	341	349	patients	T101	C0030705
27965132	355	357	FG	T047	C0238419
27965132	361	377	Washington State	T083	C0043038
27965132	383	399	Washington State	T083	C0043038
27965132	400	413	Comprehensive	T080	C1880156
27965132	423	441	Abstract Reporting	T057	C0000857
27965132	474	493	hospital discharges	UnknownType	C0541652
27965132	497	507	Washington	T083	C0043038
27965132	523	531	patients	T101	C0030705
27965132	537	539	FG	T047	C0238419
27965132	572	601	diagnosis and treatment codes	T170	C0282574
27965132	617	627	stratified	T080	C0205363
27965132	646	664	low-volume centers	T073,T093	C3494217
27965132	666	670	LVCs	T073,T093	C3494217
27965132	675	694	high-volume centers	T073,T093	C3494218
27965132	696	700	HVCs	T073,T093	C3494218
27965132	708	723	transfer status	T033	C0586512
27965132	766	778	debridements	T061	C0011079
27965132	780	792	septic shock	T046	C0036983
27965132	794	813	acute renal failure	T047	C0022660
27965132	815	840	acute respiratory failure	T047	C0264490
27965132	842	867	length of hospitalization	T058	C3694481
27965132	873	878	death	T033	C1306577
27965132	898	900	FG	T047	C0238419
27965132	901	909	patients	T101	C0030705
27965132	918	921	HVC	T073,T093	C3494218
27965132	922	929	treated	T169	C1522326
27965132	942	944	FG	T047	C0238419
27965132	945	953	patients	T101	C0030705
27965132	964	981	Overall mortality	T081	C0205848
27965132	997	1005	patients	T101	C0030705
27965132	1017	1024	treated	T169	C1522326
27965132	1037	1041	LVCs	T073,T093	C3494217
27965132	1050	1058	patients	T101	C0030705
27965132	1059	1066	treated	T169	C1522326
27965132	1074	1077	HVC	T073,T093	C3494218
27965132	1103	1106	LVC	T073,T093	C3494217
27965132	1108	1126	High-volume center	T073,T093	C3494218
27965132	1136	1144	patients	T101	C0030705
27965132	1166	1179	comorbidities	T078	C0009488
27965132	1203	1212	mortality	T081	C0205848
27965132	1249	1261	septic shock	T046	C0036983
27965132	1277	1296	respiratory failure	T047	C1145670
27965132	1322	1325	LVC	T073,T093	C3494217
27965132	1326	1334	patients	T101	C0030705
27965132	1342	1345	HVC	T073,T093	C3494218
27965132	1348	1368	transferred patients	T058	C0030704
27965132	1370	1379	immediate	T079	C0205253
27965132	1394	1401	delayed	T079	C0205421
27965132	1415	1430	associated with	T080	C0332281
27965132	1437	1449	debridements	T061	C0011079
27965132	1477	1489	septic shock	T046	C0036983
27965132	1506	1525	acute renal failure	T047	C0022660
27965132	1538	1546	Patients	T101	C0030705
27965132	1547	1554	treated	T169	C1522326
27965132	1562	1565	HVC	T073,T093	C3494218
27965132	1576	1587	acutely ill	T033	C2051411
27965132	1593	1602	mortality	T081	C0205848
27965132	1629	1637	patients	T101	C0030705
27965132	1638	1645	treated	T169	C1522326
27965132	1656	1660	LVCs	T073,T093	C3494217
27965132	1703	1718	acuity patients	T080	C3494263
27965132	1720	1729	Immediate	T079	C0205253
27965132	1733	1740	delayed	T079	C0205421
27965132	1762	1764	FG	T047	C0238419
27965132	1765	1780	health outcomes	T170	C1550208
27965132	1821	1828	disease	T047	C0012634
27965132	1829	1847	acuity of patients	T080	C3494263
27965132	1861	1876	transfer status	T033	C0586512

27490927|t|TLR and NLRP3 inflammasome - dependent innate immune responses to tumor-derived autophagosomes (DRibbles)
27490927|a|Autophagosomes derived from tumor cells, also referred to as defective ribosomal products in blebs (DRibbles), have been previously shown to stimulate potent T-cell responses and mediate tumor regression when used as therapeutic cancer vaccines in multiple preclinical cancer models. In this report, we investigated the underlining mechanisms by which DRibbles induced T-cell activation, particularly how DRibbles activated antigen-presenting cells (APCs). We found that DRibbles could induce a rapid differentiation of monocytes and DC precursor (pre-DC) cells into functional APCs. DRibbles triggered innate receptor signaling via Toll-like Receptors (TLR)-2, TLR4, TLR7, TLR8, and nucleotide-binding oligomerization domain-containing protein 2 (NOD2), but not TLR3, TLR5, or TLR9. DRibbles induced PBMCs to produce pro-inflammatory cytokines, such as IL-6, IL-10, TNF-α, and IL-1β. DRibbles induced IL-1β release from PBMC or THP-1 cells without LPS priming, but required the core machinery of NLRP3 inflammasomes. Active endocytosis was required for inflammasome activation and cross presentation, and blocking endosome acidification or the ER-associated degradation (ERAD) pathway resulted in opposite effects on these two processes. Our data show that DRibbles could induce strong innate immune responses via multiple pattern recognition receptors, and explain why DRibbles could function as excellent antigen carriers to induce adaptive immune responses to both tumor cells and viruses. In contrast to the well-established inhibitory effect of autophagy on the inflammasome activation of APCs, our study demonstrates that isolated autophagosomes (DRibbles) from antigen donor cells activate inflammasomes by providing first and second signals required for IL-1β production by PMBC.
27490927	0	3	TLR	T116,T192	C0670896
27490927	8	13	NLRP3	T116,T123	C1384660
27490927	14	26	inflammasome	T116,T123	C2936529
27490927	29	38	dependent	T080	C0851827
27490927	39	62	innate immune responses	T032	C0020969
27490927	66	79	tumor-derived	T169	C1519667
27490927	80	94	autophagosomes	T026	C3887595
27490927	96	104	DRibbles	T026	C3887595
27490927	106	120	Autophagosomes	T026	C3887595
27490927	121	128	derived	T080	C1441547
27490927	134	145	tumor cells	T025	C0597032
27490927	167	195	defective ribosomal products	T026	C3887595
27490927	199	204	blebs	T046	C0005758
27490927	206	214	DRibbles	T026	C3887595
27490927	247	256	stimulate	T169	C0205245
27490927	264	270	T-cell	T025	C0039194
27490927	271	280	responses	T043	C0007613
27490927	293	309	tumor regression	T201	C1718423
27490927	323	334	therapeutic	T169	C0302350
27490927	335	350	cancer vaccines	T116,T121,T129	C0376659
27490927	354	362	multiple	T081	C0439064
27490927	363	374	preclinical	T080	C1709630
27490927	375	388	cancer models	T050	C1516211
27490927	398	404	report	T170	C0684224
27490927	409	421	investigated	T169	C1292732
27490927	438	448	mechanisms	T169	C0441712
27490927	458	466	DRibbles	T026	C3887595
27490927	467	474	induced	T169	C0205263
27490927	475	492	T-cell activation	T043	C1155065
27490927	511	519	DRibbles	T026	C3887595
27490927	520	529	activated	T043	C1326120
27490927	530	554	antigen-presenting cells	T025	C0003315
27490927	556	560	APCs	T025	C0003315
27490927	577	585	DRibbles	T026	C3887595
27490927	592	598	induce	T169	C0205263
27490927	607	622	differentiation	T043	C0007589
27490927	626	635	monocytes	T025	C0026473
27490927	640	667	DC precursor (pre-DC) cells	T025	C0003315
27490927	673	683	functional	T169	C0205245
27490927	684	688	APCs	T025	C0003315
27490927	690	698	DRibbles	T026	C3887595
27490927	699	708	triggered	T080	C1444748
27490927	709	734	innate receptor signaling	T044	C1514762
27490927	739	766	Toll-like Receptors (TLR)-2	T116,T192	C0754728
27490927	768	772	TLR4	T116,T192	C1411976
27490927	774	778	TLR7	T116,T129,T192	C1579758
27490927	780	784	TLR8	T116,T192	C1579755
27490927	790	852	nucleotide-binding oligomerization domain-containing protein 2	T116	C2698508
27490927	854	858	NOD2	T116	C2698508
27490927	869	873	TLR3	T116,T192	C1534866
27490927	875	879	TLR5	T116,T192	C0966553
27490927	884	888	TLR9	T116,T129,T192	C0963057
27490927	890	898	DRibbles	T026	C3887595
27490927	899	906	induced	T169	C0205263
27490927	907	912	PBMCs	T025	C1321301
27490927	924	950	pro-inflammatory cytokines	T116,T129	C0079189
27490927	960	964	IL-6	T116,T129	C0021760
27490927	966	971	IL-10	T116,T129	C0085295
27490927	973	978	TNF-α	T116,T129	C1456820
27490927	984	989	IL-1β	T116,T129	C0021753
27490927	991	999	DRibbles	T026	C3887595
27490927	1000	1007	induced	T169	C0205263
27490927	1008	1013	IL-1β	T116,T129	C0021753
27490927	1014	1021	release	T169	C1283071
27490927	1027	1031	PBMC	T025	C1321301
27490927	1035	1046	THP-1 cells	T025	C0682523
27490927	1055	1058	LPS	T109	C0023810
27490927	1059	1066	priming	T169	C0871133
27490927	1085	1089	core	T082	C0444669
27490927	1090	1099	machinery	T080	C0205556
27490927	1103	1122	NLRP3 inflammasomes	T026	C3156614
27490927	1124	1130	Active	T169	C0205177
27490927	1131	1142	endocytosis	T043	C0014139
27490927	1160	1183	inflammasome activation	T044	C3272080
27490927	1188	1206	cross presentation	T043	C1257986
27490927	1212	1220	blocking	T169	C0332206
27490927	1221	1229	endosome	T026	C0034850
27490927	1230	1243	acidification	T043	C1522821
27490927	1251	1291	ER-associated degradation (ERAD) pathway	T043	C4235027
27490927	1313	1320	effects	T080	C1280500
27490927	1334	1343	processes	T067	C1522240
27490927	1349	1353	data	T078	C1511726
27490927	1364	1372	DRibbles	T026	C3887595
27490927	1379	1385	induce	T169	C0205263
27490927	1393	1416	innate immune responses	T032	C0020969
27490927	1421	1429	multiple	T081	C0439064
27490927	1430	1459	pattern recognition receptors	T116,T129,T192	C1564907
27490927	1477	1485	DRibbles	T026	C3887595
27490927	1492	1500	function	T169	C0542341
27490927	1514	1521	antigen	T129	C0003320
27490927	1522	1530	carriers	T169	C0205245
27490927	1534	1540	induce	T169	C0205263
27490927	1541	1566	adaptive immune responses	T043	C1155229
27490927	1575	1586	tumor cells	T025	C0597032
27490927	1591	1598	viruses	T005	C0042776
27490927	1636	1653	inhibitory effect	T043	C0007613
27490927	1657	1666	autophagy	T043	C0004391
27490927	1674	1697	inflammasome activation	T044	C3272080
27490927	1701	1705	APCs	T025	C0003315
27490927	1711	1716	study	T062	C2603343
27490927	1735	1743	isolated	T169	C0205409
27490927	1744	1758	autophagosomes	T026	C3887595
27490927	1760	1768	DRibbles	T026	C3887595
27490927	1775	1782	antigen	T129	C0003320
27490927	1783	1794	donor cells	T025	C0007634
27490927	1795	1817	activate inflammasomes	T044	C3272080
27490927	1831	1836	first	T081	C0205435
27490927	1841	1847	second	T081	C0205436
27490927	1848	1855	signals	T067	C1710082
27490927	1869	1874	IL-1β	T116,T129	C0021753
27490927	1875	1885	production	T169	C0205245
27490927	1889	1893	PMBC	T025	C1321301

27446232|t|Perfusion Angiography in Acute Ischemic Stroke
27446232|a|Visualization and quantification of blood flow are essential for the diagnosis and treatment evaluation of cerebrovascular diseases. For rapid imaging of the cerebrovasculature, digital subtraction angiography (DSA) remains the gold standard as it offers high spatial resolution. This paper lays out a methodological framework, named perfusion angiography, for the quantitative analysis and visualization of blood flow parameters from DSA images. The parameters, including cerebral blood flow (CBF) and cerebral blood volume (CBV), mean transit time (MTT), time-to-peak (TTP), and T max, are computed using a bolus tracking method based on the deconvolution of the time-density curve on a pixel-by-pixel basis. The method is tested on 66 acute ischemic stroke patients treated with thrombectomy and/or tissue plasminogen activator (tPA) and also evaluated on an estimation task with known ground truth. This novel imaging tool provides unique insights into flow mechanisms that cannot be observed directly in DSA sequences and might be used to evaluate the impact of endovascular interventions more precisely.
27446232	0	9	Perfusion	T061	C0031001
27446232	10	21	Angiography	T060	C0002978
27446232	25	30	Acute	T079	C0205178
27446232	31	46	Ischemic Stroke	T047	C0948008
27446232	65	79	quantification	T081	C1709793
27446232	83	93	blood flow	T039	C0232338
27446232	98	107	essential	T080	C0205224
27446232	116	125	diagnosis	T033	C0011900
27446232	130	150	treatment evaluation	T058	C0557980
27446232	154	178	cerebrovascular diseases	T047	C0007820
27446232	184	189	rapid	T080	C0456962
27446232	190	197	imaging	T060	C0011923
27446232	205	223	cerebrovasculature	T022	C0225992
27446232	225	256	digital subtraction angiography	T060	C0002979
27446232	258	261	DSA	T060	C0002979
27446232	275	288	gold standard	T080	C0150110
27446232	302	325	high spatial resolution	T059	C1719039
27446232	349	373	methodological framework	T077	C1709697
27446232	381	390	perfusion	T061	C0031001
27446232	391	402	angiography	T060	C0002978
27446232	412	433	quantitative analysis	T059	C0200767
27446232	455	465	blood flow	T039	C0232338
27446232	466	476	parameters	T033	C0449381
27446232	482	485	DSA	T060	C0002979
27446232	486	492	images	T170	C1704922
27446232	498	508	parameters	T033	C0449381
27446232	520	539	cerebral blood flow	T033	C0428714
27446232	541	544	CBF	T033	C0428714
27446232	550	571	cerebral blood volume	T032	C4277714
27446232	573	576	CBV	T032	C4277714
27446232	579	596	mean transit time	T079	C0040223
27446232	598	601	MTT	T079	C0040223
27446232	604	616	time-to-peak	T201	C2923471
27446232	618	621	TTP	T201	C2923471
27446232	628	633	T max	T081	C2348796
27446232	639	647	computed	T052	C1880157
27446232	656	677	bolus tracking method	T061	C1511237
27446232	691	704	deconvolution	T066	C1707643
27446232	762	768	method	T170	C0025663
27446232	785	790	acute	T079	C0205178
27446232	791	806	ischemic stroke	T047	C0948008
27446232	807	815	patients	T101	C0030705
27446232	816	828	treated with	T061	C0332293
27446232	829	841	thrombectomy	T061	C0162578
27446232	849	877	tissue plasminogen activator	T116,T123	C0042145
27446232	879	882	tPA	T116,T123	C0042145
27446232	893	902	evaluated	T058	C0220825
27446232	909	919	estimation	T041	C0680844
27446232	920	924	task	T057	C3540678
27446232	955	960	novel	T080	C0205314
27446232	961	973	imaging tool	T074	C1512629
27446232	990	998	insights	T041	C0233820
27446232	1009	1019	mechanisms	T169	C0441712
27446232	1035	1043	observed	T169	C1441672
27446232	1056	1059	DSA	T060	C0002979
27446232	1091	1099	evaluate	T058	C0220825
27446232	1104	1110	impact	T080	C4049986
27446232	1114	1140	endovascular interventions	T061	C0411282

27494020|t|Reduction in Hospital-Wide Clinical Laboratory Specimen Identification Errors following Process Interventions: A 10- Year Retrospective Observational Study
27494020|a|Accurate patient identification and specimen labeling at the time of collection are crucial steps in the prevention of medical errors, thereby improving patient safety. All patient specimen identification errors that occurred in the outpatient department (OPD), emergency department (ED), and inpatient department (IPD) of a 3,800- bed academic medical center in Taiwan were documented and analyzed retrospectively from 2005 to 2014. To reduce such errors, the following series of strategies were implemented: a restrictive specimen acceptance policy for the ED and IPD in 2006; a computer-assisted barcode positive patient identification system for the ED and IPD in 2007 and 2010, and automated sample labeling combined with electronic identification systems introduced to the OPD in 2009. Of the 2000345 specimens collected in 2005, 1023 (0.0511%) were identified as having patient identification errors, compared with 58 errors (0.0015%) among 3761238 specimens collected in 2014, after serial interventions; this represents a 97% relative reduction. The total number (rate) of institutional identification errors contributed from the ED, IPD, and OPD over a 10- year period were 423 (0.1058%), 556 (0.0587%), and 44 (0.0067%) errors before the interventions, and 3 (0.0007%), 52 (0.0045%) and 3 (0.0001%) after interventions, representing relative 99%, 92% and 98% reductions, respectively. Accurate patient identification is a challenge of patient safety in different health settings. The data collected in our study indicate that a restrictive specimen acceptance policy, computer-generated positive identification systems, and interdisciplinary cooperation can significantly reduce patient identification errors.
27494020	0	9	Reduction	T080	C0392756
27494020	13	26	Hospital-Wide	T073,T093	C0019994
27494020	27	70	Clinical Laboratory Specimen Identification	T059	C0200344
27494020	71	77	Errors	T080	C0743559
27494020	88	109	Process Interventions	UnknownType	C0814452
27494020	117	121	Year	T079	C0439234
27494020	122	155	Retrospective Observational Study	T062	C0035363
27494020	156	164	Accurate	T080	C0443131
27494020	165	187	patient identification	T058	C1269815
27494020	192	209	specimen labeling	T058	C1254363
27494020	240	253	crucial steps	T077	C1254372
27494020	261	271	prevention	T062	C1706420
27494020	275	289	medical errors	T080	C0376531
27494020	299	308	improving	T080	C1272745
27494020	309	323	patient safety	T058	C1113679
27494020	329	345	patient specimen	T031	C1292459
27494020	346	360	identification	T080	C0205396
27494020	361	367	errors	T080	C0743559
27494020	373	381	occurred	T052	C1709305
27494020	389	410	outpatient department	T082	C1547116
27494020	412	415	OPD	T082	C1547116
27494020	418	438	emergency department	T073,T093	C0562508
27494020	440	442	ED	T073,T093	C0562508
27494020	449	469	inpatient department	T082	C1547116
27494020	471	474	IPD	T082	C1547116
27494020	488	491	bed	T073	C0004916
27494020	492	515	academic medical center	T073,T093	C0000872
27494020	519	525	Taiwan	T083	C0039260
27494020	531	541	documented	T058	C1301725
27494020	546	554	analyzed	T058	C1254363
27494020	593	599	reduce	T080	C0392756
27494020	605	611	errors	T080	C0743559
27494020	627	633	series	T081	C0205549
27494020	637	647	strategies	T170	C0679716
27494020	668	706	restrictive specimen acceptance policy	T089	C0680575
27494020	715	717	ED	T073,T093	C0562508
27494020	722	725	IPD	T082	C1547116
27494020	737	754	computer-assisted	T059	C2362103
27494020	755	762	barcode	T170	C0004738
27494020	763	801	positive patient identification system	T073,T170	C0009612
27494020	810	812	ED	T073,T093	C0562508
27494020	817	820	IPD	T082	C1547116
27494020	843	852	automated	T169	C0205554
27494020	853	868	sample labeling	T058	C1254363
27494020	869	877	combined	T080	C0205195
27494020	883	916	electronic identification systems	T058	C3687093
27494020	917	927	introduced	T169	C1292748
27494020	935	938	OPD	T082	C1547116
27494020	963	972	specimens	T031	C1550655
27494020	973	982	collected	T169	C1516698
27494020	1012	1022	identified	T033	C0243095
27494020	1033	1055	patient identification	T058	C1269815
27494020	1056	1062	errors	T080	C0743559
27494020	1081	1087	errors	T080	C0743559
27494020	1112	1121	specimens	T031	C1550655
27494020	1122	1131	collected	T169	C1516698
27494020	1154	1167	interventions	T058	C1273869
27494020	1191	1199	relative	T080	C0205345
27494020	1200	1209	reduction	T080	C0392756
27494020	1215	1227	total number	T081	C4288115
27494020	1229	1233	rate	T081	C1521828
27494020	1238	1266	institutional identification	T058	C1254363
27494020	1267	1273	errors	T080	C0743559
27494020	1295	1297	ED	T073,T093	C0562508
27494020	1299	1302	IPD	T082	C1547116
27494020	1308	1311	OPD	T082	C1547116
27494020	1323	1327	year	T079	C0439234
27494020	1328	1334	period	T079	C1948053
27494020	1387	1393	errors	T080	C0743559
27494020	1394	1400	before	T079	C0332152
27494020	1405	1418	interventions	T058	C1273869
27494020	1466	1471	after	T079	C0687676
27494020	1472	1485	interventions	T058	C1273869
27494020	1500	1508	relative	T080	C0205345
27494020	1526	1536	reductions	T080	C0392756
27494020	1552	1560	Accurate	T080	C0443131
27494020	1561	1583	patient identification	T058	C1269815
27494020	1602	1616	patient safety	T058	C1113679
27494020	1630	1636	health	T078	C0018684
27494020	1637	1645	settings	T081	C1318139
27494020	1651	1665	data collected	T033	C4019276
27494020	1673	1678	study	T062	C2603343
27494020	1695	1733	restrictive specimen acceptance policy	T089	C0680575
27494020	1735	1753	computer-generated	T059	C0022885
27494020	1754	1785	positive identification systems	T073,T170	C0009612
27494020	1839	1845	reduce	T080	C0392756
27494020	1846	1868	patient identification	T058	C1269815
27494020	1869	1875	errors	T080	C0743559

28328236|t|Treated Prevalence of Attention-Deficit/Hyperactivity Disorder Increased from 2009 to 2015 Among School-Aged Children and Adolescents in the United States
28328236|a|The purpose of this brief is to describe changes in the treated prevalence of medically managed attention-deficit/hyperactivity disorder (ADHD) among insured school-aged children and adolescents in the United States from 2009 to 2015. We examine the differences between those with employer-sponsored insurance (ESI) and with Medicaid insurance. We utilized two large longitudinal administrative datasets containing medical and drug claims data on individuals with ESI and Medicaid insurance from Truven Health MarketScan(®) Administrative Claims Databases. Treated prevalence was measured as the percentage of school-aged children and adolescents enrolled in a calendar year who met the criteria for medically managed ADHD in the same calendar year. Subjects were eligible for inclusion if they were aged 6-17 years and were continuously enrolled during a calendar year. The annual prevalence of treated ADHD among school-aged children and adolescents with ESI increased from 4.5% in 2009 to 6.7% in 2015. Among those with Medicaid it increased from 11.3% in 2009 to 13.3% in 2012, and fell after 2012, remaining steady from 2013 through 2015. Treated prevalence of ADHD increased continuously over time among school-aged children and adolescents with ESI, but declined slightly after 2012 among those in the Medicaid sample.
28328236	0	7	Treated	T061	C0087111
28328236	8	18	Prevalence	T081	C0033105
28328236	22	62	Attention-Deficit/Hyperactivity Disorder	T048	C1263846
28328236	63	72	Increased	T081	C0205217
28328236	97	117	School-Aged Children	T100	C2827631
28328236	122	133	Adolescents	T100	C0205653
28328236	141	154	United States	T083	C0041703
28328236	159	166	purpose	T169	C1285529
28328236	187	195	describe	T078	C1552738
28328236	196	203	changes	T169	C0392747
28328236	211	218	treated	T061	C0087111
28328236	219	229	prevalence	T081	C0033105
28328236	233	242	medically	T169	C0205476
28328236	243	250	managed	T058	C0184516
28328236	251	291	attention-deficit/hyperactivity disorder	T048	C1263846
28328236	293	297	ADHD	T048	C1263846
28328236	305	312	insured	T170	C1548605
28328236	313	333	school-aged children	T100	C2827631
28328236	338	349	adolescents	T100	C0205653
28328236	357	370	United States	T083	C0041703
28328236	393	400	examine	T033	C0332128
28328236	405	416	differences	T081	C1705241
28328236	436	464	employer-sponsored insurance	T081	C3824871
28328236	466	469	ESI	T081	C3824871
28328236	480	498	Medicaid insurance	T058	C0021682
28328236	522	534	longitudinal	T082	C0205127
28328236	535	558	administrative datasets	T170	C0150098
28328236	570	577	medical	T169	C0205476
28328236	582	586	drug	T121	C0013227
28328236	587	593	claims	T058	C3824919
28328236	594	598	data	T078	C1511726
28328236	602	613	individuals	T098	C0237401
28328236	619	622	ESI	T081	C3824871
28328236	627	645	Medicaid insurance	T058	C0021682
28328236	651	710	Truven Health MarketScan(®) Administrative Claims Databases	T170	C0242356
28328236	712	719	Treated	T061	C0087111
28328236	720	730	prevalence	T081	C0033105
28328236	735	743	measured	T080	C0444706
28328236	751	761	percentage	T081	C0439165
28328236	765	785	school-aged children	T100	C2827631
28328236	790	801	adolescents	T100	C0205653
28328236	816	829	calendar year	T079	C0456586
28328236	842	850	criteria	T078	C0243161
28328236	855	864	medically	T169	C0205476
28328236	865	872	managed	T058	C0184516
28328236	873	877	ADHD	T048	C1263846
28328236	890	903	calendar year	T079	C0456586
28328236	905	913	Subjects	T098	C0080105
28328236	919	927	eligible	T080	C1548635
28328236	932	941	inclusion	T080	C1512693
28328236	955	959	aged	T032	C0001779
28328236	965	970	years	T079	C0439234
28328236	980	992	continuously	T078	C0549178
28328236	1011	1024	calendar year	T079	C0456586
28328236	1030	1036	annual	T079	C0332181
28328236	1037	1047	prevalence	T081	C0033105
28328236	1051	1058	treated	T061	C0087111
28328236	1059	1063	ADHD	T048	C1263846
28328236	1070	1090	school-aged children	T100	C2827631
28328236	1095	1106	adolescents	T100	C0205653
28328236	1112	1115	ESI	T081	C3824871
28328236	1116	1125	increased	T081	C0205217
28328236	1178	1186	Medicaid	T058	C0021682
28328236	1190	1199	increased	T081	C0205217
28328236	1268	1274	steady	T080	C0205361
28328236	1299	1306	Treated	T061	C0087111
28328236	1307	1317	prevalence	T081	C0033105
28328236	1321	1325	ADHD	T048	C1263846
28328236	1326	1335	increased	T081	C0205217
28328236	1336	1348	continuously	T078	C0549178
28328236	1354	1358	time	T079	C0040223
28328236	1365	1385	school-aged children	T100	C2827631
28328236	1390	1401	adolescents	T100	C0205653
28328236	1407	1410	ESI	T081	C3824871
28328236	1416	1424	declined	T081	C0205216
28328236	1464	1479	Medicaid sample	T058	C0021682

28096034|t|Twelve months effect of self-referral to inpatient treatment on patient activation, recovery, symptoms and functioning: A randomized controlled study
28096034|a|To investigate the effect of having a contract for self-referral to inpatient treatment (SRIT) in patients with severe mental disorders. A randomized controlled trial with 53 adult patients; 26 participants received a SRIT contract, which they could use to refer themselves into a Community Mental Health Centre up to five days for each referral without contacting a doctor in advance. Outcomes were assessed after 12 months with the self-report questionnaires Patient Activation Measure (PAM-13), Recovery Assessment Scale (RAS), and the Behavior and Symptom Identification Scale (BASIS-32) and analyzed using linear mixed and regression models. There was no significant effect on PAM-13 (estimated mean difference (emd) -0.41, 95% CI (CI):-7.49-6.67), nor on the RAS (emd 0.02, CI:-0.27-0.31) or BASIS-32 (0.09, CI:-0.28-0.45). An exploratory post hoc analysis showed effect of SRIT in those with low PAM below ≤47 (p=0.049). There were no group differences after 12 months, but both groups maintained their baseline levels. SRIT contracts can be recommended as it supports the rights to self-determination, promote user participation in decision-making in own treatment without any indication of adverse effects.
28096034	24	37	self-referral	T058	C0237824
28096034	41	60	inpatient treatment	T058	C0019993
28096034	64	82	patient activation	T058	C3853034
28096034	84	92	recovery	T052	C0237820
28096034	94	102	symptoms	T184	C1457887
28096034	107	118	functioning	T039	C0677610
28096034	122	149	randomized controlled study	T062	C0242481
28096034	188	196	contract	T170	C0332522
28096034	201	237	self-referral to inpatient treatment	T058	C0420403
28096034	239	243	SRIT	T058	C0420403
28096034	248	256	patients	T101	C0030705
28096034	269	285	mental disorders	T048	C0004936
28096034	289	316	randomized controlled trial	T062	C0242481
28096034	325	330	adult	T100	C0001675
28096034	331	339	patients	T101	C0030705
28096034	344	356	participants	T101	C0030705
28096034	368	372	SRIT	T058	C0420403
28096034	373	381	contract	T170	C0332522
28096034	431	461	Community Mental Health Centre	T073,T093	C0338050
28096034	487	495	referral	T058	C0034927
28096034	517	523	doctor	T097	C0031831
28096034	536	544	Outcomes	T169	C1274040
28096034	584	595	self-report	T062	C0681906
28096034	596	610	questionnaires	T170	C0034394
28096034	611	637	Patient Activation Measure	T170	C4075707
28096034	639	645	PAM-13	T170	C4075707
28096034	648	673	Recovery Assessment Scale	T170	C4304837
28096034	675	678	RAS	T170	C4304837
28096034	689	730	Behavior and Symptom Identification Scale	T170	C0450973
28096034	732	740	BASIS-32	T170	C0450973
28096034	761	773	linear mixed	T081	C0023732
28096034	778	795	regression models	T081,T170	C0026348
28096034	832	838	PAM-13	T170	C4075707
28096034	915	918	RAS	T170	C4304837
28096034	948	956	BASIS-32	T170	C0450973
28096034	983	1012	exploratory post hoc analysis	T080	C0205556
28096034	1030	1034	SRIT	T058	C0420403
28096034	1053	1056	PAM	T170	C4075707
28096034	1160	1168	baseline	T081	C1442488
28096034	1169	1175	levels	T080	C0441889
28096034	1177	1181	SRIT	T058	C0420403
28096034	1182	1191	contracts	T170	C0332522
28096034	1240	1258	self-determination	T078	C0036595
28096034	1290	1305	decision-making	T041	C0011109
28096034	1313	1322	treatment	T169	C0039798
28096034	1349	1364	adverse effects	T046	C0879626

27251157|t|Stimulation of cell proliferation by glutathione monoethyl ester in aged bone marrow stromal cells is associated with the assistance of TERT gene expression and telomerase activity
27251157|a|The proliferation and differentiation potential of aged bone marrow stromal cells (BMSCs) are significantly reduced. In order to improve the performance of the aged BMSCs, these cells were treated with 2 mM glutathione monoethyl ester (GSH-MEE) for 24 h. Proliferation rate, telomerase activity, telomere length, and differentiation to cholinergic neuron-like cells (CNLCs) were observed to increase. Though, the expression level of telomerase reverse transcriptase gene increased, but CTC1 and TEN1 genes from Ctc1-Stn1-Ten1 complex encoding proteins with regulatory function significantly decreased. Trypan blue exclusion assay was used to analyze the proliferation and, while telomere length, its several related gene expressions, and telomerase activity were measured using the real time reverse transcription-polymerase chain reaction and polymerase chain reaction enzyme-linked immunosorbent assay techniques, respectively. CNLCs differentiation potential was evaluated by estimating the percentage of choline acetyltransferase immunereactive cells .The results suggested that GSH-MEE could improve aged rat BMSC properties and would be of potential benefit for enhancing the performance of aged people's BMSCs.
27251157	0	11	Stimulation	T169	C1704686
27251157	15	33	cell proliferation	T043	C0596290
27251157	37	64	glutathione monoethyl ester	T116,T121	C0073870
27251157	68	98	aged bone marrow stromal cells	T025	C1640380
27251157	102	117	associated with	T080	C0332281
27251157	136	140	TERT	T028	C1367342
27251157	141	156	gene expression	T045	C0017262
27251157	161	180	telomerase activity	T045	C1148756
27251157	185	198	proliferation	T043	C0596290
27251157	203	218	differentiation	T043	C0007589
27251157	219	228	potential	T080	C3245505
27251157	232	262	aged bone marrow stromal cells	T025	C1640380
27251157	264	269	BMSCs	T025	C1640380
27251157	289	296	reduced	T080	C0392756
27251157	310	317	improve	T033	C0184511
27251157	341	345	aged	T032	C0001779
27251157	346	351	BMSCs	T025	C1640380
27251157	359	364	cells	T025	C0007634
27251157	370	377	treated	T169	C1522326
27251157	388	415	glutathione monoethyl ester	T116,T121	C0073870
27251157	417	424	GSH-MEE	T116,T121	C0073870
27251157	436	449	Proliferation	T043	C0596290
27251157	450	454	rate	T081	C1521828
27251157	456	475	telomerase activity	T045	C1148756
27251157	477	485	telomere	T026	C0085187
27251157	486	492	length	T081	C1444754
27251157	498	513	differentiation	T043	C0007589
27251157	517	546	cholinergic neuron-like cells	T025	C2333949
27251157	548	553	CNLCs	T025	C2333949
27251157	572	580	increase	T169	C0442805
27251157	594	610	expression level	T081	C3244092
27251157	614	651	telomerase reverse transcriptase gene	T028	C1367342
27251157	652	661	increased	T169	C0442805
27251157	667	671	CTC1	T028	C1824460
27251157	676	686	TEN1 genes	T028	C2751072
27251157	692	714	Ctc1-Stn1-Ten1 complex	T026	C0243092
27251157	715	723	encoding	T052	C2700640
27251157	724	732	proteins	T116,T123	C0033684
27251157	738	757	regulatory function	T045	C0017263
27251157	772	781	decreased	T081	C0205216
27251157	783	810	Trypan blue exclusion assay	T059	C0005507
27251157	835	848	proliferation	T043	C0596290
27251157	860	868	telomere	T026	C0085187
27251157	869	875	length	T081	C1444754
27251157	897	913	gene expressions	T045	C0017262
27251157	919	938	telomerase activity	T045	C1148756
27251157	963	1020	real time reverse transcription-polymerase chain reaction	T063	C0599161
27251157	1025	1050	polymerase chain reaction	T063	C0032520
27251157	1051	1095	enzyme-linked immunosorbent assay techniques	T059	C0014441
27251157	1111	1116	CNLCs	T025	C2333949
27251157	1117	1132	differentiation	T043	C0007589
27251157	1133	1142	potential	T080	C3245505
27251157	1189	1214	choline acetyltransferase	T028	C1413376
27251157	1215	1235	immunereactive cells	T025	C0007634
27251157	1264	1271	GSH-MEE	T116,T121	C0073870
27251157	1278	1285	improve	T033	C0184511
27251157	1291	1294	rat	T015	C0034721
27251157	1295	1299	BMSC	T025	C1640380
27251157	1300	1310	properties	T080	C0871161
27251157	1337	1344	benefit	T081	C0814225
27251157	1349	1358	enhancing	T052	C2349975
27251157	1378	1391	aged people's	T098	C0027361
27251157	1392	1397	BMSCs	T025	C1640380

28256192|t|The Insect Pathogens
28256192|a|Fungi are the most common disease-causing agents of insects; aside from playing a crucial role in natural ecosystems, insect -killing fungi are being used as alternatives to chemical insecticides and as resources for biotechnology and pharmaceuticals. Some common experimentally tractable genera, such as Metarhizium spp ., exemplify genetic diversity and dispersal because they contain numerous intraspecific variants with distinct environmental and insect host ranges. The availability of tools for molecular genetics and multiple sequenced genomes has made these fungi ideal experimental models for answering basic questions on the genetic and genomic processes behind adaptive phenotypes. For example, comparative genomics of entomopathogenic fungi has shown they exhibit diverse reproductive modes that often determine rates and patterns of genome evolution and are linked as cause or effect with pathogenic strategies. Fungal - insect pathogens represent lifestyle adaptations that evolved numerous times, and there are significant differences in host range and pathogenic strategies between the major groups. However, typically, spores landing on the cuticle produce appressoria and infection pegs that breach the cuticle using mechanical pressure and cuticle - degrading enzymes. Once inside the insect body cavity, fungal pathogens face a potent and comprehensively studied immune defense by which the host attempts to eliminate or reduce an infection. The Fungal Kingdom stands alone in the range, extent, and complexity of their manipulation of arthropod behavior. In part, this is because most only sporulate on cadavers, so they must ensure the dying host positions itself to allow efficient transmission.
28256192	4	10	Insect	T204	C0021585
28256192	11	20	Pathogens	T001	C0450254
28256192	21	26	Fungi	T004	C0016832
28256192	47	69	disease-causing agents	T169	C0015127
28256192	73	80	insects	T204	C0021585
28256192	119	137	natural ecosystems	T070	C0162358
28256192	139	145	insect	T204	C0021585
28256192	155	160	fungi	T004	C0016832
28256192	195	216	chemical insecticides	T131	C0021576
28256192	224	233	resources	T078	C0035201
28256192	238	251	biotechnology	T091	C0005574
28256192	256	271	pharmaceuticals	T093	C0013185
28256192	285	316	experimentally tractable genera	T185	C1708235
28256192	326	341	Metarhizium spp	T004	C0997671
28256192	355	372	genetic diversity	T070	C0042333
28256192	377	386	dispersal	T067	C1522240
28256192	417	439	intraspecific variants	T080	C0205419
28256192	454	467	environmental	T082	C0014406
28256192	472	478	insect	T204	C0021585
28256192	479	490	host ranges	T070	C2936413
28256192	522	540	molecular genetics	T091	C0086345
28256192	564	571	genomes	T028	C0017428
28256192	587	592	fungi	T004	C0016832
28256192	599	618	experimental models	T170	C0086272
28256192	656	663	genetic	T070	C1136308
28256192	668	685	genomic processes	T070	C1254365
28256192	702	712	phenotypes	T032	C0031437
28256192	739	747	genomics	T091	C0887950
28256192	751	773	entomopathogenic fungi	T004	C0016832
28256192	805	823	reproductive modes	T039	C0442692
28256192	845	850	rates	T081	C1521828
28256192	855	863	patterns	T082	C0449774
28256192	867	873	genome	T028	C0017428
28256192	874	883	evolution	T045	C0015219
28256192	902	907	cause	T169	C0015127
28256192	911	917	effect	T080	C1280500
28256192	923	944	pathogenic strategies	T169	C0543483
28256192	946	952	Fungal	T169	C0521033
28256192	955	961	insect	T204	C0021585
28256192	962	971	pathogens	T001	C0450254
28256192	982	1003	lifestyle adaptations	T038	C0392673
28256192	1047	1058	significant	T078	C0750502
28256192	1059	1070	differences	T081	C1705241
28256192	1074	1084	host range	T070	C2936413
28256192	1089	1110	pathogenic strategies	T169	C0543483
28256192	1129	1135	groups	T078	C0441833
28256192	1157	1163	spores	T001	C0038027
28256192	1179	1186	cuticle	T002	C2699479
28256192	1195	1206	appressoria	T040	C2611330
28256192	1211	1225	infection pegs	T046	C3714514
28256192	1242	1249	cuticle	T002	C2699479
28256192	1256	1275	mechanical pressure	T067	C0596891
28256192	1280	1287	cuticle	T002	C2699479
28256192	1290	1299	degrading	T044	C0314674
28256192	1300	1307	enzymes	T116,T126	C0014442
28256192	1325	1331	insect	T204	C0021585
28256192	1332	1343	body cavity	T030	C0333343
28256192	1345	1361	fungal pathogens	T004	C0016832
28256192	1404	1410	immune	T169	C0439662
28256192	1411	1418	defense	T077	C1880266
28256192	1432	1436	host	T001	C1167395
28256192	1462	1468	reduce	T080	C0392756
28256192	1472	1481	infection	T046	C3714514
28256192	1487	1501	Fungal Kingdom	T004	C0016832
28256192	1522	1527	range	T081	C1514721
28256192	1529	1535	extent	T082	C0439792
28256192	1541	1551	complexity	T080	C0439855
28256192	1561	1573	manipulation	T053	C0018578
28256192	1577	1586	arthropod	T204	C0003903
28256192	1587	1595	behavior	T053	C0004935
28256192	1632	1641	sporulate	T043	C2613267
28256192	1645	1653	cadavers	T017	C0006629
28256192	1679	1684	dying	T040	C0184532
28256192	1685	1689	host	T001	C1167395
28256192	1716	1725	efficient	T080	C0442799
28256192	1726	1738	transmission	T070	C1521797

28062192|t|Direct effects of glucose, insulin, GLP-1, and GIP on bulbospinal neurons in the rostral ventrolateral medulla in neonatal wistar rats
28062192|a|Although patients with diabetes mellitus (DM) often exhibit hypertension, the mechanisms responsible for this correlation are not well known. We hypothesized that the bulbospinal neurons in the rostral ventrolateral medulla (RVLM) are affected by the levels of glucose, insulin, or incretins (glucagon like peptide-1 [GLP-1] or glucose-dependent insulinotropic peptide [GIP]) in patients with DM. To investigate whether RVLM neurons are activated by glucose, insulin, GLP-1, or GIP, we examined changes in the membrane potentials of bulbospinal RVLM neurons using whole-cell patch-clamp technique during superfusion with various levels of glucose or these hormones in neonatal Wistar rats. A brainstem - spinal cord preparation was used for the experiments. A low level of glucose stimulated bulbospinal RVLM neurons. During insulin superfusion, almost all the RVLM neurons were depolarized, while during GLP-1 or GIP superfusion, almost all the RVLM neurons were hyperpolarized. Next, histological examinations were performed to examine transporters for glucose and receptors for insulin, GLP-1, and GIP on RVLM neurons. Low - level glucose - depolarized RVLM neurons exhibited the presence of glucose transporter 3 (GLUT3). Meanwhile, insulin - depolarized, GLP-1 - hyperpolarized, and GIP - hyperpolarized RVLM neurons showed each of the respective specific receptor. These results indicate that a low level of glucose stimulates bulbospinal RVLM neurons via specific transporters on these neurons, inducing hypertension. Furthermore, an increase in insulin or a reduction in incretins may also activate the sympathetic nervous system and induce hypertension by activating RVLM neurons via their own receptors.
28062192	7	17	effects of	T080	C1704420
28062192	18	25	glucose	T109,T121,T123	C0017725
28062192	27	34	insulin	T116,T121,T125	C0021641
28062192	36	41	GLP-1	T116	C0061355
28062192	47	50	GIP	T116,T121,T125	C0017132
28062192	54	65	bulbospinal	T029	C0005898
28062192	66	73	neurons	T025	C0027882
28062192	81	110	rostral ventrolateral medulla	T023	C2328883
28062192	114	122	neonatal	T100	C0021289
28062192	123	134	wistar rats	T015	C0034716
28062192	144	152	patients	T101	C0030705
28062192	158	175	diabetes mellitus	T047	C0011849
28062192	177	179	DM	T047	C0011849
28062192	195	207	hypertension	T047	C0020538
28062192	213	223	mechanisms	T169	C0441712
28062192	245	256	correlation	T080	C1707520
28062192	302	313	bulbospinal	T029	C0005898
28062192	314	321	neurons	T025	C0027882
28062192	329	358	rostral ventrolateral medulla	T023	C2328883
28062192	360	364	RVLM	T023	C2328883
28062192	370	378	affected	T169	C0392760
28062192	386	392	levels	T080	C0441889
28062192	396	403	glucose	T109,T121,T123	C0017725
28062192	405	412	insulin	T116,T121,T125	C0021641
28062192	417	426	incretins	T116,T121,T125	C1562292
28062192	428	451	glucagon like peptide-1	T116	C0061355
28062192	453	458	GLP-1	T116	C0061355
28062192	463	503	glucose-dependent insulinotropic peptide	T116,T121,T125	C0017132
28062192	505	508	GIP	T116,T121,T125	C0017132
28062192	514	522	patients	T101	C0030705
28062192	528	530	DM	T047	C0011849
28062192	535	546	investigate	T169	C1292732
28062192	555	559	RVLM	T023	C2328883
28062192	560	567	neurons	T025	C0027882
28062192	572	581	activated	T052	C1879547
28062192	585	592	glucose	T109,T121,T123	C0017725
28062192	594	601	insulin	T116,T121,T125	C0021641
28062192	603	608	GLP-1	T116	C0061355
28062192	613	616	GIP	T116,T121,T125	C0017132
28062192	630	637	changes	T169	C0392747
28062192	645	664	membrane potentials	T043	C0025251
28062192	668	679	bulbospinal	T029	C0005898
28062192	680	684	RVLM	T023	C2328883
28062192	685	692	neurons	T025	C0027882
28062192	699	709	whole-cell	T025	C0007634
28062192	710	731	patch-clamp technique	T062	C0242625
28062192	739	750	superfusion	T067	C1254366
28062192	764	770	levels	T080	C0441889
28062192	774	781	glucose	T109,T121,T123	C0017725
28062192	791	799	hormones	T125	C0019932
28062192	803	811	neonatal	T100	C0021289
28062192	812	823	Wistar rats	T015	C0034716
28062192	827	836	brainstem	T023	C0006121
28062192	839	850	spinal cord	T023	C0037925
28062192	851	862	preparation	T052	C1521827
28062192	880	891	experiments	T062	C0681814
28062192	895	898	low	T080	C0205251
28062192	899	904	level	T080	C0441889
28062192	908	915	glucose	T109,T121,T123	C0017725
28062192	927	938	bulbospinal	T029	C0005898
28062192	939	943	RVLM	T023	C2328883
28062192	944	951	neurons	T025	C0027882
28062192	960	967	insulin	T116,T121,T125	C0021641
28062192	968	979	superfusion	T067	C1254366
28062192	996	1000	RVLM	T023	C2328883
28062192	1001	1008	neurons	T025	C0027882
28062192	1014	1025	depolarized	T043	C0234081
28062192	1040	1045	GLP-1	T116	C0061355
28062192	1049	1052	GIP	T116,T121,T125	C0017132
28062192	1053	1064	superfusion	T067	C1254366
28062192	1081	1085	RVLM	T023	C2328883
28062192	1086	1093	neurons	T025	C0027882
28062192	1099	1113	hyperpolarized	T043	C0522208
28062192	1121	1146	histological examinations	T059	C0019637
28062192	1173	1197	transporters for glucose	T116,T123	C0017742
28062192	1202	1211	receptors	T116,T192	C0597357
28062192	1216	1223	insulin	T116,T121,T125	C0021641
28062192	1225	1230	GLP-1	T116	C0061355
28062192	1236	1239	GIP	T116,T121,T125	C0017132
28062192	1243	1247	RVLM	T023	C2328883
28062192	1248	1255	neurons	T025	C0027882
28062192	1257	1260	Low	T080	C0205251
28062192	1263	1268	level	T080	C0441889
28062192	1269	1276	glucose	T109,T121,T123	C0017725
28062192	1279	1290	depolarized	T043	C0234081
28062192	1291	1295	RVLM	T023	C2328883
28062192	1296	1303	neurons	T025	C0027882
28062192	1318	1326	presence	T080	C3854307
28062192	1330	1351	glucose transporter 3	T116,T123	C0119484
28062192	1353	1358	GLUT3	T116,T123	C0119484
28062192	1372	1379	insulin	T116,T121,T125	C0021641
28062192	1382	1393	depolarized	T043	C0234081
28062192	1395	1400	GLP-1	T116	C0061355
28062192	1403	1417	hyperpolarized	T043	C0522208
28062192	1423	1426	GIP	T116,T121,T125	C0017132
28062192	1429	1443	hyperpolarized	T043	C0522208
28062192	1444	1448	RVLM	T023	C2328883
28062192	1449	1456	neurons	T025	C0027882
28062192	1487	1495	specific	T080	C0205369
28062192	1496	1504	receptor	T116,T192	C0597357
28062192	1536	1539	low	T080	C0205251
28062192	1540	1545	level	T080	C0441889
28062192	1549	1556	glucose	T109,T121,T123	C0017725
28062192	1557	1567	stimulates	T070	C1948023
28062192	1568	1579	bulbospinal	T029	C0005898
28062192	1580	1584	RVLM	T023	C2328883
28062192	1585	1592	neurons	T025	C0027882
28062192	1597	1605	specific	T080	C0205369
28062192	1606	1618	transporters	T116,T123	C0017742
28062192	1628	1635	neurons	T025	C0027882
28062192	1637	1645	inducing	T169	C0205263
28062192	1646	1658	hypertension	T047	C0020538
28062192	1676	1684	increase	T169	C0442805
28062192	1688	1695	insulin	T116,T121,T125	C0021641
28062192	1701	1710	reduction	T080	C0392756
28062192	1714	1723	incretins	T116,T121,T125	C1562292
28062192	1733	1741	activate	T052	C1879547
28062192	1746	1772	sympathetic nervous system	T022	C0039044
28062192	1777	1783	induce	T169	C0205263
28062192	1784	1796	hypertension	T047	C0020538
28062192	1800	1810	activating	T052	C1879547
28062192	1811	1815	RVLM	T023	C2328883
28062192	1816	1823	neurons	T025	C0027882
28062192	1838	1847	receptors	T116,T192	C0597357

28388882|t|An abdominal ectopic pregnancy following a frozen-thawed ART cycle: a case report and r eview of the literature
28388882|a|Ectopic pregnancy (EP) occurs in 1% of pregnancies and is reported to be more common in in vitro fertilization / intracytoplasmic sperm injection (IVF / ICSI) pregnancies. An abdominal ectopic pregnancy (AEP) is a rare form of EP, and there are few reports of an AEP after IVF / ICSI. In this case report, a rare case of AEP after frozen-thawed cycle of ICSI is presented. After a frozen-thawed cycle of ICSI, the beta-human chorionic gonadotropin (HCG) level at 4 weeks 0 days of gestation was 3.4 IU/L. Subsequent dysfunctional uterine bleeding was mistaken for menstruation; however, an AEP of 9 weeks with a fetal heart beat was observed by ultrasound. After the AEP was observed by ultrasound, it was extracted laparoscopically. A rare case of an AEP, which developed after frozen-thawed cycle of ICSI, presented with a very low serum HCG level. Even if the HCG titer is low, follow-up HCG levels and frequent medical examinations are necessary.
28388882	3	12	abdominal	T029	C0000726
28388882	13	30	ectopic pregnancy	T046	C0032987
28388882	31	40	following	T079	C0332282
28388882	43	66	frozen-thawed ART cycle	T061	C0872104
28388882	70	81	case report	T170	C0085973
28388882	88	111	eview of the literature	T170	C0282441
28388882	112	129	Ectopic pregnancy	T046	C0032987
28388882	130	134	(EP)	T046	C0032987
28388882	151	162	pregnancies	T040	C0032961
28388882	170	178	reported	T170	C0684224
28388882	190	196	common	T081	C0205214
28388882	200	222	in vitro fertilization	T061	C0015915
28388882	225	257	intracytoplasmic sperm injection	T061	C0455164
28388882	259	262	IVF	T061	C0015915
28388882	265	269	ICSI	T061	C0455164
28388882	271	282	pregnancies	T040	C0032961
28388882	287	296	abdominal	T029	C0000726
28388882	297	314	ectopic pregnancy	T046	C0032987
28388882	315	320	(AEP)	T046	C0032987
28388882	326	330	rare	T080	C0522498
28388882	339	341	EP	T046	C0032987
28388882	361	368	reports	T170	C0684224
28388882	375	378	AEP	T046	C0032987
28388882	385	388	IVF	T061	C0015915
28388882	391	395	ICSI	T061	C0455164
28388882	405	416	case report	T170	C0085973
28388882	420	424	rare	T080	C0522498
28388882	425	429	case	T077	C1706256
28388882	433	436	AEP	T046	C0032987
28388882	443	462	frozen-thawed cycle	T061	C0087111
28388882	466	470	ICSI	T061	C0455164
28388882	493	512	frozen-thawed cycle	T061	C0087111
28388882	516	520	ICSI	T061	C0455164
28388882	526	559	beta-human chorionic gonadotropin	T116,T125	C0106132
28388882	560	565	(HCG)	T116,T125	C0106132
28388882	566	571	level	T080	C0441889
28388882	577	582	weeks	T079	C0439230
28388882	585	589	days	T079	C0439228
28388882	593	602	gestation	T040	C0032961
28388882	611	615	IU/L	T081	C0439457
28388882	628	658	dysfunctional uterine bleeding	T046	C0025874
28388882	676	688	menstruation	T040	C0025344
28388882	702	705	AEP	T046	C0032987
28388882	711	716	weeks	T079	C0439230
28388882	724	729	fetal	T018	C0015965
28388882	730	740	heart beat	T042	C0425583
28388882	745	753	observed	T169	C1441672
28388882	757	767	ultrasound	T060	C0041618
28388882	779	782	AEP	T046	C0032987
28388882	787	795	observed	T169	C1441672
28388882	799	809	ultrasound	T060	C0041618
28388882	818	827	extracted	T061	C0185115
28388882	828	844	laparoscopically	T060	C0031150
28388882	848	852	rare	T080	C0522498
28388882	853	857	case	T077	C1706256
28388882	864	867	AEP	T046	C0032987
28388882	891	910	frozen-thawed cycle	T170	C0282574
28388882	914	918	ICSI	T061	C0455164
28388882	920	929	presented	T078	C0449450
28388882	942	945	low	T080	C0205251
28388882	946	951	serum	T031	C0229671
28388882	952	955	HCG	T116,T125	C0106132
28388882	956	961	level	T080	C0441889
28388882	975	978	HCG	T116,T125	C0106132
28388882	979	984	titer	T081	C0475208
28388882	988	991	low	T080	C0205251
28388882	993	1002	follow-up	T058	C1522577
28388882	1003	1006	HCG	T116,T125	C0106132
28388882	1007	1013	levels	T080	C0441889
28388882	1018	1026	frequent	T079	C0332183
28388882	1027	1047	medical examinations	T058	C0582103
28388882	1052	1061	necessary	T080	C3898777

28342010|t|Aridity promotes bet hedging via delayed hatching: a case study with two temporary pond crustaceans along a latitudinal gradient
28342010|a|Climate change does affect not only average rainfall and temperature but also their variation, which can reduce the predictability of suitable conditions for growth and reproduction. This situation is problematic for inhabitants of temporary waters whose reproductive success depends on rainfall and evaporation that determine the length of the aquatic phase. For organisms with long-lived dormant life stages, bet hedging models suggest that a fraction of these should stay dormant during each growing season to buffer against the probability of total reproductive failure in variable environments. Thus far, however, little empirical evidence supports this prediction in aquatic organisms. We study geographic variation in delayed hatching of dormant eggs in natural populations of two crustaceans, Branchinella longirostris and Paralimnadia badia, that occur in temporary rock pools along a 725 km latitudinal aridity gradient in Western Australia. Consistent with bet hedging theory, populations of both species were characterised by delayed hatching under common garden conditions and hatching fractions decreased towards the drier end of the gradient where the probability of reproductive success was shown to be lower. This decrease was most pronounced in the species with the longer maturation time, presumably because it is more sensitive to the higher prevalence of short inundations. Overall, these findings illustrate that regional variation in climate can be reflected in differential investment in bet hedging and hints at a higher importance of delayed hatching to persist when the climate becomes harsher. Such strategies could become exceedingly relevant as determinants of vulnerability under climate change.
28342010	0	7	Aridity	T080	C0205556
28342010	33	40	delayed	T079	C0205421
28342010	41	49	hatching	T040	C0598016
28342010	53	63	case study	T170	C0085973
28342010	73	82	temporary	T079	C0205374
28342010	83	87	pond	T083	C0337048
28342010	88	99	crustaceans	T204	C0010395
28342010	108	128	latitudinal gradient	T081	C0812409
28342010	129	143	Climate change	T070	C2718051
28342010	165	172	average	T081	C1510992
28342010	173	181	rainfall	T070	C0034640
28342010	186	197	temperature	T081	C0039476
28342010	213	222	variation	T080	C0205419
28342010	245	259	predictability	T041	C2371925
28342010	287	293	growth	T040	C0018270
28342010	298	310	reproduction	T040	C0035150
28342010	361	370	temporary	T079	C0205374
28342010	384	404	reproductive success	T040	C0035154
28342010	416	424	rainfall	T070	C0034640
28342010	429	440	evaporation	T070	C0596539
28342010	474	487	aquatic phase	T067	C0563034
28342010	493	502	organisms	T001	C0029235
28342010	508	538	long-lived dormant life stages	T079	C0680083
28342010	552	558	models	T170	C3161035
28342010	574	582	fraction	T081	C1264633
28342010	604	611	dormant	T039	C0678686
28342010	624	638	growing season	T079	C0036497
28342010	661	672	probability	T081	C0033204
28342010	682	702	reproductive failure	T033	C3671958
28342010	706	714	variable	T080	C0439828
28342010	715	727	environments	T082	C0014406
28342010	765	773	evidence	T078	C3887511
28342010	788	798	prediction	T078	C0681842
28342010	802	819	aquatic organisms	T001	C0596121
28342010	824	829	study	T062	C2603343
28342010	830	850	geographic variation	T078	C1171306
28342010	854	861	delayed	T079	C0205421
28342010	862	870	hatching	T040	C0598016
28342010	874	881	dormant	T039	C0678686
28342010	882	886	eggs	T025	C0029974
28342010	890	909	natural populations	T081	C0032659
28342010	917	928	crustaceans	T204	C0010395
28342010	930	955	Branchinella longirostris	T204	C1222854
28342010	960	978	Paralimnadia badia	T204	C4210886
28342010	994	1003	temporary	T079	C0205374
28342010	1042	1049	aridity	T080	C0205556
28342010	1050	1058	gradient	T081	C0812409
28342010	1062	1079	Western Australia	T083	C0043128
28342010	1117	1128	populations	T081	C0032659
28342010	1137	1144	species	T185	C1705920
28342010	1150	1163	characterised	T052	C1880022
28342010	1167	1174	delayed	T079	C0205421
28342010	1175	1183	hatching	T040	C0598016
28342010	1197	1214	garden conditions	T080	C4019428
28342010	1219	1227	hatching	T040	C0598016
28342010	1238	1247	decreased	T081	C0205216
28342010	1277	1285	gradient	T081	C0812409
28342010	1296	1307	probability	T081	C0033204
28342010	1311	1331	reproductive success	T040	C0035154
28342010	1360	1368	decrease	T081	C0547047
28342010	1396	1403	species	T185	C1705920
28342010	1413	1419	longer	T080	C0205166
28342010	1420	1430	maturation	T040	C0678723
28342010	1431	1435	time	T079	C0040223
28342010	1467	1476	sensitive	T169	C0332324
28342010	1484	1501	higher prevalence	T081	C1512456
28342010	1511	1522	inundations	T080	C2346714
28342010	1539	1547	findings	T033	C0243095
28342010	1564	1572	regional	T082	C0205147
28342010	1573	1593	variation in climate	T070	C2718051
28342010	1614	1626	differential	T080	C0443199
28342010	1689	1696	delayed	T079	C0205421
28342010	1697	1705	hatching	T040	C0598016
28342010	1726	1733	climate	T070	C0008946
28342010	1742	1749	harsher	T033	C4068826
28342010	1804	1816	determinants	T169	C1521761
28342010	1820	1833	vulnerability	T033	C1821973
28342010	1840	1854	climate change	T070	C2718051

27886280|t|Starvation - and antibiotics -induced formation of persister cells in Pseudomonas aeruginosa
27886280|a|Planktonic stationary and exponential cultures of Pseudomonas aeruginosa are highly resistant to killing by bactericidal antimicrobials because of the presence of persisters, cells that are multidrug tolerant and play a key role in the recalcitrance of biofilm infections. The aim of this study was to investigate the formation of persister cells in P. aeruginosa stationary vs. exponential cultures using different class antimicrobials. The susceptibilities of P. aeruginosa PAO1 wild-type and mutant strains to antimicrobials were determined by standard microtiter broth dilution method. In order to determine persister formation, dose - and time -dependent killing experiments were performed with antibiotics. Ceftazidime (Cephalosporin) showed little efficacy against either culture. Stationary-phase cells were more tolerant to imipenem (Carbapenem) than exponential cells, leaving a small fraction of persisters at high imipenem concentration in both populations. Polymyxin B (Polymyxin) appeared to be ineffective at low concentrations against both cell populations. Very high polymyxin B concentration completely eradicated exponential cells and regrowth was seen in a stationary population. Stationary cells were more tolerant to tobramycin (Aminoglycoside) than exponential cells but a higher concentration of tobramycin completely eliminated survivors. Ciprofloxacin (Fluoroquinolone) at a low concentration resulted in killing of both cultures of P. aeruginosa, producing persisters that were invulnerable to killing. Stationary cells appear to be somewhat more tolerant than exponential cells in all of these assays. We also showed that nutrient deprivation (serine starvation) regulated by stringent and general stress response, contribute to the increased tolerance of P. aeruginosa exponential and stationary planktonic cells via production of persisters.
27886280	0	10	Starvation	T033	C0038187
27886280	17	28	antibiotics	T195	C0003232
27886280	38	47	formation	T043	C0007613
27886280	51	66	persister cells	T007	C0563199
27886280	70	92	Pseudomonas aeruginosa	T007	C0033809
27886280	93	103	Planktonic	T007,T204	C0032071
27886280	104	139	stationary and exponential cultures	T059	C0430402
27886280	143	165	Pseudomonas aeruginosa	T007	C0033809
27886280	170	186	highly resistant	T169	C0332325
27886280	190	197	killing	T033	C1306577
27886280	201	228	bactericidal antimicrobials	T195	C0003232
27886280	256	266	persisters	T007	C0563199
27886280	268	273	cells	T007	C0563199
27886280	283	301	multidrug tolerant	T033	C0013220
27886280	329	342	recalcitrance	T169	C0205245
27886280	346	353	biofilm	T007	C0081786
27886280	354	364	infections	T046	C3714514
27886280	382	387	study	T170	C0085973
27886280	395	406	investigate	T169	C1292732
27886280	411	420	formation	T043	C0007613
27886280	424	439	persister cells	T007	C0563199
27886280	443	456	P. aeruginosa	T007	C0033809
27886280	457	467	stationary	T059	C0430402
27886280	472	492	exponential cultures	T059	C0430402
27886280	499	508	different	T080	C1705242
27886280	509	514	class	T170	C0456387
27886280	515	529	antimicrobials	T195	C0003232
27886280	535	551	susceptibilities	T169	C1264642
27886280	555	583	P. aeruginosa PAO1 wild-type	T007	C0033809
27886280	588	602	mutant strains	T001	C1518614
27886280	606	620	antimicrobials	T195	C0003232
27886280	640	681	standard microtiter broth dilution method	T059	C2827874
27886280	705	714	persister	T007	C0563199
27886280	715	724	formation	T043	C0007613
27886280	726	730	dose	T081	C1512045
27886280	737	741	time	T079	C0040223
27886280	753	772	killing experiments	T059	C0022885
27886280	778	787	performed	T169	C0884358
27886280	793	804	antibiotics	T195	C0003232
27886280	806	817	Ceftazidime	T109,T195	C0007559
27886280	819	832	Cephalosporin	T109,T195	C3536856
27886280	848	856	efficacy	T080	C1280519
27886280	872	879	culture	T059	C0430402
27886280	881	903	Stationary-phase cells	T007	C0563199
27886280	914	922	tolerant	T033	C0013220
27886280	926	934	imipenem	T109,T195	C0020933
27886280	936	946	Carbapenem	T109,T195	C0006968
27886280	953	970	exponential cells	T007	C0563199
27886280	988	999	fraction of	T081	C1264633
27886280	1000	1010	persisters	T007	C0563199
27886280	1014	1018	high	T080	C0205250
27886280	1019	1027	imipenem	T109,T195	C0020933
27886280	1028	1041	concentration	T081	C0392762
27886280	1050	1061	populations	T098	C1257890
27886280	1063	1074	Polymyxin B	T116,T195	C0032535
27886280	1076	1085	Polymyxin	T116,T195	C0032539
27886280	1117	1135	low concentrations	T081	C0392762
27886280	1149	1165	cell populations	T098	C1257890
27886280	1177	1188	polymyxin B	T116,T195	C0032535
27886280	1189	1202	concentration	T081	C0392762
27886280	1225	1242	exponential cells	T007	C0563199
27886280	1247	1255	regrowth	T169	C0205245
27886280	1270	1291	stationary population	T098	C1257890
27886280	1293	1309	Stationary cells	T007	C0563199
27886280	1320	1328	tolerant	T033	C0013220
27886280	1332	1342	tobramycin	T109,T195	C0040341
27886280	1344	1358	Aminoglycoside	T109,T121	C0002556
27886280	1365	1382	exponential cells	T007	C0563199
27886280	1389	1409	higher concentration	T081	C0392762
27886280	1413	1423	tobramycin	T109,T195	C0040341
27886280	1435	1445	eliminated	T080	C0849355
27886280	1446	1455	survivors	T078	C0441833
27886280	1457	1470	Ciprofloxacin	T109,T121	C0008809
27886280	1472	1487	Fluoroquinolone	T109,T121	C0949665
27886280	1494	1511	low concentration	T081	C0392762
27886280	1524	1531	killing	T033	C1306577
27886280	1540	1548	cultures	T059	C0430402
27886280	1552	1565	P. aeruginosa	T007	C0033809
27886280	1577	1587	persisters	T007	C0563199
27886280	1614	1621	killing	T033	C1306577
27886280	1623	1639	Stationary cells	T007	C0563199
27886280	1667	1675	tolerant	T033	C0013220
27886280	1681	1698	exponential cells	T007	C0563199
27886280	1715	1721	assays	T059	C0005507
27886280	1743	1751	nutrient	T168	C0678695
27886280	1752	1763	deprivation	T080	C0871712
27886280	1765	1771	serine	T116,T121,T123	C0036720
27886280	1772	1782	starvation	T033	C0038187
27886280	1797	1834	stringent and general stress response	T039	C0149784
27886280	1854	1873	increased tolerance	T033	C0151956
27886280	1877	1890	P. aeruginosa	T007	C0033809
27886280	1891	1934	exponential and stationary planktonic cells	T007	C0563199
27886280	1939	1949	production	T043	C0007613
27886280	1953	1963	persisters	T007	C0563199

27422746|t|The blood lipid regulation of Monascus -produced monascin and ankaflavin via the suppression of low-density lipoprotein cholesterol assembly and stimulation of apolipoprotein A1 expression in the liver
27422746|a|Monascin (MS) and ankaflavin (AK) produced by Monascus purpureus NTU 568 were proven to show excellent hypolipidemic effects in our previous studies; however, the mechanism is still unclear. This study used MS, AK, and monacolin K as test substances and performed tests on rats fed high-fat and high-cholesterol diet for 8 weeks. The lipid levels and the related protein levels of the rats were assessed to understand the effects of MS, AK, and monacolin K on lipid metabolism. MS and AK lowered low-density lipoprotein cholesterol (LDL-C) and preserved high-density lipoprotein cholesterol contents. MS and AK inhibited acetyl-coenzyme A acetyltransferase, microsomal triglyceride transfer protein, and apolipoprotein (apo) B-100 expression, thereby preventing LDL assembly. In addition, enhanced LDL - receptor expression increased the transport of LDL-C to the liver for metabolism. MS and AK also significantly increase apo A1 expression, which facilitates high-density lipoprotein cholesterol formation. Monascus - fermented MS and AK can perform blood lipid regulation via the suppression of LDL-C assembly and stimulation of apo A1 expression in liver.
27422746	4	26	blood lipid regulation	T043	C1158445
27422746	30	38	Monascus	T004	C0997448
27422746	49	57	monascin	T109	C1871155
27422746	62	72	ankaflavin	T109,T123	C1568221
27422746	81	92	suppression	T040	C0301625
27422746	96	131	low-density lipoprotein cholesterol	T109,T123	C0023824
27422746	145	156	stimulation	T061	C1292856
27422746	160	177	apolipoprotein A1	T116,T123	C0085201
27422746	178	188	expression	T045	C1171362
27422746	196	201	liver	T023	C0023884
27422746	202	210	Monascin	T109	C1871155
27422746	212	214	MS	T109	C1871155
27422746	220	230	ankaflavin	T109,T123	C1568221
27422746	232	234	AK	T109,T123	C1568221
27422746	248	274	Monascus purpureus NTU 568	T004	C0997449
27422746	305	326	hypolipidemic effects	T033	C0243095
27422746	343	350	studies	T062	C2603343
27422746	365	374	mechanism	T044	C0678659
27422746	398	403	study	T062	C2603343
27422746	409	411	MS	T109	C1871155
27422746	413	415	AK	T109,T123	C1568221
27422746	421	432	monacolin K	T109,T121	C0024027
27422746	436	451	test substances	T167	C0439861
27422746	456	465	performed	T169	C0884358
27422746	466	471	tests	T170	C0392366
27422746	475	479	rats	T015	C0034721
27422746	484	492	high-fat	T061	C0521974
27422746	497	518	high-cholesterol diet	T061	C3661832
27422746	587	591	rats	T015	C0034721
27422746	597	605	assessed	T052	C1516048
27422746	624	634	effects of	T080	C1704420
27422746	635	637	MS	T109	C1871155
27422746	639	641	AK	T109,T123	C1568221
27422746	647	658	monacolin K	T109,T121	C0024027
27422746	680	682	MS	T109	C1871155
27422746	687	689	AK	T109,T123	C1568221
27422746	698	733	low-density lipoprotein cholesterol	T109,T123	C0023824
27422746	735	740	LDL-C	T109,T123	C0023824
27422746	756	792	high-density lipoprotein cholesterol	T109,T123	C0023822
27422746	803	805	MS	T109	C1871155
27422746	810	812	AK	T109,T123	C1568221
27422746	813	822	inhibited	T080	C0311403
27422746	823	858	acetyl-coenzyme A acetyltransferase	T116,T126	C0001019
27422746	860	900	microsomal triglyceride transfer protein	T116,T126	C0207079
27422746	906	932	apolipoprotein (apo) B-100	T116,T123	C0205666
27422746	933	943	expression	T045	C1171362
27422746	964	967	LDL	T109,T123	C0023823
27422746	968	976	assembly	T044	C0872376
27422746	1000	1003	LDL	T109,T123	C0023823
27422746	1006	1025	receptor expression	T045	C0597360
27422746	1040	1049	transport	T043	C0005528
27422746	1053	1058	LDL-C	T109,T123	C0023824
27422746	1066	1071	liver	T023	C0023884
27422746	1076	1086	metabolism	T040	C0025519
27422746	1088	1090	MS	T109	C1871155
27422746	1095	1097	AK	T109,T123	C1568221
27422746	1103	1125	significantly increase	T169	C0442805
27422746	1126	1132	apo A1	T116,T123	C0085201
27422746	1133	1143	expression	T045	C1171362
27422746	1163	1199	high-density lipoprotein cholesterol	T109,T123	C0023822
27422746	1211	1219	Monascus	T004	C0997448
27422746	1222	1231	fermented	T044	C0015852
27422746	1232	1234	MS	T109	C1871155
27422746	1239	1241	AK	T109,T123	C1568221
27422746	1246	1253	perform	T169	C0884358
27422746	1254	1276	blood lipid regulation	T043	C1158445
27422746	1285	1296	suppression	T040	C0301625
27422746	1300	1305	LDL-C	T109,T123	C0023824
27422746	1306	1314	assembly	T044	C0872376
27422746	1319	1330	stimulation	T061	C1292856
27422746	1334	1340	apo A1	T116,T123	C0085201
27422746	1341	1351	expression	T045	C1171362
27422746	1355	1360	liver	T023	C0023884

27898362|t|Psychogenic non-epileptic seizure in patients with intellectual disability with special focus on choice of therapeutic intervention
27898362|a|There have been a number of studies exploring treatments for psychogenic non-epileptic seizure (PNES) but largely neglecting the sizable subgroup of patients with intellectual disability (ID). In the present study, we attempted to demonstrate effects and preferred modes of therapeutic intervention in PNES patients with ID being treated at a Japanese municipal center with a short referral chain. We examined 46 PNES patients with ID (ID group) and 106 PNES patients without ID (non-ID group) retrospectively in case charts. In addition to examining basic demographic and clinical data, effects of different therapeutic intervention were examined as a function of decrease or disappearance of PNES attacks in the ID group. Age at the first visit as well as PNES onset was younger in the ID than in the non-ID group (t=2.651, p=0.009; t=3.528, p=0.001, respectively). PNES -free ratio at the last visit tended to be higher in the non-ID group (chi square =3.455; p=0.063). Psychosis was more often encountered in the ID group (chi square =13.443; p=0.001). Although cognitive therapy and pharmaco-therapeutic approaches were quite similarly distributed in both groups, environmental adjustment was often introduced in the ID group (44%) as compared to the non-ID group (15%) (chi square =14.299; p=0.001). Brief weekly visit service is also more often utilized by the patients with ID (54%) than by those without ID (35%) (chi square =5.021, p=0.025). Optimal treatment approaches in this sizable patient subgroup should be the subject of future prospective studies.
27898362	0	33	Psychogenic non-epileptic seizure	T048	C1142430
27898362	37	45	patients	T101	C0030705
27898362	51	74	intellectual disability	T048	C3714756
27898362	97	103	choice	T052	C1707391
27898362	107	131	therapeutic intervention	T061	C0808232
27898362	160	167	studies	T062	C2603343
27898362	178	188	treatments	T061	C0087111
27898362	193	226	psychogenic non-epileptic seizure	T048	C1142430
27898362	228	232	PNES	T048	C1142430
27898362	246	256	neglecting	T033	C0243095
27898362	269	277	subgroup	T185	C1515021
27898362	281	289	patients	T101	C0030705
27898362	295	318	intellectual disability	T048	C3714756
27898362	320	322	ID	T048	C3714756
27898362	332	339	present	T079	C0521116
27898362	340	345	study	T062	C2603343
27898362	350	359	attempted	T051	C1516084
27898362	363	374	demonstrate	T169	C0205319
27898362	375	382	effects	T080	C1704420
27898362	387	396	preferred	T078	C0558295
27898362	406	430	therapeutic intervention	T061	C0808232
27898362	434	438	PNES	T048	C1142430
27898362	439	447	patients	T101	C0030705
27898362	453	455	ID	T048	C3714756
27898362	462	469	treated	T169	C1522326
27898362	475	500	Japanese municipal center	T093	C1708333
27898362	508	513	short	T081	C1806781
27898362	514	528	referral chain	T058	C0034927
27898362	533	541	examined	T033	C0332128
27898362	545	549	PNES	T048	C1142430
27898362	550	558	patients	T101	C0030705
27898362	564	566	ID	T048	C3714756
27898362	568	570	ID	T048	C3714756
27898362	571	576	group	T078	C0441833
27898362	586	590	PNES	T048	C1142430
27898362	591	599	patients	T101	C0030705
27898362	608	610	ID	T048	C3714756
27898362	612	618	non-ID	T033	C0243095
27898362	619	624	group	T078	C0441833
27898362	626	641	retrospectively	T080	C1514923
27898362	645	656	case charts	T170	C3842891
27898362	658	672	In addition to	T169	C0332287
27898362	673	682	examining	T033	C0332128
27898362	689	700	demographic	T090	C0011298
27898362	705	718	clinical data	T170	C1516606
27898362	720	730	effects of	T080	C1704420
27898362	731	740	different	T080	C1705242
27898362	741	765	therapeutic intervention	T061	C0808232
27898362	771	779	examined	T033	C0332128
27898362	785	793	function	T169	C0542341
27898362	797	805	decrease	T081	C0547047
27898362	809	822	disappearance	T079	C2746065
27898362	826	830	PNES	T048	C1142430
27898362	846	848	ID	T048	C3714756
27898362	849	854	group	T078	C0441833
27898362	856	859	Age	T032	C0001779
27898362	873	878	visit	T058	C1512346
27898362	890	894	PNES	T048	C1142430
27898362	895	900	onset	T080	C0332162
27898362	905	912	younger	T079	C0332239
27898362	920	922	ID	T048	C3714756
27898362	935	941	non-ID	T033	C0243095
27898362	942	947	group	T078	C0441833
27898362	1000	1004	PNES	T048	C1142430
27898362	1011	1016	ratio	T081	C0456603
27898362	1029	1034	visit	T058	C1512346
27898362	1048	1054	higher	T080	C0205250
27898362	1062	1068	non-ID	T033	C0243095
27898362	1069	1074	group	T078	C0441833
27898362	1069	1074	group	T078	C0441833
27898362	1076	1086	chi square	T081	C1552646
27898362	1105	1114	Psychosis	T048	C0033975
27898362	1149	1151	ID	T048	C3714756
27898362	1152	1157	group	T078	C0441833
27898362	1159	1169	chi square	T081	C1552646
27898362	1198	1215	cognitive therapy	T061	C0009244
27898362	1220	1240	pharmaco-therapeutic	T061	C0013216
27898362	1263	1272	similarly	T080	C2348205
27898362	1273	1284	distributed	T169	C1704711
27898362	1293	1299	groups	T078	C0441833
27898362	1301	1314	environmental	T082	C0014406
27898362	1315	1325	adjustment	T169	C0456081
27898362	1336	1346	introduced	T169	C1292748
27898362	1354	1356	ID	T048	C3714756
27898362	1357	1362	group	T078	C0441833
27898362	1372	1380	compared	T052	C1707455
27898362	1388	1394	non-ID	T033	C0243095
27898362	1395	1400	group	T078	C0441833
27898362	1408	1418	chi square	T081	C1552646
27898362	1438	1443	Brief	T079	C1879313
27898362	1444	1450	weekly	T079	C0332174
27898362	1451	1464	visit service	T058	C1512346
27898362	1484	1492	utilized	T169	C0042153
27898362	1500	1508	patients	T101	C0030705
27898362	1514	1516	ID	T048	C3714756
27898362	1545	1547	ID	T048	C3714756
27898362	1555	1565	chi square	T081	C1552646
27898362	1584	1591	Optimal	T080	C2698651
27898362	1592	1601	treatment	T061	C0087111
27898362	1629	1636	patient	T101	C0030705
27898362	1637	1645	subgroup	T185	C1515021
27898362	1660	1667	subject	T078	C1706203
27898362	1671	1677	future	T079	C0016884
27898362	1678	1697	prospective studies	T062	C0033522

27272523|t|Intron Derived Size Polymorphism in the Mitochondrial Genomes of Closely Related Chrysoporthe Species
27272523|a|In this study, the complete mitochondrial (mt) genomes of Chrysoporthe austroafricana (190,834 bp), C. cubensis (89,084 bp) and C. deuterocubensis (124,412 bp) were determined. Additionally, the mitochondrial genome of another member of the Cryphonectriaceae, namely Cryphonectria parasitica (158,902 bp), was retrieved and annotated for comparative purposes. These genomes showed high levels of synteny, especially in regions including genes involved in oxidative phosphorylation and electron transfer, unique open reading frames (uORFs), ribosomal RNAs (rRNAs) and transfer RNAs (tRNAs), as well as intron positions. Comparative analyses revealed signatures of duplication events, intron number and length variation, and varying intronic ORFs which highlighted the genetic diversity of mt genomes among the Cryphonectriaceae. These mt genomes showed remarkable size polymorphism. The size polymorphism in the mt genomes of these closely related Chrysoporthe species was attributed to the varying number and length of introns, coding sequences and to a lesser extent, intergenic sequences. Compared to publicly available fungal mt genomes, the C. austroafricana mt genome is the second largest in the Ascomycetes thus far.
27272523	0	6	Intron	T114,T123	C0021920
27272523	7	14	Derived	T080	C1441547
27272523	15	19	Size	T082	C0456389
27272523	20	32	Polymorphism	T045	C0032529
27272523	40	61	Mitochondrial Genomes	T028	C1819716
27272523	65	80	Closely Related	T080	C0439849
27272523	81	101	Chrysoporthe Species	T004	C1633289
27272523	121	129	complete	T080	C0205197
27272523	130	156	mitochondrial (mt) genomes	T028	C1819716
27272523	160	187	Chrysoporthe austroafricana	T004	C1907678
27272523	202	213	C. cubensis	T004	C1641019
27272523	230	248	C. deuterocubensis	T004	C3717325
27272523	267	277	determined	T080	C0521095
27272523	297	317	mitochondrial genome	T028	C1819716
27272523	343	360	Cryphonectriaceae	T004	C1947056
27272523	369	393	Cryphonectria parasitica	T004	C0997457
27272523	412	421	retrieved	T080	C0205556
27272523	426	435	annotated	T080	C1552720
27272523	440	460	comparative purposes	T062	C0683941
27272523	468	475	genomes	T028	C0017428
27272523	498	505	synteny	T044	C0314656
27272523	521	528	regions	T082	C1254362
27272523	529	538	including	T169	C0332257
27272523	539	544	genes	T028	C0017337
27272523	545	556	involved in	T169	C1314939
27272523	557	582	oxidative phosphorylation	T044	C0030013
27272523	587	604	electron transfer	T044	C0013846
27272523	606	632	unique open reading frames	T028	C0079941
27272523	633	640	(uORFs)	T028	C0079941
27272523	642	656	ribosomal RNAs	T114,T123	C0035701
27272523	657	664	(rRNAs)	T114,T123	C0035701
27272523	669	682	transfer RNAs	T114,T123	C0035711
27272523	683	690	(tRNAs)	T114,T123	C0035711
27272523	703	709	intron	T114,T123	C0021920
27272523	710	719	positions	T082	C0733755
27272523	721	741	Comparative analyses	T062	C0683941
27272523	742	750	revealed	T080	C0443289
27272523	751	761	signatures	T169	C1708225
27272523	765	776	duplication	T045	C0017261
27272523	777	783	events	T051	C0441471
27272523	785	791	intron	T114,T123	C0021920
27272523	792	819	number and length variation	T070	C0042333
27272523	825	832	varying	T070	C0042333
27272523	833	841	intronic	T114,T123	C0021920
27272523	842	846	ORFs	T028	C0079941
27272523	869	886	genetic diversity	T070	C0042333
27272523	890	900	mt genomes	T028	C1819716
27272523	911	928	Cryphonectriaceae	T004	C1947056
27272523	936	946	mt genomes	T028	C1819716
27272523	965	969	size	T082	C0456389
27272523	970	982	polymorphism	T045	C0032529
27272523	988	992	size	T082	C0456389
27272523	993	1005	polymorphism	T045	C0032529
27272523	1013	1023	mt genomes	T028	C1819716
27272523	1033	1048	closely related	T080	C0439849
27272523	1049	1069	Chrysoporthe species	T004	C1633289
27272523	1092	1117	varying number and length	T070	C0042333
27272523	1121	1128	introns	T114,T123	C0021920
27272523	1130	1146	coding sequences	T028	C0079941
27272523	1156	1162	lesser	T080	C0547044
27272523	1163	1169	extent	T082	C0439792
27272523	1171	1191	intergenic sequences	T114,T123	C0887857
27272523	1193	1201	Compared	T052	C1707455
27272523	1224	1230	fungal	T169	C0521033
27272523	1231	1241	mt genomes	T028	C1819716
27272523	1247	1264	C. austroafricana	T004	C1907678
27272523	1265	1274	mt genome	T028	C1819716
27272523	1289	1296	largest	T081	C0443228
27272523	1304	1315	Ascomycetes	T004	C1960228

27627778|t|Gelsolin in Onychophora and Tardigrada with notes on its variability in the Ecdysozoa
27627778|a|Rearrangements of the filamentous actin network involve a broad range of actin binding proteins. Among these, the gelsolin proteins sever actin filaments, cap their fast growing end and nucleate actin assembly in a calcium - dependent manner. Here, we focus on the gelsolin of the onychophoran Peripatoides novaezealandiae and the eutardigrade Hypsibius dujardini. From the cDNA of P. novaezealandiae we obtained the complete coding sequence with an open reading frame of 2178 bp. It encodes a protein of 726 amino acids with a calculated molecular mass of 82,610.9Da and a pI of 5.57. This sequence is comprised of six segments (S1-S6). However, analysis of data from TardiBase reveals that the gelsolin of the eutardigrade Hypsibius dujardini has only three segments (S1-S3). The coding sequence consist of 1119 bp for 373 amino acids with a calculated molecular mass of 42,440.95Da and a pI of 6.17. The Peripatoides and Hypsibius gelsolin revealed both conserved binding motifs for G-actin, F-actin and phosphatidylinositol 4,5-bisphosphate (PIP2), along with a full set of type-1 and type-2 Ca(2+) - binding sites which could result in the binding of eight and four calcium ions, respectively. Both gelsolin proteins lack a C-terminal latch-helix indicating a more rapid activation in the submicromolar Ca(2+) range. We suggest that a gelsolin with three segments was present in the last common ancestor of the ecdysozoan clade Panarthropoda (Onychophora, Tardigrada, Arthropoda), primarily because the gelsolin of all non-Ecdysozoa studied so far (except Chordata) reveals this number of segments. Mapping of our molecular data onto a well-established phylogeny revealed that the number of gelsolin segments does not correlate with the phylogenetic lineage but rather with particular functional demands to alter the kinetics of actin polymerization.
27627778	0	8	Gelsolin	T116,T123	C0061187
27627778	12	23	Onychophora	T204	C1001576
27627778	28	38	Tardigrada	T204	C1010027
27627778	57	68	variability	T077	C2827666
27627778	76	85	Ecdysozoa	T204	C3578917
27627778	86	100	Rearrangements	T067	C0596965
27627778	108	133	filamentous actin network	T116,T123	C1180307
27627778	150	155	range	T081	C1514721
27627778	159	181	actin binding proteins	T116,T123	C0001239
27627778	200	217	gelsolin proteins	T116,T123	C0061187
27627778	224	239	actin filaments	T026	C0025979
27627778	251	263	fast growing	T033	C4086299
27627778	272	280	nucleate	T044	C1155976
27627778	281	295	actin assembly	T043	C2610250
27627778	301	308	calcium	T121,T123,T196	C0006675
27627778	311	320	dependent	T080	C0851827
27627778	351	359	gelsolin	T116,T123	C0061187
27627778	367	379	onychophoran	T204	C1001576
27627778	380	408	Peripatoides novaezealandiae	T204	C1083155
27627778	417	429	eutardigrade	T204	C1010027
27627778	430	449	Hypsibius dujardini	T204	C1465325
27627778	460	464	cDNA	T114	C0006556
27627778	468	486	P. novaezealandiae	T204	C1083155
27627778	490	498	obtained	T169	C1301820
27627778	512	527	coding sequence	T028	C0079941
27627778	536	554	open reading frame	T028	C0079941
27627778	563	565	bp	T044	C0600436
27627778	570	577	encodes	T052	C2700640
27627778	580	587	protein	T116,T123	C0033684
27627778	595	606	amino acids	T116,T121,T123	C0002520
27627778	614	624	calculated	T052	C1441506
27627778	625	639	molecular mass	T081	C3152252
27627778	677	685	sequence	T087	C0002518
27627778	689	698	comprised	T052	C2700400
27627778	706	714	segments	T082	C0441635
27627778	733	741	analysis	T062	C0936012
27627778	745	749	data	T078	C1511726
27627778	755	764	TardiBase	T170	C0242356
27627778	765	772	reveals	T080	C0443289
27627778	782	790	gelsolin	T116,T123	C0061187
27627778	798	810	eutardigrade	T204	C1010027
27627778	811	830	Hypsibius dujardini	T204	C1465325
27627778	846	854	segments	T082	C0441635
27627778	868	883	coding sequence	T028	C0079941
27627778	900	902	bp	T044	C0600436
27627778	911	922	amino acids	T116,T121,T123	C0002520
27627778	930	940	calculated	T052	C1441506
27627778	941	955	molecular mass	T081	C3152252
27627778	993	1005	Peripatoides	T204	C1014425
27627778	1010	1019	Hypsibius	T204	C1481832
27627778	1020	1028	gelsolin	T116,T123	C0061187
27627778	1029	1037	revealed	T080	C0443289
27627778	1043	1052	conserved	T086	C0009802
27627778	1053	1067	binding motifs	T116,T123	C1956035
27627778	1072	1079	G-actin	T116,T123	C0016890
27627778	1081	1088	F-actin	T116,T123	C1180307
27627778	1093	1130	phosphatidylinositol 4,5-bisphosphate	T109,T123	C0070798
27627778	1132	1136	PIP2	T109,T123	C0070798
27627778	1164	1170	type-1	T192	C0005456
27627778	1175	1181	type-2	T192	C0005456
27627778	1182	1188	Ca(2+)	T121,T196	C0596235
27627778	1191	1204	binding sites	T192	C0005456
27627778	1217	1223	result	T169	C1274040
27627778	1231	1238	binding	T044	C1167622
27627778	1257	1269	calcium ions	T121,T196	C0596235
27627778	1290	1307	gelsolin proteins	T116,T123	C0061187
27627778	1308	1312	lack	T080	C0332268
27627778	1315	1325	C-terminal	T087	C1514562
27627778	1326	1337	latch-helix	T082	C1704821
27627778	1356	1361	rapid	T080	C0456962
27627778	1362	1372	activation	T052	C1879547
27627778	1394	1406	Ca(2+) range	T059	C0201925
27627778	1426	1434	gelsolin	T116,T123	C0061187
27627778	1446	1454	segments	T082	C0441635
27627778	1459	1466	present	T033	C0150312
27627778	1486	1494	ancestor	T099	C0870134
27627778	1502	1512	ecdysozoan	T204	C3578917
27627778	1519	1532	Panarthropoda	T204	C1039396
27627778	1534	1545	Onychophora	T204	C1001576
27627778	1547	1557	Tardigrada	T204	C1010027
27627778	1559	1569	Arthropoda	T204	C0003903
27627778	1572	1581	primarily	T080	C0205225
27627778	1594	1602	gelsolin	T116,T123	C0061187
27627778	1624	1631	studied	T062	C2603343
27627778	1647	1655	Chordata	T008	C0920312
27627778	1657	1664	reveals	T080	C0443289
27627778	1680	1688	segments	T082	C0441635
27627778	1690	1697	Mapping	T059	C0030944
27627778	1705	1719	molecular data	T170	C0026382
27627778	1727	1743	well-established	T080	C0443211
27627778	1744	1753	phylogeny	T078	C0031797
27627778	1754	1762	revealed	T080	C0443289
27627778	1782	1790	gelsolin	T116,T123	C0061187
27627778	1791	1799	segments	T082	C0441635
27627778	1809	1818	correlate	T080	C1707520
27627778	1828	1840	phylogenetic	T078	C0031797
27627778	1841	1848	lineage	T077	C1881379
27627778	1876	1886	functional	T169	C0205245
27627778	1898	1903	alter	T169	C0392747
27627778	1908	1916	kinetics	T070	C0022702
27627778	1920	1940	actin polymerization	T043	C1155982

28520661|t|Traumatic Brain Injury and Depression in a Community - Based Sample: A Cohort Study Across the Adult Life Span
28520661|a|To determine whether self-reported traumatic brain injuries (TBIs) are associated with " cases " of clinically significant depression in the general community. To examine interactions between variables previously linked to depression after a TBI. Population -based community study (Canberra and Queanbeyan, Australia). Three age cohorts: young, middle-aged, and older adults (aged 20-24, 40-44, and 60-64 years at baseline) randomly selected from the electoral roll and followed across 3 waves (4 years apart). A total of 7397, 6621, and 6042 people provided their TBI history in waves 1 to 3. Lifetime (TBIlifetime: sustained at any time since birth), recent (TBIrecent: in the preceding 4 years), and multiple (TBImultiple: more than 1) TBIs, current depression, and known risk factors for depression (age, sex, marital / employment status, prior history of depression, medical conditions, recent life events, alcohol consumption, social support, physical activity). Generalized estimating equations demonstrated a significant association between sustaining a TBI and experiencing clinically significant depression (cases), even after controlling for multiple demographic and health / lifestyle factors. There is an enduring association between depression and TBI, suggesting that, following a TBI, individuals should be monitored and supported to optimize their long-term psychological health.
28520661	0	22	Traumatic Brain Injury	T037	C0876926
28520661	27	37	Depression	T048	C0011570
28520661	43	52	Community	T096	C0009462
28520661	55	60	Based	T169	C1527178
28520661	71	83	Cohort Study	T081	C0009247
28520661	95	100	Adult	T100	C0001675
28520661	101	110	Life Span	T102	C0870809
28520661	146	170	traumatic brain injuries	T037	C0876926
28520661	172	176	TBIs	T037	C0876926
28520661	182	197	associated with	T080	C0332281
28520661	200	205	cases	T077	C1706256
28520661	211	233	clinically significant	T033	C2826293
28520661	234	244	depression	T048	C0011570
28520661	252	269	general community	T096	C0009462
28520661	282	294	interactions	T169	C1704675
28520661	303	312	variables	T081	C1705098
28520661	334	344	depression	T048	C0011570
28520661	353	356	TBI	T037	C0876926
28520661	358	368	Population	T098	C1257890
28520661	376	385	community	T096	C0009462
28520661	386	391	study	T062	C2603343
28520661	393	401	Canberra	T083	C0454764
28520661	406	416	Queanbeyan	UnknownType	C0681784
28520661	418	427	Australia	T083	C0004340
28520661	430	435	Three	T081	C0205449
28520661	436	447	age cohorts	T098	C2348001
28520661	449	454	young	T079	C0332239
28520661	456	467	middle-aged	T100	C0205847
28520661	473	478	older	T098	C0001792
28520661	479	485	adults	T100	C0001675
28520661	487	491	aged	T032	C0001779
28520661	510	521	60-64 years	T100	C4035747
28520661	525	533	baseline	T081	C1442488
28520661	535	543	randomly	T080	C0439605
28520661	544	552	selected	T052	C1707391
28520661	581	589	followed	T079	C0332283
28520661	608	619	years apart	T079	C0439234
28520661	654	660	people	T098	C0027361
28520661	676	679	TBI	T037	C0876926
28520661	705	713	Lifetime	T079	C4071830
28520661	728	737	sustained	T169	C0443318
28520661	745	749	time	T079	C0040223
28520661	750	755	since	T079	C1711239
28520661	756	761	birth	T040	C0005615
28520661	764	770	recent	T079	C0332185
28520661	790	799	preceding	T079	C0332152
28520661	802	807	years	T079	C0439234
28520661	814	822	multiple	T081	C0439064
28520661	850	854	TBIs	T037	C0876926
28520661	856	863	current	T079	C0521116
28520661	864	874	depression	T048	C0011570
28520661	886	898	risk factors	T033	C0035648
28520661	903	913	depression	T048	C0011570
28520661	915	918	age	T032	C0001779
28520661	920	923	sex	T032	C0079399
28520661	925	932	marital	T102	C0024819
28520661	935	952	employment status	T033	C0242271
28520661	954	967	prior history	T033	C2133631
28520661	971	981	depression	T048	C0011570
28520661	983	1001	medical conditions	T033	C0243095
28520661	1010	1021	life events	T051	C0441471
28520661	1023	1042	alcohol consumption	T055	C0001948
28520661	1044	1058	social support	T054	C0037438
28520661	1060	1077	physical activity	T056	C0026606
28520661	1103	1112	equations	T077	C0552449
28520661	1140	1151	association	T080	C0439849
28520661	1173	1176	TBI	T037	C0876926
28520661	1194	1216	clinically significant	T033	C2826293
28520661	1217	1227	depression	T048	C0011570
28520661	1229	1234	cases	T077	C1706256
28520661	1248	1259	controlling	T067	C2239193
28520661	1264	1272	multiple	T081	C0439064
28520661	1273	1284	demographic	T078	C0011292
28520661	1289	1295	health	T078	C0018684
28520661	1298	1307	lifestyle	T054	C0023676
28520661	1308	1315	factors	T169	C1521761
28520661	1338	1349	association	T080	C0439849
28520661	1358	1368	depression	T048	C0011570
28520661	1373	1376	TBI	T037	C0876926
28520661	1407	1410	TBI	T037	C0876926
28520661	1412	1423	individuals	T098	C0237401
28520661	1434	1443	monitored	T097	C1521743
28520661	1476	1485	long-term	T079	C0443252
28520661	1486	1506	psychological health	T041	C0025353

27686952|t|Predicting violence and recidivism in a large sample of males on probation or parole
27686952|a|This study evaluated the utility of items and scales from the Iowa Violence and Victimization Instrument in a sample of 1961 males from the state of Iowa who were on probation or released from prison to parole supervision. This is the first study to examine the potential of the Iowa Violence and Victimization Instrument to predict criminal offenses. The males were followed for 30 months immediately following their admission to probation or parole. AUC analyses indicated fair to good predictive power for the Iowa Violence and Victimization Instrument for charges of violence and victimization, but chance predictive power for drug offenses. Notably, both scales of the instrument performed equally well at the 30- month follow-up. Items on the Iowa Violence and Victimization Instrument not only predicted violence, but are straightforward to score. Violence management strategies are discussed as they relate to the current findings, including the potential to expand the measure to other jurisdictions and populations.
27686952	0	10	Predicting	T078	C0681842
27686952	11	19	violence	T048	C0042693
27686952	24	34	recidivism	T055	C0680458
27686952	56	61	males	T032	C0086582
27686952	65	74	probation	T089	C0687758
27686952	78	84	parole	T089	C0814701
27686952	90	95	study	T062	C2603343
27686952	96	105	evaluated	T078	C1550157
27686952	147	151	Iowa	T083	C0022037
27686952	152	160	Violence	T048	C0042693
27686952	165	178	Victimization	T068	C0376695
27686952	179	189	Instrument	T170	C0038951
27686952	210	215	males	T032	C0086582
27686952	234	238	Iowa	T083	C0022037
27686952	251	260	probation	T089	C0687758
27686952	264	284	released from prison	T033	C0425147
27686952	288	294	parole	T089	C0814701
27686952	295	306	supervision	T057	C1273870
27686952	326	331	study	T062	C2603343
27686952	347	356	potential	T080	C3245505
27686952	364	368	Iowa	T083	C0022037
27686952	369	377	Violence	T048	C0042693
27686952	382	395	Victimization	T068	C0376695
27686952	396	406	Instrument	T170	C0038951
27686952	410	417	predict	T078	C0681842
27686952	418	435	criminal offenses	UnknownType	C0680468
27686952	441	446	males	T032	C0086582
27686952	468	474	months	T079	C0439231
27686952	503	512	admission	T079	C0457453
27686952	516	525	probation	T089	C0687758
27686952	529	535	parole	T089	C0814701
27686952	537	540	AUC	T081	C0376690
27686952	541	549	analyses	T062	C0936012
27686952	573	583	predictive	T080	C0681890
27686952	598	602	Iowa	T083	C0022037
27686952	603	611	Violence	T048	C0042693
27686952	616	629	Victimization	T068	C0376695
27686952	630	640	Instrument	T170	C0038951
27686952	656	664	violence	T048	C0042693
27686952	669	682	victimization	T068	C0376695
27686952	695	705	predictive	T080	C0681890
27686952	716	729	drug offenses	UnknownType	C0680484
27686952	759	769	instrument	T170	C0038951
27686952	804	809	month	T079	C0439231
27686952	810	819	follow-up	T058	C1522577
27686952	834	838	Iowa	T083	C0022037
27686952	839	847	Violence	T048	C0042693
27686952	852	865	Victimization	T068	C0376695
27686952	866	876	Instrument	T170	C0038951
27686952	886	895	predicted	T078	C0681842
27686952	896	904	violence	T048	C0042693
27686952	940	948	Violence	T048	C0042693
27686952	1007	1014	current	T079	C0521116
27686952	1015	1023	findings	T169	C2607943
27686952	1039	1048	potential	T080	C3245505
27686952	1052	1058	expand	T082	C0205229
27686952	1080	1093	jurisdictions	T170	C0680647
27686952	1098	1109	populations	T098	C1257890

27540584|t|A novel mechanical simulator for cannulation and sphincterotomy after Billroth II or Roux-en-Y reconstruction
27540584|a|In patients with Billroth II (B II) or Roux-en-Y anatomy, endoscopic retrograde cholangiopancreatography (ERCP) is demanding. Here, we describe a novel simulator with simulated fluoroscopy for cannulation and sphincterotomy training in such situations. A custom-made simulation system was built based upon a common chassis of a series of previously described ERCP simulators. The papilla is made out of organic material and can be cut by high frequency current. The advancement of guidewires and other instruments within transparent mock bile ducts can be viewed in the window of the simulator without the need for fluoroscopy. The ERCP B II / Roux-en-Y simulation system was first evaluated during an ERCP course. There were no technical problems related to the novel simulator during the course. After sphincterotomy, the organic papillae could easily be exchanged within a few seconds. Overall, the novel B II / Roux-en-Y simulator achieved favorable results by trainees and expert endoscopists in all categories assessed. The new B II / Roux-en-Y mechanical simulator is simple and practicable. A first evaluation during an ERCP course showed promising results.
27540584	2	7	novel	T080	C0205314
27540584	8	28	mechanical simulator	T074	C0183309
27540584	33	44	cannulation	T061	C0917707
27540584	49	63	sphincterotomy	T061	C0748895
27540584	70	81	Billroth II	T061	C0192444
27540584	85	109	Roux-en-Y reconstruction	T061	C0372024
27540584	113	121	patients	T101	C0030705
27540584	127	138	Billroth II	T061	C0192444
27540584	140	144	B II	T061	C0192444
27540584	149	158	Roux-en-Y	T061	C0372024
27540584	159	166	anatomy	T017	C0700276
27540584	168	214	endoscopic retrograde cholangiopancreatography	T060	C0008310
27540584	216	220	ERCP	T060	C0008310
27540584	256	261	novel	T080	C0205314
27540584	262	271	simulator	T074	C0183309
27540584	277	286	simulated	T062	C0679083
27540584	287	298	fluoroscopy	T060	C0016356
27540584	303	314	cannulation	T061	C0917707
27540584	319	333	sphincterotomy	T061	C0748895
27540584	334	342	training	T065	C0220931
27540584	377	394	simulation system	T074	C4075558
27540584	399	404	built	T052	C1706853
27540584	418	424	common	T081	C0205214
27540584	425	432	chassis	T073	C1707356
27540584	438	444	series	T081	C0205549
27540584	448	458	previously	T079	C0205156
27540584	469	473	ERCP	T060	C0008310
27540584	474	484	simulators	T074	C0183309
27540584	490	497	papilla	T023	C3714556
27540584	513	520	organic	T080	C0747055
27540584	521	529	material	T167	C0520510
27540584	541	544	cut	T067	C1883724
27540584	548	562	high frequency	T079	C0205212
27540584	563	570	current	T070	C1705970
27540584	576	587	advancement	T169	C1280477
27540584	591	601	guidewires	T073	C1708264
27540584	612	623	instruments	T074	C0348000
27540584	631	642	transparent	T080	C0522503
27540584	648	658	bile ducts	T023	C0005400
27540584	680	686	window	T073	C1704674
27540584	694	703	simulator	T074	C0183309
27540584	725	736	fluoroscopy	T060	C0016356
27540584	742	746	ERCP	T060	C0008310
27540584	747	751	B II	T061	C0192444
27540584	754	763	Roux-en-Y	T061	C0372024
27540584	764	781	simulation system	T074	C4075558
27540584	792	801	evaluated	T058	C0220825
27540584	812	816	ERCP	T060	C0008310
27540584	817	823	course	T079	C0750729
27540584	839	857	technical problems	T067	C1710348
27540584	873	878	novel	T080	C0205314
27540584	879	888	simulator	T074	C0183309
27540584	900	906	course	T079	C0750729
27540584	914	928	sphincterotomy	T061	C0748895
27540584	934	941	organic	T080	C0747055
27540584	942	950	papillae	T023	C3714556
27540584	967	976	exchanged	T169	C0205245
27540584	990	997	seconds	T079	C0457385
27540584	1012	1017	novel	T080	C0205314
27540584	1018	1022	B II	T061	C0192444
27540584	1025	1034	Roux-en-Y	T061	C0372024
27540584	1035	1044	simulator	T074	C0183309
27540584	1054	1063	favorable	T080	C3640814
27540584	1064	1071	results	T169	C1274040
27540584	1075	1083	trainees	T097	C1522486
27540584	1088	1094	expert	T097	C1611835
27540584	1095	1107	endoscopists	T097	C1522486
27540584	1115	1125	categories	T170	C0683312
27540584	1126	1134	assessed	T052	C1516048
27540584	1144	1148	B II	T061	C0192444
27540584	1151	1160	Roux-en-Y	T061	C0372024
27540584	1161	1181	mechanical simulator	T074	C0183309
27540584	1185	1191	simple	T080	C0205352
27540584	1196	1207	practicable	T080	C0205556
27540584	1217	1227	evaluation	T058	C0220825
27540584	1238	1242	ERCP	T060	C0008310
27540584	1243	1249	course	T079	C0750729
27540584	1267	1274	results	T169	C1274040

28523090|t|Penetrating Craniomaxillofacial Injury Caused by a Pneumatic Nail Gun
28523090|a|Craniomaxillofacial injuries can be complex, requiring a multidisciplinary approach. The primary survey is always the first step in trauma management prior to proceeding with further evaluation and treatment. A 26- year -old man presented with a penetrating nail gun injury through the oral and nasal cavities. He did not present in extremis but required elective endotracheal intubation for intraoperative assessment and treatment. Airway management was enhanced by the use of lingual nerve and inferior alveolar nerve blocks via the Vazirani-Akinosi technique to maintain spontaneous respiration while the tongue was distracted from the palate. The nail was removed and rapid sequence induction initiated for orotracheal intubation. Local nerve blocks can be an effective tool in the armamentarium of the craniomaxillofacial trauma surgeon in managing blunt and penetrating injuries. We demonstrate its utility in airway management when a penetrating foreign body in the upper airway precludes orotracheal or nasotracheal intubation.
28523090	0	11	Penetrating	T169	C0205321
28523090	12	38	Craniomaxillofacial Injury	T037	C0024961
28523090	12	69	Craniomaxillofacial Injury Caused by a Pneumatic Nail Gun	T037	C0418073
28523090	51	69	Pneumatic Nail Gun	T073	C3273359
28523090	268	277	treatment	T169	C1522326
28523090	316	327	penetrating	T169	C0205321
28523090	356	360	oral	T030	C0226896
28523090	365	379	nasal cavities	T030	C0027423
28523090	492	501	treatment	T169	C1522326
28523090	525	533	enhanced	T052	C2349975
28523090	548	561	lingual nerve	T061	C0394805
28523090	566	596	inferior alveolar nerve blocks	T061	C0394801
28523090	635	643	maintain	T052	C0024501
28523090	644	667	spontaneous respiration	T033	C0412771
28523090	678	684	tongue	T023	C0040408
28523090	689	699	distracted	T033	C0243095
28523090	709	715	palate	T023	C0700374
28523090	1043	1055	upper airway	T023	C0458827

27366508|t|Does Video Laryngoscopy Offer Advantages over Direct Laryngoscopy during Cardiopulmonary Resuscitation?
27366508|a|Interruption of chest compressions should be minimized because of its negative effects on survival. This randomized, controlled, cross-over study aimed to analyze the effectiveness of Macintosh, Miller, McCoy and McGrath laryngoscopes during with or without chest compressions in the scope of a simulated cardiopulmonary resuscitation scenario. The time required for successful tracheal intubation, number of attempts, dental trauma severity and the need for optimization manoeuvres were recorded during cardiopulmonary resuscitation with and without chest compressions. The experience with computer games during the last 10 years were asked to the participants and recorded. McCoy laryngoscope yielded the shortest time for successful tracheal intubation both in the presence of and without chest compressions. During the use of McCoy laryngoscopes, fewer tracheal intubation attempts, lower incidence of dental trauma and lower visual analogue scale scores on the ease of intubation were recorded. Participants who are experienced computer game players using Macintosh, McCoy and McGrath achieved successful tracheal intubation in a significantly shorter time during resuscitation without chest compressions. Dental trauma incidence and number of tracheal intubation attempts did not show any significant difference between the four laryngoscopes being related to the rate of playing computer games. McGrath video laryngoscopes do not appear to have advantages over direct laryngoscopes for securing a smooth and successful tracheal intubation during rhythmic chest compressions. We believe that as McCoy laryngoscope provided tracheal intubation in a shorter time and with fewer attempts, this laryngoscope may increase the success rate of resuscitation.
27366508	5	23	Video Laryngoscopy	T074	C2363575
27366508	30	40	Advantages	T080	C0205556
27366508	46	65	Direct Laryngoscopy	T060	C0392823
27366508	66	72	during	T079	C0347984
27366508	73	102	Cardiopulmonary Resuscitation	T061	C0007203
27366508	104	116	Interruption	T079	C1512900
27366508	120	138	chest compressions	T058	C4032596
27366508	149	158	minimized	T080	C0392756
27366508	174	182	negative	T033	C0205160
27366508	183	190	effects	T080	C1280500
27366508	194	202	survival	T081	C0038954
27366508	209	219	randomized	T062	C0034656
27366508	221	231	controlled	T169	C2587213
27366508	233	249	cross-over study	T062	C0150097
27366508	250	255	aimed	T078	C1947946
27366508	259	266	analyze	T062	C0936012
27366508	271	284	effectiveness	T080	C1280519
27366508	288	297	Macintosh	T074	C1531939
27366508	299	305	Miller	T074	C1532566
27366508	307	312	McCoy	T074	C0563580
27366508	317	338	McGrath laryngoscopes	T074	C0180453
27366508	339	345	during	T079	C0347984
27366508	362	380	chest compressions	T058	C4032596
27366508	388	393	scope	T077	C1710028
27366508	409	438	cardiopulmonary resuscitation	T061	C0007203
27366508	439	447	scenario	T169	C0683579
27366508	453	457	time	T079	C0040223
27366508	458	466	required	T169	C1514873
27366508	471	481	successful	T080	C1272703
27366508	482	501	tracheal intubation	T061	C0021932
27366508	503	521	number of attempts	T201	C3163850
27366508	523	536	dental trauma	T037	C1301685
27366508	537	545	severity	T080	C0439793
27366508	554	558	need	T080	C0027552
27366508	563	575	optimization	T052	C2698650
27366508	576	586	manoeuvres	T052	C0441655
27366508	592	600	recorded	T033	C0243095
27366508	601	607	during	T079	C0347984
27366508	608	637	cardiopulmonary resuscitation	T061	C0007203
27366508	655	673	chest compressions	T058	C4032596
27366508	679	689	experience	T041	C0596545
27366508	695	709	computer games	T073	C0870328
27366508	710	716	during	T079	C0347984
27366508	729	734	years	T079	C0439234
27366508	753	765	participants	T098	C0679646
27366508	770	778	recorded	T033	C0243095
27366508	780	798	McCoy laryngoscope	T074	C0563580
27366508	811	824	shortest time	T079	C0040223
27366508	829	839	successful	T080	C1272703
27366508	840	859	tracheal intubation	T061	C0021932
27366508	872	880	presence	T033	C0150312
27366508	896	914	chest compressions	T058	C4032596
27366508	916	922	During	T079	C0347984
27366508	927	930	use	T169	C0042153
27366508	934	953	McCoy laryngoscopes	T074	C0563580
27366508	955	960	fewer	T081	C0205388
27366508	961	980	tracheal intubation	T061	C0021932
27366508	981	989	attempts	T051	C1516084
27366508	991	1006	lower incidence	T081	C0021149
27366508	1010	1023	dental trauma	T037	C1301685
27366508	1028	1033	lower	T052	C2003888
27366508	1034	1062	visual analogue scale scores	T201	C2960751
27366508	1078	1088	intubation	T061	C0021925
27366508	1094	1102	recorded	T033	C0243095
27366508	1104	1116	Participants	T098	C0679646
27366508	1125	1136	experienced	T041	C0596545
27366508	1137	1150	computer game	T073	C0870328
27366508	1151	1158	players	T098	C1257890
27366508	1165	1174	Macintosh	T074	C1531939
27366508	1176	1181	McCoy	T074	C0563580
27366508	1186	1193	McGrath	T074	C0180453
27366508	1194	1202	achieved	T033	C0432600
27366508	1203	1213	successful	T080	C1272703
27366508	1214	1233	tracheal intubation	T061	C0021932
27366508	1239	1252	significantly	T078	C0750502
27366508	1253	1265	shorter time	T079	C0040223
27366508	1266	1272	during	T079	C0347984
27366508	1273	1286	resuscitation	T061	C0035273
27366508	1295	1313	chest compressions	T058	C4032596
27366508	1315	1328	Dental trauma	T037	C1301685
27366508	1329	1338	incidence	T081	C0021149
27366508	1343	1349	number	T081	C0237753
27366508	1353	1372	tracheal intubation	T061	C0021932
27366508	1373	1381	attempts	T051	C1516084
27366508	1399	1410	significant	T078	C0750502
27366508	1411	1421	difference	T080	C1705242
27366508	1434	1438	four	T081	C0205450
27366508	1439	1452	laryngoscopes	T074	C0180453
27366508	1474	1478	rate	T081	C1521828
27366508	1482	1489	playing	T052	C0441655
27366508	1490	1504	computer games	T073	C0870328
27366508	1506	1533	McGrath video laryngoscopes	T074	C2363575
27366508	1556	1566	advantages	T080	C0205556
27366508	1572	1592	direct laryngoscopes	T060	C0392823
27366508	1608	1614	smooth	T080	C0205556
27366508	1619	1629	successful	T080	C1272703
27366508	1630	1649	tracheal intubation	T061	C0021932
27366508	1650	1656	during	T079	C0347984
27366508	1657	1684	rhythmic chest compressions	T058	C4032596
27366508	1705	1723	McCoy laryngoscope	T074	C0563580
27366508	1724	1732	provided	T052	C1999230
27366508	1733	1752	tracheal intubation	T061	C0021932
27366508	1758	1770	shorter time	T079	C0040223
27366508	1780	1785	fewer	T081	C0205388
27366508	1786	1794	attempts	T051	C1516084
27366508	1801	1813	laryngoscope	T074	C0180453
27366508	1818	1826	increase	T169	C0442805
27366508	1831	1843	success rate	T081	C1521828
27366508	1847	1860	resuscitation	T061	C0035273

26867927|t|Radiofrequency ablation of posteroseptal accessory pathways associated with coronary sinus diverticula
26867927|a|Posteroseptal accessory pathways may be associated with a coronary sinus (CS) diverticulum. Our purpose was to describe the clinical characteristics, mapping and ablation of these pathways. This was a retrospective study of all patients who underwent ablation of posteroseptal accessory pathways in a single centre. Patients with a diverticulum of the CS or one of its tributaries were included in group I, while the other patients formed group II. Clinical presentation, ablation procedure and outcome were compared between the two groups. A total of 51 patients were included, 16 in group I and 35 in group II. There were no significant differences in age or sex distribution. Atrial fibrillation (AF) and previous unsuccessful ablation were more common in group I. A negative delta wave in lead II was the ECG finding with best sensitivity and specificity for the presence of a diverticulum. A pathway potential was common at the successful site in group I, and the interval between local ventricular electrogram and delta wave onset was shorter (19.5 ± 8 vs 33.1 ± 7.6 ms, p < 0.001). There was a trend toward lower procedural success rate and higher recurrence rate in group I, although this was not significant. CS diverticula should be suspected in patients with manifest posteroseptal accessory pathways who have a previous failed ablation, documented AF or typical electrocardiographic signs. A discrete potential is frequently seen at the successful site, but the local ventricular electrogram is not as early as in other accessory pathways.
26867927	0	23	Radiofrequency ablation	T061	C0850292
26867927	27	59	posteroseptal accessory pathways	T023	C0447025
26867927	60	75	associated with	T080	C0332281
26867927	76	102	coronary sinus diverticula	T019,T047	C3163894
26867927	103	135	Posteroseptal accessory pathways	T023	C0447025
26867927	143	158	associated with	T080	C0332281
26867927	161	193	coronary sinus (CS) diverticulum	T019,T047	C3163894
26867927	227	251	clinical characteristics	T201	C0683325
26867927	253	260	mapping	T052	C1283195
26867927	265	291	ablation of these pathways	T061	C3275043
26867927	304	323	retrospective study	T062	C0035363
26867927	331	339	patients	T101	C0030705
26867927	354	362	ablation	T061	C0547070
26867927	366	398	posteroseptal accessory pathways	T023	C0447025
26867927	404	417	single centre	T082	C0205099
26867927	419	427	Patients	T101	C0030705
26867927	435	457	diverticulum of the CS	T019,T047	C3163894
26867927	472	483	tributaries	T023	C1180121
26867927	501	508	group I	T078	C0441833
26867927	526	534	patients	T101	C0030705
26867927	542	550	group II	T078	C0441833
26867927	552	573	Clinical presentation	T170	C2708283
26867927	575	593	ablation procedure	T061	C0547070
26867927	636	642	groups	T078	C0441833
26867927	658	666	patients	T101	C0030705
26867927	688	695	group I	T078	C0441833
26867927	706	714	group II	T078	C0441833
26867927	757	760	age	T081	C0001782
26867927	764	780	sex distribution	T081	C0036878
26867927	782	801	Atrial fibrillation	T047	C0004238
26867927	803	805	AF	T047	C0004238
26867927	833	841	ablation	T061	C0547070
26867927	862	869	group I	T078	C0441833
26867927	873	881	negative	T033	C0205160
26867927	882	892	delta wave	T033	C1880434
26867927	896	903	lead II	T078	C0441833
26867927	912	915	ECG	T060	C1623258
26867927	916	923	finding	T033	C0243095
26867927	934	945	sensitivity	T081	C1511883
26867927	950	961	specificity	T081	C1511884
26867927	984	996	diverticulum	T046	C0012817
26867927	1000	1007	pathway	T023	C0447025
26867927	1008	1017	potential	T080	C3245505
26867927	1047	1051	site	T082	C0205145
26867927	1055	1062	group I	T078	C0441833
26867927	1089	1118	local ventricular electrogram	T060	C0849666
26867927	1123	1133	delta wave	T033	C1880434
26867927	1144	1151	shorter	T081	C1806781
26867927	1217	1222	lower	T080	C0205251
26867927	1242	1246	rate	T081	C1521828
26867927	1251	1257	higher	T080	C0205250
26867927	1258	1268	recurrence	T067	C0034897
26867927	1269	1273	rate	T081	C1521828
26867927	1277	1284	group I	T078	C0441833
26867927	1308	1319	significant	T078	C0750502
26867927	1321	1335	CS diverticula	T019,T047	C3163894
26867927	1359	1367	patients	T101	C0030705
26867927	1382	1414	posteroseptal accessory pathways	T023	C0447025
26867927	1442	1450	ablation	T061	C0547070
26867927	1463	1465	AF	T047	C0004238
26867927	1477	1503	electrocardiographic signs	T033	C0438154
26867927	1516	1525	potential	T080	C3245505
26867927	1577	1606	local ventricular electrogram	T060	C0849666
26867927	1635	1653	accessory pathways	T023	C0006383

27612680|t|Early Development Challenges for Drug Products Containing Nanomaterials
27612680|a|The vast majority of drug product candidates in early development fail to progress to clinics. This is true for products containing nanomaterials just as for other types of pharmaceuticals. Early development pathways should therefore place high priority on experiments that help candidates fail faster and less expensively. Nanomedicines fail for many reasons, but some are more avoidable than others. Some of the points of failure are not considerations in the development of small molecules or biopharmaceuticals, and so may be unexpected, even to those with previous experience bringing drug products to the clinic. This article reviews experiments that have proven useful in providing "go/no-go" decision-making data for nanomedicines in early preclinical development. Of course, the specifics depend on the particulars of the drug product and the nanomaterial type, and not every product shares the same development pathway or the same potential points of failure. Here, we focus on challenges that differ from those in the development of traditional small molecule therapeutics, and on experiments that reveal deficiencies that can only be corrected by essentially starting over-altering the nanomedicine to an extent that all previous characterization and proof-of-concept testing must be repeated. Conducting these experiments early in the development process can save significant resources and time and allow developers to focus on derisked candidates with a greater likelihood of ultimate success.
27612680	0	17	Early Development	T033	C1856550
27612680	18	28	Challenges	T058	C0805586
27612680	33	46	Drug Products	T121	C0013227
27612680	58	71	Nanomaterials	T073	C1450053
27612680	93	105	drug product	T121	C0013227
27612680	106	116	candidates	T098	C1257890
27612680	120	137	early development	T033	C1856550
27612680	138	142	fail	T169	C0231175
27612680	146	154	progress	T169	C1280477
27612680	158	165	clinics	T073,T093	C0442592
27612680	184	192	products	T121	C0013227
27612680	204	217	nanomaterials	T073	C1450053
27612680	236	241	types	T080	C0332307
27612680	245	260	pharmaceuticals	T121	C1254351
27612680	262	279	Early development	T033	C1856550
27612680	280	288	pathways	T170	C0282654
27612680	312	325	high priority	T079	C1273516
27612680	329	340	experiments	T062	C0681814
27612680	351	361	candidates	T098	C1257890
27612680	362	366	fail	T169	C0231175
27612680	396	409	Nanomedicines	T090	C1328814
27612680	410	414	fail	T169	C0231175
27612680	496	503	failure	T169	C0231174
27612680	512	526	considerations	T033	C0518609
27612680	534	545	development	T169	C1527148
27612680	549	564	small molecules	T109	C1328819
27612680	568	586	biopharmaceuticals	T123	C0005515
27612680	642	652	experience	T041	C0596545
27612680	662	675	drug products	T121	C0013227
27612680	683	689	clinic	T073,T093	C0442592
27612680	696	703	article	T170	C1706852
27612680	704	711	reviews	T170	C0282443
27612680	712	723	experiments	T062	C0681814
27612680	772	792	decision-making data	T078	C1511726
27612680	797	810	nanomedicines	T090	C1328814
27612680	814	843	early preclinical development	T062	C1512070
27612680	903	915	drug product	T121	C0013227
27612680	924	936	nanomaterial	T073	C1450053
27612680	937	941	type	T080	C0332307
27612680	957	964	product	T121	C0013227
27612680	981	992	development	T169	C1527148
27612680	993	1000	pathway	T077	C1705987
27612680	1033	1040	failure	T169	C0231174
27612680	1060	1070	challenges	T058	C0805586
27612680	1101	1112	development	T169	C1527148
27612680	1116	1127	traditional	T169	C0443324
27612680	1128	1142	small molecule	T109	C1328819
27612680	1143	1155	therapeutics	T121	C1254351
27612680	1164	1175	experiments	T062	C0681814
27612680	1188	1200	deficiencies	T169	C0011155
27612680	1252	1265	over-altering	T169	C0205245
27612680	1270	1282	nanomedicine	T090	C1328814
27612680	1314	1330	characterization	T052	C1880022
27612680	1335	1359	proof-of-concept testing	T062	C0242481
27612680	1368	1376	repeated	T169	C0205341
27612680	1395	1406	experiments	T062	C0681814
27612680	1407	1412	early	T079	C1279919
27612680	1420	1439	development process	T169	C1527148
27612680	1449	1460	significant	T078	C0750502
27612680	1461	1470	resources	T078	C0035201
27612680	1475	1479	time	T079	C0040223
27612680	1490	1500	developers	T098	C1257890
27612680	1513	1532	derisked candidates	T098	C1257890
27612680	1548	1558	likelihood	T081	C0033204
27612680	1571	1578	success	T054	C0597535

27428958|t|Transcriptome and Metabolome Analyses of Glucosinolates in Two Broccoli Cultivars Following Jasmonate Treatment for the Induction of Glucosinolate Defense to Trichoplusia ni (Hübner)
27428958|a|Lepidopteran larvae growth is influenced by host plant glucosinolate (GS) concentrations, which are, in turn, influenced by the phytohormone jasmonate (JA). In order to elucidate insect resistance biomarkers to lepidopteran pests, transcriptome and metabolome analyses following JA treatments were conducted with two broccoli cultivars, Green Magic and VI-158, which have differentially induced indole GSs, neoglucobrassicin and glucobrassicin, respectively. To test these two inducible GSs on growth of cabbage looper (Trichoplusia ni), eight neonate cabbage looper larvae were placed onto each of three plants per JA treatments (0, 100, 200, 400 µM) three days after treatment. After five days of feeding, weight of larvae and their survival rate was found to decrease with increasing JA concentrations in both broccoli cultivars. JA - inducible GSs were measured by high performance liquid chromatography. Neoglucobrassicin in Green Magic and glucobrassicin in VI-158 leaves were increased in a dose-dependent manner. One or both of these glucosinolates and/or their hydrolysis products showed significant inverse correlations with larval weight and survival (five days after treatment) while being positively correlated with the number of days to pupation. This implies that these two JA - inducible glucosinolates can influence the growth and survival of cabbage looper larvae. Transcriptome profiling supported the observed changes in glucosinolate and their hydrolysis product concentrations following JA treatments. Several genes related to GS metabolism differentiate the two broccoli cultivars in their pattern of transcriptional response to JA treatments. Indicative of the corresponding change in indole GS concentrations, transcripts of the transcription factor MYB122, core structure biosynthesis genes (CYP79B2, UGT74B1, SUR1, SOT16, SOT17, and SOT18), an indole glucosinolate side chain modification gene (IGMT1), and several glucosinolate hydrolysis genes (TGG1, TGG2, and ESM1) were significantly increased in Green Magic (statistically significant in most cases at 400 µM) while UGT74B1 and MYB122 were significantly increased in VI-158. Therefore, these metabolite and transcript biomarker results indicate that transcriptome profiling can identify genes associated with the formation of two different indole GS and their hydrolysis products. Therefore, these metabolite and transcript biomarkers could be useful in an effective marker - assisted breeding strategy for resistance to generalist lepidopteran pests in broccoli and potentially other Brassica vegetables.
27428958	0	13	Transcriptome	T086	C3178810
27428958	18	28	Metabolome	T070	C2350399
27428958	29	37	Analyses	T062	C0936012
27428958	41	55	Glucosinolates	T109	C0017767
27428958	63	81	Broccoli Cultivars	T002	C0330498
27428958	92	101	Jasmonate	T109	C1176128
27428958	102	111	Treatment	T169	C1522326
27428958	120	129	Induction	T169	C0205263
27428958	133	146	Glucosinolate	T109	C0017767
27428958	147	154	Defense	T077	C1880266
27428958	158	173	Trichoplusia ni	T204	C0998450
27428958	175	181	Hübner	T170	C0805191
27428958	183	195	Lepidopteran	T204	C0023338
27428958	196	202	larvae	T204	C0023047
27428958	203	209	growth	T040	C0018270
27428958	213	223	influenced	T077	C4054723
27428958	227	231	host	T001	C1167395
27428958	232	237	plant	T002	C0032098
27428958	238	251	glucosinolate	T109	C0017767
27428958	253	255	GS	T109	C0017767
27428958	257	271	concentrations	T081	C1446561
27428958	293	303	influenced	T077	C4054723
27428958	311	323	phytohormone	T116,T125	C0032082
27428958	324	333	jasmonate	T109	C1176128
27428958	335	337	JA	T109	C1176128
27428958	362	368	insect	T204	C0021585
27428958	369	379	resistance	T169	C4281815
27428958	380	390	biomarkers	T045	C0017393
27428958	394	406	lepidopteran	T204	C0023338
27428958	407	412	pests	T008	C0869004
27428958	414	427	transcriptome	T086	C3178810
27428958	432	442	metabolome	T070	C2350399
27428958	443	451	analyses	T062	C0936012
27428958	462	464	JA	T109	C1176128
27428958	465	475	treatments	T169	C1522326
27428958	500	518	broccoli cultivars	T002	C0330498
27428958	520	531	Green Magic	T002	C0330498
27428958	536	542	VI-158	T002	C0330498
27428958	570	577	induced	T169	C0205263
27428958	578	588	indole GSs	T109	C0017767
27428958	590	607	neoglucobrassicin	T109	C2975109
27428958	612	626	glucobrassicin	T109	C0061370
27428958	645	649	test	T169	C0039593
27428958	660	669	inducible	T169	C0205263
27428958	670	673	GSs	T109	C0017767
27428958	677	683	growth	T040	C0018270
27428958	687	701	cabbage looper	T204	C0684063
27428958	703	718	Trichoplusia ni	T204	C0998450
27428958	735	756	cabbage looper larvae	T204	C0023047
27428958	788	794	plants	T002	C0032098
27428958	799	801	JA	T109	C1176128
27428958	802	812	treatments	T169	C1522326
27428958	841	845	days	T079	C0439228
27428958	852	861	treatment	T169	C1522326
27428958	874	878	days	T079	C0439228
27428958	882	889	feeding	T052	C2987508
27428958	891	897	weight	T081	C0043100
27428958	901	907	larvae	T204	C0023047
27428958	918	931	survival rate	T081	C0038954
27428958	945	953	decrease	T081	C0547047
27428958	959	969	increasing	T169	C0442805
27428958	970	972	JA	T109	C1176128
27428958	973	987	concentrations	T081	C1446561
27428958	996	1014	broccoli cultivars	T002	C0330498
27428958	1016	1018	JA	T109	C1176128
27428958	1021	1030	inducible	T169	C0205263
27428958	1031	1034	GSs	T109	C0017767
27428958	1040	1048	measured	T080	C0444706
27428958	1052	1090	high performance liquid chromatography	T059	C0008562
27428958	1092	1109	Neoglucobrassicin	T109	C2975109
27428958	1113	1124	Green Magic	T002	C0330498
27428958	1129	1143	glucobrassicin	T109	C0061370
27428958	1147	1153	VI-158	T002	C0330498
27428958	1154	1160	leaves	T002	C0242724
27428958	1166	1175	increased	T081	C0205217
27428958	1181	1195	dose-dependent	T081	C1512045
27428958	1225	1239	glucosinolates	T109	C0017767
27428958	1253	1263	hydrolysis	T070	C0020291
27428958	1264	1272	products	T071	C1514468
27428958	1292	1299	inverse	T080	C0439850
27428958	1300	1312	correlations	T080	C1707520
27428958	1318	1324	larval	T204	C0023047
27428958	1325	1331	weight	T081	C0043100
27428958	1336	1344	survival	T052	C0038952
27428958	1351	1355	days	T079	C0439228
27428958	1362	1371	treatment	T169	C1522326
27428958	1385	1395	positively	T033	C1446409
27428958	1396	1406	correlated	T080	C1707520
27428958	1426	1430	days	T079	C0439228
27428958	1434	1442	pupation	T040	C1326578
27428958	1472	1474	JA	T109	C1176128
27428958	1477	1486	inducible	T169	C0205263
27428958	1487	1501	glucosinolates	T109	C0017767
27428958	1506	1515	influence	T077	C4054723
27428958	1520	1526	growth	T040	C0018270
27428958	1531	1539	survival	T052	C0038952
27428958	1543	1564	cabbage looper larvae	T204	C0023047
27428958	1566	1589	Transcriptome profiling	T059,T063	C0752248
27428958	1613	1620	changes	T169	C0392747
27428958	1624	1637	glucosinolate	T109	C0017767
27428958	1648	1658	hydrolysis	T070	C0020291
27428958	1659	1666	product	T071	C1514468
27428958	1667	1681	concentrations	T081	C1446561
27428958	1692	1694	JA	T109	C1176128
27428958	1695	1705	treatments	T169	C1522326
27428958	1715	1720	genes	T028	C0017337
27428958	1732	1734	GS	T109	C0017767
27428958	1735	1745	metabolism	T040	C0025519
27428958	1746	1759	differentiate	T169	C2945687
27428958	1768	1786	broccoli cultivars	T002	C0330498
27428958	1796	1803	pattern	T082	C0449774
27428958	1807	1822	transcriptional	T045	C0040649
27428958	1823	1831	response	T032	C0871261
27428958	1835	1837	JA	T109	C1176128
27428958	1838	1848	treatments	T169	C1522326
27428958	1882	1888	change	T169	C0392747
27428958	1892	1901	indole GS	T109	C0017767
27428958	1902	1916	concentrations	T081	C1446561
27428958	1918	1929	transcripts	T114	C1519595
27428958	1937	1957	transcription factor	T116,T123	C0040648
27428958	1958	1964	MYB122	T116,T123	C0040648
27428958	1981	1993	biosynthesis	T169	C0005572
27428958	1994	1999	genes	T028	C0017337
27428958	2001	2008	CYP79B2	T028	C0017337
27428958	2010	2017	UGT74B1	T028	C0017337
27428958	2019	2023	SUR1	T028	C1412082
27428958	2025	2030	SOT16	T028	C0017337
27428958	2032	2037	SOT17	T028	C0017337
27428958	2043	2048	SOT18	T028	C0017337
27428958	2054	2074	indole glucosinolate	T104	C1254350
27428958	2086	2098	modification	T033	C3840684
27428958	2099	2103	gene	T028	C0017337
27428958	2105	2110	IGMT1	T028	C0017337
27428958	2125	2138	glucosinolate	T109	C0017767
27428958	2139	2149	hydrolysis	T070	C0020291
27428958	2157	2161	TGG1	T028	C0017337
27428958	2163	2167	TGG2	T028	C0017337
27428958	2173	2177	ESM1	T028	C1414460
27428958	2198	2207	increased	T081	C0205217
27428958	2211	2222	Green Magic	T002	C0330498
27428958	2281	2288	UGT74B1	T028	C0017337
27428958	2293	2299	MYB122	T028	C0017337
27428958	2319	2328	increased	T081	C0205217
27428958	2332	2338	VI-158	T002	C0330498
27428958	2357	2367	metabolite	T123	C0870883
27428958	2372	2382	transcript	T114	C1519595
27428958	2383	2392	biomarker	T045	C0017393
27428958	2415	2438	transcriptome profiling	T059,T063	C0752248
27428958	2443	2451	identify	T080	C0205396
27428958	2452	2457	genes	T028	C0017337
27428958	2478	2487	formation	T169	C1522492
27428958	2505	2514	indole GS	T109	C0017767
27428958	2525	2535	hydrolysis	T070	C0020291
27428958	2536	2544	products	T071	C1514468
27428958	2563	2573	metabolite	T123	C0870883
27428958	2578	2588	transcript	T114	C1519595
27428958	2589	2599	biomarkers	T045	C0017393
27428958	2622	2631	effective	T080	C1704419
27428958	2632	2638	marker	T045	C0017393
27428958	2641	2649	assisted	T080	C1269765
27428958	2650	2658	breeding	T040	C0006159
27428958	2672	2682	resistance	T169	C4281815
27428958	2697	2709	lepidopteran	T204	C0023338
27428958	2710	2715	pests	T008	C0869004
27428958	2719	2727	broccoli	T002	C0330498
27428958	2750	2769	Brassica vegetables	T168	C0453113

27457539|t|Safety and immunogenecity of a live attenuated Rift Valley fever vaccine (CL13T) in camels
27457539|a|Rift Valley fever is an emerging zoonotic viral disease, enzootic and endemic in Africa and the Arabian Peninsula, which poses a significant threat to both human and animal health. The disease is most severe in ruminants causing abortions in pregnant animals, especially sheep animals and high mortality in young populations. High mortality rates and severe clinical manifestation have also been reported among camel populations in Africa, to attend however none of the currently available live vaccines against RVF have been tested for safety and efficacy in this species. In this study, the safety and efficacy (through a neutralizing antibody response) of the thermostable live attenuated RVF CL13T vaccine were evaluated in camels in two different preliminary experiments involving 16 camels, (that 12 camels and 4 pregnant camels). The study revealed that the CL13T vaccine was safe to use in camels and no abortions or teratogenic effects were observed. The single dose of the vaccine stimulated a strong and long-lasting neutralizing antibody response for up to 12 months. The presence of neutralization antibodies is likely to correlate with protection; however protection would need to be confirmed by challenge experiments using the virulent RVF virus.
27457539	0	6	Safety	T068	C0036043
27457539	11	25	immunogenecity	T062	C4054739
27457539	36	46	attenuated	T121,T129	C0042211
27457539	47	72	Rift Valley fever vaccine	T121,T129	C1548485
27457539	74	79	CL13T	T121,T129	C1548485
27457539	84	90	camels	T015	C0006801
27457539	91	108	Rift Valley fever	T047	C0035613
27457539	124	132	zoonotic	T001	C1628327
27457539	133	146	viral disease	T047	C0042769
27457539	148	156	enzootic	T047	C0277551
27457539	161	168	endemic	T047	C0277550
27457539	172	178	Africa	T083	C0001737
27457539	187	204	Arabian Peninsula	T083	C0003671
27457539	220	231	significant	T078	C0750502
27457539	232	238	threat	T078	C0749385
27457539	247	252	human	T016	C0086418
27457539	257	263	animal	T008	C0003062
27457539	264	270	health	T047	C3534575
27457539	276	283	disease	T047	C0035613
27457539	292	298	severe	T080	C0205082
27457539	302	311	ruminants	T015	C0035950
27457539	312	319	causing	T169	C0678227
27457539	320	329	abortions	T046	C0149814
27457539	333	341	pregnant	T040	C0032961
27457539	342	349	animals	T008	C0003062
27457539	362	375	sheep animals	T015	C0036945
27457539	385	394	mortality	T081	C0205848
27457539	398	403	young	T079	C0332239
27457539	404	415	populations	T098	C1257890
27457539	422	437	mortality rates	T081	C0205848
27457539	442	448	severe	T080	C0205082
27457539	449	457	clinical	T080	C0205210
27457539	458	471	manifestation	T080	C1280464
27457539	487	495	reported	T170	C0684224
27457539	502	507	camel	T015	C0006801
27457539	508	519	populations	T098	C1257890
27457539	523	529	Africa	T083	C0001737
27457539	561	570	currently	T079	C0521116
27457539	571	580	available	T169	C0470187
27457539	581	594	live vaccines	T121,T129	C0042211
27457539	603	606	RVF	T047	C0035613
27457539	617	623	tested	T169	C0039593
27457539	628	634	safety	T068	C0036043
27457539	639	647	efficacy	T080	C1280519
27457539	656	663	species	T185	C1705920
27457539	673	678	study	T062	C2603343
27457539	684	690	safety	T068	C0036043
27457539	695	703	efficacy	T080	C1280519
27457539	715	736	neutralizing antibody	T116,T129	C0475463
27457539	737	745	response	T032	C0871261
27457539	754	782	thermostable live attenuated	T121,T129	C0042211
27457539	783	800	RVF CL13T vaccine	T121,T129	C1548485
27457539	806	815	evaluated	T058	C0220825
27457539	819	825	camels	T015	C0006801
27457539	833	842	different	T080	C1705242
27457539	843	854	preliminary	T079	C0439611
27457539	855	866	experiments	T062	C0681814
27457539	880	886	camels	T015	C0006801
27457539	897	903	camels	T015	C0006801
27457539	910	918	pregnant	T040	C0032961
27457539	919	925	camels	T015	C0006801
27457539	932	937	study	T062	C2603343
27457539	938	946	revealed	T080	C0443289
27457539	956	969	CL13T vaccine	T121,T129	C1548485
27457539	974	978	safe	T068	C0036043
27457539	982	985	use	T169	C0457083
27457539	989	995	camels	T015	C0006801
27457539	1003	1012	abortions	T046	C0149814
27457539	1016	1035	teratogenic effects	T046	C0232910
27457539	1041	1049	observed	T169	C1441672
27457539	1062	1066	dose	T081	C0178602
27457539	1074	1081	vaccine	T121,T129	C0042211
27457539	1095	1101	strong	T080	C0442821
27457539	1119	1140	neutralizing antibody	T116,T129	C0475463
27457539	1141	1149	response	T032	C0871261
27457539	1163	1169	months	T079	C0439231
27457539	1175	1183	presence	T033	C0150312
27457539	1187	1212	neutralization antibodies	T116,T129	C0475463
27457539	1226	1240	correlate with	T080	C0332281
27457539	1241	1251	protection	T033	C1545588
27457539	1261	1271	protection	T033	C1545588
27457539	1289	1301	confirmed by	T080	C0521093
27457539	1312	1323	experiments	T062	C0681814
27457539	1334	1342	virulent	T080	C1520022
27457539	1343	1352	RVF virus	T005	C0035614

27688111|t|Prognostic significance of non-HPV16 genotypes in oropharyngeal squamous cell carcinoma
27688111|a|Recent studies have found that cases with oropharyngeal squamous cell carcinoma (OPSCC) positive for HPV16 genotype have better overall survival compared with cases positive for other HPV genotypes. We sought to further replicate these studies and determine if this relationship is modified by expression of p16 tumor suppressor protein. We identified 238 OPSCC cases from the Carolina Head and Neck Cancer Study (CHANCE) study, a population based case-control study. Tumors that tested positive solely for HPV16 genotype and no other genotypes with PCR were classified as HPV16-positive. Tumors positive for any other high-risk HPV genotype were classified as non-HPV16-positive. Expression of p16 in the tumor was determined with immunohistochemistry. Follow-up time was calculated from the date of diagnosis to date of death or December 31, 2013. Overall survival was compared with the Kaplan-Meier curves and log-rank test. Hazard ratios (HR) adjusted for smoking, alcohol use, sex, race, and age was calculated with the Cox proportional hazard regression. Cases with HPV16-positive OPSCC had better overall survival than cases with non-HPV16-positive OPSCC (log-rank p-value: 0.010). When restricted to OPSCC cases positive for p16 expression, the same trend continued (log-rank p-value: 0.002). In the adjusted model, cases with non-HPV16-positive OPSCC had greater risk of death compared to cases with HPV16-positive tumors (HR: 1.92; 95% CI: 1.03, 3.60). This finding indicates that HPV genotyping carries valuable prognostic significance in addition to p16 status and future survival studies of OPSCC should take into account differing HPV genotypes.
27688111	0	23	Prognostic significance	T201	C1514474
27688111	27	46	non-HPV16 genotypes	T032	C0017431
27688111	50	87	oropharyngeal squamous cell carcinoma	T191	C0280313
27688111	130	167	oropharyngeal squamous cell carcinoma	T191	C0280313
27688111	169	174	OPSCC	T191	C0280313
27688111	176	184	positive	T034	C4288937
27688111	189	203	HPV16 genotype	T114,T123	C3872681
27688111	209	215	better	T080	C0332272
27688111	216	232	overall survival	T081	C4086681
27688111	233	241	compared	T052	C1707455
27688111	272	285	HPV genotypes	T114,T123	C0807283
27688111	308	317	replicate	T080	C1883725
27688111	370	381	modified by	T080	C0205349
27688111	382	392	expression	T045	C1171362
27688111	396	424	p16 tumor suppressor protein	T116,T123	C0249880
27688111	444	449	OPSCC	T191	C0280313
27688111	465	500	Carolina Head and Neck Cancer Study	T062	C1516225
27688111	502	508	CHANCE	T062	C1516225
27688111	519	554	population based case-control study	T062	C1709599
27688111	556	562	Tumors	T191	C0027651
27688111	575	590	positive solely	T034	C4288937
27688111	595	609	HPV16 genotype	T114,T123	C3872681
27688111	623	632	genotypes	T032	C0017431
27688111	638	641	PCR	T063	C0032520
27688111	647	657	classified	T185	C0008902
27688111	661	675	HPV16-positive	T034	C4288937
27688111	677	683	Tumors	T191	C0027651
27688111	684	696	positive for	T034	C4288937
27688111	707	716	high-risk	T033	C0332167
27688111	717	729	HPV genotype	T114,T123	C3872595
27688111	735	745	classified	T185	C0008902
27688111	749	767	non-HPV16-positive	T034	C4288937
27688111	769	779	Expression	T045	C1171362
27688111	783	786	p16	T116,T123	C0249880
27688111	794	799	tumor	T191	C0027651
27688111	804	814	determined	T080	C0521095
27688111	820	840	immunohistochemistry	T060	C0021044
27688111	881	898	date of diagnosis	T079	C2316983
27688111	902	915	date of death	T079	C1148348
27688111	938	954	Overall survival	T081	C4086681
27688111	977	996	Kaplan-Meier curves	T081	C1720944
27688111	1001	1014	log-rank test	T081	C0242928
27688111	1016	1029	Hazard ratios	T081	C2985465
27688111	1031	1033	HR	T081	C2985465
27688111	1048	1055	smoking	T055	C0037369
27688111	1057	1068	alcohol use	T055	C0001948
27688111	1070	1073	sex	T032	C0079399
27688111	1075	1079	race	T098	C0034510
27688111	1085	1088	age	T032	C0001779
27688111	1113	1147	Cox proportional hazard regression	T081,T170	C0010235
27688111	1160	1174	HPV16-positive	T034	C4288937
27688111	1175	1180	OPSCC	T191	C0280313
27688111	1185	1191	better	T080	C0332272
27688111	1192	1208	overall survival	T081	C4086681
27688111	1225	1243	non-HPV16-positive	T034	C4288937
27688111	1244	1249	OPSCC	T191	C0280313
27688111	1296	1301	OPSCC	T191	C0280313
27688111	1308	1316	positive	T033	C1446409
27688111	1321	1335	p16 expression	T045	C1171362
27688111	1346	1351	trend	T079	C1521798
27688111	1423	1441	non-HPV16-positive	T034	C4288937
27688111	1442	1447	OPSCC	T191	C0280313
27688111	1452	1467	greater risk of	T033	C0332167
27688111	1468	1473	death	T033	C1306577
27688111	1497	1511	HPV16-positive	T034	C4288937
27688111	1512	1518	tumors	T191	C0027651
27688111	1520	1522	HR	T081	C2985465
27688111	1556	1563	finding	T033	C0243095
27688111	1564	1573	indicates	T033	C1444656
27688111	1579	1582	HPV	T005	C0021344
27688111	1583	1593	genotyping	T059	C2368152
27688111	1602	1634	valuable prognostic significance	T201	C1514474
27688111	1650	1653	p16	T116,T123	C0249880
27688111	1654	1660	status	T080	C0449438
27688111	1692	1697	OPSCC	T191	C0280313
27688111	1733	1746	HPV genotypes	T114,T123	C0807283

28459654|t|Developmental Hypoxia Has Negligible Effects on Long-Term Hypoxia Tolerance and Aerobic Metabolism of Atlantic Salmon (Salmo salar)
28459654|a|Exposure to developmental hypoxia can have long-term impacts on the physiological performance of fish because of irreversible plasticity. Wild and captive-reared Atlantic salmon (Salmo salar) can be exposed to hypoxic conditions during development and continue to experience fluctuating oxygen levels as juveniles and adults. Here, we examine whether developmental hypoxia impacts subsequent hypoxia tolerance and aerobic performance of Atlantic salmon. Individuals at 8°C were exposed to 50% (hypoxia) or 100% (normoxia) dissolved oxygen (DO) saturation (as percent of air saturation) from fertilization for ∼100 d (800 degree days) and then raised in normoxic conditions for a further 15 mo. At 18 mo after fertilization, aerobic scope was calculated in normoxia (100% DO) and acute (18 h) hypoxia (50% DO) from the difference between the minimum and maximum oxygen consumption rates ([Formula: see text] and [Formula: see text], respectively) at 10°C. Hypoxia tolerance was determined as the DO at which loss of equilibrium (LOE) occurred in a constantly decreasing DO environment. There was no difference in [Formula: see text], [Formula: see text], or aerobic scope between fish raised in hypoxia or normoxia. There was some evidence that hypoxia tolerance was lower (higher DO at LOE) in hypoxia - raised fish compared with those raised in normoxia, but the magnitude of the effect was small (12.52% DO vs. 11.73% DO at LOE). Acute hypoxia significantly reduced aerobic scope by reducing [Formula: see text], while [Formula: see text] remained unchanged. Interestingly, acute hypoxia uncovered individual -level relationships between DO at LOE and [Formula: see text], [Formula: see text], and aerobic scope. We discuss our findings in the context of developmental trajectories and the role of aerobic performance in hypoxia tolerance.
28459654	0	13	Developmental	T080	C0458003
28459654	14	21	Hypoxia	T046	C0242184
28459654	26	36	Negligible	T080	C0332269
28459654	37	44	Effects	T080	C1280500
28459654	48	57	Long-Term	T079	C0443252
28459654	58	65	Hypoxia	T046	C0242184
28459654	66	75	Tolerance	T080	C1704410
28459654	80	98	Aerobic Metabolism	T043	C0282636
28459654	102	117	Atlantic Salmon	T013	C0327949
28459654	119	130	Salmo salar	T013	C0327949
28459654	132	143	Exposure to	T080	C0332157
28459654	144	157	developmental	T080	C0458003
28459654	158	165	hypoxia	T046	C0242184
28459654	175	184	long-term	T079	C0443252
28459654	185	192	impacts	T080	C4049986
28459654	200	213	physiological	T039	C0031845
28459654	214	225	performance	T052	C1882330
28459654	229	233	fish	T013	C0016163
28459654	245	257	irreversible	T169	C0205245
28459654	258	268	plasticity	T070	C0678558
28459654	270	274	Wild	T170	C0445392
28459654	279	293	captive-reared	T033	C0243095
28459654	294	309	Atlantic salmon	T013	C0327949
28459654	311	322	Salmo salar	T013	C0327949
28459654	331	341	exposed to	T080	C0332157
28459654	342	349	hypoxic	T046	C0242184
28459654	350	360	conditions	T080	C0348080
28459654	368	379	development	T169	C1527148
28459654	384	392	continue	T078	C0549178
28459654	407	418	fluctuating	T079	C0231241
28459654	419	425	oxygen	T121,T123,T196	C0030054
28459654	426	432	levels	T080	C0441889
28459654	436	445	juveniles	T100	C3146221
28459654	450	456	adults	T100	C0001675
28459654	467	474	examine	T033	C0332128
28459654	483	496	developmental	T080	C0458003
28459654	497	504	hypoxia	T046	C0242184
28459654	505	512	impacts	T080	C4049986
28459654	513	523	subsequent	T079	C0332282
28459654	524	531	hypoxia	T046	C0242184
28459654	532	541	tolerance	T080	C1704410
28459654	546	553	aerobic	T080	C1510824
28459654	554	565	performance	T052	C1882330
28459654	569	584	Atlantic salmon	T013	C0327949
28459654	586	597	Individuals	T013	C0016163
28459654	610	620	exposed to	T080	C0332157
28459654	626	633	hypoxia	T046	C0242184
28459654	644	652	normoxia	T070	C0311411
28459654	654	686	dissolved oxygen (DO) saturation	T044	C0369768
28459654	702	716	air saturation	T070	C0522534
28459654	723	736	fertilization	T040	C3826354
28459654	775	781	raised	T080	C0442818
28459654	785	793	normoxic	T070	C0311411
28459654	794	804	conditions	T080	C0348080
28459654	841	854	fertilization	T040	C3826354
28459654	856	863	aerobic	T080	C1510824
28459654	864	869	scope	T077	C1710028
28459654	874	884	calculated	T052	C1441506
28459654	888	896	normoxia	T070	C0311411
28459654	903	905	DO	T121,T123,T196	C0030054
28459654	911	916	acute	T079	C0205178
28459654	924	931	hypoxia	T046	C0242184
28459654	937	939	DO	T121,T123,T196	C0030054
28459654	950	960	difference	T080	C1705242
28459654	973	980	minimum	T080	C1524031
28459654	985	992	maximum	T081	C0806909
28459654	993	1011	oxygen consumption	T201	C0030055
28459654	1012	1017	rates	T081	C1521828
28459654	1087	1094	Hypoxia	T046	C0242184
28459654	1095	1104	tolerance	T080	C1704410
28459654	1109	1119	determined	T080	C0521095
28459654	1127	1129	DO	T121,T123,T196	C0030054
28459654	1139	1158	loss of equilibrium	T184	C0278126
28459654	1160	1163	LOE	T184	C0278126
28459654	1165	1173	occurred	T052	C1709305
28459654	1190	1200	decreasing	T033	C0442797
28459654	1201	1203	DO	T121,T123,T196	C0030054
28459654	1227	1240	no difference	T033	C3842396
28459654	1289	1296	aerobic	T080	C1510824
28459654	1297	1302	scope	T077	C1710028
28459654	1311	1315	fish	T013	C0016163
28459654	1316	1322	raised	T080	C0442818
28459654	1326	1333	hypoxia	T046	C0242184
28459654	1337	1345	normoxia	T070	C0311411
28459654	1362	1370	evidence	T078	C3887511
28459654	1376	1383	hypoxia	T046	C0242184
28459654	1384	1393	tolerance	T080	C1704410
28459654	1398	1403	lower	T052	C2003888
28459654	1412	1414	DO	T121,T123,T196	C0030054
28459654	1418	1421	LOE	T184	C0278126
28459654	1426	1433	hypoxia	T046	C0242184
28459654	1436	1442	raised	T080	C0442818
28459654	1443	1447	fish	T013	C0016163
28459654	1468	1474	raised	T080	C0442818
28459654	1478	1486	normoxia	T070	C0311411
28459654	1496	1505	magnitude	T081	C1704240
28459654	1513	1519	effect	T080	C1280500
28459654	1524	1529	small	T081	C0700321
28459654	1538	1540	DO	T121,T123,T196	C0030054
28459654	1552	1554	DO	T121,T123,T196	C0030054
28459654	1558	1561	LOE	T184	C0278126
28459654	1564	1569	Acute	T079	C0205178
28459654	1570	1577	hypoxia	T046	C0242184
28459654	1592	1599	reduced	T080	C0392756
28459654	1600	1607	aerobic	T080	C1510824
28459654	1608	1613	scope	T077	C1710028
28459654	1617	1625	reducing	T080	C0392756
28459654	1682	1691	unchanged	T033	C0442739
28459654	1708	1713	acute	T079	C0205178
28459654	1714	1721	hypoxia	T046	C0242184
28459654	1732	1742	individual	T013	C0016163
28459654	1750	1763	relationships	T080	C0439849
28459654	1772	1774	DO	T121,T123,T196	C0030054
28459654	1778	1781	LOE	T184	C0278126
28459654	1832	1839	aerobic	T080	C1510824
28459654	1840	1845	scope	T077	C1710028
28459654	1862	1870	findings	T169	C2607943
28459654	1889	1902	developmental	T080	C0458003
28459654	1932	1939	aerobic	T080	C1510824
28459654	1940	1951	performance	T052	C1882330
28459654	1955	1962	hypoxia	T046	C0242184
28459654	1963	1972	tolerance	T080	C1704410

28544452|t|A Conserved Role for VEGF Signaling in Specification of Homologous Mesenchymal Cell Types Positioned at Spatially Distinct Developmental Addresses in Early Development of Sea Urchins
28544452|a|Comparative studies of early development in echinoderms are revealing the tempo and mode of alterations to developmental gene regulatory networks and to the cell types they specify. In euechinoid sea urchins, skeletogenic mesenchyme (SM) ingresses prior to gastrulation at the vegetal pole and aligns into a ring-like array with two bilateral pockets of cells, the sites where spiculogenesis will later occur. In cidaroid sea urchins, the anciently diverged sister clade to euechinoid sea urchins, a homologous SM cell type ingresses later in development, after gastrulation has commenced, and consequently at a distinct developmental address. Thus, a heterochronic shift of ingression of the SM cell type occurred in one of the echinoid lineages. In euechinoids, specification and migration of SM are facilitated by vascular endothelial growth factor (VEGF) signaling. We describe spatiotemporal expression of vegf and vegfr and experimental manipulations targeting VEGF signaling in the cidaroid Eucidaris tribuloides. Spatially, vegf and vegfr mRNA localizes similarly as in euechinoids, suggesting conserved deployment in echinoids despite their spatially distinct development addresses of ingression. Inhibition of VEGF signaling in E. tribuloides suggests its role in SM specification is conserved in echinoids. Temporal discrepancies between the onset of vegf expression and SM ingression likely result in previous observations of SM "random wandering" behavior. Our results indicate that, although the SM cell type in echinoids ingresses into distinct developmental landscapes, it retains a signaling mechanism that restricts their spatial localization to a conserved developmental address where spiculogenesis later occurs.
28544452	12	16	Role	T077	C1705810
28544452	21	35	VEGF Signaling	T044	C3271788
28544452	56	66	Homologous	T032	C0301883
28544452	67	78	Mesenchymal	T018	C0162415
28544452	79	89	Cell Types	T025	C0007634
28544452	90	100	Positioned	T082	C0733755
28544452	123	136	Developmental	T040	C0678723
28544452	137	146	Addresses	T029	C1515974
28544452	150	167	Early Development	T040	C0678723
28544452	171	182	Sea Urchins	T204	C0036488
28544452	183	202	Comparative studies	T062	C1579762
28544452	206	223	early development	T040	C0678723
28544452	227	238	echinoderms	T204	C0013507
28544452	257	262	tempo	T079	C0040223
28544452	267	271	mode	T169	C1513371
28544452	275	286	alterations	T078	C1515926
28544452	290	303	developmental	T028	C0017340
28544452	304	328	gene regulatory networks	T044	C1720950
28544452	340	350	cell types	T025	C0007634
28544452	368	378	euechinoid	T204	C0998680
28544452	379	390	sea urchins	T204	C0036488
28544452	392	415	skeletogenic mesenchyme	T018	C0162415
28544452	417	419	SM	T018	C0162415
28544452	421	430	ingresses	T042	C4242052
28544452	440	452	gastrulation	T040	C0259902
28544452	491	506	ring-like array	T082	C1510941
28544452	516	525	bilateral	T082	C0238767
28544452	526	542	pockets of cells	T025	C0007634
28544452	548	553	sites	T082	C0205145
28544452	596	604	cidaroid	T204	C0998672
28544452	605	616	sea urchins	T204	C0036488
28544452	641	653	sister clade	T204	C0684063
28544452	657	667	euechinoid	T204	C0998680
28544452	668	679	sea urchins	T204	C0036488
28544452	683	693	homologous	T032	C0301883
28544452	694	696	SM	T018	C0162415
28544452	697	706	cell type	T025	C0007634
28544452	707	716	ingresses	T042	C4242052
28544452	726	737	development	T040	C0678723
28544452	745	757	gastrulation	T040	C0259902
28544452	804	817	developmental	T040	C0678723
28544452	818	825	address	T029	C1515974
28544452	835	854	heterochronic shift	T040	C1160201
28544452	858	868	ingression	T042	C4242052
28544452	876	878	SM	T018	C0162415
28544452	879	888	cell type	T025	C0007634
28544452	912	920	echinoid	T204	C0036488
28544452	921	929	lineages	T078	C0282637
28544452	934	945	euechinoids	T204	C0998680
28544452	965	974	migration	T042	C2755542
28544452	978	980	SM	T018	C0162415
28544452	1000	1051	vascular endothelial growth factor (VEGF) signaling	T044	C3271788
28544452	1065	1090	spatiotemporal expression	T045	C1171362
28544452	1094	1098	vegf	T116,T123	C1256770
28544452	1103	1108	vegfr	T116,T126,T192	C0148199
28544452	1150	1164	VEGF signaling	T044	C3271788
28544452	1172	1202	cidaroid Eucidaris tribuloides	T204	C0998676
28544452	1215	1219	vegf	T116,T123	C1256770
28544452	1224	1229	vegfr	T116,T126,T192	C0148199
28544452	1230	1234	mRNA	T114,T123	C0035696
28544452	1235	1244	localizes	T082	C0392752
28544452	1261	1272	euechinoids	T204	C0998680
28544452	1295	1305	deployment	T052	C2825812
28544452	1309	1318	echinoids	T204	C0036488
28544452	1352	1363	development	T040	C0678723
28544452	1364	1373	addresses	T029	C1515974
28544452	1377	1387	ingression	T042	C4242052
28544452	1389	1417	Inhibition of VEGF signaling	T044	C3547942
28544452	1421	1435	E. tribuloides	T204	C0998676
28544452	1449	1453	role	T077	C1705810
28544452	1457	1459	SM	T018	C0162415
28544452	1490	1499	echinoids	T204	C0036488
28544452	1501	1509	Temporal	T082	C0442043
28544452	1510	1523	discrepancies	T033	C1290905
28544452	1536	1541	onset	T080	C0332162
28544452	1545	1549	vegf	T116,T123	C1256770
28544452	1550	1560	expression	T045	C1171362
28544452	1565	1567	SM	T018	C0162415
28544452	1568	1578	ingression	T042	C4242052
28544452	1621	1623	SM	T018	C0162415
28544452	1693	1695	SM	T018	C0162415
28544452	1696	1705	cell type	T025	C0007634
28544452	1709	1718	echinoids	T204	C0036488
28544452	1719	1728	ingresses	T042	C4242052
28544452	1743	1756	developmental	T040	C0678723
28544452	1782	1801	signaling mechanism	T044	C0037080
28544452	1807	1816	restricts	T169	C0443288
28544452	1823	1843	spatial localization	T169	C0475264
28544452	1859	1872	developmental	T040	C0678723
28544452	1873	1880	address	T029	C1515974

28092486|t|Use of polyclonal / monoclonal antibody therapies in transplantation
28092486|a|For over thirty years, antibody (mAb)-based therapies have been a standard component of transplant immunosuppression, and yet much remains to be learned in order for us to truly harness their therapeutic capabilities. Current mAbs used in transplant directly target and destroy graft-destructive immune cells, interrupt cytokine and costimulation -dependent T and B cell activation, and prevent down-stream complement activation. Areas covered: This review summarizes our current approaches to using antibody-based therapies to prevent and treat allograft rejection. It also provides examples of promising novel mAb therapies, and discusses the potential for future mAb development in transplantation. Expert opinion: The broad capability of antibodies, in parallel with our growing ability to synthetically modulate them, offers exciting opportunities to develop better biologic therapeutics. In order to do so, we must further our understanding about the basic biology underlying allograft rejection, and gain better appreciation of how characteristics of therapeutic antibodies affect their efficacy.
28092486	0	6	Use of	T169	C1524063
28092486	7	17	polyclonal	T061	C0281176
28092486	20	49	monoclonal antibody therapies	T061	C0279694
28092486	53	68	transplantation	T061	C0040732
28092486	92	122	antibody (mAb)-based therapies	T061	C0279694
28092486	157	185	transplant immunosuppression	T061	C0599989
28092486	261	285	therapeutic capabilities	T169	C0039798
28092486	295	299	mAbs	T116,T129	C0003250
28092486	308	318	transplant	T061	C0040732
28092486	328	334	target	T169	C0205245
28092486	339	346	destroy	T169	C0205245
28092486	347	377	graft-destructive immune cells	T025	C0312740
28092486	389	397	cytokine	T116,T129	C0079189
28092486	402	415	costimulation	T043	C1622567
28092486	427	428	T	T043	C2259065
28092486	433	450	B cell activation	T043	C2259068
28092486	456	463	prevent	T080	C2700409
28092486	464	497	down-stream complement activation	T044	C0009528
28092486	519	525	review	T170	C0282443
28092486	549	559	approaches	T169	C1292724
28092486	569	593	antibody-based therapies	T061	C0281176
28092486	597	604	prevent	T080	C2700409
28092486	609	614	treat	T169	C1522326
28092486	615	634	allograft rejection	T169	C2984265
28092486	681	694	mAb therapies	T061	C0279694
28092486	735	738	mAb	T116,T129	C0003250
28092486	739	750	development	T169	C1527148
28092486	754	769	transplantation	T061	C0040732
28092486	797	807	capability	T080	C2698977
28092486	811	821	antibodies	T116,T129	C0003241
28092486	844	859	growing ability	T039	C0220844
28092486	863	876	synthetically	T169	C0205245
28092486	877	885	modulate	T169	C0205245
28092486	940	961	biologic therapeutics	T061	C0087111
28092486	1032	1039	biology	T080	C0205460
28092486	1051	1070	allograft rejection	T169	C2984265
28092486	1108	1123	characteristics	T080	C1521970
28092486	1127	1138	therapeutic	T169	C0302350
28092486	1139	1149	antibodies	T116,T129	C0003241
28092486	1163	1171	efficacy	T080	C1280519

27785853|t|Helicobacter pylori infection and its related factors in junior high school students in Nagano Prefecture, Japan
27785853|a|There have been few reports on Helicobacter pylori (H. pylori) infection in asymptomatic Japanese children and adolescents. We hypothesized that the prevalence of H. pylori infection is very low among Japanese children and that clinical variables such as serum pepsinogen and iron levels are associated with H. pylori infection. We conducted a cross-sectional analysis of a sample of 454 junior high school students aged 12-15 years in four areas in Nagano Prefecture. A commercial ELISA kit (E-plate Eiken H. pylori antibody) was used to measure IgG antibody against H. pylori. Serum pepsinogen and iron levels were also measured using standard methods. A urea breath test was performed for seropositive students. The overall prevalence of H. pylori was 3.1% (14/454). There were no significant differences in H. pylori prevalence among mountain, rural, and urban areas. The mean level of both serum pepsinogen (PG I) and PG II was significantly increased in the seropositive subjects compared with the seronegative subjects. When the cutoff values for adults (PG I: 70 ng/mL and PG I / II ratio: 3) were used, 4 of 14 subjects had PG I ≤70 ng/mL and PG I / II ratio ≤3. The results of a logistic regression analysis showed that low serum iron levels were significantly associated with H. pylori infection (P=.02). The prevalence of H. pylori infection is as low as 3% among junior high school students aged 12- 15 years in Japan. The disappearance of H. pylori is accelerating in Japanese children.
27785853	0	29	Helicobacter pylori infection	T047	C0850666
27785853	57	84	junior high school students	T098	C0687733
27785853	88	105	Nagano Prefecture	T083	C0017446
27785853	107	112	Japan	T083	C0022341
27785853	144	163	Helicobacter pylori	T007	C0079488
27785853	165	174	H. pylori	T007	C0079488
27785853	176	201	infection in asymptomatic	T047	C0275522
27785853	202	210	Japanese	T098	C1556094
27785853	211	219	children	T100	C0008059
27785853	224	235	adolescents	T100	C0205653
27785853	262	272	prevalence	T081	C0220900
27785853	276	295	H. pylori infection	T047	C0850666
27785853	314	322	Japanese	T098	C1556094
27785853	323	331	children	T100	C0008059
27785853	341	359	clinical variables	T033	C3810252
27785853	368	373	serum	T031	C0229671
27785853	374	384	pepsinogen	T116,T123	C0030913
27785853	389	400	iron levels	T059	C1318312
27785853	405	420	associated with	T080	C0332281
27785853	421	440	H. pylori infection	T047	C0850666
27785853	457	481	cross-sectional analysis	T062	C0010362
27785853	501	528	junior high school students	T098	C0687733
27785853	563	580	Nagano Prefecture	T083	C0017446
27785853	584	594	commercial	T170	C0680536
27785853	595	600	ELISA	T059	C0014441
27785853	606	619	E-plate Eiken	T170	C0282574
27785853	620	638	H. pylori antibody	T116,T129	C0369303
27785853	652	672	measure IgG antibody	T059	C0202087
27785853	681	690	H. pylori	T007	C0079488
27785853	692	697	Serum	T031	C0229671
27785853	698	708	pepsinogen	T116,T123	C0030913
27785853	713	724	iron levels	T059	C1318312
27785853	735	743	measured	T080	C0444706
27785853	750	766	standard methods	T170	C0025663
27785853	770	786	urea breath test	T060	C0430720
27785853	791	800	performed	T169	C0884358
27785853	805	817	seropositive	T080	C0521143
27785853	818	826	students	T098	C0038492
27785853	840	850	prevalence	T081	C0220900
27785853	854	863	H. pylori	T007	C0079488
27785853	894	920	no significant differences	T033	C3694175
27785853	924	933	H. pylori	T007	C0079488
27785853	934	944	prevalence	T081	C0220900
27785853	951	959	mountain	T083	C0442533
27785853	961	966	rural	T082	C0178837
27785853	972	983	urban areas	T082	C0178876
27785853	1008	1013	serum	T031	C0229671
27785853	1014	1024	pepsinogen	T116,T123	C0030913
27785853	1026	1030	PG I	T116,T126	C0077923
27785853	1036	1041	PG II	T116,T123	C0030915
27785853	1046	1069	significantly increased	T081	C4055637
27785853	1077	1089	seropositive	T080	C0521143
27785853	1090	1098	subjects	T098	C0080105
27785853	1117	1129	seronegative	T034	C0521144
27785853	1130	1138	subjects	T098	C0080105
27785853	1167	1173	adults	T100	C0001675
27785853	1175	1179	PG I	T116,T126	C0077923
27785853	1194	1198	PG I	T116,T126	C0077923
27785853	1201	1203	II	T116,T123	C0030915
27785853	1233	1241	subjects	T098	C0080105
27785853	1246	1250	PG I	T116,T126	C0077923
27785853	1265	1269	PG I	T116,T126	C0077923
27785853	1272	1274	II	T116,T123	C0030915
27785853	1289	1296	results	T034	C0456984
27785853	1302	1330	logistic regression analysis	UnknownType	C0681925
27785853	1347	1364	serum iron levels	T059	C1318312
27785853	1384	1399	associated with	T080	C0332281
27785853	1400	1419	H. pylori infection	T047	C0850666
27785853	1433	1443	prevalence	T081	C0220900
27785853	1447	1466	H. pylori infection	T047	C0850666
27785853	1489	1516	junior high school students	T098	C0687733
27785853	1538	1543	Japan	T083	C0022341
27785853	1566	1575	H. pylori	T007	C0079488
27785853	1595	1603	Japanese	T098	C1556094
27785853	1604	1612	children	T100	C0008059

27768814|t|Non-specific transient mutualism between the plant parasitic nematode, Bursaphelenchus xylophilus, and the opportunistic bacterium Serratia quinivorans BXF1, a plant-growth promoting pine endophyte with antagonistic effects
27768814|a|The aim of this study is to understand the biological role of Serratia quinivorans BXF1, a bacterium commonly found associated with Bursaphelenchus xylophilus, the plant parasitic nematode responsible for pine wilt disease. Therefore, we studied strain BXF1 effect in pine wilt disease. We found that strain BXF1 promoted in vitro nematode reproduction. Moreover, the presence of bacteria led to the absence of nematode chitinase gene (Bxcht-1) expression, suggesting an effect for bacterial chitinase in nematode reproduction. Nevertheless, strain BXF1 was unable to colonize the nematode interior, bind to its cuticle with high affinity or protect the nematode from xenobiotic stress. Interestingly, strain BXF1 was able to promote tomato and pine plant-growth, as well as to colonize its interior, thus, acting like a plant-growth promoting endophyte. Consequently, strain BXF1 failed to induce wilting symptoms when inoculated in pine shoot artificial incisions. This bacterium also presented strong antagonistic activities against fungi and bacteria isolated from Pinus pinaster. Our results suggest that B. xylophilus does not possess a strict symbiotic community capable of inducing pine wilt disease symptoms as previously hypothesized. We show that bacteria like BXF1, which possess plant-growth promoting and antagonistic effects, may be opportunistically associated with B. xylophilus, possibly acquired from the bacterial endophytic community of the host pine.
27768814	23	32	mutualism	T070	C0599514
27768814	45	69	plant parasitic nematode	T204	C0321773
27768814	71	97	Bursaphelenchus xylophilus	T204	C0997987
27768814	121	130	bacterium	T007	C0004611
27768814	131	156	Serratia quinivorans BXF1	T007	C0445754
27768814	160	172	plant-growth	T040	C0597252
27768814	183	187	pine	T002	C0330186
27768814	188	197	endophyte	T004	C1265415
27768814	203	215	antagonistic	T120	C0243076
27768814	216	223	effects	T080	C1280500
27768814	240	245	study	T062	C2603343
27768814	286	311	Serratia quinivorans BXF1	T007	C0445754
27768814	315	324	bacterium	T007	C0004611
27768814	356	382	Bursaphelenchus xylophilus	T204	C0997987
27768814	388	412	plant parasitic nematode	T204	C0321773
27768814	429	433	pine	T002	C0330186
27768814	434	446	wilt disease	T047	C0032080
27768814	470	481	strain BXF1	T007	C0445754
27768814	492	496	pine	T002	C0330186
27768814	497	509	wilt disease	T047	C0032080
27768814	525	536	strain BXF1	T007	C0445754
27768814	546	554	in vitro	T080	C1533691
27768814	555	563	nematode	T204	C1704319
27768814	564	576	reproduction	T040	C0035150
27768814	604	612	bacteria	T007	C0004611
27768814	635	643	nematode	T204	C1704319
27768814	644	668	chitinase gene (Bxcht-1)	T028	C0017337
27768814	669	679	expression	T045	C0017262
27768814	706	715	bacterial	T007	C0004611
27768814	716	725	chitinase	T116,T126	C0008145
27768814	729	737	nematode	T204	C1704319
27768814	738	750	reproduction	T040	C0035150
27768814	766	777	strain BXF1	T007	C0445754
27768814	792	800	colonize	T033	C4289767
27768814	805	813	nematode	T204	C1704319
27768814	836	843	cuticle	T023	C0596796
27768814	878	886	nematode	T204	C1704319
27768814	892	902	xenobiotic	T123,T131	C0043335
27768814	903	909	stress	T046	C0449430
27768814	926	937	strain BXF1	T007	C0445754
27768814	958	964	tomato	T002	C0032098
27768814	969	973	pine	T002	C0330186
27768814	974	986	plant-growth	T040	C0597252
27768814	1002	1010	colonize	T033	C4289767
27768814	1045	1057	plant-growth	T040	C0597252
27768814	1068	1077	endophyte	T004	C1265415
27768814	1093	1104	strain BXF1	T007	C0445754
27768814	1122	1138	wilting symptoms	T184	C1457887
27768814	1158	1162	pine	T002	C0330186
27768814	1163	1168	shoot	T002	C2700376
27768814	1169	1189	artificial incisions	T169	C3496294
27768814	1196	1205	bacterium	T007	C0004611
27768814	1228	1240	antagonistic	T120	C0243076
27768814	1241	1251	activities	T052	C0441655
27768814	1260	1265	fungi	T004	C0016832
27768814	1270	1278	bacteria	T007	C0004611
27768814	1293	1307	Pinus pinaster	T002	C1028819
27768814	1334	1347	B. xylophilus	T204	C0997987
27768814	1374	1393	symbiotic community	T001	C0562641
27768814	1414	1418	pine	T002	C0330186
27768814	1419	1431	wilt disease	T047	C0032080
27768814	1432	1440	symptoms	T184	C1457887
27768814	1482	1490	bacteria	T007	C0004611
27768814	1496	1500	BXF1	T007	C0445754
27768814	1516	1528	plant-growth	T040	C0597252
27768814	1543	1555	antagonistic	T120	C0243076
27768814	1556	1563	effects	T080	C1280500
27768814	1606	1619	B. xylophilus	T204	C0997987
27768814	1648	1657	bacterial	T007	C0004611
27768814	1658	1678	endophytic community	T004	C1265415
27768814	1686	1690	host	T001	C1167395
27768814	1691	1695	pine	T002	C0330186

27770391|t|The effectiveness of disc synoptoscope on patients with abnormal binocular vision: a prospective cohort study
27770391|a|We performed a prospective cohort study to evaluate the effectiveness of disc synoptoscope on binocularity in patients with abnormal binocular vision. 39 eligible subjects were recruited for visual therapy with disc synoptoscope in treatment group and 38 were just observed as control. Simultaneous perception in treatment group was better than controls at 6- month visit (p < 0.05). Fusional amplitude improved in treatment group but decreased in control group at 3- and 6- months visits (p < 0.001). Near and distance stereopsis in treatment group were better than controls at 3- and 6- months (p < 0.05). The improvements of monocular and binocular acuity in treatment group were better than controls at 3- and 6- months (p < 0.05). Postoperative recurrence rate in treatment group was lower than controls (p < 0.05). Visual therapy with disc synoptoscope is effective in improving short-term binocular vision for the patients with abnormal binocular vision; disc synoptoscope could serve as an effective home -based visual therapy instrument.
27770391	4	17	effectiveness	T080	C1280519
27770391	21	38	disc synoptoscope	T074	C0025080
27770391	42	50	patients	T101	C0030705
27770391	56	64	abnormal	T033	C0205161
27770391	65	81	binocular vision	T041	C0042794
27770391	85	109	prospective cohort study	T062	C1709709
27770391	113	122	performed	T169	C0884358
27770391	125	149	prospective cohort study	T062	C1709709
27770391	166	179	effectiveness	T080	C1280519
27770391	183	200	disc synoptoscope	T074	C0025080
27770391	204	216	binocularity	T041	C0042794
27770391	220	228	patients	T101	C0030705
27770391	234	242	abnormal	T033	C0205161
27770391	243	259	binocular vision	T041	C0042794
27770391	273	281	subjects	T098	C0080105
27770391	301	315	visual therapy	T061	C0150177
27770391	321	338	disc synoptoscope	T074	C0025080
27770391	342	357	treatment group	T098	C1257890
27770391	387	394	control	T096	C0009932
27770391	396	419	Simultaneous perception	UnknownType	C0544681
27770391	423	438	treatment group	T098	C1257890
27770391	455	463	controls	T096	C0009932
27770391	470	475	month	T079	C0439231
27770391	476	481	visit	T058	C0589121
27770391	494	512	Fusional amplitude	T033	C0429558
27770391	513	521	improved	T033	C0184511
27770391	525	540	treatment group	T098	C1257890
27770391	545	554	decreased	T081	C0205216
27770391	558	571	control group	T096	C0009932
27770391	585	591	months	T079	C0439231
27770391	592	598	visits	T058	C0589121
27770391	612	616	Near	T080	C1706276
27770391	621	629	distance	T081	C0012751
27770391	630	640	stereopsis	T041	C0011586
27770391	644	659	treatment group	T098	C1257890
27770391	677	685	controls	T096	C0009932
27770391	699	705	months	T079	C0439231
27770391	722	734	improvements	T077	C2986411
27770391	738	747	monocular	T042	C0042797
27770391	752	761	binocular	T041	C0042794
27770391	762	768	acuity	T201	C0042812
27770391	772	787	treatment group	T098	C1257890
27770391	805	813	controls	T096	C0009932
27770391	827	833	months	T079	C0439231
27770391	846	859	Postoperative	T079	C0032790
27770391	860	875	recurrence rate	T081	C1521828
27770391	879	894	treatment group	T098	C1257890
27770391	910	918	controls	T096	C0009932
27770391	931	945	Visual therapy	T061	C0087111
27770391	951	968	disc synoptoscope	T074	C0025080
27770391	972	981	effective	T080	C1704419
27770391	995	1005	short-term	T079	C0443303
27770391	1006	1022	binocular vision	T041	C0042794
27770391	1031	1039	patients	T101	C0030705
27770391	1045	1053	abnormal	T033	C0205161
27770391	1054	1070	binocular vision	T041	C0042794
27770391	1072	1089	disc synoptoscope	T074	C0025080
27770391	1108	1117	effective	T080	C1704419
27770391	1118	1122	home	T082	C0442519
27770391	1130	1144	visual therapy	T061	C0150177
27770391	1145	1155	instrument	T074	C0348000

27328333|t|Uveitis in children
27328333|a|The review provides updates on novel risk markers for the development of pediatric inflammatory uveitis and a severe disease course, on treatment of refractory disease, and on the measurement of visual outcomes. There are several new genetic markers, biomarkers, and clinical factors that may influence a child's uveitis disease course. It is important to identify children at risk for poor visual outcomes and who are refractory to traditional therapy. Racial disparities have recently been reported. We describe agents of potential benefit. In addition, we discuss the importance of patient reported outcomes in this population. Uveitis can lead to vision-threatening complications. Timely and aggressive treatment of children identified to be at risk for a severe uveitis course may lead to improved outcomes.
27328333	0	7	Uveitis	T047	C0042164
27328333	11	19	children	T100	C0008059
27328333	51	56	novel	T080	C0205314
27328333	57	69	risk markers	T080	C1519104
27328333	78	89	development	T169	C1527148
27328333	93	102	pediatric	T080	C1521725
27328333	103	123	inflammatory uveitis	T047	C0042164
27328333	130	151	severe disease course	T046	C0242656
27328333	156	165	treatment	T061	C0087111
27328333	169	187	refractory disease	T033	C1514815
27328333	200	211	measurement	T169	C0242485
27328333	215	230	visual outcomes	T169	C1274040
27328333	254	269	genetic markers	T045	C0017393
27328333	271	281	biomarkers	T201	C0005516
27328333	287	295	clinical	T080	C0205210
27328333	296	303	factors	T169	C1521761
27328333	325	332	child's	T100	C0008059
27328333	333	340	uveitis	T047	C0042164
27328333	341	355	disease course	T046	C0242656
27328333	385	393	children	T100	C0008059
27328333	397	401	risk	T078	C0035647
27328333	406	426	poor visual outcomes	T169	C1274040
27328333	439	449	refractory	T169	C0332325
27328333	453	472	traditional therapy	T061	C3650840
27328333	474	492	Racial disparities	T033	C0243095
27328333	512	520	reported	T170	C0684224
27328333	534	540	agents	T120	C0450442
27328333	544	561	potential benefit	T081	C0814225
27328333	605	630	patient reported outcomes	T170	C2987124
27328333	639	649	population	T101	C0030705
27328333	651	658	Uveitis	T047	C0042164
27328333	671	703	vision-threatening complications	T046	C0009566
27328333	705	736	Timely and aggressive treatment	T061	C0087111
27328333	740	748	children	T100	C0008059
27328333	769	773	risk	T078	C0035647
27328333	780	801	severe uveitis course	T046	C0242656
27328333	814	831	improved outcomes	T169	C1274040

28352958|t|The epigenetic landscape of age - related diseases: the geroscience perspective
28352958|a|In this review, we summarize current knowledge regarding the epigenetics of age - related diseases, focusing on those studies that have described DNA methylation landscape in cardio-vascular diseases, musculoskeletal function and frailty. We stress the importance of adopting the conceptual framework of " geroscience ", which starts from the observation that advanced age is the major risk factor for several of these pathologies and aims at identifying the mechanistic links between aging and age - related diseases. DNA methylation undergoes a profound remodeling during aging, which includes global hypomethylation of the genome, hypermethylation at specific loci and an increase in inter-individual variation and in stochastic changes of DNA methylation values. These epigenetic modifications can be an important contributor to the development of age - related diseases, but our understanding on the complex relationship between the epigenetic signatures of aging and age - related disease is still poor. The most relevant results in this field come from the use of the so called " epigenetics clocks " in cohorts of subjects affected by age - related diseases. We report these studies in final section of this review.
28352958	4	24	epigenetic landscape	T045	C1516924
28352958	28	31	age	T032	C0001779
28352958	34	41	related	T169	C1552599
28352958	42	50	diseases	T047	C0012634
28352958	56	67	geroscience	T090	C1518533
28352958	68	79	perspective	T078	C1254370
28352958	88	94	review	T170	C0282443
28352958	141	152	epigenetics	T045	C1516924
28352958	156	159	age	T032	C0001779
28352958	162	169	related	T169	C1552599
28352958	170	178	diseases	T047	C0012634
28352958	198	205	studies	T062	C0008972
28352958	226	251	DNA methylation landscape	T044	C0376452
28352958	255	279	cardio-vascular diseases	T047	C0007222
28352958	281	305	musculoskeletal function	T042	C0026861
28352958	310	317	frailty	T033	C0424594
28352958	360	380	conceptual framework	T077	C1254372
28352958	386	397	geroscience	T090	C1518533
28352958	440	448	advanced	T098	C0001792
28352958	449	452	age	T032	C0001779
28352958	466	477	risk factor	T033	C0035648
28352958	499	510	pathologies	T169	C0205469
28352958	515	519	aims	T078	C1947946
28352958	539	556	mechanistic links	T080	C0439849
28352958	565	570	aging	T040	C0001811
28352958	575	578	age	T032	C0001779
28352958	581	588	related	T169	C1552599
28352958	589	597	diseases	T047	C0012634
28352958	599	614	DNA methylation	T044	C0376452
28352958	636	646	remodeling	UnknownType	C0678692
28352958	654	659	aging	T040	C0001811
28352958	676	698	global hypomethylation	T045	C2613367
28352958	706	712	genome	T028	C0017428
28352958	714	730	hypermethylation	T045	C1512554
28352958	734	742	specific	T080	C0205369
28352958	743	747	loci	T028	C0678933
28352958	755	763	increase	T169	C0442805
28352958	767	793	inter-individual variation	T070	C0042333
28352958	801	811	stochastic	T081	C0038347
28352958	812	819	changes	T169	C0392747
28352958	823	838	DNA methylation	T044	C0376452
28352958	839	845	values	T080	C0042295
28352958	853	863	epigenetic	T045	C1516924
28352958	864	877	modifications	T033	C3840684
28352958	917	928	development	T169	C1527148
28352958	932	935	age	T032	C0001779
28352958	938	945	related	T169	C1552599
28352958	946	954	diseases	T047	C0012634
28352958	985	992	complex	T080	C0439855
28352958	993	1005	relationship	T080	C0439849
28352958	1018	1039	epigenetic signatures	T045	C1516924
28352958	1043	1048	aging	T040	C0001811
28352958	1053	1056	age	T032	C0001779
28352958	1059	1066	related	T169	C1552599
28352958	1067	1074	disease	T047	C0012634
28352958	1099	1107	relevant	T080	C2347946
28352958	1108	1115	results	T033	C2825142
28352958	1167	1185	epigenetics clocks	T045	C1516924
28352958	1191	1198	cohorts	T098	C0599755
28352958	1202	1210	subjects	T098	C0080105
28352958	1211	1219	affected	T169	C0392760
28352958	1223	1226	age	T032	C0001779
28352958	1229	1236	related	T169	C1552599
28352958	1237	1245	diseases	T047	C0012634
28352958	1263	1270	studies	T062	C0008972
28352958	1296	1302	review	T170	C0282443

27484439|t|Prevalence of depression in patients of type 2 diabetes mellitus: A cross sectional study in a tertiary care centre
27484439|a|The present study aims to study the prevalence of depression in patients with uncomplicated type II diabetes mellitus and to find its association with various socio-demographic factors in the same. A cross-sectional, single interview study was performed in an outpatient department of an endocrinology institute. Total 80 type II DM patients without any associated complications of diabetes were included in this study. To diagnose Depressive Episode, structured clinical interview for DSM V was applied. Severity of depression was assessed by Hamilton Rating Scale for Depression (HAM-D). To assess socio-demographic characteristics of the patients, all of them were evaluated with a semi-structured socio-demographic performa. 38.75% patients (N=31) were found to be suffering from depression. Among them 48.38% were moderately depressed and none were suffering from very severe depression. Significant association was not found between depression and socio-demographic factors of age (p=0.920), gender (p=0.251), economic profile (p=0.583), local background of the patient (p=0.646), educational qualification (p=0.935) and marital status (p=0.644). Similarly no association was found with duration of diabetes, HbA1c and BMI. Exclusion of complicated cases didn't seem to influence overall prevalence of depression, although reduction in severity was apparent. Thus even in those diabetic patients who are leading a complication free life, a detailed psychiatric analysis to rule out depression is mandatory.
27484439	0	10	Prevalence	T081	C0033105
27484439	14	24	depression	T048	C0011570
27484439	28	36	patients	T101	C0030705
27484439	40	64	type 2 diabetes mellitus	T047	C0011860
27484439	68	89	cross sectional study	T062	C0010362
27484439	95	115	tertiary care centre	T073,T093	C0587437
27484439	128	133	study	T062	C2603343
27484439	134	138	aims	T078	C1947946
27484439	142	147	study	T062	C2603343
27484439	152	162	prevalence	T081	C0033105
27484439	166	176	depression	T048	C0011570
27484439	180	188	patients	T101	C0030705
27484439	194	233	uncomplicated type II diabetes mellitus	T047	C0546950
27484439	250	261	association	T080	C0439849
27484439	275	300	socio-demographic factors	T078	C0011292
27484439	316	331	cross-sectional	T062	C0010362
27484439	333	349	single interview	T052	C0021822
27484439	350	355	study	T062	C2603343
27484439	376	397	outpatient department	T073,T093	C0557824
27484439	404	417	endocrinology	T091	C0014137
27484439	418	427	institute	T092	C0021622
27484439	438	494	type II DM patients without any associated complications	T047	C0546950
27484439	498	506	diabetes	T047	C0011847
27484439	529	534	study	T062	C2603343
27484439	539	547	diagnose	T033	C0011900
27484439	548	566	Depressive Episode	T048	C0349217
27484439	568	597	structured clinical interview	T060	C0935589
27484439	602	607	DSM V	T170	C1137105
27484439	621	629	Severity	T080	C0439793
27484439	633	643	depression	T048	C0011570
27484439	648	656	assessed	T052	C1516048
27484439	660	696	Hamilton Rating Scale for Depression	T170	C0451203
27484439	698	703	HAM-D	T170	C0451203
27484439	709	715	assess	T058	C0184514
27484439	716	733	socio-demographic	T080	C0205556
27484439	734	749	characteristics	T080	C1521970
27484439	757	765	patients	T101	C0030705
27484439	784	793	evaluated	T058	C0220825
27484439	801	816	semi-structured	T080	C0205556
27484439	817	834	socio-demographic	T080	C0205556
27484439	852	860	patients	T101	C0030705
27484439	885	894	suffering	T048	C0683278
27484439	900	910	depression	T048	C0011570
27484439	935	955	moderately depressed	T170	C3828991
27484439	970	979	suffering	T048	C0683278
27484439	990	996	severe	T080	C0439793
27484439	997	1007	depression	T048	C0011570
27484439	1009	1020	Significant	T078	C0750502
27484439	1021	1032	association	T080	C0439849
27484439	1055	1065	depression	T048	C0011570
27484439	1070	1095	socio-demographic factors	T078	C0011292
27484439	1099	1102	age	T032	C0001779
27484439	1114	1120	gender	T032	C0079399
27484439	1132	1148	economic profile	T102	C0337781
27484439	1160	1191	local background of the patient	T201	C1717036
27484439	1203	1228	educational qualification	T033	C0013658
27484439	1243	1257	marital status	T102	C0024819
27484439	1282	1293	association	T080	C0439849
27484439	1309	1317	duration	T079	C0449238
27484439	1321	1329	diabetes	T047	C0011847
27484439	1331	1336	HbA1c	T116,T123	C0019018
27484439	1341	1344	BMI	T201	C1305855
27484439	1346	1355	Exclusion	T052	C2828389
27484439	1359	1370	complicated	T169	C0231242
27484439	1371	1376	cases	T169	C0868928
27484439	1392	1401	influence	T077	C4054723
27484439	1402	1409	overall	T080	C1561607
27484439	1410	1420	prevalence	T081	C0033105
27484439	1424	1434	depression	T048	C0011570
27484439	1445	1454	reduction	T080	C0392756
27484439	1458	1466	severity	T080	C0439793
27484439	1500	1508	diabetic	T033	C0241863
27484439	1509	1517	patients	T101	C0030705
27484439	1536	1553	complication free	T033	C4032686
27484439	1554	1558	life	T078	C0376558
27484439	1571	1582	psychiatric	T169	C0205487
27484439	1583	1591	analysis	T062	C0936012
27484439	1604	1614	depression	T048	C0011570

28125734|t|Identification of MiR-21-5p as a Functional Regulator of Mesothelin Expression Using MicroRNA Capture Affinity Coupled with Next Generation Sequencing
28125734|a|MicroRNAs (miRNAs) are small non-coding RNAs that regulate mRNA expression mainly by silencing target transcripts via binding to miRNA recognition elements (MREs) in the 3'untranslated region (3'UTR). The identification of bona fide targets is challenging for researchers working on the functional aspect of miRNAs. Recently, we developed a method (miR-CATCH) based on biotinylated DNA antisense oligonucleotides that capture the mRNA of interest and facilitates the characterisation of miRNAs::mRNA interactions in a physiological cellular context. Here, the miR-CATCH technique was applied to the mesothelin (MSLN) gene and coupled with next generation sequencing (NGS), to identify miRNAs that regulate MSLN mRNA and that may be responsible for its increased protein levels found in malignant pleural mesothelioma (MPM). Biotinylated MSLN oligos were employed to isolate miRNA::MSLN mRNA complexes from a normal cell line (Met-5A) which expresses low levels of MSLN. MiRNAs targeting the MSLN mRNA were identified by NGS and miR-21-5p and miR-100-5p were selected for further validation analyses. MiR-21-5p was shown to be able to modulate MSLN expression in miRNA mimic experiments in a panel of malignant and non-malignant cell lines. Further miRNA inhibitor experiments and luciferase assays in Mero-14 cells validated miR-21-5p as a true regulator of MSLN. Moreover, in vitro experiments showed that treatment with miR-21-5p mimic reduced proliferation of MPM cell lines. Altogether, this work shows that the miR-CATCH technique, coupled with NGS and in vitro validation, represents a reliable method to identify native miRNA::mRNA interactions. MiR-21-5p is suggested as novel regulator of MSLN with a possible functional role in cellular growth.
28125734	0	14	Identification	T080	C0205396
28125734	18	27	MiR-21-5p	T114,T123	C1101610
28125734	33	53	Functional Regulator	T028	C0017362
28125734	57	67	Mesothelin	T028	C1334533
28125734	68	78	Expression	T045	C0017262
28125734	85	93	MicroRNA	T114,T123	C1101610
28125734	102	110	Affinity	T070	C1510827
28125734	111	118	Coupled	T169	C1948027
28125734	124	150	Next Generation Sequencing	T063	C2936622
28125734	151	160	MicroRNAs	T114,T123	C1101610
28125734	162	168	miRNAs	T114,T123	C1101610
28125734	174	195	small non-coding RNAs	T114	C0887909
28125734	201	209	regulate	T045	C0017263
28125734	210	225	mRNA expression	T045	C1515670
28125734	236	245	silencing	T045	C0598496
28125734	246	252	target	T169	C1521840
28125734	253	264	transcripts	T114	C1519595
28125734	269	276	binding	T044	C1167622
28125734	280	313	miRNA recognition elements (MREs)	T086	C0314659
28125734	321	342	3'untranslated region	T086,T123	C0600600
28125734	344	349	3'UTR	T086,T123	C0600600
28125734	356	370	identification	T080	C0205396
28125734	374	383	bona fide	T082	C2323869
28125734	384	391	targets	T169	C1521840
28125734	411	430	researchers working	T033	C0243095
28125734	438	455	functional aspect	T169	C0205245
28125734	459	465	miRNAs	T114,T123	C1101610
28125734	492	510	method (miR-CATCH)	T169	C0449851
28125734	520	532	biotinylated	T044	C1159274
28125734	533	536	DNA	T114,T123	C0012854
28125734	537	563	antisense oligonucleotides	T114,T123,T130	C0079925
28125734	581	585	mRNA	T114,T123	C0035696
28125734	638	663	miRNAs::mRNA interactions	T045	C1523523
28125734	669	691	physiological cellular	T043	C1325880
28125734	711	730	miR-CATCH technique	T169	C0449851
28125734	750	772	mesothelin (MSLN) gene	T028	C1334533
28125734	777	784	coupled	T169	C1948027
28125734	790	816	next generation sequencing	T063	C2936622
28125734	818	821	NGS	T063	C2936622
28125734	836	842	miRNAs	T114,T123	C1101610
28125734	848	856	regulate	T045	C0017263
28125734	857	866	MSLN mRNA	T028	C1334533
28125734	913	927	protein levels	T034	C0428479
28125734	937	967	malignant pleural mesothelioma	T191	C0812413
28125734	969	972	MPM	T191	C0812413
28125734	975	987	Biotinylated	T044	C1159274
28125734	988	999	MSLN oligos	T028	C1334533
28125734	1025	1051	miRNA::MSLN mRNA complexes	T114,T116,T123	C1099355
28125734	1066	1084	cell line (Met-5A)	T025	C0007600
28125734	1091	1100	expresses	T045	C1171362
28125734	1115	1119	MSLN	T116,T129	C0380162
28125734	1121	1127	MiRNAs	T114,T123	C1101610
28125734	1128	1137	targeting	T169	C1521840
28125734	1142	1151	MSLN mRNA	T028	C1334533
28125734	1171	1174	NGS	T063	C2936622
28125734	1179	1188	miR-21-5p	T114,T123	C1101610
28125734	1193	1203	miR-100-5p	T114,T123	C1101610
28125734	1230	1249	validation analyses	T062	C0936012
28125734	1251	1260	MiR-21-5p	T114,T123	C1101610
28125734	1285	1293	modulate	T082	C0443264
28125734	1294	1298	MSLN	T028	C1334533
28125734	1299	1309	expression	T045	C0017262
28125734	1313	1318	miRNA	T114,T123	C1101610
28125734	1319	1324	mimic	T061	C0393040
28125734	1325	1336	experiments	T062	C0681814
28125734	1351	1360	malignant	T025	C0334227
28125734	1379	1389	cell lines	T025	C0007600
28125734	1399	1404	miRNA	T114,T123	C1101610
28125734	1405	1414	inhibitor	T080	C1999216
28125734	1415	1426	experiments	T062	C0681814
28125734	1431	1441	luciferase	T116,T126,T130	C0024075
28125734	1442	1448	assays	T059	C0005507
28125734	1452	1465	Mero-14 cells	T025	C0007634
28125734	1476	1485	miR-21-5p	T114,T123	C1101610
28125734	1496	1505	regulator	T028	C0017362
28125734	1509	1513	MSLN	T028	C1334533
28125734	1525	1545	in vitro experiments	T062	C0681828
28125734	1558	1567	treatment	T061	C0087111
28125734	1573	1582	miR-21-5p	T114,T123	C1101610
28125734	1583	1588	mimic	T061	C0393040
28125734	1597	1610	proliferation	T169	C1514485
28125734	1614	1617	MPM	T191	C0812413
28125734	1618	1628	cell lines	T025	C0007600
28125734	1667	1686	miR-CATCH technique	T169	C0449851
28125734	1688	1695	coupled	T169	C1948027
28125734	1701	1704	NGS	T063	C2936622
28125734	1709	1717	in vitro	T080	C1533691
28125734	1718	1728	validation	T062	C1519941
28125734	1752	1758	method	T169	C0449851
28125734	1778	1802	miRNA::mRNA interactions	T045	C1523523
28125734	1804	1813	MiR-21-5p	T114,T123	C1101610
28125734	1836	1845	regulator	T028	C0017362
28125734	1849	1853	MSLN	T028	C1334533
28125734	1870	1885	functional role	T169	C0205245
28125734	1889	1904	cellular growth	T043	C0007595

27680598|t|Sustained delivery of vincristine inside an orthotopic mouse sarcoma model decreases tumor growth
27680598|a|Sarcoma accounts for 20% of solid tumors in children. Surgery has significant morbidity. We hypothesized that delivering chemotherapy directly into tumors through sustained release silk systems could slow tumor growth. Human Ewing sarcoma cells A673 were cultured with vincristine and doxorubicin to determine half maximal inhibitory concentration (IC50). Cells were injected into mouse hind leg to create orthotopic tumors. Tumor volumes were measured using ultrasound. When volume reached >250mm(3,) interventions included: implantation of drug-free silk foam (Control -F), doxorubicin 400μg foam (Dox400 -F), vincristine 50μg foam (Vin50 -F), drug-free silk gel (Control -G), vincristine 50μg gel (Vin50 -G), or single dose intravenous vincristine 50μg (Vin50 -IV). End-point was volume>1000mm(3). Kaplan Meier and ANOVA were used. IC50 for vincristine and doxorubicin was 0.5ng/mL and 200ng/mL, respectively. There was no difference between Dox400 -F [6± 1days to end point (DTEP)] and Control -F (5±1.3 DTEP). Vin50 -F (12.4±3.5 DTEP) had slower growth compared to Control -F (p<0.001), and there was no difference between Vin50 -F and Vin50 -IV (14±0 DTEP). Growth was slowest with Vin50 -G, 28±10.3 DTEP compared to all other treatment groups (p<0.05). Sustained delivery of vincristine inside the sarcoma tumor with silk gel decreased tumor growth. Applying this intratumoral treatment strategy may potentially decrease the extent of surgical excision.
27680598	0	18	Sustained delivery	T122	C1710261
27680598	22	33	vincristine	T109,T121	C0042679
27680598	44	54	orthotopic	T082	C0574893
27680598	55	68	mouse sarcoma	T191	C1522023
27680598	75	84	decreases	T081	C0547047
27680598	85	97	tumor growth	T191	C0598934
27680598	98	105	Sarcoma	T191	C1261473
27680598	126	138	solid tumors	T191	C0280100
27680598	142	150	children	T100	C0008059
27680598	152	159	Surgery	T061	C0543467
27680598	176	185	morbidity	T081	C0026538
27680598	219	231	chemotherapy	T061	C3665472
27680598	246	252	tumors	T191	C0027651
27680598	261	278	sustained release	T122	C1710261
27680598	279	283	silk	T116,T121,T123	C0074529
27680598	303	315	tumor growth	T191	C0598934
27680598	317	322	Human	T016	C0086418
27680598	323	336	Ewing sarcoma	T191	C0553580
27680598	337	347	cells A673	T025	C0334227
27680598	353	361	cultured	T059	C0430400
27680598	367	378	vincristine	T109,T121	C0042679
27680598	383	394	doxorubicin	T109,T195	C0013089
27680598	408	445	half maximal inhibitory concentration	T081	C0600495
27680598	447	451	IC50	T081	C0600495
27680598	454	459	Cells	T025	C0334227
27680598	479	484	mouse	T015	C0025929
27680598	485	493	hind leg	T023	C1522391
27680598	504	514	orthotopic	T082	C0574893
27680598	515	521	tumors	T191	C0027651
27680598	523	536	Tumor volumes	T081	C0475276
27680598	557	567	ultrasound	T060	C0041618
27680598	600	613	interventions	T061	C0184661
27680598	624	636	implantation	T061	C0021107
27680598	640	649	drug-free	UnknownType	C0683584
27680598	650	654	silk	T116,T121,T123	C0074529
27680598	661	668	Control	T096	C0009932
27680598	674	685	doxorubicin	T109,T195	C0013089
27680598	697	704	(Dox400	T109,T195	C0013089
27680598	710	721	vincristine	T109,T121	C0042679
27680598	733	738	Vin50	T109,T121	C0042679
27680598	744	753	drug-free	UnknownType	C0683584
27680598	754	758	silk	T116,T121,T123	C0074529
27680598	759	762	gel	T167	C1382104
27680598	764	771	Control	T096	C0009932
27680598	777	788	vincristine	T109,T121	C0042679
27680598	794	797	gel	T167	C1382104
27680598	799	804	Vin50	T109,T121	C0042679
27680598	825	836	intravenous	T082	C0348016
27680598	837	848	vincristine	T109,T121	C0042679
27680598	855	860	Vin50	T109,T121	C0042679
27680598	867	876	End-point	T080	C2349179
27680598	899	911	Kaplan Meier	T081	C1720943
27680598	916	921	ANOVA	T081	C0002780
27680598	933	937	IC50	T081	C0600495
27680598	942	953	vincristine	T109,T121	C0042679
27680598	958	969	doxorubicin	T109,T195	C0013089
27680598	1043	1049	Dox400	T109,T195	C0013089
27680598	1057	1062	1days	T079	C0439228
27680598	1066	1075	end point	T080	C2349179
27680598	1077	1081	DTEP	T080	C2349179
27680598	1088	1095	Control	T096	C0009932
27680598	1106	1110	DTEP	T080	C2349179
27680598	1113	1118	Vin50	T109,T121	C0042679
27680598	1132	1136	DTEP	T080	C2349179
27680598	1142	1155	slower growth	T033	C4086857
27680598	1168	1175	Control	T096	C0009932
27680598	1226	1231	Vin50	T109,T121	C0042679
27680598	1239	1244	Vin50	T109,T121	C0042679
27680598	1255	1259	DTEP	T080	C2349179
27680598	1262	1280	Growth was slowest	T033	C4086857
27680598	1286	1291	Vin50	T109,T121	C0042679
27680598	1304	1308	DTEP	T080	C2349179
27680598	1358	1376	Sustained delivery	T122	C1710261
27680598	1380	1391	vincristine	T109,T121	C0042679
27680598	1403	1410	sarcoma	T191	C1261473
27680598	1411	1416	tumor	T191	C0027651
27680598	1422	1426	silk	T116,T121,T123	C0074529
27680598	1427	1430	gel	T167	C1382104
27680598	1431	1440	decreased	T081	C0547047
27680598	1441	1453	tumor growth	T191	C0598934
27680598	1469	1491	intratumoral treatment	T061	C1831733
27680598	1517	1525	decrease	T081	C0547047
27680598	1540	1557	surgical excision	T061	C0728940

27569088|t|Prevalence of HPV genotypes in cervical adenocarcinoma: a study in Greek women
27569088|a|To study the prevalence of human papillomavirus (HPV) genotypes among cervical adenocarcinomas in Greek women. The study group comprised 78 adenocarcinoma cases (20 in situ and 58 invasive). HPV DNA was amplified using polymerase chain reaction (PCR) and HPV genotypes were identified by reverse hybridization. There was a high prevalence of HPV infection both for in situ (95%) or invasive (94.83%) adenocarcinomas, comprising also cancers of unusual morphology. HPV 16 was the commonest strain (N=57, 73.08%) followed by HPV 18 (N=28, 35.90%). Interestingly, 13 cases (16.67%) were also HPV 52 positive (as co-infection with HPV 16 or 18). All other strains with the exception of HPV 66 were found only as co-infections. No significant age difference was noted in terms of any HPV strain positivity. HPV DNA was found in the large majority of cervical adenocarcinomas. As opposed to other studies, HPV 52 was the third most commonly encountered strain after HPV 16 and HPV 18. The above findings would probably be of help in decision making concerning vaccination policy for the prevention of HPV infection in Greece.
27569088	0	10	Prevalence	T081	C0033105
27569088	14	17	HPV	T005	C0021344
27569088	18	27	genotypes	T032	C0017431
27569088	31	54	cervical adenocarcinoma	T191	C0279672
27569088	58	63	study	T062	C2603343
27569088	67	72	Greek	T098	C0337806
27569088	73	78	women	T098	C0043210
27569088	82	87	study	T062	C2603343
27569088	92	102	prevalence	T081	C0033105
27569088	106	126	human papillomavirus	T005	C0021344
27569088	128	131	HPV	T005	C0021344
27569088	133	142	genotypes	T032	C0017431
27569088	149	173	cervical adenocarcinomas	T191	C0279672
27569088	177	182	Greek	T098	C0337806
27569088	183	188	women	T098	C0043210
27569088	194	205	study group	UnknownType	C0681860
27569088	219	233	adenocarcinoma	T191	C0001418
27569088	234	239	cases	T077	C1706256
27569088	244	251	in situ	T191	C0007099
27569088	259	267	invasive	T191	C1334274
27569088	270	277	HPV DNA	T114,T123	C3872595
27569088	282	291	amplified	T045	C0683230
27569088	298	323	polymerase chain reaction	T063	C0032520
27569088	325	328	PCR	T063	C0032520
27569088	334	337	HPV	T005	C0021344
27569088	338	347	genotypes	T032	C0017431
27569088	353	363	identified	T080	C0205396
27569088	367	388	reverse hybridization	T063	C0221902
27569088	402	417	high prevalence	T081	C0033105
27569088	421	434	HPV infection	T047	C0343641
27569088	444	451	in situ	T191	C0007099
27569088	461	494	invasive (94.83%) adenocarcinomas	T191	C1334274
27569088	512	519	cancers	T191	C0006826
27569088	523	541	unusual morphology	T080	C0332437
27569088	543	549	HPV 16	T005	C0999806
27569088	558	567	commonest	T081	C0205214
27569088	568	574	strain	T001	C1518614
27569088	602	608	HPV 18	T005	C0999807
27569088	643	648	cases	T077	C1706256
27569088	668	683	HPV 52 positive	T005	C3641016
27569088	688	700	co-infection	T047	C0275524
27569088	706	712	HPV 16	T005	C0999806
27569088	716	718	18	T005	C0999807
27569088	731	738	strains	T001	C1518614
27569088	748	757	exception	T077	C1705847
27569088	761	767	HPV 66	T005	C3641020
27569088	787	800	co-infections	T047	C0275524
27569088	817	831	age difference	T100	C0699810
27569088	858	861	HPV	T005	C0021344
27569088	862	868	strain	T001	C1518614
27569088	869	879	positivity	T033	C1446409
27569088	881	888	HPV DNA	T114,T123	C3872595
27569088	906	920	large majority	T054	C0680220
27569088	924	948	cervical adenocarcinomas	T191	C0279672
27569088	970	977	studies	T062	C0008972
27569088	979	985	HPV 52	T005	C3641016
27569088	1005	1013	commonly	T081	C0205214
27569088	1014	1025	encountered	T058	C0422301
27569088	1026	1032	strain	T001	C1518614
27569088	1039	1045	HPV 16	T005	C0999806
27569088	1050	1056	HPV 18	T005	C0999807
27569088	1098	1102	help	T080	C1269765
27569088	1106	1121	decision making	T041	C0011109
27569088	1133	1144	vaccination	T061	C0042196
27569088	1145	1151	policy	T170	C0242456
27569088	1160	1170	prevention	T080	C2700409
27569088	1174	1187	HPV infection	T047	C0343641
27569088	1191	1197	Greece	T083	C0018226

28542641|t|Platelet proteome reveals novel pathways of platelet activation and platelet - mediated immunoregulation in dengue
28542641|a|Dengue is the most prevalent human arbovirus disease worldwide. Dengue virus (DENV) infection causes syndromes varying from self-limiting febrile illness to severe dengue. Although dengue pathophysiology is not completely understood, it is widely accepted that increased inflammation plays important roles in dengue pathogenesis. Platelets are blood cells classically known as effectors of hemostasis which have been increasingly recognized to have major immune and inflammatory activities. Nevertheless, the phenotype and effector functions of platelets in dengue pathogenesis are not completely understood. Here we used quantitative proteomics to investigate the protein content of platelets in clinical samples from patients with dengue compared to platelets from healthy donors. Our assays revealed a set of 252 differentially abundant proteins. In silico analyses associated these proteins with key molecular events including platelet activation and inflammatory responses, and with events not previously attributed to platelets during dengue infection including antigen processing and presentation, proteasome activity, and expression of histones. From these results, we conducted functional assays using samples from a larger cohort of patients and demonstrated evidence for platelet activation indicated by P-selectin (CD62P) translocation and secretion of granule-stored chemokines by platelets. In addition, we found evidence that DENV infection triggers HLA class I synthesis and surface expression by a mechanism depending on functional proteasome activity. Furthermore, we demonstrate that cell-free histone H2A released during dengue infection binds to platelets, increasing platelet activation. These findings are consistent with functional importance of HLA class I, proteasome subunits, and histones that we found exclusively in proteome analysis of platelets in samples from dengue patients. Our study provides the first in-depth characterization of the platelet proteome in dengue, and sheds light on new mechanisms of platelet activation and platelet - mediated immune and inflammatory responses.
28542641	0	8	Platelet	T025	C0005821
28542641	9	17	proteome	T116,T123	C0751973
28542641	18	25	reveals	T080	C0443289
28542641	32	40	pathways	T077	C1705987
28542641	44	63	platelet activation	T042	C0032173
28542641	68	76	platelet	T025	C0005821
28542641	79	87	mediated	T080	C1280500
28542641	88	104	immunoregulation	T040	C0678889
28542641	108	114	dengue	T047	C0011311
28542641	115	121	Dengue	T047	C0011311
28542641	144	149	human	T016	C0086418
28542641	150	167	arbovirus disease	T047	C0599941
28542641	168	177	worldwide	T082	C0332464
28542641	179	208	Dengue virus (DENV) infection	T047	C0011311
28542641	209	215	causes	T169	C0015127
28542641	216	225	syndromes	T047	C0039082
28542641	253	268	febrile illness	T047	C0743841
28542641	272	285	severe dengue	T047	C0019100
28542641	296	302	dengue	T047	C0011311
28542641	303	318	pathophysiology	T169	C0031847
28542641	322	325	not	T169	C1518422
28542641	326	336	completely	T080	C0205197
28542641	337	347	understood	T041	C0162340
28542641	376	385	increased	T081	C0205217
28542641	386	398	inflammation	T046	C0021368
28542641	415	420	roles	T077	C1705810
28542641	424	430	dengue	T047	C0011311
28542641	431	443	pathogenesis	T046	C0699748
28542641	445	454	Platelets	T025	C0005821
28542641	459	470	blood cells	T025	C0005773
28542641	483	488	known	T080	C0205309
28542641	505	515	hemostasis	T042	C0019116
28542641	564	569	major	T080	C0205164
28542641	570	576	immune	T169	C0439662
28542641	581	593	inflammatory	T169	C0333348
28542641	594	604	activities	T052	C0441655
28542641	624	633	phenotype	T032	C0031437
28542641	638	656	effector functions	T043	C0007613
28542641	660	669	platelets	T025	C0005821
28542641	673	679	dengue	T047	C0011311
28542641	680	692	pathogenesis	T046	C0699748
28542641	697	700	not	T169	C1518422
28542641	701	711	completely	T080	C0205197
28542641	712	722	understood	T041	C0162340
28542641	737	749	quantitative	T081	C0392762
28542641	750	760	proteomics	T059	C1327760
28542641	764	775	investigate	T169	C1292732
28542641	780	795	protein content	T059	C0202202
28542641	799	808	platelets	T025	C0005821
28542641	812	820	clinical	T080	C0205210
28542641	821	828	samples	T031	C0178913
28542641	834	842	patients	T101	C0030705
28542641	848	854	dengue	T047	C0011311
28542641	855	863	compared	T052	C1707455
28542641	867	876	platelets	T025	C0005821
28542641	882	889	healthy	T080	C3898900
28542641	890	896	donors	T098	C0005795
28542641	902	908	assays	T059	C1510438
28542641	909	917	revealed	T080	C0443289
28542641	931	945	differentially	T080	C0443199
28542641	946	954	abundant	T080	C2346714
28542641	955	963	proteins	T116,T123	C0033684
28542641	965	974	In silico	T066	C3489666
28542641	975	983	analyses	T062	C0936012
28542641	984	994	associated	T080	C0332281
28542641	1001	1009	proteins	T116,T123	C0033684
28542641	1019	1028	molecular	T080	C1521991
28542641	1029	1035	events	T051	C0441471
28542641	1036	1045	including	T169	C0332257
28542641	1046	1065	platelet activation	T042	C0032173
28542641	1070	1092	inflammatory responses	T046	C1155266
28542641	1103	1109	events	T051	C0441471
28542641	1110	1113	not	T169	C1518422
28542641	1125	1135	attributed	T080	C1879746
28542641	1139	1148	platelets	T025	C0005821
28542641	1149	1155	during	T079	C0347984
28542641	1156	1162	dengue	T047	C0011311
28542641	1163	1172	infection	T046	C3714514
28542641	1173	1182	including	T169	C0332257
28542641	1183	1190	antigen	T129	C0003320
28542641	1191	1201	processing	T052	C1709694
28542641	1206	1218	presentation	T078	C0449450
28542641	1220	1239	proteasome activity	T044	C1622946
28542641	1245	1255	expression	T045	C1171362
28542641	1259	1267	histones	T116,T123	C0019652
28542641	1280	1287	results	T169	C1274040
28542641	1302	1312	functional	T169	C0205245
28542641	1313	1319	assays	T059	C1510438
28542641	1320	1325	using	T169	C1524063
28542641	1326	1333	samples	T167	C0370003
28542641	1341	1347	larger	T081	C0549177
28542641	1348	1354	cohort	T098	C0599755
28542641	1358	1366	patients	T101	C0030705
28542641	1384	1392	evidence	T078	C3887511
28542641	1397	1416	platelet activation	T042	C0032173
28542641	1417	1426	indicated	T033	C1444656
28542641	1430	1440	P-selectin	T116,T129	C0134835
28542641	1442	1447	CD62P	T116,T129	C0134835
28542641	1449	1462	translocation	T043	C0599893
28542641	1467	1476	secretion	T038	C0036536
28542641	1495	1505	chemokines	T116,T129	C0282554
28542641	1509	1518	platelets	T025	C0005821
28542641	1536	1541	found	T033	C0150312
28542641	1542	1550	evidence	T078	C3887511
28542641	1556	1570	DENV infection	T047	C0011311
28542641	1571	1579	triggers	T080	C1444748
28542641	1580	1591	HLA class I	T116,T129	C4038479
28542641	1592	1601	synthesis	T044	C0597295
28542641	1606	1613	surface	T082	C0205148
28542641	1614	1624	expression	T045	C1171362
28542641	1630	1639	mechanism	T169	C0441712
28542641	1653	1663	functional	T169	C0205245
28542641	1664	1683	proteasome activity	T044	C1622946
28542641	1718	1739	cell-free histone H2A	T116,T123	C0019646
28542641	1740	1748	released	T169	C0391871
28542641	1749	1755	during	T079	C0347984
28542641	1756	1772	dengue infection	T047	C0011311
28542641	1773	1778	binds	T044	C1167622
28542641	1782	1791	platelets	T025	C0005821
28542641	1793	1803	increasing	T169	C0442808
28542641	1804	1823	platelet activation	T042	C0032173
28542641	1831	1839	findings	T033	C0243095
28542641	1844	1859	consistent with	T078	C0332290
28542641	1860	1870	functional	T169	C0205245
28542641	1871	1881	importance	T080	C3898777
28542641	1885	1896	HLA class I	T116,T129	C4038479
28542641	1898	1908	proteasome	T116,T126	C0208355
28542641	1909	1917	subunits	T116	C0599220
28542641	1923	1931	histones	T116,T123	C0019652
28542641	1940	1945	found	T033	C0150312
28542641	1961	1969	proteome	T116,T123	C0751973
28542641	1970	1978	analysis	T169	C1524024
28542641	1982	1991	platelets	T025	C0005821
28542641	1995	2002	samples	T031	C0178913
28542641	2008	2014	dengue	T047	C0011311
28542641	2015	2023	patients	T101	C0030705
28542641	2029	2034	study	T062	C2603343
28542641	2035	2043	provides	T052	C1999230
28542641	2063	2079	characterization	T052	C1880022
28542641	2087	2095	platelet	T025	C0005821
28542641	2096	2104	proteome	T116,T123	C0751973
28542641	2108	2114	dengue	T047	C0011311
28542641	2139	2149	mechanisms	T169	C0441712
28542641	2153	2172	platelet activation	T042	C0032173
28542641	2177	2185	platelet	T025	C0005821
28542641	2188	2196	mediated	T080	C1280500
28542641	2197	2203	immune	T042	C0301872
28542641	2208	2230	inflammatory responses	T046	C1155266

27283081|t|Sinus augmentation using a histone deacetylase inhibitor in a calcium sulfate carrier in rabbit: A pilot study
27283081|a|Histone deacetylase inhibitors such as sodium butyrate (SB) have been suggested to be promising candidate small molecules for bone regeneration. In this study, the capacity of SB loaded onto calcium sulfate (CaS) to enhance bone formation was investigated in a rabbit sinus model. Following preparation of the sinus access window on a randomly selected side, SB loaded onto CaS (CaS / SB) was grafted in five rabbits, and CaS alone (control) was grafted in another five rabbits. The animals were euthanized after 4 weeks for radiographic, histometric, and immunohistochemical analyses. There was a statistically significant difference in the total augmented volume between the groups in the radiographic analysis (158.22 ± 39.31 mm(3) and 107.09 ± 39.69 mm(3), respectively, p = 0.040). The CaS / SB group showed a larger portion of mature lamellar bone and a higher level of mineralization of bone trabeculae, characterized by more intense labeling with osteocalcin compared with the control group in the immunohistochemical analysis. The number of osteocalcin-positive cells within the central area of the augmented sinus was significantly higher in the CaS / SB group than in the control group (179 ± 26.0 mm(2) and 123 ± 33.2 mm(2), respectively, p = 0.027). In conclusion, CaS / SB exhibited superior osteogenic potential, especially in the central portion of the augmented sinus as well as improvement of the volume maintenance for sinus augmentation. © 2016 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 2016.
27283081	0	18	Sinus augmentation	T061	C2236586
27283081	27	56	histone deacetylase inhibitor	T116,T121,T126	C1512474
27283081	62	77	calcium sulfate	T121,T122,T197	C0006720
27283081	78	85	carrier	T122	C0013161
27283081	89	95	rabbit	T015	C3887509
27283081	99	110	pilot study	T062	C0031928
27283081	111	141	Histone deacetylase inhibitors	T116,T121,T126	C1512474
27283081	150	165	sodium butyrate	T109,T121	C0142812
27283081	167	169	SB	T109,T121	C0142812
27283081	207	232	candidate small molecules	T121	C1254351
27283081	237	254	bone regeneration	T042	C0005972
27283081	275	283	capacity	T081	C1516240
27283081	287	289	SB	T109,T121	C0142812
27283081	290	296	loaded	T052	C1708715
27283081	302	317	calcium sulfate	T121,T122,T197	C0006720
27283081	319	322	CaS	T121,T122,T197	C0006720
27283081	327	334	enhance	T052	C2349975
27283081	335	349	bone formation	T042	C0029433
27283081	372	390	rabbit sinus model	T008	C0599779
27283081	421	426	sinus	T030	C0030471
27283081	427	433	access	T169	C1554204
27283081	464	468	side	T082	C0441987
27283081	470	472	SB	T109,T121	C0142812
27283081	473	479	loaded	T052	C1708715
27283081	485	488	CaS	T121,T122,T197	C0006720
27283081	490	493	CaS	T121,T122,T197	C0006720
27283081	496	498	SB	T109,T121	C0142812
27283081	504	511	grafted	T061	C1961139
27283081	520	527	rabbits	T015	C3887509
27283081	533	536	CaS	T121,T122,T197	C0006720
27283081	544	551	control	T096	C0009932
27283081	557	564	grafted	T061	C1961139
27283081	581	588	rabbits	T015	C3887509
27283081	594	601	animals	T008	C0003062
27283081	607	617	euthanized	T058	C1136183
27283081	636	648	radiographic	T060	C1962945
27283081	650	661	histometric	T059	C0344441
27283081	667	686	immunohistochemical	T059	C1441616
27283081	687	695	analyses	T062	C0936012
27283081	709	734	statistically significant	T081	C0237881
27283081	759	768	augmented	T081	C0205217
27283081	769	775	volume	T082	C0456389
27283081	788	794	groups	T078	C0441833
27283081	802	823	radiographic analysis	T060	C1962945
27283081	902	905	CaS	T121,T122,T197	C0006720
27283081	908	910	SB	T109,T121	C0142812
27283081	911	916	group	T078	C0441833
27283081	926	932	larger	T081	C0549177
27283081	933	940	portion	T082	C0449719
27283081	944	950	mature	T079	C0205286
27283081	951	964	lamellar bone	T024	C0682560
27283081	987	1001	mineralization	T042	C2350989
27283081	1005	1020	bone trabeculae	T024	C2826619
27283081	1052	1060	labeling	T059	C0887853
27283081	1066	1077	osteocalcin	T116,T123	C0029419
27283081	1096	1109	control group	T096	C0009932
27283081	1117	1136	immunohistochemical	T059	C1441616
27283081	1137	1145	analysis	T062	C0936012
27283081	1161	1181	osteocalcin-positive	T116,T123	C0029419
27283081	1182	1187	cells	T025	C0007634
27283081	1199	1211	central area	T082	C0205099
27283081	1219	1228	augmented	T081	C0205217
27283081	1229	1234	sinus	T030	C0030471
27283081	1253	1259	higher	T080	C0205250
27283081	1267	1270	CaS	T121,T122,T197	C0006720
27283081	1273	1275	SB	T109,T121	C0142812
27283081	1276	1281	group	T078	C0441833
27283081	1294	1307	control group	T096	C0009932
27283081	1389	1392	CaS	T121,T122,T197	C0006720
27283081	1395	1397	SB	T109,T121	C0142812
27283081	1408	1416	superior	T080	C0205250
27283081	1417	1437	osteogenic potential	T042	C0029433
27283081	1457	1472	central portion	T082	C0449719
27283081	1480	1489	augmented	T081	C0205217
27283081	1490	1495	sinus	T030	C0030471
27283081	1507	1518	improvement	T077	C2986411
27283081	1526	1532	volume	T082	C0456389
27283081	1533	1544	maintenance	T052	C0024501
27283081	1549	1567	sinus augmentation	T061	C2236586

27695358|t|The correlation between CYP2D6 isoenzyme activity and haloperidol efficacy and safety profile in patients with alcohol addiction during the exacerbation of the addiction
27695358|a|Today, it is proved that isoenzymes CYP2D6 and CYP3A4 are involved in metabolism of haloperidol. In our previous investigation, we found a medium correlation between the efficacy and safety of haloperidol and the activity of CYP3A4 in patients with alcohol abuse. The aim of this study was to evaluate the correlation between the activity of CYP2D6 and the efficacy and safety of haloperidol in patients with diagnosed alcohol abuse. The study involved 70 men (average age: 40.83±9.92 years) with alcohol addiction. A series of psychometric scales were used in the research. The activity of CYP2D6 was evaluated by high-performance liquid chromatography with mass spectrometry using the ratio of 6-hydroxy-1,2,3,4-tetrahydro-beta-carboline to pinoline. Genotyping of CYP2D6 (1846G>A) was performed using real-time polymerase chain reaction. According to results of correlation analysis, statistically significant values of Spearman correlation coefficient (rs) between the activity of CYP2D6 and the difference of points in psychometric scale were obtained in patients receiving haloperidol in injection form (Sheehan Clinical Anxiety Rating Scale =-0.721 [P<0.001] and Udvald for Kliniske Undersogelser Side Effect Rating Scale =0.692 [P<0.001]) and in those receiving haloperidol in tablet form (Covi Anxiety Scale =-0.851 [P<0.001] and Udvald for Kliniske Undersogelser Side Effect Rating Scale =0.797 [P<0.001]). This study demonstrated the correlations between the activity of CYP2D6 isozyme and the efficacy and safety of haloperidol in patients with alcohol addiction.
27695358	4	15	correlation	T080	C1707520
27695358	24	30	CYP2D6	T116,T126	C0057223
27695358	31	49	isoenzyme activity	T044	C0243102
27695358	54	65	haloperidol	T109,T121	C0018546
27695358	66	74	efficacy	T080	C1280519
27695358	79	93	safety profile	T169	C2003903
27695358	97	105	patients	T101	C0030705
27695358	111	128	alcohol addiction	T048	C0001973
27695358	140	152	exacerbation	T033	C4086268
27695358	160	169	addiction	T048	C0001973
27695358	195	205	isoenzymes	T116,T126	C0022173
27695358	206	212	CYP2D6	T116,T126	C0057223
27695358	217	223	CYP3A4	T116,T126	C1142644
27695358	240	250	metabolism	T040	C0025519
27695358	254	265	haloperidol	T109,T121	C0018546
27695358	283	296	investigation	T169	C1292732
27695358	316	327	correlation	T080	C1707520
27695358	340	348	efficacy	T080	C1280519
27695358	353	359	safety	T068	C0036043
27695358	363	374	haloperidol	T109,T121	C0018546
27695358	383	391	activity	T044	C0243102
27695358	395	401	CYP3A4	T116,T126	C1142644
27695358	405	413	patients	T101	C0030705
27695358	419	432	alcohol abuse	T048	C0085762
27695358	450	455	study	T062	C2603343
27695358	463	471	evaluate	T169	C1292732
27695358	476	487	correlation	T080	C1707520
27695358	500	508	activity	T044	C0243102
27695358	512	518	CYP2D6	T116,T126	C0057223
27695358	527	535	efficacy	T080	C1280519
27695358	540	546	safety	T068	C0036043
27695358	550	561	haloperidol	T109,T121	C0018546
27695358	565	573	patients	T101	C0030705
27695358	589	602	alcohol abuse	T048	C0085762
27695358	608	613	study	T062	C2603343
27695358	626	629	men	T098	C0025266
27695358	639	642	age	T032	C0001779
27695358	655	660	years	T079	C0439234
27695358	667	684	alcohol addiction	T048	C0001973
27695358	698	717	psychometric scales	T170	C0349674
27695358	735	743	research	T062	C0035168
27695358	749	757	activity	T044	C0243102
27695358	761	767	CYP2D6	T116,T126	C0057223
27695358	785	823	high-performance liquid chromatography	T059	C0008562
27695358	829	846	mass spectrometry	T059	C0037813
27695358	857	862	ratio	T081	C0456603
27695358	866	909	6-hydroxy-1,2,3,4-tetrahydro-beta-carboline	T109	C0049585
27695358	913	921	pinoline	T109,T121	C0049646
27695358	923	933	Genotyping	T059	C1285573
27695358	937	943	CYP2D6	T116,T126	C0057223
27695358	974	1009	real-time polymerase chain reaction	T063	C1709846
27695358	1035	1055	correlation analysis	T062,T170	C0010101
27695358	1057	1082	statistically significant	T081	C0237881
27695358	1083	1089	values	T080	C0042295
27695358	1093	1125	Spearman correlation coefficient	T081	C0242929
27695358	1127	1129	rs	T081	C0242929
27695358	1143	1151	activity	T044	C0243102
27695358	1155	1161	CYP2D6	T116,T126	C0057223
27695358	1194	1212	psychometric scale	T170	C0349674
27695358	1230	1238	patients	T101	C0030705
27695358	1249	1260	haloperidol	T109,T121	C0018546
27695358	1264	1278	injection form	T122	C1272883
27695358	1280	1317	Sheehan Clinical Anxiety Rating Scale	T081,T170	C0681889
27695358	1340	1398	Udvald for Kliniske Undersogelser Side Effect Rating Scale	T081,T170	C0681889
27695358	1440	1451	haloperidol	T109,T121	C0018546
27695358	1455	1466	tablet form	T122	C0993159
27695358	1468	1486	Covi Anxiety Scale	T170	C0451073
27695358	1509	1567	Udvald for Kliniske Undersogelser Side Effect Rating Scale	T081,T170	C0681889
27695358	1592	1597	study	T062	C2603343
27695358	1615	1627	correlations	T080	C1707520
27695358	1640	1648	activity	T044	C0243102
27695358	1652	1666	CYP2D6 isozyme	T116,T126	C0057223
27695358	1675	1683	efficacy	T080	C1280519
27695358	1688	1694	safety	T068	C0036043
27695358	1698	1709	haloperidol	T109,T121	C0018546
27695358	1713	1721	patients	T101	C0030705
27695358	1727	1744	alcohol addiction	T048	C0001973

27565870|t|Molecular Characterization of Equine APRIL and its Expression Analysis During the Adipogenic Differentiation of Equine Adipose - Derived Stem Cell In Vitro
27565870|a|A proliferation inducing ligand (APRIL) is a member of the TNF superfamily. It shares two receptors with B-cell activating factor (BAFF), B-cell maturation antigen (BCMA), and transmembrane activator and CAML interactor (TACI). Herein, the equine APRIL was identified from equine adipose-derived stem cell (ASC), and the protein expression of APRIL and its related molecules were detected during the adipogenic differentiation of equine ASC in vitro. The equine APRIL gene was located on chromosome 11, spans 1852 base pairs (bp). Its open reading frame covers 753 bp, encoding a 250-amino acid protein with the typical TNF structure domain. During the two weeks' adipogenic differentiation of equine ASC, although the protein expression of APRIL and TACI had an insignificant change, that of BCMA increased significantly. Moreover, with the addition of recombinant protein His6-sAPRIL, a reduced differentiation of equine ASC toward adipocyte was detected. These results may provide the basis for investigating the role of APRIL in ASC adipogenic differentiation.
27565870	0	9	Molecular	T080	C1521991
27565870	10	26	Characterization	T052	C1880022
27565870	30	36	Equine	T015	C0019944
27565870	37	42	APRIL	T116,T123	C1706374
27565870	51	70	Expression Analysis	T059	C1882495
27565870	71	77	During	T079	C0347984
27565870	82	92	Adipogenic	T044	C0596843
27565870	93	108	Differentiation	T043	C0007589
27565870	112	118	Equine	T015	C0019944
27565870	119	126	Adipose	T024	C0001527
27565870	129	136	Derived	T080	C1441547
27565870	137	146	Stem Cell	T025	C0038250
27565870	147	155	In Vitro	T080	C1533691
27565870	158	187	proliferation inducing ligand	T116,T123	C1706374
27565870	189	194	APRIL	T116,T123	C1706374
27565870	201	210	member of	T082	C1292711
27565870	215	218	TNF	T116,T129	C0041368
27565870	219	230	superfamily	T077	C1883220
27565870	246	255	receptors	T116,T192	C0597357
27565870	261	285	B-cell activating factor	T116,T123	C1682317
27565870	287	291	BAFF	T116,T123	C1682317
27565870	294	319	B-cell maturation antigen	T116,T192	C1706297
27565870	321	325	BCMA	T116,T192	C1706297
27565870	332	375	transmembrane activator and CAML interactor	T116,T192	C1706295
27565870	377	381	TACI	T116,T192	C1706295
27565870	396	402	equine	T015	C0019944
27565870	403	408	APRIL	T116,T123	C1706374
27565870	413	423	identified	T080	C0205396
27565870	429	435	equine	T015	C0019944
27565870	436	461	adipose-derived stem cell	T025	C1636199
27565870	463	466	ASC	T025	C1636199
27565870	477	495	protein expression	T045	C1171362
27565870	499	504	APRIL	T116,T123	C1706374
27565870	521	530	molecules	T167	C0567416
27565870	536	544	detected	T033	C0442726
27565870	545	551	during	T079	C0347984
27565870	556	566	adipogenic	T044	C0596843
27565870	567	582	differentiation	T043	C0007589
27565870	586	592	equine	T015	C0019944
27565870	593	596	ASC	T025	C1636199
27565870	597	605	in vitro	T080	C1533691
27565870	611	617	equine	T015	C0019944
27565870	618	628	APRIL gene	T028	C1420815
27565870	633	640	located	T082	C0332285
27565870	644	657	chromosome 11	T026	C0008633
27565870	659	680	spans 1852 base pairs	T086	C0004793
27565870	682	684	bp	T086	C0004793
27565870	691	709	open reading frame	T028	C0079941
27565870	717	723	753 bp	T086	C0004793
27565870	736	758	250-amino acid protein	T116,T123	C0033684
27565870	776	779	TNF	T116,T129	C0041368
27565870	780	796	structure domain	T087	C1514562
27565870	798	804	During	T079	C0347984
27565870	820	830	adipogenic	T044	C0596843
27565870	831	846	differentiation	T043	C0007589
27565870	850	856	equine	T015	C0019944
27565870	857	860	ASC	T025	C1636199
27565870	875	893	protein expression	T045	C1171362
27565870	897	902	APRIL	T116,T123	C1706374
27565870	907	911	TACI	T116,T192	C1706295
27565870	919	939	insignificant change	T033	C0243095
27565870	949	953	BCMA	T116,T192	C1706297
27565870	954	963	increased	T081	C0205217
27565870	964	977	significantly	T078	C0750502
27565870	1010	1029	recombinant protein	T116	C0034861
27565870	1030	1041	His6-sAPRIL	T116	C0034861
27565870	1045	1052	reduced	T080	C0392756
27565870	1053	1068	differentiation	T043	C0007589
27565870	1072	1078	equine	T015	C0019944
27565870	1079	1082	ASC	T025	C1636199
27565870	1090	1099	adipocyte	T025	C0206131
27565870	1104	1112	detected	T033	C0442726
27565870	1120	1127	results	T169	C1274040
27565870	1132	1139	provide	T052	C1999230
27565870	1144	1149	basis	T169	C1527178
27565870	1154	1167	investigating	T169	C1292732
27565870	1172	1176	role	T077	C1705810
27565870	1180	1185	APRIL	T116,T123	C1706374
27565870	1189	1192	ASC	T025	C1636199
27565870	1193	1203	adipogenic	T044	C0596843
27565870	1204	1219	differentiation	T043	C0007589

27429935|t|The clinical prognosis of implants that are placed against super-erupted opposing dentition
27429935|a|If teeth are missing, super-eruption of teeth in the opposing arch can occur in the area and can change the occlusal plane. When missing teeth are replaced with implants, the oral surgeon must determine whether or not the super-erupted teeth need to be treated in order to normalize the occlusal plane. In this study, we evaluated the clinical prognosis of dentition after implant placement and prosthetic treatment were completed in an occlusal plane altered by super-erupted teeth in the opposing arch without additional treatment of the super-erupted teeth. Twenty-two patients (9 males, 13 females) were treated with implants and prosthetics without addressing the super-erupted opposing dentition from April 2004 to August 2012 at Seoul National University Bundang Hospital. A total of 33 implants were placed. Values of crestal bone loss, survival rates, and surgical and prosthetic complications for an average of 29.6 months after prosthetic loading were recorded. In one case, the cover screw was exposed after implant surgery. The mean crestal bone loss was 0.09±0.30 mm. Of the 33 implants, 31 survived, a survival rate of 93.94%. A prosthetic complication occurred in one case but functioned well after correction. Favorable clinical results from prosthetic complications, crestal bone loss, and implant survival rates were exhibited in implants next to a super-erupted opposing tooth.
27429935	4	22	clinical prognosis	T033	C1317293
27429935	26	34	implants	T074	C0021102
27429935	59	72	super-erupted	T047	C3839493
27429935	82	91	dentition	T023	C0011443
27429935	95	100	teeth	T023	C0040426
27429935	105	112	missing	T020	C0080233
27429935	114	137	super-eruption of teeth	T047	C3839493
27429935	145	158	opposing arch	T082	C1254362
27429935	176	180	area	T082	C0205146
27429935	200	214	occlusal plane	T042	C0524544
27429935	221	234	missing teeth	T020	C0080233
27429935	253	261	implants	T074	C0021102
27429935	267	279	oral surgeon	T097	C0260272
27429935	314	333	super-erupted teeth	T023	C0040426
27429935	345	352	treated	T169	C1522326
27429935	365	374	normalize	T062	C1882115
27429935	379	393	occlusal plane	T042	C0524544
27429935	403	408	study	T062	C0008972
27429935	413	422	evaluated	T058	C0220825
27429935	427	445	clinical prognosis	T033	C1317293
27429935	449	458	dentition	T023	C0011443
27429935	465	482	implant placement	T061	C0021107
27429935	487	507	prosthetic treatment	T061	C0204076
27429935	513	522	completed	T080	C0205197
27429935	529	543	occlusal plane	T042	C0524544
27429935	555	574	super-erupted teeth	T023	C0040426
27429935	582	595	opposing arch	T082	C1254362
27429935	615	624	treatment	T169	C1522326
27429935	632	651	super-erupted teeth	T023	C0040426
27429935	664	672	patients	T101	C0030705
27429935	676	681	males	T032	C0086582
27429935	686	693	females	T032	C0086287
27429935	700	707	treated	T169	C1522326
27429935	713	721	implants	T074	C0021102
27429935	726	737	prosthetics	T074	C0175649
27429935	761	774	super-erupted	T047	C3839493
27429935	784	793	dentition	T023	C0011443
27429935	828	833	Seoul	T083	C3850150
27429935	834	870	National University Bundang Hospital	T073,T093	C0019994
27429935	886	894	implants	T074	C0021102
27429935	918	935	crestal bone loss	T047	C0002382
27429935	937	951	survival rates	T081	C0038954
27429935	957	965	surgical	T046	C0274311
27429935	970	994	prosthetic complications	T046	C0274320
27429935	1018	1024	months	T079	C0439231
27429935	1031	1049	prosthetic loading	T061	C0204076
27429935	1072	1076	case	T077	C1706256
27429935	1082	1093	cover screw	T074	C0021102
27429935	1112	1127	implant surgery	T061	C0543467
27429935	1138	1155	crestal bone loss	T047	C0002382
27429935	1184	1192	implants	T074	C0021102
27429935	1197	1205	survived	T067	C3179277
27429935	1209	1222	survival rate	T081	C0038954
27429935	1236	1259	prosthetic complication	T046	C0274320
27429935	1276	1280	case	T077	C1706256
27429935	1329	1345	clinical results	T034	C0456984
27429935	1351	1375	prosthetic complications	T046	C0274320
27429935	1377	1394	crestal bone loss	T047	C0002382
27429935	1400	1407	implant	T074	C0021102
27429935	1408	1422	survival rates	T081	C0038954
27429935	1441	1449	implants	T074	C0021102
27429935	1460	1488	super-erupted opposing tooth	T023	C0040426

27942049|t|Potassium depletion stimulates Na-Cl cotransporter via phosphorylation and inactivation of the ubiquitin ligase Kelch-like 3
27942049|a|Kelch-like 3 (KLHL3) is a component of an E3 ubiquitin ligase complex that regulates blood pressure by targeting With-No-Lysine (WNK) kinases for degradation. Mutations in KLHL3 cause constitutively increased renal salt reabsorption and impaired K(+) secretion, resulting in hypertension and hyperkalemia. Although clinical studies have shown that dietary K(+) intake affects blood pressure, the mechanisms have been obscure. In this study, we demonstrate that the KLHL3 ubiquitin ligase complex is involved in the low- K(+) -mediated activation of Na-Cl cotransporter (NCC) in the kidney. In the distal convoluted tubules of mice eating a low-K(+) diet, we found increased KLHL3 phosphorylation at S433 (KLHL3(S433-P)), a modification that impairs WNK binding, and also reduced total KLHL3 levels. These changes are accompanied by the accumulation of the target substrate WNK4, and activation of the downstream kinases SPAK (STE20 / SPS1 -related proline-alanine-rich protein kinase) and OSR1 (oxidative stress-responsive 1), resulting in NCC phosphorylation and its accumulation at the plasma membrane. Increased phosphorylation of S433 was explained by increased levels of active, phosphorylated protein kinase C (but not protein kinase A), which directly phosphorylates S433. Moreover, in HEK cells expressing KLHL3 and WNK4, we showed that the activation of protein kinase C by phorbol 12-myristate 13-acetate induces KLHL3(S433-P) and increases WNK4 levels by abrogating its ubiquitination. These data demonstrate the role of KLHL3 in low- K(+) -mediated induction of NCC; this physiologic adaptation reduces distal electrogenic Na(+) reabsorption, preventing further renal K(+) loss but promoting increased blood pressure.
27942049	0	19	Potassium depletion	T047	C1971021
27942049	20	30	stimulates	T070	C1948023
27942049	31	50	Na-Cl cotransporter	T116,T123	C0074782
27942049	55	70	phosphorylation	T044	C0031715
27942049	75	87	inactivation	T169	C0544461
27942049	95	111	ubiquitin ligase	T116,T126	C0077678
27942049	112	124	Kelch-like 3	T116	C4042100
27942049	125	137	Kelch-like 3	T116	C4042100
27942049	139	144	KLHL3	T116	C4042100
27942049	151	160	component	T116,T123	C1179435
27942049	167	194	E3 ubiquitin ligase complex	T116,T126	C0077678
27942049	200	209	regulates	T038	C1327622
27942049	210	224	blood pressure	T040	C0005823
27942049	228	237	targeting	T169	C1521840
27942049	238	266	With-No-Lysine (WNK) kinases	T116,T126	C0031727
27942049	271	282	degradation	T169	C0243125
27942049	284	293	Mutations	T045	C0026882
27942049	297	302	KLHL3	T116	C4042100
27942049	324	357	increased renal salt reabsorption	T033	C3278017
27942049	362	370	impaired	T169	C0221099
27942049	371	375	K(+)	T123,T196	C0032821
27942049	376	385	secretion	T038	C0036536
27942049	400	412	hypertension	T047	C0020538
27942049	417	429	hyperkalemia	T033	C0020461
27942049	440	456	clinical studies	T062	C0008972
27942049	473	485	dietary K(+)	T168	C0162800
27942049	486	492	intake	T169	C1512806
27942049	493	500	affects	T169	C0392760
27942049	501	515	blood pressure	T040	C0005823
27942049	521	531	mechanisms	T169	C0441712
27942049	542	549	obscure	T033	C3845108
27942049	590	595	KLHL3	T116	C4042100
27942049	596	612	ubiquitin ligase	T116,T126	C0077678
27942049	613	620	complex	T116,T123	C1180347
27942049	645	649	K(+)	T123,T196	C0032821
27942049	660	670	activation	T045	C0599177
27942049	674	693	Na-Cl cotransporter	T116,T123	C0074782
27942049	695	698	NCC	T116,T123	C0074782
27942049	707	713	kidney	T023	C0022646
27942049	722	747	distal convoluted tubules	T023	C0022676
27942049	751	755	mice	T015	C0025929
27942049	756	762	eating	T040	C0013470
27942049	765	778	low-K(+) diet	T061	C0948941
27942049	799	804	KLHL3	T116	C4042100
27942049	805	820	phosphorylation	T044	C0031715
27942049	824	828	S433	T082	C1254362
27942049	829	844	(KLHL3(S433-P))	T116	C4042100
27942049	848	860	modification	T033	C3840684
27942049	866	873	impairs	T169	C0221099
27942049	874	877	WNK	T116,T126	C0031727
27942049	878	885	binding	T052	C1145667
27942049	910	915	KLHL3	T116	C4042100
27942049	916	922	levels	T080	C0441889
27942049	961	973	accumulation	T033	C4055506
27942049	981	987	target	T169	C1521840
27942049	988	997	substrate	T167	C3891814
27942049	998	1002	WNK4	T116,T126	C1452813
27942049	1008	1018	activation	T045	C0599177
27942049	1026	1036	downstream	T082	C0522506
27942049	1037	1049	kinases SPAK	T116,T126	C1436950
27942049	1051	1056	STE20	T116,T126	C4307920
27942049	1059	1063	SPS1	T116,T126	C1436950
27942049	1073	1108	proline-alanine-rich protein kinase	T116,T126	C1312482
27942049	1114	1118	OSR1	T116,T123	C1438448
27942049	1120	1149	oxidative stress-responsive 1	T116,T123	C1438448
27942049	1165	1168	NCC	T116,T123	C0074782
27942049	1169	1184	phosphorylation	T044	C0031715
27942049	1193	1205	accumulation	T033	C4055506
27942049	1213	1228	plasma membrane	T026	C0007603
27942049	1240	1255	phosphorylation	T044	C0031715
27942049	1259	1263	S433	T082	C1254362
27942049	1291	1297	levels	T080	C0441889
27942049	1301	1307	active	T169	C0205177
27942049	1324	1340	protein kinase C	T116,T126	C0033634
27942049	1350	1366	protein kinase A	T116,T126	C0010531
27942049	1384	1398	phosphorylates	T044	C0031715
27942049	1399	1403	S433	T082	C1254362
27942049	1418	1427	HEK cells	T025	C2936239
27942049	1428	1438	expressing	T045	C1171362
27942049	1439	1444	KLHL3	T116	C4042100
27942049	1449	1453	WNK4	T116,T126	C1452813
27942049	1474	1484	activation	T045	C0599177
27942049	1488	1504	protein kinase C	T116,T126	C0033634
27942049	1508	1539	phorbol 12-myristate 13-acetate	T109,T121,T131	C0039654
27942049	1540	1547	induces	T169	C0205263
27942049	1548	1561	KLHL3(S433-P)	T116	C4042100
27942049	1576	1580	WNK4	T116,T126	C1452813
27942049	1581	1587	levels	T080	C0441889
27942049	1606	1620	ubiquitination	T044	C1519751
27942049	1628	1632	data	T078	C1511726
27942049	1649	1653	role	T077	C1705810
27942049	1657	1662	KLHL3	T116	C4042100
27942049	1671	1675	K(+)	T123,T196	C0032821
27942049	1686	1695	induction	T169	C0205263
27942049	1699	1702	NCC	T116,T123	C0074782
27942049	1709	1731	physiologic adaptation	T040	C0001400
27942049	1740	1746	distal	T082	C0205108
27942049	1747	1759	electrogenic	T042	C0232633
27942049	1760	1778	Na(+) reabsorption	T039	C2610987
27942049	1780	1790	preventing	T169	C1292733
27942049	1799	1804	renal	T023	C0022646
27942049	1805	1809	K(+)	T123,T196	C0032821
27942049	1810	1814	loss	T081	C1517945
27942049	1819	1828	promoting	T052	C0033414
27942049	1839	1853	blood pressure	T040	C0005823

27505310|t|A comparison of the extent and pattern of cognitive impairment among predialysis, dialysis and transplant patients: a cross sectional study from Australia
27505310|a|A comparison of the extent and pattern of cognitive impairment among predialysis, dialysis and transplant patients: a cross sectional study from Australia AIM: The aim of this study was to compare the extent of cogntive impairment and the types of cognitive deficits in an Australian cohort of four patient groups with end stage kidney disease. Characteristics predicting the presence of cognitive impairment were also evaluated. Observational cross sectional study of one hundred and fifty five patients with end stage kidney disease recruited from a regional Australian renal unit. Eligible participants included those whose estimated Glomerular Filtration Rate was < 30 ml/min/1.73 m(2); were undertaking peritoneal or hemodialysis, or had received a kidney transplant. The Montreal Cognitive Assessment tool was used to screen the study participants for cognitive impairment and evaluate cognitive deficits. Cognitive impairment was defined as a total Montreal Cognitive Assessment tool score ≤24/30. The extent of cognitive impairment varied between the four groups with end stage kidney disease. Factors predicting the presence of cognitive impairment included undertaking dialysis, age ≥65, male gender, and the presence of diabetes or cerebrovascular disease. Deficits in executive function, attention, language, visuospatial skills, memory and orientation were common amongst the study participants, and these deficits varied according to which end stage kidney disease group the participants were in. Limitations to the study included the cross sectional design and that the presence of confounders like depression were not recorded. The impact of disparities in the cognitive capabilities identified in this study are likely to be far reaching. Tailoring of education and self management programs to the cognitive deficits of individuals is required.
27505310	20	26	extent	T082	C0439792
27505310	31	38	pattern	T082	C0449774
27505310	42	62	cognitive impairment	T048	C0338656
27505310	69	80	predialysis	T079	C1254367
27505310	82	90	dialysis	T061	C0011946
27505310	95	105	transplant	T061	C0022671
27505310	106	114	patients	T101	C0030705
27505310	118	139	cross sectional study	T062	C0010362
27505310	145	154	Australia	T083	C0004340
27505310	175	181	extent	T082	C0439792
27505310	186	193	pattern	T082	C0449774
27505310	197	217	cognitive impairment	T048	C0338656
27505310	224	235	predialysis	T079	C1254367
27505310	237	245	dialysis	T061	C0011946
27505310	250	260	transplant	T061	C0022671
27505310	261	269	patients	T101	C0030705
27505310	273	294	cross sectional study	T062	C0010362
27505310	300	309	Australia	T083	C0004340
27505310	356	362	extent	T082	C0439792
27505310	366	385	cogntive impairment	T048	C0338656
27505310	403	421	cognitive deficits	T048	C0009241
27505310	428	445	Australian cohort	T098	C0238711
27505310	454	468	patient groups	T101	C0030705
27505310	474	498	end stage kidney disease	T047	C0022661
27505310	531	539	presence	T080	C3854307
27505310	543	563	cognitive impairment	T048	C0338656
27505310	574	583	evaluated	T058	C0220825
27505310	585	598	Observational	T062	C0302523
27505310	599	620	cross sectional study	T062	C0010362
27505310	651	659	patients	T101	C0030705
27505310	665	689	end stage kidney disease	T047	C0022661
27505310	739	760	Eligible participants	T098	C0679646
27505310	782	818	estimated Glomerular Filtration Rate	T059	C3811844
27505310	851	862	undertaking	T090	C0041666
27505310	863	873	peritoneal	T029	C0442034
27505310	877	889	hemodialysis	T061	C0019004
27505310	909	926	kidney transplant	T061	C0022671
27505310	932	966	Montreal Cognitive Assessment tool	T170	C3496286
27505310	990	1008	study participants	T096	C0681850
27505310	1013	1033	cognitive impairment	T048	C0338656
27505310	1038	1046	evaluate	T058	C0220825
27505310	1047	1065	cognitive deficits	T048	C0009241
27505310	1067	1087	Cognitive impairment	T048	C0338656
27505310	1111	1145	Montreal Cognitive Assessment tool	T170	C3496286
27505310	1146	1151	score	T081	C0449820
27505310	1164	1170	extent	T082	C0439792
27505310	1174	1194	cognitive impairment	T048	C0338656
27505310	1219	1225	groups	T078	C0441833
27505310	1231	1255	end stage kidney disease	T047	C0022661
27505310	1280	1288	presence	T080	C3854307
27505310	1292	1312	cognitive impairment	T048	C0338656
27505310	1322	1333	undertaking	T090	C0041666
27505310	1334	1342	dialysis	T061	C0011946
27505310	1344	1351	age ≥65	T033	C4062450
27505310	1353	1364	male gender	T032	C0086582
27505310	1374	1382	presence	T080	C3854307
27505310	1386	1394	diabetes	T047	C0011847
27505310	1398	1421	cerebrovascular disease	T047	C0007820
27505310	1423	1453	Deficits in executive function	T048	C4062324
27505310	1455	1464	attention	T048	C0041671
27505310	1466	1474	language	T048	C0023015
27505310	1476	1495	visuospatial skills	T048	C0563622
27505310	1497	1503	memory	T048	C0233794
27505310	1508	1519	orientation	T048	C0233407
27505310	1544	1562	study participants	T096	C0681850
27505310	1574	1582	deficits	T080	C2987487
27505310	1609	1633	end stage kidney disease	T047	C0022661
27505310	1634	1639	group	T078	C0441833
27505310	1644	1656	participants	T098	C0679646
27505310	1704	1726	cross sectional design	T062	C0010362
27505310	1740	1748	presence	T080	C3854307
27505310	1769	1779	depression	T048	C0011570
27505310	1789	1797	recorded	T170	C0034869
27505310	1832	1841	cognitive	T041	C0009240
27505310	1842	1854	capabilities	T080	C2698977
27505310	1911	1962	Tailoring of education and self management programs	T170	C0282574
27505310	1970	1988	cognitive deficits	T048	C0009241
27505310	1992	2003	individuals	T098	C0237401

27325547|t|Benchmark study on fine-mode aerosol in a big urban area and relevant doses deposited in the human respiratory tract
27325547|a|It is well-known that the health effects of PM increase as particle size decreases: particularly, great concern has risen on the role of UltraFine Particles (UFPs). Starting from the knowledge that the main fraction of atmospheric aerosol in Rome is characterized by significant levels of PM2.5 (almost 75% of PM10 fraction is PM2.5), the paper is focused on submicron particles in such great urban area. The daytime / nighttime, work- / weekdays and cold / hot seasonal trends of submicron particles will be investigated and discussed along with NOx and total PAH drifts demonstrating the primary origin of UFPs from combustion processes. Furthermore, moving from these data, the total dose of submicron particles deposited in the respiratory system (i.e., head, tracheobronchial and alveolar regions in different lung lobes) has been estimated. Dosimeter estimates were performed with the Multiple-Path Particle Dosimetry model (MPPD v.2.1). The paper discusses the aerosol doses deposited in the respiratory system of individuals exposed in proximity of traffic. During traffic peak hours, about 6.6 × 10(10) particles are deposited into the respiratory system. Such dose is almost entirely made of UFPs. According to the greater dose estimated, right lung lobes are expected to be more susceptible to respiratory pathologies than left lobes.
27325547	10	15	study	T062	C2603343
27325547	19	36	fine-mode aerosol	T073	C0001712
27325547	42	56	big urban area	UnknownType	C0814837
27325547	61	75	relevant doses	T081	C0178602
27325547	76	85	deposited	T169	C0333562
27325547	93	98	human	T016	C0086418
27325547	99	116	respiratory tract	T023	C0282335
27325547	143	149	health	T078	C0018684
27325547	150	157	effects	T080	C1280500
27325547	161	163	PM	T131	C1510837
27325547	176	189	particle size	T081	C0030608
27325547	254	273	UltraFine Particles	T104	C0597177
27325547	275	279	UFPs	T104	C0597177
27325547	324	335	fraction of	T081	C1264633
27325547	336	347	atmospheric	T070	C0004178
27325547	348	355	aerosol	T073	C0001712
27325547	359	363	Rome	T083	C0035831
27325547	396	402	levels	T080	C0441889
27325547	406	411	PM2.5	T131	C1510837
27325547	427	431	PM10	T131	C1510837
27325547	444	449	PM2.5	T131	C1510837
27325547	476	495	submicron particles	T104	C0597177
27325547	504	520	great urban area	UnknownType	C0814837
27325547	526	533	daytime	T079	C0332169
27325547	536	545	nighttime	T079	C3844540
27325547	547	552	work-	T079	C0680192
27325547	555	563	weekdays	T079	C0680189
27325547	568	572	cold	T070	C0009264
27325547	575	578	hot	T070	C2350229
27325547	579	594	seasonal trends	T079	C0036497
27325547	598	617	submicron particles	T104	C0597177
27325547	664	667	NOx	T197	C0028167
27325547	678	681	PAH	T109	C0032458
27325547	725	729	UFPs	T104	C0597177
27325547	735	755	combustion processes	T067	C1522240
27325547	804	808	dose	T081	C0178602
27325547	812	831	submicron particles	T104	C0597177
27325547	832	841	deposited	T169	C0333562
27325547	849	867	respiratory system	T022	C0035237
27325547	875	879	head	T029	C0018670
27325547	881	897	tracheobronchial	T023	C0458580
27325547	902	918	alveolar regions	T023	C1440080
27325547	932	942	lung lobes	T023	C0225752
27325547	964	973	Dosimeter	T074	C0180488
27325547	974	983	estimates	T081	C0750572
27325547	1008	1046	Multiple-Path Particle Dosimetry model	T170	C3161035
27325547	1048	1058	MPPD v.2.1	T170	C3161035
27325547	1085	1092	aerosol	T073	C0001712
27325547	1093	1098	doses	T081	C0178602
27325547	1099	1108	deposited	T169	C0333562
27325547	1116	1134	respiratory system	T022	C0035237
27325547	1138	1149	individuals	T098	C0237401
27325547	1150	1157	exposed	T080	C0332157
27325547	1174	1181	traffic	T033	C3840880
27325547	1190	1197	traffic	T033	C3840880
27325547	1203	1208	hours	T079	C0439227
27325547	1229	1238	particles	T104	C0597177
27325547	1243	1252	deposited	T169	C0333562
27325547	1262	1280	respiratory system	T022	C0035237
27325547	1287	1291	dose	T081	C0178602
27325547	1319	1323	UFPs	T104	C0597177
27325547	1350	1354	dose	T081	C0178602
27325547	1355	1364	estimated	T081	C0750572
27325547	1366	1382	right lung lobes	T023	C0446959
27325547	1407	1418	susceptible	T169	C0231204
27325547	1422	1433	respiratory	T169	C0521346
27325547	1434	1445	pathologies	T046	C0677042
27325547	1451	1461	left lobes	T023	C0446960

27703342|t|Chronic Pseudomonas aeruginosa infection - induced chronic bronchitis and emphysematous changes in CCSP - deficient mice
27703342|a|The club cell secretory protein (CCSP) is a regulator of lung inflammation following acute respiratory infection or lung injury. Recently, the relationship between CCSP and COPD has been reported. Since COPD results from an abnormal inflammatory response, we hypothesized that CCSP could have a protective role against chronic inflammation - induced lung damage. To address this issue, the pathophysiology of chronic lung inflammation induced by Pseudomonas aeruginosa in CCSP - deficient mice was determined. A tube of 5 mm in length was soaked in a fluid containing P. aeruginosa (PAO01 strain) for 1 week and inserted into the trachea of CCSP - deficient mice. One week later, P. aeruginosa was administered into the trachea. Five weeks after insertion of tube, the mice were sacrificed. Bronchoalveolar lavage fluids were collected to determine the bacterial growth, and the lung histology and physiology were also examined. P. aeruginosa was continuously detected in bronchoalveolar lavage fluids during the study. Neutrophils were increased in the bronchoalveolar lavage fluids from the CCSP - deficient mice in comparison to wild-type mice. A histological study demonstrated chronic inflammation around bronchus, serious bronchial stenosis, and alveolar enlargement in the CCSP - deficient mice. The lung physiology study demonstrated an increase in the lung compliance of the CCSP - deficient mice. Chronic P. aeruginosa inflammation resulted in chronic bronchitis and emphysematous changes in the CCSP - deficient mice. CCSP could play an important role in protecting the host from the chronic inflammation - induced lung damage.
27703342	0	40	Chronic Pseudomonas aeruginosa infection	T047	C0854135
27703342	43	50	induced	T169	C0205263
27703342	51	69	chronic bronchitis	T047	C0008677
27703342	74	95	emphysematous changes	UnknownType	C0743482
27703342	99	103	CCSP	T116,T121	C1505368
27703342	106	115	deficient	T169	C0011155
27703342	116	120	mice	T015	C0025929
27703342	125	152	club cell secretory protein	T116,T121	C1505368
27703342	154	158	CCSP	T116,T121	C1505368
27703342	165	174	regulator	T077	C1704735
27703342	178	195	lung inflammation	T047	C0032285
27703342	206	233	acute respiratory infection	T047	C0339901
27703342	237	248	lung injury	T037	C0273115
27703342	285	289	CCSP	T116,T121	C1505368
27703342	294	298	COPD	T047	C0024117
27703342	308	316	reported	T058	C0700287
27703342	324	328	COPD	T047	C0024117
27703342	345	375	abnormal inflammatory response	T190	C4022805
27703342	380	392	hypothesized	T078	C1512571
27703342	398	402	CCSP	T116,T121	C1505368
27703342	440	460	chronic inflammation	T046	C0021376
27703342	463	470	induced	T169	C0205263
27703342	471	482	lung damage	T037	C0273115
27703342	511	526	pathophysiology	T169	C0031847
27703342	530	555	chronic lung inflammation	T047	C0032285
27703342	556	563	induced	T169	C0205263
27703342	567	589	Pseudomonas aeruginosa	T007	C0033809
27703342	593	597	CCSP	T116,T121	C1505368
27703342	600	609	deficient	T169	C0011155
27703342	610	614	mice	T015	C0025929
27703342	633	637	tube	T077	C1561954
27703342	660	666	soaked	T061	C0204774
27703342	672	677	fluid	T167	C1704353
27703342	689	702	P. aeruginosa	T007	C0033809
27703342	704	716	PAO01 strain	T001	C1518614
27703342	733	741	inserted	T169	C1883719
27703342	751	758	trachea	T023	C0040578
27703342	762	766	CCSP	T116,T121	C1505368
27703342	769	778	deficient	T169	C0011155
27703342	779	783	mice	T015	C0025929
27703342	801	814	P. aeruginosa	T007	C0033809
27703342	841	848	trachea	T023	C0040578
27703342	867	884	insertion of tube	T169	C1883719
27703342	890	894	mice	T015	C0025929
27703342	912	941	Bronchoalveolar lavage fluids	T031	C0006279
27703342	974	983	bacterial	T007	C0004611
27703342	984	990	growth	T040	C0018270
27703342	1000	1004	lung	T023	C0024109
27703342	1005	1014	histology	T169	C4048239
27703342	1019	1029	physiology	T039	C0031843
27703342	1050	1063	P. aeruginosa	T007	C0033809
27703342	1093	1122	bronchoalveolar lavage fluids	T031	C0006279
27703342	1141	1152	Neutrophils	T025	C0027950
27703342	1175	1204	bronchoalveolar lavage fluids	T031	C0006279
27703342	1214	1218	CCSP	T116,T121	C1505368
27703342	1221	1230	deficient	T169	C0011155
27703342	1231	1235	mice	T015	C0025929
27703342	1263	1267	mice	T015	C0025929
27703342	1271	1289	histological study	T091	C0019638
27703342	1303	1323	chronic inflammation	T046	C0021376
27703342	1331	1339	bronchus	T023	C0006255
27703342	1341	1367	serious bronchial stenosis	T190	C0151536
27703342	1373	1393	alveolar enlargement	T047	C0012634
27703342	1401	1405	CCSP	T116,T121	C1505368
27703342	1408	1417	deficient	T169	C0011155
27703342	1418	1422	mice	T015	C0025929
27703342	1428	1432	lung	T023	C0024109
27703342	1433	1443	physiology	T039	C0031843
27703342	1482	1497	lung compliance	T042	C0024112
27703342	1505	1509	CCSP	T116,T121	C1505368
27703342	1512	1521	deficient	T169	C0011155
27703342	1522	1526	mice	T015	C0025929
27703342	1536	1549	P. aeruginosa	T007	C0033809
27703342	1550	1562	inflammation	T046	C0021376
27703342	1575	1593	chronic bronchitis	T047	C0008677
27703342	1598	1619	emphysematous changes	UnknownType	C0743482
27703342	1627	1631	CCSP	T116,T121	C1505368
27703342	1634	1643	deficient	T169	C0011155
27703342	1644	1648	mice	T015	C0025929
27703342	1650	1654	CCSP	T116,T121	C1505368
27703342	1702	1706	host	T001	C1167395
27703342	1716	1736	chronic inflammation	T046	C0021376
27703342	1739	1746	induced	T169	C0205263
27703342	1747	1758	lung damage	T037	C0273115

28424240|t|The Histone Acetyltransferase Gcn5 Positively Regulates T Cell Activation
28424240|a|Histone acetyltransferases (HATs) regulate inducible transcription in multiple cellular processes and during inflammatory and immune response. However, the functions of general control nonrepressed-protein 5 (Gcn5), an evolutionarily conserved HAT from yeast to human, in immune regulation remain unappreciated. In this study, we conditionally deleted Gcn5 (encoded by the Kat2a gene) specifically in T lymphocytes by crossing floxed Gcn5 and Lck-Cre mice, and demonstrated that Gcn5 plays important roles in multiple stages of T cell functions including development, clonal expansion, and differentiation. Loss of Gcn5 functions impaired T cell proliferation, IL-2 production, and Th1 / Th17, but not Th2 and regulatory T cell differentiation. Gcn5 is recruited onto the il-2 promoter by interacting with the NFAT in T cells upon TCR stimulation. Interestingly, instead of directly acetylating NFAT, Gcn5 catalyzes histone H3 lysine H9 acetylation to promote IL-2 production. T cell -specific suppression of Gcn5 partially protected mice from myelin oligodendrocyte glycoprotein - induced experimental autoimmune encephalomyelitis, an experimental model for human multiple sclerosis. Our study reveals previously unknown physiological functions for Gcn5 and a molecular mechanism underlying these functions in regulating T cell immunity. Hence Gcn5 may be an important new target for autoimmune disease therapy.
28424240	4	34	Histone Acetyltransferase Gcn5	T116,T123	C1571486
28424240	35	73	Positively Regulates T Cell Activation	T043	C1326165
28424240	74	100	Histone acetyltransferases	T116,T126	C0062773
28424240	102	106	HATs	T116,T126	C0062773
28424240	108	140	regulate inducible transcription	T045	C1158770
28424240	144	152	multiple	T081	C0439064
28424240	153	171	cellular processes	T043	C1325880
28424240	183	195	inflammatory	T046	C1155266
28424240	200	215	immune response	T042	C0301872
28424240	230	239	functions	T044	C1527118
28424240	243	281	general control nonrepressed-protein 5	T116,T123	C1571486
28424240	283	287	Gcn5	T116,T123	C1571486
28424240	318	321	HAT	T116,T126	C0062773
28424240	327	332	yeast	T004	C0043393
28424240	336	341	human	T016	C0086418
28424240	346	363	immune regulation	T040	C1327458
28424240	394	399	study	T062	C0008972
28424240	418	425	deleted	T045	C0017260
28424240	426	430	Gcn5	T116,T123	C1571486
28424240	432	439	encoded	T052	C2700640
28424240	447	457	Kat2a gene	T028	C1415020
28424240	475	488	T lymphocytes	T025	C0039194
28424240	492	500	crossing	T045	C0010366
28424240	501	512	floxed Gcn5	T028	C1415020
28424240	517	524	Lck-Cre	T028	C0919477
28424240	525	529	mice	T015	C0025929
28424240	553	557	Gcn5	T116,T123	C1571486
28424240	564	579	important roles	T077	C1705810
28424240	592	598	stages	T079	C1306673
28424240	602	618	T cell functions	T043	C0007613
28424240	629	640	development	T043	C0815089
28424240	642	658	clonal expansion	T046	C1516670
28424240	664	679	differentiation	T043	C0007589
28424240	681	688	Loss of	T033	C0243095
28424240	689	693	Gcn5	T116,T123	C1571486
28424240	704	733	impaired T cell proliferation	T049	C4022557
28424240	735	750	IL-2 production	T040	C1819447
28424240	756	759	Th1	T025	C0242632
28424240	762	766	Th17	T025	C2936411
28424240	776	779	Th2	T025	C0242633
28424240	784	817	regulatory T cell differentiation	T043	C1155041
28424240	819	823	Gcn5	T116,T123	C1571486
28424240	846	850	il-2	T028	C0879590
28424240	851	859	promoter	T114,T123	C0086860
28424240	863	874	interacting	T169	C1704675
28424240	884	888	NFAT	T116,T123	C0288011
28424240	892	899	T cells	T025	C0039194
28424240	905	908	TCR	T116,T129,T192	C0034790
28424240	905	920	TCR stimulation	T044	C2259054
28424240	957	968	acetylating	T044	C0001038
28424240	969	973	NFAT	T116,T123	C0288011
28424240	975	979	Gcn5	T116,T123	C1571486
28424240	980	989	catalyzes	T070	C0007382
28424240	990	1022	histone H3 lysine H9 acetylation	T044	C2613321
28424240	1026	1033	promote	T052	C0033414
28424240	1034	1049	IL-2 production	T040	C1819447
28424240	1051	1057	T cell	T025	C0039194
28424240	1068	1079	suppression	T169	C1260953
28424240	1083	1087	Gcn5	T116,T123	C1571486
28424240	1108	1112	mice	T015	C0025929
28424240	1118	1153	myelin oligodendrocyte glycoprotein	T116,T123	C0069428
28424240	1156	1163	induced	T169	C0205263
28424240	1164	1205	experimental autoimmune encephalomyelitis	T050	C0014072
28424240	1210	1228	experimental model	T170	C0086272
28424240	1233	1238	human	T016	C0086418
28424240	1239	1257	multiple sclerosis	T047	C0026769
28424240	1269	1276	reveals	T080	C0443289
28424240	1296	1319	physiological functions	T039	C1254359
28424240	1324	1328	Gcn5	T116,T123	C1571486
28424240	1335	1354	molecular mechanism	T044	C3537153
28424240	1372	1381	functions	T044	C1527118
28424240	1385	1411	regulating T cell immunity	T038	C1818823
28424240	1419	1423	Gcn5	T116,T123	C1571486
28424240	1459	1477	autoimmune disease	T047	C0004364
28424240	1478	1485	therapy	T061	C0087111

28122051|t|Low Cytochrome Oxidase 1 Links Mitochondrial Dysfunction to Atherosclerosis in Mice and Pigs
28122051|a|Cytochrome oxidase IV complex regulates energy production in mitochondria. Therefore, we determined the relation of COX genes with atherosclerosis in mice and pigs. First, we compared atherosclerosis in the aortic arch of age-matched (24 weeks) C57BL/6J control (n = 10), LDL-receptor deficient (n = 8), leptin - deficient ob/ob (n = 10), and double knock-out (lacking LDL-receptor and leptin) mice (n = 12). Low aortic mitochondria -encoded cytochrome oxidase 1 in obese diabetic double knock-out mice was associated with a larger plaque area and higher propensity of M1 macrophages and oxidized LDL. Caloric restriction increased mitochondria -encoded cytochrome oxidase 1 and reduced plaque area and oxidized LDL. This was associated with a reduction of titer of anti-oxidized LDL antibodies, a proxy of systemic oxidative stress. Low of mitochondria -encoded cytochrome oxidase 1 was related to low expression of peroxisome proliferative activated receptors α, δ, and γ and of peroxisome proliferative activated receptor, gamma, co-activator 1 alpha reflecting mitochondrial dysfunction. Caloric restriction increased them. To investigate if there was a diabetic / obesity requirement for mitochondria -encoded cytochrome oxidase 1 to be down-regulated, we then studied atherosclerosis in LAD of hypercholesterolemic pigs (n = 37). Pigs at the end of the study were divided in three groups based on increasing LAD plaque complexity according to Stary (Stary I: n = 12; Stary II: n = 13; Stary III: n = 12). Low mitochondria -encoded cytochrome oxidase 1 in isolated plaque macrophages was associated with more complex coronary plaques and oxidized LDL. Nucleus -encoded cytochrome oxidase 4I1 and cytochrome oxidase 10 did not correlate with plaque complexity and oxidative stress. In mice and pigs, MT-COI was inversely related to insulin resistance. Low MT-COI is related to mitochondrial dysfunction, oxidative stress and atherosclerosis and plaque complexity.
28122051	0	3	Low	T080	C0205251
28122051	4	24	Cytochrome Oxidase 1	T116,T126	C4284184
28122051	31	56	Mitochondrial Dysfunction	T033	C4021734
28122051	60	75	Atherosclerosis	T047	C0004153
28122051	79	83	Mice	T015	C0026809
28122051	88	92	Pigs	T015	C0039005
28122051	93	122	Cytochrome oxidase IV complex	T116,T126	C0751066
28122051	133	150	energy production	T039	C0014272
28122051	154	166	mitochondria	T026	C0026237
28122051	209	218	COX genes	T028	C0017337
28122051	224	239	atherosclerosis	T047	C0004153
28122051	243	247	mice	T015	C0026809
28122051	252	256	pigs	T015	C0039005
28122051	277	292	atherosclerosis	T047	C0004153
28122051	300	311	aortic arch	T023	C0003489
28122051	365	377	LDL-receptor	T116,T192	C0034821
28122051	378	387	deficient	T169	C0011155
28122051	397	403	leptin	T116,T125	C0299583
28122051	406	415	deficient	T169	C0011155
28122051	443	452	knock-out	T050	C1522225
28122051	462	474	LDL-receptor	T116,T192	C0034821
28122051	479	485	leptin	T116,T125	C0299583
28122051	487	491	mice	T015	C0026809
28122051	502	505	Low	T080	C0205251
28122051	506	512	aortic	T023	C0003483
28122051	513	525	mitochondria	T026	C0026237
28122051	535	555	cytochrome oxidase 1	T116,T126	C4284184
28122051	559	564	obese	T047	C0028754
28122051	565	573	diabetic	T047	C0011847
28122051	581	595	knock-out mice	T015	C0206745
28122051	600	615	associated with	T080	C0332281
28122051	625	631	plaque	T033	C0332461
28122051	632	636	area	T082	C0205146
28122051	641	658	higher propensity	T081	C2718044
28122051	662	676	M1 macrophages	T025	C0024432
28122051	681	693	oxidized LDL	T116,T123	C0348035
28122051	695	714	Caloric restriction	T061	C1135809
28122051	715	724	increased	T081	C0205217
28122051	725	737	mitochondria	T026	C0026237
28122051	747	767	cytochrome oxidase 1	T116,T126	C4284184
28122051	780	786	plaque	T033	C0332461
28122051	787	791	area	T082	C0205146
28122051	796	808	oxidized LDL	T116,T123	C0348035
28122051	819	834	associated with	T080	C0332281
28122051	837	846	reduction	T080	C0392756
28122051	850	887	titer of anti-oxidized LDL antibodies	T059	C2322174
28122051	909	925	oxidative stress	T049	C0242606
28122051	927	930	Low	T080	C0205251
28122051	934	946	mitochondria	T026	C0026237
28122051	956	976	cytochrome oxidase 1	T116,T126	C4284184
28122051	992	995	low	T080	C0205251
28122051	996	1006	expression	T045	C1171362
28122051	1010	1056	peroxisome proliferative activated receptors α	T116,T123	C1451469
28122051	1065	1066	γ	T116,T123	C1743838
28122051	1074	1146	peroxisome proliferative activated receptor, gamma, co-activator 1 alpha	T116,T123	C1570275
28122051	1158	1183	mitochondrial dysfunction	T033	C4021734
28122051	1185	1204	Caloric restriction	T061	C1135809
28122051	1205	1214	increased	T081	C0205217
28122051	1224	1235	investigate	T169	C1292732
28122051	1251	1259	diabetic	T047	C0011847
28122051	1262	1269	obesity	T047	C0028754
28122051	1286	1298	mitochondria	T026	C0026237
28122051	1308	1328	cytochrome oxidase 1	T116,T126	C4284184
28122051	1335	1349	down-regulated	T044	C0013081
28122051	1367	1382	atherosclerosis	T047	C0004153
28122051	1386	1389	LAD	T023	C0226032
28122051	1393	1413	hypercholesterolemic	T033	C3540840
28122051	1414	1418	pigs	T015	C0039005
28122051	1429	1433	Pigs	T015	C0039005
28122051	1507	1510	LAD	T023	C0226032
28122051	1511	1517	plaque	T033	C0332461
28122051	1518	1528	complexity	T169	C3496294
28122051	1604	1607	Low	T080	C0205251
28122051	1608	1620	mitochondria	T026	C0026237
28122051	1630	1650	cytochrome oxidase 1	T116,T126	C4284184
28122051	1663	1669	plaque	T033	C0332461
28122051	1670	1681	macrophages	T025	C0024432
28122051	1686	1701	associated with	T080	C0332281
28122051	1707	1714	complex	T080	C0439855
28122051	1715	1723	coronary	T082	C1522318
28122051	1724	1731	plaques	T033	C0332461
28122051	1736	1748	oxidized LDL	T116,T123	C0348035
28122051	1750	1757	Nucleus	T026	C0007610
28122051	1767	1789	cytochrome oxidase 4I1	T116,T126	C4077632
28122051	1794	1815	cytochrome oxidase 10	T116,T126	C1723754
28122051	1839	1845	plaque	T033	C0332461
28122051	1846	1856	complexity	T169	C3496294
28122051	1861	1877	oxidative stress	T049	C0242606
28122051	1882	1886	mice	T015	C0026809
28122051	1891	1895	pigs	T015	C0039005
28122051	1897	1903	MT-COI	T028	C1537985
28122051	1929	1947	insulin resistance	T046	C0021655
28122051	1949	1952	Low	T080	C0205251
28122051	1953	1959	MT-COI	T028	C1537985
28122051	1974	1999	mitochondrial dysfunction	T033	C4021734
28122051	2001	2017	oxidative stress	T049	C0242606
28122051	2022	2037	atherosclerosis	T047	C0004153
28122051	2042	2048	plaque	T033	C0332461
28122051	2049	2059	complexity	T169	C3496294

27301553|t|Plasmodium falciparum parasite population structure and gene flow associated to anti-malarial drugs resistance in Cambodia
27301553|a|Western Cambodia is recognized as the epicentre of emergence of Plasmodium falciparum multi-drug resistance. The emergence of artemisinin resistance has been observed in this area since 2008-2009 and molecular signatures associated to artemisinin resistance have been characterized in k13 gene. At present, one of the major threats faced, is the possible spread of Asian artemisinin resistant parasites over the world threatening millions of people and jeopardizing malaria elimination programme efforts. To anticipate the diffusion of artemisinin resistance, the identification of the P. falciparum population structure and the gene flow among the parasite population in Cambodia are essential. To this end, a mid-throughput PCR - LDR-FMA approach based on LUMINEX technology was developed to screen for genetic barcode in 533 blood samples collected in 2010-2011 from 16 health centres in malaria endemics areas in Cambodia. Based on successful typing of 282 samples, subpopulations were characterized along the borders of the country. Each 11-loci barcode provides evidence supporting allele distribution gradient related to subpopulations and gene flow. The 11-loci barcode successfully identifies recently emerging parasite subpopulations in western Cambodia that are associated with the C580Y dominant allele for artemisinin resistance in k13 gene. A subpopulation was identified in northern Cambodia that was associated to artemisinin (R539T resistant allele of k13 gene) and mefloquine resistance. The gene flow between these subpopulations might have driven the spread of artemisinin resistance over Cambodia.
27301553	0	21	Plasmodium falciparum	T204	C0032150
27301553	22	30	parasite	T204	C0030498
27301553	31	51	population structure	T102	C0598617
27301553	56	65	gene flow	T045	C1565556
27301553	66	76	associated	T080	C0332281
27301553	80	93	anti-malarial	T121	C0003374
27301553	94	110	drugs resistance	T038	C0013203
27301553	114	122	Cambodia	T083	C0006797
27301553	123	139	Western Cambodia	T083	C0006797
27301553	174	183	emergence	T046	C2745965
27301553	187	208	Plasmodium falciparum	T204	C0032150
27301553	209	230	multi-drug resistance	T032	C0242640
27301553	236	245	emergence	T046	C2745965
27301553	249	260	artemisinin	T109,T121	C0052430
27301553	261	271	resistance	T038	C0013203
27301553	298	302	area	T083	C0017446
27301553	323	343	molecular signatures	T169	C1704864
27301553	344	354	associated	T080	C0332281
27301553	358	369	artemisinin	T109,T121	C0052430
27301553	370	380	resistance	T038	C0013203
27301553	408	416	k13 gene	T028	C0017337
27301553	447	454	threats	T078	C0749385
27301553	488	493	Asian	T083	C0003980
27301553	494	505	artemisinin	T109,T121	C0052430
27301553	506	515	resistant	T038	C0013203
27301553	516	525	parasites	T204	C0030498
27301553	565	571	people	T098	C0027361
27301553	589	596	malaria	T047	C0024530
27301553	597	618	elimination programme	T058	C0679897
27301553	659	670	artemisinin	T109,T121	C0052430
27301553	671	681	resistance	T038	C0013203
27301553	687	701	identification	T080	C0205396
27301553	709	722	P. falciparum	T204	C0032150
27301553	723	743	population structure	T102	C0598617
27301553	752	761	gene flow	T045	C1565556
27301553	772	780	parasite	T204	C0030498
27301553	781	791	population	T078	C0441833
27301553	795	803	Cambodia	T083	C0006797
27301553	849	852	PCR	T063	C0032520
27301553	855	862	LDR-FMA	T059	C0005507
27301553	881	899	LUMINEX technology	T059	C0005507
27301553	928	943	genetic barcode	T087	C2936548
27301553	951	964	blood samples	T031	C0178913
27301553	996	1010	health centres	T073,T093	C0475309
27301553	1014	1021	malaria	T047	C0024530
27301553	1022	1030	endemics	T169	C0243130
27301553	1040	1048	Cambodia	T083	C0006797
27301553	1070	1076	typing	T059	C0005844
27301553	1084	1091	samples	T031	C0178913
27301553	1093	1107	subpopulations	T078	C0441833
27301553	1152	1159	country	T083	C0454664
27301553	1166	1181	11-loci barcode	T087	C2936548
27301553	1191	1199	evidence	T078	C3887511
27301553	1211	1217	allele	T028	C0002085
27301553	1218	1230	distribution	T169	C1704711
27301553	1231	1239	gradient	T081	C0812409
27301553	1251	1265	subpopulations	T078	C0441833
27301553	1270	1279	gene flow	T045	C1565556
27301553	1285	1300	11-loci barcode	T087	C2936548
27301553	1343	1351	parasite	T204	C0030498
27301553	1352	1366	subpopulations	T078	C0441833
27301553	1370	1386	western Cambodia	T083	C0006797
27301553	1396	1406	associated	T080	C0332281
27301553	1416	1437	C580Y dominant allele	T028	C0683222
27301553	1442	1453	artemisinin	T109,T121	C0052430
27301553	1454	1464	resistance	T038	C0013203
27301553	1468	1476	k13 gene	T028	C0017337
27301553	1480	1493	subpopulation	T078	C0441833
27301553	1512	1529	northern Cambodia	T083	C0006797
27301553	1539	1549	associated	T080	C0332281
27301553	1553	1564	artemisinin	T109,T121	C0052430
27301553	1566	1588	R539T resistant allele	T028	C0002085
27301553	1592	1600	k13 gene	T028	C0017337
27301553	1606	1616	mefloquine	T109,T121	C0025153
27301553	1617	1627	resistance	T038	C0013203
27301553	1633	1642	gene flow	T045	C1565556
27301553	1657	1671	subpopulations	T078	C0441833
27301553	1704	1715	artemisinin	T109,T121	C0052430
27301553	1716	1726	resistance	T038	C0013203
27301553	1732	1740	Cambodia	T083	C0006797

28228055|t|Increased Enoxaparin Dosing for Venous Thromboembolism Prophylaxis in General Trauma Patients
28228055|a|To review the evidence regarding increased enoxaparin dosing for venous thromboembolism (VTE) prophylaxis in the general trauma patient population. A search of MEDLINE databases (1946 to October 2016) was conducted using the search terms enoxaparin, thromboembolism prophylaxis, venous thromboembolism, trauma, anti-factor Xa, and weight -based dosing. Additional references were identified from a review of literature citations. Search results were limited to English-language studies conducted in humans. Trials that included only obese patients or nontrauma patients were excluded. A total of 7 trials (958 patients) explored the use of increased dosing of enoxaparin for VTE prophylaxis in trauma patients. Patients were divided by enoxaparin dosing strategies: standard dosing of 30 mg twice daily (BID; n = 509), higher initial dosing regimen (n = 216), or dosing based on anti-FXa level adjustments (n = 233). The majority of the 42 total VTE events (64.3%) occurred in the standard dosing regimen. Within each group, VTE was reported in 5.3% of patients in the standard dosing group, 3.2% in the higher initial dosing group, and 4% in the anti-FXa adjustment group. Initial subtherapeutic anti-FXa levels occurred in 33% to 92% of standard dose patients and 9% to 39% of higher initial dose patients. The average weight -based dose required to achieve a therapeutic level ranged between 0.43 and 0.54 mg/kg/ dose BID. The overall rate of bleeding was low, with 3 incidents (0.37%) reported. Standard - dose enoxaparin prophylaxis may not be optimal for the general trauma patient population. Weight -based enoxaparin dosing (0.5 mg/kg/ dose BID) is an option in trauma patients considered to be at a lower risk of bleeding complications.
28228055	0	9	Increased	T081	C0205217
28228055	10	20	Enoxaparin	T109,T121	C0206460
28228055	21	27	Dosing	T081	C0178602
28228055	32	66	Venous Thromboembolism Prophylaxis	T061	C0199242
28228055	78	84	Trauma	T037	C3714660
28228055	85	93	Patients	T101	C0030705
28228055	97	103	review	T080	C1704362
28228055	108	116	evidence	T078	C3887511
28228055	127	136	increased	T081	C0205217
28228055	137	147	enoxaparin	T109,T121	C0206460
28228055	148	154	dosing	T081	C0178602
28228055	159	199	venous thromboembolism (VTE) prophylaxis	T061	C0199242
28228055	215	221	trauma	T037	C3714660
28228055	222	229	patient	T101	C0030705
28228055	230	240	population	T098	C1257890
28228055	244	250	search	T052	C1706202
28228055	254	271	MEDLINE databases	T170	C0025141
28228055	319	325	search	T052	C1706202
28228055	326	331	terms	T078	C1705313
28228055	332	342	enoxaparin	T109,T121	C0206460
28228055	344	371	thromboembolism prophylaxis	T061	C0199242
28228055	373	395	venous thromboembolism	T047	C1861172
28228055	397	403	trauma	T037	C3714660
28228055	405	419	anti-factor Xa	T116,T129	C0443793
28228055	425	431	weight	T081	C0043100
28228055	439	445	dosing	T081	C0178602
28228055	492	512	review of literature	T170	C0282441
28228055	513	522	citations	T170	C0552371
28228055	524	530	Search	T052	C1706202
28228055	531	538	results	T169	C1274040
28228055	555	571	English-language	T171	C0376245
28228055	572	579	studies	T062	C2603343
28228055	593	599	humans	T016	C0086418
28228055	601	607	Trials	T062	C0008976
28228055	627	632	obese	T047	C0028754
28228055	633	641	patients	T101	C0030705
28228055	645	663	nontrauma patients	T101	C0030705
28228055	669	677	excluded	T052	C2828389
28228055	692	698	trials	T062	C0008976
28228055	704	712	patients	T101	C0030705
28228055	734	743	increased	T081	C0205217
28228055	744	750	dosing	T081	C0178602
28228055	754	764	enoxaparin	T109,T121	C0206460
28228055	769	784	VTE prophylaxis	T061	C0199242
28228055	788	794	trauma	T037	C3714660
28228055	795	803	patients	T101	C0030705
28228055	805	813	Patients	T101	C0030705
28228055	830	840	enoxaparin	T109,T121	C0206460
28228055	841	847	dosing	T081	C0178602
28228055	860	868	standard	T080	C1442989
28228055	869	875	dosing	T081	C0178602
28228055	885	896	twice daily	T079	C0585361
28228055	898	901	BID	T079	C0585361
28228055	928	934	dosing	T081	C0178602
28228055	935	942	regimen	T061	C0040808
28228055	957	963	dosing	T081	C0178602
28228055	973	987	anti-FXa level	T034	C1318056
28228055	988	999	adjustments	T061	C2945673
28228055	1040	1043	VTE	T047	C1861172
28228055	1044	1050	events	T051	C0441471
28228055	1075	1083	standard	T080	C1442989
28228055	1084	1090	dosing	T081	C0178602
28228055	1091	1098	regimen	T061	C0040808
28228055	1112	1117	group	T101	C0030705
28228055	1119	1122	VTE	T047	C1861172
28228055	1147	1155	patients	T101	C0030705
28228055	1163	1171	standard	T080	C1442989
28228055	1172	1178	dosing	T081	C0178602
28228055	1179	1184	group	T101	C0030705
28228055	1213	1219	dosing	T081	C0178602
28228055	1220	1225	group	T101	C0030705
28228055	1241	1249	anti-FXa	T116,T129	C0443793
28228055	1250	1260	adjustment	T061	C2945673
28228055	1261	1266	group	T101	C0030705
28228055	1276	1290	subtherapeutic	T169	C0302350
28228055	1291	1306	anti-FXa levels	T034	C1318056
28228055	1333	1341	standard	T080	C1442989
28228055	1342	1346	dose	T081	C0178602
28228055	1347	1355	patients	T101	C0030705
28228055	1388	1392	dose	T081	C0178602
28228055	1393	1401	patients	T101	C0030705
28228055	1415	1421	weight	T081	C0043100
28228055	1429	1433	dose	T081	C0178602
28228055	1456	1473	therapeutic level	T034	C0580398
28228055	1510	1514	dose	T081	C0178602
28228055	1515	1518	BID	T079	C0585361
28228055	1532	1536	rate	T081	C1521828
28228055	1540	1548	bleeding	T046	C0019080
28228055	1553	1556	low	T080	C0205251
28228055	1593	1601	Standard	T080	C1442989
28228055	1604	1608	dose	T081	C0178602
28228055	1609	1619	enoxaparin	T109,T121	C0206460
28228055	1620	1631	prophylaxis	T061	C0199242
28228055	1667	1673	trauma	T037	C3714660
28228055	1674	1681	patient	T101	C0030705
28228055	1682	1692	population	T098	C1257890
28228055	1694	1700	Weight	T081	C0043100
28228055	1708	1718	enoxaparin	T109,T121	C0206460
28228055	1719	1725	dosing	T081	C0178602
28228055	1738	1742	dose	T081	C0178602
28228055	1743	1746	BID	T079	C0585361
28228055	1764	1770	trauma	T037	C3714660
28228055	1771	1779	patients	T101	C0030705
28228055	1802	1807	lower	T080	C0205251
28228055	1808	1812	risk	T078	C0035647
28228055	1816	1824	bleeding	T046	C0019080
28228055	1825	1838	complications	T046	C0009566

28240655|t|Impending Atypical Femoral Fracture in Patients With Medullary Thyroid Cancer With Skeletal Metastasis Treated With Long-term Bisphosphonate and Denosumab
28240655|a|Atypical femoral fractures (AFFs) occur in osteoporosis patients receiving long-term bisphosphonate. Atypical femoral fractures also occur in cancer patients receiving long-term bisphosphonate or denosumab, but the prevalence is low. We describe a 53- year -old woman with a history of medullary thyroid cancer and skull metastasis who was prescribed bisphosphonate for 6 years and denosumab for 1.5 years, consecutively. Bone scintigraphy performed because of spontaneous groin pain showed uptake in the lateral aspect of the left femur, which was confirmed as impending AFF. In oncological patients receiving long-term bisphosphonate or denosumab, AFF should be included as a differential diagnosis with focal femoral findings.
28240655	0	9	Impending	T079	C0332190
28240655	10	35	Atypical Femoral Fracture	T046	C4268744
28240655	39	47	Patients	T101	C0030705
28240655	53	77	Medullary Thyroid Cancer	T191	C0238462
28240655	83	91	Skeletal	T082	C0521324
28240655	92	102	Metastasis	T046	C4255448
28240655	103	110	Treated	T169	C1522326
28240655	116	125	Long-term	T079	C0443252
28240655	126	140	Bisphosphonate	T121	C2267018
28240655	145	154	Denosumab	T116,T121,T129	C1690432
28240655	155	181	Atypical femoral fractures	T046	C4268744
28240655	183	187	AFFs	T046	C4268744
28240655	198	210	osteoporosis	T047	C0029456
28240655	211	219	patients	T101	C0030705
28240655	230	239	long-term	T079	C0443252
28240655	240	254	bisphosphonate	T121	C2267018
28240655	256	282	Atypical femoral fractures	T046	C4268744
28240655	297	312	cancer patients	T101	C1516213
28240655	323	332	long-term	T079	C0443252
28240655	333	347	bisphosphonate	T121	C2267018
28240655	351	360	denosumab	T116,T121,T129	C1690432
28240655	370	380	prevalence	T081	C0033105
28240655	384	387	low	T080	C0205251
28240655	407	411	year	T079	C0439234
28240655	417	422	woman	T098	C0043210
28240655	441	465	medullary thyroid cancer	T191	C0238462
28240655	470	486	skull metastasis	T191	C2026272
28240655	495	505	prescribed	T058	C0278329
28240655	506	520	bisphosphonate	T121	C2267018
28240655	527	532	years	T079	C0439234
28240655	537	546	denosumab	T116,T121,T129	C1690432
28240655	555	560	years	T079	C0439234
28240655	562	575	consecutively	T080	C1707491
28240655	577	594	Bone scintigraphy	T060	C3889015
28240655	595	604	performed	T169	C0884358
28240655	616	627	spontaneous	T169	C0205359
28240655	628	638	groin pain	T184	C0239783
28240655	646	652	uptake	T039	C0243144
28240655	682	692	left femur	T023	C0817320
28240655	717	726	impending	T079	C0332190
28240655	727	730	AFF	T046	C4268744
28240655	735	746	oncological	T191	C0027651
28240655	747	755	patients	T101	C0030705
28240655	766	775	long-term	T079	C0443252
28240655	776	790	bisphosphonate	T121	C2267018
28240655	794	803	denosumab	T116,T121,T129	C1690432
28240655	805	808	AFF	T046	C4268744
28240655	833	855	differential diagnosis	T060	C0011906
28240655	861	866	focal	T082	C0205234
28240655	867	874	femoral	T023	C0015811
28240655	875	883	findings	T033	C0243095

27912013|t|Sprouting as a gardening strategy to obtain superior supplementary food: evidence from a seed - caching marine worm
27912013|a|Only a handful of non-human animals are known to grow their own food by cultivating high-yield fungal or algal crops as staple food. Here we report an alternative strategy utilized by an omnivorous marine worm, Hediste diversicolor, to supplement its diet: gardening by sprouting seeds. In addition to having many other known feeding modes, we showed using video recordings and manipulative mesocosm experiments that this species can also behave like gardeners by deliberately burying cordgrass seeds in their burrows, which has been previously shown to reduce the loss of seeds to water. These seeds, however, are protected by the seed husk, and we used feeding experiments to show that they were not edible for H. diversicolor until they had sprouted or the seed husk had been artificially removed. Additionally, sprouts were shown to be highly nutritious, permitting higher growth rates in H. diversicolor than the low - quality basal food, detritus. We propose both a proximate cause (seed husk as a physical barrier) and ultimate cause (nutritional demand) for this peculiar feeding behavior. Our findings suggest that sprouting may be a common strategy used by seed - collecting animals to exploit nutrients from well-protected seeds.
27912013	0	9	Sprouting	T040	C1160189
27912013	15	24	gardening	T056	C0868963
27912013	44	52	superior	T082	C1282910
27912013	53	71	supplementary food	T168	C0242295
27912013	73	81	evidence	T078	C3887511
27912013	89	93	seed	T002	C0036563
27912013	96	103	caching	T169	C1516698
27912013	104	115	marine worm	T204	C0032444
27912013	134	151	non-human animals	T008	C0003062
27912013	165	169	grow	T052	C0441655
27912013	180	184	food	T168	C0016452
27912013	188	199	cultivating	T052	C0441655
27912013	211	217	fungal	T004	C0016832
27912013	221	232	algal crops	T204	C0002028
27912013	236	247	staple food	T168	C0016452
27912013	303	325	omnivorous marine worm	T204	C0032444
27912013	327	347	Hediste diversicolor	T204	C1060974
27912013	352	371	supplement its diet	T168	C0242295
27912013	373	382	gardening	T056	C0868963
27912013	386	395	sprouting	T040	C1160189
27912013	396	401	seeds	T002	C0036563
27912013	442	449	feeding	T052	C2987508
27912013	473	489	video recordings	T073	C0042650
27912013	494	527	manipulative mesocosm experiments	T062	C0681814
27912013	538	545	species	T185	C1705920
27912013	567	576	gardeners	T097	C0335454
27912013	593	600	burying	T052	C0441655
27912013	601	610	cordgrass	T002	C1000995
27912013	611	616	seeds	T002	C0036563
27912013	626	633	burrows	T082	C1254362
27912013	670	676	reduce	T080	C0392756
27912013	681	685	loss	T081	C1517945
27912013	689	694	seeds	T002	C0036563
27912013	698	703	water	T121,T197	C0043047
27912013	711	716	seeds	T002	C0036563
27912013	731	740	protected	T033	C1545588
27912013	748	757	seed husk	T002	C0557858
27912013	771	778	feeding	T052	C2987508
27912013	779	790	experiments	T062	C0681814
27912013	814	824	not edible	T033	C1513916
27912013	829	844	H. diversicolor	T204	C1060974
27912013	860	868	sprouted	T040	C1160189
27912013	876	885	seed husk	T002	C0557858
27912013	908	915	removed	T080	C0849355
27912013	931	938	sprouts	T002	C0242437
27912013	956	962	highly	T080	C0205250
27912013	963	973	nutritious	T168	C0453857
27912013	986	992	higher	T080	C0205250
27912013	993	1005	growth rates	T079	C0449249
27912013	1009	1024	H. diversicolor	T204	C1060974
27912013	1034	1037	low	T080	C0205251
27912013	1040	1047	quality	T080	C0332306
27912013	1048	1058	basal food	T168	C0016452
27912013	1060	1068	detritus	T167	C0440266
27912013	1105	1114	seed husk	T002	C0557858
27912013	1120	1136	physical barrier	T080	C4045969
27912013	1158	1169	nutritional	T080	C1521739
27912013	1170	1176	demand	T033	C0562447
27912013	1196	1203	feeding	T052	C2987508
27912013	1204	1212	behavior	T053	C0004927
27912013	1240	1249	sprouting	T040	C1160189
27912013	1283	1287	seed	T002	C0036563
27912013	1290	1300	collecting	T169	C1516698
27912013	1301	1308	animals	T008	C0003062
27912013	1320	1329	nutrients	T168	C0678695
27912013	1335	1349	well-protected	T033	C1545588
27912013	1350	1355	seeds	T002	C0036563

28103941|t|Involvement of the endocannabinoid system in the physiological response to transient common carotid artery occlusion and reperfusion
28103941|a|The transient global cerebral hypoperfusion / reperfusion achieved by induction of Bilateral Common Carotid Artery Occlusion followed by Reperfusion (BCCAO / R) may trigger a physiological response in an attempt to preserve tissue and function integrity. There are several candidate molecules among which the endocannabinoid system (ECS) and/or peroxisome-proliferator activated receptor-alpha (PPAR-alpha) may play a role in modulating oxidative stress and inflammation. The aims of the present study are to evaluate whether the ECS, the enzyme cyclooxygenase-2 (COX-2) and PPAR-alpha are involved during BCCAO / R in rat brain, and to identify possible markers of the ongoing BCCAO / R - induced challenge in plasma. Adult Wistar rats underwent BCCAO / R with 30 min hypoperfusion followed by 60 min reperfusion. The frontal and temporal - occipital cortices and plasma were analyzed by high performance liquid chromatography-mass spectrometry (HPLC-MS) to determine concentrations of endocannabinoids (eCBs) and related molecules behaving as ligands of PPAR-alpha, and of oxidative-stress markers such as lipoperoxides, while Western Blot and immunohistochemistry were used to study protein expression of cannabinoid receptors, COX-2 and PPAR-alpha. Unpaired Student's t-test was used to evaluate statistical differences between groups. The acute BCCAO / R procedure is followed by increased brain tissue levels of the eCBs 2-arachidonoylglycerol and anandamide, palmitoylethanolamide, an avid ligand of PPAR-alpha, lipoperoxides, type 1 (CB1) and type 2 (CB2) cannabinoid receptors, and COX-2, and decreased brain tissue concentrations of docosahexaenoic acid (DHA), one of the major targets of lipid peroxidation. In plasma, increased levels of anandamide and lipoperoxides were observed. The BCCAO / R stimulated early molecular changes that can be easily traced in brain tissue and plasma, and that are indicative of the tissue physiological response to the reperfusion - induced oxidative stress and inflammation. The observed variations suggest that the positive modulation of the ECS and the increase of proinflammatory substances are directly correlated events. Increase of plasmatic levels of anandamide and lipoperoxides further suggests that dysregulation of these molecules may be taken as an indicator of an ongoing hypoperfusion / reperfusion challenge.
28103941	19	41	endocannabinoid system	T044	C3156138
28103941	49	71	physiological response	T039	C0542478
28103941	92	116	carotid artery occlusion	T047	C0265101
28103941	121	132	reperfusion	T038	C0684253
28103941	147	176	global cerebral hypoperfusion	T047	C1695782
28103941	179	190	reperfusion	T038	C0684253
28103941	216	257	Bilateral Common Carotid Artery Occlusion	T046	C1386627
28103941	270	281	Reperfusion	T038	C0684253
28103941	283	288	BCCAO	T046	C1386627
28103941	291	292	R	T038	C0684253
28103941	308	330	physiological response	T039	C0542478
28103941	348	356	preserve	T052	C0024501
28103941	357	376	tissue and function	T042	C1254358
28103941	377	386	integrity	T080	C1947912
28103941	416	425	molecules	T167	C0567416
28103941	442	464	endocannabinoid system	T044	C3156138
28103941	466	469	ECS	T044	C3156138
28103941	478	526	peroxisome-proliferator activated receptor-alpha	T116,T192	C0166415
28103941	528	538	PPAR-alpha	T116,T192	C0166415
28103941	559	569	modulating	T082	C0443264
28103941	570	586	oxidative stress	T049	C0242606
28103941	591	603	inflammation	T046	C0021368
28103941	609	613	aims	T078	C1947946
28103941	629	634	study	T062	C0008972
28103941	642	650	evaluate	T058	C0220825
28103941	663	666	ECS	T044	C3156138
28103941	672	678	enzyme	T116,T126	C0014442
28103941	679	695	cyclooxygenase-2	T116,T126	C0387583
28103941	697	702	COX-2	T116,T126	C0387583
28103941	708	718	PPAR-alpha	T116,T192	C0166415
28103941	739	744	BCCAO	T046	C1386627
28103941	747	748	R	T038	C0684253
28103941	752	761	rat brain	T023	C1882598
28103941	788	795	markers	T201	C0005516
28103941	811	816	BCCAO	T046	C1386627
28103941	819	820	R	T038	C0684253
28103941	823	830	induced	T169	C0205263
28103941	844	850	plasma	T031	C0032105
28103941	858	869	Wistar rats	T015	C0034716
28103941	880	885	BCCAO	T046	C1386627
28103941	888	889	R	T038	C0684253
28103941	902	915	hypoperfusion	T046	C0442856
28103941	935	946	reperfusion	T038	C0684253
28103941	952	959	frontal	T023	C0016733
28103941	964	972	temporal	T023	C0039485
28103941	975	993	occipital cortices	T023	C3811911
28103941	998	1004	plasma	T031	C0032105
28103941	1010	1018	analyzed	T062	C0936012
28103941	1022	1078	high performance liquid chromatography-mass spectrometry	T059	C3641325
28103941	1080	1087	HPLC-MS	T059	C3641325
28103941	1102	1116	concentrations	T081	C1446561
28103941	1120	1136	endocannabinoids	T109,T123	C1172779
28103941	1138	1142	eCBs	T109,T123	C1172779
28103941	1156	1165	molecules	T167	C0567416
28103941	1178	1185	ligands	T103	C0023688
28103941	1189	1199	PPAR-alpha	T116,T192	C0166415
28103941	1208	1224	oxidative-stress	T049	C0242606
28103941	1225	1232	markers	T201	C0005516
28103941	1241	1254	lipoperoxides	T109	C0023776
28103941	1262	1274	Western Blot	T059	C0949466
28103941	1279	1299	immunohistochemistry	T060	C0021044
28103941	1313	1318	study	T062	C0008972
28103941	1319	1337	protein expression	T045	C1171362
28103941	1341	1362	cannabinoid receptors	T116,T192	C0054594
28103941	1364	1369	COX-2	T116,T126	C0387583
28103941	1374	1384	PPAR-alpha	T116,T192	C0166415
28103941	1386	1411	Unpaired Student's t-test	T170	C1710574
28103941	1424	1432	evaluate	T058	C0220825
28103941	1433	1444	statistical	T081	C2828391
28103941	1445	1456	differences	T080	C1705242
28103941	1465	1471	groups	T078	C0441833
28103941	1477	1482	acute	T079	C0205178
28103941	1483	1488	BCCAO	T046	C1386627
28103941	1491	1492	R	T038	C0684253
28103941	1528	1540	brain tissue	T023	C0459385
28103941	1555	1559	eCBs	T109,T123	C1172779
28103941	1560	1582	2-arachidonoylglycerol	T109,T121	C0299477
28103941	1587	1597	anandamide	T109,T123	C0211726
28103941	1599	1620	palmitoylethanolamide	T109,T121	C0069964
28103941	1630	1636	ligand	T103	C0023688
28103941	1640	1650	PPAR-alpha	T116,T192	C0166415
28103941	1652	1665	lipoperoxides	T109	C0023776
28103941	1667	1673	type 1	T116,T192	C0378126
28103941	1675	1678	CB1	T116,T192	C0378126
28103941	1684	1690	type 2	T116,T192	C0208757
28103941	1692	1695	CB2	T116,T192	C0208757
28103941	1697	1718	cannabinoid receptors	T116,T192	C0054594
28103941	1724	1729	COX-2	T116,T126	C0387583
28103941	1745	1757	brain tissue	T023	C0459385
28103941	1758	1772	concentrations	T081	C1446561
28103941	1776	1796	docosahexaenoic acid	T109,T121,T123	C0012968
28103941	1798	1801	DHA	T109,T121,T123	C0012968
28103941	1821	1828	targets	T169	C1521840
28103941	1832	1850	lipid peroxidation	T044	C0023775
28103941	1855	1861	plasma	T031	C0032105
28103941	1883	1893	anandamide	T109,T123	C0211726
28103941	1898	1911	lipoperoxides	T109	C0023776
28103941	1917	1925	observed	T169	C1441672
28103941	1931	1936	BCCAO	T046	C1386627
28103941	1939	1940	R	T038	C0684253
28103941	1941	1951	stimulated	T070	C1948023
28103941	1958	1967	molecular	T080	C1521991
28103941	1968	1975	changes	T169	C0392747
28103941	2005	2017	brain tissue	T023	C0459385
28103941	2022	2028	plasma	T031	C0032105
28103941	2043	2053	indicative	T078	C3146298
28103941	2061	2067	tissue	T024	C0040300
28103941	2068	2090	physiological response	T039	C0542478
28103941	2098	2109	reperfusion	T038	C0684253
28103941	2112	2119	induced	T169	C0205263
28103941	2120	2136	oxidative stress	T049	C0242606
28103941	2141	2153	inflammation	T046	C0021368
28103941	2159	2167	observed	T169	C1441672
28103941	2168	2178	variations	T080	C0205419
28103941	2205	2215	modulation	T082	C0443264
28103941	2223	2226	ECS	T044	C3156138
28103941	2247	2262	proinflammatory	T123	C0574031
28103941	2318	2327	plasmatic	T031	C0032105
28103941	2338	2348	anandamide	T109,T123	C0211726
28103941	2353	2366	lipoperoxides	T109	C0023776
28103941	2389	2402	dysregulation	T038	C1327622
28103941	2412	2421	molecules	T167	C0567416
28103941	2441	2450	indicator	T169	C1522602
28103941	2465	2478	hypoperfusion	T046	C0442856
28103941	2481	2492	reperfusion	T038	C0684253

27616751|t|Anti-CD45RB and donor-specific spleen cells transfusion inhibition allograft skin rejection mediated by memory T cells
27616751|a|Donor-reactive memory T (Tm)cells mediate accelerated rejection, which is known as a barrier to the survival of transplanted organs. Selective interference with the anti-CD45RB monoclonal antibody (α-CD45RB) reliably induces donor - specific tolerance. In this study, pre-sensitization to female C57BL/6 mice with the skin of female BLAB/c mice generated a large number of Tm cells and resulted in rapid rejection of the secondly transplanted allografts. α-CD45RB did induce the tolerance to skin allograft primarily transplanted but failed to induce tolerance in the pre-sensitized mice. Donor-specific spleen cell transfusion (DST) alone also failed to induce the tolerance in the pre-sensitized recipients. Interestingly, combination of α-CD45RB with DST inhibited the rejection induced by memory T cells in the pre-sensitized mice. CD25+ T-cell depletion in α-CD45RB combined with DST therapy recipients could prevent skin allograft tolerance from establishing. In addition, adoptive transfer of donor -primed memory T cells into the tolerant recipients markedly broke the established tolerance. Our findings indicate that α-CD45RB and DST can synergistically inhibit the accelerated rejection mediated by memory T cells and induce long-term skin allograft acceptance in mice.
27616751	0	11	Anti-CD45RB	T116,T129	C0003250
27616751	16	55	donor-specific spleen cells transfusion	T169	C0199960
27616751	56	66	inhibition	T052	C3463820
27616751	67	91	allograft skin rejection	T046	C2891288
27616751	104	118	memory T cells	T025	C0682639
27616751	134	152	memory T (Tm)cells	T025	C0682639
27616751	173	182	rejection	T042	C0018129
27616751	231	250	transplanted organs	T023	C0524930
27616751	284	326	anti-CD45RB monoclonal antibody (α-CD45RB)	T116,T129	C0003250
27616751	344	349	donor	T098	C0013018
27616751	352	360	specific	T080	C0205369
27616751	361	370	tolerance	T040	C0887937
27616751	380	385	study	T062	C2603343
27616751	387	404	pre-sensitization	T079	C1254367
27616751	408	414	female	T032	C0086287
27616751	415	427	C57BL/6 mice	T015	C1521751
27616751	437	441	skin	T022	C1123023
27616751	445	451	female	T032	C0086287
27616751	452	463	BLAB/c mice	T015	C0026809
27616751	492	500	Tm cells	T025	C0682639
27616751	523	532	rejection	T042	C0018129
27616751	540	548	secondly	T081	C0205436
27616751	549	561	transplanted	T169	C0700106
27616751	562	572	allografts	T122	C0450127
27616751	574	582	α-CD45RB	T116,T129	C0003250
27616751	598	607	tolerance	T040	C0887937
27616751	611	625	skin allograft	T122	C0440814
27616751	626	635	primarily	T080	C0205225
27616751	636	648	transplanted	T169	C0700106
27616751	670	679	tolerance	T040	C0887937
27616751	687	706	pre-sensitized mice	T015	C0026809
27616751	708	746	Donor-specific spleen cell transfusion	T169	C0199960
27616751	748	751	DST	T169	C0199960
27616751	785	794	tolerance	T040	C0887937
27616751	802	816	pre-sensitized	T079	C1254367
27616751	817	827	recipients	T101	C0376387
27616751	859	867	α-CD45RB	T116,T129	C0003250
27616751	873	876	DST	T169	C0199960
27616751	891	900	rejection	T042	C0018129
27616751	912	926	memory T cells	T025	C0682639
27616751	934	953	pre-sensitized mice	T015	C0026809
27616751	955	967	CD25+ T-cell	T025	C0039194
27616751	968	977	depletion	T061	C0677960
27616751	981	989	α-CD45RB	T116,T129	C0003250
27616751	1004	1007	DST	T169	C0199960
27616751	1008	1015	therapy	T061	C0087111
27616751	1016	1026	recipients	T101	C0376387
27616751	1041	1055	skin allograft	T122	C0440814
27616751	1056	1065	tolerance	T040	C0887937
27616751	1098	1115	adoptive transfer	T061	C0376518
27616751	1119	1124	donor	T098	C0013018
27616751	1133	1147	memory T cells	T025	C0682639
27616751	1157	1165	tolerant	T040	C0887937
27616751	1166	1176	recipients	T101	C0376387
27616751	1208	1217	tolerance	T040	C0887937
27616751	1223	1231	findings	T033	C0243095
27616751	1246	1254	α-CD45RB	T116,T129	C0003250
27616751	1259	1262	DST	T169	C0199960
27616751	1307	1316	rejection	T042	C0018129
27616751	1329	1343	memory T cells	T025	C0682639
27616751	1365	1379	skin allograft	T122	C0440814
27616751	1380	1390	acceptance	T039	C0301944
27616751	1394	1398	mice	T015	C0026809

28301284|t|Immunogenicity and protective efficacy of recombinant Bacille Calmette-Guerin strains expressing mycobacterium antigens Ag85A, CFP10, ESAT-6, GM-CSF and IL-12p70
28301284|a|This study aimed to evaluate the immunogenicity and protective efficacy of recombinant bacille calmette-guerin (rBCG) strains expressing Ag85A (A), CFP10 (C), ESAT6 (E), IL-12p70 (I), and fusion protein GM-CSF (G). rBCGs were established by integrating of A, C, E, I, G, AE, CE, IE, GC, GE and GCE into Mycobacterium bovis BCG-1173 and BCG-SH. The macro- effects of rBCGs on mice were evaluated by phenotype and weight. The immunogenicity of rBCGs was analyzed by lgG, lgG1 and lgG2a antibody titers, and IFN-γ and IL-4 contents through Enzyme-linked immunosorbent assay (ELISA). Meanwhile, the proportions of CD4(+) and CD8(+) T splenic lymphocytes were determined using flow cytometry. The protective efficacy of rBCGs was evaluated by bacterial load in spleen and lung tissues from immunized mice. rBCGs exhibited no obvious side effects on mice. The antibody titers of lgG, lgG1 and lgG2a, proportion of CD4(+) and CD8(+) T cells, and concentrations of IFN-γ were found to be significantly higher in multiple - gene rBCGs than that in single-gene rBCGs (P < 0.05). Bacterial load in both spleen and lung tissues from mice infected with M. tuberculosis H37Rv were significantly reduced by rBCGs. A significantly lower bacterial load was revealed in rBCG -1173:A compared with multiple - gene rBCGs (P < 0.05). Immunogenicity was better on multiple - gene rBCGs than on single-gene rBCGs, while excellent protective efficacy was exhibited on rBCG-1173:A and BCG-1173.
28301284	0	14	Immunogenicity	T062	C4054739
28301284	30	38	efficacy	T062	C1707887
28301284	42	53	recombinant	T001	C1514798
28301284	54	77	Bacille Calmette-Guerin	T007	C0085957
28301284	78	85	strains	T001	C0682518
28301284	97	110	mycobacterium	T007	C0026912
28301284	111	119	antigens	T129	C0003320
28301284	120	125	Ag85A	T116,T126,T129	C0675617
28301284	127	132	CFP10	T116,T123	C1506203
28301284	134	140	ESAT-6	T116,T129	C1744314
28301284	142	148	GM-CSF	T116,T129	C0079460
28301284	153	161	IL-12p70	T116,T121,T129	C0123759
28301284	167	172	study	T062	C2603343
28301284	173	178	aimed	T078	C1947946
28301284	182	190	evaluate	T058	C0220825
28301284	195	209	immunogenicity	T062	C4054739
28301284	225	233	efficacy	T062	C1707887
28301284	237	248	recombinant	T001	C1514798
28301284	249	272	bacille calmette-guerin	T007	C0085957
28301284	274	278	rBCG	T007	C0085957
28301284	280	287	strains	T001	C0682518
28301284	299	304	Ag85A	T116,T126,T129	C0675617
28301284	306	307	A	T116,T126,T129	C0675617
28301284	310	315	CFP10	T116,T123	C1506203
28301284	317	318	C	T116,T123	C1506203
28301284	321	326	ESAT6	T116,T129	C1744314
28301284	328	329	E	T116,T129	C1744314
28301284	332	340	IL-12p70	T116,T121,T129	C0123759
28301284	342	343	I	T116,T121,T129	C0123759
28301284	350	364	fusion protein	T116,T123	C0162768
28301284	365	371	GM-CSF	T116,T129	C0079460
28301284	373	374	G	T116,T129	C0079460
28301284	377	382	rBCGs	T007	C0085957
28301284	388	399	established	T080	C0443211
28301284	403	414	integrating	UnknownType	C0678673
28301284	418	419	A	T116,T126,T129	C0675617
28301284	421	422	C	T116,T123	C1506203
28301284	424	425	E	T116,T129	C1744314
28301284	427	428	I	T116,T121,T129	C0123759
28301284	430	431	G	T116,T129	C0079460
28301284	433	435	AE	T116,T129	C3181051
28301284	437	439	CE	T116,T123	C0162768
28301284	441	443	IE	T116,T123	C0162768
28301284	445	447	GC	T116,T123	C0162768
28301284	449	451	GE	T116,T123	C0162768
28301284	456	459	GCE	T116,T123	C0162768
28301284	465	493	Mycobacterium bovis BCG-1173	T007	C0085957
28301284	498	504	BCG-SH	T007	C0085957
28301284	517	524	effects	T080	C1280500
28301284	528	533	rBCGs	T007	C0085957
28301284	537	541	mice	T015	C0025929
28301284	547	556	evaluated	T058	C0220825
28301284	560	569	phenotype	T032	C0031437
28301284	574	580	weight	T081	C0043100
28301284	586	600	immunogenicity	T062	C4054739
28301284	604	609	rBCGs	T007	C0085957
28301284	626	629	lgG	T026	C2754943
28301284	631	635	lgG1	T026	C2754944
28301284	640	654	lgG2a antibody	T026	C2754946
28301284	655	661	titers	T081	C0475208
28301284	667	672	IFN-γ	T116,T121,T129	C0021745
28301284	677	681	IL-4	T116,T129	C0021758
28301284	682	690	contents	T077	C0456205
28301284	699	732	Enzyme-linked immunosorbent assay	T059	C0014441
28301284	734	739	ELISA	T059	C0014441
28301284	757	768	proportions	T081	C1709707
28301284	772	778	CD4(+)	T025	C0039215
28301284	783	811	CD8(+) T splenic lymphocytes	T025	C0242629
28301284	834	848	flow cytometry	T059	C0016263
28301284	865	873	efficacy	T062	C1707887
28301284	877	882	rBCGs	T007	C0085957
28301284	887	896	evaluated	T058	C0220825
28301284	900	914	bacterial load	T081	C2936404
28301284	918	924	spleen	T024	C0771377
28301284	929	941	lung tissues	T024	C0819757
28301284	957	961	mice	T015	C0025929
28301284	963	968	rBCGs	T007	C0085957
28301284	990	1002	side effects	T046	C0879626
28301284	1006	1010	mice	T015	C0025929
28301284	1016	1024	antibody	T116,T129	C0003241
28301284	1025	1031	titers	T081	C0475208
28301284	1035	1038	lgG	T026	C2754943
28301284	1040	1044	lgG1	T026	C2754944
28301284	1049	1054	lgG2a	T026	C2754946
28301284	1056	1066	proportion	T081	C1709707
28301284	1070	1076	CD4(+)	T025	C0039215
28301284	1081	1095	CD8(+) T cells	T025	C0242629
28301284	1101	1115	concentrations	T081	C1446561
28301284	1119	1124	IFN-γ	T116,T121,T129	C0021745
28301284	1142	1162	significantly higher	T081	C4055637
28301284	1166	1174	multiple	T081	C0439064
28301284	1177	1181	gene	T028	C0017337
28301284	1182	1187	rBCGs	T007	C0085957
28301284	1201	1212	single-gene	T028	C0017337
28301284	1213	1218	rBCGs	T007	C0085957
28301284	1231	1245	Bacterial load	T081	C2936404
28301284	1254	1260	spleen	T024	C0771377
28301284	1265	1277	lung tissues	T024	C0819757
28301284	1283	1287	mice	T015	C0025929
28301284	1288	1296	infected	T033	C0439663
28301284	1302	1323	M. tuberculosis H37Rv	T007	C1449831
28301284	1329	1350	significantly reduced	T081	C4055638
28301284	1354	1359	rBCGs	T007	C0085957
28301284	1363	1382	significantly lower	T081	C4055638
28301284	1383	1397	bacterial load	T081	C2936404
28301284	1402	1410	revealed	T080	C0443289
28301284	1414	1418	rBCG	T007	C0085957
28301284	1427	1435	compared	T052	C1707455
28301284	1441	1449	multiple	T081	C0439064
28301284	1452	1456	gene	T028	C0017337
28301284	1457	1462	rBCGs	T007	C0085957
28301284	1475	1489	Immunogenicity	T062	C4054739
28301284	1504	1512	multiple	T081	C0439064
28301284	1515	1519	gene	T028	C0017337
28301284	1520	1525	rBCGs	T007	C0085957
28301284	1534	1545	single-gene	T028	C0017337
28301284	1546	1551	rBCGs	T007	C0085957
28301284	1580	1588	efficacy	T062	C1707887
28301284	1606	1617	rBCG-1173:A	T007	C0085957
28301284	1622	1630	BCG-1173	T007	C0085957

27294544|t|Nanocatalysts promote Streptococcus mutans biofilm matrix degradation and enhance bacterial killing to suppress dental caries in vivo
27294544|a|Dental biofilms (known as plaque) are notoriously difficult to remove or treat because the bacteria can be enmeshed in a protective extracellular matrix. It can also create highly acidic microenvironments that cause acid-dissolution of enamel - apatite on teeth, leading to the onset of dental caries. Current antimicrobial agents are incapable of disrupting the matrix and thereby fail to efficiently kill the microbes within plaque - biofilms. Here, we report a novel strategy to control plaque - biofilms using catalytic nanoparticles (CAT-NP) with peroxidase -like activity that trigger extracellular matrix degradation and cause bacterial death within acidic niches of caries -causing biofilm. CAT-NP containing biocompatible Fe3O4 were developed to catalyze H2O2 to generate free-radicals in situ that simultaneously degrade the biofilm matrix and rapidly kill the embedded bacteria with exceptional efficacy (>5-log reduction of cell-viability). Moreover, it displays an additional property of reducing apatite demineralization in acidic conditions. Using 1-min topical daily treatments akin to a clinical situation, we demonstrate that CAT-NP in combination with H2O2 effectively suppress the onset and severity of dental caries while sparing normal tissues in vivo. Our results reveal the potential to exploit nanocatalysts with enzyme-like activity as a potent alternative approach for treatment of a prevalent biofilm -associated oral disease.
27294544	0	13	Nanocatalysts	T067	C0175921
27294544	22	42	Streptococcus mutans	T007	C0038409
27294544	43	57	biofilm matrix	T024	C3548526
27294544	58	69	degradation	T169	C0243125
27294544	74	81	enhance	T052	C2349975
27294544	82	99	bacterial killing	T034	C1318001
27294544	103	111	suppress	T169	C1260953
27294544	112	125	dental caries	T047	C0011334
27294544	126	133	in vivo	T082	C1515655
27294544	134	140	Dental	T080	C0226984
27294544	141	149	biofilms	T007	C0081786
27294544	160	166	plaque	T047	C0011389
27294544	172	193	notoriously difficult	T080	C0332218
27294544	207	212	treat	T169	C1522326
27294544	225	233	bacteria	T007	C0004611
27294544	255	286	protective extracellular matrix	T024	C0015350
27294544	314	338	acidic microenvironments	T082	C0014406
27294544	370	376	enamel	T031	C0011350
27294544	379	386	apatite	T197	C0003522
27294544	390	395	teeth	T023	C0040426
27294544	421	434	dental caries	T047	C0011334
27294544	444	464	antimicrobial agents	T121	C1136254
27294544	469	478	incapable	T033	C1550518
27294544	482	492	disrupting	T080	C0332454
27294544	497	503	matrix	T024	C0015350
27294544	536	540	kill	T054	C0162388
27294544	545	553	microbes	T001	C0445623
27294544	561	567	plaque	T047	C0011389
27294544	570	578	biofilms	T007	C0081786
27294544	624	630	plaque	T047	C0011389
27294544	633	641	biofilms	T007	C0081786
27294544	648	671	catalytic nanoparticles	T067	C0175921
27294544	673	679	CAT-NP	T067	C0175921
27294544	686	696	peroxidase	T116,T126	C0027021
27294544	725	745	extracellular matrix	T024	C0015350
27294544	746	757	degradation	T169	C0243125
27294544	768	783	bacterial death	T033	C1306577
27294544	808	814	caries	T047	C0011334
27294544	824	831	biofilm	T007	C0081786
27294544	833	839	CAT-NP	T067	C0175921
27294544	851	864	biocompatible	T122	C0005479
27294544	865	870	Fe3O4	T197	C0919332
27294544	889	897	catalyze	T070	C0007382
27294544	898	902	H2O2	T121,T130,T197	C0020281
27294544	915	928	free-radicals	T104,T123	C0016693
27294544	929	936	in situ	T082	C0444498
27294544	957	964	degrade	T169	C0243125
27294544	969	983	biofilm matrix	T024	C3548526
27294544	996	1000	kill	T054	C0162388
27294544	996	1000	kill	T054	C0162388
27294544	1005	1022	embedded bacteria	T007	C0004611
27294544	1028	1048	exceptional efficacy	T080	C1280519
27294544	1070	1084	cell-viability	T043	C0007620
27294544	1144	1151	apatite	T197	C0003522
27294544	1152	1168	demineralization	T046	C0700185
27294544	1172	1189	acidic conditions	T080	C0348080
27294544	1211	1216	daily	T079	C0332173
27294544	1217	1227	treatments	T169	C1522326
27294544	1238	1256	clinical situation	T041	C0004448
27294544	1278	1284	CAT-NP	T067	C0175921
27294544	1305	1309	H2O2	T121,T130,T197	C0020281
27294544	1322	1330	suppress	T169	C1260953
27294544	1345	1353	severity	T080	C0439793
27294544	1357	1370	dental caries	T047	C0011334
27294544	1392	1399	tissues	T024	C0040300
27294544	1400	1407	in vivo	T082	C1515655
27294544	1413	1420	results	T034	C0456984
27294544	1432	1441	potential	T080	C3245505
27294544	1453	1466	nanocatalysts	T067	C0175921
27294544	1472	1492	enzyme-like activity	T044	C0243102
27294544	1530	1539	treatment	T061	C0087111
27294544	1555	1562	biofilm	T007	C0081786
27294544	1575	1587	oral disease	T047	C0026636

28027163|t|The Business of Health Physics - Jobs In A Changing Market
28027163|a|The health physics profession was born abruptly when once rare and precious radioactive materials became commonplace. The technological advancements that triggered an industrial complex and ended World War II demanded radiation safety on an unprecedented scale. Until then, protective measures against radiation were largely absent in laboratories. Over the subsequent decades, health physicists began protecting people and the environment in a wide range of settings including medical, research, and industrial. The use of radioactive materials and radiation-generating devices is prevalent today. Radiation doses occur continuously including during airline flights, in our homes, during medical procedures, and in energy production. Radiation is integral to numerous applications including those in medicine, dentistry, manufacturing, construction, scientific research, nuclear electric power generation, and oil and gas exploration. Activities that were once groundbreaking have now become routine and scripted. At higher doses, health effects are understood and avoided. Instruments for the detection and measurement of radiation are at times smarter than their users. Ironically, the same health physics community that has been successful in demonstrating that exposures to radiation and to radioactive materials can be effectively managed is shrinking at an increasingly rapid rate. This paper highlights the creation of past and current jobs, predicts the future opportunities in the profession, and makes recommendations necessary to protect the disappearing specialties.
28027163	4	12	Business	UnknownType	C0680840
28027163	16	30	Health Physics	T091	C0018725
28027163	33	37	Jobs	T090	C0028811
28027163	43	58	Changing Market	T057	C0024825
28027163	63	77	health physics	T091	C0018725
28027163	78	88	profession	T090	C0028811
28027163	135	156	radioactive materials	T122	C0182598
28027163	164	175	commonplace	T081	C0205214
28027163	181	207	technological advancements	UnknownType	C0681519
28027163	226	244	industrial complex	T080	C0439855
28027163	255	267	World War II	T051	C0681710
28027163	277	293	radiation safety	T067	C3825766
28027163	300	319	unprecedented scale	T170	C0349674
28027163	333	370	protective measures against radiation	T068	C3494257
28027163	394	406	laboratories	T073,T093	C0022877
28027163	437	454	health physicists	T097	C0334722
28027163	461	478	protecting people	T061	C0034533
28027163	487	498	environment	T064	C0242228
28027163	537	544	medical	T058	C0199168
28027163	546	554	research	T062	C0035168
28027163	560	570	industrial	T057	C0021267
28027163	576	604	use of radioactive materials	T033	C4060843
28027163	609	637	radiation-generating devices	T074	C2094479
28027163	641	656	prevalent today	T082	C0205391
28027163	658	673	Radiation doses	T081	C4019308
28027163	710	725	airline flights	T073	C0001881
28027163	748	766	medical procedures	T058	C0199171
28027163	794	803	Radiation	T070	C0851346
28027163	807	840	integral to numerous applications	T169	C0205245
28027163	860	868	medicine	T091	C0025118
28027163	870	879	dentistry	T091	C0011438
28027163	881	894	manufacturing	T090	C0682029
28027163	910	929	scientific research	T062	C0683933
28027163	931	964	nuclear electric power generation	T073	C0242446
28027163	970	993	oil and gas exploration	T070	C3179122
28027163	1052	1059	routine	T080	C0205547
28027163	1064	1072	scripted	T170	C0871893
28027163	1077	1089	higher doses	T081	C4019308
28027163	1091	1105	health effects	T033	C4060919
28027163	1110	1132	understood and avoided	T169	C0205245
28027163	1134	1192	Instruments for the detection and measurement of radiation	T074	C3873809
28027163	1253	1267	health physics	T091	C0018725
28027163	1325	1347	exposures to radiation	T037	C0015333
28027163	1355	1376	radioactive materials	T122	C0182598
28027163	1384	1403	effectively managed	T058	C0024679
28027163	1436	1446	rapid rate	T081	C1521828
28027163	1474	1482	creation	T052	C1706214
28027163	1503	1507	jobs	T090	C0028811
28027163	1529	1560	opportunities in the profession	T078	C1516834
28027163	1572	1587	recommendations	T078	C0034866
28027163	1613	1637	disappearing specialties	T091	C1273796

27252074|t|The Chinese Herbal Mixture Tien-Hsien Liquid Augments the Anticancer Immunity in Tumor Cell - Vaccinated Mice
27252074|a|Background The Chinese herbal mixture, Tien-Hsien liquid (THL), has been used as an anticancer dietary supplement for more than 20 years. Our previous studies have shown that THL can modulate immune response and inhibit tumor growth. In this study, we further evaluated the effect of THL on anticancer immune response in mice vaccinated with γ-ray - irradiated tumor cells. Methods The antitumor effect of THL was determined in mice vaccinated with low-tumorigenic CT-26-low colon cancer cells or γ-ray-irradiated high-tumorigenic CT-26-high colon cancer cells. The number of natural killer (NK) cells and T lymphocytes in the spleen was analyzed by flow cytometry. The tumor - killing activities of NK cells and cytotoxic T lymphocytes (CTLs) were analyzed by flow cytometry using YAC-1 and CT-26-high cells, respectively, as target cells. The levels of IFN-γ, IL-2, and TNF-α were determined by ELISA. Results THL suppressed the growth of CT-26-high tumor in mice previously vaccinated with low-tumorigenic CT-26-low cells or γ-irradiated CT-26-high cells. THL increased the populations of NK cells and CD4+ T lymphocytes in the spleen and enhanced the tumor - killing activities of NK cells and CTL in mice vaccinated with γ-irradiated CT-26-high cells. THL increased the production of IFN-γ, IL-2, and TNF-α in mice vaccinated with γ-irradiated CT-26-high cells. Conclusion THL can enhance the antitumor immune responses in mice vaccinated with killed tumor cells. These results suggest that THL may be used as a complementary medicine for cancer patients previously treated with killed tumor cell vaccines, radiotherapy, or chemotherapy.
27252074	4	18	Chinese Herbal	T080	C3146288
27252074	19	26	Mixture	T167	C0439962
27252074	27	44	Tien-Hsien Liquid	T109,T121	C1528399
27252074	45	53	Augments	T081	C0205217
27252074	58	68	Anticancer	T080	C2986475
27252074	69	77	Immunity	T039	C0020964
27252074	81	91	Tumor Cell	T025	C0597032
27252074	94	104	Vaccinated	T033	C1116171
27252074	105	109	Mice	T015	C0025929
27252074	125	139	Chinese herbal	T080	C3146288
27252074	140	147	mixture	T167	C0439962
27252074	149	166	Tien-Hsien liquid	T109,T121	C1528399
27252074	168	171	THL	T109,T121	C1528399
27252074	194	204	anticancer	T080	C2986475
27252074	205	223	dietary supplement	T168	C0242295
27252074	241	246	years	T079	C0439234
27252074	252	260	previous	T079	C0205156
27252074	261	268	studies	T062	C2603343
27252074	285	288	THL	T109,T121	C1528399
27252074	293	301	modulate	T082	C0443264
27252074	302	317	immune response	T042	C0301872
27252074	322	329	inhibit	T052	C3463820
27252074	330	342	tumor growth	T191	C0598934
27252074	352	357	study	T062	C2603343
27252074	370	379	evaluated	T058	C0220825
27252074	384	390	effect	T080	C1280500
27252074	394	397	THL	T109,T121	C1528399
27252074	401	411	anticancer	T080	C2986475
27252074	412	427	immune response	T042	C0301872
27252074	431	435	mice	T015	C0025929
27252074	436	446	vaccinated	T033	C1116171
27252074	452	457	γ-ray	T070	C0017011
27252074	460	470	irradiated	T070	C1282930
27252074	471	482	tumor cells	T025	C0597032
27252074	496	505	antitumor	T080	C2986475
27252074	506	512	effect	T080	C1280500
27252074	516	519	THL	T109,T121	C1528399
27252074	524	534	determined	T080	C0521095
27252074	538	542	mice	T015	C0025929
27252074	543	553	vaccinated	T033	C1116171
27252074	559	603	low-tumorigenic CT-26-low colon cancer cells	T025	C0085983
27252074	607	623	γ-ray-irradiated	T061	C2985557
27252074	624	670	high-tumorigenic CT-26-high colon cancer cells	T025	C0085983
27252074	676	682	number	T081	C0237753
27252074	686	711	natural killer (NK) cells	T025	C0022688
27252074	716	729	T lymphocytes	T025	C0039194
27252074	737	743	spleen	T023	C0037993
27252074	748	756	analyzed	T062	C0936012
27252074	760	774	flow cytometry	T059	C0016263
27252074	780	785	tumor	T191	C0027651
27252074	788	795	killing	T043	C0599733
27252074	796	806	activities	T052	C0441655
27252074	810	818	NK cells	T025	C0022688
27252074	823	846	cytotoxic T lymphocytes	T025	C0039195
27252074	848	852	CTLs	T025	C0039195
27252074	859	867	analyzed	T062	C0936012
27252074	871	885	flow cytometry	T059	C0016263
27252074	892	897	YAC-1	T025	C0085983
27252074	902	918	CT-26-high cells	T025	C0085983
27252074	937	943	target	T169	C1521840
27252074	944	949	cells	T025	C0007634
27252074	955	961	levels	T080	C0441889
27252074	965	970	IFN-γ	T116,T121,T129	C0021745
27252074	972	976	IL-2	T116,T129	C0021756
27252074	982	987	TNF-α	T116,T129	C1456820
27252074	993	1006	determined by	T080	C0521095
27252074	1007	1012	ELISA	T059	C0014441
27252074	1022	1025	THL	T109,T121	C1528399
27252074	1026	1036	suppressed	T169	C1260953
27252074	1041	1047	growth	T040	C0018270
27252074	1051	1067	CT-26-high tumor	T025	C0085983
27252074	1071	1075	mice	T015	C0025929
27252074	1087	1097	vaccinated	T033	C1116171
27252074	1103	1134	low-tumorigenic CT-26-low cells	T025	C0085983
27252074	1138	1150	γ-irradiated	T061	C2985557
27252074	1151	1167	CT-26-high cells	T025	C0085983
27252074	1169	1172	THL	T109,T121	C1528399
27252074	1173	1182	increased	T081	C0205217
27252074	1202	1210	NK cells	T025	C0022688
27252074	1215	1233	CD4+ T lymphocytes	T025	C0039215
27252074	1241	1247	spleen	T023	C0037993
27252074	1252	1260	enhanced	T052	C2349975
27252074	1265	1270	tumor	T191	C0027651
27252074	1273	1280	killing	T043	C0599733
27252074	1281	1291	activities	T052	C0441655
27252074	1295	1303	NK cells	T025	C0022688
27252074	1308	1311	CTL	T025	C0039195
27252074	1315	1319	mice	T015	C0025929
27252074	1320	1330	vaccinated	T033	C1116171
27252074	1336	1348	γ-irradiated	T061	C2985557
27252074	1349	1365	CT-26-high cells	T025	C0085983
27252074	1367	1370	THL	T109,T121	C1528399
27252074	1371	1380	increased	T081	C0205217
27252074	1385	1395	production	T169	C0205245
27252074	1399	1404	IFN-γ	T116,T121,T129	C0021745
27252074	1406	1410	IL-2	T116,T129	C0021756
27252074	1416	1421	TNF-α	T116,T129	C1456820
27252074	1425	1429	mice	T015	C0025929
27252074	1430	1440	vaccinated	T033	C1116171
27252074	1446	1458	γ-irradiated	T061	C2985557
27252074	1459	1475	CT-26-high cells	T025	C0085983
27252074	1488	1491	THL	T109,T121	C1528399
27252074	1496	1503	enhance	T052	C2349975
27252074	1508	1517	antitumor	T080	C2986475
27252074	1518	1534	immune responses	T042	C0301872
27252074	1538	1542	mice	T015	C0025929
27252074	1543	1553	vaccinated	T033	C1116171
27252074	1559	1565	killed	T169	C0205245
27252074	1566	1577	tumor cells	T025	C0597032
27252074	1585	1592	results	T169	C1274040
27252074	1606	1609	THL	T109,T121	C1528399
27252074	1627	1649	complementary medicine	T091	C1148474
27252074	1654	1660	cancer	T191	C0006826
27252074	1661	1669	patients	T101	C0030705
27252074	1670	1680	previously	T079	C0205156
27252074	1681	1688	treated	T169	C1522326
27252074	1694	1720	killed tumor cell vaccines	T116,T121,T129	C0376659
27252074	1722	1734	radiotherapy	T061	C1522449
27252074	1739	1751	chemotherapy	T061	C3665472

27696737|t|Highly polygenic architecture of antidepressant treatment response: Comparative analysis of SSRI and NRI treatment in an animal model of depression
27696737|a|Response to antidepressant (AD) treatment may be a more polygenic trait than previously hypothesized, with many genetic variants interacting in yet unclear ways. In this study we used methods that can automatically learn to detect patterns of statistical regularity from a sparsely distributed signal across hippocampal transcriptome measurements in a large-scale animal pharmacogenomic study to uncover genomic variations associated with AD. The study used four inbred mouse strains of both sexes, two drug treatments, and a control group (escitalopram, nortriptyline, and saline). Multi-class and binary classification using Machine Learning (ML) and regularization algorithms using iterative and univariate feature selection methods, including InfoGain, mRMR, ANOVA, and Chi Square, were used to uncover genomic markers associated with AD response. Relevant genes were selected based on Jaccard distance and carried forward for gene-network analysis. Linear association methods uncovered only one gene associated with drug treatment response. The implementation of ML algorithms, together with feature reduction methods, revealed a set of 204 genes associated with SSRI and 241 genes associated with NRI response. Although only 10% of genes overlapped across the two drugs, network analysis shows that both drugs modulated the CREB pathway, through different molecular mechanisms. Through careful implementation and optimisations, the algorithms detected a weak signal used to predict whether an animal was treated with nortriptyline (77%) or escitalopram (67%) on an independent testing set. The results from this study indicate that the molecular signature of AD treatment may include a much broader range of genomic markers than previously hypothesized, suggesting that response to medication may be as complex as the pathology. The search for biomarkers of antidepressant treatment response could therefore consider a higher number of genetic markers and their interactions. Through predominately different molecular targets and mechanisms of action, the two drugs modulate the same Creb1 pathway which plays a key role in neurotrophic responses and in inflammatory processes. © 2016 The Authors. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics Published by Wiley Periodicals, Inc.
27696737	7	29	polygenic architecture	T045	C1148552
27696737	33	47	antidepressant	T121	C0003289
27696737	48	66	treatment response	T201	C0521982
27696737	68	88	Comparative analysis	T062	C0683941
27696737	92	96	SSRI	T121	C0360105
27696737	101	104	NRI	T121	C1319272
27696737	105	114	treatment	T061	C0087111
27696737	121	147	animal model of depression	T050	C0012644
27696737	148	156	Response	T201	C0521982
27696737	160	174	antidepressant	T121	C0003289
27696737	176	178	AD	T045	C4277630
27696737	180	189	treatment	T061	C0087111
27696737	204	219	polygenic trait	T045	C1148552
27696737	260	276	genetic variants	T045	C4277630
27696737	318	323	study	T062	C2603343
27696737	332	339	methods	T170	C0025663
27696737	349	362	automatically	T033	C3842331
27696737	372	378	detect	T061	C1511790
27696737	379	387	patterns	T082	C0449774
27696737	391	413	statistical regularity	T080	C0449581
27696737	421	441	sparsely distributed	T169	C1704711
27696737	442	448	signal	T067	C1710082
27696737	456	467	hippocampal	T023	C0019564
27696737	468	481	transcriptome	T086	C3178810
27696737	482	494	measurements	T169	C0242485
27696737	512	518	animal	T008	C0003062
27696737	519	540	pharmacogenomic study	T062	C1709519
27696737	552	570	genomic variations	T045	C2717924
27696737	571	586	associated with	T080	C0332281
27696737	587	589	AD	T045	C4277630
27696737	595	600	study	T062	C2603343
27696737	611	631	inbred mouse strains	T015	C0025927
27696737	640	645	sexes	T032	C0079399
27696737	651	666	drug treatments	T061	C0013216
27696737	674	687	control group	T096	C0009932
27696737	689	701	escitalopram	T109,T121	C1099456
27696737	703	716	nortriptyline	T109,T121	C0028420
27696737	722	728	saline	T167	C0036082
27696737	731	742	Multi-class	T185	C0008902
27696737	747	768	binary classification	T185	C0008902
27696737	775	791	Machine Learning	T066	C0376284
27696737	793	795	ML	T066	C0376284
27696737	801	826	regularization algorithms	T170	C0002045
27696737	833	842	iterative	T080	C0205556
27696737	847	865	univariate feature	T080	C2348519
27696737	866	883	selection methods	T170	C0025663
27696737	895	903	InfoGain	T062	C1510568
27696737	905	909	mRMR	T062	C1510568
27696737	911	916	ANOVA	T081	C0002780
27696737	922	932	Chi Square	T081	C1552646
27696737	955	970	genomic markers	T045	C0017393
27696737	971	986	associated with	T080	C0332281
27696737	987	989	AD	T045	C4277630
27696737	990	998	response	T201	C0521982
27696737	1000	1008	Relevant	T080	C2347946
27696737	1009	1014	genes	T028	C0017337
27696737	1038	1054	Jaccard distance	T081	C0392762
27696737	1079	1091	gene-network	T044	C1720950
27696737	1092	1100	analysis	T062	C0936012
27696737	1102	1128	Linear association methods	T170	C0025663
27696737	1148	1152	gene	T028	C0017337
27696737	1153	1168	associated with	T080	C0332281
27696737	1169	1173	drug	T121	C0013227
27696737	1174	1192	treatment response	T201	C0521982
27696737	1198	1212	implementation	T052	C1708476
27696737	1216	1218	ML	T066	C0376284
27696737	1219	1229	algorithms	T170	C0002045
27696737	1245	1270	feature reduction methods	T170	C0025663
27696737	1294	1299	genes	T028	C0017337
27696737	1300	1315	associated with	T080	C0332281
27696737	1316	1320	SSRI	T121	C0360105
27696737	1329	1334	genes	T028	C0017337
27696737	1335	1350	associated with	T080	C0332281
27696737	1351	1354	NRI	T121	C1319272
27696737	1355	1363	response	T201	C0521982
27696737	1386	1391	genes	T028	C0017337
27696737	1392	1402	overlapped	T079	C1948020
27696737	1418	1423	drugs	T121	C0013227
27696737	1425	1441	network analysis	T170	C0868995
27696737	1458	1463	drugs	T121	C0013227
27696737	1478	1490	CREB pathway	T044	C1511454
27696737	1510	1530	molecular mechanisms	T044	C1148560
27696737	1548	1562	implementation	T052	C1708476
27696737	1567	1580	optimisations	T052	C2698650
27696737	1586	1596	algorithms	T170	C0002045
27696737	1608	1619	weak signal	T033	C0243095
27696737	1647	1653	animal	T008	C0003062
27696737	1658	1670	treated with	T061	C0332293
27696737	1671	1684	nortriptyline	T109,T121	C0028420
27696737	1694	1706	escitalopram	T109,T121	C1099456
27696737	1748	1755	results	T169	C1274040
27696737	1766	1771	study	T062	C2603343
27696737	1790	1809	molecular signature	T169	C1704864
27696737	1813	1815	AD	T045	C4277630
27696737	1816	1825	treatment	T061	C0087111
27696737	1862	1877	genomic markers	T045	C0017393
27696737	1924	1932	response	T201	C0521982
27696737	1936	1946	medication	T121	C0013227
27696737	1972	1981	pathology	T169	C0205469
27696737	1998	2008	biomarkers	T201	C0005516
27696737	2012	2026	antidepressant	T121	C0003289
27696737	2027	2045	treatment response	T201	C0521982
27696737	2090	2105	genetic markers	T045	C0017393
27696737	2116	2128	interactions	T169	C1704675
27696737	2162	2179	molecular targets	T104,T120	C1513403
27696737	2184	2204	mechanisms of action	T169	C1524059
27696737	2214	2219	drugs	T121	C0013227
27696737	2220	2228	modulate	T061	C0279532
27696737	2238	2251	Creb1 pathway	T044	C1511454
27696737	2278	2300	neurotrophic responses	T201	C0521982
27696737	2308	2330	inflammatory processes	T046	C0021368

28500879|t|Role of forensic medicine in evaluating non-fatal physical violence against women by their husbands in Jordan
28500879|a|Intimate partner violence against women is a major health problem in most nations, but to date, there has been little awareness of the extent or seriousness of this issue in Jordan. Forensic medical practitioners play a significant role in diagnosing, evaluating and reporting these cases. The Jordanian judicial system is dependent on forensic reports. This study aims to assess the role of forensic medicine in evaluating the physical injuries sustained by women who are abused by their husbands. A retrospective review of 158 forensic reports of Jordanian women alleging assault by their husbands and who were seen at Jordan University Hospital over the period 2010-2015. Of the 158 women who presented, 87 had multiple injuries. The majority of injuries were soft tissue injuries, but others included fractures, tympanic membrane perforation, burns and neck contusions. Twelve women were pregnant at the time of the assessment. The period of incapacity caused by these injuries (an important factor for the Jordanian judicial system) was between 1 and 14 days. Intimate partner violence can present with a range of injuries from relatively minor to potentially disabling or life threatening. Forensic medicine has a role in documenting and evaluating these injuries and advising the judicial system in these cases. These are all key elements in increasing the awareness of the nature and extent of this behavior and its impact on women (and men) and the wider society.
28500879	8	25	forensic medicine	T091	C0016557
28500879	29	39	evaluating	T062	C0178628
28500879	40	67	non-fatal physical violence	T048	C0476480
28500879	76	81	women	T098	C0043210
28500879	91	99	husbands	T099	C0242664
28500879	103	109	Jordan	T083	C0022418
28500879	110	135	Intimate partner violence	T053	C4042876
28500879	144	149	women	T098	C0043210
28500879	161	175	health problem	T033	C1398682
28500879	184	191	nations	T092	C1555720
28500879	228	237	awareness	T041	C0004448
28500879	255	266	seriousness	T055	C0871902
28500879	275	280	issue	T033	C0033213
28500879	284	290	Jordan	T083	C0022418
28500879	292	322	Forensic medical practitioners	T097	C1306754
28500879	350	360	diagnosing	T033	C0011900
28500879	362	372	evaluating	T062	C0178628
28500879	377	386	reporting	T064	C0376485
28500879	393	398	cases	T169	C0868928
28500879	404	429	Jordanian judicial system	UnknownType	C0680776
28500879	446	462	forensic reports	T170	C0684224
28500879	502	519	forensic medicine	T091	C0016557
28500879	523	533	evaluating	T062	C0178628
28500879	538	555	physical injuries	T037	C3263723
28500879	556	565	sustained	T169	C0443318
28500879	569	589	women who are abused	T101	C0242810
28500879	599	607	husbands	T099	C0242664
28500879	611	631	retrospective review	T170	C0282443
28500879	639	655	forensic reports	T170	C0684224
28500879	659	674	Jordanian women	T098	C0043210
28500879	675	691	alleging assault	T037	C0004063
28500879	701	709	husbands	T099	C0242664
28500879	731	737	Jordan	T083	C0022418
28500879	738	757	University Hospital	T073,T093	C0020028
28500879	767	773	period	T079	C1948053
28500879	796	801	women	T098	C0043210
28500879	824	841	multiple injuries	T037	C0026771
28500879	859	867	injuries	T037	C3263723
28500879	873	893	soft tissue injuries	T037	C0037578
28500879	915	924	fractures	T037	C0016658
28500879	926	955	tympanic membrane perforation	T037	C0206504
28500879	957	962	burns	T037	C0006434
28500879	967	982	neck contusions	T037	C0274215
28500879	991	996	women	T098	C0043210
28500879	1002	1010	pregnant	T169	C0553641
28500879	1018	1022	time	T079	C0040223
28500879	1030	1040	assessment	T058	C0220825
28500879	1046	1052	period	T079	C1948053
28500879	1083	1091	injuries	T037	C3263723
28500879	1121	1146	Jordanian judicial system	UnknownType	C0680776
28500879	1169	1173	days	T079	C0439228
28500879	1175	1200	Intimate partner violence	T053	C4042876
28500879	1229	1237	injuries	T037	C3263723
28500879	1275	1284	disabling	T033	C4061999
28500879	1288	1304	life threatening	T033	C2826244
28500879	1306	1323	Forensic medicine	T091	C0016557
28500879	1338	1349	documenting	T058	C1301725
28500879	1354	1364	evaluating	T062	C0178628
28500879	1371	1379	injuries	T037	C3263723
28500879	1384	1392	advising	T052	C1828381
28500879	1397	1412	judicial system	UnknownType	C0680776
28500879	1422	1427	cases	T169	C0868928
28500879	1459	1469	increasing	T169	C0442808
28500879	1474	1483	awareness	T041	C0004448
28500879	1491	1497	nature	T169	C1262865
28500879	1517	1525	behavior	T053	C0004927
28500879	1544	1549	women	T098	C0043210
28500879	1555	1558	men	T098	C0025266
28500879	1568	1581	wider society	T092	C0037455

28157688|t|Pattern recognition of enrichment levels of SELEX -based candidate aptamers for human C-reactive protein
28157688|a|Selecting aptamers for human C-reactive protein (CRP) would be of critical importance in predicting the risk for cardiovascular disease. The enrichment level of DNA aptamers is an important parameter for selecting candidate aptamers for further affinity and specificity determination. This paper is the first report on pattern recognition used for CRP aptamer enrichment levels in the systematic evolution of ligands by exponential enrichment (SELEX) process, by applying structure-activity relationship models. After generating 10 rounds of graphene oxide (GO)- SELEX and 1670 molecular descriptors, eight molecular descriptors were selected and five latent variables were then obtained with principal component analysis (PCA), to develop a support vector classification (SVC) model. The SVC model (C=8.1728 and γ=0.2333) optimized by the particle swarm optimization (PSO) algorithm possesses an accuracy of 88.15% for the training set. Prediction results of enrichment levels for the sequences with the frequencies of 6 and 5 are reasonable and acceptable, with accuracies of 70.59% and 76.37%, respectively.
28157688	0	19	Pattern recognition	T044	C1749339
28157688	23	33	enrichment	T081	C4086355
28157688	34	40	levels	T080	C0441889
28157688	44	49	SELEX	T062	C1567938
28157688	67	75	aptamers	T114	C0599013
28157688	80	104	human C-reactive protein	T116,T129	C4048285
28157688	105	114	Selecting	T045	C0036576
28157688	115	123	aptamers	T114	C0599013
28157688	128	152	human C-reactive protein	T116,T129	C4048285
28157688	154	157	CRP	T116,T129	C4048285
28157688	194	204	predicting	T078	C0681842
28157688	209	213	risk	T078	C0035647
28157688	218	240	cardiovascular disease	T047	C0007222
28157688	246	256	enrichment	T081	C4086355
28157688	266	278	DNA aptamers	T114	C1567953
28157688	329	337	aptamers	T114	C0599013
28157688	350	358	affinity	T070	C1510827
28157688	363	374	specificity	T081	C0037791
28157688	375	388	determination	T059	C1148554
28157688	424	443	pattern recognition	T044	C1749339
28157688	453	456	CRP	T116,T129	C4048285
28157688	457	464	aptamer	T114	C0599013
28157688	465	475	enrichment	T081	C4086355
28157688	476	482	levels	T080	C0441889
28157688	490	547	systematic evolution of ligands by exponential enrichment	T062	C1567938
28157688	549	554	SELEX	T062	C1567938
28157688	577	608	structure-activity relationship	T080	C0038477
28157688	609	615	models	T170	C3161035
28157688	647	655	graphene	T196	C2936695
28157688	656	661	oxide	T197	C0030015
28157688	663	665	GO	T197	C0030015
28157688	668	673	SELEX	T062	C1567938
28157688	683	692	molecular	T080	C1521991
28157688	693	704	descriptors	T170	C0282354
28157688	712	721	molecular	T080	C1521991
28157688	722	733	descriptors	T170	C0282354
28157688	757	773	latent variables	UnknownType	C0814889
28157688	798	826	principal component analysis	T081	C0429865
28157688	828	831	PCA	T081	C0429865
28157688	847	888	support vector classification (SVC) model	T081	C2699740
28157688	894	903	SVC model	T081	C2699740
28157688	928	937	optimized	T052	C2698650
28157688	945	988	particle swarm optimization (PSO) algorithm	T170	C0002045
28157688	1002	1010	accuracy	T080	C0443131
28157688	1043	1053	Prediction	T078	C0681842
28157688	1054	1061	results	T169	C1274040
28157688	1065	1075	enrichment	T081	C4086355
28157688	1076	1082	levels	T080	C0441889
28157688	1091	1100	sequences	T086	C0162326
28157688	1110	1121	frequencies	T079	C0439603
28157688	1137	1147	reasonable	T080	C0205556
28157688	1152	1162	acceptable	T080	C1879533
28157688	1169	1179	accuracies	T080	C0443131

27348135|t|Multimorbidity in Heart Failure: Effect on Outcomes
27348135|a|To investigate the effect of the number and type of comorbid conditions on death and hospitalizations in individuals with incident heart failure (HF). Population-based cohort study. Olmsted County, Minnesota. Olmsted County, Minnesota, residents with incident HF from 2000 to 2010 (mean age 76 ± 14, 56% female) (N = 1,714). The prevalence of 16 chronic conditions obtained at HF diagnosis classified into three groups: cardiovascular (CV) related, other physical, and mental. The mean number of conditions per participant was 2.6 ± 1.5 for CV -related conditions, 1.3 ± 1.1 for other physical conditions, and 0.30 ± 0.61 for mental conditions. After a mean follow-up of 4.2 years, 1,073 death s and 6,306 hospitalizations had occurred. After adjustment for age, sex, ejection fraction, in- or outpatient status, and number of other conditions, an increase of one other physical condition was associated with a 14% (HR = 1.14, 95% CI = 1.08-1.20) greater risk of death and a 26% (HR = 1.26, 95% CI = 1.20-1.32) greater risk of hospitalization, and an increase of one mental condition was associated with a 31% (HR = 1.31, 95% CI = 1.19-1.44) greater risk of death and an 18% (HR = 1.18, 95% CI = 1.07-1.29) greater risk of hospitalization. In contrast, an increase of one CV -related condition was not associated with greater risk of death and was associated with a 10% (HR = 1.10, 95% CI = 1.06-1.15) greater risk of hospitalization. CV -related conditions are the most common type of comorbid conditions in individuals with HF, but other physical and mental conditions are more strongly associated with death and hospitalizations. This underscores the effect of non-CV conditions on outcomes in HF.
27348135	0	14	Multimorbidity	T078	C1535889
27348135	18	31	Heart Failure	T047	C0018801
27348135	43	51	Outcomes	T033	C0679250
27348135	55	66	investigate	T169	C1292732
27348135	104	123	comorbid conditions	T033	C1275743
27348135	127	132	death	T040	C0011065
27348135	137	153	hospitalizations	T058	C0019993
27348135	157	168	individuals	T098	C0027361
27348135	183	196	heart failure	T047	C0018801
27348135	198	200	HF	T047	C0018801
27348135	203	219	Population-based	T062	C1709599
27348135	220	232	cohort study	T081	C0009247
27348135	234	259	Olmsted County, Minnesota	T083	C3828711
27348135	261	286	Olmsted County, Minnesota	T083	C3828711
27348135	312	314	HF	T047	C0018801
27348135	334	338	mean	T081	C0444504
27348135	339	342	age	T032	C0001779
27348135	356	362	female	T032	C0086287
27348135	398	405	chronic	T079	C0205191
27348135	406	416	conditions	T033	C2707292
27348135	429	431	HF	T047	C0018801
27348135	432	441	diagnosis	T062	C1704656
27348135	472	486	cardiovascular	T029	C3887460
27348135	488	490	CV	T029	C3887460
27348135	507	515	physical	T169	C0205485
27348135	521	527	mental	T041	C0229992
27348135	533	537	mean	T081	C0444504
27348135	548	558	conditions	T033	C2707292
27348135	563	574	participant	T098	C0679646
27348135	593	595	CV	T029	C3887460
27348135	605	615	conditions	T033	C2707292
27348135	637	656	physical conditions	T032	C3714565
27348135	678	695	mental conditions	T080	C3840291
27348135	705	709	mean	T081	C0444504
27348135	727	732	years	T079	C0439234
27348135	740	745	death	T040	C0011065
27348135	758	774	hospitalizations	T058	C0019993
27348135	810	813	age	T032	C0001779
27348135	815	818	sex	T032	C0079399
27348135	820	837	ejection fraction	T060	C0489482
27348135	846	856	outpatient	T101	C0029921
27348135	885	895	conditions	T033	C2707292
27348135	922	940	physical condition	T032	C3714565
27348135	968	970	HR	T201	C0018810
27348135	983	985	CI	T081	C0009667
27348135	1007	1011	risk	T078	C0035647
27348135	1015	1020	death	T040	C0011065
27348135	1032	1034	HR	T201	C0018810
27348135	1047	1049	CI	T081	C0009667
27348135	1071	1075	risk	T078	C0035647
27348135	1079	1094	hospitalization	T058	C0019993
27348135	1119	1135	mental condition	T080	C3840291
27348135	1163	1165	HR	T201	C0018810
27348135	1178	1180	CI	T081	C0009667
27348135	1202	1206	risk	T078	C0035647
27348135	1210	1215	death	T040	C0011065
27348135	1228	1230	HR	T201	C0018810
27348135	1243	1245	CI	T081	C0009667
27348135	1267	1271	risk	T078	C0035647
27348135	1275	1290	hospitalization	T058	C0019993
27348135	1324	1326	CV	T029	C3887460
27348135	1336	1345	condition	T033	C2707292
27348135	1378	1382	risk	T078	C0035647
27348135	1386	1391	death	T040	C0011065
27348135	1423	1425	HR	T201	C0018810
27348135	1438	1440	CI	T081	C0009667
27348135	1462	1466	risk	T078	C0035647
27348135	1470	1485	hospitalization	T058	C0019993
27348135	1487	1489	CV	T029	C3887460
27348135	1499	1509	conditions	T033	C2707292
27348135	1538	1557	comorbid conditions	T033	C1275743
27348135	1561	1572	individuals	T098	C0027361
27348135	1578	1580	HF	T047	C0018801
27348135	1592	1600	physical	T169	C0205485
27348135	1605	1622	mental conditions	T080	C3840291
27348135	1657	1662	death	T040	C0011065
27348135	1667	1683	hospitalizations	T058	C0019993
27348135	1716	1733	non-CV conditions	T033	C2707292
27348135	1749	1751	HF	T047	C0018801

27939374|t|Mesenchymal stromal cell - secreted chemerin is a novel immunomodulatory molecule driving the migration of ChemR23 - expressing cells
27939374|a|Mesenchymal stromal cells (MSCs) are multipotent cells characterized by broad immunomodulatory properties exploited for the treatment of inflammatory disorders. However, the efficacy of MSC -based therapy is highly variable and tightly linked to MSC culture conditions and treatment schedule. Thus, the identification of novel key molecules regulating MSC immunomodulatory activities in vivo might constitute a crucial step toward the optimization of currently available clinical protocols. In this regard, herein, we sought to determine whether the newly identified chemotactic protein, chemerin, plays a role in MSC -mediated regulation of inflammation. Chemerin production by human MSCs was investigated under different culture conditions using enzyme-linked immunosorbent assay (ELISA). After purification, MSC - secreted chemerin was identified using mass spectrometry analysis and the biological activity of secreted isoforms was evaluated using migration assay. Bone marrow - derived MSCs secrete chemerin and express its receptors ChemR23 and CCRL2. Chemerin production is dependent on culture conditions and increases upon stimulation with inflammatory cytokines. In particular, platelet lysate (PL)- MSCs produce higher levels of chemerin compared with fetal bovine serum (FBS)- MSCs. Furthermore, chemerin is secreted by MSCs as an inactive precursor, which can be converted into its active form by exogenous chemerin - activating serine and cysteine proteases. Our data indicate that, in response to various inflammatory stimuli, MSCs secrete high amounts of inactive chemerin, which can then be activated by inflammation - induced tissue proteases. In light of these initial findings, we propose that further analysis of chemerin functions in vivo might constitute a crucial step toward optimizing MSC -based therapy for inflammatory diseases.
27939374	0	24	Mesenchymal stromal cell	T025	C3178844
27939374	27	35	secreted	T043	C1327616
27939374	36	44	chemerin	T116,T123	C1312957
27939374	56	81	immunomodulatory molecule	T061	C1963758
27939374	94	103	migration	T039	C1533574
27939374	107	114	ChemR23	T116,T192	C1307877
27939374	117	127	expressing	T045	C0597360
27939374	134	159	Mesenchymal stromal cells	T025	C3178844
27939374	161	165	MSCs	T025	C3178844
27939374	171	188	multipotent cells	T025	C1136335
27939374	212	239	immunomodulatory properties	T061	C1963758
27939374	258	267	treatment	T061	C0087111
27939374	271	293	inflammatory disorders	T047	C1290884
27939374	308	316	efficacy	T080	C1280519
27939374	320	323	MSC	T025	C3178844
27939374	331	338	therapy	T061	C0087111
27939374	342	348	highly	T080	C0205250
27939374	349	357	variable	T080	C0439828
27939374	380	383	MSC	T025	C3178844
27939374	384	402	culture conditions	T059	C0007585
27939374	407	425	treatment schedule	T061	C0040808
27939374	437	451	identification	UnknownType	C0679807
27939374	461	474	key molecules	T123	C0574031
27939374	486	489	MSC	T025	C3178844
27939374	490	517	immunomodulatory activities	T061	C1963758
27939374	518	525	in vivo	T082	C1515655
27939374	545	557	crucial step	T077	C1261552
27939374	569	581	optimization	T052	C2698650
27939374	605	623	clinical protocols	T061	C0008971
27939374	690	700	identified	T080	C0205396
27939374	701	730	chemotactic protein, chemerin	T116,T123	C1312957
27939374	748	751	MSC	T025	C3178844
27939374	762	772	regulation	T038	C1327622
27939374	776	788	inflammation	T046	C0021368
27939374	790	798	Chemerin	T116,T123	C1312957
27939374	799	809	production	T169	C0005572
27939374	813	818	human	T016	C0086418
27939374	819	823	MSCs	T025	C3178844
27939374	828	840	investigated	T169	C1292732
27939374	847	856	different	T080	C1705242
27939374	857	875	culture conditions	T059	C0007585
27939374	882	915	enzyme-linked immunosorbent assay	T059	C0014441
27939374	917	922	ELISA	T059	C0014441
27939374	931	943	purification	T169	C1998793
27939374	945	948	MSC	T025	C3178844
27939374	951	959	secreted	T043	C1327616
27939374	960	968	chemerin	T116,T123	C1312957
27939374	973	983	identified	T080	C0205396
27939374	990	1007	mass spectrometry	T059	C0037813
27939374	1008	1016	analysis	T062	C0936012
27939374	1025	1044	biological activity	T169	C0599112
27939374	1048	1056	secreted	T043	C1327616
27939374	1057	1065	isoforms	T116	C0597298
27939374	1086	1101	migration assay	T059	C1513300
27939374	1103	1114	Bone marrow	T024	C0005953
27939374	1117	1124	derived	T080	C1441547
27939374	1125	1129	MSCs	T025	C3178844
27939374	1130	1137	secrete	T043	C1327616
27939374	1138	1146	chemerin	T116,T123	C1312957
27939374	1151	1158	express	T045	C0597360
27939374	1163	1180	receptors ChemR23	T116,T192	C1307877
27939374	1185	1190	CCRL2	T116,T192	C1453427
27939374	1192	1200	Chemerin	T116,T123	C1312957
27939374	1201	1211	production	T169	C0005572
27939374	1215	1224	dependent	T080	C0851827
27939374	1228	1246	culture conditions	T059	C0007585
27939374	1251	1260	increases	T169	C0442805
27939374	1266	1277	stimulation	T061	C1292856
27939374	1283	1295	inflammatory	T169	C0333348
27939374	1296	1305	cytokines	T043	C0010813
27939374	1322	1337	platelet lysate	T025	C0005821
27939374	1344	1348	MSCs	T025	C3178844
27939374	1357	1363	higher	T080	C0205250
27939374	1364	1370	levels	T080	C0441889
27939374	1374	1382	chemerin	T116,T123	C1312957
27939374	1383	1391	compared	T052	C1707455
27939374	1397	1415	fetal bovine serum	T130	C3812213
27939374	1417	1420	FBS	T130	C3812213
27939374	1423	1427	MSCs	T025	C3178844
27939374	1442	1450	chemerin	T116,T123	C1312957
27939374	1454	1462	secreted	T043	C1327616
27939374	1466	1470	MSCs	T025	C3178844
27939374	1477	1485	inactive	T080	C0205254
27939374	1486	1495	precursor	T078	C1709634
27939374	1529	1535	active	T169	C0205177
27939374	1544	1553	exogenous	T169	C0205228
27939374	1554	1562	chemerin	T116,T123	C1312957
27939374	1565	1575	activating	T052	C1879547
27939374	1576	1582	serine	T116,T126	C2717971
27939374	1587	1605	cysteine proteases	T116,T126	C0769345
27939374	1611	1615	data	T078	C1511726
27939374	1634	1642	response	T032	C0871261
27939374	1654	1666	inflammatory	T169	C0333348
27939374	1667	1674	stimuli	T067	C0234402
27939374	1676	1680	MSCs	T025	C3178844
27939374	1681	1688	secrete	T043	C1327616
27939374	1689	1693	high	T080	C0205250
27939374	1694	1701	amounts	T081	C1265611
27939374	1705	1713	inactive	T080	C0205254
27939374	1714	1722	chemerin	T116,T123	C1312957
27939374	1742	1751	activated	T052	C1879547
27939374	1755	1767	inflammation	T046	C0021368
27939374	1770	1777	induced	T169	C0205263
27939374	1778	1784	tissue	T024	C0040300
27939374	1785	1794	proteases	T116,T126	C0030940
27939374	1822	1830	findings	T033	C0243095
27939374	1856	1864	analysis	T062	C0936012
27939374	1868	1876	chemerin	T116,T123	C1312957
27939374	1877	1886	functions	T169	C0542341
27939374	1887	1894	in vivo	T082	C1515655
27939374	1914	1926	crucial step	T077	C1261552
27939374	1934	1944	optimizing	T052	C2698650
27939374	1945	1948	MSC	T025	C3178844
27939374	1956	1963	therapy	T061	C0087111
27939374	1968	1989	inflammatory diseases	T047	C1290884

27521418|t|Defining the sham environment for post-myocardial infarction studies in mice
27521418|a|The purpose of this study was to evaluate the effect of sham surgery in a minimally invasive surgical model of permanent coronary artery occlusion used to generate myocardial infarction (MI) in mice. Adult male C57BL/6J mice (3-6 mo old) were divided into five groups: day (D) 0 (no surgical operation), D1 Sham, D1 MI, D7 Sham, and D7 MI. A refined MI surgery technique was used to approach the coronary artery without the ribs being cut. Both sham and MI mice had the left ventricle (LV) exposed through a small incision. To test the effects of surgery alone, the suture was passed around the coronary artery but not ligated. The MI mice were subjected to permanent coronary artery ligation. The mice were killed at D1 or D7 postsurgical procedure. Compared with D0 no surgery controls, the D1 and D7 sham groups exhibited no surgical mortality and similar necropsy and echocardiographic variables. Surgery alone did not induce an inflammatory cell response, as evidenced by the lack of leukocyte infiltration in the sham groups. Analysis of 165 inflammatory cytokines and extracellular matrix factors in sham revealed that a minor gene response was initiated but not translated to protein levels. Collagen deposition did not occur in the absence of MI. In contrast, the D1 and D7 MI groups showed the expected robust inflammatory and scar formation responses. When a minimally invasive procedure to generate MI in mice was used, the D0 (no surgical operation) control was an adequate replacement for the use of sham surgery groups.
27521418	13	17	sham	T061	C0032042
27521418	18	29	environment	T082	C0014406
27521418	34	60	post-myocardial infarction	T047	C0152107
27521418	61	68	studies	T062	C2603343
27521418	72	76	mice	T015	C0025929
27521418	81	88	purpose	T169	C1285529
27521418	97	102	study	T062	C2603343
27521418	110	118	evaluate	T058	C0220825
27521418	123	129	effect	T080	C1280500
27521418	133	137	sham	T061	C0032042
27521418	138	145	surgery	T061	C0543467
27521418	151	178	minimally invasive surgical	T061	C0282624
27521418	179	184	model	T050	C0012644
27521418	188	197	permanent	T079	C0205355
27521418	198	223	coronary artery occlusion	T047	C0151814
27521418	232	240	generate	T052	C3146294
27521418	241	262	myocardial infarction	T047	C0027051
27521418	264	266	MI	T047	C0027051
27521418	271	275	mice	T015	C0025929
27521418	283	287	male	T032	C0086582
27521418	288	301	C57BL/6J mice	T015	C1521751
27521418	320	327	divided	T169	C0332849
27521418	338	344	groups	T078	C0441833
27521418	357	378	no surgical operation	T033	C0243095
27521418	384	388	Sham	T061	C0032042
27521418	393	395	MI	T047	C0027051
27521418	400	404	Sham	T061	C0032042
27521418	413	415	MI	T047	C0027051
27521418	427	429	MI	T047	C0027051
27521418	430	437	surgery	T061	C0543467
27521418	438	447	technique	T169	C0449851
27521418	473	488	coronary artery	T023	C0205042
27521418	501	505	ribs	T023	C0223074
27521418	522	526	sham	T061	C0032042
27521418	531	533	MI	T047	C0027051
27521418	534	538	mice	T015	C0025929
27521418	547	561	left ventricle	T023	C0225897
27521418	563	565	LV	T023	C0225897
27521418	567	574	exposed	T080	C0332157
27521418	585	590	small	T081	C0700321
27521418	591	599	incision	T061	C0184898
27521418	604	608	test	T169	C0039593
27521418	613	620	effects	T080	C1280500
27521418	624	631	surgery	T061	C0543467
27521418	643	649	suture	T074	C0038969
27521418	672	687	coronary artery	T023	C0205042
27521418	696	703	ligated	T061	C0023690
27521418	709	711	MI	T047	C0027051
27521418	712	716	mice	T015	C0025929
27521418	735	744	permanent	T079	C0205355
27521418	745	769	coronary artery ligation	T061	C0396819
27521418	775	779	mice	T015	C0025929
27521418	785	791	killed	T078	C0681205
27521418	804	816	postsurgical	T079	C0032790
27521418	817	826	procedure	T169	C2700391
27521418	828	836	Compared	T052	C1707455
27521418	848	855	surgery	T061	C0543467
27521418	856	864	controls	T096	C0009932
27521418	880	884	sham	T061	C0032042
27521418	885	891	groups	T078	C0441833
27521418	905	913	surgical	T061	C0543467
27521418	914	923	mortality	T081	C0205848
27521418	928	935	similar	T080	C2348205
27521418	936	944	necropsy	T060	C0004398
27521418	949	966	echocardiographic	T060	C0013516
27521418	967	976	variables	T080	C0439828
27521418	978	985	Surgery	T061	C0543467
27521418	1000	1006	induce	T169	C0205263
27521418	1010	1036	inflammatory cell response	T046	C1155266
27521418	1041	1050	evidenced	T078	C3887511
27521418	1058	1062	lack	T080	C0332268
27521418	1066	1088	leukocyte infiltration	T033	C0333361
27521418	1096	1100	sham	T061	C0032042
27521418	1101	1107	groups	T078	C0441833
27521418	1109	1117	Analysis	T062	C0936012
27521418	1125	1137	inflammatory	T169	C0333348
27521418	1138	1147	cytokines	T116,T129	C0079189
27521418	1152	1172	extracellular matrix	T024	C0015350
27521418	1173	1180	factors	T129	C0021054
27521418	1184	1188	sham	T061	C0032042
27521418	1189	1197	revealed	T080	C0443289
27521418	1205	1210	minor	T080	C0205165
27521418	1211	1215	gene	T028	C0017337
27521418	1216	1224	response	T032	C0871261
27521418	1229	1238	initiated	T169	C1704686
27521418	1247	1257	translated	T045	C1519614
27521418	1261	1268	protein	T116,T123	C0033684
27521418	1269	1275	levels	T080	C0441889
27521418	1277	1285	Collagen	T116	C0009325
27521418	1286	1296	deposition	T169	C0333562
27521418	1305	1310	occur	T052	C1709305
27521418	1318	1325	absence	T169	C0332197
27521418	1329	1331	MI	T047	C0027051
27521418	1360	1362	MI	T047	C0027051
27521418	1363	1369	groups	T078	C0441833
27521418	1381	1389	expected	T170	C1517001
27521418	1390	1396	robust	T080	C2986815
27521418	1397	1409	inflammatory	T169	C0333348
27521418	1414	1428	scar formation	T033	C1822291
27521418	1429	1438	responses	T032	C0871261
27521418	1447	1475	minimally invasive procedure	T169	C2711297
27521418	1479	1487	generate	T052	C3146294
27521418	1488	1490	MI	T047	C0027051
27521418	1494	1498	mice	T015	C0025929
27521418	1517	1538	no surgical operation	T033	C0243095
27521418	1540	1547	control	T096	C0009932
27521418	1555	1563	adequate	T080	C0205411
27521418	1564	1575	replacement	T169	C0559956
27521418	1591	1595	sham	T061	C0032042
27521418	1596	1603	surgery	T061	C0543467
27521418	1604	1610	groups	T078	C0441833

28466814|t|Association of leukemia inhibitory factor gene polymorphism and in vitro fertilization outcome in a population in northern Iran
28466814|a|Several studies have been demonstrated that endometrial leukemia inhibitory factor (LIF) is important in embryo implantation. LIF is a secreted glycoprotein with a variety of biological functions including stimulation of cell proliferation, differentiation and survival that are all essential for blastocyete development and implantation. The LIF receptor activates several signaling pathways in diverse cell types, including Jak/STAT, MAPK and PI3-kinase pathways in the endometrium of fertile woman. It has been suggested that the initial lower expression of LIF in proliferative phase may be one of the causes for multiple failure of implantation. The aim of this study was to evaluate the association between maternal genotype of SNP 3951C/T LIF and in vitro fertilization and embryo transfer (IVF - ET) outcome in infertile women. This case-control study was comprised of infertile patients (n=70) and women having one healthy child as controls (n=73). Genotyping for SNP-3951C/T was performed by PCR/RFLP. Allele and genotype distribution did not differ significantly between patients and controls (P>0.05). The LIF genotype frequencies amongst the 70 cases were C/C =40%, C/T =52.8% and T/T =7.2%; the C and T allele frequencies were 66% and 34%, respectively. The LIF genotype frequencies amongst the 73 controls were C/C =45.20%, C/T =50.70% and T/T =4.1%; the C and T allele frequencies were 70% and 30%, respectively. In conclusion, the results of this study indicate that SNP 3951C/T of LIF may not be associated with IVF - ET outcome in this population. Although more studies should be considered with larger number of patients and control subjects to confirm our results.
28466814	0	11	Association	T080	C0439849
28466814	15	46	leukemia inhibitory factor gene	T028	C1366463
28466814	47	59	polymorphism	T045	C0678951
28466814	64	72	in vitro	T080	C1533691
28466814	73	86	fertilization	T040	C0015914
28466814	87	94	outcome	T169	C1274040
28466814	100	110	population	T098	C1257890
28466814	114	127	northern Iran	T083	C0022065
28466814	136	143	studies	T062	C2603343
28466814	172	183	endometrial	T082	C0227843
28466814	184	210	leukemia inhibitory factor	T116,T129	C0125606
28466814	212	215	LIF	T116,T129	C0125606
28466814	233	252	embryo implantation	T040	C0029976
28466814	254	257	LIF	T116,T129	C0125606
28466814	272	284	glycoprotein	T116,T123	C0017968
28466814	303	323	biological functions	T038	C3714634
28466814	334	345	stimulation	T070	C1948023
28466814	349	367	cell proliferation	T043	C0596290
28466814	369	384	differentiation	T043	C0007589
28466814	389	397	survival	T043	C0007620
28466814	411	420	essential	T080	C0205224
28466814	425	436	blastocyete	T018	C0005705
28466814	437	448	development	T169	C1527148
28466814	453	465	implantation	T040	C0029976
28466814	471	483	LIF receptor	T116,T129,T192	C0125607
28466814	484	493	activates	T052	C1879547
28466814	502	520	signaling pathways	T044	C0037080
28466814	524	542	diverse cell types	T170	C0449475
28466814	554	562	Jak/STAT	T169	C2984327
28466814	564	568	MAPK	T116,T126	C0752312
28466814	573	583	PI3-kinase	T116,T126	C0044602
28466814	584	592	pathways	T044	C0037080
28466814	600	611	endometrium	T023	C0014180
28466814	615	622	fertile	T040	C0015895
28466814	623	628	woman	T098	C0043210
28466814	675	685	expression	T045	C1171362
28466814	689	692	LIF	T116,T129	C0125606
28466814	696	709	proliferative	T046	C0334094
28466814	710	715	phase	T079	C0205390
28466814	754	761	failure	T169	C0231174
28466814	765	777	implantation	T061	C0021107
28466814	795	800	study	T062	C2603343
28466814	821	832	association	T080	C0439849
28466814	841	849	maternal	T033	C1858460
28466814	850	858	genotype	T032	C0017431
28466814	862	873	SNP 3951C/T	T086	C0752046
28466814	874	877	LIF	T116,T129	C0125606
28466814	882	904	in vitro fertilization	T061	C0015915
28466814	909	924	embryo transfer	T061	C0013938
28466814	926	929	IVF	T061	C0015915
28466814	932	934	ET	T061	C0013938
28466814	936	943	outcome	T080	C0085415
28466814	947	956	infertile	T046	C0021359
28466814	957	962	women	T098	C0043210
28466814	969	987	case-control study	T062	C0007328
28466814	1005	1014	infertile	T046	C0021359
28466814	1015	1023	patients	T101	C0030705
28466814	1035	1040	women	T098	C0043210
28466814	1052	1065	healthy child	T033	C0686744
28466814	1069	1077	controls	T096	C0009932
28466814	1086	1096	Genotyping	T059	C1285573
28466814	1101	1112	SNP-3951C/T	T086	C0752046
28466814	1130	1138	PCR/RFLP	T059	C3714764
28466814	1140	1146	Allele	T028	C0002085
28466814	1151	1159	genotype	T032	C0017431
28466814	1160	1172	distribution	T169	C1704711
28466814	1210	1218	patients	T101	C0030705
28466814	1223	1231	controls	T096	C0009932
28466814	1246	1249	LIF	T116,T129	C0125606
28466814	1250	1258	genotype	T032	C0017431
28466814	1259	1270	frequencies	T081	C0017270
28466814	1286	1291	cases	T169	C0868928
28466814	1297	1300	C/C	T086	C0004793
28466814	1307	1310	C/T	T086	C0004793
28466814	1322	1325	T/T	T086	C0004793
28466814	1345	1351	allele	T028	C0002085
28466814	1352	1363	frequencies	T081	C0017270
28466814	1400	1403	LIF	T116,T129	C0125606
28466814	1404	1412	genotype	T032	C0017431
28466814	1413	1424	frequencies	T081	C0017270
28466814	1440	1448	controls	T096	C0009932
28466814	1454	1457	C/C	T086	C0004793
28466814	1467	1470	C/T	T086	C0004793
28466814	1483	1486	T/T	T086	C0004793
28466814	1506	1512	allele	T028	C0002085
28466814	1513	1524	frequencies	T081	C0017270
28466814	1576	1583	results	T169	C1274040
28466814	1612	1623	SNP 3951C/T	T086	C0752046
28466814	1627	1630	LIF	T116,T129	C0125606
28466814	1642	1657	associated with	T080	C0332281
28466814	1658	1661	IVF	T061	C0015915
28466814	1664	1666	ET	T061	C0013938
28466814	1667	1674	outcome	T080	C0085415
28466814	1683	1693	population	T098	C1257890
28466814	1709	1716	studies	T062	C2603343
28466814	1760	1768	patients	T101	C0030705
28466814	1773	1789	control subjects	T096	C0009932
28466814	1793	1800	confirm	T080	C1456348
28466814	1805	1812	results	T169	C1274040

27358905|t|The Demand for Cigarettes in Tanzania and Implications for Tobacco Taxation Policy
27358905|a|The study attempts to estimate the demand for cigarettes in Tanzania and presents simulation results on the effect of the cigarette excise tax on smoking participation, government revenue, and related topics. After briefly summarizing the magnitude and spread of cigarette consumption in the country, the paper reviews some empirical estimates from African and other countries. The 2008 Tanzanian household budget survey was used to estimate the demand for cigarettes in Tanzania. The descriptive statistics suggest that the smoking prevalence for Tanzania is 15.35 percent with low variability across expenditure (income) groups. Smoking intensity and per capita consumption were estimated at 7.08 cigarettes and 1.33 cigarettes, respectively, a relatively low value. A two-part demand equation model was used to estimate various elasticities. For the overall equation, the price elasticities of smoking participation, smoking intensity, and total elasticity were estimated at -0.879, -0.853, and -1.732, respectively. Compared to similar results in other developing countries, the estimates appear quite high. When estimated by expenditure (income) groups, the magnitude of the elasticity appears higher among high expenditure groups than among low expenditure groups. Two simulation exercises were undertaken. First, the effect of different excise rates on smoking participation rate, cigarette consumption, tax revenue, and related responses was estimated and highlighted. Second, the same exercise was undertaken to determine the effect of a given increase in the cigarette excise tax on various expenditure groups. The overall results suggest that an increase in the excise tax on cigarettes in Tanzania would reduce cigarette consumption and increase government tax revenue.
27358905	15	25	Cigarettes	T073	C0677453
27358905	29	37	Tanzania	T083	C0039298
27358905	42	54	Implications	UnknownType	C0814846
27358905	59	66	Tobacco	T109,T131	C0040329
27358905	67	82	Taxation Policy	UnknownType	C0681007
27358905	87	92	study	T062	C2603343
27358905	129	139	cigarettes	T073	C0677453
27358905	143	151	Tanzania	T083	C0039298
27358905	165	175	simulation	T062	C0679083
27358905	176	183	results	T169	C1274040
27358905	191	197	effect	T080	C1280500
27358905	205	214	cigarette	T073	C0677453
27358905	215	225	excise tax	UnknownType	C0681045
27358905	229	236	smoking	T055	C0037369
27358905	237	250	participation	T169	C0679823
27358905	252	270	government revenue	UnknownType	C0681043
27358905	322	331	magnitude	T081	C1704240
27358905	346	367	cigarette consumption	T033	C0459840
27358905	375	382	country	T083	C0454664
27358905	432	439	African	T083	C0454695
27358905	450	459	countries	T083	C0454664
27358905	470	479	Tanzanian	T083	C0039298
27358905	480	496	household budget	T170	C0006347
27358905	497	503	survey	T170	C0038951
27358905	540	550	cigarettes	T073	C0677453
27358905	554	562	Tanzania	T083	C0039298
27358905	608	615	smoking	T055	C0037369
27358905	631	639	Tanzania	T083	C0039298
27358905	685	712	expenditure (income) groups	UnknownType	C0681860
27358905	714	721	Smoking	T055	C0037369
27358905	736	758	per capita consumption	UnknownType	C0681013
27358905	782	792	cigarettes	T073	C0677453
27358905	802	812	cigarettes	T073	C0677453
27358905	854	884	two-part demand equation model	T170	C3161035
27358905	914	926	elasticities	UnknownType	C0680960
27358905	944	952	equation	T077	C0552449
27358905	958	976	price elasticities	UnknownType	C0814751
27358905	980	987	smoking	T055	C0037369
27358905	988	1001	participation	T169	C0679823
27358905	1003	1010	smoking	T055	C0037369
27358905	1032	1042	elasticity	UnknownType	C0680960
27358905	1140	1160	developing countries	T080	C0011750
27358905	1213	1240	expenditure (income) groups	UnknownType	C0681860
27358905	1246	1255	magnitude	T081	C1704240
27358905	1263	1273	elasticity	UnknownType	C0680960
27358905	1295	1318	high expenditure groups	UnknownType	C0681860
27358905	1330	1352	low expenditure groups	UnknownType	C0681860
27358905	1358	1368	simulation	T062	C0679083
27358905	1407	1413	effect	T080	C1280500
27358905	1427	1433	excise	UnknownType	C0681045
27358905	1434	1439	rates	T081	C1521828
27358905	1443	1450	smoking	T055	C0037369
27358905	1451	1469	participation rate	T081	C1521828
27358905	1471	1492	cigarette consumption	T033	C0459840
27358905	1494	1505	tax revenue	UnknownType	C0681043
27358905	1618	1624	effect	T080	C1280500
27358905	1636	1644	increase	T169	C0442805
27358905	1652	1661	cigarette	T073	C0677453
27358905	1662	1672	excise tax	UnknownType	C0681045
27358905	1684	1702	expenditure groups	UnknownType	C0681860
27358905	1716	1723	results	T169	C1274040
27358905	1740	1748	increase	T169	C0442805
27358905	1756	1766	excise tax	UnknownType	C0681045
27358905	1770	1780	cigarettes	T073	C0677453
27358905	1784	1792	Tanzania	T083	C0039298
27358905	1806	1827	cigarette consumption	T033	C0459840
27358905	1832	1840	increase	T169	C0442805
27358905	1841	1863	government tax revenue	UnknownType	C0681043

28341156|t|Long-range interactions between protein - coated particles and POEGMA brush layers in a serum environment
28341156|a|Hydrophilic poly[oligo(ethylene glycol) methyl methacrylate] (POEGMA) brush layers with different thickness and graft densities were prepared by surface-initiated atom transfer radical polymerization (SI-ATRP) to construct a model surface to examine protein - surface interactions in a serum environment. The thickness of the POEGMA brush layers could be well controlled by the polymerization time and density of the immobilized initiators. The interactions between these brush - modified surfaces and the protein - coated polystyrene (PS) particles in newborn calf serum (NBCS) environment were then measured by total internal reflection microscopy (TIRM). In addition, protein adsorption properties onto the polymer brush surface layers were examined by atomic force microscopy (AFM). Relatively large amounts of protein adsorbed to short (4nm and 9nm-thick) POEGMA - coated surfaces or surfaces grafted with a low density of polymer chains. It was considered that shorter polymer chains or chains with low grafted density cannot fully cover the surfaces, proteins in serum could directly interact with the material surface and then deposited to form an adsorbed layer. The TIRM measurements showed that such adsorbed protein layer could mediate the interactions between the two surfaces by generating steric or bridging forces, resulting in different interaction potentials. Some particles were freely diffusing, some experienced intermittent diffusion and more than 50% of particles were irreversibly deposited to the surfaces covered by short polymer brushes. However, for longer (17 and 30nm-thick) POEGMA brush layer surfaces, material surface would be sufficiently covered by the dense coating and the first step of protein adsorption on surface was avoided. TIRM measurements showed that around 95% of the protein - coated particles could freely move in the serum and no attractive force between two surfaces was detected. The steric repulsion generated from the long POEGMA brush layer in the swollen state was long-range and strong so that the protein adsorption is very unlikely. These results concluded that the adsorbed protein layer on POEGMA surfaces plays an important role in regulating the interaction between protein - coated particles and POEGMA surfaces which are highly repellent toward protein adsorption.
28341156	0	23	Long-range interactions	T169	C1704675
28341156	32	39	protein	T116,T123	C0033684
28341156	42	48	coated	T080	C1522408
28341156	49	58	particles	T104	C0597177
28341156	63	75	POEGMA brush	T104,T122	C0032521
28341156	76	82	layers	T080	C1522408
28341156	88	105	serum environment	T031	C0229671
28341156	106	181	Hydrophilic poly[oligo(ethylene glycol) methyl methacrylate] (POEGMA) brush	T104,T122	C0032521
28341156	182	188	layers	T080	C1522408
28341156	204	213	thickness	T080	C1280412
28341156	218	223	graft	T169	C0205245
28341156	224	233	densities	T081	C0178587
28341156	239	247	prepared	T033	C4082130
28341156	251	305	surface-initiated atom transfer radical polymerization	T067	C0314672
28341156	307	314	SI-ATRP	T067	C0314672
28341156	331	336	model	T170	C3161035
28341156	337	344	surface	T082	C0205148
28341156	356	363	protein	T116,T123	C0033684
28341156	366	373	surface	T082	C0205148
28341156	374	386	interactions	T169	C1704675
28341156	392	409	serum environment	T031	C0229671
28341156	415	424	thickness	T080	C1280412
28341156	432	444	POEGMA brush	T104,T122	C0032521
28341156	445	451	layers	T080	C1522408
28341156	484	498	polymerization	T067	C0314672
28341156	499	503	time	T079	C0040223
28341156	508	515	density	T081	C0178587
28341156	523	545	immobilized initiators	T067	C0175921
28341156	551	563	interactions	T169	C1704675
28341156	578	583	brush	T104,T122	C0032521
28341156	586	594	modified	T169	C0392747
28341156	595	603	surfaces	T082	C0205148
28341156	612	619	protein	T116,T123	C0033684
28341156	622	628	coated	T080	C1522408
28341156	629	640	polystyrene	T109,T122	C0032604
28341156	642	644	PS	T109,T122	C0032604
28341156	646	655	particles	T104	C0597177
28341156	659	666	newborn	T008	C0003065
28341156	667	671	calf	T015	C3668829
28341156	672	696	serum (NBCS) environment	T031	C0229671
28341156	707	715	measured	T080	C0444706
28341156	719	755	total internal reflection microscopy	T059	C0026018
28341156	757	761	TIRM	T059	C0026018
28341156	777	784	protein	T116,T123	C0033684
28341156	785	806	adsorption properties	T080	C0871161
28341156	816	829	polymer brush	T104,T122	C0032521
28341156	830	844	surface layers	T080	C1522408
28341156	862	885	atomic force microscopy	T059	C0242849
28341156	887	890	AFM	T059	C0242849
28341156	921	928	protein	T116,T123	C0033684
28341156	967	973	POEGMA	T104,T122	C0032521
28341156	976	982	coated	T080	C1522408
28341156	983	991	surfaces	T082	C0205148
28341156	995	1003	surfaces	T082	C0205148
28341156	1004	1011	grafted	T169	C0205245
28341156	1019	1022	low	T080	C0205251
28341156	1023	1030	density	T081	C0178587
28341156	1034	1048	polymer chains	T104,T122	C0032521
28341156	1073	1095	shorter polymer chains	T104,T122	C0032521
28341156	1099	1105	chains	T104,T122	C0032521
28341156	1111	1114	low	T080	C0205251
28341156	1115	1122	grafted	T169	C0205245
28341156	1123	1130	density	T081	C0178587
28341156	1154	1162	surfaces	T082	C0205148
28341156	1164	1172	proteins	T116,T123	C0033684
28341156	1176	1181	serum	T031	C0229671
28341156	1197	1205	interact	T169	C1704675
28341156	1215	1223	material	T104,T122	C0032521
28341156	1224	1231	surface	T082	C0205148
28341156	1262	1276	adsorbed layer	T080	C1522408
28341156	1282	1286	TIRM	T059	C0026018
28341156	1287	1299	measurements	T169	C0242485
28341156	1317	1333	adsorbed protein	T116,T123	C0033684
28341156	1334	1339	layer	T080	C1522408
28341156	1358	1370	interactions	T169	C1704675
28341156	1387	1395	surfaces	T082	C0205148
28341156	1410	1416	steric	T067	C0441722
28341156	1420	1435	bridging forces	T067	C0441722
28341156	1460	1471	interaction	T169	C1704675
28341156	1472	1482	potentials	T080	C3245505
28341156	1489	1498	particles	T104	C0597177
28341156	1511	1520	diffusing	T070	C0012222
28341156	1539	1551	intermittent	T079	C0205267
28341156	1552	1561	diffusion	T070	C0012222
28341156	1583	1592	particles	T104	C0597177
28341156	1628	1636	surfaces	T082	C0205148
28341156	1654	1669	polymer brushes	T104,T122	C0032521
28341156	1711	1723	POEGMA brush	T104,T122	C0032521
28341156	1724	1729	layer	T080	C1522408
28341156	1730	1738	surfaces	T082	C0205148
28341156	1749	1756	surface	T082	C0205148
28341156	1794	1807	dense coating	T080	C1522408
28341156	1830	1837	protein	T116,T123	C0033684
28341156	1838	1848	adsorption	T059	C0001674
28341156	1852	1859	surface	T082	C0205148
28341156	1873	1877	TIRM	T059	C0026018
28341156	1878	1890	measurements	T169	C0242485
28341156	1921	1928	protein	T116,T123	C0033684
28341156	1931	1937	coated	T080	C1522408
28341156	1938	1947	particles	T104	C0597177
28341156	1973	1978	serum	T031	C0229671
28341156	1983	1985	no	T033	C0205160
28341156	1986	2002	attractive force	T067	C0441722
28341156	2015	2023	surfaces	T082	C0205148
28341156	2028	2036	detected	T033	C0442726
28341156	2042	2058	steric repulsion	T067	C0441722
28341156	2083	2095	POEGMA brush	T104,T122	C0032521
28341156	2096	2101	layer	T080	C1522408
28341156	2109	2122	swollen state	T033	C0038999
28341156	2142	2148	strong	T080	C0442821
28341156	2161	2168	protein	T116,T123	C0033684
28341156	2169	2179	adsorption	T059	C0001674
28341156	2231	2247	adsorbed protein	T116,T123	C0033684
28341156	2248	2253	layer	T080	C1522408
28341156	2257	2263	POEGMA	T104,T122	C0032521
28341156	2264	2272	surfaces	T082	C0205148
28341156	2292	2296	role	T077	C1705810
28341156	2315	2326	interaction	T169	C1704675
28341156	2335	2342	protein	T116,T123	C0033684
28341156	2345	2351	coated	T080	C1522408
28341156	2352	2361	particles	T104	C0597177
28341156	2366	2372	POEGMA	T104,T122	C0032521
28341156	2373	2381	surfaces	T082	C0205148
28341156	2416	2423	protein	T116,T123	C0033684
28341156	2424	2434	adsorption	T059	C0001674

28215507|t|Significance of uterine corpus tumor invasion in early-stage cervical cancer
28215507|a|To examine characteristics and survival outcomes of women with surgically-treated cervical cancer exhibiting uterine corpus tumor invasion. We utilized The Surveillance, Epidemiology, and End Results Program to identify cervical cancer patients who underwent hysterectomy between 1973 and 2003. Logistic regression models were used to identify risk factors for uterine corpus tumor invasion on multivariable analysis. Association of uterine corpus tumor invasion and cause-specific survival (CSS) from cervical cancer was examined with Cox proportional hazard regression models on multivariable analysis. We identified 837 (4.9%) cases of uterine corpus invasion and 16,237 (95.1%) cases of non-invasion. Median follow-up time was 14.0 years. There were 1642 deaths due to cervical cancer. Uterine corpus invasion was independently associated with older age, non-squamous histology, high-grade tumors, large tumor size, and nodal metastasis on multivariable analysis (all, P < 0.001). On univariable analysis, uterine corpus tumor invasion was significantly associated with decreased CSS compared to the non-invasion (5-year rates, 79.0% versus 94.5%, P < 0.001). After controlling for other significant prognostic factors, uterine corpus tumor invasion remained an independent prognostic factor for decreased CSS (adjusted-hazard ratio 1.45, 95% confidence interval 1.21-1.74). Among stage T1b cases (n = 6730), uterine corpus tumor invasion remained an independent prognostic factor for decreased CSS (adjusted-hazard ratio 1.95, 95%CI 1.47-2.60). Uterine corpus tumor invasion was significantly associated with decreased CSS in stage T1b1 disease (74.5% versus 90.7%, P < 0.001) and in stage T1b2 disease (67.0% versus 79.5%, P = 0.01). Uterine corpus tumor invasion is an independent prognostic factor for decreased survival of women with early-stage cervical cancer.
28215507	0	12	Significance	T078	C0750502
28215507	16	36	uterine corpus tumor	T191	C0153574
28215507	37	45	invasion	T033	C1269955
28215507	49	60	early-stage	T185	C1517886
28215507	61	76	cervical cancer	T191	C0007847
28215507	88	103	characteristics	T080	C1521970
28215507	108	116	survival	T052	C0038952
28215507	117	125	outcomes	T169	C1274040
28215507	129	134	women	T098	C0043210
28215507	140	158	surgically-treated	T061	C0543467
28215507	159	174	cervical cancer	T191	C0007847
28215507	186	206	uterine corpus tumor	T191	C0153574
28215507	207	215	invasion	T033	C1269955
28215507	233	284	Surveillance, Epidemiology, and End Results Program	T093	C0242638
28215507	297	312	cervical cancer	T191	C0007847
28215507	313	321	patients	T101	C0030705
28215507	336	348	hysterectomy	T061	C0020699
28215507	372	398	Logistic regression models	UnknownType	C0681925
28215507	421	433	risk factors	T033	C0035648
28215507	438	458	uterine corpus tumor	T191	C0153574
28215507	459	467	invasion	T033	C1269955
28215507	471	493	multivariable analysis	T081	C0026777
28215507	495	506	Association	T080	C0439849
28215507	510	530	uterine corpus tumor	T191	C0153574
28215507	531	539	invasion	T033	C1269955
28215507	544	567	cause-specific survival	T081	C1707318
28215507	569	572	CSS	T081	C1707318
28215507	579	594	cervical cancer	T191	C0007847
28215507	613	654	Cox proportional hazard regression models	T170	C0034980
28215507	658	680	multivariable analysis	T081	C0026777
28215507	716	730	uterine corpus	T191	C0153574
28215507	731	739	invasion	T033	C1269955
28215507	768	780	non-invasion	T169	C0205303
28215507	782	788	Median	T081	C0876920
28215507	789	798	follow-up	T058	C1522577
28215507	799	803	time	T079	C0040223
28215507	836	842	deaths	T040	C0011065
28215507	850	865	cervical cancer	T191	C0007847
28215507	867	881	Uterine corpus	T191	C0153574
28215507	882	890	invasion	T033	C1269955
28215507	895	908	independently	T078	C0085862
28215507	909	924	associated with	T080	C0332281
28215507	925	934	older age	T032	C0001779
28215507	936	958	non-squamous histology	T169	C4048239
28215507	960	977	high-grade tumors	T191	C1334017
28215507	979	995	large tumor size	T082	C0475440
28215507	1001	1006	nodal	T082	C0443268
28215507	1007	1017	metastasis	T191	C0027627
28215507	1021	1043	multivariable analysis	T081	C0026777
28215507	1065	1085	univariable analysis	T062	C0683962
28215507	1087	1107	uterine corpus tumor	T191	C0153574
28215507	1108	1116	invasion	T033	C1269955
28215507	1135	1150	associated with	T080	C0332281
28215507	1151	1160	decreased	T081	C0205216
28215507	1161	1164	CSS	T081	C1707318
28215507	1181	1193	non-invasion	T169	C0205303
28215507	1247	1258	controlling	T067	C2239193
28215507	1269	1280	significant	T078	C0750502
28215507	1281	1299	prognostic factors	T201	C1514474
28215507	1301	1321	uterine corpus tumor	T191	C0153574
28215507	1322	1330	invasion	T033	C1269955
28215507	1343	1354	independent	T078	C0085862
28215507	1355	1372	prognostic factor	T201	C1514474
28215507	1377	1386	decreased	T081	C0205216
28215507	1387	1390	CSS	T081	C1707318
28215507	1392	1413	adjusted-hazard ratio	T081	C2985465
28215507	1424	1443	confidence interval	T081	C0009667
28215507	1462	1471	stage T1b	T185	C0475385
28215507	1490	1510	uterine corpus tumor	T191	C0153574
28215507	1511	1519	invasion	T033	C1269955
28215507	1532	1543	independent	T078	C0085862
28215507	1544	1561	prognostic factor	T201	C1514474
28215507	1566	1575	decreased	T081	C0205216
28215507	1576	1579	CSS	T081	C1707318
28215507	1581	1602	adjusted-hazard ratio	T081	C2985465
28215507	1627	1647	Uterine corpus tumor	T191	C0153574
28215507	1648	1656	invasion	T033	C1269955
28215507	1675	1690	associated with	T080	C0332281
28215507	1691	1700	decreased	T081	C0205216
28215507	1701	1704	CSS	T081	C1707318
28215507	1708	1718	stage T1b1	T170	C0730458
28215507	1719	1726	disease	T191	C0153574
28215507	1766	1776	stage T1b2	T170	C0730459
28215507	1777	1784	disease	T191	C0153574
28215507	1817	1837	Uterine corpus tumor	T191	C0153574
28215507	1838	1846	invasion	T033	C1269955
28215507	1853	1864	independent	T078	C0085862
28215507	1865	1882	prognostic factor	T201	C1514474
28215507	1887	1896	decreased	T081	C0205216
28215507	1897	1905	survival	T052	C0038952
28215507	1909	1914	women	T098	C0043210
28215507	1920	1931	early-stage	T185	C1517886
28215507	1932	1947	cervical cancer	T191	C0007847

28472521|t|The Value of Biosamples in Smoking Cessation Trials: A Review of Genetic, Metabolomic, and Epigenetic Findings
28472521|a|Evidence is emerging that certain genotypes and biomarkers are associated with smoking cessation success and efficacy of smoking cessation treatments. We review key findings that open potential avenues for personalizing smoking cessation treatment according to an individual's genetic or metabolic profile. These results provide important incentive for smoking cessation researchers to collect biosamples and perform genotyping in research studies and clinical trials.
28472521	13	23	Biosamples	T077	C1706958
28472521	27	44	Smoking Cessation	T055	C0085134
28472521	45	51	Trials	T062	C0008976
28472521	65	72	Genetic	T034	C0730319
28472521	74	85	Metabolomic	T091	C1328813
28472521	91	101	Epigenetic	T045	C1516924
28472521	102	110	Findings	T033	C0243095
28472521	145	154	genotypes	T032	C0017431
28472521	159	169	biomarkers	T201	C0005516
28472521	190	207	smoking cessation	T055	C0085134
28472521	232	260	smoking cessation treatments	T061	C1095963
28472521	331	358	smoking cessation treatment	T061	C1095963
28472521	375	387	individual's	T098	C0237401
28472521	388	395	genetic	T059	C2986505
28472521	399	416	metabolic profile	T039	C3853758
28472521	450	459	incentive	T080	C0021147
28472521	464	481	smoking cessation	T055	C0085134
28472521	482	493	researchers	T097	C0687734
28472521	505	515	biosamples	T077	C1706958
28472521	528	538	genotyping	T059	C1285573
28472521	542	558	research studies	T062	C0681814
28472521	563	578	clinical trials	T062	C0008976

27606118|t|Variation in the Obturator Vasculature During Routine Anatomy Dissection of a Cadaver
27606118|a|The obturator artery normally originates from the internal iliac artery while the obturator vein drains into the internal iliac vein. During a routine gross anatomy dissection class for undergraduate students at the All India Institute of Medical Sciences, New Delhi, India, in 2016, a rare unilateral variation in the obturator vasculature was found in a female cadaver of approximately 55 years of age. In this case, the left obturator artery originated from the superior gluteal artery and the left obturator vein drained into the external iliac vein. Knowledge of such variations is necessary during hernia procedures, ligation of the internal iliac artery and muscle graft surgeries.
27606118	0	9	Variation	T070	C3494476
27606118	17	26	Obturator	T030	C0223670
27606118	27	38	Vasculature	T017	C3714653
27606118	46	53	Routine	T080	C0205547
27606118	54	61	Anatomy	T017	C0700276
27606118	62	72	Dissection	T059	C4263282
27606118	78	85	Cadaver	T017	C0006629
27606118	90	106	obturator artery	T023	C0226369
27606118	136	157	internal iliac artery	T023	C0226364
27606118	168	182	obturator vein	T023	C0226776
27606118	199	218	internal iliac vein	T023	C0226764
27606118	229	236	routine	T080	C0205547
27606118	237	242	gross	T080	C0439806
27606118	243	250	anatomy	T017	C0700276
27606118	251	261	dissection	T059	C4263282
27606118	262	267	class	T073	C0870287
27606118	272	294	undergraduate students	T098	C0814964
27606118	302	341	All India Institute of Medical Sciences	T093	C1274109
27606118	343	352	New Delhi	T083	C0017446
27606118	354	359	India	T083	C0021201
27606118	377	387	unilateral	T082	C0205092
27606118	388	397	variation	T070	C3494476
27606118	405	414	obturator	T030	C0223670
27606118	415	426	vasculature	T017	C3714653
27606118	442	448	female	T098	C0043210
27606118	449	456	cadaver	T017	C0006629
27606118	477	482	years	T079	C0439234
27606118	486	489	age	T032	C0001779
27606118	509	530	left obturator artery	T023	C0737410
27606118	551	574	superior gluteal artery	T023	C0226371
27606118	583	602	left obturator vein	T023	C0737446
27606118	620	639	external iliac vein	T023	C0226761
27606118	659	669	variations	T070	C3494476
27606118	690	707	hernia procedures	T061	C0019328
27606118	709	717	ligation	T061	C0023690
27606118	725	746	internal iliac artery	T023	C0226364
27606118	751	763	muscle graft	T061	C0185471
27606118	764	773	surgeries	T061	C0543467

28254329|t|How do wettability, zeta potential and hydroxylation degree affect the biological response of biomaterials?
28254329|a|It is well known that composition, electric charge, wettability and roughness of implant surfaces have great influence on their interaction with the biological fluids and tissues, but systematic studies of different materials in the same experimental conditions are still lacking in the scientific literature. The aim of this research is to investigate the correlations between some surface characteristics (wettability, zeta potential and hydroxylation degree) and the biological response (protein adsorption, blood wettability, cell and bacterial adhesion) to some model biomaterials. The resulting knowledge can be applied for the development of future innovative surfaces for implantable biomaterials. Roughness was not considered as a variable because it is a widely explored feature: smooth surfaces prepared by a controlled protocol were compared in order to have no roughness effects. Three oxides (ZrO2, Al2O3, SiO2), three metals (316LSS steel, Ti, Nb) and two polymers (corona treated polystyrene for cell culture and untreated polystyrene for bacteria culture), widely used for biomedical applications, were considered. The surfaces were characterized by contact profilometry, SEM - EDS, XPS, FTIR, zeta potential and wettability with different fluids. Protein adsorption, blood wettability, bacterial and cell adhesion were evaluated in order to investigate the correlations between the surface physiochemical properties and biological responses. From a methodological standpoint, XPS and electrokinetic measurements emerged as the more suitable techniques respectively for the evaluation of hydroxylation degree and surface charge / isoelectric point. Moreover, determination of wettability by blood appeared a specific and crucial test, the results of which are not easily predictable by using other type of tests. Hydroxylation degree resulted correlated to the wettability by water, but not directly to surface charge. Wetting tests with different media showed the possibility to highlight some differences among look-alike materials. A dependence of protein absorption on hydroxylation degree, charge and wettability was evidenced and its maximum was registered for surfaces with low wettability in both water based and protein containing media and a moderate surface charge. As far as bacterial adhesion is concerned, no effect of surface charge or protein adsorption was evidenced, while the presence of a high acid component of the surface energy appeared significant. Finally, the combination of hydroxylation degree, wettability, surface charge and energy (polar component) emerged as a key parameter for cell adhesion and viability.
28254329	7	18	wettability	T080	C0162598
28254329	20	34	zeta potential	T067	C0597697
28254329	39	52	hydroxylation	T070	C0020365
28254329	39	59	hydroxylation degree	T033	C0243095
28254329	71	90	biological response	T033	C0243095
28254329	94	106	biomaterials	T122	C0005479
28254329	130	141	composition	T080	C0205556
28254329	143	158	electric charge	T070	C0563548
28254329	160	171	wettability	T080	C0162598
28254329	176	185	roughness	T080	C0205556
28254329	189	196	implant	T074	C0021102
28254329	197	205	surfaces	T082	C0205148
28254329	217	226	influence	T077	C4054723
28254329	236	247	interaction	T169	C1704675
28254329	257	274	biological fluids	T031	C0005889
28254329	279	286	tissues	T024	C0040300
28254329	292	310	systematic studies	T062	C0242481
28254329	324	333	materials	T167	C0520510
28254329	346	369	experimental conditions	T080	C0348080
28254329	380	387	lacking	T080	C0332268
28254329	395	416	scientific literature	T170	C0023866
28254329	434	442	research	T062	C0035168
28254329	449	460	investigate	T169	C1292732
28254329	465	477	correlations	T080	C1707520
28254329	491	514	surface characteristics	T080	C0449588
28254329	516	527	wettability	T080	C0162598
28254329	529	543	zeta potential	T067	C0597697
28254329	548	561	hydroxylation	T070	C0020365
28254329	548	568	hydroxylation degree	T033	C0243095
28254329	578	597	biological response	T033	C0243095
28254329	599	606	protein	T116,T123	C0033684
28254329	599	617	protein adsorption	T033	C0243095
28254329	619	624	blood	T031	C0005767
28254329	625	636	wettability	T080	C0162598
28254329	638	642	cell	T043	C0007577
28254329	647	665	bacterial adhesion	T040	C0004614
28254329	681	693	biomaterials	T122	C0005479
28254329	775	783	surfaces	T082	C0205148
28254329	788	812	implantable biomaterials	T122	C0005479
28254329	814	823	Roughness	T080	C0205556
28254329	898	913	smooth surfaces	T082	C0205148
28254329	928	947	controlled protocol	T170	C2348563
28254329	982	999	roughness effects	T080	C0205556
28254329	1007	1013	oxides	T197	C0030015
28254329	1015	1019	ZrO2	T197	C0021521
28254329	1021	1026	Al2O3	T122,T130,T197	C0002374
28254329	1028	1032	SiO2	T122,T197	C0037098
28254329	1041	1047	metals	T197	C0025552
28254329	1049	1061	316LSS steel	T122,T197	C0038239
28254329	1063	1065	Ti	T196	C0040302
28254329	1067	1069	Nb	T196	C0028101
28254329	1079	1087	polymers	T104,T122	C0032521
28254329	1089	1115	corona treated polystyrene	T109,T122	C0032604
28254329	1120	1132	cell culture	T059	C1331092
28254329	1137	1158	untreated polystyrene	T109,T122	C0032604
28254329	1163	1179	bacteria culture	T059	C0430402
28254329	1198	1221	biomedical applications	T073	C3273359
28254329	1244	1252	surfaces	T082	C0205148
28254329	1258	1271	characterized	T052	C1880022
28254329	1275	1295	contact profilometry	T062	C0242481
28254329	1297	1300	SEM	T059	C0026020
28254329	1303	1306	EDS	T059	C2699997
28254329	1308	1311	XPS	T059	C2700282
28254329	1313	1317	FTIR	T062	C0206055
28254329	1319	1333	zeta potential	T067	C0597697
28254329	1338	1349	wettability	T080	C0162598
28254329	1365	1371	fluids	T167	C0302908
28254329	1373	1380	Protein	T116,T123	C0033684
28254329	1373	1391	Protein adsorption	T033	C0243095
28254329	1393	1398	blood	T031	C0005767
28254329	1399	1410	wettability	T080	C0162598
28254329	1412	1421	bacterial	T040	C0004614
28254329	1426	1439	cell adhesion	T043	C0007577
28254329	1467	1478	investigate	T169	C1292732
28254329	1483	1495	correlations	T080	C1707520
28254329	1508	1541	surface physiochemical properties	T070	C0038884
28254329	1546	1566	biological responses	T033	C0243095
28254329	1602	1605	XPS	T059	C2700282
28254329	1610	1637	electrokinetic measurements	T081	C0392762
28254329	1667	1677	techniques	T169	C0449851
28254329	1713	1726	hydroxylation	T070	C0020365
28254329	1713	1733	hydroxylation degree	T033	C0243095
28254329	1738	1752	surface charge	T081	C0392762
28254329	1755	1772	isoelectric point	T081	C0022171
28254329	1801	1812	wettability	T080	C0162598
28254329	1816	1821	blood	T031	C0005767
28254329	1854	1858	test	T170	C0392366
28254329	1931	1936	tests	T170	C0392366
28254329	1938	1951	Hydroxylation	T070	C0020365
28254329	1938	1958	Hydroxylation degree	T033	C0243095
28254329	1986	1997	wettability	T080	C0162598
28254329	2001	2006	water	T121,T197	C0043047
28254329	2028	2042	surface charge	T081	C0392762
28254329	2044	2057	Wetting tests	T062	C0242481
28254329	2073	2078	media	T167	C1705217
28254329	2149	2158	materials	T167	C0520510
28254329	2176	2183	protein	T116,T123	C0033684
28254329	2176	2194	protein absorption	T033	C0243095
28254329	2198	2211	hydroxylation	T070	C0020365
28254329	2198	2218	hydroxylation degree	T033	C0243095
28254329	2220	2226	charge	T081	C0392762
28254329	2231	2242	wettability	T080	C0162598
28254329	2265	2272	maximum	T081	C0806909
28254329	2292	2300	surfaces	T082	C0205148
28254329	2310	2321	wettability	T080	C0162598
28254329	2330	2335	water	T121,T197	C0043047
28254329	2346	2353	protein	T116,T123	C0033684
28254329	2365	2370	media	T167	C1705217
28254329	2386	2400	surface charge	T081	C0392762
28254329	2412	2430	bacterial adhesion	T040	C0004614
28254329	2445	2454	no effect	T080	C1301751
28254329	2458	2472	surface charge	T081	C0392762
28254329	2476	2483	protein	T116,T123	C0033684
28254329	2476	2494	protein adsorption	T033	C0243095
28254329	2539	2553	acid component	T080	C0205556
28254329	2561	2575	surface energy	T081	C1442080
28254329	2626	2639	hydroxylation	T070	C0020365
28254329	2626	2646	hydroxylation degree	T033	C0243095
28254329	2648	2659	wettability	T080	C0162598
28254329	2661	2675	surface charge	T081	C0392762
28254329	2680	2686	energy	T081	C1442080
28254329	2688	2703	polar component	T080	C0205556
28254329	2736	2749	cell adhesion	T043	C0007577
28254329	2754	2763	viability	T043	C0007620

27729252|t|Lower perinatal mortality in preterm born twins than in singletons: a nationwide study from The Netherlands
27729252|a|Twin pregnancies are at increased risk for perinatal morbidity and death because of many factors that include a high incidence of preterm delivery. Compared with singleton pregnancies, overall perinatal risk of death is higher in twin pregnancies; however, for the preterm period, the perinatal mortality rate has been reported to be lower in twins. The purpose of this study was to compare perinatal mortality rates in relation to gestational age at birth between singleton and twin pregnancies, taking into account socioeconomic status, fetal sex, and parity. We studied perinatal mortality rates according to gestational age at birth in 1,502,120 singletons pregnancies and 51,658 twin pregnancies without congenital malformations who were delivered between 2002 and 2010 after 28 weeks of gestation. Data were collected from the nationwide Netherlands Perinatal Registry. Overall the perinatal mortality rate in twin pregnancies (6.6/1000 infants) was higher than in singleton pregnancies (4.1/1000 infants). However, in the preterm period, the perinatal mortality rate in twin pregnancies was substantially lower than in singleton pregnancies (10.4 per 1000 infants as compared with 34.5 per 1000 infants, respectively) for infants who were born at <37 weeks of gestation; this held especially for antepartum deaths. After 39 weeks of gestation, the perinatal mortality rate was high er in twin pregnancies. Differences in parity, fetal sex, and socioeconomic status did not explain the observed differences in outcome. Overall the perinatal mortality rate was higher in twin pregnancies than in singleton pregnancies, which is most likely caused by the high preterm birth rate in twins and not by a higher mortality rate for gestation, apart from term pregnancies. During the preterm period, the antepartum mortality rate was much lower in twin pregnancies than in singleton pregnancies. We suggest that this might be partially due to a closer monitoring of twin pregnancies, which indirectly suggests a need for closer surveillance of singleton pregnancies.
27729252	0	5	Lower	T080	C0205251
27729252	6	25	perinatal mortality	T033	C0701826
27729252	29	47	preterm born twins	T101	C0233318
27729252	56	66	singletons	T033	C4284193
27729252	70	80	nationwide	T092	C1555720
27729252	81	86	study	T062	C2603343
27729252	96	107	Netherlands	T083	C0027778
27729252	108	124	Twin pregnancies	T033	C0152150
27729252	132	146	increased risk	T033	C0332167
27729252	151	170	perinatal morbidity	T046	C0848215
27729252	175	180	death	T040	C0011065
27729252	197	204	factors	T169	C1521761
27729252	210	217	include	T052	C2700399
27729252	220	224	high	T080	C0205250
27729252	225	234	incidence	T081	C0021149
27729252	238	254	preterm delivery	T033	C0151526
27729252	256	264	Compared	T052	C1707455
27729252	270	291	singleton pregnancies	T040	C0341899
27729252	293	300	overall	T080	C1561607
27729252	301	315	perinatal risk	T033	C1171167
27729252	319	324	death	T040	C0011065
27729252	328	334	higher	T080	C0205250
27729252	338	354	twin pregnancies	T033	C0152150
27729252	373	387	preterm period	T079	C2964377
27729252	393	412	perinatal mortality	T033	C0701826
27729252	413	417	rate	T081	C1521828
27729252	427	435	reported	T058	C0700287
27729252	442	447	lower	T080	C0205251
27729252	451	456	twins	T033	C0233365
27729252	462	469	purpose	T169	C1285529
27729252	478	483	study	T062	C2603343
27729252	491	498	compare	T052	C1707455
27729252	499	518	perinatal mortality	T033	C0701826
27729252	519	524	rates	T081	C1521828
27729252	528	539	relation to	T080	C0205345
27729252	540	555	gestational age	T032	C0017504
27729252	559	564	birth	T040	C0005615
27729252	573	582	singleton	T040	C0341899
27729252	587	603	twin pregnancies	T033	C0152150
27729252	617	624	account	T033	C0518609
27729252	625	645	socioeconomic status	T080	C0086996
27729252	647	656	fetal sex	T032	C4086850
27729252	662	668	parity	T033	C0030563
27729252	673	680	studied	T062	C2603343
27729252	681	700	perinatal mortality	T033	C0701826
27729252	701	706	rates	T081	C1521828
27729252	707	716	according	T054	C0680240
27729252	720	735	gestational age	T032	C0017504
27729252	739	744	birth	T040	C0005615
27729252	758	780	singletons pregnancies	T040	C0341899
27729252	792	808	twin pregnancies	T033	C0152150
27729252	817	841	congenital malformations	T019	C0000768
27729252	851	860	delivered	T040	C0005615
27729252	901	910	gestation	T040	C0032961
27729252	912	931	Data were collected	T062	C0010995
27729252	941	951	nationwide	T092	C1555720
27729252	952	963	Netherlands	T083	C0027778
27729252	964	973	Perinatal	T079	C0178795
27729252	974	982	Registry	T058	C1514821
27729252	984	991	Overall	T080	C1561607
27729252	996	1015	perinatal mortality	T033	C0701826
27729252	1016	1020	rate	T081	C1521828
27729252	1024	1040	twin pregnancies	T033	C0152150
27729252	1051	1058	infants	T100	C0021270
27729252	1064	1070	higher	T080	C0205250
27729252	1079	1100	singleton pregnancies	T040	C0341899
27729252	1111	1118	infants	T100	C0021270
27729252	1137	1151	preterm period	T079	C2964377
27729252	1157	1176	perinatal mortality	T033	C0701826
27729252	1177	1181	rate	T081	C1521828
27729252	1185	1201	twin pregnancies	T033	C0152150
27729252	1220	1225	lower	T080	C0205251
27729252	1234	1255	singleton pregnancies	T040	C0341899
27729252	1271	1278	infants	T100	C0021270
27729252	1282	1290	compared	T052	C1707455
27729252	1310	1317	infants	T100	C0021270
27729252	1337	1344	infants	T100	C0021270
27729252	1354	1358	born	T040	C0005615
27729252	1375	1384	gestation	T040	C0032961
27729252	1411	1421	antepartum	T079	C0456336
27729252	1422	1428	deaths	T040	C0011065
27729252	1448	1457	gestation	T040	C0032961
27729252	1463	1482	perinatal mortality	T033	C0701826
27729252	1483	1487	rate	T081	C1521828
27729252	1492	1496	high	T080	C0205250
27729252	1503	1519	twin pregnancies	T033	C0152150
27729252	1521	1532	Differences	T081	C1705241
27729252	1536	1542	parity	T033	C0030563
27729252	1544	1553	fetal sex	T032	C4086850
27729252	1559	1579	socioeconomic status	T080	C0086996
27729252	1600	1608	observed	T169	C1441672
27729252	1609	1620	differences	T081	C1705241
27729252	1624	1631	outcome	T033	C0032972
27729252	1633	1640	Overall	T080	C1561607
27729252	1645	1664	perinatal mortality	T033	C0701826
27729252	1665	1669	rate	T081	C1521828
27729252	1674	1680	higher	T080	C0205250
27729252	1684	1700	twin pregnancies	T033	C0152150
27729252	1709	1730	singleton pregnancies	T040	C0341899
27729252	1741	1752	most likely	T078	C0750501
27729252	1767	1771	high	T080	C0205250
27729252	1772	1779	preterm	T079	C2964377
27729252	1780	1790	birth rate	T081	C0005608
27729252	1794	1799	twins	T033	C0233365
27729252	1813	1819	higher	T080	C0205250
27729252	1820	1834	mortality rate	T081	C0205848
27729252	1839	1848	gestation	T040	C0032961
27729252	1861	1877	term pregnancies	T040	C0232991
27729252	1890	1904	preterm period	T079	C2964377
27729252	1910	1920	antepartum	T079	C0456336
27729252	1921	1935	mortality rate	T081	C0205848
27729252	1945	1950	lower	T080	C0205251
27729252	1954	1970	twin pregnancies	T033	C0152150
27729252	1979	2000	singleton pregnancies	T040	C0341899
27729252	2032	2041	partially	T081	C0728938
27729252	2051	2057	closer	T033	C3810854
27729252	2058	2068	monitoring	T058	C1283169
27729252	2072	2088	twin pregnancies	T033	C0152150
27729252	2096	2106	indirectly	T080	C0439852
27729252	2118	2122	need	T080	C0027552
27729252	2127	2133	closer	T033	C3810854
27729252	2134	2146	surveillance	T061	C0038842
27729252	2150	2171	singleton pregnancies	T040	C0341899

28454015|t|Air pollution characteristics and health risks in Henan Province, China
28454015|a|Events of severe air pollution occurred frequently in China recently, thus understanding of the air pollution characteristics and its health risks is very important. In this work, we analyzed a two-year dataset (March 2014 - February 2016) including daily concentrations of six criteria pollutants (PM2.5, PM10, CO, SO2, NO2, and O3) from 18 cities in Henan province. Results reveal the serious air pollution status in Henan province, especially the northern part, and Zhengzhou is the city with the worst air quality. Annual average PM2.5 concentrations exceed the second grade of Chinese Ambient Air Quality Standard (75μg/m(3)) at both 2014 and 2015. PM2.5 is typically the major pollutant, but ozone pollution can be significant during summer. Furthermore, as the commonly used air quality index (AQI) neglects the mutual health effects from multiple pollutants, we introduced the aggregate air quality index (AAQI) and health-risk based air quality index (HAQI) to evaluate the health risks. Results show that based on HAQI, the current AQI system likely significantly underestimate the health risks of air pollution, highlighting that the general public may need stricter health protection measures. The population -weighted two-year average HAQI data further demonstrates that all population in the studied cities in Henan province live with polluted air - 72% of the population is exposed to air that is unhealthy for sensitive people, while 28% of people is exposed to air that can be harmful to healthy people; and the health risks are much greater during winter than during other seasons. Future works should further improve the HAQI algorithm, and validate the links between the clinical / epidemiologic data and the HAQI values.
28454015	0	13	Air pollution	T069	C0001873
28454015	14	29	characteristics	T080	C1521970
28454015	34	46	health risks	T061	C0679809
28454015	50	64	Henan Province	T083	C1514578
28454015	66	71	China	T083	C0008115
28454015	82	88	severe	T080	C0205082
28454015	89	102	air pollution	T069	C0001873
28454015	126	131	China	T083	C0008115
28454015	168	181	air pollution	T069	C0001873
28454015	182	197	characteristics	T080	C1521970
28454015	206	212	health	T078	C0018684
28454015	213	218	risks	T078	C0035647
28454015	275	282	dataset	T170	C0150098
28454015	322	327	daily	T079	C0332173
28454015	328	342	concentrations	T081	C1446561
28454015	359	369	pollutants	T131	C0001869
28454015	371	376	PM2.5	T167	C1720884
28454015	378	382	PM10	T167	C1720884
28454015	384	386	CO	T131,T197	C0007018
28454015	388	391	SO2	T131,T197	C0038777
28454015	393	396	NO2	T131,T197	C0028160
28454015	402	404	O3	T103	C0030106
28454015	424	438	Henan province	T083	C1514578
28454015	467	480	air pollution	T069	C0001873
28454015	481	487	status	T080	C0449438
28454015	491	505	Henan province	T083	C1514578
28454015	522	535	northern part	T082	C1709269
28454015	541	550	Zhengzhou	T083	C0008848
28454015	558	562	city	T083	C0008848
28454015	572	577	worst	T080	C1522166
28454015	578	589	air quality	T080	C2371710
28454015	606	611	PM2.5	T167	C1720884
28454015	612	626	concentrations	T081	C1446561
28454015	654	690	Chinese Ambient Air Quality Standard	T081	C0034925
28454015	726	731	PM2.5	T167	C1720884
28454015	755	764	pollutant	T131	C0599786
28454015	770	775	ozone	T103	C0030106
28454015	776	785	pollution	T069	C0001873
28454015	812	818	summer	T079	C0241301
28454015	854	871	air quality index	T170	C0918012
28454015	873	876	AQI	T170	C0918012
28454015	898	904	health	T078	C0018684
28454015	927	937	pollutants	T131	C0599786
28454015	957	984	aggregate air quality index	T170	C0918012
28454015	986	990	AAQI	T170	C0918012
28454015	996	1031	health-risk based air quality index	T170	C0918012
28454015	1033	1037	HAQI	T170	C0918012
28454015	1042	1067	evaluate the health risks	T061	C0679809
28454015	1096	1100	HAQI	T170	C0918012
28454015	1114	1117	AQI	T170	C0918012
28454015	1164	1170	health	T078	C0018684
28454015	1171	1176	risks	T078	C0035647
28454015	1180	1193	air pollution	T069	C0001873
28454015	1217	1231	general public	T098	C0683971
28454015	1250	1276	health protection measures	T058	C1254363
28454015	1282	1292	population	T081	C0032659
28454015	1320	1324	HAQI	T170	C0918012
28454015	1360	1370	population	T081	C0032659
28454015	1386	1392	cities	T083	C0008848
28454015	1396	1410	Henan province	T083	C1514578
28454015	1421	1433	polluted air	T069	C0001873
28454015	1447	1457	population	T081	C0032659
28454015	1461	1471	exposed to	T080	C0332157
28454015	1472	1475	air	T167	C0001861
28454015	1484	1493	unhealthy	T033	C0243095
28454015	1498	1507	sensitive	T169	C0332324
28454015	1508	1514	people	T098	C0027361
28454015	1529	1535	people	T098	C0027361
28454015	1539	1549	exposed to	T080	C0332157
28454015	1550	1553	air	T167	C0001861
28454015	1577	1584	healthy	T080	C3898900
28454015	1585	1591	people	T098	C0027361
28454015	1601	1607	health	T078	C0018684
28454015	1608	1613	risks	T078	C0035647
28454015	1638	1644	winter	T079	C0241737
28454015	1663	1670	seasons	T079	C0036497
28454015	1712	1716	HAQI	T170	C0918012
28454015	1717	1726	algorithm	T170	C0002045
28454015	1763	1771	clinical	T170	C1516606
28454015	1774	1787	epidemiologic	T169	C0014508
28454015	1788	1792	data	T170	C0150098
28454015	1801	1805	HAQI	T170	C0918012

28336597|t|Draft Genome Sequence of Providencia stuartii PS71, a Multidrug-Resistant Strain Associated with Nosocomial Infections in Greece
28336597|a|Providencia stuartii is frequently associated with nosocomial outbreaks and displays intrinsic resistance to many commonly used antimicrobials. We report here the draft genome sequence of a P. stuartii strain carrying acquired resistance genes conferring panresistance to cephalosporins (blaSHV-5 and blaVEB-1), carbapenems (blaVIM-1), and aminoglycosides (rmtB) involved in an outbreak in Greek hospitals.
28336597	0	12	Draft Genome	T028	C0017428
28336597	13	21	Sequence	T086	C0314659
28336597	25	50	Providencia stuartii PS71	T007	C0315286
28336597	54	73	Multidrug-Resistant	T032	C0242640
28336597	74	80	Strain	T001	C1518614
28336597	81	96	Associated with	T080	C0332281
28336597	97	118	Nosocomial Infections	T047	C0205721
28336597	122	128	Greece	T083	C0018226
28336597	129	149	Providencia stuartii	T007	C0315286
28336597	153	163	frequently	T079	C0332183
28336597	164	179	associated with	T080	C0332281
28336597	180	200	nosocomial outbreaks	T047	C0205721
28336597	214	223	intrinsic	T082	C0205102
28336597	224	234	resistance	T169	C4281815
28336597	243	251	commonly	T081	C0205214
28336597	257	271	antimicrobials	T121	C1136254
28336597	292	304	draft genome	T028	C0017428
28336597	305	313	sequence	T086	C0314659
28336597	319	337	P. stuartii strain	T007	C0315286
28336597	347	355	acquired	T080	C0439661
28336597	356	372	resistance genes	T028	C2945710
28336597	384	397	panresistance	T169	C4281815
28336597	401	415	cephalosporins	T109,T195	C3536856
28336597	417	425	blaSHV-5	T028	C0017337
28336597	430	438	blaVEB-1	T028	C0017337
28336597	441	452	carbapenems	T109,T195	C0006968
28336597	454	462	blaVIM-1	T028	C0017337
28336597	469	484	aminoglycosides	T109,T121	C0002556
28336597	486	490	rmtB	T028	C0017337
28336597	507	515	outbreak	T067	C0012652
28336597	519	524	Greek	T083	C0018226
28336597	525	534	hospitals	T073,T093	C0019994

27488290|t|Direct Repair of Lumbar Pars Interarticularis Defects by Utilizing Intraoperative O-Arm-Based Navigation and Microendoscopic Techniques
27488290|a|A retrospective analysis of the clinical outcomes of eight patients with the lumbar pars interarticulars defects treated by direct repair with the aid of intraoperative O-arm based navigation and microendoscopic techniques. The aim of this study was to investigate the efficacy and safety of direct screw repair by using minimally invasive surgery for the lumbar pars interarticulars defects in a pilot study. Direct repair of pars interarticulars defects has been used to treat young adult patients. Reports concerning direct repair by minimally invasive techniques for pars interarticulars defects are quite rare. Review of medical records identified eight consecutive patients treated with intraoperative O-arm based navigation and microendoscopic techniques. Debridement and autograft of pars interarticularis defects was performed under microendoscopic procedure. Then, percutaneous bilateral intralaminar screws were inserted by utilizing intraoperative navigation. The clinical and radiological data were collected and analyzed retrospectively. Eight patients had a mean age of 28.4 years, and five were 30 years or younger at the time of treatment. Symptoms included axial back pain in 100% of patients without concomitant radiculopathy. Autograft was used in all cases. The average follow-up duration was 27.4 months with a range of 20 to 33 months. Symptoms resolved completely or partially in all patients. Low back pain visual analog scores decrease from preoperative 6.8 to postoperative 1.4 of eight cases. Of 16 pars defects, healing was observed in 13 (81.3%) at last radiological follow-up. One patient with bilateral fusion failure refused revision surgery because of mild complaint. No complications such as dural tear, nerve root injury, and infection occurred. Minimally invasive direct repair of the pars interarticularis defects with intralaminar screws by using microendoscopic system and navigation procedure can provide safe and effective treatment of spondylolysis with satisfactory clinical and radiological outcomes, which need some special tools with steep learning curve. 4.
27488290	0	6	Direct	T080	C1947931
27488290	7	13	Repair	T058	C1705181
27488290	17	45	Lumbar Pars Interarticularis	T023	C3874316
27488290	46	53	Defects	T169	C1457869
27488290	57	66	Utilizing	T169	C0042153
27488290	67	104	Intraoperative O-Arm-Based Navigation	T074	C0392304
27488290	109	135	Microendoscopic Techniques	T060	C0014245
27488290	138	160	retrospective analysis	T062	C0035363
27488290	168	185	clinical outcomes	T033	C2985631
27488290	195	203	patients	T101	C0030705
27488290	213	240	lumbar pars interarticulars	T023	C3874316
27488290	241	248	defects	T169	C1457869
27488290	249	256	treated	T033	C0332154
27488290	260	266	direct	T080	C1947931
27488290	267	273	repair	T058	C1705181
27488290	283	286	aid	T080	C1269765
27488290	290	327	intraoperative O-arm based navigation	T074	C0392304
27488290	332	358	microendoscopic techniques	T060	C0014245
27488290	364	367	aim	T078	C1947946
27488290	376	381	study	T062	C2603343
27488290	389	400	investigate	T169	C1292732
27488290	405	413	efficacy	T080	C1280519
27488290	418	424	safety	T068	C0036043
27488290	428	434	direct	T080	C1947931
27488290	435	440	screw	T074	C0301559
27488290	441	447	repair	T058	C1705181
27488290	451	456	using	T169	C0457083
27488290	457	483	minimally invasive surgery	T061	C0282624
27488290	492	519	lumbar pars interarticulars	T023	C3874316
27488290	520	527	defects	T169	C1457869
27488290	533	544	pilot study	T062	C2603343
27488290	546	552	Direct	T080	C1947931
27488290	553	559	repair	T058	C1705181
27488290	563	583	pars interarticulars	T023	C3874316
27488290	584	591	defects	T169	C1457869
27488290	601	605	used	T169	C0457083
27488290	609	614	treat	T061	C0087111
27488290	615	626	young adult	T100	C0238598
27488290	627	635	patients	T101	C0030705
27488290	637	644	Reports	T170	C0684224
27488290	645	655	concerning	T078	C2699424
27488290	656	662	direct	T080	C1947931
27488290	663	669	repair	T058	C1705181
27488290	673	702	minimally invasive techniques	T061	C0282624
27488290	707	727	pars interarticulars	T023	C3874316
27488290	728	735	defects	T169	C1457869
27488290	746	750	rare	T080	C0522498
27488290	752	758	Review	T078	C1552617
27488290	762	777	medical records	T170	C0025102
27488290	778	788	identified	T080	C0205396
27488290	795	806	consecutive	T080	C1707491
27488290	807	815	patients	T101	C0030705
27488290	816	823	treated	T033	C0332154
27488290	829	866	intraoperative O-arm based navigation	T074	C0392304
27488290	871	897	microendoscopic techniques	T060	C0014245
27488290	899	910	Debridement	T061	C0011079
27488290	915	924	autograft	T061	C0040736
27488290	928	949	pars interarticularis	T023	C3874316
27488290	950	957	defects	T169	C1457869
27488290	962	971	performed	T169	C0884358
27488290	978	1003	microendoscopic procedure	T060	C0014245
27488290	1011	1023	percutaneous	T082	C0522523
27488290	1024	1033	bilateral	T082	C0238767
27488290	1034	1046	intralaminar	T082	C0205274
27488290	1047	1053	screws	T074	C0301559
27488290	1059	1067	inserted	T058	C0441587
27488290	1071	1080	utilizing	T169	C0042153
27488290	1081	1106	intraoperative navigation	T074	C0392304
27488290	1112	1120	clinical	T170	C1516606
27488290	1125	1137	radiological	T091	C0039431
27488290	1138	1142	data	T078	C1511726
27488290	1148	1157	collected	T078	C1516695
27488290	1162	1170	analyzed	T062	C0936012
27488290	1171	1186	retrospectively	T080	C1514923
27488290	1194	1202	patients	T101	C0030705
27488290	1209	1213	mean	T081	C0444504
27488290	1214	1217	age	T032	C0001779
27488290	1259	1266	younger	T079	C0332239
27488290	1274	1278	time	T079	C0040223
27488290	1282	1291	treatment	T061	C0087111
27488290	1293	1301	Symptoms	T184	C1457887
27488290	1302	1310	included	T052	C2700399
27488290	1311	1316	axial	T082	C0205131
27488290	1317	1326	back pain	T184	C0004604
27488290	1338	1346	patients	T101	C0030705
27488290	1355	1366	concomitant	T079	C0521115
27488290	1367	1380	radiculopathy	T047	C0700594
27488290	1382	1391	Autograft	T061	C0040736
27488290	1396	1400	used	T169	C0457083
27488290	1408	1413	cases	T077	C1706256
27488290	1419	1426	average	T081	C1510992
27488290	1427	1436	follow-up	T058	C1522577
27488290	1437	1445	duration	T079	C0449238
27488290	1469	1474	range	T081	C1514721
27488290	1495	1503	Symptoms	T184	C1457887
27488290	1504	1512	resolved	T033	C3714811
27488290	1513	1523	completely	T080	C0205197
27488290	1527	1536	partially	T081	C0728938
27488290	1544	1552	patients	T101	C0030705
27488290	1554	1567	Low back pain	T184	C0024031
27488290	1568	1588	visual analog scores	T201	C2960751
27488290	1589	1597	decrease	T081	C0547047
27488290	1603	1615	preoperative	T079	C0445204
27488290	1623	1636	postoperative	T079	C0032790
27488290	1650	1655	cases	T077	C1706256
27488290	1663	1667	pars	T023	C0229962
27488290	1668	1675	defects	T169	C1457869
27488290	1677	1684	healing	T040	C2004454
27488290	1689	1697	observed	T169	C1441672
27488290	1720	1732	radiological	T091	C0039431
27488290	1733	1742	follow-up	T058	C1522577
27488290	1748	1755	patient	T101	C0030705
27488290	1761	1785	bilateral fusion failure	T019	C0332917
27488290	1786	1793	refused	T052	C1705116
27488290	1794	1810	revision surgery	T061	C0035110
27488290	1822	1836	mild complaint	T033	C0436343
27488290	1838	1854	No complications	T033	C4032686
27488290	1863	1873	dural tear	T037	C1504340
27488290	1875	1892	nerve root injury	T037	C0854396
27488290	1898	1907	infection	T046	C3714514
27488290	1908	1916	occurred	T052	C1709305
27488290	1918	1936	Minimally invasive	T061	C0282624
27488290	1937	1943	direct	T080	C1947931
27488290	1944	1950	repair	T058	C1705181
27488290	1958	1979	pars interarticularis	T023	C3874316
27488290	1980	1987	defects	T169	C1457869
27488290	1993	2005	intralaminar	T082	C0205274
27488290	2006	2012	screws	T074	C0301559
27488290	2016	2021	using	T169	C0457083
27488290	2022	2044	microendoscopic system	T060	C0014245
27488290	2049	2069	navigation procedure	T074	C0392304
27488290	2074	2081	provide	T052	C1999230
27488290	2091	2100	effective	T080	C1704419
27488290	2101	2110	treatment	T061	C0087111
27488290	2114	2127	spondylolysis	T047	C0038018
27488290	2133	2145	satisfactory	T080	C0205410
27488290	2146	2154	clinical	T080	C0205210
27488290	2159	2171	radiological	T091	C0039431
27488290	2172	2180	outcomes	T169	C1274040
27488290	2188	2192	need	T080	C0027552
27488290	2198	2211	special tools	T074	C0025080
27488290	2217	2222	steep	T080	C0332218
27488290	2223	2237	learning curve	T041	C0023185

27536134|t|RBBP6: a potential biomarker of apoptosis induction in human cervical cancer cell lines
27536134|a|Overexpression of RBBP6 in cancers of the colon, lung, and esophagus makes it a potential target in anticancer therapy. This is especially important because RBBP6 associates with the tumor suppressor gene p53, the inactivation of which has been linked to over 50% of all cancer types. However, the expression of RBBP6 in cancer and its interaction with p53 are yet to be understood in order to determine whether or not RBBP6 is cancer promoting and therefore a potential biomarker. In this study, we manipulated RBBP6 expression levels followed by treatment with either camptothecin or γ-aminobutyric acid in cervical cancer cells to induce apoptosis or cell cycle arrest. We began by staining human cervical cancer tissue sections with anti-RBBP6 monoclonal antibody to evaluate the extent of expression of RBBP6 in patients ' specimens. We followed on with silencing the overexpression of RBBP6 and treatment with anticancer agents to evaluate how the specimens respond to combinational therapy. Apoptosis induction was evaluated through confocal microscope, and flow cytometry using annexin V staining, and also by checking the mitochondrial and caspase-3/7 activity. Cell cycle arrest was evaluated using flow cytometry through staining with propidium iodide. RBBP6 was highly expressed in cervical cancer tissue sections that were in stage II or III of development. Silencing RBBP6 followed by treatment with γ-aminobutyric acid and camptothecin seems to sensitize cells to apoptosis induction rather than cell cycle arrest. Overexpression of RBBP6 seems to promote S-phase in cell cycle and cell proliferation. These results predict a proliferative role of RBBP6 in cancer progression rather than as a cancer-causing gene. Furthermore, sensitization of cells to camptothecin - induced apoptosis by RBBP6 targeting suggests a promising tool for halting cervical cancer progression.
27536134	0	5	RBBP6	T028	C1419291
27536134	9	18	potential	T080	C3245505
27536134	19	28	biomarker	T201	C0005516
27536134	32	41	apoptosis	T043	C0162638
27536134	42	51	induction	T045	C0017391
27536134	55	60	human	T016	C0086418
27536134	61	81	cervical cancer cell	T191	C0742133
27536134	82	87	lines	T025	C0007600
27536134	88	102	Overexpression	T045	C0017262
27536134	106	111	RBBP6	T028	C1419291
27536134	115	135	cancers of the colon	T191	C0699790
27536134	137	141	lung	T191	C0684249
27536134	147	156	esophagus	T191	C0152018
27536134	168	177	potential	T080	C3245505
27536134	178	184	target	T169	C1521840
27536134	188	206	anticancer therapy	T061	C0920425
27536134	245	250	RBBP6	T028	C1419291
27536134	251	266	associates with	T080	C0332281
27536134	271	296	tumor suppressor gene p53	T028	C0079419
27536134	302	314	inactivation	T169	C0544461
27536134	359	371	cancer types	T191	C0006826
27536134	386	396	expression	T045	C0017262
27536134	400	405	RBBP6	T028	C1419291
27536134	409	415	cancer	T191	C0006826
27536134	424	435	interaction	T045	C0596610
27536134	441	444	p53	T028	C0079419
27536134	507	512	RBBP6	T028	C1419291
27536134	516	532	cancer promoting	T028	C0919437
27536134	549	558	potential	T080	C3245505
27536134	559	568	biomarker	T201	C0005516
27536134	578	583	study	T059	C0947630
27536134	588	599	manipulated	T061	C0947647
27536134	600	605	RBBP6	T028	C1419291
27536134	606	623	expression levels	T081	C3244092
27536134	636	645	treatment	T169	C1522326
27536134	658	670	camptothecin	T109,T121	C0006812
27536134	674	693	γ-aminobutyric acid	T116,T123	C0016904
27536134	697	718	cervical cancer cells	T191	C0742133
27536134	722	728	induce	T045	C0017391
27536134	729	738	apoptosis	T043	C0162638
27536134	742	759	cell cycle arrest	T043	C1155873
27536134	773	781	staining	T059	C0487602
27536134	782	787	human	T016	C0086418
27536134	788	819	cervical cancer tissue sections	T191	C0742133
27536134	836	855	monoclonal antibody	T116,T129	C0003250
27536134	859	867	evaluate	T058	C0220825
27536134	882	892	expression	T045	C0017262
27536134	896	901	RBBP6	T028	C1419291
27536134	905	913	patients	T101	C0030705
27536134	916	925	specimens	T077	C2347026
27536134	947	956	silencing	T045	C0598496
27536134	961	975	overexpression	T045	C0017262
27536134	979	984	RBBP6	T028	C1419291
27536134	989	998	treatment	T169	C1522326
27536134	1004	1021	anticancer agents	T109,T121	C0003392
27536134	1025	1033	evaluate	T058	C0220825
27536134	1042	1051	specimens	T077	C2347026
27536134	1063	1076	combinational	T080	C0205195
27536134	1077	1084	therapy	T061	C0087111
27536134	1086	1095	Apoptosis	T043	C0162638
27536134	1096	1105	induction	T045	C0017391
27536134	1110	1119	evaluated	T058	C0220825
27536134	1128	1147	confocal microscope	T074	C1626420
27536134	1153	1167	flow cytometry	T059	C0016263
27536134	1174	1183	annexin V	T116,T123	C0059249
27536134	1184	1192	staining	T059	C0487602
27536134	1206	1214	checking	T052	C1283174
27536134	1219	1232	mitochondrial	T026	C0026237
27536134	1237	1257	caspase-3/7 activity	T044	C1150130
27536134	1259	1276	Cell cycle arrest	T043	C1155873
27536134	1281	1290	evaluated	T058	C0220825
27536134	1297	1311	flow cytometry	T059	C0016263
27536134	1320	1328	staining	T059	C0487602
27536134	1334	1350	propidium iodide	T109,T130	C0033470
27536134	1352	1357	RBBP6	T028	C1419291
27536134	1362	1368	highly	T080	C0205250
27536134	1369	1378	expressed	T045	C0017262
27536134	1382	1413	cervical cancer tissue sections	T191	C0742133
27536134	1427	1435	stage II	T170	C0441767
27536134	1439	1457	III of development	T170	C0441771
27536134	1459	1468	Silencing	T045	C0598496
27536134	1469	1474	RBBP6	T028	C1419291
27536134	1487	1496	treatment	T169	C1522326
27536134	1502	1521	γ-aminobutyric acid	T116,T123	C0016904
27536134	1526	1538	camptothecin	T109,T121	C0006812
27536134	1548	1563	sensitize cells	T025	C0312864
27536134	1567	1576	apoptosis	T043	C0162638
27536134	1577	1586	induction	T045	C0017391
27536134	1599	1616	cell cycle arrest	T043	C1155873
27536134	1618	1632	Overexpression	T045	C0017262
27536134	1636	1641	RBBP6	T028	C1419291
27536134	1651	1658	promote	T052	C0033414
27536134	1659	1666	S-phase	T079	C0080129
27536134	1670	1680	cell cycle	T043	C0007586
27536134	1685	1703	cell proliferation	T043	C0596290
27536134	1711	1718	results	T033	C2825142
27536134	1751	1756	RBBP6	T028	C1419291
27536134	1760	1778	cancer progression	T046	C1947901
27536134	1796	1815	cancer-causing gene	T028	C0029016
27536134	1830	1843	sensitization	T040	C1325847
27536134	1847	1852	cells	T025	C0007634
27536134	1856	1868	camptothecin	T109,T121	C0006812
27536134	1871	1878	induced	T046	C0007994
27536134	1879	1888	apoptosis	T043	C0162638
27536134	1892	1897	RBBP6	T028	C1419291
27536134	1898	1907	targeting	T063	C0242613
27536134	1938	1945	halting	T052	C1947925
27536134	1946	1973	cervical cancer progression	T046	C1947901

28165579|t|A national appraisal of haemodialysis vascular access provision in Scotland
28165579|a|Published registry data demonstrate longstanding variation in the utilisation of different vascular access (VA) modalities between Scottish renal units; this may reflect different clinical processes between centres. A comprehensive appraisal was undertaken to understand the processes underpinning VA creation and maintenance across Scotland. A mixed methods approach was utilised. Fifty-two semi-structured interviews were conducted with patients and clinicians in all ten, adult and paediatric, Scottish renal units. Interview transcripts were subjected to thematic analysis. Clinical activity data were prospectively collected for six weeks, and correlated with registry data. VA accounts for a large clinical workload. There was significant inter-centre variation in the utilisation of different VA modalities, and patients described frustrating, dissatisfying experiences. VA creation and maintenance pathways functioned best when nephrologists, surgeons and radiologists were co-located on the same campus with close multi-disciplinary working, protected clinical time, and proactive VA maintenance. No unit routinely measured or discussed procedure outcomes or strategic aspects of their service. Varied clinical outcomes reflected varied clinical processes. Optimised clinical pathways, staff education and measurement of clinical outcomes may improve VA service quality and facilitate safer, more effective, patient-centred care.
28165579	2	10	national	T082	C0681788
28165579	11	20	appraisal	T058	C0220825
28165579	24	37	haemodialysis	T061	C0019004
28165579	38	53	vascular access	T074	C0750138
28165579	54	63	provision	T058	C2584455
28165579	67	75	Scotland	T083	C0036453
28165579	76	94	Published registry	T170	C0034975
28165579	95	99	data	T078	C1511726
28165579	125	134	variation	T080	C0205419
28165579	142	153	utilisation	T169	C0042153
28165579	167	182	vascular access	T074	C0750138
28165579	184	186	VA	T074	C0750138
28165579	188	198	modalities	T078	C0695347
28165579	207	215	Scottish	T083	C0036453
28165579	216	227	renal units	T073,T093	C0019007
28165579	256	274	clinical processes	T058	C1254363
28165579	283	290	centres	T073,T093	C0475309
28165579	294	307	comprehensive	T080	C1880156
28165579	308	317	appraisal	T058	C0220825
28165579	351	360	processes	T058	C1254363
28165579	374	376	VA	T074	C0750138
28165579	377	385	creation	T052	C1706214
28165579	390	401	maintenance	T052	C0024501
28165579	409	417	Scotland	T083	C0036453
28165579	421	443	mixed methods approach	T082	C0449445
28165579	468	494	semi-structured interviews	UnknownType	C0681913
28165579	515	523	patients	T101	C0030705
28165579	528	538	clinicians	T097	C0871685
28165579	551	556	adult	T100	C0001675
28165579	561	571	paediatric	T100	C0008059
28165579	573	581	Scottish	T083	C0036453
28165579	582	593	renal units	T073,T093	C0019007
28165579	595	616	Interview transcripts	T170	C0935630
28165579	635	652	thematic analysis	UnknownType	C0681942
28165579	654	671	Clinical activity	T185	C1516654
28165579	672	676	data	T078	C1511726
28165579	714	719	weeks	T079	C0439230
28165579	725	735	correlated	T080	C1707520
28165579	741	749	registry	T170	C0034975
28165579	750	754	data	T078	C1511726
28165579	756	758	VA	T074	C0750138
28165579	780	788	clinical	T080	C0205210
28165579	789	797	workload	T081	C0085122
28165579	834	843	variation	T080	C0205419
28165579	851	862	utilisation	T169	C0042153
28165579	876	878	VA	T074	C0750138
28165579	879	889	modalities	T078	C0695347
28165579	895	903	patients	T101	C0030705
28165579	914	925	frustrating	T041	C0016770
28165579	927	940	dissatisfying	T041	C0870433
28165579	941	952	experiences	T055	C0683573
28165579	954	956	VA	T074	C0750138
28165579	957	965	creation	T052	C1706214
28165579	970	981	maintenance	T052	C0024501
28165579	982	990	pathways	T077	C1705987
28165579	1012	1025	nephrologists	T097	C0260039
28165579	1027	1035	surgeons	T097	C0582175
28165579	1040	1052	radiologists	T097	C0260194
28165579	1081	1087	campus	T073,T093	C0475309
28165579	1118	1125	working	T057	C0043227
28165579	1137	1145	clinical	T080	C0205210
28165579	1146	1150	time	T079	C0040223
28165579	1166	1168	VA	T074	C0750138
28165579	1169	1180	maintenance	T052	C0024501
28165579	1190	1199	routinely	T080	C0205547
28165579	1222	1231	procedure	T169	C2700391
28165579	1232	1240	outcomes	T169	C1274040
28165579	1271	1278	service	T058	C0018747
28165579	1287	1295	clinical	T080	C0205210
28165579	1296	1304	outcomes	T169	C1274040
28165579	1322	1340	clinical processes	T058	C1254363
28165579	1352	1369	clinical pathways	T170	C0282654
28165579	1371	1386	staff education	T065	C0588974
28165579	1391	1402	measurement	T169	C0242485
28165579	1406	1414	clinical	T080	C0205210
28165579	1415	1423	outcomes	T169	C1274040
28165579	1436	1438	VA	T074	C0750138
28165579	1439	1454	service quality	T058	C0034379
28165579	1482	1491	effective	T080	C1704419
28165579	1493	1513	patient-centred care	T058	C0017313

27867860|t|Laparoscopic sleeve gastrectomy for the treatment of diabetes mellitus type 2 patients -single center early experience
27867860|a|In recent years, laparoscopic sleeve gastrectomy (LSG) has become one of the most commonly used primary bariatric procedures for morbid obesity. While laparoscopic Roux-en-Y gastric bypass (LRYGB) has well documented positive clinical influence on type 2 diabetes, the role of LSG in diabetes treatment is debatable. The main aim of this study is to present our early experience in LSG as a method of bariatric treatment in patients with type 2 diabetes or abnormalities in glucose homeostasis. Prospectively collected data of patients operated for morbid obesity at the 2nd Department of Surgery. The study was designed to assess the influence of LSG on type 2 diabetes and glucose homeostasis. The primary endpoint was the diabetes type 2 remission. Secondary endpoint was the change of glucose metabolism parameters after LSG. Patients were assessed preoperatively and allocated to two groups: group 1 -with any preoperative abnormalities in glucose homeostasis (prediabetes, diabetes) and group 2 -with non-elevated fasting glucose level. During follow-up (6 months after surgery) all glucose homeostasis parameters were analyzed again. One hundred and thirty-six patients after LSG were enrolled in the study (90 females, 46 males; mean age 40.5±9.9 years). Preoperative abnormalities in glucose homeostasis were confirmed in 64 (47%) patients. Twenty (15%) patients in this group had diabetes. We observed significant reduction of body mass index (BMI) after surgery. Mean percent of EBMIL for all groups after 6 months from surgery was 59.90% (46.75-69.28%). There were no full remissions after surgery in patients with preoperative diabetes. We found significant improvement in biochemical markers of glucose homeostasis. We observed significant reduction of HbA1c % after surgery in both groups. The level of postoperative HbA1c % was related to BMI loss after surgery. LSG leads to significant improvement in biochemical glucose homeostasis and can be considered as a method of treatment in morbidly obese patients with glucose metabolism abnormalities. LSG as a method of treatment for patients with clinical type 2 diabetes still needs some further observation.
27867860	0	31	Laparoscopic sleeve gastrectomy	T061	C1960816
27867860	40	49	treatment	T169	C1522326
27867860	53	77	diabetes mellitus type 2	T047	C0011860
27867860	78	86	patients	T101	C0030705
27867860	136	167	laparoscopic sleeve gastrectomy	T061	C1960816
27867860	169	172	LSG	T061	C1960816
27867860	223	243	bariatric procedures	T061	C2315331
27867860	248	262	morbid obesity	T047	C0028756
27867860	270	307	laparoscopic Roux-en-Y gastric bypass	T061	C1504133
27867860	309	314	LRYGB	T061	C1504133
27867860	336	344	positive	T033	C1446409
27867860	345	353	clinical	T080	C0205210
27867860	354	363	influence	T077	C4054723
27867860	367	382	type 2 diabetes	T047	C0011860
27867860	396	399	LSG	T061	C1960816
27867860	403	411	diabetes	T047	C0011847
27867860	412	421	treatment	T169	C1522326
27867860	457	462	study	T062	C2603343
27867860	501	504	LSG	T061	C1960816
27867860	510	516	method	T170	C0025663
27867860	520	539	bariatric treatment	T061	C1456587
27867860	543	551	patients	T101	C0030705
27867860	557	572	type 2 diabetes	T047	C0011860
27867860	576	589	abnormalities	T033	C1704258
27867860	593	612	glucose homeostasis	T039	C1326961
27867860	614	627	Prospectively	T062	C0033522
27867860	638	642	data	T078	C1511726
27867860	646	654	patients	T101	C0030705
27867860	655	663	operated	T052	C3241922
27867860	668	682	morbid obesity	T047	C0028756
27867860	690	715	2nd Department of Surgery	T093	C0038896
27867860	721	726	study	T062	C2603343
27867860	743	749	assess	T058	C0184514
27867860	754	763	influence	T077	C4054723
27867860	767	770	LSG	T061	C1960816
27867860	774	789	type 2 diabetes	T047	C0011860
27867860	794	813	glucose homeostasis	T039	C1326961
27867860	819	835	primary endpoint	T130	C2986535
27867860	844	869	diabetes type 2 remission	T047	C3839591
27867860	871	880	Secondary	T081	C0205436
27867860	881	889	endpoint	T080	C2349179
27867860	908	926	glucose metabolism	T044	C0596620
27867860	927	937	parameters	T077	C0549193
27867860	944	947	LSG	T061	C1960816
27867860	949	957	Patients	T101	C0030705
27867860	963	971	assessed	T052	C1516048
27867860	972	986	preoperatively	T079	C0445204
27867860	1008	1014	groups	T078	C0441833
27867860	1016	1023	group 1	T078	C0441833
27867860	1034	1046	preoperative	T079	C0445204
27867860	1047	1060	abnormalities	T033	C1704258
27867860	1064	1083	glucose homeostasis	T039	C1326961
27867860	1085	1096	prediabetes	T047	C0362046
27867860	1098	1106	diabetes	T047	C0011847
27867860	1112	1119	group 2	T078	C0441833
27867860	1126	1160	non-elevated fasting glucose level	T034	C1261430
27867860	1169	1178	follow-up	T058	C1522577
27867860	1182	1188	months	T079	C0439231
27867860	1195	1202	surgery	T169	C0038895
27867860	1208	1227	glucose homeostasis	T039	C1326961
27867860	1228	1238	parameters	T077	C0549193
27867860	1244	1252	analyzed	T062	C0936012
27867860	1287	1295	patients	T101	C0030705
27867860	1302	1305	LSG	T061	C1960816
27867860	1327	1332	study	T062	C2603343
27867860	1337	1344	females	T032	C0086287
27867860	1349	1354	males	T032	C0086582
27867860	1361	1364	age	T032	C0001779
27867860	1374	1379	years	T079	C0439234
27867860	1382	1394	Preoperative	T079	C0445204
27867860	1395	1408	abnormalities	T033	C1704258
27867860	1412	1431	glucose homeostasis	T039	C1326961
27867860	1459	1467	patients	T101	C0030705
27867860	1482	1490	patients	T101	C0030705
27867860	1499	1504	group	T078	C0441833
27867860	1509	1517	diabetes	T047	C0011847
27867860	1543	1552	reduction	T080	C0392756
27867860	1556	1571	body mass index	T170	C4055400
27867860	1573	1576	BMI	T170	C4055400
27867860	1584	1591	surgery	T169	C0038895
27867860	1609	1614	EBMIL	T033	C0243095
27867860	1623	1629	groups	T078	C0441833
27867860	1638	1644	months	T079	C0439231
27867860	1650	1657	surgery	T169	C0038895
27867860	1704	1714	remissions	T033	C0544452
27867860	1721	1728	surgery	T169	C0038895
27867860	1732	1740	patients	T101	C0030705
27867860	1746	1758	preoperative	T079	C0445204
27867860	1759	1767	diabetes	T047	C0011847
27867860	1805	1824	biochemical markers	T080	C0206015
27867860	1828	1847	glucose homeostasis	T039	C1326961
27867860	1873	1882	reduction	T080	C0392756
27867860	1886	1891	HbA1c	T116,T123	C0019018
27867860	1900	1907	surgery	T169	C0038895
27867860	1916	1922	groups	T078	C0441833
27867860	1937	1950	postoperative	T079	C0032790
27867860	1951	1956	HbA1c	T116,T123	C0019018
27867860	1974	1977	BMI	T170	C4055400
27867860	1978	1982	loss	T081	C1517945
27867860	1989	1996	surgery	T169	C0038895
27867860	1998	2001	LSG	T061	C1960816
27867860	2038	2049	biochemical	T169	C0205474
27867860	2050	2069	glucose homeostasis	T039	C1326961
27867860	2097	2103	method	T170	C0025663
27867860	2107	2116	treatment	T169	C1522326
27867860	2120	2134	morbidly obese	T047	C0028756
27867860	2135	2143	patients	T101	C0030705
27867860	2149	2167	glucose metabolism	T044	C0596620
27867860	2168	2181	abnormalities	T033	C1704258
27867860	2183	2186	LSG	T061	C1960816
27867860	2192	2198	method	T170	C0025663
27867860	2202	2211	treatment	T169	C1522326
27867860	2216	2224	patients	T101	C0030705
27867860	2230	2238	clinical	T080	C0205210
27867860	2239	2254	type 2 diabetes	T047	C0011860
27867860	2280	2291	observation	T062	C0302523

27594346|t|Recognizing the impact of endemic hepatitis D virus on hepatitis B virus eradication
27594346|a|Hepatitis delta virus (HDV) in conjunction with hepatitis B virus (HBV) increases adult morbidity and mortality. A number of studies have performed cost-benefit analyses for HBV interventions, but they have ignored the impact of HDV on these outcomes. Using a mathematical model of HBV - HDV epidemiology, we compare health benefits and cost outcomes of four interventions: testing with HBV adult vaccination (diagnosis), diagnosis with antiviral treatment for HBV infections (mono - infections), diagnosis with antiviral treatment for HBV - HDV infections (dual - infections), and awareness programs. The relationship between optimal levels and outcomes of each of these interventions and HDV prevalence in HBV infected individuals ranging from 0 to 50% is determined. Over a 50 year period under no intervention, HBV prevalence, per capita total cost and death toll increase by 2.25%, -$11 and 2.6-fold respectively in moderate HDV endemic regions compared to mono - infected regions; the corresponding values for high HDV endemic regions are 4.2%, -$21 and 3.9-fold. Optimal interventions can be strategized similarly in mono and dually endemic regions. Only implementation of all four interventions achieves a very low HBV prevalence of around 1.5% in a moderate HDV endemic region such as China, with 2.8 million fewer deaths compared to no intervention. Although the policy of implementation of all four interventions costs additional $382 billion compared to no intervention, it still remains cost - effective with an incremental cost - effectiveness ratio of $1400/ QALY. Very high efficacy awareness programs achieve less prevalence with fewer deaths at a lower cost compared to treatment and/or vaccination programs. HDV substantially affects the performance of any HBV - related intervention. Its exclusion results in over-estimation of the effectiveness of HBV interventions.
27594346	16	22	impact	T080	C4049986
27594346	26	51	endemic hepatitis D virus	T005	C0011220
27594346	55	72	hepatitis B virus	T005	C0019169
27594346	73	84	eradication	T058	C3178994
27594346	85	106	Hepatitis delta virus	T005	C0011220
27594346	108	111	HDV	T005	C0011220
27594346	116	127	conjunction	T078	C2699427
27594346	133	150	hepatitis B virus	T005	C0019169
27594346	152	155	HBV	T005	C0019169
27594346	157	166	increases	T169	C0442805
27594346	167	172	adult	T100	C0001675
27594346	173	182	morbidity	T081	C0026538
27594346	187	196	mortality	T081	C0205848
27594346	200	206	number	T081	C0237753
27594346	210	217	studies	T062	C2603343
27594346	223	232	performed	T169	C0884358
27594346	233	254	cost-benefit analyses	T057	C0010174
27594346	259	262	HBV	T005	C0019169
27594346	263	276	interventions	T061	C0184661
27594346	292	299	ignored	T078	C1554079
27594346	304	310	impact	T080	C4049986
27594346	314	317	HDV	T005	C0011220
27594346	327	335	outcomes	T169	C1274040
27594346	345	363	mathematical model	T170	C0876936
27594346	367	370	HBV	T005	C0019169
27594346	373	376	HDV	T005	C0011220
27594346	377	389	epidemiology	T169	C0014508
27594346	394	401	compare	T052	C1707455
27594346	402	417	health benefits	T081	C0086387
27594346	422	426	cost	T081	C0010186
27594346	427	435	outcomes	T169	C1274040
27594346	439	443	four	T081	C0205450
27594346	444	457	interventions	T061	C0184661
27594346	459	466	testing	T169	C0039593
27594346	472	475	HBV	T005	C0019169
27594346	476	481	adult	T100	C0001675
27594346	482	493	vaccination	T061	C0042196
27594346	495	504	diagnosis	T062	C1704656
27594346	507	516	diagnosis	T062	C1704656
27594346	522	541	antiviral treatment	T061	C2363964
27594346	546	560	HBV infections	T047	C0019163
27594346	562	566	mono	T081	C0205171
27594346	569	579	infections	T046	C3714514
27594346	582	591	diagnosis	T062	C1704656
27594346	597	616	antiviral treatment	T061	C2363964
27594346	621	624	HBV	T005	C0019169
27594346	627	630	HDV	T005	C0011220
27594346	631	641	infections	T046	C3714514
27594346	643	647	dual	T080	C1706942
27594346	650	660	infections	T046	C3714514
27594346	677	685	programs	T169	C3484370
27594346	691	703	relationship	T080	C0439849
27594346	712	719	optimal	T080	C2698651
27594346	720	726	levels	T080	C0441889
27594346	731	739	outcomes	T169	C1274040
27594346	757	770	interventions	T061	C0184661
27594346	775	778	HDV	T005	C0011220
27594346	779	789	prevalence	T081	C0220900
27594346	793	796	HBV	T005	C0019169
27594346	797	805	infected	T033	C0439663
27594346	806	817	individuals	T098	C0027361
27594346	855	859	Over	T079	C0347984
27594346	865	869	year	T079	C0439234
27594346	870	876	period	T079	C1948053
27594346	883	898	no intervention	T033	C0243095
27594346	900	903	HBV	T005	C0019169
27594346	904	914	prevalence	T081	C0220900
27594346	916	926	per capita	T081	C0392762
27594346	927	932	total	T080	C0439810
27594346	933	937	cost	T081	C0010186
27594346	942	947	death	T033	C1306577
27594346	948	952	toll	T080	C0439810
27594346	953	961	increase	T169	C0442805
27594346	1006	1014	moderate	T080	C1881878
27594346	1015	1018	HDV	T005	C0011220
27594346	1027	1034	regions	UnknownType	C0681784
27594346	1035	1043	compared	T052	C1707455
27594346	1047	1051	mono	T081	C0205171
27594346	1054	1062	infected	T033	C0439663
27594346	1063	1070	regions	UnknownType	C0681784
27594346	1090	1096	values	T080	C0042295
27594346	1101	1105	high	T080	C0205250
27594346	1106	1109	HDV	T005	C0011220
27594346	1118	1125	regions	UnknownType	C0681784
27594346	1155	1162	Optimal	T080	C2698651
27594346	1163	1176	interventions	T061	C0184661
27594346	1196	1205	similarly	T080	C2348205
27594346	1209	1213	mono	T081	C0205171
27594346	1218	1224	dually	T080	C1706942
27594346	1233	1240	regions	UnknownType	C0681784
27594346	1247	1261	implementation	T052	C1708476
27594346	1269	1273	four	T081	C0205450
27594346	1274	1287	interventions	T061	C0184661
27594346	1288	1296	achieves	T033	C0432600
27594346	1304	1307	low	T080	C0205251
27594346	1308	1311	HBV	T005	C0019169
27594346	1312	1322	prevalence	T081	C0220900
27594346	1352	1355	HDV	T005	C0011220
27594346	1364	1370	region	UnknownType	C0681784
27594346	1379	1384	China	T083	C0008115
27594346	1395	1402	million	T081	C1881839
27594346	1403	1408	fewer	T081	C1611820
27594346	1409	1415	deaths	T081	C0205848
27594346	1416	1424	compared	T052	C1707455
27594346	1428	1443	no intervention	T033	C0243095
27594346	1458	1464	policy	T170	C0242456
27594346	1468	1482	implementation	T052	C1708476
27594346	1490	1494	four	T081	C0205450
27594346	1495	1508	interventions	T061	C0184661
27594346	1509	1514	costs	T081	C0010186
27594346	1515	1525	additional	T169	C1524062
27594346	1531	1538	billion	T081	C0392762
27594346	1539	1547	compared	T052	C1707455
27594346	1551	1566	no intervention	T033	C0243095
27594346	1585	1589	cost	T081	C0010186
27594346	1592	1601	effective	T080	C1704419
27594346	1610	1621	incremental	T081	C1705117
27594346	1622	1626	cost	T081	C0010186
27594346	1629	1642	effectiveness	T080	C1280519
27594346	1643	1648	ratio	T081	C0456603
27594346	1659	1663	QALY	T079	C0080071
27594346	1670	1674	high	T080	C0205250
27594346	1675	1683	efficacy	T080	C1280519
27594346	1694	1702	programs	T169	C3484370
27594346	1711	1715	less	T080	C0205251
27594346	1716	1726	prevalence	T081	C0220900
27594346	1732	1737	fewer	T081	C1611820
27594346	1738	1744	deaths	T081	C0205848
27594346	1750	1755	lower	T080	C0205251
27594346	1756	1760	cost	T081	C0010186
27594346	1761	1769	compared	T052	C1707455
27594346	1773	1782	treatment	T061	C0087111
27594346	1790	1801	vaccination	T061	C0042196
27594346	1802	1810	programs	T169	C3484370
27594346	1812	1815	HDV	T005	C0011220
27594346	1842	1853	performance	T052	C1882330
27594346	1861	1864	HBV	T005	C0019169
27594346	1867	1874	related	T078	C1254370
27594346	1875	1887	intervention	T061	C0184661
27594346	1893	1902	exclusion	T052	C2828389
27594346	1937	1950	effectiveness	T080	C1280519
27594346	1954	1957	HBV	T005	C0019169
27594346	1958	1971	interventions	T061	C0184661

27720181|t|Association between ventricular filling patterns and the extent of late enhancement on magnetic resonance imaging in patients with hypertrophic cardiomyopathy
27720181|a|To explore the relationship between ventricular filling curves and the extent of late enhancement on cardiac magnetic resonance imaging (MRI) in patients with hypertrophic cardiomyopathy. We retrospectively included consecutive patients with suspected and/or confirmed hypertrophic cardiomyopathy and a control group of patients matched for age and sex who underwent cardiac MRI with evaluation of late enhancement. Among other determinations, we evaluated the following parameters on cine sequences: peak filling rate, time to the first peak filling rate, and filling rate normalized to the filling volume. Late enhancement was observed in 29 (73%) of the 40 patients with hypertrophic cardiomyopathy. The normalized peak filling rate was significantly lower in patients with late enhancement (4.9 ± 1.6 in those with hypertrophic cardiomyopathy positive for late enhancement vs. 5.8 ± 2.2 in those with hypertrophic cardiomyopathy negative for late enhancement vs. 6.3 ± 1.5 in controls, p = 0.008) and the time to peak filling was longer in patients with late enhancement (540.6 ± 89.7 ms vs. 505.5 ± 99.3 ms in those with hypertrophic cardiomyopathy negative for late enhancement vs. 486.9 ± 86.3 ms in controls, p = 0.02). When the population was stratified into three groups in function of the normalized peak filling rate, significant differences were observed among groups for age (p = 0.002), mean wall thickness (p = 0.036), and myocardial mass (p = 0.046) and atrial dimensions, whereas no significant differences with respect to late enhancement were seen. In patients with hypertrophic cardiomyopathy, we found a significant association between ventricular filling patterns and age, wall thicknesses, and atrial dimensions, but not with the extent of late enhancement.
27720181	0	11	Association	T080	C0439849
27720181	20	48	ventricular filling patterns	T034	C1254360
27720181	67	83	late enhancement	T060	C0079595
27720181	87	113	magnetic resonance imaging	T060	C0024485
27720181	117	125	patients	T101	C0030705
27720181	131	158	hypertrophic cardiomyopathy	T047	C0007194
27720181	195	221	ventricular filling curves	T034	C1254360
27720181	240	256	late enhancement	T060	C0079595
27720181	260	267	cardiac	T023	C0018787
27720181	268	294	magnetic resonance imaging	T060	C0024485
27720181	296	299	MRI	T060	C0024485
27720181	304	312	patients	T101	C0030705
27720181	318	345	hypertrophic cardiomyopathy	T047	C0007194
27720181	387	395	patients	T101	C0030705
27720181	428	455	hypertrophic cardiomyopathy	T047	C0007194
27720181	462	475	control group	T096	C0009932
27720181	479	487	patients	T101	C0030705
27720181	500	503	age	T032	C0001779
27720181	508	511	sex	T032	C1522384
27720181	526	533	cardiac	T023	C0018787
27720181	534	537	MRI	T060	C0024485
27720181	557	573	late enhancement	T060	C0079595
27720181	630	640	parameters	T033	C0449381
27720181	660	677	peak filling rate	T081	C1521828
27720181	679	714	time to the first peak filling rate	T081	C4284945
27720181	720	732	filling rate	T081	C1521828
27720181	751	765	filling volume	T081	C0449468
27720181	767	783	Late enhancement	T060	C0079595
27720181	819	827	patients	T101	C0030705
27720181	833	860	hypertrophic cardiomyopathy	T047	C0007194
27720181	877	894	peak filling rate	T081	C1521828
27720181	922	930	patients	T101	C0030705
27720181	936	952	late enhancement	T060	C0079595
27720181	978	1005	hypertrophic cardiomyopathy	T047	C0007194
27720181	1006	1014	positive	T033	C1446409
27720181	1019	1035	late enhancement	T060	C0079595
27720181	1064	1091	hypertrophic cardiomyopathy	T047	C0007194
27720181	1092	1100	negative	T033	C0205160
27720181	1105	1121	late enhancement	T060	C0079595
27720181	1168	1188	time to peak filling	T081	C4284945
27720181	1193	1199	longer	T080	C0205166
27720181	1203	1211	patients	T101	C0030705
27720181	1217	1233	late enhancement	T060	C0079595
27720181	1285	1312	hypertrophic cardiomyopathy	T047	C0007194
27720181	1313	1321	negative	T033	C0205160
27720181	1326	1342	late enhancement	T060	C0079595
27720181	1396	1406	population	T098	C1257890
27720181	1411	1421	stratified	T080	C0205363
27720181	1433	1439	groups	T078	C0441833
27720181	1470	1487	peak filling rate	T081	C1521828
27720181	1533	1539	groups	T078	C0441833
27720181	1544	1547	age	T032	C0001779
27720181	1561	1580	mean wall thickness	T034	C1254360
27720181	1598	1613	myocardial mass	T033	C4068707
27720181	1630	1647	atrial dimensions	T034	C1254360
27720181	1700	1716	late enhancement	T060	C0079595
27720181	1731	1739	patients	T101	C0030705
27720181	1745	1772	hypertrophic cardiomyopathy	T047	C0007194
27720181	1797	1808	association	T080	C0439849
27720181	1817	1845	ventricular filling patterns	T034	C1254360
27720181	1850	1853	age	T032	C0001779
27720181	1855	1871	wall thicknesses	T034	C1254360
27720181	1877	1894	atrial dimensions	T034	C1254360
27720181	1923	1939	late enhancement	T060	C0079595

27381890|t|Monosubstituted Benzene Derivatives from Fruits of Ficus hirta and Their Antifungal Activity against Phytopathogen Penicillium italicum
27381890|a|Ficus hirta, a widely consumed food by Hakka people, has been reported to show potent antifungal activity against phytopathogen Penicillium italicum. However, there is no report of chemical constituents responsible for the antifungal activity. In the current study, nine monosubstituted benzene derivatives, including three new derivatives (1-3), were isolated from the fruits of F. hirta. The structures of these isolates were elucidated on the basis of the analysis of spectroscopic data (mass spectrometry and nuclear magnetic resonance). All of the isolates were evaluated for antifungal activities against P. italicum. At an equivalent concentration, compound 1 exhibited stronger antifungal activity than that of the ethanol extract of F. hirta fruits.
27381890	0	35	Monosubstituted Benzene Derivatives	T109	C0005037
27381890	41	47	Fruits	T168	C0016767
27381890	51	62	Ficus hirta	T002	C1624432
27381890	73	92	Antifungal Activity	T033	C0243095
27381890	93	100	against	T080	C0521124
27381890	101	114	Phytopathogen	T001	C0450254
27381890	115	135	Penicillium italicum	T004	C1008772
27381890	136	147	Ficus hirta	T002	C1624432
27381890	167	171	food	T168	C0016452
27381890	175	180	Hakka	UnknownType	C0814942
27381890	181	187	people	T098	C0027361
27381890	198	206	reported	T058	C0700287
27381890	222	241	antifungal activity	T033	C0243095
27381890	242	249	against	T080	C0521124
27381890	250	263	phytopathogen	T001	C0450254
27381890	264	284	Penicillium italicum	T004	C1008772
27381890	307	313	report	T058	C0700287
27381890	317	338	chemical constituents	T167	C0729650
27381890	359	378	antifungal activity	T033	C0243095
27381890	395	400	study	T062	C2603343
27381890	407	442	monosubstituted benzene derivatives	T109	C0005037
27381890	464	475	derivatives	T104	C0243072
27381890	488	496	isolated	T169	C0205409
27381890	506	512	fruits	T168	C0016767
27381890	516	524	F. hirta	T002	C1624432
27381890	530	540	structures	T082	C0678594
27381890	550	558	isolates	T121	C1875400
27381890	582	587	basis	T169	C1527178
27381890	595	603	analysis	T062	C0936012
27381890	607	620	spectroscopic	T090	C2713504
27381890	621	625	data	T078	C1511726
27381890	627	644	mass spectrometry	T059	C0037813
27381890	649	675	nuclear magnetic resonance	T070	C0028580
27381890	689	697	isolates	T121	C1875400
27381890	703	712	evaluated	T058	C0220825
27381890	717	738	antifungal activities	T033	C0243095
27381890	739	746	against	T080	C0521124
27381890	747	758	P. italicum	T004	C1008772
27381890	766	776	equivalent	T081	C0439185
27381890	777	790	concentration	T081	C1446561
27381890	792	800	compound	T080	C0205198
27381890	813	821	stronger	T080	C0442821
27381890	822	841	antifungal activity	T033	C0243095
27381890	859	866	ethanol	T109,T121	C0001962
27381890	867	874	extract	T167	C2828366
27381890	878	886	F. hirta	T002	C1624432
27381890	887	893	fruits	T168	C0016767

28377738|t|Four-Dimensional Graded Consciousness
28377738|a|Both the multidimensional phenomenon and the polysemous notion of consciousness continue to prove resistant to consistent measurement and unambiguous definition. This is hardly surprising, given that there is no agreement even as regards the most fundamental issues they involve. One of the basic disagreements present in the continuing debate about consciousness pertains to its gradational nature. The general aim of this article is to show how consciousness might be graded and multidimensional at the same time. We therefore focus on the question of what it is, exactly, that is or could be graded in cases of consciousness, and how we can measure it. Ultimately, four different gradable aspects of consciousness will be described: quality, abstractness, complexity and usefulness, which belong to four different dimensions, these being understood, respectively, as phenomenal, semantic, physiological, and functional. Consequently, consciousness may be said to vary with respect to phenomenal quality, semantic abstraction, physiological complexity, and functional usefulness. It is hoped that such a four-dimensional approach will help to clarify and justify claims about the hierarchical nature of consciousness. The approach also proves explanatorily advantageous, as it enables us not only to draw attention to certain new and important differences in respect of subjective measures of awareness and to justify how a given creature may be ranked higher in one dimension of consciousness and lower in terms of another, but also allows for innovative explanations of a variety of well-known phenomena (amongst these, the interpretations of blindsight and locked-in syndrome will be briefly outlined here). Moreover, a 4D framework makes possible many predictions and hypotheses that may be experimentally tested (We point out a few such possibilities pertaining to interdimensional dependencies).
28377738	0	16	Four-Dimensional	T082	C2347299
28377738	17	23	Graded	T185	C0441800
28377738	24	37	Consciousness	T041	C0234421
28377738	47	63	multidimensional	T082	C2347299
28377738	64	74	phenomenon	T067	C1882365
28377738	83	100	polysemous notion	T080	C0205556
28377738	104	117	consciousness	T041	C0234421
28377738	136	145	resistant	T169	C0332325
28377738	149	159	consistent	T078	C0332290
28377738	160	171	measurement	T169	C0242485
28377738	176	198	unambiguous definition	T170	C1704788
28377738	247	259	no agreement	T033	C0243095
28377738	297	303	issues	T033	C0033213
28377738	335	348	disagreements	T054	C0012742
28377738	375	381	debate	T052	C0870392
28377738	388	401	consciousness	T041	C0234421
28377738	418	429	gradational	T185	C0441800
28377738	430	436	nature	T078	C0349590
28377738	462	469	article	T170	C1706852
28377738	485	498	consciousness	T041	C0234421
28377738	508	514	graded	T185	C0441800
28377738	519	535	multidimensional	T082	C2347299
28377738	548	552	time	T079	C0040223
28377738	580	588	question	T170	C1522634
28377738	633	639	graded	T185	C0441800
28377738	643	648	cases	T169	C0868928
28377738	652	665	consciousness	T041	C0234421
28377738	682	689	measure	T081	C0079809
28377738	721	729	gradable	T185	C0441800
28377738	730	737	aspects	T080	C1879746
28377738	741	754	consciousness	T041	C0234421
28377738	774	781	quality	T080	C0332306
28377738	783	795	abstractness	T170	C0679195
28377738	797	807	complexity	T041	C0237521
28377738	812	822	usefulness	T080	C3827682
28377738	855	865	dimensions	T081	C0439534
28377738	908	918	phenomenal	T080	C3898065
28377738	920	928	semantic	T078	C0036612
28377738	930	943	physiological	T169	C0205463
28377738	949	959	functional	T169	C0542341
28377738	975	988	consciousness	T041	C0234421
28377738	1025	1035	phenomenal	T080	C3898065
28377738	1036	1043	quality	T080	C0332306
28377738	1045	1053	semantic	T078	C0036612
28377738	1054	1065	abstraction	T170	C0679195
28377738	1067	1080	physiological	T169	C0205463
28377738	1081	1091	complexity	T041	C0237521
28377738	1097	1107	functional	T169	C0542341
28377738	1108	1118	usefulness	T080	C3827682
28377738	1144	1160	four-dimensional	T082	C2347299
28377738	1220	1239	hierarchical nature	T078	C0349590
28377738	1243	1256	consciousness	T041	C0234421
28377738	1262	1270	approach	T082	C0449445
28377738	1297	1309	advantageous	T080	C3898777
28377738	1345	1354	attention	T041	C0004268
28377738	1374	1383	important	T080	C3898777
28377738	1384	1395	differences	T080	C1705242
28377738	1410	1420	subjective	T080	C0205556
28377738	1421	1429	measures	T081	C0079809
28377738	1433	1442	awareness	T041	C0004448
28377738	1470	1478	creature	T008	C0003062
28377738	1486	1492	ranked	T170	C0699794
28377738	1493	1499	higher	T080	C0205250
28377738	1520	1533	consciousness	T041	C0234421
28377738	1585	1608	innovative explanations	T170	C0681841
28377738	1636	1645	phenomena	T067	C1882365
28377738	1666	1681	interpretations	T170	C0459471
28377738	1685	1695	blindsight	T080	C0205556
28377738	1700	1718	locked-in syndrome	T047	C0023944
28377738	1763	1765	4D	T082	C2347299
28377738	1796	1807	predictions	T078	C0681842
28377738	1812	1822	hypotheses	T078	C1512571
28377738	1835	1849	experimentally	T062	C0681814
28377738	1850	1856	tested	T169	C0039593
28377738	1910	1939	interdimensional dependencies	T169	C3244310

28286958|t|Construction of Fused Polyheterocycles through Sequential [4 + 2] and [3 + 2] Cycloadditions
28286958|a|A method for Pd - catalyzed aerobic oxidative reaction of quinazolinones and alkynes has been developed for sequential [4 + 2] and [3 + 2] cycloadditions to assemble a novel fused-polycyclic system containing tetrahydropyridine and dihydrofuran rings. The reaction process involves C-H and N-H bond functionalization for the formation of tetrahydropyridine and an oxygen radical cyclization for the dihydrofuran ring. This atom - and step- economical synthesis is highly efficient and has good substrate tolerance, which provides a new approach for the construction of polycyclic molecules with potential pharmaceutical interest.
28286958	0	12	Construction	T070	C0007987
28286958	16	38	Fused Polyheterocycles	T104	C1254350
28286958	47	57	Sequential	T080	C1705294
28286958	58	92	[4 + 2] and [3 + 2] Cycloadditions	T067	C0598128
28286958	106	108	Pd	T196	C0030230
28286958	111	120	catalyzed	T070	C0007382
28286958	121	128	aerobic	T080	C1510824
28286958	129	147	oxidative reaction	T044	C0030011
28286958	151	165	quinazolinones	T109	C1720912
28286958	170	177	alkynes	T109	C0002078
28286958	201	211	sequential	T080	C1705294
28286958	212	246	[4 + 2] and [3 + 2] cycloadditions	T067	C0598128
28286958	250	258	assemble	T052	C1706853
28286958	261	266	novel	T080	C0205314
28286958	267	290	fused-polycyclic system	T104	C1254350
28286958	302	320	tetrahydropyridine	T109	C0044607
28286958	325	343	dihydrofuran rings	T109	C0029224
28286958	349	365	reaction process	T067	C0596319
28286958	375	391	C-H and N-H bond	T044	C0813982
28286958	418	427	formation	T169	C1522492
28286958	431	449	tetrahydropyridine	T109	C0044607
28286958	457	471	oxygen radical	T121,T123,T196	C0030054
28286958	472	483	cyclization	T070	C0010546
28286958	492	509	dihydrofuran ring	T109	C0029224
28286958	516	520	atom	T196	C0567415
28286958	533	553	economical synthesis	T090	C0013556
28286958	587	596	substrate	T167	C3891814
28286958	597	606	tolerance	T080	C1704410
28286958	646	658	construction	T070	C0007987
28286958	662	682	polycyclic molecules	T104	C1254350
28286958	698	722	pharmaceutical interest.	T091	C0008003

27172917|t|Malignancy is associated with microcalcification and higher AP/T ratio in ultrasonography, but not with Hashimoto's thyroiditis in histopathology in patients with thyroid nodules evaluated as Bethesda Category III (AUS / FLUS) in cytology
27172917|a|The predictors of malignancy are important for the decision of appropriate management in nodules with atypia of undetermined significance / follicular lesion of undetermined significance (AUS / FLUS). Our aim was to determine the ultrasonographical, clinical, and biochemical predictors of malignancy in these patients. A total of 427 patients with cytologically Bethesda Category III (AUS / FLUS) thyroid nodules were included in this retrospective study. We divided the nodules into two subgroups according to the histopathology as benign and malignant, and compared the preoperative ultrasonographical, clinical, and biochemical findings. In overall, 427 patients with 449 AUS / FLUS nodules who had undergone surgery, the rate of malignancy was 23.4 % (105/449). When evaluated separately, the rate of malignancy was 25.8 % in nodules with AUS (82/318) and 17.6 % in nodules with FLUS (23/131) (p = 0.061). The vast majority of malignant specimens in histopathology consisted of papillary thyroid carcinoma (PTC) (n = 91, 86.7 %). Preoperative ultrasonographic features of 105 malignant nodules in histopathology were compared with the 344 benign nodules in histopathology. Anteroposterior/Transverse (AP/T) ratio was significantly higher in malignant group compared to benign group (p = 0.013). In multiple logistic analysis, we found that higher AP/T ratio and microcalcification were independently associated with malignancy (p < 0.05). The malignancy -associated cut-off value of AP/T ratio at maximum sensitivity and specificity was ≥0.81. We did not find any correlation between malignancy and Hashimoto's thyroiditis in histopathology in multivariate analysis (p > 0.05). In Bethesda Category III nodules with higher AP/T ratio and microcalcification, surgery might be considered as a first therapeutic option instead of repeat fine-needle aspiration biopsy or observation.
27172917	0	10	Malignancy	T191	C4282132
27172917	14	29	associated with	T080	C0332281
27172917	30	48	microcalcification	T046	C0521174
27172917	53	70	higher AP/T ratio	T081	C0456603
27172917	74	89	ultrasonography	T060	C0041618
27172917	104	127	Hashimoto's thyroiditis	T047	C0677607
27172917	131	145	histopathology	T059	C0430445
27172917	149	157	patients	T101	C0030705
27172917	163	178	thyroid nodules	T191	C0040137
27172917	192	213	Bethesda Category III	T191	C0040137
27172917	215	218	AUS	T049	C0522580
27172917	221	225	FLUS	T033	C1272585
27172917	230	238	cytology	T059	C1305671
27172917	243	253	predictors	T170	C0683956
27172917	257	267	malignancy	T191	C4282132
27172917	314	324	management	T058	C0376636
27172917	328	335	nodules	T191	C0040137
27172917	341	376	atypia of undetermined significance	T049	C0522580
27172917	379	425	follicular lesion of undetermined significance	T033	C1272585
27172917	427	430	AUS	T049	C0522580
27172917	433	437	FLUS	T033	C1272585
27172917	469	487	ultrasonographical	T170	C0683956
27172917	489	497	clinical	T170	C0683956
27172917	503	525	biochemical predictors	T170	C0683956
27172917	529	539	malignancy	T191	C4282132
27172917	549	557	patients	T101	C0030705
27172917	574	582	patients	T101	C0030705
27172917	588	623	cytologically Bethesda Category III	T191	C0040137
27172917	625	628	AUS	T049	C0522580
27172917	631	635	FLUS	T033	C1272585
27172917	637	652	thyroid nodules	T191	C0040137
27172917	675	694	retrospective study	T062	C0035363
27172917	711	718	nodules	T191	C0040137
27172917	728	737	subgroups	T098	C1257890
27172917	755	769	histopathology	T059	C0430445
27172917	773	779	benign	T080	C0205183
27172917	784	793	malignant	T080	C0205282
27172917	812	824	preoperative	T079	C0445204
27172917	825	843	ultrasonographical	T201	C1720195
27172917	845	853	clinical	T201	C3854293
27172917	859	879	biochemical findings	T033	C0243095
27172917	897	905	patients	T101	C0030705
27172917	915	918	AUS	T049	C0522580
27172917	921	925	FLUS	T033	C1272585
27172917	926	933	nodules	T191	C0040137
27172917	952	959	surgery	T061	C0543467
27172917	973	983	malignancy	T191	C4282132
27172917	1045	1055	malignancy	T191	C4282132
27172917	1070	1077	nodules	T191	C0040137
27172917	1083	1086	AUS	T049	C0522580
27172917	1110	1117	nodules	T191	C0040137
27172917	1123	1127	FLUS	T033	C1272585
27172917	1171	1190	malignant specimens	T077	C2347026
27172917	1194	1208	histopathology	T059	C0430445
27172917	1222	1249	papillary thyroid carcinoma	T191	C0238463
27172917	1251	1254	PTC	T191	C0238463
27172917	1274	1286	Preoperative	T079	C0445204
27172917	1287	1312	ultrasonographic features	T201	C1720195
27172917	1320	1337	malignant nodules	T191	C0040137
27172917	1341	1355	histopathology	T059	C0430445
27172917	1383	1397	benign nodules	T191	C0749467
27172917	1401	1415	histopathology	T059	C0430445
27172917	1417	1456	Anteroposterior/Transverse (AP/T) ratio	T081	C0456603
27172917	1485	1500	malignant group	T098	C1257890
27172917	1513	1525	benign group	T098	C1257890
27172917	1542	1568	multiple logistic analysis	T062	C0936012
27172917	1584	1601	higher AP/T ratio	T081	C0456603
27172917	1606	1624	microcalcification	T046	C0521174
27172917	1644	1659	associated with	T080	C0332281
27172917	1660	1670	malignancy	T191	C4282132
27172917	1687	1697	malignancy	T191	C4282132
27172917	1727	1737	AP/T ratio	T081	C0456603
27172917	1749	1776	sensitivity and specificity	T081	C0036668
27172917	1808	1819	correlation	T080	C1707520
27172917	1828	1838	malignancy	T191	C4282132
27172917	1843	1866	Hashimoto's thyroiditis	T047	C0677607
27172917	1870	1884	histopathology	T059	C0430445
27172917	1888	1909	multivariate analysis	T081	C0026777
27172917	1925	1954	Bethesda Category III nodules	T191	C0040137
27172917	1960	1977	higher AP/T ratio	T081	C0456603
27172917	1982	2000	microcalcification	T046	C0521174
27172917	2002	2009	surgery	T061	C0543467
27172917	2078	2107	fine-needle aspiration biopsy	T060	C1510483
27172917	2111	2122	observation	T062	C0302523

27551992|t|Engaging adolescent girls in transactional sex through compensated dating
27551992|a|Transactional sex through so-called compensated dating in adolescent girls is a problem in need of public concern. Compensated dating typically involves the use of information communication technology to advertise, search, bargain, and eventually arrange for transactional sex. The technology enables the sexual partners to maintain privacy and secrecy in transactional sex. Such secrecy necessitates the girls ' disclosure about their life experiences in order to address the concern. The disclosure is the focus of the present qualitative study of 27 girls practicing the dating in Hong Kong, China. Based on the disclosure, the study presents a grounded theory that epitomizes engagement in compensated dating by referential choice. Such a referential choice theory unravels that choice with reference to the family push and social norms sustains the engagement. Meanwhile, the choice rests on expectancy and reinforcement from experiential learning about compensated dating. The theory thus implies ways to undercut the engagement through diverting the referential choice of the dating.
27551992	0	8	Engaging	T033	C2937292
27551992	9	25	adolescent girls	T100	C0001588
27551992	29	46	transactional sex	T054	C0033595
27551992	47	54	through	T169	C0332273
27551992	55	66	compensated	T080	C0205432
27551992	67	73	dating	T054	C0237553
27551992	74	91	Transactional sex	T054	C0033595
27551992	92	99	through	T169	C0332273
27551992	110	121	compensated	T080	C0205432
27551992	122	128	dating	T054	C0237553
27551992	132	148	adolescent girls	T100	C0001588
27551992	154	161	problem	T033	C0033213
27551992	165	169	need	T080	C0027552
27551992	173	179	public	T092	C0678367
27551992	180	187	concern	T078	C2699424
27551992	189	200	Compensated	T080	C0205432
27551992	201	207	dating	T054	C0237553
27551992	231	237	use of	T169	C1524063
27551992	238	274	information communication technology	T170	C0683867
27551992	278	287	advertise	T057	C0001690
27551992	289	295	search	T052	C1706202
27551992	297	304	bargain	T054	C0871661
27551992	333	350	transactional sex	T054	C0033595
27551992	356	366	technology	T170	C0683867
27551992	367	374	enables	T041	C1171285
27551992	379	394	sexual partners	T098	C0036911
27551992	398	406	maintain	T052	C0024501
27551992	407	414	privacy	T078	C0080048
27551992	419	426	secrecy	T078	C0871315
27551992	430	447	transactional sex	T054	C0033595
27551992	454	461	secrecy	T078	C0871315
27551992	462	474	necessitates	T080	C0027552
27551992	479	484	girls	T098	C0043210
27551992	487	497	disclosure	T055	C0012625
27551992	510	526	life experiences	T067	C0023672
27551992	530	535	order	T080	C1705176
27551992	551	558	concern	T078	C2699424
27551992	564	574	disclosure	T055	C0012625
27551992	582	587	focus	T169	C1285542
27551992	603	620	qualitative study	T062	C0949415
27551992	627	632	girls	T098	C0043210
27551992	633	643	practicing	T041	C0237607
27551992	648	654	dating	T054	C0237553
27551992	658	667	Hong Kong	T083	C0019907
27551992	669	674	China	T083	C0008115
27551992	676	681	Based	T169	C1527178
27551992	689	699	disclosure	T055	C0012625
27551992	705	710	study	T062	C2603343
27551992	722	737	grounded theory	T170	C1510611
27551992	754	764	engagement	T033	C2937292
27551992	768	779	compensated	T080	C0205432
27551992	780	786	dating	T054	C0237553
27551992	790	808	referential choice	T055	C0008300
27551992	817	842	referential choice theory	T078	C0871935
27551992	857	863	choice	T055	C0008300
27551992	869	878	reference	T169	C0205543
27551992	886	892	family	T099	C0015576
27551992	893	897	push	T067	C0441722
27551992	902	914	social norms	T078	C0237750
27551992	915	923	sustains	T169	C0443318
27551992	928	938	engagement	T033	C2937292
27551992	955	961	choice	T055	C0008300
27551992	971	981	expectancy	T078	C0679138
27551992	986	999	reinforcement	T169	C0442805
27551992	1005	1026	experiential learning	T065	C0243012
27551992	1033	1044	compensated	T080	C0205432
27551992	1045	1051	dating	T054	C0237553
27551992	1057	1063	theory	T078	C0871935
27551992	1098	1108	engagement	T033	C2937292
27551992	1109	1116	through	T169	C0332273
27551992	1117	1126	diverting	T080	C0743226
27551992	1131	1149	referential choice	T055	C0008300
27551992	1157	1163	dating	T054	C0237553

27284491|t|Mutation profiles of synchronous colorectal cancers from a patient with Lynch syndrome suggest distinct oncogenic pathways
27284491|a|Patients with Lynch syndrome often present with multiple synchronous or metachronous colorectal cancers (CRCs). The presence of multiple CRCs with distinct genetic profiles and driver mutations could complicate treatment as each cancer may respond differently to therapy. Studies of sporadic CRCs suggested that synchronous tumors have distinct etiologies, but could not rule out differences in genetic background. The presence of multiple cancers in a patient with a predisposing mutation provides an opportunity to profile synchronous cancers in the same genetic background. Here, we describe the case of a patient with Lynch syndrome that presented with six synchronous CRCs. Microsatellite instability (MSI) and genomic profiling indicated that each lesion had a unique pattern of instability and a distinct profile of affected genes. These findings support the idea that in Lynch syndrome, synchronous CRCs can develop in parallel with distinct mutation profiles and that these differences may inform treatment decisions.
27284491	0	8	Mutation	T045	C0026882
27284491	9	17	profiles	T169	C2003903
27284491	21	32	synchronous	T191	C0027663
27284491	33	51	colorectal cancers	T191	C1527249
27284491	59	66	patient	T101	C0030705
27284491	72	86	Lynch syndrome	T191	C1333990
27284491	104	113	oncogenic	T191	C0596263
27284491	114	122	pathways	T077	C1705987
27284491	123	131	Patients	T101	C0030705
27284491	137	151	Lynch syndrome	T191	C1333990
27284491	171	191	multiple synchronous	T191	C0027663
27284491	195	207	metachronous	T191	C1334703
27284491	208	226	colorectal cancers	T191	C1527249
27284491	228	232	CRCs	T191	C1527249
27284491	251	259	multiple	T081	C0439064
27284491	260	264	CRCs	T191	C1527249
27284491	279	295	genetic profiles	T059	C2986505
27284491	307	316	mutations	T045	C0026882
27284491	323	333	complicate	T169	C0231242
27284491	334	343	treatment	T169	C0039798
27284491	352	358	cancer	T191	C0006826
27284491	363	370	respond	T032	C0871261
27284491	371	382	differently	T080	C1705242
27284491	386	393	therapy	T061	C0087111
27284491	406	414	sporadic	T033	C1853237
27284491	415	419	CRCs	T191	C1527249
27284491	435	453	synchronous tumors	T191	C0027663
27284491	459	478	distinct etiologies	T169	C0015127
27284491	518	536	genetic background	T032	C4042916
27284491	554	570	multiple cancers	T191	C0346429
27284491	576	583	patient	T101	C0030705
27284491	591	603	predisposing	T169	C0231203
27284491	604	612	mutation	T045	C0026882
27284491	625	636	opportunity	T062	C0683937
27284491	640	647	profile	T169	C2003903
27284491	648	667	synchronous cancers	T191	C0027663
27284491	680	698	genetic background	T032	C4042916
27284491	732	739	patient	T101	C0030705
27284491	745	759	Lynch syndrome	T191	C1333990
27284491	784	795	synchronous	T191	C0027663
27284491	796	800	CRCs	T191	C1527249
27284491	802	828	Microsatellite instability	T046	C0920269
27284491	830	833	MSI	T046	C0920269
27284491	839	856	genomic profiling	T059	C2986505
27284491	877	883	lesion	T033	C0221198
27284491	890	896	unique	T080	C1710548
27284491	897	904	pattern	T082	C0449774
27284491	908	919	instability	T033	C1444783
27284491	926	942	distinct profile	T169	C2003903
27284491	946	960	affected genes	T028	C0017337
27284491	968	976	findings	T169	C2607943
27284491	1002	1016	Lynch syndrome	T191	C1333990
27284491	1018	1034	synchronous CRCs	T191	C0027663
27284491	1073	1081	mutation	T045	C0026882
27284491	1082	1090	profiles	T169	C2003903
27284491	1129	1148	treatment decisions	T033	C4061230

27357607|t|Development of chrysin loaded poloxamer micelles and toxicity evaluation in fish embryos
27357607|a|Poloxamer micelles promise safety and efficacy for many water insoluble drugs. Chrysin has been reported to have anticancer, anti-inflammatory, antioxidant, and anti-aromatase activities but its water insoluble properties limit its pharmaceutical application. In the present study, chrysin loaded poloxamer micelles were developed. Two types of poloxamers, Pluronic F-68 and Pluronic F-127 were compared. It was found that chrysin loaded Pluronic F-68 micelles (CS-P68) and chrysin loaded Pluronic F-127 micelles (CS-P127) obviously increase the aqueous solubility of chrysin. The results also indicated that the type of polymer and ratio of drug to polymer affected size and desirable characteristics of the micelles. The micelle system of CS-P68 and CS-P127 formed at drug to polymer ratios of 1:4 and 1:2, respectively, was found to be the most suitable monodispersed system with a nanosize-range diameter. The in vivo study in zebrafish eggs indicates that the toxicity of CS-P68 and CS-P127 is a dose response. CS-P68 and CS-P127 at a drug dose of 10 ng/mL or less is safe for zebrafish embryo growth. The results of this study indicate enhanced water solubility of chrysin. Chrysin loaded poloxamer micelles are promising for further use in in vivo studies in mammalian animals and humans.
27357607	0	11	Development	T039	C0243107
27357607	15	22	chrysin	T109,T121	C0055661
27357607	30	39	poloxamer	T109,T122,T130	C0600615
27357607	53	61	toxicity	T080	C0040539
27357607	62	72	evaluation	T058	C0220825
27357607	76	80	fish	T013	C0016163
27357607	81	88	embryos	T018	C0013935
27357607	89	98	Poloxamer	T109,T122,T130	C0600615
27357607	99	107	micelles	T109	C0025938
27357607	99	107	micelles	T109	C0025938
27357607	116	122	safety	T068	C0036043
27357607	127	135	efficacy	T080	C1280519
27357607	145	150	water	T121,T197	C0043047
27357607	151	160	insoluble	T080	C0205556
27357607	161	166	drugs	T121	C0013227
27357607	168	175	Chrysin	T109,T121	C0055661
27357607	202	212	anticancer	T080	C2986475
27357607	214	231	anti-inflammatory	T080	C1515999
27357607	233	244	antioxidant	T039	C3179302
27357607	250	275	anti-aromatase activities	T044	C1148560
27357607	284	289	water	T121,T197	C0043047
27357607	290	299	insoluble	T080	C0205556
27357607	300	310	properties	T080	C0871161
27357607	321	347	pharmaceutical application	T091	C0039429
27357607	371	378	chrysin	T109,T121	C0055661
27357607	386	395	poloxamer	T109,T122,T130	C0600615
27357607	396	404	micelles	T109	C0025938
27357607	434	444	poloxamers	T109,T122,T130	C0600615
27357607	446	459	Pluronic F-68	T109	C0032254
27357607	464	478	Pluronic F-127	T109,T121	C0032253
27357607	512	519	chrysin	T109,T121	C0055661
27357607	527	540	Pluronic F-68	T109	C0032254
27357607	541	549	micelles	T109	C0025938
27357607	551	557	CS-P68	T109	C0025938
27357607	563	570	chrysin	T109,T121	C0055661
27357607	578	592	Pluronic F-127	T109,T121	C0032253
27357607	593	601	micelles	T109	C0025938
27357607	603	610	CS-P127	T109	C0025938
27357607	622	630	increase	T169	C0442805
27357607	635	642	aqueous	T080	C0599956
27357607	643	653	solubility	T080	C0037628
27357607	657	664	chrysin	T109,T121	C0055661
27357607	670	677	results	T169	C1274040
27357607	710	717	polymer	T104,T122	C0032521
27357607	731	735	drug	T121	C0013227
27357607	739	746	polymer	T104,T122	C0032521
27357607	756	760	size	T082	C0456389
27357607	775	790	characteristics	T080	C1521970
27357607	798	806	micelles	T109	C0025938
27357607	812	826	micelle system	T109	C0025938
27357607	830	836	CS-P68	T109	C0025938
27357607	841	848	CS-P127	T109	C0025938
27357607	859	863	drug	T121	C0013227
27357607	867	874	polymer	T104,T122	C0032521
27357607	875	881	ratios	T081	C0456603
27357607	974	997	nanosize-range diameter	T081	C1301886
27357607	1003	1016	in vivo study	T062	C0681829
27357607	1020	1029	zebrafish	T013	C0043457
27357607	1030	1034	eggs	T025	C0029974
27357607	1054	1062	toxicity	T080	C0040539
27357607	1066	1072	CS-P68	T109	C0025938
27357607	1077	1084	CS-P127	T109	C0025938
27357607	1090	1103	dose response	T078	C1546996
27357607	1105	1111	CS-P68	T109	C0025938
27357607	1116	1123	CS-P127	T109	C0025938
27357607	1129	1138	drug dose	T081	C0678766
27357607	1154	1158	less	T080	C0547044
27357607	1171	1180	zebrafish	T013	C0043457
27357607	1181	1187	embryo	T018	C0013935
27357607	1188	1194	growth	T040	C0018270
27357607	1216	1221	study	T062	C2603343
27357607	1231	1239	enhanced	T052	C2349975
27357607	1240	1256	water solubility	T081	C0597682
27357607	1260	1267	chrysin	T109,T121	C0055661
27357607	1269	1276	Chrysin	T109,T121	C0055661
27357607	1284	1293	poloxamer	T109,T122,T130	C0600615
27357607	1294	1302	micelles	T109	C0025938
27357607	1336	1351	in vivo studies	T062	C0681829
27357607	1355	1364	mammalian	T015	C0024660
27357607	1365	1372	animals	T008	C0003062
27357607	1377	1383	humans	T016	C0086418

27610437|t|Test result audit and feedback (TRAFk) as a supervision method for rational test ordering in general practice training
27610437|a|The use of medical investigations is increasing, with most testing occurring in primary care. The interpretation of test results is challenging for general practice registrars. Additionally, emerging evidence suggests that over-testing is a significant problem and has the potential for patient harm. Test result audit and feedback (TRAFk) is a teaching and supervision method in general practice training, but no previous studies have investigated its utility. The objective of this article is to describe the outcomes of an educational intervention for general practice supervisors on TRAFk. We developed and delivered a workshop to general practice supervisors and administered pre- and post-workshop surveys. Of the 54 supervisors who participated in the study, a substantial proportion (79.6%) used TRAFk after the workshop. Participants highly rated the method across a range of supervision areas, including clinical reasoning, test ordering quality and patient safety. Our findings reinforce the educational utility of this supervision method in general practice training for the teaching and assessment of registrars.
27610437	0	30	Test result audit and feedback	T170	C0282574
27610437	32	37	TRAFk	T170	C0282574
27610437	44	62	supervision method	T170	C0025663
27610437	67	80	rational test	T170	C0392366
27610437	81	89	ordering	UnknownType	C0683313
27610437	93	118	general practice training	T065	C0220931
27610437	130	137	medical	T169	C0205476
27610437	138	152	investigations	T058	C0220825
27610437	178	185	testing	T169	C0039593
27610437	199	211	primary care	T058	C0033137
27610437	217	231	interpretation	T170	C0459471
27610437	235	247	test results	T034	C0456984
27610437	267	294	general practice registrars	T097	C0401974
27610437	319	327	evidence	T078	C3887511
27610437	342	354	over-testing	T169	C0039593
27610437	372	379	problem	T033	C0033213
27610437	406	418	patient harm	T080	C3658342
27610437	420	450	Test result audit and feedback	T170	C0282574
27610437	452	457	TRAFk	T170	C0282574
27610437	464	472	teaching	T065	C0039403
27610437	477	495	supervision method	T170	C0025663
27610437	499	524	general practice training	T065	C0220931
27610437	630	638	outcomes	T169	C1274040
27610437	645	669	educational intervention	T061	C0281163
27610437	674	702	general practice supervisors	T097	C0403172
27610437	706	711	TRAFk	T170	C0282574
27610437	742	750	workshop	T065	C0242262
27610437	754	782	general practice supervisors	T097	C0403172
27610437	800	822	pre- and post-workshop	T065	C0242262
27610437	823	830	surveys	T170	C0038951
27610437	842	853	supervisors	T097	C0403172
27610437	887	909	substantial proportion	T081	C1709707
27610437	923	928	TRAFk	T170	C0282574
27610437	939	947	workshop	T065	C0242262
27610437	949	961	Participants	T098	C0679646
27610437	979	985	method	T170	C0025663
27610437	1004	1021	supervision areas	T082	C0205146
27610437	1033	1041	clinical	T080	C0205210
27610437	1042	1051	reasoning	T041	C0684328
27610437	1053	1057	test	T170	C0392366
27610437	1058	1066	ordering	UnknownType	C0683313
27610437	1067	1074	quality	T080	C0332306
27610437	1079	1093	patient safety	T058	C1113679
27610437	1122	1141	educational utility	T065	C0013652
27610437	1150	1168	supervision method	T170	C0025663
27610437	1172	1197	general practice training	T065	C0220931
27610437	1206	1214	teaching	T065	C0220924
27610437	1219	1229	assessment	T058	C0220825
27610437	1233	1243	registrars	T097	C0401974

27315518|t|Ag nanoclusters could efficiently quench the photoresponse of CdS quantum dots for novel energy transfer -based photoelectrochemical bioanalysis
27315518|a|Herein the influence of ultrasmall Ag nanoclusters (Ag NCs) against CdS quantum dots (QDs) in a photoelectrochemical (PEC) nanosystem was exploited for the first time, based on which a novel PEC bioanalysis was successfully developed via the efficient quenching effect of Ag NCs against the CdS QDs. In a model system, DNA assay was achieved by using molecular beacon (MB) probes anchored on a CdS QDs modified electrode, and the MB probes contain two segments that can hybridize with both target DNA sequence and the label of DNA encapsulated Ag NCs. After the MB probe was unfolded by the target DNA sequence, the labels of oligonucleotide encapsulated Ag NCs would be brought in close proximity to the CdS QDs electrode surface, and efficient photocurrent quenching of QDs could be resulted from an energy transfer process that originated from NCs. Thus, by monitoring the attenuation in the photocurrent signal, an elegant and sensitive PEC DNA bioanalysis could be accomplished. The developed biosensor displayed a linear range from 1.0pM to 10nM and the detection limit was experimentally found to be of 0.3pM. This work presents a feasible signaling principle that could act as a common basis for general PEC bioanalysis development.
27315518	0	2	Ag	T196	C0037125
27315518	3	15	nanoclusters	T073	C1450053
27315518	22	33	efficiently	T080	C0442799
27315518	34	40	quench	T043	C3546682
27315518	45	58	photoresponse	T067	C1254366
27315518	62	65	CdS	T131,T197	C0054417
27315518	66	78	quantum dots	T073	C1258084
27315518	89	104	energy transfer	T044	C0014274
27315518	112	144	photoelectrochemical bioanalysis	UnknownType	C0259857
27315518	180	182	Ag	T196	C0037125
27315518	183	195	nanoclusters	T073	C1450053
27315518	197	199	Ag	T196	C0037125
27315518	200	203	NCs	T073	C1450053
27315518	213	216	CdS	T131,T197	C0054417
27315518	217	229	quantum dots	T073	C1258084
27315518	231	234	QDs	T073	C1258084
27315518	241	261	photoelectrochemical	UnknownType	C0259857
27315518	263	266	PEC	UnknownType	C0259857
27315518	268	278	nanosystem	T073	C1450053
27315518	336	351	PEC bioanalysis	UnknownType	C0259857
27315518	356	368	successfully	T080	C1272703
27315518	369	378	developed	T169	C1527148
27315518	387	396	efficient	T080	C0442799
27315518	397	406	quenching	T043	C3546682
27315518	417	419	Ag	T196	C0037125
27315518	420	423	NCs	T073	C1450053
27315518	436	439	CdS	T131,T197	C0054417
27315518	440	443	QDs	T073	C1258084
27315518	450	462	model system	T075	C0026336
27315518	464	473	DNA assay	T059	C0201794
27315518	496	512	molecular beacon	T114	C1254348
27315518	514	516	MB	T114	C1254348
27315518	518	524	probes	T074	C0182400
27315518	525	533	anchored	T061	C1293132
27315518	539	542	CdS	T131,T197	C0054417
27315518	543	546	QDs	T073	C1258084
27315518	556	565	electrode	T073	C1705652
27315518	575	577	MB	T114	C1254348
27315518	578	584	probes	T074	C0182400
27315518	615	624	hybridize	T067	C1254366
27315518	635	641	target	T169	C1521840
27315518	642	654	DNA sequence	T086	C0162326
27315518	663	668	label	T073	C0181496
27315518	672	675	DNA	T114,T123	C0012854
27315518	676	688	encapsulated	T080	C0205223
27315518	689	691	Ag	T196	C0037125
27315518	692	695	NCs	T073	C1450053
27315518	707	709	MB	T114	C1254348
27315518	710	715	probe	T074	C0182400
27315518	736	742	target	T169	C1521840
27315518	743	755	DNA sequence	T086	C0162326
27315518	761	767	labels	T073	C0181496
27315518	771	786	oligonucleotide	T114	C0028953
27315518	787	799	encapsulated	T080	C0205223
27315518	800	802	Ag	T196	C0037125
27315518	803	806	NCs	T073	C1450053
27315518	833	842	proximity	T082	C1514583
27315518	850	853	CdS	T131,T197	C0054417
27315518	854	857	QDs	T073	C1258084
27315518	858	875	electrode surface	T073	C1705652
27315518	881	890	efficient	T080	C0442799
27315518	891	913	photocurrent quenching	T067	C1254366
27315518	917	920	QDs	T073	C1258084
27315518	930	938	resulted	T169	C1274040
27315518	947	962	energy transfer	T044	C0014274
27315518	963	970	process	T067	C1522240
27315518	992	995	NCs	T073	C1450053
27315518	1006	1016	monitoring	T058	C1283169
27315518	1021	1032	attenuation	T052	C0599946
27315518	1040	1059	photocurrent signal	T067	C1710082
27315518	1076	1085	sensitive	T169	C0332324
27315518	1086	1089	PEC	UnknownType	C0259857
27315518	1090	1105	DNA bioanalysis	T059	C0200898
27315518	1133	1142	developed	T169	C1527148
27315518	1143	1152	biosensor	T075	C0600364
27315518	1153	1162	displayed	T169	C0870432
27315518	1165	1171	linear	T082	C0205132
27315518	1172	1177	range	T081	C1514721
27315518	1205	1214	detection	T061	C1511790
27315518	1215	1220	limit	T078	C1549649
27315518	1225	1239	experimentally	T080	C1517586
27315518	1240	1245	found	T033	C0150312
27315518	1267	1271	work	T057	C0043227
27315518	1302	1311	principle	UnknownType	C0678989
27315518	1357	1372	PEC bioanalysis	UnknownType	C0259857
27315518	1373	1384	development	T169	C1527148

27347474|t|Online public reactions to frequency of diagnostic errors in US outpatient care
27347474|a|Diagnostic errors pose a significant threat to patient safety but little is known about public perceptions of diagnostic errors. A study published in BMJ Quality & Safety in 2014 estimated that diagnostic errors affect at least 5% of US adults (or 12 million) per year. We sought to explore online public reactions to media reports on the reported frequency of diagnostic errors in the US adult population. We searched the World Wide Web for any news article reporting findings from the study. We then gathered all the online comments made in response to the news articles to evaluate public reaction to the newly reported diagnostic error frequency (n=241). Two coders conducted content analyses of the comments and an experienced qualitative researcher resolved differences. Overall, there were few comments made regarding the frequency of diagnostic errors. However, in response to the media coverage, 44 commenters shared personal experiences of diagnostic errors. Additionally, commentary centered on diagnosis - related quality of care as affected by two emergent categories: (1) US health care providers (n=79; 63 commenters) and (2) US health care reform-related policies, most commonly the Affordable Care Act (ACA) and insurance/reimbursement issues (n=62; 47 commenters). The public appears to have substantial concerns about the impact of the ACA and other reform initiatives on the diagnosis - related quality of care. However, policy discussions on diagnostic errors are largely absent from the current national conversation on improving quality and safety. Because outpatient diagnostic errors have emerged as a major safety concern, researchers and policymakers should consider evaluating the effects of policy and practice changes on diagnostic accuracy.
27347474	0	23	Online public reactions	T033	C0243095
27347474	27	36	frequency	T079	C0439603
27347474	40	57	diagnostic errors	T080	C0011922
27347474	61	63	US	T083	C0041703
27347474	64	79	outpatient care	T073,T093	C4035927
27347474	80	97	Diagnostic errors	T080	C0011922
27347474	117	123	threat	T078	C0749385
27347474	127	141	patient safety	T058	C1113679
27347474	168	174	public	T092	C0678367
27347474	175	186	perceptions	T041	C0030971
27347474	190	207	diagnostic errors	T080	C0011922
27347474	211	216	study	T062	C2603343
27347474	217	226	published	T057	C0034037
27347474	230	250	BMJ Quality & Safety	T170	C0282574
27347474	274	291	diagnostic errors	T080	C0011922
27347474	314	316	US	T083	C0041703
27347474	317	323	adults	T100	C0001675
27347474	340	348	per year	T079	C0439508
27347474	371	394	online public reactions	T033	C0243095
27347474	398	403	media	T170	C0009458
27347474	404	411	reports	T170	C0684224
27347474	428	437	frequency	T079	C0439603
27347474	441	458	diagnostic errors	T080	C0011922
27347474	466	468	US	T083	C0041703
27347474	469	474	adult	T100	C0001675
27347474	475	485	population	T081	C0032659
27347474	503	517	World Wide Web	T073	C0282111
27347474	526	530	news	T170	C0282425
27347474	531	538	article	T170	C1706852
27347474	549	557	findings	T169	C2607943
27347474	567	572	study	T062	C2603343
27347474	599	605	online	T073,T170	C0029038
27347474	606	614	comments	T170	C0947611
27347474	623	631	response	T170	C1706817
27347474	639	643	news	T170	C0282425
27347474	644	652	articles	T170	C1706852
27347474	656	664	evaluate	T058	C0220825
27347474	665	680	public reaction	T033	C0243095
27347474	703	719	diagnostic error	T080	C0011922
27347474	720	729	frequency	T079	C0439603
27347474	743	749	coders	T097	C1554661
27347474	760	776	content analyses	T062	C0681915
27347474	784	792	comments	T170	C0947611
27347474	800	811	experienced	T041	C0596545
27347474	812	823	qualitative	T080	C0205556
27347474	824	834	researcher	T097	C0035173
27347474	835	843	resolved	T033	C3714811
27347474	844	855	differences	T080	C1705242
27347474	881	889	comments	T170	C0947611
27347474	909	918	frequency	T079	C0439603
27347474	922	939	diagnostic errors	T080	C0011922
27347474	953	961	response	T170	C1706817
27347474	969	983	media coverage	T057	C0681284
27347474	988	998	commenters	T097	C1522486
27347474	1006	1026	personal experiences	T055	C0683573
27347474	1030	1047	diagnostic errors	T080	C0011922
27347474	1063	1073	commentary	T170	C0282411
27347474	1086	1095	diagnosis	T080	C1704338
27347474	1098	1105	related	T169	C1552599
27347474	1106	1121	quality of care	T058	C0034379
27347474	1150	1160	categories	T170	C0683312
27347474	1166	1168	US	T083	C0041703
27347474	1169	1190	health care providers	T097	C0018724
27347474	1201	1211	commenters	T097	C1522486
27347474	1221	1223	US	T083	C0041703
27347474	1224	1259	health care reform-related policies	T089	C0018735
27347474	1279	1298	Affordable Care Act	T089	C2936611
27347474	1300	1303	ACA	T089	C2936611
27347474	1309	1339	insurance/reimbursement issues	T090	C1512805
27347474	1350	1360	commenters	T097	C1522486
27347474	1367	1373	public	T092	C0678367
27347474	1390	1410	substantial concerns	T078	C2699424
27347474	1421	1427	impact	T080	C4049986
27347474	1435	1438	ACA	T089	C2936611
27347474	1449	1467	reform initiatives	T041	C0424093
27347474	1475	1484	diagnosis	T080	C1704338
27347474	1487	1494	related	T169	C1552599
27347474	1495	1510	quality of care	T058	C0034379
27347474	1521	1527	policy	T170	C0242456
27347474	1528	1539	discussions	T054	C2584313
27347474	1543	1560	diagnostic errors	T080	C0011922
27347474	1573	1579	absent	T169	C0332197
27347474	1597	1618	national conversation	T054	C0871703
27347474	1632	1639	quality	T080	C0332306
27347474	1644	1650	safety	T068	C0036043
27347474	1660	1670	outpatient	T101	C0029921
27347474	1671	1688	diagnostic errors	T080	C0011922
27347474	1713	1719	safety	T068	C0036043
27347474	1720	1727	concern	T078	C2699424
27347474	1729	1740	researchers	T097	C0035173
27347474	1745	1757	policymakers	T097	C1522486
27347474	1774	1784	evaluating	T058	C0220825
27347474	1789	1799	effects of	T080	C1704420
27347474	1800	1806	policy	T170	C0242456
27347474	1811	1819	practice	T041	C0032893
27347474	1820	1827	changes	T169	C0392747
27347474	1831	1850	diagnostic accuracy	T080	C0598285

28263460|t|Asunaprevir: An HCV Protease Inhibitor With Preferential Liver Distribution
28263460|a|Asunaprevir is an inhibitor of the hepatitis C virus (HCV) NS3/4A protease, demonstrating efficacy in clinical studies in patients infected with HCV genotype 1 or 4, with either peginterferon / ribavirin or combinations of direct-acting antivirals. Because of preferential distribution of asunaprevir to the liver via organic anion-transporting polypeptide (OATP)- mediated transport, asunaprevir demonstrates high apparent oral clearance and very low plasma concentrations. Asunaprevir plasma concentrations are markedly increased by single-dose rifampin (an OATP inhibitor) and in subjects with moderate to severe hepatic impairment. In addition, modestly higher plasma concentrations of asunaprevir have been noted in subjects infected with HCV relative to healthy subjects and in Asian subjects relative to whites. At the marketed dose, infrequent hepatic transaminase abnormalities were poorly predicted by plasma concentrations. For a compound with these characteristics, hepatic concentrations may have provided an improved understanding of the in vivo pharmacokinetic and pharmacodynamic data to support decision making during development.
28263460	0	11	Asunaprevir	T109,T121	C3491974
28263460	16	38	HCV Protease Inhibitor	T121	C4049839
28263460	57	62	Liver	T023	C0023884
28263460	63	75	Distribution	T039	C1378698
28263460	76	87	Asunaprevir	T109,T121	C3491974
28263460	94	150	inhibitor of the hepatitis C virus (HCV) NS3/4A protease	T121	C4049839
28263460	166	174	efficacy	T080	C1280519
28263460	178	194	clinical studies	T062	C0008972
28263460	198	206	patients	T101	C0030705
28263460	207	215	infected	T033	C0439663
28263460	221	235	HCV genotype 1	T005	C3532919
28263460	239	240	4	T005	C3532922
28263460	254	267	peginterferon	T116,T121,T129	C0982327
28263460	270	279	ribavirin	T114,T121	C0035525
28263460	283	295	combinations	T121	C0013162
28263460	299	323	direct-acting antivirals	T121	C3653501
28263460	336	361	preferential distribution	T039	C1378698
28263460	365	376	asunaprevir	T109,T121	C3491974
28263460	384	389	liver	T023	C0023884
28263460	394	432	organic anion-transporting polypeptide	T116,T123	C0949791
28263460	434	438	OATP	T116,T123	C0949791
28263460	441	459	mediated transport	T043	C0700215
28263460	461	472	asunaprevir	T109,T121	C3491974
28263460	500	504	oral	T030	C0226896
28263460	505	514	clearance	T080	C0449297
28263460	528	549	plasma concentrations	T081	C0683150
28263460	551	562	Asunaprevir	T109,T121	C3491974
28263460	563	584	plasma concentrations	T081	C0683150
28263460	598	607	increased	T081	C0205217
28263460	611	622	single-dose	T081	C0178602
28263460	623	631	rifampin	T109,T195	C0035608
28263460	636	640	OATP	T116,T123	C0949791
28263460	641	650	inhibitor	T080	C1999216
28263460	659	667	subjects	T098	C0080105
28263460	685	691	severe	T080	C0205082
28263460	692	710	hepatic impairment	T047	C0948807
28263460	741	762	plasma concentrations	T081	C0683150
28263460	766	777	asunaprevir	T109,T121	C3491974
28263460	797	805	subjects	T098	C0080105
28263460	806	814	infected	T033	C0439663
28263460	820	823	HCV	T005	C0220847
28263460	836	852	healthy subjects	T098	C1708335
28263460	860	865	Asian	T098	C0078988
28263460	866	874	subjects	T098	C0080105
28263460	887	893	whites	T098	C0080105
28263460	911	915	dose	T081	C0178602
28263460	917	927	infrequent	T079	C0521114
28263460	928	935	hepatic	T029	C0205054
28263460	936	948	transaminase	T116,T126	C0002594
28263460	949	962	abnormalities	T033	C0151625
28263460	988	1009	plasma concentrations	T081	C0683150
28263460	1017	1025	compound	T080	C0205198
28263460	1037	1052	characteristics	T080	C1521970
28263460	1054	1061	hepatic	T029	C0205054
28263460	1062	1076	concentrations	T081	C1446561
28263460	1128	1135	in vivo	T082	C1515655
28263460	1136	1151	pharmacokinetic	T062	C0201734
28263460	1156	1171	pharmacodynamic	T062	C1709518
28263460	1172	1176	data	T078	C1511726
28263460	1211	1222	development	T091	C0872152

28360224|t|Ultrasound evaluation of diaphragm function in mechanically ventilated patients: comparison to phrenic stimulation and prognostic implications
28360224|a|In intensive care unit (ICU) patients, diaphragm dysfunction is associated with adverse clinical outcomes. Ultrasound measurements of diaphragm thickness, excursion (EXdi) and thickening fraction (TFdi) are putative estimators of diaphragm function, but have never been compared with phrenic nerve stimulation. Our aim was to describe the relationship between these variables and diaphragm function evaluated using the change in endotracheal pressure after phrenic nerve stimulation (Ptr,stim), and to compare their prognostic value. Between November 2014 and June 2015, Ptr,stim and ultrasound variables were measured in mechanically ventilated patients <24 hours after intubation (' initiation of mechanical ventilation (MV)', under assist-control ventilation, ACV) and at the time of switch to pressure support ventilation ('switch to PSV '), and compared using Spearman's correlation and receiver operating characteristic curve analysis. Diaphragm dysfunction was defined as Ptr,stim <11 cm H2O. 112 patients were included. At initiation of MV, Ptr,stim was not correlated to diaphragm thickness (p=0.28), EXdi (p=0.66) or TFdi (p=0.80). At switch to PSV, TFdi and EXdi were respectively very strongly and moderately correlated to Ptr,stim, (r=0.87, p<0.001 and 0.45, p=0.001), but diaphragm thickness was not (p=0.45). A TFdi <29% could reliably identify diaphragm dysfunction (sensitivity and specificity of 85% and 88%), but diaphragm thickness and EXdi could not. This value was associated with increased duration of ICU stay and MV, and mortality. Under ACV, diaphragm thickness, EXdi and TFdi were uncorrelated to Ptr,stim. Under PSV, TFdi was strongly correlated to diaphragm strength and both were predictors of remaining length of MV and ICU and hospital death.
28360224	0	10	Ultrasound	T060	C0041618
28360224	11	21	evaluation	T058	C0220825
28360224	25	43	diaphragm function	T042	C0678866
28360224	47	70	mechanically ventilated	T061	C0199470
28360224	71	79	patients	T101	C0030705
28360224	95	114	phrenic stimulation	T061	C4291858
28360224	119	129	prognostic	T170	C0220901
28360224	146	180	intensive care unit (ICU) patients	T058	C0010337
28360224	182	203	diaphragm dysfunction	T047	C0152097
28360224	223	230	adverse	T046	C0879626
28360224	231	248	clinical outcomes	T169	C1274040
28360224	250	273	Ultrasound measurements	T060	C0430022
28360224	277	286	diaphragm	T023	C0011980
28360224	287	296	thickness	T080	C1280412
28360224	298	307	excursion	T184	C0232086
28360224	309	313	EXdi	T184	C0232086
28360224	319	338	thickening fraction	T033	C0243095
28360224	340	344	TFdi	T033	C0243095
28360224	373	391	diaphragm function	T042	C0678866
28360224	427	452	phrenic nerve stimulation	T061	C4291858
28360224	523	541	diaphragm function	T042	C0678866
28360224	572	593	endotracheal pressure	T033	C0243095
28360224	600	625	phrenic nerve stimulation	T061	C4291858
28360224	627	635	Ptr,stim	T061	C4291858
28360224	659	675	prognostic value	T081	C0449821
28360224	714	722	Ptr,stim	T061	C4291858
28360224	727	737	ultrasound	T060	C0041618
28360224	765	788	mechanically ventilated	T061	C0199470
28360224	789	797	patients	T101	C0030705
28360224	814	824	intubation	T061	C0021925
28360224	828	864	initiation of mechanical ventilation	T061	C2065087
28360224	866	868	MV	T061	C2065087
28360224	878	904	assist-control ventilation	T061	C2223981
28360224	906	909	ACV	T061	C2223981
28360224	940	968	pressure support ventilation	T061	C2223980
28360224	981	984	PSV	T061	C2223980
28360224	1008	1030	Spearman's correlation	T170	C0282574
28360224	1035	1083	receiver operating characteristic curve analysis	T081	C0035787
28360224	1085	1106	Diaphragm dysfunction	T047	C0152097
28360224	1122	1130	Ptr,stim	T061	C4291858
28360224	1147	1155	patients	T101	C0030705
28360224	1174	1190	initiation of MV	T061	C2065087
28360224	1192	1200	Ptr,stim	T061	C4291858
28360224	1223	1232	diaphragm	T023	C0011980
28360224	1233	1242	thickness	T080	C1280412
28360224	1253	1257	EXdi	T184	C0232086
28360224	1270	1274	TFdi	T033	C0243095
28360224	1298	1301	PSV	T061	C2223980
28360224	1303	1307	TFdi	T033	C0243095
28360224	1312	1316	EXdi	T184	C0232086
28360224	1378	1386	Ptr,stim	T061	C4291858
28360224	1429	1438	diaphragm	T023	C0011980
28360224	1439	1448	thickness	T080	C1280412
28360224	1469	1473	TFdi	T033	C0243095
28360224	1503	1524	diaphragm dysfunction	T047	C0152097
28360224	1575	1584	diaphragm	T023	C0011980
28360224	1585	1594	thickness	T080	C1280412
28360224	1599	1603	EXdi	T184	C0232086
28360224	1668	1671	ICU	T073,T093	C0021708
28360224	1672	1676	stay	T079	C3489408
28360224	1681	1683	MV	T061	C0199470
28360224	1689	1698	mortality	T081	C0205848
28360224	1706	1709	ACV	T061	C2223981
28360224	1711	1720	diaphragm	T023	C0011980
28360224	1721	1730	thickness	T080	C1280412
28360224	1732	1736	EXdi	T184	C0232086
28360224	1741	1745	TFdi	T033	C0243095
28360224	1767	1775	Ptr,stim	T061	C4291858
28360224	1783	1786	PSV	T061	C2223980
28360224	1788	1792	TFdi	T033	C0243095
28360224	1820	1829	diaphragm	T023	C0011980
28360224	1830	1838	strength	T042	C0517349
28360224	1887	1889	MV	T061	C2065087
28360224	1894	1897	ICU	T073,T093	C0021708
28360224	1902	1916	hospital death	T033	C0277608

27312487|t|Osteopontin expression in co-cultures of human squamous cell carcinoma -derived cells and osteoblastic cells and its effects on the neoplastic cell phenotype and osteoclastic activation
27312487|a|This study evaluated the temporal expression of osteopontin (OPN) in co-cultures of human osteoblastic cells (SAOS-2) and oral squamous cell carcinoma (OSCC)-derived cells (SCC9) and examined the effects of osteoblast -derived OPN on the neoplastic cell phenotype. Additionally, the effects of these co-cultures on subsequent osteoclastic activity were explored. SCC9 cells were plated on Transwell® membranes that were either coated or not coated with Matrigel and were then co-cultured with SAOS-2 cells during the peak of OPN expression. SCC9 cells exposed to OPN -silenced SAOS-2 cultures and SCC9 cells cultured alone served as controls. SCC9 cells were quantitatively evaluated for cell adhesion, proliferation, migration, and invasion into Matrigel. The impact of co-culturing SAOS-2 and SCC9 cells on the resorptive capacity of U-937 -derived osteoclastic cells was also investigated. Furthermore, a reciprocal induction of SAOS-2 and SCC9 cells in terms of OPN expression over the co-culture interval was identified. SAOS-2 -secreted OPN altered the SCC9 cell phenotype, leading to enhanced cell adhesion and proliferation and higher Matrigel invasion. This invasion was also enhanced, albeit to a lesser degree, by co-culture with OPN - silenced SAOS-2 cells. Cell migration was not affected. Co-culture with SAOS-2 cells -mainly during the period of peak OPN expression -promoted over-expression of IL-6 and IL-8 by SCC9 cells and enhanced the resorptive capacity of osteoclastic cells. Taken together, these results suggest that osteoblast -derived OPN affects the interactions among OSCC -derived epithelial cells, osteoblasts, and osteoclasts, which could contribute to the process of bone destruction during bone invasion by OSCC.
27312487	0	11	Osteopontin	T116,T123	C0069676
27312487	12	22	expression	T045	C1171362
27312487	26	37	co-cultures	T025	C0007600
27312487	41	46	human	T016	C0086418
27312487	47	70	squamous cell carcinoma	T191	C0007137
27312487	80	85	cells	T025	C0085983
27312487	90	108	osteoblastic cells	T025	C0029418
27312487	117	124	effects	T080	C1280500
27312487	132	147	neoplastic cell	T025	C0597032
27312487	148	157	phenotype	T032	C1318444
27312487	162	174	osteoclastic	T025	C0029431
27312487	175	185	activation	T043	C1326120
27312487	191	196	study	T062	C2603343
27312487	197	206	evaluated	T169	C1292732
27312487	211	219	temporal	T079	C2362314
27312487	220	230	expression	T045	C1171362
27312487	234	245	osteopontin	T116,T123	C0069676
27312487	247	250	OPN	T116,T123	C0069676
27312487	255	266	co-cultures	T025	C0007600
27312487	270	275	human	T016	C0086418
27312487	276	294	osteoblastic cells	T025	C0029418
27312487	296	302	SAOS-2	T025	C0029418
27312487	308	336	oral squamous cell carcinoma	T191	C0585362
27312487	338	342	OSCC	T191	C0585362
27312487	352	357	cells	T025	C0085983
27312487	359	363	SCC9	T025	C0085983
27312487	369	377	examined	T033	C0332128
27312487	382	389	effects	T080	C1280500
27312487	393	403	osteoblast	T025	C0029418
27312487	413	416	OPN	T116,T123	C0069676
27312487	424	439	neoplastic cell	T025	C0597032
27312487	440	449	phenotype	T032	C1318444
27312487	469	476	effects	T080	C1280500
27312487	486	497	co-cultures	T025	C0007600
27312487	512	524	osteoclastic	T025	C0029431
27312487	525	533	activity	T043	C0007613
27312487	549	559	SCC9 cells	T025	C0085983
27312487	575	595	Transwell® membranes	T073	C1706182
27312487	613	619	coated	T080	C1522408
27312487	639	647	Matrigel	T116,T130	C0065749
27312487	662	673	co-cultured	T059	C0007585
27312487	679	691	SAOS-2 cells	T025	C0029418
27312487	711	714	OPN	T116,T123	C0069676
27312487	715	725	expression	T045	C1171362
27312487	727	737	SCC9 cells	T025	C0085983
27312487	749	752	OPN	T116,T123	C0069676
27312487	763	769	SAOS-2	T025	C0029418
27312487	770	778	cultures	T025	C0007600
27312487	783	793	SCC9 cells	T025	C0085983
27312487	794	802	cultured	T059	C0007585
27312487	819	827	controls	T096	C0009932
27312487	829	839	SCC9 cells	T025	C0085983
27312487	845	869	quantitatively evaluated	T081	C0034384
27312487	874	887	cell adhesion	T043	C0007577
27312487	889	902	proliferation	T043	C0596290
27312487	904	913	migration	T043	C1622501
27312487	919	927	invasion	T046	C2699153
27312487	933	941	Matrigel	T116,T130	C0065749
27312487	957	969	co-culturing	T059	C0007585
27312487	970	976	SAOS-2	T025	C0029418
27312487	981	991	SCC9 cells	T025	C0085983
27312487	1022	1027	U-937	T025	C0600531
27312487	1037	1055	osteoclastic cells	T025	C0029431
27312487	1065	1077	investigated	T169	C1292732
27312487	1094	1104	reciprocal	T080	C1882911
27312487	1105	1114	induction	T169	C0205263
27312487	1118	1124	SAOS-2	T025	C0029418
27312487	1129	1139	SCC9 cells	T025	C0085983
27312487	1152	1155	OPN	T116,T123	C0069676
27312487	1156	1166	expression	T045	C1171362
27312487	1176	1186	co-culture	T025	C0007600
27312487	1212	1218	SAOS-2	T025	C0029418
27312487	1229	1232	OPN	T116,T123	C0069676
27312487	1245	1254	SCC9 cell	T025	C0085983
27312487	1255	1264	phenotype	T032	C1318444
27312487	1277	1285	enhanced	T081	C0205217
27312487	1286	1299	cell adhesion	T043	C0007577
27312487	1304	1317	proliferation	T043	C0596290
27312487	1329	1337	Matrigel	T116,T130	C0065749
27312487	1338	1346	invasion	T046	C2699153
27312487	1353	1361	invasion	T046	C2699153
27312487	1411	1421	co-culture	T025	C0007600
27312487	1427	1430	OPN	T028	C2987232
27312487	1433	1441	silenced	T045	C0598496
27312487	1442	1454	SAOS-2 cells	T025	C0029418
27312487	1456	1470	Cell migration	T043	C1622501
27312487	1489	1499	Co-culture	T025	C0007600
27312487	1505	1517	SAOS-2 cells	T025	C0029418
27312487	1552	1555	OPN	T116,T123	C0069676
27312487	1556	1566	expression	T045	C1171362
27312487	1577	1592	over-expression	T045	C1171362
27312487	1596	1600	IL-6	T116,T129	C0021760
27312487	1605	1609	IL-8	T116,T129	C0079633
27312487	1613	1623	SCC9 cells	T025	C0085983
27312487	1641	1651	resorptive	T052	C1948029
27312487	1664	1682	osteoclastic cells	T025	C0029431
27312487	1706	1713	results	T033	C0683954
27312487	1727	1737	osteoblast	T025	C0029418
27312487	1747	1750	OPN	T116,T123	C0069676
27312487	1751	1758	affects	T169	C0392760
27312487	1763	1775	interactions	T043	C0007582
27312487	1782	1786	OSCC	T191	C0585362
27312487	1796	1812	epithelial cells	T025	C0014597
27312487	1814	1825	osteoblasts	T025	C0029418
27312487	1831	1842	osteoclasts	T025	C0029431
27312487	1874	1881	process	T067	C1522240
27312487	1885	1901	bone destruction	T047	C0238790
27312487	1909	1913	bone	T023	C0262950
27312487	1914	1922	invasion	T046	C2699153
27312487	1926	1930	OSCC	T191	C0585362

28536123|t|Randomized Controlled Trial of Mineralocorticoid Receptor Blockade in Children with Chronic Kidney Allograft Nephropathy
28536123|a|We showed that mineralocorticoid receptor blockade (MRB) prevented acute and chronic cyclosporine nephropathy (CsA-Nx) in the rat. The aim of this translational study was to investigate the effect of long-term eplerenone administration on renal allograft function in children with biopsy -proven chronic allograft nephropathy (CAN). Renal transplant children <18 years, biopsy -proven CAN, and a GFR >40 ml/min per 1.73 m(2) were included. Patients with BK virus active nephritis, recurrence of renal disease, GFR decline in previous 3 months, or treated with calcium antagonists or antifungal drugs were excluded. They were randomized to receive placebo (n=10) or eplerenone 25 mg/d for 24 months (n=13). Visits were scheduled at baseline, 6, 12, and 24 months. At each period, a complete clinical examination was performed and blood and urine samples were taken. Urine creatinine, 8-hydroxylated-guanosine, heat shock protein 72 (HSP72), and kidney injury molecule (KIM-1) levels were also assessed. In kidney biopsy samples, the tubulo-interstitial area affected by fibrosis (TIF) and glomerulosclerosis were measured at baseline and after 24 months. The baseline eGFR was 80±6 in the placebo and 86±6 ml/min per 1.73 m(2) in the eplerenone group; at 24 months it was 66±8 and 81±7 ml/min per 1.73 m(2), respectively (P=0.33; 95% confidence intervals, -18 to 33 at baseline, and -11 to 40 after 24 months). The albumin-to-creatinine ratio was 110±74 in the placebo, and 265±140 mg/g in the eplerenone group; and after 24 months it was 276±140 and 228±88 mg/g, respectively (P=0.15; 95% confidence intervals, -283 to 593, and -485 to 391, respectively). In addition, the placebo exhibited a greater TIF, glomerulosclerosis, and urinary HSP72 compared with the eplerenone group. Although this study was underpowered to provide definitive evidence that long-term eplerenone administration attenuates the progression of CAN in pediatric transplant patients, it encourages testing the potential benefit of MRB in this pediatric population.
28536123	31	57	Mineralocorticoid Receptor	T116,T192	C0066563
28536123	58	66	Blockade	T121,T196	C3540676
28536123	70	78	Children	T100	C0008059
28536123	84	120	Chronic Kidney Allograft Nephropathy	T047	C0403592
28536123	136	162	mineralocorticoid receptor	T116,T192	C0066563
28536123	163	171	blockade	T121,T196	C3540676
28536123	173	177	MRB)	T121,T196	C3540676
28536123	188	193	acute	T079	C0205178
28536123	198	230	chronic cyclosporine nephropathy	T047	C3875332
28536123	232	238	CsA-Nx	T047	C3875332
28536123	247	250	rat	T015	C0034693
28536123	268	287	translational study	T062	C3494163
28536123	331	341	eplerenone	T109,T121	C0961485
28536123	342	356	administration	T061	C1533734
28536123	360	375	renal allograft	T023	C0564454
28536123	388	396	children	T100	C0008059
28536123	402	408	biopsy	T060	C0005558
28536123	417	446	chronic allograft nephropathy	T047	C0403592
28536123	448	451	CAN	T047	C0403592
28536123	454	470	Renal transplant	T061	C0022671
28536123	471	479	children	T100	C0008059
28536123	484	489	years	T079	C0439234
28536123	491	497	biopsy	T060	C0005558
28536123	506	509	CAN	T047	C0403592
28536123	517	520	GFR	T060	C0017654
28536123	561	569	Patients	T101	C0030705
28536123	575	583	BK virus	T005	C0005670
28536123	591	600	nephritis	T047	C0027697
28536123	616	629	renal disease	T047	C0022658
28536123	631	642	GFR decline	T033	C0853068
28536123	657	663	months	T079	C0439231
28536123	668	680	treated with	T061	C0332293
28536123	681	700	calcium antagonists	T121	C0006684
28536123	704	720	antifungal drugs	T121	C0003308
28536123	768	775	placebo	T061	C0032042
28536123	786	796	eplerenone	T109,T121	C0961485
28536123	812	818	months	T079	C0439231
28536123	852	860	baseline	T081	C1442488
28536123	876	882	months	T079	C0439231
28536123	892	898	period	T079	C1948053
28536123	911	931	clinical examination	T033	C1456356
28536123	950	955	blood	T031	C0178913
28536123	960	973	urine samples	T031	C1610733
28536123	986	1002	Urine creatinine	T059	C1318439
28536123	1004	1028	8-hydroxylated-guanosine	T114,T121	C0050092
28536123	1030	1051	heat shock protein 72	T116,T123	C0256926
28536123	1053	1058	HSP72	T116,T123	C0256926
28536123	1065	1102	kidney injury molecule (KIM-1) levels	T059	C2681921
28536123	1126	1147	kidney biopsy samples	T024	C0586763
28536123	1153	1198	tubulo-interstitial area affected by fibrosis	T060	C4285457
28536123	1200	1203	TIF	T060	C4285457
28536123	1209	1227	glomerulosclerosis	T047	C0178664
28536123	1245	1253	baseline	T081	C1442488
28536123	1267	1273	months	T079	C0439231
28536123	1279	1287	baseline	T081	C1442488
28536123	1288	1292	eGFR	T060	C0017654
28536123	1309	1316	placebo	T098	C1257890
28536123	1354	1370	eplerenone group	T098	C1257890
28536123	1378	1384	months	T079	C0439231
28536123	1454	1474	confidence intervals	T081	C0009667
28536123	1489	1497	baseline	T081	C1442488
28536123	1522	1528	months	T079	C0439231
28536123	1535	1562	albumin-to-creatinine ratio	T034	C1318293
28536123	1581	1588	placebo	T098	C1257890
28536123	1614	1630	eplerenone group	T098	C1257890
28536123	1645	1651	months	T079	C0439231
28536123	1710	1730	confidence intervals	T081	C0009667
28536123	1794	1801	placebo	T061	C0032042
28536123	1822	1825	TIF	T060	C4285457
28536123	1827	1845	glomerulosclerosis	T047	C0178664
28536123	1851	1858	urinary	T031	C0042036
28536123	1859	1864	HSP72	T116,T123	C0256926
28536123	1915	1920	study	T062	C2603343
28536123	1984	1994	eplerenone	T109,T121	C0961485
28536123	1995	2009	administration	T061	C1533734
28536123	2040	2043	CAN	T047	C0403592
28536123	2047	2076	pediatric transplant patients	T101	C0030705
28536123	2125	2128	MRB	T121,T196	C3540676
28536123	2137	2157	pediatric population	T098	C1257890

28418943|t|Loss of control over alcohol seeking in rats depends on individual vulnerability and duration of alcohol consumption experience
28418943|a|Alcohol use disorder (AUD) is characterized by excessive alcohol use and persistent alcohol seeking despite knowledge of its negative consequences. Importantly, AUD typically develops after chronic excessive alcohol use in a subgroup of individuals who drink alcohol, suggesting that AUD results from an interaction between individual vulnerability and prolonged alcohol exposure. The present study assessed the contribution of prolonged exposure to alcohol and individual levels of alcohol intake to the development of loss of control over alcohol seeking in a conditioned suppression model. To investigate the impact of prolonged alcohol exposure, conditioned suppression of alcohol seeking was assessed after 2 and 4 months of intermittent alcohol access (IAA) in a subgroup of rats drinking moderate amounts of alcohol. We observed that suppression of alcohol seeking was reduced after 4 months compared with 2 months of IAA. The influence of individual levels of alcohol intake on loss of control over alcohol seeking was subsequently determined by assessing conditioned suppression in subgroups of low and high alcohol drinking rats. Unlike the low alcohol drinking rats, the high alcohol drinking rats showed aversion-resistant alcohol seeking after 2 months of IAA, although both groups showed comparable levels of conditioned freezing. These findings show that the development of loss of control over alcohol seeking, a key characteristic of AUD in humans, is dependent on both the extent of alcohol exposure and the individual's propensity to consume alcohol.
28418943	0	15	Loss of control	T080	C0243148
28418943	21	36	alcohol seeking	UnknownType	C0813934
28418943	40	44	rats	T015	C0086893
28418943	56	66	individual	T098	C0237401
28418943	67	80	vulnerability	T033	C1821973
28418943	97	116	alcohol consumption	T055	C0001948
28418943	128	148	Alcohol use disorder	T048	C0001956
28418943	150	153	AUD	T048	C0001956
28418943	175	196	excessive alcohol use	T033	C0560219
28418943	201	211	persistent	T079	C0205322
28418943	212	227	alcohol seeking	UnknownType	C0813934
28418943	289	292	AUD	T048	C0001956
28418943	318	325	chronic	T079	C0205191
28418943	326	347	excessive alcohol use	T033	C0560219
28418943	353	361	subgroup	T185	C1515021
28418943	365	376	individuals	T098	C0237401
28418943	381	394	drink alcohol	T033	C3842894
28418943	412	415	AUD	T048	C0001956
28418943	432	443	interaction	T169	C1704675
28418943	452	462	individual	T098	C0237401
28418943	463	476	vulnerability	T033	C1821973
28418943	481	507	prolonged alcohol exposure	T051	C4038778
28418943	521	526	study	T062	C2603343
28418943	527	535	assessed	T052	C1516048
28418943	556	585	prolonged exposure to alcohol	T051	C4038778
28418943	590	625	individual levels of alcohol intake	T055	C0001948
28418943	633	644	development	T169	C1527148
28418943	648	663	loss of control	T080	C0243148
28418943	669	684	alcohol seeking	UnknownType	C0813934
28418943	690	719	conditioned suppression model	T170	C3161035
28418943	724	735	investigate	T169	C1292732
28418943	750	776	prolonged alcohol exposure	T051	C4038778
28418943	778	801	conditioned suppression	T169	C1260953
28418943	805	820	alcohol seeking	UnknownType	C0813934
28418943	825	833	assessed	T052	C1516048
28418943	858	885	intermittent alcohol access	T079	C1254367
28418943	887	890	IAA	T079	C1254367
28418943	897	905	subgroup	T185	C1515021
28418943	909	913	rats	T015	C0086893
28418943	969	980	suppression	T169	C1260953
28418943	984	999	alcohol seeking	UnknownType	C0813934
28418943	1053	1056	IAA	T079	C1254367
28418943	1062	1071	influence	T077	C4054723
28418943	1096	1110	alcohol intake	T055	C0001948
28418943	1114	1129	loss of control	T080	C0243148
28418943	1135	1150	alcohol seeking	UnknownType	C0813934
28418943	1168	1181	determined by	T080	C0521095
28418943	1182	1191	assessing	T052	C1516048
28418943	1192	1215	conditioned suppression	T169	C1260953
28418943	1219	1228	subgroups	T185	C1515021
28418943	1232	1261	low and high alcohol drinking	T080	C0205556
28418943	1262	1266	rats	T015	C0086893
28418943	1279	1299	low alcohol drinking	T080	C0205556
28418943	1300	1304	rats	T015	C0086893
28418943	1310	1331	high alcohol drinking	T080	C0205556
28418943	1332	1336	rats	T015	C0086893
28418943	1344	1362	aversion-resistant	T169	C0332325
28418943	1363	1378	alcohol seeking	UnknownType	C0813934
28418943	1397	1400	IAA	T079	C1254367
28418943	1416	1422	groups	T078	C0441833
28418943	1517	1532	loss of control	T080	C0243148
28418943	1538	1553	alcohol seeking	UnknownType	C0813934
28418943	1579	1582	AUD	T048	C0001956
28418943	1586	1592	humans	T016	C0086418
28418943	1629	1645	alcohol exposure	T051	C4038778
28418943	1654	1666	individual's	T098	C0237401

27237301|t|Clinical value of pathologic examination of non-neoplastic kidney in patients with upper urinary tract malignancies
27237301|a|While surgical resection remains the standard of care in the treatment of upper urinary tract malignancies, nephrectomy is a risk factor for the development of chronic kidney disease (CKD). The aim of this study was to determine whether histologic evaluation of non-neoplastic kidney could enable early identification of unrecognized kidney disease and could be of prognostic value in predicting postoperative renal outcomes. We retrospectively analyzed 51 patients with upper urinary tract malignancies who received uninephrectomy or uninephroureterectomy. A thorough pathologic evaluation of non-neoplastic kidney including special stains, immunofluorescence, and electron microscopic studies was performed. The degree of parenchymal changes was graded from 0 to 15. Of 51 patients, only 13 showed normal kidney pathology. Fifteen patients showed glomerular abnormalities, 14 showed diabetic nephropathy, and 11 showed vascular nephropathy. There was one case each of reflux nephropathy and chronic pyelonephritis. The median histologic score was 5 points. Only 25.4% of patients had ≤ 3 points. Score more than 5 was observed in 47.1% of patients. Postoperative estimated glomerular filtration rate (eGFR) at 3 to 36 months were obtained from 90.2% of patients, and of those, 34.8% had de novo CKD. Since no one had CKD in partial nephrectomized patients, we determined risk factors for CKD in radical nephrectomized patients. Cox regression analysis revealed that postoperative AKI, preoperative eGFR, and histologic score of non-neoplastic kidney were the independent predictors for CKD. We conclude that routine pathologic evaluation of non-neoplastic kidney provides valuable diagnostic and prognostic information.
27237301	0	14	Clinical value	T033	C2826293
27237301	18	40	pathologic examination	T060	C4086729
27237301	44	65	non-neoplastic kidney	T023	C0022646
27237301	69	77	patients	T101	C0030705
27237301	83	102	upper urinary tract	T022	C1278977
27237301	103	115	malignancies	T191	C4282132
27237301	122	140	surgical resection	T061	C0728940
27237301	165	169	care	T052	C1947933
27237301	177	186	treatment	T061	C0087111
27237301	190	209	upper urinary tract	T022	C1278977
27237301	210	222	malignancies	T191	C4282132
27237301	224	235	nephrectomy	T061	C0027695
27237301	241	252	risk factor	T033	C0035648
27237301	261	272	development	T169	C1527148
27237301	276	298	chronic kidney disease	T047	C1561643
27237301	300	303	CKD	T047	C1561643
27237301	322	327	study	T062	C2603343
27237301	353	363	histologic	T169	C0205462
27237301	364	374	evaluation	T058	C0220825
27237301	378	399	non-neoplastic kidney	T023	C0022646
27237301	413	433	early identification	T061	C0814435
27237301	450	464	kidney disease	T047	C0022658
27237301	481	491	prognostic	T170	C0220901
27237301	512	525	postoperative	T079	C0032790
27237301	526	531	renal	T023	C0022646
27237301	532	540	outcomes	T080	C0085415
27237301	545	569	retrospectively analyzed	T062	C0035363
27237301	573	581	patients	T101	C0030705
27237301	587	606	upper urinary tract	T022	C1278977
27237301	607	619	malignancies	T191	C4282132
27237301	633	647	uninephrectomy	T061	C0027695
27237301	651	672	uninephroureterectomy	T061	C0027732
27237301	685	695	pathologic	T169	C1521733
27237301	696	706	evaluation	T058	C0220825
27237301	710	731	non-neoplastic kidney	T023	C0022646
27237301	742	756	special stains	T061	C2038188
27237301	758	776	immunofluorescence	T059	C0079603
27237301	782	810	electron microscopic studies	T059	C0026019
27237301	830	836	degree	T081	C0449286
27237301	840	851	parenchymal	T023	C0933845
27237301	852	859	changes	T169	C0392747
27237301	891	899	patients	T101	C0030705
27237301	923	929	kidney	T023	C0022646
27237301	930	939	pathology	T091	C0030664
27237301	949	957	patients	T101	C0030705
27237301	965	989	glomerular abnormalities	T047	C1398788
27237301	1001	1021	diabetic nephropathy	T047	C0011881
27237301	1037	1045	vascular	T023	C0005847
27237301	1046	1057	nephropathy	T061	C0027695
27237301	1086	1104	reflux nephropathy	T047	C3495566
27237301	1109	1131	chronic pyelonephritis	T047	C0085697
27237301	1144	1160	histologic score	T081	C0449820
27237301	1189	1197	patients	T101	C0030705
27237301	1214	1219	Score	T081	C0449820
27237301	1257	1265	patients	T101	C0030705
27237301	1267	1280	Postoperative	T079	C0032790
27237301	1281	1317	estimated glomerular filtration rate	T059	C3811844
27237301	1319	1323	eGFR	T059	C3811844
27237301	1336	1342	months	T079	C0439231
27237301	1371	1379	patients	T101	C0030705
27237301	1413	1416	CKD	T047	C1561643
27237301	1435	1438	CKD	T047	C1561643
27237301	1450	1473	nephrectomized patients	T101	C0030705
27237301	1489	1501	risk factors	T033	C0035648
27237301	1506	1509	CKD	T047	C1561643
27237301	1521	1544	nephrectomized patients	T101	C0030705
27237301	1546	1569	Cox regression analysis	T170	C0034980
27237301	1584	1597	postoperative	T079	C0032790
27237301	1598	1601	AKI	T037	C2609414
27237301	1603	1615	preoperative	T079	C0445204
27237301	1616	1620	eGFR	T059	C3811844
27237301	1626	1636	histologic	T169	C0205462
27237301	1646	1667	non-neoplastic kidney	T023	C0022646
27237301	1689	1699	predictors	T078	C2698872
27237301	1704	1707	CKD	T047	C1561643
27237301	1734	1744	pathologic	T169	C1521733
27237301	1745	1755	evaluation	T058	C0220825
27237301	1759	1780	non-neoplastic kidney	T023	C0022646
27237301	1799	1809	diagnostic	T169	C0348026
27237301	1814	1824	prognostic	T170	C0220901

27599297|t|Detection of busulfan adducts on proteins
27599297|a|Busulfan is a bifunctional alkyl sulfonate antineoplastic drug. This alkylating agent was described as forming covalent adducts on proteins. However, only limited data are available regarding the interaction of busulfan with proteins. Mass spectrometry and bioinformatics were used to identify busulfan adducts on human serum albumin and hemoglobin. Albumin and hemoglobin were incubated with busulfan or control compounds, digested with trypsin and analyzed by LC-MS / MS on a Thermo Fisher LTQ Orbitrap Velos Pro. MS data were used to generate spectral libraries of non-modified peptides and an open modification search was performed to identify potential adduct mass shifts and possible modification sites. Results were confirmed by a second database search including identified mass shifts and by visual inspection of annotated tandem mass spectra of adduct -carrying peptides. Five structures of busulfan adducts were detected and a chemical structure could be attributed to four of them. Two were primary adducts corresponding to busulfan monoalkylation and alkylation of two amino acid residues by a single busulfan molecule. Two others corresponded to secondary adducts generated during sample processing. Adducts were mainly detected on Asp, Glu, and His residues. These findings were confirmed by subsequent database searches and experiments with synthetic peptides. The combination of in vitro incubation of proteins with the drug of interest or control compounds, high-resolution mass spectrometry, and open modification search allowed confirming direct interaction of busulfan with proteins and characterizing resulting adducts. Our results also showed that careful analysis of the data is required to detect experimental artifacts.
27599297	0	9	Detection	T061	C1511790
27599297	13	21	busulfan	T109,T121,T131	C0006463
27599297	22	29	adducts	T104	C0596040
27599297	33	41	proteins	T116,T123	C0033684
27599297	42	50	Busulfan	T109,T121,T131	C0006463
27599297	69	84	alkyl sulfonate	T109	C0002072
27599297	85	104	antineoplastic drug	T109,T121	C0003392
27599297	111	127	alkylating agent	T121,T131	C0002073
27599297	153	161	covalent	T044	C1511539
27599297	162	169	adducts	T104	C0596040
27599297	173	181	proteins	T116,T123	C0033684
27599297	238	249	interaction	T044	C0687133
27599297	253	261	busulfan	T109,T121,T131	C0006463
27599297	267	275	proteins	T116,T123	C0033684
27599297	277	294	Mass spectrometry	T059	C0037813
27599297	299	313	bioinformatics	T091	C1140694
27599297	336	344	busulfan	T109,T121,T131	C0006463
27599297	345	352	adducts	T104	C0596040
27599297	356	361	human	T016	C0086418
27599297	362	375	serum albumin	T116	C0036773
27599297	380	390	hemoglobin	T116,T123	C0019046
27599297	392	399	Albumin	T116,T123	C0001924
27599297	404	414	hemoglobin	T116,T123	C0019046
27599297	420	429	incubated	T059	C1439852
27599297	435	443	busulfan	T109,T121,T131	C0006463
27599297	447	464	control compounds	T121	C1254351
27599297	466	474	digested	T039	C0868946
27599297	480	487	trypsin	T116,T121,T126	C0041236
27599297	504	509	LC-MS	T059	C0872318
27599297	512	514	MS	T059	C0037813
27599297	520	556	Thermo Fisher LTQ Orbitrap Velos Pro	T073	C0699733
27599297	558	560	MS	T059	C0037813
27599297	561	565	data	T078	C1511726
27599297	597	606	libraries	T116,T130	C0376436
27599297	623	631	peptides	T116	C0030956
27599297	644	656	modification	T169	C0392747
27599297	657	663	search	T052	C1706202
27599297	700	706	adduct	T104	C0596040
27599297	732	744	modification	T169	C0392747
27599297	787	795	database	T170	C0242356
27599297	796	802	search	T052	C1706202
27599297	843	860	visual inspection	T058	C3669138
27599297	874	893	tandem mass spectra	T063	C0599748
27599297	897	903	adduct	T104	C0596040
27599297	914	922	peptides	T116	C0030956
27599297	929	939	structures	T082	C0678594
27599297	943	951	busulfan	T109,T121,T131	C0006463
27599297	952	959	adducts	T104	C0596040
27599297	980	998	chemical structure	T170	C0220807
27599297	1053	1060	adducts	T104	C0596040
27599297	1078	1086	busulfan	T109,T121,T131	C0006463
27599297	1087	1101	monoalkylation	T070	C0002074
27599297	1106	1116	alkylation	T070	C0002074
27599297	1124	1143	amino acid residues	T116,T121,T123	C0002520
27599297	1156	1164	busulfan	T109,T121,T131	C0006463
27599297	1212	1219	adducts	T104	C0596040
27599297	1237	1243	sample	T167	C0370003
27599297	1244	1254	processing	T052	C1709694
27599297	1256	1263	Adducts	T104	C0596040
27599297	1288	1291	Asp	T116,T123	C0004015
27599297	1293	1296	Glu	T116,T121,T123	C0061472
27599297	1302	1314	His residues	T116,T121,T123	C0019602
27599297	1322	1330	findings	T033	C0243095
27599297	1360	1368	database	T170	C0242356
27599297	1369	1377	searches	T052	C1706202
27599297	1382	1393	experiments	T062	C0681814
27599297	1399	1417	synthetic peptides	T116	C0597551
27599297	1423	1434	combination	T080	C0205195
27599297	1438	1446	in vitro	T080	C1533691
27599297	1447	1457	incubation	T059	C1439852
27599297	1461	1469	proteins	T116,T123	C0033684
27599297	1479	1483	drug	T121	C1254351
27599297	1499	1516	control compounds	T121	C1254351
27599297	1518	1551	high-resolution mass spectrometry	T059	C0037813
27599297	1562	1574	modification	T169	C0392747
27599297	1575	1581	search	T052	C1706202
27599297	1608	1619	interaction	T044	C0687133
27599297	1623	1631	busulfan	T109,T121,T131	C0006463
27599297	1637	1645	proteins	T116,T123	C0033684
27599297	1675	1682	adducts	T104	C0596040
27599297	1721	1729	analysis	T062	C0936012
27599297	1737	1741	data	T078	C1511726
27599297	1777	1786	artifacts	T068	C0085089

28152285|t|Correction
28152285|a|In an interview with Fresenius Medical Care chief medical officer Frank Maddux, MD in the July issue of NN&l ("CMO looks at ways to put meaning behind 'quality care'"), we asked Dr. Maddux if he believed that patients wanted more engagement at home via telehealth with their caregivers. His response should have read, 'For many of our patients, it's not about diagnosing the disease. It is about preventing the known crises events from occurring ." The original printed response had read, "...it is about preventing the non-crisis events from occurring ."
28152285	0	10	Correction	T170	C1705565
28152285	17	26	interview	T052	C0021822
28152285	32	54	Fresenius Medical Care	T093	C3824689
28152285	55	60	chief	T097	C1709473
28152285	61	76	medical officer	T097	C0557516
28152285	77	89	Frank Maddux	T170	C0282574
28152285	91	178	MD in the July issue of NN&l ("CMO looks at ways to put meaning behind 'quality care'")	T170	C0282574
28152285	189	199	Dr. Maddux	T170	C0282574
28152285	206	214	believed	T080	C1272684
28152285	220	228	patients	T101	C0030705
28152285	241	251	engagement	T079	C0003629
28152285	255	259	home	T082	C0442519
28152285	264	274	telehealth	T058	C1328956
28152285	286	296	caregivers	T097	C0085537
28152285	302	310	response	T170	C1706817
28152285	323	327	read	T056	C0034754
28152285	346	354	patients	T101	C0030705
28152285	371	381	diagnosing	T033	C0011900
28152285	386	393	disease	T047	C0012634
28152285	407	417	preventing	T169	C1292733
28152285	422	427	known	T080	C0205309
28152285	428	434	crises	T033	C0231224
28152285	435	441	events	T051	C0441471
28152285	447	456	occurring	T052	C1709305
28152285	464	472	original	T078	C0205313
28152285	481	489	response	T170	C1706817
28152285	494	498	read	T056	C0034754
28152285	516	526	preventing	T169	C1292733
28152285	531	548	non-crisis events	T051	C0441471
28152285	554	563	occurring	T052	C1709305

27802454|t|Impact of SPARC expression on outcome in patients with advanced pancreatic cancer not receiving nab-paclitaxel: a pooled analysis from prospective clinical and translational trials
27802454|a|Conflicting results on the role of secreted protein acidic and rich in cysteins (SPARC) expression have been reported in resected pancreatic ductal adenocarcinoma (PDAC), and its prognostic and/or predictive role in advanced PDAC (aPDAC) has not been extensively investigated yet. This study was designed to evaluate SPARC expression as a biomarker in aPDAC patients (pts) not receiving nab-paclitaxel. Using immunohistochemistry, we examined the stromal as well as the tumoral (i.e., cytoplasmic) SPARC expression in tumour tissue (primary tumours and metastases) of 134 aPDAC pts participating in completed prospective clinical and biomarker trials. The SPARC expression levels were correlated to the pts' clinicopathological parameters and survival times. Sixty-seven per cent of the analysed tumours showed high stromal SPARC expression, which was not associated with overall survival (OS, median 9.1 vs 7.6 months, P=0.316). A positive cytoplasmic SPARC expression was detected in 55% of the tumours and correlated significantly with inferior progression-free survival (PFS, 6.2 vs 8.6 months, P=0.004) and OS (7.8 vs 8.4 months, P=0.032). This association was strongest for pts, where primary tumour tissue was examined (PFS: 6.7 vs 10.8 months, P=0.004; OS: 7.9 vs 11.9 months, P=0.030), whereas no significant correlation was detected for pts, where only metastatic tissue was available (PFS: 5.8 vs 6.6 months, P=0.502; OS: 7.0 vs 7.8 months, P=0.452). In pts receiving gemcitabine -based chemotherapy cytoplasmic SPARC expression was significantly associated with an inferior PFS and OS (PFS: 6.2 vs 9.2 months, P=0.002; OS 7.3 vs 9.9 months, P=0.012), whereas no such association was detected for stromal SPARC expression or for pts receiving fluoropyrimidine -based chemotherapy. We identified cytoplasmic SPARC expression in the primary tumour as a biomarker associated with inferior PFS and OS in aPDAC. Cytoplasmic SPARC expression may furthermore act as a negative predictive biomarker in pts treated with gemcitabine -based chemotherapy.
27802454	0	6	Impact	T080	C4049986
27802454	10	15	SPARC	T116,T123	C3530142
27802454	16	26	expression	T045	C1171362
27802454	30	37	outcome	T169	C1274040
27802454	41	49	patients	T101	C0030705
27802454	55	81	advanced pancreatic cancer	T191	C0030297
27802454	96	110	nab-paclitaxel	T109,T121	C1527223
27802454	114	129	pooled analysis	UnknownType	C0814924
27802454	147	155	clinical	T062	C0008976
27802454	160	180	translational trials	T062	C3494163
27802454	216	260	secreted protein acidic and rich in cysteins	T116,T123	C3530142
27802454	262	267	SPARC	T116,T123	C3530142
27802454	269	279	expression	T045	C1171362
27802454	302	310	resected	T080	C1521996
27802454	311	343	pancreatic ductal adenocarcinoma	T191	C1335302
27802454	345	349	PDAC	T191	C1335302
27802454	360	370	prognostic	T170	C0220901
27802454	397	410	advanced PDAC	T191	C1335302
27802454	412	417	aPDAC	T191	C1335302
27802454	498	503	SPARC	T116,T123	C3530142
27802454	504	514	expression	T045	C1171362
27802454	520	529	biomarker	T201	C0005516
27802454	533	538	aPDAC	T191	C1335302
27802454	539	547	patients	T101	C0030705
27802454	549	552	pts	T101	C0030705
27802454	568	582	nab-paclitaxel	T109,T121	C1527223
27802454	590	610	immunohistochemistry	T060	C0021044
27802454	615	623	examined	T033	C0332128
27802454	628	635	stromal	T025	C0162597
27802454	651	658	tumoral	T025	C0597032
27802454	666	677	cytoplasmic	T026	C0521449
27802454	679	684	SPARC	T116,T123	C3530142
27802454	685	695	expression	T045	C1171362
27802454	699	712	tumour tissue	T024	C0475358
27802454	714	729	primary tumours	T191	C0027667
27802454	734	744	metastases	T191	C0027627
27802454	753	758	aPDAC	T191	C1335302
27802454	759	762	pts	T101	C0030705
27802454	802	810	clinical	T062	C0008976
27802454	815	831	biomarker trials	T063	C1879847
27802454	837	842	SPARC	T116,T123	C3530142
27802454	843	853	expression	T045	C1171362
27802454	866	876	correlated	T080	C1707520
27802454	884	888	pts'	T101	C0030705
27802454	889	919	clinicopathological parameters	T169	C1521733
27802454	924	938	survival times	T201	C2919552
27802454	977	984	tumours	T191	C0027651
27802454	997	1004	stromal	T025	C0162597
27802454	1005	1010	SPARC	T116,T123	C3530142
27802454	1011	1021	expression	T045	C1171362
27802454	1037	1052	associated with	T080	C0332281
27802454	1053	1069	overall survival	T081	C4086681
27802454	1071	1073	OS	T081	C4086681
27802454	1075	1081	median	T082	C0549183
27802454	1093	1099	months	T079	C0439231
27802454	1122	1133	cytoplasmic	T026	C0521449
27802454	1134	1139	SPARC	T116,T123	C3530142
27802454	1140	1150	expression	T045	C1171362
27802454	1178	1185	tumours	T191	C0027651
27802454	1190	1200	correlated	T080	C1707520
27802454	1220	1254	inferior progression-free survival	T081	C0242792
27802454	1256	1259	PFS	T081	C0242792
27802454	1272	1278	months	T079	C0439231
27802454	1293	1295	OS	T081	C4086681
27802454	1308	1314	months	T079	C0439231
27802454	1331	1342	association	T080	C0439849
27802454	1361	1364	pts	T101	C0030705
27802454	1372	1393	primary tumour tissue	T024	C0475358
27802454	1398	1406	examined	T033	C0332128
27802454	1408	1411	PFS	T081	C0242792
27802454	1425	1431	months	T079	C0439231
27802454	1442	1444	OS	T081	C4086681
27802454	1458	1464	months	T079	C0439231
27802454	1499	1510	correlation	T080	C1707520
27802454	1528	1531	pts	T101	C0030705
27802454	1544	1561	metastatic tissue	T024	C0475358
27802454	1577	1580	PFS	T081	C0242792
27802454	1593	1599	months	T079	C0439231
27802454	1610	1612	OS	T081	C4086681
27802454	1625	1631	months	T079	C0439231
27802454	1646	1649	pts	T101	C0030705
27802454	1660	1671	gemcitabine	T114,T121	C0045093
27802454	1679	1691	chemotherapy	T061	C3665472
27802454	1692	1703	cytoplasmic	T026	C0521449
27802454	1704	1709	SPARC	T116,T123	C3530142
27802454	1710	1720	expression	T045	C1171362
27802454	1739	1754	associated with	T080	C0332281
27802454	1758	1770	inferior PFS	T081	C0242792
27802454	1775	1777	OS	T081	C4086681
27802454	1779	1782	PFS	T081	C0242792
27802454	1795	1801	months	T079	C0439231
27802454	1812	1814	OS	T081	C4086681
27802454	1826	1832	months	T079	C0439231
27802454	1860	1871	association	T080	C0439849
27802454	1889	1896	stromal	T025	C0162597
27802454	1897	1902	SPARC	T116,T123	C3530142
27802454	1903	1913	expression	T045	C1171362
27802454	1921	1924	pts	T101	C0030705
27802454	1935	1951	fluoropyrimidine	T114,T121	C0596581
27802454	1959	1971	chemotherapy	T061	C3665472
27802454	1987	1998	cytoplasmic	T026	C0521449
27802454	1999	2004	SPARC	T116,T123	C3530142
27802454	2005	2015	expression	T045	C1171362
27802454	2023	2037	primary tumour	T191	C0027667
27802454	2043	2052	biomarker	T201	C0005516
27802454	2053	2068	associated with	T080	C0332281
27802454	2069	2081	inferior PFS	T081	C0242792
27802454	2086	2088	OS	T081	C4086681
27802454	2092	2097	aPDAC	T191	C1335302
27802454	2099	2110	Cytoplasmic	T026	C0521449
27802454	2111	2116	SPARC	T116,T123	C3530142
27802454	2117	2127	expression	T045	C1171362
27802454	2173	2182	biomarker	T201	C0005516
27802454	2186	2189	pts	T101	C0030705
27802454	2190	2202	treated with	T061	C0332293
27802454	2203	2214	gemcitabine	T114,T121	C0045093
27802454	2222	2234	chemotherapy	T061	C3665472

27805887|t|Successful Restoration of Severely Mutilated Primary Incisors Using a Novel Method to Retain Zirconia Crowns - Two Year Results
27805887|a|This manuscript describes a simple reliable technique for restoring severely mutilated primary anterior teeth. A rigid glass ionomer post is created over which zirconia crowns can be fitted to achieve a long-term stable esthetic restoration for primary anterior teeth. Children aged 2-5 years with two up to six extensively decayed upper primary incisors were included. Fuji IX was condensed into an intracanal space created to a depth of 3mm, to provide a core which also extended 3mm supragingivally. Crown preparations were completed upon these cores. Zirconia crowns (Nusmile, Houston Texas USA) were fitted and cemented over the prepared cores. All patients were recalled at regular intervals. Twenty-three healthy children with 86 restorations participated in the study. The overall survival of the restorations was 95.3% after 12 months and 80.2% after 24 months. According to Kaplan-Meier survival analysis, the median survival time was not reached while the estimated mean survival time was 22.9 months. This newly described clinical technique is simple and reliable to use for restoration of extensively decayed primary incisors. Use of zirconia crowns retained using this technique offers superior esthetic, durable restorations with remarkable gingival response up to 24 months.
27805887	0	22	Successful Restoration	T061	C0399059
27805887	35	44	Mutilated	T037	C0332811
27805887	45	61	Primary Incisors	T023	C0021156
27805887	93	101	Zirconia	T074	C3503915
27805887	102	108	Crowns	T074	C3853546
27805887	111	119	Two Year	T079	C0439234
27805887	120	127	Results	T169	C1274040
27805887	133	143	manuscript	T073,T170	C0600659
27805887	163	181	reliable technique	T169	C0449851
27805887	186	195	restoring	T061	C0399059
27805887	205	214	mutilated	T037	C0332811
27805887	215	237	primary anterior teeth	T023	C0021156
27805887	247	265	glass ionomer post	T122	C0017597
27805887	288	296	zirconia	T074	C3503915
27805887	297	303	crowns	T074	C3853546
27805887	331	340	long-term	T079	C0443252
27805887	348	356	esthetic	T061	C0010163
27805887	357	368	restoration	T061	C0399059
27805887	373	395	primary anterior teeth	T023	C0021156
27805887	397	405	Children	T100	C0008059
27805887	415	420	years	T079	C0439234
27805887	452	459	decayed	T047	C0011334
27805887	460	482	upper primary incisors	T023	C0021156
27805887	498	505	Fuji IX	T122	C0671561
27805887	528	544	intracanal space	T061	C0282543
27805887	558	563	depth	T082	C0205125
27805887	585	589	core	T082	C0444669
27805887	614	629	supragingivally	T061	C0086959
27805887	631	649	Crown preparations	T061	C0399013
27805887	676	681	cores	T082	C0444669
27805887	683	691	Zirconia	T074	C3503915
27805887	692	698	crowns	T074	C3853546
27805887	700	707	Nusmile	T170	C0947322
27805887	709	722	Houston Texas	T083	C3812709
27805887	723	726	USA	T083	C0041703
27805887	733	739	fitted	T067	C3714578
27805887	744	752	cemented	T031	C0011343
27805887	771	776	cores	T082	C0444669
27805887	782	790	patients	T101	C0030705
27805887	796	804	recalled	T061	C1707680
27805887	808	825	regular intervals	T079	C1272706
27805887	848	856	children	T100	C0008059
27805887	865	877	restorations	T061	C0399059
27805887	898	903	study	T062	C2603343
27805887	909	925	overall survival	T081	C4086681
27805887	933	945	restorations	T061	C0399059
27805887	965	971	months	T079	C0439231
27805887	991	997	months	T079	C0439231
27805887	1012	1042	Kaplan-Meier survival analysis	T062	C0038953
27805887	1048	1068	median survival time	T079	C2986586
27805887	1105	1123	mean survival time	T081	C0086595
27805887	1133	1139	months	T079	C0439231
27805887	1162	1180	clinical technique	T058	C0376583
27805887	1195	1203	reliable	T170	C3858758
27805887	1215	1226	restoration	T061	C0399059
27805887	1242	1249	decayed	T047	C0011334
27805887	1250	1266	primary incisors	T023	C0021156
27805887	1275	1283	zirconia	T074	C3503915
27805887	1284	1290	crowns	T074	C3853546
27805887	1311	1320	technique	T169	C0449851
27805887	1328	1345	superior esthetic	T080	C0004898
27805887	1355	1367	restorations	T061	C0399059
27805887	1384	1401	gingival response	T033	C0541981
27805887	1411	1417	months	T079	C0439231

27371818|t|Design considerations for patient-specific surgical templates for total hip arthroplasty with respect to acetabular cartilage
27371818|a|Patient-specific instruments (PSIs) are clinically used to support the surgeon during a planned intervention. The planning is typically done based on volumetric image data from medical imaging systems, e.g. computed tomography (CT). The PSI uses the known surface structure of a bone for orientation during the intervention. Some surfaces of human bone are covered with a layer of cartilage which is hardly visible in clinically applied CT-imaging. This experimental study investigates ten different PSI designs and their effect to the overall accuracy when neglecting the cartilage in the design process. Therefore, a model of an acetabulum is used to simulate the use case of PSI in total hip arthroplasty. The concept of the different designs is to create structural elasticities in the PSI to avoid shifting of the whole instrument and rather have a small part of it deformed by cartilage. A needle array structure, for instance, should also be able to oust or penetrate remaining soft tissue in the acetabulum.
27371818	0	6	Design	T052	C1707689
27371818	7	21	considerations	T033	C0518609
27371818	26	42	patient-specific	T080	C0205556
27371818	43	61	surgical templates	T074	C0581264
27371818	66	88	total hip arthroplasty	T061	C0040508
27371818	105	115	acetabular	T030	C0229984
27371818	116	125	cartilage	T024	C0007301
27371818	126	154	Patient-specific instruments	T074	C0025080
27371818	156	160	PSIs	T074	C0025080
27371818	166	176	clinically	T080	C0205210
27371818	197	204	surgeon	T097	C0582175
27371818	214	234	planned intervention	T081	C2347528
27371818	240	248	planning	T041	C0032074
27371818	276	286	volumetric	T082	C0445383
27371818	287	297	image data	T170	C0282574
27371818	303	318	medical imaging	T060	C0025086
27371818	319	326	systems	T169	C0449913
27371818	333	352	computed tomography	T060	C0040405
27371818	354	356	CT	T060	C0040405
27371818	363	366	PSI	T074	C0025080
27371818	382	409	surface structure of a bone	T023	C1960754
27371818	414	425	orientation	T082	C1704322
27371818	437	449	intervention	T061	C0184661
27371818	456	478	surfaces of human bone	T023	C1960754
27371818	483	490	covered	T169	C0439844
27371818	498	503	layer	T023	C0934502
27371818	507	516	cartilage	T024	C0007301
27371818	526	532	hardly	T033	C3898981
27371818	533	540	visible	T080	C0205379
27371818	544	554	clinically	T080	C0205210
27371818	555	562	applied	T169	C4048755
27371818	563	573	CT-imaging	T060	C0729619
27371818	580	598	experimental study	T062	C0681814
27371818	599	611	investigates	T169	C1292732
27371818	616	625	different	T080	C1705242
27371818	626	629	PSI	T074	C0025080
27371818	630	637	designs	T052	C1707689
27371818	648	654	effect	T080	C1280500
27371818	662	669	overall	T080	C1561607
27371818	670	678	accuracy	T080	C0443131
27371818	699	708	cartilage	T024	C0007301
27371818	716	722	design	T052	C1707689
27371818	723	730	process	T067	C1522240
27371818	745	750	model	T075	C0026339
27371818	757	767	acetabulum	T023	C0000962
27371818	779	787	simulate	T062	C0679083
27371818	796	800	case	T169	C0868928
27371818	804	807	PSI	T074	C0025080
27371818	811	833	total hip arthroplasty	T061	C0040508
27371818	839	846	concept	T078	C0178566
27371818	854	863	different	T080	C1705242
27371818	864	871	designs	T052	C1707689
27371818	878	884	create	T052	C1706214
27371818	885	895	structural	T082	C0678594
27371818	896	908	elasticities	T080	C0205556
27371818	916	919	PSI	T074	C0025080
27371818	929	937	shifting	T169	C0333051
27371818	951	961	instrument	T074	C0348000
27371818	997	1005	deformed	T169	C0333067
27371818	1009	1018	cartilage	T024	C0007301
27371818	1022	1044	needle array structure	T074	C0025080
27371818	1091	1100	penetrate	T169	C0205321
27371818	1111	1122	soft tissue	T024	C0225317
27371818	1130	1140	acetabulum	T023	C0000962

28530664|t|Flexible information routing by transient synchrony
28530664|a|Perception, cognition and behavior rely on flexible communication between microcircuits in distinct cortical regions. The mechanisms underlying rapid information rerouting between such microcircuits are still unknown. It has been proposed that changing patterns of coherence between local gamma rhythms support flexible information rerouting. The stochastic and transient nature of gamma oscillations in vivo, however, is hard to reconcile with such a function. Here we show that models of cortical circuits near the onset of oscillatory synchrony selectively route input signals despite the short duration of gamma bursts and the irregularity of neuronal firing. In canonical multiarea circuits, we find that gamma bursts spontaneously arise with matched timing and frequency and that they organize information flow by large-scale routing states. Specific self-organized routing states can be induced by minor modulations of background activity.
28530664	0	8	Flexible	T080	C0443220
28530664	9	20	information	T078	C1533716
28530664	21	28	routing	T067	C1522240
28530664	32	41	transient	T079	C0205374
28530664	42	51	synchrony	T060	C0010114
28530664	52	62	Perception	T041	C0030971
28530664	64	73	cognition	T041	C0009240
28530664	78	91	behavior rely	T053	C0004927
28530664	95	103	flexible	T080	C0443220
28530664	104	117	communication	T054	C0009452
28530664	126	139	microcircuits	UnknownType	C0814033
28530664	152	168	cortical regions	T029	C0005898
28530664	174	184	mechanisms	T169	C0441712
28530664	202	213	information	T078	C1533716
28530664	214	223	rerouting	T067	C1522240
28530664	237	250	microcircuits	UnknownType	C0814033
28530664	296	304	changing	T169	C0392747
28530664	317	326	coherence	T080	C0205556
28530664	335	354	local gamma rhythms	T042	C3850154
28530664	363	371	flexible	T080	C0443220
28530664	372	383	information	T078	C1533716
28530664	384	393	rerouting	T067	C1522240
28530664	399	409	stochastic	T081	C0038347
28530664	414	423	transient	T079	C0205374
28530664	424	430	nature	T080	C0205556
28530664	434	452	gamma oscillations	T061	C0695434
28530664	453	460	in vivo	T082	C1515655
28530664	482	491	reconcile	UnknownType	C0677371
28530664	504	512	function	T169	C0542341
28530664	532	538	models	T075	C0026336
28530664	542	559	cortical circuits	UnknownType	C0814033
28530664	578	589	oscillatory	T061	C0695434
28530664	590	599	synchrony	T060	C0010114
28530664	612	617	route	T067	C1522240
28530664	618	631	input signals	T067	C1710082
28530664	644	658	short duration	T080	C0439593
28530664	662	674	gamma bursts	T042	C1254358
28530664	683	695	irregularity	T080	C0205271
28530664	699	714	neuronal firing	T042	C1254358
28530664	719	747	canonical multiarea circuits	T023	C0229962
28530664	762	774	gamma bursts	T042	C1254358
28530664	775	788	spontaneously	T169	C0205359
28530664	800	807	matched	T080	C1708943
28530664	808	814	timing	T079	C0449243
28530664	819	828	frequency	T079	C0439603
28530664	843	851	organize	T169	C1300196
28530664	852	868	information flow	T042	C1254358
28530664	872	898	large-scale routing states	T067	C1522240
28530664	909	923	self-organized	T169	C1300196
28530664	924	938	routing states	T067	C1522240
28530664	946	953	induced	T169	C0205263
28530664	963	974	modulations	T169	C0205245
28530664	989	997	activity	T052	C0441655

28486810|t|A Facile Strategy to Prepare an Enzyme - Responsive Mussel Mimetic Coating for Drug Delivery Based on Mesoporous Silica Nanoparticles
28486810|a|Surface functional mesoporous silica nanoparticles (MSNs) have been widely used as promosing materials for drug delivery. Herein, we reported a facile strategy to construct MSNs coated by enzyme - resposive polylysine - dopamine (PLDA) films through self-polymerization of dopamine derivative lysine - dopamine, in which the drug could be loaded and delivered efficiently. In detail, RhB or DOX was used as a drug model and loaded in functional MSNs via a one-pot procedure among MSNs, drug, and lysine - dopamine (LDA) under basic conditions. Owing to the fact that the peptide bonds between lysine and dopamine can be cleaved under triggering by pepsin, the resulting RhB / DOX @ PLDA - MSNs exibit enzyme - responsive characterization. After the DOX @ PLDA - MSNs enter into the cancer cells, the drug can be released effectively through degradation of peptide bonds under the influence of enzyme in cancer cells, which shows marked anticancer activity in vitro. This facile strategy may provide a new platform to construct enzyme - responsive controlled drug delivery systems.
28486810	2	8	Facile	T080	C0205352
28486810	9	17	Strategy	T062	C0035171
28486810	32	38	Enzyme	T116,T126	C0014442
28486810	41	51	Responsive	T169	C0205342
28486810	52	58	Mussel	T204	C0026871
28486810	59	66	Mimetic	T091	C0920591
28486810	67	74	Coating	T080	C1522408
28486810	79	92	Drug Delivery	T058	C1881966
28486810	102	119	Mesoporous Silica	T122,T197	C0037098
28486810	120	133	Nanoparticles	T073	C1450054
28486810	134	141	Surface	T082	C0205148
28486810	142	152	functional	T169	C0205245
28486810	153	170	mesoporous silica	T122,T197	C0037098
28486810	171	184	nanoparticles	T073	C1450054
28486810	186	190	MSNs	T122,T197	C0037098
28486810	227	236	materials	T122	C0005479
28486810	241	254	drug delivery	T058	C1881966
28486810	278	284	facile	T080	C0205352
28486810	285	293	strategy	T062	C0035171
28486810	307	311	MSNs	T122,T197	C0037098
28486810	312	318	coated	T080	C1522408
28486810	322	328	enzyme	T116,T126	C0014442
28486810	331	340	resposive	T169	C0205342
28486810	341	351	polylysine	T116	C0032518
28486810	354	362	dopamine	T109,T121,T123	C0013030
28486810	364	368	PLDA	T109,T121,T123	C0013030
28486810	370	375	films	T167	C1561572
28486810	384	403	self-polymerization	T067	C0314672
28486810	407	415	dopamine	T109,T121,T123	C0013030
28486810	427	433	lysine	T116,T121,T123	C0024337
28486810	436	444	dopamine	T109,T121,T123	C0013030
28486810	459	463	drug	T121	C0013227
28486810	473	479	loaded	T052	C1708715
28486810	484	493	delivered	T169	C1705822
28486810	494	505	efficiently	T080	C0442799
28486810	518	521	RhB	T109,T130	C0073194
28486810	525	528	DOX	T109,T195	C0013089
28486810	543	547	drug	T121	C1254351
28486810	548	553	model	T062	C1515654
28486810	558	564	loaded	T052	C1708715
28486810	568	578	functional	T169	C0205245
28486810	579	583	MSNs	T122,T197	C0037098
28486810	614	618	MSNs	T122,T197	C0037098
28486810	620	624	drug	T121	C1254351
28486810	630	636	lysine	T116,T121,T123	C0024337
28486810	639	647	dopamine	T109,T121,T123	C0013030
28486810	649	652	LDA	T109,T121,T123	C0013030
28486810	660	665	basic	T120	C0178499
28486810	666	676	conditions	T080	C0348080
28486810	705	718	peptide bonds	UnknownType	C0678595
28486810	727	733	lysine	T116,T121,T123	C0024337
28486810	738	746	dopamine	T109,T121,T123	C0013030
28486810	754	761	cleaved	T067	C0596311
28486810	768	781	triggering by	T080	C1444748
28486810	782	788	pepsin	T116,T121,T126	C0030909
28486810	804	807	RhB	T109,T130	C0073194
28486810	810	813	DOX	T109,T195	C0013089
28486810	816	820	PLDA	T109,T121,T123	C0013030
28486810	823	827	MSNs	T122,T197	C0037098
28486810	835	841	enzyme	T116,T126	C0014442
28486810	844	854	responsive	T169	C0205342
28486810	855	871	characterization	T052	C1880022
28486810	883	886	DOX	T109,T195	C0013089
28486810	889	893	PLDA	T109,T121,T123	C0013030
28486810	896	900	MSNs	T122,T197	C0037098
28486810	916	928	cancer cells	T025	C0334227
28486810	934	938	drug	T121	C1254351
28486810	946	954	released	T169	C0391871
28486810	955	966	effectively	T080	C1280519
28486810	975	1003	degradation of peptide bonds	T044	C0597304
28486810	1014	1023	influence	T077	C4054723
28486810	1027	1033	enzyme	T116,T126	C0014442
28486810	1037	1049	cancer cells	T025	C0334227
28486810	1070	1080	anticancer	T109,T121	C0003392
28486810	1081	1089	activity	T169	C0205177
28486810	1090	1098	in vitro	T080	C1533691
28486810	1105	1111	facile	T080	C0205352
28486810	1112	1120	strategy	T062	C0035171
28486810	1161	1167	enzyme	T116,T126	C0014442
28486810	1170	1180	responsive	T169	C0205342
28486810	1181	1191	controlled	T169	C2587213
28486810	1192	1213	drug delivery systems	T058	C1881966

27725659|t|Rare deleterious mutations are associated with disease in bipolar disorder families
27725659|a|Bipolar disorder (BD) is a common, complex and heritable psychiatric disorder characterized by episodes of severe mood swings. The identification of rare, damaging genomic mutations in families with BD could inform about disease mechanisms and lead to new therapeutic interventions. To determine whether rare, damaging mutations shared identity-by-descent in families with BD could be associated with disease, exome sequencing was performed in multigenerational families of the NIMH BD Family Study followed by in silico functional prediction. Disease association and disease specificity was determined using 5090 exomes from the Sweden - Schizophrenia (SZ) Population -Based Case- Control Exome Sequencing study. We identified 14 rare and likely deleterious mutations in 14 genes that were shared identity-by-descent among affected family members. The variants were associated with BD (P<0.05 after Bonferroni's correction) and disease specificity was supported by the absence of the mutations in patients with SZ. In addition, we found rare, functional mutations in known causal genes for neuropsychiatric disorders including holoprosencephaly and epilepsy. Our results demonstrate that exome sequencing in multigenerational families with BD is effective in identifying rare genomic variants of potential clinical relevance and also disease modifiers related to coexisting medical conditions. Replication of our results and experimental validation are required before disease causation could be assumed.Molecular Psychiatry advance online publication, 11 October 2016; doi:10.1038/mp.2016.181.
27725659	5	26	deleterious mutations	T049	C2985436
27725659	47	54	disease	T047	C0012634
27725659	58	74	bipolar disorder	T048	C0005586
27725659	75	83	families	T099	C0015576
27725659	84	100	Bipolar disorder	T048	C0005586
27725659	102	104	BD	T048	C0005586
27725659	119	126	complex	T080	C0439855
27725659	131	140	heritable	T047	C0019247
27725659	141	161	psychiatric disorder	T048	C0004936
27725659	179	187	episodes	T048	C0338614
27725659	198	209	mood swings	T048	C0085633
27725659	248	265	genomic mutations	T045	C0596611
27725659	269	277	families	T099	C0015576
27725659	283	285	BD	T048	C0005586
27725659	305	312	disease	T047	C0012634
27725659	340	365	therapeutic interventions	T061	C0808232
27725659	403	412	mutations	T045	C0596611
27725659	443	451	families	T099	C0015576
27725659	457	459	BD	T048	C0005586
27725659	485	492	disease	T047	C0012634
27725659	494	510	exome sequencing	T063	C3640077
27725659	528	545	multigenerational	T079	C0079411
27725659	546	554	families	T099	C0015576
27725659	562	566	NIMH	T093	C0027466
27725659	567	569	BD	T048	C0005586
27725659	570	582	Family Study	T060	C0199236
27725659	595	626	in silico functional prediction	T063	C1514534
27725659	628	647	Disease association	T079	C1511978
27725659	652	659	disease	T047	C0012634
27725659	660	671	specificity	T081	C0037791
27725659	698	704	exomes	T028	C3178814
27725659	714	720	Sweden	T083	C0038995
27725659	723	736	Schizophrenia	T048	C0036341
27725659	738	740	SZ	T048	C0036341
27725659	742	752	Population	T081	C0032659
27725659	766	796	Control Exome Sequencing study	T063	C3640077
27725659	831	852	deleterious mutations	T049	C2985436
27725659	859	864	genes	T028	C0017337
27725659	917	931	family members	T099	C0086282
27725659	937	945	variants	T028	C0678941
27725659	967	969	BD	T048	C0005586
27725659	984	1007	Bonferroni's correction	T170	C0237913
27725659	1013	1020	disease	T047	C0012634
27725659	1021	1032	specificity	T081	C0037791
27725659	1069	1078	mutations	T045	C0596611
27725659	1082	1090	patients	T101	C0030705
27725659	1096	1098	SZ	T048	C0036341
27725659	1128	1148	functional mutations	T033	C4313936
27725659	1158	1170	causal genes	T028	C0017337
27725659	1175	1201	neuropsychiatric disorders	T047	C3203509
27725659	1212	1229	holoprosencephaly	T019	C0079541
27725659	1234	1242	epilepsy	T047	C0014544
27725659	1273	1289	exome sequencing	T063	C3640077
27725659	1293	1310	multigenerational	T079	C0079411
27725659	1311	1319	families	T099	C0015576
27725659	1325	1327	BD	T048	C0005586
27725659	1361	1377	genomic variants	T045	C2717924
27725659	1391	1409	clinical relevance	T033	C1953337
27725659	1419	1426	disease	T047	C0012634
27725659	1448	1458	coexisting	T047	C0679225
27725659	1459	1477	medical conditions	T048	C1410011
27725659	1554	1571	disease causation	T169	C1314792

27373429|t|Homogeneous synthesis of Ag nanoparticles -doped water-soluble cellulose acetate for versatile applications
27373429|a|We report a facile and efficient approach for synthesis of well-dispersed and stable silver nanoparticles (Ag NPs) using water-soluble cellulose acetate (CA) as both reductant and stabilizer. Partially substituted CA with highly active hydroxyl groups and excellent water-solubility is able to reduce silver ions in homogeneous aqueous medium effectively. The synthesized Ag NPs were characterized by UV-vis spectroscopy, X-ray diffraction, X-ray photoelectron spectroscopy, transmission electron microscopy and energy dispersive X-ray spectroscope analysis. The as- prepared Ag NPs were well-dispersed, showing a surface plasmon resonance peak at 426 nm. The resulted Ag NPs @ CA nanohybrids exhibit high catalytic activity for the reduction of 4-nitrophenol to 4-aminophenol in the presence of NaBH4. Meanwhile, the nanohybrids are also effective in inhibiting the growth of bacterial. This environmentally friendly method promotes the use of renewable natural resources to prepare a variety of inorganic-organic materials for catalysis, antibacterial, sensors and other applications.
27373429	0	11	Homogeneous	T080	C1881065
27373429	12	21	synthesis	T052	C1883254
27373429	25	41	Ag nanoparticles	T073	C1721060
27373429	49	80	water-soluble cellulose acetate	T109,T122,T130	C0050505
27373429	85	94	versatile	T080	C0205556
27373429	95	107	applications	T169	C4048755
27373429	111	117	report	T170	C0684224
27373429	120	126	facile	T080	C0205352
27373429	131	140	efficient	T080	C0442799
27373429	141	149	approach	T082	C0449445
27373429	154	163	synthesis	T052	C1883254
27373429	167	181	well-dispersed	T082	C0332624
27373429	186	192	stable	T080	C0205360
27373429	193	213	silver nanoparticles	T073	C1721060
27373429	215	221	Ag NPs	T073	C1721060
27373429	229	260	water-soluble cellulose acetate	T109,T122,T130	C0050505
27373429	262	264	CA	T109,T122,T130	C0050505
27373429	274	283	reductant	T130	C0376446
27373429	288	298	stabilizer	T167	C1550603
27373429	300	309	Partially	T081	C0728938
27373429	322	324	CA	T109,T122,T130	C0050505
27373429	330	336	highly	T080	C0205250
27373429	337	343	active	T169	C0205177
27373429	344	359	hydroxyl groups	T197	C0700307
27373429	364	373	excellent	T080	C1961136
27373429	374	390	water-solubility	T081	C0597682
27373429	394	398	able	T033	C1299581
27373429	402	408	reduce	T070	C0301630
27373429	409	420	silver ions	T196	C0022023
27373429	424	435	homogeneous	T080	C1881065
27373429	436	443	aqueous	T080	C0599956
27373429	444	450	medium	T167	C1705217
27373429	451	462	effectively	T080	C1704419
27373429	468	479	synthesized	T052	C1883254
27373429	480	486	Ag NPs	T073	C1721060
27373429	492	505	characterized	T052	C1880022
27373429	509	528	UV-vis spectroscopy	T059	C0037812
27373429	530	547	X-ray diffraction	T059	C0043301
27373429	549	581	X-ray photoelectron spectroscopy	T059	C2700282
27373429	583	615	transmission electron microscopy	T059	C0678118
27373429	620	656	energy dispersive X-ray spectroscope	T059	C2699997
27373429	657	665	analysis	T059	C0002778
27373429	675	683	prepared	T033	C4082130
27373429	684	690	Ag NPs	T073	C1721060
27373429	696	710	well-dispersed	T082	C0332624
27373429	722	747	surface plasmon resonance	T063	C0597731
27373429	748	752	peak	T080	C0444505
27373429	760	762	nm	T081	C0439202
27373429	777	783	Ag NPs	T073	C1721060
27373429	786	788	CA	T109,T122,T130	C0050505
27373429	789	800	nanohybrids	T073	C1721059
27373429	809	813	high	T080	C0205250
27373429	814	832	catalytic activity	T169	C1264638
27373429	841	850	reduction	T070	C0301630
27373429	854	867	4-nitrophenol	T109,T130,T131	C0048581
27373429	871	884	4-aminophenol	T109	C0048047
27373429	904	909	NaBH4	T130,T197	C0074728
27373429	926	937	nanohybrids	T073	C1721059
27373429	947	956	effective	T080	C1704419
27373429	960	970	inhibiting	T052	C3463820
27373429	975	981	growth	T040	C0018270
27373429	985	994	bacterial	T007	C0004611
27373429	1001	1032	environmentally friendly method	T057	C2350566
27373429	1033	1041	promotes	T052	C0033414
27373429	1046	1052	use of	T169	C1524063
27373429	1053	1080	renewable natural resources	T078	C0027492
27373429	1084	1091	prepare	T052	C1521827
27373429	1094	1101	variety	T077	C2346866
27373429	1105	1132	inorganic-organic materials	T167	C0520510
27373429	1137	1146	catalysis	T070	C0007382
27373429	1148	1161	antibacterial	T195	C0279516
27373429	1163	1170	sensors	T073	C0183210
27373429	1181	1193	applications	T169	C4048755

28343654|t|Negative concordant T waves during paced ventricular rhythm: An honest enemy is better than a false friend
28343654|a|The ECG diagnosis of myocardial infarction and ischemia in pacemaker patients is often challenging. The three criteria, proposed by Sgarbossa et al. in 1996, useful to suspect myocardial ischaemia in patient with left bundle branch block were demonstrated to be valid also in pacemaker patients. In the last years, concordant negative T waves in patients with ventricular paced rhythm were linked to various expressions of acute myocardial injury. If available, comparison with previous ECG is crucial. Partial persistence of cardiac memory during fusion beats created an anomalous concordance between negative T waves and QRS axis and could induce erroneous suspicions. AV delay modification could help to unmask this situation.
28343654	0	8	Negative	T033	C0205160
28343654	20	27	T waves	T201	C0429104
28343654	35	59	paced ventricular rhythm	T033	C1168318
28343654	111	114	ECG	T033	C0013798
28343654	115	124	diagnosis	T033	C0011900
28343654	128	149	myocardial infarction	T047	C0027051
28343654	154	162	ischemia	T046	C0022116
28343654	166	175	pacemaker	T074	C0178611
28343654	176	184	patients	T101	C0030705
28343654	217	225	criteria	T078	C0243161
28343654	283	303	myocardial ischaemia	T047	C0151744
28343654	307	314	patient	T101	C0030705
28343654	320	344	left bundle branch block	T047	C0023211
28343654	383	392	pacemaker	T074	C0178611
28343654	393	401	patients	T101	C0030705
28343654	433	441	negative	T033	C0205160
28343654	442	449	T waves	T201	C0429104
28343654	453	461	patients	T101	C0030705
28343654	467	491	ventricular paced rhythm	T033	C1168318
28343654	515	526	expressions	T061	C0185117
28343654	536	553	myocardial injury	T037	C0746730
28343654	594	597	ECG	T033	C0013798
28343654	618	647	persistence of cardiac memory	T033	C0243095
28343654	655	667	fusion beats	T046	C0232213
28343654	679	688	anomalous	T033	C3277934
28343654	709	717	negative	T033	C0205160
28343654	718	725	T waves	T201	C0429104
28343654	730	738	QRS axis	T201	C0429012
28343654	756	765	erroneous	T078	C1547323
28343654	766	776	suspicions	T041	C0242114
28343654	778	786	AV delay	T033	C0243095
28343654	787	799	modification	T033	C3840684

28426667|t|Bioenergetic status modulates motor neuron vulnerability and pathogenesis in a zebrafish model of spinal muscular atrophy
28426667|a|Degeneration and loss of lower motor neurons is the major pathological hallmark of spinal muscular atrophy (SMA), resulting from low levels of ubiquitously-expressed survival motor neuron (SMN) protein. One remarkable, yet unresolved, feature of SMA is that not all motor neurons are equally affected, with some populations displaying a robust resistance to the disease. Here, we demonstrate that selective vulnerability of distinct motor neuron pools arises from fundamental modifications to their basal molecular profiles. Comparative gene expression profiling of motor neurons innervating the extensor digitorum longus (disease-resistant), gastrocnemius (intermediate vulnerability), and tibialis anterior (vulnerable) muscles in mice revealed that disease susceptibility correlates strongly with a modified bioenergetic profile. Targeting of identified bioenergetic pathways by enhancing mitochondrial biogenesis rescued motor axon defects in SMA zebrafish. Moreover, targeting of a single bioenergetic protein, phosphoglycerate kinase 1 (Pgk1), was found to modulate motor neuron vulnerability in vivo. Knockdown of pgk1 alone was sufficient to partially mimic the SMA phenotype in wild-type zebrafish. Conversely, Pgk1 overexpression, or treatment with terazosin (an FDA -approved small molecule that binds and activates Pgk1), rescued motor axon phenotypes in SMA zebrafish. We conclude that global bioenergetics pathways can be therapeutically manipulated to ameliorate SMA motor neuron phenotypes in vivo.
28426667	0	12	Bioenergetic	T040	C0005486
28426667	13	19	status	T080	C0449438
28426667	20	29	modulates	T082	C0443264
28426667	30	42	motor neuron	T025	C0026609
28426667	43	56	vulnerability	T033	C1821973
28426667	61	73	pathogenesis	T046	C0699748
28426667	79	88	zebrafish	T013	C0043457
28426667	89	94	model	T050	C0012644
28426667	98	121	spinal muscular atrophy	T047	C0026847
28426667	122	166	Degeneration and loss of lower motor neurons	T033	C3809750
28426667	180	192	pathological	T169	C1521733
28426667	205	228	spinal muscular atrophy	T047	C0026847
28426667	230	233	SMA	T047	C0026847
28426667	288	323	survival motor neuron (SMN) protein	T116,T123	C4283935
28426667	368	371	SMA	T047	C0026847
28426667	388	401	motor neurons	T025	C0026609
28426667	414	422	affected	T169	C0392760
28426667	434	445	populations	T098	C1257890
28426667	466	491	resistance to the disease	T040	C1136180
28426667	529	542	vulnerability	T033	C1821973
28426667	555	567	motor neuron	T025	C0026609
28426667	598	611	modifications	T169	C0392747
28426667	621	645	basal molecular profiles	T169	C1704864
28426667	659	684	gene expression profiling	T059,T063	C0752248
28426667	688	701	motor neurons	T025	C0026609
28426667	718	743	extensor digitorum longus	T023	C0224464
28426667	745	762	disease-resistant	T040	C1136180
28426667	765	778	gastrocnemius	T023	C0242691
28426667	780	806	intermediate vulnerability	T033	C1821973
28426667	813	830	tibialis anterior	T023	C0242690
28426667	832	842	vulnerable	T169	C0231204
28426667	844	851	muscles	T023	C1995013
28426667	855	859	mice	T015	C0025929
28426667	860	868	revealed	T080	C0443289
28426667	874	896	disease susceptibility	T201	C0012655
28426667	933	945	bioenergetic	T040	C0005486
28426667	946	953	profile	T059	C1979963
28426667	955	964	Targeting	T169	C1521840
28426667	968	978	identified	T080	C0205396
28426667	979	991	bioenergetic	T040	C0005486
28426667	992	1000	pathways	T077	C1705987
28426667	1014	1038	mitochondrial biogenesis	T043	C3494456
28426667	1047	1057	motor axon	T026	C2335621
28426667	1058	1065	defects	T169	C0243067
28426667	1069	1072	SMA	T047	C0026847
28426667	1073	1082	zebrafish	T013	C0043457
28426667	1094	1103	targeting	T169	C1521840
28426667	1116	1128	bioenergetic	T040	C0005486
28426667	1129	1136	protein	T116,T123	C0033684
28426667	1138	1163	phosphoglycerate kinase 1	T116,T126	C3814452
28426667	1165	1169	Pgk1	T116,T126	C3814452
28426667	1185	1193	modulate	T082	C0443264
28426667	1194	1206	motor neuron	T025	C0026609
28426667	1207	1220	vulnerability	T033	C1821973
28426667	1221	1228	in vivo	T082	C1515655
28426667	1230	1239	Knockdown	T063	C2350567
28426667	1243	1247	pgk1	T028	C1418508
28426667	1258	1268	sufficient	T080	C0205410
28426667	1292	1295	SMA	T047	C0026847
28426667	1296	1305	phenotype	T032	C0031437
28426667	1309	1318	wild-type	T028	C1883559
28426667	1319	1328	zebrafish	T013	C0043457
28426667	1342	1346	Pgk1	T028	C1418508
28426667	1347	1361	overexpression	T045	C1514559
28426667	1366	1375	treatment	T061	C0087111
28426667	1381	1390	terazosin	T109,T121	C0076107
28426667	1395	1398	FDA	T170	C2700205
28426667	1409	1423	small molecule	T109	C1328819
28426667	1429	1434	binds	T052	C1145667
28426667	1439	1448	activates	T052	C1879547
28426667	1449	1453	Pgk1	T116,T126	C3814452
28426667	1464	1474	motor axon	T026	C2335621
28426667	1475	1485	phenotypes	T032	C0031437
28426667	1489	1492	SMA	T047	C0026847
28426667	1493	1502	zebrafish	T013	C0043457
28426667	1528	1541	bioenergetics	T040	C0005486
28426667	1542	1550	pathways	T077	C1705987
28426667	1558	1573	therapeutically	T169	C0302350
28426667	1600	1603	SMA	T047	C0026847
28426667	1604	1616	motor neuron	T025	C0026609
28426667	1617	1627	phenotypes	T032	C0031437
28426667	1628	1635	in vivo	T082	C1515655

28065172|t|INCORPORATING ENVIRONMENTAL OUTCOMES INTO A HEALTH ECONOMIC MODEL
28065172|a|Traditional economic evaluations for most health technology assessments (HTAs) have previously not included environmental outcomes. With the growing interest in reducing the environmental impact of human activities, the need to consider how to include environmental outcomes into HTAs has increased. We present a simple method of doing so. We adapted an existing clinical - economic model to include environmental outcomes (carbon dioxide [CO2] emissions) to predict the consequences of adding insulin to an oral antidiabetic (OAD) regimen for patients with type 2 diabetes mellitus (T2DM) over 30 years, from the United Kingdom payer perspective. Epidemiological, efficacy, healthcare costs, utility, and carbon emissions data were derived from published literature. A scenario analysis was performed to explore the impact of parameter uncertainty. The addition of insulin to an OAD regimen increases costs by 2,668 British pounds per patient and is associated with 0.36 additional quality-adjusted life-years per patient. The insulin - OAD combination regimen generates more treatment and disease management - related CO2 emissions per patient (1,686 kg) than the OAD -only regimen (310 kg), but generates fewer emissions associated with treating complications (3,019 kg versus 3,337 kg). Overall, adding insulin to OAD therapy generates an extra 1,057 kg of CO2 emissions per patient over 30 years. The model offers a simple approach for incorporating environmental outcomes into health economic analyses, to support a decision-maker's objective of reducing the environmental impact of health care. Further work is required to improve the accuracy of the approach; in particular, the generation of resource-specific environmental impacts.
28065172	0	13	INCORPORATING	T169	C0243126
28065172	14	27	ENVIRONMENTAL	T082	C0014406
28065172	28	36	OUTCOMES	T081	C0086749
28065172	44	50	HEALTH	T078	C0018684
28065172	51	65	ECONOMIC MODEL	T081,T170	C0013554
28065172	78	98	economic evaluations	T057	C0150099
28065172	108	137	health technology assessments	T058	C0039423
28065172	139	143	HTAs	T058	C0039423
28065172	174	187	environmental	T082	C0014406
28065172	188	196	outcomes	T081	C0086749
28065172	227	235	reducing	T080	C0392756
28065172	240	260	environmental impact	T067	C0282165
28065172	264	280	human activities	T052	C0020115
28065172	318	331	environmental	T082	C0014406
28065172	332	340	outcomes	T081	C0086749
28065172	346	350	HTAs	T058	C0039423
28065172	355	364	increased	T081	C0205217
28065172	429	437	clinical	T080	C0205210
28065172	440	454	economic model	T081,T170	C0013554
28065172	466	479	environmental	T082	C0014406
28065172	480	488	outcomes	T081	C0086749
28065172	490	504	carbon dioxide	T123,T197	C0007012
28065172	506	509	CO2	T123,T197	C0007012
28065172	511	520	emissions	T167	C2349995
28065172	525	532	predict	T078	C0681842
28065172	537	552	consequences of	T169	C0686907
28065172	560	567	insulin	T116,T121,T125	C0021641
28065172	574	578	oral	T082	C0442027
28065172	579	591	antidiabetic	T121	C0935929
28065172	593	596	OAD	T121	C0935929
28065172	598	605	regimen	T061	C0040808
28065172	610	618	patients	T101	C0030705
28065172	624	648	type 2 diabetes mellitus	T047	C0011860
28065172	650	654	T2DM	T047	C0011860
28065172	664	669	years	T079	C0439234
28065172	680	694	United Kingdom	T083	C0041700
28065172	695	700	payer	T092	C2348942
28065172	714	729	Epidemiological	T062	C0002783
28065172	731	739	efficacy	T062	C1707887
28065172	741	757	healthcare costs	T081	C0085552
28065172	772	778	carbon	T123,T197	C0007012
28065172	779	788	emissions	T167	C2349995
28065172	789	793	data	T078	C1511726
28065172	799	806	derived	T080	C1441547
28065172	812	832	published literature	T170	C0023866
28065172	836	844	scenario	T169	C0683579
28065172	845	853	analysis	T062	C0936012
28065172	858	867	performed	T169	C0884358
28065172	883	889	impact	T080	C4049986
28065172	893	902	parameter	T077	C0549193
28065172	903	914	uncertainty	T033	C0087130
28065172	932	939	insulin	T116,T121,T125	C0021641
28065172	946	949	OAD	T121	C0935929
28065172	950	957	regimen	T061	C0040808
28065172	958	967	increases	T169	C0442805
28065172	968	973	costs	T081	C0010186
28065172	1002	1009	patient	T101	C0030705
28065172	1017	1032	associated with	T080	C0332281
28065172	1038	1048	additional	T169	C1524062
28065172	1049	1076	quality-adjusted life-years	T079	C0080071
28065172	1081	1088	patient	T101	C0030705
28065172	1094	1101	insulin	T116,T121,T125	C0021641
28065172	1104	1107	OAD	T121	C0935929
28065172	1108	1119	combination	T080	C0205195
28065172	1120	1127	regimen	T061	C0040808
28065172	1143	1152	treatment	T169	C0039798
28065172	1157	1175	disease management	T058	C0376636
28065172	1178	1185	related	T080	C0439849
28065172	1186	1189	CO2	T123,T197	C0007012
28065172	1190	1199	emissions	T167	C2349995
28065172	1204	1211	patient	T101	C0030705
28065172	1232	1235	OAD	T121	C0935929
28065172	1242	1249	regimen	T061	C0040808
28065172	1280	1289	emissions	T167	C2349995
28065172	1290	1305	associated with	T080	C0332281
28065172	1306	1314	treating	T169	C1522326
28065172	1315	1328	complications	T046	C0009566
28065172	1373	1380	insulin	T116,T121,T125	C0021641
28065172	1384	1387	OAD	T121	C0935929
28065172	1388	1395	therapy	T061	C0087111
28065172	1427	1430	CO2	T123,T197	C0007012
28065172	1431	1440	emissions	T167	C2349995
28065172	1445	1452	patient	T101	C0030705
28065172	1461	1466	years	T079	C0439234
28065172	1472	1477	model	T075	C0026336
28065172	1507	1520	incorporating	T169	C0243126
28065172	1521	1534	environmental	T082	C0014406
28065172	1535	1543	outcomes	T081	C0086749
28065172	1549	1555	health	T078	C0018684
28065172	1556	1573	economic analyses	T057	C0150099
28065172	1618	1626	reducing	T080	C0392756
28065172	1631	1651	environmental impact	T067	C0282165
28065172	1655	1666	health care	T058	C0086388
28065172	1696	1703	improve	T033	C0184511
28065172	1708	1716	accuracy	T080	C0443131
28065172	1753	1763	generation	T052	C3146294
28065172	1785	1806	environmental impacts	T067	C0282165

27753022|t|Implementing Non-Invasive Prenatal Diagnosis (NIPD) in a National Health Service Laboratory; From Dominant to Recessive Disorders
27753022|a|Our UK National Health Service regional genetics laboratory offers NIPD for autosomal dominant and de novo conditions (achondroplasia, thanataphoric dysplasia, Apert syndrome), paternal mutation exclusion for cystic fibrosis and a range of bespoke tests. NIPD avoids the risks associated with invasive testing, making prenatal diagnosis more accessible to families at high genetic risk. However, the challenge remains in offering definitive diagnosis for autosomal recessive diseases, which is complicated by the predominance of the maternal mutant allele in the cell-free DNA sample and thus requires a variety of different approaches. Validation and diagnostic implementation for NIPD of congenital adrenal hyperplasia (CAH) is further complicated by presence of a pseudogene that requires a different approach. We have used an assay targeting approximately 6700 heterozygous SNPs around the CAH gene (CYP21A2) to construct the high-risk parental haplotypes and tested this approach in five cases, showing that inheritance of the parental alleles can be correctly identified using NIPD. We are evaluating various measures of the fetal fraction to help determine inheritance of parental mutations. We are currently exploring the utility of an NIPD multi-disorder panel for autosomal recessive disease, to make testing more widely applicable to families with a variety of serious genetic conditions.
27753022	0	12	Implementing	T052	C1708476
27753022	13	25	Non-Invasive	T169	C0205303
27753022	26	44	Prenatal Diagnosis	T060	C0033053
27753022	46	50	NIPD	T060	C0033053
27753022	57	91	National Health Service Laboratory	T073,T093	C0022877
27753022	98	106	Dominant	T169	C1527180
27753022	110	119	Recessive	T045	C0678943
27753022	120	129	Disorders	T047	C0012634
27753022	134	189	UK National Health Service regional genetics laboratory	T073,T093	C0022877
27753022	197	201	NIPD	T060	C0033053
27753022	206	224	autosomal dominant	T045	C0443147
27753022	229	236	de novo	T078	C1515568
27753022	237	247	conditions	T080	C0348080
27753022	249	263	achondroplasia	T019	C0001080
27753022	265	288	thanataphoric dysplasia	T019	C0039743
27753022	290	304	Apert syndrome	T019	C0001193
27753022	307	315	paternal	T080	C0337493
27753022	316	324	mutation	T045	C0026882
27753022	325	334	exclusion	T169	C0680251
27753022	339	354	cystic fibrosis	T047	C0010674
27753022	370	383	bespoke tests	T060	C0683443
27753022	385	389	NIPD	T060	C0033053
27753022	401	406	risks	T033	C0035648
27753022	407	422	associated with	T080	C0332281
27753022	423	439	invasive testing	T060	C0430022
27753022	448	466	prenatal diagnosis	T060	C0033053
27753022	467	471	more	T081	C0205172
27753022	486	494	families	T099	C0015576
27753022	498	502	high	T080	C0205250
27753022	503	515	genetic risk	T081	C1517512
27753022	560	570	definitive	T079	C0443196
27753022	571	580	diagnosis	T033	C0011900
27753022	585	613	autosomal recessive diseases	T047	C0265388
27753022	624	635	complicated	T169	C0231242
27753022	643	655	predominance	T080	C0332251
27753022	663	671	maternal	T099	C0026591
27753022	672	678	mutant	T049	C0596988
27753022	679	685	allele	T028	C0002085
27753022	693	706	cell-free DNA	T114	C4289789
27753022	707	713	sample	T077	C2347026
27753022	734	741	variety	T077	C2346866
27753022	745	754	different	T080	C1705242
27753022	755	765	approaches	T082	C0449445
27753022	767	777	Validation	T062	C1519941
27753022	782	792	diagnostic	T169	C0348026
27753022	793	807	implementation	T052	C1708476
27753022	812	816	NIPD	T060	C0033053
27753022	820	850	congenital adrenal hyperplasia	T047	C0001627
27753022	852	855	CAH	T047	C0001627
27753022	868	879	complicated	T169	C0231242
27753022	883	891	presence	T033	C0150312
27753022	897	907	pseudogene	T028	C0033799
27753022	924	933	different	T080	C1705242
27753022	934	942	approach	T082	C0449445
27753022	960	965	assay	T059	C0005507
27753022	966	975	targeting	T169	C1521840
27753022	976	989	approximately	T080	C0332232
27753022	995	1007	heterozygous	T032	C0019425
27753022	1008	1012	SNPs	T086	C0752046
27753022	1024	1032	CAH gene	T028	C1413861
27753022	1034	1041	CYP21A2	T028	C1413861
27753022	1060	1069	high-risk	T033	C0332167
27753022	1070	1078	parental	T099	C0030551
27753022	1079	1089	haplotypes	T032	C0018591
27753022	1106	1114	approach	T082	C0449445
27753022	1143	1154	inheritance	T081	C0242538
27753022	1162	1170	parental	T099	C0030551
27753022	1171	1178	alleles	T028	C0002085
27753022	1196	1206	identified	T080	C0205396
27753022	1213	1217	NIPD	T060	C0033053
27753022	1245	1253	measures	T081	C0079809
27753022	1261	1266	fetal	T018	C0015965
27753022	1294	1305	inheritance	T081	C0242538
27753022	1309	1317	parental	T099	C0030551
27753022	1318	1327	mutations	T045	C0026882
27753022	1360	1367	utility	T080	C3827682
27753022	1374	1378	NIPD	T060	C0033053
27753022	1379	1399	multi-disorder panel	T059	C0022885
27753022	1404	1431	autosomal recessive disease	T047	C0265388
27753022	1441	1448	testing	T169	C0039593
27753022	1461	1471	applicable	T080	C1706839
27753022	1475	1483	families	T099	C0015576
27753022	1502	1509	serious	T080	C0205404
27753022	1510	1528	genetic conditions	T047	C0019247

28515464|t|Systems Immunology of Diabetes - Tuberculosis Comorbidity Reveals Signatures of Disease Complications
28515464|a|Comorbid diabetes mellitus (DM) increases tuberculosis (TB) risk and adverse outcomes but the pathological interactions between DM and TB remain incompletely understood. We performed an integrative analysis of whole blood gene expression and plasma analytes, comparing South Indian TB patients with and without DM to diabetic and non-diabetic controls without TB. Luminex assay of plasma cytokines and growth factors delineated a distinct biosignature in comorbid TBDM in this cohort. Transcriptional profiling revealed elements in common with published TB signatures from cohorts that excluded DM. Neutrophil count correlated with the molecular degree of perturbation, especially in TBDM patients. Body mass index and HDL cholesterol were negatively correlated with molecular degree of perturbation. Diabetic complication pathways including several pathways linked to epigenetic reprogramming were activated in TBDM above levels observed with DM alone. Our data provide a rationale for trials of host-directed therapies in TBDM, targeting neutrophilic inflammation and diabetic complication pathways to address the greater morbidity and mortality associated with this increasingly prevalent dual burden of communicable and non-communicable diseases.
28515464	0	18	Systems Immunology	UnknownType	C0681949
28515464	22	30	Diabetes	T047	C0011847
28515464	33	45	Tuberculosis	T047	C0041296
28515464	46	57	Comorbidity	T078	C0009488
28515464	58	65	Reveals	T080	C0443289
28515464	66	76	Signatures	T169	C1704864
28515464	80	101	Disease Complications	T046	C0544688
28515464	102	110	Comorbid	T078	C0009488
28515464	111	128	diabetes mellitus	T047	C0011849
28515464	130	132	DM	T047	C0011849
28515464	134	143	increases	T081	C0205217
28515464	144	156	tuberculosis	T047	C0041296
28515464	158	160	TB	T047	C0041296
28515464	162	166	risk	T078	C0035647
28515464	171	187	adverse outcomes	T033	C1705586
28515464	196	208	pathological	T169	C1521733
28515464	209	221	interactions	T169	C1704675
28515464	230	232	DM	T047	C0011849
28515464	237	239	TB	T047	C0041296
28515464	275	284	performed	T169	C0884358
28515464	288	299	integrative	T080	C0205195
28515464	300	308	analysis	T062	C0936012
28515464	312	323	whole blood	T031	C0370231
28515464	324	339	gene expression	T045	C0017262
28515464	344	359	plasma analytes	T031	C1609077
28515464	361	370	comparing	T052	C1707455
28515464	371	383	South Indian	T098	C1257890
28515464	384	386	TB	T047	C0041296
28515464	387	395	patients	T101	C0030705
28515464	413	415	DM	T047	C0011849
28515464	419	427	diabetic	T033	C0241863
28515464	445	453	controls	T096	C0009932
28515464	462	464	TB	T047	C0041296
28515464	466	479	Luminex assay	T059	C0005507
28515464	483	499	plasma cytokines	T201	C1544815
28515464	504	518	growth factors	T116,T123	C0018284
28515464	519	529	delineated	T033	C0150312
28515464	541	553	biosignature	T169	C1704864
28515464	557	570	comorbid TBDM	T033	C1275743
28515464	579	585	cohort	T098	C0599755
28515464	587	612	Transcriptional profiling	T063	C1513400
28515464	613	621	revealed	T080	C0443289
28515464	646	655	published	T170	C1704324
28515464	656	658	TB	T047	C0041296
28515464	659	669	signatures	T169	C1704864
28515464	675	682	cohorts	T098	C0599755
28515464	688	696	excluded	T052	C2828389
28515464	697	699	DM	T047	C0011849
28515464	701	717	Neutrophil count	T059	C0200633
28515464	718	728	correlated	T080	C1707520
28515464	738	747	molecular	T080	C1521991
28515464	748	754	degree	T081	C0449286
28515464	758	770	perturbation	T169	C0332453
28515464	786	799	TBDM patients	T101	C0030705
28515464	801	816	Body mass index	T201	C1305855
28515464	821	836	HDL cholesterol	T109,T123	C0023822
28515464	842	852	negatively	T033	C0205160
28515464	853	863	correlated	T080	C1707520
28515464	869	878	molecular	T080	C1521991
28515464	879	885	degree	T081	C0449286
28515464	889	901	perturbation	T169	C0332453
28515464	903	911	Diabetic	T033	C0241863
28515464	912	924	complication	T046	C0544688
28515464	925	933	pathways	T077	C1705987
28515464	952	960	pathways	T077	C1705987
28515464	971	995	epigenetic reprogramming	T045	C1516924
28515464	1001	1010	activated	T052	C1879547
28515464	1014	1018	TBDM	T033	C1275743
28515464	1025	1031	levels	T080	C0441889
28515464	1046	1048	DM	T047	C0011849
28515464	1060	1064	data	T078	C1511726
28515464	1075	1084	rationale	T078	C2699007
28515464	1089	1095	trials	T062	C0008976
28515464	1099	1122	host-directed therapies	T169	C0039798
28515464	1126	1130	TBDM	T033	C1275743
28515464	1132	1141	targeting	T043	C0599894
28515464	1142	1154	neutrophilic	T025	C0027950
28515464	1155	1167	inflammation	T046	C0021368
28515464	1172	1180	diabetic	T033	C0241863
28515464	1181	1193	complication	T046	C0544688
28515464	1194	1202	pathways	T077	C1705987
28515464	1226	1235	morbidity	T081	C0026538
28515464	1240	1249	mortality	T033	C1306577
28515464	1250	1265	associated with	T080	C0332281
28515464	1271	1293	increasingly prevalent	T081	C1512456
28515464	1299	1305	burden	T078	C2828008
28515464	1309	1321	communicable	T047	C0009450

28389368|t|Silk I and Silk II studied by fast scanning calorimetry
28389368|a|Using fast scanning calorimetry (FSC), we investigated the glass transition and crystal melting of samples of B. mori silk fibroin containing Silk I and/or Silk II crystal s. Due to the very short residence times at high temperatures during such measurements, thermal decomposition of silk protein can be significantly suppressed. FSC was performed at 2000K/s using the Mettler Flash DSC1 on fibroin films with masses around 130-270ng. Films were prepared with different crystalline fractions (ranging from 0.26 to 0.50) and with different crystal structures (Silk I, Silk II, or mixed) by varying the processing conditions. These included water annealing at different temperatures, exposure to 50% MeOH in water, or autoclaving. The resulting crystal structure was examined using wide angle X-ray scattering. Degree of crystallinity was evaluated from Fourier transform infrared (FTIR) spectroscopy and from analysis of the heat capacity increment at the glass transition temperature. Silk fibroin films prepared by water annealing at 25°C were the least crystalline and had Silk I structure. FTIR and FSC studies showed that films prepared by autoclaving or 50% MeOH exposure were the most crystalline and had Silk II structure. Intermediate crystalline fraction and mixed Silk I / Silk II structure s were found in films prepared by water annealing at 37°C. FSC results indicate that Silk I I crystals exhibit endotherms of narrower width and have higher mean melting temperature Tm(II)=351±2.6°C, compared to Silk I crystals which melt at Tm(I)=292±3.8°C. Films containing mixed Silk I / Silk II structure showed two clearly separated endothermic peaks. Evidence suggests that the two types of crystal s melt separately and do not thermal ly interconvert on the extremely short time scale (0.065s between onset and end of melting) of the FSC experiment. Silkworm silk is a naturally occurring biomaterial. The fibroin component of silk forms two types of crystals. Silk properties depend upon the amount and type of crystals, and their stability. One measure of stability is crystal melting temperature. Crystal s which are more stable have a higher melting temperature. Until now, it has been challenging to study thermal behavior of silk crystal s because they degrade at high temperature. To avoid degradation, and study the melting properties of silk biomaterial, we heated silk at a very fast rate of 2000K/s using a special calorimeter. We have shown that the two crystal types have very different melting temperature s, indicating that one crystal type is much more stable than the other.
28389368	0	6	Silk I	T116,T121,T123	C0074529
28389368	11	18	Silk II	T116,T121,T123	C0074529
28389368	19	26	studied	T062	C2603343
28389368	30	55	fast scanning calorimetry	T059	C0006780
28389368	62	87	fast scanning calorimetry	T059	C0006780
28389368	89	92	FSC	T059	C0006780
28389368	98	110	investigated	T169	C1292732
28389368	115	131	glass transition	T052	C2700061
28389368	136	143	crystal	T104	C0444626
28389368	144	151	melting	T070	C0599882
28389368	155	162	samples	T167	C0370003
28389368	166	173	B. mori	T204	C0323309
28389368	174	186	silk fibroin	T116,T123	C1449666
28389368	198	204	Silk I	T116,T121,T123	C0074529
28389368	212	219	Silk II	T116,T121,T123	C0074529
28389368	220	227	crystal	T104	C0444626
28389368	247	252	short	T081	C1806781
28389368	253	262	residence	T082	C0237096
28389368	263	268	times	T079	C0040223
28389368	272	276	high	T080	C0205250
28389368	277	289	temperatures	T081	C0039476
28389368	302	314	measurements	T169	C0242485
28389368	316	323	thermal	T070	C0018837
28389368	324	337	decomposition	T067	C2700592
28389368	341	353	silk protein	T116,T121,T123	C0074529
28389368	361	374	significantly	T078	C0750502
28389368	375	385	suppressed	T080	C0443189
28389368	387	390	FSC	T059	C0006780
28389368	395	404	performed	T169	C0884358
28389368	426	444	Mettler Flash DSC1	T059	C0006780
28389368	448	455	fibroin	T116,T123	C0016042
28389368	456	461	films	T167	C1561572
28389368	467	473	masses	T081	C1306372
28389368	492	497	Films	T167	C1561572
28389368	517	526	different	T080	C1705242
28389368	527	538	crystalline	T104	C0444626
28389368	539	548	fractions	T081	C1264633
28389368	586	595	different	T080	C1705242
28389368	596	614	crystal structures	T104	C0444626
28389368	616	622	Silk I	T116,T121,T123	C0074529
28389368	624	631	Silk II	T116,T121,T123	C0074529
28389368	658	668	processing	T052	C1709694
28389368	669	679	conditions	T080	C0348080
28389368	696	701	water	T121,T197	C0043047
28389368	702	711	annealing	T061	C0150247
28389368	715	724	different	T080	C1705242
28389368	725	737	temperatures	T081	C0039476
28389368	739	750	exposure to	T080	C0332157
28389368	755	759	MeOH	T109,T131	C0001963
28389368	763	768	water	T121,T197	C0043047
28389368	773	784	autoclaving	T074	C0179177
28389368	790	799	resulting	T169	C1274040
28389368	800	817	crystal structure	T104	C0444626
28389368	837	847	wide angle	T082	C0205143
28389368	848	864	X-ray scattering	T060	C1306645
28389368	866	872	Degree	T081	C0449286
28389368	876	889	crystallinity	T104	C0444626
28389368	894	903	evaluated	T033	C0332128
28389368	909	955	Fourier transform infrared (FTIR) spectroscopy	T062	C0206055
28389368	965	973	analysis	T062	C0936012
28389368	981	994	heat capacity	T081	C2349063
28389368	995	1004	increment	T081	C1705117
28389368	1012	1040	glass transition temperature	T080	C1257885
28389368	1042	1054	Silk fibroin	T116,T123	C1449666
28389368	1055	1060	films	T167	C1561572
28389368	1073	1078	water	T121,T197	C0043047
28389368	1079	1088	annealing	T061	C0150247
28389368	1112	1123	crystalline	T104	C0444626
28389368	1132	1138	Silk I	T116,T121,T123	C0074529
28389368	1139	1148	structure	T116	C1510464
28389368	1150	1154	FTIR	T062	C0206055
28389368	1159	1162	FSC	T059	C0006780
28389368	1163	1170	studies	T062	C2603343
28389368	1183	1188	films	T167	C1561572
28389368	1201	1212	autoclaving	T074	C0179177
28389368	1220	1224	MeOH	T109,T131	C0001963
28389368	1225	1233	exposure	T080	C0332157
28389368	1248	1259	crystalline	T104	C0444626
28389368	1268	1275	Silk II	T116,T121,T123	C0074529
28389368	1276	1285	structure	T116	C1510464
28389368	1287	1299	Intermediate	T082	C0205103
28389368	1300	1311	crystalline	T104	C0444626
28389368	1312	1320	fraction	T081	C1264633
28389368	1331	1337	Silk I	T116,T121,T123	C0074529
28389368	1340	1347	Silk II	T116,T121,T123	C0074529
28389368	1348	1357	structure	T116	C1510464
28389368	1374	1379	films	T167	C1561572
28389368	1392	1397	water	T121,T197	C0043047
28389368	1398	1407	annealing	T061	C0150247
28389368	1417	1420	FSC	T059	C0006780
28389368	1421	1428	results	T033	C0683954
28389368	1443	1449	Silk I	T116,T121,T123	C0074529
28389368	1443	1451	Silk I I	T116,T121,T123	C0074529
28389368	1452	1460	crystals	T104	C0444626
28389368	1469	1479	endotherms	T080	C0205556
28389368	1483	1497	narrower width	T080	C0333164
28389368	1507	1513	higher	T080	C0205250
28389368	1514	1518	mean	T081	C0444504
28389368	1519	1538	melting temperature	T081	C1456458
28389368	1557	1565	compared	T052	C1707455
28389368	1569	1575	Silk I	T116,T121,T123	C0074529
28389368	1576	1584	crystals	T104	C0444626
28389368	1591	1595	melt	T070	C0599882
28389368	1616	1621	Films	T167	C1561572
28389368	1639	1645	Silk I	T116,T121,T123	C0074529
28389368	1648	1655	Silk II	T116,T121,T123	C0074529
28389368	1656	1665	structure	T116	C1510464
28389368	1677	1684	clearly	T080	C2963144
28389368	1685	1694	separated	T080	C0443299
28389368	1695	1706	endothermic	T080	C0205556
28389368	1707	1712	peaks	T080	C0444505
28389368	1714	1722	Evidence	T078	C3887511
28389368	1754	1761	crystal	T104	C0444626
28389368	1764	1768	melt	T070	C0599882
28389368	1769	1779	separately	T080	C0443299
28389368	1791	1798	thermal	T070	C0018837
28389368	1802	1814	interconvert	T169	C0439836
28389368	1822	1831	extremely	T080	C0205403
28389368	1832	1837	short	T081	C1806781
28389368	1838	1848	time scale	T079	C0040223
28389368	1882	1889	melting	T070	C0599882
28389368	1898	1912	FSC experiment	T059	C0006780
28389368	1914	1922	Silkworm	T204	C0037119
28389368	1923	1927	silk	T116,T121,T123	C0074529
28389368	1933	1942	naturally	T169	C0205296
28389368	1953	1964	biomaterial	T169	C1704781
28389368	1970	1987	fibroin component	T116,T123	C0016042
28389368	1991	2001	silk forms	T116,T121,T123	C0074529
28389368	2015	2023	crystals	T104	C0444626
28389368	2025	2029	Silk	T116,T121,T123	C0074529
28389368	2030	2040	properties	T080	C0871161
28389368	2057	2063	amount	T081	C1265611
28389368	2076	2084	crystals	T104	C0444626
28389368	2096	2105	stability	T080	C0205360
28389368	2111	2118	measure	T081	C0079809
28389368	2122	2131	stability	T080	C0205360
28389368	2135	2142	crystal	T104	C0444626
28389368	2143	2162	melting temperature	T081	C1456458
28389368	2164	2171	Crystal	T104	C0444626
28389368	2189	2195	stable	T080	C0205360
28389368	2203	2209	higher	T080	C0205250
28389368	2210	2229	melting temperature	T081	C1456458
28389368	2269	2274	study	T062	C2603343
28389368	2275	2282	thermal	T070	C0018837
28389368	2283	2291	behavior	T053	C0004927
28389368	2295	2299	silk	T116,T121,T123	C0074529
28389368	2300	2307	crystal	T104	C0444626
28389368	2323	2330	degrade	T169	C1880269
28389368	2334	2338	high	T080	C0205250
28389368	2339	2350	temperature	T081	C0039476
28389368	2361	2372	degradation	T169	C0243125
28389368	2378	2383	study	T062	C2603343
28389368	2388	2395	melting	T070	C0599882
28389368	2396	2406	properties	T080	C0871161
28389368	2410	2414	silk	T116,T121,T123	C0074529
28389368	2415	2426	biomaterial	T169	C1704781
28389368	2431	2437	heated	T067	C1522240
28389368	2438	2442	silk	T116,T121,T123	C0074529
28389368	2482	2501	special calorimeter	UnknownType	C0175896
28389368	2530	2537	crystal	T104	C0444626
28389368	2554	2563	different	T080	C1705242
28389368	2564	2583	melting temperature	T081	C1456458
28389368	2607	2614	crystal	T104	C0444626
28389368	2615	2619	type	T080	C0332307
28389368	2633	2639	stable	T080	C0205360

28366539|t|Influence of the different anteromedial portal on femoral tunnel orientation during anatomic ACL reconstruction
28366539|a|The purpose of this study was to evaluate the effect of femoral tunnel orientation, drilled through the accessory anteromedial (AAM) portal or the high AM portal in anatomic anterior cruciate ligament (ACL) reconstruction. In 16 cadaver knees, using o'clock method, centers of the ACL femoral footprint were drilled with an 8-mm reamer via an AAM portal (eight knees) or a high AM portal (eight knees). Computed tomography (CT) scans were taken of each knee. Three-dimensional (3D) models were constructed to identify the femoral tunnel orientation and to create femoral tunnel virtual cylinders for measuring tunnel angles and length. In two of the 16 specimens, we observed a posterior femoral cortex blowout (PFCB) when drilling through a high AM portal. When drilled through the high AM portal, the femoral tunnel length was significantly shorter than when using an AAM portal (30.3 ± 3.8 mm and 38.2 ± 3.1 mm, p < 0.001). The femoral tunnel length was significantly shorter in the group with PFCB compared to the group with no PFCB (25.9 ± 0.6 mm and 35.5 ± 4.5 mm, p = 0.011). The axial obliquity of the high AM portal was significantly higher than that of the AAM portal (52.2 ± 5.9° and 43.0 ± 2.3°, p = 0.003). In anatomic ACL reconstruction, a mal-positioned AM portal can cause abnormal tunnel orientation, which may lead to mechanical failure during ACL reconstruction. Therefore, it is important to select accurate AM portal positioning, and possibly using an AAM portal by measuring an accurate position when drilling a femoral tunnel in anatomic ACL reconstruction.
28366539	17	26	different	T080	C1705242
28366539	27	46	anteromedial portal	T061	C0185154
28366539	50	64	femoral tunnel	T023	C0015811
28366539	65	76	orientation	T082	C1704322
28366539	84	92	anatomic	T080	C0220784
28366539	93	111	ACL reconstruction	T061	C0188185
28366539	145	153	evaluate	T058	C0220825
28366539	158	164	effect	T080	C1280500
28366539	168	182	femoral tunnel	T023	C0015811
28366539	183	194	orientation	T082	C1704322
28366539	196	203	drilled	T061	C0337279
28366539	216	251	accessory anteromedial (AAM) portal	T061	C0185154
28366539	259	273	high AM portal	T061	C0185154
28366539	277	333	anatomic anterior cruciate ligament (ACL) reconstruction	T061	C0188185
28366539	341	348	cadaver	T017	C0006629
28366539	349	354	knees	T023	C0022742
28366539	362	376	o'clock method	T061	C1293156
28366539	378	385	centers	T082	C0205099
28366539	393	414	ACL femoral footprint	T023	C0078960
28366539	420	427	drilled	T061	C0337279
28366539	441	447	reamer	T074	C3853551
28366539	455	465	AAM portal	T061	C0185154
28366539	473	478	knees	T023	C0022742
28366539	485	499	high AM portal	T061	C0087111
28366539	507	512	knees	T023	C0022742
28366539	515	545	Computed tomography (CT) scans	T060	C0040405
28366539	565	569	knee	T023	C0022742
28366539	571	600	Three-dimensional (3D) models	T075	C0026336
28366539	634	648	femoral tunnel	T023	C0015811
28366539	649	660	orientation	T082	C1704322
28366539	668	674	create	T052	C1706214
28366539	675	707	femoral tunnel virtual cylinders	T023	C0015811
28366539	712	721	measuring	T080	C0444706
28366539	722	735	tunnel angles	T030	C0229984
28366539	740	746	length	T081	C1444754
28366539	765	774	specimens	T167	C0370003
28366539	779	787	observed	T169	C1441672
28366539	790	822	posterior femoral cortex blowout	T046	C0021890
28366539	824	828	PFCB	T046	C0021890
28366539	835	843	drilling	T061	C0337279
28366539	844	851	through	T169	C0332273
28366539	854	868	high AM portal	T061	C0185154
28366539	875	882	drilled	T061	C0337279
28366539	883	890	through	T169	C0332273
28366539	895	909	high AM portal	T061	C0185154
28366539	915	929	femoral tunnel	T023	C0015811
28366539	930	936	length	T081	C1444754
28366539	941	954	significantly	T078	C0750502
28366539	955	962	shorter	T081	C1806781
28366539	982	992	AAM portal	T061	C0185154
28366539	1043	1057	femoral tunnel	T023	C0015811
28366539	1058	1064	length	T081	C1444754
28366539	1069	1082	significantly	T078	C0750502
28366539	1083	1090	shorter	T081	C1806781
28366539	1098	1103	group	T078	C0441833
28366539	1109	1113	PFCB	T046	C0021890
28366539	1114	1122	compared	T052	C1707455
28366539	1130	1135	group	T078	C0441833
28366539	1141	1148	no PFCB	T033	C0243095
28366539	1199	1214	axial obliquity	T082	C0205315
28366539	1222	1236	high AM portal	T061	C0185154
28366539	1241	1254	significantly	T078	C0750502
28366539	1255	1261	higher	T080	C0205250
28366539	1279	1289	AAM portal	T061	C0185154
28366539	1335	1343	anatomic	T080	C0220784
28366539	1344	1362	ACL reconstruction	T061	C0188185
28366539	1366	1380	mal-positioned	T082	C0333042
28366539	1381	1390	AM portal	T061	C0185154
28366539	1401	1409	abnormal	T033	C0205161
28366539	1410	1416	tunnel	T023	C0015811
28366539	1417	1428	orientation	T082	C1704322
28366539	1448	1458	mechanical	T169	C0443254
28366539	1474	1492	ACL reconstruction	T061	C0188185
28366539	1531	1539	accurate	T080	C0443131
28366539	1540	1549	AM portal	T061	C0185154
28366539	1550	1561	positioning	T082	C0733755
28366539	1585	1595	AAM portal	T061	C0185154
28366539	1599	1608	measuring	T080	C0444706
28366539	1612	1620	accurate	T080	C0443131
28366539	1621	1629	position	T082	C0733755
28366539	1635	1643	drilling	T061	C0337279
28366539	1646	1660	femoral tunnel	T023	C0015811
28366539	1664	1672	anatomic	T080	C0220784
28366539	1673	1691	ACL reconstruction	T061	C0188185

27265654|t|Conservation education and habitat restoration for the endangered Sagalla caecilian (Boulengerula niedeni) in Sagalla Hill, Kenya
27265654|a|The Sagalla caecilian (Boulengerula niedeni) is an endangered amphibian endemic to Sagalla Hill in the Taita Hills. This burrowing worm -like species prefers soft soil with high moisture and organic matter. The major threats to the Sagalla caecilian are soil erosion caused by steep slopes, bare ground and water siphoning / soil hardening from exotic eucalyptus trees. The purpose of this study was to get a better understanding of the local people's attitude towards this species and how they can contribute to its continued conservation through restoration of its remaining habitat. In this study, it was found that 96% of Sagalla people are aware of the species, its habits and its association with soils high in organic matter. It was also found that 96% of Sagalla people use organic manure from cow dung in their farms. Habitat restoration through planting of indigenous plants was found to be ongoing, especially on compounds of public institutions as well as on private lands. Although drought was found to be a challenge for seedlings development especially on the low elevation sites, destruction by livestock especially during the dry season is also a major threat. In this study, it was recommended that any future habitat restoration initiative should include strong chain-link fencing to protect the seedlings from livestock activity. Recognizing that the preferred habitats for the species are in the valleys, systematic planting of keystone plant species such as fig trees (Ficus) creates the best microhabitats. These are better than general woodlots of indigenous trees.
27265654	0	22	Conservation education	T065	C0013652
27265654	27	34	habitat	T082	C0871648
27265654	35	46	restoration	T169	C0205245
27265654	55	65	endangered	T098	C2717882
27265654	66	83	Sagalla caecilian	T011	C2999417
27265654	85	105	Boulengerula niedeni	T011	C2999417
27265654	110	122	Sagalla Hill	T083	C0022558
27265654	124	129	Kenya	T083	C0022558
27265654	134	151	Sagalla caecilian	T011	C2999417
27265654	153	173	Boulengerula niedeni	T011	C2999417
27265654	181	191	endangered	T098	C2717882
27265654	192	201	amphibian	T011	C0002668
27265654	202	209	endemic	UnknownType	C0681784
27265654	213	225	Sagalla Hill	T083	C0022558
27265654	233	244	Taita Hills	T083	C0022558
27265654	251	265	burrowing worm	T204	C0018893
27265654	272	279	species	T185	C1705920
27265654	288	292	soft	T080	C0205358
27265654	293	297	soil	T167	C0037592
27265654	303	307	high	T080	C0205250
27265654	308	316	moisture	T167	C0868994
27265654	321	335	organic matter	T167	C0439861
27265654	341	346	major	T080	C0205164
27265654	347	354	threats	T078	C0749385
27265654	362	379	Sagalla caecilian	T011	C2999417
27265654	384	396	soil erosion	T070	C1254365
27265654	397	403	caused	T169	C0678227
27265654	407	419	steep slopes	T082	C1254362
27265654	426	432	ground	T083	C0242744
27265654	437	452	water siphoning	T067	C1254366
27265654	455	469	soil hardening	T067	C1254366
27265654	475	498	exotic eucalyptus trees	T002	C0015148
27265654	520	525	study	T062	C2603343
27265654	539	545	better	T080	C0332272
27265654	546	559	understanding	T041	C0162340
27265654	567	572	local	T082	C0205276
27265654	573	581	people's	T098	C0027361
27265654	582	590	attitude	T041	C0004271
27265654	604	611	species	T185	C1705920
27265654	629	639	contribute	T052	C1880177
27265654	647	656	continued	T078	C0549178
27265654	657	669	conservation	T080	C2347858
27265654	678	689	restoration	T169	C0205245
27265654	697	706	remaining	T080	C1527428
27265654	707	714	habitat	T082	C0871648
27265654	724	729	study	T062	C2603343
27265654	738	743	found	T033	C0150312
27265654	756	763	Sagalla	T083	C0022558
27265654	764	770	people	T098	C0027361
27265654	775	780	aware	T041	C0004448
27265654	788	795	species	T185	C1705920
27265654	801	807	habits	T055	C0018464
27265654	833	838	soils	T167	C0037592
27265654	839	843	high	T080	C0205250
27265654	847	861	organic matter	T167	C0439861
27265654	875	880	found	T033	C0150312
27265654	893	900	Sagalla	T083	C0022558
27265654	901	907	people	T098	C0027361
27265654	912	919	organic	T080	C0747055
27265654	920	926	manure	T167	C0024765
27265654	932	935	cow	T015	C0007452
27265654	936	940	dung	T031	C0015733
27265654	950	955	farms	T082	C0557759
27265654	957	964	Habitat	T082	C0871648
27265654	965	976	restoration	T169	C0205245
27265654	985	993	planting	T052	C0441655
27265654	997	1007	indigenous	T082	C0205276
27265654	1008	1014	plants	T002	C0032098
27265654	1019	1024	found	T033	C0150312
27265654	1031	1038	ongoing	T078	C0549178
27265654	1040	1050	especially	T080	C0205555
27265654	1054	1063	compounds	T103	C1706082
27265654	1067	1086	public institutions	T092	C1552744
27265654	1101	1114	private lands	UnknownType	C0681784
27265654	1125	1132	drought	T070	C0013140
27265654	1137	1142	found	T033	C0150312
27265654	1165	1174	seedlings	T002	C0242437
27265654	1175	1186	development	T169	C1527148
27265654	1205	1208	low	T080	C0205251
27265654	1209	1218	elevation	T082	C0702240
27265654	1219	1224	sites	T082	C0205145
27265654	1226	1237	destruction	T052	C1948029
27265654	1241	1250	livestock	T008	C2936506
27265654	1262	1268	during	T079	C0347984
27265654	1273	1276	dry	T080	C0205222
27265654	1277	1283	season	T079	C0036497
27265654	1294	1299	major	T080	C0205164
27265654	1300	1306	threat	T078	C0749385
27265654	1316	1321	study	T062	C2603343
27265654	1330	1341	recommended	T078	C0034866
27265654	1351	1357	future	T079	C0016884
27265654	1358	1365	habitat	T082	C0871648
27265654	1366	1377	restoration	T169	C0205245
27265654	1378	1388	initiative	T041	C0424093
27265654	1396	1403	include	T169	C0332257
27265654	1404	1410	strong	T080	C0442821
27265654	1411	1421	chain-link	T073	C3273359
27265654	1422	1429	fencing	T052	C0441655
27265654	1445	1454	seedlings	T002	C0242437
27265654	1460	1469	livestock	T008	C2936506
27265654	1470	1478	activity	T052	C0441655
27265654	1501	1510	preferred	T078	C0558295
27265654	1511	1519	habitats	T082	C0871648
27265654	1528	1535	species	T185	C1705920
27265654	1547	1554	valleys	T082	C0563004
27265654	1556	1566	systematic	T169	C0220922
27265654	1567	1575	planting	T052	C0441655
27265654	1579	1593	keystone plant	T002	C0032098
27265654	1594	1601	species	T185	C1705920
27265654	1610	1619	fig trees	T002	C0969754
27265654	1621	1626	Ficus	T002	C0969754
27265654	1628	1635	creates	T052	C1706214
27265654	1645	1658	microhabitats	T082	C0871648
27265654	1670	1676	better	T080	C0332272
27265654	1682	1689	general	T082	C0205246
27265654	1690	1698	woodlots	T082	C1254362
27265654	1702	1712	indigenous	T082	C0205276
27265654	1713	1718	trees	T002	C0040811

27667559|t|Effects of an early intervention using human amniotic epithelial cells in a COPD rat model
27667559|a|The study aimed to investigate the effect of an early intervention using human amniotic epithelial cell (hAEC) in a rat model of chronic obstructive pulmonary disease (COPD). Twenty-four specific pathogen-free Wistar rats were randomized to the control, COPD, and COPD + hAEC groups. COPD was established by intratracheal LPS injection combined with smoke fumigation over 30 days. On the first day of model establishment rats in the AEC group also received intratracheal instillation of 500,000 hAECs isolated from the placenta of healthy donors. The mean linear intercept (MLI) and mean alveolar number (MAN) were used to assess the degree of lung emphysema. IL-8 was measured using a radioimmunoassay, surfactant protein D (SP-D) was measured by ELISA, and matrix metalloproteinase (MMP)2 and MMP8 expression was assessed by PCR. Smoke fumigation combined to LPS injection successfully established a COPD rat model with significant emphysema and airway inflammation, elevated MLI and MAN, elevated systemic and lung tissue levels of IL-8 and SP-D (P<0.05), and high expression of MMP2 and MMP8. Rats in the COPD + hAEC group exhibited alleviated lung damage, MLI and MAN (P<0.05), reduced systemic and lung tissue levels of IL-8 and SP-D (P<0.05) and MMP2 and MMP8 expression (P<0.05). Early intervention using hAECs could delay disease progression in rats with COPD.
27667559	0	7	Effects	T080	C1280500
27667559	20	32	intervention	T061	C0184661
27667559	39	44	human	T016	C0086418
27667559	45	53	amniotic	T018	C0002630
27667559	54	70	epithelial cells	T025	C0014597
27667559	76	80	COPD	T047	C0024117
27667559	81	84	rat	T015	C0034716
27667559	85	90	model	T075	C0026336
27667559	95	100	study	T062	C2603343
27667559	110	121	investigate	T169	C1292732
27667559	126	132	effect	T080	C1280500
27667559	145	157	intervention	T061	C0184661
27667559	164	169	human	T016	C0086418
27667559	170	178	amniotic	T018	C0002630
27667559	179	194	epithelial cell	T025	C0014597
27667559	196	200	hAEC	T025	C0014597
27667559	207	210	rat	T015	C0034716
27667559	211	216	model	T075	C0026336
27667559	220	257	chronic obstructive pulmonary disease	T047	C0024117
27667559	259	263	COPD	T047	C0024117
27667559	278	300	specific pathogen-free	T001	C0162470
27667559	301	312	Wistar rats	T015	C0034716
27667559	318	328	randomized	T062,T170	C0206034
27667559	336	343	control	T096	C0009932
27667559	345	349	COPD	T047	C0024117
27667559	355	359	COPD	T047	C0024117
27667559	362	366	hAEC	T025	C0014597
27667559	367	373	groups	T078	C0441833
27667559	375	379	COPD	T047	C0024117
27667559	399	412	intratracheal	T169	C1555389
27667559	413	416	LPS	T109	C0023810
27667559	441	446	smoke	T131	C0037366
27667559	447	457	fumigation	T068	C0016804
27667559	466	470	days	T079	C0439228
27667559	485	488	day	T079	C0439228
27667559	492	497	model	T075	C0026336
27667559	512	516	rats	T015	C0034716
27667559	524	527	AEC	T025	C0014597
27667559	528	533	group	T078	C0441833
27667559	548	574	intratracheal instillation	T169	C1555389
27667559	586	591	hAECs	T025	C0014597
27667559	610	618	placenta	T018	C0032043
27667559	622	629	healthy	T080	C3898900
27667559	630	636	donors	T098	C0013018
27667559	642	663	mean linear intercept	T081	C1444754
27667559	665	668	MLI	T081	C1444754
27667559	674	694	mean alveolar number	T081	C0237753
27667559	696	699	MAN	T081	C0237753
27667559	735	749	lung emphysema	T047	C0034067
27667559	751	755	IL-8	T116,T129	C0079633
27667559	777	793	radioimmunoassay	T059	C0034580
27667559	795	815	surfactant protein D	T116,T123	C0084692
27667559	817	821	SP-D	T116,T123	C0084692
27667559	839	844	ELISA	T059	C0014441
27667559	850	881	matrix metalloproteinase (MMP)2	T116,T126	C0172537
27667559	886	890	MMP8	T116,T126	C0172956
27667559	891	901	expression	T045	C1171362
27667559	918	921	PCR	T063	C0032520
27667559	923	928	Smoke	T131	C0037366
27667559	929	939	fumigation	T068	C0016804
27667559	952	955	LPS	T109	C0023810
27667559	993	997	COPD	T047	C0024117
27667559	998	1001	rat	T015	C0034716
27667559	1002	1007	model	T075	C0026336
27667559	1025	1034	emphysema	T047	C0034067
27667559	1039	1058	airway inflammation	T046	C0021368
27667559	1060	1068	elevated	T080	C3163633
27667559	1069	1072	MLI	T081	C1444754
27667559	1077	1080	MAN	T081	C0237753
27667559	1082	1090	elevated	T080	C3163633
27667559	1091	1099	systemic	T169	C0205373
27667559	1104	1108	lung	T023	C0024109
27667559	1109	1115	tissue	T024	C0040300
27667559	1116	1122	levels	T080	C0441889
27667559	1126	1130	IL-8	T116,T129	C0079633
27667559	1135	1139	SP-D	T116,T123	C0084692
27667559	1159	1169	expression	T045	C1171362
27667559	1173	1177	MMP2	T116,T126	C0172537
27667559	1182	1186	MMP8	T116,T126	C0172956
27667559	1188	1192	Rats	T015	C0034716
27667559	1200	1204	COPD	T047	C0024117
27667559	1207	1211	hAEC	T025	C0014597
27667559	1212	1217	group	T078	C0441833
27667559	1228	1238	alleviated	T080	C0392756
27667559	1239	1243	lung	T023	C0024109
27667559	1244	1250	damage	T037	C0010957
27667559	1252	1255	MLI	T081	C1444754
27667559	1260	1263	MAN	T081	C0237753
27667559	1274	1281	reduced	T080	C0392756
27667559	1282	1290	systemic	T169	C0205373
27667559	1295	1299	lung	T023	C0024109
27667559	1300	1306	tissue	T024	C0040300
27667559	1307	1313	levels	T080	C0441889
27667559	1317	1321	IL-8	T116,T129	C0079633
27667559	1326	1330	SP-D	T116,T123	C0084692
27667559	1344	1348	MMP2	T116,T126	C0172537
27667559	1353	1357	MMP8	T116,T126	C0172956
27667559	1358	1368	expression	T045	C1171362
27667559	1385	1397	intervention	T061	C0184661
27667559	1404	1409	hAECs	T025	C0014597
27667559	1422	1441	disease progression	T046	C0242656
27667559	1445	1449	rats	T015	C0034716
27667559	1455	1459	COPD	T047	C0024117

27792644|t|Challenging Achievement of Bidirectional Block After Linear Ablation Affects the Rhythm Outcome in Patients With Persistent Atrial Fibrillation
27792644|a|It is not clear whether bidirectional block (BDB) of linear ablations reduces atrial fibrillation (AF) recurrence after radiofrequency catheter ablation. We hypothesized that BDB of linear ablation has prognostic significance after radiofrequency catheter ablation for persistent AF. Among 1793 consecutive patients in the Yonsei AF ablation cohort, this observational cohort study included 398 patients with persistent AF (75.6% male; age, 59.8±10.3 years) who underwent catheter ablation with a consistent ablation protocol of the Dallas lesion set: circumferential pulmonary vein isolation; cavotricuspid isthmus ablation (CTI); roof line (RL); posterior-inferior line (PIL); and anterior line (AL). BDB rates of de novo ablation lines were 100% in circumferential pulmonary vein isolation, 100% in CTI, 84.7% in RL, 44.7% in PIL, and 63.6% in AL. During 29.0±18.4 months of follow-up, 31.7% (126/398) of the patients showed clinical recurrence. Left atrial posterior wall (LAPW) isolation (BDBs of RL and PIL) was independently associated with lower clinical AF / atrial tachycardia recurrence (hazard ratio, 0.68; 95% CI, 0.47-0.98; P=0.041; log-rank, P=0.017), whereas BDBs of RL or AL were not (log-rank, P=0.178 for RL; P=0.764 for AL). Among 52 patients who underwent repeat procedures (23.0±16.1 months after de novo procedure), the BDB maintenance rates for CTI, RL, PIL, and AL were 94.2% (49 of 52), 63.5% (33 of 47), 62.1% (18 of 29), and 61.8% (21 of 34), respectively. Although PIL crosses the esophageal contact area, LAPW isolation is important for better clinical outcome in catheter ablation with a linear ablation strategy for patients with persistent AF.
27792644	0	23	Challenging Achievement	T033	C0474414
27792644	27	46	Bidirectional Block	T047	C0018794
27792644	53	68	Linear Ablation	T061	C0547070
27792644	81	95	Rhythm Outcome	T039	C1523018
27792644	99	107	Patients	T101	C0030705
27792644	113	143	Persistent Atrial Fibrillation	T046	C2585653
27792644	168	187	bidirectional block	T047	C0018794
27792644	189	192	BDB	T047	C0018794
27792644	197	213	linear ablations	T061	C0547070
27792644	214	221	reduces	T080	C0392756
27792644	222	241	atrial fibrillation	T047	C0004238
27792644	243	245	AF	T047	C0004238
27792644	264	296	radiofrequency catheter ablation	T061	C0162561
27792644	301	313	hypothesized	T062	C0681918
27792644	319	322	BDB	T047	C0018794
27792644	326	341	linear ablation	T061	C0547070
27792644	346	369	prognostic significance	T081	C0449821
27792644	376	408	radiofrequency catheter ablation	T061	C0162561
27792644	413	426	persistent AF	T046	C2585653
27792644	439	459	consecutive patients	T101	C0030705
27792644	467	492	Yonsei AF ablation cohort	T098	C0599755
27792644	499	525	observational cohort study	T081	C0009247
27792644	539	547	patients	T101	C0030705
27792644	553	566	persistent AF	T046	C2585653
27792644	574	578	male	T032	C0086582
27792644	580	583	age	T032	C0001779
27792644	595	600	years	T079	C0439234
27792644	616	633	catheter ablation	T061	C0162561
27792644	652	669	ablation protocol	T061	C0040808
27792644	677	694	Dallas lesion set	T170	C0025663
27792644	696	736	circumferential pulmonary vein isolation	T061	C3544330
27792644	738	768	cavotricuspid isthmus ablation	T061	C4087388
27792644	770	773	CTI	T061	C4087388
27792644	776	785	roof line	T061	C0162563
27792644	787	789	RL	T061	C0162563
27792644	792	815	posterior-inferior line	T061	C0162563
27792644	817	820	PIL	T061	C0162563
27792644	827	840	anterior line	T061	C0162563
27792644	842	844	AL	T061	C0162563
27792644	847	850	BDB	T047	C0018794
27792644	851	856	rates	T081	C1521828
27792644	868	882	ablation lines	T061	C0162563
27792644	896	936	circumferential pulmonary vein isolation	T061	C3544330
27792644	946	949	CTI	T061	C4087388
27792644	960	962	RL	T061	C0162563
27792644	973	976	PIL	T061	C0162563
27792644	991	993	AL	T061	C0162563
27792644	1012	1018	months	T079	C0439231
27792644	1022	1031	follow-up	T058	C1522577
27792644	1056	1064	patients	T101	C0030705
27792644	1072	1091	clinical recurrence	T067	C0034897
27792644	1093	1119	Left atrial posterior wall	T023	C0504042
27792644	1121	1125	LAPW	T023	C0504042
27792644	1127	1136	isolation	T061	C0204727
27792644	1138	1142	BDBs	T047	C0018794
27792644	1146	1148	RL	T061	C0162563
27792644	1153	1156	PIL	T061	C0162563
27792644	1176	1191	associated with	T080	C0332281
27792644	1192	1197	lower	T080	C0205251
27792644	1198	1209	clinical AF	T047	C0004238
27792644	1212	1230	atrial tachycardia	T046	C0546959
27792644	1243	1255	hazard ratio	T081	C2985465
27792644	1267	1269	CI	T081	C0009667
27792644	1291	1299	log-rank	T170	C0392366
27792644	1319	1323	BDBs	T047	C0018794
27792644	1327	1329	RL	T061	C0162563
27792644	1333	1335	AL	T061	C0162563
27792644	1368	1370	RL	T061	C0162563
27792644	1384	1386	AL	T061	C0162563
27792644	1398	1406	patients	T101	C0030705
27792644	1421	1438	repeat procedures	T058	C0520262
27792644	1450	1456	months	T079	C0439231
27792644	1463	1480	de novo procedure	T059	C0022885
27792644	1487	1490	BDB	T047	C0018794
27792644	1503	1508	rates	T081	C1521828
27792644	1513	1516	CTI	T061	C4087388
27792644	1518	1520	RL	T061	C0162563
27792644	1522	1525	PIL	T061	C0162563
27792644	1531	1533	AL	T061	C0162563
27792644	1638	1641	PIL	T061	C0162563
27792644	1654	1677	esophageal contact area	T023	C0014876
27792644	1679	1683	LAPW	T023	C0504042
27792644	1684	1693	isolation	T061	C0204727
27792644	1711	1734	better clinical outcome	T033	C1333602
27792644	1738	1755	catheter ablation	T061	C0162561
27792644	1763	1787	linear ablation strategy	T061	C0547070
27792644	1792	1800	patients	T101	C0030705
27792644	1806	1819	persistent AF	T046	C2585653

28322744|t|Basal ryanodine receptor activity suppresses autophagic flux
28322744|a|The inositol 1,4,5-trisphosphate receptors (IP3Rs) and intracellular Ca(2+) signaling are critically involved in regulating different steps of autophagy, a lysosomal degradation pathway. The ryanodine receptors (RyR), intracellular Ca(2+)-release channels mainly expressed in excitable cell types including muscle and neurons, have however not yet been extensively studied in relation to autophagy. Yet, aberrant expression and excessive activity of RyRs in these tissues has been implicated in the onset of several diseases including Alzheimer's disease, where impaired autophagy regulation contributes to the pathology. In this study, we determined whether pharmacological RyR inhibition could modulate autophagic flux in ectopic RyR - expressing models, like HEK293 cells and in cell types that endogenously express RyR s, like C2C12 myoblasts and primary hippocampal neurons. Importantly, RyR3 overexpression in HEK293 cells impaired the autophagic flux. Conversely, in all cell models tested, pharmacological inhibition of endogenous or ectopically expressed RyRs, using dantrolene or ryanodine, augmented autophagic flux by increasing lysosomal turn-over (number of autophagosomes and autolysosomes measured as mCherry - LC3 punctae / cell increased from 70.37±7.81 in control HEK RyR3 cells to 111.18±7.72 and 98.14±7.31 after dantrolene and ryanodine treatments, respectively). Moreover, in differentiated C2C12 cells, transmission electron microscopy demonstrated that dantrolene treatment decreased the number of early autophagic vacuoles from 5.9±2.97 to 1.8±1.03 per cellular cross section. The modulation of the autophagic flux could be linked to the functional inhibition of RyR channels as both RyR inhibitors efficiently diminished the number of cells showing spontaneous RyR3 activity in the HEK293 cell model (from 41.14%±2.12 in control cells to 18.70%±2.25 and 9.74%±2.67 after dantrolene and ryanodine treatments, respectively). In conclusion, basal RyR -mediated Ca(2+)-release events suppress autophagic flux at the level of the lysosomes.
28322744	0	5	Basal	T082	C0205112
28322744	6	33	ryanodine receptor activity	T044	C1753335
28322744	34	44	suppresses	T169	C1260953
28322744	45	55	autophagic	T026	C0333781
28322744	56	60	flux	T070	C2348693
28322744	65	103	inositol 1,4,5-trisphosphate receptors	T116,T192	C0063592
28322744	105	110	IP3Rs	T116,T192	C0063592
28322744	116	146	intracellular Ca(2+) signaling	T043	C3158759
28322744	151	161	critically	T080	C1511545
28322744	162	170	involved	T169	C1314939
28322744	174	184	regulating	T038	C1327622
28322744	185	194	different	T080	C1705242
28322744	195	200	steps	T077	C1261552
28322744	204	213	autophagy	T043	C0004391
28322744	217	226	lysosomal	T026	C0024369
28322744	227	246	degradation pathway	T077	C1511758
28322744	252	271	ryanodine receptors	T116,T192	C0917729
28322744	273	276	RyR	T116,T192	C0917729
28322744	279	316	intracellular Ca(2+)-release channels	T044	C1153434
28322744	324	333	expressed	T045	C1171362
28322744	337	346	excitable	T033	C1562285
28322744	347	357	cell types	T170	C0449475
28322744	358	367	including	T169	C0332257
28322744	368	374	muscle	T024	C0026845
28322744	379	386	neurons	T025	C0027882
28322744	414	425	extensively	T080	C0205231
28322744	426	433	studied	T062	C2603343
28322744	449	458	autophagy	T043	C0004391
28322744	465	473	aberrant	T080	C0443127
28322744	474	484	expression	T045	C1171362
28322744	489	498	excessive	T080	C0442802
28322744	499	507	activity	T044	C1537044
28322744	511	515	RyRs	T116,T192	C0917729
28322744	525	532	tissues	T024	C0040300
28322744	542	552	implicated	T033	C2945640
28322744	560	568	onset of	T080	C0332162
28322744	569	576	several	T081	C0443302
28322744	577	585	diseases	T047	C0012634
28322744	586	595	including	T169	C0332257
28322744	596	615	Alzheimer's disease	T047	C0002395
28322744	623	631	impaired	T169	C0221099
28322744	632	641	autophagy	T043	C0004391
28322744	642	652	regulation	T038	C1327622
28322744	653	664	contributes	T052	C1880177
28322744	672	681	pathology	T169	C0205469
28322744	691	696	study	T062	C2603343
28322744	701	711	determined	T059	C1148554
28322744	720	735	pharmacological	T038	C0007992
28322744	736	739	RyR	T116,T192	C0917729
28322744	740	750	inhibition	T052	C3463820
28322744	757	765	modulate	T082	C0443264
28322744	766	776	autophagic	T026	C0333781
28322744	777	781	flux	T070	C2348693
28322744	785	792	ectopic	T082	C0574895
28322744	793	796	RyR	T116,T192	C0917729
28322744	799	809	expressing	T045	C1171362
28322744	810	816	models	T170	C3161035
28322744	823	835	HEK293 cells	T025	C2936239
28322744	843	853	cell types	T170	C0449475
28322744	859	871	endogenously	T169	C0205227
28322744	872	879	express	T045	C1171362
28322744	880	883	RyR	T116,T192	C0917729
28322744	892	907	C2C12 myoblasts	T025	C0596995
28322744	912	919	primary	T080	C0205225
28322744	920	931	hippocampal	T023	C0019564
28322744	932	939	neurons	T025	C0027882
28322744	941	952	Importantly	T080	C3898777
28322744	954	958	RyR3	T116,T192	C0524964
28322744	959	973	overexpression	T045	C1171362
28322744	977	989	HEK293 cells	T025	C2936239
28322744	990	998	impaired	T169	C0221099
28322744	1003	1013	autophagic	T026	C0333781
28322744	1014	1018	flux	T070	C2348693
28322744	1039	1043	cell	T025	C0007634
28322744	1044	1050	models	T170	C3161035
28322744	1051	1057	tested	T169	C0039593
28322744	1059	1074	pharmacological	T038	C0007992
28322744	1075	1085	inhibition	T052	C3463820
28322744	1089	1099	endogenous	T169	C0205227
28322744	1103	1114	ectopically	T082	C0574895
28322744	1115	1124	expressed	T045	C1171362
28322744	1125	1129	RyRs	T116,T192	C0917729
28322744	1137	1147	dantrolene	T109,T121	C0010976
28322744	1151	1160	ryanodine	T109,T121	C0035983
28322744	1162	1171	augmented	T081	C0205217
28322744	1172	1182	autophagic	T026	C0333781
28322744	1183	1187	flux	T070	C2348693
28322744	1191	1201	increasing	T169	C0442808
28322744	1202	1211	lysosomal	T026	C0024369
28322744	1212	1221	turn-over	T044	C0597297
28322744	1223	1229	number	T081	C0237753
28322744	1233	1247	autophagosomes	T026	C3887595
28322744	1252	1265	autolysosomes	T026	C0230822
28322744	1266	1274	measured	T080	C0444706
28322744	1278	1285	mCherry	T116,T123	C3489546
28322744	1288	1299	LC3 punctae	T116	C3540600
28322744	1302	1306	cell	T025	C0007634
28322744	1307	1316	increased	T081	C0205217
28322744	1336	1343	control	T096	C0009932
28322744	1344	1358	HEK RyR3 cells	T025	C0007634
28322744	1395	1405	dantrolene	T109,T121	C0010976
28322744	1410	1419	ryanodine	T109,T121	C0035983
28322744	1420	1430	treatments	T061	C1533734
28322744	1460	1474	differentiated	T043	C1159966
28322744	1475	1486	C2C12 cells	T025	C0596995
28322744	1488	1520	transmission electron microscopy	T059	C0678118
28322744	1521	1533	demonstrated	T080	C0443289
28322744	1539	1549	dantrolene	T109,T121	C0010976
28322744	1550	1559	treatment	T061	C1533734
28322744	1560	1569	decreased	T081	C0205216
28322744	1574	1580	number	T081	C0237753
28322744	1590	1600	autophagic	T026	C0333781
28322744	1601	1609	vacuoles	T026	C0042219
28322744	1640	1648	cellular	T025	C0007634
28322744	1649	1662	cross section	T082	C0552389
28322744	1668	1678	modulation	UnknownType	C0678672
28322744	1686	1696	autophagic	T026	C0333781
28322744	1697	1701	flux	T070	C2348693
28322744	1725	1735	functional	T169	C0205245
28322744	1736	1746	inhibition	T052	C3463820
28322744	1750	1762	RyR channels	T116,T192	C0054493
28322744	1771	1774	RyR	T116,T192	C0917729
28322744	1775	1785	inhibitors	T120	C0243077
28322744	1786	1797	efficiently	T080	C0442799
28322744	1813	1819	number	T081	C0237753
28322744	1823	1828	cells	T025	C0007634
28322744	1837	1848	spontaneous	T169	C0205359
28322744	1849	1853	RyR3	T116,T192	C0524964
28322744	1854	1862	activity	T044	C1537044
28322744	1870	1881	HEK293 cell	T025	C2936239
28322744	1882	1887	model	T170	C3161035
28322744	1909	1916	control	T096	C0009932
28322744	1917	1922	cells	T025	C0007634
28322744	1959	1969	dantrolene	T109,T121	C0010976
28322744	1974	1983	ryanodine	T109,T121	C0035983
28322744	1984	1994	treatments	T061	C1533734
28322744	2014	2024	conclusion	T078	C1707478
28322744	2026	2031	basal	T082	C0205112
28322744	2032	2035	RyR	T116,T192	C0917729
28322744	2046	2067	Ca(2+)-release events	T044	C1820193
28322744	2068	2076	suppress	T169	C1260953
28322744	2077	2087	autophagic	T026	C0333781
28322744	2088	2092	flux	T070	C2348693
28322744	2100	2105	level	T080	C0441889
28322744	2113	2122	lysosomes	T026	C0024369

27468990|t|Chitinibacter fontanus sp. nov., isolated from a spring
27468990|a|A bacterial strain, designated STM-7T, was isolated from a spring in Taiwan and characterized using a polyphasic taxonomy approach. Cells of strain STM-7T were Gram-staining-negative, aerobic, poly--hydroxybutyrate -accumulating, motile by a single polar flagellum, rod-shaped that were surrounded by a thick capsule and forming milky white colored colonies. Growth occurred at 15-37 oC (optimum, 25-30 °C), at pH 6-8 (optimum, pH 6-7) and with 0-2 % NaCl (optimum, 0-1 %). Phylogenetic analyses based on 16S rRNA gene sequences showed that strain STM-7T belonged to the genus Chitinibacter and was most closely related to Chitinibacter tainanensis S1T with sequence similarity of 97.3 %. Strain STM-7T contained summed feature 3 (comprising C16:17c and/or C16:16c) and C 16:0 as the predominant f atty acids. The major h ydroxyl fatty acids were C12:0 3-OH and C16:0 3-OH. The polar lipid profile consisted of phosphatidylethanolamine, phosphatidylglycerol, diphosphatidylglycerol, an uncharacterized aminophospholipid, an uncharacterized glycolipid and an uncharacterized phospholipid. The major isoprenoid quinone was Q-8. The DNA G+C content of the genomic DNA was 52.4 mol%. The DNA-DNA hybridization value for strain STM-7T with Chitinibacter tainanensis S1T was less than 47 %. On the basis of the phylogenetic inference and phenotypic data, strain STM-7T should be classified as a novel species, for which the name Chitinibacter fontanus sp. nov. is proposed. The type strain is STM-7T (=BCRC 80923T =LMG 29289T =KCTC 42982T).
27468990	0	31	Chitinibacter fontanus sp. nov.	T007	C1464214
27468990	33	41	isolated	T169	C0205409
27468990	49	55	spring	T070	C3179043
27468990	58	74	bacterial strain	T001	C1518614
27468990	87	93	STM-7T	T001	C1518614
27468990	99	107	isolated	T169	C0205409
27468990	115	121	spring	T070	C3179043
27468990	125	131	Taiwan	T083	C0039260
27468990	136	149	characterized	T052	C1880022
27468990	158	186	polyphasic taxonomy approach	T170	C0682467
27468990	188	193	Cells	T025	C0007634
27468990	197	210	strain STM-7T	T007	C1464214
27468990	216	247	Gram-staining-negative, aerobic	T007	C0018148
27468990	249	271	poly--hydroxybutyrate	T109	C0071478
27468990	287	293	motile	T033	C1979933
27468990	299	321	single polar flagellum	T026	C0016192
27468990	323	333	rod-shaped	T082	C1947942
27468990	366	373	capsule	T026	C1325531
27468990	386	405	milky white colored	T080	C0205556
27468990	406	414	colonies	T025	C1947989
27468990	416	422	Growth	T043	C0007595
27468990	445	452	optimum	T080	C2698651
27468990	468	470	pH	T081	C0020283
27468990	476	483	optimum	T080	C2698651
27468990	485	487	pH	T081	C0020283
27468990	508	512	NaCl	T121,T123,T197	C0037494
27468990	514	521	optimum	T080	C2698651
27468990	531	552	Phylogenetic analyses	T062	C1519068
27468990	562	570	16S rRNA	T114	C3537372
27468990	571	585	gene sequences	T086	C0162327
27468990	598	611	strain STM-7T	T001	C1518614
27468990	628	633	genus	T185	C1708235
27468990	634	647	Chitinibacter	T007	C1464214
27468990	680	709	Chitinibacter tainanensis S1T	T007	C1464215
27468990	715	723	sequence	T086	C0162327
27468990	746	759	Strain STM-7T	T001	C1518614
27468990	770	786	summed feature 3	T080	C1521970
27468990	799	807	C16:17c	T109	C0015684
27468990	815	824	C16:16c)	T109	C0015684
27468990	831	835	16:0	T109,T123	C0030234
27468990	857	868	atty acids.	T109	C0015684
27468990	881	900	ydroxyl fatty acids	T109	C0596739
27468990	906	916	C12:0 3-OH	T109	C0047466
27468990	921	931	C16:0 3-OH	T109	C0665943
27468990	937	956	polar lipid profile	T059	C0850354
27468990	970	994	phosphatidylethanolamine	T109,T121	C1450468
27468990	996	1016	phosphatidylglycerol	T109,T123	C0031614
27468990	1018	1040	diphosphatidylglycerol	T109	C0086164
27468990	1045	1060	uncharacterized	T080	C1519762
27468990	1061	1078	aminophospholipid	T109,T123	C0031676
27468990	1083	1098	uncharacterized	T080	C1519762
27468990	1099	1109	glycolipid	T109,T123	C0017950
27468990	1117	1132	uncharacterized	T080	C1519762
27468990	1133	1145	phospholipid	T109,T123	C0031676
27468990	1157	1175	isoprenoid quinone	T109	C0034435
27468990	1180	1183	Q-8	T109	C0077663
27468990	1189	1192	DNA	T114,T123	C0012854
27468990	1193	1204	G+C content	T081	C1135899
27468990	1212	1223	genomic DNA	T114,T123	C0012854
27468990	1243	1264	DNA-DNA hybridization	T063	C0221902
27468990	1275	1288	strain STM-7T	T001	C1518614
27468990	1294	1323	Chitinibacter tainanensis S1T	T007	C1464215
27468990	1364	1386	phylogenetic inference	T062	C1519068
27468990	1391	1406	phenotypic data	T078	C1511726
27468990	1408	1421	strain STM-7T	T001	C1518614
27468990	1432	1442	classified	T185	C0008902
27468990	1448	1461	novel species	T185	C1705920
27468990	1482	1513	Chitinibacter fontanus sp. nov.	T007	C1464214
27468990	1536	1542	strain	T001	C1518614
27468990	1546	1552	STM-7T	T001	C1518614
27468990	1554	1591	=BCRC 80923T =LMG 29289T =KCTC 42982T	T001	C1518614

27430924|t|Experimental study of GeneXpert(®) system in the diagnosis of extra-pulmonary tuberculosis
27430924|a|To explore the application value of GeneXpert MTB/RIF for detection of extra-pulmonary tuberculosis and resistance to rifampin. A total of 150 samples were collected, including 33 needle aspirates from lymphoid tuberculosis, 23 needle aspirates from spinal tuberculosis, 49 from tuberculous pleural effusions, 24 from cerebrospinal fluid of tuberculous cephalomeningitis, and 21 urinary sediment samples from renal tuberculosis. Smear microscopy, mycobacterium tuberculosis culture and the MTB/RIF method were used to examine these samples and their positive rates were compared. Rifampin susceptibility tests was performed for culture-positive strains using proportion method, which was compared with the result from GeneXpert MTB/RIF method. Of the 150 cases of extra-pulmonary tuberculosis, 17 samples were smear-positive, with a sensitivity of 11.3% (17/150); 30 were culture-positive with a sensitivity of 20.0% (30/150); and 96 were positive by MTB/RIF method with a sensitivity of 64.0% (96/150). There was a significant difference between MTB/RIF method and the culture method (χ(2)=59.61, P<0.01). The differences were also significant when the MTB/RIF method was compared with the smear method (χ(2)=88.60, P<0.01) or compared with culture plus smear methods (χ(2)=4.26, P<0.05). Separately, the differences were statistically significant between GeneXpert MTB/RIF method and other 2 methods for diagnosis of lymphoid tuberculosis (n=33, χ(2)=20.56, P<0.01 vs. culture method; χ(2)=27.13, P<0.01 vs. smear results) while no difference was found between culture and smear method (χ(2)=0.67, P>0.05), spinal tuberculosis (n=23, χ(2)=12.74, P<0.01 vs. culture method; χ(2)=14.81, P< 0.01 vs. smear method), tuberculous pleurisy (n=49, χ(2)=32.34, P<0.01 vs. culture method; χ(2)=49.69, P<0.01 vs. smear method) and renal tuberculosis (n=21, χ(2)=4.20, P<0.05 vs. culture method; χ(2) =8.40, P<0.01 vs. smear results). The sensitivity for tuberculous meningitis had no difference among these 3 methods (n=24, P>0.05). Rifampicin-resistance of the strains from the 30 culture-positive cases of extra-pulmonary tuberculosis (20.0%, 6/30) exhibited agreement with GeneXpert MTB/RIF test. The simplicity and high sensitivity of GeneXpert MTB/RIF technology make it a good diagnostic test for rapid detection of extra-pulmonary tuberculosis and resistance to rifampin.
27430924	0	18	Experimental study	T062	C0681814
27430924	22	41	GeneXpert(®) system	T074	C0025080
27430924	49	58	diagnosis	T062	C1704656
27430924	62	90	extra-pulmonary tuberculosis	T047	C0679362
27430924	127	144	GeneXpert MTB/RIF	T059	C0200932
27430924	149	158	detection	T061	C1511790
27430924	162	190	extra-pulmonary tuberculosis	T047	C0679362
27430924	195	205	resistance	T038	C0013203
27430924	209	217	rifampin	T109,T195	C0035608
27430924	234	241	samples	T031	C0542550
27430924	271	277	needle	T074	C0181959
27430924	278	287	aspirates	T031	C0370199
27430924	293	314	lymphoid tuberculosis	T047	C0041296
27430924	319	325	needle	T074	C0181959
27430924	326	335	aspirates	T031	C0370199
27430924	341	360	spinal tuberculosis	T047	C0041330
27430924	370	399	tuberculous pleural effusions	T047	C0041326
27430924	409	428	cerebrospinal fluid	T031	C0007806
27430924	432	461	tuberculous cephalomeningitis	T047	C0275908
27430924	470	494	urinary sediment samples	T031	C1261248
27430924	500	518	renal tuberculosis	T047	C0041328
27430924	520	536	Smear microscopy	T059	C0026018
27430924	538	572	mycobacterium tuberculosis culture	T059	C2585384
27430924	581	595	MTB/RIF method	T059	C0200932
27430924	671	700	Rifampin susceptibility tests	T059	C0201179
27430924	719	743	culture-positive strains	T001	C1518614
27430924	809	833	GeneXpert MTB/RIF method	T059	C0200932
27430924	855	883	extra-pulmonary tuberculosis	T047	C0679362
27430924	901	915	smear-positive	T033	C1514241
27430924	924	935	sensitivity	T081	C1511883
27430924	963	979	culture-positive	T033	C0159125
27430924	987	998	sensitivity	T081	C1511883
27430924	1030	1038	positive	T033	C1514241
27430924	1042	1056	MTB/RIF method	T059	C0200932
27430924	1064	1075	sensitivity	T081	C1511883
27430924	1138	1152	MTB/RIF method	T059	C0200932
27430924	1161	1175	culture method	T059	C0430402
27430924	1245	1259	MTB/RIF method	T059	C0200932
27430924	1282	1294	smear method	T060	C0444186
27430924	1333	1359	culture plus smear methods	T059	C0871511
27430924	1448	1472	GeneXpert MTB/RIF method	T059	C0200932
27430924	1485	1492	methods	T059	C0871511
27430924	1497	1506	diagnosis	T062	C1704656
27430924	1510	1531	lymphoid tuberculosis	T047	C0041296
27430924	1562	1576	culture method	T059	C0430402
27430924	1601	1614	smear results	T034	C1254360
27430924	1654	1661	culture	T059	C0430402
27430924	1666	1678	smear method	T060	C0444186
27430924	1700	1719	spinal tuberculosis	T047	C0041330
27430924	1750	1764	culture method	T059	C0430402
27430924	1790	1802	smear method	T060	C0444186
27430924	1805	1825	tuberculous pleurisy	T047	C0041326
27430924	1856	1870	culture method	T059	C0430402
27430924	1895	1907	smear method	T060	C0444186
27430924	1913	1931	renal tuberculosis	T047	C0041328
27430924	1961	1975	culture method	T059	C0430402
27430924	2000	2013	smear results	T034	C1254360
27430924	2020	2031	sensitivity	T081	C1511883
27430924	2036	2058	tuberculous meningitis	T047	C0041318
27430924	2091	2098	methods	T059	C0871511
27430924	2115	2136	Rifampicin-resistance	T038	C0013203
27430924	2144	2151	strains	T001	C1518614
27430924	2164	2186	culture-positive cases	T033	C0159125
27430924	2190	2218	extra-pulmonary tuberculosis	T047	C0679362
27430924	2258	2280	GeneXpert MTB/RIF test	T059	C0200932
27430924	2306	2317	sensitivity	T081	C1511883
27430924	2321	2349	GeneXpert MTB/RIF technology	T059	C0200932
27430924	2365	2380	diagnostic test	T060	C0086143
27430924	2391	2400	detection	T061	C1511790
27430924	2404	2432	extra-pulmonary tuberculosis	T047	C0679362
27430924	2437	2447	resistance	T038	C0013203
27430924	2451	2459	rifampin	T109,T195	C0035608

28149591|t|Non-intubated subxiphoid uniportal video-assisted thoracoscopic thymectomy using glasses-free 3D vision
28149591|a|Trans-sternal thymectomy has long been accepted as the standard surgical procedure for thymic masses. Recently, minimally invasive methods, such as video-assisted thoracoscopic surgery (VATS) and, even more recently, non-intubated anesthesia, have emerged. These methods provide advantages including reductions in surgical trauma, postoperative associated pain, and in regards to VATS, provide certain cosmetic benefits. Considering these advantages, we herein present a case of subxiphoid uniportal VATS for thymic mass using a glasses-free 3D thoracoscopic display system.
28149591	0	13	Non-intubated	T061	C0087111
28149591	14	24	subxiphoid	T082	C4039027
28149591	25	74	uniportal video-assisted thoracoscopic thymectomy	T061	C4304660
28149591	64	74	thymectomy	T061	C0040071
28149591	81	93	glasses-free	T033	C0243095
28149591	94	96	3D	T082	C0450363
28149591	97	103	vision	T040	C0042789
28149591	104	128	Trans-sternal thymectomy	T061	C0405560
28149591	143	151	accepted	T080	C1272684
28149591	159	167	standard	T080	C1442989
28149591	168	186	surgical procedure	T061	C0543467
28149591	191	204	thymic masses	T023	C0040113
28149591	206	214	Recently	T079	C0332185
28149591	216	225	minimally	T080	C0547040
28149591	226	234	invasive	T169	C0038895
28149591	235	242	methods	T170	C0025663
28149591	252	288	video-assisted thoracoscopic surgery	T061	C4304660
28149591	289	295	(VATS)	T061	C4304660
28149591	321	334	non-intubated	T061	C0087111
28149591	335	345	anesthesia	T061	C0002903
28149591	352	359	emerged	T080	C0700364
28149591	367	374	methods	T170	C0025663
28149591	383	393	advantages	T081	C0814225
28149591	394	403	including	T169	C0332257
28149591	404	414	reductions	T080	C0392756
28149591	418	433	surgical trauma	T033	C4060629
28149591	435	464	postoperative associated pain	T184	C0030201
28149591	484	488	VATS	T061	C4304660
28149591	506	514	cosmetic	T061	C0442965
28149591	515	523	benefits	T081	C0814225
28149591	525	536	Considering	T078	C0750591
28149591	543	553	advantages	T081	C0814225
28149591	583	593	subxiphoid	T082	C4039027
28149591	594	608	uniportal VATS	T061	C4304660
28149591	613	624	thymic mass	T024	C1515430
28149591	633	645	glasses-free	T033	C0243095
28149591	646	648	3D	T082	C0450363
28149591	649	662	thoracoscopic	T082	C0442425
28149591	663	677	display system	T170	C0871584

27568206|t|AKT / GSK3β Signaling in Glioblastoma
27568206|a|Glioblastoma (GBM) is the most aggressive of primary brain tumors. Despite the progress in understanding the biology of the pathogenesis of glioma made during the past decade, the clinical outcome of patients with GBM remains still poor. Deregulation of many signaling pathways involved in growth, survival, migration and resistance to treatment has been implicated in pathogenesis of GBM. One of these pathways is phosphatidylinositol-3 kinases (PI3K)/protein kinase B (AKT) / rapamycin-sensitive mTOR-complex (mTOR) pathway, intensively studied and widely described so far. Much less attention has been paid to the role of glycogen synthase kinase 3 β (GSK3β), a target of AKT. In this review we focus on the function of AKT / GSK3β signaling in GBM.
27568206	0	3	AKT	T116,T126	C0164786
27568206	6	11	GSK3β	T116,T126	C0244988
27568206	12	21	Signaling	T044	C0037080
27568206	25	37	Glioblastoma	T191	C0017636
27568206	38	50	Glioblastoma	T191	C0017636
27568206	52	55	GBM	T191	C0017636
27568206	91	103	brain tumors	T191	C0006118
27568206	147	154	biology	T091	C0005532
27568206	162	174	pathogenesis	T046	C0699748
27568206	178	184	glioma	T191	C0017638
27568206	218	234	clinical outcome	T034	C0456984
27568206	238	246	patients	T101	C0030705
27568206	252	255	GBM	T191	C0017636
27568206	270	274	poor	T080	C0542537
27568206	276	288	Deregulation	T052	C1880287
27568206	297	315	signaling pathways	T044	C0037080
27568206	328	334	growth	T191	C1516170
27568206	336	344	survival	T169	C0220921
27568206	346	355	migration	T191	C0027627
27568206	360	370	resistance	T169	C4281815
27568206	374	383	treatment	T061	C0087111
27568206	407	419	pathogenesis	T046	C0699748
27568206	423	426	GBM	T191	C0017636
27568206	441	449	pathways	T044	C0037080
27568206	453	513	phosphatidylinositol-3 kinases (PI3K)/protein kinase B (AKT)	T169	C2984369
27568206	516	563	rapamycin-sensitive mTOR-complex (mTOR) pathway	T044	C1515673
27568206	663	691	glycogen synthase kinase 3 β	T116,T126	C0244988
27568206	693	698	GSK3β	T116,T126	C0244988
27568206	713	716	AKT	T116,T126	C0164786
27568206	749	757	function	T169	C0542341
27568206	761	764	AKT	T116,T126	C0164786
27568206	767	772	GSK3β	T116,T126	C0244988
27568206	773	782	signaling	T044	C0037080
27568206	786	789	GBM	T191	C0017636

27669305|t|Protective Effects of Sporoderm-Broken Spores of Ganderma lucidum on Growth Performance, Antioxidant Capacity and Immune Function of Broiler Chickens Exposed to Low Level of Aflatoxin B₁
27669305|a|This study was conducted to investigate the toxic effects of aflatoxin B₁ (AFB₁) and evaluate the effects of sporoderm-broken spores of Ganoderma lucidum (SSGL) in relieving aflatoxicosis in broilers. A total of 300 one-day-old male Arbor Acre broiler chickens were randomly divided into four dietary treatments; the treatment diets were: Control (a basal diet containing normal peanut meal); AFB₁ (the basal diet containing AFB₁ - contaminated peanut meal); SSGL (basal diet with 200 mg/kg of SSGL); AFB₁ + SSGL (supplementation of 200 mg/kg of SSGL in AFB₁ diet). The contents of AFB₁ in AFB₁ and AFB₁ + SSGL diets were 25.0 μg/kg in the starter period and 22.5 μg/kg in the finisher period. The results showed that diet contaminated with a low level of AFB₁ significantly decreased (p < 0.05) the average daily feed intake and average daily gain during the entire experiment and reduced (p < 0.05) serum contents of total protein IgA and IgG. Furthermore, a dietary low level of AFB₁ not only increased (p < 0.05) levels of hydrogen peroxide and lipid peroxidation, but also decreased (p < 0.05) total antioxidant capability, catalase, glutathione peroxidase, and hydroxyl radical scavenger activity in the liver and spleen of broilers. Moreover, the addition of SSGL to AFB₁ - contaminated diet counteracted these negative effects, indicating that SSGL has a protective effect against aflatoxicosis.
27669305	22	45	Sporoderm-Broken Spores	T004	C0038029
27669305	49	65	Ganderma lucidum	T002	C0752326
27669305	69	75	Growth	T040	C0018270
27669305	76	87	Performance	T052	C1882330
27669305	89	109	Antioxidant Capacity	T044	C1148564
27669305	114	129	Immune Function	T042	C1817756
27669305	133	149	Broiler Chickens	T012	C2698565
27669305	174	186	Aflatoxin B₁	T109,T131	C0085180
27669305	192	197	study	T062	C2603343
27669305	215	226	investigate	T169	C1292732
27669305	231	244	toxic effects	T037	C0600688
27669305	248	260	aflatoxin B₁	T109,T131	C0085180
27669305	262	266	AFB₁	T109,T131	C0085180
27669305	272	280	evaluate	T058	C0220825
27669305	296	319	sporoderm-broken spores	T004	C0038029
27669305	323	340	Ganoderma lucidum	T002	C0752326
27669305	342	346	SSGL	T004	C0038029
27669305	361	374	aflatoxicosis	T037	C0274911
27669305	378	386	broilers	T012	C2698565
27669305	403	414	one-day-old	T032	C0001779
27669305	415	419	male	T032	C0086582
27669305	420	447	Arbor Acre broiler chickens	T012	C2698565
27669305	480	498	dietary treatments	T058	C0012159
27669305	504	519	treatment diets	T168	C0012155
27669305	526	533	Control	T096	C0009932
27669305	537	547	basal diet	T168	C2983588
27669305	566	572	peanut	T168	C0949399
27669305	573	577	meal	T056	C1998602
27669305	580	584	AFB₁	T109,T131	C0085180
27669305	590	600	basal diet	T168	C2983588
27669305	612	616	AFB₁	T109,T131	C0085180
27669305	619	631	contaminated	T169	C0205279
27669305	632	638	peanut	T168	C0949399
27669305	639	643	meal	T056	C1998602
27669305	646	650	SSGL	T004	C0038029
27669305	652	662	basal diet	T168	C2983588
27669305	681	685	SSGL	T004	C0038029
27669305	688	692	AFB₁	T109,T131	C0085180
27669305	695	699	SSGL	T004	C0038029
27669305	701	716	supplementation	T061	C0242297
27669305	733	737	SSGL	T004	C0038029
27669305	741	745	AFB₁	T109,T131	C0085180
27669305	746	750	diet	T168	C0012155
27669305	769	773	AFB₁	T109,T131	C0085180
27669305	777	781	AFB₁	T109,T131	C0085180
27669305	786	790	AFB₁	T109,T131	C0085180
27669305	793	797	SSGL	T004	C0038029
27669305	798	803	diets	T168	C0012155
27669305	827	834	starter	T079	C0439659
27669305	835	841	period	T079	C1948053
27669305	864	872	finisher	T079	C1522314
27669305	873	879	period	T079	C1948053
27669305	885	892	results	T033	C0683954
27669305	905	909	diet	T168	C0012155
27669305	910	922	contaminated	T169	C0205279
27669305	943	947	AFB₁	T109,T131	C0085180
27669305	948	961	significantly	T078	C0750502
27669305	987	994	average	T081	C1510992
27669305	1001	1005	feed	T168	C0016452
27669305	1006	1012	intake	T169	C1512806
27669305	1017	1024	average	T081	C1510992
27669305	1054	1064	experiment	T062	C0681814
27669305	1088	1093	serum	T031	C0229671
27669305	1112	1119	protein	T116,T123	C0033684
27669305	1120	1123	IgA	T116,T129	C0020835
27669305	1128	1131	IgG	T116,T121,T129	C0020852
27669305	1148	1155	dietary	T168	C0012155
27669305	1169	1173	AFB₁	T109,T131	C0085180
27669305	1214	1231	hydrogen peroxide	T121,T130,T197	C0020281
27669305	1236	1254	lipid peroxidation	T044	C0023775
27669305	1292	1314	antioxidant capability	T044	C1148564
27669305	1316	1324	catalase	T116,T126	C0007367
27669305	1326	1348	glutathione peroxidase	T116,T126	C0017822
27669305	1354	1370	hydroxyl radical	T197	C0063146
27669305	1371	1389	scavenger activity	T044	C1152848
27669305	1397	1402	liver	T023	C0023884
27669305	1407	1413	spleen	T023	C0037993
27669305	1417	1425	broilers	T012	C2698565
27669305	1453	1457	SSGL	T004	C0038029
27669305	1461	1465	AFB₁	T109,T131	C0085180
27669305	1468	1480	contaminated	T169	C0205279
27669305	1481	1485	diet	T168	C0012155
27669305	1539	1543	SSGL	T004	C0038029
27669305	1576	1589	aflatoxicosis	T037	C0274911

28486935|t|Emergency department use and barriers to wellness: a survey of emergency department frequent users
28486935|a|There is no common understanding of how needs of emergency department (ED) frequent users differ from other patients. This study sought to examine how to best serve this population. Examinations of why ED frequent users present to the ED, what barriers to care exist, and what service offerings may help these patients achieve an optimal level of health were conducted. We performed a prospective study of frequent ED users in an adult only, level 1 trauma center with approximately 90,000 visits per year. Frequent ED users were defined as those who make four or more ED visits in a 12 month period. Participants were administered a piloted structured interview by a trained researcher querying demographics, ED usage, perceived barriers to care, and potential aids to maintaining health. Of 1,523 screened patients, 297 were identified as frequent ED users. One hundred frequent ED users were enrolled. The mean age was 48 years (95% CI 45-51). The majority of subjects were female (64%, 64/100, 95% CI 55-73%), white (61%, 60/98, 95% CI 52-71%) and insured by Medicaid (55%, 47/86, 95% CI 44-65%) or Medicare (23%, 20/86, 95% CI 14-32%). Subjects had a median of 6 ED visits, and 2 inpatient admissions in the past 12 months at this hospital. Most frequent ED users (61%, 59/96, 95% CI 52-71%) stated the primary reason for their visit was that they felt that their health problem could only be treated in an ED. Transportation presented as a major barrier to few patients (7%, 7/95, 95% CI 3-14%). Subjects stated that " after-hours options, besides the ED for minor health issues " (63%, 60/95, 95% CI 53-73%) and having "a nurse to work with you one-on-one to help manage health care needs " (53%, 50/95, 95% CI 43-63%) would be most helpful in achieving optimal health. This study characterized ED frequent users and identified several opportunities to better serve this population. By understanding barriers to care from the patient perspective, health systems can potentially address unmet needs that prevent wellness in this population.
28486935	0	20	Emergency department	T073,T093	C0562508
28486935	21	24	use	T169	C0457083
28486935	29	37	barriers	T080	C0679881
28486935	41	49	wellness	T078	C0018684
28486935	53	59	survey	T170	C0038951
28486935	63	83	emergency department	T073,T093	C0562508
28486935	84	92	frequent	T079	C0332183
28486935	93	98	users	T098	C1706077
28486935	139	144	needs	T080	C0027552
28486935	148	168	emergency department	T073,T093	C0562508
28486935	170	172	ED	T073,T093	C0562508
28486935	174	182	frequent	T079	C0332183
28486935	183	188	users	T098	C1706077
28486935	207	215	patients	T101	C0030705
28486935	222	227	study	T062	C2603343
28486935	269	279	population	T098	C1257890
28486935	281	293	Examinations	T058	C0582103
28486935	301	303	ED	T073,T093	C0562508
28486935	304	312	frequent	T079	C0332183
28486935	313	318	users	T098	C1706077
28486935	319	326	present	T033	C0150312
28486935	334	336	ED	T073,T093	C0562508
28486935	343	351	barriers	T080	C0679881
28486935	355	359	care	T058	C0017313
28486935	360	365	exist	T077	C2987476
28486935	376	383	service	T057	C0557854
28486935	409	417	patients	T101	C0030705
28486935	429	436	optimal	T080	C2698651
28486935	437	442	level	T080	C0441889
28486935	446	452	health	T078	C0018684
28486935	484	501	prospective study	T062	C0033522
28486935	505	513	frequent	T079	C0332183
28486935	514	516	ED	T073,T093	C0562508
28486935	517	522	users	T098	C1706077
28486935	529	534	adult	T100	C0001675
28486935	541	562	level 1 trauma center	T073,T093	C0040786
28486935	568	581	approximately	T080	C0332232
28486935	589	595	visits	T058	C1512346
28486935	596	604	per year	T079	C0439508
28486935	606	614	Frequent	T079	C0332183
28486935	615	617	ED	T073,T093	C0562508
28486935	618	623	users	T098	C1706077
28486935	668	677	ED visits	T058	C0586082
28486935	686	691	month	T079	C0439231
28486935	692	698	period	T079	C1948053
28486935	700	712	Participants	T098	C0679646
28486935	718	730	administered	T169	C1521801
28486935	733	761	piloted structured interview	UnknownType	C0681913
28486935	767	785	trained researcher	T097	C0035173
28486935	786	794	querying	T170	C1522634
28486935	795	807	demographics	T090	C0011298
28486935	809	811	ED	T073,T093	C0562508
28486935	812	817	usage	T169	C0457083
28486935	819	837	perceived barriers	T080	C0205556
28486935	841	845	care	T058	C0017313
28486935	861	865	aids	T080	C0205556
28486935	869	887	maintaining health	T055	C2371475
28486935	898	906	screened	T058	C1710032
28486935	907	915	patients	T101	C0030705
28486935	926	936	identified	T080	C0205396
28486935	940	948	frequent	T079	C0332183
28486935	949	951	ED	T073,T093	C0562508
28486935	952	957	users	T098	C1706077
28486935	971	979	frequent	T079	C0332183
28486935	980	982	ED	T073,T093	C0562508
28486935	983	988	users	T098	C1706077
28486935	1008	1016	mean age	T032	C0001779
28486935	1024	1029	years	T079	C1510829
28486935	1035	1037	CI	T081	C0009667
28486935	1062	1070	subjects	T098	C0080105
28486935	1076	1082	female	T098	C0043210
28486935	1101	1103	CI	T081	C0009667
28486935	1113	1118	white	T098	C1257890
28486935	1136	1138	CI	T081	C0009667
28486935	1151	1158	insured	T170	C1548605
28486935	1162	1170	Medicaid	T064	C0025071
28486935	1188	1190	CI	T081	C0009667
28486935	1202	1210	Medicare	T064	C0018717
28486935	1228	1230	CI	T081	C0009667
28486935	1240	1248	Subjects	T098	C0080105
28486935	1255	1261	median	T081	C0439536
28486935	1267	1276	ED visits	T058	C0586082
28486935	1284	1304	inpatient admissions	T169	C0420512
28486935	1312	1316	past	T079	C1444637
28486935	1320	1326	months	T079	C0439231
28486935	1335	1343	hospital	T073,T093	C0019994
28486935	1350	1358	frequent	T079	C0332183
28486935	1359	1361	ED	T073,T093	C0562508
28486935	1362	1367	users	T098	C1706077
28486935	1385	1387	CI	T081	C0009667
28486935	1407	1421	primary reason	T078	C1549995
28486935	1432	1437	visit	T058	C1512346
28486935	1468	1482	health problem	T033	C1398682
28486935	1497	1504	treated	T169	C1522326
28486935	1511	1513	ED	T073,T093	C0562508
28486935	1515	1529	Transportation	T078	C1554194
28486935	1545	1550	major	T080	C0205164
28486935	1551	1558	barrier	T080	C0205556
28486935	1562	1565	few	T081	C0205388
28486935	1566	1574	patients	T101	C0030705
28486935	1590	1592	CI	T081	C0009667
28486935	1601	1609	Subjects	T098	C0080105
28486935	1624	1643	after-hours options	T058	C1136313
28486935	1657	1659	ED	T073,T093	C0562508
28486935	1664	1669	minor	T080	C0205165
28486935	1670	1683	health issues	T078	C2362508
28486935	1703	1705	CI	T081	C0009667
28486935	1728	1733	nurse	T097	C0028661
28486935	1737	1741	work	T057	C0043227
28486935	1751	1761	one-on-one	T061	C0557987
28486935	1770	1776	manage	T058	C0184516
28486935	1777	1788	health care	T058	C0086388
28486935	1789	1794	needs	T080	C0027552
28486935	1814	1816	CI	T081	C0009667
28486935	1860	1867	optimal	T080	C2698651
28486935	1868	1874	health	T078	C0018684
28486935	1881	1886	study	T062	C2603343
28486935	1887	1900	characterized	T052	C1880022
28486935	1901	1903	ED	T073,T093	C0562508
28486935	1904	1912	frequent	T079	C0332183
28486935	1913	1918	users	T098	C1706077
28486935	1923	1933	identified	T080	C0205396
28486935	1934	1941	several	T081	C0443302
28486935	1942	1955	opportunities	T062	C0683937
28486935	1977	1987	population	T098	C1257890
28486935	2006	2014	barriers	T080	C0205556
28486935	2018	2022	care	T058	C0017313
28486935	2032	2039	patient	T101	C0030705
28486935	2053	2067	health systems	T064	C1456613
28486935	2098	2103	needs	T080	C0027552
28486935	2109	2116	prevent	T080	C2700409
28486935	2117	2125	wellness	T078	C0018684
28486935	2134	2144	population	T098	C1257890

27969034|t|The effect of the support program on the resilience of female family caregivers of stroke patients: Randomized controlled trial
27969034|a|The purpose of the study was to determine the effect of a support program on the resilience of female family caregivers of stroke patients. This is a randomized controlled trial. The sample consisted 70 female family caregivers (34 experimental, 36 control group). Data were collected three times (pretest-posttest, follow-up test). Data were collected using the demographical data form, the Family Index of Regenerativity and Adaptation-General. A significant difference was determined between the experimental and control group's follow-up test scores for relative and friend support, social support and family-coping coherence. A significant difference was determined between the experimental group's mean pretest, posttest and follow-up test scores in terms of family strain, relative and friend support, social support, family coping-coherence, family hardiness and family distress. These results suggest that the Support Program contributes to the improvement of the components of resilience of family caregivers of stroke patients.
27969034	4	10	effect	T080	C1280500
27969034	18	33	support program	UnknownType	C0680682
27969034	41	51	resilience	T055	C0683253
27969034	55	61	female	T098	C0043210
27969034	62	79	family caregivers	T099	C0086279
27969034	83	89	stroke	T047	C0038454
27969034	90	98	patients	T101	C0030705
27969034	100	127	Randomized controlled trial	T062,T170	C1096777
27969034	147	152	study	T062	C2603343
27969034	174	180	effect	T080	C1280500
27969034	186	201	support program	UnknownType	C0680682
27969034	209	219	resilience	T055	C0683253
27969034	223	229	female	T098	C0043210
27969034	223	229	female	T098	C0043210
27969034	230	247	family caregivers	T099	C0086279
27969034	251	257	stroke	T047	C0038454
27969034	258	266	patients	T101	C0030705
27969034	278	305	randomized controlled trial	T062,T170	C1096777
27969034	331	337	female	T098	C0043210
27969034	338	355	family caregivers	T099	C0086279
27969034	360	372	experimental	T080	C1517586
27969034	377	390	control group	T096	C0009932
27969034	393	397	Data	T078	C1511726
27969034	426	442	pretest-posttest	T170	C0032919
27969034	444	458	follow-up test	T062	C0016441
27969034	461	465	Data	T078	C1511726
27969034	491	504	demographical	T062	C0011289
27969034	505	514	data form	T170	C0282574
27969034	520	573	Family Index of Regenerativity and Adaptation-General	T058	C1255665
27969034	577	599	significant difference	T081	C1705241
27969034	627	639	experimental	T080	C1517586
27969034	644	659	control group's	T096	C0009932
27969034	660	674	follow-up test	T062	C0016441
27969034	675	681	scores	T080	C0237855
27969034	686	694	relative	T099	C0080103
27969034	699	713	friend support	T077	C1521721
27969034	715	729	social support	T054	C0037438
27969034	734	757	family-coping coherence	T054	C1319178
27969034	761	783	significant difference	T081	C1705241
27969034	811	823	experimental	T080	C1517586
27969034	824	831	group's	T078	C0441833
27969034	837	844	pretest	T081	C0449820
27969034	846	854	posttest	T081	C0449820
27969034	859	880	follow-up test scores	T081	C0449820
27969034	893	906	family strain	T041	C2987481
27969034	908	916	relative	T099	C0080103
27969034	921	935	friend support	T077	C1521721
27969034	937	951	social support	T054	C0037438
27969034	953	976	family coping-coherence	T054	C1319178
27969034	978	994	family hardiness	T032	C0870635
27969034	999	1014	family distress	T033	C0743827
27969034	1022	1029	results	T169	C1274040
27969034	1047	1062	Support Program	UnknownType	C0680682
27969034	1082	1093	improvement	T077	C2986411
27969034	1101	1111	components	T077	C1705248
27969034	1115	1125	resilience	T055	C0683253
27969034	1129	1146	family caregivers	T099	C0086279
27969034	1150	1156	stroke	T047	C0038454
27969034	1157	1165	patients	T101	C0030705

27614145|t|Midodrine and tolvaptan in patients with cirrhosis and refractory or recurrent ascites: a randomised pilot study
27614145|a|Splanchnic arterial vasodilatation and subsequent sodium and water retention play an important role in cirrhotic ascites. Midodrine and tolvaptan have been used separately in these patients. However, there are no reports on the use of combination of midodrine and tolvaptan in the control of ascites. The aim of this study was to evaluate the safety and efficacy of midodrine, tolvaptan and their combination in control of refractory or recurrent ascites in cirrhotics. Fifty cirrhotic patients with refractory or recurrent ascites were randomised to receive midodrine (n=13), tolvaptan (n=12) or both (n=13) plus standard medical therapy (SMT) or SMT alone (n=12). A significant increase in urinary volume and urinary sodium at 1 and 3 months (P<.05) was observed in all groups except SMT. There was no worsening of renal or hepatic function in any group. There was deterioration of model for end-stage liver disease (MELD) in SMT. Midodrine as well as combination of midodrine and tolvaptan but not tolvaptan alone was superior to SMT in control of ascites at 3 months (P<.05). The combination therapy was also superior to midodrine in the control of ascites at 1 month. The morbidity and mortality were similar in all the groups except SMT. The results of this pilot study suggest that midodrine and combination with tolvaptan better controls ascites without any renal or hepatic dysfunction. The combination therapy rapidly controls ascites as compared to midodrine or tolvaptan alone.
27614145	0	9	Midodrine	T109,T121	C0026078
27614145	14	23	tolvaptan	T109,T121	C1176308
27614145	27	35	patients	T101	C0030705
27614145	41	50	cirrhosis	T047	C0023890
27614145	55	65	refractory	T033	C3532188
27614145	69	86	recurrent ascites	UnknownType	C0741243
27614145	90	100	randomised	T062	C0034656
27614145	101	112	pilot study	T062	C0031928
27614145	113	147	Splanchnic arterial vasodilatation	T042	C1372887
27614145	163	169	sodium	T047	C0020488
27614145	174	189	water retention	T033	C0542203
27614145	216	233	cirrhotic ascites	T047	C0401037
27614145	235	244	Midodrine	T109,T121	C0026078
27614145	249	258	tolvaptan	T109,T121	C1176308
27614145	294	302	patients	T101	C0030705
27614145	348	359	combination	T061	C0013218
27614145	363	372	midodrine	T109,T121	C0026078
27614145	377	386	tolvaptan	T109,T121	C1176308
27614145	405	412	ascites	T047	C0401037
27614145	443	451	evaluate	T058	C0220825
27614145	456	462	safety	T068	C0036043
27614145	467	475	efficacy	T080	C1280519
27614145	479	488	midodrine	T109,T121	C0026078
27614145	490	499	tolvaptan	T109,T121	C1176308
27614145	510	521	combination	T061	C0013218
27614145	536	546	refractory	T033	C3532188
27614145	550	567	recurrent ascites	UnknownType	C0741243
27614145	571	581	cirrhotics	T047	C0023890
27614145	589	598	cirrhotic	T080	C0439686
27614145	599	607	patients	T101	C0030705
27614145	613	623	refractory	T033	C3532188
27614145	627	644	recurrent ascites	UnknownType	C0741243
27614145	650	660	randomised	T062	C0034656
27614145	672	681	midodrine	T109,T121	C0026078
27614145	690	699	tolvaptan	T109,T121	C1176308
27614145	736	751	medical therapy	T061	C0418981
27614145	753	756	SMT	T061	C0418981
27614145	761	764	SMT	T061	C0418981
27614145	781	819	significant increase in urinary volume	T033	C1287298
27614145	824	838	urinary sodium	T047	C3671887
27614145	850	856	months	T079	C0439231
27614145	885	891	groups	T098	C1257890
27614145	899	902	SMT	T061	C0418981
27614145	917	926	worsening	T080	C0332271
27614145	930	935	renal	T033	C0232805
27614145	939	955	hepatic function	T042	C0232741
27614145	963	968	group	T098	C1257890
27614145	980	993	deterioration	T067	C0868945
27614145	997	1030	model for end-stage liver disease	T185	C3826979
27614145	1032	1036	MELD	T185	C3826979
27614145	1046	1055	Midodrine	T109,T121	C0026078
27614145	1067	1078	combination	T061	C0013218
27614145	1082	1091	midodrine	T109,T121	C0026078
27614145	1096	1105	tolvaptan	T109,T121	C1176308
27614145	1114	1123	tolvaptan	T109,T121	C1176308
27614145	1146	1149	SMT	T061	C0418981
27614145	1164	1171	ascites	T047	C0401037
27614145	1177	1183	months	T079	C0439231
27614145	1197	1216	combination therapy	T061	C0013218
27614145	1238	1247	midodrine	T109,T121	C0026078
27614145	1266	1273	ascites	T047	C0401037
27614145	1279	1284	month	T079	C0439231
27614145	1290	1299	morbidity	T081	C0026538
27614145	1304	1313	mortality	T081	C0205848
27614145	1338	1344	groups	T098	C1257890
27614145	1352	1355	SMT	T061	C0418981
27614145	1377	1388	pilot study	T062	C0031928
27614145	1402	1411	midodrine	T109,T121	C0026078
27614145	1416	1427	combination	T061	C0013218
27614145	1433	1442	tolvaptan	T109,T121	C1176308
27614145	1459	1466	ascites	T047	C0401037
27614145	1479	1484	renal	T047	C1565489
27614145	1488	1507	hepatic dysfunction	T046	C0086565
27614145	1513	1532	combination therapy	T061	C0013218
27614145	1550	1557	ascites	T047	C0401037
27614145	1573	1582	midodrine	T109,T121	C0026078
27614145	1586	1595	tolvaptan	T109,T121	C1176308

27481881|t|Coffee - Antihypertensive Drug Interaction: A Hemodynamic and Pharmacokinetic Study With Felodipine
27481881|a|A period of abstinence from coffee to permit caffeine elimination appears to enable increased blood pressure on subsequent exposure. We hypothesized that this would offset the antihypertensive effect of the dihydropyridine calcium channel blocker felodipine. A randomized, single-dose, crossover study assessed hemodynamic and pharmacokinetic effects following 2 days without coffee and caffeine - containing foods. Consistently brewed black coffee (2×300ml), felodipine maximum recommended dose (10mg), and coffee plus felodipine were tested in middle-aged normotensive subjects. Pretreatment plasma caffeine concentrations were unquantifiable. After coffee, blood pressure changes (mm Hg) averaged over study hours 1-4 were increased for brachial systolic (7.6, P < 0.001) and diastolic (4.9, P < 0.001) and aortic systolic (7.4, P < 0.001), pulse (3.0, P < 0.05) and augmentation (1.4, P < 0.05) relative to baseline. After coffee plus felodipine, they were higher for brachial systolic (4.0, P < 0.05) and diastolic (3.9, P < 0.001) and aortic systolic (4.6, P < 0.05) compared to felodipine alone. The pressor effects of coffee and its modulation by felodipine were variable among individuals. Coffee containing caffeine (127mg) caused maximum pressor effect. Caffeine and felodipine pharmacokinetics were similar for coffee and felodipine given alone or in combination indicating an interaction having a pharmacodynamic basis. Plasma felodipine concentration - diastolic blood pressure reduction relationship shifted with coffee such that doubling the felodipine concentration would eliminate the pressor effect. However, this may increase the risk of adverse drug events particularly during the timeframe without coffee. Intermittent coffee ingestion might complicate hypertension diagnosis and management for many individuals.
27481881	0	6	Coffee	T168	C0009237
27481881	9	30	Antihypertensive Drug	T121	C0003364
27481881	31	42	Interaction	T169	C1704675
27481881	46	57	Hemodynamic	T042	C0019010
27481881	62	83	Pharmacokinetic Study	T062	C0201734
27481881	89	99	Felodipine	T109,T121	C0015772
27481881	102	108	period	T079	C1948053
27481881	112	122	abstinence	T055	C0039475
27481881	128	134	coffee	T168	C0009237
27481881	138	144	permit	T089	C0023636
27481881	145	153	caffeine	T109,T121	C0006644
27481881	154	165	elimination	T039	C0221102
27481881	166	173	appears	T080	C0700364
27481881	184	193	increased	T081	C0205217
27481881	194	208	blood pressure	T040	C0005823
27481881	212	222	subsequent	T079	C0332282
27481881	223	231	exposure	T080	C0332157
27481881	236	248	hypothesized	T078	C1512571
27481881	265	271	offset	T081	C1711330
27481881	276	292	antihypertensive	T121	C0003364
27481881	293	299	effect	T080	C1280500
27481881	307	346	dihydropyridine calcium channel blocker	T121	C2945601
27481881	347	357	felodipine	T109,T121	C0015772
27481881	361	371	randomized	T062	C0034656
27481881	373	384	single-dose	T081	C0178602
27481881	386	401	crossover study	T062	C0150097
27481881	402	410	assessed	T052	C1516048
27481881	411	422	hemodynamic	T042	C0019010
27481881	427	450	pharmacokinetic effects	T044	C1709520
27481881	461	467	2 days	T079	C1442455
27481881	468	475	without	T080	C0332288
27481881	476	482	coffee	T168	C0009237
27481881	487	495	caffeine	T109,T121	C0006644
27481881	498	508	containing	T169	C0332256
27481881	509	514	foods	T168	C0016452
27481881	516	528	Consistently	T078	C0332290
27481881	529	535	brewed	T057	C0700104
27481881	536	548	black coffee	T168	C0452435
27481881	560	570	felodipine	T109,T121	C0015772
27481881	571	578	maximum	T081	C0806909
27481881	579	590	recommended	T078	C0034866
27481881	591	595	dose	T081	C0178602
27481881	608	614	coffee	T168	C0009237
27481881	615	619	plus	T169	C0332287
27481881	620	630	felodipine	T109,T121	C0015772
27481881	636	642	tested	T169	C0039593
27481881	646	657	middle-aged	T100	C0205847
27481881	658	670	normotensive	T033	C2712122
27481881	671	679	subjects	T098	C0080105
27481881	681	693	Pretreatment	T052	C3539076
27481881	694	700	plasma	T031	C0032105
27481881	701	724	caffeine concentrations	T059	C0202348
27481881	730	744	unquantifiable	T081	C0392762
27481881	752	758	coffee	T168	C0009237
27481881	760	774	blood pressure	T040	C0005823
27481881	775	782	changes	T169	C0392747
27481881	784	789	mm Hg	T081	C0439475
27481881	791	799	averaged	T081	C1510992
27481881	805	810	study	T062	C0681814
27481881	811	816	hours	T079	C0439227
27481881	826	835	increased	T081	C0205217
27481881	840	848	brachial	T082	C0445456
27481881	849	857	systolic	T079	C0039155
27481881	879	888	diastolic	T201	C0012000
27481881	910	916	aortic	T023	C0003483
27481881	917	925	systolic	T079	C0039155
27481881	944	949	pulse	T058	C0034107
27481881	970	982	augmentation	T081	C0205217
27481881	1011	1019	baseline	T081	C1442488
27481881	1027	1033	coffee	T168	C0009237
27481881	1034	1038	plus	T169	C0332287
27481881	1039	1049	felodipine	T109,T121	C0015772
27481881	1061	1067	higher	T080	C0205250
27481881	1072	1080	brachial	T082	C0445456
27481881	1081	1089	systolic	T079	C0039155
27481881	1110	1119	diastolic	T201	C0012000
27481881	1141	1147	aortic	T023	C0003483
27481881	1148	1156	systolic	T079	C0039155
27481881	1173	1181	compared	T052	C1707455
27481881	1185	1195	felodipine	T109,T121	C0015772
27481881	1207	1214	pressor	T121	C0237795
27481881	1215	1222	effects	T080	C1280500
27481881	1226	1232	coffee	T168	C0009237
27481881	1241	1251	modulation	T082	C0443264
27481881	1255	1265	felodipine	T109,T121	C0015772
27481881	1271	1279	variable	T080	C0439828
27481881	1286	1297	individuals	T098	C0237401
27481881	1299	1305	Coffee	T168	C0009237
27481881	1317	1325	caffeine	T109,T121	C0006644
27481881	1341	1348	maximum	T081	C0806909
27481881	1349	1356	pressor	T121	C0237795
27481881	1357	1363	effect	T080	C1280500
27481881	1365	1373	Caffeine	T109,T121	C0006644
27481881	1378	1388	felodipine	T109,T121	C0015772
27481881	1389	1405	pharmacokinetics	T039	C0031327
27481881	1411	1418	similar	T080	C2348205
27481881	1423	1429	coffee	T168	C0009237
27481881	1434	1444	felodipine	T109,T121	C0015772
27481881	1463	1474	combination	T080	C0205195
27481881	1489	1500	interaction	T169	C1704675
27481881	1510	1525	pharmacodynamic	T038	C0851347
27481881	1526	1531	basis	T169	C1527178
27481881	1533	1539	Plasma	T031	C0032105
27481881	1540	1550	felodipine	T109,T121	C0015772
27481881	1551	1564	concentration	T081	C1446561
27481881	1567	1576	diastolic	T201	C0012000
27481881	1577	1591	blood pressure	T040	C0005823
27481881	1592	1601	reduction	T080	C0392756
27481881	1602	1614	relationship	T080	C0439849
27481881	1628	1634	coffee	T168	C0009237
27481881	1645	1653	doubling	T052	C1705764
27481881	1658	1668	felodipine	T109,T121	C0015772
27481881	1669	1682	concentration	T081	C1446561
27481881	1689	1698	eliminate	T080	C0849355
27481881	1703	1710	pressor	T121	C0237795
27481881	1711	1717	effect	T080	C1280500
27481881	1737	1745	increase	T169	C0442805
27481881	1750	1754	risk	T078	C0035647
27481881	1758	1777	adverse drug events	T046	C0041755
27481881	1791	1797	during	T079	C0347984
27481881	1812	1819	without	T080	C0332288
27481881	1820	1826	coffee	T168	C0009237
27481881	1828	1840	Intermittent	T079	C0205267
27481881	1841	1847	coffee	T168	C0009237
27481881	1848	1857	ingestion	T038	C0232478
27481881	1864	1874	complicate	T169	C0231242
27481881	1875	1887	hypertension	T047	C0020538
27481881	1888	1897	diagnosis	T033	C0011900
27481881	1902	1912	management	T058	C0376636
27481881	1922	1933	individuals	T098	C0237401

28002976|t|Exposure to organophosphate (OP) pesticides and health conditions in agricultural and non-agricultural workers from Maule, Chile
28002976|a|The objective was to evaluate the characteristics of exposure to OP pesticides and health status in Chilean farm workers from the Maule Region. An occupational health questionnaire was administered in 207 agricultural and non-agricultural workers. For the group of agricultural workers, we asked about specific occupational exposure history and symptoms of OP pesticide poisoning. The main health problem of the exposed group was previous OP pesticide poisoning (p < 0.001). Fifty-six percent of agricultural workers reported symptoms consistent with acute OP pesticide poisoning. The use of respiratory personal protective equipment and younger age were protective against these symptoms, and number of years of OP pesticide exposure was positively associated with reporting symptoms of poisoning. Of the pesticide applicators 47 % reported using chlorpyrifos. The regulations regarding use and application of pesticides should be strengthened, as should training and intervention with workers to improve the use of personal protective equipment.
28002976	0	11	Exposure to	T080	C0332157
28002976	12	43	organophosphate (OP) pesticides	T109,T131	C0360429
28002976	48	65	health conditions	T033	C2707292
28002976	69	81	agricultural	T090	C4048190
28002976	86	110	non-agricultural workers	T090	C1306056
28002976	116	121	Maule	UnknownType	C0681784
28002976	123	128	Chile	T083	C0008107
28002976	163	178	characteristics	T080	C1521970
28002976	182	193	exposure to	T080	C0332157
28002976	194	207	OP pesticides	T109,T131	C0360429
28002976	212	225	health status	T080	C0018759
28002976	229	236	Chilean	T098	C0239045
28002976	237	249	farm workers	T097	C0335421
28002976	259	271	Maule Region	UnknownType	C0681784
28002976	276	309	occupational health questionnaire	T170	C0451208
28002976	334	346	agricultural	T090	C4048190
28002976	351	375	non-agricultural workers	T090	C1306056
28002976	385	390	group	T078	C0441833
28002976	394	414	agricultural workers	T090	C4048190
28002976	440	469	occupational exposure history	T033	C0489537
28002976	474	482	symptoms	T184	C1457887
28002976	486	498	OP pesticide	T109,T131	C0360429
28002976	499	508	poisoning	T037	C0032343
28002976	519	533	health problem	T033	C1398682
28002976	541	554	exposed group	T098	C2348484
28002976	568	580	OP pesticide	T109,T131	C0360429
28002976	581	590	poisoning	T037	C0032343
28002976	625	645	agricultural workers	T090	C4048190
28002976	655	663	symptoms	T184	C1457887
28002976	664	679	consistent with	T078	C0332290
28002976	680	685	acute	T079	C0205178
28002976	686	698	OP pesticide	T109,T131	C0360429
28002976	699	708	poisoning	T037	C0032343
28002976	714	720	use of	T169	C1524063
28002976	721	732	respiratory	T169	C0521346
28002976	733	762	personal protective equipment	T073	C1443871
28002976	767	774	younger	T079	C0332239
28002976	775	778	age	T032	C0001779
28002976	809	817	symptoms	T184	C1457887
28002976	833	838	years	T079	C0439234
28002976	842	854	OP pesticide	T109,T131	C0360429
28002976	855	863	exposure	T080	C0332157
28002976	868	878	positively	T033	C1446409
28002976	879	894	associated with	T080	C0332281
28002976	905	913	symptoms	T184	C1457887
28002976	917	926	poisoning	T037	C0032343
28002976	935	956	pesticide applicators	UnknownType	C0260117
28002976	977	989	chlorpyrifos	T109,T131	C0013328
28002976	995	1006	regulations	T064	C0851285
28002976	1025	1036	application	T169	C4048755
28002976	1040	1050	pesticides	T131	C0031253
28002976	1085	1093	training	T065	C0220931
28002976	1098	1110	intervention	T058	C1273869
28002976	1116	1123	workers	T098	C1527116
28002976	1139	1145	use of	T169	C1524063
28002976	1146	1175	personal protective equipment	T073	C1443871

28005775|t|Fully Endoscope - Controlled Clipping Bilateral Middle Cerebral Artery Aneurysm Via Unilateral Supraorbital Keyhole Approach
28005775|a|Clipping bilateral middle cerebral artery (bMCA) aneurysms via unilateral approach in a single-stage operation is considered as a challenge procedure. To our knowledge, there is no study in surgical management of patients with bMCA aneurysms by fully endoscope - controlled techniques. The author reported a patient with bMCA aneurysms who underwent aneurysms clipping via a unilateral supraorbital keyhole approach by endoscope - controlled microneurosurgery, and the patient had an uneventful postoperative course without neurologic impairment and complication. Furthermore, the author discussed the advantages and adaptation of endoscope - controlled clipping bMCA aneurysms via unilateral supraorbital keyhole approach.
28005775	0	5	Fully	T080	C0443225
28005775	6	15	Endoscope	T074	C0014243
28005775	18	28	Controlled	T169	C2587213
28005775	29	37	Clipping	T061	C0189711
28005775	38	79	Bilateral Middle Cerebral Artery Aneurysm	T047	C0740385
28005775	84	124	Unilateral Supraorbital Keyhole Approach	T061	C0087111
28005775	125	133	Clipping	T061	C0189711
28005775	134	183	bilateral middle cerebral artery (bMCA) aneurysms	T047	C0740385
28005775	188	207	unilateral approach	T061	C0087111
28005775	213	235	single-stage operation	T061	C0543467
28005775	315	334	surgical management	T058	C1515089
28005775	338	346	patients	T101	C0030705
28005775	352	366	bMCA aneurysms	T047	C0740385
28005775	376	385	endoscope	T074	C0014243
28005775	388	398	controlled	T169	C2587213
28005775	399	409	techniques	T169	C0449851
28005775	433	440	patient	T101	C0030705
28005775	446	460	bMCA aneurysms	T047	C0740385
28005775	475	493	aneurysms clipping	T061	C0189711
28005775	500	540	unilateral supraorbital keyhole approach	T061	C0087111
28005775	544	553	endoscope	T074	C0014243
28005775	556	566	controlled	T169	C2587213
28005775	567	584	microneurosurgery	T061	C0524850
28005775	594	601	patient	T101	C0030705
28005775	620	640	postoperative course	T079	C0032790
28005775	641	648	without	T080	C0332288
28005775	649	659	neurologic	T080	C0205494
28005775	660	670	impairment	T046	C0684336
28005775	675	687	complication	T046	C0009566
28005775	742	752	adaptation	T170	C1706477
28005775	756	765	endoscope	T074	C0014243
28005775	768	778	controlled	T169	C2587213
28005775	779	787	clipping	T061	C0189711
28005775	788	802	bMCA aneurysms	T047	C0740385
28005775	807	847	unilateral supraorbital keyhole approach	T061	C0087111

27511629|t|The Bindex(®) ultrasound device: reliability of cortical bone thickness measures and their relationship to regional bone mineral density
27511629|a|The Bindex(®) quantitative ultrasound (QUS) device is currently available and this study analyzed (I) its relative and absolute intra- and inter-session reliability and (II) the relationship between the data provided by Bindex(®)-QUS and the bone mineral density (BMD) measured by dual-energy x-ray absorptiometry at corresponding skeletal sites in young and healthy subjects (age: 25.0 ± 3.6 years). Bindex(®)-QUS calculates a density index on the basis of the thickness of cortical bone measured at the distal radius and the distal plus proximal tibia. The data show a very good relative and absolute intra- (ICC = 0.977, CV = 1.5%) and inter-session reliability (ICC = 0.978, CV = 1.4%) for the density index. The highest positive correlations were found between cortical thickness and BMD for the distal radius and distal tibia (r ⩾ 0.71, p < 0.001). The data indicate that the Bindex(®)-QUS parameters are repeatable within and between measurement sessions. Furthermore, the measurements reflect the BMD at specific skeletal sites. Bindex(®)-QUS might be a useful tool for the measurement of skeletal adaptations.
27511629	4	31	Bindex(®) ultrasound device	T074	C1875843
27511629	33	44	reliability	T081	C2347947
27511629	48	61	cortical bone	T023	C0222652
27511629	62	71	thickness	T080	C1280412
27511629	72	80	measures	T081	C0079809
27511629	91	103	relationship	T080	C0439849
27511629	107	115	regional	T082	C0205147
27511629	116	136	bone mineral density	T201	C0005938
27511629	141	187	Bindex(®) quantitative ultrasound (QUS) device	T074	C1875843
27511629	220	225	study	T062	C2603343
27511629	226	234	analyzed	T062	C0936012
27511629	243	251	relative	T080	C0205345
27511629	256	264	absolute	T080	C0205344
27511629	265	301	intra- and inter-session reliability	T081	C2347947
27511629	315	327	relationship	T080	C0439849
27511629	340	344	data	T078	C1511726
27511629	357	370	Bindex(®)-QUS	T074	C1875843
27511629	379	399	bone mineral density	T201	C0005938
27511629	401	404	BMD	T201	C0005938
27511629	406	414	measured	T080	C0444706
27511629	418	450	dual-energy x-ray absorptiometry	T060	C1510486
27511629	468	482	skeletal sites	T082	C1282387
27511629	486	491	young	T098	C0080105
27511629	496	512	healthy subjects	T098	C1708335
27511629	514	517	age	T032	C0001779
27511629	530	535	years	T079	C1510829
27511629	538	551	Bindex(®)-QUS	T074	C1875843
27511629	552	562	calculates	T052	C1441506
27511629	565	578	density index	T201	C0005938
27511629	599	608	thickness	T080	C1280412
27511629	612	625	cortical bone	T023	C0222652
27511629	626	634	measured	T080	C0444706
27511629	642	655	distal radius	T023	C0588207
27511629	664	670	distal	T023	C0588200
27511629	676	690	proximal tibia	T023	C0588198
27511629	696	700	data	T078	C1511726
27511629	718	726	relative	T080	C0205345
27511629	731	739	absolute	T080	C0205344
27511629	740	746	intra-	T081	C2347947
27511629	748	751	ICC	T081	C0392762
27511629	761	763	CV	T081	C0681921
27511629	776	801	inter-session reliability	T081	C2347947
27511629	803	806	ICC	T081	C0392762
27511629	816	818	CV	T081	C0681921
27511629	835	848	density index	T201	C0005938
27511629	854	861	highest	T080	C1522410
27511629	862	870	positive	T033	C1446409
27511629	871	883	correlations	T080	C1707520
27511629	903	911	cortical	T023	C0222652
27511629	912	921	thickness	T080	C1280412
27511629	926	929	BMD	T201	C0005938
27511629	938	951	distal radius	T023	C0588207
27511629	956	968	distal tibia	T023	C0588200
27511629	996	1000	data	T078	C1511726
27511629	1019	1032	Bindex(®)-QUS	T074	C1875843
27511629	1033	1043	parameters	T033	C0449381
27511629	1078	1089	measurement	T169	C0242485
27511629	1090	1098	sessions	T077	C1883017
27511629	1117	1129	measurements	T169	C0242485
27511629	1142	1145	BMD	T201	C0005938
27511629	1149	1157	specific	T080	C0205369
27511629	1158	1172	skeletal sites	T082	C1282387
27511629	1174	1187	Bindex(®)-QUS	T074	C1875843
27511629	1219	1230	measurement	T169	C0242485
27511629	1234	1254	skeletal adaptations	T039	C2248552

27783097|t|Breast cancer cells and bone marrow mesenchymal stromal cells: a regulated modulation of the breast tumor in the context of immune response
27783097|a|The role of direct cell-cell interactions mediating selective bone metastasis by breast cancer cells (BCCs) niche is still mostly unknown. Conditioned medium and direct cell-cell contacts experiments were used to investigate the effect of bone marrow -derived mesenchymal stromal cells (MSCs), osteoprogenitor-like cells (MG-63) and osteosarcoma cells (SaOS-2) on luminal-like (MCF-7) and basal-like (MDA-MB-231) BCCs flow cytometry was used to assess the purity of isolated BCCs and osteoblasts. Expression of osteoblastic markers was investigated by semi-quantitative RT-PCR. RANKL and OPG levels were measured by ELISA. Conditioned medium from MSCs and osteoblasts induced the expression of osteoblastic markers in BCCs. While co-culture assays with SaOS-2 increased the expression of osteoblastic markers in MCF-7 cells, SaOS-2 cell conditioned medium increased the expression of RANKL, PTHrP, VEGF and NOGGIN in MCF-7 cells. Co-cultures with either MG-63 cells or MSCs induced OPG and MMP-2 in both tumor cell lines. Interestingly, conditioned medium from co-cultures of MSCs and MDA-MB-231 cells significantly decreased the proliferation of activated T lymphocytes which was reversed by addition of anti-OPG antibodies to the co-cultures. Our data suggest that MSCs strongly contribute to the adaptation and invasiveness of breast cancer cells in skeletal tissues.
27783097	0	19	Breast cancer cells	T025	C1512505
27783097	24	35	bone marrow	T024	C0005953
27783097	36	61	mesenchymal stromal cells	T025	C3178844
27783097	93	105	breast tumor	T191	C1458155
27783097	113	120	context	T078	C0449255
27783097	124	139	immune response	T042	C0301872
27783097	159	181	cell-cell interactions	T043	C0007582
27783097	202	206	bone	T024	C0391978
27783097	207	217	metastasis	T191	C0027627
27783097	221	240	breast cancer cells	T025	C1512505
27783097	242	246	BCCs	T025	C1512505
27783097	279	297	Conditioned medium	T130	C0162518
27783097	309	327	cell-cell contacts	T043	C0007582
27783097	353	364	investigate	T169	C1292732
27783097	369	375	effect	T080	C1280500
27783097	379	390	bone marrow	T024	C0005953
27783097	400	425	mesenchymal stromal cells	T025	C3178844
27783097	427	431	MSCs	T025	C3178844
27783097	434	460	osteoprogenitor-like cells	T025	C0007634
27783097	462	467	MG-63	T025	C0007634
27783097	473	491	osteosarcoma cells	T025	C0007634
27783097	493	499	SaOS-2	T025	C0007634
27783097	504	516	luminal-like	T025	C0007634
27783097	518	523	MCF-7	T025	C0007634
27783097	529	539	basal-like	T025	C0596155
27783097	541	551	MDA-MB-231	T025	C0596155
27783097	553	557	BCCs	T025	C1512505
27783097	558	572	flow cytometry	T059	C0016263
27783097	585	591	assess	T058	C0184514
27783097	596	602	purity	T081	C1882508
27783097	606	614	isolated	T169	C0205409
27783097	615	619	BCCs	T025	C1512505
27783097	624	635	osteoblasts	T025	C0029418
27783097	637	647	Expression	T045	C1171362
27783097	651	663	osteoblastic	T025	C0029418
27783097	664	671	markers	T201	C0005516
27783097	676	688	investigated	T169	C1292732
27783097	692	709	semi-quantitative	T081	C0522525
27783097	710	716	RT-PCR	T063	C0599161
27783097	718	723	RANKL	T116,T123	C0666364
27783097	728	731	OPG	T116,T192	C0538161
27783097	732	738	levels	T080	C0441889
27783097	744	752	measured	T080	C0444706
27783097	756	761	ELISA	T059	C0014441
27783097	763	781	Conditioned medium	T130	C0162518
27783097	787	791	MSCs	T025	C3178844
27783097	796	807	osteoblasts	T025	C0029418
27783097	820	830	expression	T045	C1171362
27783097	834	846	osteoblastic	T025	C0029418
27783097	847	854	markers	T201	C0005516
27783097	858	862	BCCs	T025	C1512505
27783097	870	880	co-culture	T059	C0282547
27783097	881	887	assays	T059	C1510438
27783097	893	899	SaOS-2	T025	C0007634
27783097	900	909	increased	T081	C0205217
27783097	914	924	expression	T045	C1171362
27783097	928	940	osteoblastic	T025	C0029418
27783097	941	948	markers	T201	C0005516
27783097	952	963	MCF-7 cells	T025	C0007634
27783097	965	976	SaOS-2 cell	T025	C0007634
27783097	977	995	conditioned medium	T130	C0162518
27783097	996	1005	increased	T081	C0205217
27783097	1010	1020	expression	T045	C1171362
27783097	1024	1029	RANKL	T116,T123	C0666364
27783097	1031	1036	PTHrP	T116,T125	C0070099
27783097	1038	1042	VEGF	T116,T123	C0078058
27783097	1047	1053	NOGGIN	T116,T123	C4084599
27783097	1057	1068	MCF-7 cells	T025	C0007634
27783097	1070	1081	Co-cultures	T059	C0282547
27783097	1094	1105	MG-63 cells	T025	C0007634
27783097	1109	1113	MSCs	T025	C3178844
27783097	1114	1121	induced	T169	C0205263
27783097	1122	1125	OPG	T116,T192	C0538161
27783097	1130	1135	MMP-2	T116,T126	C0623362
27783097	1144	1160	tumor cell lines	T025	C0085983
27783097	1177	1195	conditioned medium	T130	C0162518
27783097	1201	1212	co-cultures	T059	C0282547
27783097	1216	1220	MSCs	T025	C3178844
27783097	1225	1241	MDA-MB-231 cells	T025	C0596155
27783097	1242	1265	significantly decreased	T081	C4055638
27783097	1270	1283	proliferation	T043	C0596290
27783097	1287	1310	activated T lymphocytes	T025	C2737322
27783097	1345	1364	anti-OPG antibodies	T116,T129	C0003241
27783097	1372	1383	co-cultures	T059	C0282547
27783097	1389	1393	data	T078	C1511726
27783097	1394	1401	suggest	T078	C1705535
27783097	1407	1411	MSCs	T025	C3178844
27783097	1421	1431	contribute	T052	C1880177
27783097	1439	1449	adaptation	T038	C0392673
27783097	1454	1466	invasiveness	T080	C1301757
27783097	1470	1489	breast cancer cells	T025	C1512505
27783097	1493	1509	skeletal tissues	T024	C0586827

27286759|t|Spatial analysis of drug poisoning deaths in the American West, particularly Utah
27286759|a|Most states in the Western US have high rates of drug poisoning death (DPD), especially New Mexico, Nevada, Arizona and Utah (UT). This seems paradoxical in UT where illicit drug use, smoking and drinking rates are low. To investigate this, spatial analysis of county level DPD data and other relevant factors in the Western US and UT was undertaken. Poisson kriging was used to smooth the DPD data, populate data gaps and improve the reliability of rates recorded in sparsely populated counties. Links between DPD and economic, environmental, health, lifestyle, and demographic factors were investigated at four scales using multiple linear regression. LDS church membership and altitude, factors not previously considered, were included. Spatial change in the strength and sign of relationships was investigated using geographically weighted regression and significant DPD clusters were identified using the Local Moran's I. Economic factors, like the sharp social gradient between rural and urban areas were important to DPD throughout the west. Higher DPD rates were also found in areas of higher elevation and the desert rural areas in the south. The unique characteristics of DPD in UT in terms of health and lifestyle factors, as well as the demographic structure of DPD in the most LDS populous states (UT, Idaho, Wyoming), suggest that high DPD in heavily LDS areas are predominantly prescription opioid related whereas in other Western states a larger proportion of DPD might come from illicit drugs. Drug policies need to be adapted to the geographical differences in the dominant type of drug causing death. Educational materials need to be marketed to the demographic groups at greatest risk and take into account differences in population characteristics between and within States. Some suggestions about how such adaptations can be made are given and future research needs outlined.
27286759	0	16	Spatial analysis	T062	C0814926
27286759	20	34	drug poisoning	T037	C0013221
27286759	35	41	deaths	T040	C0011065
27286759	49	62	American West	T083	C0041703
27286759	77	81	Utah	T083	C0042124
27286759	87	93	states	T083	C1301808
27286759	101	111	Western US	T083	C0041703
27286759	122	127	rates	T081	C0205848
27286759	131	145	drug poisoning	T037	C0013221
27286759	146	151	death	T040	C0011065
27286759	153	156	DPD	T040	C0011065
27286759	170	180	New Mexico	T083	C0027972
27286759	182	188	Nevada	T083	C0027951
27286759	190	197	Arizona	T083	C0003787
27286759	202	206	Utah	T083	C0042124
27286759	208	210	UT	T083	C0042124
27286759	224	235	paradoxical	T080	C0205310
27286759	239	241	UT	T083	C0042124
27286759	248	264	illicit drug use	T055	C0281875
27286759	266	273	smoking	T055	C0037369
27286759	278	292	drinking rates	T055	C0001948
27286759	297	300	low	T080	C0205251
27286759	323	339	spatial analysis	T062	C0814926
27286759	343	349	county	T083	C0079170
27286759	356	359	DPD	T040	C0011065
27286759	360	364	data	T078	C1511726
27286759	375	383	relevant	T080	C2347946
27286759	384	391	factors	T169	C1521761
27286759	399	409	Western US	T083	C0041703
27286759	414	416	UT	T083	C0042124
27286759	433	448	Poisson kriging	T062	C3494287
27286759	472	475	DPD	T040	C0011065
27286759	476	480	data	T078	C1511726
27286759	491	495	data	T078	C1511726
27286759	517	528	reliability	T081	C2347947
27286759	532	537	rates	T081	C0205848
27286759	550	577	sparsely populated counties	T083	C0079170
27286759	593	596	DPD	T040	C0011065
27286759	601	609	economic	T081	C0205749
27286759	611	624	environmental	T169	C1516998
27286759	626	632	health	T078	C0018684
27286759	634	643	lifestyle	T054	C0023676
27286759	649	668	demographic factors	T078	C0011292
27286759	708	734	multiple linear regression	T081	C0023733
27286759	736	757	LDS church membership	UnknownType	C0683988
27286759	762	770	altitude	T081	C0002349
27286759	772	779	factors	T169	C1521761
27286759	822	836	Spatial change	T082	C0012727
27286759	844	852	strength	T078	C0808080
27286759	865	878	relationships	T080	C0439849
27286759	902	936	geographically weighted regression	T081	C4046053
27286759	953	956	DPD	T040	C0011065
27286759	957	965	clusters	T081	C1704332
27286759	992	1007	Local Moran's I	T062	C3825653
27286759	1009	1025	Economic factors	T081	C0205749
27286759	1042	1048	social	T169	C0728831
27286759	1049	1057	gradient	T081	C0812409
27286759	1066	1071	rural	T082	C0178837
27286759	1076	1087	urban areas	T082	C0178876
27286759	1106	1109	DPD	T040	C0011065
27286759	1131	1137	Higher	T080	C0205250
27286759	1138	1147	DPD rates	T081	C0205848
27286759	1167	1172	areas	T082	C0205146
27286759	1176	1182	higher	T080	C0205250
27286759	1183	1192	elevation	T082	C0702240
27286759	1201	1219	desert rural areas	T082	C0178837
27286759	1227	1232	south	T082	C1710133
27286759	1245	1260	characteristics	T080	C1521970
27286759	1264	1267	DPD	T040	C0011065
27286759	1271	1273	UT	T083	C0042124
27286759	1286	1292	health	T033	C0810377
27286759	1297	1306	lifestyle	T054	C0023676
27286759	1331	1352	demographic structure	T102	C0683970
27286759	1356	1359	DPD	T040	C0011065
27286759	1372	1391	LDS populous states	T083	C1301808
27286759	1393	1395	UT	T083	C0042124
27286759	1397	1402	Idaho	T083	C0020787
27286759	1404	1411	Wyoming	T083	C0043287
27286759	1432	1435	DPD	T040	C0011065
27286759	1439	1456	heavily LDS areas	T083	C0017446
27286759	1488	1494	opioid	T109,T121,T131	C0242402
27286759	1520	1534	Western states	T083	C0041703
27286759	1558	1561	DPD	T040	C0011065
27286759	1578	1591	illicit drugs	T131	C0086190
27286759	1593	1606	Drug policies	UnknownType	C0683727
27286759	1633	1657	geographical differences	T033	C0935553
27286759	1665	1673	dominant	T169	C1527180
27286759	1682	1686	drug	T121	C0013227
27286759	1695	1700	death	T040	C0011065
27286759	1702	1723	Educational materials	T065	C2919937
27286759	1735	1743	marketed	T080	C3640197
27286759	1751	1769	demographic groups	T078	C0441833
27286759	1773	1781	greatest	T081	C0205393
27286759	1782	1786	risk	T078	C0035647
27286759	1809	1820	differences	T080	C1705242
27286759	1824	1850	population characteristics	T102	C0032661
27286759	1870	1876	States	T083	C1301808
27286759	1883	1894	suggestions	T078	C1705535

27425447|t|Triterpenoids from the stems of Tripterygium regelii
27425447|a|Three new triterpenoids, triregelolides A, B (1, 2), and triregeloic acid (3), were isolated from the stems of Tripterygium regelii along with twenty known triterpene analogues (4-23). The structures of three new compounds were identified by analyzing their NMR spectroscopic and HRESIMS data. Compounds 4, 7, 8, 10, 13, 14, 17, 21-23 were isolated from T. regelii for the first time. Compounds 3, 5, 6, 8, 9, 10, 14 and 16 showed inhibitory effects on the proliferation of human breast cancer cells MCF-7 by 24.1%, 69.6%, 72.8%, 21.6%, 23.1%, 43.3%, 25.5% and 23.5% (p<0.05) at a concentration of 10μM, respectively.
27425447	0	13	Triterpenoids	T109	C1519655
27425447	23	28	stems	T002	C0242767
27425447	32	52	Tripterygium regelii	T002	C1059497
27425447	63	76	triterpenoids	T109	C1519655
27425447	78	92	triregelolides	T109	C1519655
27425447	110	126	triregeloic acid	T109	C1519655
27425447	137	145	isolated	T169	C0205409
27425447	155	160	stems	T002	C0242767
27425447	164	184	Tripterygium regelii	T002	C1059497
27425447	209	219	triterpene	T109	C0041113
27425447	220	229	analogues	T104	C0002776
27425447	266	275	compounds	T109	C0041113
27425447	311	328	NMR spectroscopic	T060	C0877853
27425447	333	340	HRESIMS	T059	C0596495
27425447	347	356	Compounds	T109	C0041113
27425447	357	358	4	T109	C0041113
27425447	360	361	7	T109	C0041113
27425447	363	364	8	T109	C0041113
27425447	366	368	10	T109	C0041113
27425447	370	372	13	T109	C0041113
27425447	374	376	14	T109	C0041113
27425447	378	380	17	T109	C0041113
27425447	382	387	21-23	T109	C0041113
27425447	393	401	isolated	T169	C0205409
27425447	407	417	T. regelii	T002	C1059497
27425447	438	447	Compounds	T109	C1519655
27425447	448	449	3	T109	C1519655
27425447	451	452	5	T109	C0041113
27425447	454	455	6	T109	C0041113
27425447	457	458	8	T109	C0041113
27425447	460	461	9	T109	C0041113
27425447	463	465	10	T109	C0041113
27425447	467	469	14	T109	C0041113
27425447	474	476	16	T109	C0041113
27425447	484	523	inhibitory effects on the proliferation	T043	C1156236
27425447	527	552	human breast cancer cells	T025	C1512505
27425447	553	558	MCF-7	T025	C0596890
27425447	634	647	concentration	T081	C0392762

27297523|t|A case of bilateral pneumothoraces resulting from tracheostomy for advanced laryngeal cancer
27297523|a|Pneumothorax is a possible complication of tracheostomy. We report a rare case of bilateral pneumothoraces resulting from tracheostomy in an advanced laryngeal cancer patient. A 59-year-old man was referred to our clinic for evaluation and treatment of laryngeal tumor. Laryngeal endoscopy showed limited movement of bilateral vocal cords, and computed tomography revealed a tumor lesion extending from the vocal cords to the subglottic area. Three days after the first visit, the patient developed respiratory difficulty, and we elected to perform emergency tracheostomy for airway management. Immediately after the start of the procedure, he began hyperventilating, and complained of respiratory discomfort and chest pain. We then recognized a mediastinal air leak, and we suspected pneumothorax resulting from the tracheostomy. Chest X-ray showed bilateral pneumothoraces; therefore, we inserted bilateral chest drainage tubes, which stabilized his respiratory condition. We speculated that the pathogenesis of the bilateral pneumothoraces was weakened alveolar walls secondary to long-term smoking, and a significant rise in airway pressure because of airway constriction by the neck-extended position and hyperventilation, during tracheostomy.
27297523	2	6	case	T077	C1706256
27297523	10	19	bilateral	T082	C0238767
27297523	20	34	pneumothoraces	T047	C0032326
27297523	50	62	tracheostomy	T061	C0040590
27297523	67	75	advanced	UnknownType	C0679246
27297523	76	92	laryngeal cancer	T191	C0007107
27297523	93	105	Pneumothorax	T047	C0032326
27297523	120	132	complication	T046	C0009566
27297523	136	148	tracheostomy	T061	C0040590
27297523	153	159	report	T058	C0700287
27297523	175	184	bilateral	T082	C0238767
27297523	185	199	pneumothoraces	T047	C0032326
27297523	215	227	tracheostomy	T061	C0040590
27297523	234	242	advanced	UnknownType	C0679246
27297523	243	259	laryngeal cancer	T191	C0007107
27297523	260	267	patient	T101	C0030705
27297523	283	286	man	T032	C0086582
27297523	307	313	clinic	T073,T093	C0442592
27297523	318	328	evaluation	T058	C0220825
27297523	333	342	treatment	T061	C0087111
27297523	346	361	laryngeal tumor	T191	C0023055
27297523	363	382	Laryngeal endoscopy	T060	C0023072
27297523	390	406	limited movement	T033	C0243095
27297523	410	431	bilateral vocal cords	T023	C0459363
27297523	437	456	computed tomography	T060	C0040405
27297523	468	473	tumor	T191	C0027651
27297523	474	480	lesion	T033	C0221198
27297523	500	511	vocal cords	T023	C0042930
27297523	519	534	subglottic area	T023	C0456475
27297523	542	546	days	T079	C0439228
27297523	557	568	first visit	T033	C4287881
27297523	574	581	patient	T101	C0030705
27297523	592	614	respiratory difficulty	T184	C0013404
27297523	642	664	emergency tracheostomy	T061	C0498305
27297523	669	686	airway management	T061	C0150126
27297523	723	732	procedure	T061	C0543467
27297523	743	759	hyperventilating	T033	C0020578
27297523	779	801	respiratory discomfort	T033	C4062414
27297523	806	816	chest pain	T184	C0008031
27297523	839	850	mediastinal	T029	C0025066
27297523	851	859	air leak	T047	C2242512
27297523	868	877	suspected	T080	C0332147
27297523	878	890	pneumothorax	T047	C0032326
27297523	910	922	tracheostomy	T061	C0040590
27297523	924	935	Chest X-ray	T060	C0039985
27297523	943	952	bilateral	T082	C0238767
27297523	953	967	pneumothoraces	T047	C0032326
27297523	983	991	inserted	T058	C0441587
27297523	992	1001	bilateral	T082	C0238767
27297523	1002	1007	chest	T029	C0817096
27297523	1008	1022	drainage tubes	T074	C0184114
27297523	1030	1040	stabilized	T033	C0184512
27297523	1045	1066	respiratory condition	T033	C4062804
27297523	1091	1103	pathogenesis	T046	C0699748
27297523	1111	1120	bilateral	T082	C0238767
27297523	1121	1135	pneumothoraces	T047	C0032326
27297523	1140	1148	weakened	T080	C1762617
27297523	1149	1163	alveolar walls	T023	C0225695
27297523	1177	1186	long-term	T079	C0443252
27297523	1187	1194	smoking	T055	C0037369
27297523	1214	1218	rise	T169	C0442805
27297523	1222	1237	airway pressure	T201	C0428719
27297523	1249	1268	airway constriction	T184	C0231818
27297523	1276	1298	neck-extended position	T082	C0577754
27297523	1303	1319	hyperventilation	T033	C0020578
27297523	1328	1340	tracheostomy	T061	C0040590

27882455|t|Memory consolidation effects on memory stabilization and item integration in older adults
27882455|a|This study examined the differential effects of aging on consolidation processes that strengthen newly acquired memory traces in veridical form (memory stabilization) versus consolidation processes that are responsible for integrating these memory traces into an existing body of knowledge (item integration). Older adults learned 13 nonwords and were tested on their memory for the nonwords, and on whether these nonwords impacted upon processing of similar-sounding English words immediately and 24 hours later. Participants accurately recognized the nonwords immediately, but showed significant decreases in delayed recognition and recall. In comparison, the nonwords impacted upon processing of similar-sounding words only in the delayed test. Together, these findings suggest that memory consolidation processes may be more evident in item integration than memory stabilization processes for new declarative memories in older adults.
27882455	0	20	Memory consolidation	T041	C0679057
27882455	21	28	effects	T080	C1280500
27882455	32	52	memory stabilization	T041	C0025361
27882455	57	73	item integration	T041	C0025361
27882455	77	89	older adults	T098	C0001792
27882455	95	100	study	T062	C2603343
27882455	114	134	differential effects	T169	C1274040
27882455	138	143	aging	T040	C0001811
27882455	147	170	consolidation processes	T041	C0679057
27882455	202	215	memory traces	T041	C0870873
27882455	235	255	memory stabilization	T041	C0025361
27882455	264	287	consolidation processes	T041	C0679057
27882455	313	324	integrating	T041	C0025361
27882455	331	344	memory traces	T041	C0870873
27882455	370	379	knowledge	T170	C0376554
27882455	381	397	item integration	T041	C0025361
27882455	400	412	Older adults	T098	C0001792
27882455	413	420	learned	T041	C0023185
27882455	424	432	nonwords	T170	C0282574
27882455	458	464	memory	T041	C0025260
27882455	473	481	nonwords	T170	C0282574
27882455	504	512	nonwords	T170	C0282574
27882455	558	565	English	T171	C0376245
27882455	566	571	words	T170	C0282574
27882455	591	596	hours	T079	C0439227
27882455	604	616	Participants	T098	C0679646
27882455	643	651	nonwords	T170	C0282574
27882455	709	720	recognition	T041	C0524637
27882455	725	731	recall	T041	C0034770
27882455	752	760	nonwords	T170	C0282574
27882455	775	785	processing	T052	C1709694
27882455	789	811	similar-sounding words	T170	C0282574
27882455	824	836	delayed test	T170	C0451414
27882455	876	906	memory consolidation processes	T041	C0679057
27882455	930	946	item integration	T041	C0025361
27882455	952	982	memory stabilization processes	T041	C0025361
27882455	1003	1011	memories	T041	C0025260
27882455	1015	1027	older adults	T098	C0001792

28039389|t|Low efficacy of albendazole against Trichuris trichiura infection in schoolchildren from Port Elizabeth, South Africa
28039389|a|Albendazole is one of two standard drugs for the control of soil-transmitted helminthiasis. A total of 149 schoolchildren from Port Elizabeth, South Africa, were examined for soil-transmitted helminth infections using duplicate Kato-Katz thick smears before and 2 weeks after administration of albendazole (400 mg). Trichuris trichiura was the predominant soil-transmitted helminth species (prevalence 60.4%), followed by Ascaris lumbricoides (47.7%). While albendazole was highly efficacious against A. lumbricoides (cure rate [CR] 97.2%; egg reduction rate [ERR] 94.3%), it lacked efficacy against T. trichiura (CR 1.1%; ERR 46.0%). Our study confirms low efficacy of single dose albendazole against T. trichiura. There is a need for safe and efficacious drugs against T. trichiura.
28039389	0	3	Low	T080	C0205251
28039389	4	12	efficacy	T080	C1280519
28039389	16	27	albendazole	T109,T121	C0001911
28039389	36	65	Trichuris trichiura infection	T047	C0040954
28039389	69	83	schoolchildren	T100	C0260267
28039389	89	103	Port Elizabeth	UnknownType	C0681784
28039389	105	117	South Africa	T083	C0037712
28039389	118	129	Albendazole	T109,T121	C0001911
28039389	153	158	drugs	T121	C1254351
28039389	167	174	control	T169	C2587213
28039389	178	208	soil-transmitted helminthiasis	T047	C0018889
28039389	212	217	total	T080	C0439810
28039389	225	239	schoolchildren	T100	C0260267
28039389	245	259	Port Elizabeth	UnknownType	C0681784
28039389	261	273	South Africa	T083	C0037712
28039389	280	288	examined	T033	C0332128
28039389	293	329	soil-transmitted helminth infections	T047	C0018889
28039389	336	368	duplicate Kato-Katz thick smears	T059	C0022885
28039389	382	387	weeks	T079	C0439230
28039389	394	408	administration	T061	C1533734
28039389	412	423	albendazole	T109,T121	C0001911
28039389	434	453	Trichuris trichiura	T204	C0040913
28039389	462	473	predominant	T080	C1542147
28039389	474	507	soil-transmitted helminth species	T204	C0018893
28039389	509	519	prevalence	T081	C0033105
28039389	528	539	followed by	T079	C0332283
28039389	540	560	Ascaris lumbricoides	T204	C0003955
28039389	576	587	albendazole	T109,T121	C0001911
28039389	599	610	efficacious	T080	C1280519
28039389	619	634	A. lumbricoides	T204	C0003955
28039389	636	645	cure rate	T081	C1521828
28039389	647	649	CR	T081	C1521828
28039389	658	676	egg reduction rate	T081	C1521828
28039389	678	681	ERR	T081	C1521828
28039389	701	709	efficacy	T080	C1280519
28039389	718	730	T. trichiura	T204	C0040913
28039389	732	734	CR	T081	C1521828
28039389	741	744	ERR	T081	C1521828
28039389	757	762	study	T062	C2603343
28039389	772	775	low	T080	C0205251
28039389	776	784	efficacy	T080	C1280519
28039389	788	799	single dose	T081	C0178602
28039389	800	811	albendazole	T109,T121	C0001911
28039389	820	832	T. trichiura	T204	C0040913
28039389	863	874	efficacious	T080	C1280519
28039389	875	880	drugs	T121	C1254351
28039389	889	901	T. trichiura	T204	C0040913

27453556|t|Reintervention after endovascular repair for aortic dissection: A systematic review and meta-analysis
27453556|a|Thoracic endovascular aortic repair has been chosen as a less-invasive alternative to open surgery for the treatment of aortic dissections; however, the advantages have been challenged by the postoperative reintervention during the follow-up period. This study aimed at evaluating the incidence, reasons, and potential risk factors for reintervention. Studies reporting reintervention after endovascular repair were identified by searching PubMed and Embase in accordance with preferred reporting items for systematic reviews and meta-analyses guidelines, and by reviewing the reference lists of retrieved articles. Sensitivity analysis and subgroup analyses were performed to determine the sources of heterogeneity. Funnel plot and Egger's test were used to determine the publication bias. A total of 27 studies encompassing 2403 patients with aortic dissection were identified. The pooled incidence of reintervention after endovascular repair was 15% (95% confidence interval, 12-19) during 33.7 months of follow-up. The 3 most common reasons for reintervention were endoleak (33.2%), false lumen perfusion and aortic dilation (19.8%), and new dissection (6.9%). The potential factors for reintervention were the mean age of onset and diabetes mellitus determined by performing a single meta-regression analysis (P < .001 and .044, respectively). Current data suggest that the incidence of reintervention after endovascular therapy is relatively high during midterm follow-up. Advanced age of onset is a risk factor and diabetes mellitus is a protective factor of reintervention after endovascular therapy. The possible mechanism that diabetes mellitus protects patients from reintervention should be explored further.
27453556	0	14	Reintervention	T061	C0184661
27453556	21	40	endovascular repair	T061	C3468484
27453556	45	62	aortic dissection	T047	C0340643
27453556	66	83	systematic review	T170	C1955832
27453556	88	101	meta-analysis	T062	C0920317
27453556	102	137	Thoracic endovascular aortic repair	T061	C3468484
27453556	159	172	less-invasive	T080	C0205281
27453556	173	184	alternative	T077	C1523987
27453556	188	200	open surgery	T061	C4283938
27453556	209	218	treatment	T169	C1522326
27453556	222	240	aortic dissections	T047	C0340643
27453556	294	307	postoperative	T079	C0032790
27453556	308	322	reintervention	T061	C0184661
27453556	334	343	follow-up	T058	C1522577
27453556	344	350	period	T079	C1948053
27453556	387	396	incidence	T081	C0021149
27453556	398	405	reasons	T078	C0392360
27453556	411	420	potential	T080	C3245505
27453556	421	433	risk factors	T033	C0035648
27453556	438	452	reintervention	T061	C0184661
27453556	472	486	reintervention	T061	C0184661
27453556	493	512	endovascular repair	T061	C3468484
27453556	518	528	identified	T080	C0205396
27453556	532	541	searching	T052	C1706202
27453556	542	548	PubMed	T170	C1138432
27453556	553	559	Embase	T170	C0282574
27453556	609	627	systematic reviews	T170	C1955832
27453556	632	645	meta-analyses	T062	C0920317
27453556	646	656	guidelines	T170	C0162791
27453556	665	674	reviewing	T080	C1704362
27453556	679	694	reference lists	T170	C1317676
27453556	698	716	retrieved articles	T170	C1706852
27453556	718	729	Sensitivity	T081	C0036667
27453556	730	738	analysis	T062	C0936012
27453556	743	751	subgroup	T185	C1515021
27453556	752	760	analyses	T062	C0936012
27453556	766	775	performed	T169	C0884358
27453556	793	800	sources	T033	C0449416
27453556	804	817	heterogeneity	T080	C0019409
27453556	819	830	Funnel plot	T081	C0392762
27453556	835	847	Egger's test	T081	C0392762
27453556	875	891	publication bias	T080	C0206086
27453556	933	941	patients	T101	C0030705
27453556	947	964	aortic dissection	T047	C0340643
27453556	970	980	identified	T080	C0205396
27453556	986	992	pooled	T169	C2349200
27453556	993	1002	incidence	T081	C0021149
27453556	1006	1020	reintervention	T061	C0184661
27453556	1027	1046	endovascular repair	T061	C3468484
27453556	1060	1079	confidence interval	T081	C0009667
27453556	1100	1106	months	T079	C0439231
27453556	1110	1119	follow-up	T058	C1522577
27453556	1139	1146	reasons	T078	C0392360
27453556	1151	1165	reintervention	T061	C0184661
27453556	1171	1179	endoleak	T046	C1504464
27453556	1189	1210	false lumen perfusion	T046	C3805269
27453556	1215	1230	aortic dilation	T033	C4229558
27453556	1244	1247	new	T080	C0205314
27453556	1248	1258	dissection	T047	C0340643
27453556	1271	1280	potential	T080	C3245505
27453556	1281	1288	factors	T169	C1521761
27453556	1293	1307	reintervention	T061	C0184661
27453556	1322	1334	age of onset	T081	C0206132
27453556	1339	1356	diabetes mellitus	T047	C0011849
27453556	1384	1415	single meta-regression analysis	T170	C0034980
27453556	1459	1463	data	T078	C1511726
27453556	1481	1490	incidence	T081	C0021149
27453556	1494	1508	reintervention	T061	C0184661
27453556	1515	1535	endovascular therapy	T061	C2936204
27453556	1562	1569	midterm	T079	C1515273
27453556	1570	1579	follow-up	T058	C1522577
27453556	1590	1602	age of onset	T081	C0206132
27453556	1608	1619	risk factor	T033	C0035648
27453556	1624	1641	diabetes mellitus	T047	C0011849
27453556	1647	1664	protective factor	T055	C0679688
27453556	1668	1682	reintervention	T061	C0184661
27453556	1689	1709	endovascular therapy	T061	C2936204
27453556	1724	1733	mechanism	T169	C0441712
27453556	1739	1756	diabetes mellitus	T047	C0011849
27453556	1766	1774	patients	T101	C0030705
27453556	1780	1794	reintervention	T061	C0184661
27453556	1814	1821	further	T082	C1517331

27795266|t|Characterization of Beak and Feather Disease Virus Genomes from Wild Musk Lorikeets (Glossopsitta concinna)
27795266|a|Three complete genomes of beak and feather disease virus (BFDV) were recovered from wild musk lorikeets (Glossopsitta concinna). The genomes consisted of 2,008 to 2,010 nucleotides (nt) and encode two major proteins transcribing in opposing directions. This is the first report of BFDV complete genome sequences obtained from this host species.
27795266	0	16	Characterization	T052	C1880022
27795266	20	50	Beak and Feather Disease Virus	T005	C0206410
27795266	51	58	Genomes	T028	C0017428
27795266	64	68	Wild	T170	C0445392
27795266	69	83	Musk Lorikeets	T012	C1670393
27795266	85	106	Glossopsitta concinna	T012	C1670393
27795266	123	130	genomes	T028	C0017428
27795266	134	164	beak and feather disease virus	T005	C0206410
27795266	166	170	BFDV	T005	C0206410
27795266	192	196	wild	T170	C0445392
27795266	197	211	musk lorikeets	T012	C1670393
27795266	213	234	Glossopsitta concinna	T012	C1670393
27795266	241	248	genomes	T028	C0017428
27795266	277	288	nucleotides	T114	C0028630
27795266	290	292	nt	T114	C0028630
27795266	298	304	encode	T085	C0017380
27795266	315	323	proteins	T116,T123	C0033684
27795266	324	336	transcribing	T033	C4036062
27795266	379	385	report	T170	C0684224
27795266	389	393	BFDV	T005	C0206410
27795266	403	419	genome sequences	T028	C0017428
27795266	439	451	host species	T070	C2936412

28153991|t|Sex -Based Differences in Cardiometabolic Biomarkers
28153991|a|Few data are available comparing cardiovascular disease (CVD) biomarker profiles between women and men in the general population. We analyzed sex -based differences in multiple biomarkers reflecting distinct pathophysiological pathways, accounting for differences between women and men in CVD risk factors, body composition, and cardiac morphology. A cross-sectional analysis was performed using data from the Dallas Heart Study, a multiethnic population-based study. Associations between sex and 30 distinct biomarkers representative of 6 pathophysiological categories were evaluated using multivariable linear regression adjusting for age, race, traditional CVD risk factors, kidney function, insulin resistance, MRI and dual-energy x-ray absorptiometry measures of body composition and fat distribution, and left ventricular mass. After excluding participants with CVD, the study population included 3439 individuals, mean age 43 years, 56% women, and 52% black. Significant sex -based differences were seen in multiple categories of biomarkers, including lipids, adipokines, and biomarkers of inflammation, endothelial dysfunction, myocyte injury and stress, and kidney function. In fully adjusted models, women had higher levels of high-density lipoprotein cholesterol and high-density lipoprotein particle concentration, leptin, d-dimer, homoarginine, and N-terminal pro B-type natriuretic peptide, and lower levels of low-density lipoprotein cholesterol, adiponectin, lipoprotein - associated phospholipase A2 mass and activity, monocyte chemoattractant protein-1, soluble endothelial cell adhesion molecule, symmetrical dimethylarginine, asymmetrical dimethylarginine, high-sensitivity troponin T, and cystatin C. Biomarker profiles differ significantly between women and men in the general population. Sex differences were most apparent for biomarkers of adiposity, endothelial dysfunction, inflammatory cell recruitment, and cardiac stress and injury. Future studies are needed to characterize whether pathophysiological processes delineated by these biomarkers contribute to sex -based differences in the development and complications of CVD.
28153991	0	3	Sex	T032	C0079399
28153991	11	22	Differences	T080	C1705242
28153991	26	41	Cardiometabolic	T029	C3887460
28153991	42	52	Biomarkers	T201	C0005516
28153991	57	61	data	T078	C1511726
28153991	66	75	available	T169	C0470187
28153991	86	108	cardiovascular disease	T047	C0007222
28153991	110	113	CVD	T047	C0007222
28153991	115	124	biomarker	T201	C0005516
28153991	125	133	profiles	T169	C2003903
28153991	142	147	women	T098	C0043210
28153991	152	155	men	T098	C0025266
28153991	163	181	general population	T098	C0683971
28153991	186	194	analyzed	T062	C0936012
28153991	195	198	sex	T032	C0079399
28153991	206	217	differences	T080	C1705242
28153991	221	229	multiple	T081	C0439064
28153991	230	240	biomarkers	T201	C0005516
28153991	261	279	pathophysiological	T169	C0031847
28153991	280	288	pathways	T077	C1705987
28153991	305	316	differences	T080	C1705242
28153991	325	330	women	T098	C0043210
28153991	335	338	men	T098	C0025266
28153991	342	345	CVD	T047	C0007222
28153991	346	358	risk factors	T033	C0035648
28153991	360	376	body composition	T032	C0005885
28153991	382	389	cardiac	T023	C0018787
28153991	390	400	morphology	T080	C0332437
28153991	404	428	cross-sectional analysis	T062	C0010362
28153991	433	442	performed	T169	C0884358
28153991	449	453	data	T078	C1511726
28153991	463	481	Dallas Heart Study	T062	C0681876
28153991	485	519	multiethnic population-based study	T062	C0681876
28153991	521	533	Associations	T080	C0439849
28153991	542	545	sex	T032	C0079399
28153991	562	572	biomarkers	T201	C0005516
28153991	593	611	pathophysiological	T169	C0031847
28153991	612	622	categories	T170	C0683312
28153991	628	637	evaluated	T058	C0220825
28153991	644	657	multivariable	T081	C0439064
28153991	658	675	linear regression	T081	C0023733
28153991	676	685	adjusting	T169	C0456081
28153991	690	693	age	T032	C0001779
28153991	695	699	race	T098	C0034510
28153991	701	712	traditional	T169	C0443324
28153991	713	716	CVD	T047	C0007222
28153991	717	729	risk factors	T033	C0035648
28153991	731	746	kidney function	T042	C0232804
28153991	748	766	insulin resistance	T046	C0021655
28153991	768	771	MRI	T060	C0024485
28153991	776	808	dual-energy x-ray absorptiometry	T060	C1510486
28153991	809	817	measures	T081	C0079809
28153991	821	837	body composition	T032	C0005885
28153991	842	858	fat distribution	T033	C0424621
28153991	864	885	left ventricular mass	T033	C0455825
28153991	903	915	participants	T098	C0679646
28153991	921	924	CVD	T047	C0007222
28153991	930	946	study population	T098	C2348561
28153991	961	972	individuals	T098	C0027361
28153991	974	978	mean	T081	C0444504
28153991	979	982	age	T032	C0001779
28153991	986	991	years	T079	C0439234
28153991	997	1002	women	T098	C0043210
28153991	1012	1017	black	T098	C0005680
28153991	1019	1030	Significant	T078	C0750502
28153991	1031	1034	sex	T032	C0079399
28153991	1042	1053	differences	T080	C1705242
28153991	1067	1075	multiple	T081	C0439064
28153991	1076	1086	categories	T170	C0683312
28153991	1090	1100	biomarkers	T201	C0005516
28153991	1112	1118	lipids	T109	C0023779
28153991	1120	1130	adipokines	T116,T123	C1955907
28153991	1136	1146	biomarkers	T201	C0005516
28153991	1150	1162	inflammation	T046	C0021368
28153991	1164	1187	endothelial dysfunction	T047	C0856169
28153991	1189	1196	myocyte	T025	C0596981
28153991	1197	1203	injury	T049	C0599732
28153991	1208	1214	stress	T049	C1516360
28153991	1220	1235	kidney function	T042	C0232804
28153991	1246	1254	adjusted	T169	C0456081
28153991	1263	1268	women	T098	C0043210
28153991	1273	1279	higher	T080	C0205250
28153991	1280	1286	levels	T080	C0441889
28153991	1290	1326	high-density lipoprotein cholesterol	T109,T123	C0023822
28153991	1331	1364	high-density lipoprotein particle	T116,T123	C0023821
28153991	1365	1378	concentration	T081	C1446561
28153991	1380	1386	leptin	T116,T125	C0299583
28153991	1388	1395	d-dimer	T116,T123	C0060323
28153991	1397	1409	homoarginine	T116	C0019877
28153991	1415	1456	N-terminal pro B-type natriuretic peptide	T116,T123	C0754710
28153991	1462	1467	lower	T080	C0205251
28153991	1468	1474	levels	T080	C0441889
28153991	1478	1513	low-density lipoprotein cholesterol	T109,T123	C0023824
28153991	1515	1526	adiponectin	T116,T123	C0389071
28153991	1528	1539	lipoprotein	T116,T123	C0023820
28153991	1542	1552	associated	T080	C0332281
28153991	1553	1569	phospholipase A2	T116,T126	C0031667
28153991	1579	1587	activity	T044	C0243102
28153991	1589	1623	monocyte chemoattractant protein-1	T116,T129	C0128897
28153991	1625	1632	soluble	T080	C1948047
28153991	1633	1667	endothelial cell adhesion molecule	T116,T123	C3253526
28153991	1669	1680	symmetrical	T033	C0332516
28153991	1681	1697	dimethylarginine	T116	C1453836
28153991	1699	1711	asymmetrical	T082	C0332514
28153991	1712	1728	dimethylarginine	T116	C1453836
28153991	1730	1746	high-sensitivity	T059	C1441604
28153991	1747	1757	troponin T	T116,T123	C0077404
28153991	1763	1773	cystatin C	T116,T121	C0071744
28153991	1775	1784	Biomarker	T201	C0005516
28153991	1785	1793	profiles	T169	C2003903
28153991	1823	1828	women	T098	C0043210
28153991	1833	1836	men	T098	C0025266
28153991	1844	1862	general population	T098	C0683971
28153991	1864	1867	Sex	T032	C0079399
28153991	1868	1879	differences	T080	C1705242
28153991	1890	1898	apparent	T078	C0750489
28153991	1903	1913	biomarkers	T201	C0005516
28153991	1917	1926	adiposity	T032	C1563743
28153991	1928	1951	endothelial dysfunction	T047	C0856169
28153991	1953	1982	inflammatory cell recruitment	T033	C0243095
28153991	1988	2002	cardiac stress	T033	C2317276
28153991	2007	2013	injury	T037	C0018805
28153991	2065	2083	pathophysiological	T169	C0031847
28153991	2084	2093	processes	T067	C1522240
28153991	2114	2124	biomarkers	T201	C0005516
28153991	2139	2142	sex	T032	C0079399
28153991	2150	2161	differences	T080	C1705242
28153991	2169	2180	development	T169	C1527148
28153991	2185	2198	complications	T046	C0009566
28153991	2202	2205	CVD	T047	C0007222

27285494|t|Parasympathetic Activity and Bronchial Hyperresponsiveness in Athletes
27285494|a|A high prevalence of asthma and bronchial hyperresponsiveness (BHR) is reported in swimmers and cross-country skiers. It has been suggested that increased parasympathetic nervous activity is involved in asthma development in endurance athletes. We aimed to assess the associations of BHR to parasympathetic activity in healthy and asthmatic swimmers and cross-country skiers and healthy non athletes. Parasympathetic activity was measured by pupillometry and heart rate variability at the onset of exercise with the cardiac vagal index calculated in 28 cross-country skiers (♂18/♀10), 29 swimmers (♂17/♀12), and 30 healthy nonathlete controls (♂14/♀16) on two different days. All subjects performed a methacholine bronchial challenge with the provocation dose causing 20% decrease in the forced expiratory volume in 1 s calculated (PD20met). Data were analyzed by robust regression analysis and presented as β coefficients with 95% confidence intervals (CI). PD20met was negatively associated with cardiac vagal index (-13.9, 95% CI = -26.8 to -1.0) in all subjects. When adjusted to the type of sport, this association was stronger in swimmers (-8.3, 95% CI = -13.0 to -3.6) as compared with controls and nonsignificant in cross-country skiers. Percent pupil constriction was significantly associated with PD20met in swimmers (-9.4, 95% CI = -15.4 to -3.4) only after adjusting for the type of sport. Fourteen swimmers (48%) and 16 cross-country skiers (57%) had doctor-diagnosed asthma in combination with current BHR and/or current use of asthma drugs. Seventy-two percent swimmers, 44% cross-country skiers, and 39% controls had a PD20met ≤8 μmol (P = 0.015). Fourteen swimmers had a PD20met ≤2 μmol as compared with one cross-country skier (P < 0.001). Parasympathetic activity measured in the heart is more closely related to BHR as compared with parasympathetic activity measured in the pupils. The type of sport influences BHR severity and its relationship to parasympathetic activity.
27285494	0	15	Parasympathetic	T023	C0459522
27285494	16	24	Activity	T043	C0234075
27285494	29	58	Bronchial Hyperresponsiveness	T047	C0085129
27285494	62	70	Athletes	T097	C0238703
27285494	73	88	high prevalence	T081	C1512456
27285494	92	98	asthma	T047	C0004096
27285494	103	132	bronchial hyperresponsiveness	T047	C0085129
27285494	134	137	BHR	T047	C0085129
27285494	154	162	swimmers	T098	C0450068
27285494	167	187	cross-country skiers	T033	C0425040
27285494	216	225	increased	T081	C0205217
27285494	226	241	parasympathetic	T023	C0459522
27285494	242	258	nervous activity	T043	C0234075
27285494	274	280	asthma	T047	C0004096
27285494	296	305	endurance	T033	C0518031
27285494	306	314	athletes	T097	C0238703
27285494	328	334	assess	T058	C0184514
27285494	355	358	BHR	T047	C0085129
27285494	362	377	parasympathetic	T023	C0459522
27285494	378	386	activity	T043	C0234075
27285494	390	397	healthy	T080	C3898900
27285494	402	411	asthmatic	T047	C0004096
27285494	412	420	swimmers	T098	C0450068
27285494	425	445	cross-country skiers	T033	C0425040
27285494	450	457	healthy	T080	C3898900
27285494	462	470	athletes	T097	C0238703
27285494	472	487	Parasympathetic	T023	C0459522
27285494	488	496	activity	T043	C0234075
27285494	501	509	measured	T080	C0444706
27285494	513	525	pupillometry	T060	C0260180
27285494	530	540	heart rate	T201	C0018810
27285494	541	552	variability	T077	C2827666
27285494	560	568	onset of	T080	C0332162
27285494	569	577	exercise	T056	C0015259
27285494	587	606	cardiac vagal index	T081	C0392762
27285494	624	644	cross-country skiers	T033	C0425040
27285494	772	784	methacholine	T109,T121	C0600370
27285494	785	804	bronchial challenge	T060	C2061924
27285494	814	825	provocation	T067	C0449428
27285494	826	830	dose	T081	C0178602
27285494	891	901	calculated	T052	C1441506
27285494	903	910	PD20met	T121	C1254351
27285494	913	917	Data	T078	C1511726
27285494	923	931	analyzed	T062	C0936012
27285494	935	941	robust	T080	C2986815
27285494	942	961	regression analysis	T170	C0034980
27285494	1003	1023	confidence intervals	T081	C0009667
27285494	1025	1027	CI	T081	C0009667
27285494	1030	1037	PD20met	T121	C1254351
27285494	1053	1068	associated with	T080	C0332281
27285494	1069	1088	cardiac vagal index	T081	C0392762
27285494	1101	1103	CI	T081	C0009667
27285494	1128	1136	subjects	T098	C0080105
27285494	1167	1172	sport	T056	C0038039
27285494	1207	1215	swimmers	T098	C0450068
27285494	1227	1229	CI	T081	C0009667
27285494	1264	1272	controls	T096	C0009932
27285494	1295	1315	cross-country skiers	T033	C0425040
27285494	1325	1343	pupil constriction	T047	C0026205
27285494	1362	1377	associated with	T080	C0332281
27285494	1378	1385	PD20met	T121	C1254351
27285494	1389	1397	swimmers	T098	C0450068
27285494	1409	1411	CI	T081	C0009667
27285494	1466	1471	sport	T056	C0038039
27285494	1482	1490	swimmers	T098	C0450068
27285494	1504	1524	cross-country skiers	T033	C0425040
27285494	1535	1558	doctor-diagnosed asthma	T047	C3843752
27285494	1587	1590	BHR	T047	C0085129
27285494	1613	1619	asthma	T047	C0004096
27285494	1620	1625	drugs	T121	C1254351
27285494	1647	1655	swimmers	T098	C0450068
27285494	1661	1681	cross-country skiers	T033	C0425040
27285494	1691	1699	controls	T096	C0009932
27285494	1706	1713	PD20met	T121	C1254351
27285494	1744	1752	swimmers	T098	C0450068
27285494	1759	1766	PD20met	T121	C1254351
27285494	1796	1815	cross-country skier	T033	C0425040
27285494	1829	1844	Parasympathetic	T023	C0459522
27285494	1845	1853	activity	T043	C0234075
27285494	1854	1862	measured	T080	C0444706
27285494	1870	1875	heart	T023	C0018787
27285494	1903	1906	BHR	T047	C0085129
27285494	1924	1939	parasympathetic	T023	C0459522
27285494	1940	1948	activity	T043	C0234075
27285494	1949	1957	measured	T080	C0444706
27285494	1965	1971	pupils	T023	C0034121
27285494	1985	1990	sport	T056	C0038039
27285494	2002	2005	BHR	T047	C0085129
27285494	2039	2054	parasympathetic	T023	C0459522
27285494	2055	2063	activity	T043	C0234075

28110694|t|Tourette syndrome in the context of evolution and behavioral ecology
28110694|a|Tourette syndrome, and the closely related spectrum of tic disorders, are inherited neuropsychiatric conditions characterized by the presence of repetitive and stereotyped movements. Tics are elicited by either environmental experiences or internal signals that instruct the basal ganglia to initiate automatic or procedural movements. In most vertebrates the basal ganglia encode instructions for habitually used sequences of motor movements that are essential to survival. Tic disorders may represent evolved phenotypes with a lower threshold for basal ganglia -directed actions. This may have produced a susceptibility to extraneous tics, but also produced fast-acting tactical solutions to immediate physical problems. During periods of nonstop movement, continual foraging, and sustained vigilance, it may have been advantageous to allow subcortical motor commands to intrude into ongoing motor activities. It is clear that the engrams for individual motor responses held in the basal ganglia are selected by converging cortical and subcortical inputs. This form of convergent action selection results in the selection of the most contextually reinforced actions. Today people with Tourette's have tics that seem arbitrary and inappropriate; however, this may be due to the vast discrepancies in reinforcement between the ancestral environment and the modern one. In prehistoric environments, the motor behaviors of individuals with tic disorders may have been appropriate in environmental context, and had ecological relevance in survival and self-promotion.
28110694	0	17	Tourette syndrome	T047	C0040517
28110694	36	45	evolution	T045	C0015219
28110694	50	68	behavioral ecology	T090	C0870195
28110694	69	86	Tourette syndrome	T047	C0040517
28110694	124	137	tic disorders	T047	C0751554
28110694	143	152	inherited	T169	C0439660
28110694	153	180	neuropsychiatric conditions	T184	C4285807
28110694	181	194	characterized	T052	C1880022
28110694	202	210	presence	T033	C0150312
28110694	214	224	repetitive	T201	C1718274
28110694	229	250	stereotyped movements	T048	C0038271
28110694	252	256	Tics	T184	C2169806
28110694	261	272	elicited by	T080	C0449265
28110694	280	305	environmental experiences	T033	C1821459
28110694	309	317	internal	T082	C0205102
28110694	318	325	signals	T043	C0037083
28110694	344	357	basal ganglia	T023	C0004781
28110694	361	369	initiate	T169	C1704686
28110694	370	403	automatic or procedural movements	T040	C0026649
28110694	413	424	vertebrates	T010	C0042567
28110694	429	442	basal ganglia	T023	C0004781
28110694	443	449	encode	T052	C2700640
28110694	467	477	habitually	T079	C0205353
28110694	483	492	sequences	T169	C1519249
28110694	496	511	motor movements	T169	C1513492
28110694	521	530	essential	T080	C0205224
28110694	534	542	survival	T169	C0220921
28110694	544	557	Tic disorders	T047	C0751554
28110694	572	579	evolved	T169	C0332253
28110694	580	590	phenotypes	T032	C0031437
28110694	604	613	threshold	T080	C0449864
28110694	618	631	basal ganglia	T023	C0004781
28110694	642	649	actions	T052	C3266814
28110694	676	690	susceptibility	T032	C0220898
28110694	694	704	extraneous	T082	C0205101
28110694	705	709	tics	T184	C2169806
28110694	729	740	fast-acting	T169	C0205245
28110694	741	759	tactical solutions	T077	C2699488
28110694	773	790	physical problems	T033	C1446390
28110694	810	826	nonstop movement	T040	C0026649
28110694	828	837	continual	T079	C0439598
28110694	838	846	foraging	T055	C2752984
28110694	852	861	sustained	T169	C0443318
28110694	862	871	vigilance	T041	C0043012
28110694	912	923	subcortical	T029	C0815275
28110694	924	938	motor commands	T041	C0599907
28110694	963	979	motor activities	T169	C1513492
28110694	1002	1009	engrams	T041	C0870873
28110694	1025	1040	motor responses	T201	C1285623
28110694	1053	1066	basal ganglia	T023	C0004781
28110694	1083	1093	converging	T052	C2700387
28110694	1094	1102	cortical	T023	C0007776
28110694	1107	1118	subcortical	T029	C0815275
28110694	1119	1125	inputs	T077	C1708517
28110694	1140	1150	convergent	T052	C2700387
28110694	1151	1157	action	T052	C3266814
28110694	1158	1167	selection	T052	C1707391
28110694	1183	1192	selection	T052	C1707391
28110694	1205	1217	contextually	T041	C0237482
28110694	1218	1228	reinforced	T078	C0035011
28110694	1229	1236	actions	T052	C3266814
28110694	1244	1250	people	T098	C0027361
28110694	1256	1266	Tourette's	T047	C0040517
28110694	1272	1276	tics	T184	C2169806
28110694	1287	1296	arbitrary	T080	C1264693
28110694	1301	1314	inappropriate	T080	C1548788
28110694	1348	1366	vast discrepancies	T033	C1290905
28110694	1370	1383	reinforcement	T041	C0035007
28110694	1396	1417	ancestral environment	T082	C0014406
28110694	1441	1465	prehistoric environments	T082	C0014406
28110694	1471	1486	motor behaviors	T040	C4085668
28110694	1490	1501	individuals	T098	C0027361
28110694	1507	1520	tic disorders	T047	C0751554
28110694	1535	1546	appropriate	T080	C1548787
28110694	1550	1571	environmental context	UnknownType	C0683581
28110694	1581	1591	ecological	T082	C0565987
28110694	1592	1601	relevance	T080	C2347946
28110694	1605	1613	survival	T169	C0220921
28110694	1618	1632	self-promotion	T052	C0033414

28118389|t|Rapid Design of Knowledge-Based Scoring Potentials for Enrichment of Near - Native Geometries in Protein-Protein Docking
28118389|a|Protein-protein docking protocols aim to predict the structures of protein-protein complexes based on the structure of individual partners. Docking protocols usually include several steps of sampling, clustering, refinement and re-scoring. The scoring step is one of the bottlenecks in the performance of many state-of-the-art protocols. The performance of scoring functions depends on the quality of the generated structures and its coupling to the sampling algorithm. A tool kit, GRADSCOPT (GRid Accelerated Directly SCoring OPTimizing), was designed to allow rapid development and optimization of different knowledge-based scoring potentials for specific objectives in protein-protein docking. Different atomistic and coarse-grained potentials can be created by a grid-accelerated directly scoring dependent Monte-Carlo annealing or by a linear regression optimization. We demonstrate that the scoring functions generated by our approach are similar to or even outperform state-of-the-art scoring functions for predicting near - native solutions. Of additional importance, we find that potentials specifically trained to identify the native bound complex perform rather poorly on identifying acceptable or medium quality (near - native) solutions. In contrast, atomistic long-range contact potentials can increase the average fraction of near - native poses by up to a factor 2.5 in the best scored 1% decoys (compared to existing scoring), emphasizing the need of specific docking potentials for different steps in the docking protocol.
28118389	16	31	Knowledge-Based	T170	C0022752
28118389	32	39	Scoring	T062	C0036449
28118389	40	50	Potentials	T080	C3245505
28118389	69	73	Near	T080	C1706276
28118389	76	82	Native	T169	C0302891
28118389	83	93	Geometries	T090	C0449829
28118389	97	120	Protein-Protein Docking	T044	C1760028
28118389	121	144	Protein-protein docking	T044	C1760028
28118389	174	184	structures	T116	C1510464
28118389	188	213	protein-protein complexes	T116,T126	C0751283
28118389	251	259	partners	T116,T123	C0033684
28118389	261	278	Docking protocols	T044	C1760028
28118389	312	320	sampling	T078	C0870078
28118389	322	332	clustering	T081	C1704332
28118389	349	359	re-scoring	T062	C0036449
28118389	365	377	scoring step	T062	C0036449
28118389	431	457	state-of-the-art protocols	UnknownType	C0700033
28118389	478	485	scoring	T062	C0036449
28118389	536	546	structures	T116	C1510464
28118389	580	589	algorithm	T170	C0002045
28118389	603	612	GRADSCOPT	T170	C0282574
28118389	614	658	GRid Accelerated Directly SCoring OPTimizing	T170	C0282574
28118389	731	746	knowledge-based	T170	C0022752
28118389	747	754	scoring	T062	C0036449
28118389	755	765	potentials	T080	C3245505
28118389	793	816	protein-protein docking	T044	C1760028
28118389	828	837	atomistic	T078	C0870168
28118389	842	867	coarse-grained potentials	T080	C3245505
28118389	888	953	grid-accelerated directly scoring dependent Monte-Carlo annealing	T081	C0026507
28118389	962	979	linear regression	T081	C0023733
28118389	1018	1035	scoring functions	T062	C0036449
28118389	1096	1130	state-of-the-art scoring functions	UnknownType	C0700033
28118389	1146	1150	near	T080	C1706276
28118389	1153	1159	native	T169	C0302891
28118389	1210	1220	potentials	T080	C3245505
28118389	1258	1264	native	T169	C0302891
28118389	1330	1336	medium	T081	C0439536
28118389	1346	1350	near	T080	C1706276
28118389	1353	1359	native	T169	C0302891
28118389	1385	1394	atomistic	T078	C0870168
28118389	1414	1424	potentials	T080	C3245505
28118389	1462	1466	near	T080	C1706276
28118389	1469	1475	native	T169	C0302891
28118389	1589	1597	specific	T080	C0205369
28118389	1598	1605	docking	T044	C1760028
28118389	1606	1616	potentials	T080	C3245505
28118389	1644	1660	docking protocol	T044	C1760028

27771814|t|Factor Analysis of Therapist -Identified Treatment Targets in Community -Based Children's Mental Health
27771814|a|The present study used exploratory and confirmatory factor analyses to identify underlying latent factors affecting variation in community therapists ' endorsement of treatment targets. As part of a statewide practice management program, therapist completed monthly reports of treatment targets (up to 10 per month) for a sample of youth (n = 790) receiving intensive in-home therapy. Nearly 75 % of youth were diagnosed with multiple co-occurring disorders. Five factors emerged: Disinhibition, Societal Rules Evasion, Social Engagement Deficits, Emotional Distress, and Management of Biodevelopmental Outcomes. Using logistic regression, primary diagnosis predicted therapist selection of Disinhibition and Emotional Distress targets. Client age predicted endorsement of Societal Rules Evasion targets. Practice-to-research implications are discussed.
27771814	0	15	Factor Analysis	T081	C0015483
27771814	19	28	Therapist	T097	C0871525
27771814	41	50	Treatment	T061	C0087111
27771814	51	58	Targets	T169	C1521840
27771814	62	71	Community	T096	C0009462
27771814	79	89	Children's	T100	C0008059
27771814	90	103	Mental Health	T041	C0025353
27771814	116	121	study	T062	C2603343
27771814	127	138	exploratory	T062	C1515369
27771814	143	171	confirmatory factor analyses	T080	C0870334
27771814	195	209	latent factors	UnknownType	C0814889
27771814	233	242	community	T096	C0009462
27771814	243	253	therapists	T097	C0871525
27771814	271	280	treatment	T061	C0087111
27771814	281	288	targets	T169	C1521840
27771814	313	340	practice management program	T058	C0032895
27771814	342	351	therapist	T097	C0871525
27771814	362	369	monthly	T079	C0332177
27771814	370	377	reports	T170	C0684224
27771814	381	390	treatment	T061	C0087111
27771814	391	398	targets	T169	C1521840
27771814	413	418	month	T079	C0439231
27771814	436	441	youth	T100	C0087178
27771814	472	487	in-home therapy	T058	C0204977
27771814	504	509	youth	T100	C0087178
27771814	515	524	diagnosed	T033	C0011900
27771814	552	561	disorders	T047	C0012634
27771814	585	598	Disinhibition	T048	C0424296
27771814	600	614	Societal Rules	T078	C0237750
27771814	615	622	Evasion	T041	C0870186
27771814	624	650	Social Engagement Deficits	T033	C4060648
27771814	652	670	Emotional Distress	T033	C0700361
27771814	676	706	Management of Biodevelopmental	T040	C0678723
27771814	707	715	Outcomes	T169	C1274040
27771814	723	742	logistic regression	T062	C0206031
27771814	744	761	primary diagnosis	T080	C0332137
27771814	772	781	therapist	T097	C0871525
27771814	795	808	Disinhibition	T048	C0424296
27771814	813	831	Emotional Distress	T033	C0700361
27771814	841	847	Client	T096	C0008942
27771814	848	851	age	T032	C0001779
27771814	877	891	Societal Rules	T078	C0237750
27771814	892	899	Evasion	T041	C0870186
27771814	900	907	targets	T169	C1521840

28322352|t|Gene -based genome-wide association study identified 19p13.3 for lean body mass
28322352|a|Lean body mass (LBM) is a complex trait for human health. To identify genomic loci underlying LBM, we performed a gene -based genome-wide association study of lean mass index (LMI) in 1000 unrelated Caucasian subjects, and replicated in 2283 unrelated Caucasians subjects. Gene -based association analyses highlighted the significant associations of three genes UQCR, TCF3 and MBD3 in one single locus 19p13.3 (discovery p = 6.10 × 10(-5), 1.65 × 10(-4) and 1.10 × 10(-4); replication p = 2.21 × 10(-3), 1.84 × 10(-3) and 6.95 × 10(-3); combined p = 2.26 × 10(-6), 4.86 × 10(-6) and 1.15 × 10(-5), respectively). These results, together with the known functional relevance of the three genes to LMI, suggested that the 19p13.3 region containing UQCR, TCF3 and MBD3 genes was a novel locus underlying lean mass variation.
28322352	0	4	Gene	T028	C0017337
28322352	12	41	genome-wide association study	T063	C2350277
28322352	42	52	identified	T080	C0205396
28322352	53	60	19p13.3	T026	C1520850
28322352	65	79	lean body mass	T201	C0424678
28322352	80	94	Lean body mass	T201	C0424678
28322352	96	99	LBM	T201	C0424678
28322352	114	119	trait	T032	C0599883
28322352	124	129	human	T016	C0086418
28322352	130	136	health	T078	C0018684
28322352	150	162	genomic loci	T028	C0678933
28322352	174	177	LBM	T201	C0424678
28322352	194	198	gene	T028	C0017337
28322352	206	235	genome-wide association study	T063	C2350277
28322352	239	254	lean mass index	T081	C0392762
28322352	256	259	LMI	T081	C0392762
28322352	269	278	unrelated	T033	C0445356
28322352	279	288	Caucasian	T098	C0043157
28322352	289	297	subjects	T098	C0080105
28322352	303	313	replicated	T169	C0205173
28322352	322	331	unrelated	T033	C0445356
28322352	332	342	Caucasians	T098	C0043157
28322352	343	351	subjects	T098	C0080105
28322352	353	357	Gene	T028	C0017337
28322352	365	385	association analyses	T063	C2350277
28322352	414	426	associations	T080	C0439849
28322352	436	441	genes	T028	C0017337
28322352	442	446	UQCR	T028	C1540163
28322352	448	452	TCF3	T028	C1336596
28322352	457	461	MBD3	T028	C1417051
28322352	469	475	single	T081	C0205171
28322352	476	481	locus	T028	C0678933
28322352	482	489	19p13.3	T026	C1520850
28322352	491	500	discovery	T080	C0205556
28322352	553	564	replication	T080	C1883725
28322352	732	742	functional	T169	C0205245
28322352	743	752	relevance	T080	C2347946
28322352	766	771	genes	T028	C0017337
28322352	775	778	LMI	T081	C0392762
28322352	799	806	19p13.3	T026	C1520850
28322352	807	813	region	T082	C0205147
28322352	825	829	UQCR	T028	C1540163
28322352	831	835	TCF3	T028	C1336596
28322352	840	850	MBD3 genes	T028	C1417051
28322352	863	868	locus	T028	C0678933
28322352	880	889	lean mass	T201	C0424678
28322352	890	899	variation	T070	C0042333

27928742|t|Implementation of infrared and Raman modalities for glycosaminoglycan characterization in complex systems
27928742|a|Glycosaminoglycans (GAGs) are natural, linear and negatively charged heteropolysaccharides which are incident in every mammalian tissue. They consist of repeating disaccharide units, which are composed of either sulfated or non-sulfated monosaccharides. Depending on tissue types, GAGs exhibit structural heterogeneity such as the position and degree of sulfation or within their disaccharide units composition being heparin, heparan sulfate, chondroitine sulfate, dermatan sulfate, keratan sulfate, and hyaluronic acid. They are covalently linked to a core protein (proteoglycans) or as free chains (hyaluronan). GAGs affect cell properties and functions either by direct interaction with cell receptors or by sequestration of growth factors. These evidences of divert biological roles of GAGs make their characterization at cell and tissue levels of importance. Thus, non-invasive techniques are interesting to investigate, to qualitatively and quantitatively characterize GAGs in vitro in order to use them as diagnostic biomarkers and/or as therapeutic targets in several human diseases including cancer. Infrared and Raman microspectroscopies and imaging are sensitive enough to differentiate and classify GAG types and subtypes in spite of their close molecular structures. Spectroscopic markers characteristic of reference GAG molecules were identified. Beyond these investigations of the standard GAG spectral signature, infrared and Raman spectral signatures of GAG were searched in complex biological systems like cells. The aim of the present review is to describe the implementation of these complementary vibrational spectroscopy techniques, and to discuss their potentials, advantages and disadvantages for GAG analysis. In addition, this review presents new data as we show for the first time GAG infrared and Raman spectral signatures from conditioned media and live cells, respectively.
27928742	0	14	Implementation	T052	C1708476
27928742	18	26	infrared	T059	C0260249
27928742	31	36	Raman	T059	C0037815
27928742	37	47	modalities	T078	C0695347
27928742	52	69	glycosaminoglycan	T109,T121,T123	C0017973
27928742	70	86	characterization	T185	C0243175
27928742	90	97	complex	T080	C0439855
27928742	98	105	systems	T169	C0449913
27928742	106	124	Glycosaminoglycans	T109,T121,T123	C0017973
27928742	126	130	GAGs	T109,T121,T123	C0017973
27928742	136	143	natural	T169	C0205296
27928742	145	151	linear	T082	C0205132
27928742	156	174	negatively charged	T196	C0003075
27928742	175	196	heteropolysaccharides	T109,T121	C0032594
27928742	207	215	incident	T067	C1551358
27928742	225	234	mammalian	T015	C0024660
27928742	235	241	tissue	T024	C0040300
27928742	269	281	disaccharide	T109	C0012611
27928742	282	287	units	T081	C0439148
27928742	318	326	sulfated	T109	C1954876
27928742	330	358	non-sulfated monosaccharides	T109	C0026492
27928742	373	379	tissue	T024	C0040300
27928742	380	385	types	T080	C0332307
27928742	387	391	GAGs	T109,T121,T123	C0017973
27928742	400	410	structural	T082	C0678594
27928742	411	424	heterogeneity	T080	C0019409
27928742	437	445	position	T082	C0733755
27928742	450	456	degree	T081	C0449286
27928742	460	469	sulfation	T067	C0597538
27928742	486	498	disaccharide	T109	C0012611
27928742	499	504	units	T081	C0439148
27928742	505	516	composition	T080	C0205556
27928742	523	530	heparin	T109,T121,T123	C0019134
27928742	532	547	heparan sulfate	T109,T123	C0019143
27928742	549	569	chondroitine sulfate	T109,T121,T123	C0008466
27928742	571	587	dermatan sulfate	T109,T123	C0011602
27928742	589	604	keratan sulfate	T109,T123	C0022563
27928742	610	625	hyaluronic acid	T109,T121,T123	C0020196
27928742	636	653	covalently linked	T044	C1511539
27928742	659	663	core	T082	C0444669
27928742	664	671	protein	T116,T123	C0033684
27928742	673	686	proteoglycans	T116,T123	C0033692
27928742	694	698	free	T080	C1996904
27928742	699	705	chains	T078	C1524075
27928742	707	717	hyaluronan	T109,T121,T123	C0813622
27928742	720	724	GAGs	T109,T121,T123	C0017973
27928742	732	736	cell	T025	C0007634
27928742	737	747	properties	T080	C0871161
27928742	752	761	functions	T043	C0007613
27928742	772	778	direct	T080	C0439851
27928742	779	790	interaction	T169	C1704675
27928742	796	810	cell receptors	T116,T192	C0034800
27928742	817	830	sequestration	T169	C0443301
27928742	834	848	growth factors	T116,T123	C0018284
27928742	856	868	evidences of	T169	C0332120
27928742	869	875	divert	T080	C0743226
27928742	876	886	biological	T080	C0205460
27928742	887	892	roles	T077	C1705810
27928742	896	900	GAGs	T109,T121,T123	C0017973
27928742	912	928	characterization	T185	C0243175
27928742	932	936	cell	T025	C0007634
27928742	941	947	tissue	T024	C0040300
27928742	948	954	levels	T080	C0441889
27928742	976	988	non-invasive	T169	C0205303
27928742	989	999	techniques	T169	C0449851
27928742	1019	1030	investigate	T169	C1292732
27928742	1035	1048	qualitatively	T080	C0205556
27928742	1053	1067	quantitatively	T081	C0392762
27928742	1081	1085	GAGs	T109,T121,T123	C0017973
27928742	1086	1094	in vitro	T080	C1533691
27928742	1119	1129	diagnostic	T169	C0348026
27928742	1130	1140	biomarkers	T201	C0005516
27928742	1151	1162	therapeutic	T169	C0302350
27928742	1163	1170	targets	T074	C0085104
27928742	1182	1187	human	T016	C0086418
27928742	1188	1196	diseases	T047	C0012634
27928742	1207	1213	cancer	T191	C0006826
27928742	1215	1223	Infrared	T059	C0260249
27928742	1228	1253	Raman microspectroscopies	T059	C0037815
27928742	1258	1265	imaging	T060	C0079595
27928742	1270	1279	sensitive	T169	C0332324
27928742	1308	1316	classify	T185	C0008902
27928742	1317	1320	GAG	T109,T121,T123	C0017973
27928742	1321	1326	types	T080	C0332307
27928742	1331	1339	subtypes	T185	C0449560
27928742	1364	1384	molecular structures	T082	C0678594
27928742	1386	1399	Spectroscopic	T059	C0037812
27928742	1400	1407	markers	T080	C0206015
27928742	1436	1439	GAG	T109,T121,T123	C0017973
27928742	1440	1449	molecules	T167	C0567416
27928742	1455	1465	identified	T080	C0205396
27928742	1480	1494	investigations	T058	C1261322
27928742	1511	1514	GAG	T109,T121,T123	C0017973
27928742	1535	1543	infrared	T059	C0260249
27928742	1548	1553	Raman	T059	C0037815
27928742	1577	1580	GAG	T109,T121,T123	C0017973
27928742	1598	1605	complex	T080	C0439855
27928742	1606	1616	biological	T080	C0205460
27928742	1617	1624	systems	T169	C0449913
27928742	1630	1635	cells	T025	C0007634
27928742	1686	1700	implementation	T052	C1708476
27928742	1724	1759	vibrational spectroscopy techniques	T059	C0022885
27928742	1827	1830	GAG	T109,T121,T123	C0017973
27928742	1831	1839	analysis	T059	C0002778
27928742	1914	1917	GAG	T109,T121,T123	C0017973
27928742	1918	1926	infrared	T059	C0260249
27928742	1931	1936	Raman	T059	C0037815
27928742	1962	1979	conditioned media	T130	C0162518
27928742	1984	1994	live cells	T025	C0007634

27330705|t|Comparison of the Antibacterial Effect of 810 nm Diode Laser and Photodynamic Therapy in Reducing the Microbial Flora of Root Canal in Endodontic Retreatment in Patients With Periradicular Lesions
27330705|a|The aim of this study was to compare the antibacterial efficacy of diode laser 810nm and photodynamic therapy (PDT) in reducing bacterial microflora in endodontic retreatment of teeth with periradicular lesion. In this in vivo clinical trial, 20 patients who needed endodontic retreatment were selected. After conventional chemo mechanical preparation of root canals, microbiological samples were taken with sterile paper point (PP), held in thioglycollate broth, and then were transferred to the microbiological lab. In the first group, PDT with methylene blue (MB) and diode laser (810 nm, 0.2 W, 40 seconds) was performed and in the second group diode laser (810 nm, 1.2 W, 30 seconds) was irradiated. Then second samples were taken from all canals. CFU/ml amounts showed statistically significant reduction in both groups (P < 0.001). CFU/ml amounts were compared between the two groups and there was no statistical difference. PDT and diode laser 810 nm irradiation are effective methods for root canal disinfection. PDT is a suitable alternative for diode laser 810 nm irradiation, because of lower thermal risk on root dentin.
27330705	18	38	Antibacterial Effect	T043	C1516022
27330705	49	60	Diode Laser	T074	C0392254
27330705	65	85	Photodynamic Therapy	T074	C0750653
27330705	102	117	Microbial Flora	T007	C0004611
27330705	121	131	Root Canal	T030	C0086881
27330705	135	157	Endodontic Retreatment	T061	C3642515
27330705	161	169	Patients	T101	C0030705
27330705	175	196	Periradicular Lesions	T033	C0221198
27330705	213	218	study	T062	C2603343
27330705	238	260	antibacterial efficacy	T043	C1516022
27330705	264	275	diode laser	T074	C0392254
27330705	286	306	photodynamic therapy	T074	C0750653
27330705	308	311	PDT	T074	C0750653
27330705	325	345	bacterial microflora	T007	C0004611
27330705	349	371	endodontic retreatment	T061	C3642515
27330705	375	380	teeth	T023	C0040426
27330705	386	406	periradicular lesion	T033	C0221198
27330705	416	423	in vivo	T082	C1515655
27330705	424	438	clinical trial	T062	C0008976
27330705	443	451	patients	T101	C0030705
27330705	463	485	endodontic retreatment	T061	C3642515
27330705	520	548	chemo mechanical preparation	T061	C0087111
27330705	552	563	root canals	T030	C0086881
27330705	565	588	microbiological samples	T077	C2347026
27330705	605	624	sterile paper point	T122	C0490788
27330705	626	628	PP	T122	C0490788
27330705	639	659	thioglycollate broth	T109	C0039899
27330705	694	713	microbiological lab	T073,T093	C0022877
27330705	728	733	group	T078	C0441833
27330705	735	738	PDT	T074	C0750653
27330705	744	758	methylene blue	T109,T121,T130	C0025746
27330705	760	762	MB	T109,T121,T130	C0025746
27330705	768	779	diode laser	T074	C0392254
27330705	840	845	group	T078	C0441833
27330705	846	857	diode laser	T074	C0392254
27330705	890	900	irradiated	T070	C1282930
27330705	914	921	samples	T077	C2347026
27330705	942	948	canals	T030	C0086881
27330705	950	956	CFU/ml	T081	C0439361
27330705	1016	1022	groups	T078	C0441833
27330705	1036	1042	CFU/ml	T081	C0439361
27330705	1081	1087	groups	T078	C0441833
27330705	1129	1132	PDT	T074	C0750653
27330705	1137	1148	diode laser	T074	C0392254
27330705	1156	1167	irradiation	T070	C1282930
27330705	1194	1204	root canal	T030	C0086881
27330705	1205	1217	disinfection	T061	C0012683
27330705	1219	1222	PDT	T074	C0750653
27330705	1253	1264	diode laser	T074	C0392254
27330705	1272	1283	irradiation	T070	C1282930
27330705	1302	1314	thermal risk	T033	C4060533
27330705	1318	1329	root dentin	T031	C0011429

27871881|t|Targeting brain and peripheral plasticity of the lipidome in acute kainic acid - induced epileptic seizures in mice via quantitative mass spectrometry
27871881|a|Epilepsy is a highly common chronic neurological disorder, manifested in many different types, affecting ~1% of the worldwide human population. The molecular mechanisms of epileptogenesis have not yet been clarified, and pharmacoresistance exhibited by 30-40% of epilepsy patients remains a major obstacle in medical care. Growing evidence indicates a role of lipid signalling pathways in epileptogenesis, thus lipid signals emerge as potential biomarkers for the onset and evolving course of the epileptic disorder, as well as potential therapeutic agents and targets. For this purpose, we applied a lipidomic strategy to unravel lipid alterations in brain regions, periphery tissues and plasma that are specific for acute epileptic seizures in mice at 1h after seizure induction by systemic kainic acid injection as compared to vehicle controls. Specifically, levels of (i) selected phospholipids and sphingomyelins, (ii) the endocannabinoids anandamide (AEA) and 2-arachidonoyl glycerol (2-AG), and the endocannabinoid -related compounds oleoylethanolamide (OEA) and palmitoylethanolamide (PEA), (iii) arachidonic acid (AA), (iv) selected eicosanoids, and (v) fatty acyl content of lipidome were determined in pulverized tissues from six brain regions of kainic acid induced epileptic seizure models and vehicle controls: hypothalamus, hippocampus, thalamus, striatum, cerebellum and cerebral cortex, and from peripheral organs, such as heart and lungs, and in plasma. Alterations in lipid levels after acute epileptic seizures as compared to non-seizure controls were found to be brain region - and periphery tissue - specific, including specific plasma lipid correlates, highlighting their value as marker candidates in translational research studies, and/or drug discovery and response monitoring.
27871881	0	9	Targeting	T169	C1521840
27871881	10	15	brain	T023	C0006104
27871881	20	41	peripheral plasticity	T042	C0027880
27871881	49	57	lipidome	T109	C0023779
27871881	61	66	acute	T079	C0205178
27871881	67	78	kainic acid	T109,T121	C0022471
27871881	81	88	induced	T169	C0205263
27871881	89	107	epileptic seizures	T047	C0014544
27871881	111	115	mice	T015	C0025929
27871881	120	150	quantitative mass spectrometry	T059	C3525763
27871881	151	159	Epilepsy	T047	C0014544
27871881	179	208	chronic neurological disorder	T047	C1290882
27871881	210	220	manifested	T169	C0205319
27871881	239	244	types	T080	C0332307
27871881	277	282	human	T016	C0086418
27871881	283	293	population	T098	C1257890
27871881	299	319	molecular mechanisms	T044	C1148560
27871881	323	338	epileptogenesis	T047	C0014544
27871881	372	390	pharmacoresistance	T047	C2712961
27871881	414	422	epilepsy	T047	C0014544
27871881	423	431	patients	T101	C0030705
27871881	460	467	medical	T169	C0205476
27871881	468	472	care	T058	C0086388
27871881	482	490	evidence	T078	C3887511
27871881	511	516	lipid	T109	C0023779
27871881	517	536	signalling pathways	T044	C0037080
27871881	540	555	epileptogenesis	T047	C0014544
27871881	562	567	lipid	T109	C0023779
27871881	568	575	signals	T044	C0037080
27871881	586	595	potential	T080	C3245505
27871881	596	606	biomarkers	T201	C0005516
27871881	648	666	epileptic disorder	T047	C0014544
27871881	679	688	potential	T080	C3245505
27871881	689	707	therapeutic agents	T121	C1611640
27871881	712	719	targets	T169	C1521840
27871881	752	761	lipidomic	T109	C0023779
27871881	762	770	strategy	T062	C0035171
27871881	782	787	lipid	T109	C0023779
27871881	803	816	brain regions	T029	C1273723
27871881	818	835	periphery tissues	T024	C0040300
27871881	840	846	plasma	T031	C0032105
27871881	856	864	specific	T080	C0205369
27871881	869	874	acute	T079	C0205178
27871881	875	893	epileptic seizures	T047	C0014544
27871881	897	901	mice	T015	C0025929
27871881	914	921	seizure	T047	C0014544
27871881	922	931	induction	T169	C0205263
27871881	935	943	systemic	T062	C3494163
27871881	944	955	kainic acid	T109,T121	C0022471
27871881	956	965	injection	T062	C3494163
27871881	969	977	compared	T052	C1707455
27871881	981	997	vehicle controls	T096	C0009932
27871881	1013	1019	levels	T080	C0441889
27871881	1036	1049	phospholipids	T109,T123	C0031676
27871881	1054	1068	sphingomyelins	T109,T123	C0037906
27871881	1079	1095	endocannabinoids	T109,T123	C1172779
27871881	1096	1106	anandamide	T109,T123	C0211726
27871881	1108	1111	AEA	T109,T123	C0211726
27871881	1117	1140	2-arachidonoyl glycerol	T109,T121	C0299477
27871881	1142	1146	2-AG	T109,T121	C0299477
27871881	1157	1172	endocannabinoid	T109,T123	C1172779
27871881	1182	1191	compounds	T103	C1706082
27871881	1192	1210	oleoylethanolamide	T109	C1454896
27871881	1212	1215	OEA	T109	C1454896
27871881	1221	1242	palmitoylethanolamide	T109,T121	C0069964
27871881	1244	1247	PEA	T109,T121	C0069964
27871881	1256	1272	arachidonic acid	T109	C0003695
27871881	1274	1276	AA	T109	C0003695
27871881	1293	1304	eicosanoids	T109	C0013725
27871881	1314	1324	fatty acyl	T123	C0574031
27871881	1336	1344	lipidome	T109	C0023779
27871881	1364	1374	pulverized	T062	C3494163
27871881	1375	1382	tissues	T023	C0459385
27871881	1392	1405	brain regions	T029	C1273723
27871881	1409	1420	kainic acid	T109,T121	C0022471
27871881	1421	1428	induced	T169	C0205263
27871881	1429	1446	epileptic seizure	T047	C0014544
27871881	1447	1453	models	T075	C0026336
27871881	1458	1474	vehicle controls	T096	C0009932
27871881	1476	1488	hypothalamus	T023	C0020663
27871881	1490	1501	hippocampus	T023	C0019564
27871881	1503	1511	thalamus	T023	C0039729
27871881	1513	1521	striatum	T023	C0010097
27871881	1523	1533	cerebellum	T023	C0007765
27871881	1538	1553	cerebral cortex	T023	C0007776
27871881	1564	1574	peripheral	T082	C0205100
27871881	1575	1581	organs	T023	C0178784
27871881	1591	1596	heart	T023	C0018787
27871881	1601	1606	lungs	T023	C0024109
27871881	1615	1621	plasma	T031	C0032105
27871881	1638	1643	lipid	T109	C0023779
27871881	1657	1662	acute	T079	C0205178
27871881	1663	1681	epileptic seizures	T047	C0014544
27871881	1685	1693	compared	T052	C1707455
27871881	1697	1717	non-seizure controls	T096	C0009932
27871881	1735	1747	brain region	T029	C1273723
27871881	1754	1770	periphery tissue	T024	C0040300
27871881	1773	1781	specific	T080	C0205369
27871881	1793	1801	specific	T080	C0205369
27871881	1802	1808	plasma	T031	C0032105
27871881	1809	1814	lipid	T109	C0023779
27871881	1855	1872	marker candidates	T201	C0005516
27871881	1890	1906	research studies	T062	C0681814
27871881	1915	1929	drug discovery	T062	C0920472
27871881	1934	1953	response monitoring	T058	C0085421

27477569|t|Intravascular Inflammation Triggers Intracerebral Activated Microglia and Contributes to Secondary Brain Injury After Experimental Subarachnoid Hemorrhage (eSAH)
27477569|a|Activation of innate immunity contributes to secondary brain injury after experimental subarachnoid hemorrhage (eSAH). Microglia accumulation and activation within the brain has recently been shown to induce neuronal cell death after eSAH. In isolated mouse brain capillaries after eSAH, we show a significantly increased gene expression for intercellular adhesion molecule-1 (ICAM-1) and P-selectin. Hence, we hypothesized that extracerebral intravascular inflammatory processes might initiate the previously reported microglia accumulation within the brain tissue. We therefore induced eSAH in knockout mice for ICAM-1 (ICAM-1(-/-)) and P-selectin glycoprotein ligand-1 (PSGL-1(-/-)) to find a significant decrease in neutrophil - endothelial interaction within the first 7 days after the bleeding in a chronic cranial window model. This inhibition of neutrophil recruitment to the endothelium results in significantly ameliorated microglia accumulation and neuronal cell death in knockout animals in comparison to controls. Our results suggest an outside-in activation of the CNS innate immune system at the vessel / brain interface following eSAH. Microglia cells, as part of the brain's innate immune system, are triggered by an inflammatory reaction in the microvasculature after eSAH, thus contributing to neuronal cell death. This finding offers a whole range of new research targets, as well as possible therapy options for patients suffering from eSAH.
27477569	0	13	Intravascular	T082	C0442123
27477569	14	26	Inflammation	T046	C0021368
27477569	27	35	Triggers	T080	C1444748
27477569	36	49	Intracerebral	T082	C0442111
27477569	50	59	Activated	T052	C1879547
27477569	60	69	Microglia	T025	C0206116
27477569	89	111	Secondary Brain Injury	T037	C0270611
27477569	118	130	Experimental	T080	C1517586
27477569	131	154	Subarachnoid Hemorrhage	T047	C0038525
27477569	156	160	eSAH	T047	C0038525
27477569	162	172	Activation	T052	C1879547
27477569	176	191	innate immunity	T032	C0020969
27477569	207	229	secondary brain injury	T037	C0270611
27477569	236	248	experimental	T080	C1517586
27477569	249	272	subarachnoid hemorrhage	T047	C0038525
27477569	274	278	eSAH	T047	C0038525
27477569	281	290	Microglia	T025	C0206116
27477569	291	303	accumulation	T033	C4055506
27477569	308	318	activation	T052	C1879547
27477569	330	335	brain	T023	C0006104
27477569	370	389	neuronal cell death	T043	C2754100
27477569	396	400	eSAH	T047	C0038525
27477569	405	413	isolated	T169	C0205409
27477569	414	419	mouse	T015	C0025929
27477569	420	425	brain	T023	C0006104
27477569	426	437	capillaries	T023	C0935624
27477569	444	448	eSAH	T047	C0038525
27477569	484	499	gene expression	T045	C0017262
27477569	504	537	intercellular adhesion molecule-1	T028	C1334074
27477569	539	545	ICAM-1	T028	C1334074
27477569	551	561	P-selectin	T028	C1335809
27477569	573	585	hypothesized	T078	C1512571
27477569	591	604	extracerebral	T082	C1254362
27477569	605	618	intravascular	T082	C0442123
27477569	619	641	inflammatory processes	T046	C1155266
27477569	672	680	reported	T058	C0700287
27477569	681	690	microglia	T025	C0206116
27477569	691	703	accumulation	T033	C4055506
27477569	715	727	brain tissue	T023	C0459385
27477569	750	754	eSAH	T047	C0038525
27477569	758	771	knockout mice	T015	C0206745
27477569	776	782	ICAM-1	T028	C1334074
27477569	784	795	ICAM-1(-/-)	T028	C1334074
27477569	801	833	P-selectin glycoprotein ligand-1	T028	C1419941
27477569	835	846	PSGL-1(-/-)	T028	C1419941
27477569	882	892	neutrophil	T025	C0027950
27477569	895	906	endothelial	T025	C0225336
27477569	907	918	interaction	T043	C0007582
27477569	953	961	bleeding	T046	C0019080
27477569	967	974	chronic	T079	C0205191
27477569	975	982	cranial	T082	C3163632
27477569	983	995	window model	T075	C0026339
27477569	1002	1012	inhibition	T052	C3463820
27477569	1016	1038	neutrophil recruitment	T039	C0751982
27477569	1046	1057	endothelium	T025	C0225336
27477569	1083	1094	ameliorated	T033	C0243095
27477569	1095	1104	microglia	T025	C0206116
27477569	1105	1117	accumulation	T033	C4055506
27477569	1122	1141	neuronal cell death	T043	C2754100
27477569	1145	1161	knockout animals	T008	C1171353
27477569	1223	1233	activation	T052	C1879547
27477569	1241	1251	CNS innate	T022	C3714787
27477569	1252	1265	immune system	T022	C0020962
27477569	1273	1279	vessel	T029	C0042591
27477569	1282	1287	brain	T023	C0006104
27477569	1308	1312	eSAH	T047	C0038525
27477569	1314	1323	Microglia	T025	C0206116
27477569	1324	1329	cells	T025	C0007634
27477569	1346	1353	brain's	T023	C0006104
27477569	1354	1374	innate immune system	T032	C0020969
27477569	1380	1389	triggered	T080	C1444748
27477569	1396	1417	inflammatory reaction	T046	C0021368
27477569	1425	1441	microvasculature	T042	C0243079
27477569	1448	1452	eSAH	T047	C0038525
27477569	1475	1494	neuronal cell death	T043	C2754100
27477569	1537	1545	research	T062	C0035168
27477569	1546	1553	targets	T169	C1521840
27477569	1575	1582	therapy	T169	C0039798
27477569	1595	1603	patients	T101	C0030705
27477569	1619	1623	eSAH	T047	C0038525

28101973|t|Heparin cross-linked collagen sponge scaffolds improve functional regeneration of rat tracheal epithelium
28101973|a|Tracheal epithelial cells maintain airway homeostasis by mediating mucociliary clearance. Following tracheal reconstruction, timely epithelial regeneration is required to prevent respiratory compromise and infectious diseases. To achieve rapid tracheal epithelial regeneration, a heparin cross-linked collagen sponge containing fibroblast growth factor-2 (FGF-2) was prepared as a graft for tracheal reconstruction. The heparin cross-linked sponge exhibited a high FGF-2 retaining capacity, and tracheal epithelial and mesenchymal cells cultured in this sponge containing FGF-2 showed high proliferative capacities. Subsequently, heparin -free collagen sponge scaffolds (C/F scaffold) and collagen sponge scaffolds cross-linked with 10 μg/ml heparin retained FGF-2 (C/H10/F scaffold), and were transplanted into rats with tracheal defects. Invasion of both epithelial and non-epithelial cells was greater in rats treated with the C/H10/F scaffold at 1 week post- transplantation than in rats treated with the C/F scaffold. Moreover, at 2 weeks after transplantation, improved cilia formation was observed in the C/H10/F scaffold group, with higher motility and more potent posterior-anterior flow generation than in the C/F scaffold group. These results suggest that heparin improves functional regeneration of tracheal epithelium. Copyright © 2017 John Wiley & Sons, Ltd.
28101973	0	7	Heparin	T109,T121,T123	C0019134
28101973	8	20	cross-linked	T070	C0178576
28101973	21	29	collagen	T116	C0009325
28101973	30	46	sponge scaffolds	T122	C0597587
28101973	55	78	functional regeneration	T042	C0034963
28101973	82	85	rat	T015	C0034693
28101973	86	105	tracheal epithelium	T024	C1179002
28101973	106	114	Tracheal	T023	C0040578
28101973	115	131	epithelial cells	T025	C0014597
28101973	141	147	airway	T023	C0458827
28101973	148	159	homeostasis	T038	C0019868
28101973	173	194	mucociliary clearance	T201	C0026687
28101973	206	229	tracheal reconstruction	T061	C0189421
28101973	238	248	epithelial	T024	C0014609
28101973	249	261	regeneration	T042	C0034963
28101973	277	284	prevent	T061	C0199176
28101973	285	307	respiratory compromise	T046	C0035229
28101973	312	331	infectious diseases	T047	C0009450
28101973	344	349	rapid	T080	C0456962
28101973	350	358	tracheal	T023	C0040578
28101973	359	369	epithelial	T024	C0014609
28101973	370	382	regeneration	T042	C0034963
28101973	386	393	heparin	T109,T121,T123	C0019134
28101973	394	406	cross-linked	T070	C0178576
28101973	407	415	collagen	T116	C0009325
28101973	416	422	sponge	T122	C0597587
28101973	434	460	fibroblast growth factor-2	T116,T123	C0380603
28101973	462	467	FGF-2	T116,T123	C0380603
28101973	487	492	graft	T024	C0332835
28101973	497	520	tracheal reconstruction	T061	C0189421
28101973	526	533	heparin	T109,T121,T123	C0019134
28101973	534	546	cross-linked	T070	C0178576
28101973	547	553	sponge	T122	C0597587
28101973	566	570	high	T080	C0205250
28101973	571	576	FGF-2	T116,T123	C0380603
28101973	577	586	retaining	T169	C0333118
28101973	587	595	capacity	T081	C1516240
28101973	601	609	tracheal	T023	C0040578
28101973	610	620	epithelial	T025	C0014597
28101973	625	642	mesenchymal cells	T025	C1257975
28101973	643	651	cultured	T169	C0220814
28101973	660	666	sponge	T122	C0597587
28101973	678	683	FGF-2	T116,T123	C0380603
28101973	691	695	high	T080	C0205250
28101973	696	709	proliferative	T046	C0334094
28101973	710	720	capacities	T081	C1516240
28101973	736	743	heparin	T109,T121,T123	C0019134
28101973	750	758	collagen	T116	C0009325
28101973	759	775	sponge scaffolds	T122	C0597587
28101973	777	789	C/F scaffold	T122	C0597587
28101973	795	803	collagen	T116	C0009325
28101973	804	820	sponge scaffolds	T122	C0597587
28101973	821	833	cross-linked	T070	C0178576
28101973	848	855	heparin	T109,T121,T123	C0019134
28101973	865	870	FGF-2	T116,T123	C0380603
28101973	872	888	C/H10/F scaffold	T122	C0597587
28101973	900	912	transplanted	T169	C0700106
28101973	918	922	rats	T015	C0034693
28101973	928	944	tracheal defects	T033	C4062796
28101973	946	954	Invasion	T046	C2699153
28101973	963	973	epithelial	T025	C0014597
28101973	978	998	non-epithelial cells	T025	C0007634
28101973	1014	1018	rats	T015	C0034693
28101973	1019	1031	treated with	T061	C0332293
28101973	1036	1052	C/H10/F scaffold	T122	C0597587
28101973	1069	1084	transplantation	T061	C0040732
28101973	1093	1097	rats	T015	C0034693
28101973	1098	1110	treated with	T061	C0332293
28101973	1115	1127	C/F scaffold	T122	C0597587
28101973	1156	1171	transplantation	T061	C0040732
28101973	1182	1187	cilia	T026	C0008778
28101973	1188	1197	formation	T169	C1522492
28101973	1218	1234	C/H10/F scaffold	T122	C0597587
28101973	1247	1253	higher	T080	C0205250
28101973	1254	1262	motility	T040	C1510470
28101973	1279	1297	posterior-anterior	T082	C1999039
28101973	1298	1302	flow	T070	C0806140
28101973	1303	1313	generation	T052	C3146294
28101973	1326	1338	C/F scaffold	T122	C0597587
28101973	1373	1380	heparin	T109,T121,T123	C0019134
28101973	1390	1413	functional regeneration	T042	C0034963
28101973	1417	1436	tracheal epithelium	T024	C1179002

27920636|t|Identifying CNVs in 15q11q13 and 16p11.2 of Patients with Seizures Increases the Rates of Detecting Pathogenic Changes
27920636|a|Chromosomal changes are frequently observed in patients with syndromic seizures. Understanding the genetic etiology of this pathology is crucial for the guidance and genetic counseling of families as well as for the establishment of appropriate treatment. A combination of MLPA kits was used to identify pathogenic CNVs in a group of 70 syndromic patients with seizures. Initially, a screening was performed for subtelomeric changes (MLPA P036 and P070 kits) and for the regions most frequently related to microdeletion / microduplication syndromes (MLPA P064). Subsequently, the MLPA P343 was used to identify alterations in the 15q11q13, 16p11.2, and 22q13 regions. Screening with MLPA P343 allowed a 10-15.7% increase in the detection rate of CNVs reinforcing the importance of investigating changes in 15q11q13 and 16p11.2 in syndromic patients with seizures. We also demonstrated that the MLPA technique is an alternative with a great diagnostic potential, and we proposed its use as part of the initial assessment of syndromic patients with seizures.
27920636	12	16	CNVs	T039	C0009850
27920636	20	28	15q11q13	T026	C1953345
27920636	33	40	16p11.2	T026	C1520678
27920636	44	52	Patients	T101	C0030705
27920636	58	66	Seizures	T184	C0036572
27920636	67	76	Increases	T169	C0442805
27920636	81	86	Rates	T081	C1521828
27920636	90	99	Detecting	T061	C1511790
27920636	100	110	Pathogenic	T169	C0543483
27920636	111	118	Changes	T169	C0392747
27920636	119	138	Chromosomal changes	UnknownType	C0544871
27920636	166	174	patients	T101	C0030705
27920636	180	198	syndromic seizures	T184	C0036572
27920636	218	234	genetic etiology	T169	C1314792
27920636	243	252	pathology	T046	C0677042
27920636	272	280	guidance	T201	C3854153
27920636	285	303	genetic counseling	T061	C0017382
27920636	307	315	families	T099	C0015576
27920636	335	348	establishment	T061	C0511063
27920636	352	373	appropriate treatment	T201	C3640049
27920636	377	388	combination	T080	C0205195
27920636	392	401	MLPA kits	T063	C3494189
27920636	423	433	pathogenic	T169	C0543483
27920636	434	438	CNVs	T039	C0009850
27920636	444	449	group	UnknownType	C0681860
27920636	456	474	syndromic patients	T101	C0030705
27920636	480	488	seizures	T184	C0036572
27920636	503	512	screening	T058	C0220908
27920636	531	543	subtelomeric	T026	C1953345
27920636	544	551	changes	T169	C0392747
27920636	553	562	MLPA P036	T063	C3494189
27920636	567	576	P070 kits	T063	C3494189
27920636	590	597	regions	T026	C1953345
27920636	625	638	microdeletion	T047	C1954751
27920636	641	667	microduplication syndromes	T047	C0039082
27920636	669	678	MLPA P064	T063	C3494189
27920636	699	708	MLPA P343	T063	C3494189
27920636	730	741	alterations	UnknownType	C0544871
27920636	749	757	15q11q13	T026	C1953345
27920636	759	766	16p11.2	T026	C1520678
27920636	772	785	22q13 regions	T026	C1521113
27920636	787	796	Screening	T058	C0220908
27920636	802	811	MLPA P343	T063	C3494189
27920636	831	839	increase	T169	C0442805
27920636	847	856	detection	T061	C1511790
27920636	857	861	rate	T081	C1521828
27920636	865	869	CNVs	T039	C0009850
27920636	900	913	investigating	T169	C1292732
27920636	914	921	changes	UnknownType	C0544871
27920636	925	933	15q11q13	T026	C1953345
27920636	938	945	16p11.2	T026	C1520678
27920636	949	967	syndromic patients	T101	C0030705
27920636	973	981	seizures	T184	C0036572
27920636	1013	1027	MLPA technique	T063	C3494189
27920636	1034	1045	alternative	T077	C1523987
27920636	1059	1069	diagnostic	T169	C0348026
27920636	1070	1079	potential	T080	C3245505
27920636	1120	1138	initial assessment	T033	C0150637
27920636	1142	1160	syndromic patients	T101	C0030705
27920636	1166	1174	seizures	T184	C0036572

28203067|t|Silent strain of caregiving: exploring the best predictors of distress in family carers of geriatric patients
28203067|a|The aim of this article was to identify the best predictors of distress suffered by family carers (FCs) of geriatric patients. A cross-sectional study of 100 FC - geriatric patient dyads was conducted. The negative impact of care (NIoC) subscale of the COPE index was dichotomized to identify lower stress (score of ≤15 on the scale) and higher stress (score of ≥16 on the scale) exerted on FCs by the process of providing care. The set of explanatory variables comprised a wide range of sociodemographic and care-related attributes, including patient-related results from comprehensive geriatric assessments and disease profiles. The best combination of explanatory variables that provided the highest predictive powe r for distress among FCs in the multiple logistic regression (LR) model was determined according to statistical information criteria. The statistical robustness of the observed relationships and the discriminative power of the model were verified with the cross-validation method. The mean age of FCs was 57.2 (±10.6) years, whereas that of geriatric patients was 81.7 (±6.4) years. Despite the broad initial set of potential explanatory variables, only five predictors were jointly selected for the best statistical model. A higher level of distress was independently predicted by lower self-evaluation of health; worse self-appraisal of coping well as a caregiver; lower sense of general support; more hours of care per week; and the motor retardation of the cared -for person measured with the speed of the Timed Up and Go (TUG) test. Worse performance on the TUG test was only the patient -related predictor of distress among the variables examined as contributors to the higher NIoC. Enhancing the mobility of geriatric patients through suitably tailored kinesitherapeutic methods during their hospital stay may mitigate the burden endured by FCs.
28203067	0	27	Silent strain of caregiving	T054	C1328742
28203067	43	58	best predictors	T033	C0035648
28203067	62	70	distress	T033	C0231303
28203067	74	87	family carers	T099	C0086279
28203067	91	109	geriatric patients	T101	C0870602
28203067	154	169	best predictors	T033	C0035648
28203067	173	190	distress suffered	T033	C0231303
28203067	194	207	family carers	T099	C0086279
28203067	209	212	FCs	T099	C0086279
28203067	217	235	geriatric patients	T101	C0870602
28203067	239	260	cross-sectional study	T062	C0010362
28203067	268	270	FC	T099	C0086279
28203067	273	290	geriatric patient	T101	C0870602
28203067	291	296	dyads	T098	C0870454
28203067	316	339	negative impact of care	T033	C0243095
28203067	341	345	NIoC	T033	C0243095
28203067	347	355	subscale	T081	C0459443
28203067	363	373	COPE index	T081	C0392762
28203067	403	415	lower stress	T033	C4075362
28203067	448	461	higher stress	T033	C4075362
28203067	501	504	FCs	T099	C0086279
28203067	512	537	process of providing care	T058	C2735110
28203067	550	561	explanatory	T170	C0681841
28203067	562	571	variables	T033	C2673413
28203067	598	614	sociodemographic	T078	C0011292
28203067	619	642	care-related attributes	T058	C0086388
28203067	654	677	patient-related results	T033	C0243095
28203067	697	718	geriatric assessments	T058	C0017463
28203067	723	730	disease	T047	C0012634
28203067	731	739	profiles	T058	C0747306
28203067	765	776	explanatory	T170	C0681841
28203067	777	786	variables	T033	C2673413
28203067	805	828	highest predictive powe	T080	C0681890
28203067	835	843	distress	T033	C0231303
28203067	850	853	FCs	T099	C0086279
28203067	861	900	multiple logistic regression (LR) model	UnknownType	C0681925
28203067	891	893	LR	UnknownType	C0681925
28203067	929	961	statistical information criteria	T081	C0237881
28203067	967	989	statistical robustness	T081	C0237881
28203067	1028	1048	discriminative power	T169	C2945687
28203067	1056	1061	model	T075	C0026336
28203067	1085	1108	cross-validation method	T062	C0681935
28203067	1119	1122	age	T032	C0001779
28203067	1126	1129	FCs	T099	C0086279
28203067	1170	1188	geriatric patients	T101	C0870602
28203067	1255	1266	explanatory	T170	C0681841
28203067	1267	1276	variables	T033	C2673413
28203067	1288	1298	predictors	T033	C0035648
28203067	1334	1351	statistical model	T081,T170	C0026348
28203067	1371	1379	distress	T033	C0231303
28203067	1411	1442	lower self-evaluation of health	T058	C0175637
28203067	1450	1464	self-appraisal	T041	C2936632
28203067	1468	1474	coping	T055	C0009967
28203067	1485	1494	caregiver	T099	C0086279
28203067	1496	1501	lower	T080	C0205251
28203067	1511	1526	general support	T058	C1276367
28203067	1542	1546	care	T052	C1947933
28203067	1565	1582	motor retardation	T033	C0424230
28203067	1590	1595	cared	T052	C1947933
28203067	1639	1665	Timed Up and Go (TUG) test	T060	C3161512
28203067	1692	1700	TUG test	T060	C3161512
28203067	1714	1721	patient	T101	C0030705
28203067	1731	1740	predictor	T033	C0035648
28203067	1744	1752	distress	T033	C0231303
28203067	1763	1772	variables	T033	C2673413
28203067	1812	1816	NIoC	T033	C0243095
28203067	1832	1862	mobility of geriatric patients	T061	C2094221
28203067	1889	1914	kinesitherapeutic methods	T061	C0087111
28203067	1928	1941	hospital stay	T079	C3489408
28203067	1977	1980	FCs	T099	C0086279

28299515|t|The influence of slope on Spartium junceum root system: morphological, anatomical and biomechanical adaptation
28299515|a|Root systems have a pivotal role in plant anchorage and their mechanical interactions with the soil may contribute to soil reinforcement and stabilization of slide-prone slopes. In order to understand the responses of root system to mechanical stress induced by slope, samples of Spartium junceum L., growing in slope and in plane natural conditions, were compared in their morphology, biomechanical properties and anatomical features. Soils sampled in slope and plane revealed similar characteristics, with the exception of organic matter content and penetrometer resistance, both higher in slope. Slope significantly influenced root morphology and in particular the distribution of lateral roots along the soil depth. Indeed, first-order lateral roots of plants growing on slope condition showed an asymmetric distribution between up- and down-slope. Contrarily, this asymmetric distribution was not observed in plants growing in plane. The tensile strength was higher in lateral roots growing up-slope and in plane conditions than in those growing down-slope. Anatomical investigations revealed that, while roots grown up-slope had higher area covered by xylem fibers, the ratio of xylem and phloem fibers to root diameter did not differ among the three conditions, as also, no differences were found for xylem fiber cell wall thickness. Roots growing up-slope were the main contributors to anchorage properties, which included higher strength and higher number of fibers in the xylematic tissues. Results suggested that a combination of root - specific morphological, anatomical and biomechanical traits, determines anchorage functions in slope conditions.
28299515	4	13	influence	T077	C4054723
28299515	17	22	slope	T082	C1254362
28299515	26	42	Spartium junceum	T002	C1014924
28299515	43	54	root system	T002	C0242726
28299515	56	69	morphological	T080	C0332437
28299515	71	81	anatomical	T080	C0220784
28299515	86	99	biomechanical	T080	C0205556
28299515	100	110	adaptation	T038	C0392673
28299515	111	123	Root systems	T002	C0242726
28299515	139	143	role	T077	C1705810
28299515	147	152	plant	T002	C0032098
28299515	153	162	anchorage	T052	C2825961
28299515	173	196	mechanical interactions	T169	C1704675
28299515	206	210	soil	T167	C0037592
28299515	229	233	soil	T167	C0037592
28299515	234	247	reinforcement	T169	C0205245
28299515	252	265	stabilization	T080	C0205360
28299515	269	287	slide-prone slopes	T082	C1254362
28299515	316	325	responses	T032	C0871261
28299515	329	340	root system	T002	C0242726
28299515	344	361	mechanical stress	T070	C0038442
28299515	362	369	induced	T169	C0205263
28299515	373	378	slope	T082	C1254362
28299515	380	387	samples	T167	C0370003
28299515	391	410	Spartium junceum L.	T002	C1014924
28299515	412	419	growing	T169	C0205245
28299515	423	428	slope	T082	C1254362
28299515	436	441	plane	T082	C1254362
28299515	442	460	natural conditions	T169	C0205296
28299515	485	495	morphology	T080	C0332437
28299515	497	521	biomechanical properties	T080	C0871161
28299515	526	545	anatomical features	T082	C0502371
28299515	547	552	Soils	T167	C0037592
28299515	553	560	sampled	T078	C0870078
28299515	564	569	slope	T082	C1254362
28299515	574	579	plane	T082	C1254362
28299515	597	612	characteristics	T080	C1521970
28299515	623	632	exception	T077	C1705847
28299515	636	650	organic matter	T167	C0439861
28299515	651	658	content	T077	C0456205
28299515	663	686	penetrometer resistance	T169	C4281815
28299515	703	708	slope	T082	C1254362
28299515	710	715	Slope	T082	C1254362
28299515	730	740	influenced	T077	C4054723
28299515	741	745	root	T002	C0242726
28299515	746	756	morphology	T080	C0332437
28299515	779	791	distribution	T169	C1704711
28299515	795	802	lateral	T082	C0205093
28299515	803	808	roots	T002	C0242726
28299515	819	823	soil	T167	C0037592
28299515	824	829	depth	T082	C0205125
28299515	839	850	first-order	T169	C1373201
28299515	851	858	lateral	T082	C0205093
28299515	859	864	roots	T002	C0242726
28299515	868	874	plants	T002	C0032098
28299515	875	882	growing	T169	C0205245
28299515	886	891	slope	T082	C1254362
28299515	892	901	condition	T080	C0348080
28299515	912	922	asymmetric	T082	C0332514
28299515	923	935	distribution	T169	C1704711
28299515	944	947	up-	T082	C1254362
28299515	952	962	down-slope	T082	C1254362
28299515	981	991	asymmetric	T082	C0332514
28299515	992	1004	distribution	T169	C1704711
28299515	1025	1031	plants	T002	C0032098
28299515	1032	1039	growing	T169	C0205245
28299515	1043	1048	plane	T082	C1254362
28299515	1054	1070	tensile strength	T081	C0039526
28299515	1085	1092	lateral	T082	C0205093
28299515	1093	1098	roots	T002	C0242726
28299515	1099	1106	growing	T169	C0205245
28299515	1107	1115	up-slope	T082	C1254362
28299515	1123	1128	plane	T082	C1254362
28299515	1129	1139	conditions	T080	C0348080
28299515	1154	1161	growing	T169	C0205245
28299515	1162	1172	down-slope	T082	C1254362
28299515	1174	1199	Anatomical investigations	T062	C0242481
28299515	1221	1226	roots	T002	C0242726
28299515	1233	1241	up-slope	T082	C1254362
28299515	1253	1257	area	T082	C0205146
28299515	1269	1281	xylem fibers	T002	C1720877
28299515	1287	1292	ratio	T081	C0456603
28299515	1296	1301	xylem	T002	C1720877
28299515	1306	1319	phloem fibers	T002	C1720878
28299515	1323	1327	root	T002	C0242726
28299515	1328	1336	diameter	T081	C1301886
28299515	1368	1378	conditions	T080	C0348080
28299515	1389	1403	no differences	T033	C3842396
28299515	1419	1430	xylem fiber	T002	C1720877
28299515	1431	1440	cell wall	T026	C0007623
28299515	1441	1450	thickness	T080	C1280412
28299515	1452	1457	Roots	T002	C0242726
28299515	1458	1465	growing	T169	C0205245
28299515	1466	1474	up-slope	T082	C1254362
28299515	1505	1514	anchorage	T052	C2825961
28299515	1515	1525	properties	T080	C0871161
28299515	1549	1557	strength	T081	C0039526
28299515	1579	1585	fibers	T002	C1260603
28299515	1593	1602	xylematic	T002	C1720877
28299515	1603	1610	tissues	T025	C1514137
28299515	1652	1656	root	T002	C0242726
28299515	1659	1667	specific	T080	C0205369
28299515	1668	1681	morphological	T080	C0332437
28299515	1683	1693	anatomical	T080	C0220784
28299515	1698	1711	biomechanical	T080	C0205556
28299515	1712	1718	traits	T032	C0599883
28299515	1731	1740	anchorage	T052	C2825961
28299515	1741	1750	functions	T169	C0542341
28299515	1754	1759	slope	T082	C1254362
28299515	1760	1770	conditions	T080	C0348080

27681813|t|Clinical comparison of oral administration and viscosupplementation of hyaluronic acid (HA) in early knee osteoarthritis
27681813|a|Osteoarthritis (OA) is a progressive, chronic and degenerative joint disease characterized by a loss of articular cartilage. Treatment of OA is largely palliative based on nonsteroidal anti-inflammatory drugs, opioids and injections of steroids. Regarding conservative treatment, intra-articular injections of hyaluronic acid (HA) can play a role in early symptomatic knee OA. Between August 2015 and September 2015, sixty patients (32 males and 28 females) between 40 and 70 years old were randomly allocated into two groups: Half were treated with three weekly intra-articular injections of hyaluronic acid 1.6 % (group A), while the others were treated with Syalox 300 Plus(®) (hyaluronic acid 300 mg + Boswellia serrata extract 100 mg) 1 tab / die for 20 days and afterward Syalox 150(®) (hyaluronic acid 150 mg) 1 tab / die for other 20 days (group B). All patients were evaluated clinically with American Knee Society Score (AKSS) and visual analogue scale (VAS) for the pain before the treatment and after 3 months. AKSS of the patients in both groups was significantly increased by the treatment, and VAS score was significantly reduced. In both groups, two subgroups were created with patients older than 60 years and patients younger than 60 years. Better results are reported in younger patients of group A and older subjects in group B. Despite several limitations, the results of the study have shown that HA injection and oral administration may have beneficial therapeutic effects on patients with early osteoarthritis. Different outcomes in younger and older subject suggested a combined therapy first with local infiltrations and then with oral composition.
27681813	0	19	Clinical comparison	T058	C0949168
27681813	23	42	oral administration	T061	C0001563
27681813	47	67	viscosupplementation	T061	C2350507
27681813	71	86	hyaluronic acid	T109,T121,T123	C0020196
27681813	88	90	HA	T109,T121,T123	C0020196
27681813	101	120	knee osteoarthritis	T047	C0409959
27681813	121	135	Osteoarthritis	T047	C0029408
27681813	137	139	OA	T047	C0029408
27681813	146	157	progressive	T169	C0205329
27681813	159	166	chronic	T079	C0205191
27681813	171	197	degenerative joint disease	T047	C0029408
27681813	217	221	loss	T081	C1517945
27681813	225	244	articular cartilage	T024	C0007303
27681813	246	255	Treatment	T061	C0087111
27681813	259	261	OA	T047	C0029408
27681813	273	283	palliative	T080	C1285530
27681813	293	329	nonsteroidal anti-inflammatory drugs	T121	C0003211
27681813	331	338	opioids	T109,T121,T131	C0242402
27681813	343	365	injections of steroids	T061	C1261311
27681813	377	399	conservative treatment	T061	C0459914
27681813	401	427	intra-articular injections	T061	C0021488
27681813	431	446	hyaluronic acid	T109,T121,T123	C0020196
27681813	448	450	HA	T109,T121,T123	C0020196
27681813	489	496	knee OA	T047	C0409959
27681813	544	552	patients	T101	C0030705
27681813	557	562	males	T032	C0086582
27681813	570	577	females	T032	C0086287
27681813	597	602	years	T079	C0439234
27681813	603	606	old	T079	C0580836
27681813	640	646	groups	T078	C0441833
27681813	658	670	treated with	T061	C0332293
27681813	684	710	intra-articular injections	T061	C0021488
27681813	714	729	hyaluronic acid	T109,T121,T123	C0020196
27681813	737	744	group A	T185	C0441835
27681813	769	781	treated with	T061	C0332293
27681813	782	800	Syalox 300 Plus(®)	T091	C0025118
27681813	802	817	hyaluronic acid	T109,T121,T123	C0020196
27681813	827	852	Boswellia serrata extract	T121	C1712544
27681813	863	866	tab	T122	C0039225
27681813	869	872	die	T079	C0439228
27681813	880	884	days	T079	C0439228
27681813	899	912	Syalox 150(®)	T091	C0025118
27681813	914	929	hyaluronic acid	T109,T121,T123	C0020196
27681813	940	943	tab	T122	C0039225
27681813	946	949	die	T079	C0439228
27681813	963	967	days	T079	C0439228
27681813	969	976	group B	T185	C0441836
27681813	983	991	patients	T101	C0030705
27681813	1007	1017	clinically	T080	C0205210
27681813	1023	1050	American Knee Society Score	T081	C0449820
27681813	1052	1056	AKSS	T081	C0449820
27681813	1062	1083	visual analogue scale	T060	C3536884
27681813	1085	1088	VAS	T060	C3536884
27681813	1098	1102	pain	T184	C0030193
27681813	1114	1123	treatment	T061	C0087111
27681813	1134	1142	3 months	T079	C1442461
27681813	1144	1148	AKSS	T081	C0449820
27681813	1156	1164	patients	T101	C0030705
27681813	1173	1179	groups	T078	C0441833
27681813	1198	1207	increased	T081	C0205217
27681813	1215	1224	treatment	T061	C0087111
27681813	1230	1233	VAS	T060	C3536884
27681813	1234	1239	score	T081	C0449820
27681813	1258	1265	reduced	T080	C0392756
27681813	1275	1281	groups	T078	C0441833
27681813	1287	1296	subgroups	T185	C1515021
27681813	1315	1323	patients	T101	C0030705
27681813	1324	1343	older than 60 years	T033	C4062446
27681813	1348	1356	patients	T101	C0030705
27681813	1357	1364	younger	T079	C0332239
27681813	1373	1378	years	T079	C0439234
27681813	1411	1418	younger	T079	C0332239
27681813	1419	1427	patients	T101	C0030705
27681813	1431	1438	group A	T185	C0441835
27681813	1443	1448	older	T098	C0001792
27681813	1461	1468	group B	T185	C0441836
27681813	1518	1523	study	T062	C2603343
27681813	1540	1542	HA	T109,T121,T123	C0020196
27681813	1543	1552	injection	T122	C1272883
27681813	1557	1576	oral administration	T061	C0001563
27681813	1597	1616	therapeutic effects	T201	C1527144
27681813	1620	1628	patients	T101	C0030705
27681813	1640	1654	osteoarthritis	T047	C0029408
27681813	1678	1685	younger	T079	C0332239
27681813	1690	1695	older	T098	C0001792
27681813	1725	1732	therapy	T061	C0087111
27681813	1750	1763	infiltrations	T061	C0702249
27681813	1778	1782	oral	T030	C0226896
27681813	1783	1794	composition	T201	C0486616

27938921|t|Night-waking trajectories and associated factors in French preschoolers from the EDEN birth-cohort
27938921|a|Night waking in preschoolers has been associated with adverse health outcomes in cross-sectional studies, but has rarely been analyzed in a longitudinal setting. Therefore, little is known about the evolution of night waking in early childhood. The objectives of the present study were: to identify night-waking trajectories in preschoolers, and to examine the risk factors associated with those trajectories. Analyses were based on the French birth-cohort study EDEN, which recruited 2002 pregnant women between 2003 and 2006. Data on a child's night waking at the ages of two, three, and five, six years, and potential confounders, were collected through parental self-reported questionnaires. Night-waking trajectories were computerized using group-based trajectory modeling on 1346 children. Two distinct developmental patterns were identified: the "2-5 rare night-waking " (77% of the children) and the "2-5 common night-waking " pattern. Logistic regressions were performed to identify the factors associated with the trajectories. Risk factors for belonging to the "2-5 common night-waking " trajectory were: exposure to passive smoking at home, daycare in a collective setting, watching television for extended periods, bottle feeding at night, high emotionality, and low shyness. This approach allowed identification of risk factors associated with night waking during a critical age window, and laid the groundwork for identifying children at higher risk of deleterious sleep patterns. Those risk factors were mainly living habits, which indicated that prevention and intervention programs could be highly beneficial in this population.
27938921	0	12	Night-waking	T048	C0393761
27938921	13	25	trajectories	T082	C1704322
27938921	30	40	associated	T080	C0332281
27938921	41	48	factors	T169	C1521761
27938921	52	58	French	T098	C1556084
27938921	59	71	preschoolers	T100	C0008100
27938921	81	98	EDEN birth-cohort	T081	C1706962
27938921	99	111	Night waking	T048	C0393761
27938921	115	127	preschoolers	T100	C0008100
27938921	137	152	associated with	T080	C0332281
27938921	153	160	adverse	T033	C1513916
27938921	161	176	health outcomes	T170	C1550208
27938921	180	203	cross-sectional studies	T062	C0010362
27938921	239	259	longitudinal setting	T062	C0023981
27938921	311	323	night waking	T048	C0393761
27938921	327	342	early childhood	T079	C0599196
27938921	348	358	objectives	T170	C0018017
27938921	374	379	study	T062	C2603343
27938921	398	410	night-waking	T048	C0393761
27938921	411	423	trajectories	T082	C1704322
27938921	427	439	preschoolers	T100	C0008100
27938921	460	472	risk factors	T033	C0035648
27938921	473	488	associated with	T080	C0332281
27938921	495	507	trajectories	T082	C1704322
27938921	509	517	Analyses	T062	C0936012
27938921	536	542	French	T098	C1556084
27938921	543	555	birth-cohort	T081	C1706962
27938921	562	566	EDEN	T081	C1706962
27938921	574	583	recruited	T052	C2949735
27938921	589	603	pregnant women	T098	C0033011
27938921	637	644	child's	T100	C0008059
27938921	645	657	night waking	T048	C0393761
27938921	665	669	ages	T032	C0001779
27938921	710	719	potential	T080	C3245505
27938921	720	731	confounders	T169	C0009673
27938921	738	747	collected	T169	C1516698
27938921	756	764	parental	T099	C0030551
27938921	765	778	self-reported	T062	C2700446
27938921	779	793	questionnaires	T170	C0034394
27938921	795	807	Night-waking	T048	C0393761
27938921	808	820	trajectories	T082	C1704322
27938921	826	838	computerized	T066	C0009609
27938921	845	876	group-based trajectory modeling	T062	C0870071
27938921	885	893	children	T100	C0008059
27938921	908	921	developmental	T080	C0458003
27938921	922	930	patterns	T082	C0449774
27938921	936	946	identified	T080	C0205396
27938921	957	961	rare	T080	C0522498
27938921	962	974	night-waking	T048	C0393761
27938921	989	997	children	T100	C0008059
27938921	1012	1018	common	T081	C0205214
27938921	1019	1031	night-waking	T048	C0393761
27938921	1034	1041	pattern	T082	C0449774
27938921	1043	1063	Logistic regressions	T062	C0206031
27938921	1069	1078	performed	T169	C0884358
27938921	1095	1102	factors	T169	C1521761
27938921	1103	1118	associated with	T080	C0332281
27938921	1123	1135	trajectories	T082	C1704322
27938921	1137	1149	Risk factors	T033	C0035648
27938921	1176	1182	common	T081	C0205214
27938921	1183	1195	night-waking	T048	C0393761
27938921	1198	1208	trajectory	T082	C1704322
27938921	1215	1226	exposure to	T080	C0332157
27938921	1227	1242	passive smoking	T069	C0037370
27938921	1246	1250	home	T082	C0442519
27938921	1252	1259	daycare	T073,T092	C0008070
27938921	1285	1304	watching television	T056	C3273801
27938921	1309	1317	extended	T169	C0231448
27938921	1318	1325	periods	T079	C1948053
27938921	1327	1341	bottle feeding	T061	C0006042
27938921	1345	1350	night	T079	C0240526
27938921	1352	1356	high	T080	C0205250
27938921	1357	1369	emotionality	T048	C0237593
27938921	1375	1378	low	T080	C0205251
27938921	1379	1386	shyness	T054	C0037020
27938921	1393	1401	approach	T082	C0449445
27938921	1410	1424	identification	T080	C0205396
27938921	1428	1440	risk factors	T033	C0035648
27938921	1441	1456	associated with	T080	C0332281
27938921	1457	1469	night waking	T048	C0393761
27938921	1470	1476	during	T079	C0347984
27938921	1479	1487	critical	T080	C1511545
27938921	1488	1491	age	T032	C0001779
27938921	1492	1498	window	T079	C1272706
27938921	1528	1539	identifying	T058	C0683510
27938921	1540	1548	children	T100	C0008059
27938921	1549	1563	at higher risk	T033	C3843761
27938921	1567	1593	deleterious sleep patterns	T033	C0474396
27938921	1601	1613	risk factors	T033	C0035648
27938921	1633	1639	habits	T055	C0018464
27938921	1662	1672	prevention	T170	C0679717
27938921	1677	1698	intervention programs	T061	C0599917
27938921	1708	1714	highly	T080	C0205250
27938921	1715	1725	beneficial	T081	C0814225
27938921	1734	1744	population	T098	C1257890

28490376|t|The effects of clinical supervision on supervisees and patients in cognitive-behavioral therapy: a study protocol for a systematic review
28490376|a|Clinical supervision by a senior therapist is a very common practice in psychotherapist training and psychiatric care settings. Though clinical supervision is advocated by most educational and governing institutions, the effects of clinical supervision on the supervisees ' competence, e.g., attitudes, behaviors, and skills, as well as on treatment outcomes and other patient variables are debated and largely unknown. Evidence-based practice is advocated in clinical settings but has not yet been fully implemented in educational or clinical training settings. The aim of this systematic review is to synthesize and present the empirical literature regarding effects of clinical supervision in cognitive-behavioral therapy. This study will include a systematic review of the literature to identify studies that have empirically investigated the effects of supervision on supervised psychotherapists and/or the supervisees' patients. A comprehensive search strategy will be conducted to identify published controlled studies indexed in the MEDLINE, EMBASE, PsycINFO, and Cochrane Library databases. Data on supervision outcomes in both psychotherapists and their patients will be extracted, synthesized, and reported. Risk of bias and quality of the included studies will be assessed systematically. This systematic review will rigorously follow established guidelines for systematic reviews in order to summarize and present the evidence base for clinical supervision in cognitive-behavioral therapy and may aid further research and discussion in this area. PROSPERO CRD42016046834.
28490376	4	14	effects of	T080	C1704420
28490376	15	35	clinical supervision	T057	C0870294
28490376	39	50	supervisees	T098	C1257890
28490376	55	63	patients	T101	C0030705
28490376	67	95	cognitive-behavioral therapy	T061	C0009244
28490376	99	113	study protocol	T170	C2348563
28490376	120	137	systematic review	T170	C1955832
28490376	138	158	Clinical supervision	T057	C0870294
28490376	164	180	senior therapist	T097	C0871525
28490376	198	206	practice	T041	C0032893
28490376	210	225	psychotherapist	T097	C0557555
28490376	226	234	training	T065	C0220931
28490376	239	255	psychiatric care	T061	C0597312
28490376	273	293	clinical supervision	T057	C0870294
28490376	315	353	educational and governing institutions	UnknownType	C0681325
28490376	370	390	clinical supervision	T057	C0870294
28490376	398	409	supervisees	T098	C1257890
28490376	412	422	competence	T080	C0086035
28490376	430	439	attitudes	T041	C0004271
28490376	441	450	behaviors	T053	C0004927
28490376	456	462	skills	T055	C0678856
28490376	478	496	treatment outcomes	T080	C0085415
28490376	507	514	patient	T101	C0030705
28490376	558	581	Evidence-based practice	T169	C1510541
28490376	598	615	clinical settings	T082	C3176918
28490376	717	734	systematic review	T170	C1955832
28490376	768	788	empirical literature	T170	C0023866
28490376	810	830	clinical supervision	T057	C0870294
28490376	834	862	cognitive-behavioral therapy	T061	C0009244
28490376	890	907	systematic review	T170	C1955832
28490376	915	925	literature	T170	C0023866
28490376	1011	1038	supervised psychotherapists	T097	C0557555
28490376	1063	1071	patients	T101	C0030705
28490376	1164	1171	indexed	T170	C0918012
28490376	1179	1186	MEDLINE	T170	C0025141
28490376	1188	1194	EMBASE	T170	C0282574
28490376	1196	1204	PsycINFO	T170	C1140129
28490376	1210	1236	Cochrane Library databases	T170	C0282574
28490376	1238	1242	Data	T078	C1511726
28490376	1275	1291	psychotherapists	T097	C0557555
28490376	1302	1310	patients	T101	C0030705
28490376	1347	1355	reported	T170	C0684224
28490376	1444	1461	systematic review	T170	C1955832
28490376	1497	1507	guidelines	T170	C0162791
28490376	1512	1530	systematic reviews	T170	C1955832
28490376	1587	1607	clinical supervision	T057	C0870294
28490376	1611	1639	cognitive-behavioral therapy	T061	C0009244
28490376	1660	1668	research	T062	C0035168

27771058|t|Involvement of NF-κB in regulation of Actinobacillus pleuropneumoniae exotoxin ApxI -induced proinflammatory cytokine production in porcine alveolar macrophages
27771058|a|Actinobacillus pleuropneumoniae is a crucial respiratory pathogen that causes fibrinous, hemorrhagic, necrotizing pleuropneumonia in pigs. A. pleuropneumoniae exotoxins (ApxI to IV) are the major virulence factors contributing to A. pleuropneumoniae pathogenesis. Previously, we demonstrated that ApxI induces the expression of proinflammatory cytokines in porcine alveolar macrophages (PAMs) via the mitogen-activated protein kinases (MAPKs) p38 and cJun NH2-terminal kinase (JNK). Nonetheless, the role of nuclear factor (NF)-κB -a transcription factor widely implicated in immune and inflammatory responses -in ApxI -elicited cytokine production has yet to be defined. In the present study, we examined the involvement of NF-κB in ApxI -elicited production of interleukin (IL)-1β, IL-8, and tumor necrosis factor (TNF)-α in PAMs and investigated the correlation between NF-κB and MAPK (p38 and JNK) pathways in this event. The results of Western blot analysis, confocal microscopy, and a DNA binding activity assay revealed that the classical NF-κB pathway was activated by ApxI, as evidenced by the decreased levels of IκB and subsequent NF-κB translocation and activation in ApxI -stimulated PAMs. Moreover, the blocking of ApxI -induced NF-κB activation significantly attenuated the levels of mRNA and protein secretion of IL-1β, IL-8, and TNF-α in PAMs. Notably, the attenuation of JNK activation by a specific inhibitor (SP600125) reduced ApxI -induced NF-κB activation, whereas a p38 blocker (SB203580) had no effect on the NF-κB pathway. Further examination revealed that the level of phosphorylation at serine 536 on the NF-κB p65 subunit was dependent on JNK activity. Collectively, this study, for the first time, demonstrates a pivotal role of NF-κB in ApxI -induced IL-1β, IL-8, and TNF-α production; JNK, but not p38, may positively affect the activation of the classical NF-κB pathway.
27771058	15	20	NF-κB	T116,T129	C0079904
27771058	24	34	regulation	T038	C1327622
27771058	38	69	Actinobacillus pleuropneumoniae	T007	C0085489
27771058	70	78	exotoxin	T131	C0015309
27771058	79	83	ApxI	T116,T121	C1430061
27771058	93	128	proinflammatory cytokine production	T040	C1327413
27771058	132	139	porcine	T015	C3665571
27771058	140	160	alveolar macrophages	T025	C0085236
27771058	161	192	Actinobacillus pleuropneumoniae	T007	C0085489
27771058	206	217	respiratory	T039	C0035203
27771058	218	226	pathogen	T001	C0450254
27771058	239	248	fibrinous	T046	C0333353
27771058	250	261	hemorrhagic	T046	C0019080
27771058	263	274	necrotizing	T047	C0264515
27771058	275	290	pleuropneumonia	T047	C0032241
27771058	294	298	pigs	T015	C0039005
27771058	300	319	A. pleuropneumoniae	T007	C0085489
27771058	320	329	exotoxins	T131	C0015309
27771058	331	341	ApxI to IV	T131	C0015309
27771058	357	374	virulence factors	T109,T123,T131	C1136170
27771058	391	410	A. pleuropneumoniae	T007	C0085489
27771058	411	423	pathogenesis	T046	C0699748
27771058	458	462	ApxI	T116,T121	C1430061
27771058	475	485	expression	T045	C1171362
27771058	489	514	proinflammatory cytokines	T116,T129	C0079189
27771058	518	525	porcine	T015	C3665571
27771058	526	546	alveolar macrophages	T025	C0085236
27771058	548	552	PAMs	T025	C0085236
27771058	562	607	mitogen-activated protein kinases (MAPKs) p38	T116,T126	C1120843
27771058	612	636	cJun NH2-terminal kinase	T116,T126	C0248813
27771058	638	641	JNK	T116,T126	C0248813
27771058	669	691	nuclear factor (NF)-κB	T116	C0382369
27771058	695	715	transcription factor	T116,T123	C0040648
27771058	737	743	immune	T042	C0301872
27771058	748	770	inflammatory responses	T046	C1155266
27771058	775	779	ApxI	T116,T121	C1430061
27771058	790	809	cytokine production	T040	C1327413
27771058	848	853	study	T062	C2603343
27771058	886	891	NF-κB	T116,T129	C0079904
27771058	895	899	ApxI	T116,T121	C1430061
27771058	924	943	interleukin (IL)-1β	T116,T129	C0021753
27771058	945	949	IL-8	T116,T129	C0079633
27771058	955	984	tumor necrosis factor (TNF)-α	T116,T129	C1456820
27771058	988	992	PAMs	T025	C0085236
27771058	1034	1039	NF-κB	T116,T129	C0079904
27771058	1044	1048	MAPK	T116,T126	C0752312
27771058	1050	1053	p38	T116,T126	C1120843
27771058	1058	1061	JNK	T116,T126	C0248813
27771058	1063	1071	pathways	T044	C0037080
27771058	1102	1123	Western blot analysis	T059	C0949466
27771058	1125	1144	confocal microscopy	T059	C0242842
27771058	1152	1163	DNA binding	T045	C1148673
27771058	1164	1178	activity assay	T059	C1510438
27771058	1207	1212	NF-κB	T116,T129	C0079904
27771058	1213	1220	pathway	T044	C0037080
27771058	1238	1242	ApxI	T116,T121	C1430061
27771058	1284	1287	IκB	T116,T126	C0663914
27771058	1303	1308	NF-κB	T116,T129	C0079904
27771058	1309	1322	translocation	T043	C0599893
27771058	1327	1337	activation	T044	C1749855
27771058	1341	1345	ApxI	T116,T121	C1430061
27771058	1358	1362	PAMs	T025	C0085236
27771058	1390	1394	ApxI	T116,T121	C1430061
27771058	1404	1420	NF-κB activation	T044	C1749855
27771058	1460	1464	mRNA	T114,T123	C0035696
27771058	1469	1486	protein secretion	T043	C1159339
27771058	1490	1495	IL-1β	T116,T129	C0021753
27771058	1497	1501	IL-8	T116,T129	C0079633
27771058	1507	1512	TNF-α	T116,T129	C1456820
27771058	1516	1520	PAMs	T025	C0085236
27771058	1550	1553	JNK	T116,T126	C0248813
27771058	1554	1564	activation	UnknownType	C0678666
27771058	1590	1598	SP600125	T109,T121	C0968383
27771058	1608	1612	ApxI	T116,T121	C1430061
27771058	1622	1638	NF-κB activation	T044	C1749855
27771058	1650	1661	p38 blocker	T116,T126	C1120843
27771058	1663	1671	SB203580	T109,T121	C0297666
27771058	1694	1699	NF-κB	T116,T129	C0079904
27771058	1700	1707	pathway	T044	C0037080
27771058	1756	1771	phosphorylation	T044	C0031715
27771058	1775	1781	serine	T116,T121,T123	C0036720
27771058	1793	1810	NF-κB p65 subunit	T116,T123	C0214222
27771058	1828	1840	JNK activity	T044	C1150583
27771058	1861	1866	study	T062	C2603343
27771058	1919	1924	NF-κB	T116,T129	C0079904
27771058	1928	1932	ApxI	T116,T121	C1430061
27771058	1942	1947	IL-1β	T040	C1819435
27771058	1949	1953	IL-8	T040	C1819461
27771058	1959	1975	TNF-α production	T040	C1819464
27771058	1977	1980	JNK	T116,T126	C0248813
27771058	1990	1993	p38	T116,T126	C1120843
27771058	2021	2031	activation	UnknownType	C0678666
27771058	2049	2054	NF-κB	T116,T129	C0079904
27771058	2055	2062	pathway	T044	C0037080

27921269|t|Graded Structure in Sexual Definitions: Categorizations of Having " Had Sex " and Virginity Loss Among Homosexual and Heterosexual Men and Women
27921269|a|Definitions of sexual behavior display a robust hierarchy of agreement regarding whether or not acts should be classed as, for example, sex or virginity loss. The current research offers a theoretical explanation for this hierarchy, proposing that sexual definitions display graded categorical structure, arising from goodness of membership judgments. Moderation of this graded structure is also predicted, with the focus here on how sexual orientation identity affects sexual definitions. A total of 300 18- to 30- year -old participants completed an online survey, rating 18 behaviors for how far each constitutes having " had sex " and virginity loss. Participants fell into one of four groups: heterosexual male or female, gay male or lesbian. The predicted ratings hierarchy emerged, in which bidirectional genital acts were rated significantly higher than unidirectional or nonpenetrative contact, which was in turn rated significantly higher than acts involving no genital contact. Moderation of graded structure was also in line with predictions. Compared to the other groups, the lesbian group significantly upgraded ratings of genital contact that was either unidirectional or nonpenetrative. There was also evidence of upgrading by the gay male sample of anal intercourse ratings. These effects are theorized to reflect group -level variation in experience, contextual perspective, and identity -management. The implications of the findings in relation to previous research are discussed. It is suggested that a graded structure approach can greatly benefit future research into sexual definitions, by permitting variable definitions to be predicted and explained, rather than merely identified.
27921269	0	16	Graded Structure	T185	C0008902
27921269	20	26	Sexual	T053	C0036864
27921269	27	38	Definitions	T170	C1704788
27921269	40	55	Categorizations	T185	C0008902
27921269	68	75	Had Sex	T033	C0243095
27921269	82	91	Virginity	T055	C0282349
27921269	92	96	Loss	T169	C0745777
27921269	103	113	Homosexual	T098	C0019898
27921269	118	130	Heterosexual	T098	C1527360
27921269	131	134	Men	T098	C0025266
27921269	139	144	Women	T098	C0043210
27921269	145	156	Definitions	T170	C1704788
27921269	160	175	sexual behavior	T053	C0036864
27921269	193	202	hierarchy	T080	C0019523
27921269	241	245	acts	T052	C0441655
27921269	281	284	sex	T040	C0009253
27921269	288	297	virginity	T055	C0282349
27921269	298	302	loss	T169	C0745777
27921269	316	324	research	T062	C0035168
27921269	334	345	theoretical	T078	C0871935
27921269	346	357	explanation	T170	C0681841
27921269	367	376	hierarchy	T080	C0019523
27921269	393	399	sexual	T053	C0036864
27921269	400	411	definitions	T170	C1704788
27921269	420	448	graded categorical structure	T185	C0008902
27921269	475	485	membership	T055	C0680038
27921269	486	495	judgments	T041	C0022423
27921269	497	507	Moderation	T080	C1881878
27921269	516	532	graded structure	T185	C0008902
27921269	579	597	sexual orientation	T032	C0205949
27921269	598	606	identity	T041	C0424215
27921269	615	621	sexual	T053	C0036864
27921269	622	633	definitions	T170	C1704788
27921269	661	665	year	T079	C1510829
27921269	671	683	participants	T098	C0679646
27921269	697	710	online survey	T170	C0038951
27921269	712	718	rating	T052	C0871208
27921269	722	731	behaviors	T053	C0004927
27921269	770	777	had sex	T033	C0243095
27921269	784	793	virginity	T055	C0282349
27921269	794	798	loss	T169	C0745777
27921269	800	812	Participants	T098	C0679646
27921269	835	841	groups	UnknownType	C0681860
27921269	843	855	heterosexual	T098	C1527360
27921269	856	860	male	T098	C0025266
27921269	864	870	female	T098	C0043210
27921269	872	880	gay male	T098	C0242657
27921269	884	891	lesbian	T098	C1533642
27921269	907	914	ratings	T052	C0871208
27921269	915	924	hierarchy	T080	C0019523
27921269	943	969	bidirectional genital acts	T053	C0036864
27921269	975	980	rated	T052	C0871208
27921269	995	1001	higher	T080	C0205250
27921269	1007	1021	unidirectional	T053	C0036864
27921269	1025	1047	nonpenetrative contact	T033	C0563018
27921269	1067	1072	rated	T052	C0871208
27921269	1087	1093	higher	T080	C0205250
27921269	1099	1103	acts	T052	C0441655
27921269	1114	1132	no genital contact	T033	C0243095
27921269	1134	1144	Moderation	T080	C1881878
27921269	1148	1164	graded structure	T185	C0008902
27921269	1187	1198	predictions	T078	C0681842
27921269	1222	1228	groups	UnknownType	C0681860
27921269	1234	1247	lesbian group	UnknownType	C0681860
27921269	1271	1278	ratings	T052	C0871208
27921269	1282	1297	genital contact	T053	C0036864
27921269	1314	1328	unidirectional	T053	C0036864
27921269	1332	1346	nonpenetrative	T033	C0563018
27921269	1363	1371	evidence	T078	C3887511
27921269	1392	1400	gay male	T098	C0242657
27921269	1411	1427	anal intercourse	T054	C0556628
27921269	1428	1435	ratings	T052	C0871208
27921269	1443	1450	effects	T080	C1280500
27921269	1476	1481	group	UnknownType	C0681860
27921269	1489	1498	variation	T080	C0205419
27921269	1502	1512	experience	T041	C0596545
27921269	1514	1536	contextual perspective	T041	C0004271
27921269	1542	1550	identity	T041	C0424215
27921269	1568	1580	implications	T078	C3146298
27921269	1588	1596	findings	T033	C0243095
27921269	1621	1629	research	T062	C0035168
27921269	1668	1684	graded structure	T185	C0008902
27921269	1706	1713	benefit	T081	C0814225
27921269	1721	1729	research	T062	C0035168
27921269	1735	1741	sexual	T053	C0036864
27921269	1742	1753	definitions	T170	C1704788
27921269	1778	1789	definitions	T170	C1704788

28217505|t|Noncommunicable disease in rural India: Are we seriously underestimating the risk? The Nallampatti noncommunicable disease study
28217505|a|To assess the prevalence of noncommunicable diseases in a true rural farming population in South India and compare the data with the landmark contemporary Indian Council of Medical Research-India Diabetes (ICMR-INDIAB) study. Local Ethics Committee approval and informed consent was obtained from all participants. Inclusion criteria were participants, aged ≥20 and ≤85 years, from Nallampatti, a classical farming village from Tamil Nadu state, India. All participants were administered a detailed questionnaire, had anthropometric measurements including height, weight, and waist circumference. Bloods were drawn for random blood glucose, glycated hemoglobin (HbA1c), nonfasting lipid profile, Cystatin C, uric acid, and hemoglobin. All participants had carotid intima-media thickness (CIMT) done by high-resolution B-mode carotid ultrasound. More than 50% of the population had either diabetes or prediabetes based on HbA1c. Nearly, 40% of the population had hypertension with suboptimal control in those with known hypertension. Nearly, a third of the population had dyslipidemia, elevated cystatin C levels, and abnormal CIMT. The burden was higher than the comparable ICMR-INDIAB study in rural Tamil Nadu. One-third to one-half of this rural farming population is at risk of cardiovascular disease, with poor control of preexisting cardiovascular risk factors. Current Indian data may underestimate the risk in different ethnic populations and regions of India. Long-term follow-up of this cohort for the incident cardiovascular disease will shed light on the true cardiovascular risk in a typical South Indian rural farming population.
28217505	0	23	Noncommunicable disease	T047	C0007222
28217505	27	38	rural India	T083	C0021201
28217505	77	81	risk	T080	C1444641
28217505	87	98	Nallampatti	T083	C0017446
28217505	99	122	noncommunicable disease	T047	C0007222
28217505	123	128	study	T062	C2603343
28217505	157	181	noncommunicable diseases	T047	C0007222
28217505	192	205	rural farming	T090	C0001829
28217505	206	216	population	T098	C1257890
28217505	220	231	South India	T083	C0021201
28217505	262	353	landmark contemporary Indian Council of Medical Research-India Diabetes (ICMR-INDIAB) study	T170	C0451290
28217505	355	377	Local Ethics Committee	T097	C0085546
28217505	430	442	participants	T098	C0679646
28217505	444	462	Inclusion criteria	T080	C1512693
28217505	468	480	participants	T098	C0679646
28217505	511	522	Nallampatti	T083	C0017446
28217505	536	543	farming	T090	C0001829
28217505	544	551	village	T083	C0562518
28217505	557	573	Tamil Nadu state	T083	C0017446
28217505	575	580	India	T083	C0021201
28217505	586	598	participants	T098	C0679646
28217505	628	641	questionnaire	T170	C0034394
28217505	647	674	anthropometric measurements	T081	C0815129
28217505	685	691	height	T032	C0489786
28217505	693	699	weight	T081	C0043100
28217505	705	724	waist circumference	T201	C0455829
28217505	726	732	Bloods	T031	C0005767
28217505	748	768	random blood glucose	T059	C0428567
28217505	770	789	glycated hemoglobin	T059	C0202054
28217505	791	796	HbA1c	T059	C0202054
28217505	799	823	nonfasting lipid profile	T059	C0430044
28217505	825	835	Cystatin C	T059	C1619716
28217505	837	846	uric acid	T059	C0202239
28217505	852	862	hemoglobin	T059	C0518015
28217505	868	880	participants	T098	C0679646
28217505	885	915	carotid intima-media thickness	T201	C1960466
28217505	917	921	CIMT	T201	C1960466
28217505	931	946	high-resolution	T059	C1719039
28217505	947	972	B-mode carotid ultrasound	T060	C0554757
28217505	995	1005	population	T098	C1257890
28217505	1017	1025	diabetes	T047	C0011847
28217505	1029	1040	prediabetes	T047	C0362046
28217505	1050	1055	HbA1c	T116,T123	C0017853
28217505	1076	1086	population	T098	C1257890
28217505	1091	1103	hypertension	T047	C0020538
28217505	1109	1127	suboptimal control	T080	C2984009
28217505	1148	1160	hypertension	T047	C0020538
28217505	1185	1195	population	T098	C1257890
28217505	1200	1212	dyslipidemia	T047	C0242339
28217505	1214	1240	elevated cystatin C levels	T059	C1619716
28217505	1246	1254	abnormal	T033	C0205161
28217505	1255	1259	CIMT	T201	C1960466
28217505	1303	1320	ICMR-INDIAB study	T170	C0451290
28217505	1324	1340	rural Tamil Nadu	T083	C0017446
28217505	1372	1385	rural farming	T090	C0001829
28217505	1386	1396	population	T098	C1257890
28217505	1403	1407	risk	T080	C1444641
28217505	1411	1433	cardiovascular disease	T047	C0007222
28217505	1468	1495	cardiovascular risk factors	T047	C0850624
28217505	1505	1511	Indian	T098	C1524069
28217505	1539	1543	risk	T047	C0850624
28217505	1557	1575	ethnic populations	T098	C0015031
28217505	1591	1596	India	T083	C0021201
28217505	1598	1617	Long-term follow-up	T058	C1517942
28217505	1626	1632	cohort	T081	C0009247
28217505	1650	1672	cardiovascular disease	T047	C0007222
28217505	1701	1720	cardiovascular risk	T047	C0850624
28217505	1734	1746	South Indian	T083	C0021201
28217505	1747	1760	rural farming	T090	C0001829
28217505	1761	1771	population	T098	C1257890

27779702|t|Extract of Caulis Spatholobi, a novel blocker targeting tumor cell ‑induced platelet aggregation, inhibits breast cancer metastasis
27779702|a|Metastasis of breast cancer is the vital step for malignant progression. During such a process, hematogenous metastasis is an indispensable approach for the dissemination of cancer cells. A platelet, contributes to hypercoagulable state, and is also identified the crucial factor in the coagulation system for supporting metastasis. Therefore, the relationship of a platelet and a tumor cell plays a critical role in tumor cell metastasis. Consequently, inhibiting tumor cell ‑induced platelet aggregation (TCIPA) is recongnized as a crucial target on suppression of tumor metastasis such as aspirin (ASA). Under such circumstance, here we report that, through dissociating the tumor‑platelet (T‑P) complex, 80% ethanol extracts of Caulis Spatholobi (SET) successfully alleviated the hypercoagulation state, thereby reducing tumor metastasis and improving the prospects of survival in breast cancer cell model. Through MTT and anti‑aggregation assay stimulated by ADP, we detected the optimum treatment time and the optimum dose of SET. By using confocal microscopy, we observed that SET can strongly block the formation of T‑P complex i n vitro. The result was further quantified and confirmed by the FACS analysis. The fluorescent value of T‑P complex was obviously decreased in the drug‑treated groups. In vivo, 4T1 cells were injected through the mouse tail vein for dynamic visualization by small animal imaging system. The metastatic intensity was quantified and the survival curve was analyzed. Additionally, general observation and hematoxylin and eosin (H&E) staining of lung tissue was performed. SET exerted an obvious effect on the inhibition of metastasis and increasing the survival rate of mice. For the molecular mechanism study of anti‑TCIPA, zymography and R T‑PCR assay preliminarily revealed the molecular mechanism of SET in the regulation of P ‑T interaction. Collectively, through drug efficacy identification and pharmacological revealing, we have obtained a promising candidate for the interference of breast metastasis by suppressing TCIPA, which will be beneficial for clinical cancer treatment.
27779702	0	28	Extract of Caulis Spatholobi	T123	C0032081
27779702	11	28	Caulis Spatholobi	T002	C0242767
27779702	38	45	blocker	T121	C1254351
27779702	56	66	tumor cell	T025	C0597032
27779702	56	96	tumor cell ‑induced platelet aggregation	T043	C0032176
27779702	107	120	breast cancer	T191	C0006142
27779702	121	131	metastasis	T191	C0027627
27779702	132	142	Metastasis	T191	C0027627
27779702	146	159	breast cancer	T191	C0006142
27779702	182	203	malignant progression	T191	C0948048
27779702	228	251	hematogenous metastasis	T191	C0027627
27779702	306	318	cancer cells	T025	C0334227
27779702	322	330	platelet	T025	C0005821
27779702	347	368	hypercoagulable state	T047	C0398623
27779702	405	411	factor	T169	C1521761
27779702	419	430	coagulation	T042	C0005778
27779702	431	437	system	T169	C0449913
27779702	453	463	metastasis	T191	C0027627
27779702	498	506	platelet	T025	C0005821
27779702	513	523	tumor cell	T025	C0597032
27779702	549	559	tumor cell	T025	C0597032
27779702	560	570	metastasis	T191	C0027627
27779702	597	607	tumor cell	T025	C0597032
27779702	597	637	tumor cell ‑induced platelet aggregation	T043	C0032176
27779702	639	644	TCIPA	T043	C0032176
27779702	684	695	suppression	T044	C1519692
27779702	699	715	tumor metastasis	T191	C0027627
27779702	724	731	aspirin	T109,T121	C0004057
27779702	733	736	ASA	T109,T121	C0004057
27779702	810	839	tumor‑platelet (T‑P) complex,	T026	C0243092
27779702	844	851	ethanol	T109,T121	C0001962
27779702	852	881	extracts of Caulis Spatholobi	T123	C0032081
27779702	864	881	Caulis Spatholobi	T002	C0242767
27779702	883	886	SET	T123	C0032081
27779702	916	938	hypercoagulation state	T047	C0398623
27779702	957	973	tumor metastasis	T191	C0027627
27779702	1005	1013	survival	T052	C0038952
27779702	1017	1023	breast	T023	C0006141
27779702	1024	1035	cancer cell	T025	C0334227
27779702	1036	1041	model	T075	C0026336
27779702	1051	1054	MTT	T059	C0201596
27779702	1059	1099	anti‑aggregation assay stimulated by ADP	T059	C0005507
27779702	1117	1139	optimum treatment time	T079	C0040223
27779702	1148	1160	optimum dose	T081	C0178602
27779702	1164	1167	SET	T123	C0032081
27779702	1178	1197	confocal microscopy	T059	C0242842
27779702	1216	1219	SET	T123	C0032081
27779702	1243	1252	formation	T169	C1522492
27779702	1256	1267	T‑P complex	T026	C0243092
27779702	1270	1277	n vitro	T080	C1533691
27779702	1334	1347	FACS analysis	T059	C0079366
27779702	1353	1370	fluorescent value	T081	C0392762
27779702	1374	1385	T‑P complex	T026	C0243092
27779702	1417	1437	drug‑treated groups.	T078	C0441833
27779702	1438	1445	In vivo	T082	C1515655
27779702	1447	1456	4T1 cells	T025	C0597032
27779702	1462	1470	injected	T061	C1533685
27779702	1483	1488	mouse	T015	C0025929
27779702	1489	1498	tail vein	T023	C2985205
27779702	1503	1524	dynamic visualization	T060	C0430022
27779702	1528	1555	small animal imaging system	T073	C2697665
27779702	1561	1581	metastatic intensity	T081	C0392762
27779702	1605	1619	survival curve	T081	C0392762
27779702	1624	1632	analyzed	T062	C0936012
27779702	1672	1708	hematoxylin and eosin (H&E) staining	T059	C0523207
27779702	1712	1716	lung	T023	C0024109
27779702	1717	1723	tissue	T024	C0040300
27779702	1739	1742	SET	T123	C0032081
27779702	1776	1786	inhibition	T052	C3463820
27779702	1790	1800	metastasis	T191	C0027627
27779702	1820	1833	survival rate	T081	C0038954
27779702	1837	1841	mice	T015	C0025929
27779702	1851	1870	molecular mechanism	T044	C1148560
27779702	1871	1876	study	T062	C2603343
27779702	1880	1890	anti‑TCIPA	T059	C0005507
27779702	1892	1902	zymography	T062	C1517469
27779702	1909	1920	T‑PCR assay	T063	C0599161
27779702	1948	1967	molecular mechanism	T044	C1148560
27779702	1971	1974	SET	T123	C0032081
27779702	1998	2012	‑T interaction	T043	C0007582
27779702	2036	2049	drug efficacy	T080	C0598333
27779702	2069	2084	pharmacological	T169	C0205464
27779702	2159	2165	breast	T023	C0006141
27779702	2166	2176	metastasis	T191	C0027627
27779702	2192	2197	TCIPA	T043	C0032176
27779702	2228	2236	clinical	T080	C0205210
27779702	2237	2253	cancer treatment	T061	C0920425

27282236|t|Efficient patient modeling for visuo - haptic VR simulation using a generic patient atlas
27282236|a|This work presents a new time-saving virtual patient modeling system by way of example for an existing visuo - haptic training and planning virtual reality (VR) system for percutaneous transhepatic cholangio-drainage (PTCD). Our modeling process is based on a generic patient atlas to start with. It is defined by organ - specific optimized models, method modules and parameters, i.e. mainly individual segmentation masks, transfer functions to fill the gaps between the masks and intensity image data. In this contribution, we show how generic patient atlases can be generalized to new patient data. The methodology consists of patient - specific, locally-adaptive transfer functions and dedicated modeling methods such as multi-atlas segmentation, vessel filtering and spline-modeling. Our full image volume segmentation algorithm yields median DICE coefficients of 0.98, 0.93, 0.82, 0.74, 0.51 and 0.48 regarding soft-tissue, liver, bone, skin, blood and bile vessels for ten test patients and three selected reference patients. Compared to standard slice-wise manual contouring time saving is remarkable. Our segmentation process shows out efficiency and robustness for upper abdominal puncture simulation systems. This marks a significant step toward establishing patient - specific training and hands-on planning systems in a clinical environment.
27282236	10	17	patient	T101	C0030705
27282236	18	26	modeling	T062	C0870071
27282236	31	36	visuo	T169	C0234621
27282236	39	45	haptic	T042	C0871762
27282236	46	59	VR simulation	T066	C0871582
27282236	76	83	patient	T101	C0030705
27282236	84	89	atlas	T073,T170	C0004171
27282236	127	134	virtual	T066	C0871582
27282236	135	142	patient	T101	C0030705
27282236	143	158	modeling system	T062	C0870071
27282236	193	198	visuo	T169	C0234621
27282236	201	207	haptic	T042	C0871762
27282236	208	216	training	T065	C0220931
27282236	230	257	virtual reality (VR) system	T066	C0871582
27282236	262	306	percutaneous transhepatic cholangio-drainage	T061	C1504490
27282236	308	312	PTCD	T061	C1504490
27282236	319	335	modeling process	T062	C0870071
27282236	358	365	patient	T101	C0030705
27282236	366	371	atlas	T073,T170	C0004171
27282236	404	409	organ	T023	C0178784
27282236	412	420	specific	T080	C0205369
27282236	421	430	optimized	T052	C2698650
27282236	431	437	models	T170	C3161035
27282236	439	453	method modules	T170	C0025663
27282236	458	468	parameters	T077	C0549193
27282236	493	505	segmentation	T066	C2697664
27282236	506	511	masks	T080	C2346471
27282236	513	531	transfer functions	T066	C0024931
27282236	544	548	gaps	T082	C3887622
27282236	561	566	masks	T080	C2346471
27282236	571	586	intensity image	T080	C2346471
27282236	587	591	data	T078	C1511726
27282236	635	642	patient	T101	C0030705
27282236	643	650	atlases	T073,T170	C0004171
27282236	677	689	patient data	T170	C2707520
27282236	719	726	patient	T101	C0030705
27282236	729	737	specific	T080	C0205369
27282236	756	774	transfer functions	T066	C0024931
27282236	789	805	modeling methods	T062	C0870071
27282236	814	838	multi-atlas segmentation	T066	C2697664
27282236	840	856	vessel filtering	T170	C0025663
27282236	861	876	spline-modeling	T170	C0025663
27282236	887	912	image volume segmentation	T066	C2697664
27282236	913	922	algorithm	T170	C0002045
27282236	930	954	median DICE coefficients	T081	C0392762
27282236	1006	1017	soft-tissue	T024	C0225317
27282236	1019	1024	liver	T023	C0023884
27282236	1026	1030	bone	T024	C0005931
27282236	1032	1036	skin	T022	C1123023
27282236	1038	1043	blood	T023	C0005847
27282236	1048	1060	bile vessels	T031	C0005388
27282236	1074	1082	patients	T101	C0030705
27282236	1112	1120	patients	T101	C0030705
27282236	1143	1171	slice-wise manual contouring	T066	C2697664
27282236	1203	1223	segmentation process	T066	C2697664
27282236	1234	1244	efficiency	T081	C0013682
27282236	1249	1259	robustness	T080	C2986815
27282236	1270	1288	abdominal puncture	T037	C2089285
27282236	1289	1307	simulation systems	T066	C0009609
27282236	1322	1333	significant	T078	C0750502
27282236	1359	1366	patient	T101	C0030705
27282236	1369	1377	specific	T080	C0205369
27282236	1378	1386	training	T065	C0220931
27282236	1422	1442	clinical environment	T061	C0008971

27653173|t|Percutaneous coronary intervention and heart surgery learning needs of patients in Jordan
27653173|a|This study aimed to identify and prioritize the perceived learning needs of patients who underwent percutaneous coronary intervention or open-heart surgery. Identifying learning needs for post-cardiac intervention patients is essential to establish successful health education programmes based on patient central care. A descriptive comparative design was employed on a convenience sample of 260 patients who underwent a percutaneous coronary intervention and 105 patients who underwent open-heart surgery patients. Participants had completed the Patient Learning Needs Scale. Data were collected between 1 October 2014 and 31 June 2015. Patients from the two groups highly requesting health and recovery related information. They scored all learning need topics as important or highly important for them. The top priority learning need for both patient groups was ' information about wound care ', and the lowest priority learning need topic was ' physical activity '. The learning needs of both groups were very close, which indicated that educational secondary prevention programmes ' content can be prepared in a unified structure for those patients. Although, specific headings can be used to address the unique needs that emerge from having a specific cardiac interventional procedure. The fact that wound care and medications are areas of highest learning needs for patients requires health policy decision makers to address these topics at the time of hospital discharge. In addition, a policy focus on considering patients ' actual learning needs requires establishment and managerial support. As patients ' learning needs might change later after discharge, the health services should be proactive and focus on continuous support for patients after hospital discharge. Secondary prevention programmes should incorporate health education topics based on patients ' own views. This can be done by giving higher priority to understand patients' needs, put much more effort into how to meet patients ' information needs and to create a more engaging learning environment for patients and their families.
27653173	0	34	Percutaneous coronary intervention	T061	C1532338
27653173	39	52	heart surgery	T061	C0018821
27653173	53	61	learning	T041	C0023185
27653173	62	79	needs of patients	T169	C0686904
27653173	83	89	Jordan	T083	C0022418
27653173	123	133	prioritize	T079	C0549179
27653173	138	147	perceived	T041	C0030971
27653173	148	156	learning	T041	C0023185
27653173	157	174	needs of patients	T169	C0686904
27653173	189	223	percutaneous coronary intervention	T061	C1532338
27653173	227	245	open-heart surgery	T061	C0189745
27653173	259	267	learning	T041	C0023185
27653173	278	303	post-cardiac intervention	T061	C0184661
27653173	304	312	patients	T101	C0030705
27653173	350	377	health education programmes	T058	C0679897
27653173	387	394	patient	T101	C0030705
27653173	395	407	central care	T058	C1279810
27653173	435	441	design	T052	C1707689
27653173	460	471	convenience	T080	C3831015
27653173	472	478	sample	T098	C1257890
27653173	486	494	patients	T101	C0030705
27653173	511	545	percutaneous coronary intervention	T061	C1532338
27653173	554	562	patients	T101	C0030705
27653173	577	595	open-heart surgery	T061	C0189745
27653173	596	604	patients	T101	C0030705
27653173	606	618	Participants	T098	C0679646
27653173	637	644	Patient	T101	C0030705
27653173	645	665	Learning Needs Scale	T170	C0282574
27653173	667	671	Data	T078	C1511726
27653173	728	736	Patients	T101	C0030705
27653173	750	756	groups	T078	C0441833
27653173	775	814	health and recovery related information	T058	C0846605
27653173	832	845	learning need	T041	C0023185
27653173	846	852	topics	T170	C1555712
27653173	904	912	priority	T079	C0549179
27653173	913	921	learning	T041	C0023185
27653173	936	950	patient groups	T101	C0030705
27653173	957	968	information	T078	C1533716
27653173	975	985	wound care	T061	C0886052
27653173	1004	1012	priority	T079	C0549179
27653173	1013	1021	learning	T041	C0023185
27653173	1027	1032	topic	T170	C1555712
27653173	1039	1056	physical activity	T056	C0026606
27653173	1064	1072	learning	T041	C0023185
27653173	1073	1078	needs	T080	C0027552
27653173	1087	1093	groups	T078	C0441833
27653173	1132	1175	educational secondary prevention programmes	T170	C0679717
27653173	1235	1243	patients	T101	C0030705
27653173	1264	1272	headings	T170	C0038545
27653173	1307	1312	needs	T080	C0027552
27653173	1348	1355	cardiac	T023	C0018787
27653173	1356	1380	interventional procedure	T061	C0184661
27653173	1396	1406	wound care	T061	C0886052
27653173	1411	1422	medications	T058	C2081612
27653173	1444	1452	learning	T041	C0023185
27653173	1453	1458	needs	T080	C0027552
27653173	1463	1471	patients	T101	C0030705
27653173	1481	1494	health policy	T089	C0018735
27653173	1495	1510	decision makers	T097	C0242170
27653173	1528	1534	topics	T170	C1555712
27653173	1542	1546	time	T079	C0040223
27653173	1550	1568	hospital discharge	T058	C0586003
27653173	1585	1591	policy	T089	C0018735
27653173	1613	1621	patients	T101	C0030705
27653173	1631	1639	learning	T041	C0023185
27653173	1640	1645	needs	T080	C0027552
27653173	1655	1668	establishment	T073	C0442594
27653173	1673	1691	managerial support	T054	C0037438
27653173	1696	1704	patients	T101	C0030705
27653173	1707	1715	learning	T041	C0023185
27653173	1716	1721	needs	T080	C0027552
27653173	1747	1756	discharge	T058	C0586003
27653173	1762	1777	health services	T058	C0018747
27653173	1822	1829	support	T054	C0037438
27653173	1834	1842	patients	T101	C0030705
27653173	1849	1867	hospital discharge	T058	C0586003
27653173	1869	1900	Secondary prevention programmes	T170	C0679717
27653173	1920	1936	health education	T065	C0018701
27653173	1937	1943	topics	T170	C1555712
27653173	1953	1961	patients	T101	C0030705
27653173	2009	2017	priority	T079	C0549179
27653173	2032	2047	patients' needs	T169	C0686904
27653173	2087	2095	patients	T101	C0030705
27653173	2098	2109	information	T078	C1533716
27653173	2110	2115	needs	T080	C0027552
27653173	2146	2154	learning	T041	C0023185
27653173	2155	2166	environment	T082	C0014406
27653173	2171	2179	patients	T101	C0030705
27653173	2190	2198	families	T099	C0015576

27853255|t|Mimicking the cell membrane: bio-inspired simultaneous functions with monovalent anion selectivity and antifouling properties of anion exchange membrane
27853255|a|A new bio-inspired method was applied in this study to simultaneously improve the monovalent anion selectivity and antifouling properties of anion exchange membranes (AEMs). Three-layer architecture was developed by deposition of polydopamine (PDA) and electro-deposition of N-O-sulfonic acid benzyl chitosan (NSBC). The innermost and outermost layers were PDA with different deposition time. The middle layer was prepared by NSBC. Fourier transform infrared spectroscopy and scanning electron microscopy confirmed that PDA and NSBC were successfully modified on the surfaces of AEMs. The contact angle of the membranes indicated an improved hydrophilicity of the modified membranes. A series of electrodialysis experiments in which Cl(-) / SO4(2-) separation was studied, demonstrating the monovalent anion selectivity of the samples. The Cl(-) / SO4(2-) permselectivity of the modified membranes can reach up to 2.20, higher than that of the commercial membrane (only 0.78) during 90 minutes in electrodialysis (ED). The increase value of the resistance of the membranes was also measured to evaluate the antifouling properties. Sodium dodecyl benzene sulfonate (SDBS) was used as the fouling material in the ED process and the membrane area resistance of modified membrane increase value of was only 0.08 Ωcm(2) 30 minutes later.
27853255	14	27	cell membrane	T026	C3161472
27853255	29	41	bio-inspired	T090	C0872312
27853255	42	54	simultaneous	T079	C0521115
27853255	70	80	monovalent	UnknownType	C0678553
27853255	81	86	anion	T196	C0003075
27853255	87	98	selectivity	T052	C1707391
27853255	103	125	antifouling properties	T070	C0243178
27853255	129	134	anion	T196	C0003075
27853255	144	152	membrane	T074	C0025256
27853255	159	178	bio-inspired method	T090	C0872312
27853255	208	222	simultaneously	T079	C0521115
27853255	235	245	monovalent	UnknownType	C0678553
27853255	246	251	anion	T196	C0003075
27853255	252	263	selectivity	T052	C1707391
27853255	268	290	antifouling properties	T070	C0243178
27853255	294	299	anion	T196	C0003075
27853255	309	318	membranes	T074	C0025256
27853255	383	395	polydopamine	T109,T121	C3252413
27853255	397	400	PDA	T109,T121	C3252413
27853255	428	461	N-O-sulfonic acid benzyl chitosan	T109,T121	C0162969
27853255	463	467	NSBC	T109,T121	C0162969
27853255	474	483	innermost	T082	C0205102
27853255	488	497	outermost	T082	C0205101
27853255	498	504	layers	T167	C1561572
27853255	510	513	PDA	T109,T121	C3252413
27853255	550	556	middle	T082	C0444598
27853255	557	562	layer	T167	C1561572
27853255	579	583	NSBC	T109,T121	C0162969
27853255	585	624	Fourier transform infrared spectroscopy	T062	C0206055
27853255	629	657	scanning electron microscopy	T059	C0026020
27853255	673	676	PDA	T109,T121	C3252413
27853255	681	685	NSBC	T109,T121	C0162969
27853255	763	772	membranes	T074	C0025256
27853255	795	809	hydrophilicity	T080	C0475370
27853255	826	835	membranes	T074	C0025256
27853255	849	876	electrodialysis experiments	UnknownType	C0683122
27853255	886	891	Cl(-)	T196	C0596019
27853255	894	901	SO4(2-)	T196	C3536965
27853255	944	954	monovalent	UnknownType	C0678553
27853255	955	960	anion	T196	C0003075
27853255	961	972	selectivity	T052	C1707391
27853255	993	998	Cl(-)	T196	C0596019
27853255	1001	1008	SO4(2-)	T196	C3536965
27853255	1009	1024	permselectivity	T070	C0031164
27853255	1041	1050	membranes	T074	C0025256
27853255	1097	1116	commercial membrane	T074	C0025256
27853255	1150	1165	electrodialysis	UnknownType	C0683122
27853255	1167	1169	ED	UnknownType	C0683122
27853255	1216	1225	membranes	T074	C0025256
27853255	1260	1282	antifouling properties	T070	C0243178
27853255	1284	1316	Sodium dodecyl benzene sulfonate	T109,T121	C0142877
27853255	1318	1322	SDBS	T109,T121	C0142877
27853255	1340	1347	fouling	T070	C3826310
27853255	1364	1366	ED	UnknownType	C0683122
27853255	1383	1391	membrane	T074	C0025256
27853255	1411	1428	modified membrane	T074	C0025256

28077689|t|Giant cell arteritis and vascular disease-risk factors and outcomes: a cohort study using UK Clinical Practice Research Datalink
28077689|a|To evaluate the associations between GCA and vascular diseases and other comorbidities in patients with GCA compared with non-vasculitis patients. Using the UK-based Clinical Practice Research Datalink we identified 9778 newly diagnosed GCA patients in 1990-2014, and up to 10 non-vasculitis patients randomly matched to each case on age, sex, practice and years of history before cohort entry. We compared the distributions of 9 different pre-existing vascular diseases and 11 other comorbidities, and risks of incident vascular diseases and other comorbidities after cohort entry between GCA and non-vasculitis patients. Patients with GCA were more likely to have a history of vascular diseases and other comorbidities except myocardial infarction, type 2 diabetes, obesity and cancer, compared with non-vasculitis patients. Patients with GCA had increased risks for all types of incident vascular disease compared with non-vasculitis patients: adjusted hazard ratios were 1.57 (95% CI: 1.36, 1.82) for myocardial infarction, 1.41 (95% CI: 1.29, 1.55) for stroke, 1.75 (95% CI: 1.49, 2.06) for peripheral vascular disease, 1.98 (95% CI: 1.50, 2.62) for aortic aneurysm and 2.03 (95% CI: 1.77, 2.33) for venous thromboembolism. Patients with GCA also had increased risks for other incident comorbidities (type 2 diabetes, depression, etc.), but not for cancer. Patients with GCA had more prior vascular diseases and other comorbidities before the diagnosis and they also had increased risks for incident vascular diseases and many other incident comorbidities after the diagnosis compared with non-vasculitis population.
28077689	0	20	Giant cell arteritis	T047	C0039483
28077689	25	54	vascular disease-risk factors	T058	C2584745
28077689	59	67	outcomes	T062	C0543472
28077689	71	83	cohort study	T081	C0009247
28077689	90	92	UK	T083	C0041700
28077689	93	128	Clinical Practice Research Datalink	T170	C0282451
28077689	129	140	To evaluate	T058	C0220825
28077689	145	157	associations	T080	C0439849
28077689	166	169	GCA	T047	C0039483
28077689	174	191	vascular diseases	T047	C0042373
28077689	202	215	comorbidities	T078	C0009488
28077689	219	227	patients	T101	C0030705
28077689	233	236	GCA	T047	C0039483
28077689	251	274	non-vasculitis patients	T101	C0030705
28077689	286	294	UK-based	T083	C0041700
28077689	295	330	Clinical Practice Research Datalink	T170	C0282451
28077689	334	344	identified	T080	C0205396
28077689	350	365	newly diagnosed	T080	C1518321
28077689	366	369	GCA	T047	C0039483
28077689	370	378	patients	T101	C0030705
28077689	382	391	1990-2014	T079	C0585341
28077689	406	429	non-vasculitis patients	T101	C0030705
28077689	430	446	randomly matched	T062	C0034656
28077689	450	459	each case	T077	C1706256
28077689	463	466	age	T032	C0001779
28077689	468	471	sex	T032	C0079399
28077689	473	481	practice	T041	C0237607
28077689	486	502	years of history	T033	C2004062
28077689	503	509	before	T079	C0332152
28077689	510	522	cohort entry	T081	C0009247
28077689	527	535	compared	T052	C1707455
28077689	540	553	distributions	T169	C1704711
28077689	559	568	different	T080	C1705242
28077689	569	581	pre-existing	T080	C2347662
28077689	582	599	vascular diseases	T047	C0042373
28077689	613	626	comorbidities	T078	C0009488
28077689	632	649	risks of incident	T033	C1113667
28077689	650	667	vascular diseases	T047	C0042373
28077689	678	691	comorbidities	T078	C0009488
28077689	698	710	cohort entry	T081	C0009247
28077689	719	722	GCA	T047	C0039483
28077689	727	750	non-vasculitis patients	T101	C0030705
28077689	752	760	Patients	T101	C0030705
28077689	766	769	GCA	T047	C0039483
28077689	775	786	more likely	T080	C0205556
28077689	797	807	history of	T033	C0683519
28077689	808	825	vascular diseases	T047	C0042373
28077689	836	849	comorbidities	T078	C0009488
28077689	857	878	myocardial infarction	T047	C0027051
28077689	880	895	type 2 diabetes	T047	C0011860
28077689	897	904	obesity	T047	C0028754
28077689	909	915	cancer	T191	C0006826
28077689	917	925	compared	T052	C1707455
28077689	931	954	non-vasculitis patients	T101	C0030705
28077689	956	964	Patients	T101	C0030705
28077689	970	973	GCA	T047	C0039483
28077689	978	987	increased	T081	C0205217
28077689	988	1019	risks for all types of incident	T033	C0580320
28077689	1020	1036	vascular disease	T047	C0042373
28077689	1037	1045	compared	T052	C1707455
28077689	1051	1074	non-vasculitis patients	T101	C0030705
28077689	1076	1084	adjusted	T169	C0456081
28077689	1085	1098	hazard ratios	T081	C2985465
28077689	1114	1116	CI	T081	C0009667
28077689	1134	1155	myocardial infarction	T047	C0027051
28077689	1167	1169	CI	T081	C0009667
28077689	1187	1193	stroke	T047	C0038454
28077689	1205	1207	CI	T081	C0009667
28077689	1225	1252	peripheral vascular disease	T047	C0085096
28077689	1264	1266	CI	T081	C0009667
28077689	1284	1299	aortic aneurysm	T047	C0003486
28077689	1314	1316	CI	T081	C0009667
28077689	1334	1356	venous thromboembolism	T047	C1861172
28077689	1358	1366	Patients	T101	C0030705
28077689	1372	1375	GCA	T047	C0039483
28077689	1385	1394	increased	T081	C0205217
28077689	1395	1419	risks for other incident	T033	C1281905
28077689	1420	1433	comorbidities	T078	C0009488
28077689	1435	1450	type 2 diabetes	T047	C0011860
28077689	1452	1462	depression	T048	C0011570
28077689	1483	1489	cancer	T191	C0006826
28077689	1491	1499	Patients	T101	C0030705
28077689	1505	1508	GCA	T047	C0039483
28077689	1524	1541	vascular diseases	T047	C0042373
28077689	1552	1565	comorbidities	T078	C0009488
28077689	1566	1572	before	T079	C0332152
28077689	1577	1586	diagnosis	T033	C0011900
28077689	1605	1614	increased	T081	C0205217
28077689	1615	1633	risks for incident	T033	C1281905
28077689	1634	1651	vascular diseases	T047	C0042373
28077689	1667	1675	incident	T067	C1551358
28077689	1676	1689	comorbidities	T078	C0009488
28077689	1700	1709	diagnosis	T033	C0011900
28077689	1710	1718	compared	T052	C1707455
28077689	1724	1749	non-vasculitis population	T101	C0030705

27437094|t|A Web-based Alternative Non-animal Method Database for Safety Cosmetic Evaluations
27437094|a|Animal testing was used traditionally in the cosmetics industry to confirm product safety, but has begun to be banned; alternative methods to replace animal experiments are either in development, or are being validated, worldwide. Research data related to test substances are critical for developing novel alternative tests. Moreover, safety information on cosmetic materials has neither been collected in a database nor shared among researchers. Therefore, it is imperative to build and share a database of safety information on toxicological mechanisms and pathways collected through in vivo, in vitro, and in silico methods. We developed the CAMSEC database (named after the research team; the Consortium of Alternative Methods for Safety Evaluation of Cosmetics) to fulfill this purpose. On the same website, our aim is to provide updates on current alternative research methods in Korea. The database will not be used directly to conduct safety evaluations, but researchers or regulatory individuals can use it to facilitate their work in formulating safety evaluations for cosmetic materials. We hope this database will help establish new alternative research methods to conduct efficient safety evaluations of cosmetic materials.
27437094	2	50	Web-based Alternative Non-animal Method Database	T170	C0242356
27437094	55	61	Safety	T068	C0036043
27437094	62	70	Cosmetic	T073	C0010164
27437094	71	82	Evaluations	T062	C0178628
27437094	83	97	Animal testing	T062	C1510899
27437094	128	137	cosmetics	T073	C0010164
27437094	138	146	industry	T057	C0021267
27437094	158	172	product safety	T064	C3825790
27437094	194	200	banned	T054	C0683610
27437094	202	221	alternative methods	T062	C0086912
27437094	233	251	animal experiments	T062	C0205664
27437094	266	277	development	T169	C1527148
27437094	314	327	Research data	T062	C0681873
27437094	339	343	test	T169	C0039593
27437094	344	354	substances	T167	C0439861
27437094	383	388	novel	T080	C0205314
27437094	389	406	alternative tests	T170	C0392366
27437094	418	436	safety information	T170	C2964262
27437094	440	458	cosmetic materials	T073	C0010164
27437094	476	485	collected	T169	C1516698
27437094	491	499	database	T170	C0242356
27437094	517	528	researchers	T097	C0035173
27437094	579	587	database	T170	C0242356
27437094	591	609	safety information	T170	C2964262
27437094	613	637	toxicological mechanisms	T169	C0441712
27437094	642	650	pathways	T077	C1705987
27437094	651	660	collected	T169	C1516698
27437094	669	676	in vivo	T082	C1515655
27437094	678	686	in vitro	T080	C1533691
27437094	692	701	in silico	T066	C3489666
27437094	702	709	methods	T062	C0086912
27437094	728	743	CAMSEC database	T170	C0242356
27437094	761	774	research team	T096	C0871489
27437094	780	848	Consortium of Alternative Methods for Safety Evaluation of Cosmetics	T092	C1561598
27437094	839	848	Cosmetics	T073	C0010164
27437094	887	894	website	T170	C2349146
27437094	937	965	alternative research methods	T062	C0086912
27437094	969	974	Korea	T083	C0022771
27437094	980	988	database	T170	C0242356
27437094	1026	1032	safety	T068	C0036043
27437094	1033	1044	evaluations	T062	C0178628
27437094	1050	1061	researchers	T097	C0035173
27437094	1065	1075	regulatory	T077	C1704735
27437094	1076	1087	individuals	T098	C0237401
27437094	1139	1145	safety	T068	C0036043
27437094	1146	1157	evaluations	T062	C0178628
27437094	1162	1180	cosmetic materials	T073	C0010164
27437094	1195	1203	database	T170	C0242356
27437094	1214	1223	establish	T080	C0443211
27437094	1228	1256	alternative research methods	T062	C0086912
27437094	1278	1284	safety	T068	C0036043
27437094	1285	1296	evaluations	T062	C0178628
27437094	1300	1318	cosmetic materials	T073	C0010164

27446550|t|Heat-shock protein 60 of Porphyromonas gingivalis may induce dysfunction of human umbilical endothelial cells via regulation of endothelial-nitric oxide synthase and vascular endothelial-cadherin
27446550|a|Accumulating evidence has established that periodontitis was an independent risk factor for coronary heart disease (CAD). Porphyromonus gingivalis (P. gingivalis), a major periodontal pathogen, has already been shown to have a significant role in the inflammatory response of CAD in vivo. The aim of the present study was to identify whether P. gingivalis heat-shock protein 60 (HSP60) induced the dysfunction of human umbilical vein endothelial cells (HUVECs) in vitro. HUVECs were stimulated with a range of P. gingivalis HSP60 concentrations (1, 10 and 100 ng/l) at different time-points. The levels of vascular endothelial (VE)-cadherin, endothelial nitric oxide synthase (eNOS) and cysteinyl aspartate-specific protease-3 (caspase-3) were measured using western blot analysis. The apoptotic rate of HUVECs was detected using flow cytometry. P. gingivalis HSP60 at a concentration of 10 ng/l significantly decreased the expression levels of VE-cadherin and eNOS protein at 24 h stimulation, whereas no difference in these proteins was identified following a low dose of P. gingivalis HSP60 (1 ng/l). P. gingivalis HSP60 at 100 ng/l significantly downregulated the expression levels of VE-cadherin and eNOS protein at 12 h in HUVECs. However, the cleavage of caspase-3 showed an opposing change at different concentrations. Consistently, P. gingivalis HSP60 induced apoptosis of HUVECs in a concentration - dependent manner. These results indicated that P. gingivalis HSP60 may induce dysfunction and apoptosis in HUVECs via downregulating the expression levels of VE-cadherin and eNOS, and promoting the cleavage of caspase-3.
27446550	0	21	Heat-shock protein 60	T116,T123	C0109272
27446550	25	49	Porphyromonas gingivalis	T007	C0085478
27446550	61	72	dysfunction	T077	C3887504
27446550	76	109	human umbilical endothelial cells	T025	C3179121
27446550	114	124	regulation	T038	C1327622
27446550	128	161	endothelial-nitric oxide synthase	T116,T126	C0669365
27446550	166	195	vascular endothelial-cadherin	T116,T129	C0300423
27446550	239	252	periodontitis	T047	C0031099
27446550	272	283	risk factor	T033	C0035648
27446550	288	310	coronary heart disease	T047	C0010068
27446550	312	315	CAD	T047	C0010068
27446550	318	342	Porphyromonus gingivalis	T007	C0085478
27446550	344	357	P. gingivalis	T007	C0085478
27446550	368	379	periodontal	T080	C0332275
27446550	380	388	pathogen	T001	C0450254
27446550	447	468	inflammatory response	T046	C1155266
27446550	472	475	CAD	T047	C0010068
27446550	476	483	in vivo	T082	C1515655
27446550	508	513	study	T062	C2603343
27446550	538	551	P. gingivalis	T007	C0085478
27446550	552	573	heat-shock protein 60	T116,T123	C0109272
27446550	575	580	HSP60	T116,T123	C0109272
27446550	594	605	dysfunction	T077	C3887504
27446550	609	647	human umbilical vein endothelial cells	T025	C3179121
27446550	649	655	HUVECs	T025	C3179121
27446550	657	665	in vitro	T080	C1533691
27446550	667	673	HUVECs	T025	C3179121
27446550	679	689	stimulated	T070	C1948023
27446550	706	719	P. gingivalis	T007	C0085478
27446550	720	725	HSP60	T116,T123	C0109272
27446550	726	740	concentrations	T081	C0392762
27446550	775	786	time-points	T079	C2348792
27446550	792	798	levels	T080	C0441889
27446550	802	836	vascular endothelial (VE)-cadherin	T116,T129	C0300423
27446550	838	871	endothelial nitric oxide synthase	T116,T126	C0669365
27446550	873	877	eNOS	T116,T126	C0669365
27446550	883	922	cysteinyl aspartate-specific protease-3	T116,T126	C0291573
27446550	924	933	caspase-3	T116,T126	C0291573
27446550	955	967	western blot	T059	C0949466
27446550	968	976	analysis	T062	C0936012
27446550	982	991	apoptotic	T043	C0162638
27446550	992	996	rate	T081	C1521828
27446550	1000	1006	HUVECs	T025	C3179121
27446550	1026	1040	flow cytometry	T059	C0016263
27446550	1042	1055	P. gingivalis	T007	C0085478
27446550	1056	1061	HSP60	T116,T123	C0109272
27446550	1067	1080	concentration	T081	C0392762
27446550	1120	1130	expression	T045	C1171362
27446550	1131	1137	levels	T080	C0441889
27446550	1141	1152	VE-cadherin	T116,T129	C0300423
27446550	1157	1169	eNOS protein	T116,T126	C0669365
27446550	1176	1177	h	T079	C0439227
27446550	1178	1189	stimulation	T070	C1948023
27446550	1222	1230	proteins	T116,T123	C0033684
27446550	1258	1266	low dose	T081	C0445550
27446550	1270	1283	P. gingivalis	T007	C0085478
27446550	1284	1289	HSP60	T116,T123	C0109272
27446550	1300	1313	P. gingivalis	T007	C0085478
27446550	1314	1319	HSP60	T116,T123	C0109272
27446550	1346	1359	downregulated	T044	C0013081
27446550	1364	1374	expression	T045	C1171362
27446550	1375	1381	levels	T080	C0441889
27446550	1385	1396	VE-cadherin	T116,T129	C0300423
27446550	1401	1413	eNOS protein	T116,T126	C0669365
27446550	1425	1431	HUVECs	T025	C3179121
27446550	1446	1454	cleavage	T067	C0596311
27446550	1458	1467	caspase-3	T116,T126	C0291573
27446550	1507	1521	concentrations	T081	C0392762
27446550	1537	1550	P. gingivalis	T007	C0085478
27446550	1551	1556	HSP60	T116,T123	C0109272
27446550	1565	1574	apoptosis	T043	C0162638
27446550	1578	1584	HUVECs	T025	C3179121
27446550	1590	1603	concentration	T081	C0392762
27446550	1606	1615	dependent	T169	C3244310
27446550	1630	1637	results	T169	C1274040
27446550	1653	1666	P. gingivalis	T007	C0085478
27446550	1667	1672	HSP60	T116,T123	C0109272
27446550	1684	1695	dysfunction	T077	C3887504
27446550	1700	1709	apoptosis	T043	C0162638
27446550	1713	1719	HUVECs	T025	C3179121
27446550	1724	1738	downregulating	T044	C0013081
27446550	1743	1753	expression	T045	C1171362
27446550	1754	1760	levels	T080	C0441889
27446550	1764	1775	VE-cadherin	T116,T129	C0300423
27446550	1780	1784	eNOS	T116,T126	C0669365
27446550	1804	1812	cleavage	T067	C0596311
27446550	1816	1825	caspase-3	T116,T126	C0291573

27293123|t|Everyday (in)equality at home: complex constructions of gender in South African families
27293123|a|High rates of violence and HIV have been documented within the South African context. Constructions of masculinity and femininity that position men as dominant and highly sexually active and women as subordinate and acquiescent have been found to contribute towards gender inequality. This inequality is in turn related to negative health consequences, specifically violence against women, children, and other men, as well as sexual risk. Within this context it becomes important to explore how problematic constructions of gender are being (re) produced and how these constructions are being challenged. Families have been identified as key sites in which gender is both constructed and enacted on a daily basis and it is within this space that children are first exposed to notions of gender. This article draws from a study that was intended to expand on the limited understandings of the ways in which gender (in)equality is constructed and conveyed within the context of South African families on an everyday basis. Children and parents in 18 families from a range of different material and cultural backgrounds were interviewed about the meanings and practices of gender within their homes. Data were analysed using a Foucauldian discourse analysis. The data reveal how problematic constructions of masculinity and femininity are (re) produced but also challenged within a range of different families. Gender and gender (in)equality are therefore routinely accomplished in complex ways. These findings have important implications for promoting gender equality and therefore for disrupting violence and sexual risk as gendered health issues.
27293123	0	8	Everyday	T079	C0332173
27293123	9	21	(in)equality	T080	C0680381
27293123	25	29	home	T082	C0442519
27293123	56	62	gender	T032	C0079399
27293123	66	79	South African	T098	C0238605
27293123	80	88	families	T099	C0015576
27293123	89	93	High	T080	C0205250
27293123	94	99	rates	T081	C1521828
27293123	103	111	violence	T048	C0042693
27293123	116	119	HIV	T047	C0019693
27293123	130	140	documented	T058	C1301725
27293123	152	173	South African context	T098	C0238605
27293123	192	203	masculinity	T032	C0042757
27293123	208	218	femininity	T032	C0233894
27293123	233	236	men	T098	C0025266
27293123	240	248	dominant	T054	C0037413
27293123	260	275	sexually active	T033	C0241028
27293123	280	285	women	T098	C0043210
27293123	289	300	subordinate	T077	C2983704
27293123	305	316	acquiescent	T033	C0564543
27293123	355	372	gender inequality	T054	C0242448
27293123	379	389	inequality	T054	C0242448
27293123	421	440	health consequences	T169	C0686907
27293123	455	463	violence	T048	C0042693
27293123	472	477	women	T098	C0043210
27293123	479	487	children	T100	C0008059
27293123	499	502	men	T098	C0025266
27293123	515	526	sexual risk	T033	C1563228
27293123	613	619	gender	T032	C0079399
27293123	635	643	produced	T079	C2745955
27293123	694	702	Families	T099	C0015576
27293123	746	752	gender	T032	C0079399
27293123	790	795	daily	T079	C0332173
27293123	835	843	children	T100	C0008059
27293123	865	872	notions	T078	C0178566
27293123	876	882	gender	T032	C0079399
27293123	889	896	article	T170	C0282420
27293123	910	915	study	T062	C2603343
27293123	995	1014	gender (in)equality	T054	C0242448
27293123	1054	1078	context of South African	T098	C0238605
27293123	1079	1087	families	T099	C0015576
27293123	1094	1102	everyday	T079	C0332173
27293123	1110	1118	Children	T100	C0008059
27293123	1123	1130	parents	T099	C0030551
27293123	1137	1145	families	T099	C0015576
27293123	1185	1205	cultural backgrounds	T078	C0010447
27293123	1259	1265	gender	T032	C0079399
27293123	1279	1284	homes	T082	C0442519
27293123	1286	1290	Data	T078	C1511726
27293123	1296	1304	analysed	T062	C0936012
27293123	1313	1343	Foucauldian discourse analysis	T062	C0870428
27293123	1349	1353	data	T078	C1511726
27293123	1394	1405	masculinity	T032	C0042757
27293123	1410	1420	femininity	T032	C0233894
27293123	1430	1438	produced	T079	C2745955
27293123	1487	1495	families	T099	C0015576
27293123	1497	1503	Gender	T032	C0079399
27293123	1508	1527	gender (in)equality	T054	C0242448
27293123	1639	1645	gender	T032	C0079399
27293123	1646	1654	equality	T080	C0237595
27293123	1673	1683	disrupting	T080	C0332454
27293123	1684	1692	violence	T048	C0042693
27293123	1697	1708	sexual risk	T033	C1563228

28240634|t|Torsed and Nontorsed Inguinal Undescended Testis: Comparison of Computed Tomography Findings
28240634|a|The aim of this study was to compare the computed tomography imaging features of a torsed inguinal testis with nontorsed inguinal testes. Computed tomography scans of patients with undescended testes were retrospectively collected (2011-2016). Imaging features of nontorsed undescended testis were compared with a case of an inguinal torsed testis. Observations included location of the undescended testis, size (length × width) and texture of each testis, peritesticular findings, position of testicular vessels, and enhancement patterns. Twelve nontorsed inguinal undescended testes were compared with 1 torsed undescended testicle. Torsed testis was larger than nontorsed (44 × 27 mm vs 32.9 ± 6.1 × 22.9 ± 4.9 mm), surrounded by fat stranding and fluid, with heterogeneous texture, enhancement of its outer layers, and an upward kink of its vessels. Because torsed undescended testis can mimic a groin abscess and because torsion is a medical emergency, radiologists should be aware of this entity and its distinguishing imaging features. Color Doppler examination can ascertain absence / reduction of blood flow.
28240634	0	6	Torsed	T046	C1265748
28240634	11	29	Nontorsed Inguinal	T029	C0018246
28240634	30	48	Undescended Testis	T017	C3537044
28240634	50	60	Comparison	T052	C1707455
28240634	64	83	Computed Tomography	T060	C0040405
28240634	84	92	Findings	T169	C2607943
28240634	109	114	study	T062	C2603343
28240634	122	129	compare	T052	C1707455
28240634	134	161	computed tomography imaging	T060	C0729619
28240634	162	170	features	T080	C2348519
28240634	176	182	torsed	T046	C1265748
28240634	183	191	inguinal	T029	C0018246
28240634	192	198	testis	T023	C0039597
28240634	204	222	nontorsed inguinal	T029	C0018246
28240634	223	229	testes	T023	C0039597
28240634	231	256	Computed tomography scans	T060	C0870067
28240634	260	268	patients	T101	C0030705
28240634	274	292	undescended testes	T017	C3537044
28240634	298	313	retrospectively	T080	C1514923
28240634	314	323	collected	T169	C1516698
28240634	337	344	Imaging	T060	C0025086
28240634	345	353	features	T080	C2348519
28240634	357	385	nontorsed undescended testis	T017	C3537044
28240634	391	399	compared	T052	C1707455
28240634	418	426	inguinal	T029	C0018246
28240634	427	433	torsed	T046	C1265748
28240634	434	440	testis	T023	C0039597
28240634	455	463	included	T169	C0332257
28240634	464	472	location	T082	C0450429
28240634	480	498	undescended testis	T017	C3537044
28240634	500	504	size	T082	C0456389
28240634	506	512	length	T081	C1444754
28240634	515	520	width	T081	C0487742
28240634	526	533	texture	T080	C0449582
28240634	542	548	testis	T023	C0039597
28240634	550	564	peritesticular	T082	C0205070
28240634	565	573	findings	T169	C2607943
28240634	575	583	position	T082	C0733755
28240634	587	605	testicular vessels	T023	C4266473
28240634	611	622	enhancement	T052	C2349975
28240634	623	631	patterns	T082	C0449774
28240634	633	639	Twelve	T081	C0205458
28240634	640	658	nontorsed inguinal	T029	C0018246
28240634	659	677	undescended testes	T017	C3537044
28240634	683	691	compared	T052	C1707455
28240634	699	705	torsed	T046	C1265748
28240634	706	726	undescended testicle	T017	C3537044
28240634	728	734	Torsed	T046	C1265748
28240634	735	741	testis	T023	C0039597
28240634	812	822	surrounded	T082	C1282914
28240634	826	839	fat stranding	T024	C0222331
28240634	844	849	fluid	T031	C0005889
28240634	856	869	heterogeneous	T080	C0019409
28240634	870	877	texture	T080	C0449582
28240634	879	890	enhancement	T052	C2349975
28240634	898	910	outer layers	T023	C0934502
28240634	919	925	upward	T082	C1282911
28240634	926	930	kink	T169	C0333177
28240634	938	945	vessels	T023	C4266473
28240634	955	961	torsed	T046	C1265748
28240634	962	980	undescended testis	T017	C3537044
28240634	993	1006	groin abscess	T047	C0263109
28240634	1019	1026	torsion	T046	C1265748
28240634	1051	1063	radiologists	T097	C0260194
28240634	1088	1094	entity	T071	C1551338
28240634	1118	1125	imaging	T060	C0025086
28240634	1126	1134	features	T080	C2348519
28240634	1136	1161	Color Doppler examination	T060	C0474781
28240634	1176	1183	absence	T169	C0332197
28240634	1186	1195	reduction	T080	C0392756
28240634	1199	1209	blood flow	T039	C0232338

27647760|t|The relationship between polymorphisms of BDNFOS and BDNF genes and heroin addiction in the Han Chinese population
27647760|a|The number of heroin addicts is increasing in the world. Both environmental and genetic factors both play critical roles in the process of heroin addiction. We aimed to investigate the associations between single nucleotide polymorphisms (SNPs) in LIN7C, BDNFOS and BDNF genes and drug addiction in the Han Chinese population. We conducted a case-control study among 692 cases and 700 healthy controls from Xi'an, China. Eight SNPs were selected and genotyped using MassARRAY technology (Sequenom, San Diego, CA, USA). Odds ratios (OR) and 95% confidence intervals (CIs) were calculated by unconditional logistic regression adjusting for age and sex. Using the chi-squared test, we found that rs7481311 (OR =1.275, 95% CI = 1.087-1.497, p = 0.009) and rs11030096 (OR =1.227, 95% CI = 1.049-1.436, p = 0.011) in the BNDFOS were associated with an increased risk of heroin addiction. By contrast, rs988712 located in BDNFOS showed a decreased risk of heroin addiction (OR =0.734, 95% CI = 0.582-0.925, p = 0.003). By genetic model analysis, we found that the 'T' allele of rs988712 in BDNFOS had a protective role for heroin addiction in the additive model and dominant model (p < 0.05). By contrast, the allele 'T' of rs7481311 in BDNFOS significantly elevated the risk of heroin addiction in the additive model, recessive model and dominant model (p < 0.05). We also found that allele 'C ' of rs11030096 was associated with an increased risk of addiction in the dominant model and additive model (p < 0.05). Additionally, we found that rs6265, rs11030104 and rs10767664 in BDNF were associated with a decreased risk of heroin addiction (p < 0.05). However, only rs7481311 in BDNFOS remained significant after Bonferroni correction (p < 0.00625). These results suggest that polymorphisms of BDNFOS play an important role in heroin addiction susceptibility in the Chinese Han population.
27647760	4	16	relationship	T080	C0439849
27647760	25	38	polymorphisms	T045	C0032529
27647760	42	48	BDNFOS	T028	C1538322
27647760	53	63	BDNF genes	T028	C1332408
27647760	68	84	heroin addiction	T048	C0019337
27647760	92	114	Han Chinese population	UnknownType	C0814942
27647760	129	135	heroin	T109,T121,T131	C0011892
27647760	136	143	addicts	T101	C0858354
27647760	147	157	increasing	T169	C0442808
27647760	165	170	world	T098	C2700280
27647760	177	190	environmental	T080	C0686732
27647760	195	210	genetic factors	T080	C0814299
27647760	221	229	critical	T080	C1511545
27647760	243	250	process	T067	C1522240
27647760	254	270	heroin addiction	T048	C0019337
27647760	275	280	aimed	T078	C1947946
27647760	284	295	investigate	T169	C1292732
27647760	300	312	associations	T080	C0439849
27647760	321	352	single nucleotide polymorphisms	T086	C0752046
27647760	354	358	SNPs	T086	C0752046
27647760	363	368	LIN7C	T028	C1425077
27647760	370	376	BDNFOS	T028	C1538322
27647760	381	391	BDNF genes	T028	C1332408
27647760	396	410	drug addiction	T048	C1510472
27647760	418	440	Han Chinese population	UnknownType	C0814942
27647760	457	475	case-control study	T062	C0007328
27647760	486	491	cases	T169	C0868928
27647760	500	516	healthy controls	T080	C2986479
27647760	522	527	Xi'an	UnknownType	C0681784
27647760	529	534	China	T083	C0008115
27647760	542	546	SNPs	T086	C0752046
27647760	552	560	selected	T052	C1707391
27647760	565	574	genotyped	T059	C1285573
27647760	581	601	MassARRAY technology	T170	C0282574
27647760	603	611	Sequenom	T073,T092	C0683757
27647760	613	626	San Diego, CA	T083	C3828258
27647760	628	631	USA	T083	C0041703
27647760	634	645	Odds ratios	T081	C0028873
27647760	647	649	OR	T081	C0028873
27647760	659	679	confidence intervals	T081	C0009667
27647760	681	684	CIs	T081	C0009667
27647760	691	701	calculated	T052	C1441506
27647760	705	738	unconditional logistic regression	T062	C0206031
27647760	753	756	age	T032	C0001779
27647760	761	764	sex	T032	C0079399
27647760	776	792	chi-squared test	T170	C0008041
27647760	808	817	rs7481311	T028	C0678941
27647760	819	821	OR	T081	C0028873
27647760	834	836	CI	T081	C0009667
27647760	867	877	rs11030096	T028	C0678941
27647760	879	881	OR	T081	C0028873
27647760	894	896	CI	T081	C0009667
27647760	930	936	BNDFOS	T028	C1538322
27647760	942	957	associated with	T080	C0332281
27647760	961	970	increased	T081	C0205217
27647760	971	975	risk	T078	C0035647
27647760	979	995	heroin addiction	T048	C0019337
27647760	1010	1018	rs988712	T028	C0678941
27647760	1030	1036	BDNFOS	T028	C1538322
27647760	1046	1055	decreased	T081	C0205216
27647760	1056	1060	risk	T078	C0035647
27647760	1064	1080	heroin addiction	T048	C0019337
27647760	1082	1084	OR	T081	C0028873
27647760	1097	1099	CI	T081	C0009667
27647760	1130	1143	genetic model	T170	C0026343
27647760	1144	1152	analysis	T062	C0936012
27647760	1172	1182	'T' allele	T028	C0002085
27647760	1186	1194	rs988712	T028	C0678941
27647760	1198	1204	BDNFOS	T028	C1538322
27647760	1231	1247	heroin addiction	T048	C0019337
27647760	1255	1269	additive model	T170	C0026343
27647760	1274	1288	dominant model	T170	C0026343
27647760	1318	1328	allele 'T'	T028	C0002085
27647760	1332	1341	rs7481311	T028	C0678941
27647760	1345	1351	BDNFOS	T028	C1538322
27647760	1366	1374	elevated	T080	C3163633
27647760	1379	1383	risk	T078	C0035647
27647760	1387	1403	heroin addiction	T048	C0019337
27647760	1411	1425	additive model	T170	C0026343
27647760	1427	1442	recessive model	T170	C0026343
27647760	1447	1461	dominant model	T170	C0026343
27647760	1493	1502	allele 'C	T028	C0002085
27647760	1508	1518	rs11030096	T028	C0678941
27647760	1523	1538	associated with	T080	C0332281
27647760	1542	1551	increased	T081	C0205217
27647760	1552	1556	risk	T078	C0035647
27647760	1560	1569	addiction	T048	C0019337
27647760	1577	1591	dominant model	T170	C0026343
27647760	1596	1610	additive model	T170	C0026343
27647760	1651	1657	rs6265	T028	C0678941
27647760	1659	1669	rs11030104	T028	C0678941
27647760	1674	1684	rs10767664	T028	C0678941
27647760	1688	1692	BDNF	T028	C1332408
27647760	1698	1713	associated with	T080	C0332281
27647760	1716	1725	decreased	T081	C0205216
27647760	1726	1730	risk	T078	C0035647
27647760	1734	1750	heroin addiction	T048	C0019337
27647760	1777	1786	rs7481311	T028	C0678941
27647760	1790	1796	BDNFOS	T028	C1538322
27647760	1806	1817	significant	T078	C0750502
27647760	1824	1845	Bonferroni correction	T081	C2347434
27647760	1867	1874	results	T033	C2825142
27647760	1888	1901	polymorphisms	T045	C0032529
27647760	1905	1911	BDNFOS	T028	C1538322
27647760	1920	1929	important	T080	C3898777
27647760	1938	1954	heroin addiction	T048	C0019337
27647760	1955	1969	susceptibility	T169	C1264642
27647760	1977	1999	Chinese Han population	UnknownType	C0814942

27558793|t|Highly fluorescent gold nanoclusters stabilized by food proteins: From preparation to application in detection of food contaminants and bioactive nutrients
27558793|a|Applications of nanotechnology in food have rapidly increased in the past decades. Ultra-small gold nanoclusters (Au NCs), composed of several to roughly a hundred atoms, represent a kind of novel nanomaterials. The Au NCs directed by food proteins have drawn considerable research attention due to their environmentally friendly preparation, strong fluorescence, excellent photo-stability and favorable biocompatibility. These interesting protein-Au hybrids have opened up a new area at the nano-bio-food interface, not only did they provide the missing link between single metal atoms and plasmonic metal nanoparticles, but also developed the hybrid system between biomacromolecule and inorganic ions. In this review, we highlighted the synthesis strategies and optical properties of the Au NCs stabilized by typical food proteins as well as their applications in detection of food contaminants or bioactive nutrients. In addition, we discussed current challenges and future development in food proteins directed gold nanoclusters for size-controlled synthesis and multifunctional applications.
27558793	7	18	fluorescent	T070	C0016315
27558793	19	23	gold	T121,T196	C0018026
27558793	24	36	nanoclusters	T073	C1721060
27558793	51	64	food proteins	T116	C0012177
27558793	101	110	detection	T061	C1511790
27558793	114	118	food	T168	C0016452
27558793	119	131	contaminants	T167	C2827365
27558793	136	155	bioactive nutrients	T167	C3714412
27558793	172	186	nanotechnology	T090	C0872323
27558793	190	194	food	T168	C0016452
27558793	239	268	Ultra-small gold nanoclusters	T073	C1721060
27558793	270	276	Au NCs	T073	C1721060
27558793	353	366	nanomaterials	T073	C1450053
27558793	372	378	Au NCs	T073	C1721060
27558793	391	404	food proteins	T116	C0012177
27558793	461	497	environmentally friendly preparation	T057	C2350565
27558793	506	518	fluorescence	T070	C0016315
27558793	530	545	photo-stability	T080	C0205556
27558793	560	576	biocompatibility	T044	C0596177
27558793	596	614	protein-Au hybrids	T073	C1721059
27558793	648	671	nano-bio-food interface	T093	C1708333
27558793	724	742	single metal atoms	T196	C0567415
27558793	747	756	plasmonic	T062	C2603343
27558793	757	776	metal nanoparticles	T073	C1721060
27558793	801	814	hybrid system	T122	C1881073
27558793	823	839	biomacromolecule	T167	C1179809
27558793	844	853	inorganic	T077	C1881215
27558793	854	858	ions	T196	C0022023
27558793	895	904	synthesis	T052	C1883254
27558793	920	938	optical properties	T080	C0871161
27558793	946	952	Au NCs	T073	C1721060
27558793	975	988	food proteins	T116	C0012177
27558793	1022	1031	detection	T061	C1511790
27558793	1035	1039	food	T168	C0016452
27558793	1040	1052	contaminants	T167	C2827365
27558793	1056	1075	bioactive nutrients	T167	C3714412
27558793	1148	1161	food proteins	T116	C0012177
27558793	1171	1188	gold nanoclusters	T073	C1721060
27558793	1209	1218	synthesis	T052	C1883254

27601937|t|Molecular mechanism leading to SAHA - induced autophagy in tumor cells: evidence for a p53 -dependent pathway
27601937|a|Recent studies indicated that histone deacetylase inhibitors (HDACi), a class of anticancer agents, are in addition to their ability of apoptosis induction also capable of provoking autophagy. Promoted by the treatment of malignant uterine sarcoma cells with the HDACi suberoylanilide hydroxamic acid (SAHA), we previously demonstrated predominant dose-dependent activation of autophagy in ESS-1 cells, but prevalent induction of apoptosis in MES-SA cells. In order to extend our previous studies, SAHA - treated ESS-1 and MES-SA cells were monitored for protein expression to reveal differences in known markers of apoptosis explaining the different cytotoxic responses. Further analysis of the identified candidate protein included cell rescue experiments by gene transfer followed by subsequent screening of cells for induction of apoptosis and autophagy by immunoblotting, caspase activity as well as LC3 and MDC / PI staining. LDH release assays were performed to assess the amount of cell -mediated cytotoxicity. In our search for responsible autophagic regulatory genes upstream of mammalian target of rapamycin (mTOR), we now discovered that, in contrast to MES-SA cells, a TP53-637C>T nonsense mutation located in the transactivating domain of the oncogenic suppressor p53 causes loss of its protein and consequently reduced PUMA induction in ESS-1 cells. Upon re-introduction of wild-type TP53, SAHA - treated ESS-1 cells underwent immediate apoptotic cell death as supported by upregulation of PUMA and caspase-9 as well as by activation of caspases-3 and - 7 and PARP-1 cleavage. Concurrent downregulation of autophagy was noticed by upregulated mTor and phospho-mTOR expression as well as monitoring autophagosome formation employing LC3 and MDC staining. Previously, cytoplasmic master regulatory activities of the oncogenic suppressor p53 in inhibiting autophagy and triggering apoptosis were unravelled. Accordingly, p53 - deficiency could explain both, the previously documented apoptosis resistance and prevailing SAHA - induced autophagy in ESS-1 cells. Using MES-SA cells with RNAi-silenced p53 expression and several p53 - deficient tumor cell lines undergoing SAHA - induced autophagy, we could generally validate our finding suggesting an inhibitory role for p53 in the autophagic pathway in response to SAHA treatment. Conclusively, these results could identify cytoplasmic p53 protein as a molecular switch that directly mediates the cytotoxic response of SAHA and thus open new therapeutic avenues.
27601937	0	19	Molecular mechanism	T044	C3537153
27601937	31	35	SAHA	T109,T121	C0672708
27601937	38	45	induced	T169	C0205263
27601937	46	55	autophagy	T043	C0004391
27601937	59	70	tumor cells	T025	C0431085
27601937	87	90	p53	T116,T123	C0080055
27601937	102	109	pathway	T044	C1704259
27601937	117	124	studies	T062	C2603343
27601937	140	170	histone deacetylase inhibitors	T116,T121,T126	C1512474
27601937	172	177	HDACi	T116,T121,T126	C1512474
27601937	191	208	anticancer agents	T109,T121	C0003392
27601937	246	265	apoptosis induction	T043	C1326205
27601937	292	301	autophagy	T043	C0004391
27601937	319	328	treatment	T061	C0087111
27601937	332	341	malignant	T191	C0006826
27601937	342	357	uterine sarcoma	T191	C0338113
27601937	358	363	cells	T025	C0007634
27601937	373	378	HDACi	T116,T121,T126	C1512474
27601937	379	410	suberoylanilide hydroxamic acid	T109,T121	C0672708
27601937	412	416	SAHA	T109,T121	C0672708
27601937	458	472	dose-dependent	T081	C1512045
27601937	473	483	activation	T052	C1879547
27601937	487	496	autophagy	T043	C0004391
27601937	500	511	ESS-1 cells	T025	C0007600
27601937	527	536	induction	T169	C0205263
27601937	540	549	apoptosis	T043	C0162638
27601937	553	565	MES-SA cells	T025	C0007600
27601937	599	606	studies	T062	C2603343
27601937	608	612	SAHA	T109,T121	C0672708
27601937	615	622	treated	T169	C1522326
27601937	623	628	ESS-1	T025	C0007600
27601937	633	645	MES-SA cells	T025	C0007600
27601937	665	683	protein expression	T045	C1171362
27601937	715	722	markers	T201	C0005516
27601937	726	735	apoptosis	T043	C0162638
27601937	761	770	cytotoxic	T169	C1511636
27601937	771	780	responses	T032	C0871261
27601937	790	798	analysis	T062	C0936012
27601937	827	834	protein	T116,T123	C0033684
27601937	844	848	cell	T025	C0007634
27601937	856	867	experiments	T062	C0681814
27601937	871	884	gene transfer	T063	C1517499
27601937	921	926	cells	T025	C0007634
27601937	931	940	induction	T169	C0205263
27601937	944	953	apoptosis	T043	C0162638
27601937	958	967	autophagy	T043	C0004391
27601937	971	985	immunoblotting	T059	C0020985
27601937	987	1003	caspase activity	T044	C1150130
27601937	1015	1018	LC3	T116,T123	C1144120
27601937	1023	1026	MDC	T109,T121	C0066746
27601937	1029	1031	PI	T109,T130	C0033470
27601937	1032	1040	staining	T059	C0487602
27601937	1042	1045	LDH	T116,T126	C0022917
27601937	1054	1060	assays	T059	C0005507
27601937	1100	1104	cell	T025	C0007634
27601937	1115	1127	cytotoxicity	T049	C0596402
27601937	1159	1169	autophagic	T026	C0333781
27601937	1170	1186	regulatory genes	T028	C0017362
27601937	1199	1228	mammalian target of rapamycin	T028	C1414805
27601937	1230	1234	mTOR	T028	C1414805
27601937	1276	1288	MES-SA cells	T025	C0007600
27601937	1292	1303	TP53-637C>T	T045	C0026882
27601937	1304	1321	nonsense mutation	T049	C0544885
27601937	1337	1352	transactivating	T045	C0040624
27601937	1367	1391	oncogenic suppressor p53	T028	C0079419
27601937	1411	1418	protein	T116,T123	C0033684
27601937	1444	1448	PUMA	T116,T123	C1310243
27601937	1449	1458	induction	T169	C0205263
27601937	1462	1473	ESS-1 cells	T025	C0007600
27601937	1499	1508	wild-type	T028	C1883559
27601937	1509	1513	TP53	T028	C0079419
27601937	1515	1519	SAHA	T109,T121	C0672708
27601937	1522	1529	treated	T169	C1522326
27601937	1530	1541	ESS-1 cells	T025	C0007600
27601937	1562	1582	apoptotic cell death	T043	C0162638
27601937	1599	1611	upregulation	T044	C0041904
27601937	1615	1619	PUMA	T116,T123	C1310243
27601937	1624	1633	caspase-9	T116,T126	C0910167
27601937	1648	1658	activation	T052	C1879547
27601937	1662	1672	caspases-3	T116,T126	C0010656
27601937	1679	1680	7	T116,T126	C0010656
27601937	1685	1691	PARP-1	T116,T126	C1567710
27601937	1713	1727	downregulation	T044	C0013081
27601937	1731	1740	autophagy	T043	C0004391
27601937	1756	1767	upregulated	T044	C0041904
27601937	1768	1772	mTor	T116,T126	C1307407
27601937	1777	1789	phospho-mTOR	T116,T126	C1307407
27601937	1790	1800	expression	T045	C1171362
27601937	1823	1846	autophagosome formation	T043	C2611772
27601937	1857	1860	LC3	T116,T123	C1144120
27601937	1865	1868	MDC	T109,T121	C0066746
27601937	1869	1877	staining	T059	C0487602
27601937	1891	1902	cytoplasmic	T026	C0521449
27601937	1910	1920	regulatory	T038	C1327622
27601937	1921	1931	activities	T052	C0441655
27601937	1939	1963	oncogenic suppressor p53	T116,T123	C0080055
27601937	1967	1977	inhibiting	T052	C3463820
27601937	1978	1987	autophagy	T043	C0004391
27601937	2003	2012	apoptosis	T043	C0162638
27601937	2043	2046	p53	T116,T123	C0080055
27601937	2049	2059	deficiency	T169	C0011155
27601937	2106	2115	apoptosis	T043	C0162638
27601937	2116	2126	resistance	T039	C1514892
27601937	2142	2146	SAHA	T109,T121	C0672708
27601937	2149	2156	induced	T169	C0205263
27601937	2157	2166	autophagy	T043	C0004391
27601937	2170	2181	ESS-1 cells	T025	C0007600
27601937	2189	2201	MES-SA cells	T025	C0007600
27601937	2207	2220	RNAi-silenced	T045	C1136031
27601937	2221	2224	p53	T116,T123	C0080055
27601937	2225	2235	expression	T045	C1171362
27601937	2248	2251	p53	T116,T123	C0080055
27601937	2254	2263	deficient	T169	C0011155
27601937	2264	2280	tumor cell lines	T025	C0085983
27601937	2292	2296	SAHA	T109,T121	C0672708
27601937	2299	2306	induced	T169	C0205263
27601937	2307	2316	autophagy	T043	C0004391
27601937	2372	2382	inhibitory	T052	C3463820
27601937	2392	2395	p53	T116,T123	C0080055
27601937	2403	2413	autophagic	T026	C0333781
27601937	2414	2421	pathway	T044	C1704259
27601937	2437	2441	SAHA	T109,T121	C0672708
27601937	2442	2451	treatment	T061	C0087111
27601937	2496	2507	cytoplasmic	T026	C0521449
27601937	2508	2519	p53 protein	T116,T123	C0080055
27601937	2525	2541	molecular switch	T044	C3893721
27601937	2569	2578	cytotoxic	T169	C1511636
27601937	2579	2587	response	T032	C0871261
27601937	2591	2595	SAHA	T109,T121	C0672708
27601937	2614	2625	therapeutic	T061	C0087111

28492483|t|PCVMZM: Using the Probabilistic Classification Vector Machines Model Combined with a Zernike Moments Descriptor to Predict Protein-Protein Interactions from Protein Sequences
28492483|a|Protein-protein interactions (PPIs) are essential for most living organisms ' process. Thus, detecting PPIs is extremely important to understand the molecular mechanisms of biological systems. Although many PPIs data have been generated by high-throughput technologies for a variety of organisms, the whole interatom is still far from complete. In addition, the high-throughput technologies for detecting PPIs has some unavoidable defects, including time consumption, high cost, and high error rate. In recent years, with the development of machine learning, computational methods have been broadly used to predict PPIs, and can achieve good prediction rate. In this paper, we present here PCVMZM, a computational method based on a Probabilistic Classification Vector Machines (PCVM) model and Zernike moments (ZM) descriptor for predicting the PPIs from protein amino acids sequences. Specifically, a Zernike moments (ZM) descriptor is used to extract protein evolutionary information from Position-Specific Scoring Matrix (PSSM) generated by Position-Specific Iterated Basic Local Alignment Search Tool (PSI-BLAST). Then, PCVM classifier is used to infer the interactions among protein. When performed on PPIs datasets of Yeast and H. Pylori, the proposed method can achieve the average prediction accuracy of 94.48% and 91.25%, respectively. In order to further evaluate the performance of the proposed method, the state-of-the-art support vector machines (SVM) classifier is used and compares with the PCVM model. Experimental results on the Yeast dataset show that the performance of PCVM classifier is better than that of SVM classifier. The experimental results indicate that our proposed method is robust, powerful and feasible, which can be used as a helpful tool for proteomics research.
28492483	0	6	PCVMZM	T062	C1516769
28492483	18	100	Probabilistic Classification Vector Machines Model Combined with a Zernike Moments	T062	C1516769
28492483	115	122	Predict	T078	C0681842
28492483	123	151	Protein-Protein Interactions	T044	C0872079
28492483	157	174	Protein Sequences	T087	C0002518
28492483	175	203	Protein-protein interactions	T044	C0872079
28492483	205	209	PPIs	T044	C0872079
28492483	234	250	living organisms	T001	C0029235
28492483	278	282	PPIs	T044	C0872079
28492483	324	333	molecular	T080	C1521991
28492483	334	344	mechanisms	T169	C0441712
28492483	348	366	biological systems	T169	C0449913
28492483	382	386	PPIs	T044	C0872079
28492483	415	443	high-throughput technologies	T170	C0872047
28492483	461	470	organisms	T001	C0029235
28492483	537	565	high-throughput technologies	T170	C0872047
28492483	580	584	PPIs	T044	C0872079
28492483	594	613	unavoidable defects	T169	C1457869
28492483	625	641	time consumption	T079	C0040223
28492483	648	652	cost	T081	C0010186
28492483	663	673	error rate	T081	C0392762
28492483	716	732	machine learning	T066	C0376284
28492483	734	755	computational methods	T062	C1516769
28492483	790	794	PPIs	T044	C0872079
28492483	817	827	prediction	T078	C0681842
28492483	865	871	PCVMZM	T062	C1516769
28492483	875	895	computational method	T062	C1516769
28492483	907	964	Probabilistic Classification Vector Machines (PCVM) model	T081	C2699740
28492483	969	1000	Zernike moments (ZM) descriptor	T081,T170	C0026346
28492483	1005	1015	predicting	T078	C0681842
28492483	1020	1024	PPIs	T044	C0872079
28492483	1030	1037	protein	T116,T123	C0033684
28492483	1038	1059	amino acids sequences	T087	C0002518
28492483	1077	1108	Zernike moments (ZM) descriptor	T081,T170	C0026346
28492483	1128	1135	protein	T116,T123	C0033684
28492483	1149	1160	information	T078	C1533716
28492483	1166	1198	Position-Specific Scoring Matrix	T081	C2717845
28492483	1200	1204	PSSM	T081	C2717845
28492483	1219	1291	Position-Specific Iterated Basic Local Alignment Search Tool (PSI-BLAST)	T170	C2698333
28492483	1299	1314	PCVM classifier	T081	C2699740
28492483	1336	1348	interactions	T044	C0872079
28492483	1355	1362	protein	T116,T123	C0033684
28492483	1382	1386	PPIs	T044	C0872079
28492483	1399	1404	Yeast	T004	C0043393
28492483	1409	1418	H. Pylori	T007	C0079488
28492483	1464	1474	prediction	T078	C0681842
28492483	1475	1483	accuracy	T080	C0443131
28492483	1593	1609	state-of-the-art	T170	C0038199
28492483	1610	1633	support vector machines	T081	C2699740
28492483	1635	1650	SVM) classifier	T081	C2699740
28492483	1681	1691	PCVM model	T081	C2699740
28492483	1693	1713	Experimental results	T033	C2825142
28492483	1721	1726	Yeast	T004	C0043393
28492483	1764	1779	PCVM classifier	T081	C2699740
28492483	1803	1817	SVM classifier	T081	C2699740
28492483	1823	1843	experimental results	T033	C2825142
28492483	1952	1971	proteomics research	T062	C0035168

27514242|t|Botulinum Toxin Use in Refractory Pain and Other Symptoms in Parkinsonism
27514242|a|Parkinson's disease (PD) and other parkinsonian syndromes are chronic, progressive neurodegenerative diseases. With advancing disease, both motor and non-motor symptoms represent a considerable burden and symptom relief and quality of life improvement become the main goal of treatment. Botulinum toxins (BTX) are an effective treatment modality for many neurological conditions. To understand the potential usefulness of BTX in this population, we performed a retrospective chart review of all patients with a clinical diagnosis of idiopathic PD and atypical parkinsonism who received treatment with BTX injections in our center from 1995 to 2014 for a variety of symptoms. Response to BTX was assessed using a subjective Clinical Global Impression. Records of 160 patients were reviewed. Probable idiopathic PD was the diagnosis in 117 patients (73.1%). The main indication for BTX treatment was pain (50.6% of cases). Other indications were the treatment of functional impairment resulting from dystonia (26.25%), sialorrhea (18.75%), freezing of gait, and camptocormia. Considering pain as indication, 81% of all patients with PD reported benefits after the first BTX injections. This benefit was maintained after the last recorded visit without significant difference in outcome compared with the first injection (p=0.067). Similar results were observed in patients with atypical parkinsonism. Our results confirm the safety and efficacy of different uses of BTX in the symptomatic treatment of patients with parkinsonism even in advanced stages of the disease, and suggest BTX treatment could have a safe and useful role in the treatment of pain in this population.
27514242	0	15	Botulinum Toxin	T116,T121,T131	C0006055
27514242	23	38	Refractory Pain	T184	C0030200
27514242	49	57	Symptoms	T184	C1457887
27514242	61	73	Parkinsonism	T047	C0242422
27514242	74	93	Parkinson's disease	T047	C0030567
27514242	95	97	PD	T047	C0030567
27514242	109	131	parkinsonian syndromes	T047	C0242422
27514242	136	143	chronic	T079	C0205191
27514242	145	156	progressive	T169	C0205329
27514242	157	183	neurodegenerative diseases	T047	C0524851
27514242	200	207	disease	T047	C0012634
27514242	214	219	motor	T184	C0426980
27514242	224	242	non-motor symptoms	T184	C1457887
27514242	268	274	burden	T078	C2828008
27514242	279	286	symptom	T184	C1457887
27514242	287	293	relief	T033	C0564405
27514242	298	313	quality of life	T078	C0034380
27514242	314	325	improvement	T077	C2986411
27514242	342	346	goal	T170	C0018017
27514242	350	359	treatment	T061	C0087111
27514242	361	377	Botulinum toxins	T116,T121,T131	C0006055
27514242	379	382	BTX	T116,T121,T131	C0006055
27514242	391	400	effective	T080	C1704419
27514242	401	410	treatment	T061	C0087111
27514242	411	419	modality	T078	C0695347
27514242	429	452	neurological conditions	T047	C0027765
27514242	472	481	potential	T080	C3245505
27514242	482	492	usefulness	T080	C3827682
27514242	496	499	BTX	T116,T121,T131	C0006055
27514242	508	518	population	T098	C1257890
27514242	523	532	performed	T169	C0884358
27514242	535	548	retrospective	T080	C1514923
27514242	549	561	chart review	T058	C0541653
27514242	569	577	patients	T101	C0030705
27514242	585	603	clinical diagnosis	T060	C0332140
27514242	607	620	idiopathic PD	T047	C0865475
27514242	625	646	atypical parkinsonism	T047	C4302185
27514242	660	669	treatment	T169	C0039798
27514242	675	689	BTX injections	T061	C1321035
27514242	697	703	center	T093	C1708333
27514242	739	747	symptoms	T184	C1457887
27514242	749	757	Response	T032	C0871261
27514242	761	764	BTX	T116,T121,T131	C0006055
27514242	769	777	assessed	T052	C1516048
27514242	786	823	subjective Clinical Global Impression	T170	C3639708
27514242	825	832	Records	T170	C0034869
27514242	840	848	patients	T101	C0030705
27514242	854	862	reviewed	T080	C1709940
27514242	873	886	idiopathic PD	T047	C0865475
27514242	895	904	diagnosis	T033	C0011900
27514242	912	920	patients	T101	C0030705
27514242	939	949	indication	T078	C3146298
27514242	954	957	BTX	T116,T121,T131	C0006055
27514242	958	967	treatment	T061	C0087111
27514242	972	976	pain	T184	C0030193
27514242	1001	1012	indications	T078	C3146298
27514242	1022	1031	treatment	T061	C0087111
27514242	1035	1056	functional impairment	T033	C4062321
27514242	1057	1066	resulting	T169	C0678226
27514242	1072	1080	dystonia	T184	C0013421
27514242	1091	1101	sialorrhea	T047	C0037036
27514242	1112	1128	freezing of gait	T184	C0860515
27514242	1134	1146	camptocormia	T020	C0264162
27514242	1160	1164	pain	T184	C0030193
27514242	1168	1178	indication	T078	C3146298
27514242	1191	1199	patients	T101	C0030705
27514242	1205	1207	PD	T047	C0030567
27514242	1208	1216	reported	T058	C0700287
27514242	1217	1225	benefits	T081	C0814225
27514242	1242	1256	BTX injections	T061	C1321035
27514242	1263	1270	benefit	T081	C0814225
27514242	1275	1285	maintained	T169	C1314677
27514242	1296	1315	last recorded visit	T058	C1512346
27514242	1336	1346	difference	T080	C1705242
27514242	1350	1357	outcome	T169	C1274040
27514242	1358	1366	compared	T052	C1707455
27514242	1382	1391	injection	T061	C0021485
27514242	1411	1418	results	T169	C1274040
27514242	1436	1444	patients	T101	C0030705
27514242	1450	1471	atypical parkinsonism	T047	C4302185
27514242	1477	1484	results	T169	C1274040
27514242	1508	1516	efficacy	T080	C1280519
27514242	1520	1529	different	T080	C1705242
27514242	1530	1534	uses	T169	C0457083
27514242	1538	1541	BTX	T116,T121,T131	C0006055
27514242	1549	1560	symptomatic	T169	C0231220
27514242	1561	1570	treatment	T169	C1522326
27514242	1574	1582	patients	T101	C0030705
27514242	1588	1600	parkinsonism	T047	C0242422
27514242	1609	1617	advanced	T080	C0205179
27514242	1618	1624	stages	T079	C1306673
27514242	1632	1639	disease	T047	C0012634
27514242	1645	1652	suggest	T078	C1705535
27514242	1653	1656	BTX	T116,T121,T131	C0006055
27514242	1657	1666	treatment	T061	C0087111
27514242	1696	1700	role	T077	C1705810
27514242	1708	1717	treatment	T169	C1522326
27514242	1721	1725	pain	T184	C0030193
27514242	1734	1744	population	T098	C1257890

27254091|t|Using Evolutionary Theory to Guide Mental Health Research
27254091|a|Evolutionary approaches to medicine can shed light on the origins and etiology of disease. Such an approach may be especially useful in psychiatry, which frequently addresses conditions with heterogeneous presentation and unknown causes. We review several previous applications of evolutionary theory that highlight the ways in which psychiatric conditions may persist despite and because of natural selection. One lesson from the evolutionary approach is that some conditions currently classified as disorders (because they cause distress and impairment) may actually be caused by functioning adaptations operating " normally " (as designed by natural selection). Such conditions suggest an alternative illness model that may generate alternative intervention strategies. Thus, the evolutionary approach suggests that psychiatry should sometimes think differently about distress and impairment. The complexity of the human brain, including normal functioning and potential for dysfunctions, has developed over evolutionary time and has been shaped by natural selection. Understanding the evolutionary origins of psychiatric conditions is therefore a crucial component to a complete understanding of etiology.
27254091	6	25	Evolutionary Theory	T170	C0237604
27254091	35	48	Mental Health	T041	C0025353
27254091	49	57	Research	T062	C0035168
27254091	58	81	Evolutionary approaches	T082	C0449445
27254091	85	93	medicine	T091	C0025118
27254091	98	108	shed light	T052	C2986669
27254091	116	123	origins	T079	C0439659
27254091	128	147	etiology of disease	T169	C1314792
27254091	157	165	approach	T082	C0449445
27254091	194	204	psychiatry	T058	C3526598
27254091	233	243	conditions	T080	C0348080
27254091	249	262	heterogeneous	T080	C0019409
27254091	280	294	unknown causes	T033	C3840856
27254091	299	305	review	T078	C1552617
27254091	323	335	applications	UnknownType	C0869019
27254091	339	358	evolutionary theory	T170	C0237604
27254091	392	414	psychiatric conditions	T047	C1718246
27254091	450	467	natural selection	T070	C0086685
27254091	489	510	evolutionary approach	T082	C0449445
27254091	524	534	conditions	T080	C0348080
27254091	545	555	classified	T185	C0008902
27254091	559	568	disorders	T048	C0004936
27254091	589	597	distress	T033	C0231303
27254091	602	612	impairment	T046	C0684336
27254091	640	651	functioning	T169	C0205245
27254091	652	663	adaptations	T038	C0392673
27254091	676	684	normally	T080	C0205307
27254091	703	720	natural selection	T070	C0086685
27254091	728	738	conditions	T080	C0348080
27254091	762	775	illness model	T050	C0684309
27254091	806	829	intervention strategies	T061	C0184661
27254091	841	862	evolutionary approach	T082	C0449445
27254091	877	887	psychiatry	T058	C3526598
27254091	911	922	differently	T080	C1705242
27254091	929	937	distress	T033	C0231303
27254091	942	952	impairment	T046	C0684336
27254091	958	968	complexity	T080	C0439855
27254091	976	981	human	T016	C0086418
27254091	982	987	brain	T023	C0006104
27254091	999	1005	normal	T080	C0205307
27254091	1006	1017	functioning	T042	C0678908
27254091	1022	1031	potential	T080	C3245505
27254091	1036	1048	dysfunctions	T047	C0262405
27254091	1069	1086	evolutionary time	T079	C0040223
27254091	1110	1127	natural selection	T070	C0086685
27254091	1147	1167	evolutionary origins	T079	C0439659
27254091	1171	1193	psychiatric conditions	T047	C1718246
27254091	1209	1216	crucial	T080	C1511545
27254091	1217	1226	component	T077	C1705248
27254091	1258	1266	etiology	T169	C1314792

27549420|t|Establishing in- hospital geriatrics services in Africa: Insights from the University of Benin Teaching Hospital geriatrics project
27549420|a|Unawareness of the peculiar healthcare needs of the elderly and resource constraints may be some reasons why until recently, Nigerian hospitals have not been equipped with the human and infrastructural resources required to meet older adults ' special healthcare needs. There is paucity of specialized health services for the elderly in Africa. Nigeria, with a population of over 170 million, did not have any healthcare facility with dedicated services for the elderly until 2012. The University of Benin Teaching Hospital (UBTH) in Nigeria was established in 1973 and created its geriatrics unit in October 2013. A prepared environment and trained interdisciplinary teams are pivotal in providing effective healthcare services for the elderly. The ongoing UBTH geriatrics project aims to provide specialized interdisciplinary health services to older adults and to provide training and continuing professional development in geriatrics for healthcare staff. In developing our inpatient services, we adopted the acute care for elders (ACE) model and worked in tandem with the "ABCs" of implementing ACE units. In the face of limited resources, it was possible to establish a functional geriatrics unit with a trained interdisciplinary team. Family participation is central in our practice. Since October 2013, residents and house officers in internal medicine have been undertaking 4- and 12- weekly rotations, respectively. There is also a robust academic program, which includes once- weekly geriatric pharmacotherapy seminars, once- weekly interdisciplinary seminars, and 2- weekly journal club meetings alternating with seminars on geriatric assessment tools. It is possible to establish geriatric services and achieve best practices in resource-limited settings by investing on improving available human resources and infrastructure. We also make recommendations for setting up similar services in other parts of Africa.
27549420	17	25	hospital	T073,T093	C0019994
27549420	26	45	geriatrics services	T093	C4041524
27549420	49	55	Africa	T083	C0001737
27549420	75	112	University of Benin Teaching Hospital	T073,T093	C0019994
27549420	113	123	geriatrics	T091	C0017469
27549420	124	131	project	T077	C1709701
27549420	160	170	healthcare	T058	C0086388
27549420	171	176	needs	T080	C0027552
27549420	184	191	elderly	T098	C0001792
27549420	196	204	resource	T078	C0035201
27549420	205	216	constraints	T169	C0443288
27549420	257	265	Nigerian	T083	C0028075
27549420	266	275	hospitals	T073,T093	C0019994
27549420	308	313	human	T081	C0700103
27549420	318	343	infrastructural resources	T081	C0392762
27549420	361	373	older adults	T098	C0001792
27549420	384	394	healthcare	T058	C0086388
27549420	395	400	needs	T080	C0027552
27549420	434	449	health services	T093	C0557829
27549420	458	465	elderly	T098	C0001792
27549420	469	475	Africa	T083	C0001737
27549420	477	484	Nigeria	T083	C0028075
27549420	493	503	population	T098	C1257890
27549420	542	561	healthcare facility	T073,T093	C0018704
27549420	577	585	services	T058	C1704289
27549420	594	601	elderly	T098	C0001792
27549420	618	655	University of Benin Teaching Hospital	T073,T093	C0019994
27549420	657	661	UBTH	T073,T093	C0019994
27549420	666	673	Nigeria	T083	C0028075
27549420	714	724	geriatrics	T091	C0017469
27549420	774	805	trained interdisciplinary teams	T058	C0086390
27549420	841	860	healthcare services	T093	C0557829
27549420	869	876	elderly	T098	C0001792
27549420	890	894	UBTH	T073,T093	C0019994
27549420	895	905	geriatrics	T091	C0017469
27549420	906	913	project	T077	C1709701
27549420	942	959	interdisciplinary	T058	C0597720
27549420	960	975	health services	T058	C0018747
27549420	979	991	older adults	T098	C0001792
27549420	1007	1015	training	T065	C0220931
27549420	1031	1055	professional development	T057	C0871147
27549420	1059	1069	geriatrics	T091	C0017469
27549420	1074	1090	healthcare staff	T097	C0557570
27549420	1110	1119	inpatient	T101	C0021562
27549420	1120	1128	services	T058	C1704289
27549420	1145	1166	acute care for elders	T058	C0683810
27549420	1168	1171	ACE	T058	C0683810
27549420	1173	1178	model	T170	C0596657
27549420	1232	1241	ACE units	T170	C0596657
27549420	1266	1275	resources	T078	C0035201
27549420	1319	1334	geriatrics unit	T091	C0017469
27549420	1350	1372	interdisciplinary team	T058	C0086390
27549420	1374	1380	Family	T099	C0015576
27549420	1381	1394	participation	T169	C0679823
27549420	1413	1421	practice	T091	C0086343
27549420	1443	1452	residents	T098	C2347958
27549420	1457	1471	house officers	T097	C0401975
27549420	1475	1492	internal medicine	T121	C0013227
27549420	1526	1532	weekly	T079	C0332174
27549420	1533	1542	rotations	T169	C0035868
27549420	1581	1597	academic program	T033	C3844065
27549420	1620	1626	weekly	T079	C0332174
27549420	1627	1636	geriatric	T080	C1704440
27549420	1637	1652	pharmacotherapy	T061	C0013216
27549420	1653	1661	seminars	T058	C2029815
27549420	1669	1675	weekly	T079	C0332174
27549420	1694	1702	seminars	T058	C2029815
27549420	1711	1717	weekly	T079	C0332174
27549420	1718	1739	journal club meetings	T052	C0556656
27549420	1757	1765	seminars	T058	C2029815
27549420	1769	1795	geriatric assessment tools	T170	C2585718
27549420	1825	1843	geriatric services	T093	C4041524
27549420	1861	1870	practices	T091	C0086343
27549420	1936	1951	human resources	T081	C0700103
27549420	1956	1970	infrastructure	T185	C1514880
27549420	2024	2032	services	T093	C0557829
27549420	2051	2057	Africa	T083	C0001737

27608043|t|Antibiotic Treatment in End-of-Life Cancer Patients -A Retrospective Observational Study at a Palliative Care Center in Sweden
27608043|a|The aim of this study was to elucidate whether palliative cancer patients benefit from antibiotic treatment in the last two weeks of life when an infection is suspected. We reviewed medical records from 160 deceased palliative cancer patients that had been included in previous studies on vitamin D and infections. Patients treated with antibiotics during the last two weeks of life were identified and net effects of treatment (symptom relief) and possible adverse events were extracted from medical records. Seventy-nine patients (49%) had been treated with antibiotics during the last two weeks in life. In 37% (n = 29), the treatment resulted in evident symptom relief and among these 50% had a positive bacterial culture, 43% had a negative culture and in 7% no culture was taken. Among the patients with no or unknown effect of antibiotics, 50% had a positive culture. When the indication for antibiotic treatment was to avoid or treat sepsis, symptom relief was achieved in 50% of the patients (n = 19). Only 4% (n = 3) of the patients experienced adverse events of the treatment (diarrhea, nausea). Treating infections with antibiotics in the last weeks of life may improve the quality of life for palliative cancer patients, especially if sepsis is suspected or confirmed. According to our results, the beneficial effects outweigh the potentially negative outcomes.
27608043	0	20	Antibiotic Treatment	T061	C0338237
27608043	24	35	End-of-Life	T058	C0039548
27608043	36	51	Cancer Patients	T101	C1516213
27608043	55	68	Retrospective	T062	C0035363
27608043	69	88	Observational Study	T062	C1518527
27608043	94	116	Palliative Care Center	T093	C0587605
27608043	120	126	Sweden	T083	C0038995
27608043	131	134	aim	T078	C1947946
27608043	143	148	study	T062	C2603343
27608043	174	184	palliative	T080	C1285530
27608043	185	200	cancer patients	T101	C1516213
27608043	214	234	antibiotic treatment	T061	C0338237
27608043	251	256	weeks	T079	C0439230
27608043	260	264	life	T078	C0376558
27608043	273	282	infection	T046	C3714514
27608043	286	295	suspected	T080	C0332147
27608043	309	324	medical records	T170	C0025102
27608043	343	353	palliative	T080	C1285530
27608043	354	369	cancer patients	T101	C1516213
27608043	405	412	studies	T062	C2603343
27608043	416	425	vitamin D	T109,T121,T127	C0042866
27608043	430	440	infections	T046	C3714514
27608043	442	450	Patients	T101	C0030705
27608043	451	463	treated with	T061	C0332293
27608043	464	475	antibiotics	T195	C0003232
27608043	496	501	weeks	T079	C0439230
27608043	505	509	life	T078	C0376558
27608043	545	554	treatment	T061	C0087111
27608043	556	563	symptom	T184	C1457887
27608043	564	570	relief	T033	C0564405
27608043	585	599	adverse events	T046	C0877248
27608043	620	635	medical records	T170	C0025102
27608043	650	658	patients	T101	C0030705
27608043	674	686	treated with	T061	C0332293
27608043	687	698	antibiotics	T195	C0003232
27608043	719	724	weeks	T079	C0439230
27608043	728	732	life	T078	C0376558
27608043	755	764	treatment	T061	C0087111
27608043	785	792	symptom	T184	C1457887
27608043	793	799	relief	T033	C0564405
27608043	826	852	positive bacterial culture	T034	C1142047
27608043	864	880	negative culture	T034	C0855652
27608043	891	901	no culture	T033	C0243095
27608043	923	931	patients	T101	C0030705
27608043	961	972	antibiotics	T195	C0003232
27608043	984	1000	positive culture	T034	C1142047
27608043	1026	1046	antibiotic treatment	T061	C0338237
27608043	1063	1068	treat	T061	C0087111
27608043	1069	1075	sepsis	T047	C0243026
27608043	1077	1084	symptom	T184	C1457887
27608043	1085	1091	relief	T033	C0564405
27608043	1119	1127	patients	T101	C0030705
27608043	1161	1169	patients	T101	C0030705
27608043	1182	1196	adverse events	T046	C0877248
27608043	1204	1213	treatment	T061	C0087111
27608043	1215	1223	diarrhea	T184	C0011991
27608043	1225	1231	nausea	T184	C0027497
27608043	1234	1242	Treating	T169	C1522326
27608043	1243	1253	infections	T046	C3714514
27608043	1259	1270	antibiotics	T195	C0003232
27608043	1283	1288	weeks	T079	C0439230
27608043	1292	1296	life	T078	C0376558
27608043	1313	1320	quality	T080	C0332306
27608043	1324	1328	life	T078	C0376558
27608043	1333	1343	palliative	T080	C1285530
27608043	1344	1359	cancer patients	T101	C1516213
27608043	1375	1381	sepsis	T047	C0243026
27608043	1385	1394	suspected	T080	C0332147
27608043	1426	1433	results	T033	C0683954
27608043	1439	1457	beneficial effects	UnknownType	C0683156
27608043	1492	1500	outcomes	T080	C0085415

27669294|t|Triceps and Subscapular Skinfold Thickness Percentiles and Cut-Offs for Overweight and Obesity in a Population-Based Sample of Schoolchildren and Adolescents in Bogota, Colombia
27669294|a|The assessment of skinfold thickness is an objective measure of adiposity. The aims of this study were to establish Colombian smoothed centile charts and LMS L (Box-Cox transformation), M (median), and S (coefficient of variation) tables for triceps, subscapular, and triceps + subscapular skinfolds; appropriate cut-offs were selected using receiver operating characteristic (ROC) analysis based on a population-based sample of children and adolescents in Bogotá, Colombia. A cross-sectional study was conducted in 9618 children and adolescents (55.7% girls; age range of 9-17.9 years). Triceps and subscapular skinfold measurements were obtained using standardized methods. We calculated the triceps + subscapular skinfold (T + SS) sum. Smoothed percentile curves for triceps and subscapular skinfold thickness were derived using the LMS method. ROC curve analyses were used to evaluate the optimal cut-off point of skinfold thickness for overweight and obesity, based on the International Obesity Task Force definitions. Subscapular and triceps skinfolds and T + SS were significantly higher in girls than in boys (p < 0.001). The ROC analysis showed that subscapular and triceps skinfolds and T + SS have a high discriminatory power in the identification of overweight and obesity in the sample population in this study. Our results provide sex - and age -specific normative reference standards for skinfold thickness values from a population from Bogotá, Colombia.
27669294	0	7	Triceps	T023	C3146295
27669294	12	42	Subscapular Skinfold Thickness	T033	C0518023
27669294	43	54	Percentiles	T081	C1264641
27669294	72	82	Overweight	T184	C0497406
27669294	87	94	Obesity	T047	C0028754
27669294	100	123	Population-Based Sample	T081	C1709598
27669294	127	141	Schoolchildren	T100	C0260267
27669294	146	157	Adolescents	T100	C0205653
27669294	161	167	Bogota	T083	C0017446
27669294	169	177	Colombia	T083	C3245499
27669294	182	192	assessment	T052	C1516048
27669294	196	214	skinfold thickness	T060	C0037302
27669294	231	238	measure	T081	C0079809
27669294	242	251	adiposity	T032	C1563743
27669294	294	303	Colombian	T098	C1553372
27669294	304	327	smoothed centile charts	T170	C0684240
27669294	332	335	LMS	T081	C0392762
27669294	339	361	Box-Cox transformation	T081	C0392762
27669294	367	373	median	T081	C0876920
27669294	383	407	coefficient of variation	T081	C0681921
27669294	409	415	tables	T170	C1706074
27669294	420	427	triceps	T023	C3146295
27669294	429	440	subscapular	T023	C0229962
27669294	446	453	triceps	T201	C0518022
27669294	456	477	subscapular skinfolds	T033	C0518023
27669294	520	553	receiver operating characteristic	T081	C0034772
27669294	555	558	ROC	T081	C0034772
27669294	560	568	analysis	T062	C0936012
27669294	580	603	population-based sample	T081	C1709598
27669294	607	615	children	T100	C0008059
27669294	620	631	adolescents	T100	C0205653
27669294	635	641	Bogotá	T083	C0017446
27669294	643	651	Colombia	T083	C3245499
27669294	655	676	cross-sectional study	T062	C0010362
27669294	699	707	children	T100	C0008059
27669294	712	723	adolescents	T100	C0205653
27669294	731	736	girls	T100	C0870604
27669294	738	741	age	T032	C0001779
27669294	758	763	years	T079	C0439234
27669294	766	773	Triceps	T023	C3146295
27669294	778	789	subscapular	T023	C0229962
27669294	790	811	skinfold measurements	T058	C1963769
27669294	845	852	methods	T170	C0025663
27669294	872	879	triceps	T201	C0518022
27669294	882	902	subscapular skinfold	T033	C0518023
27669294	904	905	T	T201	C0518022
27669294	908	910	SS	T033	C0518023
27669294	917	943	Smoothed percentile curves	T082	C0205134
27669294	948	955	triceps	T023	C3146295
27669294	960	990	subscapular skinfold thickness	T033	C0518023
27669294	1014	1024	LMS method	T170	C0025663
27669294	1026	1035	ROC curve	T081	C0035787
27669294	1036	1044	analyses	T062	C0936012
27669294	1096	1114	skinfold thickness	T060	C0037302
27669294	1119	1129	overweight	T184	C0497406
27669294	1134	1141	obesity	T047	C0028754
27669294	1156	1200	International Obesity Task Force definitions	T170	C1704788
27669294	1202	1213	Subscapular	T033	C0518023
27669294	1218	1235	triceps skinfolds	T201	C0518022
27669294	1240	1241	T	T201	C0518022
27669294	1244	1246	SS	T033	C0518023
27669294	1276	1281	girls	T100	C0870604
27669294	1290	1294	boys	T100	C0870221
27669294	1312	1315	ROC	T081	C0034772
27669294	1316	1324	analysis	T062	C0936012
27669294	1337	1348	subscapular	T033	C0518023
27669294	1353	1370	triceps skinfolds	T201	C0518022
27669294	1375	1376	T	T201	C0518022
27669294	1379	1381	SS	T033	C0518023
27669294	1422	1436	identification	T041	C0020792
27669294	1440	1450	overweight	T184	C0497406
27669294	1455	1462	obesity	T047	C0028754
27669294	1470	1487	sample population	T098	C2348150
27669294	1496	1501	study	T062	C2603343
27669294	1523	1526	sex	T032	C1522384
27669294	1533	1536	age	T032	C0001779
27669294	1557	1576	reference standards	T081	C0034925
27669294	1581	1599	skinfold thickness	T060	C0037302
27669294	1600	1606	values	T081	C1522609
27669294	1614	1624	population	T098	C1257890
27669294	1630	1636	Bogotá	T083	C0017446
27669294	1638	1646	Colombia	T083	C3245499

27659457|t|Prognostic significance of blood pressure response during vasodilator stress Rb-82 positron emission tomography myocardial perfusion imaging
27659457|a|A drop in blood pressure (BP) or blunted BP response is an established high-risk marker during exercise myocardial perfusion imaging (MPI); however, data are sparse regarding the prognostic value of BP response in patients undergoing vasodilator stress rubidium-82 (Rb-82) Positron Emission Tomography (PET) MPI. From the PET Prognosis Multicenter Registry, a cohort of 3413 patients underwent vasodilator stress Rb-82 PET MPI with dipyridamole or adenosine. We used multivariable Cox proportional hazard regression to analyze the association with mortality of four BP variables: stress minus rest systolic BP (∆SBP), stress minus rest diastolic BP (∆DBP), resting systolic BP (rSBP), and resting diastolic BP (rDBP). Covariates that had univariate P values <.10 were entered into the multivariable model. After median 1.7 years follow-up, 270 patients died. In univariate analyses, ∆SBP (P = .082), rSBP (P = .008), and rDBP (P < .001) were of potential prognostic value (P < .10), but ∆DBP was not (P = .96). After adjustment for other clinical and MPI variables, ∆SBP no longer independently predicted mortality (P = .082); only lower rSBP (P = .026) and lower rDBP (P = .045) remained independently prognostic. In patients undergoing vasodilator stress MPI, only lower resting BP is an independent predictor of mortality along with other clinical and MPI variables; BP response does not appear to add to risk stratification in these patients.
27659457	0	10	Prognostic	T170	C0220901
27659457	11	23	significance	T078	C0750502
27659457	27	50	blood pressure response	T201	C1997183
27659457	58	140	vasodilator stress Rb-82 positron emission tomography myocardial perfusion imaging	T060	C3525535
27659457	143	147	drop	T081	C0547047
27659457	151	165	blood pressure	T040	C0005823
27659457	167	169	BP	T040	C0005823
27659457	174	181	blunted	T080	C1997138
27659457	182	184	BP	T040	C0005823
27659457	185	193	response	T032	C0871261
27659457	212	228	high-risk marker	T080	C1514475
27659457	236	244	exercise	T056	C0015259
27659457	245	273	myocardial perfusion imaging	T060	C2350390
27659457	275	278	MPI	T060	C2350390
27659457	290	294	data	T078	C1511726
27659457	320	330	prognostic	T170	C0220901
27659457	331	336	value	T081	C1522609
27659457	340	342	BP	T040	C0005823
27659457	343	351	response	T032	C0871261
27659457	355	363	patients	T101	C0030705
27659457	375	452	vasodilator stress rubidium-82 (Rb-82) Positron Emission Tomography (PET) MPI	T060	C3525535
27659457	444	447	PET	T060	C0032743
27659457	463	466	PET	T060	C0032743
27659457	467	497	Prognosis Multicenter Registry	T062	C0920631
27659457	501	507	cohort	T098	C0599755
27659457	516	524	patients	T101	C0030705
27659457	535	567	vasodilator stress Rb-82 PET MPI	T060	C3525535
27659457	573	585	dipyridamole	T109,T121	C0012582
27659457	589	598	adenosine	T114,T121,T123	C0001443
27659457	608	656	multivariable Cox proportional hazard regression	T080	C0681923
27659457	672	688	association with	T080	C0332281
27659457	689	698	mortality	T081	C0205848
27659457	707	709	BP	T040	C0005823
27659457	710	719	variables	T080	C0439828
27659457	721	727	stress	T033	C2039712
27659457	734	750	rest systolic BP	T033	C2039694
27659457	752	756	∆SBP	T060	C1306620
27659457	759	765	stress	T033	C2183325
27659457	772	789	rest diastolic BP	T033	C2183311
27659457	791	795	∆DBP	T060	C1306620
27659457	798	817	resting systolic BP	T033	C2036238
27659457	819	823	rSBP	T033	C2036238
27659457	830	850	resting diastolic BP	T033	C2036196
27659457	852	856	rDBP	T033	C2036196
27659457	859	869	Covariates	T080	C0205556
27659457	879	889	univariate	T080	C0205556
27659457	892	898	values	T081	C1522609
27659457	926	945	multivariable model	T081,T170	C0023965
27659457	953	959	median	T082	C2939193
27659457	964	969	years	T079	C0439234
27659457	985	993	patients	T101	C0030705
27659457	994	998	died	T033	C1306577
27659457	1003	1022	univariate analyses	T062	C0683962
27659457	1024	1028	∆SBP	T060	C1306620
27659457	1041	1045	rSBP	T033	C2036238
27659457	1062	1066	rDBP	T033	C2036196
27659457	1096	1106	prognostic	T170	C0220901
27659457	1107	1112	value	T081	C1522609
27659457	1128	1132	∆DBP	T060	C1306620
27659457	1179	1187	clinical	T080	C0205210
27659457	1192	1195	MPI	T060	C2350390
27659457	1196	1205	variables	T080	C0439828
27659457	1207	1211	∆SBP	T060	C1306620
27659457	1246	1255	mortality	T081	C0205848
27659457	1279	1283	rSBP	T033	C2036238
27659457	1305	1309	rDBP	T033	C2036196
27659457	1344	1354	prognostic	T170	C0220901
27659457	1359	1367	patients	T101	C0030705
27659457	1379	1401	vasodilator stress MPI	T060	C2350390
27659457	1414	1424	resting BP	T033	C0243095
27659457	1443	1452	predictor	T078	C2698872
27659457	1456	1465	mortality	T081	C0205848
27659457	1483	1491	clinical	T080	C0205210
27659457	1496	1499	MPI	T060	C2350390
27659457	1500	1509	variables	T080	C0439828
27659457	1511	1513	BP	T040	C0005823
27659457	1514	1522	response	T032	C0871261
27659457	1549	1553	risk	T078	C0035647
27659457	1554	1568	stratification	T062	C1514983
27659457	1578	1586	patients	T101	C0030705

27794742|t|Ensuring better births for women in England
27794742|a|In July I was delighted to take part in an event highlighting the exciting developments in maternity care following the publication of the report of the National Maternity Review: Better Births.
27794742	0	22	Ensuring better births	T058	C1254363
27794742	27	32	women	T098	C0043210
27794742	36	43	England	T083	C0014282
27794742	47	51	July	T080	C3829447
27794742	58	67	delighted	T041	C3830544
27794742	87	92	event	T051	C0441471
27794742	119	131	developments	T169	C1527148
27794742	135	149	maternity care	T091	C0028773
27794742	164	175	publication	T073,T170	C0034036
27794742	183	189	report	T170	C0684224
27794742	197	222	National Maternity Review	T170	C0282443
27794742	224	237	Better Births	T058	C1254363

28280149|t|Engineering the ribosomal DNA in a megabase synthetic chromosome
28280149|a|We designed and synthesized a 976,067-base pair linear chromosome, synXII, based on native chromosome XII in Saccharomyces cerevisiae SynXII was assembled using a two-step method, specified by successive megachunk integration and meiotic recombination-mediated assembly, producing a functional chromosome in S. cerevisiae. Minor growth defect " bugs " detected in synXII, caused by deletion of tRNA genes, were rescued by introducing an ectopic copy of a single tRNA gene. The ribosomal gene cluster (rDNA) on synXII was left intact during the assembly process and subsequently replaced by a modified rDNA unit used to regenerate rDNA at three distinct chromosomal locations. The signature sequences within rDNA, which can be used to determine species identity, were swapped to generate a Saccharomyces synXII strain that would be identified as Saccharomyces bayanus by standard DNA barcoding procedures.
28280149	0	11	Engineering	T063	C0017387
28280149	16	29	ribosomal DNA	T114,T123	C0012933
28280149	35	64	megabase synthetic chromosome	T075	C0872017
28280149	95	130	976,067-base pair linear chromosome	T075	C0872017
28280149	132	138	synXII	T075	C0872017
28280149	156	170	chromosome XII	T026	C0008642
28280149	174	198	Saccharomyces cerevisiae	T004	C0036025
28280149	199	205	SynXII	T075	C0872017
28280149	228	243	two-step method	T169	C0449851
28280149	269	290	megachunk integration	T063	C0017387
28280149	295	334	meiotic recombination-mediated assembly	T063	C0017387
28280149	348	358	functional	T169	C0205245
28280149	359	369	chromosome	T026	C0008642
28280149	373	386	S. cerevisiae	T004	C0036025
28280149	388	407	Minor growth defect	T169	C1457869
28280149	410	414	bugs	T169	C1457869
28280149	417	425	detected	T033	C0442726
28280149	429	435	synXII	T075	C0872017
28280149	447	455	deletion	T045	C0017260
28280149	459	463	tRNA	T114,T123	C0035711
28280149	464	469	genes	T028	C0017337
28280149	502	514	ectopic copy	T028	C0017337
28280149	520	531	single tRNA	T114,T123	C0035711
28280149	532	536	gene	T028	C0017337
28280149	542	564	ribosomal gene cluster	T028	C0017258
28280149	566	570	rDNA	T028	C0017258
28280149	575	581	synXII	T075	C0872017
28280149	609	625	assembly process	T063	C0017387
28280149	657	665	modified	T169	C0392747
28280149	666	670	rDNA	T028	C0017258
28280149	684	694	regenerate	T169	C0334213
28280149	695	699	rDNA	T028	C0017258
28280149	718	739	chromosomal locations	T026	C0008633
28280149	755	764	sequences	T086	C0004793
28280149	772	776	rDNA	T028	C0017258
28280149	809	816	species	T185	C1705920
28280149	817	825	identity	T033	C0243095
28280149	854	867	Saccharomyces	T004	C0036024
28280149	868	874	synXII	T075	C0872017
28280149	875	881	strain	T001	C1518614
28280149	896	906	identified	T080	C0205396
28280149	910	931	Saccharomyces bayanus	T004	C1504647
28280149	935	943	standard	T080	C1442989

27881529|t|Co-occurrence and clustering of health conditions at age 11: cross-sectional findings from the Millennium Cohort Study
27881529|a|To identify patterns of co-occurrence and clustering of 6 common adverse health conditions in 11- year -old children and explore differences by sociodemographic factors. Nationally representative prospective cohort study. Children born in the UK between 2000 and 2002. 11 399 11- year -old singleton children for whom data on all 6 health conditions and sociodemographic information were available (complete cases). Prevalence, co-occurrence and clustering of 6 common health conditions: wheeze; eczema; long-standing illness (excluding wheeze and eczema); injury; socioemotional difficulties (measured using Strengths and Difficulties Questionnaire) and unfavourable weight (thin / overweight / obese vs normal). 42.4% of children had 2 or more adverse health conditions (co-occurrence). Co-occurrence was more common in boys and children from lower income households. Latent class analysis identified 6 classes: ' normative ' (57.4%): ' atopic burdened ' (14.0%); ' socioemotional burdened ' (11.0%); ' unfavourable weight / injury ' (7.7%); ' eczema / injury ' (6.0%) and ' eczema / unfavourable weight ' (3.9%). As with co-occurrence, class membership differed by sociodemographic factors: boys, children of mothers with lower educational attainment and children from lower income households were more likely to be in the ' socioemotional burdened ' class. Children of mothers with higher educational attainment were more likely to be in the ' normative ' and ' eczema / unfavourable weight ' classes. Co-occurrence of adverse health conditions at age 11 is common and is associated with adverse socioeconomic circumstances. Holistic, child focused care, particularly in boys and those in lower income groups, may help to prevent and reduce co-occurrence in later childhood and adolescence.
27881529	0	13	Co-occurrence	T079	C2745955
27881529	18	28	clustering	T081	C0012641
27881529	32	38	health	T078	C0018684
27881529	39	49	conditions	T080	C0348080
27881529	53	56	age	T032	C0001779
27881529	61	76	cross-sectional	T062	C0010362
27881529	77	85	findings	T169	C2607943
27881529	95	118	Millennium Cohort Study	T081	C0009247
27881529	143	156	co-occurrence	T079	C2745955
27881529	161	171	clustering	T081	C0012641
27881529	184	191	adverse	T046	C0877248
27881529	192	198	health	T078	C0018684
27881529	199	209	conditions	T080	C0348080
27881529	217	221	year	T079	C1510829
27881529	227	235	children	T100	C0008059
27881529	248	259	differences	T080	C1705242
27881529	263	287	sociodemographic factors	T078	C0011292
27881529	315	339	prospective cohort study	T062	C1709709
27881529	341	349	Children	T100	C0008059
27881529	362	364	UK	T083	C0041700
27881529	399	403	year	T079	C1510829
27881529	409	418	singleton	T099	C1313913
27881529	419	427	children	T100	C0008059
27881529	437	441	data	T078	C1511726
27881529	451	457	health	T078	C0018684
27881529	458	468	conditions	T080	C0348080
27881529	473	501	sociodemographic information	T078	C1533716
27881529	518	526	complete	T080	C0205197
27881529	527	532	cases	T169	C0868928
27881529	535	545	Prevalence	T081	C0220900
27881529	547	560	co-occurrence	T079	C2745955
27881529	565	575	clustering	T081	C0012641
27881529	588	594	health	T078	C0018684
27881529	595	605	conditions	T080	C0348080
27881529	607	613	wheeze	T184	C0043144
27881529	615	621	eczema	T047	C0013595
27881529	623	644	long-standing illness	T184	C0221423
27881529	656	662	wheeze	T184	C0043144
27881529	667	673	eczema	T047	C0013595
27881529	676	682	injury	T037	C3263723
27881529	684	711	socioemotional difficulties	T048	C0013985
27881529	728	768	Strengths and Difficulties Questionnaire	T170	C3472494
27881529	774	793	unfavourable weight	T032	C0005910
27881529	795	799	thin	T033	C0041667
27881529	802	812	overweight	T184	C0497406
27881529	815	820	obese	T047	C0028754
27881529	824	830	normal	T032	C0005910
27881529	842	850	children	T100	C0008059
27881529	865	872	adverse	T046	C0877248
27881529	873	879	health	T078	C0018684
27881529	880	890	conditions	T080	C0348080
27881529	892	905	co-occurrence	T079	C2745955
27881529	908	921	Co-occurrence	T079	C2745955
27881529	941	945	boys	T100	C0870221
27881529	950	958	children	T100	C0008059
27881529	970	976	income	T081	C0021162
27881529	977	987	households	T099	C0020052
27881529	989	1010	Latent class analysis	T062	C0936012
27881529	1024	1031	classes	T170	C0456387
27881529	1035	1044	normative	T080	C0205307
27881529	1058	1064	atopic	T046	C0392707
27881529	1065	1073	burdened	T078	C2828008
27881529	1087	1110	socioemotional burdened	T048	C0013985
27881529	1124	1143	unfavourable weight	T032	C0005910
27881529	1146	1152	injury	T037	C3263723
27881529	1165	1171	eczema	T047	C0013595
27881529	1174	1180	injury	T037	C3263723
27881529	1196	1202	eczema	T047	C0013595
27881529	1205	1224	unfavourable weight	T032	C0005910
27881529	1243	1256	co-occurrence	T079	C2745955
27881529	1258	1263	class	T170	C0456387
27881529	1264	1274	membership	T055	C0680038
27881529	1287	1311	sociodemographic factors	T078	C0011292
27881529	1313	1317	boys	T100	C0870221
27881529	1319	1327	children	T100	C0008059
27881529	1331	1338	mothers	T099	C0026591
27881529	1350	1372	educational attainment	T033	C0013658
27881529	1377	1385	children	T100	C0008059
27881529	1397	1403	income	T081	C0021162
27881529	1404	1414	households	T099	C0020052
27881529	1447	1470	socioemotional burdened	T048	C0013985
27881529	1473	1478	class	T170	C0456387
27881529	1480	1488	Children	T100	C0008059
27881529	1492	1499	mothers	T099	C0026591
27881529	1512	1534	educational attainment	T033	C0013658
27881529	1567	1576	normative	T080	C0205307
27881529	1585	1591	eczema	T047	C0013595
27881529	1594	1613	unfavourable weight	T032	C0005910
27881529	1616	1623	classes	T170	C0456387
27881529	1625	1638	Co-occurrence	T079	C2745955
27881529	1642	1649	adverse	T046	C0877248
27881529	1650	1656	health	T078	C0018684
27881529	1657	1667	conditions	T080	C0348080
27881529	1671	1674	age	T032	C0001779
27881529	1695	1710	associated with	T080	C0332281
27881529	1711	1718	adverse	T046	C0877248
27881529	1719	1732	socioeconomic	T077	C0748878
27881529	1733	1746	circumstances	T077	C1254372
27881529	1748	1756	Holistic	T078	C0019844
27881529	1758	1763	child	T100	C0008059
27881529	1772	1776	care	T052	C1947933
27881529	1794	1798	boys	T100	C0870221
27881529	1818	1824	income	T081	C0021162
27881529	1825	1831	groups	T078	C0441833
27881529	1845	1852	prevent	T080	C2700409
27881529	1857	1863	reduce	T080	C0392756
27881529	1864	1877	co-occurrence	T079	C2745955
27881529	1881	1886	later	T079	C0205087
27881529	1887	1896	childhood	T079	C0231335
27881529	1901	1912	adolescence	T079	C0001578

27626498|t|DRG1 is a potential oncogene in lung adenocarcinoma and promotes tumor progression via spindle checkpoint signaling regulation
27626498|a|Developmentally regulated GTP binding protein 1 (DRG1), a member of the DRG family, plays important roles in regulating cell growth. However, the molecular basis of DRG1 in cell proliferation regulation and the relationship between DRG1 and tumor progression remain poorly understood. Here, we demonstrate that DRG1 is elevated in lung adenocarcinomas while weakly expressed in adjacent lung tissues. DRG1 knockdown causes growth inhibition of tumor cells by significantly increasing the proportion of cells in M phase. Overexpression of DRG1 leads to chromosome missegregation which is an important index for tumorigenesis. Interestingly, ectopic of DRG1 reduces taxol induced apoptosis of lung adenocarcinoma cells. Mechanistic analyses confirm that DRG1 localizes at mitotic spindles in dividing cells and binds to spindle checkpoint signaling proteins in vivo. These studies highlight the expanding role of DRG1 in tumorigenesis and reveal a mechanism of DRG1 in taxol resistance.
27626498	0	4	DRG1	T028	C1414151
27626498	20	28	oncogene	T028	C0029016
27626498	32	51	lung adenocarcinoma	T191	C0152013
27626498	56	64	promotes	T052	C0033414
27626498	65	82	tumor progression	T191	C0178874
27626498	87	115	spindle checkpoint signaling	T043	C3156402
27626498	116	126	regulation	T038	C1327622
27626498	153	174	GTP binding protein 1	T116,T126	C1430718
27626498	176	180	DRG1	T116,T123	C0905573
27626498	199	209	DRG family	T116,T123	C1335532
27626498	236	258	regulating cell growth	T043	C0596286
27626498	273	288	molecular basis	T078	C1853126
27626498	292	296	DRG1	T116,T123	C0905573
27626498	300	329	cell proliferation regulation	T043	C1156235
27626498	359	363	DRG1	T116,T123	C0905573
27626498	368	385	tumor progression	T191	C0178874
27626498	438	442	DRG1	T116,T123	C0905573
27626498	458	478	lung adenocarcinomas	T191	C0152013
27626498	492	501	expressed	T045	C1171362
27626498	514	518	lung	T023	C0024109
27626498	519	526	tissues	T024	C0040300
27626498	528	532	DRG1	T028	C1414151
27626498	533	542	knockdown	T063	C2350567
27626498	550	567	growth inhibition	T043	C2244509
27626498	571	582	tumor cells	T025	C0597032
27626498	629	634	cells	T025	C0007634
27626498	638	645	M phase	T043	C0007591
27626498	647	661	Overexpression	T045	C1171362
27626498	665	669	DRG1	T116,T123	C0905573
27626498	679	689	chromosome	T026	C0008633
27626498	690	704	missegregation	T045	C0314627
27626498	737	750	tumorigenesis	T191	C0007621
27626498	767	774	ectopic	T045	C1512167
27626498	778	782	DRG1	T028	C1414151
27626498	791	796	taxol	T109,T121	C0678133
27626498	797	804	induced	T169	C0205263
27626498	805	814	apoptosis	T043	C0162638
27626498	818	837	lung adenocarcinoma	T191	C0152013
27626498	838	843	cells	T025	C0007634
27626498	845	856	Mechanistic	T022	C0598002
27626498	857	865	analyses	T062	C0936012
27626498	879	883	DRG1	T116,T123	C0905573
27626498	884	893	localizes	T082	C0392752
27626498	897	913	mitotic spindles	T026	C0026258
27626498	917	931	dividing cells	T025	C0230517
27626498	936	941	binds	T044	C1167622
27626498	945	973	spindle checkpoint signaling	T043	C3156402
27626498	974	982	proteins	T116,T123	C1335962
27626498	983	990	in vivo	T082	C1515655
27626498	998	1005	studies	T062	C2603343
27626498	1038	1042	DRG1	T028	C1414151
27626498	1046	1059	tumorigenesis	T191	C0007621
27626498	1073	1082	mechanism	T169	C0441712
27626498	1086	1090	DRG1	T028	C1414151
27626498	1094	1099	taxol	T109,T121	C0678133

27647474|t|Cadmium - induced oxidative damages in the human BJAB cells correlate with changes in intracellular trace elements levels and zinc transporters expression
27647474|a|Cadmium (Cd), a potent toxic heavy metal, is a widespread environmental contaminant. Its cellular traffic via pathways dedicated to transition metals contributes to the toxicity mechanisms. Zinc (Zn) homeostasis is complex, involving both zinc importers (Zip) and zinc exporters (ZnT). Cellular signal transduction pathways are influenced by Zn and redox status of the cell. The aim of the present study is to examine if the accumulation of Cd in the human lymphocyte B cell line BJAB and its capacity to promote oxidative stress and adverse effects could result from changes in the mRNA expression pattern of Zn transporters and metallothioneins. Cells were exposed to 5, 10, 20 and 40μM of CdCl2 equivalent to 0.91, 1.83, 3.66 and 7.33μg/ml respectively, for 24h. Cd significantly reduced the viability of BJAB cells and induced a dose-dependent increase in DNA damage. Cd also induced the formation of 8-hydroxy-2'-deoxyguanosine adducts and augmented MTF1 expression in BJAB cells. We observed interesting responses in relative gene expression to Cd exposure among the seven transporters we analyzed. Cd exposure increased the expression of DMT1 and caused an up-regulation of ZnT1. However, the T calcium channel alpha1G subunit could not be detected. A change in expression of ZnTs and Zips in response to Cd exposure emphasizes the involvement of Zn transporters in Cd cellular metabolism and induced oxidative stress.
27647474	0	7	Cadmium	T131,T196	C0006632
27647474	10	17	induced	T046	C0007994
27647474	18	27	oxidative	T169	C0311404
27647474	28	35	damages	T049	C0599732
27647474	43	48	human	T016	C0086418
27647474	49	59	BJAB cells	T025	C0004561
27647474	60	69	correlate	T080	C1707520
27647474	86	99	intracellular	T082	C0178719
27647474	100	114	trace elements	T123,T196	C0040577
27647474	115	121	levels	T080	C0441889
27647474	126	143	zinc transporters	T116,T123	C1608304
27647474	144	154	expression	T045	C1171362
27647474	155	162	Cadmium	T131,T196	C0006632
27647474	164	166	Cd	T131,T196	C0006632
27647474	178	183	toxic	T080	C1407029
27647474	184	195	heavy metal	T196	C0347988
27647474	202	212	widespread	T082	C0205391
27647474	213	238	environmental contaminant	T131	C0014417
27647474	244	252	cellular	T025	C0007634
27647474	253	260	traffic	T033	C3840880
27647474	265	273	pathways	T044	C1704259
27647474	287	304	transition metals	T196	C0682906
27647474	324	332	toxicity	T037	C0600688
27647474	333	343	mechanisms	T169	C0441712
27647474	345	366	Zinc (Zn) homeostasis	T043	C1156277
27647474	370	377	complex	T080	C0439855
27647474	394	398	zinc	T121,T123,T196	C0043481
27647474	399	414	importers (Zip)	T043	C1159683
27647474	419	423	zinc	T121,T123,T196	C0043481
27647474	424	439	exporters (ZnT)	T043	C1159683
27647474	441	469	Cellular signal transduction	T043	C3825288
27647474	470	478	pathways	T044	C1704259
27647474	483	493	influenced	T077	C4054723
27647474	497	499	Zn	T121,T123,T196	C0043481
27647474	504	509	redox	T044	C0030012
27647474	510	516	status	T080	C0449438
27647474	524	528	cell	T025	C0007634
27647474	553	558	study	T062	C0008972
27647474	565	572	examine	T169	C1524024
27647474	580	592	accumulation	T033	C4055506
27647474	596	598	Cd	T131,T196	C0006632
27647474	606	611	human	T016	C0086418
27647474	612	639	lymphocyte B cell line BJAB	T025	C0004561
27647474	648	656	capacity	T081	C1516240
27647474	660	667	promote	T052	C0033414
27647474	668	684	oxidative stress	T049	C0242606
27647474	689	704	adverse effects	T046	C0879626
27647474	738	753	mRNA expression	T045	C1515670
27647474	754	761	pattern	T082	C0449774
27647474	765	780	Zn transporters	T116,T123	C1608304
27647474	785	801	metallothioneins	T116,T123	C0025545
27647474	803	808	Cells	T025	C0007634
27647474	814	824	exposed to	T080	C0332157
27647474	847	852	CdCl2	T131,T197	C0054412
27647474	853	863	equivalent	T080	C0205163
27647474	921	923	Cd	T131,T196	C0006632
27647474	924	937	significantly	T078	C0750502
27647474	938	945	reduced	T080	C0392756
27647474	950	959	viability	T043	C0007620
27647474	963	973	BJAB cells	T025	C0004561
27647474	978	985	induced	T046	C0007994
27647474	988	1002	dose-dependent	T081	C1512045
27647474	1015	1025	DNA damage	T049	C0012860
27647474	1027	1029	Cd	T131,T196	C0006632
27647474	1035	1042	induced	T046	C0007994
27647474	1047	1056	formation	T169	C1522492
27647474	1060	1087	8-hydroxy-2'-deoxyguanosine	T114,T123	C0050078
27647474	1088	1095	adducts	T104	C0596040
27647474	1100	1109	augmented	T081	C0205217
27647474	1110	1114	MTF1	T028	C1417419
27647474	1115	1125	expression	T045	C0017262
27647474	1129	1139	BJAB cells	T025	C0004561
27647474	1165	1174	responses	T032	C0871261
27647474	1187	1202	gene expression	T045	C0017262
27647474	1206	1208	Cd	T131,T196	C0006632
27647474	1209	1217	exposure	T080	C0332157
27647474	1234	1246	transporters	T116,T123	C0596902
27647474	1250	1258	analyzed	T062	C0936012
27647474	1260	1262	Cd	T131,T196	C0006632
27647474	1263	1271	exposure	T080	C0332157
27647474	1272	1281	increased	T081	C0205217
27647474	1286	1296	expression	T045	C0017262
27647474	1300	1304	DMT1	T028	C1420089
27647474	1309	1315	caused	T169	C0015127
27647474	1319	1332	up-regulation	T044	C0041904
27647474	1336	1340	ZnT1	T116,T123	C1438948
27647474	1355	1388	T calcium channel alpha1G subunit	T116,T123	C0752118
27647474	1402	1410	detected	T033	C0442726
27647474	1424	1434	expression	T045	C1171362
27647474	1438	1442	ZnTs	T043	C1159683
27647474	1447	1451	Zips	T043	C1159683
27647474	1455	1463	response	T032	C0871261
27647474	1467	1469	Cd	T131,T196	C0006632
27647474	1470	1478	exposure	T080	C0332157
27647474	1494	1505	involvement	T169	C1314939
27647474	1509	1524	Zn transporters	T116,T123	C1608304
27647474	1528	1530	Cd	T131,T196	C0006632
27647474	1531	1550	cellular metabolism	T025	C3826603
27647474	1555	1562	induced	T046	C0007994
27647474	1563	1579	oxidative stress	T049	C0242606

27771746|t|Identification and functional analysis of the GTPV bidirectional promoter region
27771746|a|The goat pox chick embryo-attenuated virus (GTPV) has been developed as an effective vaccine that can elicit protective immune responses. It possesses a large genome and a robust ability to express exogenous genes. Thus, this virus is an ideal vector for recombinant live vaccines for infectious diseases in ruminant animals. In this study, we identified a novel bidirectional promoter region of GTPV through screening named PbVV(±). PbVV(±) is located between ETF-l and VITF-3, which are transcribed in opposite directions. A new recombinant goat pox virus (rGTPV) was constructed, in which duplicate PbVV(+) was used as a promoter element to enhance Brucella OMP31 expression, and duplicate PbVV (-) was used as a promoter element to regulate enhanced green fluorescent protein (EGFP) at the same time as the selection marker. PbVV(-) promoter activity was compared to that of the P7.5 promoter of vaccinia virus, as measured by EGFP expression; the fluorescence intensity of EGFP expressed in cells was confirmed by fluorescence microscopy and flow cytometry. PbVV(+) promoter activity was measured by Brucella OMP31 expression. Interaction with the anti-Brucella-OMP31 monoclonal antibody was confirmed by western blotting, and OMP31 mRNA expression was assessed by qRT-PCR. The results of this study will be useful for the further study of effective multivalent vaccines based on rGTPV. This study also provides a theoretical basis for overcoming the problem of low expression of exogenous genes.
27771746	46	50	GTPV	T005	C0206574
27771746	51	64	bidirectional	T080	C1706937
27771746	65	80	promoter region	T114,T123	C0033413
27771746	85	123	goat pox chick embryo-attenuated virus	T005	C0206574
27771746	125	129	GTPV	T005	C0206574
27771746	166	173	vaccine	T121,T129	C0042210
27771746	201	217	immune responses	T042	C0301872
27771746	240	246	genome	T028	C0017428
27771746	271	278	express	T045	C0017262
27771746	279	288	exogenous	T169	C0205228
27771746	289	294	genes	T028	C0017337
27771746	307	312	virus	T005	C0206574
27771746	319	324	ideal	T080	C1512612
27771746	325	331	vector	T114	C0599566
27771746	336	361	recombinant live vaccines	T116,T121,T129	C0034862
27771746	366	385	infectious diseases	T047	C0009450
27771746	389	405	ruminant animals	T015	C0035950
27771746	444	457	bidirectional	T080	C1706937
27771746	458	473	promoter region	T114,T123	C0033413
27771746	477	481	GTPV	T005	C0206574
27771746	506	513	PbVV(±)	T114,T123	C0086860
27771746	515	522	PbVV(±)	T114,T123	C0086860
27771746	542	547	ETF-l	T116,T123	C0082367
27771746	552	558	VITF-3	T116,T123	C0040648
27771746	570	581	transcribed	T045	C0040649
27771746	585	593	opposite	T082	C1521805
27771746	594	604	directions	T082	C0449738
27771746	612	638	recombinant goat pox virus	T005	C0206574
27771746	640	645	rGTPV	T005	C0206574
27771746	683	690	PbVV(+)	T114,T123	C0086860
27771746	705	713	promoter	T114,T123	C0086860
27771746	725	732	enhance	T052	C2349975
27771746	733	747	Brucella OMP31	T116,T123	C1621913
27771746	748	758	expression	T045	C1171362
27771746	774	778	PbVV	T114,T123	C0086860
27771746	797	813	promoter element	T114,T123	C0086860
27771746	826	860	enhanced green fluorescent protein	T116,T130	C1258415
27771746	862	866	EGFP	T116,T130	C1258415
27771746	910	926	PbVV(-) promoter	T114,T123	C0086860
27771746	964	977	P7.5 promoter	T114,T123	C0086860
27771746	981	995	vaccinia virus	T005	C0042216
27771746	1012	1016	EGFP	T116,T130	C1258415
27771746	1017	1027	expression	T045	C1171362
27771746	1033	1055	fluorescence intensity	T059	C0026022
27771746	1059	1063	EGFP	T116,T130	C1258415
27771746	1064	1073	expressed	T045	C1171362
27771746	1077	1082	cells	T025	C0007634
27771746	1100	1123	fluorescence microscopy	T059	C0026022
27771746	1128	1142	flow cytometry	T059	C0016263
27771746	1144	1160	PbVV(+) promoter	T114,T123	C0086860
27771746	1186	1200	Brucella OMP31	T116,T123	C1621913
27771746	1201	1211	expression	T045	C1171362
27771746	1234	1273	anti-Brucella-OMP31 monoclonal antibody	T116,T129	C0003250
27771746	1291	1307	western blotting	T059,T063	C0005863
27771746	1313	1318	OMP31	T116,T123	C1621913
27771746	1319	1334	mRNA expression	T045	C1515670
27771746	1351	1358	qRT-PCR	T063	C1514628
27771746	1426	1435	effective	T080	C1704419
27771746	1436	1456	multivalent vaccines	T121,T129	C1514218
27771746	1466	1471	rGTPV	T005	C0206574
27771746	1552	1562	expression	T045	C1171362
27771746	1566	1575	exogenous	T169	C0205228
27771746	1576	1581	genes	T028	C0017337

27234031|t|Improved diagnostic yield of neuromuscular disorders applying clinical exome sequencing in patients arising from a consanguineous population
27234031|a|Neuromuscular diseases (NMDs) include a broad range of disorders affecting muscles, nerves and neuromuscular junctions. Their overlapping phenotypes and heterogeneous genetic nature have created challenges in diagnosis which calls for the implementation of massive parallel sequencing as a candidate strategy to increase the diagnostic yield. In this study, total of 45 patients, mostly offspring of consanguineous marriages were examined using whole exome sequencing. Data analysis was performed to identify the most probable pathogenic rare variants in known NMD genes which led to identification of causal variants for 33 out of 45 patients (73.3%) in the following known genes: CAPN3, Col6A1, Col6A3, DMD, DYSF, FHL1, GJB1, ISPD, LAMA2, LMNA, PLEC1, RYR1, SGCA, SGCB, SYNE1, TNNT1 and 22 novel pathogenic variants were detected. Today, the advantage of whole exome sequencing in clinical diagnostic strategies of heterogeneous disorders is clear. In this cohort, a diagnostic yield of 73.3% was achieved which is quite high compared to the overall reported diagnostic yield of 25% to 50%. This could be explained by the consanguineous background of these patients and is another strong advantage of offering clinical exome sequencing in diagnostic laboratories, especially in populations with high rate of consanguinity.
27234031	0	8	Improved	T033	C0184511
27234031	9	25	diagnostic yield	T080	C0205556
27234031	29	52	neuromuscular disorders	T047	C0027868
27234031	62	70	clinical	T080	C0205210
27234031	71	87	exome sequencing	T063	C3640077
27234031	91	99	patients	T101	C0030705
27234031	115	129	consanguineous	UnknownType	C0680040
27234031	130	140	population	T098	C1257890
27234031	141	163	Neuromuscular diseases	T047	C0027868
27234031	165	169	NMDs	T047	C0027868
27234031	196	205	disorders	T047	C0012634
27234031	216	223	muscles	T024	C0026845
27234031	225	231	nerves	T024	C0027740
27234031	236	259	neuromuscular junctions	T026	C0027869
27234031	279	289	phenotypes	T032	C0031437
27234031	294	322	heterogeneous genetic nature	T032	C0242960
27234031	350	359	diagnosis	T033	C0011900
27234031	380	394	implementation	T052	C1708476
27234031	398	425	massive parallel sequencing	T063	C2936622
27234031	466	482	diagnostic yield	T080	C0205556
27234031	492	497	study	T062	C2603343
27234031	511	519	patients	T101	C0030705
27234031	528	537	offspring	T099	C0680063
27234031	541	565	consanguineous marriages	T054	C0870340
27234031	586	608	whole exome sequencing	T063	C3640077
27234031	610	623	Data analysis	T057	C0010992
27234031	668	678	pathogenic	T033	C3816499
27234031	679	692	rare variants	T028	C0678941
27234031	702	705	NMD	T047	C0027868
27234031	706	711	genes	T028	C0017337
27234031	743	758	causal variants	T080	C0205419
27234031	776	784	patients	T101	C0030705
27234031	816	821	genes	T028	C0017337
27234031	823	828	CAPN3	T028	C1413113
27234031	830	836	Col6A1	T028	C1413589
27234031	838	844	Col6A3	T028	C1413591
27234031	846	849	DMD	T028	C1414083
27234031	851	855	DYSF	T028	C1414209
27234031	857	861	FHL1	T028	C1414612
27234031	863	867	GJB1	T028	C1415076
27234031	869	873	ISPD	T028	C2829592
27234031	875	880	LAMA2	T028	C1416776
27234031	882	886	LMNA	T028	C1416877
27234031	888	893	PLEC1	T028	C1418643
27234031	895	899	RYR1	T028	C1419778
27234031	901	905	SGCA	T028	C1420005
27234031	907	911	SGCB	T028	C1420006
27234031	913	918	SYNE1	T028	C1424736
27234031	920	925	TNNT1	T028	C1420827
27234031	939	949	pathogenic	T033	C3816499
27234031	950	958	variants	T028	C0678941
27234031	964	972	detected	T033	C0442726
27234031	998	1020	whole exome sequencing	T063	C3640077
27234031	1024	1043	clinical diagnostic	T060	C0332140
27234031	1058	1081	heterogeneous disorders	T033	C1858576
27234031	1100	1106	cohort	T098	C0599755
27234031	1110	1126	diagnostic yield	T080	C0205556
27234031	1169	1177	compared	T052	C1707455
27234031	1185	1192	overall	T080	C1561607
27234031	1202	1218	diagnostic yield	T080	C0205556
27234031	1265	1279	consanguineous	UnknownType	C0680040
27234031	1300	1308	patients	T101	C0030705
27234031	1353	1361	clinical	T080	C0205210
27234031	1362	1378	exome sequencing	T063	C3640077
27234031	1382	1392	diagnostic	T169	C0348026
27234031	1393	1405	laboratories	T073,T093	C0022877
27234031	1421	1432	populations	T098	C1257890
27234031	1451	1464	consanguinity	T033	C0009789

28224642|t|Methodological considerations for designing a community water fluoridation cessation study
28224642|a|High-quality, up-to-date research on community water fluoridation (CWF), and especially on the implications of CWF cessation for dental health, is limited. Although CWF cessation studies have been conducted, they are few in number; one of the major reasons is the methodological complexity of conducting such a study. This article draws on a systematic review of existing cessation studies (n=15) to explore methodological considerations of conducting CWF cessation studies in future. We review nine important methodological aspects (study design, comparison community, target population, time frame, sampling strategy, clinical indicators, assessment criteria, covariates and biomarkers) and provide recommendations for planning future CWF cessation studies that examine effects on dental caries. There is no one ideal study design to answer a research question. However, recommendations proposed regarding methodological aspects to conduct an epidemiological study to observe the effects of CWF cessation on dental caries, coupled with our identification of important methodological gaps, will be useful for researchers who are looking to optimize resources to conduct such a study with standards of rigour.
28224642	0	29	Methodological considerations	T080	C1879746
28224642	46	55	community	T096	C0009462
28224642	56	74	water fluoridation	T069	C0016323
28224642	75	84	cessation	T052	C1880019
28224642	85	90	study	T062	C2603343
28224642	91	103	High-quality	T062	C0814847
28224642	116	124	research	T062	C0242481
28224642	128	137	community	T096	C0009462
28224642	138	156	water fluoridation	T069	C0016323
28224642	158	161	CWF	T069	C0016323
28224642	202	205	CWF	T069	C0016323
28224642	206	215	cessation	T052	C1880019
28224642	220	233	dental health	T058	C0011365
28224642	256	259	CWF	T069	C0016323
28224642	260	269	cessation	T052	C1880019
28224642	270	277	studies	T062	C2603343
28224642	355	380	methodological complexity	T169	C0237523
28224642	402	407	study	T062	C2603343
28224642	433	450	systematic review	T170	C1955832
28224642	463	472	cessation	T052	C1880019
28224642	473	480	studies	T062	C2603343
28224642	499	528	methodological considerations	T080	C1879746
28224642	543	546	CWF	T069	C0016323
28224642	547	556	cessation	T052	C1880019
28224642	557	564	studies	T062	C2603343
28224642	568	574	future	T079	C0016884
28224642	601	623	methodological aspects	T080	C1879746
28224642	625	637	study design	T062	C0035171
28224642	639	659	comparison community	T096	C0009462
28224642	661	678	target population	T098	C0039309
28224642	680	690	time frame	T079	C0872291
28224642	692	709	sampling strategy	T170	C0449370
28224642	711	730	clinical indicators	T169	C1522602
28224642	732	751	assessment criteria	T170	C0935549
28224642	768	778	biomarkers	T201	C0005516
28224642	792	807	recommendations	T078	C2936699
28224642	812	820	planning	T058	C0018727
28224642	821	827	future	T079	C0016884
28224642	828	831	CWF	T069	C0016323
28224642	832	841	cessation	T052	C1880019
28224642	842	849	studies	T062	C2603343
28224642	874	887	dental caries	T047	C0011334
28224642	911	923	study design	T062	C0035171
28224642	936	953	research question	T078	C0681799
28224642	964	979	recommendations	T078	C0034866
28224642	999	1021	methodological aspects	T080	C1879746
28224642	1036	1057	epidemiological study	T062	C0002783
28224642	1084	1087	CWF	T069	C0016323
28224642	1088	1097	cessation	T052	C1880019
28224642	1101	1114	dental caries	T047	C0011334
28224642	1201	1212	researchers	T097	C0035173
28224642	1232	1240	optimize	T052	C2698650
28224642	1241	1250	resources	T078	C0035201
28224642	1269	1274	study	T062	C2603343

28049415|t|Improving protein complex prediction by reconstructing a high-confidence protein-protein interaction network of Escherichia coli from different physical interaction data sources
28049415|a|Although different protein-protein physical interaction (PPI) datasets exist for Escherichia coli, no common methodology exists to integrate these datasets and extract reliable modules reflecting the existing biological process and protein complexes. Naïve Bayesian formula is the highly accepted method to integrate different PPI datasets into a single weighted PPI network, but detecting proper weights in such network is still a major problem. In this paper, we proposed a new methodology to integrate various physical PPI datasets into a single weighted PPI network in a way that the detected modules in PPI network exhibit the highest similarity to available functional modules. We used the co-expression modules as functional modules, and we shown that direct functional modules detected from Gene Ontology terms could be used as an alternative dataset. After running this integrating methodology over six different physical PPI datasets, orthologous high-confidence interactions from a related organism and two AP-MS PPI datasets gained high weights in the integrated networks, while the weights for one AP-MS PPI dataset and two other datasets derived from public databases have converged to zero. The majority of detected modules shaped around one or few hub protein(s). Still, a large number of highly interacting protein modules were detected which are functionally relevant and are likely to construct protein complexes. We provided a new high confidence protein complex prediction method supported by functional studies and literature mining.
28049415	0	9	Improving	T080	C1272745
28049415	10	25	protein complex	T116,T123	C1180347
28049415	26	36	prediction	T078	C0681842
28049415	40	54	reconstructing	T170	C0282574
28049415	57	72	high-confidence	T080	C1704725
28049415	73	108	protein-protein interaction network	T169	C3178902
28049415	112	128	Escherichia coli	T007	C0014834
28049415	144	164	physical interaction	T169	C1704675
28049415	165	177	data sources	T081	C0011001
28049415	197	233	protein-protein physical interaction	T044	C0872079
28049415	235	238	PPI	T044	C0872079
28049415	240	248	datasets	T170	C0150098
28049415	259	275	Escherichia coli	T007	C0014834
28049415	287	298	methodology	T078	C3266812
28049415	309	318	integrate	T066	C1705422
28049415	325	333	datasets	T170	C0150098
28049415	355	362	modules	T077	C1709061
28049415	387	405	biological process	T038	C3714634
28049415	410	427	protein complexes	T116,T123	C1180347
28049415	429	451	Naïve Bayesian formula	T170	C0489829
28049415	485	494	integrate	T066	C1705422
28049415	505	508	PPI	T044	C0872079
28049415	509	517	datasets	T170	C0150098
28049415	532	540	weighted	T081	C0043100
28049415	541	552	PPI network	T169	C3178902
28049415	575	582	weights	T081	C0043100
28049415	591	598	network	T169	C1882071
28049415	658	669	methodology	T078	C3266812
28049415	673	682	integrate	T066	C1705422
28049415	691	703	physical PPI	T044	C0872079
28049415	704	712	datasets	T170	C0150098
28049415	727	735	weighted	T081	C0043100
28049415	736	747	PPI network	T169	C3178902
28049415	766	774	detected	T033	C0442726
28049415	775	782	modules	T077	C1709061
28049415	786	797	PPI network	T169	C3178902
28049415	842	852	functional	T169	C0205245
28049415	853	860	modules	T077	C1709061
28049415	874	887	co-expression	T061	C0185117
28049415	888	895	modules	T077	C1709061
28049415	899	909	functional	T169	C0205245
28049415	910	917	modules	T077	C1709061
28049415	944	954	functional	T169	C0205245
28049415	955	962	modules	T077	C1709061
28049415	963	971	detected	T033	C0442726
28049415	977	990	Gene Ontology	T170	C1138831
28049415	991	996	terms	T078	C1254370
28049415	1029	1036	dataset	T170	C0150098
28049415	1057	1068	integrating	T066	C1705422
28049415	1069	1080	methodology	T078	C3266812
28049415	1100	1112	physical PPI	T044	C0872079
28049415	1113	1121	datasets	T170	C0150098
28049415	1123	1134	orthologous	T080	C1709346
28049415	1135	1150	high-confidence	T080	C1704725
28049415	1151	1163	interactions	T169	C1704675
28049415	1179	1187	organism	T001	C0029235
28049415	1196	1201	AP-MS	T059	C0037813
28049415	1202	1205	PPI	T044	C0872079
28049415	1206	1214	datasets	T170	C0150098
28049415	1215	1234	gained high weights	T033	C0043094
28049415	1242	1252	integrated	T066	C1705422
28049415	1253	1261	networks	T169	C1882071
28049415	1273	1280	weights	T081	C0043100
28049415	1289	1294	AP-MS	T059	C0037813
28049415	1295	1298	PPI	T044	C0872079
28049415	1299	1306	dataset	T170	C0150098
28049415	1321	1329	datasets	T170	C0150098
28049415	1343	1359	public databases	T170	C0242356
28049415	1400	1408	detected	T033	C0442726
28049415	1409	1416	modules	T077	C1709061
28049415	1442	1456	hub protein(s)	T116,T129	C3179452
28049415	1502	1509	protein	T116,T123	C0033684
28049415	1510	1517	modules	T077	C1709061
28049415	1523	1531	detected	T033	C0442726
28049415	1542	1554	functionally	T169	C0205245
28049415	1555	1563	relevant	T080	C2347946
28049415	1582	1591	construct	T185	C2827421
28049415	1592	1609	protein complexes	T116,T123	C1180347
28049415	1629	1644	high confidence	T080	C1704725
28049415	1645	1660	protein complex	T116,T123	C1180347
28049415	1661	1671	prediction	T078	C0681842
28049415	1692	1702	functional	T169	C0205245
28049415	1715	1725	literature	T170	C0023866

28177993|t|Effects of Hysterectomy on Pelvic Floor Disorders: A Longitudinal Study
28177993|a|Hysterectomy might adversely affect pelvic floor functions and result in many different symptoms, such as urinary and anal incontinence, obstructed defecation, and constipation. The aim of this prospective study was to evaluate the influence of hysterectomy on pelvic floor disorders. This was a prospective and longitudinal study. The study was conducted at the Ankara University Department of Surgery and the Dr Zekai Tahir Burak Women's Health Research and Education Hospital between September 2008 and March 2011. The study was performed on patients who underwent hysterectomy for benign pathologies. A questionnaire about urinary incontinence (International Continence Society scoring), anal incontinence, constipation, and obstructed defecation (Rome criteria and constipation severity score), along with an extensive obstetric history, was administered preoperatively and postoperatively annually for 4 years. Patients (N = 327) who had completed each of the 4 annual postoperative follow-ups were included in this study. Compared with the preoperative observations, the occurrence of each symptom was significantly increased at each of the follow-up years (p < 0.001). Over the 4 postoperative years, the frequencies for constipation (n = 245) were 7.8%, 8.2%, 8.6%, and 5.3%; those for obstructed defecation (n = 269) were 4.5%, 5.2%, 4.1%, and 3.0%; those for anal incontinence (n = 252) were 4.8%, 6.3%, 6.0%, and 5.2%, and those for urinary incontinence (n = 99) were 12.1%, 12.1%, 11.1%, and 13.1%. In addition, patients who had no preoperative symptom (n = 70) from any of the selected symptoms showed a postoperative occurrence of at least 1 of these symptoms of 15.8%, 14.3%, 11.4%, and 8.6% for the postoperative years 1, 2, 3, and 4. Although the study had several limitations, no comparison with a control population was the most important one. Hysterectomy for benign gynecologic pathologies had a significant negative impact on pelvic floor functions in patients who had no previous symptoms.
28177993	0	10	Effects of	T080	C1704420
28177993	11	23	Hysterectomy	T061	C0020699
28177993	27	39	Pelvic Floor	T023	C0206248
28177993	40	49	Disorders	T047	C0012634
28177993	53	71	Longitudinal Study	T062	C0023981
28177993	72	84	Hysterectomy	T061	C0020699
28177993	91	107	adversely affect	T169	C0392760
28177993	108	120	pelvic floor	T023	C0206248
28177993	121	130	functions	T169	C0542341
28177993	135	141	result	T169	C1274040
28177993	150	159	different	T080	C1705242
28177993	160	168	symptoms	T184	C1457887
28177993	178	185	urinary	T046	C0042024
28177993	190	194	anal	T023	C0003461
28177993	195	207	incontinence	T047	C0021167
28177993	209	230	obstructed defecation	T184	C2107752
28177993	236	248	constipation	T184	C0009806
28177993	266	283	prospective study	T062	C0033522
28177993	304	313	influence	T077	C4054723
28177993	317	329	hysterectomy	T061	C0020699
28177993	333	345	pelvic floor	T023	C0206248
28177993	346	355	disorders	T047	C0012634
28177993	368	379	prospective	T062	C0033522
28177993	384	402	longitudinal study	T062	C0023981
28177993	435	452	Ankara University	T073,T092	C0041740
28177993	453	474	Department of Surgery	T092	C1561598
28177993	483	550	Dr Zekai Tahir Burak Women's Health Research and Education Hospital	T093	C0013623
28177993	559	568	September	T079	C3828193
28177993	578	583	March	T079	C3829202
28177993	604	613	performed	T169	C0884358
28177993	617	625	patients	T101	C0030705
28177993	640	652	hysterectomy	T061	C0020699
28177993	657	663	benign	T080	C0205183
28177993	664	675	pathologies	T046	C0677042
28177993	679	692	questionnaire	T170	C0034394
28177993	699	719	urinary incontinence	T046	C0042024
28177993	721	761	International Continence Society scoring	T170	C0282574
28177993	764	768	anal	T023	C0003461
28177993	769	781	incontinence	T047	C0021167
28177993	783	795	constipation	T184	C0009806
28177993	801	822	obstructed defecation	T184	C2107752
28177993	824	869	Rome criteria and constipation severity score	T170	C0282574
28177993	886	895	extensive	T080	C0205231
28177993	896	913	obstetric history	T033	C0425963
28177993	919	931	administered	T169	C1521801
28177993	932	946	preoperatively	T079	C0445204
28177993	951	966	postoperatively	T079	C0032790
28177993	967	975	annually	T079	C0332181
28177993	982	987	years	T079	C0439234
28177993	989	997	Patients	T101	C0030705
28177993	1016	1025	completed	T078	C1556116
28177993	1040	1046	annual	T079	C0332181
28177993	1047	1071	postoperative follow-ups	T058	C2585426
28177993	1077	1085	included	T169	C0332257
28177993	1094	1099	study	T062	C2603343
28177993	1101	1109	Compared	T052	C1707455
28177993	1119	1131	preoperative	T079	C0445204
28177993	1132	1144	observations	T058	C0700325
28177993	1150	1160	occurrence	T079	C2745955
28177993	1169	1176	symptom	T184	C1457887
28177993	1181	1204	significantly increased	T081	C4055637
28177993	1220	1229	follow-up	T058	C1522577
28177993	1230	1235	years	T079	C0439234
28177993	1260	1273	postoperative	T079	C0032790
28177993	1274	1279	years	T079	C0439234
28177993	1285	1296	frequencies	T079	C0439603
28177993	1301	1313	constipation	T184	C0009806
28177993	1367	1388	obstructed defecation	T184	C2107752
28177993	1442	1446	anal	T023	C0003461
28177993	1447	1459	incontinence	T047	C0021167
28177993	1517	1537	urinary incontinence	T046	C0042024
28177993	1597	1605	patients	T101	C0030705
28177993	1617	1629	preoperative	T079	C0445204
28177993	1630	1637	symptom	T184	C1457887
28177993	1663	1671	selected	T052	C1707391
28177993	1672	1680	symptoms	T184	C1457887
28177993	1690	1703	postoperative	T079	C0032790
28177993	1704	1714	occurrence	T079	C2745955
28177993	1738	1746	symptoms	T184	C1457887
28177993	1788	1801	postoperative	T079	C0032790
28177993	1802	1807	years	T079	C0439234
28177993	1847	1866	several limitations	T169	C0449295
28177993	1871	1881	comparison	T052	C1707455
28177993	1889	1896	control	T096	C0009932
28177993	1897	1907	population	T098	C1257890
28177993	1921	1930	important	T080	C3898777
28177993	1936	1948	Hysterectomy	T061	C0020699
28177993	1953	1959	benign	T080	C0205183
28177993	1960	1983	gynecologic pathologies	T091	C1512289
28177993	1990	2001	significant	T078	C0750502
28177993	2002	2010	negative	T033	C0205160
28177993	2011	2017	impact	T080	C4049986
28177993	2021	2033	pelvic floor	T023	C0206248
28177993	2034	2043	functions	T169	C0542341
28177993	2047	2055	patients	T101	C0030705
28177993	2067	2075	previous	T079	C0205156
28177993	2076	2084	symptoms	T184	C1457887

28523479|t|Fatty Acids Have Different Adipogenic Differentiation Potentials in Stromal Vascular Cells Isolated from Abdominal Fat in Laying Hens
28523479|a|This study was conducted to examine the effects of fatty acids (FA) with/without chicken serum (CS) on the expression of adipogenic transcripts and adipogenesis in chicken stromal vascular cells (SVC). In experiment 1, SVC were grown in DMEM containing 10% FBS (Control) and treated with 300 µM oleic acid (OLA) + FBS, linoleic acid (LNA) + FBS, palmitic acid (PAM) + FBS, or stearic acid (STA) + FBS for 48 h. In experiment 2, cells were grown in DMEM containing 5% CS and treated with 300 µM OLA (CS + OLA), PAM (CS + PAM), STA (CS + STA) or 200 µM LNA (CS + LNA) for 48 h. Adipogenesis was determined using Oil Red O staining and glycerol-3-phosphate dehydrogenase (GPDH) activity. The proportion of OLA, PAM, or STA was increased (P < 0.05) in SVC grown in either FBS or CS with OLA, PAM or STA. Adipogenesis was induced in FBS + OLA, FBS + LNA, FBS + PAM, FBS + STA, CS + OLA, CS + LNA, CS + PAM, or CS + STA compared to FBS. GPDH activity was significantly higher in FBS + OLA and FBS + LNA than one in FBS. Compared to FBS, the expression of FABP4 mRNA increased (P < 0.05) in FBS + OLA, FBS + LNA, or FBS + PAM, whereas that of C/EBPα, C/EBPβ, and ATGL increased (P < 0.05) in FBS + OLA or FBS + LNA cells. Expression of FABP4 and C/EBPβ mRNA was higher in CS, CS + OLA, CS + LNA, CS + PAM, or CS + STA compared with (FBS, whereas the expression of ATGL and C/EBPα was higher in CS, CS + OLA, or CS + LNA than FBS cells. In conclusion, these results showed that FA have different potentials to induce adipogenesis, LNA is the most potent among the tested FA, and these potentials can be improved in the presence of CS.
28523479	0	11	Fatty Acids	T109	C0015684
28523479	17	26	Different	T080	C1705242
28523479	27	53	Adipogenic Differentiation	T044	C0596843
28523479	54	64	Potentials	T080	C3245505
28523479	68	90	Stromal Vascular Cells	T025	C0162597
28523479	91	99	Isolated	T169	C0205409
28523479	105	118	Abdominal Fat	T024	C1563742
28523479	122	128	Laying	T040	C1622979
28523479	129	133	Hens	T012	C0008051
28523479	139	144	study	T062	C2603343
28523479	174	184	effects of	T080	C1704420
28523479	185	196	fatty acids	T109	C0015684
28523479	198	200	FA	T109	C0015684
28523479	215	228	chicken serum	T129	C1440440
28523479	230	232	CS	T129	C1440440
28523479	241	251	expression	T045	C0017262
28523479	255	265	adipogenic	T044	C0596843
28523479	266	277	transcripts	T114	C1519595
28523479	282	294	adipogenesis	T044	C0596843
28523479	298	305	chicken	T012	C0008051
28523479	306	328	stromal vascular cells	T025	C0162597
28523479	330	333	SVC	T025	C0162597
28523479	353	356	SVC	T025	C0162597
28523479	371	375	DMEM	T121	C1665363
28523479	391	394	FBS	T130	C3812213
28523479	396	403	Control	T096	C0009932
28523479	409	416	treated	T169	C1522326
28523479	429	439	oleic acid	T109,T121	C0028928
28523479	441	444	OLA	T109,T121	C0028928
28523479	448	451	FBS	T130	C3812213
28523479	453	466	linoleic acid	T109,T121,T123	C0023749
28523479	468	471	LNA	T109,T121,T123	C0023749
28523479	475	478	FBS	T130	C3812213
28523479	480	493	palmitic acid	T109,T123	C0030234
28523479	495	498	PAM	T109,T123	C0030234
28523479	502	505	FBS	T130	C3812213
28523479	510	522	stearic acid	T109,T121	C0038229
28523479	524	527	STA	T109,T121	C0038229
28523479	531	534	FBS	T130	C3812213
28523479	562	567	cells	T025	C0007634
28523479	582	586	DMEM	T121	C1665363
28523479	601	603	CS	T129	C1440440
28523479	608	615	treated	T169	C1522326
28523479	628	631	OLA	T109,T121	C0028928
28523479	633	635	CS	T129	C1440440
28523479	638	641	OLA	T109,T121	C0028928
28523479	644	647	PAM	T109,T123	C0030234
28523479	649	651	CS	T129	C1440440
28523479	654	657	PAM	T109,T123	C0030234
28523479	660	663	STA	T109,T121	C0038229
28523479	665	667	CS	T129	C1440440
28523479	670	673	STA	T109,T121	C0038229
28523479	685	688	LNA	T109,T121,T123	C0023749
28523479	690	692	CS	T129	C1440440
28523479	695	698	LNA	T109,T121,T123	C0023749
28523479	710	722	Adipogenesis	T044	C0596843
28523479	744	762	Oil Red O staining	T059	C1294000
28523479	767	817	glycerol-3-phosphate dehydrogenase (GPDH) activity	T044	C1151278
28523479	837	840	OLA	T109,T121	C0028928
28523479	842	845	PAM	T109,T123	C0030234
28523479	850	853	STA	T109,T121	C0038229
28523479	858	867	increased	T081	C0205217
28523479	882	885	SVC	T025	C0162597
28523479	902	905	FBS	T130	C3812213
28523479	909	911	CS	T129	C1440440
28523479	917	920	OLA	T109,T121	C0028928
28523479	922	925	PAM	T109,T123	C0030234
28523479	929	932	STA	T109,T121	C0038229
28523479	934	946	Adipogenesis	T044	C0596843
28523479	951	958	induced	T169	C0205263
28523479	962	965	FBS	T130	C3812213
28523479	968	971	OLA	T109,T121	C0028928
28523479	973	976	FBS	T130	C3812213
28523479	979	982	LNA	T109,T121,T123	C0023749
28523479	984	987	FBS	T130	C3812213
28523479	990	993	PAM	T109,T123	C0030234
28523479	995	998	FBS	T130	C3812213
28523479	1001	1004	STA	T109,T121	C0038229
28523479	1006	1008	CS	T129	C1440440
28523479	1011	1014	OLA	T109,T121	C0028928
28523479	1016	1018	CS	T129	C1440440
28523479	1021	1024	LNA	T109,T121,T123	C0023749
28523479	1026	1028	CS	T129	C1440440
28523479	1031	1034	PAM	T109,T123	C0030234
28523479	1039	1041	CS	T129	C1440440
28523479	1044	1047	STA	T109,T121	C0038229
28523479	1060	1063	FBS	T130	C3812213
28523479	1065	1078	GPDH activity	T044	C1151278
28523479	1083	1103	significantly higher	T081	C4055637
28523479	1107	1110	FBS	T130	C3812213
28523479	1113	1116	OLA	T109,T121	C0028928
28523479	1121	1124	FBS	T130	C3812213
28523479	1127	1130	LNA	T109,T121,T123	C0023749
28523479	1143	1146	FBS	T130	C3812213
28523479	1160	1163	FBS	T130	C3812213
28523479	1169	1179	expression	T045	C0017262
28523479	1183	1188	FABP4	T028	C1333527
28523479	1189	1193	mRNA	T114,T123	C0035696
28523479	1194	1203	increased	T081	C0205217
28523479	1218	1221	FBS	T130	C3812213
28523479	1224	1227	OLA	T109,T121	C0028928
28523479	1229	1232	FBS	T130	C3812213
28523479	1235	1238	LNA	T109,T121,T123	C0023749
28523479	1243	1246	FBS	T130	C3812213
28523479	1249	1252	PAM	T109,T123	C0030234
28523479	1270	1276	C/EBPα	T028	C1413322
28523479	1278	1284	C/EBPβ	T028	C1413323
28523479	1290	1294	ATGL	T028	C1538686
28523479	1295	1304	increased	T081	C0205217
28523479	1319	1322	FBS	T130	C3812213
28523479	1325	1328	OLA	T109,T121	C0028928
28523479	1332	1335	FBS	T130	C3812213
28523479	1338	1341	LNA	T109,T121,T123	C0023749
28523479	1342	1347	cells	T025	C0007634
28523479	1349	1359	Expression	T045	C0017262
28523479	1363	1368	FABP4	T028	C1333527
28523479	1373	1379	C/EBPβ	T028	C1413323
28523479	1380	1384	mRNA	T114,T123	C0035696
28523479	1389	1395	higher	T080	C0205250
28523479	1399	1401	CS	T129	C1440440
28523479	1403	1405	CS	T129	C1440440
28523479	1408	1411	OLA	T109,T121	C0028928
28523479	1413	1415	CS	T129	C1440440
28523479	1418	1421	LNA	T109,T121,T123	C0023749
28523479	1423	1425	CS	T129	C1440440
28523479	1428	1431	PAM	T109,T123	C0030234
28523479	1436	1438	CS	T129	C1440440
28523479	1441	1444	STA	T109,T121	C0038229
28523479	1445	1453	compared	T052	C1707455
28523479	1460	1463	FBS	T130	C3812213
28523479	1477	1487	expression	T045	C0017262
28523479	1491	1495	ATGL	T028	C1538686
28523479	1500	1506	C/EBPα	T028	C1413322
28523479	1511	1517	higher	T080	C0205250
28523479	1521	1523	CS	T129	C1440440
28523479	1525	1527	CS	T129	C1440440
28523479	1530	1533	OLA	T109,T121	C0028928
28523479	1538	1540	CS	T129	C1440440
28523479	1543	1546	LNA	T109,T121,T123	C0023749
28523479	1552	1555	FBS	T130	C3812213
28523479	1556	1561	cells	T025	C0007634
28523479	1584	1591	results	T033	C2825142
28523479	1604	1606	FA	T109	C0015684
28523479	1612	1621	different	T080	C1705242
28523479	1622	1632	potentials	T080	C3245505
28523479	1636	1642	induce	T169	C0205263
28523479	1643	1655	adipogenesis	T044	C0596843
28523479	1657	1660	LNA	T109,T121,T123	C0023749
28523479	1673	1679	potent	T080	C3245505
28523479	1697	1699	FA	T109	C0015684
28523479	1711	1721	potentials	T080	C3245505
28523479	1745	1753	presence	T033	C0150312
28523479	1757	1759	CS	T129	C1440440

27526315|t|Expression and methylation in posttraumatic stress disorder and resilience; evidence of a role for odorant receptors
27526315|a|Post-traumatic stress disorder (PTSD) is a common and potentially disabling disorder that develops in 1/5 to 1/3 of people exposed to severe trauma. Twin studies indicate that genetic factors account for at least one third of the variance in the risk for developing PTSD, however, the specific role for genetic factors in the pathogenesis of PTSD is not well understood. We studied genome-wide gene expression and DNA methylation profiles in 12 participants with PTSD and 12 participants who were resilient to similar severity trauma exposure. Close to 4000 genes were differentially expressed with adjusted p<0.05, fold-change >2, with all but 3 upregulated with PTSD. Eight odorant/olfactory receptor related genes were up-regulated with PTSD as well as genes related to immune activation, the Gamma-Aminobutyric Acid A (GABAA) receptor, and vitamin D synthesis. No differences with adjusted significance for DNA methylation were found. We conclude that increased gene expression may play an important role in PTSD and this expression may not be a consequence of DNA methylation. The role of odorant receptor expression warrants independent replication.
27526315	0	10	Expression	T045	C0017262
27526315	15	26	methylation	T044	C0376452
27526315	30	59	posttraumatic stress disorder	T048	C0038436
27526315	64	74	resilience	T055	C0683253
27526315	76	84	evidence	T078	C3887511
27526315	90	94	role	T077	C1705810
27526315	99	116	odorant receptors	T116,T192	C0164313
27526315	117	147	Post-traumatic stress disorder	T048	C0038436
27526315	149	153	PTSD	T048	C0038436
27526315	171	182	potentially	T080	C3245505
27526315	183	201	disabling disorder	T047	C0596452
27526315	233	239	people	T098	C0027361
27526315	240	250	exposed to	T080	C0332157
27526315	251	257	severe	T080	C0205082
27526315	258	264	trauma	T037	C3714660
27526315	266	278	Twin studies	T170	C1096782
27526315	293	300	genetic	T169	C0314603
27526315	301	308	factors	T169	C1521761
27526315	347	355	variance	T080	C1711260
27526315	383	387	PTSD	T048	C0038436
27526315	402	410	specific	T080	C0205369
27526315	411	415	role	T077	C1705810
27526315	420	427	genetic	T169	C0314603
27526315	428	435	factors	T169	C1521761
27526315	443	455	pathogenesis	T046	C0699748
27526315	459	463	PTSD	T048	C0038436
27526315	499	510	genome-wide	T063	C2350277
27526315	511	526	gene expression	T045	C0017262
27526315	531	546	DNA methylation	T044	C0376452
27526315	547	555	profiles	T081	C0237801
27526315	562	574	participants	T098	C0679646
27526315	580	584	PTSD	T048	C0038436
27526315	592	604	participants	T098	C0679646
27526315	614	623	resilient	T055	C0683253
27526315	635	643	severity	T080	C0392364
27526315	644	650	trauma	T037	C3714660
27526315	651	659	exposure	T080	C0332157
27526315	675	680	genes	T028	C0017337
27526315	686	700	differentially	T080	C0443199
27526315	701	710	expressed	T045	C0017262
27526315	716	724	adjusted	T169	C0456081
27526315	733	744	fold-change	T081	C1880833
27526315	764	775	upregulated	T044	C0041904
27526315	781	785	PTSD	T048	C0038436
27526315	793	819	odorant/olfactory receptor	T116,T192	C0164313
27526315	828	833	genes	T028	C0017337
27526315	839	851	up-regulated	T044	C0041904
27526315	857	861	PTSD	T048	C0038436
27526315	873	878	genes	T028	C0017337
27526315	890	907	immune activation	T043	C1155000
27526315	913	955	Gamma-Aminobutyric Acid A (GABAA) receptor	T116,T192	C0206518
27526315	961	980	vitamin D synthesis	T044	C1157731
27526315	1002	1010	adjusted	T169	C0456081
27526315	1011	1023	significance	T078	C0750502
27526315	1028	1043	DNA methylation	T044	C0376452
27526315	1073	1082	increased	T081	C0205217
27526315	1083	1098	gene expression	T045	C0017262
27526315	1111	1120	important	T080	C3898777
27526315	1121	1125	role	T077	C1705810
27526315	1129	1133	PTSD	T048	C0038436
27526315	1143	1153	expression	T045	C0017262
27526315	1167	1181	consequence of	T169	C0686907
27526315	1182	1197	DNA methylation	T044	C0376452
27526315	1203	1207	role	T077	C1705810
27526315	1211	1227	odorant receptor	T116,T192	C0164313
27526315	1228	1238	expression	T045	C0597360
27526315	1248	1259	independent	T169	C0332291
27526315	1260	1271	replication	T045	C0598312

27863736|t|Moberg Picking-Up Test in patients with hand osteoarthritis
27863736|a|Clinical measurement. The Moberg Pick-up Test (MPUT) was previously used to evaluate functional performance in patients with hand inflammatory disease. This is the first study using the MPUT in hand osteoarthritis (OA). Compare the functional performance (MPUT) in hand OA patients and healthy controls. Fifty hand OA patients and 50 controls were assessed using the MPUT, AUSCAN and Cochin questionnaires, grip and pinch strength, pain using a visual analog scale and a Likert scale regarding difficulty to perform MPUT. In the MPUT evaluation, the OA group presented a statistically significant difference from the control group. The OA group spent more time executing test. The grip and pinch strength measurements showed higher values for the control group. The OA group reported a greater difficulty than the control group in performing the test. The MPUT is a short and easy to apply test, which can be safely used to assess the functional performance of the hand OA. II.
27863736	0	22	Moberg Picking-Up Test	T059	C1293918
27863736	26	34	patients	T101	C0030705
27863736	40	59	hand osteoarthritis	T047	C0263746
27863736	60	80	Clinical measurement	T058	C0947289
27863736	86	105	Moberg Pick-up Test	T059	C1293918
27863736	107	111	MPUT	T059	C1293918
27863736	145	167	functional performance	T033	C3853978
27863736	171	179	patients	T101	C0030705
27863736	185	189	hand	T023	C0018563
27863736	190	210	inflammatory disease	T047	C1290884
27863736	246	250	MPUT	T059	C1293918
27863736	254	273	hand osteoarthritis	T047	C0263746
27863736	275	277	OA	T047	C0263746
27863736	292	314	functional performance	T033	C3853978
27863736	316	320	MPUT	T059	C1293918
27863736	325	332	hand OA	T047	C0263746
27863736	333	341	patients	T101	C0030705
27863736	346	362	healthy controls	T080	C2986479
27863736	370	377	hand OA	T047	C0263746
27863736	378	386	patients	T101	C0030705
27863736	394	402	controls	T096	C0009932
27863736	427	431	MPUT	T059	C1293918
27863736	433	439	AUSCAN	T170	C3891717
27863736	444	465	Cochin questionnaires	T170	C0034394
27863736	467	471	grip	T033	C0518032
27863736	476	490	pinch strength	T060	C1720876
27863736	492	496	pain	T184	C0030193
27863736	505	524	visual analog scale	T060	C0042815
27863736	531	543	Likert scale	T170	C0451267
27863736	576	580	MPUT	T059	C1293918
27863736	589	593	MPUT	T059	C1293918
27863736	594	604	evaluation	T058	C1261322
27863736	610	612	OA	T047	C0263746
27863736	631	656	statistically significant	T081	C0237881
27863736	677	690	control group	T096	C0009932
27863736	696	698	OA	T047	C0263746
27863736	711	715	more	T081	C0205172
27863736	716	720	time	T079	C0040223
27863736	731	735	test	T170	C0392366
27863736	741	745	grip	T033	C0518032
27863736	750	777	pinch strength measurements	T060	C1720876
27863736	807	820	control group	T096	C0009932
27863736	826	828	OA	T047	C0263746
27863736	854	864	difficulty	T080	C0332218
27863736	874	887	control group	T096	C0009932
27863736	906	910	test	T170	C0392366
27863736	916	920	MPUT	T059	C1293918
27863736	950	954	test	T170	C0392366
27863736	995	1017	functional performance	T033	C3853978
27863736	1025	1032	hand OA	T047	C0263746

28240640|t|Comparison of 270 Versus 320 mg I/mL of Iodixanol in 1 Image Assessment of Both Renal Arteries and Veins With Dual-Energy Spectral CT Imaging in Late Arterial Phase and Their Influence on Renal Function
28240640|a|The objective of this study was to compare the image quality of renal arteries and veins with dual-energy spectral computed tomography (CT) imaging in late arterial phase using 270 and 320 mg I/mL of iodixanol and their influence on renal function. A total of 1062 patients underwent renal CT angiography with 270 or 320 mg I/mL of iodixanol with dual-energy spectral CT imaging in late arterial phase. Image quality and their influence on renal function were compared. There were no significant differences of CT value, signal-to-noise ratio, contrast-to-noise ratio, and subjective score of renal vessels between 2 groups (all P > 0.05). The incidence of contrast-induced nephropathy in patients with abnormal renal function using 320 mg I/mL of iodixanol was significantly higher than using 270 mg I/mL of iodixanol (P = 0.043). The renal arteries and veins can be fully assessed in late arterial phase with 270 mg I/mL of iodixanol using dual-energy spectral CT scan with better preserved renal function.
28240640	0	10	Comparison	T052	C1707455
28240640	14	17	270	T200	C0977876
28240640	25	49	320 mg I/mL of Iodixanol	T200	C0977877
28240640	55	71	Image Assessment	T058	C4076410
28240640	80	94	Renal Arteries	T023	C0035065
28240640	99	104	Veins	T023	C0042449
28240640	110	141	Dual-Energy Spectral CT Imaging	T060	C0729619
28240640	145	164	Late Arterial Phase	T079	C0205390
28240640	175	184	Influence	T077	C4054723
28240640	188	202	Renal Function	T042	C0232804
28240640	225	230	study	T062	C2603343
28240640	238	245	compare	T052	C1707455
28240640	250	263	image quality	T080	C0806487
28240640	267	281	renal arteries	T023	C0035065
28240640	286	291	veins	T023	C0042449
28240640	297	350	dual-energy spectral computed tomography (CT) imaging	T060	C0729619
28240640	354	373	late arterial phase	T079	C0205390
28240640	380	383	270	T200	C0977876
28240640	388	412	320 mg I/mL of iodixanol	T200	C0977877
28240640	423	432	influence	T077	C4054723
28240640	436	450	renal function	T042	C0232804
28240640	468	476	patients	T101	C0030705
28240640	487	507	renal CT angiography	T060	C1637292
28240640	513	516	270	T200	C0977876
28240640	520	544	320 mg I/mL of iodixanol	T200	C0977877
28240640	550	581	dual-energy spectral CT imaging	T060	C0729619
28240640	585	604	late arterial phase	T079	C0205390
28240640	606	619	Image quality	T080	C0806487
28240640	630	639	influence	T077	C4054723
28240640	643	657	renal function	T042	C0232804
28240640	663	671	compared	T052	C1707455
28240640	714	722	CT value	T081	C1522609
28240640	724	745	signal-to-noise ratio	T081	C2986823
28240640	747	770	contrast-to-noise ratio	T081	C0456603
28240640	787	792	score	T081	C0449820
28240640	796	809	renal vessels	T023	C0580863
28240640	847	856	incidence	T081	C0021149
28240640	860	888	contrast-induced nephropathy	T047	C4055183
28240640	892	900	patients	T101	C0030705
28240640	906	929	abnormal renal function	T046	C0151746
28240640	936	960	320 mg I/mL of iodixanol	T200	C0977877
28240640	997	1021	270 mg I/mL of iodixanol	T200	C0977876
28240640	1039	1053	renal arteries	T023	C0035065
28240640	1058	1063	veins	T023	C0042449
28240640	1089	1108	late arterial phase	T079	C0205390
28240640	1114	1138	270 mg I/mL of iodixanol	T200	C0977876
28240640	1145	1173	dual-energy spectral CT scan	T060	C0177779
28240640	1196	1210	renal function	T042	C0232804

28232582|t|PUMILIO / FOXP1 signaling drives expansion of hematopoietic stem/progenitor and leukemia cells
28232582|a|RNA-binding proteins (RBPs) have emerged as important regulators of invertebrate adult stem cells, but their activities remain poorly appreciated in mammals. Using a short hairpin RNA strategy, we demonstrate here that the 2 mammalian RBPs, PUMILIO (PUM)1 and PUM2, members of the PUF family of posttranscriptional regulators, are essential for hematopoietic stem/progenitor cell (HSPC) proliferation and survival in vitro and in vivo upon reconstitution assays. Moreover, we found that PUM1 / 2 sustain myeloid leukemic cell growth. Through a proteomic approach, we identified the FOXP1 transcription factor as a new target of PUM1 / 2. Contrary to its canonical repressive activity, PUM1 / 2 rather promote FOXP1 expression by a direct binding to 2 canonical PUM responsive elements present in the FOXP1 - 3' untranslated region (UTR). Expression of FOXP1 strongly correlates with PUM1 and PUM2 levels in primary HSPCs and myeloid leukemia cells. We demonstrate that FOXP1 by itself supports HSPC and leukemic cell growth, thus mimicking PUM activities. Mechanistically, FOXP1 represses the expression of the p21(-CIP1) and p27(-KIP1) cell cycle inhibitors. Enforced FOXP1 expression reverses shPUM antiproliferative and proapoptotic activities. Altogether, our results reveal a novel regulatory pathway, underscoring a previously unknown and interconnected key role of PUM1 / 2 and FOXP1 in regulating normal HSPC and leukemic cell growth.
28232582	0	7	PUMILIO	T116,T123	C1144521
28232582	10	15	FOXP1	T116,T123	C1450221
28232582	16	25	signaling	T038	C3537152
28232582	33	42	expansion	T043	C0007595
28232582	46	75	hematopoietic stem/progenitor	T025	C0018956
28232582	80	88	leukemia	T191	C0023418
28232582	89	94	cells	T025	C0007634
28232582	95	115	RNA-binding proteins	T116,T123	C0085177
28232582	117	121	RBPs	T116,T123	C0085177
28232582	163	175	invertebrate	T204	C0021948
28232582	176	192	adult stem cells	T025	C1171322
28232582	222	228	poorly	T080	C0205169
28232582	244	251	mammals	T015	C0024660
28232582	261	278	short hairpin RNA	T114	C2930586
28232582	279	287	strategy	T041	C0679199
28232582	320	329	mammalian	T015	C0024660
28232582	330	334	RBPs	T116,T123	C0085177
28232582	336	343	PUMILIO	T116,T123	C1144521
28232582	345	350	PUM)1	T116,T123	C1174251
28232582	355	359	PUM2	T116	C1174252
28232582	376	386	PUF family	T116,T123	C0085177
28232582	390	420	posttranscriptional regulators	T045	C2611903
28232582	440	495	hematopoietic stem/progenitor cell (HSPC) proliferation	T043	C2754627
28232582	500	508	survival	T169	C0220921
28232582	509	517	in vitro	T080	C1533691
28232582	522	529	in vivo	T082	C1515655
28232582	535	556	reconstitution assays	T059	C0005507
28232582	582	586	PUM1	T116,T123	C1174251
28232582	589	590	2	T116	C1174252
28232582	599	615	myeloid leukemic	T191	C0023470
28232582	616	627	cell growth	T043	C0007595
28232582	639	648	proteomic	T091	C0872252
28232582	677	682	FOXP1	T028	C1414688
28232582	683	703	transcription factor	T116,T123	C0040648
28232582	713	719	target	T169	C1521840
28232582	723	727	PUM1	T116,T123	C1174251
28232582	730	731	2	T116	C1174252
28232582	759	778	repressive activity	T045	C0920533
28232582	780	784	PUM1	T116,T123	C1174251
28232582	787	788	2	T116	C1174252
28232582	804	809	FOXP1	T028	C1414688
28232582	810	820	expression	T045	C0017262
28232582	833	840	binding	T044	C1167622
28232582	856	859	PUM	T116,T123	C1144521
28232582	860	879	responsive elements	T114,T123	C0600508
28232582	895	900	FOXP1	T028	C1414688
28232582	903	925	3' untranslated region	T086,T123	C0600600
28232582	927	930	UTR	T114	C0600680
28232582	933	943	Expression	T045	C0017262
28232582	947	952	FOXP1	T116,T123	C1450221
28232582	978	982	PUM1	T116,T123	C1174251
28232582	987	991	PUM2	T116	C1174252
28232582	1010	1015	HSPCs	T025	C0018956
28232582	1020	1036	myeloid leukemia	T191	C0023470
28232582	1037	1042	cells	T025	C0007634
28232582	1064	1069	FOXP1	T116,T123	C1450221
28232582	1089	1093	HSPC	T025	C0018956
28232582	1098	1106	leukemic	T191	C0023470
28232582	1107	1118	cell growth	T043	C0007595
28232582	1135	1138	PUM	T116,T123	C1144521
28232582	1168	1173	FOXP1	T116,T123	C1450221
28232582	1188	1198	expression	T045	C1171362
28232582	1206	1216	p21(-CIP1)	T116,T123	C0288472
28232582	1221	1231	p27(-KIP1)	T116,T123	C0169665
28232582	1232	1242	cell cycle	T043	C0007586
28232582	1243	1253	inhibitors	T120	C0243077
28232582	1264	1269	FOXP1	T028	C1414688
28232582	1270	1280	expression	T045	C0017262
28232582	1290	1295	shPUM	T116,T123	C1144521
28232582	1376	1381	novel	T080	C0205314
28232582	1382	1400	regulatory pathway	T169	C1514829
28232582	1467	1471	PUM1	T116,T123	C1174251
28232582	1474	1475	2	T116	C1174252
28232582	1480	1485	FOXP1	T116,T123	C1450221
28232582	1507	1511	HSPC	T025	C0018956
28232582	1516	1524	leukemic	T191	C0023418
28232582	1525	1536	cell growth	T043	C0007595

27760981|t|Arterial thoracic outlet syndrome: rare and triggering
27760981|a|Arterial thoracic outlet syndrome (TOS) is the least common type of TOS. Patient's symptoms, clinical examination and duplex ultrasonography usually suffice in deciding patient's management. Our proposed treatment strategies are based on the Scher classification. The choice of the procedure and approach should depend on surgeon's experience and need for arterial reconstruction.
27760981	0	33	Arterial thoracic outlet syndrome	T047	C1956395
27760981	35	39	rare	T080	C0522498
27760981	55	88	Arterial thoracic outlet syndrome	T047	C1956395
27760981	90	93	TOS	T047	C1956395
27760981	123	126	TOS	T047	C0039984
27760981	128	137	Patient's	T101	C0030705
27760981	138	146	symptoms	T184	C1457887
27760981	148	168	clinical examination	T033	C1456356
27760981	173	195	duplex ultrasonography	T060	C3825392
27760981	224	244	patient's management	T058	C1610129
27760981	259	279	treatment strategies	T061	C0087111
27760981	297	317	Scher classification	T185	C0008902
27760981	323	329	choice	T052	C1707391
27760981	337	346	procedure	T061	C0237403
27760981	377	386	surgeon's	T097	C0582175
27760981	387	397	experience	T041	C0237607
27760981	411	434	arterial reconstruction	T061	C2937236

28332776|t|Interferon gamma and interleukin 10 polymorphisms in Chinese children with hemophagocytic lymphohistiocytosis
28332776|a|The aim of the study is to investigate the association of interferon gamma (IFN-γ) and interleukin-10 (IL-10) gene single nucleotide polymorphisms with the susceptibility of hemophagocytic lymphohistiocytosis (HLH) in Chinese children without known family history of HLH. Forty children with HLH and 160 age - and gender -matched healthy controls from Xuzhou Children's Hospital were enrolled in the study. Serum IFN-γ and IL-10 levels were measured by enzyme linked-immunosorbent assay. Polymorphisms of the IFN-γ gene at position +874 and +2109, and IL-10 at position -1082 were analyzed by allele - specific PCR. Median serum concentrations of IFN -γ and IL-10 were significantly higher in children with HLH compared to healthy controls. The frequencies of IFN-γ +874 T/A and T/T genotypes, as well as T allele, were significantly higher in the HLH group compared with those in the control group. The frequencies of IL-10 -1082 G/A genotype and G allele were significantly increased in HLH patients compared with healthy controls. No significant difference was found in the distribution of IFN-γ +2109 G/A genotypes between children with HLH and controls. This study presents preliminary evidence for the association between IFN +874 T/A, T/T, IL-10 -1082 A/G genotypes, and HLH susceptibility in Chinese children with HLH.
28332776	0	16	Interferon gamma	T028	C1334085
28332776	21	35	interleukin 10	T028	C1334098
28332776	36	49	polymorphisms	T045	C0678951
28332776	53	60	Chinese	T098	C0152035
28332776	61	69	children	T100	C0008059
28332776	75	109	hemophagocytic lymphohistiocytosis	T047	C0024291
28332776	125	130	study	T062	C2603343
28332776	137	148	investigate	T169	C1292732
28332776	168	184	interferon gamma	T028	C1334085
28332776	186	191	IFN-γ	T028	C1334085
28332776	197	211	interleukin-10	T028	C1334098
28332776	213	218	IL-10	T028	C1334098
28332776	220	224	gene	T028	C0017337
28332776	225	256	single nucleotide polymorphisms	T086	C0752046
28332776	266	280	susceptibility	T201	C0012655
28332776	284	318	hemophagocytic lymphohistiocytosis	T047	C0024291
28332776	320	323	HLH	T047	C0024291
28332776	328	335	Chinese	T098	C0152035
28332776	336	344	children	T100	C0008059
28332776	345	376	without known family history of	T033	C0332123
28332776	377	380	HLH	T047	C0024291
28332776	388	396	children	T100	C0008059
28332776	402	405	HLH	T047	C0024291
28332776	414	417	age	T032	C0001779
28332776	424	430	gender	T032	C0079399
28332776	440	456	healthy controls	T080	C2986479
28332776	462	488	Xuzhou Children's Hospital	T073,T093	C0019994
28332776	510	515	study	T062	C2603343
28332776	517	522	Serum	T031	C0229671
28332776	523	528	IFN-γ	T116,T121,T129	C3539881
28332776	533	538	IL-10	T116,T129	C0085295
28332776	551	559	measured	T080	C0444706
28332776	563	596	enzyme linked-immunosorbent assay	T059	C0014441
28332776	598	611	Polymorphisms	T045	C0678951
28332776	619	629	IFN-γ gene	T028	C1334085
28332776	662	667	IL-10	T028	C1334098
28332776	691	699	analyzed	T033	C2963401
28332776	703	709	allele	T028	C0002085
28332776	712	720	specific	T080	C0205369
28332776	721	724	PCR	T063	C0032520
28332776	726	738	Median serum	T031	C0229671
28332776	739	753	concentrations	T081	C1446561
28332776	757	763	IFN -γ	T116,T121,T129	C3539881
28332776	768	773	IL-10	T116,T129	C0085295
28332776	779	799	significantly higher	T081	C4055637
28332776	803	811	children	T100	C0008059
28332776	817	820	HLH	T047	C0024291
28332776	821	829	compared	T052	C1707455
28332776	833	849	healthy controls	T080	C2986479
28332776	855	866	frequencies	T079	C0439603
28332776	870	875	IFN-γ	T028	C1334085
28332776	881	902	T/A and T/T genotypes	T032	C0017431
28332776	915	923	T allele	T028	C0002085
28332776	930	950	significantly higher	T081	C4055637
28332776	958	961	HLH	T047	C0024291
28332776	968	976	compared	T052	C1707455
28332776	995	1008	control group	T096	C0009932
28332776	1014	1025	frequencies	T079	C0439603
28332776	1029	1034	IL-10	T028	C1334098
28332776	1041	1053	G/A genotype	T032	C0017431
28332776	1058	1066	G allele	T028	C0002085
28332776	1072	1095	significantly increased	T081	C4055637
28332776	1099	1102	HLH	T047	C0024291
28332776	1103	1111	patients	T101	C0030705
28332776	1112	1120	compared	T052	C1707455
28332776	1126	1142	healthy controls	T080	C2986479
28332776	1144	1158	No significant	T033	C1273937
28332776	1159	1169	difference	T033	C3842396
28332776	1187	1199	distribution	T169	C1704711
28332776	1203	1208	IFN-γ	T028	C1334085
28332776	1215	1228	G/A genotypes	T032	C0017431
28332776	1237	1245	children	T100	C0008059
28332776	1251	1254	HLH	T047	C0024291
28332776	1259	1267	controls	T080	C0243148
28332776	1274	1279	study	T062	C2603343
28332776	1280	1288	presents	T033	C0150312
28332776	1289	1300	preliminary	T079	C0439611
28332776	1301	1309	evidence	T078	C3887511
28332776	1338	1341	IFN	T028	C1334085
28332776	1347	1355	T/A, T/T	T032	C0017431
28332776	1357	1362	IL-10	T028	C1334098
28332776	1369	1382	A/G genotypes	T032	C0017431
28332776	1388	1391	HLH	T047	C0024291
28332776	1392	1406	susceptibility	T201	C0012655
28332776	1410	1417	Chinese	T098	C0152035
28332776	1418	1426	children	T100	C0008059
28332776	1432	1435	HLH	T047	C0024291

27494907|t|Cluster - dependent colistin hetero-resistance in Enterobacter cloacae complex
27494907|a|Aims of this study were to: (i) evaluate whether the cluster membership could have an impact on hetero-resistance phenotype to colistin in the Enterobacter cloacae complex (ECC); and (ii) determine the genetic mechanism of colistin hetero-resistance in ECC. A collection of 124 clinical isolates belonging to 13 clusters were used to analyse the hetero-resistance phenotype (MICs were determined using the broth microdilution method, Etest and population analysis profiling). Different mutants (ΔphoP, ΔphoQ, ΔphoPQ, ΔpmrA, ΔpmrB, ΔpmrAB, ΔarnE, ΔarnF and ΔarnBCADTEF) were constructed and tested for their colistin hetero-resistance phenotype. Based on broth microdilution and Etest results, it was shown that the hetero-resistance to colistin depended on the cluster: strains from clusters I, II, IV, VII, IX, X, XI and XII were usually hetero-resistant, whereas those from clusters III, V, VI, VIII and XIII were categorized as susceptible. However, for some cluster V and VIII strains, a small proportion (<10(-7)) of cells appeared resistant when tested by population analysis profiling. From a mechanistic point of view, analysis of mutants revealed that the mechanism of hetero-resistance was mainly due to the expression of the arn operon and the phoP / phoQ two-component regulatory system. Because the colistin hetero-resistance appeared cluster - dependent in the ECC, it should be advocated to determine the cluster of the strain associated with the infection in parallel with the MIC of colistin. The resistance mechanism may not be similar to other Enterobacteriaceae since only the two-component regulatory system PhoP / PhoQ (and not PmrA / PmrB) seemed to play a role in resistance regulation.
27494907	0	7	Cluster	T081	C1704332
27494907	10	19	dependent	T080	C0851827
27494907	20	28	colistin	T116,T195	C0009316
27494907	29	46	hetero-resistance	T169	C4281815
27494907	50	78	Enterobacter cloacae complex	T007	C0085484
27494907	111	119	evaluate	T058	C0220825
27494907	132	139	cluster	T081	C1704332
27494907	165	171	impact	T080	C4049986
27494907	175	192	hetero-resistance	T169	C4281815
27494907	193	202	phenotype	T032	C0031437
27494907	206	214	colistin	T116,T195	C0009316
27494907	222	250	Enterobacter cloacae complex	T007	C0085484
27494907	252	255	ECC	T007	C0085484
27494907	281	288	genetic	T169	C0314603
27494907	289	298	mechanism	T169	C0441712
27494907	302	310	colistin	T116,T195	C0009316
27494907	311	328	hetero-resistance	T169	C4281815
27494907	332	335	ECC	T007	C0085484
27494907	339	349	collection	T169	C1516698
27494907	357	365	clinical	T080	C0205210
27494907	366	374	isolates	T123	C1764827
27494907	391	399	clusters	T081	C1704332
27494907	413	420	analyse	T062	C0936012
27494907	425	442	hetero-resistance	T169	C4281815
27494907	443	452	phenotype	T032	C0031437
27494907	454	458	MICs	T059	C0427978
27494907	464	480	determined using	T080	C0521095
27494907	485	511	broth microdilution method	T059	C0441667
27494907	513	518	Etest	T059	C3850116
27494907	523	552	population analysis profiling	T059	C0022885
27494907	555	564	Different	T080	C1705242
27494907	565	572	mutants	T049	C0596988
27494907	574	579	ΔphoP	T028	C0678941
27494907	581	586	ΔphoQ	T028	C0678941
27494907	588	594	ΔphoPQ	T028	C0678941
27494907	596	601	ΔpmrA	T028	C0678941
27494907	603	608	ΔpmrB	T028	C0678941
27494907	610	616	ΔpmrAB	T028	C0678941
27494907	618	623	ΔarnE	T028	C0678941
27494907	625	630	ΔarnF	T028	C0678941
27494907	635	646	ΔarnBCADTEF	T028	C0678941
27494907	653	664	constructed	T169	C1522492
27494907	669	675	tested	T169	C0039593
27494907	686	694	colistin	T116,T195	C0009316
27494907	695	712	hetero-resistance	T169	C4281815
27494907	713	722	phenotype	T032	C0031437
27494907	733	752	broth microdilution	T059	C0441667
27494907	757	762	Etest	T059	C3850116
27494907	763	770	results	T034	C0456984
27494907	794	811	hetero-resistance	T169	C4281815
27494907	815	823	colistin	T116,T195	C0009316
27494907	840	847	cluster	T081	C1704332
27494907	849	856	strains	T001	C1518614
27494907	862	870	clusters	T081	C1704332
27494907	918	934	hetero-resistant	T169	C4281815
27494907	955	963	clusters	T081	C1704332
27494907	995	1006	categorized	T052	C0871968
27494907	1010	1021	susceptible	T169	C0231204
27494907	1041	1048	cluster	T081	C1704332
27494907	1060	1067	strains	T001	C1518614
27494907	1071	1076	small	T081	C0700321
27494907	1077	1087	proportion	T081	C1709707
27494907	1101	1106	cells	T025	C0007634
27494907	1116	1125	resistant	T169	C0332325
27494907	1131	1137	tested	T169	C0039593
27494907	1206	1214	analysis	T062	C0936012
27494907	1218	1225	mutants	T049	C0596988
27494907	1226	1234	revealed	T080	C0443289
27494907	1244	1253	mechanism	T169	C0441712
27494907	1257	1274	hetero-resistance	T169	C4281815
27494907	1297	1307	expression	T045	C0017262
27494907	1315	1325	arn operon	T028	C0029073
27494907	1334	1338	phoP	T116,T123	C1429451
27494907	1341	1345	phoQ	T116,T123	C1437563
27494907	1346	1377	two-component regulatory system	T123	C0574031
27494907	1391	1399	colistin	T116,T195	C0009316
27494907	1400	1417	hetero-resistance	T169	C4281815
27494907	1427	1434	cluster	T081	C1704332
27494907	1437	1446	dependent	T080	C0851827
27494907	1454	1457	ECC	T007	C0085484
27494907	1499	1506	cluster	T081	C1704332
27494907	1514	1520	strain	T001	C1518614
27494907	1521	1536	associated with	T080	C0332281
27494907	1541	1550	infection	T046	C3714514
27494907	1572	1575	MIC	T059	C0427978
27494907	1579	1587	colistin	T116,T195	C0009316
27494907	1593	1603	resistance	T169	C4281815
27494907	1604	1613	mechanism	T169	C0441712
27494907	1642	1660	Enterobacteriaceae	T007	C0014346
27494907	1676	1707	two-component regulatory system	T123	C0574031
27494907	1708	1712	PhoP	T116,T123	C1429451
27494907	1715	1719	PhoQ	T116,T123	C1437563
27494907	1729	1733	PmrA	T116,T123	C1429861
27494907	1736	1740	PmrB	T116,T123	C1449385
27494907	1767	1777	resistance	T169	C4281815
27494907	1778	1788	regulation	T038	C1327622

27766178|t|Total Arsenic, Cadmium, and Lead Determination in Brazilian Rice Samples Using ICP-MS
27766178|a|This study is aimed at investigating a suitable method for rice sample preparation as well as validating and applying the method for monitoring the concentration of total arsenic, cadmium, and lead in rice by using Inductively Coupled Plasma Mass Spectrometry (ICP-MS). Various rice sample preparation procedures were evaluated. The analytical method was validated by measuring several parameters including limit of detection (LOD), limit of quantification (LOQ), linearity, relative bias, and repeatability. Regarding the sample preparation, recoveries of spiked samples were within the acceptable range from 89.3 to 98.2% for muffle furnace, 94.2 to 103.3% for heating block, 81.0 to 115.0% for hot plate, and 92.8 to 108.2% for microwave. Validation parameters showed that the method fits for its purpose, being the total arsenic, cadmium, and lead within the Brazilian Legislation limits. The method was applied for analyzing 37 rice samples (including polished, brown, and parboiled), consumed by the Brazilian population. The total arsenic, cadmium, and lead contents were lower than the established legislative values, except for total arsenic in one brown rice sample. This study indicated the need to establish monitoring programs for emphasizing the study on this type of cereal, aiming at promoting the Public Health.
27766178	0	5	Total	T080	C0439810
27766178	6	13	Arsenic	T121,T131,T196	C0003818
27766178	15	22	Cadmium	T131,T196	C0006632
27766178	28	32	Lead	T131,T196	C0023175
27766178	33	46	Determination	T059	C1148554
27766178	50	64	Brazilian Rice	T168	C0035567
27766178	65	72	Samples	T167	C0370003
27766178	79	85	ICP-MS	T059	C1553183
27766178	91	96	study	T062	C2603343
27766178	109	122	investigating	T169	C1292732
27766178	134	140	method	T170	C0025663
27766178	145	149	rice	T168	C0035567
27766178	150	156	sample	T167	C0370003
27766178	157	168	preparation	T052	C1521827
27766178	180	190	validating	T062	C1519941
27766178	195	203	applying	T169	C0205245
27766178	208	214	method	T170	C0025663
27766178	219	229	monitoring	T169	C0205245
27766178	234	247	concentration	T081	C1446561
27766178	251	256	total	T080	C0439810
27766178	257	264	arsenic	T121,T131,T196	C0003818
27766178	266	273	cadmium	T131,T196	C0006632
27766178	279	283	lead	T131,T196	C0023175
27766178	287	291	rice	T168	C0035567
27766178	301	345	Inductively Coupled Plasma Mass Spectrometry	T059	C1553183
27766178	347	353	ICP-MS	T059	C1553183
27766178	364	368	rice	T168	C0035567
27766178	369	375	sample	T167	C0370003
27766178	376	387	preparation	T052	C1521827
27766178	388	398	procedures	T169	C2700391
27766178	419	436	analytical method	T170	C0178476
27766178	441	450	validated	T062	C1519941
27766178	454	463	measuring	T169	C0242485
27766178	472	482	parameters	T033	C0449381
27766178	493	511	limit of detection	T081	C2718050
27766178	513	516	LOD	T081	C2718050
27766178	519	542	limit of quantification	T081	C1709793
27766178	544	547	LOQ	T081	C1709793
27766178	550	559	linearity	T081	C0392762
27766178	561	574	relative bias	T078	C0242568
27766178	580	593	repeatability	T080	C0205556
27766178	609	615	sample	T167	C0370003
27766178	616	627	preparation	T052	C1521827
27766178	629	639	recoveries	T033	C0683340
27766178	643	657	spiked samples	T167	C0370003
27766178	674	690	acceptable range	T081	C1514721
27766178	714	728	muffle furnace	T073	C1708110
27766178	749	762	heating block	T074	C0181153
27766178	783	792	hot plate	T074	C0182315
27766178	817	826	microwave	T073	C0336756
27766178	828	838	Validation	T062	C1519941
27766178	839	849	parameters	T033	C0449381
27766178	866	872	method	T170	C0025663
27766178	905	910	total	T080	C0439810
27766178	911	918	arsenic	T121,T131,T196	C0003818
27766178	920	927	cadmium	T131,T196	C0006632
27766178	933	937	lead	T131,T196	C0023175
27766178	983	989	method	T170	C0025663
27766178	1006	1015	analyzing	T062	C0936012
27766178	1019	1023	rice	T168	C0035567
27766178	1024	1031	samples	T167	C0370003
27766178	1043	1051	polished	T168	C0035567
27766178	1053	1058	brown	T168	C0452710
27766178	1064	1073	parboiled	T168	C0035567
27766178	1092	1112	Brazilian population	T081	C0032659
27766178	1118	1123	total	T080	C0439810
27766178	1124	1131	arsenic	T121,T131,T196	C0003818
27766178	1133	1140	cadmium	T131,T196	C0006632
27766178	1146	1150	lead	T131,T196	C0023175
27766178	1151	1159	contents	T077	C0456205
27766178	1192	1203	legislative	T170	C2937257
27766178	1204	1210	values	T080	C0042295
27766178	1223	1228	total	T080	C0439810
27766178	1229	1236	arsenic	T121,T131,T196	C0003818
27766178	1244	1254	brown rice	T168	C0452710
27766178	1255	1261	sample	T167	C0370003
27766178	1268	1273	study	T062	C2603343
27766178	1306	1316	monitoring	T169	C0205245
27766178	1317	1325	programs	T169	C3484370
27766178	1346	1351	study	T062	C2603343
27766178	1360	1364	type	T080	C0332307
27766178	1368	1374	cereal	T168	C0007757
27766178	1400	1413	Public Health	T170	C3244304

27348576|t|Heterogeneous silicon mesostructures for lipid -supported bioelectric interfaces
27348576|a|Silicon -based materials have widespread application as biophysical tools and biomedical devices. Here we introduce a biocompatible and degradable mesostructured form of silicon with multi-scale structural and chemical heterogeneities. The material was synthesized using mesoporous silica as a template through a chemical vapour deposition process. It has an amorphous atomic structure, an ordered nanowire -based framework and random submicrometre voids, and shows an average Young's modulus that is 2-3 orders of magnitude smaller than that of single-crystalline silicon. In addition, we used the heterogeneous silicon mesostructures to design a lipid-bilayer -supported bioelectric interface that is remotely controlled and temporally transient, and that permits non - genetic and subcellular optical modulation of the electrophysiology dynamics in single dorsal root ganglia neurons. Our findings suggest that the biomimetic expansion of silicon into heterogeneous and deformable forms can open up opportunities in extracellular biomaterial or bioelectric systems.
27348576	0	13	Heterogeneous	T080	C0019409
27348576	14	21	silicon	T196	C0037107
27348576	22	36	mesostructures	T122	C0005479
27348576	41	46	lipid	T109	C0023779
27348576	58	69	bioelectric	T074	C0005485
27348576	70	80	interfaces	T044	C0596179
27348576	81	88	Silicon	T196	C0037107
27348576	96	105	materials	T167	C0520510
27348576	111	121	widespread	T082	C0205391
27348576	137	148	biophysical	T070	C2350452
27348576	149	154	tools	T073	C0336791
27348576	159	177	biomedical devices	T074	C0025080
27348576	199	212	biocompatible	T122	C0005479
27348576	217	227	degradable	T122	C0872311
27348576	228	242	mesostructured	T122	C0005479
27348576	251	258	silicon	T196	C0037107
27348576	264	286	multi-scale structural	T085	C0026383
27348576	291	299	chemical	T169	C0079107
27348576	300	315	heterogeneities	T080	C0019409
27348576	321	329	material	T167	C0520510
27348576	334	345	synthesized	T052	C1883254
27348576	352	369	mesoporous silica	T122,T197	C0037098
27348576	375	383	template	T078	C1705542
27348576	394	428	chemical vapour deposition process	T067	C1522240
27348576	440	449	amorphous	T080	C1979848
27348576	450	456	atomic	T196	C0567415
27348576	457	466	structure	T082	C0678594
27348576	471	478	ordered	T080	C1705176
27348576	479	487	nanowire	T073	C1721063
27348576	509	515	random	T080	C0439605
27348576	516	529	submicrometre	T081	C0439201
27348576	530	535	voids	T082	C1883067
27348576	550	557	average	T081	C1510992
27348576	558	573	Young's modulus	T081	C2350289
27348576	596	605	magnitude	T081	C1704240
27348576	606	618	smaller than	T081	C1553887
27348576	627	645	single-crystalline	T104	C0444626
27348576	646	653	silicon	T196	C0037107
27348576	680	693	heterogeneous	T080	C0019409
27348576	694	701	silicon	T196	C0037107
27348576	702	716	mesostructures	T122	C0005479
27348576	729	742	lipid-bilayer	T026	C0023768
27348576	754	765	bioelectric	T039	C0598362
27348576	766	775	interface	T044	C0596179
27348576	784	792	remotely	T082	C0205157
27348576	793	803	controlled	T169	C0332298
27348576	808	828	temporally transient	T079	C0205374
27348576	839	846	permits	T080	C0521104
27348576	847	850	non	T169	C1518422
27348576	853	860	genetic	T169	C0314603
27348576	865	876	subcellular	T026	C3893246
27348576	877	895	optical modulation	UnknownType	C0678672
27348576	903	920	electrophysiology	UnknownType	C0678837
27348576	921	929	dynamics	T070	C3826426
27348576	933	939	single	T081	C0205171
27348576	940	959	dorsal root ganglia	T023	C0017070
27348576	960	967	neurons	T025	C0027882
27348576	999	1009	biomimetic	T090	C0872312
27348576	1010	1019	expansion	T082	C0205229
27348576	1023	1030	silicon	T196	C0037107
27348576	1036	1049	heterogeneous	T080	C0019409
27348576	1054	1064	deformable	T169	C0333067
27348576	1065	1070	forms	T080	C0348078
27348576	1100	1113	extracellular	T026	C0521119
27348576	1114	1125	biomaterial	T122	C0005479
27348576	1129	1148	bioelectric systems	T074	C0005485

27849637|t|Pneumonia, Intake Problems, and Survival Among Nursing Home Residents With Variable Stages of Dementia in the Netherlands: Results From a Prospective Observational Study
27849637|a|We explored how pneumonia and intake problems affect survival in nursing home residents in variable stages of dementia. In a longitudinal observational study (372 residents) with up to 3.5 years of follow-up, we examined relationships between dementia severity, the development of pneumonia, intake problems, and mortality using joint modeling, Cox models, and mediation analyses. Dementia severity was measured semiannually with the Bedford Alzheimer Nursing Severity-Scale (BANS-S). The median BANS-S score at baseline was 13 (range, 7 to 28). Pneumonia occurred in 103 (28%) and intake problems in 126 (34%) of 367 residents with complete registration of pneumonia and intake problems. Compared with dementia severity, incident pneumonia and, even more so, incident intake problems were more strongly associated with mortality risk. Pneumonia and intake problems both mediated the relationship between more severe dementia and mortality. Developing pneumonia and intake problems affects survival, and this is not limited to advanced dementia. The occurrence of pneumonia and intake problems are important signals to consider a palliative care approach in nursing home residents with dementia, and an active focus on advance care planning is needed. Future studies should investigate whether this is also relevant for patients in primary care.
27849637	0	9	Pneumonia	T047	C0032285
27849637	11	17	Intake	T169	C1512806
27849637	18	26	Problems	T033	C0033213
27849637	32	40	Survival	T081	C0038954
27849637	47	69	Nursing Home Residents	T098	C0682287
27849637	75	83	Variable	T080	C0439828
27849637	84	90	Stages	T079	C1306673
27849637	94	102	Dementia	T048	C0497327
27849637	110	121	Netherlands	T083	C0027778
27849637	138	169	Prospective Observational Study	T062	C1518527
27849637	186	195	pneumonia	T047	C0032285
27849637	200	206	intake	T169	C1512806
27849637	207	215	problems	T033	C0033213
27849637	223	231	survival	T081	C0038954
27849637	235	257	nursing home residents	T098	C0682287
27849637	261	269	variable	T080	C0439828
27849637	270	276	stages	T079	C1306673
27849637	280	288	dementia	T048	C0497327
27849637	295	327	longitudinal observational study	T062	C1518527
27849637	333	342	residents	T098	C0682287
27849637	359	364	years	T079	C0439234
27849637	368	377	follow-up	T058	C1522577
27849637	391	404	relationships	T080	C0439849
27849637	413	421	dementia	T048	C0497327
27849637	422	430	severity	T080	C0439793
27849637	436	447	development	T169	C1527148
27849637	451	460	pneumonia	T047	C0032285
27849637	462	468	intake	T169	C1512806
27849637	469	477	problems	T033	C0033213
27849637	483	492	mortality	T081	C0205848
27849637	499	513	joint modeling	T062	C0870071
27849637	515	525	Cox models	T081,T170	C0010234
27849637	531	549	mediation analyses	UnknownType	C0814912
27849637	551	559	Dementia	T048	C0497327
27849637	560	568	severity	T080	C0439793
27849637	573	581	measured	T080	C0444706
27849637	582	594	semiannually	T079	C0332181
27849637	604	644	Bedford Alzheimer Nursing Severity-Scale	T170	C0282574
27849637	646	652	BANS-S	T170	C0282574
27849637	666	672	BANS-S	T170	C0282574
27849637	673	678	score	T081	C0449820
27849637	682	690	baseline	T081	C1442488
27849637	716	725	Pneumonia	T047	C0032285
27849637	726	734	occurred	T052	C1709305
27849637	752	758	intake	T169	C1512806
27849637	759	767	problems	T033	C0033213
27849637	788	797	residents	T098	C0682287
27849637	803	811	complete	T080	C0205197
27849637	812	824	registration	T058	C1514821
27849637	828	837	pneumonia	T047	C0032285
27849637	842	848	intake	T169	C1512806
27849637	849	857	problems	T033	C0033213
27849637	859	867	Compared	T052	C1707455
27849637	873	881	dementia	T048	C0497327
27849637	882	890	severity	T080	C0439793
27849637	892	900	incident	T067	C1551358
27849637	901	910	pneumonia	T047	C0032285
27849637	930	938	incident	T067	C1551358
27849637	939	945	intake	T169	C1512806
27849637	946	954	problems	T033	C0033213
27849637	974	989	associated with	T080	C0332281
27849637	990	999	mortality	T081	C0205848
27849637	1000	1004	risk	T058	C0086930
27849637	1006	1015	Pneumonia	T047	C0032285
27849637	1020	1026	intake	T169	C1512806
27849637	1027	1035	problems	T033	C0033213
27849637	1054	1066	relationship	T080	C0439849
27849637	1080	1095	severe dementia	T048	C3494652
27849637	1100	1109	mortality	T081	C0205848
27849637	1122	1131	pneumonia	T047	C0032285
27849637	1136	1142	intake	T169	C1512806
27849637	1143	1151	problems	T033	C0033213
27849637	1160	1168	survival	T081	C0038954
27849637	1197	1205	advanced	T080	C0205179
27849637	1206	1214	dementia	T048	C0497327
27849637	1220	1230	occurrence	T079	C2745955
27849637	1234	1243	pneumonia	T047	C0032285
27849637	1248	1254	intake	T169	C1512806
27849637	1255	1263	problems	T033	C0033213
27849637	1268	1277	important	T080	C3898777
27849637	1278	1285	signals	T078	C0010439
27849637	1289	1297	consider	T078	C0750591
27849637	1300	1324	palliative care approach	T058	C3693860
27849637	1328	1350	nursing home residents	T098	C0682287
27849637	1356	1364	dementia	T048	C0497327
27849637	1373	1379	active	T169	C0205177
27849637	1380	1385	focus	T169	C1285542
27849637	1389	1410	advance care planning	T058	C0600371
27849637	1414	1420	needed	T080	C0027552
27849637	1422	1428	Future	T079	C0016884
27849637	1429	1436	studies	T062	C2603343
27849637	1444	1455	investigate	T169	C1292732
27849637	1477	1485	relevant	T080	C2347946
27849637	1490	1498	patients	T101	C0030705
27849637	1502	1514	primary care	T058	C0033137

28356129|t|The effects of probiotic and synbiotic supplementation on metabolic syndrome indices in adults at risk of type 2 diabetes: study protocol for a randomized controlled trial
28356129|a|The incidence of type 2 diabetes, cardiovascular diseases, and obesity has been rising dramatically; however, their pathogenesis is particularly intriguing. Recently, dysbiosis of the intestinal microbiota has emerged as a new candidate that may be linked to metabolic diseases. We hypothesize that selective modulation of the intestinal microbiota by probiotic or synbiotic supplementation may improve metabolic dysfunction and prevent diabetes in prediabetics. In this study, a synthesis and study of synbiotics will be carried out for the first time in Iran. In a randomized triple-blind controlled clinical trial, 120 adults with impaired glucose tolerance based on the inclusion criteria will be selected by a simple random sampling method and will be randomly allocated to 6 months of 6 g/d probiotic, synbiotic or placebo. The fecal abundance of bacteria, blood pressure, height, weight, and waist and hip circumferences will be measured at baseline and following treatment. Also, plasma lipid profiles, HbA1C, fasting plasma glucose, and insulin levels, will be measured and insulin resistance (HOMA-IR) and beta-cell function (HOMA-B) will be calculated at baseline and will be repeated at months 3, 6, 12, and 18. The data will be compared within and between groups using statistical methods. The results of this trial could contribute to the evidence-based clinical guidelines that address gut microbiota manipulation to maximize health benefits in prevention and management of metabolic syndrome in prediabetes. Iranian Registry of Clinical Trials: IRCT201511032321N2. Registered on 27 February 2016.
28356129	4	14	effects of	T080	C1704420
28356129	15	24	probiotic	T007	C0525033
28356129	29	38	synbiotic	T168	C2936470
28356129	39	54	supplementation	T061	C0242296
28356129	58	76	metabolic syndrome	T047	C0524620
28356129	77	84	indices	T078	C0010439
28356129	88	94	adults	T100	C0001675
28356129	98	102	risk	T078	C0035647
28356129	106	121	type 2 diabetes	T047	C0011860
28356129	123	137	study protocol	T170	C1507394
28356129	144	171	randomized controlled trial	T062	C0206035
28356129	176	185	incidence	T081	C0021149
28356129	189	204	type 2 diabetes	T047	C0011860
28356129	206	229	cardiovascular diseases	T047	C0007222
28356129	235	242	obesity	T047	C0028754
28356129	252	258	rising	T169	C0442805
28356129	288	300	pathogenesis	T046	C0699748
28356129	317	327	intriguing	T041	C0543488
28356129	339	348	dysbiosis	T046	C3658208
28356129	356	377	intestinal microbiota	T001	C2985398
28356129	395	398	new	T080	C0205314
28356129	399	408	candidate	T078	C0392360
28356129	431	449	metabolic diseases	T047	C0025517
28356129	499	520	intestinal microbiota	T001	C2985398
28356129	524	533	probiotic	T007	C0525033
28356129	537	546	synbiotic	T168	C2936470
28356129	547	562	supplementation	T061	C0242296
28356129	563	574	may improve	T080	C1272747
28356129	575	596	metabolic dysfunction	T047	C0025517
28356129	601	608	prevent	T080	C0392756
28356129	609	617	diabetes	T047	C0011847
28356129	621	633	prediabetics	T047	C0362046
28356129	643	648	study	T062	C2603343
28356129	652	661	synthesis	T052	C1883254
28356129	666	671	study	T062	C2603343
28356129	675	685	synbiotics	T168	C2936470
28356129	694	701	carried	T052	C0206243
28356129	728	732	Iran	T083	C0022065
28356129	739	788	randomized triple-blind controlled clinical trial	T062	C0206035
28356129	794	800	adults	T100	C0001675
28356129	806	832	impaired glucose tolerance	T047	C0271650
28356129	846	864	inclusion criteria	T080	C1512693
28356129	873	881	selected	T052	C1707391
28356129	894	900	random	T080	C0439605
28356129	901	916	sampling method	T170	C0449370
28356129	929	937	randomly	T080	C0439605
28356129	938	947	allocated	T052	C1706778
28356129	953	959	months	T079	C0439231
28356129	969	978	probiotic	T007	C0525033
28356129	980	989	synbiotic	T168	C2936470
28356129	993	1000	placebo	T122	C1696465
28356129	1006	1011	fecal	T031	C0015733
28356129	1012	1021	abundance	T080	C2346714
28356129	1025	1033	bacteria	T007	C0004611
28356129	1035	1049	blood pressure	T040	C0005823
28356129	1051	1057	height	T032	C0489786
28356129	1059	1065	weight	T032	C0005910
28356129	1071	1076	waist	T201	C0455829
28356129	1081	1099	hip circumferences	T201	C0562350
28356129	1108	1116	measured	T080	C0444706
28356129	1120	1128	baseline	T081	C1442488
28356129	1133	1142	following	T079	C0332282
28356129	1143	1152	treatment	T061	C0087111
28356129	1160	1181	plasma lipid profiles	T059	C0850354
28356129	1183	1188	HbA1C	T116,T123	C0019018
28356129	1190	1212	fasting plasma glucose	T059	C0583513
28356129	1218	1225	insulin	T116,T121,T125	C0021641
28356129	1226	1232	levels	T080	C0441889
28356129	1242	1250	measured	T080	C0444706
28356129	1255	1273	insulin resistance	T059	C4049994
28356129	1275	1282	HOMA-IR	T059	C4049994
28356129	1288	1306	beta-cell function	T059	C4055385
28356129	1308	1314	HOMA-B	T059	C4055385
28356129	1324	1334	calculated	T052	C1441506
28356129	1338	1346	baseline	T081	C1442488
28356129	1359	1367	repeated	T169	C0205341
28356129	1371	1377	months	T079	C0439231
28356129	1400	1404	data	T078	C1511726
28356129	1413	1421	compared	T052	C1707455
28356129	1441	1447	groups	UnknownType	C0681860
28356129	1448	1453	using	T169	C1524063
28356129	1454	1473	statistical methods	T062	C1710191
28356129	1479	1486	results	T169	C1274040
28356129	1495	1500	trial	T062	C0206035
28356129	1507	1517	contribute	T052	C1880177
28356129	1525	1559	evidence-based clinical guidelines	T170	C0282451
28356129	1573	1587	gut microbiota	T001	C2985398
28356129	1588	1600	manipulation	T061	C0087111
28356129	1604	1612	maximize	T169	C0442805
28356129	1613	1628	health benefits	T081	C0086387
28356129	1632	1642	prevention	T061	C0199176
28356129	1647	1657	management	T058	C0376636
28356129	1661	1679	metabolic syndrome	T047	C0524620
28356129	1683	1694	prediabetes	T047	C0362046
28356129	1696	1712	Iranian Registry	T170	C0034975
28356129	1716	1731	Clinical Trials	T062	C0008976
28356129	1733	1751	IRCT201511032321N2	T170	C0282574

27989147|t|2,2',3,5',6-Pentachlorobiphenyl (PCB 95) Is Atropselectively Metabolized to para-Hydroxylated Metabolites by Human Liver Microsomes
27989147|a|Exposure to neurotoxic, chiral PCBs has been associated with neurodevelopmental disorders, but their metabolism in humans remains unexplored. We investigated the enantioselective metabolism of PCB 95 by human liver microsomes (HLMs) to potentially neurotoxic, hydroxylated metabolites (OH-PCBs). OH-PCB profiles formed in experiments with HLMs differed from metabolite profiles reported for rodent species. The second eluting atropisomer of 2,2',3,5',6-pentachlorobiphenyl-4'-ol, the major metabolite, was preferentially formed by all HLM preparations investigated. Differences in metabolite formation rates were observed with single donor HLMs. The metabolism of PCBs and its role in PCB-mediated neurodevelopmental disorders need to be further characterized.
27989147	0	31	2,2',3,5',6-Pentachlorobiphenyl	T109	C0377470
27989147	33	39	PCB 95	T109	C0377470
27989147	44	72	Atropselectively Metabolized	T040	C0005576
27989147	76	105	para-Hydroxylated Metabolites	T123	C0870883
27989147	109	114	Human	T016	C0086418
27989147	115	131	Liver Microsomes	T026	C0026030
27989147	132	143	Exposure to	T080	C0332157
27989147	144	154	neurotoxic	T131	C0260049
27989147	156	162	chiral	T067	C3539649
27989147	163	167	PCBs	T109	C0377470
27989147	177	192	associated with	T080	C0332281
27989147	193	221	neurodevelopmental disorders	T048	C1535926
27989147	233	243	metabolism	T040	C0025519
27989147	247	253	humans	T016	C0086418
27989147	277	289	investigated	T169	C1292732
27989147	294	321	enantioselective metabolism	T040	C0025519
27989147	325	331	PCB 95	T109	C0377470
27989147	335	340	human	T016	C0086418
27989147	341	357	liver microsomes	T026	C0026030
27989147	359	363	HLMs	T026	C0026030
27989147	368	379	potentially	T080	C3245505
27989147	380	390	neurotoxic	T131	C0260049
27989147	392	416	hydroxylated metabolites	T123	C0870883
27989147	418	425	OH-PCBs	T123	C0870883
27989147	428	434	OH-PCB	T123	C0870883
27989147	435	443	profiles	T039	C3853758
27989147	454	465	experiments	T062	C0681814
27989147	471	475	HLMs	T026	C0026030
27989147	490	509	metabolite profiles	T039	C3853758
27989147	510	518	reported	T170	C0684224
27989147	523	537	rodent species	T015	C0035804
27989147	558	610	atropisomer of 2,2',3,5',6-pentachlorobiphenyl-4'-ol	T123	C0870883
27989147	616	621	major	T080	C0205164
27989147	622	632	metabolite	T123	C0870883
27989147	653	659	formed	T169	C0205431
27989147	667	670	HLM	T026	C0026030
27989147	671	683	preparations	T052	C1521827
27989147	684	696	investigated	T169	C1292732
27989147	713	723	metabolite	T123	C0870883
27989147	724	733	formation	T169	C1522492
27989147	734	739	rates	T081	C1521828
27989147	745	753	observed	T169	C1441672
27989147	772	776	HLMs	T026	C0026030
27989147	782	792	metabolism	T040	C0025519
27989147	796	800	PCBs	T109	C0377470
27989147	817	829	PCB-mediated	T109	C0377470
27989147	830	858	neurodevelopmental disorders	T048	C1535926
27989147	878	891	characterized	T052	C1880022

27550416|t|Modulation of IL-6 induced RANKL expression in arthritic synovium by a transcription factor SOX5
27550416|a|Receptor activator of nuclear factor κB ligand (RANKL) is critically involved in bone erosion of rheumatoid arthritis (RA). We previously reported association between younger age at onset of RA and a RANKL promoter SNP that conferred an elevated promoter activity via binding to a transcription factor SOX5. Here we study the regulation of SOX5 levels in relation to RANKL expression in RA synovial fibroblasts (SF) and the development of bone erosion in the collagen-induced arthritis (CIA) mouse. Our data indicated SOX5 levels were higher in synovium and synovial fluid from RA compared to osteoarthritis patients. Pro-inflammatory cytokines upregulated SOX5 and RANKL expression in both primary RA SF and the rheumatoid synovial fibroblast cell line, MH7A. Overexpression of SOX5 resulted in significantly increased RANKL levels, while knockdown of SOX5 resulted in diminished IL-6 mediated RANKL upregulation in MH7A cells. Chromatin immunoprecipitation (ChIP) showed approximately 3-fold enrichment of RANKL-specific DNA in anti-SOX5 immunoprecipitate in IL-6 treated MH7A cells as compared to untreated cells. Locally silencing SOX5 gene significantly diminished RANKL positive cells and bone erosion in CIA mice. These findings suggest SOX5 is an important regulator of IL-6 - induced RANKL expression in RA SF.
27550416	0	10	Modulation	T082	C0443264
27550416	14	18	IL-6	T116,T129	C0021760
27550416	19	26	induced	T169	C0205263
27550416	27	32	RANKL	T116,T123	C0666364
27550416	33	43	expression	T045	C1171362
27550416	47	56	arthritic	T047	C0003864
27550416	57	65	synovium	T023	C0039099
27550416	71	96	transcription factor SOX5	T116,T123	C2350546
27550416	97	143	Receptor activator of nuclear factor κB ligand	T116,T123	C0666364
27550416	145	150	RANKL	T116,T123	C0666364
27550416	155	165	critically	T080	C1511545
27550416	178	190	bone erosion	T046	C0587240
27550416	194	214	rheumatoid arthritis	T047	C0003873
27550416	216	218	RA	T047	C0003873
27550416	224	234	previously	T079	C0205156
27550416	264	275	younger age	T032	C0001779
27550416	288	290	RA	T047	C0003873
27550416	297	302	RANKL	T116,T123	C0666364
27550416	312	315	SNP	T086	C0752046
27550416	334	342	elevated	T080	C3163633
27550416	365	372	binding	T052	C1145667
27550416	378	403	transcription factor SOX5	T116,T123	C2350546
27550416	413	418	study	T062	C2603343
27550416	423	433	regulation	T043	C1157519
27550416	437	441	SOX5	T116,T123	C2350546
27550416	464	469	RANKL	T116,T123	C0666364
27550416	470	480	expression	T045	C1171362
27550416	484	486	RA	T047	C0003873
27550416	487	495	synovial	T023	C0039099
27550416	496	507	fibroblasts	T025	C0016030
27550416	509	511	SF	T025	C0016030
27550416	521	532	development	T169	C1527148
27550416	536	548	bone erosion	T046	C0587240
27550416	556	582	collagen-induced arthritis	T050	C0971858
27550416	584	587	CIA	T050	C0971858
27550416	589	594	mouse	T015	C0026809
27550416	600	604	data	T170	C0150098
27550416	605	614	indicated	T033	C1444656
27550416	615	619	SOX5	T116,T123	C2350546
27550416	642	650	synovium	T023	C0039099
27550416	655	669	synovial fluid	T031	C0039097
27550416	675	677	RA	T047	C0003873
27550416	678	686	compared	T052	C1707455
27550416	690	704	osteoarthritis	T047	C0029408
27550416	705	713	patients	T101	C0030705
27550416	715	731	Pro-inflammatory	T169	C0333348
27550416	732	741	cytokines	T116,T129	C0079189
27550416	742	753	upregulated	T044	C0041904
27550416	754	758	SOX5	T116,T123	C2350546
27550416	763	768	RANKL	T116,T123	C0666364
27550416	769	779	expression	T045	C1171362
27550416	796	798	RA	T047	C0003873
27550416	799	801	SF	T025	C0016030
27550416	830	850	fibroblast cell line	UnknownType	C0682524
27550416	852	856	MH7A	T025	C0007634
27550416	858	872	Overexpression	T045	C1514559
27550416	876	880	SOX5	T116,T123	C2350546
27550416	881	889	resulted	T169	C1274040
27550416	893	916	significantly increased	T081	C0205217
27550416	917	922	RANKL	T116,T123	C0666364
27550416	937	946	knockdown	T063	C2350567
27550416	950	954	SOX5	T028	C1420328
27550416	955	963	resulted	T169	C1274040
27550416	967	977	diminished	T081	C0205216
27550416	978	982	IL-6	T116,T129	C0021760
27550416	992	997	RANKL	T116,T123	C0666364
27550416	998	1010	upregulation	T044	C0041904
27550416	1014	1024	MH7A cells	T025	C0007634
27550416	1026	1055	Chromatin immunoprecipitation	T059	C1328856
27550416	1057	1061	ChIP	T059	C1328856
27550416	1070	1083	approximately	T080	C0332232
27550416	1105	1123	RANKL-specific DNA	T114,T123	C0012854
27550416	1127	1154	anti-SOX5 immunoprecipitate	T129	C0301871
27550416	1158	1162	IL-6	T116,T129	C0021760
27550416	1163	1170	treated	T169	C1522326
27550416	1171	1181	MH7A cells	T025	C0007634
27550416	1185	1193	compared	T052	C1707455
27550416	1197	1212	untreated cells	T033	C0243095
27550416	1222	1231	silencing	T045	C0598496
27550416	1232	1241	SOX5 gene	T028	C1420328
27550416	1242	1266	significantly diminished	T081	C0205216
27550416	1267	1272	RANKL	T116,T123	C0666364
27550416	1273	1281	positive	T033	C1514241
27550416	1282	1287	cells	T025	C0007634
27550416	1292	1304	bone erosion	T046	C0587240
27550416	1308	1311	CIA	T050	C0971858
27550416	1312	1316	mice	T015	C0026809
27550416	1324	1332	findings	T033	C0243095
27550416	1333	1340	suggest	T078	C1705535
27550416	1341	1345	SOX5	T116,T123	C2350546
27550416	1362	1371	regulator	T077	C1704735
27550416	1375	1379	IL-6	T116,T129	C0021760
27550416	1382	1389	induced	T169	C0205263
27550416	1390	1395	RANKL	T116,T123	C0666364
27550416	1396	1406	expression	T045	C1171362
27550416	1410	1412	RA	T047	C0003873
27550416	1413	1415	SF	T025	C0016030

27855073|t|The Loop 2 Region of Ribosomal Protein uS5 Influences Spectinomycin Sensitivity, Translational Fidelity, and Ribosome Biogenesis
27855073|a|Ribosomal protein uS5 is an essential component of the small ribosomal subunit that is involved in subunit assembly, maintenance of translational fidelity, and the ribosome's response to the antibiotic spectinomycin. While many of the characterized uS5 mutations that affect decoding map to its interface with uS4, more recent work has shown that residues distant from the uS4-uS5 interface can also affect the decoding process. We targeted one such interface-remote area, the loop 2 region (residues 20 to 31), for mutagenesis in Escherichia. coli and generated 21 unique mutants. A majority of the loop 2 alterations confer resistance to spectinomycin and affect the fidelity of translation. However, only a minority show altered rRNA processing or ribosome biogenesis defects.
27855073	4	17	Loop 2 Region	T087	C1514562
27855073	21	42	Ribosomal Protein uS5	T116	C0073335
27855073	54	67	Spectinomycin	T109,T195	C0001268
27855073	68	79	Sensitivity	T033	C0427965
27855073	81	103	Translational Fidelity	T044	C3824282
27855073	109	128	Ribosome Biogenesis	T043	C1156140
27855073	129	150	Ribosomal protein uS5	T116	C0073335
27855073	157	176	essential component	T077	C1705248
27855073	184	207	small ribosomal subunit	T026	C1167012
27855073	228	244	subunit assembly	T043	C1156143
27855073	246	283	maintenance of translational fidelity	T044	C3824282
27855073	293	303	ribosome's	T026	C0035553
27855073	304	312	response	T032	C0871261
27855073	320	344	antibiotic spectinomycin	T109,T195	C0001268
27855073	378	391	uS5 mutations	T045	C0026882
27855073	404	412	decoding	T044	C1148560
27855073	424	433	interface	T044	C1148560
27855073	439	442	uS4	T116,T123	C0073333
27855073	476	484	residues	T077	C1709915
27855073	502	519	uS4-uS5 interface	T044	C1148560
27855073	540	556	decoding process	T067	C1522240
27855073	579	600	interface-remote area	T082	C1254362
27855073	606	619	loop 2 region	T087	C1514562
27855073	621	629	residues	T077	C1709915
27855073	645	656	mutagenesis	T044	C0079866
27855073	660	677	Escherichia. coli	T007	C0014834
27855073	695	709	unique mutants	T049	C0596988
27855073	729	735	loop 2	T087	C1514562
27855073	755	765	resistance	T169	C4281815
27855073	769	782	spectinomycin	T109,T195	C0001268
27855073	798	821	fidelity of translation	T044	C3824282
27855073	861	865	rRNA	T114,T123	C0035701
27855073	880	899	ribosome biogenesis	T043	C1156140
27855073	900	907	defects	T169	C1457869

28040771|t|Transplantation in a patient on extracorporeal membrane oxygenation with infective endocarditis, pericarditis and heparin-induced thrombocytopenia
28040771|a|Heart failure patients with pacemaker or defibrillator-associated endocarditis in cardiogenic shock have few treatment options. We present a case of an INTERMACS I patient who developed device infection, sepsis, bacterial pericarditis and heparin-induced thrombocytopenia. The patient was stabilized with extracorporeal membrane oxygenation and successfully transplanted.
28040771	0	15	Transplantation	T061	C0040732
28040771	21	28	patient	T101	C0030705
28040771	32	67	extracorporeal membrane oxygenation	T061	C0015357
28040771	73	95	infective endocarditis	T047	C1541923
28040771	97	109	pericarditis	T047	C0031046
28040771	114	146	heparin-induced thrombocytopenia	T047	C0272285
28040771	147	160	Heart failure	T047	C0018801
28040771	161	169	patients	T101	C0030705
28040771	175	184	pacemaker	T074	C0030163
28040771	188	225	defibrillator-associated endocarditis	T047	C0012634
28040771	229	246	cardiogenic shock	T046	C0036980
28040771	256	273	treatment options	T061	C0683525
28040771	299	310	INTERMACS I	T170	C0282574
28040771	311	318	patient	T101	C0030705
28040771	333	339	device	T073	C0699733
28040771	340	349	infection	T046	C3714514
28040771	351	357	sepsis	T047	C0243026
28040771	359	381	bacterial pericarditis	T047	C0340445
28040771	386	418	heparin-induced thrombocytopenia	T047	C0272285
28040771	424	431	patient	T101	C0030705
28040771	452	487	extracorporeal membrane oxygenation	T061	C0015357
28040771	505	517	transplanted	T061	C0040732

27503608|t|In vivo assessment of periodontal structures and measurement of gingival sulcus with Optical Coherence Tomography: a pilot study
27503608|a|There has been increasing interest on the development of clinically acceptable, more sensitive and specific methods for non-invasive diagnosis in Periodontics. In this pilot study, the performance of an Optical Coherence Tomography (OCT) system in imaging periodontal structures in humans was evaluated. Gingival sulcus depth measurements were obtained and compared with traditional probes. In total, 445 sites of 23 periodontally healthy individuals were measured by 3 instruments: North Carolina manual probe, Florida automated probe and OCT at 1325 nm. To obtain quantitative measurements from OCT images, the gingival refractive index was also determined. Discomfort / pain perception and the duration of examinations were compared among the instruments. The analysis of OCT images allowed the identification of relevant anatomic dental and periodontal regions. The average sulcus depth measured by OCT, 0.85 ± 0.27 mm and 0.87 ± 0.28 mm, was lower than the values obtained by manual and automated probing. Discomfort / pain were prevalent for traditional probes, which are invasive methods, than for the non-invasive OCT technique. OCT has the potential to be a reliable tool for in vivo periodontal tissues evaluation and for reproducible sulcus depth measurements in healthy sites. Further technological advances are required to reduce the procedure time and promote evaluation of posterior oral regions. Photonic assessment of periodontal tissue with OCT (top) in a clinical environment, showing tooth / gingiva features (bottom).
27503608	0	7	In vivo	T082	C1515655
27503608	8	18	assessment	T058	C0220825
27503608	22	33	periodontal	T024	C0031104
27503608	34	44	structures	T082	C0678594
27503608	49	60	measurement	T169	C0242485
27503608	64	79	gingival sulcus	T030	C0447436
27503608	85	113	Optical Coherence Tomography	T060	C0920367
27503608	117	128	pilot study	T062	C0031928
27503608	171	182	development	T169	C1527148
27503608	186	196	clinically	T080	C0205210
27503608	197	207	acceptable	T080	C1879533
27503608	214	223	sensitive	T169	C0332324
27503608	228	236	specific	T080	C0205369
27503608	249	261	non-invasive	T169	C0205303
27503608	262	271	diagnosis	T033	C0011900
27503608	275	287	Periodontics	T091	C0031098
27503608	297	308	pilot study	T062	C0031928
27503608	332	360	Optical Coherence Tomography	T060	C0920367
27503608	362	365	OCT	T060	C0920367
27503608	377	384	imaging	T060	C0011923
27503608	385	396	periodontal	T024	C0031104
27503608	397	407	structures	T082	C0678594
27503608	411	417	humans	T016	C0086418
27503608	422	431	evaluated	T058	C0220825
27503608	433	448	Gingival sulcus	T030	C0447436
27503608	449	454	depth	T082	C0205125
27503608	455	467	measurements	T169	C0242485
27503608	473	481	obtained	T169	C1301820
27503608	486	494	compared	T052	C1707455
27503608	500	511	traditional	T169	C0443324
27503608	512	518	probes	T074	C0182400
27503608	534	539	sites	T082	C0205145
27503608	546	559	periodontally	T080	C0332275
27503608	560	567	healthy	T080	C3898900
27503608	568	579	individuals	T098	C0027361
27503608	585	593	measured	T080	C0444706
27503608	599	610	instruments	T074	C0348000
27503608	612	639	North Carolina manual probe	T074	C0182400
27503608	641	664	Florida automated probe	T074	C0182400
27503608	669	672	OCT	T060	C0920367
27503608	695	707	quantitative	T081	C0392762
27503608	708	720	measurements	T169	C0242485
27503608	726	729	OCT	T060	C0920367
27503608	730	736	images	T078	C1551337
27503608	742	750	gingival	T030	C0447436
27503608	751	767	refractive index	T081	C0034952
27503608	789	799	Discomfort	T184	C0231218
27503608	802	806	pain	T184	C0030193
27503608	807	817	perception	T041	C0030971
27503608	826	834	duration	T079	C0449238
27503608	838	850	examinations	T058	C0582103
27503608	856	864	compared	T052	C1707455
27503608	875	886	instruments	T074	C0348000
27503608	904	907	OCT	T060	C0920367
27503608	908	914	images	T078	C1551337
27503608	954	962	anatomic	T080	C0220784
27503608	963	969	dental	T080	C0226984
27503608	974	985	periodontal	T024	C0031104
27503608	986	993	regions	T029	C0005898
27503608	999	1006	average	T081	C1510992
27503608	1007	1013	sulcus	T030	C1184482
27503608	1014	1019	depth	T082	C0205125
27503608	1020	1028	measured	T080	C0444706
27503608	1032	1035	OCT	T060	C0920367
27503608	1110	1116	manual	T169	C0175674
27503608	1121	1130	automated	T169	C0205554
27503608	1131	1138	probing	T061	C1882338
27503608	1140	1150	Discomfort	T184	C0231218
27503608	1153	1157	pain	T184	C0030193
27503608	1163	1172	prevalent	T081	C0220900
27503608	1177	1188	traditional	T169	C0443324
27503608	1189	1195	probes	T074	C0182400
27503608	1207	1215	invasive	T080	C0205281
27503608	1216	1223	methods	T169	C0449851
27503608	1238	1250	non-invasive	T169	C0205303
27503608	1251	1254	OCT	T060	C0920367
27503608	1255	1264	technique	T169	C0449851
27503608	1266	1269	OCT	T060	C0920367
27503608	1278	1287	potential	T080	C3245505
27503608	1305	1309	tool	T073	C0336791
27503608	1314	1321	in vivo	T082	C1515655
27503608	1322	1341	periodontal tissues	T024	C0031104
27503608	1342	1352	evaluation	T058	C0220825
27503608	1374	1380	sulcus	T030	C1184482
27503608	1381	1386	depth	T082	C0205125
27503608	1387	1399	measurements	T169	C0242485
27503608	1403	1410	healthy	T080	C3898900
27503608	1426	1448	technological advances	UnknownType	C0681519
27503608	1465	1471	reduce	T080	C0392756
27503608	1476	1485	procedure	T061	C0087111
27503608	1486	1490	time	T079	C0040223
27503608	1495	1502	promote	T052	C0033414
27503608	1503	1513	evaluation	T058	C0220825
27503608	1517	1526	posterior	T082	C0205095
27503608	1527	1539	oral regions	T029	C0230028
27503608	1541	1549	Photonic	T185	C1328817
27503608	1550	1560	assessment	T058	C0220825
27503608	1564	1582	periodontal tissue	T024	C0031104
27503608	1588	1591	OCT	T060	C0920367
27503608	1593	1596	top	T082	C1704458
27503608	1603	1611	clinical	T080	C0205210
27503608	1612	1623	environment	T082	C0014406
27503608	1633	1638	tooth	T023	C0040426
27503608	1641	1648	gingiva	T024	C0017562
27503608	1649	1657	features	T080	C2348519
27503608	1659	1665	bottom	T082	C1511276

27692572|t|Characterization of exposure in epidemiological studies on air pollution from biodegradable wastes: Misclassification and comparison of exposure assessment strategies
27692572|a|The assignment of exposure is one of the main challenges faced by environmental epidemiologists. However, misclassification of exposures has not been explored in population epidemiological studies on air pollution from biodegradable wastes. The objective of this study was to investigate the use of different approaches for assessing exposure to air pollution from biodegradable wastes by analyzing (1) the misclassification of exposure that is committed by using these surrogates, (2) the existence of differentia l misclassification (3) the effects that misclassification may have on health effect estimates and the interpretation of epidemiological results, and (4) the ability of the exposure measures to predict health outcomes using 10-fold cross validation. Four different exposure assessment approaches were studied: ammonia concentrations at the residence (Metric I), distance to the closest source (Metric II), number of sources within certain distances from the residence (Metric IIIa, b) and location in a specific region (Metric IV). Exposure-response models based on Metric I provided the highest predictive ability (72.3%) and goodness-of-fit, followed by IV, III and II. When compared to Metric I, Metric IV yielded the best results for exposure misclassification analysis and interpretation of health effect estimates, followed by Metric IIIb, IIIa and II. The study showed that modelled NH3 concentrations provide more accurate estimations of true exposure than distances-based surrogates, and that distance-based surrogates (especially those based on distance to the closest point source) are imprecise methods to identify exposed populations, although they may be useful for initial studies.
27692572	0	16	Characterization	T052	C1880022
27692572	20	28	exposure	T037	C0014412
27692572	32	55	epidemiological studies	T062	C0002783
27692572	59	72	air pollution	T069	C0001873
27692572	78	91	biodegradable	T080	C0205556
27692572	92	98	wastes	T167	C0043045
27692572	100	117	Misclassification	T185	C0008902
27692572	122	132	comparison	T052	C1707455
27692572	136	144	exposure	T037	C0014412
27692572	145	155	assessment	T058	C0220825
27692572	156	166	strategies	T062	C0035171
27692572	185	193	exposure	T037	C0014412
27692572	233	246	environmental	T082	C0014406
27692572	247	262	epidemiologists	T097	C1516908
27692572	273	290	misclassification	T185	C0008902
27692572	294	303	exposures	T037	C0014412
27692572	329	339	population	T098	C1257890
27692572	340	363	epidemiological studies	T062	C0002783
27692572	367	380	air pollution	T069	C0001873
27692572	386	399	biodegradable	T080	C0205556
27692572	400	406	wastes	T167	C0043045
27692572	412	421	objective	T078	C2985627
27692572	430	435	study	T062	C2603343
27692572	443	454	investigate	T169	C1292732
27692572	501	509	exposure	T037	C0014412
27692572	513	526	air pollution	T069	C0001873
27692572	532	545	biodegradable	T080	C0205556
27692572	546	552	wastes	T167	C0043045
27692572	556	565	analyzing	T062	C0936012
27692572	574	591	misclassification	T185	C0008902
27692572	595	603	exposure	T037	C0014412
27692572	637	647	surrogates	T096	C1551364
27692572	670	681	differentia	T080	C0443199
27692572	684	701	misclassification	T185	C0008902
27692572	710	717	effects	T080	C1280500
27692572	723	740	misclassification	T185	C0008902
27692572	753	759	health	T078	C0018684
27692572	760	766	effect	T080	C1280500
27692572	767	776	estimates	T081	C0750572
27692572	785	799	interpretation	T169	C1285553
27692572	803	818	epidemiological	T062	C0002783
27692572	819	826	results	T033	C0683954
27692572	855	863	exposure	T037	C0014412
27692572	884	899	health outcomes	T170	C1550208
27692572	914	930	cross validation	T062	C0681935
27692572	947	955	exposure	T037	C0014412
27692572	956	966	assessment	T058	C0220825
27692572	983	990	studied	T062	C2603343
27692572	992	999	ammonia	T121,T197	C0002607
27692572	1000	1014	concentrations	T081	C1446561
27692572	1022	1031	residence	T082	C0237096
27692572	1033	1041	Metric I	T081	C0025867
27692572	1044	1052	distance	T081	C0012751
27692572	1068	1074	source	T033	C0449416
27692572	1076	1085	Metric II	T081	C0025867
27692572	1098	1105	sources	T033	C0449416
27692572	1121	1130	distances	T081	C0012751
27692572	1140	1149	residence	T082	C0237096
27692572	1151	1162	Metric IIIa	T081	C0025867
27692572	1164	1165	b	T081	C0025867
27692572	1171	1179	location	T082	C0450429
27692572	1194	1200	region	T083	C0017446
27692572	1202	1211	Metric IV	T081	C0025867
27692572	1214	1238	Exposure-response models	T170	C3161035
27692572	1248	1256	Metric I	T081	C0025867
27692572	1309	1324	goodness-of-fit	T080	C0870608
27692572	1338	1340	IV	T081	C0025867
27692572	1342	1345	III	T081	C0025867
27692572	1350	1352	II	T081	C0025867
27692572	1371	1379	Metric I	T081	C0025867
27692572	1381	1390	Metric IV	T081	C0025867
27692572	1408	1415	results	T033	C0683954
27692572	1420	1428	exposure	T037	C0014412
27692572	1429	1446	misclassification	T185	C0008902
27692572	1447	1455	analysis	T062	C0936012
27692572	1460	1474	interpretation	T169	C1285553
27692572	1478	1484	health	T078	C0018684
27692572	1485	1491	effect	T080	C1280500
27692572	1492	1501	estimates	T081	C0750572
27692572	1515	1526	Metric IIIb	T081	C0025867
27692572	1528	1532	IIIa	T081	C0025867
27692572	1537	1539	II	T081	C0025867
27692572	1545	1550	study	T062	C2603343
27692572	1572	1575	NH3	T121,T197	C0002607
27692572	1576	1590	concentrations	T081	C1446561
27692572	1613	1624	estimations	T081	C0750572
27692572	1633	1641	exposure	T037	C0014412
27692572	1663	1673	surrogates	T096	C1551364
27692572	1699	1709	surrogates	T096	C1551364
27692572	1737	1745	distance	T081	C0012751
27692572	1767	1773	source	T033	C0449416
27692572	1817	1828	populations	T098	C1257890
27692572	1870	1877	studies	T062	C2603343

28087131|t|Incidence and effect of variant histology on oncological outcomes in patients with bladder cancer treated with radical cystectomy
28087131|a|We sought to describe incidence of histological variants after radical cystectomy (RC) due to bladder cancer (BCa). Moreover, we investigated survival outcomes accounting for this parameter. We retrospectively evaluated data from 1,067 patients with BCa treated with RC between 1990 and 2013 at a single tertiary care referral center. All specimen were evaluated by dedicated uropathologists. Univariable and multivariable Cox regression analyses tested the effect of different histopathological variant on recurrence, cancer-specific mortality (CSM), and overall mortality (OM) after accounting for all available confounders. Of 1,067 patients, 729 (68.3%) harbored pure urothelial BCa while 338 (31.7%) were found to have a variant. Considering uncommon variants, 21 (2.0%) were sarcomatoid, 10 (0.9%) lymphoepitelial, 19 (1.8%) small cell, 109 (10.2%) squamous, 89 (8.3%) micropapillary, 23 (2.2%) glandular, 34 (3.2%) mixed variants, and 33 (3.1%) were found with other types of variants. With a median follow-up of 6.2 years, 343 recurrence, 365 CSM, and 451 OM were recorded, respectively. At multivariable Cox regression analyses, the presence of small cell variant was associated with higher recurrence (hazard ratio [HR] = 3.47, P<0.001), CSM (HR = 3.30, P<0.04), and OM (HR = 2.97, P<0.003) as compared with pure urothelial cancer. Conversely, no survival differences were recorded considering other histological variants (all P> 0.1). Our study confirms that histological variant is not an infrequent event at RC specimen. However, in our single-center series, only patients found with small cell variant were associated with a negative effect on survival after RC.
28087131	0	9	Incidence	T081	C0021149
28087131	14	23	effect of	T080	C1704420
28087131	24	31	variant	T080	C0205419
28087131	32	41	histology	T091	C0019638
28087131	45	65	oncological outcomes	T080	C0085415
28087131	69	77	patients	T101	C0030705
28087131	83	97	bladder cancer	T191	C0005684
28087131	98	105	treated	T169	C1522326
28087131	111	129	radical cystectomy	T061	C0194401
28087131	152	161	incidence	T081	C0021149
28087131	165	177	histological	T169	C0205462
28087131	178	186	variants	T080	C0205419
28087131	193	211	radical cystectomy	T061	C0194401
28087131	213	215	RC	T061	C0194401
28087131	224	238	bladder cancer	T191	C0005684
28087131	240	243	BCa	T191	C0005684
28087131	272	280	survival	T169	C0220921
28087131	281	289	outcomes	T080	C0085415
28087131	324	339	retrospectively	T080	C1514923
28087131	340	349	evaluated	T058	C0220825
28087131	350	354	data	T078	C1511726
28087131	366	374	patients	T101	C0030705
28087131	380	383	BCa	T191	C0005684
28087131	384	391	treated	T169	C1522326
28087131	397	399	RC	T061	C0194401
28087131	427	463	single tertiary care referral center	T073,T093	C0587437
28087131	469	477	specimen	T167	C0370003
28087131	483	492	evaluated	T058	C0220825
28087131	506	521	uropathologists	T097	C1522486
28087131	523	576	Univariable and multivariable Cox regression analyses	T170	C0034980
28087131	588	597	effect of	T080	C1704420
28087131	608	625	histopathological	T169	C0243140
28087131	626	633	variant	T080	C0205419
28087131	637	647	recurrence	T067	C0034897
28087131	649	674	cancer-specific mortality	T081	C1516192
28087131	676	679	CSM	T081	C1516192
28087131	686	703	overall mortality	T081	C0205848
28087131	705	707	OM	T081	C0205848
28087131	744	755	confounders	T169	C0009673
28087131	766	774	patients	T101	C0030705
28087131	797	816	pure urothelial BCa	T191	C0751571
28087131	856	863	variant	T080	C0205419
28087131	886	894	variants	T080	C0205419
28087131	911	922	sarcomatoid	T191	C0205697
28087131	934	949	lymphoepitelial	T191	C0334254
28087131	961	971	small cell	T191	C0262584
28087131	985	993	squamous	T191	C0007137
28087131	1005	1019	micropapillary	T191	C3472608
28087131	1031	1040	glandular	T191	C0205854
28087131	1058	1066	variants	T080	C0205419
28087131	1113	1121	variants	T080	C0205419
28087131	1130	1136	median	T081	C0876920
28087131	1137	1146	follow-up	T058	C1522577
28087131	1154	1159	years	T079	C0439234
28087131	1165	1175	recurrence	T067	C0034897
28087131	1181	1184	CSM	T081	C1516192
28087131	1194	1196	OM	T081	C0205848
28087131	1229	1266	multivariable Cox regression analyses	T170	C0034980
28087131	1284	1302	small cell variant	T191	C0262584
28087131	1307	1322	associated with	T080	C0332281
28087131	1330	1340	recurrence	T067	C0034897
28087131	1342	1354	hazard ratio	T081	C2985465
28087131	1356	1358	HR	T081	C2985465
28087131	1378	1381	CSM	T081	C1516192
28087131	1383	1385	HR	T081	C2985465
28087131	1407	1409	OM	T081	C0205848
28087131	1411	1413	HR	T081	C2985465
28087131	1453	1470	urothelial cancer	T191	C0751571
28087131	1484	1507	no survival differences	T033	C3842396
28087131	1540	1552	histological	T169	C0205462
28087131	1553	1561	variants	T080	C0205419
28087131	1580	1585	study	T077	C1706256
28087131	1600	1612	histological	T169	C0205462
28087131	1613	1620	variant	T080	C0205419
28087131	1651	1653	RC	T061	C0194401
28087131	1654	1662	specimen	T167	C0370003
28087131	1680	1700	single-center series	T093	C1708333
28087131	1707	1715	patients	T101	C0030705
28087131	1727	1745	small cell variant	T191	C0262584
28087131	1751	1766	associated with	T080	C0332281
28087131	1769	1777	negative	T033	C0205160
28087131	1778	1784	effect	T080	C1280500
28087131	1788	1796	survival	T169	C0220921
28087131	1803	1805	RC	T061	C0194401

27651569|t|Examining Cesarean Delivery Rates Using the Robson's Ten-group Classification
27651569|a|To examine Cesarean delivery rates based on the Robson's Ten-group classification system (TGCS), over a 10- year period. All Vaginal Deliveries and cesarean sections (CSs) performed over a 10- year period from 2004 to 2013 were included in the analysis. The data were compiled according to Robson's TGCS of cesarean section for every year. Risk Ratios (crude RRs) with 95 % confidence intervals for delivery by cesarean section were calculated for each Robson's group. The TGCS was easily applied in this large dataset of 40,086 deliveries. The 10- year overall cesarean section rate (CSR) was 25.17 %. Groups 1 and 3 represented 60 % of the total obstetric population. The largest contributions to the total CSR are group 1 (37.62 %) and group 5 (17.06 %). Group 3 which was the second largest group contributed 15 % to the overall CSR. Group 2 and group 4 had high group CSRs of 47.28 and 34.74 % respectively, although the total group size was small (n = 1375;3.43 %). Maternal age and presentation were found to have an independent association with mode of delivery on logistic regression. The Ten-group classification helped to identify the main groups of subjects who contribute most to the overall CSR. It also helped to identify subgroups requiring closer monitoring for more in-depth analyses of the indications for caesarean section. It is important to focus on the first four TGCS groups which constitute about 75 % of all deliveries. It is in the low-risk groups that one is likely to find the highest and most inappropriate indications for cesarean sections.
27651569	0	9	Examining	T169	C1292732
27651569	10	27	Cesarean Delivery	T061	C0007876
27651569	28	33	Rates	T081	C1521828
27651569	44	77	Robson's Ten-group Classification	T170	C0282574
27651569	81	88	examine	T169	C1292732
27651569	89	106	Cesarean delivery	T061	C0007876
27651569	107	112	rates	T081	C1521828
27651569	126	166	Robson's Ten-group classification system	T170	C0282574
27651569	168	172	TGCS	T170	C0282574
27651569	186	190	year	T079	C0439234
27651569	191	197	period	T079	C1948053
27651569	203	221	Vaginal Deliveries	T033	C0566690
27651569	226	243	cesarean sections	T061	C0007876
27651569	245	248	CSs	T061	C0007876
27651569	271	275	year	T079	C0439234
27651569	276	282	period	T079	C1948053
27651569	322	330	analysis	T062	C0936012
27651569	336	340	data	T078	C1511726
27651569	368	381	Robson's TGCS	T170	C0282574
27651569	385	401	cesarean section	T061	C0007876
27651569	412	416	year	T079	C0439234
27651569	418	429	Risk Ratios	T081	C0242492
27651569	431	440	crude RRs	T081	C0242492
27651569	452	472	confidence intervals	T081	C0009667
27651569	477	485	delivery	T040	C0005615
27651569	489	505	cesarean section	T061	C0007876
27651569	531	545	Robson's group	T078	C0441833
27651569	551	555	TGCS	T170	C0282574
27651569	589	596	dataset	T170	C0150098
27651569	607	617	deliveries	T040	C0005615
27651569	627	631	year	T079	C0439234
27651569	640	656	cesarean section	T061	C0007876
27651569	657	661	rate	T081	C1521828
27651569	663	666	CSR	T081	C1521828
27651569	681	689	Groups 1	T078	C0441833
27651569	694	695	3	T078	C0441833
27651569	726	735	obstetric	T169	C0205484
27651569	736	746	population	T098	C1257890
27651569	760	773	contributions	T052	C1880177
27651569	787	790	CSR	T081	C1521828
27651569	795	802	group 1	T078	C0441833
27651569	817	824	group 5	T078	C0441833
27651569	836	843	Group 3	T078	C0441833
27651569	873	878	group	T078	C0441833
27651569	879	890	contributed	T052	C1880177
27651569	911	914	CSR	T081	C1521828
27651569	916	923	Group 2	T078	C0441833
27651569	928	935	group 4	T078	C0441833
27651569	945	950	group	T078	C0441833
27651569	951	955	CSRs	T081	C1521828
27651569	1010	1020	group size	T102	C0237884
27651569	1050	1062	Maternal age	T079	C0024915
27651569	1067	1079	presentation	T046	C1404746
27651569	1102	1113	independent	T078	C0085862
27651569	1114	1125	association	T080	C0439849
27651569	1139	1147	delivery	T040	C0005615
27651569	1151	1170	logistic regression	T062	C0206031
27651569	1176	1200	Ten-group classification	T170	C0282574
27651569	1229	1235	groups	T078	C0441833
27651569	1283	1286	CSR	T081	C1521828
27651569	1315	1324	subgroups	T078	C0441833
27651569	1342	1352	monitoring	T058	C1283169
27651569	1371	1379	analyses	T062	C0936012
27651569	1387	1398	indications	T078	C3146298
27651569	1403	1420	caesarean section	T061	C0007876
27651569	1465	1469	TGCS	T170	C0282574
27651569	1470	1476	groups	T078	C0441833
27651569	1512	1522	deliveries	T040	C0005615
27651569	1537	1545	low-risk	T081	C3538919
27651569	1546	1552	groups	T078	C0441833
27651569	1615	1626	indications	T078	C3146298
27651569	1631	1648	cesarean sections	T061	C0007876

28150378|t|Challenging some assumptions about empathy
28150378|a|In New Zealand little nursing or medical curricula time, if any, is specifically devoted to the enhancement of empathy. If being empathic is important in the context of patient care, it is a quality that is already present in students or is learned by students during their practicum in the company of experienced clinicians. This study aimed to compare self-reported empathy ratings between different groups of medical students and one cohort of nursing students who were either exposed or not exposed to explicit empathy training or learning in clinical settings in the presence of patients. The Jefferson Scale of Physician Empathy (JSPE) was completed before and after groups of medical and nursing students had been exposed to various extended periods of practicum. Some medical student cohorts undertook brief empathy training, whereas others had no exposure. The nursing student cohort had no formal, explicit empathy training. Irrespective of profession, length of practicum or exposure to specific empathy training, there were no significant differences in the self-reported JSPE scores across the seven different cohorts of students. Empathy is a quality that is already present in students or is learned by students during their practicum DISCUSSION: If empathy is caught rather than taught, then brief efforts to enhance empathy may be futile. To optimise the inherent empathic qualities of aspirant health professionals, explicit consideration should be given to how empathy is influenced by the practicum experience.
28150378	0	11	Challenging	T058	C0805586
28150378	35	42	empathy	T055	C0013989
28150378	46	57	New Zealand	T083	C0027978
28150378	65	72	nursing	T065	C0013636
28150378	76	93	medical curricula	T065	C0013631
28150378	94	98	time	T079	C0040223
28150378	139	150	enhancement	T052	C2349975
28150378	154	161	empathy	T055	C0013989
28150378	172	180	empathic	T033	C0564547
28150378	184	193	important	T080	C3898777
28150378	212	224	patient care	T058	C0017313
28150378	269	277	students	T098	C0038492
28150378	295	303	students	T098	C0038492
28150378	317	326	practicum	T065	C0032929
28150378	345	356	experienced	T041	C0237607
28150378	357	367	clinicians	T097	C0871685
28150378	374	379	study	T062	C2603343
28150378	389	396	compare	T052	C1707455
28150378	397	410	self-reported	T062	C2700446
28150378	411	418	empathy	T055	C0013989
28150378	445	451	groups	T098	C1257890
28150378	455	471	medical students	T097	C0038495
28150378	480	486	cohort	T098	C0599755
28150378	490	506	nursing students	T097	C0038496
28150378	558	565	empathy	T055	C0013989
28150378	566	574	training	T065	C0220931
28150378	578	586	learning	T041	C0023185
28150378	590	607	clinical settings	T082	C3176918
28150378	627	635	patients	T101	C0030705
28150378	641	677	Jefferson Scale of Physician Empathy	T080	C0034375
28150378	679	683	JSPE	T080	C0034375
28150378	726	733	medical	T097	C0038495
28150378	738	754	nursing students	T097	C0038496
28150378	783	791	extended	T079	C0439590
28150378	792	799	periods	T079	C1948053
28150378	803	812	practicum	T065	C0032929
28150378	819	834	medical student	T097	C0038495
28150378	835	842	cohorts	T098	C0599755
28150378	853	858	brief	T079	C1879313
28150378	859	866	empathy	T055	C0013989
28150378	867	875	training	T065	C0220931
28150378	867	875	training	T065	C0220931
28150378	913	928	nursing student	T097	C0038496
28150378	929	935	cohort	T098	C0599755
28150378	940	949	no formal	T033	C0557286
28150378	960	967	empathy	T055	C0013989
28150378	968	976	training	T065	C0220931
28150378	994	1004	profession	T090	C0028811
28150378	1006	1012	length	T079	C0023980
28150378	1016	1025	practicum	T065	C0032929
28150378	1050	1057	empathy	T055	C0013989
28150378	1058	1066	training	T065	C0220931
28150378	1079	1105	no significant differences	T033	C3842396
28150378	1113	1126	self-reported	T062	C2700446
28150378	1127	1138	JSPE scores	T080	C0034375
28150378	1166	1173	cohorts	T098	C0599755
28150378	1177	1185	students	T098	C0038492
28150378	1187	1194	Empathy	T055	C0013989
28150378	1200	1207	quality	T080	C0332306
28150378	1224	1231	present	T033	C0150312
28150378	1235	1243	students	T098	C0038492
28150378	1250	1260	learned by	T041	C0023185
28150378	1261	1269	students	T098	C0038492
28150378	1283	1292	practicum	T065	C0032929
28150378	1293	1303	DISCUSSION	T054	C2584313
28150378	1308	1315	empathy	T055	C0013989
28150378	1319	1325	caught	T055	C0679140
28150378	1338	1344	taught	T080	C0348054
28150378	1368	1375	enhance	T052	C2349975
28150378	1376	1383	empathy	T055	C0013989
28150378	1391	1397	futile	T033	C3840836
28150378	1415	1442	inherent empathic qualities	T033	C0564547
28150378	1455	1475	health professionals	T097	C1704312
28150378	1486	1499	consideration	T033	C0518609
28150378	1523	1530	empathy	T055	C0013989
28150378	1534	1544	influenced	T077	C4054723
28150378	1552	1561	practicum	T065	C0032929
28150378	1562	1572	experience	T041	C0237607

28457143|t|Typical Skin Injuries in Children With Autism Spectrum Disorder
28457143|a|Pediatric skin injuries have primarily been described in typically developing children. Our objectives were to describe the prevalence and pattern of skin injuries of children with autism spectrum disorder (ASD), to describe how this compared with previously demonstrated skin injury locations in typically developing children, and to identify differences in skin injury frequency and locations between autistic children with and without self-injurious behaviors (SIBs). Children with ASD were recruited between September of 2011 and September of 2014. Demographic information was obtained from the caregiver. All skin injuries and their locations were documented. Of the 41 children enrolled, half were reported to have SIBs. The most identified skin injury locations were the legs, knees, and back. Children with autism (1) obtain skin injuries frequently and in similar locations as typically developing children and (2) rarely obtain skin injuries to locations that are considered uncommon for accidental injuries despite reports of SIBs.
28457143	8	21	Skin Injuries	T037	C0281980
28457143	25	33	Children	T100	C0008059
28457143	39	63	Autism Spectrum Disorder	T048	C1510586
28457143	64	73	Pediatric	T080	C1521725
28457143	74	87	skin injuries	T037	C0281980
28457143	131	150	developing children	T100	C0008059
28457143	156	166	objectives	T170	C0018017
28457143	188	198	prevalence	T081	C0683921
28457143	203	210	pattern	T082	C0449774
28457143	214	227	skin injuries	T037	C0281980
28457143	231	239	children	T100	C0008059
28457143	245	269	autism spectrum disorder	T048	C1510586
28457143	271	274	ASD	T048	C1510586
28457143	336	347	skin injury	T037	C0281980
28457143	348	357	locations	T033	C0552513
28457143	371	390	developing children	T100	C0008059
28457143	408	419	differences	T080	C1705242
28457143	423	434	skin injury	T037	C0281980
28457143	435	444	frequency	T079	C0439603
28457143	449	458	locations	T033	C0552513
28457143	467	484	autistic children	T101	C0175842
28457143	502	526	self-injurious behaviors	T055	C0085271
28457143	528	532	SIBs	T055	C0085271
28457143	535	543	Children	T100	C0008059
28457143	549	552	ASD	T048	C1510586
28457143	576	585	September	T079	C3828193
28457143	598	607	September	T079	C3828193
28457143	617	640	Demographic information	T078	C0011292
28457143	663	672	caregiver	T097	C0085537
28457143	678	691	skin injuries	T037	C0281980
28457143	702	711	locations	T033	C0552513
28457143	717	727	documented	T058	C1301725
28457143	739	747	children	T100	C0008059
28457143	785	789	SIBs	T055	C0085271
28457143	811	822	skin injury	T037	C0281980
28457143	823	832	locations	T033	C0552513
28457143	842	846	legs	T023	C1140621
28457143	848	853	knees	T023	C0022742
28457143	859	863	back	T029	C0004600
28457143	865	873	Children	T100	C0008059
28457143	879	885	autism	T048	C0004352
28457143	897	910	skin injuries	T037	C0281980
28457143	937	946	locations	T033	C0552513
28457143	960	979	developing children	T100	C0008059
28457143	1002	1015	skin injuries	T037	C0281980
28457143	1019	1028	locations	T033	C0552513
28457143	1062	1081	accidental injuries	T037	C0151736
28457143	1101	1105	SIBs	T055	C0085271

27381206|t|Catastrophic health expenditure: a comparative analysis of empty-nest and non-empty-nest households with seniors in Shandong, China
27381206|a|The aim of this study was to compare the catastrophic health expenditure (CHE) prevalence and its determinants between empty-nest and non-empty-nest elderly households. Shandong province of China. A total of 2761 elderly households are included in the analysis. CHE incidence among elderly households was 44.9%. The CHE incidence of empty-nest singles (59.3%, p=0.000, OR=3.19) and empty-nest couples (52.9%, p=0.000, OR=2.45) are both statistically higher than that of non-empty-nest elderly households (31.4%). An inverse association was observed between CHE incidence and income level in all elderly household types. Factors including 1 or more household elderly members with non-communicable chronic diseases in the past 6 months, 1 or more elderly household members being hospitalised in the past year and lower household income, are significant risk factors for CHE in all 3 household types (p<0.05). Health insurance status was found to be a significant determinant of CHE among empty-nest singles and non-empty-nest households (p<0.05). CHE incidence among elderly households is high in China. Empty-nest households are at higher risk for CHE than non-empty-nest households. Based on these findings, we suggest that special insurance be developed to broaden the coverage of health services and heighten the reimbursement rate for empty-nest elderly in the existing health insurance schemes. Financial and social protection interventions are also essential for identifie d at-risk subgroups among different types of elderly households.
27381206	0	12	Catastrophic	T047	C0007397
27381206	13	31	health expenditure	T081	C0015318
27381206	35	55	comparative analysis	T062	C0683941
27381206	59	69	empty-nest	T078	C0870492
27381206	74	88	non-empty-nest	T078	C1254370
27381206	89	99	households	T099	C0020052
27381206	105	112	seniors	T098	C0001792
27381206	116	131	Shandong, China	T083	C0008115
27381206	136	139	aim	T078	C1947946
27381206	148	153	study	T062	C2603343
27381206	161	168	compare	T052	C1707455
27381206	173	185	catastrophic	T047	C0007397
27381206	186	204	health expenditure	T081	C0015318
27381206	206	209	CHE	T081	C0015318
27381206	211	221	prevalence	T081	C0683919
27381206	230	242	determinants	T169	C1521761
27381206	251	261	empty-nest	T078	C0870492
27381206	266	280	non-empty-nest	T078	C1254370
27381206	281	288	elderly	T098	C0001792
27381206	289	299	households	T099	C0020052
27381206	301	327	Shandong province of China	T083	C0008115
27381206	331	336	total	T080	C0439810
27381206	345	352	elderly	T098	C0001792
27381206	353	363	households	T099	C0020052
27381206	368	376	included	T169	C0332257
27381206	384	392	analysis	T062	C0936012
27381206	394	397	CHE	T081	C0015318
27381206	398	407	incidence	T081	C0021149
27381206	414	421	elderly	T098	C0001792
27381206	422	432	households	T099	C0020052
27381206	448	451	CHE	T081	C0015318
27381206	452	461	incidence	T081	C0021149
27381206	465	475	empty-nest	T078	C0870492
27381206	476	483	singles	T033	C1549113
27381206	514	524	empty-nest	T078	C0870492
27381206	525	532	couples	T099	C0010222
27381206	568	581	statistically	T081	C0871425
27381206	582	588	higher	T080	C0205250
27381206	602	616	non-empty-nest	T078	C1254370
27381206	617	624	elderly	T098	C0001792
27381206	625	635	households	T099	C0020052
27381206	648	667	inverse association	T077	C1708567
27381206	672	680	observed	T169	C1441672
27381206	689	692	CHE	T081	C0015318
27381206	693	702	incidence	T081	C0021149
27381206	707	719	income level	T080	C0870689
27381206	727	734	elderly	T098	C0001792
27381206	735	744	household	T099	C0020052
27381206	745	750	types	T080	C0332307
27381206	752	759	Factors	T169	C1521761
27381206	760	769	including	T169	C0332257
27381206	780	789	household	T099	C0020052
27381206	790	805	elderly members	T098	C0001792
27381206	811	844	non-communicable chronic diseases	T047	C0008679
27381206	877	884	elderly	T098	C0001792
27381206	885	902	household members	T099	C0015578
27381206	909	921	hospitalised	T033	C0701159
27381206	929	938	past year	T079	C4086728
27381206	943	948	lower	T052	C2003888
27381206	949	958	household	T099	C0020052
27381206	959	965	income	T081	C0021162
27381206	971	982	significant	T078	C0750502
27381206	983	995	risk factors	T033	C0035648
27381206	1000	1003	CHE	T081	C0015318
27381206	1013	1022	household	T099	C0020052
27381206	1023	1028	types	T080	C0332307
27381206	1039	1055	Health insurance	T058	C0021682
27381206	1056	1062	status	T080	C0449438
27381206	1081	1092	significant	T078	C0750502
27381206	1093	1104	determinant	T169	C1521761
27381206	1108	1111	CHE	T081	C0015318
27381206	1118	1128	empty-nest	T078	C0870492
27381206	1129	1136	singles	T033	C1549113
27381206	1141	1155	non-empty-nest	T078	C1254370
27381206	1156	1166	households	T099	C0020052
27381206	1177	1180	CHE	T081	C0015318
27381206	1181	1190	incidence	T081	C0021149
27381206	1197	1204	elderly	T098	C0001792
27381206	1205	1215	households	T099	C0020052
27381206	1219	1223	high	T080	C0205250
27381206	1227	1232	China	T083	C0008115
27381206	1234	1244	Empty-nest	T078	C0870492
27381206	1245	1255	households	T099	C0020052
27381206	1263	1269	higher	T080	C0205250
27381206	1270	1274	risk	T078	C0035647
27381206	1279	1282	CHE	T081	C0015318
27381206	1288	1302	non-empty-nest	T078	C1254370
27381206	1303	1313	households	T099	C0020052
27381206	1330	1338	findings	T033	C0243095
27381206	1343	1350	suggest	T078	C1705535
27381206	1356	1363	special	T080	C0205555
27381206	1364	1373	insurance	T058	C0021682
27381206	1390	1397	broaden	T082	C0332464
27381206	1402	1410	coverage	T078	C1551362
27381206	1414	1429	health services	T058	C0018747
27381206	1434	1442	heighten	T080	C0442803
27381206	1447	1465	reimbursement rate	T058	C0554896
27381206	1470	1480	empty-nest	T078	C0870492
27381206	1481	1488	elderly	T098	C0001792
27381206	1505	1521	health insurance	T058	C0021682
27381206	1522	1529	schemes	T170	C1519193
27381206	1531	1540	Financial	T080	C2350008
27381206	1545	1562	social protection	T064	C0242457
27381206	1563	1576	interventions	T058	C0262765
27381206	1586	1595	essential	T080	C0205224
27381206	1600	1609	identifie	T080	C0205396
27381206	1612	1619	at-risk	T080	C1444641
27381206	1620	1629	subgroups	T185	C1515021
27381206	1655	1662	elderly	T098	C0001792
27381206	1663	1673	households	T099	C0020052

27757318|t|Adoptively transferred natural killer cells maintain long-term antitumor activity by epigenetic imprinting and CD4(+) T cell help
27757318|a|Natural killer (NK) cell infusions can induce remissions in subsets of patients with different types of cancer. The optimal strategies for NK cell activation prior to infusion are still under debate. There is recent evidence that NK cells can acquire long-term functional competence by preactivation with the cytokines IL-12 / 15 / 18. The mechanisms supporting the maintenance of long-term NK cell antitumor activity are incompletely under-stood. Here, we show that NK cells preactivated in vitro with IL-12 / 15 / 18, but not with IL-15 alone, maintained high antitumor activity even 1 mo after transfer into lymphopenic RAG-2(-/-) γc(-/-) mice. The NK cell intrinsic ability for IFNγ production coincided with demethylation of the conserved non-coding sequence (CNS) 1 in the Ifng locus, previously shown to enhance transcription of Ifng. In a xenograft melanoma mouse model, human IL-12 / 15 / 18 -preactivated NK cells rejected tumors more efficiently. In RAG-2(-/-) γc(-/-) mice, co-transfer of CD4(+) T cells further improved the long-term competence of NK cells for IFNγ production that was dependent on IL-2. CD4(+) T cell activation during homeostatic proliferation required macrophages and further promoted the long-term NK cell antitumor activity. Thus, NK cells can "remember" a previous exposure to cytokines by epigenetic imprinting resulting in a remarkable stability of the IFNγ -producing phenotype after adoptive transfer. In addition, our results support combination of cytokine -preactivated NK cells with CD4(+) T cell activation upon lymphopenic conditioning to achieve long-term NK cell effector function for cancer immunotherapy.
27757318	23	43	natural killer cells	T025	C0022688
27757318	63	81	antitumor activity	T033	C0243095
27757318	85	106	epigenetic imprinting	T045	C0242614
27757318	111	124	CD4(+) T cell	T025	C0039215
27757318	130	154	Natural killer (NK) cell	T025	C0022688
27757318	155	164	infusions	T061	C0574032
27757318	201	209	patients	T101	C0030705
27757318	234	240	cancer	T191	C0006826
27757318	269	276	NK cell	T025	C0022688
27757318	277	287	activation	T043	C1326120
27757318	297	305	infusion	T061	C0574032
27757318	360	368	NK cells	T025	C0022688
27757318	439	448	cytokines	T116,T129	C0079189
27757318	449	454	IL-12	T116,T121,T129	C0123759
27757318	457	459	15	T116,T129	C0254610
27757318	462	464	18	T116,T129	C0383327
27757318	521	528	NK cell	T025	C0022688
27757318	529	547	antitumor activity	T033	C0243095
27757318	597	605	NK cells	T025	C0022688
27757318	619	627	in vitro	T059,T062	C3850137
27757318	633	638	IL-12	T116,T121,T129	C0123759
27757318	641	643	15	T116,T129	C0254610
27757318	646	648	18	T116,T129	C0383327
27757318	663	668	IL-15	T116,T129	C0254610
27757318	692	710	antitumor activity	T033	C0243095
27757318	716	720	1 mo	T079	C1254367
27757318	741	752	lymphopenic	T047	C0024312
27757318	753	763	RAG-2(-/-)	T028	C1419248
27757318	772	776	mice	T015	C0026809
27757318	782	789	NK cell	T025	C0022688
27757318	812	816	IFNγ	T116,T121,T129	C0021745
27757318	874	893	non-coding sequence	T114,T123	C0021920
27757318	895	898	CNS	T114,T123	C0021920
27757318	909	913	Ifng	T028	C1334085
27757318	914	919	locus	T082	C1708726
27757318	949	962	transcription	T045	C0040649
27757318	966	970	Ifng	T028	C1334085
27757318	977	1007	xenograft melanoma mouse model	T050	C0012644
27757318	1009	1014	human	T016	C0086418
27757318	1015	1020	IL-12	T116,T121,T129	C0123759
27757318	1023	1025	15	T116,T129	C0254610
27757318	1028	1030	18	T116,T129	C0383327
27757318	1045	1053	NK cells	T025	C0022688
27757318	1063	1069	tumors	T191	C0027651
27757318	1091	1101	RAG-2(-/-)	T028	C1419248
27757318	1110	1114	mice	T015	C0026809
27757318	1131	1145	CD4(+) T cells	T025	C0039215
27757318	1191	1199	NK cells	T025	C0022688
27757318	1204	1208	IFNγ	T116,T121,T129	C0021745
27757318	1242	1246	IL-2	T116,T129	C0021756
27757318	1248	1261	CD4(+) T cell	T025	C0039215
27757318	1262	1272	activation	T043	C1326120
27757318	1280	1305	homeostatic proliferation	T043	C1326161
27757318	1315	1326	macrophages	T025	C0024432
27757318	1362	1369	NK cell	T025	C0022688
27757318	1370	1388	antitumor activity	T033	C0243095
27757318	1396	1404	NK cells	T025	C0022688
27757318	1443	1452	cytokines	T116,T129	C0079189
27757318	1456	1477	epigenetic imprinting	T045	C0242614
27757318	1521	1525	IFNγ	T116,T121,T129	C0021745
27757318	1537	1546	phenotype	T032	C0031437
27757318	1620	1628	cytokine	T116,T129	C0079189
27757318	1643	1651	NK cells	T025	C0022688
27757318	1657	1670	CD4(+) T cell	T025	C0039215
27757318	1671	1681	activation	T043	C1326120
27757318	1687	1698	lymphopenic	T047	C0024312
27757318	1733	1740	NK cell	T025	C0022688
27757318	1763	1783	cancer immunotherapy	T061	C0278348

27306834|t|Naïve CD8(+) T cell derived tumor - specific cytotoxic effectors as a potential remedy for overcoming TGF-β immunosuppression in the tumor microenvironment
27306834|a|Despite of the potential implications for cancer immunotherapy, conventional approaches using in vitro expanded CD8(+) T cells have suboptimal outcomes, mostly due to loss of functionality from cellular exhaustion. We therefore investigated the phenotypic and functional differences among in vitro activated CD8(+) T cells of three different sources, namely naïve (NTeff), memory (MTeff) and tumor-infiltrating lymphocytes (TILeff) from human and mice, to better understand mechanisms behind potent effector functions and potential for overcoming current limitations. In line with the greater proliferation activity and longer telomere lengths of NTeff populations, cells of naïve origin exhibited significantly less amounts of T cell exhaustion markers than those of MTeff and TILeff, and moreover, acquired distinct expression patterns of memory-promoting transcription factors, T-bet and Eomes, induced in a rapid and sustainable manner. NTeff cells appeared to have lower expression of Foxp1 and were refractory to apoptosis upon TGF-β conditioning, implying better survival potential and resistance to tumor - induced immune suppression. Of CD8(+) T cell pools activated to tumor - specific CTLs, naïve cell generated effectors possessed the most potent cytotoxic activity, validating implications for use in rational design of adoptive immunotherapy.
27306834	0	5	Naïve	T025	C3641721
27306834	6	19	CD8(+) T cell	T025	C0242629
27306834	28	33	tumor	T191	C0027651
27306834	36	44	specific	T080	C0205369
27306834	45	64	cytotoxic effectors	T025	C3641722
27306834	80	86	remedy	T077	C1880198
27306834	102	107	TGF-β	T116,T123	C0040690
27306834	108	125	immunosuppression	T047	C4048329
27306834	133	155	tumor microenvironment	T070	C2936626
27306834	198	218	cancer immunotherapy	T061	C0278348
27306834	220	232	conventional	T080	C0439858
27306834	233	243	approaches	T169	C1292724
27306834	250	258	in vitro	T080	C1533691
27306834	259	267	expanded	T082	C0205229
27306834	268	282	CD8(+) T cells	T025	C0242629
27306834	288	298	suboptimal	T080	C2984009
27306834	299	307	outcomes	T080	C0085415
27306834	323	327	loss	T081	C1517945
27306834	331	344	functionality	T169	C0542341
27306834	350	358	cellular	T025	C0007634
27306834	359	369	exhaustion	UnknownType	C0678684
27306834	401	411	phenotypic	T032	C0031437
27306834	416	426	functional	T169	C0205245
27306834	427	438	differences	T080	C1705242
27306834	445	453	in vitro	T080	C1533691
27306834	454	463	activated	T052	C1879547
27306834	464	478	CD8(+) T cells	T025	C0242629
27306834	498	505	sources	T033	C0449416
27306834	514	519	naïve	T025	C3641721
27306834	521	526	NTeff	T025	C3641721
27306834	529	535	memory	T025	C0682639
27306834	537	542	MTeff	T025	C0682639
27306834	548	578	tumor-infiltrating lymphocytes	T025	C0079722
27306834	580	586	TILeff	T025	C0079722
27306834	593	598	human	T016	C0086418
27306834	603	607	mice	T015	C0025929
27306834	630	640	mechanisms	T169	C0441712
27306834	655	663	effector	T025	C3641722
27306834	664	673	functions	T169	C0542341
27306834	711	722	limitations	T169	C0449295
27306834	749	762	proliferation	T043	C0596873
27306834	763	771	activity	T052	C0441655
27306834	783	791	telomere	T026	C0085187
27306834	792	799	lengths	T081	C1444754
27306834	803	820	NTeff populations	T025	C3641721
27306834	822	827	cells	T025	C0007634
27306834	831	843	naïve origin	T079	C0439659
27306834	884	890	T cell	T025	C0039194
27306834	891	901	exhaustion	UnknownType	C0678684
27306834	902	909	markers	T201	C0005516
27306834	924	929	MTeff	T025	C0682639
27306834	934	940	TILeff	T025	C0079722
27306834	974	993	expression patterns	T045	C1171362
27306834	997	1035	memory-promoting transcription factors	T116,T123	C0040648
27306834	1037	1042	T-bet	T116	C0913648
27306834	1047	1052	Eomes	T116,T123	C1454790
27306834	1054	1061	induced	T169	C0205263
27306834	1067	1072	rapid	T080	C0456962
27306834	1077	1088	sustainable	T169	C0443318
27306834	1089	1095	manner	T169	C0205245
27306834	1097	1108	NTeff cells	T025	C3641721
27306834	1132	1142	expression	T045	C1171362
27306834	1146	1151	Foxp1	T116	C3273485
27306834	1175	1184	apoptosis	T043	C0162638
27306834	1190	1195	TGF-β	T116,T123	C0040690
27306834	1196	1208	conditioning	T169	C0205245
27306834	1226	1234	survival	T043	C0007620
27306834	1235	1244	potential	T080	C3245505
27306834	1249	1259	resistance	T169	C4281815
27306834	1263	1268	tumor	T191	C0027651
27306834	1271	1278	induced	T169	C0205263
27306834	1279	1297	immune suppression	T047	C4048329
27306834	1302	1315	CD8(+) T cell	T025	C0242629
27306834	1322	1331	activated	T052	C1879547
27306834	1335	1340	tumor	T191	C0027651
27306834	1343	1351	specific	T080	C0205369
27306834	1352	1356	CTLs	T025	C0039195
27306834	1358	1368	naïve cell	T025	C3641721
27306834	1369	1378	generated	T052	C3146294
27306834	1379	1388	effectors	T025	C3641722
27306834	1415	1433	cytotoxic activity	T033	C0243095
27306834	1479	1485	design	T052	C1707689
27306834	1489	1511	adoptive immunotherapy	T061	C0079613

28526565|t|Efficacy of indefinite chronic oral antimicrobial suppression for prosthetic joint infection in the elderly: a comparative study
28526565|a|During prosthetic joint infection (PJI), surgical management is sometimes impossible, indefinite chronic oral antimicrobial suppression (ICOAS) may sometimes be the only option. We evaluated the outcome of elderly patients who benefited from ICOAS for a strictly palliative goal METHODS: We performed a national retrospective cohort study in France of patients aged >75years old with PJI, and managed with ICOAS planned for life long from 2009 to 2014, and compared the population with an event versus the population free of event. Event was defined as a composite outcome in patients under ICOAS, including: local or systemic progression of the infection; death or discontinuation of antimicrobial therapy because of adverse drug reaction. Twenty-one patients were included, with a median age of 85 (IQR: 81; 88) years old. There were 8/21 patients with an event: 1 patient with adverse drug reaction; 3 patients had systemic progression of sepsis; and 2 had local progression. A total of 2/21 patients died. No deaths were related to ICOAS or infection. There was no significant difference (p >0.05) between the population with an event and free of event considering demographic, clinical and microbiological characteristics. In our cohort, ICOAS seems to be an effective and safe option.
28526565	0	8	Efficacy	T062	C1707887
28526565	12	61	indefinite chronic oral antimicrobial suppression	T061	C0087111
28526565	66	92	prosthetic joint infection	T047	C0410808
28526565	100	107	elderly	T098	C0001792
28526565	111	128	comparative study	T062	C1579762
28526565	136	162	prosthetic joint infection	T047	C0410808
28526565	164	167	PJI	T047	C0410808
28526565	170	189	surgical management	T058	C1515089
28526565	215	264	indefinite chronic oral antimicrobial suppression	T061	C0087111
28526565	266	271	ICOAS	T061	C0087111
28526565	310	319	evaluated	T058	C0220825
28526565	324	331	outcome	T169	C1274040
28526565	335	342	elderly	T098	C0001792
28526565	343	351	patients	T101	C0030705
28526565	371	376	ICOAS	T061	C0087111
28526565	392	407	palliative goal	T091	C0030231
28526565	432	467	national retrospective cohort study	T062	C2985505
28526565	471	477	France	T083	C0016674
28526565	481	489	patients	T101	C0030705
28526565	513	516	PJI	T047	C0410808
28526565	535	540	ICOAS	T061	C0087111
28526565	553	562	life long	T079	C4274169
28526565	599	609	population	T098	C1257890
28526565	618	623	event	T051	C0441471
28526565	635	645	population	T098	C1257890
28526565	654	659	event	T051	C0441471
28526565	661	666	Event	T051	C0441471
28526565	694	701	outcome	T033	C1624730
28526565	705	713	patients	T101	C0030705
28526565	720	725	ICOAS	T061	C0087111
28526565	738	767	local or systemic progression	T046	C0242656
28526565	775	784	infection	T046	C3714514
28526565	786	791	death	T033	C1306577
28526565	795	810	discontinuation	T033	C1444662
28526565	814	827	antimicrobial	T121	C1136254
28526565	828	835	therapy	T061	C0087111
28526565	847	868	adverse drug reaction	T046	C0041755
28526565	881	889	patients	T101	C0030705
28526565	970	978	patients	T101	C0030705
28526565	987	992	event	T051	C0441471
28526565	996	1003	patient	T101	C0030705
28526565	1009	1030	adverse drug reaction	T046	C0041755
28526565	1034	1042	patients	T101	C0030705
28526565	1047	1067	systemic progression	T046	C0242656
28526565	1071	1077	sepsis	T047	C0243026
28526565	1089	1106	local progression	T046	C0242656
28526565	1124	1132	patients	T101	C0030705
28526565	1133	1137	died	T033	C1306577
28526565	1139	1148	No deaths	T052	C0038952
28526565	1165	1170	ICOAS	T061	C0087111
28526565	1174	1183	infection	T046	C3714514
28526565	1243	1253	population	T098	C1257890
28526565	1262	1267	event	T051	C0441471
28526565	1272	1285	free of event	T081	C0242793
28526565	1280	1285	event	T051	C0441471
28526565	1298	1309	demographic	T102	C0683970
28526565	1311	1319	clinical	T201	C0683325
28526565	1324	1355	microbiological characteristics	T001	C0029235
28526565	1364	1370	cohort	T062	C2985505
28526565	1372	1377	ICOAS	T201	C1456627
28526565	1372	1377	ICOAS	T061	C0087111
28526565	1393	1402	effective	T080	C1704419
28526565	1407	1411	safe	T068	C0036043

27721600|t|Sonic hedgehog in oral squamous cell carcinoma: An immunohistochemical study
27721600|a|Recent studies have revealed the involvement of hedgehog (Hh) signaling component in proliferation and invasive behavior of many carcinomas. This study aims to identify the expression of sonic Hh (SHH) protein of SHH pathway in oral epithelial dysplasia and oral squamous cell carcinoma (OSCC) using SHH (H-160) (Santa Cruz, sc-9042) which could have therapeutic implication in future. A total of 250 cases comprising 50 normal oral mucosa, 50 cases of oral epithelial dysplasia, 50 well, 50 moderate and 50 poorly differentiated OSCCs were included in the study. Immunohistochemical evaluation of SHH protein expression was conducted using monoclonal antibody. Interpretation of the expression was done by immunoreactive score of Remmele and Stegner (IRS) scoring method. Chi-Square test was used to analyze the results. The study showed that SHH signaling molecules are highly expressed in OSCC, and their expression was mainly in the cytoplasm of epithelial cells. The SHH signaling component is associated with the pathological parameter in OSCC and oral epithelial dysplasia.
27721600	0	14	Sonic hedgehog	T116,T123	C1457880
27721600	18	46	oral squamous cell carcinoma	UnknownType	C0747035
27721600	51	70	immunohistochemical	T059	C1441616
27721600	71	76	study	T062	C2603343
27721600	84	91	studies	T062	C2603343
27721600	97	105	revealed	T080	C0443289
27721600	125	148	hedgehog (Hh) signaling	T044	C1155468
27721600	149	158	component	T116,T123	C1179435
27721600	162	175	proliferation	T169	C1514485
27721600	180	197	invasive behavior	T080	C0205281
27721600	206	216	carcinomas	T191	C0007097
27721600	223	228	study	T062	C2603343
27721600	250	260	expression	T045	C1171362
27721600	264	286	sonic Hh (SHH) protein	T116,T123	C1457880
27721600	290	301	SHH pathway	T044	C1519425
27721600	305	309	oral	T030	C0226896
27721600	310	330	epithelial dysplasia	T191	C0878500
27721600	335	363	oral squamous cell carcinoma	UnknownType	C0747035
27721600	365	369	OSCC	UnknownType	C0747035
27721600	377	380	SHH	T116,T123	C1457880
27721600	382	387	H-160	T116,T123	C1457880
27721600	428	451	therapeutic implication	T061	C0087111
27721600	505	509	oral	T030	C0226896
27721600	510	516	mucosa	T024	C0026724
27721600	530	534	oral	T030	C0226896
27721600	535	555	epithelial dysplasia	T191	C0878500
27721600	569	577	moderate	T080	C0205081
27721600	585	606	poorly differentiated	T080	C0205617
27721600	607	612	OSCCs	UnknownType	C0747035
27721600	634	639	study	T062	C2603343
27721600	641	660	Immunohistochemical	T059	C1441616
27721600	661	671	evaluation	T058	C0220825
27721600	675	686	SHH protein	T116,T123	C1457880
27721600	687	697	expression	T045	C1171362
27721600	718	737	monoclonal antibody	T116,T129	C0003250
27721600	739	753	Interpretation	T170	C0459471
27721600	761	771	expression	T045	C1171362
27721600	784	848	immunoreactive score of Remmele and Stegner (IRS) scoring method	T062	C0036449
27721600	850	865	Chi-Square test	T170	C0008041
27721600	878	885	analyze	T062	C0936012
27721600	890	897	results	T169	C1274040
27721600	903	908	study	T062	C2603343
27721600	921	934	SHH signaling	T044	C3158055
27721600	956	965	expressed	T045	C1171362
27721600	969	973	OSCC	UnknownType	C0747035
27721600	985	995	expression	T045	C1171362
27721600	1014	1043	cytoplasm of epithelial cells	T026	C2325751
27721600	1049	1072	SHH signaling component	T044	C3158055
27721600	1096	1108	pathological	T169	C1521733
27721600	1109	1118	parameter	T081	C0392762
27721600	1122	1126	OSCC	UnknownType	C0747035
27721600	1131	1135	oral	T030	C0226896
27721600	1136	1156	epithelial dysplasia	T191	C0878500

27898317|t|Ammonia tolerant inocula provide a good base for anaerobic digestion of microalgae in third generation biogas process
27898317|a|This study investigated the ability of an ammonia - acclimatized inoculum to digest efficiently protein -rich microalgae for continuous 3rd generation biogas production. Moreover, we investigated whether increased C / N ratio could alleviate ammonia toxicity. The biochemical methane potential (BMP) of five different algae (Chlorella vulgaris)/ manure (cattle) mixtures showed that the mixture of 80/20 (on VS basis) resulted in the highest BMP value (431mL CH4 gVS(-1)), while the BMP of microalgae alone (100/0) was 415mL CH4 gVS(-1). Subsequently, anaerobic digestion of those two substrates was tested in continuous stirred tank reactors (CSTR). Despite of the high ammonium levels (3.7-4.2g NH4 (+)-NL(-1)), CSTR reactors using ammonia tolerant inoculum resulted in relatively high methane yields (i.e. 77.5% and 84% of the maximum expected, respectively). These results demonstrated that ammonia tolerant inocula could be a promising approach to successfully digest protein -rich microalgae and achieve a 3rd generation biogas production.
27898317	0	7	Ammonia	T121,T197	C0002607
27898317	8	16	tolerant	T169	C0231198
27898317	49	58	anaerobic	T080	C3641081
27898317	59	68	digestion	T040	C0012238
27898317	72	82	microalgae	T204	C2936330
27898317	103	109	biogas	T109	C2717893
27898317	110	117	process	T067	C1522240
27898317	160	167	ammonia	T121,T197	C0002607
27898317	170	182	acclimatized	T040	C0000934
27898317	195	201	digest	T039	C0868946
27898317	214	221	protein	T116,T123	C0033684
27898317	228	238	microalgae	T204	C2936330
27898317	269	275	biogas	T109	C2717893
27898317	332	333	C	T196	C0007009
27898317	336	337	N	T123,T196	C0028158
27898317	360	376	ammonia toxicity	T037	C3686881
27898317	382	393	biochemical	T169	C0205474
27898317	394	401	methane	T109	C0025617
27898317	402	411	potential	T080	C3245505
27898317	413	416	BMP	T080	C3245505
27898317	436	441	algae	T204	C0002028
27898317	443	461	Chlorella vulgaris	T002	C0996438
27898317	464	470	manure	T167	C0024765
27898317	472	478	cattle	T015	C0007452
27898317	560	563	BMP	T080	C3245505
27898317	564	569	value	T081	C1522609
27898317	577	580	CH4	T109	C0025617
27898317	601	604	BMP	T080	C3245505
27898317	608	618	microalgae	T204	C2936330
27898317	643	646	CH4	T109	C0025617
27898317	670	679	anaerobic	T080	C3641081
27898317	680	689	digestion	T040	C0012238
27898317	728	760	continuous stirred tank reactors	T073	C3273359
27898317	762	766	CSTR	T073	C3273359
27898317	789	804	ammonium levels	T034	C1304736
27898317	815	818	NH4	T197	C0002611
27898317	832	845	CSTR reactors	T073	C3273359
27898317	860	868	tolerant	T169	C0231198
27898317	906	913	methane	T109	C0025617
27898317	914	920	yields	T081	C0392762
27898317	1013	1020	ammonia	T121,T197	C0002607
27898317	1021	1029	tolerant	T169	C0231198
27898317	1084	1090	digest	T039	C0868946
27898317	1091	1098	protein	T116,T123	C0033684
27898317	1105	1115	microalgae	T204	C2936330
27898317	1145	1151	biogas	T109	C2717893
27898317	1152	1162	production	T067	C1522240

28229178|t|The consummatory and motivational behaviors for natural rewards following long-term withdrawal from morphine: no anhedonia but persistent maladaptive behaviors for high-value rewards
28229178|a|The negative affective state, e.g., anhedonia, emerges after abstinence from abused drugs may be linked to the motivational processes of drug craving and relapse. Although anhedonia diminishes over time with drug abstinence, it is not yet rather explicit whether anhedonia exists or not following protracted withdrawal. The behavioral responses to natural rewards were examined after 2 to 3 weeks withdrawal from morphine. Male rats were pretreated with either a binge-like morphine paradigm or daily saline injection for 5 days. The consummatory and motivational behaviors for three natural rewards (sucrose solutions 4, 15, and 60%, social stimulus: male rat, and sexual stimulus: estrous female rat) were examined under varied testing conditions. The morphine - withdrawn rats significantly increased their intake of 15% sucrose solution during the 1-h consumption test and their operant responding for 15% sucrose solution under a progressive ratio (PR) schedule of reinforcement. When obtaining a reinforcer was associated with a 0.5 mA foot shock under a PR-punishment schedule, the morphine - withdrawn rats showed a higher performance for 60% sucrose solution. Meanwhile, the morphine - withdrawn rats displayed a higher motivation to sexual stimulus during the free-approach test and more approaching behaviors towards sexual stimulus in a conflict-based approach test (concurrent presence of reward and aversive stimulus). No anhedonia -like behavior but sensitized behaviors for natural rewards were found after long-term morphine withdrawal. Notably, the morphine - withdrawn rats displayed persistent motivated behaviors for high-value rewards (60% sucrose and sexual stimulus) in the conflict tests suggesting impairments in inhibitory control in morphine - treated rats.
28229178	4	16	consummatory	T054	C0009829
28229178	21	33	motivational	T041	C0026605
28229178	34	43	behaviors	T053	C0004927
28229178	48	55	natural	T169	C0205296
28229178	56	63	rewards	T041	C0035397
28229178	84	94	withdrawal	T061	C1707825
28229178	100	108	morphine	T109,T121	C0026549
28229178	113	122	anhedonia	T048	C0178417
28229178	138	159	maladaptive behaviors	T033	C0562443
28229178	175	182	rewards	T041	C0035397
28229178	219	228	anhedonia	T048	C0178417
28229178	244	254	abstinence	T061	C3843422
28229178	260	272	abused drugs	T131	C0086190
28229178	294	306	motivational	T041	C0026605
28229178	307	316	processes	T067	C1522240
28229178	320	332	drug craving	T033	C0556446
28229178	337	344	relapse	T067	C0035020
28229178	355	364	anhedonia	T048	C0178417
28229178	391	406	drug abstinence	T055	C0237443
28229178	446	455	anhedonia	T048	C0178417
28229178	491	501	withdrawal	T061	C1707825
28229178	507	517	behavioral	T053	C0004927
28229178	518	527	responses	T032	C0871261
28229178	531	538	natural	T169	C0205296
28229178	539	546	rewards	T041	C0035397
28229178	574	579	weeks	T079	C0439230
28229178	580	590	withdrawal	T061	C1707825
28229178	596	604	morphine	T109,T121	C0026549
28229178	606	610	Male	T032	C0086582
28229178	611	615	rats	T015	C0034693
28229178	657	665	morphine	T109,T121	C0026549
28229178	666	674	paradigm	T062	C0681797
28229178	678	683	daily	T079	C0332173
28229178	684	700	saline injection	T061	C0199797
28229178	707	711	days	T079	C0439228
28229178	717	729	consummatory	T054	C0009829
28229178	734	746	motivational	T041	C0026605
28229178	747	756	behaviors	T053	C0004927
28229178	767	774	natural	T169	C0205296
28229178	775	782	rewards	T041	C0035397
28229178	784	801	sucrose solutions	T109,T121,T123	C0038636
28229178	818	824	social	T169	C0728831
28229178	825	833	stimulus	T067	C0234402
28229178	835	839	male	T032	C0086582
28229178	840	843	rat	T015	C0034693
28229178	849	855	sexual	T054	C0036865
28229178	856	864	stimulus	T067	C0234402
28229178	866	873	estrous	T040	C0014948
28229178	874	880	female	T032	C0086287
28229178	881	884	rat	T015	C0034693
28229178	913	931	testing conditions	T080	C0449910
28229178	937	945	morphine	T109,T121	C0026549
28229178	948	957	withdrawn	T061	C1707825
28229178	958	962	rats	T015	C0034693
28229178	1007	1023	sucrose solution	T109,T121,T123	C0038636
28229178	1039	1055	consumption test	T060	C0683443
28229178	1066	1084	operant responding	T041	C0009651
28229178	1093	1109	sucrose solution	T109,T121,T123	C0038636
28229178	1118	1166	progressive ratio (PR) schedule of reinforcement	T062	C0871209
28229178	1185	1195	reinforcer	T078	C0178826
28229178	1225	1229	foot	T023	C0016504
28229178	1230	1235	shock	T061	C0013870
28229178	1244	1266	PR-punishment schedule	T062	C0035008
28229178	1272	1280	morphine	T109,T121	C0026549
28229178	1283	1292	withdrawn	T061	C1707825
28229178	1293	1297	rats	T015	C0034693
28229178	1334	1350	sucrose solution	T109,T121,T123	C0038636
28229178	1367	1375	morphine	T109,T121	C0026549
28229178	1378	1387	withdrawn	T061	C1707825
28229178	1388	1392	rats	T015	C0034693
28229178	1412	1422	motivation	T041	C0026605
28229178	1426	1432	sexual	T054	C0036865
28229178	1433	1441	stimulus	T067	C0234402
28229178	1453	1471	free-approach test	T060	C0683443
28229178	1493	1502	behaviors	T053	C0004927
28229178	1511	1517	sexual	T054	C0036865
28229178	1518	1526	stimulus	T067	C0234402
28229178	1532	1560	conflict-based approach test	T060	C0683444
28229178	1585	1591	reward	T041	C0035397
28229178	1596	1613	aversive stimulus	T169	C1510994
28229178	1616	1618	No	T033	C1513916
28229178	1619	1628	anhedonia	T048	C0178417
28229178	1635	1643	behavior	T053	C0004927
28229178	1648	1658	sensitized	T169	C0332324
28229178	1659	1668	behaviors	T053	C0004927
28229178	1673	1680	natural	T169	C0205296
28229178	1681	1688	rewards	T041	C0035397
28229178	1716	1724	morphine	T109,T121	C0026549
28229178	1725	1735	withdrawal	T061	C1707825
28229178	1750	1758	morphine	T109,T121	C0026549
28229178	1761	1770	withdrawn	T061	C1707825
28229178	1771	1775	rats	T015	C0034693
28229178	1797	1806	motivated	T041	C0026605
28229178	1807	1816	behaviors	T053	C0004927
28229178	1832	1839	rewards	T041	C0035397
28229178	1845	1852	sucrose	T109,T121,T123	C0038636
28229178	1857	1863	sexual	T054	C0036865
28229178	1864	1872	stimulus	T067	C0234402
28229178	1881	1895	conflict tests	T060	C0683443
28229178	1944	1952	morphine	T109,T121	C0026549
28229178	1955	1962	treated	T169	C1522326
28229178	1963	1967	rats	T015	C0034693

28169492|t|Comparison of biofilm formation and motility processes in arsenic - resistant Thiomonas spp. strains revealed divergent response to arsenite
28169492|a|Bacteria of the genus Thiomonas are found ubiquitously in arsenic contaminated waters such as acid mine drainage (AMD), where they contribute to the precipitation and the natural bioremediation of arsenic. In these environments, these bacteria have developed a large range of resistance strategies among which the capacity to form particular biofilm structures. The biofilm formation is one of the most ubiquitous adaptive response observed in prokaryotes to various stresses, such as those induced in the presence of toxic compounds. This study focused on the process of biofilm formation in three Thiomonas strains (CB1, CB2 and CB3) isolated from the same AMD. The results obtained here show that these bacteria are all capable of forming biofilms, but the architecture and the kinetics of formation of these biofilms differ depending on whether arsenite is present in the environment and from one strain to another. Indeed, two strains favoured biofilm formation, whereas one favoured motility in the presence of arsenite. To identify the underlying mechanisms, the patterns of expression of some genes possibly involved in the process of biofilm formation were investigated in Thiomonas sp. CB2 in the presence and absence of arsenite, using a transcriptomic approach (RNA-seq). The findings obtained here shed interesting light on how the formation of biofilms, and the motility processes contribute to the adaptation of Thiomonas strains to extreme environments.
28169492	0	10	Comparison	T052	C1707455
28169492	14	31	biofilm formation	T043	C1325881
28169492	36	54	motility processes	T040	C0007608
28169492	58	65	arsenic	T121,T131,T196	C0003818
28169492	68	77	resistant	T169	C0332325
28169492	78	100	Thiomonas spp. strains	T007	C1003865
28169492	101	109	revealed	T080	C0443289
28169492	132	140	arsenite	T121,T197	C0052418
28169492	141	149	Bacteria	T007	C0004611
28169492	157	162	genus	T185	C1708235
28169492	163	172	Thiomonas	T007	C1003865
28169492	177	195	found ubiquitously	T033	C0150312
28169492	199	206	arsenic	T121,T131,T196	C0003818
28169492	207	226	contaminated waters	T069	C0043056
28169492	235	253	acid mine drainage	T069	C0043056
28169492	255	258	AMD	T069	C0043056
28169492	272	282	contribute	T052	C1880177
28169492	290	303	precipitation	T070	C0032931
28169492	312	334	natural bioremediation	T069	C0598015
28169492	338	345	arsenic	T121,T131,T196	C0003818
28169492	356	368	environments	T082	C0014406
28169492	376	384	bacteria	T007	C0004611
28169492	417	438	resistance strategies	T169	C4281815
28169492	455	463	capacity	T081	C1516240
28169492	467	471	form	T043	C1325881
28169492	483	490	biofilm	T043	C1325881
28169492	491	501	structures	T082	C0678594
28169492	507	524	biofilm formation	T043	C1325881
28169492	555	563	adaptive	T169	C0231193
28169492	564	572	response	T032	C0871261
28169492	573	581	observed	T169	C1441672
28169492	585	596	prokaryotes	T001	C0686817
28169492	608	616	stresses	T032	C2350026
28169492	632	639	induced	T169	C0205263
28169492	659	664	toxic	T037	C0600688
28169492	665	674	compounds	T103	C1706082
28169492	681	686	study	T062	C2603343
28169492	713	730	biofilm formation	T043	C1325881
28169492	740	757	Thiomonas strains	T007	C1003865
28169492	759	762	CB1	T007	C2650684
28169492	764	767	CB2	T007	C2650685
28169492	772	775	CB3	T007	C2650686
28169492	777	785	isolated	T169	C0205409
28169492	800	803	AMD	T069	C0043056
28169492	817	825	obtained	T169	C1301820
28169492	847	855	bacteria	T007	C1003865
28169492	875	891	forming biofilms	T043	C1325881
28169492	922	930	kinetics	T070	C0022702
28169492	934	961	formation of these biofilms	T043	C1325881
28169492	990	998	arsenite	T121,T197	C0052418
28169492	1002	1009	present	T033	C0150312
28169492	1017	1028	environment	T082	C0014406
28169492	1042	1048	strain	T001	C1518614
28169492	1073	1080	strains	T001	C1518614
28169492	1081	1089	favoured	T080	C3640814
28169492	1090	1107	biofilm formation	T043	C1325881
28169492	1121	1129	favoured	T080	C3640814
28169492	1130	1138	motility	T043	C0007613
28169492	1146	1154	presence	T033	C0150312
28169492	1158	1166	arsenite	T121,T197	C0052418
28169492	1171	1179	identify	T080	C0205396
28169492	1195	1205	mechanisms	T169	C0441712
28169492	1211	1219	patterns	T082	C0449774
28169492	1223	1233	expression	T045	C0017262
28169492	1242	1247	genes	T028	C0017337
28169492	1284	1301	biofilm formation	T043	C1325881
28169492	1307	1319	investigated	T169	C1292732
28169492	1323	1340	Thiomonas sp. CB2	T007	C2650685
28169492	1348	1356	presence	T033	C0150312
28169492	1361	1368	absence	T169	C0332197
28169492	1372	1380	arsenite	T121,T197	C0052418
28169492	1390	1413	transcriptomic approach	T059,T063	C0752248
28169492	1415	1422	RNA-seq	T059,T063	C0752248
28169492	1438	1446	obtained	T169	C1301820
28169492	1469	1474	light	T070	C0023693
28169492	1486	1507	formation of biofilms	T043	C1325881
28169492	1517	1535	motility processes	T040	C0007608
28169492	1536	1546	contribute	T052	C1880177
28169492	1554	1564	adaptation	T038	C0392673
28169492	1568	1585	Thiomonas strains	T007	C1003865
28169492	1597	1609	environments	T082	C0014406

28482033|t|Long-term survival outcome after postoperative recurrence of non-small-cell lung cancer: who is ' cured ' from postoperative recurrence?
28482033|a|Since survival after postoperative non-small-cell lung cancer (NSCLC) recurrence is extremely poor, the long-term post - recurrence outcomes are not well understood. The purpose of this study was to evaluate the long-term post - recurrence outcomes and clarify who are possibly ' cured ' in recent clinical practice. We reviewed the medical records of 635 patients who developed postoperative recurrence until 2012 after R0 resection for pathological Stage IA-IIIA NSCLC between 1993 and 2006. Factors associated with post - recurrence surviva l (PRS) and the characteristics of the long-term (≥5 years) survivors were analysed retrospectively. The 5- year PRS rate of all 635 patients was 13%. Multivariable analysis revealed that female [hazard ratio (HR) = 0.78], adenocarcinoma (HR = 0.77), locoregional (only) recurrence (HR = 0.59) and longer recurrence -free survival (HR = 0.99) were favourably associated with PRS. A total of 51 patients achieved 5- year PRS; however, 32 (63%) were cancer -bearing patients in their fifth post-recurrent year who were mainly treated by epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI). Subsequent PRS curves for cancer - controlled and cancer -bearing groups were different (8- year PRS: 94% vs 31%, P = 0.003). Among 19 cancer - controlled patients in their fifth post-recurrent year, 17 (89%) patients initially received radical local therapy for their recurrence. Two-thirds of 5- year survivors after postoperative NSCLC recurrence had a cancer -bearing status and showed deteriorated subsequent survival. Curability of postoperative NSCLC recurrence should be evaluated in terms of the ' cancer - controlled ' status, and ' cured ' population is included in the patients who are ' cancer controlled ' at the fifth post-recurrent year.
28482033	0	9	Long-term	T079	C0443252
28482033	10	18	survival	T052	C0038952
28482033	19	26	outcome	T169	C1274040
28482033	33	46	postoperative	T079	C0032790
28482033	47	57	recurrence	T191	C1458156
28482033	61	87	non-small-cell lung cancer	T191	C0007131
28482033	98	103	cured	T033	C0438113
28482033	111	124	postoperative	T079	C0032790
28482033	125	135	recurrence	T191	C1458156
28482033	143	151	survival	T052	C0038952
28482033	158	171	postoperative	T079	C0032790
28482033	172	198	non-small-cell lung cancer	T191	C0007131
28482033	200	205	NSCLC	T191	C0007131
28482033	207	217	recurrence	T191	C1458156
28482033	231	235	poor	T080	C2700379
28482033	241	250	long-term	T079	C0443252
28482033	251	255	post	T079	C0687676
28482033	258	268	recurrence	T191	C1458156
28482033	269	277	outcomes	T169	C1274040
28482033	336	344	evaluate	T058	C0220825
28482033	349	358	long-term	T079	C0443252
28482033	359	363	post	T079	C0687676
28482033	366	376	recurrence	T191	C1458156
28482033	377	385	outcomes	T169	C1274040
28482033	390	397	clarify	T052	C2986669
28482033	417	422	cured	T033	C0438113
28482033	428	434	recent	T079	C0332185
28482033	435	452	clinical practice	T057	C0205897
28482033	457	465	reviewed	T080	C1709940
28482033	470	485	medical records	T170	C0025102
28482033	493	501	patients	T101	C0030705
28482033	516	529	postoperative	T079	C0032790
28482033	530	540	recurrence	T191	C1458156
28482033	558	570	R0 resection	T061	C0728940
28482033	575	607	pathological Stage IA-IIIA NSCLC	T191	C0007131
28482033	631	638	Factors	T169	C1521761
28482033	639	654	associated with	T080	C0332281
28482033	655	659	post	T079	C0687676
28482033	662	672	recurrence	T191	C1458156
28482033	673	680	surviva	T052	C0038952
28482033	684	687	PRS	T052	C0038952
28482033	697	712	characteristics	T080	C1521970
28482033	720	729	long-term	T079	C0443252
28482033	734	739	years	T079	C0439234
28482033	741	750	survivors	T101	C0206194
28482033	756	780	analysed retrospectively	T062	C0035363
28482033	789	793	year	T079	C0439234
28482033	794	797	PRS	T052	C0038952
28482033	798	802	rate	T081	C1521828
28482033	814	822	patients	T101	C0030705
28482033	832	854	Multivariable analysis	T081	C0026777
28482033	855	863	revealed	T080	C0443289
28482033	869	875	female	T032	C0086287
28482033	877	889	hazard ratio	T081	C2985465
28482033	891	893	HR	T081	C2985465
28482033	904	918	adenocarcinoma	T191	C0001418
28482033	920	922	HR	T081	C2985465
28482033	932	962	locoregional (only) recurrence	T191	C0027643
28482033	952	962	recurrence	T191	C1458156
28482033	964	966	HR	T081	C2985465
28482033	979	1011	longer recurrence -free survival	T033	C2919733
28482033	986	996	recurrence	T191	C1458156
28482033	1013	1015	HR	T081	C2985465
28482033	1040	1055	associated with	T080	C0332281
28482033	1056	1059	PRS	T052	C0038952
28482033	1075	1083	patients	T101	C0030705
28482033	1096	1100	year	T079	C0439234
28482033	1101	1104	PRS	T052	C0038952
28482033	1129	1135	cancer	T191	C0006826
28482033	1145	1153	patients	T101	C0030705
28482033	1169	1183	post-recurrent	T079	C1254367
28482033	1184	1188	year	T079	C0439234
28482033	1205	1212	treated	T169	C1522326
28482033	1216	1274	epidermal growth factor receptor-tyrosine kinase inhibitor	T121	C1443775
28482033	1276	1284	EGFR-TKI	T121	C1443775
28482033	1298	1301	PRS	T052	C0038952
28482033	1302	1308	curves	T170	C0681493
28482033	1313	1319	cancer	T191	C0006826
28482033	1322	1332	controlled	T033	C2911690
28482033	1337	1343	cancer	T191	C0006826
28482033	1353	1359	groups	T078	C0441833
28482033	1365	1374	different	T080	C1705242
28482033	1379	1383	year	T079	C0439234
28482033	1384	1387	PRS	T052	C0038952
28482033	1422	1428	cancer	T191	C0006826
28482033	1431	1441	controlled	T033	C2911690
28482033	1442	1450	patients	T101	C0030705
28482033	1466	1485	post-recurrent year	T079	C0439234
28482033	1496	1504	patients	T101	C0030705
28482033	1524	1545	radical local therapy	T061	C2986520
28482033	1556	1566	recurrence	T191	C1458156
28482033	1585	1589	year	T079	C0439234
28482033	1590	1599	survivors	T101	C0206194
28482033	1606	1619	postoperative	T079	C0032790
28482033	1620	1625	NSCLC	T191	C0007131
28482033	1626	1636	recurrence	T191	C1458156
28482033	1643	1649	cancer	T191	C0006826
28482033	1659	1665	status	T080	C0449438
28482033	1677	1689	deteriorated	T033	C1457868
28482033	1701	1709	survival	T052	C0038952
28482033	1725	1738	postoperative	T079	C0032790
28482033	1739	1744	NSCLC	T191	C0007131
28482033	1745	1755	recurrence	T191	C1458156
28482033	1766	1775	evaluated	T058	C0220825
28482033	1794	1800	cancer	T191	C0006826
28482033	1803	1813	controlled	T033	C2911690
28482033	1816	1822	status	T080	C0449438
28482033	1830	1835	cured	T033	C0438113
28482033	1838	1848	population	T098	C1257890
28482033	1868	1876	patients	T101	C0030705
28482033	1887	1893	cancer	T191	C0006826
28482033	1894	1904	controlled	T033	C2911690
28482033	1920	1939	post-recurrent year	T079	C0439234

28379194|t|Characteristics of N-Acylhomoserine Lactones Produced by Hafnia alvei H4 Isolated from Spoiled Instant Sea Cucumber
28379194|a|This study aimed to identify N-acylhomoserine lactone (AHL) produced by Hafnia alvei H4, which was isolated from spoiled instant sea cucumber, and to investigate the effect of AHLs on biofilm formation. Two biosensor strains, Chromobacterium violaceum CV026 and Agrobacterium tumefaciens KYC55, were used to detect the quorum sensing (QS) activity of H. alvei H4 and to confirm the existence of AHL -mediated QS system. Thin layer chromatography (TLC) and high resolution triple quadrupole liquid chromatography/mass spectrometry (LC/MS) analysis of the AHLs extracted from the culture supernatant of H. alvei H4 revealed the existence of at least three AHL s: N-hexanoyl-l-homoserine lactone (C6-HSL), N-(3-oxo-octanoyl)-l-homoserine lactone (3-oxo-C8-HSL), and N-butyryl-l-homoserine lactone (C4-HSL). This is the first report of the production of C4-HSL by H. alvei. In order to determine the relationship between the production of AHL by H. alvei H4 and bacterial growth, the β-galactosidase assay was employed to monitor AHL activity during a 48-h growth phase. AHLs production reached a maximum level of 134.6 Miller unites at late log phase (after 18 h) and then decreased to a stable level of about 100 Miller unites. AHL production and bacterial growth displayed a similar trend, suggesting that growth of H. alvei H4 might be regulated by QS. The effect of AHLs on biofilm formation of H. alvei H4 was investigated by adding exogenous AHLs (C4-HSL, C6-HSL and 3-oxo-C8-HSL) to H. alvei H4 culture. Biofilm formation was significantly promoted (p < 0.05) by 5 and 10 µM C6-HSL, inhibited (p < 0.05) by C4-HSL (5 and 10 µM) and 5 µM 3-oxo-C8-HSL, suggesting that QS may have a regulatory role in the biofilm formation of H. alvei H4.
28379194	0	15	Characteristics	T080	C1521970
28379194	19	44	N-Acylhomoserine Lactones	T109	C1313745
28379194	57	72	Hafnia alvei H4	T007	C0315259
28379194	73	81	Isolated	T169	C0205409
28379194	103	115	Sea Cucumber	T204	C0036485
28379194	121	126	study	T062	C2603343
28379194	145	169	N-acylhomoserine lactone	T109	C1313745
28379194	171	174	AHL	T109	C1313745
28379194	188	203	Hafnia alvei H4	T007	C0315259
28379194	215	223	isolated	T169	C0205409
28379194	245	257	sea cucumber	T204	C0036485
28379194	292	296	AHLs	T109	C1313745
28379194	300	317	biofilm formation	T043	C1325881
28379194	323	340	biosensor strains	T007	C0004611
28379194	342	373	Chromobacterium violaceum CV026	T007	C0315057
28379194	378	409	Agrobacterium tumefaciens KYC55	T007	C0085472
28379194	435	449	quorum sensing	T043	C1154599
28379194	451	453	QS	T043	C1154599
28379194	467	478	H. alvei H4	T007	C0315259
28379194	511	514	AHL	T109	C1313745
28379194	525	534	QS system	T043	C1154599
28379194	536	561	Thin layer chromatography	T059	C0008569
28379194	563	566	TLC	T059	C0008569
28379194	572	645	high resolution triple quadrupole liquid chromatography/mass spectrometry	T059	C3641325
28379194	647	652	LC/MS	T059	C3641325
28379194	654	662	analysis	T062	C0936012
28379194	670	674	AHLs	T109	C1313745
28379194	694	701	culture	T059	C0430400
28379194	717	728	H. alvei H4	T007	C0315259
28379194	770	773	AHL	T109	C1313745
28379194	777	808	N-hexanoyl-l-homoserine lactone	T109,T123	C0536858
28379194	810	816	C6-HSL	T109,T123	C0536858
28379194	819	858	N-(3-oxo-octanoyl)-l-homoserine lactone	T116,T121	C0379888
28379194	860	872	3-oxo-C8-HSL	T116,T121	C0379888
28379194	879	909	N-butyryl-l-homoserine lactone	T109	C0536860
28379194	911	917	C4-HSL	T109	C0536860
28379194	952	962	production	T038	C3714634
28379194	966	972	C4-HSL	T109	C0536860
28379194	976	984	H. alvei	T007	C0315259
28379194	1037	1047	production	T038	C3714634
28379194	1051	1054	AHL	T109	C1313745
28379194	1058	1069	H. alvei H4	T007	C0315259
28379194	1074	1090	bacterial growth	T034	C0427944
28379194	1096	1111	β-galactosidase	T116,T121,T126	C0005220
28379194	1112	1117	assay	T059	C0005507
28379194	1142	1145	AHL	T109	C1313745
28379194	1183	1187	AHLs	T109	C1313745
28379194	1188	1198	production	T038	C3714634
28379194	1342	1345	AHL	T109	C1313745
28379194	1346	1356	production	T038	C3714634
28379194	1361	1377	bacterial growth	T034	C0427944
28379194	1421	1427	growth	T034	C0427944
28379194	1431	1442	H. alvei H4	T007	C0315259
28379194	1465	1467	QS	T043	C1154599
28379194	1483	1487	AHLs	T109	C1313745
28379194	1491	1508	biofilm formation	T043	C1325881
28379194	1512	1523	H. alvei H4	T007	C0315259
28379194	1551	1560	exogenous	T169	C0205228
28379194	1561	1565	AHLs	T109	C1313745
28379194	1567	1573	C4-HSL	T109	C0536860
28379194	1575	1581	C6-HSL	T109,T123	C0536858
28379194	1586	1598	3-oxo-C8-HSL	T116,T121	C0379888
28379194	1603	1614	H. alvei H4	T007	C0315259
28379194	1624	1641	Biofilm formation	T043	C1325881
28379194	1695	1701	C6-HSL	T109,T123	C0536858
28379194	1727	1733	C4-HSL	T109	C0536860
28379194	1757	1769	3-oxo-C8-HSL	T116,T121	C0379888
28379194	1787	1789	QS	T043	C1154599
28379194	1824	1841	biofilm formation	T043	C1325881
28379194	1845	1856	H. alvei H4	T007	C0315259

28544492|t|Epistatic influence in tomato Ve1 - mediated resistance
28544492|a|Resistance to Verticillium wilt disease is associated with the tomato Ve-locus; however, the individual functional roles of Ve1 and Ve2 in host plants remain controversial. As a first step towards Ve mutational analyses in planta, the Ve1 coding region from a resistant tomato near-isoline (cv. Craigella GCR218) was introduced into a susceptible near-isoline (cv. Craigella GCR26). 35S:Ve1 plants segregated into two distinct classes; roughly half were resistant and half were susceptible. Ve1 transcript levels were upregulated in both classes compared to wild-type plants, showing stable transgenic expression. Expression analysis of Ve2 revealed that mRNA levels were similar between 35S:Ve1 and wild-type tomatoes, demonstrating that Ve1 transgene introduction does not alter endogenous Ve2 expression. Overall, the results of this study confirm the functional role of Ve1 protein in resistance to the vascular fungal pathogen V. dahliae race 1 (Vd1), but suggest that a yet undefined factor exerts an epistatic influence on the Ve1 gene. This article is protected by copyright. All rights reserved.
28544492	0	9	Epistatic	T045	C0014589
28544492	10	19	influence	T077	C4054723
28544492	23	29	tomato	T168	C0242772
28544492	30	33	Ve1	T028	C0017337
28544492	36	44	mediated	T054	C0680727
28544492	45	55	resistance	T040	C1136180
28544492	56	66	Resistance	T040	C1136180
28544492	70	95	Verticillium wilt disease	T047	C0012634
28544492	99	114	associated with	T080	C0332281
28544492	119	125	tomato	T168	C0242772
28544492	126	134	Ve-locus	T028	C0678933
28544492	160	176	functional roles	T077	C1705810
28544492	180	183	Ve1	T028	C0017337
28544492	188	191	Ve2	T028	C0017337
28544492	195	206	host plants	UnknownType	C0868970
28544492	214	227	controversial	T054	C0680243
28544492	253	275	Ve mutational analyses	T059,T063	C0012878
28544492	279	285	planta	T002	C0032098
28544492	291	294	Ve1	T028	C0017337
28544492	295	308	coding region	T114,T123	C0015295
28544492	316	325	resistant	T169	C0332325
28544492	326	367	tomato near-isoline (cv. Craigella GCR218	T168	C0242772
28544492	403	437	near-isoline (cv. Craigella GCR26)	T168	C0242772
28544492	439	453	35S:Ve1 plants	T002	C0032098
28544492	474	490	distinct classes	T170	C0456387
28544492	500	504	half	T081	C2825407
28544492	510	519	resistant	T169	C0332325
28544492	524	528	half	T081	C2825407
28544492	534	545	susceptible	T169	C0231204
28544492	547	550	Ve1	T028	C0017337
28544492	551	561	transcript	T114	C1519595
28544492	562	568	levels	T080	C0441889
28544492	574	585	upregulated	T044	C0041904
28544492	594	601	classes	T170	C0456387
28544492	614	623	wild-type	T028	C1883559
28544492	624	630	plants	T002	C0032098
28544492	640	646	stable	T080	C0205360
28544492	647	657	transgenic	T028	C0282641
28544492	658	668	expression	T045	C0017262
28544492	670	689	Expression analysis	T063	C1880945
28544492	693	696	Ve2	T028	C0017337
28544492	711	715	mRNA	T114,T123	C0035696
28544492	716	722	levels	T080	C0441889
28544492	728	735	similar	T080	C2348205
28544492	744	751	35S:Ve1	T002	C0032098
28544492	756	765	wild-type	T028	C1883559
28544492	766	774	tomatoes	T168	C0242772
28544492	795	798	Ve1	T028	C0017337
28544492	799	808	transgene	T028	C0282641
28544492	809	821	introduction	T169	C0579004
28544492	837	847	endogenous	T169	C0205227
28544492	848	851	Ve2	T028	C0017337
28544492	852	862	expression	T045	C0017262
28544492	877	884	results	T169	C1274040
28544492	893	898	study	T062	C2603343
28544492	911	926	functional role	T077	C1705810
28544492	930	941	Ve1 protein	T116,T123	C0033684
28544492	945	955	resistance	T040	C1136180
28544492	963	987	vascular fungal pathogen	T004	C0016832
28544492	988	1005	V. dahliae race 1	T004	C1001432
28544492	1007	1010	Vd1	T004	C1001432
28544492	1036	1045	undefined	T078	C0750600
28544492	1046	1052	factor	T169	C1521761
28544492	1053	1059	exerts	T040	C0015264
28544492	1063	1072	epistatic	T045	C0014589
28544492	1073	1082	influence	T077	C4054723
28544492	1090	1098	Ve1 gene	T028	C0017337

27714861|t|Mechanically Reinforced Skin - Electronics with Networked Nanocomposite Elastomer
27714861|a|Mechanically reinforced skin - electronics are presented by exploiting networked nanocomposite elastomers where high quality metal nanowires serve as conducting paths. Theoretical and experimental studies show that the established skin - electronics exhibit superior mechanical enhancements against crack and delamination phenomena. Device applications include a class of biomedical devices that offers the ability of thermotherapeutic stimulation and electrophysiological monitoring, all via the skin.
27714861	0	23	Mechanically Reinforced	T169	C0443254
27714861	24	28	Skin	T022	C1123023
27714861	31	42	Electronics	T091	C0013851
27714861	48	57	Networked	T169	C1882071
27714861	58	71	Nanocomposite	T073	C1721059
27714861	72	81	Elastomer	T109,T122	C0013766
27714861	82	105	Mechanically reinforced	T169	C0443254
27714861	106	110	skin	T022	C1123023
27714861	113	124	electronics	T091	C0013851
27714861	153	162	networked	T169	C1882071
27714861	163	176	nanocomposite	T073	C1721059
27714861	177	187	elastomers	T109,T122	C0013766
27714861	199	206	quality	T080	C0332306
27714861	207	212	metal	T197	C0025552
27714861	213	222	nanowires	T073	C1721063
27714861	232	248	conducting paths	T042	C0814024
27714861	250	261	Theoretical	T062,T170	C0039778
27714861	266	286	experimental studies	T062	C0681814
27714861	313	317	skin	T022	C1123023
27714861	320	331	electronics	T091	C0013851
27714861	340	348	superior	T082	C1282910
27714861	349	372	mechanical enhancements	T061	C0699886
27714861	381	386	crack	T067	C1881706
27714861	391	413	delamination phenomena	T051	C1706215
27714861	415	434	Device applications	T061	C1283079
27714861	454	472	biomedical devices	T074	C0025080
27714861	500	529	thermotherapeutic stimulation	T061	C0020548
27714861	534	554	electrophysiological	T040	C2350528
27714861	555	565	monitoring	T058	C0026429
27714861	579	583	skin	T022	C1123023

28423855|t|EHR Improvement Using Incident Reports
28423855|a|This paper discusses reactive improvement of clinical software using methods for incident analysis. We used the "Five Whys" method because we had only descriptive data and depended on a domain expert for the analysis. The analysis showed that there are two major root causes for EHR software failure, and that they are related to human and organizational errors. A main identified improvement is allocating more resources to system maintenance and user training.
28423855	0	3	EHR	T073	C4035898
28423855	4	15	Improvement	T077	C2986411
28423855	22	38	Incident Reports	T058	C0178896
28423855	60	68	reactive	T080	C0205332
28423855	69	80	improvement	T077	C2986411
28423855	84	92	clinical	T080	C0205210
28423855	93	101	software	T073,T170	C0037585
28423855	108	115	methods	T170	C0025663
28423855	120	128	incident	T067	C1551358
28423855	129	137	analysis	T062	C0936012
28423855	151	169	"Five Whys" method	T170	C0025663
28423855	190	206	descriptive data	T078	C1511726
28423855	211	219	depended	T169	C3244310
28423855	225	238	domain expert	T057	C0015325
28423855	247	255	analysis	T062	C0936012
28423855	261	269	analysis	T062	C0936012
28423855	292	295	two	T081	C0205448
28423855	302	313	root causes	T033	C0566251
28423855	318	321	EHR	T073	C4035898
28423855	322	330	software	T073,T170	C0037585
28423855	331	338	failure	T169	C0231175
28423855	369	374	human	T016	C0086418
28423855	379	393	organizational	T080	C0220885
28423855	394	400	errors	T080	C0743559
28423855	409	419	identified	T080	C0205396
28423855	420	431	improvement	T077	C2986411
28423855	451	460	resources	T078	C0035201
28423855	464	482	system maintenance	T169	C1883060
28423855	487	500	user training	T065	C0009616

27472389|t|Dimerization of EGFR and HER2 induces breast cancer cell motility through STAT1 -dependent ACTA2 induction
27472389|a|The dimerization of EGFR and HER2 is associated with poor prognosis such as induction of tumor growth and cell invasion compared to when EGFR remains as a homodimer. However, the mechanism for events after dimerization in breast cancer models is not clear. We found that expressions of alpha-smooth muscle actin (ACTA2) and signal transducer and activator of transcription 1 (STAT1) significantly increased with transient or stable overexpression of HER2 in EGFR - positive breast cancer cells. ACTA2 and STAT1 expression was also increased in HER2 - positive breast cancer patients. In contrast, ACTA2 expression was decreased by HER2 siRNA. Next, we investigated the co-relation between STAT1 and ACTA2 expression. Basal ACTA2 expression was significantly decreased by treatment with the STAT1 inhibitor fludarabine or the JAK2 inhibitor AG490. In contrast, ACTA2 expression was increased by STAT1 overexpression. Levels of ACTA2, STAT1, and HER2 were increased and relapse free survival was decreased in high-risk breast cancer patients. We also investigated the effect of ACTA2 on cell motility, which was suppressed by ACTA2 shRNA overexpression in MDA-MB231 HER2 and 4T1 mammary carcinoma cells. The number of lung metastatic nodules was significantly decreased in ACTA2 knockdown mice. Taken together, these results demonstrated that induction of ACTA2 by EGFR and HER2 dimerization was regulated through a JAK2 / STAT1 signaling pathway, and aberrant ACTA2 expression accelerated the invasiveness and metastasis of breast cancer cells.
27472389	0	12	Dimerization	T067	C2350408
27472389	16	20	EGFR	T116,T126,T192	C0034802
27472389	25	29	HER2	T116,T126,T192	C0069515
27472389	38	51	breast cancer	T191	C0006142
27472389	52	65	cell motility	T040	C0007608
27472389	74	79	STAT1	T116,T123	C0287920
27472389	91	96	ACTA2	T116,T123	C2716282
27472389	97	106	induction	T169	C0205263
27472389	111	123	dimerization	T067	C2350408
27472389	127	131	EGFR	T116,T126,T192	C0034802
27472389	136	140	HER2	T116,T126,T192	C0069515
27472389	165	174	prognosis	T058	C0033325
27472389	183	192	induction	T169	C0205263
27472389	196	208	tumor growth	T191	C0598934
27472389	213	226	cell invasion	T046	C2699153
27472389	227	235	compared	T052	C1707455
27472389	244	248	EGFR	T116,T126,T192	C0034802
27472389	262	271	homodimer	T104	C0596448
27472389	286	295	mechanism	T169	C0441712
27472389	313	325	dimerization	T067	C2350408
27472389	329	342	breast cancer	T191	C0006142
27472389	343	349	models	T075	C0026336
27472389	378	389	expressions	T045	C1171362
27472389	393	418	alpha-smooth muscle actin	T116,T123	C2716282
27472389	420	425	ACTA2	T116,T123	C2716282
27472389	431	481	signal transducer and activator of transcription 1	T116,T123	C0287920
27472389	483	488	STAT1	T116,T123	C0287920
27472389	504	513	increased	T081	C0205217
27472389	539	553	overexpression	T045	C1514559
27472389	557	561	HER2	T116,T126,T192	C0069515
27472389	565	569	EGFR	T116,T126,T192	C0034802
27472389	572	580	positive	T033	C1446409
27472389	581	594	breast cancer	T191	C0006142
27472389	595	600	cells	T025	C0007634
27472389	602	607	ACTA2	T116,T123	C2716282
27472389	612	617	STAT1	T116,T123	C0287920
27472389	618	628	expression	T045	C1171362
27472389	638	647	increased	T081	C0205217
27472389	651	655	HER2	T116,T126,T192	C0069515
27472389	658	666	positive	T033	C1446409
27472389	667	680	breast cancer	T191	C0006142
27472389	681	689	patients	T101	C0030705
27472389	704	709	ACTA2	T116,T123	C2716282
27472389	710	720	expression	T045	C1171362
27472389	725	734	decreased	T081	C0205216
27472389	738	748	HER2 siRNA	T114,T123	C1099354
27472389	796	801	STAT1	T116,T123	C0287920
27472389	806	811	ACTA2	T116,T123	C2716282
27472389	812	822	expression	T045	C1171362
27472389	830	835	ACTA2	T116,T123	C2716282
27472389	836	846	expression	T045	C1171362
27472389	865	874	decreased	T081	C0205216
27472389	878	887	treatment	T061	C0087111
27472389	897	912	STAT1 inhibitor	T121	C1254351
27472389	913	924	fludarabine	T114,T121	C0059985
27472389	932	946	JAK2 inhibitor	T121	C1254351
27472389	947	952	AG490	T109,T121	C0381241
27472389	967	972	ACTA2	T116,T123	C2716282
27472389	973	983	expression	T045	C1171362
27472389	988	997	increased	T081	C0205217
27472389	1001	1006	STAT1	T116,T123	C0287920
27472389	1007	1021	overexpression	T045	C1514559
27472389	1033	1038	ACTA2	T116,T123	C2716282
27472389	1040	1045	STAT1	T116,T123	C0287920
27472389	1051	1055	HER2	T116,T126,T192	C0069515
27472389	1061	1070	increased	T081	C0205217
27472389	1083	1096	free survival	T081	C0242793
27472389	1101	1110	decreased	T081	C0205216
27472389	1114	1123	high-risk	T033	C0332167
27472389	1124	1137	breast cancer	T191	C0006142
27472389	1138	1146	patients	T101	C0030705
27472389	1156	1168	investigated	T169	C1292732
27472389	1183	1188	ACTA2	T116,T123	C2716282
27472389	1192	1205	cell motility	T040	C0007608
27472389	1217	1227	suppressed	T169	C1260953
27472389	1231	1242	ACTA2 shRNA	T114	C2930586
27472389	1243	1257	overexpression	T045	C1514559
27472389	1261	1270	MDA-MB231	T025	C1512505
27472389	1271	1275	HER2	T116,T126,T192	C0069515
27472389	1280	1307	4T1 mammary carcinoma cells	T025	C1512505
27472389	1323	1346	lung metastatic nodules	T033	C0034079
27472389	1365	1374	decreased	T081	C0205216
27472389	1378	1383	ACTA2	T116,T123	C2716282
27472389	1384	1398	knockdown mice	T015	C0206745
27472389	1448	1457	induction	T169	C0205263
27472389	1461	1466	ACTA2	T116,T123	C2716282
27472389	1470	1474	EGFR	T116,T126,T192	C0034802
27472389	1479	1483	HER2	T116,T126,T192	C0069515
27472389	1484	1496	dimerization	T067	C2350408
27472389	1521	1525	JAK2	T116,T126	C0169661
27472389	1528	1533	STAT1	T116,T123	C0287920
27472389	1534	1551	signaling pathway	T044	C0037080
27472389	1566	1571	ACTA2	T116,T123	C2716282
27472389	1572	1582	expression	T045	C1171362
27472389	1572	1582	expression	T045	C1171362
27472389	1599	1611	invasiveness	T046	C0027626
27472389	1616	1626	metastasis	T191	C0027627
27472389	1630	1643	breast cancer	T191	C0006142
27472389	1644	1649	cells	T025	C0007634

28159418|t|The role of p62 / SQSTM1 in sporadic inclusion body myositis
28159418|a|We examined selective autophagy against ubiquitinated protein aggregates in sporadic inclusion body myositis (s-IBM) patients. The form of autophagy requires phosphorylation of serine 403 in p62 / SQSTM1 to bind to Lys63 -linked ubiquitin and the binding of the p62 - ubiquitinated protein conjugates to LC3. In muscle biopsy specimens from 16 s-IBM patients, we compared the distribution of p62 (aa120-440) with 1) Ser403 - phosphorylated p62 (S403 - p p62), 2) Lys63 -linked ubiquitin and 3) LC3 in double-colour immunofluorescence microscopy. S403 - p p62, Lys63 -linked ubiquitin and LC3 colocalised with p62 aggregates, 79.05% ± 13.64% (mean ± SD), 66.54% ± 19.91% and 51.84% ± 14.1%, respectively. Although positive deposits of S403 - p p62 and Lys63 -linked ubiquitin were always observed within p62 aggregates, LC3 often showed dissociated distribution from p62. We also found fibres containing small, numerous p62 - positive dots that were negative for all three markers and were also observed in myositis controls. The results indicate that p62, Lys63 -linked ubiquitin and LC3 in s-IBM join to perform selective autophagy. p62 could be induced by some cellular stresses in all types of myositis; however, in s-IBM, compromised binding of the p62 - ubiquitinated protein complex to LC3 could stop the autophagy process in its initial stages, which causes the formation of aggregates of p62 - oligomers with Lys63 - ubiquitinated proteins.
28159418	4	8	role	T077	C1705810
28159418	12	15	p62	T116	C0134965
28159418	18	24	SQSTM1	T116,T123	C1137054
28159418	28	60	sporadic inclusion body myositis	T047	C0751713
28159418	83	92	autophagy	T043	C0004391
28159418	101	122	ubiquitinated protein	T116	C1956096
28159418	123	133	aggregates	T080	C0205418
28159418	137	169	sporadic inclusion body myositis	T047	C0751713
28159418	171	176	s-IBM	T047	C0751713
28159418	178	186	patients	T101	C0030705
28159418	200	209	autophagy	T043	C0004391
28159418	219	234	phosphorylation	T044	C0031715
28159418	238	248	serine 403	T116,T121,T123	C0036720
28159418	252	255	p62	T116	C0134965
28159418	258	264	SQSTM1	T116,T123	C1137054
28159418	268	272	bind	T044	C1167622
28159418	276	281	Lys63	T116,T121,T123	C0024337
28159418	290	299	ubiquitin	T116,T123	C0041538
28159418	308	315	binding	T044	C1167622
28159418	323	326	p62	T116	C0134965
28159418	329	350	ubiquitinated protein	T116	C1956096
28159418	365	368	LC3	T116,T123	C1144120
28159418	373	396	muscle biopsy specimens	T024	C0587033
28159418	405	410	s-IBM	T047	C0751713
28159418	411	419	patients	T101	C0030705
28159418	437	449	distribution	T169	C1704711
28159418	453	456	p62	T116	C0134965
28159418	458	467	aa120-440	T087	C0002518
28159418	477	483	Ser403	T116,T121,T123	C0036720
28159418	486	500	phosphorylated	T116	C1519061
28159418	501	504	p62	T116	C0134965
28159418	506	510	S403	T116,T121,T123	C0036720
28159418	513	514	p	T116	C1519061
28159418	515	518	p62	T116	C0134965
28159418	524	529	Lys63	T116,T121,T123	C0024337
28159418	538	547	ubiquitin	T116,T123	C0041538
28159418	555	558	LC3	T116,T123	C1144120
28159418	562	605	double-colour immunofluorescence microscopy	T059	C0079604
28159418	607	611	S403	T116,T121,T123	C0036720
28159418	614	615	p	T116	C1519061
28159418	616	619	p62	T116	C0134965
28159418	621	626	Lys63	T116,T121,T123	C0024337
28159418	635	644	ubiquitin	T116,T123	C0041538
28159418	649	652	LC3	T116,T123	C1144120
28159418	670	673	p62	T116	C0134965
28159418	674	684	aggregates	T080	C0205418
28159418	703	707	mean	T081	C0444504
28159418	710	712	SD	T081	C0871420
28159418	774	782	positive	T033	C1446409
28159418	783	791	deposits	T169	C0333562
28159418	795	799	S403	T116,T121,T123	C0036720
28159418	802	803	p	T116	C1519061
28159418	804	807	p62	T116	C0134965
28159418	812	817	Lys63	T116,T121,T123	C0024337
28159418	826	835	ubiquitin	T116,T123	C0041538
28159418	848	856	observed	T169	C1441672
28159418	864	867	p62	T116	C0134965
28159418	868	878	aggregates	T080	C0205418
28159418	880	883	LC3	T116,T123	C1144120
28159418	909	921	distribution	T169	C1704711
28159418	927	930	p62	T116	C0134965
28159418	946	952	fibres	T024	C1304649
28159418	964	969	small	T081	C0700321
28159418	971	979	numerous	T081	C0439064
28159418	980	983	p62	T116	C0134965
28159418	986	994	positive	T033	C1446409
28159418	1010	1018	negative	T033	C0205160
28159418	1033	1040	markers	T201	C0005516
28159418	1055	1063	observed	T169	C1441672
28159418	1067	1075	myositis	T047	C0027121
28159418	1076	1084	controls	T096	C0009932
28159418	1090	1097	results	T169	C1274040
28159418	1112	1115	p62	T116	C0134965
28159418	1117	1122	Lys63	T116,T121,T123	C0024337
28159418	1131	1140	ubiquitin	T116,T123	C0041538
28159418	1145	1148	LC3	T116,T123	C1144120
28159418	1152	1157	s-IBM	T047	C0751713
28159418	1166	1173	perform	T169	C0884358
28159418	1184	1193	autophagy	T043	C0004391
28159418	1195	1198	p62	T116	C0134965
28159418	1208	1215	induced	T169	C0205263
28159418	1224	1241	cellular stresses	T049	C1516373
28159418	1258	1266	myositis	T047	C0027121
28159418	1280	1285	s-IBM	T047	C0751713
28159418	1287	1298	compromised	T033	C2945640
28159418	1299	1306	binding	T044	C1167622
28159418	1314	1317	p62	T116	C0134965
28159418	1320	1341	ubiquitinated protein	T116	C1956096
28159418	1342	1349	complex	T104	C1704241
28159418	1353	1356	LC3	T116,T123	C1144120
28159418	1363	1367	stop	T052	C1947925
28159418	1372	1381	autophagy	T043	C0004391
28159418	1382	1389	process	T067	C1522240
28159418	1405	1411	stages	T079	C1306673
28159418	1430	1439	formation	T169	C1522492
28159418	1443	1453	aggregates	T080	C0205418
28159418	1457	1460	p62	T116	C0134965
28159418	1463	1472	oligomers	T087	C0599219
28159418	1478	1483	Lys63	T116,T121,T123	C0024337
28159418	1486	1508	ubiquitinated proteins	T116	C1956096

27869761|t|Effect of Fusarium -Derived Metabolites on the Barrier Integrity of Differentiated Intestinal Porcine Epithelial Cells (IPEC-J2)
27869761|a|The human, animal and plant pathogen Fusarium, which contaminates agricultural commodities worldwide, produces numerous secondary metabolites. An example is the thoroughly-investigated deoxynivalenol (DON), which severely impairs gastrointestinal barrier integrity. However, to date, the toxicological profile of other Fusarium -derived metabolites, such as enniatins, beauvericin, moniliformin, apicidin, aurofusarin, rubrofusarin, equisetin and bikaverin, are poorly characterized. Thus we examined their effects-as metabolites alone and as metabolites in combination with DON -on the intestinal barrier function of differentiated intestinal porcine epithelial cells (IPEC-J2) over 72 h. Transepithelial electrical resistance (TEER) was measured at 24-h intervals, followed by evaluation of cell viability using neutral red (NR) assay. Enniatins A, A1, B and B1, apicidin, aurofusarin and beauvericin significantly reduced TEER. Moniliformin, equisetin, bikaverin and rubrofusarin had no effect on TEER. In the case of apicidin, aurofusarin and beauvericin, TEER reductions were further substantiated by the addition of otherwise no-effect DON concentrations. In all cases, viability was unaffected, confirming that TEER reductions were not due to compromised viability. Considering the prevalence of mycotoxin contamination and the diseases associated with intestinal barrier disruption, consumption of contaminated food or feed may have substantial health implications.
27869761	10	18	Fusarium	T004	C0016871
27869761	28	39	Metabolites	T123	C0870883
27869761	47	64	Barrier Integrity	T080	C1947912
27869761	83	93	Intestinal	T023	C0021853
27869761	94	101	Porcine	T015	C0039005
27869761	102	118	Epithelial Cells	T025	C0014597
27869761	120	127	IPEC-J2	T025	C0014597
27869761	133	138	human	T016	C0086418
27869761	140	146	animal	T008	C0003062
27869761	151	156	plant	T002	C0032098
27869761	157	174	pathogen Fusarium	T004	C0016871
27869761	182	194	contaminates	T169	C0205279
27869761	195	219	agricultural commodities	T002	C0242775
27869761	249	270	secondary metabolites	T123	C0870883
27869761	314	328	deoxynivalenol	T109,T131	C0057445
27869761	330	333	DON	T109,T131	C0057445
27869761	351	358	impairs	T169	C1883709
27869761	359	375	gastrointestinal	T082	C0521362
27869761	376	393	barrier integrity	T080	C1947912
27869761	417	438	toxicological profile	T059	C0852616
27869761	448	456	Fusarium	T004	C0016871
27869761	466	477	metabolites	T123	C0870883
27869761	487	496	enniatins	T116,T195	C0059362
27869761	498	509	beauvericin	T116,T195	C0053065
27869761	511	523	moniliformin	T109,T131	C0066713
27869761	525	533	apicidin	T109,T121	C0531691
27869761	535	546	aurofusarin	T109	C0661658
27869761	548	560	rubrofusarin	T109,T121	C0084424
27869761	562	571	equisetin	T109,T121	C0059495
27869761	576	585	bikaverin	T109	C0053576
27869761	647	658	metabolites	T123	C0870883
27869761	672	683	metabolites	T123	C0870883
27869761	704	707	DON	T109,T131	C0057445
27869761	716	743	intestinal barrier function	T074	C3688176
27869761	762	772	intestinal	T023	C0021853
27869761	773	780	porcine	T015	C0039005
27869761	781	797	epithelial cells	T025	C0014597
27869761	799	806	IPEC-J2	T025	C0014597
27869761	819	834	Transepithelial	T043	C2753390
27869761	835	856	electrical resistance	T070	C0162535
27869761	858	862	TEER	T070	C0162535
27869761	922	936	cell viability	T043	C1516362
27869761	943	965	neutral red (NR) assay	T059	C1293998
27869761	967	978	Enniatins A	T116,T195	C0116182
27869761	980	982	A1	T116,T195	C0059362
27869761	984	985	B	T116,T195	C0116183
27869761	990	992	B1	T116,T195	C0059362
27869761	994	1002	apicidin	T109,T121	C0531691
27869761	1004	1015	aurofusarin	T109	C0661658
27869761	1020	1031	beauvericin	T116,T195	C0053065
27869761	1054	1058	TEER	T070	C0162535
27869761	1060	1072	Moniliformin	T109,T131	C0066713
27869761	1074	1083	equisetin	T109,T121	C0059495
27869761	1085	1094	bikaverin	T109	C0053576
27869761	1099	1111	rubrofusarin	T109,T121	C0084424
27869761	1129	1133	TEER	T070	C0162535
27869761	1150	1158	apicidin	T109,T121	C0531691
27869761	1160	1171	aurofusarin	T109	C0661658
27869761	1176	1187	beauvericin	T116,T195	C0053065
27869761	1189	1193	TEER	T070	C0162535
27869761	1271	1274	DON	T109,T131	C0057445
27869761	1305	1314	viability	T043	C1516362
27869761	1347	1351	TEER	T070	C0162535
27869761	1352	1362	reductions	T080	C0392756
27869761	1391	1400	viability	T043	C1516362
27869761	1432	1441	mycotoxin	T109,T131	C0026955
27869761	1442	1455	contamination	T078	C2349974
27869761	1464	1472	diseases	T047	C0012634
27869761	1489	1507	intestinal barrier	T074	C3688176
27869761	1508	1518	disruption	T169	C0332453
27869761	1520	1560	consumption of contaminated food or feed	T033	C0559583
27869761	1570	1601	substantial health implications	T033	C0243095

27365044|t|Evaluation of Local CYP17A1 and CYP19A1 Expression Levels as Prognostic Factors in Postmenopausal Invasive Ductal Breast Cancer Cases
27365044|a|There is growing attention focused on local estrogen production in the breast tissue and its possible role in breast cancer initiation and progression. Understanding the underlying mechanisms for estrogen synthesis and the microenvironment consisting of tumor and its surrounding adipose tissue might open new avenues in breast cancer prevention, prognosis and treatment. In order to obtain insight, we compared peritumoral and tumor tissue expressions of CYP17A1 and CYP19A1 genes, which play an important role in estrogen biosynthesis. The paired tissue samples of 20 postmenopausal ER(+) / PR(+) patients diagnosed with invasive ductal breast cancer were studied. In addition, 12 breast tissue samples obtained from premenopausal women without a history of breast cancer were also investigated as representative of normal conditions. Peritumoral adipose tissues expressed CYP19A1 approximately threefold higher than tumor itself (p = 0.001). A nonsignificant trend toward low expression of CYP17A1 was observed in peritumoral compared to tumor tissue (p = 0.687). Clinicopathological parameters and patient characteristics which are accepted as risk factors for breast cancer were also associated with individual and combined expressions of CYP17A1 and CYP19A1. This study offers that evaluation of CYP17A1 and CYP19A1 local expression levels might be useful for deciding on personalized treatment approaches and more accurate diagnosis, when evaluated together with several clinicopathological and disease risk factors. Considering the key role of these CYPs in estrogen synthesis, determining their expression levels may be useful as a postdiagnostic marker and for choosing the right treatment method in addition to the conventional approach.
27365044	0	10	Evaluation	T058	C0220825
27365044	14	19	Local	T082	C0205276
27365044	20	27	CYP17A1	T028	C1413858
27365044	32	39	CYP19A1	T028	C1366496
27365044	40	57	Expression Levels	T081	C3244092
27365044	61	79	Prognostic Factors	T201	C1514474
27365044	83	97	Postmenopausal	T033	C0232970
27365044	98	127	Invasive Ductal Breast Cancer	T191	C1134719
27365044	128	133	Cases	T077	C1706256
27365044	172	177	local	T082	C0205276
27365044	178	197	estrogen production	T044	C1157310
27365044	205	218	breast tissue	T024	C1521747
27365044	236	240	role	T077	C1705810
27365044	244	257	breast cancer	T191	C0006142
27365044	258	268	initiation	T169	C1704686
27365044	273	284	progression	T046	C1947901
27365044	315	325	mechanisms	T169	C0441712
27365044	330	348	estrogen synthesis	T044	C1157310
27365044	357	373	microenvironment	T070	C2936626
27365044	388	393	tumor	T191	C0027651
27365044	414	428	adipose tissue	T024	C0001527
27365044	455	479	breast cancer prevention	T061	C0281189
27365044	481	490	prognosis	T201	C1516221
27365044	495	504	treatment	T061	C0087111
27365044	546	557	peritumoral	T082	C3897941
27365044	562	574	tumor tissue	T024	C0475358
27365044	575	586	expressions	T045	C0017262
27365044	590	597	CYP17A1	T028	C1413858
27365044	602	609	CYP19A1	T028	C1366496
27365044	649	670	estrogen biosynthesis	T044	C1157310
27365044	683	697	tissue samples	T024	C0475358
27365044	704	718	postmenopausal	T033	C0232970
27365044	719	724	ER(+)	T034	C0279754
27365044	727	732	PR(+)	T034	C0279759
27365044	733	741	patients	T101	C0030705
27365044	742	751	diagnosed	T033	C0011900
27365044	757	786	invasive ductal breast cancer	T191	C1134719
27365044	817	838	breast tissue samples	T023	C0444070
27365044	853	866	premenopausal	T033	C0279752
27365044	867	872	women	T098	C0043210
27365044	894	907	breast cancer	T191	C0006142
27365044	952	969	normal conditions	T033	C0231162
27365044	971	982	Peritumoral	T082	C3897941
27365044	983	998	adipose tissues	T024	C0001527
27365044	1009	1016	CYP19A1	T028	C1366496
27365044	1053	1058	tumor	T191	C0027651
27365044	1109	1112	low	T080	C0205251
27365044	1113	1123	expression	T045	C0017262
27365044	1127	1134	CYP17A1	T028	C1413858
27365044	1151	1162	peritumoral	T082	C3897941
27365044	1175	1187	tumor tissue	T024	C0475358
27365044	1201	1231	Clinicopathological parameters	T077	C0549193
27365044	1236	1259	patient characteristics	T201	C0815172
27365044	1282	1294	risk factors	T033	C0035648
27365044	1299	1312	breast cancer	T191	C0006142
27365044	1363	1374	expressions	T045	C0017262
27365044	1378	1385	CYP17A1	T028	C1413858
27365044	1390	1397	CYP19A1	T028	C1366496
27365044	1422	1432	evaluation	T058	C0220825
27365044	1436	1443	CYP17A1	T028	C1413858
27365044	1448	1455	CYP19A1	T028	C1366496
27365044	1456	1461	local	T082	C0205276
27365044	1462	1479	expression levels	T081	C3244092
27365044	1512	1524	personalized	T080	C1709510
27365044	1525	1545	treatment approaches	UnknownType	C0679624
27365044	1550	1563	more accurate	T080	C0443131
27365044	1564	1573	diagnosis	T033	C0011900
27365044	1580	1589	evaluated	T058	C0220825
27365044	1612	1631	clinicopathological	T169	C0205245
27365044	1636	1656	disease risk factors	T033	C0850664
27365044	1674	1682	key role	T077	C1705810
27365044	1692	1696	CYPs	T028	C0796517
27365044	1700	1718	estrogen synthesis	T044	C1157310
27365044	1738	1755	expression levels	T081	C3244092
27365044	1775	1796	postdiagnostic marker	T201	C0005516
27365044	1818	1823	right	T080	C2349182
27365044	1824	1840	treatment method	T061	C0087111

27388962|t|Resistance Exercise in Pregnancy and Outcome
27388962|a|As the health benefits of exercise are increasingly recognized, the traditional advice to rest during pregnancy has changed toward a more healthy and active pregnancy, therefore different forms of exercise have been integrated into the life of the pregnant woman. Although the benefits of using a combination of resistance and aerobic exercises are not yet determined, studies about resistance and strengthen training programs are few although no adverse outcomes were reported.
27388962	0	10	Resistance	T169	C4281815
27388962	11	19	Exercise	T056	C0015259
27388962	23	32	Pregnancy	T040	C0032961
27388962	37	44	Outcome	T033	C0032972
27388962	52	67	health benefits	T081	C0086387
27388962	71	79	exercise	T056	C0015259
27388962	113	131	traditional advice	T058	C0150600
27388962	135	139	rest	T056	C0035253
27388962	147	156	pregnancy	T040	C0032961
27388962	161	168	changed	T169	C0392747
27388962	183	190	healthy	T080	C3898900
27388962	195	201	active	T169	C0205177
27388962	202	211	pregnancy	T040	C0032961
27388962	242	250	exercise	T056	C0015259
27388962	281	285	life	T078	C0376558
27388962	293	307	pregnant woman	T098	C0033011
27388962	322	330	benefits	T081	C0814225
27388962	342	353	combination	T080	C0205195
27388962	357	367	resistance	T169	C4281815
27388962	372	389	aerobic exercises	T061	C0001701
27388962	414	421	studies	T062	C2603343
27388962	428	438	resistance	T169	C4281815
27388962	454	471	training programs	T065	C0040607
27388962	489	499	no adverse	T184	C0853204
27388962	500	508	outcomes	T033	C0032972

27340878|t|Undiagnosed Primary Open-Angle Glaucoma in Korea: The Korean National Health and Nutrition Examination Survey 2008-2009
27340878|a|To evaluate the characteristics of patients with previously undiagnosed primary open-angle glaucoma (POAG) in Korea. This study examined data from 391 subjects obtained from the 2008-2009 Korean National Health and Nutrition Examination Survey (KNHANES). The KNHANES is a population-based, cross-sectional epidemiological survey. Participants aged 19 years or older completed standardized interviews and dilated ocular examinations, including measurement of intraocular pressure, visual fields with frequency doubling perimetry, and fundus photography. Data from the 361 patients with previously undiagnosed POAG were analyzed and compared with data from the 30 patients with previously diagnosed glaucoma. A total of 92.3% of POAG cases were undiagnosed before this study. Adjusted for age and sex, the strongest risk factor for undiagnosed glaucoma was longer elapsed time since last eye doctor visit. Glaucoma patients who had not visited an eye specialist in the last 3 years were 22 times (95% confidence interval, CI, 4.49-105.64, p < 0.001) more likely to have undiagnosed disease compared with patients who had visited an eye specialist in the last month. Another significant factor for previously undiagnosed glaucoma was smaller cup-to-disc ratio (odds ratio, OR, 0.60/0.1 units, 95% CI 0.43-0.85/0.1 units, p = 0.004). The higher vertical cup-to-disc ratio of a subject's two eyes was significantly different between those with previously undiagnosed (0.69) and diagnosed (0.78) POAG (p = 0.001). The undiagnosed POAG group had a longer interval from last eye doctor visit and smaller vertical cup-to-disc ratio compared to the diagnosed group.
27340878	0	11	Undiagnosed	T033	C1408353
27340878	12	39	Primary Open-Angle Glaucoma	T047	C0339573
27340878	43	48	Korea	T083	C0022771
27340878	54	109	Korean National Health and Nutrition Examination Survey	T062	C0018762
27340878	123	131	evaluate	T058	C0220825
27340878	136	151	characteristics	T080	C1521970
27340878	155	163	patients	T101	C0030705
27340878	180	191	undiagnosed	T033	C1408353
27340878	192	219	primary open-angle glaucoma	T047	C0339573
27340878	221	225	POAG	T047	C0339573
27340878	230	235	Korea	T083	C0022771
27340878	242	247	study	T062	C2603343
27340878	257	261	data	T078	C1511726
27340878	271	279	subjects	T098	C0080105
27340878	280	288	obtained	T169	C1301820
27340878	308	363	Korean National Health and Nutrition Examination Survey	T062	C0018762
27340878	365	372	KNHANES	T062	C0018762
27340878	379	386	KNHANES	T062	C0018762
27340878	392	408	population-based	T062	C1709599
27340878	410	448	cross-sectional epidemiological survey	T062	C0018762
27340878	450	462	Participants	T098	C0679646
27340878	463	467	aged	T032	C0001779
27340878	468	476	19 years	T079	C0439234
27340878	480	485	older	T100	C0001675
27340878	496	519	standardized interviews	T052	C0021822
27340878	524	551	dilated ocular examinations	T058	C0582103
27340878	563	574	measurement	T169	C0242485
27340878	578	598	intraocular pressure	T042	C0021888
27340878	600	613	visual fields	T082	C0042826
27340878	619	647	frequency doubling perimetry	T060	C1271444
27340878	653	671	fundus photography	T060	C0200189
27340878	673	677	Data	T078	C1511726
27340878	691	699	patients	T101	C0030705
27340878	705	715	previously	T079	C0205156
27340878	716	727	undiagnosed	T033	C1408353
27340878	728	732	POAG	T047	C0339573
27340878	738	746	analyzed	T062	C0936012
27340878	751	759	compared	T052	C1707455
27340878	765	769	data	T078	C1511726
27340878	782	790	patients	T101	C0030705
27340878	807	816	diagnosed	T033	C0011900
27340878	817	825	glaucoma	T047	C0339573
27340878	847	851	POAG	T047	C0339573
27340878	863	874	undiagnosed	T033	C1408353
27340878	887	892	study	T062	C2603343
27340878	894	902	Adjusted	T169	C0456081
27340878	907	910	age	T032	C0001779
27340878	915	918	sex	T032	C1522384
27340878	924	945	strongest risk factor	T033	C0035648
27340878	950	961	undiagnosed	T033	C1408353
27340878	962	970	glaucoma	T047	C0339573
27340878	982	994	elapsed time	T079	C2826303
27340878	1006	1022	eye doctor visit	T061	C0847195
27340878	1024	1032	Glaucoma	T047	C0339573
27340878	1033	1041	patients	T101	C0030705
27340878	1054	1079	visited an eye specialist	T061	C0847195
27340878	1094	1099	years	T079	C0439234
27340878	1119	1138	confidence interval	T081	C0009667
27340878	1140	1142	CI	T081	C0009667
27340878	1188	1199	undiagnosed	T033	C1408353
27340878	1200	1207	disease	T047	C0339573
27340878	1208	1216	compared	T052	C1707455
27340878	1222	1230	patients	T101	C0030705
27340878	1239	1264	visited an eye specialist	T061	C0847195
27340878	1277	1282	month	T079	C0439231
27340878	1292	1310	significant factor	T169	C1521761
27340878	1326	1337	undiagnosed	T033	C1408353
27340878	1338	1346	glaucoma	T047	C0339573
27340878	1359	1376	cup-to-disc ratio	T033	C0423471
27340878	1378	1388	odds ratio	T081	C0028873
27340878	1390	1392	OR	T081	C0028873
27340878	1414	1416	CI	T081	C0009667
27340878	1461	1487	vertical cup-to-disc ratio	T201	C1299676
27340878	1493	1502	subject's	T098	C0080105
27340878	1507	1511	eyes	T023	C0015392
27340878	1559	1569	previously	T079	C0205156
27340878	1570	1581	undiagnosed	T033	C1408353
27340878	1593	1602	diagnosed	T033	C0011900
27340878	1610	1614	POAG	T047	C0339573
27340878	1632	1643	undiagnosed	T033	C1408353
27340878	1644	1648	POAG	T047	C0339573
27340878	1661	1676	longer interval	T079	C1272706
27340878	1687	1703	eye doctor visit	T061	C0847195
27340878	1716	1742	vertical cup-to-disc ratio	T201	C1299676
27340878	1759	1774	diagnosed group	T033	C0011900

28270369|t|RELIABILITY AND VALIDITY OF THE DIABETES EATING PROBLEM SURVEY-REVISED ON TURKISH CHILDREN AND ADOLESCENTS WITH TYPE 1 DIABETES MELLITUS
28270369|a|The aim of this study was to examine the reliability and validity of Turkish version of Diabetes Eating Problem Survey-Revised (DEPS-R) for children and adolescent with Type 1 Diabetes Mellitus. A total of 200 children and adolescents with type 1 diabetes, ages 9-18 years, completed the DEPS-R Turkish version. In addition to tests of validity, confirmatory factor analysis was conducted to investigate the factor structure of the 16-item Turkish version of DEPS-R. The Turkish version of DEPS-R demonstrated satisfactory Cronbach's ∝ (0.847) and was significantly correlated with ag e (r=0.194; p<0.01), hemoglobin A1c levels (r=0.303; p<0.01) and BMI - SDS (r=0.412; p<0.01) indicating criterion validity. Median DEPS-R scores of Turkish version for the total samples, females and males were as follows: 11.0, 11.5 and 10.5 respectively. Disturbed eating behaviors and insulin restriction were associated with poor metabolic control. A short, self-administered diabetes specific screening tool for disordered eating behavior can be used routinely in the clinical care of adolescents with type 1 diabetes. The Turkish version of DEPS-R is a valid screening tool for disordered eating behaviors in type 1 diabetes and it is potentially important to early detect disordered eating behaviors.
28270369	0	24	RELIABILITY AND VALIDITY	T080	C0035036
28270369	32	70	DIABETES EATING PROBLEM SURVEY-REVISED	T058	C0012158
28270369	74	81	TURKISH	T098	C0549217
28270369	82	90	CHILDREN	T100	C0008059
28270369	95	106	ADOLESCENTS	T100	C0205653
28270369	112	136	TYPE 1 DIABETES MELLITUS	T047	C0011854
28270369	153	158	study	T062	C2603343
28270369	166	173	examine	T169	C1292732
28270369	178	202	reliability and validity	T080	C0035036
28270369	206	213	Turkish	T098	C0549217
28270369	214	221	version	T170	C0333052
28270369	225	263	Diabetes Eating Problem Survey-Revised	T058	C0012158
28270369	265	271	DEPS-R	T058	C0012158
28270369	277	285	children	T100	C0008059
28270369	290	300	adolescent	T100	C0205653
28270369	306	330	Type 1 Diabetes Mellitus	T047	C0011854
28270369	347	355	children	T100	C0008059
28270369	360	371	adolescents	T100	C0205653
28270369	377	392	type 1 diabetes	T047	C0011854
28270369	394	398	ages	T032	C0001779
28270369	404	409	years	T079	C0439234
28270369	425	431	DEPS-R	T058	C0012158
28270369	432	439	Turkish	T098	C0549217
28270369	440	447	version	T170	C0333052
28270369	464	469	tests	T169	C0039593
28270369	473	481	validity	T081	C2349101
28270369	483	511	confirmatory factor analysis	T080	C0870334
28270369	529	540	investigate	T169	C1292732
28270369	545	561	factor structure	T081	C0870541
28270369	577	584	Turkish	T098	C0549217
28270369	585	592	version	T170	C0333052
28270369	596	602	DEPS-R	T058	C0012158
28270369	608	615	Turkish	T098	C0549217
28270369	616	623	version	T170	C0333052
28270369	627	633	DEPS-R	T058	C0012158
28270369	647	659	satisfactory	T080	C0205410
28270369	660	670	Cronbach's	T081	C0870731
28270369	703	713	correlated	T080	C1707520
28270369	719	721	ag	T032	C0001779
28270369	743	764	hemoglobin A1c levels	T034	C1261236
28270369	787	790	BMI	T201	C1305855
28270369	793	796	SDS	T081	C0449820
28270369	826	844	criterion validity	T081	C2699472
28270369	853	859	DEPS-R	T058	C0012158
28270369	860	866	scores	T081	C0449820
28270369	870	877	Turkish	T098	C0549217
28270369	878	885	version	T170	C0333052
28270369	900	907	samples	T098	C1257890
28270369	909	916	females	T032	C0086287
28270369	921	926	males	T032	C0086582
28270369	978	1004	Disturbed eating behaviors	T048	C4062871
28270369	1009	1016	insulin	T116,T121,T125	C0021641
28270369	1017	1028	restriction	T169	C0443288
28270369	1055	1072	metabolic control	T044	C1513158
28270369	1083	1100	self-administered	T169	C1519231
28270369	1101	1109	diabetes	T047	C0011854
28270369	1119	1128	screening	T058	C1710032
28270369	1138	1164	disordered eating behavior	T048	C4062871
28270369	1194	1202	clinical	T080	C0205210
28270369	1203	1207	care	T058	C0086388
28270369	1211	1222	adolescents	T100	C0205653
28270369	1228	1243	type 1 diabetes	T047	C0011854
28270369	1249	1256	Turkish	T098	C0549217
28270369	1257	1264	version	T170	C0333052
28270369	1268	1274	DEPS-R	T058	C0012158
28270369	1286	1295	screening	T058	C1710032
28270369	1305	1332	disordered eating behaviors	T048	C4062871
28270369	1336	1351	type 1 diabetes	T047	C0011854
28270369	1400	1427	disordered eating behaviors	T048	C4062871

28536031|t|Lactate induces osteoblast differentiation by stabilization of HIF1α
28536031|a|Aerobic glycolysis is involved in osteoblast differentiation induced by Wnt signaling or PTH treatment. However, it is still unclear whether lactate, the end product of aerobic glycolysis, plays any role in osteoblast differentiation. Herein we report that in cultures of osteoblast-lineage cells, lactate promoted alkaline phosphatase -positive cell formation, increased the activity of alkaline phosphatase, and induced the expression of osteocalcin. This osteoblast differentiation -inducing effect of lactate can be inhibited by blocking its entry into cells with MCT1 siRNA or inhibitors, and by interfering with its metabolism by using specific siRNAs for LDHB and PDH. Moreover, lactate stabilized HIF1α expression and inhibited HIF1α activity, with BAY87-2243 lowering the osteoblast differentiation -inducing effect of lactate. Thus, these findings reveal an unrecognized role for aerobic glycolysis in osteoblast differentiation via its end product, lactate.
28536031	0	7	Lactate	T109	C0022924
28536031	16	42	osteoblast differentiation	T043	C1159974
28536031	46	59	stabilization	T044	C1152620
28536031	63	68	HIF1α	T116,T123	C0965644
28536031	69	87	Aerobic glycolysis	T044	C0598754
28536031	103	129	osteoblast differentiation	T043	C1159974
28536031	141	154	Wnt signaling	T044	C1520113
28536031	158	161	PTH	T116,T121,T125	C0030520
28536031	162	171	treatment	T169	C1522326
28536031	210	217	lactate	T109	C0022924
28536031	238	256	aerobic glycolysis	T044	C0598754
28536031	276	302	osteoblast differentiation	T043	C1159974
28536031	329	337	cultures	T059	C0007585
28536031	341	365	osteoblast-lineage cells	T025	C0029418
28536031	367	374	lactate	T109	C0022924
28536031	384	404	alkaline phosphatase	T116,T126	C0002059
28536031	415	429	cell formation	T043	C0007613
28536031	445	453	activity	T044	C0243102
28536031	457	477	alkaline phosphatase	T116,T126	C0002059
28536031	495	505	expression	T045	C1171362
28536031	509	520	osteocalcin	T116,T123	C0029419
28536031	527	553	osteoblast differentiation	T043	C1159974
28536031	574	581	lactate	T109	C0022924
28536031	589	598	inhibited	T080	C0311403
28536031	602	610	blocking	T169	C0332206
28536031	626	631	cells	T025	C0007634
28536031	637	641	MCT1	T116,T123	C3812715
28536031	642	647	siRNA	T114,T123	C1099354
28536031	651	661	inhibitors	T121	C0033671
28536031	691	701	metabolism	T040	C0025519
28536031	720	726	siRNAs	T114,T123	C1099354
28536031	731	735	LDHB	T116,T126	C0022918
28536031	740	743	PDH	T116,T126	C0034343
28536031	755	762	lactate	T109	C0022924
28536031	774	779	HIF1α	T116,T123	C0965644
28536031	780	790	expression	T045	C1171362
28536031	795	804	inhibited	T080	C0311403
28536031	805	810	HIF1α	T116,T123	C0965644
28536031	811	819	activity	T044	C1537044
28536031	826	836	BAY87-2243	T121	C0033671
28536031	850	876	osteoblast differentiation	T043	C1159974
28536031	897	904	lactate	T109	C0022924
28536031	918	926	findings	T033	C0243095
28536031	959	977	aerobic glycolysis	T044	C0598754
28536031	981	1007	osteoblast differentiation	T043	C1159974
28536031	1029	1036	lactate	T109	C0022924

28431885|t|Safety of Adding Oats to a Gluten-free Diet for Patients with Celiac Disease: Systematic Review and Meta-analysis of Clinical and Observational Studies
28431885|a|Patients with celiac disease should maintain a gluten-free diet (GFD), excluding wheat, rye, and barley. Oats might increase the nutritional value of a GFD, but their including is controversial. We performed a systematic review and meta-analysis to evaluate the safety of oats as part of a GFD in patients with celiac disease. We searched the Cochrane Central Register of Controlled Trials, MEDLINE, and EMBASE databases for clinical trials and observational studies of the effects of including oats in GFD of patients with celiac disease. The studies reported patients ' symptoms, results from serology tests, and findings from histologic analyses. We used the GRADE approach to assess the quality of evidence. We identified 433 studies; 28 were eligible for analysis. Of these, 6 were randomized and 2 were not-randomized controlled trials comprising a total of 661 patients -the remaining studies were observational. All randomized controlled trials used pure/uncontaminated oats. Oat consumption for 12 months did not affect symptoms (standardized mean difference: reduction in symptom scores in patients who did and did not consumed oats, -0.22; 95% CI: -0.56 to 0.13; P=.22), histologic scores (relative risk for histologic findings in patients who consumed oats, 0.24; 95% CI, 0.01 to 4.8; P=.35), intraepithelial lymphocyte counts (standardized mean difference: 0.21; 95% CI, reduction of 1.44 to increase in 1.86), or results from serologic tests. Subgroup analyses of adults vs children did not reveal differences. The overall quality of evidence was low. In a systematic review and meta-analysis, we found no evidence that addition of oats to a GFD affects symptoms, histology, immunity, or serologic features of patients with celiac disease. However, there were few studies for many endpoints, as well as limited geographic distribution and low quality of evidence. Rigorous double-blind, placebo-controlled, randomized controlled trials, using commonly available oats sourced from different regions, are needed.
28431885	0	6	Safety	T068	C0036043
28431885	17	21	Oats	T168	C0028753
28431885	27	43	Gluten-free Diet	T058	C0344351
28431885	48	56	Patients	T101	C0030705
28431885	62	76	Celiac Disease	T047	C0007570
28431885	78	95	Systematic Review	T170	C1955832
28431885	100	113	Meta-analysis	T062	C0920317
28431885	117	125	Clinical	T062	C0008972
28431885	130	151	Observational Studies	T062	C1518527
28431885	152	160	Patients	T101	C0030705
28431885	166	180	celiac disease	T047	C0007570
28431885	199	215	gluten-free diet	T058	C0344351
28431885	217	220	GFD	T058	C0344351
28431885	233	238	wheat	T168	C0043137
28431885	240	243	rye	T168	C0035984
28431885	249	255	barley	T168	C1095831
28431885	257	261	Oats	T168	C0028753
28431885	281	298	nutritional value	T080	C0028722
28431885	304	307	GFD	T058	C0344351
28431885	362	379	systematic review	T170	C1955832
28431885	384	397	meta-analysis	T062	C0920317
28431885	414	420	safety	T068	C0036043
28431885	424	428	oats	T168	C0028753
28431885	442	445	GFD	T058	C0344351
28431885	449	457	patients	T101	C0030705
28431885	463	477	celiac disease	T047	C0007570
28431885	495	541	Cochrane Central Register of Controlled Trials	T170	C0242356
28431885	543	550	MEDLINE	T170	C0025141
28431885	556	572	EMBASE databases	T170	C0242356
28431885	577	592	clinical trials	T062	C0008976
28431885	597	618	observational studies	T062	C1518527
28431885	626	636	effects of	T080	C1704420
28431885	647	651	oats	T168	C0028753
28431885	655	658	GFD	T058	C0344351
28431885	662	670	patients	T101	C0030705
28431885	676	690	celiac disease	T047	C0007570
28431885	713	721	patients	T101	C0030705
28431885	724	732	symptoms	T184	C1457887
28431885	747	761	serology tests	T059	C0036743
28431885	767	775	findings	T169	C2607943
28431885	781	800	histologic analyses	T059	C0344441
28431885	814	828	GRADE approach	T058	C1254363
28431885	832	838	assess	T058	C0184514
28431885	843	850	quality	T080	C0332306
28431885	854	862	evidence	T078	C3887511
28431885	867	877	identified	T080	C0205396
28431885	912	920	analysis	T062	C0936012
28431885	939	949	randomized	T062	C0206035
28431885	961	993	not-randomized controlled trials	T062	C2985410
28431885	1020	1028	patients	T101	C0030705
28431885	1044	1070	studies were observational	T062	C1518527
28431885	1076	1104	randomized controlled trials	T062	C0206035
28431885	1110	1134	pure/uncontaminated oats	T168	C0028753
28431885	1136	1139	Oat	T168	C0028753
28431885	1140	1151	consumption	T052	C2983605
28431885	1159	1165	months	T079	C0439231
28431885	1181	1189	symptoms	T184	C1457887
28431885	1191	1219	standardized mean difference	T081	C0392762
28431885	1221	1230	reduction	T080	C0392756
28431885	1234	1248	symptom scores	T033	C3476546
28431885	1252	1260	patients	T101	C0030705
28431885	1290	1294	oats	T168	C0028753
28431885	1307	1309	CI	T081	C0009667
28431885	1334	1351	histologic scores	T170	C0807321
28431885	1353	1366	relative risk	T081	C0242492
28431885	1371	1390	histologic findings	T033	C0586683
28431885	1394	1402	patients	T101	C0030705
28431885	1416	1420	oats	T168	C0028753
28431885	1432	1434	CI	T081	C0009667
28431885	1457	1472	intraepithelial	T082	C1512942
28431885	1473	1490	lymphocyte counts	T059	C0200635
28431885	1492	1520	standardized mean difference	T081	C0392762
28431885	1532	1534	CI	T081	C0009667
28431885	1536	1545	reduction	T080	C0392756
28431885	1592	1607	serologic tests	T059	C0036743
28431885	1609	1626	Subgroup analyses	T062	C0242481
28431885	1630	1636	adults	T100	C0001675
28431885	1640	1648	children	T100	C0008059
28431885	1664	1675	differences	T081	C1705241
28431885	1689	1696	quality	T080	C0332306
28431885	1700	1708	evidence	T078	C3887511
28431885	1723	1740	systematic review	T170	C1955832
28431885	1745	1758	meta-analysis	T062	C0920317
28431885	1769	1780	no evidence	T080	C0332125
28431885	1798	1802	oats	T168	C0028753
28431885	1808	1811	GFD	T058	C0344351
28431885	1820	1828	symptoms	T184	C1457887
28431885	1830	1839	histology	T169	C4048239
28431885	1841	1849	immunity	T039	C0020964
28431885	1854	1863	serologic	T169	C0205473
28431885	1864	1872	features	T080	C1521970
28431885	1876	1884	patients	T101	C0030705
28431885	1890	1904	celiac disease	T047	C0007570
28431885	1969	1976	limited	T169	C0439801
28431885	1977	2000	geographic distribution	T079	C0681686
28431885	2009	2016	quality	T080	C0332306
28431885	2020	2028	evidence	T078	C3887511
28431885	2039	2051	double-blind	T062	C0013072
28431885	2053	2071	placebo-controlled	T062,T170	C0599724
28431885	2073	2101	randomized controlled trials	T062	C0206035
28431885	2128	2132	oats	T168	C0028753
28431885	2156	2163	regions	T083	C0017446

28540429|t|Identification of markers for quiescent pancreatic stellate cells in the normal human pancreas
28540429|a|Pancreatic stellate cells (PSCs) play a central role as source of fibrogenic cells in pancreatic cancer and chronic pancreatitis. In contrast to quiescent hepatic stellate cells (qHSCs), a specific marker for quiescent PSCs (qPSCs) that can be used in formalin-fixed and paraffin embedded (FFPE) normal human pancreatic tissue has not been identified. The aim of this study was to identify a marker enabling the identification of qPSCs in normal human FFPE pancreatic tissue. Immunohistochemical (IHC), double-IHC, immunofluorescence (IF) and double-IF analyses were carried out using a tissue microarray consisting of cores with normal human pancreatic tissue. Cores with normal human liver served as control. Antibodies directed against adipophilin, α-SMA, CD146, CRBP-1, cytoglobin, desmin, GFAP, nestin, S100A4 and vinculin were examined, with special emphasis on their expression in periacinar cells in the normal human pancreas and perisinusoidal cells in the normal human liver. The immunolabelling capacity was evaluated according to a semiquantitative scoring system. Double-IF of the markers of interest together with markers for other periacinar cells was performed. Moreover, the utility of histochemical stains for the identification of human qPSCs was examined, and their ultrastructure was revisited by electron microscopy. Adipophilin, CRBP-1, cytoglobin and vinculin were expressed in qHSCs in the liver, whereas cytoglobin and adipophilin were expressed in qPSCs in the pancreas. Adipophilin immunohistochemistry was highly dependent on the preanalytical time interval (PATI) from removal of the tissue to formalin fixation. Cytoglobin, S100A4 and vinculin were expressed in periacinar fibroblasts (FBs). The other examined markers were negative in human qPSCs. Our data indicate that cytoglobin and adipophilin are markers of qPSCs in the normal human pancreas. However, the use of adipophilin as a qPSC marker may be limited due to its high dependence on optimal PATI. Cytoglobin, on the other hand, is a sensitive marker for qPSCs but is expressed in FBs as well.
28540429	18	25	markers	T201	C0005516
28540429	30	39	quiescent	T080	C3686820
28540429	40	65	pancreatic stellate cells	T025	C2936598
28540429	73	79	normal	T080	C0205307
28540429	80	85	human	T016	C0086418
28540429	86	94	pancreas	T023	C0030274
28540429	95	120	Pancreatic stellate cells	T025	C2936598
28540429	122	126	PSCs	T025	C2936598
28540429	161	177	fibrogenic cells	T025	C0007634
28540429	181	198	pancreatic cancer	T191	C0235974
28540429	203	223	chronic pancreatitis	T047	C0149521
28540429	240	249	quiescent	T080	C3686820
28540429	250	272	hepatic stellate cells	T025	C2340138
28540429	274	279	qHSCs	T025	C2340138
28540429	293	299	marker	T201	C0005516
28540429	304	313	quiescent	T080	C3686820
28540429	314	318	PSCs	T025	C2936598
28540429	320	325	qPSCs	T025	C2936598
28540429	347	421	formalin-fixed and paraffin embedded (FFPE) normal human pancreatic tissue	T024	C2711483
28540429	525	530	qPSCs	T025	C2936598
28540429	534	540	normal	T080	C0205307
28540429	541	546	human	T016	C0086418
28540429	547	569	FFPE pancreatic tissue	T024	C2711483
28540429	571	590	Immunohistochemical	T059	C1441616
28540429	592	595	IHC	T059	C1441616
28540429	598	608	double-IHC	T059	C1441616
28540429	610	628	immunofluorescence	T059	C0079603
28540429	630	632	IF	T059	C0079603
28540429	638	656	double-IF analyses	T059	C0079603
28540429	682	699	tissue microarray	T075	C1519522
28540429	725	731	normal	T080	C0205307
28540429	732	737	human	T016	C0086418
28540429	738	755	pancreatic tissue	T024	C0587009
28540429	768	774	normal	T080	C0205307
28540429	775	780	human	T016	C0086418
28540429	781	786	liver	T023	C0023884
28540429	797	804	control	T096	C0009932
28540429	806	816	Antibodies	T116,T129	C0003241
28540429	834	845	adipophilin	T116,T123	C1505480
28540429	847	852	α-SMA	T116,T123	C2716282
28540429	854	859	CD146	T116,T129	C0386212
28540429	861	867	CRBP-1	T116,T123	C1872428
28540429	869	879	cytoglobin	T116,T126	C1450216
28540429	881	887	desmin	T116,T123	C0011696
28540429	889	893	GFAP	T116,T123	C0017626
28540429	895	901	nestin	T116,T123	C3711758
28540429	903	909	S100A4	T116,T123	C0287850
28540429	914	922	vinculin	T116,T123	C1454484
28540429	983	993	periacinar	T082	C0442156
28540429	994	999	cells	T025	C0007634
28540429	1007	1013	normal	T080	C0205307
28540429	1014	1019	human	T016	C0086418
28540429	1020	1028	pancreas	T023	C0030274
28540429	1033	1053	perisinusoidal cells	T025	C0227531
28540429	1061	1067	normal	T080	C0205307
28540429	1068	1073	human	T016	C0086418
28540429	1074	1079	liver	T023	C0023884
28540429	1085	1100	immunolabelling	T059	C0079609
28540429	1101	1109	capacity	T081	C1516240
28540429	1139	1170	semiquantitative scoring system	T057	C2986822
28540429	1172	1181	Double-IF	T059	C0079603
28540429	1189	1196	markers	T201	C0005516
28540429	1223	1230	markers	T201	C0005516
28540429	1241	1251	periacinar	T082	C0442156
28540429	1252	1257	cells	T025	C0007634
28540429	1298	1318	histochemical stains	T059	C1508788
28540429	1345	1350	human	T016	C0086418
28540429	1351	1356	qPSCs	T025	C2936598
28540429	1381	1395	ultrastructure	T078	C0041623
28540429	1413	1432	electron microscopy	T059	C0013842
28540429	1434	1445	Adipophilin	T116,T123	C1505480
28540429	1447	1453	CRBP-1	T116,T123	C1872428
28540429	1455	1465	cytoglobin	T116,T126	C1450216
28540429	1470	1478	vinculin	T116,T123	C1454484
28540429	1497	1502	qHSCs	T025	C2340138
28540429	1510	1515	liver	T023	C0023884
28540429	1525	1535	cytoglobin	T116,T126	C1450216
28540429	1540	1551	adipophilin	T116,T123	C1505480
28540429	1570	1575	qPSCs	T025	C2936598
28540429	1583	1591	pancreas	T023	C0030274
28540429	1593	1604	Adipophilin	T116,T123	C1505480
28540429	1605	1625	immunohistochemistry	T060	C0021044
28540429	1654	1681	preanalytical time interval	T079	C0872291
28540429	1683	1687	PATI	T079	C0872291
28540429	1709	1715	tissue	T024	C0040300
28540429	1719	1736	formalin fixation	T059	C3536615
28540429	1738	1748	Cytoglobin	T116,T126	C1450216
28540429	1750	1756	S100A4	T116,T123	C0287850
28540429	1761	1769	vinculin	T116,T123	C1454484
28540429	1788	1798	periacinar	T082	C0442156
28540429	1799	1810	fibroblasts	T025	C0016030
28540429	1812	1815	FBs	T025	C0016030
28540429	1837	1844	markers	T201	C0005516
28540429	1862	1867	human	T016	C0086418
28540429	1868	1873	qPSCs	T025	C2936598
28540429	1898	1908	cytoglobin	T116,T126	C1450216
28540429	1913	1924	adipophilin	T116,T123	C1505480
28540429	1929	1936	markers	T201	C0005516
28540429	1940	1945	qPSCs	T025	C2936598
28540429	1953	1959	normal	T080	C0205307
28540429	1960	1965	human	T016	C0086418
28540429	1966	1974	pancreas	T023	C0030274
28540429	1996	2007	adipophilin	T116,T123	C1505480
28540429	2013	2017	qPSC	T025	C2936598
28540429	2078	2082	PATI	T079	C0872291
28540429	2084	2094	Cytoglobin	T116,T126	C1450216
28540429	2130	2136	marker	T201	C0005516
28540429	2141	2146	qPSCs	T025	C2936598
28540429	2167	2170	FBs	T025	C0016030

28394042|t|metabolic profiling of Parkinson's disease and mild cognitive impairment
28394042|a|Early diagnosis of Parkinson's disease and mild cognitive impairment is important to enable prompt treatment and improve patient welfare, yet no standard diagnostic test is available. Metabolomics is a powerful tool used to elucidate disease mechanisms and identify potential biomarkers. The objective of this study was to use metabolic profiling to understand the pathoetiology of Parkinson's disease and to identify potential disease biomarkers. This study compared the serological metabolomic profiles of early-stage Parkinson's patients (diagnosed < 12 months) to asymptomatic matched controls using an established array based detection system (DiscoveryHD4™, Metabolon, UK), correlating metabolite levels to clinical measurements of cognitive impairment. A total of 1434 serological metabolites were assessed in early-stage Parkinson's disease cases (n = 41) and asymptomatic matched controls (n = 40). Post-quality control, statistical analysis identified n = 20 metabolites, predominantly metabolites of the fatty acid oxidation pathway, associated with Parkinson's disease and mild cognitive impairment. Receiver operator curve assessment confirmed that the nine fatty acid oxidation metabolites had good predictive accuracy (area under curve = 0.857) for early-stage Parkinson's disease and mild cognitive impairment (area under curve = 0.759). Our study indicates that fatty acid oxidation may be an important component in the pathophysiology of Parkinson's disease and may have potential as a diagnostic biomarker for disease onset and mild cognitive impairment. © 2017 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.
28394042	0	19	metabolic profiling	T091	C1328813
28394042	23	42	Parkinson's disease	T047	C0030567
28394042	47	72	mild cognitive impairment	T048	C1270972
28394042	73	88	Early diagnosis	T060	C0596473
28394042	92	111	Parkinson's disease	T047	C0030567
28394042	116	141	mild cognitive impairment	T048	C1270972
28394042	158	181	enable prompt treatment	T169	C0039798
28394042	186	209	improve patient welfare	T033	C0243095
28394042	218	242	standard diagnostic test	T060	C0086143
28394042	257	269	Metabolomics	T091	C1328813
28394042	297	325	elucidate disease mechanisms	T062	C1515006
28394042	339	359	potential biomarkers	T201	C0005516
28394042	400	419	metabolic profiling	T091	C1328813
28394042	438	451	pathoetiology	T169	C0205469
28394042	455	474	Parkinson's disease	T047	C0030567
28394042	491	519	potential disease biomarkers	T201	C0005516
28394042	545	556	serological	T169	C0205473
28394042	557	577	metabolomic profiles	T091	C1328813
28394042	581	592	early-stage	T079	C2363430
28394042	593	604	Parkinson's	T047	C0030567
28394042	605	613	patients	T101	C0030705
28394042	615	624	diagnosed	T033	C0011900
28394042	641	670	asymptomatic matched controls	T033	C0231221
28394042	692	720	array based detection system	T170	C3204041
28394042	722	735	DiscoveryHD4™	T170	C3204041
28394042	737	746	Metabolon	T170	C3204041
28394042	748	750	UK	T083	C0041700
28394042	753	782	correlating metabolite levels	T033	C0243095
28394042	786	807	clinical measurements	T058	C0947289
28394042	811	831	cognitive impairment	T048	C0338656
28394042	849	860	serological	T169	C0205473
28394042	861	872	metabolites	T123	C0870883
28394042	878	886	assessed	T052	C1516048
28394042	890	901	early-stage	T079	C2363430
28394042	902	921	Parkinson's disease	T047	C0030567
28394042	941	970	asymptomatic matched controls	T033	C0231221
28394042	981	1001	Post-quality control	T079	C1254367
28394042	1003	1023	statistical analysis	T062	C0871424
28394042	1042	1053	metabolites	T123	C0870883
28394042	1069	1080	metabolites	T123	C0870883
28394042	1088	1116	fatty acid oxidation pathway	T169	C2984156
28394042	1118	1133	associated with	T080	C0332281
28394042	1134	1153	Parkinson's disease	T047	C0030567
28394042	1158	1183	mild cognitive impairment	T048	C1270972
28394042	1185	1219	Receiver operator curve assessment	T170	C0450973
28394042	1244	1264	fatty acid oxidation	T044	C1158366
28394042	1265	1276	metabolites	T123	C0870883
28394042	1281	1305	good predictive accuracy	T033	C0589148
28394042	1307	1323	area under curve	T081	C0376690
28394042	1337	1348	early-stage	T079	C2363430
28394042	1349	1368	Parkinson's disease	T047	C0030567
28394042	1373	1398	mild cognitive impairment	T048	C1270972
28394042	1400	1416	area under curve	T081	C0376690
28394042	1452	1472	fatty acid oxidation	T044	C1158366
28394042	1510	1525	pathophysiology	T169	C0031847
28394042	1529	1548	Parkinson's disease	T047	C0030567
28394042	1577	1597	diagnostic biomarker	T060	C1880302
28394042	1602	1615	disease onset	T079	C0277793
28394042	1620	1645	mild cognitive impairment	T048	C1270972

27933173|t|A rare case of gestational thyrotoxicosis as a cause of acute myocardial infarction
27933173|a|Angina pectoris in pregnancy is unusual and Prinzmetal's angina is much rarer. It accounts for 2% of all cases of angina. It is caused by vasospasm, but the mechanism of spasm is unknown but has been linked with hyperthyroidism in some studies. Patients with thyrotoxicosis - induced acute myocardial infarction are unusual and almost all reported cases have been associated with Graves' disease. Human chorionic gonadotropin hormone - induced hyperthyroidism occurs in about 1.4% of pregnant women, mostly when hCG levels are above 70-80 000 IU/L. Gestational transient thyrotoxicosis is transient and generally resolves spontaneously in the latter half of pregnancy, and specific antithyroid treatment is not required. Treatment with calcium channel blockers or nitrates reduces spasm in most of these patients. Overall, the prognosis for hyperthyroidism - associated coronary vasospasm is good. We describe a very rare case of an acute myocardial infarction in a 27- year-old female, at 9 weeks of gestation due to right coronary artery spasm secondary to gestational hyperthyroidism with free thyroxine of 7.7 ng/dL and TSH <0.07 IU/L. AMI and cardiac arrest due to GTT despite optimal medical therapy is extremely rare. Gestational hyperthyroidism should be considered in pregnant patients presenting with ACS -like symptoms especially in the setting of hyperemesis gravidarum .Our case highlights the need for increased awareness of general medical community that GTT can lead to significant cardiac events. Novel methods of controlling GTT as well as medical interventions like ICD need further study.
27933173	2	6	rare	T080	C0522498
27933173	7	11	case	T169	C0868928
27933173	15	41	gestational thyrotoxicosis	T047	C0342138
27933173	47	52	cause	T169	C0015127
27933173	56	83	acute myocardial infarction	T047	C0155626
27933173	84	99	Angina pectoris	T184	C0002962
27933173	103	112	pregnancy	T040	C0032961
27933173	116	123	unusual	T080	C2700116
27933173	128	147	Prinzmetal's angina	T047	C0002963
27933173	151	155	much	T033	C4281574
27933173	156	161	rarer	T080	C0522498
27933173	185	188	all	T081	C0444868
27933173	189	194	cases	T169	C0868928
27933173	198	204	angina	T184	C0002962
27933173	212	218	caused	T169	C0015127
27933173	222	231	vasospasm	T046	C0085616
27933173	241	259	mechanism of spasm	T067	C0460140
27933173	263	270	unknown	T080	C0439673
27933173	296	311	hyperthyroidism	T047	C0020550
27933173	320	327	studies	T062	C2603343
27933173	329	337	Patients	T101	C0030705
27933173	343	357	thyrotoxicosis	T047	C0040156
27933173	360	367	induced	T169	C0205263
27933173	368	395	acute myocardial infarction	T047	C0155626
27933173	400	407	unusual	T080	C2700116
27933173	419	422	all	T081	C0444868
27933173	423	431	reported	T058	C0700287
27933173	432	437	cases	T169	C0868928
27933173	448	463	associated with	T080	C0332281
27933173	464	479	Graves' disease	T047	C0018213
27933173	481	517	Human chorionic gonadotropin hormone	T116,T121,T125	C1141639
27933173	520	527	induced	T169	C0205263
27933173	528	543	hyperthyroidism	T047	C0020550
27933173	544	550	occurs	T079	C2745955
27933173	568	582	pregnant women	T098	C0033011
27933173	596	606	hCG levels	T034	C1318379
27933173	633	669	Gestational transient thyrotoxicosis	T047	C0342138
27933173	673	682	transient	T079	C0205374
27933173	706	719	spontaneously	T169	C0205359
27933173	727	733	latter	T079	C0205087
27933173	734	738	half	T081	C2825407
27933173	742	751	pregnancy	T040	C0032961
27933173	766	777	antithyroid	T121,T125	C0040125
27933173	778	787	treatment	T169	C0039798
27933173	791	803	not required	T078	C1611645
27933173	805	844	Treatment with calcium channel blockers	UnknownType	C0741865
27933173	848	856	nitrates	T104	C0028125
27933173	857	864	reduces	T080	C0392756
27933173	865	870	spasm	T184	C0037763
27933173	874	878	most	T081	C0205393
27933173	888	896	patients	T101	C0030705
27933173	898	905	Overall	T080	C1561607
27933173	911	920	prognosis	T058	C0033325
27933173	925	940	hyperthyroidism	T047	C0020550
27933173	943	953	associated	T080	C0332281
27933173	954	972	coronary vasospasm	T047	C0010073
27933173	976	980	good	T080	C0205170
27933173	985	993	describe	T078	C1552738
27933173	1001	1005	rare	T080	C0522498
27933173	1006	1010	case	T169	C0868928
27933173	1017	1044	acute myocardial infarction	T047	C0155626
27933173	1054	1062	year-old	T100	C0001675
27933173	1063	1069	female	T098	C0043210
27933173	1074	1094	9 weeks of gestation	T033	C3646604
27933173	1095	1101	due to	T169	C0678226
27933173	1108	1129	coronary artery spasm	T047	C0010073
27933173	1130	1142	secondary to	T080	C0175668
27933173	1143	1170	gestational hyperthyroidism	T047	C0342138
27933173	1176	1190	free thyroxine	T034	C0428418
27933173	1208	1211	TSH	T034	C0428414
27933173	1224	1227	AMI	T047	C0155626
27933173	1232	1246	cardiac arrest	T047	C0018790
27933173	1247	1253	due to	T169	C0678226
27933173	1254	1257	GTT	T047	C0342138
27933173	1266	1273	optimal	T080	C2698651
27933173	1274	1289	medical therapy	T061	C0418981
27933173	1293	1302	extremely	T080	C0205403
27933173	1303	1307	rare	T080	C0522498
27933173	1309	1336	Gestational hyperthyroidism	T047	C0342138
27933173	1347	1357	considered	T078	C0750591
27933173	1361	1369	pregnant	T098	C0033011
27933173	1370	1378	patients	T101	C0030705
27933173	1395	1398	ACS	T047	C0948089
27933173	1405	1413	symptoms	T184	C1457887
27933173	1443	1465	hyperemesis gravidarum	T184	C0020450
27933173	1471	1475	case	T169	C0868928
27933173	1491	1495	need	T080	C0027552
27933173	1500	1509	increased	T081	C0205217
27933173	1510	1519	awareness	T184	C1389777
27933173	1523	1548	general medical community	T073,T093	C1562642
27933173	1554	1557	GTT	T047	C0342138
27933173	1582	1596	cardiac events	T047	C0741923
27933173	1598	1603	Novel	T080	C0205314
27933173	1604	1611	methods	T061	C0087111
27933173	1615	1626	controlling	T061	C0920467
27933173	1627	1630	GTT	T047	C0342138
27933173	1642	1663	medical interventions	T061	C0184661
27933173	1669	1672	ICD	T074	C0162589
27933173	1673	1677	need	T080	C0027552
27933173	1678	1685	further	T082	C1517331
27933173	1686	1691	study	T062	C2603343

28439067|t|Perfluorooctanesulfonate (PFOS)- induced Sertoli cell injury through a disruption of F-actin and microtubule organization is mediated by Akt1 / 2
28439067|a|PFOS (perfluorooctanesulfonate, or perfluorooctane sulfonic acid) is an anthropogenic fluorosurfactant widely used in consumer products. While its use in Europe, Canada and the U.S. has been banned due to its human toxicity, it continues to be used in China and other developing countries as a global pollutant. Herein, using an in vitro model of Sertoli cell blood-testis barrier (BTB), PFOS was found to induce Sertoli cell injury by perturbing actin cytoskeleton through changes in the spatial expression of actin regulatory proteins. Specifically, PFOS caused mis-localization of Arp3 (actin-related protein 3, a branched actin polymerization protein) and palladin (an actin bundling protein). These disruptive changes thus led to a dis-organization of F-actin across Sertoli cell cytosol, causing truncation of actin microfilament, thereby failing to support the Sertoli cell morphology and adhesion protein complexes (e.g., occludin - ZO-1, CAR - ZO-1, and N-cadherin - ß-catenin), through a down-regulation of p-Akt1-S473 and p-Akt2-S474. The use of SC79, an Akt1 / 2 inhibitor, was found to block the PFOS - induced Sertoli cell injury by rescuing the PFOS - induced F-actin dis-organization. These findings thus illustrate PFOS exerts its disruptive effects on Sertoli cell function downstream through Akt1 / 2. As such, PFOS - induced male reproductive dysfunction can possibly be managed through an intervention on Akt1 / 2 expression.
28439067	0	24	Perfluorooctanesulfonate	T109,T121	C1872584
28439067	26	30	PFOS	T109,T121	C1872584
28439067	33	40	induced	T169	C0205263
28439067	41	53	Sertoli cell	T025	C0036770
28439067	54	60	injury	T037	C3263722
28439067	71	81	disruption	T169	C0332453
28439067	85	92	F-actin	T116,T123	C1180307
28439067	97	108	microtubule	T026	C0026046
28439067	109	121	organization	T039	C0029237
28439067	125	133	mediated	T054	C0680727
28439067	137	141	Akt1	T116,T126	C0285558
28439067	144	145	2	T116,T126	C1312419
28439067	146	150	PFOS	T109,T121	C1872584
28439067	152	176	perfluorooctanesulfonate	T109,T121	C1872584
28439067	181	210	perfluorooctane sulfonic acid	T109,T121	C0172926
28439067	218	231	anthropogenic	T078	C1254370
28439067	232	248	fluorosurfactant	T120	C0038891
28439067	264	281	consumer products	T080	C0596381
28439067	300	306	Europe	T083	C0015176
28439067	308	314	Canada	T083	C0006823
28439067	323	326	U.S	T083	C0041703
28439067	337	343	banned	T054	C0683610
28439067	355	369	human toxicity	T080	C0040539
28439067	398	403	China	T083	C0008115
28439067	414	434	developing countries	T080	C0011750
28439067	440	456	global pollutant	T131	C0599786
28439067	475	489	in vitro model	T062	C1515654
28439067	493	505	Sertoli cell	T025	C0036770
28439067	506	526	blood-testis barrier	T042	C0005856
28439067	528	531	BTB	T042	C0005856
28439067	534	538	PFOS	T109,T121	C1872584
28439067	552	558	induce	T169	C0205263
28439067	559	571	Sertoli cell	T025	C0036770
28439067	572	578	injury	T037	C3263722
28439067	582	592	perturbing	T169	C0332453
28439067	593	611	actin cytoskeleton	T026	C0025979
28439067	643	653	expression	T045	C1171362
28439067	657	662	actin	T116,T123	C0001271
28439067	663	682	regulatory proteins	T116,T123	C0815047
28439067	698	702	PFOS	T109,T121	C1872584
28439067	710	726	mis-localization	T039	C1254359
28439067	730	734	Arp3	T116,T123	C0676794
28439067	736	759	actin-related protein 3	T116,T123	C0676794
28439067	763	800	branched actin polymerization protein	T116,T123	C0676794
28439067	806	814	palladin	T116	C2703161
28439067	819	841	actin bundling protein	T116,T123	C1179885
28439067	850	868	disruptive changes	T033	C0474416
28439067	883	899	dis-organization	T039	C1254359
28439067	903	910	F-actin	T116,T123	C1180307
28439067	918	930	Sertoli cell	T025	C0036770
28439067	931	938	cytosol	T026	C1383501
28439067	948	981	truncation of actin microfilament	T049	C1706395
28439067	1014	1026	Sertoli cell	T025	C0036770
28439067	1027	1037	morphology	T080	C0332437
28439067	1042	1068	adhesion protein complexes	T026	C3821354
28439067	1076	1084	occludin	T116,T192	C0250400
28439067	1087	1091	ZO-1	T116,T123	C3503764
28439067	1093	1096	CAR	T116,T123	C3539542
28439067	1099	1103	ZO-1	T116,T123	C3503764
28439067	1109	1119	N-cadherin	T116,T123	C0027215
28439067	1122	1131	ß-catenin	T116,T123	C0105770
28439067	1144	1159	down-regulation	T044	C0013081
28439067	1163	1174	p-Akt1-S473	T116	C3699952
28439067	1179	1190	p-Akt2-S474	T116,T126	C1312419
28439067	1203	1207	SC79	T109	C4307495
28439067	1212	1216	Akt1	T116,T126	C0285558
28439067	1219	1220	2	T116,T126	C1312419
28439067	1221	1230	inhibitor	T080	C1999216
28439067	1245	1250	block	T046	C0028778
28439067	1255	1259	PFOS	T109,T121	C1872584
28439067	1262	1269	induced	T169	C0205263
28439067	1270	1282	Sertoli cell	T025	C0036770
28439067	1283	1289	injury	T037	C3263722
28439067	1306	1310	PFOS	T109,T121	C1872584
28439067	1313	1320	induced	T169	C0205263
28439067	1321	1328	F-actin	T116,T123	C1180307
28439067	1329	1345	dis-organization	T039	C1254359
28439067	1378	1382	PFOS	T109,T121	C1872584
28439067	1383	1389	exerts	T040	C0015264
28439067	1394	1412	disruptive effects	T033	C0474416
28439067	1416	1428	Sertoli cell	T025	C0036770
28439067	1429	1437	function	T169	C0542341
28439067	1457	1461	Akt1	T116,T126	C0285558
28439067	1464	1465	2	T116,T126	C1312419
28439067	1476	1480	PFOS	T109,T121	C1872584
28439067	1483	1490	induced	T169	C0205263
28439067	1491	1508	male reproductive	T022	C1963704
28439067	1509	1520	dysfunction	T077	C3887504
28439067	1556	1568	intervention	T061	C0184661
28439067	1572	1576	Akt1	T116,T126	C0285558
28439067	1579	1580	2	T116,T126	C1312419
28439067	1581	1591	expression	T045	C1171362

27569995|t|Antidepressant -like effects of scopolamine in mice are enhanced by the group II mGlu receptor antagonist LY341495
27569995|a|Clinical studies have shown that the muscarinic receptor antagonist scopolamine induces a potent and rapid antidepressant effect relative to conventional antidepressants. However, potential undesirable effects, including memory impairment, partially limit the use of scopolamine in psychiatry. In the present study, we propose to overcome these limitations and enhance the therapeutic effects of scopolamine via administration in combination with the group II metabotropic glutamate (mGlu) receptor antagonist, LY341495. Joint administration of sub-effective doses of scopolamine (0.03 or 0.1 mg/kg, i.p.) with a sub-effective dose of LY341495 (0.1 mg/kg, i.p.) induced a profound antidepressant effect in the tail suspension test (TST) and in the forced swim test (FST) in mice. This drug combination did not impair memory, as measured using the Morris water maze (MWM), and did not influence the locomotor activity of mice. Furthermore, we found that an AMPA receptor antagonist, NBQX (10 mg/kg), completely reversed the antidepressant-like activity of a mixture of scopolamine and LY341495 in the TST. However, this effect was not influenced by para-chlorophenylalanine (PCPA) pre-treatment, indicating a lack of involvement of serotonergic system activation in the antidepressant-like effects of jointly given scopolamine and LY341495. Therefore, the combined administration of low doses of the antimuscarinic drug scopolamine and the group II mGlu receptor antagonist LY341495 might be a new, effective and safe strategy in the therapy of depression.
27569995	0	14	Antidepressant	T121	C0003289
27569995	21	31	effects of	T080	C1704420
27569995	32	43	scopolamine	T109,T121	C0036442
27569995	47	51	mice	T015	C0025929
27569995	72	94	group II mGlu receptor	T116,T192	C0206529
27569995	95	105	antagonist	T121	C1254351
27569995	106	114	LY341495	T109,T121	C0757826
27569995	115	131	Clinical studies	T062	C0008972
27569995	152	171	muscarinic receptor	T116,T192	C0034826
27569995	172	182	antagonist	T121	C1254351
27569995	183	194	scopolamine	T109,T121	C0036442
27569995	222	243	antidepressant effect	T033	C0243095
27569995	269	284	antidepressants	T121	C0003289
27569995	305	324	undesirable effects	T169	C0001688
27569995	336	353	memory impairment	T048	C0233794
27569995	355	370	partially limit	T169	C0439801
27569995	382	393	scopolamine	T109,T121	C0036442
27569995	397	407	psychiatry	T091	C0033873
27569995	424	429	study	T062	C2603343
27569995	460	471	limitations	T169	C0449295
27569995	488	507	therapeutic effects	T201	C1527144
27569995	511	522	scopolamine	T109,T121	C0036442
27569995	527	541	administration	T061	C1533734
27569995	545	556	combination	T080	C0205195
27569995	566	613	group II metabotropic glutamate (mGlu) receptor	T116,T192	C0206529
27569995	614	624	antagonist	T121	C1254351
27569995	626	634	LY341495	T109,T121	C0757826
27569995	636	656	Joint administration	T061	C1533734
27569995	660	679	sub-effective doses	T081	C0178602
27569995	683	694	scopolamine	T109,T121	C0036442
27569995	728	746	sub-effective dose	T081	C0178602
27569995	750	758	LY341495	T109,T121	C0757826
27569995	777	784	induced	T169	C0205263
27569995	796	817	antidepressant effect	T033	C0243095
27569995	825	845	tail suspension test	T060	C0683444
27569995	847	850	TST	T060	C0683444
27569995	863	879	forced swim test	T060	C0683444
27569995	881	884	FST	T060	C0683444
27569995	889	893	mice	T015	C0025929
27569995	900	916	drug combination	T121	C0013162
27569995	925	938	impair memory	T048	C0233794
27569995	962	979	Morris water maze	T060	C4277747
27569995	981	984	MWM	T060	C4277747
27569995	1013	1031	locomotor activity	T040	C0023946
27569995	1035	1039	mice	T015	C0025929
27569995	1071	1084	AMPA receptor	T116,T192	C0072899
27569995	1085	1095	antagonist	T121	C1254351
27569995	1097	1101	NBQX	T109,T121	C0045376
27569995	1138	1166	antidepressant-like activity	T033	C0243095
27569995	1172	1179	mixture	T167	C0439962
27569995	1183	1194	scopolamine	T109,T121	C0036442
27569995	1199	1207	LY341495	T109,T121	C0757826
27569995	1215	1218	TST	T060	C0683444
27569995	1234	1240	effect	T080	C1280500
27569995	1263	1287	para-chlorophenylalanine	T116,T121	C0030135
27569995	1289	1293	PCPA	T116,T121	C0030135
27569995	1295	1308	pre-treatment	T079	C2709094
27569995	1346	1376	serotonergic system activation	T044	C1148560
27569995	1384	1411	antidepressant-like effects	T033	C0243095
27569995	1429	1440	scopolamine	T109,T121	C0036442
27569995	1445	1453	LY341495	T109,T121	C0757826
27569995	1470	1493	combined administration	T061	C1533734
27569995	1497	1506	low doses	T081	C0178602
27569995	1514	1533	antimuscarinic drug	T121	C0003385
27569995	1534	1545	scopolamine	T109,T121	C0036442
27569995	1554	1576	group II mGlu receptor	T116,T192	C0206529
27569995	1577	1587	antagonist	T121	C1254351
27569995	1588	1596	LY341495	T109,T121	C0757826
27569995	1613	1622	effective	T080	C1280519
27569995	1632	1640	strategy	T170	C0679716
27569995	1648	1655	therapy	T061	C0087111
27569995	1659	1669	depression	T048	C0011570

27555478|t|Activation of the Na(+)/H(+) exchanger in isolated cardiomyocytes through β-Raf dependent pathways. Role of Thr(653) of the cytosolic tail
27555478|a|The mammalian Na(+)/H(+) exchanger isoform 1 (NHE1) is a ubiquitous plasma membrane protein that is a key regulator of intracellular pH in isolated cardiomyocytes. A 500 amino acid membrane domain removes protons and is regulated by a 315 amino acid cytosolic domain. In the myocardium, aberrant regulation of NHE1 contributes to ischemia reperfusion damage and to heart hypertrophy. We examined mechanisms of regulation of NHE1 in the myocardium by endothelin and β-Raf. Endothelin stimulated NHE1 activity and activated Erk-dependent pathways. Inhibition of β-Raf reduced NHE1 activity and Erk-pathway activation. We demonstrated that myocardial β-Raf binds to the C-terminal 182 amino acids of the NHE1 protein and that β-Raf is associated with NHE1 in intact cardiomyocytes. NHE1 was phosphorylated in vivo and the protein kinase inhibitor sorafenib reduced NHE1 phosphorylation levels. Immunoprecipitates of β-Raf from cardiomyocytes phosphorylated the C-terminal 182 amino acids of NHE1 and mass spectrometry analysis showed that amino acid Thr(653) was phosphorylated. Mutation of this amino acid to Ala resulted in defective activity while mutation to Asp restored the activity. The results demonstrate that Thr(653) is an important regulator y amino acid of NHE1 that is activated through β-Raf dependent pathways by phosphorylation either directly or indirectly by β-Raf, and this affects NHE1 activity.
27555478	0	10	Activation	T052	C1879547
27555478	18	38	Na(+)/H(+) exchanger	T116,T123	C0074785
27555478	42	50	isolated	T169	C0205409
27555478	51	65	cardiomyocytes	T025	C0225828
27555478	74	79	β-Raf	T116,T123	C1259929
27555478	90	98	pathways	T044	C1704259
27555478	108	116	Thr(653)	T116,T121,T123	C0040005
27555478	124	138	cytosolic tail	T026	C1511625
27555478	143	152	mammalian	T015	C0024660
27555478	153	183	Na(+)/H(+) exchanger isoform 1	T116,T123	C1113671
27555478	185	189	NHE1	T116,T123	C1113671
27555478	207	230	plasma membrane protein	T116,T123	C1179841
27555478	245	274	regulator of intracellular pH	T040	C1655052
27555478	278	286	isolated	T169	C0205409
27555478	287	301	cardiomyocytes	T025	C0225828
27555478	309	335	amino acid membrane domain	T087	C1513110
27555478	344	351	protons	T196	C0033727
27555478	378	388	amino acid	T116,T121,T123	C0002520
27555478	389	405	cytosolic domain	T026	C1511625
27555478	414	424	myocardium	T024	C0027061
27555478	426	434	aberrant	T080	C0443127
27555478	435	445	regulation	T038	C1327622
27555478	449	453	NHE1	T116,T123	C1113671
27555478	469	496	ischemia reperfusion damage	T037	C0035126
27555478	504	521	heart hypertrophy	T046	C1383860
27555478	526	534	examined	T033	C0332128
27555478	535	545	mechanisms	T169	C0441712
27555478	549	559	regulation	T038	C1327622
27555478	563	567	NHE1	T116,T123	C1113671
27555478	575	585	myocardium	T024	C0027061
27555478	589	599	endothelin	T116,T123	C0079284
27555478	604	609	β-Raf	T116,T123	C1259929
27555478	611	621	Endothelin	T116,T123	C0079284
27555478	633	637	NHE1	T116,T123	C1113671
27555478	638	646	activity	T052	C0441655
27555478	651	660	activated	T052	C1879547
27555478	661	683	Erk-dependent pathways	T044	C3179234
27555478	699	704	β-Raf	T116,T123	C1259929
27555478	713	717	NHE1	T116,T123	C1113671
27555478	718	726	activity	T052	C0441655
27555478	731	742	Erk-pathway	T044	C3179234
27555478	743	753	activation	T052	C1879547
27555478	776	786	myocardial	T024	C0027061
27555478	787	792	β-Raf	T116,T123	C1259929
27555478	793	798	binds	T052	C1145667
27555478	806	832	C-terminal 182 amino acids	T087	C1707271
27555478	840	852	NHE1 protein	T116,T123	C1113671
27555478	862	867	β-Raf	T116,T123	C1259929
27555478	871	886	associated with	T080	C0332281
27555478	887	891	NHE1	T116,T123	C1113671
27555478	895	901	intact	T080	C0205266
27555478	902	916	cardiomyocytes	T025	C0225828
27555478	918	922	NHE1	T116,T123	C1113671
27555478	927	941	phosphorylated	T044	C0031715
27555478	942	949	in vivo	T082	C1515655
27555478	958	982	protein kinase inhibitor	T116,T121	C1449702
27555478	983	992	sorafenib	T109,T121	C1516119
27555478	1001	1005	NHE1	T116,T123	C1113671
27555478	1006	1021	phosphorylation	T044	C0031715
27555478	1030	1048	Immunoprecipitates	T129	C0301871
27555478	1052	1057	β-Raf	T116,T123	C1259929
27555478	1063	1077	cardiomyocytes	T025	C0225828
27555478	1078	1092	phosphorylated	T044	C0031715
27555478	1097	1123	C-terminal 182 amino acids	T087	C1707271
27555478	1127	1131	NHE1	T116,T123	C1113671
27555478	1136	1162	mass spectrometry analysis	T059	C0037813
27555478	1175	1185	amino acid	T116,T121,T123	C0002520
27555478	1186	1194	Thr(653)	T116,T121,T123	C0040005
27555478	1199	1213	phosphorylated	T044	C0031715
27555478	1215	1223	Mutation	T045	C0026882
27555478	1232	1242	amino acid	T116,T121,T123	C0002520
27555478	1246	1249	Ala	T116,T123	C0001898
27555478	1262	1271	defective	T169	C0332452
27555478	1272	1280	activity	T052	C0441655
27555478	1287	1295	mutation	T045	C0026882
27555478	1299	1302	Asp	T116,T123	C0085845
27555478	1316	1324	activity	T052	C0441655
27555478	1330	1337	results	T034	C0456984
27555478	1355	1363	Thr(653)	T116,T121,T123	C0040005
27555478	1380	1389	regulator	T077	C1704735
27555478	1392	1402	amino acid	T116,T121,T123	C0002520
27555478	1406	1410	NHE1	T116,T123	C1113671
27555478	1419	1428	activated	T052	C1879547
27555478	1437	1442	β-Raf	T116,T123	C1259929
27555478	1453	1461	pathways	T044	C1704259
27555478	1465	1480	phosphorylation	T044	C0031715
27555478	1514	1519	β-Raf	T116,T123	C1259929
27555478	1538	1542	NHE1	T116,T123	C1113671
27555478	1543	1551	activity	T052	C0441655

27793676|t|Hormonal and testicular changes in rats submitted to congenital hypothyroidism in early life
27793676|a|The goal of this study was to evaluate the influence of hypothyroidism induced by MMI, during gestation (G) or gestation plus lactation (GL) on testis and its relation with leptin in rats. Six to eight pups were killed at 90 days of age. For statistical analysis One-way ANOVA followed by the Holm-Sìdak post hoc test was used. Hypothyroidism resulted in a significant reduction in LH, FSH and testosterone and an increase in leptin serum levels (p < 0.04). There was a significant decrease in StAR, AR, FSHR, LHR, pSTAT3 and SOCS3 (p < 0.04) protein expression and in the fertility parameters (p < 0.04). We can conclude that hypothyroidism is associated with reduction of steroidogenesis and spermatogenesis leading to a low fertility potential in these animals. This outcome could be a consequence of low pituitary stimulus and testicular response and probably are not related with leptin hormone since its signaling pathway is down-regulated in the testis.
27793676	0	8	Hormonal	T059	C0441683
27793676	13	23	testicular	T023	C0039597
27793676	24	31	changes	T169	C0392747
27793676	35	39	rats	T015	C0034721
27793676	53	78	congenital hypothyroidism	T047	C0010308
27793676	82	92	early life	T078	C0376558
27793676	97	101	goal	T078	C1947946
27793676	110	115	study	T059	C0947630
27793676	123	131	evaluate	T058	C0220825
27793676	136	145	influence	T077	C4054723
27793676	149	163	hypothyroidism	T047	C0020676
27793676	164	171	induced	T046	C0007994
27793676	175	178	MMI	T109,T121	C0025644
27793676	187	196	gestation	T040	C0032961
27793676	198	199	G	T040	C0032961
27793676	204	213	gestation	T040	C0032961
27793676	219	228	lactation	T042	C0022925
27793676	237	243	testis	T023	C0039597
27793676	266	272	leptin	T116,T125	C0299583
27793676	276	280	rats	T015	C0034721
27793676	305	311	killed	T078	C0681205
27793676	318	322	days	T079	C0439228
27793676	326	329	age	T032	C0001779
27793676	335	355	statistical analysis	T062	C0871424
27793676	356	369	One-way ANOVA	T081	C1709320
27793676	386	410	Holm-Sìdak post hoc test	T170	C0237913
27793676	421	435	Hypothyroidism	T047	C0020676
27793676	462	471	reduction	T080	C0392756
27793676	475	477	LH	T116,T121,T125	C0023607
27793676	479	482	FSH	T116,T121,T125	C0733758
27793676	487	499	testosterone	T109,T121,T125	C0039601
27793676	507	538	increase in leptin serum levels	T033	C2747815
27793676	575	583	decrease	T081	C0547047
27793676	587	591	StAR	T116,T123	C1613886
27793676	593	595	AR	T116,T192	C0034786
27793676	597	601	FSHR	T116,T192	C0034806
27793676	603	606	LHR	T116,T192	C0034823
27793676	608	614	pSTAT3	T116,T123	C0253050
27793676	619	624	SOCS3	T116,T123	C1527557
27793676	636	654	protein expression	T045	C1171362
27793676	666	675	fertility	T040	C0015895
27793676	676	686	parameters	T077	C0549193
27793676	720	734	hypothyroidism	T047	C0020676
27793676	738	753	associated with	T080	C0332281
27793676	754	763	reduction	T080	C0392756
27793676	767	782	steroidogenesis	T044	C0597513
27793676	787	802	spermatogenesis	T043	C0037864
27793676	816	839	low fertility potential	T033	C0243095
27793676	849	856	animals	T008	C0003062
27793676	863	870	outcome	T169	C1274040
27793676	882	896	consequence of	T169	C0686907
27793676	897	900	low	T080	C0205251
27793676	901	910	pituitary	T023	C0032005
27793676	911	919	stimulus	T067	C0234402
27793676	924	943	testicular response	T032	C0871261
27793676	978	992	leptin hormone	T116,T125	C0299583
27793676	1003	1020	signaling pathway	T044	C0037080
27793676	1024	1038	down-regulated	T044	C0013081
27793676	1046	1052	testis	T023	C0039597

27568672|t|Diagnosing a rare case of desmoplastic small round cell tumour on liver biopsy
27568672|a|A 50- year -old male of Indian descent presented with jaundice and right hypochondrium pain. Following a computed tomography (CT) scan of the abdomen, a segment 7 liver lesion was visualized, accompanied by extensive peritoneal tumour deposits. An ultrasound guided liver biopsy was performed and histology showed loose nests and sheets of tumour cells with a small blue round cell morphology. The tumour cells showed patchy strong immunopositivity for cytokeratins (AE1/3, CK7, CK19) and synaptophysin, while showing diffuse strong perinuclear positivity for desmin. Interphase fluorescence in-situ hybridization (FISH) study using EWSR1 breakapart probe was positive for EWSR1 gene rearrangement. Desmoplastic small round cell tumour is a rare but aggressive intra-abdominal mesenchymal tumour. While the primary sites of involvement are usually the peritoneum and omentum, visceral involvement can occur. We wish to highlight the importance of considering this entity when evaluating a liver biopsy especially in a less than classical clinical context.
27568672	0	10	Diagnosing	T062	C1704656
27568672	26	62	desmoplastic small round cell tumour	T191	C0281508
27568672	66	78	liver biopsy	T060	C0193388
27568672	85	89	year	T079	C0439234
27568672	95	99	male	T032	C0086582
27568672	103	117	Indian descent	T098	C1524069
27568672	133	141	jaundice	T033	C2010848
27568672	146	170	right hypochondrium pain	T184	C0235299
27568672	184	213	computed tomography (CT) scan	T060	C0040405
27568672	221	228	abdomen	T029	C0000726
27568672	232	254	segment 7 liver lesion	T033	C0577053
27568672	259	269	visualized	T169	C0234621
27568672	296	306	peritoneal	T029	C0442034
27568672	307	313	tumour	T191	C0027651
27568672	314	322	deposits	T169	C0333562
27568672	327	357	ultrasound guided liver biopsy	T060	C0860886
27568672	376	385	histology	T091	C0019638
27568672	393	404	loose nests	T082	C1254362
27568672	409	415	sheets	T082	C0439643
27568672	419	431	tumour cells	T025	C0597032
27568672	439	471	small blue round cell morphology	T201	C1521816
27568672	477	489	tumour cells	T025	C0597032
27568672	511	527	immunopositivity	T033	C0243095
27568672	532	544	cytokeratins	T116	C0010803
27568672	546	551	AE1/3	T116	C0010803
27568672	553	556	CK7	T116	C0672250
27568672	558	562	CK19	T116,T123	C4082253
27568672	568	581	synaptophysin	T116,T123	C0085255
27568672	612	634	perinuclear positivity	T033	C0243095
27568672	639	645	desmin	T116,T123	C0011696
27568672	647	692	Interphase fluorescence in-situ hybridization	T063	C0162789
27568672	694	698	FISH	T063	C0162789
27568672	700	705	study	T062	C0008972
27568672	712	734	EWSR1 breakapart probe	T130	C0016321
27568672	739	747	positive	T033	C1446409
27568672	752	757	EWSR1	T028	C0808901
27568672	758	776	gene rearrangement	T045	C0017287
27568672	778	814	Desmoplastic small round cell tumour	T191	C0281508
27568672	840	855	intra-abdominal	T082	C1512910
27568672	856	874	mesenchymal tumour	T191	C0025464
27568672	886	899	primary sites	T082	C0449695
27568672	903	914	involvement	T169	C1314939
27568672	931	941	peritoneum	T024	C0031153
27568672	946	953	omentum	T023	C0028977
27568672	955	963	visceral	T082	C0442045
27568672	964	975	involvement	T169	C1314939
27568672	1068	1080	liver biopsy	T060	C0193388
27568672	1117	1133	clinical context	T078	C0449255

27883264|t|Mucosa - associated biohydrogenating microbes protect the simulated colon microbiome from stress associated with high concentrations of poly-unsaturated fat
27883264|a|Polyunsaturated fatty acids (PUFAs) may affect colon microbiome homeostasis by exerting (specific) antimicrobial effects and/or interfering with mucosal biofilm formation at the gut mucosal interface. We used standardized batch incubations and the Mucosal-Simulator of the Human Microbial Intestinal Ecosystem (M-SHIME) to show the in vitro luminal and mucosal effects of the main PUFA in the Western diet, linoleic acid (LA). High concentrations of LA were found to decrease butyrate production and Faecalibacterium prausnitzii numbers dependent on LA biohydrogenation to vaccenic acid (VA) and stearic acid (SA). In faecal batch incubations, LA biohydrogenation and butyrate production were positively correlated and SA did not inhibit butyrate production. In the M-SHIME, addition of a mucosal environment stimulated biohydrogenation to SA and protected F. prausnitzii from inhibition by LA. This was probably due to the preference of two biohydrogenating genera Roseburia and Pseudobutyrivibrio for the mucosal niche. Co-culture batch incubations using Roseburia hominis and F. prausnitzii validated these observations. Correlations networks further uncovered the central role of Roseburia and Pseudobutyrivibrio in protecting luminal and mucosal SHIME microbiota from LA - induced stress. Our results confirm how cross-shielding interactions provide resilience to the microbiome and demonstrate the importance of biohydrogenating, mucosal bacteria for recovery from LA stress.
27883264	0	6	Mucosa	T031	C0026727
27883264	9	19	associated	T080	C0332281
27883264	20	45	biohydrogenating microbes	T001	C0445623
27883264	68	73	colon	T204	C3888384
27883264	74	84	microbiome	T001	C1956108
27883264	90	96	stress	T033	C0038435
27883264	97	112	associated with	T080	C0332281
27883264	113	132	high concentrations	T081	C1446561
27883264	136	156	poly-unsaturated fat	T109,T168	C2362518
27883264	157	184	Polyunsaturated fatty acids	T109,T123	C0032615
27883264	186	191	PUFAs	T109,T123	C0032615
27883264	204	209	colon	T204	C3888384
27883264	210	220	microbiome	T001	C1956108
27883264	221	232	homeostasis	T038	C0019868
27883264	236	244	exerting	T040	C0015264
27883264	246	254	specific	T080	C0205369
27883264	256	269	antimicrobial	T195	C0003232
27883264	270	277	effects	T080	C1280500
27883264	302	309	mucosal	T031	C0026727
27883264	310	317	biofilm	T167	C1561572
27883264	318	327	formation	T169	C1522492
27883264	335	356	gut mucosal interface	T023	C0836209
27883264	366	396	standardized batch incubations	T059	C1439852
27883264	405	466	Mucosal-Simulator of the Human Microbial Intestinal Ecosystem	T170	C0282574
27883264	468	475	M-SHIME	T170	C0282574
27883264	489	497	in vitro	T080	C1533691
27883264	498	505	luminal	T030	C0524461
27883264	510	517	mucosal	T031	C0026727
27883264	518	528	effects of	T080	C1704420
27883264	538	542	PUFA	T109,T123	C0032615
27883264	550	562	Western diet	T061	C3849996
27883264	564	577	linoleic acid	T109,T121,T123	C0023749
27883264	579	581	LA	T109,T121,T123	C0023749
27883264	584	603	High concentrations	T081	C1446561
27883264	607	609	LA	T109,T121,T123	C0023749
27883264	624	632	decrease	T081	C0547047
27883264	633	641	butyrate	T109	C0006521
27883264	642	652	production	T169	C0205245
27883264	657	685	Faecalibacterium prausnitzii	T007	C0317558
27883264	707	709	LA	T109,T121,T123	C0023749
27883264	710	726	biohydrogenation	T070	C0020286
27883264	730	743	vaccenic acid	T109	C0301702
27883264	745	747	VA	T109	C0301702
27883264	753	765	stearic acid	T109,T121	C0038229
27883264	767	769	SA	T109,T121	C0038229
27883264	775	781	faecal	T031	C0015733
27883264	782	799	batch incubations	T059	C1439852
27883264	801	803	LA	T109,T121,T123	C0023749
27883264	804	820	biohydrogenation	T070	C0020286
27883264	825	833	butyrate	T109	C0006521
27883264	834	844	production	T169	C0205245
27883264	850	871	positively correlated	T080	C1707520
27883264	876	878	SA	T109,T121	C0038229
27883264	887	894	inhibit	T052	C3463820
27883264	895	903	butyrate	T109	C0006521
27883264	904	914	production	T169	C0205245
27883264	923	930	M-SHIME	T170	C0282574
27883264	946	953	mucosal	T031	C0026727
27883264	954	965	environment	T082	C0014406
27883264	966	976	stimulated	T070	C1948023
27883264	977	993	biohydrogenation	T070	C0020286
27883264	997	999	SA	T109,T121	C0038229
27883264	1014	1028	F. prausnitzii	T007	C0317558
27883264	1034	1044	inhibition	T052	C3463820
27883264	1048	1050	LA	T109,T121,T123	C0023749
27883264	1081	1091	preference	T078	C0558295
27883264	1099	1115	biohydrogenating	T070	C0020286
27883264	1116	1122	genera	T185	C1708235
27883264	1123	1132	Roseburia	T007	C0995401
27883264	1137	1155	Pseudobutyrivibrio	T007	C1012458
27883264	1164	1171	mucosal	T031	C0026727
27883264	1179	1189	Co-culture	T059	C0282547
27883264	1190	1207	batch incubations	T059	C1439852
27883264	1214	1231	Roseburia hominis	T007	C1667633
27883264	1236	1250	F. prausnitzii	T007	C0317558
27883264	1251	1260	validated	T062	C1519941
27883264	1267	1279	observations	T062	C0302523
27883264	1281	1293	Correlations	T080	C1707520
27883264	1294	1302	networks	T169	C1882071
27883264	1341	1350	Roseburia	T007	C0995401
27883264	1355	1373	Pseudobutyrivibrio	T007	C1012458
27883264	1388	1395	luminal	T030	C0524461
27883264	1400	1424	mucosal SHIME microbiota	T059	C3496041
27883264	1430	1432	LA	T109,T121,T123	C0023749
27883264	1435	1449	induced stress	T033	C0038435
27883264	1455	1462	results	T169	C1274040
27883264	1475	1503	cross-shielding interactions	T169	C1704675
27883264	1530	1540	microbiome	T001	C1956108
27883264	1561	1571	importance	T080	C3898777
27883264	1575	1591	biohydrogenating	T070	C0020286
27883264	1593	1600	mucosal	T031	C0026727
27883264	1601	1609	bacteria	T007	C0004611
27883264	1614	1622	recovery	T052	C0237820
27883264	1628	1630	LA	T109,T121,T123	C0023749
27883264	1631	1637	stress	T033	C0038435

28322885|t|Fluoride concentration in saliva and biofilm fluid following the application of three fluoride varnishes
28322885|a|Most of the commercially available fluoride varnishes (FV) have not been evaluated for their cariostatic properties. Consequently, the aim of this in vivo study was to investigate intra - oral fluoride retention and clearance patterns from three different FV. Eighteen subjects (7-11 years) participated in a laboratory analyst - blinded, randomized, crossover study comparing the ability of 5% sodium fluoride varnishes (CavityShield-CS, Enamel Pro-EP, Vanish-V) to enhance fluoride concentrations in biofilm fluid, centrifuged and whole saliva over a period of 48h after a single FV application. Similar fluoride concentration × time patterns were noted for all investigated FV and studied variables, with the highest fluoride concentrations observed for the first biological sample collected after FV application (30min). Mean±SE (area under fluoride clearance curve) values were (μg F/g or ml×min): biofilm fluid - CS (472±191), EP (423±75), V (1264±279); centrifuged saliva - CS (42±7), EP (19±3), V (41±8); whole saliva - CS (68±11), EP (64±10), V (60±7). V delivered more fluoride to biofilm fluid than CS (p=0.0116) and EP (p=0.0065), which did not differ (p=0.27). For centrifuged saliva, CS and V were not significantly different (p=0.86), but resulted in higher fluoride retention than EP (p<0.0008). No significant differences among FV were observed for whole saliva (p=0.79). The present study has shown that FV vary in their ability to deliver fluoride intra - orally potentially related to formulation differences. To what extent the present findings relate to clinical efficacy remains, however, to be determined. Clinical research that investigates fluoride release patterns into saliva and biofilm fluid from different FV products is insufficient. More research is needed to investigate different FV formulations for their efficacy in order to help clinicians make better evidence based treatment choices.
28322885	0	8	Fluoride	T121,T197	C0016327
28322885	9	22	concentration	T081	C1446561
28322885	26	32	saliva	T031	C0036087
28322885	37	50	biofilm fluid	T007	C0081786
28322885	65	76	application	T058	C0185125
28322885	86	104	fluoride varnishes	T122,T197	C0016326
28322885	140	158	fluoride varnishes	T122,T197	C0016326
28322885	160	162	FV	T122,T197	C0016326
28322885	178	187	evaluated	T058	C0220825
28322885	198	220	cariostatic properties	T039	C3179394
28322885	222	234	Consequently	T033	C3845876
28322885	240	243	aim	T078	C1947946
28322885	252	259	in vivo	T082	C1515655
28322885	260	265	study	T062	C2603343
28322885	273	284	investigate	T058	C0220825
28322885	285	290	intra	T082	C0442107
28322885	293	297	oral	T082	C0442027
28322885	298	306	fluoride	T121,T197	C0016327
28322885	307	316	retention	T169	C0333117
28322885	321	339	clearance patterns	T033	C0231360
28322885	361	363	FV	T122,T197	C0016326
28322885	374	382	subjects	T098	C0080105
28322885	389	394	years	T079	C1510829
28322885	414	424	laboratory	T073,T093	C0022877
28322885	425	432	analyst	T097	C0870132
28322885	435	442	blinded	T062	C0150108
28322885	444	454	randomized	T062	C0034656
28322885	456	471	crossover study	T062	C0150097
28322885	472	481	comparing	T052	C1707455
28322885	486	493	ability	T032	C0085732
28322885	500	525	sodium fluoride varnishes	T122,T197	C0016326
28322885	527	542	CavityShield-CS	T122,T197	C0016326
28322885	544	557	Enamel Pro-EP	T122,T197	C0016326
28322885	559	567	Vanish-V	T122,T197	C0016326
28322885	572	579	enhance	T052	C2349975
28322885	580	588	fluoride	T121,T197	C0016327
28322885	589	603	concentrations	T081	C1446561
28322885	607	620	biofilm fluid	T007	C0081786
28322885	622	633	centrifuged	T031	C3897072
28322885	638	643	whole	T081	C0444667
28322885	644	650	saliva	T031	C0036087
28322885	658	664	period	T079	C1948053
28322885	687	689	FV	T122,T197	C0016326
28322885	711	719	fluoride	T121,T197	C0016327
28322885	720	733	concentration	T081	C1446561
28322885	736	749	time patterns	T079	C0439545
28322885	755	760	noted	T170	C1317574
28322885	769	781	investigated	T080	C0449433
28322885	782	784	FV	T122,T197	C0016326
28322885	789	796	studied	T062	C2603343
28322885	797	806	variables	T080	C0439828
28322885	817	824	highest	T080	C1522410
28322885	825	833	fluoride	T121,T197	C0016327
28322885	834	848	concentrations	T081	C1446561
28322885	849	857	observed	T169	C1441672
28322885	872	889	biological sample	T077	C2347026
28322885	890	899	collected	T169	C1516698
28322885	906	908	FV	T122,T197	C0016326
28322885	930	937	Mean±SE	T081	C2348148
28322885	939	974	area under fluoride clearance curve	T081	C0376690
28322885	976	982	values	T080	C0042295
28322885	1008	1021	biofilm fluid	T007	C0081786
28322885	1024	1026	CS	T122,T197	C0016326
28322885	1038	1040	EP	T122,T197	C0016326
28322885	1051	1052	V	T122,T197	C0016326
28322885	1065	1076	centrifuged	T031	C3897072
28322885	1077	1083	saliva	T031	C0036087
28322885	1086	1088	CS	T122,T197	C0016326
28322885	1097	1099	EP	T122,T197	C0016326
28322885	1108	1109	V	T122,T197	C0016326
28322885	1118	1123	whole	T081	C0444667
28322885	1124	1130	saliva	T031	C0036087
28322885	1133	1135	CS	T122,T197	C0016326
28322885	1145	1147	EP	T122,T197	C0016326
28322885	1157	1158	V	T122,T197	C0016326
28322885	1167	1168	V	T122,T197	C0016326
28322885	1184	1192	fluoride	T121,T197	C0016327
28322885	1196	1209	biofilm fluid	T007	C0081786
28322885	1215	1217	CS	T122,T197	C0016326
28322885	1233	1235	EP	T122,T197	C0016326
28322885	1283	1294	centrifuged	T031	C3897072
28322885	1295	1301	saliva	T031	C0036087
28322885	1303	1305	CS	T122,T197	C0016326
28322885	1310	1311	V	T122,T197	C0016326
28322885	1321	1334	significantly	T078	C0750502
28322885	1359	1367	resulted	T169	C1274040
28322885	1371	1377	higher	T080	C1522410
28322885	1378	1386	fluoride	T121,T197	C0016327
28322885	1387	1396	retention	T169	C0333117
28322885	1402	1404	EP	T122,T197	C0016326
28322885	1420	1431	significant	T078	C0750502
28322885	1450	1452	FV	T122,T197	C0016326
28322885	1458	1466	observed	T169	C1441672
28322885	1471	1476	whole	T081	C0444667
28322885	1477	1483	saliva	T031	C0036087
28322885	1498	1505	present	T033	C0150312
28322885	1506	1511	study	T062	C2603343
28322885	1527	1529	FV	T122,T197	C0016326
28322885	1544	1551	ability	T032	C0085732
28322885	1563	1571	fluoride	T121,T197	C0016327
28322885	1572	1577	intra	T082	C0442107
28322885	1580	1586	orally	T082	C0442027
28322885	1587	1598	potentially	T080	C3245505
28322885	1599	1606	related	T080	C0439849
28322885	1622	1633	differences	T080	C1705242
28322885	1643	1649	extent	T082	C0439792
28322885	1654	1661	present	T033	C0150312
28322885	1662	1670	findings	T033	C0243095
28322885	1671	1677	relate	T080	C0439849
28322885	1681	1698	clinical efficacy	T080	C3850123
28322885	1723	1733	determined	T059	C1148554
28322885	1735	1752	Clinical research	T062	C0008972
28322885	1758	1770	investigates	T058	C0220825
28322885	1771	1779	fluoride	T121,T197	C0016327
28322885	1780	1787	release	T080	C0205556
28322885	1788	1796	patterns	T082	C0449774
28322885	1802	1808	saliva	T031	C0036087
28322885	1813	1826	biofilm fluid	T007	C0081786
28322885	1842	1853	FV products	T122,T197	C0016326
28322885	1857	1869	insufficient	T080	C0231180
28322885	1876	1884	research	T062	C0242481
28322885	1898	1909	investigate	T058	C0220825
28322885	1920	1935	FV formulations	T122,T197	C0016326
28322885	1946	1954	efficacy	T080	C1280519
28322885	1972	1982	clinicians	T097	C0871685
28322885	1988	1994	better	T080	C0332272
28322885	1995	2003	evidence	T078	C3887511
28322885	2010	2019	treatment	T169	C1522326

28343062|t|The material, moral, and affective worlds of dealing and crime among young men entrenched in an inner city drug scene
28343062|a|A large body of previous research has elucidated how involvement in drug dealing and crime among marginalized urban youth who use drugs is shaped by the imperatives of addiction and survival in the context of poverty. However, a growing body of research has examined how youth's involvement in these activities is shaped by more expansive desires and moralities. In this paper, we examine the material, moral, and affective worlds of loosely gang affiliated, street level dealing and crime among one group of young men in Vancouver, Canada. Drawing on longitudinal interviews with 44 young men from 2008 to 2016, and ethnographic fieldwork with a group of approximately 15 of those young men over the same time period, we argue that for these youth, dealing and crime were not solely about economic survival, or even the accrual of highly meaningful forms of "street capital" in the margins. Rather, as "regimes of living," dealing and crime also opened up new value systems, moral logics, and affects in relation to the tremendous risks, potential rewards, and crushing boredom of life in the margins. These activities were also understood as a way into deeply desired forms of social spatial belonging in the city, which had previously only been imagined. However, across time dealing and crime ultimately "embedded" young men in cycles of incarceration, destitution, addictions, and mental health crises that ultimately reinforced their exclusion -from legal employment, but also within the world of crime. The findings of this study underscore the importance of adopting a life course perspective in order to meaningfully address the harms associated with involvement in dealing and crime among youth in our setting.
28343062	4	12	material	T167	C0520510
28343062	14	19	moral	T078	C0026532
28343062	25	41	affective worlds	T041	C0871641
28343062	45	52	dealing	T057	C0687750
28343062	57	62	crime	T054	C0680456
28343062	69	78	young men	T100	C0238598
28343062	96	106	inner city	T083	C0557849
28343062	107	117	drug scene	UnknownType	C0814614
28343062	143	151	research	T062	C0035168
28343062	171	182	involvement	T169	C1314939
28343062	186	198	drug dealing	T057	C0687750
28343062	203	208	crime	T054	C0680456
28343062	228	233	urban	T083	C0442529
28343062	234	239	youth	T100	C0087178
28343062	248	253	drugs	T121,T131	C0027415
28343062	257	263	shaped	T082	C0332479
28343062	286	295	addiction	T048	C0085281
28343062	300	308	survival	T052	C0038952
28343062	327	334	poverty	T102	C0032854
28343062	347	371	growing body of research	T097	C0035173
28343062	389	396	youth's	T100	C0087178
28343062	432	438	shaped	T082	C0332479
28343062	457	464	desires	T041	C0871633
28343062	469	479	moralities	T078	C0026531
28343062	511	519	material	T167	C0520510
28343062	521	526	moral	T078	C0026532
28343062	532	548	affective worlds	T041	C0871641
28343062	560	575	gang affiliated	T098	C0680397
28343062	590	597	dealing	T057	C0687750
28343062	602	607	crime	T054	C0680456
28343062	627	636	young men	T100	C0238598
28343062	640	649	Vancouver	T083	C0017446
28343062	651	657	Canada	T083	C0006823
28343062	670	693	longitudinal interviews	T052	C0021822
28343062	702	711	young men	T100	C0087178
28343062	735	757	ethnographic fieldwork	T057	C0578393
28343062	765	770	group	T098	C1257890
28343062	800	809	young men	T100	C0087178
28343062	824	835	time period	T079	C1948053
28343062	861	866	youth	T100	C0087178
28343062	868	875	dealing	T057	C0687750
28343062	880	885	crime	T054	C0680456
28343062	908	926	economic survival,	T169	C0220921
28343062	939	946	accrual	T169	C2346721
28343062	1042	1049	dealing	T057	C0687750
28343062	1054	1059	crime	T054	C0680456
28343062	1075	1092	new value systems	T185	C0008902
28343062	1094	1106	moral logics	T078	C0026532
28343062	1139	1155	tremendous risks	T078	C0035647
28343062	1157	1174	potential rewards	T041	C0035397
28343062	1189	1204	boredom of life	T041	C0006019
28343062	1227	1237	activities	T052	C0441655
28343062	1280	1287	desired	T041	C0871633
28343062	1297	1321	social spatial belonging	T082	C1254362
28343062	1329	1333	city	T083	C0008848
28343062	1366	1374	imagined	T041	C0020913
28343062	1392	1396	time	T079	C0040223
28343062	1397	1404	dealing	T057	C0687750
28343062	1409	1414	crime	T054	C0680456
28343062	1437	1446	young men	T100	C0087178
28343062	1460	1473	incarceration	T033	C4237139
28343062	1475	1486	destitution	T033	C0557161
28343062	1488	1498	addictions	T048	C0085281
28343062	1504	1517	mental health	T041	C0025353
28343062	1518	1524	crises	T033	C0231224
28343062	1558	1567	exclusion	T052	C2828389
28343062	1574	1590	legal employment	T080	C0014003
28343062	1621	1626	crime	T054	C0680456
28343062	1632	1640	findings	T033	C0243095
28343062	1649	1654	study	T062	C2603343
28343062	1695	1706	life course	T079	C1510618
28343062	1707	1718	perspective	UnknownType	C0678958
28343062	1756	1761	harms	UnknownType	C0549012
28343062	1778	1789	involvement	T169	C1314939
28343062	1793	1800	dealing	T057	C0687750
28343062	1805	1810	crime	T054	C0680456
28343062	1817	1822	youth	T100	C0087178

27988342|t|Prognostic factors in patients with spinal metastasis: a systematic review and meta-analysis
27988342|a|Incidence of symptomatic spinal metastasis has increased owing to improvement in treatment of the disease. One of the key factors that influences decision-making is expected patient survival. To our knowledge, no systematic reviews or meta-analysis have been conducted that review independent prognostic factors in spinal metastases. This study aimed to determine independent prognostic factors that affect outcome in patients with metastatic spine disease. This is a systematic literature review and meta-analysis of publications for prognostic factors in spinal metastatic disease. Pooled patient results from cohort and observational studies. Meta-analysis for poor prognostic factors as determined by hazard ratio (HR) and 95% confidential interval (95% CI). We systematically searched relevant publications in PubMed and Embase. The following search terms were used: ("' spinal metastases '" OR "' vertebral metastases '" OR " spinal metastasis " OR ' vertebral metastases ') AND ('" prognostic factors "' OR "' survival '"). Inclusion criteria were prospective and retrospective cohort series that report HR and 95% CI of independent prognostic factors from multivariate analysis. Two reviewers independently assessed all papers. The quality of included papers was assessed by using Newcastle-Ottawa Scale for cohort studies and publication bias was assessed by using funnel plot, Begg test, and Egger test. The prognostic factors that were mentioned in at least three publications were pooled. Meta-analysis was performed using HR and 95% CI as the primary outcomes of interest. Heterogeneity was assessed using the I(2) method. A total of 3,959 abstracts (1,382 from PubMed and 2,577 from Embase) were identified through database search and 40 publications were identified through review of cited publications. The reviewers selected a total of 51 studies for qualitative synthesis and 43 studies for meta-analysis. Seventeen poor prognostic factors were identified. These included presence of a neurologic deficit before surgery, non-ambulatory status before radiotherapy (RT), non-ambulatory status before surgery, presence of bone metastases, presence of multiple bone metastases (>2 sites), presence of multiple spinal metastases (>3 sites), development of motor deficit in <7 days before initiating RT, development of motor deficit in <14 days before initiating RT, time interval from cancer diagnosis to RT <15 months, Karnofsky Performance Score (KPS) 10-40, KPS 50-70, KPS <70, Eastern Cooperative Oncology Group (ECOG) grade 3-4, male gender, presence of visceral metastases, moderate growth tumor on Tomita score (TS) classification, and rapid growth tumor on TS classification. Seventeen independent poor prognostic factors were identified in this study. These can be categorized into cancer - specific and nonspecific prognostic factors. A tumor -based prognostic scoring system that combines all specific and general factors may enhance the accuracy of survival prediction in patients with metastatic spine disease.
27988342	0	18	Prognostic factors	T201	C1514474
27988342	22	30	patients	T101	C0030705
27988342	36	53	spinal metastasis	T191	C0347016
27988342	57	74	systematic review	T170	C1955832
27988342	79	92	meta-analysis	T062	C0920317
27988342	93	102	Incidence	T169	C0220856
27988342	106	117	symptomatic	T169	C0231220
27988342	118	135	spinal metastasis	T191	C0347016
27988342	140	149	increased	T081	C0205217
27988342	159	170	improvement	T077	C2986411
27988342	174	183	treatment	T169	C1522326
27988342	191	198	disease	T047	C0012634
27988342	215	222	factors	T169	C1521761
27988342	228	238	influences	T077	C4054723
27988342	239	254	decision-making	T041	C0011109
27988342	267	274	patient	T101	C0030705
27988342	275	283	survival	T169	C0220921
27988342	306	324	systematic reviews	T170	C1955832
27988342	328	341	meta-analysis	T062	C0920317
27988342	367	373	review	T169	C0699752
27988342	374	385	independent	T078	C0085862
27988342	386	404	prognostic factors	T201	C1514474
27988342	408	425	spinal metastases	T191	C0347016
27988342	432	437	study	T062	C0008972
27988342	457	468	independent	T078	C0085862
27988342	469	487	prognostic factors	T201	C1514474
27988342	500	507	outcome	T080	C0085415
27988342	511	519	patients	T101	C0030705
27988342	525	549	metastatic spine disease	T191	C0347016
27988342	561	571	systematic	T169	C0220922
27988342	572	589	literature review	T170	C0282441
27988342	594	607	meta-analysis	T062	C0920317
27988342	628	646	prognostic factors	T201	C1514474
27988342	650	675	spinal metastatic disease	T191	C0347016
27988342	677	683	Pooled	T169	C2349200
27988342	684	691	patient	T101	C0030705
27988342	705	711	cohort	T081	C0009247
27988342	716	737	observational studies	T062	C1518527
27988342	739	752	Meta-analysis	T062	C0920317
27988342	762	780	prognostic factors	T201	C1514474
27988342	798	810	hazard ratio	T081	C2985465
27988342	812	814	HR	T081	C2985465
27988342	824	845	confidential interval	T081	C0009667
27988342	851	853	CI	T081	C0009667
27988342	859	873	systematically	T169	C0220922
27988342	883	891	relevant	T080	C2347946
27988342	892	904	publications	T073,T170	C0034036
27988342	908	914	PubMed	T170	C1138432
27988342	919	925	Embase	T170	C0282574
27988342	969	986	spinal metastases	T191	C0347016
27988342	996	1016	vertebral metastases	T191	C0347016
27988342	1025	1042	spinal metastasis	T191	C0347016
27988342	1050	1070	vertebral metastases	T191	C0347016
27988342	1082	1100	prognostic factors	T201	C1514474
27988342	1110	1118	survival	T169	C0220921
27988342	1124	1142	Inclusion criteria	T080	C1512693
27988342	1148	1159	prospective	T080	C0205556
27988342	1164	1177	retrospective	T080	C1514923
27988342	1178	1191	cohort series	T081	C0009247
27988342	1204	1206	HR	T081	C2985465
27988342	1215	1217	CI	T081	C0009667
27988342	1221	1232	independent	T078	C0085862
27988342	1233	1251	prognostic factors	T201	C1514474
27988342	1257	1278	multivariate analysis	T081	C0026777
27988342	1284	1293	reviewers	T098	C1882950
27988342	1294	1307	independently	T078	C0085862
27988342	1308	1316	assessed	T052	C1516048
27988342	1333	1340	quality	T080	C0332306
27988342	1364	1372	assessed	T052	C1516048
27988342	1382	1404	Newcastle-Ottawa Scale	T170	C0282574
27988342	1409	1423	cohort studies	T081	C0009247
27988342	1428	1439	publication	T073,T170	C0034036
27988342	1440	1444	bias	T078	C0242568
27988342	1449	1457	assessed	T052	C1516048
27988342	1467	1478	funnel plot	T170	C0237913
27988342	1480	1489	Begg test	T170	C0237913
27988342	1495	1505	Egger test	T170	C0237913
27988342	1511	1529	prognostic factors	T201	C1514474
27988342	1568	1580	publications	T073,T170	C0034036
27988342	1586	1592	pooled	T169	C2349200
27988342	1594	1607	Meta-analysis	T062	C0920317
27988342	1628	1630	HR	T081	C2985465
27988342	1639	1641	CI	T081	C0009667
27988342	1657	1665	outcomes	T169	C1274040
27988342	1679	1692	Heterogeneity	T080	C0019409
27988342	1697	1705	assessed	T052	C1516048
27988342	1716	1727	I(2) method	T062	C0242481
27988342	1746	1755	abstracts	T170	C0600678
27988342	1768	1774	PubMed	T170	C1138432
27988342	1790	1796	Embase	T170	C0282574
27988342	1803	1813	identified	T080	C0205396
27988342	1822	1830	database	T170	C0242356
27988342	1845	1857	publications	T073,T170	C0034036
27988342	1863	1873	identified	T080	C0205396
27988342	1882	1888	review	T169	C0699752
27988342	1898	1910	publications	T073,T170	C0034036
27988342	1916	1925	reviewers	T098	C1882950
27988342	1961	1972	qualitative	T080	C0205556
27988342	1973	1982	synthesis	T052	C1883254
27988342	2002	2015	meta-analysis	T062	C0920317
27988342	2032	2050	prognostic factors	T201	C1514474
27988342	2056	2066	identified	T080	C0205396
27988342	2083	2091	presence	T033	C0150312
27988342	2097	2115	neurologic deficit	T033	C0521654
27988342	2123	2130	surgery	T091	C1274039
27988342	2132	2146	non-ambulatory	T033	C0560046
27988342	2147	2153	status	T080	C0449438
27988342	2161	2173	radiotherapy	T061	C0085203
27988342	2175	2177	RT	T061	C0085203
27988342	2180	2194	non-ambulatory	T033	C0560046
27988342	2195	2201	status	T080	C0449438
27988342	2209	2216	surgery	T091	C1274039
27988342	2218	2226	presence	T033	C0150312
27988342	2230	2245	bone metastases	T191	C0153690
27988342	2247	2255	presence	T033	C0150312
27988342	2259	2267	multiple	T081	C0439064
27988342	2268	2283	bone metastases	T191	C0153690
27988342	2288	2293	sites	T029	C1515974
27988342	2296	2304	presence	T033	C0150312
27988342	2308	2316	multiple	T081	C0439064
27988342	2339	2344	sites	T029	C1515974
27988342	2347	2358	development	T039	C0243107
27988342	2362	2375	motor deficit	T033	C0521654
27988342	2382	2386	days	T079	C0439228
27988342	2405	2407	RT	T061	C0085203
27988342	2409	2420	development	T039	C0243107
27988342	2424	2437	motor deficit	T033	C0521654
27988342	2445	2449	days	T079	C0439228
27988342	2468	2470	RT	T061	C0085203
27988342	2472	2485	time interval	T079	C0872291
27988342	2491	2507	cancer diagnosis	T060	C0920688
27988342	2511	2513	RT	T061	C0085203
27988342	2518	2524	months	T079	C0439231
27988342	2526	2553	Karnofsky Performance Score	T170	C0282574
27988342	2555	2558	KPS	T170	C0282574
27988342	2567	2570	KPS	T170	C0282574
27988342	2578	2581	KPS	T170	C0282574
27988342	2587	2621	Eastern Cooperative Oncology Group	T093	C1512162
27988342	2623	2627	ECOG	T093	C1512162
27988342	2629	2638	grade 3-4	T185	C0441800
27988342	2640	2651	male gender	T032	C0086582
27988342	2653	2661	presence	T033	C0150312
27988342	2665	2673	visceral	T082	C0442045
27988342	2674	2684	metastases	T191	C0027627
27988342	2686	2694	moderate	T080	C0205081
27988342	2695	2701	growth	T040	C0018270
27988342	2702	2707	tumor	T191	C0027651
27988342	2711	2743	Tomita score (TS) classification	T170	C0282574
27988342	2749	2754	rapid	T080	C0456962
27988342	2755	2761	growth	T040	C0018270
27988342	2762	2767	tumor	T191	C0027651
27988342	2771	2788	TS classification	T170	C0282574
27988342	2800	2811	independent	T078	C0085862
27988342	2812	2816	poor	T080	C0542537
27988342	2817	2835	prognostic factors	T201	C1514474
27988342	2841	2851	identified	T080	C0205396
27988342	2860	2865	study	T062	C0008972
27988342	2880	2891	categorized	T052	C0871968
27988342	2897	2903	cancer	T191	C0006826
27988342	2906	2914	specific	T080	C0205369
27988342	2919	2930	nonspecific	T078	C0750540
27988342	2931	2949	prognostic factors	T201	C1514474
27988342	2953	2958	tumor	T191	C0027651
27988342	2966	2991	prognostic scoring system	T170	C0282574
27988342	3010	3018	specific	T080	C0205369
27988342	3031	3038	factors	T169	C1521761
27988342	3043	3050	enhance	T052	C2349975
27988342	3055	3063	accuracy	T080	C0443131
27988342	3067	3075	survival	T169	C0220921
27988342	3076	3086	prediction	T078	C0681842
27988342	3090	3098	patients	T101	C0030705
27988342	3104	3128	metastatic spine disease	T191	C0347016

28182705|t|Low implementation of Xpert MTB/RIF among HIV / TB co-infected adults in the International epidemiologic Databases to Evaluate AIDS (IeDEA) program
28182705|a|Xpert MTB/RIF is recommended by the World Health Organization (WHO) as the initial tuberculosis (TB) diagnostic test in individuals suspected of HIV - associated TB. We sought to evaluate field implementation of Xpert among a cohort of HIV / TB co-infected individuals, including availability, utilization and outcomes. Observational cohort study (patient-level data) and cross-sectional study (site-level Xpert availability data). Data were collected at 30 participating International epidemiologic Databases to Evaluate AIDS (IeDEA) sites in 18 countries from January 2012- January 2016. All patients were HIV-infected and diagnosed with TB, either bacteriologically or clinically, and followed until a determination of TB treatment outcome. We used multivariable modified Poisson regression to estimate adjusted relative risk (RR) and 95% confidence intervals for unfavorable TB treatment outcomes. Most sites (63%) had access to Xpert, either in the clinic (13%), in the same facility (20%) or offsite (30%). Among 2722 HIV / TB patients included, median age was 35.4 years and 41% were female; BMI and CD4 count were low. Overall, most patients (76%) received at least one TB test; 45% were positive. Only 4% of all patients were tested using Xpert: 64% were Xpert - positive, 13% showed rifampicin (RIF) resistance and 30% were extrapulmonary (EPTB) or both pulmonary - EPTB. Treatment outcomes were mostly favorable (77%) and we found little association between Xpert use and an unfavorable TB treatment outcome (RR 1.25, 95% CI: 0.83, 1.90). In this cohort, Xpert utilization was low even though the majority of sites had access to the test. Our findings show the need for expanded implementation and further research exploring barriers to use in low-resource settings.
28182705	0	3	Low	T080	C0205251
28182705	4	18	implementation	T052	C1708476
28182705	22	35	Xpert MTB/RIF	T060	C0430022
28182705	42	45	HIV	T047	C0019693
28182705	48	50	TB	T047	C0041296
28182705	51	62	co-infected	T047	C0275524
28182705	63	69	adults	T100	C0001675
28182705	77	131	International epidemiologic Databases to Evaluate AIDS	T170	C0282574
28182705	133	138	IeDEA	T170	C0282574
28182705	140	147	program	T169	C3484370
28182705	148	161	Xpert MTB/RIF	T060	C0430022
28182705	165	176	recommended	T078	C0034866
28182705	184	209	World Health Organization	T093	C0043237
28182705	211	214	WHO	T093	C0043237
28182705	231	243	tuberculosis	T047	C0041296
28182705	245	247	TB	T047	C0041296
28182705	249	264	diagnostic test	T060	C0086143
28182705	268	279	individuals	T098	C0237401
28182705	280	289	suspected	T078	C0750491
28182705	293	296	HIV	T047	C0019693
28182705	299	309	associated	T078	C0750490
28182705	310	312	TB	T047	C0041296
28182705	327	335	evaluate	T058	C0220825
28182705	336	341	field	T077	C1521738
28182705	342	356	implementation	T052	C1708476
28182705	360	365	Xpert	T060	C0430022
28182705	374	380	cohort	T098	C0599755
28182705	384	387	HIV	T047	C0019693
28182705	390	392	TB	T047	C0041296
28182705	393	404	co-infected	T047	C0275524
28182705	405	416	individuals	T098	C0237401
28182705	428	440	availability	T169	C0470187
28182705	442	453	utilization	T169	C0042153
28182705	458	466	outcomes	T169	C1274040
28182705	482	494	cohort study	T081	C0009247
28182705	496	514	patient-level data	T033	C0586019
28182705	520	541	cross-sectional study	T062	C0010362
28182705	543	553	site-level	T080	C0441889
28182705	554	559	Xpert	T060	C0430022
28182705	560	577	availability data	T033	C4035953
28182705	580	584	Data	T078	C1511726
28182705	590	599	collected	T169	C1516698
28182705	606	619	participating	T169	C0679823
28182705	620	674	International epidemiologic Databases to Evaluate AIDS	T170	C0282574
28182705	676	681	IeDEA	T170	C0282574
28182705	683	688	sites	T082	C0205145
28182705	695	704	countries	T083	C0454664
28182705	710	717	January	T080	C3829466
28182705	724	731	January	T080	C3829466
28182705	742	750	patients	T101	C0030705
28182705	756	768	HIV-infected	T047	C0019693
28182705	773	782	diagnosed	T033	C0011900
28182705	788	790	TB	T047	C0041296
28182705	799	816	bacteriologically	T169	C0205465
28182705	820	830	clinically	T080	C0205210
28182705	853	866	determination	T080	C0205259
28182705	870	872	TB	T047	C0041296
28182705	873	890	treatment outcome	T080	C0085415
28182705	900	941	multivariable modified Poisson regression	T170	C0034980
28182705	945	953	estimate	T081	C0750572
28182705	963	976	relative risk	T081	C0242492
28182705	978	980	RR	T081	C0242492
28182705	990	1010	confidence intervals	T081	C0009667
28182705	1015	1026	unfavorable	T080	C3640815
28182705	1027	1029	TB	T047	C0041296
28182705	1030	1048	treatment outcomes	T080	C0085415
28182705	1055	1060	sites	T082	C0205145
28182705	1071	1077	access	T082	C0444454
28182705	1081	1086	Xpert	T060	C0430022
28182705	1102	1108	clinic	T073,T093	C0442592
28182705	1128	1136	facility	T073	C1547538
28182705	1146	1153	offsite	T082	C3828730
28182705	1172	1175	HIV	T047	C0019693
28182705	1178	1180	TB	T047	C0041296
28182705	1181	1189	patients	T101	C0030705
28182705	1200	1210	median age	T032	C0001779
28182705	1220	1225	years	T079	C0439234
28182705	1239	1245	female	T032	C0086287
28182705	1247	1250	BMI	T201	C1305855
28182705	1255	1264	CD4 count	T059	C1277791
28182705	1270	1273	low	T080	C0205251
28182705	1289	1297	patients	T101	C0030705
28182705	1304	1312	received	T080	C1514756
28182705	1326	1333	TB test	T060	C2242734
28182705	1344	1352	positive	T033	C1446409
28182705	1369	1377	patients	T101	C0030705
28182705	1383	1389	tested	T169	C0039593
28182705	1396	1401	Xpert	T060	C0430022
28182705	1412	1417	Xpert	T060	C0430022
28182705	1420	1428	positive	T033	C1446409
28182705	1441	1451	rifampicin	T109,T195	C0035608
28182705	1453	1456	RIF	T109,T195	C0035608
28182705	1458	1468	resistance	T169	C4281815
28182705	1482	1496	extrapulmonary	T047	C0679362
28182705	1498	1502	EPTB	T047	C0679362
28182705	1512	1521	pulmonary	T047	C0041327
28182705	1524	1528	EPTB	T047	C0679362
28182705	1530	1548	Treatment outcomes	T080	C0085415
28182705	1561	1570	favorable	T080	C3640814
28182705	1597	1608	association	T080	C0439849
28182705	1617	1622	Xpert	T060	C0430022
28182705	1634	1645	unfavorable	T080	C3640815
28182705	1646	1648	TB	T047	C0041296
28182705	1649	1666	treatment outcome	T080	C0085415
28182705	1668	1670	RR	T081	C0242492
28182705	1681	1683	CI	T081	C0009667
28182705	1706	1712	cohort	T098	C0599755
28182705	1714	1719	Xpert	T060	C0430022
28182705	1720	1731	utilization	T169	C0042153
28182705	1736	1739	low	T080	C0205251
28182705	1756	1764	majority	T054	C0680220
28182705	1768	1773	sites	T082	C0205145
28182705	1778	1784	access	T082	C0444454
28182705	1792	1796	test	T170	C0392366
28182705	1802	1810	findings	T033	C0243095
28182705	1829	1837	expanded	T082	C0205229
28182705	1838	1852	implementation	T052	C1708476
28182705	1865	1873	research	T062	C0035168
28182705	1903	1915	low-resource	T078	C0035201

28317716|t|A nano-delivery system for bioactive ingredients using supercritical carbon dioxide and its release behaviors
28317716|a|For the purpose of ensuring the bioavailability of bioactive ingredients, a nano-delivery system with low toxicity was developed using supercritical carbon dioxide (SC - CO2). Compared to thin-film hydration (TFH), obtaining nano-scale liposomes is easier using SC - CO2. The characteristic of these liposomes was also demonstrated by the analysis of particle size and morphology. An in vitro release study showed that liposomes produced using SC - CO2 were resistant to low pH in simulated gastric conditions. In a simulated intestinal environment, enteric solubility of these liposomes was enhanced, which are important properties for controlled releasing bioactive ingredient. Furthermore, SC - CO2 -produced liposomes had a higher storage stability than those produced using TFH. Analysis of the organic solvent residue in the liposomes by gas chromatography-mass spectrometry (GC-MS) indicated that SC - CO2 -produced liposomes had lower toxicity than those produced by TFH. A chemical free nano-delivery system using SC - CO2 has been revealed for storage and controlled release of bioactive ingredients.
28317716	2	22	nano-delivery system	T169	C0449914
28317716	27	48	bioactive ingredients	T167	C3714412
28317716	55	68	supercritical	T080	C0205556
28317716	69	83	carbon dioxide	T123,T197	C0007012
28317716	92	109	release behaviors	T169	C0391871
28317716	118	125	purpose	T169	C1285529
28317716	142	157	bioavailability	T081	C0005508
28317716	161	182	bioactive ingredients	T167	C3714412
28317716	186	206	nano-delivery system	T169	C0449914
28317716	212	215	low	T080	C0205251
28317716	216	224	toxicity	T080	C0040539
28317716	245	258	supercritical	T080	C0205556
28317716	259	273	carbon dioxide	T123,T197	C0007012
28317716	275	277	SC	T080	C0205556
28317716	280	283	CO2	T123,T197	C0007012
28317716	286	294	Compared	T052	C1707455
28317716	298	317	thin-film hydration	T059	C0022885
28317716	319	322	TFH	T059	C0022885
28317716	335	345	nano-scale	T082	C1254362
28317716	346	355	liposomes	T109	C0023828
28317716	372	374	SC	T080	C0205556
28317716	377	380	CO2	T123,T197	C0007012
28317716	386	400	characteristic	T080	C1521970
28317716	410	419	liposomes	T109	C0023828
28317716	449	457	analysis	T062	C0936012
28317716	461	474	particle size	T081	C0030608
28317716	479	489	morphology	T080	C0332437
28317716	494	502	in vitro	T080	C1533691
28317716	503	510	release	T061	C1963578
28317716	511	516	study	T062	C2603343
28317716	529	538	liposomes	T109	C0023828
28317716	554	556	SC	T080	C0205556
28317716	559	562	CO2	T123,T197	C0007012
28317716	568	577	resistant	T169	C0332325
28317716	581	584	low	T080	C0205251
28317716	585	587	pH	T081	C0020283
28317716	591	600	simulated	T080	C0205556
28317716	601	608	gastric	T080	C1704242
28317716	609	619	conditions	T080	C0348080
28317716	626	635	simulated	T080	C0205556
28317716	636	646	intestinal	T023	C0021853
28317716	647	658	environment	T030	C0229984
28317716	660	667	enteric	T082	C1304890
28317716	668	678	solubility	T080	C0037628
28317716	688	697	liposomes	T109	C0023828
28317716	702	710	enhanced	T052	C2349975
28317716	722	731	important	T080	C3898777
28317716	732	742	properties	T080	C0871161
28317716	747	767	controlled releasing	T079	C0868939
28317716	768	788	bioactive ingredient	T167	C3714412
28317716	803	805	SC	T080	C0205556
28317716	808	811	CO2	T123,T197	C0007012
28317716	822	831	liposomes	T109	C0023828
28317716	838	844	higher	T080	C0205250
28317716	845	862	storage stability	T033	C0243095
28317716	889	892	TFH	T059	C0022885
28317716	894	902	Analysis	T062	C0936012
28317716	910	917	organic	T080	C0747055
28317716	918	925	solvent	T130	C0037638
28317716	926	933	residue	T077	C1709915
28317716	941	950	liposomes	T109	C0023828
28317716	954	990	gas chromatography-mass spectrometry	T059	C0024868
28317716	992	997	GC-MS	T059	C0024868
28317716	999	1008	indicated	T033	C1444656
28317716	1014	1016	SC	T080	C0205556
28317716	1019	1022	CO2	T123,T197	C0007012
28317716	1033	1042	liposomes	T109	C0023828
28317716	1047	1052	lower	T080	C0205251
28317716	1053	1061	toxicity	T080	C0040539
28317716	1085	1088	TFH	T059	C0022885
28317716	1092	1105	chemical free	T080	C0205556
28317716	1106	1126	nano-delivery system	T169	C0449914
28317716	1133	1135	SC	T080	C0205556
28317716	1138	1141	CO2	T123,T197	C0007012
28317716	1151	1159	revealed	T080	C0443289
28317716	1164	1171	storage	T169	C1698986
28317716	1176	1194	controlled release	T079	C0868939
28317716	1198	1219	bioactive ingredients	T167	C3714412

28447586|t|Serum vascular endothelial growth factor receptor-3 levels in patients with esophageal squamous cell cancer
28447586|a|Esophageal cancer is one of the most aggressive tumors of the gastrointestinal tract. In this study, we quantified the serum vascular endothelial growth factor-3 (VEGFR-3) expression in patients with esophageal squamous cell carcinoma (ESCC) to evaluate the role of VEGFR-3 in ESCC. Ninety five patients with ESCC were studied. Pre-therapy and preoperative samples were stored and ELISA was used to designate the concentrations of VEGFR-3. The serum values of VEGFR-3 were significantly higher in patients with ESCC than in healthy donors (p<0.0001). The results imply a very good sensitivity of VEGFR-3 in ESCC. VEGFR-3 may be a good diagnostic biomarker for ESCC. Biomarker, ESCC, VEGFR-3.
28447586	0	5	Serum	T031	C0229671
28447586	6	51	vascular endothelial growth factor receptor-3	T116,T126,T192	C0169539
28447586	52	58	levels	T081	C1446561
28447586	62	70	patients	T101	C0030705
28447586	76	107	esophageal squamous cell cancer	T191	C0279626
28447586	108	125	Esophageal cancer	T191	C0014859
28447586	156	192	tumors of the gastrointestinal tract	T191	C0017185
28447586	227	232	serum	T031	C0229671
28447586	233	269	vascular endothelial growth factor-3	T116,T126,T192	C0169539
28447586	271	278	VEGFR-3	T116,T126,T192	C0169539
28447586	280	290	expression	T045	C1171362
28447586	294	302	patients	T101	C0030705
28447586	308	342	esophageal squamous cell carcinoma	T191	C0279626
28447586	344	348	ESCC	T191	C0279626
28447586	374	381	VEGFR-3	T116,T126,T192	C0169539
28447586	385	389	ESCC	T191	C0279626
28447586	403	411	patients	T101	C0030705
28447586	417	421	ESCC	T191	C0279626
28447586	436	447	Pre-therapy	T079	C1882440
28447586	452	464	preoperative	T079	C0445204
28447586	465	472	samples	T031	C1550100
28447586	489	494	ELISA	T059	C0014441
28447586	539	546	VEGFR-3	T116,T126,T192	C0169539
28447586	552	564	serum values	T081	C0683149
28447586	568	575	VEGFR-3	T116,T126,T192	C0169539
28447586	605	613	patients	T101	C0030705
28447586	619	623	ESCC	T191	C0279626
28447586	632	639	healthy	T080	C3898900
28447586	640	646	donors	T098	C0013018
28447586	689	700	sensitivity	T081	C1511883
28447586	704	711	VEGFR-3	T116,T126,T192	C0169539
28447586	715	719	ESCC	T191	C0279626
28447586	721	728	VEGFR-3	T116,T126,T192	C0169539
28447586	743	753	diagnostic	T169	C0348026
28447586	754	763	biomarker	T201	C0005516
28447586	768	772	ESCC	T191	C0279626
28447586	774	783	Biomarker	T201	C0005516
28447586	785	789	ESCC	T191	C0279626
28447586	791	798	VEGFR-3	T116,T126,T192	C0169539

27766634|t|Reliability of 30-Day Readmission Measures Used in the Hospital Readmission Reduction Program
27766634|a|To assess the reliability of risk-standardized readmission rates (RSRRs) for medical conditions and surgical procedures used in the Hospital Readmission Reduction Program (HRRP). State Inpatient Databases for six states from 2011 to 2013 were used to identify patient cohorts for the six conditions used in the HRRP, which was augmented with hospital characteristic and HRRP penalty data. Hierarchical logistic regression models estimated hospital -level RSRRs for each condition, the reliability of each RSRR, and the extent to which socioeconomic and hospital factors further explain RSRR variation. We used publicly available data to estimate payments for excess readmissions in hospitals with reliable and unreliable RSRRs. Only RSRRs for surgical procedures exceeded the reliability benchmark for most hospitals, whereas RSRRs for medical conditions were typically below the benchmark. Additional adjustment for socioeconomic and hospital factors modestly explained variation in RSRRs. Approximately 25 percent of payments for excess readmissions were tied to unreliable RSRRs. Many of the RSRRs employed by the HRRP are unreliable, and one quarter of payments for excess readmissions are associated with unreliable RSRRs. Unreliable measures blur the connection between hospital performance and incentives, and threaten the success of the HRRP.
27766634	0	11	Reliability	T081	C2347947
27766634	22	42	Readmission Measures	T058	C0030700
27766634	55	93	Hospital Readmission Reduction Program	T058	C0679897
27766634	97	103	assess	T058	C0184514
27766634	108	119	reliability	T081	C2347947
27766634	123	158	risk-standardized readmission rates	T081	C1521828
27766634	160	165	RSRRs	T081	C1521828
27766634	171	189	medical conditions	T033	C3843040
27766634	194	213	surgical procedures	T061	C0543467
27766634	226	264	Hospital Readmission Reduction Program	T058	C0679897
27766634	266	270	HRRP	T058	C0679897
27766634	273	278	State	T083	C1301808
27766634	279	288	Inpatient	T101	C0021562
27766634	289	298	Databases	T170	C0242356
27766634	307	313	states	T083	C1301808
27766634	354	369	patient cohorts	T098	C0599755
27766634	382	392	conditions	T046	C0243082
27766634	405	409	HRRP	T058	C0679897
27766634	421	430	augmented	T081	C0205217
27766634	436	459	hospital characteristic	T080	C1510665
27766634	464	468	HRRP	T058	C0679897
27766634	469	481	penalty data	T078	C1511726
27766634	483	495	Hierarchical	T080	C0205556
27766634	496	522	logistic regression models	UnknownType	C0681925
27766634	523	532	estimated	T081	C0750572
27766634	533	541	hospital	T073,T093	C0019994
27766634	549	554	RSRRs	T081	C1521828
27766634	564	573	condition	T046	C0243082
27766634	579	590	reliability	T081	C2347947
27766634	599	603	RSRR	T081	C1521828
27766634	629	642	socioeconomic	T102	C0037464
27766634	647	663	hospital factors	T080	C1510665
27766634	680	684	RSRR	T081	C1521828
27766634	685	694	variation	T080	C0205419
27766634	723	727	data	T078	C1511726
27766634	731	739	estimate	T081	C0750572
27766634	740	748	payments	T081	C0680264
27766634	760	785	readmissions in hospitals	T058	C0600290
27766634	791	799	reliable	T170	C3858758
27766634	804	814	unreliable	T078	C0749770
27766634	815	820	RSRRs	T081	C1521828
27766634	827	832	RSRRs	T081	C1521828
27766634	837	856	surgical procedures	T061	C0543467
27766634	870	881	reliability	T081	C2347947
27766634	882	891	benchmark	T081	C0525063
27766634	901	910	hospitals	T073,T093	C0019994
27766634	920	925	RSRRs	T081	C1521828
27766634	930	948	medical conditions	T033	C3843040
27766634	974	983	benchmark	T081	C0525063
27766634	996	1006	adjustment	T169	C0456081
27766634	1011	1024	socioeconomic	T102	C0037464
27766634	1029	1045	hospital factors	T080	C1510665
27766634	1065	1074	variation	T080	C0205419
27766634	1078	1083	RSRRs	T081	C1521828
27766634	1113	1121	payments	T081	C0680264
27766634	1133	1145	readmissions	T058	C0600290
27766634	1159	1169	unreliable	T078	C0749770
27766634	1170	1175	RSRRs	T081	C1521828
27766634	1189	1194	RSRRs	T081	C1521828
27766634	1211	1215	HRRP	T058	C0679897
27766634	1220	1230	unreliable	T078	C0749770
27766634	1240	1247	quarter	T081	C2825406
27766634	1251	1259	payments	T081	C0680264
27766634	1271	1283	readmissions	T058	C0600290
27766634	1304	1314	unreliable	T078	C0749770
27766634	1315	1320	RSRRs	T081	C1521828
27766634	1322	1332	Unreliable	T078	C0749770
27766634	1342	1346	blur	T080	C1511231
27766634	1351	1361	connection	T082	C0449379
27766634	1370	1378	hospital	T073,T093	C0019994
27766634	1379	1390	performance	T052	C1882330
27766634	1395	1405	incentives	T080	C0021147
27766634	1439	1443	HRRP	T058	C0679897

27593461|t|Exploring the genetic variability in water use efficiency: Evaluation of inter and intra cultivar genetic diversity in grapevines
27593461|a|Genetic improvement of crop Water Use Efficiency (WUE) is a general goal because the increasing water scarcity and the trend to a more sustainable agriculture. For grapevines, this subject is relevant and need an urgent response because their wide distribution in semi-arid areas. New cultivars are difficult to introduce in viticulture due to the narrow dependency of consumer appreciation often linked to a certain particular wine taste. Clones of reputed cultivars would presumably be more accepted but little is known on the intra-cultivar genetic variability of the WUE. The present work compares, on the basis of two field assays, the variability of intrinsic water use efficiency (WUEi) in a large collection of cultivars in contrast with a collection of clones of Tempranillo cultivar. The results show that clonal variability of WUEi was around 80% of the inter-cultivar, thus providing a first assessment on the opportunity for clonal selection by WUE. Plotting the WUEi data against stem water potential or stomatal conductance it was possible to identify cultivars and clones out of the confidence intervals of this linear regression thus with significantly higher and lower WUEi values. The present results contribute to open the expectative for a genetic improvement of grapevine WUE.
27593461	14	21	genetic	T169	C0314603
27593461	22	33	variability	T077	C2827666
27593461	37	42	water	T121,T197	C0043047
27593461	43	46	use	T169	C0457083
27593461	47	57	efficiency	T081	C0013682
27593461	73	78	inter	T079	C1548610
27593461	83	97	intra cultivar	T002	C0032098
27593461	98	115	genetic diversity	T070	C0042333
27593461	119	129	grapevines	T002	C0330100
27593461	130	137	Genetic	T169	C0314603
27593461	138	149	improvement	T077	C2986411
27593461	153	157	crop	T002	C0242775
27593461	158	163	Water	T121,T197	C0043047
27593461	164	167	Use	T169	C0457083
27593461	168	178	Efficiency	T081	C0013682
27593461	180	183	WUE	T081	C0013682
27593461	198	202	goal	T078	C1571704
27593461	215	225	increasing	T169	C0442808
27593461	226	231	water	T121,T197	C0043047
27593461	232	240	scarcity	T169	C0231179
27593461	265	276	sustainable	T169	C0443318
27593461	277	288	agriculture	T090	C0001829
27593461	294	304	grapevines	T002	C0330100
27593461	311	318	subject	T078	C1706203
27593461	322	330	relevant	T080	C2347946
27593461	378	390	distribution	T169	C1704711
27593461	394	403	semi-arid	T070	C0011673
27593461	404	409	areas	T082	C0205146
27593461	415	424	cultivars	T002	C0032098
27593461	429	438	difficult	T080	C0332218
27593461	442	451	introduce	T169	C1292748
27593461	455	466	viticulture	UnknownType	C0681558
27593461	499	507	consumer	T098	C1707496
27593461	508	520	appreciation	T077	C2346843
27593461	558	562	wine	T168	C0043188
27593461	563	568	taste	T081	C1547046
27593461	570	576	Clones	T024	C1522642
27593461	588	597	cultivars	T002	C0032098
27593461	623	631	accepted	T080	C1272684
27593461	659	673	intra-cultivar	T002	C0032098
27593461	674	681	genetic	T169	C0314603
27593461	682	693	variability	T077	C2827666
27593461	701	704	WUE	T081	C0013682
27593461	723	731	compares	T052	C1707455
27593461	753	758	field	T090	C0001829
27593461	771	782	variability	T077	C2827666
27593461	796	801	water	T121,T197	C0043047
27593461	802	805	use	T169	C0457083
27593461	806	816	efficiency	T081	C0013682
27593461	818	822	WUEi	T081	C0013682
27593461	835	845	collection	T169	C1516698
27593461	849	858	cultivars	T002	C0032098
27593461	862	870	contrast	T080	C1979874
27593461	878	888	collection	T169	C1516698
27593461	892	898	clones	T024	C1522642
27593461	902	922	Tempranillo cultivar	T002	C0032098
27593461	928	935	results	T169	C1274040
27593461	946	952	clonal	T080	C1704387
27593461	953	964	variability	T077	C2827666
27593461	968	972	WUEi	T081	C0013682
27593461	977	983	around	T078	C0750503
27593461	995	1009	inter-cultivar	T002	C0032098
27593461	1034	1044	assessment	T052	C1516048
27593461	1068	1074	clonal	T080	C1704387
27593461	1075	1084	selection	T052	C1707391
27593461	1088	1091	WUE	T081	C0013682
27593461	1106	1110	WUEi	T081	C0013682
27593461	1111	1115	data	T078	C1511726
27593461	1124	1128	stem	T002	C0242767
27593461	1129	1134	water	T121,T197	C0043047
27593461	1135	1144	potential	T080	C3245505
27593461	1148	1168	stomatal conductance	T039	C1326524
27593461	1176	1184	possible	T033	C0332149
27593461	1188	1196	identify	T080	C0205396
27593461	1197	1206	cultivars	T002	C0032098
27593461	1211	1217	clones	T024	C1522642
27593461	1229	1249	confidence intervals	T081	C0009667
27593461	1258	1275	linear regression	T081	C0023733
27593461	1286	1306	significantly higher	T081	C4055637
27593461	1311	1316	lower	T081	C4055638
27593461	1317	1321	WUEi	T081	C0013682
27593461	1322	1328	values	T081	C1522609
27593461	1342	1349	results	T169	C1274040
27593461	1350	1360	contribute	T052	C1880177
27593461	1391	1398	genetic	T169	C0314603
27593461	1399	1410	improvement	T077	C2986411
27593461	1414	1423	grapevine	T002	C0330100
27593461	1424	1427	WUE	T081	C0013682

28284588|t|Did Contraceptive Use Patterns Change after the Affordable Care Act? A Descriptive Analysis
28284588|a|The Affordable Care Act (ACA) substantially increased rates of insurance coverage within the first year of implementation, including among women of reproductive age. The ACA also requires that private insurance plans cover contraceptives without any out-of-pocket costs. These provisions may have led more women to start using prescription contraception. We conducted two cross-sectional studies, collecting data from 8,062 women aged 18 to 39 in the fall 2012 and spring 2015. We examined contraceptive use patterns during both time periods. We used logistic regression to determine whether differences between the two time periods were significant, adjusting for the demographic characteristics of respondents. We observed no changes in contraceptive use patterns among sexually active women. However, use of the pill nearly doubled, from 21% to 40%, among young women aged 18 to 24 who had not had sex in the last month. Many of these women cited benefits of the pill in addition to pregnancy prevention. It may be that the ACA has yet to affect contraceptive use patterns, and it is possible that it will do so in the future, but the evidence thus far suggests the importance of further research into contraceptive access and sources of care.
28284588	4	30	Contraceptive Use Patterns	T033	C1820880
28284588	48	67	Affordable Care Act	T089	C2936611
28284588	71	91	Descriptive Analysis	T170	C0678257
28284588	96	115	Affordable Care Act	T089	C2936611
28284588	117	120	ACA	T089	C2936611
28284588	155	173	insurance coverage	T078	C0376629
28284588	199	213	implementation	T052	C1708476
28284588	231	236	women	T098	C0043210
28284588	240	252	reproductive	T040	C0035150
28284588	253	256	age	T032	C0001779
28284588	262	265	ACA	T089	C2936611
28284588	285	308	private insurance plans	T170	C0679933
28284588	315	329	contraceptives	T121	C0009871
28284588	342	361	out-of-pocket costs	T081	C3815933
28284588	398	403	women	T098	C0043210
28284588	419	445	prescription contraception	T061	C1411103
28284588	464	487	cross-sectional studies	T062	C0010362
28284588	500	504	data	T078	C1511726
28284588	516	521	women	T098	C0043210
28284588	522	526	aged	T032	C0001779
28284588	543	547	fall	T079	C0238715
28284588	557	563	spring	T079	C0241232
28284588	582	608	contraceptive use patterns	T033	C1820880
28284588	621	633	time periods	T079	C1948053
28284588	643	662	logistic regression	T062	C0206031
28284588	712	724	time periods	T079	C1948053
28284588	730	741	significant	T078	C0750502
28284588	761	788	demographic characteristics	T102	C0683970
28284588	792	803	respondents	T098	C0282122
28284588	817	827	no changes	T033	C3842396
28284588	831	857	contraceptive use patterns	T033	C1820880
28284588	864	879	sexually active	T033	C0241028
28284588	880	885	women	T098	C0043210
28284588	907	911	pill	T121	C0009905
28284588	957	962	women	T098	C0043210
28284588	963	967	aged	T032	C0001779
28284588	1030	1035	women	T098	C0043210
28284588	1058	1062	pill	T121	C0009905
28284588	1078	1098	pregnancy prevention	T058	C1998750
28284588	1119	1122	ACA	T089	C2936611
28284588	1141	1167	contraceptive use patterns	T033	C1820880
28284588	1283	1291	research	T062	C0035168
28284588	1297	1310	contraceptive	T121	C0009871
28284588	1311	1317	access	T080	C0814423
28284588	1333	1337	care	T052	C1947933

27778231|t|Identification of potential predictive markers of dexamethasone resistance in childhood acute lymphoblastic leukemia
27778231|a|Response to dexamethasone (DEXA), as a hallmark drug in the treatment of childhood acute lymphoblastic leukemia (ALL), is one of the pivotal prognostic factors in the prediction of outcome in ALL. Identification of predictive markers of chemoresistance is beneficial to selecting of the best therapeutic protocol with the lowest effect adverse. Hence, we aimed to find drug targets using the 2DE / MS proteomics study of a DEXA - resistant cell line (REH) as a model for poor DEXA responding patients before and after drug treatment. Using the proteomic methods, three differentially expressed proteins were detected, including voltage dependent anion channel 1 (VDAC1), sorting Nexin 3 (SNX3), and prefoldin subunit 6 (PFDN6). We observed low expression of three proteins after DEXA treatment in REH cells. We subsequently verified low expression of resulted proteins at the mRNA level using the quantitative PCR method. These proteins are promising proteins because of their important roles in drug resistance and regulation of apoptosis (VDAC1), protein trafficking (SNX3), and protein folding (PFDN6). Additionally, mRNA expression level of these proteins was assessed in 17 bone marrow samples from children with newly diagnosed ALL and 7 non-cancerous samples as controls. The results indicated that independent of the molecular subtypes of leukemia, mRNA expression of VDAC1, SNX3, and PFDN6 decreased in ALL samples compared with non-cancerous samples particularly in VDAC1 (p < 0.001). Additionally, mRNA expression of three proteins was also declined in high-risk samples compared with standard risk cases. These results demonstrated diagnostic and prognostic value of these proteins in childhood ALL. Furthermore, investigation of protein-protein interaction using STRING database indicated that these proteins involved in the signaling pathway of NR3C1 as dexamethasone target. In conclusion, our proteomic study in DEXA resistant leukemic cells revealed VDAC1, SNX3, and PFDN6 are promising proteins that might serve as potential biomarkers of prognosis and chemotherapy in childhood ALL.
27778231	0	14	Identification	T080	C0205396
27778231	28	38	predictive	T080	C0681890
27778231	39	46	markers	T080	C0008963
27778231	50	63	dexamethasone	T109,T121	C0011777
27778231	64	74	resistance	T038	C0013203
27778231	78	87	childhood	T079	C0231335
27778231	88	116	acute lymphoblastic leukemia	T191	C0023449
27778231	117	125	Response	T040	C0683154
27778231	129	142	dexamethasone	T109,T121	C0011777
27778231	144	148	DEXA	T109,T121	C0011777
27778231	156	169	hallmark drug	T121	C1254351
27778231	177	186	treatment	T169	C0039798
27778231	190	199	childhood	T079	C0231335
27778231	200	228	acute lymphoblastic leukemia	T191	C0023449
27778231	230	233	ALL	T191	C0023449
27778231	258	276	prognostic factors	T201	C1514474
27778231	284	305	prediction of outcome	T058	C0033325
27778231	309	312	ALL	T191	C0023449
27778231	314	328	Identification	T080	C0205396
27778231	332	342	predictive	T080	C0681890
27778231	343	350	markers	T080	C0008963
27778231	354	369	chemoresistance	T038	C0013203
27778231	409	429	therapeutic protocol	T061	C0040808
27778231	446	460	effect adverse	T046	C0879626
27778231	486	498	drug targets	T074	C0085104
27778231	509	512	2DE	T059	C0013860
27778231	515	517	MS	T059	C0037813
27778231	518	534	proteomics study	T059	C0022885
27778231	540	544	DEXA	T109,T121	C0011777
27778231	547	566	resistant cell line	T025	C0007600
27778231	568	571	REH	T025	C0007600
27778231	578	583	model	T075	C0026336
27778231	593	597	DEXA	T109,T121	C0011777
27778231	609	617	patients	T101	C0030705
27778231	635	649	drug treatment	T061	C0013216
27778231	661	678	proteomic methods	T059	C0022885
27778231	701	710	expressed	T045	C1171362
27778231	711	719	proteins	T116,T123	C0033684
27778231	725	733	detected	T033	C0442726
27778231	745	778	voltage dependent anion channel 1	T116,T123	C0753015
27778231	780	785	VDAC1	T116,T123	C0753015
27778231	788	803	sorting Nexin 3	T116,T123	C1741224
27778231	805	809	SNX3	T116,T123	C1741224
27778231	816	835	prefoldin subunit 6	T116,T123	C1743484
27778231	837	842	PFDN6	T116,T123	C1743484
27778231	861	871	expression	T045	C1171362
27778231	881	889	proteins	T116,T123	C0033684
27778231	896	900	DEXA	T109,T121	C0011777
27778231	901	910	treatment	T169	C0039798
27778231	914	923	REH cells	T025	C0007600
27778231	954	964	expression	T045	C1171362
27778231	977	985	proteins	T116,T123	C0033684
27778231	993	997	mRNA	T114,T123	C0035696
27778231	998	1003	level	T080	C0441889
27778231	1014	1037	quantitative PCR method	T059	C2733022
27778231	1045	1053	proteins	T116,T123	C0033684
27778231	1068	1076	proteins	T116,T123	C0033684
27778231	1104	1109	roles	T077	C1705810
27778231	1113	1128	drug resistance	T038	C0013203
27778231	1133	1156	regulation of apoptosis	T043	C1148568
27778231	1158	1163	VDAC1	T116,T123	C0753015
27778231	1166	1185	protein trafficking	T043	C0599895
27778231	1187	1191	SNX3	T116,T123	C1741224
27778231	1198	1213	protein folding	T044	C0162847
27778231	1215	1220	PFDN6	T116,T123	C1743484
27778231	1237	1241	mRNA	T114,T123	C0035696
27778231	1242	1258	expression level	T081	C3244092
27778231	1268	1276	proteins	T116,T123	C0033684
27778231	1281	1289	assessed	T052	C1516048
27778231	1296	1315	bone marrow samples	T031	C0438737
27778231	1321	1329	children	T100	C0008059
27778231	1335	1350	newly diagnosed	T080	C1518321
27778231	1351	1354	ALL	T191	C0023449
27778231	1361	1382	non-cancerous samples	T167	C0370003
27778231	1386	1394	controls	T096	C0009932
27778231	1442	1460	molecular subtypes	T185	C0449560
27778231	1464	1472	leukemia	T191	C0023418
27778231	1474	1478	mRNA	T114,T123	C0035696
27778231	1479	1489	expression	T045	C1171362
27778231	1493	1498	VDAC1	T116,T123	C0753015
27778231	1500	1504	SNX3	T116,T123	C1741224
27778231	1510	1515	PFDN6	T116,T123	C1743484
27778231	1529	1532	ALL	T191	C0023449
27778231	1533	1540	samples	T167	C0370003
27778231	1555	1576	non-cancerous samples	T167	C0370003
27778231	1593	1598	VDAC1	T116,T123	C0753015
27778231	1626	1630	mRNA	T114,T123	C0035696
27778231	1631	1641	expression	T045	C1171362
27778231	1651	1659	proteins	T116,T123	C0033684
27778231	1681	1690	high-risk	T033	C0332167
27778231	1691	1698	samples	T167	C0370003
27778231	1713	1721	standard	T080	C1442989
27778231	1722	1726	risk	T078	C0035647
27778231	1727	1732	cases	T169	C0868928
27778231	1761	1771	diagnostic	T169	C0348026
27778231	1776	1786	prognostic	T170	C0220901
27778231	1787	1792	value	T080	C0042295
27778231	1802	1810	proteins	T116,T123	C0033684
27778231	1814	1823	childhood	T079	C0231335
27778231	1824	1827	ALL	T191	C0023449
27778231	1842	1855	investigation	T058	C0220825
27778231	1859	1886	protein-protein interaction	T044	C0872079
27778231	1893	1899	STRING	T170	C1547402
27778231	1900	1908	database	T170	C0242356
27778231	1930	1938	proteins	T116,T123	C0033684
27778231	1955	1972	signaling pathway	T044	C0037080
27778231	1976	1981	NR3C1	T116,T192	C1370369
27778231	1985	1998	dexamethasone	T109,T121	C0011777
27778231	1999	2005	target	T033	C0243095
27778231	2026	2041	proteomic study	T059	C0022885
27778231	2045	2049	DEXA	T109,T121	C0011777
27778231	2050	2059	resistant	T038	C0013203
27778231	2060	2074	leukemic cells	T025	C1517806
27778231	2084	2089	VDAC1	T116,T123	C0753015
27778231	2091	2095	SNX3	T116,T123	C1741224
27778231	2101	2106	PFDN6	T116,T123	C1743484
27778231	2121	2129	proteins	T116,T123	C0033684
27778231	2160	2170	biomarkers	T201	C0005516
27778231	2174	2183	prognosis	T058	C0033325
27778231	2188	2200	chemotherapy	T061	C3665472
27778231	2204	2213	childhood	T079	C0231335
27778231	2214	2217	ALL	T191	C0023449

28056892|t|Correlations between physical activity and neurocognitive domain functions in patients with schizophrenia: a cross-sectional study
28056892|a|Neurocognitive dysfunction is a critical target symptom of schizophrenia treatment. A positive correlation between physical activity level and neurocognitive function has been reported in healthy individuals, but it is unclear whether such a correlation exists in patients with schizophrenia and whether the relationship is different according to inpatients or outpatients. This study aimed to examine the differences in the correlations between physical activity and multiple neurocognitive domains in inpatients and outpatients with schizophrenia and obtain suggestions for further study to facilitate this field. Twenty-nine patients with schizophrenia were examined (16 inpatients and 13 outpatients, 56.0 ± 11.4 years of age). Current symptoms were assessed using the Positive and Negative Symptom Scale and neurocognitive functions using Cognitrax, which yields a composite neurocognitive index (NCI) and 11 domain scores. After testing, participants wore an HJA-750C accelerometer for one week to measure physical activity levels and durations. Partial correlation analyses were performed between exercise and cognitive parameters. In the outpatient group, higher physical activity was associated with faster Motor and Psychomotor Speeds in outpatients. However, higher physical activity was associated with lower overall NCI, Attention score, and Memory scores in inpatients. Although higher physical activity was associated with better neurocognitive functions of outpatients, in inpatients with non-remitted schizophrenia, higher physical activity was associated with worsening of several cognitive domains. In a future study examining the relationship between physical activity and neurocognitive function for facilitating this research field, separation between inpatients and outpatients are needed because the relationship is different between inpatients and outpatients.
28056892	0	12	Correlations	T080	C1707520
28056892	21	38	physical activity	T056	C0026606
28056892	43	74	neurocognitive domain functions	T041	C0392335
28056892	78	86	patients	T101	C0030705
28056892	92	105	schizophrenia	T048	C0036341
28056892	109	130	cross-sectional study	T062	C0010362
28056892	131	157	Neurocognitive dysfunction	T048	C4041080
28056892	179	186	symptom	T184	C1457887
28056892	190	203	schizophrenia	T048	C0036341
28056892	204	213	treatment	T061	C0087111
28056892	226	237	correlation	T080	C1707520
28056892	246	263	physical activity	T056	C0026606
28056892	274	297	neurocognitive function	T041	C0392335
28056892	319	338	healthy individuals	T098	C0237401
28056892	373	384	correlation	T080	C1707520
28056892	395	403	patients	T101	C0030705
28056892	409	422	schizophrenia	T048	C0036341
28056892	439	451	relationship	T080	C0439849
28056892	478	488	inpatients	T101	C0021562
28056892	492	503	outpatients	T101	C0029921
28056892	510	515	study	T062	C2603343
28056892	525	532	examine	T058	C0582103
28056892	556	568	correlations	T080	C1707520
28056892	577	594	physical activity	T056	C0026606
28056892	608	630	neurocognitive domains	T041	C0392335
28056892	634	644	inpatients	T101	C0021562
28056892	649	660	outpatients	T101	C0029921
28056892	666	679	schizophrenia	T048	C0036341
28056892	691	702	suggestions	T078	C1705535
28056892	715	720	study	T062	C2603343
28056892	759	767	patients	T101	C0030705
28056892	773	786	schizophrenia	T048	C0036341
28056892	792	800	examined	T058	C0582103
28056892	805	815	inpatients	T101	C0021562
28056892	823	834	outpatients	T101	C0029921
28056892	848	853	years	T079	C0439234
28056892	857	860	age	T032	C0001779
28056892	871	879	symptoms	T184	C1457887
28056892	885	893	assessed	T052	C1516048
28056892	904	912	Positive	T033	C1446409
28056892	917	925	Negative	T033	C0205160
28056892	926	939	Symptom Scale	T170	C0429688
28056892	944	968	neurocognitive functions	T041	C0392335
28056892	975	984	Cognitrax	T170	C0871696
28056892	1011	1031	neurocognitive index	T060	C0872227
28056892	1033	1036	NCI	T060	C0872227
28056892	1052	1058	scores	T081	C0449820
28056892	1075	1087	participants	T098	C0679646
28056892	1096	1118	HJA-750C accelerometer	T074	C0178951
28056892	1123	1131	one week	T079	C4082116
28056892	1135	1142	measure	T081	C0079809
28056892	1143	1160	physical activity	T056	C0026606
28056892	1172	1181	durations	T079	C0449238
28056892	1183	1211	Partial correlation analyses	T062,T170	C0010101
28056892	1235	1243	exercise	T056	C0015259
28056892	1248	1257	cognitive	T041	C0009240
28056892	1258	1268	parameters	T033	C0449381
28056892	1277	1287	outpatient	T101	C0029921
28056892	1295	1301	higher	T080	C0205250
28056892	1302	1319	physical activity	T056	C0026606
28056892	1347	1352	Motor	T169	C1513492
28056892	1357	1368	Psychomotor	T041	C0033923
28056892	1369	1375	Speeds	T081	C0678536
28056892	1379	1390	outpatients	T101	C0029921
28056892	1401	1407	higher	T080	C0205250
28056892	1408	1425	physical activity	T056	C0026606
28056892	1430	1445	associated with	T080	C0332281
28056892	1446	1451	lower	T080	C0205251
28056892	1460	1463	NCI	T060	C0872227
28056892	1465	1474	Attention	T041	C0004268
28056892	1475	1480	score	T081	C0449820
28056892	1486	1492	Memory	T041	C0025260
28056892	1493	1499	scores	T081	C0449820
28056892	1503	1513	inpatients	T101	C0021562
28056892	1524	1530	higher	T080	C0205250
28056892	1531	1548	physical activity	T056	C0026606
28056892	1553	1568	associated with	T080	C0332281
28056892	1576	1600	neurocognitive functions	T041	C0392335
28056892	1604	1615	outpatients	T101	C0029921
28056892	1620	1630	inpatients	T101	C0021562
28056892	1649	1662	schizophrenia	T048	C0036341
28056892	1664	1670	higher	T080	C0205250
28056892	1671	1688	physical activity	T056	C0026606
28056892	1693	1708	associated with	T080	C0332281
28056892	1730	1747	cognitive domains	T041	C0392335
28056892	1761	1766	study	T062	C2603343
28056892	1767	1776	examining	T058	C0582103
28056892	1781	1793	relationship	T080	C0439849
28056892	1802	1819	physical activity	T056	C0026606
28056892	1824	1847	neurocognitive function	T041	C0392335
28056892	1905	1915	inpatients	T101	C0021562
28056892	1920	1931	outpatients	T101	C0029921
28056892	1955	1967	relationship	T080	C0439849
28056892	1989	1999	inpatients	T101	C0021562
28056892	2004	2015	outpatients	T101	C0029921

27806658|t|The association between maternal hydronephrosis and acute flank pain during pregnancy: a prospective pilot-study
27806658|a|Maternal hydronephrosis may cause flank pain during pregnancy. We aimed to investigate the association between maternal hydronephrosis and flank pain intensity. From 2014 to 2015, all consecutive women with singleton pregnancies, who presented at our tertiary center due to acute flank pain, were prospectively evaluated by renal ultrasonography and pain questionnaires. A visual analogue scale was used to assess pain intensity. The study had 90% power to detect a significant correlation between hydronephrosis and flank pain (Spearman's test). A total of 51 consecutive women with left-sided (13.7%), right-sided (64.7%) or bilateral (21.6%) pain were enrolled. The mean gestational age of these women, who presented due to their pain, was 27.5 ± 6.8 weeks at the time of consultation. The mean VAS score was 7.6 ± 2.2. In 43/51 (84.3%) women, hydronephrosis was found on renal sonograms. No correlation was found between the grade of hydronephrosis and pain intensity (p = 0.466; r= -0.28). Women delivered at a mean gestational age of 38.1 ± 2.4 weeks and their infants had a mean birthweight of 3138 ± 677 g. Hydronephrosis is a common finding among pregnant women with acute flank pain. The grade of hydronephrosis does not affect pain intensity. This study suggests normal pregnancy outcomes in these women.
27806658	4	15	association	T080	C0439849
27806658	24	32	maternal	T033	C1858460
27806658	33	47	hydronephrosis	T047	C0020295
27806658	52	57	acute	T079	C0205178
27806658	58	68	flank pain	T184	C0016199
27806658	76	85	pregnancy	T040	C0032961
27806658	89	100	prospective	T062	C0033522
27806658	101	112	pilot-study	T062	C0031928
27806658	113	121	Maternal	T033	C1858460
27806658	122	136	hydronephrosis	T047	C0020295
27806658	147	157	flank pain	T184	C0016199
27806658	165	174	pregnancy	T040	C0032961
27806658	179	184	aimed	T078	C1947946
27806658	188	199	investigate	T169	C1292732
27806658	224	232	maternal	T033	C1858460
27806658	233	247	hydronephrosis	T047	C0020295
27806658	252	262	flank pain	T184	C0016199
27806658	263	272	intensity	T201	C1320357
27806658	297	308	consecutive	T080	C1707491
27806658	309	314	women	T098	C0043210
27806658	320	341	singleton pregnancies	T040	C0032961
27806658	387	392	acute	T079	C0205178
27806658	393	403	flank pain	T184	C0016199
27806658	410	423	prospectively	T062	C0033522
27806658	424	433	evaluated	T058	C0220825
27806658	437	442	renal	T023	C0022646
27806658	443	458	ultrasonography	T060	C0041618
27806658	463	467	pain	T184	C0030193
27806658	468	482	questionnaires	T170	C0034394
27806658	486	507	visual analogue scale	T060	C0042815
27806658	527	541	pain intensity	T201	C1320357
27806658	547	552	study	T062	C2603343
27806658	579	590	significant	T078	C0750502
27806658	591	602	correlation	T080	C1707520
27806658	611	625	hydronephrosis	T047	C0020295
27806658	630	640	flank pain	T184	C0016199
27806658	642	657	Spearman's test	T170	C1710141
27806658	674	685	consecutive	T080	C1707491
27806658	686	691	women	T098	C0043210
27806658	697	707	left-sided	T082	C0443246
27806658	717	728	right-sided	T082	C0444532
27806658	740	749	bilateral	T082	C0238767
27806658	758	762	pain	T184	C0030193
27806658	782	786	mean	T081	C0444504
27806658	787	802	gestational age	T032	C0017504
27806658	812	817	women	T098	C0043210
27806658	846	850	pain	T184	C0030193
27806658	867	872	weeks	T079	C0439230
27806658	888	900	consultation	T058	C0009818
27806658	906	910	mean	T081	C0444504
27806658	911	920	VAS score	T201	C1508029
27806658	953	958	women	T098	C0043210
27806658	960	974	hydronephrosis	T047	C0020295
27806658	988	993	renal	T023	C0022646
27806658	1008	1019	correlation	T080	C1707520
27806658	1051	1065	hydronephrosis	T047	C0020295
27806658	1070	1084	pain intensity	T201	C1320357
27806658	1108	1113	Women	T098	C0043210
27806658	1129	1133	mean	T081	C0444504
27806658	1134	1149	gestational age	T032	C0017504
27806658	1164	1169	weeks	T079	C0439230
27806658	1180	1187	infants	T100	C0021270
27806658	1194	1198	mean	T081	C0444504
27806658	1199	1210	birthweight	T032	C0005612
27806658	1228	1242	Hydronephrosis	T047	C0020295
27806658	1255	1262	finding	T033	C0243095
27806658	1269	1283	pregnant women	T098	C0033011
27806658	1289	1294	acute	T079	C0205178
27806658	1295	1305	flank pain	T184	C0016199
27806658	1320	1334	hydronephrosis	T047	C0020295
27806658	1351	1365	pain intensity	T201	C1320357
27806658	1372	1377	study	T062	C2603343
27806658	1387	1403	normal pregnancy	T033	C0232989
27806658	1404	1412	outcomes	T033	C0032972
27806658	1422	1427	women	T098	C0043210

28025021|t|Inflammatory pain -related traits of sensory DRG neurons innervating the hip joints
28025021|a|Hip pain is transmitted to the dorsal horn of the spinal cord via the dorsal root ganglion (DRG), which contains two types of neurons with differential sensitivity to neurotrophic factors. If either type predominantly innervates the hip joint, it may represent a good target for hip joint pain treatment. Inflammation was induced in the left hip joint of rats (n = 10) by using complete Freund's adjuvant. Fluoro-Gold (FG) was applied to the hip joint after 7 days, and T12 - L6 DRGs were double-stained for calcitonin gene-related peptide (CGRP) and isolection-IB4 1 week later. FG -labeled neurons in the control group were distributed throughout the left DRG from T13 to L5, primarily in L2 to L4, and CGRP -positive neurons were significantly more frequent than IB4 - binding neurons. In the inflammatory group, FG -labeled neurons were similarly distributed, primarily at L3 and L4, and CGRP -positive neurons were significantly more frequent than IB4 - binding neurons. The percentage of CGRP -positive neurons was significantly greater in the inflammatory group (P < 0.05). Most small neurons innervating the hip joint express CGRP. Furthermore, hip joint inflammation caused an increase in CGRP -positive neurons, but not in IB4 - binding neurons. Our results suggest that CGRP - expressing nerve growth factor -dependent neurons are primarily responsible for hip joint pain and may represent therapeutic targets.
28025021	0	17	Inflammatory pain	T184	C0234251
28025021	27	33	traits	T032	C0599883
28025021	45	48	DRG	T023	C0017070
28025021	49	56	neurons	T025	C0027882
28025021	73	83	hip joints	T030	C0019558
28025021	84	92	Hip pain	T184	C0019559
28025021	96	107	transmitted	T169	C0332289
28025021	115	145	dorsal horn of the spinal cord	T023	C0228575
28025021	154	174	dorsal root ganglion	T023	C0017070
28025021	176	179	DRG	T023	C0017070
28025021	210	217	neurons	T025	C0027882
28025021	236	247	sensitivity	T080	C1522640
28025021	251	271	neurotrophic factors	T116,T123	C0027754
28025021	317	326	hip joint	T030	C0019558
28025021	363	377	hip joint pain	T184	C0019559
28025021	378	387	treatment	T061	C0087111
28025021	389	401	Inflammation	T046	C0021368
28025021	421	435	left hip joint	T030	C1285113
28025021	439	443	rats	T015	C0086893
28025021	471	488	Freund's adjuvant	T121,T129	C0016712
28025021	490	501	Fluoro-Gold	T109,T130	C0060552
28025021	503	505	FG	T109,T130	C0060552
28025021	526	535	hip joint	T030	C0019558
28025021	544	548	days	T079	C0439228
28025021	554	557	T12	T023	C0459957
28025021	560	562	L6	T023	C4281578
28025021	563	567	DRGs	T023	C0017070
28025021	573	587	double-stained	T059	C0487602
28025021	592	623	calcitonin gene-related peptide	T116,T125	C0006669
28025021	625	629	CGRP	T116,T125	C0006669
28025021	635	649	isolection-IB4	T116,T123	C0752549
28025021	652	656	week	T079	C0439230
28025021	664	666	FG	T109,T130	C0060552
28025021	676	683	neurons	T025	C0027882
28025021	691	704	control group	T096	C0009932
28025021	737	745	left DRG	T023	C0017070
28025021	751	754	T13	T023	C0223388
28025021	758	760	L5	T023	C0223552
28025021	775	777	L2	T023	C0223507
28025021	781	783	L4	T023	C0223537
28025021	789	793	CGRP	T116,T125	C0006669
28025021	804	811	neurons	T025	C0027882
28025021	850	853	IB4	T116,T123	C0752549
28025021	856	863	binding	T044	C1167622
28025021	864	871	neurons	T025	C0027882
28025021	880	898	inflammatory group	T078	C0441833
28025021	900	902	FG	T109,T130	C0060552
28025021	912	919	neurons	T025	C0027882
28025021	961	963	L3	T023	C0223522
28025021	968	970	L4	T023	C0223537
28025021	976	980	CGRP	T116,T125	C0006669
28025021	991	998	neurons	T025	C0027882
28025021	1037	1040	IB4	T116,T123	C0752549
28025021	1043	1050	binding	T044	C1167622
28025021	1051	1058	neurons	T025	C0027882
28025021	1078	1082	CGRP	T116,T125	C0006669
28025021	1093	1100	neurons	T025	C0027882
28025021	1134	1152	inflammatory group	T078	C0441833
28025021	1176	1183	neurons	T025	C0027882
28025021	1200	1209	hip joint	T030	C0019558
28025021	1210	1217	express	T045	C1171362
28025021	1218	1222	CGRP	T116,T125	C0006669
28025021	1237	1246	hip joint	T030	C0019558
28025021	1247	1259	inflammation	T046	C0021368
28025021	1282	1286	CGRP	T116,T125	C0006669
28025021	1297	1304	neurons	T025	C0027882
28025021	1317	1320	IB4	T116,T123	C0752549
28025021	1323	1330	binding	T044	C1167622
28025021	1331	1338	neurons	T025	C0027882
28025021	1365	1369	CGRP	T116,T125	C0006669
28025021	1372	1382	expressing	T045	C1171362
28025021	1383	1402	nerve growth factor	T116,T123	C0027752
28025021	1414	1421	neurons	T025	C0027882
28025021	1452	1466	hip joint pain	T184	C0019559
28025021	1485	1496	therapeutic	T169	C0302350
28025021	1497	1504	targets	T169	C1521840

27798730|t|Cost-effectiveness analysis of apatinib treatment for chemotherapy - refractory advanced gastric cancer
27798730|a|Apatinib, a third-line or later treatment for advanced gastric cancer (aGC), was shown to improve overall survival and progression-free survival (PFS) compared with placebo in the phase III trial. Given the modest benefit with high costs, we further evaluated the cost-effectiveness of apatinib for patients with chemotherapy - refractory aGC. A Markov model was developed to simulate the disease process of aGC (PFS, progressive disease, and death) and estimate the incremental cost-effectiveness ratio (ICER) of apatinib to placebo. The health outcomes and utility scores were derived from the phase III trial and previously published sources, respectively. Total costs were calculated from the perspective of the Chinese health-care payer. Sensitivity analysis was used to explore model uncertainties. Treatment with apatinib was estimated to provide an incremental 0.09 quality-adjusted life years (QALYs) at an incremental cost of $8113.86 compared with placebo, which resulted in an ICER of $90,154.00 per QALY. Sensitivity analysis showed that across the wide variation of parameters, the ICER exceeded the willingness-to-pay threshold of $23,700.00 per QALY which was three times the Gross Domestic Product per Capita in China. Apatinib is not a cost-effective option for patients with aGC who experienced failure of at least two lines chemotherapy in China. However, for its positive clinical value and subliminal demand, apatinib can provide a new therapeutic option.
27798730	0	27	Cost-effectiveness analysis	T057	C1511536
27798730	31	39	apatinib	T121	C2346836
27798730	40	49	treatment	T061	C0087111
27798730	54	66	chemotherapy	T061	C3665472
27798730	69	79	refractory	T169	C0205269
27798730	80	103	advanced gastric cancer	T191	C0699791
27798730	104	112	Apatinib	T121	C2346836
27798730	116	126	third-line	T061	C2986605
27798730	136	145	treatment	T061	C0087111
27798730	150	173	advanced gastric cancer	T191	C0699791
27798730	175	178	aGC	T191	C0699791
27798730	202	218	overall survival	T081	C4086681
27798730	223	248	progression-free survival	T081	C0242792
27798730	250	253	PFS	T081	C0242792
27798730	269	276	placebo	T061	C0032042
27798730	284	299	phase III trial	T062	C0282461
27798730	336	341	costs	T081	C0010186
27798730	354	363	evaluated	T058	C0220825
27798730	368	386	cost-effectiveness	T081	C0010181
27798730	390	398	apatinib	T121	C2346836
27798730	403	411	patients	T101	C0030705
27798730	417	429	chemotherapy	T061	C3665472
27798730	432	442	refractory	T169	C0205269
27798730	443	446	aGC	T191	C0699791
27798730	450	462	Markov model	T066	C0009609
27798730	480	488	simulate	T062	C0679083
27798730	493	500	disease	T047	C0012634
27798730	501	508	process	T067	C1522240
27798730	512	515	aGC	T191	C0699791
27798730	517	520	PFS	T081	C0242792
27798730	522	541	progressive disease	T047	C1335499
27798730	547	552	death	T040	C0011065
27798730	571	582	incremental	T081	C1705117
27798730	583	601	cost-effectiveness	T081	C0010181
27798730	602	607	ratio	T081	C0456603
27798730	609	613	ICER	T081	C0456603
27798730	618	626	apatinib	T121	C2346836
27798730	630	637	placebo	T061	C0032042
27798730	643	658	health outcomes	T170	C1550208
27798730	663	670	utility	T169	C3669222
27798730	671	677	scores	T081	C0449820
27798730	700	715	phase III trial	T062	C0282461
27798730	731	748	published sources	T170	C1704324
27798730	770	775	costs	T081	C0010186
27798730	820	845	Chinese health-care payer	T092	C2348942
27798730	859	867	analysis	T062	C0936012
27798730	888	893	model	T066	C0009609
27798730	894	907	uncertainties	T033	C0087130
27798730	909	918	Treatment	T061	C0087111
27798730	924	932	apatinib	T121	C2346836
27798730	961	972	incremental	T081	C1705117
27798730	978	1005	quality-adjusted life years	T079	C0080071
27798730	1007	1012	QALYs	T079	C0080071
27798730	1020	1031	incremental	T081	C1705117
27798730	1032	1036	cost	T081	C0010186
27798730	1063	1070	placebo	T061	C0032042
27798730	1093	1097	ICER	T081	C0456603
27798730	1116	1120	QALY	T079	C0080071
27798730	1134	1142	analysis	T062	C0936012
27798730	1200	1204	ICER	T081	C0456603
27798730	1265	1269	QALY	T079	C0080071
27798730	1296	1318	Gross Domestic Product	T081	C2936646
27798730	1333	1338	China	T083	C0008115
27798730	1340	1348	Apatinib	T121	C2346836
27798730	1358	1372	cost-effective	T081	C0010181
27798730	1384	1392	patients	T101	C0030705
27798730	1398	1401	aGC	T191	C0699791
27798730	1418	1425	failure	T169	C0231174
27798730	1448	1460	chemotherapy	T061	C3665472
27798730	1464	1469	China	T083	C0008115
27798730	1497	1505	clinical	T080	C0205210
27798730	1516	1526	subliminal	T080	C0443151
27798730	1535	1543	apatinib	T121	C2346836
27798730	1562	1573	therapeutic	T061	C0087111

27730636|t|Assessment of interbreeding and introgression of farm genes into a small Scottish Atlantic salmon Salmo salar stock: ad hoc samples - ad hoc results?
27730636|a|An eclectic set of tissues and existing data, including purposely collected samples, spanning 1997-2006, was used in an ad hoc assessment of hybridization and introgression of farmed wild Atlantic salmon Salmo salar in the small Loch na Thull (LnT) catchment in north-west Scotland. The catchment is in an area of marine farm production and contains freshwater smolt rearing cages. The LnT S. salar stock was found to be genetically distinctive from stocks in neighbouring rivers and, despite regular reports of feral farm S. salar, there was no evidence of physical or genetic mixing. This cannot be completely ruled out, however, and low level mixing with other local wild stocks has been suggested. The LnT population appeared underpinned by relatively smaller effective number of breeders (Neb) and showed relatively low levels of genetic diversity, consistent with a small effective population size. Small sample sizes, an incomplete farm baseline and the use of non-diagnostic molecular markers, constrain the power of the analysis but the findings strongly support the LnT catchment having a genetically distinct wild S. salar population little affected by interbreeding with feral farm escapes.
27730636	0	10	Assessment	T062	C0242481
27730636	14	27	interbreeding	T045	C0020202
27730636	32	45	introgression	T169	C0205245
27730636	49	53	farm	T082	C0557759
27730636	54	59	genes	T028	C0017337
27730636	67	72	small	T081	C0700321
27730636	73	109	Scottish Atlantic salmon Salmo salar	T013	C0327949
27730636	110	115	stock	T078	C0441833
27730636	117	131	ad hoc samples	T167	C0370003
27730636	134	148	ad hoc results	T169	C1274040
27730636	153	165	eclectic set	T077	C1705195
27730636	169	176	tissues	T024	C0040300
27730636	181	189	existing	T080	C2347662
27730636	190	194	data	T078	C1511726
27730636	216	225	collected	T078	C1516695
27730636	226	233	samples	T167	C0370003
27730636	235	243	spanning	T079	C1254367
27730636	270	287	ad hoc assessment	T062	C0242481
27730636	291	304	hybridization	T045	C0020202
27730636	309	322	introgression	T169	C0205245
27730636	326	365	farmed wild Atlantic salmon Salmo salar	T013	C0327949
27730636	373	378	small	T081	C0700321
27730636	379	408	Loch na Thull (LnT) catchment	T083	C2360150
27730636	412	431	north-west Scotland	T083	C0036453
27730636	437	446	catchment	T083	C2360150
27730636	456	460	area	T083	C0017446
27730636	464	470	marine	T001	C0599383
27730636	471	475	farm	T082	C0557759
27730636	500	510	freshwater	T167	C0016710
27730636	511	530	smolt rearing cages	T073	C0179512
27730636	536	539	LnT	T083	C2360150
27730636	540	548	S. salar	T013	C0327949
27730636	549	554	stock	T078	C0441833
27730636	571	582	genetically	T080	C0205556
27730636	600	606	stocks	T078	C0441833
27730636	610	622	neighbouring	T082	C0205107
27730636	623	629	rivers	T070	C0337050
27730636	662	672	feral farm	T082	C0557759
27730636	673	681	S. salar	T013	C0327949
27730636	693	707	no evidence of	T080	C0332125
27730636	708	716	physical	T169	C0205485
27730636	720	727	genetic	T169	C0314603
27730636	728	734	mixing	T169	C0205430
27730636	751	761	completely	T080	C0205197
27730636	762	771	ruled out	T033	C0205160
27730636	786	789	low	T080	C0205251
27730636	790	795	level	T080	C0441889
27730636	796	802	mixing	T169	C0205430
27730636	814	819	local	T082	C0205276
27730636	820	831	wild stocks	T078	C0441833
27730636	856	859	LnT	T083	C2360150
27730636	860	870	population	T098	C1257890
27730636	906	913	smaller	T081	C0700321
27730636	914	942	effective number of breeders	T081	C0392762
27730636	944	947	Neb	T081	C0392762
27730636	971	974	low	T080	C0205251
27730636	975	981	levels	T080	C0441889
27730636	985	1002	genetic diversity	T070	C0042333
27730636	1022	1027	small	T081	C0700321
27730636	1028	1037	effective	T080	C1704419
27730636	1038	1053	population size	T081	C0032683
27730636	1055	1060	Small	T081	C0700321
27730636	1061	1073	sample sizes	T081	C0242618
27730636	1078	1088	incomplete	T080	C0205257
27730636	1089	1093	farm	T082	C0557759
27730636	1094	1102	baseline	T081	C1442488
27730636	1111	1117	use of	T169	C1524063
27730636	1118	1150	non-diagnostic molecular markers	T201	C0005516
27730636	1152	1161	constrain	T077	C1707494
27730636	1179	1187	analysis	T062	C0936012
27730636	1196	1204	findings	T169	C2607943
27730636	1226	1239	LnT catchment	T083	C2360150
27730636	1249	1260	genetically	T080	C0205556
27730636	1270	1283	wild S. salar	T013	C0327949
27730636	1284	1294	population	T098	C1257890
27730636	1314	1327	interbreeding	T045	C0020202
27730636	1333	1343	feral farm	T082	C0557759
27730636	1344	1351	escapes	T080	C0205556

27336239|t|Professional reinventions: Swedish psychologists, 1990-2010
27336239|a|Since the early 20th century, the Swedish psychology profession has undergone several changes in its essential tasks, epistemological foundations, and social roles. These changes occurred through an ongoing "tuning" with Swedish society, in which the profession strove to appear relevant to society's concerns and problems as well as enroll others to share the profession's goals and aims. Studying the history of the profession can thus shed light on the changing definitions and contours of the psychology profession itself as well as on the organization of the society in which it acts. This article examines the history of the Swedish psychology profession from 1990 to 2010, through an analysis of the discussions and debates taking place in the Swedish Psychological Association's journal. The analytical framework used draws on work done within actor-network theory and science studies. We argue that the profession's institutional connections, defining tasks, epistemological underpinnings, and social position have changed in major ways during these 2 decades. Overall, as a result of an increasingly felt insecurity, the profession has turned outward and tried to find new ways to legitimize itself to politicians, the media, patients, and customers through means such as a more economized vocabulary and novel forms of empirical research. These changes have led to a more socialized profession, now more closely tuned to other actors in Swedish society, leading to conflicts within the profession over whether this is an opportunity to better control their own destiny or if it will lead to a loss of autonomy. (PsycINFO Database Record
27336239	0	25	Professional reinventions	T170	C0282574
27336239	27	34	Swedish	T098	C1710263
27336239	35	48	psychologists	T097	C0033908
27336239	76	88	20th century	T079	C0681748
27336239	94	101	Swedish	T098	C1710263
27336239	102	123	psychology profession	T091	C0033909
27336239	146	153	changes	T169	C0392747
27336239	161	176	essential tasks	T052	C0441655
27336239	178	205	epistemological foundations	T170	C0376553
27336239	211	223	social roles	T054	C0035820
27336239	231	238	changes	T169	C0392747
27336239	239	247	occurred	T052	C1709305
27336239	281	288	Swedish	T098	C1710263
27336239	289	296	society	T092	C0037455
27336239	311	321	profession	T090	C0028811
27336239	351	360	society's	T092	C0037455
27336239	361	369	concerns	T078	C2699424
27336239	374	382	problems	T033	C0033213
27336239	421	433	profession's	T090	C0028811
27336239	434	439	goals	T170	C0018017
27336239	444	448	aims	T078	C1947946
27336239	463	470	history	T169	C0019665
27336239	478	488	profession	T090	C0028811
27336239	516	524	changing	T169	C0392747
27336239	525	536	definitions	T170	C1704788
27336239	541	549	contours	T082	C0876954
27336239	557	578	psychology profession	T091	C0033909
27336239	604	616	organization	T169	C1300196
27336239	624	631	society	T092	C0037455
27336239	655	662	article	T170	C1706852
27336239	676	683	history	T169	C0019665
27336239	691	698	Swedish	T098	C1710263
27336239	699	720	psychology profession	T091	C0033909
27336239	751	759	analysis	T062	C0936012
27336239	767	778	discussions	T054	C2584313
27336239	783	790	debates	T052	C0870392
27336239	811	818	Swedish	T098	C1710263
27336239	819	854	Psychological Association's journal	T073,T170	C0162443
27336239	860	880	analytical framework	T077	C1254372
27336239	912	932	actor-network theory	T170	C0683613
27336239	937	952	science studies	T062	C0242481
27336239	972	984	profession's	T090	C0028811
27336239	985	1010	institutional connections	T080	C0439849
27336239	1021	1026	tasks	T052	C0441655
27336239	1028	1043	epistemological	T170	C0376553
27336239	1044	1057	underpinnings	T078	C1254370
27336239	1063	1078	social position	UnknownType	C0680375
27336239	1084	1091	changed	T169	C0392747
27336239	1121	1128	decades	T081	C2981279
27336239	1175	1185	insecurity	T041	C0233497
27336239	1191	1201	profession	T090	C0028811
27336239	1251	1261	legitimize	T169	C1552821
27336239	1272	1283	politicians	T097	C0682232
27336239	1289	1294	media	T170	C0009458
27336239	1296	1304	patients	T101	C0030705
27336239	1310	1319	customers	T077	C2981734
27336239	1349	1359	economized	T169	C0013557
27336239	1360	1370	vocabulary	T170	C0042926
27336239	1375	1380	novel	T080	C0205314
27336239	1390	1408	empirical research	T062	C0376367
27336239	1416	1423	changes	T169	C0392747
27336239	1443	1453	socialized	T054	C2371613
27336239	1454	1464	profession	T090	C0028811
27336239	1498	1504	actors	T097	C0335083
27336239	1508	1515	Swedish	T098	C1710263
27336239	1516	1523	society	T092	C0037455
27336239	1536	1545	conflicts	T080	C1705242
27336239	1557	1567	profession	T090	C0028811
27336239	1614	1621	control	T080	C0243148
27336239	1664	1680	loss of autonomy	T033	C4061233
27336239	1683	1707	PsycINFO Database Record	T170	C0242356

27583127|t|Improved hematopoietic differentiation of human pluripotent stem cells via estrogen receptor signaling pathway
27583127|a|Aside from its importance in reproduction, estrogen (E2) is known to regulate the proliferation and differentiation of hematopoietic stem cells in rodents. However, the regulatory role of E2 in human hematopoietic system has not been investigated. The purpose of this study is to investigate the effect of E2 on hematopoietic differentiation using human pluripotent stem cells (hPSCs). E2 improved hematopoietic differentiation of hPSCs via estrogen receptor alpha (ER-α)-dependent pathway. During hematopoietic differentiation of hPSCs, ER-α is persistently maintained and hematopoietic phenotypes (CD34 and CD45) were exclusively detected in ER-α positive cells. Interestingly, continuous E2 signaling is required to promote hematopoietic output from hPSCs. Supplementation of E2 or an ER-α selective agonist significantly increased the number of hemangioblasts and hematopoietic progenitors, and subsequent erythropoiesis, whereas ER-β selective agonist did not. Furthermore, ICI 182,780 (ER antagonist) completely abrogated the E2 -induced hematopoietic augmentation. Not only from hPSCs but also from human umbilical cord bloods, does E2 signaling potentiate hematopoietic development, suggesting universal function of E2 on hematopoiesis. Our study identifies E2 as positive regulator of human hematopoiesis and suggests that endocrine factors such as E2 influence the behavior of hematopoietic stem cells in various physiological conditions.
27583127	0	8	Improved	T033	C0184511
27583127	9	38	hematopoietic differentiation	T043	C2262995
27583127	42	47	human	T016	C0086418
27583127	48	70	pluripotent stem cells	T025	C0872076
27583127	75	110	estrogen receptor signaling pathway	T044	C1155500
27583127	140	152	reproduction	T040	C0035150
27583127	154	162	estrogen	T109,T121,T125	C0014939
27583127	164	166	E2	T109,T121,T125	C0014939
27583127	180	188	regulate	T077	C1704735
27583127	193	206	proliferation	T169	C1514485
27583127	211	254	differentiation of hematopoietic stem cells	T043	C2262995
27583127	258	265	rodents	T015	C0035804
27583127	280	295	regulatory role	T077	C1704735
27583127	299	301	E2	T109,T121,T125	C0014939
27583127	305	310	human	T016	C0086418
27583127	311	331	hematopoietic system	T022	C0018957
27583127	345	357	investigated	T169	C1292732
27583127	363	384	purpose of this study	UnknownType	C0681832
27583127	391	402	investigate	T169	C1292732
27583127	407	416	effect of	T080	C1704420
27583127	417	419	E2	T109,T121,T125	C0014939
27583127	423	452	hematopoietic differentiation	T043	C2262995
27583127	459	487	human pluripotent stem cells	T025	C0872076
27583127	489	494	hPSCs	T025	C0872076
27583127	497	499	E2	T109,T121,T125	C0014939
27583127	500	508	improved	T033	C0184511
27583127	509	538	hematopoietic differentiation	T043	C2262995
27583127	542	547	hPSCs	T025	C0872076
27583127	552	575	estrogen receptor alpha	T116,T192	C0665341
27583127	552	600	estrogen receptor alpha (ER-α)-dependent pathway	T044	C1155500
27583127	577	581	ER-α	T116,T192	C0665341
27583127	609	638	hematopoietic differentiation	T043	C2262995
27583127	642	647	hPSCs	T025	C0872076
27583127	649	653	ER-α	T116,T192	C0665341
27583127	670	680	maintained	T169	C1314677
27583127	685	698	hematopoietic	T169	C0229601
27583127	699	709	phenotypes	T032	C0031437
27583127	711	715	CD34	T116,T129	C0054953
27583127	720	724	CD45	T116,T126,T129	C0054961
27583127	743	751	detected	T033	C0442726
27583127	755	774	ER-α positive cells	T025	C0007634
27583127	791	801	continuous	T078	C0549178
27583127	802	804	E2	T109,T121,T125	C0014939
27583127	805	814	signaling	T044	C0037080
27583127	838	858	hematopoietic output	T169	C0229601
27583127	864	869	hPSCs	T025	C0872076
27583127	871	886	Supplementation	T061	C0087111
27583127	890	892	E2	T109,T121,T125	C0014939
27583127	899	921	ER-α selective agonist	T121	C2987634
27583127	922	945	significantly increased	T033	C0243095
27583127	960	974	hemangioblasts	T025	C2350248
27583127	979	1004	hematopoietic progenitors	T025	C2350248
27583127	1021	1035	erythropoiesis	T042	C0014819
27583127	1045	1049	ER-β	T116,T192	C0529099
27583127	1045	1067	ER-β selective agonist	T121	C2987634
27583127	1090	1101	ICI 182,780	T109,T121	C1123005
27583127	1103	1116	ER antagonist	T121	C2267020
27583127	1118	1138	completely abrogated	T033	C0243095
27583127	1143	1145	E2	T109,T121,T125	C0014939
27583127	1155	1168	hematopoietic	T169	C0229601
27583127	1169	1181	augmentation	T061	C1293122
27583127	1197	1202	hPSCs	T025	C0872076
27583127	1217	1222	human	T016	C0086418
27583127	1223	1244	umbilical cord bloods	T031	C0162371
27583127	1251	1253	E2	T109,T121,T125	C0014939
27583127	1254	1263	signaling	T044	C0037080
27583127	1275	1300	hematopoietic development	T042	C2610238
27583127	1313	1331	universal function	T169	C0205245
27583127	1335	1337	E2	T109,T121,T125	C0014939
27583127	1341	1354	hematopoiesis	T042	C0018951
27583127	1377	1379	E2	T109,T121,T125	C0014939
27583127	1383	1401	positive regulator	T077	C1704735
27583127	1405	1410	human	T016	C0086418
27583127	1411	1424	hematopoiesis	T042	C0018951
27583127	1443	1460	endocrine factors	T169	C0521425
27583127	1469	1471	E2	T109,T121,T125	C0014939
27583127	1472	1481	influence	T077	C4054723
27583127	1498	1522	hematopoietic stem cells	T025	C0018956
27583127	1534	1558	physiological conditions	T039	C0031843

27698544|t|Esomeprazole - or rabeprazole -based triple therapy eradicated Helicobacter pylori comparably regardless of clarithromycin susceptibility and CYP2C19 genotypes
27698544|a|The aim of this study was to assess the efficacy of esomeprazole -based triple therapy compared with rabeprazole -based triple therapy according to CYP2C19 genotype and clarithromycin susceptibility status for first-line eradication therapy of Helicobacter pylori (H. pylori) in Japan. We enrolled 219 H. pylori - infected patients, and randomly allocated patients to the EAC group (esomeprazole 20 mg, clarithromycin 200 mg, amoxicillin 750 mg for one week, with all drugs given twice daily) or RAC group (rabeprazole 10 mg, clarithromycin 200 mg, amoxicillin 750 mg for one week, with all drugs given twice daily). The H. pylori eradication rate according to the PP analyses was 75.0% (95% CI: 65.2-82.8%) in the EAC group and 71.4% (95% CI: 61.4-79.1%) in the RAC group. There were no statistically significant differences. The eradication rates of the clarithromycin -resistant /- sensitive strains were, respectively, 45.0% (95% CI: 30.7-60.2%)/98.0% (95% CI: 88.7-100%) in the EAC group and 39.5% (95% CI: 25.6-55.3%)/93.5% (95% CI: 81.9-98.4%) in the RAC group. The eradication rate of the clarithromycin - sensitive strains was significantly higher than that of the resistant strains in both groups. In conclusion, EAC and RAC therapies show a comparable efficacy regardless of the CYP2C19 genotype and clarithromycin susceptibility status in Japan.
27698544	0	12	Esomeprazole	T109,T121	C0937846
27698544	18	29	rabeprazole	T109,T121	C0378482
27698544	37	43	triple	T081	C0205174
27698544	44	51	therapy	T061	C0087111
27698544	63	82	Helicobacter pylori	T007	C0079488
27698544	94	104	regardless	T080	C3641650
27698544	108	122	clarithromycin	T109,T195	C0055856
27698544	123	137	susceptibility	T169	C1264642
27698544	142	149	CYP2C19	T028	C1332828
27698544	150	159	genotypes	T032	C0017431
27698544	176	181	study	T062	C2603343
27698544	189	195	assess	T052	C1516048
27698544	200	208	efficacy	T080	C1280519
27698544	212	224	esomeprazole	T109,T121	C0937846
27698544	232	238	triple	T081	C0205174
27698544	239	246	therapy	T061	C0087111
27698544	247	255	compared	T052	C1707455
27698544	261	272	rabeprazole	T109,T121	C0378482
27698544	280	286	triple	T081	C0205174
27698544	287	294	therapy	T061	C0087111
27698544	308	315	CYP2C19	T028	C1332828
27698544	316	324	genotype	T032	C0017431
27698544	329	343	clarithromycin	T109,T195	C0055856
27698544	344	358	susceptibility	T169	C1264642
27698544	359	365	status	T080	C0449438
27698544	381	423	eradication therapy of Helicobacter pylori	T061	C0559761
27698544	425	434	H. pylori	T007	C0079488
27698544	439	444	Japan	T083	C0022341
27698544	462	471	H. pylori	T007	C0079488
27698544	474	491	infected patients	T101	C0030705
27698544	497	505	randomly	T080	C0439605
27698544	506	515	allocated	T052	C1706778
27698544	516	524	patients	T101	C0030705
27698544	532	541	EAC group	T101	C0030705
27698544	543	555	esomeprazole	T109,T121	C0937846
27698544	563	577	clarithromycin	T109,T195	C0055856
27698544	586	597	amoxicillin	T109,T195	C0002645
27698544	613	617	week	T079	C0439230
27698544	628	633	drugs	T121	C0013227
27698544	634	639	given	T169	C1947971
27698544	640	651	twice daily	T079	C0585361
27698544	656	665	RAC group	T101	C0030705
27698544	667	678	rabeprazole	T109,T121	C0378482
27698544	686	700	clarithromycin	T109,T195	C0055856
27698544	709	720	amoxicillin	T109,T195	C0002645
27698544	736	740	week	T079	C0439230
27698544	751	756	drugs	T121	C0013227
27698544	757	762	given	T169	C1947971
27698544	763	774	twice daily	T079	C0585361
27698544	781	790	H. pylori	T007	C0079488
27698544	791	807	eradication rate	T081	C1521828
27698544	825	836	PP analyses	T062	C0936012
27698544	852	854	CI	T081	C0009667
27698544	875	884	EAC group	T101	C0030705
27698544	900	902	CI	T081	C0009667
27698544	923	932	RAC group	T101	C0030705
27698544	974	985	differences	T080	C1705242
27698544	991	1008	eradication rates	T081	C1521828
27698544	1016	1030	clarithromycin	T109,T195	C0055856
27698544	1016	1041	clarithromycin -resistant	T046	C0860039
27698544	1045	1054	sensitive	T169	C0332324
27698544	1055	1062	strains	T007	C0004611
27698544	1094	1096	CI	T081	C0009667
27698544	1121	1123	CI	T081	C0009667
27698544	1143	1152	EAC group	T101	C0030705
27698544	1168	1170	CI	T081	C0009667
27698544	1195	1197	CI	T081	C0009667
27698544	1218	1227	RAC group	T101	C0030705
27698544	1233	1249	eradication rate	T081	C1521828
27698544	1257	1271	clarithromycin	T109,T195	C0055856
27698544	1274	1283	sensitive	T169	C0332324
27698544	1284	1291	strains	T007	C0004611
27698544	1310	1316	higher	T080	C0205250
27698544	1334	1351	resistant strains	T046	C0860039
27698544	1355	1359	both	T080	C1706086
27698544	1360	1366	groups	T078	C0441833
27698544	1383	1386	EAC	T101	C0030705
27698544	1391	1394	RAC	T101	C0030705
27698544	1395	1404	therapies	T061	C0087111
27698544	1423	1431	efficacy	T080	C1280519
27698544	1432	1442	regardless	T080	C3641650
27698544	1450	1457	CYP2C19	T028	C1332828
27698544	1458	1466	genotype	T032	C0017431
27698544	1471	1485	clarithromycin	T109,T195	C0055856
27698544	1486	1500	susceptibility	T169	C1264642
27698544	1501	1507	status	T080	C0449438
27698544	1511	1516	Japan	T083	C0022341

27453213|t|Aurantimonas endophytica sp. nov., a novel endophytic bacterium isolated from roots of Anabasis elatior (C. A. Mey.) Schischk
27453213|a|An orange-coloured, aerobic, motile and short-rods bacterial strain, designated EGI 6500337T, was isolated from the surface-sterilized root of a halophyte Anabasis elatior (C. A. Mey.) Schischk collected from Urumqi, Xinjiang province, north-west China. Growth occurred at 5-35 °C (optimum 30 °C), at pH 6.0-9.0 (optimum pH 7.0), and in the presence of 0-6 % NaCl (w/v) (optimum 0-1 %). Phylogenetic tree based on 16S rRNA gene sequences indicated that strain EGI 6500337T formed a distinct lineage in the cluster that comprised the genera Aurantimonas and Aureimonas in the family Aurantimonadaceae. The 16S rRNA gene sequence of strain EGI 6500337T shared the highest similarities to those of Aurantimonas coralicida DSM 14790T (97.15 %) and Aurantimonas manganoxydans DSM 21871T (97.15 %). Strain EGI 6500337T contained Q-10 as the dominant isoprenoid quinone. The major cellular fatty acids were C18:1 7c (66.4 %) and C19:0 8c cyclo (23.3 %). The polar lipid profile of strain EGI 6500337T contained diphosphatidylglycerol, phosphatidylglycerol, phosphatidylcholine, phosphatidylethanolamine as major components, similarly to the members of the genus Aurantimonas. The DNA G+C content of strain EGI 6500337T was 66.8 mol%. The DNA - DNA relatedness between strain EGI 6500337T and Aurantimonas coralicida DSM 14790T was 24.7 ± 2.9 %. On the basis of the phylogenetic analysis, chemotaxonomic data and phenotypic characteristics, strain EGI 6500337T represents a novel species of the genus Aurantimonas, for which the name Aurantimonas endophytica sp. nov. is proposed. The type strain is EGI 6500337T (= KCTC 52296T = CPCC 100904T).
27453213	0	33	Aurantimonas endophytica sp. nov.	T007	C1207105
27453213	43	63	endophytic bacterium	T004	C1265415
27453213	78	83	roots	T002	C0242726
27453213	87	125	Anabasis elatior (C. A. Mey.) Schischk	T002	C3012678
27453213	129	144	orange-coloured	T080	C1313858
27453213	146	153	aerobic	T080	C1510824
27453213	155	161	motile	T033	C1979933
27453213	166	193	short-rods bacterial strain	T007	C0004611
27453213	206	218	EGI 6500337T	T007	C0004611
27453213	261	265	root	T002	C0242726
27453213	271	280	halophyte	T002	C2350261
27453213	281	319	Anabasis elatior (C. A. Mey.) Schischk	T002	C3012678
27453213	335	341	Urumqi	T083	C0017446
27453213	343	360	Xinjiang province	T083	C0017446
27453213	362	378	north-west China	T083	C0008115
27453213	380	386	Growth	T040	C0018270
27453213	427	429	pH	T081	C0020283
27453213	447	449	pH	T081	C0020283
27453213	485	489	NaCl	T121,T123,T197	C0037494
27453213	513	530	Phylogenetic tree	T080	C1519069
27453213	540	548	16S rRNA	T114	C3537372
27453213	549	563	gene sequences	T086	C0162327
27453213	579	598	strain EGI 6500337T	T007	C0004611
27453213	659	678	genera Aurantimonas	T007	C1207105
27453213	683	693	Aureimonas	T007	C1894985
27453213	701	725	family Aurantimonadaceae	T007	C1494877
27453213	731	739	16S rRNA	T114	C3537372
27453213	740	753	gene sequence	T086	C0162327
27453213	757	776	strain EGI 6500337T	T007	C0004611
27453213	821	855	Aurantimonas coralicida DSM 14790T	T007	C1207106
27453213	870	907	Aurantimonas manganoxydans DSM 21871T	T007	C2783928
27453213	919	938	Strain EGI 6500337T	T007	C0004611
27453213	949	953	Q-10	T109	C0034435
27453213	970	988	isoprenoid quinone	T109	C0034435
27453213	1009	1020	fatty acids	T109	C0015684
27453213	1026	1035	C18:1 7c	T109	C2599892
27453213	1049	1064	C19:0 8c cyclo	T109	C0015684
27453213	1085	1098	lipid profile	T109	C0023779
27453213	1102	1121	strain EGI 6500337T	T007	C0004611
27453213	1132	1154	diphosphatidylglycerol	T109	C0023779
27453213	1156	1176	phosphatidylglycerol	T109,T123	C0031619
27453213	1178	1197	phosphatidylcholine	T109,T121,T123	C1959616
27453213	1199	1223	phosphatidylethanolamine	T109,T123	C0031618
27453213	1277	1295	genus Aurantimonas	T007	C1207105
27453213	1301	1304	DNA	T114,T123	C0012854
27453213	1305	1316	G+C content	T081	C1135899
27453213	1320	1339	strain EGI 6500337T	T007	C0004611
27453213	1359	1362	DNA	T114,T123	C0012854
27453213	1365	1368	DNA	T114,T123	C0012854
27453213	1389	1408	strain EGI 6500337T	T007	C0004611
27453213	1413	1447	Aurantimonas coralicida DSM 14790T	T007	C1207106
27453213	1486	1507	phylogenetic analysis	T062	C1519068
27453213	1509	1528	chemotaxonomic data	T078	C1511726
27453213	1533	1559	phenotypic characteristics	T032	C0031437
27453213	1561	1580	strain EGI 6500337T	T007	C0004611
27453213	1615	1633	genus Aurantimonas	T007	C1207105
27453213	1654	1687	Aurantimonas endophytica sp. nov.	T007	C1207105
27453213	1710	1716	strain	T007	C0004611
27453213	1720	1732	EGI 6500337T	T007	C0004611
27453213	1736	1747	KCTC 52296T	T007	C0004611
27453213	1750	1762	CPCC 100904T	T007	C0004611

28166079|t|Osteomyelitis of Humerus and Intramuscular Abscess Due to Melioidosis
28166079|a|Melioidosis is a clinically diverse disease caused by gram negative bacterium Burkholderia pseudomallei. It is a potential bioterrorism agent. The high risk group includes the agricultural and construction workers whose contact with contaminated soil and water may expose them to bacteria. The clinical manifestations varies from asymptomatic infection to overwhelming sepsis. To diagnose melioidosis a high index of suspicion along with isolation and identification of the organism from the clinical samples is needed. Early diagnosis and treatment is essential for better outcome. We are reporting a case of melioidosis which presented as osteomyelitis of humerus with intramuscular abscess.
28166079	0	24	Osteomyelitis of Humerus	T047	C3670047
28166079	29	42	Intramuscular	T082	C0442117
28166079	43	50	Abscess	T047	C0000833
28166079	58	69	Melioidosis	T047	C0025229
28166079	70	81	Melioidosis	T047	C0025229
28166079	106	113	disease	T047	C0012634
28166079	114	123	caused by	T169	C1314792
28166079	124	147	gram negative bacterium	T007	C0018150
28166079	148	173	Burkholderia pseudomallei	T007	C0033819
28166079	183	192	potential	T080	C3245505
28166079	193	211	bioterrorism agent	T131	C1955854
28166079	217	232	high risk group	T098	C0684030
28166079	233	241	includes	T169	C0332257
28166079	246	258	agricultural	T090	C4048190
28166079	263	283	construction workers	T097	C0403066
28166079	290	302	contact with	T169	C0332158
28166079	303	320	contaminated soil	T069	C0522737
28166079	325	330	water	T069	C0043056
28166079	350	358	bacteria	T007	C0004611
28166079	364	372	clinical	T080	C0205210
28166079	373	387	manifestations	T169	C0205319
28166079	400	422	asymptomatic infection	T047	C0275522
28166079	439	445	sepsis	T047	C0243026
28166079	450	458	diagnose	T033	C0011900
28166079	459	470	melioidosis	T047	C0025229
28166079	487	496	suspicion	T041	C0242114
28166079	508	517	isolation	T169	C0205409
28166079	522	536	identification	T080	C0205396
28166079	544	552	organism	T001	C0029235
28166079	562	570	clinical	T080	C0205210
28166079	571	578	samples	T077	C2347026
28166079	590	605	Early diagnosis	T060	C0596473
28166079	610	619	treatment	T061	C0087111
28166079	623	632	essential	T080	C0205224
28166079	637	643	better	T080	C0332272
28166079	644	651	outcome	T169	C1274040
28166079	660	669	reporting	T058	C0700287
28166079	680	691	melioidosis	T047	C0025229
28166079	711	735	osteomyelitis of humerus	T047	C3670047
28166079	741	754	intramuscular	T082	C0442117
28166079	755	762	abscess	T047	C0000833

28113116|t|Metabolic Interference of sod gene mutations on catalase activity in Escherichia coli exposed to Gramoxone ® (paraquat) herbicide
28113116|a|Herbicides are continuously used to minimize the loss of crop productivity in agricultural environments. They can, however, cause damage by inhibiting the growth of microbiota via oxidative stress, due to the increased production of reactive oxygen species (ROS). Cellular responses to ROS involve the action of enzymes, including superoxide dismutase (SOD) and catalase (CAT). The objective of this study was to evaluate adaptive responses in Escherichia coli K-12 to paraquat, the active ingredient in the herbicide Gramoxone ®. Mutant bacterial strains carrying deletions in genes encoding Mn-SOD (sodA) and Fe-SOD (sodB) were used and resulted in distinct levels of hydrogen peroxide production, interference in malondialdehyde, and viability. Mutations also resulted in different levels of interference with the activity of CAT isoenzymes and in the inactivation of Cu/Zn-SOD activity. These mutations may be responsible for metabolic differences among the evaluated strains, resulting in different patterns of antioxidative responses, depending on mutation background. While damage to the Δ sodB strain was minor at late log phase, the reverse was true at mid log phase for the Δ sodA strain. These results demonstrate the important role of these genes in defense against oxidative stress in different periods of growth. Furthermore, the lack of Cu/Zn-SOD activity in both mutant strains indicated that common metal cofactors likely interfere in SOD activity regulation. These results also indicate that E. coli K-12, a classical non-environmental strain, constitutes a model of phenotypic plasticity for adaptation to a redox-cycling herbicide through redundancy of different isoforms of SOD and CAT enzymes.
28113116	0	9	Metabolic	T169	C0311400
28113116	10	22	Interference	T169	C0521102
28113116	26	29	sod	T116,T121,T126	C0038838
28113116	30	44	gene mutations	T045	C0596611
28113116	48	65	catalase activity	T044	C1151515
28113116	69	85	Escherichia coli	T007	C0014834
28113116	86	96	exposed to	T080	C0332157
28113116	97	106	Gramoxone	T109,T131	C0282285
28113116	110	118	paraquat	T109,T131	C0030493
28113116	120	129	herbicide	T131	C0019236
28113116	130	140	Herbicides	T131	C0019236
28113116	179	183	loss	T081	C1517945
28113116	187	191	crop	T002	C0242775
28113116	192	204	productivity	T081	C0033269
28113116	208	233	agricultural environments	T082	C0562975
28113116	260	266	damage	T169	C1883709
28113116	270	280	inhibiting	T052	C3463820
28113116	285	305	growth of microbiota	T040	C0597252
28113116	310	326	oxidative stress	T049	C0242606
28113116	349	359	production	T057	C0033268
28113116	363	386	reactive oxygen species	T123,T196	C0162772
28113116	388	391	ROS	T123,T196	C0162772
28113116	394	419	Cellular responses to ROS	T043	C2612730
28113116	432	438	action	T052	C3266814
28113116	442	449	enzymes	T116,T126	C0014442
28113116	461	481	superoxide dismutase	T116,T121,T126	C0038838
28113116	483	486	SOD	T116,T121,T126	C0038838
28113116	492	500	catalase	T116,T126	C0007367
28113116	502	505	CAT	T116,T126	C0007367
28113116	552	570	adaptive responses	T043	C2752209
28113116	574	595	Escherichia coli K-12	T007	C0596533
28113116	599	607	paraquat	T109,T131	C0030493
28113116	613	630	active ingredient	T120	C1372955
28113116	638	647	herbicide	T131	C0019236
28113116	648	657	Gramoxone	T109,T131	C0282285
28113116	661	667	Mutant	T049	C0596988
28113116	668	685	bacterial strains	T007	C0004611
28113116	695	704	deletions	T045	C0017260
28113116	708	713	genes	T028	C0017337
28113116	714	722	encoding	T052	C2700640
28113116	723	729	Mn-SOD	T116,T126	C0024708
28113116	731	735	sodA	T028	C1420307
28113116	741	747	Fe-SOD	T116,T126	C0022091
28113116	749	753	sodB	T028	C0017337
28113116	769	780	resulted in	T169	C0332294
28113116	800	817	hydrogen peroxide	T121,T130,T197	C0020281
28113116	818	828	production	T057	C0033268
28113116	830	842	interference	T169	C0521102
28113116	846	861	malondialdehyde	T109,T123	C0024643
28113116	867	876	viability	T080	C0443348
28113116	878	887	Mutations	T045	C0026882
28113116	893	904	resulted in	T169	C0332294
28113116	925	942	interference with	T169	C0521102
28113116	947	962	activity of CAT	T044	C1151515
28113116	963	973	isoenzymes	T116,T126	C0022173
28113116	985	997	inactivation	T169	C0544461
28113116	1001	1010	Cu/Zn-SOD	T044	C2261927
28113116	1011	1019	activity	T052	C0441655
28113116	1027	1036	mutations	T045	C0026882
28113116	1060	1069	metabolic	T169	C0311400
28113116	1070	1081	differences	T080	C1705242
28113116	1102	1109	strains	T007	C0004611
28113116	1111	1123	resulting in	T169	C0332294
28113116	1146	1159	antioxidative	T121	C0003402
28113116	1160	1169	responses	T032	C0871261
28113116	1184	1192	mutation	T045	C0026882
28113116	1211	1217	damage	T169	C1883709
28113116	1227	1231	sodB	T028	C0017337
28113116	1232	1238	strain	T007	C0004611
28113116	1316	1320	sodA	T028	C1420307
28113116	1321	1327	strain	T007	C0004611
28113116	1335	1342	results	T169	C1274040
28113116	1383	1388	genes	T028	C0017337
28113116	1392	1424	defense against oxidative stress	T043	C1155312
28113116	1449	1455	growth	T040	C0018270
28113116	1482	1491	Cu/Zn-SOD	T044	C2261927
28113116	1492	1500	activity	T052	C0441655
28113116	1509	1515	mutant	T049	C0596988
28113116	1516	1523	strains	T007	C0004611
28113116	1524	1533	indicated	T033	C1444656
28113116	1546	1551	metal	T197	C0025552
28113116	1552	1561	cofactors	T123	C0178555
28113116	1582	1585	SOD	T116,T121,T126	C0038838
28113116	1586	1605	activity regulation	T044	C1327623
28113116	1613	1620	results	T169	C1274040
28113116	1640	1652	E. coli K-12	T007	C0596533
28113116	1684	1690	strain	T007	C0004611
28113116	1715	1725	phenotypic	T032	C0031437
28113116	1726	1736	plasticity	T070	C0678558
28113116	1741	1751	adaptation	T038	C0392673
28113116	1757	1770	redox-cycling	T044	C0030012
28113116	1771	1780	herbicide	T131	C0019236
28113116	1813	1821	isoforms	T116,T126	C0022173
28113116	1825	1828	SOD	T116,T121,T126	C0038838
28113116	1833	1844	CAT enzymes	T116,T126	C0007367

27990642|t|Anemia tolerance during normo -, hypo -, and hypervolemia
27990642|a|Restrictive intraoperative fluid management has been demonstrated to improve outcome of visceral and lung surgery in several studies. However, subsequent hypovolemia (HOV) may be accompanied by a decrease of anemia tolerance, resulting in increased transfusion needs. We therefore investigated the effect of volume status on anemia tolerance. Eighteen domestic pigs of either sex (mean weight, 23.5 ± 4.8 kg) were anesthetized, ventilated, and randomized into three experimental groups: normovolemia (no intervention), HOV (blood loss of 40% of blood volume), and hypervolemia (HEV; volume infusion of 40% of blood volume). The animals were then hemodiluted until their individual critical hemoglobin concentrations (Hbcrit) were reached by the exchange of whole blood for hydroxyethyl starch (HES; 130:0.4). Subsequently, organ-specific hypoxia was assessed using pimonidazole tissue staining in relevant organs. Hemodynamic and metabolic variables were also investigated. Despite significant differences in exchangeable blood volume, Hbcrit was the same in all groups (2.3 g/dL, NS). During HOV, tissue hypoxia was aggravated in the myocardium, brain, and kidneys, whereas tissue oxygenation of the liver and intestine was not influenced by volume status. HEV increased tissue hypoxia in the lungs, but did not impact tissue oxygenation of other organs. The combination of hemorrhagic HOV with subsequent anemia leads to accentuated tissue hypoxia, revealed by a significant increase in pimonidazole binding at Hbcrit, in heart, lungs, brain, and kidney. The lungs were the only organ that showed increased tissue hypoxia after pretreatment of HES infusion and subsequent anemia by normovolemic hemodilution.
27990642	0	6	Anemia	T047	C0002871
27990642	7	16	tolerance	T080	C1704410
27990642	24	29	normo	T039	C0232091
27990642	33	37	hypo	T033	C0546884
27990642	45	57	hypervolemia	T047	C0546817
27990642	70	84	intraoperative	T058	C0021889
27990642	85	101	fluid management	T061	C0553741
27990642	146	154	visceral	T082	C0442045
27990642	159	171	lung surgery	T061	C0038903
27990642	212	223	hypovolemia	T033	C0546884
27990642	225	228	HOV	T033	C0546884
27990642	266	272	anemia	T047	C0002871
27990642	273	282	tolerance	T080	C1704410
27990642	307	318	transfusion	T061	C0005841
27990642	366	379	volume status	T201	C0005850
27990642	383	389	anemia	T047	C0002871
27990642	390	399	tolerance	T080	C1704410
27990642	410	423	domestic pigs	T015	C1136016
27990642	434	437	sex	T032	C1522384
27990642	472	484	anesthetized	T033	C1720436
27990642	486	496	ventilated	T169	C0231923
27990642	537	543	groups	T096	C1642385
27990642	545	557	normovolemia	T039	C0232091
27990642	577	580	HOV	T033	C0546884
27990642	582	592	blood loss	T046	C0019080
27990642	603	615	blood volume	T201	C0005850
27990642	622	634	hypervolemia	T047	C0546817
27990642	636	639	HEV	T047	C0546817
27990642	641	647	volume	T201	C0005850
27990642	648	656	infusion	T061	C0574032
27990642	667	679	blood volume	T201	C0005850
27990642	686	693	animals	T008	C0003062
27990642	704	715	hemodiluted	T061	C0019009
27990642	739	773	critical hemoglobin concentrations	T034	C1318517
27990642	775	781	Hbcrit	T034	C1318517
27990642	815	826	whole blood	T031	C0370231
27990642	831	850	hydroxyethyl starch	T109,T121	C0020352
27990642	852	855	HES	T109,T121	C0020352
27990642	896	903	hypoxia	T046	C0242184
27990642	923	935	pimonidazole	T109,T130	C0071072
27990642	936	951	tissue staining	T059	C0487602
27990642	964	970	organs	T023	C0003055
27990642	972	983	Hemodynamic	T042	C0019010
27990642	988	997	metabolic	T040	C0025519
27990642	998	1007	variables	T080	C0439828
27990642	1080	1092	blood volume	T201	C0005850
27990642	1094	1100	Hbcrit	T034	C1318517
27990642	1121	1127	groups	T096	C1642385
27990642	1151	1154	HOV	T033	C0546884
27990642	1163	1170	hypoxia	T046	C0242184
27990642	1193	1203	myocardium	T024	C0027061
27990642	1205	1210	brain	T023	C0006104
27990642	1216	1223	kidneys	T023	C0022646
27990642	1233	1251	tissue oxygenation	T042	C0872293
27990642	1259	1264	liver	T023	C0023884
27990642	1269	1278	intestine	T023	C0021853
27990642	1301	1314	volume status	T201	C0005850
27990642	1316	1319	HEV	T047	C0546817
27990642	1330	1344	tissue hypoxia	T046	C0242184
27990642	1352	1357	lungs	T023	C0024109
27990642	1378	1396	tissue oxygenation	T042	C0872293
27990642	1406	1412	organs	T023	C0003055
27990642	1433	1444	hemorrhagic	T046	C0019080
27990642	1445	1448	HOV	T033	C0546884
27990642	1465	1471	anemia	T047	C0002871
27990642	1493	1507	tissue hypoxia	T046	C0242184
27990642	1547	1559	pimonidazole	T109,T130	C0071072
27990642	1571	1577	Hbcrit	T034	C1318517
27990642	1582	1587	heart	T023	C0018787
27990642	1589	1594	lungs	T023	C0024109
27990642	1596	1601	brain	T023	C0006104
27990642	1607	1613	kidney	T023	C0022646
27990642	1619	1624	lungs	T023	C0024109
27990642	1639	1644	organ	T023	C0003055
27990642	1667	1681	tissue hypoxia	T046	C0242184
27990642	1704	1707	HES	T109,T121	C0020352
27990642	1708	1716	infusion	T061	C0574032
27990642	1732	1738	anemia	T047	C0002871
27990642	1742	1754	normovolemic	T039	C0232091
27990642	1755	1767	hemodilution	T061	C0019009

27610145|t|Development of a Curcumin Bioadhesive Monolithic Tablet for Treatment of Vaginal Candidiasis
27610145|a|The present investigation was designed to formulate a natural tablet for the treatment of vaginal candidiasis in order to eliminate side effects that are caused by existing antifungal drugs. Curcumin has promising antifungal activity in comparison with the existing azole antifungal drugs. Bioadhesive curcumin vaginal tablets were prepared by direct compression with different ratios of biadhesive polymers like xanthan gum, guar gum and HPMC. Curcumin tablets were characterized by studies of friability, hardness, hydration, DSC, mucoadhesion, In-vitro release and antifungal activity. DSC and FT-IR data indicate there was no interaction between the drug and the excipients and also polymer concentration has some effects on melting point of curcumin. Formulation F3 showed the best results in terms of swelling and mucoadhesion together with prolonged drug release. The antifungal activity of the Curcumin tablet has demonstrated a significant effect against Candida albicans. Hence, the study indicates the possible and effective use of curcumin bioadhesive monolithic vaginal tablet for vaginal candidiasis as a promising natural antifungal treatment.
27610145	0	11	Development	T169	C1527148
27610145	17	25	Curcumin	T109,T121,T130	C0010467
27610145	26	55	Bioadhesive Monolithic Tablet	T122	C0042264
27610145	60	69	Treatment	T061	C0087111
27610145	73	92	Vaginal Candidiasis	T047	C0006852
27610145	105	118	investigation	T058	C0220825
27610145	135	144	formulate	T121	C1254351
27610145	147	161	natural tablet	T122	C0042264
27610145	170	179	treatment	T061	C0087111
27610145	183	202	vaginal candidiasis	T047	C0006852
27610145	215	224	eliminate	T080	C0849355
27610145	225	237	side effects	T046	C0879626
27610145	266	282	antifungal drugs	T121	C0003308
27610145	284	292	Curcumin	T109,T121,T130	C0010467
27610145	307	317	antifungal	T121	C0003308
27610145	318	326	activity	T169	C0205177
27610145	330	340	comparison	T052	C1707455
27610145	359	381	azole antifungal drugs	T109,T121	C0360363
27610145	383	403	Bioadhesive curcumin	T109,T121,T130	C0010467
27610145	404	419	vaginal tablets	T122	C0042264
27610145	444	455	compression	T070	C0728907
27610145	471	477	ratios	T081	C0456603
27610145	481	500	biadhesive polymers	T104,T122	C0032521
27610145	506	517	xanthan gum	T109,T121	C0078596
27610145	519	527	guar gum	T109,T121	C0061996
27610145	532	536	HPMC	T109,T121	C0063242
27610145	538	546	Curcumin	T109,T121,T130	C0010467
27610145	547	554	tablets	T122	C0042264
27610145	577	584	studies	T062	C2603343
27610145	588	598	friability	T080	C0332535
27610145	600	608	hardness	T080	C0018599
27610145	610	619	hydration	T033	C1321013
27610145	621	624	DSC	T059	C0006780
27610145	626	638	mucoadhesion	T070	C0175633
27610145	640	648	In-vitro	T080	C1533691
27610145	649	656	release	T169	C1283071
27610145	661	671	antifungal	T121	C0003308
27610145	672	680	activity	T169	C0205177
27610145	682	685	DSC	T059	C0006780
27610145	690	695	FT-IR	T059	C0920528
27610145	696	700	data	T078	C1511726
27610145	747	751	drug	T121	C1254351
27610145	760	770	excipients	T122	C0015237
27610145	780	787	polymer	T104,T122	C0032521
27610145	788	801	concentration	T081	C1446561
27610145	822	835	melting point	T070	C1881775
27610145	839	847	curcumin	T109,T121,T130	C0010467
27610145	849	863	Formulation F3	T121	C1254351
27610145	880	887	results	T169	C1274040
27610145	900	908	swelling	T033	C0038999
27610145	913	925	mucoadhesion	T070	C0175633
27610145	940	949	prolonged	T079	C0439590
27610145	950	962	drug release	T070	C3850077
27610145	968	978	antifungal	T121	C0003308
27610145	979	987	activity	T169	C0205177
27610145	995	1003	Curcumin	T109,T121,T130	C0010467
27610145	1004	1010	tablet	T122	C0042264
27610145	1042	1048	effect	T080	C1280500
27610145	1057	1073	Candida albicans	T004	C0006837
27610145	1086	1091	study	T062	C2603343
27610145	1106	1114	possible	T033	C0332149
27610145	1119	1128	effective	T080	C1704419
27610145	1136	1144	curcumin	T109,T121,T130	C0010467
27610145	1145	1182	bioadhesive monolithic vaginal tablet	T122	C0042264
27610145	1187	1206	vaginal candidiasis	T047	C0006852
27610145	1230	1250	antifungal treatment	T061	C2363963

28437199|t|The Correlation of Arterial Stiffness with Biophysical Parameters and Blood Biochemistry
28437199|a|Type 2 diabetes presents with numerous macrovascular and microvascular impairments, which in turn lead to various co-morbidities. Vascular co-morbidities can be seen when examining arterial stiffness (AS), which is a predictor for endothelial health and cardiovascular disease risk. Pulse wave analysis (PWA) and pulse wave velocity (PWV) are two tests that are commonly used to measure AS. Currently, disease states and progression are tracked via blood biochemistry. These gold standards in monitoring diabetes are expensive and need optimization. To investigate which biophysical and biochemical parameters correlated best with AS, which may reduce the number of biochemical tests and biophysical parameter measurements needed to track disease progression. Data from 42 subjects with type 2 diabetes mellitus for ≤10 years, aged 40-70 years, were analyzed at a single time point. We investigated various blood biochemistry, body composition, and AS parameters. A combination of fat mass and fat-free mass was most associated with PWA over any other parameters. Leptin and high-sensitivity C-reactive protein seem to be the next two parameters that correlate with augmentation index. No other parameters had strong correlations to either PWA or PWV values. Body composition methods seemed to be better predictors of type 2 diabetes mellitus patient's vascular disease progression. Our study indicates that body composition measurements may help replace expensive tests. This may have public health and health surveillance implications in countries facing financial challenges.
28437199	4	15	Correlation	T080	C1707520
28437199	19	37	Arterial Stiffness	T039	C0599949
28437199	43	65	Biophysical Parameters	T081	C0392762
28437199	70	75	Blood	T031	C0005767
28437199	76	88	Biochemistry	T090	C0005477
28437199	89	104	Type 2 diabetes	T047	C0011860
28437199	128	141	macrovascular	T047	C0042373
28437199	146	171	microvascular impairments	T047	C0042373
28437199	203	217	co-morbidities	T078	C0009488
28437199	219	227	Vascular	T023	C0005847
28437199	228	242	co-morbidities	T078	C0009488
28437199	270	288	arterial stiffness	T039	C0599949
28437199	290	292	AS	T039	C0599949
28437199	306	315	predictor	T078	C2698872
28437199	320	331	endothelial	T024	C0014257
28437199	332	338	health	T078	C0018684
28437199	343	365	cardiovascular disease	T047	C0007222
28437199	366	370	risk	T078	C0035647
28437199	372	391	Pulse wave analysis	T060	C3494430
28437199	393	396	PWA	T060	C3494430
28437199	402	421	pulse wave velocity	T081	C3494431
28437199	423	426	PWV	T081	C3494431
28437199	468	475	measure	T169	C0242485
28437199	476	478	AS	T039	C0599949
28437199	491	505	disease states	T033	C3887610
28437199	510	521	progression	T046	C0242656
28437199	526	533	tracked	T057	C0681689
28437199	538	543	blood	T031	C0005767
28437199	544	556	biochemistry	T090	C0005477
28437199	564	578	gold standards	T080	C0150110
28437199	582	592	monitoring	T058	C1283169
28437199	593	601	diabetes	T047	C0011847
28437199	606	615	expensive	T033	C0243095
28437199	625	637	optimization	T052	C2698650
28437199	660	671	biophysical	T081	C0392762
28437199	676	698	biochemical parameters	T081	C0392762
28437199	720	722	AS	T039	C0599949
28437199	755	772	biochemical tests	T059	C0430027
28437199	777	798	biophysical parameter	T081	C0392762
28437199	799	811	measurements	T169	C0242485
28437199	822	827	track	T057	C0681689
28437199	828	847	disease progression	T046	C0242656
28437199	862	870	subjects	T096	C0681850
28437199	876	900	type 2 diabetes mellitus	T047	C0011860
28437199	939	947	analyzed	T062	C0936012
28437199	953	970	single time point	T079	C2348792
28437199	996	1001	blood	T031	C0005767
28437199	1002	1014	biochemistry	T090	C0005477
28437199	1016	1032	body composition	T032	C0005885
28437199	1038	1040	AS	T039	C0599949
28437199	1041	1051	parameters	T081	C0392762
28437199	1070	1078	fat mass	T032	C3656665
28437199	1083	1096	fat-free mass	T033	C0424679
28437199	1106	1121	associated with	T080	C0332281
28437199	1122	1125	PWA	T060	C3494430
28437199	1141	1151	parameters	T081	C0392762
28437199	1153	1159	Leptin	T116,T125	C0299583
28437199	1181	1199	C-reactive protein	T116,T129	C0006560
28437199	1224	1234	parameters	T081	C0392762
28437199	1255	1273	augmentation index	T081	C0392762
28437199	1284	1294	parameters	T081	C0392762
28437199	1329	1332	PWA	T060	C3494430
28437199	1336	1339	PWV	T081	C3494431
28437199	1348	1372	Body composition methods	T059	C0022885
28437199	1393	1403	predictors	T078	C2698872
28437199	1407	1431	type 2 diabetes mellitus	T047	C0011860
28437199	1432	1441	patient's	T101	C0030705
28437199	1442	1458	vascular disease	T047	C0042373
28437199	1459	1470	progression	T046	C0242656
28437199	1476	1481	study	T062	C2603343
28437199	1497	1526	body composition measurements	T201	C1285593
28437199	1544	1559	expensive tests	T059	C0022885
28437199	1575	1588	public health	T058	C0699943
28437199	1593	1612	health surveillance	T058	C3494318
28437199	1629	1638	countries	T083	C0454664
28437199	1646	1666	financial challenges	T033	C0549106

27483491|t|Hierarchical Address Event Routing for Reconfigurable Large-Scale Neuromorphic Systems
27483491|a|We present a hierarchical address-event routing (HiAER) architecture for scalable communication of neural and synaptic spike events between neuromorphic processors, implemented with five Xilinx Spartan-6 field-programmable gate arrays and four custom analog neuromophic integrated circuits serving 262k neurons and 262M synapses. The architecture extends the single-bus address-event representation protocol to a hierarchy of multiple nested buses, routing events across increasing scales of spatial distance. The HiAER protocol provides individually programmable axonal delay in addition to strength for each synapse, lending itself toward biologically plausible neural network architectures, and scales across a range of hierarchies suitable for multichip and multiboard systems in reconfigurable large-scale neuromorphic systems. We show approximately linear scaling of net global synaptic event throughput with number of routing nodes in the network, at $3.6x10^7$ synaptic events per second per 16k- neuron node in the hierarchy.
27483491	54	86	Large-Scale Neuromorphic Systems	T170	C0282574
27483491	143	155	architecture	T078	C0009596
27483491	169	182	communication	T052	C0441655
27483491	186	192	neural	T022	C0027763
27483491	197	205	synaptic	T030	C0039062
27483491	206	218	spike events	T051	C0441471
27483491	227	250	neuromorphic processors	T073	C1707713
27483491	274	321	Xilinx Spartan-6 field-programmable gate arrays	T073	C0699733
27483491	345	376	neuromophic integrated circuits	T073	C0699733
27483491	390	397	neurons	T025	C0027882
27483491	407	415	synapses	T030	C0039062
27483491	421	433	architecture	T078	C0009596
27483491	486	494	protocol	T170	C0442711
27483491	513	534	multiple nested buses	T080	C0205556
27483491	536	550	routing events	T051	C0441471
27483491	579	595	spatial distance	T081	C0012751
27483491	607	615	protocol	T170	C0442711
27483491	651	657	axonal	T026	C0004461
27483491	658	663	delay	T079	C0205421
27483491	697	704	synapse	T030	C0039062
27483491	751	779	neural network architectures	T040	C0598941
27483491	835	844	multichip	T073	C3273359
27483491	849	867	multiboard systems	T073	C3273359
27483491	886	918	large-scale neuromorphic systems	T170	C0282574
27483491	942	956	linear scaling	T052	C1947916
27483491	960	985	net global synaptic event	T051	C0441471
27483491	971	979	synaptic	T030	C0039062
27483491	1012	1025	routing nodes	T077	C1254372
27483491	1033	1040	network	T169	C1882071
27483491	1056	1064	synaptic	T030	C0039062
27483491	1065	1071	events	T051	C0441471
27483491	1092	1098	neuron	T025	C0027882
27483491	1099	1103	node	T077	C1254372

27680099|t|Mandibular intraosseous pseudocarcinomatous hyperplasia: a case report
27680099|a|Mandibular pseudocarcinomatous hyperplasia is a rare and generally benign pathology. We report on one of these rare cases. The case history of a 73-year-old white man stated that he had a carcinoma of the oropharynx, which was primarily treated with radiotherapy and chemotherapy 4 years prior. As a result of radiotherapy he developed an osteoradionecrosis of his mandible and a consecutive pathological fracture of his left mandibular angle. Subsequent osteosynthesis was performed with a reconstruction plate. When we first saw him, his reconstruction plate was partially exposed with intraoral and extraoral fistulation. The resected bone of his defect-bordering jaw showed the typical pathohistological findings of an intraosseous mandibular pseudocarcinomatous hyperplasia. After a first reconstruction attempt with an iliac crest graft failed, definitive reconstruction of his mandible with a microvascular anastomosed fibula graft was achieved. Intraosseous pseudocarcinomatous hyperplasia of the mandible is a rare differential diagnosis in maxillofacial surgery. Besides other benign epithelial neoplasms, such as calcifying epithelial odontogenic tumor, squamous odontogenic tumor, or different forms of ameloblastoma, the far more frequent invasive squamous cell carcinoma needs to be excluded. A misinterpretation of pseudocarcinomatous hyperplasia as squamous cell carcinoma must be avoided because it can lead to a massive overtreatment.
27680099	0	10	Mandibular	T023	C0024687
27680099	11	23	intraosseous	T061	C0162590
27680099	24	55	pseudocarcinomatous hyperplasia	T046	C0333988
27680099	71	81	Mandibular	T023	C0024687
27680099	82	113	pseudocarcinomatous hyperplasia	T046	C0333988
27680099	119	123	rare	T080	C0522498
27680099	138	144	benign	T080	C0205183
27680099	145	154	pathology	T091	C0030664
27680099	182	186	rare	T080	C0522498
27680099	198	210	case history	T170	C0085970
27680099	234	237	man	T032	C0086582
27680099	259	286	carcinoma of the oropharynx	T191	C2349952
27680099	308	320	treated with	T061	C0332293
27680099	321	333	radiotherapy	T061	C1522449
27680099	338	350	chemotherapy	T061	C3665472
27680099	381	393	radiotherapy	T061	C1522449
27680099	410	444	osteoradionecrosis of his mandible	T047	C1290728
27680099	463	484	pathological fracture	T046	C0016663
27680099	492	513	left mandibular angle	T033	C2227484
27680099	526	540	osteosynthesis	T061	C0016642
27680099	562	576	reconstruction	T061	C0524865
27680099	577	582	plate	T074	C0005971
27680099	611	625	reconstruction	T061	C0524865
27680099	626	631	plate	T074	C0005971
27680099	659	668	intraoral	T082	C0442119
27680099	673	682	extraoral	T082	C0442089
27680099	683	694	fistulation	T190	C0011361
27680099	700	708	resected	T061	C0015252
27680099	738	741	jaw	T023	C0022359
27680099	761	778	pathohistological	T091	C0677043
27680099	779	787	findings	T169	C2607943
27680099	794	806	intraosseous	T061	C0162590
27680099	807	817	mandibular	T023	C0024687
27680099	818	849	pseudocarcinomatous hyperplasia	T046	C0333988
27680099	865	879	reconstruction	T061	C0524865
27680099	896	907	iliac crest	T023	C0223651
27680099	908	913	graft	T024	C0332835
27680099	914	920	failed	T169	C0231175
27680099	922	963	definitive reconstruction of his mandible	T061	C0185678
27680099	971	1009	microvascular anastomosed fibula graft	T061	C0188192
27680099	1024	1036	Intraosseous	T061	C0162590
27680099	1037	1068	pseudocarcinomatous hyperplasia	T046	C0333988
27680099	1076	1084	mandible	T023	C0024687
27680099	1090	1094	rare	T080	C0522498
27680099	1090	1094	rare	T080	C0522498
27680099	1095	1117	differential diagnosis	T060	C0011906
27680099	1121	1142	maxillofacial surgery	T091	C0038908
27680099	1158	1164	benign	T080	C0205183
27680099	1165	1185	epithelial neoplasms	T191	C1368683
27680099	1195	1234	calcifying epithelial odontogenic tumor	T191	C0334574
27680099	1236	1262	squamous odontogenic tumor	T191	C1458142
27680099	1286	1299	ameloblastoma	T191	C0002448
27680099	1323	1331	invasive	T080	C0205281
27680099	1332	1355	squamous cell carcinoma	T191	C0007137
27680099	1401	1432	pseudocarcinomatous hyperplasia	T046	C0333988
27680099	1436	1459	squamous cell carcinoma	T191	C0007137
27680099	1501	1508	massive	T080	C0522501
27680099	1509	1522	overtreatment	T058	C4046039

27768391|t|Single-Nucleotide Polymorphism rs17611 of Complement Component 5 Shows Association with Ischemic Stroke in Northeast Chinese Population
27768391|a|Complement component 5 (C5) has been described to play an important role in the development and progression of atherosclerosis and cardiovascular disease. Our aim was to determine whether genetic variation of C5 was associated with ischemic stroke (IS) in northeast Chinese population. We used a case-control study involving 386 IS patients and 386 non-IS controls from a rural population and determined the genotypes of five polymorphisms (rs12237774, rs17611, rs4837805, rs7026551, and rs1017119) of C5 gene by Snapshot single-nucleotide polymorphism genotyping assays to assess any links with IS. In univariate analysis, rs17611 was significantly associated with IS in the additive model, the dominant model, and recessive model (additive p 0.031, dominant p 0.034, and recessive p 0.027). After adjustment for Binary Logistic Regression, rs17611 polymorphism was still significant in three models (adjusted odds ratio (OR) = 1.306, 95% confidence interval (CI) = 1.069-1.595, p-value = 0.009 in an additive model; OR = 1.378, 95% CI = 1.024-1.856, p-value = 0.035 in a dominant model; and OR = 1.511, 95% CI = 1.048-2.18, p-value = 0.027 in a recessive model). In this sample of patients, genetic variation of rs17611 in C5 is associated with higher prevalence of IS.
27768391	0	30	Single-Nucleotide Polymorphism	T086	C0752046
27768391	31	38	rs17611	T086	C0752046
27768391	42	64	Complement Component 5	T028	C1367710
27768391	88	103	Ischemic Stroke	T047	C0948008
27768391	107	135	Northeast Chinese Population	T098	C0152035
27768391	136	158	Complement component 5	T116,T129	C0009519
27768391	160	162	C5	T116,T129	C0009519
27768391	216	227	development	T169	C1527148
27768391	232	243	progression	T046	C0242656
27768391	247	262	atherosclerosis	T047	C0004153
27768391	267	289	cardiovascular disease	T047	C0007222
27768391	295	298	aim	T078	C1947946
27768391	324	341	genetic variation	T070	C0042333
27768391	345	347	C5	T028	C1367710
27768391	368	383	ischemic stroke	T047	C0948008
27768391	385	387	IS	T047	C0948008
27768391	392	420	northeast Chinese population	T098	C0152035
27768391	432	450	case-control study	T062	C0007328
27768391	465	467	IS	T047	C0948008
27768391	468	476	patients	T101	C0030705
27768391	485	491	non-IS	T080	C3898900
27768391	492	500	controls	T096	C0009932
27768391	508	524	rural population	T098	C0035962
27768391	544	553	genotypes	T032	C0017431
27768391	562	575	polymorphisms	T045	C0032529
27768391	577	587	rs12237774	T086	C0752046
27768391	589	596	rs17611	T086	C0752046
27768391	598	607	rs4837805	T086	C0752046
27768391	609	618	rs7026551	T086	C0752046
27768391	624	633	rs1017119	T086	C0752046
27768391	638	645	C5 gene	T028	C1367710
27768391	658	706	single-nucleotide polymorphism genotyping assays	T059	C1285573
27768391	710	716	assess	T052	C1516048
27768391	732	734	IS	T047	C0948008
27768391	739	758	univariate analysis	T062	C0683962
27768391	760	767	rs17611	T086	C0752046
27768391	772	785	significantly	T078	C0750502
27768391	802	804	IS	T047	C0948008
27768391	812	826	additive model	T170	C0026343
27768391	832	846	dominant model	T170	C0026343
27768391	852	867	recessive model	T170	C0026343
27768391	869	885	additive p 0.031	T170	C0026343
27768391	887	903	dominant p 0.034	T170	C0026343
27768391	909	926	recessive p 0.027	T170	C0026343
27768391	950	976	Binary Logistic Regression	T062	C0206031
27768391	978	998	rs17611 polymorphism	T086	C0752046
27768391	1047	1057	odds ratio	T081	C0028873
27768391	1059	1061	OR	T081	C0028873
27768391	1076	1095	confidence interval	T081	C0009667
27768391	1097	1099	CI	T081	C0009667
27768391	1116	1123	p-value	T081	C1709380
27768391	1138	1152	additive model	T170	C0026343
27768391	1154	1156	OR	T081	C0028873
27768391	1170	1172	CI	T081	C0009667
27768391	1188	1195	p-value	T081	C1709380
27768391	1209	1223	dominant model	T170	C0026343
27768391	1229	1231	OR	T081	C0028873
27768391	1245	1247	CI	T081	C0009667
27768391	1262	1269	p-value	T081	C1709380
27768391	1283	1298	recessive model	T170	C0026343
27768391	1309	1315	sample	T167	C0370003
27768391	1319	1327	patients	T101	C0030705
27768391	1329	1346	genetic variation	T070	C0042333
27768391	1350	1357	rs17611	T086	C0752046
27768391	1361	1363	C5	T028	C1367710
27768391	1390	1400	prevalence	T081	C0033105
27768391	1404	1406	IS	T047	C0948008

28416855|t|Production and characterization of functional properties of protein hydrolysates from egg shell membranes by lactic acid bacteria fermentation
28416855|a|This study aimed to ferment the chicken eggshell membrane (ESM) using the lactic acid bacteria, Lactobacillus plantarum for preparation of functional and bioactive protein hydrolysates. Cultivation at an initial pH of 8.0 for 36 h resulted in maximum protein concentration (177.3 mg/g) and degree of hydrolysis (25.1%) of the hydrolysates. Fermentation resulted in the production of hydrolysates that demonstrated excellent solubility (90.7%), good foaming capacity (36.7%) and emulsification activity (94.6 m(2)/g). Additionally, these protein hydrolysates exhibited remarkable bioactive properties for instance reducing power (2.53), protection from DPPH radical (70.5%) and angiotensin I converting enzyme inhibition (49.3%). The fermented protein hydrolysates were also found effective against various foodborne pathogens. The protein hydrolysates obtained by fermentation of ESM can be potentially incorporated in functional foods and nutraceuticals resulting in valorization of the ESM waste.
28416855	15	31	characterization	T052	C1880022
28416855	35	45	functional	T169	C0205245
28416855	46	56	properties	T080	C0871161
28416855	60	80	protein hydrolysates	T116,T121	C0033631
28416855	86	105	egg shell membranes	T109,T121	C3651790
28416855	109	129	lactic acid bacteria	T007	C0678170
28416855	130	142	fermentation	T044	C0015852
28416855	163	170	ferment	T044	C0015852
28416855	175	182	chicken	T012	C0008051
28416855	183	200	eggshell membrane	T109,T121	C3651790
28416855	202	205	ESM	T109,T121	C3651790
28416855	217	237	lactic acid bacteria	T007	C0678170
28416855	239	262	Lactobacillus plantarum	T007	C0317608
28416855	282	292	functional	T169	C0205245
28416855	307	327	protein hydrolysates	T116,T121	C0033631
28416855	355	357	pH	T081	C0020283
28416855	394	401	protein	T116,T123	C0033684
28416855	402	415	concentration	T081	C1446561
28416855	433	453	degree of hydrolysis	T081	C0392762
28416855	469	481	hydrolysates	T116,T121	C0033631
28416855	483	495	Fermentation	T044	C0015852
28416855	526	538	hydrolysates	T116,T121	C0033631
28416855	567	577	solubility	T080	C0037628
28416855	587	608	good foaming capacity	T120	C0599512
28416855	621	644	emulsification activity	T061	C1292839
28416855	680	700	protein hydrolysates	T116,T121	C0033631
28416855	722	742	bioactive properties	T033	C0243095
28416855	756	770	reducing power	T081	C0392762
28416855	795	799	DPPH	T109	C2936710
28416855	800	807	radical	T104	C0302912
28416855	820	851	angiotensin I converting enzyme	T116,T126,T129	C0022709
28416855	852	862	inhibition	T039	C1524081
28416855	876	885	fermented	T044	C0015852
28416855	886	906	protein hydrolysates	T116,T121	C0033631
28416855	949	958	foodborne	T169	C3242390
28416855	959	968	pathogens	T001	C0450254
28416855	974	994	protein hydrolysates	T116,T121	C0033631
28416855	1007	1019	fermentation	T044	C0015852
28416855	1023	1026	ESM	T109,T121	C3651790
28416855	1062	1078	functional foods	T168	C2717755
28416855	1083	1097	nutraceuticals	T168	C1518478
28416855	1131	1134	ESM	T109,T121	C3651790

27936395|t|Population based report on health related quality of life in adolescents born very preterm
27936395|a|As the survival rate of preterm infants constantly improves, knowledge on the impact of prematurity on long-term health-related quality of life (HRQoL) is important for clinical and parental guidance. We aimed to assess HRQoL in a national cohort of young adolescents born very preterm, and to identify predictors for poorer HRQoL. All surviving Swiss live-born children below 30weeks of gestation during the year 2000 (290 subjects) were contacted at age 12years, together with their parents (262 families). HRQoL of the study children was assessed using both the Kidscreen-27 (KS-27) self- and parent forms. Neonatal data of the cohort were prospectively collected. Among the contacted families, 176 returned the complete set of questionnaires for 194 adolescents (67%): 100 (51%) females, mean (range) gestational age was 27.8 (24.1-29.9) weeks, birth weight 1025 (420-1730) grams, mean age at assessment 12.0 (11.0-13.0) years. Included children had similar neonatal and socio-demographic characteristics as non-responders. Average self - and parent -reported HRQoL of former preterms was similar to Swiss KS-27 norms. According to the multivariable models (r(2)=0.2), surgical closure of patent ductus arteriosus, attention deficit/hyperactivity disorder, severe neurodevelopment impairment were negatively associated with both self - and parent -reported HRQoL. HRQoL in this population -based cohort of adolescents born very preterm is good. Surgical closure of patent ductus arteriosus, attention deficit/hyperactivity disorder, severe neurodevelopment impairment were identified as predictors of poorer HRQoL using multivariable models, explaining however only a low proportion of variance in HRQoL.
27936395	0	10	Population	T098	C1257890
27936395	17	23	report	T170	C0684224
27936395	27	57	health related quality of life	T078	C4279947
27936395	61	72	adolescents	T100	C0205653
27936395	73	77	born	T040	C0005615
27936395	78	90	very preterm	T033	C4053870
27936395	98	111	survival rate	T081	C0038954
27936395	115	130	preterm infants	T100	C4048294
27936395	169	175	impact	T080	C4049986
27936395	179	190	prematurity	T033	C0151526
27936395	194	203	long-term	T079	C0443252
27936395	204	234	health-related quality of life	T078	C4279947
27936395	236	241	HRQoL	T078	C4279947
27936395	260	268	clinical	T058	C0150600
27936395	273	290	parental guidance	T058	C0150600
27936395	304	310	assess	T058	C0220825
27936395	311	316	HRQoL	T078	C4279947
27936395	322	337	national cohort	T098	C0599755
27936395	341	346	young	T079	C0332239
27936395	347	358	adolescents	T100	C0205653
27936395	359	363	born	T040	C0005615
27936395	364	376	very preterm	T033	C4053870
27936395	394	404	predictors	T170	C0683956
27936395	409	415	poorer	T080	C0542537
27936395	416	421	HRQoL	T078	C4279947
27936395	437	442	Swiss	T098	C0241315
27936395	443	461	live-born children	T033	C0481667
27936395	468	488	30weeks of gestation	T079	C0233037
27936395	515	523	subjects	T098	C0080105
27936395	543	546	age	T032	C0001779
27936395	576	583	parents	T099	C0030551
27936395	589	597	families	T099	C0015576
27936395	600	605	HRQoL	T078	C4279947
27936395	613	627	study children	T100	C0008059
27936395	632	640	assessed	T052	C1516048
27936395	656	699	Kidscreen-27 (KS-27) self- and parent forms	T170	C0034394
27936395	701	709	Neonatal	T079	C2939425
27936395	710	714	data	T078	C1511726
27936395	722	728	cohort	T098	C0599755
27936395	779	787	families	T099	C0015576
27936395	822	836	questionnaires	T170	C0034394
27936395	845	856	adolescents	T100	C0205653
27936395	874	881	females	T032	C0086287
27936395	883	887	mean	T081	C0444504
27936395	896	911	gestational age	T032	C0017504
27936395	940	952	birth weight	T032	C0005612
27936395	976	980	mean	T081	C0444504
27936395	981	984	age	T032	C0001779
27936395	988	998	assessment	T058	C0220825
27936395	1032	1040	children	T100	C0008059
27936395	1053	1061	neonatal	T100	C0021289
27936395	1066	1099	socio-demographic characteristics	T080	C1521970
27936395	1127	1131	self	T078	C0036588
27936395	1138	1144	parent	T099	C0030551
27936395	1155	1160	HRQoL	T078	C4279947
27936395	1171	1179	preterms	T047	C0021294
27936395	1195	1200	Swiss	T098	C0241315
27936395	1195	1212	Swiss KS-27 norms	UnknownType	C0680355
27936395	1231	1251	multivariable models	T170	C0282574
27936395	1264	1280	surgical closure	T061	C0185003
27936395	1284	1308	patent ductus arteriosus	T019	C0013274
27936395	1310	1350	attention deficit/hyperactivity disorder	T048	C4237455
27936395	1352	1358	severe	T080	C0205082
27936395	1359	1375	neurodevelopment	T042	C0599855
27936395	1376	1386	impairment	T169	C0221099
27936395	1424	1428	self	T078	C0036588
27936395	1435	1441	parent	T099	C0030551
27936395	1452	1457	HRQoL	T078	C4279947
27936395	1459	1464	HRQoL	T078	C4279947
27936395	1473	1483	population	T098	C1257890
27936395	1491	1497	cohort	T098	C0599755
27936395	1501	1512	adolescents	T100	C0205653
27936395	1513	1517	born	T040	C0005615
27936395	1518	1530	very preterm	T033	C4053870
27936395	1540	1556	Surgical closure	T061	C0185003
27936395	1560	1584	patent ductus arteriosus	T019	C0013274
27936395	1586	1626	attention deficit/hyperactivity disorder	T048	C4237455
27936395	1628	1634	severe	T080	C0205082
27936395	1635	1651	neurodevelopment	T042	C0599855
27936395	1652	1662	impairment	T169	C0221099
27936395	1682	1692	predictors	T170	C0683956
27936395	1696	1702	poorer	T080	C0542537
27936395	1703	1708	HRQoL	T078	C4279947
27936395	1715	1735	multivariable models	T170	C0282574
27936395	1793	1798	HRQoL	T078	C4279947

27602058|t|The cnidarian Hydractinia echinata employs canonical and highly adapted histones to pack its DNA
27602058|a|Cnidarians are a group of early branching animals including corals, jellyfish and hydroids that are renowned for their high regenerative ability, growth plasticity and longevity. Because cnidarian genomes are conventional in terms of protein-coding genes, their remarkable features are likely a consequence of epigenetic regulation. To facilitate epigenetics research in cnidarians, we analysed the histone complement of the cnidarian model organism Hydractinia echinata using phylogenomics, proteomics, transcriptomics and mRNA in situ hybridisations. We find that the Hydractinia genome encodes 19 histones and analyse their spatial expression patterns, genomic loci and replication -dependency. Alongside core and other replication - independent histone variants, we find several histone replication -dependent variants, including a rare replication -dependent H3.3, a female germ cell - specific H2A.X and an unusual set of five H2B variants, four of which are male germ cell - specific. We further confirm the absence of protamines in Hydractinia. Since no protamines are found in hydroids, we suggest that the novel H2B variants are pivotal for sperm DNA packaging in this class of Cnidaria. This study adds to the limited number of full histone gene complements available in animals and sets a comprehensive framework for future studies on the role of histones and their post-translational modifications in cnidarian epigenetics. Finally, it provides insight into the evolution of spermatogenesis.
27602058	4	13	cnidarian	T204	C0009222
27602058	14	34	Hydractinia echinata	T204	C1005711
27602058	43	52	canonical	T080	C0443211
27602058	72	80	histones	T116,T123	C0019652
27602058	84	96	pack its DNA	T045	C1158486
27602058	97	107	Cnidarians	T204	C0009222
27602058	114	119	group	T098	C1257890
27602058	129	146	branching animals	T008	C0003062
27602058	157	163	corals	T204	C0324034
27602058	165	174	jellyfish	T204	C0022381
27602058	179	187	hydroids	T204	C0997871
27602058	221	233	regenerative	T042	C0034963
27602058	234	241	ability	T032	C0085732
27602058	243	249	growth	T040	C0018270
27602058	250	260	plasticity	T070	C0678558
27602058	265	274	longevity	T079	C0023980
27602058	284	293	cnidarian	T204	C0009222
27602058	294	301	genomes	T028	C0017428
27602058	331	351	protein-coding genes	T028	C3839127
27602058	407	428	epigenetic regulation	T043	C1160454
27602058	444	455	epigenetics	T045	C1516924
27602058	456	464	research	T062	C0035168
27602058	468	478	cnidarians	T204	C0009222
27602058	483	491	analysed	T062	C0936012
27602058	496	503	histone	T116,T123	C0019652
27602058	504	514	complement	T116,T129	C0312743
27602058	522	531	cnidarian	T204	C0009222
27602058	532	546	model organism	T075	C0026339
27602058	547	567	Hydractinia echinata	T204	C1005711
27602058	574	587	phylogenomics	T062	C0035177
27602058	589	599	proteomics	T062	C0035177
27602058	601	616	transcriptomics	T062	C0035177
27602058	621	648	mRNA in situ hybridisations	T062	C0035177
27602058	667	678	Hydractinia	T204	C1000548
27602058	679	685	genome	T028	C0017428
27602058	697	705	histones	T116,T123	C0019652
27602058	710	717	analyse	T062	C0936012
27602058	724	742	spatial expression	T045	C1171362
27602058	743	751	patterns	T082	C0449774
27602058	753	765	genomic loci	T028	C0678933
27602058	770	781	replication	T045	C0598312
27602058	820	831	replication	T045	C0598312
27602058	834	845	independent	T078	C0085862
27602058	846	853	histone	T116,T123	C0019652
27602058	854	862	variants	T080	C0205419
27602058	880	887	histone	T116,T123	C0019652
27602058	888	899	replication	T045	C0598312
27602058	911	919	variants	T080	C0205419
27602058	938	949	replication	T045	C0598312
27602058	961	965	H3.3	T116,T123	C0086412
27602058	969	975	female	T032	C0086287
27602058	976	985	germ cell	T025	C0017471
27602058	988	996	specific	T080	C0205369
27602058	997	1002	H2A.X	T116,T123	C0019652
27602058	1030	1033	H2B	T116,T123	C0086411
27602058	1034	1042	variants	T080	C0205419
27602058	1062	1066	male	T032	C0086582
27602058	1067	1076	germ cell	T025	C0017471
27602058	1079	1087	specific	T080	C0205369
27602058	1123	1133	protamines	T116,T121,T123	C0033603
27602058	1137	1148	Hydractinia	T204	C1000548
27602058	1159	1169	protamines	T116,T121,T123	C0033603
27602058	1183	1191	hydroids	T204	C0997871
27602058	1219	1222	H2B	T116,T123	C0086411
27602058	1223	1231	variants	T080	C0205419
27602058	1248	1253	sperm	T025	C0037868
27602058	1254	1267	DNA packaging	T045	C1158486
27602058	1285	1293	Cnidaria	T204	C0009222
27602058	1300	1305	study	T062	C2603343
27602058	1341	1348	histone	T116,T123	C0019652
27602058	1349	1353	gene	T028	C0017337
27602058	1349	1365	gene complements	T116,T129	C0009498
27602058	1379	1386	animals	T008	C0003062
27602058	1433	1440	studies	T062	C2603343
27602058	1456	1464	histones	T116,T123	C0019652
27602058	1475	1507	post-translational modifications	T044	C0033666
27602058	1511	1520	cnidarian	T204	C0009222
27602058	1521	1532	epigenetics	T045	C1516924
27602058	1572	1581	evolution	T045	C0015219
27602058	1585	1600	spermatogenesis	T043	C0037864

28135680|t|Biofunctional polyethylene glycol coatings on titanium: An in vitro -based comparison of functionalization methods
28135680|a|Three methods for the production of Polyethylene glycol (PEG) coatings on titanium are compared, i.e. plasma polymerization, electrodeposition and silanization. The compared deposition methods presented similar wettability (hydrophilic coatings), chemical composition assessed by XPS and thickness around 1nm. The coatings lowered albumin adsorption and presented a decreased fibroblast, Streptococcus sanguinis and Lactobacillus salivarius adhesion. Immobilization of a cell adhesion peptide (RGD) presented a higher fibroblast adhesion and no alteration of the bacterial adhesion, giving three methods for the biofunctionalization of titanium for dental implants. The feasibility of each methodology is compared in terms of the process parameters in order to provide a guide for the election of the methodology.
28135680	0	13	Biofunctional	T169	C0205245
28135680	14	33	polyethylene glycol	T109,T121,T122	C0032483
28135680	34	42	coatings	T080	C1522408
28135680	46	54	titanium	T196	C0040302
28135680	59	67	in vitro	T080	C1533691
28135680	75	85	comparison	T052	C1707455
28135680	89	106	functionalization	T169	C0205245
28135680	107	114	methods	T170	C0025663
28135680	121	128	methods	T170	C0025663
28135680	137	147	production	T057	C0033268
28135680	151	170	Polyethylene glycol	T109,T121,T122	C0032483
28135680	172	175	PEG	T109,T121,T122	C0032483
28135680	177	185	coatings	T080	C1522408
28135680	189	197	titanium	T196	C0040302
28135680	202	210	compared	T052	C1707455
28135680	217	223	plasma	T031	C0032105
28135680	224	238	polymerization	T067	C0314672
28135680	240	257	electrodeposition	T070	C0013866
28135680	262	274	silanization	T067	C1254366
28135680	280	288	compared	T052	C1707455
28135680	289	299	deposition	T169	C0333562
28135680	300	307	methods	T170	C0025663
28135680	308	317	presented	T078	C0449450
28135680	318	325	similar	T080	C2348205
28135680	326	337	wettability	T080	C0162598
28135680	339	350	hydrophilic	T080	C0475370
28135680	351	359	coatings	T080	C1522408
28135680	362	382	chemical composition	T070	C0243176
28135680	383	391	assessed	T052	C1516048
28135680	395	398	XPS	T059	C2700282
28135680	403	412	thickness	T080	C1280412
28135680	429	437	coatings	T080	C1522408
28135680	438	445	lowered	T081	C1272755
28135680	446	453	albumin	T116,T123	C0001924
28135680	454	464	adsorption	T059	C3826777
28135680	469	478	presented	T078	C0449450
28135680	481	490	decreased	T081	C0205216
28135680	491	501	fibroblast	T025	C0016030
28135680	503	526	Streptococcus sanguinis	T007	C0038412
28135680	531	555	Lactobacillus salivarius	T007	C0317593
28135680	556	564	adhesion	T040	C0004614
28135680	566	580	Immobilization	T061	C0020944
28135680	586	607	cell adhesion peptide	T116,T123	C0007578
28135680	609	612	RGD	T116,T123	C0052350
28135680	614	623	presented	T078	C0449450
28135680	633	643	fibroblast	T025	C0016030
28135680	644	652	adhesion	T043	C0007577
28135680	660	670	alteration	T078	C1515926
28135680	678	696	bacterial adhesion	T040	C0004614
28135680	711	718	methods	T170	C0025663
28135680	727	747	biofunctionalization	T169	C0205245
28135680	751	759	titanium	T196	C0040302
28135680	764	779	dental implants	T074	C0376511
28135680	785	796	feasibility	T080	C0443348
28135680	805	816	methodology	T078	C3266812
28135680	820	828	compared	T052	C1707455
28135680	845	852	process	T067	C1522240
28135680	853	863	parameters	T077	C0549193
28135680	876	883	provide	T052	C1999230
28135680	900	908	election	T052	C1707391
28135680	916	927	methodology	T078	C3266812

28450207|t|Drug release studies from lipid nanoparticles in physiological media by a new DSC method
28450207|a|Lipid nanoparticles are an interesting parenteral delivery system for poorly water-soluble drugs. In order to approach physiological conditions when conducting release studies from such systems the release media should preferentially contain lipophilic acceptor compartments such as lipoproteins or other colloidal lipophilic components. In practice, drug release studies under such close to physiological conditions may be complicated by the small size of lipid nanoparticles, which is in the same range as that of the potential acceptor particles. This study describes a novel differential scanning calorimetry (DSC) method for drug release measurements which works without separation of donor and acceptor particles. The technique is based on measuring the crystallization temperature of trimyristin nanoparticles by DSC. The crystallization temperature of the nanoparticles decreases proportionally with the amount of active ingredient incorporated and thus increases as a result of drug release. Liquid trimyristin nanoparticles loaded with fenofibrate, orlistat, tocopherol acetate and ubidecarenone were studied in three different release media with increasing complexity and comparability to physiological conditions: a rapeseed oil nanoemulsion, porcine serum and porcine blood. Using the new method, a correlation between release behavior and drug lipophilicity was observed: the higher the logP value of the drug, the slower the release. The extent of drug release was influenced by partition equilibrium as indicated by increased drug release in the rapeseed oil nanoemulsion compared to porcine serum and blood.
28450207	0	12	Drug release	T070	C3850077
28450207	13	20	studies	T062	C2603343
28450207	26	31	lipid	T109	C0023779
28450207	32	45	nanoparticles	T073	C1450054
28450207	49	62	physiological	T169	C0205463
28450207	63	68	media	T130	C0010454
28450207	78	81	DSC	T059	C0006780
28450207	82	88	method	T170	C0025663
28450207	89	94	Lipid	T109	C0023779
28450207	95	108	nanoparticles	T073	C1450054
28450207	128	154	parenteral delivery system	T169	C1518896
28450207	166	185	water-soluble drugs	T121	C1254351
28450207	208	221	physiological	T169	C0205463
28450207	222	232	conditions	T080	C0348080
28450207	257	264	studies	T062	C2603343
28450207	295	300	media	T130	C0010454
28450207	331	341	lipophilic	T081	C0598631
28450207	342	363	acceptor compartments	T082	C1254362
28450207	372	384	lipoproteins	T116,T123	C0023820
28450207	394	403	colloidal	T122	C0009361
28450207	404	414	lipophilic	T081	C0598631
28450207	415	425	components	T077	C1705248
28450207	440	452	drug release	T070	C3850077
28450207	453	460	studies	T062	C2603343
28450207	481	494	physiological	T169	C0205463
28450207	495	505	conditions	T080	C0348080
28450207	532	542	small size	T033	C0748864
28450207	546	551	lipid	T109	C0023779
28450207	552	565	nanoparticles	T073	C1450054
28450207	619	637	acceptor particles	T104	C0597177
28450207	644	649	study	T062	C2603343
28450207	668	701	differential scanning calorimetry	T059	C0006780
28450207	703	706	DSC	T059	C0006780
28450207	708	714	method	T170	C0025663
28450207	719	731	drug release	T070	C3850077
28450207	732	744	measurements	T169	C0242485
28450207	779	784	donor	T104	C0597177
28450207	789	807	acceptor particles	T104	C0597177
28450207	813	822	technique	T169	C0449851
28450207	849	864	crystallization	T070	C0010423
28450207	865	876	temperature	T081	C0039476
28450207	880	891	trimyristin	T109,T121	C0077214
28450207	892	905	nanoparticles	T073	C1450054
28450207	909	912	DSC	T059	C0006780
28450207	918	933	crystallization	T070	C0010423
28450207	934	945	temperature	T081	C0039476
28450207	953	966	nanoparticles	T073	C1450054
28450207	1076	1088	drug release	T070	C3850077
28450207	1097	1108	trimyristin	T109,T121	C0077214
28450207	1109	1122	nanoparticles	T073	C1450054
28450207	1135	1146	fenofibrate	T109,T121	C0033228
28450207	1148	1156	orlistat	T109,T121	C0076275
28450207	1158	1176	tocopherol acetate	T109,T121,T127	C0078373
28450207	1181	1194	ubidecarenone	T109,T121,T123	C0056077
28450207	1235	1240	media	T130	C0010454
28450207	1289	1302	physiological	T169	C0205463
28450207	1303	1313	conditions	T080	C0348080
28450207	1317	1342	rapeseed oil nanoemulsion	T121	C3191795
28450207	1344	1351	porcine	T015	C0039005
28450207	1352	1357	serum	T031	C0229671
28450207	1362	1369	porcine	T015	C0039005
28450207	1370	1375	blood	T031	C0005767
28450207	1387	1397	new method	T170	C0025663
28450207	1442	1446	drug	T121	C1254351
28450207	1447	1460	lipophilicity	T081	C0598631
28450207	1490	1500	logP value	T081	C1522609
28450207	1508	1512	drug	T121	C1254351
28450207	1552	1564	drug release	T070	C3850077
28450207	1631	1643	drug release	T070	C3850077
28450207	1651	1676	rapeseed oil nanoemulsion	T121	C3191795
28450207	1689	1696	porcine	T015	C0039005
28450207	1697	1702	serum	T031	C0229671
28450207	1707	1712	blood	T031	C0005767

27905097|t|Novel biomarkers in primary breast core biopsies to predict poor response to neoadjuvant chemotherapy and appearance of metastases
27905097|a|Drug resistance has been one of the major obstacles limiting the success of cancer chemotherapy. In two thirds of breast cancer patients, large (>1cm) residual tumors are present after neoadjuvant chemotherapy (NCT). The residual tumor and involved nodes have been indicators of relapse and survival very important in breast cancer. The goal of this preliminary study was to assess the predictive significance of a panel of molecular biomarkers, related with the response to treatment or drug resistance to NCT, as determined on the diagnostic tumor. The expression of 22 proteins was examined using immunohistochemistry in tissue microarrays (TMA) from 115 patients of stage II - III breast cancer, treated with NCT. Among studied proteins, there are some that are anti-apoptotic, pro-proliferative, cancer stem cell markers and the Vitamin D Receptor. Other proteins are involved in the identification of molecular subtype, cell cycle regulation or DNA repair. Next, a predictive signature of poor response was generated from independent markers of predictive value. Tumors that expressed four or five conditions (biomarkers of chemoresistance with a determinated cutoff) were associated with a 9-fold increase in the chances of these patients of having a poor response to NCT. Additionally, we also found a worse prognostic signature, generated from independent markers of prognostic value. Tumors which expressed two or three conditions of worst prognostic, were associated with a 6-fold reduction in Distant Disease Free Survival. In conclusion, finding biomarkers of chemoresitance (ypTNM II-III) and metastases can become a stepping stone for future studies that will need to be assessed in a bigger scale.
27905097	6	16	biomarkers	T123	C0041366
27905097	20	27	primary	T080	C0205225
27905097	28	48	breast core biopsies	T060	C0191853
27905097	60	73	poor response	T033	C1320680
27905097	77	101	neoadjuvant chemotherapy	T061	C4272610
27905097	106	116	appearance	T080	C0205556
27905097	120	130	metastases	T191	C0027627
27905097	131	146	Drug resistance	T038	C0013203
27905097	196	203	success	T080	C0679864
27905097	207	213	cancer	T191	C0006826
27905097	214	226	chemotherapy	T061	C3665472
27905097	245	258	breast cancer	T191	C0006142
27905097	259	267	patients	T101	C0030705
27905097	282	297	residual tumors	T191	C0543478
27905097	316	340	neoadjuvant chemotherapy	T061	C4272610
27905097	342	345	NCT	T061	C4272610
27905097	352	366	residual tumor	T191	C0543478
27905097	380	385	nodes	T023	C0746922
27905097	396	406	indicators	T130	C0021212
27905097	410	417	relapse	T067	C0035020
27905097	422	430	survival	T169	C0220921
27905097	449	462	breast cancer	T191	C0006142
27905097	506	512	assess	T058	C0184514
27905097	517	527	predictive	T080	C0681890
27905097	528	540	significance	T078	C0750502
27905097	546	551	panel	T078	C0441833
27905097	555	575	molecular biomarkers	T123	C0041366
27905097	594	615	response to treatment	T201	C0521982
27905097	619	634	drug resistance	T038	C0013203
27905097	638	641	NCT	T061	C4272610
27905097	664	674	diagnostic	T169	C0348026
27905097	675	680	tumor	T191	C0027651
27905097	686	696	expression	T045	C1171362
27905097	703	711	proteins	T116,T123	C0033684
27905097	731	751	immunohistochemistry	T060	C0021044
27905097	755	773	tissue microarrays	T075	C1519522
27905097	775	778	TMA	T075	C1519522
27905097	789	797	patients	T101	C0030705
27905097	801	809	stage II	T191	C0278486
27905097	812	829	III breast cancer	T191	C0278487
27905097	831	838	treated	T169	C1522326
27905097	844	847	NCT	T061	C4272610
27905097	863	871	proteins	T116,T123	C0033684
27905097	897	911	anti-apoptotic	T123	C0574031
27905097	913	930	pro-proliferative	T123	C0574031
27905097	932	956	cancer stem cell markers	T123	C0574031
27905097	965	983	Vitamin D Receptor	T116,T192	C0108082
27905097	991	999	proteins	T116,T123	C0033684
27905097	1038	1055	molecular subtype	T185	C0449560
27905097	1057	1078	cell cycle regulation	T043	C1155872
27905097	1082	1092	DNA repair	T045	C0012899
27905097	1102	1112	predictive	T080	C0681890
27905097	1113	1122	signature	T169	C1704864
27905097	1131	1139	response	T044	C1148560
27905097	1159	1170	independent	T078	C0085862
27905097	1171	1178	markers	T123	C0041366
27905097	1182	1198	predictive value	T080	C1514307
27905097	1200	1206	Tumors	T191	C0027651
27905097	1235	1245	conditions	T080	C0348080
27905097	1247	1257	biomarkers	T123	C0041366
27905097	1261	1276	chemoresistance	T169	C4281815
27905097	1297	1303	cutoff	T169	C1442160
27905097	1310	1325	associated with	T080	C0332281
27905097	1335	1343	increase	T169	C0442805
27905097	1368	1376	patients	T101	C0030705
27905097	1389	1402	poor response	T033	C1320680
27905097	1406	1409	NCT	T061	C4272610
27905097	1447	1467	prognostic signature	T169	C1704864
27905097	1484	1495	independent	T078	C0085862
27905097	1496	1503	markers	T123	C0041366
27905097	1507	1523	prognostic value	T080	C0205556
27905097	1525	1531	Tumors	T191	C0027651
27905097	1561	1571	conditions	T080	C0348080
27905097	1581	1591	prognostic	T080	C0205556
27905097	1598	1613	associated with	T080	C0332281
27905097	1623	1632	reduction	T081	C0547047
27905097	1636	1665	Distant Disease Free Survival	T081	C0242793
27905097	1682	1689	finding	T033	C0243095
27905097	1690	1700	biomarkers	T123	C0041366
27905097	1704	1718	chemoresitance	T169	C4281815
27905097	1720	1732	ypTNM II-III	T185	C0008902
27905097	1738	1748	metastases	T191	C0027627

27559734|t|Plasticity and Adult Neurogenesis in Amphibians and Reptiles: More Questions than Answers
27559734|a|Studies of the relationship between behavioral plasticity and new cells in the adult brain in amphibians and reptiles are sparse but demonstrate that environmental and hormonal variables do have an effect on the amount of cell proliferation and/or migration. The variables that are reviewed here are: enriched environment, social stimulation, spatial area use, season, photoperiod and temperature, and testosterone. Fewer data are available for amphibians than for reptiles, but for both groups many issues are still to be resolved. It is to be hoped that the questions raised here will generate more answers in future studies.
27559734	0	10	Plasticity	T070	C0678558
27559734	15	20	Adult	T100	C0001675
27559734	21	33	Neurogenesis	T040	C0814002
27559734	37	47	Amphibians	T011	C0002668
27559734	52	60	Reptiles	T014	C0035161
27559734	126	136	behavioral	T053	C0004927
27559734	137	147	plasticity	T070	C0678558
27559734	156	161	cells	T025	C0007634
27559734	169	174	adult	T100	C0001675
27559734	175	180	brain	T023	C0006104
27559734	184	194	amphibians	T011	C0002668
27559734	199	207	reptiles	T014	C0035161
27559734	240	253	environmental	T082	C0014406
27559734	258	266	hormonal	T080	C0458083
27559734	267	276	variables	T080	C0439828
27559734	302	308	amount	T081	C1265611
27559734	312	330	cell proliferation	T043	C0596290
27559734	338	347	migration	T043	C1622501
27559734	353	362	variables	T080	C0439828
27559734	400	411	environment	T082	C0014406
27559734	413	431	social stimulation	T070	C1948023
27559734	433	445	spatial area	T082	C1254362
27559734	451	457	season	T079	C0036497
27559734	459	470	photoperiod	T079	C0162811
27559734	475	486	temperature	T081	C0039476
27559734	492	504	testosterone	T109,T121,T125	C0039601
27559734	512	516	data	T078	C1511726
27559734	535	545	amphibians	T011	C0002668
27559734	555	563	reptiles	T014	C0035161
27559734	613	621	resolved	T033	C3714811
27559734	650	659	questions	T078	C0681799
27559734	691	698	answers	T033	C1826996
27559734	709	717	studies.	T062	C2603343

28407625|t|Comparison of Occlusive and Open Application in a Psoriasis Plaque Test Design, Exemplarily Using Investigations of Mapracorat 0.1% Ointment versus Vehicle and Reference Drugs
28407625|a|Psoriasis plaque tests (PPTs) are important tools in the early phases of antipsoriatic drug development. Two distinct PPT design variants (open vs. occluded drug application) are commonly used, but no previous work has aimed to directly compare and contrast their performance. We compared the antipsoriatic efficacy of mapracorat 0.1% ointment and reference drugs reported in 2 separate studies, representing open and occluded PPT designs. The drug effect size was measured by sonography (mean change in echo-poor band thickness), chromametry, and standardized clinical assessment. Antipsoriatic effects were detectable for the study drugs in both occluded and open PPTs. Differences between the potency of antipsoriatic drugs and vehicle were observable. The total antipsoriatic effect size appeared to be higher in the occluded PPT than the open PPT, despite the shorter treatment duration (2 vs. 4 weeks). Effect dynamics over time revealed greater differences between some study drugs in the open PPT compared to the occluded PPT. Taking the higher technical challenges for the open PPT into account, we recommend the occluded PPT as a standard screening setting in early drug development. In special cases, considering certain drug aspects or study objectives that would require procedural adaptations, an open PPT could be the better-suited design. Finally, both PPT models show clear advantages: classification as phase I studies, small number of psoriatic subjects, relatively short study duration, excellent discrimination between compounds and concentrations, parallel measurement of treatment response, and go/no go decisions very early in clinical development.
28407625	0	10	Comparison	T052	C1707455
28407625	14	23	Occlusive	T169	C1947917
28407625	28	32	Open	T082	C0175566
28407625	33	44	Application	T169	C4048755
28407625	50	78	Psoriasis Plaque Test Design	T062	C0008976
28407625	98	112	Investigations	T169	C1292732
28407625	116	126	Mapracorat	T109,T121	C3252363
28407625	132	140	Ointment	T122	C0028912
28407625	148	155	Vehicle	T122	C0042444
28407625	160	169	Reference	T077	C1706462
28407625	170	175	Drugs	T121	C0013227
28407625	176	198	Psoriasis plaque tests	T062	C0008976
28407625	200	204	PPTs	T062	C0008976
28407625	249	262	antipsoriatic	T121	C1874314
28407625	263	279	drug development	T091	C0872152
28407625	294	304	PPT design	T062	C0008976
28407625	315	319	open	T169	C0013153
28407625	324	349	occluded drug application	T169	C0013153
28407625	469	482	antipsoriatic	T121	C1874314
28407625	495	505	mapracorat	T109,T121	C3252363
28407625	511	519	ointment	T122	C0028912
28407625	524	533	reference	T077	C1706462
28407625	534	539	drugs	T121	C0013227
28407625	563	570	studies	T062	C2603343
28407625	585	589	open	T062	C0008976
28407625	594	614	occluded PPT designs	T062	C0008976
28407625	620	631	drug effect	T169	C0728866
28407625	653	663	sonography	T060	C0041618
28407625	695	704	thickness	T080	C1280412
28407625	707	718	chromametry	T059	C0022885
28407625	737	756	clinical assessment	T033	C3845884
28407625	758	771	Antipsoriatic	T121	C1874314
28407625	772	779	effects	T169	C0728866
28407625	804	809	study	T062	C2603343
28407625	810	815	drugs	T121	C0013227
28407625	824	832	occluded	T062	C0008976
28407625	837	846	open PPTs	T062	C0008976
28407625	872	879	potency	T038	C0678792
28407625	883	902	antipsoriatic drugs	T121	C1874314
28407625	907	914	vehicle	T122	C0042444
28407625	942	955	antipsoriatic	T121	C1874314
28407625	956	962	effect	T169	C0728866
28407625	997	1009	occluded PPT	T062	C0008976
28407625	1019	1027	open PPT	T062	C0008976
28407625	1049	1067	treatment duration	T079	C0444921
28407625	1077	1082	weeks	T079	C0439230
28407625	1085	1091	Effect	T169	C0728866
28407625	1092	1100	dynamics	T070	C3826426
28407625	1106	1110	time	T079	C0040223
28407625	1153	1158	study	T062	C2603343
28407625	1159	1164	drugs	T121	C0013227
28407625	1172	1180	open PPT	T062	C0008976
28407625	1197	1209	occluded PPT	T062	C0008976
28407625	1229	1249	technical challenges	T067	C1710348
28407625	1258	1266	open PPT	T062	C0008976
28407625	1298	1310	occluded PPT	T062	C0008976
28407625	1325	1334	screening	T062	C0013206
28407625	1346	1351	early	T079	C1279919
28407625	1352	1368	drug development	T091	C0872152
28407625	1408	1412	drug	T121	C0013227
28407625	1413	1420	aspects	T080	C1879746
28407625	1424	1429	study	T062	C2603343
28407625	1487	1495	open PPT	T062	C0008976
28407625	1545	1548	PPT	T062	C0008976
28407625	1579	1593	classification	T185	C0008902
28407625	1597	1612	phase I studies	T062	C0920321
28407625	1667	1672	study	T062	C2603343
28407625	1673	1681	duration	T079	C0449238
28407625	1716	1725	compounds	T103	C1706082
28407625	1730	1744	concentrations	T081	C1264643
28407625	1755	1766	measurement	T169	C0242485
28407625	1770	1788	treatment response	T201	C0521982
28407625	1818	1823	early	T079	C1279919
28407625	1827	1847	clinical development	T062	C1512068

27010511|t|Application of an Analytical Solution as a Screening Tool for Sea Water Intrusion
27010511|a|Sea water intrusion into aquifers is problematic in many coastal areas. The physics and chemistry of this issue are complex, and sea water intrusion remains challenging to quantify. Simple assessment tools like analytical models offer advantages of rapid application, but their applicability to field situations is unclear. This study examines the reliability of a popular sharp-interface analytical approach for estimating the extent of sea water in a homogeneous coastal aquifer subjected to pumping and regional flow effects and under steady-state conditions. The analytical model is tested against observations from Canada, the United States, and Australia to assess its utility as an initial approximation of sea water extent for the purposes of rapid groundwater management decision making. The occurrence of sea water intrusion resulting in increased salinity at pumping wells was correctly predicted in approximately 60% of cases. Application of a correction to account for dispersion did not markedly improve the results. Failure of the analytical model to provide correct predictions can be attributed to mismatches between its simplifying assumptions and more complex field settings. The best results occurred where the toe of the salt water wedge is expected to be the closest to the coast under predevelopment conditions. Predictions were the poorest for aquifers where the salt water wedge was expected to extend further inland under predevelopment conditions and was therefore more dispersive prior to pumping. Sharp-interface solutions remain useful tools to screen for the vulnerability of coastal aquifers to sea water intrusion, although the significant sources of uncertainty identified in this study require careful consideration to avoid misinterpreting sharp-interface results.
27010511	0	11	Application	T169	C4048755
27010511	18	28	Analytical	T170	C0178476
27010511	29	37	Solution	T077	C2699488
27010511	43	52	Screening	T058	C0220908
27010511	53	57	Tool	T170	C0025663
27010511	62	71	Sea Water	T167	C0036499
27010511	72	81	Intrusion	T067	C1254366
27010511	82	91	Sea water	T167	C0036499
27010511	92	101	intrusion	T067	C1254366
27010511	107	115	aquifers	T070	C3178977
27010511	119	130	problematic	T033	C0033213
27010511	139	152	coastal areas	T082	C0557760
27010511	158	165	physics	T090	C0031837
27010511	170	179	chemistry	T169	C0079107
27010511	198	205	complex	T080	C0439855
27010511	211	220	sea water	T167	C0036499
27010511	221	230	intrusion	T067	C1254366
27010511	254	262	quantify	T081	C1709793
27010511	271	287	assessment tools	T170	C0282574
27010511	293	310	analytical models	T170	C0026350
27010511	337	348	application	T169	C4048755
27010511	411	416	study	T062	C2603343
27010511	455	490	sharp-interface analytical approach	T170	C0178476
27010511	495	505	estimating	T081	C0750572
27010511	520	529	sea water	T167	C0036499
27010511	535	546	homogeneous	T080	C1881065
27010511	547	554	coastal	T082	C0557760
27010511	555	562	aquifer	T070	C3178977
27010511	576	583	pumping	T169	C0205245
27010511	588	601	regional flow	T067	C1254366
27010511	602	609	effects	T080	C1280500
27010511	620	643	steady-state conditions	T070	C0678587
27010511	649	665	analytical model	T170	C0026350
27010511	669	675	tested	T169	C0039593
27010511	684	696	observations	T078	C1554188
27010511	702	708	Canada	T083	C0006823
27010511	714	727	United States	T083	C0041703
27010511	733	742	Australia	T083	C0004340
27010511	746	752	assess	T058	C0184514
27010511	771	778	initial	T079	C0205265
27010511	779	792	approximation	T061	C1283102
27010511	796	805	sea water	T167	C0036499
27010511	839	850	groundwater	T082	C0596631
27010511	851	861	management	T057	C1273870
27010511	862	877	decision making	T041	C0011109
27010511	883	893	occurrence	T079	C2745955
27010511	897	906	sea water	T167	C0036499
27010511	907	916	intrusion	T067	C1254366
27010511	930	939	increased	T081	C0205217
27010511	940	948	salinity	T034	C1956027
27010511	952	965	pumping wells	T073	C3146287
27010511	993	1006	approximately	T080	C0332232
27010511	1014	1019	cases	T169	C0868928
27010511	1021	1032	Application	T169	C4048755
27010511	1038	1048	correction	T169	C1947976
27010511	1064	1074	dispersion	T082	C0332624
27010511	1092	1099	improve	T033	C0184511
27010511	1104	1111	results	T169	C1274040
27010511	1113	1120	Failure	T169	C0231175
27010511	1128	1144	analytical model	T170	C0026350
27010511	1156	1163	correct	T080	C2349182
27010511	1164	1175	predictions	T078	C0681842
27010511	1197	1207	mismatches	T080	C1881865
27010511	1286	1293	results	T169	C1274040
27010511	1324	1334	salt water	T197	C0337055
27010511	1335	1340	wedge	T082	C0439639
27010511	1378	1383	coast	T083	C0017446
27010511	1390	1415	predevelopment conditions	T080	C0348080
27010511	1417	1428	Predictions	T078	C0681842
27010511	1450	1458	aquifers	T070	C3178977
27010511	1469	1479	salt water	T197	C0337055
27010511	1480	1485	wedge	T082	C0439639
27010511	1517	1523	inland	T083	C0442536
27010511	1530	1555	predevelopment conditions	T080	C0348080
27010511	1599	1606	pumping	T169	C0205245
27010511	1608	1633	Sharp-interface solutions	T077	C2699488
27010511	1648	1653	tools	T170	C0025663
27010511	1657	1663	screen	T058	C0220908
27010511	1672	1685	vulnerability	T033	C1821973
27010511	1689	1696	coastal	T082	C0557760
27010511	1697	1705	aquifers	T070	C3178977
27010511	1709	1718	sea water	T167	C0036499
27010511	1719	1728	intrusion	T067	C1254366
27010511	1797	1802	study	T062	C2603343
27010511	1858	1881	sharp-interface results	T169	C1274040

28152029|t|Clonal and serotype dynamics of serogroup 6 isolates causing invasive pneumococcal disease in Portugal: 1999-2012
28152029|a|Although serogroup 6 was among the first to be recognized among Streptococcus pneumoniae, several new serotypes were identified since the introduction of pneumococcal conjugate vaccines (PCVs). A decrease of the 6B-2 variant among invasive pneumococcal disease (IPD), but not 6B-1, was noted post conjugate vaccine introduction, underpinned by a decrease of CC273 isolates. Serotype 6C was associated with adult IPD and increased in this age group representing two lineages (CC315 and CC395), while the same lineages expressed other serogroup 6 serotypes in children. Taken together, these findings suggest a potential cross-protection of PCVs against serotype 6C IPD among vaccinated children but not among adults. Serotype 6A became the most important serogroup 6 serotype in children but it decreased in adult IPD. No other serogroup 6 serotypes were detected, so available phenotypic or simple genotypic assays remain adequate for distinguishing serotypes within serogroup 6 isolates.
28152029	0	6	Clonal	T024	C1522642
28152029	11	19	serotype	T170	C0449943
28152029	20	28	dynamics	T070	C3826426
28152029	32	43	serogroup 6	T007	C1532752
28152029	44	52	isolates	T123	C1764827
28152029	61	90	invasive pneumococcal disease	T047	C1320214
28152029	94	102	Portugal	T083	C0032729
28152029	123	134	serogroup 6	T007	C1532752
28152029	178	202	Streptococcus pneumoniae	T007	C0038410
28152029	216	225	serotypes	T170	C0449943
28152029	231	241	identified	T080	C0205396
28152029	252	264	introduction	T169	C0579004
28152029	268	299	pneumococcal conjugate vaccines	T121,T129	C0206515
28152029	301	305	PCVs	T121,T129	C0206515
28152029	310	318	decrease	T081	C0547047
28152029	326	338	6B-2 variant	T080	C0205419
28152029	345	374	invasive pneumococcal disease	T047	C1320214
28152029	376	379	IPD	T047	C1320214
28152029	390	394	6B-1	T080	C0205419
28152029	406	410	post	T079	C0687676
28152029	411	428	conjugate vaccine	T121,T129	C0206515
28152029	429	441	introduction	T169	C0579004
28152029	460	468	decrease	T081	C0547047
28152029	472	486	CC273 isolates	T123	C1764827
28152029	488	499	Serotype 6C	T007	C3697188
28152029	504	519	associated with	T080	C0332281
28152029	520	525	adult	T100	C0001675
28152029	526	529	IPD	T047	C1320214
28152029	534	543	increased	T081	C0205217
28152029	552	561	age group	T100	C0027362
28152029	579	587	lineages	T078	C0282637
28152029	589	594	CC315	T078	C0282637
28152029	599	604	CC395	T078	C0282637
28152029	622	630	lineages	T078	C0282637
28152029	631	640	expressed	T045	C1171362
28152029	647	658	serogroup 6	T007	C1532752
28152029	659	668	serotypes	T170	C0449943
28152029	672	680	children	T100	C0008059
28152029	704	712	findings	T169	C2607943
28152029	733	749	cross-protection	T044	C2717886
28152029	753	757	PCVs	T121,T129	C0206515
28152029	766	777	serotype 6C	T007	C3697188
28152029	778	781	IPD	T047	C1320214
28152029	788	798	vaccinated	T033	C1519885
28152029	799	807	children	T100	C0008059
28152029	822	828	adults	T100	C0001675
28152029	830	841	Serotype 6A	T007	C2732283
28152029	868	879	serogroup 6	T007	C1532752
28152029	880	888	serotype	T170	C0449943
28152029	892	900	children	T100	C0008059
28152029	908	917	decreased	T081	C0205216
28152029	921	926	adult	T100	C0001675
28152029	927	930	IPD	T047	C1320214
28152029	941	952	serogroup 6	T007	C1532752
28152029	953	962	serotypes	T170	C0449943
28152029	968	976	detected	T033	C0442726
28152029	991	1001	phenotypic	T032	C0031437
28152029	1012	1021	genotypic	T032	C0017431
28152029	1022	1028	assays	T059	C1510438
28152029	1036	1044	adequate	T080	C0205411
28152029	1064	1073	serotypes	T170	C0449943
28152029	1081	1092	serogroup 6	T007	C1532752
28152029	1093	1101	isolates	T123	C1764827

27486082|t|Single-cell analyses of X Chromosome inactivation dynamics and pluripotency during differentiation
27486082|a|Pluripotency, differentiation, and X Chromosome inactivation (XCI) are key aspects of embryonic development. However, the underlying relationship and mechanisms among these processes remain unclear. Here, we systematically dissected these features along developmental progression using mouse embryonic stem cells (mESCs) and single-cell RNA sequencing with allelic resolution. We found that mESCs grown in a ground state 2i condition displayed transcriptomic profiles diffused from preimplantation mouse embryonic cells, whereas EpiStem cells closely resembled the post-implantation epiblast. Sex -related gene expression varied greatly across distinct developmental states. We also identified novel markers that were highly enriched in each developmental state. Moreover, we revealed that several novel pathways, including PluriNetWork and Focal Adhesion, were responsible for the delayed progression of female EpiStem cells. Importantly, we " digitalized " XCI progression using allelic expression of active and inactive X Chromosomes and surprisingly found that XCI states exhibited profound variability in each developmental state, including the 2i condition. XCI progression was not tightly synchronized with loss of pluripotency and increase of differentiation at the single-cell level, although these processes were globally correlated. In addition, highly expressed genes, including core pluripotency factors, were in general biallelically expressed. Taken together, our study sheds light on the dynamics of XCI progression and the asynchronicity between pluripotency, differentiation, and XCI.
27486082	0	20	Single-cell analyses	T059	C0597452
27486082	24	49	X Chromosome inactivation	T033	C1507147
27486082	50	58	dynamics	T070	C3826426
27486082	63	75	pluripotency	T169	C1514185
27486082	83	98	differentiation	T043	C0007589
27486082	99	111	Pluripotency	T169	C1514185
27486082	113	128	differentiation	T043	C0007589
27486082	134	159	X Chromosome inactivation	T033	C1507147
27486082	161	164	XCI	T033	C1507147
27486082	185	206	embryonic development	T042	C0013936
27486082	232	244	relationship	T080	C0439849
27486082	249	259	mechanisms	T169	C0441712
27486082	272	281	processes	T067	C1254366
27486082	307	321	systematically	T169	C0220922
27486082	322	331	dissected	T169	C0205239
27486082	353	366	developmental	T080	C0458003
27486082	367	378	progression	T169	C0449258
27486082	385	411	mouse embryonic stem cells	T025	C4042879
27486082	413	418	mESCs	T025	C4042879
27486082	424	435	single-cell	T025	C0007634
27486082	436	450	RNA sequencing	T059,T063	C0917793
27486082	456	463	allelic	T028	C0002085
27486082	464	474	resolution	T077	C2699488
27486082	490	495	mESCs	T025	C4042879
27486082	507	532	ground state 2i condition	T130	C0010454
27486082	543	566	transcriptomic profiles	T081	C1956267
27486082	581	596	preimplantation	T059	C0022885
27486082	597	618	mouse embryonic cells	T025	C4042879
27486082	628	641	EpiStem cells	T025	C0038250
27486082	664	681	post-implantation	T059	C0022885
27486082	682	690	epiblast	T018	C1516906
27486082	692	695	Sex	T032	C0079399
27486082	705	720	gene expression	T045	C0017262
27486082	752	772	developmental states	T079	C0870411
27486082	793	806	novel markers	T045	C0017393
27486082	817	823	highly	T080	C0205250
27486082	841	860	developmental state	T079	C0870411
27486082	897	911	novel pathways	T077	C1705987
27486082	923	935	PluriNetWork	T169	C1882071
27486082	940	954	Focal Adhesion	T026	C0887870
27486082	961	976	responsible for	T033	C1273518
27486082	989	1000	progression	T169	C0449258
27486082	1004	1010	female	T032	C0086287
27486082	1011	1024	EpiStem cells	T025	C0038250
27486082	1044	1055	digitalized	T080	C1883674
27486082	1058	1061	XCI	T033	C1507147
27486082	1062	1073	progression	T169	C0449258
27486082	1080	1087	allelic	T028	C0002085
27486082	1088	1098	expression	T045	C0017262
27486082	1102	1121	active and inactive	T078	C1547601
27486082	1122	1135	X Chromosomes	T026	C0043292
27486082	1164	1167	XCI	T033	C1507147
27486082	1168	1174	states	T169	C1442792
27486082	1214	1233	developmental state	T079	C0870411
27486082	1249	1261	2i condition	T080	C0348080
27486082	1263	1266	XCI	T033	C1507147
27486082	1267	1278	progression	T169	C0449258
27486082	1295	1307	synchronized	T079	C0439580
27486082	1313	1317	loss	T081	C1517945
27486082	1321	1333	pluripotency	T169	C1514185
27486082	1338	1346	increase	T169	C0442805
27486082	1350	1365	differentiation	T043	C0007589
27486082	1373	1384	single-cell	T025	C0007634
27486082	1407	1416	processes	T067	C1254366
27486082	1456	1462	highly	T080	C0205250
27486082	1463	1478	expressed genes	T028	C0017337
27486082	1495	1507	pluripotency	T169	C1514185
27486082	1533	1546	biallelically	T028	C0002085
27486082	1547	1556	expressed	T045	C0017262
27486082	1603	1611	dynamics	T070	C3826426
27486082	1615	1618	XCI	T033	C1507147
27486082	1619	1630	progression	T169	C0449258
27486082	1639	1653	asynchronicity	T079	C0439581
27486082	1662	1674	pluripotency	T169	C1514185
27486082	1676	1691	differentiation	T169	C2945687
27486082	1697	1700	XCI	T033	C1507147

28112685|t|Chemogenetic stimulation of striatal projection neurons modulates responses to Parkinson's disease therapy
28112685|a|Parkinson's disease (PD) patients experience loss of normal motor function (hypokinesia), but can develop uncontrollable movements known as dyskinesia upon treatment with L-DOPA. Poverty or excess of movement in PD has been attributed to overactivity of striatal projection neurons forming either the indirect (iSPNs) or the direct (dSPNs) pathway, respectively. Here, we investigated the two pathways ' contribution to different motor features using SPN type-specific chemogenetic stimulation in rodent models of PD (PD mice) and L-DOPA-induced dyskinesia (LID mice). Using the activatory Gq-coupled human M3 muscarinic receptor (hM3Dq), we found that chemogenetic stimulation of dSPNs mimicked, while stimulation of iSPNs abolished the therapeutic action of L-DOPA in PD mice. In LID mice, hM3Dq stimulation of dSPNs exacerbated dyskinetic responses to L-DOPA, while stimulation of iSPNs inhibited these responses. In the absence of L-DOPA, only chemogenetic stimulation of dSPNs mediated through the Gs-coupled modified rat muscarinic M3 receptor (rM3Ds) induced appreciable dyskinesia in PD mice. Combining D2 receptor agonist treatment with rM3Ds-dSPN stimulation reproduced all symptoms of LID. These results demonstrate that dSPNs and iSPNs oppositely modulate both therapeutic and dyskinetic responses to dopamine replacement therapy in PD. We also show that chemogenetic stimulation of different signaling pathways in dSPNs leads to markedly different motor outcomes. Our findings have important implications for the design of effective antiparkinsonian and antidyskinetic drug therapies.
28112685	0	24	Chemogenetic stimulation	T044	C1148560
28112685	28	55	striatal projection neurons	T025	C0027882
28112685	56	65	modulates	UnknownType	C0544633
28112685	66	75	responses	T032	C0871261
28112685	79	98	Parkinson's disease	T047	C0030567
28112685	99	106	therapy	T061	C0087111
28112685	107	126	Parkinson's disease	T047	C0030567
28112685	128	130	PD	T047	C0030567
28112685	132	140	patients	T101	C0030705
28112685	141	151	experience	T041	C0596545
28112685	152	181	loss of normal motor function	T033	C1864672
28112685	183	194	hypokinesia	T033	C0086439
28112685	213	237	uncontrollable movements	T047	C0013384
28112685	247	257	dyskinesia	T047	C0013384
28112685	263	272	treatment	T061	C0087111
28112685	278	284	L-DOPA	T116,T121,T123	C0023570
28112685	286	293	Poverty	T102	C0032854
28112685	307	315	movement	T040	C0026649
28112685	319	321	PD	T047	C0030567
28112685	345	357	overactivity	T033	C1536696
28112685	361	388	striatal projection neurons	T025	C0027882
28112685	418	423	iSPNs	T025	C0027882
28112685	440	445	dSPNs	T025	C0027882
28112685	447	454	pathway	T023	C0027792
28112685	500	508	pathways	T023	C0027792
28112685	537	542	motor	T025	C0026609
28112685	543	551	features	T080	C2348519
28112685	558	600	SPN type-specific chemogenetic stimulation	T044	C1148560
28112685	604	617	rodent models	T050	C1519106
28112685	621	623	PD	T047	C0030567
28112685	625	627	PD	T047	C0030567
28112685	628	632	mice	T015	C0025929
28112685	638	663	L-DOPA-induced dyskinesia	T033	C3552620
28112685	665	668	LID	T033	C3552620
28112685	669	673	mice	T015	C0025929
28112685	686	736	activatory Gq-coupled human M3 muscarinic receptor	T116,T192	C0289799
28112685	738	743	hM3Dq	T116,T192	C0289799
28112685	760	784	chemogenetic stimulation	T044	C1148560
28112685	788	793	dSPNs	T025	C0027882
28112685	810	821	stimulation	T044	C1148560
28112685	825	830	iSPNs	T025	C0027882
28112685	845	863	therapeutic action	T038	C2712171
28112685	867	873	L-DOPA	T116,T121,T123	C0023570
28112685	877	879	PD	T047	C0030567
28112685	880	884	mice	T015	C0025929
28112685	889	892	LID	T033	C3552620
28112685	893	897	mice	T015	C0025929
28112685	899	904	hM3Dq	T116,T192	C0289799
28112685	905	916	stimulation	T044	C1148560
28112685	920	925	dSPNs	T025	C0027882
28112685	938	958	dyskinetic responses	T032	C0871261
28112685	962	968	L-DOPA	T116,T121,T123	C0023570
28112685	976	987	stimulation	T044	C1148560
28112685	991	996	iSPNs	T025	C0027882
28112685	997	1006	inhibited	T080	C0311403
28112685	1013	1022	responses	T032	C0871261
28112685	1042	1048	L-DOPA	T116,T121,T123	C0023570
28112685	1055	1079	chemogenetic stimulation	T044	C1148560
28112685	1083	1088	dSPNs	T025	C0027882
28112685	1110	1156	Gs-coupled modified rat muscarinic M3 receptor	T116,T192	C0289799
28112685	1158	1163	rM3Ds	T116,T192	C0289799
28112685	1165	1172	induced	T169	C0205263
28112685	1185	1195	dyskinesia	T047	C0013384
28112685	1199	1201	PD	T047	C0030567
28112685	1202	1206	mice	T015	C0025929
28112685	1218	1229	D2 receptor	T116,T192	C0058698
28112685	1230	1237	agonist	T121	C2987634
28112685	1238	1247	treatment	T169	C1522326
28112685	1253	1275	rM3Ds-dSPN stimulation	T044	C1148560
28112685	1291	1299	symptoms	T184	C1457887
28112685	1303	1306	LID	T033	C3552620
28112685	1339	1344	dSPNs	T025	C0027882
28112685	1349	1354	iSPNs	T025	C0027882
28112685	1366	1374	modulate	UnknownType	C0544633
28112685	1380	1416	therapeutic and dyskinetic responses	T032	C0871261
28112685	1420	1428	dopamine	T109,T121,T123	C0013030
28112685	1429	1448	replacement therapy	T061	C0279033
28112685	1452	1454	PD	T047	C0030567
28112685	1474	1498	chemogenetic stimulation	T044	C1148560
28112685	1512	1530	signaling pathways	T044	C0037080
28112685	1534	1539	dSPNs	T025	C0027882
28112685	1568	1582	motor outcomes	T080	C0085415
28112685	1588	1596	findings	T169	C2607943
28112685	1653	1703	antiparkinsonian and antidyskinetic drug therapies	T061	C0013216

28374639|t|Pesticide residues in orange fruit from citrus orchards in Nuevo Leon State, Mexico
28374639|a|Some international organisations established maximum residue limits (MRLs) in food to protect human health. Mexico lacks regulations in this matter, affecting national and international trade from agroindustry. The aim of this study was to diagnose pesticide residues in oranges from Nuevo Leon, México, in citrus orchards. In May 2014, 100 orange fruit samples were taken randomly from orchards and subjected to analysis for 93 pesticides at residual level by GC / QQQ-MS and LCQ-TOF-MS. Results showed the presence of 15 pesticide residues in the samples. The comparison of the residual levels of pesticides found in orange samples among the MRLs allowed by USA, EU and Japanese regulations demonstrated that all samples were below MRLs issued by USA and Japan. Some orange samples were above MRLs issued by the EU. This provides a basis to establish strategies in order to satisfy International Standards to protect human health and encourage Food Safety in Mexico.
28374639	0	18	Pesticide residues	T131	C0031251
28374639	22	34	orange fruit	T168	C0440277
28374639	40	55	citrus orchards	T082	C0562975
28374639	59	75	Nuevo Leon State	T083	C3828746
28374639	77	83	Mexico	T083	C0025885
28374639	103	116	organisations	T093	C1708333
28374639	117	128	established	T080	C0443211
28374639	129	151	maximum residue limits	T080	C0441889
28374639	153	157	MRLs	T080	C0441889
28374639	162	166	food	T168	C0016452
28374639	170	177	protect	T033	C1545588
28374639	178	183	human	T016	C0086418
28374639	184	190	health	T078	C0018684
28374639	192	198	Mexico	T083	C0025885
28374639	199	204	lacks	T080	C0332268
28374639	205	216	regulations	T064	C0851285
28374639	233	242	affecting	T169	C0392760
28374639	256	275	international trade	T169	C0681067
28374639	281	293	agroindustry	T057	C0021267
28374639	311	316	study	T062	C2603343
28374639	324	332	diagnose	T033	C0011900
28374639	333	351	pesticide residues	T131	C0031251
28374639	355	362	oranges	T168	C0440277
28374639	368	378	Nuevo Leon	T083	C3828746
28374639	380	386	México	T083	C0025885
28374639	391	406	citrus orchards	T082	C0562975
28374639	425	437	orange fruit	T168	C0440277
28374639	438	445	samples	T167	C0370003
28374639	457	465	randomly	T080	C0439605
28374639	471	479	orchards	T082	C0562975
28374639	497	505	analysis	T059	C0002778
28374639	513	523	pesticides	T131	C0031253
28374639	527	535	residual	T131	C0031251
28374639	536	541	level	T080	C0441889
28374639	545	547	GC	T059	C0008555
28374639	550	556	QQQ-MS	T059	C0037813
28374639	561	571	LCQ-TOF-MS	T059	C0599827
28374639	573	580	Results	T169	C1274040
28374639	592	600	presence	T033	C0150312
28374639	607	625	pesticide residues	T131	C0031251
28374639	633	640	samples	T167	C0370003
28374639	664	672	residual	T131	C0031251
28374639	673	679	levels	T080	C0441889
28374639	683	693	pesticides	T131	C0031253
28374639	703	709	orange	T168	C0440277
28374639	710	717	samples	T167	C0370003
28374639	728	732	MRLs	T080	C0441889
28374639	744	747	USA	T083	C0041703
28374639	749	751	EU	T092	C0015179
28374639	756	764	Japanese	T083	C0022341
28374639	765	776	regulations	T064	C0851285
28374639	799	806	samples	T167	C0370003
28374639	818	822	MRLs	T080	C0441889
28374639	833	836	USA	T083	C0041703
28374639	841	846	Japan	T083	C0022341
28374639	853	859	orange	T168	C0440277
28374639	860	867	samples	T167	C0370003
28374639	879	883	MRLs	T080	C0441889
28374639	898	900	EU	T092	C0015179
28374639	927	936	establish	T080	C0443211
28374639	982	991	Standards	T081	C0034925
28374639	995	1002	protect	T033	C1545588
28374639	1003	1008	human	T016	C0086418
28374639	1009	1015	health	T078	C0018684
28374639	1030	1041	Food Safety	T057	C1456535
28374639	1045	1051	Mexico	T083	C0025885

27344476|t|Parent's pro-health awareness concerning oral health of their children in the light of survey research
27344476|a|Oral hygiene is a crucial part of caring for young children. This problem is frequently marginalized or even ignored by parents / guardians, what affects child's whole further life. The assessment of parents' knowledge concerning oral hygiene and prevention of dental caries in infants and young children. The test group consisted of parents, as well as men and women currently expecting a child. The study was conducted in a form of a survey, using an original questionnaire, which was carried out in several hospitals in Lodz and online, on a popular local forum for parents. The data obtained were analyzed statistically, allowing the assessment of health awareness of respondents and the creation of various profiles of parental knowledge on the subject investigated. Most of respondents knew the age at which milk and permanent teeth erupt, gave the correct frequency of brushing child's teeth and were in favor of limiting sweets in the diet. A total of 59% correctly gave the number of deciduous teeth and 66% had heard of the " bottle tooth decay ". All respondents thought that helping and controlling a child while brushing their teeth is indispensable, but they did not know the best time to start using the toothpaste with fluoride. The information about child's oral hygiene was more often looked for by women (67%) than by men (29%). The study also showed that if a training on the given subject was organized, 60% of respondents would be willing to participate in it. In the test group, pro-health awareness is insufficient to maintain the oral health of the offspring and requires constant developing. oral health behaviors, oral health, prophylaxis of dental caries, parent questionnaire survey.
27344476	0	8	Parent's	T099	C0030551
27344476	9	29	pro-health awareness	T033	C1328734
27344476	41	52	oral health	T058	C0029162
27344476	62	70	children	T100	C0008059
27344476	87	102	survey research	T062	C0683942
27344476	103	115	Oral hygiene	T055	C0029164
27344476	137	143	caring	T052	C1947933
27344476	154	162	children	T100	C0008059
27344476	169	176	problem	T033	C0033213
27344476	180	190	frequently	T079	C0332183
27344476	191	203	marginalized	T169	C1522326
27344476	212	219	ignored	T078	C1554079
27344476	223	230	parents	T099	C0030551
27344476	233	242	guardians	T099	C1274041
27344476	249	256	affects	T169	C0392760
27344476	257	264	child's	T100	C0008059
27344476	271	278	further	T082	C1517331
27344476	279	283	life	T078	C0376558
27344476	289	299	assessment	T052	C1516048
27344476	303	311	parents'	T099	C0030551
27344476	312	321	knowledge	T033	C0518904
27344476	333	345	oral hygiene	T055	C0029164
27344476	350	360	prevention	T169	C1292733
27344476	364	377	dental caries	T047	C0011334
27344476	381	388	infants	T100	C0021270
27344476	393	398	young	T079	C0332239
27344476	399	407	children	T100	C0008059
27344476	413	423	test group	UnknownType	C0681860
27344476	437	444	parents	T099	C0030551
27344476	457	460	men	T098	C0025266
27344476	465	470	women	T098	C0043210
27344476	493	498	child	T100	C0008059
27344476	504	509	study	T062	C2603343
27344476	514	523	conducted	T169	C0884358
27344476	539	545	survey	T170	C0038951
27344476	556	578	original questionnaire	T170	C0034394
27344476	605	612	several	T081	C0443302
27344476	613	622	hospitals	T073,T093	C0019994
27344476	626	630	Lodz	UnknownType	C0681784
27344476	635	641	online	UnknownType	C0683828
27344476	662	667	forum	UnknownType	C0683828
27344476	672	679	parents	T099	C0030551
27344476	685	689	data	T078	C1511726
27344476	690	698	obtained	T169	C1301820
27344476	704	726	analyzed statistically	T062	C0871424
27344476	741	751	assessment	T052	C1516048
27344476	755	771	health awareness	T033	C1328734
27344476	775	786	respondents	T098	C0282122
27344476	795	803	creation	T052	C1706214
27344476	827	845	parental knowledge	T033	C1319152
27344476	853	860	subject	T078	C1706203
27344476	861	873	investigated	T169	C1292732
27344476	883	894	respondents	T098	C0282122
27344476	904	907	age	T032	C0001779
27344476	917	921	milk	T031	C0026131
27344476	926	941	permanent teeth	T023	C0348070
27344476	942	947	erupt	T169	C0205177
27344476	966	975	frequency	T079	C0439603
27344476	979	987	brushing	T061	C0040461
27344476	988	995	child's	T100	C0008059
27344476	996	1001	teeth	T023	C0040426
27344476	1023	1031	limiting	T169	C0439801
27344476	1032	1038	sweets	T168	C0453447
27344476	1046	1050	diet	T168	C0012155
27344476	1054	1059	total	T080	C0439810
27344476	1086	1092	number	T081	C0237753
27344476	1096	1111	deciduous teeth	T023	C3266841
27344476	1139	1157	bottle tooth decay	T047	C1290632
27344476	1165	1176	respondents	T098	C0282122
27344476	1190	1197	helping	T080	C1269765
27344476	1202	1213	controlling	T169	C2587213
27344476	1216	1221	child	T100	C0008059
27344476	1228	1236	brushing	T061	C0040461
27344476	1243	1248	teeth	T023	C0040426
27344476	1293	1302	best time	T079	C0040223
27344476	1306	1311	start	T079	C0439659
27344476	1322	1346	toothpaste with fluoride	T200	C0450164
27344476	1352	1363	information	T078	C1533716
27344476	1370	1377	child's	T100	C0008059
27344476	1378	1390	oral hygiene	T055	C0029164
27344476	1420	1425	women	T098	C0043210
27344476	1440	1443	men	T098	C0025266
27344476	1455	1460	study	T062	C2603343
27344476	1483	1491	training	T065	C0220931
27344476	1505	1512	subject	T078	C1706203
27344476	1517	1526	organized	T169	C1300196
27344476	1535	1546	respondents	T098	C0282122
27344476	1556	1563	willing	T033	C0600109
27344476	1567	1578	participate	T169	C0679823
27344476	1593	1603	test group	UnknownType	C0681860
27344476	1605	1625	pro-health awareness	T033	C1328734
27344476	1629	1641	insufficient	T080	C0231180
27344476	1645	1653	maintain	T052	C0024501
27344476	1658	1669	oral health	T058	C0029162
27344476	1677	1686	offspring	T099	C0680063
27344476	1691	1699	requires	T169	C1514873
27344476	1700	1708	constant	T080	C1948059
27344476	1721	1742	oral health behaviors	T201	C1831008
27344476	1744	1755	oral health	T058	C0029162
27344476	1757	1768	prophylaxis	T061	C0011393
27344476	1772	1785	dental caries	T047	C0011334
27344476	1787	1793	parent	T099	C0030551
27344476	1794	1807	questionnaire	T170	C0034394
27344476	1808	1814	survey	T170	C0038951

28466379|t|Bayesian and Phylogenic Approaches for Studying Relationships among Table Olive Cultivars
28466379|a|To enhance table olive tree authentication, relationship, and productivity, we consider the analysis of 18 worldwide table olive cultivars (Olea europaea L.) based on morphological, biological, and physicochemical markers analyzed by bioinformatic and biostatistic tools. Accordingly, we assess the relationships between the studied varieties, on the one hand, and the potential productivity - quantitative parameter links on the other hand. The bioinformatic analysis based on the graphical representation of the matrix of Euclidean distances, the principal components analysis, unweighted pair group method with arithmetic mean, and principal coordinate analysis (PCoA) revealed three major clusters which were not correlated with the geographic origin. The statistical analysis based on Kendall's and Spearman correlation coefficients suggests two highly significant associations with both fruit color and pollinization and the productivity character. These results are confirmed by the multiple linear regression prediction models. In fact, based on the coefficient of determination (R (2)) value, the best model demonstrated the power of the pollinization on the tree productivity (R (2) = 0.846). Moreover, the derived directed acyclic graph showed that only two direct influences are detected: effect of tolerance on fruit and stone symmetry on side and effect of tolerance on stone form and oil content on the other side. This work provides better understanding of the diversity available in worldwide table olive cultivars and supplies an important contribution for olive breeding and authenticity.
28466379	0	8	Bayesian	T081	C0242196
28466379	13	34	Phylogenic Approaches	T062	C1519068
28466379	48	61	Relationships	T080	C0439849
28466379	68	89	Table Olive Cultivars	T002	C0996956
28466379	101	117	table olive tree	T002	C0996956
28466379	118	132	authentication	T080	C0205556
28466379	134	146	relationship	T080	C0439849
28466379	152	164	productivity	T081	C0033269
28466379	182	190	analysis	T062	C0936012
28466379	207	228	table olive cultivars	T002	C0996956
28466379	230	246	Olea europaea L.	T002	C0996956
28466379	257	270	morphological	T080	C0332437
28466379	272	282	biological	T080	C0205460
28466379	288	311	physicochemical markers	T045	C0017393
28466379	324	337	bioinformatic	T170	C0037589
28466379	342	360	biostatistic tools	T170	C0037589
28466379	389	402	relationships	T080	C0439849
28466379	423	432	varieties	T080	C0205419
28466379	469	481	productivity	T081	C0033269
28466379	484	496	quantitative	T081	C0392762
28466379	497	506	parameter	T077	C0549193
28466379	536	549	bioinformatic	T170	C0037589
28466379	550	558	analysis	T062	C0936012
28466379	572	596	graphical representation	T170	C0870616
28466379	604	633	matrix of Euclidean distances	T062	C1880593
28466379	639	668	principal components analysis	T081	C0429865
28466379	670	698	unweighted pair group method	T062	C1881045
28466379	704	719	arithmetic mean	T081	C0444504
28466379	725	754	principal coordinate analysis	T062	C0936012
28466379	756	760	PCoA	T062	C0936012
28466379	783	791	clusters	T081	C1704332
28466379	827	837	geographic	T082	C1517526
28466379	838	844	origin	T033	C0584985
28466379	850	870	statistical analysis	T062	C0871424
28466379	894	927	Spearman correlation coefficients	T081	C0242929
28466379	960	972	associations	T080	C0439849
28466379	983	988	fruit	T168	C0016767
28466379	989	994	color	T080	C0009393
28466379	999	1012	pollinization	T040	C1522786
28466379	1021	1033	productivity	T081	C0033269
28466379	1051	1058	results	T169	C1274040
28466379	1080	1124	multiple linear regression prediction models	T081	C0023733
28466379	1148	1176	coefficient of determination	T081	C2827748
28466379	1178	1183	R (2)	T081	C2827748
28466379	1201	1206	model	T170	C3161035
28466379	1224	1229	power	T081	C3854080
28466379	1237	1250	pollinization	T040	C1522786
28466379	1263	1275	productivity	T081	C0033269
28466379	1277	1282	R (2)	T081	C2827748
28466379	1315	1337	directed acyclic graph	T170	C1706232
28466379	1366	1376	influences	T077	C4054723
28466379	1381	1389	detected	T033	C0442726
28466379	1391	1397	effect	T080	C1280500
28466379	1401	1410	tolerance	T080	C1704410
28466379	1414	1419	fruit	T168	C0016767
28466379	1424	1438	stone symmetry	T080	C0205556
28466379	1451	1457	effect	T080	C1280500
28466379	1461	1470	tolerance	T080	C1704410
28466379	1474	1484	stone form	T080	C0205556
28466379	1489	1492	oil	T109	C0028908
28466379	1493	1500	content	T077	C0456205
28466379	1567	1576	diversity	T080	C1880371
28466379	1600	1621	table olive cultivars	T002	C0996956
28466379	1665	1670	olive	T002	C0996956
28466379	1671	1679	breeding	T040	C0006159
28466379	1684	1696	authenticity	T080	C0205556

27825443|t|Natural competence for transformation
27825443|a|While most molecular biologists are familiar with the artificial transformation of bacteria in the context of laboratory cloning experiments, natural competence for transformation refers to a specific physiological state in which prokaryotes are able to take up genetic material from their surroundings. Occasionally, such absorbed DNA is recombined into the organism's own genome, resulting in natural transformation (Figure 1). As a consequence, natural competence for transformation is considered a primary mode of horizontal gene transfer (HGT) in prokaryotes, together with conjugation (direct cell to cell transfer of DNA via a specialized conjugal pilus) and phage transduction (DNA transfer mediated by viruses). HGT plays a major role in bacterial evolution, and past research has demonstrated that HGT, including natural competence for transformation, contributes to the emergence of pathogens and the spread of virulence factors. Indeed, Frederick Griffith discovered natural competence for transformation in 1928 while he was investigating the exchange of pathogenic traits in pneumococci. Due to the increase in the abundance and spread of multidrug-resistant microbes, research on HGT is even more important today than ever before.
27825443	0	7	Natural	T169	C0205296
27825443	8	18	competence	T080	C0086035
27825443	23	37	transformation	T045	C0040683
27825443	49	69	molecular biologists	T097	C0260017
27825443	92	102	artificial	T080	C2004457
27825443	103	129	transformation of bacteria	T045	C0040683
27825443	137	144	context	T078	C0449255
27825443	148	158	laboratory	T073,T093	C0022877
27825443	159	166	cloning	T062	C0009015
27825443	167	178	experiments	T062	C0681814
27825443	180	187	natural	T169	C0205296
27825443	188	198	competence	T080	C0086035
27825443	203	217	transformation	T045	C0040683
27825443	230	238	specific	T080	C0205369
27825443	239	252	physiological	T169	C0205463
27825443	253	258	state	T169	C1442792
27825443	268	279	prokaryotes	T001	C0686817
27825443	300	316	genetic material	T028	C0440471
27825443	328	340	surroundings	T082	C1282914
27825443	361	369	absorbed	T169	C0205245
27825443	370	373	DNA	T114,T123	C0012854
27825443	377	387	recombined	T080	C0205195
27825443	397	407	organism's	T001	C0029235
27825443	412	418	genome	T028	C0017428
27825443	433	440	natural	T169	C0205296
27825443	441	455	transformation	T045	C0040683
27825443	473	484	consequence	T169	C0686907
27825443	486	493	natural	T169	C0205296
27825443	494	504	competence	T080	C0086035
27825443	509	523	transformation	T045	C0040683
27825443	540	547	primary	T080	C0205225
27825443	548	552	mode	T169	C1513371
27825443	556	580	horizontal gene transfer	T045	C0887912
27825443	582	585	HGT	T045	C0887912
27825443	590	601	prokaryotes	T001	C0686817
27825443	617	628	conjugation	T045	C0009757
27825443	630	636	direct	T080	C1947931
27825443	637	641	cell	T025	C0007634
27825443	645	649	cell	T025	C0007634
27825443	650	658	transfer	T078	C3244299
27825443	662	665	DNA	T114,T123	C0012854
27825443	672	683	specialized	T077	C1704211
27825443	684	698	conjugal pilus	T026	C0242435
27825443	704	709	phage	T005	C0004651
27825443	710	722	transduction	T045	C0040667
27825443	724	727	DNA	T114,T123	C0012854
27825443	728	736	transfer	T078	C3244299
27825443	749	756	viruses	T005	C0042776
27825443	759	762	HGT	T045	C0887912
27825443	785	794	bacterial	T080	C0521009
27825443	795	804	evolution	T045	C0015219
27825443	810	814	past	T079	C1444637
27825443	815	823	research	T062	C0035168
27825443	846	849	HGT	T045	C0887912
27825443	861	868	natural	T169	C0205296
27825443	869	879	competence	T080	C0086035
27825443	884	898	transformation	T045	C0040683
27825443	900	911	contributes	T052	C1880177
27825443	932	941	pathogens	T001	C0450254
27825443	950	956	spread	T080	C0332261
27825443	960	977	virulence factors	T109,T123,T131	C1136170
27825443	1017	1024	natural	T169	C0205296
27825443	1025	1035	competence	T080	C0086035
27825443	1040	1054	transformation	T045	C0040683
27825443	1076	1089	investigating	T169	C1292732
27825443	1094	1102	exchange	T045	C1749881
27825443	1106	1116	pathogenic	T033	C3816499
27825443	1117	1123	traits	T032	C0599883
27825443	1127	1138	pneumococci	T007	C0038410
27825443	1151	1159	increase	T169	C0442805
27825443	1167	1176	abundance	T080	C2346714
27825443	1181	1187	spread	T080	C0332261
27825443	1191	1219	multidrug-resistant microbes	T007	C4076168
27825443	1221	1229	research	T062	C0035168
27825443	1233	1236	HGT	T045	C0887912

27683416|t|Prolyl-4-hydroxylase 2 and 3 coregulate murine erythropoietin in brain pericytes
27683416|a|A classic response to systemic hypoxia is the increased production of red blood cells due to hypoxia-inducible factor (HIF)-mediated induction of erythropoietin (EPO). EPO is a glycoprotein hormone that is essential for normal erythropoiesis and is predominantly synthesized by peritubular renal interstitial fibroblast-like cells, which express cellular markers characteristic of neuronal cells and pericytes. To investigate whether the ability to synthesize EPO is a general functional feature of pericytes, we used conditional gene targeting to examine the von Hippel-Lindau / prolyl-4-hydroxylase domain (PHD)/HIF axis in cell - expressing neural glial antigen 2, a known molecular marker of pericytes in multiple organs. We found that pericytes in the brain synthesized EPO in mice with genetic HIF activation and were capable of responding to systemic hypoxia with the induction of Epo. Using high-resolution multiplex in situ hybridization, we determined that brain pericytes represent an important cellular source of Epo in the hypoxic brain (up to 70% of all Epo - expressing cells). We furthermore determined that Epo transcription in brain pericytes was HIF-2 dependent and cocontrolled by PHD2 and PHD3, oxygen - and 2-oxoglutarate -dependent prolyl-4-hydroxylases that regulate HIF activity. In summary, our studies provide experimental evidence that pericytes in the brain have the ability to function as oxygen sensors and respond to hypoxia with EPO synthesis. Our findings furthermore suggest that the ability to synthesize EPO may represent a functional feature of pericytes in the brain and kidney.
27683416	0	22	Prolyl-4-hydroxylase 2	T116,T123	C1451071
27683416	27	28	3	T116,T126	C2002278
27683416	40	46	murine	T109,T121	C0591833
27683416	47	61	erythropoietin	T116,T121,T125	C0014822
27683416	65	70	brain	T023	C0006104
27683416	71	80	pericytes	T025	C0598800
27683416	91	99	response	T033	C1704632
27683416	103	111	systemic	T169	C0205373
27683416	112	119	hypoxia	T046	C0242184
27683416	127	136	increased	T081	C0205217
27683416	137	166	production of red blood cells	T042	C0014819
27683416	174	198	hypoxia-inducible factor	T116,T123	C0215848
27683416	200	203	HIF	T116,T123	C0215848
27683416	214	223	induction	T169	C0205263
27683416	227	241	erythropoietin	T116,T121,T125	C0014822
27683416	243	246	EPO	T116,T121,T125	C0014822
27683416	249	252	EPO	T116,T121,T125	C0014822
27683416	258	278	glycoprotein hormone	T109,T125	C0312438
27683416	301	322	normal erythropoiesis	T042	C0014819
27683416	359	370	peritubular	T082	C0456918
27683416	371	411	renal interstitial fibroblast-like cells	T025	C1514842
27683416	427	443	cellular markers	T201	C0005516
27683416	462	476	neuronal cells	T025	C0027882
27683416	481	490	pericytes	T025	C0598800
27683416	495	506	investigate	T169	C1292732
27683416	541	544	EPO	T116,T121,T125	C0014822
27683416	558	568	functional	T169	C0205245
27683416	569	576	feature	T080	C2348519
27683416	580	589	pericytes	T025	C0598800
27683416	611	625	gene targeting	T063	C0242613
27683416	641	658	von Hippel-Lindau	T047	C0019562
27683416	661	698	prolyl-4-hydroxylase domain (PHD)/HIF	T116,T126	C3658213
27683416	707	711	cell	T025	C0007634
27683416	714	724	expressing	T045	C1171362
27683416	725	747	neural glial antigen 2	T116,T129	C1311695
27683416	757	773	molecular marker	T201	C0005516
27683416	777	786	pericytes	T025	C0598800
27683416	790	805	multiple organs	T023	C0178784
27683416	821	830	pericytes	T025	C0598800
27683416	838	843	brain	T023	C0006104
27683416	856	859	EPO	T116,T121,T125	C0014822
27683416	863	867	mice	T015	C0026809
27683416	873	880	genetic	T169	C0314603
27683416	881	884	HIF	T116,T123	C0215848
27683416	885	895	activation	T052	C1879547
27683416	930	938	systemic	T169	C0205373
27683416	939	946	hypoxia	T046	C0242184
27683416	956	965	induction	T169	C0205263
27683416	969	972	Epo	T116,T121,T125	C0014822
27683416	980	995	high-resolution	T059	C1719039
27683416	1006	1027	in situ hybridization	T063	C0162788
27683416	1048	1053	brain	T023	C0006104
27683416	1054	1063	pericytes	T025	C0598800
27683416	1087	1102	cellular source	T025	C0007634
27683416	1106	1109	Epo	T116,T121,T125	C0014822
27683416	1117	1124	hypoxic	T046	C0242184
27683416	1125	1130	brain	T023	C0006104
27683416	1149	1152	Epo	T116,T121,T125	C0014822
27683416	1155	1165	expressing	T045	C1171362
27683416	1166	1171	cells	T025	C0007634
27683416	1205	1208	Epo	T116,T121,T125	C0014822
27683416	1209	1222	transcription	T045	C0040649
27683416	1226	1231	brain	T023	C0006104
27683416	1232	1241	pericytes	T025	C0598800
27683416	1246	1251	HIF-2	T116,T123	C0215848
27683416	1282	1286	PHD2	T116,T123	C1451071
27683416	1291	1295	PHD3	T116,T126	C2002278
27683416	1297	1303	oxygen	T121,T123,T196	C0030054
27683416	1310	1324	2-oxoglutarate	T109,T121	C1291208
27683416	1336	1357	prolyl-4-hydroxylases	T116,T126	C3658213
27683416	1372	1375	HIF	T116,T123	C0215848
27683416	1376	1384	activity	T044	C0243102
27683416	1418	1430	experimental	T080	C1517586
27683416	1431	1439	evidence	T078	C3887511
27683416	1445	1454	pericytes	T025	C0598800
27683416	1462	1467	brain	T023	C0006104
27683416	1500	1514	oxygen sensors	T074	C0183211
27683416	1530	1537	hypoxia	T046	C0242184
27683416	1543	1546	EPO	T116,T121,T125	C0014822
27683416	1562	1570	findings	T169	C2607943
27683416	1622	1625	EPO	T116,T121,T125	C0014822
27683416	1642	1652	functional	T169	C0205245
27683416	1653	1660	feature	T080	C2348519
27683416	1664	1673	pericytes	T025	C0598800
27683416	1681	1686	brain	T023	C0006104
27683416	1691	1697	kidney	T023	C0022646

28149055|t|Computational analysis of conserved coil functional residues in the mitochondrial genomic sequences of dermatophytes
28149055|a|Dermatophyte is a group of closely related fungi that have the capacity to invade keratinized tissue of humans and other animals. The infection known as dermatophytosis, caused by members of the genera Microsporum, Trichophyton, and Epidermophyton includes infection to the groin (tinea cruris), beard (tinea barbae), scalp (tinea capitis), feet (tinea pedis), glabrous skin (tinea corporis), nail (tinea unguium), and hand (tinea manuum). The identification of evolutionary relationship between these three genera of dermatophyte is epidemiologically important to understand their pathogenicity. Mitochondrial DNA evolves more rapidly than a nuclear DNA due to higher rate of mutation but is very less affected by genetic recombination, making it an important tool for phylogenetic studies. Thus, here we present a novel scheme to identify the conserved coil functional residues of Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum and Microsporum canis. Protein coding sequences of the mitochondrial genome were aligned for their similar sequences and homology modelling was performed for structure and pocket identification. The results obtained from comparative analysis of the protein sequences revealed the presence of functionally active sites in all the species of the genera Trichophyton and Microsporum. However in Epidermophyton floccosum it was observed in three protein sequences of the five studied. The absence of these conserved coil functional residues in E. floccusum may be correlated with lesser infectivity of this organism. The functional residues identified in the present study could be responsible for the disease and thus can act as putative target sites for drug designing.
28149055	0	22	Computational analysis	T059	C4297010
28149055	26	40	conserved coil	T082	C0444764
28149055	41	60	functional residues	T077	C1709915
28149055	68	99	mitochondrial genomic sequences	T059	C3863348
28149055	103	116	dermatophytes	T004	C0011635
28149055	117	129	Dermatophyte	T004	C0011635
28149055	160	165	fungi	T004	C0016832
28149055	192	198	invade	T080	C1517574
28149055	199	210	keratinized	T169	C0232387
28149055	211	217	tissue	T024	C0040300
28149055	221	227	humans	T016	C0086418
28149055	238	245	animals	T008	C0003062
28149055	251	260	infection	T046	C3714514
28149055	270	285	dermatophytosis	T047	C0011636
28149055	312	318	genera	T185	C1708235
28149055	319	330	Microsporum	T004	C0026033
28149055	332	344	Trichophyton	T004	C0040933
28149055	350	364	Epidermophyton	T004	C0014529
28149055	374	383	infection	T046	C3714514
28149055	391	396	groin	T029	C0018246
28149055	398	410	tinea cruris	T047	C1384589
28149055	413	418	beard	T023	C0221982
28149055	420	432	tinea barbae	T047	C2349994
28149055	435	440	scalp	T023	C0036270
28149055	442	455	tinea capitis	T047	C0040250
28149055	458	462	feet	T023	C0016504
28149055	464	475	tinea pedis	T047	C0040259
28149055	478	491	glabrous skin	T023	C1180283
28149055	493	507	tinea corporis	T047	C0040252
28149055	510	514	nail	T023	C0027342
28149055	516	529	tinea unguium	T047	C0040261
28149055	536	540	hand	T023	C0018563
28149055	542	554	tinea manuum	T047	C0153246
28149055	579	591	evolutionary	T045	C0015219
28149055	592	604	relationship	T080	C0439849
28149055	619	631	three genera	T185	C1708235
28149055	635	647	dermatophyte	T004	C0011635
28149055	651	678	epidemiologically important	T169	C1516907
28149055	699	712	pathogenicity	T032	C1136169
28149055	714	731	Mitochondrial DNA	T114,T123	C0012929
28149055	732	739	evolves	T038	C0282688
28149055	740	752	more rapidly	T080	C0456962
28149055	760	771	nuclear DNA	T114,T123	C1179920
28149055	786	802	rate of mutation	T080	C3178846
28149055	815	828	less affected	T169	C0392760
28149055	832	853	genetic recombination	T045	C0034865
28149055	868	882	important tool	T073	C2827396
28149055	887	907	phylogenetic studies	T062	C1519068
28149055	962	976	conserved coil	T082	C0444764
28149055	977	996	functional residues	T077	C1709915
28149055	1000	1019	Trichophyton rubrum	T004	C0040935
28149055	1021	1048	Trichophyton mentagrophytes	T004	C0040934
28149055	1050	1074	Epidermophyton floccosum	T004	C0014530
28149055	1079	1096	Microsporum canis	T004	C0319950
28149055	1098	1122	Protein coding sequences	T028	C0079941
28149055	1130	1150	mitochondrial genome	T028	C1819716
28149055	1174	1191	similar sequences	T086	C0162326
28149055	1196	1214	homology modelling	T063	C1512489
28149055	1233	1242	structure	T116	C1510464
28149055	1247	1253	pocket	T087	C0599218
28149055	1254	1268	identification	T062	C0936012
28149055	1296	1316	comparative analysis	T062	C0683941
28149055	1324	1341	protein sequences	T087	C0002518
28149055	1380	1392	active sites	T169	C0205681
28149055	1419	1425	genera	T185	C1708235
28149055	1426	1438	Trichophyton	T004	C0040933
28149055	1443	1454	Microsporum	T004	C0026033
28149055	1467	1491	Epidermophyton floccosum	T004	C0014530
28149055	1517	1534	protein sequences	T087	C0002518
28149055	1577	1591	conserved coil	T082	C0444764
28149055	1592	1611	functional residues	T077	C1709915
28149055	1615	1627	E. floccusum	T004	C0014530
28149055	1651	1669	lesser infectivity	T080	C0030657
28149055	1678	1686	organism	T001	C0029235
28149055	1692	1711	functional residues	T077	C1709915
28149055	1773	1780	disease	T047	C0012634
28149055	1801	1822	putative target sites	T169	C1521840
28149055	1827	1841	drug designing	T090	C0013171

28260547|t|Surrogate inaccuracy in predicting older adults' desire for life-sustaining interventions in the event of decisional incapacity: is it due in part to erroneous quality-of-life assessments?
28260547|a|Family members are often called upon to make decisions for an incapacitated relative. Yet they have difficulty predicting a loved one's desire to receive treatments in hypothetical situations. We tested the hypothesis that this difficulty could in part be explained by discrepant quality-of-life assessments. The data come from 235 community-dwelling adults aged 70 years and over who rated their quality of life and desire for specified interventions in four health states (current state, mild to moderate stroke, incurable brain cancer, and severe dementia). All ratings were made on Likert-type scales. Using identical rating scales, a surrogate chosen by the older adult was asked to predict the latter's responses. Linear mixed models were fitted to determine whether differences in quality-of-life ratings between the older adult and surrogate were associated with surrogates' inaccuracy in predicting desire for treatment. The difference in quality-of-life ratings was a significant predictor of prediction inaccuracy for the three hypothetical health states (p < 0.01) and nearly significant for the current health state (p = 0.077). All regression coefficients were negative, implying that the more the surrogate overestimated quality of life compared to the older adult, the more he or she overestimated the older adult 's desire to be treated. Discrepant quality-of-life ratings are associated with surrogates' difficulty in predicting desire for life-sustaining interventions in hypothetical situations. This finding underscores the importance of discussing anticipated quality of life in states of cognitive decline, to better prepare family members for making difficult decisions for their loved ones. ISRCTN89993391.
28260547	0	9	Surrogate	T099	C4053457
28260547	10	20	inaccuracy	T080	C0443236
28260547	35	48	older adults'	T098	C0001792
28260547	49	55	desire	T041	C0871633
28260547	60	89	life-sustaining interventions	T061	C0871803
28260547	106	116	decisional	T041	C0679006
28260547	117	127	incapacity	T201	C3176592
28260547	150	159	erroneous	T078	C1547323
28260547	160	187	quality-of-life assessments	T060	C0281588
28260547	189	203	Family members	T099	C0086282
28260547	234	243	decisions	T041	C0679006
28260547	265	273	relative	T099	C0080103
28260547	325	331	desire	T041	C0871633
28260547	343	353	treatments	T061	C0087111
28260547	469	496	quality-of-life assessments	T060	C0281588
28260547	502	506	data	T078	C1511726
28260547	521	539	community-dwelling	T056	C4045975
28260547	540	546	adults	T100	C0001675
28260547	555	560	years	T079	C0439234
28260547	586	601	quality of life	T078	C0034380
28260547	606	612	desire	T041	C0871633
28260547	627	640	interventions	T061	C0184661
28260547	649	662	health states	T033	C0683314
28260547	664	677	current state	T033	C0683314
28260547	679	683	mild	T080	C2945599
28260547	687	695	moderate	T080	C0205081
28260547	696	702	stroke	T047	C0038454
28260547	714	726	brain cancer	T191	C0006118
28260547	732	738	severe	T080	C0205082
28260547	739	747	dementia	T048	C0497327
28260547	754	761	ratings	T052	C0871208
28260547	775	793	Likert-type scales	T170	C0451267
28260547	811	824	rating scales	T081,T170	C0681889
28260547	828	837	surrogate	T099	C4053457
28260547	852	863	older adult	T098	C0001792
28260547	977	992	quality-of-life	T078	C0034380
28260547	993	1000	ratings	T052	C0871208
28260547	1013	1024	older adult	T098	C0001792
28260547	1029	1038	surrogate	T099	C4053457
28260547	1060	1071	surrogates'	T099	C4053457
28260547	1072	1082	inaccuracy	T080	C0443236
28260547	1097	1103	desire	T041	C0871633
28260547	1108	1117	treatment	T061	C0087111
28260547	1137	1152	quality-of-life	T078	C0034380
28260547	1153	1160	ratings	T052	C0871208
28260547	1179	1188	predictor	T078	C2698872
28260547	1203	1213	inaccuracy	T080	C0443236
28260547	1241	1254	health states	T033	C0683314
28260547	1297	1317	current health state	T033	C0683314
28260547	1335	1358	regression coefficients	T081	C1707429
28260547	1364	1372	negative	T033	C0205160
28260547	1401	1410	surrogate	T099	C4053457
28260547	1425	1440	quality of life	T078	C0034380
28260547	1457	1468	older adult	T098	C0001792
28260547	1507	1518	older adult	T098	C0001792
28260547	1522	1528	desire	T041	C0871633
28260547	1555	1570	quality-of-life	T078	C0034380
28260547	1571	1578	ratings	T052	C0871208
28260547	1599	1610	surrogates'	T099	C4053457
28260547	1636	1642	desire	T041	C0871633
28260547	1647	1676	life-sustaining interventions	T061	C0871803
28260547	1771	1786	quality of life	T078	C0034380
28260547	1800	1817	cognitive decline	T046	C0234985
28260547	1837	1851	family members	T099	C0086282
28260547	1873	1882	decisions	T041	C0679006

27414407|t|Learning Is Better with the Hands Free: The Role of Posture in the Memory of Manipulable Objects
27414407|a|Grounded cognition proposes that memory shares processing resources with sensorimotor systems. The aim of the present study was to show that motor simulation participates in the conceptual representation of manipulable objects in long-term memory. In two experiments, lists of manipulable and nonmanipulable objects were presented. Participants were instructed to memorize the items while adopting different postures. In the control condition, they had to keep their hands at rest in front of them. In the interference condition, participants had to keep their hands crossed behind their back to make their hands less free for action. After each list, participants had to perform first a distractive task, and then an oral free recall. The results showed that the interfering posture produced a specific decrease in the recall of manipulable objects, but not of nonmanipulable ones. This decrease was similar when the items were presented as pictures (Experiment 1) or as words (Experiment 2), thus excluding a purely visual effect. These results provide strong evidence that the motor simulation plays a role in the memory trace of the object.
27414407	0	8	Learning	T041	C0023185
27414407	12	18	Better	T080	C0332272
27414407	28	38	Hands Free	T169	C0332296
27414407	44	48	Role	T078	C0086939
27414407	52	59	Posture	T032	C1262869
27414407	67	73	Memory	T041	C0025260
27414407	77	96	Manipulable Objects	T072	C0347997
27414407	97	105	Grounded	T170	C1510611
27414407	106	115	cognition	T041	C0009240
27414407	116	124	proposes	T080	C1553874
27414407	130	136	memory	T041	C0025260
27414407	144	154	processing	T052	C1709694
27414407	155	164	resources	T078	C0035201
27414407	170	190	sensorimotor systems	T022	C0599408
27414407	196	199	aim	T078	C1947946
27414407	215	220	study	T062	C2603343
27414407	238	243	motor	T023	C0231502
27414407	244	254	simulation	T062	C0679083
27414407	255	267	participates	T169	C0679823
27414407	275	300	conceptual representation	T041	C0237661
27414407	304	323	manipulable objects	T072	C0347997
27414407	327	343	long-term memory	T041	C0423909
27414407	352	363	experiments	T062	C0681814
27414407	365	370	lists	T170	C0745732
27414407	374	385	manipulable	T072	C0347997
27414407	390	412	nonmanipulable objects	T072	C0347997
27414407	418	427	presented	T078	C0449450
27414407	429	441	Participants	T098	C0679646
27414407	447	457	instructed	T170	C1442085
27414407	474	479	items	T072	C0347997
27414407	495	504	different	T080	C1705242
27414407	505	513	postures	T032	C1262869
27414407	522	539	control condition	T080	C0243148
27414407	564	569	hands	T023	C0018563
27414407	573	577	rest	T056	C0035253
27414407	603	625	interference condition	T041	C0679066
27414407	627	639	participants	T098	C0679646
27414407	658	663	hands	T023	C0018563
27414407	664	671	crossed	T082	C0205203
27414407	685	689	back	T029	C0004600
27414407	704	709	hands	T023	C0018563
27414407	715	719	free	T169	C0332296
27414407	724	730	action	T052	C3266814
27414407	743	747	list	T170	C0745732
27414407	749	761	participants	T098	C0679646
27414407	769	776	perform	T169	C0884358
27414407	785	801	distractive task	T056	C0034872
27414407	815	819	oral	T082	C0442027
27414407	820	824	free	T169	C0332296
27414407	825	831	recall	T041	C0034770
27414407	837	844	results	T169	C1274040
27414407	861	872	interfering	T169	C0521102
27414407	873	880	posture	T032	C1262869
27414407	892	909	specific decrease	T081	C0547047
27414407	917	923	recall	T041	C0034770
27414407	927	946	manipulable objects	T072	C0347997
27414407	959	978	nonmanipulable ones	T072	C0347997
27414407	985	993	decrease	T081	C0547047
27414407	998	1005	similar	T080	C2348205
27414407	1015	1020	items	T072	C0347997
27414407	1026	1035	presented	T078	C0449450
27414407	1039	1047	pictures	T073	C0441469
27414407	1049	1059	Experiment	T062	C0681814
27414407	1069	1074	words	T170	C0042926
27414407	1076	1086	Experiment	T062	C0681814
27414407	1096	1105	excluding	T169	C0332196
27414407	1115	1121	visual	T169	C0234621
27414407	1122	1128	effect	T080	C1280500
27414407	1136	1143	results	T169	C1274040
27414407	1159	1167	evidence	T078	C3887511
27414407	1177	1182	motor	T023	C0231502
27414407	1183	1193	simulation	T062	C0679083
27414407	1202	1206	role	T078	C0086939
27414407	1214	1226	memory trace	T041	C0870873
27414407	1234	1240	object	T072	C0347997

28120711|t|Lipoprotein (a) management: lifestyle and hormones
28120711|a|Cardiovascular disease (CVD) continues to be the first cause of mortality developed countries. Moreover, far from diminishing, the cardiovascular risk factors leading towards the development of CVD are on the rise. Therefore, the preventive and therapeutic management which is currently in place is clearly not enough to stop this pandemic. In this context, a major resurgence in interest in lipoprotein (a) [Lp(a)] has occurred in light of its association with CVD. This series aims to review the basic and clinical aspects of Lp(a) biology. Specifically, the present review considers the current situation regarding the influence of lifestyle, hormones and other physiological or pathological conditions on Lp(a) plasma concentrations which might mitigate the harmful effects of this lipoprotein.
28120711	0	15	Lipoprotein (a)	T116,T123	C0065058
28120711	16	26	management	T169	C0012160
28120711	28	37	lifestyle	T054	C0851537
28120711	42	50	hormones	T125	C0019932
28120711	51	73	Cardiovascular disease	T047	C0007222
28120711	75	78	CVD	T047	C0007222
28120711	115	124	mortality	T081	C0681679
28120711	125	144	developed countries	T080	C0282613
28120711	165	176	diminishing	T081	C0205216
28120711	182	209	cardiovascular risk factors	T047	C0850624
28120711	230	241	development	T169	C1527148
28120711	245	248	CVD	T047	C0007222
28120711	281	291	preventive	T058	C0150369
28120711	296	318	therapeutic management	T061	C0087111
28120711	328	337	currently	T079	C0521116
28120711	382	390	pandemic	T067	C1615608
28120711	400	407	context	T078	C0449255
28120711	443	458	lipoprotein (a)	T116,T123	C0065058
28120711	460	465	Lp(a)	T116,T123	C0065058
28120711	471	479	occurred	T079	C2745955
28120711	496	512	association with	T080	C0332281
28120711	513	516	CVD	T047	C0007222
28120711	559	575	clinical aspects	T201	C0683325
28120711	579	584	Lp(a)	T116,T123	C0065058
28120711	585	592	biology	T091	C0005532
28120711	612	626	present review	T078	C1552617
28120711	627	636	considers	T078	C0750591
28120711	641	648	current	T079	C0521116
28120711	673	695	influence of lifestyle	T054	C0851537
28120711	697	705	hormones	T125	C0019932
28120711	716	729	physiological	T169	C0205463
28120711	733	756	pathological conditions	T184	C0039058
28120711	760	765	Lp(a)	T116,T123	C0065058
28120711	766	787	plasma concentrations	T081	C0683150
28120711	800	808	mitigate	T067	C1553901
28120711	813	828	harmful effects	T046	C0879626
28120711	837	848	lipoprotein	T116,T123	C0023820

28101523|t|Spatial Mnemonic Encoding: Theta Power Decreases and Medial Temporal Lobe BOLD Increases Co-Occur during the Usage of the Method of Loci
28101523|a|The method of loci is one, if not the most, efficient mnemonic encoding strategy. This spatial mnemonic combines the core cognitive processes commonly linked to medial temporal lobe (MTL) activity: spatial and associative memory processes. During such processes, fMRI studies consistently demonstrate MTL activity, while electrophysiological studies have emphasized the important role of theta oscillations (3-8 Hz) in the MTL. However, it is still unknown whether increases or decreases in theta power co-occur with increased BOLD signal in the MTL during memory encoding. To investigate this question, we recorded EEG and fMRI separately, while human participants used the spatial method of loci or the pegword method, a similarly associative but nonspatial mnemonic. The more effective spatial mnemonic induced a pronounced theta power decrease source localized to the left MTL compared with the nonspatial associative mnemonic strategy. This effect was mirrored by BOLD signal increases in the MTL. Successful encoding, irrespective of the strategy used, elicited decreases in left temporal theta power and increases in MTL BOLD activity. This pattern of results suggests a negative relationship between theta power and BOLD signal changes in the MTL during memory encoding and spatial processing. The findings extend the well known negative relation of alpha / beta oscillations and BOLD signals in the cortex to theta oscillations in the MTL.
28101523	0	7	Spatial	T041	C0814087
28101523	8	16	Mnemonic	T041	C0679055
28101523	17	25	Encoding	T041	C0679058
28101523	27	38	Theta Power	T042	C0039829
28101523	39	48	Decreases	T081	C0547047
28101523	53	59	Medial	T082	C0205098
28101523	60	73	Temporal Lobe	T023	C0039485
28101523	74	78	BOLD	T060	C1705491
28101523	79	88	Increases	T169	C0442805
28101523	89	97	Co-Occur	T052	C1709305
28101523	109	114	Usage	T169	C0457083
28101523	122	136	Method of Loci	T058	C3898430
28101523	141	155	method of loci	T058	C3898430
28101523	191	199	mnemonic	T041	C0679055
28101523	200	208	encoding	T041	C0679058
28101523	209	217	strategy	T041	C0679199
28101523	224	231	spatial	T041	C0814087
28101523	232	240	mnemonic	T041	C0679055
28101523	254	278	core cognitive processes	T041	C0025361
28101523	298	304	medial	T082	C0205098
28101523	305	318	temporal lobe	T023	C0039485
28101523	320	323	MTL	T023	C0039485
28101523	325	333	activity	T042	C1254358
28101523	335	342	spatial	T041	C0814087
28101523	359	375	memory processes	T041	C0679052
28101523	389	398	processes	T067	C1522240
28101523	400	404	fMRI	T060	C0376335
28101523	405	412	studies	T062	C2603343
28101523	438	441	MTL	T023	C0039485
28101523	442	450	activity	T042	C1254358
28101523	458	486	electrophysiological studies	T060	C0850293
28101523	517	521	role	T077	C1705810
28101523	525	543	theta oscillations	T042	C0039829
28101523	560	563	MTL	T023	C0039485
28101523	602	611	increases	T169	C0442805
28101523	615	624	decreases	T081	C0547047
28101523	628	639	theta power	T042	C0039829
28101523	640	648	co-occur	T052	C1709305
28101523	654	663	increased	T081	C0205217
28101523	664	668	BOLD	T060	C1705491
28101523	669	675	signal	T067	C1710082
28101523	683	686	MTL	T023	C0039485
28101523	694	700	memory	T041	C0025260
28101523	701	709	encoding	T041	C0679058
28101523	714	725	investigate	T169	C1292732
28101523	753	756	EEG	T060	C0013819
28101523	761	765	fMRI	T060	C0376335
28101523	784	789	human	T016	C0086418
28101523	790	802	participants	T098	C0679646
28101523	812	819	spatial	T041	C0814087
28101523	820	834	method of loci	T058	C3898430
28101523	842	856	pegword method	T058	C3898430
28101523	897	905	mnemonic	T041	C0679055
28101523	916	925	effective	T080	C1704419
28101523	926	933	spatial	T041	C0814087
28101523	934	942	mnemonic	T041	C0679055
28101523	943	950	induced	T169	C0205263
28101523	964	975	theta power	T042	C0039829
28101523	976	984	decrease	T081	C0547047
28101523	1009	1013	left	T082	C0205091
28101523	1014	1017	MTL	T023	C0039485
28101523	1059	1067	mnemonic	T041	C0679055
28101523	1068	1076	strategy	T041	C0679199
28101523	1083	1089	effect	T080	C1280500
28101523	1106	1110	BOLD	T060	C1705491
28101523	1111	1117	signal	T067	C1710082
28101523	1118	1127	increases	T169	C0442805
28101523	1135	1138	MTL	T023	C0039485
28101523	1151	1159	encoding	T041	C0679058
28101523	1181	1189	strategy	T041	C0679199
28101523	1196	1204	elicited	T080	C0449265
28101523	1205	1214	decreases	T081	C0547047
28101523	1218	1222	left	T082	C0205091
28101523	1223	1231	temporal	T023	C0039485
28101523	1232	1243	theta power	T042	C0039829
28101523	1248	1257	increases	T169	C0442805
28101523	1261	1264	MTL	T023	C0039485
28101523	1265	1269	BOLD	T060	C1705491
28101523	1270	1278	activity	T052	C0441655
28101523	1345	1356	theta power	T042	C0039829
28101523	1361	1365	BOLD	T060	C1705491
28101523	1366	1372	signal	T067	C1710082
28101523	1373	1380	changes	T169	C0392747
28101523	1388	1391	MTL	T023	C0039485
28101523	1399	1405	memory	T041	C0025260
28101523	1406	1414	encoding	T041	C0679058
28101523	1419	1437	spatial processing	T041	C3850026
28101523	1474	1482	negative	T033	C0205160
28101523	1495	1500	alpha	T042	C0039829
28101523	1503	1520	beta oscillations	T042	C0039829
28101523	1525	1529	BOLD	T060	C1705491
28101523	1530	1537	signals	T067	C1710082
28101523	1545	1551	cortex	T023	C0007776
28101523	1555	1573	theta oscillations	T042	C0039829
28101523	1581	1584	MTL	T023	C0039485

27447827|t|Effect of Low - Dose MDCT and Iterative Reconstruction on Trabecular Bone Microstructure Assessment
27447827|a|We investigated the effects of low - dose multi detector computed tomography (MDCT) in combination with statistical iterative reconstruction algorithms on trabecular bone microstructure parameters. Twelve donated vertebrae were scanned with the routine radiation exposure used in our department (standard-dose) and a low - dose protocol. Reconstructions were performed with filtered backprojection (FBP) and maximum-likelihood based statistical iterative reconstruction (SIR). Trabecular bone microstructure parameters were assessed and statistically compared for each reconstruction. Moreover, fracture loads of the vertebrae were biomechanically determined and correlated to the assessed microstructure parameters. Trabecular bone microstructure parameters based on low - dose MDCT and SIR significantly correlated with vertebral bone strength. There was no significant difference between microstructure parameters calculated on low - dose SIR and standard - dose FBP images. However, the results revealed a strong dependency on the regularization strength applied during SIR. It was observed that stronger regularization might corrupt the microstructure analysis, because the trabecular structure is a very small detail that might get lost during the regularization process. As a consequence, the introduction of SIR for trabecular bone microstructure analysis requires a specific optimization of the regularization parameters. Moreover, in comparison to other approaches, superior noise - resolution trade-offs can be found with the proposed methods.
27447827	0	6	Effect	T080	C1280500
27447827	10	13	Low	T080	C0205251
27447827	16	20	Dose	T081	C0034524
27447827	21	25	MDCT	T060	C0040405
27447827	30	54	Iterative Reconstruction	T060	C2986769
27447827	58	73	Trabecular Bone	T024	C0222660
27447827	74	88	Microstructure	T082	C0678594
27447827	89	99	Assessment	T052	C1516048
27447827	103	115	investigated	T169	C1292732
27447827	120	130	effects of	T080	C1704420
27447827	131	134	low	T080	C0205251
27447827	137	141	dose	T081	C0034524
27447827	142	176	multi detector computed tomography	T060	C0040405
27447827	178	182	MDCT	T060	C0040405
27447827	187	198	combination	T080	C0205195
27447827	204	240	statistical iterative reconstruction	T060	C2986769
27447827	241	251	algorithms	T170	C0002045
27447827	255	270	trabecular bone	T024	C0222660
27447827	271	285	microstructure	T082	C0678594
27447827	286	296	parameters	T077	C0549193
27447827	298	304	Twelve	T081	C0205458
27447827	305	312	donated	T058	C3854058
27447827	313	322	vertebrae	T023	C0549207
27447827	328	335	scanned	T060	C0441633
27447827	345	352	routine	T080	C0205547
27447827	353	371	radiation exposure	T060	C1313941
27447827	384	394	department	T092	C1704729
27447827	396	409	standard-dose	T081	C0034524
27447827	417	420	low	T080	C0205251
27447827	423	427	dose	T081	C0034524
27447827	428	436	protocol	T061	C0040808
27447827	438	453	Reconstructions	T061	C0524865
27447827	459	468	performed	T169	C0884358
27447827	474	497	filtered backprojection	T060	C2986750
27447827	499	502	FBP	T060	C2986750
27447827	508	526	maximum-likelihood	T062	C0870863
27447827	533	569	statistical iterative reconstruction	T060	C2986769
27447827	571	574	SIR	T060	C2986769
27447827	577	592	Trabecular bone	T024	C0222660
27447827	593	607	microstructure	T082	C0678594
27447827	608	618	parameters	T077	C0549193
27447827	624	632	assessed	T052	C1516048
27447827	637	650	statistically	T090	C0038215
27447827	651	659	compared	T052	C1707455
27447827	669	683	reconstruction	T061	C0524865
27447827	695	709	fracture loads	T037	C0016658
27447827	717	726	vertebrae	T023	C0549207
27447827	732	747	biomechanically	T060	C0846602
27447827	763	773	correlated	T080	C1707520
27447827	781	789	assessed	T052	C1516048
27447827	790	804	microstructure	T082	C0678594
27447827	805	815	parameters	T077	C0549193
27447827	817	832	Trabecular bone	T024	C0222660
27447827	833	847	microstructure	T082	C0678594
27447827	848	858	parameters	T077	C0549193
27447827	868	871	low	T080	C0205251
27447827	874	878	dose	T081	C0034524
27447827	879	883	MDCT	T060	C0040405
27447827	888	891	SIR	T060	C2986769
27447827	906	916	correlated	T080	C1707520
27447827	922	936	vertebral bone	T023	C0549207
27447827	937	945	strength	T081	C0237897
27447827	957	971	no significant	T033	C0243095
27447827	991	1005	microstructure	T082	C0678594
27447827	1006	1016	parameters	T077	C0549193
27447827	1031	1034	low	T080	C0205251
27447827	1037	1041	dose	T081	C0034524
27447827	1042	1045	SIR	T060	C2986769
27447827	1050	1058	standard	T080	C1442989
27447827	1061	1065	dose	T081	C0034524
27447827	1066	1069	FBP	T060	C2986750
27447827	1070	1076	images	T170	C1704254
27447827	1099	1107	revealed	T080	C0443289
27447827	1110	1116	strong	T080	C0442821
27447827	1117	1127	dependency	T080	C1701901
27447827	1135	1149	regularization	T067	C1522240
27447827	1150	1158	strength	T078	C0808080
27447827	1174	1177	SIR	T060	C2986769
27447827	1200	1208	stronger	T080	C0442821
27447827	1209	1223	regularization	T067	C1522240
27447827	1230	1237	corrupt	T169	C1883709
27447827	1242	1256	microstructure	T082	C0678594
27447827	1257	1265	analysis	T169	C1524024
27447827	1279	1289	trabecular	T024	C0222660
27447827	1290	1299	structure	T082	C0678594
27447827	1305	1309	very	T080	C0442824
27447827	1310	1315	small	T081	C0700321
27447827	1338	1342	lost	T169	C0745777
27447827	1354	1376	regularization process	T067	C1522240
27447827	1383	1394	consequence	T169	C0686907
27447827	1400	1412	introduction	T169	C0579004
27447827	1416	1419	SIR	T060	C2986769
27447827	1424	1439	trabecular bone	T024	C0222660
27447827	1440	1454	microstructure	T082	C0678594
27447827	1455	1463	analysis	T169	C1524024
27447827	1475	1483	specific	T080	C0205369
27447827	1484	1496	optimization	T052	C2698650
27447827	1504	1518	regularization	T067	C1522240
27447827	1519	1529	parameters	T077	C0549193
27447827	1544	1554	comparison	T052	C1707455
27447827	1564	1574	approaches	T169	C1292724
27447827	1576	1584	superior	T080	C0205250
27447827	1585	1590	noise	T067	C0028263
27447827	1593	1603	resolution	T077	C2699488
27447827	1604	1614	trade-offs	T080	C0205556
27447827	1637	1645	proposed	T080	C1553874
27447827	1646	1653	methods	T170	C0025663

27485947|t|Geometric morphometrics reveals restrictions on the shape of the female os coxae
27485947|a|The methodology for sex determination in human skeletal remains depends on the different bone morphologies presented by men and women. Due to their direct implications in reproduction, the whole pelvis, particularly the os coxae, shows different characteristics in either sex. The sacrum and the os coxae constitute the birth cana l. In this research study, the os coxae shape is analyzed using geometric morphometrics, providing information on morphology, regardless of size or any other factor beyond the geometry itself. A total of 46 adult ossa coxae from a Spanish archaeological collection were studied using geometric morphometrics. The results show that there is a restriction on the shape of female os coxae. In contrast, male os coxae presents a greater range of variation. The biological reason for this difference is the obstetrical dilemma; a concept defined as the anatomical conflict between bipedalism and the full-term birth of a neonate whose large head requires greater dimensions in the pelvic cavity. Our experimental data reinforce the validity of the obstetrical dilemma as source of the restriction on the shape of female ossa coxae. Additionally, according to the results obtained, size itself does not represent a condition for belonging to one sex or another.
27485947	0	9	Geometric	T082	C1254362
27485947	10	23	morphometrics	T059	C0200760
27485947	32	44	restrictions	T169	C0443288
27485947	52	57	shape	T082	C0332479
27485947	65	71	female	T032	C0086287
27485947	72	80	os coxae	T023	C0030786
27485947	85	96	methodology	T078	C3266812
27485947	101	118	sex determination	T038	C1367886
27485947	122	136	human skeletal	T022	C3826167
27485947	170	174	bone	T023	C0262950
27485947	175	187	morphologies	T080	C0332437
27485947	201	204	men	T098	C0025266
27485947	209	214	women	T098	C0043210
27485947	252	264	reproduction	T040	C0035150
27485947	276	282	pelvis	T023	C0030797
27485947	301	309	os coxae	T023	C0030786
27485947	327	342	characteristics	T080	C1521970
27485947	353	356	sex	T032	C0079399
27485947	362	368	sacrum	T029	C3669209
27485947	377	385	os coxae	T023	C0030786
27485947	401	411	birth cana	T023	C0230288
27485947	443	451	os coxae	T023	C0030786
27485947	452	457	shape	T082	C0332479
27485947	476	485	geometric	T082	C1254362
27485947	486	499	morphometrics	T059	C0200760
27485947	511	522	information	T078	C1533716
27485947	526	536	morphology	T080	C0332437
27485947	552	556	size	T032	C1450569
27485947	588	596	geometry	T082	C1254362
27485947	619	624	adult	T100	C0001675
27485947	625	635	ossa coxae	T023	C0030786
27485947	643	650	Spanish	T098	C0086409
27485947	651	665	archaeological	T090	C0003733
27485947	666	676	collection	T059	C0200345
27485947	696	705	geometric	T082	C1254362
27485947	706	719	morphometrics	T059	C0200760
27485947	754	765	restriction	T169	C0443288
27485947	773	778	shape	T082	C0332479
27485947	782	788	female	T032	C0086287
27485947	789	797	os coxae	T023	C0030786
27485947	812	816	male	T032	C0086582
27485947	817	825	os coxae	T023	C0030786
27485947	854	863	variation	T080	C0205419
27485947	869	886	biological reason	T033	C0243095
27485947	914	933	obstetrical dilemma	T078	C1512571
27485947	937	944	concept	T078	C0178566
27485947	960	970	anatomical	T080	C0220784
27485947	971	979	conflict	T080	C1705242
27485947	988	998	bipedalism	T040	C0023946
27485947	1017	1022	birth	T040	C0005615
27485947	1028	1035	neonate	T100	C0021289
27485947	1042	1052	large head	T033	C4083076
27485947	1070	1080	dimensions	T081	C0439534
27485947	1088	1101	pelvic cavity	T030	C0559769
27485947	1107	1124	experimental data	T078	C1511726
27485947	1139	1147	validity	T081	C2349101
27485947	1155	1174	obstetrical dilemma	T078	C1512571
27485947	1192	1203	restriction	T169	C0443288
27485947	1211	1216	shape	T082	C0332479
27485947	1220	1226	female	T032	C0086287
27485947	1227	1237	ossa coxae	T023	C0030786
27485947	1270	1277	results	T033	C2825142
27485947	1288	1292	size	T032	C1450569
27485947	1321	1330	condition	T080	C0348080
27485947	1352	1355	sex	T032	C0079399

28300431|t|The Psychometric Costs of Applicants ' Faking: Examining Measurement Invariance and Retest Correlations Across Response Conditions
28300431|a|This study examines the stability of the response process and the rank-order of respondents responding to 3 personality scales in 4 different response conditions. Applicants to the University College of Teacher Education Styria (N = 243) completed personality scales as part of their college admission process. Half a year later, they retook the same personality scales in 1 of 3 randomly assigned experimental response conditions: honest, faking-good, or reproduce. Longitudinal means and covariance structure analyses showed that applicants ' response processes could be partially reproduced after half a year, and respondents seemed to rely on an honest response behavior as a frame of reference. Additionally, applicants ' faking behavior and instructed faking (faking-good) caused differences in the latent retest correlations and consistently affected measurement properties. The varying latent retest correlations indicated that faking can distort respondents ' rank-order and thus the fairness of subsequent selection decisions, depending on the kind of faking behavior. Instructed faking (faking-good) even affected weak measurement invariance, whereas applicants ' faking behavior did not. Consequently, correlations with personality scales -which can be utilized for predictive validity -may be readily interpreted for applicants. Faking behavior also introduced a uniform bias, implying that the classically observed mean raw score differences may not be readily interpreted.
28300431	4	22	Psychometric Costs	T060	C0033920
28300431	26	36	Applicants	T098	C0696628
28300431	39	45	Faking	T055	C0871743
28300431	57	68	Measurement	T169	C0242485
28300431	84	103	Retest Correlations	T062	C0237828
28300431	111	130	Response Conditions	T041	C0009647
28300431	142	164	examines the stability	T080	C0205360
28300431	172	188	response process	T041	C0009647
28300431	197	207	rank-order	T062,T170	C0871206
28300431	211	222	respondents	T098	C0282122
28300431	223	233	responding	T041	C0009647
28300431	239	257	personality scales	T170	C0582654
28300431	273	292	response conditions	T041	C0009647
28300431	294	304	Applicants	T098	C0696628
28300431	312	351	University College of Teacher Education	T073,T092	C0041740
28300431	352	358	Styria	T083	C0017446
28300431	379	397	personality scales	T170	C0582654
28300431	415	440	college admission process	T170	C0009352
28300431	482	500	personality scales	T170	C0582654
28300431	511	528	randomly assigned	UnknownType	C0814868
28300431	542	561	response conditions	T041	C0009647
28300431	563	569	honest	T055	C0870663
28300431	571	582	faking-good	T055	C0871743
28300431	598	616	Longitudinal means	T062	C0023981
28300431	621	650	covariance structure analyses	T081	C0814908
28300431	663	673	applicants	T098	C0696628
28300431	676	694	response processes	T041	C0009647
28300431	748	759	respondents	T098	C0282122
28300431	781	787	honest	T055	C0870663
28300431	788	805	response behavior	T041	C0009647
28300431	811	829	frame of reference	T077	C1711364
28300431	845	855	applicants	T098	C0696628
28300431	858	873	faking behavior	T055	C0871743
28300431	889	895	faking	T055	C0871743
28300431	897	908	faking-good	T055	C0871743
28300431	936	942	latent	T080	C0205275
28300431	943	962	retest correlations	T062	C0237828
28300431	989	1000	measurement	T169	C0242485
28300431	1025	1031	latent	T080	C0205275
28300431	1032	1051	retest correlations	T062	C0237828
28300431	1052	1061	indicated	T033	C1444656
28300431	1067	1073	faking	T055	C0871743
28300431	1078	1085	distort	T169	C0700135
28300431	1086	1097	respondents	T098	C0282122
28300431	1100	1110	rank-order	T062,T170	C0871206
28300431	1124	1132	fairness	T080	C2911689
28300431	1147	1166	selection decisions	T041	C0011109
28300431	1193	1208	faking behavior	T055	C0871743
28300431	1221	1227	faking	T055	C0871743
28300431	1229	1240	faking-good	T055	C0871743
28300431	1261	1272	measurement	T169	C0242485
28300431	1293	1303	applicants	T098	C0696628
28300431	1306	1321	faking behavior	T055	C0871743
28300431	1345	1357	correlations	T080	C1707520
28300431	1363	1381	personality scales	T170	C0582654
28300431	1409	1428	predictive validity	T080	C0681898
28300431	1445	1456	interpreted	T169	C1285553
28300431	1461	1471	applicants	T098	C0696628
28300431	1473	1488	Faking behavior	T055	C0871743
28300431	1507	1519	uniform bias	T078	C0242568
28300431	1560	1574	mean raw score	T081	C0392762
28300431	1606	1617	interpreted	T169	C1285553

27387068|t|Is Localized Scleroderma Caused by Borrelia burgdorferi?
27387068|a|Despite considerable achievements in the study of localized scleroderma, the etiology of the disease has not been investigated completely. Borrelia burgdorferi -the agent of Lyme disease -is suggested to be one of the possible etiological factors of localized scleroderma. However, among scientists, this hypothesis is quite controversial. We have conducted investigations of the level of IgM and IgG class antibodies to B. burgdorferi in the serum of patients with localized scleroderma. To rationally substantiate the role of B. burgdorferi in the occurrence of localized scleroderma, thirty-two patients with localized scleroderma treated at an in-patient department were examined. The level of anti-Borrelia antibodies was determined in ELISA. Diagnostic levels of IgM and/or IgG were detected in 18.8% of patients with localized scleroderma, which is more than in the population (p < 0.01). Positive levels of anti-Borrelia antibodies in patients with localized scleroderma confirm the borreliosis nature of the disease, requiring conduction of complex antimicrobial treatment.
27387068	3	24	Localized Scleroderma	T047	C0036420
27387068	25	34	Caused by	T169	C0015127
27387068	35	55	Borrelia burgdorferi	T007	C0006034
27387068	98	103	study	T062	C2603343
27387068	107	128	localized scleroderma	T047	C0036420
27387068	134	142	etiology	T169	C1314792
27387068	150	157	disease	T047	C0012634
27387068	171	183	investigated	T169	C1292732
27387068	196	216	Borrelia burgdorferi	T007	C0006034
27387068	231	243	Lyme disease	T047	C0024198
27387068	284	303	etiological factors	T169	C0015127
27387068	307	328	localized scleroderma	T047	C0036420
27387068	345	355	scientists	T097	C0402112
27387068	362	372	hypothesis	T078	C1512571
27387068	382	395	controversial	T054	C0680243
27387068	415	429	investigations	T058	C0220825
27387068	437	442	level	T080	C0441889
27387068	446	449	IgM	T116,T129	C0020861
27387068	454	457	IgG	T116,T121,T129	C0020852
27387068	464	474	antibodies	T116,T129	C0003241
27387068	478	492	B. burgdorferi	T007	C0006034
27387068	500	505	serum	T031	C0229671
27387068	509	517	patients	T101	C0030705
27387068	523	544	localized scleroderma	T047	C0036420
27387068	585	599	B. burgdorferi	T007	C0006034
27387068	621	642	localized scleroderma	T047	C0036420
27387068	655	663	patients	T101	C0030705
27387068	669	690	localized scleroderma	T047	C0036420
27387068	691	698	treated	T169	C1522326
27387068	705	715	in-patient	T101	C0021562
27387068	716	726	department	T082	C1547116
27387068	746	751	level	T080	C0441889
27387068	755	779	anti-Borrelia antibodies	T116,T129	C0003241
27387068	798	803	ELISA	T059	C0014441
27387068	805	815	Diagnostic	T169	C0348026
27387068	816	822	levels	T080	C0441889
27387068	826	829	IgM	T116,T129	C0020861
27387068	837	840	IgG	T116,T121,T129	C0020852
27387068	867	875	patients	T101	C0030705
27387068	881	902	localized scleroderma	T047	C0036420
27387068	930	940	population	T098	C1257890
27387068	953	968	Positive levels	T033	C1514241
27387068	972	996	anti-Borrelia antibodies	T116,T129	C0003241
27387068	1000	1008	patients	T101	C0030705
27387068	1014	1035	localized scleroderma	T047	C0036420
27387068	1048	1059	borreliosis	T047	C0006035
27387068	1060	1081	nature of the disease	T080	C0449786
27387068	1115	1128	antimicrobial	T121	C1136254
27387068	1129	1138	treatment	T061	C0087111

27727312|t|Importance of Ecological Factors and Colony Handling for Optimizing Health Status of Apiaries in Mediterranean Ecosystems
27727312|a|We analyzed six apiaries in several natural environments with a Mediterranean ecosystem in Madrid, central Spain, in order to understand how landscape and management characteristics may influence apiary health and bee production in the long term. We focused on five criteria (habitat quality, landscape heterogeneity, climate, management and health), as well as 30 subcriteria, and we used the analytic hierarchy process (AHP) to rank them according to relevance. Habitat quality proved to have the highest relevance, followed by beehive management. Within habitat quality, the following subcriteria proved to be most relevant: orographic diversity, elevation range and important plant species located 1.5 km from the apiary. The most important subcriteria under beehive management were honey production, movement of the apiary to a location with a higher altitude and wax renewal. Temperature was the most important subcriterion under climate, while pathogen and Varroa loads were the most significant under health. Two of the six apiaries showed the best values in the AHP analysis and showed annual honey production of 70 and 28 kg/ colony. This high productivity was due primarily to high elevation range and high orographic diversity, which favored high habitat quality. In addition, one of these apiaries showed the best value for beehive management, while the other showed the best value for health, reflected in the low pathogen load and low average number of viruses. These results highlight the importance of environmental factors and good sanitary practices to maximize apiary health and honey productivity.
27727312	0	10	Importance	T080	C3898777
27727312	14	32	Ecological Factors	T077	C0870460
27727312	37	43	Colony	T078	C0441833
27727312	44	52	Handling	T033	C1832073
27727312	57	67	Optimizing	T052	C2698650
27727312	68	81	Health Status	T080	C0018759
27727312	85	93	Apiaries	T073	C3273359
27727312	97	110	Mediterranean	T098	C0240321
27727312	111	121	Ecosystems	T070	C0162358
27727312	125	133	analyzed	T062	C0936012
27727312	138	146	apiaries	T073	C3273359
27727312	158	178	natural environments	T082	C0557745
27727312	186	199	Mediterranean	T098	C0240321
27727312	200	209	ecosystem	T070	C0162358
27727312	213	219	Madrid	T083	C0037747
27727312	221	234	central Spain	T083	C0037747
27727312	248	258	understand	T041	C0162340
27727312	263	272	landscape	T082	C0870781
27727312	277	287	management	T170	C0680830
27727312	288	303	characteristics	T080	C1521970
27727312	308	317	influence	T077	C4054723
27727312	318	324	apiary	T073	C3273359
27727312	325	331	health	T078	C0018684
27727312	336	339	bee	T204	C0004923
27727312	358	367	long term	T079	C0443252
27727312	372	379	focused	T169	C1285542
27727312	388	396	criteria	T078	C0243161
27727312	398	405	habitat	T082	C0871648
27727312	406	413	quality	T080	C0332306
27727312	415	424	landscape	T082	C0870781
27727312	425	438	heterogeneity	T080	C0019409
27727312	440	447	climate	T070	C0008946
27727312	449	459	management	T170	C0680830
27727312	464	470	health	T078	C0018684
27727312	487	498	subcriteria	T078	C0243161
27727312	516	542	analytic hierarchy process	T062	C0035177
27727312	544	547	AHP	T062	C0035177
27727312	552	556	rank	T170	C0699794
27727312	575	584	relevance	T080	C2347946
27727312	586	593	Habitat	T082	C0871648
27727312	594	601	quality	T080	C0332306
27727312	629	638	relevance	T080	C2347946
27727312	652	659	beehive	T073	C3273359
27727312	660	670	management	T170	C0680830
27727312	679	686	habitat	T082	C0871648
27727312	687	694	quality	T080	C0332306
27727312	710	721	subcriteria	T078	C0243161
27727312	740	748	relevant	T080	C2347946
27727312	750	770	orographic diversity	T080	C1880371
27727312	772	781	elevation	T082	C0702240
27727312	782	787	range	T081	C1514721
27727312	792	801	important	T080	C3898777
27727312	802	807	plant	T002	C0032098
27727312	808	815	species	T185	C1705920
27727312	816	823	located	T082	C0332285
27727312	840	846	apiary	T073	C3273359
27727312	857	866	important	T080	C3898777
27727312	867	878	subcriteria	T078	C0243161
27727312	885	892	beehive	T073	C3273359
27727312	893	903	management	T170	C0680830
27727312	909	914	honey	T168	C0019906
27727312	915	925	production	T057	C0033268
27727312	943	949	apiary	T073	C3273359
27727312	955	963	location	T082	C0450429
27727312	978	986	altitude	T081	C0002349
27727312	991	994	wax	T122	C0004924
27727312	995	1002	renewal	T169	C0205245
27727312	1004	1015	Temperature	T081	C0039476
27727312	1039	1051	subcriterion	T078	C0243161
27727312	1058	1065	climate	T070	C0008946
27727312	1073	1081	pathogen	T001	C0450254
27727312	1086	1092	Varroa	T204	C0323623
27727312	1093	1098	loads	T033	C0243095
27727312	1113	1124	significant	T078	C0750502
27727312	1131	1137	health	T078	C0018684
27727312	1154	1162	apiaries	T073	C3273359
27727312	1174	1185	best values	T081	C1299381
27727312	1193	1196	AHP	T062	C0035177
27727312	1197	1205	analysis	T062	C0936012
27727312	1217	1223	annual	T079	C0332181
27727312	1224	1229	honey	T168	C0019906
27727312	1230	1240	production	T057	C0033268
27727312	1258	1264	colony	T078	C0441833
27727312	1276	1288	productivity	T081	C0033269
27727312	1315	1324	elevation	T082	C0702240
27727312	1325	1330	range	T081	C1514721
27727312	1340	1360	orographic diversity	T080	C1880371
27727312	1381	1388	habitat	T082	C0871648
27727312	1389	1396	quality	T080	C0332306
27727312	1424	1432	apiaries	T073	C3273359
27727312	1444	1454	best value	T081	C1299381
27727312	1459	1466	beehive	T073	C3273359
27727312	1467	1477	management	T170	C0680830
27727312	1506	1516	best value	T081	C1299381
27727312	1521	1527	health	T078	C0018684
27727312	1546	1549	low	T080	C0205251
27727312	1550	1558	pathogen	T001	C0450254
27727312	1559	1563	load	T033	C0243095
27727312	1568	1571	low	T080	C0205251
27727312	1572	1579	average	T081	C1510992
27727312	1580	1586	number	T081	C0237753
27727312	1590	1597	viruses	T005	C0042776
27727312	1605	1612	results	T169	C1274040
27727312	1627	1637	importance	T080	C3898777
27727312	1641	1662	environmental factors	T077	C0870460
27727312	1672	1690	sanitary practices	T169	C0205245
27727312	1703	1709	apiary	T073	C3273359
27727312	1710	1716	health	T078	C0018684
27727312	1721	1726	honey	T168	C0019906
27727312	1727	1739	productivity	T081	C0033269

27565311|t|Effects of morphology and surface hydroxyl on the toxicity of BiOCl in human HaCaT cells
27565311|a|Recently, bismuth oxychloride nanomaterials (BiOCls) are showing great promise in pollutant removal. Residues from these environmental remediations are potential hazardous materials. Unfortunately, human health risks of BiOCls are still unexplored widely. In the present study, we focused on the influence of physicochemical properties on the cytotoxicity of BiOCls toward a human skin derived cell line (HaCaT). Results showed that morphology and surface hydroxyl both had a profound effect on the toxicity of BiOCls. Microsphere-shaped BiOCl caused less toxicity than nanosheet-shaped BiOCl because of weaker particle-membrane interactions, while the presence of surface hydroxyl on microsphere-shaped BiOCl significantly raised the toxicity owing to the increased interaction with cell membrane. Both microsphere-shaped BiOCl with surface hydroxyl and nanosheet-shaped BiOCl caused significant cell membrane damage (PI uptake and LDH release), however, based on the different mechanism. The former may be a predominant "chemical" mechanism involved an oxidative stress paradigm, as manifested by elevated ROS and depleted GSH, while the latter is mainly due to a direct " physical " damage to cell membrane. Both " physical " and "chemical" response led to cell death. Furthermore, a set of experiments including MMP collapse, cell cycle arrest, and apoptosis / necrosis were conducted to propose a scenario for toxicological aspects of BiOCls. Data presented here would help to enable the rational design of BiOCls for either reducing their unintended consequences or increasing their application potentials.
27565311	11	21	morphology	T080	C0332437
27565311	26	42	surface hydroxyl	T197	C0700307
27565311	50	58	toxicity	T037	C0600688
27565311	62	67	BiOCl	T121,T197	C0053787
27565311	71	76	human	T016	C0086418
27565311	77	88	HaCaT cells	T025	C0022567
27565311	99	118	bismuth oxychloride	T121,T197	C0053787
27565311	119	132	nanomaterials	T185	C1881976
27565311	134	140	BiOCls	T121,T197	C0053787
27565311	171	180	pollutant	T131	C0599786
27565311	181	188	removal	T052	C1883720
27565311	190	198	Residues	T131	C0599786
27565311	210	236	environmental remediations	T069	C3853059
27565311	251	270	hazardous materials	T131	C0018626
27565311	287	292	human	T016	C0086418
27565311	293	305	health risks	T058	C0086930
27565311	309	315	BiOCls	T121,T197	C0053787
27565311	360	365	study	T062	C2603343
27565311	398	424	physicochemical properties	T080	C0871161
27565311	432	444	cytotoxicity	T049	C0596402
27565311	448	454	BiOCls	T121,T197	C0053787
27565311	464	469	human	T016	C0086418
27565311	470	474	skin	T022	C1123023
27565311	483	492	cell line	T025	C0007634
27565311	494	499	HaCaT	T025	C0022567
27565311	522	532	morphology	T080	C0332437
27565311	537	553	surface hydroxyl	T197	C0700307
27565311	588	596	toxicity	T037	C0600688
27565311	600	606	BiOCls	T121,T197	C0053787
27565311	608	626	Microsphere-shaped	T082	C0332479
27565311	627	632	BiOCl	T121,T197	C0053787
27565311	645	653	toxicity	T037	C0600688
27565311	659	675	nanosheet-shaped	T082	C0332479
27565311	676	681	BiOCl	T121,T197	C0053787
27565311	693	730	weaker particle-membrane interactions	T043	C0007613
27565311	754	770	surface hydroxyl	T197	C0700307
27565311	774	792	microsphere-shaped	T082	C0332479
27565311	793	798	BiOCl	T121,T197	C0053787
27565311	824	832	toxicity	T037	C0600688
27565311	856	867	interaction	T043	C0007613
27565311	873	886	cell membrane	T026	C0007603
27565311	893	911	microsphere-shaped	T082	C0332479
27565311	912	917	BiOCl	T121,T197	C0053787
27565311	923	939	surface hydroxyl	T197	C0700307
27565311	944	960	nanosheet-shaped	T082	C0332479
27565311	961	966	BiOCl	T121,T197	C0053787
27565311	986	999	cell membrane	T026	C0007603
27565311	1000	1006	damage	T049	C0599732
27565311	1008	1010	PI	T109,T130	C0033470
27565311	1008	1017	PI uptake	T059	C0005507
27565311	1022	1025	LDH	T116,T126	C0022917
27565311	1022	1033	LDH release	T059	C0005507
27565311	1068	1077	mechanism	T043	C0007613
27565311	1111	1131	"chemical" mechanism	T043	C1623221
27565311	1144	1169	oxidative stress paradigm	T062	C0681797
27565311	1197	1200	ROS	T123,T196	C0162772
27565311	1214	1217	GSH	T116,T123	C0017817
27565311	1264	1272	physical	T169	C0205485
27565311	1275	1281	damage	T049	C0599732
27565311	1285	1298	cell membrane	T026	C0007603
27565311	1307	1315	physical	T043	C1623221
27565311	1322	1341	"chemical" response	T043	C1623221
27565311	1349	1359	cell death	T043	C0007587
27565311	1383	1394	experiments	T062	C0681814
27565311	1405	1408	MMP	T043	C1720920
27565311	1419	1436	cell cycle arrest	T043	C1155873
27565311	1442	1451	apoptosis	T043	C0162638
27565311	1454	1462	necrosis	T042	C0027540
27565311	1504	1525	toxicological aspects	T080	C0040539
27565311	1529	1535	BiOCls	T121,T197	C0053787
27565311	1537	1541	Data	T078	C1511726
27565311	1582	1597	rational design	T052	C1707689
27565311	1601	1607	BiOCls	T121,T197	C0053787
27565311	1634	1657	unintended consequences	T080	C0205556
27565311	1678	1700	application potentials	T080	C3245505

27773526|t|An S116R Phosphorylation Site Mutation in Human Fibroblast Growth Factor-1 Differentially Affects Mitogenic and Glucose-Lowering Activities
27773526|a|Fibroblast growth factor-1 (FGF-1), a potent human mitogen and insulin sensitizer, signals through both tyrosine kinase receptor -mediated autocrine / paracrine pathways as well as a nuclear intracrine pathway. Phosphorylation of FGF-1 at serine 116 (S116) has been proposed to regulate intracrine signaling. Position S116 is located within a ∼17 amino acid C-terminal loop that contains a rich set of functional determinants including heparin ∖ heparan sulfate affinity, thiol reactivity, nuclear localization, pharmacokinetics, functional half-life, nuclear ligand affinity, stability, and structural dynamics. Mutational targeting of specific functionality in this region without perturbing other functional determinants is a design challenge. S116R is a non-phosphorylatable variant present in bovine FGF-1 and other members of the human FGF family. We show that the S116R mutation in human FGF-1 is accommodated with no perturbation of biophysical or structural properties, and is therefore an attractive mutation with which to elucidate the functional role of phosphorylation. Characterization of S116R shows reduction in NIH 3T3 fibroblast mitogenic stimulation, increase in fibroblast growth factor receptor-1c activation, and prolonged duration of glucose lowering in ob/ob hyperglycemic mice. A novel FGF-1 / fibroblast growth factor receptor-1c dimerization interaction combined with non-phosphorylatable intracrine signaling is hypothesized to be responsible for these observed functional effects.
27773526	3	29	S116R Phosphorylation Site	T087	C1519254
27773526	30	38	Mutation	T045	C0026882
27773526	42	47	Human	T016	C0086418
27773526	48	74	Fibroblast Growth Factor-1	T116,T123	C0079349
27773526	98	107	Mitogenic	T043	C1752930
27773526	112	139	Glucose-Lowering Activities	T033	C0860801
27773526	140	166	Fibroblast growth factor-1	T116,T123	C0079349
27773526	168	173	FGF-1	T116,T123	C0079349
27773526	185	190	human	T016	C0086418
27773526	191	198	mitogen	T116,T123	C0018284
27773526	203	210	insulin	T116,T121,T125	C0021641
27773526	223	230	signals	T044	C0037080
27773526	244	268	tyrosine kinase receptor	T116,T126,T192	C0206364
27773526	279	288	autocrine	T043	C0525010
27773526	291	309	paracrine pathways	UnknownType	C0678844
27773526	323	330	nuclear	T082	C0521447
27773526	331	349	intracrine pathway	T044	C1154545
27773526	351	366	Phosphorylation	T044	C0031715
27773526	370	375	FGF-1	T116,T123	C0079349
27773526	379	389	serine 116	T116,T121,T123	C0036720
27773526	391	395	S116	T116,T121,T123	C0036720
27773526	418	426	regulate	T044	C3158094
27773526	427	447	intracrine signaling	T044	C1154545
27773526	458	462	S116	T116,T121,T123	C0036720
27773526	487	513	amino acid C-terminal loop	T087	C1707271
27773526	542	565	functional determinants	T123	C0574031
27773526	576	583	heparin	T109,T121,T123	C0019134
27773526	586	601	heparan sulfate	T109,T123	C0019143
27773526	602	610	affinity	T070	C1510827
27773526	612	617	thiol	T109	C0038734
27773526	618	628	reactivity	T169	C0443286
27773526	630	650	nuclear localization	T087	C0525021
27773526	652	668	pharmacokinetics	T169	C0031328
27773526	670	680	functional	T169	C0205245
27773526	681	690	half-life	T079	C0018517
27773526	692	699	nuclear	T082	C0521447
27773526	700	706	ligand	T103	C0023688
27773526	707	715	affinity	T070	C1510827
27773526	717	726	stability	T080	C0205360
27773526	732	751	structural dynamics	T044	C0596957
27773526	753	763	Mutational	T045	C0026882
27773526	764	773	targeting	T169	C1521840
27773526	823	833	perturbing	T169	C0332453
27773526	840	863	functional determinants	T123	C0574031
27773526	887	892	S116R	T116,T121,T123	C0036720
27773526	898	918	non-phosphorylatable	T033	C0243095
27773526	919	926	variant	T080	C0205419
27773526	938	944	bovine	T015	C3667982
27773526	945	950	FGF-1	T116,T123	C0079349
27773526	976	981	human	T016	C0086418
27773526	982	992	FGF family	T116,T123	C0016026
27773526	1011	1025	S116R mutation	T045	C0026882
27773526	1029	1034	human	T016	C0086418
27773526	1035	1040	FGF-1	T116,T123	C0079349
27773526	1065	1077	perturbation	T169	C0332453
27773526	1081	1092	biophysical	T070	C2350452
27773526	1096	1106	structural	T085	C0026383
27773526	1139	1149	attractive	T080	C2346874
27773526	1150	1158	mutation	T045	C0026882
27773526	1187	1197	functional	T169	C0205245
27773526	1206	1221	phosphorylation	T044	C0031715
27773526	1223	1239	Characterization	T052	C1880022
27773526	1243	1248	S116R	T116,T121,T123	C0036720
27773526	1268	1275	NIH 3T3	T025	C1257739
27773526	1276	1286	fibroblast	T025	C0016030
27773526	1287	1308	mitogenic stimulation	T043	C1752930
27773526	1310	1318	increase	T169	C0442805
27773526	1322	1358	fibroblast growth factor receptor-1c	T116,T126,T192	C0170936
27773526	1359	1369	activation	T043	C1514758
27773526	1397	1413	glucose lowering	T033	C0860801
27773526	1417	1422	ob/ob	T047	C0028754
27773526	1423	1436	hyperglycemic	T047	C0020456
27773526	1437	1441	mice	T015	C0025929
27773526	1445	1450	novel	T080	C0205314
27773526	1451	1456	FGF-1	T116,T123	C0079349
27773526	1459	1495	fibroblast growth factor receptor-1c	T116,T126,T192	C0170936
27773526	1496	1508	dimerization	T070	C0376525
27773526	1509	1520	interaction	T169	C1704675
27773526	1521	1529	combined	T080	C0205195
27773526	1535	1555	non-phosphorylatable	T033	C0243095
27773526	1556	1576	intracrine signaling	T044	C1154545
27773526	1621	1629	observed	T169	C1441672

28410205|t|Variant 2 of KIAA0101, antagonizing its oncogenic variant 1, might be a potential therapeutic strategy in hepatocellular carcinoma
28410205|a|Hepatocellular carcinoma (HCC) is one of the most lethal malignant tumors worldwide and effective therapies, including molecular therapy, remain elusive. Our previous work demonstrates that oncogenic KIAA0101 transcript variant (tv) 1 promotes HCC development and might be a HCC therapeutic target. However, the function of another KIAA0101 variant, KIAA0101 tv2, remains unknown. In this study, we reported that KIAA0101 tv2 was highly expressed in adjacent non-tumorous liver tissues (NTs) compared to HCC tissues. In vivo and in vitro results showed that KIAA0101 tv2 decreased cell survival, colony formation, tumor xenografts, migration, and invasion, as well as induced cell cycle arrest and apoptosis. Interestingly, it could inhibit the function of KIAA0101 tv1 by partially down-regulating KIAA0101 tv1, acting similar to KIAA0101 tv1 short hairpin RNA (shRNA). Further studies illustrated that KIAA0101 tv2 could increase the activity of p53 by competing with KIAA0101 tv1 for P53 binding. In conclusion, KIAA0101 tv2 exerts anti-tumor activity in HCC and acts as an endogenous competitor of tumor-associated KIAA0101 tv1. KIAA0101 tv2 has a potential to work as a therapeutic drug targeting the KIAA0101 tv1 in HCC.
28410205	0	9	Variant 2	T028	C0678941
28410205	13	21	KIAA0101	T028	C1537443
28410205	40	49	oncogenic	T028	C0029016
28410205	50	59	variant 1	T028	C0678941
28410205	82	102	therapeutic strategy	T061	C0087111
28410205	106	130	hepatocellular carcinoma	T191	C2239176
28410205	131	155	Hepatocellular carcinoma	T191	C2239176
28410205	157	160	HCC	T191	C2239176
28410205	181	187	lethal	T033	C3151529
28410205	188	204	malignant tumors	T191	C0006826
28410205	205	214	worldwide	T098	C2700280
28410205	229	238	therapies	T061	C0087111
28410205	250	267	molecular therapy	T061	C0017296
28410205	276	283	elusive	T080	C0332218
28410205	321	330	oncogenic	T028	C0029016
28410205	331	339	KIAA0101	T028	C1537443
28410205	340	358	transcript variant	T028	C0678941
28410205	359	365	(tv) 1	T028	C0678941
28410205	366	374	promotes	T052	C0033414
28410205	375	378	HCC	T191	C2239176
28410205	379	390	development	T169	C1527148
28410205	406	409	HCC	T191	C2239176
28410205	410	421	therapeutic	T169	C0302350
28410205	422	428	target	T169	C1521840
28410205	443	451	function	T169	C0542341
28410205	463	471	KIAA0101	T028	C1537443
28410205	472	479	variant	T028	C0678941
28410205	481	489	KIAA0101	T028	C1537443
28410205	490	493	tv2	T028	C0678941
28410205	503	510	unknown	T080	C0439673
28410205	544	552	KIAA0101	T028	C1537443
28410205	553	556	tv2	T028	C0678941
28410205	561	567	highly	T080	C0205250
28410205	568	577	expressed	T045	C0017262
28410205	581	589	adjacent	T082	C0205117
28410205	590	616	non-tumorous liver tissues	T023	C0736268
28410205	618	621	NTs	T023	C0736268
28410205	623	631	compared	T052	C1707455
28410205	635	638	HCC	T191	C2239176
28410205	639	646	tissues	T023	C0736268
28410205	648	655	In vivo	T062	C0681829
28410205	660	668	in vitro	T062	C0681828
28410205	669	683	results showed	T033	C0683954
28410205	689	697	KIAA0101	T028	C1537443
28410205	698	701	tv2	T028	C0678941
28410205	702	711	decreased	T081	C0205216
28410205	712	725	cell survival	T043	C0007620
28410205	727	733	colony	T025	C1947989
28410205	734	743	formation	T169	C1522492
28410205	745	761	tumor xenografts	T059	C0917891
28410205	763	772	migration	T043	C1622501
28410205	778	786	invasion	T033	C1269955
28410205	799	806	induced	T169	C0205263
28410205	807	824	cell cycle arrest	T043	C1155873
28410205	829	838	apoptosis	T043	C0162638
28410205	864	871	inhibit	T052	C3463820
28410205	876	884	function	T169	C0542341
28410205	888	896	KIAA0101	T028	C1537443
28410205	897	900	tv1	T028	C0678941
28410205	904	913	partially	T081	C0728938
28410205	914	929	down-regulating	T169	C1260953
28410205	930	938	KIAA0101	T028	C1537443
28410205	939	942	tv1	T028	C0678941
28410205	962	970	KIAA0101	T028	C1537443
28410205	971	974	tv1	T028	C0678941
28410205	975	992	short hairpin RNA	T114	C2930586
28410205	994	999	shRNA	T114	C2930586
28410205	1035	1043	KIAA0101	T028	C1537443
28410205	1044	1047	tv2	T028	C0678941
28410205	1054	1062	increase	T169	C0442805
28410205	1067	1075	activity	T169	C0205177
28410205	1079	1082	p53	T028	C0079419
28410205	1101	1109	KIAA0101	T028	C1537443
28410205	1110	1113	tv1	T028	C0678941
28410205	1118	1129	P53 binding	T044	C1817303
28410205	1146	1154	KIAA0101	T028	C1537443
28410205	1155	1158	tv2	T028	C0678941
28410205	1166	1176	anti-tumor	T080	C2986475
28410205	1177	1185	activity	T169	C0205177
28410205	1189	1192	HCC	T191	C2239176
28410205	1208	1218	endogenous	T169	C0205227
28410205	1233	1258	tumor-associated KIAA0101	T028	C1537443
28410205	1259	1262	tv1	T028	C0678941
28410205	1264	1272	KIAA0101	T028	C1537443
28410205	1273	1276	tv2	T028	C0678941
28410205	1306	1322	therapeutic drug	T121	C1254351
28410205	1323	1332	targeting	T063	C0242613
28410205	1337	1345	KIAA0101	T028	C1537443
28410205	1346	1349	tv1	T028	C0678941
28410205	1353	1356	HCC	T191	C2239176

28339928|t|Opioid Use in Chronic Pain Patients with Chronic Kidney Disease: A Systematic Review
28339928|a|To investigate the prevalence of chronic pain and opioid management among patients with chronic kidney disease (CKD). Systematic review. A systematic search was performed, including citations from 1960 to May 2015. The review highlights methodological quality assessment of the selected studies; prevalence of pain; type, dose, and reason for opioid use; effectiveness of pain control and associated adverse effects of opioids in CKD patients. Twelve of 131 articles met inclusion criteria. There were no randomized controlled trials (RCT) evaluable, and 12 were observational studies. Out of 12 studies, four were of high quality, six were of moderate quality, and the remaining two were low - quality studies. The studies were from different countries with sample size ranging from 10 to 12,782. Several studies showed a high prevalence of chronic uncontrolled pain. The effectiveness of different categories of opioids, dose, duration, and commonly prescribed opioids varied across studies. Based on a systematic review of the current literature, there is fair evidence for the high prevalence of chronic pain among patients with CKD, which is not being effectively managed, probably due to underprescription of analgesics or opioids in the CKD population. Clinicians are in need of additional and well-designed randomized control trials that focus on the indications for opioid therapy, appropriate opioid doses and dosing intervals, outcomes with adequacy of symptom control, and reporting on the incidence of adverse side effects.
28339928	0	6	Opioid	T109,T121,T131	C0242402
28339928	14	26	Chronic Pain	T184	C0150055
28339928	27	35	Patients	T101	C0030705
28339928	41	63	Chronic Kidney Disease	T047	C1561643
28339928	67	84	Systematic Review	T170	C1955832
28339928	104	114	prevalence	T081	C0220900
28339928	118	130	chronic pain	T184	C0150055
28339928	135	141	opioid	T109,T121,T131	C0242402
28339928	142	152	management	T058	C1611232
28339928	159	167	patients	T101	C0030705
28339928	173	195	chronic kidney disease	T047	C1561643
28339928	197	200	CKD	T047	C1561643
28339928	203	220	Systematic review	T170	C1955832
28339928	322	355	methodological quality assessment	UnknownType	C0815254
28339928	372	379	studies	T170	C0085973
28339928	381	391	prevalence	T081	C0220900
28339928	395	399	pain	T184	C0030193
28339928	401	405	type	T080	C0332307
28339928	407	411	dose	T081	C0678766
28339928	428	434	opioid	T109,T121,T131	C0242402
28339928	440	453	effectiveness	T080	C1280519
28339928	457	469	pain control	T061	C1304888
28339928	485	500	adverse effects	T046	C0879626
28339928	504	511	opioids	T109,T121,T131	C0242402
28339928	515	518	CKD	T047	C1561643
28339928	519	527	patients	T101	C0030705
28339928	556	574	inclusion criteria	T080	C1512693
28339928	590	618	randomized controlled trials	T062,T170	C0282440
28339928	620	623	RCT	T062,T170	C0282440
28339928	648	669	observational studies	T170	C3658316
28339928	681	688	studies	T170	C0085973
28339928	703	707	high	T080	C0205250
28339928	708	715	quality	T080	C0332306
28339928	729	737	moderate	T081	C0439536
28339928	738	745	quality	T080	C0332306
28339928	774	777	low	T080	C0205251
28339928	780	787	quality	T080	C0332306
28339928	788	795	studies	T170	C0085973
28339928	801	808	studies	T170	C0085973
28339928	829	838	countries	T083	C0454664
28339928	844	855	sample size	T081	C0242618
28339928	891	898	studies	T170	C0085973
28339928	913	923	prevalence	T081	C0220900
28339928	927	934	chronic	T079	C0205191
28339928	935	952	uncontrolled pain	T184	C0747149
28339928	999	1006	opioids	T109,T121,T131	C0242402
28339928	1008	1012	dose	T081	C0678766
28339928	1014	1022	duration	T081	C0920470
28339928	1037	1047	prescribed	T058	C0278329
28339928	1048	1055	opioids	T109,T121,T131	C0242402
28339928	1070	1077	studies	T170	C0085973
28339928	1090	1107	systematic review	T170	C1955832
28339928	1171	1181	prevalence	T081	C0220900
28339928	1185	1197	chronic pain	T184	C0150055
28339928	1204	1212	patients	T101	C0030705
28339928	1218	1221	CKD	T047	C1561643
28339928	1279	1296	underprescription	UnknownType	C0679863
28339928	1300	1310	analgesics	T109,T121,T131	C0002771
28339928	1314	1321	opioids	T109,T121,T131	C0242402
28339928	1329	1332	CKD	T047	C1561643
28339928	1333	1343	population	T081	C2361270
28339928	1345	1355	Clinicians	T097	C0871685
28339928	1400	1425	randomized control trials	T062,T170	C0282440
28339928	1460	1466	opioid	T109,T121,T131	C0242402
28339928	1467	1474	therapy	T061	C0087111
28339928	1488	1494	opioid	T109,T121,T131	C0242402
28339928	1495	1500	doses	T081	C0678766
28339928	1505	1511	dosing	T081	C0678766
28339928	1512	1521	intervals	T079	C0031084
28339928	1537	1545	adequacy	T080	C0814633
28339928	1549	1564	symptom control	T061	C1274136
28339928	1600	1620	adverse side effects	T046	C0879626

28457384|t|Liver Retransplantation for Hepatic Abscess Due to Hepatic Artery Thrombosis: A Case Report
28457384|a|Hepatic artery thrombosis (HAT) is a well-recognized complication of liver transplantation (LT). HAT is an important risk factor for infectious, in particular hepatic abscess, which can cause graft loss and increasing morbidity and mortality. We present a case report of complicated LT in a 52- year-old Caucasian man with primary sclerosing cholangitis. In 2007 the patient was included on the waiting list in Padua for LT. In 2012 the patient underwent percutaneous transhepatic biliary drainage for bile duct stricture, complicated with acute pancreatitis. A diagnostic laparoscopy was performed with choledochotomy and Kehr's T tube drainage. On February 14, 2012, the patient underwent LT with arterial reconstruction and choledochojejunostomy. The postoperative course was complicated with HAT, multiple liver abscesses, and sepsis associated with bacteremia due to Enterococcus faecium despite massive intravenous antibiotic therapy and percutaneous drainages. On November 28, 2012, the patient underwent retransplantation. Four years after transplantation the patient is still in good general condition. Hepatic abscess formation secondary to HAT following LT is a major complication associated with important morbidity and mortality. In selected cases retransplantation should be considered as our case demonstrates.
28457384	0	23	Liver Retransplantation	T061	C4087552
28457384	28	43	Hepatic Abscess	T047	C0023885
28457384	51	76	Hepatic Artery Thrombosis	T046	C0392106
28457384	92	117	Hepatic artery thrombosis	T046	C0392106
28457384	119	122	HAT	T046	C0392106
28457384	145	157	complication	T046	C0009566
28457384	161	182	liver transplantation	T061	C0023911
28457384	184	186	LT	T061	C0023911
28457384	189	192	HAT	T046	C0392106
28457384	209	220	risk factor	T033	C0035648
28457384	225	235	infectious	T080	C1550587
28457384	251	266	hepatic abscess	T047	C0023885
28457384	284	294	graft loss	T046	C0877042
28457384	310	319	morbidity	T081	C0026538
28457384	324	333	mortality	T081	C0026565
28457384	375	377	LT	T061	C0023911
28457384	387	395	year-old	T100	C0596728
28457384	396	405	Caucasian	T098	C0043157
28457384	406	409	man	T032	C0086582
28457384	415	445	primary sclerosing cholangitis	T047	C0566602
28457384	459	466	patient	T101	C0030705
28457384	487	499	waiting list	T170	C0043010
28457384	503	508	Padua	T170	C0451365
28457384	513	515	LT	T061	C0023911
28457384	529	536	patient	T101	C0030705
28457384	547	589	percutaneous transhepatic biliary drainage	T061	C1504490
28457384	594	613	bile duct stricture	T047	C0235982
28457384	632	650	acute pancreatitis	T047	C0001339
28457384	654	676	diagnostic laparoscopy	T060	C1880304
28457384	696	737	choledochotomy and Kehr's T tube drainage	T058	C3522222
28457384	742	750	February	T080	C3830166
28457384	765	772	patient	T101	C0030705
28457384	783	785	LT	T061	C0023911
28457384	791	814	arterial reconstruction	T061	C2937236
28457384	819	840	choledochojejunostomy	T061	C0008343
28457384	888	891	HAT	T046	C0392106
28457384	893	917	multiple liver abscesses	T047	C0023885
28457384	923	929	sepsis	T047	C0243026
28457384	946	956	bacteremia	T047	C0004610
28457384	964	984	Enterococcus faecium	T007	C0085495
28457384	1001	1031	intravenous antibiotic therapy	T061	C0559680
28457384	1036	1058	percutaneous drainages	T061	C0400410
28457384	1063	1071	November	T079	C3828767
28457384	1086	1093	patient	T101	C0030705
28457384	1104	1121	retransplantation	T061	C0597409
28457384	1128	1133	years	T079	C0585341
28457384	1140	1155	transplantation	T061	C0040732
28457384	1160	1167	patient	T101	C0030705
28457384	1204	1219	Hepatic abscess	T047	C0023885
28457384	1243	1246	HAT	T046	C0392106
28457384	1257	1259	LT	T061	C0023911
28457384	1271	1283	complication	T046	C0009566
28457384	1310	1319	morbidity	T081	C0026538
28457384	1324	1333	mortality	T081	C0026565
28457384	1353	1370	retransplantation	T061	C0597409

28230977|t|Extracellular Self-Assembly of Functional and Tunable Protein Conjugates from Bacillus subtilis
28230977|a|The ability to stably and specifically conjugate recombinant proteins to one another is a powerful approach for engineering multifunctional enzymes, protein therapeutics, and novel biological materials. While many of these applications have been illustrated through in vitro and in vivo intracellular protein conjugation methods, extracellular self-assembly of protein conjugates offers unique advantages: simplifying purification, reducing toxicity and burden, and enabling tunability. Exploiting the recently described SpyTag-SpyCatcher system, we describe here how enzymes and structural proteins can be genetically encoded to covalently conjugate in culture media following programmable secretion from Bacillus subtilis. Using this approach, we demonstrate how self-conjugation of a secreted industrial enzyme, XynA, dramatically increases its resilience to boiling, and we show that cellular consortia can be engineered to self-assemble functional protein-protein conjugates with tunable composition. This novel genetically encoded modular system provides a flexible strategy for protein conjugation harnessing the substantial advantages of extracellular self-assembly.
28230977	0	13	Extracellular	T026	C0521119
28230977	14	27	Self-Assembly	T044	C0872376
28230977	31	41	Functional	T169	C0205245
28230977	46	72	Tunable Protein Conjugates	T116,T123	C0033684
28230977	78	95	Bacillus subtilis	T007	C0004595
28230977	111	117	stably	T080	C0205360
28230977	135	144	conjugate	T043	C1160466
28230977	145	165	recombinant proteins	T116	C0034861
28230977	208	219	engineering	T063	C0017387
28230977	220	235	multifunctional	T169	C0205245
28230977	236	243	enzymes	T116,T126	C0014442
28230977	245	265	protein therapeutics	T121	C0872285
28230977	271	276	novel	T080	C0205314
28230977	277	297	biological materials	T122	C0005479
28230977	319	331	applications	UnknownType	C0869019
28230977	362	370	in vitro	T080	C1533691
28230977	375	382	in vivo	T082	C1515655
28230977	383	396	intracellular	T082	C0178719
28230977	397	416	protein conjugation	T043	C1160466
28230977	426	439	extracellular	T026	C0521119
28230977	440	453	self-assembly	T044	C0872376
28230977	457	475	protein conjugates	T116,T123	C0033684
28230977	514	526	purification	T059	C0597301
28230977	528	536	reducing	T080	C0392756
28230977	537	545	toxicity	T037	C0600688
28230977	550	556	burden	T078	C2828008
28230977	571	581	tunability	T080	C0205556
28230977	617	641	SpyTag-SpyCatcher system	T059	C0022885
28230977	664	671	enzymes	T116,T126	C0014442
28230977	676	695	structural proteins	T116,T123	C0582263
28230977	703	722	genetically encoded	T045	C0314627
28230977	726	736	covalently	T044	C1511539
28230977	737	746	conjugate	T043	C1160466
28230977	750	763	culture media	T130	C0010454
28230977	774	796	programmable secretion	T043	C1327616
28230977	802	819	Bacillus subtilis	T007	C0004595
28230977	861	877	self-conjugation	T043	C1160466
28230977	883	891	secreted	T043	C1327616
28230977	903	909	enzyme	T116,T126	C0014442
28230977	911	915	XynA	T116,T126	C0149034
28230977	930	939	increases	T081	C0205217
28230977	944	954	resilience	T033	C1821534
28230977	958	965	boiling	T069	C0018851
28230977	984	1002	cellular consortia	T025	C0007634
28230977	1010	1020	engineered	T063	C0017387
28230977	1024	1037	self-assemble	T044	C0872376
28230977	1038	1048	functional	T169	C0205245
28230977	1049	1075	protein-protein conjugates	T116,T123	C0033684
28230977	1107	1112	novel	T080	C0205314
28230977	1113	1132	genetically encoded	T045	C0314627
28230977	1133	1147	modular system	T169	C0449913
28230977	1159	1176	flexible strategy	T080	C0443220
28230977	1181	1200	protein conjugation	T043	C1160466
28230977	1242	1255	extracellular	T026	C0521119
28230977	1256	1269	self-assembly	T044	C0872376

28391978|t|Recombinant protein transduction domain - Cu/Zn superoxide dismutase alleviates bone cancer pain via peroxiredoxin 4 modulation and antioxidation
28391978|a|Bone cancer pain (BCP) is a serious chronic clinical condition and reactive oxygen species (ROS) were considered to be involved in its development and persistency. Normally, superoxide dismutase (SOD) converts superoxide anions to hydrogen peroxide (H2O2) and H2O2 is then naturalized to be water by peroxiredoxin 4. We reported previously that recombinant protein transduction domain (PTD)- Cu/Zn SOD effectively scavenged excessive ROS and prevented cardiomyocytes from hypoxia-reoxygenation damage. However, whether PTD - Cu/Zn SOD would prevent BCP development is unknown. In the current study, we found that an implanted carcinoma in the rat tibia induced remarkable hyperalgesia, increased H2O2 levels and decreased SOD and peroxiredoxin 4 levels. After administration of recombinant PTD - Cu/Zn SOD to these tumor-burden rats, their hyperalgesia was significantly attenuated and peroxiredoxin 4 expression was significantly increased. In addition, an increased expression of N-methyl-d-aspartic acid (NMDA) receptors and a decreased expression of γ-aminobutyric acid (GABA) receptors in this cancer pain were prevented by PTD - Cu/Zn SOD administration or peroxiredoxin 4 overexpression. Our data suggested that reactive oxygen species, at least in part, play a role in cancer metastatic pain development and persistency which can be attenuated by the adminstration of recombinant PTD - Cu/Zn SOD via the peroxiredoxin 4 modulation from oxidative stress.
28391978	0	11	Recombinant	T116	C0034861
28391978	12	39	protein transduction domain	T087	C1514562
28391978	42	68	Cu/Zn superoxide dismutase	T116,T126	C0010461
28391978	69	79	alleviates	T080	C0392756
28391978	80	91	bone cancer	T191	C0279530
28391978	92	96	pain	T184	C0596240
28391978	101	116	peroxiredoxin 4	T116,T126	C0914290
28391978	117	127	modulation	T044	C1148560
28391978	132	145	antioxidation	T044	C1148560
28391978	146	157	Bone cancer	T191	C0279530
28391978	158	162	pain	T184	C0596240
28391978	164	167	BCP	T184	C0596240
28391978	174	181	serious	T080	C0205404
28391978	182	189	chronic	T079	C0205191
28391978	190	208	clinical condition	T080	C0348080
28391978	213	236	reactive oxygen species	T123,T196	C0162772
28391978	238	241	ROS	T123,T196	C0162772
28391978	248	258	considered	T078	C0750591
28391978	265	273	involved	T169	C1314939
28391978	281	292	development	T169	C1527148
28391978	297	308	persistency	T079	C0205322
28391978	310	318	Normally	T080	C0205307
28391978	320	340	superoxide dismutase	T116,T121,T126	C0038838
28391978	342	345	SOD	T116,T121,T126	C0038838
28391978	356	373	superoxide anions	T196	C0038836
28391978	377	394	hydrogen peroxide	T121,T130,T197	C0020281
28391978	396	400	H2O2	T121,T130,T197	C0020281
28391978	406	410	H2O2	T121,T130,T197	C0020281
28391978	437	442	water	T121,T197	C0043047
28391978	446	461	peroxiredoxin 4	T116,T126	C0914290
28391978	466	474	reported	T170	C0684224
28391978	491	502	recombinant	T116	C0034861
28391978	503	530	protein transduction domain	T087	C1514562
28391978	532	535	PTD	T087	C1514562
28391978	538	547	Cu/Zn SOD	T116,T126	C0010461
28391978	548	559	effectively	T080	C1704419
28391978	560	569	scavenged	T044	C1148560
28391978	570	579	excessive	T080	C0442802
28391978	580	583	ROS	T123,T196	C0162772
28391978	588	597	prevented	T169	C1292733
28391978	598	612	cardiomyocytes	T025	C0225828
28391978	618	639	hypoxia-reoxygenation	T169	C0542341
28391978	640	646	damage	T169	C1883709
28391978	665	668	PTD	T087	C1514562
28391978	671	680	Cu/Zn SOD	T116,T126	C0010461
28391978	687	694	prevent	T169	C1292733
28391978	695	698	BCP	T184	C0596240
28391978	699	710	development	T169	C1527148
28391978	714	721	unknown	T080	C0439673
28391978	730	737	current	T079	C0521116
28391978	738	743	study	T062	C0681814
28391978	748	753	found	T033	C0150312
28391978	762	771	implanted	T074	C0021102
28391978	772	781	carcinoma	T191	C0007097
28391978	789	792	rat	T015	C0034721
28391978	793	798	tibia	T023	C0040184
28391978	799	806	induced	T169	C0205263
28391978	818	830	hyperalgesia	T184	C0020429
28391978	832	841	increased	T081	C0205217
28391978	842	846	H2O2	T121,T130,T197	C0020281
28391978	847	853	levels	T080	C0441889
28391978	858	867	decreased	T081	C0205216
28391978	868	871	SOD	T116,T121,T126	C0038838
28391978	876	891	peroxiredoxin 4	T116,T126	C0914290
28391978	892	898	levels	T080	C0441889
28391978	906	920	administration	T169	C1521801
28391978	924	935	recombinant	T116	C0034861
28391978	936	939	PTD	T087	C1514562
28391978	942	951	Cu/Zn SOD	T116,T126	C0010461
28391978	961	973	tumor-burden	T081	C1516167
28391978	974	978	rats	T015	C0034721
28391978	986	998	hyperalgesia	T184	C0020429
28391978	1003	1016	significantly	T078	C0750502
28391978	1017	1027	attenuated	T052	C0599946
28391978	1032	1047	peroxiredoxin 4	T116,T126	C0914290
28391978	1048	1058	expression	T045	C1171362
28391978	1063	1086	significantly increased	T081	C4055637
28391978	1088	1099	In addition	T169	C0332287
28391978	1104	1113	increased	T081	C0205217
28391978	1114	1124	expression	T045	C0597360
28391978	1128	1169	N-methyl-d-aspartic acid (NMDA) receptors	T116,T192	C0080093
28391978	1176	1185	decreased	T081	C0205216
28391978	1186	1196	expression	T045	C0597360
28391978	1200	1236	γ-aminobutyric acid (GABA) receptors	T116,T192	C0206518
28391978	1245	1256	cancer pain	T184	C0596240
28391978	1262	1271	prevented	T169	C1292733
28391978	1275	1278	PTD	T087	C1514562
28391978	1281	1290	Cu/Zn SOD	T116,T126	C0010461
28391978	1291	1305	administration	T169	C1521801
28391978	1309	1324	peroxiredoxin 4	T116,T126	C0914290
28391978	1325	1339	overexpression	T045	C1514559
28391978	1345	1349	data	T078	C1511726
28391978	1350	1359	suggested	T078	C1705535
28391978	1365	1388	reactive oxygen species	T123,T196	C0162772
28391978	1415	1419	role	T077	C1705810
28391978	1423	1440	cancer metastatic	T191	C0027627
28391978	1441	1445	pain	T184	C0596240
28391978	1446	1457	development	T169	C1527148
28391978	1462	1473	persistency	T079	C0205322
28391978	1487	1500	attenuated by	T080	C0332161
28391978	1505	1518	adminstration	T169	C1521801
28391978	1522	1537	recombinant PTD	T116	C0034861
28391978	1540	1549	Cu/Zn SOD	T116,T126	C0010461
28391978	1558	1573	peroxiredoxin 4	T116,T126	C0914290
28391978	1574	1584	modulation	T044	C1148560
28391978	1590	1606	oxidative stress	T049	C0242606

27392380|t|Energy Expenditure and Intensity of Classroom Physical Activity in Elementary School Children
27392380|a|There is limited data regarding objectively measured energy cost and intensity of classroom instruction. Therefore, the purpose of current study was to objectively measure energy cost and subsequently calculate MET values using a portable indirect calorimeter (IC) for both normal classroom instruction (NCI) and active classroom instruction (ACI). We assessed energy expenditure (EE) and intensity levels (METs) in elementary school children (17 boys and 15 girls) using an IC (COSMED K4b2). Independent t-tests were used to evaluate potential sex and grade level differences for age, BMI, VO2, EE, and METs. The average EE for NCI and ACI were 1.8 ± 0.4 and 3.9 ± 1.0, respectively. The average intensity level for NCI and ACI were 1.9 ± 0.4 and 4.2 ± 0.9 METs, respectively. PA delivered through ACI can elicit EE at a moderate intensity level. These results provide evidence for ACI as a convenient/feasible avenue for increasing PA in youth without decreasing instruction time.
27392380	0	18	Energy Expenditure	T039	C0014272
27392380	23	32	Intensity	T080	C0522510
27392380	36	45	Classroom	T073	C0870287
27392380	46	63	Physical Activity	T056	C0026606
27392380	67	84	Elementary School	T170	C0683859
27392380	85	93	Children	T100	C0260267
27392380	103	115	limited data	T078	C1511726
27392380	138	146	measured	T080	C0444706
27392380	147	153	energy	T081	C1442080
27392380	154	158	cost	T169	C0220812
27392380	163	172	intensity	T080	C0522510
27392380	176	197	classroom instruction	T065	C0871627
27392380	233	238	study	T062	C2603343
27392380	258	265	measure	T081	C0079809
27392380	266	272	energy	T081	C1442080
27392380	273	277	cost	T169	C0220812
27392380	295	304	calculate	T052	C1441506
27392380	305	315	MET values	T060	C2355577
27392380	324	332	portable	T082	C4299032
27392380	333	353	indirect calorimeter	T074	C1458006
27392380	355	357	IC	T074	C1458006
27392380	368	374	normal	T080	C0205307
27392380	375	396	classroom instruction	T065	C0871627
27392380	398	401	NCI	T065	C0871627
27392380	407	413	active	T169	C0205177
27392380	414	435	classroom instruction	T065	C0871627
27392380	437	440	ACI	T065	C0871627
27392380	446	454	assessed	T052	C1516048
27392380	455	473	energy expenditure	T039	C0014272
27392380	475	477	EE	T039	C0014272
27392380	483	492	intensity	T080	C0522510
27392380	493	499	levels	T080	C0441889
27392380	501	505	METs	T060	C2355577
27392380	510	527	elementary school	T170	C0683859
27392380	528	536	children	T100	C0260267
27392380	541	545	boys	T100	C0870221
27392380	553	558	girls	T100	C0870604
27392380	569	571	IC	T074	C1458006
27392380	573	584	COSMED K4b2	T074	C1458006
27392380	587	606	Independent t-tests	T170	C0871472
27392380	620	628	evaluate	T058	C0220825
27392380	639	642	sex	T032	C1522384
27392380	647	658	grade level	T080	C0870612
27392380	675	678	age	T032	C0001779
27392380	680	683	BMI	T201	C1305855
27392380	685	688	VO2	T060	C1305742
27392380	690	692	EE	T039	C0014272
27392380	698	702	METs	T060	C2355577
27392380	708	715	average	T081	C1510992
27392380	716	718	EE	T039	C0014272
27392380	723	726	NCI	T065	C0871627
27392380	731	734	ACI	T065	C0871627
27392380	783	790	average	T081	C1510992
27392380	791	800	intensity	T080	C0522510
27392380	801	806	level	T080	C0441889
27392380	811	814	NCI	T065	C0871627
27392380	819	822	ACI	T065	C0871627
27392380	852	856	METs	T060	C2355577
27392380	872	874	PA	T056	C0026606
27392380	893	896	ACI	T065	C0871627
27392380	908	910	EE	T039	C0014272
27392380	925	934	intensity	T080	C0522510
27392380	935	940	level	T080	C0441889
27392380	964	972	evidence	T078	C3887511
27392380	977	980	ACI	T065	C0871627
27392380	1017	1027	increasing	T169	C0442808
27392380	1028	1030	PA	T056	C0026606
27392380	1034	1039	youth	T100	C0087178
27392380	1048	1058	decreasing	T033	C0442797
27392380	1059	1070	instruction	T170	C1442085
27392380	1071	1075	time	T079	C0040223

27354236|t|Novel insights into development of diabetic bladder disorder provided by metabolomic analysis of the rat nondiabetic and diabetic detrusor and urothelial layer
27354236|a|There are at present no published studies providing a global overview of changes in bladder metabolism resulting from diabetes. Such studies have the potential to provide mechanistic insight into the development of diabetic bladder disorder (DBD). In the present study, we compared the metabolome of detrusor and urothelial layer in a 1-mo streptozotocin -induced rat model of type 1 diabetes with nondiabetic controls. Our studies revealed that diabetes caused both common and differential changes in the detrusor and urothelial layer's metabolome. Diabetes resulted in similar changes in the levels of previously described diabetic markers in both tissues, such as glucose, lactate, 2-hydroxybutyrate, branched-chain amino acid degradation products, bile acids, and 1,5-anhydroglucitol, as well as markers of oxidative stress. In the detrusor (but not the urothelial layer), diabetes caused activation of the pentose-phosphate and polyol pathways, concomitant with a reduction in the TCA cycle and β-oxidation. Changes in detrusor energy-generating pathways resulted in an accumulation of sorbitol that, through generation of advanced glycation end products, is likely to play a central role in the development of DBD. In the diabetic urothelial layer there was decreased flux of glucose via glycolysis and changes in lipid metabolism, particularly prostaglandin synthesis, which also potentially contributes to detrusor dysfunction.
27354236	35	43	diabetic	T033	C0241863
27354236	44	60	bladder disorder	T047	C0005686
27354236	73	93	metabolomic analysis	T091	C1328813
27354236	101	104	rat	T015	C0034721
27354236	121	129	diabetic	T033	C0241863
27354236	130	138	detrusor	T023	C1180419
27354236	143	159	urothelial layer	T024	C0227692
27354236	233	240	changes	T169	C0392747
27354236	244	251	bladder	T023	C0005682
27354236	252	262	metabolism	T040	C0025519
27354236	278	286	diabetes	T047	C0011847
27354236	375	383	diabetic	T033	C0241863
27354236	384	406	bladder disorder (DBD)	T047	C0005686
27354236	446	456	metabolome	T070	C2350399
27354236	460	468	detrusor	T023	C1180419
27354236	473	489	urothelial layer	T024	C0227692
27354236	500	514	streptozotocin	T109,T195	C0038432
27354236	524	527	rat	T015	C0034721
27354236	528	533	model	T050	C0012644
27354236	537	552	type 1 diabetes	T047	C0011854
27354236	558	578	nondiabetic controls	T096	C0009932
27354236	606	614	diabetes	T047	C0011847
27354236	651	658	changes	T169	C0392747
27354236	666	674	detrusor	T023	C1180419
27354236	679	697	urothelial layer's	T024	C0227692
27354236	698	708	metabolome	T070	C2350399
27354236	710	718	Diabetes	T047	C0011847
27354236	739	746	changes	T169	C0392747
27354236	785	793	diabetic	T047	C0011847
27354236	794	801	markers	T201	C0005516
27354236	810	817	tissues	T024	C0040300
27354236	827	834	glucose	T109,T121,T123	C0017725
27354236	836	843	lactate	T109,T121,T123	C0064582
27354236	845	862	2-hydroxybutyrate	T109,T123	C0046188
27354236	864	910	branched-chain amino acid degradation products	T116	C3494275
27354236	912	922	bile acids	T109,T123	C0005390
27354236	928	947	1,5-anhydroglucitol	T109	C0044029
27354236	960	967	markers	T201	C0005516
27354236	971	987	oxidative stress	T049	C0242606
27354236	996	1004	detrusor	T023	C1180419
27354236	1018	1034	urothelial layer	T024	C0227692
27354236	1037	1045	diabetes	T047	C0011847
27354236	1071	1088	pentose-phosphate	T109	C0030893
27354236	1093	1099	polyol	T109	C0071629
27354236	1100	1108	pathways	T044	C1704259
27354236	1146	1155	TCA cycle	T044	C1516586
27354236	1160	1171	β-oxidation	T044	C1158368
27354236	1173	1180	Changes	T169	C0392747
27354236	1184	1192	detrusor	T023	C1180419
27354236	1193	1219	energy-generating pathways	T044	C1158271
27354236	1251	1259	sorbitol	T109,T121	C0037688
27354236	1288	1319	advanced glycation end products	T109,T123	C0162574
27354236	1376	1379	DBD	T047	C0005686
27354236	1388	1396	diabetic	T033	C0241863
27354236	1397	1413	urothelial layer	T024	C0227692
27354236	1434	1438	flux	T070	C2348693
27354236	1442	1449	glucose	T109,T121,T123	C0017725
27354236	1454	1464	glycolysis	T044	C0017952
27354236	1469	1476	changes	T169	C0392747
27354236	1469	1476	changes	T169	C0392747
27354236	1480	1496	lipid metabolism	T044	C0598783
27354236	1511	1524	prostaglandin	T109,T121,T125	C0033554
27354236	1525	1534	synthesis	T052	C1883254
27354236	1574	1582	detrusor	T023	C1180419
27354236	1583	1594	dysfunction	T046	C0277785

28033500|t|Autonomous assembly of ordered metastable DNA nanoarchitecture and in situ visualizing of intracellular microRNAs
28033500|a|Facile assembly of intelligent DNA nanoobjects with the ability to exert in situ visualization of intracellular microRNAs (miRNAs) has long been concerned in the fields of DNA nanotechnology and basic medical study. Here, we present a driving primer (DP)-triggered polymerization -mediated metastable assembly (PMA) strategy to prepare a well-ordered metastable DNA nanoarchitecture composed of only two hairpin probes (HAPs), which has never been explored by assembly methods. Its structural features and functions are characterized by atomic force microscope (AFM) and gel electrophoresis. Even if with a metastable molecular structure, this nanoarchitecture is relatively stable at physiological temperature. The assembly strategy can be expanded to execute microRNA-21 (miRNA-21) in situ imaging inside cancer cells by labelling one of the HAPs with fluorophore and quencher. Compared with the conventional fluorescence probe -based in situ hybridization (FISH) technique, confocal images revealed that the proposed DNA nanoassembly can not only achieve greatly enhanced imaging effect within cancer cells, but also reflect the miRNA-21 expression level sensitively. We believe that the easily constructed DNA nanoarchitecture and in situ profiling strategy are significant progresses in DNA assembly and molecule imaging in cells.
28033500	0	19	Autonomous assembly	T044	C0872376
28033500	31	41	metastable	T080	C0205360
28033500	42	45	DNA	T114,T123	C0012854
28033500	46	62	nanoarchitecture	T073	C1450053
28033500	67	74	in situ	T082	C0444498
28033500	75	86	visualizing	T169	C0234621
28033500	90	103	intracellular	T082	C0178719
28033500	104	113	microRNAs	T114,T123	C1101610
28033500	121	129	assembly	T044	C0872376
28033500	133	148	intelligent DNA	T114,T123	C0012854
28033500	149	160	nanoobjects	T073	C1450053
28033500	187	194	in situ	T082	C0444498
28033500	195	208	visualization	T169	C0234621
28033500	212	225	intracellular	T082	C0178719
28033500	226	235	microRNAs	T114,T123	C1101610
28033500	237	243	miRNAs	T114,T123	C1101610
28033500	286	289	DNA	T114,T123	C0012854
28033500	290	304	nanotechnology	T090	C1513398
28033500	315	328	medical study	T062	C2603343
28033500	349	363	driving primer	T114	C0206416
28033500	365	367	DP	T114	C0206416
28033500	379	393	polymerization	T067	C0314672
28033500	404	414	metastable	T080	C0205360
28033500	415	423	assembly	T044	C0872376
28033500	425	428	PMA	T044	C0872376
28033500	465	475	metastable	T080	C0205360
28033500	476	479	DNA	T114,T123	C0012854
28033500	480	496	nanoarchitecture	T073	C1450053
28033500	518	532	hairpin probes	T114,T130	C0012893
28033500	534	538	HAPs	T114,T130	C0012893
28033500	574	582	assembly	T044	C0872376
28033500	583	590	methods	T170	C0025663
28033500	596	629	structural features and functions	T091	C1171305
28033500	651	674	atomic force microscope	T059	C0242849
28033500	676	679	AFM	T059	C0242849
28033500	685	704	gel electrophoresis	T059	C0596607
28033500	721	731	metastable	T080	C0205360
28033500	732	751	molecular structure	T085	C0026383
28033500	758	774	nanoarchitecture	T073	C1450053
28033500	799	824	physiological temperature	T032	C0005903
28033500	830	838	assembly	T044	C0872376
28033500	875	886	microRNA-21	T114,T123	C1999986
28033500	888	896	miRNA-21	T114,T123	C1999986
28033500	898	905	in situ	T082	C0444498
28033500	906	913	imaging	T060	C1537000
28033500	921	933	cancer cells	T025	C0334227
28033500	958	962	HAPs	T114,T130	C0012893
28033500	968	979	fluorophore	T121,T130	C0598447
28033500	984	992	quencher	T167	C0439861
28033500	1025	1043	fluorescence probe	T130	C0016321
28033500	1051	1089	in situ hybridization (FISH) technique	T063	C0162788
28033500	1091	1106	confocal images	T059	C0242842
28033500	1134	1137	DNA	T114,T123	C0012854
28033500	1138	1150	nanoassembly	T044	C0872376
28033500	1189	1203	imaging effect	T060	C0079595
28033500	1211	1223	cancer cells	T025	C0334227
28033500	1246	1254	miRNA-21	T114,T123	C1999986
28033500	1255	1271	expression level	T081	C3244092
28033500	1324	1344	DNA nanoarchitecture	T073	C1450053
28033500	1349	1356	in situ	T082	C0444498
28033500	1357	1375	profiling strategy	T063	C1513400
28033500	1406	1409	DNA	T114,T123	C0012854
28033500	1410	1418	assembly	T044	C0872376
28033500	1423	1439	molecule imaging	T059	C4277686
28033500	1443	1448	cells	T025	C0007634

27892235|t|Shout louder about poor pay
27892235|a|It seems increasingly clear to me that the NHS pay campaign is not making waves either in the NHS or with the public.
27892235	19	27	poor pay	T081	C0871051
27892235	71	74	NHS	T058	C0027462
27892235	75	78	pay	T081	C0871051
27892235	79	87	campaign	UnknownType	C0680899
27892235	122	125	NHS	T058	C0027462
27892235	138	144	public	T098	C0683971

27479867|t|Subepidermal Calcified Nodules of the Eyelid Differ in Children and Adults
27479867|a|Subepidermal calcified nodule of the eyelid is considered as one of the types of calcinosis cutis. It generally occurs in children, and is not known to be associated with systemic disease. The authors report histopathological and clinical findings in 14 cases of subepidermal calcified nodule of the eyelid, including 3 older patients with unique microscopic features. Clinical records and pathological materials were critically reviewed in each case, including von kossa, CD3, CD20, and CD68 stains. The 14 cases presented clinically as nodular eyelid lesions. All were treated with surgical excision. The authors found 2 distinct histopathological patterns which correlated with the patients ' age. In young patients, the authors observed multiple, small calcified bodies within the dermis surrounded by chronic inflammation and granulomatous foreign body reaction. On the other hand, in elderly patients, lesions were characterized by a single, large, well-demarcated amorphous calcified deposit surrounded by fibrous tissue, without chronic inflammation or foreign body reaction. One of these patients, a 70- year-old man, also suffered from gout. The presence of subepidermal calcified nodule was not documented as a preoperative diagnostic possibility in any of the cases. Subepidermal calcified nodule of the eyelid is a rare condition, but should be considered in any patient presenting with a painless white to yellowish colored nodule of the ocular adnexa, particularly during the teenage years. Clinicians and pathologists should be aware that this entity has a distinct appearance and could be associated with systemic conditions in elderly patients.
27479867	0	12	Subepidermal	T029	C0221935
27479867	13	30	Calcified Nodules	T169	C0332558
27479867	38	44	Eyelid	T023	C0015426
27479867	55	63	Children	T100	C0008059
27479867	68	74	Adults	T100	C0001675
27479867	75	87	Subepidermal	T029	C0221935
27479867	88	104	calcified nodule	T169	C0332558
27479867	112	118	eyelid	T023	C0015426
27479867	147	152	types	T080	C0332307
27479867	156	172	calcinosis cutis	T047	C0006664
27479867	187	193	occurs	T079	C2745955
27479867	197	205	children	T100	C0008059
27479867	230	245	associated with	T080	C0332281
27479867	246	262	systemic disease	T047	C0442893
27479867	268	275	authors	T097	C3812881
27479867	276	282	report	T058	C0700287
27479867	283	300	histopathological	T169	C0243140
27479867	305	322	clinical findings	T201	C3854293
27479867	329	334	cases	T077	C1706256
27479867	338	350	subepidermal	T029	C0221935
27479867	351	367	calcified nodule	T169	C0332558
27479867	375	381	eyelid	T023	C0015426
27479867	395	400	older	T098	C0001792
27479867	401	409	patients	T101	C0030705
27479867	422	433	microscopic	T080	C0205288
27479867	434	442	features	T080	C1521970
27479867	444	460	Clinical records	T170	C2735296
27479867	465	477	pathological	T169	C1521733
27479867	478	487	materials	T167	C0520510
27479867	504	512	reviewed	T080	C1709940
27479867	521	525	case	T077	C1706256
27479867	537	546	von kossa	T059	C1293943
27479867	548	551	CD3	T130	C0038128
27479867	553	557	CD20	T130	C0038128
27479867	563	574	CD68 stains	T130	C0038128
27479867	583	588	cases	T077	C1706256
27479867	599	609	clinically	T080	C0205210
27479867	613	620	nodular	T080	C0205297
27479867	621	635	eyelid lesions	T033	C0578590
27479867	646	653	treated	T169	C1522326
27479867	659	676	surgical excision	T061	C0728940
27479867	682	689	authors	T097	C3812881
27479867	707	733	histopathological patterns	T169	C0243140
27479867	740	750	correlated	T080	C1707520
27479867	760	768	patients	T101	C0030705
27479867	771	774	age	T032	C0001779
27479867	779	784	young	T079	C0332239
27479867	785	793	patients	T101	C0030705
27479867	799	806	authors	T097	C3812881
27479867	816	824	multiple	T081	C0439064
27479867	826	831	small	T081	C0700321
27479867	832	848	calcified bodies	T033	C0243095
27479867	860	866	dermis	T024	C0011646
27479867	867	877	surrounded	T082	C1282914
27479867	881	901	chronic inflammation	T046	C0021376
27479867	906	941	granulomatous foreign body reaction	T046	C0018193
27479867	965	972	elderly	T098	C0001792
27479867	973	981	patients	T101	C0030705
27479867	983	990	lesions	T033	C0578590
27479867	996	1009	characterized	T052	C1880022
27479867	1015	1021	single	T081	C0205171
27479867	1023	1028	large	T081	C0549177
27479867	1030	1073	well-demarcated amorphous calcified deposit	T042	C1533591
27479867	1074	1084	surrounded	T082	C1282914
27479867	1088	1102	fibrous tissue	T024	C0225331
27479867	1112	1132	chronic inflammation	T046	C0021376
27479867	1136	1157	foreign body reaction	T046	C0016549
27479867	1172	1180	patients	T101	C0030705
27479867	1188	1196	year-old	T079	C1510829
27479867	1197	1200	man	T098	C0025266
27479867	1231	1239	presence	T033	C0150312
27479867	1243	1255	subepidermal	T029	C0221935
27479867	1256	1272	calcified nodule	T169	C0332558
27479867	1281	1291	documented	T058	C1301725
27479867	1297	1309	preoperative	T079	C0445204
27479867	1310	1320	diagnostic	T169	C0348026
27479867	1321	1332	possibility	T080	C0205556
27479867	1347	1352	cases	T077	C1706256
27479867	1354	1366	Subepidermal	T029	C0221935
27479867	1367	1383	calcified nodule	T169	C0332558
27479867	1391	1397	eyelid	T023	C0015426
27479867	1403	1407	rare	T080	C0522498
27479867	1408	1417	condition	T080	C0348080
27479867	1451	1458	patient	T101	C0030705
27479867	1477	1485	painless	T169	C0234226
27479867	1486	1519	white to yellowish colored nodule	T033	C0243095
27479867	1527	1540	ocular adnexa	T023	C0229243
27479867	1566	1573	teenage	T079	C0001578
27479867	1574	1579	years	T079	C0439234
27479867	1581	1591	Clinicians	T097	C0871685
27479867	1596	1608	pathologists	T097	C0334901
27479867	1635	1641	entity	T071	C1551338
27479867	1657	1667	appearance	T081	C1547010
27479867	1681	1696	associated with	T080	C0332281
27479867	1697	1716	systemic conditions	T047	C0442893
27479867	1720	1727	elderly	T098	C0001792
27479867	1728	1736	patients	T101	C0030705

27742821|t|HieranoiDB: a database of orthologs inferred by Hieranoid
27742821|a|HieranoiDB (http://hieranoiDB.sbc.su.se) is a freely available on-line database for hierarchical groups of orthologs inferred by the Hieranoid algorithm. It infers orthologs at each node in a species guide tree with the InParanoid algorithm as it progresses from the leaves to the root. Here we present a database HieranoiDB with a web interface that makes it easy to search and visualize the output of Hieranoid, and to download it in various formats. Searching can be performed using protein description, identifier or sequence. In this first version, orthologs are available for the 66 Quest for Orthologs reference proteomes. The ortholog trees are shown graphically and interactively with marked speciation and duplication nodes that show the inferred evolutionary scenario, and allow for correct extraction of predicted orthologs from the Hieranoid trees.
27742821	0	10	HieranoiDB	T170	C0950132
27742821	26	35	orthologs	T028	C1335144
27742821	48	57	Hieranoid	T170	C0950132
27742821	58	68	HieranoiDB	T170	C0950132
27742821	121	137	on-line database	T170	C3841595
27742821	142	154	hierarchical	T169	C0699032
27742821	165	174	orthologs	T028	C1335144
27742821	191	210	Hieranoid algorithm	T170	C0002045
27742821	222	231	orthologs	T028	C1335144
27742821	240	244	node	T077	C2697524
27742821	258	268	guide tree	T170	C0282574
27742821	278	298	InParanoid algorithm	T170	C0002045
27742821	339	343	root	T078	C1705917
27742821	363	382	database HieranoiDB	T170	C0950132
27742821	461	470	Hieranoid	T170	C0950132
27742821	544	551	protein	T116,T123	C0033684
27742821	552	563	description	T170	C0678257
27742821	565	575	identifier	T170	C0600091
27742821	579	587	sequence	T087	C0002518
27742821	612	621	orthologs	T028	C1335144
27742821	647	652	Quest	T078	C0750565
27742821	657	666	Orthologs	T028	C1335144
27742821	677	686	proteomes	T116,T123	C0751973
27742821	692	700	ortholog	T028	C1335144
27742821	701	706	trees	T169	C0699032
27742821	717	728	graphically	T170	C0870616
27742821	733	746	interactively	T169	C1704675
27742821	759	769	speciation	T070	C1563692
27742821	774	785	duplication	T045	C0017261
27742821	786	791	nodes	T077	C2697524
27742821	815	836	evolutionary scenario	T045	C3825184
27742821	884	893	orthologs	T028	C1335144
27742821	903	918	Hieranoid trees	T170	C0950132

28541529|t|Statistical algorithms improve accuracy of gene fusion detection
28541529|a|Gene fusions are known to play critical roles in tumor pathogenesis. Yet, sensitive and specific algorithms to detect gene fusions in cancer do not currently exist. In this paper, we present a new statistical algorithm, MACHETE (Mismatched Alignment CHimEra Tracking Engine), which achieves highly sensitive and specific detection of gene fusions from RNA-Seq data, including the highest Positive Predictive Value (PPV) compared to the current state-of-the-art, as assessed in simulated data. We show that the best performing published algorithms either find large numbers of fusions in negative control data or suffer from low sensitivity detecting known driving fusions in gold standard settings, such as EWSR1-FLI1. As proof of principle that MACHETE discovers novel gene fusions with high accuracy in vivo, we mined public data to discover and subsequently PCR validate novel gene fusions missed by other algorithms in the ovarian cancer cell line OVCAR3. These results highlight the gains in accuracy achieved by introducing statistical models into fusion detection, and pave the way for unbiased discovery of potentially driving and druggable gene fusions in primary tumors.
28541529	0	22	Statistical algorithms	T170	C0002045
28541529	23	30	improve	T077	C2986411
28541529	31	39	accuracy	T080	C0443131
28541529	43	54	gene fusion	T063	C0178648
28541529	55	64	detection	T033	C0442726
28541529	65	77	Gene fusions	T063	C0178648
28541529	105	110	roles	T077	C1705810
28541529	114	119	tumor	T191	C0027651
28541529	120	132	pathogenesis	T046	C0699748
28541529	139	148	sensitive	T169	C0332324
28541529	153	161	specific	T080	C0205369
28541529	162	172	algorithms	T170	C0002045
28541529	176	182	detect	T033	C0442726
28541529	183	195	gene fusions	T063	C0178648
28541529	199	205	cancer	T191	C0006826
28541529	262	283	statistical algorithm	T170	C0002045
28541529	285	292	MACHETE	T170	C0282574
28541529	294	339	Mismatched Alignment CHimEra Tracking Engine)	T170	C0282574
28541529	363	372	sensitive	T169	C0332324
28541529	377	385	specific	T080	C0205369
28541529	386	395	detection	T033	C0442726
28541529	399	411	gene fusions	T063	C0178648
28541529	417	429	RNA-Seq data	T170	C0026382
28541529	445	452	highest	T080	C1522410
28541529	453	484	Positive Predictive Value (PPV)	T081	C1514243
28541529	530	538	assessed	T052	C1516048
28541529	542	556	simulated data	T078	C1511726
28541529	591	600	published	T170	C0993637
28541529	601	611	algorithms	T170	C0002045
28541529	624	637	large numbers	T081	C0449788
28541529	641	648	fusions	T063	C0178648
28541529	652	660	negative	T033	C0205160
28541529	661	673	control data	T078	C1511726
28541529	689	692	low	T080	C0205251
28541529	693	704	sensitivity	T169	C0332324
28541529	705	714	detecting	T033	C0442726
28541529	729	736	fusions	T063	C0178648
28541529	772	782	EWSR1-FLI1	T028	C1860425
28541529	811	818	MACHETE	T170	C0282574
28541529	829	834	novel	T080	C0205314
28541529	835	847	gene fusions	T063	C0178648
28541529	858	866	accuracy	T080	C0443131
28541529	867	874	in vivo	T082	C1515655
28541529	885	891	public	T092	C0678367
28541529	892	896	data	T078	C1511726
28541529	900	908	discover	T052	C1880355
28541529	926	929	PCR	T063	C0032520
28541529	930	938	validate	T062	C1519941
28541529	939	944	novel	T080	C0205314
28541529	945	957	gene fusions	T063	C0178648
28541529	958	964	missed	T080	C1705492
28541529	974	984	algorithms	T170	C0002045
28541529	992	1006	ovarian cancer	T191	C1140680
28541529	1007	1016	cell line	T025	C0334227
28541529	1017	1023	OVCAR3	T025	C0334227
28541529	1031	1038	results	T033	C0683954
28541529	1062	1070	accuracy	T080	C0443131
28541529	1095	1113	statistical models	T081,T170	C0026348
28541529	1119	1125	fusion	T063	C0178648
28541529	1126	1135	detection	T033	C0442726
28541529	1167	1176	discovery	T052	C1880355
28541529	1180	1191	potentially	T080	C3245505
28541529	1214	1226	gene fusions	T063	C0178648
28541529	1230	1244	primary tumors	T191	C0677930

28428488|t|Improvement in Exercise Capacity by Exercise Training Associated With Favorable Clinical Outcomes in Advanced Heart Failure With High B-Type Natriuretic Peptide Level
28428488|a|The efficacy of exercise training (ET) programs and its relationship with long-term clinical outcomes in advanced heart failure (HF) patients with high levels of B-type natriuretic peptide (BNP) remain uncertain.Methods and Results:We studied 340 consecutive HF patients with ejection fraction (EF) <45% who completed a 3- month ET program. Patients with BNP ≥200 pg/mL (High - BNP, n=170) had more advanced HF characteristics, including lower EF (25.0±8.6% vs. 28.1±8.0%, P=0.0008), than those with BNP <200 pg/mL. In the High - BNP patients, peak oxygen uptake (V̇O2) was significantly increased by 8.3±16.2% during the ET program, and changes in peak V̇O2 inversely correlated with changes in BNP (R=-0.453, P<0.0001) and changes in ventilatory efficiency (V̇E / V̇CO2 slope) (R=-0.439, P<0.0001). During a median follow-up of 46 months, patients in the upper tertile of changes in peak V̇O2 (≥13.0%), compared with those in the lower tertile (<1.0%), had lower rates of the composite of all-cause death or HF hospitalization (37.9% vs. 54.4%, P=0.036) and all-cause death (8.6% vs. 24.6%, P=0.056). In the multivariate analysis, change in peak V̇O2 was a significant independent predictor of the composite outcome and all-cause death. Even among advanced HF p atient s with high BNP level, an ET program significantly improved exercise capacity, and a greater improvement in exercise capacity was associated with greater decreases in BNP level and V̇E / V̇CO2 slope and more favorable long-term clinical outcomes.
28428488	0	11	Improvement	T077	C2986411
28428488	15	32	Exercise Capacity	T081	C1516240
28428488	36	53	Exercise Training	T056	C4279936
28428488	54	69	Associated With	T080	C0332281
28428488	70	97	Favorable Clinical Outcomes	T033	C1333602
28428488	101	123	Advanced Heart Failure	T047	C0018801
28428488	129	133	High	T080	C0205250
28428488	134	160	B-Type Natriuretic Peptide	T116,T121,T125	C0054015
28428488	171	179	efficacy	T080	C1280519
28428488	183	200	exercise training	T056	C4279936
28428488	202	204	ET	T056	C4279936
28428488	206	214	programs	T169	C3484370
28428488	223	235	relationship	T080	C0439849
28428488	241	250	long-term	T079	C0443252
28428488	251	268	clinical outcomes	T080	C0085415
28428488	272	294	advanced heart failure	T047	C0018801
28428488	296	298	HF	T047	C0018801
28428488	300	308	patients	T101	C0030705
28428488	314	318	high	T080	C0205250
28428488	319	325	levels	T080	C0441889
28428488	329	355	B-type natriuretic peptide	T116,T121,T125	C0054015
28428488	357	360	BNP	T116,T121,T125	C0054015
28428488	402	409	studied	T062	C2603343
28428488	414	425	consecutive	T080	C1707491
28428488	426	428	HF	T047	C0018801
28428488	429	437	patients	T101	C0030705
28428488	443	460	ejection fraction	T060	C0489482
28428488	462	464	EF	T060	C0489482
28428488	475	484	completed	T080	C0205197
28428488	490	495	month	T079	C0439231
28428488	496	498	ET	T056	C4279936
28428488	499	506	program	T169	C3484370
28428488	508	516	Patients	T101	C0030705
28428488	522	525	BNP	T116,T121,T125	C0054015
28428488	538	542	High	T080	C0205250
28428488	545	548	BNP	T116,T121,T125	C0054015
28428488	566	574	advanced	T079	C3854260
28428488	575	577	HF	T047	C0018801
28428488	578	593	characteristics	T080	C1521970
28428488	605	613	lower EF	T033	C0743400
28428488	667	670	BNP	T116,T121,T125	C0054015
28428488	690	694	High	T080	C0205250
28428488	697	700	BNP	T116,T121,T125	C0054015
28428488	701	709	patients	T101	C0030705
28428488	711	729	peak oxygen uptake	T033	C0429693
28428488	731	735	V̇O2	T033	C0429693
28428488	755	764	increased	T081	C0205217
28428488	789	791	ET	T056	C4279936
28428488	792	799	program	T169	C3484370
28428488	805	812	changes	T169	C0392747
28428488	816	825	peak V̇O2	T033	C0429693
28428488	836	846	correlated	T080	C1707520
28428488	852	859	changes	T169	C0392747
28428488	863	866	BNP	T116,T121,T125	C0054015
28428488	892	899	changes	T169	C0392747
28428488	903	925	ventilatory efficiency	T081	C0013682
28428488	927	930	V̇E	T081	C0013682
28428488	933	938	V̇CO2	T033	C0429247
28428488	984	993	follow-up	T058	C1522577
28428488	1000	1006	months	T079	C0439231
28428488	1008	1016	patients	T101	C0030705
28428488	1030	1037	tertile	T080	C0205556
28428488	1041	1048	changes	T169	C0392747
28428488	1052	1061	peak V̇O2	T033	C0429693
28428488	1072	1080	compared	T052	C1707455
28428488	1105	1112	tertile	T080	C0205556
28428488	1132	1137	rates	T081	C1521828
28428488	1145	1154	composite	T080	C0205199
28428488	1168	1173	death	T040	C0011065
28428488	1177	1179	HF	T047	C0018801
28428488	1180	1195	hospitalization	T058	C0019993
28428488	1237	1242	death	T040	C0011065
28428488	1277	1298	multivariate analysis	T081	C0026777
28428488	1300	1306	change	T169	C0392747
28428488	1310	1319	peak V̇O2	T033	C0429693
28428488	1326	1337	significant	T078	C0750502
28428488	1350	1359	predictor	T078	C2698872
28428488	1367	1376	composite	T080	C0205199
28428488	1377	1384	outcome	T169	C1274040
28428488	1399	1404	death	T040	C0011065
28428488	1426	1428	HF	T047	C0018801
28428488	1431	1437	atient	T101	C0030705
28428488	1445	1449	high	T080	C0205250
28428488	1450	1453	BNP	T116,T121,T125	C0054015
28428488	1454	1459	level	T080	C0441889
28428488	1464	1466	ET	T056	C4279936
28428488	1467	1474	program	T169	C3484370
28428488	1489	1497	improved	T033	C0184511
28428488	1498	1506	exercise	T056	C0015259
28428488	1507	1515	capacity	T081	C1516240
28428488	1531	1542	improvement	T077	C2986411
28428488	1546	1554	exercise	T056	C0015259
28428488	1555	1563	capacity	T081	C1516240
28428488	1568	1583	associated with	T080	C0332281
28428488	1592	1601	decreases	T033	C0442797
28428488	1605	1608	BNP	T116,T121,T125	C0054015
28428488	1609	1614	level	T080	C0441889
28428488	1619	1622	V̇E	T081	C0013682
28428488	1625	1630	V̇CO2	T033	C0429247
28428488	1646	1683	favorable long-term clinical outcomes	T033	C1333602

28033725|t|Untypeable hepatitis C virus subtypes in Pakistan: A neglected section
28033725|a|Diagnostically untypeable subtypes contribute a considerable percent of hepatitis C virus (HCV) subtypes in Pakistan. In the present study, chronically infected HCV patients with known viremia were subjected to HCV genotyping. Among the total retrieved samples, 92.7% (64/69) were found typeable while 7.24% (5/69) were diagnostically untypeable. In conclusion, the presence of large number of untypeable HCV subtypes emphasizes the need of an updated type - specific genotyping assay and consideration of primers for proportionally rare subtypes to minimize the number of untypeable HCV subtypes.
28033725	0	10	Untypeable	T080	C0205370
28033725	11	28	hepatitis C virus	T005	C0220847
28033725	29	37	subtypes	T185	C0449560
28033725	41	49	Pakistan	T083	C0030211
28033725	71	85	Diagnostically	T169	C0348026
28033725	86	96	untypeable	T080	C0205370
28033725	97	105	subtypes	T185	C0449560
28033725	143	160	hepatitis C virus	T005	C0220847
28033725	162	165	HCV	T005	C0220847
28033725	167	175	subtypes	T185	C0449560
28033725	179	187	Pakistan	T083	C0030211
28033725	204	209	study	T062	C2603343
28033725	211	231	chronically infected	T047	C0151317
28033725	232	235	HCV	T005	C0220847
28033725	236	244	patients	T101	C0030705
28033725	256	263	viremia	T047	C0042749
28033725	282	285	HCV	T005	C0220847
28033725	286	296	genotyping	T059	C2368152
28033725	324	331	samples	T077	C2347026
28033725	358	366	typeable	T080	C0205309
28033725	391	405	diagnostically	T169	C0348026
28033725	406	416	untypeable	T080	C0205370
28033725	421	431	conclusion	T078	C1707478
28033725	465	475	untypeable	T080	C0205370
28033725	476	479	HCV	T005	C0220847
28033725	480	488	subtypes	T185	C0449560
28033725	523	527	type	T080	C0332307
28033725	530	538	specific	T080	C0205369
28033725	539	549	genotyping	T059	C2368152
28033725	550	555	assay	T059	C0005507
28033725	577	584	primers	T114	C0206416
28033725	604	608	rare	T080	C0522498
28033725	609	617	subtypes	T185	C0449560
28033725	621	629	minimize	T080	C0392756
28033725	644	654	untypeable	T080	C0205370
28033725	655	658	HCV	T005	C0220847
28033725	659	667	subtypes	T185	C0449560

27688904|t|C1Q Assay Results in Complement-Dependent Cytotoxicity Crossmatch Negative Renal Transplant Candidates with Donor-Specific Antibodies: High Specificity but Low Sensitivity When Predicting Flow Crossmatch
27688904|a|The aim of the present study was to describe the association of positive flow cross match (FXM) and C1q-SAB. Methods. In this observational, cross-sectional, and comparative study, patients included had negative AHG-CDC-XM and donor specific antibodies (DSA) and were tested with FXM. All pretransplant sera were tested with C1q-SAB assay. Results. A total of 50 donor / recipient evaluations were conducted; half of them had at least one C1q+ Ab (n = 26, 52%). Ten patients (20.0%) had DSA C1q+ Ab. Twenty-five (50%) FXMs were positive. Factors associated with a positive FXM were the presence of C1q+ Ab (DSA C1q+ Ab: OR 27, 2.80-259.56, P = 0.004, and no DSA C1q+ Ab: OR 5, 1.27-19.68, P = 0.021) and the DSA LABScreen-SAB MFI (OR 1.26, 95% CI 1.06-1.49, P = 0.007). The cutoff point of immunodominant LABScreen SAB DSA - MFI with the greatest sensitivity and specificity to predict FXM was 2,300 (sensitivity: 72% and specificity: 75%). For FXM prediction, DSA C1q+ Ab was the most specific (95.8%, 85-100) and the combination of DSA - MFI > 2,300 and C1q+ Ab was the most sensitive (92.0%, 79.3-100). Conclusions. C1q+ Ab and LABScreen SAB DSA - MFI were significantly associated with FXM. DSA C1q+ Ab was highly specific but with low sensitivity.
27688904	0	9	C1Q Assay	T059	C1167938
27688904	21	54	Complement-Dependent Cytotoxicity	T059	C4084772
27688904	55	65	Crossmatch	T059	C0855279
27688904	66	74	Negative	T033	C0205160
27688904	75	91	Renal Transplant	T061	C0022671
27688904	92	102	Candidates	T098	C1257890
27688904	108	133	Donor-Specific Antibodies	T116,T129	C0003241
27688904	135	139	High	T080	C0205250
27688904	140	151	Specificity	T081	C0037791
27688904	156	159	Low	T080	C0205251
27688904	160	171	Sensitivity	T081	C1511883
27688904	177	187	Predicting	T078	C0681842
27688904	188	203	Flow Crossmatch	T059	C0201644
27688904	253	264	association	T080	C0439849
27688904	268	276	positive	T033	C1446409
27688904	277	293	flow cross match	T059	C0201644
27688904	295	298	FXM	T059	C0201644
27688904	304	311	C1q-SAB	T059	C1167938
27688904	330	343	observational	T062	C1518527
27688904	345	360	cross-sectional	T062	C0010362
27688904	366	383	comparative study	T062	C1579762
27688904	385	393	patients	T101	C0030705
27688904	407	415	negative	T033	C0205160
27688904	416	426	AHG-CDC-XM	T059	C0855279
27688904	431	456	donor specific antibodies	T116,T129	C0003241
27688904	458	461	DSA	T116,T129	C0003241
27688904	484	487	FXM	T059	C0201644
27688904	493	511	pretransplant sera	T031	C0229671
27688904	529	542	C1q-SAB assay	T059	C1167938
27688904	567	572	donor	T098	C0013018
27688904	575	584	recipient	T098	C1709854
27688904	585	596	evaluations	T058	C0220825
27688904	643	650	C1q+ Ab	T116,T129	C1717709
27688904	670	678	patients	T101	C0030705
27688904	691	694	DSA	T116,T129	C0003241
27688904	695	702	C1q+ Ab	T116,T129	C1717709
27688904	722	726	FXMs	T059	C0201644
27688904	732	740	positive	T033	C1446409
27688904	742	749	Factors	T169	C1521761
27688904	750	765	associated with	T080	C0332281
27688904	768	776	positive	T033	C1446409
27688904	777	780	FXM	T059	C0201644
27688904	790	798	presence	T033	C0150312
27688904	802	809	C1q+ Ab	T116,T129	C1717709
27688904	811	814	DSA	T116,T129	C0003241
27688904	815	822	C1q+ Ab	T116,T129	C1717709
27688904	824	826	OR	T081	C0028873
27688904	862	865	DSA	T116,T129	C0003241
27688904	866	873	C1q+ Ab	T116,T129	C1717709
27688904	875	877	OR	T081	C0028873
27688904	912	915	DSA	T116,T129	C0003241
27688904	916	929	LABScreen-SAB	T129	C0078968
27688904	930	933	MFI	T081	C0392762
27688904	935	937	OR	T081	C0028873
27688904	948	950	CI	T081	C0009667
27688904	978	990	cutoff point	T169	C1442160
27688904	994	1022	immunodominant LABScreen SAB	T129	C0078968
27688904	1023	1026	DSA	T116,T129	C0003241
27688904	1029	1032	MFI	T081	C0392762
27688904	1042	1050	greatest	T081	C0205393
27688904	1051	1062	sensitivity	T081	C1511883
27688904	1067	1078	specificity	T081	C0037791
27688904	1082	1089	predict	T078	C0681842
27688904	1090	1093	FXM	T059	C0201644
27688904	1105	1116	sensitivity	T081	C1511883
27688904	1126	1137	specificity	T081	C0037791
27688904	1149	1152	FXM	T059	C0201644
27688904	1153	1163	prediction	T078	C0681842
27688904	1165	1168	DSA	T116,T129	C0003241
27688904	1169	1176	C1q+ Ab	T116,T129	C1717709
27688904	1185	1189	most	T081	C0205393
27688904	1190	1198	specific	T080	C0205369
27688904	1238	1241	DSA	T116,T129	C0003241
27688904	1244	1247	MFI	T081	C0392762
27688904	1260	1267	C1q+ Ab	T116,T129	C1717709
27688904	1276	1280	most	T081	C0205393
27688904	1281	1290	sensitive	T169	C0332324
27688904	1323	1330	C1q+ Ab	T116,T129	C1717709
27688904	1335	1348	LABScreen SAB	T129	C0078968
27688904	1349	1352	DSA	T116,T129	C0003241
27688904	1355	1358	MFI	T081	C0392762
27688904	1378	1393	associated with	T080	C0332281
27688904	1394	1397	FXM	T059	C0201644
27688904	1399	1402	DSA	T116,T129	C0003241
27688904	1403	1410	C1q+ Ab	T116,T129	C1717709
27688904	1422	1430	specific	T080	C0205369
27688904	1440	1443	low	T080	C0205251
27688904	1444	1455	sensitivity	T081	C1511883

28453826|t|Unplanned readmissions within 30 days after discharge: improving quality through easy prediction
28453826|a|To propose an easy predictive model for the risk of rehospitalization, built from hospital administrative data, in order to prevent repeated admissions and to improve transitional care. Retrospective cohort study. Azienda Ospedaliero Universitaria Pisana (Pisa University Hospital). Patients residing in the territory of the province of Pisa (Tuscany Region) with at least one unplanned hospital admission leading to a medical Diagnosis-Related Group (DRG) in the calendar year 2012. We compared two groups of patients: patients coded as 'RA30' (readmitted within 30 days after the previous discharge) and patients coded as 'NRA30' (either admitted only once or readmitted after 30 days since the latest discharge). The effect of age, sex, length of stay, number of diagnoses, normalized number of admissions and presence of diseases on the probability of rehospitalization within 30 days after discharge was evaluated. The significant variables included in the predictive model were: age, odds ratio (OR) = 1.018, 95% confidence interval (CI) = 1.011-1.026; normalized number of admissions, OR = 1.257, CI = 1.225-1.290; number of diagnoses, OR = 1.306, CI = 1.174-1.452 and presence of cancer diagnosis, OR = 1.479, CI = 1.088-2.011. The model can be easily applied when discharging patients who have been hospitalized after an access to the Emergency Department to predict the risk of rehospitalization within 30 days. The prediction can be used to activate focused hospital-primary care transitional interventions. The model has to be validated first in order to be implemented in clinical practice.
28453826	10	22	readmissions	T058	C0030700
28453826	33	37	days	T079	C0439228
28453826	44	53	discharge	T058	C0030685
28453826	65	72	quality	T080	C0332306
28453826	86	96	prediction	T078	C0681842
28453826	116	132	predictive model	T081,T170	C0026348
28453826	141	166	risk of rehospitalization	T033	C2735448
28453826	179	187	hospital	T073,T093	C0019994
28453826	188	202	administrative	T169	C1292785
28453826	203	207	data	T078	C1511726
28453826	229	237	repeated	T169	C0205341
28453826	238	248	admissions	T058	C0030673
28453826	264	281	transitional care	T058	C4019071
28453826	283	309	Retrospective cohort study	T062	C2985505
28453826	311	351	Azienda Ospedaliero Universitaria Pisana	T073,T093	C0020028
28453826	353	377	Pisa University Hospital	T073,T093	C0020028
28453826	380	388	Patients	T101	C0030705
28453826	389	397	residing	T052	C2982691
28453826	405	414	territory	T083	C2983136
28453826	422	430	province	T083	C1514578
28453826	434	438	Pisa	T083	C0017446
28453826	440	454	Tuscany Region	T083	C0017446
28453826	484	502	hospital admission	T058	C0184666
28453826	524	547	Diagnosis-Related Group	T170	C0011928
28453826	549	552	DRG	T170	C0011928
28453826	561	574	calendar year	T079	C0456586
28453826	584	592	compared	T052	C1707455
28453826	593	603	two groups	T098	C1257890
28453826	607	615	patients	T101	C0030705
28453826	617	625	patients	T101	C0030705
28453826	643	653	readmitted	T058	C0184666
28453826	664	668	days	T079	C0439228
28453826	688	697	discharge	T058	C0030685
28453826	703	711	patients	T101	C0030705
28453826	737	745	admitted	T058	C0184666
28453826	759	769	readmitted	T058	C0184666
28453826	779	783	days	T079	C0439228
28453826	801	810	discharge	T058	C0030685
28453826	817	823	effect	T080	C1280500
28453826	827	830	age	T032	C0001779
28453826	832	835	sex	T032	C1522384
28453826	837	851	length of stay	T079	C0023303
28453826	853	859	number	T081	C0237753
28453826	863	872	diagnoses	T062	C1704656
28453826	885	905	number of admissions	T033	C0574846
28453826	910	918	presence	T033	C0150312
28453826	922	930	diseases	T047	C0012634
28453826	938	949	probability	T081	C0033204
28453826	953	970	rehospitalization	T058	C0019993
28453826	981	985	days	T079	C0439228
28453826	992	1001	discharge	T058	C0030685
28453826	1006	1015	evaluated	T058	C0220825
28453826	1021	1042	significant variables	T081	C0237881
28453826	1059	1075	predictive model	T081,T170	C0026348
28453826	1082	1085	age	T032	C0001779
28453826	1087	1097	odds ratio	T081	C0028873
28453826	1099	1101	OR	T081	C0028873
28453826	1116	1135	confidence interval	T081	C0009667
28453826	1137	1139	CI	T081	C0009667
28453826	1167	1187	number of admissions	T033	C0574846
28453826	1189	1191	OR	T081	C0028873
28453826	1201	1203	CI	T081	C0009667
28453826	1229	1238	diagnoses	T062	C1704656
28453826	1240	1242	OR	T081	C0028873
28453826	1252	1254	CI	T081	C0009667
28453826	1285	1301	cancer diagnosis	T060	C0920688
28453826	1303	1305	OR	T081	C0028873
28453826	1315	1317	CI	T081	C0009667
28453826	1337	1342	model	T081,T170	C0026348
28453826	1357	1364	applied	T169	C4048755
28453826	1370	1390	discharging patients	T058	C0030685
28453826	1405	1417	hospitalized	T058	C0019993
28453826	1441	1461	Emergency Department	T073,T093	C0562508
28453826	1477	1502	risk of rehospitalization	T033	C2735448
28453826	1513	1517	days	T079	C0439228
28453826	1523	1533	prediction	T078	C0681842
28453826	1549	1557	activate	T052	C1879547
28453826	1566	1587	hospital-primary care	T073,T093	C0337952
28453826	1588	1600	transitional	T058	C4019071
28453826	1601	1614	interventions	T061	C0184661
28453826	1620	1625	model	T081,T170	C0026348
28453826	1682	1699	clinical practice	T057	C0205897

28493125|t|Conditional Knockdown of Endogenous MicroRNAs in CHO Cells Using TET-ON-SanDI Sponge Vectors
28493125|a|MicroRNAs (miRNAs) are small, noncoding RNAs of about 22 nucleotides in length and have proven to be useful targets for genetic modifications for desirable phenotype in the biotech industry. The use of constitutively expressed " miRNA sponge" vectors in which multiple, tandem miRNA binding sites containing transcripts are transcriptionally regulated by a constitutive promoter for down regulating the levels of endogenous microRNAs in Chinese hamster ovary (CHO) cells has shown to be more advantageous than using synthetic antisense oligonucleotides. The application of miRNA sponges in biotechnological processes, however, could be more effective, if expression of miRNA sponges could be tuned. In this chapter, we present a method for the generation of stable CHO cell lines expressing a TET-ON-SanDI-miRNA-sponge that is in theory expressed only in the presence of an inducer.
28493125	0	11	Conditional	T080	C1701901
28493125	12	21	Knockdown	T063	C2350567
28493125	25	35	Endogenous	T169	C0205227
28493125	36	45	MicroRNAs	T114,T123	C1101610
28493125	49	58	CHO Cells	T025	C0085080
28493125	65	92	TET-ON-SanDI Sponge Vectors	T114	C0017397
28493125	93	102	MicroRNAs	T114,T123	C1101610
28493125	104	110	miRNAs	T114,T123	C1101610
28493125	123	137	noncoding RNAs	T114	C0887909
28493125	150	161	nucleotides	T114	C0028630
28493125	201	208	targets	T169	C1521840
28493125	213	234	genetic modifications	T063	C4277689
28493125	249	258	phenotype	T032	C0031437
28493125	266	273	biotech	T091	C0005574
28493125	274	282	industry	T057	C0021267
28493125	322	343	miRNA sponge" vectors	T114	C0017397
28493125	363	375	tandem miRNA	T114,T123	C1101610
28493125	376	389	binding sites	T192	C0005456
28493125	401	412	transcripts	T114	C1519595
28493125	417	444	transcriptionally regulated	T045	C1158770
28493125	463	471	promoter	T114,T123	C0086860
28493125	476	491	down regulating	T044	C0013081
28493125	506	516	endogenous	T169	C0205227
28493125	517	526	microRNAs	T114,T123	C1101610
28493125	530	563	Chinese hamster ovary (CHO) cells	T025	C0085080
28493125	619	645	antisense oligonucleotides	T114,T123,T130	C0079925
28493125	666	679	miRNA sponges	T114	C0599566
28493125	683	699	biotechnological	T091	C0005574
28493125	700	709	processes	T067	C1522240
28493125	734	743	effective	T080	C1704419
28493125	748	758	expression	T045	C0017262
28493125	762	775	miRNA sponges	T114	C0599566
28493125	858	872	CHO cell lines	T025	C0085080
28493125	873	883	expressing	T045	C0017262
28493125	886	911	TET-ON-SanDI-miRNA-sponge	T114	C0599566
28493125	967	974	inducer	T167	C3898767

27777558|t|Pre-Activation Negativity (PrAN) in Brain Potentials to Unfolding Words
27777558|a|We describe an event-related potential (ERP) effect termed the " pre-activation negativity " (PrAN), which is proposed to index the degree of pre-activation of upcoming word - internal morphemes in speech processing. Using lexical competition measures based on word-initial speech fragments (WIFs), as well as statistical analyses of ERP data from three experiments, it is shown that the PrAN is sensitive to lexical competition and that it reflects the degree of predictive certainty: the negativity is larger when there are fewer upcoming lexical competitors.
27777558	0	25	Pre-Activation Negativity	T033	C0243095
27777558	27	31	PrAN	T033	C0243095
27777558	36	41	Brain	T023	C0006104
27777558	42	52	Potentials	T080	C3245505
27777558	56	71	Unfolding Words	T041	C0025361
27777558	87	110	event-related potential	T042	C0282171
27777558	112	115	ERP	T042	C0282171
27777558	117	123	effect	T080	C1280500
27777558	137	162	pre-activation negativity	T033	C0243095
27777558	166	170	PrAN	T033	C0243095
27777558	194	199	index	T170	C0918012
27777558	204	228	degree of pre-activation	T081	C0392762
27777558	241	245	word	T078	C1705313
27777558	248	256	internal	T082	C0205102
27777558	257	266	morphemes	T170	C0870914
27777558	270	276	speech	T040	C0037817
27777558	277	287	processing	T052	C1709694
27777558	295	314	lexical competition	T067	C1882365
27777558	315	323	measures	T081	C0079809
27777558	333	362	word-initial speech fragments	T068	C0037829
27777558	364	368	WIFs	T068	C0037829
27777558	382	402	statistical analyses	T062	C0871424
27777558	406	409	ERP	T042	C0282171
27777558	410	414	data	T078	C1511726
27777558	426	437	experiments	T062	C0681814
27777558	460	464	PrAN	T033	C0243095
27777558	481	500	lexical competition	T067	C1882365
27777558	526	532	degree	T081	C0449286
27777558	536	546	predictive	T080	C0681890
27777558	547	556	certainty	T080	C0205423
27777558	562	572	negativity	T033	C0205160
27777558	576	582	larger	T081	C0549177
27777558	598	603	fewer	T081	C0205388
27777558	613	620	lexical	T078	C1705313
27777558	621	632	competitors	T098	C1257890

28420066|t|Disease evolution in late-onset and early-onset systemic lupus erythematosus
28420066|a|Objective The objective of this study was to compare clinical features, disease activity, and outcome in late-onset versus early-onset systemic lupus erythematosus (SLE) over 5 years of follow up Method Patients with SLE since 1970 were followed prospectively according to standard protocol and tracked on a computerized database. Patients entering the cohort within one year of diagnosis constitute the inception cohort. Patients with late-onset (age at diagnosis ≥50) disease were identified and matched 1:2 based on gender and first clinic visit (±5) years with patients with early-onset disease (age at diagnosis 18-40 years). Results A total of 86 patients with late-onset disease (84.9% female, 81.4% Caucasian, mean age at SLE diagnosis ± SD 58.05 ± 7.30) and 169 patients with early-onset disease (86.4% female, 71% Caucasian, mean age at SLE diagnosis ± SD 27.80 ± 5.90) were identified. At enrollment, late-onset SLE patients had a lower total number of American College of Rheumatology (ACR) criteria, with less renal and neurologic manifestations. Mean SLE Disease Activity Index 2000 (SLEDAI-2K) scores were lower in late-onset SLE, especially renal features and anti-dsDNA positivity. Over 5 years, mean SLEDAI-2K scores decreased in both groups, while mean Systemic Lupus International Collaborating Clinics/ACR Damage Index (SDI) scores increased more significantly in the late-onset group; they developed more cardiovascular, renal, and ocular damage, and had higher prevalence of cardiovascular risk factors. Conclusion Although the late-onset SLE group had a milder presentation and less active disease, with the evolution of disease, they developed more organ damage likely as a consequence of cardiovascular risk factors and aging.
28420066	0	17	Disease evolution	T070	C1254365
28420066	21	31	late-onset	T079	C4025592
28420066	36	47	early-onset	T033	C1833334
28420066	48	76	systemic lupus erythematosus	T047	C0024141
28420066	91	100	objective	T170	C0018017
28420066	109	114	study	T062	C2603343
28420066	130	138	clinical	T080	C0205210
28420066	139	147	features	T080	C2348519
28420066	149	165	disease activity	T060	C4065474
28420066	171	178	outcome	T033	C0679250
28420066	182	192	late-onset	T079	C4025592
28420066	200	211	early-onset	T033	C1833334
28420066	212	240	systemic lupus erythematosus	T047	C0024141
28420066	242	245	SLE	T047	C0024141
28420066	254	259	years	T079	C0439234
28420066	263	272	follow up	T058	C1522577
28420066	280	288	Patients	T101	C0030705
28420066	294	297	SLE	T047	C0024141
28420066	350	367	standard protocol	T061	C0008971
28420066	385	406	computerized database	T170	C0871696
28420066	408	416	Patients	T101	C0030705
28420066	430	436	cohort	T098	C0599755
28420066	444	452	one year	T079	C4082117
28420066	456	465	diagnosis	T033	C0011900
28420066	481	497	inception cohort	UnknownType	C0150101
28420066	499	507	Patients	T101	C0030705
28420066	513	523	late-onset	T079	C4025592
28420066	525	528	age	T032	C0001779
28420066	532	541	diagnosis	T033	C0011900
28420066	547	554	disease	T047	C0012634
28420066	560	570	identified	T080	C0205396
28420066	596	602	gender	T032	C0079399
28420066	613	625	clinic visit	T058	C0008952
28420066	631	636	years	T079	C0439234
28420066	642	650	patients	T101	C0030705
28420066	656	675	early-onset disease	T047	C0814120
28420066	677	680	age	T032	C0001779
28420066	684	693	diagnosis	T033	C0011900
28420066	700	705	years	T079	C0439234
28420066	730	738	patients	T101	C0030705
28420066	744	754	late-onset	T079	C4025592
28420066	755	762	disease	T047	C0012634
28420066	770	776	female	T032	C0086287
28420066	784	793	Caucasian	T098	C0043157
28420066	795	799	mean	T081	C0444504
28420066	800	803	age	T032	C0001779
28420066	807	810	SLE	T047	C0024141
28420066	811	820	diagnosis	T033	C0011900
28420066	848	856	patients	T101	C0030705
28420066	862	881	early-onset disease	T047	C0814120
28420066	889	895	female	T032	C0086287
28420066	901	910	Caucasian	T098	C0043157
28420066	912	916	mean	T081	C0444504
28420066	917	920	age	T032	C0001779
28420066	924	927	SLE	T047	C0024141
28420066	928	937	diagnosis	T033	C0011900
28420066	962	972	identified	T080	C0205396
28420066	989	999	late-onset	T079	C4025592
28420066	1000	1003	SLE	T047	C0024141
28420066	1004	1012	patients	T101	C0030705
28420066	1041	1088	American College of Rheumatology (ACR) criteria	T170	C4055473
28420066	1110	1135	neurologic manifestations	T033	C0027854
28420066	1137	1141	Mean	T081	C0444504
28420066	1142	1192	SLE Disease Activity Index 2000 (SLEDAI-2K) scores	T170	C0451528
28420066	1198	1203	lower	T080	C0205251
28420066	1207	1217	late-onset	T079	C4025592
28420066	1218	1221	SLE	T047	C0024141
28420066	1234	1248	renal features	T201	C1285911
28420066	1253	1274	anti-dsDNA positivity	T034	C2747927
28420066	1283	1288	years	T079	C0439234
28420066	1290	1294	mean	T081	C0444504
28420066	1295	1311	SLEDAI-2K scores	T170	C0451528
28420066	1312	1321	decreased	T081	C0205216
28420066	1330	1336	groups	UnknownType	C0681860
28420066	1344	1348	mean	T081	C0444504
28420066	1349	1429	Systemic Lupus International Collaborating Clinics/ACR Damage Index (SDI) scores	T170	C4049882
28420066	1430	1439	increased	T081	C0205217
28420066	1466	1482	late-onset group	UnknownType	C0681860
28420066	1504	1518	cardiovascular	T037	C0560570
28420066	1520	1525	renal	T033	C1408258
28420066	1531	1544	ocular damage	T033	C4061128
28420066	1554	1571	higher prevalence	T081	C1512456
28420066	1575	1602	cardiovascular risk factors	T047	C0850624
28420066	1628	1648	late-onset SLE group	UnknownType	C0681860
28420066	1679	1690	less active	T033	C0243095
28420066	1691	1698	disease	T047	C0012634
28420066	1709	1729	evolution of disease	T070	C1254365
28420066	1751	1756	organ	T023	C0178784
28420066	1757	1763	damage	T169	C1883709
28420066	1776	1787	consequence	T169	C0686907
28420066	1791	1818	cardiovascular risk factors	T047	C0850624
28420066	1823	1828	aging	T040	C0001811

27741201|t|Outcomes With Cerclage Alone Compared With Cerclage Plus 17α-Hydroxyprogesterone Caproate
27741201|a|To examine the differences in perinatal outcomes among women with a prior preterm birth who received cerclage compared with cerclage plus 17α-hydroxyprogesterone caproate. Women with transvaginal cerclage placement and a prior delivery between 16 and 36 weeks of gestation were identified over a 10- year period (July 2002 to May 2012) in this retrospective cohort study. Exclusion criteria were delivery at another institution, abdominal cerclage, multiple gestations, and major fetal anomalies. Maternal demographics, gestational age at cerclage, gestational age at delivery, preterm prelabor rupture of membranes (PROM), and birth weight were compared between women with a cerclage and cerclage plus 17α-hydroxyprogesterone caproate. The primary outcome was delivery at less than 24 weeks of gestation. Of the 411 women who had a cerclage, 260 met inclusion criteria. Of these, 171 received a cerclage alone and 89 received cerclage plus 17α-hydroxyprogesterone caproate. The two groups were not different with respect to maternal demographics and gestational age at cerclage. There was a significant difference among those who received indomethacin at the time of cerclage, betamethasone administration, and history of a loop electrosurgical excision procedure - cold knife cone and cerclage. Delivery at less than 24 weeks of gestation occurred in 6% of women receiving both 17α-hydroxyprogesterone caproate and cerclage compared with 16% in the cerclage only group (odds ratio [OR] 0.31, 95% confidence interval 0.10-0.78, P=.01). In the multivariate analysis controlling for indomethacin use, prior cerclage, and loop electrosurgical excision procedure - cold knife cone there was a 73% reduction in delivery in the combined treatment group compared with cerclage alone (adjusted OR 0.26, P=.02). A multivariant analysis was conducted with correction for indomethacin at the time of cerclage, prior cerclage, and loop electrosurgical excision procedure - cold knife cone and cerclage surgery. Even after controlling for significant variables, there remained a 73% reduction in delivery at less than 24 weeks of gestation in the cerclage plus 17α-hydroxyprogesterone caproate cohort (adjusted OR 0.26, P=.02). Women receiving transvaginal cerclage plus 17α-hydroxyprogesterone caproate had a 69% relative reduction in delivery at less than 24 weeks of gestation when compared with women receiving cerclage alone. We found no difference in overall preterm delivery or preterm PROM. In this cohort, compared with cerclage alone, the likelihood of a viable neonate improves with both treatments.
27741201	0	8	Outcomes	T169	C1274040
27741201	14	22	Cerclage	T061	C0994592
27741201	29	37	Compared	T052	C1707455
27741201	43	51	Cerclage	T061	C0994592
27741201	57	89	17α-Hydroxyprogesterone Caproate	T109,T121,T125	C0044971
27741201	105	116	differences	T080	C1705242
27741201	120	138	perinatal outcomes	T169	C1274040
27741201	145	150	women	T098	C0043210
27741201	164	177	preterm birth	T033	C0151526
27741201	191	199	cerclage	T061	C0994592
27741201	200	208	compared	T052	C1707455
27741201	214	222	cerclage	T061	C0994592
27741201	228	260	17α-hydroxyprogesterone caproate	T109,T121,T125	C0044971
27741201	262	267	Women	T098	C0043210
27741201	273	294	transvaginal cerclage	T061	C0994592
27741201	311	325	prior delivery	UnknownType	C0747969
27741201	344	349	weeks	T079	C0439230
27741201	353	362	gestation	T040	C0032961
27741201	390	394	year	T079	C0439234
27741201	395	401	period	T079	C1948053
27741201	434	460	retrospective cohort study	T062	C2985505
27741201	462	480	Exclusion criteria	T169	C0680251
27741201	486	494	delivery	T040	C0005615
27741201	506	517	institution	T073,T093	C0018704
27741201	519	537	abdominal cerclage	T061	C1292825
27741201	539	558	multiple gestations	T033	C0032989
27741201	570	575	fetal	T018	C0015965
27741201	576	585	anomalies	T033	C1704258
27741201	587	595	Maternal	T099	C0026591
27741201	596	608	demographics	T081	C2828391
27741201	610	625	gestational age	T032	C0017504
27741201	629	637	cerclage	T061	C0994592
27741201	639	654	gestational age	T032	C0017504
27741201	658	666	delivery	T040	C0005615
27741201	668	705	preterm prelabor rupture of membranes	T046	C0015944
27741201	707	711	PROM	T046	C0015944
27741201	718	730	birth weight	T032	C0005612
27741201	736	744	compared	T052	C1707455
27741201	753	758	women	T098	C0043210
27741201	766	774	cerclage	T061	C0994592
27741201	779	787	cerclage	T061	C0994592
27741201	793	825	17α-hydroxyprogesterone caproate	T109,T121,T125	C0044971
27741201	839	846	outcome	T169	C1274040
27741201	851	859	delivery	T040	C0005615
27741201	873	894	24 weeks of gestation	T033	C0730522
27741201	907	912	women	T098	C0043210
27741201	923	931	cerclage	T061	C0994592
27741201	941	959	inclusion criteria	T080	C1512693
27741201	986	994	cerclage	T061	C0994592
27741201	1017	1025	cerclage	T061	C0994592
27741201	1031	1063	17α-hydroxyprogesterone caproate	T109,T121,T125	C0044971
27741201	1073	1079	groups	T098	C0043210
27741201	1115	1123	maternal	T099	C0026591
27741201	1124	1136	demographics	T081	C2828391
27741201	1141	1156	gestational age	T032	C0017504
27741201	1160	1168	cerclage	T061	C0994592
27741201	1230	1242	indomethacin	T109,T121	C0021246
27741201	1258	1266	cerclage	T061	C0994592
27741201	1268	1281	betamethasone	T109,T121,T125	C0005308
27741201	1282	1296	administration	T061	C1533734
27741201	1302	1354	history of a loop electrosurgical excision procedure	T033	C4039811
27741201	1357	1372	cold knife cone	T060	C0195325
27741201	1377	1385	cerclage	T061	C0994592
27741201	1387	1395	Delivery	T040	C0005615
27741201	1409	1430	24 weeks of gestation	T033	C0730522
27741201	1449	1454	women	T098	C0043210
27741201	1470	1502	17α-hydroxyprogesterone caproate	T109,T121,T125	C0044971
27741201	1507	1515	cerclage	T061	C0994592
27741201	1516	1524	compared	T052	C1707455
27741201	1541	1549	cerclage	T061	C0994592
27741201	1555	1560	group	T098	C0043210
27741201	1562	1572	odds ratio	T081	C0028873
27741201	1574	1576	OR	T081	C0028873
27741201	1588	1607	confidence interval	T081	C0009667
27741201	1634	1655	multivariate analysis	T081	C0026777
27741201	1672	1684	indomethacin	T109,T121	C0021246
27741201	1696	1704	cerclage	T061	C0994592
27741201	1710	1749	loop electrosurgical excision procedure	T061	C0184930
27741201	1752	1767	cold knife cone	T060	C0195325
27741201	1797	1805	delivery	T040	C0005615
27741201	1832	1837	group	T098	C0043210
27741201	1838	1846	compared	T052	C1707455
27741201	1852	1860	cerclage	T061	C0994592
27741201	1877	1879	OR	T081	C0028873
27741201	1896	1917	multivariant analysis	T062	C0936012
27741201	1952	1964	indomethacin	T109,T121	C0021246
27741201	1980	1988	cerclage	T061	C0994592
27741201	1996	2004	cerclage	T061	C0994592
27741201	2010	2049	loop electrosurgical excision procedure	T061	C0184930
27741201	2052	2067	cold knife cone	T060	C0195325
27741201	2072	2080	cerclage	T061	C0994592
27741201	2081	2088	surgery	T061	C0543467
27741201	2174	2182	delivery	T040	C0005615
27741201	2196	2217	24 weeks of gestation	T033	C0730522
27741201	2225	2233	cerclage	T061	C0994592
27741201	2239	2271	17α-hydroxyprogesterone caproate	T109,T121,T125	C0044971
27741201	2272	2278	cohort	T098	C0599755
27741201	2289	2291	OR	T081	C0028873
27741201	2306	2311	Women	T098	C0043210
27741201	2322	2343	transvaginal cerclage	T061	C0994592
27741201	2349	2381	17α-hydroxyprogesterone caproate	T109,T121,T125	C0044971
27741201	2414	2422	delivery	T040	C0005615
27741201	2436	2457	24 weeks of gestation	T033	C0730522
27741201	2463	2471	compared	T052	C1707455
27741201	2477	2482	women	T098	C0043210
27741201	2493	2501	cerclage	T061	C0994592
27741201	2543	2559	preterm delivery	T033	C0151526
27741201	2563	2575	preterm PROM	T046	C0015944
27741201	2585	2591	cohort	T098	C0599755
27741201	2593	2601	compared	T052	C1707455
27741201	2607	2615	cerclage	T061	C0994592
27741201	2650	2657	neonate	T100	C0021289
27741201	2677	2687	treatments	T061	C0087111

27689542|t|Safe Routes to Play? Pedestrian and Bicyclist Crashes Near Parks in Los Angeles
27689542|a|Areas near parks may present active travelers with higher risks than in other areas due to the confluence of more pedestrians and bicyclists, younger travelers, and the potential for increased traffic volumes. These risks may be amplified in low-income and minority neighborhoods due to generally higher rates of active travel or lack of safety infrastructure. This paper examines active travel crashes near parks and builds on existing research around disparities in park access and extends research from the Safe Routes to School and Safe Routes to Transit movements to parks. We utilized the Green Visions Parks coverage, encompassing Los Angeles County and several other cities in the LA Metropolitan area. We used negative bionomial regression modeling techniques and ten years of geolocated pedestrian and bicyclist crash data to assess the number of active travel injuries within a quarter mile (~400m) buffer around parks. We controlled for differential exposures to active travel using travel survey data and Bayesian smoothing models. Of 1,311,736 parties involved in 608,530 crashes, there were 896,359 injuries and 7317 fatalities. The number of active travel crash injuries is higher within a quarter-mile of a park, with a ratio of 1.52 per 100,000 residents, compared to areas outside that buffer. This higher rate near parks is amplified in neighborhoods with high proportions of minority and low-income residents. Higher traffic levels are highly predictive of active travel crash injuries. Planners should consider the higher risks of active travel near parks and the socioeconomic modification of these risks. Additional traffic calming and safety infrastructure may be needed to provide safe routes to parks.
27689542	0	4	Safe	T082	C0557723
27689542	5	11	Routes	T082	C0449444
27689542	15	19	Play	T056	C0032214
27689542	21	31	Pedestrian	T098	C0450063
27689542	36	45	Bicyclist	T098	C1257890
27689542	46	53	Crashes	T067	C0000924
27689542	54	58	Near	T080	C1706276
27689542	59	64	Parks	T073	C0562547
27689542	68	79	Los Angeles	T083	C0024015
27689542	80	85	Areas	T082	C0205146
27689542	86	90	near	T080	C1706276
27689542	91	96	parks	T073	C0562547
27689542	101	108	present	T033	C0150312
27689542	109	115	active	T169	C0205177
27689542	116	125	travelers	T098	C0687759
27689542	131	143	higher risks	T078	C0035647
27689542	158	163	areas	T082	C0205146
27689542	175	185	confluence	T052	C0441655
27689542	194	205	pedestrians	T098	C0450063
27689542	210	220	bicyclists	T098	C1257890
27689542	222	239	younger travelers	T098	C0687759
27689542	249	258	potential	T080	C3245505
27689542	263	272	increased	T081	C0205217
27689542	273	280	traffic	T033	C3840880
27689542	281	288	volumes	T081	C0449468
27689542	296	301	risks	T078	C0035647
27689542	309	318	amplified	T080	C0205556
27689542	322	332	low-income	T102	C0032854
27689542	337	345	minority	T098	C0026192
27689542	346	359	neighborhoods	T083	C0027569
27689542	377	389	higher rates	T081	C1521828
27689542	393	399	active	T169	C0205177
27689542	400	406	travel	T056	C0040802
27689542	410	439	lack of safety infrastructure	T033	C2364372
27689542	446	451	paper	T170	C0282420
27689542	461	467	active	T169	C0205177
27689542	468	474	travel	T056	C0040802
27689542	475	482	crashes	T067	C0000924
27689542	483	487	near	T080	C1706276
27689542	488	493	parks	T073	C0562547
27689542	508	525	existing research	T062	C0035168
27689542	533	544	disparities	T033	C1290905
27689542	548	552	park	T073	C0562547
27689542	553	559	access	T082	C0444454
27689542	572	580	research	T062	C0035168
27689542	590	594	Safe	T082	C0557723
27689542	595	601	Routes	T082	C0449444
27689542	605	611	School	T073,T092	C0036375
27689542	616	620	Safe	T082	C0557723
27689542	621	627	Routes	T082	C0449444
27689542	631	648	Transit movements	T169	C0205245
27689542	652	657	parks	T073	C0562547
27689542	675	703	Green Visions Parks coverage	T082	C1254362
27689542	718	736	Los Angeles County	T083	C3829255
27689542	755	761	cities	T083	C0008848
27689542	769	771	LA	T083	C0024015
27689542	772	789	Metropolitan area	UnknownType	C0815251
27689542	799	848	negative bionomial regression modeling techniques	T081,T170	C0026338
27689542	853	856	ten	T081	C0205456
27689542	857	862	years	T079	C0439234
27689542	866	876	geolocated	T082	C0450429
27689542	877	887	pedestrian	T098	C0450063
27689542	892	901	bicyclist	T098	C1257890
27689542	902	907	crash	T067	C0000924
27689542	908	912	data	T078	C1511726
27689542	916	922	assess	T052	C1516048
27689542	927	933	number	T081	C0237753
27689542	937	943	active	T169	C0205177
27689542	944	950	travel	T056	C0040802
27689542	951	959	injuries	T037	C3263722
27689542	969	981	quarter mile	T081	C0331865
27689542	990	996	buffer	T080	C0205556
27689542	1004	1009	parks	T073	C0562547
27689542	1029	1054	differential exposures to	T080	C0332157
27689542	1055	1061	active	T169	C0205177
27689542	1062	1068	travel	T056	C0040802
27689542	1075	1081	travel	T056	C0040802
27689542	1082	1088	survey	T170	C0038951
27689542	1089	1093	data	T078	C1511726
27689542	1098	1123	Bayesian smoothing models	T081	C0242198
27689542	1138	1145	parties	T077	C1518904
27689542	1166	1173	crashes	T067	C0000924
27689542	1194	1202	injuries	T037	C3263722
27689542	1212	1222	fatalities	T081	C0681680
27689542	1228	1234	number	T081	C0237753
27689542	1238	1244	active	T169	C0205177
27689542	1245	1251	travel	T056	C0040802
27689542	1252	1257	crash	T067	C0000924
27689542	1258	1266	injuries	T037	C3263722
27689542	1286	1298	quarter-mile	T081	C0331865
27689542	1304	1308	park	T073	C0562547
27689542	1317	1322	ratio	T081	C0456603
27689542	1343	1352	residents	T098	C2347958
27689542	1354	1362	compared	T052	C1707455
27689542	1366	1371	areas	T082	C0205146
27689542	1385	1391	buffer	T080	C0205556
27689542	1398	1409	higher rate	T081	C1521828
27689542	1410	1414	near	T080	C1706276
27689542	1415	1420	parks	T073	C0562547
27689542	1437	1450	neighborhoods	T083	C0027569
27689542	1456	1472	high proportions	T081	C1709707
27689542	1476	1484	minority	T098	C0026192
27689542	1489	1499	low-income	T102	C0032854
27689542	1500	1509	residents	T098	C2347958
27689542	1511	1525	Higher traffic	T033	C3840880
27689542	1526	1532	levels	T080	C0441889
27689542	1537	1554	highly predictive	T080	C0681890
27689542	1558	1564	active	T169	C0205177
27689542	1565	1571	travel	T056	C0040802
27689542	1572	1577	crash	T067	C0000924
27689542	1578	1586	injuries	T037	C3263722
27689542	1588	1596	Planners	T097	C0334786
27689542	1604	1612	consider	T078	C0750591
27689542	1617	1629	higher risks	T078	C0035647
27689542	1633	1639	active	T169	C0205177
27689542	1640	1646	travel	T056	C0040802
27689542	1647	1651	near	T080	C1706276
27689542	1652	1657	parks	T073	C0562547
27689542	1666	1679	socioeconomic	T077	C0748878
27689542	1680	1692	modification	T169	C0392747
27689542	1702	1707	risks	T078	C0035647
27689542	1720	1727	traffic	T033	C3840880
27689542	1728	1735	calming	T169	C0205245
27689542	1740	1746	safety	T068	C0036043
27689542	1747	1761	infrastructure	T185	C1998546
27689542	1769	1775	needed	T080	C0027552
27689542	1779	1786	provide	T052	C1999230
27689542	1787	1791	safe	T082	C0557723
27689542	1792	1798	routes	T082	C0449444
27689542	1802	1807	parks	T073	C0562547

27371349|t|A Cyclin D2 -derived peptide acts on specific cell cycle phases by activating ERK1/2 to cause the death of breast cancer cells
27371349|a|Protein degradation by the proteasome generates functional intracellular peptides. Pep5, a peptide derived from Cyclin D2, induces cell death in tumor cell lines and reduces the volume of rat C6 glioblastoma tumors in vivo. Here, we chose the human MDA-MB-231 breast cancer cells to evaluate the mechanism of cell death induced by pep5 in different phases of the cell cycle. Fluorescently labeled pep5, monitored by real time confocal microscopy, entered the MDA-MB-231 cells 3min after application and localized to the nucleus and cytoplasm. Pep5 - induced cell death was increased when the MDA-MB-231 cell population was arrested at the G1/S transition or in S phase compared to asynchronous cells. Pep5 induced permanent extracellular signal-regulated kinase (ERK1/2) phosphorylation in MDA-MB-231 cells synchronized in G1/S or S phase. Affinity chromatography followed by mass spectrometry identified CLIC1 and Plectin as the only two proteins that interacted with pep5 in both asynchronous and synchronized MDA-MB-231 cells. These interactions could explain the long-lasting ERK1/2 phosphorylation and the cytoskeleton perturbations in the MDA-MB-231 cells, in which the stress fibers ' integrity is affected by pep5 treatments. These data suggest that pep5 has potential therapeutic properties for treating specific types of cancers, such as breast cancer cells. Pep5, a natural intracellular peptide formed by the degradation of Cyclin D2 through the ubiquitin-proteasome system, induces cell death when reintroduced into MDA-MB-231 breast cancer cells, which express low levels of Cyclin D2, specifically in G1/S arrested cells or in cells that are passing through S phase. Under these conditions, pep5 is able to interact with different intracellular proteins, primarily cytoskeleton and proteasome components, which can lead to cellular apoptosis. Together, our data suggest that pep5 is an intracellular peptide with therapeutic potential for treating specific types of tumors with low expression of Cyclin D2 by inhibiting cell proliferation.
27371349	2	11	Cyclin D2	T116,T123	C2718191
27371349	21	28	peptide	T116	C0030956
27371349	37	45	specific	T080	C0205369
27371349	46	63	cell cycle phases	T043	C1516337
27371349	67	77	activating	T052	C1879547
27371349	78	84	ERK1/2	T116,T126	C0600388
27371349	88	103	cause the death	T033	C0007465
27371349	107	126	breast cancer cells	T025	C1512505
27371349	127	146	Protein degradation	T044	C0597304
27371349	154	164	proteasome	T044	C1752727
27371349	175	185	functional	T169	C0205245
27371349	186	199	intracellular	T082	C0178719
27371349	200	208	peptides	T116	C0030956
27371349	210	214	Pep5	T116	C0030956
27371349	218	225	peptide	T116	C0030956
27371349	239	248	Cyclin D2	T116,T123	C2718191
27371349	250	257	induces	T169	C0205263
27371349	258	268	cell death	T043	C0007587
27371349	272	288	tumor cell lines	T025	C0085983
27371349	293	300	reduces	T080	C0392756
27371349	305	311	volume	T081	C0449468
27371349	315	318	rat	T015	C0034693
27371349	319	341	C6 glioblastoma tumors	T191	C0017636
27371349	342	349	in vivo	T082	C1515655
27371349	370	386	human MDA-MB-231	T050	C3898556
27371349	387	406	breast cancer cells	T025	C1512505
27371349	410	418	evaluate	T058	C0220825
27371349	423	446	mechanism of cell death	T043	C1708951
27371349	447	454	induced	T169	C0205263
27371349	458	462	pep5	T116	C0030956
27371349	466	475	different	T080	C1705242
27371349	476	500	phases of the cell cycle	T043	C1516337
27371349	502	523	Fluorescently labeled	T059	C0079367
27371349	524	528	pep5	T116	C0030956
27371349	543	572	real time confocal microscopy	T059	C0242842
27371349	586	596	MDA-MB-231	T050	C3898556
27371349	597	602	cells	T025	C1512505
27371349	630	639	localized	T082	C0392752
27371349	647	654	nucleus	T026	C0007610
27371349	659	668	cytoplasm	T026	C0010834
27371349	670	674	Pep5	T116	C0030956
27371349	677	684	induced	T169	C0205263
27371349	685	695	cell death	T043	C0007587
27371349	700	709	increased	T081	C0205217
27371349	719	729	MDA-MB-231	T050	C3898556
27371349	730	745	cell population	T025	C1512505
27371349	750	758	arrested	T079	C0237477
27371349	766	781	G1/S transition	T044	C1517341
27371349	788	795	S phase	T079	C0080129
27371349	796	804	compared	T052	C1707455
27371349	808	820	asynchronous	T079	C0439581
27371349	821	826	cells	T025	C0007634
27371349	828	832	Pep5	T116	C0030956
27371349	833	840	induced	T169	C0205263
27371349	841	850	permanent	T079	C0205355
27371349	851	888	extracellular signal-regulated kinase	T116,T126	C0600388
27371349	890	896	ERK1/2	T116,T126	C0600388
27371349	898	913	phosphorylation	T044	C0031715
27371349	917	927	MDA-MB-231	T050	C3898556
27371349	928	933	cells	T025	C1512505
27371349	934	946	synchronized	T079	C0439580
27371349	950	954	G1/S	T044	C1517341
27371349	958	965	S phase	T079	C0080129
27371349	967	990	Affinity chromatography	T059	C0008551
27371349	1003	1020	mass spectrometry	T059	C0037813
27371349	1021	1031	identified	T080	C0205396
27371349	1032	1037	CLIC1	T116,T123	C1314856
27371349	1042	1049	Plectin	T116,T123	C0071277
27371349	1066	1074	proteins	T116,T123	C0033684
27371349	1080	1090	interacted	T169	C1704675
27371349	1096	1100	pep5	T116	C0030956
27371349	1109	1121	asynchronous	T079	C0439581
27371349	1126	1138	synchronized	T079	C0439580
27371349	1139	1149	MDA-MB-231	T050	C3898556
27371349	1150	1155	cells	T025	C1512505
27371349	1163	1175	interactions	T169	C1704675
27371349	1207	1213	ERK1/2	T116,T126	C0600388
27371349	1214	1229	phosphorylation	T044	C0031715
27371349	1238	1250	cytoskeleton	T026	C0010853
27371349	1251	1264	perturbations	T169	C0332453
27371349	1272	1282	MDA-MB-231	T050	C3898556
27371349	1283	1288	cells	T025	C1512505
27371349	1303	1316	stress fibers	T026	C0887904
27371349	1319	1328	integrity	T080	C1947912
27371349	1344	1348	pep5	T116	C0030956
27371349	1349	1359	treatments	T061	C0087111
27371349	1367	1371	data	T078	C1511726
27371349	1385	1389	pep5	T116	C0030956
27371349	1394	1403	potential	T080	C3245505
27371349	1404	1415	therapeutic	T169	C0302350
27371349	1416	1426	properties	T080	C0871161
27371349	1431	1439	treating	T061	C0087111
27371349	1440	1454	specific types	T080	C0332307
27371349	1458	1465	cancers	T191	C0006826
27371349	1475	1494	breast cancer cells	T025	C1512505
27371349	1496	1500	Pep5	T116	C0030956
27371349	1512	1525	intracellular	T082	C0178719
27371349	1526	1533	peptide	T116	C0030956
27371349	1548	1572	degradation of Cyclin D2	T044	C0597304
27371349	1585	1612	ubiquitin-proteasome system	T044	C1523807
27371349	1614	1621	induces	T169	C0205263
27371349	1622	1632	cell death	T043	C0007587
27371349	1656	1666	MDA-MB-231	T050	C3898556
27371349	1667	1686	breast cancer cells	T025	C1512505
27371349	1702	1712	low levels	T080	C0441889
27371349	1716	1725	Cyclin D2	T116,T123	C2718191
27371349	1743	1747	G1/S	T044	C1517341
27371349	1748	1762	arrested cells	T025	C0007634
27371349	1769	1774	cells	T025	C0007634
27371349	1800	1807	S phase	T079	C0080129
27371349	1833	1837	pep5	T116	C0030956
27371349	1849	1857	interact	T169	C1704675
27371349	1873	1886	intracellular	T082	C0178719
27371349	1887	1895	proteins	T116,T123	C0033684
27371349	1907	1919	cytoskeleton	T026	C0010853
27371349	1924	1945	proteasome components	T116,T126	C0208355
27371349	1957	1961	lead	T169	C1522538
27371349	1965	1983	cellular apoptosis	T043	C0162638
27371349	1999	2003	data	T078	C1511726
27371349	2017	2021	pep5	T116	C0030956
27371349	2028	2041	intracellular	T082	C0178719
27371349	2042	2049	peptide	T116	C0030956
27371349	2055	2066	therapeutic	T169	C0302350
27371349	2067	2076	potential	T080	C3245505
27371349	2081	2089	treating	T061	C0087111
27371349	2090	2104	specific types	T080	C0332307
27371349	2108	2114	tumors	T191	C0027651
27371349	2120	2123	low	T080	C0205251
27371349	2124	2134	expression	T045	C1171362
27371349	2138	2147	Cyclin D2	T116,T123	C2718191
27371349	2151	2161	inhibiting	T052	C3463820
27371349	2162	2180	cell proliferation	T043	C0596290

28000514|t|Antimicrobial and antioxidant activities of a new metabolite from Quercus incana
28000514|a|Phytochemical investigations of Quercus incana led to the isolation of a new catechin derivative quercuschin (1), along with six known compounds: quercetin (2), methyl gallate (3), gallic acid (4), betulinic acid (5), (Z)-9-octadecenoic acid methyl ester (6) and β-sitosterol glucoside (7) from the ethyl acetate fraction of methanolic extract of the bark. Compound 1 was screened for its antibacterial, antifungal and antioxidant potential. Antibacterial and antifungal activities of the compound were tested against different bacterial and fungal strains, employing the agar well diffusion methods. The antibacterial activity was the highest against Streptococcus pyogenes with 80.0% inhibition, while the antifungal activity of the compound was the highest against Candida glabrata with 80.5% inhibition. The results of the antioxidant activity indicated that the compound exhibited antioxidant activity comparable to that of standard, butylated hydroxyanisole (51.2 μg/10 μl versus 45.9 μg/10 μl).
28000514	0	13	Antimicrobial	T034	C1271650
28000514	18	40	antioxidant activities	T044	C1148564
28000514	50	60	metabolite	T123	C0870883
28000514	66	80	Quercus incana	T002	C1634308
28000514	81	94	Phytochemical	T109,T123	C0577749
28000514	113	127	Quercus incana	T002	C1634308
28000514	139	148	isolation	T169	C0205409
28000514	158	166	catechin	T109,T121	C0007404
28000514	178	189	quercuschin	T109	C0029224
28000514	216	225	compounds	T103	C1706082
28000514	227	236	quercetin	T109,T121,T127	C0034392
28000514	242	256	methyl gallate	T109,T121	C0066248
28000514	262	273	gallic acid	T109,T130	C0016979
28000514	279	293	betulinic acid	T109,T121	C0053530
28000514	299	335	(Z)-9-octadecenoic acid methyl ester	T109	C0029224
28000514	344	366	β-sitosterol glucoside	T109	C0029224
28000514	380	393	ethyl acetate	T109,T121	C0059747
28000514	394	405	fraction of	T081	C1264633
28000514	406	416	methanolic	T109,T131	C0001963
28000514	417	424	extract	T167	C2828366
28000514	432	436	bark	T002	C2700441
28000514	438	446	Compound	T103	C1706082
28000514	470	483	antibacterial	T034	C1254360
28000514	485	495	antifungal	T034	C1254360
28000514	500	521	antioxidant potential	T034	C1254360
28000514	523	536	Antibacterial	T034	C1271650
28000514	541	562	antifungal activities	T034	C1271650
28000514	570	578	compound	T103	C1706082
28000514	609	618	bacterial	T007	C0004611
28000514	623	637	fungal strains	T004	C0016832
28000514	653	680	agar well diffusion methods	T059	C0523228
28000514	686	708	antibacterial activity	T034	C1271650
28000514	733	755	Streptococcus pyogenes	T007	C0038411
28000514	767	777	inhibition	T044	C0021469
28000514	789	808	antifungal activity	T033	C0243095
28000514	816	824	compound	T103	C1706082
28000514	849	865	Candida glabrata	T004	C0319899
28000514	877	887	inhibition	T044	C0021469
28000514	908	928	antioxidant activity	T044	C1148564
28000514	948	956	compound	T103	C1706082
28000514	967	987	antioxidant activity	T044	C1148564
28000514	1020	1044	butylated hydroxyanisole	T109,T121,T131	C0006506

28160280|t|Medication Overuse Headache: Pathophysiological Insights from Structural and Functional Brain MRI Research
28160280|a|Research imaging of brain structure and function has helped to elucidate the pathophysiology of medication overuse headache (MOH). This is a narrative review of imaging research studies that have investigated brain structural and functional alterations associated with MOH. Studies included in this review have investigated abnormal structure and function of pain processing regions in people with MOH, functional patterns that might predispose individuals to development of MOH, similarity of brain functional patterns in patients with MOH to those found in people with addiction, brain structure that could predict headache improvement following discontinuation of the overused medication, and changes in brain structure and function after discontinuation of medication overuse. MOH is associated with atypical structure and function of brain regions responsible for pain processing as well as brain regions that are commonly implicated in addiction. Several studies have shown "normalization" of structure and function in pain processing regions following discontinuation of the overused medication and resolution of MOH. However, some of the abnormalities in regions also implicated in addiction tend to persist following discontinuation of the overused medication, suggesting that they are a brain trait that predisposes certain individuals to medication overuse and MOH.
28160280	0	27	Medication Overuse Headache	T046	C2349423
28160280	29	47	Pathophysiological	T169	C0031847
28160280	62	72	Structural	T082	C0678594
28160280	77	87	Functional	T169	C0205245
28160280	88	93	Brain	T023	C0006104
28160280	94	97	MRI	T060	C0024485
28160280	98	106	Research	T062	C0035168
28160280	107	115	Research	T062	C0035168
28160280	116	123	imaging	T060	C0024485
28160280	127	142	brain structure	T023	C0006104
28160280	147	155	function	T042	C0678908
28160280	184	199	pathophysiology	T046	C0277785
28160280	203	230	medication overuse headache	T046	C2349423
28160280	232	235	MOH	T046	C2349423
28160280	268	275	imaging	T060	C0024485
28160280	276	284	research	T062	C0035168
28160280	285	292	studies	T062	C2603343
28160280	316	321	brain	T023	C0006104
28160280	322	332	structural	UnknownType	C0549658
28160280	337	359	functional alterations	T046	C0277785
28160280	376	379	MOH	T046	C2349423
28160280	381	388	Studies	T062	C2603343
28160280	431	439	abnormal	T033	C0205161
28160280	440	449	structure	T082	C0678594
28160280	454	462	function	T169	C0542341
28160280	466	470	pain	T184	C0030193
28160280	493	499	people	T098	C0027361
28160280	505	508	MOH	T046	C2349423
28160280	510	529	functional patterns	T169	C0205245
28160280	552	563	individuals	T098	C0237401
28160280	582	585	MOH	T046	C2349423
28160280	601	606	brain	T023	C0006104
28160280	607	626	functional patterns	T169	C0205245
28160280	630	638	patients	T101	C0030705
28160280	644	647	MOH	T046	C2349423
28160280	666	672	people	T098	C0027361
28160280	678	687	addiction	T048	C0085281
28160280	689	704	brain structure	T023	C0006104
28160280	724	732	headache	T184	C0018681
28160280	755	770	discontinuation	T058	C0457454
28160280	787	797	medication	T058	C2081612
28160280	814	829	brain structure	T023	C0006104
28160280	834	842	function	T169	C0542341
28160280	849	864	discontinuation	T058	C0457454
28160280	868	878	medication	T058	C2081612
28160280	879	886	overuse	T055	C3266697
28160280	888	891	MOH	T046	C2349423
28160280	920	929	structure	T082	C0678594
28160280	934	942	function	T169	C0542341
28160280	946	959	brain regions	T023	C0006104
28160280	976	980	pain	T184	C0030193
28160280	1003	1016	brain regions	T023	C0006104
28160280	1049	1058	addiction	T048	C0085281
28160280	1068	1075	studies	T062	C2603343
28160280	1106	1115	structure	T082	C0678594
28160280	1120	1128	function	T169	C0542341
28160280	1132	1136	pain	T184	C0030193
28160280	1166	1181	discontinuation	T058	C0457454
28160280	1198	1208	medication	T058	C2081612
28160280	1227	1230	MOH	T046	C2349423
28160280	1253	1266	abnormalities	T033	C1704258
28160280	1297	1306	addiction	T048	C0085281
28160280	1333	1348	discontinuation	T058	C0457454
28160280	1365	1375	medication	T058	C2081612
28160280	1404	1409	brain	T023	C0006104
28160280	1441	1452	individuals	T098	C0237401
28160280	1456	1466	medication	T058	C2081612
28160280	1467	1474	overuse	T055	C3266697
28160280	1479	1482	MOH	T046	C2349423

28346872|t|5-Bromo-2-aryl benzimidazole derivatives as non-cytotoxic potential dual inhibitors of α-glucosidase and urease enzymes
28346872|a|On the basis of previous report on promising α-glucosidase inhibitory activity of 5-bromo-2-aryl benzimidazole derivatives, these derivatives were further screened for urease inhibitory and cytotoxicity activity in order to get more potent and non-cytotoxic potential dual inhibitor for the patients suffering from diabetes as well as peptic ulcer. In this study, all compounds showed varying degree of potency in the range of (IC50 =8.15±0.03-354.67±0.19μM) as compared to standard thiourea (IC50 =21.25±0.15μM). It is worth mentioning that derivatives 7 (IC50 =12.07±0.05μM), 8 (IC50 =10.57±0.12μM), 11 (IC50 =13.76±0.02μM), 14 (IC50 =15.70±0.12μM) and 22 (IC50 =8.15±0.03μM) were found to be more potent inhibitors than standard. All compounds were also evaluated for cytotoxicity towards 3T3 mouse fibroblast cell line and found to be completely non-toxic. Previously benzimidazole 1-25 were also showed α-glucosidase inhibitory potential. In silico studies were performed on the lead molecules i.e. 2, 7, 8, 11, 14, and 22, in order to rationalize the binding interaction of compounds with the active site of urease enzyme.
28346872	0	40	5-Bromo-2-aryl benzimidazole derivatives	T109	C0005050
28346872	44	57	non-cytotoxic	T121	C2827065
28346872	58	67	potential	T080	C3245505
28346872	73	83	inhibitors	T121	C0014432
28346872	87	100	α-glucosidase	T116,T121,T126	C0002272
28346872	105	119	urease enzymes	T116,T126	C0041945
28346872	145	151	report	T170	C0684224
28346872	165	178	α-glucosidase	T116,T121,T126	C0002272
28346872	179	198	inhibitory activity	T044	C1152555
28346872	202	242	5-bromo-2-aryl benzimidazole derivatives	T109	C0005050
28346872	275	283	screened	T059	C0373483
28346872	288	294	urease	T116,T126	C0041945
28346872	295	305	inhibitory	T044	C1152555
28346872	310	331	cytotoxicity activity	T059	C0201622
28346872	348	359	more potent	T080	C3245505
28346872	364	377	non-cytotoxic	T121	C2827065
28346872	378	387	potential	T080	C3245505
28346872	393	402	inhibitor	T121	C0014432
28346872	411	419	patients	T101	C0030705
28346872	435	443	diabetes	T047	C0011847
28346872	455	467	peptic ulcer	T047	C0030920
28346872	477	482	study	T062	C2603343
28346872	488	497	compounds	T121	C1254351
28346872	513	530	degree of potency	T038	C0678792
28346872	548	552	IC50	T081	C0600495
28346872	594	602	standard	T081	C0034925
28346872	603	611	thiourea	T109,T130	C0039958
28346872	613	617	IC50	T081	C0600495
28346872	662	675	derivatives 7	T121	C1254351
28346872	677	681	IC50	T081	C0600495
28346872	698	699	8	T121	C1254351
28346872	701	705	IC50	T081	C0600495
28346872	722	724	11	T121	C1254351
28346872	726	730	IC50	T081	C0600495
28346872	747	749	14	T121	C1254351
28346872	751	755	IC50	T081	C0600495
28346872	775	777	22	T121	C1254351
28346872	779	783	IC50	T081	C0600495
28346872	820	837	potent inhibitors	T121	C0014432
28346872	843	851	standard	T081	C0034925
28346872	857	866	compounds	T121	C1254351
28346872	891	903	cytotoxicity	T059	C0201622
28346872	912	915	3T3	T025	C0085087
28346872	916	942	mouse fibroblast cell line	T025	C1513528
28346872	970	979	non-toxic	T033	C0243095
28346872	992	1010	benzimidazole 1-25	T109	C0005050
28346872	1028	1041	α-glucosidase	T116,T121,T126	C0002272
28346872	1042	1062	inhibitory potential	T044	C1152555
28346872	1064	1073	In silico	T066	C3489666
28346872	1074	1081	studies	T062	C2603343
28346872	1104	1118	lead molecules	T121	C1254351
28346872	1124	1125	2	T121	C1254351
28346872	1127	1128	7	T121	C1254351
28346872	1130	1131	8	T121	C1254351
28346872	1133	1135	11	T121	C1254351
28346872	1137	1139	14	T121	C1254351
28346872	1145	1147	22	T121	C1254351
28346872	1177	1196	binding interaction	T044	C0687133
28346872	1200	1209	compounds	T121	C1254351
28346872	1219	1230	active site	T169	C0205681
28346872	1234	1247	urease enzyme	T116,T126	C0041945

28117965|t|Photosensitizer Decorated Red Blood Cells as an Ultra-Sensitive Light-Responsive Drug Delivery System
28117965|a|Red blood cells (RBCs), the most abundant type of cells in our blood, have shown promises as a natural drug delivery system (DDS) with inherent biocompatibility. Herein, we uncover that a photosensitizer, chlorin e6 (Ce6), could be decorated into the membrane of RBCs upon simple mixing, without affecting the membrane integrity and stability in dark. Upon light irradiation with a rather low power density, the generated singlet oxygen by Ce6 as the result of photodynamic effect would lead to rather efficient disruption of RBC membrane. With doxorubicin (DOX), a typical chemotherapy drug, as the model, we engineer a unique type of light-responsive RBC-based DDS by decorating Ce6 on the cell membrane and loading DOX inside cells. The light triggered cell membrane break down would thus trigger instant release of DOX, enabling light-controlled chemotherapy with great specificity. Beyond that, our RBC system could also be utilized for loading of larger biomolecules such as enzymes, whose release as well as catalytic function is also controlled by light. Our work thus presents a unique type of biocompatible cell-based DDS that can be precisely controlled by mild external stimuli, promising not only for cancer therapy but also for other potential applications in biotechnologies.
28117965	0	15	Photosensitizer	T121	C0162713
28117965	16	25	Decorated	T067	C1254366
28117965	26	41	Red Blood Cells	T025	C0014792
28117965	48	101	Ultra-Sensitive Light-Responsive Drug Delivery System	T074	C0085104
28117965	102	117	Red blood cells	T025	C0014792
28117965	119	123	RBCs	T025	C0014792
28117965	135	143	abundant	T080	C2346714
28117965	152	157	cells	T025	C0007634
28117965	165	170	blood	T031	C0005767
28117965	197	225	natural drug delivery system	T070	C1254365
28117965	227	230	DDS	T070	C1254365
28117965	246	262	biocompatibility	T044	C0596177
28117965	290	305	photosensitizer	T121	C0162713
28117965	307	317	chlorin e6	T109,T121	C0055367
28117965	319	322	Ce6	T109,T121	C0055367
28117965	334	343	decorated	T067	C1254366
28117965	353	361	membrane	T026	C0596901
28117965	365	369	RBCs	T025	C0014792
28117965	382	388	mixing	T080	C1720722
28117965	412	420	membrane	T026	C0596901
28117965	421	430	integrity	T080	C1947912
28117965	435	444	stability	T080	C0205360
28117965	459	464	light	T070	C0023693
28117965	465	476	irradiation	T070	C1282930
28117965	501	508	density	T081	C0178587
28117965	514	523	generated	T052	C3146294
28117965	524	538	singlet oxygen	T123,T196	C0074565
28117965	542	545	Ce6	T109,T121	C0055367
28117965	553	582	result of photodynamic effect	UnknownType	C0940920
28117965	614	624	disruption	T169	C0332453
28117965	628	631	RBC	T025	C0014792
28117965	632	640	membrane	T026	C0596901
28117965	647	658	doxorubicin	T109,T195	C0013089
28117965	660	663	DOX	T109,T195	C0013089
28117965	660	663	DOX	T109,T195	C0013089
28117965	676	688	chemotherapy	T061	C3665472
28117965	689	693	drug	T121	C0013227
28117965	702	707	model	T170	C3161035
28117965	738	768	light-responsive RBC-based DDS	T074	C0085104
28117965	772	782	decorating	T067	C1254366
28117965	783	786	Ce6	T109,T121	C0055367
28117965	794	807	cell membrane	T026	C0007603
28117965	820	823	DOX	T109,T195	C0013089
28117965	831	836	cells	T025	C0007634
28117965	842	847	light	T070	C0023693
28117965	848	857	triggered	T080	C1444748
28117965	858	871	cell membrane	T026	C0007603
28117965	894	901	trigger	T080	C1444748
28117965	921	924	DOX	T109,T195	C0013089
28117965	935	964	light-controlled chemotherapy	T061	C3665472
28117965	976	987	specificity	T081	C0037791
28117965	1006	1009	RBC	T025	C0014792
28117965	1062	1074	biomolecules	T167	C0567416
28117965	1083	1090	enzymes	T116,T126	C0014442
28117965	1117	1126	catalytic	T070	C0007382
28117965	1127	1135	function	T169	C0542341
28117965	1158	1163	light	T070	C0023693
28117965	1169	1173	work	T057	C0043227
28117965	1205	1233	biocompatible cell-based DDS	T074	C0085104
28117965	1284	1291	stimuli	T067	C0234402
28117965	1316	1330	cancer therapy	T061	C0920425
28117965	1360	1372	applications	T169	C4048755
28117965	1376	1391	biotechnologies	T091	C0005574

28028852|t|Structural investigation on WlaRG from Campylobacter jejuni: A sugar aminotransferase
28028852|a|Campylobacter jejuni is a Gram-negative bacterium that represents a leading cause of human gastroenteritis worldwide. Of particular concern is the link between C. jejuni infections and the subsequent development of Guillain-Barré syndrome, an acquired autoimmune disorder leading to paralysis. All Gram-negative bacteria contain complex glycoconjugates anchored to their outer membranes, but in most strains of C. jejuni, this lipoglycan lacks the O-antigen repeating units. Recent mass spectrometry analyses indicate that the C. jejuni 81116 (Penner serotype HS:6) lipoglycan contains two dideoxyhexosamine residues, and enzymological assay data show that this bacterial strain can synthesize both dTDP-3-acetamido-3,6-dideoxy-d-glucose and dTDP-3-acetamido-3,6-dideoxy-d-galactose. The focus of this investigation is on WlaRG from C. jejuni, which plays a key role in the production of these unusual sugars by functioning as a pyridoxal 5'-phosphate dependent aminotransferase. Here, we describe the first three-dimensional structures of the enzyme in various complexes determined to resolutions of 1.7 Å or higher. Of particular significance are the external aldimine structures of WlaRG solved in the presence of either dTDP-3-amino-3,6-dideoxy-d-galactose or dTDP-3-amino-3,6-dideoxy-d-glucose. These models highlight the manner in which WlaRG can accommodate sugars with differing stereochemistries about their C-4' carbon positions. In addition, we present a corrected structure of WbpE, a related sugar aminotransferase from Pseudomonas aeruginosa, solved to 1.3 Å resolution.
28028852	0	10	Structural	T082	C0678594
28028852	11	24	investigation	T062	C0015195
28028852	28	33	WlaRG	T116,T126	C0002594
28028852	39	59	Campylobacter jejuni	T007	C0006819
28028852	63	68	sugar	T109,T121	C0242209
28028852	69	85	aminotransferase	T116,T126	C0002594
28028852	86	106	Campylobacter jejuni	T007	C0006819
28028852	112	135	Gram-negative bacterium	T007	C0018150
28028852	162	167	cause	T169	C0015127
28028852	171	176	human	T016	C0086418
28028852	177	192	gastroenteritis	T047	C0017160
28028852	246	266	C. jejuni infections	T047	C2959964
28028852	301	324	Guillain-Barré syndrome	T047	C0018378
28028852	329	357	acquired autoimmune disorder	T033	C2750154
28028852	369	378	paralysis	T033	C0522224
28028852	384	406	Gram-negative bacteria	T007	C0018150
28028852	415	422	complex	T104	C1704241
28028852	423	438	glycoconjugates	T109	C0017906
28028852	457	472	outer membranes	T026	C4236857
28028852	486	493	strains	T080	C0456178
28028852	497	506	C. jejuni	T007	C0006819
28028852	513	523	lipoglycan	T109	C0023810
28028852	534	559	O-antigen repeating units	T109,T129	C0069180
28028852	568	585	mass spectrometry	T059	C0037813
28028852	586	594	analyses	T062	C0936012
28028852	613	628	C. jejuni 81116	T170	C0449943
28028852	630	650	Penner serotype HS:6	T170	C0449943
28028852	652	662	lipoglycan	T109	C0023810
28028852	676	693	dideoxyhexosamine	T109,T123	C0019477
28028852	694	702	residues	T077	C1709915
28028852	708	727	enzymological assay	T059	C0005507
28028852	728	732	data	T078	C1511726
28028852	748	764	bacterial strain	T007	C0004611
28028852	769	779	synthesize	T052	C1883254
28028852	785	823	dTDP-3-acetamido-3,6-dideoxy-d-glucose	T114,T123	C2352508
28028852	828	868	dTDP-3-acetamido-3,6-dideoxy-d-galactose	T114	C1311058
28028852	888	901	investigation	T062	C0015195
28028852	908	913	WlaRG	T116,T126	C0002594
28028852	919	928	C. jejuni	T007	C0006819
28028852	960	970	production	T052	C1883254
28028852	988	994	sugars	T109,T121	C0242209
28028852	998	1009	functioning	T169	C0542341
28028852	1015	1037	pyridoxal 5'-phosphate	T109,T121,T127	C0034266
28028852	1048	1064	aminotransferase	T116,T126	C0002594
28028852	1094	1111	three-dimensional	T082	C0450363
28028852	1112	1122	structures	T082	C0678594
28028852	1130	1136	enzyme	T116,T126	C0014442
28028852	1148	1157	complexes	T104	C1704241
28028852	1172	1183	resolutions	T081	C1706463
28028852	1248	1256	aldimine	T109	C0020930
28028852	1257	1267	structures	T082	C0678594
28028852	1271	1276	WlaRG	T116,T126	C0002594
28028852	1310	1346	dTDP-3-amino-3,6-dideoxy-d-galactose	T109,T123	C0016945
28028852	1350	1384	dTDP-3-amino-3,6-dideoxy-d-glucose	T109,T121,T123	C0017725
28028852	1392	1398	models	T075	C0026339
28028852	1429	1434	WlaRG	T116,T126	C0002594
28028852	1451	1457	sugars	T109,T121	C0242209
28028852	1473	1490	stereochemistries	T044	C3536948
28028852	1503	1514	C-4' carbon	T196	C0007009
28028852	1562	1571	structure	T082	C0678594
28028852	1575	1579	WbpE	T116,T126	C0002594
28028852	1591	1596	sugar	T109,T121	C0242209
28028852	1597	1613	aminotransferase	T116,T126	C0002594
28028852	1619	1641	Pseudomonas aeruginosa	T007	C0033809
28028852	1659	1669	resolution	T081	C1706463

28009695|t|Elastin Is Differentially Regulated by Pressure Therapy in a Porcine Model of Hypertrophic Scar
28009695|a|Beneficial effects of pressure therapy for hypertrophic scars have been reported, but the mechanisms of action are not fully understood. This study evaluated elastin and its contribution to scar pliability. The relationship between changes in Vancouver Scar Scale (VSS) scores of pressure-treated scars and differential regulation of elastin was assessed. Hypertrophic scars were created and assessed weekly using VSS and biopsy procurement. Pressure treatment began on day 70 postinjury. Treated scars were compared with untreated shams. Treatment lasted 2 weeks, through day 84, and scars were assessed weekly through day 126. Transcript and protein levels of elastin were quantified. Pressure treatment resulted in lower VSS scores compared with sham-treated scars. Pliability (VSSP) was a key contributor to this difference. At day 70 pretreatment, VSSP = 2. Without treatment, sham-treated scars became less pliable, while pressure-treated scars became more pliable. The percentage of elastin in scars at day 70 was higher than in uninjured skin. Following treatment, the percentage of elastin increased and continued to increase through day 126. Untreated sham scars did not show a similar increase. Quantification of Verhoeff-Van Gieson staining corroborated the findings and immunofluorescence revealed the alignment of elastin fibers. Pressure treatment results in increased protein level expression of elastin compared with sham -untreated scars. These findings further characterize the extracellular matrix's response to the application of pressure as a scar treatment, which will contribute to the refinement of rehabilitation practices and ultimately improvements in functional and psychosocial outcomes for patients.
28009695	0	7	Elastin	T116	C0013765
28009695	11	35	Differentially Regulated	T045	C2755857
28009695	39	55	Pressure Therapy	T061	C1956078
28009695	61	68	Porcine	T015	C3665571
28009695	69	74	Model	T008	C0599779
28009695	78	95	Hypertrophic Scar	T020	C0162810
28009695	96	114	Beneficial effects	T080	C1280500
28009695	118	134	pressure therapy	T061	C1956078
28009695	139	157	hypertrophic scars	T020	C0162810
28009695	186	196	mechanisms	T169	C0441712
28009695	238	243	study	T062	C2603343
28009695	254	261	elastin	T116	C0013765
28009695	286	290	scar	T020	C0162810
28009695	291	301	pliability	T080	C0242808
28009695	307	319	relationship	T080	C0439849
28009695	339	359	Vancouver Scar Scale	T170	C0349674
28009695	361	364	VSS	T170	C0349674
28009695	366	372	scores	T081	C0449820
28009695	376	392	pressure-treated	T061	C1956078
28009695	393	398	scars	T020	C0162810
28009695	430	437	elastin	T116	C0013765
28009695	452	470	Hypertrophic scars	T020	C0162810
28009695	497	503	weekly	T079	C0332174
28009695	510	513	VSS	T170	C0349674
28009695	518	524	biopsy	T060	C0005558
28009695	525	536	procurement	T033	C0243095
28009695	538	556	Pressure treatment	T061	C1956078
28009695	566	569	day	T079	C0439228
28009695	573	583	postinjury	T079	C1254367
28009695	585	592	Treated	T061	C0087111
28009695	593	598	scars	T020	C0162810
28009695	604	612	compared	T052	C1707455
28009695	628	633	shams	T061	C0032042
28009695	635	644	Treatment	T061	C0087111
28009695	654	659	weeks	T079	C0439230
28009695	669	672	day	T079	C0439228
28009695	681	686	scars	T020	C0162810
28009695	701	707	weekly	T079	C0332174
28009695	716	719	day	T079	C0439228
28009695	725	735	Transcript	T114	C1519595
28009695	740	754	protein levels	T034	C0428479
28009695	758	765	elastin	T116	C0013765
28009695	771	781	quantified	T081	C1709793
28009695	783	801	Pressure treatment	T061	C1956078
28009695	820	823	VSS	T170	C0349674
28009695	824	830	scores	T081	C0449820
28009695	831	839	compared	T052	C1707455
28009695	845	857	sham-treated	T061	C0032042
28009695	858	863	scars	T020	C0162810
28009695	865	875	Pliability	T080	C0242808
28009695	877	881	VSSP	T080	C0242808
28009695	928	931	day	T079	C0439228
28009695	935	947	pretreatment	T052	C3539076
28009695	949	953	VSSP	T080	C0242808
28009695	959	976	Without treatment	T061	C0032042
28009695	978	990	sham-treated	T061	C0032042
28009695	991	996	scars	T020	C0162810
28009695	1009	1016	pliable	T080	C0242808
28009695	1024	1040	pressure-treated	T061	C1956078
28009695	1041	1046	scars	T020	C0162810
28009695	1059	1066	pliable	T080	C0242808
28009695	1086	1093	elastin	T116	C0013765
28009695	1097	1102	scars	T020	C0162810
28009695	1106	1109	day	T079	C0439228
28009695	1132	1146	uninjured skin	T022	C1123023
28009695	1158	1167	treatment	T061	C0087111
28009695	1187	1194	elastin	T116	C0013765
28009695	1195	1204	increased	T081	C0205217
28009695	1222	1230	increase	T169	C0442805
28009695	1239	1242	day	T079	C0439228
28009695	1258	1262	sham	T061	C0032042
28009695	1263	1268	scars	T020	C0162810
28009695	1292	1300	increase	T169	C0442805
28009695	1302	1316	Quantification	T081	C1709793
28009695	1320	1348	Verhoeff-Van Gieson staining	T059	C1294321
28009695	1366	1374	findings	T033	C0243095
28009695	1379	1397	immunofluorescence	T059	C0079603
28009695	1411	1420	alignment	T081	C1706765
28009695	1424	1438	elastin fibers	T116	C0013765
28009695	1440	1458	Pressure treatment	T061	C1956078
28009695	1470	1479	increased	T081	C0205217
28009695	1480	1504	protein level expression	T045	C1171362
28009695	1508	1515	elastin	T116	C0013765
28009695	1516	1524	compared	T052	C1707455
28009695	1530	1534	sham	T061	C0032042
28009695	1546	1551	scars	T020	C0162810
28009695	1559	1567	findings	T033	C0243095
28009695	1593	1615	extracellular matrix's	T024	C0015350
28009695	1647	1655	pressure	T067	C0033095
28009695	1661	1665	scar	T020	C0162810
28009695	1666	1675	treatment	T061	C0087111
28009695	1720	1734	rehabilitation	T169	C0034992
28009695	1760	1772	improvements	T077	C2986411
28009695	1776	1786	functional	T169	C0205245
28009695	1791	1803	psychosocial	T169	C0542298
28009695	1804	1812	outcomes	T169	C1274040
28009695	1817	1825	patients	T101	C0030705

27802446|t|Human Leucocyte Antigen B50 Is Associated with Conversion to Generalized Myasthenia Gravis in Patients with Pure Ocular Onset
27802446|a|The aim of this study was to investigate the associations between major histocompatibility complex (MHC) class I and II alleles and disease characteristics in Turkish patients with myasthenia gravis (MG). The MHC class I and II alleles of 108 unrelated MG patients were genotyped. The human leucocyte antigen (HLA) distribution of all MG patients and subgroups of MG patients (grouped according to disease characteristics) was compared to that of 250 healthy controls. Overall distributions of HLA-B*61 and C*05 were more frequent in MG patients (7.4 vs. 2.0% and 14.8 vs. 6.8%, respectively) than in non-MG patients. Subgroup analyses revealed that HLA-DRB1*14 and DQB1*02 alleles were more frequent in early-onset MG [n = 10 (20.8%) vs. n = 25 (10.0%) and n = 21 (43.8%) vs. n = 59 (23.6%)]. In patients seropositive for anti-AchR antibodies, the frequencies of HLA-B*50 and C*05 were higher. HLA-C*05, DRB1*01, and DRB1*11 were higher in patients with ocular MG. In addition, HLA-A*01, A*31, B*08, and DRB1*14 were higher among patients with thymic hyperplasia, whereas DQB1*03 was lower. However, all of these differences lost significance after correction of the p value for multiple comparisons. No allele association was found among patients with thymoma. Strikingly, patients with generalized MG who had pure ocular symptoms at disease onset had significantly increased HLA-B*50 compared to the controls (corrected p < 0.001, OR = 9.92; 95% CI 3.05-32.22). The HLA-B*50 allele was associated with conversion to generalized disease in patients with pure ocular symptoms at disease onset. This finding could extend our understanding of the complex interactions between the pathogenesis of MG and genetic heritage.
27802446	0	27	Human Leucocyte Antigen B50	T129	C0444008
27802446	31	41	Associated	T080	C0439849
27802446	47	57	Conversion	T169	C0439836
27802446	61	90	Generalized Myasthenia Gravis	T047	C0751339
27802446	94	102	Patients	T101	C0030705
27802446	108	119	Pure Ocular	T047	C0751340
27802446	120	125	Onset	T080	C0332162
27802446	130	133	aim	T078	C1947946
27802446	142	147	study	T062	C0008972
27802446	155	166	investigate	T169	C1292732
27802446	171	183	associations	T080	C0439849
27802446	192	224	major histocompatibility complex	T028	C0024518
27802446	226	229	MHC	T028	C0024518
27802446	231	238	class I	T028	C0017355
27802446	243	253	II alleles	T028	C0017349
27802446	258	281	disease characteristics	T046	C0599878
27802446	285	292	Turkish	T098	C0549217
27802446	293	301	patients	T101	C0030705
27802446	307	324	myasthenia gravis	T047	C0026896
27802446	326	328	MG	T047	C0026896
27802446	335	338	MHC	T028	C0024518
27802446	339	346	class I	T028	C0017355
27802446	351	361	II alleles	T028	C0017349
27802446	379	381	MG	T047	C0026896
27802446	382	390	patients	T101	C0030705
27802446	396	405	genotyped	T059	C1285573
27802446	411	434	human leucocyte antigen	T116,T129	C0019721
27802446	436	439	HLA	T116,T129	C0019721
27802446	461	463	MG	T047	C0026896
27802446	464	472	patients	T101	C0030705
27802446	477	486	subgroups	T185	C1515021
27802446	490	492	MG	T047	C0026896
27802446	493	501	patients	T101	C0030705
27802446	503	510	grouped	T082	C0439745
27802446	524	547	disease characteristics	T046	C0599878
27802446	553	561	compared	T052	C1707455
27802446	577	593	healthy controls	T080	C2986479
27802446	620	628	HLA-B*61	T116,T129	C0062847
27802446	633	637	C*05	T116,T129	C0062856
27802446	648	656	frequent	T079	C0332183
27802446	660	662	MG	T047	C0026896
27802446	663	671	patients	T101	C0030705
27802446	734	742	patients	T101	C0030705
27802446	744	752	Subgroup	T185	C1515021
27802446	753	761	analyses	T062	C0936012
27802446	776	787	HLA-DRB1*14	T028	C0002085
27802446	792	807	DQB1*02 alleles	T028	C0002085
27802446	818	826	frequent	T079	C0332183
27802446	830	841	early-onset	T033	C1833334
27802446	842	844	MG	T047	C0026896
27802446	923	931	patients	T101	C0030705
27802446	932	944	seropositive	T080	C0521143
27802446	949	969	anti-AchR antibodies	T116,T129	C0236516
27802446	975	986	frequencies	T079	C0439603
27802446	990	998	HLA-B*50	T116,T129	C0369392
27802446	1003	1007	C*05	T116,T129	C0062856
27802446	1013	1019	higher	T080	C0205250
27802446	1021	1029	HLA-C*05	T116,T129	C0062856
27802446	1031	1038	DRB1*01	T116,T129	C1566853
27802446	1044	1051	DRB1*11	T129	C1699878
27802446	1057	1063	higher	T080	C0205250
27802446	1067	1075	patients	T101	C0030705
27802446	1081	1090	ocular MG	T047	C0751340
27802446	1105	1113	HLA-A*01	T129	C0019728
27802446	1115	1119	A*31	T116,T129	C0121978
27802446	1121	1125	B*08	T116,T129	C0019737
27802446	1131	1138	DRB1*14	T116,T129	C0122040
27802446	1144	1150	higher	T080	C0205250
27802446	1157	1165	patients	T101	C0030705
27802446	1171	1189	thymic hyperplasia	T047	C0040115
27802446	1199	1206	DQB1*03	T116,T129	C0122020
27802446	1211	1216	lower	T080	C0205251
27802446	1257	1269	significance	T078	C0750502
27802446	1294	1301	p value	T081	C1709380
27802446	1306	1326	multiple comparisons	T081	C1881925
27802446	1331	1337	allele	T028	C0002085
27802446	1338	1349	association	T080	C0439849
27802446	1366	1374	patients	T101	C0030705
27802446	1380	1387	thymoma	T191	C0040100
27802446	1401	1409	patients	T101	C0030705
27802446	1415	1429	generalized MG	T047	C0751339
27802446	1438	1449	pure ocular	T047	C0751340
27802446	1450	1458	symptoms	T184	C1457887
27802446	1462	1475	disease onset	T079	C0277793
27802446	1480	1493	significantly	T078	C0750502
27802446	1494	1503	increased	T081	C0205217
27802446	1504	1512	HLA-B*50	T116,T129	C0369392
27802446	1529	1537	controls	T080	C2986479
27802446	1549	1550	p	T081	C1709380
27802446	1575	1577	CI	T081	C0009667
27802446	1595	1610	HLA-B*50 allele	T028	C0002085
27802446	1615	1625	associated	T080	C0439849
27802446	1631	1641	conversion	T169	C0439836
27802446	1645	1664	generalized disease	T047	C0849867
27802446	1668	1676	patients	T101	C0030705
27802446	1682	1693	pure ocular	T047	C0751340
27802446	1694	1702	symptoms	T184	C1457887
27802446	1706	1719	disease onset	T079	C0277793
27802446	1780	1792	interactions	T045	C0596610
27802446	1805	1817	pathogenesis	T046	C0699748
27802446	1821	1823	MG	T047	C0026896
27802446	1828	1844	genetic heritage	T169	C0314603

28480148|t|The use of informativity in the development of robust viromics -based examinations
28480148|a|Metagenomics -based studies have provided insight into many of the complex microbial communities responsible for maintaining life on this planet. Sequencing efforts often uncover novel genetic content; this is most evident for phage communities, in which upwards of 90% of all sequences exhibit no similarity to any sequence in current data repositories. For the small fraction that can be identified, the top BLAST hit is generally posited as being representative of a viral taxon present in the sample of origin. Homology -based classification, however, can be misleading as sequence repositories capture but a small fraction of phage diversity. Furthermore, lateral gene transfer is pervasive within phage communities. As such, the presence of a particular gene may not be indicative of the presence of a particular viral species. Rather, it is just that: an indication of the presence of a specific gene. To circumvent this limitation, we have developed a new method for the analysis of viral metagenomic datasets. BLAST hits are weighted, integrating the sequence identity and length of alignments as well as a taxonomic signal, such that each gene is evaluated with respect to its information content. Through this quantifiable metric, predictions of viral community structure can be made with confidence. As a proof-of-concept, the approach presented here was implemented and applied to seven freshwater viral metagenomes. While providing a robust method for evaluating viral metagenomic data, the tool is versatile and can easily be customized to investigations of any environment or biome.
28480148	32	43	development	T169	C1527148
28480148	47	62	robust viromics	T028	C0042720
28480148	70	82	examinations	T062	C0242481
28480148	83	95	Metagenomics	T090	C2717799
28480148	158	179	microbial communities	T001	C0599840
28480148	196	227	maintaining life on this planet	T058	C0184640
28480148	229	239	Sequencing	T063	C0487717
28480148	268	283	genetic content	T028,T114	C0017272
28480148	310	327	phage communities	T005	C0004651
28480148	360	369	sequences	T059,T063	C0162801
28480148	399	407	sequence	T059,T063	C0162801
28480148	419	436	data repositories	T073	C3847505
28480148	446	460	small fraction	T081	C1264633
28480148	493	498	BLAST	T170	C2698333
28480148	533	547	representative	T052	C1882932
28480148	553	564	viral taxon	T170	C0597651
28480148	598	606	Homology	T080	C2697616
28480148	614	628	classification	T185	C0008902
28480148	660	681	sequence repositories	T170	C0026382
28480148	696	710	small fraction	T081	C1264633
28480148	714	729	phage diversity	T005	C0004651
28480148	744	751	lateral	T082	C0205093
28480148	752	765	gene transfer	T063	C1517499
28480148	769	778	pervasive	T082	C0205391
28480148	786	803	phage communities	T005	C0004651
28480148	832	847	particular gene	T028	C0017337
28480148	891	915	particular viral species	T005	C0042776
28480148	945	955	indication	T078	C3146298
28480148	977	990	specific gene	T028	C0017337
28480148	1011	1021	limitation	T169	C0449295
28480148	1062	1100	analysis of viral metagenomic datasets	T059	C3854164
28480148	1102	1107	BLAST	T170	C2698333
28480148	1127	1160	integrating the sequence identity	T170	C2359783
28480148	1165	1185	length of alignments	T063	C0080143
28480148	1199	1215	taxonomic signal	T169	C0008903
28480148	1227	1236	each gene	T028	C0017337
28480148	1270	1289	information content	T078	C1533716
28480148	1304	1323	quantifiable metric	T081	C0025867
28480148	1325	1336	predictions	T078	C0681842
28480148	1340	1355	viral community	T001	C1956108
28480148	1400	1416	proof-of-concept	T078	C1254370
28480148	1450	1461	implemented	T052	C1708476
28480148	1483	1511	freshwater viral metagenomes	T028	C2717745
28480148	1531	1544	robust method	T080	C2986815
28480148	1560	1582	viral metagenomic data	T090	C2717799
28480148	1588	1592	tool	T170	C0037589
28480148	1596	1605	versatile	T080	C0205556
28480148	1624	1634	customized	T052	C1880202
28480148	1638	1652	investigations	T058	C1261322
28480148	1660	1671	environment	T082	C0014406
28480148	1675	1680	biome	T001	C1956108

27683502|t|Harmonization of Clinical Laboratory Information - Current and Future Strategies
27683502|a|According to a patient -centered viewpoint, the meaning of harmonization in the context of laboratory medicine is that the information should be comparable irrespective of the measurement procedure used and where and/or when a measurement is made. Harmonization represents a fundamental aspect of quality in laboratory medicine as its ultimate goal is to improve patient outcomes through the provision of an accurate and actionable laboratory information. Although the initial focus has to a large extent been to harmonize and standardize analytical processes and methods, the scope of harmonization goes beyond to include all other aspects of the total testing process (TTP), such as terminology and units, report formats, reference intervals and decision limits, as well as tests and test profiles request and criteria for interpretation. Two major progresses have been made in the area of harmonization in laboratory medicine: first, the awareness that harmonization should take into consideration not only the analytical phase but all steps of the TTP, thus dealing with the request, the sample, the measurement, and the report. Second, as the processes required to achieve harmonization are complicated, a systematic approach is needed. The International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) has played a fundamental and successful role in the development of standardized and harmonized assays, and now it should continue to work in the field through the collaboration and cooperation with many other stakeholders.
27683502	0	13	Harmonization	T067	C1522240
27683502	17	36	Clinical Laboratory	T073,T093	C1551301
27683502	37	48	Information	T078	C1533716
27683502	51	58	Current	T079	C0521116
27683502	63	69	Future	T079	C0016884
27683502	70	80	Strategies	T062	C0035171
27683502	96	103	patient	T101	C0030705
27683502	114	123	viewpoint	T170	C0282411
27683502	140	153	harmonization	T067	C1522240
27683502	161	168	context	T078	C0449255
27683502	172	182	laboratory	T073,T093	C0022877
27683502	183	191	medicine	T121	C0013227
27683502	204	215	information	T078	C1533716
27683502	226	236	comparable	T052	C1707455
27683502	257	268	measurement	T169	C0242485
27683502	269	278	procedure	T169	C2700391
27683502	308	319	measurement	T169	C0242485
27683502	329	342	Harmonization	T067	C1522240
27683502	356	374	fundamental aspect	T080	C1879746
27683502	378	385	quality	T080	C0332306
27683502	389	399	laboratory	T073,T093	C0022877
27683502	400	408	medicine	T121	C0013227
27683502	416	429	ultimate goal	T170	C0018017
27683502	436	443	improve	T080	C1272747
27683502	444	460	patient outcomes	T078	C1547647
27683502	489	497	accurate	T080	C0443131
27683502	513	523	laboratory	T073,T093	C0022877
27683502	524	535	information	T078	C1533716
27683502	573	585	large extent	T080	C1555602
27683502	594	603	harmonize	T067	C1522240
27683502	608	619	standardize	T080	C1442989
27683502	620	640	analytical processes	T067	C1522240
27683502	645	652	methods	T170	C0025663
27683502	658	663	scope	T077	C1710028
27683502	667	680	harmonization	T067	C1522240
27683502	714	721	aspects	T080	C1879746
27683502	729	750	total testing process	T067	C1522240
27683502	752	755	TTP	T067	C1522240
27683502	766	777	terminology	T170	C0028275
27683502	782	787	units	T081	C0439148
27683502	789	803	report formats	T170	C2919829
27683502	805	824	reference intervals	T081	C0086715
27683502	829	837	decision	T041	C0679006
27683502	838	844	limits	T169	C0439801
27683502	857	862	tests	T170	C0392366
27683502	867	880	test profiles	T059	C0200378
27683502	881	888	request	T052	C1272683
27683502	893	901	criteria	T078	C0243161
27683502	906	920	interpretation	T170	C0459471
27683502	932	942	progresses	T169	C1280477
27683502	973	986	harmonization	T067	C1522240
27683502	990	1009	laboratory medicine	T091	C0025118
27683502	1037	1050	harmonization	T067	C1522240
27683502	1095	1111	analytical phase	T062	C0936012
27683502	1133	1136	TTP	T067	C1522240
27683502	1160	1167	request	T052	C1272683
27683502	1173	1179	sample	T167	C0370003
27683502	1185	1196	measurement	T169	C0242485
27683502	1206	1212	report	T170	C0684224
27683502	1229	1238	processes	T067	C1522240
27683502	1259	1272	harmonization	T067	C1522240
27683502	1277	1288	complicated	T169	C0231242
27683502	1292	1302	systematic	T169	C0220922
27683502	1303	1311	approach	T082	C0449445
27683502	1315	1321	needed	T080	C0027552
27683502	1327	1397	International Federation of Clinical Chemistry and Laboratory Medicine	T059	C2964654
27683502	1399	1403	IFCC	T059	C2964654
27683502	1457	1468	development	T169	C1527148
27683502	1472	1484	standardized	T080	C1442989
27683502	1489	1506	harmonized assays	T059	C0005507
27683502	1526	1534	continue	T078	C0549178
27683502	1550	1555	field	T077	C1521738
27683502	1568	1581	collaboration	T054	C0282116
27683502	1586	1597	cooperation	T054	C0392337
27683502	1614	1626	stakeholders	T098	C0027361

27482676|t|Lipid digestibility and energy content of distillers' corn oil in swine and poultry
27482676|a|Two experiments were conducted to determine the DE and ME and apparent total tract digestibility of ether extract of 3 distillers' corn oil (DCO; 4.9, 12.8, or 13.9% free fatty acids [FFA]) samplescompared with a sample of refined corn oil (CO; 0.04% FFA) and an industrially hydrolyzed high-FFA DCO (93.8% FFA) in young pigs and growing broilers. In Exp. 1, 54 barrows (initial age = 28 d) were fed a common diet for 7 d and then fed their allotted dietary treatment (either 100% basal diet or 1 of 5 test diets consisting of 90% basal diet plus 10% test lipid) for the next 7 d in group pens (9 pigs / pen). For the next 10 d, pigs were moved to individual metabolism crates for continued diet and crate adaptation and to a twice-daily feeding regimen. Pigs remained on their respective diets for a 4-d total fecal and urine collection period. For Exp. 2, 567 male broilers were obtained from a commercial hatchery (1 d of age) and reared in grower battery cages that contained 9 chicks per cage. Broilers were fed a common corn - soybean meal starter diet from placement until the beginning of the trial (19 d of age). Birds were then randomly assigned to 1 of 6 dietary treatments (94% basal diet plus 6% dextrose or 94% basal diet plus 6% test lipid substituted for dextrose) on d 19 and were allowed an 8-d dietary acclimation period followed by a 48-h energy balance assay. In Exp. 1, the DCO sample with 12.8% FFA contained the lowest (< 0.05) DE (8,036 kcal/kg) content compared with the 0.04% refined CO sample and the 4.9 or 93.8% FFA DCO samples (8,814, 8,828, and 8,921 kcal/kg, respectively), with the DCO source containing 13.9% FFA having intermediate DE (8,465 kcal/kg) content. The ME content of these lipid sources also differed among treatments (< 0.01), following trends similar to their DE values, with no differences noted for ME as a percentage of DE (> 0.35) content among the lipids evaluated. In Exp. 2, lipids containing 0.04, 4.9, 12.8, and 13.9% FFA had similar nitrogen corrected apparent ME (AME) values (8,072, 7,936, 8,036, and 7,694 respectively), except for the industrially hydrolyzed DCO sample containing 93.8% FFA, which contained 6,276 kcal/kg (< 0.01). Using published prediction equations, the predicted DE of these lipids for swine was 3.5% greater than the values determined in Exp. 1 for all lipid sources, except for the DCO sample containing 93.8% FFA, which the predicted DE was underestimated. Likewise, the predicted AME of these lipids for broilers was 7.4% greater than the determined AMEn (Exp. 2) for all lipid sources.
27482676	0	5	Lipid	T109,T168	C0012171
27482676	6	19	digestibility	T033	C0243095
27482676	24	38	energy content	T080	C3840479
27482676	42	53	distillers'	UnknownType	C0682260
27482676	54	62	corn oil	T109,T168	C0010029
27482676	66	71	swine	T015	C0039005
27482676	76	83	poultry	T012	C0032850
27482676	88	99	experiments	T062	C0681814
27482676	132	134	DE	T081	C0392762
27482676	139	141	ME	T081	C0392762
27482676	146	180	apparent total tract digestibility	T033	C0243095
27482676	184	189	ether	T109,T121	C0014994
27482676	190	197	extract	T167	C2828366
27482676	203	214	distillers'	UnknownType	C0682260
27482676	215	223	corn oil	T109,T168	C0010029
27482676	225	228	DCO	T109,T168	C0010029
27482676	250	266	free fatty acids	T109	C0015688
27482676	268	271	FFA	T109	C0015688
27482676	297	303	sample	T167	C0370003
27482676	307	323	refined corn oil	T109,T168	C0010029
27482676	325	327	CO	T109,T168	C0010029
27482676	335	338	FFA	T109	C0015688
27482676	347	359	industrially	T057	C0021267
27482676	360	379	hydrolyzed high-FFA	T109	C0015688
27482676	380	383	DCO	T109,T168	C0010029
27482676	391	394	FFA	T109	C0015688
27482676	399	404	young	T079	C0332239
27482676	405	409	pigs	T015	C0039005
27482676	414	430	growing broilers	T012	C2698565
27482676	446	453	barrows	T015	C3669473
27482676	463	466	age	T032	C0001779
27482676	480	483	fed	T052	C2987508
27482676	486	492	common	T081	C0205214
27482676	493	497	diet	T168	C0012155
27482676	515	518	fed	T052	C2987508
27482676	534	541	dietary	T168	C0012155
27482676	542	551	treatment	T052	C2987508
27482676	565	575	basal diet	T168	C2983588
27482676	586	596	test diets	T061	C0452401
27482676	615	625	basal diet	T168	C2983588
27482676	626	630	plus	T169	C0332287
27482676	640	645	lipid	T109,T168	C0012171
27482676	667	677	group pens	T073	C3273359
27482676	681	685	pigs	T015	C0039005
27482676	688	691	pen	T073	C3273359
27482676	713	717	pigs	T015	C0039005
27482676	743	760	metabolism crates	T073	C3273359
27482676	765	774	continued	T078	C0549178
27482676	775	779	diet	T168	C0012155
27482676	784	789	crate	T073	C3273359
27482676	790	800	adaptation	T040	C0000934
27482676	810	821	twice-daily	T079	C0585361
27482676	822	837	feeding regimen	T061	C1627346
27482676	839	843	Pigs	T015	C0039005
27482676	873	878	diets	T168	C0012155
27482676	889	894	total	T080	C0439810
27482676	895	900	fecal	T058	C0455051
27482676	905	921	urine collection	T059	C0200354
27482676	922	928	period	T079	C1948053
27482676	946	950	male	T032	C0086582
27482676	951	959	broilers	T012	C2698565
27482676	965	973	obtained	T169	C1301820
27482676	981	1000	commercial hatchery	T092	C1880147
27482676	1009	1012	age	T032	C0001779
27482676	1018	1024	reared	T054	C0870148
27482676	1028	1048	grower battery cages	T073	C0179512
27482676	1054	1063	contained	T169	C0332256
27482676	1066	1072	chicks	T012	C3669416
27482676	1077	1081	cage	T073	C0179512
27482676	1083	1091	Broilers	T012	C2698565
27482676	1097	1100	fed	T052	C2987508
27482676	1103	1109	common	T081	C0205214
27482676	1110	1114	corn	T002	C0010028
27482676	1117	1124	soybean	T168	C0037733
27482676	1125	1129	meal	T056	C1998602
27482676	1130	1142	starter diet	T168	C0012155
27482676	1148	1157	placement	T058	C1533810
27482676	1168	1177	beginning	T079	C0439659
27482676	1185	1190	trial	T062	C0681815
27482676	1200	1203	age	T032	C0001779
27482676	1206	1211	Birds	T012	C0005595
27482676	1222	1230	randomly	T080	C0439605
27482676	1231	1239	assigned	T169	C1516050
27482676	1250	1257	dietary	T168	C0012155
27482676	1258	1268	treatments	T052	C2987508
27482676	1274	1284	basal diet	T168	C2983588
27482676	1285	1289	plus	T169	C0332287
27482676	1293	1301	dextrose	T109,T121,T123	C0017725
27482676	1309	1319	basal diet	T168	C2983588
27482676	1320	1324	plus	T169	C0332287
27482676	1333	1338	lipid	T109,T168	C0012171
27482676	1355	1363	dextrose	T109,T121,T123	C0017725
27482676	1397	1404	dietary	T168	C0012155
27482676	1405	1416	acclimation	T040	C0000934
27482676	1417	1423	period	T079	C1948053
27482676	1424	1435	followed by	T079	C0332283
27482676	1443	1463	energy balance assay	T059	C1510438
27482676	1480	1483	DCO	T109,T168	C0010029
27482676	1484	1490	sample	T167	C0370003
27482676	1502	1505	FFA	T109	C0015688
27482676	1506	1515	contained	T169	C0332256
27482676	1520	1526	lowest	T080	C1708760
27482676	1536	1538	DE	T081	C0392762
27482676	1555	1562	content	T077	C0456205
27482676	1563	1571	compared	T052	C1707455
27482676	1587	1597	refined CO	T109,T168	C0010029
27482676	1598	1604	sample	T167	C0370003
27482676	1626	1629	FFA	T109	C0015688
27482676	1630	1633	DCO	T109,T168	C0010029
27482676	1634	1641	samples	T167	C0370003
27482676	1700	1703	DCO	T109,T168	C0010029
27482676	1704	1710	source	T033	C0449416
27482676	1711	1721	containing	T169	C0332256
27482676	1728	1731	FFA	T109	C0015688
27482676	1739	1751	intermediate	T082	C0205103
27482676	1752	1754	DE	T081	C0392762
27482676	1771	1778	content	T077	C0456205
27482676	1784	1794	ME content	T081	C0392762
27482676	1804	1809	lipid	T109,T168	C0012171
27482676	1810	1817	sources	T033	C0449416
27482676	1838	1848	treatments	T052	C2987508
27482676	1859	1868	following	T079	C0332282
27482676	1876	1883	similar	T080	C2348205
27482676	1893	1902	DE values	T081	C0392762
27482676	1909	1923	no differences	T033	C3842396
27482676	1934	1936	ME	T081	C0392762
27482676	1942	1952	percentage	T081	C0439165
27482676	1956	1958	DE	T081	C0392762
27482676	1968	1975	content	T077	C0456205
27482676	1986	1992	lipids	T109,T168	C0012171
27482676	1993	2002	evaluated	T052	C1516048
27482676	2015	2021	lipids	T109,T168	C0012171
27482676	2022	2032	containing	T169	C0332256
27482676	2060	2063	FFA	T109	C0015688
27482676	2068	2075	similar	T080	C2348205
27482676	2076	2106	nitrogen corrected apparent ME	T081	C0392762
27482676	2108	2111	AME	T081	C0392762
27482676	2113	2119	values	T081	C1522609
27482676	2182	2209	industrially hydrolyzed DCO	T109,T168	C0010029
27482676	2210	2216	sample	T167	C0370003
27482676	2217	2227	containing	T169	C0332256
27482676	2234	2237	FFA	T109	C0015688
27482676	2245	2254	contained	T169	C0332256
27482676	2285	2294	published	T057	C0034037
27482676	2295	2315	prediction equations	T077	C0552449
27482676	2321	2330	predicted	T078	C0681842
27482676	2331	2333	DE	T081	C0392762
27482676	2343	2349	lipids	T109,T168	C0012171
27482676	2354	2359	swine	T015	C0039005
27482676	2369	2376	greater	T081	C1704243
27482676	2386	2392	values	T081	C1522609
27482676	2422	2427	lipid	T109,T168	C0012171
27482676	2428	2435	sources	T033	C0449416
27482676	2452	2455	DCO	T109,T168	C0010029
27482676	2456	2462	sample	T167	C0370003
27482676	2463	2473	containing	T169	C0332256
27482676	2480	2483	FFA	T109	C0015688
27482676	2495	2504	predicted	T078	C0681842
27482676	2505	2507	DE	T081	C0392762
27482676	2542	2551	predicted	T078	C0681842
27482676	2552	2555	AME	T081	C0392762
27482676	2565	2571	lipids	T109,T168	C0012171
27482676	2576	2584	broilers	T012	C2698565
27482676	2594	2601	greater	T081	C1704243
27482676	2622	2626	AMEn	T081	C0392762
27482676	2644	2649	lipid	T109,T168	C0012171
27482676	2650	2657	sources	T033	C0449416

28292240|t|Bioactive Metabolites from Pathogenic and Endophytic Fungi of Forest Trees
28292240|a|Fungi play an important role in terrestrial ecosystems interacting positively or negatively with plants. These interactions are complex and the outcomes are different depending on the fungal lifestyles, saprotrophic, mutualistic or pathogenic. Furthermore, fungi are well known for producing secondary metabolites, originating from different biosynthetic pathways, which possess biological properties of considerable biotechnological interest. Among the terrestrial ecosystems, temperate forests represent an enormous reservoir of fungal diversity. This review will highlight the goldmine of secondary metabolites produced by pathogenic and endophytic fungi of forest trees with focus on their biological activities.
28292240	0	21	Bioactive Metabolites	T123	C0870883
28292240	27	37	Pathogenic	T004	C3826297
28292240	42	52	Endophytic	T033	C3842357
28292240	53	58	Fungi	T004	C0016832
28292240	62	68	Forest	T070	C0086312
28292240	69	74	Trees	T002	C0040811
28292240	75	80	Fungi	T004	C0016832
28292240	107	129	terrestrial ecosystems	T070	C0162358
28292240	172	178	plants	T002	C0032098
28292240	186	198	interactions	T169	C1704675
28292240	203	210	complex	T080	C0439855
28292240	259	265	fungal	T004	C0016832
28292240	266	276	lifestyles	T054	C0023676
28292240	278	290	saprotrophic	T001	C0562637
28292240	292	303	mutualistic	T070	C0599514
28292240	307	317	pathogenic	T032	C1136169
28292240	332	337	fungi	T004	C0016832
28292240	367	388	secondary metabolites	T123	C0870883
28292240	417	438	biosynthetic pathways	T044	C1721101
28292240	454	464	biological	T091	C0005532
28292240	465	475	properties	T080	C0871161
28292240	492	508	biotechnological	T091	C0005574
28292240	529	551	terrestrial ecosystems	T070	C0162358
28292240	553	570	temperate forests	T070	C0086312
28292240	593	602	reservoir	T083	C0442537
28292240	606	612	fungal	T004	C0016832
28292240	613	622	diversity	T080	C0282469
28292240	667	688	secondary metabolites	T123	C0870883
28292240	701	711	pathogenic	T004	C3826297
28292240	716	726	endophytic	T033	C3842357
28292240	727	732	fungi	T004	C0016832
28292240	736	742	forest	T070	C0086312
28292240	743	748	trees	T002	C0040811
28292240	769	779	biological	T091	C0005532
28292240	780	790	activities	T052	C0441655

28108814|t|The small neurotoxin apamin blocks not only small conductance Ca(2+) activated K(+) channels (SK type) but also the voltage dependent Kv1.3 channel
28108814|a|Apamin is frequently used as a specific blocker of small-conductance Ca(2+)-activated (SK type) K(+) channels. Here we show that the small neurotoxin is not as specific as anticipated. It is also a high-affinity inhibitor with an IC50 of 13 nM of the Kv1.3 channel; it blocks the latter with potency similar to the Kv1.3 blocker PAP-1. Since SK type channels and Kv1.3 channels are frequently coexpressed in different tissues such as cells of the immune system, apamin must be used with caution as a pharmacological tool.
28108814	4	9	small	T081	C0700321
28108814	10	20	neurotoxin	T131	C0027934
28108814	21	27	apamin	T116,T123,T131	C0003521
28108814	28	34	blocks	T169	C0332206
28108814	44	92	small conductance Ca(2+) activated K(+) channels	T116,T123	C1571638
28108814	94	101	SK type	T116,T123	C1571638
28108814	116	133	voltage dependent	T043	C1160359
28108814	134	147	Kv1.3 channel	T116,T123	C0290730
28108814	148	154	Apamin	T116,T123,T131	C0003521
28108814	158	168	frequently	T079	C0332183
28108814	179	187	specific	T080	C0205369
28108814	188	195	blocker	T121	C0872245
28108814	199	257	small-conductance Ca(2+)-activated (SK type) K(+) channels	T116,T123	C1571638
28108814	281	286	small	T081	C0700321
28108814	287	297	neurotoxin	T131	C0027934
28108814	308	316	specific	T080	C0205369
28108814	320	331	anticipated	T033	C3840775
28108814	346	369	high-affinity inhibitor	T121	C0872245
28108814	378	382	IC50	T081	C0600495
28108814	399	412	Kv1.3 channel	T116,T123	C0290730
28108814	417	423	blocks	T169	C0332206
28108814	463	476	Kv1.3 blocker	T121	C0872245
28108814	477	482	PAP-1	T109	C1568197
28108814	490	506	SK type channels	T116,T123	C1571638
28108814	511	525	Kv1.3 channels	T116,T123	C0290730
28108814	530	540	frequently	T079	C0332183
28108814	541	552	coexpressed	T045	C1171362
28108814	556	565	different	T080	C1705242
28108814	566	573	tissues	T024	C0040300
28108814	582	587	cells	T025	C0007634
28108814	595	608	immune system	T022	C0020962
28108814	610	616	apamin	T116,T123,T131	C0003521
28108814	625	642	used with caution	T169	C1710588
28108814	648	668	pharmacological tool	T121	C1254351

27692888|t|Effective degradation of methylisothiazolone biocide using ozone: Kinetics, mechanisms, and decreases in toxicity
27692888|a|Methylisothiazolone (MIT) is a common biocide that is widely used in water-desalination reverse-osmosis processes. The transformation of MIT during water treatment processes is poorly understood. The kinetics and mechanisms involved in the degradation of MIT during ozonation were investigated in this study. Ozonation was found to be a useful way of degrading MIT in water, and the degradation rate constant was 0.11 (±0.1) × 10(3) L/(mol·s). The degradation rate constant did not change when the pH was increased from 3 to 9. The pre-exponential factor A and the activation energy Ea for the ozonation process were 7.564 × 10(13) L/(mol·s) and 66.74 kJ/mol, respectively. The decrease in the MIT concentration and the amount of ozone consumed were measured, and the stoichiometric factor α for the ozone consumption to MIT removal ratio was found to be 1.8. Several ozonation products were detected using time-of-flight mass spectrometry. Almost 32% of the organic sulfur in the MIT was oxidized to release sulfate ions, which caused a decrease in pH. Sulfur atoms were oxidized to sulfone species and then h ydrolyzed to give sulfate during ozonation. Addition reactions involving carbon-carbon double bonds and the oxidation of α-carbon atoms also occurred. MIT was found to be lethal to Daphnia magna Straus (D. magna) with a median lethal concentration of 18.2 μmol/L. Even though the primary ozonation products of MIT still showed some toxicity to D. magna, ozone could minimize the toxic effect after a long reaction time.
27692888	10	21	degradation	T169	C0243125
27692888	25	44	methylisothiazolone	T109,T121	C0046343
27692888	45	52	biocide	T131	C0444414
27692888	59	64	ozone	T103	C0030106
27692888	66	74	Kinetics	T070	C0022702
27692888	76	86	mechanisms	T169	C0458005
27692888	92	101	decreases	T081	C0547047
27692888	105	113	toxicity	T037	C0600688
27692888	114	133	Methylisothiazolone	T109,T121	C0046343
27692888	135	138	MIT	T109,T121	C0046343
27692888	152	159	biocide	T131	C0444414
27692888	183	201	water-desalination	T057	C0597684
27692888	202	227	reverse-osmosis processes	T067	C0678629
27692888	233	247	transformation	T169	C0439836
27692888	251	254	MIT	T109,T121	C0046343
27692888	262	277	water treatment	T057	C0597684
27692888	278	287	processes	T067	C1522240
27692888	314	322	kinetics	T070	C0022702
27692888	327	337	mechanisms	T169	C0458005
27692888	354	365	degradation	T169	C0243125
27692888	369	372	MIT	T109,T121	C0046343
27692888	380	389	ozonation	T067	C1254366
27692888	416	421	study	T062	C2603343
27692888	423	432	Ozonation	T067	C1254366
27692888	475	478	MIT	T109,T121	C0046343
27692888	482	487	water	T121,T197	C0043047
27692888	497	508	degradation	T169	C0243125
27692888	509	522	rate constant	T081	C2986811
27692888	562	573	degradation	T169	C0243125
27692888	574	587	rate constant	T081	C2986811
27692888	612	614	pH	T081	C0020283
27692888	619	628	increased	T081	C0205217
27692888	646	670	pre-exponential factor A	T081	C0392762
27692888	679	696	activation energy	T081	C1442080
27692888	697	699	Ea	T081	C1442080
27692888	708	725	ozonation process	T067	C1254366
27692888	792	800	decrease	T081	C0547047
27692888	808	811	MIT	T109,T121	C0046343
27692888	812	825	concentration	T081	C1446561
27692888	834	840	amount	T081	C1265611
27692888	844	849	ozone	T103	C0030106
27692888	864	872	measured	T080	C0444706
27692888	882	903	stoichiometric factor	T081	C0392762
27692888	904	905	α	T081	C0392762
27692888	914	919	ozone	T103	C0030106
27692888	935	938	MIT	T109,T121	C0046343
27692888	982	991	ozonation	T067	C1254366
27692888	992	1000	products	T071	C1514468
27692888	1021	1053	time-of-flight mass spectrometry	T059	C0599827
27692888	1073	1087	organic sulfur	T121,T123,T196	C0038774
27692888	1095	1098	MIT	T109,T121	C0046343
27692888	1103	1111	oxidized	T044	C0030011
27692888	1123	1135	sulfate ions	T196	C3536965
27692888	1152	1160	decrease	T081	C0547047
27692888	1164	1166	pH	T081	C0020283
27692888	1168	1180	Sulfur atoms	T121,T123,T196	C0038774
27692888	1186	1194	oxidized	T044	C0030011
27692888	1198	1213	sulfone species	T109,T121	C0038761
27692888	1225	1234	ydrolyzed	T070	C0020291
27692888	1243	1250	sulfate	T196	C3536965
27692888	1258	1267	ozonation	T067	C1254366
27692888	1269	1287	Addition reactions	T067	C0596304
27692888	1298	1324	carbon-carbon double bonds	T044	C0813982
27692888	1333	1342	oxidation	T044	C0030011
27692888	1346	1354	α-carbon	T196	C0007009
27692888	1355	1360	atoms	T196	C0567415
27692888	1376	1379	MIT	T109,T121	C0046343
27692888	1396	1402	lethal	T033	C3151529
27692888	1406	1426	Daphnia magna Straus	T204	C1081963
27692888	1428	1436	D. magna	T204	C1081963
27692888	1452	1458	lethal	T033	C3151529
27692888	1459	1472	concentration	T081	C1446561
27692888	1513	1522	ozonation	T067	C1254366
27692888	1523	1531	products	T071	C1514468
27692888	1535	1538	MIT	T109,T121	C0046343
27692888	1557	1565	toxicity	T037	C0600688
27692888	1569	1577	D. magna	T204	C1081963
27692888	1579	1584	ozone	T103	C0030106
27692888	1591	1599	minimize	T080	C0392756
27692888	1604	1616	toxic effect	T037	C0600688
27692888	1625	1629	long	T080	C0205166
27692888	1630	1643	reaction time	T079	C0034746

28396298|t|TGF-β1 functional polymorphisms: a review
28396298|a|Transforming Growth Factor β (TGF-β) is a multifunctional cytokine that plays a role in several biological processes. TGF-β1 is the most abundantly expressed isoform, associated with susceptibility to various diseases, and several polymorphisms have been described in the TGF-β1 gene structure, and some of them have been associated with functional implications. To date, eight single-nucleotide polymorphisms (SNPs) and one deletion / insertion polymorphism have been shown to affect TGF-β1 expression (rs2317130, rs11466313, rs1800468, rs1800469, rs11466314, rs1800471, rs1800470, and rs11466316); some of these interfere with transcriptional regulation by affecting the binding of transcription factors binding, while others interfere with protein production. These polymorphisms have been associated with different types of diseases (i.e., cancers, cardiac diseases, inflammatory diseases, and others) and could therefore be used as susceptibility biomarkers. Since polymorphism clusters are likely to be more reliable than single polymorphisms in this respect, it is hoped that haplotype analysis of TGF-β1 may reveal the genetic basis of disease susceptibility associated with the TGF-β1 gene.
28396298	0	6	TGF-β1	T028	C1366557
28396298	7	31	functional polymorphisms	T045	C0678951
28396298	35	41	review	T170	C0282443
28396298	42	70	Transforming Growth Factor β	T116,T123	C0040690
28396298	72	77	TGF-β	T116,T123	C0040690
28396298	84	99	multifunctional	T169	C0205245
28396298	100	108	cytokine	T116,T129	C0079189
28396298	138	158	biological processes	T038	C3714634
28396298	160	166	TGF-β1	T028	C1366557
28396298	200	207	isoform	T116	C0597298
28396298	209	224	associated with	T080	C0332281
28396298	225	239	susceptibility	T201	C0012655
28396298	251	259	diseases	T047	C0012634
28396298	273	286	polymorphisms	T045	C0678951
28396298	314	325	TGF-β1 gene	T028	C1366557
28396298	326	335	structure	T028	C1517495
28396298	364	379	associated with	T080	C0332281
28396298	420	451	single-nucleotide polymorphisms	T086	C0752046
28396298	453	457	SNPs	T086	C0752046
28396298	467	475	deletion	T045	C0017260
28396298	478	487	insertion	T049	C1955829
28396298	488	500	polymorphism	T045	C0678951
28396298	527	533	TGF-β1	T028	C1366557
28396298	534	544	expression	T045	C0017262
28396298	546	555	rs2317130	T045	C0017262
28396298	557	567	rs11466313	T045	C0017262
28396298	569	578	rs1800468	T045	C0017262
28396298	580	589	rs1800469	T045	C0017262
28396298	591	601	rs11466314	T045	C0017262
28396298	603	612	rs1800471	T045	C0017262
28396298	614	623	rs1800470	T045	C0017262
28396298	629	639	rs11466316	T045	C0017262
28396298	656	670	interfere with	T169	C0521102
28396298	671	697	transcriptional regulation	T045	C1158770
28396298	715	722	binding	T044	C0033618
28396298	726	747	transcription factors	T116,T123	C0040648
28396298	748	755	binding	T044	C0033618
28396298	770	784	interfere with	T169	C0521102
28396298	785	792	protein	T116,T123	C0033684
28396298	785	803	protein production	T044	C1148560
28396298	811	824	polymorphisms	T045	C0678951
28396298	835	850	associated with	T080	C0332281
28396298	861	878	types of diseases	T170	C0457464
28396298	886	893	cancers	T191	C0006826
28396298	895	911	cardiac diseases	T047	C0018799
28396298	913	934	inflammatory diseases	T047	C1290884
28396298	979	993	susceptibility	T201	C0012655
28396298	994	1004	biomarkers	T201	C0005516
28396298	1012	1024	polymorphism	T045	C0678951
28396298	1025	1033	clusters	T028	C0017258
28396298	1070	1090	single polymorphisms	T086	C0752046
28396298	1125	1134	haplotype	T032	C0018591
28396298	1147	1153	TGF-β1	T028	C1366557
28396298	1186	1208	disease susceptibility	T201	C0012655
28396298	1209	1224	associated with	T080	C0332281
28396298	1229	1240	TGF-β1 gene	T028	C1366557

27935268|t|Characterization of Contributing Factors to Variability in Morphine Clearance Through PBPK Modeling Implemented With OCT1 Transporter
27935268|a|Morphine shows large interindividual variability in its pharmacokinetics; however, the cause of this has not been fully addressed. The variability in morphine disposition is considered to be due to a combination of pharmacogenetic and physiological determinants related to morphine disposition. We previously reported the effect of organic cation transporter (OCT1) genotype on morphine disposition in pediatric patients. To further explore the underlying mechanisms for variability arising from relevant determinants, including OCT1, a physiologically based pharmacokinetic (PBPK) model of morphine was developed. The PBPK model predicted morphine concentration-time profiles well, in both adults and children. Almost all of the observed morphine clearances in pediatric patients fell within a twofold range of median predicted values for each OCT1 genotype in each age group. This PBPK modeling approach quantitatively demonstrates that OCT1 genotype, age-related growth, and changes in blood flow as important contributors to morphine pharmacokinetic (PK) variability.
27935268	0	16	Characterization	T052	C1880022
27935268	20	32	Contributing	T052	C1880177
27935268	33	40	Factors	T169	C1521761
27935268	44	55	Variability	T077	C2827666
27935268	59	67	Morphine	T109,T121	C0026549
27935268	68	77	Clearance	T201	C1382187
27935268	86	99	PBPK Modeling	T062	C0201734
27935268	117	133	OCT1 Transporter	T116,T123	C0291786
27935268	134	142	Morphine	T109,T121	C0026549
27935268	171	182	variability	T077	C2827666
27935268	190	206	pharmacokinetics	T169	C0031328
27935268	269	280	variability	T077	C2827666
27935268	284	292	morphine	T109,T121	C0026549
27935268	293	304	disposition	T039	C0678755
27935268	349	364	pharmacogenetic	T169	C0031328
27935268	369	382	physiological	T169	C0205463
27935268	383	395	determinants	T169	C1521761
27935268	407	415	morphine	T109,T121	C0026549
27935268	416	427	disposition	T039	C0678755
27935268	466	492	organic cation transporter	T116,T123	C0291786
27935268	494	498	OCT1	T116,T123	C0291786
27935268	500	508	genotype	T032	C0017431
27935268	512	520	morphine	T109,T121	C0026549
27935268	521	532	disposition	T039	C0678755
27935268	536	545	pediatric	T080	C1521725
27935268	546	554	patients	T101	C0030705
27935268	590	600	mechanisms	T169	C0441712
27935268	605	616	variability	T077	C2827666
27935268	639	651	determinants	T169	C1521761
27935268	663	667	OCT1	T116,T123	C0291786
27935268	671	686	physiologically	T169	C0205463
27935268	693	721	pharmacokinetic (PBPK) model	T062	C0201734
27935268	725	733	morphine	T109,T121	C0026549
27935268	753	763	PBPK model	T062	C0201734
27935268	774	782	morphine	T109,T121	C0026549
27935268	802	810	profiles	T081	C0237801
27935268	825	831	adults	T100	C0001675
27935268	836	844	children	T100	C0008059
27935268	873	881	morphine	T109,T121	C0026549
27935268	882	892	clearances	T201	C1382187
27935268	896	905	pediatric	T080	C1521725
27935268	906	914	patients	T101	C0030705
27935268	979	983	OCT1	T116,T123	C0291786
27935268	984	992	genotype	T032	C0017431
27935268	1001	1010	age group	T100	C0027362
27935268	1017	1030	PBPK modeling	T062	C0201734
27935268	1073	1077	OCT1	T116,T123	C0291786
27935268	1078	1086	genotype	T032	C0017431
27935268	1088	1106	age-related growth	T040	C0018270
27935268	1123	1133	blood flow	T039	C0232338
27935268	1147	1159	contributors	T098	C1257890
27935268	1163	1171	morphine	T109,T121	C0026549
27935268	1172	1187	pharmacokinetic	T169	C0031328
27935268	1189	1191	PK	T169	C0031328
27935268	1193	1204	variability	T077	C2827666

28444830|t|Gene expression reveals evidence for EGFR -dependent proximal-distal limb patterning in a myriapod
28444830|a|Evolution of segmented limbs is one of the key innovations of Arthropoda, allowing development of functionally specific specialized head and trunk appendages, a major factor behind their unmatched evolutionary success. Proximodistal limb patterning is controlled by two regulatory networks in the vinegar fly Drosophila melanogaster, and other insects. The first is represented by the function of the morphogens Wingless (Wg) and Decapentaplegic (Dpp); the second by the EGFR-signaling cascade. While the role of Wg and Dpp has been studied in a wide range of arthropods representing all main branches, that is, Pancrustacea (= Hexapoda + Crustacea), Myriapoda and Chelicerata, investigation of the potential role of EGFR-signaling is restricted to insects (Hexapoda). Gene expression analysis of Egfr, its potential ligands, and putative downstream factors in the pill millipede Glomeris marginata (Myriapoda: Diplopoda), reveals that-in at least mandibulate arthropods - EGFR-signaling is likely a conserved regulatory mechanism in proximodistal limb patterning.
28444830	0	15	Gene expression	T045	C0017262
28444830	24	32	evidence	T078	C3887511
28444830	37	41	EGFR	T116,T126,T192	C0034802
28444830	53	73	proximal-distal limb	T023	C0015385
28444830	74	84	patterning	T045	C0376678
28444830	90	98	myriapod	T204	C0597910
28444830	99	108	Evolution	T045	C0015219
28444830	112	127	segmented limbs	T023	C0015385
28444830	161	171	Arthropoda	T204	C0003903
28444830	231	235	head	T029	C0018670
28444830	240	245	trunk	T029	C0460005
28444830	246	256	appendages	T023	C0598782
28444830	318	336	Proximodistal limb	T023	C0015385
28444830	337	347	patterning	T045	C0376678
28444830	369	388	regulatory networks	T044	C1720950
28444830	396	407	vinegar fly	T204	C0598324
28444830	408	431	Drosophila melanogaster	T204	C0013139
28444830	443	450	insects	T204	C0021585
28444830	500	510	morphogens	T123	C0566267
28444830	511	519	Wingless	T116	C0168282
28444830	521	523	Wg	T116	C0168282
28444830	529	544	Decapentaplegic	T116,T123	C0082344
28444830	546	549	Dpp	T116,T123	C0082344
28444830	570	592	EGFR-signaling cascade	T044	C1155379
28444830	612	614	Wg	T116	C0168282
28444830	619	622	Dpp	T116,T123	C0082344
28444830	632	639	studied	T062	C2603343
28444830	659	669	arthropods	T204	C0003903
28444830	711	723	Pancrustacea	T204	C1218615
28444830	727	735	Hexapoda	T204	C1095852
28444830	738	747	Crustacea	T204	C0010395
28444830	750	759	Myriapoda	T204	C0597910
28444830	764	775	Chelicerata	T204	C0998333
28444830	777	790	investigation	T169	C1292732
28444830	816	830	EGFR-signaling	T044	C1155379
28444830	848	855	insects	T204	C0021585
28444830	857	865	Hexapoda	T204	C1095852
28444830	868	892	Gene expression analysis	T063	C1880945
28444830	896	900	Egfr	T116,T126,T192	C0034802
28444830	906	915	potential	T080	C3245505
28444830	916	923	ligands	T103	C0023688
28444830	929	956	putative downstream factors	T116,T123	C0033684
28444830	964	978	pill millipede	T204	C0323823
28444830	979	997	Glomeris marginata	T204	C1023180
28444830	999	1008	Myriapoda	T204	C0597910
28444830	1010	1019	Diplopoda	T204	C0323823
28444830	1047	1058	mandibulate	T204	C1218616
28444830	1059	1069	arthropods	T204	C0003903
28444830	1072	1086	EGFR-signaling	T044	C1155379
28444830	1109	1129	regulatory mechanism	T033	C0243095
28444830	1133	1151	proximodistal limb	T023	C0015385
28444830	1152	1162	patterning	T045	C0376678

28315039|t|Ecology and Feeding Habits Drive Infection of Water Bugs with Mycobacterium ulcerans
28315039|a|Mycobacterium ulcerans (MU), the causative agent of Buruli ulcer, is present in a wide spectrum of environments, including terrestrial and aquatic ecosystems in tropical regions. The most promising studies on the epidemiological risk of this disease suggest that some ecological settings may favor infection of animals with MU including human. A species ' needs and impacts on resources and the environment, i.e., its ecological niche, may influence its susceptibility to be infected by this microbial form. For example, some Naucoridae may dive in fresh waters to prey upon infected animals and thus may get infected with MU. However, these studies have rarely considered that inference on the ecological settings favoring infection and transmission may be confounded because host carrier sister species have similar ecological niches, and potentially the same host - microbe interactions. Hence, a relationship between the ecological niche of Naucoridae and its infection with MU may be due to a symbiotic relationship between the host and the pathogen, rather than its ecological niche. To account for this confounding effect, we investigated the relationships between surrogates of the ecological niche of water bug species and their susceptibility to MU, by performing phylogenetic comparative analyses on a large dataset of 11 families of water bugs collected in 10 different sites across Cameroon, central Africa. Our results indicate that MU circulates and infects a couple of host taxa, i.e., Belostomatidae, Naucoridae, living both in the aquatic vegetation and as predators inside the trophic network and sister species of water bugs have indeed similar host - microbe interactions with MU.
28315039	0	7	Ecology	T090	C0013546
28315039	12	26	Feeding Habits	T040	C0237617
28315039	33	42	Infection	T046	C3714514
28315039	46	56	Water Bugs	T204	C1004432
28315039	62	84	Mycobacterium ulcerans	T007	C0317759
28315039	85	107	Mycobacterium ulcerans	T007	C0317759
28315039	109	111	MU	T007	C0317759
28315039	118	133	causative agent	T033	C0449411
28315039	137	149	Buruli ulcer	T047	C0085568
28315039	154	161	present	T033	C0150312
28315039	167	171	wide	T082	C0332464
28315039	172	180	spectrum	T077	C2827424
28315039	184	196	environments	T082	C0014406
28315039	208	219	terrestrial	T070	C0162358
28315039	224	242	aquatic ecosystems	T067	C0563034
28315039	246	262	tropical regions	T083	C0017446
28315039	283	290	studies	T059	C0947630
28315039	298	313	epidemiological	T169	C1516907
28315039	314	318	risk	T078	C0035647
28315039	327	334	disease	T047	C0012634
28315039	353	372	ecological settings	T077	C0870460
28315039	383	392	infection	T046	C3714514
28315039	396	403	animals	T008	C0003062
28315039	409	411	MU	T007	C0317759
28315039	422	427	human	T016	C0086418
28315039	431	438	species	T185	C1705920
28315039	441	446	needs	T080	C0027552
28315039	451	458	impacts	T080	C4049986
28315039	462	471	resources	T078	C0027492
28315039	480	491	environment	T082	C0014406
28315039	503	519	ecological niche	T082	C0565987
28315039	525	534	influence	T077	C4054723
28315039	539	553	susceptibility	T201	C0012655
28315039	560	568	infected	T033	C0439663
28315039	577	591	microbial form	T001	C0599840
28315039	611	621	Naucoridae	T204	C1488019
28315039	626	630	dive	T056	C0012823
28315039	634	646	fresh waters	T167	C0016710
28315039	650	654	prey	T052	C3853577
28315039	660	668	infected	T033	C0439663
28315039	669	676	animals	T008	C0003062
28315039	694	702	infected	T033	C0439663
28315039	708	710	MU	T007	C0317759
28315039	727	734	studies	T059	C0947630
28315039	740	746	rarely	T080	C0522498
28315039	780	799	ecological settings	T077	C0870460
28315039	809	818	infection	T046	C3714514
28315039	823	835	transmission	T046	C0242781
28315039	843	853	confounded	T169	C0009673
28315039	862	889	host carrier sister species	T185	C1705920
28315039	903	920	ecological niches	T082	C0565987
28315039	926	937	potentially	T080	C3245505
28315039	947	951	host	T001	C1167395
28315039	954	961	microbe	T001	C0445623
28315039	962	974	interactions	T169	C1704675
28315039	985	997	relationship	T080	C0439849
28315039	1010	1026	ecological niche	T082	C0565987
28315039	1030	1040	Naucoridae	T204	C1488019
28315039	1049	1058	infection	T046	C3714514
28315039	1064	1066	MU	T007	C0317759
28315039	1083	1092	symbiotic	T169	C0231202
28315039	1093	1105	relationship	T080	C0439849
28315039	1118	1122	host	T001	C1167395
28315039	1131	1139	pathogen	T001	C0450254
28315039	1157	1173	ecological niche	T082	C0565987
28315039	1195	1213	confounding effect	T169	C0009673
28315039	1218	1230	investigated	T169	C1292732
28315039	1235	1248	relationships	T080	C0439849
28315039	1257	1267	surrogates	T099	C4053457
28315039	1275	1291	ecological niche	T082	C0565987
28315039	1295	1312	water bug species	T204	C1004432
28315039	1323	1337	susceptibility	T201	C0012655
28315039	1341	1343	MU	T007	C0317759
28315039	1348	1358	performing	T169	C0884358
28315039	1359	1392	phylogenetic comparative analyses	T062	C1519068
28315039	1404	1411	dataset	T170	C0150098
28315039	1418	1426	families	T077	C1704727
28315039	1430	1440	water bugs	T204	C1004432
28315039	1441	1450	collected	T169	C1516698
28315039	1457	1466	different	T080	C1705242
28315039	1467	1472	sites	T082	C0205145
28315039	1480	1488	Cameroon	T083	C0006802
28315039	1490	1504	central Africa	T083	C0001740
28315039	1510	1517	results	T034	C0456984
28315039	1518	1526	indicate	T078	C3146298
28315039	1532	1534	MU	T007	C0317759
28315039	1535	1545	circulates	T169	C0175630
28315039	1550	1557	infects	T033	C0439663
28315039	1570	1574	host	T001	C1167395
28315039	1575	1579	taxa	T169	C0008903
28315039	1587	1601	Belostomatidae	T204	C1007274
28315039	1603	1613	Naucoridae	T204	C1488019
28315039	1615	1621	living	T078	C0376558
28315039	1634	1641	aquatic	T067	C0563034
28315039	1642	1652	vegetation	T002	C0032098
28315039	1660	1669	predators	T001	C0029235
28315039	1681	1696	trophic network	T080	C2936391
28315039	1701	1715	sister species	T185	C1705920
28315039	1719	1729	water bugs	T204	C1004432
28315039	1750	1754	host	T001	C1167395
28315039	1757	1764	microbe	T001	C0445623
28315039	1765	1777	interactions	T169	C1704675
28315039	1783	1785	MU	T007	C0317759

28368267|t|Contextual Factors for Stunting Among Children of Age 6 to 24 Months in an Under-Privileged Community of Dhaka, Bangladesh
28368267|a|To determine factors associated with stunting among children aged 6 to 24 months in a slum of Dhaka, Bangladesh. We conducted this case control study during November 2009 to December 2012. Children were classified as case if length-for-age Z-score (LAZ) was <-2 and as control if LAZ was >-1 SD. The logistic regression model was used to find the factors associated with stunting. The significant risk factors for stunting were: child's age >12 months, maternal undernutrition, mother's education <5 years, consumption of untreated drinking water and monthly family income <100 USD. The findings of this study reiterated the role of maternal undernutrition and less education, consumption of untreated drinking water and poor family income as important associated factors of childhood stunting in resource-poor setting.
28368267	0	18	Contextual Factors	T041	C0542559
28368267	23	31	Stunting	T046	C0018273
28368267	38	46	Children	T100	C0008059
28368267	50	53	Age	T032	C0001779
28368267	62	68	Months	T079	C0439231
28368267	75	101	Under-Privileged Community	T096	C0009462
28368267	105	110	Dhaka	T083	C0004732
28368267	112	122	Bangladesh	T083	C0004732
28368267	136	143	factors	T169	C1521761
28368267	144	159	associated with	T080	C0332281
28368267	160	168	stunting	T046	C0018273
28368267	175	183	children	T100	C0008059
28368267	184	188	aged	T032	C0001779
28368267	197	203	months	T079	C0439231
28368267	209	213	slum	T080	C0037345
28368267	217	222	Dhaka	T083	C0004732
28368267	224	234	Bangladesh	T083	C0004732
28368267	254	272	case control study	T062	C0007328
28368267	312	320	Children	T100	C0008059
28368267	348	370	length-for-age Z-score	T081	C0871421
28368267	372	375	LAZ	T081	C0871421
28368267	392	399	control	T096	C0009932
28368267	403	406	LAZ	T081	C0871421
28368267	423	448	logistic regression model	UnknownType	C0681925
28368267	470	477	factors	T169	C1521761
28368267	478	493	associated with	T080	C0332281
28368267	494	502	stunting	T046	C0018273
28368267	520	532	risk factors	T033	C0035648
28368267	537	545	stunting	T046	C0018273
28368267	552	559	child's	T100	C0008059
28368267	560	563	age	T032	C0001779
28368267	568	574	months	T079	C0439231
28368267	576	584	maternal	T099	C0026591
28368267	585	599	undernutrition	T047	C0162429
28368267	601	619	mother's education	T033	C2924476
28368267	623	628	years	T079	C0439234
28368267	630	641	consumption	T040	C0684271
28368267	645	669	untreated drinking water	T167	C0599638
28368267	674	681	monthly	T079	C0332177
28368267	682	688	family	T099	C0015576
28368267	689	695	income	T081	C0021162
28368267	701	704	USD	T081	C1555442
28368267	710	718	findings	T033	C0243095
28368267	727	732	study	T062	C0007328
28368267	756	764	maternal	T099	C0026591
28368267	765	779	undernutrition	T047	C0162429
28368267	784	798	less education	T033	C0013658
28368267	800	811	consumption	T040	C0684271
28368267	815	839	untreated drinking water	T167	C0599638
28368267	849	855	family	T099	C0015576
28368267	856	862	income	T081	C0021162
28368267	876	886	associated	T080	C0332281
28368267	887	894	factors	T169	C1521761
28368267	898	907	childhood	T079	C0231335
28368267	908	916	stunting	T046	C0018273

28456751|t|Methods, tools and current perspectives in proteogenomics
28456751|a|With combined technological advancements in high-throughput next-generation sequencing and deep mass spectrometry -based proteomics, proteogenomics, i.e., the integrative analysis of proteomic and genomic data, has emerged as a new research field. Early efforts in the field were focused on improving protein identification using sample-specific genomic and transcriptomic sequencing data. More recently, integrative analysis of quantitative measurements from genomic and proteomic studies have identified novel insights into gene expression regulation, cell signaling, and disease. Many methods and tools have been developed or adapted to enable an array of integrative proteogenomic approaches and in this article, we systematically classify published methods and tools into four major categories, (1) Sequence -centric proteogenomics; (2) Analysis of proteogenomic relationships; (3) Integrative modeling of proteogenomic data; and (4) Data sharing and visualization. We provide a comprehensive review of methods and available tools in each category and highlight their typical applications.
28456751	0	7	Methods	T170	C0025663
28456751	9	14	tools	UnknownType	C0541506
28456751	19	26	current	T079	C0521116
28456751	27	39	perspectives	T078	C1254370
28456751	43	57	proteogenomics	T091	C3897816
28456751	72	98	technological advancements	UnknownType	C0681519
28456751	102	144	high-throughput next-generation sequencing	T063	C2936625
28456751	149	171	deep mass spectrometry	T059	C0037813
28456751	179	189	proteomics	T091	C0872252
28456751	191	205	proteogenomics	T091	C3897816
28456751	217	237	integrative analysis	T062	C0936012
28456751	241	267	proteomic and genomic data	T078	C1511726
28456751	290	304	research field	UnknownType	C0683945
28456751	327	332	field	UnknownType	C0683945
28456751	359	366	protein	T116,T123	C0033684
28456751	367	381	identification	T080	C0205396
28456751	388	411	sample-specific genomic	T170	C0282574
28456751	416	446	transcriptomic sequencing data	T170	C0026382
28456751	463	483	integrative analysis	T062	C0936012
28456751	487	499	quantitative	T081	C0392762
28456751	500	512	measurements	T169	C0242485
28456751	518	547	genomic and proteomic studies	T062	C0681814
28456751	553	563	identified	T080	C0205396
28456751	584	610	gene expression regulation	T045	C0017263
28456751	612	626	cell signaling	T043	C0037083
28456751	632	639	disease	T047	C0012634
28456751	646	653	methods	T170	C0025663
28456751	658	663	tools	UnknownType	C0541506
28456751	708	713	array	T082	C1510941
28456751	717	753	integrative proteogenomic approaches	T169	C1292724
28456751	766	773	article	T170	C1706852
28456751	778	792	systematically	T169	C0220922
28456751	793	801	classify	T185	C0008902
28456751	802	811	published	T057	C0034037
28456751	812	819	methods	T170	C0025663
28456751	824	829	tools	UnknownType	C0541506
28456751	840	856	major categories	T185	C1550395
28456751	862	870	Sequence	T086	C0004793
28456751	862	894	Sequence -centric proteogenomics	T091	C3897816
28456751	900	908	Analysis	T062	C0936012
28456751	912	939	proteogenomic relationships	T080	C0439849
28456751	945	965	Integrative modeling	T062	C0870071
28456751	969	987	proteogenomic data	T078	C1511726
28456751	997	1009	Data sharing	T054	C2713450
28456751	1014	1027	visualization	T041	C0175631
28456751	1042	1055	comprehensive	T080	C1880156
28456751	1056	1065	review of	T169	C0699752
28456751	1066	1073	methods	T170	C0025663
28456751	1078	1087	available	T169	C0470187
28456751	1088	1093	tools	UnknownType	C0541506
28456751	1102	1110	category	T170	C0683312
28456751	1131	1138	typical	T080	C3538928
28456751	1139	1151	applications	T169	C0205245

28416969|t|Repeatability and agreement of ultrasonography with computed tomography for evaluating forefoot structure in the coronal plane
28416969|a|Forefoot structure is important to understand some foot problems such as hallux valgus and metatarsalgia. Ultrasonography (US) is a highly portable, noninvasive, low cost, and fast imaging method, especially when compared to magnetic resonance imaging (MRI), computed tomography (CT), and radiography. As the use of US for evaluating forefoot bony structure has not been validated, except for the presence of synovitis, erosions and bursitis within the forefoot in people with inflammatory arthritis, the purpose of this study was to determine whether US is a reliable method for evaluating forefoot structure. Sixty feet (30 women, age = 40.1 ± 11.8 years) were examined by US and CT to assess agreement with CT and repeatability of US evaluation of the 2nd metatarsal head height, length between the medial sesamoid bone and 5th metatarsal head, transverse arch height, transverse arch index, sesamoid rotation angle, and area under the transverse arch. The measurement data were evaluated for agreement with CT using the intra-class correlation coefficient (ICC)3, 1, Pearson correlation coefficient, and Bland-Altman plot, and with ICC1, 1 for repeatability. The ICC3, 1 values of 0.78-0.89, Pearson correlation coefficient of 0.78-0.90, and Bland-Altman plots showed almost perfect agreements between the US and CT method for all parameters, except the area under the transverse arch (AUTA). The ICC1, 1 also showed perfect agreements (0.84-0.92) between two sets of US measurements in all parameters. The US evaluation of forefoot structure in the coronal plane showed good agreement with CT and repeatability of two ultrasonograms in adult women. This reliable evaluation method of forefoot structure can contribute to a quick clinical assessment screening for risk factors of foot problems such as hallux valgus and metatarsalgia. However, because of some limitations such as a lack of inter-observer reliability, more research is needed to validate US evaluation of forefoot structure. The current study (trial registration number: R0297) was approved by the Ethical Committee for Human Experiments of Kyoto University (http://www.ec.med.kyoto-u.ac.jp) on December 3, 2015. The first participant in this study was enrolled on November 17, 2015 and retrospectively registered.
28416969	0	13	Repeatability	T080	C1514863
28416969	18	27	agreement	T170	C4255373
28416969	31	46	ultrasonography	T060	C0041618
28416969	52	71	computed tomography	T060	C0040405
28416969	76	86	evaluating	T058	C0220825
28416969	87	105	forefoot structure	T023	C1510667
28416969	113	126	coronal plane	T082	C0205123
28416969	127	145	Forefoot structure	T023	C1510667
28416969	178	191	foot problems	T033	C0555980
28416969	200	213	hallux valgus	T190	C0018536
28416969	218	231	metatarsalgia	T184	C0025587
28416969	233	248	Ultrasonography	T060	C0041618
28416969	250	252	US	T060	C0041618
28416969	266	274	portable	T082	C4299032
28416969	276	287	noninvasive	T185	C2986496
28416969	293	297	cost	T081	C0010186
28416969	308	322	imaging method	T169	C1275506
28416969	352	378	magnetic resonance imaging	T060	C0024485
28416969	380	383	MRI	T060	C0024485
28416969	386	405	computed tomography	T060	C0040405
28416969	407	409	CT	T060	C0040405
28416969	416	427	radiography	T060	C0043299
28416969	443	445	US	T060	C0041618
28416969	450	460	evaluating	T058	C0220825
28416969	461	484	forefoot bony structure	T023	C3714617
28416969	536	545	synovitis	T047	C0039103
28416969	547	555	erosions	T046	C1959609
28416969	560	568	bursitis	T047	C0006444
28416969	580	588	forefoot	T023	C1510667
28416969	592	598	people	T098	C0027361
28416969	604	626	inflammatory arthritis	T047	C0003864
28416969	648	653	study	T062	C0008972
28416969	679	681	US	T060	C0041618
28416969	696	702	method	T170	C0025663
28416969	707	717	evaluating	T058	C0220825
28416969	718	736	forefoot structure	T023	C1510667
28416969	744	748	feet	T023	C0016504
28416969	753	758	women	T098	C0043210
28416969	790	798	examined	T033	C0332128
28416969	802	804	US	T060	C0041618
28416969	809	811	CT	T060	C0040405
28416969	822	831	agreement	T170	C4255373
28416969	837	839	CT	T060	C0040405
28416969	844	857	repeatability	T080	C1514863
28416969	861	863	US	T060	C0041618
28416969	864	874	evaluation	T058	C0220825
28416969	882	901	2nd metatarsal head	T023	C0223987
28416969	902	908	height	T032	C1317145
28416969	910	916	length	T032	C1317146
28416969	929	949	medial sesamoid bone	T023	C0036846
28416969	954	973	5th metatarsal head	T023	C0224013
28416969	975	990	transverse arch	T029	C0230471
28416969	991	997	height	T032	C1317145
28416969	999	1014	transverse arch	T029	C0230471
28416969	1022	1030	sesamoid	T023	C0036846
28416969	1031	1045	rotation angle	T201	C1562710
28416969	1051	1081	area under the transverse arch	T029	C0230471
28416969	1087	1098	measurement	T169	C0242485
28416969	1109	1118	evaluated	T058	C0220825
28416969	1123	1132	agreement	T170	C4255373
28416969	1138	1140	CT	T060	C0040405
28416969	1151	1197	intra-class correlation coefficient (ICC)3, 1,	T081	C0392762
28416969	1198	1229	Pearson correlation coefficient	T081	C0871052
28416969	1235	1252	Bland-Altman plot	T170	C0282574
28416969	1263	1267	ICC1	T081	C0392762
28416969	1275	1288	repeatability	T080	C1514863
28416969	1294	1298	ICC3	T081	C0392762
28416969	1323	1354	Pearson correlation coefficient	T081	C0871052
28416969	1373	1391	Bland-Altman plots	T170	C0282574
28416969	1414	1424	agreements	T170	C4255373
28416969	1437	1439	US	T060	C0041618
28416969	1444	1446	CT	T060	C0040405
28416969	1447	1453	method	T170	C0025663
28416969	1462	1472	parameters	T077	C0549193
28416969	1485	1522	area under the transverse arch (AUTA)	T029	C0230471
28416969	1528	1532	ICC1	T081	C0392762
28416969	1556	1566	agreements	T170	C4255373
28416969	1599	1601	US	T060	C0041618
28416969	1602	1614	measurements	T169	C0242485
28416969	1622	1632	parameters	T077	C0549193
28416969	1638	1640	US	T060	C0041618
28416969	1641	1651	evaluation	T058	C0220825
28416969	1655	1673	forefoot structure	T023	C1510667
28416969	1681	1694	coronal plane	T082	C0205123
28416969	1707	1716	agreement	T170	C4255373
28416969	1722	1724	CT	T060	C0040405
28416969	1729	1742	repeatability	T080	C1514863
28416969	1750	1764	ultrasonograms	T073	C3887754
28416969	1774	1779	women	T098	C0043210
28416969	1795	1812	evaluation method	T062	C2911685
28416969	1816	1834	forefoot structure	T023	C1510667
28416969	1855	1890	quick clinical assessment screening	T058	C0220908
28416969	1895	1907	risk factors	T033	C0035648
28416969	1911	1924	foot problems	T033	C0555980
28416969	1933	1946	hallux valgus	T190	C0018536
28416969	1951	1964	metatarsalgia	T184	C0025587
28416969	2021	2035	inter-observer	T096	C0870992
28416969	2036	2047	reliability	T081	C2347947
28416969	2054	2062	research	T062	C0035168
28416969	2085	2087	US	T060	C0041618
28416969	2088	2098	evaluation	T058	C0220825
28416969	2102	2120	forefoot structure	T023	C1510667
28416969	2134	2139	study	T062	C0008972
28416969	2141	2173	trial registration number: R0297	T170	C0282574
28416969	2195	2254	Ethical Committee for Human Experiments of Kyoto University	T073,T093	C0020028
28416969	2320	2331	participant	T098	C0679646
28416969	2340	2345	study	T062	C0008972
28416969	2384	2399	retrospectively	T080	C1514923
28416969	2400	2410	registered	T058	C1514821

27486419|t|Can We Predict Burnout among Student Nurses? An Exploration of the ICWR-1 Model of Individual Psychological Resilience
27486419|a|The nature of nursing work is demanding and can be stressful. Previous studies have shown a high rate of burnout among employed nurses. Recently, efforts have been made to understand the role of resilience in determining the psychological adjustment of employed nurses. A theoretical model of resilience was proposed recently that includes several constructs identified in the literature related to resilience and to psychological functioning. As nursing students are the future of the nursing workforce it is important to advance our understanding of the determinants of resilience in this population. Student nurses who had completed their final practicum were invited to participate in an online survey measuring the key constructs of the ICWR-1 model. 422 students from across Australia and Canada completed the survey between July 2014 and July 2015. As well as several key demographics, trait negative affect, mindfulness, self-efficacy, coping, resilience, and burnout were measured. We used structural equation modeling and found support for the major pathways of the model; namely that resilience had a significant influence on the relationship between mindfulness, self-efficacy and coping, and psychological adjustment (burnout scores). Furthermore, as predicted, Neuroticism moderated the relationship between coping and burnout. Results are discussed in terms of potential approaches to supporting nursing students who may be at risk of burnout.
27486419	7	14	Predict	T078	C0681842
27486419	15	22	Burnout	T048	C0006433
27486419	29	43	Student Nurses	T097	C0038496
27486419	67	79	ICWR-1 Model	T170	C0026347
27486419	83	93	Individual	T098	C0237401
27486419	94	118	Psychological Resilience	T055	C0683253
27486419	133	145	nursing work	T091	C0028677
27486419	149	158	demanding	T061	C0441516
27486419	170	179	stressful	T169	C0231297
27486419	211	215	high	T080	C0205250
27486419	216	220	rate	T081	C1521828
27486419	224	231	burnout	T048	C0006433
27486419	238	246	employed	T033	C0557351
27486419	247	253	nurses	T097	C0028661
27486419	314	324	resilience	T055	C0683253
27486419	344	368	psychological adjustment	T055	C0683269
27486419	372	380	employed	T033	C0557351
27486419	381	387	nurses	T097	C0028661
27486419	391	408	theoretical model	T170	C0026350
27486419	412	422	resilience	T055	C0683253
27486419	450	458	includes	T169	C0332257
27486419	459	466	several	T081	C0443302
27486419	467	477	constructs	T185	C2827421
27486419	496	506	literature	T170	C0023866
27486419	518	528	resilience	T055	C0683253
27486419	536	561	psychological functioning	T041	C0233398
27486419	566	582	nursing students	T097	C0038496
27486419	591	597	future	T079	C0016884
27486419	605	612	nursing	T091	C0028677
27486419	613	622	workforce	T097	C2700616
27486419	629	638	important	T080	C3898777
27486419	642	649	advance	T079	C3854260
27486419	675	687	determinants	T169	C1521761
27486419	691	701	resilience	T055	C0683253
27486419	710	720	population	T098	C1257890
27486419	722	736	Student nurses	T097	C0038496
27486419	745	754	completed	T078	C1556116
27486419	761	766	final	T079	C3853528
27486419	767	776	practicum	T065	C0032929
27486419	811	824	online survey	T170	C0038951
27486419	825	834	measuring	T080	C0444706
27486419	843	853	constructs	T185	C2827421
27486419	861	873	ICWR-1 model	T170	C0026347
27486419	879	887	students	T097	C0038496
27486419	900	909	Australia	T083	C0004340
27486419	914	920	Canada	T083	C0006823
27486419	921	930	completed	T078	C1556116
27486419	935	941	survey	T170	C0038951
27486419	986	993	several	T081	C0443302
27486419	998	1010	demographics	T078	C1704791
27486419	1012	1033	trait negative affect	T033	C0233849
27486419	1035	1046	mindfulness	T041	C3542996
27486419	1048	1061	self-efficacy	T041	C0600564
27486419	1063	1069	coping	T055	C0009967
27486419	1071	1081	resilience	T055	C0683253
27486419	1087	1094	burnout	T048	C0006433
27486419	1100	1108	measured	T080	C0444706
27486419	1118	1146	structural equation modeling	T062	C0681947
27486419	1173	1178	major	T080	C0205164
27486419	1179	1187	pathways	T077	C1705987
27486419	1195	1200	model	T170	C0026347
27486419	1214	1224	resilience	T055	C0683253
27486419	1231	1242	significant	T078	C0750502
27486419	1243	1252	influence	T077	C4054723
27486419	1260	1272	relationship	T080	C0439849
27486419	1281	1292	mindfulness	T041	C3542996
27486419	1294	1307	self-efficacy	T041	C0600564
27486419	1312	1318	coping	T055	C0009967
27486419	1324	1348	psychological adjustment	T055	C0683269
27486419	1350	1357	burnout	T048	C0006433
27486419	1358	1364	scores	T081	C0449820
27486419	1383	1392	predicted	T078	C0681842
27486419	1394	1405	Neuroticism	T048	C1842981
27486419	1420	1432	relationship	T080	C0439849
27486419	1441	1447	coping	T055	C0009967
27486419	1452	1459	burnout	T048	C0006433
27486419	1495	1504	potential	T080	C3245505
27486419	1505	1515	approaches	T169	C1292724
27486419	1530	1546	nursing students	T097	C0038496
27486419	1558	1565	at risk	T080	C1444641
27486419	1569	1576	burnout	T048	C0006433

27916672|t|Famous faces and voices: Differential profiles in early right and left semantic dementia and in Alzheimer's disease
27916672|a|Famous face and voice recognition is reported to be impaired both in semantic dementia (SD) and in Alzheimer's Disease (AD), although more severely in the former. In AD a coexistence of perceptual impairment in face and voice processing has also been reported and this could contribute to the altered performance in complex semantic tasks. On the other hand, in SD both face and voice recognition disorders could be related to the prevalence of atrophy in the right temporal lobe (RTL). The aim of the present study was twofold: (1) to investigate famous faces and voices recognition in SD and AD to verify if the two diseases show a differential pattern of impairment, resulting from disruption of different cognitive mechanisms; (2) to check if face and voice recognition disorders prevail in patients with atrophy mainly affecting the RTL. To avoid the potential influence of primary perceptual problems in face and voice recognition, a pool of patients suffering from early SD and AD were administered a detailed set of tests exploring face and voice perception. Thirteen SD (8 with prevalence of right and 5 with prevalence of left temporal atrophy) and 25 CE patients, who did not show visual and auditory perceptual impairment, were finally selected and were administered an experimental battery exploring famous face and voice recognition and naming. Twelve SD patients underwent cerebral PET imaging and were classified in right and left SD according to the onset modality and to the prevalent decrease in FDG uptake in right or left temporal lobe respectively. Correlation of PET imaging and famous face and voice recognition was performed. Results showed a differential performance profile in the two diseases, because AD patients were significantly impaired in the naming tests, but showed preserved recognition, whereas SD patients were profoundly impaired both in naming and in recognition of famous faces and voices. Furthermore, face and voice recognition disorders prevailed in SD patients with RTL atrophy, who also showed a conceptual impairment on the Pyramids and Palm Trees test more important in the pictorial than in the verbal modality. Finally, in 12 SD patients in whom PET was available, a strong correlation between FDG uptake and face-to-name and voice-to-name matching data was found in the right but not in the left temporal lobe. The data support the hypothesis of a different cognitive basis for impairment of face and voice recognition in the two dementias and suggest that the pattern of impairment in SD may be due to a loss of semantic representations, while a defect of semantic control, with impaired naming and preserved recognition might be hypothesized in AD. Furthermore, the correlation between face and voice recognition disorders and RTL damage are consistent with the hypothesis assuming that in the RTL person -specific knowledge may be mainly based upon non-verbal representations.
27916672	0	12	Famous faces	T041	C0870537
27916672	17	23	voices	T041	C0920674
27916672	25	37	Differential	T080	C1705242
27916672	38	46	profiles	T082	C0449774
27916672	50	55	early	T079	C1279919
27916672	56	61	right	T023	C0228232
27916672	66	70	left	T023	C0228233
27916672	71	88	semantic dementia	T048	C0338462
27916672	96	115	Alzheimer's disease	T047	C0002395
27916672	116	127	Famous face	T041	C0870537
27916672	132	149	voice recognition	T041	C0920674
27916672	168	176	impaired	T169	C0221099
27916672	185	202	semantic dementia	T048	C0338462
27916672	204	206	SD	T048	C0338462
27916672	215	234	Alzheimer's Disease	T047	C0002395
27916672	236	238	AD	T047	C0002395
27916672	255	263	severely	T080	C0205082
27916672	282	284	AD	T047	C0002395
27916672	302	312	perceptual	T041	C0030971
27916672	313	323	impairment	T169	C0221099
27916672	327	331	face	T041	C0870537
27916672	336	341	voice	T041	C0920674
27916672	342	352	processing	T041	C0025361
27916672	417	428	performance	T052	C1882330
27916672	432	439	complex	T080	C0439855
27916672	440	448	semantic	T078	C0036612
27916672	449	454	tasks	T052	C0441655
27916672	478	480	SD	T048	C0338462
27916672	486	490	face	T041	C0870537
27916672	495	512	voice recognition	T041	C0920674
27916672	513	522	disorders	T047	C0012634
27916672	547	557	prevalence	T081	C0220900
27916672	561	568	atrophy	T046	C0333641
27916672	576	595	right temporal lobe	T023	C0228232
27916672	597	600	RTL	T023	C0228232
27916672	626	631	study	T062	C2603343
27916672	652	663	investigate	T169	C1292732
27916672	664	676	famous faces	T041	C0870537
27916672	681	699	voices recognition	T041	C0920674
27916672	703	705	SD	T048	C0338462
27916672	710	712	AD	T047	C0002395
27916672	734	742	diseases	T047	C0012634
27916672	750	762	differential	T080	C1705242
27916672	763	770	pattern	T082	C0449774
27916672	774	784	impairment	T169	C0221099
27916672	801	811	disruption	T169	C0332453
27916672	825	834	cognitive	T041	C0009240
27916672	835	845	mechanisms	T169	C0441712
27916672	863	867	face	T041	C0870537
27916672	872	889	voice recognition	T041	C0920674
27916672	890	899	disorders	T047	C0012634
27916672	911	919	patients	T101	C0030705
27916672	925	932	atrophy	T046	C0333641
27916672	954	957	RTL	T023	C0228232
27916672	972	981	potential	T080	C3245505
27916672	982	991	influence	T077	C4054723
27916672	995	1002	primary	T080	C0205225
27916672	1003	1013	perceptual	T041	C0030971
27916672	1014	1022	problems	T033	C0033213
27916672	1026	1030	face	T041	C0870537
27916672	1035	1052	voice recognition	T041	C0920674
27916672	1064	1072	patients	T101	C0030705
27916672	1088	1093	early	T079	C1279919
27916672	1094	1096	SD	T048	C0338462
27916672	1101	1103	AD	T047	C0002395
27916672	1109	1121	administered	T169	C1521801
27916672	1140	1145	tests	T058	C2081632
27916672	1156	1160	face	T041	C0870537
27916672	1165	1170	voice	T041	C0920674
27916672	1171	1181	perception	T041	C0030971
27916672	1192	1194	SD	T048	C0338462
27916672	1203	1213	prevalence	T081	C0220900
27916672	1217	1222	right	T023	C0228232
27916672	1234	1244	prevalence	T081	C0220900
27916672	1248	1261	left temporal	T023	C0228233
27916672	1262	1269	atrophy	T046	C0333641
27916672	1281	1289	patients	T101	C0030705
27916672	1308	1314	visual	T169	C0234621
27916672	1319	1327	auditory	T169	C0439825
27916672	1328	1338	perceptual	T041	C0030971
27916672	1339	1349	impairment	T169	C0221099
27916672	1382	1394	administered	T169	C1521801
27916672	1398	1410	experimental	T080	C1517586
27916672	1411	1418	battery	T170	C1555716
27916672	1429	1440	famous face	T041	C0870537
27916672	1445	1462	voice recognition	T041	C0920674
27916672	1467	1473	naming	T170	C0392366
27916672	1482	1484	SD	T048	C0338462
27916672	1485	1493	patients	T101	C0030705
27916672	1504	1512	cerebral	T023	C0006104
27916672	1513	1524	PET imaging	T060	C0032743
27916672	1548	1553	right	T023	C0228232
27916672	1558	1562	left	T023	C0228233
27916672	1563	1565	SD	T048	C0338462
27916672	1589	1597	modality	T078	C0695347
27916672	1619	1627	decrease	T081	C0547047
27916672	1631	1641	FDG uptake	T109,T130	C0046056
27916672	1645	1650	right	T023	C0228232
27916672	1654	1672	left temporal lobe	T023	C0228233
27916672	1687	1698	Correlation	T080	C1707520
27916672	1702	1713	PET imaging	T060	C0032743
27916672	1718	1729	famous face	T041	C0870537
27916672	1734	1751	voice recognition	T041	C0920674
27916672	1767	1774	Results	T169	C1274040
27916672	1784	1796	differential	T080	C1705242
27916672	1797	1808	performance	T052	C1882330
27916672	1809	1816	profile	T082	C0449774
27916672	1828	1836	diseases	T047	C0012634
27916672	1846	1848	AD	T047	C0002395
27916672	1849	1857	patients	T101	C0030705
27916672	1877	1885	impaired	T169	C0221099
27916672	1893	1905	naming tests	T170	C0392366
27916672	1928	1939	recognition	T041	C0524637
27916672	1949	1951	SD	T048	C0338462
27916672	1952	1960	patients	T101	C0030705
27916672	1977	1985	impaired	T169	C0221099
27916672	1994	2000	naming	T170	C0392366
27916672	2008	2035	recognition of famous faces	T041	C0870537
27916672	2040	2046	voices	T041	C0920674
27916672	2061	2065	face	T041	C0870537
27916672	2070	2087	voice recognition	T041	C0920674
27916672	2088	2097	disorders	T047	C0012634
27916672	2111	2113	SD	T048	C0338462
27916672	2114	2122	patients	T101	C0030705
27916672	2128	2131	RTL	T023	C0228232
27916672	2132	2139	atrophy	T046	C0333641
27916672	2159	2169	conceptual	T077	C1254372
27916672	2170	2180	impairment	T169	C0221099
27916672	2188	2216	Pyramids and Palm Trees test	T170	C0451399
27916672	2261	2267	verbal	T080	C0439824
27916672	2268	2276	modality	T078	C0695347
27916672	2293	2295	SD	T048	C0338462
27916672	2296	2304	patients	T101	C0030705
27916672	2313	2316	PET	T060	C0032743
27916672	2341	2352	correlation	T080	C1707520
27916672	2361	2371	FDG uptake	T109,T130	C0046056
27916672	2376	2388	face-to-name	T080	C1708943
27916672	2393	2415	voice-to-name matching	T080	C1708943
27916672	2416	2420	data	T078	C1511726
27916672	2438	2443	right	T023	C0228232
27916672	2459	2477	left temporal lobe	T023	C0228233
27916672	2483	2487	data	T078	C1511726
27916672	2500	2510	hypothesis	T078	C1512571
27916672	2526	2535	cognitive	T041	C0009240
27916672	2546	2556	impairment	T169	C0221099
27916672	2560	2564	face	T041	C0870537
27916672	2569	2586	voice recognition	T041	C0920674
27916672	2598	2607	dementias	T048	C0338462
27916672	2629	2636	pattern	T082	C0449774
27916672	2640	2650	impairment	T169	C0221099
27916672	2654	2656	SD	T048	C0338462
27916672	2681	2689	semantic	T078	C0036612
27916672	2690	2705	representations	T052	C1882932
27916672	2725	2733	semantic	T078	C0036612
27916672	2734	2741	control	T169	C2587213
27916672	2748	2756	impaired	T169	C0221099
27916672	2757	2763	naming	T170	C0392366
27916672	2768	2789	preserved recognition	T041	C0524637
27916672	2815	2817	AD	T047	C0002395
27916672	2836	2847	correlation	T080	C1707520
27916672	2856	2860	face	T041	C0870537
27916672	2865	2882	voice recognition	T041	C0920674
27916672	2883	2892	disorders	T047	C0012634
27916672	2897	2900	RTL	T023	C0228232
27916672	2901	2907	damage	T037	C0178314
27916672	2932	2942	hypothesis	T078	C1512571
27916672	2964	2967	RTL	T023	C0228232
27916672	2968	2974	person	T098	C0027361
27916672	2985	2994	knowledge	T170	C0376554
27916672	3020	3046	non-verbal representations	T041	C0681317

28278150|t|Integrating molecular QTL data into genome-wide genetic association analysis: Probabilistic assessment of enrichment and colocalization
28278150|a|We propose a novel statistical framework for integrating the result from molecular quantitative trait loci (QTL) mapping into genome-wide genetic association analysis of complex traits, with the primary objectives of quantitatively assessing the enrichment of the molecular QTLs in complex trait - associated genetic variants and the colocalizations of the two types of association signals. We introduce a natural Bayesian hierarchical model that treats the latent association status of molecular QTLs as SNP - level annotations for candidate SNPs of complex traits. We detail a computational procedure to seamlessly perform enrichment, fine-mapping and colocalization analyses, which is a distinct feature compared to the existing colocalization analysis procedures in the literature. The proposed approach is computationally efficient and requires only summary - level statistics. We evaluate and demonstrate the proposed computational approach through extensive simulation studies and analyses of blood lipid data and the whole blood eQTL data from the GTEx project. In addition, a useful utility from our proposed method enables the computation of expected colocalization signals using simple characteristics of the association data. Using this utility, we further illustrate the importance of enrichment analysis on the ability to discover colocalized signals and the potential limitations of currently available molecular QTL data. The software pipeline that implements the proposed computation procedures, enloc, is freely available at https://github.com/xqwen/integrative.
28278150	0	11	Integrating	T052	C1881786
28278150	12	21	molecular	T080	C1521991
28278150	22	25	QTL	T028	C0597336
28278150	26	30	data	T078	C1511726
28278150	36	76	genome-wide genetic association analysis	T063	C2350277
28278150	78	91	Probabilistic	T081	C0033204
28278150	92	102	assessment	T169	C1292732
28278150	106	116	enrichment	T077	C2986411
28278150	121	135	colocalization	T169	C0475264
28278150	155	176	statistical framework	T081,T170	C0026348
28278150	181	192	integrating	T052	C1881786
28278150	197	203	result	T169	C1274040
28278150	209	218	molecular	T080	C1521991
28278150	219	242	quantitative trait loci	T028	C0597336
28278150	244	247	QTL	T028	C0597336
28278150	249	256	mapping	T052	C1283195
28278150	262	302	genome-wide genetic association analysis	T063	C2350277
28278150	306	313	complex	T080	C0439855
28278150	314	320	traits	T032	C0599883
28278150	353	367	quantitatively	T081	C0392762
28278150	368	377	assessing	T169	C1292732
28278150	382	392	enrichment	T077	C2986411
28278150	400	409	molecular	T080	C1521991
28278150	410	414	QTLs	T028	C0597336
28278150	418	425	complex	T080	C0439855
28278150	426	431	trait	T032	C0599883
28278150	434	444	associated	T080	C0332281
28278150	445	461	genetic variants	T028	C0678941
28278150	470	485	colocalizations	T169	C0475264
28278150	497	502	types	T080	C0332307
28278150	506	517	association	T080	C0439849
28278150	518	525	signals	T067	C1710082
28278150	542	577	natural Bayesian hierarchical model	T081	C0242198
28278150	601	612	association	T080	C0439849
28278150	623	632	molecular	T080	C1521991
28278150	633	637	QTLs	T028	C0597336
28278150	641	644	SNP	T086	C0752046
28278150	647	652	level	T080	C0441889
28278150	679	683	SNPs	T086	C0752046
28278150	687	694	complex	T080	C0439855
28278150	695	701	traits	T032	C0599883
28278150	715	728	computational	T052	C1880157
28278150	729	738	procedure	T169	C2700391
28278150	761	771	enrichment	T077	C2986411
28278150	773	785	fine-mapping	T052	C1283195
28278150	790	804	colocalization	T169	C0475264
28278150	805	813	analyses	T062	C0936012
28278150	826	842	distinct feature	T080	C2348519
28278150	843	851	compared	T052	C1707455
28278150	868	882	colocalization	T169	C0475264
28278150	883	891	analysis	T062	C0936012
28278150	892	902	procedures	T169	C2700391
28278150	910	920	literature	T170	C0023866
28278150	935	943	approach	T082	C0449445
28278150	947	962	computationally	T052	C1880157
28278150	963	972	efficient	T080	C0442799
28278150	991	998	summary	T170	C1706244
28278150	1001	1006	level	T080	C0441889
28278150	1007	1017	statistics	T081	C2828391
28278150	1022	1030	evaluate	T169	C1292732
28278150	1060	1073	computational	T052	C1880157
28278150	1074	1082	approach	T082	C0449445
28278150	1091	1100	extensive	T080	C0205231
28278150	1101	1111	simulation	T066	C0009609
28278150	1112	1119	studies	T062	C2603343
28278150	1124	1132	analyses	T062	C0936012
28278150	1136	1147	blood lipid	T109	C0596192
28278150	1148	1152	data	T078	C1511726
28278150	1161	1172	whole blood	T031	C0370231
28278150	1173	1177	eQTL	T028	C0597336
28278150	1178	1182	data	T078	C1511726
28278150	1192	1204	GTEx project	T062	C4289040
28278150	1228	1235	utility	T170	C0025663
28278150	1254	1260	method	T170	C0025663
28278150	1273	1284	computation	T052	C1880157
28278150	1297	1311	colocalization	T169	C0475264
28278150	1312	1319	signals	T067	C1710082
28278150	1333	1348	characteristics	T080	C1521970
28278150	1356	1367	association	T080	C0439849
28278150	1368	1372	data	T078	C1511726
28278150	1385	1392	utility	T170	C0025663
28278150	1434	1444	enrichment	T077	C2986411
28278150	1445	1453	analysis	T062	C0936012
28278150	1481	1492	colocalized	T169	C0475264
28278150	1493	1500	signals	T067	C1710082
28278150	1509	1518	potential	T080	C3245505
28278150	1519	1530	limitations	T169	C0449295
28278150	1554	1563	molecular	T080	C1521991
28278150	1564	1567	QTL	T028	C0597336
28278150	1568	1572	data	T078	C1511726
28278150	1578	1586	software	T073,T170	C0037585
28278150	1625	1636	computation	T052	C1880157
28278150	1637	1647	procedures	T169	C2700391
28278150	1649	1654	enloc	T170	C0242356
28278150	1679	1715	https://github.com/xqwen/integrative	T170	C2349146

27336004|t|Iron Deficiency Is Common During Remission in Children With Inflammatory Bowel Disease
27336004|a|The aim was to study prevalence of iron deficiency in children with inflammatory bowel disease (IBD) during remission. In addition, there was an observational evaluation of hematological response to oral iron. A population-based retrospective study including 90 Swedish children (median 13 years) with IBD was performed. Patient records covered in median 25 months. Iron deficiency was present in 70/77 children (91%) in which iron status could be assessed. In clinical and biochemical remission, iron deficiency was found in 57/67 (85%) of children, and 23 (34%) of them had iron deficiency anemia. Thirty-six iron-deficient children were prescribed oral iron supplementation and 32 (89%) improved hemoglobin levels over 6 months. In conclusion, iron deficiency is common during clinical remission in children with IBD, even in cohorts with low prevalence of anemia. Therefore, regular biochemical screening for iron deficiency is warranted during all stages of disease, irrespective of symptoms and inflammatory blood markers.
27336004	0	15	Iron Deficiency	T047	C0240066
27336004	33	42	Remission	T033	C0544452
27336004	46	54	Children	T100	C0008059
27336004	60	86	Inflammatory Bowel Disease	T047	C0021390
27336004	102	107	study	T062	C2603343
27336004	108	118	prevalence	T081	C0683921
27336004	122	137	iron deficiency	T047	C0240066
27336004	141	149	children	T100	C0008059
27336004	155	181	inflammatory bowel disease	T047	C0021390
27336004	183	186	IBD	T047	C0021390
27336004	195	204	remission	T033	C0544452
27336004	232	245	observational	T062	C1518527
27336004	246	256	evaluation	T058	C0220825
27336004	260	273	hematological	T059	C0018941
27336004	274	282	response	T032	C0871261
27336004	286	290	oral	T169	C1527415
27336004	291	295	iron	T121,T123,T196	C0302583
27336004	299	315	population-based	T062	C1709599
27336004	316	335	retrospective study	T062	C0035363
27336004	349	356	Swedish	T098	C1710263
27336004	357	365	children	T100	C0008059
27336004	367	373	median	T081	C0876920
27336004	377	382	years	T079	C0439234
27336004	389	392	IBD	T047	C0021390
27336004	408	423	Patient records	T170	C0025102
27336004	435	441	median	T081	C0876920
27336004	445	451	months	T079	C0439231
27336004	453	468	Iron deficiency	T047	C0240066
27336004	490	498	children	T100	C0008059
27336004	514	525	iron status	T059	C0337439
27336004	535	543	assessed	T052	C1516048
27336004	548	556	clinical	T080	C0205210
27336004	561	572	biochemical	T169	C0205474
27336004	573	582	remission	T033	C0544452
27336004	584	599	iron deficiency	T047	C0240066
27336004	628	636	children	T100	C0008059
27336004	663	685	iron deficiency anemia	T047	C0162316
27336004	698	712	iron-deficient	T047	C0240066
27336004	713	721	children	T100	C0008059
27336004	727	737	prescribed	T058	C0278329
27336004	738	742	oral	T061	C0001563
27336004	743	763	iron supplementation	T058	C3537005
27336004	786	803	hemoglobin levels	T034	C0019029
27336004	811	817	months	T079	C0439231
27336004	834	849	iron deficiency	T047	C0240066
27336004	867	875	clinical	T080	C0205210
27336004	876	885	remission	T033	C0544452
27336004	889	897	children	T100	C0008059
27336004	903	906	IBD	T047	C0021390
27336004	916	923	cohorts	T098	C0599755
27336004	929	943	low prevalence	T081	C1518029
27336004	947	953	anemia	T047	C0002871
27336004	974	995	biochemical screening	T059	C1278201
27336004	1000	1015	iron deficiency	T047	C0240066
27336004	1040	1046	stages	T079	C1306673
27336004	1050	1057	disease	T047	C0012634
27336004	1075	1083	symptoms	T184	C1457887
27336004	1088	1100	inflammatory	T169	C0333348
27336004	1101	1106	blood	T031	C0005767
27336004	1107	1114	markers	T201	C0005516

28460474|t|TT genotype of rs2941484 in the human HNF4G gene is associated with hyperuricemia in Chinese Han men
28460474|a|The aim of the study is to investigate the association between the human hepatocyte nuclear factor 4 gamma (HNF4G) gene and hyperuricemia in Chinese Han population. A total of 414 hyperuricemia patients and 406 gender and age -matched normouricemic controls were enrolled. Four single nucleotide polymorphisms were genotyped as genetic markers for the human HNF4G gene (rs2977939, rs1805098, rs2941484, rs4735692). Data were analyzed for two separate groups: men and women. For rs2941484, the genotype distribution frequency in hyperuricemic subjects and was significantly different from that in normouricemic controls in men (P = 0.038). Meanwhile, in recessive model of rs2941484, the distribution frequency of TT genotype and CC+CT genotypes also differed significantly between the hyperuricemia men and normouricemic men (P = 0.011). For the other 3 SNPs in both men and women, there was no difference in the genotype and allele and distribution frequency between the hyperuricemia patients and normouricemic controls. In men, after adjustments for BMI, SBP, DBP, fasting glucose, total cholesterol, triglycerides, low density lipoprotein cholesterol and creatinine, the men with the TT genotype of rs2941484 were found to have significantly higher probability of suffering from hyperuricemia than the ones with CT and CC genotypes (OR = 2.170, P < 0.001). Therefore, TT genotype of rs2941484 in the human HNF4G gene might be a gender -specific genetic marker for hyperuricemia in Chinese Han men.
28460474	0	11	TT genotype	T032	C0017431
28460474	15	24	rs2941484	T028	C0017337
28460474	32	37	human	T016	C0086418
28460474	38	48	HNF4G gene	T028	C1415631
28460474	52	67	associated with	T080	C0332281
28460474	68	81	hyperuricemia	T047	C0740394
28460474	85	96	Chinese Han	UnknownType	C0814942
28460474	97	100	men	T098	C0025266
28460474	116	121	study	T062	C2603343
28460474	144	155	association	T080	C0439849
28460474	168	173	human	T016	C0086418
28460474	174	220	hepatocyte nuclear factor 4 gamma (HNF4G) gene	T028	C1415631
28460474	225	238	hyperuricemia	T047	C0740394
28460474	242	264	Chinese Han population	UnknownType	C0814942
28460474	281	294	hyperuricemia	T047	C0740394
28460474	295	303	patients	T101	C0030705
28460474	312	318	gender	T032	C0079399
28460474	323	326	age	T032	C0001779
28460474	336	358	normouricemic controls	T096	C0009932
28460474	379	410	single nucleotide polymorphisms	T086	C0752046
28460474	416	425	genotyped	T059,T063	C3178894
28460474	429	444	genetic markers	T045	C0017393
28460474	453	458	human	T016	C0086418
28460474	459	469	HNF4G gene	T028	C1415631
28460474	471	480	rs2977939	T028	C0017337
28460474	482	491	rs1805098	T028	C0017337
28460474	493	502	rs2941484	T028	C0017337
28460474	504	513	rs4735692	T028	C0017337
28460474	560	563	men	T098	C0025266
28460474	568	573	women	T098	C0043210
28460474	579	588	rs2941484	T028	C0017337
28460474	594	602	genotype	T032	C0017431
28460474	603	625	distribution frequency	T081	C0237580
28460474	629	642	hyperuricemic	T047	C0740394
28460474	643	651	subjects	T098	C0080105
28460474	697	719	normouricemic controls	T096	C0009932
28460474	723	726	men	T098	C0025266
28460474	754	769	recessive model	T170	C0026343
28460474	773	782	rs2941484	T028	C0017337
28460474	788	810	distribution frequency	T081	C0237580
28460474	814	825	TT genotype	T032	C0017431
28460474	830	845	CC+CT genotypes	T032	C0017431
28460474	886	899	hyperuricemia	T047	C0740394
28460474	900	903	men	T098	C0025266
28460474	908	921	normouricemic	T096	C0009932
28460474	922	925	men	T098	C0025266
28460474	955	959	SNPs	T086	C0752046
28460474	968	971	men	T098	C0025266
28460474	976	981	women	T098	C0043210
28460474	993	1006	no difference	T033	C3842396
28460474	1014	1022	genotype	T032	C0017431
28460474	1027	1033	allele	T028	C0002085
28460474	1038	1060	distribution frequency	T081	C0237580
28460474	1073	1086	hyperuricemia	T047	C0740394
28460474	1087	1095	patients	T101	C0030705
28460474	1100	1122	normouricemic controls	T096	C0009932
28460474	1127	1130	men	T098	C0025266
28460474	1138	1149	adjustments	T169	C0456081
28460474	1154	1157	BMI	T201	C1305855
28460474	1159	1162	SBP	T201	C0871470
28460474	1164	1167	DBP	T201	C0428883
28460474	1169	1184	fasting glucose	T034	C0428548
28460474	1186	1203	total cholesterol	T109	C0543421
28460474	1205	1218	triglycerides	T109,T123	C0041004
28460474	1220	1255	low density lipoprotein cholesterol	T109,T123	C0023824
28460474	1260	1270	creatinine	T109,T123	C0010294
28460474	1276	1279	men	T098	C0025266
28460474	1289	1300	TT genotype	T032	C0017431
28460474	1304	1313	rs2941484	T028	C0017337
28460474	1369	1378	suffering	T184	C0751408
28460474	1384	1397	hyperuricemia	T047	C0740394
28460474	1417	1419	CT	T032	C0017431
28460474	1424	1436	CC genotypes	T032	C0017431
28460474	1473	1484	TT genotype	T032	C0017431
28460474	1488	1497	rs2941484	T028	C0017337
28460474	1505	1510	human	T016	C0086418
28460474	1511	1521	HNF4G gene	T028	C1415631
28460474	1533	1539	gender	T032	C0079399
28460474	1550	1564	genetic marker	T045	C0017393
28460474	1569	1582	hyperuricemia	T047	C0740394
28460474	1586	1597	Chinese Han	UnknownType	C0814942
28460474	1598	1601	men	T098	C0025266

28220959|t|Evaluating clinical, dietary and psychological risk factors for relapse of ulcerative colitis in clinical, endoscopic and histological remission
28220959|a|The literature on possible factors that could trigger a relapse in patients with ulcerative colitis (UC) in clinical, endoscopic and histological remission on long term follow up is scarce. To determine the relapse rate in patients with UC in clinical, endoscopic and histological remission and identify factors that may influence the risk of relapse. Patients with UC in clinical, endoscopic and histological remission were enrolled between January-July 2010 and followed up for 1 year to determine the effect of clinical, dietary and psychological factors on relapse. Information regarding factors that may affect relapse such as infection, antibiotic or NSAIDs use and any other factor which the patient felt important, and compliance with medications was obtained. 97 patients (59 males, mean age 39 + 11.9 years) were followed up for a mean duration of 9 + 2.3 months. 18(18.6%) relapsed with the median time to relapse being 3.5 months. On univariate analysis more relapsers had significantly higher NSAIDs use within 15 days of relapse, respiratory tract infection within 4 weeks, use of steroids more than once in past, higher consumption of calcium, riboflavin, vitamin A and lower consumption of sugars. On multivariate analysis, NSAIDs use [HR(95%CI):6.41(1.88-21.9)]and intake of Vitamin A [HR(95%CI):1.008(1.000-1.016)] were statistically significant predictors of relapse. With a relapse rate of 18.6% over a follow up of 9 months in patients with UC in clinical, endoscopic and histological remission, independent predictors of relapse were history of NSAIDs use within 15 days of relapse and higher intake of Vitamin A.
28220959	11	19	clinical	T080	C0205210
28220959	21	28	dietary	T168	C0012155
28220959	33	46	psychological	T169	C0205486
28220959	47	59	risk factors	T033	C0035648
28220959	64	71	relapse	T067	C0035020
28220959	75	93	ulcerative colitis	T047	C0009324
28220959	97	105	clinical	T080	C0205210
28220959	107	117	endoscopic	T082	C0442418
28220959	122	134	histological	T169	C0205462
28220959	135	144	remission	T046	C0597370
28220959	201	208	relapse	T067	C0035020
28220959	212	220	patients	T101	C0030705
28220959	226	244	ulcerative colitis	T047	C0009324
28220959	246	248	UC	T047	C0009324
28220959	253	261	clinical	T080	C0205210
28220959	263	273	endoscopic	T082	C0442418
28220959	278	290	histological	T169	C0205462
28220959	291	300	remission	T046	C0597370
28220959	314	323	follow up	T058	C1522577
28220959	352	359	relapse	T067	C0035020
28220959	368	376	patients	T101	C0030705
28220959	382	384	UC	T047	C0009324
28220959	388	396	clinical	T080	C0205210
28220959	398	408	endoscopic	T082	C0442418
28220959	413	425	histological	T169	C0205462
28220959	426	435	remission	T046	C0597370
28220959	480	484	risk	T078	C0035647
28220959	488	495	relapse	T067	C0035020
28220959	497	505	Patients	T101	C0030705
28220959	511	513	UC	T047	C0009324
28220959	517	525	clinical	T080	C0205210
28220959	527	537	endoscopic	T082	C0442418
28220959	542	554	histological	T169	C0205462
28220959	555	564	remission	T046	C0597370
28220959	609	620	followed up	T058	C1522577
28220959	627	631	year	T079	C0439234
28220959	659	667	clinical	T080	C0205210
28220959	669	676	dietary	T168	C0012155
28220959	681	694	psychological	T169	C0205486
28220959	695	702	factors	T033	C0035648
28220959	706	713	relapse	T067	C0035020
28220959	761	768	relapse	T067	C0035020
28220959	777	786	infection	T046	C3714514
28220959	788	798	antibiotic	T195	C0003232
28220959	802	808	NSAIDs	T121	C0003211
28220959	844	851	patient	T101	C0030705
28220959	872	882	compliance	T055	C1321605
28220959	888	899	medications	T058	C2081612
28220959	917	925	patients	T101	C0030705
28220959	930	935	males	T098	C0025266
28220959	942	945	age	T032	C0001779
28220959	956	961	years	T079	C0439234
28220959	968	979	followed up	T058	C1522577
28220959	1011	1017	months	T079	C0439231
28220959	1029	1037	relapsed	T067	C0035020
28220959	1062	1069	relapse	T067	C0035020
28220959	1080	1086	months	T079	C0439231
28220959	1091	1110	univariate analysis	T062	C0683962
28220959	1151	1157	NSAIDs	T121	C0003211
28220959	1172	1176	days	T079	C0439228
28220959	1180	1187	relapse	T067	C0035020
28220959	1189	1216	respiratory tract infection	T047	C0035243
28220959	1226	1231	weeks	T079	C0439230
28220959	1240	1248	steroids	T109	C0038317
28220959	1280	1291	consumption	T039	C1947907
28220959	1295	1302	calcium	T121,T123,T196	C0006675
28220959	1304	1314	riboflavin	T109,T121,T127	C0035527
28220959	1316	1325	vitamin A	T109,T121,T127	C0042839
28220959	1336	1347	consumption	T039	C1947907
28220959	1351	1357	sugars	T109,T121	C0242209
28220959	1362	1383	multivariate analysis	T081	C0026777
28220959	1385	1391	NSAIDs	T121	C0003211
28220959	1427	1433	intake	T169	C1512806
28220959	1437	1446	Vitamin A	T109,T121,T127	C0042839
28220959	1509	1519	predictors	T078	C2698872
28220959	1523	1530	relapse	T067	C0035020
28220959	1539	1546	relapse	T067	C0035020
28220959	1568	1577	follow up	T058	C1522577
28220959	1583	1589	months	T079	C0439231
28220959	1593	1601	patients	T101	C0030705
28220959	1607	1609	UC	T047	C0009324
28220959	1613	1621	clinical	T080	C0205210
28220959	1623	1633	endoscopic	T082	C0442418
28220959	1638	1650	histological	T169	C0205462
28220959	1651	1660	remission	T046	C0597370
28220959	1674	1684	predictors	T078	C2698872
28220959	1688	1695	relapse	T067	C0035020
28220959	1712	1718	NSAIDs	T121	C0003211
28220959	1733	1737	days	T079	C0439228
28220959	1741	1748	relapse	T067	C0035020
28220959	1770	1779	Vitamin A	T109,T121,T127	C0042839

28283668|t|Effect of peritoneal lavage solution temperature on body temperature in anaesthetised cats and small dogs
28283668|a|A prospective, randomised, non-blinded, clinical study to assess the effect of peritoneal lavage using warmed fluid on body temperature in anesthetised cats and dogs of less than 10 kg body mass undergoing coeliotomy. A standardised anaesthetic protocol was used. Oesophageal and rectal temperatures were measured at various time points. At the end of surgery, group 1 patients (n=10) were lavaged with 200 ml/kg sterile isotonic saline at 34±1°C and group 2 (n=10) at 40±1°C. Groups were similar with respect to age, mass, body condition and surgical incision length. Duration of anaesthesia, surgical procedures and peritoneal lavage was similar between groups. Linear regression showed no significant change in oesophageal temperature during the lavage period for group 1 (P=0.64), but a significant increase for group 2 patients (P<0.0001), with mean temperature changes of -0.5°C (from (36.3°C to 35.9°C) and +0.9°C (from 35.4°C to 36.3°C), respectively. Similar results were found for rectal temperature, with mean changes of -0.5°C and +0.8°C (P=0.922 and 0.045), respectively. The use of isotonic crystalloid solution for peritoneal lavage at a temperature of 40±1°C significantly warms small animal patients, when applied in a clinical setting, compared with lavage solution at 34±1°C.
28283668	0	9	Effect of	T080	C1704420
28283668	10	27	peritoneal lavage	T058	C0031148
28283668	28	36	solution	T167	C0037633
28283668	37	48	temperature	T081	C0039476
28283668	52	68	body temperature	T032	C0005903
28283668	72	85	anaesthetised	T033	C1720436
28283668	86	90	cats	T015	C0007450
28283668	101	105	dogs	T015	C0012984
28283668	108	119	prospective	T062	C0033522
28283668	121	131	randomised	T062,T170	C0206034
28283668	133	144	non-blinded	T062	C0242481
28283668	146	160	clinical study	T062	C0008972
28283668	175	184	effect of	T080	C1704420
28283668	185	202	peritoneal lavage	T058	C0031148
28283668	209	215	warmed	T070	C0687712
28283668	216	221	fluid	T167	C0302908
28283668	225	241	body temperature	T032	C0005903
28283668	245	257	anesthetised	T033	C1720436
28283668	258	262	cats	T015	C0007450
28283668	267	271	dogs	T015	C0012984
28283668	291	300	body mass	T033	C0518010
28283668	312	322	coeliotomy	T061	C0023038
28283668	326	359	standardised anaesthetic protocol	T170	C0442711
28283668	370	381	Oesophageal	T058	C3161742
28283668	386	405	rectal temperatures	T033	C0489749
28283668	411	419	measured	T080	C0444706
28283668	423	442	various time points	T079	C1552717
28283668	458	465	surgery	T061	C0543467
28283668	467	483	group 1 patients	T101	C0030705
28283668	496	503	lavaged	T061	C0022100
28283668	519	526	sterile	T080	C0232920
28283668	527	542	isotonic saline	T121,T197	C0445115
28283668	557	562	group	T096	C1642385
28283668	583	589	Groups	T096	C1642385
28283668	619	622	age	T100	C0596090
28283668	624	628	mass	T081	C1306372
28283668	630	644	body condition	T033	C3687361
28283668	649	666	surgical incision	T061	C0184898
28283668	675	683	Duration	T079	C0449238
28283668	687	698	anaesthesia	T061	C0002921
28283668	700	719	surgical procedures	T061	C0543467
28283668	724	741	peritoneal lavage	T058	C0031148
28283668	762	768	groups	T096	C1642385
28283668	770	787	Linear regression	T081	C0023733
28283668	795	816	no significant change	T033	C0243095
28283668	820	843	oesophageal temperature	T058	C3161742
28283668	855	861	lavage	T061	C0022100
28283668	862	868	period	T079	C1948053
28283668	873	878	group	T096	C1642385
28283668	922	938	group 2 patients	T101	C0030705
28283668	956	960	mean	T081	C0444504
28283668	961	980	temperature changes	T080	C0450031
28283668	1074	1081	results	T033	C0459422
28283668	1097	1115	rectal temperature	T033	C0489749
28283668	1122	1126	mean	T081	C0444504
28283668	1202	1210	isotonic	T121	C0022260
28283668	1211	1231	crystalloid solution	T121	C0056562
28283668	1236	1253	peritoneal lavage	T058	C0031148
28283668	1259	1270	temperature	T081	C0039476
28283668	1295	1300	warms	T070	C0687712
28283668	1301	1322	small animal patients	T101	C0030705
28283668	1342	1358	clinical setting	T082	C3176918
28283668	1374	1380	lavage	T061	C0022100

28293475|t|Nationwide hospital -based survey of idiopathic normal pressure hydrocephalus in Japan: Epidemiological and clinical characteristics
28293475|a|There have been no nationwide epidemiological studies of idiopathic normal pressure hydrocephalus (iNPH) in Japan. Therefore, a nationwide epidemiologic survey of iNPH was performed to determine the number of cases and clinical characteristics by sex and diagnostic level. The first survey examined the numbers of cases that met the diagnostic criteria of iNPH and those who underwent shunt operations in 2012. The second survey gathered patients ' details to clarify their clinical background characteristics. The estimated number of cases meeting the diagnostic criteria in 2012 was 12,900, with 6,700 undergoing shunt operations. The estimated crude prevalence was 10.2/100,000 persons. The age of onset was in the 70s in more than 50% of both men and women. Significantly higher (p < .05) frequencies of gait impairment in men and cognitive decline in women were observed as initial symptoms. At the time of definitive diagnosis, gait impairment was observed most frequently in patients with definite iNPH (77.7%). Hypertension was the most frequent comorbidity (40.0%), followed by diabetes mellitus (17.8%) and Alzheimer's disease (14.8%). Hypertension was observed more frequently in men, but diabetes was observed more frequently in women (p < .05). An LP shunt was the first-choice (55.1%) treatment of iNPH, followed by a VP shunt (43.2%). This study showed that iNPH occurs most frequently in the 70s, gait impairment and cognitive decline are the most frequent initial symptoms in men and women, respectively, and hypertension and diabetes are the most frequent comorbidities in men and women, respectively.
28293475	11	19	hospital	T073,T093	C0019994
28293475	27	33	survey	T170	C0038951
28293475	37	77	idiopathic normal pressure hydrocephalus	T047	C2047886
28293475	81	86	Japan	T083	C0022341
28293475	88	103	Epidemiological	T080	C1521970
28293475	108	132	clinical characteristics	T201	C0683325
28293475	163	186	epidemiological studies	T062	C0002783
28293475	190	230	idiopathic normal pressure hydrocephalus	T047	C2047886
28293475	232	236	iNPH	T047	C2047886
28293475	241	246	Japan	T083	C0022341
28293475	272	292	epidemiologic survey	T170	C0038951
28293475	296	300	iNPH	T047	C2047886
28293475	342	347	cases	T077	C1706256
28293475	352	376	clinical characteristics	T201	C0683325
28293475	380	383	sex	T032	C1522384
28293475	388	398	diagnostic	T169	C0348026
28293475	399	404	level	T080	C0441889
28293475	416	422	survey	T170	C0038951
28293475	447	452	cases	T077	C1706256
28293475	466	485	diagnostic criteria	T170	C0679228
28293475	489	493	iNPH	T047	C2047886
28293475	518	534	shunt operations	T061	C0543467
28293475	555	561	survey	T170	C0038951
28293475	571	579	patients	T101	C0030705
28293475	582	589	details	T080	C1522508
28293475	607	642	clinical background characteristics	T201	C0683325
28293475	668	673	cases	T077	C1706256
28293475	686	705	diagnostic criteria	T170	C0679228
28293475	748	764	shunt operations	T061	C0543467
28293475	780	796	crude prevalence	T081	C0220900
28293475	814	821	persons	T098	C0027361
28293475	827	839	age of onset	T081	C0206132
28293475	880	883	men	T098	C0025266
28293475	888	893	women	T098	C0043210
28293475	926	937	frequencies	T079	C0439603
28293475	941	956	gait impairment	T033	C3808195
28293475	960	963	men	T098	C0025266
28293475	968	985	cognitive decline	T033	C2675948
28293475	989	994	women	T098	C0043210
28293475	1012	1019	initial	T079	C0205265
28293475	1020	1028	symptoms	T184	C1457887
28293475	1037	1041	time	T079	C0040223
28293475	1056	1065	diagnosis	T033	C0011900
28293475	1067	1082	gait impairment	T033	C3808195
28293475	1101	1111	frequently	T079	C0332183
28293475	1115	1123	patients	T101	C0030705
28293475	1138	1142	iNPH	T047	C2047886
28293475	1152	1164	Hypertension	T047	C0020538
28293475	1178	1186	frequent	T079	C0332183
28293475	1187	1198	comorbidity	T078	C0009488
28293475	1220	1237	diabetes mellitus	T047	C0011849
28293475	1250	1269	Alzheimer's disease	T047	C0002395
28293475	1279	1291	Hypertension	T047	C0020538
28293475	1310	1320	frequently	T079	C0332183
28293475	1324	1327	men	T098	C0025266
28293475	1333	1341	diabetes	T047	C0011849
28293475	1360	1370	frequently	T079	C0332183
28293475	1374	1379	women	T098	C0043210
28293475	1394	1402	LP shunt	T061	C0087111
28293475	1432	1441	treatment	T061	C0087111
28293475	1445	1449	iNPH	T047	C2047886
28293475	1465	1473	VP shunt	T061	C0087111
28293475	1506	1510	iNPH	T047	C2047886
28293475	1523	1533	frequently	T079	C0332183
28293475	1546	1561	gait impairment	T033	C3808195
28293475	1566	1583	cognitive decline	T033	C2675948
28293475	1597	1605	frequent	T079	C0332183
28293475	1606	1613	initial	T079	C0205265
28293475	1614	1622	symptoms	T184	C1457887
28293475	1626	1629	men	T098	C0025266
28293475	1634	1639	women	T098	C0043210
28293475	1659	1671	hypertension	T047	C0020538
28293475	1676	1684	diabetes	T047	C0011849
28293475	1698	1706	frequent	T079	C0332183
28293475	1707	1720	comorbidities	T078	C0009488
28293475	1724	1727	men	T098	C0025266
28293475	1732	1737	women	T098	C0043210

27899384|t|Rifampicin - induced adrenal crisis in a patient with tuberculosis: a therapeutic challenge
27899384|a|A 55-year-old Indian man presented with productive cough and a large left pleural effusion. Pleural fluid culture grew Mycobacterium tuberculosis, and he was started on antituberculosis therapy. One week later, the patient presented to hospital with drowsiness, dehydration and hypotension. He was transferred to critical care and only improved after starting hydrocortisone and stopping rifampicin. His short synACTHen test subsequently confirmed primary adrenal insufficiency, and a CT of the abdomen showed bilateral adrenal enlargement. Rifampicin is known to accelerate cortisol metabolism. We report the rare case of a rifampicin - induced adrenal crisis as a first presentation of Addison's disease in a patient with tuberculous infiltration of the adrenal glands.
27899384	0	10	Rifampicin	T109,T195	C0035608
27899384	13	20	induced	T169	C0205263
27899384	21	35	adrenal crisis	T047	C0151467
27899384	41	48	patient	T101	C0030705
27899384	54	66	tuberculosis	T047	C0041296
27899384	70	81	therapeutic	T169	C0302350
27899384	82	91	challenge	T058	C0805586
27899384	94	105	55-year-old	T100	C0001675
27899384	113	116	man	T032	C0086582
27899384	132	148	productive cough	T184	C0239134
27899384	161	182	left pleural effusion	T046	C2063367
27899384	184	205	Pleural fluid culture	T059	C1536153
27899384	206	210	grew	T067	C2911660
27899384	211	237	Mycobacterium tuberculosis	T007	C0026926
27899384	261	285	antituberculosis therapy	T061	C0087111
27899384	291	295	week	T079	C0439230
27899384	307	314	patient	T101	C0030705
27899384	328	336	hospital	T073,T093	C0019994
27899384	342	352	drowsiness	T033	C0013144
27899384	354	365	dehydration	T047	C0011175
27899384	370	381	hypotension	T033	C0020649
27899384	405	418	critical care	T078	C1547136
27899384	428	436	improved	T033	C0184511
27899384	443	451	starting	T079	C0439659
27899384	452	466	hydrocortisone	T109,T121,T125	C0020268
27899384	471	479	stopping	T079	C2746065
27899384	480	490	rifampicin	T109,T195	C0035608
27899384	496	516	short synACTHen test	T059	C0430144
27899384	540	569	primary adrenal insufficiency	T047	C3887896
27899384	577	579	CT	T060	C0040405
27899384	587	594	abdomen	T029	C0000726
27899384	602	619	bilateral adrenal	T023	C1621382
27899384	620	631	enlargement	T190	C2711450
27899384	633	643	Rifampicin	T109,T195	C0035608
27899384	656	666	accelerate	T169	C0521110
27899384	667	686	cortisol metabolism	T044	C2612767
27899384	717	727	rifampicin	T109,T195	C0035608
27899384	730	737	induced	T169	C0205263
27899384	738	752	adrenal crisis	T047	C0151467
27899384	780	797	Addison's disease	T047	C0001403
27899384	803	810	patient	T101	C0030705
27899384	816	827	tuberculous	T047	C0041296
27899384	828	840	infiltration	T046	C0332448
27899384	848	862	adrenal glands	T023	C0001625

27909557|t|Eating habits, physical activity, nutrition knowledge, and self-efficacy by obesity status in upper-grade elementary school students
27909557|a|Childhood obesity has increased in recent decades in Korea. This study was designed to examine differences in the eating habits, physical activity (PA), nutrition knowledge, and self-efficacy of children by obesity status. Subjects were 5th-grade children from 70 elementary schools in 17 cities nationwide. Two-stage stratified cluster sampling was employed. Survey questionnaire included items related to general characteristics, eating habits, PA, nutrition knowledge and self-efficacy. Excluding incomplete responses, 3,531 data were analyzed using SPSS. Subjects were categorized into overweight·obesity (OW) and normal weight (NW) groups based on body mass index percentiles for age by sex. A total of 21.5% of subjects was overweight or obese. There were significant differences in gender, perceived stress, perception of body shape, body satisfaction, and interest in weight control between the OW and NW groups (P < 0.001). With respect to eating habits, the OW group ate breakfast (P < 0.05) and snacks (P < 0.01) less frequently, ate bigger meals (P < 0.001), and demonstrated less desirable behaviors during meals (P <0.05 in boys) compared to the NW group. The OW group participated in less PA than the NW group, especially boys. OW boys spent less time walking during weekdays (P < 0.05) or the weekend (P < 0.001), spent more time being sedentary during weekdays or the weekend (P < 0.001), and exercised a fewer number of days (P < 0.01). For girls, the OW group spent more time being sedentary during the weekend (P < 0.01) and exercised a fewer number of days by walking or bicycle riding (P < 0.05) than the NW group. Nutrition knowledge was not significantly different between the OW and NW groups. Self-efficacy (P < 0.01 in boys), especially PA self-efficacy (P < 0.01), was significantly lower in the OW than NW group. This study revealed differences in eating habits, PA, and self-efficacy between OW and NW children. Obesity management programs for children need to focus on increasing self-efficacy, modifying eating habits, and increasing PA.
27909557	0	13	Eating habits	T055	C1266864
27909557	15	32	physical activity	T056	C0026606
27909557	34	53	nutrition knowledge	T033	C0946257
27909557	59	72	self-efficacy	T041	C0600564
27909557	76	90	obesity status	T033	C0421268
27909557	94	132	upper-grade elementary school students	T098	C0870481
27909557	133	150	Childhood obesity	T047	C2362324
27909557	186	191	Korea	T083	C0022771
27909557	247	260	eating habits	T055	C1266864
27909557	262	279	physical activity	T056	C0026606
27909557	281	283	PA	T056	C0026606
27909557	286	305	nutrition knowledge	T033	C0946257
27909557	311	324	self-efficacy	T041	C0600564
27909557	328	336	children	T100	C0008059
27909557	340	354	obesity status	T033	C0421268
27909557	356	364	Subjects	T098	C0080105
27909557	380	388	children	T100	C0008059
27909557	397	415	elementary schools	T073,T092	C0596497
27909557	422	439	cities nationwide	T083	C0008848
27909557	441	478	Two-stage stratified cluster sampling	T062	C0681883
27909557	493	513	Survey questionnaire	T170	C1714475
27909557	565	578	eating habits	T055	C1266864
27909557	580	582	PA	T056	C0026606
27909557	584	603	nutrition knowledge	T033	C0946257
27909557	608	621	self-efficacy	T041	C0600564
27909557	633	653	incomplete responses	T080	C0205257
27909557	661	665	data	T078	C1511726
27909557	686	690	SPSS	T081	C0038205
27909557	692	700	Subjects	T098	C0080105
27909557	723	741	overweight·obesity	T047	C4237343
27909557	743	745	OW	T047	C4237343
27909557	751	764	normal weight	T033	C2712185
27909557	766	768	NW	T033	C2712185
27909557	770	776	groups	T078	C0441833
27909557	786	828	body mass index percentiles for age by sex	T033	C3838397
27909557	850	858	subjects	T098	C0080105
27909557	863	882	overweight or obese	T047	C4237343
27909557	922	928	gender	T032	C0079399
27909557	930	946	perceived stress	T170	C0582653
27909557	948	972	perception of body shape	T033	C0243095
27909557	974	991	body satisfaction	T033	C0243095
27909557	997	1023	interest in weight control	T055	C1321111
27909557	1036	1038	OW	T047	C4237343
27909557	1043	1045	NW	T033	C2712185
27909557	1046	1052	groups	T078	C0441833
27909557	1082	1095	eating habits	T055	C1266864
27909557	1101	1103	OW	T047	C4237343
27909557	1104	1109	group	T078	C0441833
27909557	1114	1123	breakfast	T056	C2698559
27909557	1139	1145	snacks	T168	C0453863
27909557	1174	1190	ate bigger meals	T056	C1998602
27909557	1221	1245	less desirable behaviors	T053	C0004927
27909557	1246	1258	during meals	T079	C0587120
27909557	1271	1275	boys	T100	C0870221
27909557	1293	1295	NW	T033	C2712185
27909557	1296	1301	group	T078	C0441833
27909557	1307	1309	OW	T047	C4237343
27909557	1310	1315	group	T078	C0441833
27909557	1310	1315	group	T078	C0441833
27909557	1337	1339	PA	T056	C0026606
27909557	1349	1351	NW	T033	C2712185
27909557	1352	1357	group	T078	C0441833
27909557	1370	1374	boys	T100	C0870221
27909557	1376	1378	OW	T047	C4237343
27909557	1379	1383	boys	T100	C0870221
27909557	1384	1407	spent less time walking	T033	C0851791
27909557	1415	1423	weekdays	T079	C0680189
27909557	1442	1449	weekend	T079	C0680190
27909557	1463	1494	spent more time being sedentary	T056	C1519977
27909557	1502	1510	weekdays	T079	C0680189
27909557	1518	1525	weekend	T079	C0680190
27909557	1543	1552	exercised	T056	C0015259
27909557	1555	1575	fewer number of days	T033	C3843681
27909557	1592	1597	girls	T100	C0870604
27909557	1603	1605	OW	T047	C4237343
27909557	1606	1611	group	T078	C0441833
27909557	1612	1643	spent more time being sedentary	T056	C1519977
27909557	1655	1662	weekend	T079	C0680190
27909557	1678	1687	exercised	T056	C0015259
27909557	1690	1710	fewer number of days	T033	C3843681
27909557	1714	1721	walking	T056	C0080331
27909557	1725	1739	bicycle riding	T033	C0577368
27909557	1760	1762	NW	T033	C2712185
27909557	1763	1768	group	T078	C0441833
27909557	1770	1789	Nutrition knowledge	T033	C0946257
27909557	1834	1836	OW	T047	C4237343
27909557	1841	1843	NW	T033	C2712185
27909557	1844	1850	groups	T078	C0441833
27909557	1852	1865	Self-efficacy	T041	C0600564
27909557	1879	1883	boys	T100	C0870221
27909557	1897	1899	PA	T056	C0026606
27909557	1900	1913	self-efficacy	T041	C0600564
27909557	1957	1959	OW	T047	C4237343
27909557	1965	1967	NW	T033	C2712185
27909557	1968	1973	group	T078	C0441833
27909557	2010	2023	eating habits	T055	C1266864
27909557	2025	2027	PA	T056	C0026606
27909557	2033	2046	self-efficacy	T041	C0600564
27909557	2055	2057	OW	T047	C4237343
27909557	2062	2064	NW	T033	C2712185
27909557	2065	2073	children	T100	C0008059
27909557	2075	2102	Obesity management programs	T058	C4273558
27909557	2107	2115	children	T100	C0008059
27909557	2144	2157	self-efficacy	T041	C0600564
27909557	2169	2182	eating habits	T055	C1266864
27909557	2199	2201	PA	T056	C0026606

27919317|t|Drosophila neprilysins control insulin signaling and food intake via cleavage of regulatory peptides
27919317|a|Insulin and IGF signaling are critical to numerous developmental and physiological processes, with perturbations being pathognomonic of various diseases, including diabetes. Although the functional roles of the respective signaling pathways have been extensively studied, the control of insulin production and release is only partially understood. Herein, we show that in Drosophila expression of insulin-like peptides is regulated by neprilysin activity. Concomitant phenotypes of altered neprilysin expression included impaired food intake, reduced body size, and characteristic changes in the metabolite composition. Ectopic expression of a catalytically inactive mutant did not elicit any of the phenotypes, which confirms abnormal peptide hydrolysis as a causative factor. A screen for corresponding substrates of the neprilysin identified distinct peptides that regulate insulin-like peptide expression, feeding behavior, or both. The high functional conservation of neprilysins and their substrates renders the characterized principles applicable to numerous species, including higher eukaryotes and humans.
27919317	0	10	Drosophila	T204	C0013138
27919317	11	22	neprilysins	T116,T126	C0025250
27919317	23	30	control	T169	C2587213
27919317	31	48	insulin signaling	T044	C1512804
27919317	53	64	food intake	T040	C0013470
27919317	69	77	cleavage	T044	C0597304
27919317	81	91	regulatory	T077	C1704735
27919317	92	100	peptides	T116	C0030956
27919317	101	108	Insulin	T044	C1512804
27919317	113	126	IGF signaling	T044	C1155394
27919317	143	151	numerous	T081	C0439064
27919317	152	165	developmental	T040	C0678723
27919317	170	193	physiological processes	T039	C0031845
27919317	200	213	perturbations	T169	C0332453
27919317	220	233	pathognomonic	T077	C2986472
27919317	245	253	diseases	T047	C0012634
27919317	265	273	diabetes	T047	C0011847
27919317	288	304	functional roles	T077	C1705810
27919317	323	341	signaling pathways	T044	C0037080
27919317	364	371	studied	T062	C2603343
27919317	377	384	control	T169	C2587213
27919317	388	395	insulin	T116,T121,T125	C0021641
27919317	396	406	production	T038	C0220781
27919317	411	418	release	T044	C1148560
27919317	473	483	Drosophila	T204	C0013138
27919317	484	494	expression	T045	C1171362
27919317	498	519	insulin-like peptides	T116,T125	C0037657
27919317	536	555	neprilysin activity	T044	C1150197
27919317	557	568	Concomitant	T079	C0521115
27919317	569	579	phenotypes	T032	C0031437
27919317	591	601	neprilysin	T116,T126	C0025250
27919317	602	612	expression	T045	C1171362
27919317	622	630	impaired	T169	C0221099
27919317	631	642	food intake	T040	C0013470
27919317	644	651	reduced	T080	C0392756
27919317	652	661	body size	T032	C0005901
27919317	667	681	characteristic	T080	C1521970
27919317	682	689	changes	T169	C0392747
27919317	697	707	metabolite	T123	C0870883
27919317	708	719	composition	T080	C0205198
27919317	721	728	Ectopic	T082	C0574895
27919317	729	739	expression	T045	C1171362
27919317	745	774	catalytically inactive mutant	T116	C1564139
27919317	801	811	phenotypes	T032	C0031437
27919317	828	836	abnormal	T033	C0205161
27919317	837	855	peptide hydrolysis	T044	C0597304
27919317	861	877	causative factor	T169	C1521761
27919317	906	916	substrates	T167	C3891814
27919317	924	934	neprilysin	T116,T126	C0025250
27919317	955	963	peptides	T116	C0030956
27919317	978	998	insulin-like peptide	T116,T125	C0037657
27919317	999	1009	expression	T045	C1171362
27919317	1011	1027	feeding behavior	T040	C0013470
27919317	1047	1057	functional	T169	C0205245
27919317	1058	1070	conservation	T080	C2347858
27919317	1074	1085	neprilysins	T116,T126	C0025250
27919317	1096	1106	substrates	T167	C3891814
27919317	1158	1166	numerous	T081	C0439064
27919317	1167	1174	species	T185	C1705920
27919317	1193	1203	eukaryotes	T204	C0684063
27919317	1208	1214	humans	T016	C0086418

28471040|t|Farnesylthiosalicylic acid -loaded lipid-polyethylene glycol-polymer hybrid nanoparticles for treatment of glioblastoma
28471040|a|We aimed to develop lipid-polyethylene glycol (PEG)-polymer hybrid nanoparticles, which have high affinity to tumour tissue with active ingredient, a new generation antineoplastic drug, farnesylthiosalicylic acid (FTA) for treatment of glioblastoma. Farnesylthiosalicylic acid -loaded poly(lactic-co-glycolic acid)-1,2 distearoyl-glycerol-3-phospho-ethanolamine-N [methoxy (PEG)-2000] ammonium salt (PLGA-DSPE-PEG) with or without 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) hybrid nanoparticles has been prepared and evaluated for in-vitro characterization. Cytotoxicity of FTA-loaded nanoparticles along with its efficacy on rat glioma-2 (RG2) cells was also evaluated both in vitro (in comparison with non-malignant cell line, L929) and in vivo. Scanning electron microscopy studies showed that all formulations prepared had smooth surface and spherical in shape. FTA and FTA-loaded nanoparticles have cytotoxic activity against RG2 glioma cell lines in cell culture studies, which further increases with addition of DOTAP. Magnetic resonance imaging and histopathologic evaluation on RG2 tumour cells in rat glioma model (49 female Wistar rats, 250-300 g) comparing intravenous and intratumoral injections of the drug have been performed and FTA-loaded nanoparticles reduced tumour size significantly in in-vivo studies, with higher efficiency of intratumoral administration than intravenous route. Farnesylthiosalicylic acid -loaded PLGA-DSPE-PEG-DOTAP hybrid nanoparticles are proven to be effective against glioblastoma in both in-vitro and in-vivo experiments.
28471040	0	26	Farnesylthiosalicylic acid	T109	C0297002
28471040	35	89	lipid-polyethylene glycol-polymer hybrid nanoparticles	T121	C1254351
28471040	94	103	treatment	T061	C0087111
28471040	107	119	glioblastoma	T191	C0017636
28471040	140	200	lipid-polyethylene glycol (PEG)-polymer hybrid nanoparticles	T121	C1254351
28471040	230	243	tumour tissue	T024	C0475358
28471040	249	266	active ingredient	T120	C1372955
28471040	274	284	generation	T079	C0079411
28471040	285	304	antineoplastic drug	T109,T121	C0003392
28471040	306	332	farnesylthiosalicylic acid	T109	C0297002
28471040	334	337	FTA	T109	C0297002
28471040	343	352	treatment	T061	C0087111
28471040	356	368	glioblastoma	T191	C0017636
28471040	370	396	Farnesylthiosalicylic acid	T109	C0297002
28471040	405	518	poly(lactic-co-glycolic acid)-1,2 distearoyl-glycerol-3-phospho-ethanolamine-N [methoxy (PEG)-2000] ammonium salt	T121	C1254351
28471040	520	533	PLGA-DSPE-PEG	T121	C1254351
28471040	551	620	1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) hybrid nanoparticles	T121	C1254351
28471040	630	638	prepared	T033	C4082130
28471040	643	652	evaluated	T058	C0220825
28471040	657	682	in-vitro characterization	T062	C0681828
28471040	684	696	Cytotoxicity	T049	C0596402
28471040	700	724	FTA-loaded nanoparticles	T109	C0297002
28471040	740	748	efficacy	T081	C0013682
28471040	752	776	rat glioma-2 (RG2) cells	T025	C0007634
28471040	786	795	evaluated	T058	C0220825
28471040	801	809	in vitro	T062	C0681828
28471040	830	859	non-malignant cell line, L929	T025	C0007600
28471040	865	872	in vivo	T062	C0681829
28471040	874	910	Scanning electron microscopy studies	T059	C0523160
28471040	927	948	formulations prepared	T077	C1705957
28471040	953	967	smooth surface	T201	C1182795
28471040	972	990	spherical in shape	T082	C0332501
28471040	992	995	FTA	T109	C0297002
28471040	1000	1024	FTA-loaded nanoparticles	T109	C0297002
28471040	1030	1048	cytotoxic activity	T049	C0596402
28471040	1057	1078	RG2 glioma cell lines	T025	C0007600
28471040	1082	1102	cell culture studies	UnknownType	C0681854
28471040	1145	1150	DOTAP	T121	C1254351
28471040	1152	1178	Magnetic resonance imaging	T060	C0024485
28471040	1183	1198	histopathologic	T091	C0677043
28471040	1199	1209	evaluation	T058	C0220825
28471040	1213	1229	RG2 tumour cells	T025	C0431085
28471040	1233	1249	rat glioma model	T050	C0012644
28471040	1261	1272	Wistar rats	T015	C0034716
28471040	1295	1306	intravenous	T169	C0021494
28471040	1311	1334	intratumoral injections	T169	C1517565
28471040	1342	1346	drug	T121	C1254351
28471040	1371	1395	FTA-loaded nanoparticles	T109	C0297002
28471040	1404	1415	tumour size	T082	C0475440
28471040	1433	1448	in-vivo studies	T062	C0681829
28471040	1462	1472	efficiency	T081	C0013682
28471040	1476	1503	intratumoral administration	T169	C1517565
28471040	1509	1526	intravenous route	T169	C1522726
28471040	1528	1554	Farnesylthiosalicylic acid	T109	C0297002
28471040	1563	1603	PLGA-DSPE-PEG-DOTAP hybrid nanoparticles	T121	C1254351
28471040	1621	1630	effective	T080	C1704419
28471040	1639	1651	glioblastoma	T191	C0017636
28471040	1660	1668	in-vitro	T062	C0681828
28471040	1673	1692	in-vivo experiments	T062	C0681829

28039304|t|Allergen Valency, Dose, and FcεRI Occupancy Set Thresholds for Secretory Responses to Pen a 1 and Motivate Design of Hypoallergens
28039304|a|Ag -mediated crosslinking of IgE - FcεRI complexes activates mast cells and basophils, initiating the allergic response. Of 34 donors recruited having self-reported shrimp allergy, only 35% had significant levels of shrimp-specific IgE in serum and measurable basophil secretory responses to rPen a 1 (shrimp tropomyosin). We report that degranulation is linked to the number of FcεRI occupied with allergen-specific IgE, as well as the dose and valency of Pen a 1. Using clustered regularly interspaced palindromic repeat-based gene editing, human RBL(rαKO) cells were created that exclusively express the human FcεRIα subunit. Pen a 1 - specific IgE was affinity purified from shrimp - positive plasma. Cells primed with a range of Pen a 1 - specific IgE and challenged with Pen a 1 showed a bell-shaped dose response for secretion, with optimal Pen a 1 doses of 0.1-10 ng/ml. Mathematical modeling provided estimates of receptor aggregation kinetics based on FcεRI occupancy with IgE and allergen dose. Maximal degranulation was elicited when ∼2700 I gE - FcεRI complexes were occupied with specific IgE and challenged with Pen a 1 (IgE epitope valency of ≥8), although measurable responses were achieved when only a few hundred FcεRI were occupied. Prolonged periods of pepsin -mediated Pen a 1 proteolysis, which simulates gastric digestion, were required to diminish secretory responses. Recombinant fragments (60-79 aa), which together span the entire length of tropomyosin, were weak secretagogues. These fragments have reduced dimerization capacity, compete with intact Pen a 1 for binding to IgE - FcεRI complexes, and represent a starting point for the design of promising hypoallergens for immunotherapy.
28039304	0	8	Allergen	T129	C0002092
28039304	9	16	Valency	T081	C0392762
28039304	18	22	Dose	T081	C0178602
28039304	28	33	FcεRI	T116,T129,T192	C0162825
28039304	34	43	Occupancy	T080	C2827063
28039304	48	58	Thresholds	T080	C0449864
28039304	63	82	Secretory Responses	T043	C1327439
28039304	86	93	Pen a 1	T116,T123	C0531911
28039304	107	113	Design	T052	C1707689
28039304	117	130	Hypoallergens	T129	C0002092
28039304	131	133	Ag	T196	C0037125
28039304	144	156	crosslinking	T070	C0178576
28039304	160	163	IgE	T116,T129	C0020846
28039304	166	171	FcεRI	T116,T129,T192	C0162825
28039304	172	181	complexes	T116,T129	C0003313
28039304	192	202	mast cells	T025	C0024880
28039304	207	216	basophils	T025	C0004827
28039304	233	250	allergic response	T046	C1527304
28039304	282	295	self-reported	T062	C0681906
28039304	296	310	shrimp allergy	T046	C1628514
28039304	347	366	shrimp-specific IgE	T116,T129	C1270759
28039304	370	375	serum	T031	C0229671
28039304	391	399	basophil	T025	C0004827
28039304	400	409	secretory	T043	C1327616
28039304	410	419	responses	T038	C0003261
28039304	423	431	rPen a 1	T129	C2924509
28039304	433	439	shrimp	T204	C0037017
28039304	440	451	tropomyosin	T116,T123	C0041197
28039304	510	515	FcεRI	T116,T129,T192	C0162825
28039304	530	551	allergen-specific IgE	T116,T129	C0443736
28039304	568	572	dose	T081	C0178602
28039304	577	584	valency	T081	C0392762
28039304	588	595	Pen a 1	T116,T123	C0531911
28039304	603	672	clustered regularly interspaced palindromic repeat-based gene editing	T063	C4277689
28039304	744	750	FcεRIα	T116,T129,T192	C0162825
28039304	760	767	Pen a 1	T116,T123	C0531911
28039304	770	782	specific IgE	T116,T129	C0443736
28039304	810	816	shrimp	T204	C0037017
28039304	819	827	positive	T033	C1514241
28039304	828	834	plasma	T031	C0032105
28039304	865	872	Pen a 1	T116,T123	C0531911
28039304	875	887	specific IgE	T116,T129	C0443736
28039304	908	915	Pen a 1	T116,T123	C0531911
28039304	937	941	dose	T081	C0178602
28039304	942	964	response for secretion	T043	C3155125
28039304	979	986	Pen a 1	T116,T123	C0531911
28039304	987	992	doses	T081	C0178602
28039304	1010	1031	Mathematical modeling	T170	C0876936
28039304	1054	1074	receptor aggregation	T044	C0034780
28039304	1075	1083	kinetics	T070	C0022702
28039304	1093	1098	FcεRI	T116,T129,T192	C0162825
28039304	1114	1117	IgE	T116,T129	C0020846
28039304	1122	1130	allergen	T129	C0002092
28039304	1131	1135	dose	T081	C0178602
28039304	1185	1187	gE	T116,T129	C1270759
28039304	1190	1195	FcεRI	T116,T129,T192	C0162825
28039304	1196	1205	complexes	T116,T129	C0003313
28039304	1225	1237	specific IgE	T116,T129	C1270759
28039304	1258	1265	Pen a 1	T116,T123	C0531911
28039304	1267	1270	IgE	T116,T129	C1270759
28039304	1271	1278	epitope	T129	C0003316
28039304	1279	1286	valency	T081	C0392762
28039304	1363	1368	FcεRI	T116,T129,T192	C0162825
28039304	1405	1411	pepsin	T116,T121,T126	C0030909
28039304	1422	1429	Pen a 1	T116,T123	C0531911
28039304	1430	1441	proteolysis	T044	C0597304
28039304	1459	1466	gastric	T080	C1704242
28039304	1467	1476	digestion	T040	C0012238
28039304	1504	1523	secretory responses	T043	C1327439
28039304	1525	1546	Recombinant fragments	T116	C0599286
28039304	1600	1611	tropomyosin	T116,T123	C0041197
28039304	1667	1679	dimerization	T044	C1323329
28039304	1680	1688	capacity	T081	C1516240
28039304	1710	1717	Pen a 1	T116,T123	C0531911
28039304	1733	1736	IgE	T116,T129	C1270759
28039304	1739	1744	FcεRI	T116,T129,T192	C0162825
28039304	1745	1754	complexes	T116,T129	C0003313
28039304	1815	1828	hypoallergens	T129	C0002092
28039304	1833	1846	immunotherapy	T061	C0021083

27512369|t|Interoception and Positive Symptoms in Schizophrenia
27512369|a|The present study focuses on the multifaceted concept of self-disturbance in schizophrenia, adding knowledge about a not yet investigated aspect, which is the interoceptive accuracy. Starting from the assumption that interoceptive accuracy requires an intact sense of self, which otherwise was proved to be altered in schizophrenia, the aim of the present study was to explore interoceptive accuracy in a group of schizophrenia patients, compared to healthy controls. Furthermore, the possible association between interoceptive accuracy and patients ' positive and negative symptomatology was assessed. To pursue these goals, a group of 23 schizophrenia patients and a group of 23 healthy controls performed a heartbeat perception task. Patients ' symptomatology was assessed by means of the Positive and Negative Syndrome Scale (PANSS). Results demonstrated significantly lower interoceptive accuracy in schizophrenia patients compared to healthy controls. This difference was not accounted for participants ' age, BMI, anxiety levels, and heart rate. Furthermore, patients ' illness severity, attention and pharmacological treatment did not influence their interoceptive accuracy levels. Interestingly, a strong positive relation between interoceptive accuracy and positive symptoms severity, especially Grandiosity, was found. The present results demonstrate for the first time that interoceptive accuracy is altered in schizophrenia. Furthermore, they prove a specific association between interoceptive accuracy and positive symptomatology, suggesting that the symptom Grandiosity might be protective against an altered basic sense of self in patients characterized by higher sensibility to their inner bodily sensations.
27512369	0	13	Interoception	T041	C3850156
27512369	18	35	Positive Symptoms	T184	C1457887
27512369	39	52	Schizophrenia	T048	C0036341
27512369	65	70	study	T062	C0008972
27512369	86	98	multifaceted	T082	C0205291
27512369	99	106	concept	T078	C0178566
27512369	110	126	self-disturbance	T048	C0150074
27512369	130	143	schizophrenia	T048	C0036341
27512369	178	190	investigated	T169	C1292732
27512369	212	225	interoceptive	T041	C3850156
27512369	226	234	accuracy	T080	C0443131
27512369	270	283	interoceptive	T041	C3850156
27512369	284	292	accuracy	T080	C0443131
27512369	312	325	sense of self	T041	C0424215
27512369	371	384	schizophrenia	T048	C0036341
27512369	409	414	study	T062	C0008972
27512369	430	443	interoceptive	T041	C3850156
27512369	444	452	accuracy	T080	C0443131
27512369	458	463	group	T098	C1257890
27512369	467	480	schizophrenia	T048	C0036341
27512369	481	489	patients	T101	C0030705
27512369	491	499	compared	T052	C1707455
27512369	503	519	healthy controls	T080	C2986479
27512369	547	558	association	T080	C0439849
27512369	567	580	interoceptive	T041	C3850156
27512369	581	589	accuracy	T080	C0443131
27512369	594	602	patients	T101	C0030705
27512369	605	641	positive and negative symptomatology	T184	C0871099
27512369	646	654	assessed	T052	C1516048
27512369	681	686	group	T098	C1257890
27512369	693	706	schizophrenia	T048	C0036341
27512369	707	715	patients	T101	C0030705
27512369	722	727	group	T098	C1257890
27512369	734	750	healthy controls	T080	C2986479
27512369	751	760	performed	T169	C0884358
27512369	763	772	heartbeat	T042	C0425583
27512369	773	783	perception	T041	C0030971
27512369	784	788	task	T057	C3540678
27512369	790	798	Patients	T101	C0030705
27512369	801	815	symptomatology	T184	C1457887
27512369	820	828	assessed	T052	C1516048
27512369	845	881	Positive and Negative Syndrome Scale	T170	C0451383
27512369	883	888	PANSS	T170	C0451383
27512369	891	898	Results	T033	C0683954
27512369	912	925	significantly	T078	C0750502
27512369	926	931	lower	T080	C0205251
27512369	932	945	interoceptive	T041	C3850156
27512369	946	954	accuracy	T080	C0443131
27512369	958	971	schizophrenia	T048	C0036341
27512369	972	980	patients	T101	C0030705
27512369	981	989	compared	T052	C1707455
27512369	993	1009	healthy controls	T080	C2986479
27512369	1049	1061	participants	T098	C0679646
27512369	1064	1067	age	T032	C0001779
27512369	1069	1072	BMI	T201	C1305855
27512369	1074	1088	anxiety levels	T033	C0564474
27512369	1094	1104	heart rate	T201	C0018810
27512369	1119	1127	patients	T101	C0030705
27512369	1130	1146	illness severity	T080	C0521117
27512369	1148	1157	attention	T041	C0004268
27512369	1162	1187	pharmacological treatment	T061	C0013216
27512369	1196	1205	influence	T077	C4054723
27512369	1212	1225	interoceptive	T041	C3850156
27512369	1226	1234	accuracy	T080	C0443131
27512369	1235	1241	levels	T080	C0441889
27512369	1267	1275	positive	T033	C1446409
27512369	1276	1284	relation	T080	C0439849
27512369	1293	1306	interoceptive	T041	C3850156
27512369	1307	1315	accuracy	T080	C0443131
27512369	1320	1346	positive symptoms severity	T033	C1319166
27512369	1359	1370	Grandiosity	T048	C0233681
27512369	1395	1402	results	T033	C0683954
27512369	1439	1452	interoceptive	T041	C3850156
27512369	1453	1461	accuracy	T080	C0443131
27512369	1476	1489	schizophrenia	T048	C0036341
27512369	1526	1537	association	T080	C0439849
27512369	1546	1559	interoceptive	T041	C3850156
27512369	1560	1568	accuracy	T080	C0443131
27512369	1573	1596	positive symptomatology	T184	C1457887
27512369	1618	1625	symptom	T184	C1457887
27512369	1626	1637	Grandiosity	T048	C0233681
27512369	1647	1657	protective	T033	C1545588
27512369	1683	1696	sense of self	T041	C0424215
27512369	1700	1708	patients	T101	C0030705
27512369	1709	1722	characterized	T052	C1880022
27512369	1733	1744	sensibility	T080	C0439823
27512369	1760	1777	bodily sensations	T033	C0542538

28523174|t|Rupture of GORE-TEX neochordae 10 years after mitral valve repair
28523174|a|The current non - resectional paradigm in mitral valve (MV) repair emphasizes the use of polytetrafluoroethylene (PTFE) for artificial chordal replacement. While excellent long-term durability of repair using PTFE neochordae has been established, there have been rare reports of neochordal rupture at various times after surgery. We report a case of artificial chordal rupture 10 years after anterior mitral leaflet repair, necessitating reoperation. This complication may have been precipitated by maldistributed intracardiac tensile forces as a consequence of a malpositioned annuloplasty band.
28523174	0	7	Rupture	T067	C1881712
28523174	11	30	GORE-TEX neochordae	T109,T122	C0018088
28523174	46	65	mitral valve repair	T061	C0869755
28523174	70	77	current	T079	C0521116
28523174	78	81	non	T169	C1518422
28523174	84	95	resectional	T061	C0015252
28523174	96	104	paradigm	T062	C0681797
28523174	108	132	mitral valve (MV) repair	T061	C0869755
28523174	148	154	use of	T169	C1524063
28523174	155	178	polytetrafluoroethylene	T109,T122	C0032611
28523174	180	184	PTFE	T109,T122	C0032611
28523174	190	220	artificial chordal replacement	T061	C0026268
28523174	228	237	excellent	T080	C1961136
28523174	238	247	long-term	T079	C0443252
28523174	248	258	durability	T067	C3179278
28523174	262	268	repair	T061	C0869755
28523174	275	290	PTFE neochordae	T109,T122	C0032611
28523174	329	333	rare	T080	C0522498
28523174	334	341	reports	T058	C0178896
28523174	345	363	neochordal rupture	T047	C0340366
28523174	367	374	various	T080	C1705242
28523174	375	380	times	T079	C1948053
28523174	387	394	surgery	T091	C0038894
28523174	408	412	case	T169	C0868928
28523174	416	426	artificial	T080	C2004457
28523174	427	442	chordal rupture	T047	C0340366
28523174	452	457	after	T079	C0687676
28523174	458	466	anterior	T082	C0205094
28523174	467	488	mitral leaflet repair	T061	C2066462
28523174	504	515	reoperation	T061	C0035110
28523174	522	534	complication	T046	C0009566
28523174	549	564	precipitated by	T080	C1444748
28523174	565	579	maldistributed	T080	C0332619
28523174	580	592	intracardiac	T023	C0729936
28523174	593	607	tensile forces	T081	C0039526
28523174	613	627	consequence of	T169	C0686907
28523174	630	643	malpositioned	T082	C0333042
28523174	644	661	annuloplasty band	T074	C2363436

27851729|t|In vivo genome editing via CRISPR/Cas9 mediated homology-independent targeted integration
27851729|a|Targeted genome editing via engineered nucleases is an exciting area of biomedical research and holds potential for clinical applications. Despite rapid advances in the field, in vivo targeted transgene integration is still infeasible because current tools are inefficient, especially for non-dividing cells, which compose most adult tissues. This poses a barrier for uncovering fundamental biological principles and developing treatments for a broad range of genetic disorders. Based on clustered regularly interspaced short palindromic repeat/Cas9 (CRISPR/Cas9) technology, here we devise a homology-independent targeted integration (HITI) strategy, which allows for robust DNA knock-in in both dividing and non-dividing cells in vitro and, more importantly, in vivo (for example, in neurons of postnatal mammals). As a proof of concept of its therapeutic potential, we demonstrate the efficacy of HITI in improving visual function using a rat model of the retinal degeneration condition retinitis pigmentosa. The HITI method presented here establishes new avenues for basic research and targeted gene therapies.
27851729	0	7	In vivo	T082	C1515655
27851729	8	22	genome editing	T063	C4279981
27851729	27	38	CRISPR/Cas9	T063	C1513384
27851729	48	89	homology-independent targeted integration	T063	C1513384
27851729	99	113	genome editing	T063	C4279981
27851729	118	128	engineered	T063	C0017387
27851729	129	138	nucleases	T116,T126	C0597094
27851729	162	181	biomedical research	T062	C0005540
27851729	206	227	clinical applications	T201	C0683325
27851729	266	273	in vivo	T082	C1515655
27851729	274	304	targeted transgene integration	T045	C1158478
27851729	341	346	tools	T063	C4279981
27851729	379	397	non-dividing cells	T025	C1512899
27851729	424	431	tissues	T024	C0040300
27851729	481	502	biological principles	T080	C0205460
27851729	518	528	treatments	T061	C0087111
27851729	550	567	genetic disorders	T047	C0019247
27851729	578	664	clustered regularly interspaced short palindromic repeat/Cas9 (CRISPR/Cas9) technology	T063	C1513384
27851729	683	740	homology-independent targeted integration (HITI) strategy	T063	C1513384
27851729	766	769	DNA	T114,T123	C0012854
27851729	770	778	knock-in	T062	C1517676
27851729	787	795	dividing	T025	C0230517
27851729	800	818	non-dividing cells	T025	C1512899
27851729	819	827	in vitro	T059,T062	C3850137
27851729	851	858	in vivo	T082	C1515655
27851729	876	883	neurons	T025	C0027882
27851729	887	896	postnatal	T079	C0443281
27851729	897	904	mammals	T015	C0024660
27851729	936	947	therapeutic	T169	C0302350
27851729	948	957	potential	T080	C3245505
27851729	990	994	HITI	T063	C1513384
27851729	1008	1023	visual function	T040	C0042789
27851729	1032	1041	rat model	T008	C0599779
27851729	1049	1069	retinal degeneration	T046	C0035304
27851729	1080	1100	retinitis pigmentosa	T047	C0035334
27851729	1106	1117	HITI method	T063	C1513384
27851729	1161	1175	basic research	T062	C0681833
27851729	1180	1188	targeted	T169	C1521840
27851729	1189	1203	gene therapies	T061	C0017296

28273224|t|Emergency cricothyrotomy: temporary measure or definitive airway? A systematic review
28273224|a|Being a fast and safe method in the hands of well trained professionals in both prehospital and intrahospital care, Cricothyrotomy has been broadly recommended as the initial surgical airway in the scenario " can't intubate, can't ventilate ", and is particularly useful when the obstruction level is above or at the glottis. Its prolonged permanence, however, is an endless source of controversy. In this review we evaluate the complications of cricothyrotomy and the need of its routine conversion to tracheotomy through a search on PubMed, LILACS and SciELO electronic databases with no restriction to the year or language of the publication. In total, we identified 791 references, retrieved 20 full text articles, and included nine studies in our review. The incidence of short-term complications ranged from zero to 31.6%, and the long-term complications, from zero to 7.86%. Subglotic stenosis was the main long-term reported complication, even though it was quite infrequent, occurring only in 2.9 to 5%. The frequency of conversion to tracheostomy varied from zero to 100%. Although a small frequency of long-term complications was found for emergency cricothyrotomy, the studies' low level of evidence does not allow the recommendation of routine use of cricothyrotomy as a secure definitive airway.
28273224	0	9	Emergency	T079	C0175673
28273224	10	24	cricothyrotomy	T061	C3826502
28273224	26	35	temporary	T079	C0205374
28273224	36	43	measure	T081	C0079809
28273224	47	57	definitive	T079	C0443196
28273224	58	64	airway	T023	C0458827
28273224	68	85	systematic review	T170	C1955832
28273224	94	98	fast	T080	C0456962
28273224	103	114	safe method	T170	C0025663
28273224	131	157	well trained professionals	T097	C0679924
28273224	166	177	prehospital	T058	C2735050
28273224	182	200	intrahospital care	T058	C0086388
28273224	202	216	Cricothyrotomy	T061	C3826502
28273224	234	245	recommended	T078	C0034866
28273224	261	276	surgical airway	T061	C0087111
28273224	295	326	can't intubate, can't ventilate	T033	C4273754
28273224	366	383	obstruction level	T082	C0449824
28273224	403	410	glottis	T029	C0017681
28273224	416	425	prolonged	T079	C0439590
28273224	426	436	permanence	T079	C0547050
28273224	515	528	complications	T046	C0009566
28273224	532	546	cricothyrotomy	T061	C3826502
28273224	567	574	routine	T080	C0205547
28273224	575	585	conversion	T169	C0439836
28273224	589	600	tracheotomy	T061	C0040591
28273224	621	627	PubMed	T170	C1138432
28273224	629	635	LILACS	T170	C0242356
28273224	640	646	SciELO	T170	C0242356
28273224	647	667	electronic databases	T170	C3841595
28273224	676	687	restriction	T169	C0443288
28273224	695	699	year	T079	C0439234
28273224	703	711	language	T171	C0023008
28273224	719	730	publication	T073,T170	C0034036
28273224	745	755	identified	T080	C0205396
28273224	760	770	references	T170	C1514811
28273224	785	803	full text articles	T170	C1706852
28273224	823	830	studies	T062	C2603343
28273224	838	844	review	T078	C1552617
28273224	863	873	short-term	T079	C0443303
28273224	874	887	complications	T046	C0009566
28273224	923	932	long-term	T079	C0443252
28273224	933	946	complications	T046	C0009566
28273224	968	986	Subglotic stenosis	T190	C0238441
28273224	1000	1009	long-term	T079	C0443252
28273224	1019	1031	complication	T046	C0009566
28273224	1058	1068	infrequent	T079	C0521114
28273224	1103	1112	frequency	T079	C0439603
28273224	1116	1126	conversion	T169	C0439836
28273224	1130	1142	tracheostomy	T061	C0040590
28273224	1186	1195	frequency	T079	C0439603
28273224	1199	1208	long-term	T079	C0443252
28273224	1209	1222	complications	T046	C0009566
28273224	1237	1246	emergency	T079	C0175673
28273224	1247	1261	cricothyrotomy	T061	C3826502
28273224	1289	1297	evidence	T078	C3887511
28273224	1317	1331	recommendation	T078	C0034866
28273224	1335	1342	routine	T080	C0205547
28273224	1343	1349	use of	T169	C1524063
28273224	1350	1364	cricothyrotomy	T061	C3826502
28273224	1377	1387	definitive	T079	C0443196
28273224	1388	1394	airway	T023	C0458827

27234004|t|Factors preventing kneeling in a group of pre-educated patients post total knee arthroplasty
27234004|a|Difficulties in kneeling, one of the poorest scoring functional outcomes post total knee arthroplasty (TKA),have been attributed to a lack of patient education. This is the first study to investigate specific factors affecting a patient's perceived ability to kneel post TKA, following exposure to a preoperative kneeling education session. A cross-sectional study was conducted following TKA with patients who had been educated about kneeling prior to the operation. Patients completed kneeling questionnaires at 6 (n = 115) and 12 (n = 82) months post TKA. In addition to the 12-month kneeling questionnaire, patients also completed the Oxford knee score (OKS) survey. Seventy-two percent of patients perceived they could kneel at 12 months post TKA. Overall, pain and discomfort were the most common factors deterring patients from kneeling. Perceived kneeling ability was the poorest scored outcome on the OKS with patients reporting mild to moderate difficulty with this task. Kneeling scores were strongly correlated with overall knee function scores (R = 0.70), strongly correlated with pain scores (R = 0.45) and weakly correlated with knee stability scores (R = 0.29). When asked about other factors preventing kneeling other than pain or discomfor t, 75 % had reasons unrelated to the knee or TKA. The most common reason was 'problems with the other knee ' (n = 19). Patients in this study were provided with education regarding their kneeling ability post TKA, yet still experienced limitations in perceived kneeling ability post operatively. Contrary to previous research, our study suggests that factors other than patient education affect a patient's perceived kneeling ability post TKA.
27234004	0	7	Factors	T169	C1521761
27234004	8	18	preventing	T169	C1292733
27234004	19	27	kneeling	T039	C2584307
27234004	33	38	group	T078	C0441833
27234004	42	54	pre-educated	T065	C2106353
27234004	55	63	patients	T101	C0030705
27234004	64	68	post	T079	C0687676
27234004	69	92	total knee arthroplasty	T061	C0086511
27234004	93	117	Difficulties in kneeling	T033	C0555092
27234004	130	165	poorest scoring functional outcomes	T033	C0243095
27234004	166	170	post	T079	C0687676
27234004	171	194	total knee arthroplasty	T061	C0086511
27234004	196	199	TKA	T061	C0086511
27234004	211	221	attributed	T078	C0449234
27234004	227	231	lack	T080	C0332268
27234004	235	242	patient	T101	C0030705
27234004	243	252	education	T065	C2106353
27234004	281	292	investigate	T169	C1292732
27234004	293	301	specific	T080	C0205369
27234004	302	309	factors	T169	C1521761
27234004	310	319	affecting	T169	C0392760
27234004	322	331	patient's	T101	C0030705
27234004	332	341	perceived	T041	C0030971
27234004	342	358	ability to kneel	T032	C0560891
27234004	359	363	post	T079	C0687676
27234004	364	367	TKA	T061	C0086511
27234004	379	390	exposure to	T080	C0332157
27234004	393	405	preoperative	T079	C0445204
27234004	406	414	kneeling	T039	C2584307
27234004	415	432	education session	T065	C2106353
27234004	436	457	cross-sectional study	T062	C0010362
27234004	482	485	TKA	T061	C0086511
27234004	491	499	patients	T101	C0030705
27234004	513	521	educated	T065	C2106353
27234004	528	536	kneeling	T039	C2584307
27234004	537	542	prior	T079	C0332152
27234004	550	559	operation	T061	C0543467
27234004	561	569	Patients	T101	C0030705
27234004	580	588	kneeling	T039	C2584307
27234004	589	603	questionnaires	T170	C0034394
27234004	635	641	months	T079	C0439231
27234004	642	646	post	T079	C0687676
27234004	647	650	TKA	T061	C0086511
27234004	671	679	12-month	T079	C0439231
27234004	680	688	kneeling	T039	C2584307
27234004	689	702	questionnaire	T170	C0034394
27234004	704	712	patients	T101	C0030705
27234004	732	749	Oxford knee score	T201	C1997265
27234004	751	754	OKS	T201	C1997265
27234004	776	783	percent	T081	C0439165
27234004	787	795	patients	T101	C0030705
27234004	796	805	perceived	T041	C0030971
27234004	817	822	kneel	T039	C2584307
27234004	829	835	months	T079	C0439231
27234004	836	840	post	T079	C0687676
27234004	841	844	TKA	T061	C0086511
27234004	855	859	pain	T184	C0030193
27234004	864	874	discomfort	T184	C2364135
27234004	896	903	factors	T169	C1521761
27234004	914	922	patients	T101	C0030705
27234004	928	936	kneeling	T039	C2584307
27234004	938	947	Perceived	T041	C0030971
27234004	948	956	kneeling	T039	C2584307
27234004	957	964	ability	T032	C0085732
27234004	988	995	outcome	T169	C1274040
27234004	1003	1006	OKS	T201	C1997265
27234004	1012	1020	patients	T101	C0030705
27234004	1031	1047	mild to moderate	T080	C1299392
27234004	1048	1058	difficulty	T033	C0555092
27234004	1075	1083	Kneeling	T039	C2584307
27234004	1105	1115	correlated	T080	C1707520
27234004	1129	1149	knee function scores	T033	C0243095
27234004	1171	1181	correlated	T080	C1707520
27234004	1187	1198	pain scores	T033	C0582148
27234004	1221	1231	correlated	T080	C1707520
27234004	1237	1258	knee stability scores	T033	C0243095
27234004	1294	1301	factors	T169	C1521761
27234004	1302	1312	preventing	T169	C1292733
27234004	1313	1321	kneeling	T039	C2584307
27234004	1333	1337	pain	T184	C0030193
27234004	1341	1350	discomfor	T184	C2364135
27234004	1371	1380	unrelated	T033	C0445356
27234004	1388	1392	knee	T023	C0022742
27234004	1396	1399	TKA	T061	C0086511
27234004	1453	1457	knee	T023	C0022742
27234004	1470	1478	Patients	T101	C0030705
27234004	1512	1521	education	T065	C2106353
27234004	1538	1546	kneeling	T039	C2584307
27234004	1547	1554	ability	T032	C0085732
27234004	1555	1559	post	T079	C0687676
27234004	1560	1563	TKA	T061	C0086511
27234004	1602	1611	perceived	T041	C0030971
27234004	1612	1620	kneeling	T039	C2584307
27234004	1629	1633	post	T079	C0687676
27234004	1702	1709	factors	T169	C1521761
27234004	1721	1728	patient	T101	C0030705
27234004	1729	1738	education	T065	C2106353
27234004	1739	1745	affect	T058	C2237113
27234004	1748	1757	patient's	T101	C0030705
27234004	1758	1767	perceived	T041	C0030971
27234004	1768	1776	kneeling	T039	C2584307
27234004	1777	1784	ability	T032	C0085732
27234004	1785	1789	post	T079	C0687676
27234004	1790	1793	TKA	T061	C0086511

28464953|t|The efficacy of human placenta -derived mesenchymal stem cells on radiation enteropathy along with proteomic biomarkers predicting a favorable response
28464953|a|Radiation enteropathy is a common complication in patients with abdominopelvic cancer, but no treatment has yet been established. Stem cell therapy may be a viable therapeutic option because intestinal stem cells are highly vulnerable to ionizing radiation (IR) and stem cell loss explains its intractability to general treatment. Here, we investigated either prophylactic or therapeutic efficacy of human placenta -derived mesenchymal stem cells (hPDSCs) against radiation enteropathy and could identify biomarkers predicting a favorable response to stem cell therapy. We challenged a radiation-induced enteropathy model with hPDSCs. After sacrifice, we checked the gross anatomy of small intestine, histology gross, and analyzed that, accompanied with molecular changes implicated in this model. hPDSCs significantly improved the outcome of mice induced with either radiation enteropathy or lethal radiation syndrome (P < 0.01). hPDSCs exerted inhibitory actions on inflammatory cytokines, the re-establishment of epithelium homeostasis was completed with increasing endogenous restorative processes as assessed with increased levels of proliferative markers in the hPDSCs group, and a significant inhibition of IR - induced apoptosis. The preservation of cells expressing lysozyme, and Musashi-1 were significantly increased in the hPDSC treatment group. Both preventive and therapeutic efficacies of hPDSCs were noted against IR-induced enteropathy. Label-free quantification was used to identify biomarkers which predict favorable responses after hPDSC treatment, and finally glutathione S-transferase-mu type, interleukin-10, and peroxiredoxin-2 were validated as proteomic biomarkers predicting a favorable response to hPDSCs in radiation enteropathy. hPDSCs may be a useful prophylactic and therapeutic cell therapy for radiation enteropathy.
28464953	4	12	efficacy	T080	C1280519
28464953	16	21	human	T016	C0086418
28464953	22	30	placenta	T018	C0032043
28464953	40	62	mesenchymal stem cells	T025	C1257975
28464953	66	87	radiation enteropathy	T047	C0341275
28464953	99	108	proteomic	T116,T123	C0751973
28464953	109	119	biomarkers	T201	C0005516
28464953	133	151	favorable response	T033	C4054987
28464953	152	173	Radiation enteropathy	T047	C0341275
28464953	186	198	complication	T046	C0009566
28464953	202	210	patients	T101	C0030705
28464953	216	237	abdominopelvic cancer	T191	C0153662
28464953	246	255	treatment	T061	C0087111
28464953	282	299	Stem cell therapy	T061	C0872278
28464953	316	327	therapeutic	T061	C0087111
28464953	343	353	intestinal	T023	C0021853
28464953	354	364	stem cells	T025	C0038250
28464953	376	386	vulnerable	T169	C0231204
28464953	390	408	ionizing radiation	T070	C0034538
28464953	410	412	IR	T070	C0034538
28464953	418	427	stem cell	T025	C0038250
28464953	428	432	loss	T081	C1517945
28464953	446	460	intractability	T169	C0205269
28464953	472	481	treatment	T061	C0087111
28464953	492	504	investigated	T169	C1292732
28464953	512	524	prophylactic	T061	C0199176
28464953	528	539	therapeutic	T061	C0087111
28464953	540	548	efficacy	T080	C1280519
28464953	552	557	human	T016	C0086418
28464953	558	566	placenta	T018	C0032043
28464953	576	598	mesenchymal stem cells	T025	C1257975
28464953	600	606	hPDSCs	T025	C1257975
28464953	616	637	radiation enteropathy	T047	C0341275
28464953	657	667	biomarkers	T201	C0005516
28464953	681	699	favorable response	T033	C4054987
28464953	703	720	stem cell therapy	T061	C0872278
28464953	738	767	radiation-induced enteropathy	T047	C0341275
28464953	768	773	model	T050	C0012644
28464953	779	785	hPDSCs	T025	C1257975
28464953	793	802	sacrifice	T078	C0681205
28464953	819	824	gross	T080	C0439806
28464953	825	832	anatomy	T017	C0700276
28464953	836	851	small intestine	T023	C0021852
28464953	853	862	histology	T080	C0002809
28464953	863	868	gross	T080	C0439806
28464953	874	882	analyzed	T062	C0936012
28464953	906	915	molecular	T080	C1521991
28464953	943	948	model	T050	C0012644
28464953	950	956	hPDSCs	T025	C1257975
28464953	957	970	significantly	T078	C0750502
28464953	984	991	outcome	T080	C0085415
28464953	995	999	mice	T015	C0025929
28464953	1000	1007	induced	T169	C0205263
28464953	1020	1041	radiation enteropathy	T047	C0341275
28464953	1045	1070	lethal radiation syndrome	T047	C0039082
28464953	1083	1089	hPDSCs	T025	C1257975
28464953	1098	1108	inhibitory	T052	C3463820
28464953	1120	1132	inflammatory	T169	C0333348
28464953	1133	1142	cytokines	T116,T129	C0079189
28464953	1148	1164	re-establishment	T080	C0443211
28464953	1168	1178	epithelium	T024	C0014609
28464953	1179	1190	homeostasis	T038	C0019868
28464953	1221	1231	endogenous	T169	C0205227
28464953	1232	1253	restorative processes	T039	C0031845
28464953	1291	1304	proliferative	T046	C0334094
28464953	1305	1312	markers	T201	C0005516
28464953	1320	1326	hPDSCs	T025	C1257975
28464953	1340	1351	significant	T078	C0750502
28464953	1352	1362	inhibition	T052	C3463820
28464953	1366	1368	IR	T070	C0034538
28464953	1371	1378	induced	T169	C0205263
28464953	1379	1388	apoptosis	T043	C0162638
28464953	1394	1406	preservation	T059	C0033085
28464953	1410	1415	cells	T025	C0007634
28464953	1427	1435	lysozyme	T116,T121,T126	C3541379
28464953	1441	1450	Musashi-1	T116,T123	C0536620
28464953	1456	1469	significantly	T078	C0750502
28464953	1487	1492	hPDSC	T025	C1257975
28464953	1493	1502	treatment	T061	C0087111
28464953	1515	1525	preventive	T061	C0679698
28464953	1530	1541	therapeutic	T061	C0087111
28464953	1542	1552	efficacies	T080	C1280519
28464953	1556	1562	hPDSCs	T025	C1257975
28464953	1582	1604	IR-induced enteropathy	T047	C0341275
28464953	1606	1631	Label-free quantification	T081	C1709793
28464953	1653	1663	biomarkers	T201	C0005516
28464953	1678	1697	favorable responses	T033	C4054987
28464953	1704	1709	hPDSC	T025	C1257975
28464953	1710	1719	treatment	T061	C0087111
28464953	1733	1761	glutathione S-transferase-mu	T116,T126	C3814418
28464953	1768	1782	interleukin-10	T116,T129	C0085295
28464953	1788	1803	peroxiredoxin-2	T116,T126	C1137156
28464953	1822	1831	proteomic	T116,T123	C0751973
28464953	1832	1842	biomarkers	T201	C0005516
28464953	1856	1874	favorable response	T033	C4054987
28464953	1878	1884	hPDSCs	T025	C1257975
28464953	1888	1909	radiation enteropathy	T047	C0341275
28464953	1911	1917	hPDSCs	T025	C1257975
28464953	1934	1946	prophylactic	T061	C0199176
28464953	1951	1962	therapeutic	T061	C0087111
28464953	1963	1975	cell therapy	T061	C0302189
28464953	1980	2001	radiation enteropathy	T047	C0341275

27687951|t|Inter-observer agreement for clinical examinations of foot lesions of sheep
27687951|a|In sheep, the diagnosis of foot lesions is routinely based on physical examination of the hoof. Correct diagnosis is important for the effective treatment, prevention and control of both infectious and non-infectious causes of lameness. Therefore, the aim of this study was to evaluate the level of inter-observer agreement for clinical examination of ovine foot lesions. Eight observers of varying experience, training and occupation performed foot examinations on a total of 1158 sheep from 38 farms across North England and Wales. On each farm, a group of two to four observers independently examined a sample of 24 to 30 sheep to diagnose the presence or absence of specific foot lesions including white line lesions (WL), contagious ovine digital dermatitis (CODD), footrot (FR), inter-digital dermatitis (ID) and toe granuloma (TG). The inter-observer agreement of foot lesion assessments was examined using Fleiss kappa (κ), and Cohen's κ examined the paired agreement between the test standard observer (TSO) and each observer. Scoring differences with the TSO were examined as the percentage of scoring errors and assessed for evidence of systematic scoring bias. With the exception of WL (maximum error rate 33.3%), few scoring differences with the TSO occurred (maximum error rate 3.3%). This suggests that observers can achieve good levels of reliability when diagnosing most of the commonly observed foot conditions associated with lameness in sheep.
27687951	0	24	Inter-observer agreement	T054	C0680240
27687951	29	50	clinical examinations	T058	C0031809
27687951	54	66	foot lesions	T033	C0744147
27687951	70	75	sheep	T015	C0036945
27687951	79	84	sheep	T015	C0036945
27687951	90	99	diagnosis	T062	C1704656
27687951	103	115	foot lesions	T033	C0744147
27687951	138	158	physical examination	T058	C0031809
27687951	166	170	hoof	T023	C0019908
27687951	180	189	diagnosis	T062	C1704656
27687951	211	220	effective	T080	C1704419
27687951	221	230	treatment	T169	C0039798
27687951	232	242	prevention	T169	C1292733
27687951	247	254	control	T067	C2239193
27687951	293	299	causes	T169	C0015127
27687951	303	311	lameness	T184	C0022976
27687951	375	399	inter-observer agreement	T054	C0680240
27687951	404	424	clinical examination	T058	C0031809
27687951	428	433	ovine	T015	C1123019
27687951	434	446	foot lesions	T033	C0744147
27687951	454	463	observers	T096	C0870992
27687951	467	485	varying experience	T033	C0557355
27687951	487	495	training	T065	C0220931
27687951	500	510	occupation	T090	C0028811
27687951	511	520	performed	T169	C0884358
27687951	521	538	foot examinations	T060	C0419882
27687951	558	563	sheep	T015	C0036945
27687951	572	577	farms	T082	C0557759
27687951	585	598	North England	T083	C0014282
27687951	603	608	Wales	T083	C0043015
27687951	618	622	farm	T082	C0557759
27687951	626	631	group	T078	C0441833
27687951	647	656	observers	T096	C0870992
27687951	671	679	examined	T033	C0332128
27687951	682	688	sample	T077	C2347026
27687951	701	706	sheep	T015	C0036945
27687951	710	718	diagnose	T033	C0011900
27687951	723	731	presence	T033	C0150312
27687951	735	742	absence	T169	C0332197
27687951	746	754	specific	T080	C0205369
27687951	755	767	foot lesions	T033	C0744147
27687951	778	788	white line	T023	C1299720
27687951	789	796	lesions	T033	C0221198
27687951	798	800	WL	T033	C0221198
27687951	803	838	contagious ovine digital dermatitis	T047	C2936324
27687951	840	844	CODD	T047	C2936324
27687951	847	854	footrot	T047	C3825329
27687951	856	858	FR	T047	C3825329
27687951	861	885	inter-digital dermatitis	T047	C3670859
27687951	887	889	ID	T047	C3670859
27687951	895	898	toe	T023	C0040357
27687951	899	908	granuloma	T046	C0018188
27687951	910	912	TG	T046	C0018188
27687951	919	943	inter-observer agreement	T054	C0680240
27687951	947	958	foot lesion	T033	C0744147
27687951	959	970	assessments	T058	C1261322
27687951	975	983	examined	T033	C0332128
27687951	990	1002	Fleiss kappa	T081	C0392762
27687951	1004	1005	κ	T081	C0392762
27687951	1012	1021	Cohen's κ	T081	C0392762
27687951	1022	1030	examined	T033	C0332128
27687951	1035	1051	paired agreement	T054	C0680240
27687951	1064	1086	test standard observer	T096	C0870992
27687951	1088	1091	TSO	T096	C0870992
27687951	1102	1110	observer	T096	C0870992
27687951	1112	1119	Scoring	T081	C0449820
27687951	1120	1131	differences	T080	C1705242
27687951	1141	1144	TSO	T096	C0870992
27687951	1150	1158	examined	T033	C0332128
27687951	1166	1176	percentage	T081	C0439165
27687951	1180	1194	scoring errors	T081	C0681899
27687951	1199	1207	assessed	T052	C1516048
27687951	1224	1247	systematic scoring bias	T078	C0005351
27687951	1271	1273	WL	T033	C0221198
27687951	1283	1288	error	T080	C0743559
27687951	1289	1293	rate	T081	C1521828
27687951	1306	1313	scoring	T081	C0449820
27687951	1314	1325	differences	T080	C1705242
27687951	1335	1338	TSO	T096	C0870992
27687951	1339	1347	occurred	T052	C1709305
27687951	1357	1362	error	T080	C0743559
27687951	1363	1367	rate	T081	C1521828
27687951	1394	1403	observers	T096	C0870992
27687951	1431	1442	reliability	T081	C2347947
27687951	1448	1458	diagnosing	T062	C1704656
27687951	1489	1493	foot	T023	C0016504
27687951	1494	1504	conditions	T080	C0348080
27687951	1505	1520	associated with	T080	C0332281
27687951	1521	1529	lameness	T184	C0022976
27687951	1533	1538	sheep	T015	C0036945

27873506|t|Development of a Robotic Colonoscopic Manipulation System, Using Haptic Feedback Algorithm
27873506|a|Colonoscopy is one of the most effective diagnostic and therapeutic tools for colorectal diseases. We aim to propose a master-slave robotic colonoscopy that is controllable in remote site using conventional colonoscopy. The master and slave robot were developed to use conventional flexible colonoscopy. The robotic colonoscopic procedure was performed using a colonoscope training model by one expert endoscopist and two unexperienced engineers. To provide the haptic sensation, the insertion force and the rotating torque were measured and sent to the master robot. A slave robot was developed to hold the colonoscopy and its knob, and perform insertion, rotation, and two tilting motions of colonoscope. A master robot was designed to teach motions of the slave robot. These measured force and torque were scaled down by one tenth to provide the operator with some reflection force and torque at the haptic device. The haptic sensation and feedback system was successful and helpful to feel the constrained force or torque in colon. The insertion time using robotic system decreased with repeated procedures. This work proposed a robotic approach for colonoscopy using haptic feedback algorithm, and this robotic device would effectively perform colonoscopy with reduced burden and comparable safety for patients in remote site.
27873506	0	11	Development	T169	C1527148
27873506	17	57	Robotic Colonoscopic Manipulation System	T170	C1738367
27873506	65	71	Haptic	T073	C1708324
27873506	72	80	Feedback	T067	C0015744
27873506	81	90	Algorithm	T170	C0002045
27873506	91	102	Colonoscopy	T060	C0009378
27873506	132	164	diagnostic and therapeutic tools	UnknownType	C0541506
27873506	169	188	colorectal diseases	T191	C0009404
27873506	210	230	master-slave robotic	T073	C0336537
27873506	231	242	colonoscopy	T060	C0009378
27873506	251	263	controllable	T080	C0243148
27873506	267	273	remote	T082	C0205157
27873506	274	278	site	T082	C0205145
27873506	285	297	conventional	T080	C0439858
27873506	298	309	colonoscopy	T060	C0009378
27873506	315	321	master	T073	C0336537
27873506	326	337	slave robot	T073	C0336537
27873506	343	352	developed	T169	C1527148
27873506	360	372	conventional	T080	C0439858
27873506	373	381	flexible	T080	C0443220
27873506	382	393	colonoscopy	T060	C0009378
27873506	399	429	robotic colonoscopic procedure	T061	C0751041
27873506	452	463	colonoscope	T074	C0180022
27873506	464	478	training model	T074	C3881670
27873506	486	492	expert	T080	C0205556
27873506	493	504	endoscopist	T097	C1522486
27873506	513	526	unexperienced	T080	C0205556
27873506	527	536	engineers	T097	C0878517
27873506	553	559	haptic	T073	C1708324
27873506	560	569	sensation	T169	C0205245
27873506	575	584	insertion	T169	C1883719
27873506	585	590	force	T067	C0441722
27873506	599	614	rotating torque	T067	C0376590
27873506	620	628	measured	T080	C0444706
27873506	645	657	master robot	T073	C0336537
27873506	661	672	slave robot	T073	C0336537
27873506	677	686	developed	T169	C1527148
27873506	699	710	colonoscopy	T060	C0009378
27873506	719	723	knob	T073	C1708612
27873506	737	746	insertion	T169	C1883719
27873506	748	756	rotation	T169	C0035868
27873506	766	781	tilting motions	T169	C0687704
27873506	785	796	colonoscope	T074	C0180022
27873506	800	812	master robot	T073	C0336537
27873506	817	825	designed	T052	C1707689
27873506	835	842	motions	T169	C0687704
27873506	850	861	slave robot	T073	C0336537
27873506	869	877	measured	T080	C0444706
27873506	878	883	force	T067	C0441722
27873506	888	894	torque	T067	C0376590
27873506	900	911	scaled down	T052	C1947916
27873506	919	924	tenth	T081	C0205444
27873506	940	948	operator	T098	C1705275
27873506	959	975	reflection force	T067	C0441722
27873506	980	986	torque	T067	C0376590
27873506	994	1007	haptic device	T073	C1708324
27873506	1013	1019	haptic	T073	C1708324
27873506	1020	1029	sensation	T169	C0205245
27873506	1034	1049	feedback system	T067	C0015744
27873506	1089	1100	constrained	T077	C1707494
27873506	1101	1106	force	T067	C0441722
27873506	1110	1116	torque	T067	C0376590
27873506	1120	1125	colon	T023	C0009368
27873506	1131	1140	insertion	T169	C1883719
27873506	1141	1145	time	T079	C0040223
27873506	1152	1166	robotic system	T170	C1738367
27873506	1167	1176	decreased	T081	C0205216
27873506	1182	1190	repeated	T169	C0205341
27873506	1191	1201	procedures	T169	C0025664
27873506	1224	1240	robotic approach	T170	C1738367
27873506	1245	1256	colonoscopy	T060	C0009378
27873506	1263	1269	haptic	T073	C1708324
27873506	1270	1278	feedback	T067	C0015744
27873506	1279	1288	algorithm	T170	C0002045
27873506	1299	1313	robotic device	T073	C0336537
27873506	1340	1351	colonoscopy	T060	C0009378
27873506	1357	1364	reduced	T080	C0392756
27873506	1365	1371	burden	T078	C2828008
27873506	1387	1406	safety for patients	T058	C1113679
27873506	1410	1416	remote	T082	C0205157
27873506	1417	1421	site	T082	C0205145

28470753|t|Stalk versus base invasion in pT1 papillary cancers of the bladder: improved substaging system predicting risk of progression
28470753|a|Pathologic stage T1 (pT1) bladder cancers are a clinically heterogeneous group. However, current staging guidelines for superficially invasive cancers do not acknowledge the variability in type and extent of lamina propria invasion in papillary urothelial carcinomas (PUC), and historically proposed substaging systems showed either high inter-observer variation or limited value in predicting patient outcomes. Herein we reappraise pT1 PUC substaging, aiming to identify a novel scheme which is reproducible and prognostically meaningful. Stage pT1 PUC diagnosed during years 1999-2015 were retrospectively reviewed and characterized as focal invasion confined to papillary stalk, focal invasion of tumor base, or extensive invasion of tumor base. Cases with concurrent flat carcinoma in-situ, angiolymphatic invasion, absent muscularis propria, or clinically advanced disease were excluded. We calculated cumulative incidence of recurrence, progression, and death by tumor subtype and evaluated differential risks using log-rank tests and Kaplan-Meier curves stratified by type and extent of invasion. Among 62 patients satisfying inclusion criteria, 22 of 29 patients with base extensive invasion progressed while 4 of 13 with base focal and 0 of 20 with stalk only invasion progressed. There was strong evidence that base extensive patients had higher risk of progression and death due to bladder cancer than base focal or stalk only counterparts (P<0.0001). However, tumor subtype was not significantly associated with risk of recurrence (P=0.21). We propose an innovative substaging approach for reporting site and extent of lamina propria invasion in patients with pT1 PUC allowing patient stratification for risk of progression. This article is protected by copyright. All rights reserved.
28470753	0	5	Stalk	T017	C1947953
28470753	13	17	base	T017	C0700276
28470753	18	26	invasion	T033	C1269955
28470753	30	33	pT1	T033	C0332391
28470753	34	66	papillary cancers of the bladder	T191	C0699885
28470753	106	110	risk	T078	C0035647
28470753	114	125	progression	T046	C0242656
28470753	126	145	Pathologic stage T1	T033	C0332391
28470753	147	150	pT1	T033	C0332391
28470753	152	167	bladder cancers	T191	C0699885
28470753	174	184	clinically	T080	C0205210
28470753	185	204	heterogeneous group	T080	C0019409
28470753	223	230	staging	T185	C0178759
28470753	246	259	superficially	T082	C0205124
28470753	260	276	invasive cancers	T191	C0677898
28470753	300	311	variability	T077	C2827666
28470753	334	357	lamina propria invasion	T033	C1269980
28470753	361	392	papillary urothelial carcinomas	T191	C1368911
28470753	394	397	PUC	T191	C1368911
28470753	464	488	inter-observer variation	T081	C0021713
28470753	492	505	limited value	T169	C0439801
28470753	520	536	patient outcomes	T058	C0030698
28470753	548	558	reappraise	T058	C0184514
28470753	559	562	pT1	T033	C0332391
28470753	563	566	PUC	T191	C1368911
28470753	579	585	aiming	T078	C1947946
28470753	589	597	identify	T080	C0205396
28470753	600	605	novel	T080	C0205314
28470753	606	612	scheme	T170	C1519193
28470753	622	634	reproducible	T080	C1524057
28470753	639	653	prognostically	T170	C0220901
28470753	666	675	Stage pT1	T033	C0332391
28470753	676	679	PUC	T191	C1368911
28470753	680	689	diagnosed	T033	C0011900
28470753	697	702	years	T079	C0439234
28470753	718	742	retrospectively reviewed	T062	C0035363
28470753	747	760	characterized	T052	C1880022
28470753	764	769	focal	T082	C0205234
28470753	770	778	invasion	T046	C2699153
28470753	791	806	papillary stalk	T017	C1947953
28470753	808	813	focal	T082	C0205234
28470753	814	822	invasion	T033	C1269955
28470753	826	831	tumor	T191	C0027651
28470753	832	836	base	T017	C0700276
28470753	851	859	invasion	T033	C1269955
28470753	863	868	tumor	T191	C0027651
28470753	869	873	base	T017	C0700276
28470753	875	880	Cases	T169	C0868928
28470753	886	896	concurrent	T079	C0205420
28470753	897	919	flat carcinoma in-situ	T033	C1300924
28470753	921	944	angiolymphatic invasion	T033	C1708790
28470753	946	952	absent	T169	C0332197
28470753	953	971	muscularis propria	T024	C0225358
28470753	976	986	clinically	T080	C0205210
28470753	987	1003	advanced disease	UnknownType	C0679246
28470753	1009	1017	excluded	T169	C0332196
28470753	1033	1043	cumulative	T080	C1511559
28470753	1044	1053	incidence	T081	C0021149
28470753	1057	1067	recurrence	T033	C0679254
28470753	1069	1080	progression	T046	C0242656
28470753	1086	1091	death	T040	C0011065
28470753	1095	1108	tumor subtype	T185	C1519691
28470753	1113	1122	evaluated	T058	C0220825
28470753	1123	1141	differential risks	T033	C0035648
28470753	1148	1162	log-rank tests	T170	C0237913
28470753	1167	1186	Kaplan-Meier curves	T081	C1720944
28470753	1187	1197	stratified	T080	C0205363
28470753	1201	1205	type	T080	C0332307
28470753	1210	1228	extent of invasion	T201	C1269793
28470753	1239	1247	patients	T101	C0030705
28470753	1259	1268	inclusion	T080	C1512693
28470753	1269	1277	criteria	T078	C0243161
28470753	1288	1296	patients	T101	C0030705
28470753	1302	1306	base	T017	C0700276
28470753	1307	1316	extensive	T080	C0205231
28470753	1317	1325	invasion	T033	C1269955
28470753	1326	1336	progressed	T169	C1280477
28470753	1356	1360	base	T017	C0700276
28470753	1361	1366	focal	T082	C0205234
28470753	1384	1389	stalk	T017	C1947953
28470753	1395	1403	invasion	T033	C1269955
28470753	1404	1414	progressed	T169	C1280477
28470753	1447	1451	base	T017	C0700276
28470753	1462	1470	patients	T101	C0030705
28470753	1482	1486	risk	T078	C0035647
28470753	1490	1501	progression	T046	C0242656
28470753	1506	1511	death	T040	C0011065
28470753	1519	1533	bladder cancer	T191	C0699885
28470753	1539	1543	base	T017	C0700276
28470753	1544	1549	focal	T082	C0205234
28470753	1553	1558	stalk	T017	C1947953
28470753	1598	1611	tumor subtype	T185	C1519691
28470753	1650	1654	risk	T078	C0035647
28470753	1658	1668	recurrence	T033	C0679254
28470753	1757	1780	lamina propria invasion	T033	C1269980
28470753	1784	1792	patients	T101	C0030705
28470753	1798	1801	pT1	T033	C0332391
28470753	1802	1805	PUC	T191	C1368911
28470753	1815	1822	patient	T101	C0030705
28470753	1823	1837	stratification	T080	C0205363
28470753	1842	1846	risk	T078	C0035647
28470753	1850	1861	progression	T046	C0242656

27469526|t|The role of sub-hippocampal versus hippocampal regions in bitemporal lobe epilepsies
27469526|a|We aimed at better delineating the functional anatomical organization of bitemporal lobe epilepsy. We studied the epileptogenic zone (EZ) by quantifying the epileptogenicity of brain structures explored by depth electrodes in patients investigated by stereoelectroencephalography (SEEG). We compared 15 patients with bilateral mesial temporal lobe epilepsy (BTLE) and 15 patients with unilateral mesial temporal lobe epilepsy (UTLE). This quantification was performed using the ' Epileptogenicity Index ' (EI). Age at epilepsy onset, and epilepsy duration, were not statistically different in both groups. UTLE patients more frequently displayed maximal epileptogenicity in hippocampal structures, whereas BTLE patients had maximal values in subhippocampal areas (entorhinal cortex, temporal pole, parahippocampal cortex). Our results suggest different organization of the EZ in the two groups. BTLE was associated with more involvement of subhippocampal regions, a result in agreement with known anatomical connections between the two temporal lobes.
27469526	4	8	role	T077	C1705810
27469526	12	27	sub-hippocampal	T029	C3496509
27469526	35	54	hippocampal regions	T029	C3496509
27469526	58	84	bitemporal lobe epilepsies	T047	C0014556
27469526	120	130	functional	T169	C0205245
27469526	131	154	anatomical organization	T040	C0026559
27469526	158	182	bitemporal lobe epilepsy	T047	C0014556
27469526	199	217	epileptogenic zone	T029	C1273723
27469526	219	221	EZ	T029	C1273723
27469526	226	237	quantifying	T081	C1709793
27469526	242	258	epileptogenicity	T169	C0205245
27469526	262	278	brain structures	T023	C0006104
27469526	291	307	depth electrodes	T074	C0491577
27469526	311	319	patients	T101	C0030705
27469526	336	364	stereoelectroencephalography	T060	C0013819
27469526	366	370	SEEG	T060	C0013819
27469526	388	396	patients	T101	C0030705
27469526	402	441	bilateral mesial temporal lobe epilepsy	T047	C0014556
27469526	443	447	BTLE	T047	C0014556
27469526	456	464	patients	T101	C0030705
27469526	470	510	unilateral mesial temporal lobe epilepsy	T047	C0014556
27469526	512	516	UTLE	T047	C0014556
27469526	524	538	quantification	T081	C1709793
27469526	565	587	Epileptogenicity Index	T081	C0392762
27469526	591	593	EI	T081	C0392762
27469526	596	599	Age	T032	C0001779
27469526	603	617	epilepsy onset	T047	C0014544
27469526	623	631	epilepsy	T047	C0014544
27469526	632	640	duration	T079	C0449238
27469526	647	674	not statistically different	T033	C0243095
27469526	683	689	groups	T078	C0441833
27469526	691	695	UTLE	T047	C0014556
27469526	696	704	patients	T101	C0030705
27469526	731	738	maximal	T080	C0205289
27469526	739	755	epileptogenicity	T169	C0205245
27469526	759	781	hippocampal structures	T023	C0019564
27469526	791	795	BTLE	T047	C0014556
27469526	796	804	patients	T101	C0030705
27469526	809	816	maximal	T080	C0205289
27469526	817	823	values	T080	C0042295
27469526	827	847	subhippocampal areas	T029	C3496509
27469526	849	866	entorhinal cortex	T023	C0175196
27469526	868	881	temporal pole	T023	C0149552
27469526	883	905	parahippocampal cortex	T024	C2950686
27469526	928	937	different	T080	C1705242
27469526	938	950	organization	T040	C0026559
27469526	958	960	EZ	T029	C1273723
27469526	972	978	groups	T078	C0441833
27469526	980	984	BTLE	T047	C0014556
27469526	989	1004	associated with	T080	C0332281
27469526	1025	1047	subhippocampal regions	T029	C3496509
27469526	1082	1092	anatomical	T080	C0220784
27469526	1093	1104	connections	T082	C0449379
27469526	1121	1135	temporal lobes	T023	C0039485

27951480|t|Development of the four-item Letter and Shape Drawing test (LSD-4): A brief bedside test of visuospatial function
27951480|a|Conventional bedside tests of visuospatial function such as the Clock Drawing (CDT) and Intersecting Pentagons (IPT) lack consistency in delivery and interpretation. We compared performance on a novel test of visuospatial ability - the LSD - with the IPT, CDT and MMSE in 180 acute elderly medical inpatients [mean age 79.7±7.1 (range 62-96); 91 females (50.6%)]. 124 (69%) scored ≤23 on the MMSE; 60 with mild (score 18-23) and 64 with severe (score ≤17) impairment. 78 (43%) scored ≥6 on the CDT, while for the IPT, 87 (47%) scored ≥4. The CDT and IPT agreed on the classification of 138 patients (77%) with modest- strong agreement with the MMSE categories. Correlation between the LSD and visuospatial tests was high. A four-item version of the LSD incorporating items 1,10,12,15 had high correlation with the LSD-15 and strong association with MMSE categories. The LSD-4 provides a brief and easily interpreted bedside test of visuospatial function that has high coverage of elderly patients with neurocognitive impairment, good agreement with conventional tests of visuospatial ability and favourable ability to identify significant cognitive impairment. [181 words].
27951480	0	11	Development	T169	C1527148
27951480	19	58	four-item Letter and Shape Drawing test	UnknownType	C0260168
27951480	60	65	LSD-4	UnknownType	C0260168
27951480	76	88	bedside test	T060	C0282662
27951480	92	113	visuospatial function	T041	C2370887
27951480	114	126	Conventional	T080	C0439858
27951480	127	140	bedside tests	T060	C0282662
27951480	144	165	visuospatial function	T041	C2370887
27951480	178	191	Clock Drawing	UnknownType	C0260168
27951480	193	196	CDT	UnknownType	C0260168
27951480	202	224	Intersecting Pentagons	UnknownType	C0260168
27951480	226	229	IPT	UnknownType	C0260168
27951480	231	235	lack	T080	C0332268
27951480	236	247	consistency	T080	C0332529
27951480	264	278	interpretation	T033	C0456377
27951480	283	291	compared	T052	C1707455
27951480	292	303	performance	T052	C1882330
27951480	323	343	visuospatial ability	T041	C0814069
27951480	350	353	LSD	UnknownType	C0260168
27951480	365	368	IPT	UnknownType	C0260168
27951480	370	373	CDT	UnknownType	C0260168
27951480	378	382	MMSE	T060	C0451306
27951480	390	395	acute	T079	C0205178
27951480	396	403	elderly	T098	C0001792
27951480	404	411	medical	T169	C0205476
27951480	412	422	inpatients	T101	C0021562
27951480	424	428	mean	T081	C0444504
27951480	429	432	age	T032	C0001779
27951480	443	448	range	T081	C1514721
27951480	460	467	females	T032	C0086287
27951480	488	494	scored	T081	C0449820
27951480	506	510	MMSE	T060	C0451306
27951480	520	524	mild	T080	C2945599
27951480	526	531	score	T081	C0449820
27951480	551	557	severe	T080	C0205082
27951480	559	564	score	T081	C0449820
27951480	570	580	impairment	T169	C0221099
27951480	591	597	scored	T081	C0449820
27951480	608	611	CDT	UnknownType	C0260168
27951480	627	630	IPT	UnknownType	C0260168
27951480	641	647	scored	T081	C0449820
27951480	656	659	CDT	UnknownType	C0260168
27951480	664	667	IPT	UnknownType	C0260168
27951480	668	674	agreed	T033	C3641827
27951480	682	696	classification	T185	C0008902
27951480	704	712	patients	T101	C0030705
27951480	732	738	strong	T080	C0442821
27951480	758	762	MMSE	T060	C0451306
27951480	763	773	categories	T170	C0683312
27951480	775	786	Correlation	T080	C1707520
27951480	799	802	LSD	UnknownType	C0260168
27951480	807	825	visuospatial tests	UnknownType	C0260168
27951480	830	834	high	T080	C0205250
27951480	838	855	four-item version	T170	C0333052
27951480	863	866	LSD	UnknownType	C0260168
27951480	881	886	items	T071	C1551338
27951480	902	906	high	T080	C0205250
27951480	907	918	correlation	T080	C1707520
27951480	928	934	LSD-15	UnknownType	C0260168
27951480	939	945	strong	T080	C0442821
27951480	946	962	association with	T080	C0332281
27951480	963	967	MMSE	T060	C0451306
27951480	968	978	categories	T170	C0683312
27951480	984	989	LSD-4	UnknownType	C0260168
27951480	1011	1017	easily	T033	C0332219
27951480	1018	1029	interpreted	T169	C1285553
27951480	1030	1042	bedside test	T060	C0282662
27951480	1046	1067	visuospatial function	T041	C2370887
27951480	1077	1081	high	T080	C0205250
27951480	1082	1090	coverage	T169	C1999244
27951480	1094	1101	elderly	T098	C0001792
27951480	1102	1110	patients	T101	C0030705
27951480	1116	1141	neurocognitive impairment	T048	C0338656
27951480	1163	1175	conventional	T080	C0439858
27951480	1185	1205	visuospatial ability	T041	C0814069
27951480	1232	1240	identify	T080	C0205396
27951480	1241	1252	significant	T078	C0750502
27951480	1253	1273	cognitive impairment	T048	C0338656

27708714|t|The presence of two rare genomic syndromes, 1q21 deletion and Xq28 duplication, segregating independently in a family with intellectual disability
27708714|a|1q21 microdeletion syndrome is a rare contiguous gene deletion disorder with de novo or autosomal dominant inheritance patterns and its phenotypic features include intellectual disability, distinctive facial dysmorphism, microcephaly, cardiac abnormalities, and cataracts. MECP2 duplication syndrome is an X-linked recessive neurodevelopmental disorder characterized by intellectual disability, global developmental delay, and other neurological complications including late-onset seizures. Previously, these two different genetic syndromes have not been reported segregating independently in a same family. Here we describe two siblings carrying either a chromosome 1q21 microdeletion or a chromosome Xq28 duplication. Using a comparative genomic hybridization (CGH) array, we identified a 1.24 Mb heterozygous deletion at 1q21 resulting in the loss of 9 genes in a girl with learning disability, hypothyroidism, short stature, sensory integration disorder, and soft dysmorphic features including cupped ears and a unilateral ear pit. We also characterized a 508 kb Xq28 duplication encompassing MECP2 in her younger brother with hypotonia, poor speech, cognitive and motor impairment. The parental CGH and quantitative PCR (qPCR) analyses revealed that the 1q21 deletion in the elder sister is de novo, but the Xq28 duplication in the younger brother was originally inherited from the maternal grandmother through the mother, both of whom are asymptomatic carriers. RT-qPCR assays revealed that the affected brother has almost double the amount of MECP2 mRNA expression compared to other family members of both genders including maternal grandmother and mother who have the same Xq28 duplication with no phenotype. This suggests the X chromosome with an Xq28 duplication in the carrier females is preferentially silenced. From our understanding, this would be the first report showing the independent segregation of two genetically unrelated syndromes, 1q21 microdeletion and Xq28 duplication, in a same family, especially in siblings. Although these two chromosomal abnormalities share some similar phenotypes such as intellectual disability, mild dysmorphic features, and cardiac abnormalities, the presence of two unrelated and rare syndromes in siblings is very unusual. Therefore, further comprehensive investigations in similar cases are required for future studies.
27708714	25	42	genomic syndromes	T047	C0019247
27708714	44	48	1q21	T028	C4267770
27708714	49	57	deletion	T047	C1954751
27708714	62	78	Xq28 duplication	T047	C2749007
27708714	111	117	family	T099	C0015576
27708714	123	146	intellectual disability	T048	C3714756
27708714	147	151	1q21	T028	C4267770
27708714	152	174	microdeletion syndrome	T047	C1954751
27708714	196	218	gene deletion disorder	T049	C1442161
27708714	224	231	de novo	T078	C1515568
27708714	235	265	autosomal dominant inheritance	T045	C0443147
27708714	283	293	phenotypic	T032	C0031437
27708714	311	334	intellectual disability	T048	C3714756
27708714	348	366	facial dysmorphism	T019	C0266617
27708714	368	380	microcephaly	T019	C0025958
27708714	382	403	cardiac abnormalities	T019	C0018798
27708714	409	418	cataracts	T020	C0086543
27708714	420	446	MECP2 duplication syndrome	T048	C1846058
27708714	453	461	X-linked	T047	C1138434
27708714	472	499	neurodevelopmental disorder	T048	C1535926
27708714	517	540	intellectual disability	T048	C3714756
27708714	542	568	global developmental delay	T048	C0557874
27708714	580	606	neurological complications	T046	C0235029
27708714	628	636	seizures	T184	C0036572
27708714	670	687	genetic syndromes	T047	C0567439
27708714	747	753	family	T099	C0015576
27708714	776	784	siblings	T099	C0037047
27708714	803	818	chromosome 1q21	T028	C4267770
27708714	819	832	microdeletion	T047	C1954751
27708714	838	865	chromosome Xq28 duplication	T047	C2749007
27708714	875	908	comparative genomic hybridization	T063	C0796358
27708714	910	913	CGH	T063	C0796358
27708714	971	975	1q21	T028	C4267770
27708714	1003	1008	genes	T028	C0017337
27708714	1014	1018	girl	T100	C0870604
27708714	1024	1043	learning disability	T048	C0751265
27708714	1045	1059	hypothyroidism	T047	C0020676
27708714	1061	1074	short stature	T033	C0349588
27708714	1076	1104	sensory integration disorder	T047	C1960557
27708714	1110	1134	soft dysmorphic features	T033	C4272951
27708714	1145	1156	cupped ears	T033	C1845447
27708714	1163	1181	unilateral ear pit	T033	C4316005
27708714	1214	1230	Xq28 duplication	T047	C2749007
27708714	1244	1249	MECP2	T028	C1417098
27708714	1257	1272	younger brother	T099	C0337538
27708714	1278	1287	hypotonia	T033	C0026827
27708714	1289	1300	poor speech	T033	C1848207
27708714	1302	1311	cognitive	T048	C0338656
27708714	1316	1332	motor impairment	T033	C0556280
27708714	1347	1350	CGH	T063	C0796358
27708714	1355	1371	quantitative PCR	T059	C2733022
27708714	1373	1377	qPCR	T059	C2733022
27708714	1406	1410	1q21	T028	C4267770
27708714	1411	1419	deletion	T047	C1954751
27708714	1433	1439	sister	T099	C0337514
27708714	1443	1450	de novo	T078	C1515568
27708714	1460	1476	Xq28 duplication	T047	C2749007
27708714	1484	1499	younger brother	T099	C0337538
27708714	1515	1524	inherited	T169	C0439660
27708714	1534	1554	maternal grandmother	T099	C1273525
27708714	1567	1573	mother	T099	C0026591
27708714	1592	1613	asymptomatic carriers	T101	C0948450
27708714	1615	1629	RT-qPCR assays	T063	C1514628
27708714	1657	1664	brother	T099	C0337527
27708714	1697	1702	MECP2	T028	C1417098
27708714	1703	1718	mRNA expression	T045	C1515670
27708714	1737	1751	family members	T099	C0086282
27708714	1760	1767	genders	T032	C0079399
27708714	1778	1798	maternal grandmother	T099	C1273525
27708714	1803	1809	mother	T099	C0026591
27708714	1828	1844	Xq28 duplication	T047	C2749007
27708714	1882	1894	X chromosome	T026	C0043292
27708714	1903	1919	Xq28 duplication	T047	C2749007
27708714	1927	1934	carrier	T033	C0007294
27708714	1935	1942	females	T032	C0086287
27708714	1961	1969	silenced	T045	C0598496
27708714	2069	2080	genetically	T169	C0314603
27708714	2081	2090	unrelated	T033	C0445356
27708714	2091	2100	syndromes	T047	C0019247
27708714	2102	2106	1q21	T028	C4267770
27708714	2107	2120	microdeletion	T047	C1954751
27708714	2125	2141	Xq28 duplication	T047	C2749007
27708714	2153	2159	family	T099	C0015576
27708714	2175	2183	siblings	T099	C0037047
27708714	2204	2229	chromosomal abnormalities	T049	C0008625
27708714	2249	2259	phenotypes	T032	C0031437
27708714	2268	2291	intellectual disability	T048	C3714756
27708714	2293	2317	mild dysmorphic features	T033	C2749190
27708714	2323	2344	cardiac abnormalities	T019	C0018798
27708714	2385	2394	syndromes	T047	C0019247
27708714	2398	2406	siblings	T099	C0037047
27708714	2443	2471	comprehensive investigations	T058	C0009586

27764968|t|The relationship between anthropometry and body composition from computed tomography: The Mediators of Atherosclerosis in South Asians Living in America Study
27764968|a|Few studies examine the relationships between anthropometry and the body composition measures they approximate, or whether they differ by sex, and no studies have examined these relationships in South Asians living in the US. We conducted a cross-sectional study of 871 participants in the Mediators of Atherosclerosis in South Asians Living in America (MASALA) Study who had BMI < 40 kg/m(2) and underwent abdominal CT scans for measurement of visceral and subcutaneous fat. Linear regression was used to model the associations between anthropometric measures and naturally log-transformed body composition measures. All measures of anthropometry, except height, were significantly associated with visceral fat and had a significant non-linear component (p < .05). The only associations for visceral fat that exhibited significant heterogeneity by sex were waist circumference (% difference in visceral fat slope: women 1.92, men 2.74, p = .007 for interaction) and waist-to-hip ratio (women 25.9, men 717.4, p < .001). Except for height, all measures of anthropometry were significantly associated with subcutaneous fat, had a significant quadratic component, and significant heterogeneity by sex (weight (kg): 2.74 for women, 4.08 for men; BMI (kg/m(2)): 10.3, 14.0; waist circumference (cm): 1.51, 3.36; hip circumference (cm): 2.53, 4.50) with p < .001 for each. In MASALA participants, the relationships of anthropometric measures with visceral and subcutaneous fat appear similar to other race / ethnic groups, but with weaker non-linearity and heterogeneity by sex. Given these results, researchers should consider separate models by sex for US South Asians when approximating subcutaneous fat or when using waist circumference to approximate visceral fat.
27764968	4	16	relationship	T080	C0439849
27764968	25	38	anthropometry	T062	C0003188
27764968	43	59	body composition	T032	C0005885
27764968	65	84	computed tomography	T060	C0040405
27764968	103	118	Atherosclerosis	T047	C0004153
27764968	122	134	South Asians	T098	C1519427
27764968	135	141	Living	T078	C0376558
27764968	145	152	America	T083	C0002454
27764968	183	196	relationships	T080	C0439849
27764968	205	218	anthropometry	T062	C0003188
27764968	227	243	body composition	T032	C0005885
27764968	297	300	sex	T032	C1522384
27764968	337	350	relationships	T080	C0439849
27764968	354	366	South Asians	T098	C1519427
27764968	381	383	US	T083	C0041703
27764968	400	421	cross-sectional study	T062	C0010362
27764968	429	441	participants	T098	C0679646
27764968	462	477	Atherosclerosis	T047	C0004153
27764968	481	493	South Asians	T098	C1519427
27764968	494	500	Living	T078	C0376558
27764968	504	511	America	T083	C0002454
27764968	512	526	(MASALA) Study	T062	C2603343
27764968	535	538	BMI	T201	C1305855
27764968	566	584	abdominal CT scans	T060	C0412620
27764968	589	600	measurement	T169	C0242485
27764968	604	612	visceral	T024	C1563740
27764968	617	633	subcutaneous fat	T024	C0222331
27764968	635	652	Linear regression	T081	C0023733
27764968	665	670	model	T170	C3161035
27764968	696	719	anthropometric measures	T170	C2598146
27764968	750	766	body composition	T032	C0005885
27764968	793	806	anthropometry	T062	C0003188
27764968	815	821	height	T032	C0005890
27764968	842	857	associated with	T080	C0332281
27764968	858	870	visceral fat	T024	C1563740
27764968	881	892	significant	T078	C0750502
27764968	951	963	visceral fat	T024	C1563740
27764968	979	990	significant	T078	C0750502
27764968	991	1004	heterogeneity	T080	C0019409
27764968	1008	1011	sex	T032	C1522384
27764968	1017	1036	waist circumference	T201	C0455829
27764968	1054	1066	visceral fat	T024	C1563740
27764968	1074	1079	women	T098	C0043210
27764968	1086	1089	men	T098	C0025266
27764968	1126	1144	waist-to-hip ratio	T032	C0205682
27764968	1146	1151	women	T098	C0043210
27764968	1158	1161	men	T098	C0025266
27764968	1191	1197	height	T032	C0005890
27764968	1215	1228	anthropometry	T062	C0003188
27764968	1248	1263	associated with	T080	C0332281
27764968	1264	1280	subcutaneous fat	T024	C0222331
27764968	1288	1299	significant	T078	C0750502
27764968	1325	1336	significant	T078	C0750502
27764968	1337	1350	heterogeneity	T080	C0019409
27764968	1354	1357	sex	T032	C1522384
27764968	1359	1365	weight	T032	C0005910
27764968	1381	1386	women	T098	C0043210
27764968	1397	1400	men	T098	C0025266
27764968	1402	1405	BMI	T201	C1305855
27764968	1429	1448	waist circumference	T201	C0455829
27764968	1467	1484	hip circumference	T201	C0562350
27764968	1537	1549	participants	T098	C0679646
27764968	1555	1568	relationships	T080	C0439849
27764968	1572	1595	anthropometric measures	T170	C2598146
27764968	1601	1609	visceral	T024	C1563740
27764968	1614	1630	subcutaneous fat	T024	C0222331
27764968	1655	1659	race	T098	C0034510
27764968	1662	1675	ethnic groups	T098	C0015031
27764968	1686	1692	weaker	T080	C1762617
27764968	1711	1724	heterogeneity	T080	C0019409
27764968	1728	1731	sex	T032	C1522384
27764968	1754	1765	researchers	T097	C0035173
27764968	1801	1804	sex	T032	C1522384
27764968	1812	1824	South Asians	T098	C1519427
27764968	1844	1860	subcutaneous fat	T024	C0222331
27764968	1875	1894	waist circumference	T201	C0455829
27764968	1910	1922	visceral fat	T024	C1563740